-DOCSTART- -5410150- O O

The DT N
need NN N
for IN N
chemotherapy NN i
after IN N
prolonged JJ p
complete JJ p
remission NN p
in IN p
acute JJ p
leukemia NN p
of IN p
childhood NN p
. . p

-DOCSTART- -20562617- O O

Hematologic NNP p
patients NNS p
' POS p
clinical JJ p
and CC p
psychosocial JJ p
experiences NNS p
with IN p
implanted JJ i
long-term JJ i
central JJ i
venous JJ i
catheter NN i
: : i
self-management JJ N
versus NN N
professionally RB N
controlled VBN N
care NN N
. . N

BACKGROUND VB N
A DT N
significant JJ N
decrease NN N
in IN N
catheter-related JJ N
infections NNS N
was VBD N
demonstrated VBN N
in IN N
our PRP$ N
earlier JJR N
randomized VBN N
controlled JJ N
trial NN N
of IN N
central JJ N
venous JJ N
catheter NN N
( ( N
CVC NNP N
) ) N
care NN N
in IN N
hematologic JJ p
patients NNS p
. . p

OBJECTIVE IN N
This DT N
article NN N
focuses VBZ N
on IN N
patients NNS N
' POS N
clinical JJ N
and CC N
psychosocial JJ N
experiences NNS N
with IN N
CVC NNP i
self-care NN i
compared VBN N
with IN N
professionally RB i
controlled VBN i
CVC NNP i
care NN i
. . i

METHODS NNP N
Eighty-two JJ p
patients NNS p
with IN p
tunneled JJ p
CVCs NNP p
were VBD N
enrolled VBN N
in IN N
the DT N
randomized NN N
controlled VBD N
trial NN N
. . N

The DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
was VBD N
trained VBN N
to TO N
perform VB N
CVC NNP i
self-care NN i
. . i

The DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
followed VBD N
standard JJ i
CVC NNP i
procedure NN i
provided VBN i
by IN i
nurses NNS i
. . i

Eighteen JJ N
patients NNS N
were VBD N
selected VBN N
for IN N
semistructured JJ N
interviews NNS N
focusing VBG N
on IN N
patients NNS N
' POS N
clinical JJ N
and CC N
psychosocial JJ N
experiences NNS N
with IN N
CVCs NNP N
. . N

RESULTS NNP N
Methods NNP N
of IN N
CVC NNP N
care NN N
have VBP N
different JJ N
influences NNS N
on IN N
the DT N
patients NNS N
' POS N
clinical JJ o
and CC o
psychosocial JJ o
outcomes NNS o
, , N
depending VBG N
on IN N
whether IN N
they PRP N
were VBD N
hospitalized VBN N
or CC N
outpatients NNS N
. . N

Central NNP i
venous JJ i
catheter NN i
was VBD N
viewed VBN N
as IN N
important JJ N
because IN N
it PRP N
was VBD N
the DT N
main JJ N
port NN N
of IN N
treatment NN N
toward IN N
a DT N
cure NN N
, , N
although IN N
patients NNS N
constantly RB N
fear VBP N
complications NNS N
. . N

Central NNP i
venous JJ i
catheter NN i
self-care NN i
increased VBD N
patients NNS o
' POS o
independence NN o
from IN N
health NN N
professionals NNS N
and CC N
supported VBD N
perceived VBN N
self-efficacy NN o
and CC N
control NN N
. . N

Central NNP N
venous JJ N
catheters NNS N
cause VBP N
psychosocial JJ o
problems NNS o
including VBG N
altered VBD o
body NN o
perception NN o
, , o
sexual JJ o
activity NN o
avoidance NN o
, , o
and CC o
feeling VBG o
stigmatized VBN o
. . o

CONCLUSIONS JJ N
Patients NNPS N
experience NN N
increased VBD N
perceived VBN o
self-control NN o
and CC o
independence NN o
when WRB N
individually RB N
supervised VBN N
and CC N
trained VBN N
in IN N
CVC NNP i
self-management NN i
. . i

Assuming VBG N
ownership NN N
of IN N
CVC NNP N
care NN N
can MD N
encourage VB N
patients NNS N
to TO N
feel VB N
less RB N
inhibited VBN N
about IN N
sexual JJ o
activity NN o
and CC o
socialization NN o
. . o

IMPLICATIONS NNP N
FOR NNP N
PRACTICE NNP N
Placement NNP N
of IN N
a DT N
tunneled JJ N
CVC NNP N
should MD N
engage VB N
nurses NNS N
to TO N
organize VB N
individualized JJ N
structured VBN N
and CC N
supervised VBN N
patient JJ N
education NN N
. . N

Stigma NNP N
originating VBG N
from IN N
CVCs NNP N
should MD N
be VB N
carefully RB N
considered VBN N
by IN N
health NN N
professionals NNS N
when WRB N
maintaining VBG N
CVC NNP N
insertion NN N
for IN N
longer JJR N
periods NNS N
. . N

Central NNP N
venous JJ N
catheters NNS N
should MD N
be VB N
removed VBN N
whenever WRB N
the DT N
potential JJ N
risks NNS N
exceed VBP N
the DT N
catheter NN N
's POS N
functional JJ N
necessity NN N
. . N

-DOCSTART- -15536093- O O

Syncope NNP p
Evaluation NNP N
in IN N
the DT N
Emergency NNP N
Department NNP N
Study NNP N
( ( N
SEEDS NNP N
) ) N
: : N
a DT N
multidisciplinary JJ N
approach NN N
to TO N
syncope VB p
management NN N
. . N

BACKGROUND VB N
The DT N
primary JJ N
aim NN N
and CC N
central JJ N
hypothesis NN N
of IN N
the DT N
study NN N
are VBP N
that IN N
a DT N
designated VBN N
syncope NN N
unit NN N
in IN N
the DT N
emergency NN N
department NN N
improves VBZ N
diagnostic JJ N
yield NN N
and CC N
reduces NNS N
hospital JJ N
admission NN N
for IN N
patients NNS p
with IN p
syncope NN p
who WP p
are VBP p
at IN p
intermediate JJ p
risk NN p
for IN p
an DT p
adverse JJ p
cardiovascular JJ p
outcome NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
single-center JJ p
study NN p
, , p
patients NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
2 CD N
treatment NN N
arms NNS N
: : N
syncope NN i
unit NN i
evaluation NN i
and CC i
standard NN i
care NN i
. . i

The DT N
2 CD N
groups NNS N
were VBD N
compared VBN N
with IN N
chi2 JJ N
test NN N
for IN N
independence NN N
of IN N
categorical JJ N
variables NNS N
. . N

Wilcoxon NNP N
rank VBD N
sum JJ N
test NN N
was VBD N
used VBN N
for IN N
continuous JJ N
variables NNS N
. . N

Survival NNP o
was VBD N
estimated VBN N
with IN N
the DT N
Kaplan-Meier NNP N
method NN N
. . N

One CD p
hundred VBD p
three CD p
consecutive JJ p
patients NNS p
( ( p
53 CD p
women NNS p
; : p
mean JJ p
age NN p
64+/-17 CD p
years NNS p
) ) p
entered VBD p
the DT p
study NN p
. . p

Fifty-one CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
syncope NN N
unit NN N
. . N

For IN N
the DT N
syncope NN N
unit NN N
and CC N
standard JJ N
care NN N
patients NNS N
, , N
the DT N
presumptive JJ o
diagnosis NN o
was VBD N
established VBN N
in IN N
34 CD N
( ( N
67 CD N
% NN N
) ) N
and CC N
5 CD N
( ( N
10 CD N
% NN N
) ) N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
hospital JJ o
admission NN o
was VBD N
required VBN N
for IN N
22 CD N
( ( N
43 CD N
% NN N
) ) N
and CC N
51 CD N
( ( N
98 CD N
% NN N
) ) N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
total JJ o
patient-hospital JJ o
days NNS o
were VBD N
reduced VBN N
from IN N
140 CD N
to TO N
64 CD N
. . N

Actuarial JJ o
survival NN o
was VBD N
97 CD N
% NN N
and CC N
90 CD N
% NN N
( ( N
P=0.30 NNP N
) ) N
, , N
and CC N
survival JJ o
free JJ o
from IN o
recurrent JJ o
syncope NN o
was VBD N
88 CD N
% NN N
and CC N
89 CD N
% NN N
( ( N
P=0.72 NNP N
) ) N
at IN N
2 CD N
years NNS N
for IN N
the DT N
syncope NN N
unit NN N
and CC N
standard JJ N
care NN N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
novel JJ N
syncope NN N
unit NN N
designed VBN N
for IN N
this DT N
study NN N
significantly RB N
improved VBN N
diagnostic JJ o
yield NN o
in IN N
the DT N
emergency NN N
department NN N
and CC N
reduced JJ N
hospital NN o
admission NN o
and CC N
total JJ o
length NN o
of IN o
hospital NN o
stay NN o
without IN N
affecting VBG N
recurrent NN N
syncope NN N
and CC N
all-cause JJ N
mortality NN o
among IN N
intermediate-risk JJ p
patients NNS p
. . p

Observations NNS N
from IN N
the DT N
present JJ N
study NN N
provide VBP N
benchmark NN N
data NNS N
for IN N
improving VBG N
patient NN N
care NN N
and CC N
effectively RB N
utilizing JJ N
healthcare JJ N
resources NNS N
. . N

-DOCSTART- -15610252- O O

B-type JJ i
natriuretic JJ i
peptide NN i
for IN N
acute JJ N
dyspnea NN N
in IN N
patients NNS p
with IN p
kidney JJ p
disease NN p
: : p
insights NNS N
from IN N
a DT N
randomized JJ N
comparison NN N
. . N

BACKGROUND NNP N
B-type NNP o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
levels NNS o
are VBP N
reliably RB N
elevated VBN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
and CC N
therefore RB N
helpful JJ N
in IN N
its PRP$ N
diagnosis NN N
. . N

However RB N
, , N
kidney FW N
disease NN N
results NNS N
in IN N
elevated JJ N
BNP NNP N
levels NNS N
independently RB N
of IN N
CHF NNP N
. . N

Accordingly RB N
, , N
the DT N
impact NN N
of IN N
kidney NN N
disease NN N
on IN N
the DT N
benefit NN N
of IN N
BNP NNP i
testing VBG N
needs NNS N
to TO N
be VB N
scrutinized VBN N
. . N

METHODS NNP N
This DT N
study NN N
evaluated VBD N
patients NNS p
with IN p
and CC p
without IN p
kidney NN p
disease NN p
[ NNP p
glomerular JJ p
filtration NN p
rate NN p
( ( p
GFR NNP p
) ) p
less JJR p
than IN p
60 CD p
mL/min/1.73 JJ p
m NN p
( ( p
2 CD p
) ) p
) ) p
presenting VBG p
with IN p
acute JJ p
dyspnea NN p
. . p

A DT N
total NN N
of IN N
452 CD p
consecutive JJ p
patients NNS p
( ( p
240 CD p
with IN p
kidney NN p
disease NN p
and CC p
212 CD p
without IN p
kidney NN p
disease NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
diagnostic JJ i
strategy NN i
with IN i
( ( i
BNP NNP i
group NN i
) ) i
or CC i
without IN i
( ( i
control NN i
group NN i
) ) i
the DT i
use NN i
of IN i
BNP NNP i
levels NNS i
provided VBN i
by IN i
a DT i
rapid JJ i
bedside NN i
assay NN i
. . i

RESULTS JJ N
Patients NNS p
with IN p
kidney JJ p
disease NN p
were VBD p
older JJR p
, , p
more RBR p
often RB p
had VBD p
CHF NNP o
as IN o
the DT o
cause NN o
of IN o
acute JJ o
dyspnea NN o
, , p
and CC p
more RBR p
often RB p
died JJ p
in-hospital JJ p
or CC p
within IN p
30 CD p
days NNS p
as RB p
compared VBN p
to TO p
patients NNS p
without IN p
kidney NN p
disease NN p
. . N

In IN N
patients NNS N
without IN N
kidney NN N
disease NN N
, , N
BNP NNP i
testing VBG i
significantly RB N
reduced VBN N
median JJ o
time NN o
to TO o
discharge VB o
( ( N
from IN N
9.5 CD N
days NNS N
to TO N
2.5 CD N
days NNS N
) ) N
( ( N
P= NNP N
0.003 CD N
) ) N
and CC N
total JJ o
cost NN o
of IN o
treatment NN o
( ( N
from IN N
7184 CD N
dollars NNS N
to TO N
4151 CD N
dollars NNS N
) ) N
( ( N
P= NNP N
0.004 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
in IN N
patients NNS N
with IN N
kidney NN N
disease NN N
, , N
time NN N
to TO N
discharge VB N
and CC N
total JJ N
cost NN N
of IN N
treatment NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
When WRB N
applying VBG N
BNP NNP i
cut-off NN N
values NNS N
without IN N
adjustment NN N
for IN N
the DT N
presence NN N
of IN N
kidney NN N
disease NN N
, , N
the DT N
use NN N
of IN N
BNP NNP o
levels NNS o
does VBZ N
significantly RB N
improve VB N
the DT N
management NN N
of IN N
patients NNS N
without IN N
kidney NN N
disease NN N
, , N
but CC N
not RB N
of IN N
those DT N
with IN N
kidney JJ N
disease NN N
. . N

-DOCSTART- -11045790- O O

Randomized VBN N
trial NN N
of IN N
fenretinide NN i
in IN N
superficial JJ p
bladder NN p
cancer NN p
using VBG N
DNA NNP N
flow JJ N
cytometry NN N
as IN N
an DT N
intermediate JJ N
end NN N
point NN N
. . N

Retinoids NNS N
have VBP N
shown VBN N
a DT N
potential JJ N
activity NN N
in IN N
preventing VBG N
tumor NN N
recurrence NN N
in IN N
superficial JJ p
bladder NN p
cancer NN p
. . p

We PRP N
assessed VBD N
the DT N
activity NN N
of IN N
the DT N
synthetic JJ i
retinoid NN i
fenretinide NN i
in IN N
superficial JJ N
bladder NN N
cancer NN N
using VBG N
DNA NNP N
flow JJ N
cytometry NN N
and CC N
conventional JJ N
cytology NN N
as IN N
surrogate JJ N
biomarkers NNS N
. . N

A DT N
total NN p
of IN p
99 CD p
subjects NNS p
with IN p
resected JJ p
superficial JJ p
bladder NN p
cancer NN p
( ( p
pTa NN p
, , p
pT1 NN p
) ) p
were VBD N
randomized VBN N
to TO N
either DT N
fenretinide NN i
( ( i
200 CD i
mg NNS i
day NN i
p.o NN i
. . i

for IN i
24 CD i
months NNS i
) ) i
or CC i
no DT i
intervention NN i
. . i

Cystoscopy NNP N
and CC N
bladder NN N
washing NN N
for IN N
DNA NNP N
flow NN N
cytometry NN N
end NN N
points NNS N
( ( N
proportion NN N
of IN N
DNA NNP N
aneuploid JJ N
histograms NN N
, , N
hyperdiploid JJ N
fraction NN N
, , N
and CC N
percentage NN N
of IN N
apoptotic JJ N
cells NNS N
) ) N
and CC N
proportion NN N
of IN N
abnormal JJ o
cytological JJ o
examinations NNS o
were VBD N
repeated VBN N
every DT N
4 CD N
months NNS N
for IN N
up IN N
to TO N
36 CD N
months NNS N
. . N

The DT N
primary JJ N
study NN N
end NN N
point NN N
was VBD N
the DT N
proportion NN o
of IN o
DNA NNP o
aneuploid JJ o
histograms NNS o
after IN N
12 CD N
months NNS N
. . N

This DT N
figure NN N
was VBD N
48.9 CD N
% NN N
in IN N
the DT N
fenretinide JJ i
arm NN N
and CC N
41.9 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
( ( N
odds NNS N
ratio NN N
, , N
1.16 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.44-3.07 JJ N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
any DT N
other JJ N
response NN o
biomarker NN o
between IN N
the DT N
two CD N
groups NNS N
up RB N
to TO N
36 CD N
months NNS N
, , N
nor CC N
was VBD N
any DT N
biomarker NN N
able JJ N
to TO N
predict VB N
recurrence NN N
risk NN N
. . N

Recurrence-free JJ o
survival NN o
was VBD N
comparable JJ N
between IN N
the DT N
arms NNS N
( ( N
27 CD N
events NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus NN N
21 CD N
in IN N
the DT N
control NN N
arm NN N
; : N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

Twelve NNP N
subjects VBZ N
in IN N
the DT N
fenretinide JJ N
arm NN N
complained VBD N
of IN N
diminished JJ N
dark NN o
adaptability NN o
, , N
and CC N
nine CD N
subjects NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus IN N
one CD N
control NN N
subject NN N
had VBD N
mild JJ o
dermatological JJ o
alterations NNS o
. . o

We PRP N
conclude VBP N
that DT N
fenretinide NN N
showed VBD N
a DT N
lack NN N
of IN N
effect NN N
on IN N
the DT N
DNA NNP N
content NN o
distribution NN o
and CC N
the DT N
morphology NN o
of IN o
urothelial JJ o
cells NNS o
obtained VBN N
in IN N
serial JJ N
bladder NN N
washings NNS N
. . N

Recurrence-free JJ o
survival NN o
was VBD N
comparable JJ N
between IN N
groups NNS N
. . N

Because IN N
our PRP$ N
data NNS N
are VBP N
hampered VBN N
by IN N
the DT N
lack NN N
of IN N
predictivity NN N
of IN N
the DT N
selected VBN N
biomarkers NNS N
, , N
additional JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
the DT N
activity NN N
of IN N
fenretinide NN N
in IN N
preventing VBG N
bladder NN p
cancer NN p
. . p

-DOCSTART- -18486741- O O

Active JJ N
symptom NN N
control NN N
with IN N
or CC N
without IN N
chemotherapy NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
malignant JJ p
pleural JJ p
mesothelioma NN p
( ( p
MS01 NNP p
) ) p
: : p
a DT N
multicentre NN N
randomised VBN N
trial NN N
. . N

BACKGROUND NNP N
Malignant NNP N
pleural JJ N
mesothelioma NN N
is VBZ N
almost RB N
always RB N
fatal JJ N
, , N
and CC N
few JJ N
treatment NN N
options NNS N
are VBP N
available JJ N
. . N

Although IN N
active JJ N
symptom NNS N
control NN N
( ( N
ASC NNP N
) ) N
has VBZ N
been VBN N
recommended VBN N
for IN N
the DT N
management NN N
of IN N
this DT N
disease NN N
, , N
no DT N
consensus NN N
exists VBZ N
for IN N
the DT N
role NN N
of IN N
chemotherapy NN N
. . N

We PRP N
investigated VBD N
whether IN N
the DT N
addition NN N
of IN N
chemotherapy NN N
to TO N
ASC NNP N
improved JJ N
survival NN o
and CC o
quality NN o
of IN o
life NN o
. . o

METHODS NNP N
409 CD p
patients NNS p
with IN p
malignant JJ p
pleural JJ p
mesothelioma NN p
, , p
from IN p
76 CD p
centres NNS p
in IN p
the DT p
UK NNP p
and CC p
two CD p
in IN p
Australia NNP p
, , N
were VBD N
randomly RB i
assigned VBN i
to TO i
ASC NNP i
alone RB i
( ( i
treatment NN i
could MD i
include VB i
steroids NNS i
, , i
analgesic JJ i
drugs NNS i
, , i
bronchodilators NNS i
, , i
palliative JJ i
radiotherapy NN i
[ NNP i
n=136 RB i
] NNP i
) ) i
; : i
to TO i
ASC NNP i
plus CC i
MVP NNP i
( ( i
four CD i
cycles NNS i
of IN i
mitomycin NN i
6 CD i
mg/m2 NN i
, , i
vinblastine VBP i
6 CD i
mg/m2 NN i
, , i
and CC i
cisplatin VBZ i
50 CD i
mg/m2 NN i
every DT i
3 CD i
weeks NNS i
[ JJ i
n=137 RB i
] NNP i
) ) i
; : i
or CC i
to TO i
ASC NNP i
plus CC i
vinorelbine NN i
( ( i
one CD i
injection NN i
of IN i
vinorelbine NN i
30 CD i
mg/m2 NN i
every DT i
week NN i
for IN i
12 CD i
weeks NNS i
[ JJ i
n=136 RB i
] NN i
) ) i
. . N

Randomisation NN N
was VBD N
done VBN N
by IN N
minimisation NN N
, , N
with IN N
stratification NN N
for IN N
WHO WP N
performance NN N
status NN N
, , N
histology NN N
, , N
and CC N
centre NN N
. . N

Follow-up NN i
was VBD i
every DT i
3 CD i
weeks NNS i
to TO i
21 CD i
weeks NNS i
after IN i
randomisation NN i
, , i
and CC i
every DT i
8 CD i
weeks NNS i
thereafter RB i
. . i

Because IN N
of IN N
slow JJ N
accrual NN N
, , N
the DT N
two CD N
chemotherapy NN N
groups NNS N
were VBD N
combined VBN N
and CC N
compared VBN N
with IN N
ASC NNP N
alone RB N
for IN N
the DT N
primary JJ N
outcome NN N
of IN N
overall JJ N
survival NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
, , N
number NN N
ISRCTN54469112 NNP N
. . N

FINDINGS NNP N
At IN N
the DT N
time NN N
of IN N
analysis NN N
, , N
393 CD N
( ( N
96 CD N
% NN N
) ) N
patients NNS N
had VBD N
died VBN o
( ( N
ASC NNP N
132 CD N
[ VBD N
97 CD N
% NN N
] NN N
, , N
ASC NNP N
plus CC N
MVP NNP N
132 CD N
[ VBD N
96 CD N
% NN N
] NN N
, , N
ASC NNP N
plus CC N
vinorelbine JJ N
129 CD N
[ JJ N
95 CD N
% NN N
] NN N
) ) N
. . N

Compared VBN N
with IN N
ASC NNP N
alone RB N
, , N
we PRP N
noted VBD N
a DT N
small JJ N
, , N
non-significant JJ o
survival NN o
benefit NN o
for IN N
ASC NNP N
plus CC N
chemotherapy NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] VBD N
0.89 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0.72-1.10 CD N
] NNP N
; : N
p=0.29 NN N
) ) N
. . N

Median JJ o
survival NN o
was VBD N
7.6 CD N
months NNS N
in IN N
the DT N
ASC NNP N
alone RB N
group NN N
and CC N
8.5 CD N
months NNS N
in IN N
the DT N
ASC NNP N
plus CC N
chemotherapy JJ N
group NN N
. . N

Exploratory NNP N
analyses VBZ N
suggested VBD N
a DT N
survival JJ o
advantage NN o
for IN N
ASC NNP N
plus CC N
vinorelbine JJ N
compared VBN N
with IN N
ASC NNP N
alone RB N
( ( N
HR NNP N
0.80 CD N
[ NNP N
0.63-1.02 JJ N
] NN N
; : N
p=0.08 NN N
) ) N
, , N
with IN N
a DT N
median JJ o
survival NN o
of IN N
9.5 CD N
months NNS N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
survival JJ o
benefit NN o
with IN N
ASC NNP N
plus CC N
MVP NNP N
( ( N
HR NNP N
0.99 CD N
[ NNP N
0.78-1.27 JJ N
] NN N
; : N
p=0.95 NN N
) ) N
. . N

We PRP N
observed VBD N
no DT N
between-group JJ N
differences NNS N
in IN N
four CD N
predefined VBD N
quality-of-life NN o
subscales NNS o
( ( o
physical JJ o
functioning NN o
, , o
pain NN o
, , o
dyspnoea NN o
, , o
and CC o
global JJ o
health NN o
status NN o
) ) o
at IN N
any DT N
of IN N
the DT N
assessments NNS N
in IN N
the DT N
first JJ N
6 CD N
months NNS N
. . N

INTERPRETATION NNP N
The DT N
addition NN N
of IN N
chemotherapy NN N
to TO N
ASC NNP N
offers VBZ N
no DT N
significant JJ N
benefits NNS N
in IN N
terms NNS N
of IN N
overall JJ N
survival NN o
or CC o
quality NN o
of IN o
life NN o
. . o

However RB N
, , N
exploratory JJ N
analyses NNS N
suggested VBD N
that IN N
vinorelbine NN N
merits NNS N
further JJ N
investigation NN N
. . N

-DOCSTART- -12886239- O O

Randomized NNP N
comparison NN N
of IN N
interferon NN i
alpha NN i
and CC i
hydroxyurea NN i
with IN N
hydroxyurea JJ N
monotherapy NN N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
CML-study NNP N
II NNP N
) ) N
: : N
prolongation NN N
of IN N
survival NN N
by IN N
the DT N
combination NN N
of IN N
interferon NN N
alpha NN N
and CC N
hydroxyurea NN N
. . N

The DT N
optimum JJ N
treatment NN N
conditions NNS N
of IN N
interferon NN i
( ( i
IFN NNP i
) ) i
alpha VBP i
therapy NN i
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
CML NNP N
) ) N
are VBP N
still RB N
controversial JJ N
. . N

To TO N
evaluate VB N
the DT N
role NN N
of IN N
hydroxyurea NN i
( ( i
HU NNP i
) ) i
for IN N
the DT N
outcome NN N
of IN N
IFN NNP i
therapy NN i
, , N
we PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
compare VB i
the DT i
combination NN i
of IN i
IFN NNP i
and CC i
HU NNP i
vs VBP i
HU NNP i
monotherapy NN i
( ( i
CML-study NNP i
II NNP i
) ) i
. . i

From IN p
February NNP p
1991 CD p
to TO p
December NNP p
1994 CD p
, , p
376 CD p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
CML NNP p
in IN p
chronic JJ p
phase NN p
were VBD N
randomized VBN N
. . N

In IN N
all DT N
, , N
340 CD p
patients NNS p
were VBD p
Ph/BCR-ABL NNP p
positive JJ p
and CC p
evaluable JJ p
. . p

Randomization NN N
was VBD N
unbalanced JJ N
1:2 CD N
in IN N
favor NN N
of IN N
the DT N
combination NN N
therapy NN N
, , N
since IN N
study NN N
conditions NNS N
were VBD N
identical JJ N
to TO N
the DT N
previous JJ N
CML-study NNP N
I PRP N
and CC N
it PRP N
had VBD N
been VBN N
planned VBN N
in IN N
advance NN N
to TO N
add VB N
the DT N
HU NNP N
patients NNS N
of IN N
study NN N
I PRP N
( ( N
n=194 RB N
) ) N
to TO N
the DT N
HU NNP N
control NN N
group NN N
. . N

Therefore RB N
, , N
a DT p
total NN p
of IN p
534 CD p
patients NNS p
were VBD p
evaluable JJ p
( ( p
226 CD p
patients NNS p
with IN p
IFN/HU NNP p
and CC p
308 CD p
patients NNS p
with IN p
HU NNP p
) ) p
. . p

Analyses NNS N
were VBD N
according VBG N
to TO N
intention-to-treat NN N
. . N

Median JJ N
observation NN N
time NN N
of IN N
nontransplanted JJ p
living NN p
patients NNS p
was VBD N
7.6 CD N
years NNS N
( ( N
7.9 CD N
years NNS N
for IN N
IFN/HU NNP N
and CC N
7.3 CD N
years NNS N
for IN N
HU NNP N
) ) N
. . N

The DT N
risk NN N
profile NN N
( ( N
new JJ N
CML NNP N
score NN N
) ) N
was VBD N
available JJ N
for IN N
532 CD N
patients NNS N
: : N
200 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
were VBD N
low JJ N
, , N
239 CD N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
intermediate NN N
, , N
and CC N
93 CD N
patients NNS N
( ( N
17 CD N
% NN N
) ) N
high JJ N
risk NN N
. . N

Complete NNP o
hematologic JJ o
response NN o
rates NNS o
were VBD N
higher JJR N
in IN N
IFN/HU-treated JJ N
patients NNS N
( ( N
59 CD N
vs RB N
32 CD N
% NN N
) ) N
. . N

Of IN N
169 CD N
evaluable JJ N
IFN/HU-treated JJ N
patients NNS N
( ( N
75 CD N
% NN N
) ) N
, , N
104 CD N
patients NNS N
( ( N
62 CD N
% NN N
) ) N
achieved VBD N
a DT N
cytogenetic JJ o
response NN o
that WDT N
was VBD N
complete JJ N
in IN N
12 CD N
% NN N
( ( N
n=21 JJ N
) ) N
, , N
major JJ N
in IN N
14 CD N
% NN N
( ( N
n=24 JJ N
) ) N
, , N
and CC N
at IN N
least JJS N
minimal JJ N
in IN N
35 CD N
% NN N
( ( N
n=59 JJ N
) ) N
. . N

Of IN N
the DT N
534 CD p
patients NNS p
, , N
105 CD N
( ( N
20 CD N
% NN N
) ) N
underwent NN N
allogeneic JJ N
stem NN N
cell NN N
transplantation NN N
in IN N
first JJ N
chronic JJ N
phase NN N
. . N

In IN N
the DT N
low-risk JJ N
group NN N
, , N
65 CD N
of IN N
200 CD N
patients NNS N
were VBD N
transplanted VBN N
( ( N
33 CD N
% NN N
) ) N
, , N
30 CD N
( ( N
13 CD N
% NN N
) ) N
in IN N
the DT N
intermediate-risk JJ N
group NN N
, , N
and CC N
nine CD N
( ( N
10 CD N
% NN N
) ) N
in IN N
the DT N
high-risk JJ N
group NN N
. . N

Duration NN o
of IN o
chronic JJ o
phase NN o
was VBD N
55 CD N
months NNS N
for IN N
IFN/HU NNP N
and CC N
41 CD N
months NNS N
for IN N
HU NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Median JJ o
survival NN o
was VBD N
64 CD N
months NNS N
for IN N
IFN/HU NNP N
and CC N
53 CD N
months NNS N
for IN N
HU-treated JJ N
patients NNS N
( ( N
P=0.0063 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
IFN NNP N
in IN N
combination NN N
with IN N
HU NNP N
achieves VBZ N
a DT N
significant JJ N
long-term JJ N
survival NN N
advantage NN N
over IN N
HU NNP N
monotherapy NN N
. . N

In IN N
view NN N
of IN N
the DT N
data NNS N
of IN N
CML-study NNP N
I PRP N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
IFN/HU NNP N
is VBZ N
also RB N
superior JJ N
to TO N
IFN NNP N
alone RB N
. . N

HU NNP N
should MD N
be VB N
combined VBN N
with IN N
IFN NNP N
in IN N
IFN-based JJ N
therapies NNS N
and CC N
for IN N
comparisons NNS N
with IN N
new JJ N
therapies NNS N
. . N

-DOCSTART- -3337028- O O

Iron NNP i
intake NN i
and CC i
iron NN i
nutritional JJ i
status NN i
of IN N
infants NNS p
fed VBN p
iron-fortified JJ i
beikost NN i
with IN i
meat NN i
. . i

We PRP N
compared VBN N
iron NNS N
intake NN N
and CC N
iron NN N
nutritional JJ N
status NN N
of IN N
two CD p
groups NNS p
of IN p
healthy JJ p
term NN p
infants NNS p
who WP p
received VBD p
meat-containing JJ i
baby NN i
foods NNS i
fortified VBN i
with IN i
ferrous JJ i
sulphate NN i
( ( p
2 CD p
mg NN p
Fe/100 NNP p
g NN p
) ) p
. . p

One CD N
group NN N
received VBD N
an DT N
Fe-fortified JJ i
formula NN i
( ( N
1.6 CD N
mg NN N
Fe/100 NNP N
kcal NN N
) ) N
and CC i
the DT i
other JJ i
a DT i
nonfortified JJ i
formula NN i
. . i

Fe NNP i
intake NN i
of IN N
the DT N
group NN N
fed VBD N
the DT N
nonfortified JJ N
formula NN N
was VBD N
significantly RB N
lower JJR N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

These DT N
infants NNS N
received VBD N
Fe NNP i
mainly RB i
from IN i
fortification NN i
Fe NNP i
with IN i
beikost NN i
( ( N
75-86 CD N
% NN N
) ) N
and CC N
less JJR N
than IN N
10 CD N
% NN N
met VBD N
the DT N
recommended JJ N
intake NN N
of IN N
1 CD N
mg.kg-1.d-1 NN N
; : N
whereas CC N
80-85 CD N
% NN N
of IN N
the DT N
infants NNS N
fed VBD N
the DT N
Fe-fortified NNP i
formula NN i
did VBD N
. . N

Hb NNP o
, , o
Hct NNP o
, , o
FEP NNP o
, , o
and CC o
ferritin NNS o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
with IN N
the DT N
exception NN N
of IN N
lower JJR N
ferritin NN N
values NNS N
at IN N
age NN N
365 CD N
d NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
in IN N
the DT N
group NN N
fed VBD N
the DT N
nonfortified JJ N
formula NN N
. . N

No DT N
infant NN N
had VBD N
hemoglobin NN o
less JJR N
than IN N
100 CD N
g/L NN N
. . N

We PRP N
conclude VBP N
that IN N
regular JJ N
consumption NN N
of IN N
commercially RB i
prepared JJ i
Fe-fortified JJ i
beikost NN i
with IN i
meat NN i
prevents NNS N
most RBS N
healthy JJ p
term NN p
infants NNS p
from IN N
Fe NNP N
deficiency NN N
even RB N
if IN N
Fe NNP N
intake NN N
is VBZ N
substantially RB N
below IN N
the DT N
recommended JJ N
intake NN N
. . N

-DOCSTART- -15188980- O O

Analgesic JJ N
effect NN N
of IN N
expressed VBN N
breast NN N
milk NN N
in IN N
procedural JJ N
pain NN N
in IN N
term NN p
neonates NNS p
: : p
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
trial NN N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
expressed VBN i
breast NN i
milk NN i
( ( N
EBM NNP N
) ) N
in IN N
reducing VBG N
pain NN o
due JJ N
to TO N
venepuncture NN N
, , N
in IN N
term NN N
neonates NNS N
, , N
as IN N
measured VBN N
by IN N
behavioural JJ o
and CC o
physiological JJ o
observations NNS o
. . o

METHODS NNP N
This DT N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
trial NN N
involved VBD N
81 CD p
full-term JJ p
neonates NNS p
, , p
up RB p
to TO p
4 CD p
wk NN p
of IN p
postnatal JJ p
age NN p
, , p
who WP p
needed VBD p
venepuncture NN p
for IN p
blood NN p
investigations NNS p
. . p

Two CD N
minutes NNS N
before IN N
the DT N
venepuncture NN i
, , N
in IN N
the DT N
intervention NN N
arm NN N
, , N
40 CD N
babies NNS N
received VBD N
5 CD N
ml NN N
of IN N
EBM NNP N
, , N
while IN N
41 CD N
babies NNS N
in IN N
control NN N
group NN N
received VBD N
5 CD i
ml NN i
of IN i
distilled JJ i
water NN i
( ( i
DW NNP i
) ) i
as IN i
placebo NN i
. . i

Two CD N
observers NNS N
who WP N
were VBD N
blinded VBN N
to TO N
the DT N
intervention NN N
recorded VBD N
the DT N
physiological JJ o
( ( o
heart NN o
rate NN o
and CC o
oxygen NN o
saturation NN o
) ) o
and CC o
behavioural JJ o
parameters NNS o
[ POS o
duration NN o
of IN o
crying VBG o
and CC o
modified VBN o
Neonatal NNP o
Facial NNP o
Coding NNP o
Scores NNP o
( ( o
NFCS NNP o
) ) o
] NN o
after IN N
the DT N
venepuncture NN i
. . i

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
baseline NN N
characteristics NNS N
of IN N
the DT N
neonates NNS N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
duration NN o
of IN o
crying NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
babies NNS N
fed VBP N
EBM NNP N
[ NNP N
median JJ N
38.5 CD N
s NN N
, , N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
9.5-57.5 CD N
s NN N
] NN N
than IN N
in IN N
those DT N
fed VBN N
DW NNP N
( ( N
median JJ N
90 CD N
s NN N
, , N
IQR NNP N
28-210 CD N
s NN N
) ) N
. . N

The DT N
mean JJ o
duration NN o
of IN o
crying VBG o
in IN N
EBM NNP i
group NN N
was VBD N
shorter JJR N
by IN N
70.7 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
36.6-104.9 JJ N
) ) N
s. VBZ N
The DT N
modified JJ o
NFCS NNP o
at IN N
0 CD N
, , N
1 CD N
and CC N
3 CD N
min NN N
was VBD N
significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
in IN N
the DT N
EBM NNP i
than IN N
in IN N
the DT N
DW NNP N
group NN N
. . N

The DT N
change NN o
in IN o
heart NN o
rate NN o
and CC o
oxygen NN o
saturation NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
EBM NNP i
group NN N
and CC N
returned VBN N
to TO N
baseline VB N
values NNS N
sooner JJR N
than IN N
in IN N
the DT N
DW NNP N
group NN N
. . N

CONCLUSION NNP N
Feeding VBG N
5 CD N
ml NN N
of IN N
EBM NNP i
before IN N
venepuncture NN i
is VBZ N
effective JJ N
in IN N
reducing VBG N
symptoms NNS o
due JJ N
to TO N
pain VB p
in IN p
term NN p
neonates NNS p
. . p

-DOCSTART- -9683043- O O

White NNP N
coat NN N
effect NN N
detected VBD N
using VBG N
self-monitoring NN i
of IN i
blood NN i
pressure NN i
at IN i
home NN i
: : i
comparison NN N
with IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
home NN o
blood NN o
pressure NN o
( ( i
HBP NNP i
) ) i
is VBZ N
a DT N
reliable JJ N
alternative NN N
to TO N
ambulatory VB i
blood NN o
pressure NN o
( ( i
ABP NNP i
) ) i
for IN N
the DT N
detection NN N
of IN N
the DT N
white JJ N
coat NN N
effect NN N
( ( N
WCE NNP N
) ) N
. . N

Hypertensive JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
measure VB N
HBP NNP i
for IN N
2 CD N
weeks NNS N
or CC N
ABP NNP i
for IN N
24 CD N
h. PDT N
The DT N
alternative JJ N
measurement NN N
was VBD N
then RB N
performed VBN N
. . N

Clinic NNP o
blood NN o
pressure NN o
( ( o
CBP NNP o
) ) o
was VBD N
measured VBN N
in IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

Subjects NNS p
with IN p
a DT p
difference NN p
of IN p
> NN p
or CC p
= $ p
20 CD p
mm NN p
Hg NNP p
systolic NN p
or CC p
> NN p
or CC p
= $ p
10 CD p
mm NN p
Hg NNP p
diastolic VBZ p
BP NNP p
between IN p
CBP NNP p
and CC p
awake VB p
ABP NNP i
or CC p
CBP NNP i
and CC p
HBP NNP i
, , N
were VBD N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
. . N

A DT p
total NN p
of IN p
189 CD p
patients NNS p
completed VBD p
the DT p
study NN p
( ( p
79 CD p
on IN p
stable JJ p
antihypertensive JJ p
treatment NN p
) ) p
. . p

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
magnitude NN N
of IN N
WCE NNP o
assessed VBD N
using VBG N
the DT N
ABP NNP o
or CC N
the DT N
HBP NNP o
method NN N
( ( N
mean JJ N
discrepancy NN N
, , N
systolic JJ o
BP NNP o
: : o
-1.5 JJ N
+/- JJ N
11.7 CD N
mm NN N
Hg NNP N
, , N
95 CD N
% NN N
CI NNP N
-3.2 NNP N
, , N
0.2 CD N
; : N
diastolic JJ o
BP NNP o
: : o
0.9 CD N
+/- JJ N
7.0 CD N
, , N
95 CD N
% NN N
CI NNP N
-0.1 NNP N
, , N
1.9 CD N
) ) N
. . N

A NNP N
strong JJ N
association NN N
existed VBD N
between IN N
WCE NNP o
calculated VBD N
using VBG N
the DT N
HBP NNP o
or CC N
the DT N
ABP NNP o
method NN N
( ( N
r VB N
= RB N
0.64/0.59 CD N
systolic/diastolic JJ N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
classified VBN N
as IN N
clinic JJ o
reactors NNS o
was VBD N
identical JJ N
using VBG N
the DT N
HBP NNP i
or CC N
the DT N
ABP NNP i
method NN N
( ( N
25.9 CD N
% NN N
) ) N
. . N

Agreement NN N
between IN N
methods NNS N
in IN N
the DT N
classification NN N
of IN N
clinic JJ N
reactors NNS N
was VBD N
found VBN N
in IN N
147 CD N
patients NNS N
( ( N
78 CD N
% NN N
) ) N
. . N

The DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
the DT N
HBP NNP i
method NN N
to TO N
classify VB N
correctly RB N
clinic JJ o
reactors NNS o
( ( i
ABP NNP i
method RB N
used VBD N
as IN N
the DT N
standard NN N
) ) N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
, , N
respectively RB N
, , N
whereas VBD N
its PRP$ N
positive JJ N
and CC N
negative JJ N
predictive JJ N
value NN N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
HBP NNP o
is VBZ N
not RB N
appropriate JJ N
as IN N
an DT N
alternative NN N
to TO N
ABP NNP i
diagnostic JJ N
testing NN N
in IN N
the DT N
detection NN N
of IN N
WCE NNP N
. . N

Nevertheless NNP N
, , N
HBP NNP o
appears VBZ N
useful JJ N
as IN N
a DT N
screening JJ N
test NN N
for IN N
the DT N
detection NN N
of IN N
this DT N
phenomenon NN N
. . N

-DOCSTART- -20048611- O O

Evaluation NN N
of IN N
a DT N
new JJ N
wound NN N
closure NN N
device NN N
for IN N
linear JJ p
surgical JJ p
incisions NNS p
: : p
3M CD i
Steri-Strip JJ i
S NNP i
Surgical NNP i
Skin NNP i
Closure NNP i
versus IN i
subcuticular JJ i
closure NN i
. . i

BACKGROUND NNP N
Technological JJ N
innovations NNS N
are VBP N
often RB N
adopted VBN N
before IN N
scientific JJ N
comparison NN N
to TO N
an DT N
accepted JJ N
standard NN N
. . N

The DT N
authors NNS N
' POS N
study NN N
compared VBN N
suture NN N
with IN N
a DT N
new JJ i
coaptive JJ i
film NN i
device NN i
, , i
3M CD i
Steri-Strip JJ i
S NNP i
Surgical NNP i
Skin NNP i
Closure NNP i
, , i
on IN i
linear JJ i
incisions NNS i
. . i

METHODS NNP N
Patients NNPS p
undergoing VBG p
Wise-pattern JJ p
breast NN p
reduction NN p
or CC p
abdominal JJ p
procedures NNS p
had VBD N
paired VBN N
incisions NNS N
randomly RB N
assigned VBN N
to TO N
Steri-Strip NNP i
S NNP i
or CC i
suture JJ i
closure NN i
. . i

Key NNP N
outcome JJ N
measures NNS N
were VBD N
closure JJ o
time NN o
, , o
patient JJ o
comfort NN o
, , o
and CC o
scar NN o
quality NN o
at IN N
6 CD N
months NNS N
by IN N
patients NNS N
and CC N
surgeons NNS N
using VBG N
a DT N
new JJ i
scar NN i
evaluation NN i
tool NN i
, , N
visual JJ N
assessment NN N
of IN N
linear JJ N
scars NNS N
. . N

Statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
closure NN N
techniques NNS N
were VBD N
assessed VBN N
by IN N
Wilcoxon NNP N
signed VBD N
rank JJ N
test NN N
. . N

RESULTS NNP N
Of IN p
59 CD p
patients NNS p
, , p
eight CD p
were VBD p
excluded VBN p
from IN p
randomization NN p
( ( N
a DT N
surgeon NN N
judged VBN N
Steri-Strip NNP N
S NNP N
to TO N
be VB N
a DT N
nonviable JJ N
closure NN N
technique NN N
for IN N
mismatched VBN N
wound NN N
edges NNS N
) ) N
. . N

Fifty-one CD p
patients NNS p
( ( p
breast NN p
, , p
n JJ p
= VBP p
24 CD p
; : p
abdomen NNS p
, , p
n JJ p
= NNP p
27 CD p
) ) p
were VBD N
randomized VBN N
. . N

Operative JJ o
time NN o
with IN N
Steri-Strip NNP i
S NNP i
for IN N
breast NN N
was VBD N
2.0 CD N
minutes NNS N
( ( N
SD NNP N
= NNP N
1.1 CD N
) ) N
versus NN N
suture NN i
closure NN i
at IN N
4.6 CD N
minutes NNS N
( ( N
SD NNP N
= NNP N
1.5 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
. . N

Similarly RB N
, , N
Steri-Strip NNP N
S NNP N
versus NN N
suture NN N
for IN N
the DT N
abdomen NNS N
was VBD N
faster RBR o
( ( N
p JJ N
< VBZ N
0.001 CD N
; : N
4.9 CD N
minutes NNS N
, , N
SD NNP N
= VBZ N
2.3 CD N
versus NN N
10.1 CD N
minutes NNS N
, , N
SD NNP N
= NNP N
3.4 CD N
) ) N
. . N

Comfort NNP o
scores NNS o
did VBD N
not RB N
differ VB N
between IN N
closures NNS N
[ VBP N
5.8 CD N
( ( N
SD NNP N
= NNP N
2.7 CD N
) ) N
versus NN N
6.9 CD N
( ( N
SD NNP N
= NNP N
2.0 CD N
) ) N
, , N
respectively RB N
, , N
on IN N
breast NN N
( ( N
p JJ N
= NNP N
0.142 CD N
) ) N
and CC N
7.7 CD N
( ( N
SD NNP N
= NNP N
1.8 CD N
) ) N
versus NN N
7.7 CD N
( ( N
SD NNP N
= NNP N
2.3 CD N
) ) N
on IN N
abdomen NNS N
( ( N
p JJ N
= NNP N
0.903 CD N
) ) N
] NN N
. . N

Complication NN o
rates NNS o
did VBD N
not RB N
differ VB N
between IN N
closure NN N
types NNS N
. . N

Patients NNS o
' POS o
visual JJ o
assessment NN o
of IN o
linear JJ o
scars NNS o
rating NN o
of IN o
breasts NNS o
was VBD N
3.8 CD N
( ( N
SD NNP N
= NNP N
2.9 CD N
) ) N
for IN N
Steri-Strip NNP N
S NNP N
and CC N
better JJR N
at IN N
2.6 CD N
( ( N
SD NNP N
= NNP N
2.9 CD N
) ) N
for IN N
suture NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

One CD N
surgeon NN N
rated VBN N
breast IN N
Steri-Strip NNP N
S NNP N
scars VBZ N
worse JJR N
than IN N
suture NN N
scars NNS N
( ( N
4.3 CD N
versus NN N
3.7 CD N
; : N
p NN N
= VBZ N
0.014 CD N
) ) N
. . N

For IN N
abdominal JJ N
scars NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
patient NN N
or CC N
surgeon NN N
ratings NNS N
. . N

CONCLUSIONS NNP N
Steri-Strip NNP i
S NNP i
permits VBZ N
faster JJR N
wound IN o
closure NN o
than IN N
suture NN i
. . i

On IN N
the DT N
basis NN N
of IN N
patient JJ N
reports NNS N
of IN N
comfort NN o
and CC o
scar NN o
quality NN o
, , N
surgeons NNS N
increase VBP N
efficiency NN o
and CC N
maintain VBP N
quality NN o
with IN N
the DT N
use NN N
of IN N
Steri-Strip NNP N
S NNP N
on IN N
abdominal JJ N
wounds NNS N
but CC N
not RB N
on IN N
breast NN N
wounds NNS N
. . N

-DOCSTART- -15206990- O O

Single NNP N
and CC N
short-term JJ N
dosing NN N
effects NNS N
of IN N
levocetirizine NN i
on IN N
adenosine JJ N
monophosphate NN N
bronchoprovocation NN N
in IN N
atopic NN N
asthma NN N
. . N

AIMS NNP N
Adenosine NNP N
monophosphate NN N
( ( N
AMP NNP N
) ) N
acts VBZ N
indirectly RB N
via IN N
primed VBN N
airway RB N
mast JJ N
cells NNS N
to TO N
induce VB N
bronchial JJ N
hyper-responsiveness NN N
, , N
which WDT N
in IN N
turn NN N
correlates NNS N
with IN N
eosinophilic JJ o
asthmatic JJ o
inflammation NN o
and CC o
atopic JJ o
disease NN o
expression NN o
. . o

We PRP N
evaluated VBD N
single JJ N
and CC N
short-term JJ N
dosing NN N
effects NNS N
of IN N
a DT N
modern JJ N
histamine NN N
H1-receptor NNP N
antagonist NN N
, , N
levocetirizine NN i
, , N
given VBN N
at IN N
the DT N
usual JJ N
clinically RB N
recommended VBD N
dose NN N
, , N
on IN N
the DT N
primary JJ N
outcome NN N
of IN N
AMP NNP N
bronchoprovocation NN N
. . N

METHODS NNP N
Fifteen NNP p
atopic NN p
asthmatics NNS p
were VBD p
randomized VBN p
in IN p
double-blind NN p
, , p
cross-over JJ p
fashion NN p
to TO p
receive VB p
for IN p
1 CD p
week NN p
either CC p
levocetirizine JJ i
5 CD i
mg NN i
or CC i
placebo NN i
. . i

There EX N
was VBD N
a DT N
1-week JJ N
washout NN N
period NN N
prior RB N
to TO N
each DT N
randomized VBN N
treatment NN N
. . N

The DT N
provocative JJ N
concentration NN N
of IN N
AMP NNP N
producing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV1 NNP N
( ( N
PC20 NNP N
) ) N
was VBD N
measured VBN N
after IN N
each DT N
washout NN N
at IN N
baseline NN N
and CC N
at IN N
4-6 JJ N
h NN N
following VBG N
the DT N
first JJ N
and CC N
last JJ N
doses NNS N
of IN N
each DT N
randomized VBN N
treatment NN N
. . N

RESULTS NNP N
Baseline NNP N
mean JJ o
+/- JJ o
SEM NNP o
values NNS o
after IN N
washout NN N
prior RB N
to TO N
each DT N
randomized VBN N
treatment NN N
comparing VBG N
levocetirizine JJ i
vs NN N
placebo NN i
were VBD N
not RB N
significantly RB N
different JJ N
for IN N
prechallenge NN N
FEV1 NNP o
( ( N
% NN N
predicted VBN N
) ) N
83 CD N
+/- JJ N
4 CD N
vs JJ N
82 CD N
+/- JJ N
4 CD N
, , N
or CC N
AMP NNP o
PC20 NNP o
( ( N
mg JJ N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
45 CD N
+/- JJ N
24 CD N
vs JJ N
45 CD N
+/- JJ N
22 CD N
, , N
respectively RB N
. . N

Airway NNP o
calibre NN o
as IN o
prechallenge NN o
FEV1 NNP o
for IN N
levocetirizine JJ i
vs NN N
placebo NN i
was VBD N
not RB N
significantly RB N
different JJ N
following VBG N
the DT N
first JJ N
dose JJ N
86 CD N
+/- JJ N
4 CD N
vs JJ N
82 CD N
+/- JJ N
4 CD N
, , N
or CC N
the DT N
last JJ N
dose JJ N
85 CD N
+/- JJ N
4 CD N
vs JJ N
83 CD N
+/- JJ N
4 CD N
, , N
respectively RB N
. . N

There EX N
were VBD N
significant JJ N
improvements NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
AMP NNP o
PC20 NNP o
comparing VBG N
levocetirizine JJ N
vs NN N
placebo NN N
following VBG N
the DT N
first JJ N
dose JJ N
123 CD N
+/- JJ N
73 CD N
vs JJ N
48 CD N
+/- JJ N
24 CD N
, , N
a DT N
1.4 CD N
doubling VBG N
dilution NN N
difference NN N
( ( N
95 CD N
% NN N
CI NNP N
0.8 CD N
, , N
1.9 CD N
) ) N
, , N
and CC N
the DT N
last JJ N
dose JJ N
127 CD N
+/- JJ N
74 CD N
vs JJ N
53 CD N
+/- JJ N
29 CD N
, , N
a DT N
1.2 CD N
doubling VBG N
dilution NN N
difference NN N
( ( N
95 CD N
% NN N
CI NNP N
0.5 CD N
, , N
2.0 CD N
) ) N
. . N

AMP NNP o
PC20 NNP o
was VBD N
also RB N
improved VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
by IN N
the DT N
first JJ N
and CC N
last JJ N
doses NNS N
of IN N
levocetirizine NN N
but CC N
not RB N
placebo VB N
, , N
vs FW N
respective JJ N
baseline NN N
values NNS N
, , N
with IN N
there EX N
being VBG N
no DT N
difference NN N
in IN N
the DT N
degree NN N
of IN N
protection NN N
between IN N
first JJ N
and CC N
last JJ N
doses NNS N
. . N

CONCLUSIONS NNP N
Single NNP N
and CC N
short-term JJ N
dosing NN N
with IN N
levocetirizine NN i
conferred VBN N
similar JJ N
improvements NNS N
in IN N
bronchial JJ o
hyper-responsiveness NN o
to TO o
AMP NNP o
challenge NN N
, , N
which WDT N
was VBD N
unrelated JJ N
to TO N
prechallenge VB N
airway RB N
calibre NN N
. . N

Further JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
the DT N
longer-term JJ N
effects NNS N
of IN N
levocetirizine NN i
on IN N
asthma JJ o
exacerbations NNS o
. . o

-DOCSTART- -21226576- O O

Treatment NN N
of IN N
acute NN p
otitis NN p
media NNS p
in IN p
children NNS p
under IN p
2 CD p
years NNS p
of IN p
age NN p
. . p

BACKGROUND NNP N
Recommendations NNP N
vary VBP N
regarding VBG N
immediate JJ i
antimicrobial JJ i
treatment NN i
versus NN i
watchful JJ i
waiting VBG i
for IN N
children NNS p
younger JJR p
than IN p
2 CD p
years NNS p
of IN p
age NN p
with IN p
acute JJ p
otitis NN p
media NNS p
. . p

METHODS NNP N
We PRP N
randomly VBP N
assigned VBN N
291 CD p
children NNS p
6 CD p
to TO p
23 CD p
months NNS p
of IN p
age NN p
, , p
with IN p
acute JJ p
otitis NN p
media NNS p
diagnosed VBN p
with IN p
the DT p
use NN p
of IN p
stringent NN p
criteria NNS p
, , N
to TO N
receive VB N
amoxicillin-clavulanate NN i
or CC i
placebo NN i
for IN N
10 CD N
days NNS N
. . N

We PRP N
measured VBD N
symptomatic JJ o
response NN o
and CC o
rates NNS o
of IN o
clinical JJ o
failure NN o
. . o

RESULTS NNP N
Among IN N
the DT N
children NNS N
who WP N
received VBD N
amoxicillin-clavulanate NN i
, , N
35 CD N
% NN N
had VBD N
initial JJ o
resolution NN o
of IN o
symptoms NNS o
by IN N
day NN N
2 CD N
, , N
61 CD N
% NN N
by IN N
day NN N
4 CD N
, , N
and CC N
80 CD N
% NN N
by IN N
day NN N
7 CD N
; : N
among IN N
children NNS N
who WP N
received VBD N
placebo NN i
, , N
28 CD N
% NN N
had VBD N
initial JJ N
resolution NN N
of IN N
symptoms NNS N
by IN N
day NN N
2 CD N
, , N
54 CD N
% NN N
by IN N
day NN N
4 CD N
, , N
and CC N
74 CD N
% NN N
by IN N
day NN N
7 CD N
( ( N
P=0.14 NNP N
for IN N
the DT N
overall JJ N
comparison NN N
) ) N
. . N

For IN N
sustained JJ N
resolution NN N
of IN N
symptoms NNS N
, , N
the DT N
corresponding JJ N
values NNS N
were VBD N
20 CD N
% NN N
, , N
41 CD N
% NN N
, , N
and CC N
67 CD N
% NN N
with IN N
amoxicillin-clavulanate JJ i
, , N
as IN N
compared VBN N
with IN N
14 CD N
% NN N
, , N
36 CD N
% NN N
, , N
and CC N
53 CD N
% NN N
with IN N
placebo NN i
( ( N
P=0.04 NNP N
for IN N
the DT N
overall JJ N
comparison NN N
) ) N
. . N

Mean JJ o
symptom NN o
scores NNS o
over IN N
the DT N
first JJ N
7 CD N
days NNS N
were VBD N
lower JJR N
for IN N
the DT N
children NNS N
treated VBN N
with IN N
amoxicillin-clavulanate JJ i
than IN N
for IN N
those DT N
who WP N
received VBD N
placebo NN i
( ( N
P=0.02 NNP N
) ) N
. . N

The DT N
rate NN o
of IN o
clinical JJ o
failure NN o
-- : o
defined VBD o
as IN N
the DT N
persistence NN N
of IN N
signs NNS N
of IN N
acute JJ o
infection NN o
on IN o
otoscopic JJ o
examination NN o
-- : o
was VBD o
also RB N
lower JJR N
among IN N
the DT N
children NNS N
treated VBN N
with IN N
amoxicillin-clavulanate JJ i
than IN N
among IN N
those DT N
who WP N
received VBD N
placebo NN i
: : i
4 CD N
% NN N
versus IN N
23 CD N
% NN N
at IN N
or CC N
before IN N
the DT N
visit NN N
on IN N
day NN N
4 CD N
or CC N
5 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
16 CD N
% NN N
versus IN N
51 CD N
% NN N
at IN N
or CC N
before IN N
the DT N
visit NN N
on IN N
day NN N
10 CD N
to TO N
12 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Mastoiditis NNP o
developed VBD N
in IN N
one CD N
child NN N
who WP N
received VBD N
placebo NN i
. . i

Diarrhea NNP o
and CC o
diaper-area JJ o
dermatitis NN o
were VBD N
more JJR N
common JJ N
among IN N
children NNS N
who WP N
received VBD N
amoxicillin-clavulanate NN i
. . i

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
either DT N
group NN N
in IN N
the DT N
rates NNS N
of IN N
nasopharyngeal JJ o
colonization NN o
with IN N
nonsusceptible JJ N
Streptococcus NNP N
pneumoniae NN N
. . N

CONCLUSIONS NNP N
Among IN N
children NNS p
6 CD p
to TO p
23 CD p
months NNS p
of IN p
age NN p
with IN p
acute JJ p
otitis NN p
media NNS p
, , N
treatment NN N
with IN N
amoxicillin-clavulanate NN i
for IN N
10 CD N
days NNS N
tended VBD N
to TO N
reduce VB N
the DT N
time NN N
to TO N
resolution NN N
of IN N
symptoms NNS N
and CC N
reduced VBD N
the DT N
overall JJ N
symptom NN N
burden NN N
and CC N
the DT N
rate NN N
of IN N
persistent JJ N
signs NNS N
of IN N
acute JJ N
infection NN N
on IN N
otoscopic JJ N
examination NN N
. . N

( ( N
Funded VBN N
by IN N
the DT N
National NNP N
Institute NNP N
of IN N
Allergy NNP N
and CC N
Infectious NNP N
Diseases NNP N
; : N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00377260 NNP N
. . N

) ) N
. . N

-DOCSTART- -15625713- O O

Group-based JJ N
HIV NNP i
risk NN i
reduction NN i
intervention NN i
for IN N
adolescent JJ p
girls NNS p
: : p
evidence NN N
of IN N
feasibility NN N
and CC N
efficacy NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
( ( N
a DT N
) ) N
to TO N
assess VB N
the DT N
feasibility NN o
of IN N
a DT N
community-based JJ i
, , i
small JJ i
group NN i
HIV NNP i
risk NN i
reduction NN i
intervention NN i
with IN N
adolescent JJ p
girls NNS p
, , N
and CC N
( ( N
b NN N
) ) N
to TO N
obtain VB N
preliminary JJ N
evidence NN N
of IN N
the DT N
efficacy NN o
of IN N
this DT N
theoretically-guided JJ i
intervention NN i
using VBG N
a DT N
controlled JJ N
design NN N
. . N

The DT N
feasibility NN N
of IN N
the DT N
intervention NN N
was VBD N
demonstrated VBN N
by IN N
successfully RB N
implementing VBG N
it PRP N
with IN N
33 CD p
sexually-active JJ p
, , p
single JJ p
girls NNS p
. . p

Preliminary JJ N
evidence NN N
of IN N
the DT N
efficacy NN N
of IN N
the DT N
intervention NN N
was VBD N
obtained VBN N
using VBG N
a DT N
randomized JJ N
trial NN N
with IN N
62 CD p
sexually-active JJ p
, , p
single JJ p
girls NNS p
. . p

Data NNS N
obtained VBD N
at IN N
a DT N
3-month JJ N
follow-up JJ N
assessment NN N
showed VBD N
that IN N
girls NNS p
who WP N
received VBD N
the DT N
HIV-related JJ i
intervention NN i
improved VBD o
their PRP$ o
HIV-related JJ o
knowledge NN o
and CC N
enhanced VBD N
their PRP$ N
motivation NN o
for IN o
risk NN o
reduction NN o
compared VBN N
to TO N
girls NNS N
who WP N
received VBD N
a DT N
control NN i
( ( i
health NN i
promotion NN i
) ) i
intervention NN i
. . i

Effect JJ o
sizes VBZ N
suggest VBP N
that IN N
the DT N
HIV NNP i
intervention NN i
also RB N
reduced VBD o
several JJ o
risk NN o
behaviors NNS o
( ( o
e.g. NN o
, , N
vaginal JJ o
sex NN o
without IN o
a DT o
condom NN o
, , o
giving VBG o
oral JJ o
sex NN o
, , o
and CC o
alcohol NN o
and CC o
drug NN o
use NN o
before IN o
sex NN o
) ) o
. . N

Challenges VBZ N
to TO N
implementation NN N
and CC N
suggestions NNS N
for IN N
intervention NN N
enhancement NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -18080171- O O

Risperidone NNP i
versus NN i
haloperidol NN i
in IN p
children NNS p
and CC p
adolescents NNS p
with IN p
AD NNP p
: : N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind JJ N
trial NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
safety NN o
, , o
efficacy NN o
and CC o
tolerability NN o
of IN N
risperidone NN i
with IN i
haloperidol NN i
in IN N
the DT N
treatment NN N
of IN N
Autistic JJ p
Disorder NNP p
( ( p
AD NNP p
) ) p
. . N

METHOD NNP N
This DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
for IN N
a DT N
12-week JJ N
period NN N
. . N

A DT p
total NN p
of IN p
30 CD p
subjects NNS p
, , p
between IN p
the DT p
ages NNS p
of IN p
8 CD p
and CC p
18 CD p
with IN p
AD NNP p
based VBN p
on IN p
DSM NNP p
IV NNP p
criteria NNS p
, , p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Behavioral NNP o
Rating VBG o
Scales NNS o
were VBD N
performed VBN N
by IN N
the DT N
investigators NNS N
and CC N
the DT N
parents NNS N
. . N

Safety NNP o
assessment NN o
included VBD N
vital JJ o
signs NNS o
, , o
electrocardiogram NN o
, , o
electroencephalogram NN o
, , o
adverse JJ o
events NNS o
, , o
laboratory NN o
tests NNS o
, , o
extrapyramidal NN o
symptoms NNS o
and CC o
the DT o
side NN o
effects NNS o
. . o

Both DT N
treatments NNS N
were VBD N
applied VBN N
in IN N
a DT N
once RB N
daily JJ N
dosage NN N
regimen NNS N
of IN N
0.01-0.08 JJ N
mg/kg/day NN N
. . N

RESULTS VB N
The DT N
reduction NN N
from IN N
baseline NN N
in IN N
Ritvo-Freeman NNP o
Real NNP o
Life NNP o
Rating NNP o
Scale NNP o
( ( o
RF-RLRS NNP o
) ) o
, , o
sensory JJ o
motor NN o
( ( o
subscale JJ o
I PRP o
) ) o
and CC o
language NN o
( ( o
subscale JJ o
V NNP o
) ) o
scores NNS o
were VBD N
significant JJ N
in IN N
risperidone NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
to TO N
haloperidol VB N
, , N
risperidone NN N
led VBD N
to TO N
a DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
and CC o
Turgay NNP o
DSM-IV NNP o
Pervasive NNP o
Developmental NNP o
Disorder NNP o
( ( o
PDD NNP o
) ) o
scale NN o
scores NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
greater JJR N
increase NN N
of IN N
prolactin NN o
in IN N
the DT N
risperidone NN N
group NN N
, , N
while IN N
alanine JJ o
amino NN o
transferase NN o
( ( o
ALT NNP o
) ) o
had VBD N
further RBR N
increased VBN N
in IN N
the DT N
haloperidol NN N
group NN N
. . N

Sensory NNP o
motor NN o
behaviors NNS o
( ( o
subscale JJ o
I PRP o
) ) o
and CC N
language NN o
at IN N
the DT N
end NN N
of IN N
the DT N
12th CD N
week NN N
, , N
RF-RLRS NNP o
sensory NN o
motor NN o
and CC o
language NN o
subscale JJ o
scores NNS o
decreased VBN N
in IN N
the DT N
risperidone NN N
group NN N
further RBR N
than IN N
the DT N
other JJ N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Risperidone NNP N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
haloperidol NN N
in IN N
the DT N
treatment NN N
of IN N
behavioral JJ o
symptoms NNS o
, , o
impulsivity NN o
, , o
language NN o
skills NNS o
, , N
and CC N
impaired JJ o
social JJ o
relations NNS o
in IN N
children NNS p
with IN p
AD NNP p
. . p

These DT N
results NNS N
demonstrated VBD N
that IN N
both DT N
drugs NNS N
were VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
AD NNP N
. . N

-DOCSTART- -7966066- O O

Osteocalcin NNP i
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
. . p

A DT N
one-year JJ N
followup NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
analyze VB N
clinical JJ N
, , N
radiological JJ N
, , N
and CC N
drug NN N
( ( N
disease NN N
modifying VBG N
antirheumatic JJ N
drug NN N
, , N
DMARD NNP N
) ) N
dependent NN N
factors NNS N
influencing VBG N
bone NN N
turnover NN N
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
. . p

METHODS NNP N
We PRP N
investigated VBD N
in IN N
a DT N
one-year JJ N
double JJ N
blind NN N
randomized VBD N
study NN N
comparing VBG N
intramuscular JJ i
( ( i
im NN i
) ) i
gold NN i
with IN i
im JJ i
methotrexate NN i
( ( i
MTX NNP i
) ) i
, , N
whether IN N
the DT N
variation NN N
of IN N
inflammatory JJ o
activity NN o
or CC N
functional JJ o
capacity NN o
, , N
the DT N
ascending VBG N
anatomic JJ N
stage NN N
, , N
or CC N
DMARD NNP N
treatments NNS N
have VBP N
an DT N
influence NN N
on IN N
bone NN N
formation NN N
( ( N
osteocalcin NN N
) ) N
in IN N
patients NNS p
with IN p
RA NNP p
. . p

RESULTS NNP N
Patients NNPS p
( ( p
n JJ p
= NNP p
48 CD p
) ) p
enrolled VBN p
at IN p
the DT p
beginning NN p
of IN p
our PRP$ p
study NN p
had VBD N
significantly RB N
increased VBN N
osteocalcin NN o
levels NNS o
( ( N
3.45 CD N
+/- JJ N
0.93 CD N
-- : N
> JJ N
4.42 CD N
+/- JJ N
1.39 CD N
ng/ml JJ N
p NN N
< NNP N
0.02 CD N
) ) N
after IN N
one CD N
year NN N
if IN N
inflammatory JJ o
activity NN o
decreased VBN N
( ( N
> CD N
or CC N
= VB N
1 CD N
SD NNP N
: : N
erythrocyte JJ o
sedimentation NN o
rate NN o
( ( o
ESR NNP o
) ) o
26.4 CD N
mm/h NN N
, , N
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
3.8 CD N
mg/dl NN N
) ) N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
negative JJ N
correlation NN N
of IN N
the DT N
one-year JJ N
CRP- NNP o
( ( N
r NN N
= NNP N
-0.44 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
or CC N
ESR NNP o
differences NNS o
( ( N
r NN N
= NNP N
-0.45 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
with IN N
the DT N
corresponding JJ N
osteocalcin NN N
differences NNS N
. . N

This DT N
was VBD N
also RB N
evident JJ N
if IN N
these DT N
patients NNS N
were VBD N
pooled VBN N
with IN N
15 CD N
patients NNS N
excluded VBN N
from IN N
the DT N
double JJ N
blind NN N
study NN N
as IN N
already RB N
receiving VBG N
DMARD NNP i
treatment NN i
( ( N
n JJ N
= VBZ N
63 CD N
; : N
p NN N
< VBZ N
0.01 CD N
) ) N
. . N

Patients NNS N
with IN N
impaired JJ N
functional JJ o
capacity NN o
also RB N
had VBD N
significantly RB N
reduced VBN N
osteocalcin NN o
levels NNS o
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

In IN N
both DT N
cases NNS N
, , N
alkaline JJ o
phosphatase NN o
showed VBD N
no DT N
significant JJ N
differences NNS N
. . N

CONCLUSIONS VB N
Our PRP$ N
data NNS N
suggest VBP N
that IN N
osteocalcin NN N
, , N
a DT N
useful JJ N
followup NN N
variable NN N
of IN N
bone NN o
turnover NN o
, , N
is VBZ N
changed VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
in IN N
patients NNS p
with IN p
RA NNP p
regarding VBG N
inflammatory JJ o
activity NN o
and CC o
functional JJ o
capacity NN o
. . o

In IN N
contrast NN N
to TO N
alkaline VB o
phosphatase NN o
, , N
a DT N
fall NN N
in IN N
inflammatory JJ N
activity NN N
stimulated VBN N
and CC N
impairment NN N
of IN N
functional JJ o
capacity NN o
significantly RB N
decreased VBD N
osteocalcin JJ N
levels NNS N
in IN N
patients NNS p
with IN p
RA NNP p
. . p

-DOCSTART- -11098982- O O

Percutaneous JJ i
tracheostomy NN i
in IN N
critically RB p
ill JJ p
patients NNS p
: : p
a DT N
prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
two CD N
techniques NNS N
. . N

OBJECTIVE NNP N
To TO N
prospectively RB N
compare VB N
two CD N
commonly RB N
used VBD N
methods NNS N
for IN N
percutaneous JJ i
dilational JJ i
tracheostomy NN i
( ( i
PDT NNP i
) ) i
in IN p
critically RB p
ill JJ p
patients NNS p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
clinical JJ N
trial NN N
. . N

SETTING NN N
Trauma NNP p
and CC p
general JJ p
intensive JJ p
care NN p
units NNS p
of IN p
a DT p
university NN p
tertiary JJ p
teaching NN p
hospital NN p
, , p
which WDT p
is VBZ p
also RB p
a DT p
level NN p
1 CD p
trauma NN p
center NN p
. . p

PATIENTS VB N
One CD p
hundred VBN p
critically RB p
ill JJ p
patients NNS p
with IN p
an DT p
indication NN p
for IN p
PDT NNP i
. . i

INTERVENTIONS NNP N
PDT NNP i
with IN i
the DT i
Ciaglia NNP i
technique NN i
using VBG i
the DT i
Ciaglia NNP i
PDT NNP i
introducer NN i
set NN i
and CC i
the DT i
Griggs NNP i
technique NN i
using VBG i
a DT i
Griggs NNP i
PDT NNP i
kit NN i
and CC i
guidewire NN i
dilating NN i
forceps NNS i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Surgical NNP o
time NN o
, , o
difficulties NNS o
, , o
and CC o
surgical JJ o
and CC o
anesthesia JJ o
complications NNS o
were VBD N
measured VBN N
at IN N
0-2 JJ N
hrs NN N
, , N
24 CD N
hrs NN N
, , N
and CC N
7 CD N
days NNS N
postprocedure NN N
. . N

Groups NNP N
were VBD N
well RB N
matched VBN N
, , N
and CC N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
methods NNS N
in IN N
surgical JJ o
time NN o
or CC N
in IN N
anesthesia JJ o
complications NNS o
. . o

Major JJ o
bleeding VBG o
complications NNS o
were VBD N
4.4 CD N
times NNS N
more RBR N
frequent JJ N
with IN N
the DT N
Griggs NNP i
PDT NNP i
kit NN N
. . N

With IN N
the DT N
Ciaglia NNP i
PDT NNP i
kit NN N
, , N
both DT N
intraoperative JJ N
and CC N
at IN N
2 CD N
and CC N
24 CD N
hrs NN N
, , N
surgical JJ o
complications NNS o
were VBD N
less JJR N
common JJ N
( ( N
p JJ N
= NNP N
.023 NNP N
) ) N
and CC N
the DT N
procedure NN N
was VBD N
more RBR N
often RB N
completed VBN N
without IN N
expert JJ N
assistance NN N
( ( N
p JJ N
= NNP N
.013 NNP N
) ) N
. . N

Tracheostomy NNP o
bleeding NN o
was VBD N
not RB N
associated VBN N
with IN N
either DT N
anticoagulant JJ N
therapy NN N
or CC N
an DT N
abnormal JJ N
clotting NN N
profile NN N
. . N

Multivariate NNP o
analysis NN o
identified VBD N
the DT N
predictors NNS N
of IN N
PDT NNP N
complications NNS N
as IN N
the DT N
Griggs NNP N
PDT NNP N
kit NN N
( ( N
p JJ N
= NNP N
.027 NNP N
) ) N
and CC N
the DT N
Acute NNP o
Physiology NNP o
and CC o
Chronic NNP o
Health NNP o
Evaluation NNP o
( ( o
APACHE NNP o
) ) o
II NNP o
score NN o
( ( N
p JJ N
= NNP N
.041 NNP N
) ) N
. . N

The DT N
significant JJ N
predictors NNS N
of IN N
time NN N
required VBN N
to TO N
complete VB N
PDT NNP i
were VBD N
the DT N
APACHE NNP o
II NNP o
score NN o
( ( N
p JJ N
= NNP N
.041 NNP N
) ) N
, , N
a DT N
less RBR N
experienced JJ N
operator NN N
( ( N
p JJ N
= NNP N
.0001 NNP N
) ) N
, , N
and CC N
a DT N
female JJ N
patient NN N
( ( N
p JJ N
= NNP N
.013 NNP N
) ) N
. . N

CONCLUSIONS JJ N
Patients NNPS p
experiencing VBG p
PDT NNP i
with IN N
the DT N
Ciaglia NNP N
PDT NNP N
kit NN N
had VBD N
a DT N
lower JJR o
surgical JJ o
complication NN o
rate NN o
( ( N
2 CD N
% NN N
vs. FW N
25 CD N
% NN N
) ) N
, , N
less RBR o
operative JJ o
and CC o
postoperative JJ o
bleeding NN o
, , N
and CC N
less RBR N
overall JJ o
technical JJ o
difficulties NNS o
than IN N
did VBD N
patients NNS p
undergoing VBG p
PDT NNP p
with IN N
the DT N
Griggs NNP i
PDT NNP i
kit NN N
. . N

Ciaglia NNP i
PDT NNP i
is VBZ N
, , N
therefore RB N
, , N
the DT N
preferred JJ N
technique NN N
for IN N
percutaneous JJ p
tracheostomy NN p
in IN p
critically RB p
ill JJ p
patients NNS p
. . p

-DOCSTART- -25797097- O O

The DT N
neural JJ N
correlates NNS N
of IN N
semantic JJ N
richness NN N
: : N
evidence NN N
from IN N
an DT N
fMRI NN N
study NN N
of IN N
word NN N
learning NN N
. . N

We PRP N
investigated VBD N
the DT N
neural JJ N
correlates NNS N
of IN N
concrete JJ N
nouns NNS N
with IN N
either DT N
many JJ N
or CC N
few JJ N
semantic JJ N
features NNS N
. . N

A DT N
group NN p
of IN p
21 CD p
participants NNS p
underwent JJ p
two CD p
days NNS p
of IN p
training NN i
and CC p
were VBD p
then RB p
asked VBN p
to TO p
categorize VB p
40 CD p
newly RB p
learned VBN p
words NNS p
and CC p
a DT p
set NN p
of IN p
matched NNS i
familiar JJ i
words NNS i
as IN i
living NN i
or CC i
nonliving NN i
in IN i
an DT i
MRI NNP i
scanner NN i
. . i

Our PRP$ N
results NNS N
showed VBD N
that IN N
the DT N
most RBS o
reliable JJ o
effects NNS o
of IN o
semantic JJ o
richness NN o
were VBD N
located VBN o
in IN o
the DT o
left NN o
angular JJ o
gyrus NN o
( ( o
AG NNP o
) ) o
and CC o
middle JJ o
temporal JJ o
gyrus NN o
( ( o
MTG NNP o
) ) o
, , N
where WRB N
activation NN o
was VBD N
higher JJR N
for IN N
semantically RB N
rich JJ N
than IN N
poor JJ N
words NNS N
. . N

Other JJ N
areas NNS N
showing VBG N
the DT N
same JJ N
pattern NN N
included VBD N
bilateral JJ N
precuneus NN N
and CC N
posterior JJ N
cingulate NN N
gyrus NN N
. . N

Our PRP$ N
findings NNS N
support VBP N
the DT N
view NN N
that IN N
AG NNP N
and CC N
anterior JJ N
MTG NNP N
, , N
as IN N
part NN N
of IN N
the DT N
multimodal NN N
network NN N
, , N
play VB N
a DT N
significant JJ N
role NN N
in IN N
representing VBG N
and CC N
integrating VBG o
semantic JJ o
features NNS o
from IN N
different JJ N
input NN N
modalities NNS N
. . N

We PRP N
propose VBP N
that DT N
activation NN N
in IN N
bilateral JJ N
precuneus NN N
and CC N
posterior JJ N
cingulate NN N
gyrus NN N
reflects VBZ N
interplay NN N
between IN N
AG NNP N
and CC N
episodic JJ N
memory NN N
systems NNS N
during IN N
semantic JJ N
retrieval NN N
. . N

-DOCSTART- -12143780- O O

Fusion NN o
surgery NN o
is VBZ N
slightly RB N
better JJR N
than IN N
non-surgical JJ i
treatment NN i
in IN N
patients NNS p
with IN p
severe JJ o
chronic JJ o
non-specific JJ o
low JJ o
back RB o
pain NN o
. . o

-DOCSTART- -25577772- O O

The DT N
development NN N
and CC N
feasibility NN N
of IN N
a DT N
composite JJ N
score NN N
of IN N
echocardiographic JJ N
indices NNS N
that WDT N
may MD N
stratify VB N
outcome NN N
in IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
. . p

BACKGROUND NNP N
Early JJ N
detection NN N
of IN N
changes NNS N
in IN N
cardiac JJ N
structure NN N
and CC N
function NN N
associated VBN N
with IN N
type NN p
2 CD p
diabetes NNS p
( ( p
T2DM NNP p
) ) p
is VBZ N
important JJ N
. . N

However RB N
when WRB N
multiple JJ N
abnormalities NNS N
are VBP N
present JJ N
, , N
combining VBG N
individual JJ N
measurements NNS N
can MD N
be VB N
subjective JJ N
. . N

This DT N
study NN N
sought VBD N
to TO N
create VB N
a DT N
simple JJ N
echo NN o
score NN o
that WDT N
summarises VBZ N
measurements NNS N
that WDT N
may MD N
detect VB N
early JJ N
and CC N
prognostically RB N
important JJ N
changes NNS N
in IN N
cardiac JJ N
function NN N
. . N

METHODS NNP N
Standard NNP i
echocardiography NN i
was VBD p
performed VBN p
on IN p
849 CD p
people NNS p
with IN p
T2DM NNP p
( ( p
median JJ p
age NN p
65years CD p
, , p
40 CD p
% NN p
female NN p
, , p
median JJ p
duration NN p
of IN p
diabetes NNS p
5.5years CD p
) ) p
. . p

Principal JJ N
components NNS N
analysis NN N
was VBD N
performed VBN N
on IN N
measurements NNS N
of IN N
LV NNP o
mass NN o
, , o
LA NNP o
volume NN o
, , o
E NN o
: : o
e NN o
' '' o
, , N
and CC N
s NN o
' '' o
, , N
to TO N
create VB N
an DT N
objective JJ o
summary NN o
score NN o
. . o

The DT N
score NN N
was VBD N
included VBN N
in IN N
two CD N
Cox NNP N
proportional JJ N
hazard NN N
models NNS N
adjusted VBN N
for IN N
CV NNP N
risk NN N
factors NNS N
: : N
one CD N
estimated VBD N
the DT N
development NN N
of IN N
heart NN o
failure NN o
( ( o
HF NNP o
) ) o
and CC N
the DT N
second JJ N
estimated VBN N
any DT o
CV NNP o
event NN o
. . o

RESULTS VB N
The DT N
first JJ N
two CD N
principal JJ N
components NNS N
represented VBD N
75 CD N
% NN N
of IN N
the DT N
variation NN N
between IN N
the DT N
four CD N
echo NN N
measurements NNS N
. . N

A DT N
continuous JJ N
score NN N
that WDT N
represents VBZ N
the DT N
residual JJ N
difference NN N
between IN N
these DT N
two CD N
components NNS N
was VBD N
derived VBN N
that IN N
only RB N
requires VBZ N
measurement NN N
of IN N
medial JJ N
E NN N
: : N
e NN N
' '' N
and CC N
s VB N
' '' N
. . N

The DT N
score NN N
was VBD N
significantly RB N
associated VBN N
with IN N
the DT N
development NN o
of IN o
HF NNP o
within IN N
four CD N
years NNS N
( ( N
hazard RB N
ratio VBZ N
1.34 CD N
; : N
95 CD N
% NN N
CI NNP N
1.15 CD N
, , N
1.56 CD N
) ) N
. . N

CONCLUSIONS NNP N
We PRP N
have VBP N
developed VBN N
a DT N
simple NN N
, , N
objective JJ N
score NN o
that WDT N
enhances VBZ N
the DT N
use NN N
of IN N
echocardiography NN i
in IN N
the DT N
detection NN N
of IN N
sub-clinical JJ N
cardiac JJ N
disease NN N
in IN N
people NNS p
with IN p
T2DM NNP p
. . p

Initial JJ N
findings NNS N
suggest VBP N
that IN N
it PRP N
may MD N
help VB N
identify VB N
those DT N
at IN N
increased VBN N
risk NN N
of IN N
developing VBG N
HF NNP N
within IN N
four CD N
years NNS N
. . N

-DOCSTART- -7862876- O O

Neuroendocrine NNP o
effects NNS o
of IN N
sumatriptan NN i
. . i

The DT N
neuroendocrine JJ N
effects NNS N
of IN N
the DT N
5-HT JJ N
receptor NN N
agonist NN N
, , N
sumatriptan NN i
( ( i
6 CD i
mg RB i
subcutaneously RB i
) ) i
, , N
were VBD N
studied VBN N
in IN N
11 CD p
healthy JJ p
male NN p
subjects NNS p
using VBG N
a DT N
placebo-controlled JJ i
, , N
cross-over JJ N
design NN N
. . N

Compared VBN N
to TO N
placebo VB i
, , i
sumatriptan VB i
significantly RB N
lowered VBN N
levels NNS N
of IN N
plasma NN o
prolactin NN o
but CC N
increased VBD N
those DT N
of IN N
plasma JJ o
growth NN o
hormone NN o
. . o

There EX N
was VBD N
no DT N
effect NN N
on IN N
plasma NN o
cortisol NN o
concentrations NNS o
. . o

The DT N
neuroendocrine JJ N
effects NNS N
of IN N
sumatriptan JJ i
differ NN N
from IN N
those DT N
of IN N
previously RB N
described VBN N
5-HT-receptor JJ N
agonists NNS N
, , N
and CC N
may MD N
be VB N
a DT N
consequence NN N
of IN N
selective JJ N
activation NN N
of IN N
5-HT1D JJ N
or CC N
5-HT1B JJ N
receptors NNS N
. . N

However RB N
, , N
the DT N
present JJ N
data NNS N
can MD N
not RB N
exclude VB N
the DT N
possibility NN N
that IN N
the DT N
neuroendocrine JJ N
changes NNS N
reflect VBP N
nonspecific JJ N
stress NN N
responses NNS N
or CC N
changes NNS N
in IN N
pituitary JJ N
blood NN N
flow NN N
. . N

-DOCSTART- -18794865- O O

A DT N
randomized JJ N
trial NN N
of IN N
etoposide NN N
and CC N
G-CSF NNP N
with IN N
or CC N
without IN N
rituximab NN i
for IN N
PBSC NNP N
mobilization NN N
in IN N
B-cell NNP p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

Some DT N
reports NNS N
have VBP N
suggested VBN N
that IN N
rituximab JJ N
administration NN N
before IN N
PBSC NNP N
mobilization NN N
may MD N
adversely RB N
affect VB N
PBSC NNP N
yield NN N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
PBSC NNP N
mobilization NN N
using VBG N
etoposide JJ i
and CC i
G-CSF JJ i
with IN i
or CC i
without IN i
rituximab NN i
to TO N
determine VB N
whether IN N
its PRP$ N
addition NN N
would MD N
adversely RB N
affect VB N
CD34+ NNP o
cell NN o
yield NN o
in IN N
patients NNS p
with IN p
non-Hodgkin JJ p
's POS p
lymphoma NN p
. . p

Twenty NNP p
seven CD p
patients NNS p
were VBD p
mobilized VBN p
with IN N
etoposide JJ i
and CC N
G-CSF NNP N
and CC N
28 CD N
with IN N
etoposide NN i
, , i
G-CSF NNP i
and CC i
rituximab NN i
. . i

There EX N
were VBD N
no DT N
adverse JJ N
consequences NNS N
of IN N
rituximab NN N
on IN N
CD34+ NNP o
cell NN o
yield NN o
, , o
or CC o
hematopoietic JJ o
recovery NN o
or CC o
immunoglobulin NN o
levels NNS o
after IN N
transplantation NN N
. . N

-DOCSTART- -7964693- O O

Therapy NN N
for IN N
progressive JJ p
supranuclear JJ p
palsy NN p
: : p
past NN N
and CC N
future NN N
. . N

Dysfunction NN N
of IN N
multiple JJ N
brain NN N
systems NNS N
in IN N
progressive JJ p
supranuclear JJ p
palsy NN p
( ( p
PSP NNP p
) ) p
has VBZ N
complicated VBN N
attempts NNS N
to TO N
treat VB N
the DT N
disease NN N
. . N

Neurotransmitter NNP i
replacement NN i
strategies NNS i
targeting VBG N
the DT N
dopaminergic NN N
, , N
cholinergic NN N
, , N
and CC N
serotonergic JJ N
systems NNS N
have VBP N
been VBN N
unsuccessful JJ N
. . N

In IN N
order NN N
to TO N
bypass VB N
the DT N
degenerated JJ N
cortico-striato-pallidal JJ N
loop NN N
, , N
we PRP N
administered VBD N
the DT N
adrenergic JJ i
agonist NN i
idazoxan NN i
( ( i
IDA NNP i
) ) i
to TO N
treat VB N
PSP NNP N
in IN N
two CD N
randomized JJ N
double-blind NN N
, , N
placebo NN i
controlled VBD N
, , N
crossover NN N
studies NNS N
. . N

Approximately RB N
one CD N
half NN N
of IN N
patients NNS p
enrolled VBN p
in IN p
these DT p
studies NNS p
showed VBD N
statistically RB o
significant JJ o
improvement NN o
in IN o
balance NN o
and CC o
manual JJ o
dexterity NN o
while IN N
taking VBG N
IDA NNP N
compared VBN N
to TO N
placebo VB i
. . i

These DT N
results NNS N
suggest VBP N
that IN N
new JJ N
therapies NNS i
that WDT N
target VBP N
structures NNS N
outside IN N
of IN N
the DT N
basal NN N
ganglia NN N
may MD N
be VB N
useful JJ N
for IN N
symptomatic JJ o
treatment NN o
of IN o
PSP NNP o
. . o

Applying VBG N
this DT N
strategy NN N
and CC N
developing VBG N
treatments NNS N
that WDT N
arrest VBP N
or CC N
reverse VB N
clinical JJ N
deterioration NN N
in IN N
PSP NNP N
will MD N
require VB N
improved JJ N
understanding NN N
of IN N
the DT N
process NN N
underlying VBG N
the DT N
illness NN N
. . N

-DOCSTART- -11561265- O O

Epidural JJ i
analgesia NNS i
compared VBN N
with IN N
intravenous JJ i
morphine JJ i
patient-controlled JJ N
analgesia NN N
: : N
postoperative JJ N
outcome NN N
measures NNS N
after IN N
mastectomy NN p
with IN p
immediate JJ p
TRAM NNP p
flap NN p
breast NN p
reconstruction NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Epidural NNP N
analgesia NN N
has VBZ N
been VBN N
shown VBN N
to TO N
provide VB N
superior JJ N
pain NN N
control NN N
compared VBN N
with IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
opioids NNS N
after IN N
major JJ N
surgical JJ N
procedures NNS N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
compared VBN N
the DT N
effect NN N
of IN N
epidural JJ N
analgesia NN N
and CC N
IV NNP N
morphine VBP N
patient-controlled JJ i
analgesia NN i
( ( i
PCA NNP i
) ) i
on IN N
pain NN N
relief NN N
, , N
duration NN N
of IN N
hospitalization NN N
, , N
oral JJ N
nutrition NN N
, , N
ambulation NN N
, , N
and CC N
side NN N
effects NNS N
in IN N
patients NNS p
undergoing VBG p
a DT p
major JJ p
surgical JJ p
procedure NN p
( ( p
i.e. FW p
, , N
unilateral JJ p
mastectomy NN p
with IN p
immediate JJ p
transverse NN p
rectus NN p
abdominis VBP p
musculocutaneous JJ p
flap JJ p
reconstruction NN p
) ) p
. . p

METHODS NNP N
Eighteen JJ p
patients NNS p
were VBD N
prospectively RB N
randomized VBN N
to TO N
receive VB N
either DT N
epidural JJ i
analgesia NN i
or CC i
PCA NNP i
during IN N
the DT N
postoperative JJ N
period NN N
. . N

The DT N
intensity NN o
of IN o
pain NN o
was VBD N
assessed VBN N
daily RB N
by IN N
a DT N
100-mm JJ N
visual JJ N
analog NN N
scale NN N
. . N

The DT N
total JJ o
length NN o
of IN o
hospital NN o
stay NN o
, , o
time NN o
to TO o
ambulation NN o
, , o
and CC o
time NN o
to TO o
oral JJ o
nutrition NN o
were VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
epidural JJ N
group NN N
had VBD N
significantly RB N
lower JJR N
pain NN o
scores NNS o
at IN N
3 CD N
evaluation NN N
times NNS N
through IN N
postoperative JJ N
day NN N
number NN N
4 CD N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
total JJ o
length NN o
of IN o
hospitalization NN o
for IN N
the DT N
epidural JJ N
group NN N
( ( N
median JJ N
, , N
101 CD N
hours NNS N
) ) N
was VBD N
significantly RB N
less JJR N
than IN N
the DT N
PCA NNP N
group NN N
( ( N
median JJ N
, , N
126 CD N
hours NNS N
; : N
P NNP N
= NNP N
.0498 NNP N
) ) N
. . N

The DT N
time NN o
to TO o
first JJ o
ambulation NN o
, , o
time NN o
to TO o
first VB o
bowel NN o
sounds NNS o
, , o
time NN o
to TO o
tolerating VBG o
oral JJ o
nutrition NN o
, , o
incidence NN o
of IN o
nausea/vomiting VBG o
or CC o
pruritus NN o
, , o
and CC o
time NN o
to TO o
first JJ o
flatus NN o
were VBD N
not RB N
statistically RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
show VBP N
that IN N
epidural JJ N
analgesia NNS N
compared VBN N
with IN N
PCA NNP N
offered VBD N
improved JJ N
pain NN N
control NN N
after IN N
breast NN N
reconstruction NN N
with IN N
immediate JJ N
transverse NN N
rectus NN N
abdominis VBP N
musculocutaneous JJ N
flap JJ N
reconstruction NN N
. . N

It PRP N
also RB N
resulted VBD N
in IN N
a DT N
25-hour JJ N
reduction NN N
in IN N
time NN N
of IN N
hospitalization NN N
. . N

-DOCSTART- -11835021- O O

The DT N
Low NNP i
Energy NNP i
Safety NNP i
Study NNP i
( ( i
LESS NNP i
) ) i
: : i
rationale NN N
, , N
design NN N
, , N
patient JJ N
characteristics NNS N
, , N
and CC N
device NN N
utilization NN N
. . N

BACKGROUND VB N
A DT N
10-J JJ N
energy NN N
safety NN N
margin NN N
has VBZ N
traditionally RB N
been VBN N
used VBN N
in IN N
programming VBG N
implantable JJ i
cardioverter NN i
defibrillators NNS i
( ( i
ICDs NNP i
) ) i
. . i

The DT N
Low NNP i
Energy NNP i
Safety NNP i
Study NNP i
( ( i
LESS NNP i
) ) i
tests VBZ N
the DT N
hypothesis NN N
that IN N
programming VBG N
shocks NNS N
to TO N
lower VB N
energy NN N
margins NNS N
is VBZ N
safe JJ N
and CC N
effective JJ N
. . N

METHODS NNP N
Patients NNPS p
with IN p
standard JJ p
ICD NNP p
indications NNS p
undergo VBP p
defibrillation NN i
threshold NN i
testing NN i
( ( i
DFT NNP i
) ) i
at IN p
the DT p
time NN p
of IN p
ICD NNP i
implant NN i
, , p
with IN p
reconfirmation NN p
of IN p
lowest JJS p
successful JJ p
energy NN p
twice RB p
( ( p
DFT++ NNP p
) ) p
. . p

Patients NNS N
are VBP N
randomized VBN N
to TO N
2 CD N
groups NNS N
: : N
the DT N
first JJ N
has VBZ N
the DT N
initial JJ i
2 CD i
shocks NNS i
for IN i
ventricular JJ i
fibrillation NN i
conversion NN i
programmed VBD i
at IN i
2 CD i
energy NN i
steps NNS i
above IN i
DFT++ NNP i
( ( i
typically RB i
4-6 JJ i
J NNP i
, , i
maximum JJ i
10 CD i
J NNP i
) ) i
with IN i
subsequent JJ i
shocks NNS i
at IN i
maximum JJ i
energy NN i
, , N
and CC N
the DT N
second JJ N
has VBZ N
all DT i
shocks NNS i
programmed VBN i
at IN i
maximum JJ i
energy NN i
. . i

Patients NNS N
are VBP N
followed VBN N
up IN N
every DT N
3 CD N
months NNS N
for IN N
2 CD N
years NNS N
to TO N
assess VB N
shock NN o
conversion NN o
efficacy NN o
of IN o
spontaneous JJ o
arrhythmias NNS o
. . o

In IN N
a DT N
subgroup NN N
of IN N
patients NNS N
, , N
there EX N
is VBZ N
a DT N
second JJ N
randomization NN N
to TO N
energy NN N
levels NNS N
of IN N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
or CC N
4 CD N
steps NNS N
above IN N
implant NN N
DFT++ NNP i
for IN N
conversion NN N
testing NN N
of IN N
3 CD N
induced JJ N
ventricular JJ N
fibrillation NN N
episodes NNS N
at IN N
prehospital JJ N
discharge NN N
, , N
3 CD N
months NNS N
, , N
and CC N
12 CD N
months NNS N
after IN N
implant JJ N
. . N

RESULTS NNP N
Enrollment NNP p
is VBZ p
complete JJ p
( ( p
702 CD p
patients NNS p
) ) p
, , N
but CC N
follow-up JJ N
results NNS N
are VBP N
pending VBG N
. . N

There EX N
were VBD N
no DT N
significant JJ N
variations NNS N
in IN N
implant JJ o
indications NNS o
and CC o
baseline VB o
antiarrhythmic JJ o
drug NN o
use NN o
over IN N
the DT N
3-year JJ N
enrollment NN N
period NN N
, , N
although IN N
an DT N
increase NN N
in IN N
the DT N
percentage NN o
of IN o
dual-chamber JJ o
ICDs NNP o
implanted VBD o
occurred VBD N
, , N
with IN N
the DT N
majority NN N
( ( N
65 CD N
% NN N
) ) N
of IN N
implanted JJ N
ICDs NNP N
being VBG N
dual-chamber JJ N
devices NNS N
by IN N
the DT N
end NN N
of IN N
the DT N
enrollment JJ N
period NN N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
LESS NNP i
should MD N
facilitate VB N
the DT N
development NN N
of IN N
algorithms NN N
for IN N
programming VBG N
ICD NNP N
energy NN o
safety NN o
margins NNS o
. . o

-DOCSTART- -5378631- O O

A DT N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
( ( i
- : i
) ) i
-hyoscine NN i
and CC i
amylobarbitone NN i
sodium NN i
on IN N
measurements NNS N
of IN N
post-rotational JJ p
turning VBG p
sensation NN p
and CC p
nystagmus NN o
. . o

-DOCSTART- -17575230- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
of IN N
two CD N
doses NNS N
of IN N
pemetrexed JJ i
as IN N
first-line JJ N
chemotherapy NN N
for IN N
advanced JJ p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
Pemetrexed NNP i
has VBZ N
shown VBN N
varied JJ N
response NN N
rates NNS N
in IN N
advanced JJ p
breast NN p
cancer NN p
. . p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
two CD N
doses NNS N
of IN N
pemetrexed NN i
in IN N
a DT N
homogeneous JJ N
population NN N
. . N

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
identify VB N
molecular JJ N
biomarkers NNS N
correlating VBG N
with IN N
response NN o
and CC o
toxicity NN o
. . o

EXPERIMENTAL NNP N
DESIGN NNP N
Patients NNPS p
with IN p
newly RB p
diagnosed VBN p
metastatic JJ p
breast NN p
cancer NN p
or CC p
locally RB p
recurrent JJ p
breast NN p
cancer NN p
received VBD N
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( i
P600 NNP i
arm NN N
) ) N
or CC N
900 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( i
P900 NNP i
arm NN N
) ) N
of IN N
pemetrexed NN i
on IN N
day NN N
1 CD N
of IN N
a DT N
21-day JJ N
cycle NN N
. . N

All DT N
patients NNS N
received VBD N
folic JJ i
acid NN i
and CC i
vitamin NN i
B NNP i
( ( i
12 CD i
) ) i
supplementation NN i
. . i

RESULTS VB N
The DT p
P600 NNP p
( ( p
47 CD p
patients NNS p
) ) p
and CC p
P900 NNP p
( ( p
45 CD p
patients NNS p
) ) p
arms NNS N
had VBD N
response NN o
rates NNS o
of IN N
17.0 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
7.7-30.8 CD N
% NN N
) ) N
and CC N
15.6 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
6.5-29.5 CD N
% NN N
) ) N
with IN N
approximately RB N
50 CD N
% NN N
stable JJ N
disease NN N
per IN N
arm NN N
, , N
median JJ o
progression-free JJ o
survival NN o
of IN N
4.2 CD N
and CC N
4.1 CD N
months NNS N
, , N
and CC N
median JJ o
times NNS o
to TO o
tumor VB o
progression NN o
of IN N
4.2 CD N
and CC N
4.6 CD N
months NNS N
, , N
respectively RB N
. . N

Both DT N
arms NNS N
exhibited VBD N
minimal JJ o
toxicity NN o
( ( N
grade JJ N
3/4 CD N
neutropenia JJ o
< RB N
20 CD N
% NN N
, , N
leukopenia NN o
< VBD N
9 CD N
% NN N
, , N
and CC N
other JJ o
toxicities NNS o
< VBP N
5 CD N
% NN N
) ) N
. . N

Tumor NN N
samples NNS N
from IN N
49 CD N
patients NNS N
were VBD N
assessed VBN N
for IN N
the DT N
expression NN N
levels NNS N
of IN N
12 CD N
pemetrexed-related JJ i
genes NNS N
. . N

Folylpolyglutamate NNP N
synthetase NN N
and CC N
thymidine JJ N
phosphorylase NN N
correlated VBN N
with IN N
efficacy NN o
. . o

Best JJS o
response NN o
rates NNS o
and CC o
median JJ o
time NN o
to TO o
tumor VB o
progression NN o
for IN N
high JJ N
versus NN N
low JJ N
thymidine NN N
phosphorylase NN N
expression NN N
were VBD N
27.6 CD N
% NN N
versus IN N
6.3 CD N
% NN N
( ( N
P NNP N
= NNP N
0.023 CD N
) ) N
and CC N
5.4 CD N
versus NN N
1.9 CD N
months NNS N
( ( N
P NNP N
= NNP N
0.076 CD N
) ) N
, , N
and CC N
for IN N
folylpolyglutamate JJ N
synthetase NN N
were VBD N
37.5 CD N
% NN N
versus IN N
10.0 CD N
% NN N
( ( N
P NNP N
= NNP N
0.115 CD N
) ) N
and CC N
8.6 CD N
versus NN N
3.0 CD N
months NNS N
( ( N
P NNP N
= NNP N
0.019 CD N
) ) N
, , N
respectively RB N
. . N

gamma-Glutamyl JJ N
hydrolase NN N
expression NN N
correlated VBN N
with IN N
grade JJ o
3/4 CD o
toxicities NNS o
: : o
78.6 CD N
% NN N
for IN N
high JJ N
versus NN N
27.3 CD N
% NN N
for IN N
low JJ N
gamma-glutamyl JJ N
hydrolase NN N
( ( N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
two CD N
pemetrexed JJ i
doses NNS N
yielded VBD N
similar JJ N
efficacy NN o
and CC o
safety NN o
profiles NNS N
. . N

Exploratory NNP N
biomarker NN N
analysis NN N
identified VBN N
efficacy NN o
and CC o
toxicity NN o
correlations NNS N
and CC N
warrants NNS N
further JJ N
evaluation NN N
. . N

-DOCSTART- -24694924- O O

An DT N
oxytocin-induced JJ N
facilitation NN N
of IN N
neural JJ o
and CC o
emotional JJ o
responses NNS o
to TO o
social JJ o
touch NN o
correlates NNS N
inversely RB N
with IN N
autism NN p
traits NNS p
. . p

Social JJ N
communication NN N
through IN N
touch NN N
and CC N
mutual JJ N
grooming NN N
can MD N
convey VB N
highly RB N
salient JJ N
socio-emotional JJ N
signals NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
to TO N
involve VB N
the DT N
neuropeptide JJ N
oxytocin NN i
( ( N
OXT NNP N
) ) N
in IN N
several JJ N
species NNS N
. . N

Less NNP N
is VBZ N
known VBN N
about IN N
the DT N
modulatory JJ N
influence NN N
of IN N
OXT NNP N
on IN N
the DT N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
human JJ N
interpersonal JJ N
touch NN N
. . N

The DT N
present JJ N
randomized VBN N
placebo NN i
( ( N
PLC NNP N
) ) N
-controlled VBD N
within-subject JJ N
pharmaco-functional JJ N
magnetic JJ i
resonance NN i
imaging NN i
( ( i
fMRI NN i
) ) i
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
single JJ i
intranasal NN i
dose NN i
of IN i
synthetic JJ i
OXT NNP i
( ( N
24 CD N
IU NNP N
) ) N
would MD N
facilitate VB N
both DT N
neural JJ N
and CC N
emotional JJ N
responses NNS N
to TO N
interpersonal VB N
touch NN N
in IN N
a DT N
context- NN N
( ( N
female JJ N
vs NN N
male NN N
touch NN N
) ) N
and CC N
trait- JJ N
( ( N
autistic JJ N
trait NN N
load NN N
) ) N
specific JJ N
manner NN N
. . N

Specifically RB N
, , N
the DT N
experimental JJ N
rationale NN N
was VBD N
to TO N
manipulate VB N
the DT N
reward NN N
value NN N
of IN N
interpersonal JJ N
touch JJ N
independent JJ N
of IN N
the DT N
intensity NN N
and CC N
type NN N
of IN N
actual JJ N
cutaneous JJ N
stimulation NN N
administered VBN N
. . N

Thus NNP p
, , p
40 CD p
heterosexual JJ p
males NNS p
believed VBN p
that IN p
they PRP p
were VBD p
touched VBN p
by IN p
either CC p
a DT p
man NN p
or CC p
a DT p
woman NN p
, , p
although IN p
in IN p
fact NN p
an DT p
identical JJ p
pattern NN p
of IN p
touch NN p
was VBD p
always RB p
given VBN p
by IN p
the DT p
same JJ p
female JJ p
experimenter NN p
blind NN p
to TO p
condition NN p
type NN p
. . p

Our PRP$ N
results NNS N
show VBP N
that IN N
OXT NNP N
increased VBD N
the DT o
perceived JJ o
pleasantness NN o
of IN o
female JJ N
, , N
but CC N
not RB o
male JJ o
touch NN o
, , o
and CC o
associated VBD o
neural JJ o
responses NNS o
in IN o
insula NN o
, , o
precuneus NN o
, , o
orbitofrontal JJ o
, , o
and CC o
pregenual JJ o
anterior JJ o
cingulate NN o
cortex NN o
. . o

Moreover RB N
, , N
the DT o
behavioral JJ o
and CC o
neural JJ o
effects NNS o
of IN o
OXT NNP o
were VBD o
negatively RB N
correlated VBN N
with IN N
autistic-like JJ N
traits NNS N
. . N

Taken VB N
together RB N
, , N
this DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
show VB N
that IN N
the DT N
perceived VBN N
hedonic JJ N
value NN N
of IN N
human JJ N
heterosexual JJ N
interpersonal JJ N
touch NN N
is VBZ N
facilitated VBN N
by IN N
OXT NNP N
in IN N
men NNS N
, , N
but CC N
that IN N
its PRP$ o
behavioral JJ o
and CC o
neural JJ o
effects NNS o
in IN o
this DT N
context NN N
are VBP N
blunted VBN N
in IN N
individuals NNS p
with IN p
autistic JJ p
traits NNS p
. . p

-DOCSTART- -6859471- O O

Postoperative JJ N
dreaming NN N
. . N

A DT N
comparison NN N
of IN N
the DT N
incidence NN N
following VBG N
pentazocine NN i
and CC N
morphine JJ i
premedication NN N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ N
dreaming NN N
following VBG N
the DT N
use NN N
of IN N
morphine NN i
and CC i
pentazocine NN i
as IN N
premedicants NNS N
in IN N
an DT N
otherwise RB N
standard JJ N
anaesthetic JJ N
sequence NN N
is VBZ N
compared VBN N
in IN N
healthy JJ p
volunteers NNS p
. . p

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
demonstrated VBN N
between IN N
the DT N
two CD N
drugs NNS N
. . N

The DT N
causes NNS N
of IN N
psychotomimetic JJ N
problems NNS N
in IN N
the DT N
postoperative JJ N
period NN N
and CC N
the DT N
difficulty NN N
of IN N
precise JJ N
definition NN N
of IN N
hallucinations NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -15701493- O O

Randomized VBN N
controlled VBD N
trial NN N
to TO N
compare VB N
the DT N
early JJ N
and CC N
mid-term JJ N
results NNS N
of IN N
stapled JJ i
versus NN i
open JJ i
hemorrhoidectomy NN i
. . i

BACKGROUND VB N
The DT N
new JJ N
technique NN N
of IN N
circular JJ N
stapler NN N
for IN N
the DT N
treatment NN N
of IN N
hemorrhoids NNS p
has VBZ N
shown VBN N
early JJ N
promise NN N
in IN N
terms NNS N
of IN N
minimal NN N
or CC N
no DT N
postoperative JJ N
pain NN N
, , N
early JJ N
discharge NN N
from IN N
hospital NN N
, , N
and CC N
quick JJ N
return NN N
to TO N
work VB N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
stapled VBN i
technique NN i
with IN i
the DT i
well-accepted JJ i
conventional JJ i
Milligan NNP i
Morgan NNP i
hemorrhoidectomy NN i
. . i

METHODS NNP N
After IN N
fulfilling VBG N
the DT N
selection NN N
criteria NNS N
, , N
84 CD p
patients NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
the DT p
stapled VBN i
( ( p
n JJ p
= NNP p
42 CD p
) ) p
or CC p
open JJ i
group NN p
( ( p
n JJ p
= NNP p
42 CD p
) ) p
. . p

All DT p
patients NNS p
were VBD p
operated VBN p
on IN p
under IN p
spinal JJ i
anesthesia NN i
. . i

The DT N
2 CD N
techniques NNS N
were VBD N
evaluated VBN N
with IN N
respect NN N
to TO N
the DT N
operative JJ o
time NN o
, , o
pain NN o
scores NNS o
, , o
complications NNS o
, , o
day NN o
of IN o
discharge NN o
, , o
return NN o
to TO o
work VB o
, , o
and CC o
level NN o
of IN o
satisfaction NN o
. . o

RESULTS VB N
The DT N
mean JJ p
age NN p
of IN p
patients NNS p
was VBD p
46.02 CD p
years NNS p
( ( p
SD NNP p
, , p
12.33 CD p
) ) p
in IN p
the DT p
stapled JJ p
group NN p
and CC p
48.64 CD p
years NNS p
( ( p
14.57 CD p
) ) p
in IN p
the DT p
open JJ p
group NN p
. . p

Grade NNP o
III NNP o
or CC o
IV NNP o
hemorrhoids NNS o
were VBD p
more JJR p
common JJ p
in IN p
men NNS p
( ( p
ie NN p
, , p
80.9 CD p
% NN p
and CC p
85.7 CD p
% NN p
in IN p
the DT p
stapled JJ p
and CC p
open JJ p
group NN p
, , p
respectively RB p
) ) p
. . p

The DT N
mean JJ o
operative JJ o
time NN o
was VBD N
shorter RBR N
in IN N
the DT N
stapled JJ N
group NN N
24.28 CD N
minutes NNS N
( ( N
4.25 CD N
) ) N
versus NN N
45.21 CD N
minutes NNS N
( ( N
5.36 CD N
) ) N
in IN N
the DT N
Milligan-Morgan NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
blood NN o
loss NN o
, , o
pain NN o
scores NNS o
and CC o
requirement NN o
of IN o
analgesics NNS o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
stapled JJ N
group NN N
. . N

Mean NNP o
hospital NN o
stay NN o
was VBD N
1.24 CD N
days NNS N
( ( N
0.62 CD N
) ) N
and CC N
2.76 CD N
days NNS N
( ( N
1.01 CD N
) ) N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
stapled JJ N
and CC N
open JJ N
group NN N
, , N
respectively RB N
. . N

The DT N
patients NNS N
in IN N
the DT N
stapled JJ N
group NN N
returned VBD o
to TO o
work VB o
or CC o
routine VB o
activities NNS o
earlier RBR N
( ( N
ie NN N
, , N
within IN N
8.12 CD N
days NNS N
[ RB N
2.48 CD N
] NN N
) ) N
as IN N
compared VBN N
with IN N
17.62 CD N
( ( N
5.59 CD N
) ) N
in IN N
the DT N
open JJ N
group NN N
. . N

Only RB N
88.1 CD N
% NN N
of IN N
patients NNS N
were VBD N
satisfied VBN o
by IN N
the DT N
open JJ N
method NN N
compared VBN N
with IN N
97.6 CD N
% NN N
after IN N
the DT N
stapled JJ N
technique NN N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
11 CD N
months NNS N
with IN N
a DT N
maximum JJ N
follow-up NN N
of IN N
19 CD N
months NNS N
( ( N
range VB N
2-19 JJ N
months NNS N
) ) N
. . N

CONCLUSIONS NNP N
Stapled NNP i
hemorrhoidectomy NN i
is VBZ N
a DT N
safe JJ o
and CC o
effective JJ o
day-care JJ N
procedure NN N
for IN N
the DT N
treatment NN N
of IN N
grade NN p
III NNP p
and CC p
grade VBD p
IV NNP p
hemorrhoids NNS p
. . p

It PRP N
ensures VBZ N
lesser RBR N
postoperative JJ o
pain NN o
, , o
early JJ o
discharge NN o
, , o
less JJR o
time NN o
off IN o
work NN o
, , o
complications NNS o
similar JJ N
to TO N
the DT N
open JJ N
technique NN N
, , N
and CC N
in IN N
the DT N
end NN N
a DT N
more RBR N
satisfied JJ o
patient NN o
with IN N
no DT N
perianal JJ N
wound NN N
. . N

However RB N
, , N
more RBR N
such JJ N
randomized JJ N
trials NNS N
are VBP N
essential JJ N
to TO N
deny VB N
any DT N
long-term JJ N
complication NN N
. . N

-DOCSTART- -16824797- O O

Effects NNS N
of IN N
two CD N
different JJ N
short-term JJ i
training NN i
programs NNS i
on IN N
the DT N
physical JJ N
and CC N
technical JJ N
abilities NNS N
of IN N
adolescent JJ p
basketball NN p
players NNS p
. . p

This DT N
study NN N
evaluated VBD N
and CC N
compared VBN N
the DT N
effectiveness NN N
of IN N
two CD N
different JJ N
off-season JJ i
, , i
short-term JJ i
basketball NN i
training NN i
programs NNS i
on IN N
physical JJ N
and CC N
technical JJ N
abilities NNS N
of IN N
young JJ p
basketball NN p
players NNS p
. . p

Twenty-seven JJ p
adolescent JJ p
basketball NN p
players NNS p
( ( p
14.7+/-0.5 CD p
years NNS p
; : p
Tanner NNP p
stage NN p
: : p
3.5+/-0.5 JJ p
) ) p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
specialized JJ i
basketball NN i
training NN i
group NN i
( ( N
SP NNP N
, , N
n=10 NN N
) ) N
, , N
a DT i
mixed JJ i
basketball NN i
plus CC i
conditioning VBG i
training NN i
group NN i
( ( N
MX NNP N
, , N
n=10 NN N
) ) N
and CC i
a DT i
control NN i
group NN i
( ( N
n=7 RB N
) ) N
. . N

Training VBG i
included VBD N
five CD N
sessions NNS N
per IN N
week NN N
( ( N
100-120 JJ N
min NNS N
each DT N
) ) N
and CC N
was VBD N
performed VBN N
for IN N
4 CD N
weeks NNS N
. . N

Maximal NNP o
oxygen NN o
uptake NN o
was VBD N
similarly RB N
improved VBN N
after IN N
SP NNP N
( ( N
4.9+/-1.8 CD N
% NN N
) ) N
and CC N
MX NNP N
( ( N
4.9+/-1.4 CD N
% NN N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
effect NN N
on IN N
ventilatory NN o
threshold NN o
. . o

Peak NNP o
and CC o
mean JJ o
power NN o
output NN o
measured VBD N
during IN N
the DT N
Wingate NNP N
test NN N
were VBD N
also RB N
improved VBN N
by IN N
a DT N
similar JJ N
magnitude NN N
after IN N
SP NNP N
( ( N
21+/-5 CD N
% NN N
) ) N
and CC N
MX NNP N
( ( N
15+/-6 CD N
% NN N
) ) N
. . N

Trunk NNP o
muscle NN o
endurance NN o
was VBD N
equally RB N
increased VBN N
( ( N
SP JJ N
: : N
23+/-4 JJ N
% NN N
, , N
MX NNP N
: : N
25+/-5 CD N
% NN N
) ) N
, , N
but CC N
arms NNS o
endurance NN o
was VBD N
improved VBN N
significantly RB N
more RBR N
after IN N
MX NNP N
( ( N
50+/-11 CD N
% NN N
) ) N
compared VBN N
to TO N
SP NNP N
( ( N
11+/-14 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

Performance NN o
in IN N
four CD N
basketball NN o
technical JJ o
skills NNS o
was VBD N
similarly RB N
increased VBN N
( ( N
by IN N
17-27 CD N
% NN N
) ) N
in IN N
both DT N
groups NNS N
, , N
with IN N
a DT N
tendency NN N
for IN N
greater JJR N
improvement NN N
of IN N
the DT N
SP NNP N
groups NNS N
in IN N
the DT N
technical JJ N
skills NNS N
of IN N
shooting NN o
and CC o
passing NN o
. . o

These DT N
results NNS N
indicate VBP N
that IN N
a DT N
SP NNP N
basketball NN N
training NN N
program NN N
, , N
performed VBD N
exclusively RB N
on-court NN N
was VBD N
as RB N
effective JJ N
as IN N
a DT N
MX NNP N
training NN N
program NN N
in IN N
terms NNS N
of IN N
aerobic NN N
and CC N
anaerobic JJ N
fitness NN N
improvement NN N
. . N

Furthermore RB N
, , N
the DT N
decrease NN N
of IN N
the DT N
total JJ N
on-court JJ N
training NN N
time NN N
in IN N
the DT N
MX NNP N
group NN N
resulted VBD N
in IN N
a DT N
tendency NN N
for IN N
a DT N
smaller JJR N
improvement NN N
of IN N
basketball NN N
technical JJ N
skills NNS N
. . N

In IN N
conclusion NN N
, , N
both DT N
SP NNP N
and CC N
MX NNP N
training NN N
are VBP N
equally RB N
effective JJ N
in IN N
order NN N
to TO N
limit VB N
and/or JJ N
reverse VB N
the DT N
detraining NN N
effects NNS N
that WDT N
occur VBP N
during IN N
the DT N
off-season NN N
in IN N
basketball NN N
. . N

-DOCSTART- -23619951- O O

The DT N
effects NNS N
of IN N
a DT N
multi-component JJ N
higher-functioning JJ p
autism NN p
anti-stigma JJ N
program NN N
on IN N
adolescent JJ p
boys NNS p
. . p

A DT N
six-session JJ N
higher-functioning JJ p
autism NN p
anti-stigma JJ N
program NN N
incorporating NN N
descriptive NN N
, , N
explanatory NN N
and CC N
directive JJ N
information NN N
was VBD N
delivered VBN N
to TO N
adolescent VB p
boys NNS p
and CC N
the DT N
impact NN N
upon IN N
knowledge NN o
, , o
attitudes NNS o
and CC o
behavioural JJ o
intentions NNS o
towards NNS N
peers NNS N
with IN N
autism NN N
was VBD N
evaluated VBN N
. . N

Participants NNS p
were VBD p
seventh- JJ p
, , p
eighth- JJ p
and CC p
ninth-grade JJ p
students NNS p
( ( p
N NNP p
= NNP p
395 CD p
) ) p
from IN p
regular JJ p
classes NNS p
in IN p
a DT p
mainstream JJ p
school NN p
. . p

Two-eighth-grade JJ p
classes NNS p
were VBD i
randomly RB i
allocated VBN i
to TO i
the DT i
intervention NN i
condition NN i
and CC i
all DT i
remaining VBG i
students NNS i
were VBD i
either RB i
allocated VBN i
to TO i
the DT i
no-intervention JJ i
peer NN i
or CC i
no-intervention JJ i
non-peer JJ i
condition NN i
. . i

The DT N
anti-stigma JJ N
program NN N
improved VBD N
the DT o
knowledge NN o
and CC o
attitudes NNS o
, , o
but CC N
not RB N
the DT o
behavioural JJ o
intentions NNS o
of IN o
participants NNS N
towards VBP N
their PRP$ N
peers NNS N
with IN N
autism NN o
. . o

Knowledge NNP o
and CC o
attitudinal JJ o
changes NNS o
were VBD o
maintained VBN N
at IN N
follow-up NN N
. . N

There EX N
were VBD N
no DT N
spill-over JJ o
effects NNS o
of IN o
the DT N
program NN N
to TO N
non-targeted JJ N
students NNS N
. . N

These DT N
results NNS N
provide VBP N
some DT N
preliminary JJ N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
multi-session NN N
anti-stigma JJ N
programs NNS N
incorporating VBG N
combined VBN N
information NN N
for IN p
adolescent NN p
students NNS p
in IN p
inclusive JJ p
educational JJ p
environments NNS p
. . p

-DOCSTART- -16753722- O O

Greater NNP N
knowledge NN o
gain NN o
with IN N
structured VBN i
than IN N
student-directed JJ i
learning NN i
in IN N
Child NNP p
Health NNP p
: : p
cluster NN N
randomized VBD N
trial NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
detect VB N
a DT N
difference NN N
in IN N
knowledge NN o
gain NN o
between IN N
students NNS p
receiving VBG p
structured JJ i
versus NN i
student-directed JJ i
learning NN i
for IN p
the DT p
two-week JJ p
Child NNP p
Health NNP p
outpatient NN p
module NN p
. . p

A DT p
total NN p
of IN p
138 CD p
phase NN p
3 CD p
( ( p
year NN p
4 CD p
) ) p
medical JJ p
students NNS p
in IN p
10 CD p
two-week JJ p
paediatric JJ p
outpatient NN p
blocks NNS p
at IN p
the DT p
Department NNP p
of IN p
Child NNP p
Health NNP p
, , p
University NNP p
of IN p
Dundee NNP p
, , p
Scotland NNP p
, , N
were VBD N
randomized VBN N
to TO N
student-directed JJ i
or CC i
structured VBN i
learning NN i
between IN N
January NNP N
and CC N
December NNP N
2002 CD N
. . N

Pre- JJ o
and CC o
post-course JJ o
tests NNS o
were VBD N
administered VBN N
at IN N
the DT N
start NN N
and CC N
the DT N
end NN N
of IN N
the DT N
attachment NN N
; : N
129 CD p
students NNS p
sat VBD p
both DT p
tests NNS p
. . p

Results NNS N
are VBP N
presented VBN N
as IN N
mean JJ N
scores NNS N
with IN N
standard JJ N
deviations NNS N
or CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
in IN N
parentheses NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
gain NN o
in IN o
knowledge NN o
of IN N
the DT N
Child NNP N
Health NNP N
core NN N
curriculum NN N
that WDT N
is VBZ N
covered VBN N
in IN N
the DT N
outpatient JJ N
setting NN N
. . N

Although IN N
pre-course JJ o
scores NNS o
were VBD N
similar JJ N
( ( N
student-directed JJ N
25.3 CD N
( ( N
7.3 CD N
) ) N
; : N
structured VBN N
24.8 CD N
( ( N
7.5 CD N
) ) N
) ) N
the DT N
structured JJ N
approach NN N
resulted VBD N
in IN N
higher JJR N
post-course NN o
scores NNS o
in IN N
comparison NN N
with IN N
the DT N
student-directed JJ N
approach NN N
( ( N
student-directed JJ N
41.8 CD N
( ( N
9.4 CD N
) ) N
; : N
structured VBN N
53.8 CD N
( ( N
8.8 CD N
) ) N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

Knowledge NNP o
gain NN o
showed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
learning NN N
approaches NNS N
( ( N
student-directed JJ N
16.5 CD N
( ( N
3.7 CD N
) ) N
; : N
structured VBN N
29.1 CD N
( ( N
3.8 CD N
) ) N
, , N
difference NN N
= VBD N
12.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.3 CD N
to TO N
13.9 CD N
) ) N
) ) N
. . N

Low JJ N
pre-course JJ o
scores NNS o
or CC N
gender VB N
did VBD N
not RB N
affect VB N
knowledge NN o
gain NN o
. . o

In IN N
the DT N
Child NNP N
Health NNP N
outpatient NN N
setting NN N
, , N
the DT N
'traditional NNP N
' POS N
structured JJ N
approach NN N
led VBD N
to TO N
significantly RB N
greater JJR N
knowledge NN o
gain NN o
in IN N
comparison NN N
with IN N
the DT N
'novel NNP N
' POS N
student-directed JJ N
approach NN N
. . N

The DT N
findings NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
careful JJ N
evaluation NN N
of IN N
novel JJ N
medical JJ N
education NN N
strategies NNS N
before IN N
their PRP$ N
implementation NN N
in IN N
medical JJ N
schools NNS N
, , N
and CC N
the DT N
need NN N
for IN N
further JJ N
research NN N
to TO N
define VB N
the DT N
effective JJ N
methods NNS N
for IN N
delivering VBG N
medical JJ N
education NN N
in IN N
Child NNP N
Health NNP N
. . N

-DOCSTART- -19931151- O O

Tetracaine NNP i
( ( i
ametop NN i
) ) i
compared VBN N
to TO N
placebo VB N
for IN N
reducing VBG N
pain NN p
associated VBN p
with IN p
intramuscular JJ p
injection NN p
of IN p
palivizumab NN p
( ( p
synagis NN p
) ) p
. . p

Infants NNS p
receive VBP p
many JJ p
painful JJ p
immunizations NNS p
before IN p
they PRP p
are VBP p
2 CD p
years NNS p
old JJ p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
topical JJ i
tetracaine NN i
reduces VBZ N
the DT N
pain NN p
of IN p
intramuscular JJ p
palivizumab NNS i
compared VBN N
to TO N
placebo VB i
. . i

There EX N
were VBD N
two CD N
study NN N
injections NNS N
, , N
one CD N
with IN N
tetracaine NN i
and CC N
one CD N
with IN N
placebo NN i
. . i

Pain NN o
was VBD N
scored VBN N
by IN N
their PRP$ N
parents NNS N
and CC N
a DT N
pediatric JJ N
nurse NN N
. . N

Topical JJ N
tetracaine NN i
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
pain NN o
score NN o
, , N
although IN N
it PRP N
did VBD N
lead VB N
to TO N
faster VB N
recovery NN o
times NNS N
. . N

Additional JJ N
pain-reduction NN N
strategies NNS N
are VBP N
required VBN N
. . N

-DOCSTART- -16714498- O O

Confidential JJ i
registration NN i
in IN N
health NN N
services NNS N
: : N
randomised VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Human NNP N
rights NNS N
legislation NN N
safeguards VBZ N
the DT N
privacy NN N
and CC N
dignity NN N
of IN N
patients NNS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
in IN N
terms NNS N
of IN N
patient NN N
assessed VBN N
privacy NN N
of IN N
confidential JJ i
registration NN i
. . i

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Emergency NNP p
Department NNP p
, , p
University NNP p
Hospital NNP p
of IN p
Wales NNP p
. . p

PARTICIPANTS VB N
A DT p
total NN p
of IN p
302 CD p
patients NNS p
aged VBN p
over IN p
15 CD p
years NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Binary NNP i
choices NNS i
and CC N
ordinal JJ i
visual JJ i
analogue NN i
scores NNS N
from IN N
a DT N
validated JJ i
questionnaire NN i
on IN i
self NN i
reported VBN i
measures NNS i
: : i
patient NN o
ability NN o
and CC o
preference NN o
to TO o
speak VB o
to TO o
receptionists NNS o
and CC o
disclose VB o
confidential JJ o
information NN o
without IN o
being VBG o
overhead JJ o
and CC o
concern NN o
about IN o
disclosure NN o
of IN o
items NNS o
of IN o
confidential JJ o
personal JJ o
information NN o
. . o

RESULTS NNP N
Patients NNPS N
who WP N
registered VBD N
in IN N
a DT N
screened JJ i
area NN i
felt VBD N
significantly RB N
more RBR N
able JJ N
to TO N
tell VB o
receptionists NNS o
things NNS o
they PRP o
did VBD o
not RB o
want VB o
others NNS o
to TO o
hear VB o
. . o

Control NNP N
patients NNS N
were VBD N
significantly RB N
more RBR N
concerned JJ N
than IN N
intervention NN N
patients NNS N
that WDT N
others NNS o
heard VBP o
their PRP$ o
name NN o
, , o
address NN o
, , o
date NN o
of IN o
birth NN o
, , o
reason NN o
for IN o
emergency NN o
department NN o
attendance NN o
, , o
and CC o
telephone NN o
number NN o
, , o
but CC o
not RB o
their PRP$ o
marital JJ o
status NN o
. . o

Overall NNP N
, , N
intervention NN N
patients NNS N
were VBD N
less RBR N
concerned JJ N
about IN N
disclosure NN o
of IN o
information NN o
and CC N
that IN N
they PRP N
had VBD N
been VBN N
overheard RB N
. . N

CONCLUSIONS NNP N
Patients NNPS N
value NN N
privacy NN N
when WRB N
they PRP N
register VBP N
and CC N
are VBP N
concerned VBN N
if IN N
others NNS N
can MD N
hear VB N
them PRP N
tell VB N
receptionists NNS N
who WP N
they PRP N
are VBP N
, , N
how WRB N
to TO N
contact VB N
them PRP N
, , N
and CC N
why WRB N
they PRP N
are VBP N
there RB N
. . N

Confidential JJ i
registration NN i
should MD N
be VB N
instituted VBN N
in IN N
health NN N
services NNS N
. . N

Confidential JJ i
registration NN i
increased VBD N
patient JJ N
privacy NN N
and CC N
should MD N
be VB N
instituted VBN N
in IN N
health NN N
services NNS N
. . N

-DOCSTART- -7196452- O O

Menstrual JJ o
cycle NN o
symptoms NNS o
in IN N
infertile JJ p
and CC p
control JJ p
subjects NNS p
: : p
a DT N
re-evaluation NN i
of IN i
the DT i
evidence NN i
for IN N
psychological JJ o
changes NNS o
. . o

-DOCSTART- -8849265- O O

Levels NNS N
of IN N
recombinant JJ o
human JJ o
granulocyte NN o
colony-stimulating NN o
factor NN o
in IN N
serum NN N
are VBP N
inversely RB N
correlated VBN N
with IN N
circulating VBG N
neutrophil JJ N
counts NNS N
. . N

Recombinant NNP i
human JJ i
granulocyte NN i
colony-stimulating NN i
factor NN i
( ( i
rhG-CSF NN i
) ) i
is VBZ N
effective JJ N
in IN N
countering VBG N
chemotherapy-induced JJ N
neutropenia NN N
. . N

However RB N
, , N
serum JJ o
rhG-CSF NN o
levels NNS o
can MD N
not RB N
be VB N
maintained VBN N
throughout IN N
the DT N
course NN N
of IN N
rhG-CSF JJ i
therapy NN i
. . i

The DT N
drop NN N
in IN N
serum JJ o
rhG-CSF JJ o
levels NNS o
may MD N
vary VB N
with IN N
the DT N
duration NN N
of IN N
rhG-CSF JJ i
administration NN N
or CC N
with IN N
the DT N
circulating VBG N
neutrophil JJ N
counts NNS N
. . N

We PRP N
investigated VBD N
the DT N
relationship NN N
between IN N
serum JJ o
G-CSF NNP o
levels NNS o
and CC N
circulating VBG o
neutrophil JJ o
counts NNS o
and CC N
the DT N
pharmacokinetics NNS N
of IN N
rhG-CSF NN N
for IN N
patients NNS p
with IN p
lung NN p
cancer NN p
who WP p
had VBD p
been VBN p
treated VBN p
with IN p
myelosuppressive JJ p
chemotherapy NN p
and CC p
then RB p
with IN p
subcutaneous JJ p
rhG-CSF NN i
( ( p
lenograstim NN p
, , p
2 CD p
micrograms NNS p
per IN p
kg NN p
of IN p
body NN p
weight JJ p
per IN p
day NN p
) ) p
. . p

Twelve CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
four CD N
groups NNS N
with IN N
different JJ N
rhG-CSF JJ i
therapy NN i
schedules NNS i
. . i

Serum NNP o
G-CSF JJ o
levels NNS o
were VBD N
measured VBN N
by IN N
an DT N
enzyme JJ N
immunoassay NN N
method NN N
. . N

Serum NNP o
G-CSF NNP o
levels NNS o
during IN N
the DT N
rhG-CSF JJ i
therapy NN i
greatly RB N
exceeded VBD N
endogenous JJ o
G-CSF NNP o
levels NNS o
and CC N
were VBD N
mainly RB N
due JJ N
to TO N
the DT N
presence NN N
of IN N
exogenous JJ N
rhG-CSF NN i
rather RB N
than IN N
increased VBN N
levels NNS N
of IN N
endogenous JJ N
G-CSF NNP N
. . N

Despite IN N
the DT N
duration NN N
of IN N
rhG-CSF JJ i
administration NN N
, , N
serum JJ o
G-CSF NNP o
levels NNS o
during IN N
rhG-CSF JJ i
therapy NN i
were VBD N
inversely RB N
correlated VBN N
with IN N
circulating VBG N
neutrophil JJ N
counts NNS N
( ( N
r2 VB N
= RB N
0.73 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
value NN N
for IN N
the DT N
area NN N
under IN N
the DT N
concentration-time JJ o
curve NN o
of IN N
rhG-CSF NN o
on IN N
the DT N
day NN N
of IN N
neutrophilia NN N
was VBD N
lower JJR N
than IN N
that DT N
on IN N
the DT N
day NN N
of IN N
neutropenia NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
the DT N
fall NN N
in IN N
serum JJ o
G-CSF NNP o
levels NNS o
during IN N
rhG-CSF JJ i
therapy NN i
may MD N
result VB N
from IN N
increased VBN N
clearance NN N
and/or NN N
decreased VBD N
absorption NN N
of IN N
rhG-CSF NN i
, , N
two CD N
processes NNS N
related VBN N
to TO N
circulating VBG N
neutrophil JJ N
counts NNS N
. . N

-DOCSTART- -12201937- O O

Effect NN N
of IN N
diuresis NN N
on IN N
extracorporeal NN N
shockwave VBP N
lithotripsy VBN N
treatment NN N
of IN N
ureteric JJ p
calculi NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
diuresis NN i
during IN N
extracorporeal JJ i
shockwave JJ i
lithotripsy NN i
( ( i
ESWL NNP i
) ) i
treatment NN N
of IN N
ureteric JJ p
calculi NN p
. . p

The DT N
purpose NN N
is VBZ N
to TO N
improve VB N
stone NN N
fragmentation NN N
and CC N
clearance NN N
rates NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
One NNP p
hundred VBD p
and CC p
six CD p
consecutive JJ p
patients NNS p
with IN p
ureteric JJ p
calculi NNS p
at IN p
different JJ p
levels NNS p
were VBD N
treated VBN N
by IN N
ESWL NNP i
using VBG N
Siemens NNP i
Lithostar NNP i
2 CD i
machine NN i
. . i

Patients NNS N
have VBP N
been VBN N
randomized VBN N
into IN N
two CD N
treatment NN N
groups NNS N
. . N

The DT N
first JJ N
group NN N
was VBD N
treated VBN N
by IN N
standard JJ i
ESWL NNP i
and CC N
included VBD N
54 CD N
patients NNS N
. . N

The DT N
second JJ N
group NN N
was VBD N
treated VBN N
by IN N
ESWL NNP i
with IN i
diuresis NN i
during IN i
the DT i
ESWL NNP i
session NN i
. . i

Shock NNP N
waves NNS N
were VBD N
given VBN N
at IN N
a DT N
rate NN N
of IN N
90 CD N
shocks/minute NN N
with IN N
energy NN N
starting VBG N
from IN N
10 CD N
up RB N
to TO N
18 CD N
KV NNP N
. . N

During IN N
the DT N
ESWL NNP N
session NN N
the DT N
patient NN N
belonging NN N
to TO N
the DT N
second JJ N
group NN N
received VBD N
i.v RB N
. . N

infusion NN N
of IN N
500 CD N
ml NNS N
normal JJ N
saline JJ N
containing VBG N
40 CD N
mg JJ N
furosemide RB N
as IN N
a DT N
diuretic JJ N
. . N

The DT N
stone NN o
fragmentation NN o
and CC o
clearance NN o
rates NNS o
were VBD N
the DT N
two CD N
end NN N
points NNS N
for IN N
evaluation NN N
. . N

RESULTS VB N
The DT N
average JJ o
number NN o
of IN o
sessions NNS o
per IN o
stone NN o
was VBD N
1.92 CD N
and CC N
1.5 CD N
and CC N
the DT N
average JJ o
number NN o
of IN o
shocks NNS o
per IN o
stone NN o
was VBD N
6295 CD N
and CC N
5300 CD N
for IN N
the DT N
first JJ N
and CC N
second JJ N
treatment NN N
groups NNS N
respectively RB N
. . N

Stone CD o
fragmentation NN o
rate NN o
was VBD N
47/54 CD N
( ( N
87 CD N
% NN N
) ) N
and CC N
50/52 CD N
( ( N
96.2 CD N
% NN N
) ) N
and CC N
the DT N
stone NN o
clearance NN o
( ( o
success NN o
) ) o
rate NN o
was VBD N
47/54 CD N
( ( N
87 CD N
% NN N
) ) N
and CC N
48/52 CD N
( ( N
92.3 CD N
% NN N
) ) N
for IN N
the DT N
first JJ N
and CC N
the DT N
second JJ N
groups NNS N
respectively RB N
. . N

Analysis NN N
of IN N
the DT N
results NNS N
in IN N
relation NN N
to TO N
stone VB N
location NN N
showed VBD N
that IN N
the DT N
two CD N
treatment NN N
groups NNS N
were VBD N
comparable JJ N
for IN N
upper JJ o
and CC o
middle JJ o
ureteric JJ o
calculi NN o
. . o

However RB N
for IN N
distal JJ N
ureteric JJ N
stones NNS N
, , N
the DT N
addition NN N
of IN N
diuresis NN N
during IN N
ESWL NNP N
was VBD N
associated VBN N
with IN N
a DT N
lower JJR N
mean JJ o
number NN o
of IN o
ESWL NNP o
sessions NNS o
and CC N
shocks NNS o
per IN o
stone NN o
compared VBN N
with IN N
standard JJ N
ESWL NNP N
: : N
1.38 CD N
and CC N
4950 CD N
for IN N
ESWL NNP N
with IN N
diuresis NN N
compared VBN N
with IN N
2.9 CD N
and CC N
8544 CD N
for IN N
standard JJ N
ESWL NNP N
respectively RB N
. . N

The DT N
stone NN o
fragmentation NN o
and CC o
3-month JJ o
clearance NN o
( ( o
success NN o
) ) o
rates NNS o
were VBD N
clearly RB N
higher JJR N
: : N
93.8 CD N
% NN N
and CC N
87.5 CD N
% NN N
respectively RB N
for IN N
ESWL NNP N
with IN N
diuresis NN N
compared VBN N
with IN N
70.6 CD N
% NN N
( ( N
for IN N
both DT N
fragmentation NN N
and CC N
clearance NN N
) ) N
with IN N
standard JJ N
ESWL NNP N
. . N

CONCLUSIONS NNP N
Diuresis NNP N
is VBZ N
a DT N
useful JJ N
, , N
inexpensive JJ N
and CC N
safe JJ N
adjunct NN N
to TO N
ESWL NNP N
of IN N
ureteric JJ N
stones NNS N
. . N

It PRP N
markedly RB N
improves VBZ N
the DT N
results NNS N
of IN N
ESWL NNP N
treatment NN N
of IN N
distal JJ N
ureteric JJ N
stones NNS N
compared VBN N
with IN N
standard JJ N
ESWL NNP N
. . N

-DOCSTART- -8841156- O O

Cost-effectiveness JJ N
analysis NN N
of IN N
serum NN i
vancomycin NN i
concentration NN i
monitoring NN i
in IN N
patients NNS p
with IN p
hematologic JJ p
malignancies NNS p
. . p

OBJECTIVE VB N
This DT N
study NN N
evaluates VBZ N
the DT N
cost-effectiveness NN N
of IN N
vancomycin NN i
serum NN i
concentration NN i
monitoring NN i
in IN N
patients NNS p
with IN p
hematologic JJ p
malignancies NNS p
. . p

METHODS NNP N
The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

Seventy NNP p
immunocompromised VBD p
febrile JJ p
patients NNS p
with IN p
hematologic JJ p
malignancies NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
vancomycin JJ i
therapeutic JJ i
drug NN i
monitoring NN i
group NN i
( ( N
TDM NNP N
group NN N
; : N
n CC N
= VB N
37 CD N
) ) N
or CC N
to TO N
a DT N
control NN i
group NN i
( ( N
n JJ N
= NNP N
33 CD N
) ) N
. . N

Intervention NN N
in IN N
the DT N
TDM NNP N
group NN N
involved VBD N
patient JJ i
follow-up NN i
by IN i
a DT i
clinical JJ i
pharmacist NN i
to TO i
obtain VB i
and CC i
pharmacokinetically RB i
interpret JJ i
serum NN i
vancomycin NN i
concentrations NNS i
for IN i
dosage NN i
individualization NN i
. . i

RESULTS NNP N
Evaluation NNP N
of IN N
all DT N
patients NNS N
included VBD N
global JJ o
clinical JJ o
response NN o
and CC N
nephrotoxicity NN o
, , N
as RB N
well RB N
as IN N
the DT N
economic JJ o
costs NNS o
and CC o
effectiveness JJ o
derived VBN N
from IN N
the DT N
vancomycin JJ i
monitoring NN N
program NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
TDM NNP N
and CC N
control NN N
groups NNS N
in IN N
the DT N
outcome NN N
measures NNS N
, , N
except IN N
for IN N
the DT N
incidence NN o
of IN o
nephrotoxicity NN o
: : o
the DT o
rates NNS o
of IN o
minor JJ o
nephrotoxicity NN o
were VBD N
33.3 CD N
% NN N
and CC N
13.5 CD N
% NN N
in IN N
the DT N
control NN N
and CC N
TDM NNP N
groups NNS N
, , N
respectively RB N
. . N

The DT N
corresponding JJ N
figures NNS N
for IN N
moderate JJ o
nephrotoxicity NN o
were VBD N
9.1 CD N
% NN N
and CC N
0 CD N
% NN N
. . N

Logistic JJ N
regression NN N
analysis NN N
confirmed VBD N
that IN N
TDM NNP N
independently RB N
reduced VBD N
the DT N
incidence NN o
of IN o
nephrotoxicity NN o
in IN N
this DT N
patient JJ N
population NN N
. . N

On IN N
the DT N
basis NN N
of IN N
this DT N
reduced JJ N
nephrotoxicity NN o
, , N
a DT N
incremental JJ o
cost NN o
of IN N
$ $ N
435 CD N
per IN N
case NN N
of IN N
nephrotoxicity NN N
prevented VBN N
was VBD N
found VBN N
for IN N
vancomycin NN i
serum NN N
concentration NN N
monitoring NN N
. . N

CONCLUSIONS VB N
A DT N
decreased JJ o
incidence NN o
of IN o
nephrotoxicity NN o
provides VBZ N
evidence NN N
of IN N
a DT N
real JJ N
clinical JJ N
benefit NN N
to TO N
patient VB N
management NN N
in IN N
patients NNS N
with IN N
hematologic JJ N
malignancies NNS N
. . N

The DT N
TDM NNP N
for IN N
vancomycin NN i
therapy NN N
in IN N
this DT N
high-risk JJ N
population NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
a DT N
cost-effective JJ N
procedure NN N
. . N

-DOCSTART- -25234471- O O

Levels NNS N
of IN N
metals NNS N
in IN N
the DT N
blood NN N
and CC N
specific JJ N
porphyrins NNS N
in IN N
the DT N
urine NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
levels NNS N
of IN N
metals NNS o
in IN o
blood NN o
( ( o
zinc NN o
( ( o
Zn NNP o
) ) o
, , o
copper NN o
( ( o
Cu NNP o
) ) o
, , o
aluminium NN o
( ( o
Al NNP o
) ) o
, , o
lead JJ o
( ( o
Pb NNP o
) ) o
and CC o
mercury NN o
( ( o
Hg NNP o
) ) o
) ) o
, , N
as RB N
well RB N
as IN N
the DT N
specific JJ N
porphyrin NN N
levels NNS N
in IN N
the DT N
urine NN N
of IN N
patients NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
compared VBN p
with IN p
patients NNS p
with IN p
other JJ p
neurological JJ p
disorders NNS p
. . p

The DT N
study NN N
was VBD N
performed VBN N
in IN N
a DT N
group NN p
of IN p
children NNS p
with IN p
ASD NNP p
( ( p
N NNP p
= NNP p
52 CD p
, , p
average JJ p
age NN p
= JJ p
6.2 CD p
years NNS p
) ) p
and CC p
a DT p
control NN p
group NN p
of IN p
children NNS p
with IN p
other JJ p
neurological JJ p
disorders NNS p
( ( p
N NNP p
= NNP p
22 CD p
, , p
average JJ p
age NN p
= JJ p
6.6 CD p
years NNS p
) ) p
, , p
matched VBN p
in IN p
terms NNS p
of IN p
intellectual JJ p
abilities NNS p
( ( p
Mann-Whitney NNP p
U NNP p
= NNP p
565.0 CD p
, , p
p NN p
= NNP p
0.595 CD i
) ) i
. . i

Measurement NN i
of IN o
metals NNS o
in IN o
blood NN o
was VBD o
performed VBN o
by IN i
atomic JJ i
absorption NN i
spectrometry NN i
, , i
while IN i
the DT i
HPLC NNP i
method NN i
via IN i
a DT i
fluorescence NN i
detector NN i
was VBD i
used VBN i
to TO i
test VB i
urinary JJ i
porphyrin NN i
levels NNS i
. . i

Results NNS N
were VBD N
compared VBN N
across IN N
groups NNS N
using VBG N
a DT N
multivariate JJ N
analysis NN N
of IN N
covariance NN N
( ( N
MANCOVA NNP N
) ) N
. . N

In IN N
addition NN N
, , N
a DT N
generalized JJ N
linear JJ N
model NN N
was VBD N
used VBN N
to TO N
establish VB N
the DT N
impact NN N
of IN N
group NN N
membership NN N
on IN N
the DT N
blood NN o
Cu/Zn NNP o
ratio NN o
. . o

In IN N
terms NNS N
of IN o
blood NN o
levels NNS o
of IN o
metals NNS o
, , o
no DT o
significant JJ o
difference NN o
between IN N
the DT N
groups NNS N
was VBD N
found VBN N
. . N

However RB N
, , N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
ASD NNP N
group NN N
had VBD N
significantly RB N
elevated VBN N
blood NN o
Cu/Zn NNP o
ratio NN o
( ( N
Wald NNP N
? . N
( ( N
2 CD N
) ) N
= NN N
6.6 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
= NNP N
0.010 CD N
) ) N
. . N

Additionally RB N
, , o
no DT o
significant JJ o
difference NN o
between IN N
the DT N
groups NNS N
was VBD N
found VBN N
in IN N
terms NNS N
of IN N
uroporphyrin NN o
I PRP o
, , o
heptacarboxyporphyrin NN o
I PRP o
, , o
hexacarboxyporphyrin NN o
and CC o
pentacarboxyporphyrin NN o
I PRP o
. . o

However RB o
, , o
the DT o
levels NNS o
of IN o
coproporphyrin NN o
I PRP o
and CC o
coproporphyrin VB o
III NNP o
were VBD o
lower JJR o
in IN o
the DT N
ASD NNP N
group NN N
compared VBN N
to TO N
the DT N
controls NNS N
. . N

Due NNP N
to TO N
observed VB N
higher JJR N
Cu/Zn NNP o
ratio NN o
, , o
it PRP o
is VBZ N
suggested VBN N
to TO N
test VB o
blood NN o
levels NNS o
of IN o
Zn NNP N
and CC N
Cu NNP N
in IN N
all DT N
autistic JJ N
children NNS N
and CC N
give VB N
them PRP N
a DT N
Zn NNP N
supplement NN N
if IN N
needed VBN N
. . N

-DOCSTART- -25142189- O O

A DT N
randomized JJ N
trial NN N
of IN N
prophylactic JJ i
palifermin NN i
on IN N
gastrointestinal JJ N
toxicity NN N
after IN N
intensive JJ N
induction NN N
therapy NN N
for IN N
acute JJ p
myeloid NN p
leukaemia NN p
. . p

Gastrointestinal NNP N
toxicity NN N
, , N
including VBG N
oral JJ N
mucositis NN N
, , N
is VBZ N
a DT N
frequent JJ N
complication NN N
of IN N
intensive JJ N
combination NN N
chemotherapy NN N
for IN N
acute JJ N
myeloid NN N
leukaemia NN N
( ( N
AML NNP N
) ) N
and CC N
contributes VBZ N
substantially RB N
to TO N
treatment-related JJ N
mortality NN N
. . N

We PRP N
conducted VBD N
a DT N
placebo-controlled JJ N
randomized JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
palifermin NN i
( ( N
keratinocyte JJ N
growth NN N
factor NN N
) ) N
, , N
given VBN N
at IN N
60 CD N
?g/kg NNS N
per IN N
daily JJ N
IV NNP N
for IN N
3 CD N
d NN N
before IN N
and CC N
after IN N
chemotherapy NN N
, , N
for IN N
mucosal NN N
protection NN N
in IN N
adult NN p
patients NNS p
with IN p
previously RB p
untreated VBN p
AML NNP p
receiving VBG p
induction NN p
therapy NN p
with IN p
idarubicin NN p
, , p
high-dose JJ p
cytarabine NN p
and CC p
etoposide NN p
. . p

Among IN p
155 CD p
randomized JJ p
patients NNS p
, , p
there EX p
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
grade NN o
3 CD o
and CC o
4 CD o
oral JJ o
mucositis NN o
( ( o
primary JJ o
study NN N
endpoint NN N
) ) N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
( ( N
three CD N
in IN N
palifermin NN i
arm NN i
( ( N
4 CD N
% NN N
) ) N
, , N
8 CD N
in IN N
placebo NN i
arm NN i
( ( N
10 CD N
% NN N
; : N
P NNP N
= NNP N
0?21 CD N
) ) N
; : N
however RB N
, , N
when WRB N
considering VBG o
the DT o
severity NN o
of IN o
oral JJ o
mucositis NN o
( ( o
World NNP o
Health NNP N
Organization NNP N
grade VBD N
0-4 NNP N
) ) N
, , N
there EX N
was VBD N
evidence NN N
of IN N
reduced JJ o
rates NNS o
of IN o
higher JJR o
grades NNS o
of IN o
oral JJ o
mucositis NN o
in IN o
the DT o
palifermin NN i
arm NN i
( ( i
P NNP N
= NNP N
0?0007 CD N
, , N
test NN N
for IN N
trend NN N
) ) N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significantly RB N
lower JJR N
rate NN o
of IN o
grades NNS o
3 CD o
and CC o
4 CD o
gastrointestinal JJ o
adverse JJ o
events NNS o
in IN o
the DT i
palifermin NN i
arm NN i
( ( i
21 CD i
% NN i
vs. FW N
44 CD N
% NN N
in IN N
placebo JJ N
arm NN N
; : N
P NNP N
= NNP N
0?003 CD N
) ) N
, , N
mainly RB N
due JJ N
to TO N
a DT N
reduction NN N
in IN N
severe JJ o
diarrhoea NN o
( ( o
8 CD N
% NN N
palifermin NN N
, , N
26 CD i
% NN i
placebo NN i
; : N
P NNP N
= NNP N
0?01 CD i
) ) i
. . i

Palifermin NNP i
has VBZ i
activity NN N
as IN N
a DT N
mucosal NN N
protectant NN N
in IN N
AML NNP N
patients NNS N
receiving VBG N
intensive JJ N
chemotherapy NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
ACTRN012605000095662 NNP N
. . N

-DOCSTART- -11414348- O O

Four-year JJ N
outcomes NNS N
from IN N
adolescent JJ i
alcohol NN i
and CC i
drug NN i
treatment NN i
. . i

OBJECTIVE NNP N
Knowledge NNP N
of IN N
treatment NN N
response NN N
for IN N
alcohol NN N
and CC N
drug NN N
problems NNS N
among IN N
adults NNS N
is VBZ N
mounting VBG N
; : N
less CC N
is VBZ N
known VBN N
about IN N
long-term JJ N
outcome NN N
for IN N
adolescents NNS p
who WP p
receive VBP p
treatment NN i
for IN i
alcohol NN i
and CC i
drug NN i
problems NNS i
. . i

The DT N
current JJ N
study NN N
examined VBD N
youth JJR N
substance NN N
involvement NN N
over IN N
4 CD N
years NNS N
( ( N
using VBG N
five CD N
waves NNS N
of IN N
data NNS N
collection NN N
) ) N
following VBG N
treatment NN i
for IN i
alcohol NN i
and CC i
drug NN i
abuse NN i
. . i

METHOD NNP N
A NNP p
cohort NN p
of IN p
youth NN p
( ( p
N NNP p
= NNP p
162 CD p
, , p
60 CD p
% NN p
male NN p
) ) p
treated VBD p
during IN p
adolescence NN p
( ( p
mean JJ p
age NN p
= VBD p
16 CD p
years NNS p
) ) p
was VBD p
followed VBN p
into IN p
young JJ p
adulthood NN p
, , N
a DT N
period NN N
associated VBN N
with IN N
stabilization NN N
of IN N
alcohol NN N
use NN N
patterns NNS N
and CC N
elevated VBN N
risk NN N
for IN N
life NN N
problems NNS N
secondary JJ N
to TO N
both DT N
alcohol NN N
and CC N
drug NN N
use NN N
. . N

Participants NNS p
( ( p
14-18 CD p
years NNS p
old JJ p
) ) p
were VBD p
consecutive JJ p
admissions NNS p
to TO p
inpatient VB p
adolescent JJ p
alcohol NN p
and CC p
drug NN p
treatment NN p
centers NNS p
in IN p
San NNP p
Diego NNP p
that WDT p
were VBD p
abstinence NN p
focused VBN p
and CC p
based VBN p
on IN p
the DT p
12-step JJ p
approach NN p
. . p

RESULTS NNP N
Alcohol NNP o
and CC o
other JJ o
drug NN o
use NN o
were VBD N
reduced VBN N
during IN N
the DT N
4 CD N
years NNS N
posttreatment JJ N
, , N
with IN N
the DT N
exception NN N
of IN N
nicotine NN N
. . N

The DT N
greatest JJS N
prevalence NN o
reduction NN o
occurred VBD N
for IN N
stimulants NNS N
; : N
modest JJ N
changes NNS N
were VBD N
evident JJ N
in IN N
alcohol NN N
and CC N
marijuana NN N
use NN N
. . N

Nicotine NN N
was VBD N
the DT N
most RBS N
commonly RB N
used VBN N
substance NN N
throughout IN N
the DT N
4 CD N
years NNS N
after IN N
treatment NN N
. . N

Several JJ N
distinct JJ N
substance NN N
involvement NN N
trajectories NNS N
were VBD N
evident JJ N
during IN N
the DT N
4 CD N
years NNS N
following VBG N
treatment NN N
. . N

CONCLUSIONS NNP N
Alcohol NNP N
and CC N
drug NN N
use NN N
patterns NNS N
during IN N
the DT N
4 CD N
years NNS N
following VBG N
treatment NN N
highlight VBD N
both DT N
changes NNS N
and CC N
diversity NN N
in IN N
substance NN N
involvement NN N
as IN N
youth NN N
make VBP N
the DT N
transitions NNS N
from IN N
middle JJ N
to TO N
late JJ N
adolescence NN N
and CC N
into IN N
young JJ N
adulthood NN N
. . N

Findings NNS N
demonstrate VBP N
the DT N
importance NN N
of IN N
identifying VBG N
transitional JJ N
periods NNS N
and CC N
the DT N
need NN N
for IN N
alternative JJ N
intervention NN N
strategies NNS N
that WDT N
may MD N
help VB N
the DT N
progression NN N
of IN N
this DT N
population NN N
into IN N
young JJ N
adulthood NN N
. . N

-DOCSTART- -1616359- O O

Double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
study NN N
of IN N
metronidazole NN i
as IN p
a DT p
disease NN p
modifying VBG p
agent NN p
in IN p
the DT p
treatment NN p
of IN p
rheumatoid JJ p
arthritis NN p
. . p

Anecdotal JJ N
reports NNS N
suggest VBP N
that IN N
metronidazole NN N
may MD N
have VB N
disease NN N
modifying VBG N
activity NN N
in IN N
the DT N
treatment NN p
of IN p
rheumatoid JJ p
arthritis NN p
. . p

To TO N
assess VB N
possible JJ N
beneficial JJ o
effects NNS o
a DT N
double JJ N
blind NN N
, , N
comparative JJ N
trial NN N
of IN i
metronidazole NN i
and CC i
placebo NN i
was VBD N
performed VBN N
. . N

Fifty JJ p
patients NNS p
with IN p
active JJ p
rheumatoid NN p
arthritis NN p
were VBD p
randomly RB p
allocated VBN p
to TO p
receive VB p
active JJ i
drug NN i
( ( p
n JJ p
= NNP p
24 CD p
) ) p
or CC i
placebo NN i
( ( p
n JJ p
= NNP p
26 CD p
) ) p
and CC p
reviewed VBN p
at IN p
weeks NNS p
0 CD p
, , p
1 CD p
, , p
4 CD p
, , p
8 CD p
, , p
12 CD p
, , p
16 CD p
, , p
and CC p
24 CD p
. . p

Detailed JJ o
assessment NN o
of IN N
drug NN o
safety NN o
, , o
biochemical JJ o
and CC o
haematological JJ o
parameters NNS o
, , N
and CC N
efficacy NN o
was VBD N
made VBN N
at IN N
these DT N
dates NNS N
. . N

Dose NNP N
regimen NNS N
was VBD N
400 CD N
mg JJ N
twice RB N
daily RB N
from IN N
weeks NNS N
0 CD N
to TO N
eight CD N
, , N
increasing VBG N
to TO N
400 CD N
mg NNS N
three CD N
times NNS N
a DT N
day NN N
from IN N
weeks NNS N
nine CD N
to TO N
24 CD N
provided VBD N
that IN N
no DT N
adverse JJ N
effects NNS N
were VBD N
recorded VBN N
. . N

Most JJS N
patients NNS N
were VBD N
unable JJ N
to TO N
tolerate VB o
metronidazole NN o
because IN N
of IN N
side NN o
effects NNS o
or CC N
lack NN o
of IN o
efficacy NN o
, , N
with IN N
only RB N
five CD N
( ( N
21 CD N
% NN N
) ) N
continuing VBG N
to TO N
take VB N
the DT N
drug NN N
at IN N
24 CD N
weeks NNS N
. . N

For IN N
those DT N
patients NNS N
attaining VBG N
12 CD N
weeks NNS N
of IN N
treatment NN N
an DT N
overall JJ o
improvement NN o
in IN o
articular JJ o
index NN o
and CC o
morning NN o
stiffness NN o
was VBD N
found VBN N
. . N

No DT N
improvement NN o
in IN N
laboratory JJ o
indices NNS o
of IN o
disease NN o
activity NN o
was VBD N
seen VBN N
, , N
however RB N
. . N

In IN N
this DT N
study NN N
metronidazole NN N
did VBD N
not RB N
have VB N
disease NN o
modifying VBG o
properties NNS o
and CC N
was VBD N
unacceptably RB o
toxic JJ o
. . o

-DOCSTART- -8731496- O O

Effect NN N
of IN N
chronic JJ i
aerobic JJ i
exercise NN i
and CC i
progressive JJ i
relaxation NN i
on IN N
motor NN N
performance NN N
and CC N
affect NN N
following VBG N
acute JJ N
stress NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
10-week JJ N
aerobic JJ i
exercise NN i
and CC i
progressive JJ i
relaxation NN i
training VBG N
program NN N
on IN N
somatic JJ N
, , N
emotional JJ N
, , N
and CC N
behavioral JJ N
responses NNS N
to TO N
acute VB N
stress NN N
, , N
as IN N
determined VBN N
by IN N
quality NN N
of IN N
motor NN N
performance NN N
and CC N
affect NN N
, , N
were VBD N
examined VBN N
. . N

The DT N
participants NNS N
consisted VBD N
of IN N
60 CD p
unfit JJ p
male NN p
university NN p
undergraduate JJ p
students NNS p
with IN p
no DT p
previous JJ p
training NN p
in IN p
stress JJ p
management NN p
who WP N
were VBD N
randomly RB N
and CC N
evenly RB N
assigned VBD N
to TO N
engage VB N
in IN N
one CD i
of IN i
four CD i
treatments NNS i
over IN i
10 CD i
weeks NNS i
: : i
( ( i
a DT i
) ) i
moderate NN i
aerobic JJ i
exercise NN i
, , i
( ( i
b NN i
) ) i
progressive NN i
relaxation NN i
, , i
( ( i
c NN i
) ) i
a DT i
placebo NN i
group NN i
that WDT i
engaged VBD i
in IN i
group NN i
discussion NN i
but CC i
did VBD i
experience VB i
acute NN i
stress NN i
, , i
and CC i
( ( i
d NN i
) ) i
a DT i
nonintervention NN i
control NN i
group NN i
that WDT i
did VBD i
not RB i
experience VB i
stress NN i
while IN i
performing VBG i
the DT i
motor NN i
task NN i
. . i

Acute NNP N
stress NN N
consisted VBD N
of IN N
losing VBG N
against IN N
a DT N
competitor NN N
of IN N
the DT N
opposite JJ N
sex NN N
on IN N
the DT N
criterion NN N
motor NN N
task NN N
while IN N
receiving VBG N
unpleasant JJ N
information NN N
about IN N
their PRP$ N
performance NN N
over IN N
30 CD N
preintervention NN N
and CC N
30 CD N
postintervention NN N
trials NNS N
. . N

Analyses NNS N
indicated VBD N
that IN N
aerobic JJ N
exercisers NNS N
, , N
in IN N
comparisons NNS N
with IN N
the DT N
other JJ N
groups NNS N
, , N
responded VBD N
to TO N
acute VB o
stress NN o
with IN N
more RBR N
positive JJ N
affect NN N
, , N
lower JJR o
stressor NN o
task JJ o
heart NN o
rate NN o
, , o
reduced VBN o
systolic JJ o
( ( o
but CC o
not RB o
diastolic JJ o
) ) o
blood NN o
pressure NN o
, , N
and CC N
superior JJ N
motor NN o
performance NN o
. . o

Progressive JJ N
relaxation NN N
markedly RB N
reduced VBD N
systolic JJ o
blood NN o
pressure NN o
but CC N
did VBD N
not RB N
favorably RB N
influence JJ N
performance NN N
or CC N
affect VB N
in IN N
response NN N
to TO N
acute VB o
stress NN o
. . o

Placebo NNP N
and CC N
control NN N
groups NNS N
were VBD N
statistically RB N
similar JJ N
on IN N
all DT N
measures NNS N
. . N

The DT N
findings NNS N
indicated VBD N
support NN N
for IN N
the DT N
use NN N
of IN N
chronic JJ N
aerobic JJ N
exercise NN N
as IN N
a DT N
strategy NN N
for IN N
improved JJ N
coping NN N
with IN N
acute JJ N
stress NN N
. . N

-DOCSTART- -21145428- O O

Right RB i
ventricular JJ i
pacing VBG i
in IN p
MADIT-II NNP p
: : p
a DT N
risk NN N
factor NN N
for IN N
increased JJ N
mortality NN o
, , N
or CC N
mainly RB N
a DT N
marker NN o
of IN o
increased VBN o
risk NN o
. . o

-DOCSTART- -20815045- O O

Comparison NNP N
of IN N
three-year JJ N
clinical JJ o
outcomes NNS o
between IN N
sirolimus-versus JJ i
paclitaxel-eluting JJ i
stents NNS i
in IN p
diabetic JJ p
patients NNS p
: : p
prospective JJ N
randomized VBN N
multicenter NN N
trial NN N
. . N

BACKGROUND NNP N
Three-year JJ N
follow-up NN N
of IN N
major JJ o
adverse JJ o
cardiovascular JJ o
event NN o
( ( o
MACE NNP o
) ) o
( ( o
death NN o
, , o
nonfatal JJ o
myocardial JJ o
infarction NN o
, , o
target NN o
lesion NN o
revascularization NN o
) ) o
and CC N
the DT N
predictors NNS o
of IN o
MACEs NNP o
in IN p
diabetic JJ p
patients NNS p
after IN p
sirolimus-eluting JJ i
stent NN i
( ( i
SES NNP i
) ) i
or CC i
paclitaxel-eluting JJ i
stent NN i
( ( i
PES NNP i
) ) i
implantation NN i
have VBP N
not RB N
been VBN N
reported VBN N
. . N

METHODS NNP N
Diabetic NNP p
patients NNS p
with IN p
de FW p
novo FW p
coronary JJ p
lesions NNS p
( ( p
169 CD p
patients NNS p
with IN p
190 CD p
lesions NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
prospectively RB N
to TO N
either DT N
SES NNP i
or CC i
PES NNP i
. . i

RESULTS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
rates NNS o
of IN o
MACEs NNP o
[ NNP N
5.9 CD N
% NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
in IN N
the DT N
SES NNP i
vs. FW N
9.5 CD N
% NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
in IN N
the DT N
PES NNP i
Group NNP N
, , N
P NNP N
= VBZ N
0.374 CD N
] NN N
and CC N
definite JJ o
stent JJ o
thrombosis NN o
[ VBD N
1.2 CD N
% NN N
( ( N
n JJ N
= NNP N
1 CD N
) ) N
in IN N
the DT N
SES NNP i
vs. FW N
3.6 CD N
% NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
in IN N
the DT N
PES NNP i
Group NNP N
, , N
P NNP N
= VBZ N
0.368 CD N
] NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
during IN N
the DT N
three-year JJ N
follow-up NN N
. . N

Multivariate NNP N
logistic JJ N
analysis NN N
showed VBD N
that IN N
insulin NN N
treatment NN N
was VBD N
the DT N
only JJ N
independent JJ o
predictor NN o
of IN N
MACE NNP o
[ NNP N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
8.60 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
3.25-22.76 CD N
, , N
P NNP N
< VBZ N
0.001 CD N
] NN N
and CC N
target NN o
vessel NN o
revascularization NN o
( ( o
TVR NNP o
) ) o
( ( N
OR $ N
9.50 CD N
, , N
95 CD N
% NN N
CI NNP N
3.07-29.44 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
during IN N
the DT N
three-year JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
rates NNS o
of IN o
MACEs NNP o
, , o
TVR NNP o
, , o
and CC o
stent JJ o
thrombosis NN o
during IN N
the DT N
three-year JJ N
follow-up NN N
were VBD N
similar JJ N
in IN N
the DT N
SES NNP i
and CC i
PES NNP i
Groups NNP N
. . N

Insulin NNP N
treatment NN N
was VBD N
a DT N
main JJ N
predictor NN N
of IN N
MACEs NNP o
and CC o
TVR NNP o
during IN N
the DT N
three-year JJ N
follow-up NN N
after IN N
either DT N
SES NNP i
or CC N
PES NNP i
implantation NN N
. . N

-DOCSTART- -6958487- O O

Budesonide NNP i
and CC i
beclomethasone NN i
dipropionate NN i
in IN N
hay NN p
fever NN p
- : N
a DT N
single JJ N
blind NN N
comparison NN N
. . N

93 CD p
patients NNS p
with IN p
seasonal JJ p
allergic JJ p
rhinitis NN p
took VBD N
part NN N
in IN N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
comparison NN N
of IN N
budesonide NN i
and CC i
beclomethasone NN i
dipropionate NN i
( ( i
Becotide NNP i
Nasal NNP i
) ) i
. . i

All DT p
patients NNS p
were VBD p
sensitive JJ p
to TO p
either DT p
birch NN p
or CC p
grass NN p
pollen NN p
, , p
their PRP$ p
sensitivity NN p
being VBG p
confirmed VBN p
by IN p
a DT p
skin NN p
prick NN p
test NN p
. . p

The DT N
total JJ N
daily JJ N
dose NN N
was VBD N
400 CD N
micrograms NNS N
for IN N
both DT N
drugs NNS N
. . N

Budesonide NNP i
was VBD N
administered VBN N
twice RB N
a DT N
day NN N
and CC N
Becotide NNP i
Nasal NNP i
four CD N
times NNS N
a DT N
day NN N
. . N

Symptoms NNS N
were VBD N
assessed VBN N
over IN N
a DT N
four-week JJ N
period NN N
starting VBG N
with IN N
a DT N
run-in JJ N
period NN N
of IN N
one CD N
week NN N
. . N

There EX N
was VBD N
no DT N
placebo NN N
control NN N
group NN N
. . N

Daily NNP o
pollen NN o
counts NNS o
were VBD N
measured VBN N
throughout IN N
the DT N
trial NN N
. . N

The DT N
patients NNS N
' POS N
diary JJ N
cards NNS N
revealed VBD N
that IN N
both DT N
drugs NNS N
had VBD N
a DT N
beneficial JJ N
therapeutic JJ N
effect NN N
, , N
and CC N
that IN N
budesonide NN i
was VBD N
significantly RB N
more RBR N
active JJ N
than IN N
Becotide NNP i
Nasal NNP i
. . i

The DT N
side NN o
effects NNS o
of IN N
both DT N
drugs NNS N
were VBD N
few JJ N
and CC N
transient NN N
. . N

-DOCSTART- -6844471- O O

Breathlessness NNP N
and CC N
psychiatric JJ N
morbidity NN N
in IN N
chronic JJ p
bronchitis NN p
and CC p
emphysema NN p
: : p
a DT N
study NN N
of IN N
psychotherapeutic JJ i
management NN i
. . i

This DT N
paper NN N
describes VBZ N
a DT N
study NN N
of IN N
the DT N
outcome NN N
of IN N
psychotherapy NN i
with IN N
patients NNS p
disabled VBN p
by IN p
chronic JJ p
obstructive JJ p
airways NNS p
disease NN p
giving VBG p
rise NN p
to TO p
dyspnoea VB p
. . p

Forty-three JJ p
men NNS p
and CC p
22 CD p
women NNS p
with IN p
severe JJ p
COAD NNP p
were VBD N
randomly RB N
allocated VBN N
for IN N
8 CD i
weeks NNS i
to TO i
one CD i
of IN i
three CD i
types NNS i
of IN i
psychotherapy NN i
or CC i
to TO i
an DT i
untreated JJ i
control NN i
group NN i
, , i
and CC i
were VBD i
followed VBN i
up RP i
six CD i
months NNS i
later RB i
. . i

The DT N
group NN N
treated VBN N
by IN N
a DT N
medical JJ N
nurse NN N
without IN N
training NN N
in IN N
psychotherapy NN i
experienced VBD N
sustained JJ N
relief NN N
of IN N
dyspnoea NN o
but CC N
tended VBD N
to TO N
undergo VB N
less JJR N
psychodynamic JJ o
change NN o
; : o
psychiatric JJ o
symptoms NNS o
were VBD N
reduced VBN N
in IN N
those DT N
receiving VBG N
supportive JJ N
, , N
but CC N
not RB N
analytical JJ N
, , N
psychotherapy NN i
. . i

The DT N
psychosomatic JJ N
mechanisms NNS N
involved VBN N
and CC N
the DT N
implications NNS N
for IN N
medical JJ N
and CC N
nursing JJ N
practice NN N
and CC N
for IN N
liaison JJ N
psychotherapy NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -11978277- O O

Prolonged NNP i
GnRH NNP i
agonist NN i
and CC i
add-back JJ i
therapy NN i
for IN N
symptomatic JJ o
endometriosis NN o
: : o
long-term JJ N
follow-up NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
post-treatment JJ N
effects NNS N
in IN N
endometriosis NN p
patients NNS p
of IN p
a DT p
12-month JJ p
course NN p
of IN p
GnRH NNP i
agonist VBP i
alone RB p
or CC p
with IN p
one CD p
of IN p
three CD i
add-back JJ i
regimens NNS i
. . i

METHODS NNP N
This DT N
is VBZ N
a DT N
post-treatment JJ N
follow-up JJ N
analysis NN N
of IN N
a DT N
randomized JJ N
, , N
double-masked JJ N
, , N
placebo-controlled JJ i
52-week JJ N
trial NN N
. . N

All DT p
patients NNS p
had VBD p
received VBN p
monthly JJ p
leuprolide NN i
acetate NN i
and CC N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
four CD N
groups NNS N
: : N
A-daily JJ N
placebo NN i
; : i
B-daily NNP N
norethindrone NN i
acetate NN i
5 CD N
mg NN N
; : N
C-daily NNP i
norethindrone NN i
acetate NN i
5 CD N
mg NN N
and CC N
conjugated VBD i
equine NN i
estrogens VBZ i
0.625 CD N
mg NN N
; : N
and CC N
D-daily NNP N
norethindrone NN i
acetate NN i
5 CD N
mg NN N
and CC N
conjugated VBD i
equine NN i
estrogens VBZ i
1.25 CD N
mg. NN N
Of IN N
201 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
initial JJ p
trial NN p
, , p
123 CD p
completed VBN p
at IN p
least JJS p
280 CD p
days NNS p
of IN p
therapy NN p
and CC p
entered VBD p
the DT p
follow-up JJ p
period NN p
. . p

Physical JJ o
findings NNS o
and CC o
symptoms NNS o
were VBD N
quantified VBN N
, , N
and CC N
lumbar JJS o
spine NN o
bone NN o
mineral JJ o
density NN o
was VBD N
determined VBN N
at IN N
intervals NNS N
for IN N
up IN N
to TO N
12 CD N
and CC N
24 CD N
months NNS N
post-therapy JJ N
. . N

RESULTS NNP N
Symptom NNP o
and CC o
pelvic JJ o
examination NN o
scores NNS o
remained VBD N
significantly RB N
below IN N
baseline NN N
for IN N
at IN N
least JJS N
8 CD N
months NNS N
after IN N
completion NN N
of IN N
therapy NN N
for IN N
all DT N
four CD N
groups NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Findings NNS N
were VBD N
not RB N
affected VBN N
by IN N
endometriosis NN o
scores NNS o
noted VBD N
on IN N
screening VBG N
laparoscopy NN N
. . N

Mean NNP o
bone JJ o
mineral NN o
density NN o
values NNS o
remained VBD N
at IN N
or CC N
above JJ N
baseline NN N
in IN N
all DT N
add-back JJ N
groups NNS N
. . N

The DT N
significant JJ N
mean JJ N
loss NN o
in IN o
bone NN o
density NN o
in IN N
group NN N
A NNP N
during IN N
therapy NN N
reversed VBN N
slowly RB N
and CC N
had VBD N
not RB N
returned VBN N
to TO N
baseline VB N
at IN N
the DT N
final JJ N
follow-up JJ N
visit NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSION NNP N
GnRH NNP i
agonist NN i
and CC N
norethindrone JJ i
acetate NN i
alone RB i
or CC N
combined VBN N
with IN N
low-dose JJ i
conjugated JJ i
equine NN i
estrogens NNS i
administered VBN N
to TO N
symptomatic JJ p
endometriosis NN p
patients NNS p
for IN N
12 CD N
months NNS N
provides VBZ N
extended JJ N
pain NN o
relief NN o
and CC N
bone JJ o
mineral JJ o
density NN o
preservation NN N
after IN N
completion NN N
of IN N
therapy NN N
. . N

-DOCSTART- -19155155- O O

Effectiveness NN N
of IN N
education NN N
for IN N
gastric JJ p
cancer NN p
patients NNS p
: : p
a DT N
controlled JJ N
prospective JJ N
trial NN N
comparing VBG N
interactive JJ i
vs. FW i
lecture-based JJ i
programs NNS i
. . i

OBJECTIVE CC N
Although IN N
patient JJ i
education NN i
may MD N
enhance VB N
knowledge NN N
, , N
coping VBG N
with IN N
illness NN N
, , N
and CC N
quality NN N
of IN N
life NN N
among IN N
cancer NN p
patients NNS p
, , N
it PRP N
is VBZ N
uncertain JJ N
which WDT N
didactic JJ N
method NN N
is VBZ N
most RBS N
effective JJ N
. . N

We PRP N
compared VBN N
the DT N
impact NN N
of IN N
an DT N
interactive JJ i
, , i
patient-oriented JJ i
group NN i
program NN i
to TO i
a DT i
lecture-based JJ i
, , i
information-only JJ i
program NN i
in IN N
gastric JJ p
cancer NN p
patients NNS p
. . p

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
controlled JJ N
trial NN N
, , N
121 CD p
gastric JJ p
cancer NN p
patients NNS p
attending VBG p
inpatient JJ p
rehabilitation NN p
after IN p
surgical JJ p
treatment NN p
received VBD N
either CC N
the DT N
interactive JJ i
intervention NN i
or CC i
lectures VBZ i
providing VBG i
information NN i
. . i

The DT N
outcomes NNS N
were VBD N
patients NNS o
' POS o
disease-related JJ o
knowledge NN o
, , o
active JJ o
coping VBG o
with IN o
illness NN o
, , o
and CC o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
at IN N
the DT N
end NN N
of IN N
their PRP$ N
stay NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
thereafter RB N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
improved VBD o
their PRP$ o
knowledge NN o
and CC o
QoL NNP o
during IN o
rehabilitation NN o
; : o
however RB N
, , N
knowledge NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
interactive JJ N
group NN N
compared VBN N
to TO N
the DT N
lecture NN N
group NN N
. . N

This DT N
difference NN N
was VBD N
maintained VBN N
at IN N
the DT N
6- JJ N
and CC N
12-months JJ N
follow-ups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
interactive JJ N
group NN N
proved VBD N
superior JJ N
to TO N
the DT N
lecture NN N
group NN N
regarding VBG N
active JJ o
coping NN o
with IN o
illness NN o
and CC N
QoL NNP o
at IN N
the DT N
end NN N
of IN N
rehabilitation NN N
, , N
but CC N
not RB N
during IN N
follow-up JJ N
. . N

CONCLUSIONS VB N
A DT N
structured JJ N
, , N
interactive JJ N
patient JJ N
education NN N
program NN N
proved VBD N
superior JJ N
to TO N
lecture-based JJ N
provision NN N
of IN N
information NN N
in IN N
regards NNS N
to TO N
short-term JJ N
and CC N
long-term JJ N
knowledge NN N
as RB N
well RB N
as IN N
short-term JJ N
coping NN N
and CC N
QoL NNP N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
In IN N
gastric JJ N
cancer NN N
patients NNS N
, , N
interactive JJ i
patient NN i
education NN i
seems VBZ N
preferable JJ N
over IN N
lectures NNS N
. . N

-DOCSTART- -8940983- O O

The DT N
immunogenicity NN o
of IN N
three CD N
Haemophilus NNP i
influenzae NN i
type NN i
B NNP i
conjugate NN i
vaccines NNS i
after IN p
a DT p
primary JJ p
vaccination NN p
series NN p
in IN p
Philippine NNP p
infants NNS p
. . p

Serum NNP o
antibody NN o
responses NNS o
to TO N
three CD N
Haemophilus NNP i
influenzae NN i
type NN i
b NN i
( ( i
Hib NNP i
) ) i
capsular VBD i
polysaccharide-protein JJ i
conjugate NN i
vaccine NN i
( ( i
PRP-OMP NNP i
, , i
PRP-T NNP i
, , i
and CC i
HbOC NNP i
) ) i
were VBD N
evaluated VBN N
in IN p
174 CD p
Philippine JJ p
infants NNS p
after IN p
a DT p
primary JJ p
vaccination NN p
series NN p
. . p

Children NNP N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
Hib NNP i
vaccines NNS i
( ( i
Hib NNP i
groups NNS i
) ) i
or CC i
into IN i
a DT i
control NN i
group NN i
. . i

Vaccination NNP N
was VBD N
carried VBN N
out RP N
at IN N
six CD N
, , N
10 CD N
and CC N
14 CD N
weeks NNS N
of IN N
age NN N
based VBN N
on IN N
the DT N
local JJ N
Expanded NNP N
Program NNP N
of IN N
Immunization NNP N
schedule NN N
. . N

Sera NN N
were VBD N
collected VBN N
at IN N
six CD N
weeks NNS N
of IN N
age NN N
for IN N
the DT N
Hib NNP N
groups NNS N
and CC N
one CD N
month NN N
after IN N
the DT N
third JJ N
dose NN N
for IN N
all DT N
subjects NNS N
. . N

Anti-Hib JJ o
concentrations NNS o
were VBD o
determined VBN o
by IN o
the DT o
Farr-type NNP o
radioimmunoassay NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
= NNP N
0.3626 CD N
) ) N
in IN N
the DT N
prevaccination NN o
anti-Hib JJ o
geometric JJ o
mean NN o
concentration NN o
( ( o
GMC NNP o
) ) o
among IN N
the DT N
three CD N
Hib NNP N
groups NNS N
. . N

Differences NNS N
in IN N
the DT N
GMC NNP o
after IN N
the DT N
primary JJ N
series NN N
of IN N
three CD N
doses NNS N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
; : N
GMC NNP o
was VBD N
highest JJS N
for IN N
PRP-T NNP N
( ( N
6.62 CD N
micrograms/ml NN N
) ) N
, , N
followed VBN N
by IN N
HbOC NNP N
( ( N
1.9 CD N
micrograms/ml NN N
) ) N
, , N
then RB N
PRP-OMP NNP N
( ( N
1.06 CD N
micrograms/ml NN N
) ) N
, , N
and CC N
lowest JJS N
for IN N
the DT N
control NN N
group NN N
( ( N
0.11 CD N
microgram/ml NN N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
all DT N
three CD N
Hib NNP i
conjugate NN i
vaccines NNS i
( ( i
PRP-T NNP i
, , i
HbOC NNP i
, , N
and CC N
PRP-OMP NNP i
) ) i
were VBD N
immunogenic JJ o
after IN N
three CD N
primary JJ N
doses NNS N
among IN N
Philippine JJ p
infants NNS p
. . p

-DOCSTART- -19487623- O O

Lack NN N
of IN N
efficacy NN o
of IN N
citalopram NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
high JJ p
levels NNS p
of IN p
repetitive JJ p
behavior NN p
: : p
citalopram NN i
ineffective NN N
in IN N
children NNS p
with IN p
autism NN p
. . p

CONTEXT NNP N
Selective NNP i
serotonin NN i
reuptake NN i
inhibitors NNS i
are VBP N
widely RB N
prescribed VBN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
citalopram JJ i
hydrobromide NN i
therapy NN i
for IN N
repetitive JJ N
behavior NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

DESIGN NNP N
National NNP N
Institutes NNPS N
of IN N
Health-sponsored NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Six NNP p
academic JJ p
centers NNS p
, , p
including VBG p
Mount NNP p
Sinai NNP p
School NNP p
of IN p
Medicine NNP p
, , p
North NNP p
Shore-Long NNP p
Island NNP p
Jewish NNP p
Health NNP p
System NNP p
, , p
University NNP p
of IN p
North NNP p
Carolina NNP p
at IN p
Chapel NNP p
Hill NNP p
, , p
University NNP p
of IN p
California NNP p
at IN p
Los NNP p
Angeles NNP p
, , p
Yale NNP p
University NNP p
, , p
and CC p
Dartmouth NNP p
Medical NNP p
School NNP p
. . p

PARTICIPANTS NNP N
One CD p
hundred VBD p
forty-nine JJ p
volunteers NNS p
5 CD p
to TO p
17 CD p
years NNS p
old JJ p
( ( p
mean JJ p
[ NNP p
SD NNP p
] NNP p
age NN p
, , p
9.4 CD p
[ NN p
3.1 CD p
] CD p
years NNS p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
citalopram NN i
( ( N
n JJ N
= NNP N
73 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Participants NNS p
had VBD p
autistic JJ p
spectrum NN p
disorders NNS p
, , p
Asperger NNP p
disorder NN p
, , p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
, , p
not RB p
otherwise RB p
specified VBN p
; : p
had VBD p
illness JJ p
severity NN p
ratings NNS p
of IN p
at IN p
least JJS p
moderate JJ p
on IN p
the DT p
Clinical NNP p
Global NNP p
Impressions NNP p
, , p
Severity NNP p
of IN p
Illness NNP p
Scale NNP p
; : p
and CC p
scored VBD p
at IN p
least JJS p
moderate JJ p
on IN p
compulsive JJ p
behaviors NNS p
measured VBN p
with IN p
the DT p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive NNP p
Compulsive NNP p
Scales NNP p
modified VBD p
for IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

INTERVENTIONS NNP N
Twelve NNP N
weeks NNS N
of IN N
citalopram NN i
hydrobromide NN i
( ( i
10 CD i
mg/5 RB i
mL NN i
) ) i
or CC i
placebo NN i
. . i

The DT N
mean NN N
( ( N
SD NNP N
) ) N
maximum JJ N
dosage NN N
of IN N
citalopram NN i
hydrobromide NN i
was VBD N
16.5 CD N
( ( N
6.5 CD N
) ) N
mg/d NN N
by IN N
mouth NN N
( ( N
maximum JJ N
, , N
20 CD N
mg/d NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Positive NNP N
response NN N
was VBD N
defined VBN N
by IN N
a DT N
score NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Improvement NNP o
subscale NN o
. . o

An DT N
important JJ N
secondary JJ N
outcome NN N
was VBD N
the DT N
score NN N
on IN N
the DT N
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scales NNP o
modified VBD o
for IN o
pervasive JJ o
developmental NN o
disorders NNS o
. . o

Adverse JJ o
events NNS o
were VBD N
systematically RB N
elicited VBN N
using VBG N
the DT N
Safety NNP N
Monitoring NNP N
Uniform NNP N
Report NNP N
Form NNP N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
positive JJ o
response NN o
on IN N
the DT N
Clinical NNP o
Global NNP o
Impressions NNP o
, , o
Improvement NNP o
subscale NN o
between IN N
the DT N
citalopram-treated JJ i
group NN N
( ( N
32.9 CD N
% NN N
) ) N
and CC N
the DT N
placebo NN i
group NN N
( ( N
34.2 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
, , N
0.96 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.61-1.51 JJ N
; : N
P NNP N
> NNP N
.99 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
score NN N
reduction NN N
on IN N
the DT N
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scales NNP o
modified VBD N
for IN N
pervasive JJ N
developmental JJ o
disorders NNS o
from IN N
baseline NN N
( ( N
mean JJ N
[ NNP N
SD NNP N
] NNP N
, , N
-2.0 NNP N
[ VBZ N
3.4 CD N
] NN N
points NNS N
for IN N
the DT N
citalopram-treated JJ i
group NN N
and CC N
-1.9 NNP N
[ NNP N
2.5 CD N
] NN N
points NNS N
for IN N
the DT N
placebo NN i
group NN N
; : N
P NNP N
= NNP N
.81 NNP N
) ) N
. . N

Citalopram NNP i
use NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
adverse JJ N
events NNS N
, , N
particularly RB N
increased VBD N
energy NN o
level NN o
, , o
impulsiveness NN o
, , N
decreased VBN N
concentration NN o
, , o
hyperactivity NN o
, , o
stereotypy NN o
, , o
diarrhea NN o
, , o
insomnia NN o
, , o
and CC o
dry JJ o
skin NN o
or CC o
pruritus NN o
. . o

CONCLUSION NNP N
Results NNP N
of IN N
this DT N
trial NN N
do VBP N
not RB N
support VB N
the DT N
use NN N
of IN N
citalopram NN i
for IN N
the DT N
treatment NN N
of IN N
repetitive JJ N
behavior NN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Trial JJ N
Registration NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00086645 NN N
. . N

-DOCSTART- -305873- O O

[ JJ i
Whole NNP i
gut NN i
irrigation NN i
with IN i
isotonic JJ i
mannitol NN i
solution NN i
in IN N
the DT N
treatment NN N
of IN N
gastrointestinal JJ o
bleeding NN o
due JJ p
to TO p
cirrhosis NN p
: : p
a DT N
controlled VBN N
study NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

-DOCSTART- -1860302- O O

Effect NN N
of IN N
ranitidine NN i
on IN N
the DT N
disposition NN o
of IN N
orally RB N
and CC N
intravenously RB N
administered VBN N
triazolam NN N
. . N

The DT N
effect NN N
of IN N
orally RB N
administered VBN N
ranitidine NN i
on IN N
the DT N
pharmacokinetic JJ o
properties NNS o
of IN N
orally RB N
and CC N
intravenously RB N
administered VBD N
triazolam NN i
was VBD N
determined VBN N
. . N

Twelve NNP p
healthy JJ p
males NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
35 CD p
years NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
four-way NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

Each DT N
subject NN N
received VBD N
a DT N
total NN N
of IN N
four CD N
treatments NNS N
, , N
each DT N
separated VBN N
by IN N
one CD N
week NN N
. . N

The DT N
treatments NNS N
consisted VBN N
of IN N
( ( N
1 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ i
triazolam NN i
tablet NN i
after IN i
treatment NN i
with IN i
ranitidine NN i
; : i
( ( N
2 CD N
) ) N
one CD N
orally RB N
administered VBN N
0.25-mg JJ i
triazolam NN i
tablet NN i
, , i
with IN i
no DT i
ranitidine JJ i
pretreatment NN i
; : i
( ( N
3 CD N
) ) N
a DT N
0.25-mg JJ i
intravenous JJ i
dose NN i
of IN i
triazolam NN i
after IN i
treatment NN i
with IN i
ranitidine NN i
; : i
and CC N
( ( N
4 CD N
) ) N
a DT N
0.25-mg JJ i
intravenous JJ i
dose NN i
of IN i
triazolam NN i
, , i
with IN i
no DT i
ranitidine NN i
pretreatment NN i
. . i

Ranitidine NNP i
pretreatment NN N
consisted VBD N
of IN N
five CD N
150-mg JJ N
oral JJ N
doses NNS N
( ( N
as IN N
the DT N
hydrochloride NN N
salt NN N
) ) N
given VBN N
every DT N
12 CD N
hours NNS N
; : N
the DT N
last JJ N
dose NN N
was VBD N
given VBN N
two CD N
hours NNS N
before IN N
triazolam NN i
was VBD N
administered VBN N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
at IN N
intervals NNS N
up RB N
to TO N
12 CD N
hours NNS N
after IN N
triazolam JJ N
treatment NN N
. . N

Serum NNP o
triazolam JJ o
concentrations NNS o
were VBD N
measured VBN N
by IN N
modified JJ N
high-performance NN N
liquid NN N
chromatography NN N
, , N
and CC N
pharmacokinetic JJ o
values NNS o
were VBD N
calculated VBN N
. . N

Pretreatment NN N
with IN N
ranitidine NN i
had VBD N
no DT N
effect NN N
on IN N
the DT N
disposition NN o
of IN o
intravenously RB o
administered VBN o
triazolam NN o
but CC N
significantly RB N
increased VBD N
the DT N
area NN o
under IN o
the DT o
serum JJ o
drug NN o
concentration-time JJ o
curve NN o
of IN o
oral JJ o
triazolam NN o
. . o

Ranitidine NNP i
pretreatment NN N
had VBD N
no DT N
effect NN N
on IN N
triazolam NN o
's POS o
terminal JJ o
elimination NN o
rate NN o
constant JJ o
or CC N
on IN N
the DT N
time NN o
to TO o
reach VB o
maximum JJ o
serum JJ o
triazolam NN o
concentration NN o
. . o

Ranitidine JJ i
pretreatment NN N
increased VBD N
the DT N
systemic JJ o
availability NN o
of IN o
triazolam NN o
by IN N
increasing VBG N
its PRP$ N
absorption NN o
. . o

-DOCSTART- -23039709- O O

Implementing VBG N
a DT N
simplified JJ i
neonatal JJ i
resuscitation NN i
protocol-helping JJ i
babies NNS p
breathe VBP p
at IN p
birth NN p
( ( N
HBB NNP N
) ) N
- : N
at IN N
a DT N
tertiary JJ N
level NN N
hospital NN N
in IN N
Nepal NNP p
for IN N
an DT N
increased JJ N
perinatal NN o
survival NN o
. . o

BACKGROUND NNP N
Reducing NNP N
neonatal JJ o
death NN o
has VBZ N
been VBN N
an DT N
emerging VBG N
challenge NN N
in IN N
low JJ p
and CC p
middle JJ p
income NN p
countries NNS p
in IN N
the DT N
past JJ N
decade NN N
. . N

The DT N
development NN N
of IN N
the DT N
low JJ N
cost NN N
interventions NNS N
and CC N
their PRP$ N
effective JJ N
delivery NN N
are VBP N
needed VBN N
to TO N
reduce VB N
deaths NNS o
from IN N
birth NN N
asphyxia NN N
. . N

This DT N
study NN N
will MD N
assess VB N
the DT N
impact NN N
of IN N
a DT N
simplified JJ i
neonatal JJ i
resuscitation NN i
protocol NN i
provided VBN N
by IN N
Helping VBG N
Babies NNS N
Breathe NNP N
( ( N
HBB NNP N
) ) N
at IN N
a DT N
tertiary JJ p
hospital NN p
in IN p
Nepal NNP p
. . p

Perinatal NNP N
outcomes NNS N
and CC N
performance NN N
of IN N
skilled JJ p
birth NN p
attendants NNS p
on IN N
management NN o
of IN o
intrapartum-related JJ o
neonatal JJ o
hypoxia NN o
will MD N
be VB N
the DT N
main JJ N
measurements NNS N
. . N

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
be VB N
carried VBN N
out RP N
at IN N
a DT N
tertiary JJ p
level NN p
maternity NN p
hospital NN p
in IN p
Nepal NNP p
. . p

A DT N
prospective JJ N
cohort-study NN N
will MD N
include VB N
a DT N
six-month JJ N
baseline NN N
a DT N
six CD N
month NN N
intervention NN N
period NN N
and CC N
a DT N
three-month JJ N
post NN N
intervention NN N
period NN N
. . N

A DT N
quality NN N
improvement NN N
process NN N
cycle NN N
will MD N
introduce VB N
the DT N
neonatal JJ N
resuscitation NN N
protocol NN N
. . N

A DT N
surveillance NN N
system NN N
, , N
including VBG N
CCD NNP i
cameras NNS i
and CC i
pulse JJ i
oximeters NNS i
, , N
will MD N
be VB N
set VBN N
up RP N
to TO N
evaluate VB N
the DT N
intervention NN N
. . N

DISCUSSION NNP N
Along IN N
with IN N
a DT N
technique NN N
to TO N
improve VB N
health NN o
workers NNS o
performance NN o
on IN N
the DT N
protocol NN N
, , N
the DT N
study NN N
will MD N
generate VB N
evidence NN N
on IN N
the DT N
research NN N
gap NN N
on IN N
the DT N
effectiveness NN N
of IN N
the DT N
simplified JJ N
neonatal JJ N
resuscitation NN N
protocol NN N
on IN N
intrapartum NN o
outcome NN o
and CC o
early JJ o
neonatal JJ o
survival NN o
. . o

This DT N
will MD N
generate VB N
a DT N
global JJ N
interest NN N
and CC N
inform NN N
policymaking NN N
in IN N
relation NN N
to TO N
delivery NN N
care NN N
in IN N
all DT N
income NN N
settings NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN97846009 NNP N
. . N

-DOCSTART- -22066521- O O

Feasibility NN N
of IN N
an DT N
obesity NN i
intervention NN i
for IN N
paediatric JJ N
primary JJ N
care NN N
targeting VBG N
parenting NN p
and CC p
children NNS p
: : p
Helping NNP p
HAND NNP p
. . p

BACKGROUND NNP N
The DT N
primary JJ N
care NN N
setting VBG N
offers VBZ N
the DT N
opportunity NN N
to TO N
reach VB N
children NNS p
and CC p
parents NNS p
to TO N
encourage VB N
healthy JJ N
lifestyle NN N
behaviours NNS N
, , N
and CC N
improve VB N
weight NN N
status NN N
among IN N
children NNS N
. . N

OBJECTIVE NNP N
Test NNP N
the DT N
feasibility NN N
of IN N
Helping NNP N
HAND NNP N
( ( N
Healthy NNP N
Activity NNP N
and CC N
Nutrition NNP N
Directions NNP N
) ) N
, , N
an DT N
obesity NN N
intervention NN N
for IN N
5- JJ p
to TO p
8-year-old JJ p
children NNS p
in IN p
primary JJ p
care NN p
clinics NNS p
. . p

METHODS NNP N
A NNP N
randomized VBD N
controlled VBN N
pilot NN N
study NN N
of IN N
Helping NNP i
HAND NNP i
, , N
a DT N
6-month JJ N
intervention NN N
, , N
targeted VBD N
children NNS p
with IN p
body NN p
mass NN p
index NN p
85-99 CD p
% NN p
tile NN p
and CC p
their PRP$ p
parents NNS p
. . p

Intervention NNP N
group NN N
attended VBD N
monthly JJ i
sessions NNS i
and CC i
self-selected JJ i
child NN i
behaviours NNS i
and CC i
parenting VBG i
practices NNS i
to TO N
change VB N
. . N

Control NNP N
group NN N
received VBD N
regular JJ i
paediatric JJ i
care NN i
and CC i
was VBD i
wait-listed VBN i
for IN i
Helping NNP i
HAND NNP i
. . i

Session NNP o
completion NN o
, , o
participant JJ o
satisfaction NN o
, , o
child NN o
anthropometrics NNS o
, , o
dietary JJ o
intake NN o
, , o
physical JJ o
activity NN o
, , o
TV NN o
viewing NN o
and CC o
behaviour-specific JJ o
parenting NN o
practices NNS o
were VBD N
measured VBN N
pre NN N
and CC N
post NN N
intervention NN N
. . N

RESULTS NNP N
Forty NNP p
parent-child JJ p
dyads NNS p
enrolled VBD p
: : p
82.5 CD p
% NN p
were VBD p
Hispanic NNP p
, , p
80 CD p
% NN p
had VBD p
a DT p
girl NN p
and CC p
65 CD p
% NN p
reported VBD p
income NN p
? . p
$ $ p
30 CD p
, , p
000/year CD p
. . p

There EX N
was VBD N
20 CD N
% NN N
attrition NN N
from IN i
Helping VBG i
HAND NNP i
( ( i
attended VBD N
< RB N
4/6 CD N
sessions NNS N
) ) N
. . N

Families NNS N
self-selected JJ N
4.35 CD N
( ( N
SD NNP N
1.75 CD N
) ) N
behaviours NN N
to TO N
target VB N
during IN N
the DT N
6-month JJ N
programme NN N
and CC N
each DT N
of IN N
the DT N
seven CD N
behaviours NNS N
was VBD N
selected VBN N
by IN N
45-80 JJ N
% NN N
of IN N
the DT N
families NNS N
. . N

There EX N
were VBD o
no DT o
between IN o
group NN N
differences NNS N
in IN N
the DT o
child NN o
's POS o
body NN o
mass NN o
index NN o
z-score NN o
, , o
dietary JJ o
intake NN o
or CC o
physical JJ o
activity NN o
post NN o
intervention NN o
. . o

Intervention NNP N
group NN N
viewed VBD N
14.9 CD N
( ( N
SE NNP N
2.3 CD o
) ) o
h/week NN o
of IN o
TV NN o
post NN o
intervention NN N
versus IN N
control NN N
group NN N
23.3 CD N
( ( N
SE NNP N
2.4 CD N
) ) N
h/week NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Helping NNP N
HAND NNP N
is VBZ N
feasible JJ N
, , N
due JJ N
to TO N
low JJ N
attrition NN N
, , N
good JJ N
programme NN N
attendance NN N
, , N
and CC N
clinically RB N
relevant JJ N
improvements NNS N
in IN N
some DT N
child NN N
and CC N
parenting NN N
behaviours NNS N
. . N

-DOCSTART- -15538933- O O

Blockade NN N
of IN N
endogenous JJ N
growth NN N
hormone-releasing VBG N
hormone NN N
receptors NNS N
dissociates VBZ N
nocturnal JJ o
growth NN o
hormone NN o
secretion NN o
and CC N
slow-wave JJ o
sleep NN o
. . o

OBJECTIVES CC N
A NNP N
temporal JJ N
association NN N
between IN N
non-rapid JJ N
eye NN N
movement NN N
( ( N
NREM NNP N
) ) N
sleep VBP N
stages NNS N
3 CD N
and CC N
4 CD N
and CC N
nocturnal JJ N
augmentation NN N
of IN N
GH NNP N
release NN N
was VBD N
found VBN N
long RB N
ago RB N
, , N
yet RB N
the DT N
precise NN N
mechanism NN N
for IN N
this DT N
association NN N
has VBZ N
not RB N
been VBN N
identified VBN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
, , N
however RB N
that IN N
pulsatile JJ N
GHRH NNP N
administration NN N
increases VBZ N
both DT N
slow-wave JJ o
sleep NN o
( ( o
SWS NNP o
) ) o
and CC N
GH NNP o
. . o

Based VBN N
on IN N
these DT N
data NNS N
, , N
a DT N
role NN N
for IN N
GHRH NNP N
as IN N
an DT N
inducer NN N
of IN N
SWS NNP N
was VBD N
proposed VBN N
. . N

To TO N
test VB N
this DT N
hypothesis NN N
, , N
we PRP N
have VBP N
performed VBN N
the DT N
corollary JJ N
experiment NN N
whereby WRB N
the DT N
action NN N
of IN N
endogenous JJ N
GHRH NNP N
has VBZ N
been VBN N
antagonized VBN N
. . N

DESIGN NNP N
Healthy NNP p
men NNS p
( ( p
20-33 CD p
years NNS p
old JJ p
) ) p
had VBD N
an DT N
infusion NN i
of IN i
GHRH NNP i
antagonist NN i
( ( i
( ( i
N-Ac-Tyr NNP i
( ( i
1 CD i
) ) i
, , i
D-Arg NNP i
( ( i
2 CD i
) ) i
) ) i
GHRH-29 NNP i
( ( i
NH NNP i
( ( i
2 CD i
) ) i
) ) i
) ) i
or CC i
saline NN i
for IN i
a DT i
12-h JJ i
period NN i
, , N
between IN N
2100 CD N
and CC N
0900 CD N
h. NN N
An DT N
i.v NN N
. . N

bolus NN N
of IN N
GHRH NNP i
was VBD N
given VBN N
at IN N
0700 CD N
h NN N
and CC N
GH NNP N
samples NNS N
were VBD N
drawn VBN N
from IN N
0700 CD N
to TO N
0900 CD N
h NN N
to TO N
document VB N
the DT N
efficacy NN N
of IN N
GH NNP o
suppression NN N
by IN N
the DT N
GHRH NNP N
antagonist NN N
. . N

METHODS NNP N
A NNP N
limited JJ N
montage NN N
sleep NN N
study NN N
was VBD N
recorded VBN N
from IN N
2300 CD N
to TO N
0700 CD N
h NN N
during IN N
each DT N
admission NN N
. . N

Plasma NNP o
GH NNP o
concentrations NNS o
were VBD N
analyzed VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
sensitive JJ N
chemiluminometric JJ N
assay NN N
. . N

RESULTS NNP N
Effectiveness NNP o
of IN N
the DT N
GHRH NNP N
antagonist NN N
was VBD N
validated VBN N
in IN N
all DT N
subjects NNS N
by IN N
demonstrating VBG N
93+/-1.8 CD N
% NN N
( ( N
P=0.012 NNP N
) ) N
suppression NN o
of IN o
GH NNP o
response NN o
to TO N
a DT N
GHRH NNP N
bolus NN N
. . N

Polysomnography NNP N
demonstrated VBD N
that IN N
the DT N
percentage NN N
of IN N
SWS NNP o
was VBD N
not RB N
different JJ N
when WRB N
saline NN N
and CC N
GHRH NNP N
antagonist VBP N
nights NNS N
were VBD N
compared VBN N
( ( N
P=0.607 NNP N
) ) N
; : N
other JJ N
quantifiable JJ N
sleep JJ o
parameters NNS o
were VBD N
also RB N
unchanged JJ N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that DT N
endogenous JJ N
GHRH NNP N
is VBZ N
indispensable JJ N
for IN N
the DT N
nocturnal JJ N
augmentation NN N
of IN N
GH NNP N
secretion NN N
, , N
but CC N
that IN N
it PRP N
is VBZ N
unlikely JJ N
to TO N
participate VB N
in IN N
the DT N
genesis NN N
of IN N
SWS NNP N
. . N

-DOCSTART- -25733274- O O

Effect NN N
of IN N
finasteride NN i
on IN N
serum NN N
androstenedione NN N
and CC N
risk NN N
of IN N
prostate NN N
cancer NN N
within IN N
the DT N
prostate NN N
cancer NN N
prevention NN N
trial NN N
: : N
differential JJ N
effect NN N
on IN N
high- NN N
and CC N
low-grade JJ N
disease NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
finasteride NN i
on IN N
serum JJ N
androst-4-ene-3,17-dione NN N
( ( N
androstenedione NN N
) ) N
and CC N
its PRP$ N
association NN N
with IN N
prostate NN N
cancer NN N
risk NN N
among IN N
subjects NNS p
who WP p
participated VBD p
in IN p
the DT p
Prostate NNP p
Cancer NNP p
Prevention NNP p
Trial NNP p
. . p

METHODS NNP N
We PRP N
analyzed VBD N
serum VB N
androstenedione NN N
levels NNS N
in IN N
317 CD p
prostate NN p
cancer NN p
cases NNS p
and CC p
353 CD p
controls NNS p
, , p
nested VBN p
in IN p
the DT p
Prostate NNP p
Cancer NNP p
Prevention NNP p
Trial NNP p
, , N
a DT N
randomized JJ N
placebo-controlled JJ i
trial NN N
that WDT N
found VBD N
finasteride RB i
decreased JJ N
prostate NN N
cancer NN N
risk NN N
. . N

Androstenedione NNP N
is VBZ N
the DT N
second JJ N
most RBS N
important JJ N
circulating NN N
androgen NN N
in IN N
men NNS N
besides IN N
testosterone NN N
and CC N
also RB N
a DT N
substrate NN N
for IN N
5?-reductase JJ N
enzyme NN N
. . N

RESULTS NNP N
We PRP N
observed VBD N
a DT N
22 CD N
% NN N
increase NN N
in IN o
androstenedione NN o
levels NNS N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
in IN p
subjects NNS p
who WP p
were VBD p
treated VBN p
with IN o
finasteride NN o
for IN p
3 CD p
years NNS p
. . p

This DT N
significant JJ N
increase NN N
did VBD N
not RB N
vary JJ N
by IN N
case-control NN N
status NN N
. . N

Adjusted VBN N
odds NNS N
ratio NN N
and CC N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
the DT N
third JJ N
tertile NN N
of IN N
absolute JJ N
change NN N
in IN o
androstenedione NN o
levels NNS o
compared VBN N
with IN N
the DT N
first JJ N
tertile NN N
were VBD N
0.42 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.19-0.94 NN N
) ) N
for IN N
low-grade NN N
( ( N
Gleason NNP N
score RB N
< VBZ N
7 CD N
) ) N
cases NNS N
. . N

Similar JJ N
results NNS N
were VBD N
observed VBN N
when WRB N
analyzed VBN N
using VBG N
percent NN N
change NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
associations NNS N
between IN N
serum NN N
androstenedione NN N
levels NNS N
and CC N
the DT N
risk NN N
of IN N
high-grade JJ N
disease NN N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
nested JJ N
case-control NN N
study NN N
confirm VBP N
that IN i
finasteride NN i
blocks VBZ N
the DT N
conversion NN N
of IN N
testosterone NN N
to TO N
dihydrotestosterone VB N
( ( N
DHT NNP N
) ) N
and CC N
of IN N
androstenedione NN N
to TO N
5?-androstanedione-3,17-dione CD N
, , N
which WDT N
also RB N
leads VBZ N
to TO N
the DT N
reduction NN N
of IN N
DHT NNP N
formation NN N
. . N

This DT N
decrease NN N
in IN N
DHT NNP N
may MD N
help VB N
reduce VB N
the DT N
risk NN N
of IN N
low-grade JJ N
prostate NN N
cancer NN N
in IN N
men NNS N
. . N

Our PRP$ N
data NNS N
on IN N
a DT N
differential JJ N
effect NN N
of IN N
androstenedione NN N
also RB N
suggest VBP N
that IN N
some DT N
high-grade JJ N
prostate NN N
cancers NNS N
may MD N
not RB N
require VB N
androgen NN N
for IN N
progression NN N
. . N

-DOCSTART- -24878589- O O

The DT N
effect NN N
of IN N
arm NN i
support NN i
combined VBD i
with IN i
rehabilitation NN i
games NNS i
on IN N
upper-extremity JJ o
function NN o
in IN N
subacute JJ o
stroke NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Use NNP N
of IN N
rehabilitation NN i
technology NN i
, , N
such JJ N
as IN N
( ( i
electro NN i
) ) i
mechanical JJ i
devices NNS i
or CC i
robotics NNS i
, , N
could MD N
partly RB N
relieve VB N
the DT N
increasing VBG N
strain NN N
on IN N
stroke NN N
rehabilitation NN N
caused VBN N
by IN N
an DT N
increasing VBG N
prevalence NN N
of IN N
stroke NN N
. . N

Arm NNP i
support NN i
( ( i
AS IN i
) ) i
training NN i
showed VBD N
improvement NN N
of IN N
unsupported JJ N
arm NN o
function NN o
in IN N
chronic JJ o
stroke NN o
. . o

OBJECTIVE UH N
To TO N
examine VB N
the DT N
effect NN N
of IN N
weight-supported JJ i
arm NN i
training NN i
combined VBN N
with IN N
computerized JJ i
exercises NNS i
on IN N
arm NN o
function NN o
and CC N
capacity NN o
, , N
compared VBN N
with IN N
dose-matched JJ N
conventional JJ i
reach NN i
training NN i
in IN N
subacute JJ p
stroke NN p
patients NNS p
. . p

METHODS NNP N
In IN N
a DT N
single-blind NN N
, , N
multicenter NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
, , N
70 CD p
subacute NN p
stroke NN p
patients NNS p
received VBD N
6 CD N
weeks NNS N
of IN N
training VBG i
with IN N
either DT N
an DT N
AS NNP i
device NN i
combined VBD i
with IN i
computerized JJ i
exercises NNS i
or CC i
dose-matched JJ i
conventional JJ i
training NN i
( ( i
CON NNP i
) ) i
. . i

Arm NNP N
function NN N
was VBD N
evaluated VBN N
pretraining NN N
and CC N
posttraining NN N
by IN N
Fugl-Meyer NNP o
assessment NN o
( ( o
FM NNP o
) ) o
, , o
maximal JJ o
reach NN o
distance NN o
, , o
Stroke NNP o
Upper NNP o
Limb NNP o
Capacity NNP o
Scale NNP o
( ( o
SULCS NNP o
) ) o
, , o
and CC o
arm NN o
pain NN o
via IN o
Visual NNP o
Analogue NNP o
Scale NNP o
, , N
in IN N
addition NN N
to TO N
perceived VBN N
motivation NN N
by IN N
Intrinsic NNP N
Motivation NNP N
Inventory NNP N
posttraining VBG N
. . N

RESULTS NNP N
FM NNP o
and CC o
SULCS NNP o
scores NNS o
and CC o
reach VB o
distance NN o
improved VBN N
significantly RB N
within IN N
both DT N
groups NNS N
. . N

These DT N
improvements NNS N
and CC N
experienced VBD N
pain NN o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

The DT N
AS NNP N
group NN N
reported VBD N
higher JJR o
interest/enjoyment NN o
during IN N
training NN N
than IN N
the DT N
CON NNP N
group NN N
. . N

CONCLUSIONS NNP N
AS IN N
training NN i
with IN i
computerized JJ i
exercises NNS i
is VBZ N
as RB N
effective JJ N
as IN N
conventional JJ N
therapy NN N
dedicated VBN N
to TO N
the DT N
arm NN N
to TO N
improve VB N
arm NN o
function NN o
and CC o
activity NN o
in IN N
subacute NN p
stroke NN p
rehabilitation NN N
, , N
when WRB N
applied VBN N
at IN N
the DT N
same JJ N
dose NN N
. . N

-DOCSTART- -8568534- O O

Correlation NN N
of IN N
quantitative JJ N
measures NNS N
with IN N
the DT N
modified JJ i
Ashworth NNP i
scale NN i
in IN N
the DT N
assessment NN N
of IN N
plantar NN p
flexor NN p
spasticity NN p
in IN p
patients NNS p
with IN p
traumatic JJ p
brain NN p
injury NN p
. . p

This DT N
study NN N
of IN N
plantar NN N
flexor NN N
spasticity NN N
describes VBZ N
relationships NNS N
among IN N
a DT N
traditional JJ N
qualitative JJ N
spasticity NN N
scale NN N
, , N
three CD N
potential JJ N
quantitative JJ N
spasticity NN N
measures NNS N
and CC N
a DT N
measure NN N
of IN N
voluntary JJ N
ankle NNS N
muscle NN N
function NN N
. . N

Thirty-four CD p
volunteer NN p
adult NN p
patients NNS p
with IN p
traumatic JJ p
brain NN p
injuries NNS p
participated VBD p
. . p

There EX p
were VBD p
28 CD p
males NNS p
and CC p
6 CD p
females NNS p
; : p
the DT p
mean JJ p
age NN p
was VBD p
30.3 CD p
years NNS p
. . p

A DT N
battery NN N
of IN N
five CD N
randomly NNS i
sequenced VBD i
tests NNS i
was VBD N
performed VBN N
for IN N
each DT N
subject NN N
on IN N
one CD N
ankle NN N
. . N

Tests NNS N
were VBD N
: : N
modified VBN o
Ashworth NNP o
scale NN o
( ( o
MAS NNP o
) ) o
scoring NN o
; : o
H-reflex JJ o
testing NN o
with IN o
and CC o
without IN o
Achilles NNP o
tendon CC o
vibration NN o
; : o
H-reflex JJ o
testing NN o
with IN o
and CC o
without IN o
dorsiflexor JJ o
contraction NN o
; : o
reflex CC o
threshold VB o
angle NN o
and CC o
timed VBD o
toe NN o
tapping NN o
( ( o
TTT NNP o
) ) o
. . o

Twenty-six JJ p
subjects NNS p
returned VBN p
to TO p
have VB p
the DT p
second JJ p
ankle NN p
tested VBN p
, , p
resulting VBG p
in IN p
60 CD p
ankles NNS p
for IN N
the DT N
analyses NNS N
. . N

Spearman NNP N
's POS N
coefficients NNS N
for IN N
correlation NN N
of IN N
quantitative JJ N
spasticity NN N
measures NNS N
with IN N
MAS NNP o
scores NNS o
ranged VBD N
from IN N
0.39 CD N
to TO N
0.49 CD N
with IN N
associated JJ N
probabilities NNS N
< VBP N
or CC N
= VBP N
0.002 CD N
. . N

Pearson NNP N
coefficients NNS N
for IN N
correlation NN N
of IN N
quantitative JJ N
spasticity NN N
measures NNS N
with IN N
TTT NNP o
scores NNS o
were VBD N
lower JJR N
but CC N
also RB N
significant JJ N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.07 CD N
) ) N
. . N

Multiple JJ N
correlation NN N
for IN N
the DT N
set NN N
of IN N
quantitative JJ N
measures NNS N
yielded VBN N
R NNP N
= $ N
0.614 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
MAS NNP o
scores NNS o
and CC N
R NNP N
= NNP N
0.365 CD N
( ( N
P NNP N
= NNP N
0.045 CD N
) ) N
with IN N
TTT NNP N
scores NNS N
. . N

These DT N
findings NNS N
reveal VBP N
statistically RB N
significant JJ o
relationships NNS o
of IN N
low JJ N
to TO N
moderate VB N
strength NN N
among IN N
potential JJ o
quantitative JJ o
spasticity NN o
measures NNS N
, , N
a DT N
traditional JJ o
qualitative JJ o
spasticity NN o
scale NN o
and CC N
a DT N
simple JJ o
measure NN o
of IN o
voluntary JJ o
ankle NNS o
muscle NN o
function NN o
. . o

Understanding VBG N
these DT N
relationships NNS N
is VBZ N
an DT N
essential JJ N
part NN N
of IN N
the DT N
ongoing JJ N
search NN N
for IN N
quantitative JJ N
spasticity NN N
measures NNS N
. . N

-DOCSTART- -7851604- O O

Profound NNP N
luteinizing VBG N
hormone NN N
suppression NN N
after IN N
stopping VBG N
the DT N
gonadotropin-releasing JJ i
hormone-agonist JJ i
leuprolide NN i
acetate NN i
. . i

OBJECTIVE UH N
To TO N
compare VB N
levels NNS N
of IN N
serum NN N
LH NNP N
during IN N
continued VBN N
use NN N
of IN N
leuprolide JJ i
acetate NN i
( ( i
LA NNP i
) ) i
with IN N
levels NNS N
during IN N
the DT N
first JJ N
week NN N
after IN N
discontinuing VBG N
LA NNP N
. . N

DESIGN NNP N
Prospective NNP N
controlled VBD N
study NN N
. . N

SETTING NNP N
Clinical NNP N
assisted VBD N
conception NN N
program NN N
. . N

PATIENTS NNP N
Women NNP p
undergoing VBG p
controlled JJ p
ovarian JJ p
stimulation NN p
for IN p
assisted JJ p
conception NN p
were VBD N
randomized VBN N
to TO N
receive VB N
LA NNP i
according VBG i
to TO i
short JJ i
or CC i
ultrashort JJ i
protocols NNS i
. . i

The DT N
alternative JJ N
protocol NN N
was VBD N
used VBN N
then RB N
in IN N
a DT N
second JJ N
cycle NN N
. . N

Each DT N
patient NN N
was VBD N
thus RB N
her PRP$ N
own JJ N
control NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Serum NNP o
LH NNP o
over IN o
time NN o
. . o

RESULTS VB N
When WRB N
LA NNP i
was VBD N
stopped VBN N
after IN N
5 CD N
days NNS N
of IN N
administration NN N
, , N
LH NNP o
levels NNS o
fell VBD N
profoundly RB N
when WRB N
compared VBN N
with IN N
levels NNS N
when WRB N
LA NNP i
was VBD N
continued VBN N
. . N

CONCLUSION NNP N
Loss NNP N
of IN N
LH NNP o
after IN N
stopping VBG N
LA NNP i
is VBZ N
likely JJ N
to TO N
be VB N
clinically RB N
important JJ N
in IN N
ovarian JJ N
stimulation NN N
regimens NNS N
that WDT N
use VBP N
pure JJ N
FSH NNP N
with IN N
LA NNP i
in IN N
ultrashort JJ N
protocols NNS N
. . N

The DT N
fall NN N
in IN N
LH NNP o
lasts NNS N
at IN N
least JJS N
1 CD N
week NN N
and CC N
may MD N
be VB N
explainable JJ N
by IN N
persistent JJ N
suppression NN N
of IN N
endogenous JJ N
GnRH NNP N
by IN N
LA NNP N
during IN N
this DT N
time NN N
. . N

-DOCSTART- -3803417- O O

Acipimox NNP i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
hyperlipidaemia NN p
: : p
a DT N
double JJ N
blind NN N
trial NN N
. . N

Fifty-two JJ p
patients NNS p
with IN p
Fredrickson NNP p
Type NNP p
IIb NNP p
or CC p
Type NNP p
IV NNP p
hyperlipidaemia NN p
, , p
in IN p
whom WP p
diet NN p
had VBD p
not RB p
achieved VBN p
satisfactory JJ p
lipid JJ p
levels NNS p
, , N
completed VBD N
a DT N
double JJ N
blind NN N
randomised VBD N
study NN N
of IN N
acipimox JJ i
versus NN N
placebo NN i
. . i

The DT N
patients NNS N
were VBD N
given VBN N
acipimox NNS i
, , N
250 CD N
mg NN N
three CD N
times NNS N
daily RB N
or CC N
placebo VB i
for IN N
a DT N
three CD N
month NN N
period NN N
, , N
and CC N
plasma JJ o
lipids NNS o
and CC o
glucose VB o
were VBD N
monitored VBN N
. . N

The DT N
patients NNS N
receiving VBG N
acipimox NN i
showed VBD N
a DT N
fall NN N
in IN N
the DT N
mean JJ N
concentration NN N
of IN N
plasma JJ o
triglyceride NN o
compared VBN N
to TO N
placebo VB i
( ( N
0.74 CD N
mmol/l NN N
) ) N
and CC N
this DT N
was VBD N
most RBS N
marked JJ N
in IN N
patients NNS N
whose WP$ N
initial JJ N
plasma NN o
triglyceride NN o
levels NNS o
were VBD N
greater JJR N
than IN N
3 CD N
mmol/l NN N
( ( N
1.0 CD N
mmol/l NN N
, , N
confidence NN N
limits NNS N
0.18 CD N
, , N
1.82 CD N
) ) N
. . N

Acipimox NNP i
was VBD N
well RB N
tolerated VBN o
, , N
and CC N
could MD N
be VB N
a DT N
useful JJ N
addition NN N
to TO N
the DT N
drugs NNS N
available JJ N
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
hypertriglyceridaemia NN p
. . p

-DOCSTART- -17695603- O O

Eight CD i
in-office JJ i
tooth NN i
whitening VBG i
systems NNS i
evaluated VBN N
in IN N
vivo NN N
: : N
a DT N
pilot NN N
study NN N
. . N

This DT N
in IN N
vivo NN N
pilot NN N
study NN N
evaluated VBD N
eight CD i
products NNS i
with IN i
hydrogen NN i
peroxide NN i
( ( i
HP NNP i
) ) i
concentrations NNS i
ranging VBG i
from IN i
15 CD i
% NN i
to TO i
35 CD i
% NN i
. . i

The DT N
treatment NN N
contact NN N
time NN N
varied VBN N
from IN N
15 CD N
minutes NNS N
to TO N
60 CD N
minutes NNS N
. . N

Patients NNS p
were VBD N
evaluated VBN N
for IN N
color NN N
at IN N
baseline NN N
, , N
immediately RB p
after IN p
treatment NN p
and CC N
at IN N
one CD N
, , N
two CD N
, , N
four CD N
and CC N
six CD N
weeks NNS N
after IN N
treatment NN N
using VBG N
a DT N
colorimeter NN i
, , i
shade VBD i
guide NN i
and CC i
photos NNS i
. . i

All DT N
eight CD N
products NNS N
were VBD N
effective JJ N
in IN N
bleaching VBG o
teeth NN o
. . o

Colorimeter NNP N
data NN N
for IN N
deltaE NN N
immediately RB N
after IN N
treatment NN N
was VBD N
6.77 CD N
. . N

At IN N
one CD N
and CC N
six CD N
weeks NNS N
after IN N
bleaching VBG o
, , N
there EX N
were VBD N
51 CD N
% NN N
and CC N
65 CD N
% NN N
reductions NNS N
in IN N
deltaE NN o
, , N
respectively RB N
. . N

-DOCSTART- -15746053- O O

Phase NN N
I PRP N
pharmacokinetic JJ N
, , N
food NN N
effect NN N
, , N
and CC N
pharmacogenetic JJ N
study NN N
of IN N
oral JJ N
irinotecan JJ i
given VBN N
as IN N
semisolid JJ N
matrix NN N
capsules NNS N
in IN N
patients NNS p
with IN p
solid JJ p
tumors NNS p
. . p

PURPOSE NNP N
To TO N
characterize VB N
the DT N
maximum-tolerated JJ N
dose NN N
, , N
recommended VBD N
dose NN N
, , N
dose-limiting JJ N
toxicities NNS N
( ( N
DLT NNP N
) ) N
, , N
pharmacokinetic JJ N
profile NN N
, , N
and CC N
food NN N
effect NN N
of IN N
orally RB N
administered VBN N
irinotecan JJ i
formulated VBN N
as IN N
new JJ N
semisolid JJ N
matrix NN N
capsules NNS N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
Irinotecan NNP i
was VBD N
given VBN N
orally RB N
in IN N
fasted JJ p
patients NNS p
once RB N
daily JJ N
for IN N
5 CD N
consecutive JJ N
days NNS N
and CC N
repeated VBD N
every DT N
3 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
take VB N
the DT N
drug NN N
along IN N
with IN N
a DT N
high-fat JJ i
, , i
high-calorie JJ i
breakfast NN i
for IN N
the DT N
administration NN N
at IN N
day NN N
1 CD N
of IN N
the DT N
first JJ N
or CC N
second JJ N
cycle NN N
. . N

Dosages NNS N
tested VBN N
were VBD N
70 CD N
and CC N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
. . N

RESULTS NNP N
Twenty-five JJ p
patients NNS p
received VBD N
101 CD N
cycles NNS N
of IN N
therapy NN N
( ( N
median JJ N
two CD N
cycles NNS N
, , N
range VB N
1-15 JJ N
) ) N
. . N

During IN N
the DT N
first JJ N
cycle NN N
, , N
grade VBD o
3 CD o
delayed VBN o
diarrhea NN o
and CC o
grade VBD o
3 CD o
fever NN o
were VBD N
the DT N
DLTs NNP N
at IN N
the DT N
dosage NN N
of IN N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
in IN N
three CD N
out IN N
of IN N
five CD N
patients NNS N
. . N

Hematologic NNP o
and CC o
nonhematologic JJ o
toxicities NNS o
were VBD N
mild JJ N
to TO N
moderate VB N
. . N

Exposure NN o
to TO o
the DT o
active JJ o
metabolite JJ o
SN-38 NN o
was VBD N
relatively RB N
high JJ N
compared VBN N
with IN N
i.v NN N
. . N

infusion NN N
, , N
but CC N
no DT N
relevant JJ N
accumulation NN N
was VBD N
observed VBN N
. . N

Food NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
irinotecan JJ i
pharmacokinetics NNS N
. . N

One CD N
confirmed VBD N
partial JJ o
remission NN o
and CC N
10 CD N
disease NN o
stabilizations NNS o
were VBD N
observed VBN N
in IN N
previously RB N
treated VBN N
patients NNS N
. . N

No DT N
association NN N
was VBD N
found VBN N
between IN N
the DT N
UGT1A1*28 NNP N
genotype NN N
and CC N
the DT N
risk NN N
of IN N
severe JJ o
irinotecan-induced JJ o
toxicity NN o
. . o

CONCLUSIONS NNP N
For IN N
oral JJ N
irinotecan JJ i
, , N
a DT N
dose NN N
of IN N
70 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/day NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
3 CD N
weeks NNS N
is VBZ N
recommended VBN N
for IN N
further JJ N
studies NNS N
. . N

Delayed NNP N
diarrhea NN N
was VBD N
the DT N
main JJ N
DLT NNP N
, , N
similar JJ N
to TO N
that DT N
observed VBN N
with IN N
intravenously RB N
administered VBN N
irinotecan JJ N
. . N

This DT N
study NN N
confirms VBZ N
that IN N
oral JJ N
administration NN N
of IN N
irinotecan JJ i
is VBZ N
feasible JJ N
and CC N
may MD N
have VB N
favorable JJ N
pharmacokinetic JJ N
characteristics NNS N
. . N

-DOCSTART- -10037531- O O

Xylitol NN i
for IN N
prevention NN N
of IN N
acute NN p
otitis NN p
media NNS p
. . p

-DOCSTART- -26046796- O O

Erlotinib NNP i
is VBZ N
effective JJ N
in IN N
pancreatic JJ p
cancer NN p
with IN p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
mutations NNS p
: : p
a DT N
randomized JJ N
, , N
open-label JJ N
, , N
prospective JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
analyze VB N
the DT N
efficacy NN N
of IN N
gemcitabine NN i
with IN N
or CC N
without IN N
erlotinib NN i
for IN N
pancreatic JJ N
cancer NN N
, , N
and CC N
to TO N
determine VB N
the DT N
predictive JJ N
role NN N
of IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
( ( N
EGFR NNP N
) ) N
and CC N
KRAS NNP N
mutations NNS N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-center JJ N
, , N
randomized VBN N
, , N
open-label JJ N
, , N
prospective JJ N
trial NN N
. . N

Eighty-eight JJ p
chemotherapy-na?ve JJ p
metastatic JJ p
pancreatic JJ p
cancer NN p
patients NNS p
were VBD p
randomized VBN p
for IN p
treatment NN p
with IN i
gemcitabine NN i
or CC i
gemcitabine NN i
plus CC i
erlotinib NN i
. . i

EGFR NNP N
and CC N
KRAS NNP N
mutations NNS N
were VBD N
analyzed VBN N
, , N
respectively RB N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT o
disease NN o
control NN o
rate NN o
. . o

RESULTS NNP o
Disease NNP o
control NN o
rate NN o
( ( N
64 CD N
% NN N
vs. FW N
25 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
progression-free JJ o
survival NN o
( ( N
median JJ N
3.8 CD N
vs. FW N
2.4 CD N
months NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC o
overall JJ o
survival NN o
( ( N
median JJ N
7.2 CD N
vs. FW N
4.4 CD N
months NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
were VBD N
better RBR N
in IN N
the DT i
gemcitabine NN i
plus CC i
erlotinib NN i
group NN N
than IN N
in IN N
the DT i
gemcitabine NN i
alone RB i
group NN N
. . N

In IN N
the DT i
gemcitabine NN i
plus CC i
erlotinib JJ i
group NN N
, , N
disease NN o
control NN o
( ( N
85 CD N
% NN N
vs. FW N
33 CD N
% NN N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
progression-free JJ o
survival NN o
( ( N
median JJ N
5.9 CD N
vs. FW N
2.4 CD N
months NNS N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
and CC o
overall JJ o
survival NN o
( ( N
median JJ N
8.7 CD N
vs. FW N
6.0 CD N
months NNS N
; : N
P NNP N
= NNP N
0.044 CD N
) ) N
were VBD N
better RBR N
in IN p
patients NNS p
with IN p
EGFR NNP p
mutations NNS p
than IN p
in IN p
those DT p
without IN p
EGFR NNP p
mutations NNS p
. . p

KRAS NNP N
mutation NN N
was VBD N
not RB N
associated VBN N
with IN N
treatment NN N
response NN N
or CC N
survival NN N
. . N

CONCLUSIONS NNP i
Gemcitabine NNP i
plus CC i
erlotinib NN i
is VBZ N
more RBR N
effective JJ N
than IN i
gemcitabine VB i
alone JJ i
for IN N
treating VBG p
metastatic JJ p
pancreatic JJ p
cancer NN p
patients NNS p
, , p
especially RB p
those DT p
with IN p
EGFR NNP p
mutations NNS p
. . p

ClinicalTrials.gov NNP N
number NN N
, , N
NCT01608841 NNP N
. . N

-DOCSTART- -3307842- O O

Incidence NN N
of IN N
infectious JJ o
symptoms NNS o
after IN p
radiation NN i
therapy NN i
for IN p
breast NN p
cancer NN p
. . p

Long-term JJ N
effects NNS N
. . N

The DT N
incidence NN N
of IN N
symptoms NNS N
generally RB N
associated VBN N
with IN N
infectious JJ N
disease NN N
was VBD N
assessed VBN N
by IN N
a DT N
questionnaire NN N
sent VBD N
out RB N
to TO N
519 CD p
disease-free JJ p
breast NN p
cancer NN p
patients NNS p
7 CD p
to TO p
12 CD p
years NNS p
after IN p
primary JJ p
treatment NN p
. . p

All DT N
patients NNS N
were VBD N
treated VBN N
in IN N
the DT N
context NN N
of IN N
a DT N
randomized JJ N
trial NN N
where WRB N
pre- NN i
and CC i
postoperative JJ i
radiation NN i
( ( i
45 CD i
Gy NNP i
) ) i
was VBD N
evaluated VBN N
versus NN N
surgery NN i
only RB i
. . i

The DT N
results NNS N
indicate VBP N
a DT N
significantly RB N
higher JJR o
morbidity NN o
among IN N
patients NNS N
treated VBN N
with IN N
preoperative JJ i
irradiation NN i
compared VBN N
with IN N
those DT N
irradiated JJ i
postoperative JJ i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

This DT N
increased JJ N
morbidity NN N
mainly RB N
seemed VBD N
to TO N
be VB N
caused VBN N
by IN N
symptoms NNS N
usually RB N
associated VBN N
with IN N
respiratory JJ N
tract JJ N
infection NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Although IN N
statistically RB N
not RB N
significant JJ N
the DT N
preoperatively RB i
irradiated JJ i
patients NNS N
also RB N
had VBD N
a DT N
higher JJR N
morbidity NN o
than IN N
those DT N
treated VBN N
with IN N
surgery NN i
alone RB N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
postoperatively RB i
irradiated JJ i
patients NNS N
and CC N
patients NNS N
treated VBN N
with IN N
surgery NN i
only RB N
. . N

A DT N
significantly RB N
higher JJR N
integral JJ N
dose NN N
( ( N
absorbed JJ N
energy NN N
within IN N
the DT N
body NN N
) ) N
of IN N
the DT N
pre- JJ N
compared VBN N
with IN N
the DT N
postoperative JJ N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.025 CD N
) ) N
is VBZ N
associated VBN N
with IN N
the DT N
differences NNS N
in IN N
morbidity NN N
between IN N
the DT N
two CD N
irradiated JJ N
groups NNS N
. . N

An DT N
explanation NN N
for IN N
the DT N
increased JJ N
morbidity NN o
seems VBZ N
to TO N
be VB N
that IN N
the DT N
volume NN N
of IN N
lung NN N
tissue NN N
, , N
encompassed VBD N
within IN N
the DT N
full-dose JJ N
target NN N
volume NN N
, , N
is VBZ N
the DT N
crucial JJ N
factor NN N
. . N

This DT N
volume NN N
was VBD N
considerable JJ N
in IN N
the DT N
preoperatively RB i
treated JJ i
patients NNS N
but CC N
kept VBD N
at IN N
a DT N
minimum NN N
in IN N
the DT N
postoperative JJ i
group NN N
. . N

-DOCSTART- -9806121- O O

Sunbathing VBG N
and CC N
sunbed VBN N
use NN N
related VBN N
to TO N
self-image NN N
in IN N
a DT N
randomized JJ N
sample NN N
of IN N
Swedish JJ p
adolescents NNS p
. . p

In IN N
1996 CD p
a DT p
randomized JJ p
sample NN p
of IN p
4,020 CD p
Swedish JJ p
adolescents NNS p
from IN p
three CD p
birth NN p
cohorts NNS p
were VBD N
sent VBN N
a DT N
questionnaire NN i
consisting NN N
of IN N
50 CD N
items NNS N
concerning VBG N
habitual JJ N
sun-related JJ N
behaviours NNS N
and CC N
attitudes NNS N
, , N
knowledge NN N
about IN N
melanoma NN N
, , N
risk NN N
perception NN N
and CC N
self-image NN N
. . N

A DT p
total NN p
of IN p
2,615 CD p
questionnaires NNS i
were VBD p
returned VBN p
. . p

Girls NNP p
sunbathed VBD N
and CC N
used VBD N
sunbeds NNS N
more RBR N
than IN N
boys NNS p
at IN N
all DT N
ages NNS N
. . N

Sunbathing VBG o
and CC o
sunbed VBN o
use NN o
increased VBN N
with IN N
age NN N
. . N

Boys NNS N
who WP N
were VBD N
most RBS o
satisfied JJ o
and CC N
girls NNS N
least JJS o
satisfied JJ o
with IN N
themselves PRP N
sunbathed VBD o
most JJS N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
used VBD o
sunbeds NNS o
most RBS N
frequently RB N
. . N

Girls NNP N
reported VBD N
a DT N
higher JJR o
perceived JJ o
susceptibility NN o
to TO o
melanoma VB o
than IN N
did VBD N
boys VB N
. . N

The DT N
perception NN o
of IN o
susceptibility NN o
increased VBN N
with IN N
age NN N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
reported VBD N
feeling VBG N
most RBS o
susceptible JJ o
. . o

The DT N
overall JJ N
main JJ N
reason NN o
for IN o
sunbathing NN o
was VBD N
appearance NN N
, , N
both DT N
for IN N
own JJ N
sunbathing NN N
, , N
and CC N
to TO N
an DT N
even RB N
higher JJR N
degree NN N
, , N
as IN N
a DT N
supposed JJ N
reason NN N
for IN N
other JJ N
adolescents NNS N
' POS N
behaviour NN N
, , N
and CC N
was VBD N
reported VBN N
most JJS N
frequently RB N
by IN N
girls NNS N
and CC N
the DT N
older JJR N
age NN N
groups NNS N
. . N

The DT N
second JJ N
most RBS N
'important JJ N
' POS N
reason NN N
for IN N
sunbathing NN N
was VBD N
'feeling VBG o
warm JJ o
and CC o
comfortable JJ o
' '' o
. . N

Preventive JJ N
programmes NNS N
aimed VBN N
at IN N
a DT N
change NN N
of IN N
sun NN N
related VBN N
behaviours NNS N
among IN N
Swedish JJ N
adolescents NNS N
have VBP N
to TO N
be VB N
tailored VBN N
to TO N
the DT N
climate NN N
and CC N
cultural JJ N
conditions NNS N
and CC N
must MD N
take VB N
into IN N
account NN N
that IN N
having VBG N
a DT N
tan NN N
, , N
and CC N
the DT N
warmth NN N
of IN N
the DT N
sun NN N
, , N
are VBP N
highly RB N
valued VBN N
by IN N
most JJS N
adolescents NNS N
. . N

-DOCSTART- -24280031- O O

A DT N
double-blind NN N
, , N
randomized VBN N
trial NN N
of IN N
deep JJ i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
for IN N
autism NN p
spectrum NN p
disorder NN p
. . p

BACKGROUND NNP N
Biomedical NNP N
treatment NN N
options NNS N
for IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
are VBP N
extremely RB N
limited JJ N
. . N

Repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
is VBZ N
a DT N
safe JJ N
and CC N
efficacious JJ N
technique NN N
when WRB N
targeting VBG N
specific JJ N
areas NNS N
of IN N
cortical JJ N
dysfunction NN N
in IN N
major JJ N
depressive JJ N
disorder NN N
, , N
and CC N
a DT N
similar JJ N
approach NN N
could MD N
yield VB N
therapeutic JJ N
benefits NNS N
in IN N
ASD NNP N
, , N
if IN N
applied VBN N
to TO N
relevant VB N
cortical JJ N
regions NNS N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
whether IN N
deep JJ N
rTMS NN i
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
improves VBZ N
social JJ N
relating NN N
in IN N
ASD NNP o
. . o

METHODS NNP N
28 CD p
adults NNS p
diagnosed VBN p
with IN p
either DT p
autistic JJ p
disorder NN p
( ( p
high-functioning JJ p
) ) p
or CC p
Asperger NNP p
's POS p
disorder NN p
completed VBD p
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
design NN N
with IN N
2 CD N
weeks NNS N
of IN N
daily JJ N
weekday JJ N
treatment NN N
. . N

This DT N
involved JJ N
deep JJ i
rTMS NN i
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
( ( N
5 CD N
Hz NNP N
, , N
10-s JJ N
train NN N
duration NN N
, , N
20-s JJ N
inter-train JJ N
interval NN N
) ) N
for IN N
15 CD N
min NN N
( ( N
1500 CD N
pulses VBZ N
per IN N
session NN N
) ) N
using VBG N
a DT N
HAUT-Coil NNP N
. . N

The DT N
sham NN N
rTMS NN i
coil NN N
was VBD N
encased VBN N
in IN N
the DT N
same JJ N
helmet NN N
of IN N
the DT N
active JJ N
deep JJ N
rTMS NN i
coil NN N
, , N
but CC N
no DT N
effective JJ N
field NN N
was VBD N
delivered VBN N
into IN N
the DT N
brain NN N
. . N

Assessments NNS N
were VBD N
conducted VBN N
before IN N
, , N
after IN N
, , N
and CC N
one CD N
month NN N
following VBG N
treatment NN N
. . N

RESULTS JJ N
Participants NNS N
in IN N
the DT N
active JJ N
condition NN N
showed VBD N
a DT N
near JJ N
significant JJ N
reduction NN N
in IN N
self-reported JJ o
social JJ o
relating NN o
symptoms NNS o
from IN N
pre-treatment JJ N
to TO N
one CD N
month NN N
follow-up NN N
, , N
and CC N
a DT N
significant JJ N
reduction NN N
in IN N
social JJ o
relating NN o
symptoms NNS o
( ( N
relative JJ N
to TO N
sham VB N
participants NNS N
) ) N
for IN N
both DT N
post-treatment JJ N
assessments NNS N
. . N

Those DT N
in IN N
the DT N
active JJ N
condition NN N
also RB N
showed VBD N
a DT N
reduction NN N
in IN N
self-oriented JJ o
anxiety NN o
during IN N
difficult JJ N
and CC N
emotional JJ N
social JJ N
situations NNS N
from IN N
pre-treatment NN N
to TO N
one CD N
month NN N
follow-up NN N
. . N

There EX N
were VBD N
no DT N
changes NNS N
for IN N
those DT N
in IN N
the DT N
sham JJ N
condition NN N
. . N

CONCLUSION NNP N
Deep NNP N
rTMS NN N
to TO N
bilateral JJ N
dorsomedial JJ N
prefrontal NN N
cortex NN N
yielded VBD N
a DT N
reduction NN N
in IN N
social JJ N
relating NN N
impairment NN N
and CC N
socially-related JJ N
anxiety NN N
. . N

Further NNP N
research NN N
in IN N
this DT N
area NN N
should MD N
employ VB N
extended VBD N
rTMS NN N
protocols NNS N
that WDT N
approximate VBP N
those DT N
used VBN N
in IN N
depression NN N
in IN N
an DT N
attempt NN N
to TO N
replicate VB N
and CC N
amplify VB N
the DT N
clinical JJ N
response NN N
. . N

-DOCSTART- -14596755- O O

Including VBG N
a DT N
'no CD N
active JJ N
intervention NN N
' POS N
arm NN N
in IN N
surgical JJ N
trials NNS N
is VBZ N
possible JJ N
: : N
evidence NN N
from IN N
the DT N
CLasP NNP N
randomised VBD N
trial NN N
. . N

OBJECTIVES UH N
To TO N
examine VB N
the DT N
impact NN N
of IN N
including VBG N
a DT i
'no CD i
active JJ i
intervention NN i
' POS i
arm NN i
( ( i
called VBN i
'conservative CD i
management NN i
' '' i
) ) i
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
comparing VBG N
treatments NNS N
( ( N
including VBG N
surgery NN i
) ) i
for IN N
men NNS p
with IN p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
related VBN p
to TO p
benign VB p
prostatic JJ p
enlargement NN p
. . p

METHODS NNP N
Outcomes VBZ N
7.5 CD N
months NNS N
after IN N
randomisation NN N
were VBD N
acceptability NN o
of IN o
randomisation NN o
, , o
overall JJ o
acceptability NN o
of IN o
and CC o
satisfaction NN o
with IN o
conservative JJ o
management NN o
, , o
impact NN o
on IN o
quality NN o
of IN o
life NN o
, , o
perceived VBD o
need NN o
for IN o
further JJ o
treatment NN o
and CC N
treatment NN o
failure NN o
( ( o
defined VBD o
a DT o
priori NN o
) ) o
. . o

RESULTS NNP N
In IN N
total JJ N
, , N
177 CD p
( ( p
out IN p
of IN p
755 CD p
) ) p
patients NNS p
refused VBD p
randomisation NN p
, , N
including VBG N
31 CD N
% NN N
who WP N
did VBD N
not RB N
want VB N
surgery NN N
and CC N
22 CD N
% NN N
who WP N
wanted VBD N
surgery NN N
. . N

Most JJS N
men NNS N
randomised VBD N
to TO N
conservative JJ N
management NN N
were VBD N
willing JJ N
to TO N
undertake VB N
it PRP N
as IN N
part NN N
of IN N
a DT N
trial NN N
but CC N
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
they PRP N
were VBD N
divided VBN N
between IN N
those DT N
who WP N
wanted VBD N
to TO N
continue VB N
with IN N
it PRP N
and CC N
those DT N
who WP N
expected VBD N
surgery NN N
. . N

At IN N
follow-up JJ N
, , N
39 CD N
% NN N
of IN N
conservative JJ N
management NN N
patients NNS N
requested VBD N
surgery NN N
, , N
and CC N
interference NN o
of IN o
symptoms NNS o
with IN o
life NN o
and CC N
an DT N
unsuccessful JJ o
outcome NN o
were VBD N
more JJR N
commonly RB N
reported VBN N
in IN N
this DT N
arm NN N
. . N

There EX N
were VBD N
no DT N
appreciable JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
in IN N
terms NNS N
of IN N
treatment NN o
failures NNS o
. . o

CONCLUSIONS NNP N
Including VBG N
a DT N
'no CD i
active JJ i
intervention NN i
' POS i
arm NN i
did VBD N
not RB N
appear VB N
to TO N
have VB N
a DT N
detrimental JJ N
effect NN N
on IN N
patient JJ o
recruitment NN o
or CC N
the DT N
completion NN N
of IN N
this DT N
trial NN N
in IN N
the DT N
short-term JJ N
; : N
overall JJ N
, , N
conservative JJ N
management NN N
was VBD N
successfully RB N
completed VBN N
by IN N
the DT N
majority NN N
of IN N
patients NNS N
during IN N
the DT N
trial NN N
period NN N
, , N
suggesting VBG N
that IN N
researchers NNS N
need VBP N
not RB N
avoid VB N
including VBG N
a DT N
no-intervention JJ N
arm NN N
in IN N
surgical JJ N
trials NNS N
as RB N
long RB N
as IN N
they PRP N
take VBP N
care NN N
with IN N
its PRP$ N
presentation NN N
. . N

-DOCSTART- -24104513- O O

See VB N
what WP N
I PRP N
see VBP N
, , N
do VBP N
as IN N
I PRP N
do VBP N
: : N
promoting NN i
joint JJ i
attention NN i
and CC i
imitation NN i
in IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Since IN N
imitation NN N
and CC N
joint JJ N
attention NN N
are VBP N
both DT N
important JJ N
abilities NNS N
for IN N
young JJ N
children NNS N
and CC N
since IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
show VBP N
a DT N
range NN N
of IN N
problems NNS N
in IN N
these DT N
domains NNS N
, , N
imitation NN i
and CC N
joint JJ i
attention NN i
are VBP N
important JJ N
targets NNS N
for IN N
intervention NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examined VBD N
the DT N
possibility NN N
of IN N
promoting VBG N
imitation NN i
and CC N
joint JJ i
attention NN i
by IN N
means NNS N
of IN N
a DT N
training NN i
programme NN i
specifically RB i
designed VBN i
for IN i
low-intensity NN i
, , i
non-residential JJ i
treatment NN i
. . i

Two CD p
matched VBD p
groups NNS p
of IN p
18 CD p
children NNS p
each DT p
participated VBN p
in IN p
the DT p
study NN p
. . p

The DT N
experimental JJ N
group NN N
, , N
receiving VBG o
the DT o
training NN o
programme NN o
, , N
improved VBN N
significantly RB N
more RBR N
on IN N
joint JJ o
attention NN o
than IN N
the DT N
group NN N
receiving VBG o
only RB o
treatment NN o
as IN o
usual JJ o
. . o

Only RB N
the DT N
experimental JJ N
group NN N
obtained VBD N
a DT N
significantly RB N
higher JJR o
imitation NN o
score RBR o
during IN N
the DT N
post-test JJ o
compared VBN N
to TO N
the DT N
pre-test NN o
. . o

This DT N
study NN N
shows VBZ N
that IN N
it PRP N
is VBZ N
possible JJ N
to TO N
promote VB o
joint JJ o
attention NN o
with IN N
a DT N
low-intensity JJ o
treatment NN o
programme NN o
. . o

The DT N
results NNS N
concerning VBG N
imitation NN o
are VBP o
more RBR o
modest JJ o
. . o

Future JJ N
replications NNS N
should MD N
involve VB N
measures NNS N
of IN N
stability NN o
and CC o
generalization NN o
. . o

-DOCSTART- -7801065- O O

Low JJ N
power NN N
Ga-Al-As NNP i
laser NN i
treatment NN i
of IN N
painful JJ o
osteoarthritis NN o
of IN p
the DT p
knee NN p
. . p

A DT N
double-blind JJ N
placebo-controlled JJ i
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
double-blind NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
low JJ i
power NN i
Ga-Al-As NNP i
laser NN i
treatment NN i
on IN N
chronic JJ o
pain NN o
related VBN p
to TO p
osteoarthritis NN p
of IN p
the DT p
knee NN p
with IN p
periarticular JJ p
tender NN p
points NNS p
. . p

Twenty-nine JJ p
out-patients NNS p
with IN p
uni- JJ p
or CC p
bilateral JJ p
osteoarthritis NN p
of IN p
the DT p
knee NN p
were VBD N
included VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
either DT i
laser NN i
or CC i
placebo NN i
laser NN i
. . i

Fourteen JJ p
patients NNS p
received VBD p
active JJ p
laser NN i
treatment NN i
and CC N
all DT N
patients NNS N
included VBD N
completed VBN N
the DT N
study NN N
. . N

The DT p
effect NN p
variables NNS p
were VBD p
daily JJ o
levels NNS o
of IN o
pain NN o
, , o
analgesic JJ o
requirements NNS o
, , o
palpation NN o
tenderness NN o
and CC o
isokinetic JJ o
quadriceps NNS o
strength NN o
. . o

Each DT N
patient NN N
participated VBN N
in IN N
the DT N
study NN N
for IN N
9 CD N
weeks NNS N
and CC N
registered VBD N
daily JJ o
level NN o
of IN o
pain NN o
and CC o
consumption NN o
of IN o
analgesics NNS o
. . o

In IN N
weeks NNS N
4 CD N
, , N
5 CD N
and CC N
6 CD N
the DT N
patients NNS N
received VBD N
a DT N
total NN N
of IN N
nine CD N
treatments NNS N
, , N
each DT N
of IN N
15 CD N
min NNS N
and CC N
administered VBN N
to TO N
periarticular VB N
tender NN N
points NNS N
. . N

The DT N
dose JJ N
per IN N
treatment NN N
was VBD N
22.5 CD N
joule NN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
the DT N
effect NN N
variables NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
before IN N
, , N
during IN N
or CC N
after IN N
treatment NN N
. . N

With IN N
regard NN N
to TO N
the DT N
patients NNS N
' POS N
overall JJ N
assessment NN N
there EX N
was VBD N
a DT N
clearly RB N
demonstrable JJ N
positive JJ N
effect NN N
of IN N
treatment NN N
in IN N
both DT N
groups NNS N
. . N

This DT N
is VBZ N
likely JJ N
to TO N
be VB N
due JJ N
to TO N
a DT N
placebo NN i
effect NN N
. . N

-DOCSTART- -2008691- O O

[ JJ i
Gluten-free NNP i
diet NN i
in IN N
infantile JJ p
autism NN p
. . p

A NNP N
therapeutic JJ N
trial NN N
] NN N
. . N

It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
there EX N
may MD N
be VB N
a DT N
connection NN N
between IN N
wheat-gluten/milk-casein NN N
and CC N
mental JJ N
disorders NNS N
such JJ N
as IN N
schizophrenia NN N
, , N
hyperactivity NN N
and CC N
autism NN N
. . N

In IN N
this DT N
study NN N
seven CD p
patients NNS p
with IN p
infantile JJ p
autism NN p
, , p
three CD p
before IN p
puberty NN p
and CC p
four CD p
after IN p
puberty NN p
, , N
were VBD N
given VBN N
a DT N
gluten-free JJ i
diet NN i
. . i

Three CD N
children NNS N
were VBD N
provoked VBN N
with IN N
gluten/placebo NN i
in IN N
a DT N
double-blind NN N
study NN N
. . N

Four CD N
young JJ N
patients NNS N
participated VBN N
in IN N
an DT N
open JJ N
study NN N
and CC N
were VBD N
given VBN N
a DT N
gluten-free JJ i
diet NN i
in IN i
six CD i
months NNS i
. . i

Behaviour NNP o
was VBD N
registered VBN N
before RB N
, , N
during IN N
and CC N
after IN N
the DT N
period NN N
with IN N
a DT N
gluten-free JJ i
diet NN i
. . i

Visual NNP o
Analogue NNP o
Scale NNP o
and CC o
Real NNP o
Life NNP o
Rating NNP o
Scale NNP o
were VBD N
used VBN N
to TO N
register VB N
changes NNS N
in IN N
behaviour NN N
. . N

No DT N
connection NN N
was VBD N
observed VBN N
between IN N
gluten NNS o
and CC o
behaviour VB o
typical JJ N
for IN N
these DT N
patients NNS N
. . N

On IN N
the DT N
contrary JJ N
, , N
the DT N
gluten-free JJ i
diet NN i
seemed VBD N
to TO N
be VB N
another DT N
negative JJ N
factor NN N
leading VBG N
to TO N
further JJ N
social JJ o
isolation NN o
in IN N
this DT N
group NN N
of IN N
highly RB p
socially RB p
handicapped JJ p
patients NNS p
and CC N
families NNS N
. . N

-DOCSTART- -23101741- O O

Early JJ N
behavioral JJ N
intervention NN N
is VBZ N
associated VBN N
with IN N
normalized JJ N
brain NN o
activity NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE CC N
A DT N
previously RB N
published VBN N
randomized JJ N
clinical JJ N
trial NN N
indicated VBD N
that IN N
a DT N
developmental JJ N
behavioral JJ i
intervention NN i
, , N
the DT N
Early JJ N
Start NNP N
Denver NNP N
Model NNP N
( ( N
ESDM NNP N
) ) N
, , N
resulted VBD N
in IN N
gains NNS N
in IN N
IQ NNP N
, , N
language NN N
, , N
and CC N
adaptive JJ N
behavior NN N
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

This DT N
report NN N
describes VBZ N
a DT N
secondary JJ N
outcome NN N
measurement NN N
from IN N
this DT N
trial NN N
, , N
EEG NNP o
activity NN o
. . o

METHOD NNP N
Forty-eight JJ p
18- JJ p
to TO p
30-month-old JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
were VBD N
randomized VBN N
to TO N
receive VB i
the DT i
ESDM NNP i
or CC i
referral JJ i
to TO i
community NN i
intervention NN i
for IN i
2 CD i
years NNS i
. . i

After IN N
the DT N
intervention NN N
( ( N
age NN N
48 CD N
to TO N
77 CD N
months NNS N
) ) N
, , N
EEG NNP o
activity NN o
( ( o
event-related JJ o
potentials NNS o
and CC o
spectral JJ o
power NN o
) ) o
was VBD i
measured VBN i
during IN i
the DT i
presentation NN i
of IN i
faces VBZ i
versus JJ i
objects NNS i
. . i

Age-matched JJ p
typical JJ p
children NNS p
were VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
The DT N
ESDM NNP i
group NN N
exhibited VBD N
greater JJR N
improvements NNS N
in IN N
autism NN o
symptoms NNS o
, , o
IQ NNP o
, , o
language NN o
, , o
and CC o
adaptive JJ o
and CC o
social JJ o
behaviors NNS o
than IN N
the DT N
community NN N
intervention NN N
group NN N
. . N

The DT N
ESDM NNP N
group NN N
and CC N
typical JJ N
children NNS N
showed VBD N
a DT N
shorter NN o
Nc NNP o
latency NN o
and CC o
increased VBD o
cortical JJ o
activation NN o
( ( o
decreased VBN o
? . o
power NN o
and CC o
increased VBD o
? . o
power NN o
) ) o
when WRB o
viewing VBG N
faces VBZ N
, , N
whereas IN N
the DT N
community NN N
intervention NN N
group NN N
showed VBD N
the DT N
opposite JJ N
pattern NN N
( ( N
shorter JJ o
latency NN o
event-related JJ o
potential JJ o
[ NN o
ERP NNP o
] NNP o
and CC o
greater JJR o
cortical JJ o
activation NN o
when WRB o
viewing VBG N
objects NNS o
) ) o
. . o

Greater NNP o
cortical JJ o
activation NN o
while IN o
viewing VBG N
faces VBZ N
was VBD N
associated VBN N
with IN o
improved VBN o
social JJ o
behavior NN o
. . o

CONCLUSIONS VB N
This DT N
was VBD N
the DT N
first JJ N
trial NN N
to TO N
demonstrate VB N
that DT N
early JJ N
behavioral JJ N
intervention NN N
is VBZ N
associated VBN N
with IN o
normalized JJ o
patterns NNS o
of IN o
brain NN o
activity NN o
, , o
which WDT N
is VBZ N
associated VBN N
with IN o
improvements NNS o
in IN o
social JJ o
behavior NN o
, , o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

-DOCSTART- -25673113- O O

Effects NNS N
of IN N
sodium NN i
and CC i
potassium NN i
supplementation NN i
on IN N
blood NN o
pressure NN o
and CC o
arterial JJ o
stiffness NN o
: : o
a DT N
fully RB N
controlled VBN N
dietary JJ N
intervention NN N
study NN N
. . N

We PRP N
performed VBD N
a DT N
randomised JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
sodium NN i
and CC i
potassium NN i
supplementation NN i
on IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
and CC o
arterial JJ o
stiffness NN o
in IN p
untreated JJ p
( ( p
pre NN p
) ) p
hypertensive JJ p
individuals NNS p
. . p

During IN N
the DT N
study NN N
, , N
subjects NNS p
were VBD p
on IN p
a DT p
fully RB p
controlled VBN p
diet NN p
that WDT p
was VBD p
relatively RB p
low JJ p
in IN p
sodium NN p
and CC p
potassium NN p
. . p

After IN N
a DT N
1-week JJ N
run-in JJ N
period NN N
, , N
subjects VBZ N
received VBN i
capsules NNS i
with IN i
supplemental JJ i
sodium NN i
( ( i
3 CD i
g NN i
d NN i
( ( i
-1 NNP i
) ) i
, , i
equals VBZ i
7.6 CD i
g NN i
d NN i
( ( i
-1 NNP i
) ) i
of IN i
salt NN i
) ) i
, , i
supplemental JJ i
potassium NN i
( ( i
3 CD i
g NN i
d NN i
( ( i
-1 NNP i
) ) i
) ) i
or CC i
placebo NN i
, , i
for IN i
4 CD i
weeks NNS i
each DT i
, , i
in IN i
random JJ i
order NN i
. . o

Fasting VBG o
office NN o
BP NNP o
, , o
24-h JJ o
ambulatory NN o
BP NNP o
and CC o
measures NNS o
of IN i
arterial JJ o
stiffness NN o
were VBD o
assessed VBN i
at IN i
baseline NN i
and CC i
every DT i
4 CD i
weeks NNS i
. . i

Of IN i
37 CD p
randomized JJ p
subjects NNS p
, , p
36 CD p
completed VBD p
the DT p
study NN p
. . p

They PRP N
had VBD N
a DT N
mean JJ N
pre-treatment JJ o
BP NNP o
of IN o
145/81 CD o
mm NNS N
Hg NNP N
and CC o
69 CD o
% NN o
had VBD o
systolic JJ o
BP NNP o
?140 NNP N
mm NN o
Hg NNP o
. . o

Sodium NNP o
excretion NN o
was VBD o
increased VBN N
by IN N
98 CD N
mmol NNS N
per IN N
24 CD N
h NN N
and CC o
potassium NN o
excretion NN o
by IN N
63 CD N
mmol NNS N
per IN N
24 CD N
h NN N
during IN N
active JJ N
interventions NNS N
, , N
compared VBN N
with IN N
placebo NN N
. . N

During IN i
sodium JJ i
supplementation NN o
, , o
office NN o
BP NNP o
was VBD o
significantly RB o
increased VBN N
by IN N
7.5/3.3 CD N
mm NNS N
Hg NNP N
, , o
24-h JJ o
BP NNP o
by IN N
7.5/2.7 CD N
mm NNS N
Hg NNP N
and CC N
central JJ o
BP NNP o
by IN N
8.5/3.6 CD N
mm NNS N
Hg NNP N
. . N

During IN i
potassium JJ i
supplementation NN o
, , o
24-h JJ o
BP NNP o
was VBD o
significantly RB N
reduced VBN N
by IN N
3.9/1.6 CD N
mm NNS N
Hg NNP N
and CC o
central JJ o
pulse JJ o
pressure NN o
by IN o
2.9 CD o
mm NNS o
Hg NNP o
. . o

Pulse NNP o
wave VBP o
velocity NN o
and CC o
augmentation NN o
index NN o
were VBD o
not RB N
significantly RB N
affected VBN i
by IN i
sodium NN i
or CC i
potassium NN i
supplementation NN i
. . i

In IN i
conclusion NN i
, , N
increasing VBG N
the DT N
intake NN N
of IN N
sodium NN N
caused VBD N
a DT N
substantial JJ N
increase NN N
in IN o
BP NNP o
in IN N
subjects NNS p
with IN p
untreated JJ p
elevated JJ o
BP NNP o
. . o

Increased VBD N
potassium NN N
intake NN N
, , N
on IN N
top NN N
of IN N
a DT N
relatively RB N
low-sodium JJ N
diet NN N
, , N
had VBD N
a DT N
beneficial JJ N
effect NN o
on IN o
BP NNP o
. . o

Arterial NNP o
stiffness NN o
did VBD N
not RB N
materially RB N
change VBP N
during IN N
4-week JJ N
interventions NNS N
with IN N
sodium NN N
or CC N
potassium NN N
. . N

-DOCSTART- -22985336- O O

Manuka NNP i
honey-impregnated JJ i
dressings NNS i
in IN N
the DT N
treatment NN N
of IN N
neuropathic JJ p
diabetic JJ p
foot NN p
ulcers NNS p
. . p

In IN N
this DT N
study NN N
, , N
we PRP N
investigate VBP N
the DT N
effect NN N
of IN N
manuka JJ i
honey-impregnated JJ i
dressings NNS i
( ( i
MHID NNP i
) ) i
on IN N
the DT N
healing NN p
of IN p
neuropathic JJ p
diabetic JJ p
foot NN p
ulcers NNS p
( ( p
NDFU NNP p
) ) p
. . N

A DT N
total NN N
of IN N
63 CD p
Caucasians NNPS p
, , p
type RB p
2 CD p
diabetic JJ p
patients NNS p
followed VBD p
up RP p
in IN p
the DT p
diabetic JJ p
foot NN p
outpatient NN p
clinic NN p
comprised VBD N
the DT N
study NN N
population NN N
. . N

Patients NNS N
were VBD N
randomised VBN N
in IN N
two CD N
groups NNS N
as IN N
follows VBZ N
: : N
group NN N
I PRP N
patients NNS N
were VBD N
treated VBN N
with IN N
MHID NNP i
and CC N
group NN N
II NNP N
patients NNS N
were VBD N
treated VBN N
with IN N
conventional JJ i
dressings NNS i
( ( i
CD NN i
) ) i
. . i

The DT N
patients NNS N
were VBD N
followed VBN N
up RP N
on IN N
a DT N
weekly JJ N
basis NN N
for IN N
16 CD N
weeks NNS N
. . N

Mean NNP o
healing VBG o
time NN o
was VBD N
31 CD N
? . N
4 CD N
days NNS N
in IN N
group NN N
I PRP N
versus VBP N
43 CD N
? . N
3 CD N
days NNS N
in IN N
group NN N
II NNP N
( ( N
P NNP N
< NNP N
0?05 CD N
) ) N
. . N

In IN N
group NN N
I PRP N
patients NNS N
78?13 CD N
% NN N
of IN N
ulcers NNS N
became VBD N
sterile JJ N
during IN N
the DT N
first JJ N
week NN N
versus RB N
35?5 CD N
% NN N
in IN N
group NN N
II NNP N
patients NNS N
; : N
the DT N
corresponding JJ N
percentages NNS N
for IN N
weeks NNS N
2 CD N
, , N
4 CD N
and CC N
6 CD N
were VBD N
15?62 CD N
% NN N
versus IN N
38?7 CD N
% NN N
, , N
6?25 CD N
% NN N
versus IN N
12?9 CD N
% NN N
and CC N
0 CD N
% NN N
versus IN N
12?9 CD N
% NN N
respectively RB o
. . o

The DT o
percent NN o
of IN o
ulcers NNS o
healed VBD o
did VBD o
not RB o
differ VB o
significantly RB o
between IN o
groups NNS o
( ( N
97 CD N
% NN N
for IN N
MHID NNP N
and CC N
90 CD N
% NN N
for IN i
CD NN i
) ) i
. . i

MHID NNP i
represent VBP N
an DT N
effective JJ N
treatment NN N
for IN p
NDFU NNP p
leading VBG N
to TO N
a DT N
significant JJ o
reduction NN o
in IN o
the DT o
time NN o
of IN o
healing VBG o
and CC o
rapid JJ o
disinfection NN o
of IN o
ulcers NNS o
. . N

-DOCSTART- -17505437- O O

Evaluation NN N
of IN N
the DT N
topical JJ N
hemostatic JJ N
efficacy NN o
and CC o
safety NN o
of IN N
TISSEEL NNP i
VH NNP i
S/D NNP i
fibrin NN i
sealant NN i
compared VBN N
with IN N
currently RB i
licensed VBN i
TISSEEL NNP i
VH NNP i
in IN N
patients NNS p
undergoing JJ p
cardiac JJ p
surgery NN p
: : p
a DT N
phase NN N
3 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
clinical JJ N
study NN N
. . N

AIM NNP N
TISSEEL NNP N
VH NNP N
is VBZ N
the DT N
only JJ N
commercially RB N
available JJ N
fibrin NN N
sealant NN N
indicated VBD N
as IN N
an DT N
adjunct NN N
to TO N
conventional JJ N
methods NNS N
of IN N
hemostasis NN N
during IN N
cardiac JJ N
surgery NN N
. . N

A DT N
next JJ N
generation NN N
fibrin NN i
sealant NN i
( ( i
TISSEEL NNP i
VH NNP i
S/D NNP i
) ) i
has VBZ N
been VBN N
developed VBN N
in IN N
frozen JJ N
, , N
ready-to-use JJ N
form NN N
with IN N
an DT N
added JJ N
virus NN N
inactivation NN N
step NN N
( ( N
solvent/detergent JJ N
[ NNP N
S/D NNP N
] NNP N
treatment NN N
) ) N
to TO N
provide VB N
added JJ N
safety NN N
and CC N
convenience NN N
to TO N
the DT N
currently RB N
licensed VBN N
product NN N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
compare VB N
efficacy NN o
and CC o
safety NN o
of IN N
the DT N
two CD N
products NNS N
. . N

METHODS NNP N
Phase NNP N
3 CD N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
multicenter NN N
study NN N
to TO N
compare VB N
TISSEEL NNP i
VH NNP i
S/D NNP i
to TO i
TISSEEL NNP i
VH NNP i
during IN N
cardiac JJ N
surgery NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
proportion NN o
of IN o
patients NNS o
who WP o
achieved VBD o
hemostasis NN o
at IN p
the DT p
primary JJ p
treatment NN p
site NN p
within IN p
5 CD p
min NN p
, , p
and CC p
maintained VBD p
hemostasis NN p
until IN p
surgical JJ p
closure NN p
. . p

RESULTS VB N
The DT N
proportion NN o
of IN o
patients NNS o
who WP o
achieved VBD o
hemostasis NN o
at IN N
the DT N
primary JJ N
treatment NN N
site NN N
within IN N
5 CD N
min NN N
, , N
and CC N
maintained VBD o
hemostasis NN o
until IN N
surgical JJ N
closure NN N
was VBD N
88.2 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
and CC N
89.6 CD N
% NN N
for IN N
TISSEEL NNP N
VH NNP N
in IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

The DT N
difference NN N
in IN N
proportions NNS N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
minus CC N
TISSEEL NNP N
VH NNP N
, , N
was VBD N
1.4 CD N
% NN N
with IN N
a DT N
standard JJ N
error NN N
of IN N
3.70 CD N
% NN N
. . N

The DT N
lower JJR N
97.5 CD N
% NN N
confidence NN N
bound NN N
of IN N
this DT N
difference NN N
was VBD N
8.6 CD N
% NN N
, , N
which WDT N
is VBZ N
above IN N
the DT N
predefined JJ N
noninferiority NN N
margin NN N
of IN N
15 CD N
% NN N
. . N

Therefore RB N
, , N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
at IN N
least JJS N
as RB N
efficacious JJ N
as IN N
TISSEEL NNP N
VH NNP N
. . N

The DT N
safety NN N
profile NN N
of IN N
TISSEEL NNP N
VH NNP N
S/D NNP N
was VBD N
very RB N
similar JJ N
to TO N
that DT N
of IN N
currently RB N
licensed VBN N
TISSEEL NNP N
VH NNP N
as IN N
assessed VBN N
by IN N
the DT N
safety NN N
endpoints NNS N
. . N

CONCLUSION NNP N
TISSEEL NNP N
VH NNP N
S/D NNP N
is VBZ N
safe JJ o
and CC N
effective JJ o
for IN N
use NN N
as IN N
an DT N
adjunct NN N
to TO N
hemostasis VB N
in IN N
patients NNS p
undergoing JJ p
cardiac JJ p
surgery NN p
. . p

-DOCSTART- -26158622- O O

Optimal JJ o
vaccination NN o
program NN i
for IN N
healthy JJ p
adults NNS p
in IN p
China NNP p
. . p

There EX N
is VBZ N
still RB N
no DT N
suitable JJ N
routine NN N
hepatitis NN i
B NNP i
immunization NN i
strategy NN N
for IN N
adults NNS p
in IN p
China NNP p
. . p

To TO N
establish VB N
an DT N
optimal JJ o
vaccination NN o
schedule NN o
for IN N
healthy JJ p
adults NNS p
, , N
we PRP N
investigated VBD N
various JJ N
schedules NNS N
in IN N
healthy JJ p
adults NNS p
. . p

In IN N
this DT N
randomized JJ N
5143 CD p
healthy JJ p
adults NNS p
received VBD p
10 CD p
?g NNP i
hepatitis NN i
B NNP i
vaccine NN i
at IN i
0 CD i
, , i
1 CD i
and CC i
3 CD i
months NNS i
( ( i
group NN i
A NNP i
) ) i
, , i
0 CD i
, , i
1 CD i
and CC i
6 CD i
months NNS i
( ( i
group NN i
B NNP i
) ) i
, , i
or CC i
0 CD i
, , i
1 CD i
and CC i
12 CD i
months NNS i
( ( i
group NN i
C NNP i
) ) i
. . i

Blood NN o
samples NNS o
were VBD N
collected VBN N
after IN N
1 CD N
month NN N
and CC N
12 CD N
months NNS N
after IN N
the DT N
third JJ N
dose NN N
. . N

The DT o
geometric JJ o
mean NN o
titer NN o
( ( o
GMT NNP o
) ) o
, , o
seroconversion NN o
rate NN o
( ( o
levels NNS o
of IN o
anti-HBs NN o
? . o
10 CD o
mIU/mL NN o
) ) o
and CC o
high JJ o
response NN o
rate NN o
( ( o
levels NNS o
of IN o
anti-HBs NN o
? . o
100 CD o
mIU/mL NN o
) ) o
were VBD o
assayed VBN N
. . N

In IN N
our PRP$ N
study NN N
, , p
2438 CD p
healthy JJ p
adults NNS p
finished VBD p
the DT p
full JJ p
vaccination NN p
program NN p
and CC p
follow-up NN p
. . p

The DT p
seroconversion/sero-protective JJ o
rate NN o
of IN N
groups NNS N
A-C NNP N
at IN N
one CD N
and CC N
12 CD N
month NN N
after IN N
administration NN N
of IN N
the DT N
third JJ N
vaccine NN N
dose NN N
was VBD N
100 CD N
% NN N
, , N
99.9 CD N
% NN N
and CC N
97.9 CD N
% NN N
verse JJ N
64.9 CD N
% NN N
, , N
75.7 CD N
% NN N
and CC N
79.0 CD N
% NN N
, , N
respectively RB o
. . o

GMT NNP o
for IN o
anti-HBs JJ o
tested VBN o
in IN N
group NN N
A NNP N
to TO N
C NNP N
within IN N
1 CD N
or CC N
12 CD N
month NN N
after IN N
the DT N
third JJ N
vaccination NN N
was VBD N
213.16 CD N
, , N
432.58 CD N
and CC N
451.47 CD N
mIU/ml NNS N
verse JJ N
22.07 CD N
, , N
46.70 CD N
and CC N
56.18 CD N
mIU/ml NN N
, , N
respectively RB N
. . N

There EX N
were VBD N
significant JJ N
differences NNS o
of IN o
seroconversion/sero-protective JJ o
rate NN o
and CC o
GMT NNP o
among IN N
the DT N
3 CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Given VBN N
the DT N
high JJ N
anti-HBs JJ o
seroconversion NN o
rate NN o
and CC o
GMT NNP o
in IN N
all DT N
3 CD N
groups NNS i
, , i
a DT i
flexible JJ i
schedule NN N
for IN N
Hepatitis NNP N
B NNP N
vaccine NN N
should MD N
be VB N
recommended VBN N
to TO N
adults NNS N
, , N
but CC N
0-1-12 JJ N
schedule NN N
is VBZ N
a DT N
better JJR N
choice NN N
. . N

-DOCSTART- -3132778- O O

[ JJ N
Total NNP N
parenteral JJ o
nutrition NN o
in IN N
colon NN i
surgery NN i
] NN i
. . N

-DOCSTART- -9788685- O O

Efficacy NN o
and CC N
safety NN o
relative VBP N
to TO N
placebo VB i
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN i
and CC N
sustained-release JJ N
pseudoephedrine NN i
in IN N
the DT N
management NN o
of IN o
nasal JJ o
congestion NN o
. . o

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
clinical JJ o
efficacy NN o
of IN N
an DT N
oral JJ N
formulation NN N
of IN N
cetirizine NN i
5 CD N
mg NN N
with IN N
sustained-release JJ N
pseudoephedrine NN i
( ( N
PSE NNP N
) ) N
120 CD N
mg JJ N
relative NN N
to TO N
placebo VB i
in IN N
patients NNS p
with IN p
nasal JJ o
congestion NN o
. . o

METHODS NNP N
Twenty-four JJ p
patients NNS p
with IN p
perennial JJ p
rhinitis NN p
due JJ p
to TO p
house-dust-mite JJ p
( ( p
HDM NNP p
) ) p
allergy NN p
were VBD p
recruited VBN p
in IN N
this DT N
crossover NN N
study NN N
. . N

A DT N
treatment NN N
period NN N
of IN N
1 CD N
week NN N
, , N
in IN N
which WDT N
cetirizine/PSE NN i
was VBD N
administered VBN N
twice RB N
daily RB N
, , N
was VBD N
followed VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
2 CD N
weeks NNS N
and CC N
a DT N
further JJ N
period NN N
of IN N
1 CD N
week NN N
in IN N
which WDT N
the DT N
alternative NN N
treatment NN N
was VBD N
given VBN N
to TO N
each DT N
patient NN N
. . N

Immediately RB N
after IN N
the DT N
first JJ N
dose NN N
of IN N
each DT N
medication NN N
( ( N
day NN N
1 CD N
) ) N
, , N
nasal JJ o
congestion NN o
and CC N
related VBN o
symptoms NNS o
were VBD N
assessed VBN N
during IN N
a DT N
7-h JJ N
challenge NN N
with IN N
HDM NNP N
feces NNS N
, , N
with IN N
the DT N
Vienna NNP N
Challenge NNP N
Chamber NNP N
( ( N
VCC NNP N
) ) N
, , N
to TO N
investigate VB N
onset NN N
of IN N
action NN N
of IN N
the DT N
preparation NN N
. . N

A DT N
second JJ N
challenge NN N
of IN N
3-h JJ N
duration NN N
, , N
carried VBD N
out RP N
at IN N
least JJS N
12 CD N
h NN N
after IN N
the DT N
final JJ N
dose NN N
, , N
was VBD N
undertaken VBN N
after IN N
1 CD N
week NN N
( ( N
mean JJ N
) ) N
of IN N
twice-daily JJ N
treatment NN N
to TO N
assess VB N
residual JJ N
effects NNS o
of IN N
the DT N
formulation NN N
after IN N
achievement NN N
of IN N
steady JJ N
state NN N
. . N

RESULTS VB N
The DT N
oral JJ N
formulation NN N
of IN N
cetirizine/PSE NN i
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
superior NN N
to TO N
placebo VB i
in IN N
improving VBG N
nasal JJ o
obstruction NN o
during IN N
both DT N
challenges NNS N
. . N

The DT N
improvement NN o
in IN o
nasal JJ o
airflow NN o
and CC o
nasal JJ o
patency NN o
was VBD N
significantly RB N
greater JJR N
with IN N
cetirizine/PSE NN i
than IN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

In IN N
addition NN N
, , N
subjective JJ N
assessment NN N
of IN N
nasal NN o
symptoms NNS o
showed VBD N
that IN N
cetirizine/PSE NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB i
in IN N
both DT N
challenges NNS N
for IN N
the DT N
sum NN o
of IN o
nasal JJ o
obstruction NN o
scores NNS o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Both DT N
medications NNS N
were VBD N
well RB N
tolerated VBN o
, , N
and CC N
no DT N
serious JJ N
adverse JJ o
events NNS o
occurred VBD N
during IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
cetirizine/PSE NN i
relieved VBD N
nasal JJ o
congestion NN o
and CC N
other JJ N
objective JJ N
and CC N
subjective JJ N
symptoms NNS o
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
than IN N
placebo NN N
. . N

No DT N
serious JJ N
adverse JJ o
events NNS o
occurred VBD N
, , N
and CC N
both DT N
regimens NNS N
were VBD N
equally RB N
well RB N
tolerated VBN o
. . o

-DOCSTART- -24930546- O O

Metal NNP o
release NN o
and CC o
metal NN o
allergy NN o
after IN N
total JJ i
hip NN i
replacement NN i
with IN i
resurfacing VBG i
versus JJ i
conventional JJ i
hybrid JJ i
prosthesis NN i
. . i

BACKGROUND NNP N
Metal-on-metal NNP i
( ( i
MOM NNP i
) ) i
total JJ i
hip NN i
arthroplasties NNS i
were VBD N
reintroduced VBN N
because IN N
of IN N
the DT N
problems NNS N
with IN N
osteolysis NN N
and CC N
aseptic JJ N
loosening NN N
related VBN N
to TO N
polyethylene VB N
wear NN N
of IN N
early JJ N
metal-on-polyethylene NN N
( ( N
MOP NNP N
) ) N
arthroplasties NNS N
. . N

The DT N
volumetric JJ N
wear NN N
rate NN N
has VBZ N
been VBN N
greatly RB N
reduced VBN N
with IN N
MOM NNP N
arthroplasties NNS N
; : N
however RB N
, , N
because IN N
of IN N
nano-size JJ N
wear JJ N
particles NNS N
, , N
the DT N
absolute NN N
number NN N
has VBZ N
been VBN N
greatly RB N
increased VBN N
. . N

Thus RB N
, , N
a DT N
source NN N
of IN N
metal NN N
ion NN N
exposure NN N
with IN N
the DT N
potential JJ N
to TO N
sensitize VB N
patients NNS N
is VBZ N
present JJ N
. . N

We PRP N
hypothesized VBD N
that IN N
higher JJR N
amounts NNS N
of IN N
wear NN N
particles NNS N
result VBP N
in IN N
increased JJ N
release NN o
of IN o
metal NN o
ions NNS o
and CC N
ultimately RB N
lead JJ N
to TO N
an DT N
increased VBN N
incidence NN o
of IN o
metal NN o
allergy NN o
. . o

METHODS NNP N
52 CD p
hips NNS p
in IN p
52 CD p
patients NNS p
( ( p
median JJ p
age NN p
60 CD p
( ( p
51-64 JJ p
) ) p
years NNS p
, , p
30 CD p
women NNS p
) ) p
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
MOM NNP i
hip NN i
resurfacing VBG i
system NN i
( ( i
ReCap NNP i
) ) i
or CC N
a DT N
standard JJ i
MOP NNP i
total JJ i
hip NN i
arthoplasty NN i
( ( i
Mallory NNP i
Head/Exeter NNP i
) ) i
. . i

Spot NNP N
urine JJ N
samples NNS N
were VBD N
collected VBN N
preoperatively RB N
, , N
postoperatively RB N
, , N
after IN N
3 CD N
months NNS N
, , N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
and CC N
5 CD N
years NNS N
and CC N
tested VBN N
with IN N
inductively RB N
coupled VBN N
plasma-sector JJ N
field NN N
mass NN N
spectrometry NN N
. . N

After IN N
5 CD N
years NNS N
, , N
hypersensitivity NN o
to TO o
metals NNS o
was VBD N
evaluated VBN N
by IN N
patch NN N
testing NN N
and CC N
lymphocyte JJ N
transformation NN N
assay NN N
. . N

In IN N
addition NN N
, , N
the DT N
patients NNS N
answered VBD N
a DT N
questionnaire NN N
about IN N
hypersensitivity NN o
. . o

RESULTS VB N
A NNP N
statistically RB N
significant JJ N
10- JJ N
to TO N
20-fold JJ N
increase NN N
in IN N
urinary JJ o
levels NNS o
of IN o
cobalt NN o
and CC o
chromium NN o
was VBD N
observed VBN N
throughout IN N
the DT N
entire JJ N
follow-up NN N
in IN N
the DT N
MOM NNP i
group NN N
. . N

The DT N
prevalence NN N
of IN N
metal NN o
allergy NN o
was VBD N
similar JJ N
between IN N
groups NNS N
. . N

INTERPRETATION NNP N
While IN N
we PRP N
observed VBD N
significantly RB N
increased VBN N
levels NNS o
of IN o
metal NN o
ions NNS o
in IN o
the DT o
urine NN o
during IN N
the DT N
entire JJ N
follow-up JJ N
period NN N
, , N
no DT N
difference NN N
in IN N
prevalence NN o
of IN o
metal NN o
allergy NN o
was VBD N
observed VBN N
in IN N
the DT N
MOM NNP i
group NN N
. . N

However RB N
, , N
the DT N
effect NN N
of IN N
long-term JJ N
metal NN N
exposure NN N
remains VBZ N
uncertain JJ N
. . N

-DOCSTART- -19798489- O O

Eye NNP N
movements NNS N
affirm NN N
: : N
automatic JJ o
overt NN o
gaze NN o
and CC o
arrow NN o
cueing NN o
for IN N
typical JJ p
adults NNS p
and CC p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

People NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
show NN N
reduced VBN N
interest NN o
towards NNS N
social JJ o
aspects NNS o
of IN o
the DT o
environment NN o
and CC N
a DT N
lesser JJR N
tendency NN o
to TO N
follow VB o
other JJ o
people NNS o
's POS o
gaze NN o
in IN N
the DT N
real JJ N
world NN N
. . N

However RB N
, , N
most JJS N
studies NNS N
have VBP N
shown VBN N
that IN N
people NNS p
with IN p
ASD NNP p
do VBP N
respond VB N
to TO N
eye-gaze JJ N
cues NNS N
in IN N
experimental JJ N
paradigms NN N
, , N
though IN N
it PRP N
is VBZ N
possible JJ N
that IN N
this DT N
behaviour NN N
is VBZ N
based VBN N
on IN N
an DT N
atypical JJ N
strategy NN N
. . N

We PRP N
tested VBD N
this DT N
possibility NN N
in IN N
adults NNS p
with IN p
ASD NNP p
using VBG N
a DT N
cueing NN i
task NN i
combined VBN i
with IN i
eye-movement JJ i
recording NN i
. . i

Both DT N
eye NN N
gaze NN N
and CC N
arrow VB N
pointing VBG N
distractors NNS N
resulted VBD N
in IN N
overt JJ o
cueing NN o
effects NNS o
, , N
both DT N
in IN N
terms NNS N
of IN N
increased VBN o
saccadic JJ o
reaction NN o
times NNS o
, , N
and CC N
in IN N
proportions NNS o
of IN o
saccades NNS o
executed VBN o
to TO o
the DT o
cued VBN o
direction NN o
instead RB o
of IN o
to TO o
the DT o
target NN o
, , N
for IN N
both DT N
participant JJ N
groups NNS N
. . N

Our PRP$ N
results NNS N
confirm VBP N
previous JJ N
reports NNS N
that IN N
eye NN N
gaze NN N
cues NNS N
as RB N
well RB N
as IN N
arrow NN N
cues NNS N
result VBP N
in IN N
automatic JJ o
orienting NN o
of IN o
overt JJ o
attention NN o
. . o

Moreover RB N
, , N
since IN N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
between IN N
arrow NN N
and CC N
eye NN N
gaze NN N
cues NNS N
, , N
we PRP N
conclude VBP N
that IN N
overt JJ o
attentional JJ o
orienting NN o
in IN N
ASD NNP N
, , N
at IN N
least JJS N
in IN N
response NN N
to TO N
centrally RB N
presented VBN N
schematic JJ N
directional JJ N
distractors NNS N
, , N
is VBZ N
typical JJ N
. . N

-DOCSTART- -25616941- O O

Hepatic JJ N
cytoprotective JJ N
effect NN N
of IN N
ischemic JJ i
and CC i
anesthetic JJ i
preconditioning NN i
before IN N
liver JJ N
resection NN N
when WRB N
using VBG N
intermittent JJ N
vascular JJ N
inflow JJ N
occlusion NN N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Ischemic NNP i
preconditioning NN i
( ( i
IPC NNP i
) ) i
and CC N
anesthetic JJ i
preconditioning NN i
( ( i
APC NNP i
) ) i
have VBP N
been VBN N
reported VBN N
to TO N
attenuate VB N
ischemia-reperfusion NN N
( ( N
IR NNP N
) ) N
injury NN N
after IN N
liver JJ N
resection NN N
under IN N
continuous JJ N
inflow JJ N
occlusion NN N
. . N

This DT N
study NN N
evaluates VBZ N
whether IN N
these DT N
strategies NNS N
enhance VBP N
hepatic JJ N
protection NN N
of IN N
remnant JJ N
liver NN N
against IN N
IR NNP N
after IN N
liver JJ p
resection NN p
with IN p
intermittent JJ i
clamping NN i
( ( i
INT NNP i
) ) i
. . i

METHODS CC N
A DT p
total NN p
of IN p
106 CD p
patients NNS p
without IN p
underlying VBG p
liver NN p
disease NN p
and CC p
submitted VBN p
to TO p
liver VB p
resection NN p
using VBG p
INT NNP p
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
: : N
IPC NNP i
( ( i
10 CD i
minutes NNS i
of IN i
inflow JJ i
occlusion NN i
followed VBN i
by IN i
10 CD i
minutes NNS i
of IN i
reperfusion NN i
before IN i
liver JJ i
transection NN i
) ) i
, , i
APC NNP i
( ( i
sevoflurane JJ i
administration NN i
for IN i
20 CD i
minutes NNS i
before IN i
liver JJ i
transection NN i
) ) i
, , i
and CC i
INT NNP i
( ( i
no DT i
preconditioning NN i
) ) i
. . i

Patients NNS N
were VBD N
also RB N
stratified VBN N
according VBG N
to TO N
the DT N
extent NN N
of IN N
the DT N
hepatectomy NN N
. . N

Cytoprotection NN o
was VBD N
evaluated VBN N
by IN N
comparing VBG o
hepatocyte NN o
and CC o
endothelial JJ o
dysfunction NN o
markers NNS o
, , o
apoptosis NN o
, , o
histologic JJ o
lesions NNS o
, , o
and CC o
postoperative JJ o
outcome NN o
. . o

RESULTS NNP N
No NNP N
differences NNS N
were VBD N
observed VBN N
in IN N
preoperative JJ o
chemotherapy NN o
and CC o
steatosis NN o
, , o
total JJ o
warm JJ o
ischemia NN o
time NN o
, , o
operative JJ o
time NN o
, , o
or CC o
blood NN o
loss NN o
. . o

Kinetics NNS o
of IN o
transaminases NNS o
( ( N
aspartate JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.137 NNP N
; : N
alanine JJ N
aminotransferase NN N
, , N
P NNP N
= NNP N
.616 NNP N
) ) N
, , N
bilirubin FW o
( ( N
P NNP N
= NNP N
.980 NNP N
) ) N
, , N
and CC N
hyaluronic JJ o
acid NN o
increase NN N
( ( N
P NNP N
= NNP N
.514 NNP N
) ) N
revealed VBD N
no DT N
differences NNS N
. . N

Significant JJ o
apoptosis NN o
was VBD N
present JJ N
in IN N
40 CD N
% NN N
of IN N
patients NNS N
, , N
mild-to-moderate JJ o
leukocyte NN o
infiltration NN o
and CC o
steatosis NN o
in IN N
45 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
mild VB o
sinusoidal JJ o
congestion NN o
in IN N
65 CD N
% NN N
, , N
with IN N
a DT N
similar JJ N
distribution NN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

When WRB N
patients NNS N
were VBD N
stratified VBN N
by IN N
major JJ N
versus NN N
minor JJ N
resections NNS N
, , N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
variables NNS N
studied VBN N
. . N

Postoperative JJ N
clinical JJ N
outcomes NNS N
were VBD N
also RB N
similar JJ N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
these DT N
protocols NNS i
of IN i
IPC NNP i
and CC i
APC NNP i
used VBD N
in IN N
this DT N
study NN N
do VBP N
not RB N
provide VB N
better JJR N
cytoprotection NN N
from IN N
IR NNP N
when WRB N
INT NNP i
is VBZ N
used VBN N
. . N

-DOCSTART- -2406863- O O

Bismuth NNP i
subsalicylate NN i
in IN N
the DT N
treatment NN N
of IN N
gastritis NN p
due JJ p
to TO p
Campylobacter NNP p
pylori NN p
. . p

Fifty JJ p
patients NNS p
completed VBD N
an DT N
investigator-blind JJ N
trial NN N
comparing VBG N
bismuth NN i
subsalicylate NN i
, , i
erythromycin JJ i
ethylsuccinate NN i
, , i
and CC i
placebo RB i
matched VBN N
to TO N
the DT N
bismuth NN i
salt NN N
in IN N
the DT N
treatment NN N
of IN N
gastritis NN p
associated VBN p
with IN p
Campylobacter NNP p
pylori NN p
. . p

C. NNP N
pylori NN N
was VBD N
cleared VBN N
from IN N
14 CD N
( ( N
77.8 CD N
% NN N
) ) N
of IN N
18 CD p
patients NNS p
given VBN N
locally RB N
active JJ i
bismuth NN i
, , N
from IN N
one CD N
( ( N
6.7 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
given VBN N
erythromycin NNS i
, , N
and CC N
from IN N
none NN N
of IN N
17 CD N
patients NNS N
given VBN N
placebo NNS i
. . i

Gastritis NNP N
resolved VBD N
in IN N
13 CD N
( ( N
81 CD N
% NN N
) ) N
of IN N
16 CD N
patients NNS N
treated VBN N
with IN N
bismuth NN i
but CC N
in IN N
only RB N
three CD N
of IN N
13 CD N
receiving VBG N
erythromycin NN i
and CC N
in IN N
none NN N
of IN N
16 CD N
patients NNS N
given VBN N
placebo NNS i
. . i

Results NNS N
of IN N
endoscopic JJ N
examination NN N
showed VBD N
greater JJR N
improvement NN N
in IN N
patients NNS N
cleared VBN N
of IN N
C. NNP N
pylori NN N
than IN N
in IN N
those DT N
with IN N
persistent JJ N
infection NN N
. . N

Heartburn NNP o
improved VBD N
in IN N
50 CD N
% NN N
of IN N
patients NNS N
who WP N
received VBD N
bismuth RB i
compared VBN N
with IN N
17 CD N
% NN N
of IN N
those DT N
given VBN N
placebo NN i
. . i

The DT N
success NN N
of IN N
bismuth NN i
is VBZ N
probably RB N
due JJ N
to TO N
its PRP$ N
local JJ o
antimicrobial JJ o
activity NN o
. . o

Erythromycin NN i
may MD N
have VB N
been VBN N
inactivated VBN N
by IN N
the DT N
low JJ N
pH NN N
in IN N
the DT N
areas NNS N
colonized VBN N
with IN N
C. NNP N
pylori NN N
. . N

Relapse NNP o
is VBZ N
less RBR N
frequent JJ N
when WRB N
a DT N
combination NN N
of IN N
bismuth NN i
and CC N
an DT N
antimicrobial JJ N
agent NN N
is VBZ N
used VBN N
; : N
such JJ N
a DT N
combination NN N
is VBZ N
characterized VBN N
by IN N
local JJ o
and CC o
systemic JJ o
activity NN o
, , o
stability NN o
at IN o
low JJ o
pH NN o
, , o
and CC o
good JJ o
penetration NN o
into IN o
gastric JJ o
mucus NN o
. . o

-DOCSTART- -1799472- O O

Randomized VBN N
study NN N
of IN N
chlorambucil NN i
( ( N
CB NNP N
) ) N
compared VBN N
to TO N
interferon VB i
( ( N
alfa-2b JJ N
) ) N
combined VBN N
with IN N
CB NNP i
in IN N
low-grade JJ N
non-Hodgkin NN p
's POS p
lymphoma NN p
: : p
an DT N
interim JJ N
report NN N
of IN N
a DT N
randomized JJ N
study NN N
. . N

Non-Hodgkin NNP p
's POS p
Lymphoma NNP p
Cooperative NNP p
Study NNP p
Group NNP p
. . p

Alpha NNP i
interferon NN i
has VBZ N
shown VBN N
initial JJ N
promise NN N
in IN N
the DT N
treatment NN N
of IN N
low-grade JJ N
non-Hodgkin NN N
's POS N
lymphoma NN N
( ( N
NHL NNP N
) ) N
, , N
especially RB N
with IN N
the DT N
nodular JJ N
form NN N
of IN N
the DT N
disease NN N
. . N

The DT N
present JJ N
study NN N
enrolled VBD N
70 CD p
NHL NNP p
patients NNS p
who WP p
received VBD p
either CC p
chlorambucil NN i
( ( p
CB NNP p
; : p
10 CD p
mg/day NN p
) ) p
or CC p
CB NNP i
plus CC i
interferon JJ i
alfa-2b NN i
( ( p
5 CD p
million CD p
units NNS p
( ( p
MU NNP p
) ) p
/m2 VBD p
subcutaneously RB p
three CD p
times NNS p
a DT p
week NN p
) ) p
. . p

Among IN N
63 CD p
evaluable JJ p
patients NNS p
, , N
similar JJ N
response NN N
rates NNS N
( ( N
62.1 CD N
% NN N
and CC N
64.7 CD N
% NN N
respectively RB N
) ) N
were VBD N
recorded VBN N
for IN N
the DT N
treatment NN N
arms NNS N
. . N

In IN N
patients NNS p
receiving VBG p
no DT p
maintenance NN p
therapy NN p
, , N
those DT N
who WP N
received VBD N
interferon JJ N
alfa-2b JJ N
during IN N
the DT N
induction NN N
phase NN N
showed VBD N
a DT N
favourable JJ N
trend NN N
in IN N
terms NNS N
of IN N
incidence NN o
of IN o
relapse NN o
compared VBN N
to TO N
those DT N
who WP N
had VBD N
received VBN N
chlorambucil NN N
alone RB N
. . N

During IN N
maintenance NN N
therapy NN N
with IN N
interferon JJ i
alfa-2b NN i
, , N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
occurrence NN o
of IN o
relapse NN o
have VBP N
yet RB N
been VBN N
seen VBN N
compared VBN N
to TO N
patients NNS p
on IN p
no DT p
maintenance NN p
therapy NN p
. . p

A NNP N
longer JJR N
observation NN N
period NN N
is VBZ N
needed VBN N
to TO N
make VB N
a DT N
definitive JJ N
conclusion NN N
about IN N
the DT N
usefulness NN N
of IN N
interferon JJ i
maintenance NN i
therapy NN i
and CC N
to TO N
evaluate VB N
further RBR N
the DT N
effects NNS N
of IN N
the DT N
combined JJ N
schedule NN N
of IN N
chlorambucil NN i
and CC N
interferon NN i
induction NN N
on IN N
the DT N
duration NN N
of IN N
remission NN N
. . N

-DOCSTART- -15741848- O O

Enjoyment JJ N
mediates NNS N
effects NNS N
of IN N
a DT N
school-based JJ i
physical-activity NN i
intervention NN i
. . i

PURPOSE VB N
The DT N
study NN N
evaluated VBD N
whether IN N
targeted VBN N
changes NNS N
in IN N
factors NNS N
influencing VBG N
enjoyment NN N
of IN N
physical JJ N
education NN N
( ( N
PE NNP N
) ) N
, , N
physical JJ N
activity NN N
enjoyment NN N
, , N
and CC N
self-efficacy NN N
beliefs NNS N
about IN N
participating VBG N
in IN N
physical JJ N
activity NN N
mediated VBD N
the DT N
effect NN N
of IN N
the DT N
Lifestyle NNP i
Education NNP i
for IN i
Activity NNP i
Program NNP i
( ( i
LEAP NNP i
) ) i
intervention NN i
on IN N
participation NN N
in IN N
physical JJ N
activity NN N
. . N

METHODS NNP N
High NNP p
schools NNS p
( ( p
N=24 NNP p
) ) p
paired VBD p
on IN p
enrollment NN p
size NN p
, , p
racial JJ p
composition NN p
, , p
urban JJ p
or CC p
rural JJ p
location NN p
, , p
and CC p
class NN p
structure NN p
were VBD p
randomized VBN p
into IN p
control NN i
( ( p
N=12 NNP p
) ) p
or CC p
experimental JJ i
( ( p
N=12 NNP p
) ) p
groups NNS p
. . p

Of IN p
the DT p
4044 CD p
girls NNS p
enrolled VBD p
and CC p
eligible JJ p
, , p
2087 CD p
( ( p
51.6 CD p
% NN p
) ) p
participated VBD p
in IN p
the DT p
measurement JJ p
component NN p
of IN p
the DT p
study NN p
. . p

There EX N
were VBD N
1038 CD p
girls NNS p
in IN p
the DT p
control NN i
group NN p
and CC p
1049 CD p
girls NNS p
in IN p
the DT p
experimental JJ i
group NN p
. . p

INTERVENTION NNP N
LEAP NNP i
was VBD N
a DT N
comprehensive JJ N
school-based JJ N
intervention NN N
emphasizing VBG N
changes NNS N
in IN N
instruction NN N
and CC N
school NN N
environment NN N
designed VBN N
to TO N
increase VB N
physical JJ N
activity NN N
among IN N
black JJ p
and CC p
white JJ p
adolescent JJ p
girls NNS p
. . p

It PRP N
was VBD N
organized VBN N
according VBG N
to TO N
the DT N
Coordinated NNP N
School NNP N
Health NNP N
Program NNP N
and CC N
included VBD N
a DT N
PE NNP i
component NN i
with IN i
core NN i
objectives NNS i
of IN N
promoting VBG N
enjoyment NN N
of IN N
PE NNP N
, , N
physical JJ N
activity NN N
enjoyment NN N
, , N
and CC N
self-efficacy NN N
. . N

RESULTS NNP N
Latent NNP N
variable JJ N
structural JJ N
equation NN N
modeling VBG N
indicated VBD N
that IN N
: : N
1 CD N
) ) N
the DT N
intervention NN N
had VBD N
direct JJ N
, , N
positive JJ N
effects NNS N
on IN N
physical JJ N
activity NN N
and CC N
factors NNS N
influencing VBG N
enjoyment NN N
of IN N
PE NNP N
, , N
which WDT N
subsequently RB N
explained VBD N
the DT N
effects NNS N
of IN N
increased JJ N
physical JJ N
activity NN N
enjoyment NN N
and CC N
self-efficacy NN o
on IN N
increased JJ N
physical JJ N
activity NN N
; : N
and CC N
2 CD N
) ) N
an DT N
additional JJ N
, , N
indirect JJ N
effect NN N
of IN N
physical JJ N
activity NN N
enjoyment NN N
on IN N
physical JJ N
activity NN N
operated VBN N
by IN N
an DT N
influence NN N
on IN N
self-efficacy NN o
. . o

CONCLUSIONS NNP N
Increases VBZ N
in IN N
enjoyment NN N
partially RB N
mediated VBD N
the DT N
positive JJ N
effect NN N
of IN N
the DT N
LEAP NNP i
intervention NN i
. . i

To TO N
our PRP$ N
knowledge NN N
, , N
we PRP N
have VBP N
provided VBN N
the DT N
first JJ N
experimental JJ N
evidence NN N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
linking VBG N
increased VBD N
enjoyment JJ N
with IN N
increased JJ N
physical JJ N
activity NN N
among IN N
black JJ p
and CC p
white JJ p
adolescent JJ p
girls NNS p
. . p

-DOCSTART- -15358853- O O

Peripheral JJ N
arterial JJ N
disease NN N
: : N
therapeutic JJ N
confidence NN N
of IN N
CT NNP i
versus NNP i
digital JJ i
subtraction NN i
angiography NN i
and CC N
effects NNS N
on IN N
additional JJ N
imaging NN N
recommendations NNS N
. . N

PURPOSE NNP N
To TO N
compare VB N
multi-detector JJ i
row NN i
computed VBN i
tomographic JJ i
( ( i
CT NNP i
) ) i
angiography NN i
and CC i
digital JJ i
subtraction NN i
angiography NN i
( ( i
DSA NNP i
) ) i
prior RB N
to TO N
revascularization NN i
in IN N
patients NNS p
with IN p
symptomatic JJ p
peripheral JJ p
arterial JJ p
disease NN p
for IN N
the DT N
purpose NN N
of IN N
assessing VBG N
recommendations NNS N
for IN N
additional JJ N
imaging NN N
and CC N
physician JJ N
confidence NN N
ratings NNS N
for IN N
chosen NN N
therapy NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
73 CD p
patients NNS p
were VBD p
assigned VBN p
to TO p
CT NNP i
angiography NN i
, , p
and CC p
72 CD p
were VBD p
assigned VBN p
to TO p
DSA NNP i
. . i

Physician JJ o
confidence NN o
in IN o
the DT o
treatment NN o
decision NN o
was VBD N
measured VBN N
as IN N
a DT N
continuous JJ N
outcome NN N
on IN N
a DT N
scale NN N
of IN N
0-10 NNP N
( ( N
uncertain JJ N
to TO N
certain JJ N
) ) N
and CC N
as IN N
a DT N
dichotomous JJ o
outcome NN o
( ( N
further JJ N
imaging NN N
recommended VBD N
, , N
yes UH N
or CC N
no DT N
) ) N
. . N

Mean JJ o
confidence NN o
scores NNS o
and CC N
additional JJ o
imaging NN o
recommendations NNS o
were VBD N
compared VBN N
between IN N
CT NNP i
and CC i
DSA NNP i
groups NNS N
in IN N
an DT N
intention-to-diagnose-and-treat JJ N
analysis NN N
. . N

To TO N
detect VB N
trends NNS N
in IN N
confidence NN N
, , N
confidence NN N
scores NNS N
were VBD N
plotted VBN N
over IN N
time NN N
, , N
and CC N
multiple JJ N
linear JJ N
regression NN N
analysis NN N
was VBD N
performed VBN N
. . N

To TO N
detect VB N
trends NNS N
in IN N
additional JJ o
imaging NN o
recommendations NNS o
, , N
logistic JJ N
regression NN N
analysis NN N
was VBD N
used VBN N
. . N

Data NNS N
from IN N
eligible JJ N
nonrandomized JJ N
patients NNS N
were VBD N
analyzed VBN N
separately RB N
. . N

RESULTS NNP N
No NNP o
statistically RB o
significant JJ o
difference NN o
in IN N
baseline NN N
characteristics NNS N
between IN N
randomized VBN N
groups NNS N
was VBD N
found VBN N
. . N

CT NNP i
had VBD N
a DT N
lower JJR o
confidence NN o
score JJR o
than IN N
did VBD N
DSA NNP i
( ( N
7.2 CD N
vs NN N
8.2 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Further JJ N
imaging NN N
was VBD N
recommended VBN N
more RBR N
often RB N
after IN N
CT NNP i
( ( N
25 CD N
of IN N
71 CD N
patients NNS N
, , N
35 CD N
% NN N
) ) N
than IN N
after IN N
DSA NNP i
( ( N
nine CD N
of IN N
66 CD N
patients NNS N
, , N
14 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

Analysis NN N
of IN N
trends NNS N
demonstrated VBN N
increasing VBG N
( ( N
but CC N
not RB N
statistically RB N
significant JJ N
) ) N
confidence NN o
in IN N
CT NNP i
and CC N
stable JJ N
confidence NN o
in IN N
DSA NNP i
. . i

No NNP o
significant JJ o
difference NN o
was VBD N
found VBN N
in IN N
baseline NN N
characteristics NNS N
between IN N
randomized VBN N
and CC N
nonrandomized JJ N
patients NNS N
. . N

Among IN N
nonrandomized JJ N
patients NNS N
, , N
no DT N
significant JJ N
difference NN N
in IN N
mean JJ o
confidence NN o
score NN o
( ( N
8.2 CD N
vs NN N
8.3 CD N
, , N
P NNP N
= NNP N
.26 NNP N
) ) N
was VBD N
found VBN N
between IN N
CT NNP i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
and CC N
DSA NNP i
( ( N
n JJ N
= NNP N
26 CD N
) ) N
. . N

CONCLUSION NN N
With IN N
CT NNP i
angiography NN i
, , N
physician JJ N
confidence NN N
decreases NNS N
with IN N
an DT N
associated JJ N
increase NN N
in IN N
additional JJ N
imaging NN N
prior RB N
to TO N
revascularization NN N
in IN N
patients NNS p
with IN p
symptomatic JJ p
peripheral JJ p
arterial JJ p
disease NN p
. . p

Given VBN N
that IN N
CT NNP i
is VBZ N
less RBR N
invasive JJ N
than IN N
DSA NNP i
, , N
results NNS N
suggest VBP N
that IN N
CT NNP i
may MD N
replace VB N
DSA NNP i
in IN N
selected VBN N
cases NNS N
. . N

-DOCSTART- -24004700- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
improve VB N
colon NN i
cancer NN i
screening VBG i
in IN N
rural JJ p
family NN p
medicine NN p
: : p
an DT N
Iowa NNP N
Research NNP N
Network NNP N
( ( N
IRENE NNP N
) ) N
study NN N
. . N

BACKGROUND NNP N
Many JJ N
adults NNS N
have VBP N
not RB N
been VBN N
screened VBN N
for IN N
colon NN N
cancer NN N
, , N
a DT N
potentially RB N
preventable JJ N
cause NN N
of IN N
death NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
conducted VBN N
between IN N
December NNP p
2008 CD p
and CC p
April NNP p
2011 CD p
to TO p
improve VB p
CRC NNP p
screening VBG p
in IN p
16 CD p
rural JJ p
family NN p
physician NN p
offices NNS p
. . p

Subjects NNS p
due JJ p
for IN p
CRC NNP i
screening VBG i
were VBD N
randomized VBN N
within IN N
each DT N
practice NN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
usual JJ i
care NN i
; : i
( ( i
2 CD i
) ) i
physician JJ i
chart NN i
reminder NN i
; : i
( ( i
3 CD i
) ) i
physician JJ i
chart NN i
reminder NN i
, , i
mailed VBN i
education NN i
, , i
CRC NNP i
reminder NN i
magnet NN i
, , i
and CC i
fecal JJ i
immunochemical JJ i
test NN i
( ( i
FIT NNP i
) ) i
( ( i
mailed JJ i
education/FIT NN i
) ) i
; : i
or CC i
( ( i
4 CD i
) ) i
all PDT i
the DT i
preceding VBG i
plus CC i
a DT i
structured JJ i
telephone NN i
call NN i
to TO i
the DT i
patient NN i
from IN i
project JJ i
staff NN i
to TO i
provide VB i
education NN i
, , i
assess JJ i
interest NN i
in IN i
screening VBG i
, , i
explain VB i
the DT i
screening NN i
tests NNS i
, , i
and CC i
address JJ i
barriers NNS i
( ( N
mailed VBN N
education/FIT RB N
plus CC N
phone NN N
call NN N
) ) N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
completion NN o
of IN o
any DT o
CRC NNP o
screening NN o
. . o

RESULTS VB N
This DT p
study NN p
enrolled VBD p
743 CD p
patients NNS p
. . p

CRC NNP o
screening NN o
was VBD N
completed VBN o
by IN N
17.8 CD N
% NN N
in IN N
the DT N
usual JJ N
care NN N
group NN N
, , N
20.5 CD N
% NN N
in IN N
the DT N
chart NN N
reminder NN N
group NN N
, , N
56.5 CD N
% NN N
in IN N
the DT N
mailed JJ N
education/FIT NN N
group NN N
, , N
and CC N
57.2 CD N
% NN N
in IN N
the DT N
mailed JJ N
education/FIT NN N
plus CC N
phone NN N
call NN N
group NN N
. . N

We PRP N
found VBD N
no DT N
effect NN N
from IN N
the DT N
chart NN N
reminder NN N
compared VBN N
with IN N
usual JJ N
care NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.2 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.7-2.0 NNP N
) ) N
; : N
and CC N
a DT N
beneficial JJ o
effect NN o
from IN N
the DT N
mailed VBN N
education/FIT NN N
( ( N
OR NNP N
, , N
6.0 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
3.7-9.6 JJ N
) ) N
and CC N
the DT N
mailed JJ N
education/FIT NN N
plus CC N
phone NN N
call NN N
( ( N
OR NNP N
, , N
6.2 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
3.8-9.9 JJ N
) ) N
. . N

Both DT N
FIT NNP o
and CC o
colonoscopy JJ o
rates NNS o
increased VBD o
significantly RB N
in IN N
both DT N
mailed JJ N
education NN N
groups NNS N
. . N

CONCLUSION NNP N
CRC NNP o
screening VBG o
rates NNS o
increased VBD N
significantly RB N
among IN N
patients NNS N
who WP N
were VBD N
overdue JJ N
for IN N
screening VBG N
after IN N
they PRP N
received VBD N
mailed VBD N
educational JJ N
materials NNS N
and CC N
a DT N
FIT NNP N
. . N

The DT N
addition NN N
of IN N
a DT N
phone NN N
call NN N
did VBD N
not RB N
further JJ N
increase NN N
screening VBG N
rates NNS N
. . N

-DOCSTART- -24662947- O O

Multicenter NNP N
randomized VBD N
phase NN N
2 CD N
clinical JJ N
trial NN N
of IN N
a DT N
recombinant JJ i
human JJ i
endostatin NN i
adenovirus NN i
in IN N
patients NNS p
with IN p
advanced JJ p
head NN p
and CC p
neck NN p
carcinoma NN p
. . p

A DT N
randomized JJ N
, , N
open-label JJ N
, , N
phase JJ N
2 CD N
, , N
multicenter RB N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
the DT N
addition NN N
of IN N
a DT N
recombinant JJ i
human JJ i
endostatin NN i
adenovirus NN i
( ( i
E10A NNP i
) ) i
to TO i
cisplatin VB i
and CC i
paclitaxel VB i
in IN N
patients NNS p
with IN p
advanced JJ p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
or CC p
nasopharyngeal JJ p
carcinoma NN p
. . p

Patients NNS p
with IN p
locally RB p
advanced JJ p
or CC p
metastatic JJ p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
or CC p
nasopharyngeal JJ p
carcinoma NN p
not RB p
suitable JJ p
for IN p
operation NN p
or CC p
radiotherapy NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
E10A NNP i
plus CC i
chemotherapy NN i
every DT N
3 CD N
weeks NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
cycles NNS N
or CC N
to TO N
receive VB N
chemotherapy NN i
only RB i
. . i

One CD p
hundred CD p
and CC p
thirty-six JJ p
eligible JJ p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
. . p

The DT N
addition NN N
of IN N
E10A NNP N
did VBD N
not RB N
significantly RB N
improve VB N
the DT N
objective JJ o
response NN o
rate NN o
( ( N
29.9 CD N
versus RB N
39.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.154 CD N
) ) N
. . N

However RB N
, , N
patients NNS N
who WP N
received VBD N
endostatin NN N
had VBD N
longer RBR N
progression-free JJ o
survival NN o
( ( N
7.03 CD N
versus NN N
3.60 CD N
months NNS N
, , N
P NNP N
= NNP N
0.006 CD N
; : N
hazard VBN N
ratio NN N
: : N
0.55 CD N
) ) N
. . N

The DT N
combination NN N
of IN N
E10A NNP N
with IN N
chemotherapy NN N
benefited VBN N
prior JJ N
chemotherapy-treated JJ N
patients NNS N
and CC N
those DT N
who WP N
received VBD N
three CD N
to TO N
four CD N
treatment NN N
cycles NNS N
( ( N
6.50 CD N
versus NN N
3.43 CD N
months NNS N
, , N
P NNP N
= NNP N
0.003 CD N
; : N
8.27 CD N
versus IN N
4.27 CD N
months NNS N
, , N
P NNP N
= NNP N
0.018 CD N
; : N
respectively RB N
) ) N
. . N

The DT N
overall JJ o
disease NN o
control NN o
rate NN o
significantly RB N
increased VBD N
from IN N
80.6 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
to TO N
92.6 CD N
% NN N
in IN N
the DT N
test NN N
group NN N
( ( N
P NNP N
= NNP N
0.034 CD N
) ) N
. . N

Except IN N
for IN N
fever NN o
, , o
no DT o
adverse JJ o
events NNS o
were VBD N
associated VBN N
with IN N
the DT N
E10A NNP N
treatment NN N
. . N

In IN N
summary JJ N
, , N
E10A NNP N
plus CC N
chemotherapy NN N
is VBZ N
a DT N
safe JJ o
and CC o
effective JJ o
therapeutic JJ o
approach NN o
in IN N
patients NNS p
with IN p
advanced JJ p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
or CC p
nasopharyngeal JJ p
carcinoma NN p
. . p

-DOCSTART- -19404150- O O

Perioperative JJ o
fever NN N
and CC N
outcome NN N
in IN N
surgical JJ p
patients NNS p
with IN p
aneurysmal JJ p
subarachnoid JJ p
hemorrhage NN p
. . p

OBJECTIVE IN N
We PRP N
examined VBD N
the DT N
incidence NN N
of IN N
perioperative JJ N
fever NN N
and CC N
its PRP$ N
relationship NN N
to TO N
outcome VB N
among IN p
patients NNS p
enrolled VBN p
in IN p
the DT p
Intraoperative NNP p
Hypothermia NNP p
for IN p
Aneurysm NNP p
Surgery NNP p
Trial NNP p
. . p

METHODS NNP N
One CD p
thousand NN p
patients NNS p
with IN p
initial JJ p
World NNP p
Federation NNP p
of IN p
Neurological NNP p
Surgeons NNP p
grades NNS p
of IN p
I PRP p
to TO p
III NNP p
undergoing VBG p
clipping NN p
of IN p
intracranial JJ p
aneurysms NNS p
after IN p
subarachnoid JJ p
hemorrhage NN p
were VBD p
randomized VBN p
to TO p
intraoperative VB i
normothermia NN i
( ( p
36 CD p
degrees NNS p
C-37 JJ p
degrees NNS p
C NNP p
) ) p
or CC p
hypothermia NN i
( ( p
32.5 CD p
degrees NNS p
C-33.5 JJ p
degrees NNS p
C NNP p
) ) p
. . p

Fever NNP o
( ( N
> CD N
or CC N
=38.5 VB N
degrees NNS N
C NNP N
) ) N
and CC N
other JJ o
complications NNS o
( ( o
including VBG o
infections NNS o
) ) o
occurring VBG o
between IN o
admission NN o
and CC o
discharge NN o
( ( o
or CC o
death NN o
) ) o
were VBD N
recorded VBN N
. . N

Functional NNP o
and CC o
neuropsychologic JJ o
outcomes NNS o
were VBD N
assessed VBN N
3 CD N
months NNS N
postoperatively RB N
. . N

The DT N
primary JJ N
outcome NN N
variable NN N
for IN N
the DT N
trial NN N
was VBD N
dichotomized VBN o
Glasgow NNP o
Outcome NNP o
Scale NNP o
( ( o
good JJ o
outcome NN o
versus IN o
all DT o
others NNS o
) ) o
. . o

RESULTS NNP N
Fever NNP o
was VBD N
reported VBN N
in IN N
41 CD N
% NN N
of IN N
patients NNS N
. . N

In IN N
97 CD N
% NN N
of IN N
these DT N
, , N
fever RB o
occurred VBD N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

The DT N
median JJ o
time NN o
from IN o
surgery NN o
to TO o
first VB o
fever NN o
was VBD N
3 CD N
days NNS N
. . N

All DT N
measures NNS N
of IN N
outcome NN N
were VBD N
worse JJR N
in IN N
patients NNS N
who WP N
developed VBD N
fever NN N
, , N
even RB N
in IN N
those DT N
without IN N
infections NNS o
or CC N
who WP N
were VBD N
World NNP N
Federation NNP N
of IN N
Neurological NNP N
Surgeons NNP N
grade VBD N
I. NNP N
Logistic NNP N
regression NN N
analyses NNS N
were VBD N
performed VBN N
to TO N
adjust VB N
for IN N
differences NNS N
in IN N
preoperative JJ N
factors NNS N
( ( N
e.g. NN N
, , N
age NN N
, , N
Fisher NNP N
grade NN N
, , N
initial JJ N
neurological JJ N
status NN N
) ) N
. . N

This DT N
demonstrated VBD N
that IN N
fever NN o
continued VBD N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
most JJS N
outcome JJ N
measures NNS N
, , N
even RB N
when WRB N
infection NN o
was VBD N
added VBN N
to TO N
the DT N
model NN N
. . N

An DT N
alternative JJ N
stepwise NN N
model NN N
selection NN N
process NN N
including VBG N
all DT N
fever-related JJ o
measures NNS N
from IN N
the DT N
preoperative NN N
and CC N
intraoperative JJ N
period NN N
( ( N
e.g. JJ N
, , N
hydrocephalus JJ N
, , N
duration NN N
of IN N
surgery NN N
, , N
intraoperative JJ N
blood NN N
loss NN N
) ) N
resulted VBD N
in IN N
the DT N
loss NN N
of IN N
significance NN N
for IN N
dichotomized JJ N
Glasgow NNP N
Outcome NNP N
Scale NNP N
, , N
but CC N
significant JJ N
associations NNS N
between IN N
fever NN o
and CC N
several JJ N
other JJ N
outcome JJ N
measures NNS N
remained VBD N
. . N

After IN N
adding VBG N
postoperative JJ N
delayed VBN o
ischemic JJ o
neurological JJ o
deficits NNS o
to TO N
the DT N
model NN N
, , N
only RB N
worsened VBD N
National NNP o
Institutes NNPS o
of IN o
Health NNP o
Stroke NNP o
Scale NNP o
score NN o
, , o
Barthel NNP o
Activities NNP o
of IN o
Daily NNP o
Living NNP o
index NN o
, , o
and CC o
discharge NN o
destination NN o
( ( N
home NN N
versus IN N
other JJ N
) ) N
remained VBD N
independently RB N
associated VBN N
with IN N
fever NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
fever NN o
is VBZ N
associated VBN N
with IN N
worsened JJ N
outcome NN N
in IN N
surgical JJ p
subarachnoid JJ p
hemorrhage NN p
patients NNS p
, , N
although IN N
, , N
because IN N
the DT N
association NN N
between IN N
fever NN o
and CC N
the DT N
primary JJ N
outcome NN N
measure NN N
for IN N
the DT N
trial NN N
is VBZ N
dependent JJ N
on IN N
the DT N
covariates NNS N
used VBN N
in IN N
the DT N
analysis NN N
( ( N
particularly RB N
operative JJ N
events NNS N
and CC N
delayed VBN o
ischemic JJ o
neurological JJ o
deficits NNS o
) ) o
, , N
we PRP N
can MD N
not RB N
rule VB N
out IN N
the DT N
possibility NN N
that IN N
fever NN o
is VBZ N
a DT N
marker NN N
for IN N
other JJ N
events NNS N
. . N

Only RB N
a DT N
formal JJ N
trial NN N
of IN N
fever NN o
treatment NN N
or CC N
prevention NN N
can MD N
address VB N
this DT N
issue NN N
. . N

-DOCSTART- -24714816- O O

Salivary NNP N
testosterone NN N
and CC N
immunoglobulin VB N
A NNP N
were VBD N
increased VBN N
by IN N
resistance NN i
training NN i
in IN N
adults NNS p
with IN p
Down NNP p
syndrome NN p
. . p

This DT N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
influence NN N
of IN N
resistance NN N
training NN N
on IN N
salivary JJ N
immunoglobulin NN N
A NNP N
( ( N
IgA NNP N
) ) N
levels NNS N
and CC N
hormone NN N
profile NN N
in IN N
sedentary JJ p
adults NNS p
with IN p
Down NNP p
syndrome NN p
( ( p
DS NNP p
) ) p
. . p

A DT N
total NN N
of IN N
40 CD p
male NN p
adults NNS p
with IN p
DS NNP p
were VBD p
recruited VBN p
for IN p
the DT p
trial NN p
through IN p
different JJ p
community NN p
support NN p
groups NNS p
for IN p
people NNS p
with IN p
intellectual JJ p
disabilities NNS p
. . p

All DT p
participants NNS p
had VBD p
medical JJ p
approval NN p
for IN p
participation NN p
in IN p
physical JJ p
activity NN p
. . p

Twenty-four CD p
adults NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
perform VB N
resistance NN i
training NN i
in IN N
a DT N
circuit NN N
with IN N
six CD N
stations NNS N
, , N
3 CD N
days NNS N
per IN N
week NN N
for IN N
12 CD N
weeks NNS N
. . N

Training VBG N
intensity NN N
was VBD N
based VBN N
on IN N
functioning VBG N
in IN N
the DT N
eight-repetition NN N
maximum NN N
( ( N
8RM CD N
) ) N
test NN N
for IN N
each DT N
exercise NN i
. . i

The DT N
control NN p
group NN p
included VBD p
16 CD p
age- JJ p
, , p
gender- JJ p
, , p
and CC p
BMI-matched NNP p
adults NNS p
with IN p
DS NNP p
. . p

Salivary NNP o
IgA NNP o
, , o
testosterone NN o
, , o
and CC o
cortisol NN o
levels NNS o
were VBD N
measured VBN N
by IN N
ELISA NNP i
. . N

Work NNP N
task NN N
performance NN N
was VBD N
assessed VBN N
using VBG N
the DT N
repetitive JJ N
weighted-box-stacking JJ N
test NN N
. . N

Resistance NNP N
training VBG N
significantly RB N
increased VBN N
salivary JJ o
IgA NNP o
concentration NN o
( ( N
P=0.0120 NNP N
; : N
d=0.94 NN N
) ) N
and CC N
testosterone NN o
levels NNS o
( ( N
P=0.0088 NNP N
; : N
d=1.57 NN N
) ) N
in IN N
the DT N
exercising VBG N
group NN N
. . N

Furthermore RB N
, , N
it PRP N
also RB N
improved VBD o
work NN o
task NN o
performance NN o
. . o

No DT N
changes NNS N
were VBD N
seen VBN N
in IN N
the DT N
controls NNS N
who WP N
had VBD N
not RB N
exercised VBN N
. . N

In IN N
conclusion NN N
, , N
a DT N
short-term JJ N
resistance NN i
training NN i
protocol NN N
improved VBD N
mucosal JJ N
immunity NN o
response NN o
as RB N
well RB N
as IN N
salivary JJ o
testosterone NN o
levels NNS N
in IN N
sedentary JJ p
adults NNS p
with IN p
DS NNP p
. . p

-DOCSTART- -23343686- O O

Effects NNS N
of IN N
coronary JJ N
sinus NN N
occlusion NN N
on IN N
myocardial JJ N
ischaemia NN N
in IN N
humans NNS N
: : N
role NN N
of IN N
coronary JJ N
collateral NN N
function NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
tested VBD N
the DT N
hypotheses NNS N
that WDT N
intermittent VBP N
coronary JJ N
sinus NN N
occlusion NN N
( ( N
iCSO NN N
) ) N
reduces VBZ N
myocardial JJ o
ischaemia NN o
, , N
and CC N
that IN N
the DT N
amount NN N
of IN N
ischaemia NN o
reduction NN N
is VBZ N
related VBN N
to TO N
coronary JJ N
collateral NN N
function NN N
. . N

DESIGN NNP N
Prospective JJ N
case-control NN N
study NN N
with IN N
intraindividual JJ N
comparison NN N
of IN N
myocardial JJ N
ischaemia NN N
during IN N
two CD N
2-min JJ N
coronary JJ N
artery NN N
balloon NN N
occlusions NNS N
with IN N
and CC N
without IN N
simultaneous JJ N
iCSO NN N
by IN N
a DT N
balloon-tipped JJ N
catheter NN N
. . N

SETTING NNP N
University NNP p
Hospital NNP p
. . p

PATIENTS VB N
35 CD p
patients NNS p
with IN p
chronic JJ p
stable JJ p
coronary JJ p
artery NN p
disease NN p
. . p

INTERVENTION NNP N
2-min JJ i
iCSO NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Myocardial NNP o
ischaemia NN o
as IN N
assessed VBN N
by IN N
intracoronary JJ o
( ( o
i.c JJ o
. . o

) ) o
ECG NNP o
ST NNP o
shift NN o
at IN i
2 CD i
min NN i
of IN i
coronary JJ i
artery NN i
balloon NN i
occlusion NN i
. . i

Collateral NNP o
flow JJ o
index NN o
( ( o
CFI NNP o
) ) o
without IN o
iCSO NN o
, , o
that WDT o
is VBZ N
, , N
the DT N
ratio NN N
between IN N
mean JJ N
distal JJ N
coronary JJ N
occlusive NN N
( ( N
Poccl NNP N
) ) N
and CC N
mean JJ N
aortic JJ N
pressure NN N
( ( N
Pao NNP N
) ) N
both DT N
minus JJ N
central JJ N
venous JJ N
pressure NN N
. . N

RESULTS NNP N
I.c NNP N
. . N

ECG NNP o
ST NNP o
segment NN o
shift NN o
( ( N
elevation NN N
in IN N
all DT N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
with IN N
iCSO JJ N
versus NN N
without IN N
iCSO NN N
was VBD N
1.33?1.25 CD N
mV JJ N
versus NN N
1.85?1.45 CD N
mV NN N
, , N
p NN N
< VBD N
0.0001 CD N
. . N

Regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
degree NN N
of IN N
i.c NN o
. . o

ECG NNP o
ST NNP o
shift NN o
reduction NN o
during IN o
iCSO NN N
was VBD N
related VBN N
to TO N
CFI NNP N
, , N
best RB N
fitting VBG N
a DT N
Lorentzian JJ N
function NN N
( ( N
r NN N
( ( o
2 CD o
) ) o
=0.61 NN o
) ) o
. . o

Ischaemia NNP o
reduction NN o
with IN o
iCSO NN o
was VBD o
greatest VBN o
at IN N
a DT N
CFI NNP N
of IN N
0.05-0.20 NNP N
, , N
whereas NN N
in IN N
the DT N
low JJ N
and CC N
high JJ N
CFI NNP N
range VBP N
the DT N
effect NN N
of IN N
iCSO NN N
was VBD N
absent JJ N
. . N

CONCLUSIONS NNP N
ICSO NNP N
reduces VBZ N
myocardial JJ N
ischaemia NN N
in IN N
patients NNS p
with IN p
chronic JJ p
coronary JJ p
artery NN p
disease NN p
. . p

Ischaemia NNP N
reduction NN N
by IN N
iCSO JJ N
depends NNS N
on IN N
coronary JJ N
collateral NN N
function NN N
. . N

A DT N
minimal JJ N
degree NN N
of IN N
collateral NN o
function NN o
is VBZ o
necessary JJ N
to TO N
render VB N
iCSO JJ N
effective JJ N
. . N

ICSO NNP N
can MD N
not RB N
manifest VB N
an DT N
effect NN N
when WRB N
collateral NN N
function NN N
prevents NNS N
ischaemia NN N
in IN N
the DT N
first JJ N
place NN N
. . N

-DOCSTART- -384574- O O

Results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
hepatic JJ i
artery NN i
infusion NN i
with IN i
5-fluorouracil JJ i
versus NN i
intravenous JJ i
5-fluorouracil JJ i
in IN N
patients NNS p
with IN p
hepatic JJ p
metastases NNS p
from IN p
colorectal JJ p
cancer NN p
: : p
A DT N
Central NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
a DT N
controlled VBN N
, , N
prospectively RB N
randomized VBN N
trial NN N
, , N
74 CD p
patients NNS p
with IN p
hepatic JJ p
metastases NNS p
from IN p
colorectal JJ p
cancer NN p
were VBD p
randomized VBN p
to TO p
either DT p
intra-arterial JJ i
hepatic JJ i
artery NN i
infusion NN i
with IN i
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
or CC i
systemic JJ i
chemotherapy NN i
with IN i
5-FU JJ i
. . i

In IN N
61 CD N
acceptable JJ N
patients NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
response NN o
rate NN o
, , o
time NN o
to TO o
progression NN o
, , o
duration NN o
of IN o
the DT o
response NN o
, , o
and CC o
survival JJ o
rate NN o
. . o

Though IN N
the DT N
response NN o
rate NN o
for IN N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
slightly RB N
higher JJR N
than IN N
for IN N
the DT N
systemic JJ N
arm NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
, , N
and CC N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
nausea NN o
, , o
vomiting VBG o
, , o
diarrhea NN o
, , o
in IN o
addition NN o
to TO o
complications NNS o
of IN o
femoral-arterial JJ o
thrombosis NN o
, , o
bleeding NN o
, , o
and CC o
infection NN o
at IN o
the DT o
catheter NN o
site NN o
not RB N
seen VBN N
in IN N
patients NNS N
treated VBN N
by IN N
systemic JJ i
chemotherapy NN i
. . i

Patients NNS N
with IN N
an DT N
objective JJ N
response NN N
to TO N
chemotherapy VB N
on IN N
either DT N
treatment NN N
arm NN N
survived VBD o
twice RB N
as RB N
long RB N
as IN N
the DT N
nonresponders NNS N
. . N

Long-term JJ o
survival NN o
in IN N
one CD N
patient NN N
, , N
77 CD N
months NNS N
, , N
can MD N
occasionally RB N
be VB N
achieved VBN N
in IN N
patients NNS p
with IN p
hepatic JJ p
metastases NNS p
. . p

-DOCSTART- -10084579- O O

Genotyping VBG i
of IN i
CYP21 NNP i
, , N
linked VBD N
chromosome NN N
6p CD N
markers NNS N
, , N
and CC N
a DT N
sex-specific JJ N
gene NN p
in IN p
neonatal JJ p
screening NN p
for IN p
congenital JJ p
adrenal JJ p
hyperplasia NN p
. . p

We PRP N
investigated VBD N
the DT N
feasibility NN o
and CC o
diagnostic JJ o
utility NN o
of IN N
genotyping VBG i
9 CD i
CYP21 NNP i
mutations NNS N
, , N
linked VBD N
chromosome NN N
6p CD N
markers NNS N
, , N
and CC N
a DT N
dimorphic JJ N
X-Y JJ N
marker NN N
from IN N
neonatal JJ p
screening NN p
samples NNS p
. . p

Blood-impregnated JJ i
filter NN i
papers NNS i
( ( N
Guthrie NNP N
cards NNS N
) ) N
from IN N
603 CD p
randomly RB p
chosen VBN p
New NNP p
Zealand NNP p
neonates NNS p
were VBD N
genotyped VBN N
blind IN N
to TO N
17-hydroxyprogesterone CD i
( ( N
17-OHP CD N
) ) N
levels NNS N
. . N

Another DT p
50 CD p
samples NNS p
from IN p
Swiss NNP p
and CC p
North NNP p
American JJ p
infants NNS p
with IN p
correlative JJ p
hormonal JJ p
data NNS N
were VBD N
also RB N
genotyped VBN N
. . N

DNA NN N
was VBD N
extracted VBN N
, , N
and CC N
gene-specific JJ N
PCR NNP N
was VBD N
performed VBN N
. . N

CYP21 NNP i
PCR NNP i
products NNS N
were VBD N
subjected VBN N
to TO N
ligase VB N
detection NN N
reaction NN N
, , N
simultaneously RB N
analyzing VBG N
9 CD N
CYP21 NNP N
mutations NNS N
; : N
PCR NNP N
products NNS N
of IN N
other JJ N
genes NNS N
were VBD N
subjected VBN N
to TO N
direct VB N
gel JJ N
analysis NN N
. . N

CYP21 NNP i
genotyping VBG N
indicated VBD N
a DT N
heterozygote NN o
rate NN o
of IN N
2.8 CD N
% NN N
for IN N
classic JJ N
mutations NNS N
( ( N
excluding VBG N
CYP21 NNP N
deletions NNS N
) ) N
, , N
and CC N
2.0 CD N
% NN N
for IN N
nonclassic JJ N
mutations NNS N
in IN N
New NNP p
Zealanders NNP p
. . p

Ten CD N
full-term JJ N
affected JJ N
neonates NNS N
showed VBD N
a DT N
wide JJ o
range NN o
of IN o
17-OHP JJ o
levels NNS o
( ( N
15-1400 JJ N
nmol/L NN N
) ) N
. . N

Sick NNP N
or CC N
preterm JJ N
infants NNS N
or CC N
infants NNS N
screened VBN N
on IN N
the DT N
first JJ N
day NN N
of IN N
life NN N
with IN N
high JJ N
17-OHP JJ o
proved VBN N
genetically RB N
unaffected JJ N
. . N

Genetic JJ o
linkage NN o
disequilibrium NN o
was VBD N
found VBN N
between IN N
two CD N
CYP21 NNP N
mutations NNS N
and CC N
chromosome NN N
6p CD N
markers NNS N
. . N

Guthrie NNP N
cards NNS N
can MD N
be VB N
used VBN N
to TO N
accurately RB N
genotype VB N
CYP21 NNP o
and CC o
other JJ o
relevant JJ o
markers NNS o
, , N
potentially RB N
enhancing VBG N
the DT N
specificity NN o
and CC o
sensitivity NN o
of IN N
congenital JJ N
adrenal JJ N
hyperplasia NN N
screening NN N
. . N

CYP21 NNP o
heterozygote JJ o
frequency NN o
for IN o
classic JJ o
mutations NNS o
is VBZ N
higher JJR N
than IN N
expected VBN N
based VBN N
on IN N
genotype NN N
compared VBN N
with IN N
that DT N
predicted VBN N
by IN N
hormonal JJ N
newborn JJ p
screening NN N
. . N

-DOCSTART- -17331237- O O

Cost-effectiveness NN o
of IN N
collaborative JJ i
care NN i
including VBG i
PST NNP i
and CC i
an DT i
antidepressant JJ i
treatment NN i
algorithm NN i
for IN N
the DT N
treatment NN N
of IN N
major JJ p
depressive JJ p
disorder NN p
in IN N
primary JJ N
care NN N
; : N
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Depressive NNP p
disorder NN p
is VBZ N
currently RB N
one CD N
of IN N
the DT N
most RBS N
burdensome JJ N
disorders NNS N
worldwide VBP N
. . N

Evidence-based JJ N
treatments NNS N
for IN N
depressive JJ p
disorder NN p
are VBP N
already RB N
available JJ N
, , N
but CC N
these DT N
are VBP N
used VBN N
insufficiently RB N
, , N
and CC N
with IN N
less JJR N
positive JJ N
results NNS N
than IN N
possible JJ N
. . N

Earlier RBR N
research NN N
in IN N
the DT N
USA NNP N
has VBZ N
shown VBN N
good JJ N
results NNS N
in IN N
the DT N
treatment NN N
of IN N
depressive JJ p
disorder NN p
based VBN N
on IN N
a DT N
collaborative JJ i
care NN i
approach NN i
with IN i
Problem NNP o
Solving NNP o
Treatment NNP o
and CC i
an DT i
antidepressant JJ i
treatment NN i
algorithm NN i
, , N
and CC N
research NN N
in IN N
the DT N
UK NNP N
has VBZ N
also RB N
shown VBN N
good JJ N
results NNS N
with IN N
Problem NNP i
Solving VBG i
Treatment NNP i
. . i

These DT N
treatment NN N
strategies NNS N
may MD N
also RB N
work VB N
very RB N
well RB N
in IN N
the DT N
Netherlands NNP N
too RB N
, , N
even RB N
though IN N
health NN N
care NN N
systems NNS N
differ VBP N
between IN N
countries NNS N
. . N

METHODS/DESIGN NNP N
This DT N
study NN N
is VBZ N
a DT N
two-armed JJ N
randomised JJ N
clinical JJ N
trial NN N
, , N
with IN N
randomization NN N
on IN N
patient-level NN N
. . N

The DT N
aim NN N
of IN N
the DT N
trial NN N
is VBZ N
to TO N
evaluate VB N
the DT N
treatment NN o
of IN N
depressive JJ N
disorder NN N
in IN N
primary JJ p
care NN p
in IN p
the DT p
Netherlands NNP p
by IN N
means NNS N
of IN N
an DT N
adapted JJ i
collaborative NN i
care NN i
framework NN i
, , i
including VBG i
contracting NN i
and CC i
adherence-improving JJ i
strategies NNS i
, , i
combined VBN i
with IN i
Problem NNP i
Solving NNP i
Treatment NNP i
and CC i
antidepressant JJ i
medication NN i
according VBG i
to TO i
a DT i
treatment NN i
algorithm NN i
. . i

Forty NNP p
general JJ p
practices NNS p
will MD N
be VB N
randomised VBN i
to TO i
either CC i
the DT i
intervention NN i
group NN i
or CC i
the DT i
control NN i
group NN i
. . i

Included VBN N
will MD N
be VB N
patients NNS p
who WP p
are VBP p
diagnosed VBN p
with IN p
moderate JJ p
to TO p
severe JJ p
depression NN p
, , p
based VBN p
on IN p
DSM-IV NNP p
criteria NNS p
, , p
and CC p
stratified VBD p
according VBG p
to TO p
comorbid VB p
chronic JJ p
physical JJ p
illness NN p
. . p

Patients NNS i
in IN i
the DT i
intervention NN i
group NN i
will MD i
receive VB i
treatment NN i
based VBN i
on IN i
the DT i
collaborative JJ i
care NN i
approach NN i
, , i
and CC i
patients NNS i
in IN i
the DT i
control NN i
group NN i
will MD i
receive VB i
care NN i
as IN i
usual JJ i
. . i

Baseline NN i
measurements NNS i
and CC i
follow VB i
up RP i
measures NNS i
( ( i
3 CD i
, , i
6 CD i
, , i
9 CD i
and CC i
12 CD i
months NNS i
) ) i
are VBP i
assessed VBN i
using VBG i
questionnaires NNS i
and CC i
an DT i
interview NN i
. . i

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
severity NN o
of IN o
depressive JJ o
symptoms NNS o
, , o
according VBG o
to TO o
the DT o
PHQ9 NNP o
. . o

Secondary NNP N
outcome NN N
measures NNS N
are VBP N
remission NN o
as IN o
measured VBN o
with IN o
the DT o
PHQ9 NNP o
and CC o
the DT o
IDS-SR NNP o
, , o
and CC o
cost-effectiveness NN o
measured VBN o
with IN o
the DT o
TiC-P NNP o
, , o
the DT o
EQ-5D NNP o
and CC o
the DT o
SF-36 NNP o
. . o

DISCUSSION NNP N
In IN N
this DT N
study NN N
, , N
an DT N
American JJ N
model NN N
to TO N
enhance VB N
care NN N
for IN N
patients NNS p
with IN p
a DT p
depressive JJ p
disorder NN p
, , N
the DT N
collaborative JJ i
care NN i
model NN i
, , N
will MD N
be VB N
evaluated VBN N
for IN N
effectiveness NN N
in IN N
the DT N
primary JJ N
care NN N
setting VBG N
. . N

If IN N
effective JJ N
across IN N
the DT N
Atlantic NNP N
and CC N
across IN N
different JJ N
health NN N
care NN N
systems NNS N
, , N
it PRP N
is VBZ N
also RB N
likely JJ N
to TO N
be VB N
an DT N
effective JJ N
strategy NN N
to TO N
implement VB N
in IN N
the DT N
treatment NN N
of IN N
major JJ p
depressive JJ p
disorder NN p
in IN N
the DT N
Netherlands NNP N
. . N

-DOCSTART- -8741469- O O

[ RB N
Intraoperative NNP N
continuous JJ N
epidural JJ N
block NN N
influences NNS N
postoperative JJ N
changes NNS N
in IN N
breathing VBG N
pattern NN N
and CC N
thoracoabdominal JJ N
movement NN N
associated VBN N
with IN N
upper JJ N
abdominal JJ N
surgery NN N
] NN N
. . N

We PRP N
have VBP N
examined VBN N
the DT N
changes NNS N
in IN N
breathing VBG N
pattern NN N
and CC N
thoracoabdominal JJ N
movement NN N
associated VBN N
with IN N
upper JJ N
abdominal JJ N
surgery NN N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
possible JJ N
influences NNS N
of IN N
nociceptive JJ N
input NN N
on IN N
respiration NN N
. . N

Sixteen JJ p
patients NNS p
scheduled VBN p
for IN p
gastrectomy NN p
were VBD p
studied VBN p
. . p

Continuous JJ i
epidural JJ i
block NN i
was VBD i
instituted VBN i
prior RB i
to TO i
the DT i
induction NN i
of IN i
anesthesia NN i
and CC i
maintained VBD i
throughout IN i
the DT i
surgery NN i
in IN i
8 CD i
of IN i
16 CD i
patients NNS i
( ( i
Group NNP i
1 CD i
) ) i
while IN i
it PRP i
was VBD i
instituted VBN i
upon IN i
the DT i
peritoneal JJ i
closure NN i
and CC i
maintained VBD i
thereafter RB i
in IN i
the DT i
remaining VBG i
8 CD i
patients NNS i
( ( i
Group NNP i
2 CD i
) ) i
. . N

Breathing VBG o
pattern NN o
and CC o
thoracoabdominal JJ o
motion NN o
were VBD N
determined VBN N
before IN N
and CC N
after IN N
surgery NN N
while IN N
the DT N
patients NNS N
awake VBP N
by IN N
respiratory NN i
inductance NN i
plethysmography NN i
( ( i
Respisomnography NNP i
, , i
Chest NNP i
MI NNP i
) ) i
. . i

Breathing NNP o
frequency NN o
and CC o
minute JJ o
ventilation NN o
increased VBD N
significantly RB N
while IN N
tidal JJ N
volume NN N
was VBD N
unchanged JJ N
after IN N
the DT N
operation NN N
regardless NN N
of IN N
the DT N
intraoperative JJ N
epidural JJ N
block NN N
. . N

Furthermore RB N
, , N
there EX N
were VBD N
identical JJ N
shortening NN N
of IN N
inspiratory JJ o
time NN o
and CC o
prolongation NN o
of IN o
duty NN o
ratio NN o
( ( N
inspiratory JJ N
time/duration NN N
of IN N
a DT N
breath NN N
) ) N
in IN N
the DT N
two CD N
groups NNS N
. . N

Contribution NN o
of IN o
rib JJ o
cage NN o
movement NN o
on IN o
tidal JJ o
volume NN o
increased VBD N
significantly RB N
postoperatively RB N
in IN N
all PDT N
the DT N
patients NNS N
. . N

However RB N
, , N
the DT N
changes NNS N
were VBD N
significantly RB N
smaller JJR N
in IN N
patients NNS p
receiving VBG p
intraoperative JJ p
epidural JJ p
block NN p
. . p

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
causes NNS N
of IN N
tachypnea NN N
and CC N
increased VBD N
minute NN N
ventilation NN N
are VBP N
different JJ N
from IN N
the DT N
mechanism NN N
responsible JJ N
for IN N
the DT N
alteration NN N
of IN N
thoracoabdominal JJ N
partitioning NN N
of IN N
ventilation NN N
after IN N
upper JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
former JJ N
may MD N
be VB N
related VBN N
to TO N
the DT N
metabolic JJ N
changes NNS N
and CC N
, , N
conceivably RB N
, , N
unaffected VBN N
by IN N
continuous JJ N
epidural JJ N
block NN N
. . N

While IN N
the DT N
latter NN N
may MD N
be VB N
the DT N
consequence NN N
of IN N
the DT N
reflex JJ N
inhibition NN N
of IN N
the DT N
diaphragmatic JJ N
function NN N
that WDT N
can MD N
be VB N
, , N
at IN N
least JJS N
partially RB N
, , N
modified VBN N
by IN N
continuous JJ N
epidural JJ N
block NN N
. . N

-DOCSTART- -16889080- O O

[ NN N
Pilot NNP N
results NNS N
of IN N
using VBG N
tamsulone-FS JJ i
in IN N
patients NNS p
with IN p
prostatic JJ p
adenoma NN p
according VBG N
to TO N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
multicenter NN p
comparative JJ N
trial NN N
] NN N
. . N

Tamsulone-FS NNP i
-- : i
a DT i
novel JJ i
Russian JJ i
alpha1A/D-adrenoblocker NN i
( ( i
Farm-Syntez NNP i
) ) i
-- : i
was VBD i
studied VBN N
in IN N
a DT N
randomized JJ N
multicenter NN N
comparative JJ N
trial NN N
in IN N
patients NNS p
with IN p
prostatic JJ p
adenoma NN p
. . p

Pilot NNP N
results NNS N
agreed VBD N
with IN N
other JJ N
trials NNS N
published VBN N
in IN N
the DT N
literature NN N
and CC N
demonstrated VBD N
tamsulone-FS JJ i
efficacy NN o
and CC o
safety NN o
for IN o
management NN o
of IN o
lower JJR o
urinary JJ o
tract NN o
symptoms NNS o
caused VBN N
by IN N
prostatic JJ N
adenoma NN N
. . N

The DT o
efficacy NN o
and CC o
safety NN o
of IN o
tamsulone-FS NN o
was VBD o
comparable JJ o
to TO o
those DT o
of IN o
omnik FW o
. . o

This DT N
drug NN N
can MD N
be VB N
recommended VBN N
for IN N
wide JJ N
clinical JJ N
practice NN N
in IN N
prostatic JJ o
adenoma NN o
. . o

It PRP N
is VBZ N
registered VBN N
by IN N
Roszdravnadzor NNP N
( ( N
certificate JJ N
N NNP N
LC-000859 NNP N
of IN N
03.11.2005 CD N
) ) N
and CC N
allowed VBN N
for IN N
production NN N
and CC N
sale NN N
. . N

-DOCSTART- -17302075- O O

[ JJ N
Occupational NNP N
exposure NN N
to TO N
nitrous JJ i
oxide NN i
and CC i
sevoflurane NN i
during IN N
pediatric JJ i
anesthesia NN i
: : i
evaluation NN o
of IN o
an DT o
anesthetic JJ o
gas NN o
extractor NN o
] NNP o
. . N

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
level NN N
of IN N
occupational JJ N
exposure NN N
to TO N
anesthetic JJ N
gases NNS N
in IN N
the DT N
absence NN N
of IN N
an DT N
extractor NN N
during IN N
pediatric JJ i
anesthesia NN i
and CC N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
purpose-built JJ N
extraction NN N
system NN N
. . N

METHODS PDT N
The DT N
patients NNS p
were VBD p
24 CD p
children NNS p
undergoing VBG p
tonsillectomy NN i
and CC p
adenoidectomy NN i
. . i

Gases NNS N
were VBD N
extracted VBN N
from IN N
the DT N
room NN N
for IN N
1 CD N
group NN N
and CC N
were VBD N
not RB N
extracted VBN N
for IN N
the DT N
other JJ N
group NN N
( ( N
n=12 RB N
in IN N
each DT N
group NN N
) ) N
. . N

Induction NN N
was VBD N
with IN N
8 CD N
% NN N
sevoflurane NN i
, , N
60 CD N
% NN N
nitrous JJ i
oxide NN i
( ( N
N2O NNP N
) ) N
, , N
40 CD N
% NN N
oxygen NN i
at IN N
a DT N
flow JJ N
rate NN N
of IN N
8 CD N
L NNP N
x NNP N
min NN N
( ( N
-1 NN N
) ) N
through IN N
a DT N
Mapleson NNP N
C NNP N
circuit NN N
. . N

Maintenance NN N
was VBD N
with IN N
2 CD N
% NN N
sevoflurane NN i
at IN N
the DT N
same JJ N
flow NN N
rate NN N
and CC N
gas NN N
mixture NN N
under IN N
spontaneous JJ i
ventilation NN i
with IN N
an DT N
endotracheal JJ i
tube NN i
and CC N
a DT N
Mapleson NNP i
D NNP i
circuit NN i
. . i

The DT N
circuits NNS N
were VBD N
equipped VBN N
with IN N
an DT N
airway JJ N
pressure-limiting JJ N
valve NN N
to TO N
allow VB N
connection NN N
to TO N
an DT N
anesthetic JJ N
gas NN N
extractor NN N
. . N

Ambient JJ o
levels NNS o
of IN o
sevoflurane NN o
and CC o
N2O NNP o
were VBD N
measured VBN N
in IN N
the DT N
breathing JJ N
area NN N
around IN N
the DT N
anesthesiologist NN N
. . N

The DT N
surgeon NN N
and CC N
the DT N
nurse NN N
were VBD N
asked VBN N
about IN N
symptoms NNS N
related VBN N
to TO N
occupational JJ N
exposure NN N
. . N

RESULTS VB N
The DT o
mean NN o
( ( o
SD NNP o
) ) o
exposure NN o
to TO o
N2O NNP o
and CC o
sevoflurane NN o
in IN N
the DT N
group NN N
without IN N
an DT N
extractor NN N
was VBD N
423 CD N
( ( N
290 CD N
) ) N
and CC N
12 CD N
( ( N
10.9 CD N
) ) N
parts NNS N
per IN N
million CD N
( ( N
ppm NN N
) ) N
, , N
respectively RB N
. . N

In IN N
the DT N
group NN N
working VBG N
with IN N
the DT N
extractor NN N
, , N
exposure NN o
was VBD N
94 CD N
% NN N
and CC N
91 CD N
% NN N
lower JJR N
: : N
24.7 CD N
( ( N
26 CD N
) ) N
and CC N
1.1 CD N
( ( N
1 CD N
) ) N
ppm NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

A DT N
higher JJR N
incidence NN N
of IN N
noticing VBG N
a DT N
smell NN o
of IN o
gas NN o
was VBD N
registered VBN N
for IN N
the DT N
group NN N
without IN N
an DT N
extractor NN N
( ( N
87 CD N
% NN N
vs JJ N
11 CD N
% NN N
in IN N
the DT N
extractor NN N
group NN N
, , N
P=.003 NNP N
) ) N
. . N

Higher JJR N
rates NNS N
were VBD N
also RB N
found VBN N
for IN N
general JJ o
discomfort NN o
( ( N
62 CD N
% NN N
vs JJ N
11 CD N
% NN N
, , N
P=.05 NNP N
) ) N
, , N
nausea NN o
( ( N
62 CD N
% NN N
vs JJ N
0 CD N
% NN N
, , N
P=.009 NNP N
) ) N
, , N
and CC N
headache NN o
( ( N
62 CD N
% NN N
vs JJ N
0 CD N
% NN N
, , N
P=.009 NNP N
) ) N
in IN N
the DT N
absence NN N
of IN N
the DT N
extractor NN N
. . N

CONCLUSIONS NNP N
Gas NNP N
extraction NN N
decreased VBD N
the DT N
level NN o
of IN o
exposure NN o
by IN N
up IN N
to TO N
94 CD N
% NN N
, , N
achieving VBG N
levels NNS N
that WDT N
were VBD N
below IN N
the DT N
recommended VBN N
limits NNS N
and CC N
greatly RB N
reducing VBG N
occupational JJ o
risk NN o
. . o

-DOCSTART- -7712308- O O

Effects NNS N
of IN N
ursodeoxycholic JJ i
acid NN i
on IN N
serum NN o
liver NN o
enzymes NNS o
in IN N
patients NNS p
with IN p
hepatitis JJ p
C NNP p
virus-related JJ p
chronic JJ p
liver NN p
disease NN p
. . p

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
ursodeoxycholic JJ i
acid NN i
( ( i
UDCA NNP i
) ) i
on IN N
serum NN o
liver NN o
enzyme NN o
levels NNS o
[ VBP o
alanine JJ o
aminotransferase NN o
( ( o
ALT NNP o
) ) o
and CC o
gamma-glutamyl JJ o
transferase NN o
( ( o
GGT NNP o
) ) o
] VBP o
in IN N
101 CD p
patients NNS p
with IN p
hepatitis JJ p
C NNP p
virus-related JJ p
chronic JJ p
liver NN p
disease NN p
. . p

METHODS NNP N
Forty-nine JJ p
patients NNS p
were VBD p
assigned VBN p
to TO p
receive VB p
UDCA NNP i
( ( p
450 CD p
mg/day NN p
) ) p
over IN p
a DT p
period NN p
of IN p
6 CD p
months NNS p
and CC p
52 CD p
to TO p
receive VB p
no DT i
treatment NN i
. . i

RESULTS NNP N
In IN N
the DT N
UDCA NNP i
group NN N
, , N
serum NN o
ALT NNP o
and CC o
GGT NNP o
levels NNS o
significantly RB N
improved VBN N
. . N

ALT NNP o
values NNS o
decreased VBN N
from IN N
pre-treatment JJ N
levels NNS N
of IN N
157.0 CD N
+/- JJ N
62.6 CD N
IU/l NNP N
to TO N
82.5 CD N
+/- JJ N
46.4 CD N
IU/l NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
GGT NNP N
fell VBD N
from IN N
141.3 CD N
+/- JJ N
86.2 CD N
IU/l NNP N
to TO N
66.0 CD N
+/- JJ N
49.5 CD N
IU/l NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
change NN N
occurred VBD N
in IN N
the DT N
mean JJ o
ALT NNP o
and CC o
GGT NNP o
levels NNS o
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Although IN N
our PRP$ N
encouraging JJ N
preliminary JJ N
results NNS N
must MD N
be VB N
validated VBN N
by IN N
double-blind JJ N
histological JJ N
trials NNS N
, , N
UDCA NNP i
may MD N
be VB N
an DT N
alternative JJ N
treatment NN N
for IN N
patients NNS p
who WP p
fail VBP p
to TO p
respond VB p
to TO p
interferon VB i
therapy NN i
. . i

-DOCSTART- -1908493- O O

Altered NNP N
growth NN o
hormone NN o
response NN o
after IN N
growth NN i
hormone NN i
releasing VBG i
hormone CD i
administration NN i
in IN N
chronic JJ N
renal JJ N
failure NN N
. . N

Eleven NNP p
chronic JJ p
renal JJ p
failure NN p
patients NNS p
and CC p
11 CD p
matched JJ p
controls NNS p
, , N
received VBD N
growth NN i
hormone NN i
GHRH NNP i
( ( i
1 CD i
microgram/kg RB i
iv NN i
) ) i
or CC i
TRH NNP i
( ( i
400 CD i
microgram RB i
iv NN i
) ) i
on IN N
separate JJ N
occasions NNS N
, , N
immediately RB N
before IN N
undergoing JJ N
hemodialysis NN N
. . N

GHRH-induced JJ i
GH NNP N
peak NN N
in IN N
uremics NNS N
( ( N
22.7 CD N
+/- JJ N
5.2 CD N
micrograms/l NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
that DT N
obtained VBN N
in IN N
control NN N
subjects NNS N
( ( N
16.0 CD N
+/- JJ N
4.3 CD N
micrograms/l NN N
) ) N
. . N

However RB N
, , N
the DT p
uremic JJ p
patients NNS p
did VBD N
not RB N
show VB N
the DT N
habitual JJ N
post-peak JJ N
fall NN N
, , N
remaining VBG N
GH NNP o
levels NNS o
over IN N
10 CD N
micrograms/l NNS N
till IN N
the DT N
end NN N
of IN N
the DT N
test NN N
. . N

Differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Uremic JJ p
patients NNS p
showed VBD N
PRL NNP o
values VBZ o
higher JJR N
than IN N
in IN N
controls NNS N
, , N
however RB N
their PRP$ N
TRH-induced JJ o
PRL NNP o
peak NN o
( ( N
20.6 CD N
+/- JJ N
6.6 CD N
micrograms/l NN N
) ) N
was VBD N
not RB N
different JJ N
from IN N
that DT N
of IN N
controls NNS N
( ( N
26.5 CD N
+/- JJ N
3.0 CD N
micrograms/l NN N
) ) N
. . N

Again NNP N
chronic JJ p
renal JJ p
failure NN p
patients NNS p
showed VBD N
PRL NNP o
plasma NN o
values NNS o
abnormally RB N
elevated VBD N
till IN N
the DT N
end NN N
of IN N
the DT N
test NN N
. . N

Differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Administration NN N
of IN N
placebo NN i
to TO N
a DT N
different JJ p
group NN p
of IN p
seven CD p
uremic JJ p
patients NNS p
did VBD N
not RB N
alter VB N
GH NNP o
and CC o
PRL NNP o
plasma NN o
levels NNS o
. . o

This DT N
sustained JJ N
secretion NN N
of IN N
both DT N
GH NNP o
and CC o
PRL NNP o
in IN N
uremia NN N
could MD N
be VB N
attributed VBN N
to TO N
reduced VB N
kidney NN N
clearance NN N
. . N

However RB N
, , N
when WRB N
subjects NNS N
were VBD N
examined VBN N
individually RB N
both DT N
the DT N
GHRH- NNP o
and CC o
the DT o
TRH-induced NNP o
hormonal JJ o
peaks NNS o
and CC o
the DT o
subsequent JJ o
fall NN o
were VBD N
not RB N
different JJ N
in IN N
both DT N
groups NNS N
. . N

Unlike IN N
with IN N
controls NNS N
, , N
in IN N
uremic JJ p
patients NNS p
GHRH-stimulated JJ i
GH NNP N
and CC N
TRH-stimulated NNP i
PRL/GH NNP o
peaks NNS o
were VBD N
dispersed VBN N
throughout IN N
the DT N
120 CD N
min JJ N
period NN N
. . N

In IN N
controls NNS N
GH NNP o
and CC o
PRL NNP o
peaks NNS N
clustered VBD N
around IN N
15-30 JJ N
min NN N
. . N

The DT N
peak JJ N
dispersion NN N
created VBD N
a DT N
false JJ N
impression NN N
of IN N
flattened JJ N
curves NNS N
or CC N
sustained VBN N
hypersecretion NN N
in IN N
uremia NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -19135235- O O

Probiotics NNS i
prevent VBP N
IgE-associated JJ N
allergy NN N
until IN N
age NN N
5 CD N
years NNS N
in IN p
cesarean-delivered JJ p
children NNS p
but CC N
not RB N
in IN N
the DT N
total JJ N
cohort NN N
. . N

BACKGROUND NNP N
Less NNP N
microbial JJ N
exposure NN N
in IN N
early JJ N
childhood NN N
is VBZ N
associated VBN N
with IN N
more RBR N
allergic JJ N
disease NN N
later RB N
. . N

Allergic NNP p
children NNS p
have VBP N
a DT N
different JJ N
fecal JJ N
microflora NN N
, , N
with IN N
less JJR N
lactobacilli NN N
and CC N
bifidobacteria NN N
. . N

Beneficial JJ N
effects NNS N
regarding VBG N
the DT N
development NN N
of IN N
allergy NNS N
have VBP N
been VBN N
suggested VBN N
to TO N
come VB N
through IN N
probiotic JJ N
supplementation NN N
. . N

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
study VB N
the DT N
effect NN N
of IN N
probiotic JJ i
and CC i
prebiotic JJ i
supplementation NN i
in IN N
preventing VBG N
allergies NNS N
. . N

METHODS NNP N
In IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
we PRP N
randomized VBD N
1223 CD p
mothers NNS p
with IN p
infants NNS p
at IN p
high JJ p
risk NN p
for IN p
allergy NN p
to TO N
receive VB N
a DT N
probiotic JJ i
mixture NN i
( ( i
2 CD i
lactobacilli NN i
, , i
bifidobacteria NN i
, , i
and CC i
propionibacteria NN i
) ) i
or CC i
placebo NN i
during IN N
the DT N
last JJ p
month NN p
of IN p
pregnancy NN p
and CC p
their PRP$ p
infants NNS p
to TO p
receive VB p
it PRP p
from IN p
birth NN p
until IN p
age NN p
6 CD p
months NNS p
. . p

Infants NNS N
also RB N
received VBD N
a DT N
prebiotic JJ i
galacto-oligosaccharide NN i
or CC i
placebo NN i
. . i

At IN N
5 CD N
years NNS N
, , N
we PRP N
evaluated VBD N
the DT N
cumulative JJ N
incidence NN N
of IN N
allergic JJ o
diseases NNS o
( ( o
eczema NN o
, , o
food NN o
allergy NN o
, , o
allergic JJ o
rhinitis NN o
, , o
and CC o
asthma NN o
) ) o
and CC o
IgE NNP o
sensitization NN o
. . o

RESULTS NNP N
Of IN p
the DT p
1018 CD p
intent-to-treat NN p
infants NNS p
, , p
891 CD p
( ( p
88 CD p
% NN p
) ) p
attended VBD p
the DT p
5-year JJ p
visit NN p
. . p

Frequencies NNS o
of IN o
allergic JJ o
and CC o
IgE-associated JJ o
allergic JJ o
disease NN o
and CC N
sensitization NN o
in IN N
the DT N
probiotic JJ i
and CC N
placebo JJ i
groups NNS N
were VBD N
similar JJ N
: : N
52.6 CD N
% NN N
versus IN N
54.9 CD N
% NN N
and CC N
29.5 CD N
% NN N
versus IN N
26.6 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
41.3 CD N
% NN N
in IN N
both DT N
. . N

No DT N
significant JJ N
difference NN N
appeared VBD N
in IN N
frequencies NNS o
of IN o
eczema NN o
( ( N
39.3 CD N
% NN N
vs JJ N
43.3 CD N
% NN N
) ) N
, , N
atopic JJ o
eczema NN o
( ( N
24.0 CD N
% NN N
vs JJ N
25.1 CD N
% NN N
) ) N
, , N
allergic JJ o
rhinitis NN o
( ( N
20.7 CD N
% NN N
vs JJ N
19.1 CD N
% NN N
) ) N
, , N
or CC N
asthma NN o
( ( N
13.0 CD N
% NN N
vs JJ N
14.1 CD N
% NN N
) ) N
between IN N
groups NNS N
. . N

However RB N
, , N
less JJR N
IgE-associated JJ o
allergic JJ o
disease NN o
occurred VBD N
in IN N
cesarean-delivered JJ N
children NNS N
receiving VBG N
probiotics NNS i
( ( N
24.3 CD N
% NN N
vs JJ N
40.5 CD N
% NN N
; : N
odds NNS N
ratio VBP N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.23 CD N
% NN N
to TO N
0.96 CD N
% NN N
; : N
P NNP N
= NNP N
.035 NNP N
) ) N
. . N

CONCLUSIONS NNP N
No NNP N
allergy-preventive JJ N
effect NN N
that WDT N
extended VBD N
to TO N
age NN N
5 CD N
years NNS N
was VBD N
achieved VBN N
with IN N
perinatal JJ N
supplementation NN N
of IN N
probiotic JJ i
bacteria NNS i
to TO N
high-risk JJ p
mothers NNS p
and CC p
children NNS p
. . p

It PRP N
conferred VBD N
protection NN N
only RB N
to TO N
cesarean-delivered JJ N
children NNS N
. . N

-DOCSTART- -25871593- O O

Feasibility NN N
of IN N
a DT N
sensory-adapted JJ N
dental NN N
environment NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE UH N
To TO N
provide VB N
an DT N
example NN N
of IN N
an DT N
occupational JJ N
therapy NN N
feasibility NN N
study NN N
and CC N
evaluate VB N
the DT N
implementation NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
pilot NN N
and CC N
feasibility NN N
trial NN N
examining VBG N
the DT N
impact NN N
of IN N
a DT N
sensory-adapted JJ N
dental NN N
environment NN N
( ( N
SADE NNP N
) ) N
to TO N
enhance VB N
oral JJ N
care NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHOD NNP N
Twenty-two JJ p
children NNS p
with IN p
ASD NNP p
and CC p
22 CD p
typically RB p
developing VBG p
children NNS p
, , p
ages VBZ p
6-12 JJ p
yr NN p
, , N
attended VBD N
a DT N
dental JJ N
clinic NN N
in IN N
an DT N
urban JJ N
hospital NN N
. . N

Participants NNS p
completed VBD N
two CD i
dental JJ i
cleanings NNS i
, , i
3-4 JJ i
mo NN i
apart RB i
, , i
one CD i
in IN i
a DT i
regular JJ i
environment NN i
and CC i
one CD i
in IN i
a DT i
SADE NNP i
. . i

Feasibility NNP N
outcome JJ N
measures NNS N
were VBD N
recruitment NN o
, , o
retention NN o
, , o
accrual JJ o
, , o
dropout NN o
, , o
and CC o
protocol NN o
adherence NN o
. . o

Intervention NNP N
outcome JJ N
measures NNS N
were VBD N
physiological JJ o
stress NN o
, , o
behavioral JJ o
distress NN o
, , o
pain NN o
, , o
and CC o
cost NN o
. . o

RESULTS NNP N
We PRP N
successfully RB N
recruited VBD N
and CC N
retained VBD N
participants NNS p
. . p

Parents NNS N
expressed VBD N
satisfaction NN N
with IN N
research NN N
study NN N
participation NN N
. . N

Dentists NNS N
stated VBD N
that IN N
the DT N
intervention NN N
could MD N
be VB N
incorporated VBN N
in IN N
normal JJ N
practice NN N
. . N

Intervention NNP N
outcome NN N
measures NNS N
favored VBD N
the DT N
SADE NNP N
condition NN N
. . N

CONCLUSION NNP N
Preliminary NNP N
positive JJ N
benefit NN N
of IN N
SADE NNP N
in IN p
children NNS p
with IN p
ASD NNP p
warrants NNS N
moving VBG N
forward RB N
with IN N
a DT N
large-scale JJ N
clinical JJ N
trial NN N
. . N

-DOCSTART- -9301391- O O

Plasma NNP o
dilution NN o
and CC N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
Ringer NNP i
's POS i
solution NN i
. . i

Changes NNS N
in IN N
the DT N
volume NN N
of IN N
the DT N
fluid JJ N
space NN N
expanded VBN N
by IN N
i.v NN N
. . N

infusion NN N
of IN N
Ringer NNP i
's POS i
acetate JJ i
solution NN i
have VBP N
been VBN N
analysed VBN N
recently RB N
using VBG N
mathematical JJ N
models NNS N
. . N

Data NNS N
obtained VBN N
by IN N
such JJ N
analyses NNS N
allow VBP N
simulation NN N
of IN N
the DT N
dilution NN N
of IN N
the DT N
plasma NN o
volume NN o
during IN N
infusion NN o
of IN N
the DT N
solution NN N
at IN N
different JJ N
rates NNS N
. . N

To TO N
obtain VB N
basic JJ N
kinetic JJ N
data NNS N
for IN N
such JJ N
simulations NNS N
, , N
the DT N
plasma JJ o
dilution-time JJ o
curves NNS o
were VBD N
measured VBN N
during IN N
and CC N
after IN N
i.v NN i
. . i

infusion NN i
of IN i
Ringer NNP i
's POS i
solution NN i
25 CD N
ml NN N
kg-1 NN N
over IN N
30 CD N
min NNS N
in IN N
15 CD p
healthy JJ p
male NN p
volunteers NNS p
( ( p
mean JJ p
age NN p
31 CD p
yr NN p
) ) p
and CC p
over IN p
30 CD p
, , p
45 CD p
and CC p
80 CD p
min NN p
in IN p
six CD p
females NNS p
( ( p
mean JJ p
age NN p
32 CD p
yr NN p
) ) p
. . p

Based VBN N
on IN N
these DT N
experiments NNS N
, , N
nomograms NNS N
were VBD N
constructed VBN N
from IN N
which WDT N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
Ringer NNP i
's POS i
solution NN i
and CC N
the DT N
infusion NN N
time NN N
required VBN N
to TO N
obtain VB N
a DT N
defined JJ N
plasma NN N
dilution NN N
in IN N
both DT N
males NNS N
and CC N
females NNS N
can MD N
be VB N
estimated VBN N
together RB N
with IN N
the DT N
infusion NN N
rate NN N
needed VBN N
to TO N
maintain VB N
the DT N
dilution NN N
at IN N
the DT N
level NN N
reached VBD N
. . N

-DOCSTART- -418433- O O

PRL-8-53 NN i
: : i
enhanced VBN N
learning NN o
and CC N
subsequent JJ N
retention NN o
in IN N
humans NNS p
as IN N
a DT N
result NN N
of IN N
low JJ N
oral JJ N
doses NNS N
of IN N
new JJ N
psychotropic NN i
agent NN N
. . N

The DT N
effect NN N
of IN N
3- JJ i
( ( i
2-benzylmethylaminoethyl JJ i
) ) i
benzoic NN i
acid JJ i
methyl NN i
ester NN i
hydrochloride NN i
( ( i
PRL-8-53 NNP i
) ) i
on IN N
learning NN o
and CC N
on IN N
retention NN o
of IN o
verbal JJ o
information NN o
in IN N
human JJ p
subjects NNS p
was VBD N
investigated VBN N
. . N

Using VBG N
the DT N
serial JJ N
anticipation NN N
method NN N
under IN N
double-blind JJ N
conditions NNS N
it PRP N
was VBD N
found VBN N
that IN N
PRL-8-53 NNP i
causes NNS N
slight JJ N
improvement NN N
of IN N
acquisition NN o
. . o

Retinetion NN o
of IN o
verbal JJ o
information NN o
was VBD N
found VBN N
improved VBN N
to TO N
a DT N
statistically RB N
significant JJ N
degree NN N
( ( N
most RBS N
P NNP N
values NNS N
better RBR N
than IN N
0.01 CD N
, , N
some DT N
better JJR N
than IN N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
for IN N
either DT N
visual JJ o
reaction NN o
time NN o
or CC o
motor NN o
control NN o
after IN N
drug NN N
when WRB N
compared VBN N
with IN N
placebo NN i
values NNS N
. . N

-DOCSTART- -21785360- O O

To TO N
share NN N
or CC N
not RB N
to TO N
share NN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
consent NN o
for IN o
data NNS o
sharing VBG o
in IN p
genome JJ p
research NN p
. . p

PURPOSE NNP N
Despite IN N
growing VBG N
concerns NNS N
toward IN N
maintaining VBG N
participants NNS N
' POS N
privacy NN N
, , N
individual JJ N
investigators NNS N
collecting VBG N
tissue NN N
and CC N
other JJ N
biological JJ N
specimens NNS N
for IN N
genomic JJ N
analysis NN N
are VBP N
encouraged VBN N
to TO N
obtain VB N
informed JJ i
consent NN i
for IN N
broad JJ N
data NNS N
sharing VBG N
. . N

Our PRP$ N
purpose NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
on IN N
research NN N
enrollment NN N
and CC N
data NNS N
sharing VBG N
decisions NNS N
of IN N
three CD N
different JJ N
consent NN N
types NNS N
( ( N
traditional JJ N
, , N
binary JJ N
, , N
or CC N
tiered VBN N
) ) N
with IN N
varying VBG N
levels NNS N
of IN N
control NN N
and CC N
choices NNS N
regarding VBG N
data NNS N
sharing VBG N
. . N

METHODS VB N
A DT N
single-blinded JJ N
, , N
randomized VBN N
controlled VBD i
trial NN N
was VBD N
conducted VBN N
with IN N
323 CD p
eligible JJ p
adult NN p
participants NNS p
being VBG p
recruited VBN p
into IN p
one CD p
of IN p
six CD p
genome JJ p
studies NNS p
at IN p
Baylor NNP p
College NNP p
of IN p
Medicine NNP p
in IN p
Houston NNP p
, , p
Texas NNP p
, , p
between IN p
January NNP p
2008 CD p
and CC p
August NNP p
2009 CD p
. . p

Participants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
three CD p
experimental JJ i
consent NN i
documents NNS i
( ( p
traditional JJ p
, , p
n JJ p
= VBP p
110 CD p
; : p
binary JJ p
, , p
n JJ p
= VBP p
103 CD p
; : p
and CC p
tiered VBD p
, , p
n JJ p
= NNP p
110 CD p
) ) p
. . p

Debriefing VBG N
in IN N
follow-up JJ N
visits NNS N
provided VBD N
participants NNS N
a DT N
detailed JJ N
review NN N
of IN N
all DT N
consent NN N
types NNS N
and CC N
the DT N
chance NN N
to TO N
change VB N
data NNS N
sharing VBG N
choices NNS N
or CC N
decline VB N
genome NN N
study NN N
participation NN N
. . N

RESULTS NNP N
Before IN N
debriefing VBG N
, , N
83.9 CD N
% NN N
of IN N
participants NNS N
chose JJ N
public JJ N
data NNS N
release NN N
. . N

After IN N
debriefing VBG N
, , N
53.1 CD N
% NN N
chose JJ N
public JJ o
data NNS o
release NN o
, , N
33.1 CD N
% NN N
chose NN N
restricted VBN o
( ( o
controlled JJ o
access NN o
database NN o
) ) o
release NN o
, , N
and CC N
13.7 CD N
% NN N
opted VBN o
out IN o
of IN o
data NNS o
sharing VBG o
. . o

Only RB N
one CD N
participant NN N
declined VBD N
genome JJ N
study NN N
participation NN N
due JJ N
to TO N
data VB o
sharing NN o
concerns NNS o
. . o

CONCLUSION NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
most JJS N
participants NNS N
are VBP N
willing JJ N
to TO N
publicly RB o
release VB o
their PRP$ N
genomic JJ N
data NNS N
; : N
however RB N
, , N
a DT N
significant JJ N
portion NN N
prefers NNS N
restricted VBD o
release NN o
. . o

These DT N
results NNS N
suggest VBP N
discordance NN N
between IN N
existing VBG N
data NNS N
sharing VBG N
policies NNS N
and CC N
participants NNS N
' POS N
judgments NNS N
and CC N
desires NNS N
. . N

-DOCSTART- -16804044- O O

Psychological JJ N
well-being NN N
correlates NNS N
with IN N
free JJ N
thyroxine NN N
but CC N
not RB N
free JJ N
3,5,3'-triiodothyronine JJ N
levels NNS N
in IN N
patients NNS p
on IN p
thyroid JJ p
hormone NN p
replacement NN p
. . p

CONTEXT NNP N
AND NNP N
OBJECTIVE NNP N
An DT N
association NN N
between IN N
mood NN N
disorders NNS N
and CC N
overt JJ N
thyroid JJ N
dysfunction NN N
is VBZ N
well RB N
established VBN N
, , N
but CC N
there EX N
are VBP N
few JJ N
data NNS N
on IN N
the DT N
potential NN N
for IN N
thyroid JJ N
hormone NN N
levels NNS N
closer RBR N
to TO N
the DT N
reference NN N
range NN N
to TO N
correlate VB N
with IN N
psychological JJ N
well-being NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
We PRP N
analyzed VBD N
the DT N
relationship NN N
between IN N
psychological JJ N
well-being NN N
and CC N
free JJ N
T NNP N
( ( N
4 CD N
) ) N
( ( N
fT4 NN N
) ) N
, , N
free JJ N
T NNP N
( ( N
3 CD N
) ) N
( ( N
fT3 NN N
) ) N
, , N
TSH NNP N
, , N
and CC N
total JJ N
rT NN N
( ( N
3 CD N
) ) N
in IN N
697 CD p
patients NNS p
on IN p
thyroid JJ i
hormone NN i
replacement NN i
therapy NN i
at IN p
entry NN p
to TO p
a DT p
randomized VBN p
, , p
controlled VBD p
trial NN p
of IN p
combined JJ i
T NNP i
( ( i
4 CD i
) ) i
and CC i
T NNP i
( ( i
3 CD i
) ) i
replacement NN i
therapy NN i
. . i

All DT p
patients NNS p
were VBD p
on IN p
100 CD p
mug NN p
or CC p
more JJR p
T NNP p
( ( p
4 CD p
) ) p
. . p

INTERVENTIONS NNP N
AND CC N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Psychological NNP o
well-being NN o
was VBD o
assessed VBN o
with IN o
General NNP o
Health NNP o
Questionnaire-12 NNP o
( ( o
GHQ-12 NNP o
) ) o
, , o
Thyroid NNP o
Symptom NNP o
Questionnaire NNP o
, , o
and CC o
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
. . o

RESULTS NNP N
fT NN N
( ( N
4 CD N
) ) N
and CC N
TSH NNP N
showed VBD N
a DT N
strong JJ N
correlation NN N
with IN N
GHQ-12 NNP o
scores NNS o
( ( N
fT4 SYM N
- : N
b NN N
: : N
-0.16 NN N
, , N
P NNP N
= NNP N
0.005 CD N
; : N
TSH NNP N
- : N
b NN N
: : N
0.663 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

No UH N
correlations NNS N
were VBD N
seen VBN N
between IN N
the DT N
GHQ NNP o
scores NNS o
and CC o
fT3 NN o
( ( N
b NN N
: : N
0.318 CD N
, , N
P NNP N
= NNP N
0.275 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
( ( N
b NN N
: : N
0.095 CD N
, , N
P NNP N
= NNP N
0.95 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
to TO N
fT4 VB N
ratio NN N
( ( N
b NN N
: : N
71.83 CD N
, , N
P NNP N
= NNP N
0.09 CD N
) ) N
or CC N
fT3 VBN N
to TO N
rT VB N
( ( N
3 CD N
) ) N
ratio NN N
( ( N
b NN N
: : N
0.05 CD N
, , N
P NNP N
= NNP N
0.32 CD N
) ) N
. . N

The DT N
correlations NNS N
remained VBD N
when WRB N
the DT N
data NN N
set NN N
was VBD N
limited VBN N
to TO N
patients NNS N
with IN N
TSH NNP N
in IN N
the DT N
range NN N
0.3-4.0 JJ N
mIU/liter NN N
. . N

Similar JJ N
correlations NNS N
were VBD N
seen VBN N
with IN N
the DT N
Thyroid NNP o
Symptom NNP o
Questionnaire NNP o
, , N
although IN N
not RB N
with IN N
the DT N
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
scores NNS o
. . o

CONCLUSIONS NNP N
Differences NNPS N
in IN N
fT4 NN N
and CC N
TSH NNP N
concentration NN N
, , N
even RB N
within IN N
the DT N
reference NN N
range NN N
, , N
may MD N
be VB N
a DT N
determinant NN N
of IN N
psychological JJ N
well-being NN N
in IN N
treated JJ p
hypothyroid NN p
patients NNS p
although IN N
not RB N
necessarily RB N
with IN N
symptoms NNS N
typical JJ N
of IN N
anxiety NN N
or CC N
depression NN N
. . N

-DOCSTART- -2076713- O O

The DT N
effect NN o
of IN N
perindopril NN i
and CC i
hydrochlorothiazide VB i
alone RB i
and CC i
in IN i
combination NN i
on IN N
blood NN N
pressure NN N
and CC N
on IN N
the DT N
renin-angiotensin NN N
system NN N
in IN p
hypertensive JJ p
subjects NNS p
. . p

The DT N
pharmacodynamic JJ o
effects NNS o
and CC N
acceptability NN o
of IN N
perindopril NN i
( ( N
4 CD N
mg NNS N
daily RB N
) ) N
and CC N
hydrochlorothiazide NN i
( ( N
25 CD N
mg NNS N
daily RB N
) ) N
given VBN N
alone RB i
or CC N
in IN i
combination NN i
for IN N
1 CD N
month NN N
were VBD N
investigated VBN N
in IN N
a DT N
double-blind NN p
, , p
placebo NN i
controlled VBD p
, , p
parallel FW p
group NN p
study NN N
. . N

The DT N
pharmacokinetics NNS o
of IN N
perindopril NN i
and CC N
its PRP$ N
active JJ N
metabolite NN N
perindoprilat NN N
and CC N
the DT N
time NN o
course NN o
of IN o
angiotensin NN o
converting VBG o
enzyme JJ o
inhibition NN o
were VBD N
studied VBN N
for IN N
72 CD N
h NN N
following VBG N
the DT N
last JJ N
dose NN N
of IN N
treatment NN N
in IN N
the DT N
two CD p
appropriate JJ p
groups NNS p
. . p

Similar JJ N
decreases NNS N
in IN N
blood NN o
pressure NN o
were VBD N
seen VBN N
24 CD N
h NN N
after IN N
the DT N
last JJ N
dose NN N
of IN N
perindopril NN i
or CC i
hydrochlorothiazide NN i
( ( N
11/7 CD N
mm NN N
Hg NNP N
supine NN N
) ) N
given VBN N
alone RB N
at IN N
these DT N
doses NNS N
. . N

The DT N
effect NN N
of IN N
these DT N
drugs NNS N
given VBN N
together RB N
was VBD N
additive JJ N
on IN N
diastolic JJ o
blood NN o
pressure NN o
and CC N
synergistic JJ N
on IN N
systolic JJ o
blood NN o
pressure NN o
( ( N
24.5/12.6 CD N
mm NN N
Hg NNP N
supine NN N
) ) N
taking VBG N
into IN N
account NN N
the DT N
placebo NN N
response NN N
. . N

The DT N
significant JJ N
increase NN N
in IN N
plasma JJ o
renin NN o
activity NN o
produced VBN N
by IN N
perindopril NN i
alone RB N
was VBD N
potentiated VBN N
by IN N
concurrent JJ N
administration NN N
of IN N
hydrochlorothiazide NN i
. . i

The DT N
formation NN N
of IN N
perindoprilat NN o
was VBD N
slightly RB N
reduced VBN N
in IN N
the DT N
group NN N
also RB N
receiving VBG N
hydrochlorothiazide NN i
and CC N
there EX N
was VBD N
a DT N
very RB N
small JJ N
reduction NN N
in IN N
ACE NNP o
inhibition NN o
in IN N
this DT N
group NN N
. . N

Perindopril NNP i
, , N
whether IN N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
hydrochlorothiazide NN i
, , N
was VBD N
well RB o
tolerated VBN o
and CC N
produced VBN N
no DT N
clinically RB o
significant JJ o
change NN o
in IN o
routine JJ o
haematology NN o
or CC o
serum JJ o
biochemistry NN o
. . o

The DT N
additive JJ N
or CC N
synergistic JJ N
effects NNS N
of IN N
perindopril NN i
and CC i
hydrochlorothiazide NN i
on IN N
blood NN N
pressure NN N
must MD N
be VB N
due JJ N
to TO N
their PRP$ N
complementary JJ N
physiological JJ N
actions NNS N
and CC N
not RB N
to TO N
a DT N
pharmacokinetic JJ N
interaction NN N
. . N

-DOCSTART- -6366148- O O

The DT N
treatment NN N
of IN N
localized JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
in IN p
children NNS p
: : p
a DT N
report NN N
from IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
. . N

Investigators NNS N
of IN N
the DT N
Children NNP N
's POS N
Cancer NNP N
Study NNP N
Group NNP N
entered VBD N
73 CD p
children NNS p
with IN p
previously RB p
untreated VBN p
localized JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
on IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
systemic JJ N
treatment NN N
with IN N
either DT N
a DT N
four-drug JJ N
program NN N
( ( i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
methotrexate NN i
, , i
prednisone NN i
[ NNP i
COMP NNP i
] NNP i
) ) i
or CC N
a DT N
10-drug JJ i
( ( i
LSA2-L2 NNP i
modified VBN i
) ) i
program NN N
of IN N
18 CD N
months NNS N
duration NN N
. . N

All DT N
patients NNS N
received VBD N
central JJ i
nervous JJ i
system NN i
prophylaxis NN i
with IN i
intrathecal JJ i
methotrexate NN i
and CC N
most JJS N
received JJ N
local JJ i
or CC i
regional JJ i
radiation NN i
treatment NN i
. . i

The DT N
three-year JJ o
relapse-free JJ o
survival NN o
rate NN o
for IN N
all DT N
patients NNS N
( ( N
N NNP N
= NNP N
73 CD N
) ) N
was VBD N
84 CD N
% NN N
; : N
for IN N
COMP NNP N
( ( N
N NNP N
= NNP N
42 CD N
) ) N
was VBD N
85 CD N
% NN N
, , N
and CC N
for IN N
LSA2-L2 NNP N
( ( N
N NNP N
= NNP N
31 CD N
) ) N
was VBD N
84 CD N
% NN N
. . N

Of IN N
the DT N
12 CD N
patients NNS N
who WP N
suffered VBD N
adverse JJ o
events NNS o
eight CD N
relapsed VBN o
and CC N
four CD N
died NN o
of IN o
toxicity NN o
. . o

Histopathology NNP N
was VBD N
reviewed VBN N
centrally RB N
. . N

Of IN N
32 CD N
patients NNS N
with IN N
nonlymphoblastic JJ N
disease NN N
treated VBD N
with IN N
COMP NNP i
only RB N
one CD N
relapsed VBD o
. . o

Of IN N
26 CD N
patients NNS N
treated VBN N
with IN N
LSA2-L2 NNP i
, , N
four CD N
relapsed VBN o
. . o

Patients NNS N
with IN N
localized JJ o
lymphoblastic JJ o
disease NN o
were VBD N
uncommon JJ N
. . N

None NN N
of IN N
three CD N
patients NNS N
treated VBN N
with IN N
LSA2-L2 NNP i
relapsed VBD N
compared VBN N
with IN N
three CD N
of IN N
nine CD N
treated VBN N
with IN N
COMP NNP N
. . N

COMP NNP i
is VBZ N
an DT N
excellent JJ N
treatment NN N
for IN N
patients NNS N
with IN N
localized JJ N
disease NN N
of IN N
nonlymphoblastic JJ N
type NN N
, , N
but CC N
the DT N
relative JJ N
value NN N
of IN N
the DT N
two CD N
regimens NNS N
for IN N
patients NNS N
with IN N
localized JJ N
lymphoblastic JJ N
disease NN N
is VBZ N
uncertain JJ N
. . N

-DOCSTART- -10554799- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
itraconazole JJ i
versus NN i
fluconazole NN i
for IN N
the DT N
prevention NN o
of IN o
fungal JJ o
infections NNS o
in IN p
patients NNS p
with IN p
haematological JJ p
malignancies NNS p
. . p

U.K. NNP N
Multicentre NNP N
Antifungal NNP N
Prophylaxis NNP N
Study NNP N
Group NNP N
. . N

Fluconazole NNP i
is VBZ N
widely RB N
used VBN N
as IN N
antifungal JJ o
prophylaxis NN o
but CC N
it PRP N
is VBZ N
ineffective JJ N
against IN N
Aspergillus NNP N
. . N

Itraconazole NNP i
has VBZ N
a DT N
broader JJR N
spectrum NN N
of IN N
activity NN N
but CC N
the DT N
capsules NNS N
give VBP N
erratic JJ N
bioavailability NN N
in IN N
neutropenic JJ N
patients NNS N
. . N

We PRP N
compared VBN N
itraconazole JJ i
oral JJ i
solution NN i
( ( N
which WDT N
has VBZ N
an DT N
improved VBN N
pharmacokinetic JJ N
profile NN N
) ) N
with IN N
fluconazole NN i
for IN N
antifungal JJ N
prophylaxis NN N
. . N

Adults NNS p
with IN p
haematological JJ p
malignancies NNS p
receiving VBG p
chemotherapy NN p
or CC p
bone NN p
marrow NN p
transplants NNS p
were VBD N
randomly RB N
allocated VBN N
5 CD N
mg/kg/d JJ N
itraconazole NN i
( ( i
itra JJ i
) ) i
solution NN N
( ( N
288 CD N
episodes NNS N
) ) N
or CC N
100 CD N
mg JJ N
fluconazole JJ i
suspension NN i
( ( i
flu NN i
) ) i
( ( N
293 CD N
episodes NNS N
) ) N
from IN N
before IN N
the DT N
onset NN N
of IN N
neutropenia NN N
until IN N
neutrophil JJ N
recovery NN N
or CC N
suspected VBN N
fungal JJ N
infection NN N
. . N

Outcomes CC N
were VBD N
assessed VBN N
by IN N
independent JJ N
reviewers NNS N
unaware NN N
of IN N
the DT N
prophylaxis JJ N
allocation NN N
. . N

More JJR N
proven JJ o
systemic JJ o
fungal JJ o
infections NNS o
occurred VBD N
in IN N
flu NN N
( ( N
Aspergillus NNP N
four CD N
, , N
Candida NNP N
tropicalis VBZ N
one CD N
, , N
C. NNP N
krusei NNP N
one NN N
) ) N
than IN N
itra NN N
( ( N
C. NNP N
albicans VBZ N
one CD N
) ) N
and CC N
more JJR N
of IN N
these DT N
were VBD N
fatal JJ N
( ( N
four CD N
versus NN N
nil NN N
) ) N
. . N

This DT N
difference NN N
reached VBD N
statistical JJ N
significance NN N
when WRB N
first RB N
study VB N
episodes NNS N
were VBD N
considered VBN N
separately RB N
( ( N
six CD N
flu NN N
versus NN N
nil JJ N
itra NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Significantly RB N
more RBR N
deaths NNS o
of IN o
presumed JJ o
fungal JJ o
origin NN o
occurred VBD N
in IN N
flu NN N
than IN N
itra JJ N
( ( N
seven CD N
versus NN N
nil NN N
, , N
P NNP N
= NNP N
0.024 CD N
) ) N
. . N

There EX N
were VBD N
significantly RB N
more JJR N
cases NNS N
of IN N
proven JJ N
aspergillosis NN o
in IN N
flu NN N
than IN N
itra JJ N
( ( N
six CD N
versus NN N
nil NN N
, , N
P NNP N
= NNP N
0.038 CD N
, , N
5/6 CD N
cases NNS N
were VBD N
fatal JJ N
) ) N
if IN N
those DT N
occurring VBG N
outside IN N
the DT N
study NN N
period NN N
are VBP N
included VBN N
. . N

Significantly RB N
more RBR p
patients NNS p
receiving VBG p
flu NN p
required VBN p
amphotericin NN i
B NNP p
( ( N
58 CD N
v NN N
39 CD N
, , N
P NNP N
= NNP N
0.043 CD N
) ) N
but CC N
this DT N
may MD N
have VB N
been VBN N
affected VBN N
by IN N
the DT N
fact NN N
that IN N
the DT N
study NN N
was VBD N
not RB N
blinded VBN N
. . N

There EX N
were VBD N
11 CD N
proven JJ N
mucosal NN o
candidal JJ o
infections NNS o
in IN N
flu NN N
and CC N
four CD N
in IN N
itra NN N
. . N

Itraconazole NNP i
solution NN i
and CC N
fluconazole JJ i
provide NN N
effective JJ N
prophylaxis NN N
against IN N
Candida NNP N
but CC N
itraconazole JJ N
affords NNS N
greater JJR N
protection NN N
against IN N
fatal JJ N
aspergillosis NN o
. . o

-DOCSTART- -7841058- O O

The DT N
efficacy NN N
of IN N
audiotapes NNS i
in IN N
promoting VBG o
psychological JJ o
well-being NN o
in IN N
cancer NN p
patients NNS p
: : p
a DT N
randomised JJ N
, , N
controlled JJ N
trial NN N
. . N

Open VB N
or CC N
uncontrolled JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
providing VBG N
cancer NN p
patients NNS p
with IN N
audiotapes NNS i
of IN N
their PRP$ N
clinical JJ N
interviews NNS N
can MD N
improve VB N
information NN o
recall NN o
and CC N
reduce VB N
psychological JJ o
distress NN o
. . o

We PRP N
tested VBD N
these DT N
hypotheses NNS N
in IN N
a DT N
'clinician-blind JJ N
' '' N
, , N
prospective JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
. . N

A DT p
total NN p
of IN p
117 CD p
patients NNS p
newly RB p
referred VBN p
to TO p
a DT p
medical JJ p
oncology NN p
clinic NN p
who WP p
were VBD p
to TO p
be VB p
given VBN p
'bad CD p
news NN p
' POS p
had VBD N
their PRP$ N
consultations NNS N
audiotaped VBN i
. . i

Blind NNP N
to TO N
the DT N
clinician JJ N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
a DT N
copy NN i
of IN i
the DT i
tape NN i
to TO i
play VB i
at IN i
home NN i
or CC i
not RB i
( ( i
control VB i
group NN i
) ) i
. . i

At IN N
6 CD N
months NNS N
follow-up JJ N
, , N
tape NN N
group NN N
patients NNS N
reported VBD N
positive JJ o
attitudes NNS o
to TO N
the DT N
audiotape NN i
and CC N
were VBD N
shown VBN N
to TO N
recall VB o
significantly RB o
more JJR o
information NN o
about IN o
their PRP$ o
illness NN o
than IN N
did VBD N
controls NNS N
. . N

Overall JJ N
improvement NN N
in IN N
psychological JJ o
distress NN o
at IN N
1 CD N
and CC N
6 CD N
months NNS N
follow-up RB N
, , N
as IN N
measured VBN N
with IN N
the DT N
30-item JJ o
General NNP o
Health NNP o
Questionnaire NNP o
and CC o
the DT o
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
was VBD N
no DT N
different JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

However RB N
, , N
a DT N
second-order JJ N
interaction NN N
suggested VBD N
that IN N
poor-prognosis NN N
patients NNS N
were VBD N
disadvantaged VBN N
specifically RB N
by IN N
access NN N
to TO N
the DT N
audiotape NN N
, , N
with IN N
less JJR N
improvement NN N
in IN N
psychological JJ o
distress NN o
at IN N
6 CD N
months NNS N
follow-up JJ N
than IN N
non-tape JJ N
controls NNS N
. . N

Patient JJ N
access NN N
to TO N
audiotapes NNS i
of IN N
clinical JJ N
interviews NNS N
promotes VBZ N
factual JJ o
retention NN o
but CC N
does VBZ N
not RB N
reliably RB N
reduce VB N
psychological JJ o
distress NN o
and CC N
may MD N
be VB N
actively RB N
unhelpful JJ N
in IN N
some DT N
subgroups NNS N
of IN N
patients NNS N
. . N

-DOCSTART- -12021824- O O

The DT N
influence NN N
of IN N
placebo NN N
awareness NN N
on IN N
stimulant JJ N
drug NN N
response NN N
in IN N
a DT N
double-blind JJ N
trial NN N
. . N

RATIONALE NNP N
Critics NNPS N
have VBP N
called VBN N
into IN N
question NN N
findings NNS N
from IN N
double-blind JJ N
placebo-controlled JJ N
studies NNS N
because IN N
subjects NNS N
are VBP N
given VBN N
drug NN N
administration NN N
instructions NNS N
informing VBG N
them PRP N
of IN N
a DT N
placebo JJ N
condition NN N
. . N

The DT N
assertion NN N
that IN N
these DT N
drug NN N
administration NN N
instructions NNS N
bias VBP N
estimates NNS N
of IN N
effectiveness NN N
has VBZ N
undergone RB N
surprisingly RB N
little JJ N
empirical JJ N
investigation NN N
. . N

OBJECTIVES CC N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
drug NN N
administration NN N
instructions NNS N
informing VBG N
subjects NNS N
of IN N
a DT N
placebo JJ i
condition NN N
affect VBP N
the DT N
drug NN N
response NN N
and CC N
affect VB N
the DT N
saliva JJ o
concentration NN o
of IN N
the DT N
stimulant NN N
. . N

METHODS NNP N
We PRP N
assessed VBD N
caffeine JJ o
responses NNS o
and CC o
levels NNS o
of IN o
saliva JJ o
concentration NN o
of IN o
caffeine NN o
in IN p
52 CD p
subjects NNS p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
one CD p
of IN p
two CD p
drug NN p
administration NN p
instructions NNS p
: : p
( ( N
a DT N
) ) N
placebo-informed JJ i
instructions NNS i
( ( N
i.e. NN N
, , N
individuals NNS i
informed VBD i
of IN i
the DT i
placebo NN i
) ) i
analogous JJ N
to TO N
those DT N
used VBN N
in IN N
double-blind JJ N
studies NNS N
and CC N
( ( N
b NN N
) ) N
placebo-uninformed JJ i
instructions NNS i
( ( N
i.e. NN N
, , N
individuals NNS i
informed VBD i
they PRP i
are VBP i
taking VBG i
an DT i
active JJ i
stimulant NN i
) ) i
. . N

RESULTS VBN N
On IN N
most JJS N
measures NNS N
( ( o
systolic JJ o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
hand NN o
steadiness NN o
, , o
reaction NN o
time NN o
, , o
fatigue NN o
, , o
and CC o
tension NN o
) ) o
, , N
drug NN N
administration NN N
instructions NNS N
did VBD N
not RB N
significantly RB N
influence VB N
caffeine JJ o
response NN o
. . o

Instructions NNP N
also RB N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
saliva JJ o
concentration NN o
of IN N
caffeine NN N
. . N

However RB N
, , N
only RB N
individuals NNS N
who WP N
were VBD N
uninformed VBN N
of IN N
the DT N
placebo NN N
condition NN N
showed VBD N
significant JJ N
diastolic JJ o
blood NN o
pressure NN o
and CC o
vigor NN o
increases NNS N
with IN N
125 CD N
mg NNS N
caffeine NN i
, , N
and CC N
significant JJ N
hand NN o
steadiness NN o
impairment NN o
and CC o
vigor NN o
increases NNS N
with IN N
325 CD N
mg NNS N
caffeine NN i
compared VBN N
to TO N
placebo VB N
. . N

CONCLUSIONS NNP N
These DT N
overall JJ N
findings NNS N
suggest VBP N
that IN N
a DT N
limited JJ N
bias NN N
is VBZ N
introduced VBN N
by IN N
drug NN N
administration NN N
instructions NNS N
. . N

The DT N
results NNS N
do VBP N
not RB N
support VB N
any DT N
suggestion NN N
that IN N
information NN N
about IN N
the DT N
existence NN N
of IN N
a DT N
placebo NN N
condition NN N
dramatically RB N
influences VBZ N
conclusions NNS N
drawn VBP N
about IN N
drug NN N
responses NNS N
in IN N
placebo-controlled JJ N
trials NNS N
. . N

-DOCSTART- -11292279- O O

Central NNP N
nervous JJ N
system NN N
serotonin JJ N
function NN N
and CC N
cardiovascular JJ o
responses NNS o
to TO N
stress VB N
. . N

OBJECTIVE VB N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
indices NNS N
of IN N
central JJ N
nervous JJ N
system NN N
( ( N
CNS NNP N
) ) N
serotonin NN N
function NN N
on IN N
cardiovascular JJ o
reactivity NN o
to TO N
mental JJ N
stress NN N
. . N

METHODS NNP N
Lumbar NNP i
puncture NN i
was VBD N
performed VBN N
on IN N
54 CD p
healthy JJ p
volunteers NNS p
to TO p
obtain VB N
cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
for IN N
determination NN N
of IN N
5-hydroxyindoleacetic JJ N
acid NN N
( ( N
5HIAA CD N
) ) N
levels NNS N
. . N

Genotypes NNS N
were VBD N
determined VBN N
with IN N
respect NN N
to TO N
a DT N
functional JJ N
polymorphism NN N
of IN N
the DT N
serotonin NN N
transporter NN N
gene NN N
promoter NN N
region NN N
( ( N
5HTTLPR CD N
) ) N
. . N

Subjects NNS N
then RB N
underwent JJ N
mental JJ N
stress NN N
testing VBG N
. . N

RESULTS JJ N
Persons NNPS p
with IN p
one CD p
or CC p
two CD p
long JJ p
( ( p
l NN p
) ) p
5HTTLPR CD p
alleles NNS p
had VBD N
CSF NNP o
levels NNS o
of IN N
the DT N
major JJ N
serotonin NN N
metabolite NN N
, , N
5HIAA CD N
, , N
that WDT N
were VBD N
50 CD N
% NN N
higher JJR N
than IN N
those DT N
of IN N
persons NNS N
with IN N
the DT N
s/s NN N
5HTTLPR CD p
genotype NN p
. . p

Persons NNS N
with IN N
one CD N
or CC N
two CD N
l JJ N
alleles NNS N
or CC N
higher JJR N
CSF NNP o
5HIAA CD o
levels NNS o
also RB N
exhibited VBD N
greater JJR N
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
responses NNS o
to TO N
a DT N
mental JJ N
stress NN N
protocol NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
the DT N
5HTTLPR CD N
polymorphism NN N
affects NNS N
CNS NNP N
serotonin NN N
function NN N
, , N
and CC N
they PRP N
are VBP N
consistent JJ N
with IN N
the DT N
general JJ N
hypothesis NN N
that WDT N
CNS NNP N
serotonin NN N
function NN N
is VBZ N
involved VBN N
in IN N
the DT N
regulation NN N
of IN N
potentially RB N
health-damaging JJ N
biobehavioral JJ N
characteristics NNS N
. . N

In IN N
particular JJ N
, , N
the DT N
l NN N
allele NN N
could MD N
contribute VB N
, , N
through IN N
its PRP$ N
association NN N
with IN N
increased JJ N
cardiovascular JJ o
reactivity NN o
to TO N
stress VB N
, , N
to TO N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

-DOCSTART- -19781408- O O

Design NN N
of IN N
the DT N
DEFINE NNP N
trial NN N
: : N
determining VBG N
the DT N
EFficacy NNP o
and CC o
tolerability NN o
of IN N
CETP NNP N
INhibition NNP N
with IN N
AnacEtrapib NNP i
. . i

BACKGROUND NNP N
Residual NNP N
cardiovascular NN N
( ( N
CV NNP N
) ) N
risk NN N
often RB N
remains VBZ N
high JJ N
despite IN N
statin JJ N
therapy NN N
to TO N
lower VB N
low-density NN o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
. . o

New NNP N
therapies NNS N
to TO N
raise VB N
high-density NN o
lipoprotein NN o
cholesterol NN o
( ( o
HDL-C NNP o
) ) o
are VBP N
currently RB N
being VBG N
investigated VBN N
. . N

Anacetrapib NNP i
is VBZ N
a DT N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
( ( N
CETP NNP N
) ) N
inhibitor NN N
that WDT N
raises VBZ N
HDL-C NNP N
and CC N
reduces NNS N
LDL-C NNP o
when WRB N
administered VBN N
alone RB N
or CC N
with IN N
a DT N
statin NN N
. . N

Adverse JJ N
effects NNS N
on IN N
blood NN N
pressure NN N
, , N
electrolytes VBZ N
, , N
and CC N
aldosterone NN N
levels NNS N
, , N
seen VBN N
with IN N
another DT N
drug NN N
in IN N
this DT N
class NN N
, , N
have VBP N
not RB N
been VBN N
noted VBN N
in IN N
studies NNS N
of IN N
anacetrapib NN i
to TO N
date NN N
. . N

METHODS NNP N
Determining VBG N
the DT N
EFficacy NNP N
and CC N
Tolerability NNP N
of IN N
CETP NNP N
INhibition NNP N
with IN N
AnacEtrapib NNP i
( ( N
DEFINE NNP N
) ) N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
profile NN o
of IN N
anacetrapib NN i
in IN N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
or CC p
CHD NNP p
risk NN p
equivalents NNS p
( ( p
clinical JJ p
trials.gov NN p
NCT00685776 NNP p
) ) p
. . p

Eligible JJ p
patients NNS p
at IN p
National NNP p
Cholesterol NNP p
Education NNP p
Program-Adult NNP p
Treatment NNP p
Panel NNP p
III NNP p
LDL-C NNP o
treatment NN p
goal NN p
on IN p
a DT p
statin NN p
, , p
with IN p
or CC p
without IN p
other JJ p
lipid-modifying JJ p
medications NNS p
, , N
are VBP N
treated VBN N
with IN N
anacetrapib NN i
, , N
100 CD N
mg NN N
, , N
or CC N
placebo NN i
for IN N
18 CD N
months NNS N
, , N
followed VBN N
by IN N
a DT N
3-month JJ N
, , N
poststudy JJ N
follow-up NN N
. . N

The DT N
primary JJ N
end NN N
points NNS N
are VBP N
percent JJ o
change NN o
from IN o
baseline NN o
in IN o
LDL-C NNP o
and CC o
the DT o
safety NN o
and CC o
tolerability NN o
of IN o
anacetrapib NN o
. . o

Comprehensive NNP N
preplanned VBD N
interim JJ N
safety NN N
analyses NNS N
will MD N
be VB N
performed VBN N
at IN N
the DT N
6- JJ N
and CC N
12-month JJ N
time NN N
points NNS N
to TO N
examine VB N
treatment NN N
effects NNS N
on IN N
key JJ N
safety NN N
end NN N
points NNS N
, , N
including VBG N
blood NN o
pressure NN o
and CC o
electrolytes NNS o
. . o

A DT N
preplanned JJ N
Bayesian JJ N
analysis NN N
will MD N
be VB N
performed VBN N
to TO N
interpret VB N
the DT N
CV NNP N
event NN N
distribution NN N
, , N
given VBN N
the DT N
limited JJ N
number NN N
of IN N
events NNS N
expected VBN N
in IN N
this DT N
study NN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
2,757 CD p
patients NNS p
were VBD p
screened VBN p
at IN p
153 CD p
centers NNS p
in IN p
20 CD p
countries NNS p
, , p
and CC p
1,623 CD p
patients NNS p
were VBD p
randomized VBN p
into IN N
the DT N
trial NN N
. . N

Lipid JJ o
results NNS o
, , o
clinical JJ o
CV NNP o
events NNS o
, , o
and CC o
safety NN o
outcomes RB o
from IN N
this DT N
trial NN N
are VBP N
anticipated VBN N
in IN N
2010 CD N
. . N

-DOCSTART- -12135593- O O

Limited JJ N
effects NNS N
of IN N
micronutrient JJ i
supplementation NN i
on IN N
strength NN o
and CC o
physical JJ o
function NN o
after IN N
abdominal JJ o
aortic JJ p
aneurysmectomy NN p
. . p

BACKGROUND NNP N
Tissue NNP N
injury NN N
following VBG N
ischemia-reperfusion NN N
is VBZ N
mediated VBN N
in IN N
part NN N
by IN N
free JJ N
oxygen NN N
radicals NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
perioperative JJ N
micronutrient NN i
supplementation NN i
would MD N
augment VB o
antioxidant JJ o
defenses NNS o
, , o
minimize VB o
muscle NN o
injury NN o
, , o
and CC o
minimize VB o
postoperative JJ o
decreases NNS o
in IN o
muscle NN o
strength NN o
and CC o
physical JJ o
function NN o
following VBG N
abdominal JJ N
aortic JJ N
aneurysmectomy NN N
. . N

SETTING VB N
A DT N
university-affiliated JJ p
hospital NN p
and CC p
regional JJ p
referral JJ p
center NN p
. . p

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
supplementation NN i
with IN i
beta-carotene NN i
, , i
vitamins VBZ i
C NNP i
and CC i
E NNP i
, , i
zinc NN i
, , i
and CC i
selenium NN i
for IN N
a DT N
period NN N
of IN N
2-3 JJ N
weeks NNS N
prior RB N
to TO N
surgery NN N
and CC N
1 CD N
week NN N
thereafter RB N
. . N

STUDY NNP N
POPULATION NNP N
Patients NNP p
undergoing VBG p
elective JJ p
abdominal JJ i
aortic JJ i
aneurysmectomy NN i
( ( p
n=18 JJ p
per IN p
group NN p
) ) p
. . p

PRINCIPAL JJ N
MEASUREMENTS NNP N
Handgrip NNP o
and CC o
other JJ o
measures NNS o
of IN o
strength NN o
and CC o
physical JJ o
function NN o
. . o

RESULTS NNP N
Handgrip NNP o
and CC o
quadriceps JJ o
strength NN o
decreased VBD N
following VBG N
surgery NN N
, , N
but CC N
not RB N
to TO N
a DT N
significantly RB N
different JJ N
extent NN N
in IN N
the DT N
placebo NN N
and CC N
supplemented VBD N
groups NNS N
. . N

Self-rated JJ o
physical JJ o
function NN o
decreased VBD N
following VBG N
surgery NN i
in IN N
the DT N
placebo NN N
group NN N
and CC N
was VBD N
preserved VBN N
in IN N
the DT N
supplemented JJ N
group NN N
. . N

CONCLUSIONS NNP N
Perioperative NNP i
supplementation NN i
with IN i
micronutrients NNS i
with IN N
antioxidant JJ N
properties NNS N
has VBZ N
limited VBN N
effects NNS N
on IN N
strength NN o
and CC o
physical JJ o
function NN o
following VBG N
major JJ N
elective JJ N
surgery NN N
. . N

-DOCSTART- -4772206- O O

The DT N
gastric JJ o
emptying NN o
and CC o
small JJ o
intestinal JJ o
transit NN o
after IN N
highly RB p
selective JJ p
vagotomy NN p
without IN p
drainage NN p
and CC p
selective JJ p
vagotomy NN p
with IN p
pyloroplasty NN p
. . p

-DOCSTART- -26442399- O O

DESFLURANE NNP N
COMPARED NNP N
TO NNP N
SEVOFLURANE NNP N
FOR NNP N
CIRRHOTIC NNP p
PATIENTS NNP p
UNDERGOING NNP p
MAJOR NNP p
LIVER NNP p
RESECTION NNP p
. . p

A NNP N
RANDOMIZED NNP N
CONTROL NNP N
STUDY NNP N
. . N

BACKGROUND NNP N
Major NNP N
liver NN N
resection NN N
is VBZ N
associated VBN N
with IN N
haemodynamic JJ N
, , N
hepatic JJ N
and CC N
renal JJ N
changes NNS N
as IN N
a DT N
result NN N
of IN N
the DT N
procedure NN N
. . N

AIM NNP N
To TO N
compare VB N
Desflurane NNP i
( ( i
D NNP i
) ) i
versus NN i
Sevoflurane NNP i
( ( i
S NNP i
) ) i
on IN N
hepatic JJ o
, , o
renal JJ o
functions NNS o
, , o
haemodynamics NNS o
and CC o
perioperative JJ o
course NN o
for IN N
cirrhotic JJ p
patients NNS p
undergoing VBG p
major JJ p
liver NN p
resection NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
control NN N
study NN N
with IN N
50 CD p
patients NNS p
( ( p
Child NNP p
A NNP p
) ) p
( ( N
D NNP N
, , N
n JJ N
= NN N
25 CD N
and CC N
S NNP N
, , N
n JJ N
= NNP N
25 CD N
) ) N
. . N

End NN o
tidal JJ o
D NNP o
or CC o
S NNP o
adjusted VBN o
with IN o
Entropy NNP o
( ( N
40-60 JJ N
) ) N
. . N

Haemodynamics NNS o
monitored VBD o
with IN o
invasive JJ o
blood NN o
pressure NN o
and CC o
trans-oesophageal JJ o
Doppler NNP o
( ( o
TED NNP o
) ) o
. . o

Liver NNP o
and CC o
kidney VB o
function NN o
tests NNS o
, , o
blood NN o
Glutathione-S-transferase NNP o
( ( o
GST NNP o
) ) o
, , o
urinary JJ o
microalbuminuria NN o
( ( o
Microalb NNP o
) ) o
were VBD o
assayed VBN o
. . o

Extubation NN o
time NN o
and CC o
anaesthetic JJ o
consumption NN o
were VBD o
recorded VBN o
. . o

RESULTS NNP N
Systemic NNP o
vascular JJ o
resistance NN o
( ( o
SVR NNP o
) ) o
post-resection NN o
and CC o
stroke NN o
volume NN o
of IN N
D NNP N
vs FW N
S NNP N
were VBD N
835.04 CD N
? . N
12.02 CD N
vs NN N
778.16 CD N
? . N
11.97 CD N
dyn.sec.cm NN N
( ( N
-5 NNP N
) ) N
, , N
P NNP N
< NNP N
0.01 CD N
, , N
and CC N
85.72 CD N
? . N
2.95 CD N
vs NN N
76.16 CD N
? . N
6.52 CD N
ml NN N
, , N
P NNP N
< VBZ N
0.01 CD N
respectively RB o
. . o

Doppler NNP o
corrected VBD o
flow JJ o
time NN o
( ( o
FTc NNP o
) ) o
between IN o
groups NNS N
were VBD N
comparable JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

No DT N
difference NN N
post-operatively RB N
regarding VBG o
hepatic JJ o
and CC o
renal JJ o
functions NNS o
, , o
and CC o
urine JJ o
Microalb NNP o
( ( o
14.76 CD o
? . N
3.95 CD N
vs NN N
l4.24 NN N
? . N
8.65 CD N
?g/ml NN N
, , N
P NNP N
= NNP N
0.78 CD N
) ) N
, , N
but CC N
a DT N
statistically RB N
difference NN N
was VBD N
found VBN N
with IN o
GST NNP o
( ( o
0.046 CD o
? . N
[ JJ N
symbols NNS N
: : N
see VB N
text JJ N
] NNP N
, , N
vs VBD N
0.043 CD N
? . N
[ JJ N
symbols NNS N
: : N
see VB N
text JJ N
] NNP N
IU/ml NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Despite IN N
a DT N
higher JJR N
D NNP o
consumption NN o
( ( o
73 CD o
? . o
17 CD o
vs NN N
64 CD N
? . N
22 CD N
ml NN N
, , N
P NNP N
= NNP N
0.102 CD N
) ) N
, , N
cost NN o
in IN o
Egyptian JJ o
pounds NNS o
( ( o
LE NNP o
) ) N
was VBD N
lower JJR N
with IN N
D NNP N
( ( N
141.14 CD N
? . N
32.90 CD N
vs NN N
320.60 CD N
? . N
114.01 CD N
, , N
LE NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . o

Extubation NN o
time NN o
and CC o
ICU NNP o
stay VBP o
with IN N
D NNP N
vS NN N
( ( N
4.52 CD N
? . N
2 CD N
vs NN N
7.72 CD N
? . N
2 CD N
min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
( ( N
1.40 CD N
0.50 CD N
vs NN N
1.64 CD N
? . N
0.48 CD N
, , N
days NNS N
P NNP N
= VBP N
0.09 CD N
) ) N
respectively RB N
. . N

CONCLUSION NNP N
Neither NNP N
D NNP N
nor CC N
S NNP N
were VBD N
clinically RB N
superior JJ N
to TO N
the DT N
other JJ N
with IN N
respect NN N
to TO N
liver VB o
and CC o
kidneys VB o
functions NNS o
, , o
but CC o
D NNP N
was VBD N
found VBN N
to TO N
preserve VB N
better JJR N
the DT o
haemodynamic JJ o
parameters NNS o
and CC o
enhance VB o
recovery NN o
at IN o
a DT o
lower JJR o
cost NN N
. . N

-DOCSTART- -10674681- O O

Efficacy NN N
of IN N
primaquine NN i
regimens NNS i
for IN N
primaquine-resistant JJ N
Plasmodium NNP N
vivax NN N
malaria NN N
in IN N
Thailand NNP p
. . p

To TO N
define VB N
the DT N
current JJ N
efficacy NN N
of IN N
Fansidar NNP i
( ( i
F. NNP i
Hoffmann-La NNP i
Roche NNP i
Ltd. NNP i
, , N
Basel NNP i
Switzerland NNP i
) ) i
( ( i
pyrimethamine NN i
and CC i
sulfadoxine NN i
) ) i
, , i
primaquine NN i
in IN N
a DT N
high JJ N
dose NN N
, , N
and CC N
artesunate NN i
for IN N
treating VBG N
acute JJ N
Plasmodium NNP N
vivax NN N
malaria NN N
, , N
we PRP N
conducted VBD N
a DT N
comparative JJ N
clinical JJ N
trial NN N
of IN N
these DT N
3 CD N
drugs NNS N
in IN N
an DT N
open-label JJ N
study NN N
. . N

Patients NNS p
( ( p
15-65 CD p
years NNS p
old JJ p
) ) p
were VBD p
assigned VBN p
to TO p
1 CD p
of IN p
4 CD p
treatments NNS p
regimens VBZ p
in IN p
a DT p
serial JJ p
order NN p
. . p

Ninety NNP p
percent NN p
of IN p
the DT p
patients NNS p
were VBD p
infected VBN p
at IN p
Thailand-Myanmar NNP p
border NN p
. . p

Patients NNS N
in IN N
group NN N
I PRP N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
received VBN N
Fansidar NNP i
( ( N
3 CD N
tablets NNS N
, , N
75 CD N
mg NN N
of IN N
pyrimethamine NN i
and CC i
1,500 CD i
mg NN i
of IN i
sulfadoxine NN i
, , N
a DT N
single JJ N
dose NN N
on IN N
the DT N
first JJ N
day NN N
) ) N
, , N
group NN N
II NNP N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
received VBN N
Fansidar NNP i
( ( i
3 CD i
tablets NNS i
, , i
75 CD i
mg NN i
of IN i
pyrimethamine NN i
and CC i
1,500 CD i
mg NN i
of IN i
sulfadoxine NN i
, , N
a DT N
single JJ N
dose NN N
on IN N
the DT N
first JJ N
day NN N
) ) N
and CC N
then RB N
received VBD N
primaquine NN i
( ( i
30 CD i
mg NN i
a DT i
day NN i
for IN i
14 CD i
days NNS i
) ) i
, , N
group NN N
III NNP N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
received VBN i
primaquine NN i
( ( i
30 CD i
mg NN i
a DT i
day NN i
for IN i
14 CD i
days NNS i
) ) i
, , N
and CC N
group NN N
IV NNP N
( ( N
n JJ N
= NNP N
23 CD N
) ) N
received VBN i
artesunate NN i
( ( N
200 CD N
mg NN N
once RB N
a DT N
day NN N
for IN N
3 CD N
days NNS N
) ) N
and CC N
then RB N
primaquine VB i
( ( N
30 CD N
mg NN N
a DT N
day NN N
for IN N
14 CD N
days NNS N
) ) N
. . N

Cure NN o
rates NNS o
on IN N
day NN N
28 CD N
of IN N
follow-up NN N
were VBD N
40 CD N
% NN N
, , N
100 CD N
% NN N
, , N
100 CD N
% NN N
, , N
and CC N
100 CD N
% NN N
in IN N
groups NNS N
I PRP N
, , N
II NNP N
, , N
II NNP N
, , N
and CC N
IV NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
4 CD N
and CC N
5 CD N
patients NNS N
in IN N
group NN N
I PRP N
showing VBG N
post-treatment JJ o
reappearance NN o
of IN o
parasitemia NN o
at IN N
< NNP N
or CC N
= VB N
16 CD N
days NNS N
and CC N
between IN N
17 CD N
and CC N
28 CD N
days NNS N
, , N
respectively RB N
. . N

Patients NNS N
in IN N
the DT N
other JJ N
3 CD N
groups NNS N
showed VBD N
negative JJ o
parasitemias NN o
within IN N
7 CD N
days NNS N
after IN N
treatment NN N
. . N

Artesunate NNP N
plus CC N
primaquine NN N
( ( N
group NN N
IV NNP N
) ) N
cleared VBD N
parasitemia NN o
faster RBR N
than IN N
the DT N
other JJ N
3 CD N
regimens NNS N
. . N

There EX N
is VBZ N
a DT N
high JJ N
proportion NN N
of IN N
ineffectiveness NN o
of IN N
Fansidar NNP N
for IN N
treatment NN N
of IN N
P. NNP N
vivax FW N
malaria NN N
and CC N
it PRP N
should MD N
be VB N
no RB N
longer RBR N
used VBN N
for IN N
treatment NN N
of IN N
P. NNP N
vivax FW N
malaria NN N
acquired VBD N
at IN N
the DT N
Thailand-Myanmar NNP N
border NN N
. . N

A DT N
high JJ N
dose NN N
of IN N
primaquine NN N
is VBZ N
safe JJ o
and CC o
effective JJ o
in IN N
the DT N
treatment NN N
of IN N
P. NNP N
vivax FW N
malaria NN N
during IN N
the DT N
28-day JJ N
follow-up JJ N
period NN N
. . N

-DOCSTART- -20201661- O O

Comparison NNP N
of IN N
neodymium-doped JJ i
yttrium NN i
aluminum NN i
garnet NN i
laser NN i
treatment NN i
with IN N
cold JJ i
knife NN i
endoscopic NN i
incision NN i
of IN N
urethral JJ N
strictures NNS N
in IN N
male JJ p
patients NNS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN o
of IN N
visual JJ i
laser NN i
ablation NN i
treatment NN i
with IN i
neodymium-doped JJ i
yttrium NN i
aluminum NN i
garnet NN i
( ( i
Nd NNP i
: : i
YAG NN i
) ) i
laser NN N
in IN p
male JJ p
patients NNS p
with IN p
urethral JJ p
strictures NNS p
and CC N
to TO N
compare VB N
the DT N
effects NNS N
with IN N
those DT N
obtained VBN N
in IN N
patients NNS N
treated VBN N
with IN N
Sachse NNP N
's POS N
optical JJ N
urethrotomy NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty NNP p
patients NNS p
aged VBD p
22 CD p
to TO p
83 CD p
( ( p
mean JJ p
age NN p
61.8 CD p
) ) p
with IN p
primary JJ p
( ( p
n JJ p
= NN p
26 CD p
, , p
52 CD p
% NN p
) ) p
and CC p
recurrent NN p
( ( p
n JJ p
= NN p
24 CD p
, , p
48 CD p
% NN p
) ) p
urethral JJ p
strictures VBZ p
0.3 CD p
to TO p
2.4 CD p
cm NNS p
long RB p
qualified VBD p
for IN p
the DT p
study NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
30 CD N
men NNS N
treated VBD N
using VBG N
visual JJ i
laser NN i
ablation NN i
of IN i
urethral JJ i
strictures NNS i
( ( i
VLASU NNP i
) ) i
with IN i
Nd NNP i
: : i
YAGlaser NN i
and CC N
20 CD N
men NNS N
treated VBN N
by IN N
correction NN i
of IN i
urethral JJ i
strictures NNS i
using VBG i
Sachse NNP i
's POS i
optical JJ i
urethrotomy NN i
. . i

RESULTS VB N
At IN N
12-month JJ N
follow-up NN N
, , N
seven CD N
( ( N
35 CD N
% NN N
) ) N
patients NNS N
who WP N
underwent JJ N
optical JJ i
urethrotomy NN i
and CC N
21 CD N
( ( N
70 CD N
% NN N
) ) N
in IN N
the DT N
VLASU NNP i
group NN N
did VBD N
not RB N
require VB N
repetition NN o
of IN o
the DT o
procedure NN o
. . o

The DT N
choice NN N
of IN N
VLASU NNP i
as IN N
a DT N
method NN N
of IN N
treatment NN N
significantly RB N
decreased VBD o
the DT o
probability NN o
of IN o
therapeutic JJ o
failure NN o
and CC o
recurrence NN o
of IN o
urethral JJ o
strictures NNS o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSION NNP N
VLASU NNP i
can MD N
be VB N
used VBN N
as IN N
a DT N
method NN N
of IN N
treatment NN N
of IN N
this DT N
disorder NN N
. . N

It PRP N
is VBZ N
an DT N
effective JJ N
, , N
modern JJ N
, , N
low-invasive JJ N
, , N
and CC N
repeatable JJ N
technique NN N
and CC N
is VBZ N
technically RB N
simple JJ N
and CC N
easy JJ N
to TO N
master NN N
. . N

It PRP N
can MD N
be VB N
used VBN N
in IN N
cases NNS N
in IN N
which WDT N
introduction NN N
of IN N
a DT N
22 CD N
Char NNP N
optical JJ N
urethrotome NN N
into IN N
the DT N
stricture NN N
site NN N
is VBZ N
impossible JJ N
, , N
as RB N
well RB N
as IN N
for IN N
treatment NN N
of IN N
multiple JJ N
strictures NNS N
during IN N
one CD N
procedure NN N
. . N

-DOCSTART- -17613280- O O

A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
clear JJ N
liquids NNS N
versus IN N
low-fat JJ N
solid JJ N
diet NN N
as IN N
the DT N
initial JJ N
meal NN N
in IN N
mild JJ p
acute JJ p
pancreatitis NN p
. . p

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS p
recovering VBG p
from IN p
mild JJ p
acute JJ p
pancreatitis NN p
typically RB N
receive VBP N
a DT N
clear JJ i
liquid NN i
diet NN i
( ( i
CLD NNP i
) ) i
when WRB N
ready JJ N
to TO N
initiate VB N
oral JJ N
nutrition NN N
. . N

Patient NNP N
discharge NN N
then RB N
depends VBZ N
on IN N
their PRP$ N
successful JJ N
advancement NN N
to TO N
solid VB N
food NN N
. . N

We PRP N
hypothesized VBD N
that IN N
initiating VBG N
oral JJ i
nutrition NN i
with IN i
a DT i
low-fat JJ i
solid JJ i
diet NN i
( ( i
LFSD NNP i
) ) i
after IN N
mild JJ N
pancreatitis NN N
would MD N
be VB N
well RB N
tolerated VBN N
and CC N
would MD N
result VB N
in IN N
a DT N
shorter JJR N
length NN o
of IN o
hospitalization NN o
( ( N
LOH NNP N
) ) N
. . N

METHODS JJ N
Patients NNS p
with IN p
mild JJ p
pancreatitis NNS p
were VBD N
randomized VBN N
to TO N
a DT N
CLD NNP i
or CC i
LFSD NNP i
when WRB N
they PRP N
were VBD N
ready JJ N
to TO N
resume VB N
oral JJ N
nutrition NN N
. . N

Decisions NNS N
about IN N
diet JJ N
advancement NN N
and CC N
hospital NN N
discharge NN N
were VBD N
at IN N
the DT N
discretion NN N
of IN N
the DT N
medical JJ N
team NN N
, , N
without IN N
input NN N
from IN N
study NN N
team NN N
members NNS N
. . N

Patients NNS N
were VBD N
monitored VBN N
daily RB N
for IN N
recurrence NN N
of IN N
pain NN o
, , o
need VBP o
to TO o
stop VB o
feeding NN o
, , o
post-refeeding JJ o
LOH NNP o
( ( N
primary JJ N
end NN N
point NN N
) ) N
, , N
and CC N
for IN N
28 CD N
days NNS N
post-refeeding JJ N
to TO N
capture VB N
re-admission NN o
rates NNS o
. . o

RESULTS NNP N
We PRP N
randomized VBD N
121 CD p
patients NNS p
: : p
66 CD p
to TO p
CLD NNP p
and CC p
55 CD p
to TO p
LFSD NNP p
. . p

The DT N
number NN o
of IN o
patients NNS o
requiring VBG o
cessation NN o
of IN o
feeding VBG o
because IN o
of IN o
pain NN o
or CC o
nausea NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
6 CD N
% NN N
for IN N
CLD NNP N
, , N
11 CD N
% NN N
for IN N
LFSD NNP N
; : N
P NNP N
= NNP N
.51 NNP N
) ) N
. . N

The DT N
median JJ o
LOH NNP o
after IN o
refeeding VBG o
was VBD N
identical JJ N
in IN N
both DT N
groups NNS N
( ( N
1-day JJ N
interquartile NN N
range NN N
, , N
1-2 JJ N
; : N
P NNP N
= NNP N
.77 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
LFSD NNP N
arm NN N
consumed VBD N
significantly RB N
more JJR N
calories NNS o
and CC o
grams NNS o
of IN o
fat NN o
than IN N
those DT N
in IN N
the DT N
CLD NNP N
arm NN N
during IN N
their PRP$ N
first JJ N
meal NN N
and CC N
on IN N
study NN N
day NN N
1 CD N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
28-day JJ o
re-admission NN o
rates NNS o
between IN N
the DT N
2 CD N
arms NNS N
. . N

CONCLUSIONS NNP N
Initiating NNP N
oral JJ N
nutrition NN N
after IN N
mild JJ o
acute JJ o
pancreatitis NN o
with IN N
an DT N
LFSD NNP o
appeared VBD N
safe JJ N
and CC N
provided VBD N
more JJR N
calories NNS N
than IN N
a DT N
CLD NNP N
, , N
but CC N
did VBD N
not RB N
result VB N
in IN N
a DT N
shorter NN N
LOH NNP o
. . o

-DOCSTART- -15474171- O O

Time NN N
intervals NNS N
production NN N
in IN N
tapping VBG p
and CC N
oscillatory JJ p
motion NN p
. . p

We PRP N
applied VBD N
spectral JJ i
analysis NN i
on IN N
series NN N
of IN N
time NN N
intervals NNS N
produced VBN N
in IN N
a DT N
synchronization-continuation JJ N
experiment NN N
. . N

In IN N
the DT N
first JJ N
condition NN N
intervals NNS N
were VBD N
produced VBN N
by IN N
finger NN p
tapping NN p
, , N
and CC N
in IN N
the DT N
second JJ N
by IN N
an DT N
oscillatory JJ p
motion NN p
of IN p
the DT p
hand NN p
. . p

Results NNS N
obtained VBD N
in IN N
tapping VBG p
were VBD N
consistent JJ N
with IN N
a DT N
discrete JJ N
, , N
event-based JJ N
timing NN N
model NN N
. . N

In IN N
the DT N
oscillatory JJ p
condition NN p
, , N
the DT N
spectra NN N
suggested VBD N
a DT N
continuous JJ N
, , N
dynamic JJ N
timing NN N
mechanism NN N
, , N
based VBN N
on IN N
the DT N
regulation NN N
of IN N
effector NN N
stiffness NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
oscillatory JJ p
character NN p
of IN N
movement NN N
can MD N
offer VB N
an DT N
important JJ N
resource NN N
for IN N
timing VBG N
control NN N
. . N

The DT N
use NN N
of IN N
an DT N
event-based JJ N
timing NN N
control NN N
such JJ N
as IN N
postulated VBN N
in IN N
the DT N
Wing-Kristoffersson NNP N
model NN N
could MD N
be VB N
restricted VBN N
to TO N
a DT N
quite RB N
limited JJ N
class NN N
of IN N
rhythmic JJ N
tasks NNS N
, , N
characterized VBN N
by IN N
the DT N
concatenation NN N
of IN N
discrete JJ N
events NNS N
. . N

-DOCSTART- -10624759- O O

Prediction NN N
of IN N
metabolic JJ N
and CC N
cardiopulmonary JJ N
responses NNS N
to TO N
maximum JJ i
cycle NN i
ergometry NN i
: : i
a DT N
randomised JJ N
study NN N
. . N

All DT N
of IN N
the DT N
most RBS N
widely-cited JJ N
studies NNS N
for IN N
the DT N
prediction NN N
of IN N
maximum JJ o
exercise NN o
responses NNS o
have VBP N
utilized VBN N
either CC p
volunteers NNS p
or CC p
referred JJ p
subjects NNS p
. . p

Therefore RB N
, , N
selection NN N
bias NN N
, , N
with IN N
overestimation NN N
of IN N
the DT N
reference NN N
values NNS N
, , N
is VBZ N
a DT N
likely JJ N
consequence NN N
. . N

In IN N
order NN N
to TO N
establish VB N
a DT N
set NN N
of IN N
predictive JJ N
equations NNS N
for IN N
the DT N
gas NN o
exchange NN o
, , o
ventilatory NN o
and CC o
cardiovascular JJ o
responses NNS o
to TO N
maximum VB i
ramp-incremental JJ i
cycle NN i
ergometry NN i
, , N
this DT p
study NN p
prospectively RB p
evaluated VBD p
120 CD p
sedentary JJ p
individuals NNS p
( ( p
60 CD p
males NNS p
, , p
60 CD p
females NNS p
, , p
aged VBD p
20-80 CD p
) ) p
, , p
randomly-selected JJ p
from IN p
> JJ p
8,000 CD p
subjects NNS p
. . p

Regular JJ N
physical JJ o
activity NN o
pattern NN o
by IN o
questionnaire NN o
, , o
body NN o
composition NN o
by IN o
anthropometry NN o
and CC o
dual JJ o
energy NN o
X-ray JJ o
absorptiometry NN o
( ( o
n JJ o
= NNP o
75 CD o
) ) o
and CC o
knee JJ o
strength NN o
by IN o
isokinetic JJ o
dynamometry NN o
were VBD N
also RB N
assessed VBN N
. . N

Previously RB N
reported VBD N
equations NNS N
typically RB N
overestimated VBD N
the DT N
subjects NNS N
' POS N
peak NN o
oxygen NN o
uptake NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Prediction NN N
linear JJ N
equations NNS N
for IN N
the DT N
main JJ N
variables NNS N
of IN N
clinical JJ N
interest NN N
were VBD N
established VBN N
by IN N
backward NN N
stepwise NN N
regression NN N
analysis NN N
including VBG N
: : N
sex NN N
, , N
age NN N
, , N
knee NN N
extensor NN N
peak NN N
torque NN N
, , N
bone-free JJ N
lean JJ N
leg NN N
mass NN N
, , N
total JJ N
and CC N
lean JJ N
body NN N
mass NN N
, , N
height NN N
, , N
and CC N
physical JJ N
activity NN N
scores NNS N
. . N

Reference NN o
intervals NNS o
( ( N
95 CD N
% NN N
confidence NN N
limits NNS N
) ) N
were VBD N
calculated VBN N
: : N
some DT N
of IN N
these DT N
values NNS N
differed VBD N
markedly RB N
from IN N
those DT N
formerly RB N
recommended VBN N
. . N

The DT N
results NNS N
therefore RB N
might MD N
provide VB N
a DT N
more RBR N
appropriate JJ N
frame NN N
of IN N
reference NN N
for IN N
interpretation NN N
of IN N
the DT N
responses NNS o
to TO o
symptom-limited JJ o
ramp JJ o
incremental JJ o
cycle NN o
ergometry NN o
in IN N
sedentary JJ p
subjects NNS p
; : p
i.e NN N
. . N

those DT N
usually RB N
referred VBN N
for IN N
clinical JJ N
cardiopulmonary JJ N
exercise NN N
tests NNS N
. . N

-DOCSTART- -25474530- O O

Mediation NN N
analysis NN N
demonstrates VBZ N
that IN N
trans-eQTLs NN o
are VBP N
often RB N
explained VBN N
by IN N
cis-mediation NN N
: : N
a DT N
genome-wide JJ N
analysis NN N
among IN N
1,800 CD p
South NNP p
Asians NNPS p
. . p

A DT N
large JJ N
fraction NN N
of IN N
human JJ N
genes NNS N
are VBP N
regulated VBN N
by IN N
genetic JJ N
variation NN N
near IN N
the DT N
transcribed JJ N
sequence NN N
( ( N
cis-eQTL JJ N
, , N
expression JJ N
quantitative JJ N
trait NN N
locus NN N
) ) N
, , N
and CC N
many JJ N
cis-eQTLs NNS N
have VBP N
implications NNS N
for IN N
human JJ N
disease NN N
. . N

Less NNP N
is VBZ N
known VBN N
regarding VBG N
the DT N
effects NNS N
of IN N
genetic JJ N
variation NN N
on IN N
expression NN o
of IN o
distant JJ o
genes NNS o
( ( o
trans-eQTLs NN o
) ) o
and CC N
their PRP$ N
biological JJ N
mechanisms NNS N
. . N

In IN N
this DT N
work NN N
, , N
we PRP N
use VBP N
genome-wide JJ i
data NNS i
on IN i
SNPs NNP i
and CC N
array-based JJ i
expression NN i
measures NNS i
from IN N
mononuclear JJ N
cells NNS N
obtained VBN N
from IN N
a DT N
population-based JJ N
cohort NN N
of IN N
1,799 CD p
Bangladeshi NNP p
individuals NNS p
to TO N
characterize VB N
cis- JJ o
and CC o
trans-eQTLs JJ o
and CC N
determine VB N
if IN N
observed VBN N
trans-eQTL JJ o
associations NNS o
are VBP N
mediated VBN N
by IN N
expression NN N
of IN N
transcripts NNS N
in IN N
cis NN N
with IN N
the DT N
SNPs NNP N
showing VBG N
trans-association NN N
, , N
using VBG N
Sobel NNP o
tests NNS o
of IN o
mediation NN o
. . o

We PRP N
observed VBD N
434 CD p
independent JJ p
trans-eQTL JJ o
associations NNS o
at IN N
a DT N
false-discovery JJ N
rate NN N
of IN N
0.05 CD N
, , N
and CC N
189 CD N
of IN N
these DT N
trans-eQTLs NNS o
were VBD N
also RB N
cis-eQTLs JJ N
( ( N
enrichment JJ N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Among IN N
these DT N
189 CD p
trans-eQTL NN o
associations NNS o
, , p
39 CD p
were VBD p
significantly RB p
attenuated VBN p
after IN N
adjusting VBG N
for IN N
a DT N
cis-mediator NN N
based VBN N
on IN N
Sobel NNP N
P NNP N
< NNP N
10-5 JJ N
. . N

We PRP N
attempted VBD N
to TO N
replicate VB N
21 CD N
of IN N
these DT N
mediation NN N
signals NNS N
in IN N
two CD N
European JJ N
cohorts NNS N
, , N
and CC N
while IN N
only RB N
7 CD N
trans-eQTL JJ o
associations NNS o
were VBD N
present JJ N
in IN N
one CD N
or CC N
both DT N
cohorts NNS N
, , N
6 CD N
showed VBD N
evidence NN N
of IN N
cis-mediation NN N
. . N

Analyses NNS N
of IN N
simulated JJ N
data NNS N
show VBP N
that IN N
complete JJ N
mediation NN N
will MD N
be VB N
observed VBN N
as IN N
partial JJ N
mediation NN N
in IN N
the DT N
presence NN N
of IN N
mediator NN N
measurement NN N
error NN N
or CC N
imperfect JJ N
LD NNP N
between IN N
measured VBN N
and CC N
causal JJ N
variants NNS N
. . N

Our PRP$ N
data NNS N
demonstrates VBZ N
that IN N
trans-associations NNS N
can MD N
become VB N
significantly RB N
stronger JJR N
or CC N
switch VB N
directions NNS N
after IN N
adjusting VBG N
for IN N
a DT N
potential JJ N
mediator NN N
. . N

Using VBG N
simulated JJ N
data NNS N
, , N
we PRP N
demonstrate VBP N
that IN N
this DT N
phenomenon NN N
is VBZ N
expected VBN N
in IN N
the DT N
presence NN N
of IN N
strong JJ N
cis-trans NNS N
confounding NN N
and CC N
when WRB N
the DT N
measured VBN N
cis-transcript NN N
is VBZ N
correlated VBN N
with IN N
the DT N
true JJ N
( ( N
unmeasured JJ N
) ) N
mediator NN N
. . N

In IN N
conclusion NN N
, , N
by IN N
applying VBG N
mediation NN N
analysis NN N
to TO N
eQTL VB N
data NNS N
, , N
we PRP N
show VBP N
that IN N
a DT N
substantial JJ N
fraction NN N
of IN N
observed JJ N
trans-eQTL JJ o
associations NNS o
can MD N
be VB N
explained VBN N
by IN N
cis-mediation NN N
. . N

Future JJ N
studies NNS N
should MD N
focus VB N
on IN N
understanding VBG N
the DT N
mechanisms JJ N
underlying JJ N
widespread JJ N
cis-mediation NN N
and CC N
their PRP$ N
relevance NN N
to TO N
disease VB N
biology NN N
, , N
as RB N
well RB N
as IN N
using VBG N
mediation NN N
analysis NN N
to TO N
improve VB N
eQTL NN N
discovery NN N
. . N

-DOCSTART- -20152225- O O

Biventricular JJ N
pacing VBG N
improves NNS N
cardiac JJ o
function NN o
and CC N
prevents NNS N
further RBR N
left VBD o
atrial JJ o
remodeling NN o
in IN N
patients NNS p
with IN p
symptomatic JJ p
atrial JJ p
fibrillation NN p
after IN p
atrioventricular JJ p
node JJ p
ablation NN p
. . p

BACKGROUND NNP N
Randomized NNP N
trials NNS N
have VBP N
demonstrated VBN N
benefits NNS N
of IN N
biventricular NN i
( ( i
BiV NNP i
) ) i
pacing NN i
in IN N
patients NNS p
with IN p
advanced JJ p
heart NN p
failure NN p
, , p
intraventricular JJ p
conduction NN p
delay NN p
, , p
and CC p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
post-atrioventricular NN p
( ( p
AV NNP p
) ) p
node NN p
ablation NN p
. . p

The DT N
AV NNP N
Node NNP N
Ablation NNP N
with IN N
CLS NNP N
and CC N
CRT NNP N
Pacing NNP N
Therapies NNP N
for IN N
Treatment NNP N
of IN N
AF NNP N
trial NN N
( ( N
AVAIL NNP N
CLS/CRT NNP N
) ) N
was VBD N
designed VBN N
to TO N
demonstrate VB N
superiority NN N
of IN N
BiV NNP N
pacing VBG N
in IN N
patients NNS N
with IN N
AF NNP N
after IN N
AV NNP N
node JJ N
ablation NN N
, , N
to TO N
evaluate VB N
its PRP$ N
effects NNS N
on IN N
cardiac JJ N
structure NN N
and CC N
function NN N
, , N
and CC N
to TO N
investigate VB N
additional JJ N
benefits NNS N
of IN N
Closed JJ N
Loop NNP N
Stimulation NNP N
( ( N
CLS NNP N
) ) N
( ( N
BIOTRONIK NNP N
, , N
Berlin NNP N
, , N
Germany NNP N
) ) N
. . N

METHODS JJ N
Patients NNS p
with IN p
refractory JJ p
AF NNP p
underwent NN p
AV NNP p
node CC p
ablation NN p
and CC N
were VBD N
randomized VBN N
( ( N
2:2:1 CD N
) ) N
to TO N
BiV NNP i
pacing VBG i
with IN i
CLS NNP i
, , i
BiV NNP i
pacing VBG i
with IN i
accelerometer NN i
, , i
or CC i
right JJ i
ventricular NN i
( ( i
RV NNP i
) ) i
pacing NN i
. . i

Echocardiography NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
, , N
with IN N
paired VBN N
data NNS N
available JJ N
for IN N
108 CD p
patients NNS p
. . p

RESULTS VB N
The DT N
RV NNP N
pacing NN N
contributed VBD N
to TO N
significant JJ N
increase NN N
in IN N
left JJ o
atrial JJ o
volume NN o
, , o
left VBD o
ventricular JJ o
( ( o
LV NNP o
) ) o
end-systolic JJ o
volume NN o
, , o
and CC o
LV NNP o
mass NN o
compared VBN N
to TO N
BiV NNP N
pacing NN N
. . N

Ejection NNP o
fraction NN o
decreased VBD N
insignificantly RB N
with IN N
RV NNP N
pacing VBG N
compared VBN N
to TO N
significant JJ N
increase NN N
with IN N
BiV NNP N
pacing VBG N
. . N

Interventricular JJ o
dyssynchrony NN o
significantly RB N
decreased VBN N
with IN N
BiV NNP N
compared VBN N
with IN N
RV NNP N
pacing VBG N
. . N

Closed VBN N
Loop NNP N
Stimulation NNP N
did VBD N
not RB N
result VB N
in IN N
additional JJ N
echocardiographic JJ o
changes NNS o
; : o
heart NN o
rate NN o
distribution NN o
was VBD N
significantly RB N
wider JJR N
with IN N
CLS NNP N
. . N

All DT N
groups NNS N
showed VBD N
significant JJ N
improvement NN N
in IN N
6-minute JJ o
walk NN o
distance NN o
, , o
quality-of-life JJ o
score NN o
, , o
and CC o
New NNP o
York NNP o
Heart NNP o
Association NNP o
class NN o
. . o

CONCLUSION NNP N
In IN N
conclusion NN N
, , N
RV NNP N
pacing VBG N
results NNS N
in IN N
significant JJ N
increase NN N
in IN N
left JJ o
atrial JJ o
volume NN o
, , o
LV NNP o
mass NN o
, , N
and CC N
worsening NN o
of IN o
LV NNP o
contractility NN o
compared VBN N
to TO N
patients NNS N
receiving VBG N
BiV NNP N
pacing VBG N
post-AV JJ N
node JJ N
ablation NN N
for IN N
refractory NN N
AF NNP N
. . N

Closed VBD N
Loop NNP N
Stimulation NNP N
was VBD N
not RB N
associated VBN N
with IN N
additional JJ N
structural JJ o
changes NNS o
but CC N
resulted VBD N
in IN N
significantly RB N
wider JJR o
heart NN o
rate NN o
distribution NN o
. . o

-DOCSTART- -8053586- O O

Deliberate NNP N
mild RBS i
intraoperative JJ i
hypothermia NN i
for IN N
craniotomy NN p
. . p

BACKGROUND NNP N
Despite IN N
enthusiasm NN N
for IN N
the DT N
use NN N
of IN N
mild JJ i
hypothermia NN i
during IN N
neurosurgical JJ N
procedures NNS N
, , N
this DT N
therapy NN N
has VBZ N
not RB N
been VBN N
evaluated VBN N
systematically RB N
. . N

This DT N
study NN N
examined VBD N
the DT N
feasibility NN N
and CC N
safety NN N
of IN N
deliberate JJ N
mild JJ N
hypothermia NN N
and CC N
rewarming NN N
. . N

METHODS NNP N
Thirty NNP p
patients NNS p
scheduled VBN p
for IN p
craniotomy NN p
were VBD p
assigned VBN p
to TO p
either VB p
a DT p
normothermic JJ i
or CC i
mildly RB i
hypothermic JJ i
group NN p
. . p

Tympanic NNP N
membrane NN N
temperature NN N
was VBD N
monitored VBN N
at IN N
anesthetic JJ N
induction NN N
, , N
throughout IN N
the DT N
isoflurane-fentanyl-N2O-O2 JJ i
anesthetic JJ i
, , N
and CC N
for IN N
18 CD N
h NN N
postoperatively RB N
. . N

Normothermic JJ N
patients NNS N
were VBD N
warmed VBN N
to TO N
36.5-37.0 JJ N
degrees NNS N
C NNP N
after IN N
an DT N
initial JJ N
temperature NN N
decrease NN N
, , N
and CC N
hypothermic JJ N
patients NNS N
were VBD N
cooled VBN N
to TO N
35 CD N
degrees NNS N
C. NNP N
In IN N
the DT N
hypothermic JJ N
group NN N
temperatures NNS N
were VBD N
allowed VBN N
to TO N
drift VB N
to TO N
34.5 CD N
degrees NNS N
C NNP N
before IN N
rewarming VBG N
was VBD N
initiated VBN N
. . N

Water NNP N
blankets NNS N
and CC N
convective JJ N
heating NN N
devices NNS N
were VBD N
used VBN N
to TO N
cool VB N
and CC N
rewarm VB N
. . N

RESULTS VB N
The DT N
minimum JJ o
temperature NN o
achieved VBN N
by IN N
the DT N
hypothermic JJ N
group NN N
was VBD N
34.3 CD N
+/- JJ N
0.4 CD N
degrees NNS N
C. NNP N
Cooling NNP o
occurred VBD N
at IN N
a DT N
rate NN N
of IN N
1.0 CD N
+/- JJ N
0.4 CD N
degrees NNS N
C/h NNP N
. . N

Rewarming VBG o
took VBD N
place NN N
at IN N
a DT N
rate NN N
of IN N
0.7 CD N
+/- JJ N
0.6 CD N
degrees NNS N
C/h NNP N
( ( N
range VB N
0.1-1.8 NN N
) ) N
in IN N
the DT N
hypothermic JJ N
group NN N
. . N

Hypothermia NNP o
did VBD N
not RB N
delay VB N
emergence NN N
from IN N
anesthesia NN o
( ( N
20 CD N
+/- JJ N
15 CD N
min NN N
) ) N
compared VBN N
with IN N
normothermia NN N
( ( N
15 CD N
+/- JJ N
15 CD N
min NN N
, , N
P NNP N
= NNP N
.45 NNP N
) ) N
. . N

Mean JJ o
temperature NN o
upon IN o
intensive JJ o
care NN o
unit NN o
admission NN o
was VBD N
35.8 CD N
+/- JJ N
1.0 CD N
degrees NNS N
C NNP N
for IN N
the DT N
hypothermic JJ N
group NN N
and CC N
37.1 CD N
+/- JJ N
0.5 CD N
degrees NNS N
C NNP N
for IN N
the DT N
normothermic JJ N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
hypothermic JJ N
patients NNS N
had VBD N
more RBR N
postoperative JJ o
shivering NN o
. . o

From IN N
8 CD N
to TO N
18 CD N
h NN N
postoperatively RB N
the DT N
temperatures NNS o
of IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
except IN N
for IN N
a DT N
slightly RB N
greater JJR N
temperature NN o
in IN N
the DT N
hypothermic JJ N
patients NNS N
at IN N
12 CD N
h NN N
( ( N
37.6 CD N
+/- JJ N
0.5 CD N
vs. FW N
37.3 CD N
+/- JJ N
0.4 CD N
degrees NNS N
C NNP N
, , N
P NNP N
= NNP N
.029 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
deliberate NN N
mild JJ N
hypothermia NN N
is VBZ N
easily RB N
achieved VBN N
intraoperatively RB N
, , N
complete JJ N
rewarming NN N
may MD N
be VB N
difficult JJ N
to TO N
attain VB N
during IN N
craniotomy NN p
with IN N
current JJ N
methods NNS N
. . N

In IN N
addition NN N
to TO N
the DT N
need NN N
for IN N
determining VBG N
whether IN N
deliberate NN N
mild NNS N
hypothermia VBP N
confers NNS N
cerebral JJ N
protection NN N
in IN N
humans NNS N
, , N
the DT N
potential JJ N
risks NNS N
of IN N
the DT N
therapy NN N
need NN N
to TO N
be VB N
further JJ N
characterized VBN N
. . N

-DOCSTART- -2947151- O O

[ RB N
Therapeutic NNP N
value NN N
of IN N
a DT N
combination NN N
of IN N
trimetazidine NN i
with IN N
a DT N
calcium NN N
inhibitor NN N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ p
coronary JJ p
insufficiency NN p
] NNP p
. . N

This DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
sought VBD N
to TO N
examine VB N
the DT N
short-term JJ N
benefit NN N
of IN N
adding VBG N
60 CD N
mg NN N
of IN N
trimetazidine NN i
to TO N
the DT N
daily JJ N
therapeutic JJ N
regimen NNS N
of IN N
29 CD p
male JJ p
patients NNS p
with IN p
coronary JJ p
insufficiency NN p
who WP p
had VBD p
persistent JJ p
ST NNP p
depression NN p
on IN p
exercise NN p
tolerance NN p
test NN p
( ( p
greater JJR p
than IN p
or CC p
equal JJ p
to TO p
1 CD p
mm NN p
) ) p
, , p
despite IN p
treatment NN p
with IN p
nifedipine JJ i
40 CD p
mg JJ p
per IN p
day NN p
. . p

As IN o
compared VBN o
with IN o
the DT o
placebo NN o
group NN o
, , o
after IN o
only RB o
14 CD o
days NNS o
, , o
the DT o
patients NNS o
treated VBN o
with IN o
trimetazidine NN o
showed VBN o
statistically RB o
significant JJ o
increases NNS o
in IN o
the DT o
maximum JJ o
workload NN o
level NN o
attained VBD o
before IN o
ST NNP o
depression NN o
occurred VBD o
( ( o
31 CD o
% NN o
versus NN o
- : o
6 CD o
% NN o
; : o
P NNP o
= NNP o
0.009 CD o
) ) o
, , o
the DT o
total JJ o
work NN o
performed VBD o
( ( o
31 CD o
% NN o
versus IN o
2 CD o
% NN o
; : o
P NNP o
= NNP o
0.024 CD o
) ) o
and CC o
a DT o
significant JJ o
decrease NN o
in IN o
the DT o
systolic JJ o
tension NN o
time NN o
( ( o
double JJ o
product NN o
) ) o
/workload NN o
ratio NN o
( ( o
-5 CD o
% NN o
versus IN o
+11 CD o
% NN o
; : o
P NNP o
= NNP o
0.005 CD o
) ) o
. . o

Throughout IN N
the DT N
study NN N
the DT N
clinical JJ N
acceptability NN N
was VBD N
excellent JJ N
, , N
with IN N
no DT N
side NN N
effects NNS N
attributable JJ N
to TO N
trimetazidine VB N
being VBG N
recorded VBN N
. . N

This DT N
study NN N
shows VBZ N
that IN N
the DT N
addition NN N
of IN N
trimetazidine NN N
to TO N
a DT N
calcium NN N
antagonist NN N
brings VBZ N
a DT N
valuable JJ N
improvement NN N
in IN N
therapeutic JJ N
results NNS N
. . N

-DOCSTART- -8376441- O O

A DT N
prospective JJ N
randomised JJ N
comparison NN N
of IN N
the DT N
dynamic JJ i
hip NN i
screw NN i
and CC p
the DT p
gamma NN i
locking VBG i
nail NN i
. . i

We PRP N
made VBD N
a DT N
randomised JJ N
prospective JJ N
comparison NN N
of IN N
the DT N
Dynamic NNP i
Hip NNP i
Screw NNP i
and CC i
the DT i
Gamma NNP i
locking VBG i
nail NN i
for IN N
the DT N
internal JJ N
fixation NN N
of IN N
200 CD p
petrochanteric JJ p
femoral JJ p
fractures NNS p
in IN p
elderly JJ p
patients NNS p
. . p

There EX N
was VBD N
less RBR N
intraoperative JJ o
blood NN o
loss NN o
and CC o
a DT o
lower JJR o
rate NN o
of IN o
wound NN o
complications NNS o
in IN N
the DT N
patients NNS N
treated VBN N
by IN N
the DT N
Gamma NNP i
nail NN i
. . i

They PRP N
had VBD N
, , N
however RB N
, , N
a DT N
high JJ N
incidence NN N
of IN N
femoral JJ o
shaft NN o
fracture NN o
which WDT N
we PRP N
relate VBP N
in IN N
part NN N
to TO N
implant VB N
design NN N
. . N

We PRP N
do VBP N
not RB N
recommend VB N
the DT N
use NN N
of IN N
the DT N
Gamma NNP i
nail NN i
for IN N
these DT N
fractures NNS N
. . N

-DOCSTART- -12131309- O O

Is VBZ N
periprostatic JJ N
local JJ N
anesthesia NN i
for IN N
transrectal JJ p
ultrasound NN p
guided VBD p
prostate NN p
biopsy NN p
associated VBN N
with IN N
increased JJ N
infectious JJ o
or CC o
hemorrhagic JJ o
complications NNS o
? . N
A DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

PURPOSE NNP N
Periprostatic NNP N
local JJ N
anesthesia NN N
for IN N
prostate NN N
biopsy NN N
requires VBZ N
2 CD N
or CC N
more JJR N
extra JJ N
needle JJ N
punctures NNS N
and CC N
injection NN N
of IN N
the DT N
local JJ N
anesthetic NN N
through IN N
the DT N
highly RB N
colonized JJ N
rectum NN N
. . N

To TO N
our PRP$ N
knowledge NN N
we PRP N
report VBP N
the DT N
first JJ N
prospective JJ N
randomized VBN N
trial NN N
to TO N
assess VB N
the DT N
infectious JJ o
or CC o
hemorrhagic JJ o
complications NNS o
associated VBN N
with IN N
this DT N
method NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
100 CD p
consecutive JJ p
patients NNS p
with IN p
sterile JJ p
urine JJ p
cultures NNS p
underwent JJ p
transrectal JJ i
ultrasound NN i
guided VBD i
prostate NN i
biopsy NN i
. . i

They PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
periprostatic JJ i
nerve NN i
block NN i
or CC i
no DT i
anesthesia NN i
. . i

Patients NNS i
were VBD i
evaluated VBN i
for IN i
the DT i
amount NN o
of IN o
rectal NN o
and CC o
urethral JJ o
bleeding NN o
, , i
and CC i
symptoms NNS i
and CC i
signs NNS i
of IN i
infection NN o
after IN o
biopsy NN o
. . o

RESULTS VB N
The DT N
amount NN o
of IN o
urethral JJ o
bleeding NN o
was VBD N
slight JJ N
and CC N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Rectal JJ o
bleeding NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
patients NNS N
who WP N
received VBD N
anesthesia NN N
. . N

High JJ o
fever NN o
( ( N
greater JJR N
than IN N
37.8C CD N
) ) N
was VBD N
more RBR N
frequent JJ N
in IN N
the DT N
nerve NN N
block NN N
group NN N
and CC N
2 CD N
patients NNS N
in IN N
this DT N
group NN N
required VBD N
rehospitalization NN N
. . N

Bacteriuria NNP o
in IN o
post-biopsy JJ o
urine JJ o
cultures NNS o
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
anesthesia NN N
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
periprostatic JJ N
local JJ N
anesthesia NN i
for IN N
prostate JJ N
biopsy NN N
does VBZ N
not RB N
increase VB N
the DT N
risk NN N
of IN N
urethral JJ o
bleeding NN o
. . o

It PRP N
is VBZ N
associated VBN N
with IN N
a DT N
decreased JJ N
incidence NN N
of IN N
rectal JJ o
bleeding NN o
, , N
presumably RB N
due JJ N
to TO N
decreased JJ N
patient NN N
discomfort NN N
. . N

The DT N
incidence NN N
of IN N
bacteriuria NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
anesthesia NN N
group NN N
. . N

High NNP o
fever NN o
and CC o
hospitalization NN o
due JJ N
to TO N
infectious JJ N
complications NNS N
were VBD N
also RB N
more RBR N
common JJ N
in IN N
the DT N
local JJ N
anesthesia NN N
group NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
. . N

Prospective JJ N
randomized JJ N
trials NNS N
seem VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimum JJ N
antibiotic JJ N
prophylaxis NN N
regimen NNS N
in IN N
patients NNS N
undergoing VBG N
biopsy NN N
with IN N
a DT N
periprostatic JJ N
nerve NN N
block NN N
. . N

-DOCSTART- -22133572- O O

Response NNP N
prediction NN N
in IN N
metastasised JJ N
colorectal NN N
cancer NN N
using VBG N
intratumoural JJ N
thymidylate JJ N
synthase NN N
: : N
results NNS N
of IN N
a DT N
randomised JJ N
multicentre NN N
trial NN N
. . N

BACKGROUND NNP N
Molecular NNP N
markers NNS N
to TO N
predict VB N
response NN N
to TO N
5-fluorouracil JJ i
( ( i
FU NNP i
) ) i
-based VBD i
treatment NN N
of IN N
recurrent NN p
or CC p
metastasised VBN p
colorectal JJ p
cancer NN p
( ( p
mCRC NN p
) ) p
are VBP N
not RB N
established VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
value NN N
of IN N
thymidylate JJ N
synthase NN N
( ( N
TS NNP N
) ) N
, , N
a DT N
key JJ N
enzyme NN N
of IN N
DNA NNP N
synthesis NN N
and CC N
target NN N
of IN N
5-FU JJ N
, , N
to TO N
predict VB o
response NN o
to TO N
chemotherapy NN N
of IN N
mCRC NN N
. . N

METHODS NNP N
Tumour NNP p
tissue NN p
was VBD p
obtained VBN p
from IN p
168 CD p
patients NNS p
with IN p
mCRC NN p
for IN p
relative JJ p
thymidylate NN o
synthase NN o
( ( o
TS NNP o
) ) o
mRNA NN p
quantitation NN p
. . p

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
5-FU/folinic JJ i
acid NN i
( ( i
FA NNP i
, , i
FUFA NNP i
) ) i
alone RB i
or CC i
in IN i
combination NN i
with IN i
irinotecan JJ i
5-fluorouracil/folinic JJ i
acid NN i
and CC i
irinotecan JJ i
( ( i
FOLFIRI NNP i
) ) i
stratified VBN i
by IN i
TS NNP i
( ( i
low JJ i
versus RB i
high JJ i
) ) i
. . N

Primary JJ N
end-point NN N
was VBD N
overall JJ o
response NN o
to TO o
first-line JJ o
treatment NN o
among IN N
TS NNP N
high JJ N
patients NNS N
. . N

All DT N
parties NNS N
, , N
except IN N
for IN N
the DT N
randomisation NN N
centre NN N
, , N
were VBD N
blinded VBN N
for IN N
TS NNP N
status NN N
. . N

RESULTS NNP N
Biopsies NNP N
( ( N
n=168 RB N
) ) N
were VBD N
taken VBN N
without IN N
complications NNS N
. . N

TS NN o
levels NNS o
were VBD N
available JJ N
for IN N
147 CD N
patients NNS N
( ( N
87.5 CD N
% NN N
) ) N
. . N

Analysing VBG N
response NN o
to TO o
FUFA NNP o
and CC o
FOLFIRI NNP o
in IN N
the DT N
per NN N
protocol NN N
set VBN N
( ( N
n=119 NN N
) ) N
after IN N
un-blinding JJ N
TS NNP N
in IN N
the DT N
data NN N
base NN N
revealed VBD N
a DT N
trend NN N
to TO N
better JJR N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
( ( N
9/19 CD N
, , N
47 CD N
% NN N
) ) N
in IN N
TS NNP N
high JJ N
compared VBN N
to TO N
FUFA NNP N
( ( N
5/23 CD N
, , N
22 CD N
% NN N
, , N
p=0.077 NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
biopsies NNS N
taken VBN N
from IN N
liver JJ N
lesions NNS N
( ( N
n=91 NN N
) ) N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
and CC N
FUFA NNP N
in IN N
TS NNP N
high NN N
was VBD N
53 CD N
% NN N
( ( N
9/17 CD N
) ) N
and CC N
18 CD N
% NN N
( ( N
3/17 CD N
) ) N
, , N
respectively RB N
( ( N
p=0.035 NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
low JJ N
TS NNP N
, , N
no DT N
remarkable JJ N
difference NN N
in IN N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
and CC N
FUFA NNP N
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Taking VBG N
a DT N
pre-treatment JJ N
biopsy NN N
is VBZ N
a DT N
safe JJ N
and CC N
feasible JJ N
procedure NN N
in IN N
mCRC NN N
. . N

After IN N
validation NN N
of IN N
our PRP$ N
data NNS N
in IN N
a DT N
larger JJR N
group NN N
TS NNP N
determination NN N
may MD N
have VB N
the DT N
potential NN N
to TO N
better JJR N
help NN N
direct VB N
systemic JJ N
treatment NN N
in IN N
patients NNS p
with IN p
primarily RB p
non-resectable JJ p
mCRC NN p
. . p

-DOCSTART- -23660099- O O

[ IN N
The DT N
effects NNS N
of IN N
early JJ i
enteral JJ i
nutrition NN i
with IN i
addition NN i
of IN i
probiotics NNS i
on IN N
the DT N
prognosis NN N
of IN N
patients NNS p
suffering VBG p
from IN p
severe JJ p
acute NN p
pancreatitis NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
curative JJ N
effect NN N
of IN N
early JJ i
enteral JJ i
nutrition NN i
( ( i
EN NNP i
) ) i
supplemented VBD i
with IN i
probiotics NNS i
( ( i
bifidobacterium NN i
) ) i
in IN N
patients NNS p
with IN p
severe JJ p
acute NN p
pancreatitis NN p
( ( p
ASP NNP p
) ) p
. . p

METHODS NNP N
Seventy NNP p
SAP NNP p
cases NNS p
admitted VBD p
from IN p
January NNP p
2005 CD p
to TO p
October NNP p
2012 CD p
were VBD p
randomly RB p
assigned VBN p
into IN N
parenteral JJ i
nutrition NN i
( ( i
PN NNP i
) ) i
group NN p
( ( p
n=22 NN p
) ) p
, , p
EN NNP i
group NN p
( ( p
n=25 CC p
) ) p
and CC p
bifidobacterium NN i
added VBD i
EN NNP i
( ( i
P+EN NNP i
) ) i
group NN p
( ( p
n=23 RB p
) ) p
. . p

In IN N
P+EN NNP i
group NN N
, , N
patients NNS N
were VBD N
given VBN N
their PRP$ N
nutrition NN N
the DT N
same JJ N
as IN N
that DT N
of IN N
EN NNP i
, , N
and CC N
also RB N
probiotics NNS i
( ( i
bifidobacterium NN i
, , N
4 CD N
capsules NNS N
every DT N
12 CD N
hours NNS N
, , N
given VBN N
through IN N
nasal JJ N
gastric JJ N
tube NN N
, , N
each DT N
capsule NN N
weighing VBG N
210 CD N
mg NN N
) ) N
. . N

The DT N
routine JJ N
treatment NN N
including VBG N
anti-infection NN i
and CC i
anti-acid JJ i
agents NNS i
, , N
and CC N
that IN N
of IN N
inhibition NN N
of IN N
pancreatic JJ N
secretion NN N
were VBD N
given VBN N
, , N
except IN N
for IN N
the DT N
different JJ N
nutritional JJ N
interventions NNS N
in IN N
all DT N
groups NNS N
. . N

The DT N
blood NN N
samples NNS N
were VBD N
collected VBN N
for IN N
e NN N
same JJ N
measurements NNS N
of IN N
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
and CC o
tumor JJ o
necrosis NN o
factor NN o
( ( o
TNF-? NNP o
) ) o
by IN N
enzyme NN N
linked VBN N
immunosorbent JJ N
assay NN N
( ( N
ELISA NNP N
) ) N
, , N
and CC N
for IN N
the DT o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
lactic JJ o
acid NN o
dehydrogenase NN o
( ( o
LDH NNP o
) ) o
, , o
white JJ o
blood NN o
cell NN o
( ( o
WBC NNP o
) ) o
count NN o
, , o
amylase NN o
and CC o
lipase NN o
by IN N
biochemistry NN N
assay VBP N
1 CD N
day NN N
before IN N
intervention NN N
of IN N
nutrition NN N
, , N
and CC N
7 CD N
days NNS N
and CC N
14 CD N
days NNS N
after IN N
intervention NN N
. . N

Changes NNS N
in IN N
organ JJ N
function NN N
and CC N
outcome NN N
were VBD N
also RB N
recorded VBN N
at IN N
the DT N
same JJ N
time NN N
points NNS N
. . N

RESULTS VB N
The DT o
plasma JJ o
levels NNS o
of IN o
IL-8 NNP o
, , o
TNF-? NNP o
, , o
CRP NNP o
, , o
LDH NNP o
, , o
WBC NNP o
count NN o
, , o
amylase NN o
and CC o
lipase NN o
were VBD o
significantly RB N
reduced VBN N
after IN N
nutritional JJ N
intervention NN N
compared VBN N
with IN N
their PRP$ N
levels NNS N
on IN N
day NN N
1 CD N
before IN N
intervention NN N
in IN N
all DT N
three CD N
groups NNS N
. . N

The DT o
plasma JJ o
IL-8 NNP o
, , o
TNF-? NNP o
, , o
CRP NNP o
, , o
lipase NN o
, , o
LDH NNP o
at IN o
14 CD N
days NNS N
after IN N
intervention NN N
of IN N
nutrition NN N
in IN N
P+EN NNP i
group NN i
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
PN NNP i
group NN N
and CC N
EN NNP i
group NN N
( ( N
IL-8 NNP N
: : N
21.00 CD N
? . N
7.07 CD N
?g/L NN N
vs. FW N
48.00 CD N
? . N
10.32 CD N
?g/L NN N
, , N
32.00 CD N
? . N
9.30 CD N
?g/L NN N
; : N
TNF-? JJ N
: : N
44.3 CD N
? . N
10.9 CD N
ng/L JJ N
vs. FW N
132.1 CD N
? . N
34.1 CD N
ng/L NN N
, , N
67.8 CD N
? . N
22.3 CD N
ng/L NN N
; : N
CRP NNP N
: : N
35.0 CD N
? . N
12.4 CD N
mg/L NN N
vs. FW N
103.2 CD N
? . N
49.2 CD N
mg/L NN N
, , N
63.0 CD N
? . N
29.2 CD N
mg/L NN N
; : N
lipase NN N
: : N
269 CD N
? . N
79 CD N
U/L NNP N
vs. FW N
670 CD N
? . N
145 CD N
U/L NNP N
, , N
310 CD N
? . N
78 CD N
U/L NNP N
; : N
LDH NNP N
: : N
21.8 CD N
? . N
10.3 CD N
U/L NNP N
vs. FW N
78.1 CD N
? . N
37.4 CD N
U/L NNP N
, , N
37.9 CD N
? . N
25.1 CD N
U/L NNP N
, , N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
WBC NNP o
count NN o
in IN o
P+EN NNP o
group NN N
was VBD N
significantly RB N
lower JJR N
than IN i
that DT i
in IN i
PN NNP i
group NN N
( ( N
5.9 CD N
? . N
3.0 CD N
? . N
10?/L CD N
, , N
6.3 CD N
? . N
3.2 CD N
? . N
10?/L CD N
vs. IN N
9.6 CD N
? . N
3.0 CD N
?10?/L NN N
, , N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
amylase NN o
between IN i
P+EN NNP i
group NN i
and CC i
PN NNP i
group NN N
( ( N
211 CD N
? . N
49 CD N
U/L NNP N
, , N
236 CD N
? . N
52 CD N
U/L NNP N
vs. FW N
298 CD N
? . N
71 CD N
U/L NNP N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT o
gastrointestinal JJ o
dysfunction NN o
score NN o
in IN o
P+EN NNP i
, , i
EN NNP i
, , i
PN NNP i
groups NNS i
14 CD N
days NNS N
after IN N
nutritional JJ N
intervention NN N
was VBD N
0.28 CD N
? . N
0.05 CD N
, , N
0.43 CD N
? . N
0.09 CD N
, , N
0.71 CD N
? . N
0.11 CD N
, , N
respectively RB N
, , N
with IN N
statistically RB N
significant JJ N
differences NNS N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Compared VBN N
with IN N
PN NNP i
and CC i
EN NNP i
groups NNS i
, , N
the DT o
incidence NN o
of IN o
upper JJ o
gastrointestinal JJ o
bleeding NN o
( ( o
1 CD o
vs. FW o
9 CD N
, , o
2 CD o
) ) o
, , o
infection NN o
and CC o
abscess NN o
( ( o
2 CD o
vs. FW N
12 CD N
, , N
5 CD N
) ) N
was VBD N
lower JJR N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
hospital JJ N
day NN N
was VBD N
significantly RB N
shortened VBN N
in IN N
P+EN NNP N
group NN N
( ( N
10.4 CD N
? . N
3.9 CD N
days NNS N
vs. FW N
25.8 CD N
? . N
6.4 CD N
days NNS N
, , N
13.4 CD N
? . N
5.2 CD N
days NNS N
, , N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT o
significant JJ o
statistical JJ o
difference NN o
in IN o
mortality NN o
rate NN o
among IN o
three CD N
groups NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicated VBD N
that IN i
early JJ i
EN NNP i
with IN i
addition NN i
of IN i
probiotics NNS i
( ( i
bifidobacterium NN i
) ) i
resulted VBD i
in IN N
significant JJ N
lowering NN o
of IN o
the DT o
level NN o
of IN o
pro-inflammatory JJ o
cytokines NNS o
, , N
earlier JJR o
restoration NN o
of IN o
gastrointestinal JJ o
function NN o
, , o
decrease NN o
of IN o
complications NNS o
such JJ o
as IN o
infection NN o
, , o
and CC o
shortening NN o
of IN o
hospital JJ o
day NN o
in IN N
patients NNS N
with IN N
SAP NNP N
. . N

-DOCSTART- -7285032- O O

[ NN o
Changes NNS o
in IN N
renal JJ o
arterial JJ o
flow NN o
during IN N
the DT N
treatment NN N
of IN N
essential JJ p
arterial JJ p
hypertension NN p
; : p
prazosin NN i
in IN i
comparison NN i
with IN i
propranolol JJ i
] NN i
. . N

-DOCSTART- -23869063- O O

Intravenous JJ N
adenosine NN i
activates NNS N
diffuse VBP N
nociceptive JJ N
inhibitory NN N
controls NNS N
in IN N
humans NNS p
. . p

Experimentally RB N
induced JJ N
pain NN N
can MD N
be VB N
attenuated VBN N
by IN N
concomitant JJ N
heterotopic NN N
nociceptive JJ N
stimuli NN N
( ( N
counterirritation NN N
) ) N
. . N

Animal NNP N
data NNS N
indicate VBP N
that IN N
this DT N
stems VBZ N
from IN N
supraspinal JJ o
diffuse NN o
noxious JJ o
inhibitory NN o
controls NNS o
( ( o
DNICs NNP o
) ) o
triggered VBN N
by IN N
C NNP N
and CC N
A? NNP N
fibers NNS N
. . N

In IN N
humans NNS N
, , N
only RB N
noxious JJ N
stimuli NNS N
induce VBP N
counterirritation NN N
. . N

This DT N
points NNS N
at IN N
C NNP N
fibers NNS N
, , N
but CC N
the DT N
effects NNS N
of IN N
pharmacologically RB N
stimulating VBG N
C NNP N
fibers NNS N
have VBP N
not RB N
been VBN N
studied VBN N
. . N

Intravenous JJ N
adenosine NN N
activates VBZ N
pulmonary JJ N
C NNP N
fibers NNS N
and CC N
induces NNS N
dyspnea RB N
. . N

This DT N
study NN N
tests VBZ N
the DT N
hypothesis NN N
that WDT N
putative JJ N
activation NN N
of IN N
pulmonary JJ N
C NNP N
fibers NNS N
by IN i
adenosine NN i
would MD N
trigger VB o
DNICs NNP o
in IN N
humans NNS N
and CC o
induce VB o
counterirritation NN o
. . o

Twelve NNP p
healthy JJ p
volunteers NNS p
were VBD p
included VBN p
( ( p
with IN p
valid JJ p
results NNS p
available JJ p
in IN p
9 CD p
) ) p
and CC N
studied VBN N
according VBG N
to TO N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
design NN N
( ( N
intravenous JJ i
adenosine NN i
, , i
140 CD i
?g?kg NN i
( ( i
-1 NNP i
) ) i
?min NNP i
( ( i
-1 NNP i
) ) i
, , i
during IN i
5 CD i
min NNS i
vs. FW i
placebo NN i
) ) i
. . i

We PRP i
measured VBD o
ventilatory JJ o
variables NNS o
and CC o
end-tidal JJ o
CO2 NNP o
tension NN o
, , o
dyspnea NN o
intensity NN o
by IN o
visual JJ o
analog NN o
scale NN o
, , o
and CC o
the DT o
intensity NN o
of IN o
putative JJ o
chest NN o
pain NN o
. . o

The DT o
primary JJ N
outcome NN N
was VBD N
the DT o
amplitude NN o
of IN o
the DT o
RIII NNP o
component NN o
of IN o
the DT o
nociceptive JJ o
flexor NN o
reflex NN o
recorded VBN o
by IN o
biceps NNS o
femoris JJ o
electromyogram VBP o
in IN o
response NN o
to TO o
painful JJ o
electrical JJ o
sural JJ o
nerve NN o
stimulation NN o
( ( o
RIII NNP o
) ) o
, , o
taken VBN o
as IN o
a DT o
substitute NN o
for IN o
pain NN o
perception NN o
. . o

Placebo NNP o
did VBD i
not RB N
induce VB N
any DT N
significant JJ N
effect NN i
. . i

Adenosine NNP i
induced VBD o
dyspnea NN o
, , o
hyperpnea NN o
, , o
tachycardia NN o
, , o
and CC o
significant JJ o
RIII NNP o
inhibition NN o
( ( o
24 CD o
? . N
8 CD N
% NN N
at IN N
the DT N
4th CD N
min NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
temporal JJ o
dynamics NNS o
of IN o
adenosine-induced JJ o
dyspnea NN o
and CC o
RIII NNP o
inhibition NN o
differed VBD o
( ( N
immediate JJ N
onset VBN N
followed VBN N
by IN N
a DT N
slow JJ N
decrease NN N
for IN N
dyspnea NN N
, , N
slower JJR N
onset NN N
for IN N
RIII NNP N
inhibition NN N
) ) N
. . N

Intravenous JJ i
adenosine NN i
in IN i
normal JJ i
humans NNS p
induces NNS o
counterirritation NN o
, , o
fueling VBG o
the DT N
notion NN N
that IN N
C-fiber NNP N
stimulation NN N
trigger NN N
DNICs NNP N
in IN N
humans NNS N
. . N

The DT N
temporal JJ N
dissociation NN N
between IN N
adenosine-induced JJ o
dyspnea NN o
and CC o
RIII NNP o
inhibition NN o
suggests VBZ o
that IN N
C NNP N
fibers VBZ N
other JJ N
than IN N
pulmonary JJ N
ones NNS N
might MD N
be VB N
involved VBN N
. . N

-DOCSTART- -10093945- O O

A DT N
comparative JJ N
study NN N
of IN N
ofloxacin NN i
and CC N
cefixime NN i
for IN N
treatment NN N
of IN N
typhoid JJ p
fever NN p
in IN p
children NNS p
. . p

The DT N
Dong NNP p
Nai NNP p
Pediatric NNP p
Center NNP p
Typhoid NNP N
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
Despite IN N
concerns NNS N
about IN N
safety NN N
in IN N
children NNS N
, , N
fluoroquinolone NN i
antibiotics NNS i
have VBP N
become VBN N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
patients NNS p
with IN p
multidrug-resistant JJ p
typhoid NN p
fever NN p
in IN p
Vietnam NNP p
. . p

However RB N
, , N
quinolone-resistant JJ N
strains NNS N
of IN N
Salmonella NNP N
typhi NN N
have VBP N
recently RB N
been VBN N
reported VBN N
from IN N
Vietnam NNP N
; : N
and CC N
if IN N
quinolone JJ N
resistance NN N
becomes NNS N
established VBN N
, , N
alternative JJ N
oral JJ N
treatment NN N
options NNS N
will MD N
be VB N
needed VBN N
. . N

OBJECTIVE NNP N
Cefixime NNP i
, , N
an DT N
orally RB N
administered VBN N
third JJ N
generation NN N
cephalosporin NN i
, , N
was VBD N
compared VBN N
with IN N
ofloxacin NN i
for IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ N
typhoid NN N
fever NN N
in IN N
children NNS N
. . N

METHODS NNP N
In IN p
an DT p
open JJ p
trial NN p
children NNS p
with IN p
suspected JJ p
typhoid NN p
fever NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ofloxacin NN i
( ( N
10 CD N
mg/kg/day NN N
in IN N
two CD N
divided JJ N
doses NNS N
) ) N
for IN N
5 CD N
days NNS N
or CC N
cefixime NN i
( ( N
20 CD N
mg/kg/day NN N
in IN N
two CD N
divided JJ N
doses NNS N
) ) N
for IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
S. NNP N
typhi NN N
was VBD N
isolated VBN N
from IN N
82 CD p
patients NNS p
( ( p
44 CD p
in IN p
the DT p
cefixime NN i
group NN p
, , p
38 CD p
in IN p
the DT p
ofloxacin JJ i
group NN p
) ) p
and CC p
70 CD p
( ( p
85 CD p
% NN p
) ) p
of IN p
the DT p
isolates NNS p
were VBD p
multidrug-resistant JJ p
. . p

Median JJ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
range NN N
) ) N
fever NN o
clearance NN o
times NNS o
were VBD N
4.4 CD N
( ( N
4 CD N
to TO N
5.2 CD N
, , N
0.2 CD N
to TO N
9.9 CD N
) ) N
days NNS N
for IN N
ofloxacin JJ i
recipients NNS N
and CC N
8.5 CD N
( ( N
4.2 CD N
to TO N
9 CD N
, , N
1.8 CD N
to TO N
15.2 CD N
) ) N
days NNS N
for IN N
cefixime-treated JJ i
patients NNS p
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

There EX N
were VBD N
11 CD N
treatment NN o
failures NNS o
( ( N
10 CD N
acute NN N
and CC N
one CD N
relapse NN N
) ) N
in IN N
the DT N
cefixime NN i
group NN N
and CC N
1 CD N
acute NN o
treatment NN o
failure NN o
in IN N
the DT N
ofloxacin NN i
group NN N
( ( N
mean JJ N
difference NN N
, , N
22 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
9 CD N
to TO N
36 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Short NNP N
course NN N
treatment NN N
with IN N
cefixime NN i
may MD N
provide VB N
a DT N
useful JJ N
alternative JJ N
treatment NN N
in IN N
cases NNS N
of IN N
uncomplicated JJ p
typhoid NN p
fever NN p
in IN p
children NNS p
, , N
but CC N
it PRP N
is VBZ N
less RBR N
effective JJ N
than IN N
short JJ N
course NN N
treatment NN N
with IN N
ofloxacin NN i
. . i

-DOCSTART- -19301086- O O

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
comparative JJ N
trial NN N
of IN N
a DT N
COX-2 NNP i
selective JJ i
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
versus NN i
placebo NN i
in IN N
inguinal JJ p
herniorrhaphy NN p
patients NNS p
. . p

OBJECTIVE IN N
The DT N
standard JJ N
opioid NN N
treatment NN N
for IN N
postoperative JJ N
pain NN N
can MD N
be VB N
associated VBN N
with IN N
nausea NN N
, , N
vomiting NN N
, , N
and CC N
constipation NN N
. . N

In IN N
addition NN N
, , N
opioids NNS N
often RB N
provide VBP N
insufficient JJ N
pain NN N
relief NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
postoperative JJ N
pain NN N
and CC N
functional JJ N
outcomes NNS N
in IN N
patients NNS p
undergoing JJ p
inguinal JJ p
herniorrhaphy NN p
who WP N
receive VBP N
a DT N
COX-2 NNP N
selective JJ N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
( ( N
COX-2 NNP N
) ) N
or CC N
placebo VB N
preoperatively RB N
and CC N
for IN N
4 CD N
days NNS N
postoperatively RB N
. . N

METHODS VB N
A DT N
prospective JJ N
, , N
randomized VBN N
, , N
blinded VBN N
, , N
placebo-controlled JJ i
trial NN N
was VBD N
conducted VBN N
in IN N
adults NNS p
undergoing VBG p
elective JJ p
, , p
outpatient JJ p
, , p
unilateral JJ p
inguinal JJ p
herniorrhaphy NN p
. . p

Patients NNS N
received VBD N
rofecoxib JJ i
( ( N
50 CD N
mg NN N
, , N
1 CD N
h NN N
prior RB N
to TO N
incision NN N
) ) N
or CC i
placebo NN i
. . i

Doses NNS N
were VBD N
re-administered JJ N
once RB N
daily JJ N
on IN N
postoperative JJ N
days NNS N
1-4 JJ N
. . N

Patients NNS N
were VBD N
also RB N
given VBN N
hydrocodone NN i
bitartrate NN i
for IN N
use NN N
as IN N
needed VBN N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

Pain VB o
outcomes NNS N
were VBD N
assessed VBN N
, , N
including VBG N
pain NN o
intensity NN o
( ( N
1-10 JJ N
visual-analogue JJ N
scale NN N
) ) N
and CC N
the DT N
use NN N
of IN N
hydrocodone NN N
bitartrate NN N
. . N

In IN N
addition NN N
, , N
functional JJ N
outcomes NNS N
such JJ N
as IN N
activity NN o
and CC o
return NN o
of IN o
bowel NN o
function NN o
were VBD N
examined VBN N
for IN N
5 CD N
postoperative JJ N
days NNS N
. . N

Incidence NN N
and CC N
severity NN N
of IN N
side NN o
effects NNS o
were VBD N
examined VBN N
. . N

Statistics NNS N
are VBP N
mean JJ N
+/- JJ N
standard NN N
deviation NN N
. . N

RESULTS NNP N
Fifty-five JJ p
subjects NNS p
completed VBD p
the DT p
study NN p
. . p

Twenty-six JJ N
patients NNS N
received VBN N
rofecoxib JJ N
and CC N
29 CD N
patients NNS N
received VBD N
placebo JJ N
. . N

Patients NNS N
who WP N
received VBD N
COX-2 NNP N
demonstrated VBD N
improved JJ N
bowel NN o
function NN o
as IN N
reflected VBN N
by IN N
more JJR N
bowel NN N
movements NNS N
on IN N
postoperative JJ N
day NN N
2 CD N
and CC N
postoperative JJ N
day NN N
3 CD N
. . N

COX-2-treated JJ N
patients NNS N
also RB N
reported VBD N
better RBR N
oral JJ o
intake NN o
on IN N
these DT N
same JJ N
days NNS N
. . N

In IN N
addition NN N
, , N
COX-2-treated JJ N
patients NNS N
had VBD N
less RBR N
difficulty NN N
coughing VBG o
on IN N
postoperative JJ N
day NN N
1 CD N
. . N

Overall JJ N
satisfaction NN N
with IN N
pain NN o
management NN o
was VBD N
better RBR N
in IN N
COX-2-treated JJ N
patients NNS N
( ( N
very RB N
satisfied VBN N
vs. FW N
satisfied VBN N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
the DT N
amount NN N
of IN N
hydrocodone NN N
bitartrate NN N
consumption NN N
. . N

There EX N
were VBD N
no DT N
complications NNS o
during IN N
the DT N
study NN N
period NN N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
a DT N
COX-2 NNP N
selective JJ N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
prior RB N
to TO N
and CC N
following VBG N
outpatient JJ N
inguinal JJ N
herniorrhaphy NN N
improves VBZ N
functional JJ N
outcomes NNS N
when WRB N
compared VBN N
with IN N
placebo NN N
and CC N
increases VBZ N
patient JJ N
satisfaction NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
multimodal NN N
pain NN N
therapy NN N
with IN N
COX-2 NNP N
inhibitors NNS N
may MD N
have VB N
a DT N
role NN N
in IN N
outpatient JJ p
inguinal JJ p
hernia NN p
repair NN p
. . p

-DOCSTART- -11819768- O O

Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
cancer NN N
: : N
current JJ N
status NN N
of IN N
the DT N
Austrain NNP p
Czech JJ p
German NNP p
gastric NN p
cancer NN p
prevention NN N
trial NN N
( ( N
PRISMA NNP N
Study NNP N
) ) N
. . N

AIM UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
Helicobacter NNP N
pylori VBZ N
eradication NN N
alone RB N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
gastric JJ o
cancer NN o
in IN N
a DT N
subgroup NN p
of IN p
individuals NNS p
with IN p
an DT p
increased VBN p
risk NN p
for IN p
this DT p
fatal JJ p
disease NN p
. . p

METHODS NNP N
It PRP N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
multinational JJ N
multicenter NN N
trial NN N
. . N

Men NN p
between IN p
55 CD p
and CC p
65 CD p
years NNS p
of IN p
age NN p
with IN p
a DT p
gastric JJ p
cancer NN p
phenotype NN p
of IN p
Helicobacter NNP p
pylori FW p
gastritis NN p
are VBP p
randomized VBN p
to TO N
receive VB N
a DT N
7 CD N
day NN N
course NN N
of IN N
omeprazole JJ i
2 CD i
X NN i
20mg CD i
, , i
clarithromycin VBD i
2 CD i
X NNP i
500mg CD i
, , i
and CC i
amoxicillin RB i
2 CD i
X NNS i
1g CD i
for IN i
7 CD i
days NNS i
, , i
or CC i
omeprazole JJ i
2 CD i
X NN i
20mg CD i
plus CC i
placebo NN i
. . i

Follow-up JJ N
endoscopy NN N
is VBZ N
scheduled VBN N
3 CD N
months NNS N
after IN N
therapy NN N
, , N
and CC N
thereafter RB N
in IN N
one-year JJ N
intervals NNS N
. . N

Predefined VBN N
study NN N
endpoints NNS N
are VBP N
gastric JJ o
cancer NN o
, , o
precancerous JJ o
lesions NNS o
( ( o
dysplasia NN o
, , o
adenoma NN o
) ) o
, , o
other JJ o
cancers NNS o
, , o
and CC o
death NN o
. . o

RESULTS NNP N
Since IN p
March NNP p
1998 CD p
, , p
1524 CD p
target NN p
patients NNS p
have VBP p
been VBN p
screened VBN p
, , p
279 CD p
patients NNS p
( ( p
18.3 CD p
% NN p
) ) p
had VBD p
a DT p
corpus NN p
dominant JJ p
type NN p
of IN p
H. NNP p
pylori FW p
gastritis NN p
, , p
and CC p
167 CD p
of IN p
those DT p
were VBD p
randomized VBN p
( ( N
58.8 CD N
% NN N
) ) N
. . N

In IN N
the DT N
active JJ N
treatment NN N
group NN N
( ( N
r NN N
= RB N
86 CD N
) ) N
, , N
H. NNP N
pylori VBZ N
infection NN N
infection NN N
was VBD N
cured VBN o
in IN N
88.9 CD N
% NN N
of IN N
patients NNS N
. . N

Currently RB N
, , N
the DT N
cumulative JJ N
follow-up JJ N
time NN N
is VBZ N
3046 CD N
months NNS N
( ( N
253.38 CD N
patient NN N
years NNS N
, , N
median NN N
follow VBP N
up RB N
16 CD N
months NNS N
) ) N
. . N

So RB N
far RB N
, , N
none NN N
of IN N
the DT N
patients NNS N
developed VBD N
gastric JJ o
cancer NN o
or CC o
any DT o
precancerous JJ o
lesion NN o
. . o

Three NNP N
( ( N
1.8 CD N
% NN N
) ) N
patients NNS N
reached VBD N
study NN o
endpoints NNS o
other JJ o
than IN o
gastric JJ o
cancer NN o
. . o

CONCLUSION NNP N
Among IN N
men NNS N
between IN N
55 CD N
and CC N
65 CD N
years NNS N
of IN N
age NN N
, , N
the DT N
gastric JJ N
cancer NN N
phenotype NN N
of IN N
H. NNP N
pylori FW N
gastritis NN N
appears VBZ N
to TO N
be VB N
more JJR N
common JJ N
than IN N
expected VBN N
. . N

Further RBR N
follow VB N
up RB N
and CC N
continuing VBG N
recruitment NN N
are VBP N
necessary JJ N
to TO N
fulfil VB N
the DT N
main JJ N
aim NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -8436747- O O

Sustained VBN N
augmentation NN N
of IN N
parasympathetic JJ N
tone NN N
with IN N
angiotensin-converting JJ i
enzyme JJ i
inhibition NN i
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
the DT N
changes NNS N
in IN N
parasympathetic JJ N
tone NN N
associated VBN N
with IN N
long-term JJ N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
therapy NN i
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

BACKGROUND NNP N
Angiotensin-converting NNP N
enzyme NN N
inhibitors NNS N
provide VBP N
hemodynamic JJ N
and CC N
symptomatic JJ N
benefit NN N
and CC N
are VBP N
associated VBN N
with IN N
improved JJ N
survival NN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

Angiotensin NNP N
II NNP N
, , N
whose WP$ N
production NN N
is VBZ N
ultimately RB N
inhibited VBN N
by IN N
these DT N
agents NNS N
, , N
exerts NNS N
significant JJ N
regulatory JJ N
influence NN N
on IN N
a DT N
variety NN N
of IN N
target NN N
organs NNS N
including VBG N
the DT N
central JJ N
and CC N
peripheral JJ N
nervous JJ N
systems NNS N
. . N

Accordingly RB N
, , N
it PRP N
would MD N
be VB N
anticipated VBN N
that IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
would MD N
significantly RB N
alter VB N
the DT N
autonomic JJ N
imbalance NN N
characteristic NN N
of IN N
patients NNS N
with IN N
congestive JJ N
heart NN N
failure NN N
and CC N
that IN N
this DT N
influence NN N
over IN N
neural JJ N
mechanisms NNS N
of IN N
cardiovascular JJ N
control NN N
may MD N
significantly RB N
contribute VB N
to TO N
the DT N
hemodynamic JJ N
benefit NN N
and CC N
improved VBN N
survival NN N
associated VBN N
with IN N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
therapy NN N
. . N

METHODS NNP N
In IN N
the DT N
current JJ N
investigation NN N
, , N
changes NNS N
in IN N
autonomic JJ N
tone NN N
associated VBN N
with IN N
long-term JJ N
administration NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
were VBD N
measured VBN N
using VBG N
spectral JJ N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
in IN N
13 CD p
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
who WP N
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
placebo-controlled JJ i
trial NN N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
zofenopril NN i
. . i

Both DT N
placebo NN i
and CC N
treatment NN N
groups NNS N
were VBD N
balanced VBN N
at IN N
baseline NN N
study NN N
in IN N
terms NNS N
of IN N
functional JJ N
class NN N
, , N
ventricular JJ N
performance NN N
and CC N
autonomic JJ N
tone NN N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
of IN N
therapy NN N
with IN N
placebo NN i
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
total JJ o
heart NN o
rate NN o
variability NN o
, , o
parasympathetically RB o
governed VBN o
high JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
or CC o
sympathetically RB o
influenced JJ o
low JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
. . o

In IN N
contrast NN N
, , N
therapy NN N
with IN N
zofenopril NN i
was VBD N
associated VBN N
with IN N
a DT N
50 CD N
% NN N
increase NN o
in IN o
total JJ o
heart NN o
rate NN o
variability NN o
( ( N
p JJ N
= NNP N
0.09 CD N
) ) N
and CC N
a DT N
significant JJ N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
twofold NN N
increase NN o
in IN o
high JJ o
frequency NN o
heart NN o
rate NN o
variability NN o
, , N
indicating VBG N
a DT N
significant JJ N
augmentation NN N
of IN N
parasympathetic JJ N
tone NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
demonstrate VBP N
that IN N
long-term JJ p
treatment NN p
of IN p
patients NNS p
having VBG p
congestive JJ p
heart NN p
failure NN p
with IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
is VBZ N
associated VBN N
with IN N
a DT N
restoration NN N
of IN N
autonomic JJ N
balance NN N
, , N
which WDT N
derives VBZ N
in IN N
part NN N
from IN N
a DT N
sustained JJ N
augmentation NN N
of IN N
parasympathetic JJ N
tone NN N
. . N

Such JJ N
augmentation NN N
of IN N
vagal JJ N
tone NN N
is VBZ N
known VBN N
to TO N
be VB N
protective JJ N
against IN N
malignant JJ N
ventricular JJ N
arrhythmias NNS N
in IN N
patients NNS p
with IN p
ischemic JJ p
heart NN p
disease NN p
and CC N
therefore NN N
may MD N
have VB N
similar JJ N
benefit NN N
in IN N
the DT N
setting NN N
of IN N
ventricular JJ N
failure NN N
, , N
thus RB N
contributing VBG N
to TO N
the DT N
improved JJ N
survival NN N
associated VBN N
with IN N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
therapy NN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
. . p

-DOCSTART- -10678548- O O

Safety NN o
of IN N
the DT N
combination NN i
of IN i
valsartan NN i
and CC i
benazepril NN i
in IN N
patients NNS p
with IN p
chronic JJ p
renal JJ p
disease NN p
. . p

European JJ N
Group NNP N
for IN N
the DT N
Investigation NNP N
of IN N
Valsartan NNP i
in IN N
Chronic NNP N
Renal NNP N
Disease NNP N
. . N

OBJECTIVE NNP N
Several JJ N
experimental JJ N
and CC N
clinical JJ N
studies NNS N
indicate VBP N
that IN N
the DT N
renin NN N
system NN N
may MD N
play VB N
a DT N
pivotal JJ N
role NN N
in IN N
progressing VBG N
renal JJ N
disease NN N
. . N

The DT N
combination NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
could MD N
provide VB N
a DT N
higher JJR N
degree NN N
of IN N
blockade NN N
of IN N
the DT N
renin-angiotensin NN N
system NN N
than IN N
either DT N
agent JJ N
alone RB N
. . N

Such JJ N
enhanced JJ N
suppression NN N
might MD N
be VB N
of IN N
benefit NN N
for IN N
patients NNS p
exhibiting VBG p
a DT p
progressive JJ p
decline NN p
in IN p
renal JJ p
function NN p
because IN p
of IN p
chronic JJ p
renal JJ p
disease NN p
. . p

METHODS NNP N
A NNP N
pilot NN N
multinational NN N
, , N
multicentre NN N
, , N
randomized VBN N
, , N
active-controlled JJ N
, , N
parallel JJ N
group NN N
open-label JJ N
study NN N
has VBZ N
been VBN N
conducted VBN N
in IN N
a DT N
group NN p
of IN p
patients NNS p
with IN p
progressive JJ p
chronic JJ p
renal JJ p
failure NN p
( ( p
creatinine JJ p
clearance NN p
20-45 JJ p
ml/min NN p
) ) p
either CC p
with IN p
or CC p
without IN p
proteinuria NNS p
and CC p
hypertension NN p
. . p

The DT N
primary JJ N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN o
and CC o
tolerability NN o
of IN N
the DT N
combination NN i
of IN i
valsartan NN i
and CC i
benazepril NN i
. . i

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
valsartan JJ i
160 CD i
mg NN i
once RB N
daily JJ N
( ( p
n JJ p
= NNP p
22 CD p
) ) p
; : p
group NN N
2 CD N
received VBD N
valsartan JJ i
80 CD i
mg NN i
once RB i
daily JJ i
plus CC i
benazepril JJ i
5 CD i
or CC i
10 CD i
mg NNS i
once RB i
daily JJ i
( ( p
n JJ p
= NNP p
42 CD p
) ) p
; : p
group NN N
3 CD N
received VBD N
valsartan JJ i
160 CD i
mg NN i
once RB N
daily JJ N
plus CC i
benazepril JJ i
5 CD i
or CC i
10 CD i
mg NNS i
once RB N
daily JJ N
( ( p
n JJ p
= NNP p
44 CD p
) ) p
. . N

The DT N
study NN N
lasted VBD N
for IN N
5 CD N
weeks NNS N
, , N
and CC N
in IN N
groups NNS N
2 CD N
and CC N
3 CD N
benazepril NN N
was VBD N
added VBN N
on IN N
top NN N
of IN N
valsartan NN N
after IN N
the DT N
first JJ N
week NN N
of IN N
therapy NN N
with IN N
the DT N
angiotensin NN N
receptor NN N
blocker NN N
. . N

RESULTS NNP N
Serum NNP o
creatinine NN o
increased VBN N
in IN N
all DT N
three CD N
groups NNS N
( ( N
mean JJ N
change NN N
within IN N
a DT N
group NN N
: : N
11 CD N
micromol/l NN N
in IN N
group NN N
1 CD N
, , N
P= NNP N
0.045 CD N
; : N
9 CD N
micromol/l NN N
in IN N
group NN N
2 CD N
, , N
P= NNP N
0.030 CD N
; : N
15 CD N
micromol/l NN N
in IN N
group NN N
3 CD N
, , N
P= NNP N
0.0006 CD N
) ) N
. . N

Serum NNP o
potassium NN o
also RB N
increased VBN N
in IN N
all DT N
three CD N
groups NNS N
of IN N
patients NNS N
( ( N
mean JJ N
change NN N
within IN N
a DT N
group NN N
: : N
0.28 CD N
mmol/l NN N
in IN N
group NN N
1 CD N
, , N
P= NNP N
0.28 CD N
; : N
0.48 CD N
mmol/l NN N
in IN N
group NN N
2 CD N
, , N
P= NNP N
0.0008 CD N
; : N
0.36 CD N
mmol/l NN N
in IN N
group NN N
3 CD N
, , N
P= NNP N
0.02 CD N
) ) N
. . N

After IN N
5 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
largest JJS N
decrease NN N
in IN N
blood NN o
pressure NN o
was VBD N
observed VBN N
in IN N
group NN N
3 CD N
( ( N
the DT N
mean NN N
change NN N
from IN N
baseline NN N
in IN N
seated VBN o
diastolic JJ o
blood NN o
pressure NN o
( ( o
SDBP NNP o
) ) o
and CC N
seated VBN o
systolic JJ o
blood NN o
pressure NN o
( ( o
SSBP NNP o
) ) o
, , N
respectively RB N
, , N
were VBD N
: : N
-2.0 NN N
and CC N
-11.5 NNP N
mmHg NN N
in IN N
group NN N
1 CD N
; : N
-7.6 NNS N
and CC N
-15.4 NNP N
mmHg NN N
in IN N
group NN N
2 CD N
; : N
-12.6 NNS N
and CC N
-21.6 NNP N
mmHg NN N
in IN N
group NN N
3 CD N
) ) N
. . N

In IN N
addition NN N
, , N
both DT N
combination NN N
treatments NNS N
resulted VBD N
in IN N
the DT N
reduction NN N
of IN N
proteinuria NN o
. . o

The DT N
total JJ o
number NN o
of IN o
patients NNS o
with IN N
adverse JJ o
experiences NNS o
were VBD N
10 CD N
( ( N
45.5 CD N
% NN N
) ) N
, , N
14 CD N
( ( N
33.3 CD N
% NN N
) ) N
and CC N
11 CD N
( ( N
25 CD N
% NN N
) ) N
in IN N
groups NNS N
1,2 CD N
and CC N
3 CD N
, , N
respectively RB N
. . N

In IN N
six CD N
patients NNS N
( ( N
5.6 CD N
% NN N
) ) N
therapy NN N
was VBD N
discontinued VBN N
as IN N
a DT N
result NN N
of IN N
adverse JJ o
experiences NNS o
. . o

Only RB N
one CD N
patient NN N
in IN N
each DT N
of IN N
the DT N
combined JJ N
therapy NN N
groups NNS N
withdrew VBD N
from IN N
the DT N
study NN N
because IN N
of IN N
hyperkalaemia NN o
and CC N
no DT N
patients NNS N
were VBD N
forced VBN N
to TO N
withdraw VB N
because IN N
of IN N
an DT N
increase NN N
in IN N
serum JJ o
creatinine NN o
, , o
acute JJ o
renal JJ o
failure NN o
or CC o
hospitalization NN o
. . o

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
short-term JJ N
combination NN N
of IN N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
and CC N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
is VBZ N
safe JJ o
and CC N
well RB o
tolerated VBN o
in IN N
patients NNS p
with IN p
moderate JJ p
chronic JJ p
renal JJ p
failure NN p
. . p

-DOCSTART- -12585724- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
study NN N
of IN N
L-carnosine NNP i
supplementation NN i
in IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

L-Carnosine NNP i
, , i
a DT i
dipeptide NN i
, , N
can MD N
enhance VB N
frontal JJ N
lobe NN N
function NN N
or CC N
be VB N
neuroprotective JJ N
. . N

It PRP N
can MD N
also RB N
correlate VB N
with IN N
gamma-aminobutyric JJ N
acid NN N
( ( N
GABA NNP N
) ) N
-homocarnosine NN N
interaction NN N
, , N
with IN N
possible JJ N
anticonvulsive JJ N
effects NNS N
. . N

We PRP N
investigated VBD N
31 CD p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
in IN p
an DT p
8-week JJ p
, , p
double-blinded JJ p
study NN p
to TO N
determine VB N
if IN N
800 CD N
mg JJ N
L-carnosine JJ i
daily NN N
would MD N
result VB N
in IN N
observable JJ N
changes NNS N
versus VBP N
placebo NN i
. . i

Outcome CC N
measures NNS N
were VBD N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
, , o
the DT o
Gilliam NNP o
Autism NNP o
Rating NNP o
Scale NNP o
, , o
the DT o
Expressive NNP o
and CC o
Receptive NNP o
One-Word NNP o
Picture NNP o
Vocabulary NNP o
tests NNS o
, , o
and CC o
Clinical NNP o
Global NNP o
Impressions NNP o
of IN o
Change NNP o
. . o

Children NNP N
on IN N
placebo NN i
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
changes NNS N
. . N

After IN N
8 CD N
weeks NNS N
on IN N
L-carnosine NNP i
, , N
children NNS N
showed VBD N
statistically RB N
significant JJ N
improvements NNS N
on IN N
the DT N
Gilliam NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
total JJ o
score NN o
and CC o
the DT o
Behavior NNP o
, , o
Socialization NNP o
, , o
and CC o
Communication NNP o
subscales NNS o
) ) o
and CC o
the DT o
Receptive JJ o
One-Word NNP o
Picture NNP o
Vocabulary NNP o
test NN o
( ( N
all DT N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Improved VBN N
trends NNS N
were VBD N
noted VBN N
on IN N
other JJ N
outcome JJ N
measures NNS N
. . N

Although IN N
the DT N
mechanism NN N
of IN N
action NN N
of IN N
L-carnosine NNP i
is VBZ N
not RB N
well RB N
understood RB N
, , N
it PRP N
may MD N
enhance VB N
neurologic JJ N
function NN N
, , N
perhaps RB N
in IN N
the DT N
enterorhinal JJ N
or CC N
temporal JJ N
cortex NN N
. . N

-DOCSTART- -24897394- O O

The DT N
effect NN N
of IN N
the DT N
use NN N
of IN N
oxytocin NN i
on IN N
blood NN o
loss NN o
during IN o
different JJ o
postpartum NN o
periods NNS o
. . o

OBJECTIVE NNP N
Postpartum NNP p
hemorrhage NN p
is VBZ N
the DT N
most RBS N
important JJ N
reason NN N
for IN N
maternal JJ N
mortality NN N
. . N

In IN N
developed JJ N
countries NNS N
, , N
the DT N
reason NN N
of IN N
13 CD N
% NN N
of IN N
maternal JJ N
deaths NNS N
is VBZ N
postpartum JJ N
hemorrhage NN N
while IN N
this DT N
percentage NN N
reaches VBZ N
more JJR N
than IN N
30 CD N
% NN N
in IN N
other JJ N
countries NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
effect NN N
of IN N
oxytocin NN i
use NN N
in IN N
different JJ N
times NNS N
at IN N
the DT N
3rd CD N
stage NN N
of IN N
delivery NN N
on IN N
changes NNS N
in IN N
the DT N
postpartum NN o
hemoglobin NN o
levels NNS o
was VBD N
compared VBN N
. . N

DESIGN NNP N
AND CC N
SETTING NNP N
In IN N
the DT N
study NN N
, , N
89 CD p
pregnant JJ p
women NNS p
to TO p
whom WP p
oxytocin NN i
was VBD i
administered VBN i
after IN i
placenta JJ i
separation NN i
were VBD p
studied VBN p
in IN p
Group NNP p
1 CD p
, , p
89 CD p
pregnant JJ p
women NNS p
were VBD p
included VBN p
in IN p
Group NNP p
2 CD p
, , p
and CC p
oxytocin NN i
was VBD i
administered VBN i
after IN i
delivery NN i
of IN i
the DT i
shoulder NN i
. . i

The DT N
levels NNS o
of IN o
hemoglobin NN o
and CC o
hematocrit NN o
before IN N
and CC N
after IN N
delivery NN N
were VBD N
quantified VBN N
. . N

RESULTS VB N
The DT N
biochemical JJ N
parameters NNS N
were VBD N
examined VBN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
differences NNS N
in IN N
the DT N
levels NNS o
of IN o
hemoglobin NN o
and CC o
hemotocrit NN o
before IN N
delivery NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

When WRB N
compared VBN N
to TO N
Group NNP N
1 CD N
, , N
?-hemoglobin JJ N
( ( N
P= NNP N
> NNP N
0.001 CD N
) ) N
, , N
?-hematocrit JJ N
( ( N
P= NNP N
> NNP N
0.001 CD N
) ) N
, , N
the DT N
change NN N
between IN N
the DT o
prepartum NN o
and CC o
postpartum NN o
hemoglobin NN o
percentage NN o
( ( o
P NNP N
< NNP N
=0.001 NNP N
) ) N
, , N
and CC N
change NN N
between IN N
the DT o
prepartum NN o
and CC o
postpartum NN o
hemotocrit NN o
percentage NN o
( ( o
P NNP N
< NNP N
=0.001 NNP N
) ) N
were VBD N
statistically RB N
lower JJR N
in IN N
Group NNP N
2 CD N
. . N

CONCLUSIONS VB N
It PRP N
was VBD N
determined VBN N
that IN N
the DT N
use NN N
of IN N
oxytocin NN i
after IN i
shoulder NN N
delivery NN N
has VBZ N
more JJR N
effects NNS N
on IN N
decreasing VBG N
the DT N
amount NN N
of IN N
postpartum NN o
hemorrhage NN o
. . o

-DOCSTART- -11213870- O O

Beneficial JJ N
effects NNS N
of IN N
a DT N
soy-based JJ i
dietary JJ i
supplement NN i
on IN N
lipid JJ o
levels NNS o
and CC o
cardiovascular JJ o
risk NN o
markers NNS o
in IN N
type NN p
2 CD p
diabetic JJ p
subjects NNS p
. . p

OBJECTIVE NNP N
Consumption NNP N
of IN N
soy NN N
protein NN N
has VBZ N
recently RB N
been VBN N
shown VBN N
to TO N
improve VB N
the DT N
blood NN o
lipid JJ o
levels NNS o
in IN N
nondiabetic JJ N
subjects NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
a DT N
dietary JJ N
supplement NN N
of IN N
soy NN i
protein NN i
, , i
isoflavones NNS i
, , i
and CC i
cotyledon VB i
fiber NN i
( ( i
Abalon NNP i
) ) i
affects VBZ N
cardiovascular JJ o
risk NN o
markers NNS o
, , o
blood NN o
glucose NN o
, , o
and CC o
insulin NN o
levels NNS o
in IN N
type NN p
2 CD p
diabetic JJ p
subjects NNS p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Twenty NNP p
type NN p
2 CD p
diabetic JJ p
subjects NNS p
participated VBN p
in IN p
a DT p
crossover NN p
trial NN p
. . p

They PRP N
were VBD N
randomized VBN N
to TO N
double-blind JJ N
supplementation NN N
for IN N
6 CD i
weeks NNS i
with IN i
Abalon NNP i
( ( i
soy JJ i
protein NN i
[ VBD N
50 CD N
g/day JJ N
] NNP N
with IN N
high JJ N
levels NNS N
of IN N
isoflavones NNS i
[ NNP N
minimum VBD N
165 CD N
mg/day NN N
] NNP N
and CC N
cotyledon VB i
fiber NN i
[ $ N
20 CD N
g/day JJ N
] NNPS N
) ) N
or CC N
placebo NN i
( ( N
casein JJ N
[ VBZ N
50 CD N
g/day NN N
] NNP N
and CC N
cellulose VB N
[ JJ N
20 CD N
g/day JJ N
] NNP N
) ) N
, , N
separated VBN N
by IN N
a DT N
3-week JJ N
wash-out JJ N
period NN N
. . N

RESULTS VB N
The DT N
results NNS N
are VBP N
expressed VBN N
as IN N
means NNS N
+/- JJ N
SD NNP N
. . N

The DT N
percentage NN N
mean JJ N
treatment NN N
difference NN N
between IN N
Abalon NNP i
and CC N
placebo NN i
demonstrated VBD N
significantly RB N
lower JJR N
mean NN N
values NNS N
after IN N
Abalon NNP i
for IN N
LDL NNP o
cholesterol NN o
( ( N
10 CD N
+/- JJ N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
LDL/UHDL NNP o
ratio NN o
( ( N
12 CD N
+/- JJ N
18 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
apolipoprotein RB o
( ( N
apo NN N
) ) N
B100 NNP N
( ( N
30 CD N
+/- JJ N
38 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
triglycerides NNS o
( ( N
22 CD N
+/- JJ N
10 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
homocysteine NN o
( ( N
14 CD N
+/- JJ N
21 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas VBD N
the DT N
total JJ o
cholesterol NN o
value NN o
tended VBD N
to TO N
be VB N
less RBR N
significant JJ N
but CC N
still RB N
lower JJR N
( ( N
8 CD N
+/- JJ N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.08 CD N
) ) N
. . N

No UH N
change NN N
occurred VBD N
in IN N
HDL NNP o
cholesterol NN o
, , o
apo JJ o
B100/apo NNP o
A1 NNP o
ratio NN o
, , o
plasminogen NN o
activator NN o
inhibitor NN o
1 CD o
, , o
factor NN o
VIIc NNP o
, , o
von NNP o
Willebrand NNP o
factor NN o
, , o
fibrinogen NN o
, , o
lipoprotein NN o
( ( o
a DT o
) ) o
, , o
glucose JJ o
, , o
HbA1c NNP o
, , o
or CC o
24-h JJ o
blood NN o
pressure NN o
. . o

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
beneficial JJ N
effects NNS N
of IN N
dietary JJ N
supplementation NN N
with IN N
Abalon NNP i
on IN N
cardiovascular JJ o
risk NN o
markers NNS o
in IN N
type NN p
2 CD p
diabetic JJ p
subjects NNS p
. . p

This DT N
improvement NN N
is VBZ N
seen VBN N
even RB N
in IN N
individuals NNS N
with IN N
near-normal JJ N
lipid JJ N
values NNS N
. . N

-DOCSTART- -26054177- O O

Placebo-controlled JJ i
clinical JJ N
trial NN N
evaluating VBG N
9.5 CD N
% NN N
hydrogen NN i
peroxide IN i
high-adhesion NN i
whitening VBG i
strips NNS i
. . i

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
and CC N
tolerability NN N
of IN N
an DT N
experimental JJ N
9.5 CD N
% NN N
hydrogen NN i
peroxide IN i
whitening VBG i
strip JJ i
relative NN N
to TO N
a DT N
placebo NN i
control NN N
over IN N
a DT N
three-week JJ N
period NN N
. . N

METHODS NNP N
In IN N
this DT N
parallel-design JJ N
, , N
double-blind JJ p
clinical JJ p
trial NN p
, , p
54 CD p
adult NN p
volunteers NNS p
were VBD N
randomized VBN N
to TO N
an DT N
experimental JJ N
9.5 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strip NN i
or CC i
placebo NN i
strip NN i
balancing NN N
for IN N
age NN N
and CC N
baseline VB N
tooth DT N
color NN N
, , N
and CC N
received VBD N
treatment NN N
. . N

Strips NNS N
were VBD N
worn VBN N
on IN N
the DT N
maxillary JJ N
arch NN N
30 CD N
minutes NNS N
daily RB N
for IN N
20 CD N
days NNS N
. . N

Efficacy NN N
was VBD N
measured VBN N
objectively RB N
as IN N
L*a*b* NNP N
color NN N
change NN N
from IN N
digital JJ N
images NNS N
at IN N
Days NNP N
4 CD N
, , N
7 CD N
, , N
15 CD N
, , N
and CC N
21 CD N
. . N

RESULTS VB N
As RB N
early JJ N
as IN N
Day NNP N
4 CD N
and CC N
at IN N
all DT N
subsequent JJ N
visits NNS N
, , N
the DT N
9.5 CD N
% NN N
strip NN N
group NN N
experienced VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
color NN o
improvement NN o
relative NN N
to TO N
placebo VB N
for IN N
b* NN N
and CC N
L* NNP N
color NN N
parameters NNS N
. . N

The DT N
amount NN N
of IN N
color NN o
improvement NN o
increased VBD N
with IN N
continuing VBG N
peroxide JJ N
strip NN N
use NN N
. . N

Mean NNP o
? . o
SE NNP o
between-group NN N
differences NNS N
in IN N
Ab* NNP N
were VBD N
-0.6 VBN N
? . N
0.16 CD N
, , N
-0.8 NNP N
? . N
0.15 CD N
, , N
-1.6 NNP N
? . N
0.19 CD N
, , N
and CC N
-1.9 VB N
? . N
0.20 CD N
at IN N
Days NNP N
4 CD N
, , N
7 CD N
, , N
15 CD N
, , N
and CC N
21 CD N
, , N
respectively RB N
. . N

Similar JJ N
results NNS N
were VBD N
noted VBN N
for IN N
AL* NNP N
. . N

Minor NNP o
tooth DT o
sensitivity NN o
was VBD o
the DT N
most RBS N
common JJ N
adverse JJ N
event NN N
, , N
as IN N
reported VBN N
by IN N
12 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
9.5 CD N
% NN N
strip NN N
group NN N
and CC N
11 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

No DT N
subjects NNS N
discontinued VBN N
treatment NN N
due JJ N
to TO N
an DT N
adverse JJ N
event NN N
. . N

CONCLUSION VB N
This DT N
placebo-controlled JJ i
clinical JJ i
trial NN N
demonstrated VBD N
that IN N
an DT N
experimental JJ N
9.5 CD N
% NN N
hydrogen NN i
peroxide NN i
strip NN i
yielded VBN i
significant JJ N
tooth JJ N
whitening VBG N
relative JJ N
to TO N
a DT N
placebo NN N
strip NN N
as RB N
early RB N
as IN N
after IN N
three CD N
days NNS N
of IN N
product NN N
use NN N
. . N

-DOCSTART- -2275907- O O

Chloroprocaine NNP i
and CC i
lidocaine JJ i
decrease NN N
hospital NN N
stay NN N
and CC N
admission NN N
rate NN N
after IN N
outpatient JJ p
epidural JJ p
anesthesia NN p
. . p

Lumbar NNP i
epidural JJ i
anesthesia NN i
with IN i
20 CD i
ml NN i
of IN i
either DT i
3 CD i
% NN i
2-chloroprocaine JJ i
( ( i
C NNP i
) ) i
, , i
1.5 CD i
% NN i
lidocaine NN i
( ( i
L NNP i
) ) i
, , i
or CC i
1.5 CD i
% NN i
mepivacaine NN i
( ( i
M NNP i
) ) i
with IN i
epinephrine NN i
was VBD N
studied VBN N
in IN N
84 CD p
outpatients NNS p
undergoing JJ p
surgery NN p
( ( p
extracorporeal JJ p
shock NN p
wave NN p
lithotripsy NN p
( ( p
ESWL NNP p
] NNP p
. . p

The DT N
average JJ o
duration NN o
of IN o
the DT o
procedure NN o
was VBD N
31.9 CD N
minutes NNS N
. . N

The DT N
total JJ o
duration NN o
of IN o
sensory JJ o
anesthesia NN o
was VBD N
133 CD N
+/- JJ N
28 CD N
minutes NNS N
( ( N
C NNP N
) ) N
, , N
182 CD N
+/- JJ N
38 CD N
( ( N
L NNP N
) ) N
, , N
and CC N
247 CD N
+/- JJ N
42 CD N
( ( N
M NNP N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Times NNS o
to TO o
discharge VB o
were VBD N
269 CD N
+/- JJ N
62 CD N
minutes NNS N
( ( N
C NNP N
) ) N
, , N
284 CD N
+/- JJ N
62 CD N
( ( N
L NNP N
) ) N
, , N
and CC N
357 CD N
+/- JJ N
71 CD N
( ( N
M NNP N
) ) N
. . N

The DT N
time NN o
to TO o
discharge VB o
with IN N
M NNP N
, , N
almost RB N
six CD N
hours NNS N
, , N
was VBD N
significantly RB N
longer JJR N
than IN N
with IN N
C NNP N
or CC N
L. NNP N
There EX N
was VBD N
a DT N
trend NN N
to TO N
an DT N
increasing VBG N
rate NN N
of IN N
unplanned JJ o
overnight JJ o
hospital NN o
admission NN o
with IN N
increasing VBG N
duration NN N
of IN N
the DT N
local JJ N
anesthetic JJ N
drug NN N
employed VBN N
. . N

Continuous JJ N
epidural JJ N
anesthesia NN N
with IN N
C NNP N
, , N
L NNP N
or CC N
M NNP N
appears VBZ N
safe JJ N
and CC N
effective JJ N
for IN N
outpatient JJ N
surgical JJ N
procedures NNS N
such JJ N
as IN N
ESWL NNP N
. . N

In IN N
contrast NN N
to TO N
previous JJ N
understanding NN N
, , N
mepivacaine NN N
produces VBZ N
significantly RB N
longer JJR N
anesthesia NN N
and CC N
recovery NN N
times NNS N
and CC N
may MD N
not RB N
be VB N
optimal JJ N
for IN N
outpatient JJ N
epidural JJ N
use NN N
. . N

-DOCSTART- -8260242- O O

The DT N
effects NNS N
of IN N
a DT N
24-h JJ N
psychological JJ i
training NN i
program NN i
on IN N
attitudes NNS o
, , o
communication NN o
skills NNS o
and CC o
occupational JJ o
stress NN o
in IN N
oncology NN N
: : N
a DT N
randomised JJ N
study NN N
. . N

The DT N
usefulness NN N
of IN N
psychological JJ i
training NN i
programs NNS i
( ( i
P.T.P NNP i
. . i

) ) i
in IN N
health NN N
care NN N
settings NNS N
devoted VBN N
to TO N
cancer NN N
care NN N
is VBZ N
beginning VBG N
to TO N
be VB N
recognised VBN N
but CC N
their PRP$ N
content NN N
, , N
form NN N
and CC N
effectiveness VB N
need NN N
further JJ N
investigation NN N
. . N

Seventy-two JJ p
oncology NN p
nurses NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
24-h JJ i
P.T.P NNP i
. . i

or CC i
to TO i
a DT i
waiting VBG i
list NN i
period NN i
. . i

Attitudes NNS o
were VBD N
assessed VBN i
by IN i
a DT i
semantic JJ o
differential NN o
questionnaire NN o
, , o
occupational JJ o
stress NN o
was VBD i
assessed VBN i
by IN i
the DT o
Nursing NNP o
Stress NNP o
Scale NNP o
and CC i
communication NN o
skills NNS o
were VBD i
assessed VBN i
by IN i
standardised JJ o
videotaped VBD o
role-playing NN o
exercises NNS o
. . o

These DT N
were VBD N
used VBN N
to TO N
compare VB N
trained JJ N
( ( N
T.S NNP N
. . N

) ) N
and CC N
control NN N
subjects NNS N
( ( N
C.S. NNP N
) ) N
. . N

The DT N
results NNS N
show VBP N
a DT N
significant JJ N
training NN N
effect NN N
on IN N
attitudes NNS o
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
especially RB N
on IN N
those DT N
related VBN N
to TO N
self VB o
concept NN o
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
and CC N
on IN N
the DT N
level NN o
of IN o
occupational JJ o
stress NN o
related VBN N
to TO N
inadequate VB N
preparation NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Limited VBN N
changes NNS N
were VBD N
found VBN N
regarding VBG N
post-training JJ N
communication NN N
skills NNS N
. . N

T.S NNP N
. . N

were VBD N
significantly RB N
more RBR N
in IN N
control NN N
of IN N
the DT N
interview NN N
than IN N
C.S NNP N
. . N

( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
24-h JJ N
P.T.P NNP i
. . i

assessed VBN N
here RB N
are VBP N
effective JJ N
. . N

The DT N
data NN N
also RB N
demonstrate VBP N
the DT N
need NN N
to TO N
consolidate VB N
the DT N
skills NNS N
acquired VBN N
by IN N
regular JJ N
post-training JJ N
sessions NNS N
. . N

-DOCSTART- -21188521- O O

Differential JJ N
effects NNS N
of IN N
vitamin NN i
K1 NNP i
on IN N
AFP NNP N
and CC N
DCP NNP N
levels NNS N
in IN N
patients NNS p
with IN p
unresectable JJ p
HCC NNP p
and CC p
in IN p
HCC NNP p
cell NN p
lines NNS p
. . p

PURPOSE NNP N
DCP NNP N
is VBZ N
a DT N
useful JJ N
HCC NNP N
tumor NN N
marker NN N
, , N
which WDT N
reflects VBZ N
a DT N
defect NN N
in IN N
vitamin NN N
K NNP N
metabolism NN N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
vitamin VBZ i
K NNP i
treatment NN N
of IN N
HCC NNP p
patients NNS p
might MD N
suppress VB N
this DT N
marker NN N
and CC N
possibly RB N
AFP NNP N
also RB N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
HCC NNP p
patients NNS p
who WP p
had VBD p
both DT p
elevated VBN p
AFP NNP p
and CC p
DCP NNP p
were VBD p
included VBN p
. . p

A DT N
phase NN N
I PRP N
cohort VBP N
was VBD N
treated VBN N
with IN N
escalating VBG N
vitamin NN i
K1 NNP i
intravenous JJ N
weekly JJ N
doses NNS N
and CC N
a DT N
27-patient JJ p
phase NN p
II NNP p
cohort NN p
was VBD N
then RB N
treated VBN N
with IN N
a DT N
fixed JJ N
oral JJ N
daily RB N
dose RB N
. . N

RESULTS VB N
A DT N
maximum JJ o
tolerated JJ o
dose NN o
was VBD N
not RB N
reached VBN N
up RP N
to TO N
100-fold JJ N
the DT N
normal JJ N
vitamin NN i
K1 NNP i
dose NN N
. . N

No CC N
toxicities NNS o
were VBD N
found VBN N
up RB N
to TO N
1,000 CD N
mg/infusion NN N
. . N

In IN N
the DT N
phase NN N
II NNP N
cohort NN N
, , N
93 CD N
% NN N
of IN N
patients NNS N
had VBD N
tumor VBN o
marker NN o
responses NNS o
by IN N
decreased JJ N
DCP NNP o
levels NNS o
, , N
but CC N
only RB N
22 CD N
% NN N
had VBD N
responses NNS N
by IN N
decreased JJ N
AFP NNP o
levels NNS o
. . o

CT NNP N
scans VBZ N
showed VBD N
11 CD N
% NN N
of IN N
patients NNS N
had VBD N
PRs NNP o
, , N
59 CD N
% NN N
had VBD N
stable JJ o
tumors NNS o
and CC N
29.6 CD N
% NN N
had VBD N
tumor VBN o
progression NN o
. . o

Mechanism NNP N
studies NNS N
showed VBD N
that IN N
vitamin NN N
K1 NNP N
induced VBD N
phosphorylation NN o
of IN o
JNK NNP o
and CC o
c-Jun JJ o
and CC o
caspase-mediated JJ o
apoptosis NN o
. . o

CONCLUSIONS NNP N
Vitamin NNP i
K1 NNP i
was VBD N
non-toxic JJ N
at IN N
high JJ N
doses NNS N
, , N
strongly RB N
inhibited VBN N
plasma NN N
DCP NNP N
levels NNS N
, , N
but CC N
weakly RB N
suppressed VBD N
AFP NNP N
levels NNS N
. . N

The DT N
results NNS N
provide VBP N
evidence NN N
that IN N
the DT N
two CD N
tumor NN N
markers NNS N
are VBP N
not RB N
directly RB N
linked VBN N
and CC N
that IN N
DCP NNP N
levels NNS N
may MD N
not RB N
reflect VB N
HCC NNP N
cell NN N
growth NN N
, , N
as IN N
DCP NNP N
levels NNS N
were VBD N
decreased VBN N
in IN N
patients NNS N
without IN N
AFP NNP N
change NN N
, , N
and CC N
were VBD N
suppressed VBN N
in IN N
vitro NN N
at IN N
1 CD N
% NN N
of IN N
the DT N
vitamin NN N
K1 NNP N
concentration NN N
needed VBD N
to TO N
inhibit VB N
AFP NNP N
. . N

-DOCSTART- -3119086- O O

Effect NN N
of IN N
fenfluramine NN i
on IN N
autistic JJ p
symptoms NNS p
. . p

-DOCSTART- -1945967- O O

Efficacy NN o
of IN N
chlorhexidine NN i
gluconate NN i
use NN N
in IN N
the DT N
prevention NN N
of IN N
perirectal JJ N
infections NNS N
in IN N
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

The DT N
frequency NN N
of IN N
rectal JJ o
infections NNS o
is VBZ N
increased VBN N
in IN N
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

Complications NNS N
associated VBN N
with IN N
rectal JJ N
lesions NNS N
may MD N
be VB N
severe JJ N
enough RB N
to TO N
cause VB N
life-threatening JJ N
septicemia NN N
. . N

Clinical JJ N
research NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
preventive JJ N
perirectal NN N
skin NN N
care NN N
is VBZ N
scarce JJ N
. . N

This DT N
study NN N
's POS N
purpose NN N
was VBD N
to TO N
determine VB N
whether IN N
using VBG N
chlorhexidine JJ i
gluconate NN i
( ( i
CHG NNP i
) ) i
in IN N
a DT N
prophylactic JJ N
perirectal JJ N
skin-care JJ N
regimen NNS N
decreases VBZ N
perirectal JJ N
infections NNS N
and CC N
whether IN N
it PRP N
produces VBZ N
more JJR N
skin JJ N
irritation NN N
than IN N
a DT N
nonmedicated JJ N
skin NN N
cleanser NN N
. . N

The DT N
sample NN p
consisted VBD p
of IN p
40 CD p
patients NNS p
, , N
16 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
use VB N
chlorhexidine NN i
and CC N
24 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
use VB N
nonmedicated JJ i
skin NN i
cleanser NN i
. . i

Chi-square JJ N
and CC N
t-tests NNS N
were VBD N
used VBN N
to TO N
analyze VB N
the DT N
incidence NN N
of IN N
skin JJ o
breakdown NN o
and CC N
rectal JJ o
infections NNS o
; : o
the DT N
correlation NN N
between IN N
the DT N
two CD N
factors NNS N
; : N
a DT N
positive JJ N
history NN N
of IN N
rectal JJ N
infections NNS N
, , N
fissures NNS N
, , N
or CC N
hemorrhoids NNS N
; : N
presence NN N
of IN N
hemorrhoids NNS N
; : N
severity NN N
of IN N
diarrhea NN N
; : N
and CC N
duration NN N
and CC N
severity NN N
of IN N
granulocytopenia NN N
. . N

A DT N
positive JJ N
relationship NN N
was VBD N
found VBN N
between IN N
the DT N
severity NN o
of IN o
granulocytopenia NN o
and CC N
the DT N
incidence NN o
of IN o
rectal JJ o
infections NNS o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
in IN N
the DT N
occurrence NN o
of IN o
perirectal JJ o
infections NNS o
( ( N
p JJ N
= NNP N
0.35 CD N
) ) N
or CC N
skin JJ o
breakdown NN o
( ( N
p JJ N
= NNP N
0.18 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
data NN N
suggest NN N
that IN N
CHG NNP N
does VBZ N
not RB N
offer VB N
increased JJ N
protection NN N
against IN N
perirectal JJ N
infections NNS N
in IN N
patients NNS N
undergoing VBG N
intensive JJ N
chemotherapy NN N
, , N
nor CC N
is VBZ N
it PRP N
more RBR N
irritating JJ N
than IN N
a DT N
nonmedicated JJ N
skin NN N
cleanser NN N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
hygienic JJ N
measures NNS N
such JJ N
as IN N
using VBG N
skin JJ N
disinfectants NNS N
to TO N
prevent VB N
infections NNS N
in IN N
patients NNS N
who WP N
are VBP N
immunocompromised VBN N
. . N

-DOCSTART- -18972730- O O

[ JJ N
Effects NNS N
of IN N
small JJ i
needle-knife JJ i
comprehensive JJ i
therapy NN i
on IN N
pain NN N
and CC N
lumbar NN N
flexion NN N
range NN N
in IN N
the DT N
chronic JJ p
nonspecific NN p
low JJ p
back RB p
pain NN p
patient NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
therapeutic JJ N
effect NN N
of IN N
small JJ i
needle-knife JJ i
comprehensive JJ i
therapy NN i
on IN N
pain NN o
and CC o
lumbar NN o
flexion NN o
range NN o
in IN N
the DT N
chronic JJ p
nonspecific NN p
low JJ p
back RB p
pain NN p
patient NN p
. . p

METHODS NNP N
Three CD p
hundred VBD p
and CC p
five CD p
cases NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
needle-knife JJ i
group NN i
of IN N
153 CD N
cases NNS N
and CC N
a DT N
physiotherapy NN i
group NN i
of IN N
152 CD N
cases NNS N
. . N

The DT N
needle-knife JJ i
group NN N
were VBD N
treated VBN N
with IN N
small JJ i
needle-knife JJ i
releasing NN i
therapy NN i
, , i
blocking VBG i
and CC i
functional JJ i
training NN i
. . i

The DT N
physiotherapy NN i
group NN N
were VBD N
treated VBN N
with IN N
ultra-short JJ i
wave NN i
, , i
modulated VBD i
medium NN i
frequency NN i
current JJ i
, , i
massage NN i
and CC i
functional JJ i
training NN i
. . i

Pain NN o
was VBD N
assessed VBN N
by IN N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
and CC o
the DT o
lumbar NN o
flexion NN o
range NN o
was VBD N
determined VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
pain NN o
and CC o
the DT o
lumbar NN o
flexion NN o
range NN o
were VBD N
significantly RB N
improved VBN N
in IN N
the DT N
two CD N
groups NNS N
; : N
and CC N
after IN N
treatment NN N
, , N
the DT N
VAS NNP o
score NN o
and CC o
the DT o
lumbar NN o
flexion NN o
range NN o
were VBD N
( ( N
1.60 CD N
+/- JJ N
0.38 CD N
) ) N
points NNS N
and CC N
( ( N
65.76 CD N
+/- JJ N
15.11 CD N
) ) N
cm NN N
in IN N
the DT N
needle-knife JJ i
group NN N
and CC N
( ( N
4.59 CD N
+/- JJ N
1.09 CD N
) ) N
points NNS N
and CC N
( ( N
53.74 CD N
+/- JJ N
15.13 CD N
) ) N
cm NN N
in IN N
the DT N
physiotherapy NN N
group NN N
, , N
respectively RB N
, , N
the DT N
needle-knife JJ i
group NN N
being VBG N
significantly RB N
better JJR N
than IN N
the DT N
physiotherapy NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Follow-up NNP N
survey NN N
of IN N
6-36 JJ N
months NNS N
showed VBD N
that IN N
the DT N
VAS NNP o
score NN o
and CC o
the DT o
lumbar NN o
flexion NN o
range NN o
in IN N
the DT N
needle-knife JJ i
group NN N
were VBD N
superior JJ N
to TO N
those DT N
in IN N
the DT N
physiotherapy NN i
group NN N
. . N

CONCLUSION NNP N
Small NNP i
needle-knife JJ i
comprehensive JJ i
therapy NN i
can MD N
significantly RB N
improve VB N
pain NN o
and CC o
lumbar NN o
flexion NN o
range NN o
in IN N
the DT N
chronic JJ p
nonspecific NN p
low JJ p
back RB p
pain NN p
patient NN p
, , N
with IN N
a DT N
stable JJ N
long-term JJ N
therapeutic JJ N
effect NN N
. . N

-DOCSTART- -3073441- O O

[ NN N
Controlled VBD N
study NN N
of IN N
the DT N
quinidine-amiodarone JJ i
combination NN i
in IN N
the DT N
reversal NN o
of IN o
auricular JJ o
fibrillation NN o
] NN o
. . N

-DOCSTART- -23995030- O O

Incremental JJ N
cost-effectiveness NN o
of IN N
pharmacotherapy NN i
and CC N
two CD N
brief JJ N
cognitive-behavioral JJ i
therapies NNS i
compared VBN N
with IN N
usual JJ N
care NN N
for IN N
panic JJ o
disorder NN o
and CC p
noncardiac JJ p
chest NN p
pain NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incremental JJ N
cost-effectiveness JJ o
ratios NNS o
( ( N
ICERs NNP N
) ) N
of IN N
two CD N
brief JJ N
cognitive-behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
-based VBD i
interventions NNS i
and CC N
a DT N
pharmacological JJ i
treatment NN i
, , N
compared VBN N
with IN N
usual JJ i
care NN i
, , N
initiated VBN N
in IN N
the DT N
emergency NN N
department NN N
( ( N
ED NNP N
) ) N
for IN N
individuals NNS p
with IN p
panic JJ o
disorder NN o
( ( p
PD NNP p
) ) p
with IN p
a DT p
chief JJ p
complaint NN p
of IN p
noncardiac JJ p
chest NN p
pain NN p
. . p

A DT N
total NN N
of IN N
69 CD p
patients NNS p
were VBD N
followed VBN N
up IN N
to TO N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome NN N
variables NNS N
were VBD N
direct JJ o
and CC o
indirect JJ o
costs NNS o
of IN o
treatment NN o
and CC o
PD NNP o
severity NN o
. . o

Panic JJ N
management NN N
( ( N
PM NNP N
) ) N
had VBD N
an DT N
ICER NNP o
of IN N
$ $ N
124.05 CD N
, , N
per IN N
the DT N
Anxiety NN N
Disorders NNP N
Interview NNP N
Schedule NNP N
for IN N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
severity NN N
score NN N
change NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
$ $ N
54.63- JJ N
$ $ N
314.57 CD N
) ) N
, , N
compared VBN N
with IN N
pharmacotherapy NN N
( ( N
paroxetine NN N
) ) N
, , N
with IN N
an DT N
ICER NNP o
of IN N
$ $ N
213.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
133.51- JJ N
$ $ N
394.94 CD N
) ) N
, , N
and CC N
brief JJ N
CBT NNP N
, , N
with IN N
an DT N
ICER NNP o
of IN N
$ $ N
309.31 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
151.27- JJ N
$ $ N
548.28 CD N
) ) N
. . N

The DT N
pharmacological JJ N
and CC N
CBT JJ N
interventions NNS N
were VBD N
associated VBN N
with IN N
a DT N
greater JJR N
clinical JJ o
improvement NN o
compared VBN N
with IN N
usual JJ N
care NN N
at IN N
posttest NN N
. . N

PM NNP N
presented VBD N
a DT N
superior JJ N
ICER NNP o
, , N
suggesting VBG N
that IN N
it PRP N
may MD N
be VB N
a DT N
promising JJ N
treatment NN N
option NN N
to TO N
implement VB N
in IN N
EDs NNP N
. . N

-DOCSTART- -9293648- O O

Intravenous JJ N
pretreatment NN N
of IN N
hypertonic JJ i
saline NN i
can MD N
prevent VB N
systemic JJ o
hypotension NN o
induced VBN N
by IN N
spinal JJ N
anesthesia NN N
. . N

BACKGROUND NNP N
Hypertonic NNP N
saline NN N
improves VBZ N
organ JJ o
perfusion NN o
and CC N
patient JJ o
survival NN o
during IN N
hemorrhagic NN N
shock NN N
because IN N
it PRP N
expands VBZ N
plasma JJ N
volume NN N
and CC N
increases VBZ N
tissue NN N
oxygenation NN N
. . N

Its PRP$ N
beneficial JJ N
results NNS N
have VBP N
been VBN N
reported VBN N
in IN N
patients NNS N
suffering VBG N
from IN N
hypotension NN N
during IN N
spinal JJ N
anesthesia NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
influence NN N
between IN N
prehydration NN N
with IN N
3 CD N
% NN N
hypertonic JJ i
saline NN i
and CC i
with IN i
isotonic JJ i
lactated VBN i
Ringer NNP i
's POS i
solution NN i
on IN N
the DT N
hemodynamic JJ N
changes NNS N
and CC N
serum NN N
electrolyte NN N
concentrations NNS N
in IN N
patients NNS p
undergoing JJ p
spinal JJ p
anesthesia NN p
. . p

METHODS NNP N
Sixty NNP p
ASA NNP p
class NN p
I PRP p
patients NNS p
scheduled VBN p
for IN p
herniorrhapy NN i
under IN p
spinal JJ p
anesthesia NN p
were VBD N
assigned VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

Group NNP p
1 CD p
= NN p
patients NNS p
were VBD N
prehydrated VBN i
with IN i
isotonic JJ i
lactated VBN i
Ringer NNP i
's POS i
solution NN i
at IN i
7 CD i
mg/kg NN i
( ( N
n JJ N
= NNP N
30 CD N
) ) N
; : N
Group NNP p
2 CD p
= NN p
patients NNS p
were VBD N
given VBN N
prehydration NN i
with IN i
3 CD i
% NN i
hypertonic JJ i
saline NN i
at IN i
7 CD i
ml/kg NN i
( ( N
n JJ N
= NNP N
30 CD N
) ) N
. . N

Following VBG N
prehydration NN N
, , N
arterial JJ o
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
were VBD N
recorded VBN N
and CC N
serum JJ o
electrolyte NN o
concentrations NNS o
were VBD N
measured VBN N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
hypotension NN o
was VBD N
17/30 CD N
( ( N
57 CD N
% NN N
) ) N
in IN N
the DT N
isotonic JJ N
lactated VBD N
Ringer NNP N
's POS N
solution NN N
group NN N
as IN N
against IN N
7/30 CD N
( ( N
23 CD N
% NN N
) ) N
in IN N
the DT N
hypertonic JJ N
saline NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ o
difference NN o
between IN N
two CD N
groups NNS N
in IN N
relation NN N
to TO N
the DT N
level NN o
of IN o
anesthesia NN o
or CC o
maximal JJ o
heart NN o
rate NN o
, , o
and CC o
electrolyte JJ o
imbalance NN o
did VBD N
not RB N
occur VB N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
Prior NNP N
to TO N
spinal VB N
anesthesia NN N
, , N
hydration NN N
with IN N
small JJ N
amount NN N
of IN N
hypertonic JJ i
saline NN i
is VBZ N
effective JJ N
to TO N
minimize VB N
hypotension NN N
associated VBN N
with IN N
spinal JJ N
anesthesia NN N
. . N

If IN N
so RB N
administered VBN N
it PRP N
would MD N
not RB N
increase VB N
bodily RB N
sodium JJ N
load NN N
and CC N
unlike IN N
isotonic JJ N
crystalloid NN N
solution NN N
it PRP N
dose VBD N
not RB N
cause JJ N
accumulation NN N
of IN N
water NN N
in IN N
the DT N
body NN N
on IN N
equipollent JJ N
basis NN N
. . N

-DOCSTART- -653534- O O

Failure NN N
of IN N
pyridoxine NN N
to TO N
suppress VB N
raised VBN o
serum NN o
prolactin NN o
levels NNS o
. . o

Pyridoxine NNP N
has VBZ N
been VBN N
reported VBN N
as IN N
having VBG N
an DT N
antilactogenic JJ N
effect NN N
, , N
presumably RB N
by IN N
suppressing VBG N
prolactin JJ o
secretion NN o
. . o

We PRP N
have VBP N
measured VBN N
serum JJ o
prolactin NN o
levels NNS o
during IN N
pyridoxine JJ i
administration NN i
in IN N
two CD p
groups NNS p
of IN p
hyperprolactinaemic JJ i
subjects NNS i
. . i

In IN N
normal JJ p
postpartum JJ p
women NNS p
, , N
the DT N
postdelivery NN N
fall NN N
in IN N
serum NN o
prolactin NN o
levels NNS o
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
treated JJ N
and CC N
control JJ N
subjects NNS N
. . N

In IN N
patients NNS p
with IN p
chlorpromazine-induced JJ p
hyperprolactinaemia NN p
and CC p
galactorrhoea NN p
, , N
pyridoxine NN N
did VBD N
not RB N
reduce VB N
the DT N
elevated JJ N
levels NNS N
. . N

In IN p
neither DT p
group NN p
was VBD p
milk VBN o
production NN o
suppressed VBN p
. . p

-DOCSTART- -1525112- O O

The DT N
implications NNS o
of IN N
introducing VBG N
the DT N
symphyseal-fundal JJ i
height-measurement NN i
. . i

A DT N
prospective JJ p
randomized NN N
controlled VBD N
trial NN N
. . N

-DOCSTART- -23108780- O O

Effects NNS N
of IN N
strontium NN i
on IN N
the DT N
quality NN o
of IN o
bone NN o
apatite JJ o
crystals NNS o
: : o
a DT N
paired JJ N
biopsy NN N
study NN N
in IN N
postmenopausal JJ p
osteoporotic JJ p
women NNS p
. . p

UNLABELLED NN N
In IN N
paired JJ p
biopsies NNS p
of IN p
osteoporotic JJ p
women NNS p
treated VBN p
with IN p
either DT p
strontium NN i
ranelate NN i
or CC p
a DT p
placebo NN i
for IN p
36 CD p
months NNS p
, , N
characteristics NNS N
of IN N
bone NN N
apatite JJ N
crystals NNS N
were VBD N
not RB N
influenced VBN N
by IN N
the DT N
presence NN N
of IN N
strontium NN i
. . i

The DT N
mean JJ o
rate NN o
of IN o
substitutions NNS o
of IN N
calcium NN N
by IN N
strontium NN N
ions NNS N
was VBD N
4.5 CD N
% NN N
. . N

INTRODUCTION NNP N
The DT N
potential JJ N
effect NN N
of IN N
strontium NN i
( ( N
Sr NNP N
) ) N
on IN N
bone NN N
apatite JJ N
crystals NNS N
was VBD N
investigated VBN N
in IN N
paired JJ p
biopsies NNS p
of IN p
osteoporotic JJ p
women NNS p
treated VBN p
with IN p
either DT p
strontium NN i
ranelate NN i
( ( i
SrRan NNP i
) ) i
or CC p
a DT p
placebo NN i
for IN p
36 CD p
months NNS p
. . p

METHODS NNP N
In IN N
ten NN p
paired JJ p
biopsies NNS p
, , N
crystallinity NN o
, , o
apparent JJ o
length NN o
and CC o
width/thickness NN o
of IN o
crystals NNS o
, , o
interplanar NN o
distances NNS o
, , o
and CC o
lattice JJ o
parameters NNS o
of IN o
unit NN o
cells NNS o
were VBD N
assessed VBN N
by IN N
X-ray JJ N
diffraction NN N
and CC N
selected VBN N
area NN N
electron NN N
diffraction NN N
. . N

RESULTS VB N
All PDT N
these DT N
parameters NNS N
, , N
reflecting VBG N
crystal NN N
and CC N
unit NN N
cell NN N
characteristics NNS N
, , N
were VBD N
not RB o
influenced VBN o
by IN N
the DT N
presence NN o
of IN o
Sr NNP o
and CC N
were VBD N
similar JJ o
in IN N
SrRan NNP i
and CC N
placebo NN i
groups NNS N
after IN N
36 CD N
months NNS N
of IN N
treatment NN N
. . N

The DT N
mean JJ o
rate NN o
of IN o
substitutions NNS o
of IN o
calcium NN o
by IN o
Sr NNP o
ions NNS o
was VBD N
4.5 CD N
% NN N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
the DT N
quality NN o
of IN o
bone NN o
apatite JJ o
crystals NNS o
was VBD N
maintained VBN N
after IN N
36 CD N
months NNS N
of IN N
treatment NN N
with IN N
SrRan NNP i
. . i

-DOCSTART- -11860915- O O

[ JJ o
Efficacy NNP o
and CC o
immune JJ o
memory NN o
of IN N
plasma-derived JJ i
hepatitis NN i
B NNP i
vaccine NN i
11 CD p
years NNS p
after IN p
primary JJ p
immunization NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
long-term JJ o
efficacy NN o
of IN N
hepatitis NN i
B NNP i
vaccine NN i
10 CD p
years NNS p
after IN p
primary JJ p
immunization NN p
to TO N
provide VB N
scientific JJ N
basis NN N
for IN N
the DT N
time NN N
of IN N
revaccination NN N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
strictly RB N
designed VBN N
with IN N
randomization NN N
, , N
double-blinding NN N
, , N
and CC N
placebo-controlled JJ i
method NN N
to TO N
observe VB N
the DT p
efficacy NN o
and CC o
immune JJ o
memory NN o
11 CD p
years NNS p
following VBG p
hepatitis NN i
B NNP i
vaccination NN i
. . i

RESULTS NNP N
Immunogenicity NNP o
and CC o
protective JJ o
rate NN o
of IN o
vaccine NN o
were VBD N
still RB N
kept VBN N
well RB N
11 CD N
years NNS N
after IN N
immunization NN N
with IN N
a DT N
protective JJ o
rate NN o
against IN N
HBV NNP N
infection NN o
of IN N
73.5 CD N
% NN N
. . N

But CC N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
HBV NNP o
infection NN o
rates NNS o
between IN N
vaccine NN p
group NN p
and CC p
placebo-controlled JJ p
group NN p
( ( N
7.89 CD N
% NN N
vs. FW N
13.25 CD N
% NN N
, , N
P NNP N
> NNP N
0.1 CD N
) ) N
nine CD N
to TO N
11 CD N
years NNS N
following VBG N
immunization NN N
. . N

There EX N
still RB N
existed VBD N
immune JJ o
memory NN o
11 CD N
years NNS N
after IN N
immunization NN N
, , N
but CC N
it PRP N
was VBD N
significantly RB N
weaker JJR N
than IN N
that DT N
within IN N
the DT N
first JJ N
10 CD N
years NNS N
after IN N
immunization NN N
. . N

CONCLUSION VB N
The DT N
efficacy NN o
of IN N
the DT N
vaccine NN o
had VBD N
begun VBN N
to TO N
drop VB N
11 CD N
years NNS N
after IN N
immunization NN N
, , N
which WDT N
should MD N
be VB N
followed VBN N
up RP N
further RBR N
to TO N
reach VB N
a DT N
clear JJ N
conclusion NN N
. . N

-DOCSTART- -18320520- O O

Bevacizumab-augmented JJ i
retinal JJ i
laser NN i
photocoagulation NN i
in IN N
proliferative JJ p
diabetic JJ p
retinopathy NN p
: : p
a DT N
randomized JJ N
double-masked JJ N
clinical JJ N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
additional JJ N
therapeutic JJ N
effect NN N
of IN N
single JJ N
intravitreal NN i
bevacizumab NN i
injection NN i
on IN N
standard JJ i
laser NN i
treatment NN i
in IN N
the DT N
management NN N
of IN N
proliferative JJ N
diabetic JJ N
retinopathy NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
, , N
fellow-eye JJ N
sham NN N
controlled VBD N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
80 CD p
eyes NNS p
of IN p
40 CD p
high-risk JJ p
characteristic JJ p
proliferative JJ p
diabetic JJ p
retinopathy NN p
type NN p
II NNP p
diabetics NNS p
. . p

All DT N
cases NNS N
received VBN N
standard JJ N
laser NN i
treatment NN i
according VBG N
to TO N
Early NNP N
Treatment NNP N
Diabetic NNP N
Retinopathy NNP N
Study NNP N
protocol NN N
. . N

Avastin-assigned JJ N
eyes NNS N
received VBD N
1.25 CD i
mg NNS i
intravitreal JJ i
bevacizumab NN i
( ( N
Genentech NNP N
Inc. NNP N
, , N
San NNP N
Francisco NNP N
, , N
CA NNP N
) ) N
on IN N
the DT N
first JJ N
session NN N
of IN N
their PRP$ N
laser NN N
treatments NNS N
. . N

Fluorescein NNP i
angiography NN i
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
weeks NNS N
6 CD N
and CC N
16 CD N
, , N
and CC N
proliferative JJ N
diabetic JJ N
retinopathy NN N
regression NN N
was VBD N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
. . N

RESULTS VB N
The DT p
median JJ p
age NN p
was VBD p
52 CD p
years NNS p
( ( p
range NN p
: : p
39-68 JJ p
) ) p
and CC p
30 CD p
% NN p
of IN p
the DT p
participants NNS p
were VBD p
male JJ p
. . p

All DT N
patients NNS N
were VBD N
followed VBN N
for IN N
16 CD N
weeks NNS N
. . N

A DT N
total NN N
of IN N
87.5 CD N
% NN N
of IN N
Avastin-injected JJ N
eyes NNS N
and CC N
25 CD N
% NN N
of IN N
sham NN N
group NN N
showed VBD N
complete JJ o
regression NN o
at IN N
week NN N
6 CD N
of IN N
follow-up NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

However RB N
, , N
at IN N
week NN N
16 CD N
, , N
PDR NNP o
recurred VBD N
in IN N
a DT N
sizable JJ N
number NN N
of IN N
the DT N
Avastin-treated JJ N
eyes NNS N
, , N
and CC N
the DT N
complete JJ o
regression NN o
rate NN o
in IN N
the DT N
two CD N
groups NNS N
became VBD N
identical JJ N
( ( N
25 CD N
% NN N
; : N
p=1.000 NN N
) ) N
; : N
partial JJ N
regression NN N
rates NNS N
were VBD N
70 CD N
% NN N
vs JJ N
65 CD N
% NN N
. . N

In IN N
the DT N
subgroup NN N
of IN N
Avastin-treated JJ i
eyes NNS N
, , N
multivariate NN N
analysis NN N
identified VBN N
hemoglobin JJ N
A1c NNP N
as IN N
the DT N
strongest JJS N
predictor NN N
of IN N
proliferative JJ o
diabetic JJ o
retinopathy NN o
recurrence NN o
( ( N
p=0.033 NN N
) ) N
. . N

CONCLUSIONS NNP N
Intravitreal NNP N
bevacizumab NN i
remarkably RB N
augmented VBD N
the DT N
short-term JJ N
response NN N
to TO N
scatter VB N
panretinal JJ N
laser NN N
photocoagulation NN N
in IN N
high-risk JJ N
characteristic JJ N
proliferative JJ N
diabetic JJ N
retinopathy NN N
but CC N
the DT N
effect NN N
was VBD N
short-lived JJ N
, , N
as IN N
many JJ N
of IN N
the DT N
eyes NNS N
showed VBD N
rapid JJ o
recurrence NN o
. . o

Alternative JJ N
dosing NN N
( ( N
multiple JJ N
and/or NN N
periodic JJ N
intravitreal NN N
Avastin NNP i
injections NNS N
) ) N
is VBZ N
recommended VBN N
for IN N
further JJ N
evaluation NN N
. . N

-DOCSTART- -8570775- O O

Low-dose JJ N
naltrexone NN i
effects NNS N
on IN N
plasma NN N
chemistries NNS N
and CC N
clinical JJ N
symptoms NNS N
in IN N
autism NN p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
effect NN N
of IN N
month-long JJ N
naltrexone NN i
( ( i
NTX NNP i
) ) i
treatment NN N
at IN N
a DT N
daily JJ i
oral JJ i
dose NN i
of IN i
0.5 CD i
mg/kg/day NN i
was VBD i
contrasted VBN i
with IN i
placebo NN i
( ( i
PLC NNP i
) ) i
in IN N
a DT N
double-blind NN N
study NN N
with IN N
conjoint NN N
clinical JJ N
and CC N
biochemical JJ N
evaluations NNS N
of IN N
therapeutic JJ N
effects NNS N
. . N

Modest NNP N
clinical JJ N
benefits NNS N
were VBD N
achieved VBN N
with IN N
both DT N
PLC NNP i
and CC N
NTX NNP i
, , N
with IN N
marginally RB N
better JJR N
overall JJ N
results NNS N
following VBG N
NTX NNP N
, , N
and CC N
degree NN N
of IN N
improvement NN N
appeared VBD N
to TO N
be VB N
related VBN N
to TO N
plasma VB N
chemical JJ N
profiles NNS N
. . N

Massively RB N
elevated JJ N
levels NNS N
of IN N
beta-endorphin NN o
were VBD N
observed VBN N
in IN N
all DT N
children NNS p
with IN N
assays NNS N
using VBG N
C-terminal JJ N
antibody NN N
but CC N
not RB N
with IN N
an DT N
N-terminal JJ N
antibody NN N
assay NN N
. . N

In IN N
addition NN N
, , N
70 CD N
% NN N
of IN N
the DT N
children NNS p
exhibited VBD N
abnormally RB N
low JJ N
levels NNS N
of IN N
adrenocorticotropic NN o
hormone NN o
, , N
and CC N
smaller JJR N
subsets NNS N
exhibited VBD N
elevated JJ N
norepinephrine NN o
( ( o
60 CD o
% NN o
) ) o
, , o
arginine-vasopressin JJ o
( ( o
50 CD o
% NN o
) ) o
, , o
and CC o
serotonin NN o
( ( N
20 CD N
% NN N
) ) N
. . N

The DT N
best JJS N
clinical JJ N
responders NNS N
exhibited VBD N
the DT N
clearest JJS N
normalization NN N
of IN N
the DT N
elevated JJ N
plasma NN o
chemistries NNS o
, , N
especially RB N
in IN N
C-terminal-beta-endorphin NNP N
and CC N
serotonin NN N
. . N

There EX N
was VBD N
some DT N
evidence NN N
of IN N
therapeutic JJ N
carry-over JJ N
effects NNS N
in IN N
both DT N
clinical JJ N
and CC N
biochemical JJ N
measures NNS N
in IN N
those DT N
children NNS p
who WP N
received VBD N
NTX NNP i
before IN N
PLC NNP i
. . i

The DT N
results NNS N
suggest VBP N
that IN N
NTX NNP i
only RB N
benefits NNS N
a DT N
subgroup NN N
of IN N
autistic JJ p
children NNS p
, , N
who WP N
may MD N
be VB N
identified VBN N
by IN N
the DT N
presence NN N
of IN N
certain JJ N
plasma JJ N
abnormalities NNS N
. . N

These DT N
results NNS N
suggest VBP N
a DT N
possible JJ N
linkage NN N
between IN N
abnormal JJ N
plasma NN N
chemistries NNS N
, , N
especially RB N
those DT N
related VBN N
to TO N
the DT N
pro-opiomelanocortin JJ N
system NN N
, , N
and CC N
autistic JJ N
symptoms NNS N
. . N

-DOCSTART- -6927657- O O

Extra JJ i
prompts NNS i
versus IN N
no DT i
extra JJ i
prompts NNS i
in IN N
self-care JJ N
training NN N
of IN N
autistic JJ p
children NNS p
and CC p
adolescents NNS p
. . p

A DT N
color-coded JJ i
extra JJ i
prompt JJ i
procedure NN i
was VBD i
compared VBN i
to TO i
a DT i
no DT i
extra JJ i
prompt JJ i
procedure NN i
in IN N
teaching VBG N
autistic JJ p
children NNS p
and CC p
adolescents VBZ p
how WRB N
to TO N
lace VB N
shoes NNS N
. . N

One CD N
randomly NN N
assigned VBN N
group NN N
of IN N
10 CD p
autistic JJ p
subjects NNS p
first RB N
learned VBD i
to TO i
lace VB i
shoes NNS i
whose WP$ i
laces NNS i
and CC i
eyelets NNS i
were VBD i
color-coded JJ i
red JJ i
and CC i
white JJ i
, , i
and CC i
then RB i
encountered VBD i
the DT i
no DT i
extra JJ i
prompt JJ i
condition NN i
in IN i
which WDT i
color NN i
codes NNS i
could MD i
no RB i
longer RB i
be VB i
depended VBN i
upon IN i
to TO i
solve VB i
the DT i
position NN i
discriminations NNS i
required VBN i
to TO i
lace VB i
properly RB i
. . i

In IN N
a DT N
counterbalanced JJ N
fashion NN N
, , N
the DT N
other JJ N
group NN N
of IN N
10 CD p
autistic JJ p
subjects NNS p
reached VBN N
criterion NN N
on IN N
the DT N
non-color-coded JJ N
, , N
naturalistic JJ N
shoe NN N
before IN N
experiencing VBG N
the DT N
extra JJ N
prompt JJ N
condition NN N
. . N

Analysis NN N
of IN N
variance NN N
and CC N
post-hoc JJ N
analyses NNS N
suggest VBP N
that IN N
subjects NNS N
who WP N
first RB N
learned VBN N
under IN N
the DT N
color-coded JJ N
, , N
extra JJ N
prompt JJ N
condition NN N
encountered VBD N
significant JJ N
difficulty NN N
in IN N
transferring VBG N
their PRP$ N
newly RB N
acquired VBN N
skill NN N
to TO N
the DT N
naturalistic JJ N
, , N
non-color-coded JJ N
condition NN N
, , N
whereas JJ N
subjects NNS N
who WP N
learned VBD N
initially RB N
without IN N
the DT N
extra JJ N
prompts NNS N
had VBD N
little JJ N
difficulty NN N
with IN N
the DT N
subsequent JJ N
color-coded JJ N
condition NN N
. . N

A DT N
follow-up JJ N
procedure NN N
requiring VBG N
all DT N
subjects NNS N
to TO N
choose VB N
between IN N
the DT N
color NN N
prompt NN N
and CC N
the DT N
position NN N
cue NN N
revealed VBD N
that IN N
11 CD N
of IN N
20 CD p
subjects NNS p
consistently RB N
chose VBD N
the DT N
color NN N
cue NN N
, , N
even RB N
though IN N
it PRP N
resulted VBD N
in IN N
improper JJ N
lacing NN N
. . N

It PRP N
is VBZ N
recommended VBN N
that IN N
clinicians NNS N
avoid VBP N
the DT N
use NN N
of IN N
highly RB N
salient JJ N
, , N
non-criterion-related JJ N
prompts NNS N
in IN N
teaching VBG N
certain JJ N
types NNS N
of IN N
adaptive JJ N
skills NNS N
to TO N
autistic JJ p
children NNS p
. . p

-DOCSTART- -26160997- O O

Transcranial NNP i
Magnetic NNP i
Stimulation NNP i
to TO N
Address NNP N
Mild NNP p
Cognitive NNP p
Impairment NNP p
in IN p
the DT p
Elderly JJ p
: : p
A DT N
Randomized NNP N
Controlled NNP N
Study NNP N
. . N

Transcranial NNP i
magnetic JJ i
stimulation NN i
( ( i
TMS NNP i
) ) i
is VBZ N
a DT N
noninvasive JJ N
brain NN N
stimulation NN N
technique NN N
with IN N
potential JJ N
to TO N
improve VB N
memory NN N
. . N

Mild NNP p
cognitive JJ p
impairment NN p
( ( p
MCI NNP p
) ) p
, , N
which WDT N
still RB N
lacks VBZ N
a DT N
specific JJ N
therapy NN N
, , N
is VBZ N
a DT N
clinical JJ N
syndrome NN N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
dementia NN N
. . N

This DT N
study NN N
aims VBZ N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
high-frequency NN i
repetitive JJ i
TMS NNP i
( ( i
HF NNP i
rTMS NN i
) ) i
on IN N
everyday JJ N
memory NN N
of IN N
the DT p
elderly JJ p
with IN p
MCI NNP p
. . p

We PRP N
conducted VBD N
a DT N
double-blinded JJ N
randomized JJ N
sham-controlled JJ N
trial NN N
using VBG N
rTMS NN i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
. . N

Thirty-four CD p
elderly JJ p
outpatients NNS p
meeting VBG p
Petersen NNP p
's POS p
MCI NNP p
criteria NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB i
10 CD i
sessions NNS i
of IN i
either DT i
active JJ i
TMS NNP i
or CC i
sham NN i
, , i
10 CD i
Hz NNP i
rTMS NN i
at IN i
110 CD i
% NN i
of IN i
motor NN i
threshold NN i
, , i
2,000 CD i
pulses NNS i
per IN i
session NN i
. . i

Neuropsychological JJ i
assessment NN i
at IN i
baseline NN i
, , i
after IN i
the DT i
last JJ i
session NN i
( ( i
10th CD i
) ) i
and CC i
at IN i
one-month JJ i
follow-up NN i
, , i
was VBD i
applied VBN i
. . i

ANOVA NNP N
on IN N
the DT N
primary JJ N
efficacy NN N
measure NN N
, , N
the DT o
Rivermead NNP o
Behavioural NNP o
Memory NNP o
Test NNP o
, , o
revealed VBD N
a DT N
significant JJ N
group-by-time JJ N
interaction NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
, , N
favoring VBG N
the DT N
active JJ N
group NN N
. . N

The DT N
improvement NN N
was VBD N
kept VBN N
after IN N
one CD N
month NN N
. . N

Other JJ N
neuropsychological JJ N
tests NNS N
were VBD o
heterogeneous JJ o
. . o

rTMS NN o
at IN o
10 CD o
Hz NNP o
enhanced VBD o
everyday JJ o
memory NN o
in IN o
elderly JJ p
with IN p
MCI NNP p
after IN N
10 CD N
sessions NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
rTMS NN i
might MD i
be VB N
effective JJ N
as IN N
a DT N
therapy NN N
for IN N
MCI NNP N
and CC N
probably RB N
a DT N
tool NN N
to TO N
delay VB N
deterioration NN N
. . N

-DOCSTART- -23045243- O O

Association NNP N
of IN N
severity NN N
of IN N
coexisting VBG N
patellofemoral JJ N
disease NN N
with IN N
increased JJ N
impairments NNS N
and CC N
functional JJ N
limitations NNS N
in IN N
patients NNS p
with IN p
knee JJ p
osteoarthritis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
association NN N
between IN N
severity NN N
of IN N
coexisting VBG N
patellofemoral JJ N
( ( N
PF NNP N
) ) N
disease NN N
with IN N
lower JJR N
extremity NN N
impairments NNS N
and CC N
functional JJ N
limitations NNS N
in IN N
patients NNS p
with IN p
tibiofemoral JJ p
( ( p
TF NNP p
) ) p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
. . p

METHODS NNP N
Radiographic NNP i
views NNS i
of IN i
the DT i
TF NNP i
and CC i
PF NNP i
compartments NNS i
, , i
knee VB i
extension NN i
strength NN i
, , i
and CC i
knee VB i
range NN i
of IN i
motion NN i
were VBD N
obtained VBN N
for IN N
167 CD p
patients NNS p
with IN p
knee JJ p
OA NNP p
. . p

Additionally RB N
, , N
knee-specific JJ o
symptoms NNS o
and CC N
functional JJ o
limitations NNS o
were VBD N
assessed VBN N
using VBG N
the DT N
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
and CC o
the DT o
Activities NNS o
of IN o
Daily NNP o
Living NNP o
Scale NNP o
( ( o
ADLS NNP o
) ) o
. . o

RESULTS NNP N
Moderate/severe NNP N
PFOA NNP N
was VBD N
associated VBN N
with IN N
lower JJR N
knee NN o
extension NN o
strength NN o
( ( N
mean VB N
? . N
SD NNP N
1.4 CD N
? . N
0.5 CD N
Nm/body NN N
weight VBD N
[ NNP N
BW NNP N
] NNP N
) ) N
compared VBN N
to TO N
no DT N
PFOA NNP N
( ( N
mean VB N
? . N
SD NNP N
1.8 CD N
? . N
0.5 CD N
Nm/BW NNP N
) ) N
. . N

Additionally RB o
, , o
total JJ o
knee NN o
range NN o
of IN o
motion NN o
was VBD o
significantly RB N
lower JJR N
for IN N
patients NNS N
with IN N
moderate/severe JJ N
PFOA NNP N
( ( N
mean VB N
? . N
SD NNP N
120.8? CD N
? . N
14.4? CD N
) ) N
compared VBN N
to TO N
no DT N
PFOA NNP N
( ( N
mean VB N
? . N
SD NNP N
133.5? CD N
? . N
10.7? CD N
) ) N
and CC N
mild JJ N
PFOA NNP N
( ( N
mean VB N
? . N
SD NNP N
125.8? CD N
? . N
13.0? CD N
) ) N
. . N

Moderate/severe NNP N
PFOA NNP N
and CC N
mild JJ N
PFOA NNP N
were VBD N
also RB N
associated VBN N
with IN N
less JJR o
pain NN o
while IN o
standing VBG o
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.2 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
0.1-0.7 JJ N
and CC N
OR NNP N
0.2 CD N
, , N
95 CD N
% NN N
CI NNP N
0.1-0.6 CD N
, , N
respectively RB N
) ) N
on IN N
the DT N
WOMAC NNP N
, , N
and CC N
moderate/severe RB N
PFOA NNP N
was VBD N
associated VBN N
with IN N
greater JJR o
difficulty NN o
with IN o
going VBG o
downstairs NNS o
( ( o
OR NNP o
2.9 CD N
, , N
95 CD N
% NN N
CI NNP N
1.0-8.1 CD N
) ) N
on IN N
the DT N
ADLS NNP N
. . N

CONCLUSION VB N
It PRP N
appears VBZ N
that IN N
knees NNS N
with IN N
more RBR N
severe JJ N
coexisting VBG N
PF NNP N
disease NN N
demonstrate NN N
features NNS N
distinct VBP N
from IN N
those DT N
observed VBN N
in IN N
TFOA NNP N
in IN N
isolation NN N
or CC N
in IN N
combination NN N
with IN N
mild JJ N
PF NNP N
disease NN N
. . N

Treatment NNP i
strategies VBZ i
targeting VBG i
the DT i
PF NNP i
joint NN i
may MD i
be VB N
warranted VBN N
to TO N
mitigate VB N
the DT N
specific JJ N
lower JJR N
extremity NN N
impairments NNS N
and CC N
functional JJ N
problems NNS N
present JJ N
in IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -24549163- O O

A DT N
randomised JJ N
double-blind NN N
control NN N
study NN N
of IN N
early JJ N
intracoronary JJ i
autologous JJ i
bone NN i
marrow NN i
cell NN i
infusion NN i
in IN N
acute JJ p
myocardial JJ p
infarction NN p
( ( N
REGENERATE-AMI NNP N
) ) N
. . N

INTRODUCTION NNP N
Acute NNP N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
remains VBZ N
a DT N
major JJ N
cause NN N
of IN N
mortality NN N
and CC N
morbidity NN N
worldwide VBP N
despite IN N
the DT N
latest JJS N
therapeutic JJ N
advances NNS N
designed VBN N
to TO N
decrease VB N
myocardial JJ N
injury NN N
. . N

Preclinical NNP N
and CC N
emerging VBG N
clinical JJ N
evidence NN N
show NN N
that IN N
the DT N
intracoronary JJ N
injection NN N
of IN N
autologous JJ i
bone NN i
marrow NN i
mononuclear JJ i
cells NNS i
( ( N
BMCs NNP N
) ) N
following VBG N
AMI NNP N
leads VBZ N
to TO N
improvement NN N
in IN N
left JJ N
ventricular JJ N
ejection NN N
function NN N
( ( N
LVEF NNP N
) ) N
. . N

In IN N
this DT N
clinical JJ N
trial NN N
we PRP N
will MD N
for IN N
the DT N
first JJ N
time NN N
assess VB N
the DT N
effect NN o
of IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
infusion NN N
of IN N
autologous JJ N
BMCs NNP N
following VBG N
AMI NNP N
on IN N
cardiac JJ N
function NN N
. . N

METHODS NNP N
AND CC N
ANALYSIS NNP N
REGENERATE-AMI NNP N
is VBZ N
a DT N
double-blind JJ N
, , N
randomised VBN N
, , N
multicentre FW p
, , N
placebo-controlled JJ i
trial NN N
to TO N
determine VB N
whether IN N
early JJ N
( ( N
< JJ N
24 CD N
h NN N
) ) N
intracoronary JJ N
infusion NN N
of IN N
BMCs NNP N
improves NNS N
LVEF NNP N
after IN N
AMI NNP N
. . N

The DT N
study NN N
will MD N
enrol VB p
100 CD p
patients NNS p
presenting VBG p
with IN p
an DT p
anterior JJ p
AMI NNP p
demonstrating VBG p
anterior JJ p
regional JJ p
wall NN p
motion NN p
abnormality NN p
. . p

Patients NNS N
will MD N
be VB N
randomised VBN N
to TO N
receive VB N
intracoronary JJ i
infusion NN i
of IN i
BMCs NNP i
or CC N
placebo NN i
( ( N
0.9 CD N
% NN N
saline NN i
) ) i
. . N

Primary JJ N
endpoint NN N
will MD N
be VB N
change NN o
in IN o
LVEF NNP o
at IN o
1 CD o
year NN o
compared VBN o
to TO o
baseline VB o
, , o
measured VBN o
by IN o
cardiac JJ o
MRI NNP o
. . o

Secondary JJ N
endpoints NNS N
at IN N
6 CD N
months NNS N
include VBP N
the DT N
change NN o
in IN o
global JJ o
LVEF NNP o
relative NN o
to TO o
baseline VB o
measured VBN o
by IN o
quantitative JJ o
left NN o
ventriculography NN o
and CC o
echocardiography NN o
, , o
as RB o
well RB o
as IN o
major JJ o
adverse JJ o
cardiac NN o
events NNS o
which WDT N
is VBZ N
also RB N
measured VBN N
at IN N
1 CD N
year NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
The DT N
study NN N
will MD N
be VB N
performed VBN N
in IN N
agreement NN N
with IN N
the DT N
Declaration NNP N
of IN N
Helsinki NNP N
and CC N
is VBZ N
approved VBN N
by IN N
local JJ N
ethics NNS N
committee NN N
( ( N
NRES NNP N
Committee NNP N
London NNP N
West NNP N
London NNP N
: : N
07/Q0603/76 CD N
) ) N
. . N

TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//clincialtrials.gov NN N
( ( N
NCT00765453 NNP N
) ) N
. . N

The DT N
results NNS N
of IN N
the DT N
trial NN N
will MD N
be VB N
published VBN N
according VBG N
to TO N
the DT N
CONSORT NNP N
statement NN N
and CC N
will MD N
be VB N
presented VBN N
at IN N
conferences NNS N
and CC N
reported VBD N
in IN N
peer-reviewed JJ N
journals NNS N
. . N

-DOCSTART- -10939601- O O

5-fluorouracil JJ i
plus CC i
folinic JJ i
acid NN i
with IN N
or CC N
without IN N
ifosfamide NN i
in IN N
advanced JJ o
colorectal JJ o
cancer NN o
: : o
a DT N
phase NN N
II NNP N
randomized VBD N
trial NN N
. . N

AIM VB N
This DT N
phase NN N
II NNP N
trial NN N
evaluated VBD N
the DT N
biomodulation NN N
of IN N
5-fluorouracil JJ o
( ( i
5-FU JJ i
) ) i
plus CC i
folinic JJ i
acid NN i
( ( i
FA NNP i
) ) i
with IN i
or CC i
without IN i
ifosfamide JJ i
( ( i
IFO NNP i
) ) i
in IN N
chemotherapy-naive JJ p
patients NNS p
with IN p
colorectal JJ p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty-eight NNP p
patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
: : N
FA NNP i
( ( N
25 CD N
mg/m2 NN N
iv NN N
bolus JJ N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
, , N
followed VBN N
by IN N
5-FU JJ i
( ( N
750 CD N
mg/m2 NN N
iv NN N
bolus JJ N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
, , N
arm VBZ N
A NNP N
; : N
or CC N
FA NNP i
( ( N
25 CD N
mg/m2 NN N
iv NN N
bolus JJ N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
, , N
followed VBN N
by IN N
5-FU JJ i
( ( N
750 CD N
mg/m2 NN N
iv NN N
bolus JJ N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
plus CC N
IFO NNP i
( ( N
2,000 CD N
mg/m2 NN N
in IN N
1000 CD N
mL JJ N
5 CD N
% NN N
dextrose NN N
in IN N
a DT N
2-hr JJ N
infusion NN N
, , N
days NNS N
1 CD N
to TO N
3 CD N
) ) N
, , N
arm JJ N
B. NNP N
Mesna NNP N
was VBD N
added VBN N
during IN N
and CC N
after IN N
IFO NNP N
to TO N
prevent VB N
hemorrhagic JJ N
cystitis NN N
. . N

Treatment NNP N
was VBD N
repeated VBN N
every DT N
21 CD N
days NNS N
in IN N
both DT N
arms NNS N
. . N

RESULTS JJ N
Forty-five JJ p
patients NNS p
were VBD p
assessable JJ p
for IN p
response NN p
: : p
in IN N
arm NN N
A NNP N
, , N
5 CD N
patients NNS N
achieved VBD N
a DT N
partial JJ o
response NN o
( ( N
overall JJ N
response NN N
, , N
25 CD N
% NN N
) ) N
, , N
and CC N
in IN N
arm NN N
B NNP N
, , N
2 CD N
patients NNS N
achieved VBD N
a DT N
complete JJ o
and CC N
1 CD N
a DT N
partial JJ o
response NN o
( ( N
overall JJ N
response NN N
, , N
12 CD N
% NN N
) ) N
. . N

Time NN o
to TO o
failure NN o
was VBD N
3.5 CD N
months NNS N
( ( N
range NN N
, , N
1-38 JJ N
) ) N
in IN N
patients NNS N
treated VBN N
with IN N
5-FU JJ N
plus CC N
FA NNP N
, , N
and CC N
3 CD N
months NNS N
( ( N
range NN N
, , N
1-21 JJ N
) ) N
in IN N
patients NNS N
treated VBN N
with IN N
the DT N
IFO NNP N
combination NN N
. . N

The DT N
median JJ o
survival NN o
time NN o
was VBD N
13.5 CD N
months NNS N
( ( N
range NN N
, , N
1-49 JJ N
months NNS N
) ) N
in IN N
arm NN N
A NN N
and CC N
16 CD N
months NNS N
( ( N
range NN N
, , N
1-43 JJ N
months NNS N
) ) N
in IN N
arm NN N
B NNP N
. . N

Diarrhea NNP o
, , o
stomatitis NN o
and CC o
vomiting NN o
were VBD N
the DT N
most RBS N
common JJ N
nonhematologic JJ o
toxicities NNS o
in IN N
both DT N
arms NNS N
. . N

The DT N
most RBS N
notable JJ N
hematologic JJ o
toxicity NN o
was VBD o
leukopenia VBN o
; : o
15 CD N
% NN N
and CC N
20 CD N
% NN N
of IN N
patients NNS N
experienced JJ N
grade VBD N
4 CD N
in IN N
arm NN N
A NN N
and CC N
arm NN N
B NNP N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
IFO NNP N
does VBZ N
not RB N
increase VB N
the DT N
activity NN N
of IN N
the DT N
5-FU JJ N
plus CC N
FA JJ N
combination NN N
in IN N
advanced JJ o
colorectal JJ o
cancer NN o
. . N

-DOCSTART- -7174605- O O

The DT N
effects NNS N
of IN N
haloperidol NN i
on IN N
learning NN o
and CC o
behavior NN o
in IN N
autistic JJ p
children NNS p
. . p

The DT N
effects NNS N
of IN N
haloperidol NN i
on IN N
behavioral JJ o
symptoms NNS o
and CC o
learning VBG o
were VBD N
critically RB N
assessed VBN N
in IN N
autistic JJ p
children NNS p
in IN N
an DT N
ongoing JJ N
double-blind JJ N
placebo-controlled JJ i
clinical JJ N
trial NN N
. . N

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
haloperidol-placebo-haloperidol JJ i
or CC i
placebo-haloperidol-placebo JJ i
treatment NN N
sequences NNS N
. . N

Statistically RB N
, , N
haloperidol NN i
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB i
in IN N
reducing VBG N
behavioral JJ o
symptoms NNS o
. . o

In IN N
discrimination NN N
learning NN N
paradigm NN N
, , N
children NNS N
receiving VBG N
haloperidol NN i
learned VBD o
the DT o
discrimination NN o
while IN N
those DT N
on IN N
placebo NNS i
did VBD N
not RB N
. . N

Discrimination NNP N
attained VBD N
on IN N
haloperidol NN i
was VBD N
retained VBN N
when WRB N
the DT N
children NNS N
were VBD N
switched VBN N
to TO N
placebo VB i
. . i

-DOCSTART- -23405947- O O

Association NNP N
between IN N
weight JJ o
loss NN o
and CC N
improvement NN o
of IN o
ventricular JJ o
systolic JJ o
function NN o
in IN N
advanced JJ p
heart NN p
failure NN p
. . p

In IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
, , N
longitudinal JJ N
changes NNS N
in IN N
ventricular JJ N
ejection NN N
fraction NN N
are VBP N
poorly RB N
studied VBN N
. . N

The DT N
authors NNS N
' POS N
objective NN N
was VBD N
to TO N
document VB N
the DT N
dynamic JJ N
changes NNS N
in IN N
systolic JJ N
function NN N
of IN N
both DT N
ventricles NNS N
during IN N
acute JJ N
HF NNP N
and CC N
after IN N
a DT N
3-month JJ N
follow-up JJ N
period NN N
, , N
and CC N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
ventricular JJ N
improvement NN N
. . N

A DT N
limited JJ N
access NN N
dataset NN N
from IN N
the DT N
Evaluation NNP N
Study NNP N
of IN N
Congestive NNP N
Heart NNP p
Failure NNP p
and CC N
Pulmonary NNP N
Artery NNP N
Catheterization NNP N
Effectiveness NNP N
( ( N
ESCAPE NNP N
) ) N
trial NN N
provided VBN N
by IN N
The DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
was VBD N
analyzed VBN N
. . N

In IN p
patients NNS p
admitted VBN p
to TO p
the DT p
hospital NN p
with IN p
acute JJ p
HF NNP p
, , p
both DT p
ventricles NNS i
were VBD i
evaluated VBN i
by IN i
echocardiography NN i
on IN p
admission NN p
, , p
at IN p
discharge NN p
, , p
and CC p
at IN p
3 CD p
months NNS p
. . p

From IN N
baseline NN N
to TO N
3 CD N
months NNS N
, , N
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
( ( o
LVEF NNP o
) ) o
increased VBD N
in IN N
43.4 CD N
% NN N
of IN N
patients NNS N
, , N
decreased VBN N
in IN N
23.9 CD N
% NN N
, , N
and CC N
remained VBD N
unchanged JJ N
in IN N
32.7 CD N
% NN N
. . N

Similarly RB N
, , N
right JJ o
ventricular NN o
systolic JJ o
function NN o
improved VBN N
in IN N
40.9 CD N
% NN N
, , N
deteriorated VBN N
in IN N
25.0 CD N
% NN N
, , N
and CC N
remained VBD N
stable JJ N
in IN N
34.1 CD N
% NN N
. . N

Weight NNP o
loss NN o
during IN o
index NN o
admission NN o
and CC o
cardiac JJ o
index/cardiac NN o
output NN o
increase NN N
were VBD N
the DT N
only JJ N
factors NNS N
associated VBN N
with IN N
LVEF NNP N
improvement NN N
from IN N
baseline NN N
to TO N
month NN N
3 CD N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
ischemic JJ N
and CC N
nonischemic JJ N
etiology NN N
. . N

In IN N
acute JJ N
HF NNP N
, , N
ischemic JJ o
or CC o
nonischemic JJ o
, , o
systolic JJ o
function NN o
of IN o
the DT o
ventricles NNS o
improved VBN N
during IN N
3 CD N
months NNS N
in IN N
about RB N
40 CD N
% NN N
of IN N
patients NNS N
and CC N
remained VBD N
unchanged JJ N
or CC N
deteriorated VBN N
in IN N
the DT N
rest NN N
. . N

Weight NNP o
loss NN o
and CC N
increase VB N
in IN N
cardiac JJ o
index/output NN o
during IN N
hospitalization NN N
was VBD N
associated VBN N
with IN N
improvement NN N
in IN N
LVEF NNP o
. . o

-DOCSTART- -19144729- O O

Effect NN N
of IN N
testosterone NN i
and CC i
a DT i
nutritional JJ i
supplement NN i
, , N
alone RB N
and CC N
in IN i
combination NN i
, , N
on IN N
hospital JJ o
admissions NNS o
in IN N
undernourished JJ p
older JJR p
men NNS p
and CC p
women NNS p
. . p

BACKGROUND NNP N
In IN p
older JJR p
people NNS p
, , N
undernutrition NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
hospitalization NN o
rates NNS o
and CC o
mortality NN o
. . o

Because IN N
weight JJ N
loss NN N
in IN N
older JJR N
people NNS N
often RB N
reflects VBZ N
a DT N
disproportionate JJ N
reduction NN N
of IN N
skeletal JJ N
muscle NN N
, , N
anabolic JJ N
treatments NNS N
may MD N
be VB N
beneficial JJ N
. . N

OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
hypothesis NN N
that WDT N
testosterone NN i
treatment NN i
and CC N
a DT N
nutritional JJ i
supplement NN i
have VBP N
additive JJ N
benefits NNS N
. . N

DESIGN NNP N
Oral NNP i
testosterone NN i
undecanoate NN i
( ( N
40 CD N
mg NNS N
daily RB N
for IN N
women NNS N
, , N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
men NNS N
) ) N
and CC i
an DT i
oral JJ i
nutritional JJ i
supplement NN i
( ( N
475 CD N
kcal/d NN N
) ) N
were VBD N
administered VBN N
, , N
alone RB i
or CC i
combined VBN i
, , N
for IN N
1 CD N
y NNS N
to TO N
49 CD p
community-dwelling NN p
, , p
undernourished JJ p
people NNS p
[ VBP p
Mini NNP p
Nutritional NNP p
Assessment NNP p
score VBD p
< JJ p
24 CD p
and CC p
low JJ p
body NN p
weight NN p
( ( p
body JJ p
mass NN p
index NN p
, , p
in IN p
kg/m NN p
( ( p
2 CD p
) ) p
: : p
< $ p
22 CD p
) ) p
or CC p
recent JJ p
weight JJ p
loss NN p
( ( p
> JJ p
7.5 CD p
% NN p
over IN p
3 CD p
mo NNS p
) ) p
] VBP p
aged VBN p
> $ p
65 CD p
y NN p
( ( p
mean JJ p
age NN p
: : p
77 CD p
y NN p
; : p
26 CD p
women NNS p
and CC p
23 CD p
men NNS p
) ) p
. . p

Hospital JJ o
admissions NNS o
and CC N
other JJ o
variables NNS o
were VBD N
assessed VBN N
. . N

RESULTS NNP N
In IN N
subjects NNS N
receiving VBG N
combined VBN i
testosterone NN i
and CC i
nutritional JJ i
supplements NNS i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
hospital NN o
admissions NNS o
, , N
whereas IN N
there EX N
were VBD N
9 CD N
admissions NNS N
( ( N
2 CD N
elective NN N
) ) N
in IN N
13 CD N
subjects NNS N
in IN N
the DT N
no-treatment JJ i
group NN N
, , N
4 CD N
in IN N
the DT N
testosterone-treated JJ i
group NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
and CC N
5 CD N
in IN N
the DT N
supplement-treated JJ i
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
; : N
P NNP N
= VBD N
0.06 CD N
with IN N
no-treatment JJ N
compared VBN N
with IN N
combined JJ N
treatment NN N
. . N

When WRB N
compared VBN N
with IN N
the DT N
no-treatment JJ i
group NN N
, , N
the DT N
combined-treatment JJ i
group NN N
had VBD N
significantly RB N
fewer JJR N
subjects NNS o
admitted VBN o
to TO o
hospital VB o
( ( N
0 CD N
compared VBN N
with IN N
5 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
fewer JJR N
days NNS o
in IN o
hospital NN o
( ( N
0 CD N
compared VBN N
with IN N
74 CD N
, , N
P NNP N
= NNP N
0.041 CD N
) ) N
, , N
and CC N
a DT N
longer JJR N
time NN N
to TO N
hospital VB N
admission NN N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
undernourished JJ p
older JJR p
people NNS p
, , N
combined VBN i
treatment NN i
with IN i
testosterone NN i
and CC i
nutritional JJ i
supplementation NN i
reduced VBD N
the DT N
number NN N
of IN N
people NNS N
hospitalized VBN N
and CC N
the DT N
duration NN N
of IN N
hospital NN N
admissions NNS N
, , N
which WDT N
are VBP N
important JJ N
endpoints NNS N
in IN N
this DT N
group NN N
. . N

Larger NNP N
, , N
confirmatory NN N
studies NNS N
are VBP N
now RB N
needed VBN N
. . N

This DT N
trial NN N
was VBD N
registered VBN N
before IN N
commencement NN N
at IN N
clinical JJ N
trials.gov NN N
as IN N
NCT00117000 NNP N
. . N

-DOCSTART- -25795413- O O

Selective JJ N
insulin NN N
resistance NN N
in IN N
homeostatic JJ N
and CC N
cognitive JJ N
control NN N
brain NN N
areas NNS N
in IN N
overweight NN p
and CC p
obese JJ p
adults NNS p
. . p

OBJECTIVE NNP N
Impaired NNP N
brain NN N
insulin NN N
action NN N
has VBZ N
been VBN N
linked VBN N
to TO N
obesity NN N
, , N
type NN N
2 CD N
diabetes NNS N
, , N
and CC N
neurodegenerative JJ N
diseases NNS N
. . N

To TO N
date NN N
, , N
the DT N
central JJ N
nervous JJ N
effects NNS N
of IN N
insulin NN N
in IN N
obese JJ N
humans NNS N
still RB N
remain VBP N
ill JJ N
defined VBN N
, , N
and CC N
no DT N
study NN N
thus RB N
far RB N
has VBZ N
evaluated VBN N
the DT N
specific JJ N
brain NN N
areas NNS N
affected VBN N
by IN N
insulin NN N
resistance NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
25 CD p
healthy JJ p
lean NN p
and CC p
23 CD p
overweight/obese JJ p
participants NNS p
, , N
we PRP N
performed VBD N
magnetic JJ i
resonance NN i
imaging NN i
to TO N
measure VB N
cerebral JJ o
blood NN o
flow NN o
( ( o
CBF NNP o
) ) o
before IN N
and CC N
15 CD N
and CC N
30 CD N
min NN N
after IN N
application NN N
of IN N
intranasal JJ i
insulin NN i
or CC i
placebo NN i
. . i

Additionally RB N
, , N
participants NNS N
explicitly RB N
rated VBN N
pictures NNS N
of IN N
high-caloric JJ N
savory NN N
and CC N
sweet VB N
food NN N
60 CD N
min NN N
after IN N
the DT N
spray NN N
for IN N
wanting VBG N
and CC N
liking VBG N
. . N

RESULTS NNP N
In IN N
response NN N
to TO N
insulin VB i
compared VBN N
with IN N
placebo NN i
, , N
we PRP N
found VBD N
a DT N
significant JJ N
CBF NNP o
decrease NN N
in IN N
the DT N
hypothalamus NN N
in IN N
both DT N
lean JJ o
and CC o
overweight/obese JJ o
participants NNS N
. . N

The DT N
magnitude NN N
of IN N
this DT N
response NN N
correlated VBD N
with IN N
visceral JJ N
adipose JJ N
tissue NN N
independent JJ N
of IN N
other JJ N
fat JJ N
compartments NNS N
. . N

Furthermore RB N
, , N
we PRP N
observed VBD N
a DT N
differential JJ N
response NN N
in IN N
the DT N
lean JJ N
compared VBN N
with IN N
the DT N
overweight/obese JJ N
group NN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
, , N
resulting VBG N
in IN N
an DT N
insulin-induced JJ o
CBF NNP o
reduction NN o
in IN N
lean JJ N
participants NNS N
only RB N
. . N

This DT N
prefrontal JJ N
cortex NN N
response NN N
significantly RB N
correlated VBN N
with IN N
peripheral JJ o
insulin NN o
sensitivity NN o
and CC o
eating VBG o
behavior JJ o
measures NNS N
such JJ N
as IN N
disinhibition NN N
and CC N
food NN N
craving NN N
. . N

Behaviorally NNP N
, , N
we PRP N
were VBD N
able JJ N
to TO N
observe VB N
a DT N
significant JJ N
reduction NN N
for IN N
the DT N
wanting NN o
of IN o
sweet JJ o
foods NNS o
after IN N
insulin JJ N
application NN N
in IN N
lean JJ N
men NNS N
only RB N
. . N

CONCLUSIONS NNP N
Brain NNP N
insulin NN N
action NN N
was VBD N
selectively RB N
impaired VBN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
in IN N
overweight NN N
and CC N
obese JJ N
adults NNS N
and CC N
in IN N
the DT N
hypothalamus NN N
in IN N
participants NNS N
with IN N
high JJ N
visceral JJ N
adipose JJ N
tissue NN N
, , N
potentially RB N
promoting VBG N
an DT N
altered JJ N
homeostatic JJ N
set NN N
point NN N
and CC N
reduced JJ N
inhibitory NN N
control NN N
contributing VBG N
to TO N
overeating VBG N
behavior NN N
. . N

-DOCSTART- -24771618- O O

Evaluation NN N
of IN N
early JJ o
weight NN o
loss NN o
thresholds NNS N
for IN N
identifying VBG N
nonresponders NNS N
to TO N
an DT N
intensive JJ N
lifestyle NN N
intervention NN N
. . N

OBJECTIVE NNP N
Weight NNP N
losses NNS N
in IN N
lifestyle JJ N
interventions NNS N
are VBP N
variable JJ N
, , N
yet CC N
prediction NN N
of IN N
long-term JJ N
success NN N
is VBZ N
difficult JJ N
. . N

The DT N
utility NN N
of IN N
using VBG N
various JJ N
weight JJ N
loss NN N
thresholds NNS N
in IN N
the DT N
first JJ N
2 CD N
months NNS N
of IN N
treatment NN N
for IN N
predicting VBG N
1-year JJ N
outcomes NNS N
was VBD N
examined VBN N
. . N

METHODS NNP N
Participants NNS p
included VBD p
2327 CD p
adults NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
( ( p
BMI:35.8 NNP p
? . p
6.0 CD p
) ) p
randomized VBN p
to TO N
the DT i
intensive JJ i
lifestyle JJ i
intervention NN i
( ( i
ILI NNP i
) ) N
of IN N
the DT N
Look NNP N
AHEAD NNP N
trial NN N
. . i

ILI NNP i
included VBD N
weekly JJ N
behavioral JJ N
sessions NNS N
designed VBN N
to TO N
increase VB o
physical JJ o
activity NN o
and CC o
reduce VB o
caloric JJ o
intake NN o
. . o

1-month JJ o
, , N
2-month JJ N
, , N
and CC N
1-year JJ o
weight NN o
changes NNS o
were VBD o
calculated VBN N
. . N

RESULTS JJ N
Participants NNS N
failing VBG N
to TO N
achieve VB o
a DT o
?2 CD o
% NN o
weight JJ o
loss NN o
at IN o
Month NNP o
1 CD o
were VBD o
5.6 CD N
( ( N
95 CD N
% NN N
CI:4.5 NNP N
, , N
7.0 CD N
) ) N
times NNS N
more RBR N
likely JJ N
to TO N
also RB N
not RB N
achieve VB N
a DT N
?10 CD N
% NN N
weight JJ o
loss NN o
at IN o
Year NNP o
1 CD o
, , o
compared VBN N
to TO N
those DT N
losing VBG N
?2 CD N
% NN N
initially RB N
. . N

These DT N
odds NNS N
were VBD N
increased VBN N
to TO N
11.6 CD N
( ( N
95 CD N
% NN N
CI:8.6 NNP N
, , N
15.6 CD N
) ) N
when WRB N
using VBG N
a DT N
3 CD N
% NN N
weight JJ o
loss NN o
threshold NN o
at IN N
Month NNP N
2 CD N
. . N

Only RB N
15.2 CD N
% NN N
and CC N
8.2 CD N
% NN N
of IN N
individuals NNS N
failing VBG N
to TO N
achieve VB N
the DT N
?2 NN N
% NN N
and CC N
?3 CD N
% NN N
thresholds NNS N
at IN N
Months NNP N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
, , N
go VB N
on IN N
to TO N
achieve VB N
a DT N
?10 CD o
% NN o
weight JJ o
loss NN o
at IN o
Year JJ o
1 CD o
. . o

CONCLUSIONS VB N
Given NNP N
the DT N
association NN N
between IN N
initial JJ N
and CC N
1-year JJ o
weight NN o
loss NN o
, , o
the DT o
first JJ N
few JJ N
months NNS N
of IN N
treatment NN N
may MD N
be VB N
an DT N
opportune JJ N
time NN N
to TO N
identify VB N
those DT N
who WP N
are VBP N
unsuccessful JJ N
and CC N
utilize JJ N
rescue NN N
efforts NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00017953 NN N
. . N

-DOCSTART- -23812661- O O

Comparative JJ N
efficacy NN N
of IN N
LEAP NNP i
, , i
TEACCH NNP i
and CC N
non-model-specific JJ i
special JJ i
education NN i
programs NNS i
for IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

LEAP NNP i
and CC i
TEACCH NNP i
represent VBP N
two CD N
comprehensive JJ N
treatment NN N
models NNS N
( ( N
CTMs NNP N
) ) N
that WDT N
have VBP N
been VBN N
widely RB N
used VBN N
across IN N
several JJ N
decades NNS N
to TO N
educate VB N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
quasi-experimental JJ N
study NN N
was VBD N
to TO N
compare VB N
high JJ i
fidelity NN i
LEAP NNP i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
and CC i
TEACCH NNP i
( ( i
n JJ N
= NNP N
25 CD N
) ) N
classrooms NNS N
to TO N
each DT N
other JJ N
and CC N
a DT N
control NN N
condition NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
, , N
in IN N
which WDT N
teachers NNS p
in IN p
high JJ p
quality NN p
special JJ p
education NN p
programs NNS p
used VBD p
non-model-specific JJ N
practices NNS N
. . N

A DT N
total NN N
of IN p
198 CD p
children NNS p
were VBD p
included VBN N
in IN N
data NNS N
analysis NN N
. . N

Across IN N
conditions NNS o
, , o
children NNS o
's POS o
performances NNS o
improved VBN o
over IN N
time NN N
. . N

This DT N
study NN N
raises VBZ N
issues NNS N
of IN N
the DT N
replication NN N
of IN N
effects NNS N
for IN N
CTMs NNP N
, , N
and CC N
whether IN N
having VBG N
access NN N
to TO N
a DT N
high JJ N
quality NN i
special JJ i
education NN i
program NN i
is VBZ i
as RB i
beneficial JJ N
as IN N
access NN N
to TO N
a DT N
specific JJ N
CTM NNP N
. . N

-DOCSTART- -6148879- O O

A DT N
comparison NN N
of IN N
propranolol NN i
and CC i
nadolol JJ i
pharmacokinetics NNS o
and CC N
clinical JJ o
effects NNS o
in IN o
thyrotoxicosis NN o
. . o

For IN N
a DT N
comparison NN N
of IN N
propranolol NN i
and CC i
nadolol JJ i
pharmacokinetics NNS o
and CC o
clinical JJ o
effects NNS o
, , N
20 CD p
newly RB p
diagnosed VBN p
patients NNS p
with IN p
thyrotoxicosis NN p
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
as IN N
sole JJ N
therapy NN N
, , N
either DT N
propranolol NN i
, , N
40 CD N
mg NN N
every DT N
6 CD N
hours NNS N
for IN N
14 CD N
days NNS N
, , N
or CC N
nadolol RB i
, , N
80 CD N
mg NNS N
each DT N
morning NN N
for IN N
14 CD N
days NNS N
. . N

The DT N
study NN N
was VBD N
repeated VBN N
when WRB N
the DT N
patients NNS N
were VBD N
in IN N
the DT N
euthyroid JJ N
state NN N
. . N

There EX N
was VBD N
a DT N
similar JJ N
and CC N
highly RB N
significant JJ N
degree NN o
of IN o
beta NN o
blockade NN o
and CC o
amelioration NN o
of IN o
symptoms NNS o
of IN o
thyrotoxicosis NN o
at IN N
the DT N
end NN N
of IN N
the DT N
dosage NN N
interval NN N
( ( N
trough IN N
) ) N
, , N
i.e. FW N
, , N
24 CD N
hours NNS N
after IN N
nadolol NN i
or CC N
6 CD N
to TO N
8 CD N
hours NNS N
after IN N
propranolol NN i
. . i

Trough NNP o
and CC o
peak VB o
serum NN o
levels NNS o
of IN o
propranolol NN o
were VBD N
significantly RB N
lower JJR N
when WRB N
the DT N
patients NNS N
were VBD N
in IN N
a DT N
thyrotoxic NN N
state NN N
than IN N
when WRB N
they PRP N
were VBD N
in IN N
a DT N
euthyroid JJ N
state NN N
, , N
whereas IN N
the DT N
pharmacokinetics NNS o
of IN N
nadolol NNS N
were VBD N
not RB N
appreciably RB N
altered VBN N
by IN N
thyrotoxicosis NN N
. . N

In IN N
thyrotoxicosis NN N
, , N
trough IN o
levels NNS o
of IN o
propranolol NN o
and CC o
nadolol NN o
were VBD N
significantly RB N
inversely RB N
correlated VBN N
with IN N
derived JJ o
creatinine JJ o
clearance NN o
values NNS o
. . o

In IN N
the DT N
symptomatic JJ p
treatment NN p
of IN p
thyrotoxicosis NN o
, , N
nadolol RB i
, , N
a DT N
once-daily JJ N
nonmetabolized JJ i
beta NN i
blocker NN i
, , N
has VBZ N
certain JJ N
advantages NNS N
compared VBN N
with IN N
propranolol NN i
. . i

It PRP N
is VBZ N
preferred VBN N
by IN N
patients NNS N
, , N
is VBZ N
more RBR N
convenient JJ o
, , N
and CC N
probably RB N
aids NNS N
compliance NN o
. . o

-DOCSTART- -3594511- O O

Effects NNS N
of IN N
pindolol NN i
and CC i
clopamide NN i
on IN N
blood NN o
lipids NNS o
in IN N
arterial JJ p
hypertensive JJ p
patients NNS p
. . p

The DT N
effects NNS N
of IN N
clopamide NN i
, , i
pindolol NN i
and CC i
its PRP$ i
combination NN i
on IN i
plasma JJ i
lipids NNS i
in IN N
49 CD p
hypertensive JJ p
patients NNS p
( ( p
WHO NNP p
I-II NNP p
) ) p
, , p
divided VBD p
into IN p
three CD p
parallel JJ p
randomized VBN p
groups NNS p
, , p
were VBD p
studied VBN p
over IN p
a DT p
6 CD p
months NNS p
period NN p
. . p

Total JJ o
cholesterol NN o
, , o
triglycerides NNS o
, , o
HDL NNP o
and CC o
LDL NNP o
cholesterol NN o
fractions NNS o
were VBD N
determined VBN N
twice RB N
during IN N
an DT N
initial JJ N
4-week JJ N
washout NN N
phase NN N
, , N
and CC N
after IN N
a DT N
1- JJ N
, , N
3- JJ N
and CC N
6-month JJ N
active JJ N
hypotensive JJ N
drug NN N
phase NN N
. . N

Patients NNS N
were VBD N
instructed VBN N
to TO N
maintain VB N
their PRP$ N
usual JJ N
dietary JJ N
habits NNS N
. . N

Daily JJ N
drug NN N
doses NNS N
were VBD N
adjusted VBN N
progressively RB N
to TO N
attain VB N
optimal JJ N
hypotensive JJ N
effects NNS N
. . N

In IN N
the DT N
clopamide NN N
monotherapy NN N
group NN N
, , N
total JJ o
cholesterol NN o
increased VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
; : N
triglycerides NNS o
and CC N
LDL NNP o
showed VBD N
a DT N
tendency NN N
to TO N
increase VB N
while IN N
for IN N
HDL NNP o
a DT N
tendency NN N
to TO N
decrease VB N
was VBD N
observed VBN N
. . N

In IN N
the DT N
pindolol NN N
monotherapy NN N
group NN N
, , N
a DT N
significant JJ N
reduction NN N
of IN N
triglycerides NNS o
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
a DT N
significant JJ N
increase NN N
of IN N
HDL NNP o
cholesterol NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
were VBD N
recorded VBN N
. . N

No DT N
significant JJ N
changes NNS N
in IN N
total JJ o
cholesterol NN o
or CC o
LDL NNP o
fraction NN o
were VBD N
observed VBN N
. . N

Combined VBN N
pindolol-clopamide JJ N
therapy NN N
decreased VBD N
total JJ o
triglycerides NNS o
( ( o
NS NNP o
) ) o
, , N
increased VBD N
HDL NNP o
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
did VBD N
not RB N
influence VB N
total JJ o
cholesterol NN o
and CC o
LDL NNP o
fraction NN o
. . o

It PRP N
is VBZ N
concluded VBN N
that IN N
pindolol NN N
does VBZ N
not RB N
negatively RB N
influence VB N
blood NN o
lipids NNS o
as IN N
the DT N
thiazide-type JJ N
diuretic JJ N
clopamide NN N
does VBZ N
, , N
and CC N
that IN N
when WRB N
both DT N
drugs NNS N
are VBP N
used VBN N
together RB N
, , N
the DT N
beta-blocker NN N
can MD N
probably RB N
counterbalance VB N
the DT N
diuretic-induced JJ N
negative JJ N
effects NNS N
on IN N
blood NN o
lipids NNS o
. . o

Accordingly RB N
, , N
it PRP N
is VBZ N
suggested VBN N
that IN N
pindolol NN N
could MD N
be VB N
a DT N
more RBR N
favorable JJ N
beta-blocker JJ N
drug NN N
to TO N
be VB N
used VBN N
on IN N
hypertensive JJ p
subjects NNS p
with IN p
metabolic JJ p
coronary JJ p
risk NN p
factors NNS p
. . p

-DOCSTART- -15848979- O O

Treatment NNP N
outcome NN N
of IN N
appliance NN i
therapy NN i
in IN N
temporomandibular JJ p
disorder NN p
patients NNS p
with IN p
myofascial JJ o
pain NN o
after IN p
6 CD p
and CC p
12 CD p
months NNS p
. . p

AIM NNP N
To TO N
compare VB N
the DT N
long-term JJ N
effect NN N
of IN N
treatment NN N
with IN N
a DT N
stabilization NN i
appliance NN i
( ( N
group NN N
T NNP N
) ) N
and CC N
treatment NN N
with IN N
a DT N
control NN i
appliance NN i
( ( N
group NN N
C NNP N
) ) N
in IN N
temporomandibular JJ p
disorder NN p
( ( p
TMD NNP p
) ) p
patients NNS p
with IN p
myofascial JJ p
pain NN p
. . p

METHODS NNP N
In IN N
this DT N
controlled JJ N
trial NN N
, , N
60 CD p
patients NNS p
( ( p
mean JJ p
age NN p
29 CD p
years NNS p
) ) p
with IN p
myofascial JJ p
pain NN p
were VBD p
evaluated VBN p
after IN p
10 CD p
weeks NNS p
of IN p
treatment NN p
with IN p
either CC p
a DT p
stabilization NN i
appliance NN i
or CC p
a DT p
control JJ i
appliance NN i
. . i

All DT N
60 CD p
patients NNS p
were VBD N
then RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
according VBG N
to TO N
demand NN N
for IN N
treatment NN N
. . N

Seventeen JJ N
patients NNS N
from IN N
group NN N
C NNP N
requested VBD N
another DT N
appliance NN N
and CC N
were VBD N
given VBN N
a DT N
stabilization NN i
appliance NN i
, , N
thus RB N
creating VBG N
a DT N
mixed JJ N
group NN N
( ( N
group NN N
M NNP N
) ) N
. . N

RESULTS VB N
A DT N
significant JJ N
difference NN N
in IN N
improvement NN o
of IN o
overall JJ o
subjective JJ o
symptoms NNS o
in IN N
an DT N
intent-to-treat JJ N
analysis NN N
between IN N
groups NNS N
T NNP N
and CC N
C NNP N
was VBD N
found VBN N
at IN N
the DT N
follow-ups NNS N
. . N

In IN N
a DT N
survival JJ N
analysis NN N
of IN N
treatment NN N
compliance NN N
, , N
a DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
groups NNS N
T NNP N
and CC N
C. NNP N
At IN N
the DT N
6- JJ N
and CC N
12-month JJ N
follow-ups NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
myofascial JJ o
pain NN N
, , N
as IN N
measured VBN N
on IN N
a DT N
visual JJ o
analog NN o
scale NN o
, , N
was VBD N
found VBN N
in IN N
all DT N
three CD N
groups NNS N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
frequency NN o
and CC o
intensity NN o
of IN o
myofascial JJ o
pain NN o
was VBD N
found VBN N
in IN N
group NN N
T NNP N
at IN N
the DT N
follow-ups NNS N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
number NN o
of IN o
tender NN o
sites NNS o
on IN o
the DT o
masticatory NN o
muscles NNS o
was VBD N
found VBN N
in IN N
group NN N
T NNP N
at IN N
the DT N
follow-ups NNS N
. . N

CONCLUSION VB N
The DT N
results NNS N
support VBD N
the DT N
conclusion NN N
that IN N
the DT N
positive JJ N
treatment NN N
outcome NN N
obtained VBN N
by IN N
use NN N
of IN N
a DT N
stabilization NN i
appliance NN i
to TO N
alleviate VB N
the DT N
signs NNS N
and CC N
symptoms NNS N
in IN N
patients NNS p
with IN p
myofascial JJ p
pain NN p
persisted VBD N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
. . N

Most JJS N
patients NNS N
in IN N
groups NNS N
T NNP N
and CC N
M NNP N
reported VBD N
positive JJ N
changes NNS N
in IN N
overall JJ o
subjective JJ o
symptoms NNS o
in IN N
this DT N
trial NN N
. . N

We PRP N
therefore VBP N
recommend JJ N
use NN N
of IN N
the DT N
stabilization NN i
appliance NN i
in IN N
the DT N
treatment NN N
of IN N
TMD NNP p
patients NNS p
with IN p
myofascial JJ o
pain NN o
. . o

-DOCSTART- -1411449- O O

[ JJ N
Physical NNP N
performance NN N
and CC N
sedation NN N
: : N
comparative JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
a DT N
benzodiazepine NN i
( ( i
temazepam NN i
) ) i
and CC N
of IN N
a DT i
non-benzodiazepine JJ i
hypnotic NN i
( ( i
zolpidem NN i
) ) i
] NN i
. . N

It PRP N
is VBZ N
well-known JJ N
that IN N
many JJ p
athletes NNS p
experience VBP N
some DT N
form NN N
of IN N
precompetition NN N
stress NN N
that WDT N
may MD N
result VB N
in IN N
insomnia NN N
during IN N
the DT N
night NN N
before IN N
their PRP$ N
competition NN N
. . N

Yet CC N
, , N
sleep VBP N
withdrawal NN N
even RB N
if IN N
only RB N
partial JJ N
, , N
has VBZ N
a DT N
negative JJ N
influence NN N
on IN N
performance NN N
, , N
particularly RB N
when WRB N
the DT N
type NN N
of IN N
exercise NN N
requires VBZ N
good JJ N
psychomotor NN N
performance NN N
The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
intake NN N
of IN N
a DT N
hypnotic JJ N
drug NN N
would MD N
have VB N
negative JJ N
effects NNS N
on IN N
physical JJ N
performance NN N
capacity NN N
. . N

The DT N
authors NNS N
have VBP N
compared VBN N
the DT N
effects NNS N
of IN N
oral JJ i
temazepam NN i
, , N
a DT N
medium NN i
half-life JJ i
benzodiazepine NN i
vs IN i
oral JJ i
zolpidem NN i
, , i
a DT i
short JJ i
half-life JJ i
non-benzodiazepine JJ i
drug NN i
, , N
vs NN N
placebo NN i
. . i

A DT N
randomized JJ N
double-blind JJ N
trial NN N
was VBD N
used VBN N
to TO N
assess VB N
endurance NN o
, , o
resistance NN o
, , o
strength NN o
and CC o
coordination NN o
in IN N
26 CD p
athletes NNS p
. . p

The DT N
results NNS N
did VBD N
not RB N
show VB N
any DT N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
, , N
neither CC N
in IN N
physical JJ o
performance NN o
characteristic JJ o
nor CC o
in IN o
coordination NN o
. . o

It PRP N
is VBZ N
concluded VBN N
that IN N
as IN N
regards NNS N
the DT N
performance NN N
capacity NN N
, , N
there EX N
is VBZ N
no DT N
risk NN N
for IN N
stressed JJ p
athletes NNS p
to TO N
use VB N
sleep JJ N
inducers NNS N
the DT N
night NN N
before IN N
their PRP$ N
competition NN N
. . N

-DOCSTART- -11915576- O O

The DT N
impact NN N
of IN N
different JJ N
doses NNS N
of IN N
medroxyprogesterone NN i
acetate NN i
on IN N
mood NN o
symptoms NNS o
in IN N
sequential JJ i
hormonal JJ i
therapy NN i
. . i

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
adverse JJ N
mood NN o
effects NNS o
of IN N
two CD N
different JJ N
doses NNS N
of IN N
medroxyprogesterone NN i
acetate NN i
( ( i
MPA NNP i
) ) i
during IN N
postmenopausal NN p
hormone CD p
replacement NN p
therapy NN p
( ( p
HRT NNP p
) ) p
in IN p
women NNS p
with IN p
and CC p
without IN p
a DT p
history NN p
of IN p
premenstrual JJ p
syndrome NN p
( ( p
PMS NNP p
) ) p
. . p

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized JJ N
double-blind JJ N
cross-over NN N
study NN N
and CC N
included VBD N
36 CD p
postmenopausal JJ p
women NNS p
at IN p
three CD p
health NN p
care NN p
areas NNS p
in IN p
northern JJ p
Sweden NNP p
. . p

The DT N
women NNS N
received VBD N
2 CD i
mg NNS i
estradiol RB i
continuously RB N
during IN N
five CD N
28-day JJ N
cycles NNS N
and CC N
10 CD N
mg NN N
or CC N
20 CD N
mg NNS N
MPA NNP N
sequentially RB N
for IN N
12 CD N
days NNS N
during IN N
each DT N
cycle NN N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
mood NN o
and CC o
physical JJ o
symptoms NNS o
noted VBD o
on IN o
a DT o
daily JJ o
rating NN o
scale NN o
. . o

We PRP N
found VBD N
that IN N
physical JJ o
symptoms NNS o
did VBD N
not RB N
differ VB N
between IN N
10 CD N
and CC N
20 CD N
mg NN N
MPA NNP N
. . N

Both DT N
women NNS N
with IN N
a DT N
history NN N
of IN N
PMS NNP N
and CC N
women NNS N
without IN N
responded VBD N
with IN N
more RBR N
negative JJ N
mood NN o
symptoms NNS o
with IN N
the DT N
lower JJR N
dose NN N
of IN N
MPA NNP N
. . N

In IN N
women NNS N
with IN N
previous JJ N
PMS NNP N
the DT N
higher JJR N
dose NN N
of IN N
MPA NNP N
enhanced VBD N
positive JJ o
mood NN o
symptoms NNS o
. . o

With IN N
respect NN N
to TO N
mood NN o
and CC o
physical JJ o
symptoms NNS o
, , N
the DT N
aim NN N
to TO N
lower VB N
MPA NNP N
doses NNS N
in IN N
HRT NNP N
is VBZ N
unwarranted JJ N
. . N

-DOCSTART- -24749259- O O

[ RB i
Dexmedetomidine NNP i
use NN N
for IN N
postoperative JJ o
adrenergic JJ o
analgesia NN o
and CC o
sedation NN o
in IN N
abdominal JJ N
surgery NN N
] NN N
. . N

Comparative NNP N
study NN N
of IN N
postoperative JJ o
analgesia NN o
and CC o
sedation NN o
with IN i
trimeperidine NN i
and CC i
dexmedetomidine NN i
and CC N
their PRP$ N
effects NNS N
on IN N
haemodynamics NNS N
and CC N
vegetative VBP N
nervous JJ N
system NN N
was VBD N
performed VBN N
. . N

Assessment NNP N
of IN N
analgesia NN N
and CC N
sedation NN i
during IN N
vagotonia NN N
( ( N
first JJ N
part NN N
of IN N
the DT N
study NN N
) ) N
and CC N
hypokinetic JJ i
type NN i
of IN i
haemodynamics NNS i
( ( N
second JJ N
part NN N
of IN N
the DT N
study NN N
) ) N
was VBD N
carried VBN N
out RP N
with IN N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
and CC o
Richmond NNP o
scale NN o
. . o

Results NNS N
of IN N
the DT N
study NN N
showed VBD N
that IN N
dexmedetomidine NN i
is VBZ N
more RBR N
effective JJ o
and CC o
safer JJR o
than IN N
trimeperidine NN i
for IN N
analgesia NN o
and CC o
sedation NN o
in IN N
patients NNS p
with IN p
spontaneous JJ p
breathing NN p
after IN p
abdominal JJ p
surgery NN p
. . p

Dexmedetomidine NNP i
use NN N
allows VBZ N
keeping VBG N
optimal JJ N
type NN N
of IN N
haemodynamics NNS N
and CC N
vegetative VBP N
nervous JJ N
system NN N
parameters NNS N
on IN N
first JJ N
day NN N
of IN N
postoperative JJ N
period NN N
. . N

-DOCSTART- -25365653- O O

Topiramate NNP i
impairs NNS N
cognitive JJ N
function NN N
in IN N
methadone-maintained JJ p
individuals NNS p
with IN p
concurrent JJ p
cocaine NN p
dependence NN p
. . p

Topiramate NNP i
is VBZ N
being VBG N
investigated VBN N
as IN N
a DT N
potential JJ N
pharmacotherapy NN i
for IN N
the DT N
treatment NN N
of IN N
addictive JJ N
disorders NNS N
. . N

However RB N
, , N
its PRP$ N
cognitive JJ N
side NN N
effects NNS N
raise VBP N
concerns NNS N
about IN N
its PRP$ N
use NN N
, , N
especially RB N
in IN N
populations NNS N
with IN N
cognitive JJ N
impairment NN N
, , N
such JJ N
as IN N
persons NNS p
with IN p
chronic JJ p
substance NN p
use NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
topiramate NN i
's POS i
cognitive JJ N
effects NNS N
in IN N
individuals NNS p
dually RB p
dependent VBP p
on IN p
cocaine NN p
and CC p
opioids NNS p
as IN N
part NN N
of IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
topiramate NN i
for IN N
cocaine NN N
dependence NN N
treatment NN N
. . N

After IN N
5 CD N
weeks NNS N
of IN N
stabilization NN N
on IN N
daily JJ N
oral JJ N
methadone NN i
( ( N
M NNP N
= VBZ N
96 CD N
mg NN N
) ) N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
topiramate VB i
( ( p
n JJ p
= NNP p
18 CD p
) ) p
or CC N
placebo NN i
( ( p
n JJ p
= NNP p
22 CD p
) ) p
. . N

Cognitive JJ N
testing VBG N
took VBD N
place NN N
at IN N
2 CD N
time NN N
points NNS N
: : N
study NN N
weeks NNS N
4 CD N
through IN N
5 CD N
to TO N
assess VB N
baseline JJ N
performance NN N
and CC N
10 CD N
to TO N
13 CD N
weeks NNS N
later RB N
to TO N
assess VB N
performance NN N
during IN N
stable JJ N
dosing NN N
( ( N
300 CD N
mg NN N
topiramate NN i
or CC N
placebo NN i
) ) i
. . N

All DT N
participants NNS N
were VBD N
maintained VBN N
on IN N
methadone NN N
at IN N
both DT N
testing VBG N
times NNS N
, , N
and CC N
testing VBG N
occurred VBD N
2 CD N
hours NNS N
after IN N
the DT N
daily JJ N
methadone NN N
plus CC N
topiramate/placebo JJ i
administration NN N
. . N

The DT N
topiramate NN i
and CC N
placebo NN i
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
sex NN N
, , N
level NN N
of IN N
education NN N
, , N
premorbid JJ N
intelligence NN N
, , N
methadone NN N
dose NN N
, , N
or CC N
illicit JJ N
drug NN N
use NN N
. . N

Topiramate NN i
slowed VBD N
psychomotor NN o
and CC o
information NN o
processing NN o
speed NN o
, , o
worsened VBD o
divided JJ o
attention NN o
, , o
reduced VBN o
n-back JJ o
working VBG o
memory NN o
accuracy NN o
, , o
and CC o
increased VBD o
the DT o
false JJ o
alarm NN o
rate NN o
in IN o
recognition NN o
memory NN o
. . o

Topiramate NNP i
had VBD N
no DT N
effects NNS N
on IN N
visual JJ o
processing NN o
, , o
other JJ o
measures NNS o
of IN o
psychomotor NN o
function NN o
, , o
risk-taking JJ o
, , o
self-control JJ o
, , o
Sternberg NNP o
working VBG o
memory NN o
, , o
free JJ o
recall NN o
, , o
and CC o
metamemory NN o
. . o

These DT N
findings NNS N
indicate VBP N
that IN N
topiramate NN N
may MD N
cause VB N
cognitive JJ o
impairment NN o
in IN N
this DT N
population NN N
. . N

This DT N
effect NN N
may MD o
limit VB o
its PRP$ o
acceptability NN o
and CC N
use NN N
as IN N
a DT N
treatment NN N
in IN N
individuals NNS p
with IN p
chronic JJ p
opioid NN p
and CC p
cocaine NN p
use NN p
disorders NNS p
, , N
among IN N
whom WP N
preexisting VBG N
cognitive JJ N
impairments NNS N
are VBP N
common JJ N
. . N

( ( N
PsycINFO JJ N
Database NNP N
Record NN N
-DOCSTART- -19435491- O O

The DT N
ADDITION-Cambridge NNP p
trial NN p
protocol NN p
: : p
a DT N
cluster NN N
-- : N
randomised VBD N
controlled JJ N
trial NN N
of IN N
screening VBG N
for IN N
type NN p
2 CD p
diabetes NNS p
and CC p
intensive JJ p
treatment NN p
for IN p
screen-detected JJ p
patients NNS p
. . p

BACKGROUND NNP N
The DT N
increasing VBG N
prevalence NN N
of IN N
type NN N
2 CD N
diabetes VBZ N
poses NNS N
a DT N
major JJ N
public JJ N
health NN N
challenge NN N
. . N

Population-based JJ N
screening NN N
and CC N
early JJ N
treatment NN N
for IN N
type NN N
2 CD N
diabetes NNS N
could MD N
reduce VB N
this DT N
growing VBG N
burden NN N
. . N

However RB N
, , N
the DT N
benefits NNS N
of IN N
such JJ N
a DT N
strategy NN N
remain NN N
uncertain JJ N
. . N

METHODS NNP N
AND CC N
DESIGN NNP N
The DT N
ADDITION-Cambridge NNP N
study NN N
aims NNS N
to TO N
evaluate VB N
the DT N
effectiveness NN o
and CC o
cost-effectiveness NN o
of IN N
( ( N
i NN N
) ) N
a DT N
stepwise NN i
screening NN i
strategy NN i
for IN i
type NN i
2 CD i
diabetes NNS i
; : i
and CC N
( ( N
ii NN N
) ) N
intensive JJ i
multifactorial JJ i
treatment NN i
for IN i
people NNS i
with IN i
screen-detected JJ i
diabetes NNS i
in IN i
primary JJ i
care NN i
. . i

63 CD p
practices NNS p
in IN p
the DT p
East NNP p
Anglia NNP p
region NN p
participated VBD p
. . p

Three CD N
undertook IN N
the DT N
pilot NN N
study NN N
, , N
33 CD N
were VBD N
allocated VBN N
to TO N
three CD N
groups NNS N
: : N
no DT i
screening NN i
( ( i
control NN i
) ) i
, , i
screening VBG i
followed VBN i
by IN i
intensive JJ i
treatment NN i
( ( i
IT NNP i
) ) i
and CC i
screening VBG i
plus CC i
routine JJ i
care NN i
( ( N
RC NNP N
) ) N
in IN N
an DT N
unbalanced JJ N
( ( N
1:3:3 CD N
) ) N
randomisation NN N
. . N

The DT N
remaining VBG N
27 CD N
practices NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
IT NNP N
and CC N
RC NNP N
. . N

A NNP N
risk NN N
score NN N
incorporating VBG N
routine JJ N
practice NN N
data NNS N
was VBD N
used VBN N
to TO N
identify VB N
people NNS p
aged VBN p
40-69 JJ p
years NNS p
at IN p
high-risk NN p
of IN p
undiagnosed JJ p
diabetes NNS p
. . p

In IN N
the DT N
screening NN N
practices NNS N
, , N
high-risk JJ N
individuals NNS N
were VBD N
invited VBN N
to TO N
take VB N
part NN N
in IN N
a DT N
stepwise NN N
screening VBG N
programme NN N
. . N

In IN N
the DT N
IT NNP N
group NN N
, , N
diabetes VBZ N
treatment NN N
is VBZ N
optimised VBN N
through IN N
guidelines NNS N
, , N
target-led JJ N
multifactorial JJ N
treatment NN N
, , N
audit NN N
, , N
feedback NN N
, , N
and CC N
academic JJ N
detailing NN N
for IN N
practice NN N
teams NNS N
, , N
alongside JJ N
provision NN N
of IN N
educational JJ N
materials NNS N
for IN N
newly RB N
diagnosed VBN N
participants NNS N
. . N

Primary JJ N
endpoints NNS N
are VBP N
modelled VBN o
cardiovascular JJ o
risk NN o
at IN o
one CD o
year NN o
, , o
and CC o
cardiovascular JJ o
mortality NN o
and CC o
morbidity NN o
at IN o
five CD o
years NNS o
after IN N
diagnosis NN N
of IN N
diabetes NNS N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
all-cause JJ o
mortality NN o
, , o
development NN o
of IN o
renal JJ o
and CC o
visual JJ o
impairment NN o
, , o
peripheral JJ o
neuropathy NN o
, , o
health NN o
service NN o
costs NNS o
, , o
self-reported JJ o
quality NN o
of IN o
life NN o
, , o
functional JJ o
status NN o
and CC o
health NN o
utility NN o
. . o

Impact NN N
of IN N
the DT N
screening NN N
programme NN N
at IN N
the DT N
population NN N
level NN N
is VBZ N
also RB N
assessed VBN N
through IN N
measures NNS N
of IN N
mortality NN o
, , o
cardiovascular JJ o
morbidity NN o
, , o
health NN o
status NN o
and CC o
health NN o
service NN o
use NN o
among IN N
high-risk JJ N
individuals NNS N
. . N

DISCUSSION NNP N
ADDITION-Cambridge NNP N
is VBZ N
conducted VBN N
in IN N
a DT N
defined JJ N
high-risk JJ N
group NN N
accessible JJ N
through IN N
primary JJ N
care NN N
. . N

It PRP N
addresses VBZ N
the DT N
feasibility NN N
of IN N
population-based JJ N
screening NN N
for IN N
diabetes NNS N
, , N
as RB N
well RB N
as IN N
the DT N
benefits NNS N
and CC N
costs NNS N
of IN N
screening VBG N
and CC N
intensive JJ N
multifactorial JJ N
treatment NN N
early RB N
in IN N
the DT N
disease NN N
trajectory NN N
. . N

The DT N
intensive JJ N
treatment NN N
algorithm NN N
is VBZ N
based VBN N
on IN N
evidence NN N
from IN N
studies NNS N
including VBG N
individuals NNS p
with IN p
clinically RB p
diagnosed VBN p
diabetes NNS p
and CC N
the DT N
education NN N
materials NNS N
are VBP N
informed VBN N
by IN N
psychological JJ N
theory NN N
. . N

ADDITION-Cambridge NNP N
will MD N
provide VB N
timely RB N
evidence NN N
concerning VBG N
the DT N
benefits NNS N
of IN N
early JJ N
intensive JJ N
treatment NN N
and CC N
will MD N
inform VB N
policy NN N
decisions NNS N
concerning VBG N
screening NN N
for IN N
type NN N
2 CD N
diabetes NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
trials NNS N
ISRCTN86769081 NNP N
. . N

-DOCSTART- -17149715- O O

A DT N
double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
zonisamide NN i
( ( i
zonegran NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
essential JJ o
tremor NN o
. . o

Medical JJ N
therapy NN N
for IN N
essential JJ o
tremor NN o
( ( o
ET NNP o
) ) o
, , N
a DT N
common JJ N
movement NN N
disorder NN N
, , N
is VBZ N
often RB N
inadequate JJ N
. . N

We PRP N
performed VBD N
a DT N
double-blind JJ N
placebo-controlled JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC N
tolerability NN o
of IN N
zonisamide NN i
( ( i
ZNS NNP i
) ) i
, , N
an DT N
antiepileptic JJ N
agent NN N
, , N
in IN N
treating VBG N
ET NNP o
. . o

Twenty CD p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
60 CD p
+/- JJ p
15 CD p
years NNS p
) ) p
with IN p
ET NNP o
were VBD N
randomized VBN N
to TO N
receive VB N
ZNS NNP i
or CC i
placebo NN i
. . i

ZNS NNP i
was VBD i
initiated VBN i
at IN i
a DT i
dosage NN i
of IN i
100 CD i
mg/day NN i
and CC i
escalated VBD i
to TO i
200 CD i
mg/day NNS i
at IN i
day NN i
14 CD i
. . i

Patients NNS N
were VBD N
evaluated VBN N
by IN N
accelerometry NN N
and CC N
the DT N
Fahn-Tolosa-Marin NNP o
( ( o
FTM NNP o
) ) o
rating NN o
scale NN o
at IN N
baseline NN N
and CC N
days NNS N
14 CD N
and CC N
28 CD N
, , N
as RB N
well RB N
as IN N
the DT N
Clinical NNP o
Global NNP o
Impression NNP o
( ( o
CGI-C NNP o
) ) o
scale NN o
at IN N
day NN N
28 CD N
. . N

At IN N
endpoint NN N
, , N
subjects NNS N
assigned VBD N
to TO N
ZNS NNP i
were VBD N
taking VBG N
a DT N
mean JJ N
dosage NN N
of IN N
160 CD N
+/- JJ N
50 CD N
mg/day NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
improvements NNS N
in IN N
the DT N
FTM NNP o
total JJ o
score NN o
or CC o
its PRP$ o
subsections NNS o
. . o

Tremor NNP o
amplitude NN o
as IN N
assessed VBN N
by IN N
accelerometry NN N
significantly RB N
improved VBN N
in IN N
the DT N
ZNS NNP i
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
at IN N
endpoint NN N
relative NN N
to TO N
baseline VB N
( ( N
-0.50 JJ N
+/- JJ N
0.72 CD N
vs. FW N
0.30 CD N
+/- JJ N
0.79 CD N
m/s NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

On IN N
the DT N
CGI-C NNP N
, , N
60 CD N
% NN N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
ZNS NNP N
group NN N
felt VBD N
that IN N
their PRP$ N
tremor NN o
was VBD N
unchanged JJ N
, , N
while IN N
the DT N
remaining VBG N
patients NNS N
felt VBD N
that IN N
their PRP$ N
tremor NN o
was VBD N
minimally RB N
improved VBN N
. . N

Thirty CD N
percent NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
of IN N
patients NNS N
taking VBG N
ZNS NNP N
discontinued VBD N
the DT N
study NN N
due JJ N
to TO N
side VB N
effects NNS N
( ( o
fatigue NN o
, , o
headache NN o
, , o
paresthesias NN o
) ) o
while IN N
taking VBG N
100 CD N
mg JJ N
per IN N
day NN N
. . N

ZNS NNP i
did VBD N
not RB N
provide VB N
significant JJ N
improvements NNS N
in IN N
clinical JJ o
rating NN o
scales NNS o
at IN N
study NN N
endpoint NN N
compared VBN N
to TO N
placebo VB N
and CC N
was VBD N
only RB N
modestly RB N
well RB N
tolerated VBN o
. . o

ZNS NNP i
was VBD N
effective JJ N
in IN N
reducing VBG N
tremor JJ o
amplitude NN o
as IN N
measured VBN N
by IN N
accelerometry NN N
. . N

-DOCSTART- -19591981- O O

Polycystic JJ N
ovary JJ N
syndrome NN N
and CC N
cardiovascular JJ N
risk NN N
in IN N
young JJ p
patients NNS p
treated VBN p
with IN p
drospirenone-ethinylestradiol NN i
or CC i
contraceptive JJ i
vaginal JJ i
ring NN i
. . i

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
pill NN i
containing VBG i
drospirenone NN i
with IN i
those DT i
of IN i
a DT i
combined JJ i
contraceptive JJ i
vaginal JJ i
ring NN i
on IN i
the DT N
lipid JJ N
and CC N
carbohydrate JJ N
metabolism NN N
and CC N
on IN N
the DT N
surrogate NN N
markers NNS N
of IN N
arterial JJ N
function NN N
. . N

SETTING NNP N
Bologna NNP p
University NNP p
School NNP p
of IN p
Medicine NNP p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
Thirty-seven NNP p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
were VBD N
randomly RB N
submitted VBN N
to TO N
drospirenone+ethinylestradiol VB i
( ( N
group NN N
I PRP N
; : N
n=19 CC N
) ) N
or CC i
combined VBN i
contraceptive JJ i
vaginal JJ i
ring NN i
( ( N
group NN N
II NNP N
; : N
n=18 CC N
) ) N
therapy NN i
. . i

The DT N
duration NN N
of IN N
the DT N
study NN N
was VBD N
6 CD N
months NNS N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
The DT N
effect NN N
of IN N
treatments NNS N
was VBD N
assessed VBN N
after IN N
6 CD i
months NNS i
of IN i
therapy NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Utero-ovarian JJ o
ultrasound JJ o
analysis NN o
and CC o
color NN o
Doppler NNP o
evaluation NN o
of IN o
uterine JJ o
and CC o
stromal JJ o
ovarian JJ o
arteries NNS o
. . o

In IN N
addition NN N
, , N
analysis NN o
of IN o
brachial JJ o
artery NN o
flow-mediated JJ o
vasodilatation NN o
and CC o
24-hour JJ o
ambulatory NN o
blood NN o
pressure NN o
monitoring NN o
were VBD N
performed VBN N
. . N

Fasting VBG o
blood NN o
samples NNS o
were VBD N
drawn VBN N
for IN N
testing VBG N
biochemical JJ N
and CC N
hormonal JJ N
parameters NNS N
and CC N
nitrites/nitrates NNS N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Both NNP N
treatments NNS N
improved VBD N
hirsutism NN o
, , o
hyperandrogenemia NN o
, , o
and CC o
ultrasound NN o
and CC o
color NN o
Doppler NNP o
ovarian JJ o
parameters NNS o
. . o

Both DT N
drospirenone+ethinylestradiol NN N
or CC N
contraceptive JJ N
vaginal JJ N
ring NN N
induced VBD N
a DT N
slight JJ N
but CC N
significant JJ N
increase NN N
of IN N
diurnal JJ o
and CC o
24-hour JJ o
blood NN o
pressure NN o
. . o

Although IN N
both DT N
therapies NNS N
worsened VBD N
the DT N
lipid JJ o
profile NN o
, , N
the DT N
oral JJ N
pill NN N
administration NN N
was VBD N
associated VBN N
with IN N
a DT N
more RBR N
evident JJ N
increase NN N
of IN N
circulating VBG o
triglycerides NNS o
. . o

The DT N
6-month JJ N
treatment NN N
with IN N
the DT N
vaginal JJ N
ring NN N
significantly RB N
improved VBD N
the DT N
area NN o
under IN o
the DT o
curve NN o
for IN o
glucose NN o
, , o
insulin NN o
, , o
and CC o
C-peptide NNP o
, , N
whereas IN N
the DT N
drospirenone+ethinylestradiol NN N
pill NN N
induced VBD N
an DT N
increase NN N
in IN N
the DT N
insulinogenic JJ o
index NN o
and CC N
homeostatic JJ o
model NN o
assessment NN o
estimate NN o
for IN o
insulin NN o
resistance NN o
values NNS o
. . o

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Vaginal NNP N
hormonal JJ N
contraception NN N
appears VBZ N
to TO N
be VB N
preferable JJ N
to TO N
oral JJ N
ethinylestradiol NN N
+ NNP N
drospirenone NN N
administration NN N
in IN N
hyperinsulinemic JJ N
patients NNS N
with IN N
PCOS NNP N
. . N

-DOCSTART- -23192919- O O

B-type JJ N
natriuretic JJ N
peptide NN N
and CC N
risk NN N
of IN N
contrast-induced JJ p
acute JJ p
kidney NN p
injury NN p
in IN p
acute JJ p
ST-segment-elevation NNP p
myocardial JJ p
infarction NN p
: : p
a DT N
substudy NN p
from IN p
the DT p
HORIZONS-AMI NNP p
trial NN p
. . p

BACKGROUND NNP N
Contrast-induced NNP p
acute NN p
kidney NN p
injury NN p
( ( p
CI-AKI NNP p
) ) p
after IN N
percutaneous JJ i
coronary JJ i
intervention NN i
is VBZ N
associated VBN N
with IN N
adverse JJ N
short- NN N
and CC N
long-term JJ N
outcomes NNS N
. . N

However RB N
, , N
identification NN N
of IN N
patients NNS p
at IN p
risk NN p
for IN p
CI-AKI NNP p
is VBZ N
challenging VBG N
. . N

Using VBG N
a DT N
large JJ N
contemporary JJ N
randomized VBN N
trial NN p
database NN p
of IN p
patients NNS p
with IN p
ST-segment-elevation NNP p
myocardial JJ p
infarction NN p
, , N
we PRP N
therefore RB N
sought VBD N
to TO N
examine VB N
whether IN N
admission NN N
B-type NNP N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
levels NNS N
predict VBP N
the DT N
development NN o
of IN N
CI-AKI NNP N
. . N

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
979 CD p
ST-segment-elevation JJ p
myocardial JJ p
infarction NN p
patients NNS p
enrolled VBN p
in IN p
the DT p
Harmonizing NNP p
Outcomes NNP p
with IN p
Revascularization NNP p
and CC p
Stents NNP p
in IN p
Acute NNP p
Myocardial NNP p
Infarction NNP p
( ( p
HORIZONS-AMI NNP p
) ) p
trial NN p
had VBD N
BNP NNP o
levels NNS o
measured VBN N
in IN N
the DT N
emergency NN N
room NN N
prior RB N
to TO N
primary JJ N
percutaneous JJ i
coronary JJ i
intervention NN i
as IN N
part NN N
of IN N
the DT N
study NN N
protocol NN N
. . N

CI-AKI NNP o
was VBD N
defined VBN N
as IN N
a DT N
relative JJ N
increase NN N
in IN N
serum JJ N
creatinine NN N
of IN N
?25 NNP N
% NN N
, , N
or CC N
an DT N
absolute JJ N
increase NN N
of IN N
?0.5 NNP N
mg/dL NN N
, , N
occurring VBG N
within IN N
48 CD N
hours NNS N
after IN N
contrast NN N
administration NN o
. . o

Logistic JJ o
regression NN o
analysis NN o
was VBD o
used VBN N
to TO N
estimate VB N
the DT N
association NN N
of IN N
admission NN N
BNP NNP N
with IN N
development NN N
of IN N
CI-AKI NNP o
. . o

CI-AKI NNP o
occurred VBD o
in IN p
131 CD p
patients NNS p
( ( p
13.3 CD p
% NN p
) ) p
. . p

Baseline NNP p
BNP NNP N
was VBD N
a DT N
significant JJ N
univariable JJ N
correlate NN o
of IN o
CI-AKI NNP o
( ( o
odds NNS o
ratio VBP N
1.31 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.14-1.51 JJ N
; : N
P=0.0001 NNP N
) ) N
. . N

After IN N
multivariable JJ N
adjustment NN N
for IN N
clinical JJ N
, , N
laboratory NN N
, , N
and CC N
angiographic JJ N
variables NNS o
, , o
BNP NNP o
remained VBD N
a DT N
significant JJ N
independent JJ N
predictor NN N
of IN N
CI-AKI NNP N
( ( N
1.29 CD N
[ RB N
1.10 CD N
, , N
1.51 CD N
] NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
net JJ N
reclassification NN N
improvement NN N
was VBD N
achieved VBN N
by IN N
addition NN N
of IN N
BNP NNP N
to TO N
the DT N
current JJ o
clinical JJ o
risk NN o
prediction NN o
model NN o
( ( o
net JJ o
reclassification NN N
improvement=0.177 NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
to TO N
the DT N
Mehran NNP o
Risk NNP o
Score NNP o
( ( o
net JJ o
reclassification NN N
improvement=0.100 NN N
; : N
P=0.015 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Measurement NNP o
of IN o
serum NN o
BNP NNP o
at IN N
hospital JJ N
admission NN N
may MD N
help VB N
identify VB p
patients NNS p
who WP p
are VBP p
at IN p
risk NN p
for IN p
developing VBG p
CI-AKI NNP p
after IN i
primary JJ i
percutaneous JJ i
coronary JJ i
intervention NN i
in IN i
ST-segment-elevation NNP p
myocardial JJ p
infarction NN p
. . p

CLINICAL NNP p
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00433966 NNP N
. . N

-DOCSTART- -18164307- O O

The DT N
effect NN N
of IN N
coenzyme NN i
Q10 NNP i
on IN N
microcirculatory JJ o
endothelial JJ o
function NN o
of IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus NN p
. . p

-DOCSTART- -20654755- O O

Effects NNS N
of IN N
two CD N
combined JJ N
hormonal JJ i
contraceptives NNS i
with IN N
the DT N
same JJ N
composition NN N
and CC N
different JJ N
doses NNS N
on IN N
female JJ p
sexual JJ N
function NN N
and CC N
plasma NN N
androgen NN N
levels NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
two CD N
contraceptive JJ i
pills NNS i
with IN N
different JJ N
doses NNS N
of IN N
the DT N
same JJ N
components NNS N
, , N
on IN N
plasma JJ o
androgen NN o
levels NNS o
and CC N
female JJ o
sexual JJ o
function NN o
among IN o
women NNS o
without IN o
previous JJ o
sexual JJ o
dysfunction NN o
. . o

STUDY NNP N
DESIGN NNP N
The DT N
participants NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
to TO N
receive VB N
pills NNS N
containing VBG N
ethynylestradiol NN i
( ( i
EE NNP i
) ) i
30 CD i
mcg NN i
and CC i
levonorgestrel NN i
( ( i
LNG NNP i
) ) i
150 CD i
mcg NN i
or CC i
EE NNP i
20 CD i
mcg NN i
and CC i
LNG NNP i
100 CD i
mcg NN i
, , N
for IN N
six CD N
cycles NNS N
. . N

Sexual JJ o
function NN o
was VBD N
assessed VBN N
using VBG N
a DT N
standardized JJ N
questionnaire NN N
[ NNP N
Female NNP N
Sexual NNP N
Function NNP N
Index NNP N
( ( N
FSFI NNP N
) ) N
] NN N
. . N

Hormone NNP o
assays NNS o
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
sixth JJ N
cycle NN N
. . N

RESULTS NNP N
Forty-nine JJ p
women NNS p
were VBD p
included VBN p
in IN p
the DT p
EE30/LNG150 NNP i
group NN p
and CC p
48 CD p
in IN p
the DT p
EE20/LNG100 NNP i
group NN p
. . p

EE30/LNG150 NNP i
group NN N
presented VBD N
54 CD N
% NN N
and CC N
67 CD N
% NN N
decreases NNS N
of IN N
total JJ o
testosterone NN o
and CC o
free JJ o
androgen NN o
index NN o
, , N
respectively RB N
, , N
with IN N
statistical JJ N
significance NN N
. . N

EE20/LNG100 NNP i
presented VBD N
reductions NNS N
of IN N
20 CD N
% NN N
and CC N
42 CD N
% NN N
, , N
respectively RB N
, , N
but CC N
without IN N
statistical JJ N
significance NN N
. . N

Both DT N
groups NNS N
showed VBD N
improvements NNS N
in IN N
the DT N
FSFI NNP o
desire NN o
score NN o
, , N
but CC N
with IN N
statistical JJ N
significance NN N
only RB N
for IN N
EE20/LNG100 NNP i
group NN N
. . N

CONCLUSIONS NNP N
EE30/LNG150 NNP i
decreased VBD N
plasma JJ N
androgen NN N
levels NNS N
, , N
but CC N
there EX N
was VBD N
no DT N
impairment NN N
in IN N
sexual JJ N
desire NN N
, , N
on IN N
the DT N
other JJ N
hand NN N
, , N
sexual JJ N
desire NN N
score NN N
increased VBD N
with IN N
EE20/LNG100 NNP i
formulation NN N
. . N

-DOCSTART- -15220594- O O

Untreated VBN p
silicone NN p
breast NN p
implant JJ p
rupture NN p
. . p

Implant JJ N
rupture NN N
is VBZ N
a DT N
well-known JJ N
complication NN N
of IN N
breast NN N
implant NN N
surgery NN N
that WDT N
can MD N
pass VB N
unnoticed JJ N
by IN N
both DT N
patient NN N
and CC N
physician NN N
. . N

To TO N
date NN N
, , N
no DT N
prospective JJ N
study NN N
has VBZ N
addressed VBN N
the DT N
possible JJ N
health NN N
implications NNS N
of IN N
silicone NN N
breast NN N
implant JJ N
rupture NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
untreated JJ N
ruptures NNS N
are VBP N
associated VBN N
with IN N
changes NNS N
over IN N
time NN N
in IN N
magnetic JJ N
resonance NN N
imaging NN N
findings NNS N
, , N
serologic JJ N
markers NNS N
, , N
or CC N
self-reported JJ N
breast NN N
symptoms NNS N
. . N

A DT N
baseline JJ N
magnetic JJ N
resonance NN N
imaging VBG N
examination NN N
was VBD N
performed VBN N
in IN N
1999 CD N
on IN N
271 CD p
women NNS p
who WP p
were VBD p
randomly RB p
chosen VBN p
from IN p
a DT p
larger JJR p
cohort NN p
of IN p
women NNS p
having VBG p
cosmetic JJ p
breast NN p
implants NNS p
for IN p
a DT p
median JJ p
period NN p
of IN p
12 CD p
years NNS p
( ( p
range NN p
, , p
3 CD p
to TO p
25 CD p
years NNS p
) ) p
. . p

A DT N
follow-up JJ N
magnetic JJ N
resonance NN N
imaging VBG N
examination NN N
was VBD N
carried VBN N
out RP N
in IN N
2001 CD N
, , N
excluding VBG N
women NNS N
who WP N
underwent JJ N
explantation NN N
in IN N
the DT N
period NN N
between IN N
the DT N
two CD N
magnetic JJ N
resonance NN N
imaging NN N
examinations NNS N
( ( N
n JJ N
= NNP N
44 CD N
) ) N
. . N

On IN N
the DT N
basis NN N
of IN N
these DT N
examinations NNS N
, , N
the DT N
authors NNS N
identified VBD N
64 CD p
women NNS p
who WP p
had VBD p
at IN p
least JJS p
one CD p
ruptured VBN p
implant NN p
at IN p
the DT p
first JJ p
magnetic JJ p
resonance NN p
imaging VBG p
examination NN p
and CC N
, , N
for IN N
comparison NN N
, , N
all DT N
women NNS N
who WP N
had VBD N
intact JJ N
implants NNS N
at IN N
both DT N
examinations NNS N
( ( N
n JJ N
= NNP N
98 CD N
) ) N
. . N

Magnetic JJ N
resonance NN N
images NNS N
from IN N
the DT N
two CD N
examinations NNS N
were VBD N
compared VBN N
and CC N
changes NNS N
in IN N
rupture NN N
configuration NN N
were VBD N
evaluated VBN N
. . N

Comparisons NNS N
were VBD N
also RB N
made VBN N
for IN N
self-reported JJ N
breast NN N
symptoms NNS N
occurring VBG N
during IN N
the DT N
study NN N
period NN N
and CC N
for IN N
changes NNS N
in IN N
serum NN N
values NNS N
of IN N
antinuclear JJ N
antibodies NNS N
, , N
rheumatoid JJ N
factor NN N
, , N
and CC N
cardiolipin NN N
antibodies NNS N
immunoglobulin VBP N
G NNP N
and CC N
immunoglobulin NN N
M. NNP N
The DT N
majority NN N
of IN N
the DT N
women NNS N
with IN N
implant JJ N
rupture NN N
had VBD N
no DT N
visible JJ N
magnetic JJ o
resonance NN o
imaging NN o
changes NNS o
of IN N
their PRP$ N
ruptured JJ N
implants NNS N
. . N

For IN N
11 CD N
implants NNS N
( ( N
11 CD N
percent NN N
) ) N
in IN N
10 CD N
women NNS N
, , N
the DT N
authors NNS N
observed VBD N
progression NN N
of IN N
silicone NN o
seepage NN o
, , N
either RB N
as IN N
a DT N
conversion NN N
from IN N
intracapsular JJ N
into IN N
extracapsular JJ N
rupture NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
as IN N
progression NN N
of IN N
extra-capsular JJ N
silicone NN N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
, , N
or CC N
as IN N
increasing VBG N
herniation NN o
of IN o
the DT o
silicone NN o
within IN o
the DT o
fibrous JJ o
capsule NN o
( ( N
n JJ N
= NNP N
1 CD N
) ) N
; : N
however RB N
, , N
in IN N
most JJS N
cases NNS N
, , N
these DT N
changes NNS N
were VBD N
minor JJ N
. . N

Some DT N
changes NNS N
could MD N
be VB N
ascribed VBN N
to TO N
trauma VB N
, , N
but CC N
others NNS N
seemed VBD N
spontaneous JJ N
. . N

There EX N
was VBD N
no DT N
increase NN N
in IN N
levels NNS o
of IN o
autoantibodies NNS o
during IN N
the DT N
study NN N
period NN N
in IN N
either DT N
study NN N
group NN N
. . N

Women NNS N
with IN N
untreated JJ N
implant NN i
ruptures NNS i
reported VBD N
a DT N
significant JJ N
increase NN N
in IN N
nonspecific JJ o
breast NN o
changes NNS o
( ( N
odds NNS N
ratio NN N
, , N
2.1 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
1.2 CD N
to TO N
3.8 CD N
) ) N
compared VBN N
with IN N
women NNS N
without IN N
ruptures NNS N
. . N

On IN N
the DT N
basis NN N
of IN N
this DT N
first JJ N
study NN N
of IN N
women NNS N
with IN N
untreated JJ N
silicone NN N
breast NN N
implant JJ N
rupture NN N
, , N
the DT N
authors NNS N
conclude VBP N
that IN N
implant JJ N
rupture NN N
is VBZ N
a DT N
relatively RB N
harmless JJ N
condition NN N
, , N
which WDT N
only RB N
rarely RB N
progresses VBZ N
and CC N
gives VBZ N
rise NN N
to TO N
notable JJ N
symptoms NNS N
. . N

Even RB N
so RB N
, , N
because IN N
of IN N
a DT N
small JJ N
risk NN N
of IN N
silicone NN N
spread NN N
, , N
the DT N
authors NNS N
suggest VBP N
that IN N
women NNS N
with IN N
implant JJ N
ruptures NNS N
be VB N
followed VBN N
clinically RB N
, , N
if IN N
not RB N
operated VBN N
on IN N
. . N

Because IN N
implant JJ N
ruptures NNS N
often RB N
occur VBP N
asymptomatically RB N
, , N
any DT N
woman NN N
with IN N
silicone NN N
implants NNS N
, , N
regardless RB N
of IN N
rupture NN N
status NN N
, , N
should MD N
be VB N
evaluated VBN N
at IN N
regular JJ N
intervals NNS N
. . N

-DOCSTART- -7825420- O O

Efficacy NN N
and CC N
safety NN N
of IN N
timolol/pilocarpine JJ i
combination NN N
drops NNS N
in IN N
glaucoma NN p
patients NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
randomized VBN N
, , N
double-blind JJ N
study NN N
with IN N
two CD N
parallel JJ N
groups NNS N
was VBD N
to TO N
examine VB N
the DT N
safety NN N
, , N
efficacy NN N
and CC N
tolerability NN N
of IN N
two CD N
combination NN N
eye NN N
drops VBZ N
containing VBG N
0.5 CD N
% NN N
timolol NN i
and CC N
2 CD N
% NN N
pilocarpine NN i
( ( N
Fotil NNP N
, , N
Leiras NNP N
, , N
Finland NNP N
, , N
and CC N
Timpilo NNP N
, , N
MSD NNP N
, , N
USA NNP N
) ) N
in IN N
patients NNS p
with IN p
glaucoma NN p
or CC p
ocular JJ p
hypertension NN p
. . p

Efficacy NN N
was VBD N
determined VBN N
based VBN N
on IN N
daytime JJ N
intraocular JJ N
pressure NN N
curve NN N
and CC N
safety NN N
by IN N
examining VBG N
visual JJ N
fields NNS N
, , N
visual JJ N
acuity NN N
, , N
optic JJ N
discs NN N
, , N
by IN N
determining VBG N
blood NN N
pressure NN N
and CC N
pulse JJ N
rate NN N
, , N
and CC N
by IN N
performing VBG N
Schirmer NNP N
and CC N
fluorescein JJ N
tests NNS N
. . N

A DT N
total NN p
of IN p
89 CD p
patients NNS p
were VBD p
enrolled VBN p
, , p
and CC p
71 CD p
completed VBD p
the DT p
10-week JJ p
treatment NN p
period NN p
. . p

This DT N
study NN N
showed VBD N
that IN N
the DT N
two CD N
combinations NNS N
of IN N
0.5 CD N
% NN N
timolol JJ i
maleate NN i
and CC N
2 CD N
% NN N
pilocarpine NN i
HCl NNP i
compared VBN N
in IN N
this DT N
study NN N
were VBD N
equally RB N
effective JJ N
in IN N
reducing VBG N
intraocular JJ o
pressure NN o
. . o

The DT N
decrease NN N
in IN N
mean JJ o
daily JJ o
intraocular JJ o
pressure NN o
from IN N
0 CD N
to TO N
10 CD N
weeks NNS N
was VBD N
7.48 CD N
mmHg NN N
for IN N
Fotil NNP N
, , N
and CC N
6.31 CD N
for IN N
Timpilo NNP N
. . N

The DT N
mean JJ N
decrease NN N
in IN N
mean JJ o
daily JJ o
intraocular JJ o
pressure NN o
was VBD N
29.3 CD N
% NN N
for IN N
Fotil NNP N
, , N
and CC N
26.0 CD N
% NN N
for IN N
Timpilo NNP N
. . N

No NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
. . N

Adverse JJ o
event NN o
were VBD N
reported VBN N
by IN N
70 CD N
out IN N
of IN N
89 CD N
patients NNS N
by IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
, , N
but CC N
were VBD N
severe RB N
enough RB N
only RB N
in IN N
11 CD N
for IN N
the DT N
treatment NN N
to TO N
be VB N
discontinued VBN N
. . N

In IN N
all DT N
others NNS N
, , N
adverse JJ o
events NNS o
were VBD N
of IN N
transient JJ N
nature NN N
and CC N
considered VBN N
mild NN N
. . N

In IN N
general JJ N
, , N
adverse JJ o
events NNS o
were VBD N
similar JJ N
in IN N
both DT N
study NN N
groups NNS N
. . N

However RB N
, , N
burning VBG o
was VBD N
more RBR N
common JJ N
in IN N
patients NNS N
on IN N
Fotil NNP N
, , N
and CC N
blurring NN o
of IN o
vision NN o
and CC o
light JJ o
sensitivity NN o
were VBD N
more JJR N
common JJ N
in IN N
patients NNS N
on IN N
Timpilo NNP N
. . N

In IN N
patients NNS N
with IN N
no DT N
contraindication NN N
to TO N
beta-blockers NNS N
, , N
these DT N
drugs NNS N
appeared VBD N
to TO N
be VB N
safe JJ N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -12638099- O O

Continuous JJ i
low-level JJ i
heatwrap NN i
therapy NN i
for IN N
treating VBG N
acute JJ N
nonspecific NN N
low JJ N
back RB N
pain NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
8 CD N
hours NNS N
of IN N
continuous JJ i
low-level JJ i
heatwrap NN i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
acute JJ p
nonspecific NN p
low JJ p
back RB p
pain NN p
( ( p
LBP NNP p
) ) p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
parallel JJ N
, , N
single-blind JJ N
( ( N
investigator NN N
) ) N
, , N
placebo-controlled JJ i
, , N
multicenter JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Five CD p
community-based JJ p
research NN p
facilities NNS p
. . p

PARTICIPANTS VB N
Two-hundred JJ p
nineteen JJ p
subjects NNS p
, , p
aged VBD p
18 CD p
to TO p
55 CD p
years NNS p
, , p
with IN p
acute JJ p
nonspecific JJ p
LBP NNP p
. . p

INTERVENTION NNP N
Subjects NNPS N
were VBD N
stratified VBN N
by IN N
baseline NN N
pain NN N
intensity NN N
and CC N
gender NN N
and CC N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
evaluation NN N
of IN N
efficacy NN N
( ( i
heatwrap NN i
, , i
n=95 RB i
; : i
oral JJ i
placebo NN i
, , i
n=96 NN i
) ) i
and CC i
blinding VBG i
( ( i
oral JJ i
ibuprofen NN i
, , i
n=12 RB i
; : i
unheated VBN i
back RB i
, , i
wrap NN i
n=16 NN i
) ) i
. . i

All DT N
treatments NNS N
were VBD N
administered VBN N
for IN N
3 CD N
consecutive JJ N
days NNS N
with IN N
2 CD N
days NNS N
of IN N
follow-up JJ N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
: : N
day NN N
1 CD N
mean NN N
pain NN o
relief NN o
( ( o
0- JJ o
to TO o
5-point JJ o
verbal JJ o
response NN o
scale NN o
) ) o
. . o

Secondary JJ N
: : N
muscle NN o
stiffness NN o
( ( o
101-point JJ o
numeric NN o
rating NN o
scale NN o
) ) o
, , o
lateral JJ o
trunk NN o
flexibility NN o
( ( o
fingertip-floor JJ o
distance NN o
) ) o
, , o
and CC o
Roland-Morris NNP o
Disability NNP o
Questionnaire NNP o
over IN N
3 CD N
days NNS N
of IN N
treatment NN N
and CC N
2 CD N
days NNS N
of IN N
follow-up JJ N
. . N

RESULTS NNP N
Heatwrap NNP i
therapy NN i
was VBD N
shown VBN N
to TO N
provide VB N
significant JJ N
therapeutic JJ o
benefits NNS o
when WRB N
compared VBN N
with IN N
placebo NN i
during IN N
both CC N
the DT N
treatment NN N
and CC N
follow-up JJ N
period NN N
. . N

On IN N
day NN N
1 CD N
, , N
the DT N
heatwrap NN i
group NN N
had VBD N
greater JJR N
pain NN o
relief NN o
( ( N
1.76+/-.10 JJ N
vs NN N
1.05+/-.11 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
less JJR N
muscle NN o
stiffness NN o
( ( N
43.1+/-1.21 JJ N
vs NN N
47.6+/-1.21 CD N
, , N
P=.008 NNP N
) ) N
, , N
and CC N
increased VBD N
flexibility NN o
( ( N
18.6+/-.44 JJ N
cm NN N
vs IN N
16.5+/-.45 JJ N
cm NN N
, , N
P=.001 NNP N
) ) N
compared VBN N
with IN N
placebo NN i
. . i

Disability NN o
was VBD N
also RB N
reduced VBN N
in IN N
the DT N
heatwrap NN i
group NN N
( ( N
5.3 CD N
vs NN N
7.4 CD N
, , N
P=.0002 NNP N
) ) N
. . N

Adverse JJ o
events NNS o
were VBD N
mild JJ N
and CC N
infrequent JJ N
. . N

CONCLUSION NNP N
Continuous NNP N
low-level JJ N
heatwrap NN i
therapy NN i
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
the DT N
treatment NN N
of IN N
acute NN N
, , N
nonspecific JJ N
LBP NNP N
. . N

-DOCSTART- -991148- O O

Study NNP N
of IN N
cytosine NN i
arabinoside NN i
( ( i
NSC-63878 NNP i
) ) i
synchronization NN i
plus CC i
vincristine NN i
( ( i
NSC-67574 NNP i
) ) i
, , i
prednisone NN i
( ( i
NSC-10023 NNP i
) ) i
, , i
and CC i
L-asparaginase NNP i
( ( i
NSC-109229 NNP i
) ) i
for IN N
remission NN N
induction NN N
in IN N
advanced JJ p
acute NN p
leukemia NN p
in IN p
children NNS p
. . p

Cytosine NNP i
arabinoside NN i
( ( i
CA NNP i
) ) i
was VBD N
utilized VBN N
in IN N
efforts NNS N
to TO N
synchronize VB N
leukemic JJ N
cells NNS N
in IN N
DNA NNP N
synthesis NN N
for IN N
treatment NN N
with IN N
vincristine NN i
, , i
prednisone NN i
, , i
and CC i
L-asparaginase NNP i
in IN N
children NNS p
with IN p
acute JJ p
leukemia NN p
in IN p
relapse NN p
. . p

The DT N
results NNS N
did VBD N
not RB N
indicate VB N
any DT N
therapeutic JJ o
advantage NN o
for IN N
patients NNS N
treated VBN N
with IN N
this DT N
combination NN N
compared VBN N
to TO N
those DT N
treated VBN N
without IN N
any DT N
attempt NN N
at IN N
CA NNP i
synchronization NN i
. . i

-DOCSTART- -1678925- O O

The DT N
safety NN N
and CC N
efficacy NN N
of IN N
terazosin NN i
in IN N
the DT N
treatment NN N
of IN N
essential JJ p
hypertension NN p
in IN p
blacks NNS p
. . p

Terazosin NNP i
, , N
a DT N
new JJ N
selective JJ N
alpha NN N
1-adrenergic JJ N
receptor NN N
antagonist NN N
, , N
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
an DT N
effective JJ N
antihypertensive JJ N
agent NN N
. . N

In IN N
a DT N
series NN N
of IN N
studies NNS N
, , N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
terazosin NN i
, , i
alone RB i
and CC i
in IN i
combination NN i
with IN i
other JJ i
antihypertensive JJ i
agents NNS i
, , N
were VBD N
evaluated VBN N
in IN N
1180 CD p
black JJ p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
essential JJ p
hypertension NN p
. . p

Terazosin NNP i
was VBD N
effective JJ N
in IN N
lowering VBG N
blood NN N
pressure NN N
when WRB N
administered VBN N
alone RB N
( ( N
in IN N
dosages NNS N
of IN N
1 CD N
to TO N
80 CD N
mg/day NN N
) ) N
and CC N
when WRB N
prescribed VBN N
( ( N
in IN N
dosages NNS N
of IN N
1 CD N
to TO N
20 CD N
mg/day NN N
) ) N
in IN N
combination NN i
with IN i
other JJ i
antihypertensive JJ i
agents NNS i
. . i

In IN N
elderly JJ p
black JJ p
patients NNS p
, , N
terazosin NN N
, , N
1 CD N
to TO N
10 CD N
mg NNS N
daily RB N
, , N
was VBD N
as IN N
effective JJ N
in IN N
lowering VBG N
blood NN o
pressure NN o
as IN N
propranolol NN i
( ( N
40 CD N
to TO N
120 CD N
mg NNS N
twice RB N
daily RB N
) ) N
. . N

Changes NNS N
( ( N
mean JJ N
+/- NNP N
SE NNP N
) ) N
in IN N
sitting VBG o
diastolic JJ o
blood NN o
pressure NN o
from IN o
baseline NN o
were VBD N
-8.1 JJ N
+/- JJ N
1.4 CD N
mm NN N
Hg NNP N
for IN N
terazosin NN N
and CC N
-5.0 VB N
+/- JJ N
1.5 CD N
mm NN N
Hg NNP N
for IN N
propranolol NN i
. . i

Terazosin NNP i
( ( N
5 CD N
mg NN N
) ) N
combined VBN N
with IN N
methyclothiazide NN N
( ( N
2.5 CD N
to TO N
5 CD N
mg NN N
) ) N
produced VBD N
a DT N
significantly RB N
greater JJR N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
antihypertensive NN o
effect NN o
than IN N
that DT N
of IN N
terazosin NN i
alone RB N
. . N

Changes NNS N
( ( N
mean JJ N
+/- NNP N
SE NNP N
) ) N
in IN N
standing VBG o
diastolic JJ o
blood NN o
pressure NN o
from IN o
baseline NN o
were VBD N
-7.9 JJ N
+/- JJ N
2.0 CD N
mm NN N
Hg NNP N
for IN N
terazosin NN i
alone RB N
, , N
-15.1 JJ N
+/- JJ N
2.1 CD N
mm NN N
Hg NNP N
for IN N
terazosin NN i
plus CC i
2.5 CD i
mg NN i
of IN i
methyclothiazide NN i
, , N
and CC N
-15.0 VBD N
+/- JJ N
2.0 CD N
mm NN N
Hg NNP N
for IN N
terazosin NN i
plus CC N
5 CD N
mg NN N
of IN N
methyclothiazide NN i
. . i

Terazosin NNP N
had VBD N
a DT N
favorable JJ N
effect NN N
on IN N
serum NN o
lipid JJ o
levels NNS o
and CC N
appeared VBD N
to TO N
compensate VB N
for IN N
the DT N
negative JJ N
lipid JJ N
effects NNS N
associated VBN N
with IN N
diuretics NNS N
and CC N
beta-blockers NNS N
when WRB N
used VBN N
in IN N
combination NN N
with IN N
these DT N
agents NNS N
. . N

Terazosin NNP N
, , N
alone RB N
and CC N
combined VBN N
with IN N
other JJ N
antihypertensive JJ N
agents NNS N
, , N
was VBD N
well RB N
tolerated VBN o
with IN N
minimal JJ N
side NN N
effects NNS N
in IN N
black JJ p
hypertensive JJ p
patients NNS p
. . p

-DOCSTART- -25455414- O O

Reducing VBG N
iodine JJ N
load NN N
in IN N
hepatic JJ N
CT NNP N
for IN N
patients NNS p
with IN p
chronic JJ p
liver NN p
disease NN p
with IN N
a DT N
combination NN i
of IN i
low-tube-voltage NN i
and CC i
adaptive JJ i
statistical JJ i
iterative JJ i
reconstruction NN i
. . i

PURPOSE NNP N
To TO N
prospectively RB N
assess VB N
the DT N
effect NN N
of IN N
reduced JJ N
iodine JJ N
load NN N
to TO N
contrast VB N
enhancement NN N
, , N
image NN N
quality NN N
, , N
and CC N
detectability NN N
of IN N
hepatocellular JJ N
carcinomas NN N
( ( N
HCCs NNP N
) ) N
in IN N
hepatic JJ N
CT NNP N
with IN N
a DT N
combination NN N
of IN N
80 CD i
kVp NNS i
tube JJ i
voltage NN i
setting NN i
and CC i
adaptive JJ i
statistical JJ i
iterative JJ i
reconstruction NN i
( ( i
ASIR NNP i
) ) i
technique NN i
in IN N
patients NNS p
with IN p
chronic JJ p
liver NN p
disease NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
HIPAA-compliant NNP N
study NN N
was VBD N
approved VBN N
by IN N
our PRP$ N
institutional JJ N
review NN N
board NN N
and CC N
written VBN N
informed JJ N
consent NN N
was VBD N
obtained VBN N
in IN N
all DT N
patients NNS N
. . N

During IN N
a DT N
recent JJ N
9-month JJ N
period NN N
, , N
170 CD p
consecutive JJ p
patients NNS p
( ( p
114 CD p
men NNS p
and CC p
56 CD p
women NNS p
; : p
age NN p
range NN p
, , p
40-85 JJ p
years NNS p
; : p
mean VB p
, , p
67.7 CD p
years NNS p
) ) p
with IN p
suspected VBN p
chronic JJ p
liver NN p
diseases NNS p
were VBD N
randomized VBN i
into IN i
three CD i
CT NNP i
groups NNS i
according VBG N
to TO N
the DT N
following JJ N
iodine-load NN i
and CC i
tube-voltage NN i
protocols NNS i
: : i
600 CD i
milligram NN i
per IN i
kilogram NN i
body NN i
weight NN i
( ( i
mg/kg NN i
) ) i
iodine NN i
load NN i
and CC i
120 CD i
peak NN i
kilovolt NN i
( ( i
kVp NN i
) ) i
tube NN i
voltage NN i
setting VBG i
( ( i
600-120 JJ i
group NN i
) ) i
, , i
500 CD i
mg/kg NN i
and CC i
80 CD i
kVp NN i
( ( i
500-80 JJ i
group NN i
) ) i
, , i
and CC i
400mg/kg CD i
and CC i
80 CD i
kVp NN i
( ( i
400-80 JJ i
group NN i
) ) i
. . N

Analysis NN N
of IN N
variance NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
differences NNS N
in IN N
CT NNP o
number NN o
, , o
background NN o
noise NN o
, , o
signal-to-noise JJ o
ratio NN o
( ( o
SNR NNP o
) ) o
, , o
effective JJ o
dose NN o
, , o
HCC-to-liver NNP o
contrast-to-noise NN o
ratio NN o
( ( o
CNR NNP o
) ) o
, , o
and CC o
figure NN o
of IN o
merit NN o
( ( o
FOM NNP o
) ) o
. . o

Sensitivity NNP o
, , o
specificity NN o
, , o
and CC o
area NN o
under IN o
the DT o
receiver-operating-characteristic JJ o
curve NN o
( ( o
AUC NNP o
) ) o
were VBD N
compared VBN N
to TO N
assess VB N
the DT N
detectability NN N
of IN N
HCCs NNP N
. . N

RESULTS NNP N
Vascular NNP o
and CC o
hepatic JJ o
enhancement NN o
in IN N
the DT N
400-80 JJ N
and CC N
500-80 JJ N
groups NNS N
was VBD N
comparable JJ N
to TO N
or CC N
greater JJR N
than IN N
that DT N
in IN N
the DT N
600-120 JJ N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Subjective JJ o
image NN o
quality NN o
was VBD N
comparable JJ N
among IN N
the DT N
three CD N
groups NNS N
. . N

Sensitivity NNP o
, , o
specificity NN o
, , o
and CC o
AUC NNP o
for IN N
detecting VBG o
HCCs NNP o
were VBD N
comparable JJ N
among IN N
the DT N
groups NNS N
. . N

The DT N
effective JJ N
dose NN N
was VBD N
kept VBN N
low JJ N
( ( N
3.3-4.1 JJ N
mSv NN N
) ) N
in IN N
all DT N
three CD N
groups NNS N
. . N

CONCLUSION NNP N
Iodine NNP N
load NN N
can MD N
be VB N
reduced VBN N
by IN N
33 CD N
% NN N
in IN N
CT NNP N
of IN N
the DT N
liver NN N
with IN N
a DT N
combination NN N
of IN N
80 CD i
kVp NNS i
tube JJ i
voltage NN i
setting NN i
and CC i
ASIR NNP i
technique NN i
, , N
without IN N
compromising VBG N
the DT N
contrast NN o
enhancement NN o
, , o
image NN o
quality NN o
, , N
and CC N
detection NN o
of IN o
HCCs NNP o
. . o

-DOCSTART- -24660272- O O

Custom NNP N
tray JJ N
application NN N
of IN N
peroxide JJ i
gel NN i
as IN N
an DT N
adjunct NN N
to TO N
scaling NN i
and CC i
root NN i
planing NN i
in IN N
the DT N
treatment NN p
of IN p
periodontitis NN p
: : p
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
after IN N
six CD N
months NNS N
. . N

OBJECTIVE NNP N
Scaling NNP i
and CC i
root NN i
planing NN i
( ( i
SRP NNP i
) ) i
is VBZ N
the DT N
primary JJ N
non-surgical JJ N
treatment NN N
for IN N
periodontitis NN N
, , N
but CC N
its PRP$ N
effectiveness NN N
is VBZ N
limited VBN N
. . N

Consequently RB N
, , N
various JJ N
adjunctive JJ N
therapies NNS N
have VBP N
been VBN N
investigated VBN N
to TO N
improve VB N
clinical JJ N
outcome NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
clinical JJ N
effects NNS N
of IN N
one CD N
SRP NNP i
procedure NN N
alone RB N
or CC N
combined VBN N
with IN N
local JJ N
administration NN N
of IN N
hydrogen NN i
peroxide NN i
gel NN i
using VBG N
customized JJ N
trays NNS N
for IN N
the DT N
treatment NN N
of IN N
subjects NNS p
with IN p
chronic JJ p
periodontitis NN p
over IN N
a DT N
period NN N
of IN N
six CD N
months NNS N
. . N

METHODS NNP N
An DT N
examiner-blind JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
30 CD p
subjects NNS p
with IN p
moderate JJ p
to TO p
advanced JJ p
periodontitis NN p
who WP N
were VBD N
randomized VBN N
to TO N
SRP VB i
alone RB N
or CC N
SRP NNP i
combined VBN i
with IN N
prescription NN N
custom-tray JJ N
application NN N
( ( N
Perio NNP N
Tray NNP N
) ) N
of IN N
1.7 CD i
% NN i
hydrogen NN i
peroxide NN i
gel NN i
( ( i
Perio NNP i
Gel NNP i
) ) i
for IN N
a DT N
period NN N
of IN N
three CD N
months NNS N
, , N
then RB N
extended VBD N
to TO N
six CD N
months NNS N
. . N

Following VBG N
impressions NNS N
for IN N
the DT N
test NN N
group NN N
, , N
all DT N
subjects NNS N
brushed VBN i
twice RB i
daily RB i
with IN i
a DT i
regular JJ i
dentifrice NN i
and CC i
toothbrush NN i
for IN N
a DT N
four-week JJ N
acclimation NN N
phase NN N
to TO N
standardize VB N
oral JJ N
conditions NNS N
( ( N
while IN N
trays NNS N
were VBD N
fabricated VBN N
) ) N
prior RB N
to TO N
initiating VBG N
the DT N
treatment NN N
phase NN N
. . N

SRP NNP i
was VBD N
performed VBN N
three CD N
weeks NNS N
after IN N
baseline NN N
, , N
and CC N
clinical JJ N
assessments NNS N
, , N
i.e. FW N
, , N
pocket NN o
probing VBG o
depth NN o
( ( o
PPD NNP o
) ) o
and CC o
bleeding VBG o
index NN o
( ( o
BI NNP o
) ) o
, , N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
13 CD N
, , N
and CC N
26 CD N
weeks NNS N
of IN N
peroxide JJ i
gel NN i
applications NNS N
. . N

Clinical JJ N
variables NNS N
were VBD N
compared VBN N
by IN N
ANCOVA NNP N
and CC N
paired VBD N
t-tests NNS N
after IN N
each DT N
treatment NN N
interval NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
13 CD p
test NN p
and CC p
15 CD p
control NN p
subjects NNS p
completed VBD N
the DT N
original JJ N
three-month JJ N
trial NN N
, , N
of IN N
whom WP N
10 CD N
test NN N
and CC N
13 CD N
control NN N
subjects NNS N
finished VBD N
the DT N
three-month JJ N
extension NN N
. . N

After IN N
two CD N
weeks NNS N
of IN N
peroxide NN i
gel NN i
use NN N
prior RB N
to TO N
SRP NNP i
, , N
mean JJ o
PPD NNP o
for IN N
the DT N
test NN N
group NN N
significantly RB N
decreased VBN N
from IN N
baseline NN N
by IN N
0.21 CD N
mm NNS N
and CC N
mean JJ o
BI NNP o
significantly RB N
dropped VBD N
by IN N
0.14 CD N
; : N
clinical JJ N
parameters NNS N
for IN N
the DT N
control NN N
group NN N
were VBD N
unchanged JJ N
. . N

Two CD N
weeks NNS N
following VBG N
SRP NNP i
, , N
mean JJ o
PPD NNP o
significantly RB N
decreased VBD N
from IN N
baseline NN N
by IN N
0.65 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.17 CD N
mm NN N
for IN N
the DT N
control NN N
; : N
mean CC N
BI NNP N
significantly RB N
dropped VBD N
by IN N
0.17 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.05 CD N
for IN N
the DT N
control NN N
. . N

Ten CD N
weeks NNS N
following VBG N
SRP NNP i
, , N
mean JJ o
PPD NNP o
decreases NNS N
were VBD N
0.77 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.13 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
mean JJ o
BI NNP o
reductions NNS N
were VBD N
0.14 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
control NN N
. . N

For IN N
subjects NNS N
who WP N
completed VBD N
the DT N
three-month JJ N
extension NN N
( ( N
i.e. JJ N
, , N
23 CD N
weeks NNS N
post-SRP NN N
) ) N
, , N
mean JJ o
PPD NNP o
decreases NNS N
were VBD N
0.72 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.13 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
mean JJ o
BI NNP o
reductions NNS N
were VBD N
0.05 CD N
for IN N
the DT N
test NN N
group NN N
and CC N
0.01 CD N
for IN N
the DT N
control NN N
. . N

Analysis NN N
of IN N
deeper JJR N
pockets NNS N
( ( N
i.e. NN N
, , N
> VBZ N
5 CD N
mm NN N
at IN N
baseline NN N
) ) N
showed VBD N
the DT N
same JJ N
relationship NN N
for IN N
PPD NNP N
, , N
but CC N
with IN N
larger JJR N
differences NNS N
between IN N
groups NNS N
. . N

For IN N
example NN N
, , N
after IN N
two CD N
weeks NNS N
of IN N
peroxide NN i
gel NN i
use NN N
prior RB N
to TO N
SRP NNP i
, , N
mean JJ o
PPD NNP o
decreased VBN N
by IN N
0.48 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
compared VBN N
to TO N
0.04 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

Two CD N
weeks NNS N
after IN N
SRP NNP i
, , N
mean JJ o
PPD NNP o
decreased VBD N
from IN N
baseline NN N
by IN N
1.40 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.60 CD N
mm NN N
for IN N
the DT N
control NN N
, , N
and CC N
10 CD N
weeks NNS N
after IN N
SRP NNP N
by IN N
1.57 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.58 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

After IN N
the DT N
extension NN N
( ( N
i.e. JJ N
, , N
23 CD N
weeks NNS N
post-SRP NN N
) ) N
, , N
mean JJ o
PPD NNP o
changed VBD N
from IN N
baseline NN N
by IN N
1.50 CD N
mm NN N
for IN N
the DT N
test NN N
group NN N
and CC N
0.55 CD N
mm NN N
for IN N
the DT N
control NN N
. . N

With IN N
the DT N
exception NN N
of IN N
BI NNP N
at IN N
23 CD N
weeks NNS N
post-SRP JJ N
, , N
all DT N
reductions NNS N
cited VBN N
above IN N
for IN N
the DT N
test NN N
group NN N
were VBD N
statistically RB N
significantly RB N
different JJ N
from IN N
the DT N
control NN N
group NN N
for IN N
both DT N
PPD NNP N
and CC N
BI NNP N
for IN N
all DT N
comparisons NNS N
. . N

CONCLUSION NN N
When WRB N
compared VBN N
with IN N
SRP NNP i
alone RB N
, , N
clinical JJ N
improvements NNS N
in IN N
PPD NNP N
( ( N
e.g. NN N
, , N
-1.0 NNP N
mm NN N
for IN N
pockets NNS N
> VBP N
5 CD N
mm NN N
at IN N
baseline NN N
) ) N
were VBD N
maintained VBN N
for IN N
up IN N
to TO N
six CD N
months NNS N
after IN N
SRP NNP i
with IN N
adjunctive JJ N
use NN N
of IN N
1.7 CD N
% NN N
hydrogen NN i
peroxide NN i
gel NN i
, , N
locally RB N
administered VBN N
using VBG N
prescription NN N
customized VBD N
trays NNS N
in IN N
the DT N
treatment NN N
of IN N
subjects NNS p
with IN p
moderate JJ p
to TO p
advanced JJ p
periodontitis NN p
. . p

-DOCSTART- -1778354- O O

Prevention NN N
of IN N
type NN p
2 CD p
( ( p
non-insulin-dependent JJ p
) ) p
diabetes VBZ p
mellitus VBN p
by IN N
diet JJ N
and CC N
physical JJ N
exercise NN N
. . N

The DT N
6-year JJ N
Malm? NNP N
feasibility NN N
study NN N
. . N

From IN N
a DT N
previously RB N
reported VBN N
5-year JJ N
screening VBG N
programme NN N
of IN p
6,956 CD p
47-49-year-old JJ p
Malm? NNP p
males NNS p
, , p
a DT p
series NN p
of IN p
41 CD p
subjects NNS p
with IN p
early-stage JJ p
Type NNP p
2 CD p
( ( p
non-insulin-dependent JJ p
) ) p
diabetes VBZ p
mellitus JJ p
and CC p
181 CD p
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
were VBD p
selected VBN N
for IN N
prospective JJ N
study NN N
and CC N
to TO N
test VB N
the DT N
feasibility NN N
aspect NN N
of IN N
long-term JJ N
intervention NN N
with IN N
an DT N
emphasis NN N
on IN N
life-style JJ i
changes NNS i
. . i

A DT N
5-year JJ N
protocol NN N
, , N
including VBG N
an DT N
initial JJ N
6-months JJ N
( ( N
randomised VBN N
) ) N
pilot NN N
study NN i
, , i
consisting VBG i
of IN i
dietary JJ i
treatment NN i
and/or JJ i
increase NN i
of IN i
physical JJ i
activity NN i
or CC i
training NN i
with IN i
annual JJ i
check-ups NNS i
, , i
was VBD N
completed VBN N
by IN N
90 CD N
% NN N
of IN N
subjects NNS o
. . o

Body NNP o
weight NN o
was VBD o
reduced VBN N
by IN N
2.3-3.7 JJ N
% NN N
among IN N
participants NNS N
, , N
whereas JJ N
values NNS N
increased VBN N
by IN N
0.5-1.7 CD N
% NN N
in IN N
non-intervened JJ N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
and CC N
in IN N
normal JJ N
control NN N
subjects NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD o
) ) o
; : o
maximal JJ o
oxygen NN o
uptake NN o
( ( o
ml.min-1.kg-1 JJ N
) ) N
was VBD N
increased VBN N
by IN N
10-14 CD N
% NN N
vs NN N
decreased VBN N
by IN N
5-9 JJ N
% NN N
, , N
respectively RB N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD o
) ) o
. . o

Glucose JJ o
tolerance NN o
was VBD o
normalized VBN N
in IN N
greater JJR N
than IN N
50 CD N
% NN N
of IN N
subjects NNS N
with IN N
impaired JJ N
glucose JJ N
tolerance NN N
, , N
the DT N
accumulated JJ o
incidence NN o
of IN o
diabetes NNS o
was VBD o
10.6 CD N
% NN N
, , N
and CC N
more JJR N
than IN N
50 CD N
% NN N
of IN N
the DT N
diabetic JJ N
patients NNS N
were VBD N
in IN N
remission NN o
after IN o
a DT N
mean JJ N
follow-up NN N
of IN N
6 CD N
years NNS o
. . o

Blood NNP o
pressure NN o
, , o
lipids NNS o
, , o
and CC o
hyperinsulinaemia NN o
were VBD o
reduced VBN N
and CC o
early JJ o
insulin NN o
responsiveness NN o
to TO o
glucose VB o
loading VBG o
preserved VBN N
. . N

Improvement NN N
in IN N
glucose JJ o
tolerance NN o
was VBD o
correlated VBN N
to TO N
weight VB o
reduction NN o
( ( o
r JJ N
= NN N
0.19 CD N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
and CC o
increased JJ o
fitness NN o
( ( o
r JJ N
= NN N
0.22 CD N
, , N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

Treatment NN N
was VBD N
safe JJ N
, , N
and CC N
mortality NN N
was VBD N
low JJ N
( ( N
in IN N
fact NN N
33 CD N
% NN N
lower JJR N
than IN N
in IN N
the DT N
remainder NN N
of IN N
the DT N
cohort NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -2544249- O O

Treatment NN N
of IN N
Wilms NNP p
' POS p
tumor NN p
. . p

Results NNS N
of IN N
the DT N
Third NNP N
National NNP p
Wilms NNP p
' POS p
Tumor NNP p
Study NNP N
. . N

The DT N
Third NNP N
National NNP p
Wilms NNP p
' POS p
Tumor NNP p
Study NNP N
sought VBD N
to TO N
reduce VB N
treatment NN N
for IN N
low-risk JJ p
patients NNS p
and CC N
find VB N
better JJR N
chemotherapy NN i
for IN N
those DT p
at IN p
high JJ p
risk NN p
for IN p
relapse NN p
. . p

Eligible JJ p
patients NNS p
( ( p
1439 CD p
) ) p
were VBD N
randomized VBN N
according VBG N
to TO N
stage NN p
( ( p
I-IV NNP p
) ) p
and CC p
histology NN p
( ( p
favorable JJ p
[ NN p
FH NNP p
] NNP p
or CC p
unfavorable JJ p
[ JJ p
UH NNP p
] NNP p
) ) p
, , p
and CC p
contributed VBD p
data NNS p
to TO p
survival VB p
and CC p
relapse-free JJ p
survival NN p
( ( p
RFS NNP p
) ) p
analyses VBZ p
. . p

Four-year JJ p
( ( p
postnephrectomy NN p
) ) p
survival NN p
percentages NNS p
and CC N
randomized VBN N
treatment NN N
regimens NNS N
for IN N
low-risk JJ N
patients NNS N
were VBD N
96.5 CD N
% NN N
for IN N
607 CD N
Stage NNP N
I/FH NNP N
patients NNS N
who WP N
received VBD N
dactinomycin NN i
( ( i
Actinomycin NNP i
D NNP i
[ NNP i
AMD NNP i
] NNP i
, , N
Merck NNP N
Sharp NNP N
& CC N
Dohme NNP N
, , N
West NNP N
Point NNP N
, , N
PA NNP N
) ) N
and CC N
vincristine NN i
( ( i
VCR NNP i
) ) i
for IN N
10 CD N
weeks NNS N
versus RB N
6 CD N
months NNS N
; : N
92.2 CD N
% NN N
for IN N
278 CD N
Stage NNP N
II/FH NNP N
patients NNS N
; : N
and CC N
86.9 CD N
% NN N
for IN N
275 CD N
Stage NNP N
III/FH NNP N
patients NNS N
who WP N
received VBD N
AMD NNP i
+ NNP i
VCR NNP i
+/- JJ i
Adriamycin NNP i
( ( i
ADR NNP i
, , N
Adria NNP N
Laboratories NNPS N
, , N
Columbus NNP N
, , N
OH NNP N
) ) N
for IN N
15 CD N
months NNS N
. . N

Stage NNP N
II/FH NNP N
patients NNS N
also RB N
had VBD N
either CC N
zero CD N
or CC N
2000 CD N
cGy NN N
irradiation NN N
( ( N
RT NNP N
) ) N
postoperatively RB N
and CC N
Stage NNP N
III/FH NNP N
patients NNS N
either RB N
1000 CD N
or CC N
2000 CD N
cGy NN N
. . N

Four-year JJ o
survival NN o
was VBD N
73.0 CD N
% NN N
for IN N
279 CD N
high-risk JJ p
patients NNS p
( ( N
any DT N
Stage NNP N
IV NNP N
, , N
all DT N
UH NNP N
) ) N
who WP N
received VBD N
postoperative JJ i
radiation NN i
therapy NN i
( ( i
RT NNP i
) ) i
and CC N
AMD NNP i
+ NNP i
VCR NNP i
+ NNP i
ADR NNP i
+/- JJ i
cyclophosphamide NN i
( ( i
CPM NNP i
) ) i
. . i

Statistical JJ N
analysis NN N
of IN N
survival NN o
and CC o
RFS NNP o
experience NN o
shows VBZ o
that IN N
the DT N
less RBR N
intensive JJ N
therapy NN N
does VBZ N
not RB N
worsen VB N
results NNS N
for IN N
low-risk JJ N
patients NNS N
and CC N
CPM NNP i
does VBZ N
not RB N
benefit VB N
those DT N
at IN N
high JJ N
risk NN N
. . N

-DOCSTART- -24930179- O O

The DT N
effects NNS o
of IN N
prism NN N
adaptation NN N
on IN N
egocentric JJ N
metric JJ o
distance NN o
estimation NN o
. . o

OBJECTIVE CC N
The DT N
present JJ N
experiment NN N
evaluated VBD N
whether IN N
training VBG N
involving VBG N
throwing VBG N
transferred VBN N
to TO N
metric JJ N
distance NN N
estimation NN N
( ( N
i.e. FW N
, , N
describing VBG N
in IN N
feet NNS N
and CC N
inches VBZ N
the DT N
distance NN N
between IN N
oneself NN N
and CC N
targets NNS N
) ) N
. . N

BACKGROUND NNP N
In IN N
prior JJ N
work NN N
, , N
we PRP N
found VBD N
that IN N
metric JJ N
estimation NN N
training NN N
negatively RB N
transferred VBN N
to TO N
throwing VBG N
. . N

We PRP N
explained VBD N
our PRP$ N
results NNS N
in IN N
terms NNS N
of IN N
cognitive JJ N
intrusion NN N
. . N

The DT N
present JJ N
study NN N
tested VBD N
that IN N
possibility NN N
by IN N
swapping VBG N
our PRP$ N
training NN N
and CC N
transfer NN N
tasks NNS N
. . N

METHOD NNP N
During IN N
pretesting VBG N
, , N
participants NNS p
verbally RB i
estimated VBD i
the DT i
metric JJ i
distances NNS i
between IN p
themselves PRP p
and CC p
targets NNS p
, , p
or CC p
they PRP p
threw VBD i
a DT i
beanbag NN i
to TO i
targets NNS i
. . i

During IN N
training NN N
, , N
participants NNS i
donned VBD i
goggles NNS i
that WDT N
distorted VBD N
their PRP$ N
vision NN N
. . N

While IN N
wearing VBG N
the DT N
goggles NNS N
, , N
they PRP N
threw VBD i
a DT i
beanbag NN i
to TO i
targets NNS i
. . i

Half NNP N
received VBD N
feedback RB N
. . N

During IN N
posttesting VBG N
, , N
participants NNS N
removed VBD N
the DT N
distorting NN N
goggles NNS i
and CC N
completed VBD N
the DT N
same JJ N
task NN N
that IN N
they PRP N
performed VBD N
during IN N
pretesting VBG N
. . N

RESULTS VB N
The DT N
results NNS N
indicated VBD N
that IN N
the DT N
distorting NN N
goggles NNS N
degraded VBD N
throwing VBG N
at IN N
the DT N
beginning NN N
of IN N
training NN N
, , N
visual JJ N
feedback NN N
improved VBD N
throwing VBG N
during IN N
training NN N
, , N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
persisted VBN N
into IN N
the DT N
throwing VBG N
posttest NN N
, , N
and CC N
the DT N
effects NNS N
of IN N
training VBG N
with IN N
feedback NN N
did VBD N
not RB N
transfer VB N
to TO N
the DT N
verbal JJ o
metric JJ o
estimation NN o
posttest NN N
. . N

CONCLUSION NNP N
Training VBG N
involving VBG N
throwing NN o
was VBD N
effective JJ o
, , N
but CC N
did VBD N
not RB N
transfer VB N
to TO N
verbal VB o
metric JJ o
distance NN o
estimation NN o
. . o

This DT N
supports VBZ N
our PRP$ N
argument NN N
that IN N
the DT N
negative JJ N
transfer NN N
observed VBN N
in IN N
our PRP$ N
previous JJ N
study NN N
stemmed VBD N
from IN N
cognitive JJ N
intrusion NN N
. . N

APPLICATION VB N
The DT N
present JJ N
experiment NN N
suggests VBZ N
that IN N
the DT N
creation NN N
of IN N
distance NN N
estimation NN N
training NN N
should MD N
begin VB N
with IN N
a DT N
careful JJ N
analysis NN N
of IN N
the DT N
transfer NN N
task NN N
, , N
and CC N
that DT N
distance NN N
estimation NN N
training NN N
programs NNS N
should MD N
explicitly RB N
teach VB N
trainees NNS p
that IN p
their PRP$ p
training NN p
will MD N
not RB N
generalize VB N
to TO N
all DT N
distance NN N
estimation NN N
tasks NNS N
. . N

-DOCSTART- -24687182- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
an DT N
inference NN i
generation NN i
strategy NN i
intervention NN i
for IN N
adults NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorder NN p
. . p

PURPOSE VB N
The DT N
present JJ N
intervention NN N
study NN N
investigated VBD N
the DT N
efficacy NN N
of IN N
the DT N
ACT NNP i
& CC i
Check NNP i
Strategy NNP i
intervention NN i
to TO N
improve VB N
inference NN o
generation NN o
when WRB o
reading NN o
, , o
metacognitive JJ o
ability NN o
, , o
general JJ o
reading NN o
comprehension NN o
, , o
and CC o
social JJ o
inference NN o
ability NN o
in IN N
adults NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorder NN p
( ( p
HF-ASD NNP p
) ) p
. . p

METHOD NNP N
Twenty-five JJ p
adults NNS p
with IN p
HF-ASD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
treatment NN N
or CC N
a DT N
control NN i
group NN i
. . i

Treatment JJ N
sessions NNS N
were VBD N
conducted VBN N
in IN N
1-hr JJ N
sessions NNS N
, , N
twice RB N
a DT N
week NN N
, , N
for IN N
a DT N
total NN N
of IN N
6 CD N
weeks NNS N
. . N

Treatment NNP N
focused VBD N
on IN N
explicit JJ i
instruction NN i
of IN i
components NNS i
of IN i
inference NN i
generation NN i
, , i
categories NNS i
of IN i
inferences NNS i
, , i
and CC i
increasingly RB i
independent JJ i
strategy NN i
use NN i
. . i

RESULTS VB N
The DT N
treatment NN N
group NN N
demonstrated VBD N
significantly RB N
superior JJ o
performance NN o
on IN o
1 CD o
of IN o
2 CD o
measures NNS o
of IN o
inference NN o
generation NN o
in IN o
reading NN o
and CC o
1 CD o
measure NN o
of IN o
metacognitive JJ o
ability NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Significant JJ N
differences NNS N
between IN N
groups NNS N
were VBD N
not RB N
found VBN N
on IN N
measures NNS o
of IN o
reading VBG o
comprehension NN o
or CC o
social JJ o
inference NN o
ability NN o
. . o

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
ACT NNP i
& CC i
Check NNP i
Strategy NNP i
was VBD N
effective JJ N
in IN N
improving VBG N
participants NNS o
' POS o
ability NN o
to TO o
generate VB o
inferences NNS o
in IN o
reading NN o
and CC o
certain JJ o
metacognitive JJ o
abilities NNS o
, , N
but CC N
the DT N
skills NNS N
do VBP N
not RB N
appear VB N
to TO N
generalize VB N
to TO N
other JJ N
social JJ N
communication NN N
contexts NNS N
, , N
such JJ N
as IN N
social JJ o
inference NN o
generation NN o
. . o

This DT N
research NN N
provides VBZ N
a DT N
measure NN N
of IN N
support NN N
for IN N
explicitly RB N
teaching VBG N
inference NN N
generation NN N
to TO N
address VB N
a DT N
reading NN o
inference NN o
deficit NN o
in IN N
adults NNS p
with IN p
HF-ASD NNP p
. . p

-DOCSTART- -20817247- O O

Oral NNP i
sucrose VBD i
as IN N
an DT N
analgesic JJ N
drug NN N
for IN N
procedural JJ N
pain NN N
in IN N
newborn JJ p
infants NNS p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Many JJ N
infants NNS p
admitted VBN p
to TO p
hospital VB p
undergo RB N
repeated VBN N
invasive JJ N
procedures NNS N
. . N

Oral NNP i
sucrose NN i
is VBZ N
frequently RB N
given VBN N
to TO N
relieve VB N
procedural JJ N
pain NN N
in IN N
neonates NNS p
on IN N
the DT N
basis NN N
of IN N
its PRP$ N
effect NN N
on IN N
behavioural JJ N
and CC N
physiological JJ N
pain NN N
scores NNS N
. . N

We PRP N
assessed VBD N
whether IN N
sucrose JJ i
administration NN N
reduces NNS N
pain-specific JJ o
brain NN o
and CC o
spinal JJ o
cord NN o
activity NN o
after IN N
an DT N
acute JJ p
noxious JJ p
procedure NN p
in IN N
newborn JJ p
infants NNS p
. . p

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
, , N
59 CD p
newborn JJ p
infants NNS p
at IN p
University NNP p
College NNP p
Hospital NNP p
( ( p
London NNP p
, , p
UK NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
0?5 CD N
mL JJ N
24 CD i
% NN i
sucrose JJ i
solution NN i
or CC N
0?5 CD N
mL NNS N
sterile JJ i
water NN i
2 CD i
min NN N
before IN N
undergoing VBG N
a DT N
clinically RB N
required VBN N
heel NN N
lance NN N
. . N

Randomisation NN N
was VBD N
by IN N
a DT N
computer-generated JJ N
randomisation NN N
code NN N
, , N
and CC N
researchers NNS N
, , N
clinicians NNS N
, , N
participants NNS N
, , N
and CC N
parents NNS N
were VBD N
masked VBN N
to TO N
the DT N
identity NN N
of IN N
the DT N
solutions NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD o
pain-specific JJ o
brain NN o
activity NN o
evoked VBN o
by IN o
one CD N
time-locked JJ N
heel NN N
lance NN o
, , o
recorded VBN o
with IN o
electroencephalography NN o
and CC o
identified VBN o
by IN o
principal JJ o
component NN o
analysis NN o
. . o

Secondary JJ N
measures NNS N
were VBD o
baseline JJ o
behavioural JJ o
and CC o
physiological JJ o
measures NNS o
, , o
observational JJ o
pain NN o
scores NNS o
( ( o
PIPP NNP o
) ) o
, , o
and CC o
spinal JJ o
nociceptive JJ o
reflex NN o
withdrawal NN o
activity NN o
. . o

Data NNS N
were VBD N
analysed VBN N
per IN N
protocol NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
, , N
number NN N
ISRCTN78390996 NNP N
. . N

FINDINGS NNP N
29 CD N
infants NNS p
were VBD p
assigned VBN N
to TO N
receive VB i
sucrose NN i
and CC i
30 CD N
to TO N
sterilised JJ i
water NN i
; : i
20 CD i
and CC N
24 CD N
infants NNS N
, , N
respectively RB N
, , N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
of IN N
the DT N
primary JJ N
outcome JJ N
measure NN o
. . o

Nociceptive JJ o
brain NN o
activity NN o
after IN o
the DT o
noxious JJ o
heel NN o
lance NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
infants NNS N
who WP N
received VBD i
sucrose JJ i
and CC i
those DT N
who WP N
received VBD i
sterile JJ i
water NN i
( ( i
sucrose JJ i
: : i
mean JJ i
0?10 CD N
, , N
95 CD N
% NN N
CI NNP N
0?04-0?16 CD i
; : i
sterile JJ i
water NN i
: : i
mean NN i
0?08 CD N
, , N
0?04-0?12 CD N
; : N
p=0?46 NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
recorded VBN N
between IN N
the DT i
sucrose NN i
and CC i
sterile JJ i
water NN i
groups NNS i
in IN N
the DT N
magnitude NN N
or CC o
latency NN o
of IN o
the DT o
spinal JJ o
nociceptive JJ o
reflex NN o
withdrawal NN o
recorded VBN o
from IN N
the DT N
biceps NNS N
femoris NN N
of IN N
the DT N
stimulated JJ N
leg NN N
. . N

The DT N
PIPP NNP o
score NN o
was VBD o
significantly RB N
lower JJR N
in IN N
infants NNS N
given VBN i
sucrose JJR i
than IN N
in IN N
those DT N
given VBN i
sterile JJ i
water NN i
( ( i
mean JJ i
5?8 CD N
, , N
95 CD N
% NN N
CI NNP N
3?7-7?8 CD N
vs NN N
8?5 CD N
, , N
7?3-9?8 CD N
; : N
p=0?02 NN N
) ) N
and CC N
significantly RB N
more JJR p
infants NNS p
had VBD p
no DT N
change NN N
in IN N
facial JJ N
expression NN N
after IN N
sucrose JJ i
administration NN i
( ( N
seven CD N
of IN N
20 CD N
[ JJ N
35 CD N
% NN N
] JJ N
vs NN N
none NN N
of IN N
24 CD N
; : N
p NN N
< VBZ N
0?0001 CD N
) ) N
. . N

INTERPRETATION NNP N
Our PRP$ N
data NNS N
suggest VBP N
that IN N
oral JJ N
sucrose NN i
does VBZ i
not RB N
significantly RB N
affect JJ N
activity NN N
in IN p
neonatal JJ p
brain NN p
or CC N
spinal JJ N
cord NN N
nociceptive JJ N
circuits NNS N
, , N
and CC N
therefore RB N
might MD N
not RB N
be VB N
an DT N
effective JJ N
analgesic JJ N
drug NN N
. . N

The DT N
ability NN N
of IN i
sucrose NN i
to TO i
reduce VB i
clinical JJ N
observational JJ N
scores NNS N
after IN N
noxious JJ N
events NNS N
in IN N
newborn JJ p
infants NNS p
should MD N
not RB N
be VB N
interpreted VBN N
as IN N
pain NN N
relief NN N
. . N

FUNDING NNP N
Medical NNP N
Research NNP N
Council NNP N
. . N

-DOCSTART- -12932301- O O

Advice NN N
or CC N
exercise NN N
for IN N
chronic JJ p
whiplash NN p
disorders NNS p
? . N
Design NNP N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Whiplash-associated JJ p
disorder NN p
( ( N
or CC N
whiplash NN N
) ) N
is VBZ N
a DT N
common JJ N
condition NN N
incurring VBG N
considerable JJ N
expense NN N
in IN N
social JJ N
and CC N
economic JJ N
terms NNS N
. . N

A DT N
lack NN N
of IN N
research NN N
on IN N
effective JJ N
therapy NN N
for IN N
patients NNS p
with IN p
chronic JJ p
whiplash NN p
associated VBN p
disorders NNS p
prompted VBD N
the DT N
design NN N
of IN N
the DT N
current JJ N
study NN N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
randomised VBN N
controlled VBN N
trial NN N
is VBZ N
to TO N
determine VB N
the DT N
effects NNS o
of IN o
a DT o
physical JJ o
activity NN o
program NN o
for IN o
people NNS o
with IN o
chronic JJ o
( ( o
symptoms NNS o
of IN o
> JJ o
3 CD o
months NNS o
duration NN o
) ) o
whiplash NN o
. . o

A DT N
secondary JJ N
aim NN N
is VBZ N
to TO N
determine VB N
if IN N
pain JJ o
severity NN o
, , o
level NN o
of IN o
disability NN o
and CC o
fear NN o
of IN o
movement/ NN o
( ( o
re NN o
) ) o
injury NN o
predict VBP N
response NN o
to TO N
a DT N
physical JJ N
activity NN N
program NN N
. . N

METHODS/DESIGN NNP N
This DT N
paper NN N
presents VBZ N
the DT N
rationale NN N
and CC N
design NN N
of IN N
a DT N
randomised VBN N
controlled VBN N
trial NN N
examining VBG N
the DT N
effects NNS o
of IN o
advice NN o
and CC o
individualized JJ o
sub-maximal JJ o
exercise NN o
programs NNS o
in IN N
the DT N
treatment NN N
of IN N
whiplash NN p
associated VBN p
disorders NNS p
. . p

DISCUSSION NNP N
This DT N
paper NN N
highlights VBZ N
the DT N
design NN N
, , N
methods NNS N
and CC N
operational JJ N
aspects NNS N
of IN N
a DT N
significant JJ N
clinical JJ N
trial NN N
in IN N
the DT N
area NN N
of IN N
whiplash NN p
and CC p
chronic JJ p
pain NN p
. . p

-DOCSTART- -18983318- O O

Two-year JJ N
prospective JJ N
clinical JJ N
comparison NN N
of IN N
immediate JJ i
replacement NN i
vs. FW i
immediate JJ i
restoration NN i
of IN i
single JJ i
tooth NN i
in IN p
the DT p
esthetic JJ p
zone NN p
. . p

AIM NNP N
To TO N
compare VB N
the DT N
immediate JJ N
restoration NN N
of IN N
single JJ i
implants NNS i
in IN N
the DT N
esthetic JJ N
zones NNS N
performed VBN N
on IN N
implants NNS N
placed VBN N
immediately RB N
after IN N
tooth JJ N
extraction NN N
or CC N
8 CD N
weeks NNS N
later RB N
( ( N
immediate JJ N
replacement NN i
vs. FW N
immediate JJ N
restoration NN i
) ) i
. . N

METHODS NNP N
Sixteen JJ p
patients NNS p
( ( p
10 CD p
women NNS p
and CC p
6 CD p
men NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
35 CD p
years NNS p
( ( p
ranging VBG p
from IN p
21 CD p
to TO p
49 CD p
years NNS p
old JJ p
) ) p
were VBD p
treated VBN p
from IN p
2004 CD p
to TO p
2005 CD p
for IN p
single-tooth JJ p
replacement NN p
in IN p
the DT p
upper JJ p
arch NN p
. . p

The DT p
patients NNS p
were VBD p
randomly RB p
divided VBN p
into IN N
two CD N
groups NNS N
: : N
in IN N
the DT N
test NN N
group NN N
patients NNS N
received VBD N
implants NNS i
placed VBN i
and CC i
restored VBN i
( ( N
non-occlusal JJ N
loading NN N
) ) N
at IN N
the DT N
time NN N
of IN N
tooth JJ N
extraction NN N
; : N
in IN N
the DT N
control NN N
group NN N
implants NNS i
were VBD i
placed VBN i
8 CD N
weeks NNS N
after IN i
tooth DT i
extraction NN i
and CC i
immediately RB i
restored VBN i
. . i

All PDT p
the DT p
patients NNS p
received VBD p
tapered JJ i
effect NN i
( ( i
TE NNP i
) ) i
implants NNS i
from IN p
the DT p
Straumann NNP p
Dental NNP p
Implant NNP p
System NNP p
. . p

The DT N
following JJ N
parameters NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
moment NN N
of IN N
provisional JJ N
restoration NN N
( ( N
within IN N
48 CD N
h NN N
after IN N
implant JJ N
placement NN N
) ) N
and CC N
at IN N
the DT N
2 CD N
years NNS N
follow-up JJ N
visit NN N
: : N
marginal JJ o
bone NN o
resorption NN o
, , o
papilla NN o
index NN o
, , o
position NN o
of IN o
the DT o
mucosal NN o
margin NN o
. . o

The DT N
implant JJ o
stability NN o
quotient NN o
was VBD N
measured VBN N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
and CC N
at IN N
the DT N
moment NN N
of IN N
the DT N
delivery NN N
of IN N
the DT N
definitive JJ N
restoration NN N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
studied JJ N
parameters NNS N
between IN N
the DT N
test NN N
and CC N
the DT N
control NN N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
implant JJ o
stability NN o
quotient NN o
values NNS o
between IN N
the DT N
test NN N
and CC N
control NN N
groups NNS N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
but CC N
were VBD N
no DT N
more RBR N
significant JJ N
at IN N
the DT N
loading NN N
of IN N
the DT N
definitive JJ N
restoration NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
suggest VBP N
that IN N
immediate JJ N
replacement NN N
without IN N
functional JJ N
loading NN N
may MD N
be VB N
considered VBN N
a DT N
valuable JJ N
therapeutic JJ N
option NN N
for IN N
selected VBN N
cases NNS N
of IN N
single-tooth JJ i
replacement NN i
in IN N
the DT N
esthetic JJ N
area NN N
when WRB N
TE NNP N
implants NNS N
are VBP N
used VBN N
. . N

Implant JJ o
stability NN o
at IN N
the DT N
moment NN N
of IN N
implant JJ N
placement NN N
is VBZ N
slightly RB N
inferior JJ N
in IN N
the DT N
immediate JJ N
replacement NN N
group NN N
, , N
but CC N
it PRP N
does VBZ N
not RB N
affect VB N
the DT N
treatment NN N
result NN N
. . N

-DOCSTART- -16299669- O O

Comparative JJ N
speed NN N
of IN N
kill NN N
of IN N
selamectin NN i
, , i
imidacloprid JJ i
, , i
and CC i
fipronil- NN i
( ( i
S NNP i
) ) i
-methoprene VBD i
spot-on JJ N
formulations NNS N
against IN N
fleas NNS o
on IN p
cats NNS p
. . p

The DT N
speed NN N
of IN N
kill NN N
of IN N
selamectin NN i
, , i
imidacloprid JJ i
, , i
and CC i
fipronil- NN i
( ( i
S NNP i
) ) i
-methoprene NN i
against IN N
Ctenocephalides NNP N
felis JJ N
infestations NNS N
on IN N
cats NNS p
for IN N
one CD N
month NN N
following VBG N
a DT N
single JJ N
treatment NN N
was VBD N
evaluated VBN N
. . N

Eighty NNP p
cats NNS p
were VBD p
randomly RB p
allocated VBN p
so RB N
that IN N
there EX N
were VBD N
20 CD N
cats NNS N
in IN N
four CD N
different JJ N
treatment NN N
groups NNS N
. . N

On IN N
Days NNPS N
-2 NNP N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
, , N
and CC N
28 CD N
, , N
each DT N
cat NN N
was VBD N
infested VBN N
with IN N
100 CD N
adult NN N
C. NNP N
felis NN N
from IN N
the DT N
Kansas NNP p
1 CD p
flea NN p
strain NN p
. . p

Following VBG N
initial JJ N
application NN N
only RB N
imidacloprid JJ i
had VBD N
caused VBN N
a DT N
significant JJ N
reduction NN o
in IN o
adult NN o
fleas NNS o
on IN N
treated JJ N
cats NNS N
within IN N
6 CD N
hours NNS N
, , N
but CC N
by IN N
24 CD N
hours NNS N
all DT N
three CD N
formulations NNS N
had VBD N
killed VBN N
96.7 CD N
% NN N
of IN N
the DT N
fleas NNS N
. . N

At IN N
7 CD N
days NNS N
post NN N
treatment NN N
, , N
all DT N
three CD N
formulations NNS N
reduced VBD N
flea JJ o
populations NNS o
within IN N
6 CD N
and CC N
24 CD N
hours NNS N
by IN N
68.4 CD N
% NN N
and CC N
99.4 CD N
% NN N
, , N
respectively RB N
. . N

At IN N
21 CD N
and CC N
28 CD N
days NNS N
after IN N
treatment NN N
, , N
none NN N
of IN N
the DT N
formulations NNS N
killed VBD N
significant JJ N
numbers NNS o
of IN o
fleas NNS o
as IN N
compared VBN N
to TO N
controls NNS N
within IN N
6 CD N
hours NNS N
of IN N
infestation NN N
. . N

At IN N
28 CD N
days NNS N
after IN N
treatment NN N
, , N
selamectin NN i
, , i
fipronil- JJ i
( ( i
S NNP i
) ) i
-methoprene NN i
, , i
and CC i
imidacloprid VB i
had VBD N
killed VBN N
99.0 CD N
% NN N
, , N
86.4 CD N
% NN N
, , N
and CC N
72.6 CD N
% NN N
of IN N
the DT N
fleas NNS o
within IN N
48 CD N
hours NNS N
of IN N
infestation NN N
, , N
respectively RB N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
the DT N
speed NN N
of IN N
kill NN N
of IN N
residual JJ N
flea NN o
products NNS o
on IN N
cats NN p
decreases NNS N
throughout IN N
the DT N
month NN N
following VBG N
application NN N
. . N

It PRP N
also RB N
demonstrated VBD N
that IN N
selamectin NN N
provided VBD N
the DT N
highest JJS N
level NN N
of IN N
residual JJ o
activity NN o
on IN N
cats NNS p
against IN N
the DT N
Kansas NNP N
1 CD N
flea NN N
strain NN N
. . N

-DOCSTART- -2885607- O O

Methotrexate/nitrous-oxide NNP N
toxic JJ o
interaction NN o
in IN N
perioperative JJ i
chemotherapy NN i
for IN p
early JJ p
breast NN p
cancer NN p
. . p

-DOCSTART- -24732316- O O

The DT N
KRAS-variant NNP N
and CC N
miRNA JJ N
expression NN N
in IN N
RTOG NNP N
endometrial JJ p
cancer NN p
clinical JJ N
trials NNS N
9708 CD N
and CC N
9905 CD N
. . N

OBJECTIVE VB N
To TO N
explore VB N
the DT N
association NN N
of IN N
a DT N
functional JJ N
germline NN N
variant NN N
in IN N
the DT N
3'-UTR CD N
of IN N
KRAS NNP N
with IN N
endometrial JJ N
cancer NN N
risk NN N
, , N
as RB N
well RB N
as IN N
the DT N
association NN N
of IN N
microRNA NN N
( ( N
miRNA NN N
) ) N
signatures NNS N
and CC N
the DT N
KRAS-variant NNP N
with IN N
clinical JJ N
characteristics NNS N
and CC N
survival JJ N
outcomes NNS N
in IN N
two CD N
prospective JJ N
RTOG NNP N
endometrial JJ N
cancer NN N
trials NNS N
. . N

METHODS/MATERIALS NNP N
The DT N
association NN N
of IN N
the DT N
KRAS-variant NNP N
with IN N
endometrial JJ N
cancer NN N
risk NN N
was VBD N
evaluated VBN N
by IN N
case-control JJ N
analysis NN N
of IN N
467 CD p
women NNS p
with IN p
type JJ p
1 CD p
or CC p
2 CD p
endometrial JJ p
cancer NN p
and CC p
582 CD p
age-matched JJ p
controls NNS p
. . p

miRNA NN N
and CC N
DNA NNP N
were VBD N
isolated VBN N
for IN N
expression NN N
profiling NN N
and CC N
genotyping VBG N
from IN N
tumor NN p
specimens NNS p
of IN p
46 CD p
women NNS p
with IN p
type JJ p
1 CD p
endometrial JJ p
cancer NN p
enrolled VBN p
in IN p
RTOG NNP p
trials NNS p
9708 CD p
and CC p
9905. CD p
miRNA JJ N
expression NN N
levels NNS N
and CC N
KRAS-variant NNP N
genotype NN N
were VBD N
correlated VBN N
with IN N
patient NN N
and CC N
tumor NN N
characteristics NNS N
, , N
and CC N
survival JJ N
outcomes NNS N
were VBD N
evaluated VBN N
by IN N
variant JJ N
allele JJ N
type NN N
. . N

RESULTS VB N
The DT N
KRAS-variant NNP N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
overall JJ o
endometrial JJ o
cancer NN o
risk NN o
( ( N
14 CD N
% NN N
controls NNS N
and CC N
17 CD N
% NN N
type NN N
1 CD N
cancers NNS N
) ) N
, , N
although IN N
was VBD N
enriched VBN N
in IN N
type NN N
2 CD N
endometrial JJ N
cancers NNS N
( ( N
24 CD N
% NN N
, , N
p NN N
= NNP N
0.2 CD N
) ) N
. . N

In IN N
the DT N
combined JJ N
analysis NN N
of IN N
RTOG NNP N
9708/9905 CD o
, , o
miRNA FW o
expression NN o
differed VBN o
by IN N
age NN N
, , N
presence NN N
of IN N
lymphovascular JJ N
invasion NN N
and CC N
KRAS-variant JJ N
status NN o
. . o

Overall JJ o
survival JJ o
rates NNS o
at IN o
3 CD N
years NNS N
for IN N
patients NNS p
with IN p
the DT p
variant NN p
and CC p
wild-type JJ p
alleles NNS p
were VBD p
100 CD N
% NN N
and CC N
77 CD N
% NN N
( ( N
HR NNP N
0.3 CD N
, , N
p NN N
= NNP N
0.24 CD N
) ) N
, , N
respectively RB N
, , N
favoring VBG N
the DT N
variant NN N
. . N

CONCLUSIONS VB N
The DT N
KRAS-variant NNP N
may MD N
be VB N
a DT N
genetic JJ N
marker NN N
of IN N
risk NN N
for IN N
type NN N
2 CD N
endometrial JJ N
cancers NNS N
. . N

In IN N
addition NN N
, , N
tumor NN N
miRNA NN N
expression NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
patient JJ N
age NN N
, , N
lymphovascular JJ N
invasion NN N
and CC N
the DT N
KRAS-variant NNP N
, , N
supporting VBG N
the DT N
hypothesis NN N
that WDT N
altered VBD N
tumor NN N
biology NN N
can MD N
be VB N
measured VBN N
by IN N
miRNA JJ N
expression NN N
, , N
and CC N
that IN N
the DT N
KRAS-variant NNP N
likely JJ N
impacts NNS N
endometrial JJ N
tumor NN N
biology NN N
. . N

-DOCSTART- -23205617- O O

An DT i
internet-based JJ i
cognitive-behavioural JJ i
training NN i
for IN N
acute JJ p
tinnitus NN p
: : p
secondary JJ N
analysis NN N
of IN N
acceptance NN N
in IN N
terms NNS N
of IN N
satisfaction NN N
, , N
trial NN N
attrition NN N
and CC N
non-usage JJ N
attrition NN N
. . N

OBJECTIVES NNP N
Recent NNP N
studies NNS N
on IN N
tinnitus NN N
have VBP N
focused VBN N
on IN N
the DT N
efficacy NN N
of IN N
Internet-based JJ i
interventions NNS i
. . i

Other JJ N
core NN N
features NNS N
of IN N
the DT N
quality NN N
of IN N
service NN N
, , N
e.g NN N
. . N

acceptance NN N
and CC N
attrition NN N
, , N
have VBP N
often RB N
been VBN N
overlooked VBN N
. . N

This DT N
study NN N
analyses VBZ N
Internet-based JJ i
training NN i
regarding VBG N
acceptance NN N
and CC N
attrition NN N
in IN N
a DT N
trial NN N
on IN N
minimal-contact JJ p
interventions NNS p
for IN p
acute JJ p
tinnitus NN p
. . p

Whenever NNP N
possible JJ N
, , N
we PRP N
give VBP N
information NN N
on IN N
other JJ N
forms NNS N
of IN N
training NN N
for IN N
comparison NN N
. . N

METHODS NNP N
In IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
337 CD p
participants NNS p
, , p
87 CD p
persons NNS p
took VBD p
part NN p
in IN p
the DT p
Internet NNP i
training NN i
. . i

RESULTS VB N
The DT p
participants NNS p
were VBD p
as IN p
satisfied JJ o
with IN p
the DT p
Internet-based JJ i
training NN i
as IN p
with IN p
a DT p
face-to-face JJ p
group NN p
training NN p
. . p

There EX N
was VBD N
a DT N
34.48 CD N
% NN N
dropout NN o
from IN N
the DT N
Internet-based JJ N
training NN N
( ( N
dropout IN N
attrition NN N
) ) N
. . N

The DT N
training NN o
attrition NN o
from IN N
the DT N
Internet-based JJ i
training NN i
was VBD N
even RB N
higher JJR N
at IN N
64.4 CD N
% NN N
. . N

CONCLUSIONS NNP N
Two CD N
out IN N
of IN N
three CD N
indicators NNS N
for IN N
acceptance-satisfaction NN o
and CC o
dropout IN o
attrition-provide JJ o
comparable JJ N
results NNS N
between IN N
the DT N
Internet-based JJ i
training NN i
and CC N
a DT N
face-to-face JJ N
group NN N
training NN N
. . N

The DT N
third JJ N
indicator NN N
, , N
training VBG o
attrition NN o
, , N
shows VBZ N
a DT N
better JJR N
result NN N
for IN N
the DT N
group NN N
training NN N
. . N

Future JJ N
research NN N
should MD N
focus VB N
on IN N
attrition NN N
in IN N
order NN N
to TO N
enhance VB N
the DT N
overall JJ N
effectiveness NN N
of IN N
training NN N
. . N

-DOCSTART- -18161677- O O

Effect NN N
of IN N
upper JJ N
arm NN N
brachial NN N
basilic NN N
and CC N
prosthetic JJ N
forearm NN N
arteriovenous JJ N
fistula NN N
on IN N
left JJ o
ventricular JJ o
hypertrophy NN o
. . N

BACKGROUND NNP N
Creation NNP N
of IN N
an DT N
arteriovenous JJ N
fistula NN N
( ( N
AVF NNP N
) ) N
may MD N
increase VB N
left VBD o
ventricular JJ o
hypertrophy NN o
in IN N
the DT N
hemodialysis NN p
population NN p
. . p

Aim NNP N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
brachial-basilic JJ i
( ( i
BB NNP i
) ) i
AVF NNP i
and CC N
the DT N
prosthetic JJ i
brachial-antecubital JJ i
forearm NN i
loop NN i
access NN i
( ( N
PTFE NNP N
) ) N
on IN N
cardiac JJ o
performance NN o
. . o

METHODS JJ N
Patients NNPS p
were VBD N
randomized VBN N
to TO N
receive VB N
BB-AVF NNP i
or CC i
prosthetic JJ i
brachial-antecubital JJ i
forearm NN i
loop NN i
access NN i
. . i

Before IN N
and CC N
three CD N
months NNS N
after IN N
AVF NNP p
creation NN p
patients NNS p
underwent VBD N
an DT N
echocardiographic JJ N
examination NN N
. . N

Mann-Whitney JJ o
U-test NNP o
was VBD N
used VBN N
to TO N
compare VB N
relative JJ N
increase NN N
between IN N
the DT N
measured JJ o
cardiac JJ o
parameters NNS o
for IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Twenty-seven JJ p
patients NNS p
participated VBN p
in IN p
the DT p
study NN p
. . p

The DT N
relative JJ N
increase NN N
in IN N
left JJ o
ventricular JJ o
parameters NNS o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Only RB N
left VBD o
ventricular JJ o
end-diastolic JJ o
diameter NN o
tended VBD N
to TO N
be VB N
of IN N
significance NN N
. . N

Mean NNP o
blood NN o
flow NN o
through IN N
the DT N
brachial JJ N
artery NN N
was VBD N
1680+/-156 JJ N
and CC N
1450+/-221 JJ N
mL/min NNS N
three CD N
months NNS N
after IN N
surgery NN N
for IN N
the DT N
PTFE NNP N
and CC N
the DT N
BB-AVF NNP N
group NN N
, , N
respectively RB N
. . N

CONCLUSION NN N
After IN N
three CD N
months NNS N
of IN N
follow-up NN N
, , N
changes NNS o
in IN o
cardiac JJ o
structure NN o
were VBD N
comparable JJ N
between IN N
patients NNS p
with IN p
BB NNP p
and CC p
PTFE NNP p
AVFs NNP p
. . p

Also RB N
access NN o
flow NN o
was VBD N
comparable JJ N
at IN N
this DT N
time NN N
. . N

In IN N
general JJ N
, , N
the DT N
effects NNS N
of IN N
creation NN N
of IN N
a DT N
fistula NN N
on IN N
LV NNP N
structure NN N
were VBD N
limited VBN N
. . N

Longer RBR N
follow VB N
up RP N
time NN N
may MD N
be VB N
needed VBN N
to TO N
explore VB N
the DT N
long JJ N
term NN N
effects NNS N
of IN N
different JJ N
vascular JJ N
accesses NNS N
on IN N
cardiac JJ o
function NN o
. . o

-DOCSTART- -12642251- O O

Iontophoretic JJ i
administration NN N
of IN N
dexamethasone NN i
sodium NN i
phosphate NN i
for IN N
acute JJ p
epicondylitis NN p
. . p

A DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

BACKGROUND NNP N
A NNP N
better RBR N
treatment NN N
modality NN N
is VBZ N
needed VBN N
to TO N
control VB N
the DT N
pain NN o
of IN p
medial NN o
or CC o
lateral JJ o
epicondylitis NN o
( ( o
tennis IN o
elbow NN o
) ) o
. . o

HYPOTHESIS NNP N
Dermal NNP N
iontophoretic JJ i
administration NN N
of IN N
dexamethasone NN i
sodium NN N
phosphate NN N
will MD N
be VB N
significantly RB N
more RBR N
effective JJ N
in IN N
controlling VBG N
pain NN o
than IN N
a DT N
placebo NN N
in IN N
patients NNS p
with IN p
medial JJ p
or CC p
lateral JJ p
elbow NN p
epicondylitis NN p
. . p

STUDY NNP N
DESIGN NNP N
Randomized NNP N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

METHODS NNP N
On IN N
six CD N
occasions NNS N
, , N
1 CD N
to TO N
3 CD N
days NNS N
apart RB N
within IN N
15 CD N
days NNS N
, , N
199 CD p
patients NNS p
with IN p
elbow JJ p
epicondylitis NN p
received VBD N
40 CD N
mA-minutes NNS N
of IN N
either DT N
active JJ N
or CC N
placebo JJ i
treatment NN N
. . N

RESULTS NNP N
Dexamethasone NNP i
produced VBD N
a DT N
significant JJ N
23-mm JJ N
improvement NN N
on IN N
the DT N
100-mm JJ o
patient NN o
visual JJ o
analog NN o
scale NN o
ratings NNS o
, , N
compared VBN N
with IN N
14 CD N
mm NNS N
for IN N
placebo NN i
at IN N
2 CD N
days NNS N
and CC N
24 CD N
mm NNS N
compared VBN N
with IN N
19 CD N
mm NNS N
at IN N
1 CD N
month NN N
. . N

More JJR N
patients NNS N
treated VBN N
with IN N
dexamethasone NN i
than IN N
those DT N
treated VBN N
with IN N
placebo NN i
scored VBN N
moderate JJ N
or CC N
better JJR N
on IN N
the DT N
investigator NN o
's POS o
global JJ o
improvement NN o
scale NN o
( ( N
52 CD N
% NN N
versus IN N
33 CD N
% NN N
) ) N
at IN N
2 CD N
days NNS N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
at IN N
1 CD N
month NN N
( ( N
54 CD N
% NN N
versus IN N
49 CD N
% NN N
) ) N
. . N

Investigator-rated JJ o
pain NN o
and CC o
tenderness NN o
scores NNS o
favored VBD N
dexamethasone NN N
over IN N
placebo NN N
at IN N
2 CD N
days NNS N
. . N

Patients NNS N
completing VBG N
six CD N
treatments NNS N
in IN N
10 CD N
days NNS N
or CC N
less JJR N
had VBD N
better RBR N
results NNS N
than IN N
those DT N
treated VBN N
over IN N
a DT N
longer JJR N
period NN N
. . N

CONCLUSIONS NNP N
Iontophoresis NNP i
treatment NN N
was VBD N
well RB N
tolerated VBN o
by IN N
most JJS N
patients NNS N
and CC N
was VBD N
effective JJ N
in IN N
reducing VBG N
symptoms NNS o
of IN o
epicondylitis NN o
at IN N
short-term JJ N
follow-up NN N
. . N

-DOCSTART- -2461017- O O

Safety NN o
and CC N
efficacy NN o
of IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
Logiparin NNP N
) ) N
versus NN N
dextran NN N
as IN N
prophylaxis NN N
against IN N
thrombosis NN o
after IN N
total JJ p
hip NN p
replacement NN p
. . p

In IN N
order NN N
to TO N
study VB N
the DT N
plasma NN N
levels NNS N
of IN N
factor NN N
XaI NNP N
and CC N
IIaI NNP N
activity NN N
an DT N
enzymatically RB i
depolymerized VBN i
low JJ i
molecular JJ i
weight NN i
heparin NN i
( ( i
LMW-heparin NNP i
; : i
Logiparin NNP i
) ) i
was VBD N
given VBN N
s.c. NN N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

once RB N
daily JJ N
for IN N
7 CD N
days NNS N
to TO N
10 CD p
patients NNS p
undergoing JJ p
total JJ p
hip NN p
replacement NN p
( ( p
THR NNP p
) ) p
in IN N
a DT N
pilot NN N
study NN N
. . N

The DT N
XaI NN N
activity NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.24 CD N
XaI NNP N
units/ml NN N
and CC N
the DT N
IIaI NNP N
activity NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.043 CD N
IIaI NNP N
mu/ml NN N
. . N

No DT N
accumulation NN N
of IN N
the DT N
activities NNS N
were VBD N
seen VBN N
. . N

No DT N
phlebographically RB o
verified VBN o
thrombi NN o
or CC N
any DT N
bleeding JJ o
complications NNS o
were VBD N
registered VBN N
. . N

From IN N
this DT N
study NN N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
given VBN N
dose NN N
of IN N
Logiparin NNP N
was VBD N
safe JJ N
with IN N
regard NN N
to TO N
bleeding VBG N
complications NNS N
. . N

Based VBN N
on IN N
these DT N
data NNS N
, , N
an DT N
open JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
was VBD N
started VBN N
. . N

In IN N
this DT N
main JJ N
study NN N
the DT N
thromboprophylactic JJ o
effect NN o
of IN N
the DT N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

once RB N
daily JJ N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
dextran NN N
70 CD N
in IN N
patients NNS p
undergoing JJ p
THR NNP p
. . p

100 CD p
patients NNS p
were VBD p
randomized VBN p
. . p

The DT N
over-all JJ o
thrombosis NN o
rate NN o
was VBD N
28 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
LMW-heparin NNP N
and CC N
39 CD N
% NN N
in IN N
those DT N
given VBN N
dextran NN N
, , N
a DT N
non-significant JJ N
difference NN N
. . N

No UH N
bleeding VBG o
complications NNS o
, , o
deaths NNS o
or CC o
pulmonary JJ o
embolism NN o
were VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Peroperative JJ o
blood NN o
loss NN o
and CC o
transfusion NN o
requirements NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
investigated JJ N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
preventing VBG N
postoperative JJ N
thromboembolism NN N
in IN N
patients NNS p
undergoing JJ p
total JJ p
hip NN p
replacement NN p
, , N
but CC N
the DT N
dosage NN N
can MD N
probably RB N
be VB N
optimized VBN N
. . N

-DOCSTART- -24274627- O O

Does VBZ N
alliance VB o
predict NN o
symptoms NNS o
throughout IN N
treatment NN N
, , N
or CC N
is VBZ N
it PRP N
the DT N
other JJ N
way NN N
around IN N
? . N
OBJECTIVE NNP N
Scholars NNP N
increasingly RB N
recognize VBP N
that IN N
therapeutic JJ o
alliance NN o
and CC o
symptomatic JJ o
change NN o
are VBP N
associated VBN N
with IN N
one CD N
another DT N
. . N

A DT N
common JJ N
assumption NN N
is VBZ N
that IN N
alliance NN o
predicts NNS o
symptomatic JJ o
change NN o
. . o

However RB N
, , N
the DT N
issue NN N
is VBZ N
far RB N
from IN N
settled VBN N
. . N

One CD N
challenge NN N
in IN N
determining VBG N
the DT N
causality NN N
is VBZ N
the DT N
establishment NN N
of IN N
temporal JJ N
precedence NN N
showing VBG N
that IN N
alliance NN N
, , N
as IN N
opposed VBN N
to TO N
previous JJ N
symptomatic JJ N
change NN N
, , N
drives VBZ N
subsequent JJ N
symptomatic JJ o
reduction NN o
. . o

METHOD NNP N
To TO N
make VB N
further JJ N
advances NNS N
in IN N
untangling VBG N
this DT N
chicken-and-egg JJ N
question NN N
, , N
we PRP N
employed VBD N
autoregressive JJ N
cross-lagged JJ N
modeling NN N
over IN N
4 CD N
time NN N
points NNS N
in IN N
a DT N
sample NN N
of IN N
149 CD p
depressive JJ p
patients NNS p
receiving VBG p
supportive-expressive JJ i
psychotherapy NN i
or CC i
clinical JJ i
management NN i
combined VBN i
with IN i
pharmacotherapy NN i
or CC i
clinical JJ i
management NN i
combined VBN i
with IN i
placebo NN i
. . i

RESULTS VB N
Using VBG N
this DT N
methodology NN N
, , N
we PRP N
found VBD N
that IN N
both DT N
alliance NN o
and CC o
symptoms NNS o
across IN N
treatment NN N
made VBN N
significant JJ N
and CC N
unique JJ N
contributions NNS o
in IN N
predicting VBG o
subsequent JJ o
symptomatic NN o
levels NNS o
throughout IN N
treatment NN N
. . N

Additionally RB N
, , N
alliance NN o
, , N
but CC N
not RB N
symptoms NNS o
, , N
predicted VBD N
subsequent JJ o
alliance NN o
levels NNS o
. . o

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
treatments NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
imply VBP N
that IN N
alliance NN o
temporally RB N
precedes VBZ N
symptomatic JJ o
levels NNS o
throughout IN N
treatment NN N
. . N

-DOCSTART- -7539544- O O

A DT N
randomized VBN N
study NN N
comparing VBG N
glucagon NN i
and CC i
hyoscine VB i
N-butyl NNP i
bromide NN i
before IN p
endoscopic NN i
retrograde NN i
cholangiopancreatography NN i
. . i

BACKGROUND NNP N
This DT N
study NN N
tried VBD N
to TO N
resolve VB N
whether IN N
glucagon NN i
is VBZ N
a DT N
better JJR N
premedication NN N
for IN N
endoscopic NN o
retrograde NN o
cholangiopancreatography NN o
( ( o
ERCP NNP o
) ) o
. . o

METHODS NNP N
We PRP N
first RB N
measured VBD N
the DT N
basal NN o
blood NN o
sugar NN o
and CC o
amylase NN o
levels NNS o
. . o

Then RB N
an DT N
endoscope NN N
was VBD N
placed VBN N
in IN N
the DT N
duodenum NN N
without IN N
premedication NN N
, , N
and CC N
basal NN o
pulse NN o
and CC o
duodenal JJ o
peristaltic JJ o
rates NNS o
were VBD N
measured VBN N
. . N

ERCP NNP N
began VBD N
after IN N
studied JJ p
subjects NNS p
were VBD N
randomly RB N
premedicated VBN N
with IN N
either DT N
1 CD i
mg NN i
glucagon NN i
( ( p
n JJ p
= NNP p
38 CD p
) ) p
or CC p
40 CD i
mg JJ i
hyoscine NN i
N-butyl NNP i
bromide NN i
( ( p
n JJ p
= NNP p
36 CD p
) ) p
intravenously RB N
. . N

Ten CD N
minutes NNS N
later RB N
the DT N
variables NNS o
were VBD N
measured VBN N
again RB N
. . N

RESULTS NNP N
Glucagon NNP i
elicited VBD N
hyperglycemia NN o
whereas NNS N
hyoscine VBP i
N-butyl NNP i
bromide NN i
manifested VBD N
an DT N
anticholinergic JJ o
effect NN o
. . o

No DT N
difference NN N
was VBD N
found VBN N
between IN N
these DT N
two CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
necessary JJ o
interval NN o
for IN o
ERCP NNP o
( ( N
20.6 CD N
+/- JJ N
14.1 CD N
min NN N
versus NN N
21.4 CD N
+/- JJ N
14.7 CD N
min NN N
; : N
NS NNP N
) ) N
or CC N
the DT N
success NN o
rate NN o
for IN o
cholangiopancreatography NN o
( ( N
92.1 CD N
% NN N
versus IN N
91.7 CD N
% NN N
; : N
NS NNP N
) ) N
. . N

Neither CC N
hyperamylasemia JJ o
nor CC o
pancreatitis NN o
was VBD N
preventable JJ N
when WRB N
glucagon NN i
was VBD N
used VBN N
. . N

CONCLUSIONS VB N
The DT N
two CD N
premedications NNS N
appear VBP N
equally RB N
effective JJ N
in IN N
the DT N
performance NN o
of IN o
ERCP NNP o
. . o

-DOCSTART- -12241650- O O

Laser NNP N
treatment NN N
of IN N
childhood NN N
haemangioma NN N
: : N
progress NN N
or CC N
not RB N
? . N
-DOCSTART- -507792- O O

Anaerobic NNP p
infection NN p
in IN p
cancer NN p
patients NNS p
: : p
comparative JJ N
evaluation NN N
of IN N
clindamycin NN i
and CC N
cefoxitin NN i
. . i

Clindamycin NNP i
and CC i
cefoxitin NN i
with IN i
or CC i
without IN i
gentamicin NNS i
were VBD N
administered VBN N
to TO N
cancer NN p
patients NNS p
having VBG p
localized VBN p
infections NNS p
presumably RB p
caused VBN p
by IN p
anaerobic JJ p
pathogens NNS p
. . p

The DT N
rates NNS p
of IN p
favorable JJ o
response NN o
were VBD p
89 CD p
% NN p
in IN p
patients NNS p
receiving VBG p
clindamycine NN i
alone RB i
and CC p
78 CD p
% NN p
in IN p
patients NNS p
receiving VBG p
cefoxitin NN i
alone RB i
. . i

When WRB N
the DT N
total JJ N
experience NN N
is VBZ N
considered VBN N
( ( i
clindamycin NN i
or CC N
cefoxitin NN i
with IN i
and CC i
without IN i
gentamicin NN i
) ) i
, , N
20 CD p
of IN p
24 CD p
patients NNS p
( ( p
83 CD p
% NN p
) ) p
responded VBD o
to TO p
clindamycin VB i
and CC p
18 CD p
of IN p
22 CD p
( ( p
82 CD p
% NN p
) ) p
responded VBD o
to TO p
cefoxitin VB i
. . i

Both DT N
therapies NNS N
were VBD N
well RB o
tolerated VBN o
. . o

Clindamycin NNP i
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ o
than IN N
cefoxitin NN N
in IN N
eradicating VBG o
the DT o
offending VBG o
anaerobic JJ o
pathogens NNS o
from IN o
the DT o
site NN o
of IN o
infection NN o
. . o

Aerobic JJ N
pathogens NNS N
were VBD N
frequently RB N
isolated VBN N
along IN N
with IN N
anaerobes NNS N
from IN N
the DT N
infectious JJ N
sites NNS N
in IN N
this DT N
series NN N
; : N
their PRP$ N
susceptibility NN N
or CC N
resistance NN N
to TO N
clindamycin VB i
or CC N
cefoxitin VB i
did VBD N
not RB N
influence VB N
the DT N
therapeutic JJ N
response NN N
. . N

-DOCSTART- -9647338- O O

Effect NN N
of IN N
aldose JJ i
reductase NN i
inhibition NN N
on IN N
cardiovascular JJ o
reflex NN o
tests NNS o
in IN N
patients NNS p
with IN p
definite JJ p
diabetic JJ p
autonomic JJ p
neuropathy NN p
over IN p
a DT p
period NN p
of IN p
2 CD p
years NNS p
. . p

The DT N
potential NN N
of IN N
the DT N
aldose JJ N
reductase NN N
inhibitor NN N
tolrestat NN i
to TO N
ameliorate VB N
definite JJ N
diabetic JJ N
autonomic NN N
neuropathy NN N
( ( N
DAN NNP N
) ) N
, , N
as IN N
defined VBN N
by IN N
standard JJ N
cardiovascular JJ N
autonomic JJ N
function NN N
tests NNS N
, , N
was VBD N
evaluated VBN N
in IN N
35 CD p
patients NNS p
over IN N
a DT N
period NN N
of IN N
2 CD N
years NNS N
, , N
with IN N
repeated VBN N
measurements NNS N
at IN N
3-month JJ N
intervals NNS N
. . N

The DT N
effect NN N
of IN N
tolrestat NN i
( ( N
200 CD N
mg NN N
a DT N
day NN N
) ) N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
placebo NN i
on IN N
35 CD p
controls NNS p
with IN p
diabetes NNS p
mellitus NNS p
, , p
of IN p
similar JJ p
age NN p
, , p
gender NN p
, , p
and CC p
glycemic JJ p
control NN p
. . p

In IN N
the DT N
placebo NN i
group NN N
, , N
a DT N
significant JJ N
deterioration NN N
of IN N
the DT N
indices NNS N
, , N
with IN N
the DT N
exception NN N
of IN N
Valsalva NNP o
ratio NN o
, , N
was VBD N
recorded VBN N
, , N
while IN N
tolrestat NN i
induced VBD N
a DT N
significant JJ N
beneficial JJ N
change NN N
in IN N
the DT N
values NNS o
of IN o
most JJS o
standard JJ o
cardiovascular JJ o
reflex NN o
tests NNS o
, , N
in IN N
comparison NN N
to TO N
baseline VB N
and CC N
placebo VB N
. . N

The DT N
deep JJ o
breathing NN o
tests NNS o
( ( o
expiration-inspiration NN o
ratio NN o
, , o
standard JJ o
deviation NN o
, , o
and CC o
mean VB o
circular JJ o
resultant NN o
of IN o
R-R NNP o
intervals NNS o
) ) o
, , o
postural JJ o
index NN o
, , o
and CC o
postural JJ o
hypotension NN o
were VBD N
favorably RB N
affected VBN N
. . N

Three CD N
of IN N
35 CD N
patients NNS N
on IN N
tolrestat NN i
( ( N
8.6 CD N
% NN N
) ) N
developed VBD N
high JJ o
transaminases NNS o
levels NNS o
( ( N
more JJR N
than IN N
threefold VB N
the DT N
upper JJ N
normal JJ N
limit NN N
) ) N
and CC N
were VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
. . N

In IN N
conclusion NN N
, , N
tolrestat NN i
improved VBD N
autonomic RB o
nervous JJ o
system NN o
function NN o
in IN N
patients NNS p
with IN p
definite JJ p
DAN NNP p
, , N
in IN N
comparison NN N
to TO N
baseline VB N
and CC N
placebo VB N
. . N

The DT N
clinical JJ N
importance NN N
of IN N
this DT N
finding NN N
needs VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -12568856- O O

Carbon NNP i
dioxide RB i
versus VBZ N
normal JJ i
saline NN i
as IN N
a DT N
uterine JJ N
distension NN N
medium NN N
for IN N
diagnostic JJ N
vaginoscopic NN N
hysteroscopy NN N
in IN N
infertile JJ p
patients NNS p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
satisfaction NN o
rate NN o
, , o
efficacy NN o
, , N
and CC N
complication NN o
rate NN o
of IN N
carbon NN i
dioxide NN i
( ( i
CO NNP i
( ( i
2 CD i
) ) i
) ) i
versus NN N
normal JJ i
saline NN i
as IN N
a DT N
uterine JJ N
distension NN N
medium NN N
for IN N
outpatient JJ N
diagnostic JJ N
vaginoscopic NN N
hysteroscopy NN N
in IN N
infertile JJ N
patients NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
multicenter NN N
study NN N
. . N

SETTING NNP N
Hysteroscopy NNP N
units NNS N
in IN N
two CD N
university NN N
hospitals NNS N
and CC N
in IN N
a DT N
private JJ N
center NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
One CD p
hundred VBN p
eighty-nine JJ p
infertile JJ p
women NNS p
undergoing VBG p
outpatient JJ p
hysteroscopy NN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Outpatient NNP N
hysteroscopy NN N
was VBD N
performed VBN N
with IN N
CO NNP i
( ( i
2 CD i
) ) i
( ( i
group NN i
A NNP i
) ) i
or CC i
normal JJ i
saline NN i
( ( i
group NN i
B NNP i
) ) i
and CC N
with IN N
endometrial JJ i
biopsy NN i
when WRB N
indicated VBN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Quality NN o
of IN o
the DT o
visualization NN o
of IN o
the DT o
uterine JJ o
cavity NN o
, , o
procedure NN o
time NN o
, , o
complications NNS o
, , o
patient JJ o
discomfort NN o
, , o
and CC o
satisfaction NN o
rate NN o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
Significantly NNP N
lower JJR N
abdominal NN o
and CC o
shoulder NN o
tip NN o
pain NN o
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
vasovagal JJ o
reactions NNS o
were VBD N
observed VBN N
in IN N
group NN p
B NNP p
in IN N
comparison NN N
with IN N
group NN p
A NNP p
. . p

A NNP N
higher JJR o
satisfaction NN o
rate NN o
and CC o
a DT o
lower JJR o
operative JJ o
time NN o
were VBD N
obtained VBN N
in IN N
the DT N
normal JJ N
saline NN N
group NN N
in IN N
comparison NN N
with IN N
the DT N
CO NNP i
( ( i
2 CD i
) ) i
group NN N
. . N

Moreover RB N
, , N
group NN N
A NNP N
required VBD N
significantly RB N
more RBR N
analgesics NNS N
after IN N
the DT N
procedure NN N
than IN N
group NN N
B NNP N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Uterine NNP N
distension NN N
with IN N
normal JJ N
saline NN N
seems VBZ N
to TO N
have VB N
less JJR N
adverse JJ N
effects NNS N
and CC N
is VBZ N
better RBR N
tolerated VBN N
by IN N
patients NNS p
. . p

Moreover RB N
, , N
it PRP N
allows VBZ N
operative JJ N
procedures NNS N
to TO N
be VB N
performed VBN N
with IN N
the DT N
new JJ N
bipolar JJ N
instruments NNS N
. . N

-DOCSTART- -3089050- O O

Caudal NNP N
analgesia NN N
for IN N
perianal JJ N
surgery NN N
. . N

A DT N
comparison NN N
between IN N
bupivacaine NN i
and CC N
diamorphine NN i
. . i

Seventy-three JJ p
patients NNS p
undergoing VBG p
elective JJ p
perianal JJ p
surgery NN p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT i
control NN i
group NN i
, , i
a DT i
group NN i
who WP i
received VBD i
a DT i
caudal JJ i
injection NN i
of IN i
20 CD i
ml NNS i
bupivacaine VBP i
0.5 CD i
% NN i
plain NN i
and CC i
a DT i
group NN i
who WP i
received VBD i
diamorphine JJ i
2.5 CD i
mg NN i
in IN i
10 CD i
ml NNS i
normal JJ i
saline NN i
by IN i
caudal JJ i
injection NN i
; : i
a DT i
comparison NN i
was VBD i
then RB i
made VBN i
of IN i
postoperative JJ i
analgesia NN i
requirements NNS i
. . i

The DT N
bupivacaine NN i
group NN N
had VBD N
better JJR N
analgesia NN o
than IN N
the DT N
control NN N
group NN N
for IN N
the DT N
first JJ N
8 CD N
hours NNS N
, , N
after IN N
which WDT N
there EX N
was VBD N
no DT N
difference NN N
. . N

The DT N
diamorphine NN i
group NN N
had VBD N
better JJR N
analgesia NN o
than IN N
the DT N
control NN N
group NN N
for IN N
the DT N
first JJ N
24 CD N
hours NNS N
postoperatively RB N
. . N

Side JJ o
effects NNS o
were VBD N
less RBR N
in IN N
the DT N
diamorphine NN i
group NN N
than IN N
the DT N
control NN N
, , N
or CC N
the DT N
bupivacaine NN i
group NN N
. . N

In IN N
particular JJ N
, , N
41 CD N
% NN N
of IN N
the DT N
bupivacaine NN i
group NN N
complained VBD N
of IN N
some DT o
degree NN o
of IN o
urinary JJ o
retention NN o
and CC N
one CD N
patient NN N
required VBN N
temporary JJ o
catheterisation NN o
. . o

It PRP N
is VBZ N
concluded VBN N
that IN N
caudal JJ N
diamorphine NN i
gives VBZ N
good JJ N
postoperative JJ N
analgesia NN N
for IN N
perianal JJ N
operations NNS N
, , N
particularly RB N
when WRB N
motor NN N
blockade NN N
is VBZ N
not RB N
wanted VBN N
by IN N
the DT N
surgeon NN N
. . N

-DOCSTART- -7789678- O O

Randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
various JJ N
agents NNS N
for IN N
endoscopic NN N
injection NN N
sclerotherapy NN N
of IN N
bleeding VBG N
canine NN N
gastric JJ N
varices NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
relative JJ o
efficacy NN o
and CC o
technical JJ o
ease NN o
of IN o
use NN o
of IN N
eight CD N
different JJ N
agents NNS N
for IN N
endoscopic JJ N
hemostasis NN N
and CC N
obliteration NN N
of IN N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
a DT N
canine NN N
model NN N
, , N
as IN N
no DT N
comparative JJ N
data NNS N
are VBP N
available JJ N
on IN N
gastric JJ N
variceal NN N
sclerotherapy NN N
. . N

Large JJ N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
20 CD p
heparinized JJ p
dogs NNS p
were VBD N
randomized VBN i
to TO i
endoscopic VB i
injection NN i
treatment NN i
with IN i
one CD i
of IN i
the DT i
following JJ i
agents NNS i
: : i
cyanoacrylate NN i
; : i
a DT i
1:1:1 CD i
mixture NN i
of IN i
sodium NN i
tetradecyl NN i
sulfate VBP i
3 CD i
% NN i
, , i
ethanol RB i
98 CD i
% NN i
, , i
and CC i
normal JJ i
saline JJ i
solution NN i
; : i
ethanolamine VB i
oleate VBP i
5 CD i
% NN i
; : i
sodium NN i
morrhuate VBP i
5 CD i
% NN i
; : i
sodium NN i
tetradecyl NN i
sulfate VBP i
1.5 CD i
% NN i
; : i
polidocanol CC i
1 CD i
% NN i
; : i
normal JJ i
saline JJ i
solution NN i
with IN i
epinephrine JJ i
1:10,000 CD i
; : i
or CC i
normal JJ i
saline JJ i
solution NN i
( ( i
control NN i
) ) i
. . i

The DT N
number NN N
and CC N
volume NN N
of IN N
injections NNS N
and CC N
the DT N
time NN N
required VBN N
to TO N
achieve VB N
complete JJ N
hemostasis NN N
were VBD N
evaluated VBN N
; : N
follow-up JJ N
endoscopy NN N
was VBD N
performed VBN N
at IN N
1 CD N
month NN N
to TO N
assess VB N
gastric JJ N
variceal NN N
obliteration NN N
. . N

Cyanoacrylate NNP N
was VBD N
the DT N
best JJS N
agent NN N
overall JJ N
in IN N
terms NNS N
of IN N
immediate JJ o
efficacy NN o
, , o
low JJ o
volume NN o
requirement NN o
, , o
time NN o
required VBN o
for IN o
initial JJ o
hemostasis NN o
, , o
and CC o
reduction NN o
of IN o
gastric JJ o
variceal NN o
size NN o
. . o

Cyanoacrylate NNP o
, , o
tetradecyl NN o
sulfate NN o
, , o
and CC o
polidocanol NN o
were VBD N
the DT N
most RBS N
effective JJ N
agents NNS N
for IN N
reducing VBG N
gastric JJ N
variceal NN N
size NN N
. . N

Epinephrine NNP N
was VBD N
effective JJ N
for IN N
controlling VBG N
induced JJ o
or CC o
secondary JJ o
bleeding NN o
caused VBN N
by IN N
puncture NN N
of IN N
the DT N
gastric JJ N
varices NNS N
with IN N
the DT N
sclerotherapy NN N
needle NN N
during IN N
intravariceal JJ N
injections NNS N
. . N

Ongoing VBG N
studies NNS N
are VBP N
evaluating VBG N
combinations NNS N
of IN N
agents NNS N
with IN N
different JJ N
mechanisms NNS N
of IN N
action NN N
, , N
such JJ N
as IN N
epinephrine NN N
( ( N
for IN N
vasoconstriction NN N
to TO N
minimize VB N
secondary JJ N
bleeding NN N
) ) N
plus CC N
alcohol NN N
, , N
and/or JJ N
tetradecyl NN N
sulfate NN N
( ( N
for IN N
variceal NN N
thrombosis NN N
and CC N
sclerosis NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -12482473- O O

Increased VBN o
concentration NN o
of IN o
corticosteroid-binding JJ o
globulin NN o
due JJ N
to TO N
antidepressant VB p
treatment NN p
with IN p
amitritpyline NN i
, , N
but CC N
not RB N
paroxetine VB i
. . i

-DOCSTART- -1291393- O O

An DT N
in IN N
vitro NN N
comparative JJ N
analysis NN N
: : N
scanning NN N
electron NN N
microscopy NN N
of IN N
dentin/restoration NN N
interfaces NNS N
. . N

One CD p
hundred VBD p
maxillary JJ p
premolar JJ p
teeth NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
ten VB p
groups NNS p
. . p

Each DT p
group NN p
was VBD N
restored VBN N
with IN N
one CD N
of IN N
ten JJ i
different JJ i
restorative NN i
techniques NNS i
. . i

The DT N
teeth NNS N
were VBD N
stored VBN N
in IN N
deionized JJ i
water NN i
for IN i
7d CD i
prior JJ i
to TO i
longitudinal JJ i
sectioning NN i
in IN i
a DT i
mesio-distal JJ i
plane NN i
. . i

Following VBG N
sectioning NN N
, , N
ten JJ N
specimens NNS N
from IN N
each DT N
group NN N
were VBD N
chosen VBN N
at IN N
random NN N
from IN N
the DT N
20 CD N
available JJ N
sections NNS N
. . N

The DT N
sectioned JJ N
surfaces NNS N
were VBD N
polished VBN i
using VBG i
600-grit JJ i
SiC NNP i
abrasive JJ i
paper NN i
and CC i
etched VBD i
for IN i
10 CD i
s NN i
with IN i
50 CD i
% NN i
phosphoric JJ i
acid NN i
to TO N
remove VB N
the DT N
smear JJ N
layer NN N
produced VBN N
by IN N
sectioning VBG N
. . N

Five CD N
tooth JJ N
sections NNS N
from IN N
the DT N
dentin NN N
bonding VBG N
resin NN N
groups NNS N
were VBD N
allowed VBN N
to TO N
dry VB N
at IN N
20 CD N
degrees NNS N
C NNP N
for IN N
24h CD N
. . N

The DT N
glass NN N
ionomer-based JJ N
groups NNS N
were VBD N
reimmersed VBN N
in IN N
deionized JJ N
water NN N
during IN N
this DT N
period NN N
. . N

The DT N
remaining VBG N
five CD N
sections NNS N
from IN N
each DT N
group NN N
were VBD N
replicated VBN N
using VBG N
an DT N
addition-cure JJ i
vinyl NN i
polysiloxane NN i
impression NN i
material NN i
and CC i
an DT i
epoxy JJ i
resin NN i
. . i

A DT N
comparison NN N
was VBD N
made VBN N
of IN N
the DT N
sections NNS N
and CC N
the DT N
replicas NN N
. . N

All DT N
tooth JJ N
specimens NNS N
were VBD N
sputter-coated JJ i
with IN i
gold NN i
for IN N
4 CD N
min NNS N
and CC N
examined VBD N
using VBG N
a DT N
scanning VBG N
electron NN N
microscope NN N
. . N

Replicas NNPS N
were VBD N
gold-coated JJ N
for IN N
3 CD N
min NN N
. . N

Different JJ N
tooth/restoration NN N
interfaces NNS N
, , N
associated VBN N
with IN N
different JJ N
materials NNS N
, , N
were VBD N
observed VBN N
. . N

A DT N
marked JJ N
difference NN o
between IN N
the DT N
replicas NN N
and CC N
tooth JJ N
sections NNS N
was VBD N
observed VBN N
for IN N
glass NN i
ionomer-based JJ i
restorations NNS i
but CC N
not RB N
for IN N
resin-based JJ i
bonding NN i
systems NNS N
. . N

Representative JJ N
samples NNS N
of IN N
replicas NN N
and CC N
specimens NNS N
are VBP N
shown VBN N
, , N
and CC N
the DT N
significance NN N
of IN N
the DT N
observed JJ N
differences NNS N
is VBZ N
discussed VBN N
. . N

-DOCSTART- -10661479- O O

Changes NNS N
in IN N
cardiac JJ o
muscle NN o
mass NN o
and CC N
function NN N
in IN N
hemodialysis NN p
patients NNS p
during IN p
growth NN i
hormone CD i
treatment NN i
. . i

BACKGROUND NNP N
Adult NNP p
patients NNS p
with IN p
chronic JJ p
renal JJ p
failure NN p
( ( p
CRF NNP p
) ) p
often RB N
show VBP N
symptoms NNS N
as IN N
fatigue NN N
, , N
wasting NN N
, , N
and CC N
reduced VBD N
working VBG N
capacity NN N
with IN N
concomitant JJ N
findings NNS N
of IN N
reduced JJ N
cardiac JJ N
performance NN N
and CC N
muscle NN N
mass NN N
. . N

This DT N
state NN N
may MD N
in IN N
part NN N
be VB N
caused VBN N
by IN N
an DT N
imbalance NN N
in IN N
the DT N
somatostatin/somatomedine NN N
axis NN N
resulting VBG N
in IN N
increased JJ N
catabolism NN N
. . N

During IN N
an DT N
attempt NN N
to TO N
correct VB N
this DT N
catabolic JJ N
state NN N
by IN N
administration NN i
of IN i
exogenous JJ i
growth NN i
hormone NN i
, , N
cardiac JJ N
muscle NN N
mass NN N
and CC N
performance NN N
were VBD N
studied VBN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
6-month JJ N
study NN N
comprising VBG N
20 CD p
adult NN p
enfeebled VBD i
hemodialysis NN i
patients NNS i
, , N
9 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
single JJ N
daily JJ N
subcutaneous JJ N
injection NN N
of IN N
recombinant JJ i
human JJ i
growth NN i
hormone NN i
( ( i
rhGH NN i
) ) i
4 CD N
IU/m2 NNP N
and CC N
11 CD N
with IN N
placebo JJ i
injections NNS N
. . N

Left NNP o
ventricular JJ o
muscle NN o
mass NN o
( ( o
LVM NNP o
) ) o
and CC N
ejection NN o
fraction NN o
( ( o
EF NNP o
) ) o
were VBD N
evaluated VBN N
by IN N
echocardiography NN N
and CC N
the DT N
maximal JJ N
working NN N
capacity NN N
( ( N
MWC NNP N
) ) N
was VBD N
measured VBN N
by IN N
a DT N
bicycle NN i
exercise NN i
test NN i
performed VBD N
before IN N
and CC N
after IN N
the DT N
treatment NN N
period NN N
. . N

Supplementary JJ N
electrocardiography NN o
( ( o
ECG NNP o
) ) o
was VBD N
performed VBN N
before IN N
and CC N
after IN N
6-month JJ N
treatment NN N
. . N

RESULTS NNP N
Median JJ o
LVM NNP o
increased VBD N
significantly RB N
from IN N
172 CD N
to TO N
220 CD N
g NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
in IN N
the DT N
rhGH-treated JJ N
group NN N
, , N
while IN N
an DT N
insignificant JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
the DT N
placebo NN N
group NN N
from IN N
281 CD N
to TO N
200 CD N
g NN N
( ( N
p JJ N
= NNP N
0.3 CD N
) ) N
. . N

The DT N
EF NNP o
showed VBD N
no DT N
significant JJ N
changes NNS N
in IN N
the DT N
two CD N
groups NNS N
. . N

MWC NNP o
showed VBD N
a DT N
slight NN N
, , N
insignificant JJ N
decrease NN N
in IN N
both DT N
groups NNS N
. . N

From IN N
ECG NNP N
no DT N
significant JJ N
ST NNP o
deviations NNS o
were VBD N
found VBN N
and CC N
no DT N
significant JJ N
changes NNS N
regarding VBG N
B-Hb NNP N
, , N
blood NN N
pressure NN N
or CC N
pulse NN N
were VBD N
observed VBN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Irregular JJ o
heart NN o
rhythm NN o
aggravated VBD N
in IN N
one CD N
patient NN N
during IN N
the DT N
first JJ N
month NN N
of IN N
treatment NN N
with IN N
rhGH NN N
, , N
but CC N
was VBD N
overcome VBN N
by IN N
a DT N
-blocking JJ N
agent NN N
. . N

CONCLUSION VB N
The DT N
treatment NN N
with IN N
rhGH NN N
of IN N
adult NN N
chronic JJ N
hemodialysis NN N
patients NNS N
for IN N
6 CD N
months NNS N
increased VBD N
the DT o
left NN o
ventricular JJ o
mass NN o
significantly RB N
, , N
but CC N
without IN N
any DT N
effect NN N
on IN N
ejection NN N
fraction NN N
or CC N
maximal JJ N
working JJ N
capacity NN N
. . N

No DT N
electrocardiographic JJ N
signs NNS N
of IN N
ischemia NN N
were VBD N
associated VBN N
with IN N
the DT N
increasing VBG N
muscle NN N
mass NN N
and CC N
only RB N
one CD N
patient NN N
developed VBD N
symptoms NNS N
that WDT N
might MD N
relate VB N
to TO N
ischemia VB N
. . N

No DT N
changes NNS N
in IN N
B-Hb NNP o
, , o
blood NN o
pressure NN o
or CC N
pulse NN N
were VBD N
observed VBN N
during IN N
the DT N
treatment NN N
period NN N
. . N

-DOCSTART- -16230665- O O

Incidence NN o
of IN o
puberty NN o
in IN N
beef NN p
heifers NNS p
fed VBP p
high- JJ i
or CC i
low-starch JJ i
diets NNS i
for IN p
different JJ p
periods NNS p
before IN p
breeding VBG p
. . p

Spring-born JJ p
Hereford NNP p
x NNP p
Angus NNP p
heifers NNS p
( ( p
n JJ p
= NNP p
206 CD p
) ) p
were VBD N
used VBN N
to TO N
determine VB N
effects NNS N
of IN N
energy NN i
supplementation NN i
programs NNS i
and CC i
amount NN i
of IN i
starch NN i
in IN N
the DT N
diet NN N
on IN N
incidence NN N
of IN N
puberty NN o
. . o

In IN N
Exp NNP N
. . N

1 CD N
, , N
heifers NNS p
( ( p
205 CD p
+/- JJ p
5 CD p
kg NN p
; : p
n CC p
= VB p
68 CD p
) ) p
grazing NN p
dormant JJ p
native JJ p
pasture NN p
were VBD N
fed VBN N
0.9 CD N
kg/d NNS N
( ( N
as-fed JJ N
basis NN N
) ) N
of IN N
a DT N
42 CD N
% NN N
CP NNP i
supplement NN i
from IN N
November NNP N
until IN N
February NNP N
14 CD N
. . N

Heifers NNS p
were VBD N
stratified VBN N
by IN N
weaning VBG N
weight NN o
and CC N
allotted VBD N
randomly RB N
to TO N
treatment NN N
before IN N
breeding VBG N
( ( N
May NNP N
to TO N
July NNP N
) ) N
. . N

Treatments NNS N
were VBD N
1 CD N
) ) N
0.9 CD N
kg NN N
( ( N
as-fed JJ N
basis NN N
) ) N
of IN N
a DT N
42 CD N
% NN N
CP NNP i
supplement/d NN i
and CC i
pasture NN i
( ( N
control NN N
) ) N
; : N
2 CD N
) ) N
a DT i
high-starch NN i
( ( i
HS NNP i
) ) i
diet NN i
( ( i
73 CD i
% NN i
corn NN N
; : N
53 CD N
% NN N
starch NN N
) ) N
fed NN N
in IN N
a DT N
drylot NN N
for IN N
60 CD N
d NN N
( ( N
HS-60 NNP N
) ) N
; : N
3 CD N
) ) N
a DT N
HS NNP i
diet JJ i
fed NN i
in IN i
drylot NN i
for IN N
30 CD N
d NN N
( ( N
HS-30 NNP N
) ) N
; : N
or CC N
4 CD N
) ) N
a DT i
low-starch NN i
( ( i
LS NNP i
) ) i
diet NN i
( ( N
49 CD N
% NN N
corn NN N
; : N
37 CD N
% NN N
starch NN N
) ) N
self-fed NN i
on IN i
pasture NN i
for IN N
30 CD N
d NN N
( ( N
LS-30 NNP N
) ) N
. . N

The DT N
HS-60 JJ i
and CC N
HS-30 JJ i
heifers NNS N
were VBD N
limited-fed JJ N
to TO N
gain VB N
0.9 CD N
kg/d NN N
, , N
and CC N
the DT N
LS-30 JJ i
heifers NNS N
had VBD N
ad NN N
libitum NN N
access NN N
to TO N
the DT N
diet JJ N
. . N

High-starch-60 JJ i
and CC N
LS-30 JJ N
heifers NNS N
were VBD N
heavier JJR o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
control NN N
and CC N
HS-30 JJ N
heifers NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
breeding NN N
season NN N
. . N

Thirty-one CD N
, , N
25 CD N
, , N
and CC N
26 CD N
% NN N
more JJR N
HS-60 JJ N
heifers NNS N
were VBD N
pubertal JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
on IN N
May NNP N
1 CD N
compared VBN N
with IN N
LS-30 NNP N
, , N
HS-30 NNP N
, , N
and CC N
control NN N
heifers NNS N
, , N
respectively RB N
. . N

At IN N
puberty NN o
, , N
HS-60 JJ N
heifers NNS N
were VBD N
24 CD N
and CC N
22 CD N
d NN N
younger JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
LS-30 NNP N
and CC N
control NN N
heifers NNS N
, , N
and CC N
31 CD N
kg NNS N
lighter JJR N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
than IN N
LS-30 JJ N
heifers NNS N
. . N

In IN N
Exp NNP N
. . N

2 CD N
, , N
heifers NNS N
grazed VBD N
dormant JJ N
pasture NN N
and CC N
were VBD N
fed VBN N
0.9 CD N
kg NNS N
( ( N
as-fed JJ N
basis NN N
) ) N
of IN N
a DT N
42 CD i
% NN i
CP NNP i
supplement/d NN i
from IN N
weaning VBG N
in IN N
October NNP N
to TO N
late VB N
February NNP N
; : N
then RB N
heifers NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
treatments NNS N
for IN N
60 CD N
d NN N
before IN N
the DT N
breeding NN N
season NN N
. . N

In IN N
two CD N
years NNS N
, , N
control NN N
heifers NNS N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
grazed VBN N
pasture NN N
and CC N
received VBD N
0.9 CD N
kg NN N
of IN N
SBM NNP i
supplement/d NN i
; : i
LS NNP N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
heifers NNS N
were VBD N
self-fed JJ N
a DT N
distiller NN i
's POS i
grain NN i
and CC i
soybean JJ i
hull-based JJ i
diet NN i
in IN N
drylot NN N
; : N
and CC N
HS NNP N
heifers NNS N
( ( N
n JJ N
= NNP N
46 CD N
) ) N
were VBD N
limited-fed JJ i
a DT i
corn-based JJ i
diet NN i
in IN N
drylot NN N
. . N

During IN N
treatment NN N
, , N
HS NNP i
and CC p
LS NNP i
heifers NNS p
had VBD N
greater JJR N
weight NN o
gains NNS o
than IN N
control NN N
heifers NNS N
. . N

Pubertal JJ o
BW NNP o
( ( N
313 CD N
+/- JJ N
6 CD N
kg NN N
) ) N
was VBD N
not RB N
influenced VBN N
by IN N
treatment NN N
, , N
but CC N
HS NNP p
and CC p
LS NNP p
heifers NNS p
were VBD N
younger JJR N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
than IN N
control NN N
heifers NNS N
at IN N
puberty NN N
. . N

During IN N
a DT N
60-d JJ N
breeding NN N
period NN N
, , N
the DT N
incidence NN o
of IN o
puberty NN o
was VBD N
greater JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
for IN N
HS NNP p
and CC p
LS NNP p
heifers NNS p
than IN N
for IN N
control NN N
heifers NNS N
and CC N
was VBD N
greater JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
HS NNP N
than IN N
in IN N
LS NNP N
heifers NNS N
in IN N
Year JJ N
1 CD N
. . N

Feeding VBG N
a DT N
LS NNP i
or CC i
a DT i
HS NNP i
diet NN i
for IN N
30 CD N
d NN N
before IN N
breeding NN N
may MD N
be VB N
inadequate JJ N
to TO N
stimulate VB N
puberty NN o
in IN N
beef NN N
heifers NNS p
, , N
but CC N
feeding VBG N
a DT N
diet JJ N
with IN N
a DT N
greater JJR N
amount NN N
of IN N
starch NN N
for IN N
60 CD N
d NN N
before IN N
breeding NN N
may MD N
increase VB N
the DT N
incidence NN o
of IN o
puberty NN o
during IN N
breeding NN N
of IN N
heifers NNS N
that WDT N
have VBP N
inadequate JJ N
yearling NN N
weight NN N
. . N

-DOCSTART- -15012924- O O

Does NNP N
aerobic VB i
training VBG i
lead NN N
to TO N
a DT N
more RBR N
active JJ o
lifestyle NN o
and CC o
improved JJ o
quality NN o
of IN o
life NN o
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
? . N
BACKGROUND NNP N
Due NNP N
to TO N
dyspnea VB N
and CC N
fatigue VB N
, , N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
are VBP N
often RB N
restricted VBN N
in IN N
the DT N
performance NN N
of IN N
everyday JJ N
activities NNS N
, , N
which WDT N
gradually RB N
may MD N
lead VB N
to TO N
hypoactivity NN N
. . N

AIMS NNP N
To TO N
assess VB N
whether IN N
aerobic JJ i
training VBG i
leads NNS N
to TO N
a DT N
more RBR N
active JJ o
lifestyle NN o
and CC o
improved JJ o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
in IN N
patients NNS p
with IN p
CHF NNP p
. . p

METHODS NNP N
Patients NNPS p
with IN p
stable JJ p
CHF NNP p
( ( p
NYHA NNP p
II/III NNP p
; : p
59 CD p
( ( p
11 CD p
) ) p
years NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
training NN i
group NN N
( ( N
n=18 JJ N
; : N
3-month JJ N
aerobic JJ i
program NN i
above IN i
standard JJ i
treatment NN i
) ) i
or CC N
control VB i
group NN i
( ( N
n=16 RB N
; : N
standard JJ i
treatment NN i
without IN i
special JJ i
advice NN i
for IN i
exercise NN i
) ) i
. . N

Measurements NNS N
were VBD N
performed VBN N
on IN N
level NN N
of IN N
everyday JJ o
physical JJ o
activity NN o
( ( o
PA NNP o
, , o
novel JJ o
accelerometry-based JJ o
activity NN o
monitor NN o
) ) o
and CC o
QoL NNP o
, , N
and CC N
on IN N
several JJ o
related JJ o
parameters NNS o
. . o

RESULTS NNP N
Training VBG N
did VBD N
not RB N
result VB N
in IN N
a DT N
more RBR N
active JJ o
lifestyle NN o
or CC o
improved VBN o
QoL NNP o
, , N
but CC N
improved VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
peak NN o
power NN o
( ( N
17 CD N
% NN N
) ) N
, , N
6-min JJ o
walk NN o
distance NN o
( ( N
10 CD N
% NN N
) ) N
, , N
muscle NN o
strength NN o
( ( N
13-15 CD N
% NN N
) ) N
and CC N
depression NN o
( ( N
-1.3 JJ N
unit NN N
) ) N
. . N

Changes NNS N
in IN N
level NN N
of IN N
everyday JJ N
PA NNP N
were VBD N
related VBN N
to TO N
changes NNS N
in IN N
peak NN o
Vo NNP o
( ( o
2 CD o
) ) o
( ( N
r=0.58 NN N
, , N
P=0.01 NNP N
) ) N
and CC N
knee $ o
extension NN o
strength NN o
( ( N
r=0.48 NN N
, , N
P=0.05 NNP N
) ) N
. . N

CONCLUSIONS NNP N
At IN N
group NN N
level NN N
training NN N
did VBD N
not RB N
result VB N
in IN N
a DT N
more RBR N
active JJ o
lifestyle NN o
or CC o
improved VBN o
QoL NNP o
. . o

However RB N
, , N
correlations NNS N
between IN N
training-related JJ N
changes NNS N
in IN N
parameters NNS N
suggest VBP N
that IN N
aerobic JJ N
training NN N
has VBZ N
the DT N
potential JJ N
to TO N
increase VB N
levels NNS N
of IN N
everyday JJ o
PA NNP o
in IN N
CHF NNP N
. . N

-DOCSTART- -8872685- O O

Effects NNS N
of IN N
enflurane NN i
and CC i
isoflurane NN i
on IN N
splanchnic JJ o
oxygenation NN o
in IN p
humans NNS p
. . p

STUDY NNP N
OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
enflurane NN i
and CC i
isoflurane NN i
on IN N
hepatic JJ o
venous JJ o
oxygen NN o
saturation NN o
( ( o
ShvO2 NNP o
) ) o
and CC o
splanchnic JJ o
oxygen NN o
( ( o
O2 NNP o
) ) o
extraction NN o
. . o

To TO N
measure VB N
hemodynamic JJ N
parameters NNS N
and CC N
ShvO2 NNP N
, , N
mixed JJ N
venous JJ N
, , N
and CC N
arterial JJ N
lactate NN N
concentrations NNS N
during IN N
enflurane NN i
and CC i
isoflurane NN i
anesthesia NN i
. . i

DESIGN NNP N
Randomized NNP N
, , N
prospective JJ N
study NN N
. . N

SETTING NNP N
University NNP N
hospital NN N
. . N

PATIENTS CC N
20 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
, , p
II NNP p
, , p
and CC p
III NNP p
adults NNS p
, , p
who WP p
underwent VBD p
major JJ p
abdominal JJ p
surgery NN p
requiring VBG p
mechanical JJ p
ventilation NN p
a DT p
few JJ p
hours NNS p
postoperatively RB p
. . p

INTERVENTIONS NNP N
After IN N
placement NN N
of IN N
catheters NNS N
in IN N
the DT N
pulmonary JJ N
artery NN N
, , N
radial JJ N
artery NN N
, , N
peripheral JJ N
and CC N
right JJ N
hepatic JJ N
vein NN N
, , N
one CD N
hour NN N
postoperatively RB N
either CC N
enflurane NN i
or CC i
isoflurane NN i
was VBD N
applied VBN N
at IN N
different JJ N
minimum JJ N
alveolar JJ N
concentration NN N
( ( N
MAC NNP N
) ) N
of IN N
0.5 CD N
, , N
1.0 CD N
, , N
and CC N
1.5 CD N
in IN N
a DT N
randomized JJ N
order NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Before NNP N
and CC N
10 CD N
minutes NNS N
after IN N
administration NN N
of IN N
each DT N
desired VBN N
end-expiratory JJ N
anesthetic JJ N
concentration NN N
, , N
the DT N
following JJ N
parameters NNS N
were VBD N
determined VBN N
: : N
hemodynamic JJ o
parameters NNS o
, , o
arterial JJ o
( ( o
SaO2 NNP o
) ) o
, , o
mixed JJ o
venous JJ o
( ( o
SvO2 NNP o
) ) o
, , o
and CC o
hepatic JJ o
venous JJ o
oxygen NN o
saturations NNS o
, , o
systemic JJ o
and CC o
splanchnic JJ o
O2 NNP o
extraction NN o
, , o
arterial JJ o
, , o
mixed JJ o
venous JJ o
, , o
and CC o
hepatic JJ o
venous JJ o
lactate NN o
concentrations NNS o
. . o

Cardiac NNP o
output NN o
( ( o
CO NNP o
) ) o
and CC o
mean JJ o
arterial JJ o
pressure NN o
( ( o
MAP NNP o
) ) o
decreased VBD N
in IN N
a DT N
dose JJ N
dependent JJ N
manner NN N
. . N

SaO2 NNP o
, , o
SvO2 NNP o
, , o
and CC o
systemic JJ o
O2 NNP o
extraction NN o
remained VBD N
unchanged JJ N
with IN N
enflurane NN N
and CC N
isoflurane NN N
anesthesia NN N
. . N

In IN N
the DT N
enflurane NN i
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
isoflurane NN N
group NN N
, , N
ShvO2 NNP o
decreased VBD N
with IN N
increasing VBG N
inhalational JJ N
concentrations NNS N
. . N

This DT N
decrease NN N
in IN N
ShvO2 NNP o
reflected VBD N
an DT N
increase NN N
in IN N
splanchnic JJ o
O2 NNP o
extraction NN o
with IN N
enflurane NN i
; : i
in IN N
contrast NN N
to TO N
isoflurane VB i
. . i

CONCLUSIONS NNP N
Enflurane NNP i
causes VBZ N
a DT N
decrease NN N
in IN N
ShvO2 NNP o
, , N
which WDT N
indicates VBZ N
an DT N
impairment NN N
of IN N
splanchnic JJ o
perfusion NN o
corresponding VBG N
to TO N
the DT N
reduction NN N
in IN N
CO NNP o
and CC o
MAP NNP o
in IN N
a DT N
dose-dependent JJ N
manner NN N
. . N

Isoflurane NNP i
maintains VBZ N
splanchnic JJ o
perfusion NN o
in IN N
contrast NN N
to TO N
enflurane VB i
. . i

-DOCSTART- -15897310- O O

Efficacy NN N
of IN N
physiotherapy JJ i
management NN i
of IN N
knee NN p
joint JJ p
osteoarthritis NN p
: : p
a DT N
randomised JJ N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
a DT N
multimodal JJ i
physiotherapy NN i
programme NN i
including VBG i
taping VBG i
, , i
exercises NNS i
, , i
and CC i
massage NN i
is VBZ N
effective JJ N
for IN N
knee NN p
osteoarthritis NN p
, , N
and CC N
if IN N
benefits NNS N
can MD N
be VB N
maintained VBN N
with IN N
self JJ N
management NN N
. . N

METHODS NNP N
Randomised VBD N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
trial NN N
; : N
140 CD p
community NN p
volunteers NNS p
with IN p
knee NN p
osteoarthritis NN p
participated VBD p
and CC p
119 CD p
completed VBD p
the DT p
trial NN p
. . p

Physiotherapy NNP i
and CC i
placebo JJ i
interventions NNS N
were VBD N
applied VBN N
by IN N
10 CD N
physiotherapists NNS N
in IN N
private JJ N
practices NNS N
for IN N
12 CD N
weeks NNS N
. . N

Physiotherapy NNP i
included VBD i
exercise NN i
, , i
massage NN i
, , i
taping VBG i
, , i
and CC i
mobilisation NN i
, , i
followed VBN i
by IN i
12 CD i
weeks NNS i
of IN i
self JJ i
management NN i
. . i

Placebo NNP i
was VBD N
sham VBN i
ultrasound JJ i
and CC i
light JJ i
application NN i
of IN i
a DT i
non-therapeutic JJ i
gel NN i
, , i
followed VBN i
by IN i
no DT i
treatment NN i
. . i

Primary JJ N
outcomes NNS N
were VBD N
pain RB o
measured VBN o
by IN o
visual JJ o
analogue NN o
scale NN o
and CC o
patient JJ o
global JJ o
change NN o
. . o

Secondary JJ N
measures NNS N
included VBD N
WOMAC NNP o
, , o
knee NN o
pain NN o
scale NN o
, , o
SF-36 NNP o
, , o
assessment NN o
of IN o
quality NN o
of IN o
life NN o
index NN o
, , o
quadriceps JJ o
strength NN o
, , o
and CC o
balance NN o
test NN o
. . o

RESULTS NNP N
Using VBG N
an DT N
intention NN N
to TO N
treat VB N
analysis NN N
, , N
physiotherapy NN p
and CC p
placebo NN p
groups NNS p
showed VBD N
similar JJ N
pain NN o
reductions NNS o
at IN N
12 CD N
weeks NNS N
: : N
-2.2 NN N
cm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-2.6 NNP N
to TO N
-1.7 VB N
) ) N
and CC N
-2.0 $ N
cm NN N
( ( N
-2.5 UH N
to TO N
-1.5 VB N
) ) N
, , N
respectively RB N
. . N

At IN N
24 CD N
weeks NNS N
, , N
pain NN o
remained VBD o
reduced VBN o
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
: : N
-2.1 NN N
( ( N
-2.6 UH N
to TO N
-1.6 VB N
) ) N
and CC N
-1.6 NNP N
( ( N
-2.2 UH N
to TO N
-1.0 VB N
) ) N
, , N
respectively RB N
. . N

Global JJ o
improvement NN o
was VBD N
reported VBN N
by IN N
70 CD N
% NN N
of IN N
physiotherapy NN N
participants NNS N
( ( N
51/73 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
59 CD N
% NN N
( ( N
43/73 CD N
) ) N
at IN N
24 CD N
weeks NNS N
. . N

Similarly RB N
, , N
global JJ o
improvement NN o
was VBD N
reported VBN N
by IN N
72 CD N
% NN N
of IN N
placebo NN N
participants NNS N
( ( N
48/67 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
49 CD N
% NN N
( ( N
33/67 CD N
) ) N
at IN N
24 CD N
weeks NNS N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
physiotherapy NN i
programme NN i
tested VBN N
in IN N
this DT N
trial NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
regular JJ N
contact NN N
with IN N
a DT N
therapist NN N
at IN N
reducing VBG N
pain NN N
and CC N
disability NN N
. . N

-DOCSTART- -11074150- O O

Effects NNS N
of IN N
nicotine NN o
on IN N
regional JJ o
cerebral JJ o
glucose JJ o
metabolism NN o
in IN N
awake JJ p
resting NN p
tobacco NN p
smokers NNS p
. . p

Eleven NNP p
healthy JJ p
tobacco NN p
smoking VBG p
adult NN p
male NN p
volunteers NNS p
of IN p
mixed JJ p
race NN p
were VBD N
tobacco JJ i
abstinent JJ i
overnight NN N
for IN N
this DT N
study NN N
. . N

In IN N
each DT N
subject NN N
, , N
positron NN o
emission NN o
tomographic JJ o
images NNS o
of IN N
regional JJ N
cerebral JJ o
metabolism NN o
of IN o
glucose JJ o
with IN N
[ JJ o
18F CD o
] NNS o
fluorodeoxyglucose JJ o
were VBD N
obtained VBN N
in IN N
two CD N
conditions NNS N
in IN N
the DT N
morning NN N
on IN N
different JJ N
days NNS N
: : N
about IN N
3min CD N
after IN N
approximately RB i
1-2mg JJ i
of IN i
nasal JJ i
nicotine JJ i
spray NN i
and CC i
after IN i
an DT i
equivalent JJ i
volume NN i
of IN i
an DT i
active JJ i
placebo NN i
spray NN i
of IN i
oleoresin NN i
of IN i
pepper NN i
in IN N
a DT N
random NN N
counterbalanced VBD N
design NN N
. . N

A DT N
Siemens/CTI JJ N
931/08-12 JJ N
scanner NN N
with IN N
the DT N
capability NN N
of IN N
15 CD N
horizontal JJ N
brain NN N
slices NNS N
was VBD N
used VBN N
. . N

The DT N
images NNS N
were VBD N
further RB N
converted VBN N
into IN N
a DT N
standard JJ N
uniform NN N
brain NN N
format NN N
in IN N
which WDT N
the DT N
mean NN N
data NNS N
of IN N
all DT N
11 CD N
subjects NNS N
were VBD N
obtained VBN N
. . N

Images NNS N
were VBD N
analysed VBN N
in IN N
stereotactic JJ N
coordinates NNS N
using VBG N
pixel-wise JJ N
t NN N
statistics NNS N
and CC N
a DT N
smoothed JJ N
Gaussian JJ N
model NN N
. . N

Peak NNP o
plasma JJ o
nicotine NN o
levels NNS o
varied VBN N
three-fold JJ N
and CC N
the DT N
areas NNS N
under IN N
the DT N
curve NN N
( ( N
0-30min JJ N
) ) N
varied VBD N
seven-fold JJ N
among IN N
the DT N
individual JJ N
subjects NNS N
. . N

Nicotine NNP i
caused VBD N
a DT N
small JJ N
overall JJ N
reduction NN N
in IN N
global JJ o
cerebral JJ o
metabolism NN o
of IN o
glucose NN o
but CC N
, , N
when WRB N
the DT N
data NNS N
were VBD N
normalized VBN N
, , N
several JJ N
brain NN N
regions NNS N
showed VBD N
relative JJ N
increases NNS o
in IN o
activity NN o
. . o

Cerebral JJ N
structures NNS N
specifically RB N
activated VBN N
by IN N
nicotine NN i
( ( N
nicotine JJ N
minus NN N
pepper NN N
, , N
Z NNP N
score VBD N
> NNP N
4.0 CD N
) ) N
included VBD N
: : N
left VBN N
inferior JJ N
frontal JJ N
gyrus NN N
, , N
left VBD N
posterior JJ N
cingulate NN N
gyrus NN N
and CC N
right JJ N
thalamus NN N
. . N

The DT N
visual JJ N
cortex NN N
, , N
including VBG N
the DT N
right NN N
and CC N
left VBD N
cuneus NN N
and CC N
left VBD N
lateral JJ N
occipito-temporal JJ N
gyrus NN N
fusiformis NN N
, , N
also RB N
showed VBD N
an DT N
increase NN N
in IN N
regional JJ o
cerebral JJ o
metabolism NN o
of IN o
glucose NN o
with IN N
Z NNP N
scores NNS N
> VBD N
3 CD N
. . N

6 CD N
. . N

Structures NNS N
with IN N
a DT N
decrease NN o
in IN o
regional JJ o
cerebral JJ o
metabolism NN o
of IN o
glucose NN o
( ( o
pepper JJ o
minus FW N
nicotine NN o
) ) o
were VBD N
the DT N
left JJ N
insula NN N
and CC N
right JJ N
inferior JJ N
occipital JJ N
gyrus NN N
, , N
with IN N
Z NNP N
scores NNS N
> VBD N
3.5 CD N
. . N

Especially RB N
important JJ N
is VBZ N
the DT N
fact NN N
that IN N
the DT N
thalamus NN N
is VBZ N
activated VBN N
by IN N
nicotine NN i
. . i

This DT N
is VBZ N
consistent JJ N
with IN N
the DT N
high JJ N
density NN N
of IN N
nicotinic JJ N
cholinoceptors NNS N
in IN N
that DT N
brain NN N
region NN N
. . N

However RB N
, , N
not RB N
all DT N
brain NN N
regions NNS N
affected VBN N
by IN N
nicotine NN N
are VBP N
known VBN N
to TO N
have VB N
many JJ N
nicotinic JJ N
cholinoceptors NNS N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
relation NN N
to TO N
the DT N
cognitive JJ o
effects NNS o
of IN o
nicotine NN o
. . o

-DOCSTART- -23066765- O O

Effects NNS N
of IN N
psychosocial JJ i
program NN i
for IN N
preparing VBG N
long-term JJ p
hospitalized JJ p
patients NNS p
with IN p
schizophrenia NN p
for IN p
discharge NN p
from IN p
hospital NN p
: : p
randomized VBN N
controlled JJ N
trial NN N
. . N

AIM VB N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
to TO N
revise VB N
the DT N
Community NNP i
Re-entry NNP i
Program-Japanese JJ i
version NN i
and CC N
to TO N
review VB N
the DT N
effectiveness NN o
of IN N
the DT N
revised VBN N
Program NNP N
, , N
named VBD N
the DT N
Discharge NNP i
Preparation NNP i
Program NNP i
. . i

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

The DT N
Discharge NNP i
Preparation NNP i
Program NNP i
( ( i
DPP NNP i
) ) i
was VBD N
the DT N
intervention NN p
condition NN p
( ( p
n JJ p
= NNP p
26 CD p
) ) p
, , N
and CC N
the DT N
usual JJ i
rehabilitation NN i
program NN i
was VBD i
the DT i
control NN i
condition NN i
( ( p
n JJ p
= NNP p
23 CD p
) ) p
. . p

Outcome JJ N
indicators NNS N
included VBD N
factors NNS o
that WDT o
make VBP o
patient JJ o
discharge NN o
difficult JJ o
( ( o
which WDT o
nurses VBZ o
evaluated VBN o
) ) o
, , o
psychiatric JJ o
symptom NN o
, , o
knowledge NN o
about IN o
the DT o
illness NN o
or CC o
medication NN o
, , o
and CC o
the DT o
number NN o
of IN o
patients NNS o
who WP o
were VBD o
discharged VBN o
within IN o
6 CD o
months NNS o
after IN o
the DT o
end NN o
of IN o
a DT o
program NN o
. . o

RESULTS NNP N
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN N
the DT N
score NN o
of IN o
the DT o
'Issues NNS o
on IN o
treatment NN o
compliance NN o
' POS o
factor NN o
and CC o
the DT o
score NN o
of IN o
the DT o
'Autistic JJ o
life NN o
' POS o
factor NN o
, , N
which WDT N
are VBP N
subscales NNS N
of IN N
the DT N
Discharge NNP o
Difficulty NNP o
Scale NNP o
, , N
for IN N
the DT N
DPP NNP i
group NN N
, , N
on IN N
two-way JJ N
ANOVA NNP N
( ( N
'Issues NNS N
on IN N
treatment NN N
compliance NN N
' '' N
: : N
F NNP N
= VBZ N
3.818 CD N
, , N
P NNP N
< NNP N
0.10 CD N
; : N
'Autistic JJ N
life NN N
' POS N
: : N
F NNP N
= VBZ N
4.155 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
These DT N
factors NNS N
affected VBD N
discharge NN o
outcome NN o
. . o

Thus RB N
, , N
the DT N
program NN N
may MD N
be VB N
capable JJ N
of IN N
promoting VBG N
discharge NN o
of IN o
long-term JJ o
hospitalized JJ o
psychiatric JJ o
patients NNS o
. . o

With IN N
regard NN N
to TO N
the DT N
number NN o
of IN o
patients NNS o
discharged VBN o
in IN o
6 CD o
months NNS o
after IN N
the DT N
end NN N
of IN N
a DT N
program NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
present JJ N
result NN N
is VBZ N
in IN N
agreement NN N
with IN N
past JJ N
studies NNS N
, , N
and CC N
the DT N
DPP NNP i
is VBZ N
useful JJ N
in IN N
discharge NN N
support NN N
for IN N
patients NNS p
with IN p
schizophrenia NN p
in IN p
Japan NNP p
. . p

-DOCSTART- -19904596- O O

Brief JJ N
Report NNP N
: : N
Randomized JJ N
test NN N
of IN N
the DT N
efficacy NN N
of IN N
picture NN i
exchange NN i
communication NN i
system NN i
on IN N
highly RB N
generalized JJ o
picture NN o
exchanges NNS o
in IN N
children NNS p
with IN p
ASD NNP p
. . p

A NNP N
randomized VBD N
control NN N
trial NN N
comparing VBG N
two CD N
social-communication JJ i
interventions NNS i
in IN N
young JJ p
children NNS p
with IN p
autism NN p
examined VBN N
far-transfer NN o
of IN o
the DT o
use NN o
of IN o
picture NN o
exchange NN o
to TO o
communicate VB o
. . o

Thirty-six JJ p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
conditions NNS N
, , N
one CD i
of IN i
which WDT i
was VBD i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
. . i

All DT N
children NNS N
had VBD N
access NN N
to TO N
picture VB i
symbols NNS i
during IN i
assessments NNS i
. . i

Post-treatment JJ N
measurement NN N
of IN N
the DT N
number NN o
of IN o
picture NN o
exchanges NNS o
in IN o
a DT o
far-transfer NN o
, , N
assessment JJ N
context NN N
favored VBD N
the DT N
PECS NNP i
intervention NN N
. . N

These DT N
findings NNS N
were VBD N
interpreted VBN N
as IN N
support NN N
for IN N
the DT N
hypothesis NN N
that IN N
the DT N
PECS NNP i
curriculum NN N
can MD N
successfully RB N
teach VB N
a DT N
generalized JJ N
means NN N
of IN N
showing VBG N
coordinated JJ o
attention NN o
to TO o
object VB o
and CC o
person NN o
without IN o
requiring VBG o
eye NN o
contact NN o
to TO N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -22112544- O O

Factors NNS N
associated VBN N
with IN N
inadequate JJ N
colorectal JJ i
cancer NN i
screening VBG i
with IN i
flexible JJ i
sigmoidoscopy NN i
. . i

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIM NNP N
Inadequate NNP N
colorectal NN N
cancer NN N
screening VBG N
wastes NNS N
limited VBD N
endoscopic JJ N
resources NNS N
. . N

We PRP N
examined VBD N
patients NNS N
factors NNS N
associated VBN N
with IN N
inadequate JJ N
flexible JJ i
sigmoidoscopy NN i
( ( i
FSG NNP i
) ) i
screening VBG i
at IN N
baseline NN N
screening NN N
and CC N
repeat NN i
screening VBG i
3-5 CD N
years NNS N
later RB N
in IN N
10 CD p
geographically-dispersed JJ p
screening NN p
centers NNS p
participating VBG p
in IN p
the DT p
ongoing JJ p
Prostate NNP p
, , p
Lung NNP p
, , p
Colorectal NNP p
, , p
and CC p
Ovarian JJ p
Cancer NNP p
Screening NNP p
Trial NNP p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
64,554 CD p
participants NNS p
( ( p
aged VBN p
55-74 NN p
) ) p
completed VBD N
baseline JJ i
questionnaires NNS i
and CC i
underwent JJ i
FSG NNP i
at IN i
baseline NN i
. . i

Of IN p
these DT p
, , p
39,385 CD p
participants NNS p
returned VBN p
for IN p
repeat NN i
screening NN i
. . i

We PRP N
used VBD N
logistic JJ N
regression NN N
models NNS N
to TO N
assess VB N
factors NNS N
that WDT N
are VBP N
associated VBN N
with IN N
inadequate JJ i
FSG NNP i
( ( N
defined VBN N
as IN N
a DT N
study NN N
in IN N
which WDT N
the DT N
depth NN N
of IN N
insertion NN N
of IN N
FSG NNP N
was VBD N
< JJ N
50 CD N
cm NN N
or CC N
visual JJ N
inspection NN N
was VBD N
limited VBN N
to TO N
< VB N
90 CD N
% NN N
of IN N
the DT N
mucosal JJ N
surface NN N
but CC N
without IN N
detection NN N
of IN N
a DT N
polyp NN N
or CC N
mass NN N
) ) N
. . N

RESULTS NNP N
Of IN N
7084 CD N
( ( N
11 CD N
% NN N
) ) N
participants NNS N
with IN N
inadequate JJ N
FSG NNP N
at IN N
baseline NN N
, , N
6496 CD N
( ( N
91.7 CD N
% NN N
) ) N
had VBD N
< $ N
50 CD N
cm NN N
depth NN N
of IN N
insertion NN N
( ( N
75.3 CD N
% NN N
due JJ N
to TO N
patient VB N
discomfort NN N
) ) N
and CC N
500 CD N
( ( N
7.1 CD N
% NN N
) ) N
participants NNS N
had VBD N
adequate JJ N
depth NN N
of IN N
insertion NN N
but CC N
suboptimal JJ N
bowel NN N
preparation NN N
. . N

Compared VBN N
to TO N
55-59 JJ N
year NN N
age NN N
group NN N
, , N
advancing VBG N
age NN N
in IN N
5-year JJ N
increments NNS N
( ( N
odds JJ N
ratios NNS N
( ( N
OR NNP N
) ) N
from IN N
1.08 CD N
to TO N
1.51 CD N
) ) N
and CC N
female JJ N
sex NN N
( ( N
OR NNP N
= VBZ N
2.40 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
2.27-2.54 JJ N
) ) N
were VBD N
associated VBN N
with IN N
inadequate JJ N
FSG NNP N
. . N

Obesity NNP o
( ( N
BMI NNP N
> VBZ N
30 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
was VBD N
associated VBN N
with IN N
reduced JJ N
odds NNS N
( ( N
OR NNP N
= VBZ N
0.67 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.62-0.72 NN N
) ) N
. . N

Inadequate NNP N
FSG NNP N
screening VBG N
at IN N
baseline NN N
was VBD N
associated VBN N
with IN N
inadequate JJ N
FSG NNP N
at IN N
repeat NN N
screening NN N
( ( N
OR NNP N
= VBZ N
6.24 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
5.78-6.75 JJ N
) ) N
. . N

CONCLUSIONS NNP N
Sedation NNP N
should MD N
be VB N
considered VBN N
for IN N
patients NNS p
with IN p
inadequate JJ p
FSG NNP p
or CC N
an DT N
alternative JJ i
colorectal NN i
cancer NN i
screening VBG i
method NN i
should MD N
be VB N
recommended VBN N
. . N

-DOCSTART- -631030- O O

[ JJ N
Long-term NNP N
treatment NN N
of IN N
cerebrovascular JJ N
changes NNS N
in IN N
the DT N
elderly JJ p
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

A DT N
prospective JJ N
study NN N
over IN N
15 CD N
months NNS N
in IN N
100 CD p
elderly JJ p
patients NNS p
with IN p
signs NNS p
of IN p
cerebro-vascular JJ p
impairment NN p
demonstrated VBN p
by IN p
psychometric JJ p
testing VBG p
that IN N
Hydergine NNP i
( ( N
an DT N
ergot NN N
alkaloid JJ N
preparation NN N
: : N
4.5 CD N
mg NNS N
daily RB N
) ) N
compensated VBD N
the DT N
signs NNS N
of IN N
dementia NN N
, , N
present NN N
in IN N
the DT N
placebo NN i
group NN N
, , N
and CC N
in IN N
some DT N
patients NNS N
actually RB N
brought VBD N
about IN N
a DT N
significant JJ N
improvement NN o
in IN o
mental JJ o
activity NN o
. . o

Similar JJ N
compensatory NN o
effect NN o
was VBD N
also RB N
demonstrable JJ N
in IN N
cerebral JJ o
haemodynamics NNS o
: : o
in IN N
the DT N
placebo NN i
group NN N
there EX N
was VBD N
a DT N
progressive JJ o
increase NN o
in IN o
cerebral JJ o
circulation NN o
time NN o
, , N
an DT N
expression NN o
of IN o
decreased JJ o
cerebral JJ o
blood NN o
flow NN o
, , N
while IN N
with IN N
Hydergine NNP i
cerebral JJ N
circulation NN N
time NN N
was VBD N
shortened VBN N
and CC N
stabilized VBN N
. . N

Serial JJ N
EEGs NNP N
, , N
obtained VBN N
in IN N
parallel JJ N
with IN N
psychometric JJ N
and CC N
circulation NN N
time NN N
tests NNS N
, , N
demonstrated VBD N
a DT N
marked JJ N
increase NN N
in IN N
the DT N
8-10 JJ o
Hz NNP o
pattern NN o
which WDT N
corresponds VBZ N
to TO N
the DT N
physiological JJ N
alpha NN N
activity NN N
in IN N
this DT N
age NN N
group NN N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
a DT N
diminished JJ N
variability NN N
in IN N
performance NN o
in IN N
the DT N
tested JJ N
frequency NN N
bands NNS N
with IN N
Hydergine NNP i
, , N
the DT N
opposite JJ N
tendency NN N
being VBG N
obtained VBN N
in IN N
the DT N
placebo NN i
group NN N
. . N

-DOCSTART- -7010662- O O

[ JJ N
Biological NNP N
and CC N
clinical JJ N
effects NNS N
of IN N
oral JJ i
magnesium NN i
and CC i
associated VBN i
magnesium-vitamin JJ i
B6 NNP i
administration NN i
on IN N
certain JJ p
disorders NNS p
observed VBN p
in IN p
infantile JJ p
autism NN p
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

-DOCSTART- -20232240- O O

RCT NNP N
of IN N
a DT N
manualized JJ N
social JJ i
treatment NN i
for IN N
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
RCT NNP N
examined VBD N
the DT N
efficacy NN N
of IN N
a DT N
manualized VBN i
social JJ i
intervention NN i
for IN N
children NNS p
with IN p
HFASDs NNP p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN i
or CC N
wait-list JJ i
conditions NNS i
. . i

Treatment NNP i
included VBD N
instruction NN i
and CC i
therapeutic JJ i
activities NNS i
targeting VBG i
social JJ i
skills NNS i
, , i
face-emotion NN i
recognition NN i
, , i
interest NN i
expansion NN i
, , i
and CC i
interpretation NN i
of IN i
non-literal JJ i
language NN i
. . i

A DT N
response-cost JJ N
program NN N
was VBD N
applied VBN N
to TO N
reduce VB N
problem NN N
behaviors NNS N
and CC N
foster JJ N
skills NNS N
acquisition NN N
. . N

Significant NNP N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
five CD o
of IN o
seven CD o
primary JJ o
outcome JJ o
measures NNS o
( ( o
parent NN o
ratings NNS o
and CC o
direct JJ o
child NN o
measures NNS o
) ) o
. . N

Secondary JJ N
measures NNS N
based VBN N
on IN N
staff NN o
ratings NNS o
( ( N
treatment NN N
group NN N
only RB N
) ) N
corroborated VBD N
gains NNS N
reported VBN N
by IN N
parents NNS N
. . N

High JJ N
levels NNS N
of IN N
parent NN o
, , o
child NN o
and CC o
staff NN o
satisfaction NN o
were VBD N
reported VBN N
, , N
along IN N
with IN N
high JJ N
levels NNS N
of IN N
treatment NN o
fidelity NN o
. . o

Standardized JJ N
effect NN N
size NN N
estimates NNS N
were VBD N
primarily RB N
in IN N
the DT N
medium NN N
and CC N
large JJ N
ranges NNS N
and CC N
favored VBD N
the DT N
treatment NN N
group NN N
. . N

-DOCSTART- -2915887- O O

5-Fluorouracil JJ i
, , i
adriamycin JJ i
, , i
cyclophosphamide NN i
( ( i
FAC NNP i
) ) i
vs. FW N
5-fluorouracil JJ i
, , i
epirubicin JJ i
, , i
cyclophosphamide NN i
( ( i
FEC NNP i
) ) i
in IN N
metastatic JJ p
breast NN p
cancer NN p
. . p

94 CD p
evaluable JJ p
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
5-fluorouracil JJ i
, , i
adriamycin JJ i
, , i
and CC i
cyclophosphamide NN i
( ( i
FAC NNP i
) ) i
or CC i
5-fluorouracil JJ i
, , i
epirubicin JJ i
, , i
and CC i
cyclophosphamide NN i
( ( i
FEC NNP i
) ) i
, , N
with IN N
cycles NNS N
repeated VBN N
every DT N
3 CD N
weeks NNS N
. . N

The DT N
objective JJ o
response NN o
rate NN o
to TO N
FAC NNP i
was VBD N
46 CD N
% NN N
versus IN N
44 CD N
% NN N
to TO N
FEC NNP i
. . i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
median JJ o
duration NN o
of IN o
response NN o
and CC o
median JJ o
survival NN o
for IN N
the DT N
two CD N
regimens NNS N
. . N

Toxicity NN o
was VBD N
more RBR N
frequent JJ N
and CC N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
FAC NNP i
. . i

Results NNP N
indicate JJ N
therapeutic JJ N
equivalence NN N
of IN N
the DT N
two CD N
regimens NNS N
and CC N
reduced JJ N
toxicity NN N
of IN N
the DT N
epirubicin JJ N
arm NN N
. . N

-DOCSTART- -24898318- O O

Improving VBG N
adolescent JJ p
social JJ p
competence NN p
and CC p
behavior NN p
: : p
a DT N
randomized JJ N
trial NN N
of IN N
an DT N
11-week JJ N
equine NN i
facilitated VBN i
learning JJ i
prevention NN i
program NN i
. . i

There EX N
is VBZ N
growing VBG N
evidence NN N
that IN N
promoting VBG i
social JJ i
competence NN i
in IN N
youth NN p
is VBZ N
an DT N
effective JJ N
strategy NN N
to TO N
prevent VB N
mental JJ N
, , N
emotional JJ N
, , N
and CC N
behavioral JJ N
disorders NNS N
in IN N
adulthood NN N
. . N

Research NNP N
suggests VBZ N
that IN N
programs NNS N
delivered VBN N
in IN N
collaboration NN N
with IN N
schools NNS N
are VBP N
particularly RB N
effective JJ N
when WRB N
they PRP N
target VBP N
social JJ N
and CC N
emotional JJ N
skill NN N
building NN N
, , N
utilize VB N
an DT N
interactive JJ N
instructional JJ N
style NN N
, , N
provide VB N
opportunities NNS N
for IN N
youth NN N
participation NN N
and CC N
self-direction NN N
, , N
and CC N
include VBP N
explicit JJ N
attempts NNS N
to TO N
enhance VB N
youth RB N
social JJ N
competence NN N
. . N

A NNP N
relatively RB N
new JJ N
but CC N
popular JJ N
approach NN N
that WDT N
incorporates VBZ N
these DT N
characteristics NNS N
is VBZ N
human JJ i
animal JJ i
interaction NN i
, , N
which WDT N
can MD N
be VB N
implemented VBN N
in IN N
educational JJ N
settings NNS N
. . N

We PRP N
report VBP N
the DT N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
examining VBG N
the DT N
effects NNS N
of IN N
an DT N
11-week JJ i
equine NN i
facilitated VBN i
learning NN i
( ( i
EFL NNP i
) ) i
program NN i
on IN N
the DT N
social JJ N
competence NN N
and CC N
behavior NN N
of IN N
5th-8th JJ p
grade NN p
children NNS p
. . p

Children NNP p
( ( p
N NNP p
= NNP p
131 CD p
) ) p
were VBD p
recruited VBN p
through IN p
referral JJ p
by IN p
school NN p
counselors NNS p
and CC p
school-based JJ p
recruitment NN p
and CC p
then RB p
screened VBD p
for IN p
low JJ p
social JJ p
competence NN p
. . p

Researchers NNP N
randomly RB N
assigned VBD N
children NNS N
to TO N
an DT N
experimental JJ i
( ( i
n JJ i
= NNP i
53 CD i
) ) i
or CC i
waitlisted VBN i
control NN i
group NN i
( ( N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Children NNP N
in IN N
the DT N
experimental JJ N
group NN N
participated VBD N
in IN N
an DT N
11-week JJ N
EFL NNP i
program NN i
consisting NN N
of IN N
once-weekly JJ N
, , N
90-min JJ N
sessions NNS N
of IN N
individual JJ N
and CC N
team-focused JJ N
activities NNS N
, , N
whereas NNS N
children NNS N
in IN N
the DT N
control NN i
group NN i
served VBD N
as IN N
a DT N
wait-listed JJ i
control NN i
and CC N
participated VBD N
16 CD N
weeks NNS N
later RB N
. . N

Parents NNS N
of IN N
children NNS N
in IN N
both DT N
groups NNS N
rated VBN N
child JJ o
social JJ o
competence NN o
at IN N
pretest NN N
and CC N
posttest NN N
. . N

Three CD N
independent JJ N
raters NNS N
observed VBD N
and CC N
reported VBD N
children NNS o
's POS o
positive JJ o
and CC o
negative JJ o
behavior NN o
using VBG N
a DT N
validated JJ N
checklist NN N
during IN N
each DT N
weekly JJ N
session NN N
. . N

Results NNS o
indicated VBD o
that IN o
program NN o
participation NN o
had VBD o
a DT o
moderate JJ o
treatment NN o
effect NN o
( ( o
d JJ o
= NNP o
.55 NNP o
) ) o
on IN o
social JJ o
competence NN o
( ( o
p JJ o
= NNP o
.02 NNP o
) ) o
that WDT o
was VBD o
independent JJ o
of IN o
pretest NN o
levels NNS o
, , o
age NN o
, , o
gender NN o
, , o
and CC o
referral JJ o
status NN o
. . o

Results NNS o
showed VBD o
that IN o
higher JJR o
levels NNS o
of IN o
program NN o
attendance NN o
predicted VBD o
children NNS o
's POS o
trajectories NNS o
of IN o
observed JJ o
positive JJ o
( ( o
? . o
= NNP o
.500 NNP o
; : o
p CC o
= NNP o
.003 NNP o
) ) o
and CC o
negative JJ o
behavior NN o
( ( o
? . o
= NNP o
-.062 NNP o
; : o
p CC o
< NNP o
.001 NNP o
) ) o
over IN o
the DT o
11-week JJ o
program NN o
. . o

-DOCSTART- -7044324- O O

Treatment NN o
of IN o
human JJ o
tungiasis NN o
with IN N
niridazole JJ i
( ( i
Ambilhar NNP i
) ) i
a DT N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

-DOCSTART- -25475363- O O

Parents NNS N
' POS N
Adoption NN N
of IN N
Social NNP i
Communication NNP i
Intervention NNP i
Strategies NNS i
: : i
Families NNS N
Including VBG N
Children NNP p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
Who NNP p
are VBP p
Minimally NNP p
Verbal NNP p
. . p

Notably RB N
absent NN N
from IN N
the DT N
intervention NN N
literature NN N
are VBP N
parent JJ N
training VBG N
programs NNS N
targeting VBG N
school-aged JJ p
children NNS p
with IN p
autism NN p
who WP p
have VBP p
limited VBN p
communication NN p
skills NNS p
( ( N
Tager-Flusberg NNP N
and CC N
Kasari NNP N
in IN N
Autism NNP N
Res NNP N
6:468-478 CD N
, , N
2013 CD N
) ) N
. . N

Sixty-one JJ p
children NNS p
with IN p
autism NN p
age NN p
5-8 JJ p
with IN p
minimal JJ p
spontaneous JJ p
communication NN p
received VBD p
a DT p
6-month JJ i
social JJ i
communication NN i
intervention NN i
including VBG i
parent NN i
training NN i
. . i

Parent-child JJ p
play NN p
interactions NNS p
were VBD N
coded VBN N
for IN N
parents NNS N
' POS N
strategy NN o
implementation NN o
and CC N
children NNS N
's POS N
time NN N
jointly RB o
engaged VBN o
( ( N
Adamson NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
39:84-96 CD N
, , N
2009 CD N
) ) N
. . N

Parents NNS p
mastered VBD o
an DT N
average NN N
of IN N
70 CD N
% NN N
of IN N
the DT N
strategies NNS N
. . N

Further JJ N
analyses NNS N
indicated VBD N
some DT N
gains NNS o
in IN o
implementation NN o
occurred VBD N
from IN N
mere JJ N
observation NN N
of IN N
sessions NNS N
, , N
while IN N
the DT N
greatest JJS N
gains NNS o
occurred VBD N
in IN N
the DT N
first JJ N
month NN N
of IN N
active JJ N
coaching NN N
and CC N
workshops NNS N
. . N

Children NNP p
's POS p
joint JJ o
engagement NN o
was VBD N
associated VBN N
with IN N
parents NNS N
' POS N
implementation NN o
success NN o
across IN N
time NN N
demonstrating VBG N
parents NNS p
' POS p
implementation NN p
was VBD N
relevant JJ N
to TO N
children NNS p
's POS p
social JJ o
engagement NN o
. . o

-DOCSTART- -12176916- O O

Cyclosporine NNP i
inhibition NN N
of IN N
P-glycoprotein NNP N
in IN N
chronic JJ p
myeloid NN p
leukemia NN p
blast NN p
phase NN p
. . p

Chronic NNP N
myeloid NN N
leukemia NN N
blast NN N
phase NN N
( ( N
CML-BP NNP N
) ) N
cells NNS N
commonly RB N
express VBP N
the DT N
multidrug NN N
transporter NN N
, , N
P-glycoprotein NNP N
( ( N
Pgp NNP N
) ) N
. . N

To TO N
determine VB N
whether IN N
Pgp NNP N
inhibition NN N
improves VBZ N
treatment NN N
outcome NN N
in IN N
CML-BP NNP N
, , N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
performed VBD N
a DT N
randomized VBN i
, , i
controlled VBN i
trial NN i
testing VBG i
the DT i
benefit NN i
of IN i
the DT i
Pgp NNP i
modulator NN i
, , i
cyclosporin VB i
A NNP i
( ( i
CsA NNP i
) ) i
. . i

Seventy-three JJ p
eligible JJ p
patients NNS p
were VBD N
assigned VBN i
to TO i
treatment NN i
with IN i
cytarabine NN i
and CC i
infusional JJ i
daunorubicin NN i
with IN i
or CC i
without IN i
intravenous JJ i
CsA NNP i
. . i

Treatment NN N
with IN N
CsA NNP N
yielded VBD N
no DT o
improvement NN o
in IN N
treatment NN N
outcome NN N
as IN N
measured VBN N
by IN N
the DT N
frequency NN o
of IN o
induction NN o
resistance NN o
( ( N
68 CD N
% NN N
vs JJ N
53 CD N
% NN N
) ) N
, , N
rate NN o
of IN o
complete JJ o
remission NN o
or CC o
restored VBN o
chronic JJ o
phase NN o
( ( N
CR/CP NNP N
, , N
8 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
, , N
and CC N
survival NN o
( ( N
3 CD N
vs RB N
5 CD N
months NNS N
) ) N
. . N

Blast NNP o
expression NN o
of IN o
Pgp NNP o
( ( N
63 CD N
% NN N
) ) N
and CC N
LRP NNP o
( ( N
71 CD N
% NN N
) ) N
was VBD N
common JJ N
, , N
whereas IN N
only RB N
Pgp NNP N
adversely RB N
impacted VBD N
the DT N
rate NN o
of IN o
CR/CP NNP o
( ( N
P NNP N
=.025 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
Pgp NNP N
has VBZ N
prognostic JJ N
relevance NN N
in IN N
CML-BP NNP N
but CC N
that IN N
the DT N
modulation NN N
of IN N
Pgp NNP N
function NN N
with IN N
CsA NNP N
as IN N
applied VBN N
in IN N
this DT N
trial NN N
is VBZ N
ineffective JJ N
. . N

-DOCSTART- -14650571- O O

Can MD N
acupuncture VB i
ease VB N
the DT N
symptoms NNS o
of IN o
menopause NN o
? . N
In IN N
a DT N
randomized JJ N
, , N
2-group JJ N
clinical JJ N
study NN N
, , N
acupuncture NN i
was VBD N
used VBN N
for IN N
the DT N
relief NN N
of IN N
menopausal NN o
hot JJ o
flushes NNS o
, , o
sleep JJ o
disturbances NNS o
, , o
and CC o
mood NN o
changes NNS o
. . o

The DT N
experimental JJ N
acupuncture NN i
treatment NN N
consisted VBD N
of IN N
specific JJ N
acupuncture NN i
body NN N
points NNS N
related VBN N
to TO N
menopausal VB o
symptoms NNS o
. . N

The DT N
comparison JJ N
acupuncture NN i
treatment NN N
consisted VBN N
of IN N
a DT N
treatment NN N
designated VBN N
as IN N
a DT N
general JJ N
tonic NN N
specifically RB N
designed VBN N
to TO N
benefit VB N
the DT N
flow NN N
of IN N
Ch'i NNP N
( ( N
energy NN N
) ) N
. . N

Results NNS N
from IN N
the DT N
experimental JJ p
acupuncture NN i
treatment NN p
group NN p
showed VBD N
a DT N
decrease NN N
in IN N
mean JJ o
monthly JJ o
hot JJ o
flush NN o
severity NN o
for IN N
site-specific JJ N
acupuncture NN N
. . N

The DT N
comparison JJ N
acupuncture NN i
treatment NN p
group NN p
had VBD N
no DT N
significant JJ N
change NN o
in IN o
severity NN o
from IN N
baseline NN N
over IN N
the DT N
treatment NN N
phase NN N
. . N

Sleep JJ o
disturbances NNS o
in IN N
the DT N
experimental JJ p
acupuncture NN i
treatment NN p
group NN p
declined VBD N
over IN N
the DT N
study NN N
. . N

Mood NNP o
changes NNS o
in IN N
both DT N
the DT N
experimental JJ p
acupuncture NN i
treatment NN p
group NN p
and CC p
the DT p
comparison NN p
acupuncture NN p
treatment NN p
group NN p
showed VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
and CC N
the DT N
third JJ N
month NN N
of IN N
the DT N
study NN N
. . N

Acupuncture NNP i
using VBG N
menopausal-specific JJ N
sites NNS N
holds VBZ N
promise NN N
for IN N
nonhormonal JJ N
relief NN o
of IN o
hot JJ o
flushes NNS o
and CC o
sleep JJ o
disturbances NNS o
. . o

-DOCSTART- -24763663- O O

MRI-detected JJ N
skull-base JJ N
invasion NN N
: : N
prognostic JJ N
value NN N
and CC N
therapeutic JJ N
implication NN N
in IN N
intensity-modulated JJ N
radiotherapy NN N
treatment NN N
for IN N
nasopharyngeal JJ p
carcinoma NN p
. . p

PURPOSE NNP N
With IN N
advances NNS N
in IN N
imaging VBG N
and CC N
radiotherapy NN N
, , N
the DT N
prognostic JJ N
value NN N
of IN N
skull-base JJ N
invasion NN N
in IN N
nasopharyngeal JJ N
carcinoma NN N
( ( N
NPC NNP N
) ) N
needs VBZ N
to TO N
be VB N
reassessed VBN N
. . N

We PRP N
aimed VBD N
to TO N
define VB N
a DT N
classification NN N
system NN N
and CC N
evaluate VB N
the DT N
prognostic JJ N
value NN N
of IN N
the DT N
classification NN N
of IN N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
-detected VBD N
skull-base JJ N
invasion NN N
in IN N
NPC NNP N
treated VBD N
with IN N
intensity-modulated JJ i
radiotherapy NN i
( ( N
IMRT NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
MATERIALS NNP N
We PRP N
retrospectively RB p
reviewed VBD p
749 CD p
patients NNS p
who WP p
underwent VBP p
MRI NNP i
and CC i
were VBD i
subsequently RB i
histologically RB i
diagnosed VBN i
with IN i
nondisseminated JJ i
NPC NNP i
and CC i
treated VBN i
with IN i
IMRT NNP i
. . i

RESULTS NNP N
MRI-detected JJ N
skull-base JJ N
invasion NN N
was VBD N
not RB N
found VBN N
to TO N
be VB N
an DT N
independent JJ N
prognostic JJ N
factor NN N
for IN N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
distant JJ o
metastasis-free JJ o
survival NN o
( ( o
DMFS NNP o
) ) o
, , o
local JJ o
relapse-free JJ o
survival NN o
( ( o
LRFS NNP o
) ) o
, , o
or CC o
disease-free JJ o
survival NN o
( ( o
DFS NNP o
; : o
p VBZ N
> $ N
0.05 CD N
for IN N
all DT N
) ) N
. . N

Skull-base JJ N
invasion NN N
was VBD N
classified VBN N
according VBG N
to TO N
the DT N
incidence NN N
of IN N
each DT N
site NN N
( ( N
type JJ N
I PRP N
sites NNS N
inside IN N
pharyngobasilar JJ N
fascia NN N
and CC N
clivus NN N
vs. FW N
type NN N
II NNP N
sites VBZ N
outside IN N
pharyngobasilar JJ N
fascia NN N
) ) N
. . N

The DT N
5-year JJ o
OS NNP o
, , o
DMFS NNP o
, , o
LRFS NNP o
, , o
and CC o
DFS NNP o
rates NNS o
in IN o
the DT N
classification NN N
of IN N
skull-base JJ N
invasion NN N
in IN N
NPC NNP N
were VBD N
83 CD N
vs. FW N
67 CD N
% NN N
, , N
85 CD N
vs.75 NN N
% NN N
, , N
95 CD N
vs. FW N
88 CD N
% NN N
, , N
and CC N
76 CD N
vs. FW N
62 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
< VBP N
0.05 CD N
for IN N
all DT N
) ) N
. . N

Multivariate NNP N
analysis NN N
indicated VBD N
the DT N
classification NN N
of IN N
skull-base JJ N
invasion NN N
was VBD N
an DT N
independent JJ N
prognostic JJ N
factor NN N
. . N

CONCLUSION NNP N
MRI-detected JJ N
skull-base JJ N
invasion NN N
is VBZ N
not RB N
an DT N
independent JJ N
prognostic JJ N
factor NN p
in IN p
patients NNS p
with IN p
NPC NNP p
treated VBD p
with IN N
IMRT NNP N
. . N

However RB N
, , N
classification NN N
according VBG N
to TO N
the DT N
site NN N
of IN N
invasion NN N
has VBZ N
prognostic JJ N
value NN N
. . N

Therefore NNP N
, , p
patients NNS p
with IN p
various JJ p
subclassifications NNS p
of IN p
stage NN p
T3 NNP p
disease NN p
may MD N
receive VB N
treatment NN N
with IN N
different JJ N
intensities NNS N
; : N
however RB N
, , N
further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
prove VB N
this DT N
. . N

-DOCSTART- -10814606- O O

Effects NNS N
of IN N
ATP NNP i
infusion NN i
on IN N
glucose JJ N
turnover NN N
and CC N
gluconeogenesis NN N
in IN N
patients NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

Cancer NNP N
cachexia NN N
is VBZ N
associated VBN N
with IN N
elevated JJ N
lipolysis NN N
, , N
proteolysis NN N
and CC N
gluconeogenesis NN N
. . N

ATP NNP i
infusion NN N
has VBZ N
been VBN N
found VBN N
to TO N
significantly RB N
inhibit VB N
loss NN N
of IN N
body NN N
weight NN N
, , N
fat JJ N
mass NN N
and CC N
fat-free JJ N
mass NN N
in IN N
patients NNS p
with IN p
advanced JJ p
lung NN p
cancer NN p
. . p

The DT N
present JJ N
study NN N
was VBD N
aimed VBN N
at IN N
exploring VBG N
the DT N
effects NNS N
of IN N
ATP NNP i
on IN N
whole-body NN N
glucose NN N
turnover NN N
, , N
alanine JJ N
turnover NN N
and CC N
gluconeogenesis NN N
from IN N
alanine NN N
. . N

Twelve CD p
patients NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
were VBD N
studied VBN N
1 CD N
week NN N
before RB N
and CC N
during IN N
22-24 JJ N
h NN N
of IN N
continuous JJ i
ATP NNP i
infusion NN i
. . i

After IN N
an DT N
overnight JJ N
fast NN N
, , N
turnover NN N
rates NNS N
of IN N
glucose NN N
and CC N
alanine NN N
, , N
and CC N
gluconeogenesis NN N
from IN N
alanine NN N
, , N
were VBD N
determined VBN N
using VBG N
primed VBN N
constant JJ N
infusions NNS N
of IN N
?6 NN i
, , i
6- JJ i
( ( i
2 CD i
) ) i
H NNP i
( ( i
2 CD i
) ) i
?lucose NN i
and CC i
?3- NN i
( ( i
13 CD i
) ) i
C?lanine NNP i
. . i

Thirteen NNP i
NSCLC NNP p
patients NNS p
and CC p
eleven RB p
healthy JJ p
subjects NNS p
were VBD p
studied VBN N
as IN N
control NN N
groups NNS N
without IN N
ATP NNP N
infusion NN N
. . N

During IN N
high-dose JJ i
ATP NNP i
infusion NN N
( ( N
75 CD N
microg.min NN o
( ( o
-1 NNP o
) ) o
.kg NNP o
( ( o
-1 NNP o
) ) o
) ) o
, , o
glucose JJ o
turnover NN o
was VBD o
0.62+/-0.07 JJ N
mmol.h NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NNP N
) ) N
, , N
compared VBN N
with IN N
0 CD N
. . N

44+/-0.13 JJ N
mmol.h NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NN N
) ) N
at IN N
baseline NN N
( ( N
P=0.04 NNP N
) ) N
. . N

For IN N
gluconeogenesis NN o
a DT o
similar JJ o
, , N
but CC N
non-significant JJ N
, , N
trend NN N
was VBD N
observed VBN N
?baseline JJ N
, , N
0.30+/-0.16 JJ N
mmol.h NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NNP N
) ) N
; : N
during IN N
ATP NNP N
, , N
0.37+/-0.13 JJ N
mmol.h NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NNP N
) ) N
( ( N
P=0.08 NNP N
) ) N
. . N

At IN N
lower JJR N
ATP NNP i
doses NNS N
( ( N
37-50 JJ N
microg NN N
. . N

min NN N
( ( N
-1 NNP N
) ) N
.kg NNP N
( ( N
-1 NNP N
) ) N
) ) N
these DT N
effects NNS N
were VBD N
not RB N
detected VBN N
. . N

The DT N
relative JJ o
increase NN o
in IN o
glucose JJ o
turnover NN o
during IN o
ATP NNP o
infusion NN o
compared VBN o
with IN N
baseline NN N
showed VBD N
a DT N
significant JJ N
correlation NN N
with IN N
the DT i
ATP NNP i
dose NN N
( ( N
r=0.58 NN N
, , N
P=0.02 NNP o
) ) o
. . o

No DT o
change NN o
in IN o
alanine NN o
turnover NN o
was VBD o
observed VBN N
at IN N
any DT i
ATP NNP i
dose NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
an DT N
increase NN o
in IN o
glucose JJ o
turnover NN o
during IN o
high-dose JJ N
ATP NNP N
infusion NN N
compared VBN N
with IN N
baseline NN N
levels NNS N
. . N

During IN N
high-dose JJ i
ATP NNP i
infusion NN o
, , o
glucose JJ o
turnover NN o
was VBD o
similar JJ N
to TO N
that DT N
during IN N
low-dose JJ N
ATP NNP N
infusion NN N
and CC N
to TO N
that DT N
in IN N
control NN N
NSCLC NNP N
patients NNS N
. . N

Between NNP i
ATP NNP i
infusions NNS N
, , N
however RB o
, , o
glucose JJ o
turnover NN o
in IN o
patients NNS o
treated VBN N
with IN N
high-dose JJ N
ATP NNP N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
low-dose JJ N
and CC N
control VB N
NSCLC NNP N
patients NNS N
( ( N
P=0.04 NNP N
and CC N
P=0.03 NNP N
respectively RB N
) ) N
, , N
and CC N
similar JJ N
to TO N
that DT N
in IN N
healthy JJ N
subjects NNS N
. . N

This DT N
would MD N
suggest VB N
that IN N
repeated JJ N
high-dose JJ i
ATP NNP i
infusions NNS N
may MD N
inhibit VB N
glucose JJ N
turnover NN N
between IN N
infusion NN N
periods NNS N
. . N

-DOCSTART- -23334070- O O

Safety NN N
and CC N
pharmacology NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
ponezumab NN i
in IN N
subjects NNS p
with IN p
mild-to-moderate JJ p
Alzheimer NNP p
disease NN p
: : p
a DT N
phase NN N
I PRP N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
dose-escalation NN N
study NN N
. . N

OBJECTIVES NNP N
Ponezumab NNP i
is VBZ N
a DT N
humanized JJ N
antiamyloid NN N
beta NN N
( ( N
A? NNP N
) ) N
monoclonal NN N
antibody NN N
designed VBN N
to TO N
treat VB N
Alzheimer NNP N
disease NN N
( ( N
AD NNP N
) ) N
. . N

METHODS NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
single-dose-escalation NN N
study NN N
evaluated VBD N
the DT N
safety NN N
, , N
pharmacokinetics NNS N
, , N
and CC N
pharmacodynamics NNS N
of IN N
0.1 CD N
, , N
0.3 CD N
, , N
1 CD N
, , N
3 CD N
, , N
and CC N
10 CD N
mg/kg NN i
ponezumab NN i
( ( N
n JJ N
= NN N
4 CD N
, , N
4 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
8 CD N
, , N
respectively RB N
) ) N
versus NN i
placebo NN i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
after IN N
a DT N
2-hour JJ N
intravenous JJ N
infusion NN N
in IN p
subjects NNS p
with IN p
mild-to-moderate JJ p
AD NNP p
. . p

Cerebrospinal NNP N
fluid NN N
( ( N
CSF NNP N
) ) N
samples NNS N
were VBD N
obtained VBN N
from IN N
the DT N
1- JJ N
and CC N
10-mg/kg JJ N
groups NNS N
at IN N
baseline NN N
and CC N
at IN N
day NN N
29 CD N
. . N

The DT N
subjects NNS N
were VBD N
followed VBN N
for IN N
1 CD N
year NN N
. . N

RESULTS NNP N
All NNP N
subjects VBZ N
completed VBN N
the DT N
trial NN N
. . N

Ponezumab NNP i
was VBD N
well RB o
tolerated VBN o
with IN N
no DT N
drug-attributed JJ o
serious JJ o
adverse JJ o
events NNS o
. . o

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD o
upper JJ o
respiratory NN o
tract NN o
infection NN o
, , o
headache NN o
, , o
and CC o
back RB o
pain NN o
, , o
all DT o
mild VBP o
to TO o
moderate VB o
. . o

One CD N
subject NN N
( ( N
10 CD N
mg/kg NN N
) ) N
experienced VBD N
a DT N
mild JJ o
hypersensitivity NN o
reaction NN o
. . o

Another DT N
subject NN N
( ( N
0.1 CD N
mg/kg NN N
) ) N
demonstrated VBD o
slight JJ o
enlargement NN o
of IN o
a DT o
preexisting NN o
midbrain NN o
lesion NN o
. . o

Electrocardiography NNP o
and CC o
laboratory NN o
values NNS o
( ( o
including VBG o
CSF NNP o
) ) o
were VBD N
unremarkable JJ N
. . N

No DT N
evidence NN N
of IN N
new JJ o
microhemorrhage NN o
, , o
vasogenic JJ o
edema NN o
, , o
or CC o
meningoencephalitis NN o
was VBD N
noted VBN N
. . N

Plasma NNP N
maximum JJ N
observed JJ N
concentration NN N
increased VBD N
approximately RB N
dose JJ N
proportionally RB N
, , N
and CC N
the DT o
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
profile NN o
from IN N
time NN N
zero CD N
extrapolated VBN N
to TO N
infinite VB N
time NN N
( ( N
AUC NNP N
( ( N
inf NN N
) ) N
) ) N
increased VBD N
slightly RB N
more JJR N
than IN N
dose VB N
proportionally RB N
. . N

Mean JJ o
terminal JJ o
half-life NN o
was VBD N
approximately RB N
6 CD N
weeks NNS N
. . N

Two CD N
subjects NNS N
( ( N
10 CD N
mg/kg NN N
) ) N
had VBD N
measurable JJ o
CSF NNP o
ponezumab NN o
concentrations NNS o
( ( N
~0.5 CD N
% NN N
of IN N
plasma NN N
values NNS N
) ) N
at IN N
day NN N
29 CD N
. . N

Plasma NNP N
A? NNP N
( ( N
1-x JJ N
) ) N
and CC N
A? NNP N
( ( N
1-40 JJ N
) ) N
increased VBD N
dose JJ N
dependently RB N
, , N
and CC N
mean JJ o
CSF NNP o
A? NNP o
( ( N
1-x JJ N
) ) N
increased VBD N
38 CD N
% NN N
from IN N
baseline NN N
with IN N
10 CD N
mg/kg NNS N
( ( N
P NNP N
= VBZ N
0.002 CD i
vs NN i
placebo NN i
) ) i
. . i

CONCLUSIONS VB i
A DT N
2-hour JJ N
infusion NN N
of IN N
0.1 CD N
to TO N
10 CD N
mg/kg NNS i
ponezumab NN i
was VBD i
well RB N
tolerated VBN N
in IN N
subjects NNS N
with IN N
mild-to-moderate JJ N
AD NNP N
. . N

Plasma NNP N
pharmacokinetic JJ N
profile NN N
was VBD N
approximately RB N
linear JJ N
. . N

Plasma NNP N
A? NNP N
increased VBD N
with IN N
dose NN N
, , N
and CC N
CSF NNP N
A? NNP N
increased VBD N
at IN N
the DT N
highest JJS N
dose NN N
, , N
suggesting VBG N
that IN N
intravenous JJ i
ponezumab NN i
alters NNS i
central JJ N
A? NNP N
levels NNS N
. . N

-DOCSTART- -21742443- O O

Influence NN N
of IN N
chestnut NN N
tannins NNS N
on IN N
welfare NN N
, , N
carcass NN N
characteristics NNS N
, , N
meat NN N
quality NN N
, , N
and CC N
lipid JJ N
oxidation NN N
in IN N
rabbits NNS p
under IN p
high JJ p
ambient JJ p
temperature NN p
. . p

A DT N
study NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
influence NN N
of IN N
chestnut NN i
tannins NNS i
( ( N
CT NNP N
) ) N
on IN N
welfare NN N
, , N
carcass NN N
characteristics NNS N
, , N
meat NN N
quality NN N
, , N
and CC N
lipid JJ N
oxidation NN N
in IN N
rabbits NNS p
under IN N
high JJ N
ambient JJ N
temperature NN N
. . N

Rabbits NNS i
in IN N
one CD N
group NN N
were VBD N
raised VBN i
at IN i
20?C CD i
and CC i
fed VBN i
with IN i
basal NN i
diet NN i
( ( i
N NNP i
) ) i
and CC i
other JJ i
three CD i
groups NNS i
( ( i
33?C CD i
) ) i
were VBD i
fed VBN i
basal JJ i
diet JJ i
with IN i
0 CD i
( ( i
C NNP i
) ) i
, , i
5 CD i
( ( i
CT5 NNP i
) ) i
, , i
and CC i
10 CD i
g NN i
( ( i
CT10 NNP i
) ) i
of IN i
CT/kg NNP i
of IN i
diet NN i
. . i

Compared VBN N
with IN N
the DT N
C NNP N
group NN N
, , N
rabbits VBZ N
in IN N
CT10 NNP N
had VBD N
higher JJR o
pH NN o
( ( o
24 CD o
) ) o
and CC o
lower JJR o
cooking NN o
loss NN o
and CC o
thiobarbituric JJ o
acid NN o
reacting VBG o
substance NN o
values NNS o
at IN o
0 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
min NN N
of IN N
forced JJ N
oxidation NN p
. . p

Rabbits NNS p
in IN p
C NNP N
group NN N
had VBD o
higher JJR o
cortisol NN o
levels NNS o
, , o
creatine NN o
kinase NN o
activities NNS o
, , o
white JJ o
blood NN o
cell NN o
counts NNS o
, , o
neutrophil JJ o
percentage NN o
, , o
neutrophil NN o
: : o
lymphocyte NN o
ratio NN o
and CC o
lower JJR o
T NNP o
( ( o
3 CD o
) ) o
, , o
T NNP o
( ( o
4 CD o
) ) o
levels NNS o
, , o
lymphocyte NN o
percentage NN o
than IN o
N NNP N
and CC N
CT10 NNP N
groups NNS N
. . N

Supplementation NN N
of IN N
CT NNP N
seemed VBD N
to TO N
have VB N
a DT N
positive JJ N
effect NN N
on IN N
growth NN o
performance NN o
, , o
welfare NN o
, , o
and CC o
meat NN o
quality NN o
of IN o
rabbits NNS o
under IN o
high JJ N
ambient JJ N
temperature NN N
. . N

-DOCSTART- -3260083- O O

[ JJ i
Propofol NNP i
infusion NN N
for IN N
the DT N
maintenance NN N
of IN N
short-term JJ p
anesthesia NN o
] NN o
. . N

The DT N
administration NN N
of IN N
propofol NN i
by IN N
infusion NN N
for IN N
maintenance NN N
of IN N
anesthesia NN N
has VBZ N
attracted VBN N
much JJ N
attention NN N
recently RB N
. . N

We PRP N
investigated VBD N
the DT N
necessary JJ N
infusion NN N
rate NN N
of IN N
propofol NN i
to TO N
maintain VB N
anesthesia NN N
for IN N
short JJ N
surgical JJ N
procedures NNS N
without IN N
loss NN N
of IN N
the DT N
evident JJ N
advantages NNS N
of IN N
this DT N
substance NN N
. . N

Forty NNP p
unpremedicated JJ p
female NN p
patients NNS p
aged VBN p
18-59 JJ p
, , p
scheduled VBN p
for IN p
minor JJ p
gynecological JJ p
procedures NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
. . N

Anesthesia NNP N
was VBD N
induced VBN N
with IN N
2.0 CD i
mg/kg NNS i
propofol JJ i
i.v NN i
. . i

and CC N
simultaneously RB N
an DT N
infusion NN N
of IN N
0.05 CD N
, , N
0.10 CD N
, , N
0.15 CD N
, , N
or CC N
0.20 CD N
mg NNS N
propofol/kg JJ i
per IN N
minute NN N
was VBD N
started VBN N
. . N

The DT N
patients NNS p
were VBD N
breathing VBG N
N2O/O2 NNP i
with IN i
FIO2 NNP i
33 CD N
% NN N
. . N

Additional NNP N
propofol NN i
was VBD N
administered VBN N
as IN N
a DT N
bolus NN N
of IN N
10 CD N
to TO N
20 CD N
mg NN N
when WRB N
the DT N
patients NNS N
moved VBD N
. . N

With IN N
0.05 CD N
mg NNS N
propofol/kg JJ i
per IN N
minute NN N
all DT N
patients NNS N
required VBN N
additional JJ N
bolus NN N
injections NNS N
of IN N
propofol NN i
; : i
with IN N
0.10 CD N
mg NNS N
8 CD N
patients NNS N
, , N
with IN N
0.15 CD N
mg NNS N
5 CD N
patients NNS N
, , N
and CC N
with IN N
0.20 CD N
mg NNS N
1 CD N
patient NN N
required VBN N
bolus JJ N
injection NN N
. . N

Therefore NNP N
, , N
0.15 CD N
mg/kg NN N
per IN N
minute NN N
can MD N
be VB N
considered VBN N
as IN N
an DT N
approximate JJ N
ED50 NNP N
value NN N
. . N

The DT N
total JJ o
propofol NN o
consumption NN o
( ( N
infusion NN N
+ NNP N
bolus NN N
) ) N
increased VBD N
from IN N
0.102 CD N
+/- JJ N
0.028 CD N
( ( N
+/- JJ N
SD NNP N
) ) N
with IN N
the DT N
lowest JJS N
infusion NN o
rate NN o
to TO N
0.202 CD N
+/- JJ N
0.006 CD N
mg/kg NNS N
per IN N
minute NN N
with IN N
the DT N
highest JJS N
infusion NN o
rate NN o
and CC o
recovery NN o
time NN o
from IN N
5.2 CD N
+/- JJ N
1.4 CD N
to TO N
9.9 CD N
+/- JJ N
2.6 CD N
min NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
propofol JJ o
consumption NN o
and CC o
recovery NN o
time NN o
. . o

After IN N
induction NN N
, , N
arterial JJ o
blood NN o
pressure NN o
decreased VBN N
by IN N
systolic/diastolic JJ N
20/10-15 JJ N
mmHg NN N
. . N

With IN N
the DT N
low JJ N
infusion NN N
rate NN N
, , N
arterial JJ o
pressure NN o
increased VBD N
to TO N
its PRP$ N
control NN N
value NN N
during IN N
operation NN N
; : N
it PRP N
remained VBD N
at IN N
the DT N
postinduction NN N
value NN N
with IN N
high JJ N
infusion NN N
rates NNS N
. . N

Side-effects NNS N
: : N
10 CD N
patients NNS N
had VBD N
salivation NN N
that IN N
in IN N
some DT N
instances NNS N
lead VBP N
to TO N
coughing VBG N
, , N
9 CD N
reported VBD N
pain NN N
at IN N
the DT N
injection NN N
site NN N
during IN N
induction NN N
, , N
and CC N
9 CD N
reported VBD N
dreams NNS N
of IN N
a DT N
pleasant JJ N
nature NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -20113305- O O

Hunter NNP N
DBT NNP N
project NN N
: : N
randomized VBN N
controlled VBD N
trial NN N
of IN N
dialectical JJ i
behaviour NN i
therapy NN i
in IN N
women NNS p
with IN p
borderline JJ p
personality NN p
disorder NN p
. . p

OBJECTIVE JJ N
Deliberate NNP N
self-harm NN N
( ( N
DSH NNP N
) ) N
, , N
general JJ N
hospital NN N
admission NN N
and CC N
psychiatric JJ N
hospital NN N
admission NN N
are VBP N
common JJ N
in IN N
women NNS p
meeting VBG p
criteria NNS p
for IN p
borderline NN p
personality NN p
disorder NN p
( ( p
BPD NNP p
) ) p
. . p

Dialectical JJ i
behaviour NN i
therapy NN i
( ( i
DBT NNP i
) ) i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
DSH NNP N
and CC N
hospitalization NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
73 CD p
female JJ p
subjects NNS p
meeting VBG p
criteria NNS p
for IN p
BPD NNP p
was VBD N
carried VBN N
out RP N
with IN N
intention-to-treat JJ N
analyses NNS N
and CC N
per-protocol JJ N
analyses NNS N
. . N

The DT N
intervention NN N
was VBD N
DBT NNP i
and CC N
the DT N
control NN N
condition NN N
was VBD N
treatment NN i
as IN i
usual JJ i
plus CC i
waiting JJ i
list NN i
for IN i
DBT NNP i
( ( i
TAU+WL NNP i
) ) i
, , N
with IN N
outcomes NNS N
measured VBN N
after IN N
6 CD N
months NNS N
. . N

Primary JJ N
outcomes NNS N
were VBD N
differences NNS N
in IN N
proportions NNS o
and CC o
event NN o
rates NNS o
of IN o
: : o
any DT o
DSH NNP o
; : o
general JJ o
hospital NN o
admission NN o
for IN o
DSH NNP o
and CC o
any DT o
psychiatric JJ o
admission NN o
; : o
and CC o
mean VB o
difference NN o
in IN o
length NN o
of IN o
stay NN o
for IN o
any DT o
hospitalization NN o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
disability NN o
and CC o
quality NN o
of IN o
life NN o
measures NNS o
. . o

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
DSH NNP o
and CC o
hospitalizations NNS o
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS o
in IN N
DSH NNP o
, , o
hospital JJ o
admissions NNS o
or CC o
length NN o
of IN o
stay NN o
in IN N
hospital NN N
between IN N
groups NNS N
. . N

Disability NNP o
( ( o
days NNS o
spent VBN o
in IN o
bed NN o
) ) o
and CC o
quality NN o
of IN o
life NN o
( ( o
Physical NNP o
, , o
Psychological NNP o
and CC o
Environmental NNP o
domains NNS o
) ) o
were VBD N
significantly RB N
improved VBN N
for IN N
the DT N
DBT NNP N
group NN N
. . N

CONCLUSION NNP N
DBT NNP i
produced VBD N
non-significant JJ N
reductions NNS N
in IN N
DSH NNP o
and CC N
hospitalization NN N
when WRB N
compared VBN N
to TO N
the DT N
TAU+WL NNP N
control NN N
, , N
due JJ N
in IN N
part NN N
to TO N
the DT N
lower JJR N
than IN N
expected VBN N
rates NNS N
of IN N
hospitalization NN N
in IN N
the DT N
control NN N
condition NN N
. . N

Nevertheless NNP N
, , N
DBT NNP i
showed VBD N
significant JJ N
benefits NNS N
for IN N
the DT N
secondary JJ N
outcomes NNS N
of IN N
improved JJ N
disability NN o
and CC o
quality NN o
of IN o
life NN o
scores NNS o
, , N
a DT N
clinically RB N
useful JJ N
result NN N
that WDT N
is VBZ N
also RB N
in IN N
keeping VBG N
with IN N
the DT N
theoretical JJ N
constructs NNS N
of IN N
the DT N
benefits NNS N
of IN N
DBT NNP i
. . i

-DOCSTART- -19102810- O O

Validation NN N
of IN N
an DT N
FFQ NNP N
for IN N
evaluation NN N
of IN N
EPA NNP o
and CC o
DHA NNP o
intake VBP o
. . o

OBJECTIVE NNP N
To TO N
validate VB N
an DT N
FFQ NNP N
for IN N
the DT N
assessment NN N
of IN N
dietary JJ N
EPA NNP o
and CC o
DHA NNP o
against IN N
their PRP$ N
relative JJ o
concentrations NNS o
in IN o
red JJ o
blood NN o
cells NNS o
( ( o
RBC NNP o
) ) o
. . o

DESIGN NNP N
Cross-sectional JJ N
analysis NN N
of IN N
baseline NN N
data NNS N
. . N

Intakes NNS N
of IN N
marine NN i
food NN i
products NNS i
and CC N
EPA NNP i
and CC N
DHA NNP i
were VBD N
estimated VBN N
by IN N
FFQ NNP N
on IN N
the DT N
basis NN N
of IN N
consumption NN N
of IN N
marine NN i
food NN i
products NNS i
in IN N
the DT N
last JJ N
month NN N
. . N

Fatty NNP N
acid JJ N
composition NN N
of IN N
RBC NNP N
membranes NNS N
was VBD N
quantified VBN N
by IN N
GC NNP N
. . N

SETTING NNP N
Saint-Fran?ois JJ p
d'Assise NN p
Hospital NNP p
, , p
Qu?bec NNP p
, , p
Canada NNP p
. . p

SUBJECTS NNP N
A NNP N
total NN N
of IN N
sixty-five JJ p
middle-aged JJ p
women NNS p
who WP p
participated VBD p
in IN p
a DT p
randomized JJ p
clinical JJ p
trial NN p
. . p

RESULTS NNP N
Spearman NNP N
's POS N
correlation NN N
coefficient NN N
between IN o
intake NN o
of IN o
EPA NNP o
, , o
DHA NNP o
and CC o
EPA NNP o
+ NNP o
DHA NNP o
and CC o
their PRP$ N
corresponding JJ o
concentration NN o
in IN o
RBC NNP o
was VBD o
0.46 CD N
, , N
0.40 CD N
and CC N
0.42 CD N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
of IN N
EPA+DHA NNP o
intake NN o
and CC o
RBC NNP o
EPA NNP o
+ NNP o
DHA NNP o
concentration NN o
indicated VBD o
positive JJ N
and CC N
significant JJ N
correlations NNS N
for IN N
oily RB N
fish JJ N
( ( N
beta JJ N
= NN N
0.44 CD N
, , N
95 CD N
% NN N
CI NNP N
0.16 CD N
, , N
0.72 CD N
, , N
P NNP N
= NNP N
0.0027 CD N
) ) N
, , N
total JJ N
fish NN N
( ( N
beta JJ N
= NN N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.19 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0005 CD N
) ) N
and CC i
marine VB i
food NN i
products NNS i
( ( i
beta NN N
= RB N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.20 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

No UH N
other JJ N
marine VB N
food NN N
products NNS N
significantly RB N
predicted VBD o
RBC NNP o
EPA NNP o
+ NNP o
DHA NNP o
concentration NN o
. . o

CONCLUSIONS NNP N
Although IN N
the DT N
present JJ N
validation NN N
study NN N
was VBD N
undertaken VBN N
among IN p
middle-aged JJ p
women NNS p
with IN p
low JJ p
consumption NN p
of IN p
marine NN p
food NN p
products NNS p
( ( p
< $ p
3 CD p
servings/week NN p
) ) p
, , p
our PRP$ N
FFQ NNP N
provided VBD N
estimates NNS N
of IN N
EPA NNP o
and CC o
DHA NNP o
intakes NNS o
that WDT o
correlated VBD N
fairly RB N
well RB N
with IN N
their PRP$ o
RBC NNP o
concentrations NNS o
. . o

However RB N
, , N
the DT N
absence NN N
of IN N
correlations NNS N
between IN o
EPA NNP o
+ NNP o
DHA NNP o
intakes NNS o
from IN o
different JJ N
marine NN N
species NNS N
suggests VBZ N
that IN N
a DT N
minimum JJ i
EPA NNP i
+ NNP i
DHA NNP i
intake NN i
is VBZ N
necessary JJ N
to TO N
observe VB N
a DT N
relationship NN N
with IN o
RBC NNP o
EPA NNP o
+ NNP o
DHA NNP o
concentrations NNS o
. . o

-DOCSTART- -16177585- O O

Effects NNS N
of IN N
an DT N
Internet-based JJ i
intervention NN i
on IN N
plasma NNS o
glucose JJ o
levels NNS o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

This DT N
study NN N
applied VBD N
a DT N
12-week JJ i
educational JJ i
intervention NN i
that WDT N
used VBD N
both DT i
the DT i
cellular JJ i
phone NN i
and CC i
the DT i
Internet NNP i
to TO i
send VB i
short JJ i
message NN i
service NN i
. . i

Forty-two NNP p
diabetic JJ p
patients NNS p
were VBD N
asked VBN N
to TO N
access NN i
a DT i
Web NNP i
site NN i
by IN i
using VBG i
a DT i
cellular JJ i
phone NN i
or CC i
wire NN i
Internet NNP i
and CC i
input VB i
their PRP$ i
blood NN o
glucose NN o
levels NNS o
every DT i
day NN i
. . i

Patients NNS N
were VBD N
sent VBN N
the DT N
optimal JJ i
recommendations NNS i
by IN N
both DT N
the DT N
cellular JJ N
phone NN N
and CC N
the DT N
Internet NNP N
. . N

After IN N
12 CD N
weeks NNS N
, , N
the DT N
patients NNS N
had VBD N
a DT N
mean JJ N
decrease NN N
of IN N
28.6 CD N
mg/dL NNS N
in IN N
fasting VBG o
plasma NN o
glucose NN o
and CC N
78.4 CD N
mg/dL NN N
in IN N
2-hour JJ o
postprandial JJ o
blood NN o
sugar NN o
levels NNS o
and CC N
a DT N
mean JJ N
increase NN N
in IN N
the DT N
care NN o
satisfaction NN o
score NN o
. . o

-DOCSTART- -11860536- O O

Laparoscopically RB i
assisted VBN i
vaginal JJ i
hysterectomy NN i
versus IN N
abdominal JJ i
hysterectomy NN i
in IN N
stage NN p
I PRP p
endometrial JJ p
cancer NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
laparoscopic JJ i
treatment NN i
for IN N
stage NN p
I PRP p
endometrial JJ p
cancer NN p
with IN N
the DT N
traditional JJ i
transabdominal JJ i
approach NN i
. . N

From IN N
July NNP N
1996 CD N
to TO N
July NNP N
1998 CD N
, , N
61 CD p
patients NNS p
with IN p
clinical JJ p
stage NN p
I PRP p
endometrial JJ p
cancer NN p
were VBD N
treated VBN N
at IN N
the DT N
Gynaecology NNP p
Oncology NNP p
Unit NNP p
at IN p
the DT p
Royal NNP p
North NNP p
Shore NNP p
of IN p
Sydney NNP p
, , p
Australia NNP p
. . p

Twenty-nine JJ p
patients NNS p
were VBD p
treated VBN p
with IN p
laparoscopic NN i
assisted VBN i
vaginal JJ i
hysterectomy NN i
( ( i
LAVH NNP i
) ) i
and CC i
bilateral JJ i
salpingo-oophrectomy NN i
( ( i
BSO NNP i
) ) i
plus CC i
minus CC i
laparoscopic JJ i
pelvic JJ i
lymphadenectomy NN i
( ( i
LPLA NNP i
) ) i
, , p
while IN p
32 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
the DT p
traditional JJ p
laparotomy NN i
and CC p
underwent JJ p
total JJ i
abdominal JJ i
hysterectomy NN i
( ( i
TAH NNP i
) ) i
and CC p
BSO NNP p
plus CC p
minus CC p
pelvic JJ i
lymphadenectomy NN i
( ( p
PLA NNP p
) ) p
. . p

The DT N
main JJ N
outcomes NNS N
studied VBN N
were VBD N
operative JJ o
time NN o
, , o
blood NN o
loss NN o
, , o
blood NN o
transfusion NN o
, , o
intraoperative JJ o
complications NNS o
, , o
postoperative JJ o
complications NNS o
, , o
duration NN o
of IN o
hospital NN o
stay NN o
, , o
and CC o
number NN o
of IN o
lymph JJ o
nodes NNS o
obtained VBN N
. . N

In IN N
conclusion NN N
, , N
laparoscopic JJ i
treatment NN i
of IN N
endometrial JJ N
cancer NN N
is VBZ N
safe JJ o
in IN N
the DT N
hands NNS N
of IN N
experienced JJ N
operators NNS N
with IN N
minimal JJ N
intraoperative JJ N
and CC N
postoperative JJ N
complications NNS N
. . N

This DT N
procedure NN N
is VBZ N
associated VBN N
with IN N
significantly RB N
less JJR N
blood JJ o
loss NN o
and CC N
shorter JJR N
hospitalization NN o
; : o
however RB N
, , N
it PRP N
is VBZ N
associated VBN N
with IN N
significantly RB N
longer RBR N
operating VBG o
time NN o
. . o

Proper NNP N
selection NN N
of IN N
patients NNS N
for IN N
the DT N
laparoscopic JJ i
procedure NN i
is VBZ N
the DT N
vital JJ N
step NN N
in IN N
achieving VBG N
the DT N
major JJ N
goals NNS N
of IN N
this DT N
approach NN N
. . N

-DOCSTART- -25471330- O O

Ranibizumab NNP i
plus CC i
verteporfin JJ i
photodynamic JJ N
therapy NN N
in IN N
neovascular JJ N
age-related JJ N
macular JJ N
degeneration NN N
: : N
12 CD N
months NNS N
of IN N
retreatment NN N
and CC N
vision NN N
outcomes NNS N
from IN N
a DT N
randomized VBN N
study NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
injection NN N
frequency NN N
and CC N
visual JJ N
acuity NN N
( ( N
VA NNP N
) ) N
outcomes VBZ N
with IN N
combination NN N
therapy NN N
( ( i
ranibizumab JJ i
plus CC i
verteporfin JJ i
photodynamic JJ i
therapy NN i
, , i
PDT NNP i
) ) i
versus NN N
monotherapy NN N
( ( i
ranibizumab NN i
) ) i
. . N

METHODS CC N
A DT N
total NN N
of IN N
40 CD p
patients NNS p
with IN p
exudative JJ p
age-related JJ p
macular JJ p
degeneration NN p
were VBD p
randomized VBN p
1:1 CD N
to TO N
ranibizumab VB i
0.3 CD i
mg JJ i
plus CC i
single JJ i
standard NN i
verteporfin NN i
PDT NNP i
or CC i
ranibizumab VB i
0.3 CD i
mg JJ i
plus CC i
sham JJ i
PDT NNP i
. . i

Ranibizumab NNP i
was VBD N
administered VBN N
3 CD N
times NNS N
monthly JJ N
followed VBN N
by IN N
'as NNP N
needed VBD N
' '' N
to TO N
month NN N
12 CD N
based VBN N
on IN N
predetermined JJ N
vision/anatomical JJ N
criteria NNS N
. . N

Retreatment NN o
rates NNS o
, , o
VA NNP o
outcomes NNS o
and CC o
safety NN o
were VBD N
assessed VBN N
. . N

RESULTS NNP N
During IN N
months NNS N
3-12 CD N
, , N
combination NN N
therapy NN N
patients NNS N
required VBD N
fewer JJR N
ranibizumab JJ i
injections NNS N
( ( N
mean VB N
1.3 CD N
) ) N
compared VBN N
with IN N
monotherapy NN N
patients NNS N
( ( N
2.8 CD N
) ) N
. . N

Mean NNP o
VA NNP o
improved VBN N
by IN N
9.0 CD N
letters NNS N
with IN N
combination NN N
therapy NN N
versus NN N
7.5 CD N
letters NNS N
in IN N
the DT N
monotherapy NN N
group NN N
at IN N
month NN N
12 CD N
. . N

Both DT N
treatment NN N
regimens NNS N
were VBD N
well RB N
tolerated VBN N
. . N

CONCLUSION VB N
The DT N
need NN N
for IN N
ranibizumab JJ i
retreatment NN N
might MD N
be VB N
reduced VBN N
by IN N
administering VBG N
a DT N
single JJ N
verteporfin NN i
PDT NNP i
on IN N
the DT N
same JJ N
day NN N
as IN N
the DT N
first JJ N
ranibizumab NN i
injection NN N
, , N
without IN N
compromising VBG N
VA NNP N
outcomes NNS N
or CC N
safety NN N
. . N

-DOCSTART- -3180669- O O

Ventilatory JJ N
function NN N
during IN N
urography NN N
: : N
a DT N
comparison NN N
of IN N
iopamidol NN i
and CC N
sodium NN i
iothalamate NN i
. . i

The DT N
effects NNS N
on IN N
respiratory JJ N
function NN N
during IN N
intravenous JJ N
urography NN N
of IN N
the DT N
ionic JJ N
contrast NN N
medium NN N
sodium NN i
iothalamate NN i
and CC N
the DT N
non-ionic JJ i
contrast NN i
medium NN i
iopamidol NN i
were VBD N
compared VBN N
. . N

Forced NNP o
expiratory JJ o
volume NN o
in IN o
1 CD o
s NN o
( ( o
FEV1 NNP o
) ) o
and CC N
forced VBN o
vital JJ o
capacity NN o
( ( o
FVC NNP o
) ) o
were VBD N
recorded VBN N
in IN N
37 CD p
non-atopic JJ p
patients NNS p
referred VBD p
for IN p
intravenous JJ p
urography NN p
. . p

Nineteen JJ p
patients NNS p
received VBD N
iopamidol JJ i
and CC i
18 CD i
patients NNS i
received VBD i
sodium JJ i
iothalamate NN i
. . i

Both CC N
the DT N
sodium NN i
iothalamate NN i
and CC N
the DT N
iopamidol NN i
groups NNS N
showed VBD N
a DT N
significant JJ N
fall NN N
in IN N
FEV1 NNP o
and CC o
FVC NNP o
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
reductions NNS N
in IN N
FEV1 NNP o
and CC o
FVC NNP o
were VBD N
comparable JJ N
and CC N
were VBD N
not RB N
symptomatic JJ N
. . N

The DT N
differences NNS N
in IN N
the DT N
percentage NN N
changes NNS N
of IN N
the DT N
FEV1 NNP o
and CC o
FVC NNP o
in IN N
the DT N
iopamidol NN i
and CC N
the DT N
sodium NN i
iothalamate NN i
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
greater JJR N
than IN N
0.5 CD N
and CC N
P NNP N
greater JJR N
than IN N
0.1 CD N
respectively RB N
) ) N
. . N

No DT N
significant JJ N
change NN N
in IN N
the DT N
ratio NN o
of IN o
the DT o
FEV1 NNP o
and CC o
the DT o
FVC NNP o
was VBD N
demonstrated VBN N
in IN N
either CC N
the DT N
iopamidol NN N
or CC N
the DT N
sodium NN N
iothalamate NN N
groups NNS N
. . N

Both CC N
the DT N
ionic NN N
and CC N
the DT N
non-ionic JJ N
contrast NN N
media NNS N
produced VBD N
a DT N
measurable JJ N
but CC N
asymptomatic JJ N
and CC N
biologically RB N
insignificant JJ N
fall NN N
in IN N
static JJ o
ventilatory NN o
function NN o
. . o

Bronchospasm NNP o
does VBZ N
not RB N
appear VB N
to TO N
be VB N
an DT N
important JJ N
contrast-induced JJ N
effect NN N
in IN N
non-atopic JJ N
individuals NNS N
. . N

Iopamidol NNP i
offers VBZ N
no DT N
advantage NN N
over IN N
sodium JJ i
iothalamate NN i
with IN N
respect NN N
to TO N
ventilatory JJ N
effects NNS N
in IN N
non-atopic JJ p
patients NNS p
undergoing VBG p
intravenous JJ p
urography NN p
. . p

-DOCSTART- -20304413- O O

Efficacy NN N
and CC N
safety NN N
of IN N
a DT N
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
diet NN i
for IN N
weight JJ N
loss NN N
in IN N
severely JJ p
obese JJ p
adolescents NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
a DT N
carbohydrate NN i
restricted VBN i
versus IN i
a DT i
low JJ i
fat NN i
diet NN i
on IN N
weight JJ o
loss NN o
, , o
metabolic JJ o
markers NNS o
, , o
body NN o
composition NN o
, , N
and CC N
cardiac JJ o
function NN o
tests NNS o
in IN N
severely RB p
obese JJ p
adolescents NNS p
. . p

STUDY NNP N
DESIGN NNP N
Subjects NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
diets NNS i
: : i
a DT i
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
( ( i
20 CD i
g/d NN i
) ) i
diet NN i
( ( i
high JJ i
protein NN i
, , i
low JJ i
carbohydrate NN i
, , i
HPLC NNP i
) ) i
or CC i
low JJ i
fat NN i
( ( i
30 CD i
% NN i
of IN i
calories NNS i
) ) i
regimen VBP i
for IN i
13 CD i
weeks NNS i
; : i
close JJ N
monitoring NN N
was VBD N
maintained VBN N
to TO N
evaluate VB N
safety NN N
. . N

After IN N
the DT N
intervention NN N
, , N
no DT N
clinical JJ N
contact NN N
was VBD N
made VBN N
until IN N
follow-up JJ N
measurements NNS N
were VBD N
obtained VBN N
at IN N
24 CD N
and CC N
36 CD N
weeks NNS N
from IN N
baseline NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
change NN o
in IN o
body NN o
mass NN o
index NN o
Z-score NNP o
for IN N
age NN N
and CC N
sex NN N
( ( o
BMI-Z NNP o
) ) o
at IN N
13 CD N
, , N
24 CD N
, , N
and CC N
36 CD N
weeks NNS N
. . N

RESULTS NNP N
Forty-six JJ p
subjects NNS p
( ( p
24 CD p
HPLC NNP p
, , p
22 CD p
in IN p
low JJ p
fat NN p
) ) p
initiated VBD p
and CC p
33 CD p
subjects NNS p
completed VBD p
the DT p
intervention NN p
; : p
follow-up JJ N
data NNS N
were VBD N
available JJ N
on IN N
approximately RB N
half NN N
of IN N
the DT N
subjects NNS N
. . N

Significant JJ N
reduction NN N
in IN N
( ( o
BMI-Z NNP o
) ) o
was VBD N
achieved VBN N
in IN N
both DT N
groups NNS N
during IN N
intervention NN N
and CC N
was VBD N
significantly RB N
greater JJR N
for IN N
the DT N
HPLC NNP N
group NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Both DT N
groups NNS N
maintained VBD N
significant JJ N
BMI-Z JJ o
reduction NN o
at IN N
follow-up NN N
; : N
changes NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

Loss NNP N
of IN N
lean JJ o
body NN o
mass NN o
was VBD N
not RB N
spared VBN N
in IN N
the DT N
HPLC NNP N
group NN N
. . N

No DT N
serious JJ o
adverse JJ o
effects NNS o
were VBD N
observed VBN N
related VBN N
to TO N
metabolic JJ o
profiles NNS o
, , o
cardiac JJ o
function NN o
, , N
or CC N
subjective JJ o
complaints NNS o
. . o

CONCLUSIONS VB N
The DT N
HPLC NNP i
diet NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
option NN N
for IN N
medically RB N
supervised VBN N
weight JJ N
loss NN N
in IN N
severely JJ p
obese JJ p
adolescents NNS p
. . p

-DOCSTART- -8159300- O O

Cyclosporin NNP i
versus NN i
cyclophosphamide NN i
for IN N
patients NNS p
with IN p
steroid-dependent JJ p
and CC p
frequently RB p
relapsing VBG p
idiopathic JJ p
nephrotic JJ p
syndrome NN p
: : p
a DT N
multicentre NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN o
( ( o
maintenance NN o
of IN o
remission NN o
) ) o
, , o
safety NN o
and CC o
tolerability NN o
of IN N
cyclosporin NN i
( ( i
CsA NNP i
) ) i
with IN N
those DT N
of IN N
cyclophosphamide NN i
in IN N
patients NNS p
with IN p
steroid-dependent JJ p
or CC p
frequently RB p
relapsing VBG p
nephrotic JJ p
syndrome NN p
( ( p
NS NNP p
) ) p
. . p

DESIGN NNP N
Open NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
, , N
controlled VBD N
study NN N
for IN N
parallel JJ N
groups NNS N
, , N
stratified VBN N
for IN N
adults NNS p
and CC p
children NNS p
. . p

The DT N
setting NN N
was VBD N
in IN N
nephrological JJ N
departments NNS N
in IN p
Italy NNP p
. . p

SUBJECTS NNP N
AND CC N
INTERVENTIONS NNP N
Seventy-three JJ p
patients NNS p
with IN p
steroid-sensitive JJ p
idiopathic JJ p
NS NNP p
admitted VBD p
to TO p
the DT p
study NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
cyclophosphamide VB i
( ( N
2.5 CD N
mg/kg/day NN N
) ) N
for IN N
8 CD N
weeks NNS N
or CC N
CsA NNP i
( ( N
5 CD N
mg/kg/day NN N
in IN N
adults NNS N
, , N
6 CD N
mg/kg/day NN N
in IN N
children NNS N
) ) N
for IN N
9 CD N
months NNS N
, , N
tapered VBD N
off RP N
by IN N
25 CD N
% NN N
every DT N
month NN N
until IN N
complete JJ N
discontinuation NN N
at IN N
month NN N
12 CD N
. . N

Seven CD N
patients NNS N
lost VBN N
to TO N
follow VB N
up RP N
were VBD N
not RB N
considered VBN N
in IN N
the DT N
analysis NN N
. . N

The DT N
remaining VBG N
66 CD N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
3-24 JJ N
months NNS N
after IN N
randomization NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Relapse-free NNP o
survival NN o
; : o
number NN o
of IN o
N.S NNP o
. . o

relapses/patient/year NN o
; : o
cumulative JJ o
dose NN o
of IN o
prednisone/patient NN o
; : o
laboratory JJ o
investigations NNS o
( ( o
kidney NN o
and CC o
liver NN o
functions NNS o
, , o
haematological JJ o
parameters NNS o
) ) o
; : o
incidence NN o
of IN o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
At IN N
month NN N
9 CD N
, , N
26 CD N
of IN N
35 CD N
CsA-treated JJ N
patients NNS N
were VBD N
still RB N
in IN N
complete JJ o
remission NN o
and CC N
a DT N
further JJ N
five CD N
patients NNS N
were VBD N
in IN N
partial JJ o
remission NN o
; : o
18 CD N
of IN N
28 CD N
cyclophosphamide-treated JJ i
patients NNS N
were VBD N
in IN N
complete JJ o
remission NN o
, , N
and CC N
one CD N
in IN N
partial JJ o
remission NN o
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

No DT N
difference NN N
between IN N
adults NNS N
and CC N
children NNS N
was VBD N
seen VBN N
with IN N
either DT N
treatment NN N
. . N

The DT N
risk NN o
of IN o
relapse NN o
was VBD N
similar JJ N
between IN N
frequent JJ N
relapsers NNS N
( ( N
19 CD N
of IN N
22 CD N
) ) N
and CC N
steroid-dependent JJ N
patients NNS N
( ( N
8 CD N
of IN N
14 CD N
) ) N
given VBN N
CsA NNP N
, , N
and CC N
those DT N
given VBN N
cyclophosphamide NN i
( ( N
5 CD N
of IN N
15 CD N
and CC N
6 CD N
of IN N
15 CD N
) ) N
. . N

The DT N
mean JJ o
number NN o
of IN o
relapses NNS o
per IN o
year NN o
and CC N
the DT N
mean NN N
dose NN o
of IN o
prednisone NN o
per IN o
year NN o
were VBD N
significantly RB N
less JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT N
groups NNS N
for IN N
the DT N
experimental JJ N
year NN N
than IN N
for IN N
the DT N
year NN N
before IN N
randomization NN N
. . N

At IN N
2 CD N
years NNS N
, , N
25 CD N
% NN N
of IN N
the DT N
patients NNS N
given VBN N
CsA NNP i
( ( N
50 CD N
% NN N
adults NNS N
and CC N
20 CD N
% NN N
children NNS N
) ) N
and CC N
63 CD N
% NN N
of IN N
those DT N
given VBN N
cyclophosphamide NN i
( ( N
40 CD N
% NN N
adults NNS N
and CC N
68 CD N
% NN N
children NNS N
) ) N
had VBD N
not RB N
had VBN N
any DT N
relapse NN o
of IN o
NS NNP o
. . o

Tolerance NN o
to TO N
the DT N
two CD N
drugs NNS N
was VBD N
generally RB N
good JJ N
. . N

The DT N
CsA-related JJ o
side-effects NNS o
were VBD N
mild JJ N
and CC N
disappeared VBD N
after IN N
drug NN N
discontinuation NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
both DT N
treatments NNS N
are VBP N
effective JJ N
and CC N
well RB N
tolerated VBD N
; : N
more RBR N
patients NNS N
given VBN N
cyclophosphamide JJ i
had VBD N
stable JJ o
remissions NNS o
. . o

-DOCSTART- -20813580- O O

Aerobic NNP i
exercise NN i
improves VBZ N
self-reported JJ o
sleep NN o
and CC o
quality NN o
of IN o
life NN o
in IN N
older JJR p
adults NNS p
with IN p
insomnia NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN o
of IN N
moderate JJ i
aerobic JJ i
physical JJ i
activity NN i
with IN N
sleep JJ N
hygiene NN N
education NN N
to TO N
improve VB o
sleep NN o
, , o
mood NN o
and CC o
quality NN o
of IN o
life NN o
in IN N
older JJR N
adults NNS N
with IN N
chronic JJ N
insomnia NN N
. . N

METHODS NNP N
Seventeen NNP p
sedentary JJ p
adults NNS p
aged VBN p
> JJ p
or=55 CD p
years NNS p
with IN p
insomnia NN p
( ( p
mean JJ p
age NN p
61.6 CD p
[ NN p
SD?4.3 NNP p
] NNP p
years NNS p
; : p
16 CD p
female NN p
) ) p
participated VBD p
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
comparing VBG i
16 CD i
weeks NNS i
of IN i
aerobic JJ i
physical JJ i
activity NN i
plus CC i
sleep JJ i
hygiene NN i
to TO i
non-physical JJ i
activity NN i
plus CC i
sleep JJ i
hygiene NN i
. . i

Eligibility NNP N
included VBD p
primary JJ p
insomnia NN p
for IN p
at IN p
least JJS p
3 CD p
months NNS p
, , p
habitual JJ p
sleep NN p
duration NN p
< POS p
6.5h CD p
and CC p
a DT p
Pittsburgh NNP p
Sleep NNP p
Quality NNP p
Index NNP p
( ( p
PSQI NNP p
) ) p
score VBD p
> JJ p
5 CD p
. . p

Outcomes NNS o
included VBD o
sleep JJ o
quality NN o
, , o
mood NN o
and CC o
quality NN o
of IN o
life NN o
questionnaires NNS o
( ( o
PSQI NNP o
, , o
Epworth NNP o
Sleepiness NNP o
Scale NNP o
[ NNP o
ESS NNP o
] NNP o
, , o
Short-form NNP o
36 CD o
[ NNP o
SF-36 NNP o
] NNP o
, , o
Center NNP o
for IN o
Epidemiological NNP o
Studies NNPS o
Depression NNP o
Scale NNP o
[ NNP o
CES-D NNP o
] NNP o
) ) o
. . o

RESULTS VB N
The DT N
physical JJ N
activity NN N
group NN N
improved VBD N
in IN o
sleep JJ o
quality NN o
on IN o
the DT o
global JJ o
PSQI NNP o
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
, , N
sleep JJ o
latency NN o
( ( N
p=.049 NN N
) ) N
, , N
sleep JJ o
duration NN o
( ( N
p=.04 NN N
) ) N
, , N
daytime JJ o
dysfunction NN o
( ( N
p=.027 NN N
) ) N
, , N
and CC o
sleep JJ o
efficiency NN o
( ( N
p=.036 NN N
) ) N
PSQI NNP N
sub-scores NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

The DT N
physical JJ N
activity NN N
group NN N
also RB N
had VBD N
reductions NNS N
in IN o
depressive JJ o
symptoms NNS o
( ( N
p=.044 NN N
) ) N
, , N
daytime JJ o
sleepiness NN o
( ( N
p=.02 NN N
) ) N
and CC o
improvements NNS o
in IN o
vitality NN o
( ( N
p=.017 NN N
) ) N
compared VBN N
to TO N
baseline VB N
scores NNS N
. . N

CONCLUSION NNP N
Aerobic NNP N
physical JJ N
activity NN N
with IN N
sleep JJ N
hygiene NN N
education NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
approach NN N
to TO N
improve VB o
sleep JJ o
quality NN o
, , o
mood NN o
and CC o
quality NN o
of IN o
life NN o
in IN p
older JJR p
adults NNS p
with IN p
chronic JJ p
insomnia NN p
. . p

-DOCSTART- -7824501- O O

[ JJ N
New NNP N
approaches NNS N
to TO N
evaluation NN N
of IN N
nonspecific JJ i
inhalation NN i
provocation NN i
( ( N
dose-response JJ N
relationship NN N
) ) N
in IN N
the DT N
comparative JJ N
evaluation NN N
of IN N
bronchial JJ p
hyperreactivity NN p
within IN N
the DT N
scope NN N
of IN N
clinical JJ N
trials NNS N
] VBP N
. . N

For IN N
the DT N
performance NN N
of IN N
clinical JJ N
drug NN N
trials NNS N
in IN N
the DT N
therapy NN N
for IN N
bronchial JJ p
hyperresponsiveness NN p
, , N
unspecific JJ N
inhalatory JJ N
provocation NN N
tests NNS N
are VBP N
generally RB N
employed VBN N
to TO N
judge VB N
therapeutic JJ N
success NN N
. . N

In IN N
particular JJ N
, , N
the DT N
parameter-specific JJ N
provocation NN N
doses NNS N
are VBP N
considered VBN N
to TO N
be VB N
the DT N
main JJ N
target NN N
values NNS N
. . N

However RB N
, , N
it PRP N
must MD N
be VB N
considered VBN N
that IN N
these DT N
provocation NN N
doses NNS N
are VBP N
not RB N
equally RB N
calculable JJ N
for IN N
every DT N
patient NN N
in IN N
the DT N
same JJ N
way NN N
and CC N
at IN N
any DT N
examination NN N
time NN N
. . N

This DT N
leads VBZ N
to TO N
the DT N
fact NN N
that IN N
the DT N
number NN N
of IN N
evaluable JJ N
case NN N
studies NNS N
is VBZ N
often RB N
appreciably RB N
lower JJR N
than IN N
the DT N
number NN N
of IN N
test NN N
participants NNS N
and CC N
that IN N
a DT N
meaningful JJ N
therapy NN N
group NN N
comparison NN N
may MD N
even RB N
not RB N
be VB N
possible JJ N
under IN N
certain JJ N
circumstances NNS N
. . N

An DT N
evaluation NN p
model NN p
is VBZ N
presented VBN N
here RB N
in IN N
order NN N
to TO N
fully RB N
exploit VB N
the DT N
obtained VBN N
data NNS N
; : N
in IN N
this DT N
the DT N
percentile JJ N
changes NNS N
of IN N
the DT N
function NN N
parameters NNS N
( ( N
estimated VBN N
by IN N
linear JJ N
regression NN N
) ) N
at IN N
a DT N
defined JJ N
dose NN N
of IN N
the DT N
provocation NN N
substance NN N
are VBP N
analyzed VBN N
. . N

In IN N
analogy NN N
, , N
a DT N
survival JJ o
time NN o
model NN o
and CC N
, , N
as IN N
a DT N
supplement NN N
, , N
a DT N
best JJS N
case/worst JJ N
case NN N
analysis NN N
are VBP N
performed VBN N
for IN N
further JJ N
statistical JJ N
evaluation NN N
. . N

With IN N
the DT N
present JJ N
procedure NN N
, , N
an DT N
evaluation NN N
with IN N
inclusion NN N
of IN N
all DT N
test NN N
participants NNS N
is VBZ N
possible JJ N
. . N

In IN N
contrast NN N
to TO N
the DT N
previously RB N
used VBN N
evaluation NN N
procedures NNS N
, , N
this DT N
allows VBZ N
a DT N
reliable JJ N
statistical JJ N
confirmation NN N
of IN N
the DT N
results NNS N
of IN N
clinical JJ N
tests NNS N
in IN N
the DT N
therapy NN N
for IN N
bronchial JJ p
hyperresponsiveness NN p
. . p

-DOCSTART- -17926617- O O

[ JJ N
Effects NNS N
of IN N
electroacupuncture NN i
combined VBN i
with IN i
behavior JJ i
therapy NN i
on IN N
intelligence NN N
and CC N
behavior NN N
of IN N
children NNS p
of IN p
autism NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
find VB N
out RP N
an DT N
effective JJ N
therapy NN N
for IN N
autism NN N
. . N

METHODS NNP N
Sixty NNP p
children NNS p
of IN p
autism NN p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
electroacupuncture NN i
( ( i
EA NNP i
) ) i
plus CC i
behavior JJ i
therapy NN i
group NN i
and CC i
a DT i
behavior JJ i
therapy NN i
group NN i
, , N
30 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

The DT N
patients NNS N
in IN N
the DT N
two CD N
groups NNS N
were VBD N
treated VBN N
with IN N
routine JJ i
behavior NN i
, , N
with IN N
EA NNP i
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Shenting NNP N
( ( N
GV NNP N
24 CD N
) ) N
, , N
Benshen NNP N
( ( N
GB NNP N
13 CD N
) ) N
, , N
Yintang NNP N
( ( N
EX-HN NNP N
3 CD N
) ) N
, , N
Naohu NNP N
( ( N
GV NNP N
17 CD N
) ) N
, , N
Naokong NNP N
( ( N
GB NNP N
19 CD N
) ) N
, , N
Neiguan NNP N
( ( N
PC NNP N
6 CD N
) ) N
and CC N
scalp JJ i
acupuncture NN i
at IN N
Speech NNP N
Areas NNP N
I PRP N
, , N
II NNP N
, , N
III NNP N
added VBD N
for IN N
the DT N
EA NNP i
plus CC i
behavior JJ i
therapy NN i
group NN N
. . N

Their PRP$ N
therapeutic JJ N
effects NNS N
were VBD N
observed VBN N
, , N
and CC N
the DT N
picture NN o
and CC o
vocabulary JJ o
scale NN o
( ( o
PPVT NNP o
) ) o
and CC N
behavior JJ o
ability NN o
were VBD N
detected VBN N
. . N

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
was VBD N
86.7 CD N
% NN N
in IN N
the DT N
EA NNP i
plus CC i
behavior JJ i
therapy NN i
group NN N
which WDT N
was VBD N
better JJR N
than IN N
56.7 CD N
% NN N
of IN N
the DT N
behavior JJ N
therapy NN N
group NN N
, , N
and CC N
had VBD N
significant JJ N
enhancement NN N
in IN N
sensation NN o
, , o
association NN o
, , o
body NN o
, , o
and CC o
ability NN o
of IN o
self-care NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
was VBD N
better JJR N
than IN N
the DT N
behavior JJ N
therapy NN N
group NN N
in IN N
sensation NN o
, , o
body NN o
and CC o
self-care JJ o
factors NNS o
, , N
with IN N
no DT N
significantly RB N
improvement NN N
in IN N
the DT N
scores NNS N
of IN N
PPVT NNP o
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
EA NNP i
combined VBD i
with IN i
behavior JJ i
therapy NN i
can MD N
significantly RB N
improve VB N
clinical JJ N
symptoms NNS N
of IN N
autism NN N
, , N
but CC N
does VBZ N
not RB N
improve VB N
intelligence NN N
. . N

-DOCSTART- -16802487- O O

Recovery NN o
after IN N
prolonged JJ p
anaesthesia NN p
for IN p
acoustic JJ p
neuroma NN p
surgery NN p
: : p
desflurane NN i
versus IN i
isoflurane NN i
. . i

In IN N
this DT N
study NN N
, , N
33 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
desflurane NN i
( ( i
D NNP i
) ) i
or CC i
isoflurane NN i
( ( i
I PRP i
) ) i
for IN i
acoustic JJ i
neuroma NN i
surgery NN i
. . i

The DT N
time NN N
from IN N
end NN N
of IN N
the DT N
procedure NN N
to TO N
spontaneous JJ N
breathing NN N
, , N
extubation NN N
, , N
eye-opening JJ N
, , N
hand-squeezing JJ N
to TO N
command VB N
, , N
and CC N
ability NN N
to TO N
state NN N
name NN N
, , N
birthdate NN N
and CC N
phone NN N
number NN N
were VBD N
recorded VBN N
. . N

The DT N
Steward NNP N
recovery NN N
score NN N
was VBD N
also RB N
recorded VBN N
every DT N
five CD N
minutes NNS N
during IN N
the DT N
first JJ N
20 CD N
minutes NNS N
postoperatively RB N
and CC N
then RB N
every DT N
10 CD N
to TO N
15 CD N
minutes NNS N
. . N

Groups NNP N
were VBD N
similar JJ N
regarding VBG N
patient NN N
characteristics NNS N
, , N
depth NN N
of IN N
anaesthesia NN N
, , N
sufentanil JJ N
total NN N
dose NN N
, , N
anaesthesia JJ N
duration NN N
( ( N
D NNP N
: : N
349.1 CD N
+/- JJ N
19.1 CD N
min NN N
; : N
I PRP N
: : N
349.2 CD N
+/- JJ N
22.9 CD N
min NN N
) ) N
, , N
haemodynamic/respiratory JJ N
parameters NNS N
, , N
and CC N
surgical JJ N
conditions NNS N
( ( N
assessed VBN N
by IN N
a DT N
bleeding NN N
score NN N
) ) N
. . N

The DT N
emergence NN o
time NN o
in IN N
the DT N
D NNP N
group NN N
was VBD N
significantly RB N
faster JJR N
than IN N
the DT N
I PRP N
group NN N
( ( o
D NNP o
: : o
14.9 CD o
+/- JJ o
2.4 CD o
min NN o
vs NN o
I PRP o
: : o
29.2 CD o
+/- JJ o
2.4 CD o
min NN o
for IN N
eye-opening NN N
) ) N
. . N

Full JJ o
recovery NN o
also RB N
occurred VBD N
earlier RBR N
in IN N
the DT N
D NNP N
group NN N
( ( o
D NNP o
: : o
22.1 CD o
+/- JJ o
3.1 CD o
min NN o
vs NN o
I PRP o
: : o
37.6 CD o
+/- JJ o
4.0 CD o
min NN o
, , o
P NNP o
< VBZ o
0.005 CD o
for IN o
stating VBG o
name NN o
) ) o
. . N

Steward JJ o
recovery NN o
scores NNS o
were VBD N
also RB N
better RBR N
during IN N
the DT N
first JJ N
postoperative JJ N
hour NN N
in IN N
the DT N
D NNP N
group NN N
( ( N
D NNP N
: : N
40 CD N
min NN N
vs NN N
I PRP N
: : N
90 CD N
min NN N
, , N
P NNP N
< VBZ N
0.005 CD N
for IN N
100 CD N
% NN N
of IN N
patients NNS N
with IN N
Steward NNP N
score NN N
of IN N
6 CD N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
desflurane NN N
is VBZ N
associated VBN N
with IN N
similar JJ N
operating NN o
conditions NNS N
and CC N
faster RBR N
postoperative JJ o
recovery NN o
following VBG N
acoustic JJ p
neuroma NN p
surgery NN p
. . p

The DT N
faster JJ N
recovery NN o
following VBG N
desflurane NN N
may MD N
be VB N
desirable JJ N
after IN N
long JJ N
surgical JJ N
procedures NNS N
, , N
enabling VBG N
the DT N
patient NN N
's POS N
full JJ N
cooperation NN N
and CC N
facilitating VBG N
early JJ N
diagnosis NN N
of IN N
any DT N
potential JJ o
neurological JJ o
deficit NN o
. . o

-DOCSTART- -16920077- O O

Omega-3 JJ i
fatty JJ i
acids NNS i
supplementation NN i
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
double-blind JJ N
randomized NN N
, , N
placebo-controlled JJ i
pilot NN N
study NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
evidence NN N
that IN N
fatty JJ N
acid JJ N
deficiencies NNS N
or CC N
imbalances NNS N
may MD N
contribute VB N
to TO N
childhood VB p
neurodevelopmental JJ p
disorders NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
6-week JJ N
pilot NN N
trial NN N
investigating VBG N
the DT N
effects NNS N
of IN N
1.5 CD i
g/d NN i
of IN i
omega-3 JJ i
fatty JJ i
acids NNS i
( ( i
.84 JJ i
g/d NN i
eicosapentaenoic NN i
acid NN i
, , i
.7 NNP i
g/d NN i
docosahexaenoic NN i
acid NN i
) ) i
supplementation NN i
in IN N
13 CD p
children NNS p
( ( p
aged VBN p
5 CD p
to TO p
17 CD p
years NNS p
) ) p
with IN p
autistic JJ p
disorders NNS p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
or CC p
self-injurious JJ p
behavior NN p
. . p

The DT N
outcome NN N
measure NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
at IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
We PRP N
observed VBD N
an DT N
advantage NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
compared VBN N
with IN N
placebo NN i
for IN N
hyperactivity NN o
and CC o
stereotypy NN o
, , N
each DT N
with IN N
a DT N
large JJ N
effect NN N
size NN N
. . N

Repeated-measures NNS N
ANOVA NNP N
indicated VBD N
a DT N
trend NN N
toward IN N
superiority NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
over IN N
placebo NN N
for IN N
hyperactivity NN o
. . o

No DT N
clinically RB N
relevant JJ N
adverse JJ o
effects NNS o
were VBD N
elicited VBN N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS VBZ N
The DT N
results NNS N
of IN N
this DT N
study NN N
provide VBP N
preliminary JJ N
evidence NN N
that IN N
omega-3 JJ i
fatty JJ i
acids NNS i
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -11435682- O O

Patient NN N
positioning VBG N
influences NNS N
oxygen JJ o
saturation NN o
in IN N
the DT N
acute JJ p
phase NN p
of IN p
stroke NN p
. . p

We PRP N
evaluated VBD N
arterial JJ o
oxygen NN o
saturation NN o
( ( o
SaO NNP o
( ( o
2 CD o
) ) o
) ) o
and CC o
heart NN o
rate NN o
in IN N
acute JJ p
stroke NN p
patients NNS p
to TO N
determine VB N
whether IN N
routine JJ N
positioning NN N
affected VBD N
these DT N
physiological JJ N
parameters NNS N
. . N

Measurements NNS N
were VBD N
recorded VBN N
at IN N
the DT N
bedside JJ N
non-invasively RB N
in IN N
five CD i
different JJ i
positions NNS i
assigned VBN N
in IN N
random JJ N
order NN N
each DT N
maintained VBD N
for IN N
10 CD N
min NN N
. . N

One CD p
hundred CD p
and CC p
twenty-nine JJ p
patients NNS p
examined VBD p
within IN p
a DT p
median NN i
of IN p
72 CD p
h NN p
, , p
lying VBG i
on IN i
the DT i
left JJ i
side NN i
resulted VBD p
in IN p
slightly RB p
lower JJR p
SaO NNP o
( ( o
2 CD o
) ) o
than IN p
lying VBG i
on IN i
the DT i
right JJ i
side NN i
, , p
which WDT p
was VBD p
statistically RB p
significant JJ p
in IN p
the DT p
patients NNS p
with IN p
a DT p
right NN p
( ( p
n JJ p
= NNP p
66 CD p
) ) p
, , p
but CC p
not RB p
left VBD p
, , p
hemiparesis NN p
. . p

Patients NNS N
able JJ N
to TO N
sit VB i
in IN i
a DT i
chair NN i
( ( N
n JJ N
= NNP N
65 CD N
) ) N
, , N
who WP N
mostly RB N
had VBD N
less RBR N
severe JJ N
strokes NNS N
, , N
had VBD N
a DT N
significantly RB N
higher JJR N
mean JJ o
SaO NNP o
( ( o
2 CD o
) ) o
and CC o
heart NN o
rate NN o
when WRB N
sitting VBG N
in IN N
the DT N
chair NN N
than IN N
when WRB N
placed VBN N
in IN N
any DT N
other JJ N
position NN N
. . N

About IN N
10 CD N
% NN N
of IN N
patients NNS N
, , N
especially RB N
those DT N
with IN N
a DT N
severe JJ N
stroke NN N
, , N
with IN N
right JJ N
hemiparesis NN N
and CC N
concomitant JJ N
chest NN N
disease NN N
, , N
experienced VBD N
falls NNS N
in IN N
SaO NNP o
( ( o
2 CD o
) ) o
to TO N
90 CD N
% NN N
or CC N
less JJR N
for IN N
> NN N
/=2 NNP N
min NN N
in IN N
certain JJ N
positions NNS N
; : N
the DT N
hypoxia NN o
was VBD N
more RBR N
likely JJ N
when WRB N
they PRP N
were VBD N
lying VBG i
on IN i
their PRP$ i
left JJ i
side NN i
. . i

These DT N
results NNS N
may MD N
have VB N
implications NNS N
for IN N
current JJ N
practice NN N
and CC N
for IN N
future JJ N
patient JJ N
positioning VBG N
strategies NNS N
to TO N
improve VB N
outcome NN N
after IN N
stroke NN N
. . N

-DOCSTART- -22492697- O O

Laryngeal JJ N
preservation NN N
with IN N
induction NN i
chemotherapy NN i
for IN N
hypopharyngeal NN p
squamous JJ p
cell NN p
carcinoma NN p
: : p
10-year JJ N
results NNS N
of IN N
EORTC NNP N
trial NN N
24891 CD N
. . N

BACKGROUND NNP N
We PRP N
report VBP N
the DT N
10-year JJ N
results NNS N
of IN N
the DT N
EORTC NNP N
trial NN N
24891 CD N
comparing VBG N
a DT N
larynx-preservation JJ i
approach NN i
to TO p
immediate VB i
surgery NN i
in IN p
hypopharynx NN p
and CC p
lateral JJ p
epilarynx NN p
squamous JJ p
cell NN p
carcinoma NN p
. . p

MATERIAL NNP N
AND CC N
METHODS NNP N
Two CD p
hundred CD p
and CC p
two CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
surgical JJ N
approach NN N
( ( i
total JJ i
laryngectomy NN i
with IN i
partial JJ i
pharyngectomy NN i
and CC i
neck NN i
dissection NN i
, , i
followed VBN i
by IN i
irradiation NN i
) ) i
or CC i
to TO i
the DT i
chemotherapy NN i
arm NN i
up IN i
to TO i
three CD i
cycles NNS i
of IN i
induction NN i
chemotherapy NN i
( ( i
cisplatin JJ i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
+ CD N
5-FU JJ N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1-5 JJ N
) ) N
followed VBD N
for IN N
complete JJ N
responders NNS N
by IN N
irradiation NN i
and CC N
otherwise RB N
by IN N
conventional JJ i
treatment NN i
. . i

The DT N
end NN N
points NNS N
were VBD N
overall JJ o
survival JJ o
[ NN N
OS NNP N
, , N
noninferiority NN N
: : N
hazard NN N
ratio NN N
( ( N
preservation/surgery NN N
) ) N
? . N
1.428 CD N
, , N
one-sided JJ N
? . N
= $ N
0.05 CD o
] NNP o
, , o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
and CC o
survival JJ o
with IN o
a DT o
functional JJ o
larynx NN o
( ( o
SFL NNP o
) ) o
. . o

RESULTS NNP o
At IN N
a DT N
median JJ N
follow-up NN N
of IN N
10.5 CD N
years NNS N
on IN N
194 CD p
eligible JJ p
patients NNS o
, , o
disease JJ o
evolution NN o
was VBD o
seen VBN N
in IN N
54 CD N
and CC N
49 CD N
patients NNS N
in IN N
the DT N
surgery NN N
and CC N
chemotherapy NN N
arm NN N
, , N
respectively RB N
, , N
and CC N
81 CD N
and CC N
83 CD N
patients NNS N
had VBD N
died VBN N
. . N

The DT N
10-year JJ o
OS NNP o
rate NN o
was VBD o
13.8 CD N
% NN N
in IN N
the DT N
surgery NN N
arm NN N
and CC N
13.1 CD N
% NN N
in IN N
the DT N
chemotherapy NN N
arm NN N
. . N

The DT N
10-year JJ o
PFS NNP o
rates NNS o
were VBD o
8.5 CD N
% NN N
and CC N
10.8 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
the DT N
chemotherapy NN N
arm NN N
, , N
the DT N
10-year JJ o
SFL NNP o
rate NN o
was VBD o
8.7 CD N
% NN N
. . N

CONCLUSION NNP N
This DT N
strategy NN N
did VBD N
not RB N
compromise VB o
disease NN o
control NN o
or CC o
survival NN o
( ( o
that IN o
remained VBD N
poor JJ N
) ) N
and CC N
allowed VBD N
more JJR N
than IN N
half NN N
of IN N
the DT N
survivors NNS N
to TO N
retain VB N
their PRP$ N
larynx NN N
. . N

-DOCSTART- -18395723- O O

Effect NN N
of IN N
intestinal JJ N
production NN N
of IN N
equol NN N
on IN N
menopausal NN o
symptoms NNS o
in IN p
women NNS p
treated VBN p
with IN p
soy JJ i
isoflavones NNS i
. . i

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
soy NN i
isoflavones NNS i
on IN N
menopausal NN N
symptoms NNS N
in IN N
women NNS p
who WP p
do VBP p
and CC p
who WP p
do VBP p
not RB p
produce VB p
equol NN p
, , N
a DT N
daidzein NN N
metabolite NN N
. . N

METHOD NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
was VBD N
conducted VBN N
over IN N
6 CD N
months NNS N
with IN N
96 CD p
healthy JJ p
menopausal NN p
women NNS p
. . p

After IN N
taking VBG N
take VB N
135 CD N
mg NN N
of IN N
isoflavones NNS i
daily RB N
for IN N
1 CD N
week NN N
, , N
the DT N
women NNS N
in IN N
the DT N
study NN N
group NN N
were VBD N
assigned VBN N
to TO N
the DT N
equol-producing NN N
( ( N
EP NNP N
) ) N
or CC N
the DT N
non-EP JJ N
group NN N
according VBG N
to TO N
the DT N
presence NN N
or CC N
absence NN N
of IN N
equol NN N
in IN N
their PRP$ N
urine NN N
. . N

Menopausal NNP N
symptoms NNS N
were VBD N
evaluated VBN N
using VBG N
a DT N
modified VBN N
Kupperman NNP N
Index NNP N
. . N

RESULT NNP N
Compared NNP N
with IN N
the DT N
placebo NN i
group NN N
, , N
the DT N
scores NNS N
for IN N
hot JJ o
flashes NNS o
and CC o
excessive JJ o
sweating NN o
were VBD N
significantly RB N
reduced VBN N
after IN N
3 CD N
months NNS N
, , N
and CC N
the DT N
scores NNS N
for IN N
weakness NN o
, , o
palpitations NNS o
, , o
limb NN o
paresthesia NN o
, , o
and CC o
total JJ o
symptoms NNS o
after IN N
6 CD N
months NNS N
, , N
in IN N
the DT N
EP NNP N
group NN N
only RB N
. . N

CONCLUSIONS NNP N
Isoflavone NNP i
supplementation NN i
improves VBZ N
menopausal NN o
symptoms NNS o
only RB N
in IN N
women NNS N
with IN N
the DT N
ability NN N
to TO N
produce VB N
equol NN N
. . N

-DOCSTART- -12151468- O O

Risperidone NN i
in IN N
children NNS p
with IN p
autism NN p
and CC p
serious JJ p
behavioral JJ p
problems NNS p
. . p

BACKGROUND NNP N
Atypical NNP N
antipsychotic JJ N
agents NNS N
, , N
which WDT N
block VBP N
postsynaptic JJ N
dopamine NN N
and CC N
serotonin NN N
receptors NNS N
, , N
have VBP N
advantages NNS N
over IN N
traditional JJ N
antipsychotic JJ N
medications NNS N
in IN N
the DT N
treatment NN N
of IN N
adults NNS N
with IN N
schizophrenia NN N
and CC N
may MD N
be VB N
beneficial JJ N
in IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
who WP N
have VBP N
serious JJ N
behavioral JJ N
disturbances NNS N
. . N

However RB N
, , N
data NNS N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
atypical JJ i
antipsychotic JJ i
agents NNS N
in IN N
children NNS N
are VBP N
limited VBN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
multisite NN N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
of IN N
risperidone NN i
as IN N
compared VBN N
with IN N
placebo NN i
for IN N
the DT N
treatment NN p
of IN p
autistic JJ p
disorder NN p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
or CC p
self-injurious JJ p
behavior NN p
in IN p
children NNS p
5 CD p
to TO p
17 CD p
years NNS p
old JJ p
. . p

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
score NN N
on IN N
the DT N
Irritability NNP N
subscale NN N
of IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
and CC N
the DT N
rating NN N
on IN N
the DT N
Clinical NNP N
Global NNP N
Impressions NNP N
- : N
Improvement NN N
( ( N
CGI-I NNP N
) ) N
scale NN N
at IN N
eight CD N
weeks NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
101 CD p
children NNS p
( ( p
82 CD p
boys NNS p
and CC p
19 CD p
girls NNS p
; : p
mean VB p
[ IN p
+/-SD JJ p
] NNP p
age NN p
, , p
8.8+/-2.7 CD p
years NNS p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
risperidone NN i
( ( p
49 CD p
children NNS p
) ) p
or CC p
placebo NN i
( ( p
52 CD p
) ) p
. . N

Treatment NN N
with IN N
risperidone NN i
for IN N
eight CD N
weeks NNS N
( ( N
dose JJ N
range NN N
, , N
0.5 CD N
to TO N
3.5 CD N
mg NNS N
per IN N
day NN N
) ) N
resulted VBD N
in IN N
a DT N
56.9 CD N
percent NN N
reduction NN N
in IN N
the DT N
Irritability NNP o
score NN o
, , N
as IN N
compared VBN N
with IN N
a DT N
14.1 CD N
percent NN N
decrease NN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
rate NN N
of IN N
a DT N
positive JJ N
response NN N
, , N
defined VBD N
as IN N
at IN N
least JJS N
a DT N
25 CD N
percent NN N
decrease NN N
in IN N
the DT N
Irritability NNP o
score NN o
and CC N
a DT N
rating NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
CGI-I NNP o
scale NN o
, , N
was VBD N
69 CD N
percent NN N
in IN N
the DT N
risperidone NN i
group NN N
( ( N
34 CD N
of IN N
49 CD N
children NNS N
had VBD N
a DT N
positive JJ N
response NN N
) ) N
and CC N
12 CD N
percent NN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
6 CD N
of IN N
52 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Risperidone NNP i
therapy NN N
was VBD N
associated VBN N
with IN N
an DT N
average JJ o
weight JJ o
gain NN o
of IN N
2.7+/-2.9 JJ N
kg NN N
, , N
as IN N
compared VBN N
with IN N
0.8+/-2.2 JJ N
kg NN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Increased VBN N
appetite RB o
, , o
fatigue NN o
, , o
drowsiness NN o
, , o
dizziness NN o
, , o
and CC o
drooling VBG o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
risperidone NN i
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
for IN N
each DT N
comparison NN N
) ) N
. . N

In IN N
two CD N
thirds NNS N
of IN N
the DT N
children NNS N
with IN N
a DT N
positive JJ N
response NN N
to TO N
risperidone VB N
at IN N
eight CD N
weeks NNS N
( ( N
23 CD N
of IN N
34 CD N
) ) N
, , N
the DT N
benefit NN N
was VBD N
maintained VBN N
at IN N
six CD N
months NNS N
. . N

CONCLUSIONS NNP N
Risperidone NNP i
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
for IN N
the DT N
treatment NN N
of IN N
tantrums NNS N
, , N
aggression NN N
, , N
or CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

The DT N
short JJ N
period NN N
of IN N
this DT N
trial NN N
limits VBZ N
inferences NNS N
about IN N
adverse JJ N
effects NNS N
such JJ N
as IN N
tardive JJ N
dyskinesia NN N
. . N

-DOCSTART- -10443725- O O

Continued JJ N
improvement NN N
in IN N
pressure-flow JJ o
parameters NNS o
in IN N
men NNS p
receiving VBG p
finasteride NN p
for IN p
2 CD p
years NNS p
. . p

Finasteride IN N
Urodynamics NNP N
Study NNP N
Group NNP N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
long-term JJ N
effects NNS N
of IN N
finasteride NN N
on IN N
pressure-flow JJ o
parameters NNS o
in IN N
men NNS p
with IN p
urodynamically RB p
documented VBN p
bladder NN p
outflow JJ p
obstruction NN p
( ( p
BOO NNP p
) ) p
. . p

METHODS NNP N
One CD p
hundred VBD p
twenty-one NN p
men NNS p
with IN p
benign JJ p
prostatic JJ p
enlargement NN p
( ( p
BPE NNP p
) ) p
and CC p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
( ( p
LUTS NNP p
) ) p
underwent VBD N
a DT N
pressure-flow JJ N
study NN N
( ( N
PFS NNP N
) ) N
at IN N
1 CD N
of IN N
11 CD N
clinical JJ N
centers NNS N
. . N

The DT N
PFS NNP N
technique NN N
was VBD N
standardized VBN N
, , N
and CC N
all DT N
tracings NNS N
were VBD N
read VBN N
by IN N
a DT N
single JJ N
reader NN N
unaware NN N
of IN N
the DT N
treatment NN N
group NN N
. . N

Patients NNS p
who WP p
were VBD p
obstructed VBN p
according VBG p
to TO p
a DT p
modified VBN o
Abrams-Griffiths JJ o
nomogram NNS o
were VBD N
randomized VBN N
to TO N
5 CD i
mg NNS i
finasteride RB i
( ( i
n JJ i
= NNP i
81 CD i
) ) i
or CC i
placebo NN i
( ( i
n JJ i
= NNP i
40 CD i
) ) i
for IN i
12 CD i
months NNS i
; : i
all DT i
patients NNS i
continuing VBG i
into IN i
an DT i
open JJ i
extension NN i
received VBD i
finasteride RB i
during IN i
the DT i
second JJ i
12 CD i
months NNS i
of IN i
therapy NN i
. . i

Results NNS N
of IN N
the DT N
initial JJ N
12-month JJ N
study NN N
demonstrated VBD N
the DT N
benefit NN N
of IN N
finasteride JJ N
treatment NN N
on IN N
PFS NNP o
parameters NNS o
. . o

To TO N
examine VB N
the DT N
continuing VBG N
effects NNS N
over IN N
time NN N
, , N
an DT N
analysis NN N
of IN N
the DT N
data NNS N
from IN N
54 CD N
patients NNS N
who WP N
completed VBD N
24 CD N
months NNS N
of IN N
treatment NN N
with IN N
finasteride NN N
is VBZ N
provided VBN N
. . N

RESULTS NNP N
Detrusor NNP o
pressure NN o
at IN N
maximum JJ N
flow NN N
( ( o
PdetQmax NNP o
) ) o
continued VBD N
to TO N
decrease VB N
during IN N
the DT N
second JJ N
12 CD N
months NNS N
of IN N
therapy NN N
( ( N
decreases NNS N
of IN N
5.3 CD N
and CC N
11.7 CD N
cm NN N
H2O NNP N
at IN N
months NNS N
12 CD N
and CC N
24 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
percentage NN N
of IN N
patients NNS N
obstructed VBN N
by IN N
Abrams-Griffiths NNP o
classification NN o
decreased VBD N
from IN N
76.2 CD N
% NN N
at IN N
baseline NN N
to TO N
66.7 CD N
% NN N
at IN N
month NN N
12 CD N
and CC N
59.6 CD N
% NN N
at IN N
month NN N
24 CD N
. . N

An DT N
intention-to-treat JJ N
analysis NN N
yielded VBD N
similar JJ N
results NNS N
. . N

CONCLUSIONS NNP N
Finasteride NNP N
improves VBZ N
urodynamic JJ N
measures NNS N
of IN N
obstruction NN N
in IN N
men NNS p
with IN p
BPE NNP p
and CC p
LUTS NNP p
, , N
with IN N
continued JJ N
improvement NN N
during IN N
the DT N
second JJ N
12 CD N
months NNS N
of IN N
therapy NN N
. . N

-DOCSTART- -24534682- O O

Evaluation NN N
of IN N
an DT N
interactive JJ N
multi-media NN N
device NN N
for IN N
delivering VBG N
information NN N
on IN N
Le NNP N
Fort NNP N
I PRP N
osteotomy VBP N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out RP N
on IN N
volunteers NNS p
to TO N
evaluate VB N
a DT N
newly RB N
developed VBN N
interactive JJ N
software NN N
package NN N
aimed VBN N
at IN N
informing VBG N
prospective JJ p
Le NNP p
Fort NNP p
I PRP p
osteotomy VBP p
patients NNS p
regarding VBG N
the DT N
surgical JJ N
technique NN N
and CC N
possible JJ N
complications NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
two CD N
methods NNS N
of IN N
information NN N
delivery NN N
; : N
a DT i
multi-media JJ i
tablet NN i
device NN i
delivering VBG i
both DT i
graphic JJ i
and CC i
verbal JJ i
information NN i
, , i
and CC i
an DT i
audio JJ i
device NN i
delivering VBG i
essentially RB i
the DT i
same JJ i
information NN i
in IN i
verbal JJ i
form NN i
only RB i
. . i

The DT N
null JJ N
hypothesis NN N
was VBD N
that IN N
there EX N
would MD N
be VB N
no DT N
difference NN N
between IN N
the DT N
efficiencies NNS o
of IN N
the DT N
two CD N
methods NNS N
. . N

The DT N
subjects NNS N
' POS N
ability NN o
to TO o
recall VB o
the DT o
information NN o
delivered VBN N
by IN N
both DT N
devices NNS N
was VBD N
assessed VBN N
using VBG N
a DT N
questionnaire NN N
. . N

The DT N
tablet NN N
device NN N
participants NNS N
scored VBD N
an DT N
average NN N
of IN N
15.48 CD N
points NNS N
, , N
while IN N
the DT N
audio JJ N
device NN N
participants NNS N
scored VBD N
an DT N
average NN N
of IN N
268 CD N
points NNS N
. . N

The DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
suggesting VBG N
that IN N
the DT N
multi-media JJ N
tablet NN N
device NN N
was VBD N
more RBR N
effective JJ N
method NN N
. . N

-DOCSTART- -24934732- O O

A DT N
randomized VBN N
, , N
prospective JJ N
, , N
parallel JJ N
group NN N
study NN N
of IN N
laparoscopic NN i
versus NN i
laparoendoscopic NN i
single JJ i
site NN i
donor NN i
nephrectomy NN i
for IN p
kidney NN p
donation NN p
. . p

Few JJ N
prospective JJ N
, , N
randomized JJ N
studies NNS N
have VBP N
assessed VBN N
the DT N
benefits NNS o
of IN N
laparoendoscopic NN i
single JJ i
site NN i
donor NN i
nephrectomy NN i
( ( i
LESS-DN NNP i
) ) i
over IN N
laparoscopic NN i
donor JJ i
nephrectomy NN i
( ( i
LDN NNP i
) ) i
. . i

Our PRP$ p
center NN p
initiated VBD p
such PDT p
a DT p
trial NN p
in IN p
January NNP p
2011 CD p
, , p
following VBG p
subjects NNS p
randomized VBN p
to TO p
LESS-DN NNP i
versus NN i
LDN NNP i
from IN p
surgery NN p
through IN p
5 CD p
years NNS p
postdonation NN p
. . p

Subjects VBZ N
complete JJ N
recovery/satisfaction NN o
questionnaires NNS o
at IN N
2 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
postdonation NN N
; : N
transplant JJ N
recipient NN N
outcomes NNS N
are VBP N
also RB N
recorded VBN N
. . N

One CD p
hundred JJ p
subjects NNS p
( ( p
49 CD p
LESS-DN NNP i
, , p
51 CD p
LDN NNP i
) ) i
underwent NN p
surgery NN p
; : p
donor CC p
demographics NNS p
were VBD p
similar JJ p
between IN p
groups NNS p
, , p
and CC p
included VBD p
a DT p
predominance NN p
of IN p
female JJ p
, , p
living-unrelated JJ p
donors NNS p
, , p
mean JJ p
age NN p
of IN p
47 CD p
years NNS p
who WP p
underwent VBP p
left VBN p
donor JJ p
nephrectomy NN p
. . p

Operative JJ p
parameters NNS p
( ( o
overall JJ o
time NN o
, , o
time NN o
to TO o
extraction NN o
, , o
warm JJ o
ischemia NN o
time NN o
, , o
blood NN o
loss NN o
) ) o
were VBD p
similar JJ p
between IN p
groups NNS p
. . p

Conversion NN o
to TO o
hand-assist JJ o
laparoscopy NN o
was VBD N
required VBN N
in IN N
3 CD N
LESS-DN JJ i
( ( N
6.1 CD N
% NN N
) ) N
versus NN N
2 CD N
LDN NNP i
( ( N
3.9 CD N
% NN N
; : N
p CC N
= VB N
0.67 CD N
) ) N
. . N

Questionnaires VBZ N
revealed VBD N
that IN N
97.2 CD N
% NN i
of IN i
LESS-DN NNP i
versus FW i
79.5 CD N
% NN i
of IN i
LDN NNP i
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
were VBD N
100 CD N
% NN o
recovered VBN o
by IN o
2 CD o
months NNS o
after IN N
donation NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
in IN N
satisfaction NN o
scores NNS o
between IN N
the DT N
groups NNS N
. . N

Recipient JJ o
outcomes NNS o
were VBD o
similar JJ o
between IN N
groups NNS N
. . N

Our PRP$ N
randomized JJ N
trial NN N
comparing VBG N
LESS NNP N
donor JJ N
nephrectomy NN i
to TO i
LDN VB i
confirms NNS N
that IN i
LESS-DN NNP i
offers VBZ N
a DT N
safe JJ o
alternative NN N
to TO N
conventional JJ N
LDN NNP N
in IN N
terms NNS N
of IN N
intra- JJ N
and CC N
post-operative JJ N
complications NNS i
. . i

LDN NNP i
and CC i
LESS-DN NNP i
offer VBP N
similar JJ N
recovery NN o
and CC o
satisfaction NN o
after IN o
donation NN o
. . N

-DOCSTART- -8908106- O O

Ganciclovir NNP i
use NN N
during IN N
mild JJ p
renal JJ o
failure NN o
in IN p
heart NN i
transplantation NN i
. . i

-DOCSTART- -9393422- O O

The DT N
influence NN N
of IN N
preoperative JJ N
antibiotics NNS i
on IN N
success NN o
of IN N
endosseous JJ i
implants NNS i
up IN p
to TO p
and CC p
including VBG p
stage NN p
II NNP p
surgery NN p
: : p
a DT p
study NN p
of IN p
2,641 CD p
implants NNS p
. . p

According VBG N
to TO N
the DT N
American NNP N
College NNP N
of IN N
Surgeons NNP N
, , N
complex JJ N
oral JJ N
surgical JJ N
procedures NNS N
, , N
including VBG N
the DT N
transoral JJ N
placement NN N
of IN N
endosseous JJ p
implants NNS p
, , N
are VBP N
of IN N
the DT N
type NN N
that WDT N
may MD N
require VB N
prophylactic JJ i
antibiotics NNS i
. . i

However RB N
, , N
the DT N
routine JJ N
use NN N
of IN N
prophylactic JJ i
antibiotics NNS i
in IN N
the DT N
field NN N
of IN N
dental JJ N
implantology NN N
continues VBZ N
to TO N
be VB N
controversial JJ N
, , N
and CC N
their PRP$ N
utilization NN N
varies NNS N
widely RB N
. . N

No UH N
data NN N
from IN N
a DT N
randomized JJ N
prospective JJ N
clinical JJ N
study NN N
of IN N
the DT N
prophylactic JJ N
use NN N
of IN N
antibiotics NNS i
in IN N
implant JJ N
surgery NN N
have VBP N
been VBN N
previously RB N
published VBN N
. . N

As IN N
part NN N
of IN N
the DT N
comprehensive JJ N
Dental NNP N
Implant NNP N
Clinical NNP N
Research NNP N
Group NNP N
clinical JJ N
implant NN N
study NN N
, , N
the DT N
preoperative NN N
or CC N
postoperative JJ N
use NN N
of IN N
antibiotics NNS i
, , N
the DT N
type NN N
used VBN N
, , N
and CC N
the DT N
duration NN N
of IN N
coverage NN N
was VBD N
left VBN N
to TO N
the DT N
discretion NN N
of IN N
the DT N
surgeon NN N
. . N

These DT N
data NNS N
were VBD N
recorded VBN N
and CC N
correlated VBN N
with IN N
failure NN o
of IN o
osseointegration NN o
during IN o
healing VBG o
( ( o
stage NN o
I PRP o
) ) o
and CC o
at IN o
stage NN o
II NNP o
surgery NN o
( ( o
uncovering VBG o
) ) o
. . o

The DT N
results NNS N
showed VBD N
that IN N
significantly RB N
fewer JJR N
failures NNS o
occurred VBD N
when WRB N
preoperative JJ N
antibiotics NNS i
were VBD N
used VBN N
. . N

-DOCSTART- -219802- O O

Estrogen NNP i
therapy NN i
for IN N
severe JJ p
persistent JJ p
depressions NNS p
in IN p
women NNS p
. . p

Positive JJ N
results NNS N
are VBP N
reported VBN N
from IN N
a DT N
double-blind JJ N
study NN N
of IN N
estrogen NN i
therapy NN i
administered VBD N
to TO N
severely RB p
depressed JJ p
, , p
inpatient JJ p
women NNS p
who WP p
had VBD p
failed VBN p
to TO p
respond VB p
to TO p
various JJ p
conventional JJ p
treatments NNS p
of IN p
depression NN p
. . p

Large JJ N
doses NNS N
of IN N
oral JJ i
conjugated VBN i
estrogen NN i
were VBD N
administered VBN N
for IN N
a DT N
three-month JJ N
period NN N
to TO N
23 CD p
premenopausal NN p
and CC p
postmenopausal JJ p
inpatient JJ p
women NNS p
. . p

Placebos NNS i
were VBD N
administered VBN N
for IN N
a DT N
comparable JJ N
period NN N
to TO N
17 CD p
similar JJ p
patients NNS p
. . p

The DT N
posttreatment JJ o
Hamilton NNP o
ratings NNS o
of IN o
depression NN o
were VBD N
significantly RB N
reduced VBN o
in IN N
the DT N
estrogen-treated JJ i
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
placebo NN i
group NN N
. . N

Possible JJ N
physiological JJ N
mechanisms NNS N
are VBP N
discussed VBN N
. . N

The DT N
risk-benefit JJ o
ratio NN o
for IN N
estrogen NN i
therapy NN i
of IN N
depression NN o
in IN N
these DT N
patients NNS N
was VBD N
judged VBN N
to TO N
be VB N
favorable JJ o
. . o

However RB N
, , N
periodic JJ N
endometrial JJ N
biopsies NNS N
are VBP N
required VBN N
to TO N
monitor VB N
the DT N
endometrial JJ N
response NN N
of IN N
women NNS p
receiving VBG p
high JJ p
doses NNS p
of IN p
estrogens NNS i
. . i

-DOCSTART- -2073645- O O

Alinidine NNP i
in IN N
chronic JJ p
stable JJ p
angina NN p
: : p
the DT N
effect NN N
on IN N
diastolic JJ o
perfusion NN o
time NN o
. . o

The DT N
present JJ N
study NN N
has VBZ N
been VBN N
performed VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
alinidine NN i
on IN N
diastolic JJ N
duration NN N
during IN N
exercise NN N
in IN N
chronic JJ p
coronary JJ p
artery NN p
disease NN p
. . p

Twelve VB p
male NN p
patients NNS p
with IN p
stable JJ p
effort NN p
angina NN p
and CC p
without IN p
previous JJ p
myocardial JJ p
infarction NN p
were VBD p
studied VBN p
. . p

They PRP N
received VBD N
alinidine NN i
or CC i
placebo NN i
in IN N
a DT N
double-blind JJ N
randomized JJ N
crossover NN N
trial NN N
for IN N
3 CD N
days NNS N
after IN N
a DT N
wash-out JJ N
period NN N
of IN N
4 CD N
days NNS N
. . N

Alinidine NNP i
was VBD N
administered VBN N
at IN N
a DT N
dosage NN N
of IN N
30 CD N
mg NN N
3 CD N
times NNS N
a DT N
day NN N
. . N

At IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
the DT N
patients NNS N
underwent JJ N
upright JJ i
bicycle NN i
exercise NN i
. . i

Left NNP o
ventricular JJ o
time NN o
intervals NNS o
were VBD N
obtained VBN o
by IN N
means NNS N
of IN N
carotid NN o
thermistor NN o
plethysmography NN o
. . o

Diastolic NNP o
duration NN o
was VBD N
calculated VBN o
by IN o
subtracting VBG o
the DT o
electromechanical JJ o
systole NN o
from IN o
the DT o
R-R NNP o
interval NN o
and CC o
expressed VBD o
as IN o
a DT o
percentage NN o
of IN o
the DT o
cardiac JJ o
cycle NN o
( ( o
% NN o
D NNP o
) ) o
. . o

Alinidine NN i
increased VBD N
both DT N
total JJ o
exercise NN o
duration NN o
from IN N
246.7 CD N
+/- JJ N
120.7 CD N
to TO N
346.6 CD N
+/- JJ N
114.1 CD N
s NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
time NN o
to TO o
0.1-mV JJ o
ST NNP o
segment NN o
depression NN o
from IN N
98.3 CD N
+/- JJ N
53 CD N
to TO N
187.2 CD N
+/- JJ N
105 CD N
s NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Similarly RB N
the DT N
drug NN N
induced VBD o
a DT o
reduction NN o
of IN o
the DT o
rate-pressure JJ o
product NN o
and CC N
of IN N
the DT N
extent NN o
of IN o
ischemic JJ o
ST NNP o
segment NN o
depression NN o
during IN N
exercise NN N
. . N

% NN o
D NNP o
was VBD N
increased VBN N
by IN N
alinidine JJ N
both DT N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
. . N

A DT N
direct JJ N
linear JJ o
regression NN o
between IN N
R-R NNP N
and CC N
% NN N
D NNP N
was VBD N
found VBN N
after IN N
both DT N
alinidine NN i
and CC N
placebo NN i
treatments NNS N
either CC N
at IN N
rest NN N
or CC N
during IN N
exercise NN N
. . N

Nevertheless NNP N
, , N
no DT o
difference NN o
was VBD o
observed VBN o
between IN o
both DT o
slopes NNS o
and CC o
intercepts NNS o
. . o

Therefore RB N
, , N
since IN N
the DT N
relationship NN o
between IN o
R-R NNP o
interval NN o
and CC o
% NN o
D NNP o
was VBD N
unaffected VBN N
by IN N
alinidine NN i
, , N
it PRP N
was VBD N
possible JJ N
to TO N
hypothesize VB N
that IN N
the DT N
changes NNS N
in IN N
diastolic JJ o
duration NN o
were VBD N
due JJ N
only RB N
to TO N
the DT N
bradycardic JJ N
action NN N
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -21484217- O O

Influence NN N
of IN N
two CD N
different JJ N
flap NNS N
designs NNS N
on IN N
the DT N
sequelae NN N
of IN N
mandibular JJ p
third JJ p
molar JJ p
surgery NN p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
influence NN N
of IN N
triangular NN N
and CC N
envelope NN N
flaps NNS N
on IN N
trismus NN o
, , o
pain NN o
, , o
and CC o
facial JJ o
swelling NN o
after IN N
mandibular JJ p
third JJ p
molar JJ p
surgery NN p
. . p

METHODS NNP N
Twenty NNP p
healthy JJ p
patients NNS p
with IN p
bilateral JJ p
, , p
symmetrically RB p
impacted JJ p
mandibular JJ p
third JJ p
molars NNS p
were VBD N
included VBN N
in IN N
this DT N
double-blinded JJ N
, , N
prospective JJ N
, , N
cross-over JJ N
, , N
randomized VBN N
study NN N
. . N

The DT N
patients NNS N
were VBD N
operated VBN i
with IN i
envelope NN i
flap NN i
on IN i
one CD i
side NN i
and CC i
triangular JJ i
flap NN i
on IN i
the DT i
other JJ i
side NN i
. . i

Trismus NNP o
was VBD i
determined VBN i
by IN i
measuring VBG i
maximum JJ i
interincisal JJ i
opening NN i
, , i
and CC i
facial JJ o
swelling NN o
was VBD i
evaluated VBN i
using VBG i
a DT i
tape NN i
measuring VBG i
method NN i
. . i

Pain NNP o
was VBD N
determined VBN N
using VBG N
visual JJ i
analog NN i
scale NN i
( ( i
VAS NNP i
) ) i
and CC i
recording VBG i
the DT i
number NN i
of IN i
pain NN i
pills NNS i
taken VBN i
. . i

RESULTS VB N
The DT N
facial JJ o
swelling NN o
measurements NNS o
and CC o
VAS NNP o
scores NNS o
were VBD N
lower JJR N
in IN N
the DT N
envelope NN N
flap NN N
group NN N
compared VBN N
to TO N
the DT N
triangular JJ N
flap NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
flap NN N
designs NNS N
in IN N
operation NN o
time NN o
, , o
maximum JJ o
interincisal NN o
opening NN o
, , o
and CC o
the DT o
number NN o
of IN o
analgesics NNS o
taken VBN o
. . o

CONCLUSION NNP N
Envelope NNP N
flap VBP N
yields NNS N
to TO N
less VB N
facial JJ o
swelling NN o
and CC N
reduced JJ N
VAS NNP o
scores NNS o
in IN N
comparison NN N
to TO N
triangular VB N
flap NN N
. . N

There EX N
is VBZ N
no DT N
clinical JJ N
difference NN N
in IN N
trismus NN N
between IN N
the DT N
two CD N
flap NN N
designs NNS N
. . N

Despite IN N
the DT N
higher JJR N
VAS NNP N
scores NNS N
with IN N
triangular JJ N
flap NN N
, , N
no DT N
additional JJ N
doses NNS N
of IN N
analgesics NNS N
were VBD N
required VBN N
in IN N
triangular JJ N
flap NN N
. . N

-DOCSTART- -21118369- O O

Removal NN N
of IN N
humoral JJ N
mediators NNS N
and CC N
the DT N
effect NN N
on IN N
the DT N
survival NN N
of IN N
septic JJ p
patients NNS p
by IN N
hemoperfusion NN i
with IN N
neutral JJ N
microporous JJ N
resin NN N
column NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
neutral JJ i
microporous JJ i
resin NN i
hemoperfusion NN i
on IN N
hemodynamic JJ N
improvement NN N
, , N
removal NN N
of IN N
inflammatory JJ N
cytokines NNS N
, , N
and CC N
mortality NN N
in IN N
critical JJ p
care NN p
patients NNS p
with IN p
severe JJ p
sepsis NN p
. . p

Forty-four CD p
patients NNS p
with IN p
severe JJ p
sepsis NN p
or CC p
septic JJ p
shock NN p
were VBD N
randomized VBN N
to TO N
HA NNP i
type NN i
hemoperfusion NN i
treatment NN i
( ( N
N=24 NNP N
) ) N
or CC i
standard JJ i
therapy NN i
( ( N
N=20 NNP N
) ) N
. . N

Those DT N
undergoing JJ N
hemoperfusion NN N
treatment NN N
received VBD N
HA330 NNP i
hemoperfusion NN i
. . i

We PRP N
measured VBD N
the DT N
plasma JJ o
concentrations NNS o
of IN o
IL-6 NNP o
and CC N
IL-8 NNP o
at IN N
the DT N
start NN N
of IN N
every DT N
hemoperfusion NN N
treatment NN N
, , N
and CC N
the DT N
following JJ N
parameters NNS N
were VBD N
compared VBN N
between IN N
the DT N
control NN N
group NN N
and CC N
the DT N
hemoperfusion NN i
group NN N
on IN N
days NNS N
3 CD N
, , N
7 CD N
, , N
and CC N
14 CD N
: : N
hemodynamics NNS o
( ( o
cardiac JJ o
index NN o
, , o
systemic JJ o
vascular NN o
resistance NN o
index NN o
, , o
heart NN o
rate NN o
, , o
and CC o
mean JJ o
arterial JJ o
pressure NN o
) ) o
; : o
change NN o
of IN o
hematology NN o
and CC o
coagulation NN o
function NN o
; : o
organ JJ o
function NN o
; : o
and CC N
the DT N
sequential JJ o
organ JJ o
failure NN o
assessment NN o
( ( o
SOFA NNP o
) ) o
score NN o
. . o

Hospital NNP o
, , o
28-day JJ o
, , o
and CC o
ICU NNP o
mortality NN o
were VBD N
also RB N
observed VBN N
. . N

Patients NNS N
treated VBD N
with IN N
HA NNP i
hemoperfusion NN i
showed VBD N
a DT N
significant JJ o
removal NN o
of IN N
plasma JJ o
IL-6 NNP o
and CC o
IL-8 NNP o
over IN N
time NN N
while IN N
in IN N
the DT N
study NN N
. . N

Patients NNS N
in IN N
the DT N
HA NNP N
group NN N
also RB N
demonstrated VBD N
significant JJ o
increases NNS o
in IN N
cardiac JJ o
index NN o
, , o
systemic JJ o
vascular NN o
resistant JJ o
index NN o
, , o
fast RB o
withdrawal NN o
of IN o
vasoactive JJ o
agents NNS o
and CC o
decreases NNS o
in IN o
heart NN o
rate NN o
compared VBN N
with IN N
the DT N
controls NNS N
at IN N
days NNS N
3 CD N
and CC N
7 CD N
. . N

Although IN N
there EX N
was VBD N
no DT N
significant JJ o
difference NN o
between IN N
the DT N
groups NNS N
in IN N
organ JJ o
dysfunction NN o
as IN N
assessed VBN N
by IN N
SOFA NNP o
scores NNS o
from IN N
day NN N
0 CD N
( ( N
baseline NN N
) ) N
to TO N
day NN N
7 CD N
, , N
significant JJ N
improvement NN N
can MD N
be VB N
demonstrated VBN N
in IN N
the DT N
hemoperfusion NN N
group NN N
at IN N
day NN N
14 CD N
. . N

There EX N
was VBD N
no DT N
significant JJ o
difference NN o
between IN N
the DT N
groups NNS N
in IN N
28-day JJ o
mortality NN o
, , o
hospital JJ o
mortality NN o
, , o
or CC o
length NN o
of IN o
hospital NN o
stay NN o
, , o
but CC o
ICU NNP o
mortality NN o
and CC o
the DT o
length NN o
of IN o
ICU NNP o
stay NN o
in IN N
the DT N
HA NNP N
group NN N
were VBD N
markedly RB N
reduced VBN o
. . o

Hemoperfusion NNP N
treatment NN N
using VBG N
the DT N
HA NNP N
type NN N
cartridge NN N
in IN N
sepsis NN N
is VBZ N
safe JJ N
and CC N
it PRP N
may MD N
improve VB N
organ JJ o
dysfunction NN o
, , o
ICU NNP o
mortality NN o
, , o
and CC o
shorten VB o
the DT o
length NN o
of IN o
ICU NNP o
stay NN o
. . o

Clinical JJ N
significant JJ N
removal NN N
of IN N
inflammatory JJ N
cytokines NNS N
such JJ N
as IN N
IL-6 NNP o
and CC o
IL-8 NNP o
from IN N
circulation NN N
by IN N
hemoperfusion NN i
may MD N
contribute VB N
to TO N
improving VBG N
a DT N
patient NN N
's POS N
outcome NN N
in IN N
an DT N
ICU NNP N
. . N

-DOCSTART- -15571828- O O

Use NNP N
of IN N
abciximab NN i
prior RB N
to TO N
primary JJ i
angioplasty NN i
in IN N
STEMI NNP p
results NNS N
in IN N
early JJ N
recanalization NN o
of IN o
the DT o
infarct-related JJ o
artery NN o
and CC N
improved VBN N
myocardial JJ o
tissue NN o
reperfusion NN o
- : N
results NNS N
of IN N
the DT N
Austrian JJ p
multi-centre JJ p
randomized VBN p
ReoPro-BRIDGING NN p
Study NNP p
. . p

AIMS NNP N
The DT N
aim NN N
of IN N
the DT N
ReoPro-BRIDGING JJ p
Austrian JJ p
multi-centre NN p
study NN p
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
abciximab NN i
( ( i
ReoPro NNP i
) ) i
on IN N
early JJ o
reperfusion NN o
in IN o
ST-elevation NNP o
myocardial JJ o
infarction NN o
prior RB N
to TO N
or CC N
during IN N
primary JJ N
percutaneous JJ i
coronary JJ i
angioplasty NN i
( ( i
pPCI NN i
) ) i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
Fifty-five JJ p
patients NNS p
with IN p
STEMI NNP p
were VBD p
randomized VBN p
either RB p
to TO p
start VB p
abciximab NN i
( ( p
0.25 CD p
mg/kg NN p
bolus NN p
followed VBN p
by IN p
10 CD p
microg/min NNS p
infusion NN p
) ) p
during IN p
the DT p
organization NN p
phase NN p
for IN p
pPCI NN p
( ( p
Group NNP p
1 CD p
, , p
n=28 NN p
) ) p
or CC p
immediately RB p
before IN p
pPCI NN p
( ( p
Group NNP p
2 CD p
, , p
n=27 NN p
) ) p
. . p

The DT N
time NN N
between IN N
first JJ N
bolus NN N
of IN N
abciximab NN i
and CC N
first JJ N
balloon NN N
inflation NN N
of IN N
pPCI NN N
was VBD N
83+/-18 JJ N
vs JJ N
21+/-13 JJ N
min NN N
in IN N
Group NNP N
1 CD N
vs NN N
2 CD N
. . N

The DT N
pre-pPCI JJ o
ST-segment JJ o
resolution NN o
( ( N
55+/-21.4 CD N
% NN N
vs JJ N
42.4+/-18.2 CD N
% NN N
, , N
p=0.005 NN N
) ) N
, , N
TIMI NNP o
flow NN o
grade VBD o
3 CD o
( ( N
29 CD N
% NN N
vs JJ N
7 CD N
% NN N
, , N
p=0.042 NN N
) ) N
, , N
corrected VBN N
TIMI NNP o
frame NN o
count NN o
( ( N
58.4+/-32.7 JJ N
vs NN N
78.9+/-28.4 JJ N
frame NN N
, , N
p=0.018 NN N
) ) N
% NN o
diameter JJ o
stenosis NN o
( ( N
76.3 CD N
/63.5-100/ JJ N
vs NN N
100 CD N
/73.5-100/ NN N
; : N
median JJ N
/interquartile NN N
range/ NN N
, , N
p=0.023 NN N
) ) N
, , N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
1 CD N
vs NN N
Group NNP N
2 CD N
. . N

Quantitative JJ N
myocardial JJ N
dye NN N
intensity NN N
measurement NN N
revealed VBD N
a DT N
significantly RB N
higher JJR N
grade NN N
of IN N
myocardial JJ o
tissue NN o
perfusion NN o
( ( N
1 CD N
/0-9.25/ JJ N
vs NN N
0 CD N
/0-3.0/ JJ N
grey NNS N
pixel JJ N
unit NN N
, , N
p=0.048 NN N
) ) N
in IN N
Group NNP N
1 CD N
before IN N
pPCI NN N
. . N

Rapid JJ N
release NN N
of IN N
cardiac JJ o
enzymes NNS o
was VBD N
observed VBN N
in IN N
Group NNP N
1 CD N
as IN N
compared VBN N
with IN N
Group NNP N
2 CD N
: : N
rate NN N
of IN N
rise NN o
of IN o
CK NNP o
was VBD N
210+/-209 JJ N
vs JJ N
97+/-95 CD N
U/l/h NNP N
( ( N
p=0.015 NN N
) ) N
. . N

QRS NNP o
score RB o
indicated VBD N
a DT N
smaller JJR N
infarct NN o
size NN o
in IN N
Group NNP N
1 CD N
( ( N
4.8+/-3.8 JJ N
vs NN N
7.6+/-3.5 CD N
, , N
p=0.011 NN N
) ) N
on IN N
day NN N
7 CD N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
abciximab NN N
in IN N
the DT N
organization NN N
phase NN N
for IN N
pPCI JJ N
results NNS N
in IN N
signs NNS o
of IN o
early JJ o
recanalization NN o
of IN o
the DT o
infarct-related JJ o
artery NN o
and CC N
a DT N
subsequent JJ N
improved VBN N
myocardial JJ o
tissue NN o
reperfusion NN o
. . o

-DOCSTART- -15472677- O O

Endoscopic NNP i
sphincterotomy NN i
by IN N
using VBG N
pure-cut JJ i
electrosurgical JJ i
current JJ i
and CC N
the DT N
risk NN N
of IN N
post-ERCP JJ p
pancreatitis NN p
: : p
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND VB N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
pure-cut JJ N
electrosurgical JJ N
current JJ N
for IN N
endoscopic JJ N
sphincterotomy NN i
may MD N
reduce VB N
the DT N
risk NN N
of IN N
post-ERCP JJ p
pancreatitis NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
pure-cut JJ i
current JJ i
reduces VBZ N
the DT N
risk NN N
of IN N
pancreatitis NN o
compared VBN N
with IN N
blend JJ N
current JJ N
. . N

METHODS NN N
Patients NNPS p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
sphincterotomy NN i
over IN i
a DT i
non-conductive JJ i
guidewire NN i
with IN i
30 CD i
W/sec NNP i
pure-cut JJ i
current JJ i
or CC i
30 CD i
W/sec JJ i
blend-2 JJ i
current JJ i
by IN i
a DT i
blinded JJ i
endoscopist NN i
. . i

Serum NNP N
amylase NN N
and CC N
lipase NN N
levels NNS N
were VBD N
determined VBN N
1 CD N
day NN N
before IN N
and CC N
within IN N
24 CD N
hours NNS N
after IN N
ERCP NNP N
. . N

Post-ERCP NNP o
pancreatitis NN o
was VBD N
the DT N
primary JJ N
outcome NN N
of IN N
interest NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
as IN N
follows VBZ N
: : N
severity NN o
of IN o
immediate JJ o
bleeding NN o
, , o
as IN o
graded VBN o
by IN o
a DT o
3-point JJ o
scale NN o
from IN o
1 CD o
( ( o
no DT o
bleeding NN o
) ) o
to TO o
3 CD o
( ( o
injection NN o
or CC o
balloon NN o
tamponade JJ o
therapy NN o
required VBN o
to TO o
stop VB o
bleeding NN o
) ) o
and CC o
evidence NN o
of IN o
delayed JJ o
bleeding VBG o
24 CD o
hours NNS o
after IN o
ERCP NNP o
. . o

Analyses NNS N
were VBD N
performed VBN N
in IN N
intention-to-treat JJ N
fashion NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
246 CD p
patients NNS p
were VBD p
randomized VBN p
( ( p
116 CD p
pure-cut JJ p
current JJ p
, , p
130 CD p
blend NN p
current JJ p
) ) p
. . p

There EX N
were VBD N
no DT N
differences NNS N
in IN N
baseline NN N
characteristics NNS N
between IN N
the DT N
groups NNS N
. . N

The DT N
overall JJ N
frequency NN N
of IN N
post-ERCP JJ o
pancreatitis NN o
was VBD N
6.9 CD N
% NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
in IN N
frequency NN N
between IN N
treatment NN N
arms NNS N
( ( N
pure JJ N
cut NN N
, , N
7.8 CD N
% NN N
vs. FW N
blend NN N
, , N
6.1 CD N
% NN N
; : N
p CC N
= VB N
0.62 CD N
) ) N
. . N

The DT N
difference NN N
in IN N
rates NNS N
of IN N
pancreatitis NN o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
1.7 CD N
% NN N
: : N
95 CD N
% NN N
CI NNP N
[ NNP N
-4.8 NNP N
% NN N
, , N
8.2 CD N
% NN N
] NN N
. . N

Six CD N
patients NNS N
( ( N
2.4 CD N
% NN N
) ) N
had VBD N
delayed VBN o
bleeding NN o
after IN N
ERCP NNP N
, , N
of IN N
which WDT N
two CD N
required VBD N
transfusion NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
minor JJ o
bleeding NN o
episodes NNS o
( ( N
grade VB N
2 CD N
) ) N
in IN N
the DT N
pure-cut JJ N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Delayed NNP o
episodes IN o
of IN o
bleeding VBG o
were VBD N
equal JJ N
( ( N
n JJ N
= NNP N
3 CD N
) ) N
in IN N
each DT N
arm NN N
. . N

CONCLUSIONS VB N
The DT N
type NN N
of IN N
current JJ i
used VBN N
when WRB N
performing VBG N
endoscopic RB i
sphincterotomy NN i
does VBZ N
not RB N
appear VB N
to TO N
alter VB N
the DT N
risk NN N
of IN N
post-ERCP JJ N
pancreatitis NN N
. . N

The DT N
selection NN N
of IN N
electrosurgical JJ i
current JJ i
for IN N
biliary JJ N
endoscopic NN i
sphincterotomy NN i
should MD N
be VB N
based VBN N
on IN N
endoscopist JJ N
preference NN N
. . N

-DOCSTART- -25568377- O O

Continual JJ i
feeding NN i
of IN N
two CD N
types NNS N
of IN N
microalgal JJ i
biomass NN i
affected VBD N
protein JJ N
digestion NN N
and CC N
metabolism NN N
in IN N
laying VBG p
hens NNS p
. . p

A DT N
14-wk JJ N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
nutritional JJ N
efficacy NN o
and CC o
ssmetabolic JJ o
impact NN o
of IN N
2 CD N
types NNS N
of IN N
microalgal JJ i
biomass NN i
as IN N
alternative JJ N
protein NN N
sources NNS N
in IN N
laying VBG p
hen JJ p
diets NNS N
. . N

Shaver NNP p
hens VBZ p
( ( p
total JJ p
= NN p
150 CD p
and CC p
26 CD p
wk NNS p
old JJ p
) ) p
were VBD N
fed VBN N
1 CD N
of IN N
5 CD N
diets NNS N
: : N
a DT i
control NN i
or CC i
a DT i
defatted JJ i
green JJ i
microalgal NN i
biomass NN i
( ( i
DG NNP i
; : i
Desmodesmus NNP i
spp NN i
. . i

) ) i
at IN N
25 CD N
% NN N
and CC N
a DT i
full-fatted JJ i
diatom NN i
biomass NN i
( ( i
FD NNP i
; : i
Staurosira NNP i
spp NN i
. . i

) ) i
at IN N
11.7 CD N
% NN N
inclusion NN i
with IN i
or CC i
without IN i
protease NN i
. . i

This DT N
experiment NN N
consisted VBD N
of IN N
5 CD N
replicates NNS N
per IN N
treatment NN N
and CC N
each DT N
replicate NN N
contained VBD N
6 CD N
hens NNS N
individually RB N
reared VBN N
in IN N
cages NNS N
( ( N
1 CD N
hen NN N
for IN N
biochemical JJ N
data/replicate NN N
) ) N
. . N

Despite IN N
decreased JJ N
ADFI NNP N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
hens VBZ N
fed JJ N
DG NNP N
or CC N
FD NNP N
had VBD N
final JJ N
BW NNP N
, , N
overall JJ N
hen-day JJ N
egg NN N
production NN N
, , N
and CC N
egg NN N
quality NN N
similar JJ N
to TO N
the DT N
controls NNS N
. . N

Feeding VBG N
DG NNP N
or CC N
FD NNP N
did VBD N
not RB N
alter VB o
plasma JJ o
concentrations NNS o
of IN o
insulin NN o
, , o
glutamine NN o
, , o
and CC o
uric JJ o
acid NN o
or CC o
alkaline JJ o
phosphatase NN o
activity NN o
at IN N
wk $ N
8 CD N
or CC N
14 CD N
but CC N
decreased VBD N
plasma JJ o
3-methyhistine JJ o
concentrations NNS o
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
and CC N
tartrate-resistant JJ o
acid NN o
phosphatase NN o
( ( o
TRAP NNP o
) ) o
activities NNS o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
at IN N
wk $ N
14 CD N
and CC N
improved VBN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
ileal NN N
total JJ N
AA NNP N
digestibility NN N
. . N

Although IN N
DG NNP N
or CC N
FD NNP N
exhibited VBD N
moderate JJ o
effects NNS o
on IN N
intestinal JJ o
brush NN o
border NN o
protease NN o
activities NNS o
and CC o
mRNA NN o
levels NNS o
of IN o
duodenal JJ o
transporters NNS o
Pept1 NNP o
, , o
Lat1 NNP o
, , o
and CC o
Cat1 NNP o
, , N
both DT N
substantially RB N
enhanced VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
phosphorylation NN o
of IN o
hepatic JJ o
protein NN o
synthesis NN o
key JJ o
regulator NN o
S6 NNP o
ribosomal NN o
protein NN o
( ( N
S6 NNP N
) ) N
and CC N
the DT N
ratio NN N
of IN N
phospho-S6 NN N
to TO N
S6 NNP N
in IN N
the DT N
liver NN N
of IN N
hens NNS N
. . N

However RB N
, , N
DG NNP N
and CC N
FD NNP N
manifested VBD N
with IN N
different JJ N
impacts NNS N
on IN N
weights NNS o
of IN o
egg NN o
and CC o
egg NN o
albumen NNS o
, , o
proteolytic JJ o
activity NN o
of IN o
jejunal JJ o
digesta NN o
, , o
plasma JJ o
TRAP NNP o
activity NN o
, , o
ileal JJ o
total JJ o
AA NNP o
digestibility NN o
, , o
and CC o
several JJ o
intestinal JJ o
genes NNS o
and CC o
hepatic JJ o
proteins NNS o
. . o

Supplemental JJ N
protease NN N
in IN N
the DT N
DG NNP N
and CC N
FD NNP N
diets NNS N
produced VBD N
mixed JJ o
effects NNS o
on IN N
a DT N
number NN o
of IN o
measures NNS o
. . o

In IN N
conclusion NN N
, , N
our PRP$ N
findings NNS N
revealed VBD N
the DT N
feasibility NN N
of IN N
including VBG N
greater JJR N
levels NNS N
of IN N
microalgal JJ i
biomass NN i
as IN N
a DT N
source NN N
of IN N
feed NN N
protein NN N
for IN N
laying VBG p
hens NNS p
and CC N
a DT N
novel JJ N
potential NN N
of IN N
the DT N
biomass NN N
in IN N
improving VBG N
dietary JJ N
protein NN N
digestion NN N
and CC N
body NN N
protein VBP N
metabolism NN N
than IN N
previously RB N
perceived VBN N
. . N

-DOCSTART- -4016785- O O

Prospectively RB N
randomized VBN N
toxicity NN o
study NN N
of IN N
high-dose JJ N
versus NN N
low-dose JJ N
treatment NN N
strategies NNS N
for IN N
lymphoblastoid JJ i
interferon NN i
. . i

It PRP N
is VBZ N
unclear JJ N
from IN N
preliminary JJ N
laboratory NN N
studies NNS N
whether IN N
a DT N
high- NN i
or CC i
a DT i
low-dose JJ i
interferon NN i
treatment NN N
strategy NN N
is VBZ N
optimal JJ N
. . N

As IN N
part NN N
of IN N
an DT N
ongoing JJ N
study NN N
of IN N
mechanisms NNS N
of IN N
interferon NN i
action NN N
, , N
we PRP N
have VBP N
evaluated VBN N
toxicity NN o
in IN N
a DT N
two-arm JJ N
protocol NN N
in IN N
which WDT N
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
lymphoblastoid JJ i
interferon NN i
by IN N
either CC N
a DT N
low-dose JJ N
treatment NN N
strategy NN N
( ( N
2 CD N
X RB N
10 CD N
( ( N
6 CD N
) ) N
units/m2 JJ N
daily JJ N
X $ N
28 CD N
days NNS N
then RB N
daily JJ N
X NNP N
5 CD N
days NNS N
every DT N
other JJ N
week NN N
by IN N
im JJ N
injection NN N
) ) N
or CC N
a DT N
high-dose JJ N
treatment NN N
strategy NN N
( ( N
5 CD N
X RB N
10 CD N
( ( N
6 CD N
) ) N
units/m2 NN N
by IN N
continuous JJ N
iv JJ N
infusion NN N
over IN N
24 CD N
hours NNS N
, , N
escalating VBG N
by IN N
5 CD N
X NNS N
10 CD N
( ( N
6 CD N
) ) N
units/m2/day NN N
as IN N
tolerated VBN N
over IN N
10 CD N
days NNS N
, , N
repeated VBD N
every DT N
28 CD N
days NNS N
) ) N
. . N

The DT N
main JJ o
toxic NN o
effects NNS o
in IN N
both DT N
arms NNS N
were VBD N
fever RB o
, , o
fatigue NN o
, , o
and CC o
anorexia RB o
. . o

Marked JJ N
interpatient NN N
differences NNS N
within IN N
each DT N
dose JJ N
arm NN N
were VBD N
greater JJR N
than IN N
differences NNS N
between IN N
arms NNS N
. . N

Additional JJ N
significant JJ o
toxic NN o
effects NNS o
included VBD o
nausea NN o
and CC o
vomiting NN o
, , o
hypotension NN o
, , o
leukopenia NN o
, , o
thrombocytopenia NN o
, , o
and CC o
evidence NN o
of IN o
hepatic JJ o
toxicity NN o
. . o

Minor JJ N
changes NNS o
in IN o
serum NN o
electrolytes NNS o
were VBD N
noted VBN N
. . N

Coagulation NNP o
studies NNS o
were VBD N
normal JJ N
. . N

The DT N
dose-limiting JJ N
toxic NN o
effect NN o
for IN N
the DT N
high-dose JJ N
arm NN N
was VBD N
myelosuppression NN o
. . o

Median JJ N
maximum NN o
tolerated VBD o
dose JJ o
among IN N
high-dose JJ N
strategy NN N
patients NNS N
was VBD N
18 CD N
X JJ N
10 CD N
( ( N
6 CD N
) ) N
units/m2 NN N
, , N
but CC N
there RB N
was VBD N
marked VBN N
interpatient JJ N
variation NN N
. . N

We PRP N
conclude VBP N
that IN N
both DT N
dose JJ N
schedules NNS N
were VBD N
relatively RB o
well-tolerated JJ o
. . o

Because IN N
of IN N
individual JJ N
variation NN N
in IN N
tolerance NN o
, , N
high-dose JJ N
treatment NN N
should MD N
include VB N
a DT N
dose JJ N
escalation NN N
strategy NN N
. . N

-DOCSTART- -11159256- O O

The DT N
response NN N
of IN N
neuropathic JJ o
pain NN o
and CC o
pain NN o
in IN o
complex JJ o
regional JJ o
pain NN o
syndrome NN o
I PRP p
to TO N
carbamazepine VB i
and CC N
sustained-release JJ i
morphine NN i
in IN N
patients NNS p
pretreated VBN p
with IN p
spinal JJ i
cord NN i
stimulation NN i
: : i
a DT N
double-blinded JJ N
randomized NN N
study NN N
. . N

Forty-three JJ p
patients NNS p
with IN p
peripheral JJ p
neuropathic JJ p
pain NN p
, , p
exclusively RB p
pain NN p
reduced VBN p
by IN p
spinal JJ i
cord NN i
stimulation NN i
( ( i
SCS NNP i
) ) i
, , p
were VBD p
switched VBN p
into IN p
a DT p
painful JJ p
state NN p
after IN p
SCS NNP i
inactivation NN p
. . p

This DT N
mode NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
pain-relieving JJ N
effect NN N
of IN N
carbamazepine NN i
( ( i
CMZ NNP i
) ) i
and CC N
opioids NNS i
in IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

In IN N
Phase NNP N
1 CD N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
CMZ NNP i
( ( i
600 CD i
mg/d NN i
) ) i
or CC i
placebo NN i
during IN N
an DT N
SCS-free JJ N
period NN N
of IN N
8 CD N
days NNS N
. . N

In IN N
Phase NNP N
2 CD N
, , N
after IN N
a DT N
CMZ NNP i
elimination NN N
interval NN N
of IN N
7 CD N
days NNS N
, , N
38 CD N
patients NNS N
received VBD N
either RB N
sustained-release JJ i
morphine NN i
( ( i
90 CD i
mg/d NN i
) ) i
or CC i
placebo NN i
for IN N
8 CD N
days NNS N
. . N

In IN N
cases NNS N
of IN N
intolerable JJ o
pain NN o
, , N
the DT N
patients NNS N
were VBD N
authorized VBN N
to TO N
reactivate VB N
their PRP$ N
SCS NNP i
. . i

The DT N
pain NN o
intensity NN o
was VBD N
rated VBN N
on IN N
a DT N
numeric JJ o
analog NN o
scale NN o
. . o

In IN N
38 CD N
patients NNS N
who WP N
completed VBD N
Phase NNP N
1 CD N
, , N
significant JJ N
delay NN o
in IN o
pain JJ o
increase NN o
was VBD N
observed VBN N
in IN N
the DT N
CMZ NNP i
group NN N
as IN N
compared VBN N
with IN N
placebo NN i
( ( N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

In IN N
Phase NNP N
2 CD N
, , N
the DT N
trend NN N
observed VBD N
with IN N
morphine NN i
was VBD N
insignificant JJ N
( ( N
P NNP N
= NNP N
0.41 CD N
) ) N
. . N

Two CD N
CMZ JJ i
patients NNS N
and CC N
one CD N
morphine NN i
patient NN N
showed VBD N
complete JJ o
pain NN o
relief NN o
and CC N
preferred VBN N
to TO N
continue VB N
the DT N
medication NN N
. . N

Thirty-five JJ N
patients NNS N
returned VBN N
to TO N
SCS NNP i
. . i

We PRP N
conclude VBP N
that DT N
CMZ NNP i
is VBZ N
effective JJ N
in IN N
peripheral JJ N
neuropathic JJ o
pain NN o
. . o

Morphine NNP i
obviously RB N
requires VBZ N
larger JJR N
individually RB N
titrated VBD N
dosages NNS N
than IN N
those DT N
used VBN N
in IN N
this DT N
study NN N
for IN N
results NNS N
to TO N
be VB N
adequately RB N
interpreted VBN N
. . N

-DOCSTART- -9322632- O O

A DT N
comparison NN N
of IN N
intermittent JJ i
vaginal JJ i
administration NN i
of IN i
misoprostol NN i
with IN N
continuous JJ i
dinoprostone NN i
for IN N
cervical JJ o
ripening NN o
and CC o
labor NN o
induction NN o
. . o

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
vaginal JJ i
administration NN i
of IN i
misoprostol NN i
( ( i
Cytotec NNP i
) ) i
with IN N
that DT N
of IN N
dinoprostone NN i
( ( i
Cervidil NNP i
) ) i
on IN N
cervical JJ o
ripening NN o
and CC o
labor NN o
induction NN o
. . o

STUDY NNP N
DESIGN NNP N
Two CD p
hundred VBD p
patients NNS p
with IN p
indications NNS p
for IN p
induction NN p
of IN p
labor NN p
and CC p
unfavorable JJ p
cervical JJ p
examinations NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
vaginally RB N
administered VBN N
misoprostol NN i
( ( i
prostaglandin JJ i
E1 NNP i
) ) i
or CC N
the DT N
dinoprostone NN i
( ( i
prostaglandin JJ i
E2 NNP i
) ) i
vaginal NN N
insert NN N
. . N

Twenty-five JJ N
microgram JJ N
tablets NNS N
of IN N
misoprostol NN i
were VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
fornix NN N
every DT N
4 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
doses NNS N
. . N

Additional NNP N
misoprostol NN i
was VBD N
not RB N
given VBN N
after IN N
either DT N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
adequate JJ N
cervical JJ N
ripening NN N
( ( N
Bishop NNP N
score NN N
of IN N
> NN N
or CC N
= VB N
8 CD N
or CC N
cervical JJ N
dilatation NN N
of IN N
> NN N
or CC N
= $ N
3 CD N
cm NN N
) ) N
, , N
or CC N
beginning NN N
of IN N
active JJ N
labor NN N
. . N

The DT N
vaginal JJ N
insert NN N
, , N
Cervidil NNP i
, , N
containing VBG N
10 CD N
mg NN N
of IN N
dinoprostone NN i
in IN N
a DT N
timed-release JJ N
preparation NN N
was VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
formix NN N
for IN N
a DT N
maximum JJ N
period NN N
of IN N
24 CD N
hours NNS N
. . N

The DT N
vaginal JJ N
insert NN N
was VBD N
removed VBN N
for IN N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
entry NN N
into IN N
active JJ N
labor NN N
, , N
adequate JJ N
cervical JJ N
ripening NN N
, , N
or CC N
abnormality NN N
of IN N
uterine JJ N
contractile NN N
pattern NN N
or CC N
fetal JJ N
cardiac JJ N
activity NN N
. . N

RESULTS NN N
Of IN p
the DT p
200 CD p
patients NNS p
enrolled VBD p
, , p
99 CD p
were VBD p
randomized VBN p
to TO p
misoprostol VB i
and CC p
101 CD p
to TO p
dinoprostone VB i
. . i

The DT N
average JJ o
interval NN o
from IN o
start NN o
of IN o
induction NN o
to TO o
vaginal JJ o
delivery NN o
was VBD N
1 CD N
hour NN N
shorter NN N
in IN N
the DT N
misoprostol NN i
group NN N
( ( N
1296.7 CD N
+/- JJ N
722.1 CD N
minutes NNS N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN i
group NN N
( ( N
1360.0 CD N
+/- JJ N
792.0 CD N
minutes NNS N
) ) N
, , N
but CC N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.97 CD N
) ) N
. . N

Oxytocin NNP o
augmentation NN o
of IN o
labor NN o
was VBD N
used VBN N
in IN N
50 CD N
( ( N
50.5 CD N
% NN N
) ) N
misoprostol-treated JJ i
patients NNS N
and CC N
43 CD N
( ( N
43.5 CD N
% NN N
) ) N
dinoprostone-treated JJ i
patients NNS N
( ( N
relative JJ N
risk NN N
1.14 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.86 CD N
to TO N
1.51 CD N
, , N
p NN N
= NNP N
0.35 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
routes NNS o
of IN o
delivery NN o
with IN N
misoprostol NN i
or CC N
dinoprostone NN i
. . i

Overall NNP N
, , N
38 CD p
patients NNS p
( ( p
19.3 CD p
% NN p
) ) p
had VBD p
cesarean JJ o
deliveries NNS o
. . o

There EX N
was VBD N
a DT N
significantly RB N
lower JJR N
prevalence NN N
of IN N
tachysystole NN o
( ( N
six CD N
or CC N
more JJR N
uterine JJ N
contractions NNS N
in IN N
a DT N
10-minute JJ N
window NN N
for IN N
two CD N
consecutive JJ N
10-minute JJ N
periods NNS N
) ) N
in IN N
the DT N
misoprostol NN i
group NN N
( ( N
7.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN i
group NN N
( ( N
18.4 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
0.52 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.31 CD N
to TO N
0.89 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
frequency NN o
of IN o
uterine JJ o
hyperstimulation NN o
or CC o
hypertonus NN o
. . o

Abnormal NNP o
fetal JJ o
heart NN o
rate NN o
tracings NNS o
were VBD N
found VBN N
in IN N
23 CD N
( ( N
23.2 CD N
% NN N
) ) N
of IN N
misoprostol-treated JJ i
patients NNS N
and CC N
35 CD N
( ( N
35.7 CD N
% NN N
) ) N
of IN N
dinoprostone-treated JJ i
patients NNS N
( ( N
relative JJ N
risk NN N
0.73 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.52 CD N
to TO N
1.01 CD N
, , N
p NN N
= NNP N
0.0546 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
meconium NN o
passage NN o
, , N
1- JJ N
or CC N
5-minute JJ N
Apgar NNP o
scores NNS o
< VBP N
7 CD N
, , N
neonatal JJ o
resuscitations NNS o
, , o
or CC o
admissions NNS o
to TO o
the DT o
neonatal JJ o
intensive JJ o
care NN o
unit NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Vaginally NNP N
administered VBD N
misoprostol NN i
is VBZ N
as RB N
effective JJ o
as IN N
dinoprostone NN N
for IN N
cervical JJ o
ripening NN o
and CC o
the DT o
induction NN o
of IN o
labor NN o
. . o

Mean JJ o
time NN o
intervals NNS o
to TO o
delivery NN o
, , o
need NN o
for IN o
oxytocin JJ o
augmentation NN o
, , o
and CC o
routes NNS o
of IN o
delivery NN o
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Incidence NN N
of IN N
uterine JJ o
tachysystole NN o
with IN N
misoprostol NN i
every DT N
4 CD N
hours NNS N
was VBD N
significantly RB N
less JJR N
than IN N
with IN N
dinoprostone NN i
. . i

-DOCSTART- -15098782- O O

Improved VBN o
intraoperative JJ o
management NN o
of IN N
anastomotic JJ o
bleeding NN o
during IN p
aortic JJ p
reconstruction NN p
: : p
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
the DT N
effectiveness NN o
of IN N
a DT N
polymeric JJ i
surgical JJ i
sealant NN i
( ( i
CoSeal NNP i
) ) i
was VBD N
compared VBN i
to TO i
Gelfoam/thrombin NNP i
for IN i
managing VBG i
anastomotic JJ o
bleeding NN o
after IN i
implantation NN i
of IN i
Dacron NNP i
grafts NNS i
during IN i
aortic JJ i
reconstruction NN i
for IN i
nonruptured JJ i
aneurysms NNS i
. . i

Each DT i
treatment NN i
was VBD i
directly RB i
applied VBN i
to TO i
the DT i
suture NN i
line NN i
after IN i
confirmation NN i
of IN i
anastomotic JJ i
bleeding NN i
. . i

The DT N
proportion NN N
of IN N
suture NN N
line NN N
sites VBZ N
that IN N
achieved VBD N
immediate JJ o
sealing NN o
and CC N
the DT N
proportion NN N
sealed VBD N
within IN N
5 CD N
minutes NNS N
were VBD N
determined VBN N
among IN N
37 CD p
experimental JJ p
( ( p
59 CD p
sites NNS p
) ) p
and CC p
17 CD p
control NN p
subjects NNS p
( ( p
27 CD p
sites NNS p
) ) p
. . p

A DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
bleeding VBG N
suture NN N
line NN N
sites NNS N
treated VBD N
with IN N
the DT N
polymeric JJ i
sealant NN i
achieved VBN N
immediate JJ o
sealing NN o
following VBG N
reestablishment NN N
of IN N
blood NN N
flow NN N
compared VBN N
with IN N
control-treated JJ N
sites NNS N
[ VBP N
48 CD N
of IN N
59 CD N
( ( N
81 CD N
% NN N
) ) N
vs VBZ N
10 CD N
of IN N
27 CD N
( ( N
37 CD N
% NN N
) ) N
; : N
P NNP N
= VBD N
0.002 CD N
] NN N
. . N

The DT N
difference NN N
between IN N
treatment NN N
groups NNS N
was VBD N
maintained VBN N
after IN N
5 CD N
minutes NNS N
with IN N
approximately RB N
85 CD N
per IN N
cent NN N
( ( N
50 CD N
of IN N
59 CD N
) ) N
of IN N
CoSeal NNP i
sites NNS N
compared VBN N
to TO N
just RB N
over IN N
one-half JJ N
( ( N
14 CD N
of IN N
27 CD N
) ) N
of IN N
control NN N
sites VBZ N
demonstrating VBG N
ultimate JJ o
sealing NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
adverse JJ N
events NNS N
related VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
polymeric JJ i
sealant NN i
in IN N
this DT N
study NN N
. . N

These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
novel JJ N
sealant NN N
for IN N
the DT N
intraoperative JJ p
management NN p
of IN p
anastomotic JJ p
bleeding NN p
during IN p
aortic JJ p
reconstruction NN p
procedures NNS p
. . p

-DOCSTART- -16555138- O O

The DT N
gluten-free JJ i
, , i
casein-free JJ i
diet NN i
in IN N
autism NN p
: : p
results NNS N
of IN N
a DT N
preliminary JJ N
double NN N
blind VB N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
efficacy NN N
of IN N
a DT N
gluten-free JJ i
and CC i
casein-free JJ i
( ( i
GFCF NNP i
) ) i
diet NN i
in IN N
treating VBG N
autism NN p
using VBG N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
repeated VBD N
measures NNS N
crossover RB N
design NN N
. . N

The DT N
sample NN N
included VBD N
15 CD p
children NNS p
aged VBN p
2-16 CD p
years NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Data NNP N
on IN N
autistic JJ o
symptoms NNS o
and CC o
urinary JJ o
peptide NN o
levels NNS o
were VBD N
collected VBN N
in IN N
the DT N
subjects NNS N
' POS N
homes NNS N
over IN N
the DT N
12 CD N
weeks NNS N
that IN N
they PRP N
were VBD N
on IN N
the DT N
diet JJ N
. . N

Group NNP N
data VBD N
indicated VBD N
no DT N
statistically RB N
significant JJ N
findings NNS N
even RB N
though IN N
several JJ N
parents NNS N
reported VBD N
improvement NN o
in IN N
their PRP$ N
children NNS N
. . N

Although IN N
preliminary JJ N
, , N
this DT N
study NN N
demonstrates VBZ N
how WRB N
a DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
the DT N
GFCF NNP i
diet NN i
can MD N
be VB N
conducted VBN N
, , N
and CC N
suggests VBZ N
directions NNS N
for IN N
future JJ N
research NN N
. . N

-DOCSTART- -19207322- O O

Comparison NNP N
of IN N
injection NN o
comfort NN o
of IN N
a DT N
new JJ N
category NN N
of IN N
cohesive JJ p
hyaluronic JJ i
acid NN i
filler NN i
with IN N
preincorporated JJ N
lidocaine NN i
and CC N
a DT N
hyaluronic JJ i
acid NN i
filler NN i
alone RB i
. . i

BACKGROUND VB N
A DT N
smooth JJ N
, , N
cohesive JJ N
, , N
24-mg/mL JJ N
hyaluronic JJ i
acid NN i
( ( i
HA NNP i
) ) i
gel NN i
with IN N
uniform JJ N
consistency NN N
, , N
even RB N
flow JJ N
characteristics NNS N
, , N
and CC N
extended VBD N
duration NN N
was VBD N
designed VBN N
for IN N
injection NN N
into IN N
the DT N
mid NN N
to TO N
deep VB N
dermis NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
injection NN N
pain NN N
of IN N
a DT N
HA NNP i
gel NN i
with IN i
preincorporated JJ i
lidocaine NN i
with IN N
that DT N
with IN N
a DT N
non-lidocaine JJ N
formulation NN N
. . N

METHODS NNP N
& CC N
MATERIALS NNP N
This DT N
double-blind NN N
study NN N
at IN N
three CD p
centers NNS p
enrolled VBD p
60 CD p
subjects NNS p
, , p
injected VBN p
with IN p
both DT p
products NNS p
, , p
randomly RB p
assigned VBN p
to TO p
left VBD p
or CC p
right JJ p
nasolabial JJ p
fold NN p
. . p

The DT N
injecting VBG N
physician NN N
assessed VBD N
severity NN N
of IN N
pain NN o
and CC N
ease NN o
of IN o
injection NN o
. . o

Subjects NNS p
used VBD p
a DT p
visual JJ p
analog NN p
scale NN p
( ( p
0-10 JJ p
) ) p
for IN p
pain NN p
assessment NN p
. . p

Adverse JJ N
events NNS N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Physician JJ N
assessment NN N
of IN N
injection NN o
pain NN o
was VBD N
none NN N
or CC N
mild NN N
in IN N
81 CD N
% NN N
of IN N
HA NNP N
gel NN N
injections NNS N
with IN N
preincorporated JJ N
lidocaine NN i
and CC N
36 CD N
% NN N
of IN N
HA-alone NNP N
injections NNS N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Mean NNP o
pain NN o
assessment NN o
by IN N
subjects NNS N
was VBD N
3.6 CD N
for IN N
HA+lidocaine NNP N
and CC N
5.8 CD N
for IN N
HA NNP N
alone RB N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Ninety-five JJ N
percent NN N
of IN N
the DT N
injections NNS N
were VBD N
considered VBN N
easy JJ N
or CC N
very RB N
easy JJ N
; : N
a DT N
greater JJR N
percentage NN N
of IN N
HA+lidocaine NNP N
injections NNS N
were VBD N
rated VBN N
very RB N
easy JJ N
. . N

Mild NNP N
to TO N
moderate VB N
adverse JJ N
events NNS N
were VBD N
reported VBN N
for IN N
both DT N
products NNS N
. . N

CONCLUSION VB N
The DT N
smooth JJ N
, , N
cohesive JJ N
HA NNP N
gel NN N
with IN N
preincorporated JJ N
lidocaine NN i
increased VBD N
subject JJ o
comfort NN o
during IN N
treatment NN N
and CC N
improved VBD N
the DT N
injection NN o
experience NN o
. . o

-DOCSTART- -24612915- O O

Intravenous JJ i
lipid JJ i
emulsion NN i
improves VBZ N
recovery NN N
time NN N
and CC N
quality NN N
from IN N
isoflurane JJ i
anaesthesia NN i
: : i
a DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

Recovery JJ N
time NN N
and CC N
quality NN N
after IN N
general JJ N
anaesthesia NN N
is VBZ N
important JJ N
for IN N
patient JJ N
safety NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
whether IN N
intravenous JJ i
lipid JJ i
emulsion NN i
could MD N
improve VB N
recovery NN N
profiles NNS N
from IN N
isoflurane NN i
anaesthesia NN i
in IN N
adult NN p
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
. . p

Sixty-six JJ p
patients NNS p
were VBD p
enrolled VBN p
. . p

After IN N
anaesthesia JJ N
induction NN N
, , N
inspired VBN N
isoflurane NN i
concentration NN N
was VBD N
adjusted VBN N
to TO N
maintain VB N
stable JJ N
vital JJ N
signs NNS N
and CC N
the DT N
suitable JJ N
conditions NNS N
for IN N
operation NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
, , N
the DT N
isoflurane NN N
was VBD N
discontinued VBN N
, , N
and CC N
either RB N
2 CD N
ml/kg VBD N
30 CD N
% NN N
lipid JJ i
emulsions NNS i
or CC N
0.9 CD N
% NN N
saline JJ i
solution NN i
was VBD N
administered VBN N
intravenously RB N
. . N

The DT N
time NN N
to TO N
eye NN N
opening NN N
, , N
extubation NN N
and CC N
exit NN N
from IN N
the DT N
operation NN N
room NN N
was VBD N
recorded VBN N
, , N
and CC N
the DT N
quality NN N
of IN N
recovery NN N
from IN N
anaesthesia NN N
was VBD N
assessed VBN N
. . N

Sixty JJ p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

The DT N
median JJ o
time NN o
to TO o
eye NN o
opening NN o
and CC o
exit NN o
from IN o
the DT o
operation NN o
room NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
lipid JJ N
emulsion NN N
group NN N
than IN N
in IN N
the DT N
saline NN N
group NN N
[ VBD N
15.5 CD N
( ( N
interquartile JJ N
range NN N
9.0 CD N
) ) N
versus NN N
20.0 CD N
( ( N
10.0 CD N
) ) N
min. NN N
, , N
p NN N
= VBD N
0.01 CD N
; : N
19.5 CD N
( ( N
8.3 CD N
) ) N
versus NN N
23.6 CD N
( ( N
6.3 CD N
) ) N
min. NN N
, , N
p NN N
= VBD N
0.04 CD N
, , N
respectively RB N
] JJ N
, , N
whereas IN N
the DT N
median JJ o
time NN o
to TO o
extubation VB o
did VBD N
not RB N
show VB N
any DT N
noticeable JJ N
difference NN N
. . N

The DT N
quality NN o
of IN o
recovery NN o
was VBD N
better RBR N
in IN N
the DT N
lipid JJ N
emulsion NN N
group NN N
than IN N
that DT N
of IN N
the DT N
saline JJ N
solution NN N
group NN N
with IN N
respect NN N
to TO N
drowsiness VB N
visual JJ o
analogue NN o
scale NN o
score NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
Observer NNP o
's POS o
Assessment NNP o
of IN o
Alertness/Sedation NNP o
score NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
Mini-Mental JJ o
State NNP o
Examination NNP o
score NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
Modified NNP o
Aldrete NNP o
Post NNP o
Anaesthesia NNP o
Recovery NNP o
score NN o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

No DT N
serious JJ o
adverse JJ o
events NNS o
were VBD N
observed VBN N
during IN N
the DT N
study NN N
period NN N
. . N

In IN N
conclusion NN N
, , N
intravenous JJ N
lipid JJ i
emulsion NN i
may MD N
effectively RB N
improve VB N
the DT N
recovery NN o
time NN o
and CC N
quality NN N
from IN N
isoflurane NN i
anaesthesia NN i
for IN N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -7620474- O O

A DT N
controlled JJ N
trial NN N
of IN N
cisapride NN i
in IN N
anorexia JJ p
nervosa NN p
. . p

To TO N
determine VB N
the DT N
efficacy NN o
of IN N
cisapride NN i
, , N
10 CD N
mg NN N
three CD N
times NNS N
daily RB N
, , N
in IN N
improving VBG N
gastric JJ o
emptying NN o
, , N
reducing VBG N
distress NN o
during IN o
meals NNS o
, , N
and CC N
facilitating VBG N
weight JJ o
gain NN o
in IN N
anorexia JJ p
nervosa NN p
, , N
we PRP N
conducted VBD N
an DT N
8-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
on IN N
29 CD p
inpatients NNS p
. . p

Measures NNS N
included VBD N
scintigraphic JJ N
gastric JJ N
emptying VBG N
studies NNS N
at IN N
0 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
8 CD N
weeks NNS N
; : N
subjective JJ o
distress NN o
during IN o
meals NNS o
measured VBN N
by IN N
visual JJ o
analogue NN o
scales NNS o
; : o
self-rating NN o
of IN o
degree NN o
of IN o
global JJ o
improvement NN o
in IN o
symptoms NNS o
associated VBN o
with IN o
eating NN o
at IN N
end NN N
of IN N
study NN N
; : N
and CC N
weight VBD o
measured VBN N
weekly RB N
. . N

Gastric NNP o
emptying VBG o
improved VBN N
significantly RB N
but CC N
equally RB N
in IN N
both DT p
groups NNS p
over IN N
the DT N
study NN N
period NN N
. . N

Yet CC N
subjective JJ N
measures NNS N
were VBD N
better RBR N
in IN N
the DT N
cisapride NN p
group NN p
; : p
they PRP N
rated VBD N
themselves PRP N
as IN N
more RBR N
hungry JJ o
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
and CC N
more JJR N
improved VBN N
on IN N
the DT N
global JJ N
measure NN N
of IN N
change NN o
in IN o
symptoms NNS o
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
. . N

Even RB N
so RB N
, , N
the DT N
cisapride NN i
group NN p
did VBD N
not RB N
gain VB N
more JJR N
weight NN o
. . o

The DT N
correlation NN N
between IN N
gastric JJ o
emptying NN o
and CC o
weight VBD o
gain NN o
was VBD N
modest JJ N
( ( N
r JJ N
= NNP N
.30 NNP N
; : N
p CC N
= NNP N
.11 NNP N
) ) N
, , N
and CC N
between IN N
gastric JJ o
emptying NN o
and CC N
the DT N
subjective JJ N
measures NNS N
, , N
virtually RB N
absent JJ N
. . N

-DOCSTART- -10674680- O O

Assessment NN N
of IN N
therapeutic JJ o
response NN N
of IN N
Plasmodium NNP N
falciparum NN N
to TO N
chloroquine VB i
and CC N
sulfadoxine-pyrimethamine VB i
in IN N
an DT N
area NN p
of IN p
low JJ p
malaria NNS p
transmission NN p
in IN p
Colombia NNP p
. . p

Although IN N
chloroquine NN i
( ( N
CQ NNP N
) ) N
resistance NN N
was VBD N
first RB N
reported VBN N
in IN N
Colombia NNP N
in IN N
1961 CD N
and CC N
sulfadoxine-pyrimethamine JJ i
( ( N
SP NNP N
) ) N
resistance NN N
in IN N
1981 CD N
, , N
the DT N
frequency NN N
of IN N
treatment NN N
failures NNS N
to TO N
these DT N
drugs NNS N
in IN N
Colombia NNP N
is VBZ N
unclear JJ N
. . N

A DT N
modified JJ N
World NNP N
Health NNP N
Organization NNP N
14-day JJ N
in IN N
vivo JJ N
drug NN N
efficacy NN N
test NN N
for IN N
uncomplicated JJ N
Plasmodium NNP N
falciparum NN N
malaria NN N
in IN N
areas NNS N
with IN N
intense JJ N
malaria NNS N
transmission NN N
was VBD N
adapted VBN N
to TO N
reflect VB N
the DT N
clinical JJ N
and CC N
epidemiologic JJ N
features NNS N
of IN N
a DT N
low-intensity JJ N
malaria NN N
transmission NN N
area NN N
in IN N
the DT N
Pacific NNP N
Coast NNP N
Region NNP N
of IN N
Colombia NNP N
. . N

Patients NNPS p
> JJ p
or CC p
=1 JJ p
year NN p
of IN p
age NN p
with IN p
a DT p
parasite JJ p
density NN p
> NN p
or CC p
=1,000 CD p
asexual JJ p
parasites NNS p
per IN p
microliter NN p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
. . p

Forty-four CD p
percent NN p
( ( p
24 CD p
of IN p
54 CD p
) ) p
of IN p
the DT p
CQ-treated JJ i
patients NNS p
were VBD p
therapeutic JJ o
failures NNS o
, , p
including VBG p
7 CD p
early JJ o
treatment NN o
failures NNS o
( ( o
ETFs NNP o
) ) o
and CC p
17 CD p
late JJ o
treatment NN o
failures NNS o
( ( o
LTFs NNP o
) ) o
. . o

Four CD p
( ( p
6 CD p
% NN p
) ) p
of IN p
67 CD p
SP-treated JJ N
patients NNS N
were VBD N
therapeutic JJ o
failures NNS o
( ( N
2 CD N
ETFs NNP N
and CC N
2 CD N
LTFs NNP N
) ) N
. . N

Therapeutic JJ o
failure NN o
in IN N
the DT N
CQ-treated JJ i
group NN N
was VBD N
associated VBN N
with IN N
an DT N
age NN N
< VBD N
15 CD N
years NNS N
old JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
was VBD N
not RB N
associated VBN N
with IN N
initial JJ N
parasite JJ N
density NN N
, , N
the DT N
presence NN N
of IN N
CQ NNP i
or CC N
sulfa-containing JJ N
drugs NNS N
in IN N
urine NN N
, , N
or CC N
a DT N
history NN N
of IN N
malaria NN N
. . N

The DT N
high JJ N
level NN N
of IN N
therapeutic JJ o
failures NNS o
to TO N
CQ NNP i
detected VBN N
in IN N
this DT N
study NN N
underscores VBZ N
the DT N
need NN N
and CC N
importance NN N
of IN N
drug NN N
efficacy NN o
evaluation NN N
in IN N
the DT N
development NN N
of IN N
a DT N
rational JJ N
national JJ N
antimalarial JJ N
drug NN N
policy NN N
. . N

The DT N
relatively RB N
low JJ N
level NN N
of IN N
therapeutic JJ o
failures NNS o
to TO N
SP NNP N
compared VBN N
with IN N
other JJ N
South JJ N
American JJ N
countries NNS N
raises VBZ N
further JJ N
questions NNS N
regarding VBG N
factors NNS N
that WDT N
might MD N
have VB N
prevented VBN N
the DT N
rapid JJ N
development NN N
of IN N
in IN N
vivo NN N
resistance NN N
to TO N
this DT N
drug NN N
combination NN N
. . N

-DOCSTART- -17178774- O O

The DT N
additional JJ N
value NN N
of IN N
a DT N
night NN i
splint NN i
to TO i
eccentric VB i
exercises NNS i
in IN N
chronic JJ p
midportion NN p
Achilles NNP p
tendinopathy NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

AIM NNP N
To TO N
assess VB N
whether IN N
the DT N
use NN i
of IN i
a DT i
night NN i
splint NN i
is VBZ N
of IN N
added JJ N
benefit NN N
on IN N
functional JJ N
outcome NN N
in IN N
treating VBG N
chronic JJ p
midportion NN p
Achilles NNP p
tendinopathy NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
single-blind JJ N
, , N
prospective JJ N
, , N
single JJ N
centre NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
set NN N
in IN N
the DT N
Sports NNP p
Medical NNP p
Department NNP p
, , p
The DT p
Hague NNP p
Medical NNP p
Centre NNP p
, , p
The DT p
Netherlands NNP p
. . p

Inclusion NNP p
criteria NNS p
were VBD p
: : p
age NN p
18-70 CD p
years NNS p
, , p
active JJ p
participation NN p
in IN p
sports NNS p
, , p
and CC p
tendon VB p
pain NN p
localised VBN p
at IN p
2-7 JJ p
cm NN p
from IN p
distal JJ p
insertion NN p
. . p

Exclusion NN p
criteria NNS p
were VBD p
: : p
insertional JJ p
disorders NNS p
, , p
partial JJ p
or CC p
complete JJ p
ruptures NNS p
, , p
or CC p
systemic JJ p
illness NN p
. . p

70 CD p
tendons NNS p
were VBD p
included VBN p
and CC N
randomised VBN N
into IN N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
eccentric JJ i
exercises NNS i
with IN i
a DT i
night NN i
splint NN i
( ( N
night NN N
splint NN N
group NN N
, , N
n RB N
= VBZ N
36 CD N
) ) N
or CC N
eccentric JJ i
exercises NNS i
only RB i
( ( N
eccentric JJ N
group NN N
, , N
n RB N
= VBZ N
34 CD N
) ) N
. . N

INTERVENTIONS NNP N
Both DT N
groups NNS N
completed VBD N
a DT N
12-week JJ N
heavy-load NN i
eccentric JJ i
training NN i
programme NN i
. . i

One CD N
group NN N
received VBD N
a DT N
night NN i
splint NN i
in IN i
addition NN i
to TO i
eccentric JJ i
exercises NNS i
. . i

At IN N
baseline NN N
and CC N
follow-up NN N
at IN N
12 CD N
weeks NNS N
, , N
patient JJ o
satisfaction NN o
, , o
Victorian NNP o
Institute NNP o
of IN o
Sport NNP o
Assessment-Achilles NNP o
questionnaire NN o
( ( o
VISA-A NNP o
) ) o
score NN o
and CC o
reported VBD o
compliance NN o
were VBD N
recorded VBN N
by IN N
a DT N
single-blind NN N
trained JJ N
researcher NN N
who WP N
was VBD N
blinded VBN N
to TO N
the DT N
treatment NN N
. . N

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
, , N
patient JJ o
satisfaction NN o
in IN N
the DT N
eccentric JJ N
group NN N
was VBD N
63 CD N
% NN N
compared VBN N
with IN N
48 CD N
% NN N
in IN N
the DT N
night NN i
splint NN i
group NN N
. . N

The DT N
VISA-A NNP o
score NN o
significantly RB N
improved VBN N
in IN N
both DT N
groups NNS N
; : N
in IN N
the DT N
eccentric JJ p
group NN p
from IN p
50.1 CD p
to TO p
68.8 CD p
( ( p
p NN p
= RB p
0.001 CD p
) ) p
and CC N
in IN N
the DT N
night NN p
splint NN p
group NN p
from IN p
49.4 CD p
to TO p
67.0 CD p
( ( p
p NN p
< RB p
0.001 CD p
) ) p
. . p

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
VISA-A NNP o
score NN o
( ( N
p JJ N
= NNP N
0.815 CD N
) ) N
and CC N
patient JJ o
satisfaction NN o
( ( N
p JJ N
= NNP N
0.261 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
night NN i
splint NN i
is VBZ N
not RB N
beneficial JJ N
in IN N
addition NN N
to TO N
eccentric VB N
exercises NNS N
in IN N
the DT N
treatment NN N
of IN N
chronic JJ N
midportion NN N
Achilles NNP N
tendinopathy NN N
. . N

-DOCSTART- -23642776- O O

Extra NNP i
virgin NN i
olive JJ i
oil NN i
( ( i
EVOO NNP i
) ) i
consumption NN N
and CC N
antioxidant JJ o
status NN o
in IN N
healthy JJ p
institutionalized VBN p
elderly JJ p
humans NNS p
. . p

Recent JJ N
studies NNS N
show VBP N
that IN N
the DT N
elderly JJ p
have VBP N
increased VBN N
oxidative JJ N
stress NN N
and CC N
impaired JJ N
antioxidant NN N
defense NN N
systems NNS N
. . N

Our PRP$ N
study NN N
aims VBZ N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
daily JJ N
consumption NN N
of IN N
EVOO NNP i
in IN N
the DT N
healthy JJ p
institutionalized JJ p
elderly RB p
. . p

We PRP N
studied VBD N
anthropometric JJ o
, , o
biochemical JJ o
and CC o
antioxidant JJ o
parameters NNS o
in IN N
62 CD p
subjects NNS p
aged VBN p
65-96 CD p
years NNS p
after IN N
a DT N
6-week JJ N
daily JJ N
intake NN N
of IN N
polyphenol-rich JJ i
EVOO NNP i
with IN i
high JJ i
oleuropein NNS i
derivative JJ i
contents NNS i
. . i

Subjects NNS N
were VBD N
divided VBN N
into IN N
a DT N
control NN i
group NN i
( ( i
CG NNP i
) ) i
who WP N
maintained VBD i
their PRP$ i
dietary JJ i
habits NNS i
( ( N
n=39 NN N
) ) N
and CC N
an DT N
olive JJ i
group NN i
( ( i
OG NNP i
) ) i
who WP i
consumed VBD i
EVOO NNP i
as IN N
the DT N
only RB N
added JJ N
fat NN N
, , N
plus CC N
a DT N
daily JJ N
dose NN N
of IN N
50ml CD N
( ( N
n=23 NN N
) ) N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
reduction NN N
of IN N
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
HDL NNP o
, , o
LDL NNP o
and CC o
TGs NNP o
in IN N
OG NNP N
subjects NNS N
and CC N
a DT N
significant JJ N
increase NN N
of IN N
HDL NNP N
levels NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
variation NN N
in IN N
the DT N
CG NNP N
parameters NNS N
. . N

In IN N
OG NNP N
the DT N
total JJ o
antioxidant JJ o
capacity NN o
( ( o
TAC NNP o
) ) o
in IN o
plasma NN o
increased VBN N
with IN N
significant JJ N
differences NNS N
over IN N
CG NNP N
. . N

Plasma NNP o
hydroxytyrosol NN o
( ( o
OH-Tyr NNP o
) ) o
concentration NN o
showed VBD N
a DT N
significant JJ N
increase NN N
after IN N
EVOO NNP i
intervention NN N
. . N

Daily JJ N
consumption NN N
of IN N
EVOO NNP i
was VBD N
found VBN N
to TO N
have VB N
positive JJ N
effects NNS N
on IN N
lipid JJ o
profiles NNS o
, , o
OH-Tyr NNP o
levels NNS o
and CC o
TAC NNP o
. . o

The DT N
results NNS N
also RB N
show VBP N
a DT N
significant JJ N
increase NN N
of IN N
catalase NN o
( ( o
CAT NNP o
) ) o
in IN N
erythrocytes NNS N
and CC N
a DT N
decrease NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
superoxide JJ o
dismutase NN o
( ( o
SOD NNP o
) ) o
and CC o
glutathione JJ o
peroxidase NN o
( ( o
GH-PX NNP o
) ) o
activity NN o
after IN N
EVOO NNP N
intake NN N
. . N

To TO N
our PRP$ N
knowledge NN N
, , N
no DT N
other JJ N
study NN N
has VBZ N
examined VBN N
the DT N
effects NNS N
of IN N
EVOO NNP i
consumption NN N
on IN N
biochemical JJ o
parameters NNS o
, , o
antioxidant JJ o
capacity NN o
and CC o
antioxidant JJ o
enzyme NN o
activity NN o
in IN N
healthy JJ p
elderly JJ p
subjects NNS p
. . p

In IN N
conclusion NN N
, , N
our PRP$ N
results NNS N
show VBP N
that IN N
nutritional JJ N
intervention NN N
with IN N
EVOO NNP i
improves VBZ N
antioxidant JJ N
status NN N
in IN N
healthy JJ p
elderly JJ p
people NNS p
. . p

-DOCSTART- -23432894- O O

Intervention NN i
for IN i
ineffective JJ o
airway JJ o
clearance NN o
in IN i
asthmatic JJ i
children NNS i
: : i
a DT N
controlled VBN N
and CC N
randomized VBN N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
analyse VB N
the DT N
effectiveness NN N
of IN N
an DT N
intervention NN N
for IN N
the DT N
nursing NN N
diagnosis NN N
of IN N
ineffective JJ o
airway JJ o
clearance NN o
in IN N
asthmatic JJ p
children NNS p
. . p

A DT N
blinded JJ N
, , N
randomized VBN N
and CC N
controlled VBN N
clinical JJ N
trial NN N
was VBD N
developed VBN N
in IN N
a DT N
paediatric JJ p
hospital NN p
located VBN p
on IN p
northeast NN p
of IN p
Brazil NNP p
with IN p
42 CD p
asthmatic JJ p
children NNS p
aged VBN p
? . p
36 CD p
months NNS p
. . p

The DT p
children NNS p
were VBD p
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
intervention NN N
and CC i
control NN i
) ) i
by IN i
means NNS N
of IN N
a DT N
simple JJ N
drawing NN N
. . N

The DT N
applied JJ N
intervention NN N
included VBD N
actions NNS N
related VBN N
to TO N
change VB i
of IN i
positioning NN i
and CC i
stimulation NN i
of IN i
cough NN i
. . i

The DT N
main JJ N
findings NNS N
of IN N
this DT N
study NN N
show VBP N
that IN N
before IN N
the DT N
intervention NN N
, , N
no DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT o
health NN o
status NN o
of IN o
the DT N
children NNS N
. . N

After IN N
the DT N
intervention NN N
, , N
the DT N
indicators NNS N
of IN N
choking VBG o
( ( o
16.83 CD N
vs. FW N
26.17 CD N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
and CC o
adventitious JJ o
breath NN o
sounds NNS o
( ( o
16.4 CD N
vs. FW N
26.6 CD N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
were VBD N
higher JJR N
, , N
on IN N
average NN N
, , N
in IN N
the DT N
intervention NN N
group NN N
. . N

It PRP N
was VBD N
observed VBN N
an DT N
improvement NN N
in IN N
obstructive JJ o
symptoms NNS o
in IN o
children NNS p
who WP p
received VBD p
the DT p
intervention NN p
proposed VBN p
. . N

-DOCSTART- -26053242- O O

Assessment NN N
from IN N
Functional JJ N
Perspectives NNS N
: : N
Using NNP N
Sensorimotor NNP i
Control NNP i
in IN i
the DT i
Hand NNP i
as IN N
an DT N
Outcome NNP N
Indicator NNP N
in IN N
the DT N
Surgical NNP N
Treatment NNP N
of IN N
Carpal NNP p
Tunnel NNP p
Syndrome NNP p
. . p

To TO N
investigate VB N
whether IN N
sensorimotor NN o
control NN o
of IN o
the DT o
hand NN o
could MD N
be VB N
an DT N
outcome NN o
indicator NN o
after IN N
carpal JJ N
tunnel NN N
release NN N
( ( N
CTR NNP N
) ) N
, , N
this DT N
work NN N
examined VBD N
changes NNS N
in IN N
the DT N
results NNS N
of IN N
patients NNS N
' POS N
manual JJ i
tactile NN i
test NN i
( ( N
MTT NNP N
) ) N
, , N
pinch-holding-up JJ i
activity NN i
( ( N
PHUA NNP N
) ) N
, , N
two-point JJ i
discrimination NN i
( ( N
2PD CD N
) ) N
and CC N
Semmes-Weinstein JJ i
monofilament NN i
( ( N
SWM NNP N
) ) N
tests NNS N
. . N

Participants NNS N
included VBD N
30 CD p
predominantly RB p
sensory JJ p
neuropathy JJ p
CTS NNP p
patients NNS p
, , p
as IN p
confirmed VBN p
by IN p
a DT p
nerve NN p
conduction NN p
study NN p
. . p

The DT N
MTT NNP o
, , o
precision NN o
pinch NN o
performance NN o
in IN o
PHUA NNP o
and CC i
traditional JJ o
sensibility NN o
( ( o
2PD CD o
and CC o
SWM NNP o
) ) o
tests NNS o
were VBD N
used VBN N
to TO N
examine VB N
different JJ N
aspects NNS N
of IN N
sensory JJ o
status NN o
at IN N
the DT N
time-points NNS N
of IN N
two CD N
weeks NNS N
before IN N
operation NN N
and CC N
one CD N
month NN N
post-operation NN N
, , N
with IN N
a DT N
single-blind JJ N
design NN N
. . N

The DT N
results NNS N
showed VBD N
significant JJ N
improvements NNS N
in IN N
the DT N
sensory JJ o
function NN o
as IN N
detected VBN N
by IN N
the DT N
2PD CD i
and CC N
SWM NNP i
tests NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
sensorimotor JJ o
function NN o
as IN N
detected VBN N
by IN N
the DT N
MTT NNP i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
PHUA NNP i
test NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
patients NNS N
receiving VBG N
CTR NNP N
. . N

The DT N
responsiveness NN N
of IN N
the DT N
SWM NNP i
, , i
MTT NNP i
and CC i
PHUA NNP i
tests NNS i
( ( N
effect NN N
size NN N
> NN N
0.5 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
are VBP N
better JJR N
than IN N
that DT N
of IN N
two-point JJ N
discrimination NN N
test NN N
( ( N
effect NN N
size NN N
< NN N
0.5 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
pinch JJ o
strength NN o
saw VBD N
a DT N
decline NN N
compared VBN N
to TO N
baseline VB N
with IN N
a DT N
moderate JJ N
effect NN N
sizes NNS N
( ( N
effect NN N
size NN N
= NN N
0.7 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

This DT N
cohort NN N
study NN N
found VBD N
that IN N
the DT N
MTT NNP i
and CC N
PHUA NNP i
test NN N
can MD N
both VB N
meet VB N
all PDT N
the DT N
statistical JJ N
criteria NNS N
with IN N
regard NN N
to TO N
assessing VBG N
treatment NN N
outcomes NNS N
for IN N
patients NNS p
with IN p
CTS NNP p
. . p

In IN N
addition NN N
, , N
the DT N
results NNS N
of IN N
this DT N
work NN N
provide RB N
clinicians VBZ N
with IN N
the DT N
information NN N
that IN N
the DT N
sensorimotor NN o
functions NNS o
of IN N
the DT N
hands NNS N
, , N
as IN N
assessed VBN N
by IN N
MTT NNP i
and CC i
PHUA NNP i
, , N
are VBP N
responsive JJ N
to TO N
clinical JJ N
changes NNS N
due JJ N
to TO N
CTR NNP N
. . N

-DOCSTART- -12604982- O O

Effects NNS N
of IN N
oral JJ i
Lactobacillus NNP i
GG NNP i
on IN N
enteric JJ o
microflora NNS o
in IN p
low-birth-weight JJ p
neonates NNS p
. . p

BACKGROUND NNP N
Colonization NNP N
patterns NNS N
, , N
especially RB N
by IN N
anaerobic JJ N
flora NNS N
, , N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
neonatal JJ p
gut NN p
function NN p
. . p

Probiotics NNS N
could MD N
affect VB N
disease NN o
risk NN o
either DT N
directly RB N
through IN N
colonization NN N
or CC N
indirectly RB N
by IN N
promoting VBG N
changes NNS N
in IN N
gut JJ N
microbial JJ N
ecology NN N
. . N

METHODS NNP N
To TO N
study VB N
the DT N
ability NN N
of IN N
Lactobacillus NNP i
GG NNP i
( ( i
LGG NNP i
) ) i
to TO N
colonize VB o
the DT o
neonatal JJ o
gut NN o
and CC o
modify VB o
its PRP$ o
microbial JJ o
ecology NN o
, , N
a DT N
prospective JJ N
, , N
randomized VBD N
study NN N
was VBD N
performed VBN N
in IN N
71 CD p
preterm JJ p
infants NNS p
of IN p
less JJR p
than IN p
2000 CD p
g JJ p
birth NN p
weight NN p
. . p

Infants VBZ p
less JJR p
than IN p
1500 CD p
g NN p
( ( N
24 CD N
treated VBN N
, , N
15 CD N
control NN N
) ) N
received VBD N
10 CD N
( ( N
9 CD N
) ) N
LGG NNP i
orally RB N
twice RB N
daily RB N
for IN N
21 CD N
days NNS N
. . N

Those DT N
infants NNS p
weighing VBG p
1500 CD p
to TO p
1999 CD p
g NN p
( ( N
23 CD N
treated VBN N
, , N
9 CD N
control NN N
) ) N
were VBD N
treated VBN N
for IN N
8 CD N
days NNS N
. . N

Stools NNS N
were VBD N
collected VBN N
before IN N
treatment NN N
and CC N
on IN N
day NN N
7 CD N
to TO N
8 CD N
( ( N
and CC N
day NN N
14 CD N
and CC N
21 CD N
, , N
in IN N
the DT N
infants NNS N
weighing VBG N
less JJR N
than IN N
1500 CD N
g NN N
) ) N
for IN N
quantitative JJ o
aerobic NN o
and CC o
anaerobic JJ o
cultures NNS o
. . o

RESULTS NNP N
Colonization NNP o
with IN o
LGG NNP o
occurred VBD o
in IN N
5 CD N
of IN N
24 CD N
( ( N
21 CD N
% NN N
) ) N
infants NNS N
who WP N
weighed VBD N
less JJR N
than IN N
1500 CD N
g JJ N
versus NN N
11 CD N
of IN N
23 CD N
( ( N
47 CD N
% NN N
) ) N
in IN N
larger JJR N
infants NNS N
. . N

Colonization NN o
was VBD N
limited VBN N
to TO N
infants NNS N
who WP N
were VBD N
not RB N
on IN N
antibiotics NNS i
within IN N
7 CD N
days NNS N
of IN N
treatment NN N
with IN N
LGG NNP N
. . N

There EX N
was VBD N
a DT N
paucity NN N
of IN N
bacterial JJ N
species NNS N
at IN N
baseline NN N
, , N
although IN N
larger JJR N
infants NNS N
had VBD N
more RBR N
bacterial JJ o
species NNS o
( ( N
1.59 CD N
+/- JJ N
0.13 CD N
( ( N
SEM NNP N
) ) N
vs VBD N
1.11 CD N
+/- JJ N
0.12 CD N
; : N
P NNP N
< NNP N
0.03 CD N
) ) N
and CC N
higher JJR N
mean NN o
log NN o
colony NN o
forming VBG o
units NNS o
( ( o
CFU NNP o
) ) o
( ( N
8.79 CD N
+/- JJ N
0.43 CD N
vs JJ N
7.22 CD N
+/- JJ N
0.63 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
compared VBN N
with IN N
infants NNS N
weighing VBG N
less JJR N
than IN N
1500 CD N
g NN N
LGG NNP N
. . N

Treatment NN N
in IN N
infants NNS p
weighing VBG p
less JJR p
than IN p
1500 CD p
g NN p
resulted VBD N
in IN N
a DT N
significant JJ N
increase NN o
in IN o
species NNS o
number NN o
by IN o
day NN o
7 CD o
, , o
with IN o
further JJ o
increases NNS o
by IN o
day NN o
21 CD o
. . o

This DT N
increase NN N
was VBD N
mainly RB N
the DT N
result NN N
of IN N
increased VBN o
Gram NNP o
( ( o
+ NNP o
) ) o
and CC o
anaerobic JJ o
species NNS o
. . o

No DT N
difference NN N
in IN N
species NNS o
number NN o
was VBD N
noted VBN N
in IN N
controls NNS N
. . N

Mean NNP o
log NN o
CFU NNP o
of IN o
Gram NNP o
( ( o
- : o
) ) o
bacteria NNS o
did VBD N
not RB N
change VB N
in IN N
treated JJ N
infants NNS N
weighing VBG N
less JJR N
than IN N
1500 CD N
g. NN N
However RB N
, , N
Gram NNP o
( ( o
+ NNP o
) ) o
mean VBP o
log NN o
CFU NNP o
showed VBD N
a DT N
significant JJ N
increase NN N
on IN N
day NN N
21 CD N
( ( N
6.1 CD N
+/- JJ N
0.9 CD N
) ) N
compared VBN N
with IN N
day NN N
0 CD N
( ( N
3.5 CD N
+/- JJ N
0.9 CD N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
changes NNS N
in IN N
species NNS o
number NN o
or CC o
quantitative JJ o
counts NNS o
were VBD N
noted VBN N
after IN N
LGG NNP N
treatment NN N
in IN N
the DT N
infants NNS N
weighing VBG N
1500 CD N
to TO N
1999 CD N
g NN N
LGG NNP o
was VBD o
well RB o
tolerated VBN o
in IN N
all DT N
infants NNS N
. . N

CONCLUSION VB N
The DT N
neonatal JJ o
response NN o
to TO o
a DT o
probiotic JJ o
preparation NN o
is VBZ N
dependent JJ N
on IN N
gestational JJ N
and CC N
post-natal JJ N
age NN N
and CC N
prior JJ N
antibiotic JJ N
exposure NN N
. . N

Although IN N
LGG NNP N
is VBZ N
a DT N
relatively RB N
poor JJ N
colonizer NN N
in IN N
infants NNS N
, , N
especially RB N
those DT N
infants NNS p
weighing VBG p
less JJR p
than IN p
1500 CD p
g NN p
at IN p
birth NN p
, , N
it PRP N
does VBZ N
appear VB N
to TO N
affect VB N
neonatal JJ o
intestinal JJ o
colonization NN o
patterns NNS o
. . o

-DOCSTART- -9076205- O O

Vitrectomy NN N
with IN N
silicone JJ i
oil NN i
or CC N
long-acting NN i
gas NN i
in IN N
eyes NNS p
with IN p
severe JJ p
proliferative JJ p
vitreoretinopathy NN p
: : p
results NNS N
of IN N
additional JJ N
and CC N
long-term JJ N
follow-up NN N
. . N

Silicone NNP N
Study NNP N
report VBD N
11 CD N
. . N

BACKGROUND VB N
The DT N
Silicone NNP N
Study NNP N
evaluated VBD N
the DT N
outcomes NNS N
of IN N
vitreoretinal JJ N
surgery NN N
for IN N
retinal JJ p
detachment NN p
with IN p
proliferative JJ p
vitreoretinopathy NN p
( ( p
PVR NNP p
) ) p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
short-term JJ N
( ( N
up IN N
to TO N
36 CD N
months NNS N
) ) N
outcomes VBZ N
in IN N
eyes NNS N
randomized VBN N
to TO N
silicone VB i
oil NN i
or CC N
perfluoropropane NN i
gas NN i
and CC N
long-term JJ N
( ( N
up IN N
to TO N
72 CD N
months NNS N
) ) N
outcomes VBZ N
in IN N
eyes NNS N
with IN N
attached JJ N
maculas NNS N
at IN N
36 CD N
months NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
multicentered VBD N
surgical JJ N
trial NN N
. . N

SETTING CC N
Community- JJ N
and CC N
university-based JJ N
vitreoretinal JJ N
practices NNS N
. . N

PATIENTS VB N
Two-hundred JJ p
sixty-five JJ p
eyes NNS p
with IN p
PVR NNP p
randomized VBD N
to TO N
perfluoropropane VB i
gas NN i
and CC N
silicone NN i
oil NN i
with IN N
follow-up NN N
through IN N
3 CD N
years NNS N
( ( N
cohort VB N
1 CD N
) ) N
and CC N
249 CD N
eyes NNS N
with IN N
attached JJ N
maculas NNS N
at IN N
36 CD N
months NNS N
( ( i
121 CD i
eyes NNS i
randomized VBN i
to TO i
long-acting JJ i
gas NN i
[ NN i
either CC i
sulfur JJ i
hexafluoride NN i
or CC i
perfluoropropane NN i
] NNS i
and CC i
128 CD i
eyes NNS i
randomized VBN i
to TO i
silicone VB i
oil NN i
) ) i
with IN i
follow-up NN i
up RB i
to TO i
6 CD i
years NNS i
( ( i
cohort VB i
2 CD i
) ) i
. . i

Both DT p
cohorts NNS p
consisted VBD p
of IN p
eyes NNS p
that WDT p
had VBD p
and CC p
had VBD p
not RB p
undergone JJ p
vitrectomy NN p
for IN p
PVR NNP p
( ( N
groups NNS N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
) ) N
before IN N
randomization NN N
. . N

Of IN N
the DT N
265 CD N
eyes NNS N
in IN N
cohort NN N
1 CD N
, , N
24-month JJ N
follow-up JJ N
data NNS N
were VBD N
available JJ N
for IN N
218 CD N
eyes NNS N
( ( N
82 CD N
% NN N
) ) N
and CC N
36-month JJ N
follow-up JJ N
data NNS N
were VBD N
available JJ N
for IN N
196 CD N
eyes NNS N
( ( N
74 CD N
% NN N
) ) N
. . N

Of IN N
208 CD N
eyes NNS N
in IN N
cohort NN N
2 CD N
, , N
48-month JJ N
follow-up JJ N
data NNS N
were VBD N
available JJ N
for IN N
146 CD N
eyes NNS N
( ( N
70 CD N
% NN N
) ) N
, , N
60-month JJ N
follow-up JJ N
data NNS N
for IN N
119 CD N
eyes NNS N
( ( N
57 CD N
% NN N
) ) N
, , N
and CC N
72-month JJ N
follow-up JJ N
data NNS N
for IN N
73 CD N
eyes NNS N
( ( N
35 CD N
% NN N
) ) N
. . N

INTERVENTIONS NNP N
Vitrectomy NNP N
surgery NN N
for IN N
PVR NNP N
with IN N
a DT N
long-acting JJ i
gas NN i
or CC N
silicone NN i
oil NN i
as IN N
the DT N
intraocular JJ N
tamponade NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Changes NNP o
in IN o
visual JJ o
acuity NN o
, , o
recurrent JJ o
retinal JJ o
detachment NN o
, , o
and CC o
incidence NN o
of IN o
complications NNS o
. . o

RESULTS NNP N
In IN N
group NN N
1 CD N
of IN N
cohort NN N
1 CD N
, , N
compared VBN N
with IN N
oil-treated JJ N
eyes NNS N
, , N
gas-treated JJ N
eyes NNS N
had VBD N
a DT N
higher JJR N
rate NN N
of IN N
complete JJ o
retinal JJ o
reattachment NN o
from IN N
18 CD N
to TO N
36 CD N
months NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

No UH N
other JJ N
differences NNS N
were VBD N
found VBN N
. . N

In IN N
group NN N
2 CD N
of IN N
cohort NN N
1 CD N
, , N
no DT N
notable JJ N
differences NNS N
were VBD N
found VBN N
between IN N
treatment NN N
arms NNS N
. . N

In IN N
cohort NN N
2 CD N
, , N
during IN N
6 CD N
years NNS N
of IN N
follow-up NN N
, , N
attachment NN o
of IN o
the DT o
macula NN o
was VBD N
maintained VBN N
for IN N
all DT N
eyes NNS N
. . N

No DT N
notable JJ N
differences NNS N
in IN N
the DT N
rates NNS o
of IN o
complete JJ o
retinal JJ o
attachment NN o
, , o
visual JJ o
acuity NN o
of IN o
5/200 CD o
or CC o
better JJR o
, , o
or CC o
glaucoma NN o
were VBD N
found VBN N
between IN N
treatment NN N
groups NNS N
. . N

In IN N
contrast NN N
, , N
gas-treated JJ N
eyes NNS N
had VBD N
more RBR N
hypotony JJ o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Silicone CD i
oil-treated JJ i
eyes NNS N
that WDT N
underwent JJ N
subsequent JJ o
surgery NN o
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
the DT N
oil NN N
retained VBN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Compared VBN N
with IN N
oil-retained JJ N
eyes NNS N
, , N
oil-removed JJ N
eyes NNS N
had VBD N
higher JJR N
rates NNS o
of IN o
complete JJ o
posterior JJ o
attachment NN o
( ( o
P NNP o
= NNP o
.01 NNP o
) ) o
and CC o
of IN o
a DT o
visual JJ o
acuity NN o
of IN o
5/200 CD o
or CC o
better JJR o
( ( o
P NNP o
< NNP o
.001 NNP o
) ) o
and CC o
less RBR o
keratopathy JJ o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Compared VBN N
with IN N
oil-removed JJ N
eyes NNS N
, , N
gas-treated JJ N
eyes NNS N
had VBD N
a DT N
worse JJ N
visual JJ o
acuity NN o
outcome NN o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
more JJR N
hypotony NN o
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
Silicone NNP N
Study NNP N
showed VBD N
that IN N
silicone NN N
oil NN N
and CC N
perfluoropropane NN N
gas NN N
were VBD N
equal JJ N
in IN N
most JJS N
respects NNS N
for IN N
the DT N
management NN N
of IN N
retinal JJ N
detachments NNS N
with IN N
PVR NNP p
. . p

Success NNP N
in IN N
the DT N
first JJ N
surgery NN N
for IN N
PVR NNP N
is VBZ N
paramount NN N
for IN N
obtaining VBG N
better JJR N
visual JJ N
results NNS N
. . N

Overall JJ N
, , N
surgery NN N
for IN N
PVR NNP N
had VBD N
a DT N
high JJ N
likelihood NN N
of IN N
retinal JJ N
reattachment NN N
, , N
and CC N
if IN N
anatomically RB N
and CC N
visually RB N
successful JJ N
at IN N
3 CD N
years NNS N
, , N
there EX N
is VBZ N
an DT N
excellent JJ N
chance NN N
that IN N
the DT N
results NNS N
will MD N
be VB N
maintained VBN N
over IN N
the DT N
long-term JJ N
. . N

-DOCSTART- -23688830- O O

The DT N
Pain NNP N
Course NNP N
: : N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
a DT N
clinician-guided JJ i
Internet-delivered JJ i
cognitive JJ i
behaviour NN i
therapy NN i
program NN i
for IN p
managing VBG p
chronic JJ p
pain NN p
and CC p
emotional JJ p
well-being NN p
. . p

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
a DT N
clinician-guided JJ i
Internet-delivered JJ i
cognitive JJ i
behaviour NN i
therapy NN i
( ( i
iCBT JJ i
) ) i
program NN i
, , N
the DT N
Pain NNP i
Course NNP i
, , N
to TO N
reduce VB N
disability NN o
, , o
anxiety NN o
, , N
and CC N
depression NN o
associated VBN N
with IN N
chronic JJ N
pain NN N
. . N

Sixty-three JJ p
adults NNS p
with IN p
chronic JJ p
pain NN p
were VBD p
randomised VBN p
to TO N
either VB N
a DT N
Treatment NNP i
Group NNP i
or CC i
waitlist VB i
Control NNP i
Group NNP i
. . i

Treatment NNP N
consisted VBD N
of IN N
5 CD i
iCBT-based JJ i
lessons NNS i
, , i
homework NN i
tasks NNS i
, , i
additional JJ i
resources NNS i
, , i
weekly JJ i
e-mail NN i
or CC i
telephone NN i
contact NN i
from IN i
a DT i
Clinical JJ i
Psychologist NN i
, , i
and CC i
automated VBD i
e-mails NNS i
. . i

Twenty-nine NN N
of IN N
31 CD p
Treatment NNP i
Group NNP i
participants NNS p
completed VBD N
the DT N
5 CD i
lessons NNS i
during IN N
the DT N
8-week JJ N
program NN N
, , N
and CC N
posttreatment NN N
and CC N
3-month JJ N
follow-up JJ N
data NNS N
were VBD N
collected VBN N
from IN N
30/31 CD N
and CC N
29/31 CD N
participants NNS N
, , N
respectively RB N
. . N

Treatment NNP i
Group NNP i
participants NNS N
obtained VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
Control NNP i
Group NNP i
participants NNS N
in IN N
levels NNS o
of IN o
disability NN o
, , o
anxiety NN o
, , o
depression NN o
, , o
and CC o
average JJ o
pain NN o
levels NNS o
at IN N
posttreatment NN N
. . N

These DT N
improvements NNS N
corresponded VBD N
to TO N
small JJ N
to TO N
large JJ N
between-groups NNS N
effect NN N
sizes VBZ N
( ( N
Cohen NNP N
's POS N
d NN N
) ) N
at IN N
posttreatment NN N
for IN N
disability NN o
( ( N
d JJ N
= NNP N
.88 NNP N
) ) N
, , N
anxiety NN o
( ( N
d JJ N
= NNP N
.38 NNP N
) ) N
, , N
depression NN o
( ( N
d JJ N
= NNP N
.66 NNP N
) ) N
, , N
and CC N
average JJ o
pain NN o
( ( N
d JJ N
= NNP N
.64 NNP N
) ) N
, , N
respectively RB N
. . N

These DT N
outcomes NNS N
were VBD N
sustained VBN N
at IN N
follow-up NN N
and CC N
participants NNS N
rated VBD N
the DT N
program NN N
as IN N
highly RB N
acceptable JJ N
. . N

Overall JJ N
, , N
the DT N
clinician JJ N
spent NN N
a DT N
total JJ o
mean JJ o
time NN o
of IN N
81.54 CD N
minutes NNS N
( ( N
SD NNP N
30.91 CD N
minutes NNS N
) ) N
contacting VBG N
participants NNS N
during IN N
the DT N
program NN N
. . N

The DT N
results NNS N
appear VBP N
better JJR N
than IN N
those DT N
reported VBN N
in IN N
iCBT NN i
studies NNS N
to TO N
date NN N
and CC N
provide VB N
support NN N
for IN N
the DT N
potential NN N
of IN N
clinician-guided JJ i
iCBT NN i
in IN N
the DT N
treatment NN N
of IN N
disability NN o
, , o
anxiety NN o
, , o
and CC o
depression NN o
for IN o
people NNS o
with IN o
chronic JJ o
pain NN o
. . o

-DOCSTART- -3519550- O O

Postoperative JJ N
radiotherapy NN i
in IN N
breast NN p
cancer NN p
-- : p
long-term JJ p
results NNS N
from IN N
the DT N
Oslo NNP p
study NN p
. . p

The DT N
long-term JJ N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT p
effect NN p
of IN p
postoperative JJ i
radiotherapy NN i
as IN p
an DT p
adjuvant NN p
to TO p
radical JJ i
mastectomy NN i
are VBP p
presented VBN p
. . p

There EX N
were VBD N
1115 CD p
patients NNS p
including VBG p
27 CD p
protocol JJ p
deviants NNS p
. . p

The DT N
follow-up JJ N
time NN N
is VBZ N
11-20 JJ N
years NNS N
. . N

In IN N
the DT N
first JJ N
part NN N
a DT N
conventional JJ i
roentgen NN i
unit NN i
was VBD N
used VBN N
, , N
and CC N
in IN N
the DT N
second JJ N
part NN N
a DT N
60Co CD i
unit NN i
, , N
with IN N
considerably RB N
increased VBN N
dosage NN N
and CC N
altered VBD N
treatment NN N
plan NN N
. . N

Both DT N
types NNS N
of IN N
radiation NN N
techniques NNS N
lowered VBD N
the DT N
incidence NN o
of IN o
loco-regional JJ o
recurrences NNS o
significantly RB N
, , N
but CC N
had VBD N
no DT N
significant JJ N
influence NN N
on IN N
the DT N
overall JJ o
survival NN o
. . o

The DT o
relapse-free JJ o
survival NN o
was VBD N
significantly RB N
improved VBN N
by IN N
60Co CD i
radiation NN i
in IN N
Stage NNP N
II NNP N
patients NNS N
, , N
but CC N
was VBD N
unaffected VBN N
by IN N
radiation NN N
in IN N
the DT N
other JJ N
subgroups NNS N
. . N

Regarding VBG N
survival NN o
, , N
Stage NNP N
II NNP N
patients NNS N
with IN N
medially RB N
located VBN N
tumors NNS N
seemed VBD N
to TO N
benefit VB N
more JJR N
from IN N
60Co CD i
radiation NN i
than IN N
those DT N
with IN N
lateral JJ N
tumors NNS N
. . N

A DT N
significant JJ N
increase NN N
in IN N
the DT N
number NN o
of IN o
deaths NNS o
caused VBN o
by IN o
myocardial JJ o
infarction NN o
was VBD N
observed VBN N
in IN N
Stage NNP N
I PRP N
patients NNS N
having VBG N
60Co CD N
radiation NN N
, , N
indicating VBG N
that IN N
the DT N
radiation NN N
dose NN N
to TO N
the DT N
heart NN N
is VBZ N
of IN N
significance NN N
. . N

-DOCSTART- -25265770- O O

Femoral NNP i
nerve NN i
block NN i
using VBG i
0.25 CD i
% NN i
or CC i
0.5 CD i
% NN i
bupivacaine NN i
for IN N
analgesia NN N
after IN p
arthroscopic JJ p
anterior JJ p
cruciate NN p
ligament NN p
reconstruction NN p
. . p

BACKGROUND NNP N
Femoral NNP i
nerve NN i
block NN i
( ( i
FNB NNP i
) ) i
with IN N
varying VBG N
concentrations NNS N
of IN N
bupivacaine NN i
is VBZ N
often RB N
used VBN N
for IN N
postoperative JJ N
analgesia NN N
after IN p
anterior JJ p
cruciate NN p
ligament NN p
( ( p
ACL NNP p
) ) p
reconstruction NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
FNB NNP i
using VBG i
0.25 CD i
% NN i
or CC i
0.5 CD i
% NN i
bupivacaine NN i
provided VBN N
better RBR N
analgesia NN N
with IN N
less JJR N
effect NN N
on IN N
quadriceps NNS N
strengths NNS N
after IN N
ACL NNP N
reconstruction NN N
. . N

MATERIAL NNP N
AND CC N
METHOD NNP N
One NNP p
hundred VBD p
patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
FNB NNP i
with IN N
20 CD i
mL NNS i
of IN i
0.25 CD i
% NN i
or CC i
0.5 CD i
% NN i
bupivacaine NN i
. . i

Data NNP o
regarding VBG o
demographic JJ o
, , o
effectiveness NN o
of IN o
FNB NNP o
, , o
time NN o
to TO o
first RB o
pain VB o
, , o
time NN o
to TO o
first JJ o
analgesic JJ o
, , o
pain NN o
scores NNS o
, , o
morphine NN o
use NN o
, , o
and CC o
recovery NN o
of IN o
sensory NN o
and CC o
motor NN o
function NN o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Median JJ o
time NN o
to TO o
first JJ o
morphine JJ o
requirement NN o
was VBD N
12 CD N
hours NNS N
in IN N
0.5 CD N
% NN N
bupivacaine NN i
group NN N
and CC N
10 CD N
hours NNS N
in IN N
0.25 CD N
% NN N
bupivacaine NN i
group NN N
( ( N
p JJ N
= NNP N
0.048 CD N
) ) N
. . N

Pain VB o
score NN o
at IN N
18 CD N
hours NNS N
was VBD N
lower JJR N
in IN N
0.5 CD i
% NN i
bupivacaine NN i
group NN N
compared VBN N
with IN N
0.25 CD i
% NN i
bupivacaine NN i
group NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

When WRB N
specify NN N
to TO N
the DT N
patellar JJ N
tendon NN N
graft NN N
subgroup NN N
, , N
the DT N
patients NNS N
requiring VBG N
morphine NN o
were VBD N
70 CD N
% NN N
in IN N
0.5 CD i
% NN i
bupivacaine NN i
group NN N
and CC N
90 CD N
% NN N
in IN N
0.25 CD i
% NN i
bupivacaine NN i
group NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

No UH N
differences NNS N
were VBD N
found VBN N
in IN N
demographic JJ N
data NNS N
, , N
effectiveness NN o
of IN o
FNB NNP o
, , o
time NN o
to TO o
first RB o
pain VB o
, , o
morphine VB o
consumption NN o
, , o
and CC o
recovery NN o
of IN o
sensorimotor NN o
function NN o
. . o

CONCLUSION NNP N
FNB NNP i
with IN i
0.5 CD i
% NN i
bupivacaine NN i
provided VBN N
longer JJR N
time NN N
to TO N
first JJ N
analgesic JJ N
and CC N
lower RBR N
narcotic JJ N
requirements NNS N
after IN N
patellar JJ N
tendon NN N
graft NN N
ACL NNP N
reconstruction NN N
when WRB N
compared VBN N
to TO N
0.25 CD i
% NN i
bupivacaine NN i
. . i

Both DT N
concentrations NNS N
showed VBD N
similar JJ N
effect NN N
on IN N
quadriceps NNS N
strengths NNS N
. . N

-DOCSTART- -9609624- O O

Long-term JJ N
evaluation NN N
of IN N
tamsulosin NN i
in IN N
benign JJ p
prostatic JJ p
hyperplasia NN p
: : p
placebo-controlled JJ i
, , N
double-blind JJ N
extension NN N
of IN N
phase NN N
III NNP N
trial NN N
. . N

Tamsulosin NNP N
Investigator NNP N
Group NNP N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
tamsulosin NN i
( ( N
0.4 CD N
and CC N
0.8 CD N
mg NN N
) ) N
, , N
a DT N
unique JJ N
selective JJ N
alpha1A-adrenoceptor NN N
antagonist NN N
in IN N
patients NNS p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
( ( N
BPH NNP N
) ) N
. . N

METHODS NNP N
This DT N
trial NN N
extended VBD N
a DT N
13-week JJ N
, , N
Phase NNP N
III NNP N
multicenter NN N
placebo-controlled JJ N
, , N
double-blind JJ N
outpatient JJ N
trial NN N
for IN N
an DT N
additional JJ N
40 CD N
weeks NNS N
. . N

Of IN N
618 CD p
patients NNS p
, , p
418 CD p
( ( p
68 CD p
% NN p
) ) p
continued VBD N
into IN N
the DT N
extension NN N
phase NN N
on IN N
the DT N
same JJ N
double-blind JJ N
medication NN N
and CC N
dose NN N
. . N

The DT N
primary JJ N
efficacy NN N
parameters NNS N
were VBD N
total JJ o
American NNP o
Urological NNP o
Association NNP o
( ( o
AUA NNP o
) ) o
symptom NN o
score NN o
and CC o
maximum JJ o
urinary JJ o
flow NN o
( ( o
Qmax NNP o
) ) o
. . o

RESULTS VB N
The DT N
mean JJ N
changes NNS N
in IN N
AUA NNP o
symptom NN o
score NN o
from IN N
baseline NN N
to TO N
end VB N
point NN N
were VBD N
statistically RB N
significant JJ N
in IN N
all DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
Qmax NNP o
for IN N
both DT N
tamsulosin JJ i
groups NNS N
but CC N
not RB N
for IN N
the DT N
placebo NN i
group NN N
. . N

The DT N
statistically RB N
significant JJ o
improvements NNS o
from IN N
baseline NN N
in IN N
efficacy NN N
parameters NNS N
observed VBD N
for IN N
each DT N
tamsulosin NN i
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
13-week JJ N
Phase NNP N
III NNP N
trial NN N
were VBD N
maintained VBN N
during IN N
the DT N
long-term JJ N
extension NN N
phase NN N
. . N

Tamsulosin NN N
at IN N
both DT N
dosages NNS N
was VBD N
well RB N
tolerated VBN o
as IN N
maintenance NN N
therapy NN N
. . N

Clinically NNP N
significant JJ N
orthostatic JJ o
hypotension NN o
was VBD N
not RB N
observed VBN N
. . N

Vital JJ o
sign NN o
changes NNS o
in IN N
either DT N
hypertensive JJ N
or CC N
normotensive JJ N
patients NNS N
were VBD N
not RB N
clinically RB N
significantly RB N
different JJ N
across IN N
the DT N
three CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Tamsulosin NNP i
once-daily RB N
at IN N
0.4 CD N
or CC N
0.8 CD N
mg NN N
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well RB N
tolerated VBN N
in IN N
the DT N
target NN p
BPH NNP p
population NN p
during IN N
long-term JJ N
use NN N
. . N

-DOCSTART- -12085177- O O

Marimastat NNP i
as IN N
maintenance NN N
therapy NN N
for IN N
patients NNS p
with IN p
advanced JJ p
gastric JJ p
cancer NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

This DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
ability NN N
of IN N
the DT N
orally RB N
administered VBN N
matrix JJ i
metalloproteinase NN i
inhibitor NN i
, , i
marimastat NN i
, , N
to TO N
prolong VB N
survival NN o
in IN N
patients NNS p
with IN p
non-resectable JJ p
gastric JJ p
and CC p
gastro-oesophageal JJ p
adenocarcinoma NN p
. . p

Three CD p
hundred VBD p
and CC p
sixty-nine JJ p
patients NNS p
with IN p
histological JJ p
proof NN p
of IN p
adenocarcinoma NN p
, , p
who WP p
had VBD p
received VBN p
no RB p
more RBR p
than IN p
a DT p
single JJ p
regimen NN p
of IN p
5-fluorouracil-based JJ i
chemotherapy NN i
, , N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
marimastat NN i
( ( i
10 CD i
mg NN i
b.d NN i
. . i

) ) i
or CC i
placebo NN i
. . i

Patients NNS N
were VBD N
treated VBN N
for IN N
as RB N
long RB N
as IN N
was VBD N
tolerable JJ N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ o
survival NN o
with IN N
secondary JJ N
endpoints NNS N
of IN N
time NN N
to TO N
disease VB o
progression NN o
and CC N
quality NN o
of IN o
life NN o
. . o

At IN N
the DT N
point NN N
of IN N
protocol-defined JJ N
study NN N
completion NN N
( ( N
85 CD N
% NN N
mortality NN N
in IN N
the DT N
placebo NN N
arm NN N
) ) N
there EX N
was VBD N
a DT N
modest JJ N
difference NN N
in IN N
survival NN N
in IN N
the DT N
intention-to-treat JJ N
population NN N
in IN N
favour NN N
of IN N
marimastat NN i
( ( N
P=0.07 NNP N
log-rank JJ N
test NN N
, , N
hazard NN N
ratio=1.23 NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
0.98-1.55 NNP N
) ) N
) ) N
. . N

This DT N
survival JJ o
benefit NN o
was VBD N
maintained VBN N
over IN N
a DT N
further JJ N
2 CD N
years NNS N
of IN N
follow-up NN N
( ( N
P=0.024 NNP N
, , N
hazard NN N
ratio=1.27 NN N
( ( N
1.03-1.57 JJ N
) ) N
) ) N
. . N

The DT N
median JJ o
survival NN o
was VBD N
138 CD N
days NNS N
for IN N
placebo NN i
and CC N
160 CD N
days NNS N
for IN N
marimastat NN i
, , N
with IN N
2-year JJ N
survival NN N
of IN N
3 CD N
% NN N
and CC N
9 CD N
% NN N
respectively RB N
. . N

A DT N
significant JJ o
survival JJ o
benefit NN o
was VBD N
identified VBN N
at IN N
study NN N
completion NN N
in IN N
the DT N
pre-defined JJ p
sub-group NN p
of IN p
123 CD p
patients NNS p
who WP p
had VBD p
received VBN p
prior RB p
chemotherapy NN i
( ( N
P=0.045 NNP N
, , N
hazard NN N
ratio=1.53 NN N
( ( N
1.00-2.34 JJ N
) ) N
) ) N
. . N

This DT N
benefit NN N
increased VBD N
with IN N
2 CD N
years NNS N
additional JJ N
follow-up NN N
( ( N
P=0.006 NNP N
, , N
hazard NN N
ratio=1.68 NN N
( ( N
1.16-2.44 JJ N
) ) N
) ) N
, , N
with IN N
2-year JJ o
survival NN o
of IN N
5 CD N
% NN N
and CC N
18 CD N
% NN N
respectively RB N
. . N

Progression-free JJ o
survival NN o
was VBD N
also RB N
significantly RB N
longer RBR N
for IN N
patients NNS N
receiving VBG N
marimastat NNS i
compared VBN N
to TO N
placebo VB i
( ( N
P=0.009 NNP N
, , N
hazard NN N
ratio=1.32 NN N
( ( N
1.07-1.63 JJ N
) ) N
) ) N
. . N

Marimastat NNP i
treatment NN N
was VBD N
associated VBN N
with IN N
the DT N
development NN N
of IN N
musculoskeletal JJ o
pain NN o
and CC o
inflammation NN o
. . o

Events NNS o
of IN o
anaemia NN o
, , o
abdominal JJ o
pain NN o
, , o
jaundice NN o
and CC o
weight JJ o
loss NN o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
placebo NN i
arm NN N
. . N

This DT N
is VBZ N
one CD N
of IN N
the DT N
first JJ N
demonstrations NNS N
of IN N
a DT N
therapeutic JJ N
benefit NN N
for IN N
a DT N
matrix JJ N
metalloproteinase NN N
inhibitor NN N
in IN N
cancer NN N
patients NNS N
. . N

The DT N
greatest JJS N
benefit NN N
was VBD N
observed VBN N
in IN N
patients NNS p
who WP p
had VBD p
previously RB p
received VBN p
chemotherapy NN i
. . i

A DT N
further RB N
randomised VBN N
study NN N
of IN N
marimastat NN i
in IN N
these DT N
patients NNS N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -14722336- O O

Effects NNS N
of IN N
a DT N
caregiver NN i
intervention NN i
on IN N
negative JJ N
caregiver NN p
appraisals NNS N
of IN N
behavior NN N
problems NNS N
in IN N
patients NNS p
with IN p
Alzheimer NNP p
's POS p
disease NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

Behavioral JJ N
problems NNS N
are VBP N
among IN N
the DT N
most RBS N
challenging JJ N
aspects NNS N
of IN N
caring VBG N
for IN N
a DT N
person NN p
with IN p
Alzheimer NNP p
's POS p
disease NN p
. . p

A DT N
sample NN N
of IN N
406 CD p
spouses-caregivers NNS p
of IN p
patients NNS p
with IN p
Alzheimer NNP p
's POS p
disease NN p
was VBD N
randomized VBN N
to TO N
an DT N
active JJ i
multicomponent NN i
counseling NN i
and CC i
support NN i
intervention NN i
condition NN i
or CC i
to TO i
a DT i
usual JJ i
care NN i
condition NN i
. . i

Caregivers NNS N
reported VBD N
on IN N
the DT N
frequency NN o
of IN o
troublesome JJ o
patient NN o
behaviors NNS o
and CC o
their PRP$ o
reactions NNS o
to TO o
them PRP o
at IN N
baseline NN N
and CC N
at IN N
regular JJ N
follow-up JJ N
interviews NNS N
. . N

Random-effects NNS N
regression NN N
models NNS N
over IN N
the DT N
first JJ N
4 CD N
years NNS N
after IN N
randomization NN N
revealed VBD N
that IN N
, , N
although IN N
the DT N
intervention NN i
did VBD N
not RB N
affect VB N
the DT N
frequency NN N
of IN N
patient JJ N
behavioral JJ N
problems NNS N
, , N
it PRP N
did VBD N
significantly RB N
reduce VB N
caregivers NNS o
' POS o
reaction NN o
ratings NNS o
. . o

Because IN N
caregiver NN i
appraisals NNS i
have VBP N
been VBN N
found VBN N
to TO N
mediate VB N
the DT N
impact NN N
of IN N
caregiving VBG N
stress NN N
on IN N
depression NN N
and CC N
to TO N
predict VB N
nursing NN N
home NN N
placement NN N
rates NNS N
, , N
they PRP N
deserve VBP N
greater JJR N
attention NN N
as IN N
an DT N
important JJ N
target NN N
of IN N
intervention NN N
services NNS N
. . N

-DOCSTART- -24708422- O O

An DT N
RCT NNP N
comparing VBG N
patient-centred JJ N
outcome NN N
variables NNS N
of IN N
guided VBN N
surgery NN N
( ( i
bone NN i
or CC i
mucosa NN i
supported VBN i
) ) i
with IN N
conventional JJ N
implant JJ N
placement NN N
. . N

AIM NNP N
To TO N
assess VB N
in IN N
a DT N
randomized JJ N
study NN N
the DT N
patient-centred JJ o
outcome NN o
of IN N
two CD N
guided JJ N
surgery NN i
systems NNS N
( ( i
mucosa NN i
or CC i
bone NN i
supported VBN i
) ) i
compared VBN N
to TO N
conventional JJ i
implant JJ i
placement NN i
, , N
in IN N
fully RB p
edentulous JJ p
patients NNS p
. . p

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifty-nine NNP p
patients NNS p
( ( p
72 CD p
jaws NNS p
) ) p
with IN p
edentulous JJ p
maxillas NNS p
and/ VBP p
or CC p
mandibles NNS p
, , p
were VBD p
consecutively RB p
recruited VBN p
and CC p
randomly RB p
assigned VBN p
to TO N
one CD N
of IN N
the DT N
treatment NN N
groups NNS N
. . N

Outcome NNP N
measures NNS N
were VBD N
the DT o
Dutch JJ o
version NN o
of IN o
the DT o
McGill NNP o
Pain NNP o
Questionnaire NNP o
( ( o
MPQ-DLV NNP o
) ) o
, , o
the DT o
Health-related JJ o
quality NN o
of IN o
life NN o
instrument NN o
( ( o
HRQOL NNP o
) ) o
, , o
visual JJ o
analogue NN o
scales NNS o
( ( o
VAS NNP o
) ) o
, , o
the DT o
duration NN o
of IN o
the DT o
procedure NN o
, , o
and CC o
the DT o
analgesic JJ o
doses NNS o
taken VBN o
each DT o
day NN o
. . o

RESULTS NNP N
Three CD N
hundred VBD N
and CC N
fourteen JJ N
implants NNS N
were VBD N
placed VBN N
successfully RB N
. . N

No DT N
statistical JJ N
differences NNS N
could MD N
be VB N
shown VBN N
between IN N
treatment NN N
groups NNS N
on IN N
pain NN o
response NN o
( ( o
MPQ-DLV NNP o
) ) o
, , o
treatment NN o
perception NN o
( ( o
VAS NNP o
) ) o
or CC N
number NN o
or CC o
kind NN o
of IN o
pain NN o
killers NNS o
. . o

For IN N
the DT N
HRQOLI-instrument NNP o
, , N
a DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
Materialise NNP i
Mucosa NNP i
and CC N
Materialise NNP i
Bone NNP i
group NN N
at IN N
day NN N
1 CD N
( ( N
p NN N
= RB N
0.02 CD N
) ) N
and CC N
day NN N
2 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
. . N

For IN N
the DT N
duration NN o
of IN o
the DT o
surgery NN o
, , N
a DT N
statistical JJ N
difference NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
was VBD N
found VBN N
between IN N
the DT N
Materialise NNP i
mucosa NN i
and CC N
the DT N
Mental NNP N
group NN N
, , N
in IN N
favour NN N
of IN N
the DT N
first JJ N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
little JJ N
difference NN N
could MD N
be VB N
found VBN N
in IN N
the DT N
patient JJ N
outcome NN N
variables NNS N
of IN N
the DT N
different JJ N
treatment NN N
groups NNS N
. . N

However RB N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
patients NNS N
treated VBN N
with IN N
conventional JJ N
flapped JJ N
implant JJ N
placement NN N
to TO N
experience VB N
the DT N
pain NN N
for IN N
a DT N
longer JJR N
period NN N
of IN N
time NN N
. . N

-DOCSTART- -22330261- O O

Bilateral NNP i
transversus NN i
abdominis NN i
plane NN i
block NN i
does VBZ N
not RB N
decrease VB N
postoperative JJ N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ i
anesthetic JJ i
infiltration NN i
of IN i
trocar NN i
insertion NN i
sites NNS i
. . i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Transversus NNP i
abdominis NN i
plane NN i
( ( i
TAP NNP i
) ) i
block NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
pain NN N
and CC N
analgesic JJ N
requirements NNS N
after IN N
abdominal JJ N
surgery NN N
. . N

Our PRP$ N
hypothesis NN N
was VBD N
that IN N
bilateral JJ i
TAP NNP i
blocks NNS i
decrease NN N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ i
anesthetic JJ i
infiltration NN i
of IN N
trocar NN N
insertion NN N
sites NNS N
. . N

METHODS NNP N
Eighty NNP p
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
bilateral JJ i
TAP NNP i
blocks NNS i
or CC i
local JJ i
anesthetic JJ i
infiltration NN i
of IN i
trocar NN i
insertion NN i
sites VBZ i
with IN i
ropivacaine JJ i
0.5 CD i
% NN i
. . i

Postoperative JJ o
pain NN o
scores NNS N
and CC N
analgesic JJ N
use NN N
for IN N
the DT N
first JJ N
24 CD N
hrs NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Eighty NNP p
patients NNS p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

After IN N
exclusions NNS N
, , N
data NNS N
were VBD N
analyzed VBN N
on IN N
39 CD N
patients NNS N
in IN N
group NN N
T NNP N
( ( N
bilateral JJ N
TAP NNP i
block NN i
) ) i
and CC N
35 CD N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
infiltration NN N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB o
significant JJ o
difference NN o
in IN N
pain NN o
scores NNS o
on IN o
the DT o
numeric JJ o
analog NN o
scale NN o
( ( N
0-10 JJ N
) ) N
between IN N
the DT N
groups NNS N
at IN N
4 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.18 CD N
) ) N
or CC N
during IN N
the DT N
24 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
. . N

The DT N
time NN o
interval NN o
from IN o
anesthesia JJ o
start NN o
to TO o
surgery VB o
start NN o
was VBD N
greater JJR N
in IN N
group NN N
T NNP N
than IN N
group NN N
I PRP N
( ( N
48 CD N
vs RB N
35 CD N
mins NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ o
difference NN o
found VBD N
in IN N
analgesic JJ o
use NN o
during IN N
the DT N
first JJ N
24 CD N
hrs NN N
after IN N
surgery NN N
. . N

CONCLUSIONS NNP N
Bilateral NNP i
ultrasound-guided JJ i
TAP NNP i
block NN i
is VBZ N
equivalent JJ N
to TO N
local JJ i
anesthetic JJ i
infiltration NN i
of IN N
trocar NN N
insertion NN N
sites VBZ N
for IN N
overall JJ N
postoperative JJ o
pain NN o
in IN N
a DT N
heterogeneous JJ N
group NN N
of IN N
patients NNS N
undergoing VBG N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -9532999- O O

The DT N
reliability NN N
of IN N
catheter-tip JJ i
transducers NNS i
for IN N
the DT N
measurement NN N
of IN N
intrauterine JJ o
pressure NN o
in IN N
the DT N
third JJ p
stage NN p
of IN p
labour NN p
. . p

In IN N
order NN N
to TO N
assess VB N
the DT N
reliability NN N
of IN N
intrauterine JJ o
pressure NN o
measurements NNS N
in IN N
the DT N
third JJ N
stage NN N
of IN N
labour NN N
, , N
catheter-tip JJ i
transducers NNS i
were VBD N
used VBN N
in IN N
20 CD p
women NNS p
randomly RB p
allocated VBN p
into IN p
two CD p
groups NNS p
of IN p
10 CD p
. . p

In IN N
each DT N
case NN N
in IN N
the DT N
first JJ N
group NN N
two CD N
catheters NNS i
were VBD N
tied VBN N
together RB N
and CC N
introduced VBN N
transcervically RB N
into IN N
the DT N
uterine JJ N
cavity NN N
after IN N
delivery NN N
of IN N
the DT N
placenta NN N
. . N

In IN N
each DT N
case NN N
in IN N
the DT N
second JJ N
group NN N
two CD N
catheters NNS N
were VBD N
inserted VBN N
independently RB N
into IN N
the DT N
same JJ N
uterine JJ N
cavity NN N
. . N

The DT N
active JJ o
and CC o
cumulative JJ o
active JJ o
pressures NNS o
recorded VBN N
from IN N
the DT N
pairs NNS N
of IN N
catheters NNS i
within IN N
each DT N
uterine JJ N
cavity NN N
were VBD N
compared VBN N
. . N

Comparison NNP N
of IN N
individual JJ o
active JJ o
pressure NN o
readings NNS N
from IN N
separate JJ N
transducers NNS N
revealed VBD N
good JJ N
agreement NN N
whether IN N
the DT N
catheters NNS i
were VBD N
tied VBN N
together RB N
or CC N
were VBD N
separate JJ N
. . N

Cumulative JJ o
active JJ o
pressure NN o
was VBD N
very RB N
similar JJ N
when WRB N
assessed VBN N
by IN N
each DT N
catheter NN i
in IN N
the DT N
same JJ N
uterus NN N
. . N

Intrauterine NNP i
catheter-tip JJ i
transducers NNS i
can MD N
be VB N
used VBN N
reliably RB N
to TO N
measure VB N
uterine JJ o
activity NN o
in IN N
the DT N
third JJ p
stage NN p
of IN p
labour JJ p
although IN N
there EX N
may MD N
be VB N
minor JJ N
contraction NN N
by IN N
contraction NN N
differences NNS N
in IN N
recordings NNS N
of IN N
individual JJ o
active JJ o
pressures NNS o
. . o

-DOCSTART- -11849797- O O

Prophylactic JJ N
use NN N
of IN N
amifostine NN i
to TO N
prevent VB N
radiochemotherapy-induced JJ N
mucositis NN N
and CC N
xerostomia NN N
in IN N
head-and-neck JJ N
cancer NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
the DT N
prophylactic JJ N
properties NNS N
of IN N
amifostine NN i
against IN N
acute JJ N
and CC N
late JJ N
toxicities NNS N
from IN N
radiochemotherapy NN N
in IN N
patients NNS p
with IN p
head-and-neck JJ p
cancer NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
Fifty NNP p
patients NNS p
were VBD p
randomized VBN p
to TO p
receive VB p
conventional JJ i
radiotherapy NN i
( ( p
RT NNP p
) ) p
( ( p
2-Gy JJ p
fractions NNS p
, , p
5 CD p
days NNS p
weekly RB p
, , p
to TO p
a DT p
total NN p
of IN p
60-74 JJ p
Gy NNP p
, , p
depending VBG p
on IN p
the DT p
tumor NN p
localization NN p
and CC p
TNM NNP p
classification NN p
) ) p
and CC p
carboplatin NN i
( ( p
90 CD p
mg/m NN p
( ( p
2 CD p
) ) p
infusion NN p
once RB p
per IN p
week NN p
before IN p
RT NNP p
) ) p
. . N

Amifostine NNP i
( ( N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
was VBD N
administered VBN N
in IN N
the DT N
study NN N
group NN N
only RB N
15-30 JJ N
min NN N
before IN N
RT NNP N
for IN N
6-7.5 JJ N
weeks NNS N
. . N

The DT N
primary JJ N
study NN N
end NN N
point NN N
was VBD N
the DT N
grading NN o
of IN o
acute NN o
and CC o
late JJ o
nonhematologic NN o
toxicities NNS o
( ( o
mucositis NN o
, , o
dysphagia NN o
, , o
xerostomia NN o
) ) o
induced VBN N
by IN N
radiochemotherapy NN i
. . i

Secondary JJ N
end NN N
points NNS N
included VBD N
treatment NN o
duration NN o
, , o
hematologic JJ o
toxicity NN o
, , o
and CC o
clinical JJ o
outcome NN o
. . o

RESULTS VB N
The DT N
treatment NN o
duration NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
amifostine-treated JJ p
group NN p
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
, , N
because IN N
treatment NN N
interruptions NNS N
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
control NN N
group NN N
. . N

Acute NNP o
toxicities NNS o
( ( o
mucositis NN o
and CC o
dysphagia NN o
) ) o
were VBD N
less JJR N
severe JJ N
in IN N
the DT N
amifostine-treated JJ N
group NN N
. . N

By IN N
Week JJ N
3 CD N
, , N
all DT N
in IN N
the DT N
control NN N
group NN N
experienced VBD N
Grade NNP o
2 CD o
mucositis NN o
compared VBN N
with IN N
only RB N
9 CD N
% NN N
in IN N
the DT N
amifostine-treated JJ N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

By IN N
Week JJ N
5 CD N
, , N
52.2 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
control NN N
group NN N
experienced VBD N
Grade NNP o
4 CD o
mucositis NN o
compared VBN N
with IN N
4.5 CD N
% NN N
in IN N
the DT N
amifostine-treated JJ N
group NN N
( ( N
p JJ N
= NNP N
0.0006 CD N
) ) N
. . N

Similar JJ N
results NNS N
were VBD N
obtained VBN N
for IN N
dysphagia NN o
. . o

At IN N
3 CD N
months NNS N
of IN N
follow-up NN N
, , N
only RB N
27 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
study NN N
group NN N
experienced VBD N
Grade NNP o
2 CD o
xerostomia NN o
compared VBN N
with IN N
73.9 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

Eighteen JJ N
months NNS N
after IN N
cessation NN N
of IN N
therapy NN N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
Grade NNP o
2 CD o
xerostomia NN o
was VBD N
4.5 CD N
% NN N
vs. FW N
30.4 CD N
% NN N
for IN N
each DT N
respective JJ N
treatment NN N
group NN N
( ( N
p JJ N
= NNP N
0.047 CD N
) ) N
. . N

Cytoprotection NN i
with IN N
amifostine NN i
did VBD N
not RB N
affect VB N
treatment NN N
outcome NN N
, , N
with IN N
90.9 CD N
% NN N
complete JJ N
responses NNS N
in IN N
the DT N
amifostine-treated JJ N
group NN N
compared VBN N
with IN N
78.3 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.414 CD N
) ) N
. . N

CONCLUSION NNP N
Amifostine NNP i
was VBD N
effective JJ N
in IN N
reducing VBG N
mucositis NN N
and CC N
dysphagia NN N
resulting VBG N
from IN N
radiochemotherapy NN N
in IN N
patients NNS p
with IN p
head-and-neck JJ p
cancer NN p
. . p

Furthermore NNP N
, , N
amifostine NN i
reduced VBD N
the DT N
severity NN N
of IN N
late JJ N
xerostomia NN N
, , N
a DT N
side NN N
effect NN N
of IN N
RT NNP N
with IN N
long-lasting JJ N
consequences NNS N
. . N

Amifostine NNP i
treatment NN N
did VBD N
not RB N
affect VB N
the DT N
clinical JJ N
outcome NN N
. . N

-DOCSTART- -8098276- O O

Short-term JJ N
effects NNS N
of IN N
denopamine NN i
on IN N
anaerobic JJ o
threshold NN o
and CC o
related JJ o
parameters NNS o
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
: : p
a DT N
double-blind JJ N
crossover NN N
study NN N
. . N

BACKGROUND IN N
The DT N
short-term JJ N
effects NNS N
of IN N
denopamine NN i
, , N
an DT N
orally RB N
available JJ N
beta-stimulant JJ N
, , N
on IN N
exercise NN N
capacity NN N
were VBD N
studied VBN N
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Nineteen NNP p
patients NNS p
entered VBD p
the DT p
study NN p
. . p

Three CD p
patients NNS p
had VBD p
ischemic JJ p
heart NN p
disease NN p
, , p
13 CD p
had VBD p
dilated VBN p
cardiomyopathy NN p
, , p
and CC p
three CD p
had VBD p
valvular JJ p
disease NN p
; : p
16 CD p
patients NNS p
were VBD p
in IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
II NNP p
, , p
and CC p
three CD p
patients NNS p
were VBD p
in IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
III NNP p
. . p

Symptom-limited JJ N
exercise NN N
testing NN N
( ( N
ramp VB N
protocol NN N
) ) N
on IN N
a DT N
bicycle NN N
ergometer NN i
with IN N
gas NN N
exchange NN N
analysis NN N
was VBD N
conducted VBN N
1 CD N
hour NN N
after IN N
oral JJ N
administration NN N
of IN N
either CC N
20 CD i
mg NN i
denopamine NN i
or CC i
placebo NN i
. . i

Drug NNP N
administration NN N
sequence NN N
was VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
method NN N
, , N
with IN N
1 CD N
week NN N
between IN N
drugs NNS N
. . N

Peak NNP o
VO2 NNP o
was VBD N
20.4 CD N
+/- JJ N
3.2 CD N
and CC N
21.2 CD N
+/- JJ N
3.1 CD N
ml/min/kg NN N
, , N
respectively RB N
, , N
for IN N
those DT N
administered VBN N
the DT N
placebo NN i
and CC N
the DT N
drug NN N
, , N
and CC N
anaerobic JJ o
threshold NN o
was VBD N
13.1 CD N
+/- JJ N
2.1 CD N
and CC N
14.0 CD N
+/- JJ N
2.0 CD N
ml/min/kg NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
peak JJ o
VO2 NNP o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
anaerobic JJ o
threshold NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
with IN N
denopamine NN i
, , N
whereas IN N
no DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
peak JJ o
work NN o
rate NN o
or CC o
exercise NN o
time NN o
. . o

Denopamine NNP i
increased VBD N
heart NN o
rate NN o
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
but CC N
had VBD N
little JJ N
effect NN N
on IN N
heart NN o
rate NN o
in IN N
patients NNS p
with IN p
sinus JJ p
rhythm NN p
. . p

CONCLUSION NNP N
Data NNP N
obtained VBD N
from IN N
gas NN N
exchange NN N
analysis NN N
are VBP N
more RBR N
sensitive JJ N
and CC N
potentially RB N
more RBR N
useful JJ N
in IN N
the DT N
detection NN N
of IN N
short-term JJ N
changes NNS N
in IN N
exercise NN o
capacity NN o
than IN N
data NNS N
obtained VBN N
from IN N
either CC N
exercise JJ N
time NN N
or CC N
peak JJ N
work NN N
rate NN N
, , N
indexes NNS N
that WDT N
are VBP N
commonly RB N
used VBN N
to TO N
assess VB N
drug NN N
therapy NN N
. . N

Patients NNS p
with IN p
mild-to-moderate JJ p
heart NN p
failure NN p
with IN p
sinus NN p
rhythm NN p
, , N
but CC N
not RB N
those DT p
with IN p
atrial JJ p
fibrillation NN p
because IN p
of IN p
its PRP$ p
frequent JJ p
induction NN p
of IN p
tachycardia NN p
, , N
may MD N
be VB N
good JJ N
candidates NNS N
for IN N
denopamine NN i
therapy NN N
. . N

-DOCSTART- -15482502- O O

A DT N
new JJ N
social JJ i
communication NN i
intervention NN i
for IN N
children NNS p
with IN p
autism NN p
: : p
pilot NN N
randomised VBD N
controlled VBN N
treatment NN N
study NN N
suggesting VBG N
effectiveness NN N
. . N

BACKGROUND NNP N
Psychosocial NNP N
treatments NNS N
are VBP N
the DT N
mainstay NN N
of IN N
management NN N
of IN N
autism NN N
in IN N
the DT N
UK NNP N
but CC N
there EX N
is VBZ N
a DT N
notable JJ N
lack NN N
of IN N
a DT N
systematic JJ N
evidence NN N
base NN N
for IN N
their PRP$ N
effectiveness NN N
. . N

Randomised VBN N
controlled JJ N
trial NN N
( ( N
RCT NNP N
) ) N
studies NNS N
in IN N
this DT N
area NN N
have VBP N
been VBN N
rare JJ N
but CC N
are VBP N
essential JJ N
because IN N
of IN N
the DT N
developmental JJ N
heterogeneity NN N
of IN N
the DT N
disorder NN N
. . N

We PRP N
aimed VBD N
to TO N
test VB N
a DT N
new JJ i
theoretically RB i
based VBN i
social JJ i
communication NN i
intervention NN i
targeting VBG i
parental JJ i
communication NN i
in IN N
a DT N
randomised JJ N
design NN N
against IN N
routine JJ i
care NN i
alone RB i
. . i

METHODS NNP N
The DT N
intervention NN i
was VBD i
given VBN i
in IN i
addition NN i
to TO i
existing VBG i
care NN i
and CC N
involved VBN N
regular JJ i
monthly JJ i
therapist NN i
contact NN i
for IN N
6 CD N
months NNS N
with IN N
a DT N
further JJ N
6 CD N
months NNS N
of IN N
2-monthly JJ N
consolidation NN N
sessions NNS N
. . N

It PRP N
aimed VBD N
to TO N
educate VB N
parents NNS N
and CC N
train VB N
them PRP N
in IN N
adapted VBN N
communication NN N
tailored VBN N
to TO N
their PRP$ N
child NN N
's POS N
individual JJ N
competencies NNS N
. . N

Twenty-eight JJ p
children NNS p
with IN p
autism NN p
were VBD N
randomised VBN N
between IN N
this DT N
treatment NN i
and CC i
routine JJ i
care NN i
alone RB i
, , N
stratified VBD p
for IN p
age NN p
and CC p
baseline NN p
severity NN p
. . p

Outcome NNP N
was VBD N
measured VBN N
at IN N
12 CD N
months NNS N
from IN N
commencement NN N
of IN N
intervention NN N
, , N
using VBG N
standardised JJ N
instruments NNS N
. . N

RESULTS NNP N
All NNP N
cases NNS N
studied VBD N
met VBN N
full JJ N
Autism NNP N
Diagnostic NNP N
Interview NNP N
( ( N
ADI NNP N
) ) N
criteria NN N
for IN N
classical JJ N
autism NN N
. . N

Treatment NN N
and CC N
controls NNS N
had VBD N
similar JJ N
routine JJ N
care NN N
during IN N
the DT N
study NN N
period NN N
and CC N
there EX N
were VBD N
no DT N
study NN N
dropouts VBZ N
after IN N
treatment NN N
had VBD N
started VBN N
. . N

The DT N
active JJ N
treatment NN N
group NN N
showed VBD N
significant JJ N
improvement NN N
compared VBN N
with IN N
controls NNS N
on IN N
the DT N
primary JJ N
outcome JJ N
measure NN o
-- : o
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
( ( o
ADOS NNP o
) ) o
total NN o
score NN o
, , o
particularly RB o
in IN o
reciprocal JJ o
social JJ o
interaction NN o
-- : o
and CC o
on IN N
secondary JJ N
measures NNS N
of IN N
expressive JJ o
language NN o
, , o
communicative JJ o
initiation NN o
and CC o
parent-child JJ o
interaction NN o
. . o

Suggestive JJ N
but CC N
non-significant JJ N
results NNS N
were VBD N
found VBN N
in IN N
Vineland NNP o
Adaptive NNP o
Behaviour NNP o
Scales NNP o
( ( o
Communication NNP o
Sub-domain NNP o
) ) o
and CC o
ADOS NNP o
stereotyped VBD o
and CC o
restricted VBD o
behaviour NN o
domain NN o
. . o

CONCLUSIONS VB N
A DT N
Randomised JJ N
Treatment NNP N
Trial NNP N
design NN N
of IN N
this DT N
kind NN N
in IN N
classical JJ N
autism NN N
is VBZ N
feasible JJ N
and CC N
acceptable JJ N
to TO N
patients NNS N
. . N

This DT N
pilot NN N
study NN N
suggests VBZ N
significant JJ N
additional JJ N
treatment NN N
benefits NNS N
following VBG N
a DT N
targeted JJ N
( ( N
but CC N
relatively RB N
non-intensive JJ N
) ) N
dyadic VBZ N
social JJ N
communication NN N
treatment NN N
, , N
when WRB N
compared VBN N
with IN N
routine JJ N
care NN N
. . N

The DT N
study NN N
needs VBZ N
replication NN N
on IN N
larger JJR N
and CC N
independent JJ N
samples NNS N
. . N

It PRP N
should MD N
encourage VB N
further JJ N
RCT NNP N
designs NNS N
in IN N
this DT N
area NN N
. . N

-DOCSTART- -12704402- O O

Effect NN N
of IN N
a DT N
high-protein JJ i
, , i
energy-restricted JJ i
diet NN i
on IN N
weight JJ o
loss NN o
and CC o
energy NN o
expenditure NN o
after IN N
weight JJ N
stabilization NN N
in IN N
hyperinsulinemic JJ p
subjects NNS p
. . p

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effect NN N
of IN N
replacing VBG N
some DT N
dietary JJ N
carbohydrate NN N
with IN N
protein NN N
, , N
during IN N
energy NN N
restriction NN N
, , N
on IN N
weight JJ o
loss NN o
, , o
total JJ o
energy NN o
expenditure NN o
( ( o
TEE NNP o
) ) o
, , o
resting VBG o
energy NN o
expenditure NN o
( ( o
REE NNP o
) ) o
, , o
respiratory JJ o
quotient NN o
( ( o
RQ NNP o
) ) o
, , o
and CC o
the DT o
thermic JJ o
effect NN o
of IN o
feeding NN o
( ( o
TEF NNP o
) ) o
in IN N
subjects NNS p
with IN p
hyperinsulinemia NN p
. . p

DESIGN NNP N
Parallel NNP N
, , N
clinical JJ N
intervention NN N
study NN N
of IN N
12 CD N
weeks NNS N
energy NN i
restriction NN i
( ( N
6.5 CD N
MJ/day NNP N
) ) N
and CC N
4 CD N
weeks NNS N
energy NN i
balance NN i
( ( N
8.2 CD N
MJ/day NNP N
) ) N
in IN N
two CD N
groups NNS N
of IN N
subjects NNS N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
high-protein NN i
( ( i
HP NNP i
) ) i
diet NN i
( ( N
27 CD N
% NN N
of IN N
energy NN N
( ( N
% NN N
E NNP N
) ) N
as IN N
protein NN N
, , N
45 CD N
% NN N
E NNP N
as IN N
carbohydrate NN N
) ) N
or CC N
a DT N
lower-protein JJ i
( ( i
LP NNP i
) ) i
diet NN i
( ( N
16 CD N
% NN N
E NNP N
as IN N
protein NN N
, , N
57 CD N
% NN N
E NNP N
as IN N
carbohydrate NN N
) ) N
. . N

SUBJECTS VB N
A DT p
total NN p
of IN p
36 CD p
obese JJ p
nondiabetic JJ p
volunteers NNS p
with IN p
hyperinsulinemia NN p
( ( p
10 CD p
males/26 NN p
females NNS p
, , p
aged VBD p
34-65 JJ p
y NN p
, , p
BMI NNP p
28-43 CD p
kg/m NN p
( ( p
2 CD p
) ) p
, , p
fasting VBG p
insulin JJ p
12-45 JJ p
mU/l NN p
) ) p
. . p

MEASUREMENTS NNP N
Body NNP o
weight VBD o
and CC o
composition NN o
, , o
TEE NNP o
, , o
REE NNP o
, , o
and CC o
RQ NNP o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
16 CD N
. . N

In IN N
addition NN N
, , N
the DT N
TEF NNP o
to TO N
an DT N
HP NNP i
or CC N
LP NNP i
meal NN N
was VBD N
determined VBN N
for IN N
3 CD N
h NN N
, , N
at IN N
baseline NN N
and CC N
at IN N
week NN N
16 CD N
. . N

RESULTS NN N
After IN N
16 CD N
weeks NNS N
, , N
weight JJ o
loss NN o
was VBD N
similar JJ N
in IN N
response NN N
to TO N
each DT N
diet NN N
; : N
the DT N
overall JJ N
decrease NN N
was VBD N
7.9+/-0.6 JJ N
kg NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
of IN N
which WDT N
6.8+/-0.5 JJ N
kg NN N
was VBD N
fat JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

REE NNP o
fell VBD N
similarly RB N
with IN N
each DT N
diet NN N
; : N
the DT N
overall JJ N
decrease NN N
was VBD N
719+/-106 JJ N
kJ/day NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
TEF NNP o
was VBD N
2 CD N
% NN N
greater JJR N
after IN N
the DT N
HP NNP i
than IN N
after IN N
the DT N
LP NNP i
meal NN N
at IN N
baseline NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
0.8 CD N
% NN N
greater JJR N
at IN N
week NN N
16 CD N
( ( N
P=0.35 NNP N
) ) N
. . N

After IN N
16 CD N
weeks NNS N
, , N
the DT N
TEF NNP o
was VBD N
not RB N
reduced VBN N
in IN N
either DT N
dietary JJ N
group NN N
. . N

There EX N
was VBD N
no DT N
change NN N
in IN N
TEE NNP o
after IN N
16 CD N
weeks NNS N
. . N

CONCLUSION NNP N
In IN N
subjects NNS p
with IN p
hyperinsulinemia PDT p
an DT N
energy-restrictive JJ N
diet NN N
containing VBG N
an DT N
increased VBN N
protein-to-carbohydrate NN o
ratio NN o
does VBZ N
not RB N
enhance VB N
weight JJ o
loss NN o
or CC o
significantly RB o
affect JJ o
energy NN o
expenditure NN o
. . o

Caloric NNP N
restriction NN N
, , N
rather RB N
than IN N
the DT N
macronutrient JJ N
composition NN N
of IN N
the DT N
diet NN N
, , N
is VBZ N
the DT N
most RBS N
important JJ N
determinant NN N
of IN N
weight JJ N
loss NN N
. . N

-DOCSTART- -15182139- O O

Predicting VBG N
completion NN N
of IN N
treatment NN N
among IN N
foreign-born JJ p
adolescents NNS p
treated VBN p
for IN p
latent JJ p
tuberculosis NN p
infection NN p
in IN p
Los NNP p
Angeles NNP p
. . p

SETTING NNP N
Two CD p
health NN p
clinics NNS p
in IN p
Los NNP p
Angeles NNP p
County NNP p
, , p
California NNP p
. . p

OBJECTIVE NNP N
To TO N
identify VB N
factors NNS N
associated VBN N
with IN N
completion NN N
of IN N
care NN N
among IN N
foreign-born JJ p
adolescents NNS p
treated VBN p
for IN p
latent JJ p
tuberculosis NN p
infection NN p
( ( p
LTBI NNP p
) ) p
. . p

DESIGN VB N
A DT p
total NN p
of IN p
766 CD p
low-income JJ p
adolescents NNS p
( ( p
79 CD p
% NN p
participation NN p
rate NN p
) ) p
, , p
including VBG p
610 CD p
foreign-born JJ p
, , p
were VBD p
recruited VBN p
. . p

In IN N
prospective JJ N
face-to-face NN i
interviews NNS i
, , N
data NNS N
were VBD N
obtained VBN N
on IN N
socio-demographic JJ N
and CC N
lifestyle JJ N
characteristics NNS N
, , N
psychosocial JJ N
factors NNS N
and CC N
clinic-related JJ N
variables NNS N
. . N

Medical JJ i
chart NN i
data NNS i
were VBD i
abstracted VBN i
regarding VBG N
clinic JJ N
appointment NN N
keeping VBG N
and CC N
completion NN N
of IN N
treatment NN N
. . N

Univariate NNP i
and CC i
multivariate VB i
logistic JJ i
regression NN i
analyses NNS i
were VBD N
performed VBN N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
completion NN N
of IN N
care NN N
. . N

RESULTS NNP N
Foreign-born JJ p
adolescents NNS p
were VBD N
more RBR N
likely JJ N
to TO N
complete VB o
care NN o
than IN N
US-born JJ N
adolescents NNS N
, , N
with IN N
82 CD N
% NN N
completion NN N
of IN N
care NN N
rate NN N
. . N

In IN N
logistic JJ N
regression NN N
analyses NNS N
after IN N
controlling VBG N
for IN N
age NN N
, , N
medication NN o
taking VBG o
behavior NN o
( ( N
OR CC N
1.26 CD N
, , N
95 CD N
% NN N
CI NNP N
1.15-1.39 CD N
) ) N
, , N
living VBG o
with IN o
both DT o
parents NNS o
( ( N
OR NNP N
1.74 CD N
, , N
95 CD N
% NN N
CI NNP N
1.02-2.97 CD N
) ) N
, , N
sexual JJ o
intercourse NN o
( ( N
OR CC N
0.66 CD N
, , N
95 CD N
% NN N
CI NNP N
0.36-1.19 NN N
) ) N
and CC N
speaking VBG o
mostly RB o
or CC o
only RB o
English JJ o
with IN o
parents NNS o
( ( N
OR NNP N
0.39 CD N
, , N
95 CD N
% NN N
CI NNP N
0.15-1.03 NN N
) ) N
were VBD N
independently RB N
associated VBN N
with IN N
completion NN N
of IN N
care NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
contribute VBP N
to TO N
our PRP$ N
understanding NN N
of IN N
the DT N
factors NNS N
that WDT N
may MD N
explain VB N
why WRB N
some DT N
adolescents NNS N
complete JJ N
care NN N
whereas IN N
others NNS N
do VBP N
not RB N
. . N

They PRP N
provide VBP N
supportive JJ N
evidence NN N
that WDT N
tailored VBD N
intervention NN N
programs NNS N
should MD N
be VB N
developed VBN N
to TO N
support VB N
the DT N
screening NN N
and CC N
completion NN N
of IN N
treatment NN N
of IN N
foreign-born JJ p
adolescents NNS p
. . p

-DOCSTART- -9732932- O O

Relationship NN N
between IN N
biliary NN N
and CC N
serum NN N
bile NN N
acids NNS N
and CC N
response NN N
to TO N
ursodeoxycholic JJ i
acid NN i
in IN N
patients NNS p
with IN p
primary JJ p
biliary JJ p
cirrhosis NN p
. . p

OBJECTIVE NNP N
Ursodeoxycholic NNP i
acid NN i
( ( i
UDCA NNP i
) ) i
improves VBZ N
liver JJ o
biochemistries NNS o
and CC N
enriches VBZ o
the DT o
bile NN o
with IN o
UDCA NNP o
in IN N
patients NNS p
with IN p
primary JJ p
biliary JJ p
cirrhosis NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
degree NN N
of IN N
enrichment NN N
of IN N
bile NN N
correlated VBN N
with IN N
that DT N
of IN N
serum NN N
and CC N
whether IN N
either DT N
of IN N
these DT N
measures NNS N
correlated VBD N
with IN N
improvement NN N
in IN N
measures NNS N
of IN N
liver NN N
disease NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
study NN N
, , N
biliary JJ N
and CC N
serum JJ N
bile NN N
acid NN N
analyses NNS N
were VBD N
performed VBN N
at IN N
entry NN N
and CC N
after IN N
2 CD N
yr NN N
of IN N
UDCA NNP i
or CC N
placebo NN i
. . i

RESULTS VB N
The DT N
percentage NN o
of IN o
ursodeoxycholic JJ o
acid NN o
in IN o
bile NN o
increased VBN N
by IN N
42 CD N
% NN N
in IN N
the DT N
UDCA NNP i
group NN N
( ( N
n JJ N
= NNP N
61 CD N
) ) N
compared VBN N
with IN N
8 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
n JJ N
= NNP N
57 CD N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Measurement NN o
of IN o
serum NN o
bile NN o
acids NNS o
in IN N
32 CD p
patients NNS p
( ( p
18 CD p
ursodeoxycholic JJ i
acid NN i
, , p
14 CD p
placebo NN i
) ) i
indicated VBD N
that IN N
at IN N
2 CD N
yr NN N
, , N
ursodeoxycholic JJ i
acid NN i
comprised VBD N
65 CD N
% NN N
of IN N
serum NN N
bile NN N
acids NNS N
in IN N
the DT N
treated JJ N
group NN N
and CC N
7 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN p
. . p

Agreement NNP N
between IN N
bile NN N
and CC N
serum NN N
was VBD N
fair JJ N
( ( N
r JJ N
= NN N
0.75 CD N
, , N
p NN N
< NN N
or CC N
= VB N
0.00002 CD N
) ) N
because IN N
in IN N
some DT N
patients NNS N
, , N
plasma NNS N
but CC N
not RB N
biliary JJ N
bile NN N
acids NNS N
were VBD N
enriched VBN N
with IN N
UDCA NNP i
. . i

Changes NNS o
in IN o
biliary JJ o
ursodeoxycholic JJ o
acid NN o
correlated VBN N
significantly RB N
but CC N
weakly RB N
with IN N
the DT N
changes NNS N
in IN N
serum NN o
alkaline NN o
phosphatase NN o
, , o
AST NNP o
, , o
bilirubin NN o
, , o
and CC o
in IN o
Mayo NNP o
risk NN o
score NN o
. . o

Correlations NNS N
between IN N
changes NNS N
in IN N
serum NN o
bile NN o
acid JJ o
composition NN o
and CC o
biochemical JJ o
measures NNS o
of IN o
disease NN o
activity NN o
were VBD N
even RB N
weaker JJR N
. . N

CONCLUSION VB N
The DT N
measurement NN N
of IN N
biliary JJ N
bile NN N
acids NNS N
is VBZ N
superior JJ N
to TO N
that DT N
of IN N
serum NN N
bile NN N
acids NNS N
for IN N
assessing VBG N
the DT N
compliance NN N
and CC N
changes NNS N
in IN N
the DT N
circulating NN N
bile JJ N
acids NNS N
in IN N
patients NNS N
receiving VBG N
ursodeoxycholic JJ i
acid NN i
for IN N
the DT N
treatment NN N
of IN N
primary JJ o
biliary JJ o
cirrhosis NN o
. . o

Furthermore NNP N
, , N
measures VBZ N
to TO N
further JJ N
increase VB N
the DT N
proportion NN N
of IN N
ursodeoxycholic JJ i
acid NN i
in IN N
circulating VBG N
bile JJ N
acids NNS N
should MD N
be VB N
explored VBN N
. . N

-DOCSTART- -1631861- O O

Biochemical NNP N
and CC N
functional JJ N
effects NNS N
of IN N
creatine NN i
phosphate NN i
in IN N
cardioplegic JJ N
solution NN N
during IN N
aortic JJ p
valve NN p
surgery NN p
-- : p
a DT p
clinical JJ N
study NN N
. . N

During IN N
myocardial JJ N
ischemia NN N
there EX N
is VBZ N
a DT N
drop NN o
in IN o
high-energy JJ o
phosphates NNS o
in IN N
the DT N
myocardium NN N
. . N

Cold NNP N
potassium NN N
cardioplegia NN N
decreases NNS N
but CC N
does VBZ N
not RB N
altogether RB N
prevent VB N
this DT N
reduction NN N
. . N

Supplementation NN N
of IN N
cardioplegic JJ N
solutions NNS N
with IN N
the DT N
high-energy JJ N
compound NN N
creatine NN i
phosphate NN i
( ( N
10 CD N
mmol/L NN N
) ) N
compared VBN N
to TO N
plain VB i
cardioplegic JJ i
solutions NNS i
was VBD N
investigated VBN N
in IN N
this DT N
study NN N
. . N

Thirty NNP p
patients NNS p
scheduled VBN p
for IN p
aortic JJ p
valve NNS p
replacement NN p
were VBD p
included VBN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
group NN N
I PRP N
( ( i
creatine VB i
phosphate NN i
) ) i
or CC N
group NN N
II NNP N
( ( i
control NN i
) ) i
. . N

Postoperative JJ N
hemodynamic JJ o
evaluation NN o
revealed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

However RB N
, , N
group NN N
I PRP N
exhibited VBD N
a DT N
tendency NN N
toward IN N
a DT N
better JJR N
stroke-work NN o
index NN o
( ( N
135 CD N
+/- JJ N
18 CD N
% NN N
vs. FW N
102 CD N
+/- JJ N
5 CD N
% NN N
recovery NN N
15 CD N
minutes NNS N
after IN N
bypass NN N
and CC N
145 CD N
+/- JJ N
16 CD N
% NN N
vs. FW N
119 CD N
+/- JJ N
11 CD N
% NN N
recovery NN N
105 CD N
min NN N
after IN N
bypass NN N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
5/15 CD N
) ) N
needing VBG o
inotropic JJ o
support NN o
compared VBN N
to TO N
group NN N
II NNP N
( ( N
9/14 CD N
) ) N
. . N

The DT N
myocardial JJ o
content NN o
of IN o
ATP NNP o
and CC o
creatine NN o
phosphate NN o
showed VBD N
no DT N
significant JJ N
differences NNS N
during IN N
ischemia NN N
and CC N
reperfusion NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
myocardial JJ N
protection NN N
during IN N
ischemia NN N
was VBD N
sufficient JJ N
to TO N
prevent VB N
significant JJ N
reductions NNS N
of IN N
myocardial JJ o
ATP NNP o
and CC o
creatine VB o
phosphate JJ o
irrespective NN N
of IN N
supplementation NN N
with IN N
CP NNP N
. . N

-DOCSTART- -11318056- O O

Variability NN N
in IN N
isochronous JJ i
tapping NN i
: : i
higher JJR N
order NN N
dependencies NNS N
as IN N
a DT N
function NN N
of IN N
intertap JJ N
interval NN N
. . N

Isochronous JJ p
serial JJ p
interval NN p
production NN p
( ( p
ISIP NNP p
) ) p
data NN N
, , N
as IN N
from IN N
unpaced JJ i
finger NN i
tapping NN i
, , N
exhibit NN N
higher JJR N
order NN N
dependencies NNS N
( ( N
drift NN N
) ) N
. . N

This DT N
fact NN N
has VBZ N
largely RB N
been VBN N
ignored VBN N
by IN N
the DT N
timing NN N
literature NN N
, , N
one CD N
reason NN N
probably RB N
being VBG N
that IN N
influential JJ N
timing NN N
models NNS N
assume VBP N
random JJ N
variability NN N
. . N

Men NNP p
and CC p
women NNS p
, , p
22-36 JJ p
years NNS p
old JJ p
, , N
performed VBD N
a DT N
synchronization-continuation NN i
task NN i
with IN i
intertap JJ i
intervals NNS i
( ( i
ITI NNP i
) ) i
from IN N
0.4 CD N
s NNS N
to TO N
2.2 CD N
s. NNS N
ISIP NNP N
variability NN N
was VBD N
partitioned VBN N
into IN N
components NNS N
attributable JJ N
to TO N
drift VB N
and CC N
1st-order JJ N
serial JJ N
correlation NN N
, , N
and CC N
the DT N
results NNS N
indicate VBP N
that IN N
( ( N
a DT N
) ) N
drift NN N
contributes VBZ N
substantially RB N
to TO N
the DT N
dispersion NN N
for IN N
longer JJR N
ITIs NNP N
, , N
( ( N
b NN N
) ) N
drift NN N
and CC N
1st-order JJ N
correlation NN N
are VBP N
different JJ N
functions NNS N
of IN N
the DT N
ITI NNP N
, , N
and CC N
( ( N
c NN N
) ) N
drift NN N
exhibits VBZ N
break VBP N
close JJ N
to TO N
1.0 CD N
s NNS N
and CC N
1.4 CD N
s NN N
ITI NNP N
. . N

These DT N
breaks NNS N
correspond NN N
to TO N
qualitative JJ N
changes NNS N
in IN N
performance NN N
for IN N
other JJ N
temporal JJ N
tasks NNS N
, , N
which WDT N
suggests VBZ N
common JJ N
timing NN N
processes VBZ N
across IN N
modalities NNS N
and CC N
tasks NNS N
. . N

-DOCSTART- -3624669- O O

Disopyramide-pyridostigmine JJ i
interaction NN N
: : N
selective JJ N
reversal NN N
of IN N
anticholinergic NN N
symptoms NNS N
with IN N
preservation NN N
of IN N
antiarrhythmic JJ N
effect NN N
. . N

This DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo FW i
crossover NN N
study NN N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
cholinesterase NN i
inhibitor NN i
-- : i
slow-release JJ i
pyridostigmine NN i
( ( N
180 CD N
mg NNS N
orally RB N
every DT N
12 CD N
hours NNS N
) ) N
-- : N
on IN N
the DT N
anticholinergic NN o
and CC o
antiarrhythmic JJ o
properties NNS o
of IN N
disopyramide NN i
. . i

Quantitative JJ N
side NN N
effects NNS N
questionnaire VBP N
scores NNS N
were VBD N
used VBN N
to TO N
guide VB N
disopyramide JJ i
administration NN N
in IN N
20 CD p
men NNS p
with IN p
ventricular JJ p
tachycardia NN p
. . p

Disopyramide NNP i
was VBD N
given VBN N
to TO N
each DT N
patient NN p
both DT p
with IN p
placebo NN i
and CC p
with IN p
active JJ p
pyridostigmine NN i
. . i

The DT N
maximal JJ N
administered VBD N
dose NN N
for IN N
each DT N
regimen NN N
was VBD N
used VBN N
in IN N
conjunction NN N
with IN N
corresponding JJ N
questionnaire NN N
scores NNS N
to TO N
calculate VB N
an DT N
index NN N
or CC N
estimate NN N
of IN N
the DT N
maximal JJ o
tolerable JJ o
dose NN o
of IN N
disopyramide NN i
. . i

Additional JJ N
evaluations NNS N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
each DT N
maximal NN N
administered VBD N
dose JJ N
regimen NNS N
included VBD N
tear JJ o
and CC o
saliva JJ o
quantitation NN o
, , o
24 CD o
hour NN o
electrocardiogram NN o
( ( o
ECG NNP o
) ) o
, , o
exercise VBP o
testing VBG o
and CC o
programmed VBD o
ventricular JJ o
stimulation NN o
. . o

Results NNS N
showed VBD N
that IN N
the DT N
maximal NN N
administered VBD N
dose NN N
of IN N
disopyramide NN i
was VBD N
greater JJR N
with IN N
active JJ N
pyridostigmine NN i
than IN N
with IN N
placebo NN N
: : N
295 CD N
+/- JJ N
75 CD N
versus NN N
245 CD N
+/- JJ N
100 CD N
mg NN N
every DT N
6 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
calculated JJ N
maximal NN o
tolerable JJ o
dose NN o
was VBD N
substantially RB N
greater JJR N
in IN N
the DT N
presence NN N
of IN N
pyridostigmine NN i
: : i
355 CD N
+/- JJ N
90 CD N
versus NN N
260 CD N
+/- JJ N
115 CD N
mg NN N
every DT N
6 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Maximal JJ o
side NN o
effects NNS o
questionnaire NN o
scores NNS o
also RB N
reflected VBD N
decreased JJ N
anticholinergic JJ o
activity NN o
in IN N
the DT N
presence NN N
of IN N
pyridostigmine NN i
compared VBN N
with IN N
placebo NN i
: : i
101.9 CD N
+/- JJ N
2.2 CD N
versus NN N
104.6 CD N
+/- JJ N
2.8 CD N
, , N
respectively RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
. . N

Baseline NNP N
tear NN N
and CC N
saliva JJ N
production NN N
was VBD N
significantly RB N
reduced VBN N
during IN N
disopyramide JJ N
therapy NN N
, , N
but CC N
was VBD N
restored VBN N
toward IN N
normal JJ N
by IN N
the DT N
addition NN N
of IN N
pyridostigmine NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -11194696- O O

Increasing VBG p
the DT p
reach NN p
of IN p
health NN o
sponsorship NN p
: : p
using VBG p
a DT p
sponsorship JJ i
kit NN i
to TO p
promote VB p
health NN p
. . p

In IN N
Australia NNP p
, , N
a DT N
tobacco NN N
tax NN N
provides VBZ N
funding NN N
for IN N
Healthway NNP N
, , N
the DT N
Western NNP N
Australian NNP N
Health NNP N
Promotion NNP N
Foundation NNP N
. . N

Healthway NNP N
provides VBZ N
sponsorships NNS N
for IN N
the DT N
arts NNS N
and CC N
racing NN N
and CC N
sporting VBG N
events NNS N
to TO N
replace VB N
funds NNS N
previously RB N
provided VBN N
by IN N
tobacco NN N
companies NNS N
. . N

These DT N
sponsorships NNS N
provide VBP N
visibility NN N
for IN N
Healthway NNP N
and CC N
positive JJ N
health NN N
messages NNS N
. . N

Normally RB N
, , N
Healthway NNP N
staff NN N
attends VBZ N
these DT N
events NNS N
to TO N
help VB N
promote VB N
health NN N
messages NNS N
. . N

To TO N
reduce VB N
Healthway NNP p
staff NN p
time NN N
spent VBN N
helping VBG N
event NN N
organizers NNS N
promote VBP N
health NN N
messages NNS N
, , N
Healthway NNP N
developed VBD N
a DT N
sponsor JJ i
kit NN i
of IN i
promotional JJ i
materials NNS i
which WDT N
communicate VBP N
health NN N
messages NNS N
without IN N
requiring VBG N
Healthway NNP p
staff NN p
to TO N
attend VB N
events NNS N
. . N

Recognition NNP o
, , o
awareness NN o
, , o
comprehension NN o
, , o
and CC o
acceptance NN o
of IN o
health NN o
messages NNS o
was VBD N
comparable JJ N
at IN N
events NNS N
that WDT N
featured VBD N
Healthway NNP N
staff NN N
versus IN N
the DT N
sponsor NN N
kits NNS N
, , N
but CC N
the DT N
average JJ N
cost NN N
of IN N
the DT N
sponsorship NN i
kits NNS i
was VBD N
only RB N
40 CD N
% NN N
of IN N
the DT N
cost NN N
when WRB N
Healthway NNP N
staff NN N
was VBD N
featured VBN N
. . N

-DOCSTART- -88754- O O

Adjvant NNP i
treatment NN i
of IN N
tongue NN p
and CC p
floor NN p
of IN p
the DT p
mouth NN p
cancers NNS p
. . p

Since IN p
January NNP p
1974 CD p
, , p
95 CD p
patients NNS p
with IN p
anterior JJ p
tongue NN p
and CC p
floor NN p
of IN p
the DT p
mouth NN p
cancers NNS p
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

After IN N
stratification NN N
according VBG N
to TO N
staging VBG N
and CC N
initial JJ N
treatment NN N
, , N
one-third NN p
of IN p
the DT p
patients NNS p
received VBD p
chemotherapy NN i
for IN i
2 CD i
years NNS i
( ( i
methotrexate VB i
400 CD i
mg NN i
followed VBN i
by IN i
citrovorum NN i
factor NN i
100 CD i
mg NN i
+ NNP i
bleomycin VBZ i
60 CD i
mg/week NN i
, , i
during IN i
the DT i
first JJ i
15 CD i
weeks NNS i
) ) i
, , i
one-third JJ i
of IN i
the DT i
patients NNS i
received VBD i
immunotherapy JJ i
with IN i
weekly JJ i
C. NNP i
parvum NN i
injections NNS i
during IN i
2 CD i
years NNS i
, , i
while IN i
the DT i
remaining VBG i
third NN i
did VBD i
not RB i
receive VB i
any DT i
treatment NN i
. . i

If IN N
adjuvant JJ N
treatment NN N
seems VBZ N
to TO N
delay VB o
recurrence NN o
it PRP N
did VBD N
not RB N
significantly RB N
decrease VB N
the DT N
recurrence NN o
rate NN o
. . o

Survival NN o
is VBZ N
also RB N
not RB N
signigicantly RB N
modified VBN N
by IN N
adjuvant JJ i
treatment NN N
and CC N
was VBD N
better JJR N
for IN N
patients NNS N
with IN N
small JJ N
tumors NNS N
. . N

Patients NNS p
who WP p
previously RB p
received VBD p
radiotherapy NN i
did VBD N
not RB N
benefit VB N
from IN N
adjuvant JJ i
therapy NN i
. . i

-DOCSTART- -17513813- O O

Randomized VBN N
trial NN N
of IN N
an DT N
allogeneic JJ i
melanoma NN i
lysate NN i
vaccine NN i
with IN i
low-dose JJ i
interferon NN i
Alfa-2b NNP i
compared VBN N
with IN N
high-dose JJ i
interferon NN i
Alfa-2b NNP i
for IN N
Resected NNP p
stage NN p
III NNP p
cutaneous JJ p
melanoma NN p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
of IN N
patients NNS p
with IN p
resected JJ p
stage NN o
III NNP o
melanoma NN o
administered VBD N
active JJ N
specific JJ i
immunotherapy NN i
and CC i
low-dose JJ i
interferon NN i
alfa-2b NN i
( ( i
IFN-alpha-2b NNP i
) ) i
with IN N
the DT N
OS NNP N
achieved VBD N
using VBG N
high-dose JJ i
IFN-alpha-2b NNP i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
An DT N
Ad NNP p
Hoc NNP p
Melanoma NNP p
Working NNP p
Group NNP p
of IN p
25 CD p
investigators NNS p
treated VBD p
604 CD p
patients NNS p
from IN p
April NNP p
1997 CD p
to TO p
January NNP p
2003 CD p
. . p

Patients NNS N
were VBD N
stratified VBN N
by IN N
sex NN N
and CC N
number NN N
of IN N
nodes NNS N
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
2 CD N
years NNS N
of IN N
treatment NN N
with IN N
active JJ i
specific JJ i
immunotherapy NN i
with IN i
allogeneic JJ i
melanoma NN i
lysates NNS i
and CC i
low-dose JJ i
IFN-alpha-2b NNP i
( ( i
arm JJ i
1 CD i
) ) i
or CC N
high-dose JJ i
IFN-alpha-2b NNP i
alone RB i
for IN N
1 CD N
year NN N
( ( N
arm IN N
2 CD N
) ) N
. . N

Active JJ N
specific JJ N
immunotherapy NN N
was VBD N
injected VBN N
subcutaneously RB N
( ( N
SC NNP N
) ) N
weekly VBD N
for IN N
4 CD N
weeks NNS N
, , N
at IN N
week NN N
8 CD N
, , N
and CC N
bimonthly RB N
thereafter RB N
. . N

IFN-alpha-2b JJ i
SC NNP i
was VBD N
begun VBN N
on IN N
week NN N
4 CD N
and CC N
continued JJ N
thrice JJ N
weekly RB N
at IN N
5 CD N
MU/m2 NNP N
for IN N
2 CD N
years NNS N
. . N

IFN-alpha-2b NN i
in IN N
arm NN N
2 CD N
was VBD N
administered VBN N
according VBG N
to TO N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
1684 CD N
study NN N
regimen NNS N
. . N

RESULTS NNP N
Median JJ o
follow-up JJ o
time NN o
was VBD N
32 CD N
months NNS N
for IN N
all DT N
patients NNS N
and CC N
42 CD N
months NNS N
for IN N
surviving VBG N
patients NNS N
. . N

Median JJ o
OS NNP o
time NN o
exceeds VBZ N
84 CD N
months NNS N
in IN N
arm NN N
1 CD N
and CC N
is VBZ N
83 CD N
months NNS N
in IN N
arm NN N
2 CD N
( ( N
P NNP N
= NNP N
.56 NNP N
) ) N
. . N

Five-year JJ o
OS NNP o
rate NN o
is VBZ N
61 CD N
% NN N
in IN N
arm NN N
1 CD N
and CC N
57 CD N
% NN N
in IN N
arm NN N
2 CD N
. . N

Estimated VBN o
5-year JJ o
relapse-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
rate NN o
is VBZ N
50 CD N
% NN N
in IN N
arm NN N
1 CD N
and CC N
48 CD N
% NN N
in IN N
arm NN N
2 CD N
, , N
with IN N
median JJ N
RFS NNP N
times NNS N
of IN N
58 CD N
and CC N
50 CD N
months NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN o
of IN o
serious JJ o
adverse JJ o
events NNS o
as IN N
a DT N
result NN N
of IN N
treatment NN N
was VBD N
the DT N
same JJ N
in IN N
both DT N
arms NNS N
, , N
but CC N
more JJR N
severe JJ N
neuropsychiatric JJ o
toxicity NN o
was VBD N
seen VBN N
in IN N
arm NN N
2 CD N
. . N

CONCLUSION NNP N
OS NNP N
and CC N
RFS NNP N
achieved VBN N
by IN N
active JJ i
specific JJ i
immunotherapy NN i
and CC i
low-dose JJ i
IFN-alpha-2b NNP i
were VBD N
indistinguishable JJ N
from IN N
those DT N
achieved VBN N
by IN N
high-dose JJ i
IFN-alpha-2b NNP i
. . i

Long NNP N
RFS NNP N
and CC N
OS NNP N
times NNS N
were VBD N
observed VBN N
in IN N
both DT N
treatment NN N
arms NNS N
. . N

-DOCSTART- -15523323- O O

Impact NN N
of IN N
angiotensin-converting JJ N
enzyme JJ N
gene NN N
polymorphism NN N
on IN N
neurohormonal JJ o
responses NNS o
to TO N
high- JJ N
versus NN N
low-dose JJ N
enalapril NN N
in IN N
advanced JJ p
heart NN p
failure NN p
. . p

BACKGROUND CC N
The DT N
impact NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
gene NN N
polymorphism NN N
on IN N
neurohormonal JJ N
dose JJ N
response NN N
to TO N
ACE NNP i
inhibitor NN N
therapy NN N
is VBZ N
unclear JJ N
. . N

METHODS NNP N
ACE NNP N
Insertion NNP N
( ( N
I PRP N
) ) N
or CC N
Deletion NNP N
( ( N
D NNP N
) ) N
genotype NN N
was VBD N
determined VBN N
in IN N
74 CD p
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
who WP N
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
either DT i
high-dose JJ i
or CC i
low-dose JJ i
enalapril NN i
over IN i
a DT i
period NN i
of IN i
6 CD i
months NNS i
. . i

Monthly JJ i
pre-enalapril JJ o
and CC o
post-enalapril JJ o
neurohormone NN o
levels NNS o
( ( o
serum JJ o
ACE NNP o
activity NN o
( ( o
sACE NN o
) ) o
, , o
plasma JJ o
angiotensin NN o
II NNP o
( ( o
A-II NNP o
) ) o
, , o
plasma JJ o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
, , o
and CC o
serum VB o
aldosterone NN o
( ( o
ALDO NNP o
) ) o
were VBD N
compared VBN N
between IN N
genotype NN N
subgroups NNS N
and CC N
between IN N
patients NNS N
who WP N
received VBD N
high- JJ N
or CC N
low-dose JJ N
enalapril NN i
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
predose/postdose JJ o
sACE NN o
and CC o
postdose JJ o
PRA NNP o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
DD NNP p
genotype NN p
. . p

At IN N
6-month JJ N
follow-up NN N
, , N
postdose JJ o
sACE NN o
was VBD N
reduced VBN N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
all DT N
three CD N
genotypes NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

However RB N
, , N
predose JJ o
and CC o
postdose JJ o
ALDO NNP o
and CC o
A-II NNP o
levels NNS o
did VBD N
not RB N
differ VB N
between IN N
each DT N
genotype NN N
subgroup NN N
at IN N
baseline NN N
or CC N
by IN N
enalapril JJ N
dose NN N
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

ALDO NNP o
escape NN o
and CC o
A-II JJ o
reactivation NN o
were VBD N
not RB N
affected VBN N
by IN N
ACE NNP p
genotype NN p
or CC N
enalapril JJ N
dosage NN N
. . N

CONCLUSIONS NNP N
Predose NNP o
sACE NN o
were VBD N
consistently RB N
higher JJR N
in IN N
the DT N
DD NNP N
genotype NN N
when WRB N
compared VBN N
with IN N
ID NNP p
or CC p
II NNP p
subgroups NNS p
. . p

Despite IN N
a DT N
dose-dependent JJ N
suppression NN o
of IN o
sACE NN o
, , N
there EX N
were VBD N
no DT N
observed VBN N
statistically RB N
significant JJ N
differences NNS N
in IN N
ALDO NNP o
and CC o
A-II NNP o
suppression NN o
or CC N
escape NN N
with IN N
escalating VBG N
doses NNS N
of IN N
enalapril NN N
within IN N
each DT N
subgroup NN N
. . N

-DOCSTART- -10735900- O O

Use NNP N
of IN N
recombinant JJ i
human JJ i
granulocyte NN i
colony-stimulating NN i
factor NN i
to TO N
increase VB N
chemotherapy JJ i
dose-intensity NN N
: : N
a DT N
randomized JJ N
trial NN N
in IN N
very RB p
high-risk JJ p
childhood NN p
acute NN p
lymphoblastic JJ p
leukemia NN p
. . p

PURPOSE NNP N
To TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
recombinant JJ i
human JJ i
granulocyte NN i
colony-stimulating NN i
factor NN i
( ( i
[ JJ i
G-CSF NNP i
] NNP i
lenogastrim NN i
) ) i
can MD N
increase VB N
the DT N
chemotherapy JJ N
dose-intensity NN N
( ( N
CDI NNP N
) ) N
delivered VBD N
during IN N
consolidation NN i
chemotherapy NN i
of IN N
childhood NN p
acute NN p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL DT p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Sixty-seven NNP p
children NNS p
with IN p
very RB p
high-risk JJ p
ALL NNP p
were VBD N
randomized VBN N
( ( N
slow JJ N
early JJ N
response NN N
to TO N
therapy VB N
, , N
55 CD N
patients NNS N
; : N
translocation NN N
t NN N
( ( N
9 CD N
; : N
22 CD N
) ) N
or CC N
t NN N
( ( N
4 CD N
; : N
11 CD N
) ) N
, , N
12 CD N
patients NNS N
) ) N
. . N

Consolidation NNP N
consisted VBD N
of IN N
six CD N
courses NNS N
of IN N
chemotherapy NN i
; : i
the DT N
first JJ N
, , N
third JJ N
, , N
and CC N
fifth JJ N
courses NNS N
were VBD N
a DT N
combination NN i
of IN i
high-dose JJ i
cytarabine NN i
, , i
etoposide RB i
, , i
and CC i
dexamethasone NN i
( ( i
R3 NNP i
) ) i
, , N
whereas VBD N
the DT N
second JJ N
, , N
fourth JJ N
, , N
and CC N
sixth JJ N
courses NNS N
included VBD N
vincristine NN i
, , i
prednisone NN i
, , i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
methotrexate NN i
( ( i
COPADM NNP i
) ) i
. . i

G-CSF NNP i
was VBD N
given VBN N
after IN N
each DT N
course NN N
, , N
and CC N
the DT N
next JJ N
scheduled JJ N
course NN N
was VBD N
started VBN N
as RB N
soon RB N
as IN N
neutrophil JJ N
count NN N
was VBD N
> JJ N
1 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
and CC N
platelet NN N
count NN N
was VBD N
> JJ N
100 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
. . N

CDI NNP o
was VBD N
calculated VBN N
using VBG N
the DT N
interval NN N
from IN N
day NN N
1 CD N
of IN N
the DT N
first JJ N
course NN N
to TO N
hematologic VB N
recovery NN N
after IN N
the DT N
fifth JJ N
course NN N
( ( N
100 CD N
% NN N
CDI NNP N
= NNP N
105-day JJ N
interval NN N
) ) N
. . N

RESULTS NNP N
CDI NNP o
was VBD N
significantly RB N
increased VBN o
in IN N
the DT N
G-CSF NNP i
group NN N
compared VBN N
with IN N
the DT N
non-G-CSF JJ i
group NN N
( ( N
mean JJ N
+/- JJ N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
105 CD N
+/- JJ N
5 CD N
% NN N
v JJ N
91 CD N
+/- JJ N
4 CD N
% NN N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

This DT N
higher JJR o
intensity NN o
was VBD N
a DT N
result NN N
of IN N
shorter JJR N
post-R3 NN o
intervals NNS o
in IN N
the DT N
G-CSF NNP i
group NN N
, , N
whereas IN N
the DT N
post-COPADM JJ i
intervals NNS N
were VBD N
not RB N
statistically RB N
reduced VBN N
. . N

After IN N
the DT N
R3 NNP N
courses NNS N
, , N
the DT N
number NN o
of IN o
days NNS o
with IN o
fever NN o
and CC o
intravenous JJ o
antibiotics NNS o
and CC o
duration NN o
of IN o
hospitalization NN o
were VBD o
significantly RB o
decreased VBN o
by IN N
G-CSF NNP i
, , N
whereas JJ N
reductions NNS o
observed VBD o
after IN o
COPADM NNP o
were VBD o
not RB o
statistically RB o
significant JJ o
. . o

Duration NN o
of IN o
granulocytopenia NN o
was VBD o
reduced VBN o
in IN N
the DT N
G-CSF NNP i
group NN N
, , N
but CC N
thrombocytopenia NN o
was VBD o
prolonged VBN o
, , N
and CC N
the DT N
number NN o
of IN o
platelet NN o
transfusions NNS o
was VBD o
increased VBN o
. . o

Finally RB N
, , N
the DT N
3-year JJ N
probability NN N
of IN N
event-free JJ o
survival NN o
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
G-CSF NNP i
can MD N
increase VB N
CDI NNP N
in IN N
high-risk JJ p
childhood NN p
ALL NNP p
. . N

Its PRP$ N
effects NNS N
depend VBP N
on IN N
the DT N
chemotherapy NN N
regimen NNS N
given VBN N
before IN N
G-CSF NNP i
administration NN i
. . i

In IN N
our PRP$ N
study NN N
, , N
a DT N
higher JJR N
CDI NNP N
did VBD N
not RB N
improve VB N
disease NN N
control NN N
. . N

-DOCSTART- -25865864- O O

Fall NN o
rates NNS o
in IN p
hospital JJ p
rehabilitation NN p
units NNS p
after IN N
individualised JJ i
patient NN i
and CC i
staff NN i
education NN i
programmes NNS i
: : i
a DT N
pragmatic JJ N
, , N
stepped-wedge JJ N
, , N
cluster-randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Falls NNP N
are VBP N
the DT N
most RBS N
frequent JJ N
adverse JJ N
events NNS N
that WDT N
are VBP N
reported VBN N
in IN N
hospitals NNS N
. . N

We PRP N
examined VBD N
the DT N
effectiveness NN N
of IN N
individualised JJ i
falls-prevention NN i
education NN i
for IN i
patients NNS i
, , N
supported VBN N
by IN N
training NN i
and CC i
feedback NN i
for IN i
staff NN i
, , N
delivered VBN N
as IN N
a DT N
ward-level JJ N
programme NN N
. . N

METHODS NNP N
Eight NNP p
rehabilitation NN p
units NNS p
in IN p
general JJ p
hospitals NNS p
in IN p
Australia NNP p
participated VBD N
in IN N
this DT N
stepped-wedge NN N
, , N
cluster-randomised JJ N
study NN N
, , N
undertaken JJ N
during IN N
a DT N
50 CD N
week NN N
period NN N
. . N

Units NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
intervention VB N
or CC N
control VB i
groups NNS N
by IN N
use NN N
of IN N
computer-generated JJ N
, , N
random JJ N
allocation NN N
sequences NNS N
. . N

We PRP p
included VBD p
patients NNS p
admitted VBN p
to TO p
the DT p
unit NN p
during IN p
the DT p
study NN p
with IN p
a DT p
Mini-Mental JJ p
State NNP p
Examination NNP p
( ( p
MMSE NNP p
) ) p
score NN p
of IN p
more JJR p
than IN p
23/30 CD p
to TO N
receive VB N
individualised JJ i
education NN i
that WDT N
was VBD N
based VBN N
on IN N
principles NNS N
of IN N
changes NNS N
in IN N
health NN o
behaviour NN o
from IN N
a DT N
trained JJ N
health NN N
professional NN N
, , N
in IN N
addition NN N
to TO N
usual JJ N
care NN N
. . N

We PRP N
provided VBD N
information NN i
about IN i
patients NNS i
' POS i
goals NNS i
, , i
feedback NN i
about IN i
the DT i
ward NN i
environment NN i
, , i
and CC i
perceived VBD i
barriers NNS i
to TO i
engagement VB i
in IN i
falls-prevention NN i
strategies NNS i
to TO N
staff NN N
who WP N
were VBD N
trained VBN N
to TO N
support VB N
the DT N
uptake NN N
of IN N
strategies NNS N
by IN N
patients NNS N
. . N

The DT N
coprimary JJ N
outcome NN N
measures NNS N
were VBD N
patient JJ o
rate NN o
of IN o
falls NNS o
per IN o
1000 CD o
patient-days NNS o
and CC N
the DT N
proportion NN o
of IN o
patients NNS o
who WP o
were VBD o
fallers NNS o
. . o

All DT N
analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
Australian JJ N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
registry NN N
, , N
number NN N
ACTRN12612000877886 NNP N
) ) N
. . N

FINDINGS NNP N
Between NNP p
Jan NNP p
13 CD p
, , p
and CC p
Dec NNP p
27 CD p
, , p
2013 CD p
, , p
3606 CD p
patients NNS p
were VBD p
admitted VBN p
to TO p
the DT p
eight CD p
units NNS p
( ( p
n=1983 JJ p
control NN p
period NN p
; : p
n=1623 CC p
intervention NN p
period NN p
) ) p
. . p

There EX N
were VBD N
fewer JJR N
falls NNS o
( ( N
n=196 NN N
, , N
7?80/1000 CD N
patient-days JJ N
vs NN N
n=380 NN N
, , N
13?78/1000 CD N
patient-days NNS N
, , N
adjusted VBN N
rate NN N
ratio NN N
0?60 CD N
[ NN N
robust JJ N
95 CD N
% NN N
CI NNP N
0?42-0?94 CD N
] NNP N
, , N
p=0?003 NN o
) ) o
, , o
injurious JJ o
falls NNS o
( ( N
n=66 NN N
, , N
2?63/1000 CD N
patient-days JJ N
vs NN N
131 CD N
, , N
4?75/1000 CD N
patient-days NNS N
, , N
0?65 CD N
[ NN N
robust JJ N
95 CD N
% NN N
CI NNP N
0?42-0?88 CD N
] NNP N
, , N
p=0?006 NN N
) ) N
, , N
and CC o
fallers NNS o
( ( N
n=136 JJ N
[ RB N
8?38 CD N
% NN N
] JJ N
vs NN N
n=248 NN N
[ VBD N
12?51 CD N
% NN N
] NN N
adjusted VBN N
odds NNS N
ratio VBP N
0?55 CD N
[ NNP N
robust JJ N
95 CD N
% NN N
CI NNP N
0?38 CD N
to TO N
0?81 CD N
] NNS N
, , N
p=0?003 NN N
) ) N
in IN N
the DT N
intervention NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
length NN o
of IN o
stay NN o
( ( N
intervention NN N
median RB N
11 CD N
days NNS N
[ JJ N
IQR NNP N
7-19 JJ N
] NNP N
, , N
control NN N
10 CD N
days NNS N
[ RB N
6-18 JJ N
] NN N
) ) N
. . N

INTERPRETATION NNP i
Individualised VBD i
patient JJ i
education NN i
programmes NNS i
combined VBN i
with IN N
training NN N
and CC N
feedback NN N
to TO N
staff NN N
added VBN N
to TO N
usual JJ N
care NN N
reduces VBZ N
the DT N
rates NNS N
of IN N
falls NNS N
and CC N
injurious JJ N
falls NNS N
in IN N
older JJR p
patients NNS p
in IN p
rehabilitation NN p
hospital-units NNS p
. . p

FUNDING NN p
State NNP N
Health NNP N
Research NNP N
Advisory NNP N
Council NNP N
, , N
Department NNP N
of IN N
Health NNP N
, , N
Government NNP N
of IN N
Western NNP N
Australia NNP N
. . N

-DOCSTART- -15191587- O O

Mandibular JJ N
overdentures NNS N
supported VBN N
by IN N
two CD N
Br?nemark NNP N
, , N
IMZ NNP i
or CC i
ITI NNP i
implants NNS i
: : i
a DT N
5-year JJ N
prospective JJ N
study NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
comparative NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT o
survival NN o
rate NN o
and CC N
the DT o
condition NN o
of IN o
the DT o
peri-implant JJ o
tissues NNS o
of IN N
the DT N
IMZ NNP i
implant NN i
system NN N
( ( N
two-stage JJ N
cylindertype NN N
) ) N
, , N
the DT i
Br?nemark NNP i
implant NN i
system NN i
( ( N
two-stage JJ N
screwtype NN N
) ) N
and CC N
the DT i
ITI NNP i
implant NN i
system NN i
( ( N
one-stage JJ N
screwtype NN N
) ) N
supporting VBG N
a DT N
mandibular JJ N
overdenture NN N
during IN N
a DT N
5-year JJ N
follow-up JJ N
period NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP p
Three NNP p
groups NNS p
of IN p
30 CD p
edentulous JJ p
patients NNS p
were VBD p
treated VBN p
with IN i
two CD i
endosseous JJ i
implants NNS i
in IN i
the DT N
interforaminal JJ N
region NN N
of IN N
the DT N
mandible JJ N
. . N

Clinical JJ N
and CC N
radiographic JJ N
parameters NNS N
were VBD N
evaluated VBN N
immediately RB N
after IN N
completion NN N
of IN N
the DT N
prosthetic JJ N
treatment NN N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
and CC N
5 CD N
years NNS N
of IN N
functional JJ N
loading NN N
. . N

RESULTS VB N
The DT o
five-year JJ o
survival NN o
rate NN o
is VBZ o
98.3 CD N
% NN N
for IN N
the DT N
IMZ NNP N
group NN N
, , N
98.3 CD N
% NN N
for IN N
the DT N
Br? NNP N
group NN N
and CC N
100 CD N
% NN N
for IN N
the DT N
ITI NNP N
group NN o
. . o

Mean NNP o
scores VBZ o
on IN o
indices NNS o
for IN o
plaque NN o
, , o
calculus NN o
, , o
gingiva NN o
and CC o
bleeding NN o
were VBD o
very RB N
low JJ N
at IN N
all DT N
evaluation NN N
periods NNS o
. . o

Mean NNP o
marginal JJ o
bone NN o
loss NN o
over IN o
a DT o
period NN o
of IN o
5 CD o
years NNS o
, , o
was VBD o
1.4 CD N
mm NN N
for IN N
the DT N
IMZ NNP N
group NN N
, , N
0.7 CD N
mm NN N
for IN N
the DT N
Br? NNP N
group NN N
and CC N
0.9 CD N
mm NN N
for IN N
the DT N
ITI NNP N
group NN N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
concluded VBN N
that IN N
two CD N
implants NNS N
placed VBN N
in IN N
the DT N
interforaminal JJ N
region NN N
, , N
connected VBN N
with IN N
a DT N
bar NN N
, , N
supply VB N
a DT N
proper JJ N
base NN N
for IN N
the DT N
support NN N
of IN N
a DT N
mandibular JJ p
overdenture NN p
in IN p
the DT p
edentulous JJ p
patient NN p
. . p

After IN p
5 CD N
years NNS N
no DT N
clinically RB N
relevant JJ N
and CC N
statistically RB N
significant JJ N
radiographic JJ N
changes NNS N
had VBD N
developed VBN N
between IN N
the DT N
three CD N
implant JJ N
systems NNS N
. . N

-DOCSTART- -1854617- O O

The DT N
influence NN N
of IN N
serum NN i
methotrexate NN i
concentrations NNS N
and CC N
drug NN N
dosage NN N
on IN N
outcome NN N
in IN N
childhood NN p
acute NN p
lymphoblastic JJ p
leukaemia NN p
. . p

Sequential JJ N
methotrexate NN i
( ( N
Mtx NNP N
) ) N
absorption NN N
studies NNS N
were VBD N
undertaken VBN N
in IN N
127 CD p
children NNS p
undergoing JJ p
treatment NN p
for IN p
childhood NN p
non-T JJ p
acute JJ p
lymphoblastic JJ p
leukaemia NN p
( ( p
ALL NNP p
) ) p
to TO N
determine VB N
whether IN N
serum JJ N
drug NN N
concentration NN N
, , N
clearance NN N
and CC N
dosage NN N
affect JJ N
event NN o
free JJ o
survival NN o
( ( N
EFS NNP N
) ) N
. . N

Higher JJR N
serum JJ N
concentration NN N
and CC N
area NN N
under IN N
the DT N
plasma JJ N
concentration NN N
curve NN N
( ( N
AUC NNP N
) ) N
were VBD N
not RB N
associated VBN N
with IN N
an DT N
improved JJ N
EFS NNP N
. . N

Methotrexate NNP o
clearance NN o
was VBD N
not RB N
found VBN N
to TO N
be VB N
of IN N
prognostic JJ N
significance NN N
. . N

Patients NNS N
who WP N
tolerated VBD N
only RB N
low JJ N
6-mercaptopurine JJ i
( ( i
6-MP JJ i
) ) i
doses VBZ N
because IN N
of IN N
neutropaenia NN N
and CC N
those DT N
who WP N
randomly VBP N
were VBD N
prescribed VBN N
higher JJR N
doses NNS N
of IN N
Mtx NNP N
had VBD N
a DT N
lower JJR N
rate NN o
of IN o
leukaemia NN o
relapse NN o
after IN N
the DT N
completion NN N
of IN N
therapy NN N
. . N

This DT N
suggests VBZ N
that IN N
the DT N
use NN N
of IN N
maintenance NN N
therapy NN N
in IN N
maximally RB N
tolerated VBN N
doses NNS N
may MD N
be VB N
associated VBN N
with IN N
an DT N
increased VBN N
survival NN o
in IN N
childhood NN p
ALL NNP p
. . p

-DOCSTART- -2108990- O O

The DT N
effect NN N
of IN N
HCG NNP i
supplementation NN i
after IN N
combined VBN i
GnRH NNP i
agonist/HMG JJ i
treatment NN i
in IN p
an DT p
IVF NNP p
programme NN p
. . p

The DT N
necessity NN N
of IN N
luteal-phase JJ i
supplementation NN i
in IN N
an DT N
IVF NNP p
programme NN p
is VBZ N
of IN N
continuing VBG N
interest NN N
. . N

After IN N
ovarian JJ N
stimulation NN N
with IN N
clomiphene NN i
and CC N
human JJ i
menopausal NN i
gonadotrophin NN i
( ( i
HMG NNP i
) ) i
, , N
the DT N
beneficial JJ N
effect NN N
of IN N
supporting VBG N
the DT N
luteal NN N
phase NN N
has VBZ N
never RB N
been VBN N
scientifically RB N
demonstrated VBN N
. . N

After IN N
ovarian JJ N
stimulation NN N
with IN N
GnRH NNP i
agonist/HMG NN i
, , N
the DT N
luteal JJ N
phase NN N
seems VBZ N
to TO N
be VB N
inadequate JJ N
, , N
but CC N
in IN N
a DT N
previous JJ N
study NN N
we PRP N
did VBD N
not RB N
find VB N
evidence NN N
to TO N
support VB N
the DT N
need NN N
for IN N
oral JJ N
progesterone NN N
supplementation NN N
. . N

To TO N
evaluate VB N
the DT N
beneficial JJ N
effect NN N
of IN N
human JJ i
chorionic NN i
gonadotrophin NN i
( ( i
HCG NNP i
) ) i
supplementation NN i
, , N
we PRP N
performed VBD N
a DT N
multicentre NN N
, , N
double-blind NN N
, , N
randomized VBN N
study NN N
with IN N
HCG NNP i
( ( p
193 CD p
transfers NNS p
) ) p
against IN p
placebo NN i
( ( p
194 CD p
transfers NNS p
) ) p
. . p

The DT N
ongoing JJ o
pregnancy NN o
rate NN o
per IN o
transfer NN o
cycle NN o
was VBD N
significantly RB N
better RBR N
with IN N
HCG NNP i
( ( N
18.7 CD N
versus IN N
9.3 CD N
) ) N
. . N

This DT N
is VBZ N
the DT N
first JJ N
truly RB N
objective JJ N
( ( N
randomized VBN N
) ) N
study NN N
demonstrating VBG N
the DT N
beneficial JJ N
effect NN N
of IN N
supporting VBG N
the DT N
luteal JJ N
phase NN N
in IN N
an DT N
IVF NNP p
programme NN p
. . p

-DOCSTART- -7655889- O O

Movement-related JJ i
potentials NNS i
in IN N
Parkinson NNP p
's POS p
disease NN p
. . p

Presence NNP N
and CC N
predictability NN N
of IN N
temporal JJ i
and CC i
spatial JJ i
cues NNS i
. . i

Activity NN N
of IN N
the DT N
supplementary JJ N
motor NN N
area NN N
may MD N
be VB N
inferred VBN N
from IN N
movement-related JJ i
potentials NNS i
( ( i
MRPs NNP i
) ) i
which WDT N
are VBP N
associated VBN N
with IN N
the DT N
preparation NN N
and CC N
execution NN N
of IN N
voluntary JJ N
, , N
or CC N
internally RB N
determined JJ N
movements NNS N
. . N

Supplementary NNP N
motor NN N
area NN N
activity NN N
may MD N
be VB N
abnormal JJ N
in IN N
Parkinson NNP p
's POS p
disease NN p
since IN N
its PRP$ N
major JJ N
input NN N
from IN N
the DT N
basal NN N
ganglia NN N
is VBZ N
disrupted VBN N
. . N

Investigation NN N
of IN N
the DT N
abnormalities NNS N
in IN N
supplementary JJ N
motor NN N
area NN N
activity NN N
associated VBN N
with IN N
movement NN N
deficits NNS N
in IN N
Parkinson NNP N
's POS N
disease NN N
may MD N
therefore VB N
reveal JJ N
functions NNS N
of IN N
the DT N
basal NN N
ganglia NN N
and CC N
the DT N
supplementary JJ N
motor NN N
area NN N
. . N

Movement-related JJ i
potentials NNS i
associated VBN i
with IN i
sequential JJ i
movements NNS i
were VBD i
investigated VBN i
under IN i
various JJ i
cueing VBG i
conditions NNS i
in IN N
Parkinson NNP p
's POS p
disease NN p
subjects NNS p
and CC p
age-matched JJ p
controls NNS i
. . i

In IN N
controls NNS N
, , N
MRPs NNP N
revealed VBD N
involvement NN N
of IN N
the DT N
supplementary JJ N
motor NN N
area NN N
in IN N
movements NNS N
which WDT N
can MD N
be VB N
internally RB N
determined VBN N
( ( i
non-cued JJ i
and CC N
externally RB i
cued VBN i
, , i
predictable JJ i
movements NNS N
, , N
but CC N
not RB i
unpredictable JJ i
movements NNS N
) ) N
. . N

In IN N
Parkinson NNP N
's POS N
disease NN N
, , N
however RB N
, , N
the DT N
supplementary JJ N
motor NN N
area NN N
was VBD N
only RB N
involved VBN N
in IN N
movements NNS N
which WDT N
must MD N
be VB N
internally RB N
determined VBN N
( ( i
non-cued JJ i
movements NNS N
, , N
but CC N
not RB i
externally RB i
cued VBN i
movements NNS N
) ) N
; : N
therefore RB N
impaired VBD N
internal JJ N
control NN N
mechanisms NNS N
, , N
operating VBG N
via IN N
the DT N
supplementary JJ N
motor NN N
area NN N
, , N
are VBP N
bypassed VBN N
when WRB N
external JJ i
cues NNS i
are VBP i
given VBN i
. . i

As IN N
a DT N
result NN N
, , N
Parkinson NNP p
's POS p
disease NN p
patients NNS p
are VBP N
more RBR N
reliant JJ N
on IN N
external JJ i
cues NNS i
and CC N
are VBP N
unable JJ N
to TO N
use VB N
predictive JJ N
models NNS N
to TO N
internally RB N
guide VB N
movement NN N
. . N

Supplementary NNP N
motor NN N
area NN N
involvement NN N
also RB N
relied VBD N
on IN N
the DT N
predictability NN N
( ( N
in IN N
controls NNS N
) ) N
or CC N
presence NN N
( ( N
in IN N
Parkinson NNP N
's POS N
disease NN N
) ) N
of IN N
timing VBG i
cues NNS i
and CC N
not RB i
spatial JJ i
cues NNS i
, , N
indicating VBG N
a DT N
role NN N
of IN N
the DT N
supplementary JJ N
motor NN N
area NN N
and CC N
basal NN N
ganglia NNS N
in IN N
the DT N
temporal JJ N
organizations NNS N
of IN N
sequential JJ N
movement NN N
rather RB N
than IN N
the DT N
programming NN N
of IN N
specific JJ N
movements NNS N
. . N

For IN N
non-cued JJ i
movements NNS N
, , N
abnormalities NNS N
in IN N
MRPs NNP N
for IN N
Parkinson NNP N
's POS N
disease NN N
subjects VBZ N
consisted VBN N
of IN N
delayed JJ o
MRP NNP o
onset NN o
and CC o
peak NN o
times NNS o
, , N
and CC N
prolonged VBD N
cortical JJ N
activity NN N
following VBG N
movement NN N
. . N

These DT N
observations NNS N
led VBD N
to TO N
a DT N
proposed VBN N
model NN N
of IN N
the DT N
interaction NN N
between IN N
the DT N
basal NN N
ganglia NN N
and CC N
the DT N
supplementary JJ N
motor NN N
area NN N
, , N
involving VBG N
the DT N
temporal JJ N
organization NN N
of IN N
voluntary JJ N
and CC N
internally RB N
determined VBD N
sequential JJ N
movements NNS N
. . N

-DOCSTART- -24090047- O O

Japan NNP N
useful JJ N
medication NN N
program NN N
for IN N
schizophrenia NN N
( ( N
JUMPs NNP N
) ) N
-long-term VBP N
study NN N
on IN N
discontinuation NN N
rate NN N
, , N
resolution NN N
and CC N
remission NN N
, , N
and CC N
improvement NN N
in IN N
social JJ N
functioning NN N
rate NN N
associated VBN N
with IN N
atypical JJ i
antipsychotic JJ i
medications NNS i
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

BACKGROUND IN N
It PRP N
is VBZ N
desirable JJ N
to TO N
establish VB N
evidence NN N
for IN N
the DT N
selection NN N
of IN N
antipsychotics NNS i
from IN N
the DT N
viewpoint NN N
of IN N
recovery NN N
of IN N
social JJ N
activity NN N
in IN N
individual JJ p
patient NN p
with IN p
schizophrenia NN p
receiving VBG p
medication NN p
. . p

From IN N
this DT N
perspective NN N
, , N
awareness NN N
of IN N
the DT N
importance NN N
of IN N
studies NNS N
about IN N
drug NN N
effectiveness NN N
on IN N
treatment NN N
discontinuation NN N
rate NN N
, , N
remission NN N
rate NN N
, , N
and CC N
improvement NN N
in IN N
QOL NNP N
has VBZ N
grown VBN N
recently RB N
. . N

In IN N
Western JJ N
countries NNS N
, , N
numerous JJ N
reports NNS N
are VBP N
available JJ N
in IN N
effectiveness JJ N
studies NNS N
, , N
which WDT N
are VBP N
related VBN N
to TO N
olanzapine VB N
and CC N
risperidone VB N
primarily RB N
, , N
whereas JJ N
evidence NN N
for IN N
other JJ N
second-generation NN N
antipsychotics NNS N
( ( N
SGAs NNP N
) ) N
is VBZ N
poor JJ N
. . N

In IN N
Japan NNP N
, , N
no DT N
effectiveness NN N
study NN N
has VBZ N
been VBN N
reported VBN N
: : N
thus RB N
, , N
it PRP N
is VBZ N
desirable JJ N
to TO N
collect VB N
data NNS N
that WDT N
will MD N
serve VB N
as IN N
evidence NN N
for IN N
selection NN N
of IN N
the DT N
3 CD N
SGAs NNP N
approved VBD N
after IN N
olanzapine NN N
. . N

METHODS NNP N
The DT N
present JJ N
study NN N
was VBD N
a DT N
long-term JJ N
effectiveness NN N
study NN N
under IN N
healthcare NN p
setting VBG p
in IN p
Japan NNP p
. . p

It PRP N
was VBD N
designed VBN N
as IN N
an DT N
open-label NN N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
comparative JJ N
study NN N
involving VBG N
104-week JJ N
oral JJ N
treatment NN N
with IN N
1 CD i
of IN i
the DT i
3 CD i
drugs NNS i
( ( i
aripiprazole NN i
, , i
blonanserin NN i
, , i
and CC i
paliperidone NN i
) ) i
in IN N
patients NNS p
with IN p
schizophrenia NN p
aged VBN p
20 CD p
years NNS p
or CC p
over IN p
who WP p
required VBD p
antipsychotic JJ i
medication NN i
or CC p
switching NN p
of IN p
the DT p
current JJ p
medication NN p
to TO p
others NNS p
for IN p
reasons NNS p
such JJ p
as IN p
lack NN p
of IN p
efficacy NN p
and CC p
intolerability NN p
. . p

The DT N
primary JJ N
endpoint NN N
is VBZ N
treatment NN o
discontinuation NN o
rate NN o
for IN o
any DT o
causes NNS o
. . o

The DT N
secondary JJ N
endpoints NNS N
include VBP N
remission NN o
rate NN o
, , o
improvement NN o
of IN o
social JJ o
activity NN o
, , o
alleviation NN o
, , o
aggravation NN o
or CC o
recurrence NN o
of IN o
psychiatric JJ o
symptoms NNS o
, , o
and CC o
safety NN o
. . o

The DT p
target NN p
number NN p
of IN p
subjects NNS p
was VBD p
set VBN p
at IN p
300 CD p
. . p

DISCUSSION NN N
Because IN N
this DT N
study NN N
is VBZ N
expected VBN N
to TO N
yield VB N
evidence NN N
regarding VBG N
the DT N
selection NN N
of IN N
antipsychotics NNS N
for IN N
facilitating VBG N
the DT N
recovery NN N
of IN N
social JJ N
activity NN N
in IN N
patients NNS p
with IN p
schizophrenia NN p
, , N
it PRP N
is VBZ N
considered VBN N
highly RB p
valuable JJ p
to TO p
perform VB p
this DT p
effectiveness NN p
study NN p
under IN p
ordinary JJ p
healthcare NN p
setting VBG p
in IN p
Japan NNP p
. . p

TRIAL NNP N
REGISTRATION NNP N
UMIN NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
000007942 CD N
. . N

-DOCSTART- -18205945- O O

Randomized VBN N
, , N
comparative JJ N
study NN N
of IN N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
artesunate JJ i
plus CC i
amodiaquine JJ i
, , N
administered VBN N
as IN N
a DT N
single JJ N
daily JJ N
intake VB N
versus JJ N
two CD N
daily JJ N
intakes NNS N
in IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ p
falciparum NN p
malaria NN p
. . p

BACKGROUND NNP N
Artesunate NNP i
plus CC i
amodiaquine NN i
is VBZ N
a DT N
coblistered JJ N
ACT NNP N
, , N
given VBN N
as IN N
a DT N
single JJ N
daily JJ N
intake NN N
. . N

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
, , N
in IN N
view NN N
of IN N
the DT N
number NN N
of IN N
tablets NNS N
to TO N
be VB N
taken VBN N
( ( N
particularly RB N
in IN N
adults NNS N
) ) N
, , N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
improve VB N
compliance NN o
by IN N
allowing VBG N
patients NNS N
to TO N
divide VB N
the DT N
daily JJ N
dose NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
randomized VBN N
, , N
comparative JJ N
, , N
open-label JJ N
, , N
multicentre JJ p
study NN p
, , p
conducted VBN p
in IN p
Senegal NNP p
and CC p
in IN p
Cameroon NNP p
in IN p
2005 CD p
, , N
was VBD N
to TO N
demonstrate VB N
the DT N
non-inferiority NN o
and CC N
to TO N
compare VB N
the DT N
safety NN o
of IN o
artesunate JJ o
plus CC o
amodiaquine JJ o
, , N
as IN N
a DT N
single JJ N
daily JJ N
intake VB N
versus JJ N
two CD N
daily JJ N
intakes NNS N
. . N

METHODS VB N
A DT N
three-day JJ N
treatment NN N
period NN N
and CC N
14-day JJ N
follow-up JJ N
period NN N
was VBD N
performed VBN N
in IN N
any DT p
subject JJ p
weighting NN p
more JJR p
than IN p
10 CD p
kg NNS p
, , p
presenting VBG p
with IN p
a DT p
malaria NN p
paroxysm NN p
confirmed VBN p
by IN p
parasitaemia NN p
> NN p
or CC p
= $ p
1,000/microl CD p
, , p
after IN p
informed JJ p
consent NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
into IN N
one CD N
of IN N
the DT N
two CD N
regimens NNS N
, , N
with IN N
dosage NN N
according VBG N
to TO N
bodyweight JJ N
range NN N
. . N

All DT N
products NNS N
were VBD N
administered VBN N
by IN N
an DT N
authorized JJ N
person NN N
, , N
blinded VBN N
to TO N
both DT N
the DT N
investigating NN N
physician NN N
and CC N
the DT N
biologist NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
an DT N
adequate JJ o
response NN o
to TO o
treatment NN o
on IN o
D14 NNP o
( ( N
WHO NNP N
definition NN N
) ) N
. . N

The DT N
two-sided JJ N
90 CD N
% NN N
confidence NN N
interval NN N
of IN N
the DT N
difference NN N
was VBD N
calculated VBN N
on IN N
intent NN N
to TO N
treat VB N
( ( N
ITT NNP N
) ) N
population NN N
; : N
the DT N
acceptance NN N
limit NN N
for IN N
non-inferiority NN N
was VBD N
3 CD N
% NN N
. . N

The DT N
safety NN o
was VBD N
evaluated VBN N
by IN N
incidence NN o
of IN o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
Three-hundred JJ p
and CC p
sixteen JJ p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

The DT N
two CD N
patient NN N
groups NNS N
were VBD N
strictly RB N
comparable JJ N
on IN N
D0 NNP N
. . N

The DT N
adequate JJ o
responses NNS o
to TO o
treatment NN o
were VBD N
similar JJ N
for IN N
the DT N
two CD N
treatment NN N
regimens NNS N
on IN N
D14 NNP N
, , N
PCR-corrected NNP N
( ( N
99,4 CD N
% NN N
in IN N
the DT N
one-daily JJ N
intake NN N
group NN N
versus VBD N
99,3 CD N
% NN N
in IN N
the DT N
comparative JJ N
group NN N
) ) N
. . N

The DT N
statistical JJ N
analyses NNS N
demonstrated VBD N
the DT N
non-inferiority NN o
of IN N
administering VBG N
artesunate/amodiaquine NN N
as IN N
two CD N
intakes NNS N
. . N

The DT N
drug NN N
was VBD N
well RB o
tolerated VBN o
. . o

The DT N
main JJ N
adverse JJ N
events NNS N
were VBD N
gastrointestinal JJ o
disorders NNS o
( ( N
2.5 CD N
% NN N
) ) N
and CC N
pruritus NN o
( ( N
2.5 CD N
% NN N
) ) N
; : N
safety NN o
profiles NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
pilot NN N
study NN N
confirms VBZ N
the DT N
efficacy NN o
and CC N
good JJ o
tolerability NN o
of IN N
artesunate JJ N
plus CC N
amodiaquine JJ i
, , N
administrated VBD N
either CC N
in IN N
one CD N
or CC N
in IN N
two CD N
daily JJ N
intakes NNS N
. . N

-DOCSTART- -15132762- O O

Increased VBN N
repetitive JJ N
behaviours NNS N
and CC N
prolactin JJ N
responsivity NN N
to TO N
oral JJ N
m-chlorophenylpiperazine NN i
in IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Autism NNP N
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
dysfunction NN N
in IN N
three CD N
primary JJ N
behavioural JJ N
domains NNS N
: : N
repetitive JJ N
behaviours NNS N
, , N
social JJ N
deficits NNS N
, , N
and CC N
language NN N
abnormalities NNS N
. . N

There EX N
is VBZ N
evidence NN N
that IN N
abnormalities NNS N
exist VBP N
in IN N
the DT N
serotonin NN N
( ( N
5-HT JJ N
) ) N
system NN N
in IN N
autism NN N
spectrum NN N
patients NNS N
. . N

Furthermore RB N
, , N
5-HT JJ N
is VBZ N
known VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
repetitive JJ N
and CC N
social JJ N
behaviours NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
m-chlorophenylpiperazine NN i
( ( i
m-CPP JJ i
) ) i
on IN N
repetitive JJ N
behaviours NNS N
and CC N
prolactin JJ N
response NN N
in IN N
11 CD p
adults NNS p
with IN p
autism NN p
or CC p
Aspergers NNS p
disorder VBP p
and CC p
8 CD p
age- JJ p
and CC p
gender-matched JJ p
healthy JJ p
controls NNS p
via IN p
randomized VBN p
double-blind NN p
, , p
m-CPP JJ p
and CC p
placebo JJ i
challenges NNS p
. . p

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
an DT N
instrument NN o
rating NN o
six CD o
repetitive JJ o
behaviours NNS o
: : o
need NN o
to TO o
know VB o
, , o
repeating VBG o
, , o
ordering VBG o
, , o
need NN o
to TO o
tell/ask VB o
, , o
self-injury NN o
, , o
and CC o
touching VBG o
. . o

Patients NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
repetitive JJ o
behaviours NNS o
at IN N
end-point NN N
following VBG N
oral JJ o
m-CPP NNS o
in IN N
comparison NN N
to TO N
placebo VB i
. . i

Additionally NNP N
subjects VBZ p
with IN p
autism NN p
spectrum NN p
disorders NNS p
showed VBD N
a DT N
significantly RB N
increased VBN N
prolactin NN o
response NN o
to TO o
m-CPP NN o
compared VBN N
to TO N
normal JJ N
controls NNS N
, , N
with IN N
neither DT N
group NN N
responding VBG N
to TO N
placebo VB N
. . N

This DT N
study NN N
provides VBZ N
further JJ N
evidence NN N
for IN N
altered JJ N
5-HT JJ N
sensitivity NN N
in IN N
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
, , N
as RB N
well RB N
as IN N
a DT N
possible JJ N
relationship NN N
between IN N
repetitive JJ N
behaviours NNS N
in IN N
autism NN N
spectrum NN N
disorders NNS N
and CC N
abnormalities NNS N
in IN N
the DT N
5-HT JJ N
system NN N
. . N

-DOCSTART- -25083601- O O

Coping VBG N
strategies NNS N
as IN N
mediators NNS N
of IN N
the DT N
effect NN N
of IN N
the DT N
START NNP i
( ( i
strategies NNS i
for IN i
RelaTives NNP i
) ) i
intervention NN i
on IN N
psychological JJ o
morbidity NN o
for IN o
family NN o
carers NNS o
of IN o
people NNS o
with IN o
dementia NN o
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Family NNP p
carers NNS p
of IN p
people NNS p
with IN p
dementia NN p
frequently RB N
become VBN N
depressed JJ N
or CC N
anxious JJ N
. . N

In IN N
observational JJ N
studies NNS N
, , N
more JJR N
emotion-focused JJ N
and CC N
less RBR N
dysfunctional JJ N
coping VBG N
predict NN N
fewer JJR N
psychological JJ N
symptoms NNS N
, , N
but CC N
no DT N
randomised VBD N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
has VBZ N
directly RB N
investigated VBN N
emotion-focused JJ N
coping NN N
as IN N
mediator NN N
of IN N
effectiveness NN N
of IN N
a DT N
successful JJ N
psychological JJ N
intervention NN N
. . N

We PRP N
hypothesised VBD N
that IN N
emotion-focused JJ N
coping VBG N
would MD N
mediate VB N
the DT N
START NNP i
psychological JJ i
intervention?s NN i
effects NNS N
in IN N
an DT N
RCT NNP N
. . N

We PRP N
tested VBD N
whether IN N
mediated JJ N
effects NNS N
were VBD N
moderated VBN N
by IN N
severity NN N
of IN N
baseline NN N
symptoms NNS N
. . N

METHODS NNP p
260 CD p
family NN p
carers NNS p
from IN p
NHS NNP p
dementia NN p
services NNS p
were VBD N
randomised VBN N
to TO i
START NNP i
( ( i
manualised VBN i
coping VBG i
skills NNS i
intervention NN i
) ) i
, , i
or CC i
treatment-as-usual JJ i
( ( i
TAU NNP i
) ) i
. . i

Blinded VBN N
raters NNS N
administered VBD N
the DT o
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
( ( o
HADS-T NNP o
) ) o
and CC o
Brief NNP o
COPE NNP o
inventory NN o
at IN N
baseline NN N
, , N
4 CD N
and CC N
8 CD N
months NNS N
. . N

HADS-T NNP N
improved VBD N
in IN N
the DT N
intervention NN N
group NN N
when WRB N
compared VBN N
to TO i
TAU VB i
at IN N
all DT N
levels NNS N
of IN N
psychological JJ N
distress NN N
. . N

We PRP N
tested VBD N
whether IN N
coping NN N
was VBD N
a DT N
mediator NN N
and CC N
for IN N
moderated JJ N
mediation NN N
, , N
and CC N
( ( N
post-hoc NN N
) ) N
subgroup NN N
treatment NN N
effects NNS N
on IN N
coping VBG N
. . N

RESULTS NNP p
Data NNP p
were VBD p
available JJ p
for IN p
187 CD p
carers NNS p
( ( p
71.9 CD p
% NN p
) ) p
for IN N
the DT N
mediation NN N
analysis NN N
. . N

The DT N
reduced JJ o
HADS-T NNP o
score NN o
in IN N
the DT N
intervention NN N
group NN N
was VBD N
mediated VBN N
by IN N
increased JJ o
emotion-focused JJ o
coping VBG o
only RB N
among IN N
carers NNS N
with IN N
higher JJR N
( ( N
16+ CD N
) ) N
baseline NN o
HADS-T JJ o
scores NNS o
( ( N
mediated VBN N
effect=-0.63 RB N
[ JJ N
-1.11 NNP N
, , N
-0.15 NNP N
] NNP N
; : N
proportion NN N
of IN N
overall JJ N
effect=33 NN N
% NN N
[ JJ N
3 CD N
% NN N
, , N
64 CD N
% NN N
] NN N
) ) N
. . N

LIMITATIONS IN N
We PRP N
did VBD N
not RB N
measure NN N
plausible JJ N
psychosocial JJ N
treatment NN N
mechanisms VBZ N
other JJ N
than IN N
coping VBG N
. . N

CONCLUSIONS NNP i
START NNP i
benefited VBD N
family NN N
carers NNS N
both DT N
in IN N
preventing NN N
and CC N
treating VBG N
psychological JJ N
morbidity NN N
, , N
through IN N
different JJ N
mechanisms NNS N
of IN N
action NN N
. . N

The DT N
most RBS N
psychologically RB N
distressed JJ N
carers NNS N
increased VBD N
their PRP$ N
emotion-focused JJ N
coping NN N
and CC N
did VBD N
not RB N
decrease VB N
their PRP$ o
dysfunctional JJ o
coping NN o
, , o
while IN N
others NNS N
benefited VBD N
but CC N
not RB N
through IN N
this DT N
mechanism NN N
. . N

-DOCSTART- -11136837- O O

Cardiovascular JJ N
effects NNS N
of IN N
tamoxifen NN i
in IN N
women NNS p
with IN p
and CC p
without IN p
heart NN p
disease NN p
: : p
breast NN N
cancer NN N
prevention NN N
trial NN N
. . N

National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
Investigators NNP N
. . N

BACKGROUND NNP N
The DT N
overall JJ N
effect NN N
of IN N
prophylactic JJ N
tamoxifen NN N
in IN N
women NNS N
depends NNS N
on IN N
the DT N
balance NN N
between IN N
the DT N
effects NNS N
of IN N
the DT N
drug NN N
, , N
which WDT N
include VBP N
preventing VBG o
breast NN o
cancer NN o
and CC N
altering VBG N
cardiovascular JJ o
risk NN o
. . o

In IN N
a DT N
recent JJ N
clinical JJ N
trial NN N
, , N
postmenopausal JJ N
estrogen-progestin JJ N
therapy NN N
was VBD N
shown VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
early JJ o
cardiovascular JJ o
events NNS o
among IN N
women NNS p
with IN p
a DT p
history NN p
of IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
. . p

The DT N
cardiovascular JJ o
effects NNS o
of IN N
tamoxifen NN N
in IN N
women NNS p
with IN p
and CC p
without IN p
CHD NNP p
are VBP N
not RB N
known VBN N
. . N

The DT N
National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
( ( N
BCPT NNP N
) ) N
is VBZ N
the DT N
only JJ N
clinical JJ N
trial NN N
that WDT N
provides VBZ N
data NNS N
to TO N
assess VB N
the DT N
cardiovascular JJ o
effects NNS o
of IN N
tamoxifen NN N
in IN N
women NNS N
with IN N
and CC N
without IN N
CHD NNP N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
13 CD p
388 CD p
women NNS p
at IN p
increased VBN p
risk NN p
for IN p
breast NN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
in IN N
the DT N
BCPT NNP N
to TO N
receive VB N
either DT N
tamoxifen NN i
( ( i
20 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
. . i

Cardiovascular JJ p
follow-up NN p
was VBD p
available JJ p
for IN p
13 CD p
194 CD p
women NNS p
, , p
1048 CD p
of IN p
whom WP p
had VBD p
prior RB p
clinical JJ p
CHD NNP p
. . p

Fatal NNP o
and CC o
nonfatal JJ o
myocardial JJ o
infarction NN o
, , o
unstable JJ o
angina NN o
, , o
and CC o
severe JJ o
angina NN o
were VBD N
tabulated VBN N
( ( N
mean JJ N
follow-up NN N
: : N
49 CD N
months NNS N
) ) N
. . N

All DT N
statistical JJ N
tests NNS N
were VBD N
two-sided JJ N
. . N

RESULTS NNP N
Cardiovascular JJ o
event NN o
rates NNS o
were VBD N
not RB N
statistically RB N
significantly RB N
different JJ N
between IN N
women NNS N
assigned VBN N
to TO N
receive VB N
tamoxifen NN N
and CC N
those DT N
assigned VBN N
to TO N
receive VB N
placebo NN N
, , N
independent JJ N
of IN N
pre-existing JJ N
CHD NNP N
. . N

Among IN N
women NNS N
without IN N
CHD NNP N
( ( N
6074 CD N
on IN N
tamoxifen NN N
versus NN N
6072 CD N
on IN N
placebo NN N
) ) N
, , N
risk JJ N
ratios NNS N
( ( N
95 CD N
% NN N
confidence NN N
intervals NNS N
[ VBP N
CIs NNP N
] NNP N
) ) N
for IN N
tamoxifen NN N
users NNS N
were VBD N
1.75 CD N
( ( N
0.44 CD N
to TO N
8.13 CD N
) ) N
for IN N
fatal JJ o
myocardial JJ o
infarction NN o
, , N
1.11 CD N
( ( N
0.55 CD N
to TO N
2.28 CD N
) ) N
for IN N
nonfatal JJ o
myocardial JJ o
infarction NN o
, , N
0.69 CD N
( ( N
0.29 CD N
to TO N
1.57 CD N
) ) N
for IN N
unstable JJ o
angina NN o
, , N
and CC N
0.83 CD N
( ( N
0.32 CD N
to TO N
2.10 CD N
) ) N
for IN N
severe JJ o
angina NN o
. . o

In IN N
women NNS N
with IN N
CHD NNP N
( ( N
516 CD N
on IN N
tamoxifen NNS N
versus $ N
532 CD N
on IN N
placebo NN N
) ) N
, , N
risk JJ o
ratios NNS o
( ( N
95 CD N
% NN N
CIs NNP N
) ) N
for IN N
tamoxifen NN N
users NNS N
were VBD N
0.00 CD N
( ( N
0 CD N
to TO N
1.58 CD N
) ) N
for IN N
fatal JJ o
myocardial JJ o
infarction NN o
, , N
1.25 CD N
( ( N
0.32 CD N
to TO N
5.18 CD N
) ) N
for IN N
nonfatal JJ o
myocardial JJ o
infarction NN o
, , N
2.26 CD N
( ( N
0.87 CD N
to TO N
6.55 CD N
) ) N
for IN N
unstable JJ o
angina NN o
, , N
and CC N
1.39 CD N
( ( N
0.23 CD N
to TO N
9.47 CD N
) ) N
for IN N
severe JJ o
angina NN o
. . o

There EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
lack NN N
of IN N
association NN N
between IN N
tamoxifen NN N
and CC N
cardiovascular JJ o
events NNS o
was VBD N
related VBN N
to TO N
an DT N
early JJ N
increase NN o
in IN o
risk NN o
that WDT N
may MD N
have VB N
been VBN N
offset VBN N
by IN N
a DT N
late JJ N
decrease NN N
in IN N
risk NN N
. . N

CONCLUSION NN N
When WRB N
used VBN N
for IN N
breast NN N
cancer NN N
prevention NN N
in IN N
women NNS p
with IN p
or CC p
without IN p
heart NN p
disease NN p
, , N
tamoxifen NN N
is VBZ N
not RB N
associated VBN N
with IN N
beneficial JJ N
or CC N
adverse JJ N
cardiovascular JJ o
effects NNS o
. . o

-DOCSTART- -26712084- O O

Pembrolizumab NNP i
versus NN N
docetaxel NN i
for IN N
previously RB p
treated VBN p
, , p
PD-L1-positive JJ p
, , p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( N
KEYNOTE-010 NNP N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Despite IN N
recent JJ N
advances NNS N
in IN N
the DT N
treatment NN N
of IN N
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
, , N
there EX N
remains VBZ N
a DT N
need NN N
for IN N
effective JJ N
treatments NNS N
for IN N
progressive JJ N
disease NN N
. . N

We PRP N
assessed VBD N
the DT N
efficacy NN N
of IN N
pembrolizumab NN i
for IN N
patients NNS N
with IN N
previously RB p
treated VBN p
, , p
PD-L1-positive JJ p
, , p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

METHODS NNP N
We PRP N
did VBD N
this DT N
randomised VBN N
, , N
open-label JJ N
, , N
phase VB N
2/3 CD N
study NN N
at IN N
202 CD p
academic JJ p
medical JJ p
centres NNS p
in IN p
24 CD p
countries NNS p
. . p

Patients NNS p
with IN p
previously RB p
treated VBN p
non-small-cell JJ p
lung NN p
cancer NN p
with IN p
PD-L1 NNP p
expression NN p
on IN p
at IN p
least JJS p
1 CD p
% NN p
of IN p
tumour JJ p
cells NNS p
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1:1 CD N
) ) N
in IN N
blocks NNS N
of IN N
six CD N
per IN N
stratum NN N
with IN N
an DT N
interactive JJ N
voice-response NN N
system NN N
to TO N
receive VB N
pembrolizumab NN i
2 CD i
mg/kg NN i
, , i
pembrolizumab VBP i
10 CD i
mg/kg NN i
, , i
or CC i
docetaxel VB i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
overall JJ N
survival NN o
and CC o
progression-free JJ o
survival NN o
both DT N
in IN N
the DT N
total JJ N
population NN N
and CC N
in IN N
patients NNS N
with IN N
PD-L1 NNP N
expression NN N
on IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
tumour JJ N
cells NNS N
. . N

We PRP N
used VBD N
a DT N
threshold NN N
for IN N
significance NN N
of IN N
p NN N
< NN N
0.00825 CD N
( ( N
one-sided JJ N
) ) N
for IN N
the DT N
analysis NN N
of IN N
overall JJ N
survival NN N
and CC N
a DT N
threshold NN N
of IN N
p NN N
< $ N
0.001 CD N
for IN N
progression-free JJ N
survival NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01905657 NNP N
. . N

FINDINGS NNP N
Between NNP p
Aug NNP p
28 CD p
, , p
2013 CD p
, , p
and CC p
Feb NNP p
27 CD p
, , p
2015 CD p
, , p
we PRP p
enrolled VBD p
1034 CD p
patients NNS p
: : p
345 CD N
allocated VBD N
to TO N
pembrolizumab VB i
2 CD N
mg/kg NN N
, , N
346 CD N
allocated VBD N
to TO N
pembrolizumab VB N
10 CD N
mg/kg NN N
, , N
and CC N
343 CD N
allocated VBN N
to TO N
docetaxel VB i
. . i

By IN N
Sept NNP N
30 CD N
, , N
2015 CD N
, , N
521 CD N
patients NNS N
had VBD N
died VBN N
. . N

In IN N
the DT N
total JJ N
population NN N
, , N
median JJ o
overall JJ o
survival NN o
was VBD N
10.4 CD N
months NNS N
with IN N
pembrolizumab JJ i
2 CD N
mg/kg NN N
, , N
12.7 CD N
months NNS N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
, , N
and CC N
8.5 CD N
months NNS N
with IN N
docetaxel NN N
. . N

Overall JJ o
survival NN o
was VBD N
significantly RB N
longer JJR N
for IN N
pembrolizumab NN i
2 CD N
mg/kg NN N
versus NN N
docetaxel NN i
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
0.71 CD N
, , N
95 CD N
% NN N
CI NNP N
0.58-0.88 CD N
; : N
p=0.0008 NN N
) ) N
and CC N
for IN N
pembrolizumab JJ i
10 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
0.61 CD N
, , N
0.49-0.75 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Median JJ o
progression-free JJ o
survival NN o
was VBD N
3.9 CD N
months NNS N
with IN N
pembrolizumab JJ N
2 CD N
mg/kg NN N
, , N
4.0 CD N
months NNS N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
, , N
and CC N
4.0 CD N
months NNS N
with IN N
docetaxel NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
for IN N
pembrolizumab NN N
2 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
0.88 CD N
, , N
0.74-1.05 CD N
; : N
p=0.07 NN N
) ) N
or CC N
for IN N
pembrolizumab JJ i
10 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
HR NNP N
0.79 CD N
, , N
95 CD N
% NN N
CI NNP N
0.66-0.94 CD N
; : N
p=0.004 NN N
) ) N
. . N

Among IN N
patients NNS N
with IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
tumour JJ N
cells NNS N
expressing VBG N
PD-L1 NNP N
, , N
overall JJ o
survival NN o
was VBD N
significantly RB N
longer RBR N
with IN N
pembrolizumab JJ i
2 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
median JJ N
14.9 CD N
months NNS N
vs RB N
8.2 CD N
months NNS N
; : N
HR NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
0.38-0.77 CD N
; : N
p=0.0002 NN N
) ) N
and CC N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
17.3 CD N
months NNS N
vs RB N
8.2 CD N
months NNS N
; : N
0.50 CD N
, , N
0.36-0.70 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Likewise NNP N
, , N
for IN N
this DT N
patient JJ N
population NN N
, , N
progression-free JJ o
survival NN o
was VBD N
significantly RB N
longer RBR N
with IN N
pembrolizumab JJ i
2 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN i
( ( N
median JJ N
5.0 CD N
months NNS N
vs RB N
4.1 CD N
months NNS N
; : N
HR NNP N
0.59 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.78 CD N
; : N
p=0.0001 NN N
) ) N
and CC N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
5.2 CD N
months NNS N
vs RB N
4.1 CD N
months NNS N
; : N
0.59 CD N
, , N
0.45-0.78 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Grade VBN o
3-5 JJ o
treatment-related JJ o
adverse JJ o
events NNS o
were VBD N
less JJR N
common JJ N
with IN N
pembrolizumab NN i
than IN N
with IN N
docetaxel NN N
( ( N
43 CD N
[ RB N
13 CD N
% NN N
] NN N
of IN N
339 CD N
patients NNS N
given VBN N
2 CD N
mg/kg NNS N
, , N
55 CD N
[ JJ N
16 CD N
% NN N
] NN N
of IN N
343 CD N
given VBN N
10 CD N
mg/kg NN N
, , N
and CC N
109 CD N
[ JJ N
35 CD N
% NN N
] NN N
of IN N
309 CD N
given VBN N
docetaxel NN i
) ) i
. . N

INTERPRETATION NNP N
Pembrolizumab NNP i
prolongs NNS N
overall JJ o
survival NN o
and CC N
has VBZ N
a DT N
favourable JJ N
benefit-to-risk JJ N
profile NN N
in IN N
patients NNS p
with IN p
previously RB p
treated VBN p
, , p
PD-L1-positive JJ p
, , p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

These DT N
data NNS N
establish VB N
pembrolizumab NN i
as IN N
a DT N
new JJ N
treatment NN N
option NN N
for IN N
this DT N
population NN N
and CC N
validate VB N
the DT N
use NN N
of IN N
PD-L1 NNP N
selection NN N
. . N

FUNDING NNP N
Merck NNP N
& CC N
Co NNP N
. . N

-DOCSTART- -2474057- O O

LNH-84 JJ N
regimen NNS N
: : N
a DT N
multicenter NN N
study NN N
of IN N
intensive JJ N
chemotherapy NN N
in IN N
737 CD p
patients NNS p
with IN p
aggressive JJ p
malignant JJ p
lymphoma NN p
. . p

From IN p
July NNP p
1984 CD p
to TO p
September NNP p
1987 CD p
, , p
737 CD p
patients NNS p
with IN p
aggressive JJ p
malignant JJ p
lymphoma NN p
( ( p
ML NNP p
) ) p
were VBD N
treated VBN N
by IN N
an DT N
intensive JJ i
regimen NNS i
( ( i
LNH-84 NNP i
) ) i
comprising VBG N
three CD i
or CC i
four CD i
courses NNS i
of IN i
doxorubicin NN i
, , i
75 CD i
mg/m2 NN i
; : i
cyclophosphamide NN i
, , i
1,200 CD i
mg/m2 NN i
; : i
vindesine NN i
, , i
2 CD i
mg/m2 NN i
x NN i
2 CD i
; : i
bleomycin NN i
, , i
10 CD i
mg NN i
x NN i
2 CD i
; : i
and CC i
prednisolone NN i
, , i
60 CD i
mg/m2 NN i
x NN i
5 CD i
( ( i
ACVB NNP i
) ) i
, , i
consolidation NN i
with IN i
high-dose JJ i
methotrexate NN i
, , i
ifosfamide NN i
, , i
etoposide RB i
, , i
asparaginase NN i
, , i
and CC i
cytarabine NN i
, , i
and CC i
a DT i
randomized VBN i
late JJ i
intensification NN i
with IN i
two CD i
courses NNS i
of IN i
cytarabine NN i
, , i
cyclophosphamide NN i
, , i
teniposide NN i
, , i
bleomycin NN i
, , i
and CC i
prednisone NN i
( ( i
AraCVmB NNP i
) ) i
. . i

Four CD p
hundred VBD p
forty-two JJ p
patients NNS p
had VBD N
intermediate-grade JJ N
ML NNP N
, , N
221 CD N
highgrade NN N
ML NNP N
, , N
and CC N
74 CD N
unclassified JJ N
ML NNP N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
had VBD N
advanced JJ N
disease NN N
: : N
stage NN N
IIE NNP N
( ( N
23 CD N
% NN N
) ) N
, , N
III NNP N
( ( N
13 CD N
% NN N
) ) N
, , N
or CC N
IV NNP N
( ( N
47 CD N
% NN N
) ) N
; : N
38 CD N
% NN N
disseminated JJ N
nodes NNS N
; : N
38 CD N
% NN N
two CD N
or CC N
more JJR N
extranodal JJ N
sites NNS N
; : N
and CC N
41 CD N
% NN N
a DT N
tumoral JJ N
mass NN N
greater JJR N
than IN N
10 CD N
cm NN N
. . N

Five CD N
hundred VBD N
fifty-three JJ N
patients NNS N
( ( N
75 CD N
% NN N
) ) N
went VBD N
into IN N
complete JJ o
remission NN o
( ( o
CR NNP o
) ) o
, , N
63 CD N
( ( N
9 CD N
% NN N
) ) N
into IN N
partial JJ o
remission NN o
, , N
62 CD N
( ( N
8 CD N
% NN N
) ) N
failed VBD o
to TO o
respond VB o
, , N
and CC N
59 CD N
( ( N
8 CD N
% NN N
) ) N
died VBD o
during IN N
ACVB NNP N
courses NNS N
, , N
17 CD N
of IN N
them PRP N
from IN N
progression NN N
of IN N
the DT N
disease NN N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
23 CD N
months NNS N
, , N
the DT N
estimated VBN N
2-year JJ N
overall JJ o
survival NN o
time NN o
to TO o
failure NN o
( ( o
TTF NNP o
) ) o
, , N
and CC N
time NN o
to TO o
relapse VB o
( ( o
TTR NNP o
) ) o
survival NN o
are VBP N
67 CD N
% NN N
, , N
56 CD N
% NN N
, , N
and CC N
67 CD N
% NN N
, , N
respectively RB N
. . N

Patients NNS N
receiving VBG N
a DT N
late JJ N
intensification NN N
had VBD N
the DT N
same JJ N
relapse NN o
rate NN o
as IN N
the DT N
other JJ N
patients NNS N
. . N

A DT N
persistent JJ o
fibronecrotic JJ o
mass NN o
was VBD N
found VBN N
in IN N
150 CD N
patients NNS N
( ( N
20 CD N
% NN N
) ) N
and CC N
did VBD N
not RB N
influence VB N
the DT N
relapse NN o
rate NN o
. . o

Toxicity NNP o
was VBD N
mainly RB N
neutropenia JJ o
and CC N
infection NN o
during IN N
the DT N
ACVB NNP N
courses NNS N
, , N
with IN N
40 CD N
patients NNS N
( ( N
5 CD N
% NN N
) ) N
dying VBG o
from IN o
septic JJ o
complications NNS o
while IN N
responding VBG N
to TO N
treatment NN N
. . N

Fifty-three JJ N
percent NN N
of IN N
the DT N
patients NNS N
had VBD N
a DT N
neutropenia NN o
less JJR N
than IN N
0.500 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
, , N
58 CD N
% NN N
fever NN N
( ( N
6 CD N
% NN N
grade JJ N
4 CD N
) ) N
, , N
and CC N
49 CD N
% NN N
a DT N
documented JJ o
infection NN o
( ( N
8 CD N
% NN N
grade JJ N
4 CD N
) ) N
. . N

These DT N
results NNS N
obtained VBD N
with IN N
the DT N
LNH-84 JJ N
regimen NNS N
demonstrate VBP N
that IN N
this DT N
therapeutic JJ N
scheme NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
aggressive JJ N
ML NNP N
. . N

-DOCSTART- -17207470- O O

Relationship NN N
of IN N
dietary JJ i
intake NN i
to TO N
gastrointestinal VB o
symptoms NNS o
in IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

BACKGROUND NNP N
Gastrointestinal NNP N
( ( N
GI NNP N
) ) N
symptoms NNS N
and CC N
abnormalities NNS N
in IN N
stool NN N
consistency NN N
are VBP N
frequently RB N
reported VBN N
by IN N
parents NNS p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
1 CD N
) ) N
describe NN N
dietary JJ N
intake NN N
of IN N
a DT N
cohort NN N
of IN N
children NNS N
with IN N
ASD NNP N
compared VBN N
with IN N
normative JJ N
data NNS N
and CC N
2 CD N
) ) N
determine NN N
whether IN N
GI NNP N
symptoms NNS N
and CC N
stool JJ N
consistency NN N
are VBP N
related VBN N
to TO N
dietary JJ N
intake NN N
. . N

METHODS NNP N
Data NNP i
from IN i
diet JJ i
diaries NNS i
of IN p
children NNS p
( ( p
3-8 CD p
years NNS p
) ) p
with IN p
ASD NNP p
( ( p
n JJ p
= NNP p
62 CD p
) ) p
were VBD p
analyzed VBN p
by IN N
a DT N
registered JJ N
pediatric JJ N
dietician NN N
to TO N
compare VB N
to TO N
RDA NNP N
standards NNS N
for IN N
total JJ N
calories NNS N
, , N
protein NN N
, , N
carbohydrate NN N
, , N
and CC N
fat NN N
. . N

Dietary NNP N
intake NN N
was VBD N
correlated VBN N
with IN N
descriptors NNS N
of IN N
stool NN N
consistency NN N
using VBG N
cumulative JJ N
logistic JJ N
regression NN N
methods NNS N
. . N

RESULTS NNP N
Intake NNP N
of IN N
calories NNS N
, , N
carbohydrates NNS N
, , N
and CC N
fat NN N
were VBD N
in IN N
the DT N
average JJ N
range NN N
; : N
protein CC N
intake VB N
was VBD N
increased VBN N
( ( N
211 CD N
% NN N
of IN N
RDA NNP N
) ) N
. . N

Reported VBN N
frequency NN o
of IN o
GI NNP o
abnormalities NNS o
, , o
including VBG o
abnormal JJ o
stool NN o
consistency NN o
( ( o
e.g. JJ o
, , N
bulky NN o
or CC o
loose JJ o
) ) o
, , N
was VBD N
increased VBN N
( ( N
54 CD N
% NN N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
relationships NNS N
between IN N
stool NN N
consistency NN N
and CC N
dietary JJ N
intake NN N
were VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
sample NN N
, , N
there EX N
was VBD N
a DT N
high JJ N
rate NN N
of IN N
reported VBN N
gastrointestinal JJ o
symptoms NNS o
, , N
despite IN N
lack NN N
of IN N
medical JJ N
causes NNS N
. . N

Intake NNP N
was VBD N
adequate JJ N
for IN N
calories NNS N
and CC N
carbohydrates NNS N
and CC N
increased VBD N
for IN N
protein NN N
. . N

The DT N
children NNS p
did VBD N
not RB N
exhibit VB N
excessive JJ N
carbohydrate NN N
intake NN N
. . N

There EX N
was VBD N
no DT N
association NN N
of IN N
nutrient JJ N
intake NN N
to TO N
changes NNS N
in IN N
stool NN N
consistency NN N
. . N

-DOCSTART- -23893101- O O

A DT N
replication NN N
and CC N
extension NN N
of IN N
the DT N
PEERS NNPS i
intervention NN i
: : i
examining JJ N
effects NNS N
on IN N
social JJ o
skills NNS o
and CC N
social JJ o
anxiety NN o
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
Program NNP i
for IN i
the DT i
Education NNP i
and CC i
Enrichment NNP i
of IN i
Relational NNP i
Skills NNP i
( ( i
PEERS NNS i
: : i
Laugeson NNP N
et CC N
al NN N
. . N

in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
39 CD N
( ( N
4 CD N
) ) N
:596-606 NN N
, , N
2009 CD N
) ) N
. . N

PEERS CC i
focuses VBZ N
on IN N
improving VBG N
friendship JJ o
quality NN o
and CC N
social JJ o
skills NNS o
among IN N
adolescents NNS p
with IN p
higher-functioning JJ p
ASD NNP p
. . p

58 CD p
participants NNS p
aged VBN p
11-16 JJ p
years-old JJ p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
immediate JJ i
treatment NN i
or CC i
waitlist NN i
comparison NN i
group NN i
. . i

Results NNP N
revealed VBD N
, , N
in IN N
comparison NN N
to TO N
the DT N
waitlist NN i
group NN N
, , N
that IN N
the DT N
experimental JJ i
treatment NN i
group NN N
significantly RB N
improved VBN N
their PRP$ N
knowledge NN o
of IN o
PEERS NNP o
concepts NNS o
and CC o
friendship NN o
skills NNS o
, , N
increased VBN N
in IN N
their PRP$ N
amount NN o
of IN o
get-togethers NNS o
, , N
and CC N
decreased VBN N
in IN N
their PRP$ N
levels NNS o
of IN o
social JJ o
anxiety NN o
, , o
core NN o
autistic NN o
symptoms NNS o
, , o
and CC o
problem NN o
behaviors NNS o
from IN o
pre-to JJ o
post-PEERS NNS o
. . o

This DT N
study NN N
provides VBZ N
the DT N
first JJ N
independent JJ N
replication NN N
and CC N
extension NN N
of IN N
the DT N
empirically-supported JJ N
PEERS NNP i
social JJ o
skills NNS o
intervention NN i
for IN N
adolescents NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -23860945- O O

Singing VBG i
can MD N
facilitate VB N
foreign JJ p
language NN p
learning NN p
. . p

This DT N
study NN N
presents VBZ N
the DT N
first JJ N
experimental JJ N
evidence NN N
that IN N
singing VBG i
can MD N
facilitate VB N
short-term JJ N
paired-associate JJ N
phrase NN N
learning NN N
in IN N
an DT N
unfamiliar JJ p
language NN p
( ( p
Hungarian JJ p
) ) p
. . p

Sixty NNP p
adult NN p
participants NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
listen-and-repeat JJ N
learning VBG N
conditions NNS N
: : N
speaking NN i
, , i
rhythmic JJ i
speaking NN i
, , N
or CC N
singing VBG i
. . i

Participants NNS N
in IN N
the DT N
singing NN N
condition NN N
showed VBD N
superior JJ N
overall JJ o
performance NN o
on IN o
a DT o
collection NN o
of IN o
Hungarian JJ o
language NN o
tests NNS o
after IN N
a DT N
15-min JJ N
learning NN N
period NN N
, , N
as IN N
compared VBN N
with IN N
participants NNS N
in IN N
the DT N
speaking NN i
and CC N
rhythmic JJ i
speaking NN i
conditions NNS i
. . i

This DT N
superior JJ o
performance NN o
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
for IN N
the DT N
two CD N
tests NNS N
that WDT N
required VBD N
participants NNS N
to TO N
recall VB N
and CC N
produce VB N
spoken JJ N
Hungarian JJ N
phrases NNS N
. . N

The DT N
differences NNS N
in IN N
performance NN o
were VBD N
not RB N
explained VBN N
by IN N
potentially RB N
influencing VBG N
factors NNS N
such JJ N
as IN N
age NN p
, , p
gender NN p
, , p
mood NN p
, , p
phonological JJ p
working VBG p
memory NN p
ability NN p
, , p
or CC p
musical JJ p
ability NN p
and CC p
training NN p
. . p

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
listen-and-sing JJ i
learning NN i
method NN i
can MD N
facilitate VB N
verbatim JJ o
memory NN o
for IN N
spoken JJ N
foreign JJ N
language NN N
phrases NNS N
. . N

-DOCSTART- -9704200- O O

Postoperative JJ N
injection NN N
of IN N
phenylbutazone NN i
does VBZ N
not RB N
influence VB N
fibrinolytic JJ o
shutdown NN o
. . o

Twenty-nine JJ p
patients NNS p
undergoing VBG p
cholecystectomy NN p
because IN p
of IN p
chronic JJ p
calculous JJ p
cholecystitis NN p
were VBD p
randomised VBN p
to TO p
receive VB p
phenylbutazone NN i
10 CD i
mg/kg NN i
intramuscularly RB i
or CC i
a DT i
control NN i
injection NN i
( ( N
vehicle-containing JJ N
local JJ N
anaesthetic NN N
) ) N
immediately RB N
after IN N
completion NN N
of IN N
surgery NN N
. . N

Fibrinogen NNP o
and CC o
plasminogen NN o
concentrations NNS o
in IN o
plasma NN o
, , o
plasminogen NN o
activator NN o
inhibitor NN o
activity NN o
in IN o
plasma NN o
and CC o
fibrinolytic JJ o
activity NN o
in IN o
concentrated JJ o
euglobulins NNS o
were VBD N
determined VBN N
before IN N
surgery NN N
and CC N
on IN N
the DT N
first JJ N
, , N
third JJ N
and CC N
seventh JJ N
postoperative JJ N
days NNS N
. . N

Phenylbutazone NNP i
delayed VBD N
the DT N
postoperative JJ N
rise NN o
of IN o
fibrinogen NN o
concentration NN o
and CC N
reduced VBD N
the DT N
plasminogen NN o
level NN o
on IN N
the DT N
first JJ N
day NN N
after IN N
surgery NN N
. . N

Fibrinolytic JJ o
activity NN o
in IN o
euglobulins NNS o
was VBD N
decreased VBN N
after IN N
the DT N
operation NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
great JJ N
dispersion NN N
of IN N
the DT N
results NNS N
of IN N
plasminogen NN o
activator NN o
inhibitor NN o
activity NN o
was VBD N
the DT N
plausible JJ N
cause NN N
of IN N
the DT N
lack NN N
of IN N
any DT N
significant JJ N
difference NN N
in IN N
this DT N
variable JJ N
. . N

The DT N
postoperative JJ o
fibrinolytic JJ o
shutdown NN o
, , N
reflected VBN N
by IN N
the DT N
decrease NN N
of IN N
fibrinolytic JJ o
activity NN o
, , N
was VBD N
unaffected VBN N
by IN N
phenylbutazone NN i
. . i

It PRP N
can MD N
be VB N
speculated VBN N
, , N
however RB N
, , N
that IN N
the DT N
decline NN N
of IN N
plasminogen NN o
concentration NN o
after IN N
surgery NN N
in IN N
patients NNS N
receiving VBG N
this DT N
drug NN N
was VBD N
the DT N
result NN N
of IN N
its PRP$ N
stimulatory JJ N
influence NN N
on IN N
the DT N
conversion NN N
of IN N
plasminogen NN N
into IN N
plasmin NN N
. . N

-DOCSTART- -12423984- O O

Effect NN N
of IN N
nitazoxanide NN i
on IN N
morbidity NN o
and CC o
mortality NN o
in IN N
Zambian JJ p
children NNS p
with IN p
cryptosporidiosis NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Cryptosporidiosis NNP p
in IN p
children NNS p
in IN p
developing VBG p
countries NNS p
causes VBZ N
persistent JJ N
diarrhoea NN N
and CC N
malnutrition NN N
and CC N
is VBZ N
associated VBN N
with IN N
increased JJ N
mortality NN N
, , N
but CC N
there EX N
is VBZ N
no DT N
effective JJ N
treatment NN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
nitazoxanide-a JJ i
new JJ i
broad-spectrum JJ i
antiparasitic JJ i
drug-on JJ i
morbidity NN o
and CC o
mortality NN o
in IN N
Zambian JJ p
children NNS p
with IN p
diarrhoea NN p
due JJ p
to TO p
Cryptosporidium NNP p
parvum NN p
. . p

METHODS NNP N
Children NNP p
with IN p
cryptosporidial JJ p
diarrhoea NNS p
who WP p
were VBD p
admitted VBN p
to TO p
the DT p
University NNP p
Teaching NNP p
Hospital NNP p
, , p
Lusaka NNP p
, , p
Zambia NNP p
, , p
between IN p
November NNP p
, , p
2000 CD p
, , p
and CC p
July NNP p
, , p
2001 CD p
, , p
and CC p
whose WP$ p
parents NNS p
consented VBD p
to TO p
their PRP$ p
having VBG p
an DT p
HIV JJ p
test NN p
were VBD p
randomly RB p
assigned VBN p
nitazoxanide RB i
( ( i
100 CD i
mg NN i
twice RB i
daily RB i
orally RB i
for IN i
3 CD i
days NNS i
) ) i
or CC i
placebo NN i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
clinical JJ o
response NN o
on IN o
day NN o
7 CD o
after IN N
the DT N
start NN N
of IN N
treatment NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
parasitological JJ o
response NN o
by IN o
day NN o
10 CD o
and CC o
mortality NN o
at IN o
day NN o
8 CD o
. . o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
, , N
with IN N
exclusion NN N
of IN N
patients NNS N
subsequently RB N
found VBN N
to TO N
be VB N
negative JJ N
for IN N
C NNP p
parvum NN p
or CC p
co-infected JJ p
at IN p
baseline NN p
. . p

The DT N
trial NN N
was VBD N
stratified VBN N
by IN N
HIV NNP N
serology NN N
. . N

FINDINGS CD N
50 CD p
HIV-seropositive JJ p
and CC p
50 CD p
HIV-seronegative JJ p
children NNS p
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
, , N
four CD N
of IN N
whom WP N
were VBD N
subsequently RB N
excluded VBN N
. . N

In IN N
HIV-seronegative JJ N
children NNS N
, , N
diarrhoea NN o
resolved VBD N
in IN N
14 CD N
( ( N
56 CD N
% NN N
) ) N
of IN N
25 CD N
receiving VBG N
nitazoxanide RB N
and CC N
5 CD N
( ( N
23 CD N
% NN N
) ) N
of IN N
22 CD N
receiving VBG N
placebo NN N
( ( N
difference NN N
33 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
7-59 CD N
; : N
p=0.037 NN N
) ) N
. . N

C NNP o
parvum NN o
was VBD N
eradicated VBN o
from IN N
stool NN N
in IN N
13 CD N
( ( N
52 CD N
% NN N
) ) N
of IN N
25 CD N
receiving VBG N
nitazoxanide NN N
and CC N
three CD N
( ( N
14 CD N
% NN N
) ) N
of IN N
22 CD N
receiving VBG N
placebo NN N
( ( N
38 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
14-63 CD N
; : N
p=0.007 NN N
) ) N
. . N

Four CD N
children NNS N
( ( N
18 CD N
% NN N
) ) N
of IN N
22 CD N
in IN N
the DT N
placebo NN N
group NN N
had VBD N
died VBN o
by IN N
day NN N
8 CD N
, , N
compared VBN N
with IN N
none NN N
of IN N
25 CD N
in IN N
the DT N
nitazoxanide JJ N
group NN N
( ( N
-18 CD N
% NN N
, , N
-34 NN N
to TO N
2 CD N
; : N
p=0.041 NN N
) ) N
. . N

HIV-seropositive JJ N
children NNS N
did VBD N
not RB N
benefit VB N
from IN N
nitazoxanide RB N
. . N

Nitazoxanide NNP N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
adverse JJ o
events NNS o
in IN N
either DT N
stratum NN N
. . N

INTERPRETATION VB N
A DT N
3-day JJ N
course NN N
of IN N
nitazoxanide JJ N
significantly RB N
improved VBN N
the DT N
resolution NN o
of IN o
diarrhoea NN o
, , o
parasitological JJ o
eradication NN o
, , o
and CC o
mortality NN o
in IN N
HIV-seronegative NNP N
, , N
but CC N
not RB N
HIV-seropositive NNP N
, , N
children NNS N
. . N

-DOCSTART- -15652441- O O

Efficacy NN o
, , o
safety NN o
, , o
and CC o
steady-state JJ o
pharmacokinetics NNS o
of IN N
once-a-day JJ N
controlled-release JJ N
morphine NN i
( ( N
MS NNP N
Contin NNP N
XL NNP N
) ) N
in IN N
cancer NN p
pain NN p
. . p

The DT N
efficacy NN o
, , o
safety NN o
, , o
and CC o
pharmacokinetics NNS o
of IN N
a DT N
novel JJ N
once-daily JJ N
morphine NN i
formulation NN i
( ( i
OAD NNP i
morphine NN i
) ) i
and CC N
a DT N
12-hourly JJ N
formulation NN N
( ( N
twice-daily JJ N
CR NNP N
morphine NN i
) ) i
were VBD N
compared VBN N
in IN N
a DT N
double-blind JJ N
, , N
multi-centered JJ N
crossover NN N
study NN N
. . N

Chronic NNP p
cancer NN p
pain NN p
patients NNS p
( ( p
n=25 JJ p
) ) p
were VBD p
randomized VBN p
to TO p
OAD NNP i
morphine NN i
( ( p
mean JJ p
238 CD p
+/- JJ p
319 CD p
mg NN p
q24h NN p
) ) p
or CC p
twice-daily JJ i
CR NNP i
morphine NN i
( ( N
mean JJ N
119 CD N
+/- JJ N
159 CD N
mg NN N
q12h NN N
) ) N
for IN N
one CD N
week NN N
. . N

They PRP N
then RB N
crossed VBD N
over IN N
to TO N
the DT N
alternate JJ N
drug NN N
, , N
which WDT N
also RB N
was VBD N
taken VBN N
for IN N
one CD N
week NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
for IN N
evaluations NNS N
of IN N
overall JJ o
pain NN o
intensity NN o
, , o
analgesic JJ o
efficacy NN o
, , o
or CC o
adverse JJ o
events NNS o
. . o

However RB N
, , N
whereas JJ N
pain NN o
scores NNS o
increased VBD N
during IN N
the DT N
day NN N
on IN N
twice-daily JJ N
CR NNP N
morphine NN i
( ( N
P=0.0108 NNP N
) ) N
, , N
they PRP N
remained VBD N
stable JJ N
on IN N
OAD NNP N
morphine NN N
. . N

Most JJS N
patients NNS N
( ( N
68 CD N
% NN N
) ) N
chose VBD N
once-daily JJ N
dosing NN N
for IN N
continuing VBG N
pain JJ o
management NN o
( ( N
P=0.015 NNP N
) ) N
. . N

The DT N
AUC NNP o
ratio NN o
was VBD N
100.3 CD N
% NN N
, , N
indicating VBG N
equivalent JJ N
absorption NN N
. . N

Fluctuation NN o
indices NNS o
were VBD N
93.5 CD N
+/- JJ N
28.8 CD N
% NN N
and CC N
179.3 CD N
+/- JJ N
41.3 CD N
% NN N
( ( N
P=0.0001 NNP N
) ) N
for IN N
OAD NNP N
morphine NN i
and CC N
twice-daily JJ N
CR NNP i
morphine NN i
, , N
respectively RB N
. . N

OAD NNP N
morphine NN i
provides VBZ N
analgesia RB o
similar JJ N
to TO N
twice-daily JJ N
CR NNP N
morphine NN N
with IN N
reduced JJ N
fluctuation NN o
in IN o
plasma JJ o
morphine NN o
concentration NN o
and CC N
more RBR N
stable JJ N
pain NN o
control NN o
. . o

-DOCSTART- -16038713- O O

Superior JJ N
efficacy NN N
of IN N
clopidogrel NN i
plus CC i
acetylsalicylic JJ i
acid NNS i
compared VBN N
with IN N
extended-release JJ i
dipyridamole JJ i
plus CC i
acetylsalicylic JJ i
acid NN i
in IN N
preventing VBG N
arterial JJ N
thrombogenesis NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

INTRODUCTION NNP N
Recent NNP N
ex NN N
vivo NN N
platelet NN N
aggregometry NN N
data NNS N
indicate VBP N
that IN N
clopidogrel NN i
75 CD N
mg/day JJ N
plus CC i
acetylsalicylic JJ i
acid NN i
( ( i
ASA NNP i
) ) i
75 CD N
mg/day NN N
is VBZ N
a DT N
more RBR N
potent JJ N
antiplatelet NN N
regimen NNS N
than IN N
the DT N
marketed JJ N
combination NN N
of IN N
dipyridamole+ASA NN i
. . i

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
antithrombotic JJ N
effect NN N
of IN N
both DT N
dual JJ i
antiplatelet NN i
regimens NNS i
using VBG N
a DT N
human JJ N
ex NN N
vivo NN N
model NN N
of IN N
arterial JJ N
thrombosis NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

During IN N
two CD N
10-day JJ N
treatment NN N
periods NNS N
separated VBN N
by IN N
a DT N
14-day JJ N
washout NN N
period NN N
, , N
23 CD p
healthy JJ p
male NN p
volunteers NNS p
received VBD N
once-daily RB N
clopidogrel JJ i
75 CD i
mg NN i
plus CC i
acetylsalicylic JJ i
acid NN i
75 CD N
mg NN N
, , N
or CC N
twice-daily RB N
extended-release JJ i
dipyridamole NN i
200 CD i
mg NN i
plus CC i
acetylsalicylic JJ i
acid NN i
25 CD N
mg NN N
. . N

Assessments NNS N
were VBD N
made VBN N
at IN N
baseline NN N
and CC N
on IN N
Day NNP N
10 CD N
of IN N
each DT N
period NN N
. . N

Arterial JJ N
thrombus NN N
formation NN N
was VBD N
induced VBN N
ex JJ N
vivo NN N
by IN N
exposing VBG N
a DT N
collagen-coated JJ N
surface NN N
in IN N
a DT N
parallel-plate JJ N
perfusion NN N
chamber NN N
to TO N
native JJ N
blood NN N
for IN N
3 CD N
min NN N
( ( N
arterial JJ N
wall NN N
shear NN N
rate NN N
2600 CD N
s NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

Total JJ o
platelet NN o
and CC o
fibrin JJ o
deposition NN o
was VBD N
determined VBN N
by IN N
immunoenzymatic JJ N
methods NNS N
. . N

RESULTS NNP N
Compared VBD N
with IN N
baseline NN N
values NNS N
, , N
the DT N
mean JJ o
inhibition NN o
of IN o
total JJ o
platelet NN o
deposition NN o
was VBD N
63.9+/-5.9 JJ N
% NN N
with IN N
clopidogrel JJ i
plus CC i
acetylsalicylic JJ i
acid NN i
, , N
compared VBN N
with IN N
18.4+/-5.6 CD N
% NN N
for IN N
extended-release JJ i
dipyridamole JJ i
plus CC i
acetylsalicylic JJ i
acid NN i
( ( N
67 CD N
% NN N
reduction NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
49-79 JJ N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Corresponding VBG N
figures NNS N
for IN N
fibrin JJ o
deposition NN o
were VBD N
64.9+/-4.8 CD N
% NN N
and CC N
18.3+/-9.7 CD N
% NN N
, , N
respectively RB N
( ( N
58 CD N
% NN N
reduction NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
45-67 JJ N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSIONS NNP N
Clopidogrel NNP i
plus CC i
acetylsalicylic JJ i
acid NN i
showed VBD N
significantly RB N
superior JJ N
antithrombotic JJ N
efficacy NN N
compared VBN N
with IN N
extended-release JJ i
dipyridamole JJ i
plus CC i
acetylsalicylic JJ i
acid NN i
in IN N
preventing VBG N
arterial JJ N
thrombogenesis NN N
in IN N
humans NNS N
. . N

-DOCSTART- -14763475- O O

Prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
diclofenac NN i
and CC N
ketorolac NN N
after IN N
refractive JJ p
surgery NN p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN o
of IN N
diclofenac NN i
and CC i
ketorolac NN i
in IN N
relieving VBG o
corneal NN o
pain NN o
after IN p
refractive JJ p
surgery NN p
, , N
and CC N
determine VB N
if IN N
there EX N
is VBZ N
a DT N
difference NN N
in IN N
stinging VBG N
on IN N
instillation NN N
. . N

METHODS NNP N
Thirty NNP p
patients NNS p
were VBD N
randomized VBN N
prospectively RB N
to TO N
postoperative VB i
diclofenac NN i
in IN i
one CD i
eye NN i
and CC i
ketorolac NN i
in IN i
the DT i
other JJ i
. . i

Patients NNS N
and CC N
surgeon NN N
did VBD N
not RB N
know VB N
which WDT N
medications NNS N
were VBD N
used VBN N
. . N

Ocular JJ o
postoperative JJ o
pain NN o
and CC o
discomfort NN o
on IN o
instillation NN o
of IN o
medication NN o
were VBD N
measured VBN N
after IN N
radial JJ N
keratotomy NN N
with IN N
a DT N
visual JJ o
analog NN o
scale NN o
and CC o
a DT o
questionnaire NN o
. . o

RESULTS NNP N
Both NNP N
medications NNS N
were VBD N
highly RB N
effective JJ o
in IN o
relieving VBG o
pain NN o
. . o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN o
relief NN o
, , N
or CC N
stinging VBG o
on IN o
instillation NN o
( ( N
P NNP N
= NNP N
.29 NNP N
) ) N
. . N

CONCLUSION NNP N
There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
effectiveness NN N
of IN N
the DT N
medications NNS N
on IN N
pain NN o
relief NN o
, , N
or CC N
in IN N
stinging VBG o
on IN o
instillation NN o
. . o

-DOCSTART- -9713225- O O

Laser NNP i
therapy NN i
combined VBN i
with IN i
brachytherapy NN i
for IN N
the DT N
palliation NN N
of IN N
malignant JJ p
dysphagia NN p
. . p

BACKGROUND/AIM NNP N
OF IN N
STUDY NNP N
Laser NNP i
therapy NN i
is VBZ N
effective JJ N
in IN N
relieving VBG N
malignant JJ o
dysphagia NN o
, , N
but CC N
repeated VBD N
treatments NNS N
at IN N
4 CD N
to TO N
6 CD N
week NN N
intervals NNS N
are VBP N
usually RB N
required VBN N
. . N

This DT N
prospective JJ N
randomised VBN N
trial NN N
is VBZ N
designed VBN N
to TO N
determine VB N
if IN N
addition NN N
of IN N
brachytherapy NN N
offers NNS N
any DT N
advantages NNS N
over IN N
laser JJR i
therapy NN i
alone RB N
. . N

METHODS JJ N
Patients NNS p
with IN p
inoperable JJ p
carcinoma NN p
of IN p
the DT p
oesophagus NN p
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
endoscopic NN i
Nd NN i
: : i
YAG NNP i
laser NN i
therapy NN i
alone RB N
, , N
or CC N
laser NN i
followed VBN N
by IN N
brachytherapy NN i
. . i

Patients NNS N
who WP N
developed VBD N
worsening VBG N
dysphagia NN N
during IN N
follow-up JJ N
were VBD N
offered VBN N
further RB N
treatment NN N
as IN N
appropriate JJ N
. . N

RESULTS NNP N
Fourteen JJ p
patients NNS p
were VBD p
randomised VBN p
to TO p
receive VB p
laser NN i
only RB i
, , p
and CC p
12 CD p
to TO p
receive VB p
laser NN p
followed VBN p
by IN p
brachytherapy NN i
. . i

Of IN N
these DT N
12 CD N
, , N
one CD N
was VBD N
lost VBN N
to TO N
follow-up JJ N
and CC N
four CD N
did VBD N
not RB N
receive VB N
brachytherapy NN i
because IN N
they PRP N
were VBD N
unfit JJ N
, , N
had VBD N
extension NN N
into IN N
the DT N
cardia NN N
or CC N
had VBD N
mainly RB N
extrinsic JJ N
compression NN N
. . N

These DT N
4 CD N
are VBP N
included VBN N
on IN N
an DT N
'intention-to-treat JJ N
' POS N
basis NN N
. . N

The DT N
mean JJ o
therapeutic JJ o
interval NN o
for IN N
the DT N
brachytherapy NN N
group NN N
was VBD N
significantly RB N
longer JJR N
, , N
83 CD N
days NNS N
compared VBN N
to TO N
36 CD N
days NNS N
for IN N
the DT N
laser NN N
group NN N
( ( N
p JJ N
= NNP N
0.026 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
degree NN o
of IN o
dysphagia NN o
relief NN o
, , o
number NN o
of IN o
endoscopic JJ o
procedures NNS o
or CC o
survival JJ o
times NNS o
. . o

CONCLUSION VB N
The DT N
preliminary JJ N
results NNS N
of IN N
this DT N
trial NN N
suggest VBP N
that IN N
brachytherapy NN i
in IN N
addition NN N
to TO N
laser VB N
therapy NN N
prolongs IN N
the DT N
first JJ N
therapeutic JJ o
interval NN o
. . o

However RB N
, , N
no DT N
long-term JJ N
advantages NNS N
have VBP N
been VBN N
shown VBN N
. . N

-DOCSTART- -9351754- O O

Postoperative JJ N
pain NN N
relief NN N
following VBG N
laparoscopic NN p
tubal JJ p
sterilization NN p
with IN N
silastic JJ N
bands NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
postoperative JJ N
pain NN N
relief NN N
of IN N
intramuscular JJ N
ketorolac NN i
, , i
topical JJ i
bupivacaine NN i
, , N
and CC N
placebo NN i
in IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
tubal JJ p
sterilization NN p
with IN p
silastic JJ p
bands NNS p
. . p

METHODS NNP N
One CD p
hundred VBD p
five CD p
women NNS p
undergoing VBG p
laparoscopic NN p
tubal JJ p
sterilization NN p
with IN p
silastic JJ p
bands NNS p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
one CD N
received VBD N
intramuscular JJ i
ketorolac NN i
and CC i
topical JJ i
placebo NN i
applied VBN N
to TO N
the DT N
fallopian JJ N
tubes NN N
, , N
the DT N
second JJ N
received VBD N
intramuscular JJ i
placebo NN i
and CC i
topical JJ i
bupivacaine NN i
, , N
and CC N
the DT N
third JJ N
received VBD N
intramuscular JJ i
placebo NN i
and CC i
topical JJ i
placebo NN i
. . i

Surgical JJ N
procedures NNS N
, , N
anesthesia NN N
, , N
and CC N
recovery NN N
were VBD N
conducted VBN N
with IN N
standardized JJ N
protocols NNS N
. . N

Postoperative JJ N
pain NN N
perception NN N
was VBD N
graded VBN N
using VBG N
the DT N
modified VBN N
McGill NNP N
pain VBP N
intensity NN N
scale NN N
at IN N
30 CD N
minutes NNS N
postoperatively RB N
, , N
at IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
, , N
and CC N
the DT N
next JJ N
morning NN N
by IN N
telephone NN N
interview NN N
. . N

Other JJ N
measured VBD N
variables NNS N
included VBD N
postoperative JJ N
vomiting NN N
, , N
additional JJ N
analgesia NN N
requirement NN N
, , N
and CC N
length NN N
of IN N
time NN N
spent VBN N
in IN N
the DT N
recovery NN N
room NN N
. . N

RESULTS NNP N
Only RB N
topical JJ N
bupivacaine NN N
was VBD N
found VBN N
to TO N
decrease VB N
postoperative JJ o
pain NN o
scores NNS o
significantly RB N
over IN N
those DT N
with IN N
placebo NN i
, , N
at IN N
30 CD N
minutes NNS N
postoperatively RB N
( ( N
median JJ N
score NN N
2 CD N
compared VBN N
with IN N
4 CD N
, , N
P NNP N
= NNP N
.002 NNP N
) ) N
and CC N
at IN N
discharge NN N
from IN N
the DT N
recovery NN N
room NN N
( ( N
median JJ N
score NN N
2 CD N
compared VBN N
with IN N
3 CD N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
decrease NN N
in IN N
pain NN o
scores NNS o
with IN N
intramuscular JJ N
ketorolac NNS i
compared VBN N
with IN N
placebo NN i
. . i

No DT N
differences NNS N
in IN N
pain NN o
scores NNS o
were VBD N
found VBN N
between IN N
the DT N
three CD N
groups NNS N
at IN N
the DT N
next JJ N
morning NN N
phone NN N
call NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
with IN N
respect NN N
to TO N
requirements NNS o
for IN o
supplemental JJ o
pain NN o
medications NNS o
in IN N
the DT N
recovery NN N
room NN N
, , N
incidence NN o
of IN o
postoperative JJ o
vomiting NN o
, , o
or CC o
length NN o
of IN o
time NN o
spent VBN o
in IN o
the DT o
recovery NN o
room NN o
. . o

CONCLUSION NNP N
Topical NNP N
bupivacaine NN i
decreases VBZ N
postoperative JJ N
pain NN N
scores NNS N
significantly RB N
compared VBN N
with IN N
placebo NN i
in IN N
women NNS N
undergoing VBG N
laparoscopic NN N
tubal JJ N
sterilization NN N
with IN N
silastic JJ N
bands NNS N
. . N

-DOCSTART- -17244294- O O

How WRB N
does VBZ N
Cash NNP i
and CC i
Counseling NNP i
affect NN N
costs NNS N
? . N
OBJECTIVE NNP N
To TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
consumer-directed JJ N
model NN N
( ( i
Cash NNP i
and CC i
Counseling NNP i
) ) i
of IN N
Medicaid NNP N
personal JJ p
care NN p
services NNS p
( ( p
PCS NNPS p
) ) p
or CC N
home- JJ N
and CC N
community-based JJ N
waiver NN N
services NNS N
( ( N
HCBS NNP N
) ) N
on IN N
the DT N
cost NN N
of IN N
Medicaid NNP N
services NNS N
. . N

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
Medicaid NNP N
claims NNS N
data NNS N
were VBD N
collected VBN N
for IN N
all DT p
enrollees NNS p
in IN p
the DT p
Cash NNP p
and CC p
Counseling NNP p
demonstration NN p
. . p

Demonstration NNP p
enrollees NNS p
included VBD p
those DT p
eligible JJ p
for IN p
PCS NNP p
( ( p
in IN p
Arkansas NNP p
) ) p
, , p
those DT p
assessed VBN p
to TO p
receive VB p
such JJ p
services NNS p
( ( p
in IN p
New NNP p
Jersey NNP p
) ) p
, , p
and CC p
recipients NNS p
of IN p
Medicaid NNP p
HCBS NNP p
( ( p
in IN p
Florida NNP p
) ) p
. . p

Enrollment NN p
occurred VBD p
from IN p
December NNP p
1998 CD p
through IN p
April NNP p
2001 CD p
. . p

The DT p
follow-up JJ p
period NN p
covered VBD p
up RB p
to TO p
24 CD p
months NNS p
after IN p
enrollment NN p
. . p

STUDY NNP N
DESIGN NNP N
Demonstration NNP p
volunteers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
the DT N
option NN N
to TO N
participate VB N
in IN N
Cash NNP i
and CC i
Counseling NNP i
( ( p
the DT p
treatment NN p
group NN p
) ) p
, , p
or CC p
to TO p
receive VB p
Medicaid NNP i
services NNS i
as RB i
usual JJ i
from IN i
an DT i
agency NN i
( ( N
the DT N
control NN N
group NN N
) ) N
. . N

Ordinary JJ N
least JJS N
squares NNS N
regressions NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
effect NN N
of IN N
the DT N
program NN N
on IN N
costs NNS o
for IN o
Medicaid NNP o
PCS/waiver NNP o
services NNS o
and CC N
other JJ N
Medicaid NNP o
services NNS o
, , N
while IN N
controlling VBG N
for IN N
consumers NNS N
' POS N
preenrollment NN N
characteristics NNS N
and CC N
preenrollment NN N
Medicaid NNP N
spending NN N
. . N

Models NNS p
were VBD p
estimated VBN p
separately RB p
for IN p
nonelderly RB p
and CC p
elderly JJ p
adults NNS p
in IN p
each DT p
state NN p
and CC p
for IN p
children NNS p
in IN p
Florida NNP p
. . p

DATA NNP N
EXTRACTION NNP N
METHODS NNP N
Each DT N
state NN N
supplied VBD N
claims NNS N
data NNS N
for IN N
demonstration NN N
enrollees NNS N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Largely NNP N
because IN N
the DT N
program NN N
increased VBD N
consumers NNS N
' POS N
ability NN N
to TO N
get VB N
the DT N
authorized JJ N
amount NN N
of IN N
paid VBN N
care NN N
, , N
expenditures VBZ o
for IN o
personal JJ o
care/waiver NN o
services NNS o
were VBD N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
in IN N
each DT N
state NN N
and CC N
age NN N
group NN N
, , N
except IN N
among IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
. . N

Higher JJR N
costs NNS o
for IN o
personal JJ o
care/waiver NN o
services NNS o
were VBD N
partially RB N
offset VBN N
by IN N
savings NNS N
in IN N
other JJ N
Medicaid NNP N
services NNS N
, , N
particularly RB N
those DT N
related VBN N
to TO N
long-term JJ N
care NN N
. . N

During IN N
year NN N
1 CD N
, , N
total JJ o
Medicaid NNP o
costs NNS o
were VBD N
generally RB N
higher JJR N
for IN N
the DT N
treatment NN N
group NN N
than IN N
for IN N
the DT N
control NN N
group NN N
, , N
with IN N
treatment-control JJ N
cost NN N
differences NNS N
ranging VBG N
from IN N
1 CD N
percent NN N
( ( N
and CC N
statistically RB N
insignificant JJ N
) ) N
for IN N
the DT N
elderly JJ N
in IN N
Florida NNP N
to TO N
17 CD N
percent NN N
for IN N
the DT N
elderly JJ N
in IN N
Arkansas NNP N
. . N

In IN N
year NN N
2 CD N
, , N
these DT N
cost NN o
differences NNS o
were VBD N
generally RB N
greater JJR N
than IN N
in IN N
year NN N
1 CD N
. . N

Only RB N
in IN N
Arkansas NNP N
did VBD N
the DT N
treatment-control NN N
difference NN N
in IN N
total JJ N
cost NN o
shrink NN o
over IN o
time-to JJ o
less JJR N
than IN N
5 CD N
percent NN N
( ( N
and CC N
statistically RB N
insignificant JJ N
) ) N
in IN N
year NN N
2 CD N
. . N

CONCLUSIONS NNP N
Medicaid NNP o
costs NNS o
were VBD N
generally RB N
higher JJR N
under IN N
Cash NNP i
and CC i
Counseling NNP i
because IN N
those DT N
in IN N
the DT N
traditional JJ N
system NN N
did VBD N
not RB N
get VB N
the DT N
services NNS N
they PRP N
were VBD N
entitled VBN N
to TO N
. . N

Compared VBN N
with IN N
the DT N
treatment NN N
group NN N
, , N
( ( N
1 CD N
) ) N
control NN N
group NN N
members NNS N
were VBD N
less RBR N
likely JJ N
to TO N
receive VB o
any DT o
services NNS o
at IN N
all DT N
( ( N
despite IN N
being VBG N
authorized VBN N
for IN N
them PRP N
) ) N
, , N
and CC N
( ( N
2 CD N
) ) N
service NN N
recipients NNS N
received VBD N
a DT N
lower JJR o
proportion NN o
of IN o
the DT o
amount NN o
of IN o
care NN o
that WDT N
was VBD N
authorized VBN N
. . N

In IN N
addition NN N
, , N
a DT N
flaw NN N
in IN N
Florida NNP N
's POS N
reassessment NN N
procedures NNS N
led VBD N
to TO N
treatment NN N
group NN N
members NNS N
receiving VBG N
more RBR N
generous JJ N
benefit NN N
amounts NNS N
than IN N
control NN N
group NN N
members NNS N
. . N

To TO N
keep VB N
total JJ N
Medicaid NNP N
costs NNS N
per IN N
recipient NN N
at IN N
the DT N
level NN N
incurred VBN N
under IN N
the DT N
traditional JJ N
system NN N
, , N
consumer-directed JJ N
programs NNS N
need VBP N
to TO N
be VB N
carefully RB N
designed VBN N
and CC N
closely RB N
monitored VBN N
. . N

-DOCSTART- -23365106- O O

Supplementation NN N
with IN N
n3 JJ i
fatty JJ i
acid NN i
ethyl NN i
esters NNS i
increases VBZ N
large JJ N
and CC N
small JJ N
artery NN N
elasticity NN o
in IN N
obese JJ p
adults NNS p
on IN p
a DT p
weight JJ p
loss NN p
diet NN p
. . p

Increased VBN N
arterial JJ N
stiffness NN N
is VBZ N
associated VBN N
with IN N
enhanced JJ N
risk NN N
of IN N
cardiovascular JJ p
disease NN p
in IN p
obese JJ p
individuals NNS p
. . p

Whether NNP N
n3 JJ i
fatty RB i
acid JJ i
ethyl NN i
ester NN i
( ( i
FAEE NNP i
) ) i
supplementation NN i
improves VBZ N
arterial JJ N
stiffness NN N
in IN N
obese JJ p
participants NNS p
on IN p
a DT p
weight JJ p
loss NN p
diet NN p
has VBZ N
not RB N
yet RB N
been VBN N
investigated VBN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
carry VB N
out RP N
a DT N
12-wk JJ N
randomized NN N
, , N
single-blind JJ N
trial NN N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
25 CD p
% NN p
energy NN i
deficit NN i
weight VBD i
loss NN i
diet NN i
alone RB i
( ( i
WL NNP i
) ) i
( ( p
n JJ p
= NNP p
12 CD p
) ) p
or CC N
WL NNP i
plus CC i
4 CD i
g/d NN i
Omacor NNP i
( ( i
46 CD i
% NN i
EPA NNP i
and CC i
38 CD i
% NN i
DHA NNP i
) ) i
supplementation NN i
( ( i
WL+FAEE NNP i
) ) i
( ( p
n JJ p
= NNP p
13 CD p
) ) p
on IN N
arterial JJ N
elasticity NN N
in IN N
obese JJ p
adults NNS p
. . p

Large NNP o
( ( o
C1 NNP o
) ) o
and CC o
small JJ o
artery NN o
elasticity NN o
( ( o
C2 NNP o
) ) o
were VBD N
measured VBN N
by IN N
pulse JJ N
contour NN N
analysis NN N
of IN N
the DT N
radial JJ N
artery NN N
. . N

WL NNP N
alone RB N
reduced VBD o
( ( N
P NNP N
< VBZ N
0.05 CD N
in IN N
all DT N
) ) N
body NN o
weight NN o
( ( N
-3 CD N
% NN N
) ) N
, , N
waist JJ o
circumference NN o
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ o
( ( N
-3 CD N
% NN N
) ) N
and CC N
diastolic JJ o
( ( N
-3 CD N
% NN N
) ) N
blood NN o
pressures NNS o
, , o
cardiac JJ o
output NN o
( ( o
-4 CD o
% NN o
) ) o
, , o
plasma JJ o
TG NNP o
concentration NN o
( ( N
-25 CD N
% NN N
) ) N
, , N
and CC N
the DT N
homeostasis NN o
model NN o
assessment NN o
( ( o
HOMA NNP o
) ) o
score NN o
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased VBD o
plasma NN o
HDL NNP o
cholesterol NN o
( ( N
+9 CD N
% NN N
) ) N
and CC N
adiponectin NN o
( ( N
+18 CD N
% NN N
) ) N
concentrations NNS o
. . o

However RB N
, , N
WL NNP i
alone RB N
did VBD N
not RB N
alter VB N
C1 NNP N
and CC N
C2 NNP N
. . N

The DT N
WL+FAEE NNP i
intervention NN i
significantly RB o
reduced VBN o
body NN o
weight NN o
( ( N
-4 CD N
% NN N
) ) N
, , N
waist JJ o
circumference NN o
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ o
( ( N
-8 CD N
% NN N
) ) N
and CC N
diastolic JJ o
( ( N
-5 CD N
% NN N
) ) N
blood NN o
pressures NNS o
, , o
pulse JJ o
pressure NN o
( ( N
-5 CD N
% NN N
) ) N
, , N
heart NN o
rate NN o
( ( N
-8 CD N
% NN N
) ) N
, , N
plasma JJ o
TG NNP o
concentration NN o
( ( N
-36 CD N
% NN N
) ) N
, , N
and CC N
HOMA NNP o
score NN o
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased JJ o
stroke NN o
volume NN o
( ( N
+3 CD N
% NN N
) ) N
, , N
plasma JJ o
HDL NNP o
cholesterol NN o
( ( N
+6 CD N
% NN N
) ) N
and CC N
adiponectin JJ o
concentrations NNS o
( ( N
+28 CD N
% NN N
) ) N
, , N
and CC N
C1 NNP o
( ( N
+20 NNP N
% NN N
) ) N
and CC N
C2 NNP o
( ( N
+22 NNP N
% NN N
) ) N
artery NN o
elasticity NN o
. . o

The DT N
changes NNS N
in IN N
systolic JJ o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
plasma NN o
TGs NNP o
, , o
C1 NNP o
, , o
and CC o
C2 NNP o
were VBD N
significantly RB o
greater JJR o
in IN N
the DT N
WL+FAEE NNP i
group NN N
than IN N
in IN N
the DT N
WL NNP i
group NN N
. . N

Supplementation NN N
with IN N
n3 JJ i
FAEEs NNP i
improves VBZ N
C1 NNP o
and CC o
C2 NNP o
independently RB N
of IN N
weight JJ o
loss NN o
in IN N
obese JJ p
adults NNS p
. . p

-DOCSTART- -22608375- O O

Healthcare NN N
costs NNS N
around IN N
the DT N
time NN N
of IN N
smoking VBG N
cessation NN N
. . N

BACKGROUND IN N
The DT N
Affordable NNP N
Care NNP N
Act NNP N
mandates VBZ N
that IN N
new JJ N
insurance NN N
plans NNS N
cover VBP N
smoking-cessation NN i
therapy NN i
without IN N
cost-sharing NN N
. . N

Previous JJ N
cost NN N
difference NN N
estimates NNS N
, , N
which WDT N
show VBP N
a DT N
spike NN N
around IN N
the DT N
time NN N
of IN N
cessation NN N
, , N
suggest VBP N
premiums NNS N
might MD N
rise VB N
as IN N
a DT N
result NN N
of IN N
covering VBG N
these DT N
services NNS N
. . N

PURPOSE VB N
The DT N
goal NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
test VB N
( ( N
1 CD N
) ) N
whether IN N
individuals NNS p
in IN p
an DT p
RCT NNP p
of IN p
pharmacotherapy NN i
and CC p
counseling VBG i
for IN p
smoking VBG p
cessation NN p
differed VBN N
in IN N
their PRP$ N
healthcare NN N
costs VBZ N
around IN N
the DT N
cessation NN N
period NN N
, , N
and CC N
( ( N
2 CD N
) ) N
whether IN N
the DT N
healthcare NN N
costs NNS N
of IN N
those DT N
in IN N
the DT N
trial NN N
who WP N
successfully RB N
quit VBP N
were VBD N
different JJ N
from IN N
a DT N
matched JJ N
sample NN N
of IN N
smokers NNS N
in IN N
the DT N
community NN N
. . N

METHODS NNP N
Generalized NNP i
linear JJ i
regression NN i
models NNS i
were VBD i
used VBN i
to TO i
analyze VB i
healthcare NN o
cost NN o
data NNS o
on IN i
individuals NNS i
enrolled VBN i
in IN i
a DT i
comparative JJ i
effectiveness NN i
trial NN i
of IN i
cessation NN i
therapies NNS i
between IN p
October NNP p
2005 CD p
and CC p
May NNP p
2007 CD p
( ( p
1346 CD p
total NN p
participants NNS p
; : p
1338 CD p
with IN p
requisite JJ p
data NNS p
for IN p
further JJ p
analysis NN p
) ) p
. . p

Cost NN o
differences NNS o
for IN N
the DT N
period NN N
preceding NN N
and CC N
subsequent JJ N
to TO N
the DT N
cessation NN N
attempt NN N
were VBD N
assessed VBN N
by IN N
trial NN N
participants NNS N
' POS N
12-month JJ N
sustained VBD N
quit NN N
status NN N
. . N

Healthcare NNP o
cost NN o
differences NNS o
between IN N
sustained VBN N
quitters NNS N
and CC N
a DT N
sample NN N
of IN N
community-dwelling JJ N
smokers NNS N
, , N
matched VBD N
to TO N
these DT N
quitters NNS N
on IN N
the DT N
basis NN N
of IN N
health NN N
services NNS N
use VBP N
around IN N
the DT N
time NN N
trial NN N
participant NN N
enrolled VBN N
and CC N
by IN N
demographics NNS N
, , N
were VBD N
also RB N
examined VBN N
. . N

Data NNS N
were VBD N
analyzed VBN N
in IN N
2011 CD N
. . N

RESULTS VB N
All DT N
three CD N
groups NNS N
had VBD N
a DT N
spike NN N
in IN N
cost NN N
associated VBN N
with IN N
the DT N
index NN N
clinic JJ N
visit NN N
. . N

Regression NNP N
results NNS N
revealed VBD N
little JJ N
difference NN N
in IN N
healthcare NN o
costs NNS o
by IN N
quit NN N
status NN N
for IN N
trial NN N
participants NNS N
until IN N
the DT N
sixth JJ N
quarter NN N
post-quit NN N
. . N

By IN N
that DT N
quarter NN N
, , N
continuous JJ N
sustained VBD N
quitters NNS N
cost VBD o
$ $ N
541 CD N
( ( N
p NN N
< RB N
0.001 CD N
) ) N
less JJR N
than IN N
continuing VBG N
smokers NNS N
. . N

Continuous JJ N
sustained VBD N
quitters NNS N
cost NN o
less JJR N
than IN N
their PRP$ N
matched JJ N
community- JJ N
dwelling VBG N
smokers NNS N
in IN N
almost RB N
every DT N
quarter NN N
observed VBN N
. . N

The DT N
cost NN N
difference NN N
ranged VBD N
from IN N
$ $ N
270 CD N
( ( N
p=0.01 NN N
) ) N
during IN N
the DT N
quarter NN N
of IN N
quit NN N
, , N
to TO N
$ $ N
490 CD N
( ( N
p NN N
< RB N
0.01 CD N
) ) N
in IN N
the DT N
6th CD N
quarter NN N
after IN N
quitting VBG N
. . N

CONCLUSIONS VB N
The DT N
inclusion NN N
of IN N
smoking-cessation JJ i
therapy NN i
does VBZ N
not RB N
appear VB N
to TO N
raise VB N
short-term JJ o
healthcare NN o
costs NNS o
. . o

By IN N
the DT N
sixth JJ N
quarter NN N
post-quit NN N
, , N
sustained VBN N
quitters NNS N
were VBD N
less RBR N
costly JJ N
than IN N
trial NN N
participants NNS N
who WP N
continued VBD N
smoking NN N
. . N

-DOCSTART- -22989921- O O

Duration NN N
of IN N
untreated JJ N
negative JJ N
and CC N
positive JJ N
symptoms NNS N
of IN N
psychosis NN p
and CC N
cognitive JJ N
impairment NN N
in IN N
first JJ p
episode NN p
psychosis NN p
. . p

BACKGROUND NNP N
Duration NNP N
of IN N
untreated JJ p
psychosis NN p
( ( p
DUP NNP p
) ) p
has VBZ N
been VBN N
significantly RB N
associated VBN N
with IN N
poor JJ o
clinical JJ o
and CC o
social JJ o
outcomes NNS o
in IN N
First NNP p
Episode NNP p
Psychosis NNP p
( ( p
FEP NNP p
) ) p
patients NNS p
, , N
but CC N
an DT N
association NN N
with IN N
cognitive JJ N
outcomes NNS N
has VBZ N
not RB N
been VBN N
clearly RB N
established VBN N
. . N

METHOD NNP N
Seventy-seven NNP p
consecutively RB p
admitted VBD p
, , p
drug-na?ve JJ p
patients NNS p
with IN p
FEP NNP p
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
at IN N
1month CD N
and CC N
6months CD N
. . N

Underlying VBG N
dimensions NNS N
of IN N
DUP NNP N
( ( N
general JJ N
prodrome NN N
and CC N
positive JJ N
, , N
negative JJ N
and CC N
disorganisation NN N
symptoms NNS N
) ) N
were VBD N
assessed VBN N
using VBG N
the DT o
Symptom NNP o
Onset NNP o
in IN o
Schizophrenia NNP o
( ( o
SOS NNP o
) ) o
inventory NN o
( ( N
Perkins NNP N
et FW N
al. NN N
, , N
2000 CD N
) ) N
. . N

To TO N
assess VB N
the DT N
effect NN N
of IN N
DUP NNP N
on IN N
the DT o
neuropsychological JJ o
status NN o
of IN N
the DT N
patients NNS N
, , N
a DT N
linear JJ N
mixed-effect JJ N
model NN N
was VBD N
fitted VBN N
to TO N
each DT N
neuropsychological JJ N
dimension NN N
. . N

These DT N
models NNS N
included VBD N
a DT N
dichotomised JJ N
version NN N
of IN N
DUP NNP N
( ( N
short JJ N
versus NN N
long JJ N
duration NN N
) ) N
as IN N
a DT N
fixed JJ N
effect NN N
, , N
several JJ N
adjusting VBG N
variables NNS N
to TO N
account VB N
for IN N
patient NN N
differences NNS N
, , N
and CC N
a DT N
random JJ N
effect NN N
to TO N
incorporate VB N
the DT N
longitudinal JJ N
structure NN N
of IN N
the DT N
data NNS N
. . N

RESULTS JJ N
Patients NNPS N
with IN N
a DT N
short JJ N
duration NN N
of IN p
untreated JJ p
negative JJ p
symptoms NNS p
( ( p
DUNS NNP p
) ) p
or CC p
a DT p
short JJ p
duration NN p
of IN p
untreated JJ p
positive JJ p
symptoms NNS p
( ( p
DUPS NNP o
) ) o
outperformed VBD N
patients NNS N
with IN N
a DT N
long JJ N
duration NN N
of IN N
untreated JJ N
symptoms NNS N
on IN o
memory NN o
tasks NNS o
and CC o
a DT o
pre-attentional JJ o
visual JJ o
task NN o
but CC N
not RB N
on IN o
measures NNS o
of IN o
verbal JJ o
fluency NN o
, , o
attention NN o
, , o
reaction NN o
time NN o
, , o
visual JJ o
processing NN o
and CC o
executive NN o
functions NNS o
. . o

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
additional JJ N
support NN N
for IN N
an DT N
early JJ N
intervention NN N
to TO N
shorten VB N
DUP NNP N
to TO N
facilitate VB N
a DT N
better JJR o
outcome NN o
in IN o
memory NN o
and CC o
attentional JJ o
domains NNS o
of IN p
FEP NNP p
patients NNS p
. . p

-DOCSTART- -12108616- O O

Efficacy NN o
of IN N
porcine NN i
secretin NN i
in IN N
children NNS p
with IN p
autism NN p
and CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

Secretin NNP i
, , N
a DT N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
hormone NN N
, , N
was VBD N
reported VBN N
in IN N
a DT N
preliminary JJ N
study NN N
to TO N
improve VB N
language NN o
and CC o
behavior NN o
in IN N
children NNS p
with IN p
autism/pervasive JJ p
developmental JJ p
disorder NN p
( ( p
PDD NNP p
) ) p
and CC p
chronic JJ p
diarrhea NN p
. . p

To TO N
determine VB N
the DT N
efficacy NN N
of IN N
secretin NN i
, , N
we PRP N
completed VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
( ( N
3 CD N
weeks NNS N
) ) N
study NN N
in IN N
children NNS p
with IN p
autism/PDD NN p
and CC p
various JJ p
GI NNP p
conditions NNS p
using VBG N
a DT N
single JJ N
dose NN N
of IN N
intravenous JJ i
porcine NN i
secretin NN i
. . i

Children NNP p
with IN p
chronic NN p
, , p
active JJ p
diarrhea NN p
showed VBD N
a DT N
reduction NN N
in IN N
aberrant JJ o
behaviors NNS o
when WRB N
treated VBN N
with IN N
the DT N
secretin NN i
but CC N
not RB N
when WRB N
treated VBN N
with IN N
the DT N
placebo NN i
. . i

Children NNP p
with IN p
no DT p
GI NNP p
problems NNS p
are VBP N
unaffected VBN N
by IN N
either DT N
secretin NN i
or CC i
placebo NN i
. . i

The DT N
improvement NN N
seen VBN N
with IN N
secretin NN i
in IN N
children NNS p
with IN p
autism/PDD NN p
and CC p
chronic JJ p
diarrhea NN p
suggests VBZ N
that IN N
there EX N
may MD N
be VB N
a DT N
subtype NN N
of IN N
children NNS N
with IN N
autism/PDD NN N
who WP N
respond VBZ N
to TO N
secretin VB i
. . i

-DOCSTART- -1622739- O O

Clinical JJ N
trials NNS N
of IN N
intrasplenic JJ N
arterial JJ N
infusion NN N
of IN N
interleukin-2 NN i
( ( i
IS-IL-2 NNP i
) ) i
to TO N
patients NNS p
with IN p
advanced JJ p
cancer NN p
. . p

We PRP N
tried VBD N
a DT N
infusion NN N
of IN N
interleukin-2 NN N
( ( N
IL-2 NNP N
) ) N
of IN N
a DT N
relatively RB N
low JJ N
dose NN N
via IN N
an DT N
intrasplenic JJ N
arterial JJ N
catheter NN N
connected VBN N
to TO N
a DT N
chronometric JJ N
infusion NN N
( ( N
IS-IL-2 NNP N
) ) N
. . N

Eighteen JJ p
patients NNS p
of IN p
colorectal JJ p
cancer NN p
with IN p
metastases NNS p
to TO p
the DT p
liver NN p
or CC p
lung NN p
or CC p
of IN p
unresectable JJ p
hepatoma NN p
received VBD N
a DT N
24 CD N
hour NN N
continuous JJ i
infusion NN i
with IN i
low JJ i
dose JJ i
recombinant NN i
of IN i
IL-2 NNP i
( ( N
mainly RB N
8 CD N
x JJ N
10 CD N
( ( N
5 CD N
) ) N
JRU/day NN N
) ) N
for IN N
25-40 JJ N
days NNS N
. . N

All DT N
patients NNS N
tolerated VBD o
this DT N
protocol NN N
of IN N
the DT N
therapy NN N
and CC N
the DT N
main JJ o
toxic NN o
effects NNS o
were VBD o
fever RB o
and CC o
general JJ o
fatigue NN o
. . o

Such JJ N
serious JJ N
toxicity NN o
as IN N
previously RB N
reported VBN N
by IN N
high JJ N
dose JJ N
IL-2 NNP N
therapy NN N
was VBD N
not RB N
observed VBN N
. . N

Data NNP N
of IN N
hepatic JJ o
and CC o
renal JJ o
functions NNS o
were VBD N
normal JJ N
. . N

IS-IL-2 JJ N
therapy NN N
induced VBD N
a DT N
high JJ N
incidence NN N
of IN N
eosinophilia NN o
( ( o
12/18 CD o
) ) o
and CC o
thrombocythemia NN o
( ( N
12/18 CD N
) ) N
. . N

Peripheral JJ o
natural JJ o
killer NN o
( ( o
NK NNP o
) ) o
and CC o
LAK NNP o
activities NNS o
were VBD N
augmented VBN N
in IN N
all DT N
patients NNS N
and CC N
total JJ o
white JJ o
blood NN o
cell NN o
counts NNS o
were VBD N
increased VBN N
during IN N
IS-IL-2 NNP N
therapy NN N
. . N

An DT N
increase NN N
in IN N
IL-2 NNP o
receptor NN o
expression NN o
of IN o
peripheral JJ o
blood NN o
mononuclear NN o
cells NNS o
and CC o
significant JJ o
rises NNS o
in IN o
numbers NNS o
of IN o
Leu11 NNP o
( ( o
CD16 NNP o
) ) o
+ NN o
, , o
OKM1 NNP o
( ( o
CD11 NNP o
) ) o
+ NN o
and CC o
OKIa1 NNP o
( ( o
HLA-DR NNP o
) ) o
+ NN o
were VBD N
observed VBN N
. . N

Of IN p
18 CD p
patients NNS p
12 CD p
were VBD p
evaluable JJ p
for IN p
their PRP$ p
response NN p
to TO p
therapy NN p
. . p

Partial JJ N
response NN N
( ( N
PR NNP N
) ) N
was VBD N
observed VBN N
in IN N
one CD N
unresectable JJ o
hepatoma NN o
and CC N
11 CD N
demonstrated VBD N
no DT o
change NN o
( ( o
NC NNP o
) ) o
or CC o
progressive JJ o
disease NN o
( ( o
PD NNP o
) ) o
. . o

Six CD N
patients NNS N
were VBD N
not RB N
evaluable JJ N
because IN N
of IN N
additional JJ N
therapy NN N
( ( N
3 CD N
cases NNS N
) ) N
or CC N
decreasing VBG N
tumor NN N
cell NN N
markers NNS N
having VBG N
no DT N
measurable JJ N
lesions NNS N
( ( N
3 CD N
cases NNS N
) ) N
. . N

Three CD N
patients NNS N
of IN N
colorectal JJ N
cancer NN N
from IN N
an DT N
unresectable JJ N
group NN N
were VBD N
presumed VBN N
to TO N
have VB N
micrometastases NNS N
to TO N
the DT N
liver NN N
as IN N
suggested VBN N
by IN N
an DT N
elevated JJ N
serum NN N
CEA NNP N
level NN N
. . N

After IN N
receiving VBG N
IS-IL-2 JJ N
therapy NN N
they PRP N
demonstrated VBD N
a DT N
decrease NN N
in IN N
the DT N
serum NN N
CEA NNP N
level NN N
for IN N
more JJR N
than IN N
3 CD N
years NNS N
after IN N
treatment NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -10632537- O O

Focal NNP o
therapeutic JJ o
efficacy NN o
of IN N
transcatheter NN N
arterial JJ N
infusion NN N
of IN N
styrene NN i
maleic NN i
acid NN i
neocarzinostatin NN N
for IN N
hepatocellular JJ N
carcinoma NN N
. . N

We PRP N
evaluated VBD N
the DT N
focal JJ o
therapeutic JJ o
effect NN o
of IN N
oily RB i
carcinostatic JJ i
agents NNS i
administered VBN N
by IN N
transcatheter NN N
arterial JJ N
infusion NN N
( ( N
TAI NNP N
) ) N
as IN N
the DT N
initial JJ N
therapy NN N
in IN N
patients NNS p
with IN p
hepatocellular JJ p
carcinoma NN p
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

Group NNP p
A NNP p
( ( p
19 CD p
patients NNS p
) ) p
received VBD N
4 CD i
mg NN i
of IN i
styrene NN i
maleic NN i
acid NN i
neocarzinostatin NN i
in IN i
4 CD i
ml NN i
of IN i
Lipiodol NNP i
, , N
and CC N
group NN p
B NNP p
( ( p
18 CD p
patients NNS p
) ) p
received VBD N
100 CD i
mg NN i
of IN i
epirubicin NN i
in IN i
4 CD i
ml NN i
of IN i
Lipiodol NNP i
via IN N
the DT N
tumor NN N
feeding VBG N
arteries NNS N
as RB N
peripherally RB N
as IN N
possible JJ N
. . N

The DT N
grade NN N
of IN N
Lipiodol NNP N
accumulation NN N
and CC N
the DT N
tumor NN N
regression NN N
rate NN N
were VBD N
determined VBN N
2 CD N
weeks NNS N
after IN N
TAI NNP N
by IN N
computerized JJ N
tomography NN N
. . N

Adverse JJ N
effects NNS N
within IN N
2 CD N
weeks NNS N
after IN N
TAI NNP N
were VBD N
evaluated VBN N
by IN N
subjective JJ N
signs NNS N
and CC N
symptoms NNS N
such JJ N
as IN N
fever NN o
( ( o
maximum JJ o
body NN o
temperature NN o
) ) o
and CC N
the DT N
frequency NN o
of IN o
shaking VBG o
chills NNS o
and CC o
abdominal JJ o
pain NN o
, , o
and CC o
by IN o
biochemical JJ o
parameters NNS o
such JJ o
as IN o
albumin NN o
, , o
prothrombin JJ o
time NN o
, , o
and CC o
aspartate NN o
and CC o
alanine NN o
aminotransferases NNS o
. . o

Lipiodol NNP o
accumulation NN o
in IN o
the DT o
tumor NN o
was VBD N
significantly RB N
greater JJR N
in IN N
group NN N
A NNP N
( ( N
12/19 CD N
; : N
63.2 CD N
% NN N
showing VBG N
grade JJ N
IV NNP N
Lipiodol NNP N
accumulation NN N
) ) N
than IN N
in IN N
group NN N
B NNP N
( ( N
3/18 CD N
; : N
16.7 CD N
% NN N
showing VBG N
grade JJ N
IV NNP N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
tumor NN o
regression NN o
rate NN o
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
group NN N
A NNP N
( ( N
8/17 CD N
; : N
47.1 CD N
% NN N
showing VBG N
more JJR N
than IN N
25 CD N
% NN N
tumor NN N
regression NN N
) ) N
than IN N
in IN N
group NN N
B NNP N
( ( N
1/13 CD N
; : N
7.7 CD N
% NN N
showing VBG N
more JJR N
than IN N
25 CD N
% NN N
tumor NN N
regression NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Although IN N
clinically RB N
significant JJ N
elevations NNS o
of IN o
aminotransferases NNS o
and CC N
reductions NNS o
of IN o
cholinesterase NN o
, , N
and CC N
shaking VBG o
chills NNS o
were VBD N
observed VBN N
more RBR N
often RB N
in IN N
group NN N
A NNP N
than IN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
these DT N
factors NNS N
had VBD N
little JJ N
influence NN N
on IN N
the DT N
clinical JJ N
outcome NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
styrene NN i
maleic NN i
acid NN i
neocarzinostatin NN i
in IN N
Lipiodol NNP N
exerts VBZ N
a DT N
more RBR o
favorable JJ o
focal JJ o
therapeutic JJ o
effect NN o
than IN N
does VBZ N
epirubicin VB i
in IN N
Lipiodol NNP i
in IN N
the DT N
initial JJ N
treatment NN N
of IN N
hepatocellular JJ N
carcinoma NN N
. . N

-DOCSTART- -18726150- O O

Faux NNP i
pas CC i
detection NN i
and CC N
intentional JJ N
action NN N
in IN N
Asperger NNP p
Syndrome NNP p
. . p

A DT N
replication NN N
on IN N
a DT N
French JJ N
sample NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
investigated VBD N
mind NN N
reading NN N
abilities NNS N
in IN N
a DT N
group NN p
of IN p
adults NNS p
with IN p
Asperger NNP p
Syndrome NNP p
( ( p
AS IN p
) ) p
by IN N
using VBG N
the DT N
faux JJ i
pas NN i
task NN i
, , i
an DT i
advanced JJ i
test NN i
of IN i
theory NN i
of IN i
mind NN i
( ( N
Baron-Cohen NNP N
et RB N
al RB N
. . N

( ( N
1999 CD N
) ) N
. . N

Journal NNP N
of IN N
Autism NNP N
and CC N
Developmental NNP N
Disorders NNP N
, , N
29 CD N
, , N
407-418 JJ N
) ) N
. . N

The DT N
faux JJ i
pas NN i
is VBZ N
a DT N
particular JJ N
case NN N
of IN N
a DT N
non-intentional JJ N
action NN N
reflecting VBG N
an DT N
involuntary JJ N
socially RB N
inappropriate JJ N
behavior NN N
. . N

Here RB N
, , N
individuals NNS p
with IN p
AS NNP p
over-detected JJ p
faux NN o
pas NN o
stories NNS o
, , N
failed VBD N
to TO N
provide VB o
correct JJ o
justifications NNS o
of IN o
the DT o
speaker NN o
's POS o
behavior NN o
and CC N
were VBD N
unaware NN N
of IN N
the DT N
mistaken JJ o
belief NN o
and CC o
of IN o
the DT o
resulting JJ o
emotional JJ o
impact NN o
, , N
whereas IN N
they PRP N
appeared VBD N
to TO N
be VB N
responsive JJ N
to TO N
social JJ N
rule NN N
violations NNS N
. . N

We PRP N
hypothesized VBD N
that IN N
because IN N
of IN N
an DT N
impaired JJ N
theory-of-mind NN N
, , N
individuals NNS p
with IN p
AS NNP p
may MD N
develop VB N
compensatory JJ N
cognitive JJ N
strategies NNS N
based VBN N
on IN N
overlearned JJ N
abstract JJ N
knowledge NN N
about IN N
normative JJ N
rules NNS N
. . N

-DOCSTART- -26217065- O O

REVIVE JJ N
Trial NN N
: : N
Retrograde JJ N
Delivery NNP N
of IN N
Autologous NNP N
Bone NNP N
Marrow NNP N
in IN N
Patients NNP p
With IN p
Heart NNP p
Failure NNP p
. . p

UNLABELLED NNP N
Cell NNP i
therapy NN i
is VBZ N
an DT N
evolving VBG N
option NN N
for IN N
patients NNS p
with IN p
end-stage JJ p
heart NN p
failure NN p
and CC p
ongoing NN p
symptoms NNS p
despite IN p
optimal JJ p
medical JJ p
therapy NN p
. . p

Our PRP$ N
goal NN N
was VBD N
to TO N
evaluate VB N
retrograde VB N
bone NN N
marrow NN N
cell NN N
delivery NN N
in IN N
patients NNS p
with IN p
either DT p
ischemic JJ p
heart NN p
failure NN p
( ( p
IHF NNP p
) ) p
or CC p
nonischemic JJ p
heart NN p
failure NN p
( ( p
NIHF NNP p
) ) p
. . p

This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
, , N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
the DT N
safety NN N
and CC N
feasibility NN N
of IN N
bone NN i
marrow NN i
aspirate NN i
concentrate NN i
( ( N
BMAC NNP N
) ) N
infused VBD N
retrograde NN i
into IN N
the DT N
coronary JJ N
sinus NN N
. . N

Sixty JJ p
patients NNS p
were VBD p
stratified VBN p
by IN p
IHF NNP p
and CC p
NIHF NNP p
and CC N
randomized VBN N
to TO N
receive VB N
either DT N
BMAC NNP i
infusion NN i
or CC N
control NN i
( ( N
standard JJ N
heart NN N
failure NN N
care NN N
) ) N
in IN N
a DT N
4:1 CD N
ratio NN N
. . N

Accordingly RB N
, , N
24 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
ischemic JJ N
BMAC NNP N
group NN N
and CC N
6 CD N
to TO N
the DT N
ischemic JJ N
control NN N
group NN N
. . N

Similarly RB N
, , N
24 CD N
subjects NNS N
were VBD N
randomized VBN N
to TO N
the DT N
nonischemic JJ N
BMAC NNP N
group NN N
and CC N
6 CD N
to TO N
the DT N
nonischemic JJ N
control NN N
group NN N
. . N

All DT p
60 CD p
patients NNS p
were VBD p
successfully RB p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

The DT N
treatment NN N
groups NNS N
received VBD N
BMAC NNP i
infusion NN i
without IN N
complications NNS N
. . N

The DT N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
in IN N
the DT N
patients NNS N
receiving VBG N
BMAC NNP N
demonstrated VBD N
significant JJ o
improvement NN o
compared VBN N
with IN N
baseline NN N
, , N
from IN N
25.1 CD N
% NN N
at IN N
screening VBG N
to TO N
31.1 CD N
% NN N
at IN N
12 CD N
months NNS N
( ( N
p=.007 NN N
) ) N
in IN N
the DT N
NIHF NNP N
group NN N
and CC N
from IN N
26.3 CD N
% NN N
to TO N
31.1 CD N
% NN N
in IN N
the DT N
IHF NNP N
group NN N
( ( N
p=.035 NN N
) ) N
. . N

The DT N
end-systolic JJ o
diameter NN o
decreased VBN o
significantly RB o
in IN N
the DT N
nonischemic JJ N
BMAC NNP i
group NN N
from IN N
55.6 CD N
to TO N
50.9 CD N
mm NN N
( ( N
p=.020 NN N
) ) N
. . N

Retrograde NNP N
BMAC NNP N
delivery NN o
is VBZ o
safe JJ o
. . o

All DT N
patients NNS N
receiving VBG N
BMAC NNP N
experienced VBD o
improvements NNS o
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
, , N
but CC N
only RB N
those DT N
with IN N
NIHF NNP N
showed VBD N
improvements NNS o
in IN N
left JJ o
ventricular JJ o
end-systolic JJ o
diameter NN o
and CC o
B-type NNP o
natriuretic JJ o
peptide NN o
. . o

These DT N
results NNS N
provide VBP N
the DT N
basis NN N
for IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
in IN N
HF NNP N
patients NNS N
. . N

SIGNIFICANCE VB N
This DT N
work NN N
is VBZ N
the DT N
first JJ N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
using VBG N
high-dose JJ N
cell NN N
therapy NN N
delivered VBN N
via IN N
a DT N
retrograde JJ N
coronary JJ N
sinus NN N
infusion NN N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

This DT N
was VBD N
a DT N
multinational JJ N
, , N
multicenter NN N
study NN N
, , N
and CC N
it PRP N
is VBZ N
novel JJ N
, , N
translatable JJ N
, , N
and CC N
scalable JJ N
. . N

On IN N
the DT N
basis NN N
of IN N
this DT N
trial NN N
and CC N
the DT N
safety NN N
of IN N
retrograde JJ N
coronary JJ N
sinus NN N
infusion NN N
, , N
there EX N
are VBP N
three CD N
other JJ N
trials NNS N
under IN N
way NN N
using VBG N
this DT N
route NN N
of IN N
delivery NN N
. . N

-DOCSTART- -20491838- O O

Influence NN o
of IN N
bony NN p
defects NNS p
on IN N
implant JJ N
stability NN N
. . N

INTRODUCTION NNP N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyze VB N
the DT N
evolution NN N
of IN N
implant JJ N
mechanical JJ N
stability NN N
in IN N
different JJ N
types/sizes NNS N
of IN N
bony NN p
defects NNS p
using VBG N
both DT N
Periotest NNP i
and CC N
Osstell NNP i
devices NNS N
as IN N
objective JJ N
tools NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-two NNP p
implants NNS p
were VBD p
randomly RB p
allocated VBN p
to TO N
one CD N
of IN N
the DT N
four CD p
types NNS p
of IN p
bone NN p
defects NNS p
: : p
marginal JJ p
bone NN p
loss NN p
, , p
peri-apical JJ p
bone NN p
defect NN p
, , p
constant JJ p
width NN p
dehiscence NN p
and CC p
constant JJ p
length NN p
dehiscences NNS p
. . p

Periotest/Osstell NNP o
measurements NNS o
were VBD N
completed VBN N
before IN N
and CC N
during IN N
staged VBN N
bone NN N
removal NN N
( ( N
to TO N
enlarge VB N
defect JJ N
size NN N
) ) N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
initial JJ N
values NNS N
were VBD N
found VBN N
after IN N
a DT N
2 CD N
mm NN N
marginal JJ N
bone NN N
removal NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
peri-apical JJ o
bone NN o
lesion NN o
, , N
after IN N
removal NN N
of IN N
5 CD N
mm NN N
( ( i
Osstell NNP i
) ) i
or CC N
8 CD N
mm NN N
( ( i
Periotest NNP i
) ) i
; : i
for IN N
a DT N
6-mm-long JJ N
dehiscence NN N
, , N
after IN N
removal NN N
up RB N
to TO N
180 CD N
degrees NNS N
of IN N
the DT N
implant JJ N
perimeter NN N
( ( N
Osstell/Periotest NNP N
) ) N
; : N
for IN N
a DT N
3-mm-wide JJ N
dehiscence NN N
, , N
after IN N
removal NN N
of IN N
10 CD N
mm NN N
( ( N
Osstell NNP N
) ) N
or CC N
6 CD N
mm NN N
( ( N
Periotest NNP N
) ) N
. . N

CONCLUSION NNP N
Periotest NNP o
and CC N
Osstell NNP o
are VBP N
in IN N
general JJ N
not RB N
very RB N
sensitive JJ N
in IN N
the DT N
identification NN N
of IN N
peri-implant JJ N
bone NN N
destruction NN N
, , N
except IN N
for IN N
marginal JJ N
bone NN N
loss NN N
. . N

-DOCSTART- -21740578- O O

The DT N
IDvIP NNP N
trial NN N
: : N
a DT N
two-centre JJ N
randomised JJ N
double-blind NN N
controlled VBD N
trial NN N
comparing VBG N
intramuscular JJ N
diamorphine NN i
and CC N
intramuscular JJ N
pethidine NN i
for IN N
labour JJ p
analgesia NN p
. . p

BACKGROUND NNP N
Intramuscular NNP N
pethidine NN i
is VBZ N
routinely RB N
used VBN N
throughout IN N
the DT N
UK NNP p
for IN N
labour JJ N
analgesia NN N
. . N

Studies NNS N
have VBP N
suggested VBN N
that IN N
pethidine NN i
provides VBZ N
little JJ N
pain NN N
relief NN N
in IN N
labour NN N
and CC N
has VBZ N
a DT N
number NN N
of IN N
side JJ N
effects NNS N
affecting VBG N
mother NN p
and CC p
neonate NN p
. . p

It PRP N
can MD N
cause VB N
nausea NN N
, , N
vomiting VBG N
and CC N
dysphoria NNS N
in IN N
mothers NNS N
and CC N
can MD N
cause VB N
reduced VBN N
fetal JJ N
heart NN N
rate NN N
variability NN N
and CC N
accelerations NNS N
. . N

Neonatal JJ N
effects NNS N
include VBP N
respiratory JJ N
depression NN N
and CC N
impaired JJ N
feeding NN N
. . N

There EX N
are VBP N
few JJ N
large JJ N
studies NNS N
comparing VBG N
the DT N
relative JJ N
side NN N
effects NNS N
and CC N
efficacy NN N
of IN N
different JJ N
opioids NNS N
in IN N
labour NN N
. . N

A DT N
small JJ N
trial NN N
comparing VBG N
intramuscular JJ N
pethidine NN i
with IN N
diamorphine NN i
, , N
showed VBD N
diamorphine NN i
to TO N
have VB N
some DT N
benefits NNS N
over IN N
pethidine NN i
when WRB N
used VBN N
for IN N
labour JJ N
analgesia NN N
but CC N
the DT N
study NN N
did VBD N
not RB N
investigate VB N
the DT N
adverse JJ N
effects NNS N
of IN N
either DT N
opioid NN N
. . N

METHODS NNP N
The DT N
Intramuscular NNP N
Diamorphine NNP i
versus IN N
Intramuscular NNP N
Pethidine NNP i
( ( N
IDvIP NNP N
) ) N
trial NN N
is VBZ N
a DT N
randomised JJ N
double-blind NN N
two CD N
centre NN N
controlled VBD N
trial NN N
comparing VBG N
intramuscular JJ N
diamorphine NN i
and CC N
pethidine NN i
regarding VBG N
their PRP$ N
analgesic JJ N
efficacy NN N
in IN N
labour NN p
and CC p
their PRP$ p
side NN p
effects NNS p
in IN p
mother NN p
, , p
fetus NN p
and CC p
neonate NN p
. . p

Information NN N
about IN N
the DT N
trial NN N
will MD N
be VB N
provided VBN N
to TO N
women NNS p
in IN p
the DT p
antenatal JJ p
period NN p
or CC p
in IN p
early JJ p
labour NN p
. . p

Consent NN N
and CC N
recruitment NN N
to TO N
the DT N
trial NN N
will MD N
be VB N
obtained VBN N
when WRB N
the DT N
mother NN N
requests VBZ N
opioid JJ N
analgesia NN N
. . N

The DT N
sample NN N
size NN N
requirement NN N
is VBZ N
406 CD p
women NNS p
with IN p
data NNS p
on IN p
primary JJ p
outcomes NNS p
. . p

The DT N
maternal JJ N
primary NN N
outcomes NNS N
are VBP N
pain JJ o
relief NN o
during IN o
the DT o
first JJ o
3 CD o
hours NNS o
after IN o
trial NN o
analgesia NN o
and CC N
specifically RB N
pain VBP o
relief NN o
after IN o
60 CD o
minutes NNS o
. . o

The DT N
neonatal JJ N
primary JJ N
outcomes NNS N
are VBP N
need VBN o
for IN o
resuscitation NN o
and CC o
Apgar NNP o
Score NNP o
< VBD o
7 CD o
at IN o
1 CD o
minute NN o
. . o

The DT N
secondary JJ N
outcomes NNS N
are VBP N
an DT N
additional JJ N
measure NN o
of IN o
pain NN o
relief NN o
, , o
maternal JJ o
sedation NN o
, , o
nausea NN o
and CC o
vomiting NN o
, , o
maternal JJ o
oxygen NN o
saturation NN o
, , o
satisfaction NN o
with IN o
analgesia NN o
, , o
whether IN o
method NN o
of IN o
analgesia NN o
would MD o
be VB o
used VBN o
again RB o
, , o
use NN o
of IN o
Entonox NNP o
, , o
umbilical JJ o
arterial NN o
and CC o
venous JJ o
pH NN o
, , o
fetal JJ o
heart NN o
rate NN o
, , o
meconium NN o
staining NN o
, , o
time NN o
from IN o
delivery NN o
to TO o
first JJ o
breath NN o
, , o
Apgar NNP o
scores VBZ o
at IN o
5 CD o
mins NNS o
, , o
naloxone JJ o
requirement NN o
, , o
transfer NN o
to TO o
neonatal JJ o
intensive JJ o
care NN o
unit NN o
, , o
neonatal JJ o
haemoglobin NN o
oxygen NN o
saturation NN o
at IN o
30 CD o
, , o
60 CD o
, , o
90 CD o
, , o
and CC o
120 CD o
mins NNS o
after IN o
delivery NN o
, , o
and CC o
neonatal JJ o
sedation NN o
and CC o
feeding VBG o
behaviour NN o
during IN o
first JJ o
2 CD o
hours NNS o
. . o

DISCUSSION NNP N
If IN N
the DT N
trial NN N
demonstrates VBZ N
that IN N
diamorphine NN i
provides VBZ N
better RBR N
analgesia NN N
with IN N
fewer JJR N
side NN N
effects NNS N
in IN N
mother NN p
and CC p
neonate NN p
this DT N
could MD N
lead VB N
to TO N
a DT N
change NN N
in IN N
national JJ N
practice NN N
and CC N
result NN N
in IN N
diamorphine NN i
becoming VBG N
the DT N
preferred JJ N
intramuscular JJ N
opioid NN i
for IN N
analgesia NN N
in IN N
labour NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN14898678Eudra NNP N
No NNP N
: : N
2006-003250-18 JJ N
, , N
REC NNP N
Reference NNP N
No NNP N
: : N
06/Q1702/95 CD N
, , N
MHRA NNP N
Authorisation NNP N
No NNP N
: : N
1443/0001/001-0001 JJ N
, , N
NIHR NNP N
UKCRN NNP N
reference NN N
6895 CD N
, , N
RfPB NNP N
grant NN N
PB-PG-0407-13170_IR5 NNP N
. . N

-DOCSTART- -16214437- O O

Effects NNS N
of IN N
glucose-insulin-potassium JJ i
infusion NN i
on IN N
ST-elevation NNP o
myocardial JJ o
infarction NN o
in IN p
patients NNS p
treated VBN p
with IN p
thrombolytic JJ i
therapy NN i
. . i

The DT N
role NN N
of IN N
glucose-insulin-potassium NN i
( ( i
GIK NNP i
) ) i
infusion NN i
in IN N
the DT N
management NN N
of IN N
acute JJ o
myocardial JJ o
infarction NN o
is VBZ N
not RB N
well RB N
established VBN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
comprised VBD N
120 CD p
patients NNS p
who WP p
had VBD p
ST-elevation NNP p
myocardial JJ p
infarction NN p
that WDT p
was VBD p
treated VBN p
within IN p
12 CD p
hours NNS p
from IN p
symptom JJ p
onset VBN p
with IN N
a DT N
high JJ N
dose NN N
of IN N
GIK NNP i
( ( i
25 CD i
% NN i
glucose NN i
, , i
50 CD i
IU NNP i
of IN i
soluble JJ i
insulin NN i
per IN i
liter NN i
, , i
and CC i
80 CD i
mmol NN i
of IN i
potassium NN i
chloride NN i
per IN i
liter NN i
at IN i
1 CD i
ml/kg/hour NN i
over IN i
24 CD i
hours NNS i
) ) i
as IN i
adjunct NN i
to TO i
thrombolytic JJ i
therapy NN i
( ( i
1.5 CD i
MU NNP i
of IN i
streptokinase/30 NN i
to TO i
60 CD i
minutes NNS i
; : i
GIK NNP i
group NN i
) ) i
or CC N
thrombolytic JJ i
therapy NN i
alone RB i
( ( i
control VB i
group NN i
) ) i
. . i

The DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
rate NN o
of IN o
major JJ o
adverse JJ o
cardiac NN o
events NNS o
( ( o
MACEs NNP o
) ) o
at IN o
1 CD o
month NN o
, , N
defined VBD N
as IN N
a DT o
composite NN o
of IN o
cardiac JJ o
death NN o
, , o
reinfarction NN o
, , o
serious JJ o
arrhythmias NN o
( ( o
ventricular JJ o
fibrillation NN o
and/or IN o
tachycardia NN o
) ) o
, , o
and CC o
severe JJ o
heart NN o
failure NN o
. . o

The DT N
secondary JJ N
end NN N
points NNS N
were VBD N
the DT N
rate NN o
of IN o
MACEs NNP o
at IN o
1 CD o
year NN o
and CC o
improvement NN o
in IN o
left JJ o
ventricular JJ o
systolic JJ o
function NN o
. . o

The DT N
incidence NN o
of IN o
MACEs NNP o
at IN o
1 CD o
month NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
GIK NNP i
group NN i
( ( N
10 CD N
% NN N
vs JJ N
32.5 CD N
% NN N
, , N
relative JJ N
risk NN N
0.24 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.09 CD N
to TO N
0.63 CD N
, , N
p NN N
= NNP N
0.0043 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
GIK NNP i
group NN N
had VBD N
significant JJ N
decreases NNS N
in IN N
ventricular JJ o
tachycardia NN o
and/or NN o
fibrillation NN o
( ( N
1.3 CD N
% NN N
vs JJ N
15.0 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
and CC N
severe JJ N
heart NN o
failure NN o
( ( N
3 CD N
% NN N
vs JJ N
12.5 CD N
% NN N
, , N
p NN N
= NNP N
0.031 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
MACEs NNP o
at IN o
1 CD o
year NN o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
GIK NNP i
group NN i
( ( N
13 CD N
% NN N
vs JJ N
40.0 CD N
% NN N
, , N
relative JJ N
risk NN N
0.22 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.09 CD N
to TO N
0.55 CD N
, , N
p NN N
= NNP N
0.0012 CD N
) ) N
. . N

After IN N
1 CD N
year NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
in IN N
the DT N
GIK NNP i
group NN i
( ( N
from IN N
48 CD N
+/- JJ N
8 CD N
% NN N
to TO N
51 CD N
+/- JJ N
10 CD N
% NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
, , N
which WDT N
was VBD N
not RB N
observed VBN N
in IN N
the DT N
control NN i
group NN N
. . N

In IN N
conclusion NN N
, , N
high-dose JJ N
GIK NNP i
, , N
used VBD N
as IN N
an DT N
adjunct NN N
to TO N
thrombolytic JJ i
therapy NN i
, , N
was VBD N
safe JJ o
and CC N
improved JJ N
clinical JJ o
outcome NN o
at IN N
1 CD N
month NN N
. . N

The DT N
beneficial JJ N
effect NN N
of IN N
GIK NNP i
infusion NN N
was VBD N
maintained VBN N
up RP N
to TO N
1 CD N
year NN N
. . N

-DOCSTART- -11554235- O O

Comparison NNP N
of IN N
tropisetron NN i
and CC i
granisetron NN i
in IN N
the DT N
control NN N
of IN N
nausea NN o
and CC o
vomiting NN o
in IN N
children NNS p
receiving VBG p
combined JJ p
cancer NN p
chemotherapy NN p
. . p

Tropisetron NNP i
and CC i
granisetron NN i
are VBP N
selective JJ N
serotonin NN N
( ( N
5-HT3 JJ N
) ) N
antagonists VBZ N
that WDT N
have VBP N
been VBN N
proven VBN N
effective JJ N
in IN N
the DT N
prevention NN N
of IN N
nausea NN o
and CC o
vomiting NN o
in IN N
adults NNS p
and CC p
children NNS p
receiving VBG p
cancer NN p
chemotherapy NN p
. . p

This DT N
prospective JJ N
, , N
randomised VBD N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
the DT N
two CD N
agents NNS N
in IN N
the DT N
prevention NN N
of IN N
vomiting VBG o
and CC o
nausea NN o
in IN N
children NNS p
receiving VBG p
highly RB p
emetogenic JJ p
chemotherapy NN p
for IN p
various JJ p
malignancies NNS p
. . p

A DT N
total NN p
of IN p
51 CD p
children NNS p
( ( p
mean JJ p
age NN p
: : p
7.7 CD p
+/- NN p
4.8 CD p
year NN p
) ) p
were VBD p
studied VBN p
in IN N
133 CD N
chemotherapy NN N
cycles NNS N
. . N

In IN N
66 CD N
chemotherapy NN N
cycles NNS N
, , N
the DT N
children NNS N
received VBD N
tropisetron RP i
as IN N
an DT N
antiemetic JJ N
agent NN N
in IN N
a DT N
dose NN N
of IN N
0.2 CD N
mg/kg/24 NNS N
h VBD N
intravenously RB N
and CC N
, , N
in IN N
67 CD N
cycles NNS N
, , N
they PRP N
received VBD N
granisetron NN i
40 CD N
micrograms/kg/24 NN N
h NN N
intravenously RB N
before IN N
cytotoxic JJ N
drug NN N
administration NN N
during IN N
the DT N
days NNS N
they PRP N
received VBD N
chemotherapy NN i
. . i

The DT N
response NN N
per IN N
24 CD N
h NN N
of IN N
chemotherapy NN N
was VBD N
defined VBN N
as IN N
complete JJ N
( ( N
no DT N
nausea NN N
and CC N
vomiting NN N
) ) N
, , N
partial JJ N
( ( N
1-4 JJ N
events NNS N
of IN N
vomiting VBG N
and/or JJ N
nausea NN N
) ) N
, , N
and CC N
failure NN N
( ( N
more JJR N
than IN N
4 CD N
events NNS N
of IN N
vomiting VBG N
and/or JJ N
nausea NN N
) ) N
. . N

Efficacy NN N
of IN N
antiemetic JJ N
therapy NN N
was VBD N
evaluated VBN N
as IN N
acute NN N
( ( N
Day NNP N
1 CD N
) ) N
and CC N
overall $ N
was VBD N
based VBN N
on IN N
the DT N
worst JJS N
day NN N
during IN N
the DT N
chemotherapy NN N
. . N

Complete NNP o
control NN o
of IN o
acute JJ o
vomiting NN o
was VBD N
achieved VBN N
in IN N
74 CD N
% NN N
of IN N
tropisetron NN i
and CC N
88 CD N
% NN N
of IN N
granisetron NN i
patients NNS N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
complete JJ N
control NN N
of IN N
acute JJ o
nausea NN o
in IN N
56 CD N
% NN N
and CC N
82 CD N
% NN N
respectively RB N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

Overall JJ o
response NN o
by IN N
means NNS N
of IN N
complete JJ N
control NN N
of IN N
both DT N
vomiting VBG o
and CC o
nausea NN o
during IN N
the DT N
whole JJ N
therapy NN N
period NN N
was VBD N
29 CD N
% NN N
of IN N
tropisetron NN i
group NN N
and CC N
55 CD N
% NN N
of IN N
granisetron NN i
group NN N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
. . N

The DT N
statistical JJ N
analysis NN N
( ( N
depending VBG N
on IN N
the DT N
emetogenicity NN N
of IN N
the DT N
chemotherapy NN N
cycles NNS N
) ) N
showed VBD N
increased JJ N
efficacy NN N
of IN N
granisetron NN N
in IN N
highly RB N
( ( N
grade VB N
3 CD N
) ) N
emetogenic JJ N
chemotherapy NN N
cycles NNS N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
, , N
whereas IN N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
very RB N
highly RB N
emetogenic JJ N
cycles NNS N
( ( N
p JJ N
= NNP N
0.7 CD N
) ) N
. . N

Also RB N
, , N
granisetron NN i
was VBD N
found VBN N
to TO N
be VB N
more RBR o
effective JJ o
than IN N
tropisetron RB i
, , N
especially RB N
in IN N
patients NNS N
heavier JJR N
than IN N
25 CD N
kg NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

The DT o
adverse JJ o
reactions NNS o
were VBD N
few JJ N
and CC N
mild JJ N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
tolerability NN o
of IN N
the DT N
two CD N
antiemetic JJ o
therapy NN o
modalities NNS o
. . o

In IN N
conclusion NN N
, , N
granisetron NN i
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
tropisetron NN N
in IN N
controlling VBG N
nausea NN o
and CC o
vomiting NN o
in IN N
children NNS p
receiving VBG p
highly RB p
emetogenic JJ p
chemotherapy NN p
. . p

This DT o
increased VBD o
antiemetic JJ o
efficacy NN o
of IN N
ganisetron NN i
might MD N
have VB N
been VBN N
related VBN N
to TO N
maximal VB N
dose JJ N
differences NNS N
according VBG N
to TO N
body NN o
weight NN o
. . o

-DOCSTART- -16864886- O O

A DT N
fenbendazole JJ i
oral JJ N
drench NN N
in IN N
addition NN N
to TO N
an DT N
ivermectin JJ i
pour-on JJ N
reduces NNS o
parasite JJ o
burden NN o
and CC o
improves VBZ o
feedlot NN o
and CC o
carcass NN o
performance NN o
of IN N
finishing VBG p
heifers NNS p
compared VBN N
with IN N
endectocides NNS N
alone RB N
. . N

Two CD N
studies NNS N
utilizing VBG N
1,862 CD p
yearling VBG p
heifers NNS p
were VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
a DT N
fenbendazole JJ i
oral JJ i
drench NN i
in IN i
addition NN i
to TO i
an DT i
ivermectin JJ i
pour-on NN i
( ( i
SG+IVPO NNP i
) ) i
, , N
compared VBN N
with IN N
an DT N
ivermectin JJ i
pour-on NN i
( ( i
IVPO NNP i
) ) i
or CC N
a DT N
doramectin NN i
injectable JJ i
( ( i
DMX NNP i
) ) i
alone RB i
, , N
on IN N
parasite JJ o
burden NN o
, , o
feedlot NN o
performance NN o
, , N
and CC N
carcass NN o
merit NN o
of IN o
feedlot NN o
cattle NNS o
. . o

In IN N
the DT N
first JJ N
study NN N
, , N
heifers NNS N
receiving VBG N
the DT N
SG+IVPO NNP N
had VBD N
fewer JJR o
( ( o
P NNP o
= NNP o
0.02 CD o
) ) o
cattle NNS o
retreated VBD o
for IN o
disease NN o
and CC N
73 CD N
% NN N
fewer JJR o
( ( o
P NNP o
= NNP o
0.06 CD o
) ) o
worm NN o
eggs NNS o
per IN o
fecal JJ o
sample NN o
98 CD N
d NN N
after IN N
treatment NN N
than IN N
heifers NNS N
treated VBN N
with IN N
IVPO NNP N
. . N

Heifers NNS N
treated VBD N
with IN N
SG+IVPO NNP N
consumed VBD N
more RBR o
DM NNP o
, , N
had VBD N
greater JJR o
ADG NNP o
, , N
were VBD N
heavier JJR o
at IN o
slaughter NN o
, , N
and CC N
had VBD N
heavier JJR o
carcasses NNS o
than IN N
IVPO-treated JJ N
heifers NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Heifers NNS N
treated VBD N
with IN N
SG+IVPO NNP N
also RB N
had VBD N
more RBR o
( ( o
P NNP o
= NNP o
0.07 CD o
) ) o
carcasses NNS o
grading VBG N
USDA NNP o
Prime NNP o
or CC o
Choice NNP o
than IN N
IVPO-treated JJ N
heifers NNS N
. . N

In IN N
the DT N
second JJ N
study NN N
, , N
heifers NNS N
treated VBD N
with IN N
SG+IVPO NNP N
had VBD N
fewer JJR o
( ( o
P NNP o
< NNP o
0.01 CD o
) ) o
worm NN o
eggs NNS o
per IN o
fecal JJ o
sample NN o
35 CD N
d NN N
after IN N
treatment NN N
and CC N
had VBD N
fewer JJR N
numbers NNS o
of IN o
adult NN o
and CC o
larval JJ o
Cooperia NNP o
and CC o
Trichostrongylus NNP o
spp NN o
. . o

in IN o
the DT o
small JJ o
intestine NN o
at IN N
slaughter NN N
( ( N
P NNP N
< NNP N
0.10 CD N
) ) N
compared VBN N
with IN N
heifers NNS N
treated VBN N
with IN N
DMX NNP N
. . N

Heifers NNS N
treated VBD N
with IN N
SG+IVPO NNP N
consumed VBD N
more RBR N
DM NNP o
, , N
were VBD N
heavier JJR N
at IN N
slaughter NN N
, , N
and CC N
had VBD N
heavier JJR N
carcasses NNS N
than IN N
DMX-treated JJ N
heifers NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
SG+IVPO-treated JJ i
heifers NNS N
also RB N
had VBD N
greater JJR o
ADG NNP o
( ( N
P NNP N
< NNP N
0.10 CD N
) ) N
. . N

The DT N
broad-spectrum JJ N
effectiveness NN N
of IN N
a DT N
combination NN N
of IN N
a DT N
fenbendazole JJ N
oral JJ N
drench NN N
and CC N
an DT N
ivermectin JJ N
pour-on NN N
reduced VBD N
parasite JJ o
burden NN o
and CC N
increased VBD o
feed NN o
intake NN o
, , o
ADG NNP o
, , N
and CC N
carcass NN o
weight NN o
in IN N
feedlot NN p
heifers NNS p
compared VBN N
with IN N
treatment NN N
with IN N
an DT N
endectocide JJ N
alone NN N
. . N

-DOCSTART- -22789149- O O

The DT N
impact NN N
of IN N
patient NN i
and CC i
physician JJ i
computer NN i
mediated VBD i
communication NN i
skill NN o
training VBG o
on IN N
reported VBN N
communication NN N
and CC N
patient JJ N
satisfaction NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
was VBD N
to TO N
evaluate VB N
parallel JJ o
patient NN o
and CC o
physician JJ o
computer-mediated JJ o
communication NN o
skill NN o
training VBG o
on IN N
participants NNS N
' POS N
report NN N
of IN N
skill NN N
use NN N
and CC N
patient JJ N
satisfaction NN N
. . N

METHODS NNP N
Separate NNP N
patient NN i
and CC i
clinician JJ i
web-tools NNS i
comprised VBN N
of IN N
over IN N
500 CD i
, , i
10-s JJ i
video NN i
clips NNS i
demonstrating VBG i
patient-centered JJ o
skills NNS o
in IN N
various JJ N
ways NNS N
. . N

Four CD p
clinician JJ p
members NNS p
of IN p
the DT p
American NNP p
Academy NNP p
of IN p
Family NNP p
Physicians NNP p
National NNP p
Research NNP p
Network NNP p
participated VBN p
by IN p
enrolling VBG p
194 CD p
patients NNS p
into IN p
a DT p
randomized JJ p
patient NN p
trial NN p
and CC p
29 CD p
physicians NNS p
into IN p
a DT p
non-randomized JJ p
clinician JJ p
trial NN p
of IN p
respective JJ p
interventions NNS p
. . p

All DT N
participants NNS N
completed VBN N
baseline NN N
and CC N
follow-up JJ N
self-report JJ N
measures NNS N
of IN N
visit NN N
communication NN o
and CC o
satisfaction NN o
. . o

RESULTS NNP N
Intervention NNP N
patients NNS N
reported VBD N
using VBG N
more JJR N
skills NNS o
than IN N
controls NNS N
in IN N
five CD N
of IN N
six CD N
skill JJ N
areas NNS N
, , N
including VBG N
identification NN o
of IN o
problems/concerns NNS o
, , o
information NN o
exchange NN o
, , o
treatment NN o
adherence NN o
, , o
shared VBN o
decision-making NN o
and CC o
interpersonal JJ o
rapport NN o
( ( N
all DT N
p NN N
< NNP N
.05 NNP N
) ) N
; : N
post VBN N
intervention NN N
, , N
physicians NNS N
reported VBD N
using VBG N
more JJR N
skills NNS N
in IN N
the DT N
same JJ N
5 CD N
areas NNS N
( ( N
all DT N
p NN N
< NNP N
.01 NNP N
) ) N
. . N

Intervention NNP N
group NN N
patients NNS N
reported VBD N
higher JJR o
levels NNS o
of IN o
satisfaction NN o
than IN N
controls NNS N
in IN N
five CD N
of IN N
six CD N
domains NNS N
( ( N
all DT N
p NN N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Communication NNP i
skill VBZ i
training VBG i
delivered VBN N
in IN N
a DT N
computer NN N
mediated VBN N
format NN N
had VBD N
a DT N
positive JJ o
and CC o
parallel JJ o
impact NN o
on IN N
both DT N
patient NN N
and CC N
clinician NN N
reported VBN N
use NN N
of IN N
patient-centered JJ o
communication NN o
and CC N
in IN N
patient JJ o
satisfaction NN o
. . o

PRACTICE NNP N
IMPLICATIONS NNP N
Computer-mediated JJ N
interventions NNS N
are VBP N
cost VBN o
and CC o
time NN o
effective JJ o
thereby RB N
increasing VBG N
patient NN N
and CC N
clinician JJ N
willingness NN N
to TO N
undertake VB N
training NN N
. . N

-DOCSTART- -12108617- O O

Double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
secretin NN i
: : i
effects NNS N
on IN N
aberrant JJ o
behavior NN o
in IN o
children NNS o
with IN o
autism NN o
. . o

Secretin NNP i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
treatment NN N
alternative NN N
for IN N
autistic JJ o
spectrum NN o
disorders NNS o
, , N
but CC N
empirical JJ N
support NN N
is VBZ N
lacking VBG N
. . N

A DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
on IN N
aberrant JJ o
behavior NN o
. . o

Parent NN p
and CC p
teacher NN p
data NNS p
from IN p
the DT p
Aberrant NNP o
Behavior NNP o
Checklist NNP o
for IN N
eight CD p
male JJ p
children NNS p
were VBD N
analyzed VBN N
for IN N
reliable JJ N
change NN N
in IN N
a DT N
clinical JJ N
replication NN N
series NN N
. . N

By IN N
parent NN N
and CC N
teacher NN N
report NN N
, , N
the DT N
majority NN N
of IN N
change NN N
occurred VBD N
either CC N
on IN N
the DT N
placebo NN i
trial NN N
or CC N
reflected VBN N
deterioration NN N
subsequent NN N
to TO N
secretin VB i
infusion NN N
. . N

Repeated-measures JJ N
multivariate JJ N
analysis NN N
of IN N
variance NN N
results NNS N
were VBD N
similar JJ N
. . N

Results NNS N
are VBP N
consistent JJ N
with IN N
other JJ N
studies NNS N
, , N
suggesting VBG N
that IN N
secretin NN i
may MD N
not RB N
be VB N
an DT N
effective JJ N
treatment NN N
option NN N
. . N

-DOCSTART- -25963675- O O

Comparison NNP N
of IN N
4 CD N
supraglotttic JJ i
devices NNS i
used VBN N
by IN N
paramedics NNS N
during IN N
simulated JJ N
CPR NNP N
: : N
a DT N
randomized VBN N
controlled VBN N
crossover RB N
trial NN N
. . N

BACKGROUND NNP N
Ensuring VBG N
an DT N
open JJ N
airway NN N
during IN N
cardiopulmonary JJ N
resuscitation NN N
is VBZ N
fundamental JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
success NN N
rate NN N
of IN N
blind JJ N
intubation NN N
during IN N
simulated JJ N
cardiopulmonary JJ N
resuscitation NN N
by IN N
untrained JJ p
personnel NNS p
. . p

METHODS NNP N
Four CD p
devices NNS p
were VBD N
compared VBN N
in IN N
a DT N
simulated JJ N
resuscitation NN N
scenario NN N
: : N
ILMA NNP i
( ( N
Intavent NNP N
Direct NNP N
Ltd NNP N
, , N
Buckinghamshire NNP N
, , N
United NNP N
Kingdom NNP N
) ) N
, , N
Cobra NNP i
PLA NNP i
( ( N
Engineered NNP N
Medical NNP N
Systems NNP N
Inc NNP N
, , N
Indianapolis NNP N
, , N
IN NNP N
) ) N
, , N
Supraglottic JJ i
Airway NNP i
Laryngopharyngeal NNP i
Tube NNP i
( ( i
SALT NNP i
) ) i
( ( N
ECOLAB NNP N
, , N
St. NNP N
Paul NNP N
, , N
MN NNP N
) ) N
, , N
and CC N
Air-Q NNP i
( ( N
Mercury NNP N
Medical NNP N
, , N
Clearwater NNP N
, , N
FL NNP N
) ) N
. . N

A DT N
group NN p
of IN p
210 CD p
paramedics NNS p
intubated VBD N
a DT N
manikin NN N
with IN N
continuous JJ N
chest NN N
compressions NNS N
. . N

RESULTS VB N
The DT N
mean JJ N
times NNS N
to TO N
intubation VB N
were VBD N
40.46 CD N
? . N
4.64 CD N
, , N
33.96 CD N
? . N
6.23 CD N
, , N
17.2 CD N
? . N
4.63 CD N
, , N
and CC N
49.23 CD N
? . N
13.19 CD N
seconds NNS N
( ( N
SALT NNP N
vs NNP N
ILMA NNP N
, , N
Cobra NNP N
PLA NNP N
, , N
and CC N
Air-Q NNP N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
success NN o
ratios NNS o
of IN o
blind JJ o
intubation NN o
for IN o
the DT N
devices NNS N
were VBD N
86.7 CD N
% NN N
, , N
85.7 CD N
% NN N
, , N
100 CD N
% NN N
, , N
and CC N
71.4 CD N
% NN N
( ( N
SALT NNP N
vs NNP N
ILMA NNP N
, , N
Cobra NNP N
PLA NNP N
, , N
and CC N
Air-Q NNP N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
study NN N
showed VBD N
that IN N
the DT N
most RBS N
efficient JJ N
device NN N
with IN N
the DT N
shortest JJS N
blind IN N
intubation NN N
time NN N
was VBD N
the DT N
SALT NNP i
device NN i
. . i

-DOCSTART- -2128415- O O

Serotonergic NNP N
control NN N
of IN N
TSH NNP o
and CC o
PRL NNP o
secretion NN o
in IN N
obese JJ p
men NNS p
. . p

To TO N
evaluate VB N
whether IN N
the DT N
inhibitory JJ N
control NN N
of IN N
TSH NNP o
and CC o
the DT o
stimulatory NN o
control NN o
of IN o
prolactin NN o
( ( o
PRL NNP o
) ) o
secretion NN o
exerted VBN N
by IN N
endogenous JJ N
serotonin NN N
was VBD N
altered VBN N
in IN N
obesity NN N
, , N
22 CD p
obese JJ p
men NNS p
and CC p
10 CD p
normal JJ p
controls NNS p
were VBD N
tested VBN i
with IN i
TRH NNP i
( ( i
200 CD i
micrograms NNS i
IV NNP i
bolus NN i
) ) i
in IN i
the DT i
presence NN i
( ( i
experimental JJ i
test NN i
) ) i
and CC i
absence NN i
( ( i
control VB i
test NN i
) ) i
of IN i
the DT i
serotonergic JJ i
agonist NN i
fenfluramine NN i
( ( i
60 CD i
mg NN i
PO NNP i
90 CD i
min NN i
before IN i
TRH NNP i
) ) i
. . i

Control NNP N
and CC N
experimental JJ N
tests NNS N
were VBD N
also RB N
performed VBN N
in IN N
seven CD p
male JJ p
patients NNS p
with IN p
subclinical JJ p
hypothyroidism NN p
and CC N
were VBD N
repeated VBN N
in IN N
the DT N
same JJ N
obese JJ p
subjects NNS p
after IN p
substantial JJ p
weight JJ p
loss NN p
. . p

Basal NNP o
TSH NNP o
levels NNS o
were VBD N
similar JJ N
in IN N
control NN p
and CC p
obese JJ p
men NNS p
. . p

Normal NNP o
TSH NNP o
responses VBZ o
to TO o
TRH NNP o
( ( N
peak NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
14 CD N
mU/L NNS N
) ) N
were VBD N
observed VBN N
in IN N
all DT N
normal JJ N
controls NNS N
( ( N
mean JJ N
peak NN N
+/- JJ N
SE NNP N
9.8 CD N
+/- JJ N
0.6 CD N
mU/L NN N
) ) N
. . N

In IN N
contrast NN N
, , N
obese JJ p
men NNS p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
nine CD N
in IN N
whom WP N
the DT N
TRH-induced NNP o
TSH NNP o
rise NN o
was VBD N
higher JJR N
than IN N
normal JJ N
( ( N
group NN N
I PRP N
: : N
mean JJ N
peak NN N
= VBD N
16.5 CD N
+/- JJ N
0.5 CD N
mU/L NN N
) ) N
and CC N
13 CD N
in IN N
whom WP N
it PRP N
was VBD N
normal JJ N
( ( N
group NN N
II NNP N
: : N
mean JJ N
peak NN N
= VBD N
10.6 CD N
+/- JJ N
0.7 CD N
mU/L NN N
) ) N
. . N

The DT N
hypothyroid JJ p
men NNS p
all DT N
had VBD N
elevated VBN N
basal NN o
and CC o
TRH-stimulated JJ o
TSH NNP o
levels NNS o
. . o

Basal NNP o
PRL NNP o
concentrations NNS o
were VBD N
similar JJ N
in IN N
the DT N
normal JJ N
controls NNS N
and CC N
both DT N
groups NNS N
of IN N
obese JJ p
subjects NNS p
. . p

The DT N
PRL NNP N
response NN N
to TO N
TRH NNP N
was VBD N
lower JJR N
in IN N
both DT N
group NN N
I PRP N
and CC N
group NN N
II NNP N
obese VBZ N
men NNS N
than IN N
in IN N
normal JJ N
controls NNS N
and CC N
was VBD N
similar JJ N
between IN N
group NN N
I PRP N
and CC N
group NN N
II NNP N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -9735531- O O

Behavioral JJ o
changes NNS o
in IN N
autistic JJ p
individuals NNS p
as IN N
a DT N
result NN N
of IN N
wearing VBG N
ambient JJ i
transitional JJ i
prism NN i
lenses NNS i
. . i

A DT N
double-blind JJ N
crossover NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
wearing VBG i
ambient JJ i
lenses NNS i
to TO N
reduce VB N
the DT N
behavioral JJ N
symptoms NNS N
of IN N
autism NN N
. . N

Eighteen NNP p
autistic JJ p
individuals NNS p
, , p
ranging VBG p
in IN p
age NN p
from IN p
7 CD p
to TO p
18 CD p
years NNS p
, , N
participated VBD N
in IN N
the DT N
study NN N
. . N

Behavior NNP o
, , o
attention NN o
, , o
and CC o
orientation NN o
were VBD N
evaluated VBN N
at IN N
1 CD N
1/2 CD N
months NNS N
, , N
2 CD N
months NNS N
, , N
3 CD N
months NNS N
, , N
and CC N
4 CD N
months NNS N
. . N

Compared VBN N
to TO N
the DT N
placebo NN i
condition NN N
, , N
the DT N
results NNS N
showed VBD N
a DT N
decrease NN N
in IN N
behavior JJ o
problems NNS o
at IN N
the DT N
1 CD N
1/2 CD N
and CC N
2 CD N
month NN N
assessment NN N
periods NNS N
and CC N
a DT N
slight JJ N
loss NN N
of IN N
these DT N
benefits NNS N
at IN N
the DT N
3 CD N
and CC N
4 CD N
month NN N
assessment NN N
periods NNS N
. . N

These DT N
findings NNS N
support VBP N
the DT N
prediction NN N
that WDT N
ambient JJ i
lenses NNS i
, , N
worn VBN N
without IN N
engaging VBG N
in IN N
visual-motor NN N
exercises NNS N
, , N
have VBP N
positive JJ N
effects NNS N
on IN N
autistic JJ p
individuals NNS p
. . p

-DOCSTART- -7981078- O O

Treatment NN N
of IN N
multiple JJ N
myeloma NN N
according VBG N
to TO N
the DT N
extension NN N
of IN N
the DT N
disease NN N
: : N
a DT N
prospective JJ N
, , N
randomised VBD N
study NN N
comparing VBG N
a DT N
less RBR N
with IN N
a DT N
more RBR N
aggressive JJ i
cystostatic JJ i
policy NN N
. . N

Cooperative NNP p
Group NNP p
of IN p
Study NNP p
and CC p
Treatment NNP p
of IN p
Multiple NNP p
Myeloma NNP p
. . p

The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
ascertain VB N
whether IN N
the DT N
prognostic JJ N
significance NN N
of IN N
staging VBG N
in IN N
multiple JJ N
myeloma NN N
( ( N
MM NNP N
) ) N
is VBZ N
influenced VBN N
by IN N
the DT N
aggressiveness NN i
of IN i
effective JJ i
induction NN i
treatment NN i
and/or NN N
by IN N
continuing VBG N
or CC N
discontinuing VBG N
maintenance NN i
chemotherapy NN i
. . i

Patients NNS p
with IN p
untreated JJ p
stage NN p
I PRP p
MM NNP p
( ( p
defined VBN p
according VBG p
to TO p
Durie NNP p
and CC p
Salmon NNP p
) ) p
were VBD N
randomised VBN N
between IN N
being VBG N
followed VBN i
without IN i
cytostatics NNS i
until IN N
the DT N
disease NN N
progressed VBD N
and CC N
receiving VBG i
six CD i
courses NNS i
of IN i
melphalan NN i
and CC i
prednisone NN i
( ( i
MP-P NNP i
) ) i
just RB N
after IN N
diagnosis NN N
; : N
stage NN p
II NNP p
patients NNS p
were VBD N
uniformly RB N
treated VBN N
with IN N
MPH-P NNP i
and CC N
stage NN p
III NNP p
patients NNS p
were VBD N
randomised VBN N
between IN N
MPH-P NNP i
and CC i
four CD i
courses NNS i
of IN i
combination NN i
chemotherapy NN i
with IN i
Peptichemio NNP i
, , i
vincristine NN i
and CC i
prednisone NN i
( ( i
PTC-VCR-P NNP i
) ) i
. . i

Within IN N
each DT N
stage NN N
, , N
responsive JJ N
patients NNS N
were VBD N
randomised VBN N
between IN N
receiving VBG N
additional JJ N
therapy NN N
only RB N
until IN N
maximal JJ N
tumour NNS N
reduction NN N
was VBD N
reached VBN N
( ( N
plateau JJ N
phase NN N
) ) N
and CC N
continuing VBG N
induction NN N
therapy NN N
indefinitely RB N
until IN N
relapse NN N
. . N

With IN N
resistant JJ N
, , N
progressive JJ N
or CC N
relapsing VBG N
disease NN N
, , N
patients NNS N
originally RB N
treated VBN N
with IN N
MPH-P NNP i
for IN N
induction NN N
received VBN N
combination NN N
chemotherapy NN N
and CC N
vice NN N
versa NN N
. . N

The DT N
overall JJ o
first JJ o
response NN o
rate NN o
was VBD N
43.8 CD N
% NN N
( ( N
42.2 CD N
% NN N
in IN N
206 CD N
stage NN N
I PRP N
, , N
II NNP N
and CC N
III NNP N
patients NNS N
treated VBD N
with IN N
MPH-P NNP i
and CC N
48.0 CD N
% NN N
in IN N
75 CD N
stage NN N
III NNP N
patients NNS N
treated VBD N
with IN N
combination NN i
chemotherapy NN i
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Combination NNP i
chemotherapy NN i
was VBD N
more RBR N
myelotoxic JJ o
than IN N
MPH-P NNP i
and CC N
, , N
in IN N
particular JJ N
, , N
caused VBD N
more RBR N
non-haematological JJ o
side-effects NNS o
. . o

Both CC N
the DT N
less JJR N
and CC N
the DT N
more RBR N
aggressive JJ N
induction NN N
policies NNS N
gave VBD N
the DT N
same JJ N
disease NN o
control NN o
. . o

Progression NN o
of IN o
disease NN o
was VBD N
statistically RB N
similar JJ N
in IN N
stage NN N
I PRP N
patients NNS N
who WP N
were VBD N
initially RB N
left VBN N
untreated JJ N
and CC N
in IN N
t JJ N
hose NN N
who WP N
received VBD N
MPH-P NNP i
just RB N
after IN N
diagnosis NN N
; : N
median JJ N
duration NN o
of IN o
first JJ o
response NN o
was VBD N
similar JJ N
in IN N
stage NN N
III NNP N
patients NNS N
receiving VBG N
MPH-P NNP i
and CC N
in IN N
those DT N
on IN N
combination NN i
chemotherapy NN i
. . i

In IN N
all DT N
stages NNS N
, , N
discontinuing VBG N
or CC N
continuing VBG N
maintenance NN N
did VBD N
not RB N
alter VB N
the DT N
median JJ o
duration NN o
of IN o
first JJ o
response NN o
. . o

The DT N
overall JJ o
second JJ o
response NN o
rate NN o
was VBD N
28.5 CD N
% NN N
( ( N
34.0 CD N
% NN N
to TO N
MPH-P NNP N
and CC N
25.3 CD N
% NN N
to TO N
combination NN N
chemotherapy NN i
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Median JJ o
survival NN o
was VBD N
greater JJR N
than IN N
78 CD N
months NNS N
in IN N
stage NN N
I PRP N
, , N
was VBD N
46.3 CD N
months NNS N
in IN N
stage NN N
II NNP N
and CC N
was VBD N
24.3 CD N
months NNS N
in IN N
stage NN N
III NNP N
patients NNS N
, , N
still RB N
independent JJ N
of IN N
both DT N
induction NN N
and CC N
post-induction NN N
policies NNS N
. . N

In IN N
MM NNP N
, , N
the DT N
significance NN N
of IN N
staging VBG N
for IN N
survival NN o
is VBZ N
independent JJ N
of IN N
both DT N
the DT N
aggressiveness NN N
of IN N
induction NN N
and CC N
of IN N
continuing VBG N
or CC N
discontinuing VBG N
maintenance NN N
chemotherapy NN N
after IN N
the DT N
maximal JJ N
tumor NN N
reduction NN N
has VBZ N
been VBN N
achieved VBN N
. . N

Both DT N
MPH-P NNP i
and CC N
and CC N
the DT N
association NN N
of IN N
PTC NNP i
, , i
VCR NNP i
and CC i
P NNP i
are VBP N
effective JJ N
in IN N
inducing VBG N
first JJ o
response NN o
and CC N
also RB N
second JJ o
response NN o
in IN N
patients NNS N
failing VBG N
on IN N
the DT N
alternative JJ N
regimen NNS N
, , N
but CC N
PTC-VCR-P NNP i
causes VBZ N
more JJR N
side JJ o
effects NNS o
. . o

Thus RB N
, , N
the DT N
overwhelming JJ N
majority NN N
of IN N
patients NNS N
with IN N
MM NNP N
can MD N
safely RB N
be VB N
given VBN N
MPH-P NNP i
as IN N
first JJ N
therapy NN N
, , N
and CC N
this DT N
treatment NN N
may MD N
be VB N
delayed VBN N
in IN N
early JJ N
diseases NNS N
. . N

-DOCSTART- -3541596- O O

Monotherapy NNP N
of IN N
mild JJ p
hypertension NN o
with IN N
nifedipine NN i
. . i

The DT N
effectiveness NN o
of IN N
nifedipine JJ i
as IN N
first-line JJ N
monotherapy NN N
for IN N
mild JJ p
diastolic JJ o
hypertension NN o
( ( p
range NN p
: : p
95 CD p
to TO p
105 CD p
mm NNS p
Hg NNP p
) ) p
was VBD N
tested VBN N
in IN N
this DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
. . N

Fifty-six JJ p
patients NNS p
were VBD p
enrolled VBN p
and CC N
, , N
after IN N
titration NN N
of IN N
the DT N
placebo NN i
or CC N
active JJ i
drug NN i
, , N
they PRP N
were VBD N
followed VBN N
for IN N
12 CD N
weeks NNS N
. . N

Significant JJ N
declines NNS N
in IN N
the DT N
sitting VBG N
systolic JJ o
and CC o
diastolic JJ o
pressures NNS o
of IN N
-19 JJ N
+/- JJ N
4 CD N
mm NN N
Hg NNP N
( ( N
standard JJ N
error NN N
) ) N
and CC N
-13 $ N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
were VBD N
observed VBN N
during IN N
this DT N
follow-up JJ N
period NN N
. . N

Overall JJ N
, , N
75 CD N
percent NN N
of IN N
patients NNS N
receiving VBG N
active JJ i
drug NN i
had VBD N
diastolic JJ o
pressures NNS o
less RBR N
than IN N
or CC N
equal JJ N
to TO N
90 CD N
mm NNS N
Hg NNP N
at IN N
the DT N
last JJ N
treatment NN N
visit NN N
. . N

Heart NNP o
rate NN o
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
the DT N
sitting VBG N
position NN N
during IN N
the DT N
treatment NN N
period NN N
, , N
and CC N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
75 CD N
percent NN N
) ) N
showed VBD N
a DT N
response NN N
to TO N
nifedipine JJ i
doses NNS N
of IN N
10 CD N
or CC N
20 CD N
mg NNS N
orally RB N
three CD N
times NNS N
daily RB N
in IN N
the DT N
capsule NN N
form NN N
. . N

The DT N
levels NNS N
of IN N
the DT N
systolic NN o
and CC o
diastolic JJ o
pressures NNS o
at IN N
entry NN N
were VBD N
not RB N
predictive JJ N
of IN N
the DT N
dose NN N
of IN N
nifedipine NN i
required VBN N
for IN N
effective JJ o
blood NN o
pressure NN o
control NN N
. . N

-DOCSTART- -288486- O O

Lithium NN i
and CC N
granulocytopenia NN N
during IN N
induction NN N
therapy NN N
of IN N
acute JJ p
myelogenous JJ p
leukemia NN p
. . p

Twenty-seven JJ p
patients NNS p
receiving VBG p
a DT p
standard JJ i
cytosine NN i
arabinoside NN i
and CC i
daunorubicin JJ i
regimen NNS i
as IN p
induction NN p
of IN p
reinduction NN p
therapy NN p
of IN p
acute JJ p
myelogenous JJ p
leukemia NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
lithium NN i
carbonate NN i
, , i
300 CD i
mg NN i
t.i.d. NN i
, , N
or CC i
no DT i
lithium NN i
. . i

Treatment NN p
groups NNS p
were VBD p
comparable JJ p
with IN p
respect NN p
to TO p
age NN p
and CC p
baseline NN p
granulocyte NN p
counts NNS p
. . p

All DT N
patients NNS N
developed VBD N
granulocyte JJ o
nadirs NNS o
below IN N
100/cu CD N
mm NN N
. . N

By IN N
actuarial JJ N
analysis NN N
, , N
the DT N
median JJ o
duration NN o
of IN o
granulocytopenia NN o
, , N
less JJR N
than IN N
1000/cu CD N
mm NN N
, , N
was VBD N
16.0 CD N
days NNS N
in IN N
the DT N
lithium NN i
group NN N
and CC N
24.6 CD N
days NNS N
in IN N
the DT N
no-lithium JJ i
group NN N
, , N
p VBP N
= JJ N
0.013 CD N
. . N

The DT N
median JJ o
duration NN o
of IN o
granulocytes NNS o
less JJR N
than IN N
500/cu CD N
mm NNS N
also RB N
favored VBD N
the DT N
lithium NN i
group NN N
but CC N
only RB N
approached VBD N
statistical JJ N
significance NN N
: : N
14.0 CD N
days NNS N
versus RB N
20.5 CD N
days NNS N
, , N
p VBP N
= JJ N
0.054 CD N
. . N

Lithium NN o
levels NNS o
between IN o
0.5 CD o
and CC o
1.0 CD o
meq/liter NN o
were VBD N
easily RB N
maintained VBN N
in IN N
11 CD N
of IN N
12 CD N
patients NNS N
receiving VBG N
lithium NN i
, , N
300 CD N
mg NN N
t.i.d. NN N
, , N
and CC N
toxicity NN o
directly RB N
attributable JJ N
to TO N
lithium VB i
was VBD N
not RB N
observed VBN N
. . N

Despite IN N
the DT N
shortened JJ o
duration NN o
of IN o
neutropenia NN o
, , N
the DT N
incidence NN N
of IN N
infections NNS N
and CC N
the DT N
rate NN N
of IN N
remission NN N
were VBD N
not RB N
affected VBN N
. . N

-DOCSTART- -19491859- O O

Safety NN o
and CC o
efficacy NN o
of IN N
a DT N
new JJ i
3.3 CD i
g NN i
b.i.d NN i
. . i

tablet NN i
formulation NN i
in IN N
patients NNS p
with IN p
mild-to-moderately-active JJ p
ulcerative JJ p
colitis NN p
: : p
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
a DT N
new JJ N
twice-daily JJ N
balsalazide NN i
disodium NN i
1.1 CD i
g NN i
tablet NN i
dosing VBG N
regimen NNS N
( ( N
6.6 CD N
g/day NN N
, , N
three CD N
tablets NNS N
twice RB N
daily RB N
) ) N
for IN N
the DT N
treatment NN N
of IN N
mild-to-moderately-active JJ N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
, , N
multicenter NN p
study NN p
patients NNS p
with IN p
symptoms NNS p
of IN p
acute JJ p
UC NNP p
and CC p
a DT p
baseline NN p
Modified NNP p
Mayo NNP p
Disease NNP p
Activity NNP p
Index NNP p
( ( p
MMDAI NNP p
) ) p
score NN p
between IN p
6 CD p
and CC p
10 CD p
, , p
inclusive JJ p
, , p
with IN p
a DT p
subscale JJ p
rating NN p
of IN p
> NNP p
or CC p
=2 NN p
for IN p
both DT p
rectal JJ p
bleeding NN p
and CC p
mucosal JJ p
appearance NN p
were VBD N
randomized VBN N
to TO N
receive VB N
3.3 CD N
g NN N
of IN N
balsalazide NN i
or CC i
placebo NN i
tablets NNS N
twice RB N
daily RB N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
achieving VBG N
clinical JJ N
improvement NN N
( ( N
> CD N
or CC N
=3 VB N
point NN N
improvement NN N
in IN N
MMDAI NNP N
) ) N
and CC N
improvement NN N
in IN N
rectal JJ N
bleeding NN N
( ( N
> CD N
or CC N
=1 VB N
point NN N
improvement NN N
) ) N
at IN N
8 CD N
weeks NNS N
. . N

Safety NN N
assessments NNS N
were VBD N
conducted VBN N
from IN N
baseline NN N
through IN N
2-weeks JJ N
post-treatment JJ N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
249 CD p
patients NNS p
( ( p
166 CD p
balsalazide NN i
, , p
83 CD p
placebo NN i
) ) i
received VBD N
at IN N
least JJS N
1 CD N
dose NN N
of IN N
study NN N
medication NN N
. . N

The DT N
mean JJ o
MMDAI NNP o
score NN o
at IN N
baseline NN N
was VBD N
7.9 CD N
; : N
62 CD N
% NN N
of IN N
patients NNS N
had VBD N
a DT N
score NN N
> NN N
or CC N
=8.0 NN N
( ( N
moderate JJ N
disease NN N
) ) N
. . N

A DT N
significantly RB N
larger JJR N
proportion NN N
of IN N
patients NNS N
achieved VBN o
clinical JJ o
improvement NN o
and CC o
improvement NN o
in IN o
rectal JJ o
bleeding NN o
in IN N
the DT N
balsalazide NN i
group NN N
vs. FW N
the DT N
placebo NN i
group NN N
( ( N
55 CD N
vs. FW N
40 CD N
% NN N
, , N
P=0.02 NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
reported VBN N
were VBD N
worsening VBG o
of IN o
UC NNP o
and CC o
headache NN o
; : o
both DT N
were VBD N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
placebo NN i
group NN N
. . N

CONCLUSIONS NNP N
Balsalazide NNP i
disodium NN i
1.1 CD N
g NN N
tablets NNS N
administered VBD N
as IN N
3.3 CD N
g JJ N
twice RB N
daily RB N
are VBP N
effective JJ o
, , o
well RB o
tolerated VBN o
and CC o
significantly RB o
better JJR o
than IN N
placebo NN i
for IN N
improving VBG o
signs NNS o
and CC o
symptoms NNS o
of IN o
mild-to-moderately-active JJ o
UC NNP o
. . o

This DT N
new JJ N
formulation NN N
with IN N
a DT N
reduced VBN N
pill NN N
and CC N
dosing VBG N
burden NN N
offers VBZ N
the DT N
potential NN N
to TO N
improve VB N
convenience NN o
and CC o
compliance NN o
in IN N
patients NNS p
with IN p
active JJ p
UC NNP p
. . p

-DOCSTART- -22377512- O O

A DT N
randomized JJ N
, , N
placebo- JJ i
and CC N
active-controlled JJ N
study NN N
of IN N
paliperidone NN i
extended-release NN N
as IN N
maintenance NN N
treatment NN N
in IN p
patients NNS p
with IN p
bipolar JJ p
I PRP p
disorder VBP p
after IN p
an DT p
acute JJ p
manic NN p
or CC p
mixed JJ p
episode NN p
. . p

BACKGROUND NNP N
Paliperidone NNP i
ER NNP i
monotherapy NN i
was VBD N
efficacious JJ N
in IN N
treating VBG N
acute NN N
mania NN N
in IN N
two CD N
3-week JJ N
studies NNS N
in IN p
patients NNS p
with IN p
bipolar JJ p
I PRP p
disorder VBP p
. . p

We PRP N
assessed VBD N
its PRP$ N
efficacy NN N
in IN N
a DT N
study NN N
investigating VBG N
maintenance NN N
treatment NN N
of IN N
clinically RB p
stable JJ p
patients NNS p
with IN p
this DT p
disorder NN p
. . p

METHODS NNP N
Patients NNPS p
( ( p
n=766 JJ p
) ) p
, , p
aged VBD p
18 CD p
to TO p
65 CD p
years NNS p
inclusive JJ p
, , p
with IN p
current JJ p
manic NN p
or CC p
mixed JJ p
episodes NNS p
were VBD p
initially RB p
randomized VBN p
( ( N
4:1 CD N
) ) N
to TO N
flexibly-dosed JJ N
paliperidone NN i
ER NNP i
( ( N
3-12 JJ N
mg/day NN N
) ) N
or CC N
olanzapine JJ i
( ( N
5-20 JJ N
mg/day NN N
; : N
3-week JJ N
acute NN N
treatment NN N
phase NN N
) ) N
; : N
responders NNS N
continued VBD N
the DT N
same JJ N
treatment NN N
( ( N
12-week JJ N
continuation NN N
phase NN N
) ) N
. . N

Patients NNS p
on IN p
paliperidone NN i
ER NNP i
who WP p
achieved VBD p
remission NN p
during IN N
this DT N
phase NN N
were VBD N
randomized VBN N
( ( N
1:1 CD N
) ) N
to TO N
fixed-dose JJ N
paliperidone NN i
ER NNP i
( ( N
n=152 NN N
) ) N
or CC N
placebo NN i
( ( N
n=148 JJ N
) ) N
; : N
those DT N
on IN N
olanzapine JJ i
continued VBN N
to TO N
receive VB N
that DT N
at IN N
fixed VBN N
dose NN N
( ( N
n=83 JJ N
) ) N
( ( N
maintenance NN N
phase NN N
) ) N
. . N

RESULTS NNP N
Median JJ o
time NN o
to TO o
recurrence VB o
of IN o
any DT o
mood NN o
symptoms NNS o
( ( o
primary JJ o
endpoint NN o
) ) o
was VBD N
: : N
558 CD N
days NNS N
( ( i
paliperidone JJ i
ER NNP i
) ) i
, , N
283 CD N
days NNS N
( ( i
placebo NN i
) ) i
and CC N
not RB N
observed VBN N
with IN N
olanzapine NN i
( ( N
< JJ N
50 CD N
% NN N
of IN N
patients NNS N
experienced JJ N
recurrence NN N
) ) N
. . N

Time NN o
to TO o
recurrence VB o
of IN o
any DT o
mood NN o
symptoms NNS o
was VBD N
significantly RB N
longer RBR N
with IN N
paliperidone NN i
ER NNP i
than IN N
placebo NN N
( ( N
p=0.017 NN N
; : N
based VBN N
on IN N
weighted JJ N
Z-test NNP N
at IN N
0.0198 CD N
significance NN N
level NN N
; : N
hazard CC N
ratio VB N
[ JJ N
placebo NN N
: : N
paliperidone NN N
ER NNP N
; : N
unweighted VBD N
95 CD N
% NN N
confidence NN N
interval JJ N
] NN N
: : N
1.43 CD N
[ $ N
1.03 CD N
; : N
1.98 CD N
] NN N
) ) N
; : N
the DT N
difference NN N
was VBD N
significant JJ N
for IN N
preventing VBG N
recurrence NN o
of IN o
manic NN o
, , N
but CC N
not RB N
depressive JJ N
, , N
symptoms NNS N
. . N

Treatment-emergent JJ o
adverse JJ o
events NNS o
( ( o
maintenance NN o
phase NN o
) ) o
occurred VBD N
more RBR N
often RB N
in IN N
olanzapine JJ i
group NN N
( ( N
64 CD N
% NN N
) ) N
than IN N
placebo NN i
( ( N
59 CD N
% NN N
) ) N
or CC N
paliperidone NN i
ER NNP i
groups NNS N
( ( N
55 CD N
% NN N
) ) N
. . N

LIMITATIONS JJ N
Responder-enriched JJ N
design NN N
prevents NNS N
extrapolation NN N
of IN N
data NNS N
to TO p
patients NNS p
not RB p
previously RB p
stabilized VBN p
on IN p
paliperidone NN i
ER NNP i
. . i

CONCLUSIONS NNP N
Paliperidone NNP i
ER NNP i
significantly RB N
delayed VBD N
the DT N
time NN N
to TO N
recurrence VB N
of IN N
any DT N
mood NN N
symptoms NNS N
, , N
versus NN N
placebo NN i
, , N
in IN p
patients NNS p
with IN p
bipolar JJ p
I PRP p
disorder VBP p
. . p

No DT N
new JJ N
safety NN N
concerns NNS N
emerged VBD N
. . N

-DOCSTART- -8780429- O O

MRI NNP i
signal JJ i
hyperintensities NNS N
in IN N
geriatric JJ p
depression NN p
. . p

OBJECTIVE CC N
The DT N
authors NNS N
rated VBD N
periventricular JJ N
and CC N
subcortical JJ N
signal NN N
hyperintensities NNS N
on IN N
magnetic JJ i
resonance NN i
imaging NN i
( ( i
MRI NNP i
) ) i
scans VBZ N
in IN N
elderly JJ p
patients NNS p
with IN p
depression NN p
and CC p
in IN p
normal JJ i
subjects NNS p
with IN N
similar JJ N
demographic JJ N
features NNS N
to TO N
examine VB N
whether IN N
such JJ N
changes NNS N
discriminate VBP N
patients NNS N
with IN N
depression NN N
from IN N
normal JJ i
subjects NNS N
and CC N
whether IN N
they PRP N
are VBP N
associated VBN N
with IN N
any DT N
clinical JJ N
variables NNS N
. . N

METHOD NNP N
Two CD p
established VBD p
hyperintensity NN p
rating NN p
systems NNS p
were VBD N
used VBN N
to TO N
compare VB N
the DT N
MRI NNP i
brain NN i
scans NNS i
of IN p
48 CD p
elderly JJ p
patients NNS p
with IN p
depression NN p
diagnosed VBN p
according VBG p
to TO p
DSM-III-R NNP p
with IN p
the DT p
scans NNS p
of IN p
39 CD p
normal JJ p
elderly JJ p
subjects NNS p
. . p

RESULTS NNP N
Elderly NNP p
depressed VBD p
patients NNS p
manifested VBN N
significantly RB N
more RBR N
severe JJ N
hyperintensity NN o
ratings NNS o
in IN N
the DT N
subcortical JJ N
gray NN N
matter NN N
than IN N
age-matched JJ N
comparison NN N
subjects NNS N
. . N

Significant JJ N
differences NNS N
were VBD N
not RB N
identified VBN N
between IN N
patients NNS N
with IN N
similar JJ N
current JJ N
ages NNS N
and CC N
cerebrovascular JJ N
disease NN N
risk NN N
who WP N
had VBD N
early-onset NN N
or CC N
late-onset JJ N
depression NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
support VBP N
those DT N
of IN N
neuroimaging VBG N
studies NNS N
implicating VBG N
the DT N
basal NN N
ganglia NN N
in IN N
depression NN N
and CC N
geriatric JJ N
depression NN N
. . N

The DT N
data NN N
suggest NN N
that IN N
the DT N
relationship NN N
observed VBD N
in IN N
some DT N
reports NNS N
between IN N
late-onset JJ N
depression NN N
and CC N
MRI NNP i
hyperintensities NNS N
is VBZ N
most RBS N
likely JJ N
a DT N
function NN N
of IN N
cerebrovascular JJ N
disease NN N
risk NN N
and CC N
age NN N
. . N

-DOCSTART- -9099448- O O

A DT p
limited JJ p
sampling NN p
method NN p
for IN p
the DT p
estimation NN o
of IN o
flunarizine JJ o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
and CC o
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
. . o

A DT N
limited JJ N
sampling NN N
model NN N
has VBZ N
been VBN N
developed VBN N
for IN N
flunarizine NN N
following VBG N
a DT N
30 CD N
mg JJ N
oral JJ N
dose NN N
in IN N
epileptic JJ p
patients NNS p
who WP p
were VBD i
receiving VBG i
phenytoin NN i
or CC i
carbamazepine NN i
or CC i
both DT i
, , i
to TO i
estimate VB o
the DT o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
and CC o
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
. . o

The DT N
model NN N
was VBD N
developed VBN N
using VBG N
training VBG N
data NNS N
sets NNS N
from IN N
30 CD p
, , p
20 CD p
, , p
15 CD p
, , p
or CC p
10 CD p
patients NNS p
at IN p
one CD p
or CC p
two CD p
time NN p
points NNS p
. . p

The DT N
equations NNS N
describing VBG N
the DT N
models NNS N
for IN N
AUC NNP N
using VBG N
two CD N
time NN N
points NNS N
( ( N
3 CD N
and CC N
24h CD N
) ) N
and CC N
Cmax NNP N
for IN N
the DT N
training NN N
data NNS N
set NN N
of IN N
30 CD N
subjects NNS N
were VBD N
AUCpredicted NNP N
= NNP N
11.1 CD N
C3h NNP N
+ VBD N
121.4 CD N
C24h NNP N
- : N
157 CD N
( ( N
r NN N
= RB N
0.80 CD N
) ) N
Cmax NNP N
( ( N
predicted VBN N
) ) N
= $ N
0.036 CD N
AUC NNP N
+ $ N
42.9 CD N
( ( N
r NN N
= RB N
0.74 CD N
) ) N
The DT N
model NN N
was VBD N
validated VBN N
on IN N
64 CD p
patients NNS p
who WP N
received VBD N
flunarizine JJ N
orally RB N
. . N

The DT N
model NN N
provided VBD N
reasonably RB N
good JJ N
estimates NNS o
for IN o
both DT o
AUC NNP o
and CC o
Cmax NNP o
. . o

The DT N
mean NN o
predicted VBD o
AUC NNP o
of IN o
flunarizine NN o
was VBD N
1230 CD N
+/- JJ N
717 CD N
ng JJ N
h NN N
mL-1 NN N
, , N
whereas IN N
the DT N
observed JJ o
AUC NNP o
was VBD N
1203 CD N
+/- JJ N
900 CD N
ng JJ N
h JJ N
mL-1 NN N
. . N

The DT N
bias NN o
of IN o
the DT o
prediction NN o
was VBD N
2 CD N
% NN N
and CC N
precision NN N
was VBD N
28 CD N
% NN N
. . N

The DT N
mean NN N
predicted VBD o
Cmax NNP o
of IN o
flunarizine NN o
was VBD N
86 CD N
+/- JJ N
32 CD N
ng JJ N
mL-1 NN N
as IN N
compared VBN N
to TO N
an DT N
observed JJ o
mean NN o
Cmax NNP o
of IN N
90 CD N
+/- JJ N
42 CD N
ng JJ N
mL-1 NN N
. . N

The DT N
bias NN o
and CC o
precision NN o
of IN o
the DT o
prediction NN o
were VBD N
4 CD N
% NN N
and CC N
24 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
method NN N
described VBD N
here RB N
may MD N
be VB N
used VBN N
to TO N
estimate VB N
AUC NNP N
and CC N
Cmax NNP N
for IN N
flunarizine NN N
without IN N
detailed JJ N
pharmacokinetic JJ N
studies NNS N
. . N

-DOCSTART- -21967909- O O

The DT N
effectiveness NN o
and CC N
cost NN o
of IN N
passive JJ o
warming NN o
in IN N
adult NN p
ambulatory NN p
surgery NN p
patients NNS p
. . p

Hypothermia NNP N
is VBZ N
a DT N
common JJ N
problem NN N
for IN N
surgical JJ p
patients NNS p
and CC N
can MD N
result VB N
in IN N
many JJ N
complications NNS N
. . N

Because IN N
few JJ N
studies NNS N
compare VBP N
methods NNS N
of IN N
passive JJ N
warming NN N
, , N
we PRP N
used VBD N
an DT N
unblinded JJ N
, , N
prospective JJ N
, , N
experimental JJ N
, , N
randomized JJ N
design NN N
to TO N
compare VB N
the DT N
effectiveness NN o
of IN N
two CD N
passive JJ N
methods NNS N
of IN N
normothermia JJ N
management NN N
in IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
( ( N
PACU NNP N
) ) N
. . N

We PRP N
assigned VBD N
a DT N
total NN N
of IN N
578 CD p
adult NN p
ambulatory NN p
surgery NN p
patients NNS p
to TO N
either VB N
a DT N
control NN i
group NN i
that WDT N
was VBD N
given VBN N
two CD i
folded JJ i
, , i
warmed JJ i
cotton NN i
blankets NNS i
or CC i
a DT i
treatment NN i
group NN i
that WDT i
was VBD i
given VBN i
a DT i
warmed NN i
, , i
unfolded JJ i
cotton NN i
sheet NN i
and CC i
cotton NN i
blanket NN i
. . i

We PRP N
recorded VBD N
patients NNS o
' POS o
temperatures NNS o
on IN o
their PRP$ o
arrival NN o
in IN o
the DT o
PACU NNP o
and CC o
at IN o
30 CD o
minutes NNS o
after IN o
arrival NN o
. . o

The DT N
treatment NN N
group NN N
had VBD N
temperatures NNS o
that WDT N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
control NN N
group NN N
30 CD N
minutes NNS N
after IN N
arrival NN N
in IN N
the DT N
PACU NNP N
, , N
and CC N
the DT N
treatment NN N
group NN N
experienced VBD N
a DT N
greater JJR N
change NN o
in IN o
temperature NN o
from IN N
baseline NN N
measurements NNS N
to TO N
those DT N
taken VBN N
at IN N
30 CD N
minutes NNS N
. . N

The DT N
treatment NN N
group NN N
also RB N
used VBD N
fewer JJR N
warmed JJ N
blankets NNS N
, , N
resulting VBG N
in IN N
cost NN N
savings NNS N
for IN N
the DT N
PACU NNP N
. . N

-DOCSTART- -11701433- O O

Oral JJ o
estrogen NN o
antagonizes VBZ o
the DT o
metabolic JJ o
actions NNS o
of IN o
growth NN o
hormone NN o
in IN o
growth NN o
hormone-deficient JJ o
women NNS o
. . o

We PRP N
have VBP N
determined VBN N
whether IN N
oral JJ i
estrogen NN i
reduces VBZ N
the DT N
biological JJ N
effects NNS N
of IN N
growth NN N
hormone NN N
( ( N
GH NNP N
) ) N
in IN N
GH-deficient NNP p
( ( p
GHD NNP p
) ) p
women NNS p
compared VBN N
with IN N
transdermal JJ i
estrogen NN i
treatment NN N
. . N

In IN p
two CD p
separate JJ p
studies NNS p
, , p
eight CD p
GHD NNP p
women NNS p
randomly RB N
received VBD N
either CC N
oral JJ i
or CC i
transdermal JJ i
estrogen NN i
for IN N
8 CD N
wk NN N
before IN N
crossing VBG N
over IN N
to TO N
the DT N
alternate JJ N
route NN N
of IN N
administration NN N
. . N

The DT N
first JJ N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
incremental JJ N
doses NNS N
of IN N
GH NNP N
( ( N
0.5 CD N
, , N
1.0 CD N
, , N
2.0 CD N
IU/day NNP N
for IN N
1 CD N
wk NNS N
each DT N
) ) N
on IN N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
levels NNS N
during IN N
each DT N
estrogen NN i
treatment NN i
phase NN N
. . N

The DT N
second JJ N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
GH NNP N
( ( N
2 CD N
IU/day NNP N
) ) N
on IN N
lipid JJ N
oxidation NN N
and CC N
on IN N
protein NN N
metabolism NN N
using VBG N
the DT N
whole JJ N
body NN N
leucine JJ N
turnover NN N
technique NN N
. . N

Mean JJ o
IGF-I JJ o
level NN o
was VBD o
significantly RB o
lower JJR o
during IN o
oral JJ o
estrogen NN o
treatment NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
rose VBD o
dose NNS o
dependently RB o
during IN o
GH NNP o
administration NN o
by IN N
a DT N
lesser JJR N
magnitude NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
compared VBN N
with IN N
transdermal JJ i
treatment NN i
. . i

Postprandial NNP o
lipid JJ o
oxidation NN o
was VBD o
significantly RB o
lower JJR o
with IN o
oral JJ o
estrogen NN o
treatment NN N
, , N
both DT N
before IN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
during IN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
GH NNP N
administration NN N
, , N
compared VBN N
with IN N
transdermal JJ N
treatment NN N
. . N

Protein NNP o
synthesis NN o
was VBD N
lower JJR N
during IN N
oral JJ N
estrogen NN i
both DT N
before IN N
and CC N
during IN N
GH NNP i
administration NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Oral JJ i
estrogen NN i
antagonizes VBZ o
several JJ o
of IN o
the DT o
metabolic JJ o
actions NNS o
of IN o
GH NNP o
. . o

It PRP N
may MD N
aggravate VB o
body NN o
composition NN o
abnormalities NNS o
already RB N
present JJ N
in IN N
GHD NNP p
women NNS p
and CC N
attenuate VB o
the DT o
beneficial JJ o
effects NNS o
of IN o
GH NNP o
therapy NN o
. . o

Estrogen NNP i
replacement NN i
in IN N
GHD NNP p
women NNS p
should MD o
be VB o
administered VBN o
by IN o
a DT o
nonoral JJ o
route NN o
. . o

-DOCSTART- -701664- O O

Poylmerized VBN i
whole JJ i
ragweed NN i
: : i
an DT N
improved JJ N
method NN N
of IN N
immunotherapy NN N
. . N

A DT N
single-blind JJ N
study NN N
compared VBN N
the DT N
effectiveness NN N
of IN N
glutaraldehyde-treated JJ i
polymerized NNS i
ragweed VBP i
with IN N
nonpolymerized JJ i
monomeric JJ i
ragweed NN i
. . i

These DT N
studies NNS N
are VBP N
an DT N
extension NN N
of IN N
those DT N
previously RB N
reported VBN N
for IN N
polymerized JJ N
AgE NNP N
using VBG N
a DT N
readily RB N
available JJ N
ragweed NN N
preparation NN N
containing VBG N
all DT N
ragweed NN i
antigens NNS N
. . N

Nineteen JJ p
ragweed-sensitive JJ p
patients NNS p
were VBD p
randomized VBN p
into IN p
2 CD p
groups NNS p
; : p
10 CD p
received VBD p
the DT p
polymerized JJ i
form NN i
and CC p
9 CD p
received VBD p
the DT p
monomeric JJ i
form NN i
. . i

Four CD N
parameters NNS N
were VBD N
followed VBN N
: : N
serum-specific JJ i
IgE NNP i
against IN N
antigen NN N
E NNP N
, , N
total JJ N
blocking VBG N
antibody NN N
against IN N
antigen NN N
E NNP N
, , N
local JJ N
and CC N
systemic JJ N
reactions NNS N
to TO N
injection NN N
therapy NN N
, , N
and CC N
symptom NN N
score NN N
indices NNS N
. . N

Pretreatment NNP N
levels NNS N
of IN N
antigen NN N
E NNP N
-- : N
specific JJ N
IgE NNP N
and CC N
blocking VBG N
antibody NN N
activity NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

After IN N
a DT N
total NN N
of IN N
15,000 CD N
protein NNS N
nitrogen JJ N
units NNS N
( ( N
PNU NNP N
) ) N
had VBD N
been VBN N
given VBN N
, , N
blocking VBG o
antibody NN o
activity NN o
in IN N
the DT N
monomer NN N
group NN N
rose VBD N
from IN N
a DT N
mean NN N
of IN N
170 CD N
ng JJ N
AgE NNP N
bound NN N
per IN N
ml NN N
to TO N
a DT N
mean NN N
of IN N
2,813 CD N
. . N

The DT N
rise NN o
in IN o
blocking VBG o
antibody NN o
activity NN o
in IN N
the DT N
polymer NN N
group NN N
was VBD N
from IN N
a DT N
mean NN N
of IN N
181 CD N
ng JJ N
AgE NNP N
bound NN N
per IN N
ml NN N
to TO N
1,574 CD N
. . N

At IN N
15,000 CD N
PNU NNP N
, , N
blocking VBG o
antibody NN o
activity NN o
levels NNS o
were VBD N
not RB N
statistically RB N
different JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

After IN N
1 CD N
year NN N
of IN N
treatment NN N
, , N
no DT N
consistent JJ N
decrease NN N
in IN N
postseasonal JJ o
specific JJ o
IgE NNP o
rise NN o
could MD N
be VB N
shown VBN N
in IN N
either DT N
group NN N
. . N

Forty NNP N
times NNS N
less RBR N
erythema JJ o
and CC N
15 CD N
times NNS N
less JJR N
induration NN o
were VBD N
found VBN N
with IN N
polymerized JJ i
ragweed NN i
. . i

There EX N
were VBD N
7 CD N
systemic JJ o
reactions NNS o
with IN N
the DT N
monomer NN N
and CC N
none NN N
with IN N
the DT N
polymer NN N
. . N

Both DT N
groups NNS N
experienced VBD N
symptomatic JJ o
improvement NN o
with IN N
treatment NN N
. . N

-DOCSTART- -11369627- O O

Immune NNP N
reconstitution NN N
after IN N
allogeneic JJ i
marrow NN i
transplantation NN i
compared VBN p
with IN p
blood NN i
stem NN i
cell NN i
transplantation NN i
. . i

Allogeneic NNP N
peripheral JJ N
blood NN N
stem NN N
cell NN N
grafts NNS N
contain VBP N
about IN N
10 CD N
times NNS N
more RBR N
T NNP N
and CC N
B NNP N
cells NNS N
than IN N
marrow JJ N
grafts NNS N
. . N

Because IN N
these DT N
cells NNS N
may MD N
survive VB N
in IN N
transplant JJ N
recipients NNS N
for IN N
a DT N
long JJ N
time NN N
, , N
recipients NNS p
of IN p
blood NN p
stem NN p
cells NNS p
may MD N
be VB N
less JJR N
immunocompromised JJ N
than IN N
recipients NNS p
of IN p
marrow NN p
. . p

Immune NNP N
reconstitution NN N
was VBD N
studied VBN N
in IN N
115 CD p
patients NNS p
randomly RB p
assigned VBN p
to TO p
receive VB p
either DT p
allogeneic JJ i
marrow NN i
or CC i
filgrastim-mobilized JJ i
blood NN i
stem NN i
cell NN i
transplantation NN i
. . i

Between NNP N
day NN N
30 CD N
and CC N
365 CD N
after IN N
transplantation NN i
, , N
counts NNS o
of IN o
most JJS o
lymphocyte JJ o
subsets NNS o
were VBD N
higher JJR N
in IN N
the DT N
blood NN N
stem NN N
cell NN N
recipients NNS N
. . N

The DT N
difference NN N
was VBD N
most RBS N
striking JJ N
for IN N
CD4 NNP o
T NNP o
cells NNS o
( ( N
about IN N
4-fold CD N
higher JJR N
counts NNS N
for IN N
CD45RA NNP N
( ( N
high JJ N
) ) N
CD4 NNP N
T NNP N
cells NNS N
and CC N
about IN N
2-fold JJ N
higher JJR N
counts NNS N
for IN N
CD45RA NNP o
( ( o
low/- JJ o
) ) o
CD4 NNP o
T NNP o
cells NNS o
; : o
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

On IN N
assessment NN N
using VBG N
phytohemagglutinin NN o
and CC N
herpesvirus VB o
antigen-stimulated JJ o
proliferation NN o
, , o
T NNP o
cells NNS o
in IN N
the DT N
2 CD N
groups NNS N
of IN N
patients NNS N
appeared VBD o
equally RB o
functional JJ o
. . o

Median JJ o
serum NN o
IgG NNP o
levels NNS o
were VBD N
similar JJ o
in IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
rate NN o
of IN o
definite NN o
infections NNS o
after IN o
engraftment NN o
was VBD N
1.7-fold JJ N
higher JJR N
in IN N
marrow NN N
recipients NNS N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

The DT N
rate NN o
of IN o
severe JJ o
( ( o
inpatient JJ o
treatment NN o
required VBN o
) ) o
definite NN o
infections NNS o
after IN o
engraftment NN o
was VBD N
2.4-fold JJ N
higher JJR N
in IN N
marrow NN N
recipients NNS N
( ( N
P NNP N
=.002 NNP N
) ) N
. . N

The DT N
difference NN o
in IN o
the DT o
rates NNS o
of IN o
definite JJ o
infections NNS o
was VBD N
greatest JJS o
for IN N
fungal JJ N
infections NNS N
, , N
intermediate NN o
for IN N
bacterial JJ N
infections NNS N
, , N
and CC N
lowest JJS o
for IN N
viral JJ N
infections NNS N
. . N

Death NNP o
associated VBD o
with IN o
a DT o
fungal NN o
or CC o
bacterial JJ o
infection NN o
occurred VBD o
between IN o
day NN o
30 CD o
and CC o
day NN o
365 CD o
after IN N
transplantation NN i
in IN N
9 CD N
marrow NN i
recipients NNS N
and CC N
no DT N
blood NN i
stem NN i
cell NN i
recipients NNS N
( ( N
P NNP N
=.008 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
blood NN i
stem NN i
cell NN i
recipients NNS N
have VBP N
higher JJR N
lymphocyte-subset JJ o
counts NNS o
and CC N
this DT N
appears VBZ N
to TO N
result VB N
in IN N
fewer JJR N
infections NNS o
. . o

( ( N
Blood NNP N
. . N

2001 CD N
; : N
97:3380-3389 CD N
) ) N
-DOCSTART- -16413605- O O

Project NN p
Towards NNP p
No NNP p
Drug NNP p
Abuse NNP p
: : p
long-term JJ N
substance NN N
use NN N
outcomes VBZ N
evaluation NN N
. . N

OBJECTIVES CC N
This DT N
paper NN N
presents VBZ N
up IN N
to TO N
5 CD N
years NNS N
post-program JJ N
outcomes NNS N
of IN N
Project NNP p
Towards NNP p
No NNP p
Drug NNP p
Abuse NNP p
( ( p
Project NNP p
TND NNP p
) ) p
, , p
a DT p
drug NN p
abuse NN p
prevention NN p
program NN p
conducted VBN p
in IN p
South NNP p
California NNP p
alternative JJ p
high JJ p
school NN p
system NN p
during IN p
years NNS p
1994-1999 JJ p
. . p

METHODS PDT N
The DT N
effects NNS N
of IN N
a DT N
9-session JJ N
health NN i
motivation NN i
-- : i
social JJ i
skills NNS i
-- : i
decision-making JJ i
curriculum NN N
were VBD N
evaluated VBN N
. . N

Twenty-one CD p
schools NNS p
recruited VBN N
were VBD N
randomly RB N
assigned VBN N
to TO N
standard VB i
care NN i
( ( i
control NN i
) ) i
, , i
classroom NN i
only RB i
, , N
or CC N
a DT N
classroom NN i
plus CC i
semester-long JJ i
school-as-community JJ i
component NN i
. . i

Last JJ N
30-day JJ N
use NN N
of IN N
cigarettes NNS N
, , N
alcohol NN N
, , N
marijuana NN N
, , N
and CC N
hard JJ N
drugs NNS N
were VBD N
assessed VBN N
at IN N
three CD N
time NN N
intervals NNS N
: : N
short-term JJ N
( ( N
year NN N
1 CD N
) ) N
, , N
middle-term JJ N
( ( N
years NNS N
2 CD N
or CC N
3 CD N
) ) N
, , N
and CC N
long-term JJ N
( ( N
years NNS N
4 CD N
or CC N
5 CD N
) ) N
. . N

Multilevel NNP N
random JJ N
coefficients NNS N
modeling VBG N
were VBD N
employed VBN N
to TO N
estimate VB N
the DT N
adjusted JJ N
levels NNS N
of IN N
substance NN N
use NN N
. . N

RESULTS NNP N
Among IN p
1578 CD p
baseline NN p
subjects NNS p
, , p
follow-up JJ p
data NNS p
were VBD p
available JJ p
for IN p
68 CD p
% NN p
( ( p
year NN p
1 CD p
) ) p
, , p
66 CD p
% NN p
( ( p
years NNS p
2 CD p
or CC p
3 CD p
) ) p
, , p
and CC p
46 CD p
% NN p
( ( p
years NNS p
4 CD p
or CC p
5 CD p
) ) p
of IN p
subjects NNS p
, , p
respectively RB p
. . p

Results NNS N
revealed VBD N
significant JJ N
positive JJ N
long-term JJ N
program NN N
effects NNS N
for IN N
hard JJ N
drug NN N
use NN N
at IN N
year NN N
4 CD N
or CC N
5 CD N
for IN N
the DT N
two CD N
program NN N
interventions NNS N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NNP N
Project NNP N
TND NNP N
reduced VBD N
hard JJ N
drug NN N
use NN N
in IN N
the DT N
46 CD N
% NN N
who WP N
were VBD N
successfully RB N
followed VBN N
. . N

It PRP N
is VBZ N
the DT N
first JJ N
program NN N
to TO N
demonstrate VB N
long-term JJ N
self-reported JJ N
behavioral JJ N
effects NNS N
on IN N
hard JJ N
drug NN N
use NN N
among IN N
high-risk JJ p
youth NN p
by IN N
using VBG N
a DT N
school-based JJ N
, , N
limited-session JJ N
model NN N
. . N

-DOCSTART- -12020338- O O

Effect NN N
of IN N
intensive JJ i
therapy NN i
on IN N
the DT N
microvascular JJ o
complications NNS o
of IN p
type NN p
1 CD p
diabetes NNS p
mellitus RB p
. . p

The DT N
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
summarize VB N
and CC N
integrate VB N
the DT N
findings NNS N
of IN N
the DT N
Diabetes NNP N
Control NNP N
and CC N
Complications NNP N
Trial NNP N
( ( N
DCCT NNP N
) ) N
, , N
a DT N
randomized VBN N
controlled JJ N
clinical JJ N
trial NN N
, , N
and CC N
the DT N
succeeding JJ N
observational JJ N
follow-up NN N
of IN N
the DT N
DCCT NNP N
cohort NN N
in IN N
the DT N
Epidemiology NNP N
of IN N
Diabetes NNP N
Interventions NNP N
and CC N
Complications NNP N
( ( N
EDIC NNP N
) ) N
study NN N
, , N
regarding VBG N
the DT N
effects NNS N
of IN N
intensive JJ i
treatment NN i
on IN N
the DT N
microvascular JJ o
complications NNS o
of IN p
type NN p
1 CD p
diabetes NNS p
mellitus RB p
. . p

The DT N
DCCT NNP N
proved VBD N
that IN N
intensive JJ i
treatment NN i
reduced VBD N
the DT N
risks NNS N
of IN N
retinopathy NN o
, , o
nephropathy JJ o
, , o
and CC o
neuropathy JJ o
by IN N
35 CD N
% NN N
to TO N
90 CD N
% NN N
compared VBN N
with IN N
conventional JJ N
treatment NN N
. . N

The DT N
absolute JJ N
risks NNS N
of IN N
retinopathy NN o
and CC N
nephropathy JJ o
were VBD N
proportional JJ N
to TO N
the DT N
mean NN o
glycosylated VBD o
hemoglobin NN o
( ( o
HbA NNP o
( ( o
1c CD o
) ) o
) ) o
level NN o
over IN N
the DT N
follow-up JJ N
period NN N
preceding VBG N
each DT N
event NN N
. . N

Intensive JJ i
treatment NN i
was VBD N
most RBS N
effective JJ N
when WRB N
begun VBN N
early RB N
, , N
before IN N
complications NNS N
were VBD N
detectable JJ N
. . N

These DT N
risk NN N
reductions NNS N
, , N
achieved VBN N
at IN N
a DT N
median JJ o
HbA NNP o
( ( o
1c CD o
) ) o
level NN o
difference NN N
of IN N
9.1 CD N
% NN N
for IN N
conventional JJ N
treatment NN N
vs RB N
7.3 CD N
% NN N
for IN N
intensive JJ i
treatment NN i
have VBP N
been VBN N
maintained VBN N
through IN N
7 CD N
years NNS N
of IN N
EDIC NNP N
, , N
even RB N
though IN N
the DT N
difference NN o
in IN o
mean JJ o
HbA NNP o
( ( o
1c CD o
) ) o
levels NNS o
of IN N
the DT N
2 CD N
former JJ N
randomized VBN N
treatment NN N
groups NNS N
was VBD N
only RB N
0.4 CD N
% NN N
at IN N
1 CD N
year NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
( ( N
8.3 CD N
% NN N
in IN N
the DT N
former JJ N
conventional JJ N
treatment NN N
group NN N
vs VBD N
7.9 CD N
% NN N
in IN N
the DT N
former JJ N
intensive JJ i
treatment NN i
group NN N
) ) N
, , N
continued VBD N
to TO N
narrow VB N
, , N
and CC N
became VBD N
statistically RB N
nonsignificant JJ N
by IN N
5 CD N
years NNS N
( ( N
8.1 CD N
% NN N
vs JJ N
8.2 CD N
% NN N
, , N
P NNP N
=.09 NNP N
) ) N
. . N

The DT N
further JJ N
rate NN o
of IN o
progression NN o
of IN o
complications NNS o
from IN N
their PRP$ N
levels NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
DCCT NNP N
remains VBZ N
less RBR N
in IN N
the DT N
former JJ N
intensive JJ i
treatment NN i
group NN N
. . N

Thus RB N
, , N
the DT N
benefits NNS N
of IN N
6.5 CD N
years NNS N
of IN N
intensive JJ i
treatment NN i
extend VBP N
well RB N
beyond IN N
the DT N
period NN N
of IN N
its PRP$ N
most RBS N
intensive JJ N
implementation NN N
. . N

Intensive JJ i
treatment NN i
should MD N
be VB N
started VBN N
as RB N
soon RB N
as IN N
is VBZ N
safely RB N
possible JJ N
after IN N
the DT N
onset NN N
of IN N
type NN p
1 CD p
diabetes NNS p
mellitus NN p
and CC N
maintained VBD N
thereafter RB N
, , N
aiming VBG N
for IN N
a DT N
practicable JJ N
target NN o
HbA NNP o
( ( o
1c CD o
) ) o
level NN o
of IN N
7.0 CD N
% NN N
or CC N
less JJR N
. . N

-DOCSTART- -2648816- O O

Adequacy NNP N
of IN N
hot JJ N
biopsy NN N
for IN N
the DT N
treatment NN N
of IN N
diminutive JJ N
polyps NNS N
: : N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

Patients NNS p
with IN p
diminutive JJ p
polyps NNS p
in IN p
the DT p
rectum NN p
or CC p
sigmoid JJ p
colon NN p
were VBD N
randomized VBN i
to TO i
hot JJ i
biopsy NN i
treatment NN i
for IN i
either DT i
1 CD i
) ) i
electrocautery NN i
for IN i
2 CD i
s NNS i
( ( i
fixed VBN i
duration NN i
cautery NN i
) ) i
or CC i
2 CD i
) ) i
cautery NN i
until IN i
visible JJ i
necrosis NN i
of IN i
the DT i
polyp NN i
base NN i
was VBD i
evident JJ i
( ( i
variable JJ i
duration NN i
cautery NN i
) ) i
. . i

Sigmoidoscopy NNP i
was VBD i
performed VBN i
4 CD i
wk NN i
after IN i
treatment NN i
to TO i
determine VB i
the DT i
adequacy NN i
of IN i
polyp JJ i
eradication NN i
. . i

In IN N
the DT N
fixed JJ N
duration NN N
cautery NN N
group NN N
, , N
11 CD N
of IN N
21 CD N
polyps NNS N
( ( N
52 CD N
% NN N
) ) N
were VBD N
eradicated VBN o
, , N
compared VBN N
with IN N
12 CD N
of IN N
14 CD N
polyps NNS N
( ( N
86 CD N
% NN N
) ) N
in IN N
the DT N
variable JJ N
duration NN N
cautery NN N
group NN N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

When WRB N
analyzed JJ N
according VBG N
to TO N
whether IN N
or CC N
not RB N
visible JJ o
necrosis NN o
was VBD N
achieved VBN N
( ( N
some DT N
of IN N
the DT N
polyps NNS N
in IN N
the DT N
fixed JJ N
duration NN N
cautery NN N
group NN N
showed VBD N
necrosis NN N
with IN N
2 CD N
s JJ N
cautery NN N
) ) N
, , N
19 CD N
of IN N
23 CD N
polyps NNS N
( ( N
83 CD N
% NN N
) ) N
were VBD N
eradicated VBN o
when WRB N
necrosis NN N
was VBD N
evident JJ N
, , N
compared VBN N
to TO N
5 CD N
of IN N
12 CD N
( ( N
42 CD N
% NN N
) ) N
without IN N
necrosis NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
hot JJ N
biopsy NN N
treatment NN N
for IN N
diminutive JJ N
polyps NNS N
is VBZ N
significantly RB N
more RBR N
effective JJ N
when WRB N
visible JJ N
necrosis NN N
is VBZ N
achieved VBN N
during IN N
cautery NN N
. . N

Furthermore NNP N
, , N
even RB N
with IN N
visible JJ N
necrosis NN N
, , N
there EX N
is VBZ N
a DT N
17 CD N
% NN N
failure NN N
rate NN N
of IN N
polyp NN N
eradication NN N
. . N

-DOCSTART- -26385172- O O

An DT N
endovascular JJ i
simulation NN i
exercise NN i
among IN N
radiology JJ p
residents NNS p
: : p
comparison NN o
of IN N
simulation NN o
performance NN o
with IN N
and CC N
without IN N
practice NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
compare VB o
resident JJ N
endovascular JJ o
simulator NN o
performance NN o
with IN N
and CC N
without IN N
prior JJ i
simulation NN i
. . i

METHODS NNP N
Radiology NNP p
residents NNS p
were VBD N
guided VBN i
through IN i
a DT i
practice NN i
simulation NN i
and CC i
lectured VBN i
on IN i
endovascular JJ i
therapy NN i
, , i
then RB i
randomized VBD i
to TO i
simulate VB i
femoral JJ i
arterial JJ i
intervention NN i
with IN i
or CC i
without IN i
prior JJ i
iliac JJ i
simulation NN i
. . i

Simulator NN o
measurements NNS o
, , o
performance NN o
grading NN o
and CC o
resident JJ o
surveys NNS o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Prior NNP i
simulation NN i
of IN i
iliac JJ i
intervention NN i
significantly RB N
improved VBN N
resident JJ o
performance NN o
. . o

In IN N
particular JJ N
, , N
it PRP N
resulted VBD N
in IN N
less RBR o
catheter JJ o
placement NN o
without IN o
a DT o
wire NN o
( ( N
P=.01 NNP N
) ) N
, , N
shorter JJR o
time NN o
to TO o
proper VB o
catheter NN o
positioning NN o
( ( N
P=.045 NNP N
) ) N
and CC N
use NN o
of IN o
oblique JJ o
digital JJ o
subtraction NN o
angiography NN o
( ( N
P=.035 NNP N
) ) N
. . N

Survey JJ N
respondents NNS N
valued VBD N
the DT N
experience NN N
. . N

CONCLUSION NNP N
Endovascular NNP i
simulator NN i
training VBG i
improves NNS N
simulation NN o
skills NNS o
. . o

Improvement NN N
of IN N
real-world JJ N
performance NN o
and CC N
generalizability NN N
remain VBP N
to TO N
be VB N
shown VBN N
. . N

-DOCSTART- -20109864- O O

Catheter NNP i
ablation NN i
of IN i
stable JJ i
ventricular JJ i
tachycardia NN i
before IN p
defibrillator NN i
implantation NN p
in IN p
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
( ( p
VTACH NNP p
) ) p
: : p
a DT N
multicentre NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
In IN N
patients NNS p
with IN p
ventricular JJ p
tachycardia NN p
( ( p
VT NNP p
) ) p
and CC p
a DT p
history NN p
of IN p
myocardial JJ p
infarction NN p
, , N
intervention NN N
with IN N
an DT N
implantable JJ i
cardioverter NN i
defibrillator NN i
( ( i
ICD NNP i
) ) i
can MD N
prevent VB N
sudden JJ N
cardiac JJ N
death NN N
and CC N
thereby RB N
reduce VB N
total JJ N
mortality NN N
. . N

However RB N
, , N
ICD NNP N
shocks NNS N
are VBP N
painful JJ N
and CC N
do VBP N
not RB N
provide VB N
complete JJ N
protection NN N
against IN N
sudden JJ N
cardiac JJ N
death NN N
. . N

We PRP N
assessed VBD N
the DT N
potential JJ N
benefit NN N
of IN N
catheter NN i
ablation NN i
before IN N
implantation NN N
of IN N
a DT N
cardioverter NN N
defibrillator NN N
. . N

METHODS NNP N
The DT p
Ventricular NNP p
Tachycardia NNP p
Ablation NNP p
in IN p
Coronary NNP p
Heart NNP p
Disease NNP p
( ( p
VTACH NNP p
) ) p
study NN p
was VBD p
a DT p
prospective JJ p
, , p
open JJ p
, , p
randomised VBD p
controlled VBN p
trial NN p
, , p
undertaken VBN p
in IN p
16 CD p
centres NNS p
in IN p
four CD p
European JJ p
countries NNS p
. . p

Patients NNS p
aged VBN p
18-80 CD p
years NNS p
were VBD p
eligible JJ p
for IN p
enrolment NN p
if IN p
they PRP p
had VBD p
stable JJ p
VT NNP p
, , p
previous JJ p
myocardial JJ p
infarction NN p
, , p
and CC p
reduced VBD p
left-ventricular JJ p
ejection NN p
fraction NN p
( ( p
LVEF NNP p
; : p
< NNP p
or=50 IN p
% NN p
) ) p
. . p

110 CD p
patients NNS p
were VBD p
randomly RB p
allocated VBN p
in IN p
a DT p
1:1 CD p
ratio NN p
to TO N
receive VB i
catheter NN i
ablation NN i
and CC i
an DT i
ICD NNP i
( ( i
ablation NN i
group NN i
, , i
n=54 RB i
) ) i
or CC i
ICD NNP i
alone RB i
( ( i
control NN i
group NN i
, , i
n=56 RB i
) ) i
. . i

Randomisation NN N
was VBD N
done VBN N
by IN N
computer-generated JJ N
randomly NNS N
permuted VBN N
blocks NNS N
and CC N
stratified VBN N
by IN N
centre NN N
and CC N
LVEF NNP N
( ( N
< JJ N
or=30 CD N
% NN N
or CC N
> VB N
30 CD N
% NN N
) ) N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
at IN N
least JJS N
1 CD N
year NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time NN o
to TO o
first JJ o
recurrence NN o
of IN o
VT NNP o
or CC o
ventricular JJ o
fibrillation NN o
( ( o
VF NNP o
) ) o
. . o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
( ( N
ITT NNP N
) ) N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00919373 NNP N
. . N

FINDINGS NNP N
107 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
ITT NNP p
population NN p
( ( i
ablation NN i
group NN i
, , p
n=52 RB p
; : p
control NN i
group NN p
, , p
n=55 RB p
) ) p
. . p

Two CD N
patients NNS N
( ( N
one CD N
in IN N
each DT N
group NN N
) ) N
withdrew VBD N
consent NN N
immediately RB N
after IN N
randomisation NN N
without IN N
any DT N
follow-up JJ N
data NNS N
and CC N
one CD N
patient NN N
( ( N
ablation NN N
group NN N
) ) N
was VBD N
excluded VBN N
because IN N
of IN N
a DT N
protocol NN N
violaton NN N
. . N

Mean JJ N
follow-up NN N
was VBD N
22.5 CD N
months NNS N
( ( N
SD NNP N
9.0 CD N
) ) N
. . N

Time NN o
to TO o
recurrence NN o
of IN o
VT NNP o
or CC o
VF NNP o
was VBD N
longer RBR N
in IN N
the DT N
ablation NN i
group NN i
( ( N
median JJ N
18.6 CD N
months NNS N
[ NNP N
lower JJR N
quartile NN N
2.4 CD N
, , N
upper JJ N
quartile NN N
not RB N
determinable JJ N
] NN N
) ) N
than IN N
in IN N
the DT N
control NN i
group NN i
( ( N
5.9 CD N
months NNS N
[ JJ N
IQR NNP N
0.8-26.7 NNP N
] NNP N
) ) N
. . N

At IN N
2 CD N
years NNS N
, , N
estimates NNS N
for IN N
survival JJ o
free JJ N
from IN N
VT NNP o
or CC o
VF NNP o
were VBD N
47 CD N
% NN N
in IN N
the DT N
ablation NN i
group NN i
and CC N
29 CD N
% NN N
in IN N
the DT N
control NN i
group NN i
( ( N
hazard JJ N
ratio NN N
0.61 CD N
; : N
95 CD N
% NN N
CI NNP N
0.37-0.99 CD N
; : N
p=0.045 NN N
) ) N
. . N

Complications NNS N
related VBN N
to TO N
the DT N
ablation NN N
procedure NN N
occurred VBD N
in IN N
two CD N
patients NNS N
; : N
no DT o
deaths NNS o
occurred VBD N
within IN N
30 CD N
days NNS N
after IN N
ablation NN N
. . N

15 CD N
device-related JJ N
complications NNS N
requiring VBG N
surgical JJ N
intervention NN N
occurred VBD N
in IN N
13 CD N
patients NNS N
( ( i
ablation NN i
group NN i
, , N
four CD N
; : N
control NN i
group NN i
, , N
nine CD N
) ) N
. . N

Nine JJ p
patients NNS p
died VBD o
during IN p
the DT p
study NN p
( ( i
ablation NN i
group NN p
, , p
five CD p
; : p
control NN i
group NN p
, , p
four CD p
) ) p
. . p

INTERPRETATION NNP N
Prophylactic NNP i
VT NNP i
ablation NN i
before IN N
defibrillator NN i
implantation NN i
seemed VBD N
to TO N
prolong VB N
time NN N
to TO N
recurrence NN N
of IN N
VT NNP N
in IN N
patients NNS p
with IN p
stable JJ p
VT NNP p
, , p
previous JJ p
myocardial JJ p
infarction NN p
, , p
and CC p
reduced VBD p
LVEF NNP p
. . p

Prophylactic NNP i
catheter NN i
ablation NN i
should MD N
therefore RB N
be VB N
considered VBN N
before IN N
implantation NN N
of IN N
a DT N
cardioverter NN i
defibrillator NN i
in IN N
such JJ N
patients NNS N
. . N

FUNDING NNP N
St NNP N
Jude NNP N
Medical NNP N
. . N

-DOCSTART- -6350412- O O

[ JJ N
Effect NNP N
on IN N
pressure NN N
after IN N
instillation NN N
of IN N
a DT N
drop NN N
of IN N
depot-pilocarpine NN i
. . i

Clinical JJ N
results NNS N
of IN N
its PRP$ N
medium-term JJ N
action NN N
] NNP N
. . N

A NNP N
clinical JJ N
comparison NN N
of IN N
an DT N
emulsion NN N
containing VBG N
a DT N
new JJ i
pilocarpine NN i
polymer NN i
( ( i
Polym NNP i
) ) i
compound NN N
to TO N
that DT N
of IN N
a DT N
traditional JJ i
pilocarpine NN i
salt NN i
solution NN i
( ( i
Plc NNP i
) ) i
on IN N
the DT N
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
has VBZ N
been VBN N
performed VBN N
in IN N
40 CD p
open-angle JJ p
patients NNS p
treated VBN p
with IN p
the DT p
long JJ p
acting JJ p
pilocarpine-complex NN p
for IN p
120 CD p
days NNS p
. . p

The DT N
treatment NN N
protocol NN N
was VBD N
divided VBN N
into IN N
3 CD N
stages NNS N
: : N
Stage NN N
1 CD N
is VBZ N
a DT N
single JJ N
dose NN N
treatment NN N
where WRB N
12 CD N
patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
groups NNS N
of IN N
6 CD N
each DT N
. . N

The DT N
patients NNS N
of IN N
each DT N
group NN N
were VBD N
given VBN i
1 CD i
drop NN i
into IN i
each DT i
eye NN i
: : i
1 CD i
drop NN i
every DT i
12 CD i
hours NNS i
for IN i
Polym NNP i
, , i
1 CD i
drop NN i
every DT i
6 CD i
hours NNS i
for IN i
Plc NNP i
. . i

The DT i
patients NNS i
were VBD i
observed VBN i
for IN i
a DT i
period NN i
of IN i
24 CD i
hours NNS i
. . i

After IN N
24 CD N
hours NNS N
without IN N
medication NN N
, , N
the DT N
treatments NNS N
were VBD N
crossed VBN N
over IN N
and CC N
nycthemeral JJ N
graph NN N
curves NNS N
were VBD N
registered VBN N
for IN N
both DT N
groups NNS N
. . N

Stage NN N
2 CD N
is VBZ N
a DT N
medium JJ N
term NN N
study NN N
were VBD N
the DT N
12 CD N
patients NNS N
used VBN N
in IN N
Stage NNP N
1 CD N
were VBD N
added VBN N
to TO N
another DT N
28 CD N
patients NNS N
. . N

All DT N
40 CD N
were VBD N
then RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
treatment NN N
groups NNS N
( ( N
2 CD N
groups NNS N
of IN N
20 CD N
patients NNS N
each DT N
) ) N
according VBG N
to TO N
a DT N
table NN N
of IN N
random NN N
numbers NNS N
. . N

Treatments NNS N
were VBD N
administered VBN N
during IN N
one CD N
month NN N
, , N
then RB N
cross-overed JJ N
again RB N
during IN N
4 CD N
weeks NNS N
. . N

Stage NN N
3 CD N
: : N
finally RB N
, , N
every DT N
patient NN N
could MD N
choose VB N
his PRP$ N
treatment NN N
( ( N
either CC N
Polym NNP i
or CC N
Plc NNP i
) ) i
for IN N
the DT N
rest NN N
of IN N
the DT N
period NN N
( ( N
2 CD N
months NNS N
) ) N
. . N

The DT N
clinical JJ N
study NN N
shows VBZ N
that IN N
the DT N
polymer NN N
complex NN N
( ( N
Polym NNP N
) ) N
produced VBD N
a DT N
prolonged JJ o
therapeutic JJ o
effect NN o
, , N
this DT N
being VBG N
consistant JJ N
with IN N
a DT N
slow JJ N
release NN N
pattern NN N
and CC N
maintained VBD N
a DT N
more RBR N
effective JJ N
around-the-clock NN N
control NN N
than IN N
pilocarpine JJ i
solution NN N
. . N

These DT N
results NNS N
were VBD N
accomplished VBN N
by IN N
two CD N
applications NNS N
per IN N
day NN N
as IN N
compared VBN N
to TO N
the DT N
four CD N
necessary JJ N
applications NNS N
of IN N
Plc NNP i
, , N
on IN N
a DT N
half JJ N
daily JJ N
pilocarpine NN i
dose NN N
with IN N
Polym NNP i
. . i

The DT N
medium JJ N
term NN N
results NNS N
confirmed VBD N
the DT N
efficacity NN o
noted VBD N
in IN N
the DT N
short JJ N
term NN N
survey NN N
. . N

Most JJS N
patients NNS N
preferred JJ N
Polym NNP i
to TO N
Plc VB i
when WRB N
they PRP N
were VBD N
asked VBN N
. . N

Throughout IN N
the DT N
4 CD N
months NNS N
study JJ N
period NN N
, , N
no DT N
adverse JJ o
side NN o
effects NNS o
were VBD N
reported VBN N
. . N

Visual JJ o
disturbances NNS o
characteristic NN N
of IN N
pilocarpine JJ i
eye-drops NNS N
were VBD N
reduced VBN N
from IN N
3 CD N
times NNS N
a DT N
day NN N
on IN N
pilocarpine NN i
salt NN i
solution NN N
to TO N
once VB N
a DT N
day NN N
on IN N
pilocarpine JJ i
polymer NN i
complex NN N
. . N

-DOCSTART- -7006663- O O

Report NN N
on IN N
the DT N
second JJ N
myelomatosis NN N
trial NN N
after IN N
five CD N
years NNS N
of IN N
follow-up NN N
. . N

Medical NNP N
Research NNP N
Council NNP N
's POS N
Working NNP N
Party NNP N
on IN N
Leukaemia NNP p
in IN p
Adults NNP p
. . p

Three CD p
hundred VBD p
and CC p
seventy-two JJ p
patients NNS p
were VBD N
randomized VBN N
between IN N
3 CD i
regimens NNS i
of IN i
chemotherapy NN i
: : i
cyclophosphamide NN i
, , i
intermittent NN i
melphalan NN i
, , i
and CC i
melphalan NN i
with IN i
prednisone NN i
, , i
and CC i
were VBD i
followed VBN i
up RP i
to TO i
death NN i
or CC i
for IN i
at IN i
least JJS i
5 CD i
years NNS i
. . i

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN o
between IN N
the DT N
treatments NNS N
, , N
either RB N
overall JJ N
or CC N
in IN N
any DT N
subgroup NN N
of IN N
patients NNS N
. . N

Therefore RB N
, , N
the DT N
choice NN N
among IN N
these DT N
3 CD N
treatments NNS N
should MD N
be VB N
guided VBN N
by IN N
the DT N
patient NN N
's POS N
comfort NN N
and CC N
convenience NN N
. . N

The DT N
most RBS N
important JJ N
prognostic JJ N
feature NN N
at IN N
presentation NN N
was VBD N
the DT N
quality NN N
of IN N
renal JJ o
function NN o
. . o

It PRP N
was VBD N
possible JJ N
to TO N
define VB N
good JJ p
, , p
intermediate JJ p
and CC p
poor JJ p
renal-function NN p
groups NNS p
which WDT N
were VBD N
highly RB N
correlated VBN N
with IN N
prognosis NN N
( ( N
X2 NNP N
for IN N
trend NN N
= NNP N
62.6 CD N
) ) N
. . N

The DT N
haemoglobin JJ o
level NN o
at IN N
presentation NN N
was VBD N
strongly RB N
correlated VBN N
with IN N
prognosis NN N
among IN N
patients NNS p
in IN p
the DT p
good JJ p
renal-function NN p
group NN p
. . p

Among IN N
107 CD p
patients NNS p
who WP p
presented VBD p
with IN p
good JJ p
renal JJ p
function NN p
and CC p
with IN p
haemoglobin NNS p
above IN p
100 CD p
g/l NN p
, , N
the DT N
5-year JJ N
survival NN o
was VBD N
43 CD N
% NN N
. . N

Other JJ N
prognostic JJ N
features NNS N
were VBD N
much RB N
less RBR N
important JJ N
when WRB N
account NN N
was VBD N
taken VBN N
of IN N
renal JJ N
function NN N
and CC N
haemoglobin JJ N
level NN N
. . N

-DOCSTART- -16880243- O O

Efficacy NN N
and CC N
safety NN N
of IN N
zoledronic JJ i
acid NN i
in IN N
patients NNS p
with IN p
breast JJ p
cancer NN p
metastatic NN p
to TO p
bone NN p
: : p
a DT N
multicenter NN N
clinical JJ N
trial NN N
. . N

PURPOSE VB N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
zoledronic JJ i
acid NN i
in IN N
breast NN p
cancer NN p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
bone NN p
metastases NNS p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Patients NNS p
diagnosed VBD p
with IN p
bone NN p
metastases NNS p
< VBP p
or CC p
= VBP p
6 CD p
weeks NNS p
prior RB p
to TO p
first JJ p
visit NN p
were VBD N
enrolled VBN N
. . N

Zoledronic JJ i
acid NN i
( ( N
4 CD N
mg NN N
) ) N
was VBD N
administered VBN N
via IN N
a DT N
15-minute JJ N
infusion NN N
every DT N
3 CD N
or CC N
4 CD N
weeks NNS N
for IN N
12 CD N
infusions NNS N
. . N

Skeletal-related JJ o
events NNS o
( ( o
SREs NNP o
) ) o
were VBD N
defined VBN N
as IN N
pathologic JJ N
bone NN N
fractures NNS N
, , N
spinal JJ N
cord NN N
compression NN N
, , N
surgery NN N
to TO N
bone VB N
, , N
radiation NN N
therapy NN N
to TO N
bone VB N
, , N
and CC N
hypercalcemia NN N
of IN N
malignancy NN N
. . N

Primary NNP N
efficacy JJ N
end NN N
points NNS N
were VBD N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
at IN N
least JJS N
one CD N
SRE NNP N
and CC N
the DT N
time NN N
to TO N
first JJ N
SRE NNP N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
pain NN o
, , o
analgesic JJ o
use NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

RESULTS NNP N
Among IN N
312 CD p
patients NNS p
enrolled VBD p
, , N
30 CD N
% NN N
experienced VBN N
at IN N
least JJS N
one CD N
SRE NNP o
during IN N
the DT N
12-month JJ N
study NN N
, , N
and CC N
22 CD N
% NN N
experienced VBD N
only RB N
one CD N
SRE NNP o
. . o

The DT N
median JJ N
time NN N
to TO N
first VB N
SRE NNP o
was VBD N
not RB N
reached VBN N
in IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

Mean NNP o
pain NN o
and CC o
analgesic JJ o
scores NNS o
declined VBD o
from IN N
baseline NN N
, , N
and CC N
quality-of-life JJ o
scores NNS o
remained VBD o
stable JJ o
to TO N
study VB N
end NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
events NNS N
, , N
regardless RB N
of IN N
relationship NN N
to TO N
study VB N
drug NN N
, , N
were VBD N
pyrexia VBN o
( ( N
22 CD N
% NN N
) ) N
and CC N
bone NN o
pain NN o
( ( N
10 CD N
% NN N
) ) N
. . N

Serum NNP o
creatinine NN o
levels NNS o
did VBD o
not RB o
significantly RB o
increase VB o
from IN N
baseline NN N
throughout IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
Breast NNP p
cancer NN p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
bone NN p
metastases NNS p
who WP N
were VBD N
treated VBN N
with IN N
zoledronic JJ i
acid NN i
had VBD N
a DT N
low JJ N
incidence NN N
of IN N
SREs NNP o
compared VBN N
with IN N
patients NNS N
who WP N
received VBD N
placebo NN i
in IN N
randomized JJ N
phase NN N
III NNP N
trials NNS N
, , N
and CC N
pain NN N
was VBD N
decreased VBN N
from IN N
baseline NN N
. . N

This DT N
study NN N
demonstrated VBD N
the DT N
favorable JJ N
risk NN N
: : N
benefit NN N
ratio NN N
of IN N
zoledronic JJ i
acid NN i
for IN N
the DT N
prevention NN N
of IN N
skeletal JJ N
complications NNS N
. . N

-DOCSTART- -25648577- O O

Baseline NNP N
distribution NN N
of IN N
participants NNS p
with IN p
depression NN p
and CC p
impaired JJ p
quality NN p
of IN p
life NN p
in IN N
the DT N
Treatment NNP N
of IN N
Preserved NNP N
Cardiac NNP N
Function NNP N
Heart NNP N
Failure NNP N
with IN N
an DT N
Aldosterone NNP N
Antagonist NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Previous NNP N
studies NNS N
have VBP N
demonstrated VBN N
the DT N
psychosocial JJ N
effect NN N
of IN N
heart NN N
failure NN N
in IN N
patients NNS p
with IN p
reduced JJ p
ejection NN p
fraction NN p
. . p

However RB N
, , N
the DT N
effects NNS N
on IN N
patients NNS N
with IN N
preserved JJ N
ejection NN N
fraction NN N
have VBP N
not RB N
yet RB N
been VBN N
elucidated VBN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
baseline NN N
characteristics NNS N
of IN N
participants NNS p
with IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
as IN N
it PRP N
relates VBZ N
to TO N
impaired JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
and CC N
depression NN N
, , N
identify JJ N
predictors NNS N
of IN N
poor JJ N
QOL NNP N
and CC N
depression NN N
, , N
and CC N
determine VB N
the DT N
correlation NN N
between IN N
QOL NNP N
and CC N
depression NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Among IN N
patients NNS p
enrolled VBN p
in IN p
the DT p
Treatment NNP p
of IN p
Preserved NNP p
Cardiac NNP p
Function NNP p
Heart NNP p
Failure NNP p
With IN p
an DT p
Aldosterone NNP i
Antagonist NNP i
Trial NNP i
( ( i
TOPCAT NNP i
) ) i
, , p
3400 CD p
patients NNS p
completed VBD p
the DT p
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
, , p
3395 CD p
patients NNS p
completed VBN p
European JJ o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
, , p
and CC p
1431 CD p
patients NNS p
in IN p
United NNP p
States NNPS p
and CC p
Canada NNP p
completed VBD p
the DT p
Patient NNP o
Health NNP o
Questionnaire-9 NNP o
. . o

The DT N
mean JJ N
summary JJ N
score NN N
on IN N
the DT N
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
was VBD N
54.8 CD N
, , N
and CC N
on IN N
European JJ o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
, , N
it PRP N
was VBD N
60.3 CD N
; : N
27 CD N
% NN N
of IN N
patients NNS N
had VBD N
moderate JJ N
to TO N
severe JJ N
depression NN N
. . N

Factors NNS N
associated VBD N
with IN N
better JJR N
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
and CC o
European NNP o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
were VBD N
American JJ N
region NN N
, , N
older JJR N
age NN N
, , N
no DT N
history NN N
of IN N
angina JJ N
pectoris NN N
or CC N
asthma NN N
, , N
no DT N
use NN N
of IN N
hypoglycemic JJ N
agent NN N
, , N
more JJR N
activity NN N
level NN N
, , N
and CC N
lower JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
. . N

Factors NNS N
associated VBD N
with IN N
depression NN N
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
included VBD N
younger JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
comorbid NN N
angina NN N
, , N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
, , N
use NN N
of IN N
a DT N
hypoglycemic JJ N
agent NN N
, , N
lower JJR N
activity NN N
level NN N
, , N
higher JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
, , N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
use NN N
. . N

There EX N
were VBD N
significant JJ N
correlations NNS N
between IN N
each DT N
of IN N
the DT N
QOL NNP o
scores NNS o
and CC o
depression NN o
. . o

CONCLUSIONS JJ N
Patients NNS p
with IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
, , p
who WP p
were VBD p
younger JJR p
had VBD p
higher JJR p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
or CC p
comorbid NN p
angina NNS p
pectoris NN p
, , p
had VBD p
lower JJR p
activity NN p
levels NNS p
, , p
lived VBD p
in IN p
Eastern NNP p
Europe NNP p
or CC p
were VBD p
taking VBG p
hypoglycemic JJ p
agents NNS p
, , N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
impaired VBN p
QOL NNP p
and CC p
depression NN p
. . p

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00094302 NNP N
. . N

-DOCSTART- -6992570- O O

Carbenicillin-trimethoprim/sulfamethoxazole JJ i
versus NN i
carbenicillin-gentamicin NN i
as IN N
empiric JJ N
therapy NN N
of IN N
infection NN N
in IN N
granulocytopenic JJ p
patients NNS p
. . p

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
. . N

The DT N
results NNS N
of IN N
therapy NN N
with IN N
carbenicillin JJ i
plus CC i
trimethoprim-sulfamethoxazole JJ i
( ( i
C-T/S NNP i
) ) i
were VBD i
compared VBN i
to TO i
those DT i
obtained VBN i
with IN i
carbenicillin JJ i
plus CC i
gentamicin JJ i
( ( i
C-G NNP i
) ) i
in IN N
a DT N
prospective JJ N
double-blind NN N
study NN N
of IN N
empiric JJ N
antibiotic JJ N
therapy NN N
in IN N
granulocytopenic JJ p
patients NNS p
. . p

Patients NNS p
were VBD p
stratified VBN p
into IN p
two CD p
groups NNS p
: : p
favorable-prognosis NN p
, , p
group NN p
1 CD p
( ( p
carcinoma NN p
, , p
lymphoma NN p
, , p
multiple JJ p
myeloma NN p
) ) p
, , p
or CC p
unfavorable-prognosis NN p
, , p
group NN p
2 CD p
( ( p
acute JJ p
leukemia NN p
, , p
bone NN p
marrow NN p
transplantation NN p
) ) p
, , p
based VBN p
on IN p
anticipated JJ p
duration NN p
of IN p
granulocytopenia NN p
. . p

Over-all NN N
, , N
empiric JJ N
antibiotic JJ N
trials NNS N
were VBD N
more RBR N
often RB N
successful JJ o
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
group NN N
1 CD N
( ( N
55 CD N
of IN N
62 CD N
patients NNS N
or CC N
89 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
group NN N
2 CD N
( ( N
42 CD N
of IN N
64 CD N
patients NNS N
, , N
66 CD N
per IN N
cent NN N
) ) N
mwithin NN N
group NN N
1 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ o
outcome NN o
in IN N
30 CD N
of IN N
32 CD N
( ( N
94 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
25 CD N
of IN N
30 CD N
( ( N
83 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
; : N
within IN N
group NN N
2 CD N
, , N
there EX N
was VBD N
a DT N
favorable JJ N
outcome NN N
in IN N
23 CD N
of IN N
30 CD N
( ( N
77 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
and CC N
in IN N
19 CD N
of IN N
34 CD N
( ( N
56 CD N
per IN N
cent NN N
) ) N
C-G NN N
trials NNS N
( ( N
P NNP N
= NNP N
0.14 CD N
) ) N
, , N
Combined VBN N
results NNS N
in IN N
both DT N
groups NNS N
indicated VBD N
a DT N
higher JJR N
proportion NN N
of IN N
favorable JJ o
outcome NN o
in IN N
C-T/S NNP N
trials NNS N
( ( N
53 CD N
of IN N
62 CD N
, , N
85 CD N
per IN N
cent NN N
) ) N
than IN N
in IN N
C-G JJ N
trials NNS N
( ( N
44 CD N
of IN N
64 CD N
, , N
69 CD N
per IN N
cent NN N
) ) N
. . N

Further JJ N
analysis NN o
( ( o
Manetl-Naenszel NNP o
test NN o
) ) o
showed VBD N
the DT N
over-all JJ N
difference NN N
in IN N
outcome NN N
to TO N
be VB N
significant JJ N
( ( N
P NNP N
= NNP N
0.049 CD N
) ) N
, , N
but CC N
the DT N
general JJ N
applicability NN N
of IN N
this DT N
result NN N
may MD N
be VB N
limited VBN N
by IN N
the DT N
rather RB N
low JJ N
incidence NN N
of IN N
gram-negative JJ N
bacterial JJ N
infections NNS N
in IN N
this DT N
study NN N
. . N

There EX N
was VBD N
no DT o
difference NN o
between IN N
the DT N
treatment NN N
regimens VBZ N
in IN N
antibiotic JJ o
toxicity NN o
, , N
and CC N
serious JJ o
superinfection NN o
occurred VBD N
only RB N
in IN N
group NN N
2 CD N
patients NNS N
( ( N
21 CD N
per IN N
cent NN N
of IN N
trials NNS N
) ) N
, , N
equally RB N
divided VBD N
between IN N
treatment NN N
arms NNS N
. . N

Initial JJ N
protocol NN N
dosing VBG N
achieved VBN N
target NN N
plasma NN N
levels NNS N
of IN N
trimethoprim NN N
( ( N
3 CD N
to TO N
8 CD N
micrograms/ml NN N
) ) N
or CC N
gentamicin NN N
( ( N
4 CD N
to TO N
10 CD N
micrograms/ml NN N
) ) N
in IN N
57 CD N
of IN N
68 CD N
( ( N
84 CD N
per IN N
cent NN N
) ) N
C-T/S NNP N
trials NNS N
compared VBN N
to TO N
21 CD N
of IN N
60 CD N
( ( N
35 CD N
per IN N
cent NN N
) ) N
C-G NNP N
trials NNS N
. . N

-DOCSTART- -15528910- O O

Acid NNP o
resistance NN o
of IN N
enamel JJ p
subsurface NN p
lesions NNS p
remineralized VBN p
by IN p
a DT p
sugar-free JJ i
chewing NN i
gum NN i
containing VBG p
casein JJ p
phosphopeptide-amorphous JJ p
calcium NN p
phosphate NN p
. . p

The DT N
aim NN N
of IN N
this DT N
clinical JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
acid JJ o
resistance NN o
of IN N
enamel JJ p
lesions NNS p
remineralized VBN p
in IN p
situ NN p
by IN p
a DT p
sugar-free JJ i
chewing NN i
gum NN i
containing VBG p
casein JJ p
phosphopeptide-amorphous JJ p
calcium NN p
phosphate NN p
nanocomplexes NNS p
( ( p
CPP-ACP JJ p
: : p
Recaldent NN p
) ) p
. . p

The DT N
study NN N
utilized VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover VB N
design NN N
with IN N
two CD N
treatments NNS N
: : N
( ( N
i NN N
) ) N
sugar-free JJ i
gum NN i
containing VBG N
18.8 CD N
mg NN N
of IN N
CPP-ACP NNP i
, , N
and CC N
( ( N
ii NN N
) ) N
sugar-free JJ i
gum NN i
not RB i
containing VBG i
CPP-ACP NNP i
as IN N
control NN N
. . N

Subjects NNS p
wore RBR p
removable JJ p
palatal JJ p
appliances NNS p
with IN p
insets NNS p
of IN p
human JJ p
enamel NN p
containing VBG p
demineralized JJ p
subsurface NN p
lesions NNS p
and CC p
chewed VBD p
the DT p
gum NN i
for IN i
20 CD p
min NN p
4 CD p
times NNS p
per IN p
day NN p
for IN p
14 CD p
days NNS p
. . p

After IN N
each DT N
treatment NN N
the DT N
enamel NN N
slabs NN N
were VBD N
removed VBN N
and CC N
half NN N
of IN N
each DT N
lesion NN N
challenged VBD o
with IN o
acid NN o
in IN o
vitro NN o
for IN N
8 CD N
or CC N
16 CD N
h. VBP N
The DT N
level NN o
of IN o
remineralization NN o
was VBD N
determined VBN N
using VBG N
microradiography NN o
. . o

The DT N
gum NN i
containing VBG i
CPP-ACP NNP i
produced VBD N
approximately RB N
twice JJ N
the DT N
level NN o
of IN o
remineralization NN o
as IN N
the DT N
control NN N
sugar-free JJ N
gum NN N
. . N

The DT N
8- JJ N
and CC N
16-hour JJ N
acid NN N
challenge NN N
of IN N
the DT N
lesions NNS o
remineralized VBN o
with IN N
the DT N
control NN i
gum NN i
resulted VBD N
in IN N
65.4 CD N
and CC N
88.0 CD N
% NN N
reductions NNS N
, , N
respectively RB N
, , N
of IN N
deposited JJ N
mineral NN N
, , N
while IN N
for IN N
the DT N
CPP-ACP-remineralized JJ N
lesions NNS N
the DT N
corresponding JJ N
reductions NNS N
were VBD N
30.5 CD N
and CC N
41.8 CD N
% NN N
. . N

The DT N
acid NN N
challenge NN N
after IN N
in IN N
situ JJ N
remineralization NN N
for IN N
both DT N
control NN N
and CC N
CPP-ACP-treated JJ N
lesions NNS N
resulted VBD N
in IN N
demineralization NN o
underneath IN N
the DT N
remineralized JJ N
zone NN N
, , N
indicating VBG N
that IN N
the DT N
remineralized JJ N
mineral NN N
was VBD N
more RBR N
resistant JJ N
to TO N
subsequent JJ N
acid NN N
challenge NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
sugar-free JJ i
gum NN i
containing VBG i
CPP-ACP NNP i
is VBZ N
superior JJ o
to TO N
an DT N
equivalent JJ N
gum NN i
not RB N
containing VBG N
CPP-ACP NNP N
in IN N
remineralization NN N
of IN N
enamel JJ N
subsurface NN N
lesions NNS N
in IN N
situ NN N
with IN N
mineral NN N
that WDT N
is VBZ N
more RBR o
resistant JJ o
to TO N
subsequent JJ N
acid NN N
challenge NN N
. . N

-DOCSTART- -7159500- O O

Treatment NN N
of IN N
familial JJ N
hypercholesterolemia NN N
with IN N
a DT N
combination NN i
of IN i
bezafibrate NN i
and CC i
guar NN i
. . i

The DT N
effect NN o
of IN N
guar NN i
( ( N
15.6 CD N
g/day NN N
) ) N
, , N
a DT i
dietary JJ i
fibre NN i
, , N
and CC N
simultaneous JJ N
administration NN N
of IN N
bezafibrate NN i
( ( N
600 CD N
mg/day NN N
) ) N
during IN N
dietetic JJ N
treatment NN N
on IN N
the DT N
plasma NN N
lipoproteins NNS N
and CC N
apolipoproteins NNS N
was VBD N
investigated VBN N
in IN N
12 CD p
patients NNS p
with IN p
familial JJ p
hypercholesterolemia NN p
( ( p
corresponding VBG p
to TO p
the DT p
HLP NNP p
type NN p
IIa NNP p
pattern NN p
) ) p
. . p

Either CC i
bezafibrate VB i
alone RB i
or CC i
bezafibrate VB i
in IN i
combination NN i
with IN i
guar NN i
was VBD i
administered VBN i
in IN i
a DT i
cross-over NN i
study NN i
for IN i
3 CD i
months NNS i
. . i

Guar NNP i
led VBD N
to TO N
an DT N
additional JJ N
lowering NN N
of IN N
the DT N
total JJ o
cholesterol NN o
in IN N
the DT N
plasma NN N
by IN N
7 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.05 CD N
) ) N
associated VBN N
with IN N
a DT N
fall NN N
of IN N
the DT N
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-cholesterol NNP o
( ( N
LDL-cholesterol NNP N
) ) N
by IN N
13 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.01 CD N
) ) N
without IN N
any DT N
changes NNS N
in IN N
the DT N
very RB N
low JJ N
density NN N
lipoprotein NN N
( ( N
VLDL NNP N
) ) N
and CC N
high JJ N
density NN N
lipoprotein NN N
( ( N
HDL NNP N
) ) N
cholesterols NNS N
. . N

In IN N
parallel NN N
with IN N
the DT N
decrease NN N
in IN N
LDL-cholesterol NNP o
, , N
the DT N
apoprotein NN o
B NNP o
also RB N
was VBD N
diminished VBN N
by IN N
20 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.05 CD N
) ) N
. . N

The DT N
plasma JJ o
triglyceride NN o
level NN o
and CC o
the DT o
triglyceride JJ o
distribution NN o
within IN N
the DT N
individual JJ N
lipoprotein NN N
fractions NNS N
were VBD N
not RB N
altered VBN N
in IN N
any DT N
consistent JJ N
manner NN N
by IN N
the DT N
addition NN N
of IN N
guar NN i
. . i

Neither CC N
the DT N
fasting NN o
plasma NN o
glucose JJ o
level NN o
nor CC o
the DT o
body NN o
weight WDT o
were VBD N
affected VBN N
. . N

The DT N
side-effects NNS N
due JJ N
to TO N
guar VB i
treatment NN i
consisted VBN N
of IN N
slight JJ o
nausea NN o
, , o
meteorism NN o
and CC o
constipation NN o
, , N
but CC N
this DT N
did VBD N
not RB N
in IN N
any DT N
of IN N
the DT N
cases NNS N
lead VBP N
to TO N
early JJ N
termination NN N
of IN N
the DT N
study NN N
. . N

These DT N
results NNS N
demonstrate VBP N
that IN N
guar NN i
exerts VBZ N
its PRP$ N
cholesterol-lowering JJ N
effect NN N
in IN N
addition NN N
to TO N
that DT N
of IN N
bezafibrate NN i
. . i

-DOCSTART- -8268649- O O

Deficiency NN o
of IN o
serum NN o
ionized JJ o
magnesium NN o
in IN N
patients NNS p
receiving VBG p
hemodialysis NN p
or CC p
peritoneal JJ p
dialysis NN p
. . p

Serum NNP N
total JJ N
magnesium NN N
( ( N
TMg NNP N
) ) N
measurements NNS N
in IN N
dialysis NN p
patients NNS p
are VBP N
variable JJ N
, , N
with IN N
some DT N
groups NNS N
reporting VBG N
hypermagnesemia NN N
and CC N
some DT N
hypomagnesemia NN N
. . N

It PRP N
had VBD N
not RB N
been VBN N
possible JJ N
to TO N
measure VB N
the DT N
biologically RB N
active JJ N
fraction NN N
, , N
ionized JJ N
magnesium NN N
( ( N
IMg2+ NNP N
) ) N
. . N

The DT N
authors NNS N
utilized VBD N
an DT N
ion-selective JJ N
electrode NN N
to TO N
measure VB N
IMg NNP o
in IN N
26 CD p
hemodialysis NN p
patients NNS p
and CC p
10 CD p
peritoneal JJ p
dialysis NN p
( ( p
CAPD NNP p
) ) p
patients NNS p
and CC p
compared VBN p
the DT p
results NNS p
with IN p
those DT p
from IN p
66 CD p
age NN p
matched VBD p
control NN p
subjects NNS p
. . p

Dialysate NNP i
magnesium NN i
was VBD N
0.375 CD N
mM/L NN N
for IN N
the DT N
hemodialysis NN N
and CC N
0.25 CD N
mM/L NN N
for IN N
the DT N
CAPD NNP N
patients NNS N
. . N

When WRB N
compared VBN N
with IN N
control NN N
subjects NNS N
, , N
both DT N
hemodialysis NN N
and CC N
CAPD NNP N
patients NNS N
had VBD N
significantly RB N
lower JJR N
IMg2+ NNP o
( ( N
0.55 CD N
+/- JJ N
0.02 CD N
and CC N
0.50 CD N
+/- JJ N
0.02 CD N
vs. FW N
0.60 CD N
+/- JJ N
0.004 CD N
mM/L NN N
; : N
p CC N
< VB N
0.05 CD N
) ) N
and CC N
greater JJR o
or CC o
normal JJ o
TMg NNP o
values NNS o
( ( N
0.99 CD N
+/- JJ N
0.04 CD N
, , N
different JJ N
at IN N
the DT N
p NN N
< VBZ N
0.001 CD N
level NN N
, , N
and CC N
0.85 CD N
+/- JJ N
0.04 CD N
vs. FW N
0.84 CD N
+/- JJ N
0.008 CD N
) ) N
. . N

Ionized VBN o
calcium NN o
( ( o
ICa2+ NNP o
) ) o
values NNS o
were VBD N
similar JJ N
for IN N
all DT N
three CD p
groups NNS p
( ( N
1.15 CD N
+/- JJ N
0.02 CD N
and CC N
1.21 CD N
+/- JJ N
0.04 CD N
vs. FW N
1.17 CD N
+/- JJ N
0.01 CD N
) ) N
, , N
resulting VBG N
in IN N
increased VBN N
mean NN N
ICa2+/IMg2+ NNP o
ratios NNS o
( ( N
2.14 CD N
+/- JJ N
0.07 CD N
and CC N
2.42 CD N
+/- JJ N
0.06 CD N
vs. FW N
1.95 CD N
+/- JJ N
0.02 CD N
for IN N
the DT N
control NN N
subjects VBZ N
; : N
p VB N
< $ N
0.05 CD N
) ) N
. . N

The DT N
percent NN N
of IN N
total JJ o
magnesium NN o
that WDT N
was VBD N
ionized VBN o
( ( o
% NN o
IMg2+ NNP o
) ) o
was VBD N
low JJ N
in IN N
both DT N
the DT N
hemodialysis NN N
and CC N
CAPD NNP N
patients NNS N
( ( N
55.6 CD N
+/- JJ N
0.93 CD N
and CC N
59.2 CD N
+/- JJ N
1.05 CD N
) ) N
compared VBN N
with IN N
that DT N
of IN N
control NN N
subjects NNS N
( ( N
72 CD N
+/- JJ N
0.61 CD N
; : N
p NN N
< VBZ N
0.05 CD N
) ) N
. . N

IMg2+ NNP N
values NNS N
correlated VBN N
with IN N
TMg NNP N
values NNS N
in IN N
both DT N
hemodialysis NN N
( ( N
r JJ N
= VBZ N
0.93 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
and CC N
CAPD NNP N
( ( N
r VB N
= RB N
0.92 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
patients NNS N
did VBD N
not RB N
correlate VB N
with IN N
age NN N
, , N
time NN N
on IN N
dialysis NN N
, , N
weight NN N
, , N
fasting VBG N
cholesterol NN N
or CC N
triglyceride NN N
, , N
albumin NN N
, , N
blood NN N
urea JJ N
nitrogen NN N
( ( N
BUN NNP N
) ) N
, , N
creatinine NN N
, , N
hematocrit NN N
, , N
phosphate NN N
, , N
or CC N
PTH NNP N
values NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -15861942- O O

Problem-based JJ i
learning NN i
: : i
is VBZ N
anatomy IN N
a DT N
casualty NN N
? . N
INTRODUCTION NNP N
The DT N
teaching NN N
of IN N
medical JJ N
anatomy NN N
is VBZ N
changing VBG N
. . N

Medical JJ N
schools NNS N
worldwide WDT N
are VBP N
moving VBG N
away RB N
from IN N
dissection NN N
and CC N
lectures VBZ N
to TO N
a DT N
more RBR N
integrated JJ N
course NN N
, , N
where WRB N
basic JJ N
science NN N
and CC N
clinical JJ N
skills NNS N
are VBP N
taught JJ N
simultaneously RB N
. . N

Medical JJ p
students NNS p
on IN N
these DT N
integrated VBN N
courses NNS N
have VBP N
reported VBN N
a DT N
lack NN N
of IN N
confidence NN N
in IN N
their PRP$ N
basic JJ N
science NN N
knowledge NN N
, , N
especially RB N
concerning VBG N
anatomy NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
perform VB N
a DT N
randomised JJ N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
to TO N
compare VB N
anatomical JJ N
knowledge NN N
of IN N
two CD p
groups NNS p
of IN p
second-year JJ p
medical JJ p
students NNS p
, , p
the DT i
first JJ i
group NN i
taught NN i
on IN i
a DT i
traditional JJ i
course NN i
, , i
the DT i
second JJ i
on IN i
an DT i
integrated JJ i
course NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
Testing NNP N
was VBD N
done VBN N
using VBG N
a DT N
Questionnaire NN N
in IN N
a DT N
True/False NNP N
format NN N
. . N

There EX N
were VBD N
80 CD p
students NNS p
in IN p
each DT p
group NN p
. . p

There EX N
was VBD N
no DT N
penalty NN N
for IN N
an DT N
incorrect JJ N
answer NN N
. . N

The DT N
test NN N
was VBD N
performed VBN N
under IN N
examination NN N
conditions NNS N
. . N

Papers NNS N
were VBD N
marked VBN N
under IN N
blind JJ N
conditions NNS N
. . N

Results NNS N
were VBD N
analysed VBN N
using VBG N
a DT N
Student NN N
's POS N
t JJ N
test NN N
analysis NN N
. . N

RESULTS NNP N
Those DT N
students NNS N
taught VBP N
on IN N
a DT N
traditional JJ N
course NN N
exhibited VBD N
a DT N
significantly RB N
higher JJR N
level NN o
of IN o
basic JJ o
anatomical JJ o
knowledge NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
than IN N
those DT N
taught VBN N
on IN N
an DT N
integrated JJ N
course NN N
. . N

The DT N
students NNS N
taught VBD N
on IN N
an DT N
integrated JJ N
course NN N
showed VBD N
a DT N
much RB N
greater JJR N
range NN o
of IN o
results NNS o
. . o

CONCLUSIONS JJ N
Students NNS N
taught VBD N
on IN N
a DT N
traditional JJ N
course NN N
have VBP N
a DT N
higher JJR N
level NN N
of IN N
anatomical JJ o
knowledge NN o
than IN N
those DT N
taught VBN N
on IN N
an DT N
integrated JJ N
course NN N
. . N

Our PRP$ N
results NNS N
differ VBP N
from IN N
previous JJ N
studies NNS N
done VBN N
in IN N
Europe NNP N
which WDT N
show VBP N
no DT N
difference NN N
between IN N
the DT N
courses NNS N
. . N

-DOCSTART- -9006598- O O

Improving VBG N
care NN p
givers NNS p
' POS p
satisfaction NN p
with IN p
information NN i
received VBN i
during IN i
hospitalization NN i
. . i

As IN N
competition NN N
for IN N
patient NN N
volume NN N
escalates VBZ N
among IN N
hospital JJ N
providers NNS N
, , N
administrators NNS N
must MD N
identify VB N
ways NNS N
to TO N
attract VB N
new JJ p
patients NNS p
and CC p
maintain NN p
or CC p
increase VB p
patient JJ p
volume NN p
. . p

Family NNP p
care NN p
givers NNS p
are VBP N
known VBN N
to TO N
greatly RB N
influence JJ N
individuals NNS N
' POS N
choices NNS N
in IN N
these DT N
matters NNS N
of IN N
selection NN N
of IN N
healthcare NN N
services NNS N
and CC N
providers NNS N
. . N

The DT N
results NNS N
of IN N
a DT N
successful JJ N
nurse-initiated JJ i
daily JJ i
phone NN i
calls VBZ i
program NN i
, , N
designed VBN N
to TO N
improve VB N
family NN N
care NN N
giver NN N
satisfaction NN N
by IN N
enhancing VBG N
the DT N
provision NN N
of IN N
patient-specific JJ i
information NN i
, , N
are VBP N
presented VBN N
. . N

The DT N
components NNS o
of IN o
the DT o
program NN o
, , o
associated VBN o
costs NNS o
, , o
and CC o
implications NNS o
on IN o
delivery NN o
of IN o
care NN o
are VBP N
discussed VBN N
. . N

-DOCSTART- -22215436- O O

Exploring VBG N
the DT N
social JJ o
impact NN o
of IN N
being VBG N
a DT N
typical JJ i
peer NN i
model NN i
for IN N
included JJ N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

This DT N
study NN N
examined VBD N
the DT N
social JJ o
impact NN o
of IN N
being VBG N
a DT N
typical JJ N
peer NN N
model NN N
as IN N
part NN N
of IN N
a DT N
social JJ i
skills NNS i
intervention NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Participants NNS N
were VBD N
drawn VBN N
from IN N
a DT N
randomized-controlled-treatment JJ N
trial NN N
that WDT N
examined VBD N
the DT N
effects NNS N
of IN N
targeted JJ N
interventions NNS i
on IN N
the DT N
social JJ o
networks NNS o
of IN N
60 CD p
elementary-aged JJ p
children NNS p
with IN p
ASD NNP p
. . p

Results NNP N
demonstrated VBD N
that DT N
typical JJ N
peer NN N
models NNS N
had VBD N
higher RBR o
social JJ o
network NN o
centrality NN o
, , o
received VBN o
friendships NNS o
, , o
friendship JJ o
quality NN o
, , o
and CC o
less JJR o
loneliness JJR o
than IN N
non-peer JJ N
models NNS N
. . N

Peer NNP i
models NNS i
were VBD N
also RB N
more RBR o
likely JJ o
to TO N
be VB N
connected VBN N
with IN N
children NNS N
with IN N
ASD NNP N
than IN N
non-peer JJ N
models NNS N
at IN N
baseline NN N
and CC N
exit NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
typical JJ N
peers NNS N
can MD N
be VB N
socially RB N
connected VBN N
to TO N
children NNS N
with IN N
ASD NNP N
, , N
as RB N
well RB N
as IN N
other JJ N
classmates NNS N
, , N
and CC N
maintain VB N
a DT N
strong JJ o
and CC o
positive JJ o
role NN o
within IN N
the DT N
classroom NN N
. . N

-DOCSTART- -3557014- O O

Sucralfate NNP i
overcomes VBZ N
adverse JJ N
effect NN N
of IN N
cigarette NN N
smoking NN N
on IN N
duodenal JJ p
ulcer NN o
healing NN o
and CC N
prolongs NNS N
subsequent JJ N
remission NN N
. . N

A DT N
unicenter JJ N
, , N
single-blind JJ N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
on IN N
283 CD p
patients NNS p
with IN p
active JJ p
duodenal JJ p
ulcer NN p
to TO p
compare VB p
possible JJ p
factors NNS p
that WDT p
may MD p
affect VB p
healing NN p
and CC p
relapse NN p
in IN p
patients NNS p
treated VBN p
with IN p
a DT p
potent JJ p
antisecretory NN i
agent NN i
, , i
cimetidine NN i
, , p
or CC p
a DT p
site-protective JJ p
and CC p
cytoprotective JJ p
agent NN p
, , p
sucralfate NN i
. . i

The DT N
endoscopic NN o
healing VBG o
rates NNS o
at IN N
4 CD N
wk NNS N
were VBD N
76 CD N
% NN N
and CC N
79 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
cross-over JJ N
treatment NN N
of IN N
the DT N
failures NNS N
for IN N
a DT N
further JJ N
4 CD N
wk NN N
resulted VBD N
in IN N
68 CD N
% NN N
healing VBG N
with IN N
cimetidine NN i
and CC N
69 CD N
% NN N
healing VBG N
with IN N
sucralfate NN i
, , N
both DT N
differences NNS N
being VBG N
not RB N
statistically RB N
different JJ N
. . N

Unlike IN N
cimetidine NN i
, , N
healing VBG N
by IN N
sucralfate NN i
was VBD N
unaffected VBN N
by IN N
cigarette NN N
smoking NN N
, , N
reluctance NN N
to TO N
give VB N
up RP N
smoking NN N
, , N
habitual JJ N
use NN N
of IN N
alcohol NN N
, , N
high JJ N
maximal JJ N
acid NN N
output NN N
, , N
and CC N
large JJ N
ulcer JJ N
diameter NN N
. . N

In IN N
particular JJ N
, , N
the DT N
healing VBG o
rate NN o
of IN N
smokers NNS N
treated VBN N
with IN N
sucralfate NN i
( ( N
82 CD N
% NN N
) ) N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
of IN N
smokers NNS N
treated VBN N
with IN N
cimetidine NN i
( ( N
63 CD N
% NN N
) ) N
. . N

Duodenal NNP N
bulb NN N
deformity NN N
significantly RB N
affected VBD N
healing NN N
in IN N
both DT p
groups NNS p
, , N
and CC N
was VBD N
the DT N
only JJ N
offsetting VBG N
factor NN N
identifiable JJ N
for IN N
sucralfate NN i
out IN N
of IN N
46 CD N
factors NNS N
examined VBD N
. . N

Of IN N
the DT N
patients NNS p
with IN p
healed JJ p
ulcers NNS p
, , p
238 CD p
participated VBN p
in IN N
a DT N
24-mo JJ N
follow-up NN N
study NN N
consisting VBG N
of IN N
interviews NNS N
at IN N
2-mo JJ N
intervals NNS N
and CC N
endoscopy NN N
at IN N
4-mo JJ N
intervals NNS N
or CC N
whenever WRB N
symptoms NNS N
recurred VBD N
. . N

The DT N
cumulative JJ o
relapse NN o
rate NN o
was VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.007 CD N
) ) N
greater JJR N
in IN N
patients NNS p
healed VBN N
with IN N
cimetidine NN i
than IN N
with IN N
sucralfate NN i
, , N
50 CD N
% NN N
relapse NN N
occurring VBG N
at IN N
6 CD N
and CC N
12 CD N
mo NN N
, , N
respectively RB N
. . N

In IN N
both DT N
, , N
the DT N
cumulative JJ o
relapse NN o
rate NN o
was VBD N
significantly RB N
greater JJR N
in IN N
cigarette NN N
smokers NNS N
than IN N
in IN N
nonsmokers NNS N
, , N
but CC N
smokers NNS N
and CC N
nonsmokers NNS N
treated VBN N
with IN N
cimetidine NN i
relapsed VBN o
( ( N
50 CD N
% NN N
at IN N
4 CD N
and CC N
8 CD N
mo NN N
, , N
respectively RB N
) ) N
faster RBR N
than IN N
the DT N
corresponding JJ N
smokers NNS N
and CC N
nonsmokers NNS N
treated VBN N
with IN N
sucralfate NN i
( ( N
50 CD N
% NN N
at IN N
8 CD N
and CC N
18 CD N
mo NN N
, , N
respectively RB N
) ) N
. . N

Furthermore UH N
, , N
in IN N
cimetidine- NN i
but CC N
not RB N
sucralfate-healed JJ i
patients NNS N
, , N
early JJ N
ulcer NN N
relapse NN N
( ( N
within IN N
6 CD N
mo NN N
) ) N
was VBD N
associated VBN N
with IN N
short JJ N
duration NN o
of IN o
illness NN o
, , N
short JJ N
remission NN o
period NN o
, , o
long JJ o
symptomatic JJ o
spell NN o
, , o
and CC o
reluctance NN o
to TO o
give VB o
up RP o
smoking VBG o
. . o

We PRP N
conclude VBP N
that IN N
smoking VBG N
adversely RB N
affects VBZ N
duodenal JJ N
ulcer NN N
healing NN N
by IN N
cimetidine NN i
and CC N
hastens VBZ N
subsequent JJ N
relapse NN N
, , N
and CC N
that IN N
sucralfate NN i
overcomes VBZ N
the DT N
adverse JJ N
effect NN N
of IN N
smoking VBG N
on IN N
healing NN N
as IN N
encountered VBN N
with IN N
cimetidine NN i
, , N
and CC N
results NNS N
in IN N
a DT N
subsequent JJ N
remission NN N
period NN N
double JJ N
that IN N
of IN N
cimetidine NN i
. . i

-DOCSTART- -1990041- O O

Treatment NN N
of IN N
beta-hemolytic JJ p
streptococcal JJ p
pharyngitis NN p
with IN N
cefaclor NN i
or CC i
penicillin NN i
. . i

Efficacy NN N
and CC N
interaction NN N
with IN N
beta-lactamase-producing JJ N
organisms NNS N
in IN N
the DT N
pharynx NN N
. . N

The DT N
recommended JJ N
treatment NN N
for IN N
group NN p
A NNP p
beta-hemolytic JJ p
streptococcal JJ p
pharyngitis NN p
has VBZ N
continued VBN N
to TO N
be VB N
penicillin JJ i
given VBN N
in IN N
parenteral JJ N
or CC N
oral JJ N
form NN N
. . N

Treatment NNP o
failures NNS o
, , N
as IN N
determined VBN N
by IN N
the DT N
continued JJ N
presence NN N
of IN N
the DT N
streptococcal JJ N
organism NN N
in IN N
the DT N
pharynx NN N
, , N
however RB N
, , N
do VBP N
occur VB N
in IN N
6 CD N
% NN N
to TO N
25 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
penicillin NN N
. . N

Furthermore RB N
, , N
beta-lactamase NN N
produced VBN N
by IN N
other JJ N
bacteria NNS N
in IN N
the DT N
pharynx NN N
could MD N
potentially RB N
inactivate VB N
the DT N
penicillin NN N
, , N
resulting VBG N
in IN N
increased VBN N
treatment NN o
failures NNS o
or CC o
infection NN o
relapses NNS o
. . o

A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
cefaclor NN i
, , N
which WDT N
is VBZ N
relatively RB N
resistant JJ N
to TO N
inactivation VB N
by IN N
beta-lactamase NN N
, , N
with IN N
penicillin NN N
for IN N
eradicating VBG N
the DT N
group NN p
A DT p
beta-hemolytic JJ p
streptococcal JJ p
organism NN p
from IN p
the DT p
throats NNS p
of IN p
93 CD p
patients NNS p
with IN p
pharyngitis NN p
. . p

Additionally RB N
, , N
extensive JJ N
cultures NNS N
for IN N
potential JJ N
beta-lactamase-producing JJ N
organisms NNS N
were VBD N
conducted VBN N
on IN N
37 CD p
patients NNS p
; : p
27 CD p
% NN p
of IN p
these DT p
had VBD p
one CD p
or CC p
more JJR p
pharyngeal JJ p
organisms NNS p
that WDT p
were VBD p
producing VBG p
beta-lactamase NN p
. . p

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
clinical JJ o
responses NNS o
or CC o
the DT o
bacteriological JJ o
cure NN o
rates NNS o
of IN N
those DT N
treated VBN N
with IN N
cefaclor NN N
and CC N
those DT N
treated VBN N
with IN N
penicillin NN N
when WRB N
stratified VBN N
by IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
beta-lactamase-producing JJ N
organisms NNS N
. . N

The DT N
prevalence NN o
of IN o
beta-lactamase-producing JJ o
organisms NNS o
in IN o
the DT o
pharynx NN o
, , N
however RB N
, , N
was VBD N
increased VBN N
after IN N
treatment NN N
with IN N
penicillin NN N
, , N
whereas IN N
no DT N
change NN N
was VBD N
noted VBN N
following VBG N
treatment NN o
with IN o
cefaclor NN o
. . o

-DOCSTART- -9796041- O O

A DT N
search NN N
for IN N
serologic JJ N
correlates NNS N
of IN N
immunity NN N
to TO N
Bordetella NNP N
pertussis NN N
cough NN N
illnesses NNS N
. . N

In IN N
a DT N
pertussis NN p
vaccine NN p
efficacy NN p
trial NN p
in IN p
Germany NNP p
we PRP N
collected VBD N
sera NN N
from IN N
vaccinees NNS i
( ( i
DTaP NNP i
or CC i
DTP NNP i
) ) i
after IN N
the DT N
third JJ N
and CC N
fourth JJ N
doses NNS N
of IN N
vaccine NN N
or CC N
at IN N
comparable JJ N
time NN N
periods NNS N
in IN N
DT NNP p
vaccine NN p
recipients NNS p
. . p

In IN N
addition NN N
, , N
sera NN N
were VBD N
collected VBN N
from IN N
a DT N
randomized JJ N
sample NN N
of IN N
subjects NNS p
in IN p
each DT p
vaccine NN p
group NN p
at IN p
approximately RB p
3-month JJ p
intervals NNS p
from IN N
which WDT N
antibody NN N
kinetic JJ N
curves NNS N
were VBD N
constructed VBN N
, , N
which WDT N
allowed VBD N
us PRP N
to TO N
estimate VB N
specific JJ N
antibody NN N
values NNS N
to TO N
pertussis VB i
toxin NN N
( ( N
PT NNP N
) ) N
, , N
filamentous JJ N
hemagglutinin NN N
( ( N
FHA NNP N
) ) N
, , N
pertactin JJ N
and CC N
fimbriae-2 JJ N
at IN N
the DT N
time NN N
of IN N
exposure NN N
in IN N
the DT N
household NN N
setting NN N
. . N

The DT N
imputed JJ N
geometric JJ N
mean NN N
antibody NN N
values NNS N
to TO N
PT NNP N
, , N
pertactin NN N
and CC N
fimbriae-2 NN N
at IN N
the DT N
time NN N
of IN N
household NN N
exposure NN N
to TO N
Bordetella NNP N
pertussis NN N
infection NN N
were VBD N
higher JJR N
( ( N
p JJ N
< VBP N
0.07 CD N
or CC N
lower JJR N
) ) N
in IN N
non-cases NNS N
compared VBN N
with IN N
cases NNS N
. . N

A DT N
multivariate NN N
( ( N
classification NN N
tree NN N
) ) N
analysis NN N
found VBD N
that IN N
only RB N
pertactin NN N
and CC N
PT NNP N
were VBD N
significant JJ N
in IN N
protection NN N
. . N

Subjects NNS N
with IN N
an DT N
imputed JJ N
pertactin NN N
value NN N
of IN N
< $ N
7 CD N
EU NNP N
ml-1 NN N
had VBD N
a DT N
67 CD N
% NN N
( ( N
18/27 CD N
) ) N
chance NN N
of IN N
infection NN N
regardless NN N
of IN N
the DT N
PT NNP N
value NN N
. . N

If IN N
the DT N
pertactin NN N
value NN N
was VBD N
> JJ N
or CC N
= JJ N
7 CD N
EU NNP N
ml-1 NN N
and CC N
the DT N
PT NNP N
value NN N
> NN N
or CC N
= $ N
66 CD N
EU NNP N
ml-1 CD N
all DT N
subjects NNS N
were VBD N
non-cases NNS N
. . N

If IN N
the DT N
pertactin NN N
value NN N
was VBD N
> JJ N
or CC N
= JJ N
7 CD N
and CC N
the DT N
PT NNP N
value NN N
was VBD N
< JJ N
66 CD N
EU NNP N
ml-1 CD N
the DT N
predicted JJ N
probability NN N
of IN N
being VBG N
a DT N
case NN N
was VBD N
31 CD N
% NN N
( ( N
15/49 CD N
) ) N
. . N

Logistic JJ o
regression NN o
analysis NN o
also RB N
found VBD N
that IN N
high JJ N
versus NN N
low JJ N
pertactin NN N
values NNS N
were VBD N
associated VBN N
with IN N
illness JJ N
prevention NN N
following VBG N
household NN N
exposure NN N
. . N

In IN N
the DT N
presence NN N
of IN N
antibody NN N
to TO N
pertactin VB N
, , N
PT NNP N
and CC N
fimbriae-2 JJ N
, , N
the DT N
additional JJ N
presence NN N
of IN N
antibody NN N
to TO N
FHA NNP N
did VBD N
not RB N
contribute VB N
to TO N
protection NN N
. . N

Our PRP$ N
data NNS N
support NN N
historical JJ N
data NNS N
indicating VBG N
that IN N
agglutinating VBG N
antibodies NNS N
are VBP N
associated VBN N
with IN N
protection NN N
and CC N
also RB N
recent JJ N
serologic JJ N
correlates NNS N
data NNS N
and CC N
clinical JJ N
efficacy NN N
data NNS N
which WDT N
indicate VBP N
that IN N
multicomponent NN i
vaccines NNS i
containing VBG i
pertactin NN i
and CC i
fimbriae NN i
have VBP N
better JJR N
efficacy NN N
than IN N
PT NNP N
or CC N
PT/FHA NNP N
vaccines NNS N
. . N

-DOCSTART- -11683484- O O

Caffeine NNP i
eliminates VBZ N
psychomotor NN o
vigilance NN o
deficits NNS o
from IN N
sleep JJ N
inertia NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
This DT N
study NN N
sought VBD N
to TO N
establish VB N
the DT N
effects NNS N
of IN N
caffeine NN i
on IN N
sleep JJ o
inertia NN o
, , N
which WDT N
is VBZ N
the DT N
ubiquitous JJ N
phenomenon NN N
of IN N
cognitive JJ N
performance NN N
impairment NN N
, , N
grogginess NN N
and CC N
tendency NN N
to TO N
return VB N
to TO N
sleep VB N
immediately RB N
after IN N
awakening VBG N
. . N

DESIGN NNP N
28 CD p
normal JJ p
adult NN p
volunteers NNS p
were VBD N
administered VBN N
sustained VBN N
low-dose JJ i
caffeine NN i
or CC i
placebo NN i
( ( N
randomized VBN N
double-blind NN N
) ) N
during IN N
the DT N
last JJ N
66 CD N
hours NNS N
of IN N
an DT N
88-hour JJ N
period NN N
of IN N
extended JJ N
wakefulness NN N
that WDT N
included VBD N
seven CD N
2-hour JJ N
naps NNS N
during IN N
which WDT N
polysomnographical JJ N
recordings NNS N
were VBD N
made VBN N
. . N

Every DT N
2 CD N
hours NNS N
of IN N
wakefulness NN N
, , N
and CC N
immediately RB N
after IN N
abrupt JJ N
awakening VBG N
from IN N
the DT N
naps NNS N
, , N
psychomotor NN o
vigilance NN o
performance NN o
was VBD N
tested VBN N
. . N

SETTING NN N
N/A NNP N
. . N

PARTICIPANTS NNP N
N/A NNP N
. . N

INTERVENTIONS NNP N
N/A NNP N
. . N

MEASUREMENTS NNP N
AND CC N
RESULTS NNP N
In IN N
the DT N
placebo NN i
condition NN N
, , N
sleep JJ o
inertia NN o
was VBD N
manifested VBN N
as IN N
significantly RB N
impaired JJ N
psychomotor NN o
vigilance NN o
upon IN N
awakening VBG N
from IN N
the DT N
naps NNS N
. . N

This DT N
impairment NN N
was VBD N
absent JJ N
in IN N
the DT N
caffeine JJ N
condition NN N
. . N

Caffeine NNP N
had VBD N
only RB N
modest JJ N
effects NNS N
on IN N
nap JJ o
sleep NN o
. . o

CONCLUSIONS NNP N
Caffeine NNP i
was VBD N
efficacious JJ N
in IN N
overcoming VBG N
sleep JJ o
inertia NN o
. . o

This DT N
suggests VBZ N
a DT N
reason NN N
for IN N
the DT N
popularity NN N
of IN N
caffeine-containing NN N
beverages NNS N
after IN N
awakening VBG N
. . N

Caffeine NNP N
's POS N
main JJ N
mechanism NN N
of IN N
action NN N
on IN N
the DT N
central JJ N
nervous JJ N
system NN N
is VBZ N
antagonism NN N
of IN N
adenosine JJ N
receptors NNS N
. . N

Thus RB N
, , N
increased VBD N
adenosine NN N
in IN N
the DT N
brain NN N
upon IN N
awakening VBG N
may MD N
be VB N
the DT N
cause NN N
of IN N
sleep JJ o
inertia NN o
. . o

-DOCSTART- -12443948- O O

Reactive JJ N
balance NN N
adjustments NNS N
to TO N
unexpected JJ i
perturbations NNS i
during IN p
human JJ p
walking NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
unexpected JJ i
forward NN i
perturbations NNS i
( ( i
FP NNP i
) ) i
during IN N
gait NN N
on IN N
lower JJR o
extremity NN o
joint NN o
mechanics NNS o
and CC o
muscle NN o
Electromyographic NNP o
( ( o
EMG NNP o
) ) o
patterns VBZ o
in IN N
healthy JJ p
adults NNS p
. . p

The DT N
muscles NNS N
surrounding VBG N
the DT N
hip NN N
were VBD N
found VBN N
to TO N
be VB N
most RBS N
important JJ N
in IN N
maintaining VBG o
control NN o
of IN o
the DT o
trunk NN o
and CC o
preventing VBG o
collapse NN o
in IN N
response NN N
to TO N
the DT N
FP NNP N
. . N

Distinct NNP o
lower JJR o
extremity NN o
joint JJ o
moment NN o
and CC o
power NN o
patterns NNS o
were VBD N
observed VBN N
in IN N
response NN N
to TO N
the DT N
FP NNP i
but CC N
an DT N
overall JJ N
positive JJ N
moment NN o
of IN o
support NN o
( ( o
M NNP o
( ( o
s PRP o
) ) o
) ) o
was VBD N
maintained VBN N
. . N

Therefore RB N
, , N
reactive JJ o
balance NN o
control NN o
was VBD N
a DT N
synchronized JJ N
effort NN N
of IN N
the DT N
lower JJR N
extremity NN N
joints NNS N
to TO N
prevent VB N
collapse NN N
during IN N
the DT N
FP NNP i
. . i

-DOCSTART- -1905592- O O

Effect NN N
of IN N
diltiazem NN i
on IN N
symptomatic JJ p
and CC p
asymptomatic JJ p
episodes NNS p
of IN p
ST NNP o
segment NN o
depression NN o
occurring VBG p
during IN p
daily JJ p
life NN p
and CC p
during IN p
exercise NN p
. . p

BACKGROUND NNP N
Silent NNP N
myocardial JJ N
ischemia NN N
is VBZ N
an DT N
adverse JJ N
prognostic JJ N
marker NN N
in IN N
patients NNS p
with IN p
coronary JJ p
disease NN p
; : p
however RB N
, , N
controlled VBN N
data NNS N
on IN N
the DT N
effect NN N
of IN N
treatment NN N
are VBP N
sparse JJ N
and CC N
contradictory NN N
, , N
and CC N
the DT N
relations NNS N
among IN N
the DT N
occurrence NN N
of IN N
ST NNP o
segment NN o
depression NN o
, , N
drug NN N
efficacy NN N
, , N
and CC N
heart NN N
rate NN N
are VBP N
unclear JJ N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Sixty NNP p
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
, , p
a DT p
positive JJ p
treadmill NN p
exercise NN p
test NN p
and CC p
asymptomatic JJ p
ST NNP p
segment NN p
depression NN p
on IN p
ambulatory JJ p
electrocardiographic JJ p
recording VBG p
were VBD p
assessed VBN p
in IN p
a DT p
multicenter NN p
, , p
double-blind JJ p
, , p
placebo-controlled JJ i
, , p
cross-over JJ p
trial NN p
. . p

Treadmill NNP o
exercise NN o
tests NNS o
and CC N
72-hour JJ o
electrocardiographic JJ o
recordings NNS o
were VBD N
obtained VBN N
at IN N
the DT N
end NN N
of IN N
two CD N
2-week JJ N
treatment NN N
periods NNS N
with IN N
sustained-release JJ i
diltiazem NN i
180 CD N
mg NN N
b.i.d NN N
. . N

or CC N
equivalent JJ N
placebo NN i
. . i

Episodes NNS o
of IN o
asymptomatic JJ o
ST NNP o
depression NN o
decreased VBN N
by IN N
50 CD N
% NN N
or CC N
more JJR N
in IN N
70 CD N
% NN N
of IN N
the DT N
patients NNS N
from IN N
a DT N
median JJ N
number NN N
of IN N
4.5 CD N
( ( N
range NN N
, , N
0-19 NN N
) ) N
to TO N
1.5 CD N
( ( N
range NN N
, , N
0-13 NN N
) ) N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
; : N
their PRP$ N
cumulative JJ o
duration NN o
also RB N
decreased VBD N
from IN N
78.5 CD N
( ( N
range NN N
, , N
0-60 NN N
) ) N
to TO N
24.5 CD N
( ( N
range NN N
, , N
0-411 NN N
) ) N
minutes NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

No DT N
circadian JJ o
variation NN o
was VBD N
found VBN N
in IN N
the DT N
efficacy NN N
of IN N
diltiazem NN i
. . i

The DT N
occurrence NN N
of IN N
ischemic JJ o
type NN o
ST NNP o
segment NN o
depression NN o
was VBD N
modulated VBN N
by IN N
changes NNS o
in IN o
heart NN o
rate NN o
rather RB N
than IN N
by IN N
absolute JJ N
heart NN N
rate NN N
. . N

Diltiazem NNP i
also RB N
improved VBD N
exercise NN o
test NN o
end NN o
points NNS o
but CC N
to TO N
a DT N
lesser JJR N
extent NN N
. . N

Time NN o
to TO o
ST NNP o
segment NN o
depression NN o
increased VBD N
to TO N
341 CD N
+/- JJ N
148 CD N
from IN N
296 CD N
+/- JJ N
154 CD N
seconds NNS N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
. . N

Although IN N
less JJR N
frequent JJ N
with IN N
diltiazem JJ i
administration NN N
( ( N
45 CD N
versus NN N
54 CD N
patients NNS N
, , N
p RB N
less JJR N
than IN N
0.03 CD N
) ) N
, , N
exercise-induced JJ o
ST NNP o
depression NN o
was VBD N
more RBR N
often RB N
asymptomatic JJ N
( ( N
98 CD N
% NN N
versus IN N
72 CD N
% NN N
of IN N
patients NNS N
, , N
p RB N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Diltiazem NNP i
reduces VBZ N
the DT N
frequency NN N
and CC N
severity NN N
of IN N
ischemic JJ o
type NN o
ST NNP o
depression NN o
in IN N
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
. . p

-DOCSTART- -14599236- O O

Modeling VBG p
hippocampal NN i
and CC i
neocortical JJ i
contributions NNS p
to TO p
recognition VB o
memory NN p
: : p
a DT p
complementary-learning-systems JJ p
approach NN p
. . p

The DT N
authors NNS N
present VBP N
a DT N
computational JJ p
neural-network JJ p
model NN p
of IN N
how WRB N
the DT N
hippocampus NN N
and CC N
medial JJ N
temporal JJ N
lobe NN N
cortex NN N
( ( N
MTLC NNP N
) ) N
contribute NN N
to TO N
recognition VB o
memory NN o
. . o

The DT N
hippocampal JJ i
component NN N
contributes NNS N
by IN N
recalling VBG N
studied VBN N
details NNS N
. . N

The DT N
MTLC NNP N
component NN N
can MD N
not RB N
support VB N
recall NN N
, , N
but CC N
one CD N
can MD N
extract VB N
a DT N
scalar JJ N
familiarity NN N
signal NN N
from IN N
MTLC NNP N
that WDT N
tracks VBZ N
how WRB N
well RB N
a DT N
test NN N
item NN N
matches NNS N
studied VBN N
items NNS N
. . N

The DT N
authors NNS N
present JJ N
simulations NNS i
that IN N
establish VB N
key JJ N
differences NNS N
in IN N
the DT N
operating NN N
characteristics NNS N
of IN N
the DT N
hippocampal-recall JJ o
and CC N
MTLC-familiarity JJ o
signals NNS o
and CC N
identify VB N
several JJ N
manipulations NNS N
( ( N
e.g. NN N
, , N
target-lure JJ N
similarity NN N
, , N
interference NN N
) ) N
that WDT N
differentially RB N
affect VBP N
the DT N
2 CD N
signals NNS N
. . N

They PRP N
also RB N
use VBP N
the DT N
model NN N
to TO N
address VB N
the DT N
stochastic JJ N
relationship NN N
between IN N
recall NN N
and CC N
familiarity NN N
and CC N
the DT N
effects NNS N
of IN N
partial JJ N
versus NN N
complete JJ N
hippocampal JJ N
lesions NNS N
on IN N
recognition NN o
. . o

-DOCSTART- -2882234- O O

Comparison NNP N
of IN N
endotracheal NN i
and CC i
peripheral JJ i
intravenous JJ i
adrenaline NN i
in IN N
cardiac JJ p
arrest NN p
. . p

Is VBZ N
the DT N
endotracheal JJ N
route NN N
reliable NN N
? . N
Twelve CD p
patients NNS p
presenting VBG p
to TO p
an DT p
accident NN p
and CC p
emergency NN p
department NN p
in IN p
asystolic JJ p
cardiac JJ p
arrest NN p
were VBD p
randomly RB p
allocated VBN p
to TO p
treatment NN p
with IN p
endotracheal JJ i
adrenaline NN i
( ( p
five CD p
patients NNS p
) ) p
or CC p
peripheral JJ i
intravenous JJ i
adrenaline NN i
( ( p
seven CD p
patients NNS p
) ) p
. . p

Femoral-artery JJ N
blood NN N
samples NNS N
were VBD N
taken VBN N
for IN N
assay NN N
of IN N
adrenaline NN i
and CC i
noradrenaline NN i
. . i

After IN N
intravenous JJ N
adrenaline NN i
there EX N
was VBD N
a DT N
good JJ N
clinical JJ o
and CC o
biochemical JJ o
response NN o
, , N
but CC N
after IN N
endotracheal JJ N
adrenaline NN N
there EX N
was VBD N
no DT o
change NN o
in IN o
serum JJ o
adrenaline NN o
and CC N
no DT o
measurable JJ o
clinical JJ o
response NN o
. . o

The DT N
endotracheal JJ N
route NN N
of IN N
adrenaline JJ i
administration NN N
is VBZ N
not RB N
reliable JJ N
in IN N
out-of-hospital JJ N
cardiac JJ N
arrest NN N
. . N

-DOCSTART- -17940245- O O

Intravenous JJ i
sodium NN i
valproate NN i
versus NN N
diazepam NN i
infusion NN i
for IN N
the DT N
control NN N
of IN N
refractory NN p
status NN p
epilepticus NN p
in IN p
children NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

An DT N
open-label JJ N
, , N
randomized VBN N
controlled VBD N
study NN N
was VBD N
conducted VBN N
at IN N
a DT N
tertiary JJ N
care NN N
teaching VBG N
hospital NN N
to TO N
compare VB N
efficacy NN N
and CC N
safety NN N
of IN N
intravenous JJ i
sodium NN i
valproate NN i
versus NN N
diazepam NN i
infusion NN i
for IN N
control NN N
of IN N
refractory NN N
status NN N
epilepticus NN N
. . N

Forty NNP p
children NNS p
with IN p
refractory NN p
status NN p
epilepticus NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
intravenous JJ i
sodium NN i
valproate NN i
or CC i
diazepam JJ i
infusion NN i
. . i

Refractory JJ o
status NN o
epilepticus NN o
was VBD N
controlled VBN N
in IN N
80 CD N
% NN N
of IN N
the DT N
valproate NN N
and CC N
85 CD N
% NN N
of IN N
the DT N
diazepam NN N
patients NNS N
. . N

The DT N
median JJ o
time NN o
to TO o
control VB o
refractory JJ o
status NN o
epilepticus NN o
was VBD N
less RBR N
in IN N
the DT N
valproate NN N
group NN N
( ( N
5 CD N
minutes NNS N
) ) N
than IN N
the DT N
diazepam NN N
group NN N
( ( N
17 CD N
minutes NNS N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
valproate NN N
group NN N
required VBN N
ventilation NN o
or CC o
developed JJ o
hypotension NN o
, , N
whereas NNS N
in IN N
the DT N
diazepam NN N
group NN N
60 CD N
% NN N
required VBN N
ventilation NN o
and CC N
50 CD N
% NN N
developed JJ N
hypotension NN o
after IN N
starting VBG N
diazepam JJ N
infusion NN N
. . N

No DT N
adverse JJ o
effects NNS o
on IN o
liver NN o
functions NNS o
were VBD N
seen VBN N
with IN N
valproate NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
intravenous JJ N
sodium NN N
valproate NN N
is VBZ N
an DT N
effective JJ N
alternative NN N
to TO N
diazepam VB N
infusion NN N
in IN N
controlling VBG N
refractory NN N
status NN N
epilepticus NN N
in IN N
children NNS p
and CC N
is VBZ N
free JJ N
of IN N
respiratory JJ N
depression NN N
and CC N
hypotension NN N
. . N

-DOCSTART- -6984358- O O

Tolfenamic NNP i
acid NN i
and CC i
caffeine NN i
: : i
a DT N
useful JJ N
combination NN N
in IN N
migraine NN o
. . o

Tolfenamic NNP i
acid NN i
is VBZ N
a DT N
potent JJ N
inhibitor NN N
of IN N
prostaglandin JJ N
biosynthesis NN N
, , N
which WDT N
has VBZ N
been VBN N
proved VBN N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
acute JJ o
migraine NN o
attacks NNS o
. . o

The DT N
usefulness NN N
of IN N
caffeine NN i
, , i
metoclopramide NN i
and CC i
pyridoxine NN i
as IN N
adjuncts NNS N
to TO N
tolfenamic VB i
acid NN i
was VBD N
tested VBN N
in IN N
acute JJ o
migraine NN o
attacks NNS o
in IN p
ten JJ p
patients NNS p
. . p

A DT N
combination NN N
of IN N
tolfenamic JJ i
acid NN i
( ( N
200 CD N
mg NN N
) ) N
with IN N
either DT i
caffeine NN i
( ( N
100 CD N
mg NN N
) ) N
, , N
metoclopramide RB i
( ( N
10 CD N
mg NN N
) ) N
or CC i
pyridoxine NN i
( ( N
300 CD N
mg NN N
) ) N
was VBD N
given VBN N
twice RB N
to TO N
each DT N
patient NN N
in IN N
random JJ N
order NN N
. . N

Thus RB N
60 CD p
attacks NNS p
were VBD N
treated VBN N
. . N

The DT N
tolfenamic JJ i
acid-caffeine JJ i
combination NN i
proved VBD N
the DT N
most RBS N
effective JJ N
as IN N
judged VBN N
by IN N
duration NN o
and CC o
intensity NN o
of IN o
attacks NNS o
, , o
working VBG o
ability NN o
, , o
vigilance NN o
, , o
and CC o
overall JJ o
evaluation NN o
of IN o
the DT o
drugs NNS o
by IN N
the DT N
patients NNS N
. . N

Metoclopramide NNP i
was VBD N
somewhat RB N
better JJR N
than IN N
pyridoxine NN i
as IN N
an DT N
additive NN N
. . N

-DOCSTART- -20957631- O O

A DT N
comparison NN N
of IN N
human JJ N
papillomavirus NN N
testing NN N
of IN N
clinician-collected JJ i
and CC i
self-collected JJ i
samples NNS i
during IN N
follow-up JJ N
after IN N
screen-and-treat NN N
. . N

Screen-and-treat JJ N
cervical JJ N
cancer NN N
prevention NN N
programs NNS N
based VBN N
on IN N
high-risk JJ N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
testing NN N
and CC N
cryotherapy NN N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
resource-limited JJ N
settings NNS N
. . N

However RB N
, , N
because IN N
cryotherapy NN N
is VBZ N
not RB N
100 CD N
% NN N
effective JJ N
, , N
follow-up JJ N
is VBZ N
needed VBN N
after IN N
treatment NN N
to TO N
detect VB N
post-treatment JJ N
failures NNS N
. . N

We PRP N
compared VBN N
the DT N
test NN N
performances NNS N
of IN N
high-risk JJ N
HPV NNP N
testing NN N
( ( N
Hybrid JJ N
Capture NNP N
2 CD N
) ) N
using VBG N
self-collected JJ i
and CC i
clinician-collected JJ i
samples NNS i
as RB N
well RB N
as IN N
cervical JJ i
cytology NN i
for IN N
identifying VBG N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
grades NNS N
2 CD N
or CC N
3 CD N
or CC N
invasive JJ N
cervical JJ N
cancer NN N
( ( N
CIN2+ NNP N
) ) N
among IN p
women NNS p
who WP p
did VBD p
( ( p
n=812 NN p
) ) p
and CC p
did VBD p
not RB p
( ( p
n=1858 JJ p
) ) p
undergo VBP p
cryotherapy NN p
in IN p
a DT p
South JJ p
African JJ p
screen-and-treat JJ p
trial NN p
. . p

At IN N
6 CD N
months NNS N
after IN N
enrolment NN N
( ( N
and CC N
after IN N
cryotherapy NN i
, , N
if IN N
performed VBN N
) ) N
, , N
women NNS N
were VBD N
tested VBN N
using VBG N
all DT N
three CD N
screening VBG N
methods NNS N
and CC N
then RB N
underwent JJ N
colposcopy/biopsy NN i
. . N

A DT N
predefined JJ N
subset NN N
of IN N
women NNS N
( ( N
n=1,455 NN N
) ) N
had VBD N
extended VBN N
follow-up NN N
with IN N
colposcopy/biopsy NN i
at IN N
12 CD N
months NNS N
. . N

A DT N
total NN N
of IN N
33 CD N
and CC N
91 CD N
cases NNS N
of IN N
CIN2+ NNP N
were VBD N
detected VBN N
among IN N
treated JJ N
and CC N
untreated JJ N
women NNS N
, , N
respectively RB N
. . N

The DT N
sensitivity NN o
of IN o
HPV NNP o
testing VBG o
using VBG N
clinician-collected JJ i
samples NNS i
and CC N
cervical JJ N
cytology NN N
did VBD N
not RB N
differ VB N
by IN N
treatment NN N
status NN N
. . N

HPV NNP N
testing VBG N
of IN N
clinician-collected JJ i
samples NNS i
detected VBN N
the DT N
most RBS N
cases NNS N
of IN N
CIN2+ NNP o
among IN N
both DT N
treated VBN N
( ( N
85 CD N
% NN N
) ) N
and CC N
untreated JJ N
( ( N
91 CD N
% NN N
) ) N
women NNS N
( ( N
p=0.31 NN N
) ) N
. . N

Cytology NNP o
( ( N
at IN N
a DT N
cutoff NN N
of IN N
atypical JJ N
squamous JJ N
cells NNS N
of IN N
undetermined JJ N
significance NN N
or CC N
greater JJR N
) ) N
detected VBD N
76 CD N
% NN N
of IN N
cases NNS N
among IN N
both DT N
treated VBN N
and CC N
untreated JJ N
women NNS N
. . N

However RB N
, , N
the DT N
sensitivity NN o
of IN o
HPV NNP o
testing VBG o
using VBG N
self-collected JJ i
samples NNS i
was VBD N
significantly RB N
lower JJR N
among IN N
treated JJ N
versus NN N
untreated JJ N
women NNS N
( ( N
55 CD N
% NN N
vs. FW N
78 CD N
% NN N
, , N
p=0.01 NN N
) ) N
. . N

HPV NNP N
testing VBG N
using VBG N
self-collected JJ i
vaginal JJ i
specimens NNS i
may MD N
be VB N
useful JJ N
in IN N
primary JJ N
screening NN N
but CC N
performs NNS N
poorly RB N
for IN N
detecting VBG N
post-treatment JJ o
failures NNS o
. . o

-DOCSTART- -11302295- O O

Psychosocial JJ i
nursing NN i
therapy NN i
following VBG p
sudden JJ p
cardiac JJ p
arrest NN p
: : p
impact NN N
on IN N
two-year JJ o
survival NN o
. . o

BACKGROUND NNP N
Although IN N
psychosocial JJ i
therapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
mortality NN o
after IN N
myocardial JJ N
infarction NN N
, , N
it PRP N
is VBZ N
unknown JJ N
whether IN N
the DT N
benefits NNS N
of IN N
psychosocial JJ i
therapy NN i
on IN N
mortality NN o
reduction NN o
extend VBP N
to TO N
out-of-hospital JJ N
sudden JJ N
cardiac NN N
arrest NN N
, , N
a DT N
main JJ N
cause NN N
of IN N
cardiovascular JJ o
mortality NN o
. . o

OBJECTIVE NNP N
Describe NNP N
efficacy NN N
of IN N
psychosocial JJ i
therapy NN i
on IN N
two-year JJ N
cardiovascular JJ o
mortality NN o
in IN N
sudden JJ p
cardiac JJ p
arrest NN p
survivors NNS p
. . p

METHOD NNP N
Survivors NNPS p
of IN p
out-of-hospital JJ p
ventricular JJ p
fibrillation NN p
or CC p
asystole NN p
( ( p
N NNP p
= NNP p
129 CD p
) ) p
, , p
documented VBN p
by IN p
electrocardiograms NNS p
from IN p
registries NNS p
of IN p
a DT p
citywide NN p
Medic NNP p
One NNP p
unit NN p
and CC p
two CD p
countywide NN p
emergency NN p
units NNS p
, , N
were VBD N
randomized VBN N
into IN N
a DT N
two CD N
group NN N
, , N
experimental JJ N
, , N
longitudinal JJ N
design NN N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
11 CD N
individual JJ N
sessions NNS N
, , N
implementing VBG N
three CD N
components NNS N
: : N
physiologic JJ N
relaxation NN N
with IN N
biofeedback NN N
training NN N
focused VBD N
on IN N
altering VBG N
autonomic JJ N
tone NN N
; : N
cognitive JJ i
behavioral JJ i
therapy NN i
aimed VBN N
at IN N
self-management JJ N
and CC N
coping VBG N
strategies NNS N
for IN N
depression NN N
, , N
anxiety NN N
, , N
and CC N
anger NN N
; : N
and CC N
cardiovascular JJ N
health NN N
education NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
cardiovascular JJ o
mortality NN o
. . o

RESULTS NNP N
Risk NNP o
of IN o
cardiovascular JJ o
death NN o
was VBD N
significantly RB N
reduced VBN N
86 CD N
% NN N
by IN N
psychosocial JJ N
therapy NN N
, , N
p NN N
= NNP N
.03 NNP N
. . N

Six NNP N
of IN N
the DT N
seven CD N
cardiovascular JJ o
deaths NNS o
in IN N
the DT N
control NN N
group NN N
were VBD N
caused VBN N
by IN N
ventricular JJ N
arrhythmias NN N
. . N

The DT o
cardiovascular JJ o
death NN o
in IN N
the DT N
therapy NN N
group NN N
was VBD N
due JJ N
to TO N
stroke VB N
. . N

Controlling VBG N
for IN N
depression NN o
, , o
previous JJ o
myocardial JJ o
infarction NN o
, , o
low JJ o
ejection NN o
fraction NN o
, , o
decreased JJ o
heart NN o
rate NN o
variability NN o
, , o
and CC o
ventricular JJ o
ectopic NN o
beats NNS o
had VBD N
little JJ N
impact NN N
on IN N
estimated VBN N
treatment NN N
effect NN N
. . N

The DT N
risk NN o
of IN o
all-cause JJ o
mortality NN o
was VBD N
reduced VBN N
by IN N
62 CD N
% NN N
in IN N
the DT N
therapy NN N
group NN N
, , N
p VBP N
= JJ N
.13 NNP N
. . N

There EX N
were VBD N
a DT N
total NN N
of IN N
three CD N
deaths NNS o
in IN N
the DT N
therapy NN N
group NN N
and CC N
eight CD N
deaths NNS o
in IN N
the DT N
control NN i
group NN N
. . N

CONCLUSIONS NNP N
Psychosocial NNP i
therapy NN i
significantly RB N
reduced VBD N
the DT N
risk NN N
of IN N
cardiovascular JJ o
death NN o
in IN N
sudden JJ p
cardiac JJ p
arrest NN p
survivors NNS p
. . p

-DOCSTART- -2405107- O O

Randomized VBN N
study NN N
of IN N
continuous JJ i
infusion NN i
fluorouracil NN i
versus NN i
fluorouracil NN i
plus CC i
cisplatin NN i
in IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

One CD p
hundred VBD p
twenty-two JJ p
chemotherapy-naive JJ p
patients NNS p
with IN p
histologically RB p
confirmed VBN p
colorectal JJ p
adenocarcinoma NN p
were VBD N
entered VBN N
into IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
infusional JJ i
fluorouracil NN i
( ( i
FU NNP i
) ) i
versus NN i
cisplatin NN i
( ( i
CDDP NNP i
) ) i
and CC i
FU NNP i
. . i

In IN p
both DT p
groups NNS p
, , p
patients NNS p
received VBD p
continuous JJ p
infusion NN p
FU NNP i
1,000 CD p
mg/m2/d NN p
for IN p
5 CD p
consecutive JJ p
days NNS p
every DT p
4 CD p
weeks NNS p
. . p

Patients NNS N
randomized VBD N
to TO N
CDDP/FU NNP i
also RB N
received VBD N
CDDP NNP i
20 CD N
mg/m2 NN N
intravenous JJ N
( ( N
IV NNP N
) ) N
bolus NN N
on IN N
days NNS N
1 CD N
to TO N
5 CD N
of IN N
each DT N
cycle NN N
. . N

Patients NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
age NN N
, , N
performance NN N
status NN N
, , N
baseline VB N
laboratory NN N
values NNS N
, , N
dominant JJ N
sites NNS N
of IN N
measurable JJ N
disease NN N
, , N
and CC N
percent NN N
of IN N
liver JJ N
involvement NN N
. . N

The DT N
partial JJ o
response NN o
rate NN o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
who WP N
received VBD N
CDDP/FU NNP i
versus NN N
FU NNP i
alone RB N
( ( N
25 CD N
% NN N
v JJ N
3 CD N
% NN N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
CDDP/FU NNP i
experienced VBD N
significantly RB N
greater JJR o
toxicity NN o
compared VBN N
with IN N
FU NNP i
alone RB N
: : N
grades NNS o
3 CD o
and CC o
4 CD o
hematologic JJ o
toxicity NN o
occurred VBD N
in IN N
22 CD N
% NN N
and CC N
0 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
; : N
grades VBZ N
2 CD N
to TO N
4 CD N
nausea NN o
and CC o
vomiting NN o
occurred VBD N
in IN N
80 CD N
% NN N
and CC N
15 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
either CC N
the DT N
duration NN o
of IN o
response NN o
( ( N
median JJ N
, , N
6 CD N
and CC N
4.7 CD N
months NNS N
for IN N
CDDP/FU NNP i
and CC N
FU NNP i
groups NNS N
, , N
respectively RB N
) ) N
or CC N
survival NN o
( ( N
median JJ N
10 CD N
, , N
and CC N
12 CD N
months NNS N
, , N
respectively RB N
) ) N
. . N

Compared VBN N
with IN N
infusional JJ N
FU NNP i
alone RB N
, , N
CDDP/FU NNP i
provided VBD N
a DT N
significantly RB N
greater JJR N
partial JJ o
response NN o
rate NN o
with IN N
increased JJ o
toxicity NN o
, , N
but CC N
it PRP N
did VBD N
not RB N
improve VB N
overall JJ o
survival NN o
in IN N
patients NNS p
with IN p
advanced JJ p
colorectal JJ p
carcinoma NN p
. . p

Therefore RB N
, , N
the DT N
use NN N
of IN N
CDDP/FU NNP i
as IN N
routine JJ N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
colorectal JJ N
carcinoma NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -8908288- O O

Final JJ N
report NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
study NN N
with IN N
streptococcal JJ N
preparation NN N
OK-432 NNP i
as IN N
a DT N
supplementary JJ N
immunopotentiator NN N
for IN N
laryngeal JJ p
cancer NN p
. . p

We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
streptococcal JJ N
preparation NN N
OK-432 NNP i
on IN N
120 CD p
newly RB p
identified VBN p
cases NNS p
of IN p
laryngeal JJ p
squamous JJ p
cell NN p
carcinoma NN p
who WP p
were VBD p
registered VBN p
at IN p
10 CD p
participating VBG p
institutions NNS p
between IN p
November NNP p
1984 CD p
and CC p
October NNP p
1989 CD p
. . p

The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
those DT N
in IN N
early JJ N
stages NNS N
( ( N
stage NN N
I PRP N
or CC N
II NNP N
) ) N
and CC N
those DT N
in IN N
advanced JJ N
stages NNS N
( ( N
stage NN N
III NNP N
or CC N
IV NNP N
) ) N
; : N
these DT N
groups NNS N
were VBD N
further RB N
subdivided VBN N
into IN N
an DT N
immunotherapy NN N
group NN N
( ( i
receiving VBG i
OK-432 NNP i
) ) i
and CC N
a DT N
control NN i
group NN N
( ( N
who WP N
did VBD N
not RB N
receive VB N
OK-432 NNP i
) ) i
. . N

The DT N
usefulness NN N
of IN N
OK-432 NNP N
was VBD N
studied VBN N
using VBG N
the DT N
sealed VBN N
envelope NN N
method NN N
. . N

The DT N
basic JJ N
therapy NN N
for IN N
all DT N
cases NNS N
was VBD N
radiotherapy NN N
and CC N
, , N
when WRB N
required VBN N
, , N
surgery NN N
. . N

As IN N
adjuvant JJ N
therapy NN N
, , N
5Fu CD N
or CC N
derivatives NNS N
were VBD N
administered VBN N
to TO N
all DT N
cases NNS N
from IN N
the DT N
beginning NN N
of IN N
the DT N
treatment NN N
period NN N
to TO N
one CD N
year NN N
after IN N
the DT N
basic JJ N
therapy NN N
, , N
with IN N
the DT N
exception NN N
of IN N
cases NNS N
in IN N
whom WP N
side NN N
effects NNS N
were VBD N
serious JJ N
enough RB N
to TO N
contraindicate VB N
use NN N
of IN N
the DT N
drug NN N
. . N

The DT N
target NN N
administration NN N
period NN N
was VBD N
5 CD N
years NNS N
. . N

Of IN p
the DT p
initial JJ p
120 CD p
cases NNS p
, , p
11 CD p
cases NNS p
were VBD p
disqualified VBN p
( ( p
3 CD p
cases NNS p
of IN p
double JJ p
cancer NN p
and CC p
8 CD p
of IN p
incomplete JJ p
primary JJ p
therapy NN p
) ) p
and CC p
the DT p
remaining VBG p
109 CD p
were VBD p
used VBN p
for IN p
evaluation NN p
. . p

The DT N
5-year JJ o
survival NN o
rate NN o
and CC o
the DT o
5-year JJ o
recurrence-free JJ o
rate NN o
were VBD N
76 CD N
% NN N
and CC N
84 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
immunized JJ N
groups NNS N
( ( N
both DT N
the DT N
early JJ N
and CC N
advanced JJ N
groups NNS N
) ) N
, , N
whereas VBP N
the DT N
same JJ N
rates NNS N
for IN N
the DT N
control NN N
groups NNS N
were VBD N
78 CD N
% NN N
and CC N
75 CD N
% NN N
. . N

There EX N
was VBD N
a DT N
tendency NN N
for IN N
the DT N
immunized JJ N
groups NNS N
to TO N
enjoy VB N
a DT N
slightly RB o
longer RBR o
recurrence-free JJ o
period NN o
. . o

Over IN N
a DT N
24-month JJ N
observation NN N
period NN N
the DT N
immunized JJ N
group NN N
always RB N
had VBD N
higher JJR N
levels NNS o
of IN o
peripheral JJ o
leukocytes NNS o
and CC o
peripheral JJ o
lymphocytes NNS o
; : o
this DT N
difference NN N
was VBD N
significant JJ N
for IN N
the DT N
first JJ N
21 CD N
months NNS N
. . N

Inhibition NN o
of IN o
bone NN o
marrow NN o
function NN o
is VBZ N
sometimes RB N
observed VBN N
with IN N
radiotherapy NN N
. . N

It PRP N
is VBZ N
hoped VBN N
that IN N
, , N
if IN N
this DT N
inhibition NN N
can MD N
be VB N
mitigated VBN N
, , N
it PRP N
will MD N
be VB N
possible JJ N
to TO N
assist VB N
the DT N
compromised VBN N
immune NN N
system NN N
and CC N
maintain VB N
a DT N
certain JJ o
level NN o
of IN o
immune JJ o
performance NN o
which WDT N
will MD N
prevent VB N
recurrence NN N
and CC N
improve VB o
survival NN o
rate NN o
. . o

In IN N
the DT N
present JJ N
study NN N
we PRP N
observed VBD N
a DT N
tendency NN N
of IN N
the DT N
lower JJR N
recurrence NN N
rate NN N
in IN N
the DT N
immunized JJ N
group NN N
, , N
and CC N
we PRP N
hypothesize VBP N
that IN N
OK-432 NNP i
is VBZ N
effective JJ N
in IN N
extending VBG N
the DT N
recurrence-free JJ N
period NN N
. . N

-DOCSTART- -10671339- O O

Granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
as IN N
immunomodulating VBG N
factor NN N
together RB N
with IN N
influenza JJ i
vaccination NN i
in IN N
stem NN p
cell NN p
transplant NN p
patients NNS p
. . p

The DT N
effect NN N
of IN N
granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( i
GM-CSF NNP i
) ) i
on IN N
the DT N
serological JJ o
response NN o
at IN N
influenza JJ i
vaccination NN i
was VBD N
studied VBN N
in IN N
117 CD p
patients NNS p
who WP p
had VBD p
undergone JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
SCT NNP p
) ) p
. . p

The DT N
vaccine NN o
response NN o
was VBD N
evaluated VBN N
as IN N
significant JJ N
increases NNS N
in IN N
levels NNS o
of IN o
influenza JJ o
hemagglutination-inhibition NN o
( ( o
HAI NNP o
) ) o
antibodies NNS o
and CC N
of IN N
IgG NNP o
antibodies NNS o
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
antibody NN o
response NN o
to TO N
either DT N
influenza VB N
A NNP N
or CC N
B NNP N
in IN N
64 CD N
patients NNS N
who WP N
received VBD N
GM-CSF NNP i
at IN N
vaccination NN N
, , N
compared VBN N
with IN N
the DT N
53 NNS N
who WP N
did VBD N
not RB N
. . N

In IN N
the DT N
subgroup NN p
of IN p
allogeneic JJ p
SCT NNP p
patients NNS p
, , N
HAI NNP N
showed VBD N
that IN N
the DT N
response NN o
rate NN o
to TO N
the DT N
influenza NN o
B NNP o
vaccine NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

ELISA NN o
showed VBD N
that IN N
autologous JJ p
SCT NNP p
patients NNS p
with IN p
breast JJ p
cancer NN p
who WP N
received VBD N
GM-CSF NNP N
had VBD N
a DT N
better JJR N
response NN o
to TO N
influenza VB o
A NNP o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
B NNP o
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

At IN N
early JJ N
vaccination NN N
, , N
4-12 JJ N
months NNS N
after IN N
stem NN N
cell NN N
transplantation NN N
, , N
these DT N
responses NNS N
were VBD N
more RBR N
pronounced JJ N
. . N

GM-CSF JJ i
appears VBZ N
to TO N
improve VB N
the DT N
response NN o
to TO o
influenza VB o
vaccination NN o
in IN N
some DT N
groups NNS N
of IN N
SCT NNP p
patients NNS p
, , N
but CC N
only RB N
to TO N
a DT N
limited JJ N
extent NN N
. . N

-DOCSTART- -1764390- O O

The DT N
EUROSCAN NNP i
Study NNP p
. . p

EUROSCAN NNP i
Steering NNP p
Committee NNP p
. . p

-DOCSTART- -24675775- O O

The DT N
effect NN N
of IN N
modified VBN i
eggs NNS i
and CC i
an DT i
egg-yolk NN i
based VBN i
beverage NN i
on IN p
serum NN o
lutein NN o
and CC o
zeaxanthin JJ o
concentrations NNS o
and CC N
macular JJ N
pigment NN N
optical JJ N
density NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

UNLABELLED CC N
Increasing VBG N
evidence NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
lutein NN N
and CC N
zeaxanthin NN N
on IN N
the DT N
progression NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
lutein NN i
or CC i
zeaxanthin NN i
enriched VBN i
eggs NNS i
or CC i
a DT i
lutein JJ i
enriched VBN i
egg-yolk NN i
based VBN i
buttermilk NN i
beverage NN i
on IN N
serum NN o
lutein NN o
and CC o
zeaxanthin JJ o
concentrations NNS o
and CC N
macular JJ N
pigment NN N
levels NNS N
. . N

Naturally RB i
enriched VBN i
eggs NNS i
were VBD N
made VBN N
by IN N
increasing VBG N
the DT N
levels NNS N
of IN N
the DT N
xanthophylls NNP N
lutein NN N
and CC N
zeaxanthin NN i
in IN N
the DT N
feed NN N
given VBN N
to TO N
laying VBG N
hens NNS N
. . N

One CD p
hundred VBD p
healthy JJ p
volunteers NNS p
were VBD p
recruited VBN p
and CC p
randomized VBN p
into IN p
5 CD p
groups NNS p
for IN p
90 CD p
days NNS p
. . p

Group NNP N
one CD N
added VBD N
one CD i
normal JJ i
egg NN i
to TO i
their PRP$ i
daily JJ i
diet NNS i
and CC N
group NN i
two CD i
received VBD i
a DT i
lutein NN i
enriched VBD i
egg-yolk NN i
based VBN i
beverage NN i
. . i

Group NNP N
three CD N
added VBD N
one CD i
lutein NN i
enriched VBD i
egg NN i
and CC N
group NN i
four CD i
one CD i
zeaxanthin NN i
enriched VBD i
egg NN i
to TO i
their PRP$ i
diet JJ i
. . i

Group NNP N
five CD N
was VBD N
the DT N
control NN i
group NN i
and CC i
individuals NNS i
in IN i
this DT i
group NN i
did VBD i
not RB i
modify VB i
their PRP$ i
daily JJ i
diet NN i
. . i

Serum NNP o
lutein NN o
and CC o
zeaxanthin JJ o
concentrations NNS o
and CC N
macular JJ o
pigment NN o
densities NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
day NN N
45 CD N
and CC N
day NN N
90 CD N
. . N

Macular JJ o
pigment NN o
density NN o
was VBD N
measured VBN N
by IN N
heterochromatic JJ N
flicker NN N
photometry NN N
. . N

Serum NNP o
lutein JJ o
concentration NN o
in IN N
the DT N
lutein NN N
enriched VBD N
egg NN N
and CC N
egg NN N
yolk-based JJ N
beverage NN N
groups NNS N
increased VBD N
significantly RB N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
76 CD N
% NN N
and CC N
77 CD N
% NN N
) ) N
. . N

A DT N
strong JJ N
increase NN N
in IN N
the DT N
serum NN o
zeaxanthin NN o
concentration NN o
was VBD N
observed VBN N
in IN N
individuals NNS N
receiving VBG N
zeaxanthin NN i
enriched VBN i
eggs NNS i
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
430 CD N
% NN N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
in IN N
macular JJ o
pigment NN o
density NN o
in IN N
the DT N
various JJ N
groups NNS N
tested VBN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
daily JJ N
consumption NN N
of IN N
lutein NN i
or CC i
zeaxanthin NN i
enriched VBN i
egg NN i
yolks NNS i
as RB N
well RB N
as IN N
an DT N
egg NN i
yolk-based JJ i
beverage NN i
show NN N
increases VBZ N
in IN N
serum NN o
lutein NN o
and CC o
zeaxanthin NN o
levels NNS o
that WDT N
are VBP N
comparable JJ N
with IN N
a DT N
daily JJ N
use NN N
of IN N
5 CD N
mg NN N
supplements NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00527553 NNP N
. . N

-DOCSTART- -24277510- O O

Comparative JJ N
evaluation NN N
of IN N
percutaneous JJ i
laser NN i
and CC N
radiofrequency NN i
ablation NN i
in IN N
patients NNS p
with IN p
HCC NNP p
smaller JJR p
than IN p
4 CD p
cm NN p
. . p

OBJECTIVE CC N
This DT N
study NN N
was VBD N
done VBN N
to TO N
compare VB N
percutaneous JJ i
laser NN i
ablation NN i
( ( i
PLA NNP i
) ) i
and CC N
radiofrequency NN i
thermoablation NN i
( ( i
RFA NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
? . p
4 CD p
cm NN p
, , p
in IN p
patients NNS p
with IN p
liver JJ p
cirrhosis NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP p
Thirty NNP p
patients NNS p
with IN p
single JJ p
HCC NNP p
? . p
4 CD p
cm NN p
in IN p
diameter NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
treatments NNS p
: : p
15 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
PLA NNP i
, , N
using VBG i
a DT i
multifibre NN i
system NN i
connected VBN i
to TO i
a DT i
neodymium JJ i
yttrium-aluminium-garnet NN i
laser NN i
source NN i
; : i
15 CD i
patients NNS p
were VBD p
treated VBN p
with IN p
RFA NNP i
, , i
using VBG i
an DT i
expandable JJ i
needle JJ i
electrode NN i
. . i

Patients NNS i
were VBD N
followed VBN N
up RP N
for IN N
up RB N
to TO N
12 CD N
months NNS N
. . N

RESULTS VB N
A NNP N
complete JJ N
response NN N
was VBD N
obtained VBN N
in IN N
87 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
PLA NNP N
and CC N
in IN N
93 CD N
% NN N
lesions NNS N
treated VBN N
with IN N
RFA NNP N
( ( N
p JJ N
= NNP N
ns NN N
) ) N
. . N

The DT N
overall JJ o
local JJ o
recurrence-free JJ o
survival NN o
rates NNS o
at IN o
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
comparable JJ N
. . N

However RB N
, , N
a DT N
higher JJR o
rate NN o
of IN o
recurrence NN o
was VBD o
observed VBN N
in IN N
the DT N
PLA NNP N
group NN N
for IN N
lesions NNS N
? . N
21 CD N
mm NN N
( ( N
p JJ N
= NNP N
0.0081 CD N
) ) o
. . o

A DT o
postablation NN o
syndrome NN o
was VBD o
documented VBN o
in IN p
13 CD p
patients NNS p
( ( p
1 CD p
PLA NNP p
; : N
12 CD N
RFA NNP N
) ) N
. . N

Tumour JJ o
necrosis NN o
factor-? NN o
was VBD o
significantly RB o
higher JJR N
in IN N
the DT N
RFA NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
RFA NNP N
is VBZ N
more RBR N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
HCC NNP N
compared VBN i
to TO i
PLA NNP i
for IN N
lesions NNS N
? . N
21 CD N
mm NN N
. . N

However RB N
, , N
PLA NNP N
should MD N
be VB N
considered VBN N
a DT N
viable JJ N
treatment NN N
option NN N
for IN N
HCC NNP N
? . N
20 CD N
mm NN N
, , N
in IN N
view NN N
of IN N
the DT N
lower JJR N
incidence NN N
of IN N
complications NNS N
. . N

-DOCSTART- -12204666- O O

Quality NN N
assurance NN N
in IN N
the DT N
EORTC NNP N
22921 CD N
trial NN N
on IN N
preoperative JJ i
radiotherapy NN i
with IN i
or CC i
without IN i
chemotherapy NN i
for IN N
resectable JJ p
rectal JJ p
cancer NN p
: : p
evaluation NN N
of IN N
the DT N
individual JJ N
case NN N
review NN N
procedure NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
any DT N
inconsistency NN N
with IN N
the DT N
protocol NN N
guidelines NNS N
for IN N
preoperative JJ i
radiotherapy NN i
for IN N
rectal JJ p
cancer NN p
among IN N
radiotherapy JJ p
institutions NNS p
participating VBG p
in IN p
the DT p
framework NN p
of IN p
a DT p
multicentre JJ p
phase-III JJ p
European JJ p
Organization NNP p
for IN p
Research NNP p
and CC p
Treatment NNP p
of IN p
Cancer NNP p
( ( p
EORTC NNP p
) ) p
clinical JJ p
trial NN p
. . p

Twelve NNP p
radiotherapy NN p
departments NNS p
with IN p
more JJR p
than IN p
10 CD p
% NN p
of IN p
the DT p
evaluable JJ p
patients NNS p
recruited VBN p
in IN p
the DT p
trial NN p
, , N
were VBD N
invited VBN N
to TO N
participate VB N
in IN N
this DT N
individual JJ N
case NN N
review NN N
. . N

Participating VBG p
institutions NNS p
were VBD N
asked VBN N
to TO N
send VB N
five CD p
full JJ p
patient NN p
records NNS p
with IN p
the DT p
chemotherapy NN p
charts NNS p
, , p
surgical JJ p
and CC p
pathology NN p
reports NNS p
, , p
radiation NN p
treatment NN p
charts NNS p
, , p
treatment NN p
planning NN p
calculations NNS p
, , p
computed VBN p
tomography NN p
( ( p
CT NNP p
) ) p
scans NNS p
, , p
portal JJ p
images NNS p
and CC p
follow-up JJ p
charts NNS p
. . p

The DT N
sample NN N
of IN N
the DT N
5 CD p
patients NNS p
per IN p
institution NN p
was VBD p
randomly RB N
selected VBN N
at IN N
the DT N
EORTC NNP N
Data NNP N
Center NNP N
. . N

All DT N
12 CD N
departments NNS N
participated VBN N
. . N

In IN N
21 CD N
( ( N
35 CD N
% NN N
) ) N
of IN N
the DT N
cases NNS N
, , N
a DT N
three-field JJ N
technique NN N
with IN N
two CD N
lateral JJ N
opposed VBD N
wedge NN N
fields NNS N
and CC N
a DT N
posterior JJ N
field NN N
was VBD N
used VBN N
, , N
while IN N
in IN N
39 CD N
( ( N
65 CD N
% NN N
) ) N
of IN N
the DT N
cases NNS N
a DT N
four-field JJ N
pelvic NN N
box NN N
technique NN N
was VBD N
used VBN N
. . N

All DT N
participants NNS N
used VBN N
linear JJ N
accelerators NNS N
with IN N
a DT N
minimum NN N
of IN N
6 CD N
MeV NNP N
photon-beam NN N
energy NN N
. . N

In IN N
general JJ N
, , N
the DT N
patients NNS N
were VBD N
eligible JJ N
, , N
documentation NN N
of IN N
clinical JJ N
data NNS N
was VBD N
fair JJ N
to TO N
good JJ N
and CC N
there EX N
were VBD N
no DT N
systematic JJ N
major JJ N
protocol NN N
deviations NNS N
. . N

The DT N
actual JJ o
total NN o
dose NN o
was VBD N
44.7+/-a JJ N
standard JJ N
deviation NN N
( ( N
S.D NNP N
. . N

) ) N
of IN N
4.6 CD N
Gy NNP N
. . N

Some DT N
variation NN N
was VBD N
found VBN N
in IN N
the DT N
fraction NN N
size NN N
. . N

All DT N
institutions NNS N
complied VBN N
with IN N
the DT N
protocol NN N
in IN N
specifying VBG N
the DT N
reference NN N
dose NN N
at IN N
the DT N
ICRU NNP N
point NN N
. . N

The DT N
clinical JJ o
target NN o
volume NN o
( ( o
CTV NNP o
) ) o
drawn NN N
on IN N
the DT N
CT NNP N
scan NN N
was VBD N
narrow JJ N
in IN N
7 CD N
( ( N
12 CD N
% NN N
) ) N
cases NNS N
, , N
but CC N
eventually RB N
the DT N
actually RB N
treated VBN N
volumes NNS N
in IN N
terms NNS N
of IN N
planned VBN o
treatment NN o
volume NN o
( ( o
PTV NNP o
) ) o
were VBD N
correct JJ N
. . N

In IN N
two CD N
institutions NNS N
, , N
although IN N
the DT N
CTV NNP o
was VBD N
drawn VBN N
correctly RB N
, , N
the DT N
fields NNS N
appeared VBD N
to TO N
be VB N
narrow JJ N
especially RB N
in IN N
cranio-caudal JJ o
direction NN o
. . o

Variations NNS N
in IN N
treated JJ o
volumes NNS o
and CC o
total JJ o
radiation NN o
dose NN o
were VBD N
encountered VBN N
in IN N
the DT N
individual JJ N
case NN N
review NN N
. . N

By IN N
providing VBG N
recommendations NNS N
early RB N
during IN N
the DT N
course NN N
of IN N
the DT N
trial NN N
, , N
we PRP N
expect VBP N
to TO N
improve VB N
the DT N
inter-institutional JJ o
consistency NN o
and CC N
to TO N
promote VB N
a DT N
high JJ N
quality NN N
treatment NN N
in IN N
all DT N
of IN N
the DT N
participating NN N
institutions NNS N
. . N

-DOCSTART- -25910710- O O

Investigating VBG N
a DT N
Multimodal NNP i
Intervention NNP i
for IN N
Children NNP p
With IN p
Limited NNP p
Expressive NNP p
Vocabularies NNP p
Associated NNP p
With IN p
Autism NNP p
. . p

PURPOSE NNP N
This DT N
study NN N
investigated VBD N
a DT N
new JJ N
intervention NN N
package NN N
aimed VBN N
at IN N
increasing VBG N
expressive JJ N
word NN N
learning NN N
by IN N
school-age JJ p
children NNS p
with IN p
autism NN p
who WP p
have VBP p
limited VBN p
expressive JJ p
vocabularies NNS p
. . p

This DT N
pilot NN N
investigation NN N
was VBD N
intended VBN N
to TO N
show VB N
proof NN N
of IN N
concept NN N
. . N

METHOD NNP N
Ten CD p
children NNS p
between IN p
the DT p
ages NNS p
of IN p
6 CD p
and CC p
10 CD p
years NNS p
participated VBD p
, , p
with IN p
educational JJ p
diagnoses NNS p
of IN p
autism NN p
and CC p
limited JJ p
expressive JJ p
vocabularies NNS p
at IN p
the DT p
outset NN p
of IN p
the DT p
study NN p
. . p

A DT N
multimodal JJ i
intervention NN i
composed VBN i
of IN i
speech NN i
sound NN i
practice NN i
and CC i
augmentative JJ i
and CC i
alternative JJ i
communication NN i
was VBD N
used VBN N
to TO N
teach VB N
individualized JJ N
vocabulary JJ N
words NNS N
that WDT N
were VBD N
selected VBN N
on IN N
the DT N
basis NN N
of IN N
initial JJ N
speech NN N
sound NN N
repertoires NNS N
and CC N
principles NNS N
of IN N
phonotactic JJ N
probability NN N
and CC N
neighborhood NN N
density NN N
. . N

A DT N
multiple-probe JJ N
design NN N
was VBD N
used VBN N
to TO N
evaluate VB N
learning NN N
outcomes NNS N
. . N

RESULTS NNP N
Five NNP N
children NNS p
showed VBD N
gains NNS N
in IN N
spoken-word NN o
learning NN o
across IN o
successive JJ o
word NN o
sets NNS o
( ( N
high JJ N
responders NNS N
) ) N
. . N

Five CD N
children NNS p
did VBD N
not RB N
meet VB N
learning VBG N
criteria NNS N
( ( N
low JJ N
responders NNS N
) ) N
. . N

Comparisons NNS N
of IN N
behaviors NNS N
measured VBN N
prior RB N
to TO N
intervention NN N
indicated VBD N
that DT N
high JJ N
responders NNS N
had VBD N
relatively RB N
higher JJR N
skills NNS N
in IN N
receptive JJ o
language NN o
, , o
prelinguistic JJ o
communication NN o
, , o
vocal/verbal JJ o
imitation NN o
, , o
adaptive JJ o
behavior NN o
, , o
and CC o
consonant JJ o
productions NNS o
. . o

CONCLUSIONS VB N
The DT N
intervention NN i
package NN i
holds VBZ N
promise NN N
for IN N
improving VBG N
spoken JJ N
word NN N
productions NNS N
for IN N
some DT N
children NNS p
with IN p
autism NN p
who WP p
have VBP p
limited VBN p
expressive JJ p
vocabularies NNS p
. . p

Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
better RBR N
describe VB N
who WP N
may MD N
most VB N
benefit VB N
from IN N
this DT N
approach NN N
as RB N
well RB N
as IN N
investigate NN N
generalized VBD N
benefits NNS N
to TO N
untaught JJ N
contexts NN N
and CC N
targets NNS N
. . N

-DOCSTART- -23942329- O O

Tissue NN N
microarray NN N
in IN N
a DT N
subset NN N
of IN N
South JJ p
African JJ p
patients NNS p
with IN p
DLBCL NNP p
. . p

Tissue NN N
samples NNS N
from IN N
93 CD p
de NNS p
novo FW p
diffuse RB p
large JJ p
B-cell NNP p
lymphoma NN p
patients NNS p
seen VBN p
between IN p
1995 CD p
and CC p
2009 CD p
randomly NN p
receiving VBG p
either CC p
standard JJ i
combination NN i
chemotherapy NN i
( ( i
CHOP NNP i
, , p
n=48 NN p
) ) p
or CC i
the DT i
identical JJ i
program NN i
with IN i
rituximab NN i
( ( p
n=45 JJ p
) ) p
were VBD N
subtyped VBN N
using VBG N
an DT N
investigational JJ N
immunohistochemical NN N
( ( N
IHC NNP N
) ) N
based VBN N
tissue NN N
microarray NN N
( ( N
TMA NNP N
) ) N
and CC N
contrasted VBN N
to TO N
the DT N
approximately RB N
corresponding JJ N
categories NNS N
as IN N
defined VBN N
either CC N
by IN N
Hans NNPS N
and CC N
associates NNS N
using VBG N
a DT N
three CD N
marker NN N
panel NN N
into IN N
germinal JJ N
or CC N
non-germinal JJ N
centre NN N
subtypes NNS N
or CC N
by IN N
Choi NNP N
and CC N
colleagues NNS N
with IN N
two CD N
additional JJ N
antibodies NNS N
into IN N
germinal JJ N
centre NN N
( ( N
GCB NNP N
) ) N
or CC N
activated VBN N
B-cells NNP N
( ( N
ABC NNP N
) ) N
. . N

Each DT N
of IN N
these DT N
primary JJ N
subdivisions NNS N
was VBD N
further RBR N
evaluated VBN o
for IN o
expression NN o
of IN o
BCL2 NNP o
and CC o
LMO2 NNP o
both DT N
of IN N
which WDT N
are VBP N
recognised VBN N
to TO N
predicate VB N
response NN N
. . N

The DT N
addition NN N
of IN N
rituximab NN N
to TO N
the DT N
uniform JJ N
drug NN N
regimen NNS N
did VBD N
not RB N
show VB N
any DT N
significant JJ N
improvement NN N
in IN N
5 CD N
years NNS N
overall JJ o
( ( N
63 CD N
% NN N
versus IN N
59 CD N
% NN N
, , N
p RB N
0.68 CD N
) ) N
or CC o
event-free JJ o
survival NN o
( ( N
42 CD N
% NN N
versus IN N
39 CD N
% NN N
, , N
p RB N
0.94 CD N
) ) N
, , N
for IN N
CHOP NNP N
versus NN N
R-CHOP NNP N
comparisons NNS N
. . N

Similarly RB N
no DT N
differences NNS N
were VBD N
evident JJ N
in IN N
subtype JJ N
analysis NN N
. . N

Interestingly RB N
however RB N
, , N
when WRB N
segregated VBN N
on IN N
the DT N
Choi NNP N
criteria NNS N
, , N
cytotoxic NN N
drugs NNS N
alone RB N
showed VBD N
a DT N
non-significant JJ N
trend NN N
in IN N
improved JJ N
survival NN N
( ( N
74 CD N
% NN N
versus IN N
55 CD N
% NN N
, , N
p RB N
0.32 CD N
) ) N
as RB N
well RB N
as IN N
event-free JJ N
survival NN N
( ( N
44 CD N
% NN N
versus IN N
40 CD N
% NN N
, , N
p RB N
0.42 CD N
) ) N
for IN N
the DT N
germinal JJ N
centre NN N
as IN N
opposed VBN N
to TO N
the DT N
activated VBN N
B-cell NNP N
subtype NN N
. . N

Nevertheless NNP N
not RB N
even RB N
a DT N
small JJ N
difference NN N
could MD N
be VB N
demonstrated VBN N
in IN N
the DT N
presence NN N
of IN N
the DT N
anti JJ N
CD NN N
20 CD N
monoclonal JJ N
antibody NN N
. . N

According VBG N
to TO N
Choi NNP N
, , N
both DT N
regimens NNS N
( ( N
chemotherapy NN N
or CC N
immunotherapy VB N
antibody NN N
) ) N
revealed VBD N
similar JJ N
results NNS N
to TO N
the DT N
Hans NNPS N
algorithm VBP N
on IN N
5 CD N
years NNS N
OS NNP N
as RB N
well RB N
as IN N
3 CD N
year NN N
EFS NNP N
when WRB N
comparing VBG N
GCB NNP N
versus NN N
ABC NNP N
or CC N
non-GCB JJ N
subgroups NNS N
. . N

BCL2 NNP N
and CC N
LMO2 NNP N
marker NNP N
expression NN N
of IN N
the DT N
respective JJ N
immunohistochemical JJ N
( ( N
IHC NNP N
) ) N
subtype NN N
, , N
despite IN N
small JJ N
sample NN N
size NN N
, , N
revealed VBD N
the DT N
following NN N
. . N

Analysis NN N
by IN N
Choi NNP N
criteria NNS N
on IN N
survival NN N
for IN N
BCL2 NNP N
, , N
no DT N
matter NN N
for IN N
which WDT N
subsets NNS N
( ( N
GCB NNP N
or CC N
ABC NNP N
) ) N
or CC N
treatment NN N
modality NN N
( ( N
chemotherapy NN N
with IN N
or CC N
without IN N
the DT N
addition NN N
of IN N
rituximab NN N
) ) N
showed VBD N
no DT N
difference NN N
in IN N
5 CD N
years NNS N
OS NNP N
or CC N
EFS NNP N
. . N

In IN N
contrast NN N
, , N
a DT N
significant JJ N
difference NN N
for IN N
better JJR N
EFS NNP N
( ( N
p=0.0015 NN N
) ) N
in IN N
the DT N
BCL2 NNP N
positive JJ N
group NN N
of IN N
the DT N
ABC NNP N
subgroups NNS N
subtypes NNS N
treated VBN N
with IN N
rituximab NN N
containing VBG N
chemotherapy NN N
. . N

For IN N
LMO2 NNP N
similar JJ N
results NNS N
on IN N
survival JJ N
outcome NN N
were VBD N
seen VBN N
thus RB N
showing VBG N
no DT N
difference NN N
in IN N
5 CD o
years NNS o
OS NNP o
or CC o
EFS NNP o
- : N
regardless NN N
of IN N
subtype NN N
or CC N
treatment NN N
modality NN N
. . N

Also RB N
here RB N
, , N
this DT N
was VBD N
contrasted VBN N
by IN N
better JJR N
EFS NNP N
( ( N
p=0.039 NN N
) ) N
in IN N
the DT N
LMO2 NNP N
positive JJ N
group NN N
of IN N
ABC NNP N
subtypes NNS N
when WRB N
treated VBN N
with IN N
the DT N
rituximab NN N
containing VBG N
regimen NNS N
. . N

The DT N
use NN N
of IN N
the DT N
IHC NNP N
based VBN N
TMA NNP N
methodology NN N
has VBZ N
shown VBN N
to TO N
be VB N
a DT N
simple JJ o
, , o
cost NN o
effective JJ o
and CC o
a DT o
robust JJ o
alternative NN o
to TO o
gene NN o
expression NN o
profiling VBG o
( ( o
GEP NNP o
) ) o
which WDT N
is VBZ N
currently RB N
regarded VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
classification NN N
in IN N
lymphomas NN N
. . N

It PRP N
provides VBZ N
a DT N
useful JJ N
prognostic JJ N
tool NN N
in IN N
stratifying VBG N
DLBCL NNP N
or CC N
other JJ N
entities NNS N
in IN N
future JJ N
, , N
even RB N
when WRB N
frozen JJ N
tissue NN N
samples NNS N
are VBP N
not RB N
available JJ N
for IN N
GEP NNP N
analysis NN N
. . N

With IN N
the DT N
current JJ N
budgetary JJ N
limitations NNS N
in IN N
South JJ p
African JJ p
public JJ p
hospitals NNS p
chemotherapy VBP N
protocols NNS N
for IN N
lymphoproliferative JJ N
disorders NNS N
exclude VBP N
agents NNS N
such JJ N
as IN N
rituximab NN N
. . N

Local JJ N
therapeutic JJ N
drug NN N
committees NNS N
consider VBP N
the DT N
approximately RB N
15 CD N
% NN N
overall JJ N
survival NN o
benefit NN o
seen VBN N
at IN N
5 CD N
years NNS N
for IN N
DLBCL NNP N
when WRB N
rituximab NN N
is VBZ N
added VBN N
to TO N
combination VB N
chemotherapy NN N
as IN N
too RB N
marginal JJ N
for IN N
justifying VBG N
the DT N
arising VBG N
additional JJ N
expenses NNS N
. . N

Accordingly RB N
, , N
demonstration NN N
that IN N
a DT N
specific JJ N
molecular JJ N
subtype NN N
accounts NNS N
for IN N
superior JJ N
outcome NN N
, , N
when WRB N
using VBG N
these DT N
regimens NNS N
, , N
is VBZ N
needed VBN N
. . N

Such JJ N
an DT N
option NN N
would MD N
provide VB N
convincing VBG N
evidence NN N
for IN N
the DT N
use NN N
of IN N
immunochemotherapy NN N
in IN N
a DT N
resource NN N
constrained VBD N
setting NN N
. . N

-DOCSTART- -9570244- O O

A DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
amoxycillin NN i
and CC i
omeprazole NN i
with IN N
and CC N
without IN N
metronidazole NN i
in IN N
the DT N
eradication NN N
treatment NN p
of IN p
Helicobacter NNP p
pylori NN p
. . p

A DT N
combination NN N
of IN i
amoxycillin NN i
and CC i
omeprazole NN i
is VBZ N
often RB N
used VBN N
to TO N
treat VB N
Helicobacter NNP p
pylori JJ p
infection NN p
. . p

A DT N
three-drug JJ N
regimen NN N
comprising VBG N
metronidazole NN i
, , i
amoxycillin NN i
and CC i
omeprazole NN i
has VBZ N
been VBN N
proposed VBN N
as IN N
an DT N
alternative JJ N
therapy NN N
. . N

In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
comparative JJ N
study NN N
, , N
we PRP N
evaluated VBD N
these DT N
two CD N
regimens NNS N
with IN N
respect NN N
to TO N
safety NN N
and CC N
efficacy NN N
in IN N
patients NNS p
with IN p
H. NNP p
pylori JJ p
infection NN p
. . p

Sixty JJ p
patients NNS p
with IN p
peptic JJ p
ulcer NN p
( ( p
gastric JJ p
, , p
32 CD p
patients NNS p
; : p
duodenal JJ p
, , p
28 CD p
patients NNS p
) ) p
who WP p
had VBD p
a DT p
history NN p
of IN p
ulcer JJ p
recurrence NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
dual JJ N
therapy NN N
with IN N
amoxycillin NN i
( ( N
500 CD N
mg NN N
three CD N
times NNS N
daily RB N
for IN N
2 CD N
weeks NNS N
) ) N
and CC N
omeprazole JJ i
( ( N
20 CD N
mg NN N
once RB N
daily JJ N
for IN N
8 CD N
weeks NNS N
) ) N
or CC N
to TO N
triple VB N
therapy NN N
with IN N
metronidazole NN i
( ( N
500 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
) ) N
plus CC i
amoxycillin JJ i
and CC i
omeprazole JJ i
, , N
given VBN N
in IN N
the DT N
same JJ N
dosages NNS N
as IN N
dual JJ N
therapy NN N
. . N

Forty-eight JJ p
patients NNS p
completed VBD p
the DT p
protocol NN p
; : p
treatment NN N
was VBD N
discontinued VBN N
because IN N
of IN N
side NN N
effects NNS N
in IN N
nine CD N
patients NNS N
, , N
and CC N
three CD N
patients NNS N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
. . N

On IN N
the DT N
basis NN N
of IN N
all DT N
patients NNS N
treated VBN N
, , N
the DT o
rate NN o
of IN o
H. NNP o
pylori FW o
eradication NN o
was VBD o
significantly RB o
higher JJR o
for IN o
triple JJ o
therapy NN o
20/23 CD o
cases NNS o
, , o
87.0 CD o
% NN o
; : o
95 CD o
% NN o
confidence NN o
interval NN o
( ( o
CI NNP o
) ) o
, , o
0.664-0.972 JJ o
) ) o
than IN o
for IN o
dual JJ o
therapy NN o
13/25 CD N
, , N
52.0 CD N
% NN N
; : N
0.313-0.722 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

On IN N
an DT N
intention-to-treat JJ N
basis NN N
, , N
the DT o
difference NN o
between IN o
the DT o
groups NNS o
in IN o
the DT o
rate NN o
of IN o
H. NNP o
pylori FW o
eradication NN o
was VBD o
marginally RB o
significant JJ o
( ( N
P NNP N
= VBZ N
0.06 CD N
[ JJ N
0.028-0.512 JJ N
] NN N
) ) N
. . N

Side JJ o
effects NNS o
were VBD o
reported VBN o
by IN o
five CD o
patients NNS o
receiving VBG o
triple JJ o
therapy NN o
( ( o
skin JJ o
rash NN o
, , N
one CD N
; : N
nausea NN o
, , N
two CD N
; : N
headache NN o
, , N
one CD N
; : N
abdominal JJ o
pain NN o
, , N
one CD N
) ) N
, , N
and CC N
four CD o
patients NNS o
receiving VBG o
dual JJ o
therapy NN o
( ( o
skin JJ o
rash NN o
, , N
two CD N
; : N
abdominal JJ o
pain NN o
, , N
one CD N
; : N
diarrhoea NN o
, , N
one CD N
) ) N
. . N

All DT o
side NN o
effects NNS o
resolved VBD o
spontaneously RB o
after IN o
termination NN o
of IN o
treatment NN o
. . o

There EX o
was VBD o
no DT o
significant JJ o
difference NN o
in IN o
safety NN o
between IN o
the DT o
two CD o
regimens NNS o
. . o

Triple JJ o
therapy NN o
with IN o
metronidazole NN o
, , o
amoxycillin NN o
, , o
and CC o
omeprazole NN o
was VBD o
significantly RB o
more RBR o
effective JJ o
for IN o
the DT o
eradication NN o
of IN o
H. NNP o
pylori FW o
than IN o
dual JJ o
therapy NN o
with IN o
amoxycillin NN o
and CC o
omeprazole JJ o
alone RB o
. . o

The DT N
safety NN N
of IN N
these DT N
regimens NNS N
was VBD N
similar JJ N
, , N
and CC N
triple JJ N
therapy NN N
was VBD N
found VBN N
to TO N
be VB N
clinically RB N
acceptable JJ N
. . N

-DOCSTART- -21900715- O O

Effect NN N
of IN N
an DT N
induction NN N
period NN N
of IN N
pegylated JJ i
interferon-?2a JJ i
and CC i
ribavirin VB i
on IN o
early JJ o
virological JJ o
response NN o
in IN p
HIV-HCV-coinfected JJ p
patients NNS p
: : p
results NNS N
from IN N
the DT N
CORAL-2 NNP N
study NN N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
uncertain JJ N
whether IN N
a DT N
4-week JJ N
induction NN N
period NN N
of IN i
pegylated JJ i
interferon NN i
and CC i
ribavirin NN i
increases NNS o
early RB o
virological JJ o
response NN o
( ( o
EVR NNP o
) ) o
in IN p
HIV-HCV-coinfected JJ p
patients NNS p
. . p

METHODS NNP p
HIV NNP p
and CC p
HCV NNP p
genotype VBP p
1- JJ p
and CC p
4-coinfected JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
receive VB i
pegylated VBN i
interferon-?2a JJ i
270 CD i
?g/week JJ i
plus CC i
ribavirin JJ i
1,600 CD i
mg JJ i
daily JJ N
and CC N
epoetin-? JJ i
for IN i
4 CD N
weeks NNS N
, , N
followed VBN i
by IN i
pegylated JJ i
interferon-?2a NN i
at IN i
standard JJ i
dosages NNS N
plus CC N
weight-based JJ N
ribavirin NN N
( ( N
WBR NNP N
) ) N
dosage NN N
for IN N
8 CD N
weeks NNS N
( ( N
induction NN N
arm NN N
[ NNP N
IA NNP N
] NNP N
) ) N
, , i
or CC i
pegylated VBD i
interferon-?2a JJ i
plus CC i
WBR NNP i
for IN i
12 CD N
weeks NNS N
( ( N
standard JJ N
therapy NN N
arm NN N
[ NNP N
SA NNP N
] NNP N
) ) N
. . N

HCV NNP o
RNA NNP o
was VBD o
determined VBN N
at IN N
weeks NNS N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
8 CD N
and CC N
12 CD N
. . o

Ribavirin NNP o
plasma VBD o
trough JJ o
concentrations NNS o
were VBD o
determined VBN N
at IN N
weeks NNS N
4 CD N
( ( N
RBV-C NNP N
( ( N
4 CD N
) ) N
) ) N
and CC N
12 CD N
( ( N
RBV-C NNP N
( ( N
12 CD N
) ) N
) ) N
. . N

RESULTS VB p
A DT p
total NN p
of IN p
67 CD p
patients NNS p
were VBD p
included VBN p
; : p
33 CD p
in IN p
the DT N
SA NNP N
and CC N
34 CD N
in IN N
the DT N
IA NNP N
. . N

Overall NNP N
, , N
25 CD N
% NN N
received VBD o
nucleoside JJ o
reverse NN o
transcriptase NN o
inhibitor NN o
( ( o
NRTI NNP o
) ) o
-sparing VBG o
regimens NNS o
. . o

More JJR o
patients NNS N
achieved VBD o
an DT o
HCV NNP o
RNA NNP o
decrease NN o
?1 NNP o
log NN o
( ( N
10 CD N
) ) N
at IN N
week NN N
4 CD N
in IN N
the DT N
IA NNP N
than IN N
in IN N
the DT N
SA NNP N
( ( N
62 CD N
% NN N
versus IN N
38 CD N
% NN N
; : N
P=0.017 NNP N
) ) N
, , o
but CC o
EVR NNP o
rates NNS o
were VBD o
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
74 CD N
% NN N
versus IN N
59 CD N
% NN N
in IN N
the DT N
IA NNP N
and CC N
SA NNP N
, , N
respectively RB N
; : N
P=0.15 NNP N
) ) N
. . N

Independent JJ N
predictors NNS N
of IN N
faster NN o
HCV NNP o
RNA NNP o
decrease NN o
at IN o
12 CD o
weeks NNS o
were VBD N
higher JJR N
RBV-C NNP N
( ( N
4 CD N
) ) N
and CC N
younger JJR N
age NN o
. . o

RBV-C NNP o
( ( o
4 CD o
) ) N
were VBD o
higher JJR o
in IN N
patients NNS N
allocated VBN N
in IN N
the DT N
IA NNP N
and CC N
in IN N
those DT N
receiving VBG N
NRTIs NNP N
( ( N
P=0.039 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
4-week JJ N
induction NN i
with IN i
pegylated JJ i
interferon-?2a JJ i
plus CC i
ribavirin NN i
was VBD i
associated VBN i
with IN N
a DT N
greater JJR N
decrease NN o
in IN o
HCV NNP o
RNA NNP o
at IN N
week NN N
4 CD N
; : N
however RB N
, , N
this DT N
did VBD N
not RB N
translate VB N
into IN N
higher JJR o
EVR NN o
rates NNS o
. . o

Higher JJR o
RBV NNP N
doses NNS N
and CC N
avoidance NN N
of IN N
NRTI-sparing NNP N
antiretroviral JJ N
regimens NNS N
might MD N
improve VB o
HCV NNP o
treatment NN o
efficacy NN o
. . N

-DOCSTART- -25246693- O O

Efficacy NN N
of IN N
artemisinin-based JJ i
combination NN i
treatments NNS i
of IN N
uncomplicated JJ N
falciparum NN N
malaria NNS N
in IN N
under-five-year-old JJ p
Nigerian JJ p
children NNS p
. . p

The DT N
efficacy NN N
of IN N
3-day JJ i
regimens NNS i
of IN i
artemether-lumefantrine JJ i
and CC i
artesunate-amodiaquine JJ i
were VBD N
evaluated VBN N
in IN N
747 CD p
children NNS p
< JJ p
5 CD p
years NNS p
of IN p
age NN p
with IN p
uncomplicated JJ p
malaria NNS p
from IN p
six CD p
geographical JJ p
areas NNS p
of IN p
Nigeria NNP p
. . p

Fever NNP N
clearance NN o
was VBD N
significantly RB N
faster RBR N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
and CC N
the DT N
proportion NN N
of IN N
children NNS N
with IN N
parasitemia NN N
1 CD N
day NN N
after IN N
treatment NN N
began VBD N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
= NNP N
0.016 CD N
) ) N
in IN N
artesunate-amodiaquine-compared JJ N
with IN N
artemether-lumefantrine-treated JJ i
children NNS N
. . N

Parasite NNP o
clearance NN o
times NNS N
were VBD N
similar JJ N
with IN N
both DT N
treatments NNS N
. . N

Overall JJ N
efficacy NN N
was VBD N
96.3 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
94.5-97.6 CD N
% NN N
) ) N
, , N
and CC N
was VBD N
similar JJ N
for IN N
both DT N
regimens NNS N
. . N

Polymerase NNP o
chain NN o
reaction-corrected JJ o
parasitologic JJ o
cure NN o
rates NNS o
on IN N
Day NNP N
28 CD N
were VBD N
96.9 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
93.9-98.2 CD N
% NN N
) ) N
and CC N
98.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
96.1-99.3 CD N
% NN N
) ) N
for IN N
artemether-lumefantrine JJ i
and CC i
artesunate-amodiaquine JJ i
, , N
respectively RB N
. . N

Gametocyte NNP o
carriage NN o
post NN o
treatment NN o
was VBD N
significantly RB N
lower JJR N
than IN N
pretreatment NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
anemic JJ p
children NNS p
, , N
mean JJ o
time NN o
to TO o
recovery NN o
from IN o
anemia NN o
was VBD N
10 CD N
days NNS N
( ( N
95 CD N
% NN N
CI NNP N
9.04-10.9 CD N
) ) N
and CC N
was VBD N
similar JJ N
for IN N
both DT N
regimens NNS N
. . N

Both DT N
treatments NNS N
were VBD N
well RB o
tolerated VBN o
and CC o
are VBP o
safe JJ o
and CC o
efficacious JJ o
treatments NNS o
of IN N
uncomplicated JJ N
falciparum NN N
malaria NN N
in IN N
young JJ p
Nigerian JJ p
children NNS p
. . p

-DOCSTART- -12546485- O O

Effects NNS N
of IN N
prelinguistic JJ i
milieu NN i
teaching NN i
and CC i
parent NN i
responsivity NN i
education NN i
on IN N
dyads NNS o
involving VBG o
children NNS o
with IN o
intellectual JJ o
disabilities NNS o
. . o

This DT N
study NN N
tested VBD N
the DT N
effect NN N
of IN N
a DT N
method NN N
of IN N
facilitating VBG i
prelinguistic JJ i
communication NN i
on IN N
parents NNS o
' POS o
responsivity NN o
and CC o
children NNS o
's POS o
communication NN o
and CC o
productive JJ o
language NN o
development NN o
. . o

The DT N
method NN N
involved VBN N
Responsivity NNP i
education NN i
for IN i
the DT i
parents NNS i
and CC p
Prelinguistic NNP i
Milieu NNP i
Teaching NNP i
for IN i
the DT i
children NNS i
( ( i
RPMT NNP i
) ) i
. . i

Thirty-nine JJ p
prelinguistic JJ p
toddlers NNS p
with IN p
intellectual JJ p
disabilities NNS p
and CC p
their PRP$ p
primary JJ p
caregivers NNS p
participated VBD p
in IN p
this DT p
study NN p
. . p

Parent-child JJ N
pairs NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
RPMT NNP i
group NN N
or CC N
a DT N
control NN i
group NN i
. . i

Communication NNP o
and CC o
language NN o
were VBD N
assessed VBN N
at IN N
study NN N
entry NN N
and CC N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
later RB N
. . N

RPMT NNP i
facilitated VBD N
parental JJ o
responsivity NN o
in IN N
the DT N
posttreatment JJ N
period NN N
. . N

The DT N
effect NN N
of IN N
RPMT NNP i
on IN N
growth NN o
rate NN o
of IN o
child-initiated JJ o
comments NNS o
( ( N
i.e. NN N
, , N
the DT N
most RBS N
common JJ N
type NN N
of IN N
initiating VBG N
joint JJ N
attention NN N
) ) N
varied VBN N
by IN N
pretreatment JJ N
measures NNS N
of IN N
that DT N
variable JJ N
. . N

The DT N
effect NN N
of IN N
RPMT NNP i
on IN N
growth NN o
rate NN o
of IN o
child-initiated JJ o
requests NNS o
( ( N
i.e. NN N
, , N
the DT N
most RBS N
common JJ N
type NN N
of IN N
initiating VBG N
behavior JJ N
regulation NN N
) ) N
varied VBN N
by IN N
presence NN N
or CC N
absence NN N
of IN N
Down NNP N
syndrome NN N
. . N

Finally RB N
, , N
the DT N
effect NN N
of IN N
RPMT NNP i
on IN N
growth NN o
of IN o
productive JJ o
language NN o
varied VBN N
by IN N
pretreatment JJ N
frequency NN N
of IN N
canonical JJ N
vocal JJ N
communication NN N
. . N

Recommended VBN N
alterations NNS N
in IN N
PMT NNP i
and CC N
implications NNS N
for IN N
defining VBG N
which WDT N
nonspeaking VBG N
children NNS N
are VBP N
appropriate JJ N
for IN N
prelinguistic JJ N
goals NNS N
and CC N
treatment NN N
were VBD N
discussed VBN N
. . N

-DOCSTART- -20608027- O O

[ JJ N
Assessment NNP N
of IN N
natriuretic JJ i
peptide NN i
indices NNS N
and CC N
oxidative JJ i
stress NN N
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
] NNP p
. . N

The DT N
authors NNS N
have VBP N
studied VBN N
indices NNS N
of IN N
natriuretic JJ i
peptide NN i
and CC N
oxidative JJ i
stress NN i
in IN N
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
. . p

52 CD i
male JJ i
patients NNS i
with IN i
postinfarction NN i
cardiosclerosis NN i
( ( i
PICS NNP i
) ) i
who WP i
have VBP i
developed VBN i
CHF NNP i
have VBP i
been VBN i
observed VBN i
. . i

The DT p
age NN p
of IN p
the DT p
patients NNS p
varied VBD p
from IN p
38 CD p
till NN p
60 CD p
. . p

It PRP N
was VBD N
established VBN N
that IN N
CHF NNP N
patients NNS N
with IN N
progression NN N
of IN N
the DT N
disease NN N
had VBD N
worsening NN N
of IN N
their PRP$ N
clinical JJ o
condition NN o
together RB N
with IN N
an DT N
increase NN N
of IN N
oxidative JJ o
stress NN o
which WDT N
was VBD N
characterized VBN N
through IN N
decrease NN N
of IN N
NO NNP o
metabolites NNS o
, , o
NADPH NNP o
-- : o
diaphorase NN o
( ( o
eNOS NN o
) ) o
, , N
increase NN N
of IN N
nitrite JJ o
reductase NN o
( ( o
iNOS NN o
) ) o
and CC o
peroxinitrite JJ o
( ( o
ONOO NNP o
) ) o
, , N
correlative JJ N
increase NN N
the DT N
level NN N
of IN N
brain NN o
natriuretic JJ o
peptide NN o
in IN o
blood NN o
plazma NN o
. . o

Reliable JJ N
connection NN N
between IN N
considerable JJ N
increase NN N
of IN N
oxidative JJ o
stress NN o
and CC N
the DT N
level NN o
of IN o
NT-pro NNP o
BNP NNP o
was VBD N
noted VBN N
in IN N
CHF NNP p
patients NNS p
, , N
which WDT N
demands VBZ N
necessity NN N
of IN N
correction NN N
of IN N
observed JJ N
disorders NNS N
. . N

-DOCSTART- -14996351- O O

Comparison NNP N
of IN N
quality NN o
of IN o
life NN o
, , o
work NN o
productivity NN o
and CC N
medical JJ o
resource NN o
utilization NN o
of IN N
peginterferon NN i
alpha NN i
2a CD i
vs IN N
the DT N
combination NN N
of IN N
interferon NN i
alpha NN i
2b CD i
plus CC i
ribavirin VB i
as IN N
initial JJ N
treatment NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
The DT N
on-treatment JJ N
impact NN N
of IN N
interferon-based JJ N
therapies NNS N
on IN N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
work NN o
productivity NN o
, , o
and CC o
medical JJ o
resource NN o
utilization NN o
has VBZ N
not RB N
been VBN N
systematically RB N
studied VBN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
peginterferon NN i
alpha NN i
( ( i
pegIFNalpha NN i
) ) i
2a CD i
monotherapy NN i
and CC N
the DT N
combination NN i
of IN i
interferon NN i
alpha NN i
( ( i
IFNalpha NNP i
) ) i
2b CD i
plus CC i
ribavirin NN i
( ( i
RBV NNP i
) ) i
on IN N
health-related JJ o
QOL NNP o
, , o
work NN o
productivity NN o
and CC o
resource NN o
utilization NN o
. . o

A DT N
total NN N
of IN N
412 CD p
patients NNS p
with IN p
hepatitis NN p
C NNP p
infection NN p
were VBD N
randomized VBN N
to TO N
open-label JJ i
treatment NN i
with IN i
either DT i
pegIFNalpha NN i
2a CD i
( ( i
n JJ i
= NNP i
206 CD i
) ) i
or CC i
IFNalpha $ i
2b/RBV CD i
( ( i
n JJ i
= NNP i
206 CD i
) ) i
. . i

PegIFNalpha $ i
2a CD i
was VBD N
administered VBN N
subcutaneously RB N
at IN N
a DT N
dose NN N
of IN N
180 CD N
microg NN N
once RB N
weekly JJ N
for IN N
48 CD N
weeks NNS N
; : N
and CC N
IFNalpha $ i
2b/RBV CD i
at IN N
doses NNS N
of IN N
3 CD N
MU NNP N
thrice JJ N
weekly RB N
subcutaneously RB N
and CC N
1000-1200 JJ N
mg/day NN N
orally RB N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
SF-36 NNP o
Health NNP o
Survey NNP o
Questionnaire NNP o
and CC o
additional JJ o
generic NN o
and CC o
specific JJ o
scales NNS o
. . o

During IN N
treatment NN N
, , N
for IN N
all DT N
SF-36 NNP N
summary NN N
and CC N
Hepatitis NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
HQLQ NNP o
) ) o
-specific NN o
scales NNS o
, , N
the DT N
pegIFNalpha NN i
2a CD i
group NN N
experienced VBD N
less JJR N
impairment JJ N
than IN N
did VBD N
the DT N
IFNalpha NNP i
2b/RBV CD i
patients NNS N
. . N

The DT N
between-treatment JJ N
differences NNS N
were VBD N
significant JJ N
for IN N
many JJ N
of IN N
the DT N
scores NNS N
particularly RB N
in IN N
the DT N
first JJ N
24 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Across IN N
all DT N
measures NNS N
of IN N
work NN N
functioning NN N
and CC N
productivity NN N
at IN N
each DT N
visit NN N
, , N
patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB i
2a CD i
treatment NN N
showed VBD N
less RBR N
impairment JJ o
relative NN N
to TO N
the DT N
group NN N
treated VBD N
with IN N
IFNalpha NNP i
2b/RBV CD i
. . i

Hence NNP N
treatment NN N
with IN N
pegIFNalpha JJ i
2a CD i
relative JJ N
to TO N
IFNalpha NNP i
2b/RBV CD i
minimizes VBZ N
the DT N
adverse JJ N
impact NN N
of IN N
therapy NN N
on IN N
health-related JJ o
QOL NNP o
. . o

Patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB i
2a CD i
had VBD N
improved VBN N
work NN o
productivity NN o
, , o
less JJR o
activity NN o
impairment NN o
, , o
decreased VBD o
need NN o
for IN o
prescription NN o
drugs NNS o
to TO o
treat VB o
adverse JJ o
effects NNS o
, , o
and CC o
better JJR o
adherence NN o
to TO o
therapy NN o
. . o

-DOCSTART- -8978338- O O

Colonoscopic NNP N
miss JJ N
rates NNS N
of IN N
adenomas NN p
determined VBN N
by IN N
back-to-back JJ N
colonoscopies NNS N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
miss JJ N
rate NN N
of IN N
colonoscopy NN N
for IN N
neoplasms NN N
is VBZ N
poorly RB N
understood JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
miss JJ N
rate NN N
of IN N
colonoscopy NN i
by IN N
same JJ N
day NN N
back-to-back JJ N
colonoscopy NN N
. . N

METHODS NNP N
Two CD N
consecutive JJ N
same JJ N
day NN N
colonoscopies NNS i
were VBD N
performed VBN N
in IN N
183 CD p
patients NNS p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB N
the DT N
second JJ i
colonoscopy NN i
by IN N
the DT N
same JJ i
or CC i
a DT i
different JJ i
endoscopist NN i
and CC i
in IN i
the DT i
same JJ i
or CC i
different JJ i
position NN i
. . i

RESULTS VB N
The DT N
overall JJ o
miss NN o
rate NN o
for IN o
adenomas NN o
was VBD N
24 CD N
% NN N
, , N
27 CD N
% NN N
for IN N
adenomas JJ N
< NN N
or CC N
= $ N
5 CD N
mm NN N
, , N
13 CD N
% NN N
for IN N
adenomas JJ N
6-9 JJ N
mm NN N
, , N
and CC N
6 CD N
% NN N
for IN N
adenomas JJ N
> NN N
or CC N
= $ N
1 CD N
cm NN N
. . N

Patients NNS p
with IN p
two CD p
or CC p
more JJR p
adenomas NNS p
at IN N
the DT N
first JJ N
examination NN N
were VBD N
more RBR N
likely JJ N
than IN N
patients NNS p
with IN p
no DT p
or CC p
one CD p
adenoma NN p
detected VBN N
at IN N
the DT N
first JJ N
examination NN N
to TO N
have VB N
one CD N
or CC N
more JJR N
adenomas NNS o
at IN N
the DT N
second JJ N
examination NN N
( ( N
odds NNS N
ratio NN N
, , N
3.3 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.69-6.46 JJ N
) ) N
. . N

Right JJ N
colon NN N
adenomas NNS N
were VBD N
missed VBN o
more RBR N
often RB N
( ( N
27 CD N
% NN N
) ) N
than IN N
left VBN N
colon NN N
adenomas NN N
( ( N
21 CD N
% NN N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

There EX N
was VBD N
evidence NN N
of IN N
variation NN o
in IN o
sensitivity NN o
between IN N
endoscopists NNS N
, , N
but CC N
significant JJ N
miss JJ o
rates NNS o
for IN o
small JJ N
adenomas NNS N
were VBD N
found VBN N
among IN N
essentially RB N
all DT N
endoscopists NNS N
. . N

CONCLUSIONS NNP N
Using NNP N
current JJ N
colonoscopic NN i
technology NN i
, , N
there EX N
are VBP N
significant JJ N
miss JJ o
rates NNS o
for IN N
adenomas JJ N
< $ N
1 CD N
cm NN N
even RB N
with IN N
meticulous JJ N
colonoscopy NN N
. . N

Miss JJ o
rates NNS o
are VBP N
low JJ N
for IN N
adenomas NN N
> NN N
or CC N
= $ N
1 CD N
cm NN N
. . N

The DT N
results NNS N
suggest VBP N
the DT N
need NN N
for IN N
improvements NNS N
in IN N
colonoscopic NN N
technology NN N
. . N

-DOCSTART- -8060436- O O

A DT N
comparison NN N
of IN N
albuterol JJ i
solution NN i
nebulized VBN i
versus NN i
albuterol NN i
powder NN i
given VBN N
by IN N
breath NN N
activated VBN N
metered VBD N
dose JJ N
inhaler NN N
. . N

The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
nebulized JJ i
vs NN i
powdered VBD i
albuterol NN i
in IN N
patients NNS p
with IN p
exacerbated JJ p
bronchial JJ p
asthma NN p
who WP p
required VBD p
hospitalization NN p
. . p

From IN p
January NNP p
to TO p
May NNP p
1990 CD p
known NN p
asthmatics NNS p
admitted VBN p
with IN p
acute JJ p
exacerbation NN p
were VBD p
included VBN p
by IN p
established VBN p
criteria NNS p
. . p

Two CD N
groups NNS N
were VBD N
randomized VBN N
. . N

Group NNP N
I PRP N
for IN N
Albuterol NNP i
powder NN i
200 CD N
micrograms NNS N
inhaled VBD N
q RB N
4 CD N
hours NNS N
. . N

Group NNP N
II NNP N
with IN N
Albuterol NNP i
nebulized JJ i
solution NN i
2.5 CD N
mg NN N
inhaled VBD N
q RB N
4 CD N
hrs NN N
. . N

Force NNP o
Vital NNP o
Capacity NNP o
and CC o
Force NNP o
Expiratory NNP o
Volume NN o
in IN N
one CD N
second NN N
were VBD N
measured VBN N
with IN N
a DT N
pressure NN N
differential JJ N
transducer NN N
upon IN N
admission NN N
, , N
30 CD N
minutes NNS N
and CC N
24-hours JJ N
following NN N
therapies NNS N
. . N

Absolute NNP o
FEV1 NNP o
improvement NN o
was VBD N
calculated VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
student NN N
's POS N
T-Test NNP N
and CC N
Fisher NNP N
's POS N
exact JJ N
Test NNP N
with IN N
significance NN N
established VBN N
at IN N
p NN N
> VBP N
0.01 CD N
% NN N
. . N

Fifteen JJ p
patients NNS p
enrolled VBN p
in IN p
both DT p
groups NNS p
, , p
two CD p
patients NNS p
of IN p
group NN p
I PRP p
were VBD p
excluded VBN p
from IN N
the DT N
statistic JJ N
analysis NN N
due JJ N
to TO N
refusal VB N
to TO N
continue VB N
with IN N
the DT N
therapy NN N
. . N

Both DT N
groups NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
sex NN N
, , N
asthma JJ N
exacerbations/year NN N
, , N
smoking VBG N
history NN N
and CC N
hospital JJ N
length NN N
of IN N
stay NN N
. . N

FVC NNP o
and CC o
FEV1 NNP o
were VBD N
comparable JJ N
also RB N
. . N

In IN N
contrast NN N
, , N
there EX N
were VBD N
significant JJ N
difference NN N
when WRB N
the DT N
absolute NN N
improvement NN N
were VBD N
compared VBN N
. . N

The DT N
mean JJ o
+/- JJ o
SE NNP o
for IN o
FEV1 NNP o
absolute JJ N
improvement NN N
at IN N
the DT N
first JJ N
30 CD N
min NN N
was VBD N
0.42 CD N
+/- JJ N
0.08 CD N
lts NNS N
for IN N
the DT N
Group NNP N
I PRP N
versus VBP N
0.65 CD N
+/- JJ N
0.6 CD N
lts NNS N
in IN N
the DT N
Group NNP N
II NNP N
. . N

In IN N
the DT N
next JJ N
24 CD N
hours NNS N
, , N
Group NNP N
I PRP N
was VBD N
0.16 CD N
+/- JJ N
0.2 CD N
lts NNS N
versus JJ N
0.30 CD N
+/- JJ N
0.7 CD N
lts NNS N
in IN N
Group NNP N
II NNP N
( ( N
p JJ N
> NNP N
.01 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
although IN N
the DT N
dose JJ N
equivalence NN N
of IN N
both DT N
delivery NN N
systems NNS N
have VBP N
not RB N
been VBN N
established VBN N
in IN N
our PRP$ N
study NN N
, , N
the DT N
nebulized JJ i
solution NN i
was VBD N
more RBR N
effective JJ N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
of IN N
hospitalization NN N
than IN N
the DT N
dry JJ i
powder NN i
. . i

-DOCSTART- -20484550- O O

Biomarkers NNS N
of IN N
dietary JJ i
exposure NN i
are VBP N
associated VBN N
with IN N
lower JJR N
risk NN N
of IN N
breast NN p
fibroadenomas NN p
in IN p
Chinese JJ p
women NNS p
. . p

Fibroadenomas NNP N
are VBP N
the DT N
most RBS N
common JJ N
benign NN N
breast JJ N
condition NN N
among IN N
women NNS N
and CC N
account NN N
for IN N
up IN N
to TO N
50 CD N
% NN N
of IN N
all DT N
breast NN N
biopsies NNS N
being VBG N
performed VBN N
. . N

Although IN N
considered VBN N
a DT N
benign JJ N
condition NN N
, , N
fibroadenomas JJ N
utilize VBP N
substantial JJ N
resources NNS N
for IN N
management NN N
and CC N
treatment NN N
to TO N
rule VB N
out RP N
potential JJ N
malignancies NNS N
. . N

Dietary JJ i
factors NNS i
may MD N
influence VB N
benign JJ N
fibrocystic JJ N
breast NN N
conditions NNS N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
of IN N
their PRP$ N
association NN N
with IN N
fibroadenomas NN N
. . N

We PRP N
examined VBD N
possible JJ N
associations NNS N
between IN N
a DT N
broad JJ N
spectrum NN N
of IN N
circulating VBG N
biomarkers NNS o
of IN o
dietary JJ o
intake NN o
and CC N
risk NN N
of IN N
fibroadenomas NN N
. . N

Participants NNS p
were VBD p
women NNS p
in IN p
a DT p
breast NN i
self-examination NN i
trial NN p
in IN p
Shanghai NNP p
, , p
China NNP p
who WP p
were VBD p
diagnosed VBN p
with IN p
fibroadenomas NN p
( ( p
n JJ p
= NNP p
258 CD p
) ) p
and CC p
1035 CD p
controls NNS p
. . p

Conditional NNP o
logistic JJ o
regression NN o
was VBD N
used VBN N
to TO N
estimate VB o
adjusted VBN o
odds NNS o
ratios NNS o
( ( o
OR NNP o
) ) o
and CC N
95 CD o
% NN o
CI NNP o
. . o

Isoflavone NNP o
concentrations NNS o
were VBD N
inversely RB N
associated VBN N
with IN N
risk NN o
of IN o
fibroadenomas NN o
. . o

Adjusted VBN o
OR NNP o
( ( o
95 CD o
% NN o
CI NNP o
) ) o
for IN N
the DT N
highest JJS N
versus NN N
the DT N
lowest JJS N
quartile NN N
of IN N
plasma JJ N
concentration NN N
were VBD N
0.36 CD N
( ( N
0.16-0.79 CD N
; : N
P-trend NNP N
< NNP N
0.001 CD N
) ) N
for IN N
daidzein NN i
and CC N
0.39 CD N
( ( N
0.19-0.84 CD N
; : N
P-trend NNP N
= NNP N
0.010 CD N
) ) N
for IN N
genistein NN i
. . i

We PRP N
also RB N
observed VBD N
inverse JJ o
associations NNS o
between IN N
higher JJR N
percentages NNS o
of IN o
the DT o
RBC NNP o
( ( o
n-3 JJ o
) ) o
fatty JJ o
acids NNS o
, , o
eicosapentaenoic JJ o
acid NN o
( ( o
EPA NNP o
) ) o
( ( N
[ $ N
0.38 CD N
( ( N
0.19-0.77 JJ N
) ) N
; : N
P-trend JJ N
= NN N
0.007 CD N
] NN N
and CC N
docosapentaenoic NN o
acid NN o
( ( o
DPA NNP o
) ) o
[ VBZ N
0.32 CD N
( ( N
0.15-0.70 JJ N
) ) N
; : N
P-trend JJ N
= NN N
0.024 CD N
] NN N
, , N
and CC N
fibroadenoma NN N
risk NN N
. . N

Circulating VBG N
concentrations NNS N
of IN N
carotenoids NNS o
, , o
vitamin FW o
C NNP o
, , o
retinol NN o
, , o
and CC o
ferritin NNS o
were VBD N
not RB N
associated VBN N
with IN N
fibroadenoma NN N
risk NN N
. . N

The DT N
inverse JJ o
associations NNS o
between IN N
plasma NN o
isoflavone NN o
concentrations NNS o
and CC N
RBC NNP o
EPA NNP o
and CC o
DPA NNP o
and CC N
fibroadenoma NN o
risk NN o
suggest VBP N
that IN N
higher JJR N
intakes NNS N
of IN N
soy JJ i
foods NNS i
and CC i
fatty JJ i
fish NN i
may MD N
lower VB N
the DT N
risk NN o
of IN o
fibroadenomas NN o
. . o

-DOCSTART- -19780729- O O

Prospective JJ N
randomised VBD p
multicentre JJ p
trial NN p
with IN p
the DT p
birth NN i
trainer NN i
EPI-NO NNP i
for IN N
the DT N
prevention NN N
of IN N
perineal JJ o
trauma NN o
. . o

BACKGROUND NNP N
In IN N
several JJ N
non-randomised JJ N
trials NNS N
training VBG N
with IN N
EPI-NO NNP i
increased VBD N
the DT N
rate NN N
of IN N
intact JJ N
perineum NN N
and CC N
decreased JJ N
episiotomy NN N
rates NNS N
, , N
shortened VBD N
the DT N
second JJ N
stage NN N
of IN N
labour NN N
and CC N
lowered VBN N
use NN N
of IN N
pain NN N
killers NNS N
. . N

AIMS NNP N
To TO N
verify VB N
the DT N
preliminary JJ N
results NNS N
with IN N
EPI-NO NNP i
in IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
. . N

METHODS NNP N
Randomised VBD p
, , p
single-blind JJ p
multicentre NN p
trial NN p
in IN p
four CD p
university NN p
hospitals NNS p
in IN p
Germany NNP p
including VBG p
276 CD p
primigravidae NN p
. . p

RESULTS NNP N
After IN N
training VBG N
with IN N
EPI-NO NNP i
we PRP N
observed VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
incidence NN o
of IN o
intact JJ o
perineum NN o
( ( N
37.4 CD N
% NN N
vs JJ N
25.7 CD N
% NN N
; : N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
a DT N
tendency NN N
towards NNS N
lower JJR o
episiotomy NN o
rates NNS o
( ( N
41.9 CD N
% NN N
vs JJ N
50.5 CD N
% NN N
; : N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD p
groups NNS p
regarding VBG N
incidence NN o
of IN o
perineal NN o
tears NNS o
, , o
duration NN o
of IN o
second JJ o
stage NN o
of IN o
labour NN o
, , o
use NN o
of IN o
pain NN o
relief NN o
and CC o
rate NN o
of IN o
vaginal JJ o
infection NN o
. . o

CONCLUSIONS NNP N
Training VBG N
with IN N
EPI-NO NNP i
increases NNS N
significantly RB N
the DT N
likelihood NN N
of IN N
having VBG o
an DT o
intact JJ o
perineum NN o
and CC o
reduces VBZ o
the DT o
episiotomy NN o
rate NN o
. . o

-DOCSTART- -23659834- O O

The DT N
efficacy NN o
, , o
safety NN o
and CC o
cost-effectiveness NN o
of IN N
hydrotalcite JJ i
versus NN N
esomeprazole NN i
in IN N
on-demand JJ N
therapy NN N
of IN N
NERD NNP N
: : N
A DT N
multicenter NN N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
in IN p
China NNP p
. . p

OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
hydrotalcite NN i
was VBD N
comparable JJ N
to TO N
esomeprazole VB i
, , N
a DT N
proton NN N
pump NN N
inhibitor NN N
, , N
in IN N
on-demand JJ N
therapy NN N
for IN N
non-erosive JJ p
reflux NN p
disease NN p
( ( p
NERD NNP p
) ) p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
open-label JJ N
clinical JJ N
trial NN N
with IN N
initial JJ N
and CC N
on-demand JJ N
therapy NN N
. . N

Patients NNS p
who WP p
had VBD p
complete JJ p
symptom NN p
relief NN p
in IN p
the DT p
initial JJ p
therapy NN p
were VBD N
randomized VBN N
to TO N
either DT N
hydrotalcite NN i
or CC i
esomeprazole NN i
in IN N
the DT N
on-demand JJ N
therapy NN N
. . N

The DT N
percentage NN o
of IN N
patients NNS o
who WP o
quit VBP o
on-demand JJ N
therapy NN N
in IN N
the DT N
two CD N
groups NNS N
and CC N
the DT N
cost-effectiveness NN o
of IN N
the DT N
treatment NN N
were VBD N
evaluated VBN N
as IN N
primary JJ N
end NN N
points NNS N
. . N

The DT N
rate NN o
of IN o
symptom NN o
relief NN o
and CC o
the DT o
improvement NN o
of IN o
symptom NN o
score NN o
for IN N
initial JJ N
therapy NN N
and CC N
the DT N
weekly JJ N
average NN N
symptom NN N
score NN N
and CC N
weekly JJ o
average NN o
number NN o
of IN o
days NNS o
on IN N
treatment NN N
for IN N
on-demand JJ N
therapy NN N
were VBD N
evaluated VBN N
as IN N
secondary JJ N
end NN N
points NNS N
. . N

RESULTS NNP N
In IN N
total JJ N
, , N
398 CD p
patients NNS p
were VBD p
recruited VBN p
in IN p
the DT p
initial JJ p
therapy NN p
group NN p
, , p
among IN p
whom WP p
253 CD p
were VBD p
included VBN p
in IN p
on-demand JJ p
therapy NN p
, , p
with IN p
127 CD p
patients NNS p
in IN p
the DT p
hydrotalcite NN i
group NN p
and CC p
the DT p
remaining VBG p
126 CD p
in IN p
the DT p
esomeprazole JJ i
group NN p
. . p

14 CD N
( ( N
11.0 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
hydrotalcite NN i
group NN N
and CC N
six CD N
( ( N
4.8 CD N
% NN N
) ) N
in IN N
the DT N
esomeprazole JJ i
group NN N
quit VBD o
the DT N
on-demand JJ N
therapy NN N
due JJ N
to TO N
unsatisfactory JJ N
symptom NN N
control NN N
( ( o
P NNP o
= NNP o
0.065 CD o
) ) o
. . o

Cost-effectiveness JJ o
calculated VBD o
as IN N
the DT N
ratio NN N
of IN N
the DT N
cost NN N
of IN i
hydrotalcite NN i
to TO i
that DT N
of IN i
esomeprazole NN i
( ( i
per IN i
person/day NN N
) ) N
was VBD N
35.3 CD N
% NN N
in IN N
the DT N
on-demand JJ N
therapy NN N
. . N

Similar JJ N
number NN N
of IN N
patients NNS N
achieved VBN o
symptom JJ o
relief NN o
in IN o
both DT N
groups NNS N
. . N

CONCLUSION NNP i
Hydrotalcite NNP i
is VBZ i
a DT N
good JJ o
option NN o
of IN o
on-demand JJ N
therapy NN N
for IN N
NERD NNP p
patients NNS p
due JJ p
to TO N
its PRP$ N
cost-effectiveness NN o
and CC o
speed NN o
of IN o
action NN o
. . o

-DOCSTART- -12378396- O O

The DT N
lunar JJ i
stent NN i
characteristics NNS N
and CC N
clinical JJ N
results NNS N
. . N

One CD N
of IN N
the DT N
frequent JJ N
long-term JJ N
complications NNS N
after IN N
stent JJ i
implantation NN i
is VBZ N
restenosis JJ N
due JJ N
to TO N
the DT N
building NN N
up IN N
of IN N
a DT N
neointima NN N
within IN N
the DT N
artery NN N
, , N
as RB N
well RB N
as IN N
endovascular JJ N
hyperplasia NN N
( ( N
tissue VB N
growth NN N
) ) N
. . N

The DT N
interesting JJ N
feature NN N
of IN N
the DT N
Lunar NNP i
stent NN i
from IN i
Inflow NNP i
Dynamics NNP i
is VBZ N
that IN N
it PRP N
is VBZ N
coated VBN N
with IN N
a DT N
layer NN N
of IN N
iridium NN N
oxide NN N
. . N

The DT N
iridium NN i
oxide IN i
coating NN N
is VBZ N
believed VBN N
to TO N
reduce VB N
restenosis NN o
by IN N
decreasing VBG N
the DT N
inflammatory JJ o
response NN o
to TO N
the DT N
stent NN N
via IN N
its PRP$ N
antioxidant JJ N
action NN N
. . N

The DT N
MOONLIGHT NNP p
( ( p
Multicenter NNP p
Objective NNP p
ObservatioNal NNP p
Lunar NNP i
Iridiumoxide NNP i
intimal JJ p
GrowtH NNP p
Trial NNP p
) ) p
study NN p
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
immediate JJ N
outcome NN N
and CC N
long-term JJ N
angiographic JJ N
success NN N
after IN N
implantation NN i
of IN i
Lunar NNP i
stents NNS i
. . i

Between IN p
March NNP p
2001 CD p
and CC p
November NNP p
2001 CD p
, , p
87 CD p
patients NNS p
with IN p
99 CD p
lesions NNS p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
and CC N
were VBD N
treated VBN N
with IN N
12 CD N
and CC N
16 CD N
mm NNS N
long JJ N
iridium-oxide JJ i
coated VBN i
Lunar NNP i
stents NNS i
. . i

Delivery NN N
of IN N
the DT N
Lunar NNP i
stent NN i
was VBD N
successful JJ N
in IN N
most JJS N
lesions NNS N
and CC N
the DT N
optimal JJ N
radiopacity NN N
facilitated VBN N
optimal JJ N
stent NN o
positioning VBG o
with IN N
optimal JJ N
immediate JJ N
clinical JJ N
and CC N
angiographic JJ N
results NNS N
is VBZ N
an DT N
unselected JJ N
patient NN N
and CC N
lesion NN N
population NN N
. . N

Preliminary JJ N
clinical JJ N
and CC N
angiographic JJ N
follow-up JJ N
show NN N
a DT N
low JJ N
rate NN o
of IN o
cardiac JJ o
events NNS o
at IN N
6 CD N
months NNS N
( ( N
16.1 CD N
% NN N
MACE NNP N
) ) N
and CC N
a DT N
moderate JJ N
hyperplastic JJ o
response NN o
. . o

-DOCSTART- -16846734- O O

Gemcitabine NNP i
and CC N
split-dose JJ N
paclitaxel NN i
or CC N
docetaxel NN i
in IN N
metastatic JJ N
breast NN N
cancer NN N
: : N
a DT N
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
activity NN o
and CC o
toxicity NN o
of IN N
split-dose JJ i
paclitaxel NN i
or CC i
docetaxel NN i
in IN i
combination NN i
with IN i
gemcitabine NN i
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
( ( p
MBC NNP p
) ) p
who WP p
had VBD p
previously RB p
received VBN p
anthracyclines NNS p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
total NN p
of IN p
210 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
gemcitabine NN i
1,250 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
paclitaxel VB i
175 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
3-h JJ i
infusion NN i
on IN i
Day NNP i
1 CD i
( ( i
GP1 NNP i
) ) i
; : i
gemcitabine $ i
1,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
paclitaxel VB i
100 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
1-h JJ i
infusion NN i
on IN i
Days NNP i
1 CD i
and CC i
8 CD i
( ( i
GP2 NNP i
) ) i
; : i
gemcitabine $ i
1,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
docetaxel VB i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
1-h JJ i
infusion NN i
on IN i
Days NNP i
1 CD i
and CC i
8 CD i
( ( i
GD NNP i
) ) i
. . N

Cycles NNS N
were VBD N
repeated VBN N
every DT N
3 CD N
weeks NNS N
. . N

RESULTS NNP N
For IN N
the DT N
204 CD p
patients NNS p
evaluable JJ p
for IN p
response NN p
assessment NN p
, , p
the DT p
response NN o
rates NNS o
were VBD p
48.6 CD p
% NN p
for IN p
GP1 NNP p
, , p
52.2 CD p
% NN p
for IN p
GP2 NNP p
, , p
and CC p
52.3 CD p
% NN p
for IN p
GD NNP p
. . p

Median JJ o
response NN o
duration NN o
, , o
time NN o
to TO o
treatment NN o
failure NN o
, , o
and CC o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
were VBD N
similar JJ N
in IN N
each DT N
arm NN N
. . N

Median JJ o
TTP NNP o
for IN N
GP1 NNP N
, , N
GP2 NNP N
and CC N
GD NNP N
was VBD N
7.5 CD N
, , N
7.0 CD N
and CC N
7.4 CD N
months NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
208 CD p
patients NNS p
evaluable JJ p
for IN p
safety NN o
, , N
the DT N
most RBS N
common JJ N
grade NN N
3/4 CD N
toxicity NN o
for IN N
each DT N
regimen NN N
was VBD N
neutropaenia RB o
, , N
with IN N
64 CD N
% NN N
, , N
57 CD N
% NN N
, , N
and CC N
68 CD N
% NN N
for IN N
GP1 NNP N
, , N
GP2 NNP N
, , N
and CC N
GD NNP N
, , N
respectively RB N
. . N

Grade VB N
4 CD N
neutropaenia NN o
, , N
grade VBD N
3/4 CD N
anaemia NN o
, , o
febrile JJ o
neutropaenia NN o
, , o
and CC o
diarrhoea NNS o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
docetaxel NN N
arm NN N
, , N
as IN N
was VBD N
the DT N
use NN N
of IN N
intravenous JJ N
antibiotics NNS N
and CC N
blood NN N
transfusions NNS N
. . N

CONCLUSION VB N
The DT N
study NN N
confirmed VBD N
the DT N
high JJ N
activity NN N
of IN N
gemcitabine-taxane JJ i
combinations NNS i
in IN N
MBC NNP N
. . N

Split-dose JJ N
paclitaxel NN i
had VBD N
similar JJ N
activity NN o
and CC N
toxicity NN o
to TO N
the DT N
3-weekly JJ N
administration NN N
. . N

The DT N
split-dose JJ N
docetaxel NN i
regimen NNS N
had VBD N
similar JJ N
activity NN o
to TO N
the DT N
paclitaxel NN i
combinations NNS i
though IN N
associated VBN N
with IN N
higher JJR N
toxicity NN o
. . o

-DOCSTART- -1394200- O O

Perioperative JJ N
immunotherapy NN N
with IN N
recombinant JJ i
interleukin JJ i
2 CD i
in IN N
patients NNS p
undergoing JJ p
surgery NN p
for IN p
colorectal JJ p
cancer NN p
. . p

Major JJ N
surgery NN N
impairs VBZ N
the DT N
cellular JJ N
immune NN N
response NN N
. . N

We PRP N
have VBP N
therefore RB N
studied VBN N
the DT N
immunological JJ N
effects NNS N
of IN N
low-dose JJ i
recombinant JJ i
interleukin NN i
2 CD i
given VBN N
to TO N
patients NNS p
undergoing VBG p
surgery NN p
for IN p
colorectal JJ p
cancer NN p
to TO N
determine VB N
whether IN N
this DT N
agent NN N
has VBZ N
potential VBN N
in IN N
perioperative JJ N
adjuvant JJ N
immunotherapy NN N
. . N

Patients NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
control VB i
( ( p
n JJ p
= NNP p
13 CD p
) ) p
or CC p
treatment NN p
groups NNS p
( ( p
n JJ p
= NNP p
12 CD p
) ) p
. . p

Immunological JJ N
studies NNS N
of IN N
both DT N
lymphocyte JJ o
function NN o
and CC N
subset VB N
number NN N
were VBD N
performed VBN N
preoperatively RB N
and CC N
on IN N
Days NNP N
1 CD N
, , N
4 CD N
, , N
7 CD N
, , N
and CC N
10 CD N
. . N

Treatment NN N
with IN N
recombinant JJ i
interleukin JJ i
2 CD i
prevented VBD N
the DT N
postoperative JJ N
fall NN N
in IN N
both DT N
natural JJ o
killer NN o
and CC o
lymphokine-activated JJ o
killer NN o
cell NN o
cytotoxicity NN o
, , N
clearly RB N
demonstrated VBN N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
treatment NN N
group NN N
also RB N
showed VBD N
in IN N
vivo JJ o
T-cell NNP o
activation NN o
with IN N
an DT N
initial JJ N
lymphopenia NN N
followed VBN N
by IN N
a DT N
rebound NN o
lymphocytosis NN o
and CC N
upregulation NN o
of IN o
the DT o
subset NN o
markers NNS o
CD25 NNP o
( ( o
interleukin JJ o
2 CD o
receptor NN o
) ) o
and CC o
CD45RO NNP o
( ( o
T-memory NNP o
cells NNS o
) ) o
. . o

These DT N
combined JJ N
effects NNS N
may MD N
have VB N
important JJ N
consequences NNS N
in IN N
controlling VBG N
metastatic JJ N
dissemination NN N
of IN N
tumor NN N
during IN N
the DT N
vulnerable JJ N
perioperative JJ N
period NN N
. . N

-DOCSTART- -21276573- O O

Initial JJ N
clinical JJ N
experience NN N
with IN N
implantation NN i
of IN i
left JJ i
ventricular JJ i
lead NN i
guided VBN i
by IN i
Overlay NNP i
Ref NNP i
for IN N
the DT N
treatment NN N
of IN N
congestive JJ N
heart NN N
failure NN N
. . N

BACKGROUND NNP N
Cardiac NNP i
resynchronization NN i
therapy NN i
( ( i
CRT NNP i
) ) i
improves VBZ N
clinical JJ N
outcome NN o
in IN N
selected VBN p
patients NNS p
with IN p
advanced JJ p
congestive JJ p
heart NN p
failure NN p
. . p

The DT N
Overlay NNP N
Ref NNP N
technique NN N
may MD N
facilitate VB N
the DT N
procedure NN N
for IN N
implanting VBG N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
pacing VBG N
leads NNS N
to TO N
deliver VB N
CRT NNP i
. . i

AIM NNP N
To TO N
assess VB N
the DT N
feasibility NN N
of IN N
deploying VBG N
a DT N
LV NNP N
pacing VBG N
lead NN N
into IN N
a DT N
coronary JJ N
sinus NN N
side NN N
branch NN N
guided VBN N
by IN N
Overlay NNP i
Ref NNP i
. . i

METHODS NNP N
Data NNP N
from IN N
88 CD p
consecutive JJ p
patients NNS p
who WP p
met VBD p
the DT p
CRT NNP i
implantation NN p
criteria NNS p
in IN p
our PRP$ p
hospital NN p
between IN p
28 CD p
November NNP p
2007 CD p
and CC p
30 CD p
December NNP p
2009 CD p
were VBD p
randomly RB p
assigned VBN p
to TO p
two CD p
groups NNS p
. . p

Forty-four CD p
patients NNS p
underwent JJ p
CRT NNP i
device NN i
implantation NN i
using VBG i
Overlay NNP i
Ref NNP i
to TO i
guide VB i
target NN i
vein JJ i
selection NN i
and CC i
advance VB i
a DT i
specifically RB i
designed VBN i
pacing VBG i
lead NN i
into IN i
the DT i
target NN i
vein NN i
( ( i
Overlay NNP i
Ref NNP i
group NN i
) ) i
; : i
44 CD i
patients NNS i
were VBD i
conventionally RB i
implanted VBN i
( ( i
control VB i
group NN i
) ) i
. . i

RESULTS NNP N
LV NNP i
lead JJ i
implantation NN i
was VBD N
successful JJ N
in IN N
all DT N
patients NNS N
. . N

Mean NNP N
CRT NNP o
total JJ o
procedure NN o
times NNS o
( ( o
skin-to-skin JJ o
) ) o
were VBD N
: : N
Overlay NNP i
Ref NNP i
group NN N
, , N
80.7 CD N
? . N
18.0 CD N
min NN N
; : N
control NN N
group NN N
, , N
98.5 CD N
? . N
32.2 CD N
min NN N
; : N
p CC N
= $ N
0.029 CD N
. . N

Mean JJ o
placement NN o
of IN o
LV NNP o
pacing VBG o
lead NN o
into IN o
target NN o
vein JJ o
times NNS o
were VBD o
: : i
Overlay NNP i
Ref NNP i
group NN i
, , N
16.2 CD N
? . N
7.7 CD N
min NN N
; : N
control NN N
group NN N
, , N
36.4 CD N
? . N
23.4 CD N
min NN N
; : N
p=0.004 NN N
. . N

Mean NNP N
total JJ o
fluoroscopy NN o
times NNS o
were VBD o
: : i
Overlay NNP i
Ref NNP i
group NN N
, , N
13.6 CD N
? . N
4.3 CD N
min NN N
; : N
control NN N
group NN N
, , N
23.8 CD N
? . N
15.7 CD N
min NN N
; : N
p=0.007 NN N
. . N

Mean NNP N
LV NNP o
lead NN o
fluoroscopy NN o
times NNS o
were VBD N
: : N
Overlay NNP i
Ref NNP i
group NN i
, , N
5.7 CD N
? . N
2.9 CD N
min NN N
; : N
control NN N
group NN N
, , N
14.4 CD N
? . N
4.6 CD N
min NN N
; : N
p=0.003 NN N
. . N

No DT N
major JJ N
complications NNS o
occurred VBD o
. . N

CONCLUSIONS NNP i
Overlay NNP i
Ref NNP i
facilitates VBZ i
location NN N
of IN N
and CC N
entry NN N
into IN N
the DT N
coronary JJ N
sinus NN N
, , N
and CC N
shortens VBZ N
the DT o
duration NN o
of IN o
LV NNP o
pacing VBG o
lead JJ o
implantation NN o
into IN o
the DT o
target NN N
vein NN N
. . N

-DOCSTART- -125133- O O

Anabolic JJ i
steroids NNS i
in IN N
athelics NNS N
: : N
crossover RB N
double-blind VBP N
trial NN N
on IN N
weightlifters NNS p
. . p

Thirteen NNP p
experienced VBD p
male JJ p
weightlifters NNS p
taking VBG p
high-protein JJ p
diets NNS p
and CC p
regular JJ p
exercise NN p
took VBD N
part NN N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
of IN N
methandienone NN i
10 CD N
or CC N
25 CD N
mg/day NN N
to TO N
seeif VB N
the DT N
drug NN N
improved VBD N
athletic JJ o
performance NN o
. . o

Their PRP$ N
improvemments NNS N
were VBD N
significantly RB N
greater JJR o
on IN N
methandienone NN i
than IN N
on IN N
placebo NN i
; : i
their PRP$ N
body NN o
weights NNS o
rose VBD o
( ( N
though IN N
this DT N
seemed VBD N
to TO N
be VB N
associated VBN N
with IN N
water NN N
retention NN N
) ) N
; : N
and CC N
systolic JJ o
blood NN o
pressure NN o
rose VBD o
significantly RB N
. . N

Methandienone NNP i
caused VBD N
many JJ N
side NN o
effects NNS o
, , N
and CC N
three CD N
men NNS N
had VBD N
to TO N
withdraw VB N
because IN N
of IN N
them PRP N
. . N

All DT N
side NN o
effects NNS o
disappeared VBD N
after IN N
the DT N
drug NN N
was VBD N
stopped VBN N
. . N

Anabolic JJ i
steroids NNS i
are VBP N
effective JJ N
only RB N
when WRB N
given VBN N
combination NN N
with IN N
exercise NN N
and CC N
high-protein JJ N
diet NN N
. . N

We PRP N
deprecate VBP N
their PRP$ N
use NN N
in IN N
athletics NNS N
but CC N
can MD N
suggest VB N
no DT N
way NN N
of IN N
stopping VBG N
it PRP N
. . N

-DOCSTART- -6482920- O O

Risk NN N
of IN N
infection NN N
after IN N
penetrating VBG N
abdominal JJ N
trauma NN N
. . N

To TO N
identify VB N
the DT N
risk NN N
factors NNS N
for IN N
the DT N
development NN N
of IN N
postoperative JJ N
septic JJ N
complications NNS N
in IN N
patients NNS p
with IN p
intestinal JJ p
perforation NN p
after IN p
abdominal JJ p
trauma NN p
, , N
and CC N
to TO N
compare VB N
the DT N
efficacies NNS N
of IN N
single-drug JJ i
and CC i
dual-drug JJ i
prophylactic JJ i
antibiotic JJ i
therapy NN i
, , N
we PRP N
studied VBD N
145 CD p
patients NNS p
who WP p
presented VBD p
with IN p
abdominal JJ p
trauma NN p
and CC p
intestinal JJ p
perforation NN p
at IN p
two CD p
hospitals NNS p
between IN p
July NNP p
1979 CD p
and CC p
June NNP p
1982 CD p
. . p

Logistic-regression NN N
analysis NN N
showed VBD N
that IN N
a DT N
higher JJR N
risk NN N
of IN N
infection NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
was VBD N
associated VBN N
with IN N
increased JJ N
age NN N
, , N
injury NN N
to TO N
the DT N
left NN N
colon NN N
necessitating VBG N
colostomy NN N
, , N
a DT N
larger JJR N
number NN N
of IN N
units NNS N
of IN N
blood NN N
or CC N
blood NN N
products NNS N
administered VBN N
at IN N
surgery NN N
, , N
and CC N
a DT N
larger JJR N
number NN N
of IN N
injured JJ N
organs NNS N
. . N

The DT N
presence NN N
of IN N
shock NN N
on IN N
arrival NN N
, , N
which WDT N
was VBD N
found VBN N
to TO N
increase VB N
the DT N
risk NN o
of IN o
infection NN o
when WRB N
this DT N
factor NN N
was VBD N
analyzed VBN N
individually RB N
, , N
did VBD N
not RB N
add VB N
predictive JJ N
power NN N
. . N

Patients NNS p
with IN p
postoperative JJ p
sepsis NN p
were VBD N
hospitalized VBN o
significantly RB o
longer RBR N
than IN N
were VBD N
patients NNS N
without IN N
infection NN N
( ( N
13.8 CD N
vs. FW N
7.7 CD N
days NNS N
, , N
P NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

Both DT N
treatment NN N
regimens VBZ i
-- : i
cefoxitin VB i
given VBN i
alone RB i
and CC i
clindamycin JJ i
and CC i
gentamicin JJ i
given VBN i
together RB i
-- : i
resulted VBD i
in IN N
similar JJ N
infection NN o
rates NNS o
, , o
drug NN o
toxicity NN o
, , o
duration NN o
of IN o
hospitalization NN o
, , o
and CC o
costs NNS o
. . o

-DOCSTART- -9116082- O O

Confounding VBG N
by IN N
indication NN N
? . N
-DOCSTART- -14626750- O O

Effects NNS N
of IN N
weight JJ i
reduction NN i
interventions NNS i
by IN N
community NN N
pharmacists NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
a DT N
meal JJ i
replacement NN i
( ( i
MR NNP i
) ) i
program NN i
with IN i
a DT i
conventional JJ i
reduced-calorie JJ i
diet NN i
( ( i
RCD NNP i
) ) i
for IN N
weight NN o
management NN o
using VBG N
the DT N
pharmacy NN i
as IN i
the DT i
setting NN i
and CC i
the DT i
pharmacist NN i
as IN i
the DT i
point NN i
of IN i
contact NN i
for IN i
dietary JJ i
advice NN i
. . i

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
, , N
open-label JJ N
trial NN N
. . N

SETTING NN N
Travis NNP p
Pharmacy NNP p
in IN p
Shenandoah NNP p
, , p
Iowa NNP p
. . p

PATIENTS NNP N
Ninety-five JJ p
patients NNS p
from IN p
southwestern JJ p
iowa NN p
and CC p
southeastern JJ p
Nebraska NNP p
were VBD N
enrolled VBN N
, , N
of IN N
whom WP N
88 CD p
were VBD p
considered VBN p
eligible JJ p
for IN p
comparison NN p
( ( p
by IN p
continuing VBG p
through IN p
week NN p
2 CD p
of IN p
the DT p
study NN p
) ) p
. . p

INTERVENTION JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
an DT N
MR NNP i
plan NN N
or CC N
a DT N
traditional JJ N
RCD NNP i
plan NN N
. . N

Patients NNS N
were VBD N
followed VBN N
for IN N
a DT N
3-month JJ N
period NN N
of IN N
active JJ N
weight JJ N
loss NN N
and CC N
a DT N
10-week JJ N
period NN N
of IN N
weight JJ N
maintenance NN N
. . N

Patients NNS N
returned VBD N
every DT N
3 CD N
weeks NNS N
for IN N
follow-up NN N
with IN N
the DT N
pharmacist NN N
, , N
for IN N
a DT N
total NN N
of IN N
13 CD N
visits NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
Weight NNP o
changes NNS o
. . o

RESULTS NNP N
During IN N
the DT N
active JJ N
weight NN N
loss NN N
phase NN N
, , N
the DT N
MR NNP p
( ( p
n JJ p
= NNP p
45 CD p
) ) p
and CC p
RCD NNP p
( ( p
n JJ p
= NNP p
43 CD p
) ) p
groups NNS N
lost VBD N
a DT N
significant JJ o
amount NN o
of IN o
weight NN o
, , N
although IN N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
groups NNS N
( ( N
mean JJ N
+/- JJ N
standard NN N
error NN N
= VBZ N
4.90 CD N
+/- JJ N
0.30 CD N
kg NN N
MR NNP N
versus NN N
4.30 CD N
+/- JJ N
0.30 CD N
kg NN N
RCD NNP N
; : N
P NNP N
= NNP N
.16 NNP N
) ) N
. . N

In IN N
the DT N
weight NN N
maintenance NN N
phase NN N
, , N
the DT N
MR NNP N
group NN N
lost VBD N
0.70 CD N
+/- JJ N
0.40 CD N
kg NN N
and CC N
the DT N
RCD NNP N
group NN N
lost VBD N
0.90 CD N
+/- JJ N
0.40 CD N
kg NN N
( ( N
P NNP N
= NNP N
.60 NNP N
) ) N
. . N

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
waist JJ o
circumference NN o
, , o
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
and CC o
triglyceride NN o
levels NNS o
. . o

No DT N
significant JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
high-density NN o
lipoprotein NN o
cholesterol NN o
or CC o
low-density NN o
lipoprotein NNS o
cholesterol NN o
levels NNS o
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
Successful NNP N
weight VBD o
management NN o
can MD N
be VB N
achieved VBN N
in IN N
a DT N
pharmacy NN N
setting NN N
. . N

Both DT N
MR NNP i
and CC i
RCD NNP i
programs NNS N
were VBD N
effective JJ N
. . N

-DOCSTART- -11804430- O O

Improved NNP o
responsiveness NN o
of IN N
PCOS NNP p
patients NNS p
to TO N
clomiphene VB i
after IN p
CYP17a NNP i
inhibitor NN i
. . i

PURPOSE NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
CYP17a NNP i
inhibitor NN i
, , i
ketoconazole NN i
, , i
on IN N
clomiphene NN N
responsiveness NN N
in IN N
PCOS NNP p
patients NNS p
. . p

METHODS NNP N
Prospective JJ N
analysis NN N
was VBD N
employed VBN N
with IN N
the DT N
setup NN N
at IN N
Alexandria NNP p
IVF/ICSI NNP p
center NN p
. . p

Ninety-seven JJ p
insulin-resistant JJ p
PCOS NNP p
patients NNS p
undergoing VBG p
ovulation NN p
induction NN p
using VBG p
clomiphene JJ i
citrate NN i
were VBD N
randomly RB N
divided VBN N
, , N
by IN N
random JJ N
number NN N
table NN N
, , N
into IN N
two CD N
groups NNS N
. . N

The DT N
first JJ N
group NN N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
received VBN N
ketoconazole NN i
( ( N
400 CD N
mg NNS N
daily RB N
) ) N
till NN N
correction NN N
of IN N
metabolic JJ N
syndrome NN N
followed VBN N
by IN N
clomiphene NN i
( ( N
100 CD N
mg/day NN N
) ) N
; : N
the DT N
second JJ N
group NN N
( ( N
n JJ N
= NNP N
48 CD N
) ) N
receiving VBG N
clomiphene NN i
without IN i
ketoconazole JJ i
pretreatment NN i
. . i

Main NNP N
outcome JJ N
measures NNS N
were VBD N
incidence NN o
of IN o
clomiphene NN o
resistance NN o
, , o
monofollicular JJ o
response NN o
, , o
fasting VBG o
insulin/glucose JJ o
ratio NN o
, , o
serum NN o
testosterone NN o
, , o
and CC o
pregnancy NN o
rates NNS o
. . o

RESULTS VB N
The DT N
ketoconazole NN i
group NN N
showed VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
incidence NN o
of IN o
monofollicular JJ o
response NN o
( ( N
38 CD N
% NN N
) ) N
, , N
higher JJR o
pregnancy NN o
rates NNS o
, , N
and CC N
significantly RB o
less JJR o
marked JJ o
antiestrogenic NN o
manifestations NNS o
than IN N
did VBD N
the DT N
control NN N
group NN N
. . N

They PRP N
also RB N
had VBD N
significantly RB N
lower JJR N
incidence NN o
of IN o
clomiphene NN o
resistance NN o
( ( N
11.6 CD N
% NN N
) ) N
, , N
lower JJR o
serum NN o
testosterone NN o
levels NNS o
, , N
less JJR N
hyperinsulinaemia NN o
, , N
than IN N
did VBD N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Ketoconazole NNP i
improved VBD N
clomiphene JJ o
responsivenss NN o
in IN o
PCOS NNP o
patients NNS o
and CC N
attenuated VBD N
its PRP$ N
untoward JJ o
biological JJ o
effects NNS o
. . o

-DOCSTART- -12630606- O O

A DT N
preliminary JJ N
study NN N
of IN N
the DT N
optimal JJ N
anesthesia NN i
positioning VBG i
for IN N
the DT N
morbidly JJ p
obese JJ p
patient NN p
. . p

BACKGROUND NNP N
Hypoxemia NNP N
during IN N
the DT N
induction NN N
of IN N
general JJ p
anesthesia NN p
for IN p
the DT p
morbidly JJ p
obese JJ p
patient NN p
is VBZ N
a DT N
major JJ N
concern NN N
of IN N
anesthesiologists NNS N
. . N

The DT N
etiology NN N
of IN N
this DT N
pathophysiological JJ N
problem NN N
is VBZ N
multifactorial JJ N
, , N
and CC N
patient JJ N
positioning NN N
may MD N
be VB N
a DT N
contributing JJ N
factor NN N
. . N

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
to TO N
identify VB N
optimal JJ N
patient NN N
positioning VBG N
for IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
that WDT N
minimizes VBZ N
the DT N
risk NN N
of IN N
hypoxemia NN N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
26 CD p
morbidly RB p
obese JJ p
patients NNS p
( ( p
body JJ p
mass NN p
index-BMI JJ p
56 CD p
+/- JJ p
3 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
positions NNS N
for IN N
induction NN N
of IN N
anesthesia NN N
: : N
1 CD N
) ) N
30 CD i
degrees NNS i
Reverse NNP i
Trendelenburg NNP i
; : i
2 CD N
) ) N
Supine-Horizontal NN i
; : i
3 CD N
) ) N
30 CD i
degrees NNS i
Back VBP i
Up RP i
Fowler NNP i
. . i

Mask NNP i
ventilation NN i
, , i
full JJ i
neuromuscular JJ i
paralysis NN i
and CC i
direct JJ i
laryngoscopy NN i
were VBD N
performed VBN N
. . N

Any DT N
airway JJ o
difficulties NNS o
were VBD N
noted VBN N
. . N

After IN N
endotracheal JJ N
tube NN N
placement NN N
, , N
subjects NNS N
were VBD N
ventilated VBN N
for IN N
5 CD N
minutes NNS N
with IN N
1 CD i
% NN i
isoflurane NN i
in IN i
a DT i
mixture NN i
of IN i
50 CD i
% NN i
oxygen/50 NN i
% NN i
air NN i
and CC N
then RB N
disconnected VBD N
from IN N
the DT N
ventilation NN N
circuit NN N
. . N

The DT N
time NN o
required VBN o
for IN o
capillary JJ o
oxygen NN o
saturation NN o
( ( o
SaO2 NNP o
) ) o
, , N
as IN N
measured VBN N
by IN N
pulse JJ N
oximeter NN N
, , N
to TO N
decline VB N
from IN N
100 CD N
% NN N
to TO N
92 CD N
% NN N
was VBD N
noted VBN N
and CC N
identified VBN N
as IN N
the DT N
safe JJ o
apnea NN o
period NN o
( ( o
SAP NNP o
) ) o
. . o

Ventilation NN N
was VBD N
then RB N
immediately RB N
re-established JJ N
. . N

The DT N
lowest JJS N
SaO2 NN o
after IN N
resuming VBG N
ventilation NN N
and CC N
the DT N
time NN N
from IN N
that DT N
nadir NN N
to TO N
an DT N
SaO2 NNP N
of IN N
97 CD N
% NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS NNP N
BMI NNP o
and CC o
hip-waist JJ o
ratios NNS o
of IN o
patients NNS o
in IN N
groups NNS N
1 CD N
, , N
2 CD N
and CC N
3 CD N
did VBD N
not RB N
significantly RB N
differ VBP N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
airway NN o
difficulties NNS o
between IN N
the DT N
different JJ N
groups NNS N
. . N

The DT N
SAP NNP o
in IN N
groups NNS N
1 CD N
, , N
2 CD N
and CC N
3 CD N
was VBD N
178 CD N
+/- JJ N
55 CD N
, , N
123 CD N
+/- JJ N
24 CD N
and CC N
153 CD N
+/- JJ N
63 CD N
seconds NNS N
, , N
respectively RB N
. . N

The DT N
SaO2 NNP o
of IN N
patients NNS N
in IN N
the DT N
reverse NN N
Trendelenburg NNP N
position NN o
dropped VBD N
the DT N
least JJS N
and CC N
took VBD N
the DT N
shortest JJ N
time NN o
to TO o
recover VB o
to TO N
97 CD N
% NN N
. . N

CONCLUSIONS NNP N
In IN N
morbidly RB N
obese JJ N
patients NNS N
, , N
the DT N
30 CD N
degrees NNS N
Reverse NNP i
Trendelenburg NNP i
position NN N
provided VBD N
the DT N
longest JJS N
SAP NN N
when WRB N
compared VBN N
to TO N
the DT N
30 CD N
degrees NNS N
Back VBP i
Up NNP i
Fowler NNP i
and CC N
Horizontal-Supine NNP i
positions NNS N
. . N

Since IN N
on IN N
induction NN N
of IN N
general JJ N
anesthesia NN N
morbidly RB N
obese JJ N
patients NNS N
may MD N
be VB N
difficult JJ N
to TO N
mask VB N
ventilate JJ N
and/or NN N
intubate NN N
, , N
this DT N
extra JJ N
time NN N
may MD N
preclude VB N
adverse JJ N
sequelae NN N
resulting VBG N
from IN N
hypoxemia NN N
. . N

Therefore RB N
, , N
Reverse NNP i
Trendelenburg NNP i
is VBZ N
recommended VBN N
as IN N
the DT N
optimal JJ N
position NN N
for IN N
induction NN N
. . N

-DOCSTART- -2607948- O O

Effects NNS N
of IN N
hydraulic JJ N
circuit NN N
training NN N
on IN N
cardiovascular JJ p
function NN p
. . p

The DT N
effect NN N
of IN N
hydraulic JJ N
circuit NN N
training NN N
( ( N
HCT NNP N
) ) N
on IN N
cardiovascular NN o
( ( o
CV NNP o
) ) o
function NN o
was VBD N
assessed VBN N
in IN N
32 CD p
healthy JJ p
middle-aged JJ p
males NNS p
( ( p
X JJ p
age NN p
= VBD p
42.2 CD p
+/- JJ p
2.1 CD p
yr NN p
) ) p
. . p

Maximal NNP o
aerobic JJ o
power NN o
( ( o
VO2max NNP o
) ) o
, , o
with IN o
simultaneous JJ o
measurement NN o
of IN o
stroke NN o
volume NN o
( ( o
SV NNP o
) ) o
and CC o
cardiac JJ o
output NN o
( ( o
CO NNP o
) ) o
, , o
by IN o
impedance NN o
cardiography NN o
, , N
was VBD N
assessed VBN N
pre- JJ N
and CC N
post-training JJ N
. . N

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
nonexercising JJ i
control NN i
group NN i
, , i
a DT i
cycle NN i
training NN i
group NN i
( ( i
cycle NN i
) ) i
, , i
or CC i
one CD i
of IN i
the DT i
two CD i
HCT NNP i
groups NNS i
. . i

Training VBG i
groups NNS i
participated VBN i
in IN i
a DT i
9 CD i
wk NN i
program NN i
, , i
3 CD i
d.wk-1 NN i
. . i

Subjects NNS i
assigned VBD i
to TO i
HCT NNP i
exercised VBN i
on IN i
a DT i
9 CD i
station NN i
circuit NN i
, , i
completing VBG i
3 CD i
circuits.d-1 JJ i
. . i

Each DT N
circuit NN N
consisted VBD N
of IN N
three CD N
20 CD N
s JJ N
work NN N
intervals NNS N
at IN N
each DT N
station NN N
with IN N
a DT N
1:1 CD N
work NN N
: : N
rest NN N
ratio NN N
. . N

One CD N
HCT NNP N
group NN N
( ( N
HCTmax NNP N
) ) N
completed VBD N
the DT N
maximal JJ N
repetitions NNS N
possible JJ N
( ( N
RM NNP N
) ) N
during IN N
each DT N
work NN N
interval NN N
. . N

The DT N
other JJ N
HCT NNP N
group NN N
( ( N
HCTsub NNP N
) ) N
exercised VBD N
at IN N
70-85 CD N
% NN N
of IN N
RM NNP N
. . N

Following VBG N
training NN N
VO2max NNP o
( ( o
ml.kg-1 JJ o
min-1 NN o
) ) o
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
training NN N
groups NNS N
( ( N
18.0 CD N
, , N
12.5 CD N
, , N
and CC N
11.3 CD N
% NN N
for IN N
cycle NN N
, , N
HCTsub NNP N
, , N
and CC N
HCTmax NNP o
groups NNS o
, , N
respectively RB N
; : N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
increase NN N
in IN N
VO2max NNP o
observed VBD N
in IN N
the DT N
cycle NN N
group NN N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
recorded VBN N
by IN N
the DT N
two CD N
HCT NNP N
groups NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

For IN N
all DT N
three CD N
training VBG N
groups NNS N
, , N
the DT N
increase NN N
in IN N
VO2max NNP o
was VBD N
associated VBN N
with IN N
increases NNS N
in IN N
SVmax NNP o
and CC o
COmax NNP o
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
for IN N
both DT N
) ) N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
both DT N
maximal JJ N
and CC N
submaximal JJ N
HCT NNP N
programs NNS N
can MD N
elicit VB N
improvements NNS N
in IN N
cardiovascular JJ o
fitness NN o
. . o

-DOCSTART- -23605805- O O

Clinical JJ N
pharmacokinetics NNS N
of IN N
buffered JJ N
propranolol JJ i
sublingual JJ i
tablet NN i
( ( i
Promptol? NNP i
) ) i
-application NN i
of IN i
a DT N
new JJ N
physiologically RB N
based VBN N
model NN N
to TO N
assess VB N
absorption NN N
and CC N
disposition NN N
. . N

Sublingual JJ N
administration NN N
of IN N
certain JJ N
buffered JJ i
propranolol NN i
may MD i
improve VB N
the DT N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
compared VBN N
to TO N
oral JJ N
administration NN N
. . N

The DT N
main JJ N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
( ( N
1 CD N
) ) N
compare VBP N
the DT N
plasma NN N
propranolol NN N
concentrations NNS N
( ( N
Cp-prop NNP N
) ) N
following VBG N
sublingual JJ N
administration NN N
of IN N
a DT N
specially RB i
buffered VBN i
formulation NN i
( ( i
Promptol? NNP i
) ) i
to TO i
that DT N
following VBG N
oral JJ N
administration NN i
of IN i
Inderal NNP i
( ( i
? . i
) ) i
and CC i
( ( N
2 CD N
) ) N
evaluate VB N
the DT N
utility NN N
of IN N
a DT N
special JJ N
pharmacokinetic JJ N
model NN N
in IN N
describing VBG N
the DT N
Cp-prop NNP N
following VBG N
sublingual JJ N
administration NN p
. . p

Eighteen NNP p
healthy JJ p
volunteers NNS p
received VBD i
10 CD i
mg NNS i
sublingual JJ i
Promptol? NNP i
or CC i
oral JJ i
Inderal NNP i
( ( i
? . i
) ) i
. . i

Multiple JJ i
Cp-prop NNP N
were VBD N
determined VBN N
and CC N
their PRP$ N
pharmacokinetics NNS N
compared VBN N
. . N

Additional NNP N
data NN N
following VBG N
sublingual JJ i
40 CD i
mg NN i
Promptol? NNP i
or CC i
Inderal NNP i
( ( i
? . i
) ) i
were VBD N
utilized VBN N
for IN N
evaluation NN N
of IN N
a DT N
special JJ N
advanced JJ N
compartmental JJ N
absorption NN N
and CC N
transit NN N
( ( N
ACAT NNP N
) ) N
model NN N
. . N

For IN N
model NN N
simulation NN N
, , N
the DT N
physicochemical JJ N
parameters NNS N
were VBD N
imported VBN N
from IN N
AMET NNP N
predictor NN N
, , N
whereas IN N
the DT N
pharmacokinetic JJ N
parameters NNS N
were VBD N
calculated VBN N
and CC N
optimized VBN N
by IN N
Gastroplus NNP N
( ( N
? . N
) ) N
. . N

Based VBN N
on IN N
this DT N
model NN N
, , N
the DT N
quantity NN N
of IN N
drug NN N
absorbed VBN N
via IN o
buccal/sublingual JJ o
mucosa NN o
was VBD o
estimated VBN o
. . N

Cp-prop NN o
was VBD o
higher JJR N
at IN N
earlier JJR N
times NNS N
with IN N
3-fold JJ N
greater JJR N
relative JJ N
bioavailability NN N
following VBG N
sublingual JJ i
Promptol? NNP i
compared VBN i
to TO N
that DT N
from IN N
oral JJ N
Inderal NNP N
( ( N
? . N
) ) N
. . N

The DT N
special JJ N
ACAT NNP N
model NN N
provided VBD N
excellent JJ N
goodness NN N
of IN N
fit NN N
of IN o
Cp-prop-time NNP o
curve NN o
and CC o
estimated VBD o
a DT N
56.6 CD N
% NN N
increase NN N
in IN N
absorption NN o
rate NN o
from IN N
Promptol? NNP N
and CC N
higher JJR N
initial JJ N
Cp-prop NNP o
compared VBN o
to TO N
the DT N
regular JJ N
formulation NN N
. . N

The DT N
modified JJ N
ACAT NNP N
model NN N
provided VBD N
a DT N
useful JJ N
approach NN N
to TO N
describe VB N
sublingual JJ N
absorption NN N
of IN N
propranolol NN N
and CC N
clearly RB N
demonstrated VBD N
an DT N
improvement NN N
of IN N
absorption NN i
of IN i
Promptol? NNP i
. . i

The DT i
sublingual JJ N
10 CD N
mg NN N
Promptol? NNP i
achieved VBD i
not RB N
only RB N
a DT N
similar JJ N
systemic JJ N
exposure NN N
as IN N
30 CD N
mg JJ N
oral JJ N
Inderal NNP N
( ( N
? . N
) ) N
but CC N
an DT N
earlier JJR N
effective JJ N
Cp-prop NNP N
which WDT N
may MD N
be VB N
advantageous JJ N
for IN N
certain JJ N
clinical JJ N
conditions NNS N
. . N

-DOCSTART- -9332112- O O

Intravenous JJ i
magnesium NN i
sulfate NN i
in IN N
acute NN o
severe JJ o
asthma NN o
not RB p
responding VBG p
to TO p
conventional JJ i
therapy NN i
. . i

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
early JJ N
administration NN N
of IN N
intravenous JJ i
Magnesium NNP i
sulfate NN i
( ( i
i.v JJ i
. . i

MgSO4 NNP i
) ) i
in IN N
children NNS p
with IN p
acute NN p
severe JJ p
asthma NN p
not RB p
responding VBG p
to TO p
conventional JJ i
therapy NN i
. . i

DESIGN NNP N
Randomized NNP N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
. . N

SETTING NN N
Pediatric NNP p
emergency NN p
service NN p
of IN p
a DT p
large JJ p
teaching NN p
hospital NN p
. . p

SUBJECTS CC N
47 CD p
children NNS p
aged VBN p
between IN p
1-12 CD p
years NNS p
with IN p
acute NN p
severe JJ p
asthma NN p
showing VBG p
inadequate JJ o
or CC o
poor JJ o
response NN o
to TO p
3 CD p
doses NNS p
of IN p
nebulized JJ i
salbutamol NN i
given VBN p
at IN p
an DT p
interval NN p
of IN p
20 CD p
min NNS p
each DT p
. . p

INTERVENTION VBZ N
The DT N
MgSO4 NNP i
group NN N
received VBD i
0.2 CD i
ml/kg NN i
of IN i
50 CD i
% NN i
MgSO4 NNP i
as IN i
intravenous JJ i
( ( i
i.v JJ i
. . i

) ) i
infusion NN i
over IN N
35 CD N
minutes NNS N
and CC N
the DT N
placebo NN i
group NN N
received VBD N
normal JJ i
saline JJ i
infusion NN i
in IN N
the DT N
same JJ N
dose NN N
and CC N
at IN N
the DT N
same JJ N
rate NN N
. . N

MgSO4 NNP i
solution NN i
and CC N
normal JJ i
saline NN i
were VBD N
coded VBN N
and CC N
dispensed VBN N
in IN N
identical JJ N
containers NNS N
. . N

Decoding VBG N
was VBD N
done VBN N
at IN N
the DT N
completion NN N
of IN N
the DT N
study NN N
. . N

All PDT N
the DT N
patients NNS N
received VBD N
oxygen NN i
, , i
nebulized JJ i
salbutamol NN i
, , i
i.v NN i
. . i

aminophylline NN i
and CC N
corticosteroids NNS i
. . i

RESULTS NNP N
MgSO4 NNP i
group NN N
showed VBD N
early JJ o
and CC o
significant JJ o
improvement NN o
as IN N
compared VBN N
to TO N
placebo VB i
group NN N
in IN N
PEFR NNP o
and CC o
SaO2 NNP o
at IN N
30 CD N
min NN N
and CC N
1 CD N
, , N
2 CD N
, , N
3 CD N
and CC N
7 CD N
hours NNS N
after IN N
stopping VBG N
the DT N
infusion NN N
( ( N
p JJ N
ranging VBG N
from IN N
< $ N
0.05 CD N
to TO N
< VB N
0.01 CD N
) ) N
. . N

The DT N
clinical JJ o
asthma NN o
score NN o
also RB N
showed VBD N
significant JJ N
improvement NN N
in IN N
the DT N
MgSO4 NNP i
group NN N
1 CD N
, , N
2 CD N
, , N
3 CD N
and CC N
11 CD N
hours NNS N
after IN N
stopping VBG N
the DT N
infusion NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Addition NNP N
of IN N
MgSO4 NNP i
to TO N
conventional JJ i
therapy NN i
helps VBZ N
in IN N
achieving VBG N
earlier RBR N
improvement NN o
in IN o
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
of IN o
asthma NN o
and CC o
PEFR NNP o
in IN N
patients NNS p
not RB p
responding VBG p
to TO p
conventional JJ p
therapy NN p
alone RB p
. . p

-DOCSTART- -17700083- O O

A DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
a DT N
home-based JJ i
intervention NN i
program NN i
for IN N
children NNS p
with IN p
autism NN p
and CC p
developmental JJ p
delay NN p
. . p

OBJECTIVE CC N
This DT N
study NN N
aimed VBN N
to TO N
( ( N
1 CD N
) ) N
investigate NN N
whether IN N
provision NN N
of IN N
a DT N
home-based JJ i
program NN i
in IN i
addition NN i
to TO i
a DT i
center-based JJ i
program NN i
improves VBZ N
development NN N
in IN N
young JJ p
children NNS p
with IN p
disabilities NNS p
and CC p
coping VBG p
abilities NNS p
of IN p
their PRP$ p
families NNS p
and CC p
( ( p
2 CD p
) ) p
describe VB p
the DT p
characteristics NNS p
of IN p
children NNS p
and CC p
families NNS p
who WP p
benefit VBP p
most RBS p
from IN p
the DT p
intervention NN p
. . p

METHODS NNP N
Fifty-nine JJ p
children NNS p
, , p
aged VBN p
3-5 CD p
years NNS p
, , p
with IN p
no DT p
cerebral JJ p
palsy NN p
, , N
participated VBN N
in IN N
the DT N
study NN N
. . N

Half NNP N
of IN N
the DT N
group NN N
was VBD N
randomized VBN N
to TO N
receive VB N
an DT N
additional JJ i
program NN i
in IN i
their PRP$ i
homes NNS i
. . i

A DT p
special JJ p
education NN p
teacher NN p
provided VBD p
40 CD p
visits NNS p
over IN p
12 CD p
months NNS p
working VBG p
with IN p
the DT p
families NNS p
to TO N
help VB N
generalize VB N
skills NNS N
to TO N
the DT N
home NN N
environment NN N
and CC N
assist NN N
with IN N
their PRP$ N
concerns NNS N
. . N

All DT N
children NNS N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
intervention NN N
, , N
and CC N
families NNS N
completed VBN N
questionnaires NNS N
assessing VBG N
family NN o
stress NN o
, , o
support NN o
, , o
and CC o
empowerment NN o
on IN N
both DT N
occasions NNS N
. . N

Differences NNS N
in IN N
change NN N
over IN N
time NN N
and CC N
between IN N
the DT N
intervention NN N
and CC N
control NN N
group NN N
were VBD N
analyzed VBN N
by IN N
repeated JJ N
measures NNS N
and CC N
the DT N
association NN N
between IN N
characteristics NNS N
of IN N
children NNS N
and CC N
families NNS N
with IN N
improved JJ N
outcome NN N
by IN N
multivariate JJ N
analysis NN N
of IN N
variance NN N
. . N

RESULTS NNP N
Change NNP o
in IN o
cognitive JJ o
development NN o
and CC o
behavior NN o
( ( N
in IN N
the DT N
centers NNS N
) ) N
over IN N
time NN N
favored VBN N
the DT N
children NNS N
who WP N
received VBD N
the DT N
extra JJ N
intervention NN N
( ( N
p JJ N
= NNP N
.007 NNP N
and CC N
p VB N
= NNP N
.007 NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB o
on IN N
any DT N
of IN N
the DT N
family NN o
measures NNS o
of IN o
change NN o
. . o

Multivariate NNP N
analysis NN N
of IN N
variance NN N
revealed VBD N
more RBR N
improvement NN N
for IN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
from IN N
higher JJR N
than IN N
lower JJR N
stressed JJ N
families NNS N
. . N

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
the DT N
need NN N
for IN N
daily JJ N
reinforcement NN N
of IN N
skills NNS N
learned VBN N
at IN N
the DT N
center-based JJ N
program NN N
and CC N
the DT N
importance NN N
of IN N
involving VBG N
families NNS N
, , N
especially RB N
those DT N
with IN N
few JJ N
resources NNS N
and CC N
relatively RB N
high JJ N
stress NN N
. . N

-DOCSTART- -12037693- O O

The DT N
impact NN N
of IN N
angiotensin NN i
II NNP i
receptor NN i
blockade NN i
and CC N
the DT N
DASH NNP i
diet NN i
on IN N
markers NNS o
of IN N
endogenous JJ p
fibrinolysis NN p
. . p

Hypertension NNP N
is VBZ N
associated VBN N
with IN N
impaired JJ N
fibrinolysis NN N
. . N

Both DT N
angiotensin JJ i
receptor NN i
blockers NNS i
( ( i
ARB NNP i
) ) i
and CC N
the DT N
DASH NNP i
( ( i
Dietary NNP i
Approaches NNP i
to TO i
Stop NNP i
Hypertension NNP i
) ) i
diet VBP i
effectively RB N
lower JJR N
blood NN o
pressure NN o
in IN N
hypertensive JJ p
patients NNS p
. . p

Some DT N
evidence NN N
suggests VBZ N
that IN N
treatment NN N
with IN N
ARBs NNP N
could MD N
increase VB N
fibrinolysis NN N
, , N
however RB N
, , N
data NNS N
is VBZ N
conflicting VBG N
. . N

The DT N
impact NN N
of IN N
the DT N
DASH NNP N
diet NN N
on IN N
fibrinolytic JJ o
parameters NNS o
is VBZ N
not RB N
known VBN N
. . N

Fifty-five JJ p
hypertensive JJ p
participants NNS p
( ( p
35 CD p
African-American JJ p
, , p
20 CD p
white JJ p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
8 CD N
weeks NNS N
of IN N
either CC N
a DT N
control NN i
diet NN i
or CC N
the DT N
DASH NNP i
diet NN i
. . i

The DT N
diets NNS N
did VBD N
not RB N
differ VB N
in IN N
sodium NN N
content NN N
( ( N
approximately RB N
3 CD N
g/day NN N
) ) N
. . N

Within IN N
each DT N
diet NN N
, , N
individuals NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
losartan NN i
or CC N
placebo NN i
for IN N
4 CD N
weeks NNS N
in IN N
double-blind NN N
, , N
cross-over JJ N
fashion NN N
. . N

Tissue NNP o
plasminogen NN o
activator NN o
( ( o
t-PA JJ o
) ) o
antigen NN o
, , o
t-PA JJ o
activity NN o
, , o
plasminogen NN o
activator NN o
inhibitor-1 JJ o
( ( o
PAI-1 NNP o
) ) o
activity NN o
and CC o
plasma NN o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
were VBD N
measured VBN N
at IN N
the DT N
end NN N
of IN N
a DT N
2-week JJ N
run-in JJ N
period NN N
on IN N
the DT N
control NN N
diet NN i
and CC N
after IN N
each DT N
treatment NN N
period NN N
. . N

The DT N
DASH NNP N
diet NN N
did VBD N
not RB N
affect JJ N
markers NNS N
of IN N
fibrinolysis NN N
. . N

Losartan NNP N
significantly RB N
lowered VBD N
t-PA JJ o
antigen NN o
levels NNS o
( ( N
-1.8 NNP N
ng/mL RB N
, , N
P NNP N
= NNP N
0.045 CD N
) ) N
, , N
but CC N
had VBD N
no DT N
effect NN N
on IN N
t-PA NN o
or CC o
PAI-1 JJ o
activities NNS o
. . o

This DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
whites NNS p
( ( N
-4.1 JJ N
ng/mL NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
) ) N
compared VBN N
with IN N
African-Americans NNP p
( ( N
-0.3 JJ N
ng/mL NN N
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
, , N
P-interaction NNP N
= NNP N
0.03 CD N
) ) N
. . N

Results NNS N
were VBD N
not RB N
materially RB N
affected VBN N
by IN N
adjustment NN N
for IN N
basline NN N
values NNS N
or CC N
changes NNS N
in IN N
blood NN o
pressure NN o
. . o

This DT N
study NN N
demonstrates VBZ N
that IN N
losartan JJ N
reduces NNS N
t-PA JJ o
antigen NN o
levels NNS o
in IN N
white JJ p
, , p
but CC p
not RB p
African-American JJ p
hypertensive JJ p
individuals NNS p
. . p

In IN N
contrast NN N
, , N
the DT N
DASH NNP N
diet NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
markers NNS o
of IN o
fibrinolysis NN o
in IN N
whites NNS p
or CC p
African-Americans NNS p
. . p

-DOCSTART- -3940160- O O

[ IN p
The DT p
use NN p
of IN p
cephalosporins NNS i
in IN p
hospital NN p
practice NN p
] NN p
. . N

-DOCSTART- -19995250- O O

Breast NNP i
reduction NN i
alleviates VBZ N
depression NN o
and CC o
anxiety NN o
and CC N
restores VBZ N
self-esteem NNS o
: : o
a DT N
prospective JJ N
randomised JJ N
clinical JJ N
trial NN N
. . N

Of IN N
women NNS p
who WP p
seek VBP p
reduction NN p
mammaplasty NN p
, , N
up RB N
to TO N
a DT N
third JJ N
have VBP p
pathological JJ p
degrees NNS p
of IN p
anxiety NN o
or CC o
depression NN o
, , p
or CC p
both DT p
. . p

The DT N
psychological JJ o
aspect NN o
of IN N
reduction NN i
mammaplasty NN i
is VBZ N
therefore RB N
an DT N
important JJ N
consideration NN N
. . N

We PRP N
did VBD N
a DT N
prospective NN N
randomised VBN N
clinical JJ N
trial NN N
to TO N
see VB N
how WRB N
reduction NN i
mammaplasty RB i
affected VBD N
macromastia JJ N
patients NNS N
' POS N
depression NN o
, , o
anxiety NN o
, , o
and CC o
self-esteem JJ o
. . o

Eighty-two JJ p
patients NNS p
were VBD p
randomised VBN p
, , p
40 CD p
to TO p
have VB p
the DT p
operation NN p
, , p
and CC p
42 CD p
patients NNS p
to TO p
conservative JJ p
treatment NN p
. . p

Both DT N
groups NNS N
were VBD N
followed VBN N
for IN N
six CD N
months NNS N
. . N

The DT N
patients NNS N
completed VBD N
the DT N
RBDI NNP o
questionnaire NN o
( ( o
Raitasalo NNP o
's POS o
modification NN o
of IN o
the DT o
short JJ o
form NN o
of IN o
the DT o
Beck NNP o
Depression NNP o
Inventory NNP o
) ) o
. . o

Twenty-nine JJ p
patients NNS p
in IN p
the DT p
operated JJ p
group NN p
and CC p
35 CD p
patients NNS p
in IN p
the DT p
conservative JJ p
group NN p
completed VBD N
the DT N
study NN N
. . N

At IN N
the DT N
second JJ N
examination NN N
, , N
the DT N
patients NNS N
who WP N
had VBD N
been VBN N
operated VBN N
on IN N
, , N
had VBD N
significantly RB N
less JJR N
depression NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
better JJR o
self-esteem NN o
( ( N
p=0.03 NN N
) ) N
than IN N
the DT N
conservative JJ N
group NN N
. . N

The DT N
proportions NNS o
of IN N
depressed JJ o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
anxious JJ o
( ( N
p=0.04 NN N
) ) N
patients NNS N
were VBD N
also RB N
smaller JJR N
in IN N
the DT N
group NN N
who WP N
were VBD N
operated VBN N
on IN N
. . N

There EX N
is VBZ N
significantly RB N
less JJR N
depression NN o
and CC o
anxiety NN o
after IN N
reduction NN N
mammaplasty NN i
, , N
and CC N
patients NNS N
' POS N
self-esteem NN o
is VBZ N
restored VBN N
. . N

-DOCSTART- -11167879- O O

Perioperative JJ i
blood NN i
transfusions NNS i
, , i
with IN i
or CC i
without IN i
allogeneic JJ i
leucocytes NNS i
, , N
relate NN N
to TO N
survival VB o
, , N
not RB N
to TO N
cancer NN o
recurrence NN o
. . o

BACKGROUND NNP N
Perioperative NNP i
blood NN i
transfusions NNS i
are VBP N
reported VBN N
to TO N
be VB N
related VBN N
to TO N
cancer NN o
recurrence NN o
and CC N
reduced JJ o
survival NN o
. . o

Different NNP N
underlying VBG N
mechanisms NNS N
have VBP N
been VBN N
proposed VBN N
, , N
and CC N
allogeneic JJ N
leucocytes NNS N
in IN N
transfused JJ N
blood NN N
have VBP N
been VBN N
suggested VBN N
to TO N
contribute VB N
to TO N
this DT N
phenomenon NN N
. . N

METHODS NNP N
Packed VBD i
red JJ i
cells NNS i
without IN i
buffy NN i
coat NN i
( ( i
PC NNP i
group NN i
) ) i
were VBD i
compared VBN i
with IN i
filtered JJ i
, , i
leucoreduced VBD i
, , i
red JJ i
cells NNS i
( ( i
LD NNP i
group NN i
) ) i
in IN N
a DT N
randomized JJ N
trial NN p
of IN p
697 CD p
patients NNS p
with IN p
colorectal JJ p
carcinoma NN p
. . p

Five-year JJ o
survival NN o
and CC o
cancer NN o
recurrence NN o
rates NNS o
were VBD N
determined VBN N
, , N
with IN N
special JJ N
emphasis NN N
on IN N
the DT N
location NN o
of IN o
recurrence NN o
. . o

RESULTS VB N
The DT N
intention-to-treat JJ N
analysis NN N
showed VBD N
a DT N
survival JJ o
rate NN o
of IN N
63.6 CD N
per IN N
cent NN N
in IN N
the DT N
PC NN N
group NN N
and CC N
65.3 CD N
per IN N
cent NN N
in IN N
the DT N
LD NNP N
group NN N
( ( N
P NNP N
= NNP N
0.69 CD N
) ) N
, , N
with IN N
recurrence NN o
rates NNS o
of IN N
27.8 CD N
and CC N
27.9 CD N
per IN N
cent NN N
respectively RB N
. . N

The DT N
observational JJ N
analysis NN N
showed VBD N
a DT N
significant JJ N
difference NN o
in IN o
survival NN o
between IN N
transfused VBN N
and CC N
non-transfused JJ N
patients NNS N
( ( N
59.6 CD N
versus NN N
72.9 CD N
per IN N
cent NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
difference NN o
in IN o
cancer NN o
recurrence NN o
rate NN o
between IN N
transfused VBN N
and CC N
non-transfused JJ N
patients NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
29.8 CD N
versus NN N
24.3 CD N
per IN N
cent NN N
; : N
P NNP N
= NNP N
0.13 CD N
) ) N
. . N

Local JJ o
recurrences NNS o
were VBD N
more RBR N
frequent JJ N
in IN N
transfused JJ N
than IN N
non-transfused JJ N
patients NNS N
( ( N
11.9 CD N
versus NN N
7.6 CD N
per IN N
cent NN N
; : N
P NNP N
= NNP N
0.09 CD N
) ) N
. . N

CONCLUSION NNP N
Leucocyte NNP N
depletion NN N
of IN N
perioperative NN i
transfused VBN i
blood NN i
has VBZ N
no DT N
effect NN N
on IN N
long-term JJ o
survival NN o
and/or NN o
cancer NN o
recurrence NN o
. . o

Perioperative JJ N
blood NN N
transfusions NNS N
are VBP N
associated VBN N
with IN N
impaired JJ N
survival NN N
, , N
but CC N
not RB N
with IN N
cancer NN N
recurrence NN N
. . N

The DT N
slight JJ N
increase NN N
in IN N
local JJ N
recurrence NN o
rate NN o
in IN N
transfused JJ p
patients NNS p
appears VBZ N
to TO N
be VB N
related VBN N
to TO N
complicated VBN N
, , N
in IN N
particular JJ N
rectal NN N
, , N
surgery NN N
. . N

-DOCSTART- -6630328- O O

A DT N
controlled JJ N
trial NN N
of IN N
'Senokot NNP i
' POS i
in IN N
faecal JJ N
soiling NN N
treated VBN N
by IN N
behavioural JJ N
methods NNS N
. . N

A DT N
double-blind JJ N
randomly NN N
controlled VBD N
trial NN N
of IN N
one CD N
particular JJ N
laxative NN N
, , N
Senokot NNP i
, , N
used VBD N
in IN N
moderate JJ N
dosage NN N
, , N
was VBD N
carried VBN N
out RP N
on IN N
a DT N
group NN N
of IN N
40 CD p
children NNS p
with IN p
severe JJ p
and CC p
persistent JJ p
soiling NN p
and CC p
often RB p
with IN p
a DT p
history NN p
of IN p
faecal JJ p
retention NN p
. . p

Significant JJ o
improvement NN o
occurred VBD N
following VBG N
three CD N
months NNS N
of IN N
outpatient JJ N
treatment NN N
using VBG N
a DT N
behavioural JJ i
approach NN i
and CC i
either DT i
Senokot NNP i
, , i
placebo NN i
or CC i
no DT i
medication NN i
. . i

However RB N
, , N
there EX N
was VBD N
no DT N
evidence NN N
either RB N
during IN N
the DT N
trial NN N
or CC N
subsequently RB N
when WRB N
Senokot NNP N
was VBD N
employed VBN N
to TO N
supplement VB N
behavioural JJ N
treatment NN N
in IN N
every DT N
child NN N
who WP N
continued VBD N
with IN N
therapy NN N
that IN N
this DT N
laxative NN N
contributed VBD N
in IN N
any DT N
way NN N
to TO N
relieving VBG o
the DT o
problem NN o
in IN N
this DT N
group NN N
of IN N
cases NNS N
. . N

-DOCSTART- -8318411- O O

Continuous JJ i
chemotherapy NN i
in IN N
responsive JJ N
metastatic JJ p
breast NN p
cancer NN p
: : p
a DT N
role NN N
for IN N
tumour NN N
markers NNS N
? . N
A DT N
biochemical JJ N
response NN N
index NN N
comprising VBG N
ESR NNP N
, , N
CEA NNP N
and CC N
CA NNP N
15.3 CD N
was VBD N
evaluated VBN N
in IN N
67 CD p
patients NNS p
with IN p
systemic JJ p
breast NN p
cancer NN p
treated VBN p
by IN p
chemotherapy NN p
; : p
55 CD p
were VBD p
assessable JJ p
by IN p
UICC NNP p
criteria NNS p
and CC p
the DT p
response NN p
index NN p
( ( p
96 CD p
% NN p
of IN p
all DT p
UICC NNP p
assessable JJ p
patients NNS p
) ) p
. . p

Marker NNP N
changes NNS N
at IN N
2 CD N
and CC N
4 CD N
months NNS N
showed VBD N
a DT N
highly RB N
significant JJ N
correlation NN N
with IN N
the DT N
UICC NNP N
assessed VBD N
response NN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
sensitivity $ N
100 CD N
% NN N
, , N
specificity NN N
87 CD N
% NN N
; : N
positive JJ N
predictive JJ N
value NN N
85 CD N
% NN N
; : N
negative JJ N
predictive JJ N
value NN N
100 CD N
% NN N
. . N

This DT N
index NN N
was VBD N
then RB N
used VBN N
to TO N
select VB N
out RP N
truly RB N
responsive JJ N
patients NNS p
and CC N
to TO N
prospectively RB N
direct VB N
their PRP$ N
chemotherapy NN i
. . i

Twenty-six JJ N
responding NN N
( ( N
biochemical/clinical JJ N
) ) N
patients NNS N
were VBD N
randomised VBN N
to TO N
discontinue VB i
cytotoxics NNS i
after IN i
6 CD i
months NNS i
and CC i
move VB i
to TO i
maintenance VB i
hormones NNS i
( ( N
n JJ N
= NNP N
13 CD N
) ) N
or CC N
continue VB i
chemotherapy NN i
whilst IN N
the DT N
biochemical JJ N
markers NNS N
kept VBD N
falling VBG N
or CC N
remained VBN N
within IN N
the DT N
normal JJ N
range NN N
. . N

Biochemical JJ N
progression NN N
prompted VBD N
a DT N
change NN N
of IN N
chemotherapy NN N
. . N

Continuous JJ i
chemotherapy NN i
in IN N
biochemically RB N
defined JJ N
responders NNS N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
lengthening NN o
of IN o
remission NN o
duration NN o
and CC o
an DT o
improved JJ o
quality NN o
of IN o
life NN o
and CC o
survival NN o
. . o

We PRP N
are VBP N
now RB N
using VBG N
the DT N
index NN N
to TO N
routinely RB N
direct JJ N
chemotherapy NN N
and CC N
select VB N
out RP N
true JJ N
responders NNS N
for IN N
maintenance NN N
chemotherapy NN N
. . N

-DOCSTART- -19169102- O O

Elastic JJ i
stable JJ i
intramedullary JJ i
nailing VBG i
versus NN N
nonoperative JJ i
treatment NN i
of IN N
displaced JJ p
midshaft NN p
clavicular JJ p
fractures-a JJ p
randomized VBN N
, , N
controlled VBN N
, , N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB o
elastic JJ i
stable JJ i
intramedullary JJ i
nailing NN i
( ( i
ESIN NNP i
) ) i
with IN N
nonoperative JJ i
treatment NN i
of IN N
fully RB p
displaced VBN p
midshaft NN p
clavicular NN p
fractures NNS p
in IN p
adults NNS p
. . p

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Level NNP p
1 CD p
trauma NN p
center NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Sixty NNP p
patients NNS p
between IN p
18 CD p
and CC p
65 CD p
years NNS p
of IN p
age NN p
participated VBN p
and CC p
completed VBN p
the DT p
study NN p
. . p

They PRP N
were VBD N
randomized VBN N
to TO N
either DT N
operative JJ N
or CC N
nonoperative JJ N
treatment NN N
with IN N
a DT N
2-year JJ N
follow-up NN N
. . N

INTERVENTION NNP N
Thirty NNP N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
simple JJ i
shoulder NN i
sling NN i
and CC N
30 CD N
patients NNS N
with IN N
ESIN NNP i
within IN N
3 CD N
days NNS N
after IN N
trauma NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASUREMENT NNP N
Complications NNP o
after IN N
operative JJ N
and CC N
nonoperative JJ N
treatments NNS N
, , N
Disabilities NNS o
of IN o
the DT o
Arm NNP o
, , o
Shoulder NNP o
and CC o
Hand NNP o
( ( o
DASH NNP o
) ) o
score NN o
and CC N
Constant JJ o
Shoulder NNP o
Score NNP o
for IN N
outcome JJ o
measurement NN o
, , N
and CC N
clavicular JJ o
shortening NN o
. . o

RESULTS NNP N
Fracture NNP o
union NN o
was VBD N
achieved VBN N
in IN N
all DT N
patients NNS N
in IN N
the DT N
operative JJ N
group NN N
, , N
whereas IN N
nonunion NN o
was VBD N
observed VBN N
in IN N
3 CD N
of IN N
30 CD N
patients NNS N
of IN N
the DT N
nonoperative JJ N
group NN N
. . N

Two CD N
symptomatic JJ o
malunions NNS o
required VBN N
corrective JJ N
osteotomy NN N
in IN N
the DT N
nonoperative JJ N
group NN N
. . N

Medial NNP o
nail JJ o
protrusion NN o
occurred VBD N
in IN N
7 CD N
cases NNS N
in IN N
the DT N
operative JJ N
group NN N
. . N

Implant JJ o
failure NN o
with IN o
revision NN o
surgery NN o
was VBD N
necessary JJ N
in IN N
2 CD N
patients NNS N
after IN N
an DT N
additional JJ N
adequate NN N
trauma NN N
. . N

DASH NNP o
scores NNS o
were VBD N
lower JJR N
in IN N
the DT N
operative JJ N
group NN N
throughout IN N
the DT N
first JJ N
6 CD N
months NNS N
and CC N
2 CD N
years NNS N
after IN N
trauma NN N
, , N
with IN N
a DT N
significant JJ N
difference NN N
during IN N
the DT N
first JJ N
18 CD N
weeks NNS N
. . N

Constant JJ o
scores NNS o
were VBD N
significantly RB N
higher JJR N
after IN N
6 CD N
months NNS N
and CC N
2 CD N
years NNS N
after IN N
intramedullary JJ N
stabilization NN N
. . N

Patients NNS N
in IN N
the DT N
operative JJ N
group NN N
showed VBD N
a DT N
significant JJ N
improvement NN N
of IN N
posttraumatic JJ o
clavicular JJ o
shortening NN o
; : o
they PRP N
were VBD N
also RB N
more RBR N
satisfied JJ o
with IN N
cosmetic JJ N
appearance NN N
and CC N
overall JJ o
outcome NN o
. . o

CONCLUSIONS NNP N
ESIN NNP N
of IN N
displaced JJ N
midshaft NN N
clavicular NN N
fractures NNS N
resulted VBD N
in IN N
a DT N
lower JJR N
rate NN N
of IN N
nonunion NN o
and CC N
delayed VBN o
union NN o
, , N
a DT N
faster JJR N
return NN o
to TO o
daily JJ o
activities NNS o
, , N
and CC N
a DT N
better JJR N
functional JJ o
outcome NN o
. . o

Clavicular JJ o
shortening NN o
was VBD N
significantly RB N
lower JJR N
, , N
and CC N
overall JJ o
satisfaction NN o
was VBD N
higher RBR N
in IN N
the DT N
operative JJ N
group NN N
. . N

-DOCSTART- -11815957- O O

Liposome-encapsulated JJ i
doxorubicin NNS i
compared VBN N
with IN N
conventional JJ i
doxorubicin NN i
in IN N
a DT N
randomized JJ N
multicenter NN N
trial NN N
as IN N
first-line JJ N
therapy NN N
of IN N
metastatic JJ p
breast NN p
carcinoma NN p
. . p

BACKGROUND IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
toxicity NN N
of IN N
the DT N
liposome-encapsulated JJ i
doxorubicin NN i
, , i
TLC NNP i
D-99 NNP i
( ( i
Myocet NNP i
, , i
Elan NNP i
Pharmaceuticals NNP i
, , i
Princeton NNP i
, , i
NJ NNP i
) ) i
, , N
and CC N
conventional JJ i
doxorubicin NN i
in IN N
first-line JJ N
treatment NN N
of IN N
metastatic JJ N
breast NN N
carcinoma NN N
( ( N
MBC NNP N
) ) N
. . N

METHODS NNP N
Two CD p
hundred VBD p
twenty-four JJ p
patients NNS p
with IN p
MBC NNP p
and CC p
no DT p
prior JJ p
therapy NN p
for IN p
metastatic JJ p
disease NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
TLC NNP i
D-99 NNP i
( ( i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
) ) i
or CC i
doxorubicin NN i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
every DT N
3 CD N
weeks NNS N
, , N
in IN N
the DT N
absence NN N
of IN N
disease NN N
progression NN N
or CC N
unacceptable JJ N
toxicity NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
response NN N
rate NN N
. . N

Responses NNS N
were VBD N
assessed VBN N
using VBG N
World NNP N
Health NNP N
Organization NNP N
criteria NNS N
and CC N
were VBD N
required VBN N
to TO N
be VB N
of IN N
at IN N
least JJS N
6 CD N
weeks NNS N
' POS N
duration NN N
. . N

The DT N
primary JJ N
safety NN N
endpoint NN N
was VBD N
cardiotoxicity NN N
. . N

Cardiac NNP N
function NN N
was VBD N
monitored VBN N
by IN N
multiple-gated JJ i
radionuclide NN i
cardioangiography NN i
scan JJ i
, , N
and CC N
the DT N
left JJ N
ventricular JJ N
ejection NN N
fraction NN N
( ( N
LVEF NNP N
) ) N
was VBD N
scored VBN N
at IN N
a DT N
central JJ N
laboratory NN N
. . N

Patients NNS p
were VBD p
removed VBN p
from IN p
study NN p
if IN p
LVEF NNP p
declined VBD p
20 CD p
or CC p
more JJR p
EF JJ p
units NNS p
from IN p
baseline NN p
to TO p
a DT p
final JJ p
value NN p
of IN p
greater JJR p
than IN p
or CC p
equal JJ p
to TO p
50 CD p
% NN p
, , p
or CC p
by IN p
10 CD p
or CC p
more JJR p
units NNS p
to TO p
a DT p
final JJ p
value NN p
of IN p
less JJR p
than IN p
50 CD p
% NN p
, , p
or CC p
onset NN p
of IN p
clinical JJ p
congestive JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
. . N

RESULTS NNP N
Median JJ p
age NN p
was VBD p
54 CD p
years NNS p
in IN p
both DT p
treatment NN p
groups NNS p
. . p

All DT N
relevant JJ N
prognostic JJ N
factors NNS N
were VBD N
balanced VBN N
, , N
with IN N
the DT N
exception NN N
that IN N
there EX N
were VBD N
significantly RB N
more JJR N
progesterone JJ N
receptor NN N
positive JJ N
patients NNS N
in IN N
the DT N
doxorubicin-treated JJ i
group NN N
. . N

Protocol-defined JJ o
cardiotoxicity NN o
was VBD N
observed VBN N
in IN N
13 CD N
% NN N
of IN N
TLC NNP N
D-99 NNP N
patients NNS N
( ( N
including VBG N
2 CD N
cases NNS N
of IN N
CHF NNP N
) ) N
compared VBN N
to TO N
29 CD N
% NN N
of IN N
doxorubicin NN i
patients NNS N
( ( N
including VBG N
9 CD N
cases NNS N
of IN N
CHF NNP N
) ) N
. . N

Median JJ o
cumulative JJ o
doxorubicin NN o
dose NN o
at IN o
onset NN o
of IN o
cardiotoxicity NN o
was VBD N
785 CD N
mg/m NN N
( ( N
2 CD N
) ) N
for IN N
TLC NNP i
D-99 NNP i
versus NN N
570 CD N
mg/m NN N
( ( N
2 CD N
) ) N
for IN N
doxorubicin NN i
( ( N
P NNP N
= NNP N
0.0001 CD N
; : N
hazard NN N
ratio NN N
, , N
3.56 CD N
) ) N
. . N

The DT N
overall JJ o
response NN o
rate NN o
was VBD N
26 CD N
% NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

The DT N
median JJ o
TTP NNP o
was VBD N
2.9 CD N
months NNS N
on IN N
TLC NNP N
D-99 NNP N
versus NN N
3.1 CD N
months NNS N
on IN N
doxorubicin NN i
. . i

Median JJ o
survival NN o
was VBD N
16 CD N
versus NN N
20 CD N
months NNS N
with IN N
a DT N
nonsignificant JJ N
trend NN N
in IN N
favor NN N
of IN N
doxorubicin NN i
( ( N
P NNP N
= NNP N
0.09 CD N
) ) N
. . N

Clinical JJ o
toxicities NNS o
, , N
commonly RB N
associated VBN N
with IN N
doxorubicin NN N
, , N
appeared VBD N
less RBR N
common JJ N
with IN N
TLC NNP N
D-99 NNP N
, , N
although IN N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

There EX N
was VBD N
only RB N
one CD N
report NN N
of IN N
palmar-plantar JJ o
erythrodysesthesia NN o
( ( N
Grade NNP N
2 CD N
) ) N
with IN N
this DT N
liposomal JJ N
formulation NN N
of IN N
doxorubicin NN i
. . i

CONCLUSIONS NNP N
Single-agent JJ N
TLC NNP i
D-99 NNP i
produces VBZ N
less JJR N
cardiotoxicity NN N
than IN N
doxorubicin NNS i
, , N
while IN N
providing VBG N
comparable JJ N
antitumor NN N
activity NN N
. . N

-DOCSTART- -26166077- O O

1H CD N
Magnetic JJ N
Resonance NNP N
Spectroscopy NNP N
Predicts NNP N
Hepatocellular NNP N
Carcinoma NNP N
in IN N
a DT N
Subset NNP N
of IN N
Patients NNPS p
With IN p
Liver NNP p
Cirrhosis NNP p
: : p
A DT N
Randomized NNP N
Trial NNP N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
utility NN N
of IN N
H NNP i
magnetic JJ i
resonance NN i
spectroscopy NN i
( ( i
H-MRS NNP i
) ) i
to TO N
quantify VB N
the DT N
differences NNS N
in IN N
liver NN N
metabolites NNS N
. . N

Magnetic JJ N
resonance NN N
spectroscopy NN N
was VBD N
used VBN N
as IN N
a DT N
means NN N
of IN N
predicting VBG N
the DT N
probability NN N
of IN N
developing VBG N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
in IN N
patients NNS p
with IN p
liver JJ p
cirrhosis NN p
secondary JJ p
to TO p
chronic VB p
hepatitis NN p
B.This NNP p
study NN p
included VBD p
20 CD p
healthy JJ p
volunteers NNS p
, , p
20 CD p
patients NNS p
with IN p
liver JJ p
cirrhosis NN p
secondary JJ p
to TO p
chronic VB p
hepatitis NN p
B NNP p
( ( p
cirrhosis NN p
group NN p
) ) p
, , p
and CC p
20 CD p
patients NNS p
with IN p
small JJ p
HCC NNP p
secondary JJ p
to TO p
cirrhosis VB p
liver RB p
parenchyma NN p
( ( p
HCC NNP p
group NN p
) ) p
. . p

All DT p
patients NNS p
underwent JJ p
routine JJ i
MRI NNP i
and CC i
H-MRS NNP i
scanning NN i
. . i

LCModel NNP N
software NN N
was VBD N
used VBN N
to TO N
quantify VB o
Cho NNP o
( ( o
Choline NNP o
) ) o
, , o
Lip NNP o
( ( o
lipid JJ o
) ) o
, , o
and CC o
Cho/Lip NNP o
in IN N
the DT N
3 CD N
groups NNS N
, , N
and CC N
a DT N
one-way JJ N
ANOVA NNP o
was VBD N
used VBN N
to TO N
compare VB N
the DT N
differences NNS N
in IN N
these DT N
metabolites NNS N
between IN N
groups.Choline NN N
levels NNS N
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
control NN N
and CC N
HCC NNP N
group NN N
and CC N
between IN N
the DT N
cirrhosis NN N
group NN N
and CC N
the DT N
HCC NNP N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
significant JJ o
difference NN o
in IN o
Lip NNP o
levels NNS o
between IN o
the DT N
control NN N
and CC N
cirrhosis NN N
group NN N
and CC N
the DT N
control NN N
and CC N
HCC NNP N
groups NNS N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
also RB N
differences NNS o
in IN o
Cho/Lip NNP o
between IN N
the DT N
control NN N
and CC N
cirrhosis NN N
groups NNS N
, , N
the DT N
control NN N
and CC N
HCC NNP N
groups NNS N
, , N
and CC N
the DT N
cirrhosis NN N
and CC N
HCC NNP N
groups NNS N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
.H-MRS NN N
followed VBN N
by IN N
the DT N
analysis NN N
with IN N
LCModel NNP N
can MD N
be VB N
used VBN N
to TO N
measure VB N
changes NNS o
in IN o
hepatic JJ o
metabolite NN o
levels NNS o
in IN o
patients NNS o
with IN N
liver JJ N
cirrhosis NN N
secondary JJ N
to TO N
chronic VB N
hepatitis NN N
B NNP N
and CC N
HCC NNP N
. . N

Thus NNP N
, , N
H-MRS NNP N
may MD N
be VB N
helpful JJ N
in IN N
monitoring VBG N
HCC NNP N
and CC N
liver RB N
cirrhosis NN N
development NN N
. . N

-DOCSTART- -5512598- O O

Effects NNS N
of IN N
progressive JJ i
relaxation NN i
on IN N
autonomic JJ i
processes NNS i
. . i

-DOCSTART- -20976617- O O

Theory NN N
of IN N
Mind NNP i
training NN i
in IN N
children NNS p
with IN p
autism NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Many JJ N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
participate NN N
in IN N
social JJ N
skills NNS N
or CC N
Theory NN i
of IN i
Mind NNP i
( ( i
ToM NNP i
) ) i
treatments NNS i
. . i

However RB N
, , N
few JJ N
studies NNS N
have VBP N
shown VBN N
evidence NN N
for IN N
their PRP$ N
effectiveness NN N
. . N

The DT N
current JJ N
study NN N
used VBD N
a DT N
randomized JJ N
controlled JJ N
design NN N
to TO N
test VB N
the DT N
effectiveness NN o
of IN N
a DT N
16-week JJ N
ToM NNP i
treatment NN i
in IN N
8-13 JJ p
year NN p
old JJ p
children NNS p
with IN p
ASD NNP p
and CC p
normal JJ p
IQs NNP p
( ( p
n JJ p
= NNP p
40 CD p
) ) p
. . p

The DT p
results NNS N
showed VBD N
that IN N
, , N
compared VBN N
to TO N
controls NNS N
, , N
the DT N
treated JJ N
children NNS N
with IN N
ASD NNP N
improved VBN o
in IN o
their PRP$ o
conceptual JJ o
ToM NNP o
skills NNS o
, , o
but CC o
their PRP$ o
elementary JJ o
understanding NN o
, , o
self PRP o
reported VBD o
empathic JJ o
skills NNS o
or CC o
parent NN o
reported VBN o
social JJ o
behaviour NN o
did VBD o
not RB N
improve VB N
. . N

Despite IN N
the DT N
effects NNS N
on IN N
conceptual JJ N
understanding NN N
, , N
the DT N
current JJ N
study NN N
does VBZ N
not RB N
indicate VB N
strong JJ N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
a DT N
ToM NNP N
treatment NN N
on IN N
the DT N
daily JJ N
life NN o
mindreading VBG o
skills NNS o
. . N

-DOCSTART- -25840599- O O

Prolonged NNP N
sirolimus NN i
administration NN N
after IN p
allogeneic JJ p
hematopoietic JJ p
cell NN p
transplantation NN p
is VBZ N
associated VBN N
with IN N
decreased JJ N
risk NN N
for IN N
moderate-severe JJ N
chronic JJ o
graft-versus-host NN o
disease NN o
. . o

Effective JJ N
pharmacological JJ N
strategies NNS N
employed VBN N
in IN N
allogeneic JJ p
hematopoietic JJ p
cell NN p
transplantation NN p
should MD N
prevent VB N
serious JJ N
chronic JJ N
graft-versus-host NN N
disease NN N
and CC N
facilitate VB N
donor-recipient JJ N
immune JJ N
tolerance NN N
. . N

Based VBN N
on IN N
demonstrated JJ N
pro-tolerogenic JJ N
activity NN N
, , N
sirolimus NN i
( ( i
rapamycin NN i
) ) i
is VBZ N
an DT N
agent NN N
with IN N
promise NN N
to TO N
achieve VB N
these DT N
goals NNS N
. . N

In IN N
a DT N
long-term JJ N
follow-up JJ N
analysis NN N
of IN N
a DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
comparing VBG N
sirolimus/tacrolimus JJ i
versus NN i
methotrexate/tacrolimus NN i
for IN N
graft-versus-host JJ N
disease NN N
prevention NN N
in IN N
matched JJ p
sibling NN p
or CC p
unrelated JJ p
donor NN p
transplant NN p
, , N
we PRP N
examined VBD N
the DT N
impact NN N
of IN N
prolonged JJ p
sirolimus NN i
administration NN p
( ( p
? . p
1 CD p
year NN p
post-transplant NN o
) ) o
. . o

Median JJ o
follow-up JJ o
time NN o
for IN o
surviving VBG o
patients NNS o
at IN o
time NN p
of IN p
this DT p
analysis NN p
was VBD p
41 CD p
months NNS p
( ( p
range VB p
27-60 CD p
) ) p
for IN i
sirolimus/tacrolimus NN i
and CC i
49 CD p
months NNS p
( ( p
range VB p
29-63 CD p
) ) p
for IN i
methotrexate/tacrolimus NN i
. . i

Sirolimus/tacrolimus NNP i
patients NNS i
had VBD N
significantly RB N
lower JJR o
National NNP o
Institutes NNPS o
of IN o
Health NNP o
Consensus NNP o
moderate-severe JJ o
chronic JJ o
graft-versus-host NN o
disease NN o
( ( o
34 CD N
% NN N
vs. FW N
65 CD N
% NN N
; : N
P=0.004 NNP N
) ) N
and CC o
late JJ o
acute NN o
graft-versus-host JJ o
disease NN o
( ( o
20 CD N
% NN N
vs. FW N
43 CD N
% NN N
; : N
P=0.04 NNP N
) ) N
. . N

While IN i
sirolimus/tacrolimus JJ i
patients NNS i
had VBD N
lower JJR o
prednisone NN o
exposure NN o
and CC o
earlier JJR o
discontinuation NN o
of IN o
tacrolimus NN o
( ( o
median JJ N
time NN N
to TO N
tacrolimus VB N
discontinuation NN N
368 CD N
days NNS N
vs. FW N
821 CD N
days NNS N
; : N
P=0.002 NNP N
) ) N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
complete JJ o
immune JJ o
suppression NN o
discontinuation NN o
( ( o
60-month JJ N
estimate NN N
: : N
43 CD N
% NN N
vs. FW N
31 CD N
% NN N
; : N
P=0.78 NNP N
) ) N
. . N

Prolonged VBN i
sirolimus JJ i
administration NN i
represents VBZ N
a DT N
viable JJ N
approach NN N
to TO N
mitigate VB N
risk NN N
for IN N
moderate-severe JJ N
chronic JJ N
and CC N
late JJ N
acute NN N
graft-versus-host JJ N
disease NN N
. . N

Further NNP N
study NN N
of IN N
determinants NNS N
of IN N
successful JJ N
immune JJ N
suppression NN N
discontinuation NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -11322670- O O

A DT N
pharmacy NN i
discharge NN i
plan NN i
for IN N
hospitalized JJ p
elderly JJ p
patients NNS p
-- : p
a DT p
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVES UH N
to TO N
investigate VB N
the DT N
effectiveness NN o
of IN o
a DT o
pharmacy NN o
discharge NN o
plan NN o
in IN N
elderly JJ p
hospitalized JJ p
patients NNS p
. . p

DESIGN NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SUBJECTS NNP N
AND CC N
SETTINGS NNP N
we PRP N
randomized VBD N
patients NNS p
aged VBN p
75 CD p
years NNS p
and CC p
older JJR p
on IN p
four CD p
or CC p
more JJR p
medicines NNS p
who WP p
had VBD p
been VBN p
discharged VBN p
from IN p
three CD p
acute JJ p
general JJ p
and CC p
one CD p
long-stay JJ p
hospital NN p
to TO p
a DT p
pharmacy NN p
intervention NN p
or CC p
usual JJ p
care NN p
. . p

INTERVENTIONS VBZ N
the DT N
hospital NN i
pharmacist NN i
developed VBD i
discharge NN i
plans NNS i
which WDT N
gave VBD N
details NNS N
of IN N
medication NN N
and CC N
support NN N
required VBN N
by IN N
the DT N
patient NN N
. . N

A DT N
copy NN N
was VBD N
given VBN N
to TO N
the DT N
patient NN N
and CC N
to TO N
all DT N
relevant JJ N
professionals NNS N
and CC N
carers NNS N
. . N

This DT N
was VBD N
followed VBN N
by IN N
a DT N
domiciliary JJ N
assessment NN N
by IN N
a DT N
community NN N
pharmacist NN N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
patients NNS N
were VBD N
discharged VBN i
from IN i
hospital NN i
following VBG i
standard JJ i
procedures NNS i
that WDT N
included VBD N
a DT N
discharge NN N
letter NN N
to TO N
the DT N
general JJ N
practitioner NN N
listing VBG N
current JJ N
medications NNS N
. . N

OUTCOMES IN N
the DT N
primary JJ N
outcome NN N
was VBD N
re-admission NN o
to TO o
hospital VB o
within IN o
6 CD o
months NNS o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
the DT N
number NN o
of IN o
deaths NNS o
, , o
attendance NN o
at IN o
hospital JJ o
outpatient NN o
clinics NNS o
and CC o
general JJ o
practice NN o
and CC o
proportion NN o
of IN o
days NNS o
in IN o
hospital NN o
over IN o
the DT o
follow-up JJ o
period NN o
, , o
together RB o
with IN o
patients NNS o
' POS o
general JJ o
well-being NN o
, , o
satisfaction NN o
with IN o
the DT o
service NN o
and CC o
knowledge NN o
of IN o
and CC o
adherence NN o
to TO o
prescribed VB o
medication NN o
. . o

RESULTS NNP N
we PRP p
recruited VBD p
362 CD p
patients NNS p
, , p
of IN p
whom WP p
181 CD p
were VBD p
randomized VBN p
to TO p
each DT p
group NN p
. . p

We PRP p
collected VBD p
hospital NN p
and CC p
general JJ p
practice NN p
data NNS p
on IN p
at IN p
least JJS p
91 CD p
and CC p
72 CD p
% NN p
of IN p
patients NNS p
respectively RB p
at IN p
each DT p
follow-up JJ p
point NN p
and CC p
interviewed VBD p
between IN p
43 CD p
and CC p
90 CD p
% NN p
of IN p
the DT p
study NN p
subjects NNS p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
the DT N
proportion NN o
of IN o
patients NNS o
re-admitted JJ o
to TO o
hospital VB o
between IN N
baseline NN N
and CC N
3 CD N
months NNS N
or CC N
3 CD N
and CC N
6 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
of IN N
the DT N
secondary JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
we PRP N
found VBD N
no DT N
evidence NN N
to TO N
suggest VB N
that IN N
the DT N
co-ordinated JJ N
hospital NN N
and CC N
community NN i
pharmacy NN i
care NN i
discharge NN i
plans NNS i
in IN N
elderly JJ N
patients NNS N
in IN N
this DT N
study NN N
influence NN N
outcomes NNS N
. . N

-DOCSTART- -9987969- O O

[ IN N
The DT N
efficacy NN N
of IN N
psychotherapy NN i
with IN i
biofeedback NN i
in IN N
the DT N
rehabilitation NN N
of IN N
hypertension NN p
patients NNS p
] VBP p
. . N

85 CD p
females NNS p
with IN p
borderline JJ p
mental JJ p
disorders NNS p
in IN p
essential JJ p
hypertension NN p
were VBD N
followed VBN N
up RP N
for IN N
a DT N
month NN N
and CC N
6 CD N
months NNS N
after IN N
the DT N
treatment NN N
( ( i
hypotensive JJ i
drugs NNS i
+ VBP i
psychotherapy NN i
with IN i
biofeedback NN i
or CC i
hypotensive JJ i
drugs NNS i
only RB i
-- : i
45 CD i
patients NNS N
and CC N
40 CD N
controls NNS i
, , N
respectively RB N
) ) N
. . N

The DT N
addition NN o
of IN o
psychotherapy NN o
to TO o
hypotensive VB o
drugs NNS o
contributed VBD o
to TO o
a DT o
higher JJR o
hypotensive JJ o
effect NN o
, , o
long-term JJ o
improvement NN o
of IN o
psychic JJ o
condition NN o
, , o
more RBR o
active JJ o
attitude NN o
to TO o
the DT o
treatment NN o
process NN o
and CC o
psychic JJ o
adaptation NN o
. . o

Better NNP o
quality NN o
of IN o
life NN o
was VBD o
achieved VBN o
. . o

-DOCSTART- -19051459- O O

Pre-operative JJ i
radiochemotherapy NN i
for IN N
rectal JJ p
cancer NN p
. . p

A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
pre-operative JJ i
vs. FW i
postoperative JJ i
radiochemotherapy NN i
in IN N
rectal JJ p
cancer NN p
patients NNS p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
find VB N
out RP N
whether IN N
pre-operative JJ i
radiochemotherapy NN i
had VBD N
any DT N
survival JJ o
advantage NN o
over IN N
postoperative JJ i
radiochemotherapy NN i
for IN N
rectal JJ p
carcinoma NN p
patients NNS p
without IN p
distant JJ p
metastasis NN p
or CC p
peritoneal JJ p
carcinomatosis NN p
. . p

MATERIAL NNP N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
1998 CD p
and CC p
December NNP p
2003 CD p
, , p
51 CD p
rectal JJ p
carcinoma NN p
patients NNS p
without IN p
distant JJ p
metastasis NN p
or CC p
peritoneal JJ p
carcinomatosis NN p
were VBD N
randomly RB N
divided VBN N
into IN N
pre-operative JJ i
( ( i
PRE NNP i
) ) i
and CC N
postoperative JJ i
( ( i
POST NNP i
) ) i
radiochemotherapy NN i
groups NNS N
. . N

Twenty-six CD N
were VBD N
assigned VBN N
to TO N
the DT N
PRE NNP N
group NN N
and CC N
were VBD N
operated VBN N
on IN N
5 CD N
to TO N
8 CD N
weeks NNS N
after IN N
the DT N
completion NN N
of IN N
radiotherapy NN i
. . i

The DT N
other JJ N
25 CD N
patients NNS N
were VBD N
operated VBN N
on IN N
immediately RB N
and CC N
received VBD N
radiotherapy NN N
postoperatively RB N
2 CD N
to TO N
4 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
between IN N
4 CD N
to TO N
51 CD N
months NNS N
. . N

RESULTS NNP N
In IN N
the DT N
PRE NNP N
group NN N
the DT N
rates NNS o
of IN o
disease-free JJ o
survival NN o
were VBD N
92 CD N
% NN N
, , N
70 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
56 CD N
% NN N
at IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
POST NNP N
group NN N
those DT N
percentages NNS N
were VBD N
83 CD N
% NN N
, , N
68 CD N
% NN N
, , N
51 CD N
% NN N
and CC N
51 CD N
% NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.707 CD N
) ) N
. . N

One-year JJ o
and CC o
4-year JJ o
overall JJ o
survival NN o
rates NNS o
in IN N
the DT N
PRE NNP N
group NN N
were VBD N
100 CD N
% NN N
and CC N
86 CD N
% NN N
respectively RB N
and CC N
100 CD N
% NN N
and CC N
60 CD N
% NN N
in IN N
the DT N
POST NNP N
group NN N
( ( N
p JJ N
= NNP N
0.520 CD N
) ) N
. . N

CONCLUSION NNP N
No NNP N
statistical JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
survival JJ o
rates NNS o
of IN N
the DT N
rectal JJ p
carcinoma NN p
patients NNS p
receiving VBG N
radiotherapy NN N
either CC N
pre-operatively RB N
or CC N
postoperatively RB N
. . N

However RB N
, , N
the DT N
disease-free JJ o
survival NN o
rates NNS o
of IN N
the DT N
PRE NNP i
group NN N
were VBD N
higher JJR N
than IN N
the DT N
POST NNP i
group NN N
's POS N
during IN N
each DT N
year NN N
and CC N
overall JJ o
survival NN o
rates NNS o
were VBD N
higher JJR N
after IN N
the DT N
third JJ N
and CC N
fourth JJ N
years NNS N
. . N

We PRP N
conclude VBP N
that IN N
pre-operative JJ i
radiotherapy NN i
is VBZ N
at IN o
least JJS o
as RB o
effective JJ o
as IN o
postoperative JJ i
radiotherapy NN i
. . i

-DOCSTART- -22412171- O O

Theta NNP i
burst JJS i
stimulation NN i
in IN N
the DT N
rehabilitation NN N
of IN N
the DT N
upper JJ N
limb NN N
: : N
a DT N
semirandomized JJ N
, , N
placebo-controlled JJ N
trial NN N
in IN N
chronic JJ p
stroke NN p
patients NNS p
. . p

BACKGROUND NNP N
Noninvasive NNP N
cortical JJ i
stimulation NN i
could MD N
represent VB N
an DT N
add-on JJ N
treatment NN N
to TO N
enhance VB N
motor NN o
recovery NN o
after IN N
stroke NN N
. . N

However RB N
, , N
its PRP$ N
clinical JJ N
value NN N
, , N
including VBG N
anticipated VBN N
size NN N
and CC N
duration NN N
of IN N
the DT N
treatment NN N
effects NNS N
, , N
remains VBZ N
largely RB N
unknown JJ N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
designed VBD N
a DT N
small JJ N
semi-randomized JJ N
clinical JJ N
trial NN N
to TO N
explore VB N
whether IN N
long-lasting JJ N
clinically RB N
important JJ N
gains NNS N
can MD N
be VB N
achieved VBN N
by IN N
adding VBG N
theta JJ i
burst JJ i
stimulation NN i
( ( i
TBS NNP i
) ) i
, , N
a DT N
form NN N
of IN N
repetitive JJ N
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
TMS NNP i
) ) i
, , N
to TO N
a DT N
rehabilitation NN N
program NN N
for IN N
the DT N
hand NN N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
41 CD p
chronic JJ p
stroke NN p
patients NNS p
received VBD p
excitatory JJ p
TBS NNP i
to TO p
the DT p
ipsilesional NN p
hemisphere NN p
or CC p
inhibitory NN i
TBS NNP i
to TO p
the DT p
contralesional NN p
hemisphere NN p
in IN p
2 CD p
centers NNS p
; : p
each DT N
active JJ N
group NN N
was VBD N
compared VBN N
with IN N
a DT N
group NN N
receiving VBG N
sham NN i
TBS NNP i
. . i

TBS NNP i
was VBD N
followed VBN N
by IN N
physical JJ N
therapy NN N
for IN N
10 CD N
working JJ N
days NNS N
. . N

Patients NNS N
and CC N
therapists NNS N
were VBD N
blinded VBN N
to TO N
the DT N
type NN N
of IN N
TBS NNP i
. . i

Primary NNP N
outcome JJ N
measures NNS N
( ( o
9-hole CD o
Peg NNP o
Test NNP o
[ VBD o
9HPT CD o
] NN o
, , o
Jebsen NNP o
Taylor NNP o
Test NNP o
[ NNP o
JTT NNP o
] NNP o
, , o
and CC o
grip NN o
and CC o
pinch-grip JJ o
dynamometry NN o
) ) o
were VBD o
assessed VBN o
4 CD N
, , N
30 CD N
, , N
and CC N
90 CD N
days NNS N
post RB N
treatment NN N
. . N

The DT N
clinically RB N
important JJ N
difference NN N
was VBD N
defined VBN N
as IN N
10 CD N
% NN N
of IN N
the DT N
maximum JJ N
score NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
active JJ N
treatment NN N
and CC N
sham NN N
groups NNS N
in IN N
any DT N
of IN N
the DT N
outcome NN N
measures NNS N
. . N

All DT N
patients NNS N
achieved VBN N
small JJ N
sustainable JJ N
improvements NNS o
-- : o
9HPT CD o
, , o
5 CD o
% NN o
of IN o
maximum NN o
( ( N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= VBD N
3 CD N
% NN N
-7 NNP N
% NN N
) ) N
; : N
JTT NNP o
, , N
5.7 CD N
% NN N
( ( N
CI NNP N
= RB N
3 CD N
% NN N
-8 NNP N
% NN N
) ) N
; : N
and CC N
grip VB o
strength NN o
, , N
6 CD N
% NN N
( ( N
CI NNP N
= RB N
2 CD N
% NN N
-10 NNP N
% NN N
) ) N
-- : N
all DT N
below IN N
the DT N
defined VBN N
clinically RB N
important JJ N
level NN N
. . N

CONCLUSIONS NNP N
Cortical NNP N
stimulation NN N
did VBD N
not RB N
augment VB N
the DT N
gains NNS N
from IN N
a DT N
late JJ N
rehabilitation NN N
program NN N
. . N

The DT N
effect NN N
size NN N
anticipated VBN N
by IN N
the DT N
authors NNS N
was VBD N
overestimated VBN N
. . N

These DT N
results NNS N
can MD N
improve VB N
the DT N
design NN N
of IN N
future JJ N
work NN N
on IN N
therapeutic JJ N
uses NNS N
of IN N
TMS NNP N
. . N

-DOCSTART- -3278754- O O

Randomized VBN N
study NN N
of IN N
13-cis JJ i
retinoic NN i
acid NN i
v NN N
placebo NN i
in IN N
the DT N
myelodysplastic JJ p
disorders NNS p
. . p

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
trial NN N
of IN N
13-cis JJ i
retinoic NN i
acid NN i
was VBD N
performed VBN N
to TO N
determine VB N
if IN N
the DT N
drug NN N
has VBZ N
a DT N
therapeutic JJ o
effect NN o
in IN N
patients NNS p
with IN p
myelodysplastic JJ p
syndromes NNS p
( ( p
MDS NNP p
) ) p
. . p

Sixty-eight JJ p
evaluable JJ p
patients NNS p
with IN p
MDS NNP p
were VBD p
randomized VBN p
to TO N
receive VB N
a DT N
single JJ N
, , N
daily JJ N
oral JJ N
dose NN N
of IN N
either DT N
13-cis JJ i
retinoic NN i
acid NN i
( ( i
13-CRA JJ i
, , N
100 CD N
mg/m2 NN N
) ) N
or CC N
matching VBG i
placebo NN i
. . i

Treatment NN N
was VBD N
continued VBN N
, , N
when WRB N
possible JJ N
, , N
for IN N
a DT N
period NN N
of IN N
6 CD N
months NNS N
. . N

Determination NNP N
of IN N
response NN N
to TO N
treatment NN N
was VBD N
based VBN N
on IN N
clinical JJ o
course NN o
, , o
repeat NN o
bone NN o
marrow NN o
biopsies NNS o
, , N
and CC N
aspirates NNS o
and CC o
blood NN o
counts NNS o
( ( o
CBC NNP o
) ) o
with IN o
WBC NNP o
differential NN o
, , o
platelet NN o
, , o
and CC o
reticulocyte JJ o
numbers NNS o
at IN o
specified JJ o
intervals NNS o
. . o

No DT N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
response NN N
to TO N
test VB N
drug NN N
( ( N
P NNP N
= NNP N
.66 NNP N
) ) N
. . N

One CD N
patient NN N
( ( N
3 CD N
% NN N
) ) N
in IN N
the DT N
13-CRA JJ i
group NN N
and CC N
two CD N
patients NNS N
( ( N
6 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
had VBD N
a DT N
minor JJ N
response NN o
. . o

Approximately RB N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
both DT N
groups NNS N
had VBD N
progression NN o
of IN o
their PRP$ o
disease NN o
, , N
and CC N
progression-free JJ o
survival NN o
was VBD N
nearly RB N
identical JJ N
. . N

Greater NNP N
than IN N
90 CD N
% NN N
of IN N
the DT N
patients NNS N
receiving VBG N
13-CRA JJ i
developed JJ N
mild NN o
or CC o
moderate JJ o
skin NN o
toxicity NN o
that WDT N
was VBD N
reversible JJ N
with IN N
decreasing VBG N
or CC N
discontinuing VBG N
the DT N
drug NN N
. . N

Our PRP$ N
study NN N
did VBD N
not RB N
find VB N
that IN N
13-CRA JJ i
exerts NNS N
a DT N
beneficial JJ N
therapeutic JJ o
effect NN o
in IN N
patients NNS p
with IN p
MDS NNP p
. . p

-DOCSTART- -19357315- O O

Feasibility NN o
of IN N
a DT N
telephone-based JJ i
intervention NN i
for IN N
support NN N
persons NNS N
to TO N
help VB N
smokers NNS o
quit VB p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Nonsmokers NNPS N
have VBP N
a DT N
potentially RB N
supportive JJ N
role NN N
in IN N
tobacco JJ N
cessation NN N
efforts NNS N
. . N

The DT N
present JJ N
study NN N
examined VBD N
the DT N
feasibility NN o
, , o
acceptability NN o
, , o
and CC o
potential JJ o
efficacy NN o
of IN N
a DT N
telephone-based JJ i
intervention NN i
for IN N
nonsmoking VBG p
support NN p
persons NNS p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
59 CD p
support NN p
persons NNS p
( ( p
mean JJ p
age NN p
= VBD p
36 CD p
years NNS p
, , p
92 CD p
% NN p
female NN p
, , p
95 CD p
% NN p
White NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN i
condition NN i
( ( N
N NNP N
= NNP N
30 CD N
; : N
written VBN i
materials NNS i
only RB i
) ) i
or CC N
to TO N
a DT N
social JJ i
cognitive JJ i
theory-based JJ i
intervention NN i
( ( N
N NNP N
= NNP N
29 CD N
; : N
written VBN i
materials NNS i
and CC i
5 CD N
weekly JJ N
, , N
20- JJ N
to TO N
30-min JJ N
telephone NN i
counseling NN i
sessions NNS i
) ) i
. . N

Both DT N
support NN p
persons NNS p
and CC N
smokers NNS p
completed VBD N
assessments NNS N
separately RB N
by IN N
mail NN N
at IN N
baseline NN N
and CC N
at IN N
weeks NNS N
6 CD N
( ( N
end NN N
of IN N
treatment NN N
) ) N
and CC N
26 CD N
. . N

RESULTS VB N
Two CD N
thirds NNS N
of IN N
the DT N
smokers NNS N
reported VBD N
low-moderate JJ N
levels NNS o
of IN o
motivation NN o
to TO o
quit VB o
at IN N
baseline NN N
as IN N
assessed VBN N
by IN N
the DT N
contemplation NN N
ladder NN N
. . N

Study NNP o
retention NN o
rates NNS o
were VBD N
excellent JJ N
, , N
with IN N
95 CD N
% NN N
of IN N
both DT N
support NN N
persons NNS N
and CC N
smokers NNS N
completing VBG N
the DT N
week NN N
26 CD N
assessment NN N
. . N

Moreover RB N
, , N
86 CD N
% NN N
of IN N
support NN N
persons NNS N
in IN N
the DT N
intervention NN N
group NN N
completed VBD N
all DT N
five CD N
telephone NN N
sessions NNS N
. . N

Treatment NNP o
acceptability NN o
was VBD N
high JJ N
for IN N
both DT N
support NN N
persons NNS N
and CC N
smokers NNS N
. . N

Compared VBN N
with IN N
the DT N
control NN N
condition NN N
, , N
the DT N
intervention NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
support JJ o
person NN o
self-efficacy NN o
to TO N
help VB N
their PRP$ N
smoker NN o
( ( N
p JJ N
= NNP N
.034 NNP N
) ) N
and CC N
outcome JJ o
expectancies NNS o
( ( N
p JJ N
= NNP N
.025 NNP N
) ) N
from IN N
baseline NN N
to TO N
week NN N
6 CD N
. . N

However RB N
, , N
the DT N
intervention NN N
was VBD N
not RB N
associated VBN N
with IN N
higher JJR o
smoking NN o
abstinence NN o
rates NNS o
or CC o
quit VB o
attempts NNS o
. . o

DISCUSSION VB N
The DT N
program NN N
was VBD N
successful JJ N
in IN N
reaching VBG N
smokers NNS N
with IN N
lower JJR o
levels NNS o
of IN o
readiness NN o
to TO o
quit VB o
. . o

The DT N
intervention NN N
was VBD N
feasible JJ o
and CC o
acceptable JJ o
to TO N
both DT N
support NN N
persons NNS N
and CC N
smokers NNS N
. . N

Although IN N
support NN N
persons NNS N
and CC N
smokers NNS N
can MD N
be VB N
engaged VBN N
in IN N
this DT N
type NN N
of IN N
outreach NN N
program NN N
, , N
refinements NNS N
in IN N
the DT N
intervention NN N
approach NN N
are VBP N
needed VBN N
to TO N
improve VB N
the DT N
smoking NN o
outcomes NNS o
. . o

-DOCSTART- -50611- O O

Evaluation NN N
of IN N
rapid JJ i
radiation NN i
treatment NN i
schedules NNS N
utilizing VBG N
two CD N
treatment NN N
sessions NNS N
per IN N
day NN N
. . N

The DT N
authors NNS N
studied VBD N
normal JJ p
human JJ p
skin NN p
reactions NNS p
to TO p
two CD p
different JJ p
rapid JJ i
radiotherapy NN i
schedules NNS i
of IN p
2 CD p
sessions NNS p
per IN p
day NN p
and CC p
evaluated VBD p
their PRP$ p
effectiveness NN p
in IN p
relief NN p
of IN p
pain NN p
and CC p
local JJ p
tumor NN p
control NN p
. . p

Patients NNS p
were VBD p
randomized VBN p
to TO p
three CD p
treatment NN p
groups NNS p
: : p
SCHEDULE VB i
A NNP i
( ( i
control NN i
) ) i
: : i
conventional JJ i
one CD i
treatment NN i
per IN i
day NN i
regimen NNS i
totalling VBG p
3,760 CD p
rads NNS i
in IN p
22-23 JJ p
days NNS p
; : p
SCHEDULE NNP p
B NNP p
: : p
2 CD i
sessions NNS i
per IN i
day NN i
totalling VBG p
3,440 CD p
rads NNS i
in IN p
10-11 JJ p
days NNS p
; : p
and CC p
SCHEDULE NNP p
C NNP p
: : p
2 CD p
sessions NNS p
per IN p
day NN p
totalling VBG p
3,568 CD p
rads NNS p
in IN p
10-11 JJ p
days NNS p
. . p

The DT N
pattern NN N
and CC N
magnitude NN N
of IN N
skin JJ o
reactions NNS o
in IN N
the DT N
three CD N
schedules NNS N
are VBP N
nearly RB N
identical JJ N
but CC N
tumor JJ o
regression NN o
and CC o
pain NN o
relief NN o
were VBD N
achieved VBN N
faster RBR N
in IN N
the DT N
rapid JJ N
fractionation NN N
schedules NNS N
. . N

-DOCSTART- -23102821- O O

Dysfunctional NNP N
attitudes NNS N
as IN N
a DT N
moderator NN N
of IN N
pharmacotherapy NN i
and CC N
psychotherapy NN i
for IN N
chronic JJ p
depression NN p
. . p

OBJECTIVE JJ N
Individuals NNS p
with IN p
chronic JJ p
depression NN p
exhibit NN N
heterogeneous JJ N
responses NNS N
to TO N
treatment NN N
. . N

Important JJ N
individual JJ N
differences NNS N
may MD N
therefore VB N
exist NN N
within IN N
this DT N
particularly RB N
difficult JJ N
to TO N
treat VB N
population NN N
that WDT N
act NN N
as IN N
moderators NNS N
of IN N
treatment NN N
response NN N
. . N

METHOD NNP N
The DT N
present JJ N
study NN N
examined VBD N
whether IN N
pretreatment NN N
levels NNS N
of IN N
dysfunctional JJ N
attitudes NNS N
( ( N
DA NNP N
) ) N
moderated VBD N
treatment NN N
response NN N
in IN N
a DT N
large JJ p
sample NN p
of IN p
chronically RB p
depressed JJ p
individuals NNS p
. . p

Data NNS N
were VBD N
taken VBN N
from IN N
the DT N
Research NNP N
Evaluating NNP N
the DT N
Value NNP N
of IN N
Augmenting NNP N
Medication NNP N
with IN N
Psychotherapy NNP N
( ( N
REVAMP NNP N
) ) N
treatment NN N
study NN N
-- : N
a DT N
multi-site JJ p
treatment NN p
and CC p
augmentation NN p
study NN p
of IN p
808 CD p
chronically RB p
depressed JJ p
individuals NNS p
. . p

REVAMP NNP N
comprised VBD N
two CD N
phases NNS N
: : N
1 CD N
) ) N
a DT N
12-week JJ i
open-label JJ i
antidepressant JJ i
trial NN i
and CC N
2 CD N
) ) N
, , N
a DT N
subsequent JJ N
phase NN N
, , N
in IN N
which WDT N
phase NN N
1 CD N
non-remitters NNS N
( ( N
N NNP N
= NNP N
491 CD N
) ) N
were VBD N
randomized VBN N
to TO N
either DT N
receive VB N
an DT N
ongoing JJ i
medication NN i
algorithm IN i
alone RB i
, , i
medication NN i
plus CC i
cognitive JJ i
behavioral JJ i
analysis NN i
system NN i
of IN i
psychotherapy NN i
, , i
or CC i
medication NN i
plus CC i
brief JJ i
supportive JJ i
psychotherapy NN i
. . i

RESULT NNP N
In IN N
phase NN N
1 CD N
, , N
compared VBN N
to TO N
the DT N
pharmacotherapy NN o
response NN o
of IN N
patients NNS N
with IN N
lower JJR N
DA NNP N
scores NNS N
, , N
the DT N
response NN N
for IN N
patients NNS N
with IN N
higher JJR N
DA NNP N
scores NNS N
was VBD N
steeper JJ N
, , N
but CC N
leveled VBD N
off RP N
toward IN N
the DT N
end NN N
of IN N
the DT N
phase NN N
. . N

In IN N
phase NN N
2 CD N
, , N
DA NNP N
predicted VBD N
a DT N
differential JJ N
response NN N
in IN N
the DT N
medication NN N
only RB N
arm NN N
, , N
but CC N
not RB N
in IN N
the DT N
two CD N
psychotherapy NN i
+ JJ i
medication NN i
conditions NNS N
. . N

Specifically RB N
, , N
in IN N
the DT N
phase NN N
2 CD N
medication NN i
only RB N
condition NN N
, , N
patients NNS N
with IN N
higher JJR N
DA NNP N
improved VBN o
while IN N
those DT N
with IN N
lower JJR N
DA NNP N
scores NNS N
did VBD N
not RB N
. . N

CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
the DT N
relation NN N
between IN N
DA NNP N
and CC N
treatment NN N
response NN N
in IN N
chronic JJ p
depression NN p
is VBZ N
complex JJ N
, , N
but CC N
suggest VBP N
that IN N
greater JJR N
DA NNP N
may MD N
be VB N
associated VBN N
with IN N
a DT N
steeper JJ N
reduction NN N
and/or RB N
better RBR N
response NN N
to TO N
pharmacotherapy NN i
. . i

-DOCSTART- -19415409- O O

The DT N
influence NN N
of IN N
dietary JJ i
fibre NN i
source NN i
and CC N
gender NN N
on IN N
the DT N
postprandial JJ o
glucose NN o
and CC o
lipid JJ o
response NN o
in IN N
healthy JJ p
subjects NNS p
. . p

BACKGROUND NNP N
Consumption NNP N
of IN N
soluble JJ i
dietary JJ i
fibre NN i
is VBZ N
correlated VBN N
with IN N
decreased JJ N
postprandial JJ o
glucose NN o
and CC o
insulin NN o
responses NNS o
and CC N
hence NN N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
the DT N
metabolic JJ o
syndrome NN o
. . o

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
investigate VB N
the DT N
effects NNS N
on IN N
postprandial JJ o
glucose NN o
, , o
insulin NN o
and CC o
triglyceride JJ o
concentrations NNS o
of IN N
meals NNS N
enriched VBN N
with IN N
soluble JJ N
dietary JJ N
fibres NNS N
from IN N
oats NNS N
, , N
rye NN N
bran NN N
, , N
sugar JJ N
beet NN N
fibre NN N
or CC N
a DT N
mixture NN N
of IN N
these DT N
three CD N
fibres NNS N
. . N

METHODS NNP N
Thirteen NNP p
healthy JJ p
human JJ p
volunteers NNS p
( ( p
6 CD p
men NNS p
and CC p
7 CD p
women NNS p
, , p
aged VBN p
20-28 CD p
years NNS p
) ) p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

The DT N
subjects NNS N
came VBD N
to TO N
the DT N
study NN N
centre NN N
once RB N
a DT N
week NN N
after IN N
an DT N
overnight JJ N
fast NN N
to TO N
ingest VB N
test NN N
meals NNS i
and CC N
a DT N
control NN N
meal NN N
in IN N
random JJ N
order NN N
. . N

The DT N
meals NNS N
contained VBD N
either CC N
oat JJ i
powder NN i
( ( N
62 CD N
g NN N
, , N
of IN N
which WDT N
2.7 CD N
soluble JJ N
fibre NN N
) ) N
, , N
rye NN i
bran NN i
( ( N
31 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
sugar JJ i
beet NN i
fibre NN i
( ( N
19 CD N
g NN N
, , N
of IN N
which WDT N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
a DT i
mixture NN i
of IN i
these DT i
three CD i
fibres NNS i
( ( N
74 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
from IN N
each DT N
source NN N
, , N
giving VBG N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
or CC i
no DT i
added JJ i
fibre NN i
( ( i
control NN i
) ) i
and CC N
were VBD N
all DT N
adjusted VBN N
to TO N
contain VB N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
available JJ N
carbohydrates NNS i
. . i

Blood NN N
samples NNS N
were VBD N
drawn VBN N
before RB N
and CC N
every DT N
30 CD N
min NN N
up RB N
to TO N
180 CD N
min NN N
after IN N
the DT N
meals NNS N
. . N

RESULTS NNP N
Meals NNP i
with IN i
rye NN i
bran NN i
gave VBD N
a DT N
lower JJR N
postprandial JJ o
glucose NN o
peak NN o
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
, , N
and CC N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
women NNS N
compared VBN N
to TO N
men NNS N
. . N

Oat NNP i
powder NN i
, , N
containing VBG N
a DT N
low JJ N
amount NN N
of IN N
total JJ N
fibre NN N
and CC N
a DT N
high JJ N
amount NN N
of IN N
carbohydrates NNS N
in IN N
liquid NN N
matrix NN N
, , N
gave VBD N
a DT N
higher JJR N
incremental JJ o
glucose JJ o
peak NN o
concentration NN o
compared VBN N
to TO N
rye VB N
bran NN N
and CC N
sugar NN N
beet NN N
fibre NN N
and CC N
higher JJR N
insulin NN o
incremental JJ o
area NN o
under IN o
curve NN o
compared VBN N
to TO N
control VB N
. . N

The DT N
oat NN i
powder NN i
also RB N
influenced VBD N
the DT N
effects NNS N
of IN N
the DT N
mixed JJ N
meal NN N
, , N
diminishing VBG N
the DT N
glucose-lowering JJ o
effects NNS o
. . o

Postprandial NNP o
triglyceride NN o
levels NNS o
tended VBD N
to TO N
be VB N
higher JJR N
after IN N
all DT N
fibre-rich JJ N
meals NNS N
, , N
but CC N
only RB N
significant JJ N
for IN N
oat NN N
powder NN N
and CC N
the DT N
mixed JJ N
meal NN i
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN i
. . i

CONCLUSIONS NNP N
Postprandial NNP o
glucose NN o
, , o
insulin NN o
and CC o
triglyceride JJ o
concentrations NNS o
are VBP N
influenced VBN N
by IN N
dietary JJ i
fibre-rich JJ i
meals NNS i
, , N
depending VBG N
on IN N
fibre NN N
source NN N
, , N
dose NN N
of IN N
soluble JJ N
and CC N
total JJ N
fibre NN N
and CC N
possibly RB N
gender NN N
. . N

-DOCSTART- -10778276- O O

Human NNP N
motor NN N
responses NNS N
to TO N
simultaneous JJ N
aversive JJ i
stimulation NN i
and CC i
failure NN i
on IN N
a DT N
valued VBN N
task NN N
. . N

The DT N
effects NNS N
of IN N
presentation NN N
of IN N
an DT N
aversive JJ i
stimulus NN i
and CC i
simultaneous JJ i
failure NN i
on IN i
a DT i
bogus JJ i
intelligence NN i
test NN i
upon IN N
a DT N
subject NN N
's POS N
aggressive JJ o
reactions NNS o
were VBD N
studied VBN N
. . N

The DT N
subject NN p
's POS p
fist NN o
clenching NN o
was VBD N
used VBN N
as IN N
an DT N
indicator NN o
of IN o
aggression NN o
. . o

Four CD N
conditions NNS N
, , N
generated VBN N
by IN N
the DT N
combinations NNS N
of IN N
two CD N
kinds NNS N
of IN N
stimulus NN N
delivered VBN N
to TO N
the DT N
subjects NNS N
( ( i
aversive JJ i
or CC i
nonaversive JJ i
) ) i
and CC N
two CD N
outcomes NNS N
of IN N
the DT N
task NN N
( ( N
failure NN N
or CC N
success NN N
) ) N
, , N
were VBD N
investigated VBN N
. . N

20 CD p
female JJ p
and CC p
20 CD p
male JJ p
students NNS p
( ( p
ages NNS p
: : p
17-34 CD p
years NNS p
) ) p
were VBD N
instructed VBN N
, , N
upon IN N
the DT N
reception NN N
of IN N
an DT N
aversive JJ i
or CC i
nonaversive JJ i
acoustic JJ i
signal NN i
, , N
to TO N
press VB N
with IN N
the DT N
right JJ N
hand NN N
a DT N
device NN N
that WDT N
displayed VBD N
a DT N
slide NN N
. . N

Each DT N
slide NN N
presented VBD N
an DT N
item NN N
from IN N
an DT N
intelligence NN N
test NN N
, , N
to TO N
which WDT N
the DT N
subjects NNS N
were VBD N
either RB N
allowed VBN N
to TO N
answer VB N
successfully RB N
( ( N
success NN N
) ) N
or CC N
not RB N
( ( N
failure NN N
) ) N
. . N

Failure NN N
increased VBD N
the DT N
subject NN N
's POS N
autonomic JJ o
arousal NN o
, , o
as IN o
measured VBN o
by IN o
photoplethysmographic JJ o
sensors NNS o
, , N
in IN N
all DT N
stimulation NN N
conditions NNS N
, , N
but CC N
only RB N
the DT N
condition NN N
with IN N
aversive JJ N
stimulation NN N
increased VBD N
the DT N
speed NN o
of IN o
clenching VBG o
. . o

This DT N
was VBD N
interpreted VBN N
as IN N
indicating VBG N
subject NN N
's POS N
tendencies NNS o
to TO o
aggression NN o
. . o

These DT N
results NNS N
are VBP N
discussed VBN N
in IN N
relation NN N
to TO N
the DT N
effects NNS N
of IN N
frustration NN N
. . N

-DOCSTART- -16950955- O O

A DT N
controlled VBN N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
supplement NN i
of IN i
cocoa NN i
husk NN i
that WDT i
is VBZ i
rich JJ i
in IN i
dietary JJ i
fiber NN i
on IN N
colonic JJ o
transit NN o
in IN N
constipated JJ p
pediatric JJ p
patients NNS p
. . p

OBJECTIVE NNP N
Although IN N
a DT N
diet JJ N
that WDT N
is VBZ N
rich JJ N
in IN N
fiber NN N
is VBZ N
widely RB N
recommended VBN N
for IN N
preventing VBG N
and CC N
treating VBG N
constipation NN N
, , N
the DT N
efficacy NN N
of IN N
fiber NN N
supplements NNS N
have VBP N
not RB N
been VBN N
tested VBN N
sufficiently RB N
in IN N
children NNS p
. . p

Our PRP$ N
aim NN N
with IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
fiber JJ N
supplementation NN N
is VBZ N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
idiopathic JJ o
chronic JJ o
constipation NN o
. . o

METHODS NNP N
Using VBG N
a DT N
parallel NN N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
, , N
we PRP N
conducted VBD N
an DT N
interventional JJ N
study NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
supplement NN i
of IN i
cocoa NN i
husk NN i
rich JJ i
in IN i
dietary JJ i
fiber NN i
on IN N
intestinal JJ N
transit NN N
time NN N
and CC N
other JJ N
indices NNS N
of IN N
constipation NN o
in IN N
children NNS p
with IN p
constipation NN p
. . p

After IN N
screening VBG N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
, , N
for IN N
a DT N
period NN N
of IN N
4 CD N
weeks NNS N
, , N
either CC N
a DT N
cocoa NN i
husk NN i
supplement NN i
or CC i
placebo NN i
plus CC i
standardized JJ i
toilet NN i
training NN i
procedures NNS i
. . i

Before IN N
and CC N
after IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
we PRP N
( ( N
1 CD N
) ) N
performed VBD N
anthropometry NN i
, , N
a DT N
physical JJ N
examination NN N
, , N
and CC N
routine JJ N
laboratory NN N
measurements NNS N
, , N
( ( N
2 CD N
) ) N
determined VBN N
total JJ N
and CC N
segmental JJ N
colonic JJ N
transit NN N
time NN N
, , N
( ( N
3 CD N
) ) N
evaluated VBD N
bowel JJ N
movement NN N
habits NNS N
and CC N
stool NN N
consistency NN N
using VBG N
a DT N
diary JJ N
, , N
and CC N
( ( N
4 CD N
) ) N
received VBD N
a DT N
subjective JJ N
evaluation NN N
from IN N
the DT N
parents NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
main JJ N
variable NN N
for IN N
verifying VBG N
the DT N
efficacy NN N
of IN N
the DT N
treatment NN N
was VBD N
the DT N
total JJ o
colonic JJ o
transit NN o
time NN o
. . o

RESULTS VB N
Fifty-six NNP p
chronically RB p
constipated VBD p
children NNS p
were VBD p
randomly RB p
assigned VBN p
into IN p
the DT p
study NN p
, , p
but CC p
only RB p
48 CD p
children NNS p
completed VBD p
it PRP p
. . p

These DT p
children NNS p
, , p
who WP p
were VBD p
aged VBN p
between IN p
3 CD p
and CC p
10 CD p
years NNS p
, , p
had VBD p
a DT p
diagnosis NN p
of IN p
chronic JJ p
idiopathic JJ p
constipation NN p
. . p

With IN N
respect NN N
to TO N
total JJ o
, , o
partial JJ o
colon NN o
, , o
and CC o
rectum VB o
transit NN o
time NN o
, , N
there EX N
seemed VBN N
to TO N
be VB N
a DT N
trend NN N
, , N
although IN N
statistically RB N
nonsignificant JJ N
, , N
toward IN N
faster JJR N
transit NN o
times NNS o
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

When WRB N
we PRP N
analyzed VBD N
the DT N
evolution NN N
of IN N
the DT N
intestinal JJ o
transit NN o
time NN N
throughout IN N
the DT N
study NN N
of IN N
children NNS N
whose WP$ N
total JJ N
basal JJ o
intestinal JJ o
transit NN o
time NN o
was VBD N
> JJ N
50th JJ N
percentile NN N
, , N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
groups NNS N
. . N

The DT N
total JJ o
transit NN o
time NN o
decreased VBN N
by IN N
45.4 CD N
+/- JJ N
38.4 CD N
hours NNS N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
and CC N
by IN N
8.7 CD N
+/- JJ N
28.9 CD N
hours NNS N
in IN N
the DT N
placebo NN N
group NN N
( ( N
-38.1 NNP N
hours NNS N
) ) N
. . N

In IN N
the DT N
case NN N
of IN N
the DT N
right JJ N
colon NN N
, , N
changes NNS o
in IN o
transit NN o
time NN o
also RB N
were VBD N
significant JJ N
between IN N
groups NNS N
. . N

Mean NNP o
changes NNS o
tended VBD N
toward IN N
faster RBR N
transit NN N
times NNS N
in IN N
the DT N
left NN N
colon NN N
and CC N
the DT N
rectum NN N
, , N
although IN N
the DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

The DT N
children NNS N
who WP N
received VBD N
cocoa NN i
husk NN i
supplements NNS i
tended VBD N
to TO N
increase VB N
the DT N
number NN o
of IN o
bowel NN o
movements NNS o
by IN N
more JJR N
than IN N
that DT N
of IN N
the DT N
children NNS N
of IN N
the DT N
placebo NN N
group NN N
. . N

We PRP N
also RB N
observed VBD N
a DT N
reduction NN N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
reported VBD N
hard JJ N
stools NNS N
( ( o
hard JJ o
scybalous JJ o
or CC o
pebble-like JJ o
stools NNS o
) ) o
, , N
although IN N
this DT N
reduction NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
cocoa NN N
husk NN N
group NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
, , N
41.7 CD N
% NN N
and CC N
75.0 CD N
% NN N
of IN N
the DT N
patients NNS N
who WP N
received VBD N
cocoa NN N
husk NN N
supplementation NN N
or CC N
placebo NN N
, , N
respectively RB N
, , N
reported VBD o
having VBG o
hard JJ o
stools NNS o
. . o

Moreover RB N
, , N
a DT N
significantly RB N
higher JJR N
number NN N
of IN N
children NNS N
( ( N
or CC N
their PRP$ N
parents NNS N
) ) N
reported VBD N
a DT N
subjective JJ N
improvement NN o
in IN o
stool JJ o
consistency NN o
. . o

No DT o
significant JJ o
adverse JJ o
effects NNS o
were VBD N
reported VBN N
during IN N
the DT N
study NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
confirms VBZ N
the DT N
beneficial JJ N
effect NN N
of IN N
a DT N
supplement NN i
of IN i
cocoa NN i
husk NN i
that WDT N
is VBZ N
rich JJ N
in IN N
dietary JJ N
fiber NN N
on IN N
chronic JJ o
idiopathic JJ o
constipation NN o
in IN p
children NNS p
. . p

These DT N
benefits NNS N
seem VBP N
to TO N
be VB N
more RBR N
evident JJ N
in IN N
pediatric JJ p
constipated JJ p
patients NNS p
with IN p
slow JJ p
colonic JJ p
transit NN p
time NN p
. . p

-DOCSTART- -17375984- O O

Safety NN o
, , o
pharmacokinetics NNS o
and CC o
pharmocodynamics NNS o
of IN N
recombinant JJ i
human JJ i
porphobilinogen NN i
deaminase NN i
in IN N
healthy JJ p
subjects NNS p
and CC p
asymptomatic JJ p
carriers NNS p
of IN p
the DT p
acute JJ p
intermittent NN p
porphyria NNS p
gene NN p
who WP p
have VBP p
increased VBN p
porphyrin NN p
precursor NN p
excretion NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Acute NNP N
intermittent NN N
porphyria NN N
is VBZ N
an DT N
autosomal JJ N
dominant JJ N
disorder NN N
caused VBN N
by IN N
deficient JJ N
activity NN N
of IN N
the DT N
third JJ N
enzyme NN N
in IN N
the DT N
haem NN N
biosynthetic JJ N
pathway NN N
, , N
porphobilinogen NN N
deaminase NN N
. . N

It PRP N
is VBZ N
characterised VBN N
by IN N
acute NN N
, , N
potentially RB N
life-threatening JJ N
neurological JJ N
attacks NNS N
that WDT N
are VBP N
precipitated VBN N
by IN N
various JJ N
drugs NNS N
, , N
reproductive JJ N
hormones NNS N
and CC N
other JJ N
factors NNS N
. . N

During IN N
acute JJ N
attacks NNS N
, , N
the DT N
porphyrin JJ N
precursors NNS N
5-aminolevulinic JJ N
acid NN N
and CC N
porphobilinogen NN N
accumulate NN N
and CC N
are VBP N
excreted VBN N
at IN N
high JJ N
concentrations NNS N
in IN N
the DT N
urine NN N
. . N

Current JJ N
treatment NN N
is VBZ N
based VBN N
on IN N
glucose JJ N
loading NN N
and CC N
parenteral JJ N
haem NN N
replenishment NN N
, , N
which WDT N
reduce VB N
the DT N
accumulation NN N
of IN N
5-aminolevulinic JJ o
acid NN o
and CC o
porphobilinogen NN o
. . o

Recently RB N
, , N
a DT N
new JJ N
form NN N
of IN N
treatment NN N
based VBN N
on IN N
porphobilinogen NN i
deaminase NN i
enzyme JJ i
replacement NN i
therapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
an DT N
acute JJ N
intermittent NN N
porphyria NN N
mouse NN N
model NN N
which WDT N
, , N
during IN N
phenobarbital JJ N
( ( N
phenobarbitone NN N
) ) N
induction NN N
of IN N
haem JJ N
biosynthesis NN N
, , N
mimics VBZ N
the DT N
biochemical JJ N
pattern NN N
of IN N
acute JJ N
porphyric JJ N
attacks NNS N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
recombinant JJ i
human JJ i
porphobilinogen NN i
deaminase NN i
( ( i
P NNP i
9808 CD i
) ) i
, , N
administered VBN N
to TO N
healthy JJ p
subjects NNS p
and CC p
asymptomatic JJ p
porphobilinogen NN p
deaminase-deficient JJ p
subjects NNS p
with IN p
high JJ p
concentrations NNS p
of IN p
porphobilinogen NN p
, , p
the DT p
substrate NN p
of IN p
porphobilinogen NN p
deaminase NN p
. . p

STUDY NNP N
DESIGN NNP N
Forty NNP p
individuals NNS p
participated VBD p
in IN p
this DT p
two-part JJ p
study NN p
: : p
20 CD p
asymptomatic JJ p
porphobilinogen NN p
deaminase-deficient JJ p
subjects NNS p
( ( p
both DT p
male NN p
and CC p
female NN p
) ) p
with IN p
> NN p
or CC p
=4 JJ p
times NNS p
the DT p
upper JJ p
reference NN p
urinary JJ p
porphobilinogen NN p
level NN p
, , p
and CC p
20 CD p
healthy JJ p
male JJ p
subjects NNS p
. . p

Four CD N
different JJ N
doses NNS N
of IN N
recombinant JJ i
human JJ i
porphobilinogen NN i
deaminase NN i
were VBD N
studied VBN N
( ( N
0.5 CD N
, , N
1 CD N
, , N
2 CD N
and CC N
4 CD N
mg/kg NNS N
bodyweight VBN N
) ) N
. . N

Part VB p
A NNP p
included VBD p
12 CD p
asymptomatic JJ p
porphobilinogen NN p
deaminase-deficient JJ p
subjects NNS p
, , p
and CC p
the DT p
enzyme NN p
was VBD p
administered VBN p
in IN p
an DT p
open-label JJ p
, , p
single-dose JJ p
design NN p
. . p

Part NN p
B NNP p
included VBD p
20 CD p
asymptomatic JJ p
porphobilinogen NN p
deaminase-deficient JJ p
subjects NNS p
and CC p
20 CD p
healthy JJ p
subjects NNS p
. . p

The DT N
same JJ N
enzyme NN N
dosages NNS N
were VBD N
administered VBN N
as IN N
divided JJ N
doses NNS N
every DT N
12 CD N
hours NNS N
for IN N
4 CD N
consecutive JJ N
days NNS N
in IN N
a DT N
randomised JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
design NN N
. . N

The DT N
washout NN N
period NN N
between IN N
Parts NNS N
A NNP N
and CC N
B NNP N
was VBD N
2 CD N
weeks NNS N
. . N

METHODS NNP N
The DT N
concentrations NNS o
of IN o
recombinant JJ o
human JJ o
porphobilinogen NN o
deaminase NN o
and CC o
titres NNS o
of IN o
antibodies NNS o
against IN o
recombinant JJ o
human JJ o
porphobilinogen NN o
deaminase NN o
were VBD N
analysed VBN N
by IN N
ELISA NNP N
. . N

Plasma NNP o
porphobilinogen NN o
and CC o
5-aminolevulinic JJ o
acid NN o
concentrations NNS o
were VBD N
analysed VBN N
using VBG N
a DT N
novel JJ N
liquid JJ N
chromatography-tandem JJ N
mass NN N
spectrometry NN N
method NN N
. . N

Urinary JJ o
porphobilinogen NN o
, , o
5-aminolevulinic JJ o
acid NN o
and CC o
porphyrin NN o
concentrations NNS o
, , N
as RB N
well RB N
as IN N
plasma NN o
porphyrin NN o
concentrations NNS o
, , N
were VBD N
analysed VBN N
using VBG N
standard JJ N
methods NNS N
. . N

The DT N
pharmacodynamic JJ N
effect NN N
of IN N
the DT N
enzyme NN N
was VBD N
studied VBN N
through IN N
changes NNS N
in IN N
plasma NN N
porphobilinogen NN N
concentrations NNS N
. . N

RESULTS NNP N
No NNP N
serious JJ o
adverse JJ o
events NNS o
were VBD N
observed VBN N
. . N

Seven JJ N
subjects NNS N
( ( N
four CD N
healthy JJ N
men NNS N
and CC N
three CD N
asymptomatic JJ N
porphobilinogen NN N
deaminase-deficient JJ N
subjects NNS N
) ) N
developed VBD N
antibodies NNS o
against IN o
recombinant JJ o
human JJ o
porphobilinogen NN o
deaminase NN o
but CC N
did VBD N
not RB N
experience VB N
allergic JJ o
manifestations NNS o
. . o

The DT N
mean JJ o
elimination NN o
half-lives NNS o
of IN o
the DT o
highest JJS o
doses NNS o
of IN o
recombinant JJ o
human JJ o
porphobilinogen NN o
deaminase NN o
ranged VBD N
between IN N
1.7 CD N
and CC N
2.5 CD N
hours NNS N
for IN N
both DT N
healthy JJ N
men NNS N
and CC N
asymptomatic JJ N
porphobilinogen NN N
deaminase-deficient JJ N
subjects NNS N
. . N

The DT N
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
curve NN o
was VBD N
proportional JJ N
to TO N
the DT N
respective JJ N
dose NN N
. . N

In IN N
asymptomatic JJ N
porphobilinogen NN N
deaminase-deficient JJ N
subjects NNS N
, , N
plasma NN o
porphobilinogen NN o
concentrations NNS o
decreased VBD N
below IN N
measurable JJ N
levels NNS N
almost RB N
instantaneously RB N
after IN N
administration NN N
of IN N
any DT N
dose NN N
of IN N
the DT N
enzyme NN N
. . N

The DT N
effect NN N
lasted VBD N
for IN N
approximately RB N
2 CD N
hours NNS N
, , N
after IN N
which WDT N
the DT N
plasma NN o
porphobilinogen NN o
concentration NN o
slowly RB N
increased VBD N
, , N
reaching VBG N
about IN N
70 CD N
% NN N
of IN N
the DT N
initial JJ N
values NNS N
12 CD N
hours NNS N
after IN N
administration NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
on IN N
plasma NN o
5-aminolevulinic JJ o
acid NN o
concentrations NNS o
, , N
and CC N
there RB N
was VBD N
a DT N
transitory JJ N
increment NN N
in IN N
porphyrin JJ o
concentrations NNS o
. . o

The DT N
corresponding JJ o
concentrations NNS o
of IN o
metabolites NNS o
in IN o
the DT o
urine NN o
reflected VBD N
the DT N
pattern NN N
observed VBN N
in IN N
the DT N
plasma NN N
. . N

CONCLUSIONS VB N
The DT N
recombinant JJ i
human JJ i
porphobilinogen NN i
deaminase NN i
enzyme JJ i
preparation NN i
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
to TO N
administer VB N
and CC N
effective JJ N
for IN N
removal NN N
of IN N
the DT N
accumulated JJ N
metabolite NN N
porphobilinogen NN N
from IN N
plasma NN N
and CC N
urine NN N
. . N

The DT N
pharmacokinetic JJ N
profile NN N
of IN N
recombinant JJ i
human JJ i
porphobilinogen NN i
deaminase NN i
showed VBD N
dose JJ N
proportionality NN N
, , N
and CC N
the DT N
elimination NN N
half-life NN N
was VBD N
about IN N
2.0 CD N
hours NNS N
for IN N
the DT N
two CD N
highest JJS N
doses NNS N
. . N

Thus RB N
, , N
clinical JJ N
grounds NNS N
were VBD N
established VBN N
for IN N
investigation NN N
of IN N
the DT N
therapeutic JJ o
efficacy NN o
of IN N
the DT N
enzyme NN N
during IN N
periods NNS N
of IN N
overt JJ N
disease NN N
in IN N
patients NNS p
with IN p
acute JJ p
intermittent NN p
porphyria NN p
. . p

-DOCSTART- -20560900- O O

Dose-response JJ p
relationship NN p
of IN p
sertindole NN i
and CC i
haloperidol NN i
using VBG p
the DT p
pharmacopsychometric JJ p
triangle NN p
. . p

OBJECTIVE NNP N
Renewed NNP N
insight VBD N
into IN N
dose-related JJ N
effects NNS N
of IN N
sertindole NN i
and CC i
haloperidol NN i
was VBD N
sought VBN N
by IN N
re-analysing NN N
published VBN N
data NNS N
for IN N
antipsychotic JJ N
effect NN N
, , N
extrapyramidal JJ N
effect NN N
, , N
and CC N
patient JJ N
wellbeing VBG N
- : N
i.e. NN N
, , N
the DT N
important JJ N
pharmacopsychometric JJ N
triangle NN N
domains NNS N
. . N

METHOD NNP N
Selected NNP p
Positive NNP p
and CC p
Negative NNP p
Syndrome NNP p
Scale NNP p
( ( p
PANSS NNP p
) ) p
subscales NNS p
and CC p
the DT p
Simpson-Angus JJ p
scale NN p
were VBD N
tested VBN N
for IN N
validity NN N
. . N

Standardized JJ N
effect NN N
sizes VBZ N
[ NNP N
last JJ N
observation NN N
carried VBD N
forward RB N
( ( N
LOCF NNP N
) ) N
] NN N
at IN N
endpoint NN N
were VBD N
calculated VBN N
. . N

RESULTS VB N
The DT N
scales NNS N
were VBD N
found VBN N
to TO N
be VB N
valid JJ N
instruments NNS N
. . N

The DT N
PANSS NNP N
( ( N
11 CD N
) ) N
psychotic JJ N
subscale NN N
showed VBD N
clinically RB N
significant JJ N
effect NN o
sizes NNS o
for IN N
all DT N
doses NNS N
of IN N
sertindole NN i
( ( N
12 CD N
, , N
20 CD N
, , N
and CC N
24 CD N
mg NN N
) ) N
and CC N
haloperidol NN i
( ( N
4 CD N
, , N
8 CD N
, , N
and CC N
16 CD N
mg NN N
) ) N
. . N

Extrapyramidal JJ o
effects NNS o
were VBD N
evident JJ N
for IN N
all DT N
doses NNS N
of IN N
haloperidol NN i
, , N
but CC N
absent NN N
for IN N
the DT N
lower JJR N
doses NNS N
of IN N
sertindole NN i
. . i

The DT N
PANSS NNP N
( ( N
6 CD N
) ) N
depression NN N
subscale NN N
, , N
a DT N
proxy JJ N
measure NN N
of IN N
quality NN o
of IN o
life NN o
, , N
showed VBD N
a DT N
clinically RB N
significant JJ N
effect NN N
for IN N
sertindole JJ i
20 CD N
mg NN N
and CC N
no DT N
effect NN N
for IN N
haloperidol NN i
. . i

CONCLUSION VB N
This DT N
re-analysis NN N
confirmed VBD N
the DT N
antipsychotic JJ N
effect NN N
and CC N
absence NN N
of IN N
extrapyramidal JJ N
effects NNS N
for IN N
sertindole NN i
and CC N
, , N
in IN N
addition NN N
, , N
showed VBD N
a DT N
clinically RB N
significant JJ N
antidepressant JJ N
effect NN N
. . N

A DT N
profile NN N
for IN N
bipolar JJ N
states NNS N
emerged VBD N
. . N

-DOCSTART- -23494559- O O

JobTIPS NN i
: : i
a DT N
transition NN N
to TO N
employment NN N
program NN N
for IN N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
evaluated VBD N
the DT N
effectiveness NN o
of IN N
an DT N
internet NN o
accessed VBD o
training VBG o
program NN o
that WDT N
included VBD N
Theory NNP N
of IN N
Mind-based JJ N
guidance NN N
, , N
video NN N
models NNS N
, , N
visual JJ N
supports NNS N
, , N
and CC N
virtual JJ N
reality NN N
practice NN N
sessions NNS N
in IN N
teaching VBG N
appropriate JJ N
job NN N
interview NN N
skills NNS N
to TO N
individuals NNS p
with IN p
high JJ p
functioning VBG p
Autism NNP p
Spectrum NNP p
Disorders NNP p
. . p

In IN N
a DT N
randomized JJ N
study NN N
, , N
twenty-two JJ p
youth NN p
, , p
ages VBZ p
16-19 JJ p
, , p
were VBD p
evaluated VBN p
during IN p
two CD p
employment NN p
interviews NNS p
. . p

Half NNP N
received VBD N
a DT N
training NN N
intervention NN N
following VBG N
the DT N
initial JJ N
interview NN N
and CC N
the DT N
half NN N
who WP N
served VBD N
as IN N
a DT N
contrast NN N
group NN N
did VBD N
not RB N
. . N

Their PRP$ N
performance NN N
pre NN N
and CC N
post NN N
intervention NN N
was VBD N
assessed VBN N
by IN N
four CD N
independent JJ N
raters NNS N
using VBG N
a DT N
scale NN N
that WDT N
included VBD N
evaluation NN N
of IN N
both DT N
Content NNP o
and CC o
Delivery NNP o
. . o

Results NNP N
suggest VBP N
that IN N
youth NN N
who WP N
completed VBD N
the DT N
JobTIPS NNP i
employment NN i
program NN i
demonstrated VBD N
significantly RB o
more RBR o
effective JJ o
verbal JJ o
content NN o
skills NNS o
than IN N
those DT N
who WP N
did VBD N
not RB N
. . N

-DOCSTART- -3816105- O O

Evaluation NN N
of IN N
three CD i
dosage-prediction NN i
methods NNS N
for IN N
initial JJ N
in-hospital JJ N
stabilization NN N
of IN N
warfarin JJ N
therapy NN N
. . N

Three CD i
dosage-prediction NN i
methods NNS i
for IN N
initial JJ N
in-hospital JJ N
stabilization NN N
of IN N
warfarin JJ i
therapy NN i
were VBD N
evaluated VBN N
. . N

Adult NNP p
inpatients NNS p
who WP p
had VBD p
received VBN p
warfarin JJ i
sodium NN i
10 CD i
mg JJ i
daily RB i
for IN p
less JJR p
than IN p
three CD p
days NNS p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
. . p

After IN N
receiving VBG N
their PRP$ N
third JJ N
warfarin NN i
dose NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
their PRP$ N
warfarin NNS i
dosages NNS N
adjusted VBD N
using VBG N
one CD N
of IN N
three CD N
dosage-prediction NN N
methods NNS N
: : N
by IN N
analog NN i
computer NN i
( ( N
n JJ N
= NNP N
31 CD N
) ) N
, , N
linear JJ i
regression NN i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
, , N
or CC N
empiric JJ i
dosing NN i
by IN i
the DT i
physician NN i
( ( N
n JJ N
= NNP N
34 CD N
) ) N
. . N

A DT N
prothrombin JJ o
time NN o
( ( o
PT NNP o
) ) o
ratio NN o
( ( N
patient JJ N
PT NNP N
divided VBN N
by IN N
control NN N
PT NNP N
) ) N
between IN N
1.3 CD N
and CC N
2.5 CD N
was VBD N
considered VBN N
to TO N
be VB N
in IN N
the DT N
therapeutic JJ N
range NN N
. . N

For IN N
patients NNS N
who WP N
achieved VBD N
a DT N
stable JJ o
PT NNP o
ratio NN o
( ( N
defined VBN N
as IN N
a DT N
PT NNP N
ratio NN N
between IN N
1.3 CD N
and CC N
2.5 CD N
that WDT N
varied VBN N
by IN N
less JJR N
than IN N
0.05 CD N
on IN N
two CD N
consecutive JJ N
days NNS N
or CC N
by IN N
less JJR N
than IN N
0.1 CD N
on IN N
three CD N
consecutive JJ N
days NNS N
without IN N
a DT N
dosage NN N
change NN N
) ) N
before IN N
discharge NN N
, , N
the DT N
number NN o
of IN o
days NNS o
( ( o
time NN o
to TO o
stabilization NN o
) ) o
from IN N
administration NN N
of IN N
the DT N
first JJ N
warfarin NN N
dose NN N
to TO N
achievement NN N
of IN N
the DT N
warfarin NN N
dosage NN N
that WDT N
produced VBD N
a DT N
stable JJ o
PT NNP o
ratio NN o
( ( o
stabilization JJ o
dosage NN o
) ) o
was VBD N
compared VBN N
. . N

A DT N
total NN p
of IN p
54 CD p
patients NNS p
met VBD p
the DT p
study NN p
criteria NNS p
for IN N
a DT N
stable JJ o
PT NNP o
ratio NN o
before IN N
hospital JJ N
discharge NN N
( ( N
analog JJ N
computer NN N
, , N
n JJ N
= VBP N
20 CD N
; : N
linear JJ N
regression NN N
, , N
n JJ N
= VBP N
15 CD N
; : N
empiric JJ N
dosing NN N
, , N
n JJ N
= NNP N
19 CD N
) ) N
. . N

The DT N
mean JJ o
times NNS o
to TO o
stabilization NN o
were VBD N
6.8 CD N
days NNS N
in IN N
the DT N
analog-computer JJ N
group NN N
, , N
7.3 CD N
days NNS N
in IN N
the DT N
linear-regression NN N
group NN N
, , N
and CC N
8.4 CD N
days NNS N
in IN N
the DT N
empiric-dosing JJ N
group NN N
; : N
these DT N
times NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

All DT N
20 CD N
stabilized VBD N
patients NNS N
in IN N
the DT N
analog-computer JJ N
group NN N
achieved VBD N
a DT N
stable JJ N
PT NNP N
ratio NN N
by IN N
the DT N
fourth JJ N
dosage NN N
prediction NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -8752254- O O

Continuous JJ N
and CC N
cyclical JJ i
clodronate NN i
therapies NNS i
and CC N
bone NN N
density NN N
in IN N
postmenopausal JJ p
bone NN p
loss NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
different JJ N
clodronate NN i
regimens NNS N
in IN N
postmenopausal JJ p
osteoporosis NN p
. . p

METHODS NNP N
In IN N
groups NNS p
of IN p
20 CD p
, , p
60 CD p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatments NNS N
: : N
oral JJ i
calcium NN i
, , i
1000 CD i
mg/day NN i
; : i
oral JJ i
calcium NN i
plus CC i
oral JJ i
clodronate NN i
, , i
400 CD i
mg/day NN i
; : i
oral JJ i
calcium NN i
plus CC i
oral JJ i
clodronate NN i
, , i
400 CD i
mg/day NN i
for IN i
30 CD i
days NNS i
, , i
followed VBN i
by IN i
a DT i
60-day JJ i
period NN i
of IN i
calcium JJ i
supplement NN i
alone RB i
. . i

This DT N
last JJ N
regimen NN N
was VBD N
repeated VBN N
four CD N
times NNS N
in IN N
the DT N
12-month JJ N
study NN N
period NN N
. . N

RESULTS JJ N
Patients NNPS p
who WP p
received VBD p
calcium NN i
alone RB i
showed VBD N
a DT N
decline NN N
in IN N
spinal JJ o
bone NN o
mass NN o
, , N
both DT N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.03 NNP N
and CC N
P NNP N
< NNP N
.005 NNP N
, , N
respectively RB N
) ) N
; : N
femoral JJ N
density NN N
in IN N
this DT N
group NN N
also RB N
decreased VBD N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.002 NNP N
and CC N
P NNP N
< NNP N
.05 NNP N
, , N
respectively RB N
) ) N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
both DT N
clodronate-treated JJ i
groups NNS N
had VBD N
increased VBN N
levels NNS N
of IN N
lumbar NN N
bone NN N
mass NN N
compared VBN N
with IN N
controls NNS N
, , N
both DT N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
therapy NN N
. . N

However RB N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
patients NNS N
treated VBD N
with IN N
cyclical JJ i
clodronate NN i
had VBD N
higher JJR N
spinal JJ o
bone NN o
mass NN o
compared VBN N
with IN N
those DT N
treated VBN N
continuously RB N
( ( N
3.32 CD N
+/- JJ N
0.71 CD N
versus NN N
0.43 CD N
+/- JJ N
0.89 CD N
% NN N
, , N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
femoral JJ o
bone NN o
density NN o
was VBD N
significantly RB N
higher JJR N
both DT N
in IN N
subjects NNS N
treated VBN N
with IN N
clodronate NN N
, , N
both DT N
cyclically RB N
and CC N
continuously RB N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
compared VBN N
with IN N
controls NNS N
. . N

Continuous JJ i
clodronate NN i
treatment NN i
resulted VBD N
in IN N
a DT N
clear JJ N
fall NN N
in IN N
biochemical JJ N
indices NNS N
of IN N
bone NN o
resorption NN o
, , N
together RB N
with IN N
a DT N
consequent JJ N
decrease NN N
in IN N
osteocalcin NN N
at IN N
6 CD N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.003 NNP N
) ) N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
parathyroid JJ o
hormone NN o
after IN N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
of IN N
therapy NN N
. . N

CONCLUSION NNP N
One-year JJ N
treatment NN N
with IN N
clodronate NN i
induces NNS N
a DT N
gain NN N
in IN N
bone NN N
mass NN N
, , N
especially RB N
in IN N
the DT N
spine NN N
. . N

The DT N
continuous JJ N
regimen NN N
does VBZ N
not RB N
result VB N
in IN N
any DT N
further JJ N
benefit NN N
in IN N
lumbar NN N
bone NN N
density NN N
over IN N
the DT N
cyclical JJ N
one CD N
, , N
probably RB N
because IN N
of IN N
a DT N
greater JJR N
suppression NN N
of IN N
bone NN N
turnover NN N
. . N

-DOCSTART- -16386890- O O

Pre-treatment JJ N
proliferation NN N
and CC N
the DT N
outcome NN N
of IN N
conventional JJ i
and CC i
accelerated JJ i
radiotherapy NN i
. . i

This DT N
study NN N
investigated VBD N
the DT N
influence NN N
of IN N
pre-treatment JJ N
proliferation NN N
characteristics NNS N
, , N
assessed VBN i
by IN i
Ki-67 NNP i
staining NN i
, , N
in IN N
patients NNS p
treated VBN p
in IN p
the DT p
CHART NNP p
trial NN p
of IN p
accelerated JJ i
radiotherapy NN i
in IN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

Histological JJ N
material NN N
from IN N
402 CD p
patients NNS p
was VBD N
collected VBN N
and CC N
stained VBN N
for IN N
the DT N
presence NN N
and CC N
pattern NN N
of IN N
Ki-67 NNP N
staining NN N
. . N

Locoregional NNP o
control NN o
and CC N
overall JJ N
survival NN N
were VBD N
the DT N
main JJ N
clinical JJ N
endpoints NNS N
. . N

Increasing VBG N
Ki-67 NNP N
positivity NN N
was VBD N
associated VBN N
with IN N
decreasing VBG N
differentiation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
increasing VBG N
N-stage NN N
( ( N
P NNP N
< NNP N
0.004 CD N
) ) N
. . N

Increasing VBG N
N-stage NN N
was VBD N
also RB N
associated VBN N
with IN N
the DT N
progression NN N
of IN N
proliferation NN N
pattern NN N
from IN N
marginal JJ N
to TO N
random VB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Using VBG N
a DT N
multivariate NN N
model NN N
, , N
a DT N
trend NN N
was VBD N
seen VBN N
towards NNS N
a DT N
greater JJR N
benefit NN N
from IN N
CHART NNP N
in IN N
the DT N
lower JJR N
Ki-67 NNP N
tumours NNS N
( ( N
P NNP N
= NNP N
0.08 CD N
) ) N
; : N
this DT N
became VBD N
significant JJ N
by IN N
pooling VBG N
the DT N
low JJ N
and CC N
intermediate JJ N
Ki-67 NNP N
groups NNS N
in IN N
comparison NN N
with IN N
the DT N
high JJ N
Ki-67 NNP N
group NN N
( ( N
P NNP N
= NNP N
0.032 CD N
) ) N
. . N

Tumours $ N
with IN N
marginal JJ N
proliferation NN N
pattern NN N
showed VBD N
a DT N
lower JJR N
hazard NN N
ratio NN N
with IN N
CHART NNP N
versus VBP N
conventional JJ N
for IN N
locoregional JJ N
control NN N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

The DT N
data NN N
presented VBN N
in IN N
this DT N
study NN N
do VBP N
not RB N
support VB N
that IN N
a DT N
high JJ N
pre-treatment JJ N
Ki-67 NNP N
is VBZ N
associated VBN N
with IN N
a DT N
therapeutic JJ o
benefit NN o
from IN N
accelerated VBN i
radiotherapy NN i
. . i

-DOCSTART- -7029293- O O

Multimodal NNP N
therapy NN N
for IN N
the DT N
management NN N
of IN N
primary JJ p
, , p
nonmetastatic JJ p
Ewing NNP p
's POS p
sarcoma NN p
of IN p
bone NN p
: : p
an DT N
Intergroup NNP N
Study NNP N
. . N

A NNP N
randomized JJ N
study NN N
of IN N
264 CD p
children NNS p
and CC p
adults NNS p
with IN p
previously RB p
untreated VBN p
localized JJ p
Ewing NNP p
's POS p
sarcoma NN p
of IN p
bone NN p
was VBD N
undertaken VBN N
between IN p
1973 CD p
and CC p
1978 CD p
by IN p
83 CD p
institutions NNS p
of IN p
three CD p
national JJ p
study NN p
groups NNS p
: : p
Children NNP p
's POS p
Cancer NNP p
Study NNP p
Group NNP p
, , p
Southwest NNP p
Oncology NNP p
Group NNP p
, , p
and CC p
Cancer NNP p
and CC p
Leukemia NNP p
Group NNP p
B NNP p
. . p

The DT N
Intergroup NNP N
Study NNP N
was VBD N
designed VBN N
to TO N
determine VB N
if IN N
the DT N
addition NN i
of IN i
adriamycin NN i
( ( i
ADR NNP i
) ) i
or CC i
bilateral JJ i
pulmonary JJ i
radiotherapy NN i
( ( i
RT NNP i
) ) i
to TO i
vincristine VB i
, , i
dactinomycin NN i
, , i
and CC i
cyclophosphamide NN i
( ( i
VAC NNP i
therapy NN i
) ) i
would MD N
improve VB o
survival NN o
and CC o
reduce VB o
local JJ o
recurrences NNS o
and CC o
metastases NNS o
. . N

All DT N
patients NNS N
received VBD N
RT NNP i
to TO N
the DT N
primary JJ N
lesion NN N
, , N
and CC N
the DT N
survival NN o
rate NN o
after IN N
3 CD N
years NNS N
was VBD N
65 CD N
% NN N
. . N

The DT N
most RBS N
effective JJ N
treatment NN N
regimen NNS N
was VBD N
VAC NNP N
plus CC N
ADR NNP N
; : N
74 CD N
% NN N
of IN N
the DT N
patients NNS N
were VBD N
free JJ N
of IN N
disease NN N
at IN N
2 CD N
years NNS N
. . N

The DT N
lengths NNS o
of IN o
disease-free JJ o
status NN o
and CC o
survival NN o
of IN o
patients NNS o
treated VBN N
with IN N
VAC NNP N
plus CC N
ADR NNP N
or CC N
VAC NNP N
plus CC N
RT NNP N
did VBD N
not RB N
differ VB N
. . N

However RB N
, , N
both DT N
regimens NNS N
were VBD N
significantly RB N
superior JJ N
to TO N
treatment NN N
with IN N
VAC NNP N
alone RB N
. . N

The DT N
addition NN N
of IN N
ADR NNP i
or CC N
bilateral JJ N
pulmonary JJ N
RT NNP N
to TO N
VAC NNP i
was VBD N
highly RB o
advantageous JJ o
to TO N
patients NNS N
with IN N
nonpelvic JJ N
primaries NNS N
. . N

Bone NN N
and CC N
lung NN N
were VBD N
the DT N
major JJ N
sites NNS N
of IN N
distant JJ N
relapse NN N
, , N
but CC N
the DT N
addition NN N
of IN N
bilateral JJ N
pulmonary JJ N
RT NNP N
showed VBD N
no DT o
advantage NN o
over IN N
that DT N
of IN N
ADR NNP N
in IN N
reducing VBG N
the DT N
occurrence NN o
of IN o
lung NN o
metastases NNS o
. . o

These DT N
recent JJ N
results NNS N
should MD N
eliminate VB N
some DT N
of IN N
the DT N
pessimism NN N
that WDT N
has VBZ N
accompanied VBN N
a DT N
diagnosis NN N
of IN N
Ewing NNP N
's POS N
sarcoma NN N
, , N
although IN N
distant JJ N
metastases NNS N
continued VBD N
to TO N
be VB N
a DT N
major JJ N
reason NN N
for IN N
failure NN N
in IN N
the DT N
control NN N
of IN N
this DT N
tumor NN N
. . N

Survival NN N
of IN N
these DT N
patients NNS N
can MD N
be VB N
improved VBN N
through IN N
well-controlled JJ N
clinical JJ N
trials NNS N
designed VBN N
to TO N
determine VB N
optimal JJ N
adjuvant JJ N
chemotherapy NN N
and CC N
treatment NN N
of IN N
the DT N
primary JJ N
lesion NN N
. . N

-DOCSTART- -15719741- O O

[ NN N
Relationship NNP N
between IN N
sCD44v6 JJ o
expression NN o
and CC N
TCM NNP N
differentiation NN N
type NN N
of IN N
gastric JJ p
carcinoma NN p
patients NNS p
and CC N
influence NN N
of IN N
weitai NN i
capsule NN i
on IN N
the DT N
expression NN o
] NNP o
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
relationship NN N
of IN N
TCM NNP N
type NN N
with IN N
serum JJ o
level NN o
of IN o
soluble JJ o
CD44v6 NNP o
( ( o
sCD44v6 NN o
) ) o
and CC N
different JJ N
histologic NN o
parameters NNS o
in IN N
gastric JJ p
carcinoma NN p
patients NNS p
and CC N
to TO N
observe VB N
the DT N
influence NN N
of IN N
Weitai NNP i
capsule NN i
( ( i
WTC NNP i
) ) i
on IN N
the DT N
sCD44v6 JJ o
expression NN o
. . o

METHODS NNP N
TCM NNP o
typing NN o
and CC N
sCD44v6 JJ o
expression NN o
were VBD N
determined VBN N
in IN N
all PDT p
the DT p
enrolled JJ p
patients NNS p
( ( p
30 CD p
in IN p
the DT p
control NN p
and CC p
32 CD p
in IN p
the DT p
trial NN p
group NN p
) ) p
before IN p
operation NN p
, , p
and CC p
3-4 JJ p
courses NNS p
of IN p
chemotherapy NN i
was VBD p
applied VBN p
to TO p
them PRP p
from IN p
3-4 JJ p
weeks NNS p
after IN p
operation NN p
. . p

To TO N
the DT N
patients NNS N
of IN N
trial NN N
group NN N
, , N
oral JJ N
administration NN N
of IN N
WTC NNP i
was VBD N
given VBN N
additionally RB N
with IN N
4 CD N
capsules NNS N
, , N
3 CD N
times NNS N
a DT N
day NN N
for IN N
consecutive JJ N
3 CD N
months NNS N
. . N

RESULTS NNP N
sCD44v6 NN o
was VBD N
significantly RB N
positive JJ N
correlated VBN N
with IN N
the DT N
degree NN o
of IN o
cancer NN o
cell NN o
differentiation NN o
, , o
infiltration NN o
and CC o
lymph NN o
node JJ o
metastasis NN o
; : o
( ( N
2 CD N
) ) N
Level NN o
of IN o
sCD44v6 NN o
was VBD N
the DT N
highest JJS N
in IN N
patients NNS p
of IN p
blood NN p
stasis NN p
type NN p
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
patients NNS p
of IN p
Pi-deficiency NNP p
type NN p
or CC p
of IN p
damp-heat JJ p
type NN p
, , N
the DT N
difference NN N
was VBD N
significant JJ N
; : N
( ( N
3 CD N
) ) N
After IN N
ending VBG N
treatment NN N
, , N
level NN o
of IN o
sCD44v6 NN o
in IN N
the DT N
trial NN N
group NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
( ( N
1 CD N
) ) N
Serum NNP o
level NN o
of IN o
sCD44v6 NN o
could MD N
be VB N
taken VBN N
as IN N
the DT N
criterion NN N
for IN N
evaluating VBG N
the DT N
development NN o
and CC o
prognosis NN o
of IN o
gastric JJ o
cancer NN o
, , N
as RB N
well RB N
as IN N
the DT N
therapeutic JJ N
target NN N
for IN N
anti-metastasis JJ N
treatment NN N
; : N
( ( N
2 CD N
) ) N
Serum NNP o
level NN o
of IN o
sCD44v6 NN o
is VBZ N
related VBN N
to TO N
some DT N
extent NN N
with IN N
TCM NNP o
type NN o
of IN o
blood NN o
stasis NN o
and CC o
Pi-deficiency NN o
; : o
( ( N
3 CD N
) ) N
WTC NNP i
combined VBN N
with IN N
chemotherapy NN i
could MD N
further RB N
inhibit VB N
the DT N
expression NN o
of IN o
serum NN o
sCD44v6 NN o
in IN N
gastric JJ N
carcinoma NN N
patients NNS N
. . N

-DOCSTART- -21938889- O O

The DT N
effects NNS N
of IN N
therapeutic JJ i
instrumental JJ i
music NN i
performance NN i
on IN N
endurance NN o
level NN o
, , o
self-perceived JJ o
fatigue NN o
level NN o
, , o
and CC o
self-perceived JJ o
exertion NN o
of IN N
inpatients NNS p
in IN p
physical JJ p
rehabilitation NN p
. . p

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
a DT N
Neurologic NNP i
Music NNP i
Therapy NNP i
( ( i
NMT NNP i
) ) i
sensory-motor NN i
rehabilitation NN i
technique NN i
, , i
Therapeutic NNP i
Instrumental NNP i
Music NNP i
Performance NNP i
( ( i
TIMP NNP i
) ) i
as IN N
compared VBN N
to TO N
Traditional NNP i
Occupational NNP i
Therapy NNP i
( ( i
TOT NNP i
) ) i
, , N
on IN N
endurance NN o
, , o
self-perceived JJ o
fatigue NN o
, , o
and CC o
self-perceived JJ o
exertion NN o
of IN N
35 CD p
hospitalized JJ p
patients NNS p
in IN p
physical JJ p
rehabilitation NN p
. . p

The DT N
present JJ N
study NN N
attempted VBD N
to TO N
examine VB N
whether IN N
an DT N
active JJ N
musical JJ N
experience NN N
such JJ N
as IN N
TIMP NNP i
with IN N
musical JJ N
cueing NN N
( ( N
i.e. FW N
, , N
rhythmic JJ N
auditory NN N
cueing VBG N
) ) N
during IN N
physical JJ N
exercises NNS N
influences VBZ N
one CD N
's POS N
perception NN o
of IN o
pain NN o
, , o
fatigue NN o
, , o
and CC o
exertion NN o
. . o

All DT p
participants NNS p
were VBD p
diagnosed VBN p
with IN p
a DT p
neurologic JJ p
disorder NN p
or CC p
had VBD p
recently RB p
undergone JJ p
orthopedic JJ p
surgery NN p
. . p

Investigators NNS N
measured VBD N
the DT N
effects NNS N
of IN N
TOT NNP i
and CC N
TIMP NNP i
during IN N
upper JJ i
extremity NN i
exercise NN i
of IN i
the DT i
less RBR i
affected JJ i
or CC i
stronger JJR i
upper JJ i
extremity NN i
. . i

Results NNP N
showed VBD N
no DT o
significant JJ o
difference NN o
on IN o
endurance NN o
measures NNS o
between IN N
the DT N
2 CD N
treatment NN N
conditions NNS N
( ( i
TIMP NNP i
and CC i
TOT NNP i
) ) i
. . N

Statistically NNP N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
TIMP NNP i
and CC N
TOT NNP i
when WRB N
measuring VBG N
their PRP$ N
effects NNS N
on IN N
perceived JJ o
exertion NN o
and CC o
perceived VBD o
fatigue NN o
. . o

TIMP NNP i
resulted VBD N
in IN N
significantly RB N
less JJR N
perception NN o
of IN o
fatigue NN o
and CC o
exertion NN o
levels NNS o
than IN N
TOT NNP i
. . i

TIMP NNP i
can MD N
be VB N
used VBN N
foran JJ N
effective JJ N
sensory-motor NN N
rehabilitation NN N
technique NN N
to TO N
decrease VB N
perceived JJ N
exertion NN o
and CC o
fatigue JJ o
level NN o
of IN N
inpatients NNS p
in IN p
physical JJ p
rehabilitation NN p
. . p

-DOCSTART- -3545842- O O

The DT N
UKEP NNP N
study NN N
: : N
multicentre JJ N
clinical JJ N
trial NN N
on IN N
two CD N
local JJ N
regimens NNS N
of IN N
urokinase NN i
in IN N
massive JJ N
pulmonary JJ N
embolism NN N
. . N

The DT N
UKEP NNP N
Study NNP N
Research NNP N
Group NNP N
. . N

A NNP i
multicentre JJ i
trial NN i
( ( i
10 CD i
centres NNS i
) ) i
of IN i
urokinase NN i
( ( i
UK NNP i
) ) i
was VBD N
performed VBN N
in IN N
patients NNS p
with IN p
acute NN p
severe JJ p
pulmonary JJ p
embolism NN p
( ( p
PE NNP p
) ) p
. . p

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
, , N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
two CD i
doses NNS i
of IN i
UK NNP i
administered VBD i
via IN i
a DT i
catheter NN i
in IN i
the DT i
pulmonary JJ i
artery NN i
: : i
2000 CD i
IU NNP i
kg-1 JJ i
h-1 NN i
for IN i
24 CD i
hours NNS i
( ( i
UK IN i
2000 CD i
) ) i
in IN i
conjunction NN i
with IN i
heparin NN i
versus NN i
4400 CD i
IU NNP i
kg-1 JJ i
h-1 JJ i
UK NNP i
alone RB i
for IN i
12 CD i
hours NNS i
( ( i
UK IN i
4400 CD i
) ) i
followed VBN i
by IN i
heparin NN i
. . i

PE NNP p
was VBD p
less JJR p
than IN p
5 CD p
days NNS p
old JJ p
and CC N
the DT N
clinical JJ N
diagnosis NN N
was VBD N
confirmed VBN N
by IN N
pulmonary JJ N
angiograms NNS N
demonstrating VBG N
a DT N
vascular JJ N
obstruction NN N
of IN N
more JJR N
than IN N
30 CD N
% NN N
( ( N
Miller NNP N
's POS N
index NN N
greater JJR N
than IN N
11 CD N
) ) N
. . N

The DT N
efficacy NN N
of IN N
treatment NN N
was VBD N
evaluated VBN N
by IN N
the DT N
degree NN o
of IN o
early JJ o
revascularization NN o
( ( N
pulmonary JJ N
angiograms NNS N
were VBD N
performed VBN N
30 CD N
to TO N
48 CD N
hours NNS N
after IN N
initiation NN N
of IN N
thrombolytic JJ i
treatment NN i
and CC N
analysed VBN N
blindly RB N
by IN N
four CD N
independent JJ N
vascular JJ N
radiologists NNS N
) ) N
. . N

133 CD p
patients NNS p
were VBD N
included VBN N
in IN N
this DT N
trial NN N
: : N
two CD p
patients NNS p
died VBD o
before IN p
treatment NN p
and CC p
two CD p
were VBD p
excluded VBN p
retrospectively RB p
, , p
leaving VBG p
129 CD p
patients NNS p
for IN p
final JJ p
analysis NN p
( ( N
67 CD N
: : N
UK NN N
2000 CD N
+ NNP N
heparin NN N
; : N
62 CD N
: : N
UK JJ N
4400 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
had VBD N
similar JJ N
pretreatment NN N
clinical JJ N
, , N
haemodynamic JJ N
and CC N
angiographic JJ N
characteristics NNS N
: : N
the DT N
Miller NNP o
angiographic JJ o
index NN o
of IN N
severity NN N
averaged VBD N
22.6 CD N
+/- JJ N
3.7 CD N
for IN N
patients NNS N
in IN N
the DT N
UK NNP N
2000 CD N
group NN N
, , N
and CC N
22.6 CD N
+/- JJ N
3.4 CD N
for IN N
patients NNS N
in IN N
the DT N
UK NNP N
4400 CD N
group NN N
( ( N
average JJ N
filling VBG N
defect NN N
of IN N
66 CD N
% NN N
on IN N
pulmonary JJ N
angiograms NNS N
) ) N
. . N

There EX N
was VBD N
a DT N
similar JJ N
and CC N
significant JJ o
degree NN o
of IN o
resolution NN o
in IN N
the DT N
two CD N
groups NNS N
: : N
26 CD N
% NN N
and CC N
20 CD N
% NN N
, , N
respectively RB N
. . N

Minor NNP o
and CC o
major JJ o
bleeding NN o
problems NNS o
were VBD N
observed VBN N
with IN N
equal JJ N
frequency NN N
in IN N
the DT N
two CD p
groups NNS p
( ( N
24 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

These DT N
bleeding VBG N
complications NNS N
were VBD N
severe RB N
in IN N
only RB N
4.5 CD N
% NN N
and CC N
3 CD N
% NN N
, , N
respectively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -10208073- O O

Clinical JJ i
hypnosis NN i
versus NN i
cognitive JJ i
behavioral JJ i
training NN i
for IN N
pain NN o
management NN o
with IN N
pediatric JJ p
cancer NN p
patients NNS p
undergoing VBG p
bone NN p
marrow NN p
aspirations NNS p
. . p

A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
clinical JJ i
hypnosis NN i
versus NN i
cognitive JJ i
behavioral NN i
( ( i
CB NNP i
) ) i
coping VBG i
skills NNS i
training VBG i
in IN N
alleviating VBG N
the DT N
pain NN o
and CC o
distress NN o
of IN N
30 CD p
pediatric JJ p
cancer NN p
patients NNS p
( ( p
age NN p
5 CD p
to TO p
15 CD p
years NNS p
) ) p
undergoing VBG p
bone NN p
marrow NN p
aspirations NNS p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
hypnosis NN i
, , i
a DT i
package NN i
of IN i
CB NNP i
coping VBG i
skills NNS i
, , i
and CC i
no DT i
intervention NN i
. . i

Patients NNS N
who WP N
received VBD N
either CC N
hypnosis NN N
or CC N
CB NNP N
reported VBD N
less JJR N
pain NN o
and CC o
pain-related JJ o
anxiety NN o
than IN N
did VBD N
control VB N
patients NNS N
and CC N
less JJR N
pain NN o
and CC o
anxiety NN o
than IN N
at IN N
their PRP$ N
own JJ N
baseline NN N
. . N

Hypnosis NNP N
and CC N
CB NNP N
were VBD N
similarly RB N
effective JJ N
in IN N
the DT N
relief NN o
of IN o
pain NN o
. . o

Results NNP N
also RB N
indicated VBD N
that IN N
children NNS N
reported VBD N
more RBR N
anxiety NN o
and CC N
exhibited VBD N
more RBR N
behavioral JJ o
distress NN o
in IN N
the DT N
CB NNP N
group NN N
than IN N
in IN N
the DT N
hypnosis NN N
group NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
hypnosis NN N
and CC N
CB NNP N
coping VBG N
skills NNS N
are VBP N
effective JJ o
in IN N
preparing VBG o
pediatric JJ p
oncology NN p
patients NNS p
for IN N
bone NN N
marrow NN N
aspiration NN N
. . N

-DOCSTART- -21552726- O O

Comparison NNP N
of IN N
the DT N
evolutional JJ o
process NN o
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
in IN N
different JJ N
language NN i
therapeutic JJ i
interventions NNS i
. . i

PURPOSE NNP N
To TO N
analyze VB N
and CC N
compare VB N
the DT o
extension NN o
and CC o
the DT o
speed NN o
of IN o
the DT o
evolutional JJ o
process NN o
of IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
in IN N
direct JJ i
and CC i
indirect JJ i
interventions NNS i
as IN N
opposed VBN N
to TO N
only RB N
indirect VB N
intervention NN N
. . N

METHODS NNP N
The DT N
design NN N
of IN N
this DT N
study NN N
is VBZ N
a DT N
clinical JJ N
trial NN N
. . N

The DT N
sample NN N
was VBD N
composed VBN N
of IN N
11 CD p
children NNS p
diagnosed VBN p
with IN p
Autism NNP p
( ( p
n=6 NN p
) ) p
and CC p
Asperger NNP p
syndrome VBP p
( ( p
n=5 NN p
) ) p
by IN p
a DT p
multidisciplinary JJ p
team NN p
, , p
that WDT p
attended VBD p
specialized JJ p
speech-language JJ p
pathology NN p
therapy NN p
at IN p
the DT p
institution NN p
were VBD p
the DT p
study NN p
was VBD p
carried VBN p
out RP p
. . p

These DT N
children NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Therapy NNP i
Group NNP i
( ( i
TG NNP i
) ) i
- : i
composed VBN i
by IN i
six CD i
subjects NNS i
receiving VBG i
both DT i
direct JJ i
and CC i
indirect JJ i
intervention NN i
; : i
and CC i
Orientation NNP i
Group NNP i
( ( i
OG NNP i
) ) i
- : i
constituted VBN i
by IN i
five CD i
subjects NNS i
receiving VBG i
exclusively RB i
indirect JJ i
intervention NN i
. . i

It PRP N
was VBD N
used VBN N
the DT N
Autism NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
to TO i
interview NN i
the DT i
mothers NNS i
, , i
and CC i
the DT i
Sample NNP o
of IN o
Vocal NNP o
Behavior NNP o
( ( o
SVB NNP o
) ) o
, , i
in IN i
three CD i
occasions NNS i
: : i
at IN i
the DT i
beginning NN i
of IN i
the DT i
intervention NN i
process NN i
( ( i
time NN i
0 CD i
) ) i
, , i
six CD i
months NNS i
later RB i
( ( i
time NN i
1 CD i
) ) i
and CC i
12 CD i
months NNS i
later RB i
( ( i
time NN i
2 CD i
) ) i
. . i

RESULTS VB N
It PRP N
was VBD N
observed VBN N
greater JJR N
speed NN o
and CC o
extension NN o
in IN o
the DT o
evolutional JJ o
process NN o
of IN N
the DT N
TG NNP N
Group NNP N
, , N
both DT N
in IN N
the DT N
analysis NN N
of IN N
the DT N
Autism NNP o
Behavior NNP o
Checklist NNP o
( ( o
total JJ o
and CC o
partial JJ o
scores NNS o
) ) o
and CC N
the DT N
Sample NNP o
of IN o
Vocal NNP o
Behavior NNP o
, , N
especially RB N
in IN N
the DT N
item NN N
Full NNP N
Language NNP N
. . N

The DT N
performance NN N
of IN N
children NNS p
with IN p
Asperger NNP p
syndrome NN p
was VBD N
considered VBN N
more RBR N
positive JJ N
when WRB N
compared VBN N
to TO N
that DT N
of IN N
children NNS p
with IN p
autism NN p
. . p

There EX N
was VBD N
greater JJR N
evolution NN o
in IN N
younger JJR N
children NNS N
and CC N
with IN N
normal JJ N
, , N
mild JJ N
, , N
and CC N
moderate JJ N
adaptive JJ o
functioning NN o
. . o

CONCLUSION VB N
The DT N
tendency NN N
towards NNS N
better RBR N
performance NN o
of IN N
the DT N
children NNS N
attending VBG N
direct JJ i
and CC i
indirect JJ i
intervention NN i
showed VBD N
that IN N
this DT N
association NN N
is VBZ N
fundamental JJ N
in IN N
the DT N
therapeutic JJ N
process NN N
of IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
. . p

-DOCSTART- -10404444- O O

Asthma NN N
: : N
communication NN N
between IN N
hospital NN N
and CC N
general JJ p
practitioners NNS p
. . p

OBJECTIVE NN N
To TO N
assess VB N
whether IN N
efforts NNS N
to TO N
actively RB N
involve VB N
General NNP p
Practitioners NNP p
( ( p
GPs NNP p
) ) p
in IN N
the DT N
postdischarge NN N
care NN N
of IN N
their PRP$ N
paediatric JJ p
asthma NN p
patients NNS p
improved VBD N
their PRP$ N
satisfaction NN o
with IN o
communication NN o
with IN o
hospital JJ o
staff NN o
. . o

METHODOLOGY NNP N
Randomized NNP N
controlled VBD N
trial NN N
involving VBG N
60 CD p
patients NNS p
admitted VBN p
to TO p
the DT p
Royal NNP p
Children NNP p
's POS p
Hospital NNP p
, , p
Melbourne NNP p
, , p
with IN p
acute JJ p
asthma NN p
and CC p
an DT p
identifiable JJ p
GP NNP p
. . p

The DT N
GPs NNP p
of IN p
the DT p
intervention NN p
patients NNS p
were VBD N
telephoned VBN N
during IN N
the DT N
admission NN N
. . N

Intervention NN N
patients NNS N
and CC N
their PRP$ N
GPs NNP N
received VBD N
printed JJ i
information NN i
detailing VBG i
the DT i
care NN i
the DT i
patient NN i
received VBD i
in IN i
hospital NN i
and CC i
the DT i
recommended VBN i
postdischarge NN i
care NN i
, , i
as RB i
well RB i
as IN i
standardized JJ i
educational JJ i
booklets NNS i
about IN i
asthma NN i
. . i

Follow-up JJ i
appointments NNS i
were VBD N
made VBN N
for IN N
intervention NN i
patients NNS N
to TO N
attend VB N
their PRP$ N
GPs NNP N
. . N

RESULTS VB N
The DT N
GPs NNP p
of IN p
intervention NN p
patients NNS p
were VBD N
more RBR N
satisfied JJ o
when WRB N
compared VBN N
to TO N
the DT N
GPs NNP N
receiving VBG N
a DT N
standard JJ N
level NN N
of IN N
communication NN N
( ( N
96.4 CD N
% NN N
vs JJ N
48.3 CD N
% NN N
of IN N
the DT N
intervention NN N
and CC N
control NN N
GPs NNP N
, , N
respectively RB N
, , N
described VBD N
the DT N
communication NN N
as IN N
good JJ N
or CC N
extremely RB N
good JJ N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

The DT N
intervention NN N
group NN N
GPs NNP N
believed VBD o
they PRP o
were VBD o
more JJR o
involved JJ o
after IN o
discharge NN o
( ( N
75.0 CD N
% NN N
vs JJ N
44.8 CD N
% NN N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
and CC N
had VBD N
greater JJR N
understanding NN o
of IN o
their PRP$ o
patient NN o
's POS o
hospitalisation NN o
( ( N
96.4 CD N
% NN N
vs JJ N
62.1 CD N
% NN N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

These DT N
differences NNS N
were VBD N
noted VBN N
despite IN N
there EX N
being VBG N
no DT N
difference NN N
in IN N
the DT N
rate NN o
of IN o
follow-up JJ o
attendance NN o
with IN N
GPs NNP N
for IN N
intervention NN N
and CC N
control NN N
patients NNS N
( ( N
85.7 CD N
% NN N
vs JJ N
72.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.2 CD N
) ) N
. . N

Qualitative JJ N
data NNS N
supported VBD N
these DT N
findings NNS N
with IN N
GPs NNP N
expressing VBG N
approval NN o
of IN o
the DT o
intervention NN o
used VBN o
. . o

CONCLUSION NNP N
Efforts NNPS N
to TO N
actively RB N
involve VB N
GPs NNP p
in IN p
the DT p
postdischarge NN p
care NN p
of IN p
their PRP$ p
paediatric JJ p
patients NNS p
with IN p
asthma JJ p
resulted VBN N
in IN N
a DT N
marked JJ N
improvement NN N
in IN N
their PRP$ N
satisfaction NN o
with IN o
the DT o
communication NN o
with IN o
medical JJ o
staff NN o
at IN N
the DT N
Royal NNP N
Children NNP N
's POS N
Hospital NNP N
, , N
Melbourne NNP N
. . N

The DT N
study NN N
had VBD N
insufficient JJ N
power NN N
to TO N
demonstrate VB N
a DT N
difference NN N
in IN N
morbidity NN N
. . N

-DOCSTART- -24972577- O O

Standardized NNP N
treatment NN N
of IN N
Chinese JJ i
medicine NN i
decoction NN i
for IN N
cancer NN p
pain NN p
patients NNS p
with IN p
opioid-induced JJ o
constipation NN o
: : o
a DT N
multi-center JJ N
prospective JJ N
randomized VBN N
controlled VBN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
efficacy NN o
and CC N
the DT N
influence NN N
on IN N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
of IN N
syndrome JJ N
differentiation NN N
treatment NN N
with IN N
Chinese JJ i
medicine NN i
( ( i
CM NNP i
) ) i
for IN N
opioid-induced JJ o
constipation NN o
as RB N
well RB N
as IN N
the DT N
safety NN o
and CC o
influence NN o
on IN o
analgesic JJ o
effect NN o
of IN o
opioids NNS o
. . o

METHODS NNP N
Totally RB p
406 CD p
cases NNS p
enrolled VBD p
from IN p
53 CD p
collaborating VBG p
medical JJ p
centers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
CM NNP i
group NN N
and CC N
a DT N
control NN N
group NN N
. . N

The DT N
CM NNP N
group NN N
were VBD N
treated VBN N
with IN N
CM NNP i
decoction NN i
based VBN N
on IN N
syndrome JJ N
differentiation NN N
, , N
and CC N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
with IN N
Phenolphthalein NNP i
Tablet NNP i
. . i

Both DT N
groups NNS N
were VBD N
treated VBN N
for IN N
14 CD N
days NNS N
. . N

Cleveland NNP o
constipation NN o
score NN o
( ( o
CCS NNP o
) ) o
, , o
numerical JJ o
rating NN o
scale NN o
( ( o
NRS NNP o
) ) o
of IN o
pain NN o
and CC o
Chinese JJ o
version NN o
of IN o
European JJ o
Organisation NNP o
for IN o
Research NNP o
and CC o
Treatment NNP o
of IN o
Cancer NNP o
, , o
Quality NNP o
of IN o
Life NNP o
Questionnaire-C30 NNP o
V3.0 NNP o
( ( o
EORTC NNP o
QLQ-C30 NNP o
V3.0 NNP o
) ) o
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
, , o
pain NN o
controlled VBD o
and CC N
QOL NNP o
status NN o
. . o

RESULTS VB N
The DT N
comparisons NNS N
of IN N
CCS NNP o
score NN o
reduction NN o
and CC N
QOL NNP o
between IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
suggested VBD N
that IN N
the DT N
improvements NNS o
of IN o
constipation NN o
and CC o
QOL NNP o
in IN N
the DT N
CM NNP N
group NN N
were VBD N
better JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
total JJ N
efficiency NN o
of IN N
the DT N
CM NNP N
group NN N
was VBD N
better JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
93.5 CD N
% NN N
vs. FW N
86.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
NRS NNP o
scores NNS o
between IN N
before IN N
and CC N
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
serious JJ N
drug-related JJ o
adverse JJ o
event NN o
during IN N
the DT N
course NN N
of IN N
study NN N
. . N

CONCLUSION NNP N
CM NNP i
decoction NN i
could MD N
effectively RB N
treat VB N
opioid-induced JJ o
constipation NN o
and CC N
improve VB N
patients NNS o
' POS o
QOL NNP o
at IN N
the DT N
same JJ N
time NN N
. . N

It PRP N
is VBZ N
safe JJ N
and CC N
does VBZ N
n't RB N
affect VB N
the DT N
analgesic JJ o
effect NN o
of IN o
opioids NNS o
when WRB N
treating VBG N
constipation NN o
. . o

-DOCSTART- -23975885- O O

Increase NN N
in IN N
2-long JJ N
terminal JJ N
repeat NN N
circles NNS N
and CC N
decrease NN N
in IN N
D-dimer NNP N
after IN N
raltegravir JJ N
intensification NN N
in IN N
patients NNS p
with IN p
treated JJ p
HIV NNP p
infection NN p
: : p
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
degree NN N
to TO N
which WDT N
human JJ N
immunodeficiency NN N
virus NN N
( ( N
HIV NNP N
) ) N
continues VBZ N
to TO N
replicate VB N
during IN N
antiretroviral JJ N
therapy NN N
( ( N
ART NNP N
) ) N
is VBZ N
controversial JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
to TO N
assess VB N
whether IN N
raltegravir JJ N
intensification NN N
reduces NNS N
low-level JJ o
viral JJ o
replication NN o
, , N
as IN N
defined VBN N
by IN N
an DT N
increase NN N
in IN N
the DT N
level NN N
of IN N
2-long JJ o
terminal JJ o
repeat NN o
( ( N
2-LTR JJ N
) ) N
circles NNS N
. . N

METHODS NNP N
Thirty-one JJ p
subjects NNS p
with IN p
an DT p
ART-suppressed JJ p
plasma NN p
HIV NNP p
RNA NNP p
level NN p
of IN p
< $ p
40 CD p
copies/mL NN p
and CC p
a DT p
CD4 NNP p
( ( p
+ NNP p
) ) p
T-cell NNP p
count NN p
of IN p
?350 NNP p
cells/mm NN p
( ( p
3 CD p
) ) p
for IN p
?1 JJ p
year NN p
were VBD p
randomly RB N
assigned VBN N
to TO N
receive VB i
raltegravir NN i
400 CD i
mg NN i
twice RB N
daily RB i
or CC i
placebo VB i
for IN i
24 CD N
weeks NNS N
. . N

2-LTR JJ N
circles NNS N
were VBD N
analyzed VBN N
by IN N
droplet NN N
digital JJ N
polymerase NN N
chain NN N
reaction NN N
at IN N
weeks NNS N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
and CC N
8 CD N
. . N

RESULTS VB N
The DT N
median JJ o
duration NN o
of IN o
ART NNP o
suppression NN o
was VBD o
3.8 CD N
years NNS N
. . N

The DT N
raltegravir NN N
group NN N
had VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
level NN o
of IN o
2-LTR JJ o
circles NNS o
, , o
compared VBN o
to TO N
the DT N
placebo NN N
group NN N
. . N

The DT N
week NN N
1 CD N
to TO N
0 CD N
ratio NN N
was VBD N
8.8-fold JJ N
higher JJR N
( ( N
P NNP N
= NNP N
.0025 NNP N
) ) N
and CC N
the DT N
week NN N
2 CD N
to TO N
0 CD N
ratio NN N
was VBD N
5.7-fold JJ N
higher JJR N
( ( N
P NNP N
= NNP N
.023 NNP N
) ) N
in IN N
the DT N
raltegravir NN N
vs. FW N
placebo NN N
group NN o
. . o

Intensification NNP o
also RB o
led VBD N
to TO N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
the DT N
D-dimer NNP o
level NN o
, , o
compared VBN o
to TO N
placebo VB N
( ( N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

CONCLUSIONS NNP i
Raltegravir NNP i
intensification NN i
resulted VBD N
in IN N
a DT N
rapid JJ N
increase NN N
in IN N
the DT N
level NN o
of IN o
2-LTR JJ o
circles NNS o
in IN o
a DT N
proportion NN N
of IN N
subjects NNS N
, , N
indicating VBG N
that IN N
low-level JJ N
viral JJ N
replication NN N
persists NNS N
in IN N
some DT N
individuals NNS N
even RB N
after IN N
long-term JJ N
ART NNP N
. . N

Intensification NNP N
also RB N
reduced VBD N
the DT N
D-dimer NNP o
level NN o
, , o
a DT o
coagulation NN N
biomarker NN N
that WDT N
is VBZ N
predictive JJ N
of IN N
morbidity NN N
and CC N
mortality NN N
among IN p
patients NNS p
receiving VBG p
treatment NN p
for IN p
HIV NNP p
infection NN p
. . p

-DOCSTART- -1584260- O O

Combined VBN i
chemotherapy NN i
and CC i
radiotherapy NN i
compared VBN N
with IN N
radiotherapy NN i
alone RB i
in IN N
patients NNS p
with IN p
cancer NN p
of IN p
the DT p
esophagus NN p
. . p

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
conventional JJ N
treatment NN N
with IN N
surgery NN N
and CC N
radiation NN N
for IN N
cancer NN N
of IN N
the DT N
esophagus NN N
is VBZ N
limited VBN N
. . N

The DT N
median JJ N
survival NN N
is VBZ N
less JJR N
than IN N
10 CD N
months NNS N
, , N
and CC N
less JJR N
than IN N
10 CD N
percent NN N
of IN N
patients NNS N
survive VBP N
for IN N
5 CD N
years NNS N
. . N

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
combined JJ i
chemotherapy NN i
and CC i
radiation NN i
therapy NN i
may MD N
result VB N
in IN N
improved JJ N
survival NN N
. . N

METHODS NNP N
This DT N
phase NN N
III NNP N
prospective NN N
, , N
randomized VBN N
, , N
and CC N
stratified VBD N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
four CD N
courses NNS N
of IN N
combined JJ N
fluorouracil NN i
( ( i
1000 CD i
mg NN i
per IN i
square JJ i
meter NN i
of IN i
body-surface JJ i
area NN i
daily RB i
for IN i
four CD i
days NNS i
) ) i
and CC i
cisplatin NN i
( ( i
75 CD i
mg NN i
per IN i
square JJ i
meter NN i
on IN i
the DT i
first JJ i
day NN i
) ) i
plus CC i
5000 CD i
cGy NN i
of IN i
radiation NN i
therapy NN i
, , N
as IN N
compared VBN N
with IN N
6400 CD i
cGy NN i
of IN i
radiation NN i
therapy NN i
alone RB N
, , N
in IN N
patients NNS N
with IN N
squamous-cell JJ N
carcinoma NN N
or CC N
adenocarcinoma NN N
of IN N
the DT N
thoracic NN N
esophagus NN N
. . N

The DT N
trial NN N
was VBD N
stopped VBN N
after IN N
the DT N
accumulated JJ N
results NNS N
in IN N
121 CD p
patients NNS p
demonstrated VBD p
a DT p
significant JJ p
advantage NN p
for IN p
survival NN p
in IN p
the DT p
patients NNS p
who WP p
received VBD p
chemotherapy NN i
and CC i
radiation NN i
therapy NN i
. . i

RESULTS VB N
The DT N
median JJ o
survival NN o
was VBD N
8.9 CD N
months NNS N
in IN N
the DT N
radiation-treated JJ N
patients NNS N
, , N
as IN N
compared VBN N
with IN N
12.5 CD N
months NNS N
in IN N
the DT N
patients NNS N
treated VBN N
with IN N
chemotherapy NN i
and CC i
radiation NN i
therapy NN i
. . i

In IN N
the DT N
former JJ N
group NN N
, , N
the DT N
survival NN o
rates NNS o
at IN N
12 CD N
and CC N
24 CD N
months NNS N
were VBD N
33 CD N
percent NN N
and CC N
10 CD N
percent NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
50 CD N
percent NN N
and CC N
38 CD N
percent NN N
in IN N
the DT N
patients NNS N
receiving VBG N
combined VBN i
therapy NN i
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Seven JJ p
patients NNS p
in IN p
the DT p
radiotherapy NN i
group NN p
and CC p
25 CD p
in IN p
the DT p
combined-therapy JJ i
group NN p
were VBD N
alive JJ o
at IN N
the DT N
time NN N
of IN N
the DT N
analysis NN N
. . N

The DT N
patients NNS N
who WP N
received VBD N
combined JJ N
treatment NN N
had VBD N
fewer JJR N
local JJ o
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
fewer JJR N
distant NN o
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
recurrences NNS o
. . o

Severe NNP o
and CC o
life-threatening JJ o
side NN o
effects NNS o
occurred VBD N
in IN N
44 CD N
percent NN N
and CC N
20 CD N
percent NN N
, , N
respectively RB N
, , N
of IN N
the DT N
patients NNS N
who WP N
received VBD N
combined JJ N
therapy NN N
, , N
as IN N
compared VBN N
with IN N
25 CD N
percent NN N
and CC N
3 CD N
percent NN N
of IN N
those DT N
treated VBN N
with IN N
radiation NN N
alone RB N
. . N

CONCLUSIONS NNP N
Concurrent NNP i
therapy NN i
with IN i
cisplatin NN i
and CC i
fluorouracil NN i
and CC i
radiation NN i
is VBZ N
superior JJ N
to TO N
radiation VB i
therapy NN i
alone RB N
in IN N
patients NNS N
with IN N
localized JJ N
carcinoma NN N
of IN N
the DT N
esophagus NN N
, , N
as IN N
measured VBN N
by IN N
control NN N
of IN N
local JJ N
tumors NNS N
, , N
distant JJ N
metastases NNS N
, , N
and CC N
survival NN N
, , N
but CC N
at IN N
the DT N
cost NN N
of IN N
increased JJ N
side NN N
effects NNS N
. . N

-DOCSTART- -16731138- O O

Neurocognitive JJ o
outcomes NNS o
in IN N
off-pump JJ i
versus NN i
on-pump JJ i
bypass NN i
surgery NN i
: : i
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Cognitive NNP N
difficulties NNS N
have VBP N
been VBN N
reported VBN N
after IN p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
using VBG p
cardiopulmonary JJ i
bypass NN i
. . i

However RB N
, , N
the DT N
cognitive JJ N
benefit NN N
of IN N
off-pump JJ N
surgery NN N
remains VBZ N
unclear JJ N
. . N

METHODS NNP N
Consecutively RB p
listed VBD p
candidates NNS p
for IN p
elective JJ p
bypass NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
off-pump JJ i
or CC i
on-pump JJ i
techniques NNS i
( ( p
n JJ p
= NNP p
107 CD p
) ) p
. . N

A DT N
battery NN N
of IN N
11 CD N
standardized JJ N
neuropsychological JJ N
tests NNS N
was VBD N
administered VBN N
before IN N
surgery NN N
, , N
and CC N
again RB N
at IN N
2 CD N
and CC N
6 CD N
months NNS N
after IN N
surgery NN N
. . N

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
using VBG N
a DT N
range NN N
of IN N
statistical JJ N
procedures NNS N
, , N
including VBG N
growth NN o
modeling NN o
. . o

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
cognitive JJ o
test NN o
scores NNS o
between IN N
the DT N
off-pump JJ i
and CC N
on-pump JJ i
groups NNS N
using VBG N
t JJ N
tests NNS N
at IN N
any DT N
of IN N
the DT N
time NN N
points NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
off-pump JJ i
and CC N
on-pump JJ i
groups NNS N
in IN N
the DT N
incidence NN o
of IN o
cognitive JJ o
deficits NNS o
at IN N
2 CD N
months NNS N
or CC N
6 CD N
months NNS N
, , N
with IN N
the DT N
exception NN N
that WDT N
fewer JJR N
off-pump NN i
patients NNS N
showed VBD N
impairment JJ N
on IN N
one CD N
test NN N
of IN N
verbal JJ o
fluency NN o
at IN N
6 CD N
months NNS N
. . N

When WRB N
the DT N
pattern NN o
of IN o
cognitive JJ o
change NN o
over IN o
time NN o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
compared VBN N
using VBG N
sophisticated JJ N
modeling NN N
techniques NNS N
, , N
the DT N
two CD N
groups NNS N
were VBD N
again RB N
comparable JJ N
, , N
except IN N
for IN N
results NNS N
on IN N
the DT N
test NN N
of IN N
verbal JJ o
fluency NN o
, , N
in IN N
which WDT N
the DT N
off-pump NN i
group NN N
showed VBD N
more RBR N
rapid JJ N
postsurgical JJ N
cognitive NN o
gains NNS o
than IN N
the DT N
on-pump JJ i
group NN N
. . N

CONCLUSIONS VB N
The DT N
off-pump JJ i
group NN N
appears VBZ N
to TO N
be VB N
generally RB N
comparable JJ N
to TO N
the DT N
on-pump JJ i
group NN N
in IN N
terms NNS N
of IN N
short-term JJ N
and CC N
long-term JJ N
postsurgical JJ N
neurocognitive JJ N
outcomes NNS N
. . N

-DOCSTART- -25197765- O O

The DT N
Impact NNP N
of IN N
Pupillary NNP i
Dilation NNP i
on IN N
Intraocular NNP N
Pressure NNP N
and CC N
Anterior NNP N
Segment NNP N
Morphology NNP N
in IN N
Subjects NNP p
with IN p
and CC p
without IN p
Pseudoexfoliation NNP p
. . p

PURPOSE NNP N
To TO N
investigate VB N
the DT N
change NN N
in IN N
pre- JJ N
and CC N
post-dilation JJ N
anterior JJ N
segment NN N
parameters NNS N
and CC N
intraocular JJ N
pressure NN N
( ( N
IOP NNP N
) ) N
of IN N
patients NNS p
with IN p
and CC p
without IN p
pseudoexfoliation NN p
, , N
after IN N
topical JJ i
application NN i
of IN i
phenylephrine NN i
HCl NNP i
10 CD i
% NN i
and CC i
tropicamide VB i
1 CD i
% NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
Totally NNP p
129 CD p
eyes NNS p
of IN p
129 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Of IN p
the DT p
129 CD p
eyes NNS p
; : p
31 CD p
had VBD p
pseudoexfoliation NN p
syndrome NN p
( ( p
PXS NNP p
) ) p
, , p
37 CD p
had VBD p
pseudoexfoliation NN p
glaucoma NN p
( ( p
PXG NNP p
) ) p
, , p
31 CD p
eyes NNS p
were VBD p
the DT p
fellow JJ p
eyes NNS p
of IN p
subjects NNS p
with IN p
unilateral JJ p
pseudoexfoliation NN p
syndrome NN p
( ( p
subclinical JJ p
PXS NNP p
) ) p
and CC p
30 CD p
eyes NNS p
were VBD p
the DT p
eyes NNS p
of IN p
subjects NNS p
without IN p
PXS NNP p
( ( p
controls NNS p
) ) p
. . p

Patients NNPS p
underwent JJ N
Pentacam NNP N
analysis NN N
and CC N
IOP NNP N
measurement NN N
before IN N
and CC N
after IN N
dilation NN N
. . N

The DT N
changes NNS o
in IN o
IOP NNP o
, , o
anterior JJ o
chamber NN o
depth NN o
( ( o
ACD NNP o
) ) o
, , o
anterior JJ o
chamber NN o
volume NN o
( ( o
ACV NNP o
) ) o
, , o
anterior JJ o
chamber NN o
angle NN o
( ( o
ACA NNP o
) ) o
, , o
central JJ o
corneal NN o
thickness NN o
( ( o
CCT NNP o
) ) o
and CC o
pupillary JJ o
diameter NN o
( ( o
PD NNP o
) ) o
were VBD N
investigated VBN N
30 CD N
min NN N
after IN N
the DT N
application NN N
of IN N
mydriatic JJ i
agents NNS i
. . i

RESULTS VB N
The DT o
mean JJ o
change NN o
of IN o
IOP NNP o
in IN o
eyes NNS o
with IN o
PXS NNP N
, , N
in IN N
eyes NNS N
with IN N
PXG NNP N
, , N
in IN N
eyes NNS N
with IN N
subclinical JJ N
PXS NNP N
and CC N
eyes NNS N
of IN N
control NN N
subjects NNS N
were VBD N
1.45 CD N
? . N
2.03 CD N
mmhg NN N
, , N
0.27 CD N
? . N
2.25 CD N
mmhg NN N
, , N
-0.35 NNP N
? . N
1.58 CD N
mmHg NN N
and CC N
-1.06 VB N
? . N
1.59mmHg CD N
, , N
respectively RB o
. . o

Post-dilation NN o
IOP NNP o
values NNS o
were VBD o
lower JJR N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
in IN N
eyes NNS N
of IN N
controls NNS N
but CC N
higher JJR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
in IN N
eyes NNS N
of IN N
PXS NNP N
than IN N
the DT N
pre-dilation NN N
levels NNS N
. . N

All DT N
patients NNS N
exhibited VBN N
statistically RB N
significant JJ N
increase NN o
in IN o
ACD NNP o
, , o
ACV NNP o
and CC o
PD NNP o
after IN o
the DT o
dilation NN N
procedure NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Additionally RB N
, , N
post NN o
dilation NN o
CCT NNP o
values NNS o
were VBD N
significantly RB N
lower JJR N
than IN N
pre-dilation NN N
values NNS N
in IN N
all DT N
groups NNS N
; : N
the DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
only RB N
for IN N
eyes NNS N
with IN N
PXG NNP N
, , N
eyes NNS N
with IN N
subclinical JJ N
PXS NNP N
and CC N
eyes NNS N
of IN N
controls NNS N
. . N

CONCLUSION NNP N
Eyes NNP N
with IN N
PXS NNP N
had VBD N
a DT N
higher JJR N
tendency NN o
of IN o
IOP NNP o
elevation NN o
after IN N
pupillary JJ N
dilation NN N
. . N

Eyes NNS N
with IN N
subclinical JJ N
PXS NNP N
, , N
however RB N
, , N
exhibited VBD N
a DT N
minor JJ N
increase NN N
in IN N
IOP NNP N
, , N
reflecting VBG N
the DT N
asymmetrical JJ N
character NN N
of IN N
the DT N
disease NN N
. . N

Anti-glaucoma JJ i
medications NNS i
may MD N
have VB N
blunted VBN o
any DT o
IOP NNP o
elevation NN o
induced VBN N
by IN N
pupillary JJ N
dilation NN N
in IN N
eyes NNS N
with IN N
PXG NNP N
. . N

-DOCSTART- -23773380- O O

Does VBZ N
the DT N
result NN N
of IN N
completion NN i
axillary JJ i
lymph NN i
node NN i
dissection NN i
influence NN N
the DT N
recommendation NN N
for IN N
adjuvant JJ i
treatment NN i
in IN N
sentinel JJ p
lymph JJ p
node-positive JJ p
patients NNS p
? . N
OBJECTIVE IN N
The DT N
Hungarian NNP N
National NNP N
Institute NNP N
of IN N
Oncology NNP N
has VBZ N
just RB N
closed VBN N
a DT N
single-center JJ N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
Optimal NNP N
Treatment NNP N
of IN N
the DT N
Axilla-Surgery NNP N
or CC N
Radiotherapy NNP N
( ( N
OTOASOR NNP N
) ) N
trial NN N
compares VBZ N
completion NN i
axillary JJ i
lymph NN i
node NN i
dissection NN i
( ( i
cALND NN i
) ) i
with IN N
regional JJ i
nodal JJ i
irradiation NN i
( ( i
RNI NNP i
) ) i
in IN N
patients NNS p
with IN p
sentinel JJ p
lymph JJ p
node-positive JJ p
( ( p
SLN+ NNP p
) ) p
primary VBP p
invasive JJ p
breast NN p
cancer NN p
. . p

In IN N
the DT N
investigational JJ N
treatment NN N
arm NN N
, , N
patients NNS N
received VBD N
50 CD N
Gy NNP N
RNI NNP i
instead RB N
of IN N
cALND NN i
. . i

In IN N
these DT N
patients NNS N
we PRP N
had VBD N
information NN N
only RB N
about IN N
the DT N
sentinel NN N
lymph NN N
node NN N
( ( N
SLN NNP N
) ) N
status NN N
, , N
but CC N
the DT N
further JJ N
axillary JJ N
nodal JJ N
involvement NN N
remained VBD N
unknown JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
result NN N
of IN N
cALND NN i
influenced VBD N
the DT N
recommendation NN N
for IN N
adjuvant JJ N
treatment NN N
in IN N
patients NNS p
with IN p
SLN+ NNP p
breast NN p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
SLN+ NNP p
primary JJ p
breast NN p
cancer NN p
were VBD N
randomized VBN N
for IN N
cALND NN i
( ( N
arm NN N
A NNP N
, , N
standard JJ N
treatment NN N
) ) N
or CC N
RNI NNP N
( ( N
arm NN N
B NNP N
, , N
investigational JJ N
treatment NN N
) ) N
. . N

Adjuvant JJ N
systemic JJ N
treatments NNS N
were VBD N
given VBN N
according VBG N
to TO N
the DT N
standard JJ N
institutional JJ N
protocol NN N
, , N
and CC N
patients NNS N
were VBD N
followed VBN N
according VBG N
to TO N
the DT N
actual JJ N
institutional JJ N
guidelines NNS N
. . N

RESULTS NNP N
Between NNP N
August NNP N
2002 CD N
and CC N
June NNP N
2009 CD N
, , N
474 CD p
SLN+ NN p
patients NNS p
were VBD N
randomized VBN N
to TO N
cALND VB i
( ( N
arm NN N
A NNP N
, , N
standard JJ N
treatment NN N
= JJ N
244 CD N
patients NNS N
) ) N
or CC N
RNI NNP i
( ( N
arm NN N
B NNP N
, , N
investigational JJ N
treatment NN N
= VBD N
230 CD N
patients NNS N
) ) N
. . N

The DT N
2 CD N
arms NNS N
were VBD N
well RB N
balanced VBN N
according VBG N
to TO N
the DT N
majority NN N
of IN N
main JJ N
prognostic JJ N
factors NNS N
. . N

However RB N
, , N
more JJR N
patients NNS p
were VBD p
premenopausal JJ p
( ( p
34 CD p
% NN p
vs. FW p
27 CD p
% NN p
; : p
P NNP p
= NNP p
.095 NNP p
) ) p
and CC p
had VBD p
pT2-3 NN p
tumors NNS p
( ( N
57 CD N
% NN N
vs. FW N
40 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
in IN N
the DT N
completion NN N
axillary JJ N
lymph NN N
node NN N
dissection NN N
( ( N
ALND NNP N
) ) N
arm NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
there EX N
were VBD N
more JJR N
patients NNS p
with IN p
known JJ p
human JJ p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
type VBD p
2 CD p
positive JJ p
tumor NN p
( ( p
12 CD p
% NN p
vs. FW p
17 CD p
% NN p
, , p
P NNP p
= NNP p
.066 NNP p
) ) p
in IN N
the DT N
RNI NNP N
arm NN N
. . N

In IN N
the DT N
ALND NNP i
and CC N
RNI NNP i
arms NNS N
, , N
78 CD N
% NN N
( ( N
190/244 CD N
) ) N
and CC N
69 CD N
% NN N
( ( N
159/230 CD N
) ) N
, , N
respectively RB N
, , N
received VBD N
chemotherapy NN i
( ( N
P NNP N
= NNP N
.020 NNP N
) ) N
. . N

Endocrine NNP i
therapy NN i
was VBD N
administered VBN N
in IN N
87 CD N
% NN N
( ( N
213/244 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
ALND NNP N
arm NN N
and CC N
89 CD N
% NN N
( ( N
204/230 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
RNI NNP N
arm NN N
( ( N
P NNP N
= NNP N
.372 NNP N
) ) N
. . N

Six CD N
patients NNS N
( ( N
2.5 CD N
% NN N
) ) N
on IN N
arm NN N
A NN N
and CC N
13 CD N
patients NNS N
( ( N
5.7 CD N
% NN N
) ) N
on IN N
arm NN N
B NNP N
received VBD N
adjuvant JJ N
trastuzumab NN N
treatment NN N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

Subgroup NNP N
analyses VBZ N
explored VBD N
that IN N
more RBR N
frequent JJ N
administration NN N
of IN N
adjuvant JJ i
chemotherapy NN i
in IN N
arm NN N
A NN N
was VBD N
associated VBN N
with IN N
the DT N
higher JJR N
percentage NN N
of IN N
premenopausal NN p
patients NNS p
and CC p
patients NNS p
with IN p
larger JJR p
( ( p
pT2-3 NN p
) ) p
tumors NNS p
. . p

CONCLUSIONS VB N
The DT N
result NN N
of IN N
cALND NN i
after IN N
positive JJ N
SLN NNP N
biopsy NN N
seems VBZ N
to TO N
have VB N
no DT N
major JJ N
impact NN N
on IN N
the DT N
administration NN N
of IN N
adjuvant JJ i
systemic JJ i
therapy NN i
. . i

-DOCSTART- -17954768- O O

Lactoferrin NNP i
supplementation NN i
to TO N
Holstein NNP p
calves NNS p
during IN p
the DT p
preweaning NN p
and CC p
postweaning NN p
phases NNS p
. . p

Sixty NNP p
Holstein NNP p
calves VBZ p
( ( p
30 CD p
bulls NNS p
, , p
30 CD p
heifers NNS p
) ) p
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
supplemental JJ i
lactoferrin NN i
on IN N
feed NN o
intake NN o
, , o
growth NN o
, , o
and CC o
health NN o
during IN N
the DT N
preweaning NN N
and CC N
postweaning NN N
periods NNS N
. . N

One CD N
of IN N
3 CD N
levels NNS N
of IN N
lactoferrin NN i
was VBD N
supplemented VBN N
from IN N
3 CD N
to TO N
56 CD N
d NN N
in IN N
either DT N
whole JJ N
milk NN N
or CC N
water NN N
to TO N
produce VB N
3 CD N
dietary JJ N
treatments NNS N
: : N
1 CD N
) ) N
0 CD N
g/d NN N
, , N
2 CD N
) ) N
0.5 CD N
g/d NN N
, , N
and CC N
3 CD N
) ) N
1 CD N
g/d NN N
. . N

Whole JJ N
milk NN N
( ( N
3.8 CD N
L/d NNP N
) ) N
containing VBG N
lactoferrin JJ i
supplements NNS i
was VBD N
fed VBN N
from IN N
bottles NNS N
until IN N
weaning VBG N
at IN N
35 CD N
d. NN N
From NNP N
d VBZ N
36 CD N
to TO N
56 CD N
, , N
lactoferrin JJ i
supplements NNS i
were VBD N
added VBN N
to TO N
water NN N
( ( N
15 CD N
to TO N
25 CD N
mL NN N
) ) N
and CC N
fed VBN N
from IN N
bottles NNS N
. . N

Lactoferrin NNP i
supplementation NN i
had VBD N
no DT N
effect NN N
on IN N
feed NN o
intake NN o
, , o
body NN o
weight NN o
, , o
average JJ o
daily JJ o
gain NN o
, , o
heart NN o
girth NN o
, , o
body NN o
temperature NN o
, , o
fecal JJ o
scores NNS o
, , o
respiratory NN o
scores NNS o
, , o
or CC o
haptoglobin JJ o
concentrations NNS o
. . o

Calves NNS p
were VBD N
housed VBN N
in IN N
individual JJ N
pens NNS N
in IN N
either DT N
an DT N
open-sided JJ N
barn NN N
or CC N
hutches NNS N
. . N

Calves NNS p
raised VBD p
in IN p
the DT p
barn NN p
consumed VBD N
more JJR N
calf JJ N
starter NN N
and CC N
therefore RB N
grew VBD N
better JJR N
than IN N
calves NNS N
raised VBN N
in IN N
hutches NNS N
. . N

Under IN N
the DT N
conditions NNS N
of IN N
this DT N
study NN N
, , N
lactoferrin JJ i
supplementation NN i
was VBD N
not RB N
beneficial JJ N
. . N

Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
elucidate VB N
the DT N
role NN N
of IN N
lactoferrin NN i
, , N
and CC N
possible JJ N
benefits NNS N
during IN N
different JJ N
feeding VBG N
conditions NNS N
or CC N
milk NN N
sources NNS N
. . N

-DOCSTART- -19886920- O O

Sustained JJ N
effect NN N
of IN N
SQ-standardized NNP N
grass NN N
allergy NN N
immunotherapy NN i
tablet NN i
on IN N
rhinoconjunctivitis NN N
quality NN N
of IN N
life NN N
. . N

BACKGROUND IN N
The DT N
prevalence NN N
of IN N
allergic JJ N
rhinoconjunctivitis NN N
has VBZ N
increased VBN N
significantly RB N
over IN N
the DT N
past JJ N
decades NNS N
with IN N
grass NN N
pollen NN N
being VBG N
a DT N
common JJ N
trigger NN N
. . N

The DT N
impact NN N
of IN N
allergy NN N
on IN N
patient NN N
's POS N
quality NN N
of IN N
life NN N
is VBZ N
substantial JJ N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
sustained JJ N
effect NN N
on IN N
quality NN N
of IN N
life NN N
during IN N
the DT N
grass NN N
pollen NN N
season NN N
1 CD N
year NN N
after IN N
3 CD N
years NNS N
of IN N
treatment NN N
with IN N
the DT N
SQ-standardized JJ N
grass NN i
allergy NN i
immunotherapy NN i
tablet NN i
( ( i
AIT NNP i
) ) i
, , N
Graza NNP N
( ( N
Phleum NNP N
pratense VBZ N
75,000 CD N
SQ-T/2800 JJ N
BAU NNP N
; : N
ALK NNP N
, , N
Denmark NNP N
) ) N
. . N

METHODS PDT N
The DT N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
in IN N
adult NN p
subjects NNS p
with IN p
a DT p
history NN p
of IN p
moderate-severe JJ p
grass NN p
pollen NN p
induced VBD p
rhinoconjunctivitis NN p
inadequately RB p
controlled VBN p
by IN p
symptomatic JJ p
medications NNS p
. . p

Subjects NNS p
received VBD N
3 CD N
years NNS N
of IN N
grass NN i
AIT NNP i
( ( N
n JJ N
= NNP N
157 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
126 CD N
) ) N
, , N
followed VBN N
by IN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

Quality NN o
of IN o
life NN o
assessments NNS N
were VBD N
based VBN N
on IN N
the DT N
standardized JJ o
rhinoconjunctivitis NN o
quality NN o
of IN o
life NN o
questionnaire NN o
( ( o
RQLQ NNP o
( ( o
S NNP o
) ) o
) ) o
; : o
completed VBN N
weekly JJ N
during IN N
the DT N
entire JJ N
grass NN N
pollen NN N
season NN N
. . N

RESULTS NNP N
During IN N
follow-up JJ N
, , N
the DT N
overall JJ N
RQLQ NNP o
( ( o
S NNP o
) ) o
score NN o
for IN N
the DT N
entire JJ N
grass NN N
pollen NN N
season NN N
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
active JJ N
group NN N
( ( N
relative JJ N
difference NN N
to TO N
placebo VB i
: : i
23 CD N
% NN N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
improvement NN N
was VBD N
higher JJR N
during IN N
the DT N
peak NN N
pollen NN N
season NN N
( ( N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
treatment NN N
effect NN N
of IN N
grass NN N
AIT NNP N
during IN N
the DT N
follow-up JJ N
year NN N
and CC N
the DT N
previous JJ N
three CD N
treatment NN N
years NNS N
was VBD N
similar JJ N
. . N

Improvements NNS N
were VBD N
found VBN N
in IN N
all DT N
seven CD N
RQLQ NNP o
( ( o
S NNP o
) ) o
domains VBZ o
. . o

The DT N
RQLQ NNP o
( ( o
S NNP o
) ) o
as IN N
a DT N
function NN N
of IN N
the DT N
weekly JJ N
average NN N
pollen NN N
counts VBZ N
showed VBD N
a DT N
clear JJ N
separation NN N
between IN N
the DT N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
subjects NNS N
inadequately RB N
controlled VBN N
by IN N
symptomatic JJ N
medications NNS N
, , N
grass NN N
AIT NNP i
provided VBD N
sustained VBN N
and CC N
clinically RB N
relevant JJ N
improvements NNS N
in IN N
rhinoconjunctivitis NN o
quality NN o
of IN o
life NN o
compared VBN N
to TO N
placebo VB i
. . i

The DT N
effect NN N
increased VBD o
with IN N
increasing VBG N
grass NN N
pollen NN N
exposure NN N
. . N

-DOCSTART- -18333888- O O

The DT N
dipeptidyl JJ i
peptidase-4 JJ i
inhibitor NN i
PHX1149 NNP i
improves VBZ N
blood NN o
glucose NN o
control NN o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus RB p
. . p

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
PHX1149 NNP i
, , N
a DT N
novel JJ N
dipeptidyl NN N
peptidase-4 NN N
( ( N
DPP4 NNP N
) ) N
inhibitor NN N
, , N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

METHODS NNP N
This DT N
is VBZ N
a DT N
multicentre NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
4-week JJ N
study NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
with IN p
suboptimal JJ p
metabolic JJ p
control NN p
. . p

Patients NNS p
with IN p
a DT p
baseline NN p
haemoglobin NN p
A NNP p
( ( p
1c CD p
) ) p
( ( p
HbA NNP p
( ( p
1c CD p
) ) p
) ) p
of IN p
7.3 CD p
to TO p
11.0 CD p
% NN p
were VBD N
randomized VBN N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
to TO N
receive VB N
once-daily JJ N
oral JJ N
therapy NN N
with IN N
either DT N
PHX1149 NNP i
( ( i
100 CD i
, , i
200 CD i
or CC i
400 CD i
mg NN i
) ) i
or CC i
placebo NN i
; : i
patients NNS N
were VBD N
on IN N
a DT N
constant JJ N
background NN N
therapy NN N
of IN N
either DT N
metformin NN N
alone RB N
or CC N
metformin JJ N
plus CC N
a DT N
glitazone NN N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
of IN N
PHX1149 NNP N
significantly RB N
decreased VBD N
postprandial JJ o
glucose JJ o
area NN o
under IN o
the DT o
curve NN o
AUC NNP o
( ( o
0-2 JJ o
h NN N
) ) N
by IN N
approximately RB N
20 CD N
% NN N
( ( N
+0.11 JJ N
+/- JJ N
0.50 CD N
, , N
-2.08 VBD N
+/- JJ N
0.51 CD N
, , N
-1.73 VBD N
+/- JJ N
0.49 CD N
and CC N
-1.88 VB N
+/- JJ N
0.48 CD N
mmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.002 CD N
, , N
0.008 CD N
and CC N
0.004 CD N
vs. FW N
placebo NN N
) ) N
. . N

Postprandial JJ o
AUC NNP o
( ( o
0-2 JJ o
h NN o
) ) o
of IN o
intact JJ o
glucagon-like JJ o
peptide-1 NN o
, , N
the DT N
principal JJ N
mediator NN N
of IN N
the DT N
biological JJ N
effects NNS N
of IN N
DPP4 NNP N
inhibitors NNS N
, , N
was VBD N
increased VBN N
by IN N
3.90 CD N
+/- JJ N
2.83 CD N
, , N
11.63 CD N
+/- JJ N
2.86 CD N
, , N
16.42 CD N
+/- JJ N
2.72 CD N
and CC N
15.75 CD N
+/- JJ N
2.71 CD N
pmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.053 CD N
, , N
0.001 CD N
and CC N
0.002 CD N
vs. FW N
placebo NN N
) ) N
. . N

Mean JJ o
HbA NNP o
( ( o
1c CD o
) ) o
was VBD N
lower JJR N
in IN N
all DT N
dose JJ N
groups NNS N
; : N
the DT N
placebo-corrected JJ N
change NN N
in IN N
the DT N
groups NNS N
receiving VBG N
400 CD N
mg JJ N
PHX1149 NNP N
was VBD N
-0.28 VBN N
% NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

DPP4 NNP o
inhibition NN o
on IN N
day NN N
28 CD N
was VBD N
53 CD N
, , N
73 CD N
and CC N
78 CD N
% NN N
at IN N
24 CD N
h NN N
postdose NN N
in IN N
the DT N
groups NNS N
receiving VBG N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
PHX1149 NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
adverse JJ o
events NNS o
between IN N
PHX1149-treated NNP N
and CC N
placebo JJ N
subjects NNS N
. . N

CONCLUSIONS NNP N
Addition NNP N
of IN N
the DT N
DPP4 NNP N
inhibitor NN N
PHX1149 NNP N
to TO N
a DT N
stable JJ N
regimen NN N
of IN N
metformin NN N
or CC N
metformin NN N
plus CC N
a DT N
glitazone NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
was VBD N
well RB o
tolerated VBN o
and CC N
improved VBN o
blood NN o
glucose NN o
control NN o
. . o

-DOCSTART- -8034784- O O

Effectiveness NN N
of IN N
a DT N
calculus NN i
scaling VBG i
gel NN i
. . i

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
a DT N
calculus NN i
scaling VBG i
gel NN i
( ( i
SofScale NNP i
) ) i
on IN N
time NN o
and CC o
ease NN o
of IN o
the DT o
scaling NN o
procedure NN o
in IN N
a DT N
double-blind JJ N
, , N
split-mouth JJ N
clinical JJ N
study NN N
of IN N
32 CD p
subjects NNS p
. . p

The DT N
Volpe-Manhold JJ o
calculus NN o
index NN o
was VBD N
used VBN N
to TO N
quantify VB N
the DT N
distribution NN N
and CC N
amount NN N
of IN N
calculus JJ N
deposition NN N
on IN N
the DT N
lingual JJ N
aspect NN N
of IN N
the DT N
mandibular JJ N
6 CD N
anterior JJ N
teeth NNS N
at IN N
baseline NN N
. . N

The DT N
gel NN i
was VBD i
applied VBN i
directly RB i
to TO i
the DT i
calculus NN i
and CC i
subgingivally RB i
to TO i
the DT i
area NN i
to TO i
be VB i
scaled VBN i
. . i

Pre- JJ i
and CC i
post-treatment JJ i
gingival NN i
and CC i
stain NN i
indices NNS i
were VBD i
taken VBN i
. . i

Operator NNP o
and CC o
subject JJ o
questionnaires NNS o
were VBD N
completed VBN N
immediately RB N
after IN N
treatment NN N
to TO N
determine VB N
ease NN N
of IN N
the DT N
scaling JJ o
procedure NN N
. . N

Results NNS N
were VBD N
analyzed VBN N
with IN N
paired JJ N
t-tests NNS N
. . N

The DT N
time NN o
difference NN o
in IN o
scaling VBG o
between IN N
the DT N
product NN N
and CC N
placebo JJ N
side NN N
was VBD N
not RB N
significant JJ N
. . N

This DT N
study NN N
found VBD N
that IN N
SofScale NNP i
is VBZ N
safe JJ N
to TO N
gingival VB o
tissues NNS o
and CC N
does VBZ N
not RB N
promote VB N
tooth JJ o
sensitivity NN o
. . o

However RB N
, , N
this DT N
study NN N
did VBD N
not RB N
find VB N
significant JJ N
differences NNS N
in IN N
scaling VBG N
time NN N
between IN N
product NN N
and CC N
placebo NN i
when WRB N
using VBG N
a DT N
2-minute JJ N
gel NN N
contact NN N
time NN N
. . N

-DOCSTART- -7598920- O O

Hemodynamic JJ N
effects NNS N
during IN N
induction NN N
, , N
laryngoscopy NN N
, , N
and CC N
intubation NN N
with IN N
eltanolone NN i
( ( i
5 CD i
beta-pregnanolone NN i
) ) i
or CC N
propofol NN i
. . i

A DT N
study NN N
in IN N
ASA NNP p
I PRP p
and CC p
II NNP p
patients NNS p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
cardiovascular JJ N
changes NNS N
following VBG N
induction NN N
of IN N
anesthesia NN N
, , N
laryngoscopy NN N
, , N
and CC N
intubation NN N
in IN N
patients NNS p
receiving VBG p
a DT p
bolus NN p
dose NN p
of IN p
either CC p
eltanolone NN i
or CC p
propofol NN i
. . i

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
, , N
blind NN N
, , N
prospective JJ N
clinical JJ N
study NN N
. . N

SETTING NNP N
General NNP N
operating VBG N
theaters NNS N
of IN N
a DT N
university NN N
hospital NN N
. . N

PATIENTS CC N
40 CD p
ASA NNP p
status NN p
I PRP p
and CC p
II NNP p
patients NNS p
scheduled VBN p
for IN p
elective JJ p
surgery NN p
. . p

INTERVENTIONS JJ N
Patients NNPS p
were VBD p
premedicated VBN i
with IN i
oral JJ i
temazepam NN i
20 CD i
mg. NN i
Anesthesia NNP i
was VBD N
induced VBN N
with IN N
either DT N
eltanolone NN i
0.58 CD i
mg/kg NN i
or CC i
propofol VB i
1.7 CD i
mg/kg NN i
, , i
neuromuscular JJ i
blockade NN i
was VBD i
achieved VBN i
with IN i
vecuronium NN i
0.1 CD i
mg/kg NN i
, , i
and CC i
anesthesia NN i
was VBD i
maintained VBN i
with IN i
enflurane JJ i
0.5 CD i
% NN i
to TO i
1.0 CD i
% NN i
in IN i
nitrous JJ i
oxide NN i
( ( i
67 CD i
% NN i
) ) i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Blood NNP o
pressure NN o
was VBD N
measured VBN N
using VBG N
an DT N
automatic JJ o
oscillometric NN o
technique NN o
, , o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
was VBD N
derived VBN N
from IN N
the DT N
ECG NNP N
, , N
oxygen NN o
saturation NN o
was VBD N
measured VBN N
by IN N
pulse JJ N
oximetry NN N
, , N
and CC N
cardiac JJ o
output NN o
( ( o
Q NNP o
) ) o
was VBD N
measured VBN N
by IN N
a DT N
thoracic JJ N
bioimpedance NN N
technique NN N
. . N

Induction NN N
of IN N
anesthesia NN N
with IN N
either DT N
drug NN N
, , N
eltanolone NN i
or CC i
propofol NN i
, , N
decreased VBN N
arterial JJ o
systolic NN o
( ( o
SAP NNP o
) ) o
and CC o
diastolic JJ o
( ( o
DAP NNP o
) ) o
blood NN o
pressure NN o
, , o
Q NNP o
, , o
and CC o
stroke NN o
volume NN o
( ( o
SV NNP o
) ) o
. . o

HR NNP o
increased VBD N
. . N

Systemic NNP o
vascular JJ o
resistance NN o
( ( o
SVR NNP o
) ) o
was VBD N
unaltered VBN N
. . N

After IN N
laryngoscopy NN N
and CC N
intubation NN N
, , N
SAP NNP o
and CC o
DAP NNP o
increased VBD N
secondary JJ N
to TO N
an DT N
increase NN N
in IN N
SVR NNP o
. . o

HR NNP o
also RB N
increased VBD N
; : N
SV NNP o
decreased VBD N
in IN N
patients NNS N
receiving VBG N
eltanolone NN N
. . N

Side JJ N
effects NNS N
( ( N
e.g. NN N
, , N
apnea NN o
occurring VBG o
for IN o
more JJR o
than IN o
30 CD o
seconds NNS o
, , o
involuntary JJ o
movements NNS o
, , o
limb FW o
hypertonus NN o
) ) o
occurred VBD N
at IN N
a DT N
similar JJ N
incidence NN N
with IN N
both DT N
treatments NNS N
, , N
but CC N
pain VBP N
following VBG N
injection NN N
was VBD N
greater JJR N
with IN N
propofol NN N
( ( N
59 CD N
% NN N
vs. FW N
9 CD N
% NN N
) ) N
. . N

CONCLUSIONS JJ N
Patients NNPS p
receiving VBG p
either CC p
eltanolone NN i
or CC i
propofol NN i
showed VBD N
similar JJ N
cardiovascular JJ N
changes NNS N
to TO N
induction NN N
of IN N
anesthesia NN N
, , N
although IN N
there EX N
were VBD N
greater JJR N
increases NNS N
in IN N
arterial JJ N
pressure NN N
and CC N
HR NNP N
in IN N
those DT N
patients NNS p
receiving VBG p
eltanolone NN i
. . i

-DOCSTART- -21600592- O O

Standardized NNP N
preoperative JJ N
corticosteroid NN i
treatment NN N
in IN N
neonates NNS p
undergoing VBG p
cardiac JJ p
surgery NN p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE CC N
A DT N
heightened JJ N
inflammatory NN N
response NN N
occurs VBZ N
after IN N
cardiac JJ N
surgery NN N
. . N

The DT N
perioperative JJ N
use NN N
of IN N
glucocorticoids NNS N
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
method NN N
to TO N
improve VB N
postoperative JJ N
outcomes NNS N
. . N

Randomized VBN N
prospective JJ N
studies NNS N
to TO N
quantify VB N
the DT N
effect NN N
of IN N
methylprednisolone NN i
on IN N
perioperative JJ N
outcomes NNS N
in IN N
neonatal JJ p
cardiac NN p
surgery NN p
have VBP N
not RB N
been VBN N
performed VBN N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
preoperative JJ N
methylprednisolone NN N
would MD N
improve VB N
postoperative JJ N
recovery NN N
in IN N
neonates NNS N
requiring VBG N
cardiac JJ N
surgery NN N
. . N

METHODS NNP N
Neonates NNP p
scheduled VBD p
for IN p
cardiac JJ p
surgery NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
either DT N
2-dose JJ N
( ( N
8 CD N
hours NNS N
preoperatively RB N
and CC N
operatively RB N
, , N
n JJ p
= NNP p
39 CD p
) ) p
or CC p
single-dose JJ N
( ( N
operatively RB p
, , p
n JJ p
= NNP i
37 CD i
) ) i
methylprednisolone NN i
( ( i
30 CD i
mg/kg NN N
per IN N
dose NN N
) ) N
in IN N
a DT N
prospective JJ N
double-blind JJ N
trial NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
incidence NN o
of IN o
low JJ o
cardiac JJ o
output NN o
syndrome NN o
( ( o
standardized VBN o
score NN N
) ) N
or CC N
death NN N
36 CD N
hours NNS N
postoperatively RB N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
death NN o
at IN o
30 CD o
days NNS o
, , o
interleukin-6 JJ o
levels NNS o
, , o
inotropic NN o
score NN o
, , o
fluid NN o
balance NN o
, , o
serum JJ o
creatinine NN o
, , o
and CC o
intensive JJ o
care NN o
unit NN o
and CC o
hospital NN o
stay NN o
. . o

RESULTS NNP o
Preoperative NNP o
plasma NN o
levels NNS o
of IN o
the DT N
inflammatory JJ o
cytokine JJ o
interleukin-6 NN o
were VBD o
reduced VBN N
by IN N
2-fold JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
2-dose JJ N
methylprednisolone NN N
group NN N
, , N
consistent NN N
with IN N
the DT N
anti-inflammatory JJ N
effects NNS N
of IN N
methylprednisolone NN N
. . N

However RB N
, , N
the DT N
incidence NN o
of IN o
low JJ o
cardiac JJ o
output NN o
syndrome NN o
was VBD o
46 CD o
% NN N
( ( N
17/37 CD N
) ) N
in IN N
the DT N
single-dose JJ N
and CC N
38 CD N
% NN N
( ( N
15/39 CD N
) ) N
in IN N
the DT N
2-dose JJ N
methylprednisolone NN N
groups NNS N
( ( N
P NNP N
= NNP N
.51 NNP N
) ) N
. . N

Two-dose JJ N
methylprednisolone NN N
was VBD N
associated VBN o
with IN o
a DT o
higher JJR o
serum NN o
creatinine NN o
( ( o
0.61 CD o
? . o
0.18 CD N
mg/dL NN N
vs NN N
0.53 CD N
? . N
0.12 CD N
mg/dL NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC o
poorer $ o
postoperative JJ o
diuresis NN o
( ( o
-96 VB o
? . N
49 CD N
mL NN N
, , N
P NNP N
= NNP N
.05 NNP N
) ) N
. . N

Inotropic NNP o
requirement NN o
, , o
duration NN o
of IN o
mechanical JJ o
ventilation NN o
, , o
intensive JJ o
care NN o
unit NN o
, , o
and CC o
hospital JJ o
stay NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Combined NNP N
preoperative NN N
and CC N
intraoperative JJ N
use NN N
of IN N
glucocorticoids NNS N
in IN N
neonatal JJ N
cardiac JJ N
surgery NN N
does VBZ N
not RB N
favorably RB N
affect VBP N
early JJ N
clinical JJ N
outcomes NNS N
and CC N
may MD N
exacerbate VB N
perioperative JJ N
renal JJ N
dysfunction NN N
. . N

-DOCSTART- -17617281- O O

Codeine/acetaminophen NNP i
and CC N
hydrocodone/acetaminophen JJ i
combination NN i
tablets NNS N
for IN N
the DT N
management NN N
of IN N
chronic JJ o
cancer NN o
pain NN o
in IN p
adults NNS p
: : p
a DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
. . N

BACKGROUND NNP N
Analgesics NNPS N
are VBP N
an DT N
essential JJ N
component NN N
of IN N
the DT N
treatment NN N
of IN N
cancer-associated JJ N
pain NN N
. . N

Pharmacologic NNP N
treatment NN N
is VBZ N
usually RB N
begun VBN N
with IN N
nonopioid JJ N
analgesics NNS N
, , N
most JJS N
frequently RB N
acetaminophen VBP i
. . i

If IN N
pain JJ o
relief NN o
is VBZ N
not RB N
achieved VBN N
, , N
the DT N
so-called JJ N
weak JJ N
opioids NNS N
, , N
such JJ N
as IN N
codeine NN i
and CC i
hydrocodone NN i
, , N
may MD N
be VB N
used VBN N
in IN i
combination NN i
with IN i
acetaminophen NN i
. . i

Adverse JJ N
effects NNS N
( ( N
AEs NNP N
) ) N
of IN N
the DT N
opioids NNS N
include VBP N
constipation NN N
, , N
somnolence NN N
, , N
nausea NN N
, , N
and CC N
vomiting VBG N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
literature NN N
search NN N
, , N
data NNS N
comparing VBG N
the DT N
effects NNS N
of IN N
the DT N
opioids NNS N
are VBP N
lacking VBG N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
analgesic JJ o
efficacy NN o
and CC o
tolerability NN o
of IN N
codeine NN i
phosphate NN i
versus IN i
hydrocodone NN i
bitartrate NN i
in IN N
combination NN N
with IN N
acetaminophen NN i
in IN N
the DT N
relief NN N
of IN N
cancer-related JJ N
pain NN N
. . N

METHODS NNP N
This DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
at IN N
3 CD N
Colombian JJ N
centers NNS N
: : N
University NNP N
Libre NNP N
, , N
Social NNP N
Security NNP N
Institute NNP N
, , N
and CC N
General NNP N
Hospital NNP N
of IN N
Medell?n NNP N
, , N
Cali NNP N
, , N
Colombia NNP N
. . N

Outpatients NNS p
with IN p
cancer NN p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
if IN p
they PRP p
were VBD p
aged VBN p
> JJ p
-18 CD p
years NNS p
and CC p
had VBD p
chronic VBN p
( ( p
duration NN p
, , p
> NNP p
/= VBZ p
3 CD p
months NNS p
) ) p
moderate VBP p
to TO p
severe VB p
cancer-related JJ p
pain NN p
( ( p
score NN p
on IN p
10-cm JJ p
visual JJ p
analog NN p
scale NN p
[ NNP p
VAS NNP p
] NNP p
, , p
> VBD p
3 CD p
cm NN p
[ NN p
moderate JJ p
] NN p
; : p
score NN p
on IN p
a DT p
4-point JJ p
verbal JJ p
pain-intensity NN p
scale NN p
, , p
> VBZ p
1 CD p
[ NN p
moderate JJ p
] NN p
) ) p
. . p

Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
tablet NN N
of IN i
codeine/acetaminophen NN i
( ( i
C/A NNP i
) ) i
30/500 CD N
mg NN N
or CC i
hydrocodone/acetaminophen NN i
( ( i
H/A NNP i
) ) i
5/500 CD N
mg NN N
PO NNP N
q4h NN N
( ( N
total JJ N
daily JJ N
doses NNS N
, , N
150/2500 CD N
and CC N
25/2500 CD N
mg NN N
, , N
respectively RB N
) ) N
for IN N
23 CD N
days NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
if IN o
pain JJ o
intensity NN o
was VBD N
rated VBN N
as IN N
> JJ N
3 CD N
on IN N
the DT N
VAS NNP N
at IN N
week NN N
1 CD N
or CC N
2 CD N
, , N
the DT N
dosage NN N
was VBD N
doubled VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT o
proportion NN o
of IN o
patients NNS o
who WP o
achieved VBD o
pain NN o
relief NN o
( ( N
defined VBN N
as IN N
a DT N
score NN N
of IN N
> $ N
1 CD N
on IN N
a DT N
5-point JJ N
verbal NN N
rating NN N
scale NN N
[ NNP N
VRS NNP N
] NNP N
( ( N
0 CD N
= NNP N
none NN N
; : N
1 CD N
= IN N
a DT N
little JJ N
; : N
2 CD N
= IN N
some DT N
; : N
3 CD N
= IN N
a DT N
lot NN N
; : N
and CC N
4 CD N
= NNP N
complete JJ N
) ) N
on IN N
study NN N
days NNS N
1 CD N
and CC N
2 CD N
and CC N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

The DT N
secondary JJ N
end NN N
point NN N
was VBD N
the DT o
proportion NN o
of IN o
patients NNS o
in IN o
whom WP o
pain NN o
was VBD o
decreased VBN o
( ( N
VAS NNP N
score RB N
, , N
< NNP N
- : N
3 CD N
cm NN N
) ) N
. . N

AEs $ N
were VBD N
self-reported VBN N
on IN N
a DT N
4-point JJ N
VRS NNP N
( ( N
0 CD N
= NNP N
absent NN N
; : N
1 CD N
= NNP N
mild NN N
; : N
2 CD N
= NN N
moderate NN N
; : N
and CC N
3 CD N
= NNP N
severe RB N
) ) N
. . N

RESULTS NNP N
Of IN N
the DT p
121 CD p
patients NNS p
who WP p
participated VBD p
, , p
59 CD N
received VBD i
C/A NNP i
and CC N
62 CD N
received VBD i
H/A NNP i
. . i

Of IN p
the DT o
total JJ o
number NN o
of IN o
cases NNS o
, , o
59 CD p
% NN p
were VBD p
aged VBN p
60 CD p
to TO p
89 CD p
years NNS p
, , p
and CC p
55 CD p
% NN p
were VBD p
men NNS p
. . p

At IN N
baseline NN N
, , N
88 CD N
% NN N
of IN N
the DT N
patients NNS N
described VBD N
their PRP$ o
pain NN o
intensity NN o
as IN N
moderate JJ N
; : N
12 CD N
% NN N
, , N
severe JJ N
. . N

Of IN N
the DT N
patients NNS N
who WP N
received VBD i
C/A NNP i
, , i
58 CD N
% NN N
responded VBD N
to TO N
the DT N
initial JJ N
dosage NN N
of IN N
150/2500 CD N
mg/d NN N
, , N
and CC N
8 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
34 CD N
% NN N
did VBD N
not RB N
experience VB o
pain NN o
relief NN o
. . o

In IN N
patients NNS N
with IN i
H/A NNP i
, , i
pain NN o
was VBD N
reported VBN N
as IN N
absent NN N
or CC N
mild NN N
in IN N
56 CD N
% NN N
of IN N
patients NNS N
at IN N
the DT N
starting VBG N
dosage NN N
of IN N
25/2500 CD N
mg/d NN N
; : N
an DT N
additional JJ N
15 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
the DT N
remaining VBG N
29 CD N
% NN N
of IN N
patients NNS N
did VBD N
not RB N
experience VB N
any DT o
pain NN o
relief NN o
. . o

None NN N
of IN N
the DT N
between-group JJ N
differences NNS N
in IN N
response NN N
rates NNS N
were VBD N
significant JJ N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
in IN N
the DT i
C/A NNP i
and CC i
H/A NNP i
groups NNS N
were VBD o
constipation NN o
( ( N
36 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
dizziness NN o
( ( N
24 CD N
% NN N
and CC N
19 CD N
% NN N
) ) N
, , N
vomiting VBG o
( ( N
24 CD N
% NN N
and CC N
16 CD N
% NN N
) ) N
, , N
and CC o
dry JJ o
mouth NN o
( ( N
15 CD N
% NN N
and CC N
18 CD N
% NN N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
efficacy NN o
and CC o
tolerability NN o
were VBD N
comparable JJ N
between IN i
C/A NNP i
and CC i
H/A NNP i
over IN N
23 CD N
days NNS N
of IN N
treatment NN N
in IN N
these DT p
patients NNS p
with IN p
moderate JJ p
or CC p
severe JJ p
, , p
chronic JJ o
, , o
cancer-related JJ o
pain NN o
. . o

-DOCSTART- -22696144- O O

The DT N
effect NN N
of IN N
magnesium NN i
added VBN N
to TO N
levobupivacaine VB i
for IN N
femoral JJ N
nerve NN N
block NN N
on IN N
postoperative JJ N
analgesia NN N
in IN N
patients NNS p
undergoing VBG p
ACL NNP p
reconstruction NN p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomised VBD N
double-blind NN N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
magnesium NN i
added VBN N
to TO N
local JJ N
anaesthetics NNS N
on IN N
postoperative JJ N
VAS NNP N
scores NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
time NN N
to TO N
first JJ N
mobilisation NN N
, , N
patient JJ N
satisfaction NN N
and CC N
rescue NN N
analgesic JJ N
requirements NNS N
in IN N
arthroscopic JJ N
ACL NNP N
reconstruction NN N
surgery NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
107 CD p
American JJ p
Society NNP p
of IN p
Anaesthesiologists NNP p
physical JJ p
status NN p
grade NN p
I PRP p
and CC p
II NNP p
patients NNS p
between IN p
18 CD p
and CC p
65 CD p
years NNS p
of IN p
age NN p
who WP p
were VBD p
scheduled VBN p
to TO p
undergo VB p
elective JJ p
anterior JJ p
crucial JJ p
ligament NN p
( ( p
ACL NNP p
) ) p
reconstruction NN p
with IN p
hamstring VBG p
autografts NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
Groups NNP N
L NNP N
( ( N
n JJ N
= NNP N
51 CD N
) ) N
and CC N
LM NNP N
( ( N
n JJ N
= NNP N
56 CD N
) ) N
using VBG N
the DT N
closed-envelope NN N
method NN N
. . N

Group NNP N
LM NNP N
was VBD N
administered VBN N
19 CD N
ml NN N
of IN N
0.25 CD i
% NN i
levobupivacaine NN i
and CC i
1 CD i
ml NN i
of IN i
15 CD i
% NN i
magnesium NN i
sulphate NN i
, , N
while IN N
Group NNP i
L NNP i
was VBD i
administered VBN i
20 CD i
ml NN i
of IN i
0.25 CD i
% NN i
levobupivacaine NN i
for IN N
femoral JJ N
blockade NN N
. . N

General NNP N
anaesthesia NN N
was VBD N
administered VBN N
using VBG N
laryngeal JJ N
airway RB N
masks NNS N
following VBG N
neural JJ N
blockade NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
heart NN o
rate NN o
and CC o
mean VB o
arterial JJ o
pressure NN o
, , o
oxygen NN o
saturation NN o
, , o
visual JJ o
analogue NN o
score NN o
( ( o
VAS NNP o
) ) o
, , o
verbal JJ o
rating NN o
scale NN o
( ( o
VRS NNP o
) ) o
, , o
rescue NN o
analgesic JJ o
requirements NNS o
, , o
total JJ o
opioid JJ o
consumption NN o
, , N
side NN N
effects NNS N
and CC N
time NN N
to TO N
first JJ N
mobilisation NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
4th CD N
, , N
6th CD N
, , N
12th CD N
and CC N
24th CD N
hours NNS N
postoperatively RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
demographic JJ o
data NNS o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
heart NN o
rate NN o
or CC o
oxygen NN o
saturation NN o
between IN N
groups NNS N
. . N

The DT N
area NN o
under IN o
the DT o
curve NN o
VAS NNP o
and CC o
VRS NNP o
scores NNS o
were VBD N
lower JJR N
at IN N
4 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NN N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.001 CD N
, , N
p NN N
= VBD N
0.016 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
rescue NN o
analgesic JJ o
requirement NN o
and CC o
the DT o
total JJ o
opioid JJ o
consumption NN o
were VBD N
significantly RB N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.015 CD N
, , N
p NN N
= VBD N
0.019 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
time NN o
to TO o
first JJ o
mobilisation NN o
and CC o
the DT o
Likert NNP o
score NN o
( ( N
completely RB N
comfortable JJ N
; : N
quite RB N
comfortable JJ N
; : N
slight JJ N
discomfort NN N
; : N
painful JJ N
; : N
very RB N
painful JJ N
) ) N
were VBD N
higher JJR N
, , N
and CC N
the DT N
block NN o
onset VBD o
time NN o
was VBD N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.014 CD N
and CC N
p VB N
= JJ N
0.012 CD N
, , N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
terms NNS N
of IN N
side NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
magnesium NN i
to TO N
levobupivacaine VB N
prolongs NNS N
the DT N
sensory NN N
and CC N
motor NN N
block NN N
duration NN N
without IN N
increasing VBG N
side NN N
effects NNS N
, , N
enhances VBZ N
the DT N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
and CC N
increases VBZ N
patient JJ N
satisfaction NN N
; : N
however RB N
, , N
the DT N
addition NN N
of IN N
magnesium NN N
delays VBZ N
the DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
decreases VBZ N
rescue NN N
analgesic JJ N
requirements NNS N
. . N

-DOCSTART- -8787889- O O

Serum NNP o
bactericidal NN o
activities NNS o
and CC o
comparative JJ o
pharmacokinetics NNS o
of IN N
meropenem NN N
and CC N
imipenem-cilastatin NN N
. . N

The DT N
pharmacokinetics NNS o
and CC o
serum NN o
bactericidal NN o
activities NNS o
( ( o
SBAs NNP o
) ) o
of IN N
imipenem NN i
and CC N
meropenem NN i
were VBD N
investigated VBN N
in IN N
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

Twelve NNP p
healthy JJ p
male NN p
volunteers NNS p
received VBD N
a DT N
constant JJ i
30-min JJ i
infusion NN i
of IN i
either CC i
1 CD i
g NN i
of IN i
imipenem JJ i
plus CC i
1 CD i
g NN i
of IN i
cilastatin NN i
or CC i
1 CD i
g NN i
of IN i
meropenem NN i
. . i

The DT N
concentrations NNS o
of IN o
the DT o
drugs NNS o
in IN o
serum NN o
and CC o
urine NN o
were VBD N
determined VBN i
by IN i
bioassay NN o
and CC o
high-pressure NN o
liquid NN o
chromatography NN o
. . o

Pharmacokinetic JJ N
parameters NNS N
were VBD N
based VBN N
on IN N
an DT N
open JJ N
two-compartment JJ i
model NN i
and CC i
a DT i
noncompartmental JJ i
technique NN i
. . i

At IN N
the DT N
end NN N
of IN N
infusion NN N
, , N
the DT N
mean JJ o
concentrations NNS o
of IN o
imipenem NN o
and CC o
meropenem NN o
measured VBN o
in IN o
serum NN o
were VBD N
61.2 CD N
+/- JJ N
9.8 CD N
and CC N
51.6 CD N
+/- JJ N
6.5 CD N
mg/liter NN N
, , N
respectively RB N
; : N
urinary JJ o
recoveries NNS o
were VBD N
48.6 CD N
% NN N
+/- JJ N
8.2 CD N
% NN N
and CC N
60.0 CD N
% NN N
+/- JJ N
6.5 CD N
% NN N
of IN N
the DT N
dose NN N
in IN N
12 CD N
h NN N
, , N
respectively RB N
; : N
and CC N
the DT N
areas NNS o
under IN o
the DT o
concentration-time JJ o
curve NN o
from IN N
time NN N
zero CD N
to TO N
infinity NN N
were VBD N
96.1 CD N
+/- JJ N
14.4 CD N
and CC N
70.5 CD N
+/- JJ N
10.3 CD N
mg.h/liter NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.02 CD N
) ) N
. . N

Imipenem NNP N
had VBD N
a DT N
mean JJ N
half-life NN N
of IN N
66.7 CD N
+/- JJ N
10.4 CD N
min NN N
; : N
that IN N
of IN N
meropenem NN N
was VBD N
64.4 CD N
+/- JJ N
6.9 CD N
min NN N
. . N

The DT N
volumes NNS N
of IN N
distribution NN N
at IN N
steady JJ N
state NN N
of IN N
imipenem NN N
and CC N
meropenem NN N
were VBD N
15.3 CD N
+/- JJ N
3.3 CD N
and CC N
18.6 CD N
+/- JJ N
3.0 CD N
liters/70 NN N
kg NN N
, , N
respectively RB N
, , N
and CC N
the DT N
mean JJ N
renal JJ N
clearances NNS N
per IN N
1.73 CD N
m2 NNS N
were VBD N
85.6 CD N
+/- JJ N
17.6 CD N
and CC N
144.6 CD N
+/- JJ N
26.0 CD N
ml/min NN N
, , N
respectively RB N
. . N

Both DT p
antibiotics NNS p
were VBD p
well RB p
tolerated VBN p
in IN p
this DT p
single-dose JJ p
administration NN p
study NN p
. . p

The DT N
SBAs NNP o
were VBD N
measured VBN N
by IN N
the DT N
microdilution NN o
method NN o
of IN o
Reller NNP o
and CC o
Stratton NNP o
( ( N
L. NNP N
B. NNP N
Reller NNP N
and CC N
C. NNP N
W. NNP N
Stratton NNP N
, , N
J. NNP N
Infect NNP N
. . N

Dis NNP N
. . N

136:196-204 CD N
, , N
1977 CD N
) ) N
against IN N
40 CD N
clinically RB N
isolated JJ N
strains NNS N
. . N

Mean NNP o
reciprocal JJ o
bactericidal NN o
titers NNS o
were VBD N
measured VBN N
1 CD N
and CC N
6 CD N
h NN N
after IN N
administration NN N
. . N

After IN N
1 CD N
and CC N
6 CD N
h NN N
the DT N
median JJ N
SBAs NNP o
for IN N
imipenem NN N
and CC N
meropenem NN N
, , N
were VBD N
409 CD N
and CC N
34.9 CD N
and CC N
97.9 CD N
and CC N
5.8 CD N
, , N
respectively RB N
, , N
against IN N
Staphylococcus NNP N
aureus NN N
, , N
19.9 CD N
and CC N
4.4 CD N
and CC N
19.4 CD N
and CC N
4.8 CD N
, , N
respectively RB N
, , N
against IN N
Pseudomonas NNP N
aeruginosa NN N
, , N
34.3 CD N
and CC N
2.2 CD N
and CC N
232 CD N
and CC N
15.5 CD N
, , N
respectively RB N
, , N
against IN N
Enterobacter NNP N
cloacae NN N
, , N
and CC N
13.4 CD N
and CC N
2.25 CD N
and CC N
90.7 CD N
and CC N
7.9 CD N
, , N
respectively RB N
, , N
against IN N
Proteus NNP N
mirabilis NN N
. . N

Both DT p
drugs NNS p
had VBD p
rather RB p
short JJ p
biological JJ p
elimination NN p
half-lives NNS o
and CC p
a DT p
predominantly RB p
renal JJ p
route NN p
of IN p
elimination NN p
. . p

Both DT N
carbapenems NNS N
revealed VBD N
high JJ N
SBAs NNP o
against IN o
clinically RB o
important JJ o
pathogens NNS o
at IN N
1 CD N
h NN N
; : N
meropenem NN N
had VBD N
a DT N
higher JJR N
SBA NNP o
against IN N
E. NNP N
cloacae NN N
and CC N
P. NNP N
mirabilis NN N
, , N
and CC N
the DT N
SBA NNP o
of IN N
imipenem NN N
against IN N
S. NNP N
aureus NN N
was VBD N
greater JJR N
than IN N
the DT N
SBA NNP N
of IN N
meropenem NN N
. . N

-DOCSTART- -19516150- O O

Aerobic NNP i
and CC i
strength NN i
training NN i
reduces NNS N
adiposity NN o
in IN N
overweight JJ p
Latina NNP p
adolescents NNS p
. . p

PURPOSE NNP N
To TO N
date NN N
, , N
no DT N
study NN N
has VBZ N
examined VBN N
the DT N
synergistic JJ N
effects NNS N
of IN N
a DT N
nutrition NN i
and CC N
combination NN i
of IN i
aerobic JJ i
and CC i
strength NN i
training NN i
( ( i
CAST NNP i
) ) i
on IN N
both DT N
adiposity NN o
and CC o
metabolic JJ o
parameters NNS o
in IN N
overweight JJ p
Latina NNP p
adolescent NN p
females NNS p
. . p

The DT N
goal NN N
was VBD N
to TO N
assess VB N
if IN N
a DT N
16-wk JJ N
nutrition NN i
plus CC N
CAST NNP i
pilot NN N
study NN N
had VBD N
stronger JJR N
effects NNS N
on IN N
reducing VBG N
adiposity NN o
and CC N
on IN N
improving VBG N
glucose/insulin NN o
indices NNS o
compared VBN N
with IN N
control NN N
( ( N
C NNP N
) ) N
, , N
nutrition NN i
only RB i
( ( N
N NNP N
) ) N
, , N
and CC N
a DT N
nutrition NN i
plus CC N
strength NN i
training NN i
( ( N
N NNP N
+ NNP N
ST NNP N
) ) N
groups NNS N
. . N

METHODS NNP N
In IN N
a DT N
16-wk JJ N
randomized JJ N
trial NN N
, , N
41 CD p
overweight JJ p
Latina NNP p
girls NNS p
( ( p
15.2 CD p
+/- JJ p
1.1 CD p
yr NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
C NNP i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
N NNP i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
, , N
N NNP i
+ NNP i
ST NNP i
( ( N
n JJ N
= NNP N
9 CD N
) ) N
, , N
or CC N
N NNP i
+ NNP i
CAST NNP i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

All DT N
intervention NN N
groups NNS N
received VBD N
modified JJ i
carbohydrate NN i
nutrition NN i
classes NNS i
( ( N
once RB N
a DT N
week NN N
) ) N
, , N
whereas IN N
the DT N
N NNP i
+ NNP i
ST NNP i
also RB N
received VBD i
strength NN i
training NN i
( ( N
twice RB N
a DT N
week NN N
) ) N
and CC N
the DT N
N NNP i
+ NNP i
CAST NNP i
received VBD N
a DT i
combination NN i
of IN i
strength NN i
and CC i
aerobic JJ i
training NN i
( ( N
twice RB N
a DT N
week NN N
) ) N
. . N

The DT N
following VBG N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
intervention NN N
: : N
strength NN o
by IN N
one CD N
repetition NN N
maximum NN N
, , N
physical JJ o
activity NN o
by IN o
the DT o
7-d JJ o
accelerometry NN o
and CC N
the DT N
3-d JJ o
physical JJ o
activity NN o
recall NN o
, , o
dietary JJ o
intake NN o
by IN o
3-d JJ o
records NNS o
, , o
body NN o
composition NN o
by IN N
dual-energy JJ N
x-ray JJ N
absorptiometry NN N
( ( N
DEXA NNP N
) ) N
, , N
glucose/insulin JJ o
indices NNS o
by IN N
oral JJ N
glucose JJ N
tolerance NN N
test NN N
, , N
and CC N
intravenous JJ o
glucose JJ o
tolerance NN o
test NN o
with IN N
minimal JJ N
modeling NN N
. . N

Across IN N
intervention NN N
group NN N
, , N
effects NNS N
were VBD N
tested VBN N
using VBG N
ANCOVA NNP N
with IN N
post NN N
hoc NN N
pairwise NN N
comparisons NNS N
. . N

RESULTS VB N
There EX N
were VBD N
significant JJ N
overall JJ N
intervention NN N
effects NNS N
for IN N
all DT N
adiposity NN o
measures NNS o
( ( o
weight NN o
, , o
body NN o
mass NN o
index NN o
[ NNP o
BMI NNP o
] NNP o
, , o
BMI NNP o
z-scores NNS o
, , o
and CC o
DEXA NNP o
total VBP o
body NN o
fat NN o
) ) o
, , N
with IN N
a DT N
decrease NN N
of IN N
3 CD N
% NN N
in IN N
the DT N
N NNP i
+ NNP i
CAST NNP i
group NN N
compared VBN N
with IN N
a DT N
3 CD N
% NN N
increase NN N
in IN N
the DT N
N NNP i
+ NNP i
ST NNP i
group NN N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
an DT N
intervention NN N
effect NN N
for IN N
fasting VBG o
glucose NN o
with IN N
the DT N
N NNP i
group NN N
increasing VBG N
by IN N
3 CD N
% NN N
and CC N
the DT N
N NNP i
+ NNP i
CAST NNP i
group NN N
decreasing VBG N
by IN N
4 CD N
% NN N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
CAST NNP i
was VBD N
more RBR N
effective JJ N
than IN N
nutrition NN i
alone RB N
or CC N
nutrition JJ i
plus CC N
strength NN i
training NN i
for IN N
reducing VBG N
multiple JJ o
adiposity NN o
outcomes NNS o
and CC o
fasting VBG o
glucose NN o
in IN N
overweight JJ p
Latina NNP p
girls NNS p
. . p

However RB N
, , N
further JJ N
research NN N
investigating NN N
and CC N
identifying VBG N
intervention NN N
approaches NNS N
that WDT N
improve VBP N
both DT N
adiposity NN o
and CC o
insulin NN o
indices NNS o
, , N
particularly RB N
in IN N
high-risk JJ N
populations NNS N
, , N
are VBP N
warranted VBN N
. . N

-DOCSTART- -23337964- O O

[ JJ N
Antiinflammatory NNP N
potential NN N
of IN N
seven CD i
plant NN i
extracts NNS i
in IN N
the DT N
ultraviolet NN N
erythema JJ N
test NN N
. . N

A DT N
randomized JJ N
, , N
placebo-controlled JJ i
study NN N
] NNP N
. . N

BACKGROUND NNP N
Phytotherapeutics NNPS N
are VBP N
widely RB N
used VBN N
in IN N
medicine NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
evaluation NN N
of IN N
the DT N
antiinflammatory JJ N
potential NN N
of IN N
seven CD i
medical JJ i
plant NN i
extracts NNS i
using VBG N
the DT N
ultraviolet- JJ N
( ( N
UV NNP N
) ) N
-erythema VBP N
test NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Randomized NNP N
, , N
placebo-controlled JJ i
study NN N
on IN N
40 CD p
healthy JJ p
subjects NNS p
. . p

Test NNP N
areas NNS N
on IN N
the DT N
upper JJ N
back NN N
were VBD N
irradiated VBN N
with IN N
the DT N
1.5 CD i
fold JJ i
UV-B NNP i
minimal NN i
erythema NN i
dose NN i
( ( N
MED NNP N
) ) N
. . N

Formulations NNS N
of IN N
Aloe NNP i
vera NN i
, , i
Chamomilla NNP i
recutita NN i
, , i
Hamamelis NNP i
virginiana NN i
, , i
Melissa NNP i
officinalis NN i
, , i
Mentha NNP i
arvensis NN i
, , i
Melaleuca NNP i
alternifolia NN i
, , i
Coriandrum NNP i
sativum NN i
as RB i
well RB i
as IN i
1 CD i
% NN i
hydrocortisone NN i
acetate NN i
and CC i
0.1 CD i
% NN i
betamethasone NN i
valerate NN i
as IN N
positive JJ N
controls NNS N
and CC N
unguentum JJ i
leniens NNS i
as IN N
vehicle NN N
control NN N
were VBD N
applied VBN N
under IN N
occlusion NN N
on IN N
the DT N
irradiated JJ N
areas NNS N
and CC N
on IN N
non-irradiated JJ N
area NN N
on IN N
the DT N
contralateral JJ N
side NN N
. . N

Photometric NNP N
assessment NN N
of IN N
the DT N
erythema NN N
was VBD N
performed VBN N
before IN N
the DT N
application NN N
of IN N
the DT N
substances NNS N
( ( N
t0 NN N
) ) N
, , N
at IN N
24 CD N
h NN N
( ( N
t1 NN N
) ) N
and CC N
at IN N
48 CD N
h NN N
( ( N
t2 NN N
) ) N
. . N

RESULTS NNP i
Aloe NNP i
vera NN i
, , i
Chamomilla NNP i
recutita NN i
, , i
Melissa NNP i
officinalis NN i
, , i
Melaleuca NNP i
alternifolia NN i
and CC i
Coriandrum NNP i
sativum NN i
showed VBD i
an DT N
antiinflammatory JJ o
effect NN o
compared VBN o
to TO N
UV-control NNP N
and CC N
unguentum JJ N
leniens NNS N
. . N

However RB N
, , N
the DT N
results NNS N
were VBD N
only RB N
statistically RB N
significant JJ N
for IN N
Aloe NNP N
vera NN N
. . N

All DT N
tested VBD N
plant NN N
extracts NNS N
were VBD N
well RB o
tolerated VBN o
. . o

CONCLUSION NNP i
Aloe NNP i
vera NN i
possesses VBZ i
an DT N
antiinflammatory JJ N
effect NN N
on IN N
UV-induced NNP N
erythemas NN N
. . N

-DOCSTART- -18397386- O O

Clinical JJ N
trial NN N
: : N
exposure NN N
to TO N
ribavirin VB N
predicts NNS N
EVR NNP N
and CC N
SVR NNP N
in IN N
patients NNS p
with IN p
HCV NNP p
genotype NN p
1 CD p
infection NN p
treated VBN p
with IN p
peginterferon NN p
alpha-2a JJ p
plus CC p
ribavirin JJ p
. . p

BACKGROUND VB N
The DT N
impact NN N
of IN N
reduced JJ N
drug NN N
exposure NN N
on IN N
outcomes NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
has VBZ N
not RB N
been VBN N
determined VBN N
in IN N
routine JJ N
clinical JJ N
practice NN N
. . N

AIM NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
exposure NN N
to TO N
peginterferon VB N
alpha-2a JJ N
and CC N
ribavirin VB N
on IN N
early JJ N
virological JJ N
response NN N
( ( N
EVR NNP N
) ) N
and CC N
sustained VBD N
virological JJ N
response NN N
( ( N
SVR NNP N
) ) N
in IN N
treatment-naive JJ p
patients NNS p
with IN p
HCV NNP p
genotype NN p
1 CD p
infection NN p
enrolled VBN p
in IN p
a DT p
large JJ p
expanded JJ p
access NN p
programme NN p
. . p

METHODS NNP N
Eight NNP p
hundred VBD p
and CC p
ninety-one JJ p
patients NNS p
treated VBD p
for IN p
48 CD p
weeks NNS p
with IN p
an DT p
initial JJ p
ribavirin NN i
dose NN i
of IN i
800 CD i
or CC i
1000/1200 CD i
mg/day NNS i
were VBD N
evaluated VBN N
. . N

Ribavirin JJ i
1000 CD N
mg/day NN N
( ( N
< JJ N
75 CD N
kg NN N
) ) N
or CC N
1200 CD N
mg/day NN N
( ( N
> JJ N
or=75 RB N
kg NN N
) ) N
and CC N
peginterferon VB i
alpha-2a JJ i
180 CD i
microg/week NN N
were VBD N
considered VBN N
optimal JJ N
. . N

The DT N
impact NN N
of IN N
reduced JJ o
drug NN o
exposure NN o
( ( N
expressed VBN N
as IN N
a DT N
percentage NN N
of IN N
optimal NN N
) ) N
on IN N
EVR NNP o
and CC o
SVR NNP o
was VBD N
evaluated VBN N
. . N

RESULTS JJ N
Mean NNP o
ribavirin NN o
exposure NN o
in IN N
week NN N
0-12 NN N
was VBD N
70 CD N
% NN N
and CC N
96 CD N
% NN N
in IN N
patients NNS N
assigned VBN N
to TO N
ribavirin VB N
800 CD N
and CC N
1000/1200 CD N
mg/day NN N
, , N
respectively RB N
. . N

EVR NNP o
and CC o
SVR NNP o
rates NNS o
were VBD N
lower JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
ribavirin VB N
800 CD N
than IN N
1000/1200 CD N
mg/day NN N
( ( N
EVR NNP N
, , N
75 CD N
% NN N
vs. FW N
84 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
SVR NNP N
, , N
45 CD N
% NN N
vs. FW N
54 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
achievement NN N
of IN N
EVR NNP o
and CC o
SVR NNP o
and CC N
ribavirin VB N
dose NN N
over IN N
the DT N
first JJ N
12 CD N
weeks NNS N
expressed VBD N
either CC N
as IN N
absolute JJ N
dose NN N
or CC N
proportion NN N
of IN N
optimal JJ N
dose NN N
received VBD N
( ( N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

CONCLUSIONS NNP N
Ribavirin NNP N
exposure NN N
to TO N
week NN N
12 CD N
is VBZ N
significantly RB N
associated VBN N
with IN N
EVR NNP N
and CC N
SVR NNP N
in IN N
genotype JJ p
1 CD p
patients NNS p
. . p

Maintenance NNP N
of IN N
an DT N
optimal JJ N
ribavirin NN N
dose NN N
is VBZ N
the DT N
most RBS N
important JJ N
modifiable JJ N
factor NN N
during IN N
combination NN N
therapy NN N
for IN N
chronic JJ N
hepatitis NN N
C NNP N
. . N

-DOCSTART- -24225475- O O

Effect NN N
of IN N
home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
on IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
: : p
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

Fatigue NNP N
is VBZ N
a DT N
common JJ N
symptom NN N
of IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
, , N
and CC N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
daily JJ N
activity NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
the DT N
disease NN N
. . N

The DT N
authors NNS N
aimed VBN N
to TO N
identify VB N
the DT N
effect NN N
of IN N
home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
on IN N
fatigue NN N
, , N
activities NNS N
of IN N
daily JJ N
living NN N
( ( N
ADL NNP N
) ) N
and CC N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
in IN N
patients NNS p
with IN p
COPD NNP p
. . p

A NNP N
block NN N
randomisation NN N
method NN N
was VBD N
used VBN N
to TO N
randomise VB N
participants NNS N
into IN N
case NN i
and CC N
control NN i
groups NNS N
. . N

Fatigue NNP o
, , o
ADL NNP o
and CC o
QOL NNP o
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
both DT N
groups NNS N
. . N

Independent NNP N
and CC N
paired VBD N
t-tests NNS N
, , N
chi-squared JJ N
tests NNS N
and CC N
covariance NN N
analysis NN N
were VBD N
used VBN N
to TO N
analysing VBG N
data NNS N
. . N

Findings NNS N
showed VBD N
the DT N
significant JJ N
decrease NN N
in IN N
the DT N
mean JJ o
scores NNS o
of IN o
fatigue NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
significant JJ N
improvement NN N
in IN N
mean JJ o
scores NNS o
of IN o
ADL NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
QOL NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
after IN N
home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
in IN N
the DT N
case NN N
group NN N
. . N

Home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
can MD N
be VB N
an DT N
effective JJ o
, , o
inexpensive JJ o
and CC o
accessible JJ o
programme NN N
for IN N
decreasing VBG o
fatigue NN o
and CC o
improving VBG o
ADL NNP o
and CC o
QOL NNP o
for IN N
patients NNS p
with IN p
COPD NNP p
. . p

-DOCSTART- -23017624- O O

A DT N
home-based JJ i
exercise NN i
program NN i
to TO N
improve VB N
function NN o
, , o
fatigue NN o
, , o
and CC o
sleep JJ o
quality NN o
in IN N
patients NNS p
with IN p
Stage NNP p
IV NNP p
lung NN p
and CC p
colorectal JJ p
cancer NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Exercise NNP N
benefits NNS N
patients NNS p
with IN p
cancer NN p
, , N
but CC N
studies NNS N
of IN N
home-based JJ N
approaches NNS N
, , N
particularly RB N
among IN N
those DT p
with IN p
Stage NNP p
IV NNP p
disease NN p
, , N
remain VBP N
small JJ N
and CC N
exploratory JJ N
. . N

OBJECTIVES NNP N
To TO N
conduct VB N
an DT N
adequately RB N
powered JJ N
trial NN N
of IN N
a DT N
home-based JJ i
exercise NN i
intervention NN i
that WDT N
can MD N
be VB N
facilely RB N
integrated VBN N
into IN N
established VBN N
delivery NN N
and CC N
reimbursement NN N
structures NNS N
. . N

METHODS NNP N
Sixty-six JJ p
adults NNS p
with IN p
Stage NNP p
IV NNP p
lung NN p
or CC p
colorectal JJ p
cancer NN p
were VBD p
randomized VBN p
, , N
in IN N
an DT N
eight-week JJ N
trial NN N
, , N
to TO N
usual JJ i
care NN i
or CC i
incremental JJ i
walking NN i
and CC i
home-based JJ i
strength NN i
training NN i
. . i

The DT N
exercising VBG N
participants NNS N
were VBD N
instructed VBN N
during IN N
a DT N
single JJ N
physiotherapy NN i
visit NN N
and CC N
subsequently RB N
exercised VBN N
four CD N
days NNS N
or CC N
more JJR N
per IN N
week NN N
; : N
training NN N
and CC N
step-count NN N
goals NNS N
were VBD N
advanced VBN N
during IN N
bimonthly RB N
telephone NN N
calls VBZ N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
mobility NN o
assessed VBN N
with IN N
the DT N
Ambulatory NNP o
Post NNP o
Acute NNP o
Care NNP o
Basic NNP o
Mobility NNP o
Short NNP o
Form NNP o
. . o

Secondary JJ N
outcomes NNS N
included VBD o
ratings NNS o
of IN o
pain NN o
and CC o
sleep JJ o
quality NN o
as RB N
well RB N
as IN N
the DT o
ability NN o
to TO o
perform VB o
daily JJ o
activities NNS o
( ( N
Ambulatory NNP N
Post NNP N
Acute NNP N
Care NNP N
Daily NNP N
Activities NNP N
Short NNP N
Form NNP N
) ) N
, , N
quality NN o
of IN o
life NN o
( ( N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-General NNP N
) ) N
, , N
and CC o
fatigue NN o
( ( N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-Fatigue NNP N
) ) N
. . N

RESULTS NNP p
Three CD p
participants NNS p
dropped VBD p
out RP p
and CC p
seven CD o
died VBD o
( ( N
five CD N
in IN N
the DT N
intervention NN N
and CC N
two CD N
in IN N
the DT N
control NN N
group NN N
, , N
P=0.28 NNP N
) ) N
. . N

At IN N
Week JJ N
8 CD N
, , N
the DT N
intervention NN N
group NN N
reported VBD N
improved JJ o
mobility NN o
( ( N
P=0.01 NNP N
) ) N
, , N
fatigue NN o
( ( N
P=0.02 NNP N
) ) N
, , N
and CC o
sleep JJ o
quality NN o
( ( N
P=0.05 NNP N
) ) N
compared VBN N
with IN N
the DT N
usual JJ N
care NN N
group NN N
, , N
but CC N
did VBD N
not RB N
differ VB N
on IN N
the DT N
other JJ N
measures NNS N
. . N

CONCLUSION VB i
A DT i
home-based JJ i
exercise NN i
program NN i
seems VBZ N
capable JJ N
of IN N
improving VBG N
the DT o
mobility NN o
, , o
fatigue NN o
, , o
and CC o
sleep JJ o
quality NN o
of IN p
patients NNS p
with IN p
Stage NNP p
IV NNP p
lung NN p
and CC p
colorectal JJ p
cancer NN p
. . p

-DOCSTART- -11292273- O O

Clinical JJ N
implications NNS N
of IN N
a DT N
reduction NN N
in IN N
psychological JJ N
distress NN N
on IN N
cardiac JJ N
prognosis NN N
in IN N
patients NNS p
participating VBG p
in IN p
a DT p
psychosocial JJ i
intervention NN i
program NN i
. . i

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
secondary JJ N
analysis NN N
was VBD N
to TO N
examine VB N
the DT N
relationships NNS N
between IN N
a DT N
reduction NN N
in IN N
psychological JJ N
distress NN N
and CC N
long-term JJ N
cardiac NN N
and CC N
psychological JJ N
outcomes NNS N
in IN N
post-myocardial JJ p
infarction NN p
patients NNS p
who WP p
participated VBD p
in IN p
a DT p
randomized JJ p
trial NN p
of IN p
home-based JJ p
psychosocial JJ p
nursing NN p
interventions NNS p
( ( p
the DT p
Montreal NNP p
Heart NNP p
Attack NNP p
Readjustment NNP p
Trial NNP p
[ NNP p
M-HART NNP p
] NNP p
) ) p
. . p

Gender VB N
differences NNS N
were VBD N
considered VBN N
. . N

METHODS NNP N
We PRP N
studied VBD i
433 CD i
patients NNS i
( ( i
36.0 CD i
% NN i
women NNS i
) ) i
from IN i
the DT i
M-HART NNP i
treatment NN i
group NN i
who WP i
received VBD i
two CD i
home NN i
visits NNS i
after IN i
achieving VBG i
a DT i
high JJ i
psychological JJ i
distress NN i
score NN i
( ( i
ie JJ i
, , i
> JJ i
or CC i
=5 NN i
) ) i
on IN i
the DT i
General NNP i
Health NNP i
Questionnaire NNP i
( ( i
GHQ NNP i
) ) i
. . i

Short-term JJ N
GHQ NNP o
success NN o
was VBD N
determined VBN N
by IN N
a DT N
return NN N
to TO N
a DT N
normal JJ N
GHQ NNP o
score NN o
( ( N
< JJ N
5 CD N
) ) N
or CC N
a DT N
reduction NN N
of IN N
> NN N
or CC N
=50 CD N
% NN N
after IN N
the DT N
two CD N
visits NNS N
. . N

Patients NNS N
with IN N
short-term JJ N
successful JJ N
and CC N
unsuccessful JJ N
GHQ NNP N
outcomes NNS N
were VBD N
compared VBN N
for IN N
mid-term JJ N
maintenance NN N
of IN N
success NN N
, , N
1-year JJ N
death NN N
and CC N
readmission NN N
rates NNS N
, , N
and CC N
1-year JJ N
depression NN N
and CC N
anxiety NN N
symptoms NNS N
. . N

RESULTS JJ N
Patients NNS N
with IN N
short-term JJ N
GHQ NNP N
success NN N
were VBD N
more RBR N
likely JJ N
to TO N
show VB N
mid-term JJ o
GHQ NNP o
success NN o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
, , N
marginally RB N
less RBR N
likely JJ N
to TO N
die VB o
of IN o
any DT o
causes NNS o
( ( N
p JJ N
= NNP N
.087 NNP N
) ) N
, , N
less RBR N
likely JJ N
to TO N
die VB o
of IN o
cardiac JJ o
causes NNS o
( ( N
p JJ N
= NNP N
.043 NNP N
) ) N
, , N
less RBR N
likely JJ N
to TO N
be VB N
readmitted VBN o
for IN N
any DT N
reason NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
and CC N
for IN N
cardiac JJ N
reasons NNS N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
high JJ o
depression NN o
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
and CC N
anxiety NN o
( ( N
p JJ N
< NNP N
.001 NN N
) ) N
at IN N
1-year JJ N
than IN N
patients NNS N
with IN N
short-term JJ N
unsuccessful JJ N
GHQ NNP o
outcomes NNS o
. . o

Results NNS N
held VBD N
for IN N
men NNS p
and CC p
women NNS p
and CC N
were VBD N
not RB N
altered VBN N
by IN N
controlling VBG N
for IN N
potential JJ N
confounders NNS N
. . N

However RB N
, , N
the DT N
number NN N
of IN N
deaths NNS o
prevented VBN N
analysis NN N
with IN N
statistical JJ N
controls NNS N
. . N

CONCLUSIONS NNP N
Post-myocardial JJ N
infarction NN N
interventions NNS N
that WDT N
reduce VB N
psychological JJ N
distress NN N
have VBP N
the DT N
potential NN N
to TO N
improve VB N
long-term JJ o
prognosis NN o
and CC N
psychological JJ o
status NN o
for IN N
both DT N
men NNS p
and CC p
women NNS p
. . p

-DOCSTART- -23160656- O O

Effect NN N
of IN N
whole-body JJ i
mild-cold JJ i
exposure NN i
on IN N
arterial JJ o
stiffness NN o
and CC o
central JJ o
haemodynamics NNS o
: : o
a DT N
randomised JJ N
, , N
cross-over JJ N
trial NN N
in IN N
healthy JJ p
men NNS p
and CC p
women NNS p
. . p

Aortic JJ o
pulse NN o
wave NN o
velocity NN o
( ( o
PWV NNP o
) ) o
and CC N
augmentation NN o
index NN o
( ( o
AIx NNP o
) ) o
are VBP N
independent JJ N
predictors NNS N
of IN N
cardiovascular JJ o
risk NN o
and CC o
mortality NN o
, , N
but CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effect NN N
of IN N
air NN N
temperature NN N
changes NNS N
on IN N
these DT N
variables NNS N
. . N

Our PRP$ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
exposure NN N
to TO N
whole-body JJ i
mild-cold JJ i
on IN N
measures NNS N
of IN N
arterial JJ o
stiffness NN o
( ( o
aortic JJ o
and CC o
brachial JJ o
PWV NNP o
) ) o
, , o
and CC o
on IN o
central JJ o
haemodynamics NNS o
[ VBP o
including VBG o
augmented VBN o
pressure NN o
( ( o
AP NNP o
) ) o
, , o
AIx NNP o
] NNP o
, , o
and CC o
aortic JJ o
reservoir NN o
components NNS o
[ VBP o
including VBG o
reservoir NN o
and CC o
excess JJ o
pressures NNS o
( ( o
P NNP o
ex NN o
) ) o
] NN o
. . o

Sixteen NNP p
healthy JJ p
volunteers NNS p
( ( p
10 CD p
men NNS p
, , p
age NN p
43 CD p
? . p
19 CD p
years NNS p
; : p
mean VB p
? . p
SD NNP p
) ) p
were VBD p
randomised VBN N
to TO N
be VB N
studied VBN N
under IN N
conditions NNS N
of IN N
12 CD i
?C NNS i
( ( i
mild-cold JJ i
) ) i
and CC i
21 CD i
?C NNP i
( ( i
control NN i
) ) i
on IN i
separate JJ N
days NNS N
. . o

Supine JJ o
resting VBG o
measures NNS o
were VBD o
taken VBN N
at IN N
baseline NN N
( ( N
ambient JJ N
temperature NN N
) ) N
and CC N
after IN N
10 CD N
, , N
30 CD N
, , N
and CC N
60 CD N
min NN N
exposure NN N
to TO N
each DT N
experimental JJ N
condition NN N
in IN N
a DT N
climate JJ N
chamber NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
change NN o
in IN o
brachial JJ o
blood NN o
pressure NN o
between IN o
mild-cold JJ i
and CC i
control JJ N
conditions NNS N
. . N

However RB N
, , N
compared VBN N
to TO N
control VB o
, , o
AP NNP o
[ NNP N
+2 NNP N
mmHg NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.36-4.36 NN N
; : N
p CC N
= $ N
0.01 CD N
] NN N
and CC N
AIx NNP o
( ( N
+6 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
1.24-10.1 CD N
; : N
p CC N
= VB N
0.02 CD N
) ) N
increased VBN N
, , N
and CC N
time NN o
to TO o
maximum VB o
P NNP o
ex FW o
( ( N
a DT N
component NN N
of IN N
reservoir NN N
function NN N
related VBN N
to TO N
timing NN N
of IN N
peak JJ N
aortic JJ N
in-flow NN N
) ) N
decreased VBD N
( ( N
-7 JJ N
ms NN N
, , N
95 CD N
% NN N
CI NNP N
-15.4 NNP N
to TO N
2.03 CD N
; : N
p NN N
= VBZ N
0.01 CD N
) ) N
compared VBN N
to TO N
control VB N
. . N

Yet CC N
there EX N
was VBD N
no DT N
significant JJ N
change NN o
in IN o
aortic JJ o
PWV NNP o
( ( N
+0.04 NNP N
m/s NN N
, , N
95 CD N
% NN N
CI NNP N
-0.47 NNP N
to TO N
0.55 CD N
; : N
p NN N
= VBZ N
0.87 CD N
) ) o
or CC o
brachial JJ o
PWV NNP o
( ( N
+0.36 NNP N
m/s NN N
; : N
-0.41 VBZ N
to TO N
1.12 CD N
; : N
p NN N
= VBZ N
0.35 CD N
) ) N
between IN N
conditions NNS N
. . N

We PRP N
conclude VBP N
that IN N
mild-cold JJ i
exposure NN i
increases VBZ o
central JJ o
haemodynamic JJ o
stress NN o
and CC o
alters NNS o
timing NN o
of IN o
peak JJ o
aortic JJ o
in-flow NN o
without IN o
differentially RB N
affecting VBG o
arterial JJ o
stiffness NN o
. . o

-DOCSTART- -7219904- O O

The DT N
effects NNS o
of IN N
prophylactic JJ i
management NN i
and CC i
therapeutics NNS i
on IN N
hypertensive JJ o
disease NN o
in IN p
pregnancy NN p
: : p
preliminary JJ N
studies NNS N
. . N

A DT N
controlled JJ N
prospective JJ N
evaluation NN N
of IN N
pregnancy NN N
complicated VBN N
by IN N
chronic JJ N
hypertension NN N
is VBZ N
proposed VBN N
and CC N
preliminary JJ N
data NNS N
on IN N
population NN o
selection NN o
and CC o
pregnancy NN o
outcome NN o
are VBP N
presented VBN N
. . N

Sixty-three JJ p
women NNS p
with IN p
evidence NN p
of IN p
underlying VBG p
hypertensive JJ p
disease NN p
were VBD p
followed VBN p
prospectively RB N
throughout IN N
pregnancy NN N
. . N

Twenty-three JJ N
patients NNS N
were VBD N
followed VBN N
in IN N
a DT N
protocol NN N
of IN N
intensified JJ N
prenatal JJ N
care NN N
and CC N
randomized JJ N
assignment NN N
of IN N
antihypertensive JJ i
agents NNS i
: : i
placebo NN i
, , i
hydralazine NN i
, , i
or CC i
methyldopa NN i
. . i

Forty CD p
patients NNS p
were VBD p
followed VBN p
in IN p
the DT p
high-risk JJ p
pregnancy NN p
clinics NNS p
at IN p
Duke NNP p
University NNP p
. . p

The DT N
incidence NN o
of IN o
preeclampsia NN o
in IN N
the DT N
randomized JJ N
prophylactic JJ N
antihypertensive JJ N
group NN N
was VBD N
statistically RB N
lower JJR N
than IN N
that DT N
in IN N
the DT N
nonrandomized JJ N
group NN N
( ( N
8.7 CD N
versus RB N
32.5 CD N
% NN N
; : N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
other JJ N
statistically RB N
significant JJ N
differences NNS o
between IN N
the DT N
groups NNS N
. . N

The DT N
63 CD p
hypertensive JJ p
women NNS p
had VBD N
a DT N
high JJ N
incidence NN N
of IN N
diabetes NNS o
mellitus NNS o
diagnosed VBD N
during IN N
pregnancy NN N
( ( N
49.2 CD N
% NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
authors NNS N
' POS N
general JJ N
obstetric JJ N
population NN N
( ( N
8.1 CD N
% NN N
) ) N
. . N

-DOCSTART- -8871414- O O

A DT N
component JJ N
analysis NN N
of IN N
cognitive-behavioral JJ i
treatment NN i
for IN N
depression NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
provide VB N
an DT N
experimental JJ N
test NN N
of IN N
the DT N
theory NN N
of IN N
change NN N
put VBN N
forth NN N
by IN N
A. NNP N
T. NNP N
Beck NNP N
, , N
A. NNP N
J NNP N
. . N

Rush NNP N
, , N
B. NNP N
F. NNP N
Shaw NNP N
, , N
and CC N
G. NNP N
Emery NNP N
( ( N
1979 CD N
) ) N
to TO N
explain VB N
the DT N
efficacy NN o
of IN N
cognitive-behavioral JJ i
therapy NN i
( ( i
CT NNP i
) ) i
for IN N
depression NN o
. . o

The DT N
comparison NN N
involved VBD N
randomly RB N
assigning VBG N
150 CD p
outpatients NNS p
with IN p
major JJ p
depression NN p
to TO p
a DT p
treatment NN p
focused VBN p
exclusively RB p
on IN p
the DT p
behavioral JJ o
activation NN o
( ( o
BA NNP o
) ) o
component NN o
of IN o
CT NNP o
, , N
a DT N
treatment NN N
that WDT N
included VBD N
both DT N
BA NNP i
and CC i
the DT i
teaching NN i
of IN i
skills NNS i
to TO i
modify VB i
automatic JJ o
thoughts NNS o
( ( o
AT NNP o
) ) o
, , i
but CC i
excluding VBG i
the DT i
components NNS i
of IN i
CT NNP i
focused VBD i
on IN i
core NN o
schema NN o
, , i
or CC i
the DT i
full JJ i
CT NNP i
treatment NN i
. . i

Four CD N
experienced VBD N
cognitive JJ N
therapists NNS N
conducted VBD N
all DT N
treatments NNS N
. . N

Despite IN N
excellent JJ N
adherence NN N
to TO N
treatment NN N
protocols NNS N
by IN N
the DT N
therapists NNS N
, , N
a DT N
clear JJ N
bias NN N
favoring VBG N
CT NNP i
, , N
and CC N
the DT N
competent JJ N
performance NN N
of IN N
CT NNP N
, , N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
complete JJ o
treatment NN o
produced VBD o
better JJR o
outcomes NNS o
, , N
at IN N
either CC N
the DT N
termination NN N
of IN N
acute JJ N
treatment NN N
or CC N
the DT N
6-month JJ N
follow-up NN N
, , N
than IN N
either DT N
component JJ N
treatment NN N
. . N

Furthermore NN N
, , N
both DT N
BA NNP N
and CC N
AT NNP N
treatments NNS N
were VBD N
just RB N
as RB N
effective JJ o
as IN N
CT NNP i
at IN N
altering VBG o
negative JJ o
thinking NN o
as RB N
well RB N
as IN N
dysfunctional JJ o
attributional JJ o
styles NNS o
. . o

Finally RB N
, , N
attributional JJ o
style NN o
was VBD N
highly RB N
predictive JJ N
of IN N
both DT N
short- JJ o
and CC o
long-term JJ o
outcomes NNS o
in IN N
the DT N
BA NNP N
condition NN N
, , N
but CC N
not RB N
in IN N
the DT N
CT NNP N
condition NN N
. . N

-DOCSTART- -22595172- O O

Effects NNS N
of IN N
skin-to-skin JJ i
contact NN i
on IN N
autonomic JJ o
pain NN o
responses NNS o
in IN N
preterm JJ p
infants NNS p
. . p

UNLABELLED IN N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
crossover NN N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
on IN N
autonomic JJ N
responses NNS N
in IN N
preterm JJ p
infants NNS p
of IN p
longer JJR p
Kangaroo NNP i
Care NNP i
( ( p
30 CD p
minutes NNS p
, , p
KC30 NNP i
) ) i
and CC p
shorter JJR p
KC NNP i
( ( p
15 CD p
minutes NNS p
, , p
KC15 NNP i
) ) i
before IN p
and CC p
throughout IN p
heel NN p
stick NNS p
compared VBN p
with IN p
incubator NN i
care NN i
( ( i
IC NNP i
) ) i
. . p

Beat-to-beat JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
and CC N
spectral JJ N
power NN N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
, , N
low JJ N
frequency NN N
power NN N
( ( N
LF NNP N
) ) N
, , N
high JJ N
frequency NN N
power NN N
( ( N
HF NNP N
) ) N
, , N
and CC N
LF/HF NNP N
ratio NN N
were VBD N
measured VBN N
in IN N
26 CD p
infants NNS p
. . p

HR NNP o
changes NNS N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
were VBD N
significantly RB N
less RBR N
in IN N
KC30 NNP N
and CC N
KC15 NNP N
than IN N
in IN N
IC NNP N
, , N
and CC N
more JJR N
infants NNS N
had VBD N
HR NNP o
decrease NN N
in IN N
IC NNP N
than IN N
in IN N
2 CD N
KC NNP N
conditions NNS N
. . N

In IN N
IC NNP N
, , N
LF NNP o
and CC o
HF NNP o
significantly RB N
increased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
dropped VBD N
from IN N
Heel NNP N
Stick NNP N
to TO N
Recovery NNP N
; : N
in IN N
2 CD N
KC NNP N
conditions NNS N
, , N
no DT N
changes NNS N
across IN N
study NN N
phases NNS N
were VBD N
found VBN N
. . N

During IN N
Heel NNP N
Stick NNP N
, , N
LF NNP o
and CC N
HF NNP o
were VBD N
significantly RB N
higher JJR N
in IN N
IC NNP N
than IN N
in IN N
KC30 NNP i
. . i

In IN N
all DT N
3 CD N
conditions NNS N
, , N
LF/HF NNP o
ratio NN o
decreased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
increased VBD N
to TO N
Recovery NNP N
; : N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
IC NNP i
and CC N
two CD N
KC NNP i
conditions NNS N
. . N

Both NNP N
longer JJR N
and CC N
shorter JJR N
KC NNP i
before IN N
and CC N
throughout IN N
heel NN N
stick NN N
can MD N
stabilize VB N
HR NNP o
response NN o
in IN N
preterm JJ N
infants NNS N
, , N
and CC N
longer JJR N
KC NNP i
significantly RB N
affected VBD N
infants NNS N
' POS N
sympathetic JJ N
and CC N
parasympathetic JJ N
responses NNS N
during IN N
heel NN N
stick NNS N
compared VBN N
with IN N
incubator NN i
care NN i
. . i

PERSPECTIVE VB N
This DT N
study NN N
showed VBD N
that IN N
KC NNP i
has VBZ N
a DT N
significant JJ N
effect NN N
on IN N
reducing VBG N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ p
infants NNS p
. . p

The DT N
findings NNS N
support NN N
that IN N
KC NNP i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pain NN N
intervention NN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
. . N

-DOCSTART- -16709205- O O

Late JJ p
miscarriage NN p
and CC p
preterm JJ p
birth NN p
after IN N
treatment NN N
with IN N
clindamycin NN i
: : i
a DT N
randomised JJ N
consent NN N
design NN N
study NN N
according VBG N
to TO N
Zelen NNP N
. . N

OBJECTIVE NNP N
To TO N
screen VB p
for IN p
bacterial JJ p
vaginosis NN p
( ( p
BV NNP p
) ) p
and CC N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
vaginal JJ N
clindamycin NN i
in IN N
order NN N
to TO N
observe VB N
the DT N
effect NN N
on IN N
late JJ o
miscarriage NN o
and CC o
delivery NN o
prior RB o
to TO o
37 CD o
completed VBN o
weeks NNS o
( ( N
primary JJ N
outcome NN N
) ) N
. . N

DESIGN NNP N
Randomised VBD N
consent NN N
design NN N
for IN N
clinical JJ N
trials NNS N
according VBG N
to TO N
Zelen NNP N
. . N

SETTING NNP N
Southeast NNP p
region NN p
of IN p
Sweden NNP p
. . p

POPULATION VB N
A DT N
total NN N
of IN N
9025 CD p
women NNS p
were VBD p
screened VBN p
in IN p
early JJ p
pregnancy NN p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
819 CD p
women NNS p
with IN p
a DT p
Nugent NNP p
score NN p
of IN p
6 CD p
and CC p
above VB p
were VBD N
considered VBN N
to TO N
have VB N
BV NNP N
and CC N
treated VBD N
according VBG N
to TO N
Zelen NNP N
allocation NN N
. . N

The DT N
incidence NN N
of IN N
late JJ o
miscarriage NN o
and CC o
spontaneous JJ o
( ( o
noniatrogenic JJ o
) ) o
preterm FW o
birth NN o
was VBD N
assessed VBN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Late NNP o
miscarriage NN o
and CC o
spontaneous JJ o
preterm NNS o
delivery NN o
before IN o
37 CD o
weeks NNS o
. . o

RESULTS NNP N
Therapy NNP N
with IN N
vaginal JJ i
clindamycin NN i
had VBD N
no DT N
significant JJ N
impact NN N
on IN N
the DT N
incidence NN o
of IN o
spontaneous JJ o
preterm JJ o
delivery NN o
prior RB N
to TO N
37 CD N
completed VBN N
weeks NNS N
; : N
OR CC N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
0.40-2.02 NN N
( ( N
primary JJ N
outcome NN N
variable NN N
) ) N
. . N

However RB N
, , N
only RB N
1 CD N
of IN N
11 CD N
women NNS N
in IN N
the DT N
treatment NN i
group NN N
versus VBD N
5 CD N
of IN N
12 CD N
in IN N
the DT N
control NN i
group NN N
delivered VBD N
prior RB N
to TO N
33 CD N
completed VBN N
weeks NNS N
; : N
OR CC N
0.14 CD N
, , N
95 CD N
% NN N
CI NNP N
0.02-0.95 NN N
. . N

Treatment NN N
was VBD N
associated VBN N
with IN N
32 CD N
days NNS N
longer JJR o
gestation NN o
for IN N
the DT N
23 CD p
participants NNS p
who WP p
had VBD p
late JJ o
miscarriage NN o
or CC o
spontaneous JJ o
preterm NNS o
birth NN o
( ( N
P= NNP N
0.024 CD N
, , N
Mann-Whitney NNP N
U NNP N
test NN N
) ) N
and CC N
significantly RB N
fewer JJR N
infants NNS N
had VBD N
a DT N
birthweight NN o
below IN o
2,500 CD o
g NN o
( ( N
secondary JJ N
outcome NN N
) ) N
. . N

A DT N
follow JJ N
up NN N
of IN N
infants NNS N
born JJ N
preterm VBP N
4 CD N
years NNS N
postnatally RB N
indicated VBD N
that IN N
extending VBG N
gestational JJ N
age NN N
did VBD N
not RB N
increase VB N
the DT N
number NN N
of IN N
sequelae NN N
. . N

CONCLUSIONS NNP N
Clindamycin NNP i
vaginal JJ N
cream NN N
therapy NN N
was VBD N
associated VBN N
with IN N
significantly RB N
prolonged VBN N
gestation NN N
and CC N
reduced JJ N
cost NN N
of IN N
neonatal JJ N
care NN N
in IN N
women NNS p
with IN p
BV NNP p
. . p

Early JJ N
screening NN N
for IN N
BV NNP N
and CC N
treatment NN N
with IN N
clindamycin NN i
saved VBD N
approximately RB N
27 CD N
euro JJ N
per IN N
woman NN N
. . N

-DOCSTART- -14674492- O O

Clinical JJ N
and CC N
radiographic JJ N
evaluation NN N
of IN N
guided JJ N
tissue NN N
regeneration NN N
in IN N
the DT N
treatment NN N
of IN N
class NN p
II NNP p
furcation NN p
defects NNS p
. . p

A DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
treatment NN N
outcomes RB o
after IN N
guided VBN i
tissue NN i
regeneration NN i
( ( i
GTR NNP i
) ) i
with IN N
a DT N
bioabsorbable JJ N
membrane NN N
in IN N
Class NNP p
II NNP p
furcation NN p
defects NNS p
in IN N
mandibular JJ N
molars NNS N
. . N

The DT N
open JJ N
flap NN N
debridement NN N
( ( N
OFD NNP N
) ) N
was VBD N
used VBN N
as IN N
the DT N
control NN N
. . N

METHODS NNP N
Nine NNP p
patients NNS p
, , p
with IN p
two CD p
comparable JJ p
Class NNP p
II NNP p
furcation NN p
defects NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

After IN N
initial JJ N
preparation NN N
, , N
the DT N
defects NNS N
were VBD N
randomly RB N
assigned VBN N
in IN N
each DT N
patient NN N
to TO N
either DT N
GTR-group NNP i
or CC p
OFD-group NNP i
. . p

Clinical JJ N
parameters NNS N
and CC N
standardized JJ N
radiographs NN N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
after IN N
the DT N
surgeries NNS N
. . N

The DT N
radiographs NN i
were VBD N
analyzed VBN N
by IN N
subtraction NN N
radiography NN N
. . N

RESULTS NNP N
Comparing NNP N
baseline NN N
to TO N
6-month JJ N
results NNS N
, , N
both DT N
groups NNS N
showed VBD N
statistically RB N
significant JJ N
probing VBG o
depth NN o
reduction NN o
( ( o
PD NNP o
) ) o
, , o
horizontal JJ o
clinical JJ o
attachment NN o
level NN o
( ( o
CAL-h NNP o
) ) o
gain NN o
, , o
and CC o
increase VB o
in IN o
gingival JJ o
recession NN o
( ( o
GR NNP o
) ) o
. . o

The DT N
vertical JJ o
clinical JJ o
attachment NN o
level NN o
( ( o
CAL-v NNP o
) ) o
gain NN o
was VBD N
statistically RB N
significant JJ N
only RB N
for IN N
the DT N
OFD-group NNP N
. . N

Comparing VBG N
the DT N
two CD N
treatments NNS N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
PD NNP o
reduction NN o
( ( N
GTR NNP N
: : N
1.67 CD N
mm NN N
; : N
OFD NNP N
: : N
2.51 CD N
mm NN N
, , N
P NNP N
= NNP N
0.26 CD N
) ) N
, , N
CAL-v JJ o
gain NN o
( ( N
GTR NNP N
: : N
0.62 CD N
mm NN N
; : N
OFD NNP N
: : N
1.16 CD N
mm NN N
, , N
P= NNP N
0.37 CD N
) ) N
, , N
and CC N
GR NNP o
increase NN o
( ( N
GTR NNP N
: : N
1.04 CD N
mm NN N
; : N
OFD NNP N
: : N
1.24 CD N
mm NN N
, , N
P NNP N
= NNP N
0.31 CD N
) ) N
. . N

GTR NNP i
provided VBD N
complete JJ N
closure NN o
of IN o
the DT o
furcation NN o
defect NN o
in IN N
two CD N
sites NNS N
and CC N
superior JJ o
horizontal JJ o
clinical JJ o
attachment NN o
level NN o
gain NN o
( ( N
GTR NNP N
: : N
2.27 CD N
mm NN N
; : N
OFD NNP N
: : N
1.01 CD N
mm NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

Subtraction NN N
radiography NN N
showed VBD N
significant JJ N
difference NN N
in IN N
bone NN N
height NN N
change NN N
between IN N
GTR-group NNP N
and CC N
OFD-group NNP N
( ( N
-0.14 NNP N
mm NN N
and CC N
0.86 CD N
mm NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.028 CD N
) ) N
at IN N
6 CD N
months NNS N
. . N

-DOCSTART- -15160783- O O

Role NNP N
of IN N
the DT N
placebo NN i
effect NN i
in IN N
evaluating VBG p
antidepressant JJ o
efficacy NN o
. . o

-DOCSTART- -8123267- O O

Recovery NN N
following VBG N
outpatient JJ i
anesthesia NN i
: : i
use NN N
of IN N
enflurane NN i
versus NN i
propofol NN i
. . i

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
the DT N
intraoperative JJ N
conditions NNS N
and CC N
postoperative JJ p
recovery NN p
of IN p
patients NNS p
following VBG p
the DT p
use NN p
of IN p
either DT p
propofol-nitrous JJ i
oxide NN i
( ( i
N2O NNP i
) ) i
or CC i
enflurane-N2O JJ i
for IN i
maintenance NN p
of IN p
outpatient JJ p
anesthesia NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
single-blind NN N
study NN N
. . N

SETTING NNP N
University NNP p
hospital NN p
outpatient NN p
surgery NN p
center NN p
. . p

PATIENTS CC N
61 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
and CC p
II NNP p
, , p
healthy JJ p
female NN p
outpatients NNS p
undergoing VBG p
laparoscopic NN p
surgery NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
anesthetic JJ N
regimens NNS N
. . N

Group NNP i
1 CD i
( ( i
control NN i
) ) i
received VBD i
thiopental JJ i
sodium NN i
4 CD i
mg/kg NN i
intravenously RB i
( ( i
i.v JJ i
. . i

) ) i
, , i
followed VBN i
by IN i
0.5 CD i
% NN i
to TO i
1.5 CD i
% NN i
enflurane NN i
and CC i
67 CD i
% NN i
N2O NNP i
in IN i
oxygen NN i
( ( i
O2 NNP i
) ) i
. . i

Group NNP i
2 CD i
received VBD i
propofol JJ i
2 CD i
mg/kg NN i
i.v. NN i
, , N
followed VBN i
by IN i
0.5 CD i
% NN i
to TO i
1.5 CD i
% NN i
enflurane NN i
and CC i
67 CD i
% NN i
N2O NNP i
in IN i
O2 NNP i
. . i

Group NNP i
3 CD i
received VBD i
propofol JJ i
2 CD i
mg/kg NN i
i.v. NN i
, , N
followed VBN i
by IN i
propofol NN i
50 CD i
to TO i
160 CD i
micrograms/kg/min NN i
i.v NN i
. . i

and CC i
67 CD i
% NN i
N2O NNP i
in IN i
O2 NNP i
. . i

All DT N
patients NNS N
received VBD N
succinylcholine JJ i
1 CD N
mg/kg NN N
i.v NN N
. . N

to TO N
facilitate VB N
tracheal JJ N
intubation NN N
and CC N
atracurium NN i
10 CD N
to TO N
20 CD N
mg NN N
i.v NN N
. . N

to TO N
provide VB N
adequate JJ N
relaxation NN N
during IN N
the DT N
maintenance NN N
period NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Recovery NNP o
from IN o
anesthesia NN o
was VBD N
assessed VBN N
by IN N
a DT N
research NN N
nurse NN N
who WP N
was VBD N
unaware NN N
of IN N
the DT N
anesthetic JJ N
technique NN N
used VBN N
. . N

The DT N
mean JJ o
+/- JJ o
SD NNP o
time NN o
to TO o
eye NN o
opening NN o
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
thiopental-enflurane-N2O JJ i
group NN i
( ( i
Group NNP i
1 CD i
) ) i
than IN N
in IN N
the DT N
propofol-propofol-N2O JJ i
group NN i
( ( i
Group NNP i
3 CD i
) ) i
( ( N
6.1 CD N
+/- JJ N
2.5 CD N
minutes NNS N
vs. IN N
3.5 CD N
+/- JJ N
2.8 CD N
minutes NNS N
, , N
respectively RB N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
mean JJ o
time NN o
to TO o
respond VB o
to TO o
verbal VB o
commands NNS o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
propofol NN i
induction NN N
groups NNS N
compared VBN N
with IN N
the DT N
thiopental JJ i
induction NN N
group NN N
. . N

However RB N
, , N
the DT N
use NN N
of IN N
enflurane NN i
versus NN N
propofol NN i
for IN N
maintenance NN N
of IN N
anesthesia NN N
did VBD N
not RB N
significantly RB N
prolong IN N
the DT N
time NN o
from IN o
arrival NN o
in IN o
the DT o
recovery NN o
room NN o
to TO o
sitting VBG o
, , o
tolerating VBG o
oral JJ o
fluids NNS o
, , o
walking VBG o
, , o
or CC o
being VBG o
judged VBN o
fit NN o
for IN o
discharge NN o
. . o

There EX N
were VBD N
no DT N
differences NNS N
among IN N
the DT N
three CD N
groups NNS N
with IN N
respect NN N
to TO N
postoperative VB o
pain NN o
or CC o
analgesic JJ o
requirements NNS o
. . o

Finally RB N
, , N
patients NNS N
who WP N
received VBD N
enflurane NN i
for IN N
maintenance NN N
of IN N
anesthesia NN N
had VBD N
a DT N
significantly RB N
higher JJR o
frequency NN o
of IN o
nausea NN o
and CC o
vomiting NN o
than IN N
the DT N
propofol JJ N
maintenance NN N
group NN N
. . N

CONCLUSION NNP N
Induction NNP N
of IN N
anesthesia NN N
with IN N
propofol NN i
is VBZ N
associated VBN N
with IN N
a DT N
more RBR o
rapid JJ o
emergence NN o
from IN o
anesthesia NN o
than IN N
induction NN N
with IN N
thiopental JJ i
. . i

Maintenance NN N
of IN N
anesthesia NN N
with IN N
enflurane NN i
did VBD N
not RB N
prolong JJ N
recovery NN o
compared VBN N
with IN N
maintenance NN N
with IN N
propofol NN i
, , N
but CC N
enflurane NN i
was VBD N
associated VBN N
with IN N
increased JJ N
frequency NN o
of IN o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
. . o

-DOCSTART- -23578065- O O

Altered NNP N
accuracy NN N
of IN N
saccadic JJ i
eye NN i
movements NNS i
in IN N
children NNS p
with IN p
fetal JJ p
alcohol NN p
spectrum NN p
disorder NN p
. . p

BACKGROUND NNP N
Prenatal NNP N
exposure NN N
to TO N
alcohol VB N
is VBZ N
a DT N
major JJ N
, , N
preventable JJ N
cause NN N
of IN N
neurobehavioral JJ N
dysfunction NN N
in IN N
children NNS N
worldwide RB N
. . N

The DT N
measurement NN N
and CC N
quantification NN N
of IN N
saccadic JJ N
eye NN N
movements NNS N
is VBZ N
a DT N
powerful JJ N
tool NN N
for IN N
assessing VBG N
sensory NN N
, , N
motor NN N
, , N
and CC N
cognitive JJ N
function NN N
. . N

The DT N
quality NN N
of IN N
the DT N
motor NN N
process NN N
of IN N
an DT N
eye NN N
movement NN N
is VBZ N
known VBN N
as IN N
saccade NN N
metrics NNS N
. . N

Saccade NNP N
accuracy NN N
is VBZ N
1 CD N
component NN N
of IN N
metrics NNS N
, , N
which WDT N
to TO N
function VB N
optimally RB N
requires VBZ N
several JJ N
cortical JJ N
brain NN N
structures NNS N
as RB N
well RB N
as IN N
an DT N
intact JJ N
cerebellum NN N
and CC N
brain-stem NN N
. . N

The DT N
cerebellum NN N
has VBZ N
frequently RB N
been VBN N
reported VBN N
to TO N
be VB N
damaged VBN N
by IN N
prenatal JJ N
alcohol NN N
exposure NN N
. . N

This DT N
study NN N
, , N
therefore RB N
, , N
tested VBD N
the DT N
hypothesis NN N
that WDT N
children NNS p
with IN p
fetal JJ p
alcohol NN p
spectrum NN p
disorder NN p
( ( p
FASD NNP p
) ) p
will MD N
exhibit VB N
deficits NNS N
in IN N
the DT N
accuracy NN N
of IN N
saccades NNS N
. . N

METHODS NNP N
A NNP p
group NN p
of IN p
children NNS p
with IN p
FASD NNP p
( ( p
n JJ p
= NNP p
27 CD p
) ) p
between IN p
the DT p
ages NNS p
of IN p
8 CD p
and CC p
16 CD p
and CC p
typically RB p
developing VBG p
control NN p
children NNS p
( ( p
n JJ p
= NNP p
27 CD p
) ) p
matched VBN p
for IN p
age NN p
and CC p
sex NN p
, , N
completed VBD N
3 CD i
saccadic JJ i
eye NN i
movement NN i
tasks NNS i
of IN i
increasing VBG i
difficulty NN i
. . i

Eye NNP N
movement NN N
performance NN N
during IN N
the DT N
tasks NNS N
was VBD N
captured VBN N
using VBG N
an DT N
infrared JJ N
eye NN N
tracker NN N
. . N

Saccade VB o
metrics NNS o
( ( o
e.g. NN o
, , N
velocity NN o
, , o
amplitude NN o
, , o
accuracy NN o
) ) o
were VBD N
quantified VBN N
and CC N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
for IN N
the DT N
3 CD N
different JJ N
tasks NNS N
. . N

RESULTS NNP N
Children NNP N
with IN N
FASD NNP N
were VBD N
more RBR N
variable JJ N
in IN N
saccade JJ o
endpoint NN o
accuracy NN o
, , N
which WDT N
was VBD N
reflected VBN N
by IN N
statistically RB N
significant JJ N
increases NNS N
in IN N
the DT N
error NN N
of IN N
the DT N
initial JJ o
saccade NN o
endpoint NN o
and CC N
the DT N
frequency NN N
of IN N
additional JJ N
, , N
corrective JJ o
saccades NNS o
required VBN N
to TO N
achieve VB N
final JJ N
fixation NN N
. . N

This DT N
increased JJ N
variability NN N
in IN N
accuracy NN o
was VBD N
amplified VBN N
when WRB N
the DT N
cognitive JJ N
demand NN N
of IN N
the DT N
tasks NNS N
increased VBD N
. . N

Children NNP N
with IN N
FASD NNP N
also RB N
displayed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
response NN o
inhibition NN o
errors NNS o
. . o

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
children NNS N
with IN N
FASD NNP N
may MD N
have VB N
deficits NNS N
in IN N
eye NN N
movement NN N
control NN N
and CC N
sensory-motor JJ N
integration NN N
including VBG N
cerebellar JJ N
circuits NNS N
, , N
thereby RB N
impairing VBG N
saccade JJ N
accuracy NN N
. . N

-DOCSTART- -19686304- O O

Assessment NN N
of IN N
elementary JJ p
school NN p
students NNS p
' POS p
sun NN o
protection NN o
behaviors NNS o
. . o

BACKGROUND/OBJECTIVES NNP N
Studies NNPS N
suggest VBP N
that IN N
excessive JJ N
sun NN N
exposure NN N
in IN N
childhood NN N
contributes NNS N
to TO N
the DT N
development NN N
of IN N
skin NN N
cancer NN N
later RBR N
in IN N
life NN N
. . N

METHODS NNP N
This DT N
study NN N
explores VBZ N
4th CD p
grade NN p
student NN p
assessment NN p
of IN p
their PRP$ p
sun NN p
protection NN p
behaviors NNS p
. . p

This DT N
study NN N
used VBN N
baseline NN N
data NNS N
collected VBN N
in IN N
the DT N
Fall NN p
of IN p
2006 CD p
for IN p
the DT p
Sun NNP p
Protection NNP p
for IN p
Florida NNP p
's POS p
Children NNP p
( ( p
SPF NNP p
) ) p
project NN p
. . p

In IN N
brief NN N
, , N
the DT N
SPF NNP N
project NN N
is VBZ N
a DT N
group NN N
randomized VBD N
trial NN N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
a DT N
school NN i
based VBN i
intervention NN i
promoting VBG i
sun JJ i
protection NN i
in IN i
general JJ i
, , i
and CC i
hat RB i
use NN i
in IN i
particular JJ i
, , N
in IN N
Hillsborough NNP p
County NNP p
Schools NNP p
, , p
Florida NNP p
. . p

The DT N
data NN N
reported VBD N
in IN N
this DT N
study NN N
were VBD N
collected VBN N
at IN N
baseline NN N
before IN N
any DT N
intervention NN N
activities NNS N
was VBD N
initiated VBN N
. . N

RESULTS VB N
The DT N
self-reported JJ o
use NN o
of IN o
various JJ o
methods NNS o
of IN o
sun NN o
protection NN o
was VBD N
low JJ N
. . N

Only RB N
a DT N
small JJ N
percentage NN N
of IN N
students NNS p
wore VBP N
long JJ o
sleeves NNS o
or CC o
a DT o
hat NN o
with IN o
a DT o
brim NN o
before IN N
leaving VBG N
for IN N
school NN N
. . N

In IN N
addition NN N
, , N
few JJ N
students NNS p
wore VBD N
a DT N
hat NN o
with IN o
a DT o
wide JJ o
brim NN o
when WRB o
outside NN o
but CC N
not RB N
at IN N
school NN N
. . N

Students NNS p
spent VBD N
an DT N
average NN N
of IN N
59.1 CD N
minutes NNS N
per IN N
week NN N
outdoors NNS N
while IN N
attending VBG N
school NN N
and CC N
35.5 CD N
minutes NNS N
during IN N
peak JJ o
sun NN o
exposure NN o
. . o

CONCLUSION NNP N
Sun NNP N
exposure NN N
at IN N
school NN N
poses NNS N
a DT N
significant JJ N
risk NN N
to TO N
student VB N
health NN N
and CC N
more JJR N
needs NNS N
to TO N
be VB N
carried VBN N
out IN N
to TO N
promote VB N
the DT N
use NN N
of IN N
a DT N
wide-brimmed JJ i
hat NN i
and CC N
limiting VBG N
student NN o
sun NN o
exposure NN o
. . o

-DOCSTART- -10770301- O O

Low JJ i
molecular-weight JJ i
heparin NN i
versus NN i
aspirin NN i
in IN N
patients NNS p
with IN p
acute JJ p
ischaemic JJ p
stroke NN p
and CC p
atrial JJ p
fibrillation NN p
: : p
a DT N
double-blind NN N
randomised VBN N
study NN N
. . N

HAEST NNP N
Study NNP N
Group NNP N
. . N

Heparin NNP N
in IN N
Acute NNP N
Embolic NNP N
Stroke NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
acute JJ p
ischaemic JJ p
stroke NN p
and CC p
atrial JJ p
fibrillation NN p
have VBP N
an DT N
increased VBN N
risk NN N
of IN N
early JJ o
stroke NN o
recurrence NN o
, , N
and CC N
anticoagulant JJ N
treatment NN N
with IN N
heparins NNS i
has VBZ N
been VBN N
widely RB N
advocated VBN N
, , N
despite IN N
missing VBG N
data NNS N
on IN N
the DT N
balance NN N
of IN N
risk NN N
and CC N
benefit NN N
. . N

METHODS NNP N
Heparin NNP i
in IN N
Acute NNP N
Embolic NNP N
Stroke NNP N
Trial NNP N
( ( N
HAEST NNP N
) ) N
was VBD N
a DT N
multicentre NN N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
and CC N
double-dummy JJ N
trial NN N
on IN N
the DT N
effect NN N
of IN N
low-molecular-weight JJ i
heparin NN i
( ( i
LMWH NNP i
, , i
dalteparin VBZ i
100 CD i
IU/kg NNP i
subcutaneously RB i
twice RB i
a DT i
day NN i
) ) i
or CC i
aspirin NN i
( ( i
160 CD i
mg NN i
every DT i
day NN i
) ) i
for IN N
the DT N
treatment NN N
of IN N
449 CD p
patients NNS p
with IN p
acute JJ p
ischaemic JJ p
stroke NN p
and CC p
atrial JJ p
fibrillation NN p
. . p

The DT N
primary JJ N
aim NN N
was VBD N
to TO N
test VB N
whether IN N
treatment NN N
with IN N
LMWH NNP i
, , N
started VBD N
within IN N
30 CD N
h NN N
of IN N
stroke NN N
onset NN N
, , N
is VBZ N
superior JJ N
to TO N
aspirin VB i
for IN N
the DT N
prevention NN N
of IN N
recurrent JJ o
stroke NN o
during IN N
the DT N
first JJ N
14 CD N
days NNS N
. . N

FINDINGS IN N
The DT N
frequency NN o
of IN o
recurrent JJ o
ischaemic JJ o
stroke NN o
during IN N
the DT N
first JJ N
14 CD N
days NNS N
was VBD N
19/244 CD N
( ( N
8.5 CD N
% NN N
) ) N
in IN N
dalteparin-allocated JJ N
patients NNS N
versus IN N
17/225 CD N
( ( N
7.5 CD N
% NN N
) ) N
in IN N
aspirin-allocated JJ N
patients NNS N
( ( N
odds NNS N
ratio=1.13 NN N
, , N
95 CD N
% NN N
CI NNP N
0.57-2.24 NN N
) ) N
. . N

The DT N
secondary JJ N
events NNS N
during IN N
the DT N
first JJ N
14 CD N
days NNS N
also RB N
revealed VBD N
no DT N
benefit NN N
of IN N
dalteparin NN i
compared VBN N
with IN N
aspirin NN i
: : i
symptomatic JJ o
cerebral JJ o
haemorrhage NN o
6/224 CD N
versus NN N
4/225 CD N
; : N
symptomatic JJ o
and CC o
asymptomatic JJ o
cerebral JJ o
haemorrhage NN o
26/224 CD N
versus NN N
32/225 CD N
; : N
progression NN o
of IN o
symptoms NNS o
within IN o
the DT o
first JJ o
48 CD o
hours NNS o
24/224 CD N
versus NN N
17/225 CD N
; : N
and CC N
death NN N
21/224 CD N
versus NN N
16/225 CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
functional JJ o
outcome NN o
or CC o
death NN o
at IN N
14 CD N
days NNS N
or CC N
3 CD N
months NNS N
. . N

INTERPRETATION NNP N
The DT N
present JJ N
data NNS N
do VBP N
not RB N
provide VB N
any DT N
evidence NN N
that IN N
LMWH NNP i
is VBZ N
superior JJ N
to TO N
aspirin VB N
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
ischaemic JJ N
stroke NN N
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
. . N

However RB N
, , N
the DT N
study NN N
could MD N
not RB N
exclude VB N
the DT N
possibility NN N
of IN N
smaller JJR N
, , N
but CC N
still RB N
worthwhile JJ N
, , N
effects NNS N
of IN N
either DT N
of IN N
the DT N
trial NN N
drugs NNS N
. . N

-DOCSTART- -25224595- O O

Caphosol NNP i
( ( i
? . i
) ) i
mouthwash NN i
gives VBZ N
no DT N
additional JJ N
protection NN N
against IN N
oral JJ N
mucositis NN N
compared VBN N
to TO i
cryotherapy VB i
alone RB N
in IN p
stem NN p
cell NN p
transplantation NN p
. . p

A DT N
pilot NN N
study NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
if IN N
adding VBG i
Caphosol NNP i
( ( i
? . i
) ) i
, , i
a DT N
mouthwash JJ N
solution NN N
, , N
to TO N
oral JJ i
cryotherapy NN i
( ( i
OC NNP N
) ) N
further RBR N
protects NNS N
against IN N
oral JJ N
mucositis NN N
( ( N
OM NNP N
) ) N
, , N
a DT N
toxic JJ N
painful JJ N
complication NN N
to TO N
high VB N
dose JJ N
chemotherapy NN N
. . N

METHOD NNP N
The DT N
study NN N
was VBD N
a DT N
randomised JJ N
, , N
controlled VBN N
, , N
study NN N
design NN p
. . p

Patients NNS p
?16 JJ p
years NNS p
scheduled VBN p
for IN p
allogeneic JJ p
stem NN p
cell NN p
transplantation NN p
were VBD p
included VBN p
consecutively RB p
and CC N
randomised VBD N
to TO N
experimental VB N
group NN N
receiving VBG i
OC NNP i
combined VBN i
with IN i
Caphosol NNP i
( ( i
? . i
) ) i
( ( i
n JJ i
= NNP i
20 CD N
) ) N
or CC i
control VB i
group NN i
receiving VBG i
OC NNP i
only RB i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

OC NNP i
was VBD N
given VBN N
from IN N
start NN N
to TO N
end VB N
of IN N
HDCT NNP N
. . N

Caphosol NNP i
( ( i
? . i
) ) i
, , i
from IN i
day NN N
0 CD N
to TO N
day NN N
21 CD N
. . N

RESULT VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
regarding VBG N
age NN N
or CC N
gender NN N
between IN N
the DT N
groups NNS N
. . o

Mucositis NNP o
was VBD o
assessed VBN o
with IN N
the DT o
World NNP o
Health NNP o
Organisation NNP o
( ( o
WHO NNP o
) ) o
grading VBG o
scale NN o
. . o

Pain NN o
was VBD N
assessed VBN N
with IN N
a DT N
10 CD o
cm NN o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
from IN N
0 CD N
= JJ N
no DT N
pain NN N
to TO N
10 CD N
= NNS N
worst RBR N
imaginable JJ N
pain NN N
. . N

Start NNP o
and CC o
duration NN o
of IN o
therapy NN o
with IN o
pain NN o
relieving VBG o
drugs NNS o
, , o
serum VBD o
C-reactive JJ o
protein NN o
values NNS o
, , o
and CC o
number NN o
of IN o
days NNS o
of IN o
hospitalisation NN o
were VBD o
collected VBN N
from IN N
the DT N
medical JJ N
records NNS o
. . o

Data NNS o
on IN o
OM NNP o
, , o
oral JJ o
pain NN o
, , o
use NN o
of IN o
i.v NN o
. . o

opioids NNS o
and CC o
total JJ o
parenteral JJ o
nutrition NN o
were VBD o
collected VBN N
during IN N
22 CD N
days NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
on IN o
OM NNP o
, , o
oral JJ o
pain NN o
, , o
use NN o
of IN o
i.v NN o
. . o

opioids NNS o
or CC o
TPN NNP o
between IN o
the DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
study NN N
showed VBD N
no DT N
additional JJ N
effect NN N
of IN N
combining VBG i
Caphosol NNP i
( ( i
? . i
) ) i
with IN i
OC NNP i
. . i

-DOCSTART- -23075031- O O

The DT N
effects NNS N
of IN N
moderate JJ i
to TO i
vigorous JJ o
aerobic JJ i
exercise NN i
on IN N
the DT N
sleep JJ p
need NN p
of IN p
sedentary JJ p
young JJ p
adults NNS p
. . p

Exercise NN i
has VBZ N
been VBN N
recommended VBN N
for IN N
enhancing VBG N
sleep NN N
; : N
a DT N
claim NN N
linked VBN N
to TO N
the DT N
belief NN N
that IN N
sleep VBP N
need MD N
- : N
defined VBN N
by IN N
sleep JJ N
duration NN N
and CC N
depth NN N
- : N
is VBZ N
increased VBN N
post-exercise NN N
to TO N
allow VB N
tissue NN N
recovery NN N
. . N

Objective JJ N
studies NNS N
investigating VBG N
exercise-sleep JJ N
responses NNS N
have VBP N
produced VBN N
mixed JJ N
outcomes NNS N
, , N
and CC N
the DT N
disparity NN N
in IN N
results NNS N
between IN N
studies NNS N
may MD N
be VB N
due JJ N
to TO N
differences NNS N
in IN N
individual JJ N
characteristics NNS N
and/or VBP N
exercise NN i
protocol NN N
, , N
emphasising VBG N
the DT N
importance NN N
of IN N
carefully RB N
controlled VBN N
trials NNS N
. . N

We PRP N
investigated VBD N
the DT N
role NN N
of IN N
exercise NN i
on IN N
the DT N
sleep JJ N
need NN N
of IN N
sedentary JJ p
adults NNS p
, , N
after IN N
controlling VBG N
for IN N
exercise NN N
mode NN N
, , N
timing NN N
and CC N
duration NN N
. . N

Twelve NNP p
healthy JJ p
volunteers NNS p
( ( p
25.2 CD p
? . p
4.0 CD p
years NNS p
, , p
9 CD p
females NNS p
, , p
[ NNP p
Vdot NNP p
] NNP p
O NNP p
( ( p
2 CD p
) ) p
max NN p
35.4 CD p
? . p
8.8 CD p
ml? NN p
kg NN p
( ( p
-1 NN p
) ) p
? . p
min NN p
( ( p
-1 NNP p
) ) p
) ) p
were VBD p
randomised VBN i
to TO i
no-exercise NN i
or CC i
to TO i
a DT i
bout NN i
of IN i
treadmill NN i
exercise NN i
at IN i
45 CD N
% NN N
, , N
55 CD N
% NN N
, , N
65 CD N
% NN N
or CC N
75 CD N
% NN N
[ JJ N
Vdot NNP N
] NNP N
O NNP N
( ( N
2 CD N
) ) N
max NN N
in IN N
a DT N
crossover NN N
design NN N
. . N

Sleep VB i
on IN i
no-exercise NN i
and CC i
exercise NN i
nights NNS i
were VBD N
assessed VBN i
by IN i
polysomnography NN i
. . i

Participants NNS i
spent VBD N
a DT N
greater JJR N
proportion NN o
of IN o
sleep NN o
in IN o
light JJ o
sleep NN o
( ( o
stage NN o
1 CD N
+ JJ N
stage NN N
2 CD N
) ) N
after IN i
exercise NN i
at IN i
both DT N
65 CD N
% NN N
and CC N
75 CD N
% NN N
[ JJ N
Vdot NNP N
] NNP N
O NNP N
( ( N
2 CD N
) ) N
max NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
than IN N
the DT N
no-exercise JJ i
condition NN i
. . N

There EX N
was VBD N
a DT N
trend NN N
of IN N
a DT N
reduced JJ N
proportion NN o
of IN o
rapid JJ o
eye NN o
movement NN o
sleep JJ o
with IN o
increased JJ o
exercise NN o
intensity NN o
( ( o
P NNP o
= NNP N
0.067 CD N
) ) N
. . N

No UH N
other JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
any DT N
other JJ N
sleep JJ N
variables NNS N
. . N

Two CD N
findings NNS N
emerged VBD N
: : N
vigorous JJ i
exercise NN i
did VBD i
not RB N
increase VB o
sleep JJ o
need NN o
; : o
however RB o
, , N
this DT N
level NN i
of IN i
exercise NN i
increased VBN o
light JJ o
sleep NN o
. . o

-DOCSTART- -24910215- O O

Intramedullary NNP i
repair NN i
device NN N
against IN N
volar JJ N
plating NN N
in IN N
the DT N
reconstruction NN N
of IN N
extra-articular JJ N
and CC N
simple JJ N
articular JJ N
distal JJ N
radius NN N
fractures NNS N
; : N
a DT N
randomized VBN N
pilot NN N
study NN N
. . N

PURPOSE VB N
This DT N
prospective JJ N
randomized NN N
pilot NN N
study NN N
reports VBZ N
our PRP$ N
institutional JJ N
experience NN N
and CC N
early JJ N
results NNS N
using VBG N
Sonoma NNP N
Wrx NNP N
( ( N
Sonoma NNP N
Orthopedic NNP N
Products NNPS N
, , N
Santa NNP N
Rosa NNP N
, , N
CA NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
extra-articular JJ N
and CC N
simple JJ N
intra-articular JJ N
distal JJ N
radius NN N
fractures NNS N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
64 CD p
patients NNS p
, , p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

They PRP p
were VBD p
considered VBN p
eligible JJ p
if IN p
they PRP p
had VBD p
; : p
unstable JJ p
extra-articular JJ p
distal JJ p
radius NN p
fractures NNS p
and CC p
simple JJ p
intra-articular JJ p
distal JJ p
radius NN p
fractures NNS p
suitable JJ p
for IN p
closed JJ p
reduction NN p
( ( p
AO NNP p
types NNS p
; : p
A2.2 NNP p
, , p
A2.3 NNP p
, , p
A3.1 NNP p
C2.1 NNP p
, , p
C2.2 NNP p
) ) p
. . p

Patients NNS p
in IN p
group NN p
I PRP N
received VBD N
intramedullary JJ i
fixation NN i
using VBG i
the DT i
Sonoma NNP i
Wrx NNP i
device NN i
and CC N
patients NNS N
in IN N
group NN N
II NNP N
received VBD N
standard JJ i
volar JJ i
locking VBG i
plate NN i
fixation NN i
. . i

Radiographic JJ N
criteria NNS N
of IN N
acceptable JJ N
healing NN N
were VBD N
used VBN N
for IN N
evaluation NN N
. . N

RESULTS NNP N
Two CD N
groups NNS N
were VBD N
similar JJ N
in IN N
terms NNS N
of IN N
baseline NN N
characteristics NNS N
. . N

Mean JJ o
time NN o
of IN o
operation NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
Group NNP p
1 CD p
vs. NN N
in IN N
group NN p
2 CD p
( ( N
36.81 CD N
? . N
7.11 CD N
vs. IN N
48.97 CD N
? . N
5.9 CD N
minutes NNS N
, , N
p VBP N
= RB N
0.001 CD N
) ) N
. . o

Time NN o
to TO o
healing NN o
of IN o
the DT o
fracture NN o
was VBD N
not RB N
different JJ N
between IN N
two CD N
groups NNS N
( ( N
5.45 CD N
? . N
1.09 CD N
vs. IN N
5.70 CD N
? . N
1.04 CD N
weeks NNS N
for IN N
Group NNP N
1 CD N
vs. FW N
2 CD N
, , N
respectively RB N
p JJ N
= NNP N
0.36 CD N
) ) N
. . N

Overall JJ o
complications NNS o
occurred VBD o
in IN N
9 CD N
patients NNS p
in IN p
group NN p
1 CD p
and CC p
in IN N
15 CD N
patients NNS N
in IN p
group NN p
2 CD p
( ( p
p NN N
= RB N
0.17 CD N
) ) N
. . N

Follow-up NN N
was VBD N
completed VBN N
in IN N
all DT N
patients NNS p
with IN p
a DT N
median JJ N
time NN N
of IN N
12 CD N
months NNS N
and CC N
13 CD N
months NNS N
in IN p
group NN p
1 CD p
and CC p
2 CD p
, , p
respectively RB N
. . N

On IN N
radiographic JJ N
evaluation NN o
radial JJ o
inclination NN o
, , o
radial JJ o
height NN o
and CC o
volar JJ o
tilt NNS o
were VBD o
not RB N
significantly RB N
different JJ N
between IN N
group NN N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
two CD N
groups NNS N
in IN N
regard NN N
to TO N
wrist VB o
rotational JJ o
degrees NNS o
measured VBN o
in IN N
last JJ N
follow-up JJ N
visit NN N
. . N

CONCLUSION NNP N
Sonoma NNP i
Wrx NNP i
Device NNP i
is VBZ i
reliable JJ N
and CC N
effective JJ N
in IN N
terms NNS N
of IN N
achieving VBG N
satisfactory JJ N
outcomes NNS N
in IN N
treatment NN N
of IN N
distal JJ N
radius NN N
fractures NNS N
. . N

It PRP N
may MD N
be VB N
reasonable JJ N
to TO N
use VB N
this DT N
device NN N
to TO N
prevent VB N
complications NNS N
that WDT N
are VBP N
related VBN N
to TO N
extensive JJ N
soft JJ N
tissue NN N
dissection NN N
. . N

-DOCSTART- -7075499- O O

[ JJ N
Dose-effect NNP N
relationship NN N
of IN N
isosorbide NN i
dinitrate NN i
in IN N
the DT N
treatment NN N
of IN N
angina JJ N
pectoris NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

Fifteen JJ p
males NNS p
with IN p
angiographic JJ p
evidence NN p
of IN p
coronary JJ p
heart NN p
disease NN p
and CC p
stable JJ p
, , p
exercise-induced JJ p
angina NN p
pectoris NN p
were VBD N
given VBN N
placebo NNS i
or CC i
isosorbide VB i
dinitrate NN i
( ( i
ISDN NNP i
) ) i
in IN N
a DT N
dialy NN N
dose NN N
of IN N
30 CD N
mg NNS N
, , N
120 CD N
mg NN N
, , N
240 CD N
mg NN N
and CC N
480 CD N
mg NN N
in IN N
a DT N
randomized JJ N
single-blind JJ N
trial NN N
. . N

The DT N
daily JJ N
doses NNS N
were VBD N
given VBN N
as IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
5 CD N
mg NNS N
, , N
20 CD N
mg NN N
, , N
40 CD N
mg NN N
and CC N
80 CD N
mg JJ N
tablets NNS N
. . N

Each DT N
dose NN N
and CC N
placebo NN N
was VBD N
given VBN N
for IN N
seven CD N
days NNS N
. . N

On IN N
the DT N
seventh JJ N
day NN N
an DT N
exercise NN o
ECG NNP o
of IN N
standardized JJ N
level NN N
and CC N
duration NN o
of IN o
exercise NN o
was VBD N
recorded VBN N
. . N

The DT N
ischaemia NN o
response NN N
in IN N
the DT N
ECG NNP N
revealed VBD N
a DT N
dose-dependent JJ N
reduction NN o
by IN N
28 CD N
% NN N
( ( N
5 CD N
mg RB N
ISDN NNP N
) ) N
, , N
43 CD N
% NN N
( ( N
20 CD N
mg NN N
) ) N
, , N
60 CD N
% NN N
( ( N
40 CD N
mg NN N
) ) N
and CC N
73 CD N
% NN N
( ( N
80 CD N
mg NN N
) ) N
. . N

The DT N
number NN o
of IN o
anginal JJ o
attacks NNS o
similarly RB N
fell VBD N
parallel RB N
to TO N
dose VB N
. . N

Plasma NNP o
level NN o
of IN o
ISDN NNP o
and CC o
the DT o
mononitrates NNS o
, , N
measured VBD N
one CD N
and CC N
four CD N
hours NNS N
after IN N
drug NN N
intake NN N
, , N
rose VBD N
almost RB N
linearly JJ N
in IN N
relation NN N
to TO N
dose VB N
. . N

Oral NNP N
ISDN NNP N
thus RB N
has VBZ N
a DT N
dose-dependent JJ N
effect NN N
on IN N
the DT N
frequency NN o
of IN o
angina NN o
and CC o
ischaemia NN o
parameters NNS o
during IN N
ergometric JJ N
exercise NN N
. . N

The DT N
protracted JJ N
anti-anginal JJ o
effect NN o
of IN N
ISDN NNP N
is VBZ N
largely RB N
due JJ N
to TO N
its PRP$ N
metabolites NNS N
. . N

At IN N
high JJ N
doses NNS N
there EX N
is VBZ N
presumably RB N
an DT N
added JJ N
effect NN N
of IN N
the DT N
high JJ N
blood NN N
level NN N
of IN N
the DT N
basic JJ N
substance.U NN N
-DOCSTART- -7936969- O O

Influence NN N
of IN N
ball NN i
weight NN i
on IN N
junior JJ p
high JJ p
school NN p
girls NNS p
' POS p
volleyball NN p
performance NN o
. . o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
influence NN o
of IN i
a DT i
lighter JJR i
ball NN i
( ( i
Tachikara NNP i
Volley NNP i
Lite NNP i
) ) i
on IN i
72 CD i
seventh-grade JJ i
girls NNS i
' POS i
tournament NN i
game NN i
play NN i
and CC i
pretest-to-posttest JJ i
improvement NN i
for IN i
a DT i
16-day JJ i
volleyball NN i
practice NN i
period NN i
. . i

Two CD N
intact JJ N
classes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
groups NNS N
, , N
one CD N
of IN N
whom WP N
used VBD N
lighter JJR i
balls NNS i
during IN N
skills NNS N
progressions NNS N
while IN N
a DT N
second JJ N
used JJ N
regulation NN i
balls NNS i
. . i

All DT N
students NNS N
used VBN N
regulation NN i
balls NNS i
during IN N
tournament JJ N
game NN N
play NN N
and CC N
skills NNS N
tests NNS N
. . N

Both DT N
groups NNS N
significantly RB N
improved VBD N
the DT N
forearm JJ o
pass NN o
from IN N
pretest NN N
to TO N
posttest VB N
. . N

Analysis NN o
of IN o
covariance NN o
indicated VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
on IN N
posttest NN N
means NNS N
for IN N
any DT N
skill NN N
. . N

A DT N
2 CD N
x NN N
6 CD N
( ( N
treatment NN N
x NNS N
game NN N
day NN N
) ) N
analysis NN N
of IN N
variance NN N
indicated VBD N
that IN N
the DT N
group NN N
practicing VBG N
with IN N
lighter JJR i
balls NNS i
had VBD N
significantly RB N
more RBR N
correct JJ o
sets NNS o
and CC N
a DT N
higher JJR o
average JJ o
daily JJ o
success NN o
rate NN o
for IN N
the DT N
set NN N
and CC N
underhand JJ N
serve NN N
on IN N
game NN N
days NNS N
than IN N
the DT N
group NN N
using VBG N
a DT N
regulation NN i
ball NN i
. . i

-DOCSTART- -22496207- O O

Effect NN N
of IN N
sulfasalazine NN i
on IN N
inflammation NN o
and CC o
endothelial JJ o
function NN o
in IN N
patients NNS p
with IN p
established VBN p
coronary JJ p
artery NN p
disease NN p
. . p

Inflammation NNP N
is VBZ N
critical JJ N
for IN N
atherosclerosis NN N
development NN N
and CC N
may MD N
be VB N
a DT N
target NN N
for IN N
risk-reduction NN N
therapy NN N
. . N

In IN N
experimental JJ N
studies NNS N
, , N
activation NN N
of IN N
the DT N
inflammatory JJ N
regulator NN N
, , N
nuclear JJ N
factor NN N
kappa NN N
B NNP N
( ( N
NFlB NNP N
) ) N
, , N
contributes VBZ N
to TO N
endothelial JJ N
activation NN N
and CC N
reduced JJ N
nitric JJ N
oxide NN N
production NN N
. . N

We PRP N
treated VBD N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
with IN N
sulfasalazine NN i
, , i
an DT i
inhibitor NN i
of IN i
NF?B NNP i
, , i
and CC i
placebo NN i
in IN i
a DT i
randomized JJ i
, , i
double-blind JJ i
, , i
crossover NN i
study NN i
design NN i
. . i

Brachial JJ o
artery JJ o
flow-mediated JJ o
dilation NN o
( ( o
FMD NNP o
) ) o
and CC o
digital JJ o
vascular JJ o
function NN o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
each DT N
6-week JJ N
treatment NN N
period NN N
. . N

Of IN N
the DT p
53 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
crossover NN p
study NN p
, , p
32 CD p
( ( p
age NN p
60 CD p
? . p
10 CD p
, , p
22 CD p
% NN p
female NN p
) ) p
completed VBD p
all PDT N
the DT N
visits NNS N
, , N
with IN N
a DT N
high JJ N
rate NN N
of IN N
study NN N
withdrawal NN N
due JJ N
to TO N
gastrointestinal JJ N
side NN N
effects NNS N
. . N

In IN N
a DT N
subset NN N
of IN N
10 CD p
participants NNS p
, , p
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
4 CD N
days NNS N
of IN N
sulfasalazine JJ i
treatment NN i
( ( N
n JJ N
= NNP N
5 CD N
) ) N
to TO N
no DT N
treatment NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
on IN N
NF?B-regulated JJ N
gene NN N
expression NN N
in IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS o
. . o

Tumor NNP o
necrosis JJ o
factor NN o
?-stimulated JJ o
expression NN o
of IN o
CD69 NNP o
and CC o
NFlB NNP o
subunit VBD o
p50 NN N
was VBD N
significantly RB N
blunted VBN N
after IN N
4 CD N
days NNS N
of IN N
sulfasalazine JJ N
treatment NN N
but CC N
not RB N
after IN N
no DT N
treatment NN N
. . N

However RB o
, , o
FMD NNP o
and CC o
digital JJ o
vasodilator NN o
response NN o
did VBD o
not RB N
significantly RB N
change VBP N
from IN N
baseline NN N
with IN N
long-term JJ i
sulfasalazine NN i
treatment NN i
. . N

Short-term JJ i
sulfasalazine NN i
inhibited VBN i
NFlB NNP N
activity NN N
; : N
however RB N
, , N
long-term JJ N
treatment NN N
was VBD N
poorly RB N
tolerated VBN N
and CC N
did VBD N
not RB N
improve VB N
endothelial JJ N
function NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
sulfasalazine JJ N
therapy NN N
is VBZ N
not RB N
the DT N
optimal JJ N
anti-inflammatory JJ N
treatment NN N
for IN N
reversing VBG N
endothelial JJ N
dysfunction NN N
in IN N
cardiovascular JJ N
disease NN N
. . N

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
investigate VB N
the DT N
potential NN N
for IN N
NFlB NNP N
inhibition NN N
to TO N
reduce VB N
cardiovascular JJ N
risk NN N
. . N

-DOCSTART- -3475309- O O

A DT N
30-month JJ N
longitudinal JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
some DT N
oral JJ i
hygiene NN i
measures NNS i
on IN N
Streptococcus NNP o
mutans NNS o
and CC o
approximal JJ o
dental JJ o
caries NNS o
. . o

The DT N
effects NNS N
of IN N
some DT N
oral JJ i
hygiene NN i
measures NNS i
on IN N
Streptococcus NNP o
mutants NNS o
and CC p
approximal JJ o
dental JJ o
caries NNS o
were VBD N
evaluated VBN N
. . N

One CD p
hundred CD p
and CC p
eighty-seven JJ p
13-year-old JJ p
individuals NNS p
with IN p
high JJ p
levels NNS p
of IN p
salivary JJ p
S. NNP o
mutans NNS o
( ( p
greater JJR p
than IN p
10 CD p
( ( p
6 CD p
) ) p
/mL NN p
) ) p
were VBD p
selected VBN p
. . p

They PRP N
were VBD N
randomly RB N
distributed VBN N
into IN N
three CD N
groups NNS N
. . N

Group NNP N
I PRP N
initially RB N
received VBD N
professional JJ i
mechanical JJ i
tooth-cleaning NN i
, , i
tongue-scraping NN i
, , i
chlorhexidine NN i
treatment NN i
, , i
and CC i
oral JJ i
hygiene NN i
instructions NNS i
concentrated VBD N
on IN N
the DT N
approximal JJ N
surfaces NNS N
most RBS N
colonized VBN N
by IN N
S. NNP N
mutans NNS N
. . N

The DT N
treatment NN N
was VBD N
given VBN N
four CD N
times NNS N
with IN N
intervals NNS N
of IN N
two CD N
days NNS N
, , N
followed VBN N
by IN N
one CD N
single JJ N
treatment NN N
every DT N
six CD N
months NNS N
throughout IN N
the DT N
experimental JJ N
period NN N
. . N

The DT N
initial JJ N
treatment NN N
period NN N
for IN N
group NN N
II NNP N
, , N
also RB N
consisting VBG N
of IN N
four CD N
visits NNS N
, , N
included VBD N
the DT N
same JJ N
oral JJ i
hygiene NN i
instructions NNS i
as IN N
for IN N
group NN N
I PRP N
. . N

The DT N
instructions NNS N
were VBD N
repeated VBN N
every DT N
six CD N
months NNS N
. . N

Group NNP N
III NNP N
was VBD N
maintained VBN N
in IN N
the DT N
preventive JJ i
program NN i
provided VBN i
by IN i
the DT i
local JJ i
Dental NNP i
Health NNP i
Office NNP i
, , N
based VBN N
on IN N
mechanical JJ i
plaque NN i
control NN i
and CC N
topical JJ i
use NN i
of IN i
fluorides NNS i
and CC i
chlorhexidine NN i
at IN N
individualized JJ N
intervals NNS N
. . N

Group NNP N
I PRP N
showed VBD N
a DT N
significant JJ N
immediate JJ N
reduction NN N
of IN N
S. NNP o
mutans NNS o
in IN o
saliva NN o
as RB N
well RB N
as IN N
an DT N
approximal JJ N
tooth NN N
surfaces NNS N
. . N

After IN N
six CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
among IN N
the DT N
three CD N
groups NNS N
regarding VBG N
these DT N
variables NNS N
. . N

Compared VBN N
with IN N
baseline NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
of IN N
S. NNP o
mutans NNS o
in IN N
all DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
caries NNS o
progression NN o
among IN N
the DT N
three CD N
groups NNS N
. . N

However RB N
, , N
the DT N
selected VBN N
high-risk JJ N
individuals NNS N
in IN N
group NN N
I PRP N
developed VBD N
0.25 CD N
new JJ N
manifest NN N
caries NNS N
lesions NNS N
approximally/year VBP N
, , N
compared VBN N
with IN N
0.27 CD N
for IN N
all DT N
children NNS N
of IN N
the DT N
same JJ N
age NN N
group NN N
in IN N
the DT N
area NN N
. . N

Seventeen JJ N
individuals NNS N
had VBD N
approximal JJ N
surfaces NNS N
with IN N
consistently RB N
high JJ N
or CC N
consistently RB N
low JJ N
S. NNP o
mutans NN o
levels NNS o
. . o

Forty-six CD N
percent NN N
of IN N
the DT N
surfaces NNS N
with IN N
high JJ N
values NNS N
developed VBD N
new JJ o
or CC o
progressive JJ o
caries NNS o
, , N
compared VBN N
with IN N
2 CD N
% NN N
of IN N
the DT N
surfaces NNS N
with IN N
low JJ N
values NNS N
. . N

-DOCSTART- -19512937- O O

Loss NNP N
of IN N
bone JJ o
mineral JJ o
density NN o
after IN N
antiretroviral JJ i
therapy NN i
initiation NN i
, , N
independent JJ N
of IN N
antiretroviral JJ N
regimen NNS N
. . N

BACKGROUND NNP N
Decreased VBD N
bone JJ o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
has VBZ N
been VBN N
described VBN N
in IN N
HIV-infected JJ p
patients NNS p
initiating VBG p
antiretroviral JJ p
therapy NN p
( ( p
ART NNP p
) ) p
, , N
but CC N
the DT N
contributions NNS N
of IN N
ART NNP N
and CC N
immunologic JJ N
and/or NN N
virologic JJ N
factors NNS N
remain VBP N
unclear JJ N
. . N

METHODS NNP N
We PRP N
compared VBN N
total JJ N
BMD NNP o
changes NNS N
over IN N
96 CD N
weeks NNS N
in IN N
106 CD p
ART-naive JJ p
HIV-infected JJ p
subjects NNS p
who WP p
were VBD p
randomized VBN p
to TO p
receive VB p
efavirenz NN i
( ( i
EFV NNP i
) ) i
+ FW i
zidovudine/lamivudine NN i
( ( i
n JJ i
= NNP i
32 CD i
) ) i
or CC i
lopinavir/ritonavir NN i
( ( i
LPV/r NNP i
) ) i
+ VBP i
zidovudine/lamivudine JJ i
induction NN i
( ( p
n JJ p
= NNP p
74 CD p
) ) p
for IN p
24-48 JJ p
weeks NNS p
followed VBN p
by IN p
LPV/r NNP i
monotherapy NN i
. . i

We PRP N
also RB N
sought VBD N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
BMD NNP N
loss NN N
, , N
including VBG N
markers NNS N
of IN N
systemic JJ N
inflammation NN N
[ NNP N
soluble JJ N
tumor NN N
necrosis NN N
factor-alpha JJ N
receptors NNS N
( ( N
sTNFR NN N
I PRP N
and CC N
II NNP N
) ) N
] NN N
. . N

RESULTS NNP N
After IN N
96 CD N
weeks NNS N
, , N
the DT N
mean JJ N
percent NN o
change NN o
from IN o
baseline NN o
in IN o
total JJ o
BMD NNP o
was VBD N
-2.5 VBN N
% NN N
( ( N
LPV/r NNP N
) ) N
and CC N
-2.3 $ N
% NN N
( ( N
EFV NNP N
) ) N
( ( N
P NNP N
< VBZ N
0.01 CD N
for IN N
within-group JJ N
changes NNS N
in IN N
either DT N
arm NN N
; : N
P NNP N
= VBZ N
0.86 CD N
for IN N
between-group JJ N
differences NNS N
) ) N
. . N

No DT N
alteration NN N
in IN N
the DT N
rate NN o
of IN o
BMD NNP o
change NN o
was VBD N
observed VBN N
upon IN N
simplification NN N
to TO N
LPV/r NNP N
monotherapy NN N
. . N

Although IN N
soluble JJ N
tumor NN N
necrosis NN N
factor-alpha JJ N
receptor NN N
II NNP N
concentrations NNS N
at IN N
baseline NN N
and CC N
24 CD N
weeks NNS N
were VBD N
at IN N
least JJS N
marginally RB N
associated VBN N
with IN N
subsequent JJ N
changes NNS N
in IN N
BMD NNP o
( ( N
P NNP N
= NNP N
0.06 CD N
and CC N
P NNP N
= NNP N
0.028 CD N
, , N
respectively RB N
) ) N
, , N
these DT N
associations NNS N
were VBD N
no RB N
longer RBR N
significant JJ N
after IN N
adjustment NN N
for IN N
CD4 NNP N
T NNP N
cell NN N
count NN N
. . N

Subjects NNS p
with IN p
lower JJR p
baseline NN p
CD4 NNP p
T NNP p
cell NN p
count NN p
, , p
non-black JJ p
race NN p
, , p
and CC p
higher JJR p
baseline NN p
glucose NN p
demonstrated VBD N
a DT N
higher JJR N
risk NN N
for IN N
> JJ N
5 CD N
% NN N
decrease NN N
in IN N
BMD NNP o
. . o

CONCLUSIONS NNP N
Similar JJ N
decreases NNS N
in IN N
BMD NNP o
over IN N
96 CD N
weeks NNS N
occurred VBD N
in IN N
ART-naive JJ p
subjects NNS p
receiving VBG N
either CC N
EFV-based JJ N
regimen NNS N
or CC N
LPV/r-based JJ N
regimen NNS N
, , N
which WDT N
was VBD N
not RB N
altered VBN N
by IN N
simplification NN N
to TO N
LPV/r NNP N
monotherapy NN N
and CC N
was VBD N
unrelated VBN N
to TO N
markers NNS N
of IN N
tumor NN N
necrosis JJ N
factor-alpha JJ N
activity NN N
. . N

-DOCSTART- -22565161- O O

Once-daily RB N
MMX NNP i
( ( i
? . i
) ) i
mesalamine NN i
for IN N
endoscopic JJ N
maintenance NN N
of IN N
remission NN N
of IN p
ulcerative JJ p
colitis NN p
. . p

OBJECTIVES NNP N
Treatment NNP N
with IN i
mesalamine NN i
to TO N
maintain VB N
endoscopic JJ N
remission NN N
( ( N
mucosal JJ N
healing VBG N
) ) N
of IN N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
relapse NN N
and CC N
is VBZ N
the DT N
recommended JJ N
first-line JJ N
maintenance NN N
therapy NN N
. . N

To TO N
improve VB N
treatment NN N
adherence NN N
, , N
a DT N
mesalamine NN N
formulation NN N
that WDT N
can MD N
be VB N
administered VBN N
once-daily RB N
, , N
MMX NNP i
( ( i
? . i
) ) i
mesalamine NN i
( ( i
Lialda NNP i
; : i
Shire NNP i
Pharmaceuticals NNP i
LLC NNP i
, , i
Wayne NNP i
, , i
PA NNP i
) ) i
, , i
was VBD N
developed VBN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ i
MMX NNP i
mesalamine NN i
compared VBN i
with IN N
twice-daily JJ i
delayed-release JJ i
mesalamine NN i
( ( i
Asacol NNP i
; : i
Warner NNP i
Chilcott NNP i
, , i
Dublin NNP i
, , i
Ireland NNP i
) ) i
for IN i
maintaining VBG N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ i
MMX NNP i
mesalamine NN i
2.4 CD i
g/day NN N
compared VBN N
with IN i
twice-daily JJ i
delayed-release JJ i
mesalamine NN i
at IN i
a DT i
total JJ i
daily JJ i
dose NN i
of IN i
1.6 CD i
g/day NN i
in IN i
patients NNS N
with IN N
UC NNP N
in IN N
endoscopic JJ N
remission NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD o
maintenance NN o
of IN o
endoscopic JJ o
remission NN o
at IN o
month NN o
6 CD o
in IN o
the DT o
per-protocol NN o
( ( o
PP NNP o
) ) o
population NN o
. . o

RESULTS NNP N
Overall NNP p
, , p
826 CD p
patients NNS p
were VBD p
randomized VBN p
and CC p
dosed VBN p
. . p

The DT N
primary JJ N
objective JJ N
( ( N
non-inferiority NN N
) ) N
was VBD N
met VBN N
. . N

At IN N
month NN N
6 CD N
, , N
83.7 CD N
and CC N
77.8 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
in IN N
the DT N
PP NNP N
and CC N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
populations NNS N
, , N
respectively RB N
, , N
had VBD N
maintained VBN o
endoscopic JJ o
remission NN o
compared VBN o
with IN N
81.5 CD N
% NN N
( ( N
PP NNP N
) ) N
and CC N
76.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
of IN N
patients NNS N
receiving VBG N
delayed-release JJ N
mesalamine NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
difference NN N
: : N
-3.9 CD N
% NN N
, , N
8.1 CD N
% NN N
( ( N
PP NNP N
) ) N
; : N
-5.0 CD N
% NN N
, , N
6.9 CD N
% NN N
( ( N
ITT NNP o
) ) o
) ) o
. . o

Time NN o
to TO o
relapse VB o
was VBD o
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
( ( N
log-rank JJ N
test NN N
, , N
P=0.5116 NNP N
( ( N
PP NNP N
) ) N
; : N
P=0.5455 NNP N
( ( N
ITT NNP N
) ) N
) ) N
. . N

The DT o
proportion NN o
of IN o
patients NNS o
with IN o
adverse JJ o
events NNS o
was VBD o
37.1 CD N
and CC N
36.0 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
and CC N
delayed-release JJ N
mesalamine NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Once-daily JJ N
dosing NN N
of IN N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
was VBD N
shown VBN N
to TO N
be VB N
well RB N
tolerated VBN N
and CC N
non-inferior JJ N
to TO N
twice-daily JJ N
dosing VBG N
with IN N
delayed-release JJ N
mesalamine NN N
1.6 CD N
g/day NN N
for IN N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

-DOCSTART- -10385063- O O

Calcitriol NNP i
for IN N
bone NN N
disease NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
. . p

BACKGROUND NNP N
Osteoporosis NNP N
is VBZ N
associated VBN N
with IN N
cirrhosis NN N
of IN N
the DT N
liver NN N
, , N
but CC N
the DT N
effects NNS N
of IN N
therapy NN N
for IN N
osteoporosis NN o
associated VBN N
with IN N
cirrhosis NN N
are VBP N
still RB N
controversial JJ N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
the DT N
effects NNS o
of IN N
calcitriol NN i
( ( i
1alpha,25-dihydroxyvitamin JJ i
D3 NNP i
) ) i
on IN N
bone NN o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
in IN N
76 CD p
patients NNS p
( ( p
26 CD p
men NNS p
and CC p
50 CD p
women NNS p
) ) p
with IN p
cirrhosis NN p
who WP N
were VBD N
assigned VBN N
randomly RB i
to TO i
receive VB i
calcitriol NN i
( ( i
0.5 CD i
mg NN i
twice RB i
per IN i
day NN i
) ) i
or CC i
not RB i
. . i

The DT N
BMD NNP o
of IN o
the DT o
lumbar NN o
vertebrae NN o
was VBD N
measured VBN i
by IN i
dual-energy JJ o
X-ray JJ o
absorptiometry NN o
at IN i
least JJS i
twice RB i
, , i
12-57 JJ i
months NNS i
apart RB i
. . i

RESULTS VB N
For IN p
men NNS p
, , p
the DT p
mean JJ p
annual JJ p
change NN o
in IN o
BMD NNP o
was VBD p
1.1 CD p
% NN p
in IN p
the DT p
treated JJ p
group NN p
and CC p
-0.4 CD p
% NN p
in IN p
the DT p
control NN p
group NN p
. . p

The DT N
median JJ N
( ( N
25th CD N
and CC N
75th CD N
percentiles NNS N
) ) N
annual JJ o
change NN o
in IN o
BMD NNP o
was VBD N
0.6 CD N
( ( N
-0.1 NN N
, , N
2.1 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
group NN N
and CC N
-1.4 NNP N
( ( N
-1.9 NNP N
, , N
1.6 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
median JJ N
annual JJ N
change NN N
between IN N
the DT N
two CD p
groups NNS p
was VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

For IN p
women NNS p
, , p
the DT p
mean JJ p
annual JJ p
change NN o
in IN o
BMD NNP o
was VBD p
-0.5 JJ p
% NN p
in IN p
the DT p
treated JJ p
group NN p
and CC p
-2.3 CD p
% NN p
in IN p
the DT p
control NN p
group NN p
. . p

The DT N
median JJ N
( ( N
25th CD N
and CC N
75th CD N
percentiles NNS N
) ) N
annual JJ N
change NN N
in IN N
BMD NNP o
was VBD N
-0.5 NNP N
( ( N
-1.8 NNP N
, , N
1.3 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
group NN N
and CC N
-1.5 NNP N
( ( N
-3.8 NNP N
, , N
-0.7 NNP N
% NN N
) ) N
in IN N
the DT N
control NN p
group NN p
. . p

This DT N
difference NN N
was VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
calcitriol NN N
can MD N
prevent VB N
bone JJ o
loss NN o
and CC N
, , N
therefore RB N
, , N
may MD N
be VB N
useful JJ N
for IN N
the DT N
treatment NN N
of IN N
bone NN N
disease NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
. . p

-DOCSTART- -17657694- O O

[ JJ N
Potentials NNS N
of IN N
monocular NN i
augmented VBN i
reality NN i
technology NN i
in IN N
automobile NN N
production NN N
] NNP N
. . N

INTRODUCTION NNP N
Augmented NNP i
reality NN i
( ( i
AR NNP i
) ) i
technologies NNS i
can MD N
enrich VB N
the DT N
real JJ N
environment NN N
with IN N
visual JJ N
data NNS N
, , N
which WDT N
has VBZ N
potential JJ N
benefits NNS N
for IN N
optimising VBG N
the DT N
operator NN N
's POS N
working VBG N
process NN N
. . N

It PRP N
offers VBZ N
the DT N
possibility NN N
to TO N
provide VB N
context-sensitive JJ N
information NN N
independently RB N
of IN N
the DT N
user NN N
's POS N
location NN N
and CC N
position NN N
. . N

Data NNS N
are VBP N
presented VBN N
to TO N
the DT N
dominant JJ N
eye NN N
on IN N
a DT N
semi-transparent JJ N
mirror NN N
using VBG N
a DT N
head-mounted JJ N
display NN N
( ( N
HMD NNP N
) ) N
unit NN N
that WDT N
works VBZ N
with IN N
retinal JJ N
laser NN N
technology NN N
. . N

In IN N
this DT N
study NN N
the DT N
potential JJ N
benefits NNS N
and CC N
drawbacks NNS N
of IN N
this DT N
new JJ N
AR NNP i
technology NN i
were VBD N
evaluated VBN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
45 CD p
participants NNS p
without IN p
any DT p
visual JJ p
impairment NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
3 CD N
groups NNS N
and CC N
completed VBD N
a DT N
variety NN N
of IN N
tasks NNS N
during IN N
a DT N
simulated JJ N
working JJ N
day NN N
. . N

Group NNP N
1 CD N
received VBD N
conventional JJ i
working JJ i
aids NNS i
( ( i
paper-based JJ i
documents NNS i
) ) i
to TO i
support VB i
the DT i
task NN i
processing NN i
. . i

Group NNP N
2 CD N
additionally RB N
wore VBD N
an DT N
HMD NNP i
unit NN i
that WDT i
was VBD i
switched VBN i
off RP i
. . i

Group NNP N
3 CD N
wore VBD N
a DT N
functioning NN N
HMD NNP i
without IN i
any DT i
additional JJ i
aids NNS i
. . i

Evaluation NN N
was VBD N
carried VBN N
out RP N
by IN N
means NNS N
of IN N
a DT N
standardised JJ N
questionnaire NN N
( ( N
BMS NNP N
) ) N
and CC N
a DT N
concentration NN N
test NN N
( ( N
d2 JJ N
Aufmerksamkeits-Belastungs-Test NNP N
) ) N
. . N

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
between IN N
the DT N
3 CD N
groups NNS N
were VBD N
found VBN N
in IN N
terms NNS N
of IN N
mental JJ o
strain NN o
, , o
concentration-test JJ o
performance NN o
and CC o
physical JJ o
or CC o
mental JJ o
complaints NNS o
reported VBN N
in IN N
a DT N
follow-up JJ N
interview NN N
. . N

Around IN N
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
noticed VBD N
a DT N
higher JJR o
pressure NN o
and CC o
blurred JJ o
vision NN o
in IN o
both DT o
eyes NNS o
as RB o
well RB o
as IN o
headaches NNS o
. . o

Half NNP N
of IN N
the DT N
participants NNS N
complained VBD N
about IN N
deficiencies NNS N
concerning VBG N
the DT N
ergonomic JJ o
hardware NN o
design NN o
of IN N
the DT N
AR NNP N
system NN N
. . N

DISCUSSION NNP N
Changes NNP N
in IN N
objective JJ N
ophthalmological JJ N
investigation NN N
parameters NNS N
were VBD N
not RB N
observed VBN N
. . N

Subjects NNS N
reported VBD N
reduced JJ N
acceptance NN N
of IN N
the DT N
HMD NNP N
based VBN N
on IN N
non-ophthalmological JJ N
reasons NNS N
, , N
for IN N
example NN N
, , N
the DT N
weight NN N
of IN N
the DT N
unit NN N
or CC N
the DT N
length NN N
of IN N
the DT N
cable NN N
. . N

However RB N
, , N
for IN N
some DT N
specific JJ N
working VBG N
tasks NNS N
, , N
advantages NNS N
in IN N
process NN N
optimisation NN N
and CC N
operator NN N
support NN N
were VBD N
observed VBN N
. . N

-DOCSTART- -8614301- O O

Effect NN N
of IN N
marine NN i
oils NNS i
supplementation NN i
on IN N
coagulation NN N
and CC N
cellular JJ N
activation NN N
in IN N
whole JJ N
blood NN N
. . N

A DT N
study NN N
was VBD N
performed VBN N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
supplemental JJ N
intake NN N
of IN N
various JJ N
marine NN N
oils NNS N
known VBN N
to TO N
be VB N
part NN N
of IN N
the DT N
Eskimo NNP p
diet NN p
. . p

Healthy JJ p
men NNS p
and CC p
women NNS p
( ( p
134 CD p
) ) p
were VBD N
randomly RB N
selected VBN N
to TO N
consume VB N
15 CD N
mL/d NN N
of IN N
oil NN i
from IN i
blubber NN i
of IN i
seal NN i
, , i
cod NN i
liver NN i
, , i
seal/cod NN i
liver NN i
, , i
blubber NN i
of IN i
Minke NNP i
whale NN i
, , i
or CC i
no DT i
oil NN i
for IN N
ten JJ N
weeks NNS N
. . N

Total JJ o
cholesterol NN o
was VBD N
unchanged JJ N
in IN N
the DT N
oil NN N
groups NNS N
, , N
whereas RB N
high JJ o
density NN o
lipoprotein VBP o
cholesterol NN o
increased VBD N
7 CD N
% NN N
in IN N
the DT N
seal/cod NN i
liver NN i
oil NN i
( ( N
CLO NNP N
) ) N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
11 CD N
% NN N
in IN N
the DT N
whale JJ i
oil NN i
group NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

Triacylglycerol NNP o
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
CLO NNP N
group NN N
only RB N
. . N

The DT N
concentration NN o
of IN o
prothrombin JJ o
fragment JJ o
1 CD o
+ JJ o
2 CD o
was VBD N
reduced VBN N
25 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
after IN N
whale JJ N
oil NN N
supplementation NN N
. . N

No DT N
change NN N
in IN N
fibrinogen NN o
or CC o
factor NN o
VIIc NNP o
was VBD N
detected VBN N
. . N

Tumor NNP o
necrosis NN o
factor NN o
generation NN o
in IN o
lipopolysaccharide NN o
( ( o
LPS NNP o
) ) o
-stimulated VBD o
blood NN o
was VBD N
30 CD N
% NN N
reduced VBN N
after IN N
whale JJ N
oil NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
was VBD N
unaffected VBN N
by IN N
intake NN N
of IN N
seal NN N
or CC N
CLO NNP N
. . N

The DT N
LPS-induced JJ o
tissue NN o
factor NN o
activity NN o
in IN o
monocytes NNS o
was VBD N
reduced VBN N
to TO N
a DT N
significant JJ N
degree NN N
only RB N
in IN N
the DT N
seal/CLO NN N
group NN N
( ( N
34 CD N
% NN N
) ) N
and CC N
whale JJ N
oil NN N
group NN N
( ( N
35 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
most RBS N
dramatic JJ N
change NN N
in IN N
thromboxane NN o
B2 NNP o
in IN N
LPS-stimulated NNP N
blood NN N
was VBD N
seen VBN N
after IN N
whale JJ N
oil NN N
intake NN N
with IN N
44 CD N
% NN N
reduction NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Supplementation NN N
of IN N
a DT N
regular JJ N
diet NN N
with IN N
a DT N
combination NN N
of IN N
seal JJ N
oil NN N
and CC N
CLO NNP N
and CC N
especially RB N
with IN N
whale JJ N
oil NN N
seems VBZ N
to TO N
have VB N
beneficial JJ N
effects NNS N
on IN N
several JJ N
products NNS N
thought VBN N
to TO N
be VB N
associated VBN N
with IN N
cardiovascular JJ N
and CC N
thrombotic JJ N
diseases NNS N
. . N

-DOCSTART- -23140338- O O

Individual JJ N
differences NNS N
in IN N
the DT N
efficacy NN N
of IN N
a DT N
short JJ i
theory NN i
of IN i
mind NN i
intervention NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Having VBG N
a DT N
'theory NN N
of IN N
mind NN N
' '' N
, , N
or CC N
having VBG N
the DT N
ability NN N
to TO N
attribute VB N
mental JJ N
states NNS N
to TO N
oneself VB N
or CC N
others NNS N
, , N
is VBZ N
considered VBN N
one CD N
of IN N
the DT N
most RBS N
central JJ N
domains NNS N
of IN N
impairment NN N
among IN N
children NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Many JJ N
interventions NNS N
focus VBP N
on IN N
improving VBG N
theory NN i
of IN i
mind NN i
skills NNS i
in IN N
children NNS p
with IN p
ASD NNP p
. . p

Nonetheless NNP N
, , N
the DT N
empirical JJ N
evidence NN N
for IN N
the DT N
effect NN N
of IN N
these DT N
interventions NNS N
is VBZ N
limited JJ N
. . N

The DT N
main JJ N
goal NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
a DT N
short JJ i
theory NN i
of IN i
mind NN i
intervention NN i
for IN N
children NNS p
with IN p
ASD NNP p
. . p

A DT N
second JJ N
objective NN N
is VBZ N
to TO N
determine VB N
which WDT N
subgroups NNS N
within IN N
the DT N
autism NN N
spectrum JJ N
profit NN N
most JJS N
from IN N
the DT N
intervention NN N
. . N

METHODS NNP N
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

One CD p
hundred VBD p
children NNS p
with IN p
ASD NNP p
, , p
aged VBD p
7 CD p
to TO p
12 CD p
years NNS p
will MD p
be VB p
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN i
or CC i
a DT i
waiting JJ i
list NN i
control NN i
group NN i
. . i

Outcome NNP N
measures VBZ N
include VBP N
the DT N
completion NN o
of IN o
theory NN o
of IN o
mind NN o
and CC o
emotion NN o
understanding NN o
tasks NNS o
, , o
and CC o
parent NN o
and CC o
teacher NN o
questionnaires NNS o
on IN o
children NNS o
's POS o
social JJ o
skills NNS o
. . o

Follow-up NNP N
data NN N
for IN N
the DT N
intervention NN i
group NN N
will MD N
be VB N
collected VBN N
6 CD N
months NNS N
after IN N
the DT N
interventions NNS N
. . N

DISCUSSION NNP N
This DT N
study NN N
evaluates VBZ N
the DT N
efficacy NN o
of IN N
a DT N
theory NN N
of IN N
mind NN i
intervention NN i
for IN N
children NNS p
with IN p
ASD NNP p
. . p

Hypotheses NNP o
, , o
strengths NNS o
, , o
and CC o
limitations NNS o
of IN N
the DT N
study NN N
are VBP N
discussed VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Netherlands NNP N
Trial NNP N
Register NNP N
NTR2327 NNP N
. . N

-DOCSTART- -25497243- O O

Rationale NNP N
and CC N
design NN N
of IN N
the DT N
Clinical NNP N
Evaluation NNP N
of IN N
Magnetic NNP i
Resonance NNP i
Imaging NNP i
in IN N
Coronary NNP N
heart NN N
disease NN N
2 CD N
trial NN N
( ( N
CE-MARC NNP N
2 CD N
) ) N
: : N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
randomized VBN N
trial NN N
of IN N
diagnostic JJ N
strategies NNS N
in IN N
suspected JJ p
coronary JJ p
heart NN p
disease NN p
. . p

BACKGROUND VB N
A DT N
number NN N
of IN N
investigative JJ N
strategies NNS N
exist VBP N
for IN N
the DT N
diagnosis NN N
of IN N
coronary JJ N
heart NN N
disease NN N
( ( N
CHD NNP N
) ) N
. . N

Despite IN N
the DT N
widespread JJ N
availability NN N
of IN N
noninvasive JJ N
imaging NN N
, , N
invasive JJ i
angiography NN i
is VBZ N
commonly RB N
used VBN N
early RB N
in IN N
the DT N
diagnostic JJ N
pathway NN N
. . N

Consequently RB N
, , N
approximately RB N
60 CD N
% NN N
of IN N
angiograms JJ N
reveal VBP N
no DT N
evidence NN N
of IN N
obstructive JJ N
coronary JJ N
disease NN N
. . N

Reducing VBG N
unnecessary JJ N
angiography NN N
has VBZ N
potential JJ N
financial JJ N
savings NNS N
and CC N
avoids NNS N
exposing VBG N
the DT N
patient NN N
to TO N
unnecessary JJ N
risk NN N
. . N

There EX N
are VBP N
no DT N
large-scale JJ N
comparative JJ N
effectiveness NN N
trials NNS N
of IN N
the DT N
different JJ N
diagnostic JJ N
strategies NNS N
recommended VBD N
in IN N
international JJ N
guidelines NNS N
and CC N
none NN N
that WDT N
have VBP N
evaluated VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
cardiovascular JJ N
magnetic JJ N
resonance NN N
. . N

TRIAL NNP N
DESIGN NNP N
CE-MARC NNP N
2 CD N
is VBZ N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
3-arm JJ N
parallel NN N
group NN N
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
patients NNS p
with IN p
suspected JJ p
CHD NNP p
( ( p
pretest JJS p
likelihood RB p
10 CD p
% NN p
-90 NNP p
% NN p
) ) p
requiring VBG p
further JJ p
investigation NN p
. . p

A DT p
total NN p
of IN p
1,200 CD p
patients NNS p
will MD p
be VB p
randomized VBN p
on IN N
a DT N
2:2:1 JJ N
basis NN N
to TO N
receive VB N
3.0-T JJ i
cardiovascular JJ i
magnetic JJ i
resonance-guided JJ i
care NN i
, , i
single-photon JJ i
emission NN i
computed VBD i
tomography-guided JJ i
care NN i
( ( N
according VBG N
to TO N
American NNP N
College NNP N
of IN N
Cardiology/American NNP N
Heart NNP N
Association NNP N
appropriate-use IN N
criteria NNS N
) ) N
, , N
or CC i
National NNP i
Institute NNP i
for IN i
Health NNP i
and CC i
Care NNP i
Excellence NNP i
guidelines-based JJ i
management NN i
. . i

The DT N
primary JJ N
( ( N
efficacy NN N
) ) N
end NN N
point NN N
is VBZ N
the DT N
occurrence NN o
of IN o
unnecessary JJ o
angiography NN o
as IN N
defined VBN N
by IN N
a DT N
normal JJ N
( ( N
> JJ N
0.8 CD N
) ) N
invasive JJ o
fractional JJ o
flow NN o
reserve NN o
. . o

Safety NN o
of IN N
each DT N
strategy NN N
will MD N
be VB N
assessed VBN N
by IN N
3-year JJ N
major JJ N
adverse JJ N
cardiovascular JJ N
event NN N
rates NNS N
. . N

Cost-effectiveness JJ o
and CC o
health-related JJ o
quality-of-life JJ o
measures NNS o
will MD N
be VB N
performed VBN N
. . N

CONCLUSIONS VB N
The DT N
CE-MARC NNP N
2 CD N
trial NN N
will MD N
provide VB N
comparative JJ N
efficacy NN N
and CC N
safety NN N
evidence NN N
for IN N
3 CD N
different JJ N
strategies NNS N
of IN N
investigating VBG N
patients NNS p
with IN p
suspected JJ p
CHD NNP p
, , N
with IN N
the DT N
intension NN N
of IN N
reducing VBG N
unnecessary JJ N
invasive JJ N
angiography NN N
rates NNS N
. . N

Evaluation NN N
of IN N
these DT N
management NN N
strategies NNS N
has VBZ N
the DT N
potential NN N
to TO N
improve VB N
patient NN N
care NN N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
the DT N
cost-effectiveness NN N
of IN N
CHD NNP N
investigation NN N
. . N

-DOCSTART- -17276748- O O

Developmental JJ N
disabilities NNS N
modification NN N
of IN N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
. . N

BACKGROUND NNP N
Interventions NNP i
for IN N
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDD NNP p
) ) p
aim NN N
to TO N
alleviate VB N
symptoms NNS N
and CC N
improve VB N
functioning NN N
. . N

To TO N
measure VB N
global JJ N
functioning NN N
in IN N
treatment NN N
studies NNS N
, , N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
was VBD N
modified VBN N
and CC N
psychometric JJ i
properties NNS i
of IN i
the DT i
revised VBN i
version NN i
( ( i
DD-CGAS NNP i
) ) i
were VBD N
assessed VBN N
in IN N
children NNS p
with IN p
PDD NNP p
. . p

METHODS NNP N
Developmental NNP N
disabilities-relevant JJ N
descriptors NNS N
were VBD N
developed VBN N
for IN N
the DT N
DD-CGAS NNP N
, , N
and CC N
administration NN N
procedures NNS N
were VBD N
established VBN N
to TO N
enhance VB N
rater NN N
consistency NN N
. . N

Ratings NNS N
of IN N
clinical JJ N
case NN N
vignettes NNS N
were VBD N
used VBN N
to TO N
assess VB N
inter-rater JJ N
reliability NN N
and CC N
temporal JJ N
stability NN N
. . N

Validity NNP N
was VBD N
assessed VBN N
by IN N
correlating VBG N
the DT N
DD-CGAS NNP N
with IN N
measures NNS N
of IN N
functioning NN N
and CC N
symptoms NNS N
in IN N
83 CD p
youngsters NNS p
with IN p
PDD NNP p
. . p

Sensitivity NNP N
to TO N
change VB N
was VBD N
assessed VBN N
by IN N
comparing VBG N
change NN N
from IN N
baseline NN N
to TO N
post-treatment JJ N
with IN N
change NN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Irritability NNP N
and CC N
Clinical NNP N
Global NNP N
Impressions-Improvement NNP N
subscale JJ N
scores NNS N
in IN N
a DT N
subset NN N
of IN N
14 CD N
children NNS N
. . N

RESULTS NNP N
Inter-rater JJ o
reliability NN o
( ( o
intraclass JJ o
correlation NN o
coefficient NN o
[ NNP o
ICC NNP o
] NNP o
= NNP o
.79 NNP o
) ) o
and CC o
temporal JJ o
stability NN o
( ( o
average JJ o
ICC NNP o
= NNP o
.86 NNP o
) ) o
were VBD o
excellent JJ o
. . o

The DT o
DD-CGAS JJ o
scores NNS o
correlated VBN o
with IN o
measures NNS o
of IN o
functioning NN o
and CC o
symptoms NNS o
with IN N
moderate JJ N
to TO N
large JJ N
effect NN N
sizes VBZ N
. . N

Changes NNS o
on IN o
the DT o
DD-CGAS NNP o
correlated VBD o
with IN o
changes NNS o
on IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist-I NNP o
( ( N
r NN N
= NNP N
-.71 NNP N
) ) N
and CC N
Global JJ o
Impressions NNP o
Scale-I NNP o
( ( N
r NN N
= NNP N
-.52 NNP N
) ) N
. . N

The DT o
pre-post JJ o
DD-CGAS NNP o
change NN o
had VBD N
an DT N
effect NN N
size NN N
of IN N
.72 NNP N
. . N

CONCLUSIONS VB N
The DT N
DD-CGAS NNP N
is VBZ N
a DT N
reliable JJ N
instrument NN N
with IN N
apparent JJ N
convergent NN N
validity NN N
for IN N
measuring VBG N
global JJ N
functioning NN N
of IN N
children NNS p
with IN p
PDD NNP p
in IN N
treatment NN N
studies NNS N
. . N

-DOCSTART- -12440177- O O

Determinants NNS N
of IN N
serum JJ N
creatinine NN N
trajectory NN N
in IN N
acute JJ p
contrast NN p
nephropathy NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
describe VB N
the DT N
trajectory NN N
of IN N
creatinine NN o
( ( o
Cr NNP o
) ) o
rise NN o
and CC N
its PRP$ N
determinants NNS N
after IN p
exposure NN p
to TO p
radiocontrast VB p
media NNS p
. . p

Included VBN N
were VBD N
98 CD p
subjects NNS p
who WP p
underwent VBP p
cardiac JJ p
catheterization NN p
and CC N
were VBD N
randomized VBN N
to TO N
forced VBN N
diuresis NN i
with IN i
i.v NN i
. . i

crystalloid NN i
, , i
furosemide RB i
, , i
mannitol NN i
( ( i
if IN i
pulmonary JJ i
capillary JJ i
wedge NN i
pressure NN i
was VBD i
< JJ i
20 CD i
mmHg NN i
) ) i
, , i
and CC i
low JJ i
dose JJ i
dopamine NN i
versus NN i
intravenous JJ i
crystalloid NN i
and CC i
matching VBG i
placebos NNS i
. . i

Baseline NNP N
and CC N
postcatheterization NN N
serum NN o
Cr NNP o
levels NNS o
were VBD N
analyzed VBN N
in IN N
a DT N
longitudinal JJ N
fashion NN N
, , N
allowing VBG N
for IN N
differences NNS N
in IN N
the DT N
time NN N
between IN N
blood NN N
draws NNS N
, , N
to TO N
determine VB N
the DT N
different JJ N
critical JJ N
trajectories NNS N
of IN N
serum NN N
Cr NNP N
. . N

The DT p
mean JJ o
age NN o
, , o
baseline NN o
serum NN o
Cr NNP o
, , o
and CC o
Cr NNP o
clearance NN o
( ( o
CrCl NNP o
) ) o
were VBD p
69.3 CD p
+/- JJ p
10.8 CD p
years NNS p
, , p
2.5 CD p
+/- JJ p
0.9 CD p
mg/dL NN p
, , p
and CC p
31.4 CD p
+/- JJ p
12.1 CD p
mL/min NN p
, , p
respectively RB p
. . p

The DT N
clinically RB o
driven JJ o
postprocedural JJ o
observation NN o
time NN o
was VBD N
5.5 CD N
+/- JJ N
5.1 CD N
days NNS N
( ( N
range VB N
19 CD N
hours NNS N
and CC N
one CD N
Cr NNP N
value NN N
to TO N
25.7 CD N
days NNS N
and CC N
18 CD N
values NNS N
) ) N
. . N

The DT N
mean JJ o
maximum NN o
Cr NNP o
was VBD N
3.3 CD N
+/- JJ N
1.4 CD N
, , N
range NN N
1.7-8.7 JJ N
mg/dL NN N
) ) N
. . N

Longitudinal JJ N
models NNS N
support VBP N
baseline JJ N
Cr NNP o
clearance NN o
predictions NNS N
for IN N
the DT N
change NN N
in IN N
Cr NNP N
at IN N
24 CD N
hours NNS N
, , N
time NN N
as IN N
the DT N
determinant NN N
of IN N
Cr NNP N
trajectory NN N
, , N
and CC N
requisite JJ N
monitoring NN N
. . N

For IN N
any DT N
given VBN N
individual NN N
, , N
a DT N
rise NN N
in IN N
Cr NNP o
of IN N
< NNP N
or CC N
= $ N
0.5 CD N
mg/dL NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
contrast NN N
exposure NN N
predicted VBD N
a DT N
favorable JJ N
outcome NN N
. . N

Baseline NNP o
renal JJ o
function NN o
is VBZ N
the DT N
major JJ N
determinant NN N
of IN N
the DT N
rate NN N
of IN N
rise NN N
, , N
height NN N
, , N
and CC N
duration NN N
of IN N
Cr NNP N
trajectory NN N
after IN N
contrast NN N
exposure NN N
. . N

Length NNP N
of IN N
observation NN N
and CC N
frequency NN N
of IN N
laboratory NN N
measures NNS N
can MD N
be VB N
anticipated VBN N
from IN N
these DT N
models NNS N
. . N

-DOCSTART- -23114568- O O

Linguistic JJ o
alignment NN o
in IN N
adults NNS p
with IN p
and CC p
without IN p
Asperger NNP p
's POS p
syndrome NN p
. . p

Individuals NNS p
with IN p
Asperger NNP p
's POS p
syndrome NN p
( ( p
AS IN p
) ) p
often RB N
have VBP N
difficulties NNS N
with IN N
social JJ N
interactions NNS N
and CC N
conversations NNS N
. . N

We PRP N
investigated VBD N
if IN N
these DT N
difficulties NNS N
could MD N
be VB N
attributable JJ N
to TO N
a DT N
deficit NN N
in IN N
the DT N
ability NN N
to TO N
linguistically RB N
converge VB N
with IN N
an DT N
interlocutor NN N
, , N
which WDT N
is VBZ N
posited VBN N
to TO N
be VB N
important JJ N
for IN N
successful JJ N
communication NN N
. . N

To TO N
that DT N
end NN N
, , N
participants NNS N
completed VBD N
two CD i
cooperative JJ i
tasks NNS i
with IN i
a DT i
confederate NN i
, , N
which WDT N
allowed VBD N
us PRP N
to TO N
measure VB N
linguistic JJ o
alignment NN o
with IN o
the DT o
confederate NN o
in IN N
terms NNS N
of IN N
lexical JJ o
choice NN o
, , o
syntactic JJ o
structure NN o
and CC o
spatial JJ o
frame NN o
of IN o
reference NN o
. . o

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
performance NN N
of IN N
individuals NNS p
with IN p
AS NNP p
and CC N
matched VBD N
controls NNS N
and CC N
both DT N
groups NNS N
showed VBD N
significant JJ N
alignment NN N
with IN N
the DT N
confederate NN N
at IN N
all DT N
three CD N
levels NNS N
. . N

We PRP N
conclude VBP N
that IN N
linguistic JJ o
alignment NN o
is VBZ N
intact JJ N
in IN N
adults NNS p
with IN p
AS NNP p
engaged VBN p
in IN p
structured JJ p
, , p
goal-directed JJ p
social JJ p
interactions NNS p
. . p

-DOCSTART- -23870440- O O

The DT N
influence NN N
of IN N
fidelity NN o
of IN o
implementation NN o
on IN N
teacher-student JJ o
interaction NN o
quality NN o
in IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
the DT N
Responsive NNP i
Classroom NNP i
approach NN i
. . i

This DT N
study NN N
examined VBD N
the DT N
direct JJ o
and CC o
indirect JJ o
effects NNS o
between IN N
training NN N
in IN N
the DT N
Responsive NNP i
Classroom? NNP i
( ( i
RC NNP i
) ) i
approach NN i
, , i
teachers NNS N
' POS N
uptake NN N
of IN N
RC NNP N
practices NNS N
, , N
and CC N
teacher-student JJ N
interaction NN N
quality NN N
, , N
using VBG N
a DT N
structural JJ i
equation NN i
modeling VBG i
framework NN i
. . i

A DT N
total NN p
of IN p
24 CD p
schools NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
experimental VB N
or CC N
control VB N
conditions NNS N
. . N

Third- CD p
and CC p
fourth-grade JJ p
teachers NNS p
in IN p
treatment NN p
schools NNS p
( ( p
n=132 NN p
) ) p
received VBD p
training NN p
in IN p
the DT i
RC NNP i
approach NN i
, , i
whereas JJ p
teachers NNS p
in IN p
control NN p
schools NNS p
( ( p
n=107 NN p
) ) p
continued VBD N
business NN i
as IN i
usual JJ i
. . i

Observers NNS N
rated VBD N
teachers NNS o
' POS o
fidelity NN o
of IN o
implementation NN o
( ( o
FOI NNP o
) ) o
of IN i
RC NNP i
practices NNS N
5 CD N
times NNS N
throughout IN N
the DT N
year NN N
using VBG N
the DT o
Classroom NNP o
Practices NNPS o
Observation NNP o
Measure NNP o
. . o

In IN N
addition NN N
, , N
teachers NNS o
completed VBD o
self-report JJ o
measures NNS o
of IN o
FOI NNP o
, , o
the DT o
Classroom NNP o
Practices NNPS o
Teacher NNP o
Survey NNP o
and CC o
Classroom NNP o
Practices NNP o
Frequency NNP o
Survey NNP o
, , o
at IN N
the DT N
end NN N
of IN N
the DT N
school NN N
year NN N
. . N

Teacher-student JJ o
interactions NNS o
were VBD N
rated VBN N
during IN N
classroom NN N
observations NNS N
using VBG N
the DT o
Classroom NNP o
Assessment NNP o
Scoring NNP o
System NNP o
. . o

Controlling VBG N
for IN N
teachers NNS N
' POS N
grade NN N
level NN N
and CC N
teacher-student JJ N
interaction NN N
quality NN N
at IN N
pretest JJS N
, , N
RC NNP N
training NN N
was VBD N
expected VBN N
to TO N
predict VB N
posttest JJS o
teacher-student JJ o
interaction NN o
quality NN o
directly RB N
and CC N
indirectly RB N
through IN N
FOI NNP N
. . N

Results NNP N
supported VBD N
only RB N
a DT N
significant JJ N
indirect JJ N
effect NN N
, , N
?=0.85 NNP N
, , N
p=.002 NN N
. . N

Specifically RB N
, , N
RC NNP N
teachers NNS N
had VBD N
higher JJR N
levels NNS N
of IN N
FOI NNP o
of IN o
RC NNP o
practices NNS o
, , o
?=1.62 NNP N
, , N
p NN N
< NNP N
.001 NNP N
, , N
R2=.69 NNP N
. . N

In IN N
turn NN N
, , N
FOI NNP N
related VBD N
to TO N
greater JJR N
improvement NN N
in IN N
teacher-student JJ o
interaction NN o
quality NN o
, , o
?=0.52 NNP o
, , N
p=.001 NN N
, , N
R2=.32 NNP N
. . N

Discussion NNP N
highlights NNS N
factors NNS N
contributing VBG N
to TO N
variability NN N
in IN N
FOI NNP N
and CC N
school NN N
administrators NNS N
roles NNS N
in IN N
supporting VBG N
FOI NNP N
. . N

-DOCSTART- -23839319- O O

Total JJ N
intravenous JJ N
anesthesia NN N
using VBG N
remifentanil NN i
in IN N
extracorporeal NN i
shock NN i
wave VBP i
lithotripsy NN i
( ( i
ESWL NNP i
) ) i
. . i

Comparison NNP N
of IN N
two CD N
dosages NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Extracorporeal NNP i
Shock NNP i
Wave NNP i
Lithotripsy NNP i
is VBZ N
usually RB N
performed VBN N
in IN N
day NN N
surgery NN N
setting NN N
, , N
consequently RB N
people NNS N
who WP N
undergo VBP N
to TO N
this DT N
procedure NN N
need VB N
a DT N
safe JJ N
and CC N
fast JJ N
recovery NN N
. . N

Conscious JJ N
sedation NN N
with IN N
remifentanil NN i
can MD N
relieve VB N
from IN N
pain NN N
and CC N
keep VB N
patients NNS N
in IN N
touch JJ N
with IN N
anaesthesiologists NNS N
. . N

Few JJ N
publications NNS N
tell VBP N
about IN N
infusion NN N
rates NNS N
administered VBD N
to TO N
perform VB N
this DT N
procedure7 NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
which WDT N
is VBZ N
the DT N
most RBS N
appropriate JJ N
infusion NN N
rate NN N
. . N

METHODS CC N
Patients NNPS p
were VBD p
randomly RB p
assigned VBN p
to TO p
two CD p
groups NNS p
. . p

Two CD N
different JJ N
infusion NN N
rates NNS N
were VBD N
compared VBN N
: : N
0,05 CD N
mcg/kg/min NN N
, , N
GROUP NNP N
A NNP N
( ( N
N.=114 NNP N
) ) N
, , N
vs. FW N
0.1 CD N
?g/kg/min NNP N
, , N
GROUP NNP N
B NNP N
( ( N
N.=114 NNP N
) ) N
. . N

Patients NNS o
' POS o
vital JJ o
signs NNS o
, , o
additional JJ o
analgesic NN o
requests NNS o
, , o
PONV NNP o
( ( o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
) ) o
and CC N
other JJ N
side NN N
effects NNS N
were VBD N
registered VBN N
. . N

The DT N
deepness NN N
of IN N
sedation NN N
and CC N
patient NN N
's POS N
satisfaction NN N
were VBD N
evaluated VBN N
referring VBG N
to TO o
Obsever NNP o
's POS o
Assessment NNP o
of IN o
Alertness NNP o
and CC o
Sedation NNP o
scale NN o
( ( N
O/ASS NNP N
) ) N
and CC N
using VBG N
a DT N
Likert NNP N
's POS N
scale NN N
respectively RB N
. . N

Pain NNP o
intensity NN o
was VBD N
assessed VBN N
with IN N
a DT N
11-points NNS N
VAS NNP N
( ( N
visual JJ N
analogue NN N
scale NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
were VBD N
analyzed VBN N
using VBG N
Student NNP N
t JJ N
test NN N
for IN N
independent JJ N
variables NNS N
. . N

The DT N
?2 JJ N
test NN N
was VBD N
used VBN N
to TO N
analyze VB N
categorical JJ N
variables NNS N
. . N

RESULTS VB N
The DT N
study NN N
enrolled VBD p
228 CD p
patients NNS p
and CC p
assigned VBD N
them PRP N
to TO N
two CD N
groups NNS N
( ( N
N.=114 NNP N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
regarding VBG o
Likert NNP o
's POS o
scale NN o
values NNS o
( ( o
P=0.20 NNP N
) ) N
, , N
additional JJ N
analgesic JJ N
request NN N
( ( N
P=0.30 NNP N
) ) N
and CC N
mean JJ o
VAS NNP o
values NNS o
( ( o
P NNP N
> NNP N
0.05 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
about IN o
PONV NNP o
, , o
hypotension NN o
, , o
oxygen NN o
desaturation NN o
and CC o
respiratory NN o
depression NN o
was VBD o
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
as IN N
a DT N
matter NN N
of IN N
fact NN N
in IN N
group NN N
A NNP N
these DT N
side NN N
effects NNS N
occurred VBD N
less RBR N
frequently RB N
. . N

The DT o
fifth JJ o
degree NN o
of IN o
O/ASS NNP o
was VBD o
estimated VBN N
in IN N
about RB N
1.61?0.19 CD N
min NNS N
and CC N
2.987?0.20 CD N
min NN N
in IN N
group NN N
A NNP N
and CC N
in IN N
group NN N
B NNP N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
According VBG N
with IN N
previous JJ N
results NNS N
remifentanil VBP N
at IN N
the DT N
infusion NN N
rate NN N
of IN N
0.05 CD N
?g/kg/min NNP N
provides VBZ N
an DT N
effective JJ N
analgesia NN N
, , N
causing VBG N
a DT N
lower JJR N
incidence NN N
of IN N
side NN N
effect NN N
than IN N
0.1 CD N
?g/kg/min NN N
, , N
granting VBG N
a DT N
fast JJ N
and CC N
safe JJ N
recovery NN N
. . N

-DOCSTART- -7554709- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
the DT N
monoamine NN i
oxidase NN i
B NNP i
inhibitor NN i
mofegiline NN i
assessed VBN N
during IN N
a DT N
phase NN N
I PRP N
dose VBP N
tolerance JJ N
trial NN N
. . N

The DT N
safety NN N
, , N
pharmacokinetics NNS i
, , i
and CC i
pharmacodynamics NNS i
of IN i
single JJ i
oral JJ i
doses NNS i
of IN i
up IN i
to TO i
48 CD i
mg NNS i
and CC i
daily JJ i
( ( i
for IN i
28 CD i
days NNS i
) ) i
doses NNS i
of IN i
up IN i
24 CD i
mg NNS i
mofegiline NN i
were VBD N
investigated VBN N
in IN N
healthy JJ p
male NN p
volunteers NNS p
. . p

Plasma NNP N
pharmacokinetics NNS N
indicated VBD N
rapid JJ N
absorption NN N
and CC N
elimination NN N
: : N
time NN N
to TO N
reach VB N
maximum JJ N
concentration NN N
occurred VBD N
at IN N
about IN N
1 CD N
hour NN N
; : N
half-life JJ N
ranged VBD N
from IN N
1 CD N
to TO N
3 CD N
hours NNS N
. . N

Maximal NNP o
plasma JJ o
concentration NN o
and CC o
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
curve NN o
increased VBD N
and CC N
oral JJ N
clearance NN N
decreased VBD N
disproportionately RB N
with IN N
dose JJ N
. . N

Mofegiline NNP o
rapidly RB o
and CC o
markedly RB o
inhibited JJ o
platelet NN o
monoamine NN o
oxidase NN o
B NNP o
( ( o
MAOB NNP o
) ) o
activity NN o
, , N
which WDT N
returned VBD N
to TO N
baseline VB N
within IN N
14 CD N
days NNS N
. . N

Urinary JJ o
excretion NN o
of IN o
phenylethylamine NN o
increased VBN N
proportionately RB N
with IN N
doses NNS N
up RB N
to TO N
24 CD N
mg. NN N
No NNP N
changes NNS N
in IN N
urinary JJ o
elimination NN o
of IN o
catecholamines NNS o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
or CC o
ECG NNP o
were VBD N
observed VBN N
. . N

A DT N
classic JJ N
maximum NN o
tolerated VBD o
dose NN o
was VBD N
not RB N
achieved VBN N
in IN N
these DT N
studies NNS N
. . N

However RB N
, , N
the DT N
48 CD N
mg NN N
single JJ N
dose NN N
and CC N
the DT N
24 CD N
mg NN N
multiple JJ N
daily JJ N
dose NN N
far RB N
exceeded VBD N
the DT N
dose NN N
( ( N
1 CD N
mg NN N
) ) N
that WDT N
was VBD N
associated VBN N
with IN N
> JJ N
90 CD N
% NN N
platelet NN N
MAOB NNP N
inhibition NN N
. . N

-DOCSTART- -8832526- O O

Long-term JJ N
results NNS N
regarding VBG N
the DT N
use NN N
of IN N
recombinant JJ i
interferon NN i
alpha-2b NN i
in IN N
the DT N
treatment NN N
of IN N
II NNP p
type NN p
mixed JJ p
essential JJ p
cryoglobulinemia NN p
. . p

Thirty-three JJ p
patients NNS p
with IN p
II NNP p
type NN p
mixed JJ p
essential JJ p
cryoglobulinemia NN p
( ( p
MEC NNP p
) ) p
were VBD p
randomized VBN p
into IN N
two CD N
groups NNS N
: : N
one CD N
to TO N
receive VB N
combined JJ i
therapy NN i
including VBG i
prednisone NN i
plus CC i
interferon NN i
, , i
the DT i
other JJ i
to TO i
receive VB i
prednisone NN i
therapy NN i
. . i

Interferon NNP i
was VBD N
administered VBN N
as IN N
induction NN N
treatment NN N
( ( N
3 CD N
Mu/day NNP N
) ) N
and CC N
then RB N
as IN N
maintenance NN N
therapy NN N
( ( N
3 CD N
Mu NNP N
three CD N
times NNS N
a DT N
week NN N
) ) N
. . N

83 CD N
% NN N
of IN N
the DT N
combined JJ N
therapy NN N
patients NNS N
responded VBD N
as IN N
opposed VBN N
to TO N
27 CD N
% NN N
of IN N
the DT N
prednisone NN N
treated VBD N
patients NNS N
. . N

Among IN N
the DT N
patients NNS N
that WDT N
responded VBD N
to TO N
combined VBN N
therapy NN N
, , N
nine CD N
of IN N
them PRP N
had VBD N
a DT N
complete JJ N
response NN N
, , N
four CD N
a DT N
partial JJ N
response NN N
, , N
and CC N
two CD N
a DT N
minor JJ N
response NN N
. . N

None NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
prednisone NN i
therapy NN N
responded VBD N
completely RB N
but CC N
only RB N
two CD N
had VBD N
a DT N
partial JJ N
and CC N
two CD N
a DT N
minor JJ N
response NN N
. . N

Four CD N
patients NNS N
( ( N
three CD N
of IN N
combined VBN i
therapy NN i
and CC N
one CD N
of IN N
prednisone NN i
therapy NN N
) ) N
showed VBD N
proteinuria NN o
before IN N
the DT N
treatment NN N
which WDT N
improved VBD N
at IN N
the DT N
end NN N
of IN N
the DT N
induction NN N
therapy NN N
. . N

Ten CD N
patients NNS N
showed VBD N
anti-HCV JJ o
positivity NN o
which WDT N
remained VBD N
unchanged JJ N
after IN N
the DT N
treatment NN N
. . N

Three CD N
patients NNS N
showed VBD N
liver JJ o
involvement NN o
secondary JJ N
to TO N
cryoglobulinemia VB o
and CC N
an DT N
improvement NN N
of IN N
histological JJ o
pattern NN o
after IN N
the DT N
induction NN N
with IN N
combined JJ N
therapy NN N
. . N

One CD N
patient NN N
showed VBD N
an DT N
improvement NN N
of IN N
peripheral JJ o
neuropathy NNS o
after IN N
induction NN N
with IN N
the DT N
combined JJ i
therapy NN i
. . i

These DT N
data NNS N
suggest VBP N
the DT N
effectiveness NN N
of IN N
interferon NN i
given VBN N
as IN N
induction NN N
and CC N
as IN N
maintenance NN N
treatment NN N
in IN N
the DT N
therapy NN N
of IN N
II NNP p
type NN p
mixed JJ p
essential JJ p
cryoglobulinemia NN p
. . p

-DOCSTART- -12401759- O O

A DT N
randomized JJ N
trial NN N
of IN N
continuous JJ N
subcutaneous JJ N
insulin NN i
infusion NN N
and CC N
intensive JJ N
injection NN N
therapy NN N
in IN N
type NN p
1 CD p
diabetes NNS p
for IN p
patients NNS p
with IN p
long-standing JJ p
poor JJ p
glycemic JJ p
control NN p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
in IN N
a DT N
randomized JJ N
crossover NN N
trial NN N
the DT N
efficacy NN N
of IN N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
in IN N
improving VBG N
glycemic JJ o
control NN o
and CC o
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
type JJ p
1 CD p
diabetic JJ p
patients NNS p
with IN p
long-standing JJ p
poor JJ p
glycemic JJ p
control NN p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
79 CD p
patients NNS p
in IN p
11 CD p
Dutch NN p
centers NNS p
were VBD N
randomized VBN N
to TO N
16 CD N
weeks NNS N
of IN N
continuous JJ i
subcutaneous JJ i
insulin NN i
infusion NN i
followed VBN i
by IN i
16 CD i
weeks NNS i
intensive JJ i
injection NN i
therapy NN i
or CC i
the DT i
reverse JJ i
order NN i
. . i

Glycemic NNP N
control NN N
was VBD N
assessed VBN N
by IN N
HbA NNP N
( ( N
1c CD N
) ) N
, , N
self-reported JJ N
hypoglycemic JJ N
events NNS N
, , N
and CC N
blood NN N
glucose JJ N
memory NN N
meter NN N
read VBD N
outs NNS N
. . N

Changes NNS N
in IN N
quality NN o
of IN o
life NN o
were VBD N
assessed VBN N
by IN N
self-report JJ N
questionnaires NNS N
administered VBN N
at IN N
baseline NN N
and CC N
16 CD N
weeks NNS N
. . N

RESULTS NNP N
As IN N
the DT N
drop-out NN N
rate NN N
after IN N
crossover NN N
was VBD N
high JJ N
( ( N
17 CD N
of IN N
79 CD N
patients NNS N
[ JJ N
22 CD N
% NN N
] NN N
) ) N
, , N
we PRP N
analyzed VBD N
the DT N
trial NN N
as IN N
a DT N
parallel JJ N
clinical JJ N
trial NN N
, , N
using VBG N
data NNS N
of IN N
the DT N
first JJ N
half NN N
of IN N
the DT N
crossover NN N
phase NN N
only RB N
. . N

At IN N
16 CD N
weeks NNS N
, , N
mean JJ o
HbA NNP o
( ( o
1c CD o
) ) o
was VBD N
0.84 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.31 NNP N
to TO N
-0.36 VB N
) ) N
lower JJR N
in IN N
the DT N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
group NN N
compared VBN N
with IN N
the DT N
insulin NN i
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Stability NN o
of IN o
blood NN o
glucose JJ o
self-measurement JJ o
values NNS o
, , N
expressed VBD N
as IN N
SD NNP N
of IN N
the DT N
nine-point JJ N
blood NN N
glucose NN N
profiles NNS N
, , N
improved VBN N
in IN N
the DT N
insulin NN N
pump NN N
group NN N
by IN N
29.3 CD N
+/- JJ N
41.1 CD N
vs. FW N
8.2 CD N
+/- JJ N
36.5 CD N
% NN N
in IN N
the DT N
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

The DT N
number NN o
of IN o
mild JJ o
hypoglycemic JJ o
episodes NNS o
per IN N
patient-week NN N
was VBD N
0.99 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.11-1.87 NN N
) ) N
higher JJR N
in IN N
the DT N
insulin NN N
pump NN N
group NN N
( ( N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

Weight NNP o
gain NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Scores NNS o
on IN o
the DT o
Short-Form JJ o
36-Item JJ o
subscales NNS o
'general POS o
health NN o
' '' o
and CC o
'mental JJ o
health NN o
' '' o
improved VBN N
in IN N
the DT N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
group NN N
, , N
compared VBN N
with IN N
stable JJ N
values NNS N
in IN N
the DT N
injection NN N
group NN N
( ( N
P NNP N
= NNP N
0.048 CD N
and CC N
0.050 CD N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Continuous NNP N
subcutaneous JJ N
insulin NN i
infusion NN N
improves VBZ N
glycemic JJ N
control NN N
and CC N
some DT N
aspects NNS N
of IN N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN p
a DT p
history NN p
of IN p
long-term JJ p
poor JJ p
glycemic JJ p
control NN p
. . p

-DOCSTART- -23820434- O O

Beliefs NNP i
underlying VBG N
the DT N
intention NN N
to TO N
donate VB N
again RB N
among IN N
first-time JJ p
blood NN p
donors NNS p
who WP p
experience VBP p
a DT p
mild JJ p
adverse JJ p
event NN p
. . p

Using VBG N
the DT N
belief JJ i
basis NN i
of IN i
the DT i
theory NN i
of IN i
planned VBN i
behavior NN i
( ( i
TPB NNP i
) ) i
, , N
the DT N
current JJ N
study NN N
explored VBD N
the DT N
rate NN o
of IN o
mild JJ o
reactions NNS o
reported VBN N
by IN N
donors NNS N
in IN N
relation NN N
to TO N
their PRP$ N
first JJ N
donation NN N
and CC N
the DT N
intention NN N
and CC N
beliefs NN N
of IN N
those DT N
donors NNS N
with IN N
regard NN N
to TO N
returning VBG N
to TO N
donate VB N
again RB N
. . N

A DT N
high JJ N
proportion NN N
of IN N
first-time JJ N
donors NNS N
indicated VBD N
that IN N
they PRP N
had VBD N
experienced VBN N
a DT N
reaction NN N
to TO N
blood VB N
donation NN N
. . N

Further NNP N
, , N
donors NNS N
who WP N
reacted VBD N
were VBD N
less RBR N
likely JJ N
to TO N
intend VB N
to TO N
return VB N
to TO N
donate VB N
. . N

Regression NNP N
analyses VBZ N
suggested VBD N
that IN N
targeting VBG i
different JJ i
beliefs NNS i
for IN N
those DT N
donors NNS N
who WP N
had VBD N
and CC N
had VBD N
not RB N
reacted VBN N
would MD N
yield VB N
most JJS N
benefit NN N
in IN N
bolstering VBG N
donors NNS N
' POS N
intentions NNS N
to TO N
remain VB N
donating JJ N
. . N

The DT N
findings NNS N
provide VBP N
insight NN N
into IN N
those DT N
messages NNS i
that WDT N
could MD N
be VB N
communicated VBN N
via IN N
the DT N
mass NN N
media NNS N
or CC N
in IN N
targeted JJ N
communications NNS N
to TO N
retain VB N
first-time JJ p
donors NNS p
who WP N
have VBP N
experienced VBN N
a DT N
mild JJ N
vasovagal JJ N
reaction NN N
. . N

-DOCSTART- -21036891- O O

PDE5 NNP i
inhibition NN i
with IN N
sildenafil JJ i
improves NNS N
left VBD N
ventricular JJ N
diastolic JJ N
function NN N
, , N
cardiac JJ N
geometry NN N
, , N
and CC N
clinical JJ N
status NN N
in IN N
patients NNS p
with IN p
stable JJ p
systolic JJ p
heart NN p
failure NN p
: : p
results NNS N
of IN N
a DT N
1-year JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
. . N

BACKGROUND NNP N
In IN N
heart NN N
failure NN N
( ( N
HF NNP N
) ) N
, , N
a DT N
defective JJ N
nitric JJ N
oxide IN N
signaling VBG N
is VBZ N
involved VBN N
in IN N
left JJ N
ventricular NN N
( ( N
LV NNP N
) ) N
diastolic NN N
abnormalities NNS N
and CC N
remodeling VBG N
. . N

PDE5 NNP N
inhibition NN N
, , N
by IN N
blocking VBG N
degradation NN N
of IN N
nitric JJ N
oxide IN N
second-messenger JJ N
cyclic JJ N
guanosine NN N
monophosphate NN N
, , N
might MD N
be VB N
beneficial JJ N
. . N

In IN N
a DT N
cohort NN N
of IN N
systolic JJ p
HF NNP p
patients NNS p
, , N
we PRP N
tested VBD N
the DT N
effects NNS N
of IN N
PDE5 NNP N
inhibition NN N
( ( i
sildenafil NN i
) ) i
on IN N
LV NNP N
ejection NN N
fraction NN N
, , N
diastolic JJ N
function NN N
, , N
cardiac JJ N
geometry NN N
, , N
and CC N
clinical JJ N
status NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Forty-five JJ p
HF NNP p
patients NNS p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
II-III NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB i
or CC i
sildenafil VB i
( ( N
50 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
) ) N
for IN N
1 CD N
year NN N
, , N
with IN N
assessment NN N
( ( N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
) ) N
of IN N
LV NNP o
ejection NN o
fraction NN o
, , o
diastolic JJ o
function NN o
, , o
geometry NN o
, , o
cardiopulmonary JJ o
exercise NN o
performance NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

In IN N
the DT N
sildenafil NN N
group NN N
only RB N
, , N
at IN N
6 CD N
months NNS N
and CC N
1 CD N
year NN N
, , N
LV NNP o
ejection NN o
fraction NN o
, , o
early JJ o
diastolic JJ o
tissue NN o
Doppler NNP o
velocities NNS o
( ( o
E NNP o
' POS o
) ) o
at IN o
the DT o
mitral JJ o
lateral JJ o
( ( N
from IN N
4.62 CD N
to TO N
5.20 CD N
and CC N
5.19 CD N
m/s NN N
) ) N
and CC N
septal JJ o
( ( N
from IN N
4.71 CD N
to TO N
5.23 CD N
and CC N
5.24 CD N
m/s NN N
) ) N
annuli VBZ o
significantly RB o
increased VBN N
, , N
whereas IN N
the DT N
ratio NN N
of IN N
early JJ N
transmitral NN N
( ( N
E NNP N
) ) N
to TO N
E NNP N
' POS N
lateral JJ N
decreased VBN N
( ( N
from IN N
13.1 CD N
to TO N
9.8 CD N
to TO N
9.4 CD N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Changes NNS N
were VBD N
accompanied VBN N
by IN N
a DT N
reverse NN o
remodeling NN o
of IN o
left JJ o
atrial JJ o
volume NN o
index NN o
( ( N
from IN N
32.0 CD N
to TO N
29.0 CD N
and CC N
29.1 CD N
mL/m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
LV NNP o
mass NNP o
index NN o
( ( N
from IN N
148.0 CD N
to TO N
130.0 CD N
and CC N
128.0 CD N
g/m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Furthermore UH N
, , N
sildenafil JJ i
improved VBN N
exercise NN o
performance NN o
( ( o
peak JJ o
Vo NNP o
( ( o
2 CD o
) ) o
) ) o
, , o
ventilation NN o
efficiency NN o
( ( o
ventilation NN o
to TO o
CO NNP o
( ( o
2 CD o
) ) o
production NN o
slope NN o
) ) o
, , o
and CC o
quality NN o
of IN o
life NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Minor JJ N
adverse JJ N
effects NNS N
were VBD N
noted VBN N
: : N
flushing NN o
in IN N
4 CD N
and CC N
headache NN o
in IN N
2 CD N
treated JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Findings NNP N
confirm NN N
that IN N
in IN N
HF NNP N
, , N
sildenafil NN i
improves VBZ N
functional JJ o
capacity NN o
and CC o
clinical JJ o
status NN o
and CC N
provide VB N
the DT N
first JJ N
human JJ N
evidence NN N
that IN N
LV NNP o
diastolic JJ o
function NN o
and CC N
cardiac JJ o
geometry NN o
are VBP N
additional JJ N
targets NNS N
of IN N
benefits NNS N
related VBN N
to TO N
chronic JJ N
PDE5 NNP N
inhibition NN N
. . N

-DOCSTART- -10850381- O O

Reduction NN o
of IN o
oral JJ o
mucositis NN o
by IN N
filgrastim NN i
( ( i
r-metHuG-CSF JJ i
) ) i
in IN N
patients NNS p
receiving VBG p
chemotherapy NN i
. . i

Mucositis NNP o
, , N
the DT N
inflammation NN N
and CC N
necrosis NN N
of IN N
mucosal NN N
membranes NNS N
, , N
is VBZ N
a DT N
serious JJ N
and CC N
debilitating VBG N
consequence NN N
of IN N
many JJ N
cancer NN N
therapies NNS N
. . N

We PRP N
were VBD N
interested JJ N
in IN N
the DT N
potential JJ N
role NN N
of IN N
filgrastim NN i
( ( i
recombinant JJ i
methionyl NN i
human JJ i
granulocyte NN i
colony-stimulating NN i
factor NN i
, , i
r-metHuG-CSF NN i
) ) i
in IN N
the DT N
reduction NN o
of IN o
mucositis NN o
. . o

Patients NNS p
with IN p
newly RB p
diagnosed VBN p
small-cell NN p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
were VBD N
treated VBN N
with IN N
CAE NNP i
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
etoposide RB i
) ) i
and CC i
placebo NN i
or CC i
filgrastim NN i
. . i

If IN N
patients NNS N
had VBD N
an DT N
episode NN N
of IN N
febrile JJ N
neutropenia NNS N
, , N
they PRP N
received VBD N
unblinded JJ N
filgrastim NN N
in IN N
subsequent JJ N
CAE NNP N
cycles NNS N
. . N

Oral NNP o
mucositis NN o
was VBD N
considered VBN N
to TO N
have VB N
occurred VBN N
if IN N
a DT N
patient NN N
reported VBD N
any DT N
clinical JJ N
sign NN N
or CC N
symptom NN o
of IN o
oral JJ o
mucositis NN o
with IN o
or CC o
without IN o
oral JJ o
candidiasis NN o
. . o

Oral NNP o
mucositis NN o
was VBD N
analyzed VBN N
using VBG N
the DT N
unadjusted JJ N
chi-square JJ N
test NN N
, , N
and CC N
time NN o
to TO o
first JJ o
episode NN o
of IN o
mucositis NN o
was VBD N
analyzed VBN N
using VBG N
the DT N
stratified JJ N
log-rank JJ N
test NN N
as RB N
well RB N
as IN N
the DT N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
model NN N
. . N

During IN N
cycle NN N
1 CD N
, , N
placebo-treated JJ N
patients NNS N
had VBD N
more RBR N
episodes NNS N
of IN N
mucositis NN o
( ( N
47 CD N
% NN N
) ) N
compared VBN N
with IN N
those DT N
patients NNS N
randomized VBN N
to TO N
filgrastim VB N
( ( N
28 CD N
% NN N
) ) N
. . N

Across IN N
all DT N
cycles NNS N
of IN N
treatment NN N
, , N
70 CD N
% NN N
of IN N
placebo-treated JJ N
patients NNS N
experienced VBD N
mucositis NN o
, , N
compared VBN N
with IN N
53 CD N
% NN N
of IN N
patients NNS N
randomized VBN N
to TO N
filgrastim VB N
. . N

A DT N
significant JJ N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
chemotherapy-related JJ N
oral JJ o
mucositis NN o
occurred VBD N
across IN N
multiple JJ N
cycles NNS N
of IN N
treatment NN N
in IN N
patients NNS N
treated VBN N
with IN N
filgrastim NN N
. . N

-DOCSTART- -11029345- O O

Tromethamine NNP i
buffer NN i
modifies VBZ N
the DT N
depressant JJ o
effect NN o
of IN N
permissive JJ N
hypercapnia NN N
on IN N
myocardial JJ N
contractility NN N
in IN N
patients NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
. . p

In IN N
patients NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
( ( p
ARDS NNP p
) ) p
, , N
permissive JJ N
hypercapnia NN N
is VBZ N
a DT N
strategy NN N
to TO N
decrease VB N
airway RB N
pressures NNS N
to TO N
prevent VB N
ventilator-induced JJ N
lung NN N
damage NN N
by IN N
lowering VBG N
tidal JJ N
volumes NNS N
and CC N
tolerating VBG N
higher JJR N
arterial JJ N
carbon NN N
dioxide NN N
tension NN N
. . N

However RB N
, , N
in IN N
experimental JJ N
studies NNS N
hypercapnia VBP N
impairs JJ N
myocardial JJ N
contractility NN N
and CC N
hemodynamic JJ N
function NN N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
short-term JJ N
permissive JJ N
hypercapnia NN N
on IN N
myocardial JJ N
contractility NN N
and CC N
hemodynamics NNS N
in IN N
patients NNS p
with IN p
ARDS NNP p
. . p

We PRP N
hypothesized VBD N
that IN N
the DT N
administration NN N
of IN N
tromethamine NN i
( ( i
THAM NNP i
) ) i
, , N
a DT N
buffer NN N
which WDT N
does VBZ N
not RB N
increase VB N
carbon NN N
dioxide NN N
production NN N
, , N
would MD N
modify VB N
these DT N
changes NNS N
. . N

In IN N
12 CD p
patients NNS p
with IN p
ARDS NNP p
, , N
permissive JJ N
hypercapnia NN N
was VBD N
implemented VBN N
for IN N
2 CD N
h NN N
with IN N
a DT N
target NN N
Pa NNP N
( ( N
CO NNP N
( ( N
2 CD N
) ) N
) ) N
of IN N
80 CD N
mm NN N
Hg NNP N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
have VB N
respiratory JJ N
acidosis NN N
corrected VBN N
by IN N
THAM NNP i
( ( N
pH-corrected JJ N
group NN N
) ) N
, , N
or CC N
not RB N
corrected VBN N
( ( N
pH-uncorrected JJ N
group NN N
) ) N
. . N

Hemodynamic JJ o
responses NNS o
were VBD N
measured VBN N
, , N
and CC N
transesophageal JJ N
echocardiography NN N
( ( N
TEE NNP N
) ) N
was VBD N
used VBN N
to TO N
determine VB N
myocardial JJ N
contractility NN N
. . N

Permissive NNP N
hypercapnia NN N
resulted VBD N
in IN N
significant JJ N
decreases NNS N
in IN N
systemic JJ o
vascular JJ o
resistance NN o
( ( o
SVR NNP o
) ) o
and CC o
increases VBZ o
in IN o
cardiac JJ o
output NN o
( ( o
Q NNP o
) ) o
. . o

Myocardial JJ o
contractility NN o
decreased VBN N
in IN N
both DT N
groups NNS N
but CC N
significantly RB N
less RBR N
in IN N
the DT N
pH-corrected JJ N
group NN N
( ( N
approximately RB N
10 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
pH-uncorrected JJ N
group NN N
( ( N
approximately RB N
18 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

Mean JJ o
arterial JJ o
pressure NN o
decreased VBN N
and CC N
mean JJ o
pulmonary JJ o
arterial JJ o
pressure NN o
increased VBD N
significantly RB N
only RB N
in IN N
the DT N
pH-uncorrected JJ N
group NN N
. . N

All DT N
values NNS N
returned VBN N
to TO N
baseline VB N
conditions NNS N
1 CD N
h NN N
after IN N
permissive JJ N
hypercapnia NN N
was VBD N
terminated VBN N
. . N

Our PRP$ N
study NN N
demonstrates VBZ N
a DT N
reversible JJ N
depression NN N
of IN N
myocardial JJ o
contractility NN o
and CC o
hemodynamic JJ o
alterations NNS o
during IN N
rapid JJ N
permissive JJ N
hypercapnia NN N
which WDT N
were VBD N
attenuated VBN N
by IN N
buffering VBG N
with IN N
THAM NNP i
. . i

This DT N
may MD N
have VB N
applicability NN N
to TO N
the DT N
clinical JJ N
strategy NN N
of IN N
permissive JJ N
hypercapnia NN N
and CC N
allow VB N
the DT N
benefit NN N
of IN N
decreased JJ N
airway NN o
pressures NNS o
to TO N
be VB N
realized VBN N
while IN N
minimizing VBG N
the DT N
adverse JJ N
hemodynamic JJ N
effects NNS N
of IN N
hypercapnic JJ N
acidosis NN N
. . N

-DOCSTART- -9825232- O O

Succinate NNP i
sumatriptan JJ i
evaluation NN N
by IN N
Doppler NNP N
echocardiography NN N
in IN N
patients NNS p
with IN p
migraine NN p
. . p

Recent JJ N
reports NNS N
show VBP N
that IN N
sumatriptan JJ N
administration NN N
increases NNS N
blood VBP o
pressure NN o
and CC o
vascular JJ o
resistance NN o
both DT N
in IN N
systemic NN N
and CC N
pulmonary JJ N
circulation NN N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
by IN N
echo-Doppler NN N
technique NN N
the DT N
hemodynamic JJ o
effects NNS o
of IN N
subcutaneous JJ N
sumatriptan JJ i
administration NN N
. . N

Forty-one CD p
migraine JJ p
subjects NNS p
( ( p
26 CD p
males NNS p
, , p
15 CD p
females NNS p
) ) p
, , p
mean JJ p
age NN p
36 CD p
+/- JJ p
2 CD p
years NNS p
( ( p
range VB p
36-39 CD p
years NNS p
) ) p
, , p
and CC p
20 CD p
healthy JJ p
control NN p
subjects NNS p
( ( p
14 CD p
males NNS p
, , p
six CD p
females NNS p
) ) p
, , p
mean JJ p
age NN p
36 CD p
+/- JJ p
2 CD p
years NNS p
( ( p
range VB p
36-39 CD p
years NNS p
) ) p
were VBD N
randomized VBN N
( ( N
double-blind NN N
) ) N
to TO N
receiving VBG N
sumatriptan NN i
( ( i
group NN i
A NNP i
) ) i
or CC i
placebo NN i
( ( i
group NN i
B NNP i
) ) i
. . i

After IN i
a DT i
2-week JJ i
complete JJ i
pharmacological NN i
washout NN i
, , i
clinical JJ i
examination NN i
, , i
electrocardiogram NN i
, , i
and CC i
Doppler NNP i
echocardiography NN i
were VBD i
performed VBN i
at IN i
baseline NN i
, , i
15 CD i
, , i
30 CD i
, , i
45 CD i
, , i
and CC i
60 CD i
min NN i
after IN i
sumatriptan NN i
or CC i
placebo JJ i
administration NN i
. . i

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
regarding VBG N
Doppler NNP N
echocardiographic JJ N
parameters NNS N
( ( o
aortic JJ o
integral NN o
, , o
pulmonary JJ o
integral JJ o
, , o
end-systolic JJ o
and CC o
end-diastolic JJ o
diameters NNS o
) ) o
and CC N
heart NN o
rate NN o
; : o
only RB N
a DT N
slight NN N
but CC N
not RB N
significant JJ N
increase NN N
in IN N
arterial JJ N
blood NN N
pressure NN N
was VBD N
observed VBN N
in IN N
group NN N
A NNP N
. . N

Our PRP$ N
data NNS N
show VBP N
that IN N
succinate JJ i
sumatriptan NNS i
can MD N
be VB N
used VBN N
with IN N
safety NN N
in IN N
patients NNS p
without IN p
hypertension NN p
and CC p
other JJ p
cardiovascular JJ p
disease NN p
. . p

-DOCSTART- -9799143- O O

Blind NNP i
versus NN i
open JJ i
approach NN i
to TO i
laparoscopic VB i
cholecystectomy NN i
: : i
a DT N
randomized JJ N
study NN N
. . N

Intraabdominal NNP N
structures NNS N
may MD N
be VB N
damaged VBN N
during IN N
blind JJ N
introduction NN N
of IN N
the DT N
first JJ N
trocar NN N
for IN N
laparoscopic JJ i
operations NNS N
. . N

In IN N
this DT N
study NN N
, , N
150 CD p
patients NNS p
with IN p
gallbladder JJ p
lithiasis NN p
who WP p
underwent JJ p
laparoscopy NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
, , N
a DT N
blind NN N
( ( N
V NNP N
group NN N
) ) N
or CC N
an DT N
open JJ N
( ( N
H NNP N
group NN N
) ) N
, , N
in IN N
order NN N
to TO N
compare VB N
the DT N
results NNS N
and CC N
the DT N
rate NN o
of IN o
complications NNS o
. . o

No DT N
mortality NN o
was VBD N
observed VBN N
. . N

Major JJ o
complications NNS o
occurred VBD N
in IN N
3/75 CD N
( ( N
4 CD N
% NN N
) ) N
patients NNS N
of IN N
the DT N
V NNP N
group NN N
and CC N
in IN N
1/75 CD N
( ( N
1.3 CD N
% NN N
) ) N
patient NN N
of IN N
the DT N
H NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Minor JJ o
complications NNS o
occurred VBD N
in IN N
5/75 CD N
( ( N
6.7 CD N
% NN N
) ) N
patients NNS N
of IN N
either DT N
group NN N
. . N

The DT N
achievement NN o
of IN o
pneumoperitoneum NN o
required VBN N
4.5+/-0.4 JJ N
min NN N
in IN N
the DT N
V NNP N
group NN N
and CC N
3.2+/-0.2 JJ N
min NN N
in IN N
the DT N
H NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
open JJ i
laparoscopic NN i
technique NN i
is VBZ N
safer JJR N
and CC N
faster RBR N
than IN N
the DT N
blind JJ i
approach NN i
; : i
therefore RB N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
this DT N
approach NN N
be VB N
routinely RB N
used VBN N
in IN N
all DT N
laparoscopic NN N
procedures NNS N
. . N

-DOCSTART- -8141163- O O

Sodium NN N
kinetics NNS N
in IN N
white JJ p
and CC p
black JJ p
normotensive JJ p
subjects NNS p
: : p
possible JJ N
relevance NN N
to TO N
salt-sensitive JJ N
hypertension NN N
. . N

The DT N
hypothesis NN N
that WDT N
sodium NN i
( ( i
Na NNP i
) ) i
kinetics NNS N
are VBP N
not RB N
a DT N
first JJ N
order NN N
process NN N
was VBD N
tested VBN N
. . N

Twelve NNP p
normotensive JJ p
white JJ p
and CC p
12 CD p
normotensive JJ p
black JJ p
men NNS p
were VBD N
given VBN N
10 CD N
, , N
200 CD N
, , N
and CC N
400 CD i
mmol/d NN i
Na NNP i
as IN i
the DT i
chloride NN i
salt NN i
for IN N
7 CD N
days NNS N
in IN N
random JJ N
order NN N
. . N

All DT N
urine JJ N
made VBN N
was VBD N
collected VBN N
. . N

No DT N
effect NN N
of IN N
Na NNP i
intake VBP N
on IN N
blood NN o
pressure NN o
was VBD N
identified VBN N
in IN N
either DT N
whites NNS p
or CC N
blacks NNS p
. . p

The DT N
half-life NN o
( ( o
T1/2 NNP o
) ) o
with IN N
decreasing VBG N
Na NNP i
intake NN N
to TO N
10 CD N
mmol/d NN N
was VBD N
1.08 CD N
days NNS N
in IN N
whites NNS N
and CC N
1.65 CD N
days NNS N
in IN N
blacks NNS N
( ( N
p VB N
= NNP N
not RB N
significant JJ N
[ NNP N
NS NNP N
] NNP N
) ) N
. . N

With IN N
increasing VBG N
Na NNP i
intake NN N
, , N
T1/2 NNP o
increased VBD o
in IN N
both DT N
whites NNS N
and CC N
blacks NNS N
; : N
at IN N
the DT N
400 CD N
mmol/d NNS N
intake NN N
, , N
the DT N
T1/2 NNP N
for IN N
whites NNS N
was VBD N
2.88 CD N
days NNS N
and CC N
for IN N
blacks NNS N
was VBD N
5.81 CD N
days NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

At IN N
that DT N
intake NN N
, , N
whites NNS N
accumulated VBD o
385 CD N
+/- JJ N
153 CD N
mmol NNS N
compared VBN N
with IN N
909 CD N
+/- JJ N
153 CD N
mmol NN N
for IN N
blacks NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
data NN N
showed VBD N
that IN N
T1/2 NNP o
increases VBZ o
with IN N
increasing VBG N
Na NNP i
intake NN N
and CC N
is VBZ N
, , N
therefore RB N
, , N
dose-dependent JJ N
or CC N
zero CD N
order NN N
. . N

The DT N
effect NN o
of IN N
dose NN N
is VBZ N
more RBR o
prominent JJ o
in IN o
blacks NNS o
than IN N
in IN N
whites NNS N
; : N
blacks NNS N
accumulate VBP o
more JJR o
Na NNP o
with IN N
increasing VBG N
Na NNP i
intake NN N
than IN N
whites NNS N
. . N

These DT N
data NNS N
may MD N
have VB N
relevance NN N
for IN N
the DT N
pathogenesis NN N
of IN N
salt-sensitive JJ p
hypertension NN p
in IN p
blacks NNS p
. . p

-DOCSTART- -20603436- O O

Comorbidity NN o
, , o
age NN o
and CC N
overall JJ o
survival NN o
in IN N
cetuximab-treated JJ i
patients NNS p
with IN p
advanced JJ p
colorectal JJ p
cancer NN p
( ( p
ACRC NNP p
) ) p
-- : p
results NNS p
from IN N
NCIC NNP N
CTG NNP N
CO.17 NNP N
: : N
a DT N
phase NN N
III NNP N
trial NN N
of IN N
cetuximab NN i
versus NN N
best RBS i
supportive JJ i
care NN i
. . i

BACKGROUND IN N
the DT N
interplay NN N
between IN N
comorbidity NN o
, , o
age NN o
and CC N
performance NN o
status NN o
( ( o
PS NNP o
) ) o
as IN N
predictors NNS N
of IN N
outcome NN N
in IN N
advanced JJ N
colorectal JJ N
cancer NN N
( ( N
ACRC NNP N
) ) N
is VBZ N
poorly JJ N
understood NN N
. . N

We PRP N
examined VBD N
these DT N
factors NNS N
as IN N
predictors NNS N
of IN N
treatment NN N
toxicity NN o
and CC N
outcome NN N
in IN N
cetuximab-treated JJ i
patients NNS p
with IN p
ACRC NNP p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
comorbidity NN N
was VBD N
independently RB N
evaluated VBN N
using VBG N
the DT N
Charlson NNP o
Comorbidity NNP o
Index NNP o
( ( o
CCI NNP o
) ) o
, , N
a DT N
validated JJ N
measure NN N
of IN N
comorbidity NN o
based VBN N
on IN N
the DT N
presence NN N
of IN N
medical JJ N
conditions NNS N
weighted VBD N
according VBG N
to TO N
their PRP$ N
effect NN N
on IN N
mortality NN N
. . N

CCI NNP o
score NN o
was VBD N
correlated VBN N
with IN N
clinical JJ N
and CC N
outcome JJ N
data NNS N
. . N

RESULTS NNP N
five CD p
hundred VBD p
and CC p
seventy-two JJ p
patients NNS p
were VBD p
included VBN p
; : p
41 CD p
% NN p
were VBD p
? . p
65 CD p
years NNS p
and CC p
25 CD p
% NN p
had VBD p
comorbidities NNS p
at IN p
randomization NN p
. . p

In IN N
multivariate JJ N
analysis NN N
( ( N
MVA NNP N
) ) N
of IN N
all DT N
covariates NNS N
, , N
only RB N
older JJR N
age NN N
was VBD N
associated VBN N
with IN N
greater JJR N
comorbidity NN N
( ( N
P NNP N
= NNP N
0.008 CD o
) ) o
. . o

Overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
was VBD o
significantly RB N
better JJR N
for IN N
patients NNS N
with IN N
greater JJR N
comorbidity NN N
in IN N
univariate JJ N
analysis NN N
( ( N
P NNP N
= NNP N
0.047 CD N
) ) N
. . N

Conversely RB N
, , N
better JJR o
PS NNP o
was VBD o
associated VBN N
with IN N
better JJR o
OS NNP o
in IN o
MVA NNP N
( ( N
hazard JJ N
ratio NN N
1.92 CD N
for IN N
PS NNP N
= NNP N
2 CD N
versus NN N
PS NNP N
= NNP N
0 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Age NNP N
was VBD N
not RB N
associated VBN N
with IN o
OS NNP o
( ( o
P NNP N
= NNP N
0.13 CD p
) ) p
. . p

Elderly JJ p
patients NNS p
had VBD p
significantly RB N
less JJR o
grade NN o
? . o
3 CD o
vomiting NN o
( ( o
P NNP o
= NNP N
0.034 CD N
) ) N
but CC N
more JJR N
dyspnea NN o
( ( o
P NNP o
= NNP N
0.005 CD p
) ) p
. . p

Patients NNS p
with IN p
greater JJR p
comorbidity NN p
had VBD p
significantly RB N
less JJR N
grade NN o
? . o
3 CD o
vomiting NN o
( ( o
P NNP o
= NNP o
0.002 CD N
) ) N
but CC N
more JJR N
non-neutropenic JJ o
fever NN o
( ( o
P NNP N
= NNP N
0.005 CD N
) ) N
. . N

CONCLUSION NNP o
better JJR o
PS NNP o
was VBD o
associated VBN N
with IN N
improved JJ N
OS NNP o
. . o

For IN o
patients NNS p
with IN p
good JJ o
PS NNP o
, , N
restricting VBG i
cetuximab NN i
use NN i
in IN i
the DT N
setting NN N
of IN N
significant JJ N
comorbidity NN N
does VBZ N
not RB N
appear VB N
justified VBN N
. . N

-DOCSTART- -17357577- O O

[ JJ N
Effect NNP N
of IN N
alpha JJ i
dihydroergocryptine NN i
in IN N
patients NNS p
with IN p
fibrocystic JJ p
breast NN p
disease NN p
] NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
alpha JJ i
dihidroergocriptine NN i
in IN N
patients NNS p
with IN p
fibrocystic JJ p
mastopathy NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
diagnosis NN p
of IN p
fibrocystic JJ p
breast NN p
disease NN p
were VBD p
included VBN p
in IN N
a DT N
prospective JJ N
longitudinal JJ N
blind NN N
double NN N
, , N
controlled VBN N
with IN N
placebo NN i
study NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
of IN N
treatment NN N
group NN N
A DT N
: : N
Alpha NNP i
dihidroergocriptine VBP i
tablets NNS i
of IN i
10 CD i
mg NNS i
, , N
group NN N
B NNP N
: : N
Placebo NN i
, , N
during IN N
6 CD N
months NNS N
. . N

After IN N
to TO N
basal VB N
evaluation NN N
, , N
the DT N
patients NNS N
were VBD N
revised VBN N
in IN N
a DT N
monthly JJ N
way NN N
evaluating VBG N
the DT N
following NN N
symptoms NNS N
and CC N
signs NNS N
: : N
mastalgia NN o
, , o
mammary JJ o
tension NN o
, , o
presence NN o
of IN o
nodules NNS o
, , o
nipple JJ o
secretion NN o
, , o
and CC o
the DT o
presence NN o
of IN o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
39 CD p
patients NNS p
with IN p
alpha JJ i
dihidroergocriptine NN i
and CC p
38 CD p
with IN p
placebo NN i
. . i

Mastodinia NNP o
, , N
a DT N
satisfactory JJ N
response NN N
was VBD N
observed VBN N
in IN N
100 CD N
% NN N
of IN N
alpha JJ i
dihidroergocriptine NN i
group NN N
vs VBD N
61.11 CD N
% NN N
of IN N
placebo NN i
group NN N
( ( N
p JJ N
= NNP N
0.0002 CD N
) ) N
. . N

Mastalgia NNP o
responded VBD N
in IN N
100 CD N
% NN N
of IN N
alpha JJ N
dihidroergocriptine NN N
group NN N
vs VBD N
64.86 CD N
% NN N
of IN N
placebo NN N
group NN N
( ( N
p JJ N
= NNP N
0.0003 CD N
) ) N
. . N

Galactorrea NNP o
responded VBD N
100 CD N
% NN N
of IN N
alpha JJ i
dihidroergocriptine NN i
group NN N
vs VBD N
93.33 CD N
% NN N
of IN N
the DT N
placebo NN N
. . N

The DT N
nodules NNS o
in IN N
the DT N
group NN N
alpha VBZ N
dihidroergocriptine NN N
disappeared VBD N
in IN N
23.1 CD N
% NN N
and CC N
in IN N
21.1 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
. . N

Ultrasound IN o
evaluation NN o
of IN o
the DT o
nodules NNS o
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
between IN N
both DT N
groups NNS N
. . N

Prolactin NNP o
levels NNS o
showed VBD N
a DT N
decrease NN N
in IN N
the DT N
group NN N
treated VBD N
with IN N
alpha JJ i
dihidroergocriptine NN i
with IN N
an DT N
important JJ N
difference NN N
between IN N
both DT N
groups NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
6 CD N
months NNS N
study JJ N
period NN N
. . N

There EX N
were VBD N
not RB N
differences NNS N
in IN N
the DT N
presence NN o
of IN o
adverse JJ o
events NNS o
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Alpha NNP i
dihidroergocriptine NN i
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
fribrocystic JJ o
breast NN o
disease NN o
with IN N
minimum JJ N
adverse JJ N
events NNS N
when WRB N
compared VBN N
with IN N
similar JJ N
drugs NNS N
. . N

-DOCSTART- -25887586- O O

Femoral NNP N
neck NN N
osteotomy NN N
guide NN N
for IN N
total JJ p
hip NN p
arthroplasty NN p
. . p

BACKGROUND NNP N
Total NNP i
hip NN i
arthroplasty NN i
( ( i
THA NNP i
) ) i
is VBZ N
a DT N
common JJ N
last-resort NN N
treatment NN N
for IN N
hip NN N
disease NN N
, , N
but CC N
postoperative JJ p
patients NNS p
often RB N
complain VBP N
of IN N
discrepancies NNS N
in IN N
leg JJ N
length NN N
. . N

This DT N
study NN N
introduces VBZ N
a DT N
device NN N
designed VBN N
to TO N
increase VB N
the DT N
precision NN o
of IN o
the DT o
femoral JJ o
neck NN o
osteotomy NN o
and CC N
reduce VB N
the DT N
incidence NN o
of IN o
leg JJ o
length NN o
discrepancy NN o
. . o

METHODS NNP N
Forty-eight JJ p
patients NNS p
undergoing VBG p
THA NNP i
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
, , N
with IN N
and CC N
without IN N
the DT N
use NN N
of IN N
the DT N
femoral JJ i
osteotomy NN i
guide NN i
. . i

All DT N
operations NNS N
were VBD N
performed VBN N
through IN N
a DT N
posterolateral JJ N
approach NN N
. . N

Differences NNS o
in IN o
leg JJ o
length NN o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
the DT N
operation NN N
. . N

Measurements NNS N
were VBD N
also RB N
made VBN N
to TO N
compare VB N
the DT N
preoperative JJ o
plan NN o
with IN N
the DT N
actual JJ o
amount NN o
of IN o
bone NN o
removed VBN o
. . o

RESULTS VB N
The DT N
mean JJ o
average JJ o
difference NN o
in IN o
femoral JJ o
neck NN o
resection NN o
height NN o
was VBD N
0.84 CD N
mm NN N
when WRB N
using VBG N
the DT N
osteotomy NN N
guide NN N
and CC N
1.69 CD N
mm NN N
without IN N
the DT N
guide NN o
. . o

Discrepancies NNS o
in IN o
postoperative JJ o
leg NN o
length NN o
were VBD o
5.45 CD N
mm NNS N
and CC N
13.37 CD N
mm NN N
in IN N
the DT N
groups NNS N
with IN N
and CC N
without IN N
the DT N
guide NN N
, , N
respectively RB N
. . N

CONCLUSION VB i
The DT i
femoral JJ i
neck NN i
osteotomy NN i
guide NN i
is VBZ i
an DT N
effectively RB N
auxiliary JJ N
tool NN N
for IN N
increasing VBG N
the DT N
accuracy NN o
of IN o
bone NN o
resection NN o
in IN o
arthroplasty JJ p
using VBG p
the DT p
posterolateral JJ p
approach NN p
. . p

TRIAL NNP p
REGISTRATION NNP N
ChiCTR-OOC-15005904 NNP N
; : N
date NN N
: : N
2015-01-30 JJ N
. . N

-DOCSTART- -19333040- O O

Diverting VBG o
stoma NN o
after IN N
low JJ N
anterior JJ N
resection NN N
: : N
more JJR N
arguments NNS N
in IN N
favor NN N
. . N

PURPOSE VB N
The DT N
necessity NN N
of IN N
a DT N
protective JJ i
stoma NN i
in IN N
patients NNS p
undergoing VBG p
low JJ i
anterior JJ i
resection NN i
with IN p
total JJ p
mesorectal JJ p
excision NN p
for IN p
primary JJ p
rectal JJ p
cancer NN p
is VBZ N
discussed VBN N
controversially RB N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
controlled VBN N
, , N
pilot-study NN N
to TO N
evaluate VB N
the DT N
need NN N
for IN N
diverting VBG o
ileostomy NN o
in IN N
patients NNS p
undergoing VBG p
low JJ p
anterior JJ p
resection NN p
[ NNP N
NCT00457327 NNP N
] NNP N
. . N

METHODS NNP N
Forty NNP p
patients NNS p
after IN p
elective JJ p
sphincter-saving JJ p
low JJ p
anterior JJ p
resection NN p
were VBD N
eligible JJ N
for IN N
intraoperative JJ N
randomization NN N
. . N

The DT N
primary JJ N
objective NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
demonstrate VB N
similar JJ o
risks NNS o
after IN N
the DT N
resection NN N
with IN N
both DT N
techniques NNS N
. . N

A DT N
priori JJ N
stopping NN N
rules NNS N
were VBD N
defined VBN N
for IN N
early JJ N
termination NN N
of IN N
the DT N
trial NN N
. . N

RESULTS NNP N
Between NNP N
July NNP N
4 CD N
, , N
2006 CD N
and CC N
March NNP N
12 CD N
, , N
2007 CD N
, , N
a DT p
total NN p
of IN p
41 CD p
patients NNS p
were VBD p
screened VBN p
and CC p
34 CD p
patients NNS p
were VBD p
randomized VBN p
. . p

Eighteen JJ p
patients NNS p
were VBD p
randomized VBN p
to TO p
the DT p
stoma NN i
group NN i
and CC p
16 CD p
patients NNS p
to TO p
the DT p
nonstoma NN i
group NN i
The DT o
symptomatic JJ o
anastomotic JJ o
leakage NN o
rate NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
nonstoma NN N
group NN N
( ( N
37.5 CD N
percent NN N
) ) N
than IN N
in IN N
the DT N
stoma NN N
group NN N
( ( N
5.5 CD N
percent NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

In IN N
all DT N
six CD N
cases NNS N
in IN N
the DT N
nonstoma NN N
group NN N
, , N
reoperations NNS o
were VBD N
necessary JJ N
. . N

The DT N
study NN N
was VBD N
stopped VBN N
after IN N
34 CD N
patients NNS N
were VBD N
included VBN N
. . N

A DT N
meta-analysis NN N
of IN N
the DT N
available JJ N
data NNS N
confirmed VBD N
the DT N
value NN N
of IN N
a DT N
protective JJ N
ostomy NN N
for IN N
patients NNS p
undergoing VBG p
low JJ p
anterior JJ p
resection NN p
. . p

CONCLUSIONS VB N
The DT N
data NN N
demonstrate NN N
a DT N
high JJ N
risk NN N
for IN N
patients NNS p
undergoing VBG p
low JJ p
anterior JJ p
resection NN p
without IN N
diverting VBG N
ileostomy NN N
. . N

-DOCSTART- -11948051- O O

Regional JJ i
ischemic JJ i
preconditioning NN i
enhances NNS N
myocardial JJ o
performance NN N
in IN N
off-pump JJ N
coronary JJ N
artery NN p
bypass NN p
grafting NN p
. . p

OBJECTIVES IN N
We PRP N
intended VBD N
to TO N
investigate VB N
whether IN N
ischemic JJ N
preconditioning NN N
( ( N
IP NNP N
) ) N
enhances VBZ N
myocardial JJ o
performance NN N
in IN N
patients NNS p
who WP p
undergo VBP p
off-pump JJ p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
( ( p
CABG NNP p
) ) p
. . p

DESIGN VB N
A DT N
controlled VBN N
, , N
randomized VBN N
, , N
prospective JJ N
study NN N
. . N

SETTING VB N
A DT N
university NN N
hospital NN N
. . N

PATIENTS VB N
Thirty-two JJ p
patients NNS p
with IN p
left JJ p
anterior JJ p
descending VBG p
coronary JJ p
artery NN p
( ( p
LAD NNP p
) ) p
or CC p
two-vessel JJ p
heart NN p
disease NN p
( ( p
including VBG p
LAD NNP p
) ) p
who WP p
were VBD p
to TO p
undergo VB p
off-pump JJ p
CABG NNP p
were VBD N
randomized VBN N
into IN N
an DT N
IP NNP N
group NN N
and CC N
a DT N
control NN N
group NN N
. . N

INTERVENTIONS NNP N
IP NNP N
was VBD N
induced VBN N
by IN N
occluding VBG i
the DT i
LAD NNP i
twice NN i
for IN i
a DT i
2-min JJ i
period NN i
followed VBN i
by IN i
3-min JJ i
LAD NNP i
reperfusion NN i
before IN i
bypass NN i
grafting NN i
of IN i
the DT i
first JJ i
coronary JJ i
vessel NN i
. . i

MEASUREMENTS NNP N
AND CC N
RESULTS NNP N
Registration NNP N
included VBD N
hemodynamic JJ N
data NNS N
from IN N
the DT N
peripheral JJ N
artery NN N
and CC N
the DT N
pulmonary JJ N
artery NN N
, , N
and CC N
the DT N
measurement NN N
of IN N
cardiac JJ o
troponin NN o
I PRP o
( ( o
CTnI NNP o
) ) o
and CC o
creatine JJ o
kinase NN o
isoenzyme NN o
MB NNP o
( ( o
CK-MB NNP o
) ) o
values NNS o
. . o

IP NNP N
resulted VBD N
in IN N
a DT N
complete JJ N
recovery NN o
of IN o
the DT o
mean JJ o
stroke NN o
volume NN o
index NN o
( ( o
SVI NNP o
) ) o
after IN N
the DT N
operation NN N
. . N

In IN N
the DT N
control NN N
subjects VBZ N
, , N
the DT N
mean NN o
SVI NNP o
showed VBD N
a DT N
significant JJ o
reduction NN o
postoperatively RB N
( ( N
p JJ N
= NNP N
0.039 CD N
) ) N
. . N

On IN N
the DT N
first JJ N
postoperative JJ N
day NN N
, , N
the DT N
increase NN N
in IN N
the DT N
mean JJ o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
IP NNP N
patients NNS N
. . N

The DT N
CTnI NNP o
level NN o
was VBD N
statistically RB N
significantly RB o
lower JJR o
in IN N
the DT N
IP NNP N
group NN N
( ( N
p JJ N
= NNP N
0.043 CD N
) ) N
, , N
and CC N
IP NNP N
patients NNS N
tended VBD N
to TO N
have VB N
a DT N
smaller JJR N
CK-MB JJ o
release NN o
after IN N
surgery NN N
( ( N
not RB N
significant JJ N
) ) N
. . N

The DT N
duration NN o
of IN o
mechanical JJ o
ventilation NN o
, , o
the DT o
length NN o
of IN o
stay NN o
in IN N
the DT N
ICU NNP o
, , N
and CC N
the DT N
use NN o
of IN o
inotropic JJ o
medication NN o
did VBD N
not RB N
increase VB N
after IN N
the DT N
IP NNP N
protocol NN N
. . N

CONCLUSIONS NNP N
Two CD N
cycles NNS N
of IN N
regional JJ N
2-min JJ N
IP NNP N
in IN N
the DT N
LAD NNP N
, , N
followed VBN N
by IN N
3 CD N
min NN N
of IN N
reperfusion NN N
, , N
proved VBD N
to TO N
be VB N
applicable JJ N
and CC N
safe JJ N
in IN N
patients NNS p
undergoing VBG p
off-pump JJ p
myocardial JJ p
revascularization NN p
, , N
it PRP N
tended VBD N
to TO N
decrease VB N
the DT N
immediate JJ N
myocardial JJ o
enzyme NN o
release NN N
, , N
it PRP N
prohibited VBD N
the DT N
postoperative JJ N
increase NN N
in IN N
HR NNP o
, , N
and CC N
it PRP N
enhanced VBD N
the DT N
recovery NN N
of IN N
SVI NNP o
. . o

-DOCSTART- -6390445- O O

Treatment NN p
of IN p
bladder NN p
cancer NN p
with IN p
intravesical JJ p
instillation NN p
of IN p
adriamycin NN i
. . i

Intravesical JJ N
treatment NN N
with IN N
adriamycin NN i
has VBZ N
been VBN N
extensively RB N
employed VBN N
in IN N
the DT N
last JJ N
decade NN N
. . N

In IN N
the DT N
treatment NN N
of IN N
carcinoma NN N
in IN N
situ JJ N
complete JJ N
responses NNS N
have VBP N
been VBN N
reported VBN N
in IN N
about RB N
60 CD N
% NN N
of IN N
cases NNS N
. . N

Its PRP$ N
efficacy NN o
is VBZ N
probably RB N
lower RBR N
in IN N
the DT N
therapy NN N
of IN N
multiple JJ N
or CC N
diffuse NN N
low JJ N
stage NN N
transitional JJ N
cell NN N
carcinoma NN N
that WDT N
is VBZ N
too RB N
extensive JJ N
to TO N
be VB N
completely RB N
resected VBN N
by IN N
conventional JJ N
transurethral JJ N
surgery NN N
. . N

In IN N
such JJ N
circumstances NNS N
, , N
including VBG N
cancer NN N
in IN N
situ NN N
, , N
adriamycin JJ i
compares VBZ N
favorably RB N
with IN N
other JJ N
local JJ N
forms NNS N
of IN N
treatment NN N
. . N

The DT N
prophylactic JJ N
use NN N
of IN N
intravesical JJ N
instillation NN N
of IN N
Adriamycin NNP i
has VBZ N
been VBN N
studied VBN N
more RBR N
extensively RB N
. . N

Preliminary JJ N
results NNS N
of IN N
controlled JJ N
randomized JJ N
trials NNS N
implemented VBN N
from IN N
the DT N
EORTC NNP N
Urological NNP N
Group NNP N
show VBP N
that IN N
adriamycin JJ i
instillations NNS N
significantly RB N
reduce VB N
recurrence NN o
rate NN o
after IN o
TUR NNP o
. . o

The DT N
treatment NN N
is VBZ N
well RB N
tolerated VBN o
. . o

Systemic JJ o
absorption NN o
is VBZ N
virtually RB N
absent JJ N
, , N
and CC N
no DT o
severe JJ o
drug-related JJ o
side NN o
effects NNS o
have VBP N
ever RB N
been VBN N
reported VBN N
. . N

Chemical NNP o
cystitis NN o
is VBZ N
occasionally RB N
observed VBN N
, , N
especially RB N
if IN N
multiple JJ N
instillations NNS N
are VBP N
started VBN N
immediately RB N
after IN N
TUR NNP N
, , N
or CC N
in IN N
the DT N
presence NN N
of IN N
additional JJ N
inflammatory NN N
conditions NNS N
, , N
such JJ N
as IN N
previous JJ N
irradiation NN N
or CC N
bacterial JJ N
cystitis NN N
. . N

-DOCSTART- -20630604- O O

Effect NN N
of IN N
explicit JJ i
instruction NN i
on IN i
Japanese JJ i
Verbal NNP i
Learning NNP i
Test NNP i
in IN N
schizophrenia NN p
patients NNS p
. . p

After IN N
random JJ N
assignment NN N
of IN N
20 CD p
schizophrenia NN p
patients NNS p
to TO N
either DT N
an DT N
explicit NN i
or CC i
normal JJ i
instruction NN i
group NN N
, , N
the DT N
Japanese JJ i
Verbal NNP i
Learning NNP i
Test NNP i
was VBD N
administered VBN N
to TO N
them PRP N
. . N

Results VB N
reveal NN N
that IN N
explicit JJ N
instruction NN N
group NN N
patients NNS N
demonstrated VBD N
more RBR N
improved JJ o
memory NN o
performance NN o
using VBG N
semantic JJ N
clustering NN N
, , N
suggesting VBG N
that IN N
explicit NN N
and CC N
direct JJ N
teaching NN N
facilitates VBZ N
patients NNS N
' POS N
learning NN N
of IN N
information NN N
. . N

-DOCSTART- -1423955- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS i
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
. . p

BACKGROUND NNP N
Diltiazem NNP i
, , N
a DT N
calcium NN N
channel NN N
blocker NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
in IN p
atrial JJ p
fibrillation NN p
and/or IN p
atrial JJ p
flutter NN p
. . p

However RB N
, , N
there EX N
have VBP N
been VBN N
no DT N
pharmacokinetic/pharmacodynamic JJ N
studies NNS N
of IN N
diltiazem NN N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
intravenous JJ i
diltiazem NNS i
were VBD N
determined VBN N
in IN N
32 CD p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
( ( p
mean JJ p
+/- NN p
SD NNP p
age NN p
, , p
66 CD p
+/- JJ p
7 CD p
years NNS p
; : p
mean VB p
baseline JJ p
heart NN p
rate NN p
, , p
131 CD p
+/- JJ p
10 CD p
beats NNS p
per IN p
minute NN p
) ) p
after IN p
20 CD p
mg NN p
or CC p
20 CD p
mg NN p
followed VBN p
by IN p
25-mg JJ p
bolus NN p
doses NNS p
and CC p
a DT p
10 CD p
and CC p
15 CD p
mg/hr NN p
infusion NN p
for IN p
24 CD p
hours NNS p
. . N

After IN N
the DT N
10 CD N
and CC N
15 CD N
mg/hr JJ N
infusions NNS N
of IN N
diltiazem NN i
, , N
mean JJ N
+/- JJ N
SD NNP N
elimination NN N
half-life NN N
was VBD N
6.8 CD N
+/- JJ N
1.8 CD N
and CC N
6.9 CD N
+/- JJ N
1.5 CD N
hours NNS N
, , N
volume NN N
of IN N
distribution NN N
was VBD N
411 CD N
+/- JJ N
151.8 CD N
and CC N
299 CD N
+/- JJ N
70.8 CD N
I PRP N
, , N
and CC N
systemic JJ N
clearance NN N
was VBD N
42 CD N
+/- JJ N
12.4 CD N
and CC N
31 CD N
+/- JJ N
8.3 CD N
l/hr NN N
, , N
respectively RB N
. . N

Percentages NNS o
of IN o
the DT o
plasma JJ o
concentrations NNS o
of IN o
the DT o
principal JJ o
metabolites NNS o
desacetyldiltiazem NNS o
and CC o
N-desmethyldiltiazem NNP o
to TO o
diltiazem VB o
were VBD N
< JJ N
15 CD N
% NN N
and CC N
< $ N
10 CD N
% NN N
, , N
respectively RB N
. . N

Thirty NNP p
of IN p
32 CD p
patients NNS p
maintained VBD N
response NN N
throughout IN N
the DT N
24-hour JJ N
infusion NN N
of IN N
diltiazem NN N
. . N

Using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
pharmacodynamic JJ N
model NN N
, , N
a DT N
strong JJ N
relation NN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
0.78 CD N
+/- JJ N
0.2 CD N
) ) N
was VBD N
observed VBN N
between IN N
plasma NN o
diltiazem NN o
concentration NN o
and CC o
percent JJ o
heart NN o
rate NN o
reduction NN o
. . o

Mean JJ o
+/- JJ o
SD NNP o
Emax NNP o
( ( N
maximum JJ N
percent NN N
reduction NN N
in IN N
heart NN N
rate NN N
from IN N
baseline NN N
) ) N
and CC N
EC50 NNP o
( ( N
plasma JJ N
diltiazem NN N
concentration NN N
that WDT N
achieves VBZ N
half DT N
Emax NNP N
) ) N
were VBD N
52 CD N
+/- JJ N
17 CD N
% NN N
and CC N
110 CD N
+/- JJ N
84 CD N
ng/ml NN N
, , N
respectively RB N
. . N

The DT N
model NN N
predicts VBZ N
that IN N
mean JJ N
plasma NN o
diltiazem NN o
concentration NN o
of IN N
79 CD N
, , N
172 CD N
, , N
and CC N
294 CD N
ng/ml NNS N
are VBP N
required VBN N
to TO N
produce VB N
a DT N
20 CD N
% NN N
, , N
30 CD N
% NN N
, , N
and CC N
40 CD N
% NN N
reduction NN N
in IN N
heart NN o
rate NN o
, , N
respectively RB N
. . N

A DT N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent NN N
change NN N
in IN N
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
or CC o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
from IN N
baseline NN N
was VBD N
not RB N
observed VBN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
r2 NN N
, , N
SBP/DBP NNP N
: : N
0.35 CD N
+/- JJ N
0.24/0.36 CD N
+/- JJ N
0.2 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
untoward JJ N
side NN N
effects NNS N
observed VBN N
. . N

CONCLUSIONS NNP N
First NNP N
, , N
the DT N
pharmacokinetics NNS N
of IN N
diltiazem NN i
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
or CC p
atrial JJ p
flutter NN p
is VBZ N
nonlinear JJ N
with IN N
an DT N
apparent JJ N
dose-dependent JJ N
decrease NN N
in IN N
systemic JJ N
clearance NN N
with IN N
increasing VBG N
infusion NN N
rate NN N
. . N

Second NNP N
, , N
using VBG N
a DT N
sigmoidal JJ N
Emax NNP N
model NN N
, , N
there EX N
is VBZ N
a DT N
strong JJ N
relation NN N
between IN N
plasma NN N
diltiazem NN N
concentration NN N
and CC N
percent JJ N
heart NN N
rate NN N
reduction NN N
. . N

Third NNP N
, , N
the DT N
plasma JJ N
concentrations NNS N
of IN N
the DT N
principal JJ N
metabolites NNS N
desacetyldiltiazem NNS N
and CC N
N-desmethyldiltiazem NNP N
are VBP N
low JJ N
and CC N
are VBP N
not RB N
expected VBN N
to TO N
contribute VB N
significantly RB N
to TO N
the DT N
pharmacodynamics NNS N
of IN N
intravenous JJ N
diltiazem NNS N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -16116013- O O

Cervical JJ N
spine NN N
motion NN N
: : N
a DT N
fluoroscopic NN N
comparison NN N
during IN N
intubation NN p
with IN N
lighted JJ N
stylet NN N
, , N
GlideScope NNP N
, , N
and CC N
Macintosh NNP N
laryngoscope NN N
. . N

The DT N
question NN N
of IN N
which WDT N
is VBZ N
the DT N
optimum JJ N
technique NN N
to TO N
intubate VB N
the DT N
trachea NN N
in IN N
a DT N
patient NN p
who WP p
may MD p
have VB p
a DT p
cervical JJ p
( ( p
C NNP p
) ) p
-spine VBP p
injury NN p
remains VBZ N
unresolved JJ N
. . N

We PRP N
compared VBN N
, , N
using VBG N
fluoroscopic JJ N
video NN N
, , N
C-spine JJ o
motion NN o
during IN N
intubation NN N
for IN N
Macintosh NNP N
3 CD N
blade NN N
, , N
GlideScope NNP N
, , N
and CC N
Intubating NNP N
Lighted NNP N
Stylet NNP N
, , N
popularly RB N
known VBN N
as IN N
the DT N
Lightwand NNP N
or CC N
Trachlight NNP N
. . N

Thirty-six NNP p
healthy JJ p
patients NNS p
were VBD p
randomized VBN p
to TO p
participate VB p
in IN p
a DT p
crossover JJ p
trial NN p
of IN N
either DT N
Lightwand NNP i
or CC i
GlideScope NNP i
to TO i
Macintosh NNP i
laryngoscopy NN i
, , i
with IN i
in-line JJ i
stabilization NN i
. . i

C-spine JJ o
motion NN o
was VBD N
examined VBN N
at IN N
the DT N
Occiput-C1 NNP N
junction NN N
, , N
C1-2 NNP N
junction NN N
, , N
C2-5 NNP N
motion NN N
segment NN N
, , N
and CC N
C5-thoracic NNP N
motion NN N
segment NN N
during IN N
manual JJ i
ventilation NN i
via IN i
bag-mask NN i
, , i
laryngoscopy NN i
, , i
and CC i
intubation NN i
. . i

Time NN o
to TO N
intubate VB N
was VBD N
also RB N
measured VBN N
. . N

C-spine JJ o
motion NN o
during IN o
bag-mask JJ o
ventilation NN o
was VBD N
82 CD N
% NN N
less JJR N
at IN N
the DT N
four CD N
motion NN N
segments NNS N
studied VBD N
than IN N
during IN N
Macintosh NNP N
laryngoscopy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

C-spine JJ o
motion NN o
using VBG o
the DT o
Lightwand NNP o
was VBD N
less JJR N
than IN N
during IN N
Macintosh NNP N
laryngoscopy NN N
, , N
averaging VBG N
57 CD N
% NN N
less JJR N
at IN N
the DT N
four CD N
motion NN N
segments NNS N
studied VBN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
time NN o
to TO o
intubate VB o
between IN N
the DT N
Lightwand NNP N
and CC N
the DT N
Macintosh NNP N
blade NN N
. . N

C-spine JJ o
motion NN o
was VBD N
reduced VBN N
50 CD N
% NN N
at IN N
the DT N
C2-5 NNP N
segment NN N
using VBG N
the DT N
GlideScope NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
but CC N
unchanged JJ N
at IN N
the DT N
other JJ N
segments NNS N
. . N

Laryngoscopy NNP N
with IN N
GlideScope NNP N
took VBD N
62 CD N
% NN N
longer JJR o
than IN N
with IN N
the DT N
Macintosh NNP N
blade NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Thus RB N
, , N
the DT N
Lightwand NNP N
( ( N
Intubating NNP N
Lighted NNP N
Stylet NNP N
) ) N
is VBZ N
associated VBN N
with IN N
reduced JJ N
C-spine JJ o
movement NN o
during IN N
endotracheal JJ N
intubation NN N
compared VBN N
with IN N
the DT N
Macintosh NNP N
laryngoscope NN N
. . N

-DOCSTART- -10382082- O O

Cycle NNP N
control NN N
with IN N
oral JJ i
contraceptives NNS i
containing VBG i
20 CD i
micrograms NNS i
of IN i
ethinyl JJ i
estradiol NN i
. . i

A DT N
multicenter NN N
, , N
randomized VBD N
comparison NN N
of IN N
levonorgestrel/ethinyl JJ i
estradiol NN i
( ( N
100 CD N
micrograms/20 NN N
micrograms NNS N
) ) N
and CC N
norethindrone/ethinyl JJ i
estradiol NN i
( ( N
1000 CD N
micrograms/20 NN N
micrograms NNS N
) ) N
. . N

A DT N
randomized JJ N
, , N
open-label JJ N
, , N
multicenter NN N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
oral JJ i
contraceptives NNS i
( ( i
OC NNP i
) ) i
containing VBG i
100 CD i
micrograms NNS i
levonorgestrel NN i
( ( i
LNG NNP i
) ) i
/20 VBP i
micrograms NNS i
ethinyl VBP i
estradiol NN i
( ( i
EE NNP i
) ) i
( ( i
Aless/Loette NNP i
) ) i
and CC N
1000 CD i
micrograms NNS i
norethindrone JJ i
acetate NN i
( ( i
NETA NNP i
) ) i
/20 VBP i
micrograms NNS i
EE NNP i
( ( i
Loestrin NNP i
Fe NNP i
1/20 CD i
) ) i
on IN N
menstrual JJ N
cycle NN N
control NN N
over IN N
four CD N
cycles NNS N
of IN N
use NN N
. . N

A DT N
total NN N
of IN N
84 CD p
evaluable JJ p
women NNS p
provided VBD p
274 CD p
cycles NNS p
of IN p
exposure NN p
in IN p
the DT p
LNG/EE NNP p
group NN p
, , p
and CC p
89 CD p
women NNS p
provided VBD p
289 CD p
cycles NNS p
of IN p
exposure NN p
in IN p
the DT p
NETA/EE NNP p
group NN p
. . p

Overall UH N
, , N
the DT N
LNG/EE NNP p
group NN p
achieved VBD N
a DT N
consistently RB N
higher JJR N
percentage NN o
of IN o
normal JJ o
menstrual JJ o
cycles NNS o
as RB N
well RB N
as IN N
a DT N
lower JJR N
rate NN o
of IN o
intermenstrual JJ o
bleeding NN o
and CC o
amenorrhea NN o
than IN N
the DT N
NETA/EE NNP N
group NN N
. . N

In IN N
cycle NN N
4 CD N
, , N
63.8 CD N
% NN N
of IN N
cycles NNS N
were VBD N
normal JJ N
in IN N
the DT N
LNG/EE NNP p
group NN p
compared VBN N
with IN N
41.9 CD N
% NN N
in IN N
the DT N
NETA/EE NNP N
group NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

Of IN N
the DT N
total JJ N
cycles NNS N
in IN N
the DT N
NETA/EE NNP p
group NN p
, , N
10 CD N
% NN N
were VBD N
amenorrheic RB o
, , N
compared VBN N
with IN N
1.1 CD N
% NN N
in IN N
the DT N
LNG/EE NNP N
group NN N
. . N

The DT N
occurrence NN o
of IN o
bleeding VBG o
and/or JJ o
spotting NN o
was VBD N
significantly RB N
lower JJR N
in IN N
cycles NNS N
2 CD N
and CC N
3 CD N
in IN N
the DT N
LNG/EE NNP p
group NN p
( ( N
41.7 CD N
% NN N
and CC N
34.8 CD N
% NN N
, , N
respectively RB N
) ) N
compared VBN N
with IN N
the DT N
NETA/EE NNP N
group NN N
( ( N
62.3 CD N
% NN N
and CC N
56.3 CD N
% NN N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

Other JJ N
cycle NN N
variables NNS N
were VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
, , N
as IN N
was VBD N
the DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
. . o

These DT N
results NNS N
demonstrate VBP N
that IN N
good JJ N
cycle NN N
control NN N
was VBD N
achieved VBN N
with IN N
an DT N
OC NNP N
containing VBG N
20 CD N
micrograms NNS N
EE NNP i
and CC N
that IN N
100 CD N
micrograms NNS N
LNG/20 NNP i
micrograms NNS N
EE NNP i
produces VBZ N
better JJR N
cycle NN N
control NN N
than IN N
1000 CD N
micrograms NNS N
NETA/20 NNP i
micrograms NNS N
EE NNP i
. . i

-DOCSTART- -15309442- O O

Rye NNP i
bran NN i
bread NN i
intake VB i
elevates NNS N
urinary JJ o
excretion NN o
of IN o
ferulic JJ o
acid NN o
in IN p
humans NNS p
, , N
but CC N
does VBZ N
not RB N
affect VB N
the DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation VB o
ex FW N
vivo FW N
. . N

BACKGROUND NNP N
Rye NNP i
bread NN i
contributes VBZ N
an DT N
important JJ N
part NN N
of IN N
the DT N
whole JJ N
grain NN N
intake NN N
in IN N
the DT N
Scandinavian JJ p
diet NN N
. . N

Ferulic NNP N
acid NN N
is VBZ N
the DT N
major JJ N
phenolic JJ N
compound NN N
in IN N
rye NN N
bran NN N
and CC N
is VBZ N
an DT N
antioxidant NN N
in IN N
vitro NN N
and CC N
may MD N
, , N
therefore RB N
, , N
contribute NN N
to TO N
cardioprotective JJ N
effects NNS N
of IN N
whole JJ N
grain NN N
consumption NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
Firstly NNP N
, , N
to TO N
evaluate VB N
the DT N
bioavailability NN o
and CC o
potential JJ o
antioxidative JJ o
effects NNS o
in IN N
humans NNS N
of IN N
ferulic JJ N
acid NN N
from IN N
rye NN N
. . N

Secondly RB N
, , N
to TO N
evaluate VB N
urine JJ o
levels NNS o
of IN o
ferulic JJ o
acid NN o
as IN N
a DT N
possible JJ N
biomarker NN N
of IN N
the DT N
ordinary JJ N
dietary JJ N
intake NN N
of IN N
ferulic JJ N
acid NN N
. . N

METHODS NNP N
We PRP N
determined VBD N
the DT N
urinary JJ o
excretion NN o
of IN o
ferulic JJ o
acid NN o
in IN N
18 CD p
postmenopausal JJ p
women NNS p
after IN p
a DT p
dietary JJ i
intake NN i
of IN i
rye NN i
bran NN i
or CC i
an DT i
inert JJ i
wheat NN i
bran NN i
( ( i
control NN i
) ) i
in IN p
a DT p
crossover NN p
study NN p
( ( p
2 CD p
x RB p
6 CD p
weeks NNS p
with IN p
4 CD p
weeks NNS p
washout NN p
) ) p
. . N

The DT N
potential JJ N
antioxidative JJ N
effect NN N
of IN N
the DT N
rye NN N
bran NN N
intervention NN N
was VBD N
investigated VBN N
by IN N
measuring VBG N
low-density NN o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
susceptibility NN o
to TO o
copper VB o
oxidation NN o
ex FW o
vivo NN o
. . o

The DT N
subjects NNS N
ingested VBN N
rye NN N
bran NN N
enriched VBD N
breads NNS N
equivalent JJ N
to TO N
approximately RB N
10.2 CD N
mg NNS N
ferulic JJ N
acid JJ N
per IN N
day NN N
. . N

RESULTS VB N
The DT N
urinary JJ o
excretion NN o
of IN o
ferulic JJ o
acid NNS o
averaged VBD N
approximately RB N
4.8 CD N
mg NNS N
per IN N
day NN N
during IN N
intervention NN N
with IN N
rye NN i
bran NN i
breads NNS i
and CC N
approximately RB N
1.9 CD N
mg NNS N
per IN N
day NN N
on IN N
the DT N
control NN i
breads VBZ i
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Rye NNP i
bran NN i
intervention NN i
had VBD N
no DT N
influence NN N
on IN N
lag NN o
time NN o
or CC o
propagation NN o
rate NN o
of IN o
the DT o
LDL NNP o
oxidation NN o
ex NN N
vivo NN N
. . N

CONCLUSIONS VB N
The DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
ferulic JJ N
acid NN N
from IN N
rye NN N
bran NN N
is VBZ N
bioavailable JJ N
and CC N
that IN N
the DT N
urinary JJ N
concentration NN N
of IN N
ferulic JJ N
acid NN N
reflects VBZ N
the DT N
dietary JJ N
intake NN N
of IN N
this DT N
hydroxycinnamic JJ N
acid NN N
. . N

Within IN N
the DT N
period NN N
of IN N
intervention NN N
, , N
the DT N
elevated JJ N
ferulic JJ N
acid NN N
did VBD N
not RB N
produce VB N
a DT N
measurable JJ N
antioxidative JJ o
effect NN o
on IN N
the DT N
subjects NNS N
' POS N
LDL NNP N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
the DT N
determination NN N
of IN N
ferulic JJ N
acid NN N
in IN N
urine NN N
is VBZ N
a DT N
useful JJ N
biomarker NN N
to TO N
assess VB N
the DT N
intake NN o
of IN o
ferulic JJ o
acid NN o
from IN N
a DT N
regular JJ N
diet NN N
. . N

-DOCSTART- -24460069- O O

A DT N
randomized JJ N
pilot NN N
study NN N
with IN N
daily JJ i
walking VBG i
during IN N
adjuvant JJ N
chemotherapy NN N
for IN N
patients NNS p
with IN p
breast NN p
and CC p
colorectal JJ p
cancer NN p
. . p

BACKGROUND NNP N
Physical NNP i
activity NN i
during IN N
chemotherapy NN N
has VBZ N
been VBN N
shown VBN N
in IN N
several JJ N
studies NNS N
to TO N
reduce VB N
fatigue NN o
, , o
improve VB o
symptoms NNS o
and CC o
impact NN o
positively RB o
on IN o
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQoL NNP o
) ) o
. . o

Challenges NNS N
associated VBN N
with IN N
intervention NN N
studies NNS N
on IN N
physical JJ i
activity NN i
during IN N
cancer NN N
treatment NN N
relate NN N
to TO N
consistent JJ N
adherence NN N
. . N

The DT N
primary JJ N
objective NN N
was VBD N
to TO N
study VB N
feasibility NN N
and CC N
adherence NN N
of IN N
physical JJ i
activity NN i
intervention NN i
among IN N
patients NNS p
with IN p
cancer NN p
during IN p
adjuvant JJ p
chemotherapy NN p
treatment NN p
. . p

The DT N
secondary JJ N
objective NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
physical JJ i
activity NN i
on IN N
health NN o
aspects NNS o
, , N
including VBG N
HRQoL NNP o
, , o
symptoms NNS o
and CC o
surrogate JJ o
markers NNS o
for IN o
cardiovascular JJ o
disease NN o
. . o

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
included VBD N
patients NNS p
with IN p
breast NN p
cancer NN p
( ( p
BRCA NNP p
) ) p
and CC p
colorectal JJ p
cancer NN p
( ( p
CRC NNP p
) ) p
during IN p
adjuvant JJ i
chemotherapy NN i
. . i

The DT i
intervention NN i
continued VBD i
for IN i
10 CD i
weeks NNS i
and CC i
included VBD i
daily JJ i
walks NNS i
of IN i
10 CD i
000 CD i
steps NNS i
and CC i
a DT i
weekly JJ i
supervised VBN i
group NN i
walk NN i
. . i

Adherence NNP o
was VBD i
assessed VBN i
by IN i
a DT i
pedometer NN i
and CC i
the DT i
number NN i
of IN i
participants NNS i
who WP i
reported VBD i
step NN i
counts NNS i
every DT i
week NN i
and CC i
percentage NN i
of IN i
participants NNS i
who WP i
achieved VBD i
the DT i
target NN i
steps NNS i
every DT i
week NN i
. . i

RESULTS NNP N
Adherence NNP o
average JJ N
reached VBD N
91 CD N
% NN N
during IN N
the DT N
intervention NN N
period NN N
; : N
in IN N
total JJ N
74 CD N
% NN N
completed VBD N
the DT N
exercise NN i
intervention NN N
. . N

The DT N
majority NN N
of IN N
the DT N
participants NNS p
achieved VBD N
an DT N
average NN N
of IN N
83 CD N
% NN N
of IN N
the DT N
target NN N
of IN N
10 CD N
000 CD N
steps NNS N
per IN N
day NN N
for IN N
10 CD N
weeks NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
daily JJ o
physical JJ o
activity NN o
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
in IN N
the DT N
intervention NN p
group NN p
. . p

Significant JJ N
differences NNS N
were VBD N
also RB N
found VBN N
for IN N
some DT N
breast NN N
cancer-specific JJ N
symptoms NNS N
[ MD o
swelling VBG o
, , o
mobility NN o
and CC o
pain NN o
( ( N
p JJ N
= NNP N
0.045 CD N
) ) N
] NN N
. . N

The DT N
study NN N
showed VBD N
a DT N
relatively RB N
small JJ o
weight NN o
gain NN o
an DT N
average NN N
of IN N
0.9 CD N
kg NNS N
in IN N
the DT N
intervention NN p
group NN p
and CC N
1.3 CD N
kg NN N
in IN N
the DT N
control NN i
group NN i
. . i

CONCLUSION NNP N
Physical NNP i
activity NN i
in IN i
the DT i
form NN i
of IN i
walking NN i
is VBZ N
feasible JJ N
during IN N
adjuvant JJ N
chemotherapy NN N
treatment NN N
despite IN N
increasing VBG N
symptoms NNS N
. . N

The DT N
physical JJ i
activity NN i
increased VBN N
in IN N
the DT N
intervention NN p
group NN p
during IN N
the DT N
study NN N
time NN N
and CC N
had VBD N
a DT N
positive JJ N
impact NN N
on IN N
breast NN o
symptoms NNS o
and CC N
the DT N
weight NN o
gain NN o
was VBD N
lower JJR N
in IN N
comparison NN N
to TO N
previous JJ N
studies NNS N
. . N

-DOCSTART- -15987536- O O

D-dimer JJ N
predicts NNS N
outcome VBP N
after IN N
aneurysmal JJ N
subarachnoid JJ p
hemorrhage NN p
: : p
no DT N
effect NN N
of IN N
thromboprophylaxis NN N
on IN N
coagulation NN o
activity NN o
. . o

OBJECTIVE NNP N
Approximately RB N
one-third NN N
of IN N
all DT N
patients NNS p
with IN p
acute JJ p
nontraumatic JJ p
subarachnoid NN p
hemorrhage NN p
( ( p
SAH NNP p
) ) p
experience NN N
complications NNS N
owing VBG N
to TO N
delayed VB N
ischemic JJ N
deficit NN N
. . N

We PRP N
reported VBD N
recently RB N
that IN N
enoxaparin VBZ i
40 CD N
mg NN N
once RB N
daily JJ N
for IN N
10 CD N
days NNS N
seems VBZ N
safe JJ N
and CC N
demonstrates VBZ N
thromboprophylactic JJ o
efficacy NN o
, , N
but CC N
it PRP N
failed VBD N
to TO N
improve VB N
outcome NN N
in IN N
a DT N
randomized JJ N
SAH NNP N
trial NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
assessed VBD N
hemostatic JJ o
variables NNS o
associated VBN N
with IN N
clinical JJ N
status NN N
and CC N
outcome NN N
of IN N
SAH NNP N
. . N

We PRP N
also RB N
monitored VBD N
the DT N
effect NN N
of IN N
enoxaparin NN i
on IN N
activation NN o
of IN o
coagulation NN o
and CC o
fibrinolysis NN o
after IN N
closure NN N
of IN N
the DT N
ruptured JJ N
aneurysm NN N
. . N

METHODS NNP N
Blood NNP o
samples NNS o
to TO N
measure VB N
activation NN o
of IN o
coagulation NN o
and CC o
fibrinolysis NN o
were VBD N
collected VBN N
from IN N
42 CD p
patients NNS p
participating VBG p
in IN p
the DT p
enoxaparin JJ i
trial NN p
for IN p
acute NN p
aneurysmal JJ p
SAH NNP p
at IN p
four CD p
time NN p
points NNS p
: : p
1 CD p
) ) p
at IN p
hospital JJ p
admission NN p
; : p
2 CD p
) ) p
12 CD p
to TO p
24 CD p
hours NNS p
after IN p
aneurysm JJ p
surgery NN p
but CC p
before IN p
initiation NN p
of IN p
enoxaparin JJ i
therapy NN p
; : p
3 CD p
) ) p
3 CD p
hours NNS p
after IN p
the DT p
first JJ p
dose NN p
; : p
and CC p
4 CD p
) ) p
at IN p
the DT p
conclusion NN p
of IN p
treatment NN p
. . p

RESULTS NNP N
At IN N
admission NN N
, , N
several JJ N
variables NNS o
of IN o
coagulation NN o
and CC o
fibrinolysis NN o
were VBD N
elevated VBN N
and CC N
correlated VBN N
well RB N
with IN N
clinical JJ N
status NN N
. . N

Specifically RB N
, , N
D-dimer NNP o
levels NNS o
at IN N
all DT N
four CD N
time NN N
points NNS N
correlated VBN N
with IN N
patients NNS N
' POS N
long-term JJ N
outcomes NNS N
. . N

A DT N
single JJ N
dose NN N
of IN N
enoxaparin NN i
suppressed VBD N
early JJ o
coagulation NN o
activity NN o
, , N
but CC N
thrombin JJ o
generation NN o
was VBD N
not RB o
inhibited VBN o
during IN N
thromboprophylaxis NN N
. . N

However RB N
, , N
PAI-1 NNP o
activity NN o
was VBD N
suppressed VBN N
. . N

CONCLUSION NNP N
D-dimer NNP N
offers VBZ N
a DT N
useful JJ N
laboratory NN N
tool NN N
for IN N
assessing VBG N
early JJ N
and CC N
late JJ N
clinical JJ N
severity NN o
of IN o
SAH NNP o
. . o

A NNP N
thromboprophylactic JJ N
dose NN N
of IN N
enoxaparin NN i
inhibited VBN N
PAI-1 JJ o
activity NN o
but CC N
failed VBD N
to TO N
down-regulate JJ N
coagulation NN o
activity NN o
and CC o
D-dimer NNP o
. . o

These DT N
findings NNS N
are VBP N
compatible JJ N
with IN N
the DT N
lack NN N
of IN N
efficacy NN N
of IN N
enoxaparin NN i
in IN N
reducing VBG N
ischemic JJ N
deficit NN N
after IN N
SAH NNP N
. . N

-DOCSTART- -16360994- O O

Prehydration NNP N
alone RB N
is VBZ N
sufficient JJ N
to TO N
prevent VB N
contrast-induced JJ N
nephropathy JJ N
after IN N
day-only JJ p
angiography NN p
procedures NNS p
-- : p
a DT p
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Contrast NNP N
agents NNS N
used VBN N
in IN N
angiography NN N
procedures NNS N
for IN N
patients NNS p
with IN p
cardiovascular JJ p
disease NN p
are VBP N
known VBN N
to TO N
cause VB N
contrast-induced JJ N
nephropathy NN N
( ( N
CIN NNP N
) ) N
, , N
which WDT N
may MD N
be VB N
partially RB N
due JJ N
to TO N
the DT N
production NN N
of IN N
nephrotoxic JJ N
oxygen-free JJ N
radicals NNS N
. . N

It PRP N
is VBZ N
uncertain JJ N
whether IN N
administration NN N
of IN N
intravenous JJ i
( ( i
IV NNP i
) ) i
anti-oxidant NN i
, , i
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
, , N
can MD N
prevent VB N
reduction NN N
in IN N
renal JJ N
function NN N
and CC N
whether IN N
this DT N
is VBZ N
a DT N
cost-effective JJ N
approach NN N
. . N

METHODS NNP N
Sixty-five JJ p
day-only JJ p
patients NNS p
with IN p
renal JJ p
impairment NN p
( ( p
mean JJ p
serum NN p
creatinine NN p
concentration NN p
0.16+/-0.03 NNP p
mmol/l NN p
) ) p
due JJ p
to TO p
undergo JJ p
coronary JJ p
or CC p
peripheral JJ p
angiography NN p
and/or NN p
stenting VBG p
were VBD N
randomly RB N
assigned VBN N
to TO N
IV NNP i
NAC NNP i
300 CD i
or CC i
600 CD i
mg NNS N
immediately RB N
before IN N
and CC N
after IN N
the DT N
procedure NN N
or CC N
IV NNP N
fluid VBP N
alone RB N
. . N

RESULTS NNP N
Of IN N
the DT N
60 CD p
patients NNS p
with IN p
complete JJ p
data NNS p
, , N
none NN N
had VBD N
acute VBN N
CIN NNP N
( ( N
increase NN N
in IN N
serum JJ N
creatinine NN N
concentration NN N
> NN N
or CC N
= $ N
0.044 CD N
mmol/l NN N
, , N
48 CD N
h NN N
after IN N
administration NN N
of IN N
contrast NN N
agent NN N
) ) N
. . N

Eight CD N
patients NNS N
( ( N
13 CD N
% NN N
) ) N
have VBP N
demonstrated VBN N
an DT N
increase NN N
in IN N
their PRP$ N
serum NN o
creatinine NN o
concentration NN o
> NN N
or CC N
= $ N
0.044 CD N
mmol/l JJ N
30 CD N
days NNS N
after IN N
administration NN N
of IN N
contrast NN N
agent NN N
: : N
2/19 CD N
( ( N
11 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
2/21 CD N
( ( N
10 CD N
% NN N
) ) N
in IN N
the DT N
600 CD N
mg NN N
NAC NNP N
group NN N
and CC N
4/20 CD N
( ( N
20 CD N
% NN N
) ) N
the DT N
300 CD N
mg NN N
NAC NNP N
group NN N
( ( N
p JJ N
= NNP N
0.66 CD N
) ) N
. . N

The DT N
mean JJ o
volumes NNS o
of IN o
contrast NN o
agent NN o
used VBN N
and CC N
prehydration NN N
given VBN N
for IN N
each DT N
of IN N
the DT N
three CD N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.83 CD N
) ) N
. . N

There EX N
was VBD N
significant JJ N
improvement NN N
in IN N
creatinine JJ o
clearance NN o
within IN N
each DT N
group NN N
from IN N
baseline NN N
to TO N
30 CD N
days NNS N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.03 CD N
) ) N
, , N
but CC N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
at IN N
48 CD N
h NN N
and CC N
30 CD N
days NNS N
( ( N
p JJ N
> NN N
or CC N
= VB N
0.43 CD N
) ) N
. . N

Considering VBG N
the DT N
cost NN N
of IN N
NAC NNP N
and CC N
its PRP$ N
administration NN N
, , N
we PRP N
estimate VBP N
that IN N
this DT N
would MD N
translate VB N
to TO N
a DT N
saving NN o
of IN N
dollar NN N
26,637 CD N
per IN N
annum NN N
. . N

CONCLUSION NNP N
For IN N
day-stay JJ p
patients NNS p
with IN p
mild-to-moderate JJ p
chronic JJ p
renal JJ p
impairment NN p
undergoing VBG p
angiography NN p
and/or NN p
intervention NN p
, , N
prehydration NN N
alone RB N
is VBZ N
less RBR N
complicated JJ N
and CC N
more RBR N
cost-effective JJ N
than IN N
a DT N
combination NN N
of IN N
IV NNP N
NAC NNP i
( ( N
at IN N
doses NNS N
used VBN N
) ) N
and CC N
hydration NN N
. . N

-DOCSTART- -12951131- O O

Observational NNP i
learning NN i
and CC N
the DT N
formation NN N
of IN N
classes NNS N
of IN N
reading VBG N
skills NNS N
by IN N
individuals NNS p
with IN p
autism NN p
and CC p
other JJ p
developmental JJ p
disabilities NNS p
. . p

We PRP N
investigated VBD N
whether IN N
individuals NNS p
with IN p
developmental JJ p
disabilities NNS p
will MD N
demonstrate VB N
stimulus NN o
classes NNS o
after IN N
observing VBG i
another DT i
individual JJ i
demonstrate NN i
the DT N
prerequisite JJ N
conditional JJ N
discriminations NNS N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
participants NNS N
learned VBD i
conditional JJ i
discriminations NNS i
among IN i
dictated JJ i
words NNS i
, , i
pictures NNS i
, , i
and CC i
printed VBD i
words NNS i
. . i

They PRP i
also RB i
observed VBD i
a DT i
model NN i
without IN i
disabilities NNS i
demonstrate VBP i
conditional JJ i
discriminations NNS i
among IN i
a DT i
different JJ i
set NN i
of IN i
dictated JJ i
words NNS i
, , i
pictures NNS i
, , i
and CC i
printed VBD i
words NNS i
. . i

The DT i
classes NNS i
assigned VBD i
to TO i
each DT i
participant NN i
belonged VBD i
to TO i
a DT i
larger JJR i
superordinate JJ i
category NN i
, , i
as IN i
did VBD i
the DT i
classes NNS i
assigned VBD i
to TO i
each DT i
model NN i
. . i

The DT N
superordinate JJ i
categories NNS i
were VBD N
different JJ N
for IN N
participants NNS N
and CC N
models NNS N
. . N

All DT N
participants NNS N
subsequently RB N
demonstrated VBD N
full JJ N
stimulus NN N
classes NNS N
with IN N
the DT N
stimuli NNS N
involved VBN N
in IN N
direct JJ N
training NN N
: : N
They PRP N
named VBD N
pictures NNS N
, , N
read VBP N
printed VBN N
words NNS N
, , N
and CC N
matched VBD N
pictures NNS N
and CC N
words NNS N
to TO N
one CD N
another DT N
. . N

However RB N
, , N
based VBN N
on IN N
observing VBG N
a DT N
model NN N
, , N
none NN N
of IN N
the DT N
participants NNS N
demonstrated VBD N
full JJ N
stimulus NN o
classes NNS o
. . o

In IN N
Experiment JJ N
2 CD N
, , N
participants NNS N
learned VBD N
conditional JJ i
discriminations NNS i
among IN i
the DT i
stimuli NNS i
in IN N
three CD N
sets NNS N
, , N
and CC N
observed VBD i
a DT i
model NN i
's POS i
training NN i
with IN N
the DT N
stimuli NNS N
in IN N
three CD N
different JJ N
sets NNS N
. . N

The DT N
classes NNS N
assigned VBD N
to TO N
each DT N
participant NN N
belonged VBD N
to TO N
the DT N
same JJ N
larger JJR N
superordinate JJ N
category NN N
as IN N
did VBD N
those DT N
assigned VBN N
to TO N
their PRP$ N
respective JJ N
model NN N
. . N

All DT N
participants NNS N
subsequently RB N
demonstrated VBD N
full JJ o
stimulus NN o
classes NNS o
with IN N
the DT N
stimuli NNS N
involved VBN N
in IN N
direct JJ N
training NN N
. . N

They PRP N
also RB N
demonstrated VBD N
full JJ o
classes NNS o
with IN N
at IN N
least JJS N
one CD N
of IN N
their PRP$ N
model NN N
's POS N
sets NNS N
of IN N
training NN N
stimuli NNS N
. . N

When WRB N
full JJ N
stimulus NN N
classes NNS N
did VBD N
not RB N
occur VB N
from IN N
observing VBG N
a DT N
model NN N
, , N
participants NNS N
named VBD N
the DT N
model NN N
's POS N
pictures NNS N
, , N
read VBD N
the DT N
model NN N
's POS N
printed JJ N
words NNS N
, , N
or CC N
matched VBD N
the DT N
model NN N
's POS N
pictures NNS N
and CC N
words NNS N
. . N

Stimulus CC i
class NN i
technology NN i
, , N
coupled VBN N
with IN N
the DT N
opportunity NN N
to TO N
observe VB i
another DT i
individual JJ i
perform NN i
a DT N
skill NN N
, , N
may MD N
be VB N
an DT N
economical JJ N
and CC N
efficient JJ N
means NNS N
of IN N
teaching VBG N
persons NNS p
with IN p
developmental JJ p
disabilities NNS p
. . p

-DOCSTART- -15817848- O O

Dairy NN i
products NNS i
do VBP N
not RB N
lead VB N
to TO N
alterations NNS N
in IN N
body NN o
weight NN o
or CC o
fat JJ o
mass NN o
in IN o
young JJ o
women NNS o
in IN N
a DT N
1-y JJ N
intervention NN N
. . N

BACKGROUND NNP N
Previous JJ N
results NNS N
suggested VBD N
that IN N
increased VBD N
intake NN N
of IN N
dairy NN i
calcium NN i
is VBZ N
associated VBN N
with IN N
reduced JJ o
weight NN o
and CC o
fat JJ o
mass NN o
. . o

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
long-term JJ N
increases NNS N
in IN N
consumption NN N
of IN N
dairy NN i
calcium NN i
alter NN N
body NN o
weight NN o
and CC o
fat JJ o
mass NN o
in IN o
young JJ o
, , o
healthy JJ o
women NNS o
. . o

DESIGN NNP N
We PRP N
used VBD N
a DT N
randomized JJ N
, , N
1-y JJ N
intervention NN N
for IN N
dairy NN N
calcium NN N
. . N

Subjects NNS p
were VBD p
155 CD p
young JJ p
( ( p
aged VBN p
18-30 CD p
y NN p
) ) p
, , p
healthy JJ p
, , p
normal-weight JJ p
women NNS p
with IN p
intake NN p
of IN p
dietary JJ i
calcium NN i
< VBZ p
800 CD p
mg/d NN p
and CC p
energy NN p
intake VBP p
< CD p
/= JJ p
2200 CD p
kcal/d NN p
. . p

Women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
1 CD N
) ) N
control NN i
: : i
continue NN i
established VBD i
dietary JJ i
intake NN i
; : i
2 CD N
) ) N
medium NN i
dairy NN i
: : i
substitute NN i
dairy NN i
products NNS i
to TO i
achieve VB i
intake NN i
of IN i
calcium NN i
of IN i
approximately RB i
1000-1100 JJ i
mg/d NN i
and CC i
maintain VB i
isocaloric JJ i
intake NN i
; : i
3 CD N
) ) N
high JJ i
dairy NN i
: : i
substitute NN i
dairy NN i
products NNS i
to TO i
achieve VB i
intake NN i
of IN i
calcium NN i
of IN i
1300-1400 JJ i
mg/d NN i
and CC i
maintain VB i
isocaloric JJ i
intake NN i
. . i

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
1-y JJ o
changes NNS o
in IN o
body NN o
weight NN o
( ( o
in IN o
kg NN o
) ) o
and CC o
fat JJ o
mass NN o
( ( o
in IN o
kg NN o
) ) o
. . N

One CD p
hundred VBD p
thirty-five JJ p
women NNS p
completed VBD p
the DT p
trial NN p
. . p

RESULTS JJ N
Mean NNP N
intakes NNS o
of IN o
calcium NN o
during IN N
the DT N
intervention NN N
were VBD N
742.4 CD N
+/- JJ N
321.5 CD N
, , N
1026.4 CD N
+/- JJ N
311.3 CD N
, , N
and CC N
1131.29 CD N
+/- JJ N
337.2 CD N
mg/d NN N
for IN N
the DT N
control NN N
, , N
medium-dairy NN N
, , N
and CC N
high-dairy JJ N
groups NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
the DT N
mean JJ o
1-y JJ o
change NN o
in IN o
body NN o
weight NN o
between IN N
the DT N
control NN N
, , N
medium-dairy NN N
, , N
and CC N
high-dairy JJ N
groups NNS N
( ( N
0.8 CD N
+/- JJ N
2.8 CD N
, , N
0.7 CD N
+/- JJ N
3.0 CD N
, , N
and CC N
1.5 CD N
+/- JJ N
4.1 CD N
kg NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.45 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
the DT N
mean JJ o
1-y JJ o
change NN o
in IN o
fat JJ o
mass NN o
between IN N
the DT N
control NN N
, , N
medium-dairy NN N
, , N
and CC N
high-dairy JJ N
groups NNS N
( ( N
-0.5 JJ N
+/- JJ N
2.5 CD N
, , N
0.3 CD N
+/- JJ N
2.7 CD N
, , N
and CC N
0.5 CD N
+/- JJ N
3.5 CD N
kg NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.26 CD N
) ) N
. . N

CONCLUSION NNP N
Increased VBD N
intake NN N
of IN N
dairy NN i
products NNS i
does VBZ N
not RB N
alter VB N
body NN o
weight NN o
or CC o
fat JJ o
mass NN o
in IN o
young JJ o
, , o
healthy JJ o
women NNS o
over IN o
1 CD o
y NNS o
. . o

-DOCSTART- -20620365- O O

Translucency NN N
of IN N
zirconia NN p
copings NNS p
made VBN N
with IN N
different JJ N
CAD/CAM NNP N
systems NNS N
. . N

STATEMENT NNP N
OF IN N
PROBLEM NNP N
Zirconia NNP p
cores NNS p
are VBP N
reported VBN N
to TO N
be VB N
less RBR N
translucent JJ N
than IN N
glass NN N
, , N
lithium NN N
disilicate NN N
, , N
or CC N
alumina JJ N
cores NNS N
. . N

This DT N
could MD N
affect VB N
the DT N
esthetic JJ N
appearance NN N
and CC N
the DT N
clinical JJ N
choices NNS N
made VBD N
when WRB N
using VBG N
zirconia-based JJ N
restorations NNS N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
in IN N
vitro NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
translucency NN o
of IN N
zirconia NN i
copings NNS i
for IN N
single JJ p
crowns NNS p
fabricated VBN N
using VBG N
different JJ N
CAD/CAM NNP N
systems NNS N
, , N
using VBG N
lithium NN i
disilicate NN i
glass NN i
ceramic NN i
as IN N
a DT N
control NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Using NNP N
impressions NNS N
made VBD N
from IN N
a DT N
stainless JJ N
steel NN N
complete-crown JJ N
master NN N
die NN N
, , N
9 CD p
stone NN p
cast NN p
replicas NN p
were VBD p
fabricated VBN p
, , p
numbered VBN p
, , p
and CC p
distributed VBD p
into IN p
8 CD p
ceramic JJ p
ZrO NNP p
( ( p
2 CD p
) ) p
CAD/CAM NNP p
system NN p
groups NNS p
( ( p
Lava NNP p
Frame NNP p
0.3 CD p
and CC p
0.5 CD p
, , p
IPS NNP p
e.max VBZ p
ZirCAD NNP p
, , p
VITA NNP p
YZ NNP p
, , p
Procera NNP p
AllZircon NNP p
, , p
Digizon NNP p
, , p
DC NNP p
Zircon NNP p
, , p
and CC p
Cercon NNP p
Base NNP p
) ) p
and CC p
to TO p
a DT p
lithium NN p
disilicate JJ p
glass-ceramic JJ p
control NN p
group NN p
( ( p
IPS NNP p
e.max RB p
Press NNP p
) ) p
using VBG p
a DT p
simple JJ p
computer-generated JJ p
randomization NN p
method NN p
. . p

From IN N
each DT N
die NN N
, , N
the DT N
manufacturer NN N
's POS N
authorized JJ N
milling NN N
centers NNS N
supplied VBD N
5 CD N
copings NNS N
per IN N
group NN N
without IN N
applying VBG N
any DT N
dying VBG N
technique NN N
to TO N
the DT N
ceramic JJ N
base NN N
material NN N
. . N

The DT N
copings NNS N
were VBD N
prepared VBN N
to TO N
allow VB N
for IN N
a DT N
40-mum JJ N
cement NN N
layer NN N
and CC N
were VBD N
of IN N
different JJ N
thicknesses NNS N
according VBG N
to TO N
system NN N
specifications NNS N
. . N

Translucency NN o
was VBD N
measured VBN N
by IN N
the DT N
direct JJ N
transmission NN N
method NN N
with IN N
a DT N
digital JJ N
photoradiometer NN N
mounted VBN N
in IN N
a DT N
dark JJ N
chamber NN N
. . N

The DT N
light JJ N
source NN N
was VBD N
a DT N
150-W JJ N
halogen NN N
lamp NN N
beam NN N
. . N

Measurements NNS N
were VBD N
repeated VBN N
3 CD N
times NNS N
for IN N
each DT N
specimen NNS N
. . N

Data NNS N
obtained VBN N
were VBD N
analyzed VBN N
using VBG N
1-way JJ N
ANOVA NNP N
and CC N
the DT N
Bonferroni NNP N
multiple NN N
comparison NN N
test NN N
( ( N
alpha=.05 NN N
) ) N
. . N

RESULTS NNP N
Among IN N
ZrO NNP N
( ( N
2 CD N
) ) N
copings NNS N
, , N
Lava NNP N
( ( N
0.3 CD N
mm NN N
and CC N
0.5 CD N
mm NNS N
thick NN N
) ) N
showed VBD N
the DT N
highest JJS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
values NNS o
of IN o
translucency NN o
measured VBN N
as IN N
light JJ N
flow JJ N
units NNS N
( ( N
3.572 CD N
+ NN N
or CC N
- : N
018 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
and CC N
3.181 CD N
+ NN N
or CC N
- : N
0.13 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
, , N
respectively RB N
) ) N
. . N

These DT N
values NNS N
represent VBP N
71.7 CD N
% NN N
and CC N
63.9 CD N
% NN N
, , N
respectively RB N
, , N
of IN N
the DT N
glass-ceramic JJ N
control NN N
group NN N
( ( N
4.98 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
lx NN N
) ) N
. . N

CONCLUSIONS NNP N
All NNP N
ZrO NNP p
( ( p
2 CD p
) ) p
copings NNS p
demonstrated VBN N
different JJ N
levels NNS N
of IN N
light JJ N
transmission NN N
, , N
with IN N
the DT N
2 CD N
Lava NNP N
specimens NNS N
showing VBG N
the DT N
highest JJS N
values NNS N
. . N

Translucency NN o
of IN N
zirconia NN p
copings NNS p
was VBD N
significantly RB N
lower JJR N
( ( N
P=.001 NNP N
) ) N
than IN N
that DT N
of IN N
the DT N
lithium NN N
disilicate JJ N
glass-ceramic JJ N
control NN N
. . N

-DOCSTART- -24365986- O O

Similar JJ N
MPA NNP N
exposure NN N
on IN N
modified JJ N
release NN N
and CC N
regular JJ p
tacrolimus NN p
. . p

Concomitant JJ N
immunosuppression NN N
may MD N
affect VB N
the DT N
mycophenolate NN o
mofetil NN o
exposure NN N
. . N

Astellas NNP N
developed VBD N
a DT N
once-daily JJ N
modified JJ N
release NN N
formulation NN N
of IN N
tacrolimus NN i
( ( N
TacMR NNP N
) ) N
with IN N
the DT N
potential JJ N
to TO N
reduce VB N
the DT N
likelihood NN N
of IN N
nonadherence NN o
. . o

It PRP N
is VBZ N
unknown JJ N
whether IN N
mycophenolic JJ i
acid NN i
( ( i
MPA NNP i
) ) i
area NN N
under IN N
the DT N
concentration-time JJ N
curve NN N
( ( N
AUC NNP N
) ) N
differs NNS N
between IN N
the DT N
2 CD N
tacrolimus NN N
( ( N
Tac NNP N
) ) N
formulations NNS N
. . N

In IN N
a DT N
2-by-2 JJ N
crossover NN N
design NN N
, , N
20 CD p
stable JJ p
renal JJ p
transplant NN p
recipients NNS p
on IN p
twice-daily JJ p
Tac NNP p
either CC N
continued VBD N
their PRP$ N
usual JJ N
Tac NNP i
therapy NN i
( ( N
n JJ N
= NN N
10 CD N
, , N
group NN N
1 CD N
) ) N
or CC i
switched VBN i
to TO i
TacMR NNP i
for IN i
a DT N
12-week JJ N
period NN N
( ( N
n JJ N
= NN N
10 CD N
, , N
group NN N
2 CD N
) ) N
, , N
after IN N
which WDT N
the DT N
patients NNS N
crossed VBD N
over IN N
to TO N
the DT N
other JJ N
formulation NN N
for IN N
another DT N
12-week JJ N
period NN N
. . N

Pharmacokinetic JJ N
profiles NNS N
using VBG N
limited JJ N
sampling NN N
strategies NNS N
were VBD N
obtained VBN N
before IN N
randomization NN N
( ( N
visit IN N
1 CD N
) ) N
, , N
and CC N
at IN N
12 CD N
( ( N
visit VB N
2 CD N
) ) N
and CC N
24 CD N
weeks NNS N
( ( N
visit IN N
3 CD N
) ) N
at IN N
steady JJ N
state NN N
. . N

MPA NNP N
AUC NNP N
was VBD N
calculated VBN N
using VBG N
the DT N
Pawinski NNP N
formula NN N
. . N

When WRB N
analyzing VBG N
visits NNS N
on IN N
Tac NNP o
, , o
TacMR NNP o
, , o
and CC o
back RB o
on IN o
Tac NNP o
combined VBD o
, , o
the DT o
MPA NNP o
AUC NNP o
for IN p
all DT p
20 CD p
patients NNS p
at IN p
baseline NN p
was VBD p
42.24 CD p
( ( p
16.98 CD p
) ) p
, , p
37.18 CD p
( ( p
13.75 CD p
) ) p
, , p
and CC p
40.09 CD p
( ( p
16.69 CD p
) ) p
mg?h?L NN p
( ( p
-1 NNP p
) ) p
, , p
respectively RB N
, , N
which WDT N
was VBD N
not RB N
statistically RB N
significant JJ N
using VBG N
repeated VBN N
measures NNS N
( ( N
P NNP N
= NNP N
0.1327 CD N
, , N
R NNP N
( ( N
2 CD N
) ) N
= FW N
0.1109 CD N
) ) N
. . N

We PRP N
conclude VBP N
that IN o
MPA NNP o
pharmacokinetic JJ o
profiles NNS o
are VBP o
not RB N
altered VBN N
when WRB N
converting VBG N
patients NNS N
from IN N
Tac NNP N
to TO N
TacMR NNP N
. . N

-DOCSTART- -20185596- O O

Reducing VBG N
polycystic JJ o
liver NN o
volume NN o
in IN p
ADPKD NNP p
: : p
effects NNS N
of IN N
somatostatin NN i
analogue NN i
octreotide NN i
. . i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
No NNP N
medical JJ N
treatment NN N
is VBZ N
available JJ N
for IN N
polycystic JJ N
liver NN N
disease NN N
, , N
a DT N
frequent JJ N
manifestation NN N
of IN N
autosomal-dominant JJ p
polycystic JJ p
kidney NN p
disease NN p
( ( p
ADPKD NNP p
) ) p
. . p

In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
, , N
6 CD N
months NNS N
of IN N
octreotide NN i
( ( N
40 CD N
mg NN N
every DT N
28 CD N
days NNS N
) ) N
therapy NN N
limited JJ N
kidney NN N
volume NN N
growth NN N
more RBR N
effectively RB N
than IN N
placebo NN i
in IN N
12 CD p
patients NNS p
with IN p
ADPKD NNP p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
In IN N
this DT N
secondary JJ N
, , N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
above NN N
study NN N
, , N
octreotide-induced JJ i
changes NNS N
in IN N
liver NN o
volumes NNS o
compared VBN N
with IN N
placebo NN i
and CC N
the DT N
relationship NN N
between IN N
concomitant NN N
changes NNS N
in IN N
liver NN N
and CC N
kidney NN N
volumes NNS N
were VBD N
evaluated VBN N
. . N

Those DT N
analyzing VBG N
liver NN o
and CC o
kidney NN o
volumes NNS o
were VBD N
blinded VBN N
to TO N
treatment NN N
. . N

RESULTS NNP N
Liver NNP o
volumes VBZ o
significantly RB o
decreased VBN o
from IN N
1595 CD N
+/- JJ N
478 CD N
ml NN N
to TO N
1524 CD N
+/- JJ N
453 CD N
ml NN N
with IN N
octreotide JJ N
whereas IN N
they PRP N
did VBD N
not RB N
appreciably RB N
change NN N
with IN N
placebo NN i
. . i

Changes NNS o
in IN o
liver NN o
volumes NNS o
were VBD N
significantly RB o
different JJ o
between IN N
the DT N
two CD N
treatment NN N
periods NNS N
( ( N
-71 JJ N
+/- JJ N
57 CD N
ml NN N
versus NN N
+14 VBD N
+/- JJ N
85 CD N
ml NN N
) ) N
. . N

Octreotide-induced JJ o
liver NN o
volume NN o
reduction NN o
was VBD N
fully RB N
explained VBN N
by IN N
a DT N
reduction NN N
in IN N
parenchyma JJ o
volume NN o
from IN N
1506 CD N
+/- JJ N
431 CD N
ml NN N
to TO N
1432 CD N
+/- JJ N
403 CD N
ml NN N
. . N

Changes NNS o
in IN o
liver NN o
volumes NNS o
were VBD N
significantly RB N
correlated VBN N
with IN N
concomitant JJ N
changes NNS N
in IN N
kidney NN o
volumes NNS o
( ( N
r VB N
= RB N
0.67 CD N
) ) N
during IN N
octreotide NN N
but CC N
not RB N
during IN N
placebo JJ N
treatment NN N
. . N

Liver NNP o
and CC o
kidney NN o
volume NN o
changes NNS o
significantly RB N
differed VBN o
with IN N
both DT N
treatments NNS N
( ( i
octreotide IN i
: : i
-71 JJ N
+/- JJ N
57 CD N
ml NN N
versus NN N
+71 VBD N
+/- JJ N
107 CD N
; : N
placebo NN i
: : i
+14 JJ N
+/- JJ N
85 CD N
ml NN N
versus NN N
+162 VBD N
+/- JJ N
114 CD N
) ) N
, , N
but CC N
net JJ o
reductions NNS o
in IN o
liver NN o
( ( N
-85 JJ N
+/- JJ N
103 CD N
ml NN N
) ) N
and CC N
kidney NN o
( ( N
-91 JJ N
+/- JJ N
125 CD N
ml NN N
) ) N
volume NN o
growth NN o
on IN N
octreotide IN i
versus NN N
placebo NN i
were VBD N
similar JJ o
. . o

CONCLUSIONS NNP N
Octreotide NNP i
therapy NN i
reduces NNS N
liver RB o
volumes NNS o
in IN N
patients NNS N
with IN N
ADPKD NNP N
and CC N
is VBZ N
safe JJ N
. . N

-DOCSTART- -24973545- O O

Riding VBG N
the DT N
rapids NNS N
: : N
living NN N
with IN N
autism NN N
or CC N
disability NN N
-- : N
an DT N
evaluation NN N
of IN N
a DT N
parenting VBG i
support NN i
intervention NN i
for IN N
parents NNS p
of IN p
disabled JJ p
children NNS p
. . p

Evidence NN N
on IN N
the DT N
effectiveness NN N
of IN N
interventions NNS N
to TO N
support VB N
parents NNS p
of IN p
disabled JJ p
children NNS p
to TO N
manage VB N
their PRP$ N
child NN N
's POS N
behaviour NN N
problems NNS N
is VBZ N
limited VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
a DT N
group-delivered JJ i
intervention NN i
( ( i
Riding VBG i
the DT i
Rapids NNP i
) ) i
which WDT N
was VBD N
specifically RB N
developed VBN N
for IN N
parents NNS p
of IN p
a DT p
child NN p
with IN p
a DT p
disability NN p
or CC p
autistic JJ p
spectrum NN p
condition NN p
. . p

This DT N
programme NN N
has VBZ N
been VBN N
routinely RB N
delivered VBN N
by IN N
a DT N
community-based JJ N
mental JJ N
health NN N
team NN N
across IN N
an DT N
urban JJ N
, , N
multi-ethnic JJ N
locality NN N
for IN N
a DT N
number NN N
of IN N
years NNS N
. . N

A DT N
non-randomised JJ N
controlled JJ i
study NN N
design NN N
comprising VBG p
an DT p
intervention NN i
group NN i
( ( p
n=48 CC p
) ) p
and CC p
comparator NN i
( ( i
no DT i
intervention NN i
) ) i
group NN p
( ( p
n=28 RB p
) ) p
was VBD p
used VBN p
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
intervention NN N
on IN N
child JJ o
behaviour NN o
( ( o
Eyberg NNP o
Child NNP o
Behaviour NNP o
Inventory NNP o
; : o
parent-set JJ o
goals NNS o
) ) o
and CC N
parenting VBG o
efficacy NN o
and CC o
satisfaction NN o
( ( o
Parents NNP o
Sense NNP o
of IN o
Competence NNP o
Scale NNP o
) ) o
at IN N
post-intervention NN N
and CC N
six-month JJ N
follow-up NN N
. . N

Data NNS N
on IN N
costs NNS N
to TO N
the DT N
service NN N
provider NN N
of IN N
delivering VBG N
the DT N
intervention NN N
were VBD N
also RB N
collected VBN N
. . N

Receipt NNP N
of IN N
the DT N
intervention NN N
was VBD N
associated VBN N
with IN N
significant JJ o
reductions NNS o
in IN N
parent-reported JJ o
behaviour NN o
problems NNS o
and CC N
significant JJ o
improvements NNS o
in IN o
parenting VBG o
efficacy NN o
and CC o
satisfaction NN o
. . o

At IN N
six-month JJ N
follow-up NN N
, , N
progress NN N
towards NNS N
achieving VBG N
parent-set JJ o
child NN o
behaviour NN o
goals NNS o
and CC N
parenting VBG o
satisfaction NN o
had VBD N
been VBN N
maintained VBN N
. . N

Post NNP N
hoc JJ N
analysis NN N
suggests VBZ N
parents NNS p
who WP p
do VBP p
not RB p
have VB p
English NNP p
as IN p
a DT p
first JJ p
language NN p
may MD N
not RB o
benefit VB o
as RB N
much RB N
as IN N
other JJ N
parents NNS N
from IN N
this DT N
intervention NN N
. . N

Findings NNS N
suggest VBP N
this DT N
is VBZ N
a DT N
promising JJ N
intervention NN i
for IN i
parents NNS i
of IN N
a DT N
child NN N
with IN N
a DT N
disability NN N
that WDT N
is VBZ N
likely JJ N
to TO N
be VB N
less JJR N
resource JJ N
intensive NN N
to TO N
service NN N
providers NNS N
than IN N
individually RB N
delivered VBN N
interventions NNS N
. . N

Limitations NNS N
and CC N
implications NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -1409770- O O

The DT N
cumulative JJ N
dose NN N
response NN N
effect NN N
of IN N
eicosapentaenoic NN i
and CC N
docosahexaenoic JJ i
acid NN i
on IN N
blood NN o
pressure NN o
, , o
plasma NN o
lipid JJ o
profile NN o
and CC o
diet JJ o
pattern NN o
in IN N
mild NN p
to TO p
moderate VB p
essential JJ p
hypertensive JJ p
black JJ p
patients NNS p
. . p

In IN N
this DT N
study NN N
eicosapentaenoic VBZ i
acid NNS i
( ( i
EPA NNP i
) ) i
and CC i
docosahexaenoic JJ i
acid NN i
( ( i
DHA NNP i
) ) i
were VBD N
given VBN N
in IN N
a DT N
cumulative JJ N
manner NN N
, , N
every DT N
6 CD N
weeks NNS N
, , N
starting VBG N
with IN N
10 CD N
mg NNS N
, , N
then RB N
100 CD N
mg NNS N
, , N
1000 CD N
mg NN N
and CC N
10,000 CD N
mg NNS N
EPA NNP i
daily RB N
to TO N
mild VB p
to TO p
moderate VB p
essential JJ p
hypertensive JJ p
black JJ p
patients NNS p
. . p

The DT N
corresponding JJ N
DHA NNP i
doses NNS N
were VBD N
3 CD N
, , N
33 CD N
, , N
333 CD N
and CC N
3333 CD N
mg. NN N
A NNP N
control NN N
group NN N
was VBD N
given VBN N
olive JJ i
oil NN i
as IN i
placebo NN i
for IN N
the DT N
entire JJ N
24 CD N
weeks NNS N
. . N

The DT N
placebo NN i
group NN N
had VBD N
lower JJR o
diastolic NN o
and CC o
systolic JJ o
blood NN o
pressures NNS o
after IN N
24 CD N
weeks NNS N
than IN N
the DT N
EPA NNP i
and CC N
DHA NNP i
group NN N
. . N

No DT N
effect NN o
was VBD N
seen VBN N
on IN N
plasma NN o
triglycerides NNS o
, , o
cholesterol NN o
, , o
HDL-cholesterol NNP o
and CC o
gamma-glutamyltranspeptidase NN o
at IN N
any DT N
stage NN N
of IN N
the DT N
trial NN N
. . N

In IN N
the DT N
EPA NNP i
group NN N
plasma VBD o
free-EPA NN o
increased VBN o
significantly RB o
from IN N
1000 CD N
mg NN N
onwards NNS N
and CC N
plasma JJ o
free-arachidonic JJ o
acid NN o
( ( o
AA NNP o
) ) o
decreased VBD o
after IN N
1000 CD N
mg NN N
EPA NNP i
. . i

No DT N
other JJ N
plasma NN o
free JJ o
essential JJ o
fatty NN o
acid RB o
changed VBD o
during IN N
the DT N
trial NN N
, , N
although IN N
the DT N
HDL NNP o
: : o
cholesterol NN o
increased VBD o
slightly RB o
but CC N
non-significantly RB o
with IN N
an DT N
increase NN o
in IN N
EPA NNP o
and CC o
DHA NNP o
. . o

No NNP N
significant JJ o
changes NNS o
in IN N
diet JJ o
pattern NN o
or CC o
body NN o
mass NN o
was VBD N
observed VBN o
. . o

It PRP N
is VBZ N
therefore RB N
concluded JJ N
that IN N
EPA NNP i
and CC N
DHA NNP i
supplementation NN i
had VBD N
no DT N
beneficial JJ N
effects NNS N
in IN N
mild NN p
to TO p
moderate VB p
essential JJ p
hypertensive JJ p
black JJ p
patients NNS p
except IN N
for IN N
a DT N
lowering NN o
of IN o
plasma NN o
AA NNP o
. . o

-DOCSTART- -15688961- O O

Effects NNS N
of IN N
an DT N
antimicrobial JJ i
additive NN i
to TO N
toothbrushes NNS p
on IN N
residual JJ o
periodontal NN o
pathogens NNS o
. . o

OBJECTIVE NNP N
Previous JJ N
studies NNS N
have VBP N
reported VBN N
the DT N
link NN N
between IN N
residual JJ N
microbial JJ N
contamination NN N
of IN N
toothbrushes NNS N
and CC N
periodontal JJ p
diseases NNS p
. . p

The DT N
goal NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
an DT i
antimicrobial JJ i
additive NN i
( ( i
Microban NNP i
) ) i
to TO N
toothbrushes NNS N
on IN N
residual JJ o
retention NN o
of IN o
periodontal JJ o
pathogens NNS o
. . o

METHODOLOGY NNP N
Twenty NNP p
patients NNS p
had VBD p
one CD p
side NN p
of IN p
their PRP$ p
mouths NNS p
brushed VBN p
with IN p
a DT p
toothbrush NN i
containing VBG i
the DT i
antimicrobial JJ i
agent NN i
( ( p
experimental JJ p
side NN p
) ) p
, , p
and CC p
the DT p
other JJ p
side NN p
with IN p
a DT p
toothbrush NN i
containing VBG i
no DT i
agent NN i
( ( p
control NN p
) ) p
. . p

Toothbrushes NNS N
were VBD N
air-dried JJ N
( ( N
25 CD N
degrees NNS N
C NNP N
) ) N
for IN N
four CD N
or CC N
24 CD N
hours NNS N
. . N

Toothbrush NNP N
heads NNS N
were VBD N
vortexed JJ N
and CC N
cultured VBD N
for IN N
Prevotella NNP N
species NNS N
( ( N
Ps NNP N
) ) N
, , N
Porphyromonas NNP N
gingivalis NN N
( ( N
Pg NNP N
) ) N
, , N
Actinobacillus NNP N
actinomycetemcomitans NNS N
( ( N
Aa NNP N
) ) N
, , N
and CC N
non-specific JJ N
colony-forming JJ N
units NNS N
( ( N
NS NNP N
) ) N
. . N

The DT N
plates NNS N
were VBD N
incubated VBN N
and CC N
counted VBN N
. . N

Means NNPS N
and CC N
standard JJ N
deviations NNS N
were VBD N
calculated VBN N
, , N
and CC N
data NNS N
were VBD N
analyzed VBN N
using VBG N
a DT N
series NN N
of IN N
t-tests NNS N
( ( N
paired VBN N
and CC N
unpaired VBN N
) ) N
and CC N
Wilcoxon NNP N
matched-pairs JJ N
signed-rank JJ N
test NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
inter- JJ N
or CC N
intra-group JJ N
differences NNS N
in IN N
mean JJ o
counts NNS o
were VBD N
found VBN N
; : N
however RB N
, , N
when WRB N
four-hour JJ N
and CC N
24-hour JJ N
data NNS N
for IN N
Aa NNP o
, , o
Pg NNP o
, , o
or CC o
NS NNP o
were VBD N
combined VBN N
, , N
experimental JJ o
counts NNS o
were VBD N
lower JJR N
than IN N
controls NNS N
in IN N
39/50 CD N
( ( N
78 CD N
% NN N
) ) N
of IN N
the DT N
matched VBN N
pairs NNS N
( ( N
Wilcoxon NNP N
signed-rank JJ N
test NN N
p NN N
= NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Toothbrushes NNP N
containing VBG N
the DT N
antimicrobial JJ i
additive NN i
showed VBD N
lower JJR N
microbial NN o
counts NNS o
than IN N
those DT N
without IN N
, , N
but CC N
between-group JJ N
means NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -12971959- O O

Cirrhosis NN i
and CC N
bleeding NN N
: : N
the DT N
need NN N
for IN N
very RB N
early JJ N
management NN N
. . N

BACKGROUND/AIMS NNP N
Retrospective NNP N
studies NNS N
suggest VBP N
that IN N
the DT N
prognosis NN N
of IN N
patients NNS p
with IN p
cirrhosis NN p
and CC p
variceal NN p
hemorrhage NN p
has VBZ N
improved VBN N
in IN N
more RBR N
recent JJ N
decades NNS N
. . N

In IN N
a DT N
prospective JJ N
cohort NN N
study NN N
in IN N
which WDT N
the DT N
choice NN N
of IN N
prophylactic JJ i
therapy NN i
was VBD N
left VBN N
to TO N
each DT N
practitioner NN N
, , N
we PRP N
followed VBD N
cirrhotic JJ p
patients NNS p
with IN p
medium/large NN p
varices NNS p
to TO N
determine VB N
factors NNS N
predictive CD N
of IN N
bleeding VBG N
and CC N
death NN N
. . N

METHODS NNP N
Three CD p
hundred VBD p
fourteen JJ p
patients NNS p
with IN p
grades NNS p
2 CD p
or CC p
3 CD p
esophageal JJ p
varices NNS p
( ( p
Child VB p
A DT p
and CC p
B/C NNP p
: : p
218 CD p
and CC p
96 CD p
) ) p
were VBD N
enrolled VBN N
. . N

One CD p
hundred VBD p
seventy-three JJ p
patients NNS p
had VBD p
no DT p
previous JJ p
history NN p
of IN p
variceal NN p
bleeding NN p
. . p

Only RB N
245 CD p
patients NNS p
( ( p
100 CD p
% NN p
of IN p
patients NNS p
with IN p
prior JJ p
variceal NN p
hemorrhage NN p
, , p
61 CD p
% NN p
of IN p
patients NNS p
without IN p
prior JJ p
hemorrhage NN p
) ) p
were VBD p
receiving VBG p
some DT p
form NN p
of IN p
prophylactic JJ i
therapy NN i
. . i

The DT N
median JJ N
follow-up NN N
was VBD N
18 CD N
months NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
76 CD N
bleeding VBG o
events NNS o
and CC N
14 CD N
related JJ o
deaths NNS o
( ( N
18 CD N
% NN N
) ) N
; : N
nine CD N
of IN N
these DT N
deaths NNS N
occurred VBD N
within IN N
24 CD N
h NN N
of IN N
bleeding VBG o
onset VBN N
( ( N
two CD N
at IN N
home NN N
, , N
two CD N
during IN N
hospital NN N
transfer NN N
, , N
and CC N
five CD N
in IN N
hospital NN N
, , N
a DT N
mean NN N
of IN N
2.5 CD N
h NN N
after IN N
onset NN N
; : N
six CD N
involved VBN N
Child NNP N
C NNP N
patients NNS N
) ) N
. . N

Twenty-five JJ N
deaths NNS o
were VBD N
not RB N
due JJ N
to TO N
bleeding VBG N
but CC N
were VBD N
closely RB N
related VBN N
to TO N
cirrhosis NN N
. . N

In IN N
a DT N
Cox NNP N
model NN N
, , N
the DT N
presence NN N
of IN N
tense NN N
ascites NNS N
( ( N
relative JJ N
risk NN N
3.4 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
CI NNP N
2.5-5.9 CD N
) ) N
and CC N
a DT N
prior JJ N
history NN N
of IN N
hemorrhage NN N
( ( N
relative JJ N
risk NN N
4.4 CD N
, , N
95 CD N
% NN N
CI NNP N
2.6-7.5 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
variceal JJ o
hemorrhage NN o
. . o

In IN N
patients NNS N
without IN N
a DT N
prior JJ N
history NN N
of IN N
bleeding NN o
, , o
bleeding VBG o
risk NN o
was VBD N
higher JJR N
with IN N
more RBR N
prolonged JJ N
prothrombin NN N
time NN N
and CC N
lower JJR N
when WRB N
patients NNS N
were VBD N
receiving VBG N
propranolol NN i
. . i

CONCLUSIONS NNP N
Despite IN N
the DT N
advent NN N
of IN N
effective JJ N
drugs NNS N
and CC N
endoscopic NN i
therapy NN i
for IN N
variceal NN N
bleeding NN N
, , N
about IN N
a DT N
quarter NN N
of IN N
deaths NNS o
occur JJ N
very RB N
early RB N
after IN N
bleeding VBG N
onset NN N
, , N
confirming VBG N
the DT N
need NN N
for IN N
rapid JJ N
specific JJ N
management NN N
. . N

-DOCSTART- -1730427- O O

Stage NN p
II NNP p
carcinoma NN p
of IN p
the DT p
ovary JJ p
: : p
an DT N
analysis NN N
of IN N
survival NN o
after IN N
comprehensive JJ N
surgical JJ i
staging NN i
and CC N
adjuvant JJ i
therapy NN i
. . i

Ninety-three JJ p
women NNS p
with IN p
FIGO NNP p
stage NN p
II NNP p
epithelial JJ p
ovarian JJ p
carcinoma NN p
underwent JJ N
comprehensive JJ N
surgical JJ N
staging NN N
and CC N
were VBD N
randomized VBN N
prospectively RB N
to TO N
therapy VB N
consisting NN N
of IN N
either DT N
intraperitoneal JJ i
radioactive JJ i
phosphorus NN i
or CC i
oral JJ i
melphalan NN i
. . i

No DT N
patient NN N
had VBD N
gross JJ N
residual JJ N
disease NN N
at IN N
the DT N
time NN N
of IN N
randomization NN N
. . N

Ten CD N
of IN N
the DT N
forty-five JJ p
women NNS p
treated VBN p
with IN p
melphalan NN i
experienced VBN N
severe JJ o
bone NN o
marrow NN o
depression NN o
at IN N
some DT N
time NN N
during IN N
therapy NN N
and CC N
two CD N
women NNS N
expired VBD o
from IN o
leukemia NN o
. . o

Four CD N
of IN N
the DT N
forty-eight JJ p
women NNS p
treated VBN p
with IN p
intraperitoneal JJ i
phosphorus NN i
required VBN N
surgical JJ o
reexploration NN o
for IN o
intestinal JJ o
obstruction NN o
or CC o
bowel NN o
injury NN o
. . o

Twenty-one JJ N
women NNS N
died VBD o
of IN N
their PRP$ N
disease NN N
. . N

Survival NNP o
was VBD N
not RB N
statistically RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
. . N

The DT N
5-year JJ o
actuarial JJ o
survival NN o
was VBD N
78 CD N
% NN N
. . N

-DOCSTART- -10870534- O O

Clinical JJ N
pathway NN N
for IN N
fractured JJ p
neck NN p
of IN p
femur NN p
: : p
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
outcomes NNS N
of IN N
using VBG N
a DT N
clinical JJ N
pathway NN N
for IN N
managing VBG N
patients NNS p
with IN p
fractured JJ p
neck NN p
of IN p
femur NN p
. . p

DESIGN NNP N
Prospective NNP N
, , N
pseudorandomised VBD N
, , N
controlled VBD N
trial NN N
. . N

SETTING NN N
St NNP p
Vincent NNP p
's POS p
Hospital NNP p
, , p
Melbourne NNP p
, , p
Victoria NNP p
( ( p
a DT p
tertiary JJ p
referral NN p
, , p
university NN p
teaching VBG p
hospital NN p
) ) p
, , p
1 CD p
October NNP p
1997 CD p
to TO p
30 CD p
November NNP p
1998 CD p
. . p

PARTICIPANTS VB N
111 CD p
patients NNS p
( ( p
80 CD p
women NNS p
and CC p
31 CD p
men NNS p
; : p
mean JJ p
age NN p
, , p
81 CD p
years NNS p
) ) p
admitted VBD p
via IN p
the DT p
emergency NN p
department NN p
with IN p
a DT p
primary JJ p
diagnosis NN p
of IN p
fractured JJ p
neck NN p
of IN p
femur NN p
. . p

INTERVENTIONS NNP N
Management NNP i
guided VBN i
by IN i
a DT i
clinical JJ i
pathway NN i
( ( i
55 CD i
patients NNS i
) ) i
or CC i
established VBN i
standard NN i
of IN i
care NN i
( ( N
control NN N
group NN N
, , N
56 CD N
patients NNS N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Timing NNP o
of IN o
referrals NNS o
and CC o
discharge NN o
planning NN o
; : o
total JJ o
length NN o
of IN o
stay NN o
; : o
and CC o
complication NN o
and CC o
readmission NN o
rates NNS o
within IN o
28 CD o
days NNS o
of IN o
discharge NN o
. . o

RESULTS JJ N
Patients NNS N
managed VBD N
according VBG N
to TO N
the DT N
clinical JJ N
pathway NN N
had VBD N
a DT N
shorter NN N
total JJ o
stay NN o
( ( N
6.6 CD N
versus NN N
8.0 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
even RB N
if IN N
assessment NN N
for IN N
placement NN N
by IN N
the DT N
Aged NNP N
Care NNP N
Assessment NNP N
Service NNP N
was VBD N
required VBN N
( ( N
9.5 CD N
versus NN N
13.6 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
complication NN o
and CC o
readmission NN o
rates NNS o
between IN N
pathway NN N
and CC N
control NN p
patients NNS p
( ( N
complication NN N
rates NNS N
, , N
24 CD N
% NN N
versus IN N
36 CD N
% NN N
; : N
P NNP N
= VBZ N
0.40 CD N
; : N
readmission NN N
rates NNS N
, , N
4 CD N
% NN N
versus IN N
11 CD N
% NN N
; : N
P NNP N
= NNP N
0.28 CD N
) ) N
. . N

CONCLUSION NNP N
Coordinated VBD N
multidisciplinary JJ N
care NN N
of IN N
patients NNS p
with IN p
fractured JJ p
neck NN p
of IN p
femur NN p
reduces NNS N
length NN o
of IN o
stay NN o
without IN N
increasing VBG N
complications NNS N
. . N

-DOCSTART- -7593698- O O

The DT N
efficacy NN N
of IN N
a DT N
herbal-based JJ i
toothpaste NN i
on IN N
the DT N
control NN N
of IN N
plaque NN p
and CC p
gingivitis NN p
. . p

A DT N
double-blind NN N
controlled VBD N
clinical JJ N
trial NN N
with IN N
parallel JJ N
groups NNS N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
a DT N
herbal-based JJ i
toothpaste NN i
in IN N
the DT N
control NN N
of IN N
plaque NN N
and CC N
gingivitis NN N
as IN N
compared VBN N
with IN N
a DT N
conventional JJ i
dentifrice NN i
. . i

70 CD p
subjects NNS p
with IN p
gingivitis NN p
completed VBN N
the DT N
6-week JJ N
study NN N
. . N

All DT p
participants NNS p
had VBD p
at IN p
least JJS p
20 CD p
natural JJ p
teeth NNS p
with IN p
no DT p
probing VBG p
depths NNS p
greater JJR p
than IN p
3 CD p
mm NNS p
and CC p
a DT p
plaque JJ p
index NN p
of IN p
2 CD p
or CC p
more JJR p
at IN p
baseline NN p
. . p

At IN N
baseline NN N
, , N
both DT N
groups NNS N
were VBD N
balanced VBN N
for IN N
the DT N
parameters NNS N
measured VBD N
: : N
plaque NN o
index NN o
, , o
plaque NN o
vitality NN o
, , o
gingival JJ o
index NN o
, , o
bleeding VBG o
on IN o
probing VBG o
and CC o
gingival JJ o
crevicular JJ o
fluid NN o
flow NN o
. . o

At IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
, , N
there EX N
were VBD N
reductions NNS N
within IN N
both DT N
groups NNS N
, , N
however RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
the DT N
herbal NN i
based VBN i
toothpaste NN i
was VBD N
as RB N
effective JJ N
as IN N
the DT N
conventionally RB i
formulated VBN i
dentifrice NN i
in IN N
the DT N
control NN N
of IN N
plaque NN N
and CC N
gingivitis NN N
. . N

-DOCSTART- -25432493- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
a DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
during IN N
robot-assisted JJ p
radical JJ p
prostatectomy NN p
. . p

Urinary JJ N
incontinence NN N
after IN N
robot-assisted JJ p
radical JJ p
prostatectomy NN p
( ( p
RARP NNP p
) ) p
is VBZ N
one CD N
of IN N
the DT N
most RBS N
bothersome JJ N
complications NNS N
affecting VBG N
patients NNS N
' POS N
daily JJ N
lives NNS N
. . N

The DT N
efficacy NN N
of IN N
the DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
technique NN i
in IN N
promoting VBG N
an DT N
earlier JJR N
return NN N
of IN N
continence NN N
was VBD N
prospectively RB N
evaluated VBN N
in IN N
158 CD p
patients NNS p
who WP p
underwent VBP p
RARP NNP p
for IN p
clinically RB p
localized VBN p
prostate NN p
cancer NN p
by IN p
a DT p
single JJ p
surgeon NN p
at IN p
our PRP$ p
institute NN p
from IN p
March NNP p
2012 CD p
to TO p
January NNP p
2013 CD p
. . p

Patients NNS N
were VBD N
randomized VBN N
1:1 CD N
to TO N
undergo VB N
surgery NN N
with IN i
( ( p
n JJ p
= NNP p
79 CD p
) ) p
or CC i
without IN i
( ( p
n JJ p
= NNP p
79 CD p
) ) p
the DT i
bladder NN i
neck NN i
plication NN i
stitch NN i
, , N
and CC N
their PRP$ N
time NN N
to TO N
recovery NN N
from IN N
incontinence NN N
, , N
defined VBD N
as IN N
being VBG N
pad JJ N
free JJ N
, , N
was VBD N
compared VBN N
. . N

Recovery NN o
from IN o
incontinence NN o
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
6 CD N
months NNS N
were VBD N
observed VBN N
in IN N
22 CD N
( ( N
27.8 CD N
% NN N
) ) N
, , N
42 CD N
( ( N
53.2 CD N
% NN N
) ) N
, , N
and CC N
57 CD N
( ( N
72.2 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
, , N
treated VBD N
with IN N
, , N
and CC N
23 CD N
( ( N
29.1 CD N
% NN N
) ) N
, , N
47 CD N
( ( N
59.5 CD N
% NN N
) ) N
, , N
and CC N
59 CD N
( ( N
74.7 CD N
% NN N
) ) N
patients NNS N
, , N
respectively RB N
, , N
treated VBD N
without IN N
the DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
, , N
with IN N
no DT N
significant JJ N
difference NN N
in IN N
time NN N
to TO N
recovery NN N
from IN N
incontinence NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Multivariate NNP N
analysis NN N
showed VBD N
that IN N
age NN o
, , o
membranous JJ o
urethral JJ o
length NN o
and CC o
shape NN o
of IN o
the DT o
prostatic JJ o
apex NN o
on IN o
magnetic JJ o
resonance NN o
imaging NN o
were VBD N
independent JJ N
predictors NNS N
of IN N
early JJ N
recovery NN N
from IN N
urinary JJ N
incontinence NN N
after IN N
RARP NNP N
. . N

The DT N
bladder NN i
neck NN i
plication NN i
stitch NN i
had VBD N
no DT N
effect NN N
on IN N
time NN o
to TO o
recovery NN o
from IN N
postoperative JJ N
urinary JJ N
incontinence NN N
following VBG N
RARP NNP N
. . N

-DOCSTART- -23275644- O O

A DT N
phase NN N
III NNP N
study NN N
of IN N
laparoscopy-assisted JJ i
versus NN i
open JJ i
distal JJ i
gastrectomy NN i
with IN N
nodal JJ N
dissection NN N
for IN N
clinical JJ N
stage NN N
IA/IB NNP N
gastric JJ N
Cancer NNP N
( ( N
JCOG0912 NNP N
) ) N
. . N

A DT N
Phase NNP N
III NNP N
study NN N
was VBD N
started VBN N
in IN N
Japan NNP p
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
overall JJ N
survival NN N
of IN N
laparoscopy-assisted JJ i
distal JJ i
gastrectomy NN i
with IN i
open JJ i
distal JJ i
gastrectomy NN i
in IN p
patients NNS p
with IN p
clinical JJ p
IA NNP p
( ( p
T1N0 NNP p
) ) p
or CC p
IB NNP p
[ NNP p
T1N1 NNP p
or CC p
T2 NNP p
( ( p
MP NNP p
) ) p
N0 NNP p
] NNP p
gastric JJ p
cancer NN p
. . p

This DT N
study NN N
followed VBD N
the DT N
previous JJ N
Phase NNP N
II NNP N
study NN N
to TO N
confirm VB N
the DT N
safety NN N
of IN N
laparoscopy-assisted JJ i
distal JJ i
gastrectomy NN i
( ( N
JCOG0703 NNP N
) ) N
and CC N
began VBD N
in IN N
March NNP N
2010 CD N
. . N

A DT N
total NN N
of IN p
920 CD p
patients NNS p
will MD p
be VB p
accrued VBN p
from IN p
33 CD p
institutions NNS p
within IN p
5 CD p
years NNS p
. . p

The DT N
primary JJ N
endpoint NN N
is VBZ N
overall JJ o
survival NN o
. . o

The DT N
secondary JJ N
endpoints NNS N
are VBP N
relapse-free JJ o
survival NN o
, , o
proportion NN o
of IN o
laparoscopy-assisted JJ o
distal JJ o
gastrectomy NN o
completion NN o
, , o
proportion NN o
of IN o
conversion NN o
to TO o
open VB o
surgery NN o
, , o
adverse JJ o
events NNS o
, , o
short-term JJ o
clinical JJ o
outcomes NNS o
, , o
postoperative JJ o
quality NN o
of IN o
life NN o
. . o

Only RB N
a DT N
credentialed JJ p
surgeon NN p
can MD N
be VB N
responsible JJ N
for IN N
both DT N
open JJ i
distal NN i
gastrectomy NN i
and CC N
laparoscopy-assisted JJ i
distal JJ i
gastrectomy NN i
. . N

-DOCSTART- -21908036- O O

Safety NN N
and CC N
efficacy NN N
of IN N
dalcetrapib NN i
on IN N
atherosclerotic JJ N
disease NN N
using VBG N
novel JJ i
non-invasive JJ i
multimodality NN i
imaging NN i
( ( i
dal-PLAQUE JJ i
) ) i
: : i
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Dalcetrapib NNP i
modulates VBZ N
cholesteryl VBP N
ester NN N
transfer NN N
protein NN N
( ( N
CETP NNP N
) ) N
activity NN N
to TO N
raise VB N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
. . N

After IN N
the DT N
failure NN N
of IN N
torcetrapib NN N
it PRP N
was VBD N
unknown JJ N
if IN N
HDL NNP N
produced VBN N
by IN N
interaction NN N
with IN N
CETP NNP N
had VBD N
pro-atherogenic JJ N
or CC N
pro-inflammatory JJ N
properties NNS N
. . N

dal-PLAQUE NN N
is VBZ N
the DT N
first JJ N
multicentre NN N
study NN N
using VBG N
novel JJ N
non-invasive JJ N
multimodality NN N
imaging VBG N
to TO N
assess VB N
structural JJ N
and CC N
inflammatory JJ N
indices NNS N
of IN N
atherosclerosis NN N
as IN N
primary JJ N
endpoints NNS N
. . N

METHODS NNP N
In IN N
this DT N
phase NN N
2b CD N
, , N
double-blind NN N
, , N
multicentre JJ N
trial NN N
, , N
patients NNS p
( ( p
aged VBN p
18-75 CD p
years NNS p
) ) p
with IN p
, , p
or CC p
with IN p
high JJ p
risk NN p
of IN p
, , p
coronary JJ p
heart NN p
disease NN p
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1 CD N
) ) N
to TO N
dalcetrapib VB i
600 CD i
mg/day NN i
or CC i
placebo NN i
for IN i
24 CD i
months NNS i
. . i

Randomisation NN N
was VBD N
done VBN N
with IN N
a DT N
computer-generated JJ N
randomisation NN N
code NN N
and CC N
was VBD N
stratified VBN N
by IN N
centre NN N
. . N

Patients NNS N
and CC N
investigators NNS N
were VBD N
masked VBN N
to TO N
treatment NN N
. . N

Coprimary JJ N
endpoints NNS N
were VBD N
MRI-assessed JJ o
indices NNS o
( ( o
total JJ o
vessel NN o
area NN o
, , o
wall JJ o
area NN o
, , o
wall NN o
thickness NN o
, , o
and CC o
normalised VBD o
wall NN o
index NN o
[ JJ N
average JJ N
carotid NN N
] NN N
) ) N
after IN N
24 CD N
months NNS N
and CC N
( ( N
18 CD N
) ) N
F-fluorodeoxyglucose NNP N
( ( N
( ( N
18 CD N
) ) N
F-FDG NN N
) ) N
PET/CT NNP N
assessment NN N
of IN N
arterial JJ N
inflammation NN N
within IN N
an DT N
index NN N
vessel NN N
( ( N
right JJ N
carotid NN N
, , N
left VBD N
carotid NN N
, , N
or CC N
ascending VBG N
thoracic JJ N
aorta NN N
) ) N
after IN N
6 CD N
months NNS N
, , N
with IN N
no-harm JJ N
boundaries NNS N
established VBN N
before IN N
unblinding NN N
of IN N
the DT N
trial NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
NCT00655473 NNP N
. . N

FINDINGS NNP N
189 CD p
patients NNS p
were VBD p
screened VBN p
and CC p
130 CD p
randomly RB p
assigned VBN p
to TO p
placebo VB i
( ( p
66 CD p
patients NNS p
) ) p
or CC p
dalcetrapib NN i
( ( p
64 CD p
patients NNS p
) ) p
. . p

For IN N
the DT N
coprimary JJ N
MRI NNP N
and CC N
PET/CT NNP N
endpoints NNS N
, , N
CIs NNP N
were VBD N
below IN N
the DT N
no-harm JJ N
boundary NN N
or CC N
the DT N
adverse JJ N
change NN N
was VBD N
numerically RB N
lower JJR N
in IN N
the DT N
dalcetrapib NN i
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
. . N

MRI-derived JJ o
change NN o
in IN o
total JJ o
vessel JJ o
area NN o
was VBD N
reduced VBN N
in IN N
patients NNS N
given VBN N
dalcetrapib NNS i
compared VBN N
with IN N
those DT N
given VBN N
placebo NNS N
after IN N
24 CD N
months NNS N
; : N
absolute JJ N
change NN N
from IN N
baseline NN N
relative NN N
to TO N
placebo VB i
was VBD N
-4?01 JJ N
mm NN N
( ( N
2 CD N
) ) N
( ( N
90 CD N
% NN N
CI NNP N
-7?23 NNP N
to TO N
-0?80 VB N
; : N
nominal JJ N
p=0?04 NN N
) ) N
. . N

The DT N
PET/CT NNP o
measure NN o
of IN o
index NN o
vessel JJ o
most-diseased-segment JJ o
target-to-background NN o
ratio NN o
( ( o
TBR NNP o
) ) o
was VBD o
not RB N
different JJ N
between IN N
groups NNS N
, , N
but CC N
carotid JJ N
artery NN N
analysis NN N
showed VBD N
a DT N
7 CD N
% NN N
reduction NN N
in IN N
most-diseased-segment JJ N
TBR NNP N
in IN N
the DT N
dalcetrapib NN i
group NN i
compared VBN N
with IN N
the DT N
placebo NN i
group NN i
( ( N
-7?3 NNP N
[ RB N
90 CD N
% NN N
CI NNP N
-13?5 NNP N
to TO N
-0?8 VB N
] NNP N
; : N
nominal JJ N
p=0?07 NN N
) ) N
. . i

Dalcetrapib NNP i
did VBD i
not RB i
increase VB N
office NN o
blood NN o
pressure NN o
and CC o
the DT o
frequency NN o
of IN o
adverse JJ o
events NNS o
was VBD N
similar JJ N
between IN N
groups NNS N
. . N

INTERPRETATION NNP i
Dalcetrapib NNP i
showed VBD i
no DT N
evidence NN N
of IN N
a DT N
pathological JJ N
effect NN N
related VBN N
to TO N
the DT N
arterial JJ N
wall NN N
over IN N
24 CD N
months NNS N
. . N

Moreover RB N
, , N
this DT N
trial NN N
suggests VBZ N
possible JJ N
beneficial JJ N
vascular JJ N
effects NNS N
of IN i
dalcetrapib NN i
, , i
including VBG i
the DT N
reduction NN N
in IN N
total JJ N
vessel JJ N
enlargement NN N
over IN N
24 CD N
months NNS N
, , N
but CC N
long-term JJ N
safety NN N
and CC N
clinical JJ N
outcomes NNS N
efficacy NN N
of IN N
dalcetrapib NNS N
need VBP N
to TO N
be VB N
analysed VBN N
. . N

FUNDING NN N
F NNP N
Hoffmann-La NNP N
Roche NNP N
Ltd NNP N
. . N

-DOCSTART- -22006202- O O

A DT N
phase NN N
IIb NNP N
dose-ranging NN N
study NN N
of IN N
the DT N
oral JJ i
JAK NNP i
inhibitor NN i
tofacitinib NN i
( ( i
CP-690,550 NNP i
) ) i
versus NN i
placebo NN i
in IN N
combination NN N
with IN N
background NN i
methotrexate NN i
in IN N
patients NNS p
with IN p
active JJ p
rheumatoid NN p
arthritis NN p
and CC p
an DT p
inadequate JJ p
response NN p
to TO p
methotrexate VB i
alone RB i
. . i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN o
, , o
safety NN o
, , o
and CC o
tolerability NN o
of IN N
6 CD N
dosages NNS N
of IN N
oral JJ i
tofacitinib NN i
( ( i
CP-690,550 NNP i
) ) i
with IN i
placebo NN i
for IN N
the DT N
treatment NN N
of IN N
active JJ p
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
in IN p
patients NNS p
receiving VBG p
a DT p
stable JJ p
background NN p
regimen NNS p
of IN p
methotrexate NN i
( ( i
MTX NNP i
) ) i
who WP p
have VBP p
an DT p
inadequate JJ p
response NN p
to TO p
MTX NNP i
monotherapy NN i
. . i

METHODS NNP N
In IN N
this DT N
24-week JJ N
, , N
double-blind JJ N
, , N
phase NN N
IIb NNP N
study NN N
, , N
patients NNS p
with IN p
active JJ p
RA NNP p
( ( p
n JJ p
= NNP p
507 CD p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
placebo NN i
or CC i
tofacitinib NN i
( ( N
20 CD N
mg/day NN N
, , N
1 CD N
mg NN N
twice RB N
daily RB N
, , N
3 CD N
mg NN N
twice RB N
daily RB N
, , N
5 CD N
mg NN N
twice RB N
daily RB N
, , N
10 CD N
mg NN N
twice RB N
daily RB N
, , N
or CC N
15 CD N
mg JJ N
twice RB N
daily RB N
) ) N
. . N

All DT N
patients NNS N
continued VBN N
to TO N
receive VB N
a DT N
stable JJ N
dosage NN N
of IN N
MTX NNP i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
American JJ o
College NNP o
of IN o
Rheumatology NNP o
20 CD o
% NN o
improvement NN o
criteria NN o
( ( o
ACR20 NNP o
) ) o
response NN o
rate NN o
at IN N
week NN N
12 CD N
. . N

RESULTS NN N
At IN N
week NN N
12 CD N
, , N
ACR20 NNP o
response NN N
rates NNS N
for IN N
patients NNS N
receiving VBG N
all DT N
tofacitinib NN i
dosages VBZ N
?3 NNP N
mg NNP N
twice RB N
daily RB N
( ( N
52.9 CD N
% NN N
for IN N
3 CD N
mg JJ N
twice RB N
daily RB N
, , N
50.7 CD N
% NN N
for IN N
5 CD N
mg JJ N
twice RB N
daily RB N
, , N
58.1 CD N
% NN N
for IN N
10 CD N
mg JJ N
twice RB N
daily RB N
, , N
56.0 CD N
% NN N
for IN N
15 CD N
mg JJ N
twice RB N
daily RB N
, , N
and CC N
53.8 CD N
% NN N
for IN N
20 CD N
mg/day NN N
) ) N
were VBD N
significantly RB N
( ( N
P NNP N
? . N
0.05 CD N
) ) N
greater JJR N
than IN N
those DT N
for IN N
placebo NN i
( ( i
33.3 CD i
% NN N
) ) N
. . N

Improvements NNS N
were VBD N
sustained VBN N
at IN N
week NN N
24 CD N
for IN N
the DT N
ACR20 NNP o
, , o
ACR50 NNP o
, , o
and CC o
ACR70 NNP o
responses NNS o
, , o
scores NNS o
for IN N
the DT N
Health NNP o
Assessment NNP o
Questionnaire NNP o
disability NN o
index NN o
, , o
the DT o
3-variable JJ o
Disease NNP o
Activity NNP o
Score NNP o
in IN o
28 CD o
joints NNS o
using VBG o
the DT o
C-reactive JJ o
protein NN o
level NN o
( ( o
DAS28-CRP NNP o
) ) o
, , o
and CC o
a DT o
3-variable JJ o
DAS28-CRP NNP o
of IN o
< NNP o
2.6 CD o
. . o

The DT o
most RBS N
common JJ N
treatment-emergent JJ o
adverse JJ o
events NNS o
occurring VBG o
in IN N
> JJ N
10 CD N
% NN N
of IN N
patients NNS N
in IN N
any DT N
tofacitinib JJ N
group NN N
were VBD N
diarrhea RB o
, , o
upper JJ o
respiratory NN o
tract NN o
infection NN o
, , o
and CC o
headache NN o
; : o
21 CD o
patients NNS N
( ( N
4.1 CD N
% NN N
) ) N
experienced VBD o
serious JJ o
adverse JJ o
events NNS o
. . o

Sporadic JJ o
increases NNS o
in IN o
transaminase NN o
levels NNS o
, , o
increases NNS o
in IN o
cholesterol NN o
and CC o
serum JJ o
creatinine NN o
levels NNS o
, , o
and CC o
decreases NNS o
in IN o
neutrophil NN o
and CC o
hemoglobin NN o
levels NNS o
were VBD o
observed VBN N
. . N

CONCLUSION NNP p
In IN p
patients NNS p
with IN p
active JJ p
RA NNP p
in IN p
whom WP p
the DT p
response NN i
to TO i
MTX NNP i
has VBZ p
been VBN p
inadequate JJ p
, , p
the DT p
addition NN i
of IN i
tofacitinib NN i
at IN i
a DT N
dosage NN N
?3 NN N
mg NN N
twice RB N
daily RB N
showed VBD N
sustained JJ N
efficacy NN N
and CC N
a DT N
manageable JJ N
safety NN N
profile NN N
over IN N
24 CD N
weeks NNS N
. . N

-DOCSTART- -25923852- O O

A DT N
trial NN N
of IN N
d-cycloserine NN i
to TO N
treat VB N
the DT N
social JJ N
deficit NN N
in IN N
older JJR p
adolescents NNS p
and CC p
young JJ p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Autism NNP p
spectrum NN p
disorders NNS p
are VBP N
difficult JJ N
for IN N
older JJR p
adolescents NNS p
and CC N
young JJ p
adults NNS p
as IN N
impaired JJ N
social JJ N
communication NN N
affects VBZ N
the DT N
transition NN N
to TO N
adult VB N
life NN N
. . N

d-Cycloserine NN i
, , N
a DT N
partial JJ N
glycine NN N
agonist NN N
at IN N
the DT N
N-methyl-d-aspartic JJ N
acid NN N
receptor NN N
, , N
was VBD N
tested VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
trial NN N
in IN N
20 CD p
older JJR p
adolescents NNS p
and CC p
young JJ p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
using VBG N
two CD N
dosing VBG N
strategies NNS N
( ( N
50 CD N
mg NNS N
daily JJ N
versus IN N
50 CD N
mg JJ N
weekly RB N
) ) N
for IN N
8 CD N
weeks NNS N
with IN N
a DT N
2-week JJ N
follow-up NN N
after IN N
discontinuation NN N
. . N

d-Cycloserine NN i
caused VBD N
statistically RB N
and CC N
clinically RB N
significant JJ N
improvement NN N
with IN N
no DT N
differentiation NN N
between IN N
dosing VBG o
strategies NNS o
on IN o
the DT o
Social NNP o
Responsiveness NNP o
Scale NNP o
and CC o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
before IN N
and CC N
after IN N
d-cycloserine JJ i
administration NN N
. . N

-DOCSTART- -12377836- O O

Home NNP i
sleep NN i
studies NNS i
in IN N
the DT N
assessment NN N
of IN N
sleep JJ o
apnea/hypopnea NN o
syndrome NN o
. . o

OBJECTIVE UH N
To TO N
determine VB N
the DT N
clinical JJ N
utility NN N
of IN N
a DT N
limited JJ N
sleep-recording JJ N
device NN N
used VBN N
unsupervised VBN N
in IN N
the DT N
patient NN N
's POS N
home NN N
, , N
compared VBN N
with IN N
in-laboratory JJ N
, , N
fully RB N
supervised VBN N
polysomnography NN N
for IN N
the DT N
diagnosis NN N
of IN N
sleep JJ o
apnea/hypopnea NN o
syndrome NN o
( ( o
SAHS NNP o
) ) o
, , N
and CC N
to TO N
assess VB N
its PRP$ N
impact NN N
on IN N
costs NNS o
. . o

DESIGN NNP N
Prospective NNP N
case NN N
study NN N
. . N

SETTING VB N
The DT N
sleep-disorders NNS N
unit NN N
of IN N
a DT N
tertiary JJ N
referral JJ N
university NN N
hospital NN N
. . N

PATIENTS VB N
Fifty-five JJ p
patients NNS p
suspected VBN p
of IN p
having VBG p
SAHS NNP p
and CC p
living VBG p
within IN p
30 CD p
km NN p
of IN p
our PRP$ p
laboratory NN p
. . p

METHODS JJ N
Patients NNPS p
were VBD p
studied VBN p
first RB p
in IN p
their PRP$ p
homes NNS p
with IN N
the DT N
limited JJ i
sleep-recording JJ i
device NN i
. . i

Polysomnography NNP i
was VBD N
performed VBN N
within IN N
30 CD N
days NNS N
of IN N
the DT N
first JJ N
study NN N
. . N

Both CC N
studies NNS N
were VBD N
read VBN N
by IN N
independent JJ N
investigators NNS N
blinded VBD N
to TO N
the DT N
results NNS N
of IN N
the DT N
other JJ N
study NN N
. . N

Diagnoses NNS N
and CC N
therapeutic JJ N
decisions NNS N
regarding VBG N
the DT N
use NN N
of IN N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
obtained VBN N
from IN N
the DT N
home NN N
and CC N
laboratory NN N
studies NNS N
were VBD N
compared VBN N
. . N

Agreement NNP N
between IN N
the DT N
home NN N
and CC N
laboratory NN N
study NN N
recordings NNS N
was VBD N
also RB N
assessed VBN N
using VBG N
receiver NN N
operating VBG N
characteristic JJ N
( ( N
ROC NNP N
) ) N
curves NNS N
and CC N
Bland-Altman NNP N
analysis NN N
. . N

One CD N
half NN N
of IN N
the DT N
home NN N
studies NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
performed VBN N
with IN N
a DT N
sleep JJ N
technician NN N
's POS N
set VBN N
up IN N
of IN N
the DT N
equipment NN N
in IN N
the DT N
patient NN N
's POS N
home NN N
( ( N
group NN N
1 CD N
) ) N
, , N
and CC N
the DT N
other JJ N
half NN N
with IN N
the DT N
patient NN N
's POS N
own JJ N
setup NN N
of IN N
the DT N
sleep-recording JJ N
device NN N
( ( N
group NN N
2 CD N
) ) N
, , N
after IN N
an DT N
instruction NN N
period NN N
in IN N
the DT N
hospital NN N
. . N

An DT N
economic JJ N
analysis NN N
was VBD N
performed VBN N
, , N
considering VBG N
the DT N
cost NN N
of IN N
repeating VBG N
studies NNS N
in IN N
cases NNS N
with IN N
faulty NN N
or CC N
inconclusive JJ N
home NN N
studies NNS N
( ( N
these DT N
patients NNS N
should MD N
undergo VB N
polysomnography NN N
as IN N
a DT N
second JJ N
step NN N
) ) N
. . N

RESULTS NNP N
Seven NNP N
percent NN N
of IN N
the DT N
home NN N
studies NNS N
in IN N
group NN N
1 CD N
, , N
and CC N
33 CD N
% NN N
in IN N
group NN N
2 CD N
produced VBD N
no DT N
interpretable JJ N
data NNS N
because IN N
of IN N
artifacts NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Sixteen JJ N
percent NN N
of IN N
the DT N
home NN N
study NN N
findings NNS N
were VBD N
inconclusive JJ N
. . N

The DT N
diagnosis NN N
obtained VBN N
from IN N
the DT N
limited JJ N
sleep-recording JJ N
device NN N
and CC N
polysomnography NN i
agreed VBD N
in IN N
75 CD N
% NN N
of IN N
the DT N
interpretable JJ N
home NN N
studies NNS N
( ( N
89 CD N
% NN N
, , N
if IN N
inconclusive JJ N
home NN N
studies NNS N
were VBD N
excluded VBN N
) ) N
. . N

The DT N
area NN o
under IN o
the DT o
ROC NNP o
curve NN o
for IN N
the DT N
home NN N
study-derived JJ N
parameters NNS N
was VBD N
between IN N
0.84 CD N
and CC N
0.89 CD N
, , N
compared VBN N
with IN N
polysomnography NN N
. . N

There EX N
was VBD N
no DT N
bias NN N
between IN N
home NN N
and CC N
polysomnography NN N
studies NNS N
in IN N
the DT N
Bland-Altman NNP N
plot NN N
. . N

The DT N
cost NN o
per IN o
study NN o
of IN o
home NN o
study NN o
recordings NNS o
was VBD N
less RBR N
expensive JJ N
than IN N
that DT N
of IN N
polysomnography NN N
( ( N
143.86 CD N
euros NN N
) ) N
, , N
either RB N
with IN N
( ( N
93.08 CD N
euros NN N
) ) N
or CC N
without IN N
( ( N
129.97 CD N
euros NNS N
) ) N
intervention NN N
of IN N
the DT N
technician NN N
in IN N
the DT N
patient NN N
's POS N
home NN N
. . N

CONCLUSION NNP N
Home NNP i
sleep NN i
studies NNS N
are VBP N
a DT N
viable JJ N
form NN N
of IN N
diagnosing VBG N
SAHS NNP N
, , N
and CC N
are VBP N
less RBR N
expensive JJ o
than IN N
polysomnography NN N
. . N

Intervention NN N
of IN N
a DT N
sleep JJ N
technician NN N
in IN N
the DT N
patient NN N
's POS N
home NN N
was VBD N
the DT N
least JJS N
expensive JJ o
strategy NN o
, , N
because IN N
of IN N
the DT N
high JJ N
percentages NNS N
of IN N
faulty JJ N
studies NNS N
with IN N
the DT N
patient NN N
's POS N
own JJ N
setup NN N
of IN N
the DT N
equipment NN N
, , N
when WRB N
using VBG N
the DT N
limited JJ N
sleep-recording JJ N
device NN N
. . N

-DOCSTART- -3114351- O O

Transdermal NNP i
nitroglycerin NN i
in IN N
angina JJ p
pectoris NN p
: : p
efficacy NN N
of IN N
intermittent JJ N
application NN N
. . N

Continuous JJ N
application NN N
of IN N
transdermal JJ i
nitroglycerin JJ i
appears VBZ N
to TO N
result VB N
in IN N
tolerance NN o
to TO o
the DT o
antianginal JJ o
effect NN o
. . o

In IN N
a DT N
double-blind NN N
study NN N
the DT N
effects NNS N
of IN N
continuous JJ N
( ( N
24 CD N
h/day NN N
) ) N
and CC N
intermittent NN N
( ( N
16 CD N
h/day NN N
) ) N
application NN N
of IN N
transdermal JJ i
nitroglycerin NN i
in IN i
a DT N
dosage NN N
of IN N
10 CD N
mg/day NN N
were VBD N
compared VBN N
with IN N
the DT N
effects NNS N
of IN N
placebo NN i
in IN N
12 CD p
patients NNS p
with IN p
chronic JJ p
stable JJ p
angina NN p
receiving VBG p
treatment NN p
with IN p
beta-adrenergic JJ i
blocking NN i
or CC i
calcium NN i
channel NNS i
blocking VBG i
agents NNS i
. . i

Exercise NN o
performance NN o
was VBD N
assessed VBN N
2 CD N
to TO N
4 CD N
hours NNS N
after IN N
initial JJ N
application NN N
and CC N
after IN N
1 CD N
week NN N
of IN N
each DT N
treatment NN N
given VBN N
in IN N
random JJ N
order NN N
with IN N
a DT N
3 CD N
day NN N
interval NN N
between IN N
treatments NNS N
. . N

Exercise NN o
time NN o
to TO o
onset VB o
of IN o
angina NN o
, , o
total JJ o
exercise NN o
duration NN o
and CC o
time NN o
to TO o
1 CD o
mm NNS o
ST NNP o
segment NN o
depression NN o
were VBD N
all DT N
significantly RB N
increased VBN N
after IN N
initial JJ N
application NN N
during IN N
the DT N
continuous JJ N
and CC N
intermittent JJ N
treatment NN N
periods NNS N
. . N

These DT N
increases NNS N
were VBD N
maintained VBN N
after IN N
1 CD N
week NN N
of IN N
intermittent NN N
but CC N
not RB N
continuous JJ N
treatment NN N
. . N

Thus VB N
the DT N
benefit NN N
of IN N
initial JJ N
application NN N
of IN N
transdermal JJ i
nitroglycerin NN i
is VBZ N
maintained VBN N
with IN N
intermittent JJ N
treatment NN N
and CC N
a DT N
daily JJ N
nitrate-free JJ N
interval NN N
, , N
whereas JJ N
tolerance NN o
to TO o
antianginal JJ o
effect NN o
occurs VBZ N
with IN N
continuous JJ N
treatment NN N
. . N

-DOCSTART- -22920273- O O

Comparing VBG N
the DT N
effectiveness NN N
of IN N
copper NN i
intrauterine NN i
devices NNS i
available JJ N
in IN N
Canada NNP p
. . p

Is VBZ N
FlexiT JJ i
non-inferior JJ N
to TO N
NovaT VB i
when WRB N
inserted VBN N
immediately RB N
after IN N
first-trimester JJ p
abortion NN p
? . N
Study NNP N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
We PRP N
describe VBP N
the DT N
rationale NN N
and CC N
protocol NN N
for IN N
a DT N
randomized JJ N
noninferiority NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
to TO N
determine VB N
if IN N
the DT N
Flexi-T380 NNP i
( ( i
+ NNP i
) ) i
copper NN i
intrauterine JJ i
contraceptive JJ i
device NN i
( ( i
IUD NNP i
) ) i
is VBZ N
comparable JJ N
in IN N
terms NNS N
of IN N
effectiveness NN N
and CC N
expulsion NN N
rates NNS N
to TO N
the DT N
most RBS N
common JJ N
Canadian JJ N
IUD NNP N
currently RB N
in IN N
use NN N
, , N
NovaT-200 NNP N
, , N
when WRB N
placed VBN N
immediately RB N
after IN N
a DT N
first-trimester JJ N
abortion NN N
. . N

METHODS/DESIGN NNP N
Consenting NNP p
women NNS p
choosing VBG p
to TO p
use VB p
an DT p
IUD NNP p
after IN p
an DT p
abortion NN p
for IN p
a DT p
pregnancy NN p
of IN p
less JJR p
than IN p
12 CD p
weeks NNS p
of IN p
gestation NN p
will MD N
be VB N
randomized VBN N
to TO N
device-type JJ N
groups NNS N
to TO N
receive VB N
immediate JJ N
post-abortion JJ N
placement NN N
of IN N
either CC N
a DT N
Flexi-T380 NNP i
( ( i
+ NNP i
) ) i
IUD NNP i
, , N
a DT N
device NN N
for IN N
which WDT N
no DT N
current JJ N
evidence NN N
on IN N
expulsion NN N
or CC N
effectiveness NN N
rates NNS N
is VBZ N
available JJ N
, , N
or CC N
the DT N
Nova-T200 JJ i
IUD NNP i
, , N
the DT N
only RB N
other JJ N
brand NN N
of IN N
copper NN N
IUD NNP N
available JJ N
in IN N
Canada NNP N
at IN N
the DT N
time NN N
of IN N
study NN N
initiation NN N
. . N

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
IUD NNP o
expulsion NN o
rate NN o
at IN o
1 CD o
year NN o
. . o

Secondary JJ N
outcomes NNS N
include VBP N
: : N
pregnancy NN o
rate NN o
, , o
method CC o
continuation NN o
rate NN o
, , o
complication NN o
rates NNS o
( ( o
infection NN o
, , o
perforation NN o
) ) o
, , o
and CC o
satisfaction NN o
with IN o
contraceptive JJ o
method NN o
. . o

A DT N
non-intervention JJ N
group NN N
of IN N
consenting VBG N
women NNS N
choosing VBG N
a DT N
range NN N
of IN N
other JJ N
post-abortion JJ N
contraception NN N
methods NNS N
, , N
including VBG N
no DT N
contraception NN N
, , N
will MD N
be VB N
included VBN N
for IN N
comparison NN N
of IN N
secondary JJ N
outcomes NNS N
. . N

Web-based JJ N
contraception NN N
satisfaction NN N
questionnaires NNS N
, , N
clinical JJ N
records NNS N
, , N
and CC N
government-linked JJ N
health NN N
administrative JJ N
databases NNS N
will MD N
be VB N
used VBN N
to TO N
assess VB N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
. . N

DISCUSSION NNP N
The DT N
RCT NNP N
design NN N
, , N
combined VBN N
with IN N
access NN N
to TO N
clinical JJ N
records NNS N
at IN N
all DT N
provincial JJ N
abortion NN N
clinics NNS N
, , N
and CC N
to TO N
information NN N
in IN N
provincial JJ N
single-payer NN N
linked VBD N
administrative JJ N
health NN N
databases NNS N
, , N
birth NN N
registry NN N
, , N
and CC N
hospital NN N
records NNS N
, , N
offers VBZ N
a DT N
unique JJ N
opportunity NN N
to TO N
determine VB N
if IN N
a DT N
novel NN N
IUD NNP N
has VBZ N
a DT N
comparable JJ N
expulsion NN o
rate NN o
to TO N
that DT N
of IN N
the DT N
current JJ N
standard NN N
IUD NNP N
in IN N
Canada NNP N
, , N
in IN N
addition NN N
to TO N
the DT N
first JJ N
opportunity NN N
to TO N
determine VB N
pregnancy NN o
rate NN o
and CC o
method NN o
satisfaction NN o
at IN N
1 CD N
year NN N
post-abortion NN N
for IN N
women NNS N
choosing VBG N
a DT N
range NN N
of IN N
post-abortion NN N
contraceptive NN N
options NNS N
. . N

We PRP N
highlight VBD N
considerations NNS N
of IN N
design NN N
, , N
implementation NN N
, , N
and CC N
evaluation NN N
of IN N
the DT N
first JJ N
trial NN N
to TO N
provide VB N
rigorous JJ N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
current JJ N
Canadian JJ N
IUDs NNP N
when WRB N
inserted VBN N
after IN N
first-trimester JJ N
abortion NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
NCT01174225 NNP N
. . N

-DOCSTART- -23614586- O O

Health-education JJ N
package NN N
to TO N
prevent VB N
worm NN N
infections NNS N
in IN N
Chinese JJ p
schoolchildren NNS p
. . p

BACKGROUND NNP N
Soil-transmitted JJ N
helminths NNS N
are VBP N
among IN N
the DT N
most RBS N
prevalent JJ N
sources NNS N
of IN N
human JJ N
infections NNS N
globally RB N
. . N

We PRP N
determined VBD N
the DT N
effect NN N
of IN N
an DT N
educational JJ N
package NN N
at IN N
rural JJ p
schools NNS p
in IN p
Linxiang NNP p
City NNP p
District NNP p
, , p
Hunan NNP p
province NN p
, , p
China NNP p
, , N
where WRB N
these DT N
worms NNS N
are VBP N
prevalent JJ N
. . N

The DT N
intervention NN N
aimed VBN N
to TO N
increase VB N
knowledge NN N
about IN N
soil-transmitted JJ N
helminths NNS N
, , N
induce VB N
behavioral JJ o
change NN o
, , N
and CC N
reduce VB N
the DT N
rate NN o
of IN o
infection NN o
. . o

METHODS NNP N
We PRP N
conducted VBD N
a DT N
single-blind NN N
, , N
unmatched JJ N
, , N
cluster-randomized JJ N
intervention NN N
trial NN N
involving VBG N
1718 CD p
children NNS p
, , p
9 CD p
to TO p
10 CD p
years NNS p
of IN p
age NN p
, , p
in IN p
38 CD p
schools NNS p
over IN p
the DT p
course NN p
of IN p
1 CD p
school NN p
year NN p
. . p

Schools NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
health-education NN i
package NN i
, , i
which WDT i
included VBD i
a DT i
cartoon NN i
video NN i
, , i
or CC i
to TO i
a DT i
control NN i
package NN i
, , i
which WDT i
involved VBD i
only RB i
the DT i
display NN i
of IN i
a DT i
health-education NN i
poster NN i
. . i

Infection NN o
rates NNS o
, , o
knowledge VB o
about IN o
soil-transmitted JJ o
helminths NNS o
( ( o
as IN o
assessed VBN o
with IN o
the DT o
use NN o
of IN o
a DT o
questionnaire NN o
) ) o
, , o
and CC o
hand-washing JJ o
behavior NN o
were VBD i
assessed VBN i
before IN i
and CC i
after IN i
the DT i
intervention NN i
. . i

Albendazole NNP i
was VBD N
administered VBN N
in IN N
all PDT N
the DT N
participants NNS N
at IN N
baseline NN N
and CC N
in IN N
all PDT N
the DT N
children NNS N
who WP N
were VBD N
found VBN N
to TO N
be VB N
positive JJ N
for IN N
infection NN N
with IN N
soil-transmitted JJ N
helminths NNS N
at IN N
the DT N
follow-up JJ N
assessment NN N
at IN N
the DT N
end NN N
of IN N
the DT N
school NN N
year NN N
. . N

RESULTS NNP N
At IN N
the DT N
follow-up JJ N
assessment NN N
, , N
the DT N
mean NN o
score NN o
for IN o
the DT o
knowledge NN o
of IN o
helminths NNS o
, , N
calculated VBD N
as IN N
a DT N
percentage NN N
of IN N
a DT N
total NN N
of IN N
43 CD N
points NNS N
on IN N
a DT N
questionnaire NN o
, , N
was VBD N
90 CD N
% NN N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
63.3 CD N
vs. FW N
33.4 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
percentage NN N
of IN N
children NNS o
who WP o
washed VBD o
their PRP$ o
hands NNS o
after IN o
using VBG o
the DT o
toilet NN o
was VBD N
nearly RB o
twice RB o
as RB N
high JJ N
in IN N
the DT N
intervention NN N
group NN N
( ( N
98.9 CD N
% NN N
, , N
vs. FW N
54.2 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
incidence NN o
of IN o
infection NN o
with IN N
soil-transmitted JJ N
helminths NNS N
was VBD N
50 CD N
% NN N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
4.1 CD N
% NN N
vs. FW N
8.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT o
adverse JJ o
events NNS o
were VBD N
observed VBN N
immediately RB N
( ( N
within IN N
15 CD N
minutes NNS N
) ) N
after IN N
albendazole JJ N
treatment NN N
. . N

CONCLUSIONS VB N
The DT N
health-education JJ N
package NN N
increased VBD N
students NNS N
' POS N
knowledge NN N
about IN N
soil-transmitted JJ N
helminths NNS N
and CC N
led VBD N
to TO N
a DT N
change NN N
in IN N
behavior NN N
and CC N
a DT N
reduced JJ N
incidence NN N
of IN N
infection NN N
within IN N
1 CD N
school NN N
year NN N
. . N

( ( N
Funded VBN N
by IN N
UBS NNP N
Optimus NNP N
Foundation NNP N
, , N
Zurich NNP N
, , N
Switzerland NNP N
; : N
Australian JJ N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
number NN N
, , N
ACTRN12610000048088 NNP N
. . N

) ) N
. . N

-DOCSTART- -10563544- O O

Intra-luminal JJ N
nicotine NN N
reduces NNS N
smooth JJ N
muscle NN N
tone NN N
and CC N
contractile NN N
activity NN N
in IN N
the DT N
distal JJ N
large JJ N
bowel NN N
. . N

BACKGROUND NNP N
Nicotine NNP N
may MD N
be VB N
of IN N
therapeutic JJ N
value NN N
in IN N
ulcerative JJ p
colitis NN p
( ( p
UC NNP p
) ) p
, , N
although IN N
its PRP$ N
mechanism NN N
of IN N
action NN N
has VBZ N
not RB N
been VBN N
established VBN N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
solution NN N
of IN N
nicotine NN N
on IN N
sustained JJ o
resting NN o
pressure NN o
( ( o
tone NN o
) ) o
and CC o
contractile JJ o
activity NN o
in IN N
the DT N
human JJ N
colon NN N
. . N

METHODS NNP N
Ten NNP p
healthy JJ p
volunteers NNS p
, , p
and CC p
seven CD p
with IN p
UC NNP p
in IN p
symptomatic JJ p
remission NN p
took VBD p
part NN p
; : p
all DT p
were VBD p
non-smokers NNS p
. . p

All DT N
17 CD p
subjects NNS p
were VBD N
given VBN i
nicotine JJ i
or CC i
placebo JJ i
solution NN i
on IN i
two CD i
separate JJ i
occasions NNS i
in IN i
a DT i
randomized JJ i
sequence NN i
. . i

A DT N
water-perfused JJ i
manometry NN i
catheter NN i
, , i
with IN i
openings NNS i
at IN i
5 CD i
, , i
10 CD i
and CC i
15 CD i
cm NN i
from IN i
the DT i
tip NN i
, , i
was VBD i
placed VBN i
by IN i
rigid JJ i
sigmoidoscopy NN i
in IN i
the DT i
recto-sigmoid JJ i
region NN i
. . i

Baseline NNP o
tone NN o
and CC o
activity NN o
were VBD i
measured VBN i
for IN i
15 CD i
min NNS i
prior RB i
to TO i
instillation NN i
of IN i
20 CD i
ml NN i
of IN i
saline JJ i
alone NN i
or CC i
with IN i
nicotine JJ i
, , i
1.2 CD i
mg NN i
, , i
at IN i
pH JJ i
4.5 CD i
. . i

Observations NNS N
were VBD N
made VBN N
over IN N
the DT N
subsequent JJ N
15-20 JJ N
min NN N
. . N

RESULTS NNP N
Baseline NNP N
spontaneous JJ N
activity NN N
in IN N
all DT N
subjects NNS N
showed VBD N
both DT N
high- JJ N
and CC N
low-frequency JJ N
components NNS N
; : N
in IN N
three CD N
patients NNS N
with IN N
UC NNP N
, , N
the DT N
low-frequency NN N
activity NN N
was VBD N
of IN N
high JJ N
amplitude NN N
. . N

The DT N
nicotine NN N
reduced VBD N
both DT N
tone NN o
and CC o
activity NN o
in IN N
all DT N
subjects NNS N
, , N
with IN N
reduction NN N
or CC N
abolition NN N
of IN N
the DT N
large JJ N
contractions NNS N
in IN N
UC NNP N
. . N

Tone NN o
in IN N
all DT N
17 CD p
subjects NNS p
was VBD N
reduced VBN N
significantly RB N
at IN N
3 CD N
min NN N
after IN N
nicotine NN N
( ( N
P NNP N
= NNP N
0.000015 CD N
, , N
sign JJ N
test NN N
) ) N
; : N
the DT N
rate NN o
of IN o
recovery NN o
varied VBN N
in IN N
individuals NNS N
. . N

Results NNS N
from IN N
normals NNS N
and CC N
UC NNP N
did VBD N
not RB N
differ VB N
significantly RB N
from IN N
each DT N
other JJ N
. . N

No DT N
significant JJ N
change NN N
in IN N
tone NN o
or CC o
activity NN o
was VBD N
observed VBN N
with IN N
the DT N
saline JJ N
solution NN N
. . N

CONCLUSION NNP N
Intra-luminal JJ N
nicotine NN N
significantly RB N
reduces VBZ N
both DT N
smooth JJ N
muscle NN N
tone NN N
and CC N
contractile NN N
activity NN N
in IN N
the DT N
recto-sigmoid JJ N
colon NN N
in IN N
both DT N
normal JJ p
subjects NNS p
and CC p
patients NNS p
with IN p
UC NNP p
. . p

-DOCSTART- -19638081- O O

Efficacy NN o
of IN N
prepackaged VBN i
, , i
low JJ i
residual JJ i
test NN i
meals NNS i
with IN i
4L CD i
polyethylene NN i
glycol NN i
versus IN i
a DT i
clear JJ i
liquid NN i
diet NN i
with IN i
4L CD i
polyethylene NN i
glycol NN i
bowel NN i
preparation NN i
: : i
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
A NNP N
prepackaged VBD N
low JJ N
residue JJ N
one-day JJ N
diet NN N
( ( N
breakfast NN N
, , N
lunch NN N
and CC N
dinner NN N
) ) N
has VBZ N
been VBN N
recently RB N
developed VBN N
to TO N
improve VB N
patient NN o
tolerance NN o
for IN o
bowel NN o
preparation NN o
prior RB N
to TO N
colonoscopy VB N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC N
tolerability NN o
of IN N
bowel NN N
preparation NN N
protocols NNS N
based VBN N
on IN N
a DT N
low JJ i
residue JJ i
diet NN i
and CC N
4L CD i
polyethylene NN i
glycol NN i
( ( i
PEG NNP i
) ) i
solution NN i
, , N
and CC N
to TO N
compare VB N
these DT N
new JJ N
options NNS N
with IN N
the DT N
traditional JJ i
liquid NN i
diet NN i
and CC i
the DT i
PEG NNP i
4L CD i
lavage NN i
. . i

METHODS NNP N
A NNP p
total NN p
of IN p
214 CD p
patients NNS p
( ( p
mean JJ p
age NN p
: : p
54.1 CD p
years NNS p
; : p
120 CD p
male NN p
, , p
94 CD p
female NN p
) ) p
from IN p
four CD p
university NN p
hospitals NNS p
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
clear JJ i
liquid NN i
diet NN i
and CC i
the DT i
PEG NNP i
4L CD i
regimen NNS i
( ( p
106 CD p
patients NNS p
) ) p
or CC N
the DT N
low JJ i
residue JJ i
test NN i
meals NNS i
and CC i
the DT i
PEG NNP i
4L CD i
regimen NNS i
( ( i
TM-PEG JJ i
4L CD N
, , N
108 CD N
patients NNS N
) ) N
. . N

The DT N
colon NN o
cleansing VBG o
efficacy NN o
of IN N
the DT N
different JJ N
preparations NNS N
was VBD N
rated VBN N
using VBG N
the DT N
Ottawa NNP o
bowel NN o
preparation NN o
scale NN o
. . o

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
treatment NN N
groups NNS N
according VBG N
to TO N
the DT N
Ottawa NNP o
cleansing VBG o
scale JJ o
findings NNS N
( ( N
PEG NNP N
4L CD N
: : N
2.97 CD N
vs IN N
TM-PEG JJ N
4L CD N
: : N
2.46 CD N
, , N
P NNP N
= NNP N
0.063 CD N
) ) N
. . N

The DT N
overall JJ o
tolerability NN o
was VBD N
higher RBR N
in IN N
the DT N
TM-PEG NNP N
4L CD N
group NN N
than IN N
in IN N
the DT N
PEG NNP N
4L CD N
group NN N
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
. . N

No DT N
difference NN N
was VBD N
found VBN N
when WRB N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
with IN N
regard NN N
to TO N
adverse JJ o
events NNS o
( ( N
P NNP N
= NNP N
0.599 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
prepackaged JJ N
low JJ N
residue JJ N
one-day JJ N
diet NN N
provided VBD N
cleansing VBG o
efficacy NN o
similar JJ N
to TO N
that DT N
of IN N
a DT N
clear JJ N
liquid NN N
diet NN N
and CC N
offered VBD N
the DT N
benefit NN N
of IN N
improved JJ o
tolerability NN o
compared VBN N
to TO N
the DT N
conventional JJ N
PEG NNP N
4L CD N
regimen NNS N
. . N

-DOCSTART- -10715372- O O

Study NN N
of IN N
the DT N
vaginal JJ N
tolerance NN N
to TO N
Acidform NNP i
, , i
an DT i
acid-buffering JJ i
, , i
bioadhesive JJ i
gel NN i
. . i

Vaginal JJ N
tolerance NN N
tests NNS N
were VBD N
performed VBN N
with IN N
a DT N
new JJ N
potential JJ N
microbicidal NN N
and CC N
spermicidal JJ N
product NN N
, , N
an DT N
acid-buffering JJ i
vaginal JJ i
gel NN i
( ( i
Acidform NNP i
) ) i
without IN i
or CC i
with IN i
nonoxynol-9 JJ i
( ( i
N-9 NNP i
) ) i
. . i

The DT N
potential JJ N
advantages NNS N
over IN N
other JJ N
vaginal JJ N
products NNS N
include VBP N
keeping VBG N
a DT N
low JJ N
pH NN N
, , N
decrease NN N
of IN N
the DT N
irritating VBG N
effect NN N
of IN N
N-9 NNP i
on IN N
the DT N
cervix NN N
or CC N
vaginal JJ N
mucosa NN N
associated VBN N
with IN N
greater JJR N
retention NN N
of IN N
the DT N
product NN N
after IN N
application NN N
, , N
and CC N
decreasing VBG N
messiness NN N
as IN N
compared VBN N
to TO N
other JJ N
vaginal JJ N
products NNS N
. . N

Three CD p
groups NNS p
of IN p
six CD p
women NNS p
were VBD p
admitted VBN p
and CC p
randomly RB p
assigned VBN p
to TO p
use VB p
Acidform NNP i
with IN p
0 CD p
% NN p
, , p
2.5 CD p
% NN p
, , p
and CC p
5 CD p
% NN p
N-9 NNP i
. . i

Colposcopic NNP N
evaluation NN N
for IN N
vulvar NN N
, , N
vaginal JJ N
, , N
and CC N
cervical JJ N
signs NNS N
of IN N
irritation NN N
was VBD N
performed VBN N
and CC N
photographs NNS N
were VBD N
taken VBN N
, , N
following VBG N
a DT N
specific JJ N
World NNP N
Health NNP N
Organization NNP N
protocol NN N
, , N
at IN N
time NN N
0 CD N
, , N
and CC N
after IN N
24 CD N
h NN N
and CC N
6 CD N
days NNS N
of IN N
application NN N
of IN N
the DT N
gel NN N
. . N

No DT o
irritation NN o
or CC o
symptom NN o
was VBD N
reported VBN N
by IN N
users NNS N
of IN N
Acidform NNP i
without IN i
N-9 NNP i
. . i

A NNP o
generalized JJ o
and CC o
intense JJ o
erythema NN o
in IN o
cervix NN o
was VBD N
observed VBN N
in IN N
10 CD N
of IN N
12 CD N
Acidform/N-9 JJ i
users NNS N
and CC N
abrasion NN N
occurred VBD N
in IN N
nine CD N
of IN N
them PRP N
. . N

Vulvar NNP o
irritation NN o
was VBD N
seen VBN N
in IN N
seven CD N
of IN N
these DT N
10 CD p
volunteers NNS p
. . p

N-9 JJ o
concentration NN o
in IN o
the DT o
gel NN o
( ( N
2.5 CD N
% NN N
or CC N
5.0 CD N
% NN N
) ) N
was VBD N
not RB N
related VBN N
to TO N
the DT N
findings NNS N
. . N

No DT o
ulcer NN o
, , o
exulceration NN o
, , o
or CC o
de-epithelialization NN o
was VBD N
observed VBN N
. . N

Acidform VB i
without IN i
N-9 NNP i
was VBD N
well RB N
tolerated VBN N
by IN N
volunteers NNS N
, , N
but CC N
it PRP N
was VBD N
unable JJ N
to TO N
protect VB N
the DT N
cervix NN N
, , N
vagina NN N
, , N
and CC N
vulva NN N
from IN N
the DT N
N-9 JJ N
effects NNS N
. . N

-DOCSTART- -2963645- O O

Flow-cytometric JJ N
studies NNS N
with IN N
eleutherococcus JJ i
senticosus NN i
extract NN i
as IN N
an DT N
immunomodulatory NN N
agent NN N
. . N

A DT N
placebo-controlled JJ i
study NN N
of IN N
the DT N
effect NN N
of IN N
an DT N
Eleutherococcus NNP i
senticosus NN i
extract NN i
( ( i
Eleukokk NNP i
) ) i
on IN N
the DT N
immune NN p
system NN p
was VBD N
performed VBN N
with IN N
36 CD p
healthy JJ p
volunteers NNS p
utilising VBG p
quantitative JJ p
multi-parameter NN p
flow NN p
cytometry NN p
with IN p
monoclonal JJ p
antibodies NNS p
directed VBN p
against IN p
specific JJ p
surface NN p
markers NNS p
of IN p
human JJ p
lymphocyte JJ p
subsets NNS p
. . p

Volunteers NNS N
in IN N
the DT N
verum NN N
group NN N
received VBD N
10 CD N
ml NN N
of IN N
an DT N
ethanolic JJ i
( ( i
vincamine JJ i
free JJ i
) ) i
eleutherococcus VBP i
senticosus JJ i
preparation NN i
, , N
3 CD N
times NNS N
daily RB N
for IN N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
placebo NN i
, , i
the DT i
eleutherococcus NN i
extract NN i
was VBD i
substituted VBN i
by IN i
additional JJ i
wine NN i
, , i
resulting VBG i
in IN i
identical JJ i
final JJ i
concentrations NNS i
of IN i
ethanol NN i
in IN i
both DT i
preparations NNS i
. . i

The DT N
purpose NN N
of IN N
the DT N
double-blind NN N
study NN N
was VBD N
the DT N
demonstration NN N
of IN N
possible JJ N
effects NNS N
on IN N
the DT N
cellular JJ o
immune NN o
status NN o
, , N
as IN N
determined VBN N
by IN N
quantitative JJ o
flow NN o
cytometry NN o
. . o

The DT N
most RBS N
salient JJ N
feature NN N
in IN N
the DT N
verum NN N
group NN N
was VBD N
a DT N
drastic JJ N
increase NN N
in IN N
the DT N
absolute JJ o
number NN o
of IN o
immunocompetent JJ o
cells NNS o
, , N
with IN N
an DT N
especially RB N
pronounced JJ N
effect NN N
on IN N
T NNP o
lymphocytes NNS o
, , N
predominantly RB N
of IN N
the DT N
helper/inducer NN o
type NN o
, , N
but CC N
also RB N
on IN N
cytotoxic NN o
and CC o
natural JJ o
killer NN o
cells NNS o
. . o

In IN N
addition NN N
, , N
a DT N
general JJ N
enhancement NN N
of IN N
the DT N
activation NN o
state NN o
of IN o
T NNP o
lymphocytes NNS o
was VBD N
observed VBN N
. . N

No DT N
side NN o
effects NNS o
were VBD N
observed VBN N
during IN N
the DT N
trial NN N
or CC N
afterwards NNS N
( ( N
observation NN N
period NN N
6 CD N
months NNS N
) ) N
. . N

-DOCSTART- -10525558- O O

An DT N
empirical JJ N
comparison NN N
of IN N
the DT N
St NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
( ( N
SGRQ NNP N
) ) N
and CC N
the DT N
Chronic NNP N
Respiratory NNP N
Disease NNP N
Questionnaire NNP N
( ( N
CRQ NNP N
) ) N
in IN N
a DT N
clinical JJ N
trial NN N
setting NN N
. . N

BACKGROUND IN N
The DT N
Chronic NNP N
Respiratory NNP N
Questionnaire NNP N
( ( N
CRQ NNP N
) ) N
and CC N
the DT N
St NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
( ( N
SGRQ NNP N
) ) N
are VBP N
the DT N
two CD N
most JJS N
widely RB N
used VBN N
quality NN N
of IN N
life NN N
questionnaires NNS N
in IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( p
COPD NNP p
) ) p
. . p

A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
directly RB N
the DT N
self-administered JJ N
version NN N
of IN N
the DT N
CRQ NNP N
and CC N
the DT N
SGRQ NNP N
with IN N
respect NN N
to TO N
feasibility NN N
, , N
internal JJ N
consistency NN N
, , N
validity NN N
, , N
and CC N
sensitivity NN N
to TO N
changes NNS N
resulting VBG N
from IN N
bronchodilator NN N
therapy NN N
. . N

METHODS NNP N
One CD p
hundred CD p
and CC p
forty VB p
four CD p
patients NNS p
with IN p
moderate JJ p
or CC p
severe JJ p
COPD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
three CD N
months NNS N
of IN N
treatment NN N
with IN N
either DT N
salmeterol NN i
, , i
salmeterol NN i
+ NNP i
ipratropium NN i
bromide NN i
, , i
or CC i
placebo NN i
. . i

Quality NN o
of IN o
life NN o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS VB N
The DT N
proportions NNS o
of IN o
missing VBG o
values NNS o
per IN N
patient NN N
were VBD N
low JJ N
for IN N
both DT N
questionnaires NNS N
( ( N
0.54 CD N
% NN N
for IN N
the DT N
CRQ NNP N
and CC N
2 CD N
% NN N
for IN N
the DT N
SGRQ NNP N
) ) N
. . N

The DT N
internal JJ o
consistency NN o
was VBD N
good JJ N
for IN N
both DT N
questionnaires NNS N
( ( N
Cronbach NNP N
's POS N
alpha NN N
coefficients NNS N
> VBP N
/= $ N
0.84 CD N
for IN N
the DT N
CRQ NNP N
and CC N
> NNP N
/= NNP N
0.76 CD N
for IN N
the DT N
SGRQ NNP N
) ) N
. . N

Factor NNP N
analysis NN N
confirmed VBD N
the DT N
original JJ N
domain NN N
structure NN N
of IN N
the DT N
CRQ NNP N
but CC N
not RB N
of IN N
the DT N
SGRQ NNP N
. . N

Correlations NNS N
with IN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( o
FEV NNP o
( ( o
1 CD o
) ) o
) ) o
% NN o
predicted VBN N
and CC N
peak JJ o
expiratory NN o
flow NN o
rate NN o
( ( o
PEFR NNP o
) ) o
were VBD N
low JJ N
for IN N
both DT N
questionnaires NNS N
but CC N
better JJR N
for IN N
the DT N
SGRQ NNP N
than IN N
for IN N
the DT N
CRQ NNP N
. . N

The DT N
ability NN N
to TO N
discriminate VB N
between IN N
subjects NNS N
with IN N
different JJ N
levels NNS N
of IN N
FEV NNP o
( ( o
1 CD o
) ) o
was VBD N
somewhat RB N
better JJR N
for IN N
the DT N
SGRQ NNP N
. . N

The DT N
correlations NNS N
with IN N
symptom JJ N
scores NNS N
were VBD N
comparable JJ N
for IN N
both DT N
questionnaires NNS N
. . N

Cross NNP N
sectionally RB N
, , N
the DT N
scores NNS N
of IN N
the DT N
two CD N
questionnaires NNS N
were VBD N
moderately RB N
to TO N
highly RB N
correlated VBN N
( ( N
coefficients NNS N
ranged VBD N
from IN N
0.35 CD N
to TO N
0.72 CD N
) ) N
. . N

Longitudinally RB N
, , N
these DT N
correlations NNS N
were VBD N
lower JJR N
( ( N
coefficients NNS N
ranged VBD N
from IN N
0.17 CD N
to TO N
0.54 CD N
) ) N
but CC N
were VBD N
still RB N
significant JJ N
. . N

The DT N
CRQ NNP o
total NN o
and CC o
emotions NNS o
score NN o
and CC o
the DT o
SGRQ NNP o
symptoms NNS o
score NN o
were VBD N
the DT N
most RBS N
responsive JJ N
to TO N
change VB N
. . N

The DT N
SGRQ NNP o
symptoms NNS o
domain NN o
was VBD N
the DT N
only JJ N
domain NN N
where WRB N
the DT N
improvement NN N
in IN N
patients NNS p
receiving VBG p
combination NN p
treatment NN p
crossed VBD N
the DT N
threshold NN N
for IN N
clinical JJ N
relevance NN N
. . N

CONCLUSIONS NNP N
Since IN N
this DT N
analysis NN N
of IN N
reliability NN N
, , N
validity NN N
, , N
and CC N
responsiveness NN N
to TO N
change VB N
did VBD N
not RB N
clearly RB N
favour VBP N
one CD N
instrument NN N
above IN N
the DT N
other JJ N
, , N
the DT N
choice NN N
between IN N
the DT N
CRQ NNP N
and CC N
the DT N
SGRQ NNP N
can MD N
be VB N
based VBN N
on IN N
other JJ N
considerations NNS N
such JJ N
as IN N
the DT N
required JJ N
sample NN N
size NN N
or CC N
the DT N
availability NN N
of IN N
reference NN N
values NNS N
. . N

-DOCSTART- -23111617- O O

Social JJ N
robots NNS N
as IN N
embedded JJ N
reinforcers NNS N
of IN N
social JJ p
behavior NN p
in IN p
children NNS p
with IN p
autism NN p
. . p

In IN N
this DT N
study NN N
we PRP N
examined VBD N
the DT N
social JJ N
behaviors NNS N
of IN N
4- JJ p
to TO p
12-year-old JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
; : p
N NNP p
= NNP p
24 CD p
) ) p
during IN p
three CD N
tradic JJ N
interactions NNS N
with IN N
an DT N
adult NN i
confederate NN i
and CC i
an DT i
interaction NN i
partner NN i
, , i
where WRB N
the DT N
interaction NN N
partner NN N
varied VBD N
randomly RB N
among IN N
( ( N
1 CD N
) ) i
another DT i
adult NN i
human NN i
, , i
( ( i
2 CD i
) ) i
a DT i
touchscreen JJ i
computer NN i
game NN i
, , i
and CC i
( ( i
3 CD i
) ) i
a DT i
social JJ i
dinosaur NN i
robot NN i
. . i

Children NNP N
spoke VBD N
more RBR N
in IN N
general JJ N
, , N
and CC N
directed VBD N
more JJR N
speech NN N
to TO N
the DT N
adult NN N
confederate NN N
, , N
when WRB N
the DT N
interaction NN N
partner NN N
was VBD N
a DT N
robot NN N
, , N
as IN N
compared VBN N
to TO N
a DT N
human NN N
or CC N
computer NN N
game NN N
interaction NN N
partner NN N
. . N

Children NNP N
spoke VBD N
as RB N
much JJ N
to TO N
the DT N
robot NN N
as IN N
to TO N
the DT N
adult NN N
interaction NN N
partner NN N
. . N

This DT N
study NN N
provides VBZ N
the DT N
largest JJS N
demonstration NN N
of IN N
social JJ N
human-robot JJ N
interaction NN N
in IN N
children NNS N
with IN N
autism NN N
to TO N
date NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
social JJ N
robots NNS N
may MD N
be VB N
developed VBN N
into IN N
useful JJ N
tools NNS N
for IN N
social JJ N
skills NNS N
and CC N
communication NN N
therapies NNS N
, , N
specifically RB N
by IN N
embedding VBG N
social JJ N
interaction NN N
into IN N
intrinsic JJ N
reinforcers NNS N
and CC N
motivators NNS N
. . N

-DOCSTART- -12876177- O O

Children NNP p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

I PRP N
: : N
comparison NN N
of IN N
placebo NN i
and CC N
single JJ N
dose NN N
of IN N
human JJ i
synthetic JJ i
secretin NN i
. . i

AIMS NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
human JJ i
synthetic JJ i
secretin NN i
( ( i
HSS NNP i
) ) i
on IN N
behaviour NN N
and CC N
communication NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
using VBG N
an DT N
objective JJ N
measure NN N
of IN N
communication NN N
and CC N
social JJ N
reciprocity NN N
and CC N
standardised VBD N
rating NN N
scales NNS N
. . N

METHODS NNP N
Randomised VBD N
, , N
crossover NN N
, , N
double JJ N
blind NN N
, , N
and CC N
placebo NN i
controlled VBD N
trial NN N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
human JJ i
synthetic JJ i
secretin NN i
( ( i
HSS NNP i
) ) i
2 CD N
CU/kg NNP N
. . N

The DT N
62 CD p
subjects NNS p
( ( p
3-8 CD p
years NNS p
) ) p
were VBD N
assigned VBN N
to TO N
group NN N
1 CD N
( ( i
saline JJ i
placebo/HSS NN i
) ) i
or CC N
group NN N
2 CD N
( ( i
HSS/saline NNP i
placebo NN i
) ) i
. . i

Diagnosis NN N
was VBD N
confirmed VBN N
by IN N
ADI-R NNP N
( ( N
Autism NNP N
Diagnostic NNP N
Interview-Revised JJ N
) ) N
algorithm NN N
. . N

Severity NN N
of IN N
symptoms NNS N
was VBD N
rated VBN N
using VBG N
the DT N
CARS NNP N
( ( N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
) ) N
. . N

Outcome NNP N
measures NNS N
included VBD N
Communication NNP o
and CC o
Symbolic NNP o
Behavior NNP o
Scale NNP o
( ( o
CSBS NNP o
) ) o
, , o
Ritvo NNP o
Real-life NNP o
Rating NNP o
Scale NNP o
, , o
weekly JJ o
Global NNP o
Rating NNP o
Scale NNP o
( ( o
GBRS NNP o
) ) o
by IN N
parents NNS N
and CC N
teachers NNS N
, , N
and CC N
daily JJ N
log NN N
of IN N
gastrointestinal JJ N
symptoms NNS N
. . N

The DT N
communication NN N
subscale NN N
of IN N
the DT N
CSBS NNP N
, , N
specifying VBG N
communication NN N
function NN N
, , N
reciprocity NN N
, , N
and CC N
social-affective JJ N
signalling NN N
was VBD N
videotaped VBN N
and CC N
scored VBN N
by IN N
a DT N
blinded JJ N
, , N
trained JJ N
observer RB N
. . N

RESULTS NNP N
Sixty NNP p
one CD p
children NNS p
completed VBD p
the DT p
study NN p
. . N

After IN N
randomisation NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
gender NN N
, , N
race NN N
, , N
age NN N
, , N
and CC N
parent NN N
and CC N
teacher NN N
GBRS NNP o
and CC N
Ritvo NNP N
Scale NNP N
between IN N
the DT N
two CD N
groups NNS N
. . N

Compared VBN N
with IN N
placebo NN i
, , i
secretin FW i
treatment NN i
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
improvement NN N
of IN N
CSBS NNP o
standard JJ o
scores NNS o
from IN N
baseline NN N
to TO N
2 CD N
or CC N
4 CD N
weeks NNS N
post-infusion NN N
. . N

Five CD N
children NNS N
showed VBD N
clinical JJ N
improvement NN N
in IN N
standard JJ N
scores NNS N
: : N
two CD N
after IN N
HSS NNP i
and CC N
three CD N
after IN N
placebo NN i
. . i

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
gastrointestinal NN o
symptoms NNS o
after IN N
HSS NNP i
or CC N
saline JJ i
placebo NN i
. . i

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
intravenous JJ N
human JJ i
secretin NN i
is VBZ N
not RB N
effective JJ N
in IN N
changing VBG N
behaviour NN N
and CC N
communication NN N
in IN N
children NNS N
with IN N
ASD NNP N
when WRB N
compared VBN N
to TO N
placebo VB i
. . i

-DOCSTART- -22421496- O O

Randomized VBN N
crossover NN N
study NN N
comparing VBG N
efficacy NN o
of IN N
transnasal NN i
endoscopy NN i
with IN i
that DT i
of IN i
standard JJ i
endoscopy NN i
to TO N
detect VB N
Barrett NNP N
's POS N
esophagus NN N
. . N

BACKGROUND NNP N
Unsedated VBD i
transnasal JJ i
endoscopy NN i
( ( i
TNE NNP i
) ) i
may MD N
be VB N
safer JJR N
and CC N
less RBR N
expensive JJ N
than IN N
standard JJ i
endoscopy NN i
( ( i
SE NNP i
) ) i
for IN N
detecting VBG N
Barrett NNP p
's POS p
esophagus NN p
( ( p
BE NNP p
) ) p
. . p

Emerging VBG N
technologies NNS N
require VBP N
robust JJ N
evaluation NN N
before IN N
routine JJ N
use NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
acceptability NN o
of IN N
TNE NNP i
in IN N
diagnosing VBG N
BE NNP N
compared VBN N
with IN N
those DT N
of IN N
SE NNP i
. . i

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
crossover NN N
study NN N
. . N

SETTING NNP N
Single NNP N
, , N
tertiary-care JJ N
referral JJ N
center NN N
. . N

PATIENTS VB N
This DT N
study NN N
enrolled VBD N
consecutive JJ p
patients NNS p
with IN p
BE NNP p
or CC p
those DT p
referred VBN p
for IN p
diagnostic JJ p
assessment NN p
. . p

INTERVENTION NNP N
All NNP N
patients NNS N
underwent JJ N
TNE NNP i
followed VBN N
by IN N
SE NNP i
or CC N
the DT N
reverse NN N
. . N

Spielberger NNP o
State-Trait JJ o
Anxiety NNP o
Inventory NNP o
short-form JJ o
questionnaires NNS o
, , o
a DT o
visual JJ o
analogue NN o
scale NN o
, , N
and CC N
a DT N
single JJ o
question NN o
addressing VBG o
preference NN o
for IN o
endoscopy NN o
type NN o
were VBD N
administered VBN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASUREMENTS NNP N
Diagnostic NNP o
accuracy NN o
and CC o
tolerability NN o
of IN N
TNE NNP i
were VBD N
compared VBN N
with IN N
those DT N
of IN N
SE NNP i
. . i

RESULTS NNP N
Of IN N
95 CD p
patients NNS p
randomized VBN p
, , p
82 CD p
completed VBD p
the DT p
study NN p
. . p

We PRP N
correctly RB N
diagnosed VBD N
48 CD N
of IN N
49 CD N
BE NNP N
cases NNS N
by IN N
TNE NNP i
for IN N
endoscopic JJ N
findings NNS N
of IN N
columnar NN N
lined VBN N
esophagus NNS N
compared VBN N
with IN N
the DT N
criterion NN N
standard NN N
, , N
SE NNP i
, , N
giving VBG N
a DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
0.98 CD N
and CC N
1.00 CD N
, , N
respectively RB N
. . N

The DT N
BE NNP o
median JJ o
length NN o
was VBD N
3 CD N
cm NN N
( ( N
interquartile JJ N
range NN N
[ NNP N
IQR NNP N
] NNP N
1-5 JJ N
cm NN N
) ) N
with IN N
SE NNP N
and CC N
3 CD N
cm NN N
( ( N
IQR NNP N
2-4 CD N
cm NN N
) ) N
with IN N
TNE NNP i
, , N
giving VBG N
high JJ N
correlations NNS N
between IN N
the DT N
two CD N
modalities NNS N
( ( N
R NNP N
( ( N
2 CD N
) ) N
= NN N
0.97 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
sensitivity NN o
and CC o
specificity NN o
for IN N
detecting VBG N
intestinal JJ N
metaplasia NN N
by IN N
TNE NNP N
compared VBN N
with IN N
those DT N
by IN N
SE NNP N
was VBD N
0.91 CD N
and CC N
1.00 CD N
, , N
respectively RB N
. . N

The DT N
mean NN N
( ( N
? . N
standard JJ N
deviation NN o
) ) o
post-endoscopy NN o
Spielberger NNP o
State-Trait NNP o
Anxiety NNP o
Inventory NNP o
short-form JJ o
score NN o
for IN i
TNE NNP i
( ( N
30.0 CD N
? . N
1.10 CD N
standard JJ N
error NN N
of IN N
the DT N
mean JJ N
[ NNP N
SEM NNP N
] NNP N
) ) N
was VBD N
lower JJR N
than IN N
that DT N
for IN i
SE NNP i
( ( i
30.7 CD N
? . N
1.29 CD N
SEM NNP N
) ) N
, , N
( ( N
P NNP N
= NNP N
.054 NNP N
) ) N
. . N

The DT N
visual JJ o
analogue NN o
scale NN o
scores NNS o
were VBD o
no DT N
different JJ N
( ( N
P NNP N
= NNP N
.07 NNP N
) ) N
. . N

The DT N
majority NN N
of IN N
patients NNS N
( ( N
59 CD N
% NN N
) ) N
expressed VBD N
a DT N
preference NN N
for IN N
TNE NNP i
. . i

LIMITATIONS NNP i
This DT N
is VBZ N
a DT N
small JJ N
study NN N
, , N
with IN N
limited JJ N
generalizability NN N
, , N
a DT N
high JJ N
prevalence NN N
of IN N
patients NNS p
with IN p
BE NNP p
, , N
differential JJ N
drop-out NN N
between IN N
the DT N
two CD N
procedures NNS N
, , N
and CC N
use NN N
of IN N
sedation NN N
. . N

CONCLUSION NNP N
TNE NNP N
is VBZ N
an DT N
accurate JJ N
and CC N
well-tolerated JJ N
method NN N
for IN N
diagnosing VBG N
BE NNP N
compared VBN N
with IN i
SE NNP i
. . i

TNE NNP i
warrants NNS i
further JJ N
evaluation NN N
as IN N
a DT N
screening NN N
tool NN N
for IN N
BE NNP N
. . N

-DOCSTART- -11295009- O O

Interferential JJ i
therapy NN i
electrode NN i
placement NN i
technique NN i
in IN N
acute NN p
low JJ p
back RB p
pain NN p
: : p
a DT N
preliminary JJ N
investigation NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
interferential JJ i
therapy NN i
( ( i
IFT NNP i
) ) i
electrode VBP i
placement NN i
technique NN i
compared VBN N
with IN N
a DT N
control NN i
treatment NN i
in IN N
subjects NNS p
with IN p
acute NN p
low JJ p
back RB p
pain NN p
( ( p
LBP NNP p
) ) p
. . p

DESIGN NNP N
Single-blind NNP N
, , N
randomized VBD N
, , N
controlled VBD N
trial NN N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

SETTING NN N
Outpatient NNP p
physiotherapy NN p
departments NNS p
in IN p
hospital NN p
and CC p
university NN p
settings NNS p
. . p

PATIENTS VB N
A DT N
random JJ N
sample NN N
of IN N
60 CD p
eligible JJ p
patients NNS p
with IN p
back JJ p
pain NN p
( ( p
28 CD p
men NNS p
, , p
32 CD p
women NNS p
) ) p
were VBD p
recruited VBN p
by IN p
general JJ p
practitioners NNS p
and CC p
self-referral JJ p
for IN N
physiotherapy NN N
treatment NN N
and CC N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

INTERVENTIONS NNP N
( ( N
1 CD N
) ) N
IFT NNP i
painful JJ i
area NN i
and CC i
The DT i
Back NNP i
Book NNP i
, , N
( ( N
2 CD N
) ) N
IFT NNP i
spinal JJ i
nerve NN i
and CC i
The DT i
Back NNP i
Book NNP i
, , N
and CC N
( ( N
3 CD N
) ) N
Control NN i
, , i
The DT i
Back NNP i
Book NNP i
only RB N
. . N

Standardized VBN N
IFT NNP i
stimulation NN N
parameters NNS N
were VBD N
used VBN N
: : N
carrier NN N
frequency NN N
3.85 CD N
kHz NN N
; : N
140 CD N
Hz NNP N
constant NN N
; : N
pulse JJ N
duration NN N
130 CD N
micros NN N
; : N
30 CD N
minutes NNS N
' POS N
duration NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Pain NNP o
Rating NNP o
Index NNP o
, , o
Roland-Morris NNP o
Disability NNP o
Questionnaire NNP o
( ( o
RMDQ NNP o
) ) o
, , o
and CC o
EuroQol NNP o
were VBD N
completed VBN N
by IN N
subjects NNS N
pretreatment JJ N
, , N
at IN N
discharge NN N
, , N
and CC N
3-month JJ N
follow-up NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
had VBD N
significant JJ N
improvements NNS N
in IN N
all DT N
outcomes NNS N
at IN N
follow-up NN N
. . N

Subjects NNS N
managed VBN N
by IN N
IFT NNP N
spinal JJ N
nerve NN N
and CC N
The DT N
Back NNP N
Book NNP N
displayed VBD N
both DT N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
.030 NNP N
) ) N
and CC N
clinically RB N
meaningful JJ N
reduction NN o
in IN o
functional JJ o
disability NN o
( ( o
RMDQ NNP o
) ) o
, , N
compared VBN N
with IN N
management NN N
via IN N
IFT NNP N
painful JJ N
area NN N
and CC N
The DT N
Back NNP N
Book NNP N
combined VBD N
or CC N
The DT N
Back JJ N
Book NNP N
alone RB N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
showed VBD N
that IN N
IFT NNP i
electrode FW i
placement NN i
technique NN i
affects VBZ N
LBP-specific JJ N
functional JJ N
disability NN N
, , N
providing VBG N
preliminary JJ N
implications NNS N
for IN N
future JJ N
clinical JJ N
studies NNS N
. . N

-DOCSTART- -8636370- O O

The DT N
individual JJ N
responsiveness NN N
to TO N
growth NN i
hormone NN i
( ( i
GH NNP i
) ) i
treatment NN i
in IN N
GH-deficient NNP p
adults NNS p
is VBZ N
dependent JJ N
on IN N
the DT N
level NN N
of IN N
GH-binding NNP N
protein NN N
, , N
body NN o
mass NN o
index NN o
, , N
age NN N
, , N
and CC N
gender NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
study VB N
the DT N
individual JJ N
responsiveness NN N
to TO N
GH NNP i
treatment NN i
in IN N
terms NNS N
of IN N
body NN N
composition NN N
and CC N
to TO N
search VB N
for IN N
possible JJ N
predictors NNS N
of IN N
the DT N
response NN N
in IN N
GH-deficient NNP N
adults NNS N
. . N

Sixty-eight JJ p
patients NNS p
( ( p
44 CD p
men NNS p
and CC p
24 CD p
women NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
44.3 CD p
( ( p
1.2 CD p
) ) p
yr NN p
and CC p
verified VBD p
GH NNP p
deficiency NN p
participated VBD p
in IN p
a DT p
2-phase JJ p
treatment NN p
trial NN p
with IN N
an DT N
initial JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
, , N
6-month JJ N
period NN N
, , N
followed VBN N
by IN N
an DT N
open JJ N
treatment NN N
period NN N
, , N
thereby RB N
ensuring VBG N
all DT N
patients NNS p
12 CD p
months NNS p
of IN p
GH NNP p
treatment NN p
. . p

Recombinant JJ i
human JJ i
GH NNP i
was VBD N
administered VBN N
sc JJ N
daily RB N
at IN N
bedtime NN N
, , N
with IN N
a DT N
target NN N
dose NN N
of IN N
12 CD N
micrograms/kg NNS N
x JJ N
day NN N
. . N

GHBP NNP N
was VBD N
measured VBN N
by IN N
ligand-mediated JJ N
immunofunctional JJ N
assay NN N
, , N
and CC N
serum JJ N
insulin-like JJ N
growth NN N
factor NN N
I PRP N
( ( N
IGF-I NNP N
) ) N
was VBD N
determined VBN N
by IN N
RIA NNP N
after IN N
acid-ethanol JJ N
extraction NN N
, , N
using VBG N
a DT N
truncated JJ N
IGF-I JJ N
analog NN N
as IN N
the DT N
radioligand NN N
. . N

Lean JJ o
body NN o
mass NN o
( ( o
LBM NNP o
) ) o
and CC o
body NN o
fat NN o
( ( o
BF NNP o
) ) o
were VBD N
determined VBN N
by IN N
dual JJ N
energy NN N
x-ray JJ N
absorptiometry NN N
, , N
and CC N
total JJ N
body NN N
water NN N
( ( N
TBW NNP N
) ) N
was VBD N
determined VBN N
by IN N
bioelectrical JJ N
impedance NN N
. . N

During IN N
the DT N
placebo NN N
control NN N
period NN N
, , N
serum JJ o
IGF-I NNP o
, , o
LBM NNP o
, , o
and CC o
TBW NNP o
increased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
BF NNP o
decreased VBD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
serum JJ o
GHBP NNP o
was VBD N
unchanged JJ N
in IN N
the DT N
group NN N
treated VBD N
with IN N
GH NNP N
compared VBN N
with IN N
the DT N
patients NNS N
treated VBN N
with IN N
placebo NN N
. . N

After IN N
12 CD N
months NNS N
of IN N
GH NNP N
treatment NN N
, , N
the DT N
individual JJ N
changes NNS N
in IN N
BF NNP o
ranged VBD N
from IN N
-12.5 NN N
to TO N
4.3 CD N
kg NNS N
and CC N
from IN N
-4.5 NNP N
to TO N
10.1 CD N
kg NNS N
in IN N
LBM NNP N
. . N

Age NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
baseline JJ o
GHBP NNP o
level NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
increase NN N
in IN N
LBM NNP N
. . N

The DT N
GH-induced JJ o
increment NN o
in IN o
IGF-I NNP o
and CC o
TBW NNP o
was VBD N
greater JJR N
in IN N
men NNS N
than IN N
in IN N
women NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas IN N
the DT N
decreases NNS N
in IN N
BF NNP o
were VBD N
similar JJ N
in IN N
men NNS N
and CC N
women NNS N
. . N

This DT N
trial NN N
demonstrates VBZ N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
GH NNP i
administration NN N
in IN N
GH-deficient NNP N
adults NNS N
. . N

The DT N
best JJS N
response NN N
to TO N
GH NNP N
was VBD N
obtained VBN N
in IN N
younger JJR N
patients NNS N
with IN N
low JJ N
GHBP NNP N
levels NNS N
. . N

Furthermore RB N
, , N
men NNS N
responded VBD N
better RBR N
than IN N
women NNS N
. . N

-DOCSTART- -14622630- O O

Measuring VBG N
adherence NN N
in IN N
a DT N
hypertension NN p
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Non-adherence NNP N
in IN N
hypertension NN N
is VBZ N
a DT N
global JJ N
problem NN N
and CC N
promoting VBG N
adherence NN N
is VBZ N
necessary JJ N
to TO N
decrease VB N
cardiovascular JJ N
mortality NN N
. . N

AIMS IN N
The DT N
purpose NN N
of IN N
this DT N
paper NN N
is VBZ N
to TO N
examine VB N
the DT N
measurement NN N
of IN N
adherence NN o
to TO N
medication NN i
taking VBG N
in IN N
hypertensive JJ p
patients NNS p
. . p

Adherence NNP N
was VBD N
evaluated VBN N
primarily RB N
by IN N
means NNS N
of IN N
MEMS NNP o
( ( o
Medication NNP o
Event NNP o
Monitoring NNP o
System NNP o
, , N
Aprex NNP N
Corporation NNP N
, , N
Fremont NNP N
, , N
California NNP N
) ) N
an DT N
electronic JJ N
system NN N
that WDT N
records VBZ N
the DT N
date NN N
and CC N
time NN N
of IN N
opening NN N
of IN N
the DT N
study NN N
medication NN N
container NN N
. . N

Additional JJ N
measurements NNS N
such JJ N
as IN N
change NN N
in IN N
urinary JJ o
potassium NN o
level NN o
, , o
capsule NN o
count NN o
, , o
client NN o
self PRP o
report NN o
and CC o
physician JJ o
estimate NN o
of IN o
adherence NN o
were VBD N
recorded VBN N
. . N

METHODS VB N
A DT N
randomised JJ N
clinical JJ N
trial NN N
was VBD N
used VBN N
to TO N
assign VB N
patients NNS p
to TO N
receive VB N
the DT N
study NN i
medication NN i
( ( i
potassium NN i
) ) i
or CC i
placebo NN i
. . i

Descriptive JJ N
statistics NNS N
were VBD N
used VBN N
to TO N
answer VB N
the DT N
research NN N
questions NNS N
. . N

Frequency NNP N
and CC N
percentage NN N
of IN N
responses NNS N
to TO N
different JJ N
measures NNS N
of IN N
adherence NN N
were VBD N
carried VBN N
out RP N
as RB N
well RB N
as IN N
correlation NN N
between IN N
the DT N
measures NNS N
. . N

RESULTS NNP N
One CD p
hundred CD p
and CC p
seven CD p
subjects NNS p
between IN p
the DT p
ages NNS p
of IN p
26 CD p
and CC p
80 CD p
participated VBN p
in IN p
the DT N
clinical JJ N
trial NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
adherence NN o
measures NNS o
varied VBN N
with IN N
lowest JJS N
adherence NN o
from IN N
two CD N
items NNS N
of IN N
self-report NN o
related VBN o
to TO o
forgetfulness VB o
( ( N
46 CD N
and CC N
55 CD N
% NN N
) ) N
and CC N
stringent JJ N
electronic JJ o
monitoring NN o
with IN o
the DT o
MEMS NNP o
( ( N
58 CD N
% NN N
) ) N
to TO N
percentages NNS N
in IN N
the DT N
80-90 JJ N
range NN N
for IN N
other JJ N
self-report JJ o
items NNS o
and CC N
the DT N
general JJ o
adherence NN o
scale NN o
. . o

Electronic JJ N
monitoring NN N
correlated VBD N
best JJS N
with IN N
capsule NN o
count NN o
at IN N
visit NN N
5 CD N
. . N

Implications NNS N
for IN N
health NN N
care NN N
providers NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -18362489- O O

Effect NN N
of IN N
finasteride JJ i
treatment NN N
on IN N
suburethral JJ N
prostatic JJ N
microvessel NN N
density NN N
in IN N
patients NNS p
with IN p
hematuria NNS p
related VBN p
to TO p
benign VB p
prostate JJ p
hyperplasia NN p
. . p

INTRODUCTION NNP N
In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
short-term JJ N
finasteride JJ i
treatment NN N
on IN N
microvessel NN N
density NN N
( ( N
MVD NNP N
) ) N
which WDT N
is VBZ N
an DT N
indicator NN N
of IN N
prostatic JJ N
angiogenesis NN N
in IN N
patients NNS p
with IN p
hematuria NNS p
secondary JJ p
to TO p
benign VB p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
. . p

MATERIALS NNP N
AND NNP N
METHODS NNP N
30 CD p
patients NNS p
who WP p
were VBD p
candidates NNS p
for IN p
BPH NNP p
surgery NN p
were VBD N
prospectively RB N
included VBN N
in IN N
the DT N
study NN N
. . N

All DT p
patients NNS p
had VBD p
history NN p
of IN p
gross JJ p
hematuria NN p
and CC p
evaluated VBN p
by IN p
ultrasonography NN p
and CC p
cystoscopy NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
two CD N
groups NNS N
before IN N
surgery NN N
. . N

The DT N
treatment NN N
group NN N
consisted VBD N
of IN N
13 CD N
patients NNS N
who WP N
were VBD N
given VBN N
5 CD i
mg JJ i
finasteride JJ i
daily NN i
for IN N
4 CD N
weeks NNS N
before RB N
surgery NN N
. . N

The DT N
control NN N
group NN N
consisted VBD N
of IN N
17 CD N
patients NNS N
who WP N
did VBD i
not RB i
receive VB i
finasteride NN i
before IN N
surgery NN N
. . N

During IN N
surgery NN N
, , N
resected VBN N
suburethral JJ N
and CC N
hyperplastic JJ N
prostate NN N
specimens NNS N
were VBD N
sent VBN N
for IN N
histopathologic JJ N
MVD NNP N
determination NN N
separately RB N
. . N

RESULTS NNP N
Mean NNP o
MVD NNP o
in IN o
the DT o
suburethral JJ o
portion NN o
of IN o
prostate NN o
was VBD o
significantly RB o
lower JJR o
in IN N
patients NNS N
treated VBN N
with IN N
finasteride NN N
when WRB N
compared VBN N
with IN N
controls NNS N
( ( N
9.08 CD N
+/- JJ N
5.6 CD N
and CC N
13.94 CD N
+/- JJ N
5.90 CD N
, , N
respectively RB N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Mean NNP o
MVD NNP o
for IN o
the DT o
hyperplastic JJ o
portion NN o
of IN o
prostate NN o
was VBD N
similar JJ N
for IN N
the DT N
finasteride NN N
and CC N
control NN N
groups NNS N
( ( N
14.21 CD N
+/- JJ N
7.10 CD N
and CC N
19.75 CD N
+/- JJ N
9.73 CD N
, , N
respectively RB N
, , N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
potential JJ N
role NN N
of IN N
finasteride NN N
on IN N
hematuria NNS N
related VBN N
to TO N
BPH NNP N
may MD N
be VB N
the DT N
suppressive JJ N
effect NN N
on IN N
MVD NNP o
in IN N
the DT N
suburethral JJ N
tissue NN N
of IN N
prostate NN N
. . N

-DOCSTART- -19470793- O O

Noninvasive JJ N
detection NN N
of IN N
candidate NN N
molecular JJ N
biomarkers NNS N
in IN p
subjects NNS p
with IN p
a DT p
history NN p
of IN p
insulin NN p
resistance NN p
and CC p
colorectal JJ p
adenomas NN p
. . p

We PRP N
have VBP N
developed VBN N
novel JJ i
molecular JJ i
methods NNS i
using VBG N
a DT N
stool NN N
sample NN N
, , N
which WDT N
contains VBZ N
intact JJ N
sloughed VBN N
colon NN N
cells NNS N
, , N
to TO N
quantify VB N
colonic JJ N
gene NN N
expression NN N
profiles NNS N
. . N

In IN N
this DT N
study NN N
, , N
our PRP$ N
goal NN N
was VBD N
to TO N
identify VB N
diagnostic JJ N
gene NN N
sets NNS N
( ( N
combinations NNS N
) ) N
for IN N
the DT N
noninvasive JJ N
classification NN N
of IN N
different JJ N
phenotypes NNS N
. . N

For IN N
this DT N
purpose NN N
, , N
the DT N
effects NNS N
of IN N
a DT N
legume-enriched JJ i
, , i
low JJ i
glycemic JJ i
index NN i
, , i
high JJ i
fermentable JJ i
fiber NN i
diet NN i
was VBD N
evaluated VBN N
in IN N
subjects NNS p
with IN p
four CD p
possible JJ p
combinations NNS p
of IN p
risk NN p
factors NNS p
, , p
including VBG p
insulin NN p
resistance NN p
and CC p
a DT p
history NN p
of IN p
adenomatous JJ p
polyps NNS p
. . p

In IN N
a DT N
randomized JJ N
crossover NN N
design NN N
controlled VBD N
feeding NN N
study NN N
, , N
each DT N
participant NN N
( ( N
a DT N
total NN p
of IN p
23 CD p
; : p
5-12 JJ N
per IN N
group NN N
) ) N
consumed VBD N
the DT N
experimental JJ i
diet NN i
( ( i
1.5 CD i
cups NNS i
of IN i
cooked JJ i
dry JJ i
beans NNS i
) ) i
and CC i
a DT i
control NN i
diet NN i
( ( i
isocaloric JJ i
average JJ i
American JJ i
diet NN i
) ) i
for IN i
4 CD i
weeks NNS i
with IN i
a DT i
3-week JJ i
washout NN i
period NN i
between IN i
diets NNS i
. . i

Using VBG N
prior JJ N
biological JJ N
knowledge NN N
, , N
the DT N
complexity NN N
of IN N
feature NN N
selection NN N
was VBD N
reduced VBN N
to TO N
perform VB N
an DT N
exhaustive JJ N
search NN N
on IN N
all DT N
allowable JJ N
feature NN N
( ( N
gene NN N
) ) N
sets NNS N
of IN N
size NN N
3 CD N
, , N
and CC N
among IN N
these DT N
, , N
27 CD N
had VBD N
( ( N
unbiased JJ N
) ) N
error NN N
estimates NNS N
of IN N
0.15 CD N
or CC N
less JJR N
. . N

Linear JJ N
discriminant JJ N
analysis NN N
was VBD N
successfully RB N
used VBN N
to TO N
identify VB N
the DT N
best JJS o
single JJ o
genes NNS o
and CC o
two- JJ o
to TO o
three-gene JJ o
combinations NNS o
for IN o
distinguishing VBG o
subjects NNS o
with IN o
insulin NN o
resistance NN o
, , p
a DT p
history NN p
of IN p
polyps NNS p
, , p
or CC p
exposure NN p
to TO p
a DT p
chemoprotective JJ p
legume-rich JJ p
diet NN p
. . p

These DT N
results NNS N
support VBD N
our PRP$ N
premise NN N
that IN N
gene NN N
products NNS N
( ( N
RNA NNP N
) ) N
isolated VBD N
from IN N
stool NN N
have VBP N
diagnostic JJ N
value NN N
in IN N
terms NNS N
of IN N
assessing VBG N
colon NN N
cancer NN N
risk NN N
. . N

-DOCSTART- -18026891- O O

Comparison NNP N
of IN N
long-term JJ o
efficacy NN o
and CC o
safety NN o
of IN N
risperidone NN i
and CC i
haloperidol NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
. . p

An DT N
open JJ N
label NN N
maintenance NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
safety NN o
, , o
efficacy NN o
and CC o
tolerability NN o
of IN N
risperidone NN i
in IN N
comparison NN N
with IN N
haloperidol NN i
in IN N
the DT N
long-term JJ N
treatment NN N
of IN N
autistic JJ p
disorder NN p
. . p

METHODS NNP N
This DT N
was VBD N
an DT N
open-label JJ N
continuation NN N
study NN N
of IN N
the DT N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBD N
trial NN N
of IN N
risperidone NN i
and CC i
haloperidol NN i
study NN N
for IN N
12 CD N
week NN N
in IN p
autistic JJ p
children NNS p
and CC p
adolescents NNS p
. . p

A DT p
total NN p
of IN p
28 CD p
subjects NNS p
between IN p
8 CD p
and CC p
18 CD p
ages NNS p
with IN p
autistic JJ p
disorder NN p
were VBD N
enrolled VBN N
to TO N
the DT N
open JJ N
label NN N
phase NN N
of IN N
the DT N
study NN N
. . N

Behavioral NNP o
rating NN o
scales NNS o
( ( o
Clinical JJ o
Global NNP o
Impression NNP o
Scale NNP o
[ NNP o
CGI-I NNP o
] NNP o
, , o
Ritvo-Freeman NNP o
Real NNP o
Life NNP o
Rating NNP o
Scale NNP o
[ NNP o
RF-RLRS NNP o
] NNP o
) ) o
, , o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
[ NNP o
ABC NNP o
] NNP o
, , o
Turgay NNP o
DSM-IV NNP o
Pervasive NNP o
Developmental NNP o
Disorder NNP o
Rating NNP o
Scale NNP o
[ NNP o
TPDDRS NNP o
] NNP o
) ) o
and CC o
safety NN o
assessment NN o
scales NNS o
( ( o
Extrapyramidal NNP o
Symptoms NNP o
Rating NNP o
Scale NNP o
[ NNP o
ESRS NNP o
] NNP o
, , o
UKU-Side JJ o
Effect NNP o
Rating NNP o
Scale NNP o
) ) o
were VBD N
performed VBN N
at IN N
12 CD N
, , N
16 CD N
, , N
20 CD N
and CC N
24 CD N
weeks NNS N
, , N
following VBG N
the DT N
12 CD N
week NN N
double-blind JJ N
phase NN N
. . N

Risperidone NN i
and CC i
haloperidol NN i
treatments NNS N
were VBD N
applied VBN N
with IN N
a DT N
once RB N
daily JJ N
dosage NN N
regimen NNS N
as IN N
0.01-0.08 JJ N
mg/kg/day NN N
. . N

RESULTS NNP N
Risperidone NNP N
led VBD N
to TO N
a DT N
significant JJ N
greater JJR N
reduction NN o
on IN N
CGI NNP o
scale NN o
. . o

There EX N
was VBD N
significant JJ N
improvement NN N
on IN N
RF-RLRS NNP o
sensory JJ o
motor NN o
and CC o
language NN o
subscale NN o
and CC o
ABC NNP o
scores NNS o
in IN N
risperidone NN N
group NN N
. . N

Weight NNP o
gain NN o
was VBD N
observed VBN N
more RBR N
frequently RB N
in IN N
the DT N
haloperidol NN N
group NN N
at IN N
week NN N
24 CD N
. . N

CONCLUSIONS VB N
These DT N
results NNS N
demonstrate VBP N
that IN N
risperidone NN N
is VBZ N
more RBR N
efficacious JJ N
and CC N
well RB N
tolerated VBN N
than IN N
haloperidol NN N
in IN N
the DT N
long-term JJ N
maintenance NN N
treatment NN N
of IN N
autistic JJ N
disorder NN N
. . N

-DOCSTART- -10969304- O O

Physostigmine JJ i
reverses VBZ N
propofol-induced JJ N
unconsciousness NN N
and CC N
attenuation NN N
of IN N
the DT N
auditory NN N
steady JJ N
state NN N
response NN N
and CC N
bispectral JJ N
index NN N
in IN N
human JJ p
volunteers NNS p
. . p

BACKGROUND IN N
It PRP N
is VBZ N
postulated VBN N
that IN N
alteration NN N
of IN N
central JJ N
cholinergic JJ N
transmission NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT N
anesthetics NNS N
produce VBP N
unconsciousness JJ N
. . N

The DT N
authors NNS N
investigated VBD N
the DT N
effect NN N
of IN N
altering VBG N
central JJ N
cholinergic JJ N
transmission NN N
, , N
by IN N
physostigmine NN i
and CC N
scopolamine NN i
, , N
on IN N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
. . N

METHODS NNP N
Propofol NNP i
was VBD N
administered VBN N
to TO N
American NNP p
Society NNP p
of IN p
Anesthesiologists NNP p
physical JJ p
status NN p
1 CD p
( ( p
n JJ p
= NNP p
17 CD p
) ) p
volunteers NNS p
with IN N
use NN N
of IN N
a DT N
computer-controlled JJ N
infusion NN N
pump NN N
at IN N
increasing VBG N
concentrations NNS N
until IN N
unconsciousness JJ N
resulted VBD N
( ( N
inability NN N
to TO N
respond VB N
to TO N
verbal VB N
commands NNS N
, , N
abolition NN N
of IN N
spontaneous JJ N
movement NN N
) ) N
. . N

Central NNP o
nervous JJ o
system NN o
function NN o
was VBD N
assessed VBN N
by IN N
use NN N
of IN N
the DT N
Auditory NNP o
Steady NNP o
State NNP o
Response NNP o
( ( o
ASSR NNP o
) ) o
and CC o
Bispectral NNP o
Index NNP o
( ( o
BIS NNP o
) ) o
analysis NN o
of IN o
electrooculogram NN o
. . o

During IN N
continuous JJ N
administration NN N
of IN N
propofol NN N
, , N
reversal NN o
of IN o
unconsciousness NN o
produced VBN N
by IN N
physostigmine NN i
( ( N
28 CD N
microgram/kg NN N
) ) N
and CC N
block NN o
of IN o
this DT o
reversal NN o
by IN N
scopolamine NN i
( ( N
8.6 CD N
microgram/kg NN N
) ) N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Propofol NNP N
produced VBD N
unconsciousness JJ o
at IN N
a DT N
plasma JJ o
concentration NN o
of IN N
3.2 CD N
+/- JJ N
0.8 CD N
( ( N
+/- JJ N
SD NNP N
) ) N
microgram/ml NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
. . N

Unconsciousness NN o
was VBD N
associated VBN N
with IN N
reductions NNS o
in IN N
ASSR NNP o
( ( N
0.10 CD N
+/- JJ N
0.08 CD N
microV NN N
[ NNP N
awake VBP N
baseline JJ N
0.32 CD N
+/- JJ N
0.18 CD N
microV NN N
] NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
BIS NNP o
( ( N
55.7 CD N
+/- JJ N
8.8 CD N
[ JJ N
awake NN N
baseline NN N
92.4 CD N
+/- JJ N
3.9 CD N
] NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Physostigmine NNP N
restored VBD o
consciousness NN o
in IN N
9 CD N
of IN N
11 CD N
subjects NNS N
, , N
with IN N
concomitant JJ N
increases NNS o
in IN N
ASSR NNP o
( ( N
0.38 CD N
+/- JJ N
0.17 CD N
microV NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
BIS NNP o
( ( N
75.3 CD N
+/- JJ N
8.3 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
all DT N
subjects NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
scopolamine NN N
blocked VBD N
the DT N
physostigmine-induced JJ o
reversal NN o
of IN o
unconsciousness NN o
and CC N
the DT N
increase NN o
of IN o
the DT o
ASSR NNP o
and CC o
BIS NNP o
( ( o
ASSR NNP o
and CC o
BIS NNP o
during IN N
propofol-induced JJ N
unconsciousness NN N
: : N
0.09 CD N
+/- JJ N
0.09 CD N
microV NN N
and CC N
58.2 CD N
+/- JJ N
7.5 CD N
, , N
respectively RB N
; : N
ASSR NNP o
and CC o
BIS NNP o
after IN N
physostigmine JJ N
administration NN N
: : N
0.08 CD N
+/- JJ N
0.06 CD N
microV NN N
and CC N
56.8 CD N
+/- JJ N
6.7 CD N
, , N
respectively RB N
, , N
NS NNP N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
is VBZ N
mediated VBN N
at IN N
least JJS N
in IN N
part NN N
via IN N
interruption NN N
of IN N
central JJ N
cholinergic NN N
muscarinic JJ N
transmission NN N
. . N

-DOCSTART- -25670541- O O

Hyperfractionated VBN i
accelerated JJ i
radiation NN i
therapy NN i
( ( i
HART NNP i
) ) i
of IN N
70.6 CD N
Gy NNP N
with IN N
concurrent JJ N
5-FU/Mitomycin JJ i
C NNP i
is VBZ N
superior JJ N
to TO N
HART NNP i
of IN N
77.6 CD N
Gy NNP N
alone RB N
in IN N
locally RB p
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
: : p
long-term JJ N
results NNS N
of IN N
the DT N
ARO NNP N
95-06 CD N
randomized JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
To TO N
report VB N
the DT N
long-term JJ N
results NNS N
of IN N
the DT N
ARO NNP N
95-06 CD N
randomized JJ N
trial NN N
comparing NN N
hyperfractionated VBD N
accelerated JJ N
chemoradiation NN N
with IN N
mitomycin JJ i
C/5-fluorouracil NNP i
( ( i
C-HART NNP i
) ) i
with IN N
hyperfractionated VBN i
accelerated JJ i
radiation NN i
therapy NN i
( ( i
HART NNP i
) ) i
alone RB i
in IN N
locally RB p
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT N
primary JJ N
endpoint NN N
was VBD N
locoregional JJ N
control NN N
( ( N
LRC NNP N
) ) N
. . N

Three CD p
hundred VBD p
eighty-four JJ p
patients NNS p
with IN p
stage NN p
III NNP p
( ( p
6 CD p
% NN p
) ) p
and CC p
IV NNP p
( ( p
94 CD p
% NN p
) ) p
oropharyngeal NN p
( ( p
59.4 CD p
% NN p
) ) p
, , p
hypopharyngeal NN p
( ( p
32.3 CD p
% NN p
) ) p
, , p
and CC p
oral JJ p
cavity NN p
( ( p
8.3 CD p
% NN p
) ) p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
30 CD i
Gy/2 NNP i
Gy NNP i
daily RB i
followed VBN i
by IN i
twice-daily JJ i
1.4 CD i
Gy NNP i
to TO i
a DT i
total NN i
of IN i
70.6 CD i
Gy NNP i
concurrently RB i
with IN i
mitomycin JJ i
C/5-FU NNP i
( ( i
C-HART NNP i
) ) i
or CC i
16 CD i
Gy/2 NNP i
Gy NNP i
daily RB i
followed VBN i
by IN i
twice-daily JJ i
1.4 CD i
Gy NNP i
to TO i
a DT i
total JJ i
dose NN i
of IN i
77.6 CD i
Gy NNP i
alone RB i
( ( i
HART NNP i
) ) i
. . i

Statistical JJ N
analyses NNS N
were VBD N
done VBN N
with IN N
the DT N
log-rank JJ N
test NN N
and CC N
univariate NN N
and CC N
multivariate NN N
Cox NNP N
regression NN N
analyses NNS N
. . N

RESULTS VB N
The DT o
median JJ o
follow-up JJ o
time NN o
was VBD o
8.7 CD N
years NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
7.8-9.7 JJ N
years NNS N
) ) N
. . N

At IN N
10 CD N
years NNS N
, , N
the DT o
LRC NNP o
rates NNS o
were VBD N
38.0 CD N
% NN N
( ( i
C-HART NNP i
) ) i
versus VBD i
26.0 CD N
% NN i
( ( i
HART NNP i
, , i
P=.002 NNP i
) ) N
. . N

The DT o
cancer-specific JJ o
survival NN o
and CC o
overall JJ o
survival NN o
rates NNS o
were VBD o
39 CD N
% NN N
and CC N
10 CD N
% NN N
( ( i
C-HART NNP i
) ) i
versus VBD i
30.0 CD N
% NN N
and CC N
9 CD N
% NN i
( ( i
HART NNP i
, , i
P=.042 NNP N
and CC N
P=.049 NNP N
) ) N
, , N
respectively RB N
. . N

According VBG N
to TO N
multivariate VB N
Cox NNP N
regression NN N
analysis NN N
, , N
the DT N
combined JJ N
treatment NN N
was VBD N
associated VBN N
with IN o
improved JJ o
LRC NNP o
( ( o
hazard JJ o
ratio NN N
[ NNP N
HR NNP N
] NN N
: : N
0.6 CD N
[ $ N
95 CD N
% NN N
CI NNP N
: : N
0.5-0.8 NN N
; : N
P=.002 NNP N
] NNP N
) ) N
. . N

The DT N
association NN N
between IN N
combined VBN N
treatment NN N
arm NN N
and CC N
increased VBD o
LRC NNP o
appeared VBD o
to TO N
be VB N
limited VBN N
to TO N
oropharyngeal VB N
cancer NN N
( ( N
P=.003 NNP N
) ) N
as IN N
compared VBN N
with IN N
hypopharyngeal NN N
or CC N
oral JJ N
cavity NN N
cancer NN N
( ( N
P=.264 NNP N
) ) N
. . N

CONCLUSIONS NNP N
C-HART NNP i
remains VBZ i
superior JJ N
to TO N
HART NNP i
in IN i
terms NNS N
of IN N
LRC NNP o
. . o

However RB o
, , N
this DT N
effect NN N
may MD N
be VB N
limited VBN N
to TO N
oropharyngeal VB p
cancer NN p
patients NNS p
. . p

-DOCSTART- -24518002- O O

Participant JJ N
characteristics NNS N
and CC N
intervention NN N
processes NNS N
associated VBN N
with IN N
reductions NNS N
in IN N
television NN o
viewing NN o
in IN N
the DT N
High NNP N
Five NNP N
for IN N
Kids NNP p
study NN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
High NNP i
Five NNP i
for IN i
Kids NNP i
intervention NN i
effect NN N
on IN N
television NN o
within IN N
subgroups NNS N
, , N
examine NN N
participant NN N
characteristics NNS N
associated VBN N
with IN N
process NN N
measures NNS N
and CC N
assess NN N
perceived VBD N
helpfulness NN N
of IN N
television NN N
intervention NN N
components NNS N
. . N

METHOD NNP N
High NNP p
Five NNP p
( ( p
randomized VBN p
controlled VBN p
trial NN p
of IN p
445 CD p
overweight/obese JJ p
2-7 JJ p
year-olds NNS p
in IN p
Massachusetts NNP p
[ NNP p
2006-2008 JJ p
] NN p
) ) p
reduced VBD i
television NN i
by IN i
0.36 CD i
h/day NN i
. . i

1-year JJ N
effects NNS N
on IN N
television NN N
viewing NN N
, , N
stratified VBN N
by IN N
subgroup NN N
, , N
were VBD N
assessed VBN N
using VBG N
linear JJ N
regression NN N
. . N

Among IN p
intervention NN p
participants NNS p
( ( p
n=253 NN p
) ) p
, , N
associations NNS N
of IN N
intervention NN i
component NN i
helpfulness NN N
with IN N
television NN o
reduction NN N
were VBD N
examined VBN N
using VBG N
linear JJ N
regression NN N
and CC N
associations NNS N
of IN N
participant JJ N
characteristics NNS N
with IN N
processes NNS N
linked VBN N
to TO N
television NN N
reduction NN N
( ( N
choosing VBG N
television NN N
and CC N
completing VBG N
intervention NN N
visits NNS N
) ) N
were VBD N
examined VBN N
using VBG N
logistic JJ N
regression NN N
. . N

RESULTS NNP N
High NNP N
Five NNP N
reduced VBD N
television NN N
across IN N
subgroups NNS N
. . N

Parents NNS p
of IN p
Latino NNP p
( ( p
versus IN p
white JJ p
) ) p
children NNS p
had VBD N
lower JJR N
odds NNS N
of IN N
completing VBG o
?2 NNP o
study NN o
visits NNS o
( ( o
Odds NNPS N
Ratio NNP N
: : N
0.39 CD N
[ $ N
95 CD N
% NN N
Confidence NN N
Interval NNP N
: : N
0.18 CD N
, , N
0.84 CD p
] NN p
) ) p
. . p

Parents NNS p
of IN p
black JJ p
( ( p
versus IN p
white JJ p
) ) p
children NNS p
had VBD p
higher JJR N
odds NNS N
of IN N
choosing VBG o
television NN o
( ( o
Odds NNP N
Ratio NNP N
: : N
2.23 CD N
[ $ N
95 CD N
% NN N
Confidence NN N
Interval NNP N
: : N
1.08 CD N
, , N
4.59 CD N
] NN N
) ) N
, , N
as IN N
did VBD p
parents NNS p
of IN p
obese JJ p
( ( p
versus JJ p
overweight NN p
) ) p
children NNS p
and CC p
children NNS p
watching VBG p
?2 NN p
h/day NN p
( ( p
versus JJ p
< NNP p
2 CD p
) ) p
at IN p
baseline NN p
. . p

Greater NNP p
perceived VBD o
helpfulness NN o
was VBD o
associated VBN N
with IN N
greater JJR N
television NN N
reduction NN N
. . N

CONCLUSION NNP i
Clinic-based JJ i
motivational JJ i
interviewing NN i
reduces NNS o
television NN o
viewing NN o
in IN o
children NNS i
. . i

Low JJ i
cost NN i
education NN i
approaches NNS i
( ( i
e.g. NN i
, , N
printed JJ N
materials NNS N
) ) N
may MD N
be VB N
well-received JJ N
. . N

Parents NNS p
of IN p
children NNS p
at IN p
higher JJR p
obesity NN p
risk NN p
could MD p
be VB N
more RBR N
motivated JJ N
to TO N
reduce VB o
television NN o
. . o

-DOCSTART- -16124442- O O

Efficacy NN o
and CC N
safety NN o
of IN N
zidovudine NN i
and CC i
zalcitabine NN i
combined VBN N
with IN N
a DT N
combination NN N
of IN N
herbs NN N
in IN N
the DT N
treatment NN N
of IN N
HIV-infected NNP p
Thai NNP p
patients NNS p
. . p

A DT N
randomized JJ N
double JJ N
blind NN N
placebo NN i
controlled VBD N
trial NN N
to TO N
determine VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
combined-herbs JJ N
( ( N
SH NNP N
) ) N
given VBN N
with IN N
zidovudine NN i
( ( N
ZDV NNP N
) ) N
and CC N
zalcitabine NN i
( ( N
ddC NN N
) ) N
for IN N
the DT N
treatment NN N
of IN N
HIV NNP p
infection NN p
in IN p
Thai NNP p
adults NNS p
was VBD p
conducted VBN p
in IN p
3 CD p
hospitals NNS p
in IN p
northern JJ p
Thailand NNP p
during IN p
2002 CD p
to TO p
2003 CD p
. . p

The DT N
eligible JJ N
subjects NNS N
were VBD N
HIV-infected JJ p
Thai NNP p
adults NNS p
who WP p
had VBD p
never RB p
received VBN p
anti-retrovirals NNS i
, , p
had VBD p
a DT p
Karnofski NNP p
Performance NNP p
Score NNP p
( ( p
KPS NNP p
) ) p
of IN p
> NN p
or CC p
= $ p
70 CD p
, , p
and CC p
had VBD p
no DT p
opportunistic JJ p
infections NNS p
. . p

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
combination NN N
of IN N
ZDV NNP i
200 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
ddC VB i
0.75 CD N
mg NN N
three CD N
times NNS N
per IN N
day NN N
, , N
and CC N
SH NNP i
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
or CC N
a DT i
combination NN i
of IN i
ZDV NNP i
200 CD i
mg NN i
three CD i
times NNS i
per IN i
day NN i
, , i
ddC VB i
0.75 CD i
mg NN i
three CD i
times NNS i
per IN i
day NN i
, , i
and CC i
placebo VBZ i
2.5 CD N
g NN N
three CD N
times NNS N
per IN N
day NN N
for IN N
24 CD N
weeks NNS N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
HIV-RNA NNP o
, , o
CD4 NNP o
cells NNS o
, , o
and CC o
blood NN o
chemistry NN o
profiles VBZ o
prior RB N
to TO N
the DT N
treatment NN N
and CC N
then RB N
every DT N
4 CD N
weeks NNS N
for IN N
24 CD N
weeks NNS N
. . N

The DT N
baseline NN N
characteristics NNS N
of IN N
60 CD p
evaluable JJ p
subjects NNS p
, , p
40 CD p
in IN p
the DT p
SH NNP i
group NN p
and CC p
20 CD p
in IN p
the DT p
placebo NN i
group NN p
, , N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

HIV NNP o
RNA NNP o
at IN N
week NN N
4 CD N
and CC N
thereafter RB N
was VBD N
significantly RB N
decreased VBN N
from IN N
the DT N
baseline NN N
value NN N
in IN N
both DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
the DT N
decline NN N
in IN N
HIV NNP o
RNA NNP o
in IN N
the DT N
SH NNP i
group NN N
was VBD N
significantly RB N
more JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
. . N

The DT N
CD4 NNP o
cells NNS o
in IN N
the DT N
SH NNP N
group NN N
at IN N
week NN N
12 CD N
and CC N
thereafter RB N
were VBD N
significantly RB N
increased VBN N
from IN N
the DT N
baseline NN N
value NN N
. . N

Serious JJ o
adverse JJ o
events NNS o
in IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
observed VBN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
an DT N
addition NN N
of IN N
SH NNP N
herbs NNS N
to TO N
two CD N
nucleoside JJ N
reverse NN N
transcriptase NN N
inhibitors NNS N
has VBZ N
greater JJR N
antiviral JJ o
activity NN o
than IN N
antiretrovirals NNS N
only RB N
. . N

The DT N
SH NNP i
herbs NN N
may MD N
be VB N
an DT N
alternative NN N
for IN N
the DT N
third JJ N
anti-retroviral JJ N
agent NN N
in IN N
the DT N
triple JJ N
drug NN N
regimen NNS N
for IN N
the DT N
treatment NN N
of IN N
HIV NNP N
infected VBD N
patients NNS N
in IN N
countries NNS N
with IN N
limited JJ N
resources NNS N
. . N

-DOCSTART- -2107116- O O

Endoscopic NNP i
versus NN i
operative JJ i
gastrostomy NN i
: : i
final JJ N
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

This DT p
study NN p
compared VBN p
operative JJ i
gastrostomy NN i
( ( i
OG NNP i
) ) i
( ( p
by IN p
surgeons NNS p
) ) p
with IN i
endoscopic NN i
gastrostomy NN i
( ( i
PEG NNP i
) ) i
( ( p
by IN p
physicians NNS p
) ) p
in IN N
a DT N
prospective JJ N
randomized VBN N
fashion NN N
to TO N
determine VB N
whether IN N
one CD N
technique NN N
was VBD N
superior JJ N
. . N

PEG NNP i
( ( i
Sachs-Vine NNP i
) ) i
and CC i
OG NNP i
( ( i
Stamm NNP i
) ) i
were VBD N
done VBN N
using VBG N
local JJ i
anesthesia NN i
. . i

Patients NNS p
were VBD p
assessed VBN p
for IN p
complications NNS o
, , o
mortality NN o
, , o
tube NN o
function NN o
, , o
and CC o
cost NN o
. . o

Groups NNP p
were VBD p
equally RB p
matched VBN p
for IN p
indications NNS p
and CC p
underlying JJ p
disease NN p
. . p

Fifty-seven NNP p
had VBD p
OG NNP p
and CC p
64 CD p
had VBD p
attempted VBN p
PEG NNP p
. . p

Complications NNS o
occurred VBD N
in IN N
26 CD N
% NN N
of IN N
OG NNP N
patients NNS N
and CC N
9 CD N
% NN N
died VBD o
. . o

Complications NNS o
occurred VBD N
in IN N
25 CD N
% NN N
of IN N
PEG NNP N
patients NNS N
and CC N
12 CD N
% NN N
died VBD o
. . o

Tube NNP N
feeding NN N
was VBD N
initiated VBN N
in IN N
both DT N
groups NNS N
within IN N
a DT N
mean NN N
of IN N
29 CD N
( ( N
24 CD N
to TO N
72 CD N
) ) N
hours NNS N
of IN N
the DT N
gastrostomy JJ N
placement NN N
. . N

OG NNP o
cost VBD o
$ $ N
1675 CD N
and CC N
PEG NNP N
$ $ N
979 CD N
to TO N
perform VB N
. . N

Twenty-one CD N
PEG NNP i
patients NNS N
required VBD N
endoscopic JJ o
tube NN o
change NN o
which WDT N
raised VBD o
their PRP$ o
total JJ o
cost NN o
to TO N
$ $ N
1574 CD N
. . N

We PRP N
conclude VBP N
there EX N
is VBZ N
no DT N
difference NN N
between IN N
OG NNP N
( ( N
using VBG N
local JJ N
anesthesia NN N
) ) N
and CC N
PEG NNP i
with IN N
regard NN N
to TO N
morbidity NN o
, , o
mortality NN o
, , o
or CC o
tube NN o
function NN o
. . o

The DT N
endoscopic NN N
technique NN N
does VBZ N
appear VB N
to TO N
have VB N
economic JJ o
advantage NN o
. . o

-DOCSTART- -25119339- O O

Effects NNS N
of IN N
iron NN i
supplements NNS i
and CC N
perinatal JJ N
factors NNS N
on IN N
fetal JJ N
hemoglobin NN N
disappearance NN N
in IN N
LBW NNP p
infants NNS p
. . p

BACKGROUND IN N
The DT N
homeostatic JJ N
mechanisms NN N
of IN N
iron NN N
metabolism NN N
and CC N
erythropoiesis NN N
in IN N
infants NNS N
are VBP N
unclear JJ N
. . N

Infants NNS N
synthesize VB N
both DT N
fetal JJ N
hemoglobin NN N
( ( N
HbF NNP N
) ) N
and CC N
adult NN N
hemoglobin NN N
( ( N
HbA NNP N
) ) N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
how WRB N
the DT N
hemoglobin NN N
switch NN N
is VBZ N
regulated VBN N
. . N

We PRP N
hypothesized VBD N
that IN N
iron NN N
supplements NNS N
to TO N
infants NNS N
affect VB N
the DT N
disappearance NN N
of IN N
HbF NNP N
. . N

METHODS NNP N
We PRP N
randomized VBD N
285 CD p
low-birth-weight JJ p
infants NNS p
( ( p
2,000-2,500 JJ p
g NN p
) ) p
into IN p
three CD N
intervention NN N
groups NNS i
receiving VBG i
0 CD i
, , i
1 CD i
, , i
or CC i
2 CD i
mg/kg/d NN i
of IN i
iron NN i
supplements NNS i
from IN i
6 CD i
wk NN i
to TO i
6 CD i
mo NN i
of IN i
age NN i
. . i

In IN N
the DT N
present JJ N
secondary JJ N
analysis NN i
, , i
we PRP i
analyzed VBD o
iron NN o
status NN o
, , o
total JJ o
hemoglobin NN o
( ( o
Hb NNP o
) ) o
, , o
and CC o
HbF NNP o
fraction NN o
at IN i
6 CD i
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
at IN N
6 CD N
mo NN N
and CC N
calculated VBD N
absolute JJ N
levels NNS N
of IN N
HbF NNP N
. . N

RESULTS NNP N
We PRP N
observed VBD N
dose-dependent JJ N
increased JJ N
levels NNS N
of IN N
Hb NNP o
in IN o
iron-supplemented JJ N
groups NNS N
at IN N
6 CD N
mo NN N
of IN N
age NN N
. . N

However RB N
, , N
for IN o
absolute JJ o
HbF NNP o
concentration NN o
, , o
there EX o
was VBD o
no DT N
similar JJ N
effect NN N
of IN N
intervention NN o
. . o

Mean NNP o
( ( o
SD NNP o
) ) o
HbF NNP o
was VBD N
81.2 CD N
( ( N
16.8 CD N
) ) N
, , N
37.0 CD N
( ( N
13.8 CD N
) ) N
, , N
and CC N
8.1 CD N
( ( N
5.6 CD N
) ) N
g/l NN N
at IN N
6 CD N
wk NN N
, , N
12 CD N
wk NN N
, , N
and CC N
6 CD N
mo NN N
, , N
respectively RB N
, , N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

In IN N
linear JJ N
regression NN N
analyses NNS N
, , N
postconceptional JJ N
age NN N
turned VBD N
out RP N
as IN N
the DT N
major JJ N
predictor NN N
of IN N
HbF NNP N
, , N
independent JJ N
of IN N
gestational JJ N
age NN N
at IN N
birth NN N
. . N

CONCLUSION NNP N
Our PRP$ N
hypothesis NN N
was VBD N
rejected VBN N
. . N

Instead RB N
, , N
we PRP N
confirmed VBD N
a DT N
close JJ N
correlation NN N
to TO N
postconceptional JJ N
age NN N
, , N
supporting VBG N
a DT N
genetically RB N
programmed VBN N
switch NN N
, , N
insensitive JJ N
to TO N
most JJS N
environmental JJ N
factors NNS N
including VBG N
birth NN N
. . N

-DOCSTART- -14636372- O O

Prophylactic JJ o
effect NN o
of IN N
phenytoin NN i
in IN N
bipolar JJ p
disorder NN p
: : p
a DT N
controlled VBN N
study NN N
. . N

OBJECTIVE NNP N
Phenytoin NNP i
is VBZ N
an DT N
effective JJ N
anticonvulsant NN N
that WDT N
has VBZ N
not RB N
previously RB N
been VBN N
studied VBN N
prophylactically RB N
in IN N
bipolar NN p
( ( p
BP NNP p
) ) p
patients NNS p
. . p

Thus VB N
a DT N
study NN N
of IN N
phenytoin NN i
prophylaxis NN N
was VBD N
undertaken JJ N
and CC N
is VBZ N
herein RB N
reported VBN N
. . N

METHOD NNP N
Bipolar JJ p
patients NNS p
were VBD p
studied VBN p
who WP p
had VBD p
at IN p
least JJS p
one CD p
episode NN p
per IN p
year NN p
in IN p
the DT p
previous JJ p
2 CD p
years NNS p
despite IN p
ongoing VBG p
prophylaxis NN p
. . p

Patients NNS p
were VBD p
stable JJ p
for IN p
a DT p
mean NN p
of IN p
4 CD p
months NNS p
( ( p
range VB p
1-13 NNS p
) ) p
before IN p
entering VBG p
the DT p
study NN p
. . p

Phenytoin NNP i
or CC i
placebo NN i
was VBD N
added VBN N
to TO N
their PRP$ N
current JJ N
therapy NN N
in IN N
a DT N
double-blind JJ N
cross-over NN N
design NN N
for IN N
6 CD N
months NNS N
in IN N
each DT N
phase NN N
. . N

Thirty NNP N
observation NN N
periods NNS N
of IN N
6 CD N
months NNS N
each DT N
were VBD N
studied VBN p
for IN p
23 CD p
patients NNS p
. . p

RESULTS NNP N
Three CD N
patients NNS N
had VBD N
relapse VBN o
on IN N
phenytoin NN i
and CC N
nine CD N
had VBD N
relapse VBN o
on IN N
placebo NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
prophylactic JJ o
effect NN o
of IN N
phenytoin NN i
in IN N
BP NNP N
disorder NN N
[ NNP o
Cox NNP o
's POS o
F-test NNP o
for IN N
comparing VBG N
survival NN o
in IN o
two CD N
groups NNS N
: : N
F NNP N
( ( N
6 CD N
, , N
18 CD N
) ) N
= NN N
3.44 CD N
, , N
p NN N
= VBD N
0.02 CD N
] NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
prophylactic JJ o
effects NNS o
of IN N
add-on JJ N
phenytoin NN i
in IN N
BP NNP N
illness NN N
. . N

However RB N
, , N
the DT N
number NN N
of IN N
patients NNS N
was VBD N
small JJ N
and CC N
confirmation NN N
is VBZ N
necessary JJ N
. . N

-DOCSTART- -23113962- O O

Assessing VBG N
the DT N
effect NN N
of IN N
CT NNP i
slice NN i
interval NN i
on IN N
unidimensional JJ o
, , o
bidimensional JJ o
and CC o
volumetric JJ o
measurements NNS o
of IN N
solid JJ N
tumours NNS N
. . N

OBJECTIVES NNP N
To TO N
study VB N
the DT N
magnitude NN o
of IN o
differences NNS o
in IN o
tumour JJ o
unidimensional JJ o
( ( o
1D CD o
) ) o
, , o
bidimensional JJ o
( ( o
2D CD o
) ) o
and CC o
volumetric JJ o
( ( o
VOL NNP o
) ) o
measurements NNS o
determined VBN N
from IN N
computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
images VBZ N
reconstructed VBN N
at IN N
5 CD N
, , N
2.5 CD N
and CC N
1.25 CD N
mm NN N
slice NN N
intervals NNS N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
118 CD p
lesions NNS p
in IN p
lung NN p
, , p
liver NN p
and CC p
lymph NN p
nodes NNS p
were VBD p
selected VBN p
from IN p
30 CD p
patients NNS p
enrolled VBN p
in IN p
early JJ p
phase NN p
clinical JJ p
trials NNS p
. . p

Each DT i
CT NNP i
scan NN i
was VBD i
reconstructed VBN i
at IN i
5 CD i
, , i
2.5 CD i
and CC i
1.25 CD i
mm NN i
slice NN i
intervals NNS i
during IN i
the DT i
image NN i
acquisition NN i
. . i

Lesions NNS i
were VBD i
semi-automatically RB i
segmented VBN i
on IN i
each DT i
interval JJ i
image NN i
series NN i
and CC i
supervised VBN i
by IN i
a DT i
radiologist NN i
. . i

1D CD o
, , o
2D CD o
and CC o
VOL NNP o
were VBD i
computed VBN i
based VBN i
on IN i
the DT i
final JJ i
segmentation NN i
results NNS i
. . i

Average JJ N
measurement JJ N
differences NNS N
across IN N
different JJ N
slice NN N
intervals NNS N
were VBD N
obtained VBN N
using VBG N
linear JJ N
mixed-effects NNS N
analysis NN N
of IN N
variance NN N
models NNS N
. . N

RESULTS NNP N
Lesion NNP o
diameters NNS o
ranged VBD N
from IN N
6.1 CD N
to TO N
80.1 CD N
mm NN N
( ( N
median JJ N
18.4 CD N
mm NN N
) ) N
. . N

The DT N
largest JJS N
difference NN N
was VBD N
seen VBN N
between IN N
1.25 CD N
and CC N
5 CD N
mm NN N
( ( N
mean JJ N
difference NN N
of IN N
7.6 CD N
% NN N
for IN N
1D CD N
[ JJ N
P NNP N
< NNP N
0.0001 CD N
] NNP N
, , N
13.1 CD N
% NN N
for IN N
2D CD N
[ JJ N
P NNP N
< NNP N
0.0001 CD N
] NNP N
, , N
-5.7 NNP N
% NN N
for IN N
VOL NNP N
[ NNP N
P NNP N
= VBD N
0.0001 CD N
] NN N
) ) N
. . N

Mean JJ N
differences NNS N
between IN N
1.25 CD N
and CC N
2.5 CD N
mm NNS N
were VBD N
all DT N
within IN N
?3.5 NNP N
% NN N
( ( N
within IN N
?6 NNP N
% NN N
confidence NN N
interval NN N
) ) N
. . N

For IN o
VOL NNP o
, , o
there EX N
was VBD N
a DT N
larger JJR N
average JJ N
difference NN N
between IN o
measurements NNS o
on IN o
different JJ o
slice NN o
intervals NNS o
for IN o
the DT N
smaller JJR N
lesions NNS N
( ( N
< $ N
10 CD N
mm NN N
) ) N
compared VBN N
with IN N
the DT N
larger JJR N
lesions NNS N
. . N

CONCLUSIONS NNP N
Different NNP N
slice NN N
intervals NNS N
may MD N
give VB N
different JJ o
1D CD o
, , o
2D CD o
and CC o
VOL NNP o
measurements NNS o
. . o

In IN N
clinical JJ N
practice NN N
, , N
it PRP N
would MD N
be VB N
prudent JJ N
to TO N
use VB N
the DT N
same JJ N
slice NN N
interval NN N
for IN N
consecutive JJ N
measurements NNS N
. . N

-DOCSTART- -23469597- O O

[ JJ N
Effects NNS N
of IN N
dujieqing VBG i
oral JJ i
liquid NN i
on IN N
the DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
Dujieqing VBG i
Oral NNP i
Liquid NNP i
( ( i
DJQ NNP i
) ) i
on IN N
the DT N
promoter NN N
methylation NN N
of IN N
the DT N
O6-methylguanine-DNA JJ N
methyltransferase NN N
( ( N
MGMT NNP N
) ) N
gene NN N
in IN N
the DT N
plasma NN N
DNA NNP N
samples NNS N
from IN N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
. . p

METHODS NNP N
Recruited VBD p
60 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
the DT N
treatment NN i
group NN i
( ( i
treated VBN i
by IN i
conventional JJ i
chemotherapy NN i
combined VBN i
DJQ NNP i
, , N
20 CD N
mL NN N
each DT N
time NN N
, , N
three CD N
times NNS N
daily RB N
) ) N
and CC N
the DT N
control NN i
group NN i
( ( i
treated VBN i
by IN i
chemotherapy NN i
alone RB i
) ) i
, , N
30 CD N
in IN N
each DT N
group NN N
. . N

The DT N
therapeutic JJ N
course NN N
was VBD N
8 CD N
weeks NNS N
. . N

The DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
the DT N
plasma NN N
DNA NNP N
samples VBZ N
form VB N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
was VBD N
detected VBN N
before IN N
and CC N
after IN N
treatment NN N
using VBG N
nested JJ N
methylation-specific JJ N
polymerase NN N
chain NN N
reaction NN N
( ( N
MSP NNP N
) ) N
. . N

Meanwhile RB N
, , N
the DT N
peripheral JJ N
hemogram NN N
was VBD N
detected VBN N
. . N

The DT N
clinical JJ o
efficacy NN o
and CC o
toxic/adverse JJ o
reactions NNS o
were VBD N
assessed VBN N
using VBG N
Karnofsky NNP N
performance NN N
scale NN N
( ( N
KPS NNP N
) ) N
. . N

RESULTS JJ N
Results NNP N
of IN N
the DT N
promoter NN N
methylation NN N
of IN N
MGMT NNP N
genes NNS N
showed VBD N
that IN N
methylation NN N
rate NN N
was VBD N
20.00 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
46.67 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
with IN N
before RB N
treatment NN N
, , N
the DT N
KPS NNP o
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
, , N
while IN N
it PRP N
significantly RB N
decreased VBD N
in IN N
the DT N
control NN N
group NN N
after IN N
treatment NN N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
statistical JJ N
difference NN N
in IN N
the DT N
KPS NNP o
between IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
toxic/adverse JJ o
reactions NNS o
were VBD N
milder VBN N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
DJQ NNP i
showed VBD N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing NN N
effects NNS N
, , N
but CC N
with IN N
no DT N
effect NN N
on IN N
the DT N
hematopoietic JJ N
function NN N
of IN N
the DT N
bone NN N
marrow NN N
. . N

MGMT NNP N
gene NN N
was VBD N
indicated VBN N
as IN N
DJQ NNP i
's POS i
target NN N
point NN N
for IN N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing NN N
. . N

The DT N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing VBG N
effects NNS N
were VBD N
achieved VBN N
by IN N
regulating VBG N
the DT N
activities NNS N
of IN N
MGMT NNP N
gene NN N
. . N

-DOCSTART- -16926619- O O

Children NNP N
's POS N
Yale-Brown JJ N
Obsessive NNP N
Compulsive NNP N
Scale NNP N
modified VBD N
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
psychometric JJ N
properties NNS N
of IN N
the DT N
Children NNP i
's POS i
Yale-Brown JJ i
Obsessive NNP i
Compulsive NNP i
Scales NNP i
( ( i
CYBOCS NNP i
) ) i
modified VBD i
for IN i
pervasive JJ i
developmental NN i
disorders NNS i
( ( i
PDDs NNP i
) ) i
. . i

METHOD NNP N
Raters NNPS N
from IN N
five CD N
Research NNP N
Units NNS N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
) ) N
Autism NNP N
Network NNP N
were VBD N
trained VBN N
to TO N
reliability NN N
. . N

The DT N
modified JJ N
scale NN N
( ( i
CYBOCS-PDD NNP i
) ) i
, , N
which WDT N
contains VBZ N
only RB N
the DT N
five CD i
Compulsion NNP i
severity NN i
items NNS i
( ( N
range VB N
0-20 NN N
) ) N
, , N
was VBD N
administered VBN p
to TO p
172 CD p
medication-free JJ p
children NNS p
( ( p
mean JJ p
8.2 CD p
+/- JJ p
2.6 CD p
years NNS p
) ) p
with IN p
PDD NNP p
( ( p
autistic JJ p
disorder NN p
, , p
n JJ p
= VBP p
152 CD p
; : p
Asperger NNP p
's POS p
disorder NN p
, , p
n JJ p
= VBP p
6 CD p
; : p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
, , p
n JJ p
= NNP p
14 CD p
) ) p
participating NN p
in IN p
RUPP NNP p
clinical JJ p
trials NNS p
. . p

Reliability NNP o
was VBD N
assessed VBN N
by IN N
intraclass NN N
correlation NN N
coefficient NN N
( ( N
ICC NNP N
) ) N
and CC N
internal JJ N
consistency NN N
by IN N
Cronbach NNP N
's POS N
alpha JJ N
coefficient NN N
. . N

Correlations NNS N
with IN N
ratings NNS N
of IN N
repetitive JJ N
behavior NN N
and CC N
disruptive JJ N
behavior NN N
were VBD N
examined VBN N
for IN N
validity NN N
. . N

RESULTS NNP N
Eleven NNP N
raters NNS N
showed VBD N
excellent JJ N
reliability NN o
( ( N
ICC NNP N
= NNP N
0.97 CD N
) ) N
. . N

The DT N
mean JJ o
CYBOCS NNP o
score NN o
was VBD N
14.4 CD N
( ( N
+/- JJ N
3.86 CD N
) ) N
with IN N
excellent JJ N
internal JJ o
consistency NN o
( ( N
alpha JJ N
= NNP N
.85 NNP N
) ) N
. . N

Correlations NNS N
with IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
ranged VBD N
from IN N
r NN N
= $ N
0.11 CD N
to TO N
r VB N
= JJ N
0.28 CD N
and CC N
were VBD N
similar JJ N
to TO N
correlations NNS N
with IN N
measures NNS o
of IN o
irritability NN o
( ( N
r JJ N
= NNP N
0.24 CD N
) ) N
and CC N
hyperactivity NN o
( ( N
r JJ N
= NNP N
0.25 CD N
) ) N
. . N

Children NNP p
with IN p
higher JJR p
scores NNS p
on IN N
the DT N
CYBOCS-PDD NNP N
had VBD N
higher JJR N
levels NNS N
of IN N
maladaptive JJ o
behaviors NNS o
and CC o
lower JJR o
adaptive JJ o
functioning NN o
. . o

CONCLUSIONS VB N
The DT N
five-item JJ N
CYBOCS-PDD NNP N
is VBZ N
reliable JJ N
, , N
distinct JJ N
from IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
, , N
and CC N
sensitive JJ N
to TO N
change VB N
. . N

-DOCSTART- -23610236- O O

A DT N
play NN i
and CC i
joint JJ i
attention NN i
intervention NN i
for IN N
teachers NNS p
of IN p
young JJ p
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
pilot VB N
test VB N
a DT N
classroom-based JJ N
intervention NN N
focused VBD N
on IN N
facilitating VBG N
play NN N
and CC N
joint JJ N
attention NN N
for IN N
young JJ p
children NNS p
with IN p
autism NN p
in IN p
self-contained JJ p
special JJ p
education NN p
classrooms NNS p
. . p

Thirty-three JJ p
children NNS p
with IN p
autism NN p
between IN p
the DT p
ages NNS p
of IN p
3 CD p
and CC p
6 CD p
years NNS p
participated VBN p
in IN p
the DT p
study NN p
with IN p
their PRP$ p
classroom NN p
teachers NNS p
( ( p
n JJ p
= NNP p
14 CD p
) ) p
. . p

The DT N
14 CD p
preschool NN p
special JJ p
education NN p
teachers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
symbolic NN i
play NN i
then RB i
joint JJ i
attention NN i
intervention NN i
, , N
( ( N
2 CD N
) ) N
joint NN i
attention NN i
then RB i
symbolic JJ i
intervention NN i
, , N
and CC N
( ( N
3 CD N
) ) N
wait-list NN i
control NN i
period NN i
then RB i
further RB i
randomized VBN i
to TO i
either DT i
group NN i
1 CD i
or CC i
group NN i
2 CD i
. . i

In IN N
the DT N
intervention NN N
, , N
teachers NNS N
participated VBD N
in IN N
eight CD N
weekly JJ N
individualized VBN N
1-h JJ N
sessions NNS N
with IN N
a DT N
researcher NN N
that WDT N
emphasized VBD N
embedding VBG N
strategies NNS N
targeting VBG N
symbolic JJ N
play NN N
and CC N
joint JJ N
attention NN N
into IN N
their PRP$ N
everyday JJ N
classroom NN N
routines NNS N
and CC N
activities NNS N
. . N

The DT N
main JJ N
child NN N
outcome NN N
variables NNS N
of IN N
interest NN N
were VBD N
collected VBN N
through IN N
direct JJ N
classroom NN N
observations NNS N
. . N

Findings NNS N
indicate VBP N
that IN N
teachers NNS N
can MD N
implement VB N
an DT N
intervention NN o
to TO o
significantly RB o
improve VB o
joint JJ o
engagement NN o
of IN N
young JJ p
children NNS p
with IN p
autism NN p
in IN p
their PRP$ p
classrooms NNS p
. . p

Furthermore RB N
, , N
multilevel NN N
analyses NNS N
showed VBD N
significant JJ o
increases NNS o
in IN o
joint JJ o
attention NN o
and CC o
symbolic JJ o
play NN o
skills NNS o
. . o

Thus RB N
, , N
these DT N
pilot NN N
data NNS N
emphasize VBP N
the DT N
need NN N
for IN N
further JJ N
research NN N
and CC N
implementation NN N
of IN N
classroom-based JJ N
interventions NNS N
targeting VBG N
play NN o
and CC o
joint JJ o
attention NN o
skills NNS o
for IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -24473220- O O

Does NNP N
privatisation NN N
of IN N
vocational JJ N
rehabilitation NN N
improve VB N
labour NN N
market NN N
opportunities NNS N
? . N
Evidence NN N
from IN N
a DT N
field NN p
experiment NN p
in IN p
Sweden NNP p
. . p

This DT N
paper NN N
analyses VBZ N
if IN N
privatisation NN i
of IN i
vocational JJ i
rehabilitation NN i
can MD N
improve VB N
labour JJ N
market NN N
opportunities NNS N
for IN N
individuals NNS p
on IN p
long-term JJ p
sickness NN p
absence NN p
. . p

We PRP N
use VBP N
a DT N
field NN N
experiment NN N
performed VBN N
by IN p
the DT p
Public NNP p
Employment NNP p
Service NNP p
and CC p
the DT p
Social NNP p
Insurance NNP p
Agency NNP p
in IN p
Sweden NNP p
during IN p
2008-2010 JJ p
, , p
in IN p
which WDT p
over IN p
4000 CD p
participants NNS p
were VBD p
randomly RB p
offered VBN p
private JJ i
and CC i
public JJ i
rehabilitation NN i
. . i

We PRP N
find VBP N
no DT N
differences NNS N
in IN N
employment NN o
rates NNS o
following VBG N
rehabilitation NN i
between IN N
individuals NNS p
who WP N
received VBD N
rehabilitation NN N
by IN N
private JJ N
and CC N
public JJ N
providers NNS N
. . N

Also RB N
the DT N
average JJ o
cost NN o
of IN o
rehabilitation NN o
was VBD N
essentially RB N
equal JJ N
for IN N
the DT N
two CD N
types NNS N
of IN N
providers NNS N
. . N

This DT N
suggests VBZ N
that IN N
there EX N
are VBP N
no DT N
large JJ N
efficiency NN o
gains NNS o
from IN N
privatising VBG N
vocational JJ N
rehabilitation NN N
. . N

-DOCSTART- -16801333- O O

Factors NNS N
that WDT N
influence NN N
cancer NN p
patients NNS p
' POS p
anxiety NN o
following VBG p
a DT p
medical JJ p
consultation NN p
: : p
impact NN N
of IN N
a DT N
communication NN i
skills VBZ i
training VBG i
programme NN i
for IN N
physicians NNS N
. . N

BACKGROUND NNP N
No NNP N
study NN N
has VBZ N
yet RB N
assessed VBN N
the DT N
impact NN N
of IN N
physicians NNS N
' POS N
skills NNS N
acquisition NN N
after IN N
a DT N
communication NN i
skills VBZ i
training VBG i
programme NN i
on IN N
the DT N
evolution NN N
of IN N
patients NNS p
' POS p
anxiety NN N
following VBG N
a DT N
medical JJ N
consultation NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
impact NN N
, , N
on IN N
patients NNS N
' POS N
anxiety NN N
, , N
of IN N
a DT N
basic JJ i
communication NN i
skills NNS i
training VBG i
programme NN i
( ( i
BT NNP i
) ) i
and CC N
the DT N
same JJ N
programme NN N
consolidated VBN N
by IN N
consolidation NN i
workshops NNS i
( ( N
CW NNP N
) ) N
, , N
and CC N
to TO N
investigate VB N
physicians NNS N
' POS N
communication NN N
variables NNS N
associated VBN N
with IN N
patients NNS N
' POS N
anxiety NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Physicians NNP p
, , p
after IN p
attending VBG p
the DT p
BT NNP i
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
CW NNP i
or CC N
to TO N
a DT N
waiting VBG i
list NN i
. . i

The DT N
control NN N
group NN N
was VBD N
not RB N
a DT N
non-intervention JJ N
group NN N
. . N

Consultations NNS N
with IN N
a DT N
cancer NN N
patient NN N
were VBD N
recorded VBN N
. . N

Patients NNS N
' POS N
anxiety NN o
was VBD N
assessed VBN N
with IN N
the DT N
State NNP o
Trait NNP o
Anxiety NNP o
Inventory NNP o
before IN N
and CC N
after IN N
a DT N
consultation NN N
. . N

Communication NNP o
skills NNS o
were VBD N
analysed VBN N
according VBG N
to TO N
the DT N
Cancer NNP N
Research NNP N
Campaign NNP N
Workshop NNP N
Evaluation NNP N
Manual NNP N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
change NN N
over IN N
time NN o
and CC N
between IN N
groups NNS N
was VBD N
observed VBN N
. . N

Mixed-effects NNS N
modelling VBG N
showed VBD N
that IN N
a DT N
decrease NN N
in IN N
patients NNS o
' POS o
anxiety NN o
was VBD N
linked VBN N
with IN N
screening JJ N
questions NNS N
( ( N
P NNP N
= NNP N
0.045 CD N
) ) N
, , N
physicians NNS o
' POS o
satisfaction NN o
about IN N
support NN N
given VBN N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
and CC N
with IN N
patients NNS N
' POS N
distress NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

An DT N
increase NN N
in IN N
anxiety NN o
was VBD N
linked VBN N
with IN N
breaking VBG N
bad JJ N
news NN N
( ( N
P NNP N
= NNP N
0.050 CD N
) ) N
and CC N
with IN N
supportive JJ N
skills NNS N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

No DT N
impact NN N
of IN N
the DT N
training NN N
programme NN N
was VBD N
observed VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
the DT N
influence NN N
of IN N
some DT N
communication NN N
skills NNS N
on IN N
the DT N
evolution NN N
of IN N
patients NNS o
' POS o
anxiety NN o
. . o

Physicians NNS p
should MD N
be VB N
aware JJ N
of IN N
these DT N
influences NNS N
. . N

-DOCSTART- -25527253- O O

Efficacy NN N
of IN N
venlafaxine NN i
XR NN i
for IN N
the DT N
treatment NN N
of IN N
pain NN N
in IN N
patients NNS p
with IN p
spinal JJ p
cord NN p
injury NN p
and CC p
major JJ p
depression NN p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
( ( N
1 CD N
) ) N
determine VB N
the DT N
efficacy NN N
of IN N
venlafaxine NN i
XR NN i
for IN N
the DT N
treatment NN N
of IN N
pain NN p
( ( p
secondary JJ p
aim NN p
) ) p
in IN p
individuals NNS p
with IN p
spinal JJ p
cord NN p
injury NN p
( ( p
SCI NNP p
) ) p
enrolled VBD p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
( ( p
RCT NNP p
) ) p
on IN p
the DT p
efficacy NN p
of IN p
venlafaxine NN i
XR NN p
for IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
( ( N
primary JJ N
aim NN N
) ) N
; : N
and CC N
( ( N
2 CD N
) ) N
test NN N
the DT N
hypothesis NN N
that WDT N
venlafaxine NN i
XR NNP N
would MD N
be VB N
effective JJ N
for IN N
both DT N
neuropathic JJ N
and CC N
nociceptive JJ N
pain NN N
. . N

DESIGN NNP N
Multisite NNP N
, , N
double-blind NN N
, , N
randomized VBN N
( ( N
1:1 CD N
) ) N
controlled VBD N
trial NN N
with IN N
subjects NNS N
block VBP N
randomized VBN N
and CC N
stratified VBN N
by IN N
site NN N
, , N
lifetime JJ N
history NN N
of IN N
substance NN N
abuse NN N
, , N
and CC N
prior JJ N
history NN N
of IN N
MDD NNP N
. . N

SETTING NN N
Six NNP p
Departments NNP p
of IN p
Physical NNP p
Medicine NNP p
and CC p
Rehabilitation NNP p
in IN p
university-based JJ p
medical JJ p
schools NNS p
. . p

PARTICIPANTS JJ N
Individuals NNS p
( ( p
N=123 NNP p
) ) p
with IN p
SCI NNP p
and CC p
major JJ p
depression NN p
between IN p
18 CD p
and CC p
64 CD p
years NNS p
of IN p
age NN p
, , p
at IN p
least JJS p
1 CD p
month NN p
post-SCI NN p
who WP p
also RB p
reported VBD p
pain NN p
. . p

INTERVENTION NNP N
Twelve-week JJ N
trial NN N
of IN N
venlafaxine NN i
XR NNP i
versus NN i
placebo NN i
using VBG i
a DT i
flexible JJ i
titration NN i
schedule NN i
. . i

OUTCOME NNP N
MEASURES NNP N
A NNP N
0-to-10 JJ o
numeric JJ o
rating NN o
scale NN o
for IN o
pain NN o
, , o
pain NN o
interference NN o
items NNS o
of IN o
the DT o
Brief NNP o
Pain NNP o
Inventory NNP o
; : o
30 CD N
% NN N
and CC N
50 CD N
% NN N
responders NNS N
. . N

RESULTS VB N
The DT N
effect NN N
of IN N
venlafaxine NN i
XR NN i
on IN N
neuropathic JJ N
pain NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
placebo NN i
. . i

However RB N
venlafaxine JJ i
XR NNP i
resulted VBD N
in IN N
statistically RB N
significant JJ N
and CC N
clinically RB N
meaningful JJ N
reductions NNS N
in IN N
nociceptive JJ N
pain NN N
site NN N
intensity NN N
and CC N
interference NN N
even RB N
after IN N
controlling VBG N
for IN N
anxiety NN o
, , o
depression NN o
, , o
and CC o
multiple JJ o
pain NN o
sites NNS o
within IN N
the DT N
same JJ N
individual NN N
. . N

For IN N
those DT N
who WP N
achieved VBD N
a DT N
minimally RB N
effective JJ N
dose NN N
of IN N
venlafaxine NN i
XR NNP i
, , N
some DT N
additional JJ N
evidence NN N
of IN N
effectiveness NN N
was VBD N
noted VBN N
for IN N
those DT N
with IN N
mixed JJ N
( ( N
both DT N
neuropathic RB N
and CC N
nociceptive JJ N
) ) N
pain NN N
sites NNS N
. . N

CONCLUSIONS NNP N
Venlafaxine NNP i
XR NNP i
could MD N
complement VB N
current JJ N
medications NNS N
and CC N
procedures NNS N
for IN N
treating VBG N
pain NN N
after IN N
SCI NNP N
and CC N
MDD NNP N
that WDT N
has VBZ N
nociceptive JJ N
features NNS N
. . N

Its PRP$ N
usefulness NN N
for IN N
treating VBG N
central JJ N
neuropathic JJ N
pain NN N
is VBZ N
likely JJ N
to TO N
be VB N
limited VBN N
. . N

Research NNP N
is VBZ N
needed VBN N
to TO N
replicate VB N
these DT N
findings NNS N
and CC N
determine VB N
whether IN N
the DT N
antinociceptive JJ N
effect NN N
of IN N
venlafaxine NN i
XR NNP i
generalizes VBZ N
to TO N
persons NNS N
with IN N
SCI NNP N
pain VBP N
without IN N
MDD NNP N
. . N

-DOCSTART- -15534261- O O

Impact NN N
of IN N
antioxidants NNS i
, , i
zinc NN i
, , i
and CC i
copper NN i
on IN N
cognition NN p
in IN p
the DT p
elderly JJ p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

Participants NNS p
in IN p
the DT p
Age-Related JJ p
Eye NNP p
Disease NNP p
Study NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
daily JJ N
antioxidants NNS i
( ( i
vitamin JJ i
C NNP i
, , i
500 CD i
mg NN i
; : i
vitamin CC i
E NNP i
, , i
400 CD i
IU NNP i
; : i
beta NN i
carotene NN i
, , i
15 CD i
mg NN i
) ) i
, , i
zinc NN i
and CC i
copper NN i
( ( i
zinc NN i
, , i
80 CD i
mg NN i
; : i
cupric JJ i
oxide NN i
, , i
2 CD i
mg NN i
) ) i
, , i
antioxidants NNS i
plus CC i
zinc NN i
and CC i
copper NN i
, , i
or CC i
placebo NN i
. . i

A DT N
cognitive JJ N
battery NN N
was VBD N
administered VBN N
to TO N
2,166 CD p
elderly JJ p
persons NNS p
after IN p
a DT p
median NN p
of IN p
6.9 CD p
years NNS p
of IN p
treatment NN p
. . p

Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
on IN N
any DT N
of IN N
the DT N
six CD o
cognitive JJ o
tests NNS o
( ( N
p JJ N
> VBP N
0.05 CD N
for IN N
all DT N
) ) N
. . N

These DT N
results NNS N
do VBP N
not RB N
support VB N
a DT N
beneficial JJ o
or CC o
harmful JJ o
effect NN o
of IN o
antioxidants NNS o
or CC o
zinc NN o
and CC o
copper NN o
on IN N
cognition NN o
in IN N
older JJR N
adults NNS N
. . N

-DOCSTART- -22129897- O O

A DT N
clinical JJ N
trial NN N
of IN N
glutathione NN N
supplementation NN N
in IN N
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND NNP N
Recent NNP N
evidence NN N
shows VBZ N
that IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
have VBP N
significantly RB N
lower JJR N
levels NNS N
of IN N
glutathione NN N
than IN N
typically RB N
developing VBG N
children NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
use NN N
of IN N
two CD N
commonly NNS N
used VBD N
glutathione NN N
supplements NNS N
in IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
to TO N
determine VB N
their PRP$ N
efficacy NN N
in IN N
increasing VBG N
blood NN o
glutathione NN o
levels NNS o
in IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
. . p

MATERIAL/METHODS NNP N
The DT N
study NN N
was VBD N
an DT N
eight-week JJ N
, , N
open-label JJ N
trial NN p
using VBG p
oral JJ i
lipoceutical JJ i
glutathione NN i
( ( i
n=13 JJ i
) ) i
or CC i
transdermal JJ i
glutathione NN i
( ( i
n=13 JJ i
) ) i
in IN p
children NNS p
, , p
3-13 CD p
years NNS p
of IN p
age NN p
, , p
with IN p
a DT p
diagnosis NN p
of IN p
an DT p
ASD NNP p
. . p

Subjects NNPS p
underwent JJ p
pre- JJ p
and CC p
post-treatment JJ p
lab NN p
testing VBG p
to TO N
evaluate VB N
plasma NN o
reduced VBN o
glutathione NN o
, , o
oxidized VBD o
glutathione NN o
, , o
cysteine NN o
, , o
taurine NN o
, , o
free JJ o
and CC o
total JJ o
sulfate NN o
, , o
and CC o
whole-blood JJ o
glutathione NN o
levels NNS o
. . o

RESULTS VB N
The DT N
oral JJ N
treatment NN N
group NN N
showed VBD N
significant JJ N
increases NNS N
in IN N
plasma NN o
reduced VBD o
glutathione NN o
, , o
but CC o
not RB o
whole-blood JJ o
glutathione NN o
levels NNS o
following VBG N
supplementation NN N
. . N

Both CC N
the DT N
oral JJ p
and CC p
transdermal JJ p
treatment NN p
groups NNS p
showed VBD N
significant JJ N
increases NNS N
in IN N
plasma NN o
sulfate NN o
, , o
cysteine NN o
, , o
and CC o
taurine NN o
following VBG N
supplementation NN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
oral JJ N
and CC N
transdermal JJ N
glutathione NN N
supplementation NN N
may MD N
have VB N
some DT N
benefit NN N
in IN N
improving VBG N
some DT N
of IN N
the DT N
transsulfuration NN N
metabolites VBZ N
. . N

Future JJ N
studies NNS N
among IN N
subjects NNS p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
should MD N
further RB N
explore VB N
the DT N
pharmacokinetics NNS N
of IN N
glutathione NN N
supplementation NN N
and CC N
evaluate VB N
the DT N
potential JJ N
effects NNS N
of IN N
glutathione NN N
supplementation NN N
upon IN N
clinical JJ N
symptoms NNS N
. . N

-DOCSTART- -21190079- O O

Comparison NNP N
of IN N
different JJ N
approaches NNS N
for IN N
assessment NN N
of IN N
HER2 NNP N
expression NN N
on IN N
protein NN N
and CC N
mRNA JJ N
level NN N
: : N
prediction NN N
of IN N
chemotherapy NN i
response NN N
in IN N
the DT N
neoadjuvant JJ N
GeparTrio NNP N
trial NN N
( ( N
NCT00544765 NNP N
) ) N
. . N

Human NNP i
epidermal JJ i
growth NN i
factor NN i
receptor NN i
2 CD i
( ( N
HER2 NNP N
) ) N
testing NN N
is VBZ N
an DT N
essential JJ N
part NN N
of IN N
pathological JJ N
assessment NN N
in IN N
breast NN p
cancer NN p
patients NNS p
, , N
as IN N
HER2 NNP N
provides VBZ N
not RB N
only RB N
prognostic JJ N
but CC N
also RB N
predictive JJ N
information NN N
on IN N
response NN N
to TO N
targeted VBN N
therapy NN N
. . N

So RB N
far RB N
, , N
HER2 NNP N
test JJS N
accuracy NN N
of IN N
immunohistochemistry/in JJ N
situ-hybridization NN N
techniques NNS N
is VBZ N
still RB N
under IN N
debate NN N
, , N
and CC N
more RBR N
reliable JJ N
and CC N
robust JJ N
technologies NNS N
are VBP N
needed VBN N
. . N

To TO N
address VB N
this DT N
issue NN N
and CC N
to TO N
evaluate VB N
the DT N
predictive JJ N
value NN N
of IN N
HER2 NNP N
on IN N
chemotherapy NN i
, , N
we PRP N
investigated VBD p
a DT p
cohort NN p
of IN p
278 CD p
patients NNS p
from IN p
the DT p
GeparTrio NNP p
trial NN p
, , N
a DT N
prospective JJ N
neoadjuvant JJ N
anthracycline/taxane-based JJ N
multicenter NN N
study NN N
. . N

In IN N
the DT N
GeparTrio NNP N
trial NN N
, , N
patients NNS N
were VBD N
not RB N
treated VBN N
with IN N
any DT N
anti-HER2 JJ i
therapy NN i
, , N
as IN N
this DT N
was VBD N
not RB N
standard JJ N
therapy NN N
at IN N
this DT N
time NN N
. . N

The DT N
HER2 NNP o
status NN o
was VBD N
analyzed VBN N
by IN N
three CD N
different JJ N
approaches NNS N
: : N
local JJ i
and CC i
central JJ i
evaluation NN i
using VBG i
immunohistochemistry NN i
combined VBN i
with IN i
in IN i
situ-hybridization NN i
as RB N
well RB N
as IN N
evaluation NN i
of IN i
HER2 NNP o
mRNA FW o
expression NN o
using VBG i
kinetic JJ i
RT-PCR JJ i
from IN i
formalin-fixed JJ i
, , i
paraffin-embedded JJ i
( ( i
FFPE NNP i
) ) i
tissue NN i
samples NNS i
using VBG N
a DT N
predefined VBN N
cutoff NN N
. . N

HER2 NNP o
overexpression/amplification NN o
was VBD N
observed VBN N
in IN N
37.3 CD N
% NN N
( ( N
91/244 CD N
) ) N
and CC N
17.9 CD N
% NN N
( ( N
41/229 CD N
) ) N
of IN N
the DT N
informative JJ N
samples NNS N
in IN N
the DT N
local JJ N
and CC N
central JJ N
evaluations NNS N
, , N
respectively RB N
. . N

Positive JJ o
HER2 NNP o
mRNA NN o
levels NNS o
were VBD N
found VBN N
in IN N
19.8 CD N
% NN N
( ( N
55/278 CD N
) ) N
. . N

We PRP N
observed VBD N
a DT N
highly RB N
significant JJ N
correlation NN o
between IN o
central JJ o
HER2 NNP o
expression NN o
and CC o
HER2 NNP o
status NN o
measured VBN o
by IN o
kinetic JJ o
RT-PCR NNP o
( ( N
r VB N
= RB N
0.856 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
an DT N
overall JJ N
agreement NN N
of IN N
95.6 CD N
% NN N
( ( N
? . N
statistic NN N
, , N
0.862 CD N
, , N
CI NNP N
0.77-0.94 NN N
) ) N
. . N

Further NNP N
, , N
central JJ o
HER2 NNP o
as RB o
well RB o
as IN o
HER2 NNP o
mRNA FW o
expression NN o
were VBD o
predictors NNS o
for IN o
a DT o
pathological JJ o
complete JJ o
response NN o
after IN o
neoadjuvant JJ o
anthracycline/taxane-based JJ o
primary JJ o
chemotherapy NN o
in IN N
a DT N
univariate JJ N
binary JJ N
logistic JJ N
regression NN N
analysis NN N
( ( N
OR CC N
3.29 CD N
, , N
P NNP N
= NNP N
0.002 CD N
; : N
OR CC N
2.65 CD N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

The DT o
predictive JJ o
value NN o
could MD N
be VB N
confirmed VBN N
for IN N
the DT o
central JJ o
HER2 NNP o
status NN o
by IN N
multivariate NN N
analysis NN N
( ( N
OR CC N
3.04 CD N
, , N
P NNP N
= NNP N
0.027 CD N
) ) N
. . N

The DT o
locally RB o
assessed VBN o
HER2 NNP o
status NN o
was VBD o
not RB o
predictive JJ o
of IN o
response NN o
to TO o
chemotherapy NN o
. . o

Our PRP$ N
results NNS N
suggest VBP N
that IN N
standardized JJ N
methods NNS N
are VBP N
preferable JJ N
for IN N
evaluation NN N
of IN N
HER2 NNP N
status NN N
. . N

The DT N
kinetic JJ N
RT-PCR NNP N
from IN N
FFPE NNP N
tissue NN N
might MD N
be VB N
an DT N
additional JJ N
approach NN N
for IN N
assessment NN N
of IN N
this DT N
important JJ N
prognostic NN N
and CC N
predictive JJ N
parameter NN N
but CC N
has VBZ N
to TO N
be VB N
confirmed VBN N
by IN N
other JJ N
studies NNS N
. . N

-DOCSTART- -10213554- O O

Isradipine NNP i
, , N
raised VBD N
glycosylated VBN N
haemoglobin NN N
, , N
and CC N
risk NN p
of IN p
cardiovascular JJ o
events NNS o
. . o

-DOCSTART- -19193781- O O

Approval JJ N
summary NN N
: : N
imatinib JJ i
mesylate NN o
in IN N
the DT N
treatment NN N
of IN N
metastatic JJ p
and/or NN p
unresectable JJ p
malignant JJ p
gastrointestinal JJ o
stromal JJ o
tumors NNS o
. . o

The DT N
purpose NN N
of IN N
the DT N
present JJ N
application NN N
was VBD N
to TO N
fulfill VB N
a DT N
postmarketing NN N
commitment NN N
to TO N
provide VB N
long-term JJ N
efficacy NN N
and CC N
safety NN N
data NNS N
on IN N
treatment NN N
with IN N
imatinib JJ o
mesylate NN o
( ( N
Gleevec NNP N
; : N
Novartis NNP N
Pharmaceuticals NNP N
, , N
East NNP N
Hanover NNP N
, , N
NJ NNP N
) ) N
in IN N
patients NNS p
with IN p
CD117 NNP p
( ( p
+ NNP p
) ) p
unresectable JJ p
and/or JJ p
metastatic JJ p
malignant JJ p
gastrointestinal JJ p
stromal NN p
tumors NNS p
( ( p
GISTs NNP p
) ) p
. . p

In IN N
addition NN N
, , N
this DT N
application NN N
also RB N
provides VBZ N
evidence NN N
to TO N
support VB N
a DT N
change NN N
in IN N
the DT N
label NN N
to TO N
allow VB N
for IN N
an DT N
escalation NN N
of IN N
imatinib NN o
dosing VBG N
to TO N
800 CD N
mg/day NN N
for IN N
patients NNS p
with IN p
progressive JJ p
disease NN p
on IN p
a DT p
lower JJR p
dose NN p
. . p

Two CD N
open-label JJ N
, , N
controlled VBN N
, , N
multicenter NN N
, , N
intergroup NN N
, , N
international JJ N
, , N
randomized JJ N
phase NN N
III NNP N
studies NNS N
were VBD N
submitted VBN N
-- : N
one CD N
conducted VBN N
by IN N
the DT N
European JJ p
Organization NNP p
for IN p
Research NNP p
and CC p
Treatment NNP p
of IN p
Cancer NNP o
( ( p
n JJ p
= NNP p
946 CD p
) ) p
and CC p
the DT p
other JJ p
by IN p
the DT p
Southwest NNP p
Oncology NNP o
Group NNP p
( ( p
n JJ p
= NNP p
746 CD p
) ) p
. . p

These DT N
studies NNS N
compared VBN N
400 CD N
mg/day NN N
of IN N
imatinib NN o
with IN N
800 CD N
mg/day NN N
of IN N
imatinib NN o
. . o

A DT N
combined JJ N
analysis NN N
of IN N
the DT N
two CD N
studies NNS N
was VBD N
prospectively RB N
defined VBN N
and CC N
agreed VBN N
to TO N
by IN N
both DT N
groups NNS N
. . N

Both DT N
protocols NNS N
allowed VBD N
patients NNS N
randomized VBN N
to TO N
the DT N
400-mg/day JJ N
imatinib NN i
arm NN N
to TO N
cross VB N
over IN N
to TO N
800 CD N
mg/day NN N
imatinib NN o
at IN N
progression NN N
. . N

Objective JJ N
responses NNS N
were VBD N
achieved VBN N
in IN N
> JJ N
50 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
either CC N
imatinib JJ o
dose NN N
. . N

The DT N
median JJ N
progression-free JJ o
survival NN o
time NN o
was VBD N
approximately RB N
20 CD N
months NNS N
and CC N
the DT N
median JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
time NN N
was VBD N
approximately RB N
49 CD N
months NNS N
. . N

In IN N
the DT N
combined JJ N
analysis NN N
, , N
347 CD N
patients NNS N
crossed VBN N
over IN N
to TO N
800 CD N
mg/day NN N
imatinib NN i
at IN N
the DT N
time NN N
of IN N
progression NN N
. . N

The DT N
median JJ o
OS NNP o
time NN N
after IN N
crossover NN N
was VBD N
14.3 CD N
months NNS N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
fluid JJ N
retention NN N
, , N
nausea NN o
, , o
fatigue NN o
, , o
skin JJ o
rash NN o
, , o
gastrointestinal JJ o
complaints NNS o
, , o
and CC o
myalgia NN o
. . o

The DT N
most RBS N
common JJ N
laboratory NN N
abnormality NN o
was VBD o
anemia VBN o
. . o

Most JJS N
often RB N
the DT N
AEs NNP o
were VBD N
of IN N
mild-to-moderate JJ N
severity NN N
. . N

Fluid NNP N
retention NN N
events NNS N
and CC N
skin JJ N
rash NN N
were VBD N
numerically RB N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
800-mg/day JJ N
treatment NN N
cohort NN N
of IN N
patients NNS N
. . N

-DOCSTART- -23539079- O O

Effects NNS N
of IN N
weighted JJ i
sled VBD i
towing VBG i
with IN i
heavy JJ i
versus NN N
light JJ i
load NN i
on IN N
sprint NN o
acceleration NN o
ability NN o
. . o

Weighted VBD i
sled JJ i
towing NN i
is VBZ N
used VBN N
by IN N
athletes NNS p
to TO N
improve VB N
sprint NN o
acceleration NN o
ability NN o
. . o

The DT N
typical JJ N
coaching NN N
recommendation NN N
is VBZ N
to TO N
use VB N
relatively RB N
light JJ N
loads NNS N
, , N
as IN N
excessively RB N
heavy JJ N
loads NNS N
are VBP N
hypothesized VBN N
to TO N
disrupt VB N
running VBG N
mechanics NNS N
and CC N
be VB N
detrimental JJ N
to TO N
sprint VB N
performance NN N
. . N

However RB N
, , N
this DT N
coaching VBG N
recommendation NN N
has VBZ N
not RB N
been VBN N
empirically RB N
tested VBN N
. . N

This DT N
study NN N
compared VBN N
the DT N
effects NNS N
of IN N
weighted JJ i
sled VBD i
towing VBG i
with IN N
2 CD N
different JJ N
external JJ N
loads NNS N
on IN N
sprint NN o
acceleration NN o
ability NN o
. . o

Twenty-one CD p
physically RB p
active JJ p
men NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
heavy- NN i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
light-load JJ i
weighted JJ i
sled VBD i
towing NN i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
groups NNS N
. . N

All DT N
subjects NNS N
participated VBN N
in IN N
2 CD N
training NN N
sessions NNS N
per IN N
week NN N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
subjects NNS N
in IN N
the DT N
heavy JJ N
and CC N
light JJ N
groups NNS N
performed VBD N
weighted JJ N
sled VBD N
towing VBG N
using VBG N
external JJ N
loads NNS N
that WDT N
reduced VBD N
sprint JJ o
velocity NN o
by IN N
approximately RB N
30 CD N
and CC N
10 CD N
% NN N
, , N
respectively RB N
. . N

Before IN N
and CC N
after IN N
the DT N
training NN N
, , N
the DT N
subjects NNS N
performed VBD N
a DT N
10-m JJ N
sprint NN N
test NN N
, , N
in IN N
which WDT N
split NN o
time NN o
was VBD N
measured VBN N
at IN N
5 CD N
and CC N
10 CD N
m NN N
from IN N
the DT N
start NN N
. . N

The DT N
heavy JJ N
group NN N
significantly RB N
improved VBN N
both DT N
the DT N
5- JJ o
and CC o
10-m JJ o
sprint NN o
time NN o
by IN N
5.7 CD N
? . N
5.7 CD N
and CC N
5.0 CD N
? . N
3.5 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
whereas IN N
only RB N
10-m JJ o
sprint NN o
time NN o
was VBD o
improved VBN N
significantly RB N
by IN N
3.0 CD N
? . N
3.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
light JJ N
group NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
in IN N
the DT N
changes NNS N
in IN N
5-m JJ o
and CC o
10-m JJ o
sprint NN o
time NN o
from IN o
pre- JJ N
to TO N
posttraining VBG N
. . N

These DT N
results NNS N
question VBP N
the DT N
notion NN N
that IN N
training VBG N
loads NNS N
that WDT N
induce VBP N
greater JJR N
than IN N
10 CD N
% NN N
reduction NN N
in IN N
sprint NN o
velocity NN o
would MD o
negatively RB N
affect VB o
sprint NN o
performance NN o
and CC o
point NN N
out RP N
the DT N
potential JJ N
benefit NN N
of IN N
using VBG i
a DT i
heavier JJR i
load NN i
for IN i
weighted JJ i
sled VBD i
towing NN i
. . i

-DOCSTART- -8627197- O O

Antifungal NNP i
pulse NN o
therapy NN i
for IN N
onychomycosis NN p
. . p

-DOCSTART- -20019137- O O

Body NN N
size NN N
indexes NNS N
for IN N
optimizing VBG N
iodine NN i
dose NN N
for IN N
aortic JJ p
and CC p
hepatic JJ p
enhancement NN p
at IN p
multidetector NN p
CT NNP p
: : p
comparison NN N
of IN N
total JJ N
body NN N
weight NN N
, , N
lean JJ N
body NN N
weight NN N
, , N
and CC N
blood NN N
volume NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
and CC N
compare VB N
total JJ o
body NN o
weight NN o
( ( o
TBW NNP o
) ) o
, , o
lean JJ o
body NN o
weight NN o
( ( o
LBW NNP o
) ) o
, , o
and CC o
estimated VBD o
blood NN o
volume NN o
( ( o
BV NNP o
) ) o
for IN N
the DT N
adjustment NN N
of IN N
the DT N
iodine NN i
dose NN i
required VBN N
for IN N
contrast NN N
material-enhanced JJ N
multidetector NN N
computed VBD N
tomography NN N
( ( N
CT NNP N
) ) N
of IN N
the DT N
aorta NN N
and CC N
liver NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Institutional NNP N
review NN N
committee NN N
approval NN N
and CC N
written VBN N
informed JJ N
consent NN N
were VBD N
obtained VBN N
. . N

One CD p
hundred VBD p
twenty NN p
patients NNS p
( ( p
54 CD p
men NNS p
, , p
66 CD p
women NNS p
; : p
mean JJ p
age NN p
, , p
64.1 CD p
years NNS p
; : p
range NN p
, , p
19-88 CD p
years NNS p
) ) p
who WP p
underwent JJ p
multidetector NN i
CT NNP i
of IN p
the DT p
upper JJ p
abdomen NNS p
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
of IN N
40 CD N
patients NNS N
each DT N
: : N
( ( N
a DT N
) ) N
TBW NNP N
group NN N
( ( N
0.6 CD N
g NN N
of IN N
iodine NN i
per IN N
kilogram NN N
of IN N
TBW NNP N
) ) N
, , N
( ( N
b NN N
) ) N
LBW NNP N
group NN N
( ( N
0.821 CD N
g NN N
of IN N
iodine NN i
per IN N
kilogram NN N
of IN N
LBW NNP N
) ) N
, , N
and CC N
( ( N
c NN N
) ) N
BV NNP N
group NN N
( ( N
men NNS N
, , N
8.6 CD N
g NN N
of IN N
iodine NN i
per IN N
liter NN N
of IN N
BV NNP N
; : N
women NNS N
, , N
9.9 CD N
g NN N
of IN N
iodine NN N
per IN N
liter NN N
of IN N
BV NNP N
) ) N
. . N

Change NN N
in IN N
CT NNP N
number NN N
between IN N
unenhanced JJ N
and CC N
contrast-enhanced JJ N
images NNS N
per IN N
gram NN N
of IN N
iodine NN N
and CC N
maximum JJ N
hepatic JJ N
enhancement NN N
( ( N
MHE NNP N
) ) N
adjusted VBD N
for IN N
iodine NN i
dose NN N
were VBD N
examined VBN N
for IN N
correlation NN N
with IN N
TBW NNP N
, , N
LBW NNP N
, , N
and CC N
BV NNP N
by IN N
using VBG N
linear JJ N
regression NN N
analysis NN N
. . N

RESULTS NNP N
In IN N
the DT N
portal JJ N
venous JJ N
phase NN N
, , N
correlation NN o
coefficients NNS o
for IN N
the DT N
correlation NN o
of IN o
change NN o
in IN o
CT NNP o
number NN o
per IN o
gram NN o
of IN N
iodine NN i
with IN N
TBW NNP o
for IN N
the DT N
aorta NN N
and CC N
liver NN N
were VBD N
-0.71 NNP N
and CC N
-0.79 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
TBW NNP N
group NN N
; : N
-0.80 CC N
and CC N
-0.86 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
LBW NNP N
group NN N
; : N
and CC N
-0.68 VB N
and CC N
-0.66 NNP N
, , N
respectively RB N
, , N
in IN N
the DT N
BV NNP N
group NN N
. . N

In IN N
the DT N
liver NN N
, , N
they PRP N
were VBD N
marginally RB N
higher JJR N
in IN N
the DT N
LBW NNP N
group NN N
than IN N
in IN N
the DT N
BV NNP N
group NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Adjusted VBN o
MHE NNP o
remained VBD N
constant JJ N
at IN N
77.9 CD N
HU NNP N
+/- JJ N
10.2 CD N
( ( N
standard JJ N
deviation NN N
) ) N
in IN N
the DT N
LBW NNP o
group NN N
with IN N
respect NN N
to TO N
TBW NNP o
, , N
but CC N
it PRP N
increased VBD N
in IN N
the DT N
TBW NNP o
( ( N
r VB N
= RB N
0.80 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
BV NNP o
( ( N
r VB N
= RB N
0.70 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
groups NNS N
as IN N
TBW NNP o
increased VBD N
. . N

CONCLUSION NN N
When WRB o
LBW NNP o
, , o
rather RB o
than IN o
TBW NNP o
or CC o
BV NNP o
, , o
is VBZ o
used VBN o
, , N
the DT N
iodine NN i
dose NN N
required VBN N
to TO N
achieve VB N
consistent JJ N
hepatic JJ N
enhancement NN N
may MD N
be VB N
estimated VBN N
more RBR N
precisely RB N
and CC N
with IN N
reduced JJ N
patient-to-patient JJ N
variability NN N
. . N

-DOCSTART- -14550686- O O

Safety NN N
of IN N
injectable JJ i
opioid JJ i
maintenance NN i
treatment NN i
for IN N
heroin NN p
dependence NN p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
growing VBG N
debate NN N
about IN N
injectable JJ i
opioid JJ i
treatment NN i
programs NNS i
in IN N
many JJ N
Western JJ p
countries NNS p
. . p

This DT N
is VBZ N
the DT N
first JJ N
placebo-controlled JJ i
study NN N
of IN N
the DT N
safety NN N
of IN N
injectable JJ i
opioids NNS i
in IN N
a DT N
controlled JJ N
treatment NN N
setting NN N
. . N

METHODS NNP N
Twenty-five JJ p
opioid-dependent JJ p
patients NNS p
on IN p
intravenous JJ i
( ( i
IV NNP i
) ) i
heroin NN i
or CC i
IV NNP i
methadone CD i
maintenance NN i
treatment NN i
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
their PRP$ N
individual JJ i
prescribed VBN i
IV NNP i
maintenance NN i
dose NN i
or CC i
placebo NN i
. . i

Acute JJ o
drug NN o
effects NNS o
were VBD N
recorded VBN N
, , N
focusing VBG N
on IN N
electrocardiography NN o
, , o
respiratory NN o
movements NNS o
, , o
arterial JJ o
blood NN o
oxygen NN o
saturation NN o
, , o
and CC o
electroencephalography NN o
( ( o
EEG NNP o
) ) o
. . o

RESULTS NNP N
After IN N
heroin JJ i
injection NN i
, , N
marked VBD N
respiratory JJ o
depression NN o
progressing VBG N
to TO N
a DT N
Cheyne-Stokes NNP o
pattern NN o
occurred VBD N
. . N

Peripheral NNP o
arterial JJ o
blood NN o
oxygenation NN o
decreased VBD N
to TO N
78.9 CD N
+/- JJ N
8.7 CD N
% NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
ranging VBG N
from IN N
52 CD N
% NN N
-90 CD N
% NN N
. . N

During IN N
hypoxia NN o
, , N
7 CD N
of IN N
the DT N
16 CD p
subjects NNS p
experienced JJ N
intermittent NN N
and CC N
somewhat RB N
severe JJ N
bradycardia NN o
. . o

Five CD N
subjects NNS N
exhibited VBN N
paroxysmal JJ o
EEG NNP o
patterns NNS o
. . o

After IN N
methadone NN i
injection NN i
, , N
respiratory JJ o
depression NN o
was VBD N
less RBR N
pronounced JJ N
than IN N
after IN N
heroin JJ i
injection NN i
. . i

No DT N
relevant JJ N
bradycardia NN o
was VBD N
noted VBN N
. . N

CONCLUSIONS NNP N
Opioid NNP i
doses VBZ N
commonly RB N
prescribed VBN N
in IN N
IV NNP i
opioid FW i
treatment NN i
induce NN N
marked VBD N
respiratory NN o
and CC o
circulatory NN o
depression NN o
, , N
as RB N
well RB N
as IN N
occasionally RB N
irregular JJ o
paroxysmal JJ o
EEG NNP o
activity NN o
. . o

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
optimize VB N
the DT N
clinical JJ N
practice NN N
of IN N
IV NNP i
opioid FW i
treatment NN i
to TO N
prevent VB N
serious JJ N
complications NNS N
. . N

Moreover RB N
, , N
the DT N
extent NN N
of IN N
the DT N
observed JJ N
effects NNS N
raises VBZ N
questions NNS N
about IN N
the DT N
appropriateness NN N
of IN N
IV NNP i
opioid FW i
treatment NN i
in IN N
the DT N
present JJ N
form NN N
. . N

-DOCSTART- -25044079- O O

Examining VBG N
the DT N
temperature NN N
of IN N
embryo JJ N
culture NN N
in IN N
in IN p
vitro JJ p
fertilization NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
comparing VBG N
traditional JJ N
core NN N
temperature NN N
( ( N
37?C CD N
) ) N
to TO N
a DT N
more RBR N
physiologic JJ N
, , N
cooler JJ N
temperature NN N
( ( N
36?C CD N
) ) N
. . N

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
culture NN N
at IN N
a DT N
more RBR N
physiologically RB N
cooler JJ N
temperature NN N
, , N
as IN N
suggested VBN N
by IN N
limited JJ N
human NN N
and CC N
animal NN N
data NNS N
, , N
would MD N
improve VB N
blastulation NN N
and CC N
pregnancy NN N
rates NNS N
in IN N
human JJ p
clinical JJ p
IVF NNP p
. . p

DESIGN NNP N
Paired NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SETTING NN N
Academic NNP N
. . N

PATIENT NNP p
( ( p
S NNP p
) ) p
Infertile NNP p
couples NNS p
( ( p
n=52 NN p
) ) p
with IN p
a DT p
female JJ p
partner NN p
less JJR p
than IN p
42 CD p
years NNS p
old JJ p
with IN p
eight CD p
or CC p
more JJR p
mature JJ p
oocytes VBZ p
retrieved VBN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Mature NNP N
oocytes VBZ N
obtained VBN N
from IN N
a DT N
single JJ N
cohort NN N
of IN N
oocytes NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS i
; : i
one CD i
was VBD i
cultured VBN i
at IN i
37?C CD i
and CC i
the DT i
other JJ i
at IN i
36?C CD i
from IN i
the DT N
time NN N
of IN i
ICSI NNP i
to TO i
the DT N
time NN i
of IN i
embryo NN i
transfer NN i
or CC i
vitrification NN i
. . i

Paired NNP i
embryo JJ N
transfers NNS N
were VBD N
accomplished VBN N
by IN N
transferring VBG N
one CD N
euploid JJ N
embryo NN N
from IN N
each DT N
group NN i
. . i

DNA NN i
fingerprinting NN i
was VBD i
used VBN N
as IN N
needed VBN N
to TO N
determine VB N
the DT N
outcome NN N
for IN N
each DT N
embryo NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP o
( ( o
S NNP o
) ) o
Rate NNP o
of IN o
development NN o
of IN o
expanded JJ o
blastocysts NNS o
suitable JJ o
for IN o
transfer NN o
or CC o
vitrification NN o
( ( o
primary JJ o
outcome NN o
) ) o
, , o
fertilization NN o
, , o
aneuploidy NN o
, , o
and CC o
sustained VBD o
implantation NN o
. . o

RESULT NNP o
( ( N
S NNP N
) ) N
A NNP N
total NN p
of IN p
805 CD p
mature NN o
oocytes NNS o
were VBD o
cultured VBN N
; : N
399 CD N
at IN N
36?C CD N
and CC N
406 CD N
at IN N
37?C CD N
. . N

Paired VBN N
analysis NN N
demonstrated VBD N
a DT N
higher JJR N
rate NN o
of IN o
usable JJ o
blastocyst NN o
formation NN o
per IN o
zygote NN o
at IN o
37?C CD o
( ( N
48.4 CD N
% NN N
) ) N
vs. NN N
at IN N
36?C CD N
( ( N
41.2 CD N
% NN N
) ) N
. . N

Rates NNS o
of IN o
fertilization NN o
, , o
aneuploidy NN o
, , o
and CC o
sustained JJ o
implantation NN o
were VBD o
equivalent JJ o
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
IVF NNP N
culture NN N
at IN N
36?C CD N
does VBZ N
not RB N
improve VB N
clinically RB N
relevant JJ N
parameters NNS N
of IN N
embryo NN N
development NN N
or CC N
sustained VBN N
implantation NN N
rates NNS N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01506089 NNP N
. . N

-DOCSTART- -8338943- O O

Prevention NN N
of IN N
regimen-related JJ N
toxicities NNS N
after IN p
bone NN p
marrow NN p
transplantation NN p
by IN p
pentoxifylline NN i
: : i
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
. . N

Elevated JJ N
levels NNS N
of IN N
tumor NN N
necrosis NN N
factor NN N
alpha NN N
( ( N
TNF-alpha NNP N
) ) N
have VBP N
been VBN N
reported VBN N
to TO N
correlate VB N
with IN N
the DT N
development NN N
of IN N
transplant-related JJ N
complications NNS N
after IN N
bone NN p
marrow NN p
transplantation NN p
( ( p
BMT NNP p
) ) p
. . p

In IN N
a DT N
recent JJ N
phase NN N
I-II NNP N
trial NN N
, , N
oral JJ N
administration NN N
of IN N
pentoxifylline NN i
( ( i
PTX NNP i
) ) i
, , N
a DT N
xanthine JJ N
derivative JJ N
capable NN N
of IN N
downregulating VBG N
TNF-alpha JJ N
production NN N
in IN N
vitro NN N
, , N
was VBD N
reported VBN N
to TO N
reduce VB N
morbidity NN N
and CC N
mortality NN N
in IN N
patients NNS p
undergoing JJ p
BMT NNP p
. . p

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
PTX NNP N
therapy NN N
among IN N
140 CD p
patients NNS p
undergoing VBG p
either CC p
allogeneic NN p
( ( p
n JJ p
= NNP p
51 CD p
) ) p
or CC p
autologous JJ p
BMT NNP p
( ( p
n JJ p
= NNP p
89 CD p
) ) p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
or CC N
not RB N
receive JJ N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
oral JJ N
PTX NNP i
, , N
1,600 CD N
mg/d NN N
in IN N
four CD N
divided JJ N
doses NNS N
from IN N
day NN N
-8 NNP N
until IN N
day NN N
+ VBD N
100 CD N
post-BMT NN N
. . N

The DT N
incidence NN o
of IN o
mucositis NN o
requiring VBG o
morphine NN o
sulfate NN o
( ( o
MSO4 NNP o
) ) o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
42.9 CD N
% NN N
) ) N
, , N
with IN N
the DT N
mean JJ N
number NN N
of IN N
days NNS N
with IN N
MSO4 NNP N
being VBG N
7.8 CD N
( ( N
SD NNP N
= NNP N
3.4 CD N
) ) N
in IN N
the DT N
PTX NNP N
group NN N
versus VBD N
8.2 CD N
( ( N
SD NNP N
= NNP N
3.4 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
NS NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
renal JJ o
insufficiency NN o
was VBD N
not RB N
affected VBN N
by IN N
PTX NNP i
administration NN N
( ( N
15.7 CD N
% NN N
in IN N
the DT N
PTX NNP N
group NN N
v VBD N
21.4 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
[ NNP N
NS NNP N
] NNP N
) ) N
and CC N
the DT N
highest JJS N
serum NN o
creatinine NN o
value NN o
during IN N
the DT N
first JJ N
100 CD N
days NNS N
post-BMT NN N
was VBD N
119 CD N
mumol/L NN N
( ( N
SD NNP N
= NNP N
82.4 CD N
) ) N
in IN N
the DT N
PTX NNP N
group NN N
versus VBD N
103.9 CD N
mumol/L NN N
( ( N
SD NNP N
= NNP N
57 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
NS NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
grade NN o
> NN o
or CC o
= VB o
2 CD o
graft-versus-host JJ o
disease NN o
was VBD N
similar JJ N
in IN N
each DT N
group NN N
( ( N
11/25 CD N
[ RB N
44 CD N
% NN N
] NN N
in IN N
the DT N
PTX NNP i
group NN N
v VBD N
12/26 CD N
[ JJ N
46 CD N
% NN N
] NN N
in IN N
the DT N
control NN N
group NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
hematologic JJ o
toxicity NN o
, , o
transfusion NN o
requirements NNS o
, , o
duration NN o
of IN o
fever NN o
, , o
and CC o
hepatic JJ o
toxicity NN o
between IN N
the DT N
treatment NN N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
study NN N
failed VBD N
to TO N
show VB N
a DT N
prophylactic JJ N
effect NN N
of IN N
PTX NNP i
in IN N
transplant-related JJ N
toxicities NNS N
after IN N
BMT NNP N
. . N

On IN N
the DT N
basis NN N
of IN N
these DT N
findings NNS N
, , N
we PRP N
can MD N
not RB N
recommend VB N
that IN N
PTX NNP i
be VB N
part NN N
of IN N
early JJ N
mortality NN N
and CC N
morbidity NN N
prevention NN N
programs NNS N
after IN p
BMT NNP p
. . p

-DOCSTART- -20090434- O O

A DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
the DT N
efficacy NN o
of IN N
scheduled JJ N
dosing NN N
of IN N
acetaminophen NN i
and CC i
hydrocodone NN i
for IN N
the DT N
management NN N
of IN N
postoperative JJ p
pain NN p
in IN p
children NNS p
after IN p
tonsillectomy NN p
. . p

OBJECTIVES UH N
To TO N
determine VB N
the DT N
effectiveness NN o
of IN N
around-the-clock NN N
( ( N
ATC NNP N
) ) N
analgesic JJ N
administration NN N
, , N
with IN N
or CC N
without IN N
nurse JJ N
coaching NN N
, , N
compared VBN N
with IN N
standard JJ N
care NN N
with IN N
as RB N
needed VBN N
( ( N
PRN NNP N
) ) N
dosing NN N
in IN N
children NNS p
undergoing VBG p
outpatient JJ p
tonsillectomy NN p
. . p

METHODS NNP N
Children NNP p
6 CD p
to TO p
15 CD p
years NNS p
of IN p
age NN p
were VBD N
randomized VBN N
to TO N
receive VB N
acetaminophen NN i
and CC i
hydrocodone NN i
( ( N
167 CD N
mg/2.5 NN N
mg/5 NN N
mL NN N
) ) N
for IN N
3 CD N
days NNS N
after IN N
surgery NN N
: : N
Group NNP N
A NNP N
( ( N
N=39 NNP N
) ) N
-every VBD N
4 CD N
hours NNS N
PRN NNP N
, , N
with IN N
standard JJ N
postoperative JJ N
instructions NNS N
; : N
Group NNP N
B NNP N
( ( N
N=34 NNP N
) ) N
-every VBD N
4 CD N
hours NNS N
ATC NNP N
, , N
with IN N
standard JJ N
postoperative JJ N
instructions NNS N
, , N
without IN i
nurse JJ i
coaching NN i
; : i
and CC N
Group NNP N
C NNP N
( ( N
N=40 NNP N
) ) N
-every VBD N
4 CD N
hours NNS N
ATC NNP N
, , N
with IN N
standard JJ N
postoperative JJ N
instructions NNS N
, , N
with IN i
coaching NN i
. . i

Parents NNS o
completed VBD o
a DT o
medication NN o
log NN o
, , o
and CC o
recorded VBD o
the DT o
presence NN o
and CC o
severity NN o
of IN o
opioid-related JJ o
adverse JJ o
effects NNS o
and CC o
children NNS o
's POS o
reports NNS o
of IN o
pain NN o
intensity NN o
using VBG o
a DT o
0 CD o
to TO o
10 CD o
numeric JJ o
rating NN o
scale NN o
. . o

RESULTS NNP N
No NNP N
differences NNS N
were VBD N
found VBN N
in IN N
analgesic JJ N
administration NN N
or CC N
pain JJ o
intensity NN o
scores NNS o
between IN N
the DT N
2 CD N
ATC NNP N
groups NNS N
. . N

Therefore RB N
, , N
they PRP N
were VBD N
combined VBN N
for IN N
comparison NN N
with IN N
the DT N
PRN NNP N
group NN N
. . N

Children NNP N
in IN N
the DT N
ATC NNP N
group NN N
received VBD N
more JJR N
analgesic JJ o
than IN N
those DT N
in IN N
the DT N
PRN NNP N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Children NNP N
in IN N
the DT N
PRN NNP N
group NN N
had VBD N
higher JJR N
pain NN o
intensity NN o
scores NNS o
compared VBN N
to TO N
children NNS N
in IN N
the DT N
ATC NNP N
group NN N
, , N
both DT N
at IN N
rest NN N
( ( N
P=0.017 NNP N
) ) N
and CC N
with IN N
swallowing NN N
( ( N
P=0.017 NNP N
) ) N
. . N

Pain NNP o
intensity NN o
scores NNS o
for IN N
both DT N
groups NNS N
were VBD N
higher JJR N
in IN N
the DT N
morning NN N
compared VBN N
with IN N
the DT N
evening NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

With IN N
the DT N
exception NN N
of IN N
constipation NN o
, , N
scheduled VBN N
analgesic JJ N
dosing VBG N
did VBD N
not RB N
increase VB N
the DT N
frequency NN o
or CC o
severity NN o
of IN o
opioid-related JJ o
adverse JJ o
effects NNS o
. . o

DISCUSSION NNP N
Scheduled VBD N
dosing NN N
of IN N
acetaminophen NN N
and CC N
hydrocodone NN N
is VBZ N
more RBR N
effective JJ N
than IN N
PRN NNP N
dosing VBG N
in IN N
reducing VBG N
pain NN N
intensity NN N
in IN N
children NNS N
after IN N
tonsillectomy NN N
. . N

Nurse CC N
coaching VBG N
does VBZ N
not RB N
impact VB N
parent NN N
's POS N
adherence NN N
to TO N
ATC NNP N
dosing NN N
. . N

-DOCSTART- -12055323- O O

Impact NN N
of IN N
interviewer NN N
's POS N
body NN N
mass NN N
index NN N
on IN N
underreporting VBG N
energy NN N
intake NN N
in IN N
overweight NN p
and CC p
obese JJ p
women NNS p
. . p

OBJECTIVE NN N
To TO N
determine VB N
if IN N
overweight JJ p
and CC p
obese JJ p
women NNS p
provide VBP N
more JJR N
accurate JJ N
reports NNS N
of IN N
their PRP$ N
energy NN N
intake NN N
by IN N
1 CD N
) ) N
in-person NN i
recall NN i
with IN i
an DT i
obese JJ i
interviewer NN i
, , N
2 CD N
) ) N
in-person NN i
recall NN i
with IN i
a DT i
lean JJ i
interviewer NN i
, , N
or CC N
3 CD N
) ) N
telephone NN i
recall NN i
with IN i
an DT i
unknown JJ i
interviewer NN i
. . i

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
Eighty-eight NNP p
overweight NN p
and CC p
obese JJ p
women NNS p
participated VBD p
in IN p
this DT p
study NN p
. . p

Subjects NNS N
completed VBD N
one CD N
telephone-administered JJ i
multiple-pass JJ i
24-hour JJ i
recall NN i
( ( N
MP24R NNP N
) ) N
with IN N
an DT N
unknown JJ i
interviewer NN i
and CC N
were VBD N
then RB N
randomly RB N
assigned VBN N
to TO N
an DT N
in-person JJ i
MP24R NNP i
with IN i
either CC i
a DT i
lean JJ i
or CC i
obese JJ i
interviewer NN i
to TO i
gather VB i
reported VBN o
energy NN o
intake NN o
( ( o
rEI NN o
) ) o
. . N

Basal NNP o
metabolic JJ o
rate NN o
( ( o
BMR NNP o
) ) o
was VBD N
measured VBN N
using VBG N
a DT N
Deltrac NNP N
monitor NN N
, , N
and CC N
physical JJ o
activity NN o
( ( o
EEPA NNP o
) ) o
was VBD N
estimated VBN N
using VBG N
a DT N
Caltrac NNP i
accelerometer NN i
. . i

Therefore RB N
, , N
estimated VBD N
energy NN N
expenditure NN N
was VBD N
determined VBN N
by IN N
: : N
estTEE NN N
= NNP N
( ( N
BMR NNP N
+ NNP N
EEPA NNP N
) ) N
x VBD N
1.10 CD N
. . N

RESULTS VB N
No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
in-person JJ N
interview NN N
modes NNS N
for IN N
subject JJ N
age NN N
, , N
weight NN N
, , N
body NN N
mass NN N
index NN N
, , N
percentage NN N
of IN N
body NN N
fat NN N
, , N
total JJ N
energy NN N
expenditure NN N
, , N
rEI NN N
, , N
and CC N
misreporting NN N
of IN N
energy NN N
intake NN N
. . N

In-person NNP N
recall NN N
data NNS N
were VBD N
combined VBN N
for IN N
comparison NN N
with IN N
the DT N
telephone NN N
recalls VBZ N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
in-person JJ N
and CC N
telephone NN N
recalls NNS N
for IN N
rEI NN o
and CC o
misreporting NN o
. . o

Mean NNP o
reported VBD o
energy NN o
intake NN o
was VBD N
significantly RB N
lower JJR N
than IN N
estimated VBN N
total JJ o
energy NN o
expenditure NN o
for IN N
the DT N
telephone NN N
recalls NNS N
and CC N
combined VBN N
( ( N
lean JJ N
and CC N
obese JJ N
modes NNS N
) ) N
in-person NN N
recalls NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
found VBD N
that IN N
interviewer NN N
body NN N
mass NN N
index NN N
had VBD N
no DT N
impact NN N
on IN N
self-reported JJ N
energy NN N
intake NN N
during IN N
an DT N
in-person JJ N
MP24R NNP N
, , N
and CC N
that IN N
telephone NN N
recall NN N
data NNS N
were VBD N
comparable JJ N
with IN N
in-person JJ N
recalls NNS N
. . N

Underreporting NNP N
was VBD N
a DT N
widespread JJ N
problem NN N
( ( N
approximately RB N
26 CD N
% NN N
) ) N
for IN N
all DT N
modes NNS N
in IN N
this DT N
sample NN N
. . N

-DOCSTART- -8918486- O O

Improved NNP N
local JJ N
control NN N
of IN N
invasive JJ N
bladder NN N
cancer NN N
by IN N
concurrent NN i
cisplatin NN i
and CC i
preoperative NN i
or CC i
definitive JJ i
radiation NN i
. . i

The DT N
National NNP N
Cancer NNP N
Institute NNP N
of IN N
Canada NNP N
Clinical NNP N
Trials NNP N
Group NNP N
. . N

PURPOSE NNP N
A NNP N
prospective JJ N
randomized VBN N
trial NN N
was VBD N
conducted VBN N
to TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
concurrent NN i
cisplatin NN i
to TO i
preoperative VB i
or CC i
definitive JJ i
radiation NN i
therapy NN i
in IN N
patients NNS p
with IN p
muscle-invasive JJ p
bladder NN p
cancer NN p
improved VBD p
local JJ o
control NN o
or CC o
survival NN o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
Ninety-nine NNP p
eligible JJ p
patients NNS p
with IN p
T2 NNP p
to TO p
T4b NNP p
transitional JJ p
cell NN p
bladder NN p
cancer NN p
participated VBD p
, , p
64 CD p
% NN p
with IN p
cT3b NN p
or CC p
cT4 NN p
. . p

Patients NNS N
and CC N
their PRP$ N
physicians NNS N
selected VBN N
either RB N
definitive JJ N
radiotherapy NN i
or CC i
precystectomy JJ i
radiotherapy NN i
; : i
patients NNS N
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
receive VB N
intravenous JJ i
cisplatin NNS i
100 CD N
mg/m2 NNS N
at IN N
2-week JJ N
intervals NNS N
for IN N
three CD N
cycles NNS N
concurrent VBP i
with IN i
pelvic JJ i
radiation NN i
, , N
or CC N
to TO N
receive VB i
radiation NN i
without IN i
chemotherapy NN i
. . i

Patients NNS N
were VBD N
stratified VBN N
by IN N
clinical JJ N
tumor NN N
stage NN N
and CC N
by IN N
radiation NN N
plan NN N
. . N

The DT N
median JJ N
follow-up JJ N
duration NN N
is VBZ N
6.5 CD N
years NNS N
. . N

RESULTS VB N
The DT N
occurrence NN o
of IN o
distant JJ o
metastases NNS o
was VBD N
the DT N
same JJ N
in IN N
both DT N
study NN N
arms NNS N
. . N

However RB N
, , N
25 CD N
of IN N
48 CD N
control NN N
patients NNS N
have VBP N
had VBD N
a DT N
first JJ o
recurrence NN o
in IN N
the DT N
pelvis NN N
, , N
compared VBN N
with IN N
15 CD N
of IN N
51 CD N
cisplatin-treated JJ i
patients NNS N
( ( N
P NNP N
= NNP N
.036 NNP N
) ) N
. . N

The DT N
pelvic JJ o
relapse NN o
rate NN o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
significantly RB N
reduced VBN N
by IN N
concurrent NN i
cisplatin NN i
( ( N
P NNP N
= NNP N
.038 NNP N
, , N
log-rank JJ N
test NN N
) ) N
and CC N
this DT N
effect NN N
was VBD N
preserved VBN N
in IN N
a DT N
stepwise NN N
Cox NNP N
regression NN N
model NN N
of IN N
prognostic JJ N
factors NNS N
( ( N
hazards NNS N
ratio NN N
, , N
0.50 CD N
; : N
90 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.29 CD N
to TO N
0.86 CD N
; : N
P NNP N
= NNP N
.036 NNP N
) ) N
. . N

The DT N
hazard NN o
reduction NN o
was VBD N
similar JJ N
for IN N
both DT N
radiation NN N
plans NNS N
. . N

Pretreatment NNP N
leukocytosis NN N
and CC N
high JJ N
clinical JJ N
stage NN N
were VBD N
independent JJ N
adverse JJ N
factors NNS N
in IN N
a DT N
Cox NNP N
model NN N
of IN N
overall JJ o
survival NN o
, , N
but CC N
the DT N
effect NN o
of IN N
cisplatin NN i
was VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Concurrent NNP i
cisplatin NN i
may MD N
improve VB N
pelvic NNS o
control NN o
of IN N
locally RB N
advanced JJ N
bladder NN N
cancer NN N
with IN N
preoperative JJ i
or CC i
definitive JJ i
radiation NN i
, , N
but CC N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
improve VB N
overall JJ o
survival NN o
. . o

The DT N
use NN N
of IN N
concurrent NN i
cisplatin NN i
had VBD N
no DT N
detectable JJ N
effect NN o
on IN N
distant JJ N
metastases NNS N
. . N

-DOCSTART- -15929820- O O

[ VB N
A DT N
multicenter NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
of IN N
intravenous JJ N
diltiazem NNS i
in IN N
treatment NN N
of IN N
unstable JJ p
angina NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
safety NN N
of IN N
intravenous JJ N
diltiazem NNS i
compared VBN N
with IN N
nitroglycerin NN i
in IN N
the DT N
patients NNS p
with IN p
unstable JJ p
angina JJ p
pectoris NN p
. . p

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
open-label JJ N
, , N
parallel JJ N
group NN N
trial NN N
was VBD N
conducted VBN N
. . N

A DT N
total NN p
of IN p
213 CD p
eligible JJ p
patients NNS p
were VBD p
enrolled VBN p
. . p

They PRP N
were VBD N
randomized VBN N
either RB N
to TO N
diltiazem VB i
or CC i
nitroglycerin VB i
treatment NN N
. . N

The DT N
diltiazem NN i
was VBD N
administered VBN N
from IN N
100 CD N
microg/min NN N
at IN N
the DT N
initiation NN N
of IN N
treatment NN N
, , N
the DT N
largest JJS N
dosage NN N
was VBD N
200 CD N
- : N
300 CD N
microg/min NN N
; : N
the DT N
nitroglycerin NN i
was VBD N
administered VBN N
from IN N
20 CD N
microg/min NN N
at IN N
the DT N
initiation NN N
of IN N
treatment NN N
. . N

The DT N
largest JJS N
dosage NN N
was VBD N
80 CD N
- : N
100 CD N
microg/min NN N
. . N

Intravenous JJ N
infusion NN N
was VBD N
kept VBN N
over IN N
48 CD N
hours NNS N
. . N

The DT N
endpoints NNS N
included VBD N
refractory JJ o
angina NN o
pectoris NN o
, , o
acute JJ o
myocardial JJ o
infarction NN o
, , o
death NN o
, , o
emergency NN o
PTCA NNP o
and CC o
CABG NNP o
. . o

RESULTS NNP N
( ( N
1 CD N
) ) N
Intravenous NNP N
diltiazem NN N
was VBD N
effective JJ N
on IN N
the DT N
improvement NN N
of IN N
symptom NN o
and CC o
electrocardiogram NN o
, , N
and CC N
its PRP$ N
effects NNS N
were VBD N
similar JJ N
to TO N
intravenous JJ N
nitroglycerin NN N
. . N

( ( N
2 CD N
) ) N
Compared VBN N
with IN N
nitroglycerin NN i
, , N
intravenous JJ N
diltiazem NN i
lowered VBD o
heart NN o
rate NN o
and CC o
myocardial JJ o
oxygen NN o
consumption NN o
index NN o
( ( N
systolic JJ N
pressure NN N
x JJ N
heart NN N
rate NN N
) ) N
to TO N
more RBR N
extent JJ N
significantly RB N
. . N

( ( N
3 CD N
) ) N
After IN N
treatment NN N
, , N
the DT N
onsets NNS o
of IN o
refractory JJ o
angina NNS o
pectoris NN o
were VBD N
reduced VBN o
more RBR o
significantly RB o
in IN N
the DT N
diltiazem NN i
group NN N
than IN N
in IN N
nitroglycerin JJ N
group NN N
[ VBD N
4 CD N
( ( N
3.8 CD N
% NN N
) ) N
vs NN N
13 CD N
( ( N
11.9 CD N
% NN N
) ) N
, , N
RR NNP N
0.32 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.11 CD N
- : N
0.96 CD N
) ) N
, , N
P NNP N
< VBZ N
0.05 CD N
] NN N
. . N

( ( N
4 CD N
) ) N
The DT N
patients NNS N
whose WP$ N
heart NN o
rate NN o
were VBD N
reduced VBN o
significantly RB o
( ( N
< JJ N
or= RB N
50 CD N
beats NNS N
per IN N
minute NN N
) ) N
in IN N
the DT N
diltiazem NN N
group NN N
were VBD N
more JJR N
than IN N
in IN N
the DT N
nitroglycerin JJ N
group NN N
[ VBD N
8 CD N
( ( N
7.7 CD N
% NN N
) ) N
vs NN N
0 CD N
( ( N
0 CD N
% NN N
) ) N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
. . N

But CC N
these DT N
patients NNS N
could MD N
tolerate VB N
the DT N
lower JJR N
heart NN o
rate NN o
very RB N
well RB N
in IN N
the DT N
diltiazem NN N
group NN N
. . N

( ( N
5 CD N
) ) N
The DT N
needs NNS N
of IN N
beta NN N
receptor NN N
blocker NN N
or CC N
calcium NN N
antagonists NNS N
were VBD N
reduced VBN N
more RBR N
significantly RB N
in IN N
the DT N
diltiazem NN i
group NN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
nitroglycerin JJ N
group NN N
[ VBD N
2 CD N
( ( N
1.9 CD N
% NN N
) ) N
vs NN N
13 CD N
( ( N
11.9 CD N
% NN N
) ) N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
. . N

CONCLUSION NNP N
Intravenous NNP N
diltiazem NN i
therapy NN N
is VBZ N
effective JJ N
and CC N
safe JJ N
for IN N
patients NNS p
with IN p
unstable JJ p
angina JJ p
pectoris NN p
. . p

It PRP N
may MD N
significantly RB N
lower VB N
the DT N
risk NN N
of IN N
refractory JJ N
angina JJ N
pectoris NNS N
compared VBN N
with IN N
intravenous JJ N
nitroglycerin NNS N
. . N

-DOCSTART- -2105256- O O

Effect NN N
of IN N
total JJ N
enteral JJ N
nutrition NN N
on IN N
the DT N
short-term JJ o
outcome NN o
of IN N
severely RB o
malnourished VBN o
cirrhotics NNS o
. . o

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

Thirty-five JJ p
severely RB p
malnourished VBN p
cirrhotic JJ p
patients NNS p
were VBD N
randomized VBN i
to TO i
receive VB i
either DT i
enteral-tube JJ i
feeding NN i
as IN i
the DT i
sole JJ i
nutritional JJ i
support NN i
( ( i
n JJ i
= NNP i
16 CD i
) ) i
or CC i
an DT i
isocaloric JJ i
, , i
isonitrogenous JJ i
, , i
low-sodium JJ i
standard JJ i
oral JJ i
diet NN i
( ( i
n JJ i
= NNP i
19 CD i
) ) i
. . N

Both DT p
groups NNS p
were VBD p
homogeneous JJ p
regarding VBG p
age NN p
, , p
sex NN p
distribution NN p
, , p
etiology NN p
of IN p
liver JJ p
cirrhosis NN p
, , p
history NN p
of IN p
previous JJ p
complications NNS p
, , p
clinical JJ p
status NN p
, , p
liver RB p
and CC p
renal JJ p
function NN p
, , p
modified VBD p
Child NNP p
's POS p
score NN p
, , p
and CC p
nutritional JJ p
status NN p
at IN p
admission NN p
. . p

The DT N
enteral JJ i
formula NN i
diet NN i
was VBD i
energy NN i
dense NN i
, , i
containing VBG i
40 CD i
mmol NN i
Na/day NNP i
, , i
whole JJ i
protein NN i
plus CC i
branched-chain JJ i
amino NN i
acids NNS i
, , i
medium- JJ i
and CC i
long-chain JJ i
triglycerides NNS i
, , i
and CC i
maltodextrin NN i
. . i

It PRP i
supplied VBD i
2115 CD i
kcal/day NN i
. . i

The DT i
amount NN i
of IN i
vitamins NNS i
and CC i
trace NN i
elements NNS i
was VBD i
at IN i
the DT i
upper JJ i
limit NN i
of IN i
the DT i
recommended JJ i
dietary JJ i
allowances NNS i
. . i

The DT i
orally RB i
fed JJ i
patients NNS i
were VBD i
encouraged VBN i
to TO i
eat VB i
all DT i
meals NNS i
served VBD i
. . i

Total JJ o
enteral JJ o
nutrition NN o
was VBD N
well RB N
tolerated VBN o
without IN N
major JJ N
complications NNS N
. . N

Serum NNP o
albumin NN o
and CC o
Child NNP o
's POS o
score NN o
improved VBD N
in IN N
the DT N
enterally RB N
fed JJ N
patients NNS N
but CC N
not RB N
in IN N
controls NNS N
. . N

Mortality NNP o
rate NN o
while IN o
in IN o
the DT o
hospital NN o
was VBD N
lower JJR N
in IN N
patients NNS N
on IN N
enteral JJ N
feeding NN N
than IN N
in IN N
controls NNS N
( ( N
12 CD N
% NN N
vs JJ N
47 CD N
% NN N
) ) N
. . N

These DT N
results NNS N
show VBP N
that IN N
total JJ N
enteral JJ N
nutrition NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
the DT N
short-term JJ o
clinical JJ o
outcome NN o
in IN N
severely RB p
malnourished JJ p
cirrhotics NNS p
. . p

-DOCSTART- -14623199- O O

Efficacy NN o
of IN N
azithromycin NN i
for IN N
the DT N
treatment NN N
of IN N
feline JJ p
chlamydophilosis NN p
. . p

The DT N
current JJ N
recommended VBD N
treatment NN N
for IN N
feline JJ p
chlamydophilosis NN p
involves VBZ N
daily RB N
oral JJ N
administration NN N
of IN N
antimicrobials NNS i
to TO N
all DT N
cats NNS p
within IN p
an DT p
affected JJ p
group NN p
for IN N
a DT N
prolonged JJ N
period NN N
of IN N
time NN N
( ( N
4-6 JJ N
weeks NNS N
) ) N
. . N

Not RB N
surprisingly RB N
, , N
owner NN N
compliance NN N
can MD N
be VB N
poor JJ N
resulting VBG N
in IN N
apparent JJ N
treatment NN N
failure NN N
. . N

Recent JJ N
anecdotal JJ N
evidence NN N
, , N
supported VBN N
by IN N
its PRP$ N
efficacy NN o
in IN N
the DT N
treatment NN N
of IN N
Chlamydia NNP N
trachomatis NN N
infection NN N
in IN N
humans NNS N
, , N
has VBZ N
suggested VBN N
that IN N
azithromycin NN i
may MD N
offer VB N
an DT N
alternative JJ N
by IN N
allowing VBG N
less JJR N
frequent JJ N
dosing NN N
for IN N
a DT N
shorter JJR N
duration NN N
. . N

A DT N
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
azithromycin NN i
for IN N
the DT N
treatment NN N
of IN N
chlamydia NN p
( ( p
Chlamydophila NNP p
felis RB p
) ) p
infection NN p
in IN p
cats NNS p
. . p

Whilst NNP N
azithromycin NN i
, , N
given VBN N
at IN N
10-15 JJ N
mg/kg NNS N
daily RB N
for IN N
3 CD N
days NNS N
and CC N
then RB N
twice RB N
weekly RB N
, , N
provided VBD N
a DT N
similar JJ o
, , o
rapid JJ o
resolution NN o
of IN o
clinical JJ o
signs NNS o
and CC o
negative JJ o
isolation NN o
scores NNS o
as IN N
doxycycline NN i
, , N
C NNP N
felis NN N
was VBD N
re-isolated VBN N
in IN N
four CD N
out IN N
of IN N
the DT N
five CD p
cats NNS p
treated VBN p
. . p

Furthermore NNP N
, , N
even RB N
daily JJ N
administration NN N
of IN N
azithromycin NN i
to TO N
chronically RB N
infected JJ N
cats NNS N
was VBD N
ineffective JJ o
in IN o
clearing VBG o
infection NN o
. . o

The DT N
azithromycin NN N
protocols NNS N
used VBN N
here RB N
were VBD N
therefore RB N
found VBN N
to TO N
be VB N
unsuccessful JJ o
in IN o
eliminating VBG o
the DT o
carriage NN o
of IN o
this DT o
strain NN o
of IN o
C NNP o
felis NN o
. . o

-DOCSTART- -7047002- O O

Corticosteroid-induced JJ N
osteopenia NN o
and CC o
vitamin NN o
D NNP o
metabolism NN o
. . o

Effect NNP N
of IN N
vitamin NN i
D2 NNP i
, , i
calcium NN i
phosphate NN i
and CC N
sodium NN i
fluoride JJ i
administration NN N
. . N

Thirty-one CD p
patients NNS p
scheduled VBN p
for IN p
long-term JJ p
( ( p
24 CD p
weeks NNS p
) ) p
treatment NN p
with IN p
prednisone NN i
in IN p
comparatively RB p
high JJ p
doses NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
further JJ N
treatment NN N
groups NNS N
. . N

Group NNP i
A NNP i
received VBD i
prednisone JJ i
plus CC i
'triple-treatment JJ i
' '' i
( ( i
vitamin FW i
D2 NNP i
45000 CD i
iu NN i
twice RB i
weekly RB i
, , i
sodium JJ i
fluoride RB i
50 CD i
mg NNS i
and CC i
calcium NN i
phosphate VBP i
4.5 CD i
g JJ i
daily RB i
) ) i
, , i
group NN i
B NNP i
received VBD i
only RB i
prednisone NN i
. . i

The DT N
study NN N
was VBD N
undertaken VBN N
in IN N
order NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prednisone- NN i
and CC N
triple-treatment JJ i
upon IN N
bone JJ o
mineral NN o
content NN o
( ( o
BMC NNP o
) ) o
and CC o
vitamin $ o
D NNP o
metabolism NN o
. . o

The DT N
groups NNS N
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
and CC N
prednisone NN N
dose NN N
. . N

BMC NNP o
fell VBD N
rapidly RB N
and CC N
similarly RB N
in IN N
both DT N
groups NNS N
, , N
demonstrating VBG N
that IN N
the DT N
triple-treatment NN N
has VBZ N
no DT N
preventive JJ N
effect NN N
on IN N
corticosteroid NN N
induced VBN N
osteopenia NN N
. . N

Serum NNP o
concentrations NNS o
of IN o
25OHD2 CD o
, , o
25OHD3 CD o
and CC o
1,25 CD o
( ( o
OH NNP o
) ) o
2D CD o
were VBD N
unchanged JJ N
in IN N
group NN N
B NNP N
( ( N
without IN N
triple-treatment NN N
) ) N
, , N
whereas RB N
in IN N
group NN N
A NNP N
25OHD2 CD o
increased VBD N
enormously RB N
, , N
25OHD3 CD o
was VBD N
suppressed VBN N
possibly RB N
by IN N
substrate NN N
competition NN N
for IN N
hydroxylation NN N
in IN N
the DT N
liver NN N
and CC N
1,25 CD o
( ( o
OH NNP o
) ) o
2D CD o
was VBD N
halved VBN N
. . N

The DT N
suppression NN N
of IN N
1,25 CD o
( ( o
OH NNP o
) ) o
2D CD o
may MD N
be VB N
an DT N
effect NN N
of IN N
raised VBD N
25OHD2 CD N
alone RB N
, , N
or CC N
in IN N
combination NN N
with IN N
corticosteroid JJ N
excess NN N
. . N

-DOCSTART- -9278836- O O

Active JJ o
warming NN o
, , o
not RB o
passive JJ o
heat NN o
retention NN o
, , N
maintains VBZ N
normothermia JJ o
during IN N
combined JJ N
epidural-general JJ N
anesthesia NN N
for IN N
hip NN p
and CC p
knee NN p
arthroplasty NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
to TO N
compare VB N
passive JJ N
heat NN N
retention NN N
by IN N
low-flow JJ N
anesthesia NN N
, , N
alone RB N
and CC N
with IN N
additional JJ N
thermal JJ N
insulation NN N
by IN N
reflective JJ N
blankets NNS N
, , N
with IN N
forced-air JJ N
warming VBG N
preventing VBG N
intraoperative JJ N
hypothermia NN N
during IN N
combined JJ N
epidural-general JJ N
anesthesia NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
study NN N
. . N

SETTING NNP N
Inpatient NNP p
anesthesia NN p
at IN p
a DT p
university NN p
department NN p
of IN p
orthopedic JJ p
surgery NN p
. . p

PATIENTS CC p
30 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
and CC p
II NNP p
patients NNS p
, , p
who WP p
were VBD p
scheduled VBN p
for IN p
elective JJ p
hip NN p
or CC p
knee VB p
arthroplasty JJ p
and CC p
were VBD p
free JJ p
from IN p
systemic JJ p
disease NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
received VBD N
epidural JJ N
block NN N
up RB N
to TO N
T10 NNP N
by IN N
alkalinized JJ i
lidocaine JJ i
2 CD i
% NN i
, , N
and CC N
then RB N
were VBD N
administered VBN N
standard JJ i
general JJ i
anesthesia NN i
by IN i
means NNS i
of IN i
low-flow JJ i
rebreathing NN i
system NN i
( ( N
fresh JJ N
gas NN N
flow NN N
= VBD N
1 CD N
L/min NNP N
) ) N
. . N

All DT N
procedures NNS N
started VBD N
between IN N
8 CD N
and CC N
10 CD N
AM NNP N
, , N
and CC N
operating NN N
room NN N
( ( N
OR NNP N
) ) N
temperature NN N
was VBD N
maintained VBN N
between IN N
21 CD N
degrees NNS N
and CC N
23 CD N
degrees NNS N
C NNP N
, , N
with IN N
relative JJ N
humidity NN N
ranging VBG N
between IN N
40 CD N
% NN N
and CC N
45 CD N
% NN N
. . N

For IN N
heat NN N
retention NN N
or CC N
warming VBG N
therapy NN N
, , N
patients NNS N
received VBD N
either RB N
low-flow JJ i
anesthesia NN i
only RB i
( ( N
control NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
low-flow JJ i
anesthesia NN i
with IN i
additional JJ i
reflective JJ i
blankets NNS i
( ( N
blanket NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
or CC N
low-flow JJ i
anesthesia NN i
with IN i
active JJ i
forced-air JJ i
warming NN i
( ( N
forced-air JJ N
, , N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Tympanic JJ o
temperature NN o
was VBD N
measured VBN N
at IN N
OR NNP N
arrival NN N
( ( N
baseline NN N
) ) N
; : N
immediately RB N
following VBG N
general JJ N
anesthesia JJ N
induction NN N
; : N
30 CD N
, , N
60 CD N
, , N
90 CD N
, , N
and CC N
120 CD N
minutes NNS N
from IN N
general JJ N
anesthesia NN N
induction NN N
; : N
and CC N
at IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Duration NNP o
of IN o
anesthesia NN o
, , o
invasiveness NN o
of IN o
surgery NN o
, , o
and CC o
baseline NN o
core NN o
temperature NN o
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Core NNP o
temperature NN o
decreased VBN N
in IN N
all PDT N
the DT N
three CD N
groups NNS N
30 CD N
minutes NNS N
after IN N
general JJ N
anesthesia NN N
induction NN N
compared VBN N
with IN N
baseline NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
; : N
afterwards NNS N
, , N
it PRP N
progressively RB N
decreased VBD N
in IN N
the DT N
control NN N
and CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
, , N
with IN N
a DT N
reduction NN o
from IN o
baseline NN o
values NNS o
measured VBN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
of IN N
2.0 CD N
degrees NNS N
C NNP N
and CC N
1.6 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

In IN N
the DT N
forced-air JJ N
group NN N
, , N
after IN N
the DT N
initial JJ N
significant JJ N
decrease NN N
( ( N
p JJ N
= $ N
0.01 CD N
vs. FW N
baseline NN N
) ) N
, , N
core JJ o
temperature NN o
progressively RB N
increased VBD N
to TO N
35.8 CD N
+/- JJ N
0.6 CD N
degrees NNS N
C NNP N
, , N
which WDT N
was VBD N
similar JJ N
to TO N
preoperative VB N
values NNS N
and CC N
significantly RB N
higher JJR N
than IN N
either CC N
the DT N
control NN N
or CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

CONCLUSIONS NNP N
During IN N
combined VBN N
epidural-general JJ N
anesthesia NN N
for IN N
elective JJ p
hip NN p
and CC p
knee NN p
arthroplasty NN p
, , N
passive JJ N
heat NN N
retention NN N
by IN N
means NNS N
of IN N
low-flow JJ i
anesthesia NN i
alone RB i
and CC i
in IN i
combination NN i
with IN i
reflective JJ i
blankets NNS i
is VBZ N
ineffective JJ N
in IN N
maintaining VBG o
intraoperative JJ o
normothermia NN o
and CC N
definitely RB N
inferior JJ N
to TO N
active JJ N
forced-air JJ N
warning NN N
. . N

-DOCSTART- -1420057- O O

Prevention NN N
of IN N
acute JJ o
postoperative JJ o
pressure NN o
rises VBZ N
in IN N
glaucoma NN p
patients NNS p
undergoing JJ p
cataract JJ p
extraction NN p
with IN p
posterior JJ p
chamber NN p
lens NNS p
implant VBP p
. . p

Acute JJ N
elevations NNS N
in IN N
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
commonly RB N
follow VBP N
extracapsular JJ N
cataract NN N
extraction NN N
and CC N
lens VBZ N
implant NN N
in IN N
glaucoma NN p
patients NNS p
. . p

Thirty NNP p
six CD p
patients NNS p
with IN p
glaucoma JJ p
undergoing JJ p
cataract NN p
extraction NN p
and CC p
posterior JJ p
chamber NN p
lens VBZ p
implantation NN p
received VBD N
one CD N
of IN N
three CD N
treatments NNS N
. . N

Group NNP N
1 CD N
: : N
500 CD N
mg NN N
of IN N
Diamox NNP i
Sustets NNP i
( ( i
acetazolamide RB i
) ) i
1 CD N
hour NN N
preoperatively RB N
( ( N
10 CD N
patients NNS N
) ) N
; : N
Group NNP N
2 CD N
: : N
peroperative JJ i
intracameral JJ i
Miochol NNP i
( ( i
acetylcholine NN i
) ) i
( ( N
11 CD N
patients NNS N
) ) N
; : N
Group NNP N
3 CD N
: : N
the DT N
above IN N
treatments NNS i
combined VBN i
( ( N
15 CD N
patients NNS N
) ) N
. . N

IOPs NNP o
were VBD N
measured VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
24 CD N
hours NNS N
postoperatively RB N
. . N

The DT N
average NN o
of IN o
the DT o
maximum JJ o
pressure NN o
rises VBZ o
above IN N
the DT N
preoperative JJ N
level NN N
over IN N
the DT N
24 CD N
hour NN N
period NN N
was VBD N
greatest JJS N
for IN N
the DT N
group NN N
receiving VBG N
acetazolamide IN i
only RB N
at IN N
8.9 CD N
mm NN N
Hg NNP N
; : N
for IN N
the DT N
acetylcholine NN i
group NN N
the DT N
average NN N
maximum JJ N
rise NN N
was VBD N
6.3 CD N
mm JJ N
Hg NNP N
; : N
while IN N
the DT N
combined JJ N
treatment NN N
group NN N
showed VBD N
a DT N
decrease NN N
of IN N
0.7 CD N
mm NN N
Hg NNP N
. . N

IOP NNP o
rises VBZ o
of IN N
> $ N
6 CD N
mm NN N
Hg NNP N
were VBD N
seen VBN N
in IN N
7 CD N
% NN N
of IN N
patients NNS N
( ( N
one CD N
of IN N
15 CD N
) ) N
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
, , N
45 CD N
% NN N
( ( N
five CD N
of IN N
11 CD N
) ) N
of IN N
the DT N
acetylcholine NN i
group NN N
, , N
and CC N
70 CD N
% NN N
( ( N
seven CD N
of IN N
10 CD N
) ) N
of IN N
the DT N
acetazolamide NN i
group NN N
. . N

IOP NNP o
rises VBZ o
of IN N
> $ N
10 CD N
mm NN N
Hg NNP N
were VBD N
seen VBN N
in IN N
7 CD N
% NN N
of IN N
the DT N
combined JJ N
treatment NN N
group NN N
, , N
in IN N
18 CD N
% NN N
of IN N
the DT N
acetylcholine NN i
only RB N
group NN N
, , N
and CC N
in IN N
50 CD N
% NN N
of IN N
the DT N
acetazolamide NN i
only RB N
group NN N
. . N

A DT N
pressure NN o
rise NN o
> VBZ o
20 CD o
mm NN o
Hg NNP o
was VBD N
seen VBN N
in IN N
one CD N
patient NN N
receiving VBG N
acetazolamide IN i
only RB N
and CC N
one CD N
patient NN N
receiving VBG N
acetylcholine NN i
only RB N
. . N

The DT N
difference NN N
between IN N
the DT N
acetylcholine NN i
group NN N
and CC N
the DT N
combined VBN N
group NN N
for IN N
rises NNS o
> VBP o
6 CD o
mm NN o
Hg NNP o
was VBD N
significant JJ N
using VBG N
the DT N
chi NN N
2 CD N
test NN N
while IN N
the DT N
acetazolamide NN i
group NN N
showed VBD N
a DT N
significant JJ N
difference NN N
for IN N
rises NNS o
> VBP o
6 CD o
and CC N
10 CD N
mm NN N
Hg NNP N
compared VBN N
with IN N
the DT N
combined VBN N
group NN N
. . N

All DT N
acute JJ o
pressure NN o
rises NNS o
were VBD N
recorded VBN N
before RB N
or CC N
at IN N
9 CD N
hours NNS N
following VBG N
operation NN N
except IN N
in IN N
the DT N
combined JJ i
treatment NN i
patient NN N
where WRB N
the DT N
rise NN N
occurred VBD N
at IN N
24 CD N
hours NNS N
. . N

To TO N
prevent VB N
the DT N
acute JJ o
IOP NNP o
rises VBZ N
seen VBN N
following VBG N
cataract NN N
surgery NN N
with IN N
lens NNS N
implant VBP N
in IN N
glaucoma NN p
patients NNS p
we PRP N
recommend VBP N
combined VBN N
ocular JJ N
hypotensive JJ N
therapy NN N
. . N

-DOCSTART- -8197064- O O

[ JJ N
Effects NNS N
of IN N
an DT N
intensive JJ i
therapy NN i
program NN i
for IN N
behaviorally RB p
disordered VBN p
mentally RB p
handicapped JJ p
patients NNS p
on IN p
staff NN p
personnel NNS p
in IN p
residential JJ p
care NN p
] NNP p
. . N

This DT N
study NN N
evaluates VBZ N
the DT N
effects NNS N
of IN N
an DT N
intensive JJ i
therapy NN i
program NN i
designed VBN N
for IN N
mentally RB p
handicapped JJ p
persons NNS p
with IN p
severely RB p
disturbed VBN p
or CC p
autistic JJ p
behavior NN p
on IN p
their PRP$ p
staff NN p
personal JJ p
which WDT p
had VBD p
an DT p
active JJ p
role NN p
in IN p
the DT p
program NN p
. . p

The DT N
staff NN N
members NNS N
rated VBD N
their PRP$ N
professional JJ N
competence NN N
, , N
quality NN N
of IN N
interaction NN N
with IN N
the DT N
client NN N
, , N
team JJ N
culture NN N
and CC N
work NN N
satisfaction NN N
before IN N
and CC N
after IN N
being VBG N
engaged VBN N
in IN N
the DT N
program NN N
, , N
with IN N
additional JJ N
ratings NNS N
of IN N
their PRP$ N
personal JJ N
aims NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
program NN N
. . N

Three NNP N
sets NNS N
of IN N
data NNS N
were VBD N
obtained VBN N
with IN N
the DT N
program NN N
being VBG N
conducted VBN N
three CD N
times NNS N
in IN N
a DT N
row NN N
. . N

The DT N
testings NNS N
of IN N
the DT N
related VBN N
as RB N
well RB N
as IN N
the DT N
independent JJ N
samples NNS N
show VBP N
differentiated JJ N
program NN N
effects NNS N
. . N

The DT N
main JJ N
effect NN N
is VBZ N
an DT N
increase NN N
of IN N
the DT N
professional JJ o
competence NN o
and CC o
quality NN o
of IN o
interaction NN o
, , N
especially RB N
by IN N
the DT N
qualified JJ N
staff NN N
members NNS N
. . N

Trainees NNP N
put VBD N
emphasis NN N
on IN N
the DT N
development NN N
of IN N
their PRP$ N
personal JJ N
relationship NN N
with IN N
the DT N
client NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
impact NN N
of IN N
learning VBG N
processes NNS N
specific JJ N
to TO N
the DT N
roles NNS N
of IN N
the DT N
staff NN N
members NNS N
and CC N
motivational JJ N
factors NNS N
on IN N
learning NN N
and CC N
therapy NN N
outcome NN N
, , N
along IN N
with IN N
institutional JJ N
conditions NNS N
influencing VBG N
successful JJ N
learning NN N
. . N

Thus VB N
the DT N
program NN N
facilitates VBZ N
the DT N
professional JJ N
and CC N
interpersonal JJ N
learning NN N
process NN N
of IN N
staff NN N
members NNS N
in IN N
a DT N
specific JJ N
way NN N
with IN N
success NN N
as RB N
well RB N
as IN N
with IN N
limitations NNS N
. . N

-DOCSTART- -24740733- O O

Correlations NNS N
between IN N
the DT N
clinical JJ o
, , o
histological JJ o
and CC o
neurophysiological JJ o
examinations NNS o
in IN N
patients NNS p
before IN p
and CC p
after IN p
parotid JJ i
gland NN i
tumor NN i
surgery NN i
: : i
verification NN N
of IN N
facial JJ N
nerve NN N
transmission NN N
. . N

Parotid NNP N
gland NN N
tumor NN N
surgery NN N
sometimes RB N
leads VBZ N
to TO N
facial JJ N
nerve NN N
paralysis NN N
. . N

Malignant NNP N
more JJR N
than IN N
benign JJ N
tumors NNS N
determine VBP N
nerve NN N
function NN N
preoperatively RB N
, , N
while IN N
postoperative JJ N
observations NNS N
based VBN N
on IN N
clinical JJ N
, , N
histological JJ N
and CC N
neurophysiological JJ N
studies NNS N
have VBP N
not RB N
been VBN N
reported VBN N
in IN N
detail NN N
. . N

The DT N
aims NNS N
of IN N
this DT N
pilot NN N
study NN N
were VBD N
evaluation NN N
and CC N
correlations NNS N
of IN N
histological JJ o
properties NNS o
of IN o
tumor NN o
( ( o
its PRP$ o
size NN o
and CC o
location NN o
) ) o
and CC N
clinical JJ o
and CC o
neurophysiological JJ o
assessment NN o
of IN o
facial JJ o
nerve NN o
function NN o
pre- NN o
and CC o
post-operatively RB o
( ( N
1 CD N
and CC N
6 CD N
months NNS N
) ) N
. . N

Comparative JJ N
studies NNS N
included VBD N
17 CD p
patients NNS p
with IN p
benign JJ p
( ( p
n JJ p
= NNP p
13 CD p
) ) p
and CC p
malignant JJ p
( ( p
n JJ p
= NNP p
4 CD p
) ) p
tumors NNS p
. . p

Clinical JJ o
assessment NN o
was VBD N
based VBN N
on IN N
House-Brackmann NNP o
scale NN o
( ( o
H-B NNP o
) ) o
, , o
neurophysiological JJ o
diagnostics NNS o
included VBD o
facial JJ o
electroneurography NN o
[ NNP o
ENG NNP o
, , o
compound NN o
muscle NN o
action NN o
potential NN o
( ( o
CMAP NNP o
) ) o
] NN o
, , o
mimetic JJ o
muscle NN o
electromyography NN o
( ( o
EMG NNP o
) ) o
and CC o
blink-reflex JJ o
examinations NNS o
( ( o
BR NNP o
) ) o
. . o

Mainly RB N
grade VBD N
I PRP N
of IN N
H-B NNP o
was VBD N
recorded VBN N
both DT N
pre- JJ N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
and CC N
post-operatively RB N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
in IN N
patients NNS p
with IN p
small JJ p
( ( p
1.5-2.4 JJ p
cm NN p
) ) p
benign NN p
tumors NNS p
located VBN p
in IN p
superficial JJ p
lobes NNS p
. . p

Patients NNS p
with IN p
medium NN p
size NN p
( ( p
2.5-3.4 JJ p
cm NN p
) ) p
malignant NN p
tumors NNS p
in IN p
both DT p
lobes NNS p
were VBD N
scored VBN N
at IN N
grade NN N
I PRP N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
and CC N
III NNP N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
pre- NN N
and CC N
mainly RB N
VI NNP N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
post-operatively RB N
. . N

CMAP NNP o
amplitudes NNS o
after IN N
stimulation NN N
of IN N
mandibular JJ N
marginal JJ N
branch NN N
were VBD N
reduced VBN N
at IN N
about RB N
25 CD N
% NN N
in IN N
patients NNS p
with IN p
benign JJ p
tumors NNS p
after IN N
surgery NN N
. . N

In IN N
the DT N
cases NNS N
of IN N
malignant JJ N
tumors NNS N
CMAPs NNP o
were VBD N
not RB N
recorded VBN N
following VBG N
stimulation NN N
of IN N
any DT N
branch NN N
. . N

A DT N
similar JJ N
trend NN N
was VBD N
found VBN N
for IN N
BR NNP o
results NNS o
. . o

H-B NNP o
and CC o
ENG NNP o
results NNS N
revealed VBD N
positive JJ N
correlations NNS N
between IN N
the DT N
type NN N
of IN N
tumor NN N
and CC N
surgery NN N
with IN N
facial JJ N
nerve NN N
function NN N
. . N

Neurophysiological JJ N
studies NNS N
detected VBN N
clinically RB o
silent JJ o
facial JJ o
nerve NN o
neuropathy NN o
of IN o
mandibular JJ o
marginal JJ o
branch NN o
in IN N
postoperative JJ N
period NN N
. . N

Needle NNP o
EMG NNP o
, , o
ENG NNP o
and CC o
BR NNP o
examinations NNS o
allow VBP N
for IN N
the DT N
evaluation NN N
of IN N
face NN o
muscles NNS o
reinnervation NN o
and CC o
facial JJ o
nerve NN o
regeneration NN o
. . o

-DOCSTART- -22709747- O O

Rationale NNP N
and CC N
study VB N
design NN N
of IN N
the DT N
increase NN N
of IN N
vagal JJ N
tone NN N
in IN N
heart NN p
failure NN p
study NN N
: : N
INOVATE-HF NNP N
. . N

BACKGROUND NNP N
Imbalance NNP N
between IN N
the DT N
parasympathetic JJ N
and CC N
sympathetic JJ N
nervous JJ N
systems NNS N
is VBZ N
a DT N
recognized VBN N
contributor NN N
to TO N
progression NN N
of IN N
chronic JJ p
heart NN p
failure NN p
. . p

Current JJ N
therapy NN N
with IN N
beta NN N
adrenergic JJ N
antagonists NNS N
is VBZ N
designed VBN N
to TO N
moderate VB N
the DT N
up-regulation NN N
of IN N
norepinephrine NN N
and CC N
sympathetic JJ N
effects NNS N
; : N
however RB N
, , N
to TO N
date NN N
, , N
there EX N
are VBP N
no DT N
therapies NNS N
that WDT N
specifically RB N
address VBP N
the DT N
withdrawal NN N
of IN N
parasympathetic JJ N
influences NNS N
on IN N
cardiac JJ N
function NN N
and CC N
structure NN N
. . N

METHODS/RESULTS NNP N
In IN N
order NN N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
vagus NN N
nerve NN N
stimulation NN N
, , N
an DT N
international JJ N
multi-center NN N
randomized VBD N
clinical JJ N
trial NN N
( ( N
INOVATE-HF NNP N
) ) N
has VBZ N
been VBN N
designed VBN N
to TO N
assess VB N
safety NN o
and CC o
efficacy NN o
of IN N
vagus NN N
nerve NN N
stimulation NN N
in IN N
symptomatic JJ p
patients NNS p
with IN p
heart NN p
failure NN p
on IN p
optimal JJ p
medical JJ p
therapy NN p
using VBG N
the DT N
CardioFit NNP i
System NNP i
( ( N
BioControl NNP N
Medical NNP N
, , N
Yehud NNP N
, , N
Israel NNP N
) ) N
. . N

Up UH p
to TO p
650 CD p
patients NNS p
from IN p
80 CD p
sites NNS p
will MD p
be VB p
recruited VBN p
and CC N
randomized VBN N
in IN N
a DT N
3:2 CD N
ratio NN N
to TO N
receive VB N
active JJ N
treatment NN N
or CC N
standard NN i
optimal JJ i
medical JJ i
therapy NN i
. . i

Inclusion NNP p
criteria NNS p
include VBP p
left JJ p
ventricular JJ p
systolic JJ p
dysfunction NN p
, , p
the DT p
presence NN p
of IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
Class NNP p
III NNP p
symptoms NNS p
, , p
sinus NN p
rhythm NN p
, , p
and CC p
QRS NNP p
width VBD p
less JJR p
than IN p
120 CD p
milliseconds NNS p
. . p

The DT N
study NN N
is VBZ N
powered VBN N
to TO N
detect VB N
differences NNS N
in IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
of IN N
all-cause JJ o
mortality NN o
and CC o
heart NN o
failure NN o
hospitalization NN o
and CC o
2 CD o
safety NN o
end NN o
points NNS o
. . o

CONCLUSION NNP N
Vagal NNP N
nerve NN N
stimulation NN N
with IN N
CardioFit NNP i
as IN N
a DT N
treatment NN N
for IN N
symptomatic JJ N
heart NN N
failure NN N
is VBZ N
under IN N
active JJ N
investigation NN N
as IN N
a DT N
novel JJ N
approach NN N
to TO N
restore VB N
balance NN N
between IN N
the DT N
sympathetic JJ N
and CC N
parasympathetic JJ N
nervous JJ N
systems NNS N
. . N

If IN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
decreasing VBG N
heart NN o
failure NN o
events NNS o
and CC o
mortality NN o
, , N
this DT N
novel JJ N
approach NN N
will MD N
impact VB N
the DT N
treatment NN N
paradigm NN N
for IN N
heart NN N
failure NN N
. . N

-DOCSTART- -17931375- O O

A DT N
study NN N
on IN N
the DT N
effect NN N
of IN N
the DT N
duration NN N
of IN N
subcutaneous JJ i
heparin NN i
injection NN i
on IN p
bruising NN p
and CC p
pain NN p
. . p

AIM NNP N
This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
injection NN N
duration NN N
on IN N
bruising NN N
and CC N
pain NN N
following VBG N
the DT N
administration NN N
of IN N
the DT N
subcutaneous JJ N
injection NN N
of IN N
heparin NN i
. . i

BACKGROUND NNP N
Although IN N
different JJ N
methods NNS N
to TO N
prevent VB N
bruising NN N
and CC N
pain NN N
following VBG N
the DT N
subcutaneous JJ N
injection NN N
of IN N
heparin NNS i
have VBP N
been VBN N
widely RB N
studied VBN N
and CC N
described VBN N
, , N
the DT N
effect NN N
of IN N
injection NN N
duration NN N
on IN N
the DT N
occurrence NN N
of IN N
bruising NN N
and CC N
pain NN N
is VBZ N
little RB N
documented JJ N
. . N

DESIGN VB N
This DT N
study NN N
was VBD N
designed VBN N
as IN N
within-subject JJ N
, , N
quasi-experimental JJ N
research NN N
. . N

METHOD NNP N
The DT N
sample NN N
for IN N
the DT N
study NN N
consisted VBD N
of IN N
50 CD p
patients NNS p
to TO p
whom WP p
subcutaneous JJ p
heparin NN i
was VBD p
administered VBN p
. . p

Heparin NNP i
was VBD N
injected VBN N
over IN N
10 CD N
seconds NNS N
on IN N
the DT N
right JJ N
abdominal JJ N
site NN N
and CC N
30 CD N
seconds NNS N
on IN N
the DT N
left JJ N
abdominal JJ N
site NN N
. . N

Injections NNS N
areas NNS N
were VBD N
assessed VBN N
for IN N
the DT N
presence NN N
of IN N
bruising VBG o
at IN N
48 CD N
and CC N
72 CD N
hours NNS N
after IN N
each DT N
injection NN N
. . N

Dimensions NNS N
of IN N
the DT N
bruising NN N
on IN N
the DT N
heparin NN N
applied VBN N
areas NNS N
were VBD N
measured VBN N
using VBG N
transparent JJ N
millimetric JJ N
measuring VBG N
paper NN N
. . N

The DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
was VBD N
used VBN N
to TO N
measure VB N
pain NN N
intensity NN N
and CC N
a DT N
stop-watch NN N
was VBD N
used VBN N
to TO N
time NN N
the DT N
pain NN N
period NN N
. . N

Data NNS N
were VBD N
analysed VBN N
using VBG N
chi-square JJ N
test NN N
, , N
Mann-Whitney NNP N
U NNP N
, , N
Wilcoxon NNP N
signed VBD N
ranks NNS N
tests NNS N
and CC N
correlation NN N
. . N

RESULTS VB N
The DT N
percentage NN o
of IN o
bruising VBG o
occurrence NN o
was VBD N
64 CD N
% NN N
with IN N
the DT N
injection NN N
of IN N
10 CD N
seconds NNS N
duration NN N
and CC N
42 CD N
% NN N
in IN N
the DT N
30-second JJ N
injection NN N
. . N

It PRP N
was VBD N
determined VBN N
that IN N
the DT N
size NN o
of IN o
the DT o
bruising NN o
was VBD N
smaller JJR N
in IN N
the DT N
30-second JJ N
injection NN N
. . N

Pain NNP o
intensity NN o
and CC o
pain NN o
period NN o
were VBD N
statistically RB N
significantly RB N
lower JJR N
for IN N
the DT N
30-second JJ N
injection NN N
than IN N
for IN N
the DT N
10-second JJ N
injection NN N
. . N

CONCLUSIONS VB N
It PRP N
was VBD N
determined VBN N
that IN N
injection NN N
duration NN N
had VBD N
an DT N
effect NN N
on IN N
bruising NN N
and CC N
pain NN N
following VBG N
the DT N
subcutaneous JJ N
administration NN N
of IN N
heparin NN i
. . i

This DT N
study NN N
should MD N
be VB N
repeated VBN N
on IN N
a DT N
larger JJR N
sample NN N
. . N

RELEVANCE NNP N
TO NNP N
CLINICAL NNP N
PRACTICE NNP N
When WRB N
administering VBG N
subcutaneous JJ N
heparin NN i
injections NNS N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
extend VB N
the DT N
duration NN N
of IN N
the DT N
injection NN N
. . N

-DOCSTART- -11783270- O O

[ RB N
Clinical NNP N
study NN N
on IN N
retarding VBG o
aging VBG o
effect NN o
of IN N
tongbu NN N
recipe NN N
to TO N
traditional JJ N
Chinese JJ N
medicine NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
mechanism NN N
of IN N
Tongbu NNP i
No NNP i
. . i

1 CD i
( ( i
TB1 NNP i
, , i
a DT i
prescription NN i
for IN i
reinforcing VBG i
Kidney NNP i
and CC i
Spleen NNP i
, , i
clearing VBG i
up RP i
the DT i
bowel NN i
viscera NN i
to TO i
send VB i
Turbid NNP i
downward NN i
and CC i
regulating NN i
Qi NNP i
and CC i
blood NN i
) ) i
in IN o
retarding VBG o
aging VBG o
. . o

METHODS NNP N
A NNP N
controlled VBD N
, , N
multiple NN N
indexes NNS N
study NN N
was VBD N
conducted VBN N
in IN N
56 CD p
old JJ p
subjects NNS p
randomized VBN p
into IN p
3 CD p
groups NNS p
. . p

RESULTS NNP N
TB1 NNP N
( ( N
containing VBG N
ginseng NN N
leaf NN N
, , N
cistanche NN N
, , N
fleeceflower JJR N
root NN N
, , N
immature NN N
bitter JJ N
orange NN N
, , N
rhubarb NN N
, , N
etc FW N
) ) N
could MD N
improve VB N
various JJ N
symptoms NNS o
of IN o
aging VBG o
, , N
and CC N
had VBD N
the DT N
effect NN N
in IN N
regulating VBG o
immune NN o
and CC o
endocrinal JJ o
function NN o
, , o
scavenging VBG o
free JJ o
radicals NNS o
and CC o
adjusting VBG o
coli JJ o
flora NNS o
. . o

The DT N
effects NNS N
of IN N
TB1 NNP N
and CC N
TB2 NNP N
( ( N
containing VBG N
ginseng NN N
leaf NN N
, , N
cistanche NN N
and CC N
fleeceflower JJR N
root NN N
) ) N
were VBD N
different JJ N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
TB1 NNP N
has VBZ N
a DT N
good JJ N
comprehensive JJ N
effect NN N
in IN N
retarding VBG o
aging NN o
. . o

-DOCSTART- -20839989- O O

Effect NN N
of IN N
a DT N
synthetic JJ i
appeasing VBG i
pheromone NN i
on IN N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
perioperative JJ N
stress NN N
responses NNS N
in IN N
dogs NNS p
. . p

OBJECTIVE NNP N
To TO N
study VB N
the DT N
effects NNS N
of IN N
a DT N
synthetic JJ i
, , i
dog-appeasing JJ i
pheromone NN i
( ( i
sDAP NN i
) ) i
on IN N
the DT N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
perioperative JJ N
stress NN N
responses NNS N
in IN N
dogs NNS p
undergoing VBG p
elective JJ p
orchiectomy NN p
or CC p
ovariohysterectomy NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

ANIMALS $ N
46 CD p
dogs NNS p
housed VBN p
in IN p
animal NN p
shelters NNS p
and CC p
undergoing VBG p
elective JJ p
orchiectomy NN p
or CC p
ovariohysterectomy NN p
. . p

PROCEDURES NNP N
Intensive NNP N
care NN N
unit NN N
cages NNS N
were VBD N
sprayed VBN N
with IN N
sDAP JJ i
solution NN i
or CC i
sham NN i
treated VBN i
with IN i
the DT i
carrier NN i
used VBN i
in IN i
the DT i
solution NN i
20 CD i
minutes NNS i
prior RB i
to TO i
use VB i
. . i

Dogs NNS N
( ( N
n JJ N
= NN N
24 CD N
and CC N
22 CD N
in IN N
the DT N
sDAP NN i
and CC N
sham JJ i
treatment NN i
exposure NN N
groups NNS N
, , N
respectively RB N
) ) N
were VBD N
placed VBN N
in IN N
treated JJ N
cages NNS N
for IN N
30 CD N
minutes NNS N
before IN N
and CC N
after IN N
surgery NN N
. . N

Indicators NNS N
of IN N
stress NN N
( ( N
ie NN N
, , N
alterations NNS N
in IN N
behavioral JJ o
, , o
neuroendocrine JJ o
, , o
immune JJ o
, , o
and CC o
acute-phase JJ o
responses NNS o
) ) o
were VBD N
evaluated VBN N
perioperatively RB N
. . N

Behavioral JJ o
response NN o
variables NNS o
, , o
salivary JJ o
cortisol NN o
concentration NN o
, , o
WBC NNP o
count NN o
, , o
and CC o
serum JJ o
concentrations NNS o
of IN o
glucose NN o
, , o
prolactin NN o
, , o
haptoglobin NN o
, , o
and CC o
C-reactive JJ o
protein NN o
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Behavioral NNP o
response NN o
variables NNS o
and CC o
serum NN o
prolactin NN o
concentration NN o
were VBD N
influenced VBN N
by IN N
sDAP NN N
exposure NN N
. . N

Dogs NNS N
exposed VBD N
to TO N
sDAP VB N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
alertness NN o
and CC o
visual JJ o
exploration NN o
behaviors NNS o
after IN N
surgery NN N
than IN N
were VBD N
dogs NNS N
exposed VBN N
to TO N
sham VB N
treatment NN N
. . N

Decreases VBZ N
in IN N
serum NN o
prolactin NN o
concentrations NNS o
in IN N
response NN N
to TO N
perioperative JJ N
stress NN N
were VBD N
significantly RB N
smaller JJR N
in IN N
dogs NNS N
exposed VBN N
to TO N
sDAP VB N
, , N
compared VBN N
with IN N
findings NNS N
in IN N
dogs NNS N
exposed VBN N
to TO N
the DT N
sham NN N
treatment NN N
. . N

Variables NNS N
examined VBD N
to TO N
evaluate VB N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
, , N
immune JJ N
system NN N
, , N
and CC N
acute-phase JJ N
responses NNS N
were VBD N
unaffected VBN N
by IN N
treatment NN N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
sDAP NN N
appeared VBD N
to TO N
affect VB N
behavioral JJ o
and CC o
neuroendocrine JJ o
perioperative JJ o
stress NN o
responses NNS o
by IN N
modification NN N
of IN N
lactotropic JJ N
axis NN N
activity NN N
. . N

Use NN N
of IN N
sDAP NN i
in IN N
a DT N
clinical JJ N
setting NN N
may MD N
improve VB N
the DT N
recovery NN o
and CC N
welfare NN N
of IN N
dogs NNS p
undergoing VBG p
surgery NN p
. . p

-DOCSTART- -9172668- O O

[ JJ N
Initial NNP N
nuclear JJ i
magnetic JJ i
resonance NN i
tomography NN i
results NNS N
of IN N
the DT N
treatment NN p
course NN p
of IN p
avascular JJ p
femur NNS p
head VBP p
necrosis NN p
after IN p
femoral JJ p
core NN p
decompression NN p
] NNP p
. . p

The DT N
vascular JJ p
femoral JJ p
head NN p
necrosis NN p
is VBZ p
a DT p
serious JJ p
illness NN p
, , p
especially RB p
when WRB p
appearing VBG p
in IN p
patients NNS p
aged VBD p
30 CD p
to TO p
50 CD p
years NNS p
. . p

Many JJ N
etiologic JJ N
factors NNS N
cause VBP N
a DT N
femoral JJ N
head NN N
necrosis NN N
such JJ N
as IN N
, , N
for IN N
example NN N
, , N
high-dose JJ p
steroids NNS p
, , p
abuse NN p
of IN p
alcohol NN p
, , p
defect NN p
of IN p
bone NN p
marrow NN p
and CC p
trauma NN p
of IN p
the DT p
hip NN p
. . p

Often VB N
the DT N
X-ray JJ N
photograph NN N
leads VBZ N
to TO N
the DT N
diagnosis NN N
in IN N
the DT N
second JJ N
stage NN N
( ( N
ARCO NNP N
1992 CD N
) ) N
or CC N
in IN N
the DT N
third JJ N
stage NN N
, , N
when WRB N
the DT N
femoral JJ N
head NN N
has VBZ N
begun VBN N
to TO N
collapse VB N
. . N

The DT N
stage NN N
IIc NNP N
and CC N
III NNP N
shows VBZ N
an DT N
evident JJ N
enhancement NN N
in IN N
contrast NN N
media NNS N
in IN N
MRI NNP i
. . i

Contrast NNP N
enhancement NN N
is VBZ N
demonstrated VBN N
by IN N
STIR NNP N
, , N
FATSAT NNP N
, , N
T1-weighted NNP N
and CC N
dynamic JJ N
screening NN N
sequence NN N
. . N

The DT N
characteristics NNS N
of IN N
the DT N
contrast NN N
media NNS N
enhancement VBP N
argue NN N
for IN N
an DT N
active JJ N
concomitant NN N
process NN N
of IN N
destruction NN N
and CC N
regeneration NN N
. . N

This DT N
stage NN N
has VBZ N
the DT N
best JJS N
chances NNS N
for IN N
a DT N
drug NN N
or CC N
a DT N
surgical JJ N
therapy NN N
. . N

The DT N
evaluation NN N
of IN N
the DT N
signal JJ N
intensity NN N
by IN N
the DT N
dynamic JJ o
screening NN o
sequence NN o
is VBZ N
considered VBN N
as IN N
an DT N
objective JJ N
contribution NN N
for IN N
the DT N
staging NN o
of IN o
the DT o
femoral JJ o
head NN o
necrosis NN o
. . o

This DT N
enables VBZ N
one CD N
to TO N
differentiate VB N
between IN p
the DT p
curable JJ o
stage NN o
IIc NNP o
and CC p
the DT p
stage NN o
III NNP o
, , p
showing VBG p
the DT p
beginning NN p
of IN p
breakdown NN o
of IN o
the DT o
femoral JJ o
head NN o
. . o

-DOCSTART- -24722560- O O

Cytokine NNP i
and CC N
clinical JJ N
response NN N
to TO N
Saccharomyces NNP i
boulardii NN i
therapy NN i
in IN N
diarrhea-dominant JJ N
irritable JJ N
bowel NN N
syndrome NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

INTRODUCTION NNP N
This DT N
preliminary JJ N
study NN N
aimed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
the DT N
probiotic JJ i
Saccharomyces NNP i
boulardii NN i
on IN N
proinflammatory NN N
and CC N
anti-inflammatory JJ N
cytokines NNS N
in IN N
patients NNS p
with IN p
diarrhea-dominant JJ p
irritable JJ p
bowel NN p
syndrome NN p
( ( p
IBS-D NNP p
) ) p
. . p

The DT N
other JJ N
objectives NNS N
were VBD N
to TO N
document VB N
any DT N
clinical JJ N
improvement NN N
as IN N
judged VBN N
by IN N
symptoms NNS N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
histology NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
trial NN N
in IN N
which WDT N
S. NNP i
boulardii NN i
, , i
750 CD i
mg/day NN i
, , i
or CC i
placebo NN i
was VBD i
administered VBN i
for IN i
6 CD i
weeks NNS i
in IN i
IBS-D NNP i
patients NNS i
, , i
in IN i
addition NN i
to TO i
ispaghula VB i
husk JJ i
standard NN i
treatment NN i
. . i

RESULTS NNP N
Thirty-seven JJ p
patients NNS p
received VBD p
S. NNP i
boulardii NNS i
and CC p
35 CD p
patients NNS p
received VBD p
the DT p
placebo NN i
. . i

As IN N
compared VBN N
with IN N
placebo NN i
, , N
the DT N
S. NNP i
boulardii NN i
group NN N
showed VBD N
a DT N
significant JJ N
decrease NN o
in IN o
blood NN o
and CC o
tissue NN o
levels NNS o
of IN o
proinflammatory NN o
cytokines NNS o
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
and CC o
tumor JJ o
necrosis NN o
factor-? NN o
( ( o
P NNP o
< NNP o
0.001 CD o
) ) o
and CC o
an DT o
increase NN o
in IN o
anti-inflammatory JJ o
IL-10 JJ o
levels NNS o
, , o
as RB o
well RB o
as IN o
an DT o
increase NN o
in IN o
the DT o
tissue NN o
IL-10/IL-12 NNP o
ratio NN o
( ( o
P NNP o
< NNP o
0.001 CD o
) ) o
. . o

No DT o
significant JJ o
change NN o
in IN o
the DT o
blood NN o
and CC o
tissue NN o
levels NNS o
of IN o
cytokines NNS o
was VBD N
found VBN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Bowel-related JJ o
IBS-D JJ o
symptoms NNS o
reported VBN N
in IN N
the DT N
patients NNS o
' POS o
daily JJ o
diary NNS o
improved VBN o
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
overall JJ o
improvement NN o
in IN o
the DT o
quality NN o
of IN o
life NN o
was VBD N
more RBR N
marked JJ N
in IN N
the DT i
S. NNP i
boulardii NN i
group NN N
. . N

Although IN N
baseline JJ N
histological JJ N
findings NNS N
were VBD o
mild JJ o
, , o
an DT o
improvement NN o
was VBD N
observed VBN N
in IN N
the DT N
probiotic JJ N
group NN N
in IN N
the DT o
lymphocyte NN o
and CC o
neutrophil JJ o
infiltrates NNS o
( ( N
P=0.017 NNP N
and CC N
0.018 CD N
) ) N
, , N
epithelial JJ o
mitosis NN o
( ( N
P=0.003 NNP N
) ) N
, , N
and CC o
intraepithelial JJ o
lymphocytes NNS o
( ( N
P=0.024 NNP N
) ) N
. . N

No DT N
serious JJ N
adverse JJ N
events NNS N
were VBD N
found VBN N
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
S. NNP i
boulardii NN i
with IN N
ispaghula JJ N
husk NN N
was VBD N
superior JJ N
to TO N
placebo VB N
with IN N
ispaghula JJ N
husk NN N
in IN N
improving VBG N
the DT N
cytokine NN N
profile NN N
, , N
histology NN N
, , N
and CC N
quality NN N
of IN N
life NN N
of IN p
patients NNS p
with IN p
IBS-D NNP p
. . p

These DT N
preliminary JJ N
results NNS N
need VBP N
to TO N
be VB N
confirmed VBN N
in IN N
a DT N
well-powered JJ N
trial NN N
. . N

-DOCSTART- -7608035- O O

Brief JJ N
report NN N
: : N
a DT N
pilot NN N
study NN N
of IN N
auditory JJ o
integration NN o
training NN i
in IN N
autism NN p
. . p

-DOCSTART- -25009139- O O

Autism NNP N
Spectrum NNP N
Social NNP N
Stories NNP N
In IN N
Schools NNP N
Trial NNP N
( ( N
ASSSIST NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
feasibility NN N
randomised VBN N
controlled VBN N
trial NN N
analysing VBG N
clinical JJ o
and CC o
cost-effectiveness NN o
of IN o
Social NNP o
Stories NNP o
in IN N
mainstream JJ N
schools NNS N
. . N

INTRODUCTION NNP N
Current NNP N
evidence NN N
suggests VBZ N
that IN N
Social NNP i
Stories NNPS i
can MD N
be VB N
effective JJ N
in IN N
tackling VBG N
problem NN o
behaviours NNS o
exhibited VBN N
by IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Exploring VBG N
the DT N
meaning NN N
of IN N
behaviour NN N
from IN N
a DT N
child NN N
's POS N
perspective JJ N
allows NNS N
stories NNS N
to TO N
provide VB N
social JJ N
information NN N
that WDT N
is VBZ N
tailored VBN N
to TO N
their PRP$ N
needs NNS N
. . N

Case NNP N
reports VBZ N
in IN N
children NNS p
with IN p
autism NN p
have VBP N
suggested VBN N
that IN N
these DT N
stories NNS N
can MD N
lead VB N
to TO N
a DT N
number NN N
of IN N
benefits NNS N
including VBG N
improvements NNS N
in IN N
social JJ o
interactions NNS o
and CC o
choice NN o
making NN o
in IN N
educational JJ N
settings NNS N
. . N

METHODS NNP N
AND CC N
ANALYSIS NNP N
The DT N
feasibility NN o
of IN o
clinical JJ o
and CC o
cost-effectiveness NN o
of IN N
a DT N
Social NNP i
Stories NNP i
toolkit NN N
will MD N
be VB N
assessed VBN N
using VBG N
a DT N
randomised VBN N
control NN N
framework NN N
. . N

Participants NNS p
( ( p
n=50 NN p
) ) p
will MD p
be VB p
randomised VBN p
to TO p
either CC p
the DT p
Social NNP i
Stories NNPS i
intervention NN i
or CC i
a DT i
comparator NN i
group NN i
where WRB p
they PRP p
will MD p
be VB p
read VBN p
standard JJ p
stories NNS p
for IN p
an DT p
equivalent JJ p
amount NN p
of IN p
time NN p
. . p

Statistics NNS N
will MD N
be VB N
calculated VBN N
for IN N
recruitment NN o
rates NNS o
, , o
follow-up JJ o
rates NNS o
and CC o
attrition NN o
. . o

Economic JJ N
analysis NN N
will MD N
determine VB N
appropriate JJ N
measures NNS o
of IN o
generic JJ o
health NN o
and CC o
resource NN o
use NN o
categories NNS o
for IN o
cost-effectiveness JJ o
analysis NN o
. . o

Qualitative JJ N
analysis NN N
will MD N
ascertain VB N
information NN N
on IN N
perceptions NNS N
about IN N
the DT N
feasibility NN o
and CC o
acceptability NN o
of IN N
the DT N
intervention NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
National NNP N
Health NNP N
Service NNP N
Ethics NNP N
Approval NNP N
( ( N
NHS NNP N
; : N
ref VBZ N
11/YH/0340 CD N
) ) N
for IN N
the DT N
trial NN N
protocol NN N
has VBZ N
been VBN N
obtained VBN N
along IN N
with IN N
NHS NNP N
Research NNP N
and CC N
Development NNP N
permission NN N
from IN N
Leeds NNP N
and CC N
York NNP N
Partnership NNP N
NHS NNP N
Foundation NNP N
Trust NNP N
. . N

All DT N
adverse JJ o
events NNS o
will MD N
be VB N
closely RB N
monitored VBN N
, , N
documented VBN N
and CC N
reported VBN N
to TO N
the DT N
study NN N
Data NNP N
Monitoring NNP N
Ethics NNP N
Committee NNP N
. . N

At IN N
least JJS N
one CD N
article NN N
in IN N
a DT N
peer NN N
reviewed VBN N
journal NN N
will MD N
be VB N
published VBN N
and CC N
research NN N
findings NNS N
presented VBN N
at IN N
relevant JJ N
conferences NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN96286707 NNP N
. . N

-DOCSTART- -1919850- O O

Effects NNS N
of IN N
propranolol NN i
on IN N
bone NN o
metabolism NN o
in IN N
the DT N
rat NN p
. . p

Propranolol NNP i
, , N
a DT N
nonspecific JJ N
beta-blocker NN N
has VBZ N
many JJ N
physiologic JJ N
effects NNS N
. . N

Its PRP$ N
effects NNS N
on IN N
bone NN o
in IN N
vivo NN N
are VBP N
unknown JJ N
, , N
although IN N
beta NN N
receptor NN N
sites NNS N
have VBP N
been VBN N
found VBN N
on IN N
osteoblasts NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
hypothesis NN N
tested VBD N
was VBD N
that IN N
low JJ N
doses NNS N
of IN N
propranolol NN i
could MD N
alter VB N
bone NN o
properties NNS o
and CC N
enhance NN N
orthotopic RB o
endochondral JJ o
bone NN o
formation NN o
. . o

In IN N
a DT N
group NN N
of IN N
nonsurgical JJ p
rats NNS p
, , N
propranolol JJ i
treatment NN N
increased VBD N
femoral JJ o
torsional JJ o
strength NN o
on IN N
biomechanical JJ N
testing NN N
. . N

In IN N
the DT N
rat NN p
surgical JJ p
model NN p
used VBN N
, , N
right JJ N
femora NNS N
were VBD N
fixed VBN N
to TO N
a DT N
polyethylene NN N
plate NN N
and CC N
then RB N
defects NNS N
were VBD N
created VBN N
mid-diaphysis NN N
and CC N
subsequently RB N
filled VBN N
with IN N
demineralized JJ N
bone NN N
matrix NN N
. . N

These DT N
rats NNS p
( ( p
defect JJ p
rats NNS p
) ) p
were VBD N
randomly RB N
divided VBN N
into IN N
groups NNS N
that WDT N
were VBD N
given VBN N
propranolol NNS i
or CC N
a DT N
saline NN i
carrier NN N
for IN N
19 CD N
consecutive JJ N
days NNS N
. . N

In IN N
the DT N
defect NN p
rats NNS p
, , N
increased VBD N
trabecular JJ o
femoral JJ o
metaphyseal JJ o
mineral JJ o
apposition NN o
rates NNS o
were VBD N
observed VBN N
in IN N
propranolol-treated JJ N
groups NNS N
. . N

Densitometry NNP N
and CC N
roentgenographic JJ N
scoring NN N
of IN N
callus NN N
formation NN N
after IN N
12 CD N
weeks NNS N
in IN N
propranolol-treated JJ N
rats NNS N
revealed VBD N
increased JJ N
callus NN o
and CC o
bone NN o
union NN o
. . o

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
propranolol NN i
treatment NN N
can MD N
significantly RB N
affect VB N
bone NN o
properties NNS o
. . o

-DOCSTART- -14985215- O O

Plasma NNP o
kinetics NNS o
of IN o
zeaxanthin NN o
and CC o
3'-dehydro-lutein JJ o
after IN N
multiple JJ N
oral JJ N
doses NNS N
of IN N
synthetic JJ i
zeaxanthin NN i
. . i

BACKGROUND NNP N
Zeaxanthin NNP i
is VBZ N
hypothesized VBN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
age-related JJ p
macular JJ p
degeneration NN p
; : p
however RB N
, , N
kinetic JJ N
information NN N
is VBZ N
limited VBN N
. . N

OBJECTIVES IN N
The DT N
objective NN N
was VBD N
to TO N
investigate VB N
the DT N
plasma NN o
kinetics NNS o
of IN o
synthetic JJ o
zeaxanthin NN o
after IN N
repeated VBN N
oral JJ N
doses NNS N
and CC N
to TO N
assess VB N
the DT N
possible JJ N
influence NN N
of IN N
other JJ N
carotenoids NNS N
on IN N
plasma NN o
zeaxanthin NN o
concentrations NNS o
. . o

DESIGN NNP N
After IN N
a DT N
run-in NN N
of IN N
3 CD N
d NN N
, , N
20 CD p
healthy JJ p
volunteers NNS p
assigned VBD N
to TO N
2 CD N
parallel NNS N
dose JJ N
groups NNS N
received VBD N
once RB N
daily JJ N
oral JJ N
doses NNS N
of IN N
either DT N
1 CD N
mg NN N
( ( N
1.76 CD N
micro RB N
mol NN N
) ) N
or CC N
10 CD N
mg NN N
( ( N
17.6 CD N
micro RB N
mol NN N
) ) N
zeaxanthin NN i
for IN N
42 CD N
d. JJ N
Plasma NNP o
concentration-time NN o
profiles NNS o
on IN N
days NNS N
1 CD N
and CC N
42 CD N
, , N
concentrations NNS N
immediately RB N
before IN N
zeaxanthin JJ i
intake NN N
during IN N
the DT N
dosing JJ N
period NN N
, , N
and CC N
concentrations NNS N
after IN N
the DT N
last JJ N
dose JJ N
until IN N
day NN N
76 CD N
were VBD N
monitored VBN N
. . N

RESULTS NNP N
all-E-Zeaxanthin JJ o
concentrations NNS o
increased VBD N
from IN N
0.048 CD N
+/- JJ N
0.026 CD N
micro NN N
mol/L NN N
at IN N
baseline NN N
to TO N
0.20 CD N
+/- JJ N
0.07 CD N
and CC N
0.92 CD N
+/- JJ N
0.28 CD N
micro NN N
mol/L NN N
with IN N
1 CD N
and CC N
10 CD N
mg NN N
zeaxanthin NN i
, , N
respectively RB N
. . N

The DT N
dose-normalized JJ o
bioavailability NN o
of IN o
all-E-zeaxanthin JJ o
after IN N
the10-mg JJ N
dose NN N
was VBD N
40 CD N
% NN N
lower JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
than IN N
after IN N
the DT N
1-mg JJ N
dose NN N
. . N

Other JJ N
kinetic JJ o
parameters NNS o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
. . N

After IN N
17 CD N
d NN N
of IN N
dosing NN N
, , N
> VB N
90 CD N
% NN N
of IN N
steady JJ N
state NN N
concentrations NNS o
were VBD N
reached VBN N
, , N
which WDT N
was VBD N
compatible JJ N
with IN N
an DT N
effective JJ N
half-life NN N
for IN N
accumulation NN N
of IN N
5 CD N
d. NN N
The DT N
terminal JJ o
elimination NN o
half-life NN o
was VBD N
12 CD N
+/- JJ N
7 CD N
d NN N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
. . N

The DT N
time NN o
course NN o
of IN o
plasma JJ o
all-E-3-'dehydro-lutein JJ o
concentrations NNS o
resembled VBD N
that IN N
of IN N
all-E-zeaxanthin JJ i
. . i

The DT N
data NN N
provided VBD N
evidence NN N
that IN N
all-E-3-'dehydro-lutein NN o
was VBD N
derived VBN N
from IN N
all-E-zeaxanthin JJ o
. . o

Concentrations NNS o
of IN o
other JJ o
carotenoids NNS o
were VBD N
not RB N
affected VBN N
. . N

Zeaxanthin NNP i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSION NNP N
Long-term JJ N
oral JJ N
intake NN N
of IN N
1 CD N
and CC N
10 CD N
mg NN N
zeaxanthin NN i
as IN N
beadlets NNS N
increases VBZ N
plasma NN o
zeaxanthin JJ o
concentrations NNS o
approximately RB N
4- JJ N
and CC N
20-fold JJ N
, , N
respectively RB N
. . N

Evidence NN N
that IN N
all-E-3-dehydro-lutein NN o
is VBZ N
formed VBN N
from IN N
zeaxanthin NN i
was VBD N
strong JJ N
. . N

-DOCSTART- -23587455- O O

Effects NNS N
of IN N
parecoxib NN i
on IN N
morphine NN N
analgesia NN N
after IN N
gynecology JJ N
tumor NN N
operation NN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
parecoxib NN i
used VBN N
in IN N
postsurgical JJ N
pain NN N
management NN N
. . N

BACKGROUND VB N
The DT N
analgesic JJ N
efficacy NN N
of IN N
parecoxib NN i
in IN N
postsurgical JJ N
pain NN N
management NN N
has VBZ N
been VBN N
confirmed VBN N
in IN N
minimally RB N
invasive JJ N
surgery NN N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
its PRP$ N
effects NNS N
used VBN N
in IN N
combination NN N
with IN N
opioids NNS N
and CC N
about IN N
its PRP$ N
potential JJ N
for IN N
opioid-sparing JJ N
effects NNS N
in IN N
complex JJ N
operations NNS N
. . N

This DT N
study NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
parecoxib NN i
on IN i
morphine NN i
analgesia NN N
after IN N
gynecological JJ N
tumor NN N
surgery NN N
. . N

METHODS NNP N
Eighty NNP p
patients NNS p
undergoing VBG p
gynecological JJ p
tumor NN p
resection NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
intravenous JJ i
parecoxib NN i
at IN i
a DT i
dose NN i
of IN i
40 CD i
mg NNS i
( ( i
Group NNP i
P NNP i
, , i
n JJ i
= NNP i
40 CD i
) ) i
followed VBN i
by IN i
40 CD i
mg NNS i
every DT i
12 CD i
h NN i
for IN i
48 CD i
h NN i
or CC i
saline NN i
as IN i
a DT i
control NN i
( ( i
Group NNP i
C NNP i
, , i
n JJ i
= NNP i
40 CD i
) ) i
30 CD i
min NN i
before IN i
induction NN i
of IN i
anesthesia NN i
, , i
followed VBN i
by IN i
saline NN i
at IN i
the DT i
same JJ i
time NN i
points NNS i
after IN i
the DT i
operation NN i
. . i

All DT i
patients NNS N
had VBD N
access NN i
to TO i
patient-controlled JJ i
analgesia NN i
with IN i
intravenous JJ i
morphine NN i
. . i

Patients NNS i
were VBD N
assessed VBN N
with IN N
respect NN o
to TO o
pain VB o
score NN o
( ( o
visual JJ o
analog NN o
scale NN o
from IN o
0-10 JJ o
) ) o
, , o
cumulative JJ o
morphine NN o
requirement NN o
, , o
satisfaction NN o
score NN o
, , o
and CC o
side JJ o
effects NNS o
at IN o
2 CD N
, , N
6 CD N
, , N
12 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS VB p
A DT p
total NN p
of IN p
79 CD p
patients NNS p
were VBD p
evaluated VBN p
. . p

The DT p
cumulative JJ o
dose NN o
of IN o
morphine NN o
administered VBN o
at IN N
each DT N
time NN N
point NN N
was VBD N
lower JJR N
in IN N
Group NNP N
P NNP N
than IN N
in IN N
Group NNP N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
at IN N
2 CD N
h NN N
( ( N
3.81 CD N
? . N
0.35 CD N
versus NN N
4.13 CD N
? . N
0.45 CD N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
6 CD N
h NN N
( ( N
16.20 CD N
? . N
1.49 CD N
versus NN N
19.60 CD N
? . N
0.35 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
12 CD N
h NN N
( ( N
26.29 CD N
? . N
2.75 CD N
versus NN N
32.49 CD N
? . N
2.42 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
24 CD N
h NN N
( ( N
41.72 CD N
? . N
2.70 CD N
versus NN N
49.97 CD N
? . N
4.53 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
48 CD N
h NN N
( ( N
60.06 CD N
? . N
4.00 CD N
versus NN N
65.68 CD N
? . N
3.23 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Compared VBN N
with IN N
Group NNP N
C NNP N
, , N
Group NNP N
P NNP N
had VBD N
significantly RB N
lower JJR N
visual JJ o
analog NN o
scale NN o
scores NNS o
at IN o
rest NN o
and CC o
with IN N
movement NN N
, , N
respectively RB N
, , N
at IN N
2 CD N
h NN N
( ( N
4.2 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
5.0 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
6 CD N
h NN N
( ( N
3.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
4.5 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
12 CD N
h NN N
( ( N
3.0 CD N
, , N
P NNP N
= NNP N
0.017 CD N
and CC N
4.0 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
24 CD N
h NN N
( ( N
2.1 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
3.4 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
48 CD N
h NN N
( ( N
1.8 CD N
, , N
P NNP N
< NNP N
0.001 CD N
and CC N
2.6 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT o
satisfaction NN o
score NN o
was VBD N
higher RBR N
in IN N
Group NNP N
P NNP N
than IN N
in IN N
Group NNP N
C NNP N
( ( N
8.6 CD N
? . N
0.3 CD N
versus NN N
6.8 CD N
? . N
0.7 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN o
side NN o
effects NNS o
between IN o
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
parecoxib NN i
with IN i
patient-controlled JJ N
analgesic JJ N
morphine NN N
in IN N
postoperative JJ N
analgesia NN N
resulted VBD N
in IN N
comprehensive JJ N
enhancement NN N
of IN N
the DT N
analgesic JJ N
efficacy NN N
, , N
reducing VBG N
the DT N
opioid JJ N
requirement NN N
and CC N
increasing VBG N
patient JJ N
satisfaction NN N
after IN N
gynecological JJ N
tumor NN N
surgery NN N
. . N

-DOCSTART- -23802768- O O

Impact NN N
of IN N
MET NNP N
expression NN N
on IN N
outcome NN N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
advanced VBD p
melanoma NN p
. . p

AIMS NNP N
Preclinical NNP N
data NN N
suggest NN N
that IN N
signalling VBG N
through IN N
the DT N
HGF-MET NNP N
pathway NN N
may MD N
confer VB N
resistance NN N
to TO N
BRAF NNP N
inhibition NN N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

Therefore RB N
, , N
blockade NN N
of IN N
HGF-MET NNP N
signalling NN N
might MD N
be VB N
a DT N
valid JJ N
therapeutic JJ N
strategy NN N
, , N
in IN N
combination NN N
with IN N
BRAF NNP i
inhibition NN i
, , N
in IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
clinical JJ N
relevance NN N
of IN N
these DT N
observations NNS N
by IN N
evaluating VBG N
the DT N
survival JJ N
impact NN N
of IN N
MET NNP N
expression NN N
in IN N
patients NNS p
with IN p
BRAF NNP p
( ( p
V600E/K NNP p
) ) p
advanced VBD p
melanoma NN p
treated VBN p
with IN p
vemurafenib NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Formalin-fixed NNP N
tissue NN N
blocks NNS N
were VBD N
obtained VBN N
of IN N
tumours NNS N
from IN N
patients NNS p
enrolled VBN p
in IN p
the DT p
BRIM2 NNP p
( ( p
n JJ p
= NNP p
59 CD p
) ) p
and CC p
BRIM3 NNP p
( ( p
n JJ p
= NNP p
150 CD p
) ) p
trials NNS N
of IN N
vemurafenib NN i
in IN N
advanced JJ N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
melanoma NN N
. . N

Immunohistochemistry NNP N
for IN N
MET NNP N
( ( N
SP44 NNP N
rabbit VBP N
monoclonal JJ N
antibody NN N
) ) N
was VBD N
performed VBN N
with IN N
a DT N
highly RB N
validated VBN N
assay NN N
and CC N
clinically RB N
validated VBN N
scoring NN N
system NN N
. . N

Pretreatment NNP N
MET NNP N
expression NN N
was VBD N
frequent JJ N
at IN N
the DT N
?1 NNP N
+ NNP N
cutoff NN N
( ( N
BRIM3 NNP N
, , N
31 CD N
% NN N
; : N
BRIM2 NNP N
, , N
49 CD N
% NN N
) ) N
, , N
but CC N
relatively RB N
infrequent JJ N
at IN N
the DT N
?2 NNP N
+ NNP N
cutoff NN N
( ( N
BRIM3 NNP N
, , N
9 CD N
% NN N
; : N
BRIM2 NNP N
, , N
19 CD N
% NN N
) ) N
. . N

Retrospective JJ N
subset NN N
analyses NNS N
showed VBD N
that IN N
, , N
irrespective NN N
of IN N
the DT N
cutoff NN N
used VBD N
or CC N
the DT N
treatment NN N
arm NN N
, , N
MET NNP o
expression NN o
did VBD o
not RB N
show VB N
prognostic JJ N
significance NN N
, , N
in IN N
terms NNS o
of IN o
objective JJ o
response NN o
rate NN o
, , o
progression-free JJ o
survival NN o
, , o
or CC o
overall JJ o
survival NN o
. . o

CONCLUSIONS NNP o
MET NNP N
is VBZ N
expressed VBN N
in IN N
a DT N
proportion NN N
of IN N
BRAF NNP N
( ( N
V600E/K NNP N
) ) N
advanced VBD N
melanomas NN N
. . N

Further JJ N
analyses NNS N
on IN N
appropriately RB N
powered VBN N
subsets NNS N
are VBP N
needed VBN N
to TO N
determine VB N
the DT N
prognostic JJ N
and CC N
predictive JJ N
significance NN N
of IN N
MET NNP N
in IN N
vemurafenib-treated JJ N
melanoma NN N
. . N

-DOCSTART- -22513516- O O

Efficacy NN o
and CC o
safety NN o
of IN N
10 CD N
% NN N
HES NNP i
130/0.4 CD N
versus NN N
10 CD N
% NN N
HES NNP i
200/0.5 CD N
for IN N
plasma NN N
volume NN N
expansion NN N
in IN N
cardiac JJ p
surgery NN p
patients NNS p
. . p

AIM NNP N
Hydroxyethyl NNP i
starch NN i
( ( N
HES NNP N
) ) N
solutions NNS N
are VBP N
frequently RB N
used VBN N
for IN N
perioperative JJ N
volume NN N
replacement NN N
. . N

Whereas NNP N
older JJR N
HES NNP N
specimen NNS N
tended VBD N
to TO N
accumulate VB N
in IN N
the DT N
plasma NN N
and CC N
to TO N
cause VB N
negative JJ N
effects NNS N
on IN N
hemostasis NN N
, , N
more RBR N
recent JJ N
products NNS N
, , N
e.g. NN N
, , N
HES NNP N
130/0.4 CD N
, , N
are VBP N
characterised VBN N
by IN N
improved JJ N
pharmacological JJ N
properties NNS N
. . N

The DT N
present JJ N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
and CC N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
. . N

METHODS NN N
In IN N
this DT N
post-hoc JJ N
analysis NN N
of IN N
a DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
, , N
multi-center JJ N
therapeutic JJ N
equivalence NN N
trial NN N
, , N
76 CD p
patients NNS p
undergoing JJ p
elective JJ p
on-pump JJ p
cardiac NN p
surgery NN p
received VBD N
perioperative JJ i
volume NN i
replacement NN i
using VBG i
either CC i
10 CD i
% NN i
HES NNP i
130/0.4 CD i
( ( i
N.=37 NNP i
) ) i
or CC i
10 CD i
% NN i
HES NNP i
200/0.5 CD i
( ( i
N.=39 NNP i
) ) i
up RB i
to TO i
a DT i
maximum JJ i
dose NN i
of IN i
20 CD i
mL JJ i
kg-1 NN i
. . i

RESULTS NNP N
Equivalent NNP o
volumes NNS o
of IN o
investigational JJ o
medication NN o
were VBD N
infused VBN N
until IN N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
( ( N
1577 CD N
vs. IN N
1540 CD N
mL NN N
; : N
treatment NN N
difference NN N
37 CD N
[ JJ N
-150 NN N
; : N
223 CD N
] NNP N
mL NN N
; : N
P NNP N
< VBZ N
0.0001 CD N
for IN N
equivalence NN N
) ) N
. . N

Whereas NNP N
standard JJ o
laboratory NN o
tests NNS o
of IN o
coagulation NN o
were VBD N
comparable JJ N
between IN N
groups NNS N
, , N
von FW o
Willebrand NNP o
factor NN o
activity NN o
on IN N
the DT N
first JJ N
postoperative JJ N
morning NN N
tended VBD N
to TO N
be VB N
higher JJR N
following VBG N
treatment NN N
with IN N
10 CD N
% NN N
HES NNP N
130/0.4 CD N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
( ( N
P=0.025 NNP N
) ) N
with IN N
this DT N
difference NN N
being VBG N
statistically RB N
significant JJ N
only RB N
in IN N
the DT N
per-protocol JJ N
analysis NN N
( ( N
P=0.02 NNP N
) ) N
. . N

Treatment JJ N
groups NNS N
were VBD N
comparable JJ N
concerning VBG N
other JJ N
safety NN o
parameters NNS o
and CC o
the DT o
incidence NN o
of IN o
adverse JJ o
drug NN o
reactions NNS o
. . o

In IN N
particular JJ N
, , N
renal JJ o
function NN o
was VBD N
well RB N
preserved VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Ten CD N
percent NN N
HES NNP N
130/0.4 CD N
was VBD N
equally RB N
effective JJ N
and CC N
safe JJ N
as IN N
compared VBN N
to TO N
10 CD N
% NN N
HES NNP N
200/0.5 CD N
for IN N
volume NN N
therapy NN N
in IN N
patients NNS p
undergoing VBG p
cardiovascular JJ p
surgery NN p
. . p

Postoperative JJ o
coagulation NN o
and CC o
renal JJ o
function NN o
, , N
as IN N
measured VBN N
by IN N
standard JJ N
laboratory NN N
tests NNS N
, , N
were VBD N
similar JJ N
among IN N
groups NNS N
. . N

-DOCSTART- -20694273- O O

Randomised VBN N
, , N
parallel-group JJ N
, , N
multicentre NN N
, , N
multinational JJ N
phase NN N
2 CD N
study NN N
comparing VBG N
edoxaban NN i
, , N
an DT N
oral JJ N
factor NN i
Xa NNP i
inhibitor NN i
, , N
with IN N
warfarin NN i
for IN N
stroke NN p
prevention NN p
in IN p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
. . p

The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
safety NN N
of IN N
four CD N
fixed-dose JJ N
regimens NNS N
of IN N
edoxaban NN i
with IN i
warfarin NN i
in IN N
patients NNS p
with IN p
non-valvular JJ p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
. . p

In IN N
this DT N
12-week JJ N
, , N
parallel-group JJ N
, , N
multicentre NN p
, , p
multinational JJ p
study NN p
, , p
1,146 CD p
patients NNS p
with IN p
AF NNP p
and CC p
risk NN p
of IN p
stroke NN p
were VBD N
randomised VBN N
to TO N
edoxaban VB i
30 CD N
mg NN N
qd NN N
, , N
30 CD N
mg NN N
bid NN N
, , N
60 CD N
mg NN N
qd NN N
, , N
or CC N
60 CD N
mg JJ N
bid NN N
or CC i
warfarin VB i
dose-adjusted JJ N
to TO N
a DT N
target NN N
international JJ N
normalised JJ N
ratio NN N
of IN N
2.0-3.0 JJ N
. . N

The DT N
study NN N
was VBD N
double-blind JJ N
to TO N
edoxaban VB i
dose JJ N
, , N
but CC N
open-label JJ N
to TO N
warfarin VB i
. . i

Primary JJ N
outcomes NNS N
were VBD N
occurrence NN N
of IN N
major JJ o
and/or NNS o
clinically RB o
relevant JJ o
non-major JJ o
bleeding NN o
and CC o
elevated VBD o
hepatic JJ o
enzymes NNS o
and/or VBP o
bilirubin NN o
. . o

Mean NNP p
age NN p
was VBD p
65 CD p
+/- JJ p
8.7 CD p
years NNS p
and CC p
64.4 CD p
% NN p
were VBD p
warfarin-na?ve JJ i
. . i

Whereas IN N
major JJ N
plus CC N
clinically JJ N
relevant JJ o
non-major JJ o
bleeding NN o
occurred VBD N
in IN N
3.2 CD N
% NN N
of IN N
patients NNS N
randomised VBN N
to TO i
warfarin VB i
, , i
the DT o
incidence NN o
of IN o
bleeding NN o
was VBD N
significantly RB N
higher JJR N
with IN N
the DT i
edoxaban NN i
60 CD N
mg NN N
bid NN N
( ( N
10.6 CD N
% NN N
; : N
p=0.002 CC N
) ) N
and CC N
30 CD N
mg NNS N
bid NN N
regimens VBZ N
( ( N
7.8 CD N
% NN N
; : N
p=0.029 NN N
) ) N
, , N
but CC N
not RB N
with IN N
the DT i
edoxaban NN i
60 CD N
mg NN N
qd NN N
( ( N
3.8 CD N
% NN N
) ) N
or CC N
30 CD N
mg NNS N
qd JJ N
regimens NNS N
( ( N
3.0 CD N
% NN N
) ) N
. . N

For IN N
the DT N
same JJ N
total JJ N
daily JJ N
dose NN N
of IN N
60 CD N
mg NN N
, , N
both DT o
bleeding VBG o
frequency NN o
and CC o
trough JJ o
edoxaban NN o
concentrations NNS o
were VBD N
higher JJR N
in IN N
the DT N
30-mg JJ N
bid NN N
group NN N
than IN N
in IN N
the DT N
60-mg JJ N
qd NN N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN o
hepatic JJ o
enzyme NN o
elevations NNS o
or CC o
bilirubin JJ o
values NNS o
among IN N
the DT N
groups NNS N
. . N

The DT N
safety NN N
profiles NNS N
of IN i
edoxaban JJ i
30 CD N
and CC N
60 CD N
mg NN N
qd NN N
in IN N
patients NNS N
with IN N
AF NNP N
were VBD N
similar JJ N
to TO i
warfarin VB i
. . i

In IN N
contrast NN N
, , N
the DT i
edoxaban JJ i
bid NN N
regimens NNS N
were VBD N
associated VBN N
with IN N
more RBR o
bleeding NN o
than IN i
warfarin NN i
. . i

These DT N
results NNS N
suggest VBP N
that IN N
in IN N
this DT N
three-month JJ N
study NN N
, , N
edoxaban VBP i
30 CD N
or CC N
60 CD N
mg NNS N
qd NNS N
are VBP o
safe JJ o
and CC o
well-tolerated JJ o
. . o

-DOCSTART- -18666040- O O

[ JJ o
No DT o
effect NN o
of IN N
spironolactone NN i
on IN N
bulimia NN N
nervosa NN N
symptoms NNS N
] NNP N
. . N

Some DT N
case NN N
reports NNS N
mention NN N
that IN N
Spironolactone NNP i
, , N
a DT N
mineral JJ i
corticoid NN i
antagonist NN i
and CC N
aldosterone NN i
antagonist NN i
, , N
reduces NNS N
binging VBG o
in IN N
patients NNS p
with IN p
bulimia JJ p
nervosa NN p
. . p

Therefore RB N
, , N
we PRP N
decided VBD N
to TO N
study VB N
these DT N
findings NNS N
by IN N
using VBG N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo NN i
controlled VBD N
study NN N
design NN N
. . N

In IN N
one CD N
study NN N
arm NN N
, , N
patients NNS p
with IN p
bulimia JJ p
nervosa NNS p
were VBD N
treated VBN N
with IN N
150 CD i
mg NNS i
Spironolactone CD i
per IN i
day NN i
; : i
in IN N
the DT N
other JJ N
arm NN N
, , N
patients NNS N
received VBD N
a DT N
placebo NN i
for IN N
a DT N
total NN N
of IN N
8 CD N
weeks NNS N
. . N

The DT N
target NN N
variables NNS N
were VBD N
the DT N
number NN o
of IN o
binges NNS o
and CC N
the DT N
bulimia NN o
scale NN o
of IN o
the DT o
Eating NNP o
Disorder NNP o
Inventory NNP o
. . o

The DT p
study NN p
included VBD p
93 CD p
patients NNS p
. . p

The DT N
results NNS N
show VBP N
that IN N
the DT N
number NN o
of IN o
binges NNS o
and CC o
the DT o
scores NNS o
on IN o
the DT o
bulimia NN o
scale NN o
decreased VBD N
somewhat RB N
, , N
but CC N
this DT N
occurred VBD N
in IN N
both DT N
groups NNS N
. . N

We PRP N
were VBD N
not RB N
able JJ N
to TO N
show VB N
any DT N
significant JJ o
statistical JJ o
differences NNS o
between IN N
the DT N
Spironolactone NNP i
group NN N
and CC N
the DT N
placebo NN N
group NN N
. . N

Additional NNP N
evaluations NNS N
, , N
executed VBN N
with IN N
data NNS N
from IN N
the DT N
Symptom-Check-List NNP o
( ( o
SCL-90R NNP o
) ) o
and CC N
with IN N
other JJ N
scales NNS N
from IN N
the DT N
EDI-2 NNP N
also RB N
showed VBD N
no DT N
effect NN N
of IN N
Spironolactone NNP i
. . i

Therefore NNP N
, , N
a DT N
treatment NN N
with IN N
Spironolactone NNP i
seems VBZ N
to TO N
have VB N
no DT o
effect NN o
on IN N
bulimia NN N
nervosa NN N
symptoms NNS N
. . N

-DOCSTART- -22471381- O O

Temporal JJ N
discounting NN N
: : N
the DT N
differential JJ N
effect NN N
of IN N
proximal NN N
and CC N
distal JJ N
consequences NNS N
on IN N
confession NN i
decisions NNS i
. . i

Drawing VBG N
on IN N
the DT N
psychological JJ N
principle NN N
that IN N
proximal JJ N
consequences NNS N
influence NN N
behavior RB N
more RBR N
strongly RB N
than IN N
distal JJ N
consequences NNS N
, , N
the DT N
authors NNS N
tested VBD N
the DT N
hypothesis NN N
that WDT N
criminal JJ p
suspects NNS p
exhibit VBP N
a DT N
short-sightedness NN p
during IN p
police NNS p
interrogation NN p
that IN N
increases VBZ N
their PRP$ N
risk NN o
for IN o
confession NN o
. . o

Consistent JJ N
with IN N
this DT N
hypothesis NN N
, , N
Experiment NNP N
1 CD N
showed VBD N
that IN N
participants NNS p
( ( p
N NNP p
= NNP p
81 CD p
) ) p
altered VBD N
how WRB N
frequently RB N
they PRP N
admitted VBD o
to TO o
criminal JJ o
and CC o
unethical JJ o
behaviors NNS o
during IN N
an DT N
interview NN N
to TO N
avoid VB N
a DT N
proximal JJ N
consequence NN N
even RB N
though IN N
doing VBG N
so RB N
increased VBN N
their PRP$ N
risk NN N
of IN N
incurring VBG N
a DT N
distal JJ o
consequence NN o
. . o

Experiment JJ p
2 CD p
( ( p
N NNP p
= NNP p
143 CD p
) ) p
yielded VBD N
the DT N
same JJ N
pattern NN N
, , N
but CC N
with IN N
a DT N
procedure NN N
that WDT N
reversed VBD N
the DT N
order NN N
of IN N
the DT N
proximal NN o
and CC o
distal JJ o
consequences NNS o
, , N
thereby RB N
ruling VBG N
out RP N
the DT N
possibility NN N
that IN N
it PRP N
was VBD N
the DT N
unique JJ N
characteristics NNS N
of IN N
the DT N
consequences NNS N
rather RB N
than IN N
their PRP$ N
proximity NN N
that IN N
influenced VBD N
the DT N
admission NN o
rate NN o
. . o

The DT N
authors NNS N
discuss VBP N
the DT N
supported JJ N
psychological JJ N
process NN N
as IN N
a DT N
potential JJ N
explanation NN N
for IN N
several JJ N
well-established JJ N
findings NNS N
reported VBN N
in IN N
the DT N
literature NN N
on IN N
confessions NNS N
. . N

-DOCSTART- -9585295- O O

Quantifying VBG N
oral JJ i
analgesic JJ i
consumption NN N
using VBG N
a DT N
novel JJ N
method NN N
and CC N
comparison NN N
with IN N
patient-controlled JJ p
intravenous JJ p
analgesic JJ i
consumption NN p
. . p

-DOCSTART- -12123333- O O

Intramuscular JJ N
depot NN N
medroxyprogesterone NN i
versus IN N
oral JJ N
megestrol NN i
for IN N
the DT N
control NN N
of IN N
postmenopausal NN N
hot JJ o
flashes NNS o
in IN N
breast NN p
cancer NN p
patients NNS p
: : p
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Hot NNP o
flashes NNS o
are VBP N
frequent JJ N
in IN N
postmenopausal JJ p
breast NN p
cancer NN p
patients NNS p
, , N
especially RB N
when WRB N
treated VBN N
with IN N
tamoxifen NN N
. . N

Estrogen NNP i
replacement NN i
therapy NN i
is VBZ N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
hot JJ o
flashes NNS o
, , N
but CC N
its PRP$ N
use NN N
is VBZ N
controversial JJ N
in IN N
breast NN N
cancer NN N
survivors NNS N
. . N

Progestins NNS N
may MD N
offer VB N
a DT N
good JJ N
alternative NN N
for IN N
the DT N
control NN N
of IN N
hot JJ o
flashes NNS o
in IN N
this DT N
setting NN N
; : N
in IN N
particular JJ N
, , N
oral JJ N
megestrol NN N
acetate NN N
has VBZ N
been VBN N
proven RB N
effective JJ N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

With IN N
the DT N
aim NN N
of IN N
further JJ N
improving VBG N
these DT N
results NNS N
, , N
we PRP N
have VBP N
designed VBN N
a DT N
randomized VBN N
study NN N
comparing VBG N
oral JJ N
megestrol NN i
acetate NN i
with IN N
depot NN N
intramuscular NN N
( ( N
i.m JJ N
. . N

) ) N
medroxyprogesterone NN i
acetate NN i
( ( i
MPA NNP i
) ) i
for IN N
the DT N
control NN N
of IN N
hot JJ N
flashes NNS N
in IN N
postmenopausal NN p
patients NNS p
with IN p
a DT p
history NN p
of IN p
breast NN p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Seventy-one NNP p
postmenopausal NN p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
an DT N
i.m NN i
. . i

injection NN i
of IN i
depot NN i
MPA NNP i
500 CD i
mg NN i
on IN i
days NNS i
1 CD i
, , i
14 CD i
and CC i
28 CD i
, , i
or CC i
oral JJ i
megestrol NN i
acetate VBP i
40 CD i
mg JJ i
daily RB i
for IN i
6 CD i
weeks NNS i
. . i

Patients NNS N
recorded VBD N
daily RB N
the DT N
number NN N
and CC N
severity NN N
of IN N
their PRP$ N
hot JJ o
flashes NNS o
; : o
response NN N
was VBD N
defined VBN N
as IN N
a DT N
> NN N
or CC N
=50 CD N
% NN N
decrease NN N
in IN N
the DT N
number NN N
and CC N
severity NN N
of IN N
hot JJ o
flashes NNS o
. . o

RESULTS NN N
At IN N
week NN N
6 CD N
, , N
hot JJ o
flashes NNS o
were VBD N
reduced VBN N
by IN N
86 CD N
% NN N
on IN N
average NN N
in IN N
the DT N
whole JJ N
group NN N
of IN N
patients NNS N
, , N
without IN N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
progestins NNS N
. . N

Response NNP N
was VBD N
obtained VBN N
by IN N
75 CD N
and CC N
67 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
MPA NNP N
or CC N
megestrol NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.5 CD N
) ) N
. . N

Responders NNPS N
were VBD N
followed VBN N
to TO N
assess VB N
maintenance NN N
of IN N
response NN N
( ( N
without IN N
further RB N
treatment NN N
) ) N
, , N
which WDT N
was VBD N
significantly RB N
better RBR N
with IN N
i.m NN N
. . N

MPA NN i
: : i
in IN N
this DT N
group NN N
, , N
89 CD N
% NN N
of IN N
responders NNS N
still RB N
showed VBD N
a DT N
benefit NN N
at IN N
week NN N
24 CD N
, , N
compared VBN N
with IN N
45 CD N
% NN N
in IN N
the DT N
megestrol NN i
group NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
shows VBZ N
that IN N
a DT N
short JJ N
cycle NN N
of IN N
i.m NN N
. . N

depot NN N
MPA NNP i
injections NNS N
provides VBZ N
significant JJ N
and CC N
long-lasting JJ N
relief NN o
from IN N
postmenopausal NN o
hot JJ o
flashes NNS o
in IN N
patients NNS p
with IN p
a DT p
history NN p
of IN p
breast NN p
cancer NN p
, , N
offering VBG N
an DT N
alternative JJ N
to TO N
estrogen VB N
replacement NN N
therapy NN N
or CC N
prolonged JJ N
administration NN N
of IN N
oral JJ N
megestrol NN i
. . i

-DOCSTART- -21457605- O O

Improving VBG N
emotion NN o
regulation NN o
with IN N
CBT NNP i
in IN N
young JJ p
children NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
This DT N
pilot NN N
study NN N
tested VBD N
the DT N
efficacy NN N
of IN N
a DT N
developmentally RB N
modified VBN N
CBT NNP i
for IN N
young JJ p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
to TO N
teach VB N
emotion NN o
regulation NN o
strategies NNS N
for IN N
reducing VBG N
anger NN o
and CC o
anxiety NN o
, , N
commonly RB N
noted VBD N
problems NNS N
in IN N
this DT N
population NN N
. . N

METHOD NNP N
Eleven NNP p
5-7 JJ p
year-old JJ p
children NNS p
participated VBN p
in IN N
a DT N
CBT-group NNP i
while IN N
parents NNS N
participated VBN i
in IN i
psychoeducation NN i
. . i

Children NNP i
were VBD i
randomly RB i
assigned VBN i
to TO i
an DT i
experimental JJ i
or CC i
delayed-treatment JJ i
control NN i
group NN i
. . i

RESULTS CC N
From IN N
pre- JJ N
to TO N
post-treatment JJ N
, , N
all DT N
children NNS N
had VBD N
less RBR N
parent NN p
reported VBD p
negativity/lability NN o
, , N
better JJR N
parent NN N
reported VBD N
emotion NN o
regulation NN o
, , o
and CC o
shorter JJR o
outbursts NNS o
, , N
and CC N
also RB N
generated VBD o
more RBR o
coping JJ o
strategies NNS o
in IN N
response NN N
to TO N
vignettes NNS N
. . N

Parents NNS N
also RB N
reported VBD N
increases NNS N
in IN N
their PRP$ N
own JJ N
confidence NN o
and CC N
their PRP$ N
child NN N
's POS N
ability NN o
to TO o
deal VB o
with IN o
anger NN o
and CC o
anxiety NN o
. . o

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
young JJ p
children NNS p
with IN p
high JJ p
functioning VBG p
ASD NNP p
may MD N
benefit VB N
from IN N
CBT NNP i
to TO N
improve VB N
regulation NN o
of IN o
anger NN o
and CC o
anxiety NN o
, , N
and CC N
parent NN N
training NN N
may MD N
improve VB N
parental JJ o
self-efficacy NN o
. . o

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
make VB N
conclusions NNS N
about IN N
its PRP$ N
efficacy NN N
. . N

-DOCSTART- -22686292- O O

Can MD N
simvastatin VB i
improve VB N
erectile JJ o
function NN o
and CC N
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
men NNS p
aged VBN p
?40 CD p
years NNS p
with IN p
erectile JJ p
dysfunction NN p
? . p
Results NNS N
of IN N
the DT N
Erectile NNP N
Dysfunction NNP N
and CC N
Statins NNP N
Trial NNP N
[ NNP N
ISRCTN66772971 NNP N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT o
effectiveness NN o
and CC o
cost-effectiveness NN o
of IN o
simvastatin NN i
on IN i
erectile JJ o
function NN o
and CC o
health-related JJ o
quality NN o
of IN o
life NN o
in IN o
men NNS p
aged VBN p
?40 CD p
years NNS p
with IN p
erectile JJ p
dysfunction NN p
( ( p
ED NNP p
) ) p
. . p

PATIENTS NNP p
AND CC N
METHODS NNP N
ED NNP N
is VBZ N
common JJ N
in IN N
men NNS N
aged VBN N
?40 CD N
years NNS N
and CC N
impacts NNS N
upon VBP N
their PRP$ N
overall JJ N
health-related JJ N
quality NN N
of IN N
life NN N
and CC N
that IN N
of IN N
their PRP$ N
partners NNS p
. . p

Men NNP p
aged VBD p
?40 CD p
years NNS p
who WP p
were VBD p
not RB p
receiving VBG p
lipid JJ p
lowering NN p
or CC p
anti-hypertensive JJ p
medication NN p
and CC p
not RB p
at IN p
high JJ p
cardiovascular JJ p
risk NN p
were VBD p
recruited VBN p
from IN p
10 CD p
general JJ p
practices NNS p
in IN p
the DT p
East NNP p
of IN p
England NNP p
. . N

In IN N
total JJ N
, , p
173 CD p
eligible JJ p
men NNS p
with IN p
untreated JJ p
ED NNP p
were VBD p
randomized VBN p
to TO p
double-blind VB p
treatment NN i
with IN i
40 CD i
mg NNS i
of IN i
simvastatin NN i
or CC i
placebo NN i
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
three CD N
points NNS N
over IN N
30 CD N
weeks NNS N
. . N

The DT N
main JJ N
outcome NN N
was VBD o
erectile JJ o
function NN o
( ( o
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function-5 NNP o
score NN o
) ) o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
male JJ o
ED-specific JJ o
quality NN o
of IN o
life NN o
( ( o
MED-QoL NNP o
) ) o
, , o
quality-adjusted JJ o
life NN o
years NNS o
( ( o
QALYs NNP o
) ) o
using VBG o
the DT o
generic JJ o
Euroqol NNP o
measure NN o
( ( o
EQ-5D NNP o
) ) o
, , o
endothelial JJ o
function NN o
, , o
cardiovascular JJ o
risk NN o
, , o
cholesterol NN o
and CC o
health NN o
service NN o
costs NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
erectile JJ o
function NN o
between IN o
the DT i
simvastatin NN i
and CC i
placebo NN i
groups NNS N
( ( N
mean JJ N
change NN N
, , N
1.28 CD N
vs NN N
0.07 CD N
, , N
z NN N
= VBD N
1.1 CD N
, , N
p NN N
= NNP N
0.27 CD N
) ) N
, , N
although IN N
a DT N
significant JJ N
improvement NN o
in IN o
MED-QoL NNP o
was VBD N
observed VBN N
( ( N
5 CD N
% NN N
vs JJ N
2 CD N
% NN N
, , N
z NN N
= VBD N
2.09 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Both DT o
10-year JJ o
cardiovascular NN o
risk NN o
and CC o
low-density NN o
lipoprotein NN o
were VBD o
reduced VBN o
( ( N
cardiovascular JJ N
risk NN N
, , N
z NN N
= NNP N
-3.67 NNP N
, , N
p NN N
< VBD N
0.001 CD N
; : N
low-density JJ N
lipoprotein NN N
, , N
z NN N
= NNP N
-5.46 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
with IN N
no DT N
consistent JJ N
change NN N
in IN o
endothelial JJ o
function NN o
. . o

The DT o
frequency NN o
of IN o
sexual JJ o
encounters NNS o
is VBZ o
correlated VBN o
with IN o
improved JJ o
erectile JJ o
function NN o
. . o

The DT o
joint JJ o
distribution NN o
of IN o
costs NNS o
and CC o
QALY NNP o
benefits NNS o
indicates VBZ o
that IN N
the DT N
probability NN N
of IN N
simvastatin NN o
being VBG o
cost-effective JJ o
for IN o
willingness-to-pay JJ o
thresholds NNS N
of IN N
?20,000 NN N
and CC N
?30,000 NN N
is VBZ N
86 CD N
% NN N
and CC N
83 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Identifying VBG p
men NNS p
with IN p
ED NNP p
provides VBZ p
an DT N
opportunity NN N
to TO N
modify VB N
future JJ N
cardiovascular JJ N
risk NN N
and CC N
to TO N
improve VB N
MED-QoL NNP N
by IN N
treating VBG N
them PRP N
with IN N
40 CD N
mg NNS N
of IN i
simvastatin NN i
. . i

The DT i
joint JJ i
analysis NN N
of IN o
costs NNS o
and CC N
QALY NNP o
benefits NNS o
suggests VBZ N
that IN N
there EX N
is VBZ N
high JJ N
probability NN N
that IN N
simvastatin NN N
is VBZ N
a DT N
cost-effective JJ N
strategy NN N
in IN N
men NNS N
with IN N
ED NNP N
. . N

The DT N
findings NNS N
could MD N
influence VB N
urological JJ N
and CC N
primary JJ N
care NN N
practice NN N
by IN N
including VBG N
questions NNS N
on IN N
ED NNP N
during IN N
routine JJ N
consultations NNS N
and CC N
relevant JJ N
clinical JJ N
protocols NNS N
. . N

This DT N
provides VBZ N
an DT N
opportunity NN N
to TO N
impart VB N
lifestyle JJ N
advice NN N
. . N

-DOCSTART- -9235679- O O

[ JJ N
Clinical NNP N
diagnosis NN N
of IN N
deep JJ N
venous JJ N
thrombosis NN N
after IN N
hip NN N
replacement NN N
surgery NN N
] NN N
. . N

Hip NNP N
replacement NN N
surgery NN N
is VBZ N
associated VBN N
with IN N
a DT N
high JJ N
frequency NN N
of IN N
postoperative JJ N
deep JJ N
vein NN N
thrombosis NN N
. . N

This DT N
prospective JJ N
study NN N
was VBD N
performed VBN N
in IN N
order NN N
to TO N
investigate VB N
if IN N
routine JJ i
bedside NN i
questioning VBG i
and CC i
examination NN i
by IN i
the DT i
visiting NN i
doctor NN i
could MD N
reveal VB N
deep JJ N
vein NN N
thrombosis NN N
in IN N
the DT N
legs NN N
of IN N
patients NNS p
who WP p
had VBD p
received VBN p
a DT p
hip NN p
replacement NN p
. . p

258 CD p
patients NNS p
were VBD p
evaluated VBN p
. . p

Thromboprophylaxis NNP i
( ( i
dextran-70 JJ i
, , i
low JJ i
molecular JJ i
weight NN i
heparin NN i
and CC i
graded VBD i
elastic JJ i
stockings NNS i
) ) i
was VBD N
given VBN N
during IN N
the DT N
first JJ N
week NN N
after IN N
operation NN N
. . N

Bilateral NNP i
venography NN i
was VBD N
performed VBN N
in IN N
all DT N
patients NNS N
on IN N
day NN N
seven CD N
after IN N
operation NN N
, , N
and CC N
showed VBD N
an DT N
overall JJ N
deep JJ N
vein NN N
thrombosis NN N
incidence NN N
of IN N
16 CD N
% NN N
. . N

The DT N
visiting NN N
doctors NNS N
had VBD N
not RB N
suspected VBN N
deep JJ N
vein NN N
thrombosis NN N
in IN N
any DT N
of IN N
the DT N
patients NNS N
. . N

This DT N
may MD N
have VB N
been VBN N
because RB N
postoperative JJ o
painful NN o
and CC o
swollen JJ o
legs NNS o
effectively RB N
masked VBD N
any DT N
signs NNS N
and CC N
symptoms NNS N
of IN N
deep JJ N
vein NN N
thrombosis NN N
. . N

Our PRP$ N
results NNS N
show VBP N
that IN N
deep JJ o
vein NN o
thrombosis NN o
during IN N
the DT N
first JJ N
week NN N
after IN N
hip NN N
replacement NN N
surgery NN N
can MD N
not RB N
be VB N
discovered VBN N
by IN N
clinical JJ N
diagnostics NNS N
. . N

The DT N
high JJ N
subclinical JJ N
frequency NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
indicates VBZ N
the DT N
importance NN N
of IN N
improving VBG N
thromboprophylaxis NN N
in IN N
order NN N
to TO N
further RBR N
minimise VB N
the DT N
occurrence NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
and CC N
the DT N
risk NN N
of IN N
thromboembolic JJ N
complications NNS N
. . N

-DOCSTART- -18565251- O O

Intra-articular JJ N
hyaluronic JJ i
acid NN i
compared VBN N
to TO N
exercise VB i
therapy NN i
in IN N
osteoarthritis NN p
of IN p
the DT p
ankle NN p
. . p

A DT N
prospective JJ N
randomized VBN N
trial NN N
with IN N
long-term JJ N
follow-up NN N
. . N

OBJECTIVE CC N
The DT N
goal NN N
of IN N
this DT N
study NN N
has VBZ N
been VBN N
to TO N
determine VB N
whether IN N
hyaluronic JJ i
acid NN i
( ( i
HA NNP i
) ) i
or CC N
exercise NN i
therapy NN i
can MD N
improve VB N
functional JJ N
parameters NNS N
in IN N
patients NNS p
with IN p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
of IN p
the DT p
ankle NN p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
clinical JJ N
trial NN N
, , N
43 CD p
ankles NNS p
( ( p
30 CD p
patients NNS p
) ) p
with IN p
radiographic JJ p
Kellgren NNP p
Lawrence NNP p
grade VBD p
III NNP p
OA NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
three CD i
intra-articular JJ i
HA NNP i
injections NNS i
, , N
with IN N
one-week JJ N
interval NN N
of IN N
or CC N
exercise NN i
therapy NN i
for IN N
six CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
by IN N
the DT N
American JJ o
Orthopaedic NNP o
Foot NNP o
and CC o
Ankle NNP o
Society NNP o
( ( o
AOFAS NNP o
) ) o
Ankle-Hindfoot NNP o
Scale NNP o
and CC N
followed-up NN N
after IN N
12 CD N
months NNS N
. . N

RESULTS NNP N
Total JJ o
AOFAS NNP o
Ankle-Hindfoot NNP o
score NN o
of IN o
OA NNP o
patients NNS o
has VBZ N
improved VBN N
in IN N
both DT N
groups NNS N
, , N
varying VBG N
from IN N
61.6+/-16.8 JJ N
to TO N
90.1+/-9.7 JJ N
with IN N
HA NNP i
treatment NN N
and CC N
from IN N
72.1+/-16.6 JJ N
to TO N
87.5+/-17.5 JJ N
using VBG N
exercise NN i
therapy NN i
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
prospective JJ N
randomized VBN N
trial NN N
confirmed VBD N
that IN N
, , N
both DT N
HA NNP i
injections NNS N
and CC N
exercise NN i
therapy NN i
provide VBP N
functional JJ N
improvement NN N
. . N

However RB N
, , N
larger JJR N
trials NNS N
with IN N
longer JJR N
follow-up NN N
are VBP N
necessary JJ N
for IN N
more RBR N
definite JJ N
conclusions NNS N
. . N

-DOCSTART- -6633131- O O

Carbon NNP i
dioxide NN i
laser NN i
treatment NN i
of IN N
vaginal JJ p
adenosis NN p
in IN p
DES-exposed JJ p
offspring NN p
: : p
a DT N
prospective JJ N
study NN N
. . N

Seventy-nine JJ p
patients NNS p
with IN p
history NN p
and CC p
physical JJ p
findings NNS p
characteristic NN p
of IN p
antenatal JJ p
DES NNP p
exposure NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Fourty-four CD p
DES-exposed JJ p
offspring VBG p
had VBD N
their PRP$ N
vaginal JJ N
adenosis NN N
treated VBN N
with IN N
the DT N
carbon NN i
dioxide NN i
laser NN i
( ( N
group NN N
I PRP N
) ) N
, , N
and CC N
the DT N
remaining VBG N
35 CD N
DES-exposed JJ N
offspring NN N
( ( N
group NN N
II NNP N
) ) N
did VBD i
not RB i
receive VB i
any DT i
specific JJ i
treatment NN i
for IN N
this DT N
condition NN N
. . N

Additionally RB N
, , N
the DT N
79 CD p
DES-exposed JJ p
offspring VBG p
were VBD N
compared VBN N
to TO N
an DT N
age-matched JJ N
control NN N
population NN N
( ( N
group NN N
III NNP N
) ) N
. . N

Treatment NN N
of IN N
vaginal JJ N
adenosis NN N
with IN N
the DT N
carbon NN i
dioxide NN i
laser NN i
did VBD N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
development NN o
of IN o
new JJ o
dysplasia NN o
in IN N
the DT N
DES-exposed JJ p
offspring NN p
. . p

This DT N
study NN N
also RB N
showed VBD N
no DT N
statistical JJ N
difference NN N
( ( N
p NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.05 CD N
) ) N
in IN N
the DT N
incidence NN o
of IN o
dysplasia NN o
in IN N
DES-exposed JJ p
offspring NN p
as IN N
compared VBN N
to TO N
a DT N
control NN N
population NN N
. . N

-DOCSTART- -25062129- O O

Contact NN N
lens VBZ N
lipid JJ N
spoliation NN N
of IN N
hydrogel NN N
and CC N
silicone NN N
hydrogel NN N
lenses NNS N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
measure VB N
contact NN i
lens VBZ i
lipid JJ i
spoliation NN i
of IN i
silicone NN i
hydrogel NN i
PureVision NNP i
( ( i
balafilcon VB i
A NNP i
) ) i
and CC i
hydrogel $ i
Acuvue NNP i
2 CD i
( ( i
etafilcon VB i
A NNP i
) ) i
contact NN i
lenses VBZ i
worn VBP p
for IN p
10 CD p
hours NNS p
single JJ p
use NN p
( ( p
DD NNP p
) ) p
and CC p
7 CD p
days NNS p
of IN p
extended JJ p
wear NN p
( ( p
EW NNP p
) ) p
. . p

METHODS NNP N
Two CD p
similar JJ p
study NN p
populations NNS p
( ( p
DD NNP p
, , p
n JJ p
= VBP p
55 CD p
; : p
EW NNP p
, , p
n JJ p
= NNP p
53 CD p
) ) p
, , N
were VBD N
enrolled VBN N
at IN N
four CD p
study NN p
sites NNS p
. . p

In IN N
each DT N
population NN N
, , N
a DT N
bilateral JJ N
, , N
randomized VBN N
, , N
crossover NN N
( ( N
lens JJ N
material NN N
) ) N
, , N
subject-masked JJ N
experimental JJ N
design NN N
was VBD N
followed VBN N
. . N

Worn NNP N
contact NN N
lenses NNS N
were VBD N
analyzed VBN N
for IN N
lipid JJ N
uptake JJ N
using VBG N
high-performance NN N
liquid NN i
chromatography NN i
by IN N
two CD N
laboratories NNS N
: : N
Alcon NNP N
Laboratories NNPS N
( ( N
right JJ N
lens NNS N
total JJ N
uptake NN N
) ) N
and CC N
OTG NNP N
Research NNP N
& CC N
Consultancy NNP N
( ( N
left VBN N
lens VBZ N
total JJ N
uptake NN N
and CC N
individual JJ N
lipid JJ N
classes NNS N
) ) N
. . N

RESULTS NNP N
Lipid NNP o
uptake NN o
was VBD N
different JJ N
for IN N
the DT N
two CD N
materials NNS N
: : N
total JJ o
lipid NN o
( ( N
p JJ N
< NNP N
0.007 CD N
) ) N
, , N
cholesterol NN o
esters NNS o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
cholesterol NN o
( ( N
p JJ N
< $ N
0.001 CD N
EW NNP N
only RB N
) ) N
, , N
and CC N
triglycerides/phospholipids NNS o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
were VBD N
higher JJR N
for IN N
balafilcon NN N
A NNP N
, , N
whereas JJ N
fatty JJ o
acid NN o
( ( N
p JJ N
< $ N
0.0025 CD N
EW NNP N
only RB N
) ) N
was VBD N
higher JJR N
for IN N
etafilcon NN N
A NNP N
. . N

The DT N
ratio NN o
of IN o
the DT o
extracted JJ o
lipids NN o
was VBD N
also RB N
different JJ N
: : N
higher JJR N
percentages NNS N
of IN N
triglycerides/phospholipids NNS o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
cholesterol NN o
( ( N
p JJ N
< $ N
0.001 CD N
EW NNP N
only RB N
) ) N
for IN N
balafilcon NN N
A DT N
and CC N
higher JJR N
percentages NNS N
of IN N
fatty JJ o
acids/di- JJ o
and CC o
monoglycerides NNS o
( ( N
p JJ N
< NNP N
0.014 CD N
) ) N
for IN N
etafilcon NN N
A NNP N
. . N

CONCLUSIONS NNP N
Total NNP o
lipid JJ o
uptake NN o
was VBD N
highly RB N
material JJ N
dependent NN N
. . N

Both DT N
laboratories NNS N
measured VBD N
a DT N
greater JJR N
uptake NN o
of IN o
lipids NNS o
by IN N
the DT N
silicone NN N
hydrogel NN N
than IN N
the DT N
hydrogel JJ N
material NN N
, , N
a DT N
difference NN N
that WDT N
was VBD N
evident JJ N
after IN N
only RB N
10 CD N
hours NNS N
of IN N
DD NNP N
. . N

Total JJ o
lipid JJ o
uptake NN o
was VBD N
greater JJR N
after IN N
7 CD N
days NNS N
of IN N
EW NNP N
compared VBN N
with IN N
10 CD N
hours NNS N
of IN N
DD NNP N
. . N

Of IN N
interest NN N
for IN N
contact NN N
lens JJ N
spoliation NN N
and CC N
its PRP$ N
avoidance NN N
was VBD N
the DT N
differential JJ N
lipid JJ N
uptake NN N
profile NN N
, , N
indicating VBG N
material NN N
selectivity NN N
. . N

Whereas NNP N
greater JJR N
differentiation NN N
between IN N
materials NNS N
was VBD N
possible JJ N
after IN N
7 CD N
days NNS N
of IN N
EW NNP N
for IN N
each DT N
material NN N
, , N
the DT N
lipid JJ N
uptake NN N
profile NN N
was VBD N
similar JJ N
for IN N
DD NNP N
and CC N
EW NNP N
, , N
indicating VBG N
a DT N
greater JJR N
material NN N
effect NN N
than IN N
a DT N
wear JJ N
modality NN N
effect NN N
. . N

-DOCSTART- -22294238- O O

Predictors NNS N
of IN N
response NN N
to TO N
ziprasidone NN i
: : i
results NNS N
from IN N
a DT N
6-week JJ N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
for IN N
acute JJ p
depressive JJ p
mixed JJ p
state NN p
. . p

INTRODUCTION NNP N
The DT N
present JJ N
study NN N
is VBZ N
aimed VBN N
at IN N
investigating VBG N
possible JJ N
predictors NNS N
of IN N
response NN N
to TO N
ziprasidone NN N
in IN N
a DT N
sample NN N
of IN N
patients NNS p
with IN p
mixed JJ p
depressive JJ p
state NN p
. . p

METHODS NNP N
72 CD p
patients NNS p
were VBD p
randomized VBN p
to TO N
either DT N
ziprasidone NN i
or CC i
placebo NN i
and CC N
treated VBD N
prospectively RB N
for IN N
6 CD N
weeks NNS N
. . N

The DT N
clinical JJ N
response NN N
and CC N
remission NN N
were VBD N
defined VBN N
with IN N
various JJ N
clinical JJ N
variables NNS N
including VBG N
Montgomery NNP o
Asberg NNP o
Depression NNP o
Rating NNP o
Scale NNP o
. . o

Further NNP N
outcome NN N
measures NNS N
included VBD N
predictors NNS N
of IN N
remission NN o
and CC N
other JJ N
clinical JJ N
variables NNS N
over IN N
time NN N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
variables NNS N
under IN N
investigation NN N
were VBD N
significantly RB N
associated VBN N
with IN N
response NN o
or CC o
remission NN o
at IN N
6 CD N
weeks NNS N
( ( N
all DT N
p-values NNS N
> VBP N
0.003 CD N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Further NNP N
investigations NNS N
are VBP N
warranted VBN N
due JJ N
to TO N
clear JJ N
limitations NNS N
, , N
mostly RB N
small JJ N
sample NN N
size NN N
and CC N
use NN N
of IN N
concomitant JJ N
medications NNS N
. . N

-DOCSTART- -11360574- O O

[ JJ N
Clinical NNP N
and CC N
experimental JJ N
research NN N
of IN N
Epimedium NNP i
brevicornum NN i
in IN N
relieving VBG p
neuroendocrino-immunological JJ o
effect NN o
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
protective JJ N
effect NN N
of IN N
Epimedium NNP i
brevicornum NN i
( ( i
EB NNP i
) ) i
on IN N
hypothalamus-pituitary-adrenal-thymus NN N
( ( N
HPAT NNP N
) ) N
axis NN N
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
. . N

METHODS NNP N
In IN N
clinical JJ N
research NN N
, , N
variation NN N
of IN N
cortisol NN N
, , N
adrenocorticotrophin NN N
( ( N
ACTH NNP N
) ) N
, , N
lymphocyte JJ N
proliferative JJ N
reaction NN N
were VBD N
observed VBN N
before IN N
and CC N
after IN N
medication NN N
in IN N
65 CD p
patients NNS p
took VBD p
prednisone NN i
, , p
and CC p
were VBD p
randomly RB p
divided VBN p
into IN p
Fufang NNP i
prednisone NN i
group NN i
( ( i
mixture NN i
of IN i
prednisone NN i
and CC i
EB NNP i
) ) i
and CC i
prednisone NN i
group NN i
. . i

An DT N
experimental JJ N
model NN N
of IN N
HPAT NNP N
axis NN N
inhibited VBN N
by IN N
corticosterone NN N
( ( N
CORT NNP N
) ) N
was VBD N
established VBN N
to TO N
observe VB N
the DT N
effect NN N
of IN N
EB NNP N
on IN N
relevant JJ N
indices NNS N
of IN N
HPAT NNP N
axis NN N
. . N

RESULTS VB N
The DT N
level NN o
of IN o
ACTH NNP o
and CC o
CORT NNP o
in IN o
plasma NN o
decreased VBN N
and CC N
lymphocyte JJ o
proliferative JJ o
reaction NN o
reduced VBN N
in IN N
patients NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
experimental JJ N
study NN N
, , N
monoaminic JJ o
transmitters NNS o
activated VBN N
in IN N
hypothalamus NN N
; : N
weight NN o
of IN o
pituitary JJ o
, , o
adrenal JJ o
and CC o
thymus NN o
decreased VBN N
; : N
number NN o
of IN o
CRH NNP o
positive JJ o
neurons NNS o
in IN o
hypothalamic JJ o
paraventricular JJ o
nucleus NN o
, , o
CRH NNP o
positive JJ o
neurofibrilin NN o
median JJ o
eminence NN o
and CC o
anterior JJ o
pituitary JJ o
ACTH NNP o
positive JJ o
secretory NN o
cells NNS o
decreased VBD N
; : N
adrenal JJ o
fasciculate NN o
zone NN o
and CC o
thymus NN o
cortex NN o
atrophies NNS o
; : o
NK NNP o
cell VBP o
cytotoxicity NN o
and CC o
the DT o
level NN o
of IN o
IL-2 NNP o
and CC o
gamma-IFN NN o
which WDT N
were VBD N
produced VBN N
by IN N
lymphocytes NNS N
reduced VBN N
in IN N
CORT-rats NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
significant JJ N
difference NN N
between IN N
Fufang NNP N
prednisone NN N
group NN N
( ( N
clinical JJ N
research NN N
) ) N
or CC N
EB NNP N
group NN N
( ( N
experimental JJ N
research NN N
) ) N
and CC N
CORT NNP N
control NN N
groups NNS N
, , N
P NNP N
< VBZ N
0.05 CD N
. . N

CONCLUSION NNP N
EB NNP N
could MD N
relieve VB N
neuroendocrino-immunological JJ o
effect NN o
inhibited VBN N
by IN N
exogenous JJ N
glucocorticoid NN N
. . N

-DOCSTART- -15877748- O O

Treatment NN N
of IN N
peri-implantitis NN N
by IN N
the DT N
Vector NNP i
system NN i
. . i

AIM NNP N
To TO N
compare VB N
the DT N
effectiveness NN o
of IN o
treatment NN o
of IN N
peri-implantitis NN N
with IN N
a DT N
novel JJ N
ultrasonic JJ N
device NN N
, , N
the DT N
Vector NNP i
system NN i
, , N
with IN N
that DT N
of IN N
subgingival JJ N
debridement NN N
with IN N
carbon NN N
fiber NN N
curettes NNS N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
, , N
comprising VBG N
11 CD p
patients NNS p
with IN p
at IN p
least JJS p
two CD p
screw JJ p
type NN p
implants NNS p
with IN p
bleeding VBG o
on IN o
probing VBG o
( ( o
BOP NNP o
) ) o
, , o
probing VBG o
pocket NN o
depth NN o
( ( o
PPD NNP o
) ) o
> VBD p
or CC p
=5 JJ p
mm NN p
, , p
and CC p
at IN p
least JJS p
1.5 CD p
mm JJ p
radiographic JJ p
bone NN o
loss NN o
and CC p
exposed VBN p
implant JJ p
threads NNS p
, , N
was VBD N
carried VBN N
out RP N
as IN N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

At IN N
baseline JJ N
one CD N
randomly NN N
chosen VBN N
implant JJ N
in IN N
each DT N
patient NN N
was VBD N
treated VBN N
by IN N
the DT N
Vector NNP i
system NN i
( ( N
test NN N
) ) N
while IN N
the DT N
other JJ N
implant NN N
( ( N
control NN N
) ) N
was VBD N
treated VBN N
by IN N
submucosal JJ N
debridement NN N
with IN N
a DT N
carbon NN i
fiber NN i
curette NN i
. . i

After IN N
3 CD N
months NNS N
, , N
the DT N
same JJ N
treatments NNS N
were VBD N
repeated VBN N
. . N

Plaque NNP o
, , o
BOP NNP o
, , o
and CC o
PPD NNP o
were VBD N
recorded VBN N
on IN N
all DT N
implant JJ N
surfaces NNS N
at IN N
baseline NN N
, , N
and CC N
after IN N
3 CD N
and CC N
6 CD N
months NNS N
. . N

Bone NN o
levels NNS o
were VBD N
recorded VBN N
on IN N
radiographs NN N
taken VBN N
prior RB N
to TO N
the DT N
start NN N
of IN N
the DT N
study NN N
, , N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Oral NNP o
hygiene NN o
around IN N
both DT N
test NN N
and CC N
control NN N
implants NNS N
was VBD N
improved VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
compared VBN N
with IN N
baseline NN N
. . N

At IN N
6 CD N
months NNS N
, , N
four CD N
of IN N
the DT N
Vector-treated NNP i
sites NNS i
, , N
and CC N
only RB N
one CD N
site NN N
treated VBN N
with IN N
curettes NNS N
, , N
had VBD N
stopped VBN N
to TO N
bleed VB o
. . o

In IN N
neither CC N
the DT N
test NN N
nor CC N
the DT N
control NN N
group NN N
, , N
were VBD N
there EX N
any DT N
differences NNS N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
regarding VBG N
PPD NNP o
and CC o
bone NN o
levels NNS o
. . o

CONCLUSION NNP N
Although IN N
there EX N
was VBD N
a DT N
greater JJR N
reduction NN N
in IN N
the DT N
number NN o
of IN o
sites NNS o
with IN o
BOP NNP o
following VBG N
treatment NN N
with IN N
the DT N
Vector NNP i
system NN i
than IN N
following VBG N
instrumentation NN N
with IN N
carbon NN N
fiber NN N
curettes NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
. . N

-DOCSTART- -21433319- O O

[ JJ N
Results NNP N
of IN N
three-year JJ N
clinical JJ N
study NN N
of IN N
prostamol NN i
uno JJ i
efficacy NN o
and CC N
safety NN o
in IN N
patients NNS p
with IN p
initial JJ p
symptoms NNS p
of IN p
prostatic JJ p
adenoma NN p
and CC p
risk NN p
of IN p
its PRP$ p
progression NN p
] NN p
. . N

Prostamol NNP i
Uno NNP i
( ( i
PU NNP i
) ) i
efficacy NN o
and CC N
safety NN o
were VBD N
studied VBN N
in IN N
a DT N
multicenter NN p
, , p
open-population NN p
, , N
randomized VBN N
and CC N
comparative JJ N
trial NN N
. . N

PU NNP i
was VBD N
given VBN N
in IN N
a DT N
single JJ N
daily JJ N
dose VB N
320 CD N
mg NN N
for IN N
36 CD N
months NNS N
to TO N
50 CD p
patients NNS p
with IN p
initial JJ p
symptoms NNS p
of IN p
prostatic JJ p
adenoma NN p
( ( p
PA NNP p
) ) p
in IN p
comparison NN p
with IN p
50 CD p
matched JJ p
controls NNS p
. . p

The DT N
trial NN N
evaluated VBD N
PU NNP i
action NN N
on IN N
the DT N
symptoms NNS o
progression NN o
and CC N
quality NN o
of IN o
life NN o
with IN N
application NN N
of IN N
questionnaires NNS o
IPSS NNP o
and CC o
QoL NNP o
( ( o
BS NNP o
) ) o
. . o

It PRP N
was VBD N
found VBN N
that IN N
PU NNP N
treatment NN N
relieved VBD N
PA NNP o
symptoms NNS o
by IN N
IPSS NNP N
, , N
while IN N
these DT N
symptoms NNS N
progressed VBD N
in IN N
the DT N
controls NNS N
. . N

QoL NNP o
improved VBD N
in IN N
the DT N
study NN N
group NN N
and CC N
deteriorated VBN N
in IN N
the DT N
control NN N
one CD N
. . N

Administration NN N
of IN N
PU NNP N
significantly RB N
increased VBD N
urinary JJ o
flow NN o
rate NN o
though IN N
in IN N
the DT N
controls NNS N
urinary JJ o
flow NN o
rate NN o
decreased VBN N
, , N
size NN o
of IN o
the DT o
prostate NN o
diminished VBD N
and CC N
increased VBD N
, , N
respectively RB N
. . N

Changes NNS N
in IN N
the DT N
PSA NNP o
were VBD N
not RB N
seen VBN N
and CC N
were VBD N
insignificant JJ N
, , N
respectively RB N
. . N

The DT N
results NNS N
of IN N
the DT N
study NN N
say VBP N
that IN N
prostamol NN N
Uno NNP N
in IN N
a DT N
dose JJ N
320 CD N
mg/day NN N
can MD N
prevent VB N
PA NNP N
progression NN N
without IN N
side JJ o
effects NNS o
. . o

-DOCSTART- -14711190- O O

Effects NNS N
of IN N
low JJ N
and CC N
high JJ N
doses NNS N
of IN N
atorvastatin NN i
on IN N
arterial JJ N
compliance NN N
. . N

At IN N
the DT N
beginning NN N
of IN N
atherosclerosis NN N
before IN N
evidence NN N
of IN N
morphological JJ o
lesions NNS o
or CC o
plaques NNS o
, , o
vascular JJ o
distensibility NN o
or CC o
arterial JJ o
compliance NN o
decreased VBN N
gradually RB N
. . N

This DT N
endothelial JJ N
dysfunction NN N
is VBZ N
regarded VBN N
as IN N
an DT N
early JJ N
feature NN N
of IN N
atherosclerosis NN N
. . N

In IN N
a DT p
randomized JJ p
, , p
double-blind JJ p
study NN p
design NN p
, , p
group NN p
1 CD p
( ( p
12 CD p
patients NNS p
; : p
7 CD p
males NNS p
, , p
5 CD p
females NNS p
) ) p
with IN p
serum JJ o
LDL-C JJ o
levels NNS o
higher JJR p
than IN p
170 CD p
mg/dL NN p
and CC p
without IN p
any DT p
other JJ p
risk NN p
factor NN p
for IN p
atherosclerosis NN p
received VBD p
three CD p
months NNS p
of IN p
20 CD p
mg/day JJ p
atorvastatin FW i
treatment NN i
while IN p
group NN p
11 CD p
( ( p
8 CD p
males NNS p
, , p
4 CD p
females NNS p
) ) p
with IN p
the DT p
same JJ p
characteristics NNS p
received VBD p
80 CD p
mg/day NN p
. . p

Baseline NNP N
and CC N
posttreatment JJ N
serum NN o
lipid JJ o
fractions NNS o
and CC o
arterial JJ o
compliance NN o
were VBD N
measured VBN N
. . N

Arterial JJ o
compliance NN o
was VBD N
measured VBN N
noninvasively RB N
in IN N
the DT N
left JJ N
common JJ N
carotid NN N
artery NN N
with IN N
color NN N
Doppler NNP N
ultrasound NN N
. . N

Atorvastatin NNP i
reduced VBD o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
LDL-C NNP o
, , o
and CC o
triglyceride NN o
levels NNS o
by IN N
32 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
40.8 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
19 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
and CC N
increased VBD o
HDL-C NNP o
by IN N
6.9 CD N
% NN N
, , N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
in IN N
the DT N
first JJ N
group NN N
. . N

In IN N
the DT N
second JJ N
group NN N
these DT N
reductions NNS N
were VBD N
38.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
46.2 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
26.78 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
increase NN o
in IN o
HDL NNP o
was VBD N
7.8 CD N
% NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

It PRP N
was VBD N
observed VBN N
that IN N
the DT N
decrease NN o
in IN o
serum NN o
TC NNP o
, , o
LDL-C NNP o
and CC o
triglyceride NN o
levels NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
second JJ N
group NN N
than IN N
the DT N
first JJ N
group NN N
. . N

With IN N
atorvastatin NN i
, , N
the DT N
distensibility NN o
coefficient NN o
( ( o
DC NNP o
) ) o
and CC o
compliance NN o
coefficient NN o
( ( o
CC NNP o
) ) o
increased VBD o
from IN N
18.7 CD N
+/- JJ N
3.4 CD N
to TO N
21.3 CD N
+/- JJ N
2.9 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.69 CD N
+/- JJ N
0.05 CD N
to TO N
0.77 CD N
+/- JJ N
0.03 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
the DT N
first JJ N
group NN N
while IN N
they PRP N
changed VBD N
from IN N
18.3 CD N
+/- JJ N
3.6 CD N
to TO N
21.9 CD N
+/- JJ N
3.0 CD N
10 CD N
( ( N
-3 NN N
) ) N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
from IN N
0.70 CD N
+/- JJ N
0.04 CD N
to TO N
0.81 CD N
+/- JJ N
0.01 CD N
mm2 NN N
x NN N
kPa NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
respectively RB N
, , N
in IN N
the DT N
second JJ N
group NN N
. . N

DC NNP o
and CC o
CC NNP o
increased VBD o
in IN N
both DT N
groups NNS N
, , N
but CC N
the DT N
differences NNS N
between IN N
the DT N
groups NNS N
were VBD N
not RB N
significant JJ N
. . N

High JJ N
doses NNS N
of IN N
atorvastatin NN i
reduce VB o
blood NN o
lipid NN o
levels NNS o
more RBR N
than IN N
conventional JJ N
doses NNS N
, , N
however RB N
, , N
the DT N
change NN N
in IN N
compliance NN N
is VBZ N
not RB N
dose-dependent JJ N
. . N

As IN N
endothelial JJ N
dysfunction NN N
is VBZ N
regarded VBN N
as IN N
an DT N
early JJ N
feature NN N
of IN N
atherosclerosis NN N
, , N
there EX N
would MD N
be VB N
no RB N
need NN N
to TO N
administer VB N
aggressive JJ N
doses NNS N
in IN N
a DT N
patient NN N
without IN N
any DT N
risk NN N
factors NNS N
other JJ N
than IN N
hyperlipidemia NN N
. . N

-DOCSTART- -16890144- O O

Dietary NNP i
sodium NN i
intake NN i
modulates VBZ N
myocardial JJ o
relaxation NN o
responsiveness NN o
to TO N
angiotensin VB N
II NNP N
. . N

Dietary NNP i
sodium NN i
alters NNS N
renovascular JJ N
responsiveness NN N
to TO N
angiotensin VB N
II NNP N
( ( N
Ang NNP N
II NNP N
) ) N
in IN N
normal JJ p
subjects NNS p
. . p

Evidence NN N
supports VBZ N
a DT N
connection NN N
among IN N
dietary JJ i
sodium NN i
, , N
the DT N
rennin-angiotensin NN N
system NN N
, , N
and CC N
myocardial JJ N
function NN N
. . N

The DT N
authors NNS N
hypothesized VBD N
that IN N
a DT N
similar JJ N
relationship NN N
would MD N
exist VB N
in IN N
the DT N
heart NN N
, , N
and CC N
that IN N
the DT N
pattern NN N
of IN N
responses NNS N
would MD N
be VB N
qualitatively RB N
similar JJ N
to TO N
the DT N
renal JJ N
vasculature NN N
. . N

Thirteen NNP p
healthy JJ p
volunteers NNS p
( ( p
aged VBN p
38.6 CD p
+/- JJ p
4 CD p
years NNS p
) ) p
entered VBD N
a DT N
2 CD N
week NN N
crossover NN N
design NN N
study NN N
( ( N
week NN N
1 CD N
, , N
high JJ i
sodium NN i
diet JJ i
[ NNP i
HS NNP i
] NNP i
> VBD N
200 CD N
mmol NN N
Na/day NNP N
; : N
week NN N
2 CD N
, , N
low JJ i
sodium NN i
diet JJ i
[ NNP i
LS NNP i
] NNP i
, , N
< VBD N
10 CD N
mmol NNS N
Na/day NNP N
) ) N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
dietary JJ N
sodium NN N
and CC N
Ang NNP N
II NNP N
on IN N
myocardial JJ N
relaxation NN N
and CC N
renal JJ o
blood NN o
flow NN o
( ( o
RBF NNP o
) ) o
. . o

At IN N
the DT N
end NN N
of IN N
each DT N
study NN N
week NN N
, , N
the DT N
authors NNS N
assessed VBD N
diastolic JJ o
function NN o
( ( o
myocardial JJ o
relaxation NN o
velocities NNS o
[ VBP o
E NNP o
' POS o
] NN o
using VBG N
tissue NN N
Doppler NNP N
imaging NN N
) ) N
and CC N
RBF NNP o
( ( o
para-aminohippurate JJ o
clearance NN o
) ) o
at IN N
baseline NN N
and CC N
after IN N
infusion NN N
of IN N
Ang NNP N
II NNP N
( ( N
3 CD N
ng/kg/min RB N
x JJ N
45 CD N
min NN N
) ) N
. . N

On IN N
HS NNP N
diet NN N
, , N
E NNP N
' POS N
and CC N
RBF NNP o
were VBD N
higher JJR N
than IN N
on IN N
LS NNP N
diet NN N
( ( N
E NNP N
' POS N
14.0 CD N
+/- JJ N
1.2 CD N
vs JJ N
12.6 CD N
+/- JJ N
1.0 CD N
cm/s NN N
, , N
P NNP N
= NNP N
0.02 CD N
; : N
RBF NNP N
596 CD N
+/- JJ N
24 CD N
vs JJ N
563 CD N
+/- JJ N
26 CD N
mL/min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Dietary JJ i
sodium NN i
significantly RB N
modulated VBD N
E NNP o
' POS o
and CC o
RBF NNP o
responsiveness NN o
to TO N
Ang NNP N
II NNP N
infusion NN N
in IN N
like JJ N
manner NN N
. . N

HS NNP N
was VBD N
associated VBN N
with IN N
increased JJ N
responsiveness NN N
compared VBN N
with IN N
a DT N
blunted JJ N
LS NNP o
response NN o
( ( N
HS NNP N
DeltaE NNP N
' POS N
-1.4 JJ N
+/- JJ N
0.4 CD N
cm/s NN N
vs NN N
LS NNP N
DeltaE NNP N
' POS N
-0.1 JJ N
+/- JJ N
0.3 CD N
cm/s NN N
, , N
P NNP N
= NNP N
0.02 CD N
; : N
HS NNP N
DeltaRBF NNP N
-135.2 NNP N
+/- JJ N
13.2 CD N
vs NN N
LS NNP N
DeltaRBF NNP N
-62.5 NNP N
+/- JJ N
10.1 CD N
mL/min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
authors NNS N
describe VBP N
for IN N
the DT N
first JJ N
time NN N
that WDT N
dietary JJ i
sodium NN i
modulates VBZ N
myocardial JJ o
relaxation NN o
and CC o
responsiveness NN o
to TO N
Ang NNP N
II NNP N
. . N

It PRP N
is VBZ N
important JJ N
to TO N
consider VB N
dietary JJ i
sodium NN i
intake NN N
when WRB N
assessing VBG N
diastolic JJ o
function NN o
. . o

Ang NNP N
II NNP N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
interaction NN N
between IN N
dietary JJ i
sodium NN i
and CC N
myocardial JJ o
relaxation NN o
. . o

Future NNP N
research NN N
will MD N
investigate VB N
whether IN N
abnormalities NNS N
in IN N
these DT N
mechanisms NNS N
play VBP N
a DT N
role NN N
in IN N
disorders NNS N
of IN N
diastolic JJ N
function NN N
. . N

-DOCSTART- -11022066- O O

Outcomes NNS o
of IN o
early JJ o
endovascular JJ o
versus NN o
surgical JJ o
treatment NN o
of IN N
ruptured JJ p
cerebral JJ o
aneurysms NNS o
. . o

A DT N
prospective JJ N
randomized NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
This DT N
prospective JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
outcomes NNS o
of IN o
surgical JJ o
clipping NN o
and CC o
endovascular JJ o
treatment NN o
in IN N
acute NN p
( ( p
< JJ p
72 CD p
hours NNS p
) ) p
aneurysmal VBP p
subarachnoid JJ p
hemorrhage NN p
( ( p
SAH NNP p
) ) p
. . p

METHODS NNP N
One CD p
hundred VBD p
nine CD p
consecutive JJ p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
either DT N
surgical JJ i
( ( N
n=57 JJ N
) ) N
or CC i
endovascular JJ i
( ( N
n=52 JJ N
) ) N
treatment NN N
. . N

Clinical JJ o
and CC o
neuropsychological JJ o
outcome NN o
was VBD N
assessed VBN N
at IN N
3 CD N
and CC N
12 CD N
months NNS N
after IN N
treatment NN N
; : N
MRI NNP N
of IN N
the DT N
brain NN N
was VBD N
performed VBN N
at IN N
12 CD N
months NNS N
. . N

Follow-up NNP i
angiography NN i
was VBD N
scheduled VBN N
after IN N
clipping VBG N
and CC N
3 CD N
and CC N
12 CD N
months NNS N
after IN N
endovascular JJ N
treatment NN N
. . N

RESULTS NNP N
One CD p
year NN p
postoperatively RB p
, , p
43/41 CD p
( ( p
surgical/endovascular JJ p
) ) p
patients NNS p
had VBD N
good JJ N
or CC N
moderate JJ N
recovery NN o
, , N
5/4 CD N
had VBD N
severe JJ o
disability NN o
or CC o
were VBD o
in IN o
a DT o
vegetative JJ o
state NN o
, , N
and CC N
9/7 CD N
had VBD N
died VBN o
( ( N
NS NNP N
) ) N
according VBG N
to TO N
intention NN N
to TO N
treat VB N
. . N

Patients NNS N
with IN N
good JJ N
clinical JJ N
recovery NN o
did VBD N
not RB N
differ VB N
in IN N
their PRP$ N
neuropsychological JJ o
test NN o
scores NNS o
. . o

Symptomatic JJ o
vasospasm NN o
( ( N
OR NNP N
2.47 CD N
; : N
95 CD N
% NN N
CI NNP N
1.45 CD N
to TO N
4.19 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
poorer JJR N
Hunt NNP o
and CC o
Hess NNP o
grade NN o
( ( N
OR NNP N
2.50 CD N
; : N
95 CD N
% NN N
CI NNP N
1.31 CD N
to TO N
4.75 CD N
; : N
P=0.005 NNP N
) ) N
, , N
need VBP o
for IN o
permanent JJ o
shunt NN o
( ( N
OR NNP N
8.90 CD N
; : N
95 CD N
% NN N
CI NNP N
1.80 CD N
to TO N
44.15 CD N
; : N
P=0.008 NNP N
) ) N
, , N
and CC N
larger JJR o
size NN o
of IN o
the DT o
aneurysm NN o
( ( N
OR CC N
1 CD N
. . N

22 CD N
; : N
95 CD N
% NN N
CI NNP N
1.02 CD N
to TO N
1.45 CD N
; : N
P=0.032 NNP N
) ) N
independently RB N
predicted VBN N
worsened VBD N
clinical JJ o
outcome NN o
regardless NN N
of IN N
the DT N
treatment NN N
modality NN N
. . N

In IN N
MRI NNP i
, , N
superficial JJ o
brain NN o
retraction NN o
deficits NNS o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
ischemic JJ o
lesions NNS o
in IN N
the DT N
territory NN N
of IN N
the DT N
ruptured JJ o
aneurysm NN o
( ( N
P=0.025 NNP N
) ) N
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
surgical JJ N
group NN N
. . N

Kaplan-Meier JJR N
analysis NN N
( ( N
mean+/-SD JJ N
follow-up JJ N
39+/-18 JJ N
months NNS N
) ) N
revealed VBD N
equal JJ N
survival NN o
in IN N
both DT N
treatment NN N
groups NNS N
. . N

No DT N
late JJ o
rebleedings NNS o
have VBP N
occurred VBN N
. . N

CONCLUSIONS NNP N
One-year JJ N
clinical JJ o
and CC o
neuropsychological JJ o
outcomes NNS o
seem VBP N
comparable JJ N
after IN N
early JJ N
surgical JJ N
and CC N
endovascular JJ N
treatment NN N
of IN N
ruptured JJ N
intracranial JJ N
aneurysms NN N
. . N

The DT N
long-term JJ N
efficacy NN N
of IN N
endovascular JJ N
treatment NN N
in IN N
preventing VBG N
rebleeding NN o
remains VBZ N
open JJ N
. . N

-DOCSTART- -17941770- O O

Tubeless NNP i
percutaneous JJ i
nephrolithotomy NN i
: : i
safe JJ N
even RB N
in IN N
supracostal JJ N
access NN N
. . N

PURPOSE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
outcome NN o
and CC o
safety NN o
of IN N
tubeless NN i
percutaneous JJ i
nephrolithotomy NN i
( ( i
PCNL NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
renal JJ p
calculi NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP p
November NNP p
2005 CD p
and CC p
March NNP p
2006 CD p
, , p
48 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
either DT p
an DT p
18F CD i
Re-entry JJ i
nephrostomy NN i
tube NN i
( ( p
group NN p
1 CD p
) ) p
or CC i
a DT i
6F CD i
Double-J JJ i
stent NN i
( ( p
group NN p
2 CD p
) ) p
. . p

The DT N
two CD N
groups NNS N
were VBD N
well RB N
matched VBN N
for IN N
age NN N
, , N
sex NN N
, , N
stone NN N
size NN N
, , N
stone NN N
laterality NN N
, , N
and CC N
number NN N
of IN N
previous JJ N
renal JJ N
procedures NNS N
. . N

All DT N
PCNL NNP N
procedures NNS N
were VBD N
performed VBN N
by IN N
the DT N
same JJ N
surgeon NN N
. . N

Postoperative JJ o
visual JJ o
analog NN o
pain NN o
scale NN o
( ( o
VAS NNP o
) ) o
scores VBZ o
at IN N
8 CD N
and CC N
24 CD N
hours NNS N
and CC N
14 CD N
days NNS N
after IN N
surgery NN N
, , N
in-hospital JJ o
analgesic JJ o
use NN o
, , o
length NN o
of IN o
hospital NN o
stay NN o
, , o
success NN o
rate NN o
, , o
blood NN o
transfusion NN o
rate NN o
, , o
and CC o
postoperative JJ o
complications NNS o
were VBD N
compared VBN N
for IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS VB N
The DT N
mean JJ o
hospital NN o
stays NNS o
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
were VBD N
3.1 CD N
and CC N
1.6 CD N
days NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
mean JJ o
VAS NNP o
scores VBZ o
8 CD N
and CC N
24 CD N
hours NNS N
after IN N
surgery NN N
were VBD N
significantly RB N
lower JJR N
in IN N
group NN N
2 CD N
than IN N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
postoperative JJ o
analgesic JJ o
requirement NN o
( ( i
diclofenac JJ i
sodium NN i
) ) i
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
1 CD N
( ( N
263 CD N
mg NN N
) ) N
than IN N
in IN N
group NN N
2 CD N
( ( N
120 CD N
mg NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
blood NN o
transfusion NN o
in IN N
the DT N
two CD N
groups NNS N
was VBD N
similar JJ N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
VAS NNP o
scores NNS o
on IN N
postoperative JJ N
day NN N
14 CD N
. . N

The DT N
number NN o
of IN o
supracostal JJ o
accesses NNS o
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
2 CD N
than IN N
in IN N
group NN N
1 CD N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
stone-free JJ o
rates NNS o
and CC o
the DT o
numbers NNS o
of IN o
patients NNS o
with IN N
insignificant JJ o
residual JJ o
fragments NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
no DT o
urine JJ o
leakage NN o
or CC o
formation NN o
of IN o
urinoma NN o
in IN N
patients NNS N
with IN N
Double-J NNP N
stents NNS N
. . N

CONCLUSION NNP N
Tubeless NNP i
PCNL NNP i
is VBZ N
safe JJ N
and CC N
effective JJ N
even RB N
after IN N
supracostal JJ N
access NN N
and CC N
is VBZ N
associated VBN N
with IN N
less RBR N
postoperative JJ o
pain NN o
and CC N
a DT o
shorter JJR o
hospital NN o
stay NN o
. . o

-DOCSTART- -12480867- O O

Galantamine NN i
may MD N
be VB N
effective JJ N
in IN N
treating VBG N
autistic JJ p
disorder NN p
. . p

-DOCSTART- -23164311- O O

Randomized VBN N
trial NN N
of IN N
early JJ i
developmental JJ i
intervention NN i
on IN N
outcomes NNS N
in IN N
children NNS p
after IN p
birth NN o
asphyxia NN o
in IN N
developing VBG N
countries NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
if IN N
early JJ i
developmental NN i
intervention NN i
( ( N
EDI NNP N
) ) N
improves VBZ N
developmental JJ N
abilities NNS N
in IN N
resuscitated JJ p
children NNS p
. . p

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
parallel JJ p
group NN p
, , N
randomized VBD N
controlled VBN N
trial NN N
of IN N
infants NNS p
unresponsive JJ p
to TO p
stimulation NN p
who WP p
received VBD p
bag NN i
and CC i
mask NN i
ventilation NN i
as IN p
part NN p
of IN p
their PRP$ p
resuscitation NN p
at IN p
birth NN p
and CC p
infants NNS p
who WP p
did VBD p
not RB p
require VB p
any DT p
resuscitation NN p
born VBN p
in IN p
rural JJ p
communities NNS p
in IN p
India NNP p
, , p
Pakistan NNP p
, , p
and CC p
Zambia NNP p
. . p

Intervention NN p
infants NNS p
received VBD N
a DT N
parent-implemented JJ i
EDI NNP i
delivered VBD N
with IN N
home NN N
visits NNS N
by IN N
parent NN N
trainers NNS N
every DT N
other JJ N
week NN N
for IN N
3 CD N
years NNS N
starting VBG N
the DT N
first JJ N
month NN N
after IN N
birth NN N
. . N

Parents NNS N
in IN N
both DT N
intervention NN N
and CC N
control NN N
groups NNS N
received VBD N
health NN i
and CC i
safety NN i
counseling NN i
during IN N
home NN N
visits NNS N
on IN N
the DT N
same JJ N
schedule NN N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Mental NNP o
Development NNP o
Index NNP o
( ( o
MDI NNP o
) ) o
of IN N
the DT N
Bayley NNP N
Scales NNP N
of IN N
Infant NNP N
Development NNP N
, , N
2nd CD N
edition NN N
, , N
assessed VBN N
at IN N
36 CD N
months NNS N
by IN N
evaluators NNS N
unaware JJ N
of IN N
treatment NN N
group NN N
and CC N
resuscitation NN N
history NN N
. . N

RESULTS NNP N
MDI NNP o
was VBD N
higher RBR N
in IN N
the DT N
EDI NNP N
( ( N
102.6 CD N
? . N
9.8 CD N
) ) N
compared VBN N
with IN N
the DT N
control NN N
resuscitated VBD N
children NNS N
( ( N
98.0 CD N
? . N
14.6 CD N
, , N
1-sided JJ N
P NNP N
= NNP N
.0202 NNP N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
nonresuscitated JJ N
children NNS N
( ( N
100.1 CD N
? . N
10.7 CD N
vs NN N
97.7 CD N
? . N
10.4 CD N
, , N
P NNP N
= NNP N
.1392 NNP N
) ) N
. . N

The DT o
Psychomotor NNP o
Development NNP o
Index NNP o
was VBD o
higher RBR o
in IN N
the DT N
EDI NNP N
group NN N
for IN N
both DT N
the DT N
resuscitated VBN N
( ( N
P NNP N
= NNP N
.0430 NNP N
) ) N
and CC N
nonresuscitated JJ N
children NNS N
( ( N
P NNP N
= NNP N
.0164 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
trial NN N
of IN N
home-based JJ N
, , N
parent NN N
provided VBD N
EDI NNP N
in IN p
children NNS p
resuscitated VBN p
at IN p
birth NN p
provides VBZ p
evidence NN p
of IN N
treatment NN N
benefits NNS o
on IN o
cognitive NN o
and CC o
psychomotor NN o
outcomes NNS o
. . o

MDI NNP o
and CC o
Psychomotor NNP o
Development NNP o
Index NNP o
scores NNS o
of IN o
both DT o
nonresuscitated JJ N
and CC p
resuscitated JJ p
infants NNS p
were VBD N
within IN N
normal JJ N
range NN N
, , N
independent JJ N
of IN N
early JJ N
intervention NN N
. . N

-DOCSTART- -7005474- O O

Comparison NNP N
of IN N
antihypertensive JJ o
effects NNS o
of IN N
captopril NN i
and CC i
propranolol NN i
in IN N
essential JJ p
hypertension NN p
. . p

The DT N
antihypertensive JJ N
effects NNS N
of IN N
the DT N
oral JJ N
converting NN N
enzyme NN N
inhibitor NN N
captopril NN i
and CC i
of IN i
propranolol NNS i
were VBD N
evaluated VBN N
in IN N
a DT N
single-blind JJ N
trial NN N
of IN N
12 CD N
weeks NNS N
in IN N
19 CD p
ambulatory JJ p
men NNS p
with IN p
moderated VBN p
essential JJ p
hypertension NN p
( ( o
supine JJ o
diastolic NN o
blood NN o
pressure NN o
[ NNP o
DPB NNP o
] NNP o
, , p
100 CD p
to TO p
120 CD p
mm NNS p
Hg NNP p
after IN p
receiving VBG p
placebo NN i
for IN p
two CD p
weeks NNS p
) ) p
whose WP$ p
sodium JJ p
intake NN p
was VBD p
unrestricted VBN p
. . p

The DT p
captopril NN i
group NN p
included VBD p
12 CD p
patients NNS p
and CC p
the DT p
propranolol NN i
group NN p
seven CD p
. . p

After IN N
the DT N
initial JJ N
dose-finding JJ N
period NN N
of IN N
four CD N
weeks NNS N
, , N
supine JJ o
DBP NNP o
was VBD N
significantly RB o
reduced VBN o
in IN N
eight CD N
patients NNS N
receiving VBG N
captopril NN i
and CC N
in IN N
four CD N
of IN N
the DT N
patients NNS N
receiving VBG N
propranolol NN i
. . i

In IN N
these DT N
patients NNS N
DBP VBP o
decreased VBN N
throughout IN N
the DT N
following JJ N
eight CD N
weeks NNS N
. . N

In IN N
the DT N
remaining VBG N
patients NNS N
from IN N
each DT N
group NN N
, , N
DBP NNP o
was VBD N
not RB N
reduced VBN N
by IN N
either DT N
drug NN N
given VBN N
alone RB N
at IN N
maximum JJ N
allowable JJ N
dosages NNS N
during IN N
dose-finding JJ N
periods NNS N
, , N
nor CC N
by IN N
combined JJ N
administration NN N
in IN N
following VBG N
weeks NNS N
. . N

No DT o
adverse JJ o
side NN o
effects NNS o
attributable JJ N
to TO N
captopril VB i
were VBD N
noted VBN N
, , N
except IN N
in IN N
one CD N
patient NN N
in IN N
whom WP N
proteinuria NN o
developed VBD N
after IN N
seven CD N
weeks NNS N
. . N

Captopril NNP i
has VBZ N
potential JJ N
value NN N
in IN N
the DT N
treatment NN N
of IN N
moderate JJ p
essential JJ p
hypertension NN p
. . p

-DOCSTART- -1415973- O O

Isoflurane NNP N
and CC N
propofol NN N
for IN N
long-term JJ o
sedation NN o
in IN N
the DT N
intensive JJ N
care NN N
unit NN N
. . N

A DT N
crossover NN N
study NN N
. . N

Propofol NNP i
and CC i
isoflurane NN i
have VBP N
been VBN N
reported VBN N
recently RB N
to TO N
offer VB N
better JJR N
sedation NN o
than IN N
alternative JJ N
agents NNS N
in IN N
patients NNS p
who WP p
require VBP p
long-term JJ p
ventilation NN p
in IN p
the DT p
Intensive NNP p
Care NNP p
Unit NNP p
. . p

This DT N
is VBZ N
the DT N
first JJ N
report NN N
of IN N
a DT N
direct JJ N
comparison NN N
between IN N
propofol NN i
and CC N
isoflurane NN i
. . i

Twenty-four CD p
patients NNS p
predicted VBN p
to TO p
require VB p
artificial JJ p
ventilation NN p
for IN p
at IN p
least JJS p
48 CD p
h NNS p
were VBD N
entered VBN N
into IN N
a DT N
randomised VBN i
crossover NN i
study NN i
to TO i
monitor VB i
sedation NN o
quality NN o
and CC o
time NN o
to TO o
recovery NN o
from IN o
sedation NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
agents NNS N
in IN N
either DT N
end-point NN N
, , N
with IN N
over IN N
95 CD N
% NN N
optimal JJ o
sedation NN o
achieved VBN N
by IN N
the DT N
use NN N
of IN N
each DT N
drug NN N
. . N

Few JJ N
adverse JJ o
events NNS o
were VBD N
noted VBN N
. . N

Technological JJ N
advances NNS N
in IN N
the DT N
administration NN N
of IN N
volatile JJ N
agents NNS N
as IN N
long-term JJ N
sedatives NNS N
in IN N
the DT N
Intensive NNP N
Care NNP N
Unit NNP N
may MD N
facilitate VB N
their PRP$ N
more JJR N
widespread JJ N
use NN N
. . N

-DOCSTART- -8131429- O O

Videofluoroscopic NNP i
evidence NN i
of IN i
aspiration NN i
predicts NNS N
pneumonia NN o
and CC o
death NN o
but CC N
not RB N
dehydration NN N
following VBG N
stroke NN N
. . N

In IN N
order NN N
to TO N
assess VB N
the DT N
risk NN N
of IN N
pneumonia NN N
, , N
dehydration NN N
, , N
and CC N
death NN N
associated VBN N
with IN N
videofluoroscopic JJ i
evidence NN N
of IN N
aspiration NN p
following VBG p
stroke NN p
, , p
the DT p
clinical JJ p
records NNS p
of IN p
26 CD p
patients NNS p
with IN p
aspiration NN p
and CC p
33 CD p
randomly RB p
selected VBN p
, , p
case-matched JJ p
, , p
dysphagic JJ p
controls NNS p
without IN p
videofluoroscopic JJ p
evidence NN p
of IN p
aspiration NN o
were VBD p
reviewed VBN p
. . p

The DT i
videofluoroscopic NN i
modified VBD i
barium NN i
swallow NN i
technique NN i
included VBD i
5 CD i
ml-thin JJ i
and CC i
thick JJ i
liquid NN i
barium NN i
, , i
5 CD i
ml NN i
barium NN i
pudding NN i
, , i
and CC i
1/4 CD i
cookie NN i
coated VBN i
with IN i
barium NN i
, , i
plus CC i
additional JJ i
20 CD i
and CC i
30 CD i
ml NN i
of IN i
thin JJ i
liquid JJ i
barium NN i
. . i

Patients NNS p
were VBD p
assessed VBN p
a DT p
mean NN p
of IN p
2 CD p
+/- JJ p
1 CD p
SD NNP p
months NNS p
poststroke NN p
and CC p
were VBD p
followed VBN p
for IN p
a DT p
mean NN p
of IN p
16 CD p
+/- JJ p
8 CD p
SD NNP p
months NNS p
poststroke RB p
. . p

The DT N
odds NNS o
ratio NN o
for IN N
developing VBG o
pneumonia NN o
was VBD N
7.6 CD N
times NNS N
greater JJR N
for IN N
those DT N
who WP N
aspirated VBD N
any DT N
amount NN N
of IN N
barium NN N
irrespective NN N
of IN N
its PRP$ N
consistency NN N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
. . N

The DT N
odds NNS N
ratio NN N
for IN N
developing VBG N
pneumonia NN o
was VBD N
5.6 CD N
times NNS N
greater JJR N
for IN N
those DT N
who WP N
aspirated VBD N
thickened JJ N
liquids NNS N
or CC N
more JJR N
solid JJ N
consistencies NNS N
compared VBN N
with IN N
those DT N
who WP N
did VBD N
not RB N
aspirate VB N
, , N
or CC N
who WP N
aspirated VBD N
thin JJ N
liquids NNS N
only RB N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Dehydration NN o
was VBD N
unrelated JJ N
to TO N
the DT N
presence NN N
or CC N
absence NN N
of IN N
aspiration NN N
. . N

The DT N
odds NNS N
ratio NN N
for IN N
death NN o
was VBD N
9.2 CD N
times NNS N
greater JJR N
for IN N
those DT N
aspirating VBG N
thickened JJ N
liquids NNS N
or CC N
more JJR N
solid JJ N
consistencies NNS N
compared VBN N
with IN N
those DT N
who WP N
did VBD N
not RB N
aspirate VB N
or CC N
who WP N
aspirated VBD N
thin JJ N
liquids NNS N
only RB N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

Aspiration NNP N
documented VBN N
by IN N
modified JJ i
videofluoroscopic NN i
barium NN i
swallow NN i
technique NN i
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
risk NN o
of IN o
pneumonia NN o
and CC N
death NN N
but CC N
not RB N
dehydration NN N
following VBG N
stroke NN N
. . N

-DOCSTART- -16217314- O O

Comparison NNP N
of IN N
needlescopic JJ i
appendectomy JJ i
versus JJ i
conventional JJ i
laparoscopic NN i
appendectomy NN i
. . i

A DT N
randomized JJ p
controlled JJ p
trial NN p
. . p

-DOCSTART- -3287999- O O

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
after IN N
thoracotomy NN N
. . N

Pain NNP o
relief NN o
and CC N
peak JJ o
expiratory NN o
flow NN o
rate NN o
-- : o
a DT o
trial NN N
of IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
. . i

Forty NNP p
patients NNS p
scheduled VBN p
to TO p
undergo VB p
thoracotomy NN p
were VBD N
randomly RB i
allocated VBN i
to TO i
receive VB i
either RB i
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
with IN i
intramuscular JJ i
papaveretum NN i
( ( i
20 CD i
patients NNS i
) ) i
or CC i
intramuscular JJ i
papaveretum NN i
alone RB i
( ( i
20 CD i
patients NNS i
) ) i
for IN i
postoperative JJ i
pain NN i
relief NN i
. . i

Total JJ o
intramuscular JJ o
analgesic NN o
requirements NNS o
in IN o
the DT o
first JJ o
24 CD o
hours NNS o
, , o
time NN o
to TO o
satisfactory VB o
transfer NN o
to TO o
oral JJ o
analgesia NN o
, , o
antiemetic JJ o
requirements NNS o
and CC o
length NN o
of IN o
stay NN o
in IN o
hospital NN o
postoperatively RB o
were VBD N
noted VBN N
. . N

Peak NNP o
expiratory JJ o
flow NN o
rate NN o
was VBD o
compared VBN o
pre- JJ o
and CC o
postoperatively RB o
in IN N
the DT N
two CD N
groups NNS N
. . N

Use NNP N
of IN N
nerve NN N
stimulation NN N
did VBD N
not RB N
significantly RB N
alter VB N
the DT N
requirements NNS N
for IN N
analgesia JJ N
although IN N
there EX N
was VBD N
a DT N
reduction NN N
in IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
in IN N
the DT N
nerve NN N
stimulation NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
with IN N
respect NN N
to TO N
changes NNS N
in IN N
peak NN o
expiratory NN o
flow NN o
rate NN o
. . o

-DOCSTART- -6189335- O O

Effect NN N
of IN N
betamethasone NN i
valerate NN i
on IN N
the DT N
normal JJ p
human JJ o
facial JJ o
skin NN o
flora NN o
. . o

Eighteen JJ p
volunteers NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
and CC N
allocated VBD N
either DT N
an DT N
active JJ i
corticosteroid NN i
preparation NN i
( ( i
Betamethasone NNP i
valerate NN i
) ) i
or CC N
the DT N
basal NN i
formulation NN i
only RB i
( ( i
placebo NN i
) ) i
. . i

The DT N
cream NN N
was VBD N
applied VBN N
to TO N
the DT N
face NN N
twice RB N
daily RB N
for IN N
one CD N
month NN N
. . N

The DT N
treated JJ N
area NN N
was VBD N
sampled VBN N
by IN N
the DT N
scrub-wash JJ N
method NN N
immediately RB N
before IN N
treatment NN N
began VBD N
and CC N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
, , N
and CC N
microorganisms NNS N
were VBD N
enumerated VBN N
and CC N
identified VBN N
. . N

Application NN N
of IN N
either DT N
cream NN N
produced VBD N
a DT N
very RB o
slight JJ o
increase NN o
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.5 CD N
log NN N
cycle NN N
) ) N
in IN N
the DT N
skin NN o
flora NN o
during IN N
the DT N
first JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
in IN N
the DT N
changes NNS N
occurring VBG N
between IN N
volunteers NNS N
treated VBN N
with IN N
placebo NN N
and CC N
those DT N
on IN N
the DT N
steroid JJ N
formulation NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
relation NN N
to TO N
theories NNS N
of IN N
pathogenesis NN N
of IN N
perioral JJ o
dermatitis NN o
and CC o
steroid JJ o
acne NN o
. . o

-DOCSTART- -9393424- O O

The DT N
influence NN N
of IN N
type NN i
of IN i
incision NN i
on IN N
the DT N
success NN N
rate NN N
of IN N
implant JJ p
integration NN p
at IN p
stage NN p
II NNP p
uncovering NN p
surgery NN i
. . i

In IN N
1991 CD N
, , N
the DT N
Dental NNP N
Implant NNP N
Clinical NNP N
Research NNP N
Group NNP N
comprising VBG N
30 CD p
Department NNP p
of IN p
Veterans NNP p
Affairs NNP p
medical JJ p
centers NNS p
and CC p
two CD p
dental JJ p
schools NNS p
initiated VBD p
a DT p
long-term JJ p
clinical JJ p
study NN p
to TO p
investigate VB p
the DT p
clinical JJ p
performance NN p
of IN p
implants NNS i
within IN p
the DT p
Spectra-System NNP p
( ( p
Core-Vent JJ p
Corporation NNP p
, , p
Las NNP p
Vegas NNP p
, , p
NV NNP p
) ) p
. . p

This DT N
article NN N
focuses VBZ N
on IN N
a DT N
portion NN N
of IN N
the DT N
study NN N
database NN N
related VBN N
to TO N
incision NN N
type NN N
, , N
implant JJ N
success NN N
rates NNS N
, , N
and CC N
response NN N
of IN N
crestal NN N
bone NN N
up RB N
to TO N
the DT N
time NN N
of IN N
surgical JJ i
uncovering NN i
. . i

The DT N
crestal JJ i
incision NN i
was VBD p
used VBN p
for IN p
1,705 CD p
implants NNS p
( ( p
381 CD p
patients NNS p
) ) p
and CC p
the DT p
remote JJ i
incision NN i
for IN p
593 CD p
implants NNS p
( ( p
141 CD p
patients NNS p
) ) p
. . p

No DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
= NNP N
.092 NNP N
chi-square JJ N
statistic NN N
) ) N
was VBD N
found VBN N
in IN N
implant JJ o
integration NN o
or CC N
the DT N
response NN o
of IN o
crestal JJ o
bone NN o
. . o

-DOCSTART- -2285166- O O

[ JJ o
Photoplethysmographic NNP o
evaluation NN o
of IN N
the DT N
effect NN N
of IN N
a DT N
vascular JJ i
tonic JJ i
drug NN i
] NN i
. . N

-DOCSTART- -15224298- O O

Retroinfusion-supported JJ i
stenting NN i
in IN N
high-risk JJ p
patients NNS p
for IN p
percutaneous JJ p
intervention NN p
and CC p
bypass NN i
surgery NN i
: : i
results NNS N
of IN N
the DT N
prospective JJ N
randomized NN N
myoprotect NN N
I PRP N
study VBP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
event-free JJ o
survival NN o
and CC o
total JJ o
treatment NN o
costs NNS o
of IN N
retroinfusion-supported JJ i
stenting NN i
in IN N
high-risk JJ p
patients NNS p
compared VBN N
to TO N
bypass VB i
surgery NN i
. . i

An DT N
increasing VBG N
number NN N
of IN N
patients NNS p
with IN p
main-stem JJ p
and CC p
main-stem-equivalent JJ p
stenosis NN p
are VBP N
treated VBN N
by IN N
stent JJ i
implantation NN i
, , N
which WDT N
appears VBZ N
to TO N
be VB N
safe JJ N
in IN N
the DT N
short-term JJ N
follow-up NN N
. . N

However RB N
, , N
there EX N
is VBZ N
a DT N
lack NN N
of IN N
randomized JJ N
studies NNS N
comparing VBG N
conventional JJ i
bypass NN i
surgery NN i
with IN N
stent JJ i
implantation NN i
, , N
particularly RB N
in IN N
patients NNS p
with IN p
high JJ p
risk NN p
for IN p
both DT p
treatments NNS p
. . p

We PRP N
here RB N
report VBP N
on IN N
the DT N
1-year JJ N
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
single-center NN N
study NN N
in IN N
patients NNS p
with IN p
symptomatic JJ p
main-stem NN p
and CC p
main-stem-equivalent JJ p
lesions NNS p
with IN p
substantially RB p
increased VBN p
risk NN p
for IN p
bypass NN i
surgery NN i
. . i

Patients NNS N
where WRB N
randomized VBN N
to TO N
undergo VB N
either RB N
percutaneous JJ i
transluminal JJ i
coronary JJ i
angioplasty/stent NN i
procedure NN i
( ( p
n JJ p
= NNP p
23 CD p
) ) p
or CC N
bypass NN i
surgery NN i
( ( p
n JJ p
= NNP p
21 CD p
) ) p
. . p

Patients NNS N
randomized VBD N
to TO N
stent VB i
implantation NN i
were VBD N
supported VBN N
by IN N
selective JJ i
pressure-regulated JJ i
retroinfusion NN i
of IN N
the DT N
anterior JJ N
cardiac JJ N
vein NN N
during IN N
ischemia NN N
. . N

Patients NNS p
of IN p
the DT p
stent NN i
group NN p
and CC p
the DT p
bypass NN i
group NN p
did VBD p
not RB p
differ VB p
in IN p
baseline NN p
characteristics NNS p
, , p
including VBG p
Parsonnet NNP o
score NN o
and CC o
quality-of-life JJ o
score NN o
. . o

Twenty-eight-day JJ o
mortality NN o
and CC o
1-year JJ o
mortality NN o
rate NN o
as RB N
well RB N
as IN N
quality-of-life JJ o
scores NNS o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Event-free JJ o
survival NN o
after IN N
1 CD N
year NN N
was VBD N
higher RBR N
in IN N
the DT N
bypass NN N
group NN N
( ( N
71.4 CD N
% NN N
vs. FW N
52.3 CD N
% NN N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
due JJ N
to TO N
a DT N
lower JJR N
target NN N
lesion NN N
revascularization NN N
rate NN N
. . N

With IN N
regard NN N
to TO N
total JJ o
treatment NN o
costs NNS o
, , N
however RB N
, , N
the DT N
stent NN N
group NN N
compared VBN N
favorably RB N
to TO N
the DT N
bypass NN N
group NN N
( ( N
9,346 CD N
+/- JJ N
807 CD N
vs. FW N
26,874 CD N
+/- JJ N
3,985 CD N
euro NN N
) ) N
, , N
predominantly RB N
as IN N
a DT N
result NN N
of IN N
a DT N
shorter NN N
intensive JJ N
care NN N
and CC N
hospital NN N
stay NN N
. . N

In IN N
this DT N
first JJ N
randomized VBN N
study NN N
in IN N
high-risk JJ p
patients NNS p
for IN p
stent JJ i
implantation NN i
and CC p
bypass NN i
surgery NN i
, , N
patients NNS N
with IN N
retroinfusion-supported JJ i
stent NN i
implantation NN i
had VBD N
a DT N
similar JJ N
1-year JJ o
outcome NN o
and CC o
quality NN o
of IN o
life NN o
compared VBN N
to TO N
patients NNS N
with IN N
bypass NN i
surgery NN i
. . i

Though IN N
in IN N
the DT N
stent JJ N
group NN N
event-free JJ o
survival NN o
was VBD N
lower JJR N
and CC N
target VB N
lesion JJ N
revascularization NN o
rate NN o
was VBD N
higher JJR N
, , N
retroinfusion-supported JJ i
stent NN i
implantation NN i
was VBD N
associated VBN N
with IN N
substantially RB N
lower JJR o
costs NNS o
and CC N
might MD N
be VB N
considered VBN N
as IN N
an DT N
alternative JJ N
treatment NN N
option NN N
in IN N
this DT N
selected VBN N
group NN N
of IN N
high-risk JJ N
patients NNS N
. . N

-DOCSTART- -23407221- O O

Rifampicin NNP i
plus CC i
isoniazid NN i
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN p
in IN p
an DT p
immigrant JJ p
population NN p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
tolerance NN N
, , N
adherence NN N
and CC N
effectiveness NN N
of IN N
two CD N
approaches NNS N
for IN N
the DT N
treatment NN N
of IN N
latent JJ N
tuberculosis NN N
infection NN N
( ( N
LTBI NNP N
) ) N
: : N
6 CD N
months NNS N
of IN N
isoniazid NN i
( ( i
6H CD i
) ) i
vs. FW N
3 CD N
months NNS N
of IN N
isoniazid JJ i
plus CC i
rifampicin JJ i
( ( i
3RH CD i
) ) i
. . i

POPULATION JJ N
Immigrants NNS p
with IN p
LTBI NNP p
. . p

METHODS NNP N
Participants NNPS N
were VBD N
enrolled VBN N
in IN N
a DT N
controlled VBN N
, , N
randomised VBD N
clinical JJ N
trial NN N
in IN p
Barcelona NNP p
, , p
Spain NNP p
, , p
from IN p
April NNP p
2001 CD p
to TO p
April NNP p
2005 CD p
. . p

Monthly JJ N
follow-up NN N
was VBD N
done VBN N
to TO N
assess VB N
tolerance NN N
, , N
side NN N
effects NNS N
and CC N
adherence NN N
. . N

Effectiveness NNP N
was VBD N
evaluated VBN N
at IN N
5 CD N
years NNS N
. . N

RESULTS NN N
In IN N
the DT N
590 CD p
subjects NNS p
enrolled VBN p
, , N
the DT N
rate NN o
of IN o
adherence NN o
was VBD N
greater JJR N
in IN N
the DT N
3RH CD N
than IN N
in IN N
the DT N
6H CD N
arm NN N
( ( N
72 CD N
% NN N
vs. FW N
52.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
study NN N
arms NNS N
were VBD N
observed VBN N
with IN N
respect NN N
to TO N
hepatotoxicity NN o
or CC o
side NN o
effects NNS o
. . o

Variables NNS N
associated VBN N
with IN N
non-adherence NN N
were VBD N
diagnosis VBN N
by IN N
screening VBG o
( ( N
OR CC N
1.88 CD N
, , N
95 CD N
% NN N
CI NNP N
1.26-2.82 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
illegal JJ o
immigration NN o
status NN o
( ( N
OR CC N
1.48 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01-2.15 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
unemployment NN o
( ( N
OR CC N
1.91 CD N
, , N
95 CD N
% NN N
CI NNP N
1.28-2.85 CD N
, , N
P NNP N
= NNP N
0.0008 CD N
) ) N
, , N
illiteracy NN o
( ( N
OR CC N
1.73 CD N
, , N
95 CD N
% NN N
CI NNP N
1.04-2.88 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
lack NN o
of IN o
family NN o
support NN o
( ( N
OR NNP N
3.7 CD N
, , N
95 CD N
% NN N
CI NNP N
2.54-5.4 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
the DT N
6-month JJ o
treatment NN o
regimen NNS o
( ( N
OR NNP N
2.45 CD N
, , N
95 CD N
% NN N
CI NNP N
1.68-3.57 CD N
, , N
P NNP N
= NNP N
0.0001 CD N
) ) N
. . N

None NN N
of IN N
the DT N
patients NNS N
who WP N
completed VBD N
either CC N
treatment NN N
developed VBD N
tuberculosis NN o
. . o

CONCLUSIONS VB N
The DT N
3RH CD i
regimen NNS i
facilitates VBZ N
adherence NN N
to TO N
LTBI NNP N
treatment NN N
and CC N
offers VBZ N
a DT N
safe JJ N
, , N
well-tolerated JJ N
and CC N
effective JJ N
alternative NN N
. . N

-DOCSTART- -2693850- O O

Dacarbazine NNP i
versus NN i
dacarbazine-vindesine NN i
in IN N
disseminated JJ N
malignant JJ N
melanoma NN N
: : N
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
. . N

In IN N
a DT N
phase NN N
II NNP N
study NN N
119 CD p
patients NNS p
with IN p
disseminated JJ p
malignant JJ p
melanoma NN p
were VBD N
randomized VBN N
to TO N
receive VB N
treatment NN N
with IN N
dacarbazine JJ i
alone NN N
or CC N
in IN N
combination NN N
with IN N
vindesine NN N
. . N

The DT N
study NN N
was VBD N
designed VBN N
to TO N
reveal VB N
an DT N
additive JJ N
response NN N
rate NN N
when WRB N
the DT N
drugs NNS N
were VBD N
combined VBN N
. . N

Dacarbazine NNP i
was VBD i
given VBN i
i.v NN i
. . i

at IN i
250 CD i
mg JJ i
m-2 JJ i
per IN i
day NN i
X NNP i
V NNP i
every DT i
4 CD i
weeks NNS i
. . i

In IN N
the DT N
combination NN N
regimen NNS N
vindesine VB i
given VBN N
at IN N
3 CD N
mg JJ N
m-2 JJ N
per IN N
week NN N
was VBD N
included VBN N
. . N

One CD p
hundred CD p
and CC p
ten JJ p
patients NNS p
were VBD p
available JJ p
for IN p
evaluation NN p
of IN p
response NN p
. . p

With IN N
dacarbazine JJ i
4/51 CD N
patients NNS N
obtained VBD N
a DT N
complete JJ o
remission NN o
( ( N
8 CD N
% NN N
) ) N
and CC N
5/51 CD N
patients NNS N
a DT N
partial JJ o
remission NN o
( ( N
10 CD N
% NN N
) ) N
. . N

Overall JJ o
response NN o
rate NN o
was VBD N
18 CD N
% NN N
. . N

With IN N
dacarbazine-vindesine JJ i
8/59 CD N
patients NNS N
obtained VBD N
a DT N
complete JJ o
remission NN o
( ( N
13 CD N
% NN N
) ) N
and CC N
7/59 CD N
patients NNS N
a DT N
partial JJ o
remission NN o
( ( N
12 CD N
% NN N
) ) N
. . N

Overall JJ o
response NN o
rate NN o
was VBD N
25 CD N
% NN N
. . N

The DT N
difference NN N
in IN N
response NN o
rates NNS o
observed VBD N
between IN N
the DT N
treatment NN N
arms NNS N
is VBZ N
not RB N
statistically RB N
significant JJ N
. . N

Median JJ N
response NN N
duration NN N
was VBD N
123 CD N
days NNS N
for IN N
dacarbazine JJ N
patients NNS N
and CC N
171 CD N
days NNS N
for IN N
patients NNS N
receiving VBG N
dacarbazine-vindesine NN N
( ( N
difference NN N
not RB N
statistically RB N
significant JJ N
) ) N
. . N

-DOCSTART- -7674231- O O

Cyclosporin VB i
A DT i
increases NNS N
somatomedin JJ o
C NNP o
insulin-like JJ o
growth NN o
factor NN o
I PRP o
levels NNS o
in IN N
chronic JJ N
rheumatic JJ N
diseases NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
anabolic JJ N
hormones NNS N
that WDT N
affect VBP N
the DT N
musculoskeletal NN N
system NN N
and CC N
active JJ N
on IN N
the DT N
immune JJ N
cells NNS N
changed VBD N
during IN N
cyclosporin NN i
A NNP i
( ( i
CysA NNP i
) ) i
therapy NN i
. . i

METHODS NNP N
We PRP N
carried VBD N
out RP N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS p
with IN p
rheumatic JJ p
disease NN p
attending VBG p
the DT p
outpatient NN p
clinic NN p
for IN p
rheumatic JJ p
diseases NNS p
. . p

Twenty-four CD p
patients NNS p
with IN p
chronic JJ p
arthritis NN p
[ VBD p
20 CD p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
and CC p
4 CD p
with IN p
psoriatic JJ p
arthritis NN p
( ( p
PsA NNP p
) ) p
] NN p
were VBD N
divided VBN N
into IN N
2 CD i
groups NNS i
( ( i
10 CD i
RA NNP i
, , i
2 CD i
PsA NNP i
) ) i
and CC i
randomly VB i
given VBN i
CysA NNP i
5 CD i
mg/kg JJ i
daily JJ i
or CC i
hydroxychloroquine NN i
( ( i
OH-Chlor NNP i
) ) i
6 CD i
mg/kg JJ i
daily RB i
in IN i
divided JJ i
doses NNS i
. . i

RESULTS VB N
A DT N
significant JJ N
increase NN N
of IN N
insulin-like JJ o
growth NN o
factor NN o
I PRP o
( ( N
IGF-I NNP N
) ) N
( ( N
somatomedin JJ N
C NNP N
) ) N
levels NNS N
and CC N
of IN N
bone NN o
Gla NNP o
protein NN o
was VBD N
shown VBN N
after IN N
2 CD N
months NNS N
in IN N
the DT N
CysA NNP N
treated VBD N
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
OH-Chlor NNP N
group NN N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
was VBD N
observed VBN N
between IN N
changes NNS N
of IN N
IGF-I NNP o
levels NNS o
and CC o
of IN o
dehydroepiandrosterone NN o
sulphate NN o
( ( o
DHEAS NNP o
) ) o
. . o

This DT p
finding NN p
was VBD p
confirmed VBN p
in IN p
a DT p
further JJ p
series NN p
of IN p
39 CD p
patients NNS p
. . p

No DT N
changes NNS N
were VBD N
seen VBN N
in IN N
25 CD N
OH-D JJ N
, , N
1-25 JJ N
( ( N
OH NNP N
) ) N
2-D3 CD N
or CC N
parathyroid VB N
hormone NN N
after IN N
CysA NNP N
. . N

CONCLUSION NNP N
The DT N
effects NNS N
of IN N
CysA NNP N
on IN N
IGF-I NNP N
may MD N
explain VB N
some DT N
of IN N
the DT N
clinical JJ N
, , N
immunologic JJ N
, , N
and CC N
metabolic JJ N
results NNS N
during IN N
CysA NNP N
treatment NN N
of IN N
rheumatic JJ N
diseases NNS N
. . N

-DOCSTART- -12396317- O O

The DT N
effects NNS N
of IN N
chloroquine NN i
, , i
amodiaquine NN i
and CC N
chloroquine NN i
plus CC i
chlorpheniramine NN i
on IN N
the DT N
disposition NN p
kinetics NNS o
of IN p
the DT p
hepatomegaly NN p
associated VBN p
with IN p
acute NN p
, , p
uncomplicated JJ p
, , p
Plasmodium NNP p
falciparum NN p
malaria NN p
in IN p
children NNS p
. . p

The DT N
effects NNS N
of IN N
chloroquine NN i
( ( i
CQ NNP i
) ) i
, , i
amodiaquine NN i
( ( i
AQ NNP i
) ) i
and CC N
CQ NNP i
plus CC i
chlorpheniramine NN i
( ( N
a DT N
histamine NN N
H NNP N
( ( N
1 CD N
) ) N
antagonist NN N
that IN N
reverses VBZ N
CQ NNP N
resistance NN N
in IN N
vitro NN N
and CC N
in IN N
vivo NN N
) ) N
on IN N
the DT N
disposition NN N
of IN N
the DT N
enlarged JJ p
liver NN p
associated VBN p
with IN p
acute NN p
, , p
symptomatic JJ p
, , p
uncomplicated JJ p
, , p
Plasmodium NNP p
falciparum NN p
malaria NNS p
were VBD N
evaluated VBN N
. . N

The DT p
subjects NNS p
, , p
131 CD p
children NNS p
aged VBN p
0.6-12 CD p
years NNS p
who WP p
lived VBD p
in IN p
an DT p
endemic JJ p
area NN p
of IN p
Nigeria NNP p
, , N
were VBD N
randomly RB N
allotted VBN N
to TO N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
cumulative JJ N
proportions NNS N
of IN N
the DT N
children NNS N
with IN N
complete JJ o
resolution NN o
of IN o
their PRP$ o
enlarged JJ o
livers NNS o
at IN N
48 CD N
, , N
96 CD N
, , N
168 CD N
or CC N
336 CD N
and CC N
504 CD N
h NN N
after IN N
commencement NN N
of IN N
treatment NN N
were VBD N
significantly RB N
higher JJR N
in IN N
those DT N
treated VBN N
with IN N
CQ NNP i
plus CC i
chlorpheniramine NN i
( ( i
CQCP NNP i
) ) i
than IN N
in IN N
the DT N
other JJ N
two CD N
treatment NN N
groups NNS N
( ( N
with IN N
P-values NNP N
of IN N
0.02 CD N
, , N
0.001 CD N
, , N
0.00000 CD N
and CC N
0.00002 CD N
, , N
respectively RB N
) ) N
. . N

Among IN N
those DT N
with IN N
complete JJ N
resolution NN N
, , N
however RB N
, , N
the DT N
times NNS N
to TO N
resolution NN N
of IN N
50 CD N
% NN N
( ( N
HR50 NNP N
) ) N
or CC N
90 CD N
% NN N
( ( N
HR90 NNP N
) ) N
of IN N
the DT N
liver NN N
enlargement NN N
were VBD N
similar JJ N
in IN N
all PDT N
the DT N
treatment NN N
groups NNS N
. . N

Complete JJ o
resolution NN o
of IN o
the DT o
enlarged JJ o
liver NN o
within IN N
168 CD N
h NN N
was VBD N
associated VBN N
with IN N
a DT N
sensitive JJ N
response NN N
to TO N
each DT N
treatment NN N
. . N

Overall JJ N
, , N
in IN N
children NNS N
with IN N
complete JJ o
or CC o
partial JJ o
resolution NN o
of IN N
their PRP$ N
enlarged JJ N
livers NNS N
, , N
the DT N
area NN o
produced VBN o
by IN o
plotting VBG o
liver JJ o
size NN o
against IN o
time NN o
( ( N
i.e NN N
. . N

the DT N
area NN N
under IN N
the DT N
curve NN N
of IN N
hepatomegaly NN N
v. NN N
time NN N
, , N
or CC N
AUC NNP N
( ( N
hp NN N
) ) N
) ) N
and CC N
the DT N
half-life NN o
of IN o
the DT o
hepatomegaly NN o
( ( N
t NN N
( ( N
1/2hp CD N
) ) N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
CQCP NNP i
group NN N
than IN N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
. . N

The DT N
volume NN o
of IN o
blood NN o
completely RB o
cleared VBD o
of IN o
the DT o
'hepatic JJ o
pathological JJ o
processes NNS o
' POS o
which WDT N
led VBD N
to TO N
the DT N
hepatomegaly NN N
( ( N
CL NNP N
( ( N
Bhp NNP N
) ) N
) ) N
and CC N
the DT N
fractional JJ o
reduction NN o
of IN o
AUC NNP o
( ( o
hp NN o
) ) o
at IN N
48 CD N
and CC N
96 CD N
h NN N
( ( N
i.e JJ N
. . N

AUC NNP N
( ( N
hpFr148 NN N
) ) N
and CC N
AUC NNP N
( ( N
hpFr96 NN N
) ) N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
CQCP NNP i
group NN N
than IN N
in IN N
the DT N
other JJ N
treatment NN N
groups NNS N
. . N

When WRB N
the DT N
children NNS N
with IN N
complete JJ N
resolution NN N
of IN N
their PRP$ N
liver NN N
enlargement NN N
were VBD N
considered VBN N
separately RB N
, , N
t NN N
( ( N
1/2hp CD N
) ) N
( ( N
P=0.0008 NNP N
) ) N
but CC N
not RB N
AUC NNP o
( ( o
hp NN o
) ) o
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
lower JJR N
, , N
and CC N
AUC NNP o
( ( o
hpFr196 NN o
) ) o
( ( N
P=0.01 NNP N
) ) N
and CC N
CL NNP o
( ( o
Bhl NNP o
) ) o
( ( N
P=0.002 NNP N
) ) N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
CQCP NNP i
group NN N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Among IN N
the DT N
children NNS N
with IN N
only RB N
partial JJ o
resolution NN o
of IN o
their PRP$ o
enlarged JJ o
livers NNS o
, , N
the DT N
indices NNS o
of IN o
resolution NN o
and CC o
the DT o
kinetic JJ o
parameters NNS o
of IN o
disposition NN o
were VBD N
similar JJ N
in IN N
all DT N
three CD N
groups NNS N
. . N

The DT N
data NN N
indicate NN N
that IN N
the DT N
addition NN N
of IN N
chlorpheniramine NN i
to TO N
chloroquine VB i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
both CC N
the DT N
early JJ p
and CC p
late JJ p
stages NNS p
of IN p
the DT p
resolution NN o
of IN o
the DT o
liver NN o
enlargement NN o
associated VBN p
with IN p
acute NN p
, , p
symptomatic JJ p
, , p
uncomplicated JJ p
, , p
P. NNP p
falciparum NN p
malaria NN p
. . p

-DOCSTART- -20806998- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
electro-acupuncture NN i
for IN N
autism NN p
spectrum NN p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
study VB N
the DT N
efficacy NN N
, , N
safety NN N
, , N
and CC N
compliance NN N
of IN N
short-term JJ N
electro-acupuncture NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
sham-controlled JJ N
, , N
clinical JJ N
trial NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Children NNP p
with IN p
ASD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
electro-acupuncture NN i
( ( i
EA NNP i
) ) i
group NN i
( ( i
n=30 JJ i
) ) i
or CC i
a DT i
sham JJ i
electro-acupuncture NN i
( ( i
SEA NNP i
) ) i
group NN i
( ( p
n=25 RB p
) ) p
matched VBN p
by IN p
age NN p
and CC p
severity NN p
of IN p
autism NN p
. . p

The DT N
EA NNP N
group NN N
received VBD N
electro-acupuncture NN N
for IN N
selected VBN N
acupoints NNS N
while IN N
the DT N
SEA NNP N
group NN N
received VBD N
sham JJ N
electro-acupuncture NN N
to TO N
sham VB N
acupoints NNS N
. . N

A DT N
total NN N
of IN N
12 CD N
EA NNP N
and CC N
SEA NNP N
sessions NNS N
over IN N
four CD N
weeks NNS N
were VBD N
given VBN N
. . N

Primary JJ o
outcome NN o
measures NNS o
included VBD o
Functional NNP o
Independence NNP o
Measure NN o
for IN o
Children NNP o
( ( o
WeeFIM NNP o
) ) o
, , o
Pediatric NNP o
Evaluation NNP o
of IN o
Disability NNP o
Inventory NNP o
( ( o
PEDI NNP o
) ) o
, , o
Leiter NNP o
International NNP o
Performance NNP o
Scale-Revised JJ o
( ( o
Leiter-R NNP o
) ) o
, , N
and CC N
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
( ( o
CGI-I NNP o
) ) o
scale NN o
. . o

Secondary JJ N
outcome NN N
measures NNS N
consisted VBN N
of IN N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
, , o
Ritvo-Freeman JJ o
Real NNP o
Life NNP o
Scale NNP o
( ( o
RFRLS NNP o
) ) o
, , o
Reynell NNP o
Developmental NNP o
Language NNP o
Scale NNP o
( ( o
RDLS NNP o
) ) o
, , o
and CC o
a DT o
standardized JJ o
parental JJ o
report NN o
. . o

Data NNP N
were VBD N
analyzed VBN N
by IN N
the DT N
Mann-Whitney NNP N
test NN N
. . N

RESULTS CC N
There EX N
were VBD N
significant JJ N
improvements NNS o
in IN o
the DT o
language NN o
comprehension NN o
domain NN o
of IN o
WeeFIM NNP o
( ( o
p=0.02 NN o
) ) o
, , o
self-care JJ o
caregiver NN o
assistant NN o
domain NN o
of IN o
PEDI NNP o
( ( o
p=0.028 NN o
) ) o
, , o
and CC o
CGI-I NNP o
( ( N
p=0.003 NN N
) ) N
in IN N
the DT N
EA NNP N
group NN N
compared VBN N
to TO N
the DT N
SEA NNP N
group NN N
. . N

As IN N
for IN N
the DT N
parental JJ N
report NN N
, , N
the DT N
EA NNP N
group NN N
also RB N
showed VBD N
significantly RB N
better RBR o
social JJ o
initiation NN o
( ( o
p=0.01 NN o
) ) o
, , o
receptive JJ o
language NN o
( ( o
p=0.006 NN o
) ) o
, , o
motor NN o
skills NNS o
( ( o
p=0.034 NN o
) ) o
, , o
coordination NN o
( ( o
p=0.07 NN o
) ) o
, , o
and CC o
attention NN o
span NN o
( ( N
p=0.003 NN N
) ) N
. . N

More JJR N
than IN N
70 CD N
percent NN N
of IN N
children NNS p
with IN p
ASD NNP p
adapted VBD o
to TO o
acupuncture VB o
easily RB o
, , N
while IN N
eight CD N
percent NN N
had VBD N
poor JJ o
acupuncture NN o
compliance NN o
. . o

Mild NNP o
side JJ o
effects NNS o
of IN o
minor JJ o
superficial JJ o
bleeding NN o
or CC o
irritability NN o
during IN o
acupuncture NN o
were VBD N
observed VBN N
. . N

CONCLUSION VB N
A DT N
short JJ N
, , N
four-week JJ N
( ( N
12 CD N
sessions NNS N
) ) N
course NN N
of IN N
electro-acupuncture NN N
is VBZ N
useful JJ N
to TO N
improve VB N
specific JJ N
functions NNS N
in IN N
children NNS p
with IN p
ASD NNP p
, , N
especially RB N
for IN N
language NN N
comprehension NN N
and CC N
self-care JJ N
ability NN N
. . N

-DOCSTART- -7704288- O O

The DT N
effect NN N
of IN N
metformin NN i
and CC i
insulin NN i
on IN N
sympathetic JJ N
nerve NN N
activity NN N
, , N
norepinephrine JJ N
spillover NN N
and CC N
blood NN N
pressure NN N
in IN N
obese JJ p
, , p
insulin JJ p
resistant NN p
, , p
normoglycemic JJ p
, , p
hypertensive JJ p
men NNS p
. . p

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
metformin NN i
on IN N
insulin NN N
sensitivity NN N
and CC N
to TO N
further RBR N
examine VB N
the DT N
relationship NN N
between IN N
insulin NN N
resistance NN N
, , N
sympathetic JJ N
nerve NN N
activity NN N
and CC N
blood NN N
pressure NN N
, , N
6 CD p
obese JJ p
insulin NN p
resistant NN p
, , p
normoglycemic JJ p
hypertensive JJ p
men NNS p
were VBD p
investigated VBN p
( ( p
age NN p
49 CD p
+/- JJ p
2 CD p
years NNS p
, , p
BMI NNP p
27.6 CD p
+/- JJ p
1.2 CD p
, , p
mean JJ p
+/- JJ p
SEM NNP p
) ) p
. . p

The DT N
study NN N
had VBD N
a DT N
placebo NN i
controlled VBN N
, , N
double JJ N
blind NN N
, , N
cross NN N
over IN N
design NN N
with IN N
6 CD N
weeks NNS N
' POS N
metformin NN i
treatment NN i
( ( i
850 CD i
mg RB i
b.i.d NN i
) ) i
vs NN i
placebo NN i
. . i

Blood NNP o
pressure NN o
was VBD N
measured VBN N
weekly RB N
. . N

At IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
, , N
glucose JJ o
infusion NN o
rate NN o
( ( o
GIR NNP o
) ) o
, , o
muscle FW o
sympathetic JJ o
nerve NN o
activity NN o
( ( o
MSA NNP o
) ) o
and CC o
renal JJ o
and CC o
total JJ o
body NN o
norepinephrine NN o
( ( o
NE NNP o
) ) o
kinetics NNS o
( ( o
radioisotope VB o
dilution NN o
) ) o
were VBD N
examined VBN N
during IN N
euglycemic JJ N
hyperinsulinemic JJ N
clamp NN N
. . N

Fasting VBG o
insulin NN o
was VBD N
13 CD N
+/- JJ N
3 CD N
and CC N
10 CD N
+/- JJ N
2 CD N
mU/l NN N
and CC N
fasting VBG N
glucose JJ N
5.3 CD N
+/- JJ N
0.2 CD N
and CC N
5.1 CD N
+/- JJ N
0.1 CD N
mmol/l NN N
after IN N
placebo NN N
and CC N
metformin NN N
treatment NN N
, , N
respectively RB N
( ( N
ns JJ N
) ) N
. . N

GIR NNP N
during IN N
the DT N
last JJ N
hour NN N
of IN N
the DT N
insulin NN N
clamp NN N
was VBD N
3.7 CD N
+/- JJ N
0.6 CD N
vs JJ N
3.6 CD N
+/- JJ N
0.6 CD N
mg/kg NN N
x NN N
min NN N
( ( N
ns JJ N
) ) N
. . N

Resting VBG o
MSA NNP o
, , o
total JJ o
body NN o
and CC o
right JJ o
renal NN o
NE NNP o
spillover NN o
did VBD N
not RB N
differ VB N
significantly RB N
after IN N
placebo NN i
and CC N
metformin NN i
treatment NN N
. . N

Systolic NNP o
and CC o
diastolic JJ o
blood NN o
pressures NNS o
were VBD N
151 CD N
+/- JJ N
10/95 CD N
+/- JJ N
5 CD N
mmHg NN N
after IN N
placebo NN N
and CC N
146 CD N
+/- JJ N
5/94 CD N
+/- JJ N
5 CD N
mmHg NN N
after IN N
metformin NN N
treatment NN N
( ( N
ns JJ N
) ) N
. . N

Thus NNP N
metformin NN i
treatment NN N
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
insulin NN N
sensitivity NN N
, , N
blood NN o
pressure NN o
or CC o
sympathetic JJ o
activity NN o
in IN N
this DT N
small JJ N
group NN N
of IN N
patients NNS N
. . N

Renal JJ N
plasma NN N
flow NN N
and CC N
MSA NNP N
increased VBD N
significantly RB N
during IN N
the DT N
insulin NN N
clamp NN N
, , N
whereas JJ N
renal JJ N
NE NNP N
and CC N
total JJ N
body NN N
NE NNP N
spillover NN N
remained VBD N
unchanged JJ N
, , N
suggesting VBG N
nonuniform JJ N
regional JJ N
sympathetic JJ N
nerve NN N
responses NNS N
to TO N
acute VB N
hyperinsulinemia NN N
. . N

-DOCSTART- -17959585- O O

Efficacy NN o
of IN N
intravenous JJ N
acetaminophen NN i
and CC N
lidocaine NN i
on IN N
propofol NN N
injection NN N
pain NN N
. . N

BACKGROUND NNP N
Different NNP N
methods NNS N
and CC N
propofol NN N
formulations NNS N
have VBP N
been VBN N
used VBN N
to TO N
decrease VB N
propofol JJ o
injection NN o
pain NN o
, , N
but CC N
it PRP N
remains VBZ N
an DT N
unresolved JJ N
problem NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
i.v NN N
. . N

acetaminophen JJ N
pretreatment NN N
on IN N
the DT N
propofol NN N
injection NN o
pain NN o
. . o

METHODS NNP N
One CD p
hundred CD p
and CC p
fifty JJ p
ASA NNP p
I-II NNP p
patients NNS p
undergoing VBG p
general JJ p
anaesthesia NN p
were VBD N
randomly RB N
allocated VBN N
into IN N
three CD N
groups NNS N
. . N

A DT N
20-gauge JJ i
catheter NN i
was VBD N
inserted VBN N
into IN N
a DT N
superficial JJ N
radial JJ N
vein NN N
of IN N
the DT N
left JJ N
hand NN N
, , N
and CC N
after IN N
the DT N
occlusion NN N
of IN N
venous JJ N
drainage NN N
, , N
Groups NNP N
I PRP N
, , N
II NNP N
, , N
and CC N
III NNP N
were VBD N
pretreated VBN N
with IN N
40 CD i
mg NNS i
of IN i
lidocaine NN i
in IN i
saline NN i
, , i
50 CD i
mg NN i
of IN i
i.v NN i
. . i

acetaminophen NN i
, , i
and CC i
5 CD i
ml NN i
of IN i
saline NN i
, , N
respectively RB N
. . N

The DT N
occlusion NN N
was VBD N
released VBN N
after IN N
2 CD N
min NN N
and CC N
one-fourth NN N
of IN N
the DT N
total JJ N
propofol NN i
dose NN N
was VBD N
injected VBN N
into IN N
the DT N
vein NN N
over IN N
a DT N
period NN N
of IN N
5 CD N
s. NN N
During IN N
the DT N
injection NN N
of IN N
both DT N
pretreatment JJ N
solution NN N
and CC N
propofol NN N
, , N
patients NNS N
' POS N
pain NN o
was VBD N
assessed VBN N
and CC N
recorded VBN N
as IN N
0-3 NN N
, , N
corresponding VBG N
to TO N
no DT N
, , N
mild RB N
, , N
moderate JJ N
or CC N
severe JJ N
pain NN N
, , N
respectively RB N
. . N

Chi2 NNP N
and CC N
Kruskal-Wallis NNP N
tests NNS N
were VBD N
used VBN N
for IN N
the DT N
statistical JJ N
analysis NN N
. . N

For IN N
all DT N
analyses NNS N
, , N
differences NNS N
were VBD N
considered VBN N
to TO N
be VB N
significant JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

RESULTS NNP N
Patient JJ N
characteristics NNS N
were VBD N
similar JJ N
among IN N
the DT N
groups NNS N
. . N

Incidence NN o
of IN o
pain NN o
on IN o
injection NN o
of IN N
propofol NN i
in IN N
control NN N
, , N
i.v NN N
. . N

acetaminophen NN i
, , N
and CC N
lidocaine NN i
groups NNS N
was VBD N
64 CD N
% NN N
, , N
22 CD N
% NN N
and CC N
8 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Pretreatment NNP N
with IN N
i.v NN N
. . N

acetaminophen NN i
seems VBZ N
to TO N
be VB N
effective JJ N
in IN N
attenuating VBG N
pain NN o
during IN N
i.v NN N
. . N

injection NN N
of IN N
propofol NN i
. . i

-DOCSTART- -12384805- O O

Randomized VBN N
trial NN N
of IN N
adoptive JJ N
transfer NN N
of IN N
melanoma JJ N
tumor-infiltrating JJ i
lymphocytes NNS i
as IN N
adjuvant JJ N
therapy NN N
for IN N
stage NN p
III NNP p
melanoma NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
demonstrate VB N
the DT N
interest NN N
of IN N
using VBG N
tumor-infiltrating JJ i
lymphocytes NNS i
( ( i
TIL NNP i
) ) i
as IN N
adjuvant JJ N
therapy NN N
for IN N
stage NN p
III NNP p
( ( p
regional JJ p
lymph NN p
nodes NNS p
) ) p
melanoma NN p
. . p

After IN N
lymph JJ N
node JJ N
excision NN N
, , N
patients NNS p
without IN p
any DT p
detectable JJ p
metastases NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
TIL NNP i
plus CC i
interleukin-2 JJ i
( ( i
IL-2 NNP i
) ) i
for IN N
2 CD N
months NNS N
, , N
or CC N
IL-2 NNP i
only RB i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
determination NN o
of IN o
the DT o
duration NN o
of IN o
the DT o
relapse-free JJ o
interval NN o
. . o

Eighty-eight JJ p
patients NNS p
determined VBD p
as IN p
eligible JJ p
for IN p
treatment NN p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
46.9 CD N
months NNS N
, , N
for IN N
the DT N
study NN N
population NN N
the DT N
analysis NN N
did VBD N
not RB N
show VB N
a DT N
significant JJ N
extension NN N
of IN N
the DT N
relapse-free JJ o
interval NN o
or CC o
overall JJ o
survival NN o
. . o

However RB N
, , N
a DT N
significant JJ N
interaction NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
was VBD N
found VBN N
between IN N
the DT N
treatment NN N
and CC N
the DT N
number NN o
of IN o
invaded JJ o
lymph NN o
nodes NNS o
. . o

In IN N
the DT N
group NN N
with IN N
only RB N
one CD N
invaded VBD N
lymph NN N
node NN N
, , N
the DT N
estimated VBN o
relapse NN o
rate NN o
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
( ( N
adjusted VBN N
) ) N
=0.0285 NN N
) ) N
and CC N
the DT N
overall JJ o
survival NN o
was VBD N
increased VBN N
( ( N
P NNP N
( ( N
adjusted VBN N
) ) N
=0.039 NN N
) ) N
in IN N
the DT N
TIL+IL-2 NNP i
arm NN N
compared VBN N
with IN N
the DT N
IL-2 NNP i
only JJ N
arm NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
two CD N
arms NNS N
, , N
either CC N
as IN N
regards NNS N
the DT N
duration NN o
of IN o
disease-free JJ o
survival NN o
or CC o
overall JJ o
survival NN o
, , N
were VBD N
noted VBN N
in IN N
the DT N
group NN N
with IN N
more JJR N
than IN N
one CD N
invaded JJ N
lymph NN N
node NN N
whatever IN N
the DT N
number NN N
of IN N
invaded JJ N
lymph NN N
nodes NNS N
. . N

Treatment NN N
was VBD N
compatible JJ N
with IN N
normal JJ N
daily JJ N
activity NN N
. . N

This DT N
study NN N
demonstrates VBZ N
for IN N
the DT N
first JJ N
time NN N
that IN N
the DT N
efficiency NN N
of IN N
TIL NNP i
in IN N
stage NN N
III NNP N
melanoma NN N
( ( N
AJCC NNP N
) ) N
is VBZ N
directly RB N
related VBN N
to TO N
the DT N
number NN N
of IN N
invaded JJ N
lymph NN N
nodes NNS N
, , N
indicating VBG N
that IN N
tumor NN N
burden NN N
might MD N
be VB N
a DT N
crucial JJ N
factor NN N
in IN N
the DT N
efficacy NN N
and/or NN N
in IN N
vitro JJ N
expansion NN N
of IN N
T NNP N
cells NNS N
specific JJ N
for IN N
autologous JJ N
tumor NN N
antigen NN N
, , N
a DT N
finding NN N
which WDT N
could MD N
be VB N
of IN N
value NN N
in IN N
future JJ N
vaccine NN N
development NN N
for IN N
the DT N
treatment NN N
of IN N
melanoma NN N
. . N

-DOCSTART- -2694356- O O

Low JJ i
power NN i
laser NN i
therapy NN i
of IN N
shoulder NN p
tendonitis NN p
. . p

30 CD p
patients NNS p
with IN p
supraspinatus NN p
or CC p
bicipital JJ p
tendonitis NN p
were VBD p
randomly RB p
allocated VBN p
to TO N
active JJ i
infrared VBN i
laser NN i
therapy NN i
at IN N
904 CD N
nm JJ N
three CD N
times NNS N
weekly RB N
for IN N
2 CD N
weeks NNS N
, , N
dummy JJ i
laser NN i
or CC i
drug NN i
treatment NN i
for IN N
2 CD N
weeks NNS N
. . N

Objectively RB N
maximum JJ N
active JJ N
extension NN N
, , N
flexion NN N
and CC N
abduction NN N
of IN N
the DT N
shoulder NN N
, , N
and CC N
subjectively RB N
pain VB N
stiffness JJ N
movement NN N
and CC N
function NN N
were VBD N
measured VBN N
at IN N
0 CD N
and CC N
2 CD N
weeks NNS N
. . N

Significant JJ o
improvement NN o
of IN o
active JJ o
over IN o
dummy JJ o
laser NN o
was VBD o
noted VBN o
for IN N
all DT N
seven CD N
assessments NNS N
. . N

Active NNP o
laser NN o
therapy NN o
produced VBD o
significant JJ o
improvement NN o
over IN o
drug NN o
therapy NN o
for IN o
all DT o
three CD o
objective JJ o
measures NNS o
and CC o
pain NN o
. . o

Naproxen NNP o
sodium NN o
significantly RB o
improved VBN o
only RB o
movement NN o
and CC o
function NN o
compared VBN o
to TO o
dummy VB o
laser NN o
. . o

These DT N
results NNS o
demonstrate VBP o
the DT o
effectiveness NN o
of IN o
laser NN o
therapy NN o
in IN o
tendonitis NN o
of IN o
the DT o
shoulder NN o
. . o

-DOCSTART- -11408369- O O

In IN N
vivo JJ N
effect NN N
of IN N
clarithromycin NN i
on IN N
multiple JJ p
cytochrome NN p
P450s NNP p
. . p

The DT N
in IN N
vivo JJ N
effects NNS N
of IN N
oral JJ N
clarithromycin JJ i
administration NN N
on IN N
the DT N
in IN N
vivo JJ N
activity NN N
of IN N
cytochrome NN N
P450 NNP N
1A2 CD N
, , N
2C9 CD N
, , N
and CC N
2D6 CD N
were VBD N
determined VBN N
. . N

The DT N
cytochrome JJ N
P450 NNP N
probes NNS N
caffeine NN i
( ( N
CYP1A2 NNP N
) ) N
, , N
tolbutamide RB i
( ( N
CYP2C9 NNP N
) ) N
, , N
and CC N
dextromethorphan NN i
( ( N
CYP2D6 NNP N
) ) N
were VBD N
administered VBN N
as IN N
an DT N
oral JJ N
cocktail NN N
prior NN N
to TO N
and CC N
7 CD N
days NNS N
after IN N
oral JJ N
clarithromycin NN i
( ( N
500 CD N
mg NN N
twice RB N
daily RB N
) ) N
administration NN N
to TO N
12 CD p
healthy JJ p
male JJ p
subjects NNS p
. . p

Blood NN o
and CC o
urine JJ o
samples NNS o
were VBD N
collected VBN N
and CC N
assayed VBN N
for IN N
each DT N
of IN N
the DT N
compounds NNS N
and CC N
their PRP$ N
metabolites NNS N
using VBG N
high-performance NN N
liquid NN N
chromatography NN N
. . N

The DT N
CYP1A2 NNP o
indices NNS o
, , o
oral JJ o
caffeine NN o
clearance NN o
( ( N
6.2 CD N
+/- JJ N
3.3 CD N
l/h NN N
before IN N
and CC N
5.7 CD N
+/- JJ N
4.2 CD N
l/h NN N
after IN N
, , N
p VBD N
> RB N
0.05 CD N
) ) N
and CC N
the DT N
6-h JJ o
paraxanthine NN o
to TO o
caffeine VB o
serum JJ o
concentration NN o
ratio NN o
( ( N
0.49 CD N
+/- JJ N
0.3 CD N
before IN N
and CC N
0.44 CD N
+/- JJ N
0.3 CD N
after IN N
, , N
p VBD N
> RB N
0.05 CD N
) ) N
, , N
were VBD N
unchanged JJ o
following VBG N
clarithromycin NN N
dosing VBG N
. . N

Neither CC N
the DT N
tolbutamide JJ o
oral JJ o
clearance NN o
( ( N
0.77 CD N
+/- JJ N
0.28 CD N
l/h NN N
before IN N
and CC N
0.72 CD N
+/-0.24 JJ N
l/h NN N
after IN N
, , N
p VBD N
> RB N
0.05 CD N
) ) N
nor CC N
the DT N
tolbutamide JJ o
urinary JJ o
metabolic NN o
ratio NN o
( ( N
779 CD N
+/- JJ N
294 CD N
before IN N
and CC N
681 CD N
+/- JJ N
416 CD N
after IN N
, , N
p VBD N
> RB N
0.05 CD N
) ) N
indices NNS N
of IN N
CYP2C9 NNP N
were VBD N
altered VBN N
by IN N
clarithromycin JJ i
administration NN N
. . N

In IN N
the DT N
case NN N
of IN N
CYP2D6 NNP N
, , N
the DT N
dextromethorphan NN o
to TO o
dextrorphan VB o
urinary JJ o
ratio NN o
was VBD N
not RB N
significantly RB o
different JJ o
before IN N
( ( N
0.021 CD N
+/- JJ N
0.04 CD N
) ) N
and CC N
after IN N
( ( N
0.024 CD N
+/- JJ N
0.06 CD N
) ) N
clarithromycin NN i
dosing VBG N
. . N

In IN N
conclusion NN N
, , N
clarithromycin NN i
does VBZ N
not RB N
appear VB N
to TO N
alter VB N
the DT N
in IN N
vivo JJ o
catalytic JJ o
activity NN o
of IN N
CYP1A2 NNP N
, , N
CYP2C9 NNP N
, , N
and CC N
CYP2D6 NNP N
in IN N
healthy JJ N
individuals NNS N
as IN N
assessed VBN N
by IN N
caffeine NN N
, , N
tolbutamide NN N
, , N
and CC N
dextromethorphan NN N
, , N
respectively RB N
. . N

-DOCSTART- -21975559- O O

Post NNP N
hoc NN N
analysis NN N
of IN N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ i
acid NNS i
versus VBP N
daily JJ N
oral JJ N
risedronate NN i
on IN N
lumbar NN N
spine NN N
bone NN N
mineral JJ N
density NN N
in IN N
different JJ N
subgroups NNS p
with IN p
glucocorticoid-induced JJ p
osteoporosis NN p
. . p

This DT N
study NN N
summarizes VBZ N
the DT N
treatment NN N
effect NN N
of IN N
zoledronic JJ i
acid JJ i
infusion NN N
on IN N
lumbar NN o
spine NN o
bone NN o
mineral JJ o
density NN o
in IN N
different JJ p
subgroups NNS p
with IN p
glucocorticoid-induced JJ p
osteoporosis NN p
. . p

Zoledronic JJ i
acid NN i
is VBZ N
significantly RB N
more RBR N
effective JJ N
than IN N
risedronate NN i
in IN N
increasing VBG N
lumbar NN o
spine NN o
( ( o
LS NNP o
) ) o
bone NN o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
in IN N
both DT N
prevention NN N
and CC N
treatment NN N
of IN N
glucocorticoid-induced JJ N
osteoporosis NN N
. . N

Introduction NN N
In IN N
patients NNS p
on IN p
glucocorticoids NNS i
, , N
a DT N
single JJ N
zoledronic NN i
acid NN i
infusion NN N
significantly RB N
increased VBD N
BMD NNP o
versus IN N
daily JJ N
oral JJ N
risedronate NN i
. . i

We PRP N
assessed VBD N
treatment NN N
effect NN N
on IN N
LS NNP o
BMD NNP o
in IN N
different JJ p
patient NN p
subgroups NNS p
at IN N
month NN N
12 CD N
that WDT N
contributed VBD N
to TO N
the DT N
risk NN N
of IN N
osteoporosis NN N
in IN N
addition NN N
to TO N
glucocorticoids NNS N
. . N

Methods NNS N
Patients NNPS p
randomized VBN N
to TO N
a DT N
single JJ N
IV NNP N
infusion NN N
of IN N
zoledronic JJ i
acid NN i
5 CD N
mg NN N
or CC N
risedronate NN i
( ( N
5 CD N
mg/day NN N
) ) N
and CC N
stratified VBN N
based VBN N
on IN N
glucocorticoids NNS i
duration NN N
[ FW N
treatment NN N
( ( N
> JJ N
3 CD N
months NNS N
) ) N
and CC N
prevention NN N
( ( N
? . N
3 CD N
months NNS N
) ) N
subpopulations NNS p
] VBP p
were VBD p
subgrouped VBN p
by IN p
age NN p
; : p
gender NN p
; : p
menopausal NN p
status NN p
in IN p
women NNS p
; : p
dose VB p
and CC p
duration NN p
of IN p
prednisone NN i
during IN i
the DT p
trial NN p
; : p
and CC p
baseline VB p
serum JJ p
25-OH JJ p
vitamin NN p
D NNP p
, , p
LS NNP p
BMD NNP p
T-score NNP p
, , p
creatinine JJ p
clearance NN p
, , p
and CC p
concomitant JJ p
medication NN p
use NN p
. . p

Results NNS N
At IN N
month NN N
12 CD N
, , i
zoledronic JJ i
acid NN i
significantly RB i
increased VBD o
LS NNP o
BMD NNP o
versus NN o
risedronate NN i
in IN i
patients NNS N
? . N
74 CD N
years NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
treatment NN N
and CC N
65-74 JJ N
years NNS N
( ( N
P NNP N
= NNP N
0.0008 CD N
) ) N
in IN N
the DT N
prevention NN N
subpopulation NN N
. . N

At IN N
month NN N
12 CD N
, , N
zoledronic JJ i
acid NN i
significantly RB i
increased VBD o
LS NNP o
BMD NNP o
versus NN i
risedronate NN i
in IN i
both DT N
subpopulations NNS N
irrespective VBP N
of IN N
gender NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
cumulative JJ N
prednisone NN N
dose NN N
( ( N
all DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
postmenopausal NN N
status NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
premenopausal JJ N
women NNS N
, , N
in IN N
both DT N
subpopulations NNS i
, , i
zoledronic JJ i
acid NN i
significantly RB i
increased VBD o
total JJ o
hip NN o
BMD NNP o
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
versus NN i
risedronate NN i
at IN i
month NN N
12 CD N
but CC N
not RB N
LS NNP o
BMD NNP o
. . N

Osteoporotic JJ p
patients NNS p
in IN p
the DT N
prevention NN N
( ( N
P=0.0189 NNP N
) ) N
and CC N
osteopenic JJ N
patients NNS N
in IN N
the DT N
treatment NN N
subpopulation NN N
( ( N
P=0.0305 NNP N
) ) N
showed VBD N
significant JJ o
LS NNP o
BMD NNP o
increases VBZ N
with IN N
zoledronic JJ i
acid NNS i
versus NN i
risedronate NN i
at IN i
month NN N
12 CD N
. . N

Conclusions NNS N
This DT N
post NN N
hoc NN N
analysis NN N
suggests VBZ N
that IN N
zoledronic JJ i
acid NN i
is VBZ i
significantly RB N
more RBR N
effective JJ N
than IN N
risedronate NN i
in IN i
increasing VBG o
LS NNP o
BMD NNP o
in IN N
prevention NN N
and CC N
treatment NN N
of IN N
glucocorticoid-induced JJ N
osteoporosis NN N
across IN N
a DT N
wide JJ N
range NN N
of IN N
patients NNS N
. . N

-DOCSTART- -2653041- O O

Treatments NNS N
of IN N
preterm JJ p
premature JJ p
rupture NN p
of IN p
the DT p
membranes NNS p
: : p
a DT N
meta-analysis NN N
. . N

The DT N
objective NN N
of IN N
this DT N
overview NN N
was VBD N
to TO N
critically RB N
evaluate VB N
published VBN N
randomized JJ N
controlled VBN N
trials NNS N
on IN N
treatments NNS N
in IN N
preterm JJ p
premature JJ p
rupture NN p
of IN p
the DT p
membranes NNS p
. . p

The DT N
Oxford NNP N
data NN N
base NN N
on IN N
perinatal JJ N
trials NNS N
, , N
MEDLINE NNP N
, , N
Excerpta NNP N
Medica NNP N
, , N
and CC N
Index NNP N
Medicus NNP N
were VBD N
searched VBN N
. . N

Through IN N
primary JJ N
and CC N
secondary JJ N
review NN N
with IN N
preset JJ N
inclusion NN N
criteria NNS N
, , N
two CD N
independent JJ N
judges NNS N
identified VBD N
27 CD p
randomized VBN p
controlled VBN p
trials NNS p
, , p
of IN p
which WDT p
13 CD p
met VBD p
inclusion NN p
criteria NNS p
. . p

The DT N
quality NN N
of IN N
these DT N
randomized VBN N
controlled VBD N
trials NNS N
was VBD N
scored VBN N
. . N

Five CD p
randomized VBN p
controlled VBN N
trials NNS N
regarding VBG N
antenatal JJ N
use NN N
of IN N
corticosteroids NNS i
to TO N
prevent VB N
respiratory JJ o
distress JJ o
syndrome NN o
could MD N
be VB N
combined VBN N
meta-analytically RB N
and CC N
showed VBD N
a DT N
reduction NN N
in IN N
respiratory NN o
distress NN o
syndrome NN o
in IN N
the DT N
treatment NN N
group NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
no DT N
significant JJ N
reduction NN N
in IN N
respiratory NN o
distress NN o
syndrome NN o
( ( N
p JJ N
= NNP N
0.286 CD N
) ) N
was VBD N
found VBN N
after IN N
one CD N
study NN N
, , N
with IN N
the DT N
lowest JJS N
quality NN N
score NN N
, , N
was VBD N
excluded VBN N
. . N

A DT N
significant JJ N
increase NN N
in IN N
endometritis NN o
and CC N
a DT N
trend NN N
toward IN N
an DT N
increase NN N
in IN N
neonatal JJ o
infections NNS o
and CC o
cesarean JJ o
section NN o
rates NNS o
were VBD N
noted VBN N
with IN N
treatment NN N
. . N

Tocolysis NN i
, , i
prophylactic JJ i
antibiotics NNS i
, , N
and CC N
other JJ N
interventions NNS N
studied VBN N
were VBD N
not RB N
found VBN N
to TO N
be VB N
of IN N
proved JJ N
benefit NN N
and CC N
therefore RB N
should MD N
not RB N
be VB N
used VBN N
outside IN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -3741313- O O

High JJ p
general JJ p
anger NN o
: : o
correlates NNS i
and CC N
treatment NN i
. . i

-DOCSTART- -19716589- O O

Treatment NN N
of IN N
sperm NN N
with IN N
platelet-activating JJ i
factor NN i
does VBZ N
not RB N
improve VB N
intrauterine JJ i
insemination NN i
outcome NN N
in IN N
unselected JJ N
cases NNS N
of IN N
mild JJ p
male JJ p
factor NN p
infertility NN p
: : p
a DT N
prospective JJ N
double-blind NN N
randomized VBN N
crossover NN N
study NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
effect NN o
of IN N
sperm JJ N
treatment NN N
with IN N
exogenous JJ i
platelet-activating JJ i
factor NN i
( ( i
PAF NNP i
) ) i
on IN N
intrauterine JJ i
insemination NN i
( ( i
IUI NNP i
) ) i
clinical JJ N
pregnancy NN N
rate NN N
in IN N
cases NNS N
of IN N
mild JJ p
male JJ p
factor NN p
infertility NN p
. . p

PAF NNP N
is VBZ N
a DT N
phospholipid JJ N
mediator NN N
, , N
which WDT N
is VBZ N
present JJ N
in IN N
human JJ N
sperm NN N
. . N

METHODS NNP N
The DT p
study NN p
was VBD p
performed VBN p
in IN p
the DT p
Assisted NNP p
Reproduction NNP p
Unit NNP p
of IN p
the DT p
2nd CD p
Department NNP p
of IN p
Obstetrics NNP p
and CC p
Gynecology NNP p
, , p
University NNP p
of IN p
Athens NNP p
, , p
Aretaieion NNP p
Hospital NNP p
, , p
Athens NNP p
, , p
Greece NNP p
, , p
and CC p
included VBD p
92 CD p
couples NNS p
who WP p
presented VBD p
with IN p
mild JJ p
male JJ p
factor NN p
infertility-all JJ p
candidates NNS p
for IN p
IUI NNP p
. . p

A NNP N
maximum NN N
of IN N
4 CD N
IUI NNP i
cycles NNS N
per IN N
couple NN N
with IN i
or CC i
without IN i
exogenous JJ i
PAF NNP i
treatment NN i
were VBD N
performed VBN N
and CC N
the DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
clinical JJ o
pregnancy NN o
rate NN o
( ( N
pregnancies NNS N
confirmed VBN N
by IN N
ultrasonography NN N
per IN N
100 CD N
cycles NNS N
) ) N
. . N

RESULTS VB N
The DT N
overall JJ o
clinical JJ o
pregnancy NN o
rate NN o
after IN N
a DT N
maximum NN N
of IN N
4 CD N
IUI NNP i
cycles NNS N
was VBD N
comparable JJ N
in IN N
cases NNS N
with IN N
and CC N
without IN N
sperm JJ i
treatment NN i
with IN i
PAF NNP i
( ( N
12.24 CD N
% NN N
vs JJ N
11.11 CD N
% NN N
) ) N
. . N

Addition NN N
or CC N
exclusion NN N
of IN N
PAF NNP i
sperm FW i
treatment NN i
in IN N
the DT N
same JJ N
patients NNS N
did VBD o
not RB o
significantly RB o
alter VB o
the DT o
outcome NN o
. . o

CONCLUSIONS VB N
The DT N
generalized JJ N
use NN N
of IN N
exogenous JJ i
PAF NNP i
for IN N
the DT N
preparation NN N
of IN N
sperm NN N
in IN N
unselected JJ N
cases NNS N
of IN N
mild JJ p
male JJ p
infertility NN p
does VBZ N
not RB N
improve VB N
the DT N
clinical JJ N
outcome NN N
of IN N
IUI NNP N
. . N

-DOCSTART- -18318721- O O

Split-face NNP N
comparison NN N
of IN N
the DT N
erbium NN i
micropeel NN i
with IN i
intense JJ i
pulsed JJ i
light NN i
. . i

BACKGROUND VB N
A DT N
variety NN N
of IN N
photorejuvenative JJ N
techniques NNS N
have VBP N
been VBN N
utilized VBN N
to TO N
reverse VB N
the DT N
signs NNS N
of IN N
cutaneous JJ N
photoaging NN N
, , N
including VBG N
ablative JJ N
and CC N
nonablative JJ N
laser NN N
resurfacing NN N
as RB N
well RB N
as IN N
light-based JJ N
devices NNS N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
split-face JJ N
randomized JJ N
prospective JJ N
open-label JJ N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
sequential JJ i
erbium NN i
: : i
yttrium-aluminum-garnet NN i
( ( i
Er NNP i
: : i
YAG NN i
) ) i
laser NN i
versus NN i
intense JJ i
pulsed VBN i
light NN i
( ( i
IPL NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
mild NN p
to TO p
moderate VB p
facial JJ p
photodamage NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Ten NNP p
subjects VBZ p
( ( p
ages IN p
35-63 NNP p
) ) p
with IN p
facial JJ p
dyschromia NN p
and CC p
rhytides NNS p
were VBD N
enrolled VBN N
. . N

Study NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
two CD N
treatment NN N
arms NNS N
, , N
Er NN i
: : i
YAG NNP i
( ( N
3.8 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
, , N
30 CD N
% NN N
pattern JJ i
overlap NN i
, , N
0 CD N
% NN N
interpulse JJ i
overlap NN i
, , N
15 CD N
microm NN N
per IN N
pass NN N
with IN N
no DT N
coagulation NN N
) ) N
and CC N
IPL NNP i
( ( N
560-nm JJ N
filter NN N
, , N
30 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
, , N
2.4/4.0-ms JJ N
pulse NN N
with IN N
10-ms JJ N
delay NN N
) ) N
, , N
each DT N
receiving VBG N
three CD N
sequential JJ N
treatments NNS N
spaced VBD N
1 CD N
month NN N
apart RB N
. . N

Subjective JJ N
and CC N
blinded VBD N
physician JJ N
evaluations NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
4 CD N
, , N
8 CD N
, , N
and CC N
20 CD N
weeks NNS N
posttreatment NN N
using VBG N
a DT N
nominal JJ N
scale NN N
from IN N
1 CD N
to TO N
4 CD N
. . N

Erythema NN N
and CC N
adverse JJ N
events NNS N
were VBD N
assessed VBN N
1 CD N
week NN N
following VBG N
each DT N
treatment NN N
. . N

RESULTS NNP N
Ten NNP p
female JJ p
subjects NNS p
with IN p
mild NN p
to TO p
moderate VB p
facial JJ p
photodamage NN p
were VBD N
treated VBN N
with IN N
one CD N
pass NN N
of IN N
either DT N
IPL NNP N
or CC N
Er NNP N
: : N
YAG NN N
in IN N
a DT N
split-face JJ N
fashion NN N
. . N

Patients NNS N
received VBD N
three CD N
treatments NNS N
each DT N
spaced VBD N
1 CD N
month NN N
apart RB N
. . N

Nine NNP p
of IN p
10 CD p
patients NNS p
completed VBD p
the DT p
trial NN p
; : p
1 CD N
withdrew VBD N
due JJ N
to TO N
pain VB o
during IN N
the DT N
second JJ N
Er NNP N
: : N
YAG PRP$ N
treatment NN N
. . N

Baseline NNP N
subjective JJ N
and CC N
blinded VBD o
physician JJ o
dyschromia NN o
and CC o
rhytid NN o
scores NNS o
revealed VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
IPL NNP N
and CC N
Er NNP N
: : N
YAG NNP N
randomly RB N
assigned VBD N
sides NNS N
. . N

Up IN N
to TO N
three CD N
IPL NNP N
or CC N
Er NNP N
: : N
YAG NN N
treatments NNS N
did VBD N
not RB N
result VB N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
rhytid NN N
scores NNS N
. . N

Subjective NNP o
and CC o
blinded VBD o
physician JJ o
dyschromia NN o
scores NNS o
improved VBD o
26 CD N
and CC N
38 CD N
% NN N
, , N
respectively RB N
, , N
3 CD N
months NNS N
after IN N
the DT N
final JJ N
IPL NNP N
treatment NN N
, , N
but CC N
only RB N
by IN N
7 CD N
and CC N
29 CD N
% NN N
, , N
respectively RB N
, , N
with IN N
Er NNP N
: : N
YAG NN N
. . N

Subjective JJ o
global JJ o
facial JJ o
appearance NN o
scores NNS o
worsened VBN N
by IN N
5 CD N
% NN N
while IN N
blinded JJ N
physician JJ N
scores NNS N
improved VBN N
by IN N
16 CD N
% NN N
3 CD N
months NNS N
after IN N
3 CD N
Er NN N
: : N
YAG NN N
treatments NNS N
, , N
but CC N
by IN N
28 CD N
and CC N
20 CD N
% NN N
for IN N
IPL NNP N
, , N
respectively RB N
. . N

The DT N
overall JJ o
incidence NN o
of IN o
adverse JJ o
events NNS o
and CC o
subsequent JJ o
downtime NN o
was VBD N
increased VBN N
for IN N
Er NN N
: : N
YAG NNP N
( ( N
1/10 CD N
patients NNS N
experienced JJ N
hyperpigmentation NN o
, , N
3/10 CD N
exfoliation NN o
, , N
1/10 CD N
blistering NN o
, , N
and CC N
5/10 CD N
discomfort NN o
) ) o
compared VBN N
to TO N
IPL NNP N
( ( N
1/10 CD N
exfoliation NN N
and CC N
1/10 CD N
discomfort NN N
) ) N
, , N
although IN N
no DT N
permanent JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
with IN N
either DT N
treatment NN N
arm NN N
. . N

CONCLUSIONS NNP N
While IN N
low-fluence JJ N
erbium NN N
resurfacing NN N
has VBZ N
a DT N
modest JJ N
effect NN N
on IN N
facial JJ p
photodamage NN p
, , N
patients NNS N
preferred VBD N
IPL NNP N
because IN N
it PRP N
resulted VBD N
in IN N
less JJR N
downtime NN N
. . N

The DT N
authors NNS N
have VBP N
indicated VBN N
no DT N
significant JJ N
interest NN N
with IN N
commercial JJ N
supporters NNS N
. . N

-DOCSTART- -9690103- O O

Impact NN N
of IN N
work NN i
site NN i
health NN i
promotion NN i
on IN N
stages NNS p
of IN p
dietary JJ p
change NN p
: : p
the DT N
Working NNP N
Well NNP N
Trial NNP N
. . N

The DT N
stages NNS N
of IN N
change NN N
construct NN N
has VBZ N
been VBN N
applied VBN N
to TO N
healthful VB N
dietary JJ N
behavior NN N
in IN N
cross-sectional JJ N
studies NNS N
. . N

This DT N
report NN N
examines VBZ N
associations NNS N
of IN N
stages NNS N
of IN N
change NN N
with IN N
diet JJ N
prospectively RB N
and CC N
addresses VBZ N
whether IN N
( ( N
1 CD N
) ) N
baseline NN N
stage NN N
of IN N
change NN N
predicts NNS N
participation NN N
, , N
( ( N
2 CD N
) ) N
forward NN N
changes NNS N
in IN N
stage NN N
movement NN N
were VBD N
greater JJR N
in IN N
treatment NN N
work NN N
sites NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
change NN N
in IN N
stage NN N
was VBD N
associated VBN N
with IN N
adoption NN N
of IN N
healthful JJ N
diets NNS N
, , N
using VBG N
data NNS N
from IN N
a DT p
cohort NN p
of IN p
11,237 CD p
employees NNS p
. . p

Findings NNS N
indicate VBP N
that IN N
persons NNS p
in IN p
later JJ p
stages NNS p
of IN p
change NN p
reported VBD N
higher JJR N
participation NN N
levels NNS N
. . N

Employees NNS p
from IN p
intervention NN p
work NN p
sites NNS p
who WP p
were VBD p
in IN p
preaction NN p
stages NNS p
at IN p
baseline NN p
were VBD N
much RB N
more RBR N
likely JJ N
to TO N
shift VB N
into IN N
action NN N
and CC N
maintenance NN N
stages NNS N
than IN N
controls NNS p
. . p

Changes NNS N
in IN N
dietary JJ N
stage NN N
of IN N
change NN N
were VBD N
associated VBN N
with IN N
decreases NNS o
in IN o
fat JJ o
intake NN o
and CC o
increases NNS o
in IN o
fiber NN o
, , o
fruit NN o
and CC o
vegetable JJ o
intake NN o
. . o

Net JJ o
change NN o
in IN N
diet JJ N
due JJ N
to TO N
the DT N
intervention NN N
was VBD N
modest JJ N
. . N

Stage NN N
of IN N
change NN N
appears VBZ N
to TO N
be VB N
useful JJ N
for IN N
understanding VBG N
mediators NNS N
of IN N
health NN N
promotion NN N
intervention NN N
effectiveness NN N
. . N

-DOCSTART- -25851025- O O

A DT N
Randomized NNP N
Double NNP N
Blind NNP N
Clinical NNP N
Trial NNP N
on IN N
a DT N
Sabgh NNP i
Formulation NNP i
for IN N
Patients NNPS p
With IN p
Vitiligo NNP p
. . p

BACKGROUND NNP N
The DT N
cosmetic JJ N
problem NN N
that WDT N
vitiligo VBZ i
produces VBZ N
affects NNS p
patients NNS p
psychologically RB p
. . p

Many JJ N
patients NNS p
with IN p
vitiligo NNS p
are VBP N
suggested VBN N
to TO N
cover VB N
their PRP$ N
white JJ N
skin NN N
patches NNS N
with IN N
cosmetic JJ N
products NNS N
. . N

There EX N
are VBP N
formulations NNS N
in IN N
traditional JJ N
Iranian JJ N
pharmacy NN N
to TO N
color VB N
these DT N
white JJ N
skin NN N
patches NNS N
. . N

In IN N
this DT N
study NN N
, , N
one CD N
of IN N
these DT N
formulations NNS i
was VBD N
compared VBN N
with IN N
a DT N
cosmetic JJ i
formulation NN i
. . i

METHODS NNP N
Two CD p
groups NNS p
of IN p
patients NNS p
were VBD p
selected VBN p
. . p

One CD N
group NN N
used VBD N
a DT N
marketed JJ i
formulation NN i
and CC N
other JJ N
group NN N
used VBD N
a DT N
traditional JJ i
Iranian JJ i
Pharmacy NNP i
formulation NN i
. . i

The DT N
quality NN o
of IN o
life NN o
of IN N
the DT N
patients NNS N
was VBD N
compared VBN N
based VBN N
on IN N
the DT N
Dermatology NNP N
Life NNP N
Quality NNP N
Index NNP N
Questionnaire NNP N
. . N

RESULTS NNP N
Both NNP N
interventions NNS N
were VBD N
associated VBN N
with IN N
statistically RB N
improved VBN N
Dermatology NNP o
Life NNP o
Quality NNP o
Index NNP o
scores VBZ o
over IN N
the DT N
8-week JJ N
intervention NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
although IN N
the DT N
difference NN N
between IN N
the DT N
2 CD N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.436 NNP N
) ) N
. . N

CONCLUSION NNP N
Traditional NNP i
Iranian JJ i
Pharmacy NNP i
formulation NN N
is VBZ N
effective JJ N
in IN N
increasing VBG N
the DT N
quality NN o
of IN o
life NN o
in IN N
vitiligo JJ N
patients NNS N
. . N

-DOCSTART- -15800226- O O

Comparison NNP N
of IN N
warfarin NN i
and CC N
aspirin NN i
for IN N
symptomatic JJ N
intracranial JJ N
arterial JJ N
stenosis NN N
. . N

BACKGROUND NNP N
Atherosclerotic NNP N
intracranial JJ N
arterial JJ N
stenosis NN N
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
stroke NN N
. . N

Warfarin NNP N
is VBZ N
commonly RB N
used VBN N
in IN N
preference NN N
to TO N
aspirin VB N
for IN N
this DT N
disorder NN N
, , N
but CC N
these DT N
therapies NNS N
have VBP N
not RB N
been VBN N
compared VBN N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBN N
patients NNS p
with IN p
transient JJ p
ischemic JJ p
attack NN p
or CC p
stroke NN p
caused VBN p
by IN p
angiographically RB p
verified VBN p
50 CD p
to TO p
99 CD p
percent NN p
stenosis NN p
of IN p
a DT p
major JJ p
intracranial JJ p
artery NN p
to TO N
receive VB i
warfarin NN i
( ( i
target VB i
international JJ i
normalized JJ i
ratio NN i
, , i
2.0 CD i
to TO i
3.0 CD i
) ) i
or CC i
aspirin NN i
( ( i
1300 CD i
mg NN i
per IN i
day NN i
) ) i
in IN i
a DT i
double-blind NN i
, , i
multicenter RB i
clinical JJ i
trial NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
ischemic JJ o
stroke NN o
, , o
brain NN o
hemorrhage NN o
, , o
or CC o
death NN o
from IN N
vascular JJ N
causes NNS N
other JJ N
than IN N
stroke NN o
. . o

RESULTS NNP N
After IN p
569 CD p
patients NNS p
had VBD p
undergone JJ p
randomization NN p
, , p
enrollment NN p
was VBD p
stopped VBN p
because IN p
of IN p
concerns NNS p
about IN p
the DT p
safety NN p
of IN p
the DT p
patients NNS p
who WP p
had VBD p
been VBN p
assigned VBN p
to TO p
receive VB p
warfarin NN i
. . i

During IN N
a DT N
mean JJ N
follow-up JJ N
period NN N
of IN N
1.8 CD N
years NNS N
, , N
adverse JJ o
events NNS o
in IN N
the DT N
two CD N
groups NNS N
included VBD N
death NN o
( ( N
4.3 CD N
percent NN N
in IN N
the DT N
aspirin NN i
group NN N
vs. FW N
9.7 CD N
percent NN N
in IN N
the DT N
warfarin NN N
group NN N
; : N
hazard CC N
ratio NN N
for IN N
aspirin JJ i
relative JJ N
to TO N
warfarin VB i
, , N
0.46 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.23 CD N
to TO N
0.90 CD N
; : N
P=0.02 NNP N
) ) N
, , N
major JJ o
hemorrhage NN o
( ( N
3.2 CD N
percent NN N
vs. FW N
8.3 CD N
percent NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
, , N
0.39 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.18 CD N
to TO N
0.84 CD N
; : N
P=0.01 NNP N
) ) N
, , N
and CC N
myocardial JJ o
infarction NN o
or CC o
sudden JJ o
death NN o
( ( N
2.9 CD N
percent NN N
vs. FW N
7.3 CD N
percent NN N
, , N
respectively RB N
; : N
hazard NN N
ratio NN N
, , N
0.40 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.18 CD N
to TO N
0.91 CD N
; : N
P=0.02 NNP N
) ) N
. . N

The DT N
rate NN o
of IN o
death NN o
from IN N
vascular JJ N
causes NNS N
was VBD N
3.2 CD N
percent NN N
in IN N
the DT N
aspirin NN N
group NN N
and CC N
5.9 CD N
percent NN N
in IN N
the DT N
warfarin NN N
group NN N
( ( N
P=0.16 NNP N
) ) N
; : N
the DT N
rate NN o
of IN o
death NN o
from IN N
nonvascular JJ N
causes NNS N
was VBD N
1.1 CD N
percent NN N
and CC N
3.8 CD N
percent NN N
, , N
respectively RB N
( ( N
P=0.05 NNP N
) ) N
. . N

The DT N
primary JJ N
end NN N
point NN N
occurred VBD N
in IN N
22.1 CD N
percent NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
aspirin NN N
group NN N
and CC N
21.8 CD N
percent NN N
of IN N
those DT N
in IN N
the DT N
warfarin NN N
group NN N
( ( N
hazard JJ N
ratio NN N
, , N
1.04 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.73 CD N
to TO N
1.48 CD N
; : N
P=0.83 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Warfarin NNP i
was VBD N
associated VBN N
with IN N
significantly RB N
higher JJR N
rates NNS N
of IN N
adverse JJ N
events NNS N
and CC N
provided VBD N
no DT N
benefit NN N
over IN N
aspirin NN N
in IN N
this DT N
trial NN N
. . N

Aspirin NNP i
should MD N
be VB N
used VBN N
in IN N
preference NN N
to TO N
warfarin VB N
for IN N
patients NNS p
with IN p
intracranial JJ p
arterial JJ p
stenosis NN p
. . p

-DOCSTART- -24309381- O O

An DT N
intervention NN N
to TO N
decrease VB N
stigma NN o
in IN N
young JJ p
adults NNS p
with IN p
sickle NN p
cell NN p
disease NN p
. . p

Young NNP p
adults NNS p
with IN p
sickle NN p
cell NN p
disease NN p
( ( p
SCD NNP p
) ) p
are VBP N
often RB N
stigmatized VBN N
when WRB N
they PRP N
seek VBP N
care NN N
for IN N
pain NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
an DT N
intervention NN N
to TO N
decrease VB N
health-related JJ o
stigma NN o
during IN N
care-seeking NN N
. . N

Young NNP p
adults NNS p
with IN p
SCD NNP p
ages VBZ p
18 CD p
to TO p
35 CD p
years NNS p
( ( p
n JJ p
= NNP p
90 CD p
) ) p
were VBD N
randomized VBN N
to TO N
either VB i
the DT i
care-seeking JJ i
intervention NN i
( ( i
CSI NNP i
) ) i
or CC i
an DT i
attention NN i
control NN i
group NN i
that WDT i
participated VBD i
in IN i
life NN i
review NN i
interviews NNS i
. . i

The DT N
two CD N
groups NNS N
were VBD N
compared VBN N
by IN N
t NN N
tests NNS N
and CC N
longitudinal JJ N
data NNS N
analyses NNS N
on IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
the DT N
last JJ N
time NN N
point NN N
in IN N
total JJ o
health-related JJ o
stigma NN o
and CC N
health-related JJ o
stigma NN o
by IN o
doctors NNS o
. . o

Findings NNS N
suggest VBP N
that IN N
the DT N
CSI NNP i
was VBD N
associated VBN N
with IN N
significant JJ N
increased JJ N
awareness NN o
of IN o
perceived JJ o
total JJ o
stigma NN o
and CC N
stigma NN o
by IN o
doctors NNS o
compared VBN N
with IN N
the DT N
attention NN N
control NN N
group NN N
. . N

These DT N
findings NNS N
are VBP N
promising VBG N
in IN N
terms NNS N
of IN N
lessons NNS N
learned VBN N
from IN N
a DT N
pilot NN N
intervention NN N
that WDT N
focused VBD N
on IN N
the DT N
role NN N
communication NN N
skills NNS N
play VBP N
in IN N
decreasing VBG N
health-related JJ N
stigma NN N
in IN N
young JJ p
adults NNS p
with IN p
SCD NNP p
. . p

-DOCSTART- -10860330- O O

A DT N
laser-powered JJ i
hydrokinetic JJ i
system NN i
for IN N
caries NNS N
removal NN N
and CC N
cavity NN N
preparation NN N
. . N

BACKGROUND NNP N
Laser NNP i
systems NNS i
have VBP N
been VBN N
developed VBN N
for IN N
the DT N
cutting NN N
of IN N
dental JJ N
hard JJ N
tissues NNS N
. . N

The DT N
erbium NN N
, , N
chromium NN N
: : N
yttrium-scandium-gallium-garnet NN N
, , N
or CC N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NN i
, , i
laser NN i
system NN i
used VBN N
in IN N
conjunction NN N
with IN N
an DT N
air-water NN N
spray NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
efficacious JJ N
in IN N
vitro NN N
for IN N
cavity NN N
preparation NN N
. . N

METHODS NNP N
The DT N
authors NNS N
randomly RB p
selected VBN p
subjects NNS p
for IN p
cavity NN p
preparation NN p
with IN p
conventional JJ i
air NN i
turbine/bur IN i
dental JJ i
surgery NN i
or CC i
an DT i
Er NNP i
, , i
Cr NNP i
: : i
YSGG PRP$ i
laser-powered JJ i
system NN i
using VBG p
a DT p
split-mouth JJ p
design NN p
. . p

They PRP N
prepared VBD N
Class NNP N
I PRP N
, , N
III NNP N
and CC N
V NNP N
cavities NNS N
, , N
placed VBD N
resin NN i
restorations NNS i
and CC N
evaluated JJ N
subjects NNS N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
and CC N
30 CD N
days NNS N
and CC N
six CD N
months NNS N
postoperatively RB N
for IN N
pulp NN o
vitality NN o
, , o
recurrent NN o
caries NNS o
, , o
pain NN o
and CC o
discomfort NN o
, , o
and CC o
restoration NN o
retention NN o
. . o

Sixty-seven JJ p
subjects NNS p
completed VBD p
the DT p
study NN p
. . p

RESULTS CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
the DT N
parameters NNS N
measured VBD N
with IN N
one CD N
exception NN N
; : N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
discomfort NN o
levels NNS o
for IN o
the DT o
laser NN o
system NN o
at IN N
the DT N
time NN N
of IN N
cavity NN N
preparation NN N
for IN N
subjects NNS N
who WP N
declined VBD N
to TO N
receive VB N
local JJ N
anesthetic NN N
. . N

CONCLUSIONS VB N
The DT N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NNP i
laser NN i
system NN i
is VBZ N
effective JJ N
for IN N
preparation NN N
of IN N
Class NNP N
I PRP N
, , N
III NNP N
and CC N
V NNP N
cavities NNS N
and CC N
resin NN N
restorations NNS N
are VBP N
retained VBN N
by IN N
lased JJ N
tooth NN N
surfaces NNS N
. . N

CLINICAL JJ N
IMPLICATIONS NNP N
Hard-tissue NNP N
cutting VBG N
lasers NNS N
are VBP N
being VBG N
introduced VBN N
for IN N
use NN N
in IN N
operative JJ N
dentistry NN N
. . N

In IN N
this DT N
study NN N
, , N
an DT N
Er NNP i
, , i
Cr NNP i
: : i
YSGG NNP i
laser NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
cavity NN N
preparation NN N
and CC N
restoration NN N
replacement NN N
. . N

-DOCSTART- -3134815- O O

The DT N
therapeutic JJ o
efficacy NN o
and CC o
cost-effectiveness NN o
of IN N
aggressive JJ N
tocolysis NN N
for IN N
premature JJ p
labor NN p
associated VBN p
with IN p
premature JJ p
rupture NN p
of IN p
the DT p
membranes NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
comparing VBG N
bed VBD i
rest NN i
with IN i
tocolysis NN i
to TO N
determine VB N
the DT N
therapeutic JJ o
efficacy NN o
, , o
safety NN o
, , o
and CC o
cost-effectiveness NN o
of IN N
tocolysis NN i
for IN N
the DT N
treatment NN N
of IN N
preterm JJ p
labor NN p
after IN p
membrane JJ p
rupture NN p
. . p

One CD p
hundred VBD p
nine CD p
women NNS p
participated VBD p
over IN p
a DT p
26-month JJ p
interval NN p
. . p

Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
gestational JJ o
age NN o
at IN o
membrane NN o
rupture NN o
, , o
gestational JJ o
age NN o
at IN o
delivery NN o
, , o
birth NN o
weight NN o
, , o
maternal JJ o
or CC o
fetal JJ o
infectious JJ o
morbidity NN o
, , o
respiratory JJ o
distress NN o
syndrome NN o
, , o
necrotizing VBG o
enterocolitis NN o
, , o
or CC o
perinatal JJ o
mortality NN o
. . o

Prolongation NN N
of IN N
intrauterine JJ N
time NN N
after IN N
the DT N
onset NN N
of IN N
uterine JJ N
contractions NNS N
was VBD N
seen VBN N
in IN N
women NNS N
receiving VBG N
tocolysis NN i
( ( N
105.2 CD N
+/- JJ N
157 CD N
hours NNS N
versus JJ N
62.1 CD N
+/- JJ N
77 CD N
hours NNS N
, , N
p VBP N
= RB N
0.06 CD N
) ) N
. . N

This DT N
prolongation NN N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
total JJ o
cost NN o
per IN N
surviving VBG N
infant NN N
( ( N
tocolysis NN N
, , N
$ $ N
38,593 CD N
+/- JJ N
$ $ N
40,887 CD N
versus NN N
bed NN N
rest NN N
, , N
$ $ N
43,158 CD N
+/- JJ N
$ $ N
37,116 CD N
; : N
p NN N
= VBZ N
0.445 CD N
) ) N
. . N

The DT N
cost NN o
difference NN o
was VBD N
artifactual JJ N
. . N

The DT N
number NN N
of IN N
very RB o
premature JJ o
infants NNS o
born VBN o
( ( N
less JJR N
than IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
) ) N
was VBD N
unequal JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
12 CD N
in IN N
the DT N
bed NN N
rest NN N
group NN N
and CC N
5 CD N
in IN N
the DT N
tocolysis NN N
group NN N
) ) N
and CC N
skewed VBD N
the DT N
results NNS N
. . N

Before IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
tocolysis NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN o
in IN o
intrauterine JJ o
time NN o
after IN N
the DT N
onset NN N
of IN N
regular JJ o
contractions NNS o
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
identifiable JJ N
perinatal JJ N
benefit NN N
garnered VBD N
from IN N
the DT N
additional JJ N
5 CD N
days NNS N
. . N

After IN N
28 CD N
weeks NNS N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
in IN N
terms NNS N
of IN N
intrauterine NN o
time NN o
after IN N
the DT N
onset NN N
of IN N
regular JJ o
contractions NNS o
and CC N
total JJ o
cost NN o
per IN N
surviving VBG N
infant NN N
. . N

Because IN N
tocolysis NN i
does VBZ N
not RB N
improve VB N
perinatal JJ N
outcome NN N
and CC N
can MD N
itself PRP N
be VB N
associated VBN N
with IN N
major JJ N
maternal JJ N
morbidity NN N
, , N
it PRP N
should MD N
be VB N
avoided VBN N
after IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
. . N

Before IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
tocolysis NN i
may MD N
greatly RB N
increase VB N
intrauterine JJ N
time NN N
, , N
but CC N
the DT N
benefit NN N
of IN N
this DT N
prolongation NN N
is VBZ N
not RB N
clear JJ N
. . N

-DOCSTART- -17290062- O O

Effectiveness NN o
of IN N
aromatherapy JJ i
massage NN i
in IN N
the DT N
management NN N
of IN N
anxiety NN o
and CC o
depression NN o
in IN p
patients NNS p
with IN p
cancer NN p
: : p
a DT N
multicenter NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
To TO N
test VB N
the DT N
effectiveness NN o
of IN N
supplementing VBG N
usual JJ N
supportive JJ N
care NN N
with IN N
aromatherapy JJ i
massage NN i
in IN N
the DT N
management NN N
of IN N
anxiety NN p
and CC p
depression NN p
in IN p
cancer NN p
patients NNS p
through IN N
a DT N
pragmatic JJ N
two-arm NN N
randomized VBD N
controlled JJ N
trial NN N
in IN N
four CD N
United NNP p
Kingdom NNP p
cancer NN N
centers NNS N
and CC N
a DT N
hospice NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Two CD p
hundred VBD p
eighty-eight JJ p
cancer NN p
patients NNS p
, , p
referred VBD p
to TO p
complementary JJ p
therapy NN p
services NNS p
with IN p
clinical JJ p
anxiety NN p
and/or NN p
depression NN p
, , N
were VBD N
allocated VBN N
randomly RB N
to TO N
a DT N
course NN N
of IN N
aromatherapy JJ i
massage NN i
or CC i
usual JJ i
supportive JJ i
care NN i
alone RB i
. . i

RESULTS JJ N
Patients NNPS N
who WP N
received VBD N
aromatherapy JJ i
massage NN i
had VBD N
no DT N
significant JJ N
improvement NN N
in IN N
clinical JJ o
anxiety NN o
and/or NN o
depression NN o
compared VBN N
with IN N
those DT N
receiving VBG N
usual JJ N
care NN N
at IN N
10 CD N
weeks NNS N
postrandomization NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.3 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.9 CD N
to TO N
1.7 CD N
; : N
P NNP N
= NNP N
.1 NNP N
) ) N
, , N
but CC N
did VBD N
at IN N
6 CD N
weeks NNS N
postrandomization NN N
( ( N
OR NNP N
, , N
1.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.1 CD N
to TO N
1.9 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Patients NNS N
receiving VBG N
aromatherapy JJ i
massage NN i
also RB N
described VBD N
greater JJR N
improvement NN N
in IN N
self-reported JJ o
anxiety NN o
at IN N
both DT N
6 CD N
and CC N
10 CD N
weeks NNS N
postrandomization NN N
( ( N
OR NNP N
, , N
3.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.2 CD N
to TO N
6.7 CD N
; : N
P NNP N
= NNP N
.04 NNP N
and CC N
OR NNP N
, , N
3.4 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.2 CD N
to TO N
6.6 CD N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Aromatherapy NNP i
massage NN i
does VBZ N
not RB N
appear VB N
to TO N
confer VB N
benefit NN o
on IN N
cancer NN p
patients NNS p
' POS p
anxiety NN o
and/or NN o
depression NN o
in IN N
the DT N
long-term JJ N
, , N
but CC N
is VBZ N
associated VBN N
with IN N
clinically RB N
important JJ N
benefit NN o
up IN N
to TO N
2 CD N
weeks NNS N
after IN N
the DT N
intervention NN N
. . N

-DOCSTART- -15181401- O O

[ JJ N
Cardiac NNP N
protection NN N
is VBZ N
a DT N
clinical JJ N
evidence NN N
] NN N
. . N

AIM NNP N
Anaesthetics NNPS N
may MD N
have VB N
protective JJ N
effect NN N
against IN N
myocardial JJ N
ischemia NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
if IN N
sevoflurane JJ N
administration NN N
could MD N
exert VB N
myocardial JJ o
protection NN o
during IN N
following VBG N
coronary JJ N
occlusion NN N
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

METHODS NNP N
a DT N
) ) N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

b NN N
) ) N
. . N

SETTING NN N
University NNP p
Hospital NNP p
, , p
cardiac JJ p
surgical JJ p
operative NN p
theatre NN p
. . p

c NN N
) ) N
. . N

PATIENTS $ N
42 CD p
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
, , p
scheduled VBN p
to TO p
undergo VB p
coronary JJ p
surgery NN p
. . p

INCLUSION NNP p
CRITERIA NNP p
severe JJ p
coronary JJ p
stenosis NN p
of IN p
anterior JJ p
descending VBG p
coronary JJ p
artery NN p
; : p
no DT p
collateral NN p
flow NN p
on IN p
angiography NN p
; : p
at IN p
least JJS p
two CD p
normokinetic JJ p
segments NNS p
in IN p
the DT p
myocardial JJ p
region NN p
supplied VBN p
by IN p
the DT p
vessel NN p
being VBG p
bypassed VBN p
. . p

PATIENTS NNS N
were VBD N
randomized VBN N
to TO i
receive VB i
( ( i
group NN i
S NNP i
) ) i
or CC i
not RB i
( ( i
group NN i
C NNP i
) ) i
sevoflurane NN i
administration NN N
for IN N
15 CD N
min NN N
just RB N
before RB N
coronary JJ N
occlusion NN N
. . N

d NN N
) ) N
. . N

INTERVENTIONS NNP N
Transoesophageal NNP i
Tissue NNP i
Doppler NNP i
echocardiographic JJ i
examination NN i
of IN i
myocardial JJ i
systolic NN i
and CC i
early JJ i
diastolic NN i
velocities NNS i
in IN i
both DT i
groups NNS i
basally RB i
and CC i
60 CD i
s NN i
after IN i
coronary JJ i
occlusion NN i
by IN i
the DT i
surgeon NN i
. . i

e NN N
) ) N
. . N

MEASURES NNP N
systolic JJ o
and CC o
early JJ o
diastolic JJ o
velocities NNS o
were VBD N
registered VBN N
by IN N
Tissue NNP N
Doppler NNP N
from IN N
a DT N
long-axis JJ N
view NN N
of IN N
the DT N
interventricular JJ N
septum NN N
or CC N
the DT N
anterior JJ N
wall NN N
of IN N
the DT N
left JJ N
ventricle NN N
. . N

RESULTS NNP N
In IN N
group NN N
C NNP N
a DT N
significant JJ N
reduction NN N
of IN N
systolic JJ o
and CC o
diastolic JJ o
intramyocardial JJ o
velocities NNS o
was VBD N
found VBN N
during IN N
myocardial JJ N
ischemia NN N
due JJ N
to TO N
coronary JJ N
occlusion NN N
. . N

CONCLUSION NNP N
Treatment NNP N
with IN N
sevoflurane NN N
before IN N
coronary JJ N
occlusion NN N
seem VBP N
effective JJ N
in IN N
reducing VBG N
functional JJ o
myocardial JJ o
impairment NN o
due JJ N
to TO N
ischemia VB N
. . N

-DOCSTART- -7572690- O O

Reducing VBG N
the DT N
risk NN N
of IN N
coronary JJ N
events NNS N
: : N
evidence NN N
from IN N
the DT N
Scandinavian JJ N
Simvastatin NNP N
Survival NNP N
Study NNP N
( ( N
4S CD N
) ) N
. . N

The DT N
Scandinavian JJ N
Simvastatin NNP N
Survival NNP N
Study NNP N
( ( N
4S CD N
) ) N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
cholesterol NN N
reduction NN N
with IN N
simvastatin NN i
on IN N
mortality NN o
and CC N
morbidity NN o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
. . p

A DT N
total NN p
of IN p
4,444 CD p
patients NNS p
with IN p
angina JJ p
pectoris NN p
or CC p
previous JJ p
myocardial JJ p
infarction NN p
and CC p
serum VB p
cholesterol NN p
levels NNS p
of IN p
213-310 JJ p
mg/dl NN p
( ( p
5.5-8.0 JJ p
mmol/liter NN p
) ) p
while IN p
treated VBN p
with IN p
a DT p
lipid-lowering JJ i
diet NN i
were VBD N
randomly RB N
assigned VBN N
to TO N
double-blind VB N
treatment NN N
with IN N
simvastatin NN i
or CC i
placebo NN i
. . i

Over IN N
the DT N
5.4 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
, , N
simvastatin NN N
produced VBD N
changes NNS N
in IN N
total JJ o
cholesterol NN o
, , o
low JJ o
density NN o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
cholesterol NN o
, , N
and CC N
high JJ o
density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
cholesterol NN o
of IN N
-25 NNP N
% NN N
, , N
-35 CD N
% NN N
, , N
and CC N
+8 NNP N
% NN N
, , N
respectively RB N
, , N
with IN N
minimal JJ N
adverse JJ o
effects NNS o
. . o

A DT N
total NN N
of IN N
256 CD p
patients NNS p
( ( N
12 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
died VBD o
compared VBN N
with IN N
182 CD N
( ( N
8 CD N
% NN N
) ) N
in IN N
the DT N
simvastatin NN N
group NN N
, , N
a DT N
risk NN N
reduction NN N
of IN N
30 CD N
% NN N
( ( N
p JJ N
= NNP N
0.0003 CD N
) ) N
attributable NN N
to TO N
a DT N
42 CD N
% NN N
reduction NN N
in IN N
the DT N
risk NN N
of IN N
coronary JJ N
death NN N
. . N

Noncardiovascular JJ o
causes NNS o
accounted VBD N
for IN N
49 CD N
and CC N
46 CD N
deaths NNS o
in IN N
the DT N
placebo NN N
and CC N
simvastatin NN N
groups NNS N
, , N
respectively RB N
. . N

Major JJ o
coronary JJ o
events NNS o
were VBD N
experienced VBN N
by IN N
622 CD N
patients NNS N
( ( N
28 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
and CC N
431 CD N
patients NNS N
( ( N
19 CD N
% NN N
) ) N
in IN N
the DT N
simvastatin NN N
group NN N
, , N
corresponding VBG N
to TO N
a DT N
risk NN o
reduction NN o
of IN N
34 CD N
% NN N
( ( N
p JJ N
< NNP N
0.00001 CD N
) ) N
. . N

This DT N
risk NN N
was VBD N
also RB N
significantly RB N
reduced VBN N
in IN N
subgroups NNS N
consisting VBG N
of IN N
women NNS p
and CC p
patients NNS p
of IN p
both DT p
sexes NNS p
aged VBN N
> CD N
or CC N
= $ N
60 CD N
years NNS N
. . N

Other JJ N
benefits NNS N
of IN N
treatment NN N
included VBD N
a DT N
37 CD N
% NN N
reduction NN N
( ( N
p JJ N
< NNP N
0.00001 CD N
) ) N
in IN N
the DT N
risk NN o
of IN o
undergoing VBG o
myocardial JJ o
revascularization NN o
procedures NNS o
. . o

Simvastatin NNP N
was VBD N
beneficial JJ N
regardless NN N
of IN N
whether IN N
patients NNS N
had VBD N
a DT N
history NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
whether IN N
they PRP N
were VBD N
smokers NNS N
or CC N
had VBD N
hypertension NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -22721596- O O

A DT N
randomized JJ N
double-blind NN N
study NN N
of IN N
atomoxetine JJ i
versus NN N
placebo NN i
for IN N
attention-deficit/hyperactivity NN p
disorder NN p
symptoms NNS p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

OBJECTIVE CC N
The DT N
efficacy NN N
of IN N
atomoxetine NN i
as IN N
treatment NN N
of IN N
symptoms NNS N
of IN N
attention-deficit/hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
in IN p
patients NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
has VBZ N
not RB N
been VBN N
established VBN N
. . N

METHOD NNP N
In IN N
this DT N
study NN N
, , N
97 CD p
patients NNS p
aged VBD p
6 CD p
to TO p
17 CD p
years NNS p
with IN p
ADHD NNP p
and CC p
ASD NNP p
were VBD p
randomly RB p
assigned VBN p
to TO N
double-blind VB N
treatment NN N
with IN N
1.2 CD N
mg/kg/day JJ N
atomoxetine NN i
or CC i
placebo NN i
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
ADHD NNP o
Rating NNP o
Scale NNP o
( ( o
ADHD-RS NNP o
) ) o
score NN o
; : o
secondary JJ o
endpoints NNS o
were VBD o
the DT o
Clinical JJ o
Global NNP o
Impression NNP o
of IN o
ADHD-Improvement NNP o
( ( o
CGI-I NNP o
) ) o
and CC o
the DT o
Conners NNP o
Teacher NNP o
Rating VBG o
Scale-Revised JJ o
: : o
Short JJ o
Form NNP o
( ( o
CTRS-R JJ o
: : o
S NN o
) ) o
score NN o
. . o

RESULTS NNP N
Baseline NNP N
mean JJ N
ADHD-RS NNP o
scores NNS N
for IN N
atomoxetine JJ i
versus NN N
placebo NN i
were VBD N
40.7 CD N
and CC N
38.6 CD N
; : N
after IN N
8 CD N
weeks NNS N
, , N
mixed-effect JJ N
model NN N
repeated-measure NN N
means NNS N
were VBD N
31.6 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
29.2-33.9 JJ N
) ) N
and CC N
38.3 CD N
( ( N
36.0-40.6 CD N
) ) N
, , N
respectively RB N
, , N
with IN N
a DT N
difference NN N
in IN N
least JJS N
square JJ N
means NNS N
of IN N
-6.7 NNP N
( ( N
-10.0 UH N
to TO N
-3.4 VB N
; : N
p CC N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
CTRS-R JJ o
: : o
S NNP o
Hyperactivity NNP N
subscore NN N
also RB N
improved VBN N
significantly RB N
for IN N
atomoxetine NN i
compared VBN N
with IN N
placebo NN i
, , N
but CC N
not RB N
the DT N
other JJ N
CTRS-R JJ o
: : o
S JJ o
subscores NNS N
. . N

However RB N
, , N
there EX N
were VBD N
not RB N
significantly RB N
more RBR N
patients NNS N
on IN N
atomoxetine NN i
( ( N
20.9 CD N
% NN N
) ) N
who WP N
improved VBD N
much RB N
, , N
or CC N
very RB N
much JJ N
according VBG N
to TO N
the DT N
CGI-I NNP N
, , N
than IN N
on IN N
placebo NN i
( ( N
8.7 CD N
% NN N
; : N
p CC N
= VB N
0.14 CD N
) ) N
. . N

Adverse JJ N
events NNS N
( ( N
mostly RB N
nausea RB o
, , N
decrease NN N
in IN N
appetite NN o
, , o
fatigue NN o
, , o
and CC o
early JJ o
morning NN o
awakening VBG o
) ) o
were VBD N
reported VBN N
in IN N
81.3 CD N
% NN N
of IN N
atomoxetine JJ i
patients NNS N
and CC N
65.3 CD N
% NN N
of IN N
placebo NN i
patients NNS N
( ( N
p JJ N
> NNP N
.1 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ o
events NNS o
. . o

CONCLUSIONS NNP N
Atomoxetine NNP i
moderately RB N
improved VBD N
ADHD NNP N
symptoms NNS N
in IN N
patients NNS N
with IN N
ASD NNP N
and CC N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

Adverse JJ N
events NNS N
in IN N
this DT N
study NN N
were VBD N
similar JJ N
to TO N
those DT N
in IN N
other JJ N
studies NNS N
with IN N
ADHD NNP p
patients NNS p
without IN p
ASD NNP p
. . p

Clinical JJ N
trial NN N
registration NN N
information-A JJ N
Randomized NNP N
Double-Blind NNP N
Study NNP N
of IN N
Atomoxetine NNP i
Versus NNP N
Placebo NNP i
for IN N
ADHD NNP N
Symptoms NNP N
in IN N
Children NNP p
with IN p
ASD NNP p
; : p
www.clinicaltrials.gov NN N
; : N
NCT00380692 NNP N
. . N

-DOCSTART- -15829494- O O

Temozolomide NNP i
and CC i
cisplatin VB i
versus NN i
temozolomide NN i
in IN N
patients NNS p
with IN p
advanced JJ p
melanoma NN p
: : p
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
of IN N
the DT N
Hellenic NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
. . N

PURPOSE NNP N
Temozolomide NNP i
( ( i
TMZ NNP i
) ) i
is VBZ N
an DT N
oral JJ N
alkylating NN N
agent NN N
that WDT N
produces VBZ N
methyl JJ N
adducts NNS N
at IN N
the DT N
0.6 CD N
position NN N
of IN N
guanine NN N
. . N

The DT N
methyl NN N
adducts NNS N
are VBP N
removed VBN N
by IN N
the DT N
DNA NNP N
repair NN N
enzyme JJ N
AGAT NNP N
. . N

As IN N
demonstrated VBN N
by IN N
in IN N
vitro NN N
studies NNS N
, , N
cisplatin NN i
( ( i
CDDP NNP i
) ) i
is VBZ N
able JJ N
to TO N
down-regulate VB N
the DT N
AGAT NNP N
activity NN N
, , N
suggesting VBG N
that IN N
CDDP NNP i
could MD N
enhance VB N
the DT N
antitumor NN o
activity NN o
of IN o
TMZ NNP o
. . o

We PRP N
designed VBD N
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
to TO N
evaluate VB N
and CC N
compare VB N
the DT N
activity NN N
and CC N
safety NN N
profile NN N
of IN N
the DT N
combination NN i
versus IN i
single-agent JJ i
TMZ NNP i
in IN N
patients NNS p
with IN p
advanced JJ p
melanoma NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP p
January NNP p
2000 CD p
to TO p
April NNP p
2002 CD p
, , p
132 CD p
patients NNS p
were VBD p
enrolled VBN p
on IN p
the DT p
study NN p
. . p

Patient NNP p
and CC p
tumor NN p
characteristics NNS p
were VBD N
well RB N
balanced VBN N
between IN N
the DT N
two CD N
arms NNS N
. . N

Patients NNS p
with IN p
cerebral JJ p
metastases NNS p
were VBD p
included VBN p
. . p

Patients NNS N
received VBD N
TMZ NNP i
200 CD i
mg/m NN i
( ( i
2 CD i
) ) i
/day NN i
orally RB i
for IN N
five CD N
consecutive JJ N
days NNS N
every DT N
4 CD N
weeks NNS N
or CC N
TMZ NNP i
+ NNP i
CDDP NNP i
200 CD N
mg/m NN N
( ( N
2 CD N
) ) N
daily RB N
on IN N
days NNS N
1-5 CD N
and CC N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
of IN N
CDDP NNP i
on IN N
day NN N
1 CD N
. . N

RESULTS NNP N
Tumor NNP o
responses VBZ o
( ( N
complete JJ N
and CC N
partial JJ N
responses NNS N
) ) N
were VBD N
seen VBN N
in IN N
16 CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
in IN N
arm NN N
A NN N
and CC N
19 CD N
patients NNS N
( ( N
29 CD N
% NN N
) ) N
in IN N
arm NN N
B NNP N
. . N

The DT N
median JJ o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
was VBD N
3.8 CD N
months NNS N
in IN N
arm NN N
A NN N
and CC N
5.8 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

The DT N
median JJ o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
was VBD N
11.5 CD N
months NNS N
in IN N
arm NN N
A NN N
and CC N
12 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

The DT N
difference NN N
between IN N
treatment NN N
arms NNS N
regarding VBG N
objective JJ o
response NN o
rates NNS o
, , o
TTP NNP o
and CC o
OS NNP o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Toxicity NN N
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
arms NNS N
for IN N
anemia NN o
, , o
leukopenia NN o
, , o
neutropenia NN o
, , o
thrombocytopenia NN o
, , o
fatigue NN o
, , o
constipation NN o
and CC o
arthralgias/myalgias NN o
. . o

There EX N
was VBD N
significantly RB N
more JJR N
grade JJ o
3 CD o
and CC o
4 CD o
emesis NN o
in IN N
the DT N
combination NN N
arm NN N
. . N

CONCLUSIONS NNP N
No NNP o
clear JJ o
benefit NN o
in IN N
terms NNS N
of IN N
response NN o
rates NNS o
, , o
median JJ o
TTP NNP o
or CC N
OS NNP N
was VBD N
shown VBN N
with IN N
the DT N
combination NN N
of IN N
TMZ NNP i
+ NNP i
CDDP NNP i
. . i

Additionally RB N
, , N
the DT N
combination NN N
was VBD N
associated VBN N
with IN N
higher JJR N
incidence NN N
of IN N
grade NN o
3 CD o
and CC o
4 CD o
emesis NN o
. . o

-DOCSTART- -20406576- O O

The DT N
ScanBrit NNP N
randomised VBD N
, , N
controlled VBD N
, , N
single-blind JJ N
study NN N
of IN N
a DT N
gluten- JJ i
and CC i
casein-free JJ i
dietary JJ i
intervention NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

There EX N
is VBZ N
increasing VBG N
interest NN N
in IN N
the DT N
use NN N
of IN N
gluten- JJ i
and CC i
casein-free JJ i
diets NNS i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
. . p

We PRP N
report VBP N
results NNS N
from IN N
a DT N
two-stage NN N
, , N
24-month JJ N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
incorporating VBG N
an DT N
adaptive JJ N
'catch-up NN N
' POS N
design NN N
and CC N
interim JJ N
analysis NN N
. . N

Stage NN N
1 CD N
of IN N
the DT N
trial NN N
saw VBD N
72 CD p
Danish JJ p
children NNS p
( ( p
aged VBN p
4 CD p
years NNS p
to TO p
10 CD p
years NNS p
11 CD p
months NNS p
) ) p
assigned VBD p
to TO p
diet VB p
( ( p
A DT p
) ) p
or CC p
non-diet JJ i
( ( p
B NNP p
) ) p
groups NNS p
by IN p
stratified JJ p
randomisation NN p
. . p

Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
( ( o
ADOS NNP o
) ) o
and CC o
the DT o
Gilliam NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
GARS NNP o
) ) o
were VBD o
used VBN o
to TO o
assess VB o
core NN o
autism NN o
behaviours NNS o
, , o
Vineland NNP o
Adaptive NNP o
Behaviour NNP o
Scales NNP o
( ( o
VABS NNP o
) ) o
to TO o
ascertain VB o
developmental JJ o
level NN o
, , N
and CC N
Attention-Deficit NNP o
Hyperactivity NNP o
Disorder NNP o
- : o
IV NNP o
scale NN o
( ( o
ADHD-IV NNP o
) ) o
to TO o
determine VB o
inattention NN o
and CC o
hyperactivity NN o
. . o

Participants NNS N
were VBD N
tested VBN N
at IN N
baseline NN N
, , N
8 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

Based VBN N
on IN N
per IN N
protocol NN N
repeated VBN N
measures NNS N
analysis NN N
, , N
data NNS N
for IN N
26 CD p
diet JJ p
children NNS p
and CC p
29 CD p
controls NNS p
were VBD N
available JJ N
at IN N
12 CD N
months NNS N
. . N

At IN N
this DT N
point NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
to TO N
mean VB N
diet JJ N
group NN N
scores NNS N
( ( N
time*treatment JJ N
interaction NN N
) ) N
on IN N
sub-domains NNS N
of IN N
ADOS NNP o
, , o
GARS NNP o
and CC o
ADHD-IV NNP o
measures NNS o
. . o

Surpassing VBG N
of IN N
predefined JJ N
statistical JJ N
thresholds NNS N
as IN N
evidence NN N
of IN N
improvement NN N
in IN N
group NN N
A NNP N
at IN N
12 CD N
months NNS N
sanctioned VBD N
the DT N
re-assignment NN N
of IN N
group NN N
B NNP N
participants NNS N
to TO N
active JJ N
dietary JJ N
treatment NN N
. . N

Stage NN N
2 CD N
data NNS N
for IN N
18 CD N
group NN N
A NNP N
and CC N
17 CD N
group NN N
B NNP N
participants NNS N
were VBD N
available JJ N
at IN N
24 CD N
months NNS N
. . N

Multiple NNP N
scenario NN N
analysis NN N
based VBN N
on IN N
inter- JJ N
and CC N
intra-group JJ N
comparisons NNS N
showed VBD N
some DT N
evidence NN N
of IN N
sustained JJ N
clinical JJ N
group NN N
improvements NNS N
although IN N
possibly RB N
indicative JJ N
of IN N
a DT N
plateau NN N
effect NN N
for IN N
intervention NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
dietary JJ i
intervention NN i
may MD N
positively RB N
affect VB N
developmental JJ N
outcome NN N
for IN N
some DT N
children NNS p
diagnosed VBN p
with IN p
ASD NNP p
. . p

In IN N
the DT N
absence NN N
of IN N
a DT N
placebo NN i
condition NN N
to TO N
the DT N
current JJ N
investigation NN N
, , N
we PRP N
are VBP N
, , N
however RB N
, , N
unable JJ N
to TO N
disqualify VB N
potential JJ N
effects NNS N
derived VBN N
from IN N
intervention NN N
outside IN N
of IN N
dietary JJ N
changes NNS N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
ascertain VB N
potential JJ N
best- NN N
and CC N
non-responders NNS N
to TO N
intervention NN N
. . N

The DT N
study NN N
was VBD N
registered VBN N
with IN N
ClincialTrials.gov NNP N
, , N
number NN N
NCT00614198 NNP N
. . N

-DOCSTART- -2510260- O O

Rioprostil NNP i
, , N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
, , N
in IN N
the DT N
once-daily JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
duodenal JJ p
ulcer JJ p
recurrence NN N
: : N
a DT N
comparison NN N
with IN N
ranitidine NN N
. . N

The DT N
efficacy NN o
of IN N
Rioprostil NNP i
( ( N
a DT N
new JJ N
prostaglandin NN N
E1 NNP N
analogue NN N
) ) N
is VBZ N
compared VBN N
with IN N
that DT N
of IN N
ranitidine NN i
in IN N
the DT N
recurrence NN N
prevention NN N
of IN N
duodenal JJ N
ulcer NN N
( ( N
s NN N
) ) N
. . N

Duration NN N
of IN N
treatment NN N
is VBZ N
6 CD N
months NNS N
. . N

Ninety-seven JJ p
patients NNS p
received VBD p
rioprostil JJ i
, , i
600 CD i
micrograms NNS i
once-daily RB i
orally RB i
, , i
and CC i
110 CD i
patients NNS i
received JJ i
ranitidine NN i
, , i
150 CD i
mg JJ i
once-daily RB i
orally RB i
. . i

On IN N
rioprostil NN i
, , N
14.9 CD N
% NN N
of IN N
patients NNS N
showed VBD N
a DT N
relapse NN o
after IN N
6 CD N
months NNS N
compared VBN N
to TO N
10.1 CD N
% NN N
on IN N
ranitidine NN i
. . i

Diarrhoea NNP o
occurred VBD N
in IN N
7 CD N
patients NNS N
on IN N
rioprostil NN i
and CC N
3 CD N
patients NNS N
on IN N
ranitidine NN i
. . i

Rioprostil NNP i
given VBN N
600 CD N
micrograms NNS N
daily RB N
in IN N
the DT N
evening NN N
is VBZ N
a DT N
highly RB N
effective JJ N
treatment NN N
for IN N
the DT N
prevention NN N
of IN N
duodenal JJ N
ulcer NN N
relapse NN N
, , N
the DT N
efficacy NN o
not RB N
being VBG N
significantly RB N
different JJ N
from IN N
ranitidine NN i
150 CD N
mg NN N
. . N

-DOCSTART- -19106322- O O

A DT N
randomized JJ N
breast-feeding JJ i
promotion NN i
intervention NN N
did VBD N
not RB N
reduce VB N
child NN N
obesity NN N
in IN N
Belarus NNP p
. . p

The DT N
evidence NN N
that IN N
breast-feeding JJ N
protects NNS N
against IN N
obesity NN N
is VBZ N
based VBN N
on IN N
observational JJ N
studies NNS N
, , N
with IN N
potential JJ N
for IN N
confounding VBG N
and CC N
selection NN N
bias NN N
. . N

This DT N
article NN N
summarizes VBZ N
a DT N
previously RB N
published VBN N
study NN N
in IN N
which WDT N
we PRP N
assessed VBD N
whether IN N
an DT N
intervention NN N
designed VBN N
to TO N
promote VB N
exclusive JJ N
and CC N
prolonged JJ N
breast-feeding NN N
affects VBZ N
children NNS N
's POS N
height NN N
, , N
weight NN N
, , N
adiposity NN N
, , N
and CC N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
at IN N
age NN N
6.5 CD N
y NN N
. . N

The DT p
Promotion NN i
of IN i
Breastfeeding NNP i
Intervention NNP p
Trial NNP p
( ( p
PROBIT NNP p
) ) p
is VBZ p
a DT p
cluster-randomized JJ p
trial NN p
of IN p
a DT p
breast-feeding JJ i
promotion NN i
intervention NN p
based VBN N
on IN N
the DT N
WHO/UNICEF NNP N
Baby-Friendly NNP N
Hospital NNP N
Initiative NNP N
. . N

A NNP N
total NN N
of IN N
17,046 CD p
healthy JJ p
breast-fed JJ p
infants NNS p
were VBD p
enrolled VBN p
from IN p
31 CD p
Belarussian JJ p
maternity NN p
hospitals NNS p
and CC p
affiliated JJ p
clinics NNS p
, , N
of IN N
whom WP N
13,889 CD p
( ( p
81.5 CD p
% NN p
) ) p
were VBD p
followed VBN i
up RP i
at IN i
6.5 CD i
y NN i
with IN i
duplicate JJ i
measurements NNS i
of IN i
height NN i
, , i
weight NN i
, , i
waist JJ i
circumference NN i
, , i
triceps NNS i
and CC i
subscapular JJ i
skinfold NN i
thicknesses NNS i
, , i
systolic JJ i
and CC i
diastolic JJ i
BP NNP i
. . i

Analysis NN N
was VBD N
based VBN N
on IN N
intention NN N
to TO N
treat VB N
, , N
with IN N
statistical JJ N
adjustment NN N
for IN N
clustering VBG N
within IN N
hospitals/clinics NNS N
to TO N
permit VB N
inferences NNS N
at IN N
the DT N
individual JJ N
level NN N
. . N

The DT N
experimental JJ N
intervention NN N
led VBD N
to TO N
a DT N
large JJ N
increase NN N
in IN N
exclusive JJ o
breast-feeding NN o
at IN o
3 CD o
mo NN o
( ( N
43.3 CD N
% NN N
vs. FW N
6.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
significantly RB N
higher JJR N
prevalence NN N
of IN N
any DT N
breast-feeding JJ N
throughout IN N
infancy NN N
. . N

No DT N
significant JJ N
intervention NN N
effects NNS N
were VBD N
observed VBN N
on IN N
height NN o
, , o
BMI NNP o
, , o
adiposity NN o
measures NNS o
, , o
or CC o
BP NNP o
. . o

The DT N
breast-feeding JJ i
promotion NN i
intervention NN i
resulted VBD N
in IN N
substantial JJ N
increases NNS o
in IN o
the DT o
duration NN o
and CC o
exclusivity NN o
of IN o
breast-feeding JJ o
yet RB o
did VBD o
not RB o
reduce VB o
measures NNS o
of IN o
adiposity NN o
at IN N
age NN N
6.5 CD N
y NN N
. . N

Previous JJ N
reports NNS N
of IN N
protective JJ N
effects NNS N
against IN N
obesity NN N
may MD N
reflect VB N
uncontrolled JJ N
bias NN N
caused VBN N
by IN N
confounding VBG N
and CC N
selection NN N
. . N

-DOCSTART- -24887304- O O

Effects NNS N
of IN N
ranolazine NN i
on IN N
quality NN o
of IN o
life NN o
among IN N
patients NNS p
with IN p
diabetes NNS p
mellitus NNS p
and CC p
stable JJ p
angina NN p
. . p

-DOCSTART- -10340153- O O

Gender NNP p
differences NNS p
in IN N
response NN N
to TO N
nicotine VB i
replacement NN i
therapy NN i
: : i
objective JJ N
and CC N
subjective JJ N
indexes NNS N
of IN N
tobacco NN p
withdrawal NN p
. . p

K. NNP N
A. NN N
Perkins NNP N
( ( N
1996 CD N
) ) N
recently RB N
proposed VBD N
that IN N
nicotine JJ i
reinforcement NN i
controls NNS p
smoking VBG p
to TO p
a DT p
greater JJR p
degree NN p
among IN p
men NNS p
than IN p
women NNS p
and CC N
that DT N
consequently RB N
, , N
nicotine JJ i
replacement NN i
therapy NN i
( ( i
NRT NNP i
) ) i
during IN N
smoking VBG N
cessation NN N
should MD N
benefit VB N
men NNS N
more JJR N
than IN N
women NNS N
. . N

The DT N
authors NNS N
tested VBD N
this DT N
hypothesis NN N
. . N

Polysomnographic JJ N
measures NNS N
of IN N
sleep NN o
and CC o
self-report NN o
indexes NNS o
of IN N
tobacco NN N
withdrawal NN N
were VBD N
collected VBN N
pre- JJ N
and CC N
postcessation NN N
from IN N
an DT N
active JJ p
nicotine NN i
patch NN i
group NN p
and CC p
a DT p
placebo NN i
patch NN i
group NN p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
( ( p
N NNP p
= NNP p
34 CD p
) ) p
. . p

Objective JJ N
sleep JJ N
parameters NNS N
supported VBD N
Perkins NNP N
's POS N
hypothesis NN N
and CC N
indicated VBD N
that IN N
among IN N
women NNS N
, , N
NRT NNP i
may MD N
be VB N
less RBR N
effective JJ N
at IN N
suppressing VBG o
certain JJ o
withdrawal NN o
responses NNS o
compared VBN N
with IN N
men NNS N
and CC N
may MD o
produce VB o
some DT o
iatrogenic JJ o
effects NNS o
. . o

Valid NNP N
and CC N
reliable JJ N
self-report JJ N
measures NNS N
of IN N
withdrawal NN o
did VBD o
not RB o
reveal VB o
gender NN o
differences NNS o
in IN o
response NN o
to TO o
NRT NNP o
. . o

-DOCSTART- -22160347- O O

The DT N
home NN i
TEACCHing NNP i
program NN i
for IN N
toddlers NNS p
with IN p
autism NN p
. . p

The DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
a DT N
parent NN i
training NN i
intervention NN i
for IN N
children NNS p
with IN p
autism NN p
based VBN p
on IN p
the DT p
TEACCH NNP i
model NN i
. . i

Twenty JJ p
families NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
or CC N
waitlist NN i
group NN N
. . N

All DT N
families NNS N
were VBD N
compared VBN N
at IN N
pre- JJ N
and CC N
post-treatment JJ N
on IN N
formal JJ N
dependent NN N
measures NNS N
. . N

Direct JJ N
measures NNS o
of IN o
behavior NN o
were VBD N
compared VBN N
across IN N
six CD N
matched VBD N
pairs NNS N
using VBG N
a DT N
multiple JJ N
baseline NN N
probe NN N
design NN N
. . N

The DT N
results NNS N
of IN N
the DT N
multiple JJ N
baseline NN N
design NN N
showed VBD N
robust JJ N
support NN N
for IN N
improvement NN o
in IN o
child NN o
and CC o
parent NN o
behavior NN o
. . o

Due NNP N
to TO N
the DT N
sample NN N
size NN N
and CC N
short JJ N
time NN N
frame NN N
, , N
results NNS N
of IN N
a DT N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
did VBD N
not RB N
reach VB N
significance NN N
. . N

-DOCSTART- -17045894- O O

Enhanced NNP N
baroreceptor NN N
control NN N
of IN N
the DT N
cardiovascular JJ N
system NN N
by IN N
polyunsaturated JJ i
Fatty NNP i
acids NNS i
in IN N
heart NN p
failure NN p
patients NNS p
. . p

OBJECTIVES IN N
The DT N
intention NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
, , N
in IN N
heart NN p
failure NN p
patients NNS p
, , N
dietary JJ i
supplementation NN i
of IN i
polyunsaturated JJ i
fatty JJ i
acids NNS i
( ( i
PUFA NNP i
) ) i
enhances VBZ N
arterial JJ N
baroreceptor NN N
control NN N
of IN N
the DT N
cardiovascular JJ N
system NN N
. . N

BACKGROUND NNP N
Administration NNP N
of IN N
PUFA NNP i
reduces VBZ N
the DT N
risk NN N
of IN N
life-threatening JJ N
arrhythmias NNS N
in IN N
patients NNS p
surviving VBG p
myocardial JJ p
infarction NN p
. . p

This DT N
might MD N
result VB N
from IN N
potentiation NN N
of IN N
arterial JJ N
baroreflexes NNS N
, , N
but CC N
whether IN N
or CC N
not RB N
PUFA NNP i
enhance NN N
baroreflex NN N
function NN N
has VBZ N
never RB N
been VBN N
studied VBN N
in IN N
humans NNS p
. . p

METHODS NNP N
Patients NNPS p
with IN p
post-myocardial JJ p
infarction NN p
left VBD p
ventricular JJ p
dysfunction NN p
underwent JJ N
beat-to-beat JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
( ( N
Finapres NNP N
, , N
Ohmeda NNP N
Inc. NNP N
, , N
Englewood NNP N
, , N
Colorado NNP N
) ) N
and CC N
R-R JJ N
interval NN N
( ( N
electrocardiogram NN N
) ) N
recording NN N
; : N
baroreceptor NN N
reflexes NNS N
were VBD N
assessed VBN N
from IN N
the DT N
bradycardic NN N
and CC N
depressor NN N
responses NNS N
to TO N
graded VB N
neck NN N
suction NN N
( ( N
NS NNP N
) ) N
as RB N
well RB N
as IN N
by IN N
computation NN N
of IN N
the DT N
alpha NN N
spontaneous JJ N
baroreflex JJ N
sensitivity NN N
index NN N
. . N

Assessments NNS N
were VBD N
repeated VBN N
after IN N
prolonged JJ N
treatment NN N
with IN N
PUFA NNP i
( ( N
2 CD N
g/die NN N
, , N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

RESULTS NNP N
Baseline NNP o
BP NNP o
and CC o
R-R NNP o
interval NN o
were VBD N
unaffected VBN N
by IN N
PUFA NNP i
. . i

Both DT N
reflex JJ o
depressor NN o
and CC o
bradycardic JJ o
responses NNS o
to TO o
NS NNP o
increased VBN N
after IN N
PUFA NNP i
( ( N
respectively RB N
from IN N
-0.09 JJ N
+/- JJ N
0.01 CD N
to TO N
-0.16 VB N
+/- JJ N
0.01 CD N
mm NN N
Hg NNP N
x NNP N
mm NN N
Hg NNP N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< NN N
0.01 CD N
, , N
and CC N
from IN N
1.25 CD N
+/- JJ N
0.9 CD N
to TO N
1.76 CD N
+/- JJ N
1.1 CD N
ms NN N
x NNP N
mm NN N
Hg NNP N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< NNP N
0.04 CD N
) ) N
but CC N
not RB N
after IN N
placebo NN i
. . i

The DT N
spontaneous JJ o
baroreflex JJ o
sensitivity NN o
increased VBN N
in IN N
the DT N
PUFA NNP i
( ( N
from IN N
8.99 CD N
+/- JJ N
1.4 CD N
to TO N
12.2 CD N
+/- JJ N
1.2 CD N
ms NN N
x NNP N
mm NN N
Hg NNP N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< NNP N
0.02 CD N
) ) N
but CC N
not RB N
in IN N
the DT N
placebo NN i
group NN N
. . N

Polyunsaturated VBN i
fatty JJ i
acids NNS i
( ( N
but CC N
not RB N
placebo VB i
) ) i
treatment NN N
also RB N
significantly RB N
increased VBD N
R-R NNP o
interval JJ o
total JJ o
variance NN o
and CC N
low-frequency NN N
and CC N
high-frequency NN N
spectral JJ N
powers NNS N
. . N

CONCLUSIONS NNP N
Dietary NNP i
PUFA NNP i
supplementation NN i
markedly RB N
potentiates VBZ N
baroreflex JJ N
function NN N
and CC N
enhances NNS N
heart NN o
rate NN o
variability NN o
in IN N
patients NNS p
with IN p
stable JJ p
congestive JJ p
heart NN p
failure NN p
. . p

-DOCSTART- -22967497- O O

Clinical JJ o
efficacy NN o
of IN N
antazoline NN i
in IN N
rapid JJ o
cardioversion NN o
of IN o
paroxysmal JJ o
atrial JJ o
fibrillation NN o
-- : o
a DT o
protocol NN N
of IN N
a DT N
single JJ N
center NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
( ( N
the DT N
AnPAF NNP N
Study NNP N
) ) N
. . N

BACKGROUND NNP N
Rapid NNP o
conversion NN o
of IN o
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
to TO o
sinus VB o
rhythm NN o
may MD N
be VB N
achieved VBN N
by IN N
the DT N
administration NN N
of IN N
class NN i
IA NNP i
, , i
IC NNP i
and CC i
III NNP i
antiarrhythmic JJ i
drugs NNS i
or CC i
vernakalant JJ i
hydrochloride NN i
. . i

However RB N
, , N
that IN N
treatment NN N
may MD N
be VB N
related VBN N
to TO N
potential JJ N
pro-arrhythmia NN N
, , N
lack NN N
of IN N
efficacy NN N
or CC N
the DT N
exceptionally RB N
high JJ N
cost NN N
of IN N
a DT N
compound NN N
used VBN N
. . N

Antazoline NNP i
is VBZ N
a DT N
first JJ N
generation NN N
antihistaminic JJ N
agent NN N
with IN N
chinidin-like JJ N
properties NNS N
. . N

When WRB N
administered VBN N
intravenously RB N
, , N
antazoline JJ i
exerts VBZ N
a DT N
strong JJ o
antiarrhythmic JJ o
effect NN o
on IN N
supraventricular JJ o
arrhythmia NN o
, , N
especially RB N
on IN N
AF NNP o
, , N
facilitating VBG N
rapid JJ o
conversion NN o
to TO o
sinus VB o
rhythm NN o
. . o

Despite IN N
a DT N
relative JJ N
lack NN N
of IN N
published VBN N
data NNS N
antazoline NN N
has VBZ N
been VBN N
marketed VBN N
in IN N
Poland NNP N
and CC N
widely RB N
used VBN N
in IN N
cardiology NN N
wards NNS N
and CC N
emergency NN N
rooms NNS N
for IN N
many JJ N
years NNS N
due JJ N
to TO N
its PRP$ N
efficacy NN N
, , N
safety NN N
and CC N
rapid JJ N
onset NN N
of IN N
action NN N
within IN N
minutes NNS N
of IN N
administration NN N
. . N

METHODS/DESIGN CC N
A DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
, , N
superiority JJ N
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
assess VB N
clinical JJ o
efficacy NN o
of IN N
antazoline NN i
in IN N
rapid JJ N
conversion NN N
of IN N
AF NNP N
to TO N
sinus VB N
rhythm NN N
. . N

Eligible JJ p
patients NNS p
will MD p
present VB p
AF NNP p
lasting VBG p
less JJR p
than IN p
43 CD p
hours NNS p
, , p
will MD p
be VB p
in IN p
stable JJ p
cardio-pulmonary JJ p
condition NN p
and CC p
will MD p
have VB p
no DT p
prior JJ p
history NN p
of IN p
advanced JJ p
heart NN p
failure NN p
or CC p
significant JJ p
valvular JJ p
disease NN p
. . p

Long-term JJ N
antiarrhythmic JJ N
therapy NN N
is VBZ N
not RB N
considered VBN N
an DT N
exclusion NN N
criterion NN N
. . N

Subjects NNS N
who WP N
fulfill VBP N
selection NN N
criteria NNS N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
receive VB N
intravenously RB N
either DT N
antazoline NN i
or CC N
placebo NN i
in IN N
divided JJ N
doses NNS N
and CC N
observed VBD N
for IN N
1.5 CD N
hours NNS N
after IN N
conversion NN N
to TO N
sinus VB N
rhythm NN N
or CC N
after IN N
the DT N
last JJ N
i.v NN N
. . N

bolus NN N
. . N

Primary JJ N
end NN N
point NN N
will MD N
be VB N
the DT N
conversion NN o
of IN o
AF NNP o
to TO o
sinus VB o
rhythm NN o
confirmed VBN o
in IN o
an DT o
electrocardiogram NN o
( ( o
ECG NNP o
) ) o
during IN N
the DT N
observation NN N
period NN N
. . N

Secondary JJ N
end NN N
points NNS N
will MD N
be VB N
comprised VBN o
of IN o
time NN o
to TO o
conversion NN o
and CC o
return NN o
of IN o
AF NNP o
during IN N
the DT N
observation NN N
period NN N
. . N

Special JJ N
consideration NN N
will MD N
be VB N
given VBN N
to TO N
the DT N
observation NN N
of IN N
any DT N
adverse JJ o
events NNS o
. . o

A DT N
sample JJ p
size NN p
of IN p
80 CD p
patients NNS p
was VBD p
calculated VBN p
based VBN N
on IN N
the DT N
following JJ N
assumptions NNS N
: : N
two-tailed JJ N
test NN N
, , N
a DT N
type NN N
I PRP N
error VBP N
of IN N
0.01 CD N
, , N
a DT N
power NN N
of IN N
90 CD N
% NN N
, , N
efficacy NN o
of IN N
placebo JJ i
5 CD N
% NN N
, , N
efficacy NN N
of IN N
antazoline JJ i
50 CD N
% NN N
and CC N
20 CD N
% NN N
drop-out JJ N
rate NN N
to TO N
fulfill VB N
the DT N
criteria NNS N
of IN N
intention-to-treat JJ N
analysis NN N
. . N

Due NNP N
to TO N
the DT N
presumed JJ N
lack NN N
of IN N
statistical JJ N
power NN N
, , N
the DT N
secondary JJ N
end NN N
points NNS N
and CC N
safety NN N
endpoints NNS N
will MD N
be VB N
considered VBN N
exploratory JJ N
. . N

CLINICAL JJ N
TRIALS NNP N
REGISTRY NNP N
ClinicalTrials.gov NNP N
, , N
NCT01527279 NNP N
. . N

-DOCSTART- -15490072- O O

[ JJ N
Long-term JJ N
effects NNS N
of IN N
7-year JJ N
growth NN i
hormone CD i
substitution NN i
on IN N
bone NN o
metabolism NN o
, , o
bone NN o
density NN o
, , o
and CC o
bone NN o
quality NN o
in IN N
growth NN p
hormone-deficient JJ p
adults NNS p
] FW p
. . p

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Subnormal NNP o
bone NN o
mineral NN o
density NN o
( ( o
BMD NNP o
) ) o
and CC o
increased JJ o
fracture NN o
risk NN o
are VBP N
described VBN N
in IN N
patients NNS p
with IN p
growth NN p
hormone NN p
deficiency NN p
( ( p
GHD NNP p
) ) p
. . p

Growth NNP i
hormone NN i
( ( i
GH NNP i
) ) i
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
beneficial JJ N
effects NNS o
on IN o
bone NN o
in IN N
GHD NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
long-term JJ N
effects NNS N
of IN N
GH NNP i
replacement NN i
therapy NN i
on IN N
bone NN o
metabolism NN o
, , o
BMD NNP o
, , o
and CC o
bone NN o
quality NN o
in IN N
patients NNS p
with IN p
GHD NNP p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
20 CD p
adult NN p
patients NNS p
with IN p
GHD NNP i
( ( p
eleven JJ p
male NN p
, , p
nine CD p
female NN p
, , p
mean JJ p
age NN p
42.5 CD p
years NNS p
) ) p
were VBD p
included VBN p
in IN p
the DT p
study NN p
and CC N
randomized VBN N
to TO N
either DT N
GH NNP i
or CC i
placebo NN i
in IN i
a DT i
dose NN i
of IN i
0.25 CD i
U/kg NNP i
body NN N
weight/week NN N
. . N

After IN N
6 CD N
months NNS N
all DT N
patients NNS N
received VBD N
GH NNP i
. . i

After IN N
a DT N
1-year JJ N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
the DT N
patients NNS N
were VBD N
followed VBN N
for IN N
another DT N
72 CD N
months NNS N
in IN N
an DT N
open JJ N
study NN N
. . N

The DT N
patients NNS N
were VBD N
compared VBN N
to TO N
20 CD N
age- JJ N
und JJ N
sex-matched JJ N
healthy JJ N
controls NNS N
. . N

Bone NNP o
turnover NN o
was VBD N
determined VBN N
by IN N
ICTP NNP N
( ( N
type NN N
I PRP N
collagen VBP N
carboxyterminal JJ N
cross-linked JJ N
telopeptide NN N
) ) N
as IN N
parameter NN N
of IN N
bone NN N
resorption NN N
and CC N
PICP NNP N
( ( N
carboxyterminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
) ) N
as IN N
marker NN N
of IN N
bone NN N
formation NN N
. . N

BMD NNP o
was VBD N
measured VBN N
at IN N
the DT N
lumbar NN N
spine NN N
by IN N
dual-photon JJ N
absorptiometry NN N
( ( N
DPA NNP N
) ) N
and CC N
at IN N
the DT N
forearm NN N
by IN N
single-photon JJ N
absorptiometry NN N
( ( N
SPA NNP N
) ) N
. . N

Apparent JJ o
phalangeal NN o
ultrasound JJ o
transmission NN o
velocity NN o
( ( o
APU NNP o
) ) o
was VBD N
assessed VBN N
as IN N
parameter NN N
of IN N
bone NN N
quality NN N
independent JJ N
of IN N
BMD NNP N
. . N

RESULTS NNP N
At IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
BMD NNP o
at IN N
both DT N
measuring VBG N
sites NNS N
was VBD N
lower JJR N
in IN N
patients NNS N
with IN N
GHD NNP i
than IN N
in IN N
healthy JJ N
controls NNS N
. . N

During IN N
the DT N
1st CD N
year NN N
of IN N
GH NNP N
replacement NN N
therapy NN N
BMD NNP o
decreased VBD N
, , N
followed VBN N
by IN N
a DT N
continuous JJ N
increase NN N
in IN N
BMD NNP o
( ( N
about IN N
12 CD N
% NN N
) ) N
up RB N
to TO N
60 CD N
months NNS N
which WDT N
remained VBD N
unchanged JJ N
thereafter RB N
, , N
building VBG N
up RP N
a DT N
plateau NN N
. . N

After IN N
72 CD N
months NNS N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
patients NNS N
and CC N
the DT N
healthy JJ N
controls NNS N
could MD N
be VB N
detected VBN N
. . N

Concerning VBG N
parameters NNS N
of IN N
bone NN o
turnover NN o
, , o
first RB o
ICTP NNP o
as IN N
marker NN o
of IN o
bone NN o
resorption NN o
showed VBD N
a DT N
significant JJ N
increase NN N
, , N
later RB N
on IN N
the DT N
marker NN o
of IN o
bone NN o
formation NN o
increased VBD N
as RB N
well RB N
. . N

APU NNP o
decreased VBD N
during IN N
the DT N
first JJ N
6 CD N
months NNS N
of IN N
treatment NN N
, , N
but CC N
had VBD N
returned VBN N
to TO N
its PRP$ N
baseline NN N
value NN N
after IN N
24 CD N
months NNS N
and CC N
remained VBD N
unchanged JJ N
throughout IN N
the DT N
rest NN N
of IN N
the DT N
study NN N
. . N

CONCLUSION NNP N
BMD NNP o
is VBZ N
subnormal JJ N
in IN N
adults NNS N
with IN N
GHD NNP i
. . i

GH NNP i
replacement NN N
therapy NN N
stimulates VBZ N
bone CD o
turnover NN o
in IN N
patients NNS N
with IN N
GHD NNP N
and CC N
in IN N
the DT N
long JJ N
term NN N
such JJ N
stimulation NN N
results NNS N
in IN N
an DT N
increased JJ N
BMD NNP o
. . o

Thereby NNP N
, , N
GH NNP i
shows VBZ N
a DT N
triphasic JJ N
action NN N
on IN N
BMD NNP o
: : o
an DT N
initial JJ N
decrease NN N
in IN N
BMD NNP o
during IN N
the DT N
1st CD N
year NN N
, , N
followed VBN N
by IN N
a DT N
continuous JJ N
increase NN N
in IN N
BMD NNP o
with IN N
buildup NN N
of IN N
a DT N
stable JJ N
plateau NN N
after IN N
60 CD N
months NNS N
. . N

The DT N
newly RB N
formed VBN N
bone NN N
seems VBZ N
to TO N
have VB N
normal JJ o
bone NN o
elasticity NN o
. . o

-DOCSTART- -12928692- O O

Evaluation NN N
of IN N
the DT N
effect NN N
of IN N
acetazolamide NN i
on IN N
cystoid NN p
macular NN p
oedema NN p
in IN p
patients NNS p
with IN p
Behcet NNP p
's POS p
disease NN p
. . p

AIM NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
acetazolamide NN i
on IN N
cystoid NN N
macular NN N
oedema NN N
( ( N
CMO NNP N
) ) N
in IN N
patients NNS p
with IN p
Behcet NNP p
's POS p
disease NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP p
total NN p
of IN p
67 CD p
eyes NNS p
of IN p
35 CD p
Behcet NNP p
's POS p
patients NNS p
with IN p
chronic JJ p
, , p
but CC p
well-controlled JJ p
uveitis NN p
, , p
and CC p
CMO NNP p
were VBD N
randomised VBN N
into IN N
a DT N
double-masked JJ N
, , N
crossover JJ N
trial NN N
comparing VBG N
the DT N
effect NN N
of IN N
acetazolamide NN i
vs NN i
placebo NN i
. . i

The DT N
patients NNS N
received VBD N
an DT N
initial JJ N
4-week JJ N
course NN N
of IN N
either CC N
250 CD N
mg NN N
acetazolamide JJ i
twice RB N
daily RB N
( ( N
b.i.d NN N
. . N

) ) N
or CC N
placebo NN i
, , N
followed VBN N
by IN N
a DT N
4-week JJ N
washout NN N
period NN N
. . N

They PRP N
then RB N
received VBD N
a DT N
4-week JJ N
course NN N
of IN N
the DT N
reverse NN N
study NN N
medication NN N
. . N

An DT N
improvement NN N
in IN N
visual JJ o
acuity NN o
and CC o
fundus NN o
fluorescein VBP o
angiographic JJ o
findings NNS o
was VBD N
assessed VBN N
. . N

RESULTS NNP N
In IN N
total JJ N
, , N
29 CD p
patients NNS p
( ( p
55 CD p
eyes NNS p
) ) p
completed VBD p
the DT p
trial NN p
and CC p
were VBD p
available JJ p
for IN p
analysis NN p
. . p

Of IN p
the DT p
29 CD p
, , p
16 CD p
men NNS p
and CC p
13 CD p
were VBD p
women NNS p
. . p

The DT p
age NN p
range NN p
was VBD p
13-50 JJ p
years NNS p
( ( p
mean JJ p
33.6 CD p
years NNS p
) ) p
. . p

Patients NNS N
on IN N
acetazolamide NN i
showed VBD N
a DT N
slightly RB N
better RBR N
improvement NN N
of IN N
angiographic JJ o
signs NNS o
( ( N
at IN N
least JJS N
by IN N
one CD N
grade NN N
improvement NN N
) ) N
over IN N
that DT N
of IN N
placebo NN i
( ( N
12 CD N
vs NN N
five CD N
eyes NNS N
) ) N
. . N

They PRP N
also RB N
had VBD N
less JJR N
deterioration NN o
of IN o
angiographic JJ o
signs NNS o
over IN N
that DT N
of IN N
placebo NN i
( ( N
three CD N
vs NN N
seven CD N
eyes NNS N
) ) N
. . N

However RB N
, , N
these DT N
findings NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P=0.99 NNP N
) ) N
. . N

Acetazolamide NNP i
had VBD N
no DT N
statistically RB N
significant JJ N
effect NN N
( ( N
P=0.53 NNP N
) ) N
on IN N
the DT N
improvement NN N
of IN N
visual JJ o
acuity NN o
of IN N
patients NNS N
over IN N
that DT N
of IN N
placebo NN i
( ( N
13 CD N
vs NN N
eight CD N
eyes NNS N
) ) N
, , N
nor CC N
on IN N
the DT N
deterioration NN N
of IN N
visual JJ o
acuity NN o
( ( N
three CD N
vs NN N
11 CD N
eyes NNS N
) ) N
. . N

CONCLUSION NNP N
Despite IN N
seemingly RB N
favourable JJ N
results NNS N
, , N
the DT N
4-week JJ N
course NN N
of IN N
acetazolamide NN i
( ( N
250 CD N
mg NN N
b.i.d NN N
. . N

) ) N
has VBZ N
no DT N
statistically RB N
significant JJ N
effect NN N
on IN N
the DT N
improvement NN N
of IN N
the DT N
visual JJ o
acuity NN o
and CC N
the DT N
fluorescein NN o
angiographic JJ o
findings NNS o
in IN N
Behcet NNP p
's POS p
patients NNS p
with IN p
CMO NNP p
. . p

-DOCSTART- -21997224- O O

Hemiarthroplasty NNP i
compared VBN N
to TO N
internal JJ i
fixation NN i
with IN i
percutaneous JJ i
cannulated VBN i
screws NNS i
as IN N
treatment NN N
of IN N
displaced JJ p
femoral JJ p
neck NN p
fractures NNS p
in IN p
the DT p
elderly JJ p
: : p
cost-utility NN N
analysis NN N
performed VBD N
alongside IN N
a DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

UNLABELLED IN N
We PRP N
estimated VBD N
the DT N
cost-effectiveness NN o
of IN N
hemiarthroplasty NN i
compared VBN N
to TO N
internal JJ i
fixation NN i
for IN N
elderly JJ p
patients NNS p
with IN p
displaced JJ p
femoral JJ p
neck NN p
fractures NNS p
. . p

Over IN N
2 CD N
years NNS N
, , N
patients NNS N
treated VBD N
with IN N
hemiarthroplasty NN i
gained VBN N
more RBR N
quality-adjusted JJ o
life NN o
years NNS o
than IN N
patients NNS N
treated VBN N
with IN N
internal JJ i
fixation NN i
. . i

In IN N
addition NN N
, , N
costs NNS N
for IN N
hemiarthroplasty NN i
were VBD N
lower JJR N
. . N

Hemiarthroplasty NNP i
was VBD N
thus RB N
cost VBN N
effective JJ N
. . N

INTRODUCTION NNP N
Estimating VBG N
the DT N
cost NN N
utility NN N
of IN N
hemiarthroplasty NN i
compared VBN N
to TO N
internal JJ i
fixation NN i
in IN N
the DT N
treatment NN N
of IN N
displaced JJ N
femoral JJ N
neck NN N
fractures NNS N
in IN N
the DT N
elderly JJ N
. . N

METHODS VB N
A DT N
cost-utility NN N
analysis NN N
( ( N
CUA NNP N
) ) N
was VBD N
conducted VBN N
alongside IN N
a DT N
clinical JJ N
randomized NN N
controlled VBD N
trial NN N
at IN p
a DT p
university NN p
hospital NN p
in IN p
Norway NNP p
; : p
166 CD p
patients NNS p
, , p
124 CD p
( ( p
75 CD p
% NN p
) ) p
women NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
82 CD p
years NNS p
were VBD N
randomized VBN N
to TO N
either DT N
internal JJ i
fixation NN i
( ( i
n JJ i
= NNP i
86 CD i
) ) i
or CC i
hemiarthroplasty JJ i
( ( i
n JJ i
= NNP N
80 CD N
) ) N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
at IN N
4 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
months NNS N
. . N

Health-related JJ N
quality NN N
of IN N
life NN N
was VBD N
assessed VBN N
with IN N
the DT N
EQ-5D NNP N
, , N
and CC N
in IN N
combination NN N
with IN N
time NN N
used VBN N
to TO N
calculate VB N
patients NNS N
' POS o
quality-adjusted JJ o
life NN o
years NNS o
( ( o
QALYs NNP o
) ) o
. . N

Resource NNP N
use NN N
was VBD N
identified VBN N
, , N
quantified VBN N
, , N
and CC N
valued VBN N
for IN N
direct JJ N
and CC N
indirect JJ N
hospital NN N
costs NNS N
and CC N
for IN N
societal JJ N
costs NNS N
. . N

Results NNS N
were VBD N
expressed VBN N
in IN N
incremental JJ N
cost-effectiveness JJ N
ratios NNS N
. . N

RESULTS NNP N
Over IN N
the DT N
2-year JJ N
period NN N
, , N
patients NNS N
treated VBD N
with IN i
hemiarthroplasty NN o
gained VBN o
0.15-0.20 CD o
more JJR o
QALYs NNP o
than IN o
patients NNS N
treated VBN N
with IN i
internal JJ i
fixation NN i
. . i

For IN i
the DT i
hemiarthroplasty NN i
group NN i
, , i
the DT o
direct JJ o
hospital NN o
costs NNS o
, , o
total JJ o
hospital NN o
costs NNS o
, , o
and CC o
total JJ o
costs NNS o
were VBD o
non-significantly RB o
less RBR o
costly JJ o
compared VBN N
with IN N
the DT N
internal JJ i
fixation NN i
group NN i
, , i
with IN N
an DT N
incremental JJ N
cost NN N
of IN N
?2,731 NNP N
( ( N
p JJ N
= NNP N
0.81 CD N
) ) N
, , N
?2,474 NNP N
( ( N
p JJ N
= NNP N
0.80 CD N
) ) N
, , N
and CC N
?14,160 NNP N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
, , N
respectively RB i
. . i

Thus RB i
, , i
hemiarthroplasty NN i
was VBD i
the DT N
dominant JJ N
treatment NN N
. . N

Sensitivity NN N
analyses NNS N
by IN N
bootstrapping VBG N
supported VBN N
these DT N
findings NNS N
. . N

CONCLUSION NNP N
Hemiarthroplasty NNP o
was VBD o
a DT o
cost-effective JJ o
treatment NN o
. . o

Trial JJ N
registration NN N
, , N
NCT00464230 NNP N
. . N

-DOCSTART- -20020319- O O

Randomized VBN N
controlled JJ N
trial NN N
for IN N
early JJ i
intervention NN i
for IN N
autism NN N
: : N
a DT N
pilot NN N
study NN N
of IN N
the DT N
Autism NNP i
1-2-3 JJ i
Project NNP i
. . i

We PRP N
piloted VBD N
a DT N
2-week JJ N
Autism-1-2-3 NNP i
early JJ i
intervention NN i
for IN p
children NNS p
with IN p
autism NN p
and CC p
their PRP$ p
parents NNS p
immediately RB N
after IN N
diagnosis NN N
that WDT N
targeted VBD N
at IN N
( ( i
1 CD i
) ) i
eye NN i
contact NN i
, , i
( ( i
2 CD i
) ) i
gesture NN i
and CC i
( ( i
3 CD i
) ) i
vocalization/words NNS i
. . i

Seventeen JJ p
children NNS p
were VBD p
randomized VBN p
into IN p
the DT p
Intervention NNP i
( ( p
n JJ p
= NNP p
9 CD p
) ) p
and CC p
Control NNP i
( ( p
n JJ p
= NNP p
8 CD p
) ) p
groups NNS p
. . p

Outcome NNP N
measures NNS N
included VBD N
the DT N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
, , o
Ritvo-Freeman NNP o
Real NNP o
Life NNP o
Rating NNP o
Scale NNP o
, , o
Symbolic NNP o
Play NNP o
Test NNP o
, , o
and CC o
Parenting NNP o
Stress NNP o
Index NNP o
. . o

Children NNP p
with IN p
autism NN p
improved VBN N
in IN N
language/communication NN o
, , o
reciprocal JJ o
social JJ o
interaction NN o
, , o
and CC o
symbolic JJ o
play NN o
. . o

Parents NNS N
perceived VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
children NNS o
's POS o
language NN o
, , o
social JJ o
interaction NN o
, , o
and CC o
their PRP$ o
own JJ o
stress NN o
level NN o
. . o

This DT N
intervention NN N
can MD N
serve VB N
as IN N
short-term JJ N
training NN i
on IN i
communication NN i
and CC i
social JJ i
interaction NN i
for IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
reduce VB N
the DT N
stress NN N
of IN N
their PRP$ N
parents NNS N
during IN N
the DT N
long JJ N
waiting NN N
time NN N
for IN N
public JJ N
health NN N
services NNS N
. . N

-DOCSTART- -12067044- O O

The DT N
effects NNS N
of IN N
physical JJ i
and CC i
emotional JJ i
status NN i
on IN N
adherence NN N
to TO N
a DT N
low-fat JJ i
dietary JJ i
pattern NN i
in IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
whether IN N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
adherance NN N
to TO N
a DT N
low-fat JJ i
( ( i
20 CD i
% NN i
energy NN i
) ) i
dietary JJ i
pattern NN i
are VBP N
mediated VBN N
by IN N
participation NN N
in IN N
an DT N
intervention NN i
program NN i
( ( i
attending VBG i
sessions NNS i
and CC i
self-monitoring NN i
) ) i
. . i

DESIGN VB N
The DT N
Baron NNP N
and CC N
Kenny NNP N
mediator NN N
model NN N
, , N
a DT N
series NN N
of IN N
4 CD N
regression NN N
analyses NNS N
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
whether IN N
: : N
a DT N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
predicted VBD N
program NN N
participation NN N
, , N
b NN N
) ) N
program NN N
participation NN N
predicted VBD N
dietary JJ N
adherence NN N
, , N
c NN N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
factors NNS N
predicted VBD N
dietary JJ i
adherence NN i
, , N
and CC N
, , N
ultimately RB N
d NN N
) ) N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
dietary JJ N
adherence NN N
were VBD N
mediated VBN N
by IN N
program NN N
participation NN N
. . N

SUBJECTS/SETTING NNP N
Data NNP p
from IN p
13,277 CD p
postmenopausal JJ p
women NNS p
randomly RB p
assigned VBN p
to TO p
the DT p
low-fat JJ i
intervention NN i
arm NN p
of IN p
the DT p
Women NNP p
's POS p
Health NNP p
Initiative NNP p
Dietary NNP p
Modification NNP p
Trial NNP p
. . p

INTERVENTION NNP N
The DT N
nutrition NN N
goals NNS N
for IN N
women NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ i
intervention NN i
were VBD N
to TO N
reduce VB i
total JJ i
fat JJ i
intake NN i
to TO i
20 CD i
% NN i
or CC i
less JJR i
of IN i
energy NN i
from IN i
fat JJ i
and CC i
to TO i
consume VB i
5 CD i
or CC i
more JJR i
fruit/vegetable JJ i
servings NNS i
daily RB i
and CC i
6 CD i
or CC i
more JJR i
grain JJ i
servings NNS i
daily RB i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Year NNP o
1 CD o
program NN o
participation NN o
( ( o
degree NN o
of IN o
attending VBG o
group NN o
sessions NNS o
and CC o
submitting VBG o
fat JJ o
scores NNS o
) ) o
and CC p
adherence NN o
to TO o
the DT o
low-fat JJ o
dietary JJ o
pattern NN o
( ( o
percent JJ o
energy NN o
from IN o
fat NN o
) ) o
as IN N
predicted VBN N
by IN N
baseline JJ N
physical JJ N
and CC N
emotional JJ N
status NN N
( ( N
eight CD N
SF-36 NNP N
Health NNP N
Survey NNP N
subscales VBZ N
) ) N
. . N

RESULTS NNP N
Participating VBG N
in IN N
the DT N
dietary JJ i
intervention NN i
program NN i
reduced VBN N
( ( N
mediated VBN N
) ) N
the DT N
negative JJ N
effect NN o
of IN o
poorer JJR o
mental JJ o
health NN o
on IN N
dietary JJ o
adherence NN o
by IN N
15 CD N
% NN N
. . N

Additional JJ N
findings NNS N
included VBD N
that IN N
a DT N
10 CD N
% NN N
increase NN N
in IN N
physical JJ o
functioning NN o
increased VBD N
session NN o
attendance NN o
by IN N
0.4 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
10 CD N
% NN N
increase NN N
in IN N
mental JJ o
health NN o
predicted VBD N
a DT N
decrease NN N
in IN N
percent NN N
energy NN o
from IN o
fat NN o
of IN N
0.3 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Program NNP N
participation NN N
had VBD N
a DT N
marked JJ N
effect NN N
on IN N
dietary JJ o
adherence NN o
: : o
a DT N
10 CD N
% NN N
increase NN N
in IN N
session NN o
attendance NN o
predicted VBD N
a DT N
1.2 CD N
% NN N
decrease NN N
in IN N
percent NN o
energy NN o
from IN o
fat JJ o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

APPLICATIONS/CONCLUSIONS NNP N
Understanding NNP N
and CC N
using VBG N
instruments NNS N
to TO N
assess VB N
the DT N
physical JJ N
and CC N
emotional JJ N
status NN N
of IN N
a DT N
target NN N
population NN N
will MD N
help VB N
dietetic JJ N
professionals NNS N
promote VBP N
healthful JJ N
dietary JJ N
change NN N
and CC N
maintenance NN N
. . N

-DOCSTART- -9932558- O O

Videotaped NNP i
training NN i
in IN i
alcohol NN i
counseling NN i
for IN N
obstetric JJ p
care NN p
practitioners NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
feasibility NN N
of IN N
videotaped JJ i
training NN i
for IN i
obstetric JJ i
care NN i
practitioners NNS i
in IN i
motivational JJ i
interviewing NN i
skills NNS i
that WDT N
could MD N
be VB N
used VBN N
in IN N
brief JJ N
patient JJ N
consultations NNS N
on IN N
problem NN N
drinking NN N
. . N

METHODS NNP N
Thirty NNP p
health NN p
care NN p
practitioners NNS p
participated VBD N
in IN N
a DT N
clinical JJ N
trial NN N
using VBG N
a DT N
20-minute JJ i
videotape NN i
to TO N
instruct VB N
them PRP N
in IN N
motivational JJ N
interviewing NN N
. . N

Participants NNS N
engaged VBN N
in IN N
a DT N
pretest JJ N
roleplay NN N
with IN N
an DT N
actress NN N
playing VBG N
a DT N
drinking NN N
pregnant JJ N
woman NN N
. . N

Those DT N
randomly RB N
assigned VBN N
to TO N
the DT N
experimental JJ N
condition NN N
watched VBD N
the DT N
motivational JJ i
interviewing NN i
videotape NN i
. . i

Control NNP i
condition NN N
participants NNS N
watched VBD N
a DT N
20-minute JJ i
docudrama NN i
of IN N
a DT N
pregnant JJ N
problem NN N
drinker NN N
. . N

Both DT N
groups NNS N
then RB N
engaged VBD N
in IN N
a DT N
post-test JJ N
roleplay NN N
similar JJ N
to TO N
the DT N
pretest NN N
. . N

Behavioral JJ o
ratings NNS o
of IN o
the DT o
roleplays NNS o
and CC o
participant JJ o
evaluations NNS o
of IN o
the DT o
motivational JJ o
interviewing NN o
video NN o
constituted VBD o
the DT o
outcome NN o
measures NNS o
. . o

RESULTS NNP N
Participant NNP N
evaluations NNS N
indicated VBD N
that IN N
the DT N
training NN i
video NN i
was VBD N
clear JJ N
in IN N
explaining VBG N
and CC N
demonstrating VBG N
the DT N
principles NNS N
and CC N
skills NNS N
of IN N
motivational JJ N
interviewing NN N
. . N

Change NN N
in IN N
behavioral JJ N
ratings NNS N
from IN N
pretest NN N
to TO N
post-test NN N
showed VBD N
significant JJ N
differences NNS N
in IN N
motivational JJ N
interviewing NN N
skills NNS N
between IN N
the DT N
experimental JJ N
and CC N
control NN N
groups NNS N
. . N

Obstetric NNP p
care NN p
practitioners NNS p
who WP N
viewed VBD N
the DT N
training NN N
video NN N
were VBD N
rated VBN N
as IN N
showing VBG N
greater JJR N
empathy NN o
, , N
minimizing VBG N
patient JJ o
defensiveness NN o
, , N
and CC N
supporting VBG o
women NNS o
's POS o
beliefs NNS o
in IN o
their PRP$ o
ability NN o
to TO o
change VB o
. . o

CONCLUSION NNP N
Obstetric NNP N
care NN N
practitioners NNS N
can MD N
improve VB N
their PRP$ N
alcohol NN N
intervention NN N
skills NNS N
through IN N
the DT N
use NN N
of IN N
a DT N
20-minute JJ N
videotaped JJ i
instruction NN i
in IN i
motivational JJ i
interviewing NN i
. . i

Clinicians NNPS N
who WP N
improve VBP N
their PRP$ N
skills NNS N
in IN N
motivational JJ N
interviewing NN N
can MD N
intervene VB N
more RBR N
effectively RB N
with IN N
their PRP$ N
drinking NN N
pregnant JJ N
patients NNS N
. . N

Using VBG N
motivational JJ i
interviewing NN i
with IN N
this DT N
population NN N
holds VBZ N
promise RB N
for IN N
helping VBG N
prevent JJ N
alcohol-related JJ N
health NN N
problems NNS N
. . N

-DOCSTART- -8624384- O O

Antibiotic JJ i
strategy NN i
after IN N
the DT N
empiric JJ N
phase NN N
in IN N
patients NNS p
treated VBN p
for IN p
a DT p
hematological JJ p
malignancy NN p
. . p

Empiric JJ i
broad-spectrum JJ i
antibiotic JJ i
therapy NN i
has VBZ N
become VBN N
a DT N
generally RB N
accepted VBN N
strategy NN N
in IN N
the DT N
treatment NN N
of IN N
febrile JJ p
neutropenic JJ p
patients NNS p
. . p

Particularly NNP N
in IN N
patients NNS p
with IN p
prolonged JJ p
neutropenia NN p
, , N
subsequent JJ N
adaptation NN N
of IN N
such JJ N
a DT N
regimen NNS N
will MD N
be VB N
the DT N
rule NN N
rather RB N
than IN N
exception NN N
. . N

Since IN N
there EX N
are VBP N
no DT N
uniformly RB N
accepted VBN N
guidelines NNS N
for IN N
the DT N
modification NN N
of IN N
antibiotic JJ i
therapy NN i
during IN N
the DT N
post-empiric JJ N
phase NN N
, , N
we PRP N
assessed VBD N
the DT N
impact NN i
of IN i
a DT i
set NN i
of IN i
rules NNS i
that WDT i
evolved VBD i
during IN i
the DT i
first JJ i
randomized JJ i
trials NNS i
. . i

Evaluation NN i
of IN i
the DT i
clinician NN i
's POS i
compliance NN i
with IN i
these DT i
rules NNS i
in IN i
1951 CD i
febrile NN i
neutropenic JJ i
episodes NNS i
was VBD i
the DT i
subject NN i
of IN i
the DT i
present JJ i
analysis NN i
. . i

Treatment NNP i
was VBD i
modified VBN i
in IN N
761 CD N
( ( N
39 CD N
% NN N
) ) N
cases NNS N
, , N
and CC N
these DT N
changes NNS N
were VBD N
made VBN N
according VBG N
to TO N
the DT N
rules NNS N
in IN N
76 CD N
% NN N
. . N

For IN N
75 CD N
% NN N
of IN N
the DT N
alterations NNS N
in IN N
treatment NN N
during IN N
the DT N
evening NN N
and CC N
night NN N
shifts NNS N
, , N
no DT N
reasonable JJ N
explanation NN N
was VBD N
established VBN N
, , N
while IN N
93 CD N
% NN N
of IN N
the DT N
modifications NNS N
during IN N
the DT N
normal JJ N
working JJ N
hours NNS N
were VBD N
made VBN N
for IN N
objective JJ N
reasons NNS N
. . N

The DT N
empiric JJ N
regimen NN N
was VBD N
more RBR N
frequently RB N
changed VBN N
in IN N
patients NNS N
with IN N
a DT N
clinical JJ N
focus NN N
of IN N
infection NN N
at IN N
the DT N
onset NN N
of IN N
fever NN N
than IN N
in IN N
patients NNS N
who WP N
showed VBD N
fever RB N
as IN N
the DT N
only JJ N
symptom NN N
of IN N
a DT N
possible JJ N
infection NN N
. . N

The DT N
perceived JJ N
need NN N
for IN N
modification NN N
amounted VBD N
to TO N
69 CD N
% NN N
in IN N
pulmonary JJ N
infections NNS N
, , N
to TO N
51 CD N
% NN N
in IN N
skin NN N
and CC N
soft-tissue NN N
infections NNS N
, , N
to TO N
44 CD N
% NN N
in IN N
patients NNS N
with IN N
abdominal JJ N
complaints NNS N
, , N
and CC N
to TO N
37 CD N
% NN N
in IN N
upper JJ N
respiratory NN N
tract NN N
infections NNS N
. . N

Glycopeptides NNP N
constituted VBD N
22 CD N
% NN N
of IN N
modifications NNS N
, , N
particularly RB N
in IN N
patients NNS N
with IN N
a DT N
central JJ N
venous JJ N
catheter NN N
, , N
and CC N
systemically RB N
active JJ N
antifungals NNS N
were VBD N
administered VBN N
in IN N
16 CD N
% NN N
of IN N
cases NNS N
. . N

Especially RB N
inexperienced JJ N
clinicians NNS N
tend VBP N
to TO N
adjust VB N
antibiotic JJ i
therapy NN i
, , N
in IN N
spite NN N
of IN N
the DT N
fact NN N
that IN N
persistence NN N
of IN N
fever NN N
alone RB N
seldom JJ N
reflects VBZ N
inadequate JJ N
treatment NN N
when WRB N
the DT N
clinical JJ N
condition NN N
of IN N
the DT N
patient NN N
is VBZ N
stable JJ N
or CC N
improving VBG N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
development NN N
of IN N
subsequent JJ N
infectious JJ N
events NNS N
emphasizes VBZ N
that IN N
a DT N
genuine JJ N
need NN N
for IN N
modification NN N
does VBZ N
frequently RB N
exist VB N
. . N

-DOCSTART- -24146455- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
of IN N
Cappra? NNP i
for IN N
the DT N
treatment NN N
of IN p
mild NN p
or CC p
mild NN p
to TO p
moderate VB p
erectile JJ p
dysfunction NN p
in IN p
Thai NNP p
male NN p
. . p

Erectile JJ N
dysfunction NN N
( ( N
ED NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
major JJ N
health NN N
concerns NNS N
affects VBZ N
the DT N
quality NN N
of IN N
life NN N
among IN p
Thai NNP p
male NN p
. . p

The DT N
treatment NN N
of IN N
ED NNP N
by IN N
the DT N
first-line JJ N
drugs NNS N
is VBZ N
limited VBN N
to TO N
a DT N
certain JJ N
group NN N
of IN N
patients NNS N
due JJ N
to TO N
their PRP$ N
side NN N
effects NNS N
and CC N
costs NNS N
. . N

Alternative JJ N
medicine NN N
can MD N
be VB N
beneficial JJ N
for IN N
the DT N
treatment NN N
of IN N
ED NNP N
. . N

This DT N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , i
crossover NN N
study NN N
aimed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN i
Cappra NNP i
( ( i
? . i
) ) i
, , i
a DT N
traditional JJ N
herbal NN N
medicine NN N
which WDT N
was VBD N
used VBN N
in IN N
Thailand NNP N
for IN N
decades NNS N
, , N
for IN N
the DT N
treatment NN N
of IN N
mild NN p
and CC p
mild NN p
to TO p
moderate VB p
ED NNP p
in IN p
Thai NNP p
patients NNS p
. . p

A DT N
total NN N
of IN N
63 CD p
patients NNS p
with IN p
mild JJ p
or CC p
mild JJ p
to TO p
moderate VB p
ED NNP p
were VBD p
randomized VBN p
to TO p
receive VB i
Cappra NNP i
( ( i
? . i
) ) i
or CC i
placebo NN i
for IN i
two CD N
weeks NNS N
in IN N
the DT N
first JJ N
period NN N
, , N
followed VBN N
by IN N
one CD N
week NN N
washout NN N
period NN N
. . N

The DT N
patients NNS N
were VBD N
switched VBN N
to TO N
the DT N
alternative JJ N
treatment NN N
in IN N
the DT N
second JJ N
period NN N
. . N

The DT N
efficacy NN o
was VBD o
assessed VBN N
by IN N
the DT N
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function NNP o
( ( o
IIEF NNP o
) ) o
questionnaire NN o
and CC o
adverse JJ o
events NNS o
. . o

Sixty NNP o
one CD N
patients NNS N
completed VBD N
the DT N
study NN N
. . N

There EX N
was VBD N
an DT N
improvement NN N
of IN N
IIEF NNP o
score NN o
for IN o
all DT N
domains NNS N
in IN N
Cappra NNP N
( ( N
? . N
) ) N
group NN N
compared VBN N
with IN N
placebo NN N
group NN N
. . N

The DT N
mean JJ o
change NN o
of IN o
IIEF NNP o
score NN o
from IN o
baseline NN N
for IN N
erectile JJ N
function NN N
domain NN N
of IN N
Cappra NNP N
( ( N
? . N
) ) N
was VBD N
significantly RB N
higher JJR N
than IN N
placebo NN N
( ( N
4.87 CD N
vs NN N
3.44 CD N
, , N
p NN N
= NNP N
0.032 CD N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
dizziness NN o
( ( o
13.3 CD o
% NN N
Cappra NNP N
( ( N
? . N
) ) N
, , N
9.6 CD N
% NN N
placebo NN o
) ) o
, , o
face NN o
numbness NN o
( ( o
1.6 CD o
% NN o
Cappra NNP N
( ( N
? . N
) ) N
, , N
0 CD N
% NN N
placebo NN N
) ) o
, , o
and CC o
tachycardia NN o
( ( o
1.6 CD o
% NN o
Cappra NNP N
( ( N
? . N
) ) N
, , N
0 CD N
% NN N
placebo NN N
) ) N
. . N

The DT N
results NNS N
from IN N
this DT N
study NN N
demonstrated VBD N
that IN N
Cappra NNP N
( ( N
? . N
) ) N
is VBZ N
effective JJ N
and CC N
well-tolerated JJ N
and CC N
can MD N
be VB N
used VBN N
as IN N
alternative JJ N
therapy NN N
for IN N
mild NN N
and CC N
mild NN N
to TO N
moderate VB N
ED NNP N
. . N

-DOCSTART- -8279616- O O

A DT N
workplace NN i
intervention NN i
for IN N
increasing VBG N
outdoor JJ p
workers NNS p
' POS p
use NN N
of IN N
solar JJ N
protection NN N
. . N

OBJECTIVES NNP N
Outdoor NNP p
workers NNS p
are VBP N
at IN N
high JJ N
risk NN N
of IN N
developing VBG N
skin JJ N
cancer NN N
. . N

Primary JJ N
prevention NN N
in IN N
this DT N
group NN N
can MD N
potentially RB N
reduce VB N
the DT N
incidence NN N
of IN N
skin NN N
cancer NN N
, , N
and CC N
also RB N
potentiates VBZ N
the DT N
spontaneous JJ N
remission NN N
of IN N
existing VBG N
solar JJ N
keratoses NNS N
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
a DT N
solar JJ i
protection NN i
intervention NN i
targeting VBG N
outdoor JJ p
workers NNS p
. . p

METHODS NNP N
Outdoor NNP p
workers NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
an DT p
intervention NN i
( ( p
n JJ p
= NNP p
65 CD p
) ) p
or CC i
control VB i
group NN i
( ( p
n JJ p
= NNP p
77 CD p
) ) p
. . p

The DT N
intervention NN N
group NN N
received VBD N
individual JJ i
skin NN i
screening NN i
by IN i
a DT i
dermatologist NN i
and CC i
participated VBD i
in IN i
an DT i
education NN i
session NN i
. . i

Pre- NNP N
and CC N
posttest JJS N
outcome NN N
measures NNS N
included VBD N
solar JJ o
protection NN o
behavior NN o
( ( N
assessed VBN N
using VBG N
a DT N
validated JJ N
diary NN N
) ) N
, , N
knowledge NN o
, , N
and CC N
attitudes NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ o
increase NN o
( ( N
16 CD N
% NN N
) ) N
in IN N
the DT N
percentage NN N
of IN N
outdoor JJ N
workers NNS N
who WP N
were VBD N
using VBG N
a DT N
high JJ o
level NN o
of IN o
solar JJ o
protection NN o
at IN N
posttest NN N
compared VBN N
to TO N
pretest VB N
in IN N
the DT N
intervention NN N
group NN N
, , N
but CC N
there EX N
was VBD N
no DT o
change NN o
in IN N
the DT N
control NN N
group NN N
. . N

Although IN N
both DT N
groups NNS N
improved VBN o
in IN N
their PRP$ N
knowledge NN o
score NN o
, , N
the DT N
intervention NN o
group NN o
showed VBD o
a DT o
significantly RB o
greater JJR o
improvement NN o
at IN N
posttest JJS N
. . N

No DT o
changes NNS o
in IN o
attitudes NNS o
were VBD N
detected VBN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
suggest VBP N
that IN N
changes NNS N
in IN N
solar JJ o
protection NN o
are VBP N
achievable JJ N
with IN N
outdoor JJ p
workers NNS p
. . p

-DOCSTART- -15673098- O O

Skeletal JJ N
muscle NN N
total JJ N
creatine NN N
content NN N
and CC N
creatine NN N
transporter NN N
gene NN N
expression NN N
in IN N
vegetarians NNS p
prior JJ N
to TO N
and CC N
following VBG N
creatine JJ i
supplementation NN i
. . i

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
vegetarianism NN N
on IN N
skeletal JJ o
muscle NN o
total JJ o
creatine NN o
( ( o
TCr NNP o
) ) o
content NN o
and CC N
creatine NN o
transporter NN o
( ( o
CreaT NNP o
) ) o
gene NN o
expression NN o
, , N
prior RB N
to TO N
and CC N
during IN N
5 CD N
d NN N
of IN N
Cr NNP i
supplementation NN i
( ( i
CrS NNP i
) ) i
. . N

In IN N
a DT N
double-blind NN N
, , N
crossover NN N
design NN N
, , N
7 CD p
vegetarians NNS p
( ( p
VEG NNP p
) ) p
and CC p
nonvegetarians NNS p
( ( p
NVEG NNP p
) ) p
were VBD N
assigned VBN N
Cr NNP i
or CC i
placebo NN i
supplements NNS i
for IN N
5 CD N
d NN N
and CC N
after IN N
5 CD N
wk NN N
, , N
received VBD N
the DT N
alternative JJ i
treatment NN i
. . i

Muscle NNP i
sampling VBG i
occurred VBD N
before IN N
, , N
and CC N
after IN N
1 CD N
and CC N
5 CD N
d NN N
of IN N
treatment NN N
ingestion NN N
. . N

Basal NNP o
muscle NN o
TCr NNP o
content NN N
was VBD N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
VEG NNP N
compared VBN N
with IN N
NVEG NNP N
. . N

Muscle NNP o
TCr NNP o
increased VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
throughout IN N
the DT N
Cr NNP i
trial NN N
in IN N
both DT N
groups NNS N
but CC N
was VBD N
greater JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
VEG NNP N
compared VBN N
with IN N
NVEG NNP N
, , N
at IN N
days NNS N
1 CD N
and CC N
5 CD N
. . N

CreaT NNP o
gene NN o
expression NN o
was VBD N
not RB N
different JJ N
between IN N
VEG NNP N
and CC N
NVEG NNP N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
VEG NNP N
have VBP N
a DT N
lower JJR N
muscle NN o
TCr NNP o
content NN o
and CC N
an DT N
increased VBN N
capacity NN o
to TO N
load VB N
Cr NNP i
into IN N
muscle NN N
following VBG N
CrS NNP i
. . i

Muscle NNP o
CreaT NNP o
gene NN o
expression NN o
does VBZ N
not RB N
appear VB N
to TO N
be VB N
affected VBN N
by IN N
vegetarianism NN p
. . p

-DOCSTART- -7976148- O O

Oesophageal JJ p
intubation NN p
can MD N
be VB N
undetected VBN N
by IN N
auscultation NN i
of IN N
the DT N
chest NN N
. . N

Prompt NNP N
detection NN N
of IN N
oesophageal JJ i
intubation NN i
is VBZ N
a DT N
primary JJ N
concern NN N
in IN N
anaesthetic JJ N
practice NN N
. . N

This DT N
blind NN N
, , N
randomised VBD N
study NN N
evaluates NNS N
three CD N
widely RB N
used JJ N
tests NNS N
of IN N
intubation NN i
. . i

Forty NNP p
patients NNS p
had VBD p
both DT p
their PRP$ p
trachea NN p
and CC p
oesophagus NN p
intubated VBN i
, , N
each DT N
patient NN N
was VBD N
studied VBN N
twice RB N
. . N

Auscultation NN o
of IN o
the DT o
epigastrium NN o
, , N
right NN N
and CC N
left VBD N
axilla NN N
is VBZ N
more RBR N
reliable JJ N
than IN N
auscultation NN N
of IN N
the DT N
chest NN N
, , N
and CC N
the DT N
anaesthetist NN p
's POS p
feeling NN p
when WRB p
he PRP p
squeezes VBZ p
the DT p
bag NN p
. . p

P NNP N
= VBD N
0.001 CD N
and CC N
P NNP N
= NNP N
0.048 CD N
, , N
respectively RB N
. . N

The DT N
tests NNS N
were VBD N
carried VBN N
out RP N
after IN N
gastric JJ N
distension NN N
with IN N
gas NN N
had VBD N
occurred VBN N
. . N

We PRP N
conclude VBP N
that DT N
auscultation NN N
of IN N
epigastrium NN N
, , N
right NN N
and CC N
left VBD N
axilla NN N
, , N
are VBP N
recommended VBN N
. . N

-DOCSTART- -3063541- O O

Comparison NNP N
of IN N
endocrine NN i
and CC N
radiation NN i
therapy NN i
in IN N
locally RB p
advanced JJ p
prostatic JJ p
cancer NN p
. . p

151 CD p
patients NNS p
with IN p
locally RB p
advanced JJ p
prostatic JJ p
cancer NN p
( ( p
T3-4 NNP p
M0 NNP p
) ) p
, , p
representing VBG p
38 CD p
% NN p
of IN p
the DT p
404 CD p
cancer NN p
patients NNS p
in IN p
a DT p
Finnish JJ p
multicenter NN p
study NN p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
orchiectomy NN i
, , i
estrogens VBZ i
or CC i
radiotherapy NN i
. . i

During IN N
the DT N
4-year JJ N
follow-up JJ N
period NN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
progression NN o
rates NNS o
( ( o
appearance NN o
of IN o
metastases NNS o
in IN o
bone NN o
scan NN o
) ) o
between IN N
the DT N
therapy NN N
groups NNS N
. . N

The DT N
frequency NN o
of IN o
thromboembolic JJ o
and CC o
other JJ o
cardiovascular JJ o
complications NNS o
was VBD N
highest JJS N
in IN N
the DT N
estrogen NN N
group NN N
( ( N
13/50 CD N
patients NNS N
) ) N
. . N

In IN N
the DT N
radiotherapy NN N
group NN N
, , N
19 CD N
of IN N
45 CD N
patients NNS N
had VBD N
bowel NN o
or CC o
bladder NN o
complications NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
orchiectomy NN N
has VBZ N
few JJ N
, , N
if IN N
any DT N
, , N
complications NNS N
. . N

The DT N
high JJ N
risk NN N
of IN N
complications NNS N
associated VBN N
with IN N
estrogens NNS N
and CC N
radiotherapy NN N
has VBZ N
to TO N
be VB N
taken VBN N
into IN N
consideration NN N
in IN N
the DT N
selection NN N
of IN N
treatment NN N
. . N

-DOCSTART- -23481373- O O

Development NNP N
of IN N
the DT N
Therapist NNP p
Empathy NNP N
Scale NNP N
. . N

BACKGROUND NNP N
Few JJ N
measures NNS N
exist VBP N
to TO N
examine VB N
therapist NN p
empathy NN N
as IN N
it PRP N
occurs VBZ N
in IN N
session NN N
. . N

AIMS VB N
A DT N
9-item JJ N
observer NN N
rating NN N
scale NN N
, , N
called VBD N
the DT N
Therapist NNP i
Empathy NNP i
Scale NNP i
( ( N
TES NNP N
) ) N
, , N
was VBD N
developed VBN N
based VBN N
on IN N
Watson NNP N
's POS N
( ( N
1999 CD N
) ) N
work NN N
to TO N
assess VB N
affective JJ N
, , N
cognitive JJ N
, , N
attitudinal JJ N
, , N
and CC N
attunement JJ N
aspects NNS N
of IN N
therapist NN N
empathy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
inter-rater JJ N
reliability NN N
, , N
internal JJ N
consistency NN N
, , N
and CC N
construct NN N
and CC N
criterion NN N
validity NN N
of IN N
the DT N
TES NNP N
. . N

METHOD NNP N
Raters NNPS N
evaluated VBD N
therapist JJ p
empathy NN N
in IN N
315 CD p
client NN i
sessions NNS i
conducted VBN p
by IN p
91 CD p
therapists NNS p
, , p
using VBG p
data NNS p
from IN p
a DT p
multi-site JJ p
therapist NN p
training NN p
trial NN p
( ( p
Martino NNP p
et RB p
al. RB p
, , N
2010 CD p
) ) p
in IN p
Motivational NNP i
Interviewing NNP i
( ( i
MI NNP i
) ) i
. . i

RESULTS JJ N
Inter-rater JJ o
reliability NN o
( ( N
ICC NNP N
= NNP N
.87 NNP N
to TO N
.91 VB N
) ) N
and CC N
internal JJ o
consistency NN o
( ( N
Cronbach NNP N
's POS N
alpha NN N
= NNP N
.94 NNP N
) ) N
were VBD N
high JJ N
. . N

Confirmatory NNP N
factor NN o
analyses NNS o
indicated VBD N
some DT N
support NN N
for IN N
single-factor JJ N
fit NN N
. . N

Convergent NNP o
validity NN o
was VBD N
supported VBN N
by IN N
correlations NNS N
between IN N
TES NNP o
scores NNS o
and CC o
MI NNP o
fundamental JJ o
adherence NN o
( ( N
r JJ N
range NN N
.50 NN N
to TO N
.67 VB N
) ) N
and CC N
competence NN o
scores NNS o
( ( N
r NN N
range NN N
.56 NN N
to TO N
.69 VB N
) ) N
. . N

Discriminant JJ o
validity NN o
was VBD N
indicated VBN N
by IN N
negative JJ N
or CC N
nonsignificant JJ N
correlations NNS N
between IN N
TES NNP N
and CC N
MI-inconsistent NNP N
behavior NN N
( ( N
r JJ N
range NN N
.05 NN N
to TO N
-.33 VB N
) ) N
. . N

CONCLUSIONS VB N
The DT N
TES NNP N
demonstrates VBZ N
excellent JJ N
inter-rater JJ N
reliability NN N
and CC N
internal JJ N
consistency NN N
. . N

RESULTS NNP N
indicate VBP N
some DT N
support NN N
for IN N
a DT N
single-factor JJ N
solution NN N
and CC N
convergent NN N
and CC N
discriminant JJ N
validity NN N
. . N

Future JJ N
studies NNS N
should MD N
examine VB N
the DT N
use NN N
of IN N
the DT N
TES NNP N
to TO N
evaluate VB N
therapist NN p
empathy NN N
in IN N
different JJ N
psychotherapy NN N
approaches NNS N
and CC N
to TO N
determine VB N
the DT N
impact NN N
of IN N
therapist NN N
empathy NN N
on IN N
client NN N
outcome NN N
. . N

-DOCSTART- -25313065- O O

Sulforaphane NNP i
treatment NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

Autism NNP N
spectrum JJ N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
characterized VBN N
by IN N
both DT N
impaired JJ N
communication NN N
and CC N
social JJ N
interaction NN N
, , N
and CC N
by IN N
stereotypic JJ N
behavior NN N
, , N
affects VBZ N
about IN N
1 CD N
in IN N
68 CD N
, , N
predominantly RB p
males NNS p
. . p

The DT N
medico-economic JJ N
burdens NNS N
of IN N
ASD NNP N
are VBP N
enormous JJ N
, , N
and CC N
no DT N
recognized VBN N
treatment NN N
targets VBZ N
the DT N
core NN N
features NNS N
of IN N
ASD NNP N
. . N

In IN N
a DT N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
, , N
young JJ p
men NNS p
( ( p
aged VBN p
13-27 NNS p
) ) p
with IN p
moderate JJ p
to TO p
severe VB p
ASD NNP p
received VBD N
the DT N
phytochemical JJ i
sulforaphane NN i
( ( i
n JJ i
= NNP i
29 CD i
) ) i
-- : i
derived VBN i
from IN i
broccoli NN i
sprout NN i
extracts NNS i
-- : i
or CC i
indistinguishable JJ i
placebo NN i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

The DT N
effects NNS N
on IN N
behavior NN N
of IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
sulforaphane NN i
( ( N
50-150 JJ N
?mol NN N
) ) N
for IN N
18 CD N
wk NN N
, , N
followed VBN N
by IN N
4 CD N
wk NNS N
without IN N
treatment NN N
, , N
were VBD N
quantified VBN N
by IN N
three CD N
widely RB N
accepted VBD N
behavioral JJ N
measures NNS N
completed VBN N
by IN N
parents/caregivers NNS N
and CC N
physicians NNS o
: : o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
, , o
Social NNP o
Responsiveness NNP o
Scale NNP o
( ( o
SRS NNP o
) ) o
, , o
and CC o
Clinical NNP o
Global NNP o
Impression NNP o
Improvement NNP o
Scale NNP o
( ( o
CGI-I NNP o
) ) o
. . o

Initial JJ o
scores NNS o
for IN o
ABC NNP o
and CC o
SRS NNP o
were VBD N
closely RB N
matched VBN N
for IN N
participants NNS N
assigned VBN N
to TO i
placebo VB i
and CC i
sulforaphane VB i
. . i

After IN N
18 CD N
wk NN N
, , N
participants NNS N
receiving VBG i
placebo NN i
experienced VBD N
minimal JJ N
change NN N
( ( N
< JJ N
3.3 CD N
% NN N
) ) N
, , N
whereas VBP N
those DT N
receiving VBG i
sulforaphane NN i
showed VBD N
substantial JJ N
declines NNS N
( ( N
improvement NN N
of IN N
behavior NN N
) ) N
: : N
34 CD N
% NN N
for IN o
ABC NNP o
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
comparing VBG N
treatments NNS N
) ) N
and CC N
17 CD N
% NN N
for IN o
SRS NNP o
scores NNS N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

On IN o
CGI-I NNP o
, , o
a DT N
significantly RB N
greater JJR N
number NN N
of IN p
participants NNS p
receiving VBG i
sulforaphane NN i
had VBD N
improvement NN N
in IN o
social JJ o
interaction NN o
, , o
abnormal JJ o
behavior NN o
, , o
and CC o
verbal JJ o
communication NN o
( ( N
P NNP N
= NNP N
0.015-0.007 NN N
) ) N
. . N

Upon IN N
discontinuation NN N
of IN i
sulforaphane NN i
, , i
total JJ N
scores NNS N
on IN N
all DT N
scales NNS N
rose VBD N
toward IN N
pretreatment JJ N
levels NNS N
. . N

Dietary NNP i
sulforaphane NN i
, , i
of IN N
recognized VBN N
low JJ N
toxicity NN N
, , N
was VBD N
selected VBN N
for IN N
its PRP$ N
capacity NN N
to TO N
reverse VB N
abnormalities NNS N
that WDT N
have VBP N
been VBN N
associated VBN N
with IN N
ASD NNP N
, , N
including VBG o
oxidative JJ o
stress NN o
and CC o
lower JJR o
antioxidant NN o
capacity NN o
, , o
depressed VBD o
glutathione NN o
synthesis NN o
, , o
reduced VBN o
mitochondrial JJ o
function NN o
and CC o
oxidative JJ o
phosphorylation NN o
, , o
increased VBD o
lipid JJ o
peroxidation NN o
, , o
and CC o
neuroinflammmation NN o
. . o

-DOCSTART- -23361064- O O

Temporal JJ N
expectation NN N
in IN N
focal JJ p
hand NN p
dystonia NN p
. . p

Patients NNS p
with IN p
writer NN p
's POS p
cramp NN p
present JJ N
sensory NN N
and CC N
representational JJ N
abnormalities NNS N
relevant VBP N
to TO N
motor VB N
control NN N
, , N
such JJ N
as IN N
impairment NN N
in IN N
the DT N
temporal JJ N
discrimination NN N
between IN N
tactile JJ N
stimuli NNS N
and CC N
in IN N
pure JJ N
motor NN N
imagery NN N
tasks NNS N
, , N
like IN N
the DT N
mental JJ N
rotation NN N
of IN N
corporeal NN N
and CC N
inanimate JJ N
objects NNS N
. . N

However RB N
, , N
only RB N
limited JJ N
information NN N
is VBZ N
available JJ N
on IN N
the DT N
ability NN N
of IN N
patients NNS p
with IN p
dystonia NN p
to TO N
process VB N
the DT N
time-dependent JJ N
features NNS N
( ( N
e.g NN N
. . N

speed NN N
) ) N
of IN N
movement NN N
in IN N
real JJ N
time NN N
. . N

The DT N
processing NN N
of IN N
time-dependent JJ N
features NNS N
of IN N
movement NN N
has VBZ N
a DT N
crucial JJ N
role NN N
in IN N
predicting VBG N
whether IN N
the DT N
outcome NN N
of IN N
a DT N
complex JJ N
motor NN N
sequence NN N
, , N
such JJ N
as IN N
handwriting NN N
or CC N
playing VBG N
a DT N
musical JJ N
passage NN N
, , N
will MD N
be VB N
consistent JJ N
with IN N
its PRP$ N
ultimate JJ N
goal NN N
, , N
or CC N
results NNS N
instead RB N
in IN N
an DT N
execution NN N
error NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
implicit JJ N
ability NN N
to TO N
perceive VB N
the DT N
temporal JJ i
outcome NN i
of IN N
different JJ N
movements NNS N
in IN N
a DT N
group NN N
of IN N
patients NNS p
with IN p
writer NN p
's POS p
cramp NN p
. . p

Fourteen JJ p
patients NNS p
affected VBN p
by IN p
writer NN p
's POS p
cramp NN p
in IN p
the DT p
right JJ p
hand NN p
and CC p
17 CD p
age- JJ p
and CC p
gender-matched JJ p
healthy JJ p
subjects NNS p
were VBD p
recruited VBN p
for IN p
the DT p
study NN p
. . p

Subjects NNS N
were VBD N
asked VBN N
to TO N
perform VB N
a DT N
temporal JJ i
expectation NN i
task NN i
by IN N
predicting VBG N
the DT N
end NN N
of IN N
visually RB N
perceived VBN N
human JJ N
body NN N
motion NN N
( ( N
handwriting VBG N
, , N
i.e NN N
. . N

the DT N
action NN N
performed VBN N
by IN N
the DT N
human JJ N
body NN N
segment NN N
specifically RB N
affected VBN N
by IN N
writer NN N
's POS N
cramp NN N
) ) N
or CC N
inanimate JJ N
object JJ N
motion NN N
( ( N
a DT N
moving VBG N
circle NN N
reaching VBG N
a DT N
spatial JJ N
target NN N
) ) N
. . N

Videos NNP i
representing VBG i
movements NNS i
were VBD N
shown VBN N
in IN N
full JJ N
before IN N
experimental JJ N
trials NNS N
; : N
the DT N
actual JJ N
tasks NNS N
consisted VBN N
of IN N
watching VBG N
the DT N
same JJ N
videos NN N
, , N
but CC N
interrupted VBD N
after IN N
a DT N
variable JJ N
interval NN N
( ( N
'pre-dark NNP N
' POS N
) ) N
from IN N
its PRP$ N
onset VBN N
by IN N
a DT N
dark JJ N
interval NN N
of IN N
variable JJ N
duration NN N
. . N

During IN N
the DT N
'dark NNP N
' POS N
interval NN N
, , N
subjects NNS N
were VBD N
asked VBN N
to TO N
indicate VB N
when WRB N
the DT N
movement NN N
represented VBN N
in IN N
the DT N
video NN N
reached VBD N
its PRP$ N
end NN N
by IN N
clicking VBG N
on IN N
the DT N
space NN N
bar NN N
of IN N
the DT N
keyboard NN N
. . N

We PRP N
also RB N
included VBD N
a DT N
visual JJ o
working JJ o
memory NN o
task NN o
. . o

Performance NN N
on IN N
the DT N
timing NN N
task NN N
was VBD N
analysed VBN N
measuring VBG N
the DT N
absolute JJ N
value NN N
of IN N
timing VBG N
error NN N
, , N
the DT N
coefficient NN N
of IN N
variability NN N
and CC N
the DT N
percentage NN N
of IN N
anticipation NN N
responses NNS N
. . N

Patients NNS p
with IN p
writer NN p
's POS p
cramp NN p
exhibited VBD N
greater JJR N
absolute JJ N
timing NN N
error NN N
compared VBN N
with IN N
control NN N
subjects NNS N
in IN N
the DT N
human JJ N
body NN N
motion NN N
task NN N
( ( N
whereas IN N
no DT N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
inanimate NN N
object JJ N
motion NN N
task NN N
) ) N
. . N

No DT N
effect NN N
of IN N
group NN N
was VBD N
documented VBN N
on IN N
the DT N
visual JJ N
working JJ N
memory NN N
tasks NNS N
. . N

Absolute NNP o
timing VBG o
error NN o
on IN N
the DT N
human JJ N
body NN N
motion NN N
task NN N
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
symptom JJ N
severity NN N
, , N
disease VB N
duration NN N
or CC N
writing VBG N
speed NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
an DT N
alteration NN N
of IN N
the DT N
writing VBG N
movement NN N
representation NN N
at IN N
a DT N
central JJ N
level NN N
and CC N
are VBP N
consistent JJ N
with IN N
the DT N
view NN N
that IN N
dystonia NN N
is VBZ N
not RB N
a DT N
purely RB N
motor NN N
disorder NN N
, , N
but CC N
it PRP N
also RB N
involves VBZ N
non-motor NN N
( ( N
sensory JJ N
, , N
cognitive JJ N
) ) N
aspects NNS N
related VBN N
to TO N
movement NN N
processing NN N
and CC N
planning NN N
. . N

-DOCSTART- -24939380- O O

Electrothermal JJ i
arthroscopic NN i
capsulorrhaphy NN i
: : i
old JJ N
technology NN N
, , N
new JJ N
evidence NN N
. . N

A DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Radiofrequency NNP N
technology NN N
for IN N
shoulder JJR p
instability NN p
was VBD N
rapidly RB N
adopted VBN N
despite IN N
limited JJ N
clinical JJ N
evidence NN N
and CC N
a DT N
poor JJ N
understanding NN N
of IN N
its PRP$ N
indications NNS N
. . N

Reports NNS N
of IN N
serious JJ N
adverse JJ N
events NNS N
followed VBD N
, , N
leading VBG N
to TO N
its PRP$ N
abandonment NN N
. . N

This DT N
paper NN N
presents VBZ N
findings NNS N
from IN N
a DT N
multicenter NN N
randomized VBN N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
electrothermal JJ i
arthroscopic NN i
capsulorrhaphy NN i
( ( i
ETAC NNP i
) ) i
compared VBN i
with IN i
open JJ i
inferior JJ i
capsular JJ i
shift NN i
( ( i
ICS NNP i
) ) i
and CC N
reviews VBZ N
the DT N
role NN N
of IN N
randomized JJ N
trials NNS N
in IN N
adopting VBG N
new JJ N
technology NN N
. . N

METHODS NNP N
Patients NNPS p
( ( p
> JJ p
14 CD p
years NNS p
) ) p
diagnosed VBD p
with IN p
multidirectional JJ p
instability NN p
or CC p
multidirectional JJ p
laxity NN p
with IN p
anteroinferior JJ p
instability NN p
and CC p
failed VBD p
nonoperative JJ p
treatment NN p
were VBD p
enrolled VBN p
. . p

Patients NNS p
with IN p
bone JJ p
lesions NNS p
or CC p
labral JJ p
, , p
biceps JJ p
anchor NN p
, , p
or CC p
full-thickness JJ p
rotator NN p
cuff NN p
tears NNS p
were VBD p
excluded VBN p
intraoperatively RB p
. . p

Outcomes NNP N
included VBD o
Western NNP o
Ontario NNP o
Shoulder NNP o
Instability NNP o
Index NNP o
, , o
function NN o
and CC o
recurrent JJ o
instability NN o
at IN o
2 CD o
years NNS o
postoperatively RB o
, , o
and CC o
surgical JJ o
times NNS o
. . o

RESULTS NNP p
Fifty-four JJ p
subjects NNS p
( ( p
mean JJ p
age NN p
, , p
23 CD p
years NNS p
; : p
37 CD p
women NNS p
) ) p
were VBD p
randomized VBN p
to TO p
ETAC NNP N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
or CC N
open JJ N
ICS NNP N
( ( N
n JJ N
= NNP N
26 CD p
) ) p
. . p

The DT p
groups NNS N
were VBD N
comparable JJ N
at IN N
baseline NN N
, , N
except IN N
for IN o
external JJ o
rotation NN o
at IN o
the DT o
side NN o
. . o

At IN N
2 CD N
years NNS N
postoperatively RB N
, , N
there EX N
were VBD N
no DT N
statistically RB N
or CC N
clinically RB N
significant JJ N
differences NNS N
between IN N
groups NNS N
for IN N
the DT o
Western NNP o
Ontario NNP o
Shoulder NNP o
Instability NNP o
Index NNP o
( ( N
P NNP N
= NNP N
.71 NNP o
) ) o
, , o
American NNP o
Shoulder NNP o
and CC o
Elbow NNP o
Surgeons NNP o
score NN o
( ( o
P NNP N
= NNP N
.43 NNP N
) ) o
, , o
Constant JJ o
score NN o
( ( o
P NNP o
= NNP N
.43 NNP N
) ) N
, , N
and CC o
active JJ o
range NN o
of IN o
motion NN o
. . o

Recurrent NNP o
instability NN o
was VBD N
not RB N
statistically RB N
different JJ N
( ( N
ETAC NNP N
, , N
2 CD N
; : N
open JJ N
, , N
4 CD N
; : N
P NNP N
= NNP N
.41 NNP N
) ) N
. . N

ETAC NNP o
( ( o
23 CD o
minutes NNS o
) ) N
was VBD N
significantly RB N
shorter JJR N
than IN N
open JJ N
ICS NNP N
( ( N
59 CD N
minutes NNS N
) ) N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
surgery NN N
. . N

Three CD N
subjects NNS N
( ( N
1 CD N
ETAC NNP N
, , N
2 CD N
open JJ N
) ) N
had VBD N
stiff JJ N
shoulders NNS N
. . N

CONCLUSIONS NNP N
At IN N
2 CD N
years NNS N
postoperatively RB o
, , o
quality NN o
of IN o
life NN o
and CC o
functional JJ o
outcomes NNS o
between IN N
groups NNS N
were VBD N
not RB N
clinically RB N
different JJ N
. . N

ETAC NNP N
had VBD N
fewer JJR o
complications NNS o
and CC o
episodes NNS o
of IN o
recurrence NN o
compared VBN o
with IN N
open JJ N
surgery NN N
. . N

This DT N
evidence NN N
reinforces VBZ N
the DT N
need NN N
to TO N
critically VB N
evaluate VB N
new JJ N
technology NN N
before IN N
widespread JJ N
clinical JJ N
use NN N
. . N

-DOCSTART- -7997386- O O

Effect NN N
of IN N
intravenous JJ i
fructose-1,6-diphosphate NN i
on IN N
myocardial JJ o
contractility NN o
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
fructose-1,6-diphosphate NN i
on IN N
myocardial JJ o
performance NN o
using VBG N
nuclear JJ N
scintigraphy NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
single-blind JJ N
, , N
parallel JJ N
study NN N
. . N

SETTING NNP N
Urban NNP p
teaching VBG p
hospital JJ p
clinical JJ p
research NN p
center NN p
. . p

PATIENTS JJ N
Individuals NNS p
with IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
functional JJ p
class NN p
II-III NNP p
heart NN p
failure NN p
( ( p
mild JJ p
to TO p
moderate VB p
) ) p
. . p

INTERVENTIONS JJ N
Subjects NNPS N
received VBD N
either DT N
intravenous JJ i
fructose-1,6-diphosphate JJ i
125 CD i
mg/kg NN i
or CC i
normal JJ i
saline JJ i
1.3 CD N
ml/kg NN N
every DT N
12 CD N
hours NNS N
over IN N
10 CD N
minutes NNS N
for IN N
four CD N
consecutive JJ N
doses NNS N
. . N

Left NNP N
ventricular JJ N
performance NN N
was VBD N
assessed VBN N
by IN N
radionuclide NN i
ventriculography NN i
at IN N
baseline NN N
and CC N
within IN N
60 CD N
minutes NNS N
after IN N
the DT N
fourth JJ N
infusion NN N
. . N

Vital JJ N
signs NNS N
were VBD N
monitored VBN N
throughout IN N
the DT N
study NN N
period NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Fructose-1,6-diphosphate NNP i
resulted VBD N
in IN N
a DT N
modest JJ N
7 CD N
% NN N
increase NN N
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Peak JJ o
ejection NN o
rate NN o
and CC o
peak VB o
diastolic JJ o
filling VBG o
rate NN o
did VBD N
not RB N
change VB N
significantly RB N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
blood NN o
pressure NN o
or CC o
heart NN o
rate NN o
with IN N
either DT N
fructose-1,6-diphosphate JJ i
or CC N
placebo NN i
. . i

CONCLUSIONS NNP N
Fructose-1,6-diphosphate NNP i
produces VBZ N
a DT N
modest JJ N
but CC N
significant JJ N
increase NN N
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
heart NN p
failure NN p
. . p

-DOCSTART- -16595217- O O

Conventional JJ i
in IN i
vitro JJ i
fertilization NN i
versus IN N
intracytoplasmic JJ i
sperm JJ i
injection NN i
in IN p
patients NNS p
with IN p
borderline JJ p
semen NNS p
: : p
a DT N
randomized JJ N
study NN N
using VBG N
sibling VBG N
oocytes NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
patients NNS p
with IN p
borderline JJ p
semen NNS p
should MD N
be VB N
treated VBN N
with IN N
conventional JJ i
IVF NNP i
or CC N
intracytoplasmic JJ i
sperm JJ i
injection NN i
( ( i
ICSI NNP i
) ) i
. . i

DESIGN NNP N
Randomized NNP N
study NN N
. . N

SETTING VB N
A DT p
university NN p
medical JJ p
center NN p
in IN p
The DT p
Netherlands NNP p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
One CD p
hundred VBN p
six CD p
couples NNS p
with IN p
borderline JJ p
semen NNS p
who WP p
were VBD p
undergoing VBG p
IVF NNP i
and CC p
ICSI NNP i
on IN p
sibling VBG p
oocytes NNS p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Performing VBG N
IVF NNP i
and CC i
ICSI NNP i
on IN N
sibling VBG N
oocytes NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Fertilization NNP o
and CC o
pregnancy NN o
rates NNS o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
One CD N
thousand CD N
five CD N
hundred VBN N
eighteen NN N
oocytes NNS N
were VBD N
collected VBN N
in IN N
106 CD N
oocyte JJ N
retrievals NNS N
: : N
849 CD N
oocytes NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
ICSI NNP N
, , N
of IN N
which WDT N
761 CD N
were VBD N
microinjected VBN i
, , N
and CC N
669 CD N
oocytes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
IVF NNP i
. . i

In IN N
26 CD N
of IN N
the DT N
106 CD N
patients NNS N
, , N
there EX N
was VBD N
fertilization NN N
only RB N
after IN N
ICSI NNP i
and CC N
not RB N
after IN N
IVF NNP i
( ( N
IVF- NNP N
group NN N
) ) N
. . N

The DT N
fertilization NN o
rate NN o
was VBD N
51 CD N
% NN N
( ( N
92/182 CD N
oocytes NNS N
) ) N
. . N

In IN p
78 CD p
patients NNS p
, , N
there EX N
was VBD N
fertilization NN N
after IN N
both DT N
IVF NNP i
and CC N
ICSI NNP i
( ( N
IVF+ NNP N
group NN N
) ) N
; : N
the DT N
fertilization NN N
rate NN N
was VBD N
51 CD N
% NN N
for IN N
both DT N
the DT N
IVF- NNP i
and CC N
ICSI-treated NNP i
oocytes NNS N
( ( N
271/528 CD N
oocytes NNS N
and CC N
334/658 CD N
oocytes NNS N
, , N
respectively RB N
) ) N
. . N

In IN N
2 CD p
patients NNS p
, , N
there EX N
was VBD N
no DT N
fertilization NN N
after IN N
either DT N
IVF NNP i
( ( N
0/6 CD N
oocytes NNS N
) ) N
or CC N
ICSI NNP i
( ( N
0/9 CD N
oocytes NNS N
) ) N
. . N

Patients NNS p
of IN p
the DT p
IVF+ NNP p
group NN N
had VBD N
a DT N
higher JJR N
total JJ o
motile JJ o
sperm NN o
count NN o
after IN N
preparation NN N
than IN N
did VBD N
those DT N
of IN N
the DT N
IVF- NNP p
group NN p
. . p

More JJR N
high-quality JJ o
embryos NN o
were VBD N
obtained VBN N
after IN N
ICSI NNP i
in IN N
patients NNS N
of IN N
the DT N
IVF+ NNP i
group NN N
. . N

In IN N
101 CD p
patients NNS p
, , N
embryo FW o
transfer NN o
was VBD N
performed VBN N
: : N
26 CD N
in IN N
the DT N
IVF- NNP i
group NN N
and CC N
75 CD N
in IN N
the DT N
IVF+ NNP i
group NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
with IN N
regard NN N
to TO N
pregnancy VB o
rates NNS o
between IN N
those DT N
two CD N
groups NNS N
: : N
pregnancy NN N
rates NNS N
were VBD N
54 CD N
% NN N
in IN N
the DT N
IVF- NNP i
group NN N
and CC N
48 CD N
% NN N
in IN N
the DT N
IVF+ NNP i
group NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
Performing VBG N
ICSI NNP i
on IN N
at IN N
least JJS N
some DT N
of IN N
the DT N
oocytes NNS N
will MD N
avoid VB N
unnecessary JJ N
fertilization NN o
failure NN o
in IN N
patients NNS p
with IN p
borderline JJ p
semen NNS p
: : p
in IN N
this DT N
study NN N
, , N
26 CD N
of IN N
104 CD N
cycles NNS N
( ( N
25 CD N
% NN N
) ) N
were VBD N
rescued VBN N
by IN N
ICSI NNP i
. . i

-DOCSTART- -9933852- O O

Erythropoiesis NN N
after IN N
therapy NN N
with IN N
recombinant JJ i
human JJ i
erythropoietin NN i
: : i
a DT N
dose-response JJ N
study NN N
in IN N
anemic JJ p
cancer NN p
surgery NN p
patients NNS p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Preoperative NNP N
treatment NN N
with IN N
600 CD N
U/kg NNP N
of IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
r-HuEPO JJ i
) ) i
effectively RB N
increases VBZ N
erythropoiesis NN o
in IN N
cancer NN p
patients NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
erythropoietic JJ o
response NN o
after IN N
different JJ N
doses NNS N
of IN N
r-HuEPO NN i
in IN N
order NN N
to TO N
find VB N
the DT N
minimum JJ N
effective JJ N
dose NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty NNP p
anemic JJ p
sideropenic JJ p
patients NNS p
( ( p
hemoglobin JJ p
< NNP p
/=110 NNP p
g/l NN p
; : p
serum CC p
iron VB p
< JJ p
600 CD p
microg/l NN p
) ) p
with IN p
cancer NN p
of IN p
the DT p
gastrointestinal JJ p
tract NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD p
groups NNS p
: : p
the DT p
first JJ p
( ( p
n JJ p
= NNP p
10 CD p
) ) p
received VBD p
400 CD i
U/kg NNP i
of IN i
r-Hu JJ i
EPO NNP i
divided VBD i
in IN i
4 CD i
doses NNS i
( ( p
100 CD p
U/kg NNP p
each DT p
, , p
every DT p
4 CD p
days NNS p
) ) p
; : p
the DT p
second JJ p
( ( p
n JJ p
= NNP p
10 CD p
) ) p
received VBD i
200 CD i
U/kg NNP i
of IN i
r-HuEPO NN i
( ( p
50 CD p
U/kg NNP p
each DT p
, , p
every DT p
4 CD p
days NNS p
) ) p
. . p

Both DT N
groups NNS N
were VBD N
given VBN N
intravenous JJ i
iron NN i
gluconate NN i
( ( N
125 CD N
mg NN N
) ) N
every DT N
day NN N
for IN N
15 CD N
days NNS N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
serum NN o
iron NN o
level NN o
significantly RB o
rose VBD o
in IN N
both DT N
groups NNS N
. . N

The DT N
production NN N
of IN N
new JJ o
red JJ o
blood NN o
cells NNS o
was VBD N
176.3+/-90.8 JJ N
ml NN N
in IN N
the DT N
200 CD N
U/kg NNP N
group NN N
and CC N
268.4+/-79.4 JJ N
ml NN N
in IN N
the DT N
400 CD N
U/kg NNP N
group NN N
( ( N
p JJ N
= NNP N
0.036 CD N
) ) N
. . N

The DT N
increase NN o
of IN o
hemoglobin NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
400 CD N
U/kg NNP N
group NN N
( ( N
22.3+/-2.0 JJ N
g/l NN N
) ) N
than IN N
in IN N
the DT N
200 CD N
U/kg NNP N
group NN N
( ( N
14.1+/-2.7 JJ N
g/l NN N
) ) N
( ( N
p JJ N
= NNP N
0.017 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
r-HuEPO JJ N
dose NN N
of IN N
400 CD N
U/kg NNP N
appears VBZ N
significantly RB N
more RBR N
effective JJ o
than IN N
the DT N
200 CD N
U/kg NNP N
to TO N
stimulate VB N
erythropoiesis NN N
in IN N
anemic JJ p
sideropenic JJ p
cancer NN p
patients NNS p
. . p

-DOCSTART- -11743411- O O

Capsular JJ N
contracture NN N
around IN N
saline-filled JJ i
fine NN i
textured VBN i
and CC i
smooth JJ i
mammary JJ i
implants NNS i
: : i
a DT N
prospective JJ N
7.5-year JJ N
follow-up NN N
. . N

In IN N
a DT N
previous JJ N
prospective JJ N
randomized VBN N
clinical JJ N
study NN N
comparing VBG N
in IN N
the DT N
same JJ N
patient NN N
textured VBD N
and CC N
smooth JJ N
saline-filled JJ i
mammary JJ i
implants NNS i
( ( i
Biocell NNP i
) ) i
with IN N
large JJ N
pore NN N
size NN N
( ( N
300 CD N
to TO N
600 CD N
microm NN N
) ) N
, , N
we PRP N
saw VBD N
no DT N
difference NN N
in IN N
capsular JJ N
contracture NN N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
in IN N
a DT N
similar JJ N
way NN N
to TO N
compare VB N
capsular JJ N
contracture NN N
around IN N
smooth JJ N
and CC N
textured VBD N
saline-filled JJ i
prostheses NNS i
with IN N
pores NNS N
of IN N
small JJ N
size NN N
. . N

During IN p
a DT p
period NN p
of IN p
7.5 CD p
years NNS p
, , N
the DT N
breast NN N
hardness NN N
was VBD N
followed VBN N
up RP N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
patient JJ N
satisfaction NN N
was VBD N
evaluated VBN N
. . N

Twenty NNP p
healthy JJ p
women NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
30 CD p
years NNS p
were VBD p
operated VBN p
on IN p
for IN p
breast NN p
augmentation NN p
. . p

Two CD N
surgeons NNS N
performed VBD N
all DT N
operations NNS N
in IN N
a DT N
standardized JJ N
way NN N
. . N

Each DT N
patient NN N
received VBD N
subglandularly RB i
a DT i
Siltex NNP i
textured VBD i
saline-filled JJ i
prosthesis NN i
with IN N
a DT N
pore NN N
size NN N
of IN N
30 CD N
to TO N
70 CD N
microm NN N
in IN N
one CD N
breast NN N
, , N
and CC N
a DT N
smooth JJ i
saline-filled JJ i
prosthesis NN i
in IN i
the DT i
other JJ i
. . i

The DT o
hardness NN o
of IN o
the DT o
breasts NNS o
was VBD N
evaluated VBN N
after IN N
0.5 CD N
, , N
1 CD N
, , N
and CC N
7.5 CD N
years NNS N
using VBG N
Baker NNP o
grading NN o
and CC o
applanation NN o
tonometry NN o
. . o

Eighteen JJ p
patients NNS p
completed VBN p
1-year JJ p
and CC p
7.5-year JJ p
follow-up NN p
. . p

Two CD N
breasts NNS N
with IN N
smooth JJ N
prostheses NNS N
were VBD N
contracted VBN N
after IN N
6 CD N
months NNS N
( ( N
Baker NNP N
III NNP N
or CC N
IV NNP N
) ) N
. . N

After IN N
1 CD N
year NN N
, , N
four CD N
patients NNS N
with IN N
smooth JJ N
prostheses NNS N
and CC N
one CD N
with IN N
a DT N
textured JJ N
prosthesis NN N
had VBD N
capsular JJ o
contracture NN o
( ( N
p JJ N
= NNP N
0.34 CD N
) ) N
. . N

Seven CD N
and CC N
one-half JJ N
years NNS N
after IN N
surgery NN N
, , N
six CD N
patents NNS N
with IN N
smooth DT N
and CC N
four CD N
with IN N
textured JJ N
implants NNS i
had VBD N
contracture NN o
( ( N
p JJ N
= NNP N
0.66 CD N
) ) N
. . N

On IN N
two CD N
patients NNS N
with IN N
smooth JJ N
prostheses NNS N
and CC N
one CD N
patient NN N
with IN N
a DT N
textured JJ N
prosthesis NN N
, , N
the DT N
capsule NN o
around IN o
the DT o
implant NN o
hardened VBD o
between IN N
6 CD N
and CC N
12 CD N
months NNS N
. . N

Between NNP N
1 CD N
year NN N
and CC N
7.5 CD N
years NNS N
, , N
three CD N
breasts NNS N
with IN N
smooth JJ o
and CC o
textured JJ o
implants NNS o
contracted VBD o
and CC o
one CD o
with IN o
a DT o
textured JJ o
implant NN o
softened.The NN o
patients NNS N
reported VBN N
on IN N
a DT N
Visual NNP o
Analogue NNP o
Scale NNP o
( ( N
1 CD N
to TO N
10 CD N
) ) N
the DT N
impact NN N
of IN N
the DT N
augmentation NN N
on IN N
their PRP$ N
quality NN o
of IN o
life NN o
to TO N
be VB N
9 CD N
+/- JJ N
1 CD N
. . N

Four CD N
patients NNS N
preferred VBD N
the DT N
breast NN N
with IN N
the DT N
smooth JJ N
prosthesis NN N
, , N
three CD N
preferred VBD N
the DT N
breast NN N
with IN N
the DT N
textured JJ N
prosthesis NN N
, , N
and CC N
the DT N
others NNS N
found VBD N
both DT N
breasts NNS N
equal VBP N
. . N

This DT N
study NN N
showed VBD N
no DT N
significant JJ o
difference NN o
of IN N
contracture NN o
with IN N
smooth JJ N
versus FW N
fine JJ N
textured VBN N
implants NNS N
. . N

The DT N
majority NN N
of IN N
the DT N
patients NNS N
preferred VBD o
the DT o
smooth JJ o
implants NNS o
. . o

The DT N
patients NNS N
reported VBD N
that IN N
the DT N
breast NN N
augmentation NN N
had VBD N
had VBN N
an DT N
extremely RB o
high JJ o
impact NN o
on IN o
their PRP$ o
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -12059064- O O

Can MD N
sedation VB N
reduce VB N
the DT N
cardiac JJ N
stress NN N
during IN N
gastrointestinal JJ N
endoscopy NN N
? . N
A DT N
study NN N
with IN N
non-invasive JJ N
automated JJ N
cardiac NN N
flow NN N
measurement NN N
by IN N
color NN N
Doppler NNP N
echocardiography NN N
. . N

BACKGROUND NNP N
Upper NNP p
gastrointestinal JJ p
endoscopy NN p
( ( p
UGIE NNP p
) ) p
may MD N
cause VB N
some DT N
cardiac JJ N
stress NN N
. . N

The DT N
effect NN N
of IN N
sedation NN N
on IN N
hemodynamics NNS N
during IN N
UGIE NNP N
has VBZ N
not RB N
been VBN N
fully RB N
studied VBN N
, , N
and CC N
therefore RB N
the DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
clarify VB N
whether IN N
or CC N
not RB N
sedation NN N
can MD N
reduce VB N
cardiac JJ N
stress NN N
dufing VBG N
UGIE NNP N
. . N

METHODS NNP N
Eight NNP p
normal JJ p
male NN p
volunteers NNS p
undergoing VBG p
UGIE NNP i
with IN i
sedation NN i
( ( i
0.1 CD i
mg/kg NN i
of IN i
midazolam NN i
) ) i
and CC p
without IN i
it PRP i
( ( i
two CD i
endoscopies NNS i
per IN i
volunteer NN i
in IN i
random JJ i
order NN i
) ) i
were VBD i
monitored VBN i
throughout IN i
the DT i
procedure NN i
by IN i
means NNS i
of IN i
electrocardiogram NN o
, , o
blood NN o
pressure NN o
and CC o
peripheral JJ o
oxygen NN o
saturation NN o
( ( i
SpO2 NNP i
) ) i
. . i

Cardiac NNP o
output NN o
was VBD o
measured VBN i
at IN i
six CD i
points NNS i
before IN i
, , i
during IN i
and CC i
after IN i
endoscopy NN i
from IN i
automated VBN i
cardiac NN i
flow NN i
measurement NN i
by IN i
color NN i
Doppler NNP i
echocardiography NN i
. . i

Serum NNP o
norepinephrine NN o
, , o
epinephrine NN o
, , o
dopamine NN o
and CC o
ACTH NNP o
concentrations NNS o
were VBD N
measured VBN N
before IN N
and CC N
after IN N
the DT N
examination NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
differences NNS N
in IN N
heart NN o
rate NN o
, , o
systolic JJ o
blood NN o
pressure NN o
, , o
rate-pressure JJ o
product NN o
, , o
cardiac JJ o
output NN o
and CC o
left VBD o
ventricular JJ o
work NN o
index NN o
were VBD N
observed VBN N
between IN N
the DT N
sedated VBN N
and CC N
non-sedated JJ N
groups NNS N
. . N

SpO2 NNP o
hardly RB N
changed VBD N
during IN N
endoscopy NN N
in IN N
the DT N
non-sedated JJ N
group NN N
, , N
but CC N
decreased VBD N
slightly RB N
in IN N
the DT N
sedated VBN N
group NN N
( ( N
P NNP N
= NNP N
0.075 CD N
) ) N
. . N

Although IN N
all DT N
serum JJ N
catecholamine NN N
concentration NN N
changes NNS N
were VBD N
within IN N
normal JJ N
limits NNS N
in IN N
both DT N
groups NNS N
, , N
after IN N
endoscopy VBG N
only RB N
epinephrine JJ N
concentration NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
sedated JJ N
group NN N
than IN N
in IN N
the DT N
non-sedated JJ N
group NN N
( ( N
P NNP N
= NNP N
0.0027 CD N
) ) N
. . N

CONCLUSIONS NNP N
Conscious NNP N
sedation NN N
with IN N
midazolam NN i
does VBZ N
not RB N
reduce VB N
the DT N
cardiac JJ N
stress NN N
during IN N
UGIE NNP N
. . N

-DOCSTART- -3287907- O O

Analgesic JJ o
efficacy NN o
of IN N
piroxicam NN i
in IN N
the DT N
treatment NN N
of IN N
postoperative JJ o
pain NN o
. . o

Two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
single-dose JJ N
studies NNS N
were VBD N
conducted VBN N
to TO N
assess VB N
the DT N
analgesic JJ o
efficacy NN o
and CC o
safety NN o
of IN N
piroxicam NN i
for IN N
the DT N
treatment NN N
of IN N
moderate JJ o
or CC o
severe JJ o
postoperative JJ o
pain NN o
. . o

Study NNP N
1 CD N
evaluated VBD N
the DT N
analgesic JJ N
efficacy NN N
of IN N
piroxicam NN i
20 CD N
mg NN N
compared VBN N
with IN N
that DT N
of IN N
codeine NN i
sulfate NN i
60 CD N
mg NN N
and CC i
placebo NN i
. . i

A DT p
final JJ p
patient NN p
population NN p
of IN p
149 CD p
subjects NNS p
rated VBN N
pain JJ o
intensity NN o
and CC o
pain NN o
relief NN o
at IN N
one CD N
half NN N
hour NN N
and CC N
one CD N
hour NN N
following VBG N
treatment NN N
and CC N
then RB N
hourly RB N
for IN N
six CD N
hours NNS N
, , N
with IN N
a DT N
global JJ N
assessment NN N
made VBN N
at IN N
the DT N
completion NN N
of IN N
24 CD N
hours NNS N
. . N

Piroxicam NNP i
20 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
efficacious JJ o
than IN N
placebo NN i
for IN N
all DT N
analgesic JJ N
variables NNS N
, , N
including VBG N
the DT N
sum NN o
of IN o
the DT o
pain NN o
intensity NN o
differences NNS o
( ( o
SPID NNP o
) ) o
, , o
total JJ o
pain NN o
relief NN o
( ( o
TOTAL NNP o
) ) o
, , o
percent JJ o
SPID NNP o
, , o
duration NN o
of IN o
effect NN o
, , o
and CC o
time NN o
to TO o
remedication NN o
. . o

Codeine VB i
60 CD N
mg NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB i
for IN N
percent NN o
SPID NNP o
and CC N
some DT N
hourly JJ N
measures NNS N
. . N

Piroxicam NNP i
20 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
codeine VBP i
60 CD N
mg NN N
for IN N
percent NN o
SPID NNP o
and CC N
a DT N
few JJ N
hourly JJ N
measures NNS N
including VBG N
time NN N
to TO N
remedication NN N
. . N

Study NNP N
2 CD N
assessed VBD N
the DT N
efficacy NN o
of IN N
piroxicam NN i
20 CD N
mg NN N
or CC N
40 CD N
mg NNS N
compared VBN N
with IN N
aspirin JJ i
648 CD N
mg NN N
and CC N
placebo NN i
. . i

Sixty CD p
patients NNS p
rated VBN N
their PRP$ N
pain NN o
intensity NN o
and CC o
relief NN o
hourly RB N
for IN N
12 CD N
hours NNS N
and CC N
at IN N
24 CD N
hours NNS N
after IN N
administration NN N
of IN N
study JJ N
medication NN N
. . N

Both DT N
doses NNS N
of IN N
piroxicam NN i
were VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
placebo NN N
from IN N
Hours $ N
2 CD N
to TO N
12 CD N
for IN N
pain NN o
intensity NN o
difference NN o
( ( o
PID NNP o
) ) o
and CC o
relief NN o
scores NNS o
, , o
as RB o
well RB o
as IN o
for IN o
SPID NNP o
and CC o
TOTAL NNP o
. . o

Aspirin NNP N
was VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
placebo NN i
from IN N
Hours $ N
2 CD N
to TO N
8 CD N
for IN N
relief NN o
and CC N
Hours $ N
2 CD N
to TO N
10 CD N
for IN N
PID NNP o
as RB o
well RB o
as IN o
SPID NNP o
and CC o
TOTAL NNP o
. . o

Piroxicam NNP i
40 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
aspirin RB i
648 CD N
mg NN N
for IN N
SPID NNP o
, , o
TOTAL NNP o
, , o
and CC o
hourly RB o
measures NNS o
beginning VBG N
with IN N
Hour NNP N
6 CD N
through IN N
Hour NNP N
12 CD N
. . N

Piroxicam VB i
20 CD N
mg NN N
was VBD N
significantly RB N
better JJR N
than IN N
aspirin NN i
for IN N
a DT N
few JJ N
hourly JJ N
measures NNS N
: : N
Hours $ N
7 CD N
to TO N
9 CD N
for IN N
relief NN N
and CC N
Hour $ N
7 CD N
for IN N
PID NNP o
. . o

In IN N
addition NN N
, , N
effects NNS N
of IN N
piroxicam NN N
20 CD N
mg NN N
had VBD N
a DT N
significantly RB N
longer JJR o
duration NN o
than IN N
aspirin NN N
. . N

Similarly RB N
, , N
piroxicam VBD i
20 CD N
mg NN N
had VBD N
a DT N
significantly RB N
longer JJR o
time NN o
to TO o
remedication VB o
compared VBN N
with IN N
aspirin NN i
and CC N
placebo NN i
. . N

The DT N
results NNS N
of IN N
these DT N
studies NNS N
provide VBP N
evidence NN N
in IN N
support NN N
of IN N
the DT N
longer JJR N
duration NN o
of IN o
analgesic JJ o
efficacy NN o
of IN N
piroxicam NNS i
compared VBN N
with IN N
codeine NN i
or CC i
aspirin NN i
in IN N
patients NNS p
with IN p
postoperative JJ o
pain NN o
. . o

-DOCSTART- -18249478- O O

Evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
human JJ N
leukocyte JJ i
IFN-alpha NN i
on IN N
the DT N
immune JJ o
response NN o
to TO o
the DT o
HBV NNP o
vaccine NN o
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

HBV NNP i
vaccine NN i
needs VBZ N
3 CD N
injections NNS N
over IN N
6 CD N
months NNS N
to TO N
induce VB N
immunity NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
adjuvants NNS N
capable JJ N
of IN N
inducing VBG N
earlier JJR N
immune JJ N
protection NN N
would MD N
be VB N
highly RB N
desirable JJ N
. . N

Most JJS N
adjuvants NNS N
may MD N
act VB N
by IN N
inducing VBG N
cytokines NNS N
, , N
and CC N
among IN N
them PRP N
, , N
type NN N
I PRP N
interferons NNS N
( ( N
IFNs NNP N
) ) N
, , N
deserve VB N
a DT N
special JJ N
attention NN N
in IN N
view NN N
of IN N
the DT N
potent JJ N
immunomostimulatory NN N
activity NN N
observed VBN N
in IN N
mouse NN N
models NNS N
and CC N
on IN N
dendritic JJ N
cell NN N
functions NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
IFN-alpha NNP i
administered VBD N
as IN N
an DT N
adjuvant NN i
of IN i
HBV NNP i
vaccine NN i
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

No DT N
significant JJ N
enhancing VBG N
effect NN N
on IN N
the DT N
antibody NN o
response NN o
was VBD N
observed VBN N
, , N
in IN N
spite NN N
of IN N
an DT N
early JJ N
and CC N
transient JJ N
upregulation NN N
of IN N
costimulatory NN N
molecule NN N
expression NN N
on IN N
peripheral JJ o
blood NN o
mononuclear NN o
cells NNS o
, , N
which WDT N
may MD N
be VB N
suggestive JJ N
of IN N
an DT N
IFN-mediated JJ N
activation NN N
of IN N
antigen NN N
presenting VBG N
cells NNS N
. . N

We PRP N
conclude VBP N
that IN N
, , N
under IN N
the DT N
conditions NNS N
used VBN N
in IN N
this DT N
trial NN N
, , N
natural JJ N
IFN-alpha NNP i
does VBZ N
not RB N
act VB N
as IN N
an DT N
adjuvant NN N
of IN N
the DT N
HBV NNP N
vaccine NN N
in IN N
healthy JJ p
unvaccinated JJ p
individuals NNS p
. . p

-DOCSTART- -1391736- O O

Treatment NN N
of IN N
peptic JJ o
ulcer JJ o
disease NN o
with IN N
furazolidone NN i
. . i

Furazolidone NNP i
( ( N
FZ NNP N
) ) N
has VBZ N
been VBN N
used VBN N
in IN N
China NNP N
as IN N
a DT N
treatment NN N
of IN N
peptic JJ o
ulcer JJ p
disease NN p
for IN N
about IN N
20 CD N
years NNS N
. . N

Clinical JJ N
and CC N
experimental JJ N
studies NNS N
suggest VBP N
that IN N
it PRP N
has VBZ N
good JJ N
short-term JJ N
and CC N
long-term JJ N
effects NNS N
on IN N
both DT N
human JJ p
and CC p
animal JJ o
ulcers NNS o
. . o

The DT N
ulcer JJ o
healing NN o
rate NN N
is VBZ N
related VBN N
to TO N
the DT N
dosage NN N
and CC N
course NN N
of IN N
treatment NN N
. . N

The DT N
healing VBG N
rate NN N
of IN N
a DT N
high JJ N
dose NN N
, , N
2 CD N
week NN N
course NN N
is VBZ N
about IN N
70-75 CD N
% NN N
and CC N
the DT N
relapse NN N
rate NN N
after IN N
3 CD N
years NNS N
is VBZ N
9.5 CD N
% NN N
. . N

The DT N
adverse JJ N
reactions NNS N
to TO N
FZ NNP N
are VBP N
not RB N
severe JJ N
, , N
and CC N
are VBP N
well RB N
tolerated VBN o
in IN N
most JJS N
patients NNS N
. . N

However RB N
the DT N
mutagenic JJ N
studies NNS N
of IN N
several JJ N
biological JJ N
systems NNS N
indicate VBP N
that IN N
it PRP N
has VBZ N
a DT N
mutagenic JJ o
effect NN N
, , N
but CC N
the DT N
mutagenic JJ N
and CC N
carcinogenic JJ o
effects NNS N
on IN N
humans NNS N
and CC N
animals NNS N
remain VBP N
questionable JJ N
, , N
because IN N
FZ NNP N
has VBZ N
been VBN N
biotransformed VBN N
into IN N
other JJ N
metabolites NNS N
. . N

The DT N
mechanisms NN N
of IN N
FZ NNP N
in IN N
the DT N
treatment NN N
of IN N
peptic JJ p
ulcer JJ p
disease NN p
are VBP N
not RB N
fully RB N
understood JJ N
, , N
perhaps RB N
partly RB N
due JJ N
to TO N
the DT N
monoamine NN o
oxidase NN o
( ( o
MAO NNP o
) ) o
inhibitory NN o
reaction NN o
and CC N
partly RB N
to TO N
the DT N
antibacterial JJ o
activity NN o
to TO o
Helicobacter NNP o
pylori NN o
( ( N
HP NNP N
) ) N
. . N

The DT N
long-term JJ N
effects NNS N
of IN N
FZ NNP N
are VBP N
still RB N
not RB N
clear JJ N
. . N

-DOCSTART- -10566623- O O

A DT N
comparison NN N
of IN N
recombinant JJ N
human JJ N
thyrotropin NN N
and CC N
thyroid VB N
hormone NN N
withdrawal NN N
for IN N
the DT N
detection NN N
of IN N
thyroid JJ N
remnant NN N
or CC N
cancer NN N
. . N

Recombinant NNP i
human JJ i
TSH NNP i
has VBZ N
been VBN N
developed VBN N
to TO N
facilitate VB N
monitoring NN N
for IN N
thyroid JJ N
carcinoma NN N
recurrence NN N
or CC N
persistence NN N
without IN N
the DT N
attendant JJ N
morbidity NN N
of IN N
hypothyroidism NN N
seen VBN N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
administered VBN i
recombinant JJ i
human JJ i
TSH NN i
with IN N
thyroid JJ N
hormone NN N
withdrawal NN N
on IN N
the DT N
results NNS N
of IN N
radioiodine JJ N
whole JJ N
body NN N
scanning VBG N
( ( N
WBS NNP N
) ) N
and CC N
serum JJ N
thyroglobulin NN N
( ( N
Tg NNP N
) ) N
levels NNS N
. . N

Two CD p
hundred CD p
and CC p
twenty-nine JJ p
adult NN p
patients NNS p
with IN p
differentiated JJ p
thyroid NN p
cancer NN p
requiring VBG p
radioiodine NN p
WBS NNP p
were VBD p
studied VBN p
. . p

Radioiodine NNP i
WBS NNP i
and CC N
serum VB N
Tg NNP N
measurements NNS N
were VBD N
performed VBN N
after IN N
administration NN N
of IN N
recombinant JJ i
human JJ i
TSH NNP i
and CC N
again RB N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
in IN N
each DT N
patient NN N
. . N

Radioiodine NNP N
whole JJ N
body NN N
scans NNS N
were VBD N
concordant JJ N
between IN N
the DT N
recombinant JJ o
TSH-stimulated JJ o
and CC o
thyroid JJ o
hormone NN o
withdrawal NN o
phases NNS o
in IN N
195 CD N
of IN N
220 CD N
( ( N
89 CD N
% NN N
) ) N
patients NNS N
. . N

Of IN N
the DT N
discordant NN N
scans NNS N
, , N
8 CD N
( ( N
4 CD N
% NN N
) ) N
had VBD N
superior JJ N
scans NNS N
after IN N
recombinant JJ i
human JJ i
TSH NNP i
administration NN i
, , N
and CC N
17 CD N
( ( N
8 CD N
% NN N
) ) N
had VBD N
superior JJ N
scans NNS N
after IN N
thyroid JJ N
hormone NN N
withdrawal NN N
( ( N
P NNP N
= NNP N
0.108 CD N
) ) N
. . N

Based VBN N
on IN N
a DT N
serum NN o
Tg NNP o
level NN o
of IN N
2 CD N
ng/mL NNS N
or CC N
more JJR N
, , N
thyroid JJ N
tissue NN N
or CC N
cancer NN N
was VBD N
detected VBN N
during IN N
thyroid JJ i
hormone NN i
therapy NN i
in IN N
22 CD N
% NN N
, , N
after IN N
recombinant JJ i
human JJ i
TSH NNP i
stimulation NN N
in IN N
52 CD N
% NN N
, , N
and CC N
after IN N
thyroid JJ i
hormone NN i
withdrawal NN i
in IN N
56 CD N
% NN N
of IN N
patients NNS p
with IN p
disease NN p
or CC p
tissue NN p
limited VBN p
to TO p
the DT p
thyroid NN p
bed NN p
and CC N
in IN N
80 CD N
% NN N
, , N
100 CD N
% NN N
, , N
and CC N
100 CD p
% NN p
of IN p
patients NNS p
, , p
respectively RB p
, , p
with IN p
metastatic JJ p
disease NN p
. . p

A DT N
combination NN N
of IN N
radioiodine NN N
WBS NNP N
and CC N
serum NN N
Tg NNP N
after IN N
recombinant JJ N
human JJ N
TSH NNP N
stimulation NN N
detected VBD N
thyroid JJ o
tissue NN o
or CC o
cancer NN o
in IN N
93 CD N
% NN N
of IN N
patients NNS p
with IN p
disease NN p
or CC p
tissue NN p
limited VBN p
to TO p
the DT p
thyroid NN p
bed NN p
and CC N
100 CD N
% NN N
of IN N
patients NNS p
with IN p
metastatic JJ p
disease NN p
. . p

In IN N
conclusion NN N
, , N
recombinant JJ i
human JJ i
TSH NNP i
administration NN i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
means NNS N
of IN N
stimulating VBG N
radioiodine JJ N
uptake NN N
and CC N
serum NN N
Tg NNP N
levels NNS N
in IN N
patients NNS p
undergoing JJ p
evaluation NN p
for IN p
thyroid JJ p
cancer NN p
persistence NN p
and CC p
recurrence NN p
. . p

-DOCSTART- -20494434- O O

Parent-mediated JJ i
communication-focused JJ i
treatment NN i
in IN N
children NNS p
with IN p
autism NN p
( ( N
PACT NNP N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Results NNP N
of IN N
small JJ N
trials NNS N
suggest VBP N
that IN N
early JJ N
interventions NNS N
for IN N
social JJ N
communication NN N
are VBP N
effective JJ N
for IN N
the DT N
treatment NN N
of IN N
autism NN p
in IN p
children NNS p
. . p

We PRP N
therefore RB N
investigated VBD N
the DT N
efficacy NN o
of IN N
such JJ N
an DT N
intervention NN N
in IN N
a DT N
larger JJR N
trial NN N
. . N

METHODS NNP N
Children NNP p
with IN p
core NN p
autism NN p
( ( p
aged VBN p
2 CD p
years NNS p
to TO p
4 CD p
years NNS p
and CC p
11 CD p
months NNS p
) ) p
were VBD p
randomly RB p
assigned VBN p
in IN p
a DT p
one-to-one JJ p
ratio NN p
to TO p
a DT p
parent-mediated JJ i
communication-focused JJ i
( ( i
Preschool NNP i
Autism NNP i
Communication NNP i
Trial NNP i
[ NNP i
PACT NNP i
] NNP i
) ) i
intervention NN i
or CC N
treatment NN i
as IN i
usual JJ i
at IN N
three CD N
specialist NN N
centres NNS N
in IN N
the DT N
UK NNP N
. . N

Those DT N
assigned VBN N
to TO N
PACT NNP N
were VBD N
also RB N
given VBN N
treatment NN N
as IN N
usual JJ N
. . N

Randomisation NN N
was VBD p
by IN p
use NN p
of IN p
minimisation NN p
of IN p
probability NN p
in IN p
the DT p
marginal JJ p
distribution NN p
of IN p
treatment NN p
centre NN p
, , p
age NN p
( ( p
< JJ p
/=42 NNP p
months NNS p
or CC p
> $ p
42 CD p
months NNS p
) ) p
, , p
and CC p
autism NN p
severity NN p
( ( p
Autism NNP p
Diagnostic NNP p
Observation NNP p
Schedule-Generic NNP p
[ NNP p
ADOS-G NNP p
] NNP p
algorithm VBZ p
score RB p
12-17 JJ p
or CC p
18-24 JJ p
) ) p
. . N

Primary JJ N
outcome NN N
was VBD N
severity NN o
of IN o
autism NN o
symptoms NNS o
( ( o
a DT o
total NN o
score NN o
of IN o
social JJ o
communication NN o
algorithm NNS o
items NNS o
from IN o
ADOS-G NNP o
, , o
higher JJR o
score NN o
indicating VBG o
greater JJR o
severity NN o
) ) o
at IN o
13 CD o
months NNS o
. . o

Complementary NNP N
secondary JJ N
outcomes NNS N
were VBD N
measures NNS o
of IN o
parent-child JJ o
interaction NN o
, , o
child JJ o
language NN o
, , o
and CC o
adaptive JJ o
functioning NN o
in IN o
school NN o
. . o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
as IN N
an DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Trial NNP N
, , N
number NN N
ISRCTN58133827 NNP N
. . N

RESULTS NNP N
152 CD p
children NNS p
were VBD p
recruited VBN p
. . p

77 CD p
were VBD p
assigned VBN p
to TO p
PACT NNP i
( ( p
London NNP p
[ NNP p
n=26 MD p
] VB p
, , p
Manchester NNP p
[ NNP p
n=26 MD p
] VB p
, , p
and CC p
Newcastle NNP p
[ NNP p
n=25 FW p
] NNP p
) ) p
; : p
and CC p
75 CD p
to TO p
treatment NN i
as IN i
usual JJ i
( ( p
London NNP p
[ NNP p
n=26 MD p
] VB p
, , p
Manchester NNP p
[ NNP p
n=26 MD p
] VB p
, , p
and CC p
Newcastle NNP p
[ NNP p
n=23 FW p
] NNP p
) ) p
. . p

At IN N
the DT N
13-month JJ N
endpoint NN N
, , N
the DT N
severity NN o
of IN o
symptoms NNS o
was VBD N
reduced VBN N
by IN N
3.9 CD N
points NNS N
( ( N
SD NNP N
4.7 CD N
) ) N
on IN N
the DT N
ADOS-G NNP N
algorithm NN N
in IN N
the DT N
group NN N
assigned VBD N
to TO N
PACT NNP N
, , N
and CC N
2.9 CD N
( ( N
3.9 CD N
) ) N
in IN N
the DT N
group NN N
assigned VBD N
to TO N
treatment NN N
as IN N
usual JJ N
, , N
representing VBG N
a DT N
between-group JJ N
effect NN N
size NN N
of IN N
-0.24 NNP N
( ( N
95 CD N
% NN N
CI NNP N
-0.59 NNP N
to TO N
0.11 CD N
) ) N
, , N
after IN N
adjustment NN N
for IN N
centre NN N
, , N
sex NN N
, , N
socioeconomic JJ N
status NN N
, , N
age NN N
, , N
and CC N
verbal JJ N
and CC N
non-verbal JJ N
abilities NNS N
. . N

Treatment NNP N
effect NN N
was VBD N
positive JJ N
for IN N
parental JJ o
synchronous JJ o
response NN o
to TO N
child VB N
( ( N
1.22 CD N
, , N
0.85 CD N
to TO N
1.59 CD N
) ) N
, , N
child JJ N
initiations NNS N
with IN N
parent NN N
( ( N
0.41 CD N
, , N
0.08 CD N
to TO N
0.74 CD N
) ) N
, , N
and CC N
for IN N
parent-child JJ N
shared VBN N
attention NN N
( ( N
0.33 CD N
, , N
-0.02 NN N
to TO N
0.68 CD N
) ) N
. . N

Effects NNS N
on IN N
directly RB o
assessed VBN o
language NN o
and CC o
adaptive JJ o
functioning NN o
in IN N
school NN N
were VBD N
small JJ N
. . N

INTERPRETATION NN N
On IN N
the DT N
basis NN N
of IN N
our PRP$ N
findings NNS N
, , N
we PRP N
can MD N
not RB N
recommend VB N
the DT N
addition NN N
of IN N
the DT N
PACT NNP i
intervention NN i
to TO N
treatment NN N
as IN N
usual JJ N
for IN N
the DT N
reduction NN N
of IN N
autism NN N
symptoms NNS N
; : N
however RB N
, , N
a DT N
clear JJ N
benefit NN N
was VBD N
noted VBN N
for IN N
parent-child JJ o
dyadic JJ o
social JJ o
communication NN o
. . o

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
, , N
and CC N
UK NNP N
Department NNP N
for IN N
Children NNP N
, , N
Schools NNP N
and CC N
Families NNP N
. . N

-DOCSTART- -12233894- O O

14 CD N
day NN N
endoscopy NN N
study NN N
comparing VBG N
risedronate NN i
and CC N
alendronate NN i
in IN N
postmenopausal JJ p
women NNS p
stratified VBN p
by IN p
Helicobacter NNP p
pylori NN p
status NN p
. . p

OBJECTIVE NNP N
Bisphosphonates NNPS i
are VBP N
effective JJ N
treatment NN N
for IN N
osteoporosis NN N
but CC N
have VBP N
been VBN N
associated VBN N
with IN N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
mucosal NN N
injury NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
incidence NN N
of IN N
gastric JJ N
ulcers NNS N
after IN N
treatment NN N
with IN N
risedronate NN i
, , i
a DT i
pyridinyl NN i
bisphosphonate NN i
, , i
or CC i
alendronate NN i
, , i
a DT i
primary JJ i
amino NN i
bisphosphonate NN i
, , N
in IN N
healthy JJ p
postmenopausal NN p
women NNS p
stratified VBN p
by IN p
Helicobacter NNP p
pylori NN p
status NN p
. . p

METHODS NNP N
Subjects NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
risedronate NN i
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
318 CD N
) ) N
or CC N
alendronate $ i
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
317 CD N
) ) N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Endoscopy NNP i
and CC N
evaluator-blind JJ N
assessments NNS N
of IN N
the DT N
esophageal NN N
, , N
gastric NN N
, , N
and CC N
duodenal JJ N
mucosa NN N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
on IN N
Days NNP N
8 CD N
and CC N
15 CD N
. . N

RESULTS NNP N
Overall NNP N
, , N
gastric JJ o
ulcers NNS o
> VBP N
or CC N
= VBP N
3 CD N
mm NNS N
were VBD N
observed VBN N
in IN N
18 CD N
( ( N
6.0 CD N
% NN N
) ) N
of IN N
300 CD N
evaluable JJ N
subjects NNS N
in IN N
the DT N
risedronate NN i
group NN N
and CC N
36 CD N
( ( N
12.1 CD N
% NN N
) ) N
of IN N
297 CD N
in IN N
the DT N
alendronate NN N
group NN N
during IN N
treatment NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
. . N

On IN N
Day NNP N
8 CD N
, , N
the DT N
incidences NNS o
of IN o
gastric JJ o
ulcers NNS o
in IN N
the DT N
risedronate NN i
and CC N
alendronate NN i
groups NNS N
were VBD N
3.6 CD N
% NN N
and CC N
6.6 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.133 CD N
) ) N
, , N
and CC N
on IN N
Day NNP N
15 CD N
, , N
they PRP N
were VBD N
3.3 CD N
% NN N
and CC N
8.7 CD N
% NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
gastric JJ o
ulcers NNS o
was VBD N
not RB N
affected VBN N
by IN N
H. NNP N
pylori NN N
status NN N
. . N

Mean NNP o
gastric JJ o
endoscopy NN o
scores NNS o
at IN N
Days NNP N
8 CD N
and CC N
15 CD N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
risedronate NN i
group NN N
than IN N
in IN N
the DT N
alendronate NN i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Mean JJ o
esophageal NN o
and CC o
duodenal JJ o
endoscopy NN o
scores NNS o
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
at IN N
Days NNP N
8 CD N
and CC N
15 CD N
. . N

When WRB N
the DT N
treatment NN N
groups NNS N
were VBD N
combined VBN N
, , N
gastric JJ o
endoscopy NN o
scores NNS o
were VBD N
significantly RB N
higher JJR N
among IN N
H. NNP N
pylori FW N
negative JJ N
than IN N
H. NNP N
pylori FW N
positive JJ N
subjects NNS N
at IN N
Days NNP N
8 CD N
and CC N
15 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
. . N

Upper NNP o
GI NNP o
adverse JJ o
events NNS o
were VBD N
reported VBN N
by IN N
18 CD N
( ( N
5.7 CD N
% NN N
) ) N
subjects VBZ N
in IN N
the DT N
risedronate NN i
group NN N
( ( N
19 CD N
events NNS N
) ) N
and CC N
28 CD N
( ( N
8.8 CD N
% NN N
) ) N
subjects VBZ N
in IN N
the DT N
alendronate NN i
group NN N
( ( N
32 CD N
events NNS N
) ) N
. . N

Symptoms NNS N
did VBD N
not RB N
predict VB N
the DT N
presence NN N
of IN N
mucosal JJ N
damage NN N
. . N

CONCLUSION NNP N
Risedronate NNP i
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
lower JJR N
incidence NN N
of IN N
gastric JJ N
ulcers NNS N
than IN N
alendronate NN i
. . i

H. NNP N
pylori JJ N
infection NN N
did VBD N
not RB N
increase VB N
the DT N
incidence NN N
of IN N
bisphosphonate NN N
related VBN N
gastric JJ N
ulcers NNS N
. . N

The DT N
findings NNS N
from IN N
this DT N
14 CD N
day NN N
study NN N
in IN N
healthy JJ N
volunteers NNS N
support VBP N
the DT N
hypothesis NN N
that WDT N
bisphosphonates VBZ N
may MD N
differ VB N
from IN N
one CD N
another DT N
in IN N
their PRP$ N
potential JJ N
to TO N
produce VB N
upper JJ N
GI NNP N
mucosal NN N
damage NN N
. . N

-DOCSTART- -9400786- O O

MSL-109 NNP i
adjuvant JJ i
therapy NN i
for IN N
cytomegalovirus NN p
retinitis NN p
in IN p
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
: : p
the DT N
Monoclonal NNP N
Antibody NNP N
Cytomegalovirus NNP N
Retinitis NNP N
Trial NNP N
. . N

The DT p
Studies NNPS p
of IN p
Ocular JJ p
Complications NNS p
of IN p
AIDS NNP p
Research NNP p
Group NNP p
. . p

AIDS NNP p
Clinical JJ p
Trials NNP p
Group NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
an DT N
intravenous JJ N
human JJ N
monoclonal NN N
antibody NN N
to TO N
cytomegalovirus VB N
( ( N
CMV NNP N
) ) N
, , N
MSL-109 NNP i
, , N
as IN N
adjuvant JJ N
treatment NN N
for IN N
CMV NNP N
retinitis NN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
nine CD p
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
and CC p
active JJ p
CMV NNP p
retinitis NN p
were VBD p
enrolled VBN p
in IN p
a DT p
multicenter NN p
, , p
phase NN p
2/3 CD p
, , p
randomized VBN p
, , p
placebo-controlled JJ i
clinical JJ p
trial NN p
. . p

Patients NNS N
received VBD N
adjuvant JJ N
treatment NN N
with IN N
MSL-109 NNP i
, , N
60 CD N
mg NN N
intravenously RB N
every DT N
2 CD N
weeks NNS N
, , N
or CC N
placebo NN i
. . i

Randomization NN N
was VBD N
stratified VBN N
on IN N
the DT N
basis NN N
of IN N
whether IN N
patients NNS N
had VBD N
untreated VBN N
or CC N
relapsed VBN N
retinitis NN N
. . N

Primary JJ i
drug NN i
therapy NN i
for IN N
CMV NNP N
retinitis NN N
was VBD N
determined VBN N
by IN N
the DT N
treating NN N
physician NN N
. . N

RESULTS VB N
The DT N
rates NNS o
of IN o
retinitis NN o
progression NN o
, , N
as IN N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
, , N
were VBD N
3.04/person-year JJ N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
and CC N
3.05/person-year JJ N
in IN N
the DT N
placebo-treated JJ i
group NN N
( ( N
P=.98 NNP N
; : N
Wald NNP N
test NN N
) ) N
; : N
the DT N
median JJ N
times NNS N
to TO N
progression NN N
were VBD N
67 CD N
days NNS N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
and CC N
65 CD N
days NNS N
in IN N
the DT N
placebo-treated JJ N
group NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
noted VBN N
in IN N
the DT N
rates NNS o
of IN o
increase NN o
in IN o
retinal JJ o
area NN o
involved VBN o
by IN o
CMV NNP o
, , o
visual JJ o
field NN o
loss NN o
, , o
or CC o
visual JJ o
acuity NN o
outcomes NNS o
. . o

The DT N
mortality NN o
rate NN o
in IN N
the DT N
MSL-109-treated NNP i
group NN N
was VBD N
0.68/person-year JJ N
, , N
and CC N
in IN N
the DT N
placebo-treated JJ i
group NN N
, , N
0.31/person-year JJ N
( ( N
P=.01 NNP N
) ) N
. . N

The DT N
mortality NN o
difference NN N
was VBD N
not RB N
explained VBN N
by IN N
differences NNS N
in IN N
baseline NN N
variables NNS N
or CC N
in IN N
concurrent JJ N
antiretroviral JJ N
therapy NN N
. . N

Among IN p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
retinitis NN p
, , N
mortality NN o
rates NNS o
were VBD N
similar JJ N
( ( N
MSL-109 NNP N
, , N
0.41/person-year JJ N
; : N
placebo NN N
, , N
0.42/person-year JJ N
; : N
P=.95 NNP N
) ) N
, , N
whereas JJ N
among IN N
patients NNS N
with IN N
relapsed JJ N
retinitis NN N
the DT N
MSL-109-treated NNP i
group NN N
had VBD N
a DT N
greater JJR N
mortality NN o
rate NN o
( ( i
MSL-109 NNP i
, , N
0.83/person-year JJ N
; : N
placebo NN i
, , N
0.24/person-year JJ N
; : N
P=.003 NNP N
) ) N
. . N

However RB N
, , N
the DT N
mortality NN o
rate NN o
in IN N
the DT N
placebo-treated JJ i
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
placebo-treated JJ N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
CMV NNP N
retinitis NN N
and CC N
lower JJR N
than IN N
that DT N
in IN N
other JJ N
trials NNS N
of IN N
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
. . N

CONCLUSIONS NNP N
Intravenous NNP N
MSL-109 NNP i
, , N
60 CD N
mg NN N
every DT N
2 CD N
weeks NNS N
, , N
appeared VBD N
to TO N
be VB N
ineffective JJ o
adjuvant JJ N
therapy NN N
for IN N
CMV NNP N
retinitis NN N
. . N

The DT N
mortality NN o
rate NN o
was VBD N
higher RBR N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
, , N
but CC N
the DT N
reasons NNS N
for IN N
this DT N
difference NN N
remain NN N
uncertain JJ N
. . N

-DOCSTART- -17717526- O O

Effects NNS N
of IN N
alfuzosin NN i
10 CD N
mg NN N
once RB N
daily RB N
on IN N
sexual JJ o
function NN o
in IN N
men NNS p
treated VBN p
for IN p
symptomatic JJ p
benign NN p
prostatic JJ p
hyperplasia NN p
. . p

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
extended-release JJ N
alfuzosin NN i
HCl NNP N
10 CD N
mg NN N
once RB N
daily JJ N
( ( N
q.d JJ N
. . N

) ) N
on IN N
sexual JJ o
function NN o
in IN N
men NNS p
with IN p
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
associated VBN p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
. . p

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
men NNS p
aged VBN p
> NN p
or CC p
= $ p
50 CD p
years NNS p
, , N
after IN N
a DT N
28-day JJ N
placebo NN N
run-in JJ N
period NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
alfuzosin NN i
10 CD N
mg NN N
q.d NN N
. . N

or CC i
matching VBG i
placebo NN i
for IN N
28 CD N
days NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
( ( N
day NN N
1 CD N
) ) N
in IN N
sexual JJ N
function NN N
on IN N
day NN N
29 CD N
was VBD N
assessed VBN N
using VBG N
the DT N
Danish JJ N
Prostate NNP N
Symptom NNP N
Score NNP N
Sex NNP N
( ( N
DAN-PSSsex NNP N
) ) N
questionnaire NN N
. . N

A DT N
total NN N
of IN N
372 CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
alfuzosin NN i
( ( N
n=186 JJ N
) ) N
or CC N
placebo NN i
( ( N
n=186 JJ N
) ) N
, , N
with IN N
355 CD p
completing VBG p
the DT p
study NN p
. . p

At IN p
baseline NN p
, , p
64 CD p
% NN p
of IN p
the DT p
patients NNS p
reported VBD p
erectile JJ o
dysfunction NN o
( ( o
ED NNP o
) ) o
and CC p
63 CD p
% NN p
reported VBD p
ejaculatory JJ o
dysfunction NN o
( ( o
EjD NNP o
) ) o
. . o

For IN N
the DT N
320 CD N
patients NNS N
who WP N
completed VBD N
the DT N
DAN-PSSsex NNP N
, , N
alfuzosin NN N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
mean JJ o
change NN o
from IN o
baseline NN o
in IN o
erectile JJ o
function NN o
on IN N
day NN N
29 CD N
compared VBN N
with IN N
placebo NN N
( ( N
P=0.02 NNP N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
the DT N
mean JJ o
change NN o
from IN o
baseline NN o
in IN o
ejaculatory JJ o
function NN o
on IN N
day NN N
29 CD N
. . N

For IN N
patients NNS N
with IN N
ED NNP N
at IN N
baseline NN N
, , N
a DT N
marginal JJ N
improvement NN N
in IN N
erectile JJ o
function NN o
was VBD N
demonstrated VBN N
with IN N
alfuzosin NN N
treatment NN N
( ( N
P=0.09 NNP N
vs NNP N
placebo NN N
) ) N
. . N

For IN N
patients NNS N
with IN N
EjD NNP N
at IN N
baseline NN N
, , N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
ejaculatory JJ o
function NN o
with IN N
alfuzosin NN N
was VBD N
comparable JJ N
to TO N
that DT N
with IN N
placebo NN N
. . N

Dizziness NNP o
was VBD N
the DT N
most RBS N
common JJ N
adverse JJ N
event NN N
with IN N
alfuzosin NN N
treatment NN N
( ( N
5 CD N
vs RB N
0 CD N
% NN N
with IN N
placebo NN N
) ) N
, , N
with IN N
other JJ N
adverse JJ N
events NNS N
reported VBN N
with IN N
comparable JJ N
frequency NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

After IN N
1 CD N
month NN N
of IN N
treatment NN N
, , N
alfuzosin RB N
10 CD N
mg NN N
q.d NN N
. . N

significantly RB N
improved VBN N
erectile JJ o
function NN o
in IN N
men NNS N
with IN N
lower JJR N
urinary JJ N
tract NN N
symptoms/ NN N
benign JJ N
prostatic JJ N
hypertrophy NN N
and CC N
had VBD N
no DT N
adverse JJ N
effect NN N
on IN N
ejaculatory NN N
function NN N
. . N

-DOCSTART- -18271235- O O

[ JJ N
Effects NNS N
of IN N
early JJ N
acupuncture NN i
on IN N
motor NN N
function NN N
of IN N
the DT N
limb NN N
in IN N
the DT N
severe JJ p
head NN p
injury NN p
patients NNS p
] VBP p
. . N

UNLABELLED NNP N
OBJECTIVE NNP N
; : N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
early JJ i
acupuncture NN i
on IN N
motor NN N
function NN N
of IN N
the DT N
limb NN N
in IN N
the DT N
severe JJ p
head NN p
injury NN p
patients NNS p
. . p

METHODS NNP N
Ninety-six JJ p
patients NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
observation NN N
group NN N
and CC N
a DT N
control NN N
group NN N
, , N
48 CD p
cases NNS p
in IN p
each DT p
group NN p
. . p

The DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
by IN N
routine JJ i
treatment NN i
of IN i
neurosurgical JJ i
operation NN i
and CC i
drug NN i
treatment NN i
( ( i
Mannitol NNP i
, , i
Citioline NNP i
Sodium NNP i
, , i
Cefeazidime NNP i
, , i
etc. NN i
) ) i
. . i

While IN N
the DT N
patient NN N
in IN N
the DT N
observation NN N
group NN N
were VBD N
treated VBN N
by IN N
the DT N
routine JJ i
treatment NN i
and CC i
acupuncture NN i
treatment NN i
48 CD i
h NN i
( ( i
-1 NNP i
) ) i
week NN i
after IN N
operation NN N
in IN N
different JJ N
stages NNS N
with IN N
different JJ N
acupoints NNS N
selected VBN N
when WRB N
the DT N
situation NN N
was VBD N
stable JJ N
. . N

The DT N
selected VBN i
main JJ i
points NNS i
were VBD i
Neiguan NNP i
( ( i
PC NNP i
6 CD i
) ) i
, , i
Qu-chi NNP i
( ( i
LI NNP i
11 CD i
) ) i
, , i
Waiguan NNP i
( ( i
TE NNP i
5 CD i
) ) i
, , i
Hegu NNP i
( ( i
LI NNP i
4 CD i
) ) i
, , i
Binao NNP i
( ( i
LI NNP i
14 CD i
) ) i
, , i
Jianyu NNP i
( ( i
LI NNP i
15 CD i
) ) i
, , i
Fengshi NNP i
( ( i
GB NNP i
31 CD i
) ) i
, , i
Xuehai NNP i
( ( i
SP NNP i
10 CD i
) ) i
, , i
Yinlingquan NNP i
( ( i
SP NNP i
9 CD i
) ) i
, , i
Sanyinjiao NNP i
( ( i
SP NNP i
6 CD i
) ) i
, , i
Taichong NNP i
( ( i
LR NNP i
3 CD i
) ) i
, , i
etc.. VBZ i
The DT N
limb NN o
motor NN o
function NN o
was VBD N
evaluated VBN N
with IN N
Fugl-Meyer NNP o
Assessment NNP o
( ( o
FMA NNP o
) ) o
scale NN o
before IN N
treatment NN N
and CC N
after IN N
10-week JJ N
treatment NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
FMA NNP o
score NN o
in IN N
the DT N
two CD N
groups NNS N
after IN N
the DT N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
comparison NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
the DT N
treatment NN N
showed VBD N
that IN N
the DT N
improvement NN o
of IN o
FMA NNP o
score NN o
in IN N
the DT N
observation NN N
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
or CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Early JJ N
acupuncture NN i
can MD N
improve VB N
the DT N
limb NN N
motor NN N
function NN N
in IN N
the DT N
severe JJ p
head NN p
injury NN p
patients NNS p
. . p

-DOCSTART- -25344395- O O

Safety NN N
and CC N
possible JJ N
effects NNS N
of IN N
low-intensity NN i
resistance NN i
training NN i
associated VBN N
with IN N
partial JJ N
blood NN N
flow NN N
restriction NN N
in IN N
polymyositis NN p
and CC p
dermatomyositis NN p
. . p

INTRODUCTION NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
low-intensity JJ i
resistance NN i
training NN i
program NN i
combined VBN N
with IN N
partial JJ N
blow NN N
flow NN N
restriction NN N
( ( N
BFR NNP N
training NN N
) ) N
in IN N
a DT N
cohort NN N
of IN N
patients NNS p
with IN p
polymyositis NN p
( ( p
PM NNP p
) ) p
and CC p
dermatomyositis NN p
( ( p
DM NNP p
) ) p
. . p

METHODS NNP N
In IN N
total JJ N
, , N
13 CD p
patients NNS p
with IN p
PM NNP p
and CC p
DM NNP p
completed VBD p
a DT N
12-week JJ N
twice NN N
a DT N
week NN N
low-intensity NN i
( ( i
that WDT i
is VBZ i
, , i
30 CD i
% NN i
one-repetition-maximum JJ i
( ( i
1RM CD i
) ) i
) ) i
resistance NN i
exercise NN i
training NN i
program NN i
combined VBN i
with IN i
partial JJ i
blood NN i
flow NN i
restriction NN i
( ( i
BFR NNP i
) ) i
. . i

Assessments NNS N
of IN N
muscle NN N
strength NN N
, , N
physical JJ N
function NN N
, , N
quadriceps NNS N
cross VBP N
sectional JJ N
( ( N
CSA NNP N
) ) N
area NN N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
clinical JJ N
and CC N
laboratory JJ N
parameters NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
intervention NN N
. . N

RESULTS VB N
The DT N
BFR NNP i
training NN N
program NN N
was VBD N
effective JJ N
in IN N
increasing VBG N
the DT N
maximal JJ o
dynamic JJ o
strength NN o
in IN N
both DT N
the DT N
leg-press NN i
( ( N
19.6 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
knee-extension NN o
exercises NNS o
( ( N
25.2 CD N
% NN N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
timed-stands NNS o
( ( N
15.1 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
timed-up-and-go JJ o
test NN o
( ( N
-4.5 CD N
% NN N
, , N
P NNP N
=0.002 NNP N
) ) N
. . N

Quadriceps NNP o
CSA NNP o
was VBD N
also RB N
significantly RB N
increased VBN N
after IN N
the DT N
intervention NN N
( ( N
4.57 CD N
% NN N
, , N
P NNP N
=0.01 NNP N
) ) N
. . N

Similarly RB N
, , N
all DT N
of IN N
the DT N
components NNS N
of IN N
the DT N
Short NNP o
Form-36 NNP o
Health NNP o
Survey NNP o
, , o
the DT o
Health NNP o
Assessment NNP o
Questionnaire NNP o
scores NNS o
, , o
and CC o
the DT o
patient- JJ o
and CC o
physician JJ o
reported VBD o
Visual NNP o
Analogue NNP o
Scale NNP o
were VBD N
significantly RB N
improved VBN N
after IN N
training NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Importantly RB N
, , N
no DT N
clinical JJ N
evidence NN N
or CC N
any DT N
other JJ N
self-reported JJ o
adverse JJ o
event NN N
were VBD N
found VBN N
. . N

Laboratory JJ o
parameters NNS o
( ( o
creatine JJ o
kinase NN o
and CC o
aldolase NN o
) ) o
were VBD N
also RB N
unchanged JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
after IN N
the DT N
intervention NN N
. . N

CONCLUSIONS NNP N
We PRP N
demonstrated VBD N
that IN N
a DT N
12-week JJ N
supervised JJ N
low-intensity NN i
resistance NN i
training NN i
program NN i
associated VBN N
with IN N
partial JJ N
blood NN N
flow NN N
restriction NN N
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
muscle NN N
strength NN N
and CC N
function NN N
as RB N
well RB N
as IN N
muscle NN N
mass NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN p
PM NNP p
and CC p
DM NNP p
. . p

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
NCT01501019 NNP N
. . N

Registered NNP N
November NNP N
29 CD N
, , N
2011 CD N
. . N

-DOCSTART- -4077545- O O

A DT N
study NN N
of IN N
a DT N
Self-Care JJ i
Rehabilitation NNP i
Program NNP i
in IN N
pediatric JJ p
asthma NN p
. . p

The DT N
Self-Care JJ i
Rehabilitation NNP i
in IN N
Pediatric NNP N
Asthma NNP N
( ( N
SCRPA NNP N
) ) N
project NN N
was VBD N
designed VBN N
to TO N
ascertain VB N
the DT N
level NN N
to TO N
which WDT N
children NNS p
with IN p
asthma NN p
are VBP p
able JJ p
to TO p
acquire VB p
the DT p
asthma NN p
knowledge NN p
and CC p
skills NNS p
presented VBN p
in IN p
a DT p
self-management JJ p
training NN p
program NN p
conducted VBN p
by IN p
the DT p
American NNP p
Lung NNP p
Association NNP p
of IN p
Utah NNP p
and CC N
the DT N
effect NN N
of IN N
such JJ N
training NN N
on IN N
the DT N
asthma JJ N
experience NN N
. . N

The DT N
preschool NN p
SCRPA NNP N
Curriculum NNP N
( ( p
ages VBZ p
2-5 CD p
) ) p
consisted VBN N
of IN N
six CD i
1-hour JJ i
classes NNS i
scheduled VBN i
twice RB i
a DT i
week NN i
for IN i
3 CD i
weeks NNS i
. . i

The DT N
first JJ N
and CC N
last JJ N
classes NNS N
were VBD N
for IN N
one CD p
or CC p
both DT p
parents NNS p
only RB N
, , N
and CC N
the DT N
middle JJ N
four CD N
sessions NNS N
were VBD N
for IN N
the DT N
child NN p
and CC p
parent NN p
( ( p
s NN p
) ) p
. . p

The DT N
school-age JJ N
SCRPA NNP N
curriculum NN N
( ( p
ages IN p
6-14 NN p
) ) p
consisted VBD N
of IN N
eight CD i
90-minute JJ i
classes NNS i
for IN i
both DT i
child NN i
and CC i
parent NN i
( ( i
s PRP i
) ) i
scheduled VBN i
twice RB N
a DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

Private JJ p
physicians NNS p
referred VBD p
21 CD p
preschool NN p
children NNS p
and CC p
38 CD p
school-age JJ p
children NNS p
into IN p
the DT p
program NN p
. . p

The DT N
school-age JJ p
children NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
study NN N
or CC N
control NN N
group NN N
, , N
and CC N
the DT N
preschool NN p
children NNS p
served VBD N
as IN N
their PRP$ N
own JJ N
controls NNS N
. . N

A DT N
comparison NN N
of IN N
asthma JJ N
episodes NNS N
during IN N
the DT N
3 CD N
months NNS N
before IN N
and CC N
after IN N
training NN N
showed VBD N
a DT N
statistically RB N
significant JJ N
decrease NN o
in IN o
the DT o
number NN o
of IN o
episodes NNS o
but CC N
no DT N
change NN N
in IN N
severity NN o
in IN N
the DT N
preschool NN N
, , N
school NN N
study NN N
, , N
and CC N
school NN N
control NN N
groups NNS N
. . N

The DT N
decrease NN N
in IN N
episodes NNS o
for IN N
the DT N
control NN N
groups NNS N
suggest VBP N
that IN N
the DT N
family NN N
record NN N
keeping VBG N
required VBN N
of IN N
all DT N
subjects NNS N
may MD N
have VB N
a DT N
beneficial JJ N
effect NN N
, , N
a DT N
phenomenon NN N
worth IN N
further JJ N
investigation NN N
. . N

Also RB N
, , N
the DT N
school-age NN N
group NN N
, , N
in IN N
pre- JJ N
and CC N
posttesting NN N
, , N
demonstrated VBD N
that IN N
the DT N
SCRPA NNP i
curriculum NN N
increased VBD N
knowledge NN o
and CC o
skills NNS o
in IN N
the DT N
study NN N
group NN N
, , N
changes VBZ N
not RB N
found VBN N
in IN N
the DT N
control NN N
group NN N
. . N

-DOCSTART- -26510728- O O

Chronic NNP N
fatigue NN N
syndrome NN N
( ( N
CFS NNP N
) ) N
or CC N
myalgic JJ N
encephalomyelitis NN N
( ( N
ME NNP N
) ) N
is VBZ N
different JJ N
in IN N
children NNS p
compared VBN N
to TO N
in IN N
adults NNS N
: : N
a DT N
study NN N
of IN N
UK NNP N
and CC N
Dutch NNP N
clinical JJ N
cohorts NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
differences NNS N
between IN N
young JJ p
children NNS p
, , p
adolescents NNS p
and CC p
adults NNS p
with IN p
chronic JJ p
fatigue NN p
syndrome/myalgic NN p
encephalomyelitis NN p
( ( p
CFS/ME NNP p
) ) p
. . p

STUDY NNP N
DESIGN NNP N
Comparison NNP N
of IN N
clinical JJ N
cohorts NNS p
from IN p
8 CD p
paediatric NN p
and CC p
27 CD p
adult NN p
CFS/ME NNP p
services NNS p
in IN p
the DT p
UK NNP p
and CC p
a DT p
paediatric NN p
randomised VBD p
controlled VBN p
trial NN p
from IN p
the DT p
Netherlands NNP p
. . p

Outcome NNP N
measures VBZ N
include VBP N
: : N
fatigue NN N
( ( N
the DT N
UK-Chalder NNP N
Fatigue NNP N
Scale NNP N
) ) N
; : N
Disability NNP N
( ( N
the DT N
UK-SF-36 NNP N
physical JJ N
function NN N
subscale NN N
; : N
the DT N
Netherlands-CHQ-CF87 NNP N
) ) N
; : N
school NN N
attendance NN N
, , N
pain NN N
, , N
anxiety NN N
and CC N
depression NN N
( ( N
the DT N
UK-Hospital NNP N
Anxiety NNP N
& CC N
Depression NNP N
Scale NNP N
, , N
Spence NNP N
Children NNP N
's POS N
Anxiety NNP N
Scale NNP N
; : N
the DT N
Netherlands-Spielberger NNP N
State-Trait NNP N
Anxiety NNP N
Inventory NNP N
for IN N
Children NNP N
, , N
Children NNP N
's POS N
Depression NNP N
Inventory NNP N
) ) N
; : N
symptoms NNS N
; : N
time-to-assessment JJ N
; : N
and CC N
body NN N
mass NN N
index NN N
. . N

We PRP N
used VBD N
multinomial JJ i
regression NN i
to TO N
compare VB N
younger JJR p
( ( p
aged VBN p
< RB p
12 CD p
years NNS p
) ) p
and CC p
older JJR p
( ( p
aged VBN p
12-18 CD p
years NNS p
) ) p
children NNS p
with IN p
adults NNS p
, , p
and CC p
logistic JJ p
regression NN p
to TO p
compare VB p
UK NNP p
and CC p
Dutch NNP p
adolescents NNS p
. . p

RESULTS NNP p
Younger NNP p
children NNS p
had VBD p
a DT p
more RBR p
equal JJ o
gender NN o
balance NN o
compared VBN o
to TO p
adolescents NNS p
and CC p
adults NNS p
. . p

Adults NNS p
had VBD p
more JJR N
disability NN o
and CC o
fatigue NN o
, , o
and CC o
had VBD N
been VBN N
ill RB o
for IN N
longer JJR p
. . p

Younger JJR p
children NNS N
were VBD N
less RBR N
likely JJ N
to TO N
have VB N
cognitive JJ o
symptoms NNS o
( ( o
OR CC o
0.18 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.13 CD N
to TO N
0.25 CD N
) ) N
) ) N
and CC N
more RBR N
likely JJ N
to TO N
present VB N
with IN N
a DT N
sore NN N
throat NN N
( ( N
OR CC N
1.42 CD N
( ( N
1.07 CD N
to TO N
1.90 CD N
) ) N
. . N

Adolescents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
headaches NNS o
( ( o
81.1 CD o
% NN N
, , N
OR CC N
1.56 CD N
( ( N
1.36 CD N
% NN N
to TO N
1.80 CD N
% NN N
) ) N
) ) N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
tender NN o
lymph NN o
nodes NNS o
, , o
palpitations NNS o
, , o
dizziness NN o
, , o
general JJ o
malaise NN o
and CC o
pain NN o
, , o
compared VBN o
to TO N
adults NNS N
. . N

Adolescents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
comorbid VBN o
depression NN o
( ( o
OR CC o
1.51 CD N
( ( N
1.33 CD N
to TO N
1.72 CD N
) ) N
) ) N
and CC N
less RBR N
likely JJ N
to TO N
have VB N
anxiety NN o
( ( o
OR CC o
0.46 CD N
( ( N
0.41 CD N
to TO N
0.53 CD N
) ) N
) ) N
compared VBN N
to TO N
adults NNS N
. . N

CONCLUSIONS NNP N
Paediatricians NNPS N
need VBP N
to TO N
recognise VB N
that DT N
children NNS p
with IN p
CFS/ME NNP p
present JJ p
differently RB N
from IN N
adults NNS N
. . N

Whether IN N
these DT N
differences NNS N
reflect VBP N
an DT N
underlying JJ N
aetiopathology NN N
requires VBZ N
further JJ N
investigation NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBERS NNP N
FITNET NNP N
trial NN N
registration NN N
numbers NNS N
are VBP N
ISRCTN59878666 NNP N
and CC N
NCT00893438 NNP N
. . N

This DT N
paper NN N
includes VBZ N
secondary JJ N
( ( N
post-results NNS N
) ) N
analysis NN N
of IN N
data NNS N
from IN N
this DT N
trial NN N
, , N
but CC N
are VBP N
unrelated JJ N
to TO N
trial NN N
outcomes NNS N
. . N

-DOCSTART- -12791549- O O

An DT i
exposure NN i
prevention NN i
rating NN i
method NN i
for IN N
intervention NN N
needs NNS N
assessment JJ N
and CC N
effectiveness JJ N
evaluation NN N
. . N

This DT N
article NN N
describes VBZ N
a DT N
new JJ N
method NN N
for IN N
( ( N
1 CD N
) ) N
systematically RB N
prioritizing VBG N
needs NNS N
for IN N
intervention NN p
on IN p
hazardous JJ p
substance NN p
exposures NNS p
in IN p
manufacturing VBG p
work NN p
sites NNS p
, , N
and CC N
( ( N
2 CD N
) ) N
evaluating VBG N
intervention NN N
effectiveness NN N
. . N

We PRP N
developed VBD N
a DT N
checklist NN i
containing VBG i
six CD N
unique JJ N
sets NNS N
of IN N
yes/no NN N
variables NNS N
organized VBN N
in IN N
a DT N
2 CD N
x NN N
3 CD N
matrix NN N
of IN N
exposure NN N
potential JJ N
versus NN N
protection NN N
( ( N
two CD N
columns NN N
) ) N
at IN N
the DT N
levels NNS N
of IN N
materials NNS N
, , N
processes NNS N
, , N
and CC N
human JJ N
interface NN N
( ( N
three CD N
rows NNS N
) ) N
. . N

The DT N
three CD N
levels NNS N
correspond VBP N
to TO N
a DT N
simplified JJ N
hierarchy NN N
of IN N
controls NNS N
. . N

Each DT N
of IN N
the DT N
six CD N
sets NNS N
of IN N
indicator NN N
variables NNS N
was VBD N
reduced VBN N
to TO N
a DT N
high/moderate/low NN N
rating NN N
. . N

Ratings NNS N
from IN N
the DT N
matrix NN N
were VBD N
then RB N
combined VBN N
to TO N
generate VB N
a DT N
single JJ N
overall JJ N
exposure NN N
prevention NN N
rating NN N
for IN N
each DT N
area NN N
. . N

Reflecting VBG N
the DT N
hierarchy NN N
of IN N
controls NNS N
, , N
material JJ N
factors NNS N
were VBD N
weighted JJ N
highest JJS N
, , N
followed VBN N
by IN N
process NN N
, , N
and CC N
then RB N
human JJ N
interface NN N
. . N

The DT N
checklist NN N
was VBD N
filled VBN N
out RP N
by IN N
an DT p
industrial JJ p
hygienist NN p
while IN N
conducting VBG N
a DT N
walk-through JJ p
inspection NN p
( ( p
N NNP p
= NNP p
131 CD p
manufacturing NN p
processes/areas NNS p
in IN p
17 CD p
large JJ p
work NN p
sites NNS p
) ) p
. . p

One CD N
area NN N
or CC N
process NN N
per IN N
manufacturing NN N
department NN N
was VBD N
assessed VBN N
and CC N
rated VBN N
. . N

Based VBN N
on IN N
the DT N
resulting JJ N
Exposure NNP o
Prevention NNP o
ratings NNS o
, , N
we PRP N
concluded VBD N
that IN N
exposures NNS o
were VBD N
well RB N
controlled VBN N
in IN N
the DT N
majority NN N
of IN N
areas NNS N
assessed VBN N
( ( N
64 CD N
% NN N
with IN N
rating NN N
of IN N
1 CD N
or CC N
2 CD N
on IN N
a DT N
6-point JJ N
scale NN N
) ) N
, , N
that IN N
there EX N
is VBZ N
some DT N
room NN N
for IN N
improvement NN N
in IN N
26 CD N
percent NN N
of IN N
areas NNS N
( ( N
rating NN N
of IN N
3 CD N
or CC N
4 CD N
) ) N
, , N
and CC N
that IN N
roughly RB N
10 CD N
percent NN N
of IN N
the DT N
areas NNS N
assessed VBN N
are VBP N
urgently RB N
in IN N
need NN N
of IN N
intervention NN N
( ( N
rated VBN N
as IN N
5 CD N
or CC N
6 CD N
) ) N
. . N

A DT p
second JJ p
hygienist NN p
independently RB N
assessed VBD N
a DT N
subset NN N
of IN N
areas NNS N
to TO N
evaluate VB N
inter-rater JJ o
reliability NN o
. . o

The DT N
reliability NN o
of IN o
the DT o
overall JJ o
exposure NN o
prevention NN o
ratings NNS o
was VBD N
excellent JJ N
( ( N
weighted JJ N
kappa NN N
= NNP N
0.84 CD N
) ) N
. . N

The DT N
rating NN N
scheme NN N
has VBZ N
good JJ N
discriminatory NN N
power NN N
and CC N
reliability NN N
and CC N
shows VBZ N
promise NN N
as IN N
a DT N
broadly RB N
applicable JJ N
and CC N
inexpensive JJ N
tool NN N
for IN N
intervention NN N
needs NNS N
assessment JJ N
and CC N
effectiveness JJ N
evaluation NN N
. . N

Validation NNP N
studies NNS N
are VBP N
needed VBN N
as IN N
a DT N
next JJ N
step NN N
. . N

This DT N
assessment JJ N
method NN N
complements NNS N
quantitative JJ N
exposure NN N
assessment NN N
with IN N
an DT N
upstream JJ N
prevention NN N
focus NN N
. . N

-DOCSTART- -15037334- O O

Correlates NNS N
of IN N
cognitive JJ o
deficits NNS o
in IN N
first JJ p
episode NN p
schizophrenia NN p
. . p

OBJECTIVE CC N
The DT N
presence NN N
of IN N
cognitive JJ o
dysfunction NN o
in IN N
schizophrenia NN p
has VBZ N
been VBN N
well RB N
documented VBN N
, , N
but CC N
questions NNS N
remain VBP N
about IN N
whether IN N
there EX N
are VBP N
relationships NNS N
between IN N
this DT N
dysfunction NN o
and CC N
clinical JJ o
symptomatology NN o
. . o

If IN N
present JJ N
, , N
such JJ N
relationships NNS N
should MD N
be VB N
most RBS N
clearly RB N
observable JJ N
in IN N
patients NNS p
with IN p
first JJ p
episode NN p
schizophrenia NN p
; : p
that WDT p
is VBZ p
, , p
before IN p
the DT p
effects NNS p
of IN p
chronic JJ p
illness NN p
, , p
institutionalization NN p
, , p
or CC p
treatment NN p
might MD N
confound VB N
them PRP N
. . N

METHOD CC N
307 CD p
schizophrenia NN p
subjects NNS p
in IN p
their PRP$ p
first JJ p
episode NN p
of IN p
illness NN p
were VBD N
recruited VBN N
to TO N
participate VB N
in IN N
a DT N
clinical JJ N
trial NN N
comparing VBG N
the DT N
long-term JJ N
efficacy NN N
of IN N
haloperidol NN i
and CC i
risperidone NN i
. . i

The DT N
psychopathology NN N
, , N
cognitive JJ N
functioning NN N
, , N
early JJ N
treatment NN N
history NN N
, , N
and CC N
duration NN N
of IN N
untreated JJ N
psychosis NN N
of IN N
these DT N
subjects NNS N
were VBD N
assessed VBN N
prior RB N
to TO N
their PRP$ N
assignment NN N
to TO N
randomized VB N
, , N
double-blind JJ N
treatment NN N
. . N

Approximately RB p
two-thirds NNS p
of IN p
the DT p
subjects NNS p
were VBD p
receiving VBG p
antipsychotic JJ i
treatment NN i
at IN p
the DT p
time NN p
of IN p
assessment NN p
; : p
however RB p
, , p
the DT p
duration NN p
of IN p
treatment NN p
was VBD p
limited VBN p
to TO p
12 CD p
weeks NNS p
or CC p
less JJR p
. . p

RESULTS VB N
The DT N
severity NN o
of IN o
negative JJ o
symptoms NNS o
at IN N
the DT N
time NN N
of IN N
assessment NN N
was VBD N
associated VBN N
with IN N
deficits NNS o
in IN o
memory NN o
, , o
verbal JJ o
fluency NN o
, , o
psychomotor NN o
speed NN o
and CC o
executive NN o
function NN o
. . o

Positive JJ o
symptoms NNS o
were VBD N
not RB N
associated VBN N
with IN N
cognitive JJ o
deficits NNS o
. . o

Also RB N
, , N
the DT N
duration NN o
of IN o
untreated JJ o
illness NN o
( ( o
DUI NNP o
) ) o
prior RB N
to TO N
assessment NN N
was VBD N
not RB N
significantly RB N
associated VBN N
with IN N
cognitive JJ o
impairment NN o
. . o

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
of IN N
first JJ p
episode NN p
schizophrenia NN p
patients NNS p
suggest VBP N
that IN N
a DT N
relationship NN o
exists VBZ o
between IN o
negative JJ o
symptoms NNS o
and CC o
cognitive JJ o
dysfunction NN o
. . o

However RB N
, , N
that IN N
relationship NN N
accounts NNS N
for IN N
only RB N
a DT N
minor JJ N
portion NN N
of IN N
the DT N
variance NN N
( ( N
i.e. JJ N
, , N
10-15 JJ N
% NN N
) ) N
in IN N
the DT N
severity NN o
of IN o
cognitive JJ o
dysfunction NN o
after IN N
controlling VBG N
for IN N
a DT N
number NN N
of IN N
potentially RB N
confounding VBG N
factors NNS N
. . N

This DT N
finding NN N
provides VBZ N
support NN N
for IN N
the DT N
theory NN N
that IN N
the DT N
neurobiological JJ N
processes NNS N
that WDT N
give VBP N
rise NN N
to TO N
symptomatology NN o
and CC N
cognitive JJ o
dysfunction NN o
in IN N
schizophrenia NN p
are VBP N
partially RB N
overlapping VBG N
. . N

-DOCSTART- -11350502- O O

Clinical JJ N
and CC N
microbial JJ N
evaluation NN N
of IN N
a DT N
histatin-containing JJ i
mouthrinse NN i
in IN N
humans NNS p
with IN p
experimental JJ p
gingivitis NN p
. . p

OBJECTIVE NNP N
P-113 NNP i
, , i
a DT i
12 CD i
amino NN i
acid JJ i
histatin-based JJ i
peptide NN i
, , N
was VBD N
evaluated VBN N
in IN N
a DT N
mouthrinse NN i
formulation NN i
for IN N
safety NN N
, , N
prevention NN N
of IN N
the DT N
development NN N
of IN N
experimental JJ N
gingivitis NN N
, , N
and CC N
for IN N
its PRP$ N
effects NNS N
on IN N
periodontal JJ N
flora NN N
. . N

METHOD NNP N
159 CD p
periodontally RB p
healthy JJ p
subjects NNS p
abstained VBN p
from IN p
oral JJ p
hygiene NN p
procedures NNS p
and CC N
self-administered JJ i
either DT i
0.005 CD i
% NN i
, , i
0.01 CD i
% NN i
, , i
0.05 CD i
% NN i
P-113 NNP i
or CC i
placebo NN i
mouthrinse NN i
formulations NNS i
twice RB i
daily RB i
over IN i
a DT i
four CD i
week NN i
treatment NN i
period NN i
. . i

During IN N
this DT N
time NN N
, , N
the DT N
safety NN o
, , o
anti-plaque JJ o
, , o
and CC o
anti-gingivitis JJ o
effects NNS o
of IN N
P-113 NNP N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
plaque NN o
( ( N
p=0.046 NN N
) ) N
and CC N
a DT N
reduction NN o
in IN o
gingivitis NN o
( ( N
p=0.086 NN N
) ) N
for IN N
subjects NNS N
using VBG N
0.01 CD N
% NN N
P-113 JJ i
mouthrinse NN i
. . i

Significantly RB N
more RBR N
subjects NNS N
in IN N
the DT N
0.01 CD N
% NN N
and CC N
0.05 CD N
% NN N
treatment NN N
groups NNS N
showed VBD N
a DT N
small JJ N
increase NN N
in IN N
plaque JJ o
index NN N
of IN N
< $ N
0.25 CD N
as IN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Similar JJ N
trends NNS N
were VBD N
noted VBN N
for IN N
changes NNS N
in IN N
the DT N
% NN N
of IN N
sites NNS N
with IN N
bleeding VBG o
on IN o
probing VBG o
in IN N
the DT N
0.01 CD N
% NN N
P-113 NNP i
group NN N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
adverse JJ o
events NNS o
, , N
and CC N
there EX N
were VBD N
no DT N
adverse JJ N
shifts NNS o
in IN o
supragingival JJ o
microflora NN o
during IN N
the DT N
study NN N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
P-113 NNP i
mouthrinse NN i
is VBZ N
safe JJ N
and CC N
reduces NNS N
plaque NN o
, , o
gingivitis NN o
and CC o
gingival NN o
bleeding NN o
in IN p
the DT p
human JJ p
experimental JJ p
gingivitis NN p
model NN p
. . p

-DOCSTART- -17535502- O O

Using VBG N
the DT N
demand-control JJ i
model NN i
of IN i
job NN i
strain NN i
to TO N
predict VB N
caregiver NN o
burden NN o
and CC N
caregiver JJ o
satisfaction NN o
in IN N
the DT N
informal JJ p
caregivers NNS p
of IN p
heart NN p
failure NN p
patients NNS p
. . p

OBJECTIVES IN N
The DT i
demand-control NN i
( ( i
D-C NNP i
) ) i
model NN i
of IN i
job NN i
strain NN i
has VBZ N
generated VBN N
a DT N
considerable JJ N
body NN N
of IN N
empirical JJ N
support NN N
in IN N
predicting VBG N
psychological JJ N
health NN N
outcomes NNS N
in IN N
the DT N
context NN N
of IN N
work NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
extend VB N
previous JJ N
work NN N
using VBG N
the DT N
D-C NNP i
model NN i
of IN i
job NN i
strain NN i
to TO N
predict VB N
caregiver NN o
burden NN o
and CC N
satisfaction NN o
in IN N
the DT N
informal JJ p
caregivers NNS p
of IN p
patients NNS p
with IN p
heart NN p
failure NN p
. . p

DESIGN NNP N
AND CC N
METHOD NNP N
Data NNP N
were VBD N
gathered VBN N
from IN N
60 CD p
caregiver/patient NN p
dyads NNS p
in IN p
a DT p
cross-sectional JJ p
design NN p
. . p

Patients NNS p
with IN p
chronic JJ p
stable JJ p
heart NN p
failure NN p
were VBD p
recruited VBN p
from IN p
out-patient JJ p
clinics NNS p
. . p

The DT N
dependent JJ N
variables NNS N
were VBD N
caregiver JJ o
burden NN o
and CC o
satisfaction NN o
. . o

Demand NNP o
and CC o
control VB o
were VBD N
measured VBN N
using VBG N
both DT N
patient- JJ o
and CC o
caregiver-derived JJ o
measures NNS o
. . o

RESULTS VB N
The DT N
D-C NNP i
model NN i
accounted VBD N
for IN N
15 CD N
and CC N
19 CD N
% NN N
of IN N
the DT N
variance NN N
in IN N
caregiver NN o
burden NN o
, , N
after IN N
controlling VBG N
for IN N
age NN N
, , N
gender NN N
and CC N
relationship NN N
to TO N
the DT N
patient NN N
. . N

Lower JJR N
control NN o
was VBD N
associated VBN N
with IN N
higher JJR o
burden NN o
. . o

The DT N
D-C JJ i
model NN i
did VBD N
not RB N
predict VB N
caregiver NN o
satisfaction NN o
. . o

CONCLUSION VB N
The DT N
D-C NNP i
model NN i
was VBD N
associated VBN N
with IN N
caregiver NN o
burden NN o
, , N
but CC N
not RB N
satisfaction NN o
in IN N
caregivers NNS N
, , N
with IN N
control NN N
being VBG N
the DT N
dominant JJ N
predictor NN N
. . N

Research NNP N
linking VBG N
the DT N
theory NN N
and CC N
findings NNS N
from IN N
job NN N
strain NN N
and CC N
informal JJ N
caregiving VBG N
studies NNS N
may MD N
elucidate VB N
both DT N
fields NNS N
of IN N
research NN N
. . N

Using VBG N
the DT N
demand-control JJ i
model NN i
of IN i
job NN i
strain NN i
to TO N
predict VB N
caregiver NN o
burden NN o
and CC N
caregiver JJ o
satisfaction NN o
in IN N
the DT N
informal JJ p
caregivers NNS p
of IN p
heart NN p
failure NN p
patients NNS p
. . p

-DOCSTART- -16942963- O O

Virtual JJ i
reality NN i
exposure NN i
therapy NN i
and CC i
standard NN i
( ( i
in IN i
vivo NN i
) ) i
exposure NN i
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
fear NN p
of IN p
flying VBG p
. . p

This DT N
controlled VBD N
clinical JJ N
trial NN N
tested VBD N
virtual JJ i
reality NN i
exposure NN i
( ( i
VRE NNP i
) ) i
therapy NN i
for IN N
the DT N
fear NN p
of IN p
flying VBG p
( ( p
FOF NNP p
) ) p
, , N
a DT N
relatively RB N
new JJ N
and CC N
innovative JJ N
way NN N
to TO N
do VB N
exposure NN N
therapy NN N
, , N
and CC N
compared VBN N
it PRP N
to TO N
standard VB i
( ( i
in IN i
vivo NN i
) ) i
exposure NN i
therapy NN i
( ( i
SE NNP i
) ) i
and CC N
a DT N
wait JJ N
list NN N
( ( N
WL NNP N
) ) N
control NN N
with IN N
a DT N
6- JJ N
and CC N
12-month JJ N
follow-up NN N
. . N

Eighty-three JJ p
participants NNS p
with IN p
FOF NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
VRE NNP N
, , N
SE NNP N
, , N
or CC N
WL NNP N
. . N

Seventy-five JJ p
participants NNS p
, , p
25 CD p
per IN p
group NN p
, , p
completed VBD p
the DT p
study NN p
. . p

Twenty-three JJ p
WL JJ p
participants NNS p
completed VBD p
randomly RB p
assigned VBN p
treatment NN p
following VBG N
the DT N
waiting VBG N
period NN N
. . N

Treatment NNP N
consisted VBD N
of IN N
4 CD i
sessions NNS i
of IN i
anxiety NN i
management NN i
training NN i
followed VBD i
either CC i
by IN i
exposure NN i
to TO i
a DT i
virtual JJ i
airplane NN i
( ( i
VRE NNP i
) ) i
or CC i
an DT i
actual JJ i
airplane NN i
at IN i
the DT i
airport NN i
( ( i
SE NNP i
) ) i
conducted VBD N
over IN N
6 CD N
weeks NNS N
. . N

Results NNS N
indicate VBP N
that IN N
VRE NNP i
was VBD N
superior JJ N
to TO N
WL VB i
on IN N
all DT N
measures NNS N
, , N
including VBG N
willingness NN o
to TO o
fly VB o
on IN o
the DT o
posttreatment NN o
flight NN o
( ( N
76 CD N
% NN N
for IN N
VRE NNP N
and CC N
SE NNP N
; : N
20 CD N
% NN N
for IN N
WL NNP N
) ) N
. . N

VRE NNP i
and CC N
SE NNP i
were VBD N
essentially RB N
equivalent JJ N
on IN N
standardized JJ o
questionnaires NNS o
, , o
willingness NN o
to TO o
fly VB o
, , o
anxiety NN o
ratings NNS o
during IN o
the DT o
flight NN o
, , o
self-ratings NNS o
of IN o
improvement NN o
, , o
and CC o
patient JJ o
satisfaction NN o
with IN o
treatment NN o
. . o

Follow-up JJ N
assessments NNS N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
indicated VBD N
that IN N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
, , N
with IN N
more JJR N
than IN N
70 CD N
% NN N
of IN N
respondents NNS N
from IN N
both DT N
groups NNS N
reporting VBG N
continued VBD N
flying VBG N
at IN N
follow-up NN N
. . N

Based VBN N
on IN N
these DT N
findings NNS N
, , N
the DT N
use NN N
of IN N
VRE NNP N
in IN N
the DT N
treatment NN N
of IN N
FOF NNP N
was VBD N
supported VBN N
in IN N
this DT N
controlled VBN N
study NN N
, , N
suggesting VBG N
that IN N
experiences NNS N
in IN N
the DT N
virtual JJ N
world NN N
can MD N
change VB N
experiences NNS N
in IN N
the DT N
real JJ N
world NN N
. . N

-DOCSTART- -24184410- O O

There EX N
is VBZ N
no DT N
sweet JJ N
escape NN N
from IN N
social JJ N
pain NN N
: : N
glucose NN N
does VBZ N
not RB N
attenuate VB N
the DT N
effects NNS p
of IN p
ostracism NN p
. . p

Ostracism NN N
causes VBZ N
social JJ N
pain NN N
and CC N
is VBZ N
known VBN N
to TO N
activate VB N
regions NNS N
of IN N
the DT N
brain NN N
that WDT N
are VBP N
involved VBN N
in IN N
the DT N
representation NN N
of IN N
physical JJ N
pain NN N
. . N

Previous JJ N
research NN N
has VBZ N
observed VBN N
that IN N
acetominophen NN i
( ( N
a DT N
common JJ N
pain NN N
reliever NN N
) ) N
can MD N
reduce VB N
the DT N
pain NN N
of IN N
exclusion NN N
. . N

The DT N
taste NN N
and CC N
consumption NN N
of IN N
glucose NN N
can MD N
also RB N
relieve VB N
physical JJ N
pain NN N
, , N
and CC N
the DT N
purpose NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
examine VB N
whether IN N
it PRP N
might MD N
also RB N
reduce VB N
the DT N
negative JJ o
emotional JJ o
effects NNS o
of IN o
ostracism NN o
. . o

In IN N
an DT N
appropriately RB N
powered JJ N
experiment NN N
, , N
participants NNS p
were VBD p
given VBN p
25g CD i
of IN i
glucose NN i
or CC i
a DT i
sucralose JJ i
placebo NN i
before IN p
being VBG p
ostracized VBN p
while IN p
playing VBG p
Cyberball NNP p
. . p

Strong NNP N
effects NNS N
of IN N
ostracism NN N
were VBD N
observed VBN N
, , N
however RB N
, , N
there EX N
was VBD N
no DT N
effect NN N
of IN N
glucose NN o
on IN N
immediate JJ o
or CC o
delayed VBN o
self-reported JJ o
needs NNS o
or CC o
mood NN o
. . o

These DT N
results NNS N
are VBP N
discussed VBN N
in IN N
reference NN N
to TO N
the DT N
possibility NN N
that IN N
social JJ N
pain NN N
is VBZ N
unlike IN N
physical JJ N
pain NN N
since IN N
the DT N
latter NN N
is VBZ N
affected VBN N
by IN N
glucose NN N
, , N
which WDT N
is VBZ N
believed VBN N
to TO N
lessen VB N
pain NN N
by IN N
increasing VBG N
endogenous JJ N
opioid NN N
activity NN N
. . N

-DOCSTART- -25579054- O O

The DT N
effects NNS N
of IN N
a DT N
single JJ i
dose NN i
of IN i
oxytocin NN i
on IN N
working VBG o
memory NN o
in IN N
schizophrenia NN p
. . p

-DOCSTART- -9044492- O O

Airway NNP o
management NN o
training NN i
using VBG N
the DT N
laryngeal NN i
mask NN i
airway NN i
: : i
a DT N
comparison NN N
of IN N
two CD N
different JJ N
training VBG N
programmes NNS N
. . N

Nurses NNS p
without IN p
prior JJ p
experience NN p
in IN p
the DT p
use NN p
of IN p
the DT p
laryngeal JJ i
mask NN i
airway NN i
( ( i
LMA NNP i
) ) i
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
to TO N
be VB N
trained VBN N
in IN N
the DT N
emergency NN i
technique NN i
of IN i
insertion NN i
of IN i
an DT i
LMA NNP i
. . i

Group NNP p
A NNP p
( ( p
32 CD p
nurses NNS p
) ) p
were VBD p
trained VBN p
only RB p
on IN p
a DT p
manikin NN i
and CC p
group NN p
B NNP p
( ( p
20 CD p
nurses NNS p
) ) p
were VBD p
trained VBN i
on IN i
a DT i
manikin NN i
and CC i
with IN i
live JJ i
anaesthetised VBN i
patient JJ i
practice NN i
in IN p
theatre NN p
( ( p
five CD p
successful JJ p
insertions NNS p
) ) p
. . p

Without IN N
further JJ N
practice NN N
, , N
both DT N
groups NNS N
were VBD N
asked VBN N
to TO N
insert VB N
an DT N
LMA NNP i
in IN N
a DT N
live JJ p
patient NN p
in IN p
theatre JJ p
3 CD N
months NNS N
after IN N
initial JJ N
training NN N
. . N

Three CD N
attempts NNS N
per IN N
nurse NN N
were VBD N
allowed VBN N
. . N

In IN N
group NN N
A NNP N
, , N
75 CD N
% NN N
passed VBD N
the DT N
LMA NNP o
successfully RB o
at IN N
the DT N
first JJ N
attempt NN N
, , N
22 CD N
% NN N
at IN N
the DT N
second JJ N
attempt NN N
and CC N
3 CD N
% NN N
( ( N
one CD N
nurse NN N
) ) N
at IN N
the DT N
third JJ N
attempt NN N
. . N

In IN N
group NN N
B NNP N
, , N
80 CD N
% NN N
were VBD N
successful JJ o
at IN N
first JJ N
attempt NN N
and CC N
20 CD N
% NN N
at IN N
the DT N
second JJ N
attempt NN N
. . N

Skill NNP o
performance NN o
and CC o
retention NN o
were VBD N
shown VBN N
to TO N
be VB N
high JJ N
following VBG N
either CC N
training VBG N
method NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
performance NN o
of IN N
either DT N
group NN N
( ( N
chi JJ N
2 CD N
) ) N
. . N

We PRP N
have VBP N
shown VBN N
that IN N
manikin-only JJ N
training NN N
in IN N
the DT N
emergency NN N
technique NN N
for IN N
LMA NNP i
insertion NN N
is VBZ N
as RB N
effective JJ o
as IN N
live JJ N
patient NN N
training NN N
. . N

It PRP N
is VBZ N
proposed VBN N
that IN N
manikin JJ N
training VBG N
alone NN N
may MD N
be VB N
adopted VBN N
as IN N
a DT N
future JJ N
training NN N
modality NN N
if IN N
, , N
as IN N
is VBZ N
expected VBN N
, , N
the DT N
use NN N
of IN N
the DT N
LMA NNP i
in IN N
resuscitation NN N
becomes NNS N
more RBR N
commonplace NN N
. . N

-DOCSTART- -23118720- O O

Clinical JJ N
trial NN N
: : N
marine NN i
lipid JJ i
suppositories NNS i
as IN N
laxatives NNS N
. . N

UNLABELLED JJ N
Cod-liver JJ N
oil NN N
and CC N
other JJ N
marine NN N
products NNS N
containing VBG N
polyunsaturated JJ N
fatty JJ N
acids NNS N
have VBP N
anti-inflammatory JJ N
, , N
anti-bacterial JJ N
and CC N
anti-viral JJ N
effects NNS N
and CC N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
various JJ N
inflammatory NN N
and CC N
infectious JJ N
diseases NNS N
. . N

We PRP N
developed VBD N
suppositories NNS i
and CC i
ointment NN i
with IN i
30 CD i
% NN i
free JJ i
fatty JJ i
acid NN i
( ( i
FFA NNP i
) ) i
extract NN i
from IN i
omega-3 JJ i
fish JJ i
oil NN i
. . i

Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN o
of IN N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
in IN N
healthy JJ p
volunteers NNS p
and CC N
to TO N
explore VB N
the DT N
laxative JJ o
effect NN o
of IN N
the DT N
suppositories NNS N
. . N

Thirty NNP p
healthy JJ p
volunteers NNS p
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
study NN N
group NN N
administrating VBG N
30 CD N
% NN N
FFA NNP i
suppositories NNS i
and CC N
applying VBG N
30 CD N
% NN N
FFA NNP i
ointment NN i
to TO N
the DT N
perianal JJ N
region NN N
twice RB N
per IN N
day NN N
for IN N
two CD N
weeks NNS N
, , N
or CC N
to TO N
a DT N
control NN N
group NN N
using VBG N
placebo NN i
suppositories NNS i
and CC N
ointment NN N
in IN N
a DT N
double JJ N
blinded JJ N
manner NN N
. . N

RESULTS NNP N
No NNP N
serious JJ o
toxic NN o
effects NNS o
or CC o
irritation NN o
were VBD N
observed VBN N
. . N

In IN N
the DT N
study NN N
group NN N
93 CD N
% NN N
felt VBD N
the DT N
urge NN o
to TO o
defecate VB o
after IN N
administration NN N
of IN N
the DT N
suppositories NNS N
as IN N
compared VBN N
to TO N
37 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Subsequently RB N
90 CD N
% NN N
in IN N
the DT N
study NN N
group NN N
defecated VBD o
, , N
compared VBN N
to TO N
33 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
marine JJ N
lipid JJ N
suppositories NNS N
and CC N
ointment NN N
were VBD N
well RB N
tolerated VBN N
with IN N
no DT N
significant JJ N
toxic JJ o
side NN o
effects NNS o
observed VBD N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
suppositories NNS N
have VBP N
a DT N
distinct JJ N
laxative JJ o
effect NN o
and CC N
we PRP N
aim VBP N
to TO N
explore VB N
this DT N
effect NN N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -12687510- O O

Validation NN N
of IN N
a DT N
novel JJ N
satisfaction NN i
questionnaire NN i
for IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
receiving VBG p
outpatient JJ p
clinical JJ p
nurse NN p
specialist NN p
care NN p
, , p
inpatient NN p
care NN p
, , p
or CC p
day NN p
patient JJ p
team NN p
care NN p
. . p

OBJECTIVES NNP N
To TO N
develop VB N
and CC N
validate VB N
a DT N
questionnaire NN N
for IN N
measuring VBG N
satisfaction NN o
with IN N
different JJ N
forms NNS N
of IN N
complex JJ N
multidisciplinary JJ N
care NN N
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
. . p

METHODS PDT N
The DT N
satisfaction NN o
questionnaire NN o
( ( N
score JJ N
range NN N
0-100 NN N
) ) N
comprised VBD N
28 CD N
items NNS N
covering VBG N
11 CD N
domains NNS N
. . N

Together RB N
with IN N
a DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
, , o
range VB o
0-100 NNP o
) ) o
on IN o
overall JJ o
satisfaction NN o
, , N
the DT N
questionnaire NN i
was VBD N
applied VBN N
in IN N
210 CD p
RA NNP p
patients NNS p
who WP p
participated VBD p
in IN p
a DT p
randomized JJ p
trial NN p
comparing VBG N
3 CD N
types NNS N
of IN N
multidisciplinary JJ N
care NN N
. . N

RESULTS VB N
The DT p
questionnaire NN p
was VBD p
returned VBN p
by IN p
174 CD p
patients NNS p
( ( p
83 CD p
% NN p
) ) p
. . p

The DT N
questionnaire NN o
and CC o
VAS NNP o
scores NNS o
in IN N
the DT N
total JJ N
group NN N
were VBD N
75 CD N
( ( N
SD NNP N
12 CD N
) ) N
and CC N
83 CD N
( ( N
SD NNP N
20 CD N
) ) N
, , N
respectively RB N
. . N

Reliability NNP N
analysis NN N
showed VBD N
Cronbach NNP N
's POS N
alpha NN N
of IN N
the DT o
questionnaire NN o
was VBD N
0.91 CD N
. . N

Spearman NNP N
's POS N
correlation NN N
coefficient NN N
between IN N
the DT N
satisfaction NN o
questionnaire NN o
score NN o
and CC o
VAS NNP o
score NN o
was VBD N
0.58 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Mean JJ o
total JJ o
satisfaction NN o
questionnaire NN o
scores NNS o
were VBD N
72 CD N
( ( N
SD NNP N
9 CD N
) ) N
, , N
76 CD N
( ( N
SD NNP N
14 CD N
) ) N
, , N
and CC N
78 CD N
( ( N
SD NNP N
11 CD N
) ) N
, , N
in IN N
the DT N
nurse JJ N
specialist NN N
, , N
inpatient JJ N
and CC N
day NN N
patient NN N
groups NNS N
, , N
respectively RB N
( ( N
nurse JJ N
specialist NN N
versus IN N
day NN N
patient NN N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

Significant JJ N
differences NNS N
between IN N
nurse JJ N
specialist NN N
and CC N
day NN N
patients NNS N
were VBD N
seen VBN N
in IN N
the DT N
following JJ N
domains NNS N
: : N
waiting VBG o
time NN o
during IN o
the DT o
treatment NN o
, , o
autonomy NN o
, , o
coordination NN o
, , o
non-financial JJ o
access NN o
, , o
and CC o
quality NN o
of IN o
general JJ o
information NN o
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
patients NNS N
were VBD N
highly RB N
satisfied VBN N
with IN N
the DT N
multidisciplinary JJ N
care NN N
they PRP N
received VBD N
. . N

Major JJ N
differences NNS N
regarding VBG N
the DT N
organization NN N
of IN N
care NN N
were VBD N
reflected VBN N
in IN N
the DT N
results NNS N
of IN N
the DT N
questionnaire NN N
scores NNS N
. . N

The DT N
satisfaction NN o
questionnaire NN o
appears VBZ N
to TO N
be VB N
a DT N
useful JJ N
instrument NN N
for IN N
measuring VBG N
satisfaction NN o
with IN N
complex JJ N
multidisciplinary NN N
care NN N
in IN N
RA NNP p
patients NNS p
. . p

-DOCSTART- -12876178- O O

Children NNP p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

II NN N
: : N
parents NNS p
are VBP N
unable JJ N
to TO N
distinguish VB N
secretin NN N
from IN N
placebo NN N
under IN N
double-blind JJ N
conditions NNS N
. . N

BACKGROUND NNP N
Standardised VBD o
measures NNS o
of IN o
behaviour NNS o
have VBP N
failed VBN N
to TO N
detect VB N
short JJ o
term NN o
improvement NN o
in IN N
children NNS p
with IN p
autism NN p
following VBG N
treatment NN N
with IN N
secretin NN i
. . i

However RB N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
standardised JJ N
measures NNS N
are VBP N
insensitive JJ N
to TO N
dimensions NNS N
of IN N
child NN N
behaviour NN N
that WDT N
are VBP N
nonetheless RB N
detectable JJ N
by IN N
parents NNS N
. . N

AIM NNP N
To TO N
determine VB N
the DT N
ability NN o
of IN o
parents NNS o
of IN o
children NNS o
with IN o
autism NN o
to TO N
guess VB N
, , N
under IN N
double JJ N
blind NN N
conditions NNS N
, , N
whether IN N
their PRP$ N
child NN N
had VBD N
received VBN N
secretin NN i
or CC N
placebo NN i
. . i

METHODS NNP N
2x2 CD N
crossover NN N
randomised VBD N
blinded VBN N
study NN N
, , N
comparing VBG N
the DT N
effect NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
2 CD N
U/kg NNP N
to TO N
placebo VB i
( ( i
saline NN i
) ) i
. . i

Sixty CD p
two CD p
children NNS p
with IN p
autism NN p
( ( p
aged VBN p
43-103 CD p
months NNS p
) ) p
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
group NN N
1 CD N
received VBD N
placebo NN i
, , i
followed VBD i
six CD i
weeks NNS i
later RB i
by IN i
secretin NN i
, , N
and CC N
group NN N
2 CD N
received VBD N
secretin NN i
followed VBN i
by IN i
placebo NN i
. . i

At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN N
, , N
parents NNS p
were VBD N
asked VBN N
to TO N
guess VB N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
. . N

RESULTS NNP N
Twenty NNP p
seven CD p
families NNS p
guessed VBD N
their PRP$ N
child NN N
's POS N
group NN N
assignment NN N
correctly RB N
and CC N
27 CD p
guessed VBN p
incorrectly RB p
. . p

In IN N
48 CD N
instances NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
improvement NN o
; : o
in IN N
six CD N
cases NNS N
, , N
parents NNS N
based VBN N
their PRP$ N
guess NN N
on IN N
perceived JJ N
deterioration NN o
. . o

Six NNP p
families NNS p
saw VBD N
no DT N
difference NN N
after IN N
either DT N
infusion NN N
, , N
and CC N
offered VBD N
no DT N
guess NN N
. . N

One CD N
family NN N
dropped VBD N
out RP N
after IN N
the DT N
first JJ N
infusion NN N
, , N
and CC N
one CD N
family NN N
was VBD N
lost VBN N
to TO N
follow VB N
up RP N
after IN N
the DT N
second JJ N
infusion NN N
. . N

CONCLUSION NNP N
In IN N
a DT N
controlled JJ N
setting NN N
, , N
parents NNS p
of IN p
young JJ p
children NNS p
with IN p
autism NN p
are VBP N
unable JJ N
to TO N
distinguish VB N
the DT N
short JJ o
term NN o
behavioural JJ o
effects NNS o
of IN N
secretin NN i
from IN N
placebo NN i
. . i

-DOCSTART- -25656334- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
guided JJ i
self-help NN i
for IN N
improving VBG N
the DT N
experience NN o
of IN o
caring VBG o
for IN o
carers NNS o
of IN p
clients NNS p
with IN p
depression NN p
. . p

AIM NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive JJ i
behaviour NN i
therapy NN i
guided VBD i
self-help JJ i
manual JJ i
for IN N
enhancing VBG N
the DT N
experience NN o
of IN o
caregiving NN o
of IN o
family NN o
carers NNS o
of IN p
individuals NNS p
with IN p
depression NN p
. . p

BACKGROUND IN N
The DT N
prevalence NN N
of IN N
depression NN N
is VBZ N
increasing VBG N
markedly RB N
in IN N
Thailand NNP p
. . p

While IN N
primary JJ p
carers NNS p
give VBP N
most JJS N
of IN N
the DT N
support NN N
for IN N
individuals NNS N
with IN N
depression NN N
, , N
they PRP N
receive VBP N
little JJ N
support NN N
from IN N
mental JJ N
health NN N
services NNS N
in IN N
this DT N
critical JJ N
role NN N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHOD NNP N
Carers NNPS p
were VBD p
randomized VBN p
to TO p
guided VBN i
self-help NN i
( ( p
n JJ p
= NNP p
27 CD p
) ) p
, , p
while IN p
the DT p
control NN i
group NN i
received VBD i
standard JJ i
information NN i
and CC i
support NN i
( ( p
n JJ p
= NNP p
27 CD p
) ) p
. . p

Both DT N
groups NNS N
also RB N
received VBD N
a DT N
short JJ i
weekly JJ i
telephone NN i
call NN i
. . i

Participants NNS N
were VBD N
assessed VBN N
at IN N
three CD N
time NN N
points NNS N
; : N
the DT N
outcome NN N
measure NN N
was VBD N
the DT N
Experience NN N
of IN N
Caregiving NNP i
Inventory NNP i
. . i

A NNP N
doubly RB N
multivariate JJ N
analysis NN N
of IN N
variance NN N
( ( N
anova JJ N
) ) N
procedure NN N
, , N
including VBG N
between-group JJ N
and CC N
within-group JJ N
factors NNS N
, , N
was VBD N
implemented VBN N
. . N

Fieldwork NNP N
was VBD N
from IN N
October NNP N
2007-May JJ N
2008 CD N
. . N

RESULTS VB N
Fifty-four JJ p
carers NNS p
completed VBD N
the DT N
study NN N
and CC N
intent-to-treat JJ N
analyses NNS N
were VBD N
undertaken VBN N
. . N

The DT N
findings NNS N
showed VBD N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
total JJ o
negative JJ o
experience NN o
of IN o
caring NN o
, , N
from IN N
baseline NN N
to TO N
post-treatment NN N
, , N
in IN N
the DT N
intervention NN N
group NN N
recipients NNS N
of IN N
the DT N
manual JJ N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
treatment NN N
effects NNS N
were VBD N
maintained VBN N
at IN N
one-month JJ N
follow-up NN N
. . N

Similarly RB N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
total JJ o
positive JJ o
experience NN o
of IN o
caring NN o
occurred VBD N
, , N
from IN N
baseline NN N
to TO N
post-treatment NN N
, , N
in IN N
the DT N
intervention NN N
group NN N
in IN N
contrast NN N
with IN N
the DT N
control NN N
group NN N
and CC N
these DT N
outcomes NNS N
were VBD N
sustained VBN N
at IN N
one-month JJ N
follow-up NN N
. . N

CONCLUSION NNP N
Guided VBD i
self-help NN i
strengthen NN N
carers NNS p
' POS p
positive JJ N
and CC N
reduces VBZ N
their PRP$ N
negative JJ N
, , N
experience NN o
of IN o
caring NN o
. . o

The DT N
study NN N
contributes VBZ N
to TO N
the DT N
limited JJ N
evidence NN N
base NN N
about IN N
this DT N
approach NN N
in IN N
a DT N
developing JJ N
country NN p
such JJ p
as IN p
Thailand NNP p
. . p

-DOCSTART- -16181541- O O

[ VB N
A DT N
clinical JJ N
study NN N
on IN N
the DT N
effect NN o
of IN N
Yinxing VBG i
Damo NNP i
combined VBN i
with IN i
betahistine JJ i
hydrochloride NN i
injection NN N
on IN N
vertebral JJ o
basilar JJ o
artery NN o
ischemic JJ o
vertigo NN o
] NN o
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
therapeutic JJ o
efficacy NN o
of IN N
Yinxing VBG i
Damo NNP i
( ( i
YXDM NNP i
) ) i
combined VBD i
with IN i
Betahistine NNP i
Hydrochloride NNP i
Injection NNP i
( ( N
BHI NNP N
) ) N
on IN N
vertebra NN o
basilar JJ o
artery NN o
ischemic JJ o
vertigo NN o
( ( o
VBIV NNP o
) ) o
. . o

METHODS NNP N
Ninety NNP p
patients NNS p
with IN p
VBIV NNP o
were VBD p
randomly RB p
divided VBN p
into IN p
two CD p
groups NNS p
; : p
45 CD N
patients NNS N
( ( N
the DT N
treated VBN N
group NN N
) ) N
were VBD N
treated VBN N
with IN N
YXDM NNP i
and CC N
BHI NNP i
intravenous JJ N
dripping NN N
, , N
once RB N
a DT N
day NN N
for IN N
14 CD N
days NNS N
. . N

Another DT p
45 CD p
patients NNS p
( ( p
control VB p
group NN p
) ) p
were VBD N
treated VBN N
with IN N
Xueshuantong NNP N
and CC N
BHI NNP N
intravenous JJ N
dripping NN N
, , N
once RB N
daily JJ N
for IN N
14 CD N
days NNS N
. . N

The DT N
clinical JJ o
syndromes NNS o
and CC o
the DT o
index NN o
of IN o
the DT o
transcranial JJ o
Doppler NNP o
( ( o
TCD NNP o
) ) o
and CC N
hemorheology NN o
were VBD N
observed VBN N
. . N

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
was VBD N
100 CD N
% NN N
in IN N
the DT N
treated JJ N
group NN N
, , N
which WDT N
was VBD N
better JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
90.5 CD N
% NN N
, , N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
indexes NNS o
of IN o
TCD NNP o
and CC o
hemorheology NN o
in IN N
the DT N
treated JJ N
group NN N
were VBD N
obviously RB N
improved VBN N
after IN N
treatment NN N
, , N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
YXDM NNP N
combined VBD N
with IN N
BHT NNP N
injection NN N
had VBD N
better RBR N
effect NN o
in IN N
treating VBG o
patients NNS o
with IN o
VBIV NNP o
is VBZ N
an DT N
ideal JJ N
drug NN N
for IN N
VBIV NNP o
. . o

-DOCSTART- -26554619- O O

The DT N
role NN N
of IN N
routinely RB N
given VBN N
hyoscine-N-butylbromide NN i
in IN N
colonoscopy NN p
: : p
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
Hyoscine-N-butylbromide NNP i
( ( i
HBB NNP i
) ) i
has VBZ N
been VBN N
proposed VBN N
to TO N
ease VB N
colonoscopy NN N
and CC N
improve VB N
mucosal NN N
visualization NN N
, , N
yet RB N
the DT N
results NNS N
from IN N
previous JJ N
studies NNS N
are VBP N
conflicting VBG N
. . N

In IN N
our PRP$ N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
study NN N
we PRP N
aimed VBD N
at IN N
evaluating VBG N
whether IN N
routine JJ N
administration NN N
of IN N
HBB NNP i
, , N
before IN N
and CC N
during IN N
colonoscopy NN N
, , N
ease VB o
the DT o
procedure NN o
or CC o
increase VB o
the DT o
detection NN o
rate NN o
for IN o
polyps NNS o
. . o

MATERIAL NNP N
AND CC N
METHODS NNP N
One CD p
hundred VBD p
fifty JJ p
outpatients NNS p
scheduled VBN p
for IN p
an DT p
elective JJ p
colonoscopy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
intravenous JJ N
injections NNS N
of IN N
either DT N
10 CD N
mg JJ N
hyoscine-N-butylbromide NN i
or CC i
saline NN i
before IN i
insertion NN N
and CC N
at IN N
cecum NN N
. . N

Patient JJ o
tolerance NN o
and CC o
technical JJ o
ease NN o
of IN o
colonoscopy NN o
were VBD N
evaluated VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
. . N

Procedure NN o
times NNS o
were VBD N
recorded VBN N
. . N

Number NNP o
of IN o
detected JJ o
polyps NNS o
per IN o
patient NN o
was VBD N
evaluated VBN N
as RB N
well RB N
. . N

Heart NNP o
rate NN o
was VBD N
monitored VBN N
with IN N
a DT N
pulse JJ N
oximetry NN N
. . N

RESULTS NNP N
HBB NNP i
did VBD N
not RB N
improve VB N
patient NN o
tolerance NN o
or CC o
technically RB o
ease VB o
the DT o
procedure NN o
as IN N
evaluated VBN N
by IN N
VAS NNP N
. . N

However RB N
, , N
HBB NNP i
led VBD N
to TO N
faster VB N
ileal JJ o
intubation NN o
( ( N
1.5 CD N
vs RB N
2.0 CD N
min NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
shorter JJR N
total JJ o
procedure NN o
time NN o
( ( N
22.0 CD N
vs RB N
24.0 CD N
min NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
HBB NNP i
also RB N
needed VBD N
less RBR N
often RB N
external JJ o
abdominal JJ o
pressure NN o
( ( N
48.6 CD N
vs RB N
66.7 CD N
% NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

HBB NNP i
did VBD N
not RB N
improve VB N
polyp JJ o
detection NN o
rate NN o
( ( N
0.89 CD N
vs NN N
0.91 CD N
, , N
p NN N
= NNP N
0.90 CD N
) ) N
. . N

HBB NNP i
induced VBD N
a DT N
significant JJ N
rise NN N
in IN N
heart NN o
rate NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
more RBR N
often RB N
tachycardia NNP o
( ( N
17.6 CD N
vs RB N
0 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Routine NNP N
administration NN N
of IN N
HBB NNP i
before IN N
and CC N
during IN N
colonoscopy NN N
yields NNS N
only RB N
limited VBD N
improvement NN N
in IN N
the DT N
technical JJ o
performance NN o
of IN o
the DT o
examination NN o
compromised VBN N
by IN N
high JJ N
incidence NN N
of IN N
tachycardia NN o
. . o

-DOCSTART- -17051443- O O

The DT N
Social NNP i
Communication NNP i
Assessment NNP i
for IN i
Toddlers NNP i
with IN i
Autism NNP i
( ( i
SCATA NNP i
) ) i
: : i
an DT N
instrument NN N
to TO N
measure VB N
the DT N
frequency NN o
, , N
form NN N
and CC N
function NN o
of IN o
communication NN o
in IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

The DT N
Social NNP i
Communication NNP i
Assessment NNP i
for IN i
Toddlers NNP i
with IN i
Autism NNP i
( ( i
SCATA NNP i
) ) i
was VBD N
designed VBN N
to TO N
measure VB N
non-verbal JJ o
communication NN o
, , o
including VBG o
early JJ o
and CC o
atypical JJ o
communication NN o
, , N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Each DT N
communicative JJ N
act NN N
is VBZ N
scored VBN N
according VBG N
to TO N
its PRP$ N
form NN N
, , N
function NN N
, , N
role NN N
and CC N
complexity NN N
. . N

The DT N
SCATA NNP i
was VBD N
used VBN N
to TO N
measure VB N
communicative JJ N
ability NN N
longitudinally RB N
in IN N
two CD N
samples NNS N
of IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Overall JJ o
frequency NN o
of IN o
non-verbal JJ o
communicative JJ o
acts NNS o
did VBD N
not RB N
change NN N
between IN N
the DT N
two CD N
assessments NNS N
. . N

However RB N
, , N
the DT N
form NN o
and CC o
complexity NN o
, , o
the DT o
function NN o
and CC o
the DT o
role NN o
the DT N
child NN N
took VBD N
in IN N
the DT N
interaction NN N
did VBD N
change VB N
with IN N
time NN N
. . N

Both DT N
frequency NN o
and CC o
function NN o
of IN o
communicative JJ o
acts NNS o
in IN N
toddlerhood NN N
were VBD N
positively RB N
associated VBN N
with IN N
later JJ o
language NN o
ability NN o
: : o
social JJ o
acts NNS o
, , o
comments NNS o
and CC o
initiations NNS o
showed VBD N
greater JJR N
predictive JJ N
association NN N
than IN N
requests NNS N
and CC N
responses NNS N
. . N

-DOCSTART- -15535495- O O

Gum NNP i
elastic JJ i
bougie-guided JJ i
insertion NN i
of IN N
the DT N
ProSeal NNP N
Laryngeal NNP N
Mask NNP N
Airway NNP N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
gum VBZ i
elastic-bougie-guided JJ i
insertion NN i
of IN N
the DT N
ProSeal NNP N
Laryngeal NNP N
Mask NNP N
Airway NNP N
is VBZ N
more RBR N
frequently RB N
successful JJ N
than IN N
introducer JJ N
tool NN N
guided VBD N
insertion NN N
after IN N
failed VBD N
digital JJ N
insertion NN N
. . N

One CD p
hundred VBD p
anaesthetized JJ p
patients NNS p
( ( p
ASA NNP p
1-2 CD p
, , p
aged VBD p
18 CD p
to TO p
80 CD p
years NNS p
) ) p
were VBD N
randomized VBN N
for IN N
the DT N
second JJ i
insertion NN i
attempt NN i
using VBG i
either CC i
the DT i
gum JJ i
elastic JJ i
bougie-guided JJ i
or CC i
introducer JJ i
tool NN i
techniques NNS i
. . i

The DT N
bougie-guided JJ i
technique NN i
involved VBN N
priming VBG N
the DT N
drain NN N
tube NN N
with IN N
the DT N
bougie NN N
, , N
placing VBG N
the DT N
bougie NN N
in IN N
the DT N
oesophagus NN N
using VBG N
laryngoscope JJ N
guidance NN N
, , N
digital JJ N
insertion NN N
along IN N
the DT N
palato-pharyngeal JJ N
curve NN N
, , N
and CC N
bougie NN N
removal NN N
. . N

The DT N
introducer JJ i
tool NN i
technique NN i
involved VBN N
attaching VBG N
the DT N
introducer NN N
tool NN N
, , N
single-handed JJ N
rotation NN N
along IN N
the DT N
palatopharyngeal NN N
curve NN N
, , N
and CC N
introducer JJ N
tool NN N
removal NN N
. . N

Failed VBD N
insertion NN N
was VBD N
classified VBN N
as IN N
( ( N
i NN N
) ) N
failed VBD N
passage NN N
into IN N
the DT N
pharynx NN N
, , N
( ( N
ii NN N
) ) N
malposition NN N
, , N
or CC N
( ( N
iii NN N
) ) N
ineffective JJ N
ventilation NN N
. . N

Any DT N
blood NN o
staining NN o
was VBD N
documented VBN N
. . N

Insertion NN o
was VBD N
more RBR N
frequently RB o
successful JJ o
( ( N
50/50 CD N
vs NN N
15/50 CD N
, , N
P=0.0002 NNP N
) ) N
and CC N
faster RBR o
( ( N
35+/-17 JJ N
s NN N
vs IN N
54+/-45 JJ N
s NN N
, , N
mean+/-SD NN N
, , N
P=0.006 NNP N
) ) N
with IN N
the DT N
bougie-guided JJ N
technique NN N
. . N

All DT N
failed VBD o
insertions NNS o
with IN N
the DT N
introducer NN N
tool NN N
technique NN N
were VBD N
successful JJ N
with IN N
the DT N
bougie-guided JJ N
technique NN N
. . N

The DT N
aetiology NN o
of IN o
failed JJ o
insertion NN o
was VBD N
similar JJ N
for IN N
the DT N
digital JJ N
and CC N
introducer JJ N
tool NN N
techniques NNS N
in IN N
94 CD N
% NN N
( ( N
33/35 CD N
) ) N
of IN N
patients NNS N
. . N

There EX N
was VBD N
no DT N
blood NN o
staining VBG o
on IN N
the DT N
bougie NN N
, , N
laryngoscope NN N
or CC N
introducer NN N
tool NN N
at IN N
removal NN N
, , N
but CC N
blood VBD o
staining NN o
was VBD N
more RBR N
common JJ N
on IN N
the DT N
ProSeal NNP N
Laryngeal NNP N
Mask NNP N
Airway NNP N
with IN N
the DT N
introducer NN N
tool NN N
technique NN N
( ( N
9/50 CD N
vs NN N
2/50 CD N
, , N
P=0.03 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
gum JJ i
elastic JJ i
bougie-guided JJ i
insertion NN i
has VBZ N
a DT N
higher JJR N
success NN o
rate NN o
and CC N
causes VBZ N
less RBR N
trauma JJ o
than IN N
the DT N
insertion NN N
tool NN i
insertion NN i
technique NN i
after IN N
failed VBD N
digital JJ N
insertion NN N
of IN N
the DT N
ProSeal NNP N
Laryngeal NNP N
Mask NNP N
Airway NNP N
. . N

-DOCSTART- -24164087- O O

Therapeutic JJ N
effect NN N
of IN N
inhaled JJ N
budesonide NN i
( ( i
Pulmicort? NNP i
Turbuhaler NNP i
) ) i
on IN N
the DT N
inflammatory JJ N
response NN N
to TO N
one-lung JJ N
ventilation NN N
. . N

This DT N
prospective JJ N
, , N
double-blind JJ N
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
inhaled JJ i
budesonide NN i
on IN o
lung NN o
function NN o
and CC o
the DT o
inflammatory JJ o
response NN o
to TO o
one-lung JJ o
ventilation NN o
. . o

One CD p
hundred VBD p
patients NNS p
scheduled VBN p
for IN p
lobectomy NN p
were VBD N
allocated VBN N
randomly RB N
to TO N
pre-operative JJ N
nebulised JJ i
budesonide NN i
or CC i
saline NN i
. . i

Bronchoalveolar JJ N
lavage NN N
fluid NN N
samples NNS N
were VBD N
collected VBN N
from IN N
either CC N
the DT N
collapsed JJ N
or CC N
the DT N
ventilated VBN N
lung NN N
both DT N
before IN N
one-lung JJ N
ventilation NN N
and CC N
30 CD N
min NN N
after IN N
re-expansion NN N
of IN N
the DT N
lung NN N
. . N

The DT o
concentrations NNS o
of IN o
serum NN o
and CC o
bronchoalveolar JJ o
lavage NN o
fluid NN o
cytokines NNS o
were VBD N
determined VBN N
. . N

Budesonide NNP i
treatment NN N
, , N
compared VBN N
with IN N
saline NN N
, , N
reduced VBD o
both DT o
peak NN o
( ( N
mean JJ N
( ( N
SD NNP N
) ) N
3.7 CD N
( ( N
0.4 CD N
) ) N
vs NN N
2.5 CD N
( ( N
0.2 CD N
) ) N
kPa NN N
) ) N
and CC o
plateau NN o
( ( N
mean JJ N
( ( N
SD NNP N
) ) N
3.1 CD N
( ( N
0.2 CD N
) ) N
vs NN N
2.2 CD N
( ( N
0.1 CD N
) ) N
kPa NN N
, , N
respectively RB N
, , N
p JJ N
< VBP N
0.001 CD N
for IN N
both DT o
) ) o
ventilatory NN o
pressures NNS o
. . o

Thirty NNP N
minutes NNS N
after IN N
re-expansion NN N
, , N
lung NN o
compliance NN o
increased VBD N
in IN N
the DT i
budesonide NN i
group NN N
compared VBN N
with IN N
saline NN N
( ( N
57.5 CD N
( ( N
4.1 CD N
) ) N
vs NN N
40.1 CD N
( ( N
3.5 CD N
) ) N
ml.cmH NN N
( ( N
2 CD N
) ) N
O NNP N
( ( N
-1 NNP N
) ) N
, , N
respectively RB N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Budesonide NNP i
also RB N
reduced VBD N
the DT o
concentrations NNS o
of IN o
tumour JJ o
necrosis NN o
factor-? NN o
, , o
interleukin-1? JJ o
, , o
interleukin-6 JJ o
and CC o
interleukin-8 JJ o
in IN o
bronchoalveolar JJ o
lavage NN o
fluid NN o
, , o
but CC o
increased VBD o
interleukin-10 JJ o
30 CD o
min NN N
after IN N
re-expansion NN N
( ( N
p JJ N
< VBP N
0.05 CD N
for IN N
all DT N
measures NNS N
) ) N
. . N

Pre-operative JJ N
nebulisation NN N
of IN N
budesonide NN i
may MD i
be VB N
effective JJ N
in IN N
improving VBG o
ventilatory NN o
mechanics NNS o
and CC o
reducing VBG o
the DT o
inflammatory JJ o
response NN o
to TO o
one-lung JJ N
ventilation NN N
during IN N
thoracic JJ N
surgery NN N
. . N

-DOCSTART- -8275903- O O

[ JJ N
Opiate NNP N
hypothesis NN N
in IN N
infantile JJ p
autism NN p
? . N
Therapeutic JJ N
trials NNS N
with IN N
naltrexone JJ i
] NN i
. . N

The DT N
opioid JJ N
hypothesis NN N
suggests VBZ N
that IN N
childhood NN N
autism NN N
may MD N
result VB N
from IN N
excessive JJ N
brain NN N
opioid JJ N
activity NN N
during IN N
neonatal JJ N
period NN N
which WDT N
may MD N
constitutionally RB N
inhibit VB N
social JJ N
motivation NN N
, , N
yielding VBG N
autistic JJ N
isolation NN N
and CC N
aloofness NN N
( ( N
Panksepp NNP N
, , N
1979 CD N
) ) N
. . N

This DT N
hypothesis NN N
has VBZ N
now RB N
received VBN N
strong JJ N
support NN N
and CC N
is VBZ N
currently RB N
based VBN N
on IN N
three CD N
types NNS N
of IN N
arguments NNS N
: : N
( ( N
1 CD N
) ) N
similarity NN N
between IN N
autistic JJ N
symptomatology NN N
and CC N
abnormal JJ N
behaviors NNS N
induced VBD N
in IN N
young JJ N
animals NNS N
by IN N
injections NNS N
of IN N
exogenous JJ N
opioids NNS N
, , N
such JJ N
as IN N
increasing VBG N
social JJ N
aloofness NN N
and CC N
decreasing VBG N
social JJ N
vocalization NN N
; : N
( ( N
2 CD N
) ) N
direct JJ N
biochemical JJ N
evidence NN N
of IN N
abnormalities NNS N
of IN N
peripheral JJ N
endogenous JJ N
opioids NNS N
being VBG N
reported VBN N
in IN N
autism NN N
and CC N
( ( N
3 CD N
) ) N
therapeutic JJ N
effects NNS N
of IN N
the DT N
long JJ N
lasting NN N
opioid JJ N
receptor NN N
blocking VBG N
agent NN N
naltrexone NN N
in IN N
autism NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
give VBP N
description NN N
of IN N
open JJ N
and CC N
double-blind JJ N
studies NNS N
of IN N
naltrexone NN i
in IN N
autism NN N
. . N

Naltrexone NN i
has VBZ N
been VBN N
tested VBN N
in IN N
several JJ N
open JJ N
studies NNS N
. . N

We PRP N
performed VBD N
an DT N
open JJ N
trial NN N
with IN N
naltrexone NN i
in IN N
2 CD p
autistic JJ p
girls NNS p
, , p
displaying VBG p
serious JJ p
self-injurious JJ p
behavior NN p
, , p
reduced VBD p
crying NN p
and CC p
a DT p
marked JJ p
preference NN p
for IN p
salty NN p
and CC p
spicy NN p
foods NNS p
, , p
symptoms NNS p
that WDT p
could MD p
be VB p
related VBN p
to TO p
a DT p
dysfunction NN p
of IN p
the DT p
opioid JJ p
system NN p
. . p

With IN N
dosages NNS N
of IN N
1 CD N
mg/kg/day NN N
, , N
we PRP N
observed VBD N
an DT N
immediate JJ N
reduction NN o
of IN o
hyperactivity NN o
, , o
self-injurious JJ o
behavior NN o
and CC o
aggressiveness NN o
, , o
while IN o
attention NN o
improved VBN o
. . o

In IN N
addition NN N
, , N
social JJ o
behaviors NNS o
, , o
smiling VBG o
, , o
social JJ o
seeking VBG o
behaviors NNS o
and CC o
play VB o
interactions NNS o
increased VBN N
( ( N
Leboyer NNP N
, , N
Bouvard NNP N
et VBZ N
Dugas NNP N
, , N
1988 CD N
) ) N
. . N

Campbell NNP N
et CC N
al NN N
. . N

( ( N
1988 CD N
) ) N
has VBZ N
also RB N
reported VBN N
a DT N
tranquilizing NN o
and CC o
a DT o
stimulating JJ o
effect NN o
in IN N
6 CD N
out IN N
of IN N
8 CD N
children NNS N
with IN N
autism NN N
. . N

We PRP N
did VBD N
confirm VB N
these DT N
preliminary JJ N
results NNS N
in IN N
a DT N
double-blind NN N
study NN N
performed VBD N
on IN N
4 CD p
children NNS p
with IN p
autism NN p
. . p

In IN N
a DT N
cross-over JJ N
double-blind NN N
study NN N
, , N
three CD N
dosages NNS N
of IN N
naltrexone NN N
( ( N
0.5 CD N
, , N
1 CD N
and CC N
2 CD N
mg/kg/day NN N
) ) N
and CC N
placebo NN N
were VBD N
compared VBN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -22982948- O O

Take VB N
a DT N
walk NN N
in IN N
the DT N
park NN N
? . N
A DT N
cross-over NN N
pilot NN N
trial NN N
comparing VBG N
brisk JJ i
walking VBG i
in IN i
two CD i
different JJ i
environments NNS i
: : i
park NN N
and CC N
urban JJ N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
differences NNS N
exist VBP N
between IN N
a DT N
30 CD i
minute NN i
brisk NN i
walk VBP i
taken VBN N
in IN N
two CD N
different JJ N
environments NNS N
in IN N
order NN N
to TO N
determine VB N
which WDT N
environment NN N
best JJS N
facilitates NNS N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
: : N
park NN N
or CC N
urban JJ N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
cross-over NN N
pilot NN N
study NN N
, , N
participants NNS p
performed VBD p
a DT p
self-timed JJ i
30 CD i
minute NN i
brisk NN i
walk VBP i
in IN i
two CD i
different JJ i
environments NNS i
, , i
park NN i
and CC i
urban JJ i
, , N
in IN N
Glasgow NNP N
, , N
Scotland NNP N
( ( N
October NNP N
2009 CD N
to TO N
January NNP N
2010 CD N
) ) N
. . N

Cadence NN o
, , N
recorded VBD N
using VBG N
the DT N
activPAL? NN N
activity NN N
monitor NN N
, , N
was VBD N
used VBN N
to TO N
measure VB N
intensity NN N
. . N

Outcome CC N
measures NNS N
were VBD o
: : o
mean JJ o
cadence NN o
; : o
moderate-to-vigorous JJ o
physical JJ o
activity NN o
time NN o
accumulated VBN o
in IN o
bouts NNS o
lasting VBG o
? . o
10 CD o
min NN o
; : o
number NN o
of IN o
walking VBG o
breaks NNS o
; : o
and CC o
duration NN o
. . o

RESULTS VB o
A DT N
convenience NN N
sample NN p
of IN p
40 CD p
healthy JJ p
adults NNS p
was VBD p
recruited VBN p
: : p
16 CD p
males NNS p
, , p
24 CD p
females NNS p
, , p
mean JJ p
age NN p
22.9 CD p
( ( p
5.5 CD p
) ) p
years NNS p
. . p

The DT p
mean JJ o
cadence NN o
for IN o
the DT o
whole JJ o
walk NN o
was VBD o
higher RBR N
in IN N
the DT N
park NN N
: : N
119.3 CD N
( ( N
8.3 CD N
) ) N
vs. FW N
110.9 CD N
( ( N
8.9 CD N
) ) N
steps/min NN p
. . p

Participants NNS p
accumulated VBD p
more RBR N
moderate-to-vigorous JJ o
physical JJ o
activity NN o
in IN o
? . o
10 CD o
minute NN o
bouts NNS o
during IN N
park JJ N
walks NNS N
: : N
25.5 CD N
( ( N
9.6 CD N
) ) N
[ NN N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
] VBZ N
vs. FW N
14.0 CD N
( ( N
20.3 CD N
) ) N
min NN N
. . N

There EX N
was VBD N
no DT N
difference NN o
in IN o
self-timed JJ o
duration NN o
between IN o
locations NNS N
. . N

CONCLUSION NNP N
Participants NNPS N
accumulated VBD o
more RBR o
moderate-to-vigorous JJ o
physical JJ o
activity NN o
in IN o
bouts NNS o
? . N
10 CD N
min NN N
in IN N
duration NN N
on IN N
park NN N
walks NNS N
due JJ N
to TO N
the DT N
lack NN N
of IN N
interruptions NNS N
in IN N
walking VBG N
. . N

Hence NNP N
the DT N
park NN N
environment NN N
better RBR N
facilitated VBD N
the DT N
achievement NN N
of IN N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
. . N

Further JJ N
research NN N
involving VBG N
a DT N
larger JJR N
, , N
more RBR N
heterogeneous JJ N
sample NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -21450630- O O

The DT N
effect NN N
of IN N
pain-free JJ i
treadmill NN i
training VBG i
on IN N
fibrinogen NN N
, , N
haematocrit NN N
, , N
and CC N
lipid JJ N
profile NN N
in IN N
patients NNS p
with IN p
claudication NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effect NN N
of IN N
pain-free JJ i
treadmill NN i
training VBG i
on IN N
changes NNS N
of IN N
plasma NN o
fibrinogen NN o
, , o
haematocrit NN o
, , o
lipid JJ o
profile NN o
, , o
and CC o
walking VBG o
ability NN o
in IN N
patients NNS p
with IN p
claudication NN p
. . p

DESIGN NNP N
Randomized NNP N
control NN N
trial NN N
. . N

METHODS NNP N
Sixty-eight JJ p
patients NNS p
with IN p
peripheral JJ p
obstructive JJ p
arterial JJ p
disease NN p
and CC p
intermittent JJ p
claudication NN p
( ( p
Fontaine NNP p
stage NN p
II NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
into IN N
the DT N
treadmill NN i
training NN i
( ( N
repetitive JJ N
intervals NNS N
to TO N
onset VB N
of IN N
claudication NN N
pain NN N
, , N
three CD N
times NNS N
a DT N
week NN N
) ) N
or CC N
a DT N
control NN i
group NN i
( ( i
no DT i
change NN i
in IN i
physical JJ i
activity NN i
) ) i
over IN N
3 CD N
months NNS N
. . N

Both DT N
groups NNS N
performed VBD N
treadmill JJ i
test NN N
to TO N
assess VB N
pain-free JJ o
walking NN o
time NN o
( ( o
PFWT NNP o
) ) o
and CC o
maximal JJ o
walking NN o
time NN o
( ( o
MWT NNP o
) ) o
and CC o
had VBD o
blood NN o
analyses NNS o
[ VBP o
for IN o
haematocrit NN o
, , o
fibrinogen NN o
, , o
triglycerides NNS o
, , o
and CC o
cholesterol NN o
: : o
total JJ o
, , o
high-density JJ o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
and CC o
low-density JJ o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
] VBD o
done VBN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
and CC N
12 CD N
weeks NNS N
of IN N
the DT N
study NN N
. . N

RESULTS NNP N
Total NNP o
and CC o
LDL NNP o
cholesterol NN o
levels NNS o
in IN o
the DT o
training NN o
group NN o
decreased VBD o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
14.8 CD N
% NN N
and CC N
20,5 CD N
% NN N
, , N
respectively RB N
. . N

Significant NNP N
( ( N
p JJ N
< NNP N
0.05 CD o
) ) o
HDL NNP o
cholesterol NN o
increased VBD o
( ( o
14.6 CD o
% NN o
) ) o
and CC o
triglycerides NNS o
decreased VBN o
( ( o
19 CD o
% NN o
) ) o
in IN o
the DT N
training NN N
group NN N
but CC N
changes NNS N
of IN N
all PDT N
these DT N
lipids NNS N
were VBD N
insignificant JJ N
in IN N
the DT N
control NN N
group NN N
over IN N
the DT N
3 CD N
months NNS N
. . N

Haematocrit NNP o
and CC o
fibrinogen NN o
changes NNS o
were VBD N
insignificant JJ N
in IN N
both DT N
groups NNS N
. . N

PFWT NNP o
was VBD o
prolonged VBN N
by IN N
109 CD N
% NN N
and CC N
MWT NNP o
increased VBN N
by IN N
54 CD N
% NN N
in IN N
the DT N
training NN N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
The DT N
improvement NN N
in IN N
walking VBG N
time NN N
over IN N
3 CD N
months NNS N
of IN N
pain-free JJ i
treadmill NN i
training NN i
parallels NNS i
with IN N
progressive JJ N
normalization NN N
of IN N
lipid JJ N
profiles NNS N
in IN N
patients NNS p
with IN p
claudication NN p
. . p

-DOCSTART- -18535816- O O

Effects NNS N
of IN N
20 CD N
mg NNS N
rosuvastatin NN i
on IN N
VLDL1- NNP N
, , N
VLDL2- NNP N
, , N
IDL- NNP N
and CC N
LDL-ApoB NNP N
kinetics NNS N
in IN N
type NN p
2 CD p
diabetes NNS p
. . p

AIMS/HYPOTHESIS NNP N
In IN N
addition NN N
to TO N
its PRP$ N
efficacy NN N
in IN N
reducing VBG N
LDL-cholesterol NNP o
, , N
rosuvastatin NN i
has VBZ N
been VBN N
shown VBN N
to TO N
significantly RB N
decrease VB N
plasma NN o
triacylglycerol NN o
. . o

The DT N
use NN N
of IN N
rosuvastatin NN i
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
, , N
who WP N
usually RB N
have VBP N
increased VBN N
triacylglycerol NN o
levels NNS o
. . o

However RB N
, , N
its PRP$ N
effects NNS N
on IN N
the DT N
metabolism NN N
of IN N
triacylglycerol-rich JJ N
lipoproteins NNS N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
remains VBZ N
unknown JJ N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
randomised JJ N
double-blind NN N
crossover NN N
trial NN N
of IN N
6-week JJ N
treatment NN N
with IN N
placebo NN i
or CC i
rosuvastatin VB i
20 CD i
mg NN i
in IN N
eight CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
were VBD p
being VBG p
treated VBN p
with IN p
oral JJ p
glucose-lowering JJ p
agents NNS p
. . p

In IN N
each DT N
patient NN N
, , N
an DT N
in IN N
vivo NN N
kinetic JJ N
study NN N
of IN N
apolipoprotein NN N
B NNP N
( ( N
ApoB NNP N
) ) N
-containing VBG N
lipoproteins NNS N
with IN N
[ JJ N
13C CD N
] JJ N
leucine NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

A DT N
central JJ N
randomisation NN N
centre NN N
used VBN N
computer-generated JJ N
tables NNS N
to TO N
allocate VB N
treatments NNS N
. . N

Participants NNS N
, , N
caregivers NNS N
and CC N
those DT N
assessing VBG N
the DT N
outcomes NNS N
were VBD N
blinded VBN N
to TO N
group NN N
assignment NN N
. . N

RESULTS NNP N
Rosuvastatin NNP i
20 CD N
mg NN N
significantly RB N
reduced VBN N
plasma JJ o
LDL-cholesterol NNP o
, , o
triacylglycerol NN o
and CC o
total JJ o
ApoB NNP o
. . o

It PRP N
also RB N
significantly RB N
reduced VBN N
ApoB NNP o
pool NN o
sizes NNS o
of IN o
larger JJR o
triacylglycerol-rich JJ o
VLDL NNP o
particles NNS o
( ( N
VLDL1 NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
, , N
smaller JJR o
VLDL NNP o
particles NNS o
( ( N
VLDL2 NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
, , N
intermediate JJ o
density NN o
lipoprotein NN o
( ( N
IDL NNP N
; : N
p VBZ N
= $ N
0.011 CD N
) ) N
and CC N
LDL NNP N
( ( N
p JJ N
= NNP N
0.011 CD N
) ) N
. . N

This DT N
reduction NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
total JJ o
fractional JJ o
catabolic NN o
rate NN o
of IN o
VLDL1-ApoB NNP o
( ( N
6.70 CD N
+/- JJ N
3.24 CD N
vs JJ N
4.52 CD N
+/- JJ N
2.34 CD N
pool/day NN N
, , N
p NN N
= NNP N
0.049 CD N
) ) N
, , N
VLDL2-ApoB NNP N
( ( N
8.72 CD N
+/- JJ N
3.37 CD N
vs JJ N
5.36 CD N
+/- JJ N
2.64 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
, , N
IDL-ApoB NNP N
( ( N
7.06 CD N
+/- JJ N
1.68 CD N
vs JJ N
4.21 CD N
+/- JJ N
1.51 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
and CC N
LDL-ApoB NNP N
( ( N
1.02 CD N
+/- JJ N
0.27 CD N
vs JJ N
0.59 CD N
+/- JJ N
0.13 CD N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

Rosuvastatin NNPS i
did VBD N
not RB N
change VB N
the DT N
production NN o
rates NNS o
of IN o
VLDL2- NNP o
, , o
IDL- NNP o
or CC o
LDL- NNP o
, , N
but CC N
did VBD N
reduce VB N
VLDL1-ApoB NNP o
production NN o
rate NN o
( ( N
12.4 CD N
+/- JJ N
4.5 CD N
vs JJ N
19.5 CD N
+/- JJ N
8.4 CD N
mg NN N
kg NN N
( ( N
-1 JJ N
) ) N
day NN N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
= NNP N
0.035 CD N
) ) N
. . N

No DT N
side NN o
effects NNS o
of IN N
rosuvastatin NN N
were VBD N
observed VBN N
during IN N
the DT N
study NN N
. . N

CONCLUSIONS/INTERPRETATION NNP N
In IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
rosuvastatin VBP i
20 CD N
mg NN N
not RB N
only RB N
induces VBZ N
a DT N
significant JJ N
increase NN N
of IN N
LDL-ApoB JJ o
catabolism NN o
( ( N
73 CD N
% NN N
) ) N
, , N
but CC N
also RB N
has VBZ N
favourable JJ N
effects NNS N
on IN N
the DT N
catabolism NN o
of IN o
triacylglycerol-rich JJ o
lipoproteins NNS o
, , N
e.g NN N
. . N

a DT N
significant JJ N
increase NN N
in IN N
the DT N
catabolism NN o
of IN o
VLDL1-ApoB NNP o
( ( N
48 CD N
% NN N
) ) N
, , N
VLDL2-ApoB NNP o
( ( N
63 CD N
% NN N
) ) N
and CC N
IDL-ApoB NNP o
( ( N
68 CD N
% NN N
) ) N
, , N
and CC N
a DT N
reduction NN N
in IN N
the DT N
production NN N
rate NN N
of IN N
VLDL1-ApoB NNP o
( ( N
-36 CD N
% NN N
) ) N
. . N

The DT N
effects NNS N
of IN N
rosuvastatin NN i
on IN N
the DT N
metabolism NN N
of IN N
triacylglycerol-rich JJ N
lipoproteins NNS N
may MD N
be VB N
beneficial JJ N
for IN N
prevention NN N
of IN N
atherosclerosis NN p
in IN p
type NN p
2 CD p
diabetic JJ p
patients NNS p
. . p

-DOCSTART- -19346279- O O

Pregabalin NNP i
versus NN N
naltrexone NN i
in IN p
alcohol NN p
dependence NN p
: : p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
comparison JJ N
trial NN N
. . N

Pregabalin NNP i
( ( i
PRE NNP i
) ) i
acts VBZ N
as IN N
a DT N
presynaptic JJ N
inhibitor NN N
of IN N
the DT N
release NN N
of IN N
excessive JJ N
levels NNS N
of IN N
excitatory NN N
neurotransmitters NNS N
by IN N
selectively RB N
binding VBG N
to TO N
the DT N
alpha NN N
( ( N
2 CD N
) ) N
-delta NN N
subunit NN N
of IN N
voltage-gated JJ N
calcium NN N
channels NNS N
. . N

In IN N
this DT N
randomised JJ N
, , N
double-blind JJ N
comparison NN N
trial NN N
with IN N
naltrexone NN i
( ( i
NAL NNP i
) ) i
, , N
we PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
PRE NNP N
on IN p
alcohol NN o
drinking NN o
indices NNS o
. . o

Craving VBG o
reduction NN o
and CC N
improvement NN o
of IN o
psychiatric JJ o
symptoms NNS o
were VBD N
the DT N
secondary JJ N
endpoints NNS N
. . N

Seventy-one CD p
alcohol-dependent JJ p
subjects NNS p
were VBD N
detoxified VBN N
and CC N
subsequently RB N
randomised VBN N
into IN N
two CD N
groups NNS N
, , N
receiving VBG i
50 CD i
mg NN i
of IN i
NAL NNP i
or CC i
150-450 JJ i
mg NN i
of IN i
PRE NNP i
. . i

Craving NNP o
( ( o
VAS NNP o
; : o
OCDS NNP o
) ) o
, , o
withdrawal NN o
( ( o
CIWA-Ar NNP o
) ) o
and CC o
psychiatric JJ o
symptoms NNS o
( ( o
SCL-90-R NNP o
) ) o
rating NN o
scales NNS o
were VBD N
applied VBN N
. . N

Alcohol NNP o
drinking NN o
indices NNS o
and CC o
craving VBG o
scores NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

Compared VBN N
with IN N
NAL NNP i
, , i
PRE NNP i
resulted VBD N
in IN N
greater JJR N
improvement NN N
of IN N
specific JJ N
symptoms NNS N
in IN N
the DT N
areas NNS N
of IN N
anxiety NN o
, , o
hostility NN o
and CC o
psychoticism NN o
, , o
and CC o
survival JJ o
function NN o
( ( o
duration NN o
of IN o
abstinence NN o
from IN o
alcohol NN o
) ) o
. . N

PRE NNP N
also RB N
resulted VBD N
in IN N
better RBR N
outcome NN N
in IN p
patients NNS p
reporting VBG p
a DT p
comorbid NN p
psychiatric JJ p
disorder NN p
. . p

Results NNS N
from IN N
this DT N
study NN N
globally RB N
place VBP N
PRE NNP i
within IN N
the DT N
same JJ N
range NN N
of IN N
efficacy NN N
as IN N
that DT N
of IN N
NAL NNP i
. . i

The DT N
mechanism NN N
involved VBN N
in IN N
the DT N
efficacy NN N
of IN N
PRE NNP i
in IN N
relapse NN N
prevention NN N
could MD N
be VB N
less RBR N
related JJ N
to TO N
alcohol VB o
craving NN o
and CC N
more RBR N
associated JJ N
with IN N
the DT N
treatment NN N
of IN N
the DT N
comorbid NN N
psychiatric JJ N
symptomatology NN N
. . N

-DOCSTART- -15781835- O O

The DT N
effect NN N
of IN N
levetiracetam NN i
on IN N
essential JJ o
tremor NN o
. . o

The DT N
effect NN N
of IN N
a DT N
single JJ p
dose NN p
of IN p
1,000 CD i
mg NN i
of IN i
levetiracetam NN i
on IN p
essential JJ p
tremor NN p
was VBD N
investigated VBN N
in IN N
24 CD p
patients NNS p
in IN p
a DT p
double-blind JJ p
, , p
placebo-controlled JJ i
trial NN p
. . p

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
of IN N
hand NN o
tremor NN o
for IN N
at IN N
least JJS N
2 CD N
hours NNS N
as IN N
measured VBN N
by IN N
accelerometry NN N
and CC N
functional JJ N
tests NNS N
. . N

-DOCSTART- -19001103- O O

Evaluating VBG N
online NN i
continuing VBG i
medical JJ i
education NN i
seminars NNS i
: : i
evidence NN p
for IN p
improving VBG p
clinical JJ p
practices NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
potential NN N
for IN N
online NN i
continuing VBG i
medical JJ i
education NN i
( ( i
CME NNP i
) ) i
seminars VBZ i
to TO N
improve VB o
quality NN o
of IN o
care NN o
. . o

Primary NNP p
care NN p
physicians NNS p
( ( p
113 CD p
) ) p
participated VBN p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
to TO p
evaluate VB p
an DT p
online NN p
CME NNP p
series NN p
. . p

Physicians NNPS p
were VBD N
randomized VBN N
to TO N
view VB N
either CC N
a DT N
seminar NN i
about IN i
type NN i
2 CD i
diabetes NNS i
or CC i
a DT i
seminar NN i
about IN i
systolic JJ i
heart NN i
failure NN i
. . i

Following VBG N
the DT N
seminar NN i
, , N
physicians NNS p
were VBD N
presented VBN N
with IN N
4 CD N
clinical JJ N
vignettes NNS N
and CC N
asked VBD N
to TO N
describe VB N
what WP N
tests NNS N
, , N
treatments NNS N
, , N
counseling VBG N
, , N
or CC N
referrals NNS N
they PRP N
would MD N
recommend VB N
. . N

Physicians NNPS N
who WP N
viewed VBD N
the DT N
seminars NNS N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
recommend VB o
guideline-consistent JJ o
care NN o
to TO N
patients NNS N
in IN N
the DT N
vignettes NNS N
. . N

For IN N
example NN N
, , N
physicians NNS N
who WP N
viewed VBD N
the DT N
diabetes NNS N
seminar VBP N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
order NN o
an DT o
eye NN o
exam NN o
for IN o
diabetes NNS o
patients NNS o
( ( N
63 CD N
% NN N
) ) N
compared VBN N
with IN N
physicians NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
27 CD N
% NN N
) ) N
. . N

For IN N
some DT N
guidelines NNS N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
. . N

These DT N
results NNS N
provide VBP N
early JJ N
evidence NN N
of IN N
the DT N
effectiveness NN N
of IN N
online JJ i
CME NNP i
programs NNS i
to TO N
improve VB o
physician JJ o
clinical JJ o
practice NN o
. . o

-DOCSTART- -25048751- O O

Transcervical NNP i
Foley NNP i
's POS i
catheter NN i
versus NN N
Cook NNP i
balloon NN i
for IN N
cervical JJ p
ripening NN p
in IN p
stillbirth NN p
with IN p
a DT p
scarred JJ p
uterus NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
the DT N
use NN N
of IN N
transcervical JJ i
Foley NNP i
's POS i
catheter NN i
versus NN N
Cook NNP i
cervical JJ i
ripening VBG i
balloon NN i
in IN N
pregnant JJ p
women NNS p
with IN p
stillbirth NN p
, , p
unfavorable JJ p
cervix NN p
and CC p
scarred VBD p
uterus NN p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
study NN N
. . N

SETTING NNP N
El NNP p
Minia NNP p
University NNP p
Hospital NNP p
, , p
El NNP p
Minia NNP p
, , p
Egypt NNP p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Two-hundred NNP p
pregnant JJ p
women NNS p
with IN p
stillbirth NN p
, , p
unfavorable JJ p
cervix NN p
and CC p
scarred VBD p
uterus NNS p
were VBD N
recruited VBN N
into IN N
this DT N
study NN N
. . N

They PRP N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
group NN N
I PRP N
( ( N
n JJ N
= NNP N
100 CD N
) ) N
, , N
cervical JJ N
ripening NN N
was VBD N
done VBN N
using VBG N
Foley NNP i
's POS i
catheter NN i
. . i

In IN N
group NN N
II NNP N
( ( N
n JJ N
= NNP N
100 CD N
) ) N
, , N
cervical JJ N
ripening NN N
was VBD N
done VBN N
using VBG N
Cook NNP i
cervical JJ i
ripening NN i
balloon NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Balloon NNP o
insertion NN o
to TO o
delivery NN o
interval NN o
, , o
successful JJ o
ripening VBG o
rate NN o
, , o
cesarean JJ o
delivery NN o
rate NN o
, , o
maternal JJ o
adverse JJ o
events NNS o
and CC o
maternal JJ o
satisfaction NN o
. . o

RESULTS JJ N
Time NNP o
from IN o
balloon NN o
insertion NN o
to TO o
expulsion NN o
and CC N
from IN N
balloon NN o
insertion NN o
to TO o
delivery NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
Foley NNP N
's POS N
catheter NN N
group NN N
. . N

However RB N
, , N
the DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
regarding VBG N
time NN o
from IN o
balloon NN o
insertion NN o
to TO o
active JJ o
labor NN o
, , o
time NN o
from IN o
balloon NN o
expulsion NN o
to TO o
delivery NN o
, , o
cervical JJ o
ripening NN o
, , o
cesarean JJ o
section NN o
, , o
instrumental JJ o
delivery NN o
, , o
pain NN o
score NN o
, , o
need VBP o
for IN o
analgesia NN o
, , o
hospital NN o
stay NN o
and CC o
maternal JJ o
satisfaction NN o
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSIONS NNP N
Foley NNP i
's POS i
catheter NN i
and CC N
Cook NNP i
cervical JJ i
ripening NN N
balloon NN N
are VBP N
comparable JJ N
regarding VBG N
efficacy NN o
and CC o
safety NN o
profile NN o
when WRB N
used VBN N
to TO N
ripen VB N
the DT N
cervix NN N
in IN N
pregnant JJ p
women NNS p
with IN p
stillbirth NN p
, , p
unfavorable JJ p
cervix NN p
and CC p
scarred VBD p
uterus NN p
. . p

However RB N
, , N
Foley NNP N
's POS N
catheter NN N
has VBZ N
a DT N
shorter JJR N
induction NN o
to TO o
delivery NN o
interval NN o
and CC N
is VBZ N
relatively RB N
cheaper JJ N
device NN N
. . N

-DOCSTART- -24387919- O O

Whole-body JJ i
CT NNP i
screening NN i
: : i
scan JJ i
delay NN i
and CC i
contrast NN i
injection NN i
duration NN N
for IN N
optimal JJ o
enhancement NN o
of IN o
abdominal JJ o
organs NNS o
and CC o
deep JJ o
vessels NNS o
. . o

PURPOSE NNP N
To TO N
assess VB N
the DT N
optimal JJ N
scan JJ N
delays NNS N
and CC N
contrast NN N
injection NN N
durations NNS N
for IN N
contrast-enhanced JJ i
whole-body NN i
computed VBN i
tomography NN i
( ( i
CT NNP i
) ) i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
One CD p
hundred VBD p
forty-two JJ p
patients NNS p
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
: : N
protocol NN i
A-scan JJ i
delay NN i
of IN i
65 CD i
s NNS i
after IN i
starting VBG i
contrast NN i
injection NN i
over IN i
30 CD i
s NNS i
; : i
protocol CC i
B-105 NNP i
and CC i
70 CD i
s NN i
; : i
and CC i
protocol VB i
C-145 NNP i
and CC i
110 CD i
s NN i
, , N
respectively RB N
. . N

Contrast NNP o
enhancement NN o
and CC o
diagnostic JJ o
acceptability NN o
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Qualitative JJ o
assessment NN o
was VBD N
subtle JJ N
among IN N
the DT N
three CD N
protocols NNS N
. . N

Homogenous JJ o
enhancement NN o
of IN o
deep JJ o
veins NNS o
was VBD N
more RBR N
assuredly RB N
achieved VBN N
with IN N
protocol NN N
C. NNP N
CONCLUSION NNP N
With IN N
protocol NN i
C NNP i
, , N
qualitatively RB N
acceptable JJ N
enhancement NN N
can MD N
be VB N
obtained VBN N
in IN N
whole-body JJ i
CT NNP i
. . i

-DOCSTART- -24391123- O O

Addressing VBG N
dental JJ p
fear NN p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
using VBG N
electronic JJ i
screen JJ i
media NNS i
. . i

BACKGROUND NNP N
Dental NNP N
care NN N
is VBZ N
a DT N
significant JJ N
unmet JJ N
health NN N
care NN N
need NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

Many JJ N
children NNS N
with IN N
ASD NNP N
do VBP N
not RB N
receive VB N
dental NN N
care NN N
because IN N
of IN N
fear NN N
associated VBN N
with IN N
dental JJ N
procedures NNS N
; : N
oftentimes VBZ N
they PRP N
require VBP N
general JJ N
anesthesia NN N
for IN N
regular JJ N
dental NN N
procedures NNS N
, , N
placing VBG N
them PRP N
at IN N
risk NN N
of IN N
associated JJ N
complications NNS N
. . N

Many JJ N
children NNS p
with IN p
ASD NNP p
have VBP N
a DT N
strong JJ N
preference NN N
for IN N
visual JJ N
stimuli NNS N
, , N
particularly RB N
electronic JJ N
screen NN N
media NNS N
. . N

The DT N
use NN N
of IN N
visual JJ N
teaching NN N
materials NNS N
is VBZ N
a DT N
fundamental JJ N
principle NN N
in IN N
designing VBG N
educational JJ N
programs NNS N
for IN N
children NNS p
with IN p
ASD NNP p
. . p

PURPOSE NNP N
To TO N
determine VB N
if IN N
an DT N
innovative JJ N
strategy NN N
using VBG N
2 CD N
types NNS N
of IN N
electronic JJ i
screen JJ i
media NNS i
was VBD N
feasible JJ N
and CC N
beneficial JJ N
in IN N
reducing VBG N
fear NN N
and CC N
uncooperative JJ N
behaviors NNS N
in IN N
children NNS p
with IN p
ASD NNP p
undergoing VBG p
dental JJ p
visits NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
at IN N
Boston NNP p
Children NNP p
's POS p
Hospital NNP p
dental NN p
clinic NN p
. . p

Eighty NNP p
( ( p
80 CD p
) ) p
children NNS p
aged VBD p
7 CD p
to TO p
17 CD p
years NNS p
with IN p
a DT p
known JJ p
diagnosis NN p
of IN p
ASD NNP p
and CC p
history NN p
of IN p
dental JJ p
fear NN p
were VBD p
enrolled VBN p
in IN N
the DT N
study NN N
. . N

Each DT N
child NN N
completed VBD N
2 CD N
preventive JJ N
dental JJ N
visits NNS N
that WDT N
were VBD N
scheduled VBN N
6 CD N
months NNS N
apart RB N
( ( N
visit NN N
1 CD N
and CC N
visit VB N
2 CD N
) ) N
. . N

After IN N
visit NN N
1 CD N
, , N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
group NN N
A NNP N
, , N
control NN i
( ( i
usual JJ i
care NN i
) ) i
; : i
( ( N
2 CD N
) ) N
group NN N
B NNP N
, , N
treatment NN i
( ( i
video JJ i
peer NN i
modeling NN i
that WDT i
involved VBD i
watching VBG i
a DT i
DVD NNP i
recording NN i
of IN i
a DT i
typically RB i
developing VBG i
child NN i
undergoing VBG i
a DT i
dental JJ i
visit NN i
) ) i
; : i
( ( N
3 CD N
) ) N
group NN N
C NNP N
, , N
treatment NN N
( ( i
video JJ i
goggles NNS i
that WDT i
involved VBD i
watching VBG i
a DT i
favorite JJ i
movie NN i
during IN i
the DT i
dental JJ i
visit NN i
using VBG i
sunglass-style JJ i
video NN i
eyewear NN i
) ) i
; : i
and CC N
( ( N
4 CD N
) ) N
group NN N
D NNP N
, , N
treatment NN N
( ( i
video JJ i
peer NN i
modeling VBG i
plus CC i
video JJ i
goggles NNS i
) ) i
. . N

Subjects NNS N
who WP N
refused VBD N
or CC N
were VBD N
unable JJ N
to TO N
wear VB N
the DT N
goggles NNS N
watched VBD N
the DT N
movie NN N
using VBG N
a DT N
handheld NN N
portable JJ N
DVD NNP N
player NN N
. . N

During IN N
both DT N
visits NNS N
, , N
the DT N
subject NN N
's POS N
level NN N
of IN N
anxiety NN N
and CC N
behavior NN N
were VBD N
measured VBN N
using VBG N
the DT N
Venham NNP N
Anxiety NNP N
and CC N
Behavior NNP N
Scales NNP N
. . N

Analyses NNS N
of IN N
variance NN N
and CC N
Fisher NNP N
's POS N
exact NN N
tests NNS N
compared VBN N
baseline JJ N
characteristics NNS N
across IN N
groups NNS N
. . N

Using VBG N
intention NN N
to TO N
treat VB N
approach NN N
, , N
repeated VBD N
measures NNS N
analyses NNS N
were VBD N
employed VBN N
to TO N
test VB N
whether IN N
the DT N
outcomes NNS N
differed VBD N
significantly RB N
: : N
( ( N
1 CD N
) ) N
between IN N
visits NNS N
1 CD N
and CC N
2 CD N
within IN N
each DT N
group NN N
and CC N
( ( N
2 CD N
) ) N
between IN N
each DT N
intervention NN N
group NN N
and CC N
the DT N
control NN N
group NN N
over IN N
time NN N
( ( N
an DT N
interaction NN N
) ) N
. . N

RESULTS NNP N
Between NNP N
visits VBZ N
1 CD N
and CC N
2 CD N
, , N
mean JJ o
anxiety NN o
and CC o
behavior NN o
scores NNS o
decreased VBN N
significantly RB N
by IN N
0.8 CD N
points NNS N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
for IN N
subjects NNS N
within IN N
groups NNS N
C NNP N
and CC N
D. NNP N
Significant NNP N
changes NNS N
were VBD N
not RB N
observed VBN N
within IN N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

Mean NNP o
anxiety NN o
and CC o
behavior JJ o
scores NNS o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
groups NNS N
over IN N
time NN N
, , N
although IN N
group NN N
A NNP N
versus NN N
C NNP N
pairwise NN N
comparisons NNS N
showed VBD N
a DT N
trend NN N
toward IN N
significance NN N
( ( N
P NNP N
= NNP N
.06 NNP N
) ) N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
certain JJ N
electronic JJ N
screen NN N
media NNS N
technologies NNS N
may MD N
be VB N
useful JJ N
tools NNS N
for IN N
reducing VBG o
fear NN o
and CC o
uncooperative JJ o
behaviors NNS o
among IN N
children NNS p
with IN p
ASD NNP p
undergoing VBG N
dental JJ N
visits NNS N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
these DT N
strategies NNS N
using VBG N
larger JJR N
sample NN N
sizes NNS N
. . N

Findings NNS N
from IN N
future JJ N
studies NNS N
could MD N
be VB N
relevant JJ N
for IN N
nondental JJ N
providers NNS N
who WP N
care VBP N
for IN N
children NNS p
with IN p
ASD NNP p
in IN N
other JJ N
medical JJ N
settings NNS N
. . N

-DOCSTART- -21811855- O O

The DT N
effect NN N
of IN N
knee NN i
position NN i
on IN N
blood NN o
loss NN o
and CC o
range NN o
of IN o
motion NN o
following VBG N
total JJ p
knee JJ p
arthroplasty NN p
. . p

PURPOSE VB N
This DT N
study NN N
prospectively RB N
assessed VBD N
the DT N
effects NNS N
of IN N
knee JJ i
position NN i
on IN N
blood NN o
loss NN o
and CC o
range NN o
of IN o
motion NN o
after IN p
primary JJ p
total JJ p
knee NN p
arthroplasty NN p
( ( p
TKA NNP p
) ) p
. . p

METHODS NNP N
One CD p
hundred CD p
and CC p
ten VB p
consecutive JJ p
TKA NNP p
patients NNS p
were VBD N
randomized VBN N
into IN N
flexion NN N
group NN N
and CC N
extension NN N
group NN N
. . N

Both DT N
groups NNS N
had VBD N
the DT N
leg NN i
elevated VBD i
30? CD i
at IN i
the DT i
hip NN i
over IN i
an DT i
inactive JJ i
CPM NNP i
for IN i
72 CD i
h NN i
postoperatively RB i
. . i

The DT N
flexion NN N
group NN N
had VBD N
the DT i
knee NN i
flexed VBD i
to TO i
30? CD i
during IN i
this DT i
period NN i
. . i

The DT N
extension NN N
group NN N
had VBD N
the DT i
knee NN i
extended VBD i
fully RB o
. . o

Perioperative JJ o
blood NN o
loss NN o
, , o
hidden JJ o
blood NN o
loss NN o
, , o
knee NN o
swelling NN o
, , o
ecchymosis NN o
, , o
analgesia NN o
requirements NNS o
, , o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
, , o
fixed VBN o
flexion NN o
deformity NN o
( ( o
FFD NNP o
) ) o
, , o
straight-leg JJ o
raising VBG o
action NN o
, , o
and CC o
postoperative JJ o
complications NNS o
within IN o
6 CD o
weeks NNS o
of IN o
surgery NN o
were VBD o
measured VBN N
for IN N
evaluation NN N
and CC N
comparison NN N
. . N

RESULTS VB N
The DT o
postoperative JJ o
hidden JJ o
blood NN o
loss NN o
, , o
knee NN o
swelling NN o
, , o
and CC o
scope NN o
of IN o
ecchymosis NN o
were VBD o
significantly RB N
lower JJR N
in IN N
the DT N
flexion NN N
group NN N
than IN N
in IN N
the DT N
extension NN N
group NN N
, , N
and CC o
ROM NNP o
and CC o
straight-leg JJ o
raising VBG o
action NN o
were VBD o
significantly RB N
higher JJR N
during IN N
the DT N
early JJ N
period NN N
after IN N
operation NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
perioperative JJ o
blood NN o
loss NN o
, , o
the DT o
amount NN o
of IN o
morphine NN o
used VBN o
, , o
or CC o
FFD NNP o
in IN o
the DT N
early JJ N
postoperative JJ N
period NN N
or CC N
in IN N
ROM NNP o
and CC o
FFD NNP o
at IN o
6 CD o
weeks NNS o
postoperatively RB o
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN i
flexion NN i
of IN i
the DT i
knee NN i
to TO i
30? CD N
with IN N
the DT N
leg NN N
elevated VBD N
30? CD N
at IN N
the DT N
hip NN N
after IN N
total JJ N
knee NN N
arthroplasty NN N
may MD N
mitigate VB o
knee NN o
swelling VBG o
and CC o
provide VB N
other JJ o
beneficial JJ o
results NNS o
during IN o
the DT N
early JJ N
rehabilitation NN N
following VBG N
TKA NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
Prospective NNP N
comparative NN N
study NN N
, , N
Level NNP N
I PRP N
. . N

-DOCSTART- -2292547- O O

A DT N
comparison NN N
between IN N
oral JJ N
ciprofloxacin NN i
and CC N
intra-peritoneal JJ i
vancomycin NN i
and CC N
gentamicin NN i
in IN N
the DT N
treatment NN N
of IN N
CAPD NNP o
peritonitis NN o
. . o

Fifty-one CD p
patients NNS p
were VBD p
included VBN p
in IN N
a DT N
prospective JJ N
, , N
randomized JJ N
comparison NN N
of IN N
oral JJ i
ciprofloxacin NN i
and CC i
intraperitoneal JJ i
vancomycin/gentamicin NN i
in IN N
the DT N
treatment NN N
of IN N
CAPD NNP p
peritonitis NN p
. . p

Staphylococcal JJ N
species NNS N
accounted VBD N
for IN N
40 CD N
% NN N
of IN N
the DT N
isolates NNS N
with IN N
an DT N
equal JJ N
incidence NN N
of IN N
Staphylococcus NNP o
aureus NN o
and CC N
coagulase NN o
negative JJ o
staphylococci NN o
. . o

Although IN N
, , N
overall JJ N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
regimens NNS N
in IN N
outcome NN N
, , N
ciprofloxacin NN i
was VBD N
significantly RB N
less RBR N
effective JJ o
when WRB N
peritonitis NN N
was VBD N
due JJ N
to TO N
coagulase VB N
negative JJ N
staphylococci NN N
. . N

-DOCSTART- -2501509- O O

TEN NNP i
versus VBZ N
TPN NNP i
following VBG N
major JJ p
abdominal JJ p
trauma NN p
-- : p
reduced VBD p
septic JJ p
morbidity NN p
. . p

Recent NNP N
animal JJ N
models NNS N
suggest VBP N
that IN N
enteral JJ i
feeding NN i
( ( i
TEN NNP i
) ) i
compared VBN N
to TO N
parenteral JJ i
nutrition NN i
( ( i
TPN NNP i
) ) i
improves VBZ N
resistance NN N
to TO N
infection NN N
. . N

This DT N
prospective JJ N
clinical JJ N
trial NN N
examined VBD N
the DT N
impact NN N
of IN N
early JJ N
TEN NNP i
vs. FW N
TPN NNP i
in IN N
the DT p
critically RB p
injured VBN p
. . p

Seventy-five JJ p
patients NNS p
with IN p
an DT p
abdominal JJ p
trauma NN p
index NN p
( ( p
ATI NNP p
) ) p
greater JJR p
than IN p
15 CD p
and CC p
less JJR p
than IN p
40 CD p
were VBD p
randomized VBN p
at IN p
initial JJ i
laparotomy NN i
to TO p
receive VB i
either RB i
TEN NNP i
( ( i
Vivonex NNP i
TEN NNP i
) ) i
or CC i
TPN NNP i
( ( i
Freamine NNP i
HBC NNP i
6.9 CD i
% NN i
and CC i
Trophamine NNP i
6 CD i
% NN i
) ) i
; : i
both DT p
regimens NNS p
contained VBD p
2.5 CD p
% NN p
fat NN p
, , p
33 CD p
% NN p
branched VBD p
chain NN p
amino NN p
acids NNS p
, , p
and CC p
had VBD p
a DT p
calorie NN p
to TO p
nitrogen VB p
ratio NN p
of IN p
150:1 CD p
. . p

TEN NN i
was VBD N
delivered VBN N
via IN N
a DT N
needle JJ N
catheter NN N
jejunostomy NN N
. . N

Nutritional JJ N
support NN N
was VBD N
initiated VBN N
within IN N
12 CD N
hours NNS N
postoperatively RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
infused VBD N
at IN N
a DT N
rate NN N
sufficient NN N
to TO N
render VB N
the DT N
patients NNS N
in IN N
positive JJ N
nitrogen NN N
balance NN N
. . N

The DT N
study NN N
groups NNS N
( ( i
TEN NNP i
= VBZ N
29 CD N
vs NN N
TPN NNP i
= NNP N
30 CD N
) ) N
were VBD N
comparable JJ N
in IN N
age NN N
, , N
injury NN N
severity NN N
and CC N
initial JJ N
metabolic JJ N
stress NN N
. . N

Jejunal NNP N
feeding NN N
was VBD N
tolerated VBN o
unconditionally RB N
in IN N
25 CD N
( ( N
86 CD N
% NN N
) ) N
of IN N
the DT N
TEN NNP i
group NN N
. . N

Nitrogen NNP o
balance NN o
remained VBD N
equivalent JJ N
throughout IN N
the DT N
study NN N
period NN N
, , N
at IN N
day NN N
5 CD N
TEN NNP i
= NNP N
-0.3 NNP N
+/- JJ N
1.0 CD N
vs. FW N
TPN NNP i
0.1 CD N
+/- JJ N
0.8 CD N
gm/day NN N
. . N

Traditional JJ N
nutritional JJ o
protein NN o
markers NNS o
( ( o
albumin NN o
, , o
transferrin NN o
, , o
and CC o
retinol VB o
binding VBG o
protein NN o
) ) o
were VBD N
restored VBN N
better RBR N
in IN N
the DT N
TEN NNP i
group NN N
. . N

Infections NNP o
developed VBD N
in IN N
5 CD N
( ( N
17 CD N
% NN N
) ) N
of IN N
the DT N
TEN NNP i
patients NNS N
compared VBN N
to TO N
11 CD N
( ( N
37 CD N
% NN N
) ) N
of IN N
the DT N
TPN NNP i
group NN N
. . N

The DT N
incidence NN N
of IN N
major JJ o
septic JJ o
morbidity NN o
was VBD N
3 CD N
% NN N
( ( N
1 CD N
= NNP N
abdominal JJ N
abscess NN N
) ) N
in IN N
the DT N
TEN NNP i
group NN N
contrasted VBD N
to TO N
20 CD N
% NN N
( ( N
2 CD N
= NNP N
abdominal JJ N
abscess NN N
, , N
6 CD N
= NNP N
pneumonia NN N
) ) N
with IN N
TPN NNP i
. . i

This DT N
clinical JJ N
study NN N
demonstrates VBZ N
that IN N
TEN NNP i
is VBZ N
well RB N
tolerated VBN N
in IN N
the DT N
severely RB p
injured JJ p
, , N
and CC N
that IN N
early JJ N
feeding NN N
via IN N
the DT N
gut NN N
reduces VBZ N
septic JJ N
complications NNS N
in IN N
the DT N
stressed JJ N
patient NN N
. . N

-DOCSTART- -17312647- O O

Injection NNP i
sclerotherapy NN i
versus NN i
electrocoagulation NN i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ p
haemorrhoids NNS p
. . p

OBJECTIVE NNP N
To TO N
study VB N
the DT N
symptomatology NN N
of IN N
early JJ p
hemorrhoids NNS p
and CC N
to TO N
compare VB N
injection NN i
sclerotherapy NN i
( ( i
IS NNP i
) ) i
with IN i
electrocoagulation NN i
( ( i
EC NNP i
) ) i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ N
haemorrhoids NNS N
with IN N
respect NN N
to TO N
pain VB o
during IN o
the DT o
procedure NN o
, , o
reduction NN o
in IN o
bleeding VBG o
per IN o
rectum NN o
, , N
and CC N
overall JJ o
patient NN o
satisfaction NN o
score NN o
. . o

METHODS NNP N
A NNP N
total NN N
of IN N
102 CD p
patients NNS p
were VBD p
included VBN p
in IN N
this DT N
experimental JJ N
study NN N
at IN p
the DT p
POF NNP p
Hospital NNP p
, , p
Wah NNP p
Cantt NNP p
from IN p
October NNP p
2004 CD p
to TO p
June NNP p
2005 CD p
. . p

A DT N
detailed JJ N
history NN N
was VBD N
taken VBN N
and CC N
proctoscopic JJ N
examination NN N
was VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
then RB N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
Lottery NNP N
method NN N
) ) N
. . N

One CD N
group NN N
was VBD N
subjected VBN N
to TO N
EC NNP N
and CC N
the DT N
other JJ N
to TO N
IS NNP N
. . N

In IN N
the DT N
EC NNP N
, , N
using VBG N
the DT N
EC NNP N
machine NN N
( ( N
Wieda NNP N
, , N
China NNP N
) ) N
, , N
direct JJ N
current JJ N
of IN N
10-20 JJ N
mA NN N
was VBD N
applied VBN N
in IN N
the DT N
submucosal JJ N
plane NN N
of IN N
each DT N
pile NN N
core NN N
for IN N
5-7 JJ N
minutes NNS N
. . N

In IN N
the DT N
IS NNP N
1-2 JJ N
ml NN N
of IN N
5 CD N
% NN N
phenol NN i
in IN i
almond NN i
oil NN i
was VBD N
injected VBN N
in IN N
the DT N
same JJ N
plane NN N
in IN N
each DT N
pile NN N
core NN N
. . N

Pain NN o
during IN o
the DT o
procedure NN o
, , o
reduction NN o
in IN o
bleeding VBG o
per IN o
rectum NN o
and CC o
overall JJ o
patient NN o
satisfaction NN o
, , N
were VBD N
studied VBN N
as IN N
outcome JJ N
measures NNS N
. . N

RESULTS VB N
The DT p
mean JJ p
age NN p
of IN p
the DT p
patients NNS p
was VBD p
44 CD p
years NNS p
, , p
86 CD p
were VBD p
males NNS p
and CC p
16 CD p
were VBD p
females NNS p
. . p

Two CD N
thirds NNS N
of IN N
the DT N
patients NNS N
were VBD N
having VBG N
symptoms NNS N
for IN N
more JJR N
than IN N
6 CD N
months NNS N
. . N

A DT N
third JJ N
of IN N
patients NNS N
had VBD N
associated VBN N
local JJ o
pain NN o
while IN N
another DT N
third JJ N
had VBD N
associated VBN N
mucous JJ o
discharge NN o
. . o

Chronic JJ o
constipation NN o
was VBD N
present JJ N
in IN N
81 CD N
% NN N
patients NNS N
. . N

Only RB N
24.5 CD p
% NN p
of IN p
the DT p
patients NNS p
had VBD p
a DT p
positive JJ p
family NN p
history NN p
of IN p
haemorrhoids NNS p
. . p

Patients NNS N
in IN N
the DT N
electrocoagulation NN N
( ( N
EC NNP N
) ) N
group NN N
experienced VBD N
more JJR N
pain NN o
during IN o
the DT o
procedure NN o
than IN N
the DT N
injection NN N
sclerotherapy NN i
( ( i
IS NNP i
) ) i
group NN N
( ( N
P NNP N
< NNP N
0.000 CD N
) ) N
, , N
but CC N
EC NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
IS NNP N
in IN N
terms NNS N
of IN N
reducing VBG N
the DT N
bleeding NN o
per IN o
rectum NN o
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
and CC N
also RB N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
were VBD N
fully RB o
satisfied VBN o
with IN N
EC NNP N
than IN N
with IN N
IS NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

CONCLUSION NNP N
EC NNP N
, , N
although IN N
more RBR N
painful JJ o
, , N
is VBZ N
a DT N
safe JJ o
, , N
more RBR N
effective JJ o
and CC N
a DT N
highly RB o
satisfying JJ o
procedure NN N
for IN N
treating VBG N
early JJ N
hemorrhoids NNS N
. . N

-DOCSTART- -19958108- O O

Comparison NNP N
between IN N
obtained VBN N
mydriasis NN p
in IN p
type NN p
2 CD p
diabetics NNS p
and CC p
non-diabetic JJ p
patients NNS p
. . p

BACKGROUND/AIMS NNP N
To TO N
evaluate VB N
and CC N
compare VB N
obtained VBN N
mydriasis NN N
with IN N
phenylephrine JJ i
10 CD N
% NN N
associated VBN N
with IN N
tropicamide JJ i
1 CD N
% NN N
in IN N
type NN p
2 CD p
diabetics NNS p
and CC p
non-diabetic JJ p
patients NNS p
. . p

METHODS NNP N
A NNP p
total NN p
of IN p
50 CD p
patients NNS p
( ( p
100 CD p
eyes NNS p
) ) p
scheduled VBD p
for IN p
fundoscopy NN p
were VBD p
dilated VBN p
with IN p
phenylephrine JJ i
10 CD i
% NN i
and CC i
yropicamide RB i
1 CD i
% NN i
( ( N
group NN N
0 CD N
: : N
n JJ N
= $ N
20 CD N
type NN N
2 CD N
diabetic JJ N
patients NNS N
, , N
40 CD N
eyes NNS N
, , N
and CC N
group NN N
1 CD N
: : N
n JJ N
= $ N
30 CD N
non-diabetic JJ N
patients NNS N
, , N
60 CD N
eyes NNS N
) ) N
. . N

Only RB N
one CD N
drop NN N
per IN N
eye NN N
of IN N
each DT N
drug NN N
was VBD N
administered VBN N
. . N

In IN N
both DT N
groups NNS N
, , N
pupil VBP o
diameter NN o
was VBD N
measured VBN N
after IN N
40 CD N
minutes NNS N
of IN N
eye NN N
drops NNS N
instillation NN N
. . N

RESULTS NNP N
Both DT N
groups NNS N
were VBD N
similar JJ N
regarding VBG N
age NN N
( ( N
p JJ N
= NN N
0.06 CD N
, , N
Mann-Whitney NNP N
test NN N
) ) N
. . N

Mean NNP o
pupil NN o
diameter NN o
in IN N
group NN N
0 CD N
was VBD N
8.57 CD N
and CC N
8.73 CD N
in IN N
group NN N
1 CD N
. . N

There EX N
was VBD N
no DT N
statistic JJ o
difference NN o
between IN N
both DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.44 CD N
) ) N
. . N

Pupil NNP o
diameter NN o
was VBD N
greater JJR N
than IN N
7 CD N
mm NNS N
in IN N
all DT N
patients NNS N
( ( N
100 CD N
% NN N
) ) N
. . N

CONCLUSION NN N
When WRB N
an DT N
appropriate JJ N
drug NN N
combination NN N
is VBZ N
used VBN N
, , N
diabetic JJ N
patients NNS N
can MD N
achieve VB N
mydriasis NN o
as RB N
satisfactory JJ N
as IN N
non-diabetic JJ N
patients NNS N
, , N
allowing VBG N
adequate JJ N
fundus NN N
examination NN N
and/or IN N
retinopathy JJ N
treatment NN N
. . N

-DOCSTART- -11218508- O O

The DT N
effect NN N
of IN N
splinting NN i
of IN i
teeth NNS i
in IN p
combination NN p
with IN p
reconstructive JJ i
periodontal NN i
surgery NN i
in IN p
humans NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
splinting VBG i
teeth NNS i
on IN N
the DT N
results NNS N
of IN N
periodontal JJ i
reconstructive JJ i
surgery NN i
using VBG N
a DT N
specific JJ N
carbonate NN N
bone NN N
replacement NN N
graft NN N
( ( N
BRG NNP N
) ) N
material NN N
. . N

Forty-five JJ p
patients NNS p
were VBD p
randomly RB p
treated VBN p
with IN p
a DT p
periodontal JJ i
surgery NN i
approach NN p
. . p

Natural JJ N
coral JJ N
calcium NN N
BRG NNP N
was VBD N
utilised VBN N
in IN N
33 CD p
patients NNS p
. . p

This DT N
33-patient JJ N
group NN N
was VBD N
divided VBN N
into IN N
three CD N
equal JJ N
groups NNS N
. . N

In IN N
the DT N
presplint NN N
group NN N
, , N
teeth EX N
were VBD N
splinted VBN i
to TO i
at IN i
least JJS i
two CD i
rigid JJ i
teeth NNS i
before IN i
surgery NN i
, , N
in IN N
the DT N
postsplint NN N
group NN N
, , N
teeth EX N
were VBD N
splinted VBN i
at IN i
suture NN i
removal NN i
, , N
and CC N
in IN N
the DT N
nonsplint NN N
group NN N
, , N
the DT N
treated JJ i
teeth NNS i
were VBD i
not RB i
splinted VBN i
at IN i
all DT i
. . i

In IN N
12 CD N
patients NNS N
, , N
teeth NNS N
were VBD N
treated VBN N
with IN N
surgical JJ N
debridement NN N
( ( N
DEBR NNP N
) ) N
alone RB N
and CC N
not RB N
splinted VBN N
. . N

Periodontal JJ o
probing VBG o
depth NN o
( ( o
PPD NNP o
) ) o
, , o
clinical JJ o
probing VBG o
attachment JJ o
level NN o
( ( o
CPAL NNP o
) ) o
, , o
and CC o
tooth DT o
mobility NN o
were VBD N
measured VBN N
using VBG N
desmodontometry NN N
( ( N
DDM NNP N
) ) N
and CC N
periotest JJS N
( ( N
PTV NNP N
) ) N
with IN N
reproducible JJ N
methods NNS N
before IN N
surgery NN N
and CC N
at IN N
various JJ N
periods NNS N
up RB N
to TO N
1 CD N
year NN N
afterwards NNS N
. . N

A DT N
decrease NN o
in IN o
PPD NNP o
( ( N
5.4 CD N
mm NN N
, , N
SD NNP N
1.4 CD N
mm NN N
) ) N
and CC N
tooth DT o
mobility NN o
( ( N
DDM-horizontal JJ N
257 CD N
microns NNS N
, , N
SD NNP N
60 CD N
microns NNS N
) ) N
and CC N
a DT N
gain NN o
of IN o
CPAL NNP o
( ( N
5.1 CD N
mm NN N
, , N
SD NNP N
1.4 CD N
mm NN N
) ) N
were VBD N
seen VBN N
following VBG N
the DT N
use NN N
of IN N
BRG NNP N
in IN N
presplint NN N
teeth NNS N
. . N

In IN N
the DT N
same JJ N
group NN N
, , N
PPD NNP o
and CC o
tooth JJ o
mobility NN o
were VBD N
significantly RB o
reduced VBN o
compared VBN N
to TO N
nonsplint VB N
teeth NNS N
. . N

DEBR NNP N
alone RB N
showed VBD N
reductions NNS o
in IN o
tooth DT o
mobility NN o
and CC o
PPD NNP o
and CC N
a DT N
significantly RB N
smaller JJR o
gain NN o
in IN N
CPAL NNP o
than IN N
in IN N
presplint NN N
teeth NNS N
treated VBN N
with IN N
BRG NNP N
. . N

The DT N
less RBR N
favourable JJ N
improvement NN N
in IN N
periodontal JJ N
function NN N
of IN N
postsplint NN N
or CC N
nonsplint NN N
teeth NNS N
seemed VBD N
to TO N
be VB N
due JJ N
to TO N
the DT N
loss NN o
of IN o
BRG NNP o
material NN o
caused VBN N
by IN N
tooth DT o
mobility NN o
. . o

These DT N
results NNS N
indicate VBP N
that IN N
an DT N
undisturbed JJ N
wound NN N
healing VBG N
process NN N
using VBG N
BRG NNP N
together RB N
with IN N
tooth DT N
stability NN N
is VBZ N
beneficial JJ N
to TO N
overall JJ o
clinical JJ o
success NN o
. . o

-DOCSTART- -11876893- O O

[ JJ N
Clinical NNP N
application NN N
of IN N
irradiated JJ N
drug-containing JJ i
porcine-cornea NN i
to TO N
patients NNS p
with IN p
ocular JJ p
burns NNS p
] FW p
. . N

OBJECTIVE UH N
To TO N
explore VB N
a DT N
new JJ N
method NN N
for IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
ocular JJ p
burns NNS p
. . p

METHODS NNP N
Fifty-five JJ p
cases NNS p
of IN p
patients NNS p
with IN p
ocular JJ p
burns NNS p
( ( p
in IN p
88 CD p
eyes NNS p
) ) p
were VBD N
randomly RB N
divided VBN N
into IN N
treatment NN N
and CC N
control NN N
groups NNS N
. . N

Thirty NNP N
cases NNS N
in IN N
treatment NN N
group NN N
with IN N
49 CD p
eyes NNS p
were VBD p
transplanted VBN p
with IN N
irradiated JJ i
drug-containing NN i
( ( i
ofloxacin UH i
, , i
acetyl JJ i
cysteine NN i
and CC i
reduced JJ i
glutathione NN i
) ) i
porcine-cornea NN i
. . i

25 CD N
cases NNS N
in IN N
control NN N
group NN N
with IN N
39 CD N
eyes NNS N
were VBD N
treated VBN N
with IN N
routine JJ N
program NN N
. . N

RESULTS NNP N
Thirty-two JJ N
eyes NNS o
were VBD o
rescued VBN o
in IN N
treatment NN N
group NN N
with IN N
the DT N
cure NN N
rate NN N
of IN N
65.3 CD N
% NN N
. . N

But CC N
only RB N
17 CD N
eyes NNS o
were VBD o
saved VBN o
in IN N
control NN N
group NN N
with IN N
the DT N
cure NN N
rate NN N
of IN N
43.59 CD N
% NN N
, , N
indicating VBG N
significant JJ N
difference NN N
of IN N
the DT N
cure NN o
rate NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Irradiated VBD N
drug-containing JJ N
porcine-cornea NN i
might MD N
well RB N
be VB N
an DT N
ideal JJ N
therapeutic JJ N
material NN N
for IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
ocular JJ p
burns NNS p
. . p

-DOCSTART- -24231167- O O

Examination NN o
of IN N
aggression NN o
and CC N
self-injury NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
serious JJ p
behavioral JJ p
problems NNS p
. . p

This DT N
study NN N
identified VBD N
subtypes NNS N
of IN N
aggression NN N
in IN N
a DT N
sample NN N
of IN N
206 CD p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
who WP p
participated VBD p
in IN p
2 CD i
risperidone NN i
trials NNS i
. . i

The DT N
narratives NNS N
were VBD N
derived VBN N
from IN N
a DT N
parent NN N
interview NN N
about IN N
each DT N
child NN N
's POS N
2 CD N
most RBS N
pressing JJ N
problems NNS N
. . N

Five CD N
subtypes NNS N
of IN N
aggression NN N
emerged VBN N
: : N
hot JJ o
aggression NN o
only RB o
, , o
cold JJ o
aggression NN o
only RB o
, , o
self-injurious JJ o
behavior NN o
( ( o
SIB NNP o
) ) o
only RB o
, , o
aggression NN o
and CC o
SIB NNP o
, , N
and CC N
nonaggressive JJ o
. . o

All DT N
groups NNS N
showed VBD N
a DT N
high JJ N
rate NN N
of IN N
positive JJ o
response NN o
to TO N
risperidone VB N
with IN N
no DT N
differences NNS N
across IN N
subtypes NNS N
. . N

These DT N
study NN N
findings NNS N
extend VBP N
understanding NN N
of IN N
aggression NN N
in IN N
ASD NNP N
and CC N
may MD N
be VB N
useful JJ N
to TO N
guide VB N
further RB N
study NN N
on IN N
biological JJ N
mechanisms NNS N
and CC N
individualized JJ N
treatment NN N
in IN N
ASD NNP N
. . N

-DOCSTART- -9315428- O O

Design NN N
of IN N
a DT N
cost-effectiveness NN N
study NN N
within IN N
a DT N
randomized JJ N
trial NN N
: : N
the DT N
LIPID NNP N
Trial NNP N
for IN N
Secondary NNP N
Prevention NNP N
of IN N
IHD NNP p
. . p

Long-term JJ N
Intervention NN N
with IN N
Pravastatin NNP i
in IN N
Ischemic NNP p
Heart NNP p
disease NN p
. . p

The DT N
Long-term JJ N
Intervention NN N
with IN N
Pravastatin NNP i
in IN N
Ischemic NNP p
Heart NNP p
Disease NNP p
( ( N
LIPID NNP N
) ) N
trial NN N
is VBZ N
a DT N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
evaluating VBG N
the DT N
long-term JJ N
effect NN N
of IN N
pravastatin NN i
on IN N
coronary JJ N
mortality NN N
in IN N
patients NNS p
with IN p
a DT p
previous JJ p
myocardial JJ p
infarction NN p
or CC p
unstable JJ p
angina-ischemic JJ p
heart NN p
disease NN p
( ( p
IHD NNP p
) ) p
. . p

It PRP N
is VBZ N
planned VBN N
to TO N
run VB N
for IN N
at IN N
least JJS N
five CD N
years NNS N
with IN N
9014 CD p
patients NNS p
from IN p
85 CD p
centers NNS p
in IN p
Australia NNP p
and CC p
New NNP p
Zealand NNP p
. . p

The DT N
trial NN N
will MD N
monitor VB N
cause-specific JJ N
mortality NN N
and CC N
major JJ N
clinical JJ N
events NNS N
associated VBN N
with IN N
each DT N
treatment NN N
. . N

Running VBG N
in IN N
parallel NN N
with IN N
the DT N
main JJ N
study NN N
is VBZ N
a DT N
prospective JJ N
economic JJ N
analysis NN N
, , N
the DT N
objectives NNS N
of IN N
which WDT N
are VBP N
( ( N
1 CD N
) ) N
to TO N
estimate VB N
the DT N
effectiveness NN N
of IN N
pravastatin NN i
compared VBN N
with IN N
placebo NN N
in IN N
terms NNS N
of IN N
survival NN o
, , o
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
and CC o
quality-adjusted JJ o
life-years NNS o
( ( o
QALY NNP o
) ) o
; : o
( ( N
2 CD N
) ) N
to TO N
estimate VB N
the DT N
resource NN N
usage NN N
associated VBN N
with IN N
pravastatin NNS i
compared VBN N
with IN N
placebo-in JJ i
particular JJ N
, , N
to TO N
study VB N
whether IN N
it PRP N
alters VBZ N
resource JJ N
usage NN N
through IN N
prevention NN N
of IN N
disease NN N
progression NN N
; : N
and CC N
( ( N
3 CD N
) ) N
to TO N
use VB N
this DT N
information NN N
for IN N
a DT N
cost-utility JJ N
analysis NN N
with IN N
cost NN N
per IN N
quality-adjusted JJ N
life-year JJ N
as IN N
the DT N
unit NN N
of IN N
analysis NN N
. . N

A DT N
novel JJ N
aspect NN N
of IN N
the DT N
design NN N
is VBZ N
the DT N
use NN N
of IN N
a DT N
preliminary JJ N
cost-effectiveness NN N
analysis NN N
, , N
based VBN N
on IN N
best-guess JJ N
values NNS N
, , N
and CC N
a DT N
sensitivity NN N
analysis NN N
over IN N
plausible JJ N
ranges NNS N
to TO N
guide VB N
the DT N
choice NN N
of IN N
subsample JJ N
size NN N
. . N

Some DT N
data NNS N
, , N
such PDT N
a DT N
mortality NN o
, , o
days NNS o
spent VBD o
in IN o
hospital NN o
, , o
major JJ o
clinical JJ o
events NNS o
, , o
and CC o
drug NN o
use NN o
, , N
are VBP N
being VBG N
collected VBN N
within IN N
the DT N
main JJ N
LIPID NNP N
trial NN N
. . N

However RB N
, , N
additional JJ N
subsamples NNS N
for IN N
the DT N
cost-effectiveness NN o
study NN N
will MD N
include VB N
information NN N
on IN N
quality NN o
of IN o
life NN o
, , o
time NN o
off RP o
work NN o
, , o
and CC o
resources NNS o
used VBN o
, , o
such JJ o
as IN o
time NN o
in IN o
hospital NN o
, , o
procedures NNS o
, , o
and CC o
medications NNS o
taken VBN o
. . o

The DT N
methods NNS N
and CC N
sample NN N
sizes NNS N
for IN N
these DT N
substudies NNS N
have VBP N
been VBN N
a DT N
crucial JJ N
issue NN N
in IN N
validity NN N
and CC N
feasibility NN N
. . N

-DOCSTART- -12614707- O O

The DT N
role NN N
of IN N
choice NN N
in IN N
health NN p
education NN p
intervention NN p
trials NNS p
: : p
a DT N
review NN N
and CC N
case NN N
study NN N
. . N

Although IN N
the DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
is VBZ N
considered VBN N
the DT N
gold JJ N
standard NN N
in IN N
research NN N
for IN N
determining VBG N
the DT N
efficacy NN N
of IN N
health NN N
education NN N
interventions NNS N
, , N
such JJ N
trials NNS N
may MD N
be VB N
vulnerable JJ N
to TO N
preference VB N
effects NNS N
; : N
that DT N
is VBZ N
, , N
differential JJ N
outcomes NNS N
depending VBG N
on IN N
whether IN N
an DT N
individual NN N
is VBZ N
randomized VBN N
to TO N
his PRP$ N
or CC N
her PRP$ N
preferred JJ N
treatment NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
review VBP N
theoretical JJ N
and CC N
empirical JJ N
literature NN N
regarding VBG N
designs NNS N
that WDT N
account VBP N
for IN N
such JJ N
effects NNS N
in IN N
medical JJ N
research NN N
, , N
and CC N
consider VB N
the DT N
appropriateness NN N
of IN N
these DT N
designs NNS N
to TO N
health NN p
education NN p
research NN p
. . p

To TO N
illustrate VB N
the DT N
application NN N
of IN N
a DT N
preference NN N
design NN N
to TO N
health NN N
education NN N
research NN N
, , N
we PRP N
present VBP N
analyses NNS N
using VBG N
process NN N
data NNS N
from IN N
a DT N
mixed JJ p
RCT/preference NNP p
trial NN p
comparing VBG p
two CD p
formats NNS p
( ( i
Group NNP i
or CC N
Self-Directed NNP i
) ) i
of IN N
the DT N
Women NNP p
take VB p
PRIDE NNP p
heart NN p
disease NN p
management NN p
program NN p
. . p

Results NNP N
indicate VBP N
that IN N
being VBG N
able JJ N
to TO N
choose VB N
one CD N
's POS N
program NN N
format NN N
did VBD N
not RB N
significantly RB N
affect VB N
the DT N
decision NN o
to TO o
participate VB o
in IN N
the DT N
study NN N
. . N

However RB N
, , N
women NNS p
who WP N
chose VBD i
the DT i
Group NNP i
format WDT i
were VBD N
over RB N
4 CD N
times NNS N
as RB N
likely JJ N
to TO N
attend VB N
at IN N
least JJS N
one CD N
class NN N
and CC N
were VBD N
twice RB N
as RB N
likely JJ N
to TO N
attend VB N
a DT N
greater JJR N
number NN N
of IN N
classes NNS N
than IN N
those DT N
who WP N
were VBD N
randomized VBN i
to TO i
the DT i
Group NNP i
format NN i
. . i

Several JJ N
predictors NNS N
of IN N
format JJ N
preference NN N
were VBD N
also RB N
identified VBN N
, , N
with IN N
important JJ N
implications NNS N
for IN N
targeting VBG N
disease-management JJ N
education NN N
to TO N
this DT N
population NN N
. . N

-DOCSTART- -23197299- O O

Thrombin-activatable JJ i
fibrinolysis NN i
inhibitor NN i
in IN N
hypothyroidism NN p
and CC p
hyperthyroxinaemia NN p
. . p

Endocrine JJ N
disorders NNS N
affect VBP N
both DT N
the DT N
coagulation NN N
and CC N
fibrinolytic JJ N
systems NNS N
, , N
and CC N
have VBP N
been VBN N
associated VBN N
with IN N
the DT N
development NN N
of IN N
cardiovascular JJ N
diseases NNS N
. . N

Thrombin-activatable JJ i
fibrinolysis NN i
inhibitor NN i
( ( i
TAFI NNP i
) ) i
is VBZ N
a DT N
link NN N
between IN N
coagulation NN N
and CC N
the DT N
fibrinolytic JJ N
system NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
thyroid NN N
hormone NN N
excess NN N
and CC N
deficiency NN N
on IN N
TAFI NNP i
levels NNS N
and CC N
function NN N
. . N

The DT N
effect NN N
of IN N
hyperthyroxinemia NN N
on IN N
TAFI NNP i
was VBD N
studied VBN N
in IN N
healthy JJ p
volunteers NNS p
who WP N
were VBD N
randomised VBN N
to TO N
receive VB N
levothyroxine NN i
or CC N
no DT i
medication NN i
for IN N
14 CD N
days NNS N
in IN N
a DT N
crossover NN N
design NN N
. . N

The DT N
effect NN N
of IN N
hypothyroidism NN N
on IN N
TAFI NNP i
was VBD N
studied VBN N
in IN N
a DT N
multicentre JJ N
observational JJ N
cohort NN N
study NN N
. . N

Blood NNP N
was VBD N
drawn VBN N
before IN N
treatment NN N
of IN N
patients NNS p
with IN p
newly RB p
diagnosed VBN p
hypothyroidism NN p
and CC p
when WRB p
euthyroidism NN p
was VBD N
achieved VBN N
. . N

Plasma NNP o
clot-lysis NN o
times NNS o
, , o
activated VBD o
TAFI NNP o
( ( o
TAFIa NNP o
) ) o
-dependent NN o
prolongation NN o
of IN o
clot-lysis NN o
and CC o
TAFI NNP o
levels NNS o
were VBD N
measured VBN N
. . N

Thyroid NNP o
hormone NN o
excess NN o
resulted VBD N
in IN N
a DT N
hypofibrinolytic JJ o
condition NN o
and CC N
in IN N
an DT N
enhanced JJ N
TAFIa-dependent JJ o
prolongation NN o
of IN o
clot NN o
lysis NN o
. . o

A DT N
trend NN N
towards NNS N
decreased VBD o
plasma JJ o
TAFI NNP o
levels NNS o
was VBD N
observed VBN N
in IN N
healthy JJ p
volunteers NNS p
who WP N
used VBD N
levothyroxine NN i
. . i

Hypothyroidism NNP N
resulted VBD N
in IN N
hyperfibrinolysis NN o
and CC N
a DT N
reduced JJ o
TAFIa-dependent JJ o
prolongation NN o
of IN o
clot NN o
lysis NN o
. . o

In IN N
conclusion NN N
, , N
alterations NNS N
of IN N
TAFIa-dependent JJ o
prolongation NN o
of IN o
clot NN o
lysis NN o
in IN N
patients NNS N
with IN N
thyroid JJ N
disorders NNS N
may MD N
cause VB N
an DT N
impaired JJ o
haemostatic JJ o
balance NN o
. . o

The DT N
disturbed JJ o
haemostatic JJ o
balance NN o
in IN N
patients NNS p
with IN p
hyperthyroidism NN p
might MD N
make VB N
them PRP N
prone VB N
to TO N
thrombosis VB N
, , N
while IN N
the DT N
risk NN N
for IN N
bleeding VBG o
may MD N
increase VB N
in IN N
patients NNS p
with IN p
hypothyroidism NN p
. . p

-DOCSTART- -1889248- O O

Bacterial NNP i
ribosomal JJ i
immunostimulants NNS i
prime JJ N
alveolar JJ N
macrophages NNS N
in IN N
vivo NN N
to TO N
produce VB N
interleukin JJ o
1 CD o
in IN N
vitro NN N
. . N

Alveolar JJ N
macrophages NNS N
( ( N
AMs NNP N
) ) N
may MD N
play VB N
a DT N
key JJ N
role NN N
in IN N
human JJ N
respiratory NN N
immune NN N
defenses NNS N
, , N
partially RB N
by IN N
synthesizing VBG N
and CC N
releasing VBG N
interleukin JJ o
1 CD o
( ( o
IL NNP o
= NNP o
1 CD o
) ) o
. . o

D53 NNP i
( ( i
Ribomunyl NNP i
) ) i
, , i
a DT i
composite JJ i
bacterial JJ i
ribosomal NN i
immunostimulant NN i
, , N
has VBZ N
been VBN N
recognized VBN N
as IN N
an DT N
efficient JJ N
prevention NN N
of IN N
respiratory NN o
tract JJ o
infections NNS o
. . o

In IN N
vitro NN N
, , N
D53 NNP i
enhances VBZ N
the DT N
IL-1 JJ o
production NN o
by IN N
mouse NN N
spleen JJ N
adherent JJ N
cells NNS N
. . N

A DT N
thymocyte JJ N
proliferative JJ N
response NN N
assay NN N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
in IN o
vitro JJ o
IL-1 JJ o
production NN o
by IN N
AMs NNP N
in IN N
healthy JJ p
subjects NNS p
who WP p
received VBD p
D53 NNP i
immunostimulant NN i
. . i

Twelve VB p
nonsmoking VBG p
healthy JJ p
subjects NNS p
took VBD N
part NN N
in IN N
a DT N
prospective JJ N
double-blind NN N
placebo NN N
control NN N
study NN N
. . N

On IN N
day NN N
1 CD N
, , N
a DT N
first JJ N
bronchoalveolar JJ N
lavage NN N
( ( N
BAL NNP N
) ) N
was VBD N
performed VBN N
to TO N
assess VB N
IL-1 NNP o
production NN o
by IN N
unstimulated JJ N
and CC N
lipopolysaccharide JJ N
( ( N
LPS NNP N
) ) N
stimulated VBD N
AM NNP N
. . N

Then RB N
, , N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
D53 NNP i
( ( N
n JJ N
= NNP N
6 CD N
) ) N
or CC N
its PRP$ N
placebo NN i
( ( N
n JJ N
= NNP N
6 CD N
) ) N
by IN N
both DT N
oral JJ N
and CC N
subcutaneous JJ N
injection NN N
routes NNS N
from IN N
day NN N
1 CD N
to TO N
day NN N
15 CD N
. . N

On IN N
day NN N
15 CD N
, , N
a DT N
second JJ N
BAL NNP N
was VBD N
done VBN N
and CC N
AM NNP o
IL-1 NNP o
production NN o
was VBD N
again RB N
tested VBN N
. . N

IL-1 JJ o
production NN o
on IN N
day NN N
15 CD N
did VBD N
not RB N
significantly RB N
differ VBP N
from IN N
day NN N
1 CD N
in IN N
both DT N
D53-treated NNP i
and CC N
placebo NN N
groups NNS N
either CC N
when WRB N
AMs NNP N
were VBD N
unstimulated JJ N
or CC N
were VBD N
stimulated VBN N
with IN N
concentrations NNS N
of IN N
LPS NNP N
resulting VBG N
in IN N
maximal JJ N
IL-1 JJ o
production NN o
. . o

However RB N
, , N
in IN N
the DT N
D53-treated NNP i
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
placebo NN i
group NN N
, , N
IL-1 NNP o
production NN o
induced VBN N
by IN N
low JJ N
LPS NNP o
concentration NN o
( ( N
5 CD N
mg/L NN N
) ) N
was VBD N
significantly RB N
higher JJR N
( ( N
mean JJ N
+/- JJ N
SEM NN N
: : N
1,238 CD N
+/- JJ N
287 CD N
U/10 NNP N
( ( N
6 CD N
) ) N
AM NNP N
) ) N
on IN N
day NN N
15 CD N
in IN N
comparison NN N
with IN N
day NN N
1 CD N
( ( N
577 CD N
+/- JJ N
113 CD N
U/10 NNP N
( ( N
6 CD N
) ) N
AM VBP N
; : N
p NN N
less JJR N
than IN N
0.05 CD N
, , N
Wilcoxon NNP N
W NNP N
test NN N
) ) N
and CC N
in IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
( ( N
day NN N
15 CD N
IL-1 JJ o
production NN N
induced VBN N
by IN N
5 CD N
mg/L NN N
LPS NNP N
, , N
758 CD N
+/- JJ N
175 CD N
U/10 NNP N
( ( N
6 CD N
) ) N
AM VBP N
; : N
p NN N
less JJR N
than IN N
0.05 CD N
, , N
Mann-Whitney NNP N
U NNP N
test NN N
) ) N
. . N

Moreover RB N
, , N
in IN N
the DT N
D53-treated NNP i
group NN N
, , N
the DT N
optimal JJ o
LPS NNP o
concentration NN o
( ( N
ie JJ N
, , N
LPS NNP N
concentration NN N
that WDT N
induced VBD N
maximal JJ N
IL-1 NNP N
production NN N
) ) N
was VBD N
significantly RB N
lower JJR N
on IN N
day NN N
15 CD N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
11 CD N
+/- JJ N
7 CD N
mg/L NN N
) ) N
than IN N
on IN N
day NN N
1 CD N
( ( N
16 CD N
+/- JJ N
7 CD N
mg/L NN N
; : N
p CC N
less JJR N
than IN N
0.05 CD N
Wilcoxon NNP N
W NNP N
test NN N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
D53 NNP i
immunostimulant NN i
in IN N
vivo NN N
primes NNS N
AM VBP N
to TO N
produce VB N
IL-1 NNP o
following VBG N
low JJ o
LPS NNP o
concentration NN o
stimulation NN N
. . N

This DT N
may MD N
partially RB N
explain VB N
the DT N
protective JJ N
effect NN N
of IN N
D53 NNP i
immunostimulant NN i
against IN N
respiratory JJ o
tract JJ o
infection NN o
. . o

-DOCSTART- -23360819- O O

Influence NN N
of IN N
SNPs NNP N
in IN N
nutrient-sensitive JJ o
candidate NN N
genes NNS o
and CC N
gene-diet JJ o
interactions NNS o
on IN o
blood NN o
lipids NNS o
: : o
the DT N
DiOGenes NNP p
study NN p
. . p

Blood NNP o
lipid JJ o
response NN N
to TO N
a DT N
given VBN i
dietary JJ i
intervention NN i
could MD N
be VB N
determined VBN N
by IN N
the DT N
effect NN N
of IN N
diet NN N
, , N
gene NN N
variants NNS N
or CC N
gene-diet JJ N
interactions NNS N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
variants NNS N
in IN N
presumed JJ N
nutrient-sensitive JJ o
genes NNS o
involved VBN o
in IN o
lipid JJ o
metabolism NN o
modified VBD N
lipid JJ o
profile NN o
after IN N
weight JJ N
loss NN N
and CC N
in IN N
response NN N
to TO N
a DT N
given VBN i
diet JJ i
, , N
among IN N
overweight JJ p
European JJ p
adults NNS p
participating VBG p
in IN p
the DT p
Diet NNP p
Obesity NNP p
and CC p
Genes NNP p
study NN p
. . p

By IN N
multiple JJ N
linear JJ N
regressions NNS N
, , N
240 CD N
SNPs NNP N
in IN N
twenty-four JJ p
candidate NN p
genes NNS p
were VBD p
investigated VBN p
for IN N
SNP NNP N
main JJ N
and CC N
SNP-diet JJ N
interaction NN N
effects NNS N
on IN N
total JJ o
cholesterol NN o
, , o
LDL-cholesterol NNP o
, , o
HDL-cholesterol NNP o
and CC o
TAG NNP o
after IN N
an DT i
8-week JJ i
low-energy JJ i
diet NN i
( ( N
only RB N
main JJ N
effect NN N
) ) N
, , N
and CC N
a DT N
6-month JJ i
ad NN i
libitum NN i
weight VBD i
maintenance NN i
diet NN i
, , N
with IN N
different JJ N
contents NNS N
of IN N
dietary JJ i
protein NN i
or CC N
glycaemic JJ i
index NN i
. . i

After IN N
adjusting VBG N
for IN N
multiple JJ N
testing NN N
, , N
a DT N
SNP-dietary JJ o
protein NN o
interaction NN o
effect NN o
on IN o
TAG NNP o
was VBD N
identified VBN N
for IN N
lipin NN N
1 CD N
( ( N
LPIN1 NNP N
) ) N
rs4315495 NN N
, , N
with IN N
a DT N
decrease NN o
in IN o
TAG NNP o
of IN N
20.26 CD N
mmol/l NNS N
per IN N
A-allele/protein NNP N
unit NN N
( ( N
95 CD N
% NN N
CI NNP N
20.38 CD N
, , N
20.14 CD N
, , N
P=0.000043 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
we PRP N
investigated VBD N
SNP-diet JJ o
interactions NNS o
for IN o
blood NN o
lipid JJ o
profiles NNS o
for IN N
240 CD N
SNPs NNP N
in IN N
twenty-four JJ N
candidate NN N
genes NNS N
, , N
selected VBN N
for IN N
their PRP$ N
involvement NN N
in IN N
lipid JJ N
metabolism NN N
pathways NNS N
, , N
and CC N
identified VBD N
one CD N
significant JJ N
interaction NN o
between IN o
LPIN1 NNP o
rs4315495 NN o
and CC o
dietary JJ o
protein NN o
for IN o
TAG NNP o
concentration NN o
. . o

-DOCSTART- -2162258- O O

Enalapril NNP i
and CC N
lisinopril NN i
in IN N
the DT N
treatment NN N
of IN N
mild NN p
to TO p
moderate VB p
essential JJ p
hypertension NN p
. . p

Hypertensive JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
5 CD i
mg NN i
of IN i
enalapril NN i
( ( p
n JJ p
= NNP p
50 CD p
) ) p
or CC p
10 CD i
mg NN i
of IN i
lisinopril NN i
( ( p
n JJ p
= NNP p
47 CD p
) ) p
daily RB p
. . p

During IN N
a DT N
four-week JJ N
titration NN N
period NN N
, , N
the DT N
doses NNS N
were VBD N
increased VBN N
weekly RB N
to TO N
a DT N
maximum NN N
of IN N
40 CD N
mg NNS N
once RB N
daily RB N
until IN N
the DT N
treatment NN N
goal NN N
of IN N
diastolic JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
of IN N
less JJR N
than IN N
90 CD N
mmHg NN N
was VBD N
reached VBN N
; : N
treatment NN N
was VBD N
then RB N
continued VBN N
for IN N
four CD N
weeks NNS N
. . N

Systolic NNP o
and CC o
diastolic JJ o
BP NNP o
declined VBD N
significantly RB N
in IN N
the DT N
two CD p
treatment NN p
groups NNS p
, , N
from IN N
147/98 CD N
mmHg NN N
in IN N
both CC N
the DT N
enalapril NN i
and CC N
lisinopril NN i
groups NNS N
to TO N
126/82 CD N
and CC N
122/81 CD N
mmHg NN N
, , N
respectively RB N
, , N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

During IN N
the DT N
first JJ N
week NN N
of IN N
treatment NN N
, , N
the DT N
goal NN N
of IN N
diastolic JJ o
BP NNP o
of IN N
less JJR N
than IN N
90 CD N
mmHg NN N
was VBD N
reached VBN N
by IN N
40 CD N
% NN N
of IN N
the DT N
enalapril NN i
group NN N
and CC N
62 CD N
% NN N
of IN N
the DT N
lisinopril NN i
group NN N
; : N
by IN N
the DT N
end NN N
of IN N
the DT N
titration NN N
period NN N
, , N
98 CD N
% NN N
and CC N
96 CD N
% NN N
, , N
respectively RB N
, , N
had VBD N
achieved VBN N
the DT N
BP NNP o
goal NN o
. . o

Few JJ N
side NN o
effects NNS o
were VBD N
reported VBN N
and CC N
there EX N
were VBD N
no DT N
abnormal JJ N
laboratory NN N
findings NNS N
during IN N
treatment NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
once-daily JJ N
administration NN N
of IN N
enalapril NN i
or CC N
lisinopril NN i
was VBD N
generally RB N
effective JJ N
and CC N
well-tolerated JJ N
in IN N
the DT N
management NN N
of IN N
mild NN p
to TO p
moderate VB p
uncomplicated JJ p
essential JJ p
hypertension NN p
. . p

-DOCSTART- -6131800- O O

The DT N
effect NN N
of IN N
Naftidrofuryl NNP i
on IN N
ethanol-induced JJ N
liver NN N
damage NN N
in IN N
chronic JJ p
alcoholic JJ p
patients NNS p
. . p

A DT N
prospective JJ N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
intramuscular JJ N
Naftidrofuryl NNP i
was VBD N
carried VBN N
out RP N
on IN N
32 CD p
randomly RB p
selected VBN p
hospitalized VBN p
male JJ p
alcoholic JJ p
patients NNS p
with IN p
clinical JJ p
, , p
biochemical JJ p
and CC p
histological JJ p
evidence NN p
of IN p
hepatic JJ p
damage NN p
. . p

Seventeen JJ N
patients NNS N
received VBD N
the DT N
drug NN N
( ( N
40 CD N
mg NN N
in IN N
5 CD N
ml NN N
i.m NN N
. . N

three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
) ) N
and CC N
15 CD N
patients NNS N
received VBD N
a DT N
placebo NN i
( ( N
5 CD N
ml NN N
in IN N
normal JJ N
saline JJ N
i.m NN N
. . N

three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
) ) N
. . N

The DT N
drug NN N
was VBD N
well RB N
tolerated VBN N
and CC N
there EX N
were VBD N
no DT N
adverse JJ o
side-effects NNS o
. . o

Naftidrofuryl NNP i
significantly RB N
improved VBD N
the DT N
physiological JJ o
function NN o
of IN o
the DT o
liver NN o
cells NNS o
as IN o
reflected VBN o
by IN o
indocyanine NN o
green NN o
( ( o
ICG NNP o
) ) o
clearance NN o
by IN N
the DT N
liver NN N
( ( N
t JJ N
= VBZ N
2.61 CD N
; : N
p NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.02 CD N
) ) N
and CC N
also RB N
caused VBD N
a DT N
larger JJR N
fall NN N
in IN N
raised VBN N
serum NN o
levels NNS o
of IN o
gamma NN o
glutamyl NN o
transpeptidase NN o
( ( o
GGT NNP o
) ) o
than IN N
did VBD N
the DT N
placebo NN i
injections NNS N
. . N

Overall JJ N
clinical JJ o
improvement NN o
( ( o
e.g NN o
. . o

appetite NN o
, , o
body NN o
weight NN o
, , o
reduced VBD o
liver JJ o
size NN o
, , o
general JJ o
sense NN o
of IN o
well-being NN o
) ) o
was VBD N
more RBR N
clearly RB N
evident JJ N
in IN N
patients NNS N
of IN N
the DT N
treated VBN N
group NN N
than IN N
in IN N
those DT N
of IN N
the DT N
placebo NN i
group NN N
. . N

Naftidrofuryl NNP i
, , N
therefore RB N
, , N
appears VBZ N
to TO N
be VB N
of IN N
benefit NN N
in IN N
ethanol-induced JJ p
liver NN p
damage NN p
and CC N
more RBR N
extensive JJ N
long-term JJ N
trials NNS N
are VBP N
suggested VBN N
in IN N
patients NNS p
with IN p
alcoholic JJ p
liver NN p
disease NN p
( ( p
ALD NNP p
) ) p
. . p

-DOCSTART- -10945514- O O

Combination NNP N
hydrocodone NN i
and CC i
ibuprofen JJ i
versus NN N
combination NN N
codeine NN i
and CC i
acetaminophen NN i
for IN N
the DT N
treatment NN p
of IN p
chronic JJ p
pain NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
combination NN N
hydrocodone NN i
7.5 CD N
mg NN N
and CC N
ibuprofen $ i
200 CD N
mg NN N
with IN N
that DT N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC N
acetaminophen $ i
300 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
pain NN N
. . N

BACKGROUND NNP N
Hydrocodone NNP i
7.5 CD N
mg NN N
with IN N
ibuprofen JJ i
200 CD N
mg NN N
is VBZ N
the DT N
only JJ N
approved VBD N
fixed-dose JJ N
combination NN N
analgesic IN N
containing VBG N
an DT N
opioid NN N
and CC N
ibuprofen NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
repeated-dose JJ N
, , N
active-comparator JJ N
, , N
4-week JJ N
, , N
multicenter NN N
study NN N
, , N
469 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
1-tablet JJ N
( ( N
n JJ N
= NNP N
156 CD N
) ) N
or CC N
2-tablet JJ N
( ( N
n JJ N
= NNP N
153 CD N
) ) N
dose NN N
of IN N
combination NN i
hydrocodone NN i
7.5 CD i
mg NN i
and CC i
ibuprofen $ i
200 CD i
mg NN i
( ( N
HI1 NNP N
and CC N
HI2 NNP N
, , N
respectively RB N
) ) N
or CC N
a DT N
2-tablet JJ i
dose NN i
of IN N
combination NN N
codeine NN i
30 CD i
mg NN i
and CC i
acetaminophen $ i
300 CD i
mg NN i
( ( N
CA NNP N
, , N
n RB N
= VBZ N
160 CD N
) ) N
, , N
the DT N
active JJ N
comparator NN N
, , N
every DT N
6 CD N
to TO N
8 CD N
hours NNS N
as IN N
needed VBN N
for IN N
pain NN N
. . N

Efficacy NN N
was VBD N
measured VBN N
through IN N
pain NN o
relief NN o
scores NNS o
, , o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
study NN o
medication NN o
, , o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
supplemental JJ o
analgesics NNS o
, , o
number NN o
of IN o
patients NNS o
who WP o
discontinued VBD o
therapy NN o
due JJ o
to TO o
an DT o
unsatisfactory JJ o
analgesic JJ o
response NN o
, , N
and CC N
global JJ N
assessment NN N
scores NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
469 CD p
patients NNS p
, , p
255 CD p
( ( p
54.4 CD p
% NN p
) ) p
were VBD p
female JJ p
and CC p
214 CD p
( ( p
45.6 CD p
% NN p
) ) p
were VBD p
male JJ p
. . p

The DT N
mean JJ p
age NN p
was VBD p
51.1 CD p
years NNS p
. . p

Types NNS p
of IN p
chronic NN p
pain NN p
included VBD p
back RB p
( ( p
214 CD p
; : p
45.6 CD p
% NN p
) ) p
, , p
arthritic JJ p
( ( p
145 CD p
; : p
30.9 CD p
% NN p
) ) p
, , p
other JJ p
musculoskeletal NN p
( ( p
65 CD p
; : p
13.9 CD p
% NN p
) ) p
, , p
cancer NN p
( ( p
6 CD p
; : p
1.3 CD p
% NN p
) ) p
, , p
diabetic JJ p
neuropathic NN p
( ( p
3 CD p
; : p
0.6 CD p
% NN p
) ) p
, , p
postherpetic JJ p
neuralgic NN p
( ( p
5 CD p
; : p
1.1 CD p
% NN p
) ) p
, , p
other JJ p
neurologic NN p
( ( p
21 CD p
; : p
4.5 CD p
% NN p
) ) p
, , p
and CC p
other JJ p
unclassified JJ p
chronic JJ p
pain NN p
( ( p
10 CD p
; : p
2.1 CD p
% NN p
) ) p
. . N

During IN N
the DT N
48 CD N
hours NNS N
prior RB N
to TO N
the DT N
study NN N
, , N
351 CD N
( ( N
74.8 CD N
% NN N
) ) N
patients NNS N
had VBD N
been VBN N
treated VBN N
with IN N
opioid JJ N
or CC N
opioid-nonopioid JJ N
combination NN N
analgesics NNS N
. . N

The DT N
overall JJ o
mean JJ o
daily JJ o
pain NN o
relief NN o
score NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.25+/-0.89 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
1.98+/-0.87 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
1.85+/-0.96 JJ N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
overall JJ o
mean JJ o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
study NN o
medication NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.94+/-0.99 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
3.23+/-0.76 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
3.26+/-0.75 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

The DT N
overall JJ o
mean JJ o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
supplemental JJ o
analgesics NNS o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
0.24+/-0.49 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
0.34+/-0.58 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
or CC N
CA NNP N
group NN N
( ( N
0.49+/-0.85 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

The DT N
number NN o
of IN o
patients NNS o
who WP o
discontinued VBD o
treatment NN o
due JJ o
to TO o
an DT o
unsatisfactory JJ o
analgesic JJ o
response NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2 CD N
; : N
1.3 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
CA NNP N
group NN N
( ( N
12 CD N
; : N
7.5 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

HI2 NNP N
was VBD N
more RBR N
effective JJ N
than IN N
HI1 NNP N
and CC N
CA NNP N
as IN N
measured VBN N
by IN N
pain NN o
relief NN o
scores NNS o
for IN N
week NN N
1 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
and CC N
week NN N
3 CD N
( ( N
P NNP N
= VBZ N
0.008 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ o
doses NNS o
of IN o
study NN o
medication NN o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.019 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.011 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ o
doses NNS o
of IN o
supplemental JJ o
analgesics NNS o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.010 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
; : N
and CC N
global JJ o
assessment NN o
scores NNS o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.018 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
= VBZ N
0.005 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
and CC N
week NN N
4 CD N
( ( N
P NNP N
= VBZ N
0.013 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.023 CD N
vs NN N
CA NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
HI1 NNP i
and CC N
CA NNP i
in IN N
any DT N
efficacy NN o
variable JJ N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN o
of IN o
patients NNS o
experiencing VBG o
adverse JJ o
events NNS o
in IN N
the DT N
HI2 NNP N
( ( N
127 CD N
; : N
83 CD N
% NN N
) ) N
, , N
HI1 NNP i
( ( N
124 CD N
; : N
79.5 CD N
% NN N
) ) N
, , N
and CC N
CA NNP i
( ( N
129 CD N
; : N
80.6 CD N
% NN N
) ) N
groups NNS N
. . N

However RB N
, , N
the DT N
mean JJ o
number NN o
of IN o
patients NNS o
who WP o
discontinued VBD o
treatment NN o
due JJ o
to TO o
adverse JJ o
events NNS o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP i
group NN N
( ( N
40 CD N
; : N
26.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
HI1 NNP i
group NN N
( ( N
23 CD N
; : N
14.7 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
hydrocodone NN i
7.5 CD N
mg NN N
and CC i
ibuprofen $ i
200 CD N
mg NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
1-tablet JJ N
doses NNS N
of IN N
this DT N
combination NN N
or CC N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC i
acetaminophen $ i
300 CD N
mg NN N
. . N

Moreover RB N
, , N
1-tablet JJ N
doses NNS N
of IN N
combination NN i
hydrocodone NN i
7.5 CD i
mg NN i
and CC i
ibuprofen $ i
200 CD N
mg NN N
may MD N
be VB N
as RB N
effective JJ N
as IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC i
acetaminophen $ i
300 CD N
mg NN N
. . N

-DOCSTART- -8966003- O O

[ JJ N
Drug NNP N
therapy NN N
of IN N
condylomata NN p
acuminata NNS p
] RB p
. . N

This DT N
study NN N
seeks VBZ N
to TO N
evaluate VB N
two CD N
candidate NN N
regimens NNS N
( ( i
5-fluorouracil JJ i
and CC N
interferon NN i
) ) i
as IN N
adjuvants NNS N
to TO N
optimally RB N
performed VBN N
laser NN i
surgery NN i
in IN N
the DT N
treatment NN p
of IN p
condylomata NN o
acuminata NNS o
. . o

Skillful NNP N
laser NN N
ablation NN N
can MD N
remove VB N
any DT N
volume NN N
of IN N
human JJ N
papillomavirus-associated JJ N
vulvar NN N
disease NN N
but CC N
can MD N
not RB N
prevent VB N
reactivation NN N
of IN N
the DT N
surrounding VBG N
latent JJ N
viral JJ N
reservoir NN N
during IN N
postoperative JJ N
healing NN N
. . N

Conversely RB N
, , N
interferon NN i
and CC N
5-fluorouracil JJ i
are VBP N
relatively RB N
ineffective JJ N
as IN N
primary JJ N
therapies NNS N
. . N

This DT N
study NN N
involves VBZ N
118 CD p
evaluable JJ p
patients NNS p
: : p
32 CD p
in IN p
the DT p
laser-CO2 JJ i
group NN p
, , p
34 CD p
in IN p
the DT p
5-fluorouracil JJ i
group NN i
and CC i
52 CD i
in IN i
the DT i
interferon NN i
group NN i
. . i

At IN N
assessment NN N
of IN N
final JJ N
outcome NN N
, , N
it PRP N
was VBD N
found VBN N
that IN N
43 CD N
of IN N
52 CD N
( ( N
82 CD N
% NN N
) ) N
assessable JJ N
patients NNS N
in IN N
the DT N
adjuvant JJ N
interferon NN i
arm NN N
were VBD N
controlled VBN o
by IN N
a DT N
single JJ o
laser NN o
ablation NN o
as IN N
compared VBN N
with IN N
only RB N
17 CD N
of IN N
34 CD N
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
5-fluorouracil JJ i
group NN N
and CC N
13 CD N
of IN N
32 CD N
( ( N
40 CD N
% NN N
) ) N
in IN N
the DT N
laser NN i
alone RB i
group NN N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
outcome NN N
within IN N
the DT N
5-fluorouracil JJ i
and CC N
laser VBZ N
only RB N
arms NNS N
. . N

Conversely RB N
, , N
a DT N
relatively RB N
low JJ N
dose NN N
of IN N
recombinant JJ N
interferon NN i
, , N
used VBN N
in IN N
combination NN N
with IN N
effective JJ N
surgical JJ i
deleulking NN i
, , N
can MD N
markedly RB N
reduce VB N
the DT N
risk NN N
of IN N
postoperative JJ o
recurrence NN o
. . o

-DOCSTART- -10439763- O O

Preoperative JJ N
small-dose JJ N
ketamine NN i
has VBZ N
no DT N
preemptive JJ N
analgesic JJ N
effect NN N
in IN N
patients NNS p
undergoing JJ p
total JJ p
mastectomy NN p
. . p

UNLABELLED IN N
We PRP N
evaluated VBD N
the DT N
preemptive JJ N
analgesic JJ N
effect NN N
of IN N
a DT N
small JJ N
dose NN N
of IN N
ketamine NN i
given VBN N
before IN N
or CC N
immediately RB N
after IN N
surgery NN N
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
study NN N
performed VBD N
in IN N
128 CD p
women NNS p
undergoing VBG p
total JJ p
mastectomy NN p
. . p

Group NNP N
1 CD N
patients NNS N
received VBD N
ketamine JJ i
0.15 CD i
mg/kg NN i
as IN i
a DT i
5-mL JJ i
i.v NN i
. . i

injection NN i
5 CD i
min NN i
before IN i
surgery NN i
and CC i
isotonic JJ i
saline NN i
5 CD i
mL NN i
i.v NN i
. . i

at IN N
the DT N
time NN N
of IN N
skin JJ N
closure NN N
. . N

Group NNP N
2 CD N
received VBD N
5 CD i
mL NN i
i.v NN i
. . i

of IN i
isotonic JJ i
saline NN i
, , i
then RB i
0.15 CD i
mg/kg NNS i
i.v NN i
. . i

ketamine NN i
. . i

A DT N
standard JJ N
general JJ N
anesthesia NN N
procedure NN N
including VBG N
sufentanil NN N
was VBD N
used VBN N
. . N

In IN N
the DT N
recovery NN N
room NN N
, , N
patient-controlled JJ N
analgesia NN N
i.v NN N
. . N

morphine NN N
was VBD N
used VBN N
for IN N
postoperative JJ N
analgesia NN N
. . N

Postoperative JJ N
pain NN N
was VBD N
assessed VBN N
by IN N
measuring VBG N
morphine JJ o
consumption NN o
and CC o
visual JJ o
analog NN o
scale NN o
pain NN o
scores NNS o
. . o

No DT N
significant JJ N
intergroup NN N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
pain NN o
scores NNS o
. . o

Patient-controlled JJ o
analgesia JJ o
morphine NN o
consumption NN o
was VBD N
lower JJR N
during IN N
the DT N
first JJ N
2 CD N
h NN N
after IN N
surgery NN N
in IN N
patients NNS N
given VBN N
ketamine VBP i
at IN N
the DT N
time NN N
of IN N
skin JJ N
closure NN N
. . N

No DT N
patient NN N
complained VBD N
of IN N
hallucinations NNS o
or CC N
nightmares NNS o
. . o

The DT N
incidence NN o
of IN o
adverse JJ o
effects NNS o
was VBD N
not RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
administering VBG N
ketamine NN i
at IN N
the DT N
end NN N
of IN N
surgery NN N
is VBZ N
more RBR N
effective JJ N
in IN N
reducing VBG N
morphine NN o
consumption NN o
than IN N
it PRP N
is VBZ N
when WRB N
given VBN N
before RB N
surgery NN N
. . N

IMPLICATIONS NNP N
We PRP N
administered VBD N
the DT N
same JJ N
small JJ N
dose NN N
of IN N
ketamine NN i
before IN N
or CC N
after IN N
surgery NN N
. . N

The DT N
preoperative JJ N
administration NN N
of IN N
0.15 CD N
mg/kg NNS N
ketamine NN i
in IN N
patients NNS p
undergoing JJ p
total JJ p
mastectomy NN p
did VBD N
not RB N
elicit VB N
a DT N
preemptive JJ N
analgesic JJ N
effect NN N
. . N

Ketamine VB i
given VBN N
at IN N
closure NN N
reduced VBD N
the DT N
patient-controlled JJ o
analgesia NN o
morphine NN o
requirement NN o
in IN N
the DT N
first JJ N
2 CD N
h NN N
after IN N
surgery NN N
. . N

-DOCSTART- -9342133- O O

Effect NN N
of IN N
esmolol JJ i
pretreatment NN N
on IN N
EEG NNP o
seizure NN o
morphology NN o
in IN N
RUL NNP N
ECT NNP N
. . N

Intravenous JJ N
beta-blockers NNS N
are VBP N
an DT N
effective JJ N
means NNS N
of IN N
controlling VBG N
heart NN o
rate NN o
and CC o
blood NN o
pressure NN o
during IN N
electroconvulsive JJ i
therapy NN i
( ( i
ECT NNP i
) ) i
, , N
but CC N
have VBP N
been VBN N
shown VBN N
to TO N
decrease VB N
seizure NN N
duration NN N
. . N

While IN N
the DT N
importance NN N
of IN N
seizure NN N
duration NN N
to TO N
the DT N
antidepressant JJ N
response NN N
of IN N
ECT NNP N
grows VBZ N
less JJR N
certain JJ N
, , N
there EX N
is VBZ N
growing VBG N
evidence NN N
that IN N
seizure NN N
morphology NN N
predicts VBZ N
the DT N
antidepressant JJ N
effect NN N
of IN N
ECT NNP N
. . N

This DT N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
esmolol JJ i
pretreatment NN N
on IN N
seizure NN o
morphology NN o
. . o

Eighteen NNP p
depressed VBD p
patients NNS p
( ( p
6 CD p
men NNS p
, , p
12 CD p
women NNS p
; : p
69 CD p
+/- JJ p
12.8 CD p
years NNS p
old JJ p
) ) p
received VBD p
ECT NNP i
with IN i
and CC i
without IN i
esmolol JJ i
pretreatment NN i
in IN N
a DT N
randomized JJ N
, , N
blinded VBD N
crossover NN N
design NN N
. . N

The DT N
seizures NNS N
were VBD N
blindly RB N
rated VBN N
for IN N
duration NN o
of IN o
motor NN o
convulsion NN o
, , o
duration NN o
of IN o
electroencephalogram NN o
( ( o
EEG NNP o
) ) o
seizure NN o
, , o
degree NN o
of IN o
seizure NN o
regularity NN o
, , o
and CC o
degree NN o
of IN o
postictal JJ o
EEG NNP o
suppression NN o
. . o

Esmolol NNP N
shortened VBD N
the DT N
duration NN N
of IN N
the DT N
motor NN N
convulsion NN N
and CC N
degraded VBD N
the DT N
quality NN o
of IN o
the DT o
ictal JJ o
regularity NN o
. . o

Routine JJ N
administration NN N
of IN N
intravenous JJ N
esmolol NN N
before IN N
ECT NNP N
may MD N
cause VB N
a DT N
decrease NN N
in IN N
ictal JJ o
regularity NN o
. . o

Careful JJ N
consideration NN N
should MD N
be VB N
given VBN N
to TO N
the DT N
potential JJ N
benefits NNS N
of IN N
esmolol NN N
versus IN N
the DT N
deleterious JJ N
effect NN N
on IN N
the DT N
electrophysiologic JJ N
process NN N
. . N

Esmolol NN N
may MD N
still RB N
be VB N
indicated VBN N
on IN N
a DT N
case-by-case JJ N
basis NN N
for IN N
extreme JJ N
tachycardia NN N
or CC N
hypertension NN N
associated VBN N
with IN N
ECT NNP N
, , N
and CC N
presumably RB N
poses VBZ N
no DT N
problem NN N
for IN N
the DT N
therapeutic JJ N
effect NN N
of IN N
ECT NNP N
if IN N
given VBN N
after IN N
the DT N
seizure NN N
is VBZ N
over IN N
. . N

-DOCSTART- -23428834- O O

Low JJ N
body NN N
mass NN N
index NN N
and CC N
dyslipidemia NN N
in IN N
dialysis NN i
patients NNS p
linked VBN N
to TO N
elevated VBN N
plasma NN N
fibroblast NN N
growth NN N
factor NN N
23 CD N
. . N

BACKGROUND NNP N
Fibroblast NNP N
growth NN N
factor NN N
23 CD N
( ( N
FGF23 NNP N
) ) N
has VBZ N
been VBN N
associated VBN N
with IN N
death NN N
in IN N
dialysis NN i
patients NNS p
. . p

Since IN N
FGF23 NNP N
shares NNS N
structural JJ N
features NNS N
with IN N
FGF19 NNP N
subfamily RB N
members NNS N
that IN N
exert JJ N
hormonal JJ N
control NN N
of IN N
fat JJ N
mass NN N
, , N
we PRP N
hypothesized VBD N
that DT N
high JJ N
circulating NN N
FGF23 NNP N
concentrations NNS N
would MD N
be VB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
a DT N
uremic JJ N
lipid NN N
profile NN N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
conducted VBN N
among IN N
654 CD p
patients NNS p
receiving VBG p
chronic JJ p
hemodialysis NN i
. . i

C-terminal JJ o
FGF23 NNP o
concentrations NNS o
were VBD i
measured VBN i
in IN i
stored JJ i
plasma NN i
samples NNS i
. . i

Linear JJ i
regression NN i
was VBD i
used VBN i
to TO i
examine VB i
the DT i
cross-sectional JJ i
associations NNS i
of IN i
plasma NN o
FGF23 NNP o
concentrations NNS o
with IN o
BMI NNP o
, , o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
low-density JJ o
lipoprotein-cholesterol NN o
( ( o
LDL-C NNP o
) ) o
, , o
high-density JJ o
lipoprotein-cholesterol NN o
( ( o
HDL-C NNP o
) ) o
and CC o
triglycerides NNS o
. . o

Cox NNP N
proportional JJ N
hazard NN N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
association NN N
between IN N
FGF23 NNP N
concentrations NNS N
and CC N
all-cause JJ N
mortality NN N
. . N

RESULTS JJ N
Participants NNS p
had VBD p
a DT p
mean JJ p
age NN p
of IN p
60 CD p
? . p
11 CD p
years NNS p
and CC p
a DT p
median JJ p
( ( p
IQR NNP p
) ) p
FGF23 NNP p
concentration NN p
of IN p
4,212 CD p
( ( p
1,411-13,816 JJ p
) ) p
RU/ml NNP p
. . p

An DT N
increase NN N
per IN N
SD NNP N
in IN N
log10 JJ N
FGF23 NNP N
was VBD N
associated VBN N
with IN N
lower JJR N
BMI NNP N
( ( N
? . N
= NNP N
-1.11 NNP N
; : N
p VBZ N
= $ N
0.008 CD N
) ) N
, , N
TC NNP N
( ( N
? . N
= NNP N
-6.46 NNP N
; : N
p VBZ N
= $ N
0.02 CD N
) ) N
, , N
LDL-C NNP N
( ( N
? . N
= NNP N
-4.73 NNP N
; : N
p VBZ N
= $ N
0.04 CD N
) ) N
and CC N
HDL-C NNP N
( ( N
? . N
= NNP N
-2.14 NNP N
; : N
p VBZ N
= $ N
0.03 CD N
) ) N
; : N
after IN N
adjusting VBG N
for IN N
age NN N
, , N
gender NN N
, , N
race NN N
, , N
cardiovascular JJ N
risk NN N
factors NNS N
, , N
serum NN N
albumin NN N
, , N
markers NNS N
of IN N
mineral JJ N
metabolism NN N
, , N
and CC N
use NN N
of IN N
lipid-lowering JJ N
drugs NNS N
. . N

The DT N
association NN N
of IN N
FGF23 NNP N
with IN N
death NN N
was VBD N
attenuated VBN N
after IN N
adjustment NN N
for IN N
HDL-C NNP N
( ( N
HR NNP N
of IN N
highest JJS N
quartile NN N
1.53 CD N
, , N
95 CD N
% NN N
CI NNP N
1.06-2.20 CD N
compared VBN N
to TO N
lowest VB N
quartile NN N
) ) N
. . N

CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
higher JJR N
plasma NN N
FGF23 NNP N
levels NNS N
are VBP N
associated VBN N
with IN N
lower JJR N
BMI NNP N
and CC N
dyslipidemia NN i
in IN i
dialysis NN i
patients NNS i
. . p

The DT p
association NN N
between IN N
FGF23 NNP N
and CC N
death NN N
may MD N
be VB N
mediated VBN N
through IN N
unexplored JJ N
metabolic JJ N
risk NN N
factors NNS N
unrelated VBD N
to TO N
mineral JJ N
metabolism NN N
. . N

-DOCSTART- -25294011- O O

Effect NN N
of IN N
orlistat NN i
on IN N
weight JJ o
loss NN o
, , o
hormonal JJ o
and CC o
metabolic JJ o
profiles NNS o
in IN N
women NNS p
with IN p
polycystic JJ p
ovarian JJ p
syndrome NN p
: : p
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

-DOCSTART- -1960378- O O

Treatment NN p
of IN p
hepatitis NN p
B NNP p
virus NN p
infection NN p
with IN p
interferon NN i
. . i

Factors NNS N
predicting VBG N
response NN N
to TO N
interferon VB i
. . i

Several JJ N
randomised VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
alpha-interferon NN i
in IN N
the DT N
therapy NN N
of IN N
chronic JJ N
hepatitis NN N
B NNP N
. . N

In IN N
patients NNS p
with IN p
HBe NNP p
antigen-positive JJ p
disease NN p
acquired VBD p
in IN p
adult NN p
life NN p
the DT N
response NN N
rates NNS N
vary VBP N
from IN N
25-50 CD N
% NN N
. . N

In IN N
those DT N
infected VBN N
at IN N
birth NN N
, , N
response NN N
rates NNS N
are VBP N
lower JJR N
. . N

Twenty-one CD p
pretreatment JJ p
variables NNS p
were VBD p
assessed VBN p
for IN p
their PRP$ p
significance NN p
in IN p
response NN o
prediction NN p
using VBG p
data NNS p
from IN p
114 CD p
patients NNS p
given VBN p
alpha-interferon NNS i
for IN p
chronic JJ p
hepatitis NN p
B NNP p
virus NN p
infection NN p
. . p

In IN N
those DT N
patients NNS N
who WP N
had VBD N
received VBN N
a DT N
minimum NN N
of IN N
90 CD N
million CD N
units NNS N
per IN N
m2 NN N
total NN N
dose NN N
over IN N
12 CD N
weeks NNS N
, , N
a DT N
negative JJ N
anti-human JJ o
immunodeficiency NN o
virus NN o
antibody NN o
status NN o
( ( N
p RB N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
chronic JJ o
active JJ o
hepatitis NN o
on IN o
liver NN o
biopsy NN o
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
, , N
high JJ N
AST NNP o
level NN o
( ( N
p RB N
less JJR N
than IN N
0.001 CD N
) ) N
, , N
low JJ N
hepatitis NN o
B NNP o
virus NN o
DNA NNP o
level NN o
( ( N
p RB N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
a DT N
history NN N
of IN N
acute JJ o
hepatitis NN o
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
were VBD N
all DT N
associated VBN N
with IN N
an DT N
increased VBN N
likelihood NN N
of IN N
response NN N
on IN N
univariate JJ N
analysis NN N
. . N

On IN N
stepwise NN N
logistic JJ N
regression NN N
analysis NN N
, , N
hepatitis NN N
B NNP N
virus NN N
DNA NNP N
, , N
AST NNP N
and CC N
a DT N
history NN N
of IN N
acute JJ N
hepatitis NN N
predicted VBD N
response NN N
independently RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
most RBS N
reliable JJ N
combination NN N
of IN N
predictive JJ N
factors NNS N
was VBD N
a DT N
negative JJ N
anti-human JJ o
immunodeficiency NN o
virus NN o
antibody NN o
status NN o
, , N
with IN N
either DT N
a DT N
positive JJ N
history NN N
of IN N
acute JJ o
icteric JJ o
hepatitis NN o
and CC N
AST NNP N
greater JJR N
than IN N
45 CD N
IU NNP N
per IN N
liter NN N
or CC N
no DT N
history NN N
of IN N
acute JJ N
icteric JJ N
hepatitis NN N
and CC N
AST NNP N
greater JJR N
than IN N
85 CD N
IU NNP N
per IN N
liter NN N
, , N
which WDT N
predicted VBD N
response NN N
in IN N
77 CD N
% NN N
with IN N
a DT N
specificity NN N
of IN N
79 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
loss NN N
of IN N
HBsAg NNP o
in IN N
addition NN N
to TO N
HBeAg NNP o
and CC N
hepatitis NN o
B NNP o
virus NN o
DNA NN o
was VBD N
more RBR N
likely JJ N
to TO N
occur VB N
in IN N
patients NNS p
with IN N
chronic JJ N
infection NN N
of IN N
less JJR N
than IN N
2 CD N
years NNS N
duration NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

-DOCSTART- -23590124- O O

Is VBZ N
the DT N
effect NN N
of IN N
mobile JJ i
phone NN i
radiofrequency NN i
waves NNS i
on IN N
human JJ N
skin JJ N
perfusion NN N
non-thermal JJ N
? . N
OBJECTIVE UH N
To TO N
establish VB N
whether IN N
SkBF NNP o
can MD N
be VB N
modified VBN N
by IN N
exposure NN N
to TO N
the DT N
radiofrequency NN i
waves NNS i
emitted VBN i
by IN i
a DT i
mobile JJ i
phone NN i
when WRB N
the DT N
latter NN N
is VBZ N
held VBN N
against IN N
the DT N
jaw NN N
and CC N
ear NN N
. . N

METHODS NNP N
Variations NNP o
in IN o
SkBF NNP o
and CC N
Tsk NNP N
in IN N
adult NN p
volunteers NNS p
were VBD N
simultaneously RB N
recorded VBN i
with IN i
a DT i
thermostatic JJ i
laser NN i
Doppler NNP i
system NN i
during IN i
a DT i
20-minute JJ i
radiofrequency NN i
exposure NN i
session NN i
and CC i
a DT i
20-minute JJ i
sham NN i
session NN i
. . i

The DT N
skin JJ N
microvessels NNS N
' POS N
vasodilatory NN N
reserve NN N
was VBD N
assessed VBN N
with IN N
a DT N
heat NN N
challenge NN N
at IN N
the DT N
end NN N
of IN N
the DT N
protocol NN N
. . N

RESULTS NNP N
During IN N
the DT N
radiofrequency NN i
exposure NN i
session NN i
, , N
SkBF NNP o
increased VBD N
( ( N
vs. FW N
baseline NN N
) ) N
more JJR N
than IN N
during IN N
the DT N
sham JJ i
exposure NN i
session NN i
. . i

The DT N
sessions NNS N
did VBD N
not RB N
differ VB N
significant JJ N
in IN N
terms NNS N
of IN N
the DT N
Tsk NNP o
time-course JJ o
response NN o
. . o

The DT N
skin JJ o
microvessels NNS o
' POS o
vasodilatory NN o
ability NN o
was VBD N
found VBN N
to TO N
be VB N
greater JJR N
during IN N
radiofrequency NN N
exposure NN N
than IN N
during IN N
sham JJ N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
reveal VBP N
the DT N
existence NN N
of IN N
a DT N
specific JJ N
vasodilatory JJ o
effect NN N
of IN N
mobile JJ i
phone NN i
radiofrequency NN i
emission NN i
on IN N
skin JJ N
perfusion NN N
. . N

-DOCSTART- -24315548- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
cutting VBG i
balloon NN i
angioplasty JJ i
versus NN N
high-pressure NN i
balloon NN i
angioplasty NN i
in IN N
hemodialysis NN p
arteriovenous JJ p
fistula NN p
stenoses VBZ p
resistant JJ p
to TO p
conventional JJ p
balloon NN p
angioplasty NN p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
cutting VBG i
balloon NN i
angioplasty NN i
( ( i
CBA NNP i
) ) i
versus IN i
high-pressure NN i
balloon NN i
angioplasty NN i
( ( i
HPBA NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
hemodialysis NN p
autogenous JJ p
fistula NN p
stenoses VBZ p
resistant JJ p
to TO p
conventional JJ p
percutaneous JJ p
transluminal JJ p
angioplasty NN p
( ( p
PTA NNP p
) ) p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
patients NNS p
with IN p
dysfunctional JJ p
, , p
stenotic JJ p
hemodialysis NN p
arteriovenous JJ p
fistulas NNS p
( ( p
AVFs NNP p
) ) p
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
CBA NNP i
or CC N
HPBA NNP i
if IN N
conventional JJ N
PTA NNP N
had VBD N
suboptimal JJ N
results NNS N
( ( N
ie JJ N
, , N
residual JJ N
stenosis NN N
> VBD N
30 CD N
% NN N
) ) N
. . N

A DT N
total NN p
of IN p
516 CD p
patients NNS p
consented VBN p
to TO p
participate VB p
in IN p
the DT p
study NN p
from IN p
October NNP p
2008 CD p
to TO p
September NNP p
2011 CD p
, , p
85 CD p
% NN p
of IN p
whom WP p
( ( p
n JJ p
= NNP p
439 CD p
) ) p
had VBD p
technically RB p
successful JJ p
conventional JJ p
PTA NNP p
. . p

The DT N
remaining VBG N
71 CD p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
60 CD p
y NN p
; : p
49 CD p
men NNS p
) ) p
with IN p
suboptimal JJ p
PTA NNP p
results NNS p
were VBD N
eventually RB N
randomized VBN N
: : N
36 CD N
to TO N
the DT N
CBA NNP i
arm NN N
and CC N
35 CD N
to TO N
the DT N
HPBA NNP N
arm NN N
. . N

Primary JJ N
and CC N
secondary JJ N
target NN N
lesion NN N
patencies NNS N
were VBD N
determined VBN N
by IN N
Kaplan-Meier NNP N
analysis NN N
. . N

RESULTS NNP N
Clinical JJ o
success NN o
rates NNS o
were VBD N
100 CD N
% NN N
in IN N
both DT N
arms NNS N
. . N

Primary JJ o
target NN o
lesion NN o
patency NN o
rates NNS o
at IN N
6 CD N
months NNS N
were VBD N
66.4 CD N
% NN N
and CC N
39.9 CD N
% NN N
for IN N
CBA NNP i
and CC N
HPBA NNP i
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Secondary JJ o
target NN o
lesion NN o
patency NN o
rates NNS o
at IN N
6 CD N
months NNS N
were VBD N
96.5 CD N
% NN N
for IN N
CBA NNP i
and CC N
80.0 CD N
% NN N
for IN N
HPBA NNP i
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

There EX N
was VBD N
a DT N
single JJ N
major JJ o
complication NN o
of IN N
venous JJ o
perforation NN o
following VBG N
CBA NNP i
. . i

The DT N
30-day JJ o
mortality NN o
rate NN o
was VBD N
1.4 CD N
% NN N
, , N
with IN N
one CD N
non-procedure-related JJ N
death NN N
in IN N
the DT N
HPBA NNP i
group NN N
. . N

CONCLUSIONS NNP N
Primary NNP N
and CC N
secondary JJ N
target NN N
lesion NN N
patency NN N
rates NNS N
of IN N
CBA NNP i
were VBD N
statistically RB N
superior JJ N
to TO N
those DT N
of IN N
HPBA NNP i
following VBG N
suboptimal JJ N
conventional JJ N
PTA NNP N
. . N

For IN N
AVF NNP N
stenoses VBZ N
resistant JJ N
to TO N
conventional JJ N
PTA NNP N
, , N
CBA NNP i
may MD N
be VB N
a DT N
better JJR N
second-line JJ N
treatment NN N
given VBN N
its PRP$ N
superior JJ N
patency NN N
rates NNS N
. . N

-DOCSTART- -3292597- O O

Antihypertensive JJ o
efficacy NN o
of IN N
cetamolol NN i
: : i
a DT N
dose-titrated JJ N
study NN N
. . N

This DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
multicenter NN N
study NN N
evaluated VBD N
the DT N
antihypertensive JJ o
efficacy NN o
and CC o
safety NN o
of IN N
cetamolol JJ i
hydrochloride NN i
in IN N
108 CD p
patients NNS p
diagnosed VBN p
as IN p
having VBG p
mild NN p
to TO p
moderate VB p
hypertension NN p
. . p

After IN N
a DT N
placebo JJ i
lead-in JJ N
period NN N
, , N
patients NNS N
received VBD N
either DT N
cetamolol JJ i
5-10-15 JJ i
mg/d NN i
( ( N
low JJ N
dose NN N
) ) N
, , N
cetamolol JJ i
15-25-50 JJ i
mg/d NN i
( ( N
high JJ N
dose NN N
) ) N
, , N
or CC N
placebo NN i
, , N
once RB N
daily JJ N
for IN N
four CD N
weeks NNS N
. . N

Patients NNS N
began VBD N
at IN N
the DT N
lowest JJS N
dose NN N
and CC N
were VBD N
titrated VBN N
to TO N
higher JJR N
doses NNS N
based VBN N
on IN N
the DT N
first JJ N
two CD N
assessments NNS N
of IN N
diastolic JJ o
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
, , N
which WDT N
were VBD N
conducted VBN N
each DT N
week NN N
after IN N
double-blind JJ N
treatment NN N
was VBD N
dispensed VBN N
. . N

After IN N
four CD N
weeks NNS N
of IN N
treatment NN N
82.4 CD N
% NN N
, , N
81.3 CD N
% NN N
, , N
and CC N
93.3 CD N
% NN N
of IN N
the DT N
low-dose JJ i
group NN N
, , N
high-dose JJ i
group NN N
, , N
and CC N
placebo NN i
group NN N
, , N
respectively RB N
, , N
were VBD N
titrated VBN N
to TO N
the DT N
maximum JJ N
dose JJ N
level NN N
. . N

After IN N
four CD N
weeks NNS N
of IN N
treatment NN N
and CC N
24 CD N
hours NNS N
since IN N
the DT N
patient NN N
's POS N
last JJ N
dose NN N
, , N
both DT N
cetamolol NN i
groups NNS N
showed VBD N
a DT N
significantly RB N
greater JJR N
( ( N
P NNP N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
.05 VB N
) ) N
reduction NN N
in IN N
supine JJ o
systolic/diastolic JJ o
blood NN o
pressure NN o
( ( N
-18.1 JJ N
+/- JJ N
2.3/-9.2 JJ N
+/- JJ N
1.5 CD N
mm NN N
Hg NNP N
[ NNP N
low JJ N
dose NN N
] NN N
and CC N
-17.3 JJ N
+/- JJ N
2.3/-8.3 JJ N
+/- JJ N
1.6 CD N
mm NN N
Hg NNP N
[ NNP N
high JJ N
dose RB N
] NNP N
) ) N
than IN N
the DT N
placebo NN N
group NN N
( ( N
-9.9 JJ N
+/- JJ N
2.5/-3.5 JJ N
+/- JJ N
1.7 CD N
mm NN N
Hg NNP N
) ) N
. . N

In IN N
general JJ N
, , N
the DT N
changes NNS o
in IN o
standing VBG o
( ( o
stabilized VBN o
) ) o
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
in IN N
supine JJ N
measurements NNS N
. . N

Significantly RB N
more RBR N
patients NNS N
receiving VBG N
cetamolol NN N
than IN N
those DT N
receiving VBG N
placebo NN N
showed VBD N
a DT N
good JJ N
response NN N
( ( N
a DT N
decrease NN N
in IN N
diastolic JJ N
blood NN N
pressure NN N
of IN N
10 CD N
mm NNS N
Hg NNP N
or CC N
more JJR N
or CC N
measuring VBG N
less JJR N
than IN N
90 CD N
mm NNS N
Hg NNP N
with IN N
a DT N
decrease NN N
of IN N
at IN N
least JJS N
4 CD N
mm JJ N
Hg NNP N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -17276969- O O

Effects NNS N
of IN N
sibutramine NN i
on IN N
thermogenesis NN N
in IN N
obese JJ p
patients NNS p
assessed VBD N
via IN N
immersion NN N
calorimetry NN N
. . N

Glucose NNP N
utilization JJ N
studies NNS N
show VBP N
that IN N
sibutramine-induced JJ i
thermogenesis NN N
is VBZ N
mediated VBN N
via IN N
selective JJ N
sympathetic JJ N
activation NN N
of IN N
brown JJ N
adipose JJ N
tissue NN N
. . N

The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
use VB N
a DT N
new JJ N
calorimetry NN N
method NN N
in IN N
which WDT N
resting VBG N
metabolic JJ N
rate NN N
is VBZ N
enhanced VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
sibutramine JJ i
treatment NN N
on IN N
thermogenesis NN N
. . N

Sixty NNP p
obese JJ p
women NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Subjects NNS N
were VBD p
divided VBN p
into IN p
2 CD p
equal JJ p
groups-the JJ p
placebo NN i
and CC N
sibutramine JJ i
treatment NN N
groups NNS N
. . N

The DT N
sibutramine NN i
group NN N
was VBD N
given VBN N
sibutramine JJ i
10 CD N
mg JJ N
daily RB N
for IN N
12 CD N
wk NN N
. . N

At IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
12-wk JJ N
treatment NN N
period NN N
, , N
thermogenic JJ N
measurements NNS N
were VBD N
taken VBN N
with IN N
the DT N
use NN N
of IN N
water NN o
immersion NN o
calorimetry NN o
. . o

Subjects NNS N
were VBD N
examined VBN N
at IN N
weeks NNS N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
of IN N
treatment NN N
to TO N
identify VB N
adverse JJ N
effects NNS N
. . N

Body NNP o
mass NN o
index NN o
, , N
measured VBN N
at IN N
31.5+/-2.05 JJ N
kg/m2 NN N
in IN N
the DT N
placebo NN N
group NN N
, , N
decreased VBN N
to TO N
30.4+/-2.94 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
after IN N
12 CD N
wk NN N
( ( N
P=.07 NNP N
) ) N
. . N

In IN N
the DT N
sibutramine NN i
group NN N
, , N
it PRP N
decreased VBD N
from IN N
33.5+/-4.1 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
to TO N
30.9+/-4.8 JJ N
kg/m NN N
( ( N
2 CD N
) ) N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

In IN N
the DT N
sibutramine NN i
group NN N
, , N
mean VBP o
thermogenic JJ o
response NN o
changed VBD N
from IN N
a DT N
baseline NN N
value NN N
of IN N
1.27+/-0.29 JJ N
kcal/kg/h NN N
to TO N
1.44+/-0.13 JJ N
kcal/kg/h NN N
after IN N
12 CD N
wk NN N
of IN N
treatment NN N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
the DT N
baseline NN N
value NN N
was VBD N
1.56+/-0.27 JJ N
kcal/kg/h NN N
; : N
it PRP N
changed VBD N
to TO N
1.33+/-0.36 JJ N
kcal/kg/h NN N
at IN N
the DT N
end NN N
of IN N
12 CD N
wk NN N
. . N

The DT N
findings NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
sibutramine NN N
treatment NN N
promotes VBZ N
thermogenesis NN o
, , N
thus RB N
facilitating VBG N
weight JJ o
loss NN o
. . o

Calorimetry NNP N
enhances VBZ N
resting VBG o
metabolism NN o
through IN N
more RBR N
efficient JJ N
heat NN o
transfer NN o
from IN o
the DT o
body NN o
. . o

-DOCSTART- -2188871- O O

Oral JJ i
S-adenosylmethionine NNP i
in IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
intrahepatic JJ o
cholestasis NN o
. . o

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

Parenteral JJ N
S-adenosylmethionine JJ i
proved VBN N
to TO N
be VB N
effective JJ N
in IN N
reversing VBG N
intrahepatic JJ o
cholestasis NN o
in IN N
pregnant JJ N
women NNS N
. . N

Based VBN N
on IN N
these DT N
findings NNS N
, , N
a DT N
prospective JJ N
multicenter NN p
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
planned VBN N
to TO N
assess VB N
whether IN N
oral JJ i
S-adenosylmethionine NNP i
is VBZ N
effective JJ N
in IN N
cholestatic JJ o
patients NNS o
with IN p
chronic JJ p
liver NN p
disease NN p
. . p

Accordingly RB N
, , N
220 CD p
inpatients NNS p
( ( p
26 CD p
% NN p
chronic JJ p
active JJ p
hepatitis NN p
, , p
68 CD p
% NN p
cirrhosis NN p
, , p
6 CD p
% NN p
primary JJ p
biliary JJ p
cirrhosis NN p
) ) p
with IN p
stable JJ p
( ( p
1 CD p
month NN p
or CC p
more JJR p
) ) p
at IN p
least JJS p
twofold JJ p
increases NNS p
in IN p
serum JJ o
total NN o
and CC o
conjugated VBD o
bilirubin NN o
and CC o
alkaline JJ o
phosphatase NN o
volunteered VBD p
for IN p
the DT p
trial NN p
. . p

Serum NNP o
markers NNS o
of IN o
cholestasis NN o
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
decreased VBN N
after IN N
oral JJ N
S-adenosylmethionine JJ i
administration NN N
( ( N
1600 CD N
mg/day NN N
) ) N
, , N
and CC N
their PRP$ N
values NNS N
were VBD N
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
lower JJR N
than IN N
the DT N
corresponding JJ N
values NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

S-adenosylmethionine NNP i
significantly RB N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
improved VBN N
subjective JJ o
symptoms NNS o
such JJ o
as IN o
pruritus NN o
, , o
fatigue NN o
, , o
and CC o
feeling NN o
of IN o
being VBG o
unwell JJ o
, , N
whereas JJ N
placebo NN N
was VBD N
ineffective JJ N
. . N

Two CD N
patients NNS N
in IN N
the DT N
S-adenosylmethionine NNP i
group NN N
and CC N
9 CD N
controls NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
withdrew NN N
from IN N
the DT N
trial NN N
for IN N
reduced VBN N
compliance NN o
because IN N
of IN N
inefficacy NN o
of IN N
treatment NN N
. . N

Oral JJ N
S-adenosylmethionine NNP i
was VBD N
tolerated VBN o
to TO N
the DT N
same JJ N
extent NN N
as IN N
placebo NN N
. . N

In IN N
conclusion NN N
, , N
short-term JJ N
administration NN N
of IN N
oral JJ i
S-adenosylmethionine NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
improving VBG N
clinical JJ o
and CC o
laboratory JJ o
measures NNS o
of IN o
intrahepatic JJ o
cholestasis NN o
and CC N
offers VBZ N
a DT N
new JJ N
therapeutic JJ N
modality NN N
for IN N
the DT N
symptomatic JJ o
management NN o
of IN N
this DT N
syndrome NN N
. . N

-DOCSTART- -21148662- O O

Randomized VBN N
trial NN N
of IN N
angiotensin JJ i
II-receptor NNP i
blocker NN i
vs. FW N
dihydropiridine NN i
calcium NN i
channel NN i
blocker NN i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ p
atrial JJ p
fibrillation NN p
with IN p
hypertension NN p
( ( N
J-RHYTHM NNP N
II NNP N
study NN N
) ) N
. . N

AIMS NNP N
Atrial NNP N
fibrillation NN N
( ( N
AF NNP N
) ) N
is VBZ N
a DT N
common JJ N
arrhythmia NN N
frequently RB N
associated VBN N
with IN N
hypertension NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
lowering VBG N
blood NN N
pressure NN N
by IN N
angiotensin JJ i
II-receptor NNP i
blockers NNS i
( ( i
ARB NNP i
) ) i
has VBZ N
more JJR N
beneficial JJ N
effects NNS N
than IN N
by IN N
conventional JJ i
calcium NN i
channel NN i
blockers NNS i
( ( i
CCB NNP i
) ) i
on IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
with IN N
hypertension NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
Japanese JJ p
Rhythm NNP p
Management NNP p
Trial NNP p
II NNP p
for IN p
Atrial NNP p
Fibrillation NNP p
( ( p
J-RHYTHM NNP p
II NNP p
study NN p
) ) p
is VBZ N
an DT N
open-label JJ N
randomized JJ N
comparison NN N
between IN N
an DT N
ARB NNP i
( ( i
candesartan NN i
) ) i
and CC N
a DT N
CCB NNP i
( ( i
amlodipine NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
paroxysmal JJ N
AF NNP N
associated VBN N
with IN N
hypertension NN N
. . N

Using VBG N
daily JJ N
transtelephonic JJ i
monitoring NN i
, , N
we PRP N
examined VBD N
asymptomatic JJ N
and CC N
symptomatic JJ N
paroxysmal NN o
AF NNP o
episodes VBZ N
during IN N
a DT N
maximum JJ N
1 CD N
year NN N
treatment NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
difference NN o
in IN o
AF NNP o
frequency NN o
between IN N
the DT N
pre-treatment JJ N
period NN N
and CC N
the DT N
final JJ N
month NN N
of IN N
the DT N
follow-up NN N
. . N

The DT N
secondary JJ N
endpoints NNS N
included VBD N
cardiovascular JJ o
events NNS o
, , o
development NN o
of IN o
persistent JJ o
AF NNP o
, , o
left VBD o
atrial JJ o
dimension NN o
, , o
and CC o
quality-of-life NN o
( ( o
QOL NNP o
) ) o
. . o

The DT p
study NN p
enrolled VBD p
318 CD p
patients NNS p
( ( p
66 CD p
years NNS p
, , p
male/female JJ p
219/99 CD p
, , p
158 CD p
in IN p
the DT p
ARB NNP i
group NN p
and CC p
160 CD p
in IN p
the DT p
CCB NNP i
group NN p
) ) p
treated VBD p
at IN p
48 CD p
sites NNS p
throughout IN p
Japan NNP p
. . p

At IN p
baseline NN p
, , p
the DT p
frequency NN o
of IN o
AF NNP o
episodes NNS o
( ( p
days/month NN p
) ) p
was VBD p
3.8 CD p
? . p
5.0 CD p
in IN p
the DT p
ARB NNP p
group NN p
vs. FW p
4.8 CD p
? . p
6.3 CD p
in IN p
the DT p
CCB NNP p
group NN p
( ( p
not RB N
significant JJ N
) ) N
. . N

During IN N
the DT N
follow-up JJ o
, , o
blood NN o
pressure NN o
was VBD o
significantly RB N
lower JJR N
in IN N
the DT N
CCB NNP N
group NN N
than IN N
in IN N
the DT N
ARB NNP N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT o
AF NNP o
frequency NN o
decreased VBD o
similarly RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
endpoint NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT o
development NN o
of IN o
persistent JJ o
AF NNP o
, , o
changes NNS o
in IN o
left JJ o
atrial JJ o
dimension NN o
, , o
occurrence NN o
of IN o
cardiovascular JJ o
events NNS o
, , o
or CC o
changes NNS o
in IN o
QOL NNP o
. . o

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
paroxysmal JJ p
AF NNP p
and CC p
hypertension NN p
, , p
treatment NN N
of IN N
hypertension NN N
by IN N
candesartan NN i
did VBD i
not RB N
have VB N
an DT N
advantage NN N
over RP i
amlodipine NN i
in IN i
the DT N
reduction NN N
in IN N
the DT N
frequency NN N
of IN N
paroxysmal JJ N
AF NNP N
( ( N
umin JJ N
CTR NNP N
C000000427 NNP N
) ) N
. . N

-DOCSTART- -14690574- O O

[ NN N
Combined VBD N
preoperative JJ i
xeloda NN i
and CC i
radiotherapy NN i
for IN N
lower JJR p
rectal NN p
cancer NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
combined JJ i
preoperative JJ i
xeloda NN i
and CC i
pelvic JJ i
radiotherapy NN i
on IN N
locally RB p
advanced VBN p
lower JJR p
rectal JJ p
cancer NN p
. . p

METHODS NNP N
Sixty NNP p
lower JJR p
rectal JJ p
cancer NN p
patients NNS p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
groups NNS N
. . N

30 CD p
patients NNS p
( ( N
Group NNP N
A NNP N
) ) N
were VBD N
treated VBN N
with IN N
operation NN i
alone RB i
and CC N
30 CD N
patients NNS N
( ( N
Group NNP N
B NNP N
) ) N
were VBD N
treated VBN N
with IN N
xeloda NNP i
and CC i
radiotherapy NN i
before IN i
operation NN i
. . i

RESULTS VB N
The DT N
operative JJ o
resection NN o
, , o
anal JJ o
preservation NN o
and CC o
local JJ o
recurrence NN o
rates NNS o
were VBD N
86.66 CD N
% NN N
, , N
33.33 CD N
% NN N
, , N
15.38 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
100 CD N
% NN N
, , N
83.33 CD N
% NN N
, , N
0 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
and CC N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Combined VBD i
preoperative JJ i
xeloda NN i
and CC i
radiotherapy NN i
for IN N
lower JJR N
rectal NN N
cancer NN N
is VBZ N
able JJ N
to TO N
significantly RB N
improve VB N
the DT N
operative JJ N
resection NN N
, , N
anal JJ N
preservation NN N
and CC N
decrease VB N
the DT N
local JJ N
recurrence NN N
rates NNS N
. . N

-DOCSTART- -22903518- O O

Is VBZ N
EEG-biofeedback NNP i
an DT N
effective JJ N
treatment NN N
in IN N
autism NN p
spectrum NN p
disorders NNS p
? . N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

EEG-biofeedback NN i
has VBZ N
been VBN N
reported VBN N
to TO N
reduce VB N
symptoms NNS N
of IN N
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
in IN N
several JJ N
studies NNS N
. . N

However RB N
, , N
these DT N
studies NNS N
did VBD N
not RB N
control VB N
for IN N
nonspecific JJ N
effects NNS N
of IN N
EEG-biofeedback NNP i
and CC N
did VBD N
not RB N
distinguish VB N
between IN N
participants NNS N
who WP N
succeeded VBD N
in IN N
influencing VBG N
their PRP$ N
own JJ N
EEG NNP N
activity NN N
and CC N
participants NNS N
who WP N
did VBD N
not RB N
. . N

To TO N
overcome VB N
these DT N
methodological JJ N
shortcomings NNS N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
EEG-biofeedback NNP N
in IN N
ASD NNP N
in IN N
a DT N
randomized JJ N
pretest-posttest JJ N
control NN N
group NN N
design NN N
with IN N
blinded JJ N
active JJ N
comparator NN N
and CC N
six CD N
months NNS N
follow-up JJ N
. . N

Thirty-eight JJ p
participants NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
EEG-biofeedback NNP i
, , i
skin JJ i
conductance NN i
( ( i
SC NNP i
) ) i
-biofeedback NN i
or CC N
waiting VBG N
list NN N
group NN N
. . N

EEG- JJ i
and CC i
SC-biofeedback JJ i
sessions NNS N
were VBD N
similar JJ N
and CC N
participants NNS N
were VBD N
blinded VBN N
to TO N
the DT N
type NN N
of IN N
feedback NN N
they PRP N
received VBD N
. . N

Assessments NNS N
pre-treatment JJ N
, , N
post-treatment JJ N
, , N
and CC N
after IN N
6 CD N
months NNS N
included VBN N
parent JJ o
ratings NNS o
of IN o
symptoms NNS o
of IN o
ASD NNP o
, , o
executive NN o
function NN o
tasks NNS o
, , o
and CC o
19-channel JJ o
EEG NNP o
recordings NNS o
. . o

Fifty-four CD N
percent NN N
of IN N
the DT N
participants NNS N
significantly RB N
reduced VBD N
delta JJ o
and/or NN o
theta NN o
power NN o
during IN N
EEG-biofeedback JJ i
sessions NNS i
and CC N
were VBD N
identified VBN N
as IN N
EEG-regulators NNS N
. . N

In IN N
these DT N
EEG-regulators NNS N
, , N
no DT N
statistically RB N
significant JJ N
reductions NNS N
of IN N
symptoms NNS o
of IN o
ASD NNP o
were VBD N
observed VBN N
, , N
but CC N
they PRP N
showed VBD N
significant JJ N
improvement NN N
in IN N
cognitive JJ o
flexibility NN o
as IN N
compared VBN N
to TO N
participants NNS N
who WP N
managed VBD N
to TO N
regulate VB N
SC NNP N
. . N

EEG-biofeedback NN N
seems VBZ N
to TO N
be VB N
an DT N
applicable JJ N
tool NN N
to TO N
regulate VB N
EEG NNP N
activity NN N
and CC N
has VBZ N
specific JJ N
effects NNS N
on IN N
cognitive JJ o
flexibility NN o
, , N
but CC N
it PRP N
did VBD N
not RB N
result VB N
in IN N
significant JJ N
reductions NNS N
in IN N
symptoms NNS o
of IN o
ASD NNP o
. . o

An DT N
important JJ N
finding NN N
was VBD N
that IN N
no DT N
nonspecific JJ N
effects NNS N
of IN N
EEG-biofeedback NNP i
were VBD N
demonstrated VBN N
. . N

-DOCSTART- -25691677- O O

Final JJ N
Report NNP N
of IN N
the DT N
Intergroup NNP N
Randomized NNP N
Study NNP N
of IN N
Combined NNP i
Androgen-Deprivation NNP i
Therapy NNP i
Plus NNP i
Radiotherapy NNP i
Versus NNP i
Androgen-Deprivation NNP i
Therapy NNP i
Alone NNP i
in IN N
Locally NNP N
Advanced NNP N
Prostate NNP N
Cancer NNP N
. . N

PURPOSE NNP N
We PRP N
have VBP N
previously RB N
reported VBN N
that IN N
radiotherapy NN i
( ( i
RT NNP i
) ) i
added VBD N
to TO N
androgen-deprivation JJ i
therapy NN i
( ( i
ADT NNP i
) ) i
improves VBZ N
survival JJ N
in IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

Here RB N
, , N
we PRP N
report VBP N
the DT N
prespecified JJ N
final JJ N
analysis NN N
of IN N
this DT N
randomized JJ N
trial NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
NCIC NNP p
Clinical NNP p
Trials NNP p
Group NNP p
PR.3/Medical NNP p
Research NNP p
Council NNP p
PR07/Intergroup NNP p
T94-0110 NNP p
was VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

Patients NNS p
with IN p
T3-4 NNP p
, , p
N0/Nx NNP p
, , p
M0 NNP p
prostate NN p
cancer NN p
or CC p
T1-2 JJ p
disease NN p
with IN p
either DT p
prostate-specific JJ p
antigen NN p
( ( p
PSA NNP p
) ) p
of IN p
more JJR p
than IN p
40 CD p
?g/L NN p
or CC p
PSA NNP p
of IN p
20 CD p
to TO p
40 CD p
?g/L NNS p
plus CC p
Gleason NNP p
score NN p
of IN p
8 CD p
to TO p
10 CD p
were VBD p
randomly RB N
assigned VBN N
to TO N
lifelong VB i
ADT NNP i
alone RB i
or CC N
to TO N
ADT+RT NNP i
. . i

The DT i
RT NNP i
dose NN i
was VBD N
64 CD N
to TO N
69 CD N
Gy NNP N
in IN N
35 CD N
to TO N
39 CD N
fractions NNS N
to TO N
the DT N
prostate NN N
and CC N
pelvis NN N
or CC N
prostate VB N
alone RB o
. . o

Overall JJ o
survival NN o
was VBD o
compared VBN N
using VBG N
a DT N
log-rank JJ N
test NN N
stratified VBD N
for IN N
prespecified JJ N
variables NNS N
. . N

RESULTS NNP p
One CD p
thousand CD p
two CD p
hundred VBD p
five CD p
patients NNS p
were VBD p
randomly RB N
assigned VBN N
between IN N
1995 CD N
and CC N
2005 CD N
, , N
602 CD N
to TO N
ADT NNP i
alone RB i
and CC N
603 CD N
to TO N
ADT+RT NNP i
. . i

At IN N
a DT N
median JJ N
follow-up JJ N
time NN N
of IN N
8 CD N
years NNS N
, , N
465 CD N
patients NNS N
had VBD N
died VBN N
, , N
including VBG N
199 CD N
patients NNS N
from IN N
prostate JJ N
cancer NN o
. . o

Overall JJ o
survival NN o
was VBD o
significantly RB N
improved VBN N
in IN N
the DT N
patients NNS N
allocated VBD N
to TO N
ADT+RT NNP i
( ( i
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.70 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.57 CD N
to TO N
0.85 CD N
; : N
P NNP N
< NNP N
.001 NNP o
) ) o
. . o

Deaths NNS o
from IN o
prostate NN o
cancer NN o
were VBD o
significantly RB N
reduced VBN N
by IN N
the DT N
addition NN N
of IN N
RT NNP i
to TO i
ADT NNP i
( ( i
HR NNP N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.34 CD N
to TO N
0.61 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Patients NNS N
on IN N
ADT+RT NNP i
reported VBD i
a DT N
higher JJR o
frequency NN o
of IN o
adverse JJ o
events NNS o
related VBN o
to TO o
bowel VB o
toxicity NN o
, , o
but CC N
only RB N
two CD N
of IN N
589 CD N
patients NNS N
had VBD o
grade VBN o
3 CD o
or CC o
greater JJR o
diarrhea NN o
at IN o
24 CD N
months NNS N
after IN i
RT NNP i
. . i

CONCLUSION NNP N
This DT N
analysis NN N
demonstrates VBZ N
that IN N
the DT N
previously RB N
reported VBN N
benefit NN N
in IN N
survival NN o
is VBZ o
maintained VBN N
at IN N
a DT N
median JJ N
follow-up NN N
of IN N
8 CD N
years NNS N
and CC N
firmly RB N
establishes VBZ N
the DT N
role NN N
of IN N
RT NNP i
in IN i
the DT N
treatment NN N
of IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

-DOCSTART- -2146875- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
intravenous JJ i
immunoglobulin NN i
therapy NN i
in IN N
patients NNS p
with IN p
chronic JJ p
fatigue NN p
syndrome NN p
. . p

PURPOSE VB N
The DT N
chronic JJ N
fatigue NN N
syndrome NN N
( ( N
CFS NNP N
) ) N
is VBZ N
characterized VBN N
by IN N
profound NN N
fatigue NN N
, , N
neuropsychiatric JJ N
dysfunction NN N
, , N
and CC N
frequent JJ N
abnormalities NNS N
in IN N
cell-mediated JJ N
immunity NN N
. . N

No DT N
effective JJ N
therapy NN N
is VBZ N
known VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty-nine NNP p
patients NNS p
( ( p
40 CD p
with IN p
abnormal JJ p
cell-mediated JJ p
immunity NN p
) ) p
participated VBD p
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
high-dose JJ N
intravenously RB i
administered VBN i
immunoglobulin NN i
G. NNP i
The DT N
patients NNS N
received VBD N
three CD N
intravenous JJ N
infusions NNS N
of IN N
a DT N
placebo JJ i
solution NN i
or CC i
immunoglobulin NN i
at IN N
a DT N
dose NN N
of IN N
2 CD N
g/kg/month NN N
. . N

Assessment NN N
of IN N
the DT N
severity NN N
of IN N
symptoms NNS N
and CC N
associated JJ N
disability NN N
, , N
both DT N
before IN N
and CC N
after IN N
treatment NN N
, , N
was VBD N
completed VBN N
at IN N
detailed JJ N
interviews NNS N
by IN N
a DT N
physician NN N
and CC N
psychiatrist NN N
, , N
who WP N
were VBD N
unaware NN N
of IN N
the DT N
treatment NN N
status NN N
. . N

In IN N
addition NN N
, , N
any DT N
change NN N
in IN N
physical JJ N
symptoms NNS N
and CC N
functional JJ N
capacity NN N
was VBD N
recorded VBN N
using VBG N
visual JJ N
analogue NN N
scales NNS N
, , N
while IN N
changes NNS N
in IN N
psychologic JJ N
morbidity NN N
were VBD N
assessed VBN N
using VBG N
patient-rated JJ N
indices NNS N
of IN N
depression NN N
. . N

Cell-mediated JJ N
immunity NN N
was VBD N
evaluated VBN N
by IN N
T-cell NNP N
subset NN N
analysis NN N
, , N
delayed-type JJ N
hypersensitivity NN N
skin NN N
testing NN N
, , N
and CC N
lymphocyte JJ N
transformation NN N
with IN N
phytohemagglutinin NN N
. . N

RESULTS NNP N
At IN N
the DT N
interview NN N
conducted VBN N
by IN N
the DT N
physician JJ N
3 CD N
months NNS N
after IN N
the DT N
final JJ N
infusion NN N
, , N
10 CD N
of IN N
23 CD N
( ( N
43 CD N
% NN N
) ) N
immunoglobulin NN N
recipients NNS N
and CC N
three CD N
of IN N
the DT N
26 CD N
( ( N
12 CD N
% NN N
) ) N
placebo NN N
recipients NNS N
were VBD N
assessed VBN N
as IN N
having VBG N
responded VBN N
with IN N
a DT N
substantial JJ o
reduction NN o
in IN o
their PRP$ o
symptoms NNS o
and CC o
recommencement NN o
of IN o
work NN o
, , o
leisure NN o
, , o
and CC o
social JJ o
activities NNS o
. . o

The DT N
patients NNS N
designated VBN N
as IN N
having VBG N
responded VBN N
had VBD N
improvement NN N
in IN N
physical JJ N
, , N
psychologic JJ N
, , N
and CC N
immunologic JJ N
measures NNS N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
for IN N
each DT N
) ) N
. . N

CONCLUSION NNP N
Immunomodulatory NNP i
treatment NN i
with IN N
immunoglobulin NN i
is VBZ N
effective JJ o
in IN o
a DT o
significant JJ o
number NN o
of IN o
patients NNS o
with IN o
CFS NNP o
, , N
a DT N
finding NN N
that WDT N
supports VBZ N
the DT N
concept NN N
that IN N
an DT N
immunologic JJ N
disturbance NN N
may MD N
be VB N
important JJ N
in IN N
the DT N
pathogenesis NN N
of IN N
this DT N
disorder NN N
. . N

-DOCSTART- -20028938- O O

Lack NN N
of IN N
lipotoxicity NN N
effect NN N
on IN N
{ ( o
beta NN o
} ) o
-cell NNP o
dysfunction NN o
in IN N
ketosis-prone NN p
type NN p
2 CD p
diabetes NNS p
. . p

OBJECTIVE NNP N
Over IN p
half NN p
of IN p
newly RB p
diagnosed VBN p
obese JJ p
African JJ p
Americans NNPS p
with IN p
diabetic JJ p
ketoacidosis NN p
( ( p
DKA NNP p
) ) p
discontinue VBP N
insulin JJ N
therapy NN N
and CC N
go VB N
through IN N
a DT N
period NN N
of IN N
near-normoglycemia JJ N
remission NN N
. . N

This DT N
subtype NN N
of IN N
diabetes NNS N
is VBZ N
known VBN N
as IN N
ketosis-prone NN N
type NN N
2 CD N
diabetes NNS N
( ( N
KPDM NNP N
) ) N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
lipotoxicity NN N
on IN N
beta-cell NN o
function NN o
, , N
eight CD p
obese JJ p
African JJ p
Americans NNPS p
with IN p
KPDM NNP p
, , p
eight CD p
obese JJ p
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
with IN p
severe JJ p
hyperglycemia NN p
without IN p
ketosis NN p
( ( p
ketosis-resistant JJ p
type NN p
2 CD p
diabetes NNS p
) ) p
, , p
and CC p
nine CD p
nondiabetic JJ p
obese NNS p
control NN p
subjects VBZ p
underwent JJ N
intravenous JJ i
infusion NN i
of IN i
20 CD i
% NN i
intralipid NN i
at IN i
40 CD i
ml/h NN i
for IN N
48 CD N
h. JJ N
beta-Cell NN o
function NN o
was VBD N
assessed VBN N
by IN N
changes NNS o
in IN o
insulin NN o
and CC o
C-peptide JJ o
concentration NN o
during IN N
infusions NNS N
and CC N
by IN N
changes NNS o
in IN o
acute JJ o
insulin NN o
response NN o
to TO o
arginine VB o
stimulation NN o
( ( o
AIR NNP o
( ( o
arg NN o
) ) o
) ) o
before IN N
and CC N
after IN N
lipid JJ i
infusion NN i
. . i

RESULTS VB N
The DT N
mean JJ o
time NN o
to TO o
discontinue VB o
insulin NN o
therapy NN o
was VBD N
11.0 CD N
+/- JJ N
8.0 CD N
weeks NNS N
in IN N
KPDM NNP N
and CC N
9.6 CD N
+/- JJ N
2.2 CD N
weeks NNS N
in IN N
ketosis-resistant JJ N
type NN N
2 CD N
diabetes NNS N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

At IN N
remission NN N
, , N
KPDM NNP N
and CC N
ketosis-resistant JJ N
type NN N
2 CD N
diabetes NNS N
had VBD N
similar JJ N
glucose NN o
( ( N
94 CD N
+/- JJ N
14 CD N
vs. FW N
109 CD N
+/- JJ N
20 CD N
mg/dl NN N
) ) N
, , N
A1C NNP N
( ( N
5.7 CD N
+/- JJ N
0.4 CD N
vs. FW N
6.3 CD N
+/- JJ N
1.1 CD N
% NN N
) ) N
, , N
and CC N
baseline VB o
AIR NNP o
( ( o
arg NN o
) ) o
response NN o
( ( N
34.8 CD N
+/- JJ N
30 CD N
vs. FW N
64 CD N
+/- JJ N
69 CD N
microU/ml NN N
) ) N
. . N

P NNP N
= NNP N
NS NNP N
despite IN N
a DT N
fourfold JJ N
increase NN N
in IN N
free JJ o
fatty JJ o
acid NN o
( ( o
FFA NNP o
) ) o
levels NNS o
( ( N
0.4 CD N
+/- JJ N
0.3 CD N
to TO N
1.8 CD N
+/- JJ N
1.1 CD N
mmol/l NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
during IN N
the DT N
48-h JJ N
intralipid JJ i
infusion NN i
; : i
the DT N
response NN o
to TO o
AIR NNP o
( ( o
arg NN o
) ) o
stimulation NN o
, , N
as RB N
well RB N
as IN N
changes NNS N
in IN N
insulin NN o
and CC o
C-peptide JJ o
levels NNS o
, , N
were VBD N
similar JJ N
among IN N
obese JJ N
patients NNS N
with IN N
KPDM NNP N
, , N
patients NNS N
with IN N
ketosis-resistant JJ N
type NN N
2 CD N
diabetes NNS N
, , N
and CC N
nondiabetic JJ N
control NN N
subjects NNS N
. . N

CONCLUSIONS NNP N
Near-normoglycemia JJ N
remission NN N
in IN N
obese JJ p
African JJ p
American JJ p
patients NNS p
with IN p
KPDM NNP p
and CC p
ketosis-resistant JJ p
type NN p
2 CD p
diabetes NNS p
is VBZ N
associated VBN N
with IN N
a DT N
remarkable JJ N
recovery NN N
in IN N
basal NN N
and CC N
stimulated VBD N
insulin NN N
secretion NN N
. . N

A DT N
high JJ N
FFA NNP N
level NN N
by IN N
intralipid JJ i
infusion NN i
for IN N
48 CD N
h NN N
was VBD N
not RB N
associated VBN N
with IN N
beta-cell JJ N
decompensation NN N
( ( N
lipotoxicity NN N
) ) N
in IN N
KPDM NNP p
patients NNS p
. . p

-DOCSTART- -20843746- O O

Pharmacokinetics NNS N
and CC N
follicular JJ N
dynamics NNS N
of IN N
corifollitropin NN i
alfa NN i
versus NN i
recombinant JJ i
FSH NNP i
during IN N
ovarian JJ p
stimulation NN p
for IN p
IVF NNP p
. . p

A NNP N
single JJ N
injection NN N
of IN N
corifollitropin NN i
alfa NN i
can MD N
replace VB N
seven CD N
daily JJ N
injections NNS N
of IN N
recombinant JJ i
FSH NNP i
( ( i
rFSH NN i
) ) i
using VBG N
a DT N
gonadotrophin-releasing JJ N
hormone NN N
antagonist NN N
protocol NN N
in IN N
ovarian JJ N
stimulation NN N
prior RB p
to TO p
IVF NNP p
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
. . N

This DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
assessed VBD N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
150?g CD i
corifollitropin NN i
alfa NN i
versus IN i
daily JJ i
200IU CD i
rFSH NN i
in IN p
1509 CD p
patients NNS p
. . p

Comparative JJ N
analyses NNS N
were VBD N
performed VBN N
on IN o
serum JJ o
concentrations NNS o
of IN o
FSH NNP o
immunoreactivity NN o
( ( N
pharmacokinetics NNS N
) ) N
, , N
and CC N
the DT o
number NN o
and CC o
size NN o
of IN o
growing VBG o
follicles NNS o
, , o
and CC o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
as IN N
biomarkers NNS N
of IN N
ovarian JJ N
response NN N
( ( N
pharmacodynamics NNS N
) ) N
. . N

The DT o
rate NN o
of IN o
follicular JJ o
development NN o
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

By IN N
stimulation NN N
day NN N
8 CD N
, , N
33 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
corifollitropin NN N
alfa NN N
reached VBD N
the DT N
criterion NN N
for IN N
human JJ N
chorionic NN N
gonadotrophin NN N
( ( N
HCG NNP N
) ) N
injection NN N
. . N

The DT o
number NN o
of IN o
follicles NNS o
?11mm NNP o
was VBD o
slightly RB N
higher JJR N
after IN i
corifollitropin NN i
alfa NN i
compared VBN i
with IN N
daily JJ N
rFSH NN N
at IN N
stimulation NN N
day NN N
8 CD N
( ( N
difference NN N
, , N
1.2 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.5-1.8 NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
on IN N
the DT N
day NN N
of IN N
HCG NNP N
injection NN N
( ( N
difference NN N
, , N
2.1 CD N
; : N
95 CD N
% NN N
CI NNP N
1.4-2.8 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
rise NN o
of IN o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
was VBD o
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Although IN N
the DT N
pharmacokinetics NNS N
of IN N
corifollitropin NN i
alfa NN i
and CC i
rFSH NN i
are VBP i
quite RB N
different JJ N
their PRP$ N
pharmacodynamic JJ N
profiles NNS N
at IN N
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

A DT N
single JJ N
injection NN N
of IN N
corifollitropin NN i
alfa NN i
can MD i
replace VB N
seven CD N
daily JJ N
injections NNS N
of IN N
recombinant JJ i
FSH NNP i
( ( i
rFSH NN i
) ) i
using VBG i
a DT N
gonadotrophin-releasing JJ N
hormone NN N
antagonist NN N
protocol NN N
in IN N
ovarian JJ N
stimulation NN N
prior RB N
to TO N
IVF NNP N
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
corifollitropin NN i
alfa JJ i
versus JJ i
daily JJ i
rFSH NN i
. . i

A DT i
total NN N
of IN N
1509 CD p
patients NNS p
were VBD p
randomized VBN N
in IN N
a DT N
double-blind NN N
, , N
controlled VBN N
trial NN N
to TO N
either VB N
a DT N
single JJ N
injection NN N
of IN N
150?g CD i
corifollitropin NN i
alfa NN i
or CC i
to TO N
daily JJ N
injections NNS N
of IN N
200IU CD i
rFSH NN i
for IN i
the DT N
first JJ N
7 CD N
days NNS N
of IN N
ovarian JJ N
stimulation NN o
. . o

Serum NNP o
levels NNS o
of IN o
FSH NNP o
immunoreactivity NN o
were VBD o
analysed VBN N
( ( N
pharmacokinetic JJ N
analysis NN N
) ) N
, , N
together RB N
with IN N
the DT N
number NN o
and CC o
size NN o
of IN o
growing VBG o
follicles NNS o
and CC o
serum NN o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
as IN o
biomarkers NNS N
of IN N
the DT N
ovarian JJ N
response NN N
( ( N
pharmacodynamic JJ N
analysis NN o
) ) o
. . o

Serum NNP o
FSH NNP o
immunoreactivity NN o
levels NNS o
were VBD o
higher JJR N
up RB N
to TO N
stimulation VB N
day NN N
5 CD N
for IN N
corifollitropin NN i
alfa NN i
compared VBN i
with IN N
the DT N
daily JJ i
rFSH NN i
regimen NNS i
but CC N
were VBD N
similar JJ N
from IN N
day NN N
8 CD N
onwards NNS N
, , N
when WRB N
patients NNS N
started VBD N
rFSH RB N
if IN N
the DT N
criteria NN N
for IN N
human JJ N
chorionic NN N
gonadotrophin NN N
were VBD N
not RB N
yet RB N
reached VBN i
. . i

Corifollitropin NNP i
alfa JJ i
treatment NN i
resulted VBD N
in IN N
a DT N
similar JJ o
growth NN o
rate NN o
of IN o
follicles NNS o
though IN o
a DT N
slightly RB o
higher JJR o
number NN o
of IN o
follicles NNS o
were VBD o
recruited VBN N
compared VBN N
with IN N
daily JJ N
rFSH NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
pharmacokinetics NNS i
of IN i
corifollitropin NN i
alfa NN i
and CC i
rFSH NN i
are VBP i
quite RB N
different JJ N
but CC N
their PRP$ N
induced JJ o
pharmacodynamic JJ o
effects NNS o
at IN o
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

-DOCSTART- -1515255- O O

Prospective NNP N
randomised VBD N
study NN N
of IN N
double JJ N
hemi-body JJ i
irradiation NN i
with IN N
and CC N
without IN N
subsequent JJ N
maintenance NN N
recombinant NN i
alpha VBD i
2b CD i
interferon NN i
on IN N
survival NN o
in IN N
patients NNS p
with IN p
relapsed JJ p
multiple JJ p
myeloma NN p
. . p

Immediately RB N
before IN N
first JJ N
hemi-body NN N
irradiation NN N
, , N
59 CD p
patients NNS p
with IN p
relapsed JJ p
multiple JJ p
myeloma NN p
were VBD N
randomised VBN N
to TO N
receive VB N
or CC N
not RB N
to TO N
receive VB N
subsequent JJ N
alpha-2b JJ i
interferon NN i
maintenance NN i
. . i

13 CD N
patients NNS N
( ( N
22 CD N
% NN N
) ) N
[ VBZ N
8 CD N
of IN N
31 CD N
( ( N
26 CD N
% NN N
) ) N
controls VBZ N
, , N
5 CD N
of IN N
28 CD N
( ( N
18 CD N
% NN N
) ) N
in IN N
the DT N
interferon NN N
arm NN N
] NN N
received VBD N
single JJ i
hemi-body JJ i
irradiation NN i
alone RB i
due JJ N
to TO N
progressive JJ N
disease NN N
and/or JJ N
persistent JJ i
cytopoenias NN i
following VBG N
the DT N
initial JJ N
procedure NN N
. . N

Mean JJ N
time NN N
between IN N
upper JJ N
and CC N
lower JJR N
hemi-body NN N
irradiation NN N
was VBD N
69 CD N
days NNS N
( ( N
range VB N
35-294 NNP N
) ) N
. . N

Of IN N
23 CD N
patients NNS N
randomised VBN N
to TO N
receive VB N
interferon NN N
and CC N
completing VBG N
double JJ N
hemi-body JJ N
irradiation NN N
, , N
15 CD N
( ( N
65 CD N
% NN N
) ) N
achieved VBD N
peripheral JJ o
blood NN o
counts NNS o
adequate VBP N
to TO N
allow VB N
interferon JJ N
administration NN N
as IN N
per IN N
study NN N
criteria NNS N
commencing VBG N
at IN N
a DT N
mean JJ N
116 CD N
days NNS N
( ( N
61-241 JJ N
) ) N
from IN N
time NN N
of IN N
study NN N
entry NN N
. . N

The DT N
mean JJ N
period NN N
of IN N
interferon NN i
therapy NN i
, , N
starting VBG N
at IN N
a DT N
mean JJ N
65 CD N
days NNS N
( ( N
26-160 JJ N
) ) N
post NN N
second JJ N
hemi-body NN N
irradiation NN N
, , N
is VBZ N
16.4 CD N
months NNS N
( ( N
2-33.5 JJ N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
median JJ o
survival NN o
durations NNS o
( ( N
10 CD N
months NNS N
) ) N
from IN N
time NN N
of IN N
initial JJ N
radiotherapy NN N
between IN N
control NN p
and CC p
interferon NN p
patients NNS p
. . p

-DOCSTART- -25323335- O O

Benefits NNS N
of IN N
an DT N
oxygen NN i
reservoir NN i
cannula NN i
versus IN i
a DT i
conventional JJ i
nasal JJ i
cannula NN i
during IN N
exercise NN N
in IN N
hypoxemic JJ p
COPD NNP p
patients NNS p
: : p
a DT N
crossover NN N
trial NN N
. . N

BACKGROUND VB N
The DT N
Oxymizer? NNP i
is VBZ N
a DT N
special JJ N
nasal NN N
cannula NN N
that WDT N
provides VBZ N
a DT N
higher JJR N
luminal JJ N
diameter NN N
in IN N
combination NN N
with IN N
an DT N
incorporated JJ N
oxygen NN N
( ( N
O2 NNP N
) ) N
reservoir NN N
. . N

It PRP N
is VBZ N
assumed VBN N
that IN N
a DT N
higher JJR N
O2 NNP N
concentration NN N
can MD N
be VB N
delivered VBN N
breath NN N
by IN N
breath NN N
in IN N
order NN N
to TO N
increase VB N
oxygenation NN N
. . N

OBJECTIVE IN N
We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
the DT i
Oxymizer NNP i
on IN o
endurance NN o
time NN o
in IN N
comparison NN N
to TO N
a DT N
conventional JJ i
nasal NN i
cannula NN i
( ( i
CNC NNP i
) ) i
. . i

METHODS NNP p
Forty-three JJ p
patients NNS p
with IN p
severe JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
, , p
age NN p
60 CD p
? . p
9 CD p
years NNS p
, , p
FEV1 NNP p
37 CD p
? . p
16 CD p
% NN p
pred VBN p
. . p

) ) p
and CC p
indications NNS p
for IN p
LTOT NNP p
were VBD p
recruited VBN p
during IN p
pulmonary JJ p
rehabilitation NN p
for IN p
this DT p
cross-over NN p
study NN p
. . p

After IN p
an DT N
initial JJ N
maximal JJ N
incremental JJ N
cycle NN N
test NN N
, , N
all DT N
patients NNS N
performed VBD i
4 CD i
cycling VBG i
endurance NN i
time NN i
tests NNS i
at IN i
70 CD N
% NN N
of IN N
their PRP$ N
peak JJ N
work NN N
rate NN N
( ( N
twice RB N
with IN N
the DT N
Oxymizer NNP i
and CC i
twice RB N
with IN i
a DT i
CNC NNP i
, , i
in IN i
reverse JJ N
order NN N
) ) N
. . N

RESULTS VB N
The DT N
endurance NN o
time NN o
was VBD o
significantly RB N
higher JJR N
when WRB N
patients NNS N
cycled VBD N
while IN N
using VBG N
the DT N
Oxymizer NNP i
in IN i
comparison NN N
to TO N
while IN N
using VBG N
the DT N
CNC NNP i
[ VBD i
858 CD i
? . N
754 CD N
vs. IN N
766 CD N
? . N
652 CD N
s NN N
; : N
between-group JJ N
difference NN N
92 CD N
s NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
32-152 JJ N
) ) N
, , N
p JJ N
< FW N
0.001 CD N
] NN N
. . N

In IN N
addition NN N
to TO N
a DT N
longer RBR o
cycling NN o
duration NN o
, , o
O2 NNP o
saturation NN o
at IN o
isotime NN o
was VBD o
significantly RB N
higher JJR N
with IN N
the DT N
Oxymizer NNP N
( ( N
93.5 CD N
? . N
5.4 CD N
vs. IN N
90.4 CD N
? . N
5.3 CD N
% NN N
; : N
p CC N
= VB N
0.027 CD N
) ) N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
a DT N
positive JJ N
correlation NN N
( ( N
r JJ N
= NN N
0.427 CD N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
between IN N
the DT o
O2 NNP o
flow NN o
rate NN o
and CC o
improvements NNS o
in IN o
the DT o
constant JJ o
work NN o
rate NN o
test NN o
, , o
showing VBG N
greater JJR N
improvements NNS N
in IN N
favor NN N
of IN N
the DT N
Oxymizer NNP i
in IN i
patients NNS i
with IN N
a DT N
higher JJR N
demand NN N
for IN N
O2 NNP N
( ( N
? . N
4 CD N
liters/min NN N
) ) N
. . N

CONCLUSION NN N
We PRP N
show VBP N
that IN N
O2 NNP N
delivery NN N
via IN i
the DT i
Oxymizer NNP i
is VBZ N
superior JJ N
to TO i
a DT i
CNC NNP i
with IN N
regard NN N
to TO N
endurance VB o
capacity NN o
and CC o
oxygenation NN o
during IN o
exercise NN o
in IN p
patients NNS p
with IN p
severe JJ p
COPD NNP p
. . p

It PRP p
seems VBZ N
that IN N
patients NNS N
with IN N
a DT N
higher JJR N
demand NN N
for IN N
O2 NNP N
( ( N
? . N
4 CD N
liters/min NN N
) ) N
, , N
in IN N
particular JJ N
, , N
may MD N
benefit VB N
more JJR N
from IN N
the DT N
use NN N
of IN N
the DT N
Oxymizer NNP i
. . i

-DOCSTART- -14745744- O O

Psychoeducational NNP i
group NN i
intervention NN i
for IN N
wives NNS p
of IN p
men NNS p
with IN p
prostate NN p
cancer NN p
. . p

OBJECTIVE CC N
The DT N
effects NNS N
of IN N
a DT N
6-week JJ N
psychoeducational JJ i
group NN i
intervention NN i
on IN N
the DT N
distress NN N
, , N
coping NN N
, , N
personal JJ N
growth NN N
, , N
and CC N
marital JJ N
communication NN N
of IN N
wives NNS p
of IN p
men NNS p
diagnosed VBN p
with IN p
prostate JJ p
cancer NN p
were VBD N
evaluated VBN N
using VBG N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
Sixty NNP p
wives NNS p
completed VBD N
measures NNS N
prior RB N
to TO N
random VB N
assignment NN N
to TO N
either VB N
the DT N
psychoeducational JJ i
group NN i
intervention NN i
or CC i
a DT i
no-treatment JJ i
control NN i
group NN i
, , N
and CC N
1 CD N
month NN N
after IN N
completion NN N
of IN N
the DT N
group NN N
. . N

RESULTS NNP N
No NNP N
differences NNS N
with IN N
regard NN N
to TO N
wives NNS N
' POS N
general JJ o
distress NN o
or CC o
cancer-specific JJ o
distress NN o
were VBD N
noted VBN N
. . N

In IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
, , N
participants NNS N
receiving VBG N
the DT N
intervention NN N
perceived VBD N
that IN N
having VBG N
a DT N
spouse NN N
with IN N
prostate NN N
cancer NN N
had VBD N
made VBN N
positive JJ N
contributions NNS N
to TO N
their PRP$ N
lives NNS N
, , N
reported VBD N
gains NNS N
in IN N
the DT N
use NN N
of IN N
positive JJ o
reappraisal NN o
coping VBG o
and CC N
reductions NNS N
in IN N
denial JJ o
coping NN o
. . o

CONCLUSION NNP N
Although IN N
the DT N
psychoeducational JJ i
intervention NN i
did VBD N
not RB N
result VB N
in IN N
changes NNS N
in IN N
psychological JJ o
distress NN o
, , N
improvements NNS N
in IN N
adaptive JJ o
coping NN o
and CC o
indicators NNS o
of IN o
psychological JJ o
growth NN o
were VBD N
found VBN N
. . N

The DT N
utility NN N
of IN N
group NN N
interventions NNS N
for IN N
spouses NNS p
of IN p
men NNS p
with IN p
prostate NN p
cancer NN p
is VBZ N
discussed VBN N
. . N

-DOCSTART- -19272375- O O

A DT N
randomized VBN N
, , N
controlled VBN N
study NN N
on IN N
the DT N
influence NN N
of IN N
acetaminophen NN i
, , i
diclofenac NN i
, , i
or CC i
naproxen RB i
on IN i
aspirin-induced JJ i
inhibition NN N
of IN N
platelet NN o
aggregation NN o
. . o

Nonsteroidal NNP i
anti-inflammatory JJ i
drugs NNS i
( ( i
NSAID NNP i
) ) i
may MD N
interfere VB N
with IN N
aspirin NN i
( ( i
acetylsalicylic JJ i
acid NN i
) ) i
and CC N
increase VB N
the DT N
risk NN N
for IN N
cardiovascular JJ o
events NNS o
. . o

The DT N
clinical JJ N
relevance NN N
is VBZ N
uncertain JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
influence NN N
of IN N
a DT N
co-administration NN N
of IN N
aspirin NN i
and CC N
NSAID NNP i
on IN N
platelet NN o
aggregation NN o
. . o

In IN N
a DT N
randomized JJ N
, , N
placebo NN N
controlled VBD N
trial NN N
, , N
eleven RB p
healthy JJ p
volunteers NNS p
were VBD N
studied VBN N
during IN N
4 CD N
separate JJ N
study NN N
periods NNS N
of IN N
4 CD N
days NNS N
each DT N
. . N

Individuals NNS N
were VBD N
treated VBN N
on IN N
each DT N
occasion NN N
with IN N
100 CD N
mg NNS N
aspirin JJ i
daily RB N
in IN N
combination NN N
with IN N
either DT N
3 CD i
x VBD i
1 CD i
g NN i
acetaminophen NN i
, , i
3 CD i
x NN i
50 CD i
mg NN i
diclofenac NN i
, , i
3 CD i
x NN i
250 CD i
mg NN i
naproxen NN i
, , i
or CC i
3 CD i
x JJ i
1 CD i
placebo NN i
. . i

Primary JJ o
hemostasis NN o
was VBD N
assessed VBN N
with IN N
a DT N
platelet NN N
function NN N
analyser NN N
( ( N
PFA-100 NNP N
) ) N
, , N
which WDT N
measures VBZ N
the DT o
closure NN o
time NN o
( ( o
CT NNP o
) ) o
of IN o
a DT o
collagen- JJ o
and CC o
epinephrine-coated JJ o
pore NN o
by IN o
aggregating VBG o
platelets NNS o
in IN o
flowing VBG o
blood NN o
. . o

Naproxen NNP i
enhanced VBD N
the DT N
anti-aggregatory JJ o
action NN o
of IN N
aspirin NN i
after IN N
24 CD N
h NN N
( ( o
CT NNP o
rising VBG N
from IN N
104+/-16 JJ N
s NN N
at IN N
baseline NN N
to TO N
212+/-69 JJ N
s NN N
at IN N
24 CD N
h NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
which WDT N
was VBD N
not RB N
seen VBN N
with IN N
any DT N
other JJ N
drug NN N
combination NN N
. . N

Diclofenac NNP i
reduced VBD N
the DT N
anti-aggregatory JJ o
action NN o
of IN N
aspirin NN i
in IN N
the DT N
first JJ N
two CD N
days NNS N
, , N
since IN N
the DT N
CT NNP o
did VBD N
not RB N
rise VB N
significantly RB N
( ( N
109+/-19 JJ N
s NN N
, , N
148+/-56 JJ N
s NN N
, , N
and CC N
168+/-66 JJ N
s NN N
at IN N
0 CD N
h NN N
, , N
24 CD N
h NN N
, , N
48 CD N
h NN N
, , N
respectively RB N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Acetaminophen NNP i
had VBD N
no DT N
effect NN N
compared VBN N
with IN N
placebo NN i
. . i

After IN N
4 CD N
days NNS N
of IN N
treatment NN N
platelet NN o
aggregation NN o
was VBD N
similarly RB N
inhibited VBN N
by IN N
all DT N
combinations NNS N
. . N

We PRP N
conclude VBP N
that IN N
a DT N
co-administration NN N
of IN N
NSAID NNP i
and CC N
aspirin NN i
may MD N
interfere VB N
with IN N
platelet NN o
inhibition NN o
at IN N
the DT N
beginning NN N
of IN N
a DT N
treatment NN N
with IN N
an DT N
increase NN N
of IN N
naproxen JJ i
and CC N
a DT N
decrease NN N
of IN N
diclofenac NN i
. . i

This DT N
effect NN N
is VBZ N
lost VBN N
after IN N
4 CD N
days NNS N
, , N
suggesting VBG N
that IN N
a DT N
regular JJ N
daily JJ N
co-administration NN N
of IN N
NSAID NNP i
does VBZ N
not RB N
have VB N
an DT N
influence NN N
on IN N
platelet NN o
inhibition NN o
by IN N
aspirin NN i
. . i

-DOCSTART- -23224592- O O

Parents NNS p
' POS p
state NN N
and CC N
trait NN N
anxiety NN N
: : N
relationships NNS N
with IN N
anxiety NN o
severity NN o
and CC N
treatment NN N
response NN N
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Comorbid NNP N
anxiety NN N
is VBZ N
common JJ N
among IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
, , p
and CC p
parents NNS p
of IN p
children NNS p
with IN p
ASD NNP p
are VBP p
more RBR p
likely JJ p
to TO p
have VB p
anxiety NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
relationship NN N
between IN N
parents NNS i
' POS i
state NN o
and CC o
trait NN o
anxiety NN o
and CC p
parent-reported JJ i
internalizing NN i
and CC i
externalizing VBG i
symptoms NNS i
among IN i
adolescents NNS i
( ( p
n JJ p
= NNP p
30 CD p
) ) p
with IN p
ASD NNP p
, , p
as RB p
well RB p
as IN p
the DT p
relationship NN p
of IN p
parents NNS o
' POS o
anxiety NN o
symptoms NNS o
and CC o
adolescent JJ o
treatment NN o
response NN o
in IN o
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN o
. . o

Parental JJ o
state NN o
anxiety NN o
correlated VBD o
with IN o
severity NN o
of IN o
adolescent JJ o
anxiety NN o
, , o
and CC o
trait NN o
anxiety NN o
in IN o
parents NNS N
correlated VBN N
with IN o
parent-reported JJ o
adolescent NN o
internalizing NN o
and CC o
externalizing NN o
symptoms NNS o
. . o

Also RB N
, , N
parents NNS N
of IN N
adolescent JJ N
treatment NN N
responders NNS N
experienced VBD N
a DT N
decrease NN o
in IN o
their PRP$ o
own JJ o
trait NN o
anxiety NN o
. . o

Findings NNS N
highlight VBD N
the DT N
importance NN N
of IN N
considering VBG o
parental JJ o
anxiety NN o
when WRB o
targeting VBG o
anxiety NN o
among IN o
youth NN N
with IN N
ASD NNP N
. . N

-DOCSTART- -17276750- O O

Positive JJ N
effects NNS N
of IN N
methylphenidate NN i
on IN N
inattention NN o
and CC p
hyperactivity NN o
in IN p
pervasive JJ p
developmental JJ p
disorders NNS p
: : p
an DT N
analysis NN N
of IN N
secondary JJ N
measures NNS N
. . N

BACKGROUND NNP N
Methylphenidate NNP i
has VBZ N
been VBN N
shown VBN N
elsewhere RB N
to TO N
improve VB N
hyperactivity NN o
in IN N
about IN N
half NN N
of IN N
treated JJ N
children NNS p
who WP p
have VBP p
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDD NNP p
) ) p
and CC p
significant JJ p
hyperactive-inattentive JJ p
symptoms NNS p
. . p

We PRP N
present JJ N
secondary JJ N
analyses NNS N
to TO N
better JJR N
define VB N
the DT N
scope NN N
of IN N
effects NNS N
of IN N
methylphenidate NN i
on IN N
symptoms NNS N
that WDT N
define VBP N
attention-deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
and CC N
oppositional JJ N
defiant NN N
disorder NN N
( ( N
ODD NNP N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
core NN N
autistic JJ N
symptom NN N
domain NN N
of IN N
repetitive JJ N
behavior NN N
. . N

METHODS NNP N
Sixty-six JJ p
children NNS p
( ( p
mean JJ p
age NN p
7.5 CD p
y NN p
) ) p
with IN p
autistic JJ p
disorder NN p
, , p
Asperger NNP p
's POS p
disorder NN p
, , p
and CC p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
, , N
were VBD N
randomized VBN N
to TO N
varying VBG N
sequences NNS N
of IN N
placebo NN i
and CC i
three CD i
different JJ i
doses NNS i
of IN i
methylphenidate NN i
during IN N
a DT N
4-week JJ N
blinded NN N
, , N
crossover NN N
study NN N
. . N

Methylphenidate NNP N
doses NNS N
used VBD N
approximated JJ N
.125 NNP N
, , N
.25 NNP N
, , N
and CC N
.5 NNP N
mg/kg VBP N
per IN N
dose NN N
, , N
twice RB N
daily RB N
, , N
with IN N
an DT N
additional JJ N
half-dose NN N
in IN N
the DT N
late JJ N
afternoon NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Swanson NNP o
, , o
Nolan NNP o
, , o
and CC o
Pelham NNP o
Questionnaire NNP o
revised VBD o
for IN o
DSM-IV NNP o
( ( o
ADHD NNP o
and CC o
ODD NNP o
scales NNS o
) ) o
and CC o
the DT o
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scales NNP o
for IN o
PDD NNP o
. . o

RESULTS NNP N
Methylphenidate NNP i
was VBD N
associated VBN N
with IN N
significant JJ N
improvement NN N
that WDT N
was VBD N
most RBS N
evident JJ N
at IN N
the DT N
.25- JJ N
and CC N
.5-mg/kg JJ N
doses NNS N
. . N

Hyperactivity NNP o
and CC o
impulsivity NN o
improved VBD N
more JJR N
than IN N
inattention NN o
. . o

There EX N
were VBD N
not RB N
significant JJ N
effects NNS N
on IN N
ODD NNP o
or CC o
stereotyped VBN o
and CC o
repetitive JJ o
behavior NN o
. . o

CONCLUSIONS NNP N
Convergent NNP N
evidence NN N
from IN N
different JJ N
assessments NNS N
and CC N
raters NNS N
confirms VBP N
methylphenidate NN i
's POS i
efficacy NN o
in IN N
relieving VBG N
ADHD NNP o
symptoms NNS o
in IN N
some DT N
children NNS p
with IN p
PDD NNP p
. . p

Optimal NNP N
dose JJ N
analyses NNS N
suggested VBD N
significant JJ N
interindividual JJ N
variability NN N
in IN N
dose JJ N
response NN N
. . N

-DOCSTART- -8126502- O O

Effect NN N
of IN N
entacapone NN i
, , N
a DT N
peripherally RB N
acting VBG N
catechol-O-methyltransferase NN N
inhibitor NN N
, , N
on IN N
the DT N
motor NN o
response NN o
to TO o
acute VB o
treatment NN o
with IN o
levodopa NN o
in IN N
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
. . p

Catechol-O-methyltransferase NNP N
( ( N
COMT NNP N
) ) N
inhibitors NNS N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
Parkinson NNP N
's POS N
disease NN N
by IN N
improving VBG N
the DT N
bioavailability NN o
of IN N
levodopa NN N
and CC N
by IN N
prolonging VBG N
its PRP$ N
effects NNS N
. . N

Entacapone NNP i
( ( i
OR-611 NNP i
) ) i
, , i
a DT i
novel JJ i
COMT NNP i
inhibitor NN i
, , N
which WDT N
does VBZ N
not RB N
cross VB N
the DT N
blood NN N
brain NN N
barrier NN N
, , N
was VBD N
assessed VBN N
in IN N
12 CD p
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
and CC p
motor NN p
fluctuations NNS p
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
single JJ N
dose NN N
study NN N
. . N

The DT N
magnitude NN N
and CC N
duration NN N
of IN N
the DT N
therapeutic JJ N
response NN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
200 CD N
mg NNS N
levodopa/50 JJ i
mg FW N
carbidopa NN i
was VBD N
evaluated VBN N
after IN N
concomitant JJ N
placebo NN i
, , N
or CC N
200 CD N
or CC N
800 CD N
mg NN N
entacapone NN i
. . i

A DT N
significant JJ N
increase NN N
in IN N
the DT N
duration NN o
of IN o
the DT o
motor NN o
response NN o
to TO o
levodopa NN o
was VBD N
seen VBN N
when WRB N
200 CD N
mg NN N
entacapone NN N
was VBD N
given VBN N
with IN N
levodopa/carbidopa NN N
. . N

Plasma NNP o
levodopa JJ o
concentrations NNS o
were VBD N
increased VBN N
with IN N
both DT N
doses NNS N
of IN N
the DT N
COMT NNP N
inhibitor NN N
. . N

The DT N
latency NN o
to TO o
onset VB o
of IN o
motor NN o
response NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
active JJ N
drug NN N
and CC N
placebo NN N
. . N

Entacapone NN N
may MD N
prove VB N
useful JJ N
in IN N
prolonging VBG o
the DT o
duration NN o
of IN o
the DT o
benefit NN o
obtained VBN N
from IN N
individual JJ N
doses NNS N
of IN N
levodopa NN N
. . N

-DOCSTART- -8667967- O O

Tight-fitting JJ i
underwear JJ i
and CC p
sperm JJ o
quality NN o
. . o

-DOCSTART- -24830937- O O

Oral JJ i
magnesium NN i
supplementation NN i
improves VBZ N
the DT N
metabolic JJ o
profile NN o
of IN N
metabolically RB p
obese JJ p
, , p
normal-weight JJ p
individuals NNS p
: : p
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
We PRP N
undertook VBD N
this DT N
study NN N
to TO N
determine VB N
the DT N
efficacy NN o
of IN N
oral JJ N
magnesium NN i
supplementation NN N
in IN N
the DT N
improvement NN N
of IN N
the DT N
metabolic JJ o
profile NN o
and CC N
blood NN o
pressure NN o
in IN N
metabolically RB p
obese JJ p
, , p
normal-weight JJ p
( ( p
MONW NNP p
) ) p
individuals NNS p
. . p

METHODS NNP N
A NNP p
total NN p
of IN p
47 CD p
MONW NNP p
individuals NNS p
with IN p
hypomagnesemia NN p
were VBD p
enrolled VBN p
in IN N
clinical JJ N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

Individuals NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD N
30 CD i
mL NN i
of IN i
MgCl2 NNP i
5 CD i
% NN i
solution NN i
( ( i
equivalent JJ i
to TO i
382 CD i
mg NN i
of IN i
magnesium NN i
) ) i
and CC i
individuals NNS i
in IN i
the DT i
control NN i
group NN i
30 CD i
mL NN i
of IN i
placebo JJ i
solution NN i
, , i
once RB i
daily JJ i
during IN i
4 CD i
months NNS i
. . i

In IN N
the DT N
absence NN N
of IN N
obesity NN N
or CC N
overweight NN N
, , N
the DT N
presence NN N
of IN N
fasting VBG o
glucose JJ o
levels NNS o
?100 VBP N
mg/dL NN o
, , o
HOMA-IR NNP o
index NN o
?3 NNP o
, , o
triglyceride NN o
levels NNS o
?150 VBP o
mg/dL NN N
and/or NN N
systolic NN o
and CC o
diastolic JJ o
blood NN o
pressure NN o
?140 NNP o
and CC N
90 CD N
mmHg NN N
defined VBD N
the DT N
presence NN N
of IN N
the DT N
MONW NNP N
phenotype NN N
. . N

Hypomagnesemia NNP N
was VBD N
defined VBN N
by IN N
serum JJ N
magnesium NN N
concentration NN N
?1.8 NNP N
mg/dL NN N
. . N

RESULTS NNP N
At IN N
basal JJ N
conditions NNS N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
. . N

At IN N
the DT N
end NN N
of IN N
follow-up NN N
, , N
changes NNS N
in IN N
the DT o
mean NN o
of IN o
systolic NN o
( ( N
-2.1 NNP N
vs. FW N
3.9 CD N
% NN N
mmHg NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
diastolic JJ o
( ( N
-3.8 NNP N
vs. FW N
7.5 CD N
% NN N
mmHg NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
blood NN o
pressures NNS o
, , o
HOMA-IR NNP o
index NN o
( ( o
-46.5 NNP o
vs. FW N
-5.4 NNP N
% NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
, , N
fasting VBG o
glucose NN o
( ( o
-12.3 JJ N
vs. FW N
-1.8 CD N
% NN N
mg/dL NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
triglyceride JJ o
levels NNS o
( ( o
-47.4 CD o
% NN N
vs. FW N
10.1 CD N
% NN N
mg/dL NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
subjects NNS N
who WP N
received VBD i
MgCl2 NNP i
compared VBN i
with IN N
individuals NNS i
in IN i
the DT i
control NN i
group NN i
. . N

CONCLUSIONS NNP i
Oral NNP i
magnesium NN i
supplementation NN N
improves VBZ N
the DT o
metabolic JJ o
profile NN o
and CC o
blood NN o
pressure NN o
of IN p
MONW NNP p
individuals NNS p
. . p

-DOCSTART- -2208619- O O

[ JJ N
Clinical NNP N
observations NNS N
on IN N
the DT N
treatment NN N
of IN N
hookworm NN p
, , p
Ascaris NNP p
and CC p
Trichuris NNP p
infection NN p
with IN N
oxibendazole JJ i
] NN i
. . N

340 CD p
cases NNS p
of IN p
hookworm NN p
infection NN p
, , p
196 CD p
cases NNS p
of IN p
ascariasis NN p
and CC p
178 CD p
cases NNS p
of IN p
trichuriasis NN p
were VBD p
treated VBN p
with IN p
an DT i
anthelmintic JJ i
, , i
oxibendazole JJ i
, , i
15mg/kg.d CD i
x JJ i
3d CD i
; : i
102 CD i
, , i
70 CD i
and CC i
66 CD i
cases NNS i
of IN i
respective JJ i
infections NNS i
were VBD i
treated VBN i
with IN i
pyrantel NN i
10mg/kg.d CD i
x NN i
3d CD i
and CC i
108 CD i
, , i
74 CD i
and CC i
63 CD i
cases NNS i
took VBD i
placebo NN i
for IN i
comparison NN i
and CC i
as IN i
control NN i
under IN i
double-blind JJ i
observations NNS i
. . i

Re-examinations NNS N
of IN N
the DT N
stool NN N
were VBD N
performed VBN N
after IN N
the DT N
treatment NN N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
oxibendazole NN N
, , N
the DT N
egg NN o
negative JJ o
conversion NN o
rates NNS o
of IN o
hookworm NN o
, , o
Ascaris NNP o
and CC o
Trichuris NNP o
were VBD N
70.3-80.6 CD N
% NN N
, , N
92.5-97.8 CD N
and CC N
67.0-71.0 CD N
% NN N
respectively RB N
. . N

The DT N
egg NN o
reduction NN o
rates NNS o
of IN o
hookworm NN o
were VBD N
98.1-98.6 CD N
% NN N
. . N

The DT N
larval JJ o
negative JJ o
conversion NN o
rates NNS o
of IN o
Ancylostoma NNP o
duodenale NN o
and CC o
Necator NNP o
americanus VBP o
were VBD N
77.7 CD N
and CC N
83.2 CD N
% NN N
respectively RB N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
pyrantel NN N
, , N
the DT N
egg NN o
negative JJ o
conversion NN o
rates NNS o
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
73.5 CD N
, , N
90.0 CD N
and CC N
28.8 CD N
% NN N
respectively RB N
. . N

The DT N
egg NN o
reduction NN o
rate NN o
of IN o
hookworm NN o
was VBD N
98.8 CD N
% NN N
. . N

Among IN N
the DT N
cases NNS N
treated VBN N
with IN N
placebo NN N
, , N
the DT N
egg NN o
negative JJ o
conversion NN o
rates NNS o
of IN N
the DT N
three CD N
above IN N
mentioned VBN N
parasites NNS N
were VBD N
6.5 CD N
, , N
29.7 CD N
and CC N
7.9 CD N
% NN N
. . N

No CC N
marked JJ N
adverse JJ N
reactions NNS N
were VBD N
observed VBN N
by IN N
clinical JJ N
and CC N
laboratory JJ N
examinations NNS N
. . N

-DOCSTART- -18322594- O O

[ NN o
Specific NNP o
T NNP o
cell NN o
immune NN o
response NN o
in IN N
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
treated VBD N
with IN N
different JJ N
doses NNS N
of IN N
recombinant JJ i
hepatitis NN i
B NNP i
vaccine NN i
] NN i
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
specific JJ o
cellular JJ o
immunoresponse NN o
of IN N
peripheral JJ N
blood NN N
lymphocytes NNS N
in IN N
the DT N
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
treated VBD p
with IN p
different JJ p
doses NNS p
of IN p
recombinant JJ i
hepatitis NN i
B NNP i
vaccine NN i
. . i

METHODS NNP N
Seventy-two NNP p
chronic JJ p
hepatitis NN p
B NNP p
patients NNS p
who WP p
did VBD p
not RB p
use VB p
any DT p
anti-HBV JJ p
drugs NNS p
within IN p
6 CD p
months NNS p
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
( ( N
90 CD N
micrograms NNS N
, , N
60 CD N
micrograms NNS N
, , N
and CC N
placebo NN i
) ) i
in IN N
a DT N
ratio NN N
of IN N
1:1:1 CD N
. . N

The DT p
patients NNS p
in IN p
different JJ p
groups NNS p
were VBD p
treated VBN p
with IN p
different JJ i
doses NNS i
of IN i
recombinant JJ i
hepatitis NN i
B NNP i
vaccine NN i
in IN i
combination NN i
with IN i
IFN NNP i
alpha VBP i
1b CD i
50 CD i
micrograms NNS i
with IN i
3 CD i
times NNS i
a DT i
week NN i
for IN i
24 CD i
weeks NNS i
. . i

All DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
24 CD N
weeks NNS N
( ( N
W24 NNP N
) ) N
. . N

HBV NNP o
DNA NNP o
, , o
HBeAg NNP o
and CC o
liver JJ o
functions NNS o
were VBD N
detected VBN N
at IN N
different JJ N
time NN N
points NNS N
, , N
and CC N
the DT N
number NN N
of IN N
cells NNS N
that WDT N
secrete VBP o
IFN-gamma NNP o
were VBD N
detected VBN N
by IN N
ELISPOT NNP o
. . o

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
difference NN N
in IN N
ELISPOT NNP o
positive JJ o
ratio NN o
among IN N
the DT N
3 CD N
groups NNS N
on IN N
baseline JJ N
detection NN N
. . N

At IN N
W24 NNP N
, , N
12 CD N
cases NNS N
, , N
12 CD N
cases NNS N
, , N
and CC N
7 CD N
cases NNS N
showed VBD N
ELISPOT NNP o
positive JJ o
in IN N
the DT N
group NN N
of IN N
90 CD N
micrograms NNS N
, , N
60 CD N
micrograms NNS N
, , N
and CC N
placebo NN N
. . N

The DT N
proportion NN N
of IN N
patients NNS p
who WP p
were VBD p
ELISPOT NNP o
positive JJ o
was VBD N
higher RBR N
in IN N
the DT N
groups NNS N
treated VBD N
with IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
including VBG N
the DT N
dose NN N
of IN N
90 CD N
micrograms NNS N
and CC N
60 CD N
micrograms NNS N
) ) N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P=0.0446 NNP N
) ) N
. . N

HBV NNP o
DNA NNP o
turned VBD N
negative JJ N
in IN N
6/24 CD N
of IN N
the DT N
patients NNS N
treated VBD N
with IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
at IN N
both DT N
the DT N
doses NNS N
of IN N
90 CD N
micrograms NNS N
and CC N
60 CD N
micrograms NNS N
) ) N
, , N
and CC N
HBeAg/Anti-HBe NNP o
seroconversion NN o
or CC o
HBeAg NNP o
became VBD N
negative JJ N
in IN N
7/24 CD N
of IN N
them PRP N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
none NN N
of IN N
the DT N
patients NNS N
showed VBD N
undetectable JJ o
HBV NNP o
DNA NNP o
, , o
HBeAg/Anti-HBe NNP o
seroconversion NN o
or CC o
HBeAg NNP o
disappearance NN o
. . o

At IN N
the DT N
24W CD N
of IN N
follow NN N
up RB N
, , N
in IN N
the DT N
patients NNS N
who WP N
were VBD N
ELISPOT NNP o
positive JJ o
, , o
HBV NNP o
DNA NNP o
became VBD N
undetectable JJ N
in IN N
4 CD N
of IN N
the DT N
patients NNS N
treated VBD N
with IN N
recombinant JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
at IN N
doses NNS N
of IN N
90 CD N
micrograms NNS N
and CC N
60 CD N
micrograms NNS N
) ) N
, , N
and CC N
HBeAg/Anti-HBe NNP o
seroconversion NN o
or CC o
HBeAg NNP o
disappearance NN o
were VBD N
found VBN N
in IN N
9 CD N
of IN N
the DT N
cases NNS N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
none NN N
of IN N
the DT N
cases NNS N
showed VBD N
undetectable JJ N
HBV NNP o
DNA NNP o
, , N
and CC N
only RB N
1 CD N
case NN N
had VBD N
HBeAg/Anti-HBe NNP o
seroconversion NN o
. . o

CONCLUSION VB N
The DT N
recombinant JJ i
hepatitis NN i
B NNP i
vaccine NN i
may MD N
increase VB N
the DT N
function NN o
of IN o
specific JJ o
T NNP o
lymphocytes NNS o
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
dose NN N
of IN N
90 CD N
micrograms NNS N
and CC N
60 CD N
micrograms NNS N
hepatitis NN N
B NNP N
vaccine NN N
. . N

-DOCSTART- -10207709- O O

Couple-responsible JJ i
therapy NN i
process NN i
: : i
positive JJ o
proximal JJ o
outcomes NNS o
. . o

Therapist-couple JJ N
struggle NN N
vs. FW N
cooperation NN N
is VBZ N
linked VBN N
to TO N
clinical JJ N
outcome NN N
. . N

This DT N
research NN N
conceptualizes NN N
and CC N
investigates VBZ N
treatment NN N
process NN N
as IN N
it PRP N
relates VBZ N
to TO N
the DT N
occurrence NN N
of IN N
struggle NN N
versus NN N
cooperation NN N
. . N

Models NNS N
of IN N
couple-responsible JJ i
and CC i
therapist-responsible JJ i
process NN i
in IN N
couple NN i
therapy NN i
were VBD N
developed VBN N
. . N

Couple-responsible JJ i
process NN i
consists VBZ i
of IN i
enactments NNS i
, , i
accommodation NN i
, , i
and CC i
inductive JJ i
process NN i
. . i

Therapist-responsible JJ i
process NN i
consists VBZ i
of IN i
primary JJ i
therapist-couple JJ i
interaction NN i
, , i
therapist JJ i
interpretation NN i
, , i
and CC i
direct JJ i
instruction NN i
. . i

In IN N
counterbalanced JJ N
order NN N
, , N
25 CD p
couples NNS p
were VBD N
exposed VBN N
to TO N
couple-responsible JJ i
and CC i
therapist-responsible JJ i
episodes NNS i
during IN N
one CD N
therapy NN N
session NN N
. . N

Couples NNP N
reviewed VBD N
videotapes NNS N
of IN N
the DT N
episodes NNS N
and CC N
completed VBD N
measures NNS N
of IN N
responsibility NN N
, , N
struggle NN N
, , N
and CC N
cooperation NN N
. . N

Perceived NNP o
responsibility NN o
was VBD N
higher JJR N
and CC N
struggle NN o
was VBD N
lower JJR N
during IN N
couple-responsible JJ i
episodes NNS i
. . i

No DT N
difference NN N
in IN N
cooperation NN o
was VBD N
found VBN N
. . N

Presence NN N
or CC N
absence NN N
of IN N
a DT N
contrast NN N
condition NN N
, , N
where WRB N
couples NNS N
reported VBD N
on IN N
one CD N
therapist NN i
process NN i
after IN N
already RB N
experiencing VBG N
its PRP$ N
opposite NN N
, , N
led VBN N
to TO N
main JJ N
effects NNS N
for IN N
responsibility NN N
and CC N
struggle NN N
, , N
and CC N
mediated VBD N
effects NNS N
of IN N
struggle NN N
and CC N
cooperation NN N
. . N

Generally NNP N
speaking NN N
, , N
responsibility NN o
was VBD N
even RB N
higher JJR N
during IN N
couple-responsible JJ i
episodes NNS i
and CC N
even RB N
lower JJR N
during IN N
therapist-responsible JJ i
episodes NNS i
when WRB N
contrast NN N
was VBD N
present JJ N
. . N

Similarly RB N
, , N
struggle NN o
was VBD N
even RB N
lower JJR N
during IN N
couple-responsible JJ i
episodes NNS i
and CC N
even RB N
higher JJR N
during IN N
therapist-responsible JJ i
episodes NNS i
when WRB N
contrast NN N
was VBD N
present JJ N
. . N

For IN N
both DT N
couple-responsible JJ N
and CC N
therapist-responsible JJ N
episodes NNS N
, , N
cooperation NN o
was VBD N
negatively RB N
affected VBN N
by IN N
a DT N
shift NN N
from IN N
the DT N
prior JJ N
, , N
opposite JJ N
therapist NN N
process NN N
. . N

Significant JJ N
proportions NNS N
of IN N
the DT N
variance NN N
in IN N
responsibility NN o
, , o
struggle NN o
, , o
and CC o
cooperation NN o
, , N
however RB N
, , N
were VBD N
not RB N
accounted VBN N
for IN N
by IN N
therapist JJ N
process NN N
alone RB N
. . N

-DOCSTART- -20576092- O O

Early JJ N
combination NN N
disease-modifying JJ N
antirheumatic JJ i
drug NN i
therapy NN i
and CC N
tight JJ N
disease NN N
control NN N
improve VB N
long-term JJ o
radiologic JJ o
outcome NN o
in IN N
patients NNS p
with IN p
early JJ p
rheumatoid NN p
arthritis NN p
: : p
the DT N
11-year JJ N
results NNS N
of IN N
the DT N
Finnish NNP N
Rheumatoid NNP N
Arthritis NNP N
Combination NNP N
Therapy NNP N
trial NN N
. . N

INTRODUCTION NNP N
Early NNP N
treatment NN N
of IN N
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
has VBZ N
been VBN N
shown VBN N
to TO N
retard VB N
the DT N
development NN o
of IN o
joint JJ o
damage NN o
for IN N
a DT N
period NN N
of IN N
up IN N
to TO N
5 CD N
years NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB o
the DT o
radiologic JJ o
progression NN o
beyond IN N
that DT N
time NN N
in IN N
patients NNS p
with IN p
early JJ p
RA NNP p
initially RB p
treated VBD p
with IN p
a DT p
combination NN p
of IN p
three CD i
disease-modifying JJ i
antirheumatic JJ i
drugs NNS i
( ( i
DMARDs NNP i
) ) i
or CC p
a DT p
single JJ i
DMARD NNP i
. . i

METHODS NNP N
A NNP N
cohort NN N
of IN N
199 CD p
patients NNS p
with IN p
early JJ p
active JJ p
RA NNP p
were VBD N
initially RB N
randomized VBN N
to TO N
receive VB N
treatment NN N
with IN N
a DT N
combination NN i
of IN i
methotrexate NN i
, , i
sulfasalazine NN i
, , i
and CC i
hydroxychloroquine NN i
with IN i
prednisolone NN i
( ( i
FIN-RACo NNP i
) ) i
, , i
or CC i
treatment NN i
with IN i
a DT i
single JJ i
DMARD NNP i
( ( i
initially RB i
, , i
sulfasalazine NN i
) ) i
with IN i
or CC i
without IN i
prednisolone NN i
( ( i
SINGLE NNP i
) ) i
. . i

After IN N
2 CD N
years NNS N
, , N
the DT N
drug-treatment JJ N
strategy NN N
became VBD N
unrestricted JJ N
, , N
but CC N
still RB N
targeted VBN N
remission NN N
. . N

The DT N
radiographs NN o
of IN N
hands NNS N
and CC N
feet NNS N
were VBD N
analyzed VBN o
by IN o
using VBG o
the DT o
Larsen NNP o
score NN o
at IN N
baseline NN N
, , N
2 CD N
, , N
5 CD N
, , N
and CC N
11 CD N
years NNS N
, , N
and CC N
the DT N
radiographs NN N
of IN N
large JJ N
joints NNS N
, , N
at IN N
11 CD N
years NNS N
. . N

RESULTS VB N
Sixty-five JJ N
patients NNS N
in IN N
the DT N
FIN-RACo NNP i
and CC N
65 CD N
in IN N
the DT N
SINGLE NNP i
group NN N
had VBD N
radiographs NN N
of IN N
hands NNS N
and CC N
feet NNS N
available JJ N
at IN N
baseline NN N
and CC N
at IN N
11 CD N
years NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
to TO N
11 CD N
years NNS N
in IN N
Larsen NNP o
score NN o
was VBD N
17 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
12 CD N
to TO N
26 CD N
) ) N
in IN N
the DT N
FIN-RACo NNP i
group NN N
and CC N
27 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
22 CD N
to TO N
33 CD N
) ) N
in IN N
the DT N
SINGLE NNP i
group NN N
( ( N
P=0.037 NNP N
) ) N
. . N

In IN N
total JJ N
, , N
87 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
74 CD N
to TO N
94 CD N
) ) N
and CC N
72 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
58 CD N
to TO N
84 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
FIN-RACo NNP N
and CC N
the DT N
SINGLE NNP N
treatment NN N
arms NNS N
, , N
respectively RB N
, , N
had VBD N
no DT N
erosive JJ o
changes NNS o
in IN N
large JJ N
joints NNS N
at IN N
11 CD N
years NNS N
. . N

CONCLUSIONS NNP N
Targeting VBG N
to TO N
remission NN N
with IN N
tight JJ N
clinical JJ N
controls NNS N
results NNS N
in IN N
low JJ N
radiologic JJ o
progression NN o
in IN N
most JJS N
RA JJ p
patients NNS p
. . p

Patients NNS N
treated VBD N
initially RB N
with IN N
a DT N
combination NN i
of IN i
DMARDs NNP i
have VBP N
less RBR N
long-term JJ o
radiologic NN o
damage NN o
than IN N
do VBP N
those DT N
treated VBN N
initially RB N
with IN N
DMARD NNP i
monotherapy NN i
. . i

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN18445519 NNP N
. . N

-DOCSTART- -10634835- O O

Randomised VBN N
controlled JJ N
trial NN N
of IN N
patient NN N
triggered VBN i
and CC i
conventional JJ i
fast JJ i
rate NN i
ventilation NN i
in IN N
neonatal JJ p
respiratory NN p
distress NN p
syndrome NN p
. . p

AIM NNP N
To TO N
compare VB N
patient NN N
triggered VBN N
, , N
with IN N
conventional JJ N
fast JJ N
rate NN N
, , N
ventilation NN N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
using VBG N
the DT N
incidence NN o
of IN o
chronic JJ o
lung NN o
disease NN o
as IN N
the DT N
primary JJ N
outcome JJ N
measure NN N
. . N

METHODS NNP N
Three CD p
hundred VBD p
and CC p
eighty JJ p
six CD p
preterm JJ p
infants NNS p
with IN p
birthweights NNS p
from IN p
1000 CD p
to TO p
2000 CD p
g NN p
, , p
and CC p
requiring VBG p
ventilation NN p
for IN p
respiratory JJ p
distress JJ p
syndrome NN p
within IN p
24 CD p
hours NNS p
of IN p
birth NN p
, , N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
conventional JJ i
or CC i
trigger JJ i
ventilation NN i
with IN i
the DT i
SLE NNP i
2000 CD i
ventilator NN i
. . i

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN o
of IN o
chronic JJ o
lung NN o
disease NN o
( ( N
28 CD N
day NN N
and CC N
36 CD N
week NN N
definitions NNS N
) ) N
, , N
death NN o
, , o
pneumothorax NN o
, , o
intraventricular JJ o
haemorrhage NN o
, , o
number NN o
of IN o
ventilator NN o
days NNS o
, , o
or CC o
length NN o
of IN o
oxygen NN o
dependency NN o
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Patient NNP N
triggered VBD N
ventilation NN N
in IN N
preterm JJ p
infants NNS p
with IN p
respiratory JJ p
distress JJ p
syndrome NN p
is VBZ N
feasible JJ N
. . N

No DT N
significant JJ N
differences NNS N
, , N
when WRB N
compared VBN N
with IN N
conventional JJ N
fast JJ N
rate NN N
ventilation NN N
in IN N
important JJ N
medium NN o
and CC o
longer JJR o
term NN o
outcome NN o
measures NNS o
, , N
were VBD N
evident JJ N
. . N

-DOCSTART- -3516395- O O

Randomized VBN N
trial NN N
of IN N
high-dose JJ N
cytarabine NN i
versus NN i
amsacrine NN i
in IN N
acute JJ p
myelogenous JJ p
leukemia NN p
in IN p
relapse NN p
: : p
a DT p
Leukemia NNP p
Intergroup NNP p
Study NNP p
. . p

Patients NNS p
with IN p
acute JJ p
myelogenous JJ p
leukemia NN p
in IN p
relapse NN p
who WP p
were VBD p
ineligible JJ p
for IN p
further JJ p
anthracycline NN i
therapy NN i
either CC p
because IN p
they PRP p
were VBD p
judged VBN p
to TO p
be VB p
anthracycline JJ i
resistant NN p
or CC p
had VBD p
received VBN p
the DT p
maximum JJ p
doses NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
high-dose JJ N
cytarabine NN i
( ( N
3 CD N
g/m2 NN N
every DT N
12 CD N
hours NNS N
for IN N
6 CD N
days NNS N
) ) N
or CC N
amsacrine NN i
( ( N
75 CD N
mg/m2 NNS N
daily RB N
for IN N
7 CD N
days NNS N
) ) N
. . N

The DT N
response NN o
rates NNS o
in IN o
both DT N
groups NNS N
were VBD N
similar JJ N
: : N
three CD p
of IN p
25 CD p
patients NNS p
given VBN p
high-dose JJ p
cytarabine NN i
and CC p
three CD p
of IN p
23 CD p
given VBN p
amsacrine NN i
obtained VBN N
complete JJ o
remissions NNS o
. . o

-DOCSTART- -9562733- O O

[ JJ N
Prevention NNP N
of IN N
vascular JJ o
complications NNS o
following VBG N
cerebral JJ N
ischemia NN N
of IN N
arterial JJ N
origin NN N
; : N
the DT N
ESPRIT NNP N
trial NN N
: : N
mild JJ i
anticoagulant JJ i
therapy NN i
, , N
combination NN N
treatment NN N
with IN N
acetylsalicylic JJ i
acid NN i
plus CC i
dipyridamole NN i
or CC i
treatment NN i
with IN i
acetylsalicylic JJ i
acid NN i
alone RB i
? . N
] UH N
. . N

The DT N
European JJ N
and CC N
Australian JJ N
Stroke NNP N
Prevention NNP N
in IN N
Reversible NNP N
Ischaemia NNP N
Trial NNP N
( ( N
ESPRIT NNP N
) ) N
is VBZ N
a DT N
randomised JJ N
clinical JJ N
trial NN N
in IN N
which WDT N
patients NNS p
with IN p
cerebral JJ p
ischaemia NN p
of IN p
arterial JJ p
origin NN p
will MD N
be VB N
randomised VBN N
between IN N
oral JJ i
anticoagulation NN i
( ( N
international JJ N
normalized VBN N
ratio NN N
( ( N
INR NNP N
) ) N
: : N
2.0-3.0 JJ N
) ) N
, , N
the DT N
combination NN N
of IN N
acetylsalicylic JJ i
acid NN i
( ( N
in IN N
any DT N
dose NN N
between IN N
30 CD N
and CC N
325 CD N
mg NNS N
per IN N
day NN N
) ) N
plus CC N
dipyridamole JJ i
( ( N
400 CD N
mg NNS N
daily RB N
) ) N
and CC N
acetylsalicylic JJ i
acid NN i
only RB N
( ( N
in IN N
any DT N
dose NN N
between IN N
30 CD N
and CC N
325 CD N
mg NNS N
per IN N
day NN N
) ) N
. . N

It PRP N
is VBZ N
planned VBN p
to TO p
enroll VB p
4500 CD p
patients NNS p
with IN p
a DT p
mean JJ p
follow-up NN p
of IN p
three CD p
years NNS p
. . p

Primary JJ N
outcome NN N
is VBZ N
the DT N
composite JJ o
event NN o
of IN o
vascular JJ o
death NN o
, , o
stroke NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
major JJ o
bleeding VBG o
complication NN o
; : o
outcome CC N
assessment NN N
will MD N
be VB N
blinded VBN N
. . N

ESPRIT NNP N
is VBZ N
an DT N
international JJ p
, , p
multicentre JJ p
study NN p
in IN p
which WDT p
60-80 JJ p
hospitals NNS p
in IN p
the DT p
Netherlands NNP p
and CC p
other JJ p
countries NNS p
in IN p
Europe NNP p
and CC p
Australia NNP p
will MD p
participate VB p
. . p

-DOCSTART- -22964266- O O

Mindfulness-based JJ i
therapy NN i
in IN N
adults NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Research NN N
shows VBZ N
that IN N
depression NN N
and CC N
anxiety NN N
disorders NNS N
are VBP N
the DT N
most RBS N
common JJ N
psychiatric JJ N
concern NN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
( ( N
ASD NNP N
) ) N
. . N

Mindfulness-based JJ i
therapy NN i
( ( i
MBT NNP i
) ) i
has VBZ N
been VBN N
found VBN N
effective JJ N
in IN N
reducing VBG N
anxiety NN o
and CC o
depression NN o
symptoms NNS o
, , N
however RB N
research NN N
in IN N
autism NN N
is VBZ N
limited VBN N
. . N

Therefore RB N
, , N
we PRP N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
modified JJ i
MBT NNP i
protocol NN i
( ( i
MBT-AS NNP i
) ) i
in IN N
high-functioning NN p
adults NNS p
with IN p
ASD NNP p
. . p

42 CD p
participants NNS p
were VBD N
randomized VBN N
into IN N
a DT N
9-week JJ N
MBT-AS JJ i
training NN i
or CC N
a DT N
wait-list JJ i
control NN i
group NN i
. . i

Results NNP N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
depression NN o
, , o
anxiety NN o
and CC o
rumination NN o
in IN N
the DT N
intervention NN N
group NN N
, , N
as IN N
opposed VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Furthermore RB N
, , N
positive JJ o
affect NN o
increased VBN N
in IN N
the DT N
intervention NN N
group NN N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

Concluding NNP N
, , N
the DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
controlled VBN N
trial NN N
to TO N
demonstrate VB N
that IN N
adults NNS p
with IN p
ASD NNP p
can MD N
benefit VB N
from IN N
MBT-AS NNP i
. . i

-DOCSTART- -8928893- O O

Age NNP N
and CC N
autonomic JJ N
effects NNS N
on IN N
interrelationships NNS N
between IN N
lung NN N
volume NN N
and CC N
heart NN N
rate NN N
. . N

To TO N
determine VB N
effects NNS N
of IN N
aging VBG N
and CC N
autonomic JJ N
input NN N
on IN N
interrelationships NNS N
between IN N
respiratory NN N
and CC N
heart NN N
rate NN N
variability NN N
, , N
we PRP N
collected VBD N
5 CD N
min NN N
of IN N
lung NN N
volume NN N
of IN N
R-R NNP N
interval NN N
data NNS N
from IN N
7 CD p
young JJ p
[ $ p
27 CD p
+/- JJ p
3 CD p
( ( p
SD NNP p
) ) p
yr NN p
] NN p
and CC p
10 CD p
older JJR p
( ( p
69 CD p
+/- JJ p
6 CD p
yr NN p
) ) p
healthy JJ p
supine NN p
humans NNS p
before IN p
and CC p
after IN p
double JJ p
pharmacological JJ p
autonomic NN p
blockade NN p
with IN p
propranolol NN i
( ( p
0.2 CD p
mg/kg RB p
iv NN p
) ) p
and CC p
atropine NN i
( ( p
0.04 CD p
mg/kg RB p
iv NN p
) ) p
. . p

Estimates NNS N
of IN N
respiratory NN N
and CC N
heart NN N
rate NN N
power NN N
spectra NN N
and CC N
linear JJ N
transfer NN N
functions NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
generated VBN N
by IN N
Fourier NNP N
analysis NN N
. . N

Age NNP N
, , N
double JJ N
blockade NN N
effects NNS N
, , N
the DT N
age-drug JJ N
interactions NNS N
were VBD N
determined VBN N
by IN N
analysis NN N
of IN N
variance NN N
for IN N
repeated JJ N
measures NNS N
. . N

Basal NNP N
R-R JJ N
intervals NNS N
were VBD N
unaffected VBN N
by IN N
age NN N
. . N

Double JJ N
blockade NN N
decreased VBD N
R-R JJ o
intervals NNS o
and CC o
variability NN o
in IN N
both DT N
age NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
R-R NNP N
intervals NNS N
decreased VBD N
less RBR N
in IN N
older JJR N
than IN N
in IN N
young JJ N
subjects NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
basal JJ o
respiratory NN o
intervals NNS o
and CC N
standard JJ N
deviation NN N
were VBD N
greater JJR N
in IN N
older JJR N
subjects NNS N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
were VBD N
unaffected VBN N
by IN N
double JJ N
blockade NN N
in IN N
young JJ p
and CC p
older JJR p
subjects NNS p
. . p

Lung NNP o
volume-to-heart JJ o
rate NN o
spectral JJ o
coherence NN o
was VBD N
highest JJS N
at IN N
frequencies NNS N
associated VBN N
with IN N
respiration NN N
and CC N
greater JJR N
in IN N
young JJ N
than IN N
in IN N
older JJR N
subjects NNS N
( ( N
P NNP N
< NNP N
0.07 CD N
) ) N
. . N

Double JJ N
blockade NN N
decreased VBD N
lung JJ o
volume-to-heart JJ o
rate NN o
variability NN o
transfer NN o
function NN o
magnitude NN o
( ( N
P NNP N
< NNP N
0.007 CD N
) ) N
and CC N
increased JJ N
phase NN o
angle NN o
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
without IN N
age NN N
effects NNS N
or CC N
age-drug JJ N
interactions NNS N
. . N

In IN N
conclusion NN N
, , N
heart NN o
rate NN o
, , o
respiration NN o
, , o
and CC o
respiration-heart JJ o
rate NN o
interrelations NNS o
are VBP N
altered VBN N
by IN N
aging VBG N
, , N
and CC N
double JJ N
autonomic JJ N
pharmacological JJ N
blockade NN N
does VBZ N
not RB N
eliminate VB N
all DT N
age-related JJ N
differences NNS N
. . N

-DOCSTART- -6761890- O O

Platelet NNP i
inhibitory NN i
drugs NNS i
: : i
an DT N
in IN N
vivo NN N
method NN o
of IN o
evaluation NN o
in IN N
patients NNS N
. . N

The DT N
measurement NN N
of IN N
platelet NN o
deposition NN o
in IN p
human JJ p
thrombi NN p
is VBZ N
essential JJ N
for IN N
the DT N
evaluation NN o
of IN o
platelet-inhibitory JJ o
drugs NNS o
and CC o
prosthetic JJ o
materials NNS o
for IN N
use NN N
in IN N
patients NNS N
. . N

The DT N
rate NN N
of IN N
111Indium-labelled JJ N
platelet NN o
accumulation NN o
on IN N
Dacron NNP p
arterial JJ p
grafts NN p
was VBD N
measured VBN N
in IN N
27 CD p
patients NNS p
randomised VBD N
to TO N
take VB N
either DT N
aspirin NN i
and CC i
dipyridamole NN i
( ( i
ASA NNP i
+ NNP i
DPM NNP i
) ) i
or CC i
placebo NN i
. . i

Autologous JJ i
platelets NNS i
were VBD i
labelled VBN i
and CC i
re-injected JJ i
seven CD i
days NNS i
following VBG i
surgery NN i
and CC i
the DT i
graft NN i
thrombogenicity NN i
index NN i
calculated VBD N
as IN N
the DT N
daily JJ N
rise NN N
in IN N
the DT N
ratio NN o
of IN o
emissions NNS o
from IN N
the DT N
graft NN N
over IN N
a DT N
reference NN N
site NN N
. . N

The DT N
mean NN N
( ( N
+/- JJ N
SD NNP N
) ) N
thrombogenicity NN o
index NN o
in IN N
12 CD N
patients NNS N
undergoing JJ N
femoro-popliteal JJ N
bypass NN N
was VBD N
0.25 CD N
+/- JJ N
0.09 CD N
on IN N
placebo NN N
and CC N
0.16 CD N
+/- JJ N
0.07 CD N
on IN N
ASA NNP N
+ NNP N
DPM NNP N
started VBD N
pre-operatively RB N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Post-operative JJ N
ASA NNP i
+ NNP i
DPM NNP i
therapy NN N
started VBD N
two CD N
days NNS N
following VBG N
platelet NN N
labelling VBG N
in IN N
15 CD N
patients NNS N
with IN N
aorto-femoral JJ N
grafts NNS N
also RB N
significantly RB N
reduce VB N
thrombogenicity NN o
to TO N
0.12 CD N
+/- JJ N
0.05 CD N
compared VBN N
with IN N
0.25 CD N
+/- JJ N
0.08 CD N
on IN N
placebo NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

In IN N
the DT N
latter JJ N
patients NNS N
the DT N
ratio NN N
of IN N
emissions NNS o
from IN N
the DT N
graft NN N
over IN N
reference NN N
fell VBD N
significantly RB N
on IN N
starting VBG N
ASA NNP i
+ NNP i
DPM NNP i
, , N
suggesting VBG N
a DT N
net JJ N
loss NN N
of IN N
platelets NNS N
from IN N
the DT N
graft NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
rate NN o
of IN o
in IN o
vivo JJ o
platelet NN o
accumulation NN o
on IN N
Dacron NNP N
grafts NNS N
can MD N
be VB N
quantitated VBN N
and CC N
that IN N
ASA NNP i
+ NNP i
DPM NNP i
reduced VBD N
this DT N
rate NN N
in IN N
man NN N
. . N

-DOCSTART- -17954800- O O

Chlorhexidine-based JJ i
antiseptic JJ i
solution NN i
vs IN N
alcohol-based JJ i
povidone-iodine NN i
for IN N
central JJ N
venous JJ N
catheter NN N
care NN N
. . N

BACKGROUND NNP N
Although IN N
chlorhexidine-based JJ i
solutions NNS i
and CC N
alcohol-based JJ i
povidone-iodine NN i
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
efficient JJ N
than IN N
aqueous JJ N
povidone-iodine NN N
for IN N
skin JJ N
disinfection NN N
at IN N
catheter NN p
insertion NN p
sites NNS p
, , N
their PRP$ N
abilities NNS N
to TO N
reduce VB N
catheter-related JJ o
infection NN o
have VBP N
never RB N
been VBN N
compared VBN N
. . N

METHODS NNP N
Consecutively RB p
scheduled VBD p
central JJ p
venous JJ p
catheters NNS p
inserted VBN p
into IN p
jugular NN p
or CC p
subclavian JJ p
veins NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
disinfected VBN N
with IN N
5 CD i
% NN i
povidone-iodine NN i
in IN i
70 CD i
% NN i
ethanol NN i
or CC i
with IN i
a DT i
combination NN i
of IN i
0.25 CD i
% NN i
chlorhexidine NN i
gluconate NN i
, , i
0.025 CD i
% NN i
benzalkonium NN i
chloride NN i
, , i
and CC i
4 CD i
% NN i
benzylic JJ i
alcohol NN i
. . i

Solutions NNS N
were VBD N
used VBN N
for IN N
skin JJ N
disinfection NN N
before IN N
catheter NN N
insertion NN N
( ( N
2 CD N
consecutive JJ N
30-second JJ N
applications NNS N
separated VBN N
by IN N
a DT N
period NN N
sufficiently RB N
long RB N
to TO N
allow VB N
for IN N
dryness NN N
) ) N
and CC N
then RB N
as IN N
single JJ N
applications NNS N
during IN N
subsequent JJ N
dressing NN N
changes NNS N
( ( N
every DT N
72 CD N
hours NNS N
, , N
or CC N
earlier RB N
if IN N
soiled VBN N
or CC N
wet VBN N
) ) N
. . N

RESULTS NNP N
Of IN N
538 CD p
catheters NNS p
randomized VBD p
, , p
481 CD p
( ( p
89.4 CD p
% NN p
) ) p
produced VBD p
evaluable JJ p
culture NN o
results NNS o
. . o

Compared VBN N
with IN N
povidone-iodine NN i
, , N
the DT N
chlorhexidine-based JJ i
solution NN i
was VBD N
associated VBN N
with IN N
a DT N
50 CD N
% NN N
decrease NN N
in IN N
the DT N
incidence NN o
of IN o
catheter NN o
colonization NN o
( ( N
11.6 CD N
% NN N
vs JJ N
22.2 CD N
% NN N
[ JJ N
P NNP N
= NNP N
.002 NNP N
] NNP N
; : N
incidence NN o
density NN o
, , N
9.7 CD N
vs NN N
18.3 CD N
per IN N
1000 CD N
catheter-days NN N
) ) N
and CC N
with IN N
a DT N
trend NN N
toward IN N
lower JJR N
rates NNS N
of IN N
catheter-related JJ o
bloodstream NN o
infection NN o
( ( N
1.7 CD N
% NN N
vs JJ N
4.2 CD N
% NN N
[ JJ N
P NNP N
= NNP N
.09 NNP N
] NNP N
; : N
incidence NN o
density NN o
, , N
1.4 CD N
vs NN N
3.4 CD N
per IN N
1000 CD N
catheter-days NN N
) ) N
. . N

Independent JJ N
risk NN N
factors NNS N
for IN N
catheter NN o
colonization NN o
were VBD N
catheter JJ N
insertion NN N
into IN N
the DT N
jugular JJ N
vein NN N
( ( N
adjusted VBN N
relative NN N
risk NN N
, , N
2.01 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.24-3.24 JJ N
) ) N
and CC N
use NN N
of IN N
povidone-iodine NN i
( ( N
adjusted VBN N
relative NN N
risk NN N
, , N
1.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.18-2.96 JJ N
) ) N
. . N

CONCLUSION NNP N
Chlorhexidine-based JJ i
solutions NNS i
should MD N
be VB N
considered VBN N
as IN N
a DT N
replacement NN N
for IN N
povidone-iodine NN i
( ( i
including VBG i
alcohol-based VBN i
) ) i
formulations NNS i
in IN N
efforts NNS N
to TO N
prevent VB N
catheter-related JJ o
infection NN o
. . o

-DOCSTART- -3166942- O O

Psoriasis NN p
of IN p
the DT p
scalp NN p
treated VBD N
with IN N
Grenz NNP i
rays NNS i
or CC N
topical JJ i
corticosteroid NN i
combined VBN i
with IN i
Grenz NNP i
rays NNS i
. . i

A DT N
comparative JJ N
randomized VBN N
trial NN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
Grenz NNP i
ray NN i
therapy NN i
alone RB N
compared VBN N
with IN N
Grenz NNP i
rays NNS i
combined VBN i
with IN i
a DT i
topical JJ i
corticosteroid NN i
( ( i
betamethasone JJ i
dipropionate NN i
) ) i
in IN N
psoriasis NN N
of IN N
the DT N
scalp NN N
, , N
40 CD p
patients NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
4 CD i
Gy NNP i
of IN i
Grenz NNP i
rays NNS i
administered VBD N
on IN N
six CD N
occasions NNS N
at IN N
intervals NNS N
of IN N
1 CD N
week NN N
and CC N
the DT N
other JJ N
group NN N
was VBD N
given VBN N
the DT N
same JJ N
Grenz NNP i
ray NN i
treatment NN i
plus CC i
topical JJ i
corticosteroid NN i
. . i

The DT N
patients NNS N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
Grenz NNP N
ray NN N
therapy NN N
and CC N
were VBD N
followed-up NNS N
for IN N
6 CD N
months NNS N
. . N

Of IN N
the DT N
37 CD p
patients NNS p
who WP p
completed VBD p
the DT p
trial NN p
16 CD N
out IN N
of IN N
19 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
Grenz NNP i
ray NN i
group NN N
, , N
and CC N
13 CD N
out IN N
of IN N
18 CD N
( ( N
72 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
combination NN N
group NN N
healed VBD o
. . o

The DT N
remission NN o
time NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Of IN N
the DT N
patients NNS p
who WP p
healed VBD o
, , N
5 CD N
of IN N
16 CD N
patients NNS N
in IN N
the DT N
Grenz NNP i
ray NN i
only RB N
group NN N
and CC N
4 CD N
of IN N
13 CD N
patients NNS N
in IN N
the DT N
combination NN N
group NN N
remained VBD o
healed VBN o
at IN N
6 CD N
months NNS N
. . N

We PRP N
conclude VBP N
that IN N
Grenz NNP i
ray NN i
therapy NN i
is VBZ N
a DT N
useful JJ N
treatment NN o
modality NN N
for IN N
scalp JJ o
psoriasis NN o
, , N
but CC N
that IN N
the DT N
addition NN N
of IN N
a DT N
topical JJ N
corticosteroid NN i
has VBZ N
only RB N
a DT N
minor JJ o
effect NN o
. . o

-DOCSTART- -24189342- O O

Central JJ N
5-HT4 JJ N
receptor NN N
binding NN N
as IN N
biomarker NN N
of IN N
serotonergic JJ N
tonus NN N
in IN N
humans NNS p
: : p
a DT N
[ $ N
11C CD N
] NNP N
SB207145 NNP N
PET NNP N
study NN N
. . N

Identification NNP N
of IN N
a DT N
biomarker NN N
that WDT N
can MD N
inform VB N
on IN N
extracellular JJ N
serotonin NN N
( ( N
5-HT JJ N
) ) N
levels NNS N
in IN N
the DT N
brains NNS N
of IN N
living NN p
humans NNS p
would MD N
enable VB N
greater JJR N
understanding NN N
of IN N
the DT N
way NN N
brain NN N
circuits NNS N
are VBP N
modulated VBN N
by IN N
serotonergic JJ N
neurotransmission NN N
. . N

Substantial JJ N
evidence NN N
from IN N
studies NNS N
in IN N
animals NNS N
and CC N
humans NNS N
indicates VBZ N
an DT N
inverse NN N
relationship NN N
between IN N
central JJ N
5-HT JJ N
tonus NN N
and CC N
5-HT JJ N
type NN N
4 CD N
receptor NN N
( ( N
5-HT4R JJ N
) ) N
density NN N
, , N
suggesting VBG N
that IN N
5-HT4R JJ N
receptor NN N
density NN N
may MD N
be VB N
a DT N
biomarker NN N
marker NN N
for IN N
5-HT JJ N
tonus NN N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
whether IN N
a DT N
3-week JJ N
administration NN N
of IN N
a DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
, , N
expected VBN N
to TO N
increase VB N
brain NN N
5-HT JJ N
levels NNS N
, , N
is VBZ N
associated VBN N
with IN N
a DT N
decline NN N
in IN N
brain NN N
5-HT4R JJ N
binding NN N
. . N

A DT p
total NN p
of IN p
35 CD p
healthy JJ p
men NNS p
were VBD p
studied VBN p
in IN N
a DT N
placebo-controlled JJ i
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
. . N

Participants NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
3 CD N
weeks NNS N
of IN N
oral JJ i
dosing VBG i
with IN i
placebo NN i
or CC i
fluoxetine NN i
, , i
40 CD i
mg NNS i
per IN i
day NN i
. . i

Brain VB o
5-HT4R JJ o
binding NN o
was VBD N
quantified VBN N
at IN N
baseline NN N
and CC N
at IN N
follow-up JJ N
with IN N
[ NNP i
( ( i
11 CD i
) ) i
C NNP i
] NNP i
SB207145 NNP i
positron NN o
emission NN o
tomography NN o
( ( o
PET NNP o
) ) o
. . o

Three CD N
weeks NNS N
of IN N
intervention NN N
with IN N
fluoxetine NN N
was VBD N
associated VBN N
with IN N
a DT N
5.2 CD N
% NN N
reduction NN N
in IN N
brain NN o
5-HT4R JJ o
binding NN o
( ( N
P=0.017 NNP N
) ) N
, , N
whereas JJ N
placebo NN N
intervention NN N
did VBD N
not RB N
change VB N
5-HT4R JJ N
binding NN N
( ( N
P=0.52 NNP N
) ) N
. . N

Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
a DT N
model NN N
, , N
wherein VBP N
the DT N
5-HT4R JJ o
density NN o
adjusts VBZ N
to TO N
changes NNS N
in IN N
the DT N
extracellular JJ N
5-HT JJ N
tonus NN N
. . N

Our PRP$ N
data NNS N
demonstrate NN N
for IN N
the DT N
first JJ N
time NN N
in IN N
humans NNS p
that IN N
the DT N
imaging NN N
of IN N
central JJ N
5-HT4R JJ N
binding NN N
may MD N
be VB N
used VBN N
as IN N
an DT N
in IN N
vivo NN N
biomarker NN N
of IN N
the DT N
central JJ N
5-HT JJ N
tonus NN N
. . N

-DOCSTART- -20647483- O O

Letter NN N
by IN N
Begg NNP N
et CC N
al NN N
regarding VBG N
article NN N
, , N
The DT N
effects NNS N
of IN N
vitamin NN i
d NN i
supplementation NN i
on IN N
physical JJ o
function NN o
and CC o
quality NN o
of IN o
life NN o
in IN N
older JJR p
heart NN p
failure NN p
patients NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -24859114- O O

Effect NN N
of IN N
glycemic JJ N
load NN N
on IN N
eating VBG o
behavior JJ o
self-efficacy NN o
during IN N
weight JJ N
loss NN N
. . N

High JJ N
eating JJ N
behavior JJ N
self-efficacy NN N
may MD N
contribute VB N
to TO N
successful JJ N
weight JJ N
loss NN N
. . N

Diet JJ i
interventions NNS i
that WDT N
maximize VBP N
eating VBG N
behavior JJ N
self-efficacy NN N
may MD N
therefore VB N
improve VB N
weight NN N
loss NN N
outcomes NNS N
. . N

However RB N
, , N
data NNS N
on IN N
the DT N
effect NN N
of IN N
diet JJ N
composition NN N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
are VBP N
sparse JJ N
. . N

To TO N
determine VB N
the DT N
effects NNS N
of IN N
dietary JJ N
glycemic JJ N
load NN N
( ( N
GL NNP N
) ) N
on IN N
eating VBG N
behavior JJ N
self-efficacy NN N
during IN N
weight JJ N
loss NN N
, , N
body NN o
weight NN o
and CC N
eating VBG o
behavior JJ o
self-efficacy NN o
were VBD N
measured VBN N
every DT N
six CD N
months NNS N
in IN N
overweight JJ p
adults NNS p
participating VBG p
in IN p
a DT p
12-mo JJ p
randomized JJ p
trial NN p
testing VBG i
energy-restricted JJ i
diets NNS i
differing VBG i
in IN i
GL NNP i
. . i

All DT N
food NN N
was VBD N
provided VBN N
during IN N
the DT N
first JJ N
six CD N
months NNS N
and CC N
self-selected JJ N
thereafter NN N
. . N

Total JJ o
mean JJ o
weight NN o
loss NN o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
, , N
and CC N
GL-level NNP N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
eating VBG o
behavior JJ o
self-efficacy NN o
. . o

In IN N
the DT N
combined JJ N
cohort NN N
, , N
individuals NNS N
losing VBG N
the DT N
most RBS N
weight JJ N
reported VBD N
improvements NNS N
in IN N
eating VBG o
behavior JJ o
self-efficacy NN o
, , N
whereas IN N
those DT N
achieving VBG N
less JJR N
weight JJ o
loss NN o
reported VBD N
decrements NNS N
in IN N
eating VBG o
behavior JJ o
self-efficacy NN o
. . o

Decrements NNS N
in IN N
eating VBG o
behavior JJ o
self-efficacy NN o
were VBD N
associated VBN N
with IN N
subsequent JJ N
weight NN o
regain NN N
when WRB N
diets NNS N
were VBD N
self-selected JJ N
. . N

While IN N
GL NNP N
does VBZ N
not RB N
appear VB N
to TO N
influence VB N
eating VBG N
behavior JJ N
self-efficacy NN N
, , N
lesser JJR N
amounts NNS N
of IN N
weight JJ N
loss NN N
on IN N
provided-food JJ i
energy NN i
restricted VBN i
diets NNS i
may MD N
deter VB N
successful JJ N
maintenance NN N
of IN N
weight JJ N
loss NN N
by IN N
attenuating VBG N
improvements NNS N
in IN N
eating VBG N
behavior JJ N
self-efficacy NN N
. . N

-DOCSTART- -25841244- O O

Coronary JJ i
artery NN i
bypass NN i
graft NN i
surgery NN i
provides VBZ N
clinically RB N
important JJ N
quality-of-life JJ o
improvements NNS o
over IN N
medical JJ N
therapy NN N
in IN N
patients NNS p
with IN p
ischaemic JJ p
left VBD p
ventricular JJ p
dysfunction NN p
. . p

-DOCSTART- -17252578- O O

Does NNP N
ambient VBD N
light JJ N
contribute NN N
to TO N
the DT N
therapeutic JJ N
effects NNS N
of IN N
topical JJ N
photodynamic JJ N
therapy NN N
( ( N
PDT NNP N
) ) N
using VBG N
aminolevulinic JJ N
acid NN N
HCl NNP N
( ( N
ALA NNP N
) ) N
? . N
-DOCSTART- -4127641- O O

Comparison NNP N
of IN N
the DT N
potassium- JJ o
retaining NN o
effects NNS o
of IN N
amiloride NN i
and CC i
spironolactone NN i
in IN N
hypertensive JJ p
patients NNS p
with IN p
thiazide-induced JJ p
hypokalaemia NN p
. . p

-DOCSTART- -16089221- O O

Hydrogen NNP i
peroxide NN i
mouth NN i
rinse NN i
: : i
an DT N
analgesic JJ N
post-tonsillectomy NN p
. . p

OBJECTIVE UH N
To TO N
compare VB N
the DT N
analgesic JJ o
efficacy NN o
of IN N
hydrogen NN i
peroxide NN i
( ( i
H2O2 NNP i
) ) i
mouth NN i
rinse NN i
with IN N
control NN i
for IN N
post-tonsillectomy JJ o
pain NN o
management NN o
. . o

DESIGN NNP N
Double-blinded NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Thirty-seven JJ p
patients NNS p
from IN p
5 CD p
to TO p
14 CD p
years NNS p
old JJ p
undergoing JJ p
electrocautery NN i
tonsillectomy NN i
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
H2O2 NNP i
mouth NN i
rinse NN i
or CC i
the DT i
water NN i
rinse NN i
( ( i
control NN i
) ) i
group NN i
. . i

For IN N
14 CD N
days NNS N
, , N
patients NNS N
recorded VBD N
pain NN o
levels NNS o
twice RB o
daily RB o
using VBG N
a DT N
visual JJ o
analogue NN o
scale NN o
. . o

Analgesic JJ N
uses NNS N
, , N
as RB N
well RB N
as IN N
any DT N
complications NNS N
, , N
were VBD N
also RB N
noted VBN N
by IN N
the DT N
patients NNS N
. . N

RESULTS NNP N
Thirty-seven JJ N
patients NNS N
completed VBD N
the DT N
study NN N
, , N
21 CD N
in IN N
the DT N
treatment NN p
group NN p
and CC N
16 CD N
in IN N
the DT N
control NN p
group NN p
. . p

Mean NNP o
postoperative JJ o
days NNS o
of IN o
pain NN o
were VBD N
10.3 CD N
and CC N
8.3 CD N
, , N
respectively RB N
, , N
and CC N
differed VBD N
significantly RB N
( ( N
p JJ N
= NNP N
.008 NNP N
) ) N
. . N

Mean JJ o
postoperative JJ o
days NNS o
of IN o
analgesic JJ o
use NN N
were VBD N
9.0 CD N
and CC N
6.7 CD N
, , N
respectively RB N
, , N
and CC N
differed VBD N
significantly RB N
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
. . N

Only RB N
one CD N
incidence NN N
of IN N
postoperative JJ o
hemorrhage NN o
occurred VBD N
in IN N
the DT N
study NN N
group NN N
. . N

CONCLUSION NNP N
In IN N
our PRP$ N
study NN N
, , N
the DT N
H2O2 NNP i
mouth NN i
rinse NN i
does VBZ N
not RB N
provide VB N
a DT N
better JJR N
analgesic JJ o
effect NN o
than IN N
the DT N
water NN N
rinse NN N
for IN N
post-tonsillectomy JJ o
pain NN o
relief NN o
. . N

-DOCSTART- -7865492- O O

The DT N
effect NN N
of IN N
eradication NN N
of IN N
Helicobacter NNP N
pylori FW N
upon IN N
the DT N
duodenal JJ o
ulcer NN o
recurrence NN o
-- : o
a DT o
24 CD N
month NN N
follow-up JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
eradication NN o
of IN N
Helicobacter NNP N
pylori FW N
( ( N
H.pylori NNP N
) ) N
in IN N
the DT N
patients NNS p
with IN p
duodenal JJ p
ulcer NN p
( ( p
Du NNP p
) ) p
upon IN p
the DT N
DU NNP o
recurrence NN o
. . o

METHODS NNP N
This DT N
study NN N
was VBD N
performed VBN N
for IN N
190 CD p
patients NNS p
with IN p
DU NNP p
. . p

Four CD N
different JJ N
methods-microscopy NN N
of IN N
Gram NNP o
stained VBD o
mucosal JJ o
smear NN o
, , o
specific JJ o
culture NN o
, , o
biopsy NN o
urease JJ o
test NN o
, , o
histology NN o
of IN o
H NNP o
& CC o
E NNP o
staining-were JJ o
taken VBN N
for IN N
identifying VBG N
colonization NN N
of IN N
H. NNP N
pylori NN N
before IN N
treatment NN N
, , N
and CC N
for IN N
finding VBG N
the DT N
eradication NN N
of IN N
H. NNP N
pylori FW N
4 CD N
weeks NNS N
after IN N
completion NN N
of IN N
therapy NN N
in IN N
each DT N
treatment NN N
group NN N
( ( i
cometidine NN i
, , i
omeprazole NN i
, , i
colloidal JJ i
bismuth NN i
subcitrate NN i
( ( i
CBS NNP i
) ) i
, , i
CBS NNP i
and CC i
metronidazole JJ i
double JJ i
therapy NN i
, , i
CBS NNP i
, , i
metronidazole NN i
and CC i
amoxicillin JJ i
triple JJ i
therapy NN i
) ) i
. . N

To TO N
detect VB N
DU NNP o
recurrence NN o
, , N
the DT N
gastroscopy NN o
was VBD N
performed VBN N
at IN N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
months NNS N
after IN N
therapy NN N
. . N

RESULTS VB N
The DT N
eradication NN o
rate NN o
of IN N
the DT N
cimetidine NN i
group NN N
the DT N
omeprazole NN i
group NN N
, , N
and CC N
the DT N
CBS NNP i
group NN N
were VBD N
0 CD N
% NN N
, , N
7.7 CD N
% NN N
, , N
0 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
that IN N
of IN N
the DT N
double JJ i
therapy NN i
group NN N
and CC N
the DT N
triple JJ i
therapy NN i
group NN N
were VBD N
44.4 CD N
% NN N
and CC N
89.3 CD N
% NN N
, , N
respectively RB N
. . N

Seventy NNP p
three CD p
patients NNS p
who WP N
were VBD N
followed VBN N
up RP N
for IN N
2 CD N
years NNS N
were VBD N
categorized VBN N
into IN N
two CD p
groups NNS p
according VBG N
to TO N
the DT N
eradication NN o
of IN o
H. NNP o
pylori NN o
. . o

The DT N
recurrence NN o
rate NN o
was VBD N
3.2 CD N
% NN N
both DT N
in IN N
1 CD N
year NN N
and CC N
2 CD N
years NNS N
later RB N
in IN N
the DT N
former JJ N
group-one NN N
consisting NN N
of IN N
31 CD p
patients NNS p
with IN N
H. NNP N
pylori NN N
eradicated VBD N
, , N
while IN N
the DT N
recurrence NN o
rate NN o
was VBD N
57.1 CD N
% NN N
in IN N
1 CD N
year NN N
and CC N
78.6 CD N
% NN N
in IN N
2 CD N
years NNS N
later RB N
, , N
in IN N
the DT N
latter JJ N
group-the JJ N
other JJ N
of IN N
42 CD p
patients NNS p
with IN p
H. NNP p
pylori FW p
not RB N
eradicated VBN N
. . N

CONCLUSION VB N
The DT N
eradication NN N
of IN N
H. NNP N
pylori NN N
in IN N
patients NNS p
with IN p
DU NNP p
reduces VBZ N
the DT N
recurrence NN o
of IN o
DU NNP o
. . o

-DOCSTART- -23027887- O O

Multiple JJ N
courses NNS N
of IN N
rituximab NN i
produce NN N
sustained VBD N
clinical JJ N
and CC N
radiographic JJ N
efficacy NN N
and CC N
safety NN N
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
and CC p
an DT p
inadequate JJ p
response NN p
to TO p
1 CD p
or CC p
more JJR p
tumor JJ i
necrosis NN i
factor NN i
inhibitors NNS i
: : i
5-year JJ N
data NNS N
from IN N
the DT N
REFLEX NNP N
study NN N
. . N

OBJECTIVE VB N
This DT N
5-year JJ N
observational JJ N
posthoc NN N
analysis NN N
of IN N
the DT N
REFLEX NNP N
study NN N
and CC N
its PRP$ N
open-label JJ N
extension NN N
assessed VBD N
clinical JJ N
efficacy NN N
, , N
radiographic JJ N
response NN N
, , N
and CC N
safety NN N
of IN N
rituximab NN i
( ( i
RTX NNP i
) ) i
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
who WP p
had VBD p
an DT p
inadequate JJ p
response NN p
to TO p
tumor VB i
necrosis NN i
factor NN i
( ( i
TNF NNP i
) ) i
inhibitors NNS i
. . i

METHODS NNP N
Patients NNPS p
in IN p
REFLEX NNP p
were VBD N
originally RB N
randomized VBN N
to TO N
placebo VB i
( ( i
PBO NNP i
) ) i
+ NN i
methotrexate NN i
( ( i
MTX NNP i
; : i
PBO-randomized NNP i
) ) i
or CC i
RTX NNP i
+ NNP i
MTX NNP i
( ( i
RTX-randomized NNP i
) ) i
. . i

PBO-randomized JJ p
patients NNS p
were VBD N
rescued VBN N
with IN N
RTX NNP N
as IN N
appropriate JJ N
. . N

Patients NNS N
responding VBG N
to TO N
initial JJ N
RTX NNP i
treatment NN N
could MD N
receive VB N
further JJ N
RTX NNP i
courses NNS N
. . N

For IN N
clinical JJ N
efficacy NN N
and CC N
safety NN N
analyses NNS N
, , N
PBO-randomized JJ N
patients NNS N
were VBD N
re-baselined JJ N
prior NN N
to TO N
first JJ N
RTX NNP i
treatment NN N
and CC N
the DT N
data NNS N
were VBD N
pooled VBN N
with IN N
RTX-randomized JJ i
patient NN N
data NNS N
. . N

Efficacy NNP N
outcomes RB N
24 CD N
weeks NNS N
after IN N
each DT N
course NN N
were VBD N
calculated VBN N
relative JJ N
to TO N
first JJ N
RTX NNP i
pretreatment NN N
baseline NN N
. . N

Radiographic JJ N
outcomes NNS N
were VBD N
assessed VBN N
relative JJ N
to TO N
randomization VB N
baseline NN N
for IN N
both DT N
PBO-randomized NNP N
and CC N
RTX-randomized NNP i
groups NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
480 CD p
patients NNS p
received VBN p
? . p
1 CD p
RTX NNP i
course NN i
. . p

At IN N
24 CD N
weeks NNS o
, , o
American NNP o
College NNP o
of IN o
Rheumatology NNP o
20/50/70 CD o
responses NNS o
were VBD o
62.0 CD N
% NN N
, , N
30.8 CD N
% NN N
, , N
and CC N
13.0 CD N
% NN N
, , N
respectively RB N
at IN N
course NN N
1 CD N
( ( N
n JJ N
= NNP N
400 CD N
) ) N
and CC N
70.3 CD N
% NN N
, , N
41.8 CD N
% NN N
, , N
and CC N
22.0 CD N
% NN N
at IN N
course NN N
5 CD N
( ( N
n JJ N
= NNP N
91 CD N
) ) o
. . o

European JJ o
League NNP o
Against NNP o
Rheumatism NNP o
good/moderate NN o
responses NNS o
were VBD o
77.2 CD N
% NN N
and CC N
84.4 CD N
% NN N
at IN N
courses NNS N
1 CD N
( ( N
n JJ N
= NNP N
390 CD N
) ) N
and CC N
5 CD N
( ( N
n JJ N
= NNP N
90 CD N
) ) o
. . o

Rates NNS o
of IN o
adverse JJ o
events NNS o
( ( o
AE NNP o
) ) o
, , o
serious JJ o
AE NNP o
, , o
and CC o
infections NNS o
generally RB o
remained VBD N
stable JJ o
. . o

Rate NNP o
of IN o
progressive JJ o
joint JJ o
damage NN o
( ( o
PJD NNP N
; : N
change NN N
in IN N
mean JJ N
Total NNP N
Sharp NNP N
Score NNP N
) ) N
decreased VBD N
over RP N
time NN N
in IN N
both DT i
PBO-randomized NNP i
( ( i
n JJ N
= NNP N
79 CD N
) ) N
and CC i
RTX-randomized NNP i
( ( i
n JJ N
= NNP N
105 CD N
) ) N
groups NNS o
. . o

Mean JJ o
change NN o
from IN o
baseline NN o
in IN o
PJD NNP o
over IN o
5 CD N
years NNS N
was VBD N
greater JJR N
in IN N
PBO-randomized NNP i
versus NN i
RTX-randomized JJ i
patients NNS i
( ( N
5.51 CD N
vs RB N
3.21 CD N
) ) N
. . N

CONCLUSION NNP i
RTX NNP i
re-treatment NN i
over IN i
5 CD N
years NNS N
is VBZ N
associated VBN N
with IN N
maintained VBN N
or CC N
improved VBN N
efficacy NN N
, , N
continued VBD N
inhibition NN N
of IN N
PJD NNP N
, , N
and CC N
a DT N
safety NN N
profile NN N
consistent JJ N
with IN N
that DT N
previously RB N
reported VBN N
. . N

A DT N
delay NN N
in IN N
initiating VBG i
RTX NNP i
treatment NN i
may MD i
result VB N
in IN N
increased JJ N
PJD NNP N
. . N

-DOCSTART- -23095369- O O

Efficacy NN N
of IN N
different JJ N
gonadotropin NN i
combinations NNS i
to TO N
support VB N
ovulation NN o
induction NN o
in IN N
WHO NNP p
type VBP p
I PRP p
anovulation VBP p
infertility NN p
: : p
clinical JJ N
evidences NNS N
of IN N
human JJ i
recombinant JJ i
FSH/human NNP i
recombinant NN i
LH NNP i
in IN N
a DT N
2:1 CD N
ratio NN N
and CC N
highly RB i
purified JJ i
human JJ i
menopausal NN i
gonadotropin NN i
stimulation NN N
protocols NNS N
. . N

BACKGROUND IN N
The DT N
World NNP N
Helath NNP N
Organization NNP N
( ( N
WHO NNP N
) ) N
Group NNP N
I PRP N
anovulation VBP N
, , N
or CC N
hypogonadotropic NN N
hypogonadism NN N
( ( N
HH NNP N
) ) N
, , N
is VBZ N
characterized VBN N
by IN N
reduced JJ N
hypothalamic/pituitary JJ N
activity NN N
which WDT N
results NNS N
in IN N
abnormally RB N
low JJ N
serum NN N
FSH NNP N
and CC N
LH NNP N
levels NNS N
and CC N
negligible JJ N
estrogen NN N
activity NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
human JJ i
recombinant JJ i
FSH NNP i
( ( i
r-hFSH NN i
) ) i
plus CC i
human JJ i
recombinant NN i
LH NNP i
( ( i
r-hLH NN i
) ) i
in IN N
a DT N
2:1 CD N
ratio NN N
with IN N
highly RB i
purified VBN i
human JJ i
menopausal NN i
gonadotropin NN i
( ( i
hMG-HP JJ i
) ) i
urinary JJ i
extract NN i
, , N
containing VBG N
LH-like JJ N
activity NN N
, , N
in IN N
women NNS p
with IN p
HH NNP p
. . p

SUBJECTS NNP N
AND CC N
METHODS NNP N
This DT N
two-arm JJ N
randomized JJ N
open-label NN N
study NN N
included VBD N
35 CD p
HH NNP p
women NNS p
( ( p
aged VBN p
25-36 CD p
yr NN p
) ) p
attending VBG p
our PRP$ p
Center NNP p
. . p

Eighteen JJ p
patients NNS p
received VBD p
150 CD i
IU NNP i
hMG-HP NN i
( ( i
150 CD i
IU NNP p
FSH NNP p
+ VBD p
150 CD p
IU NNP p
LH-like NNP p
activity NN p
) ) p
and CC p
seventeen JJ p
received VBD p
150IU CD i
r-hFSH/75IU JJ i
rhLH NNS i
daily RB N
for IN N
a DT N
maximum NN N
of IN N
16 CD N
days NNS N
. . N

Ovulation NN N
was VBD N
induced VBN N
by IN N
a DT N
single JJ N
administration NN N
of IN N
hCG NN N
on IN N
the DT N
day NN N
after IN N
the DT N
last JJ N
hMG-HP JJ i
or CC i
r-hFSH/r-hLH JJ i
. . i

RESULTS VB N
The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
ovulation JJ o
induction NN o
as IN N
measured VBN N
by IN N
follicle NN o
?17 NNP N
mm NN N
, , o
pre-ovulatory JJ o
estradiol NN o
( ( o
E NNP o
2 CD o
) ) o
?400 NN N
pmol/l NN N
and CC N
mid-luteal JJ o
phase NN o
progesterone NN o
( ( o
P NNP o
4 CD o
) ) o
?25 NN N
nmol/l NN N
. . N

Secondary JJ N
efficacy NN N
endpoints NNS N
included VBD o
E NNP o
2 CD o
levels/follicle NN o
at IN o
mid-cycle NN o
, , o
number NN o
of IN o
follicles NNS o
at IN o
mid-cycle NN o
and CC o
pregnancy NN o
rate NN o
( ( o
PR NNP o
) ) o
. . o

Following VBG N
a DT N
total NN N
of IN N
70 CD N
cycles NNS N
, , N
70 CD N
% NN N
of IN N
r-hFSH/r-hLH JJ i
treated JJ i
patients NNS N
met VBD N
the DT N
primary JJ N
endpoint NN N
vs VBD N
88 CD N
% NN N
in IN N
hMG-HP JJ i
group NN N
( ( N
p=0.11 NN N
) ) N
. . N

However RB N
, , N
PR NNP N
in IN N
r-hFSH/r-hLH JJ i
group NN i
was VBD N
55.6 CD N
% NN N
compared VBN N
to TO N
23.3 CD N
% NN N
in IN i
hMG-HP JJ i
group NN i
( ( N
p=0.01 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
primary JJ N
endpoint NN N
achievement NN N
did VBD N
not RB N
correlate VB N
with IN N
PR NNP N
. . N

This DT N
study NN N
has VBZ N
shown VBN N
the DT N
superiority NN i
of IN i
LH NNP i
compared VBN i
to TO i
hCG VB i
in IN i
supporting VBG i
FSH-induced NNP o
follicular NN o
development NN o
in IN o
HH NNP o
women NNS p
. . N

-DOCSTART- -20831671- O O

Green JJ i
banana-supplemented JJ i
diet NN i
in IN N
the DT N
home NN N
management NN N
of IN N
acute NN o
and CC o
prolonged JJ o
diarrhoea NN o
in IN o
children NNS o
: : o
a DT p
community-based JJ p
trial NN p
in IN p
rural JJ p
Bangladesh NNP p
. . p

SUMMARY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
green JJ i
banana NN i
in IN N
the DT N
home NN N
management NN N
of IN N
acute NN o
( ( p
< JJ p
7 CD p
days NNS p
) ) p
or CC p
prolonged VBN o
( ( p
? . p
7 CD p
days NNS o
) ) o
diarrhoea VBP o
at IN o
the DT N
community NN N
level NN N
. . N

METHODS NNP N
A NNP N
cluster NN N
randomized VBD N
field NN N
trial NN N
was VBD N
conducted VBN N
among IN p
2968 CD p
Bangladeshi NNP p
rural JJ p
children NNS p
6-36 JJ p
months NNS p
old JJ p
. . p

Wards NNP N
( ( N
villages NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
a DT N
standard JJ i
care NN i
group NN i
or CC i
a DT i
standard JJ i
care NN i
plus CC i
green JJ i
banana NN i
group NN i
where WRB i
mothers NNS N
were VBD N
instructed VBN N
to TO N
add VB i
cooked JJ i
green JJ i
banana NN i
to TO i
the DT N
diets NNS N
of IN N
diarrhoeal JJ p
children NNS p
. . p

Through IN N
a DT N
village-based JJ N
surveillance NN N
system NN o
, , o
diarrhoeal JJ o
morbidity NN o
data NNS o
( ( o
severity NN o
, , o
duration NN o
, , o
compliance NN o
) ) o
were VBD o
collected VBN N
for IN N
14 CD N
days NNS N
. . N

Treatment JJ N
effects NNS N
were VBD N
determined VBN N
by IN N
analysing VBG o
cumulative JJ o
probability NN o
of IN o
cure NN o
by IN o
testing VBG o
Cox NNP o
proportional JJ o
hazards NNS o
models NNS o
and CC o
relative JJ o
risk NN o
( ( o
RR NNP N
) ) N
. . N

RESULTS VB N
The DT o
cumulative JJ o
probability NN o
of IN o
cure NN o
was VBD o
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
different JJ N
in IN N
children NNS N
receiving VBG N
GB NNP N
for IN N
both DT o
acute JJ o
[ NNP o
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
= VBZ N
0.63 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.56-0.67 NN N
) ) N
] NN N
and CC o
prolonged VBD o
diarrhoea NNS o
[ NNP o
HR NNP N
= VBZ N
0.38 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.26-0.59 NN N
) ) N
] NN N
. . N

The DT o
recovery NN o
rates NNS o
of IN o
children NNS o
with IN o
acute JJ o
diarrhoea NN o
receiving VBG o
GB NNP N
( ( N
vs. FW N
control NN N
) ) N
were VBD N
significantly RB N
more JJR N
by IN N
day NN N
3 CD N
: : N
79.9 CD N
% NN N
vs NN N
. . N

53.3 CD N
% NN N
[ NN N
( ( N
RR NNP N
) ) N
= VBD N
0.47 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.41-0.55 JJ N
] NN N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
day NN N
7 CD N
: : N
96.6 CD N
% NN N
vs NN N
. . N

89.1 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.32 CD N
; : N
0.22-0.46 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Children NNP N
with IN N
prolonged JJ N
diarrhoea NN N
receiving VBG i
green JJ i
banana NN i
had VBD i
significantly RB N
higher JJR o
recovery NN o
rates NNS o
by IN o
day NN N
10 CD N
: : N
79.8 CD N
% NN N
vs NN N
. . N

51.9 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.42 CD N
; : N
0.23-0.73 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
day NN N
14 CD N
: : N
93.6 CD N
% NN N
vs NN N
. . N

67.2 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.22 CD N
; : N
0.08-0.54 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
green JJ i
banana-supplemented JJ i
diet NN o
hastened VBD o
recovery NN o
of IN o
acute NN p
and CC p
prolonged VBD p
childhood NN p
diarrhoea NN p
managed VBD p
at IN N
home NN N
in IN N
rural JJ N
Bangladesh NNP N
. . N

-DOCSTART- -24281134- O O

Predictors NNS N
of IN N
postdischarge NN N
outcomes NNS N
from IN N
information NN N
acquired VBN N
shortly RB N
after IN N
admission NN N
for IN N
acute JJ p
heart NN p
failure NN p
: : p
a DT N
report NN N
from IN N
the DT N
Placebo-Controlled NNP i
Randomized NNP N
Study NNP N
of IN N
the DT N
Selective NNP i
A1 NNP i
Adenosine NNP i
Receptor NNP i
Antagonist NNP i
Rolofylline NNP i
for IN N
Patients NNP p
Hospitalized NNP p
With IN p
Acute NNP p
Decompensated NNP p
Heart NNP p
Failure NNP p
and CC p
Volume NN p
Overload NNP p
to TO N
Assess NNP N
Treatment NNP N
Effect NNP N
on IN N
Congestion NNP N
and CC N
Renal NNP N
Function NNP N
( ( N
PROTECT NNP N
) ) N
Study NNP N
. . N

BACKGROUND NNP N
Acute NNP p
heart NN p
failure NN p
is VBZ N
a DT N
common JJ N
reason NN N
for IN N
admission NN N
, , N
and CC N
outcome NN N
is VBZ N
often RB N
poor JJ N
. . N

Improved VBN N
prognostic JJ N
risk NN N
stratification NN N
may MD N
assist VB N
in IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
and CC N
in IN N
patient JJ N
management NN N
. . N

Using VBG N
data NNS N
from IN N
a DT N
large JJ N
randomized JJ N
trial NN N
, , N
we PRP N
explored VBD N
the DT N
prognostic JJ N
value NN N
of IN N
clinical JJ N
variables NNS N
, , N
measured VBN N
at IN N
hospital JJ N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
, , N
to TO N
determine VB N
whether IN N
a DT N
few JJ N
selected VBN N
variables NNS N
were VBD N
inferior JJ N
to TO N
an DT N
extended VBN N
data NN N
set NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
prognostic JJ N
model NN N
included VBD N
37 CD N
clinical JJ N
characteristics NNS N
collected VBN N
at IN N
baseline NN N
in IN N
PROTECT NNP N
, , N
a DT N
study NN N
comparing VBG N
rolofylline NN i
and CC i
placebo NN i
in IN N
2033 CD p
patients NNS p
admitted VBN p
with IN p
acute JJ p
heart NN p
failure NN p
. . p

Prespecified VBN N
outcomes NNS N
at IN N
30 CD N
days NNS N
were VBD N
death NN o
or CC o
rehospitalization NN o
for IN o
any DT o
reason NN o
; : o
death NN o
or CC o
rehospitalization NN o
for IN o
cardiovascular NN o
or CC o
renal JJ o
reasons NNS o
; : o
and CC N
, , N
at IN N
both DT N
30 CD N
and CC N
180 CD N
days NNS N
, , N
all-cause JJ N
mortality NN N
. . N

No DT N
variable JJ N
had VBD N
a DT N
c-index NN N
> NN N
0.70 CD N
, , N
and CC N
few JJ N
had VBD N
values NNS N
> $ N
0.60 CD N
; : N
c-indices NNS N
were VBD N
lower JJR N
for IN N
composite JJ N
outcomes NNS N
than IN N
for IN N
mortality NN N
. . N

Blood NNP o
urea NN o
was VBD N
generally RB N
the DT N
strongest JJS N
single JJ N
predictor NN N
. . N

Eighteen NNP N
variables NNS N
contributed VBD N
independent JJ N
prognostic JJ N
information NN N
, , N
but CC N
a DT N
reduced JJ N
model NN N
using VBG N
only RB N
8 CD N
items NNS N
( ( N
age NN N
, , N
previous JJ N
heart NN N
failure NN N
hospitalization NN N
, , N
peripheral JJ N
edema NN N
, , N
systolic JJ N
blood NN N
pressure NN N
, , N
serum NN N
sodium NN N
, , N
urea JJ N
, , N
creatinine NN N
, , N
and CC N
albumin NN N
) ) N
performed VBD N
similarly RB N
. . N

For IN N
prediction NN N
of IN N
all-cause JJ o
mortality NN o
at IN N
180 CD N
days NNS N
, , N
the DT N
model NN N
c-index NN N
using VBG N
all DT N
variables NNS N
was VBD N
0.72 CD N
and CC N
for IN N
the DT N
simplified JJ N
model NN N
, , N
also RB N
0.72 CD N
. . N

CONCLUSIONS VB N
A NNP N
few JJ N
simple JJ N
clinical JJ N
variables NNS N
measured VBN N
on IN N
admission NN N
in IN N
patients NNS p
with IN p
acute JJ p
heart NN p
failure NN p
predict VBP N
a DT N
variety NN o
of IN o
adverse JJ o
outcomes NNS o
with IN N
accuracy NN o
similar JJ N
to TO N
more RBR N
complex JJ N
models NNS N
. . N

However RB N
, , N
predictive JJ N
models NNS N
were VBD N
of IN N
only RB N
moderate JJ o
accuracy NN o
, , N
especially RB N
for IN N
outcomes NNS o
that WDT o
included VBD o
nonfatal JJ o
events NNS o
. . o

Better NNP N
methods NNS N
of IN N
risk NN N
stratification NN N
are VBP N
required VBN N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique JJ N
identifiers NNS N
: : N
NCT00328692 NNP N
and CC N
NCT00354458 NNP N
. . N

-DOCSTART- -11267196- O O

A DT N
single-center JJ N
open JJ N
label NN N
randomized VBN N
trial NN N
of IN N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
the DT N
use NN N
of IN N
sirolimus JJ i
versus NN i
azathioprine NN i
in IN N
one-haplotype JJ p
living NN p
related VBN p
kidney NN p
transplant JJ p
recipients-preliminary JJ p
results NNS N
. . N

-DOCSTART- -23676253- O O

Effects NNS N
of IN N
single JJ N
dose NN N
intranasal NN N
oxytocin NN i
on IN N
social JJ o
cognition NN o
in IN N
schizophrenia NN p
. . p

Deficits NNS N
in IN N
social JJ N
cognition NN N
are VBP N
common JJ N
in IN N
schizophrenia NN p
and CC N
predict JJ N
poor JJ N
community NN N
functioning NN N
. . N

Given VBN N
the DT N
current JJ N
limitations NNS N
of IN N
psychosocial JJ N
treatments NNS N
and CC N
the DT N
lack NN N
of IN N
pharmacological JJ N
treatments NNS N
for IN N
social JJ N
cognitive JJ N
deficits NNS N
, , N
the DT N
development NN N
of IN N
novel JJ N
therapeutic JJ N
agents NNS N
could MD N
greatly RB N
enhance VB N
functional JJ N
recovery NN N
in IN N
schizophrenia NN N
. . N

This DT N
study NN N
evaluated VBD N
whether IN N
a DT N
single JJ N
dose NN N
of IN N
intranasal JJ N
oxytocin FW i
acutely RB N
improves VBZ N
social JJ N
cognitive JJ N
functioning NN N
in IN N
schizophrenia NN N
. . N

Twenty-three JJ p
male JJ p
veterans NNS p
with IN p
schizophrenia NN p
completed VBN N
baseline JJ N
assessments NNS N
of IN N
social JJ N
cognition NN N
that WDT N
were VBD N
divided VBN N
into IN N
lower-level JJ N
( ( o
facial JJ o
affect NN o
perception NN o
, , o
social JJ o
perception NN o
, , o
detection NN o
of IN o
lies NNS o
) ) o
and CC N
higher-level JJ N
( ( o
detection NN o
of IN o
sarcasm NN o
and CC o
deception NN o
, , o
empathy NN o
) ) o
processes VBZ N
. . N

One CD N
week NN N
later RB N
, , N
patients NNS N
received VBD N
the DT N
same JJ N
battery NN N
after IN N
being VBG N
randomized VBN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
40 CD N
IU NNP N
intranasal NN i
oxytocin NN i
or CC i
placebo NN i
. . i

Though IN N
the DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
on IN N
the DT N
social JJ o
cognition NN o
composite JJ o
score NN o
, , o
oxytocin RB o
improved VBN o
performance NN o
for IN o
the DT o
higher-level JJ o
social JJ o
cognitive NN o
tasks NNS o
( ( o
Cohen NNP o
's POS o
d=1.0 NN N
, , N
p=0.045 NN N
) ) N
. . N

Subjects NNS N
were VBD N
unable JJ N
to TO N
accurately RB N
guess VB N
which WDT N
treatment NN N
they PRP N
had VBD N
received VBN N
. . N

The DT N
improvements NNS N
found VBN N
in IN N
higher-level JJ o
social JJ o
cognition NN o
encourage VB N
further JJ N
studies NNS N
into IN N
the DT N
therapeutic JJ N
potential NN N
of IN N
oxytocin NN N
in IN N
schizophrenia NN p
. . p

-DOCSTART- -9330779- O O

Lack NN N
of IN N
effect NN o
of IN o
food NN o
on IN N
the DT N
steady JJ o
state NN o
pharmacokinetics NNS o
of IN o
BMS-181101 NNP o
, , N
an DT N
antidepressant NN N
, , N
in IN N
healthy JJ p
subjects NNS p
. . p

The DT N
effect NN o
of IN o
food NN o
on IN o
the DT o
pharmacokinetics NNS o
of IN o
BMS-181101 NNP o
, , N
a DT N
new JJ N
anti-depressant JJ N
under IN N
development NN N
, , N
was VBD N
investigated VBN N
in IN N
12 CD p
healthy JJ p
male NN p
volunteers NNS p
at IN N
steady JJ N
state NN N
. . N

Each DT N
subject NN N
received VBD N
a DT N
15 CD i
mg JJ i
oral JJ i
dose NN i
of IN i
BMS-181101 NNP i
twice NN i
a DT i
day NN i
( ( N
q JJ N
12 CD N
h NN N
) ) N
for IN N
11 CD N
days NNS N
and CC N
a DT N
morning NN i
dose NN i
of IN i
BMS-181101 NNP i
on IN i
day NN i
12 CD i
. . i

Six CD p
subjects NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
BMS-181101 NNP i
under IN N
fasted VBN p
conditions NNS p
from IN p
days NNS p
1 CD p
to TO p
6 CD p
and CC p
then RB p
crossed VBD p
over IN p
to TO p
fed VB p
conditions NNS p
from IN p
days NNS p
7 CD p
to TO p
12 CD p
. . p

The DT N
other JJ N
six CD p
subjects NNS p
received VBD N
the DT N
reverse NN N
conditions NNS N
, , N
fed VBN p
for IN p
days NNS p
1-6 CD p
and CC p
fasted VBN p
for IN p
days NNS p
7-12 CD p
. . N

Serial JJ o
blood NN o
samples NNS o
were VBD N
collected VBN N
up RB N
to TO N
12 CD N
h NNS N
on IN N
days NNS N
6 CD N
and CC N
12 CD N
following VBG N
the DT N
administration NN N
of IN N
the DT N
morning NN N
dose NN N
. . N

In IN N
addition NN N
, , N
trough IN o
blood NN o
samples NNS o
were VBD N
collected VBN N
on IN N
days NNS N
4 CD N
, , N
5 CD N
, , N
10 CD N
, , N
and CC N
11 CD N
prior RB N
to TO N
the DT N
morning NN N
dose NN N
. . N

Plasma NNP o
samples NNS o
were VBD N
analyzed VBN N
for IN N
intact JJ o
BMS-181101 NNP o
using VBG N
a DT N
validated JJ N
high-performance NN N
liquid NN N
chromatography NN N
method NN N
with IN N
an DT N
electrochemical JJ N
detector NN N
. . N

BMS-181101 NNP N
was VBD N
well RB N
tolerated VBN o
both DT N
with IN N
and CC N
without IN N
ingestion NN N
of IN N
food NN N
. . N

The DT N
statistical JJ N
evaluation NN N
of IN N
the DT N
Cmin NNP o
values NNS o
indicated VBD N
that IN N
steady JJ o
state NN o
of IN N
BMS-181101 NNP i
was VBD N
achieved VBN N
by IN N
the DT N
fourth JJ N
day NN N
of IN N
dosing VBG N
regardless NN N
of IN N
whether IN N
the DT N
subject NN N
was VBD N
fasted VBN N
or CC N
fed VBN N
. . N

When WRB N
BMS-181101 NNP N
was VBD N
administered VBN N
with IN N
food NN N
, , N
Cmax NNP o
was VBD o
reduced VBN o
by IN N
about IN N
25 CD N
% NN N
and CC N
tmax NN o
was VBD o
prolonged VBN o
by IN N
1 CD N
h. NN N
However RB N
, , N
AUCtau NNP o
, , o
t1/2 NN o
, , o
and CC o
time NN o
to TO o
attain VB o
steady JJ o
state NN o
of IN o
BMS-181101 NNP o
were VBD N
not RB N
altered VBN N
by IN N
ingestion NN N
of IN N
food NN N
. . N

In IN N
summary JJ N
, , N
BMS-181101 NNP i
can MD N
be VB N
given VBN N
with IN N
food NN N
without IN N
adversely RB N
impacting VBG N
the DT N
safety NN o
or CC N
pharmacokinetic JJ o
profiles NNS o
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -447787- O O

On IN N
the DT N
possibility NN N
of IN N
incorporating VBG p
patients NNS p
from IN p
non-randomising JJ p
centres NNS p
into IN p
a DT p
randomised JJ p
clinical JJ p
trial NN p
. . p

-DOCSTART- -7481533- O O

A DT N
randomized JJ N
surveillance NN i
study NN N
of IN N
patients NNS p
with IN p
pedunculated JJ p
and CC p
small JJ p
sessile NN p
tubular NN p
and CC p
tubulovillous JJ p
adenomas NN p
. . p

The DT N
Funen NNP N
Adenoma NNP N
Follow-up NNP N
Study NNP N
. . N

BACKGROUND NNP N
We PRP N
wanted VBD N
to TO N
assess VB N
the DT N
influence NN N
of IN N
various JJ N
surveillance NN i
intervals NNS N
on IN N
the DT N
risk NN o
of IN o
new JJ o
neoplasia NN o
after IN N
removal NN N
of IN N
pedunculated JJ N
and CC N
small JJ N
sessile NN N
tubular NN N
and CC N
tubulovillous JJ N
adenomas NN N
. . N

METHODS NNP N
After IN p
initial JJ p
colonoscopic NN p
polypectomy NN p
patients NNS p
were VBD N
randomized VBN N
to TO N
surveillance VB i
with IN N
either DT N
2 CD i
years NNS i
( ( i
group NN i
A NNP i
) ) i
or CC N
4 CD i
years NNS i
( ( N
group NN N
B NNP N
) ) N
between IN N
colorectal JJ N
examinations NNS N
. . N

RESULTS VB N
The DT N
cumulated JJ N
risk NN o
of IN o
a DT o
patient NN o
having VBG o
new JJ o
adenomas NN o
was VBD N
35.0 CD N
% NN N
( ( N
28.7-41.4 CD N
% NN N
) ) N
in IN N
group NN N
A NNP N
and CC N
35.5 CD N
% NN N
( ( N
28.4-42.7 CD N
% NN N
) ) N
in IN N
group NN N
B NNP N
after IN N
48 CD N
months NNS N
. . N

The DT N
risk NN N
increased VBD N
to TO N
44.9 CD N
% NN N
( ( N
36.0-53.9 CD N
% NN N
) ) N
and CC N
60.1 CD N
% NN N
( ( N
48.5-71.7 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
after IN N
96 CD N
months NNS N
. . N

The DT N
risk NN N
of IN N
significant JJ o
neoplasia NN o
( ( o
carcinoma NN o
or CC o
adenoma NN o
with IN o
villous JJ o
structure NN o
, , o
severe JJ o
dysplasia NN o
, , o
or CC o
diameter NN o
> VBP o
10 CD o
mm NN o
) ) o
was VBD N
5.2 CD N
% NN N
( ( N
2.3-8.1 CD N
% NN N
) ) N
and CC N
8.6 CD N
% NN N
( ( N
3.8-13.3 CD N
% NN N
) ) N
after IN N
48 CD N
months NNS N
and CC N
8.6 CD N
% NN N
( ( N
4.2-13.0 CD N
% NN N
) ) N
and CC N
17.4 CD N
% NN N
( ( N
7.6-27.2 CD N
% NN N
) ) N
after IN N
96 CD N
months NNS N
. . N

More JJR N
than IN N
one CD N
adenoma NN N
at IN N
first JJ N
examination NN N
was VBD N
associated VBN N
with IN N
higher JJR o
risk NN o
of IN o
new JJ o
adenomas NN o
. . o

Furthermore RB N
, , N
we PRP N
found VBD N
a DT N
tendency NN N
for IN N
age NN p
above IN p
60 CD p
years NNS p
and CC p
male JJ p
gender NN p
to TO N
be VB N
associated VBN N
with IN N
higher JJR N
risk NN N
of IN N
new JJ N
adenomas NN o
. . o

More JJR N
than IN N
two CD N
adenomas NNS N
at IN N
first JJ N
examination NN N
was VBD N
the DT N
only JJ N
factor NN N
found VBD N
to TO N
be VB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN o
of IN o
new JJ o
significant JJ o
neoplasia NN o
. . o

One CD N
patient NN N
in IN N
group NN N
A NNP N
and CC N
two CD N
patients NNS N
in IN N
group NN N
B NNP N
developed VBD N
cancer NN o
, , N
which WDT N
is VBZ N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
number NN N
expected VBN N
( ( N
3.43 CD N
) ) N
in IN N
the DT N
average JJ N
Danish JJ N
population NN N
( ( N
RR NNP N
= NNP N
0.9 CD N
, , N
0.2-2.6 NN N
) ) N
. . N

CONCLUSION NN N
After IN N
colonoscopy NN N
with IN N
removal NN N
of IN N
all DT N
polyps NNS N
, , N
colorectal JJ N
examination NN N
at IN N
4 CD N
years NNS N
resulted VBD N
in IN N
a DT N
similar JJ N
risk NN o
of IN o
new JJ o
adenomas NNS o
compared VBN N
with IN N
examinations NNS N
at IN N
2 CD N
and CC N
4 CD N
years NNS N
. . N

However RB N
, , N
new JJ N
significant JJ N
neoplasia NN o
tended VBD N
to TO N
be VB N
more RBR N
frequent JJ N
when WRB N
first JJ N
surveillance NN N
was VBD N
at IN N
4 CD N
years NNS N
. . N

Extending VBG N
the DT N
surveillance NN N
to TO N
8 CD N
years NNS N
also RB N
tended VBD N
to TO N
increase VB N
the DT N
risk NN N
more RBR N
in IN N
the DT N
group NN N
being VBG N
examined VBN N
every DT N
4 CD N
years NNS N
, , N
but CC N
reduction NN N
of IN N
the DT N
number NN N
of IN N
surveillance NN N
examinations NNS N
by IN N
more JJR N
than IN N
50 CD N
% NN N
and CC N
a DT N
probable JJ N
reduction NN N
of IN N
complications NNS N
from IN N
surveillance NN N
examinations NNS N
themselves PRP N
may MD N
justify VB N
a DT N
recommendation NN N
for IN N
the DT N
longest JJS N
interval NN N
. . N

-DOCSTART- -3549874- O O

Cognitive JJ o
and CC o
psychomotor JJ o
effects NNS N
of IN N
different JJ N
antidepressants NNS i
in IN N
the DT N
treatment NN N
of IN N
old JJ p
age NN p
depression NN p
. . p

-DOCSTART- -23782126- O O

Tetrahydrobiopterin NNP o
as IN N
a DT N
treatment NN N
for IN N
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
tetrahydrobiopterin NN i
( ( i
BH4 NNP i
) ) i
reduced VBD N
core NN N
symptoms NNS N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

METHOD NNP N
In IN N
this DT N
study NN N
, , N
46 CD p
children NNS p
, , p
3-7 CD p
years NNS p
of IN p
age NN p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
double-blind VB N
treatment NN N
with IN N
20 CD i
mg/kg/day JJ i
BH4 NNP i
or CC i
placebo NN i
for IN i
16 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT o
Clinical JJ o
Global NNP o
Impressions NNP o
Improvement NNP o
and CC o
Severity NNP o
Scales NNP o
( ( o
CGI-I NNP o
and CC o
CGI-S NNP o
) ) o
; : o
secondary JJ o
outcomes NNS N
were VBD N
the DT o
Preschool NNP o
Language NNP o
Scale-4 NNP o
( ( o
PLS-4 NNP o
) ) o
, , o
Social NNP o
Responsiveness NNP o
Scale NNP o
( ( o
SRS NNP o
) ) o
, , o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
, , o
and CC o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
Scales NNP o
( ( o
Vineland NNP o
) ) o
. . o

RESULTS NNP N
Overall NNP N
, , N
no DT N
differences NNS N
were VBD N
found VBN N
on IN N
global JJ N
improvement NN N
as IN N
measured VBN N
with IN N
the DT o
CGI-I NNP o
or CC o
CGI-S NNP o
. . o

Secondary JJ N
measures NNS N
indicated VBD N
significant JJ N
improvements NNS N
for IN o
BH4 NNP o
relative NN o
to TO N
placebo VB i
with IN i
regard NN N
to TO N
social JJ o
awareness NN o
, , o
autism NN o
mannerisms NNS o
, , o
hyperactivity NN o
, , o
and CC o
inappropriate JJ o
speech NN o
. . o

Side JJ N
effects NNS N
were VBD N
minimal JJ N
and CC N
similar JJ N
between IN N
both DT N
active JJ N
medication NN N
and CC i
placebo NN i
. . i

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN o
BH4 NNP o
offers VBZ o
promise NN N
in IN N
reducing VBG N
symptoms NNS N
of IN N
ASD NNP N
. . N

Clinical NNP N
Trials.gov NNP N
Identifier NNP N
: : N
NCT00850070 NN N
. . N

-DOCSTART- -25764092- O O

Lateral JJ i
MI NNP i
Explains VBZ N
the DT N
Presence NNP N
of IN N
Prominent NNP o
R NNP o
Wave NNP o
( ( N
R NNP N
? . N
S NNP N
) ) N
in IN N
V1 NNP N
. . N

AIMS NNP N
It PRP N
is VBZ N
necessary JJ N
to TO N
clarify VB N
if IN N
the DT N
presence NN N
of IN N
a DT N
prominent JJ N
R NNP N
wave NN N
in IN N
V1 NNP N
, , N
in IN N
post-myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
patients NNS p
, , p
is VBZ N
due JJ N
to TO N
the DT N
involvement NN N
of IN N
the DT i
posterior NN i
wall NN i
( ( i
currently RB i
inferobasal VBP i
segment NN i
) ) i
or CC i
the DT i
lateral JJ i
wall NN i
( ( i
as IN N
has VBZ N
been VBN N
demonstrated VBN N
recently RB N
by IN N
electrocardiographic JJ N
contrast-enhanced JJ N
cardiac JJ N
magnetic JJ N
resonance NN N
[ VBD N
ECG-CE-CMR NNP N
] NNP N
correlations NNS N
studies NNS N
) ) N
. . N

METHODS NNP N
In IN N
155 CD p
patients NNS p
with IN p
inferolateral JJ p
zone NN p
MI NNP p
, , p
as IN p
detected VBN p
by IN p
CE-CMR NNP p
, , p
the DT N
following JJ o
ECG NNP o
parameters NNS o
were VBD o
evaluated VBN N
and CC N
correlated VBN N
with IN N
MI NNP N
location NN N
according VBG N
to TO N
CE-CMR NN o
: : o
R/S NNP o
ratio NN N
in IN N
V1 NNP N
? . N
1 CD N
( ( N
classic JJ N
criteria NNS N
for IN N
posterior JJ N
MI NNP N
) ) N
, , N
R/S NNP N
ratio NN N
in IN N
V1 NNP N
? . N
0.5 CD N
, , N
and CC N
R NNP N
in IN N
V1 NNP N
? . N
3 CD N
mm NN N
. . N

RESULTS NNP N
R/S NNP N
? . N
1 CD N
criterion NN N
: : N
Present JJ N
in IN N
20 CD N
cases NNS N
: : N
3 CD N
of IN i
lateral JJ i
MI NNP i
, , i
17 CD i
of IN i
inferolateral JJ i
MI NNP i
, , i
0 CD i
of IN i
inferior JJ i
MI NNP i
. . i

Absent NNP i
in IN N
135 CD N
cases NNS N
, , N
81 CD N
of IN i
lateral/inferolateral JJ i
MI NNP i
( ( i
28/53 CD i
) ) N
, , N
54 CD N
of IN N
inferior JJ N
MI NNP N
( ( N
SE NNP N
19.8 CD N
% NN N
, , N
SP NNP N
100 CD N
% NN N
) ) N
. . N

R/S NNP N
? . N
0.5 CD N
criterion NN N
: : N
Present JJ N
in IN N
47 CD N
cases NNS N
: : N
6 CD N
of IN N
lateral JJ i
MI NNP i
, , i
39 CD i
of IN i
inferolateral JJ i
MI NNP i
, , i
2 CD i
of IN i
inferior JJ i
MI NNP N
. . N

Absent NNP N
in IN N
108 CD N
cases NNS N
, , N
56 CD N
of IN N
lateral/inferolateral JJ i
MI NNP i
( ( i
25/31 CD i
) ) i
, , i
52 CD N
of IN i
inferior JJ i
MI NNP i
( ( N
SE NNP N
44.6 CD N
% NN N
, , N
SP NNP N
96.4 CD N
% NN N
) ) N
. . N

R NNP N
? . N
3 CD N
mm JJ N
criterion NN N
: : N
Present JJ N
in IN N
30 CD N
cases NNS N
: : N
5 CD N
of IN N
IM NNP i
lateral JJ i
, , N
23 CD N
of IN N
inferolateral JJ i
MI NNP i
, , i
2 CD i
of IN i
inferior JJ i
MI NNP i
. . i

Absent NNP N
in IN N
125 CD N
cases NNS N
, , N
73 CD N
lateral/inferolateral JJ i
MI NNP i
( ( i
26/47 CD i
) ) i
, , i
52 CD i
inferior JJ i
MI NNP i
( ( i
SE NNP N
27.7 CD N
% NN N
, , N
SP NNP N
96.4 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
presence NN N
of IN N
prominent NN N
the DT N
R NNP N
wave NN N
in IN N
V1 NNP N
is VBZ N
due JJ N
to TO N
the DT N
lateral JJ i
MI NNP i
and CC i
not RB N
to TO N
the DT N
involvement NN N
of IN N
inferobasal JJ N
segment NN o
of IN o
inferior JJ o
wall NN o
( ( N
old JJ N
posterior RB N
wall NN N
) ) N
. . N

-DOCSTART- -11472320- O O

There EX N
are VBP N
some DT N
benefits NNS N
for IN N
eradicating VBG N
Helicobacter NNP N
pylori NN N
in IN N
patients NNS p
with IN p
non-ulcer JJ p
dyspepsia NN p
. . p

BACKGROUND IN N
The DT N
relationship NN N
between IN N
Helicobacter NNP N
pylori CC N
infection NN N
and CC N
non-ulcer JJ N
dyspepsia NN N
is VBZ N
not RB N
established VBN N
. . N

AIM NNP N
To TO N
determine VB N
whether IN N
eradication NN N
of IN N
H. NNP N
pylori NN N
might MD N
be VB N
of IN N
benefit NN N
in IN N
non-ulcer JJ p
dyspepsia NN p
patients NNS p
. . p

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
129 CD p
H. NNP p
pylori NN p
infected VBD p
patients NNS p
with IN p
severe JJ p
epigastric JJ p
pain NN p
, , p
without IN p
gastro-oesophageal JJ p
reflux NN p
symptoms NNS p
, , N
to TO N
receive VB N
twice RB N
daily JJ N
treatment NN N
with IN N
300 CD N
mg NNS N
of IN N
ranitidine NN i
, , N
1000 CD N
mg NN N
of IN N
amoxicillin NN i
, , N
and CC N
500 CD N
mg NN N
of IN N
clarithromycin NN i
for IN N
7 CD N
days NNS N
and CC N
124 CD p
such JJ p
patients NNS p
to TO p
receive VB p
identical-appearing JJ p
placebos NNS i
. . i

RESULTS NNP N
Treatment NNP N
was VBD N
successful JJ N
( ( N
decrease NN N
of IN N
symptoms NNS N
at IN N
12 CD N
months NNS N
) ) N
in IN N
62 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
active-treatment JJ N
group NN N
and CC N
in IN N
60 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
( ( N
N.S. NNP N
) ) N
. . N

At IN N
12 CD N
months NNS N
, , N
the DT N
rate NN o
of IN o
eradication NN o
of IN o
H. NNP o
pylori NN o
was VBD N
69 CD N
% NN N
in IN N
the DT N
active-treatment JJ N
group NN N
and CC N
18 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Complete JJ o
relief NN o
of IN o
symptoms NNS o
occurred VBD N
significantly RB N
more RBR N
frequently RB N
in IN N
patients NNS N
on IN N
the DT N
active JJ N
treatment NN N
( ( N
43 CD N
% NN N
) ) N
than IN N
in IN N
placebo-treated JJ i
patients NNS N
( ( N
31 CD N
% NN N
, , N
P=0.048 NNP N
) ) N
. . N

Within IN N
the DT N
active-treatment JJ N
group NN N
, , N
therapeutic JJ o
success NN o
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
the DT N
non-infected JJ p
patients NNS p
( ( N
84 CD N
% NN N
vs. FW N
64 CD N
% NN N
, , N
P=0.04 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
eradicating VBG N
H. NNP N
pylori NN N
is VBZ N
not RB N
likely JJ N
to TO N
relieve VB N
symptoms NNS N
in IN N
the DT N
majority NN N
of IN N
patients NNS p
with IN p
non-ulcer JJ p
dyspepsia NN p
, , N
a DT N
small JJ N
proportion NN N
of IN N
H. NNP p
pylori-infected JJ p
patients NNS p
may MD N
benefit VB N
from IN N
eradication NN N
treatment NN N
. . N

-DOCSTART- -8478759- O O

Comparison NNP N
of IN N
rectal JJ i
midazolam NN i
and CC i
diazepam NN i
for IN N
premedication NN N
in IN N
pediatric JJ p
dental JJ p
patients NNS p
. . p

Rectally RB N
administered VBN N
midazolam NN i
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
diazepam NN i
( ( N
0.70 CD N
mg/kg NN N
) ) N
were VBD N
compared VBN N
with IN N
each DT N
other JJ N
and CC N
with IN N
placebo NN i
for IN N
preanesthetic JJ N
medication NN N
in IN N
children NNS p
undergoing VBG p
dental JJ p
extractions NNS p
. . p

All DT N
rectal JJ i
medications NNS i
were VBD N
very RB N
well RB N
accepted VBN N
, , N
but CC N
mask JJ o
acceptance NN o
, , N
improvement NN N
in IN N
anxiety NN o
, , N
and CC N
sedation NN o
were VBD N
best RBS N
in IN N
the DT N
midazolam NN i
group NN N
. . N

Improvement NNP N
in IN N
anxiety NN o
and CC o
sedation NN o
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
two CD N
drug NN N
groups NNS N
than IN N
in IN N
those DT N
patients NNS N
who WP N
had VBD N
received VBN N
placebo NN i
. . i

Thirty NNP N
minutes NNS N
after IN N
rectal JJ N
administration NN N
of IN N
midazolam NNS i
, , N
patients NNS N
showed VBD N
a DT N
decrease NN N
in IN N
both DT N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
and CC o
heart NN o
rate NN o
. . o

Although IN N
these DT N
decreases NNS N
differed VBD N
significantly RB N
from IN N
the DT N
premedication NN N
values NNS N
, , N
they PRP N
were VBD N
probably RB N
of IN N
little JJ N
clinical JJ N
importance NN N
. . N

Only RB N
minor JJ o
adverse JJ o
effects NNS o
were VBD N
observed VBN N
in IN N
this DT N
study NN N
. . N

Overall NNP N
rectally RB N
administered VBD N
midazolam NNS i
appeared VBD N
to TO N
be VB N
somewhat RB N
more RBR N
efficacious JJ N
than IN N
diazepam NN i
. . i

-DOCSTART- -22676466- O O

Impact NN N
of IN N
an DT N
Asha NNP i
intervention NN i
on IN N
depressive JJ o
symptoms NNS o
among IN N
rural JJ p
women NNS p
living VBG p
with IN p
AIDS NNP p
in IN p
India NNP p
: : p
comparison NN N
of IN N
the DT N
Asha-Life NNP i
and CC i
Usual NNP i
Care NNP i
program NN i
. . i

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
pilot NN N
study NN N
is VBZ N
to TO N
conduct VB N
an DT N
intervention NN N
with IN N
68 CD p
rural JJ p
women NNS p
living VBG p
with IN p
AIDS NNP p
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
two CD N
different JJ N
programs NNS N
on IN N
depressive JJ N
symptoms NNS N
. . N

The DT N
trial NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
Asha-Life NNP i
intervention NN i
engaging VBG N
with IN N
an DT N
HIV-trained JJ N
village NN N
woman NN N
, , N
Asha NNP i
( ( i
Accredited NNP i
Social NNP i
Health NNP i
Activist NNP i
) ) i
, , N
to TO N
participate VB N
in IN N
the DT N
care NN N
of IN N
women NNS N
living VBG N
with IN N
AIDS NNP N
( ( N
WLA NNP N
) ) N
, , N
along IN N
with IN N
other JJ N
health NN N
care NN N
providers NNS N
compared VBN N
to TO N
a DT N
Usual NNP i
Care NNP i
group NN i
. . i

Two CD p
high JJ p
prevalence NN p
HIV/AIDS NNP p
villages NNS p
in IN p
rural JJ p
Andhra NNP p
Pradesh NNP p
, , p
which WDT p
were VBD p
demographically RB p
alike JJ p
and CC p
served VBN p
by IN p
distinct JJ p
Public NNP p
Health NNP p
Centers NNP p
, , p
were VBD p
selected VBN p
randomly RB p
from IN p
a DT p
total NN p
of IN p
16 CD p
villages NNS p
. . p

The DT N
findings NNS N
of IN N
this DT N
study NN N
demonstrated VBD N
that IN N
the DT N
Asha-Life JJ i
participants NNS N
significantly RB o
reduced VBD o
their PRP$ N
depressive JJ o
symptom NN o
scores NNS o
compared VBN N
to TO N
the DT N
Usual NNP N
Care NNP N
participants NNS N
. . N

Moreover RB N
, , N
women NNS p
living VBG p
with IN p
AIDS NNP p
who WP N
demonstrated VBD N
higher JJR N
depressive JJ o
symptom NN o
scores NNS o
at IN N
baseline NN N
had VBD N
greater JJR N
reduction NN N
in IN N
their PRP$ N
depressive NN o
symptoms NNS o
than IN N
women NNS N
with IN N
lower JJR N
scores NNS N
. . N

-DOCSTART- -21135366- O O

Mechanisms NNP N
underlying VBG N
the DT N
lack NN N
of IN N
effect NN N
of IN N
implantable JJ i
cardioverter-defibrillator JJ i
therapy NN i
on IN N
mortality NN o
in IN N
high-risk JJ p
patients NNS p
with IN p
recent JJ p
myocardial JJ p
infarction NN p
: : p
insights NNS N
from IN N
the DT N
Defibrillation NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
Trial NNP N
( ( N
DINAMIT NNP N
) ) N
. . N

BACKGROUND NNP N
although IN N
implantable JJ i
cardioverter-defibrillators NNS i
( ( N
ICDs NNP N
) ) N
lower JJR N
mortality NN N
in IN N
stable JJ p
patients NNS p
with IN p
low JJ p
ejection NN p
fraction NN p
late RB p
after IN p
myocardial JJ p
infarction NN p
, , N
randomized VBN N
trials NNS N
of IN N
ICD NNP i
versus FW N
control NN N
subjects NNS N
implanted VBD N
early RB N
after IN N
myocardial JJ N
infarction NN N
do VBP N
not RB N
show VB N
mortality NN N
benefit NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
investigate VB N
possible JJ N
mechanisms NNS N
underlying VBG N
the DT N
lack NN N
of IN N
mortality NN o
benefit NN N
in IN N
the DT N
Defibrillation NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
Trial NNP N
( ( N
DINAMIT NNP N
) ) N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
this DT N
is VBZ N
a DT N
secondary JJ N
analysis NN N
of IN N
the DT N
prospective JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

Outpatients NNS p
with IN p
recent JJ p
( ( p
6 CD p
to TO p
40 CD p
days NNS p
) ) p
acute VBP p
myocardial JJ p
infarction NN p
, , p
left VBD p
ventricular JJ p
dysfunction NN p
( ( p
ejection JJ p
fraction NN p
< VBD p
35 CD p
% NN p
) ) p
, , p
and CC p
low JJ p
heart NN p
rate NN p
variability NN p
were VBD N
randomized VBN N
to TO N
ICD NNP i
( ( N
n=311 NN N
) ) N
or CC N
to TO N
standard VB i
medical JJ i
therapy NN i
( ( N
n=342 JJ N
) ) N
. . N

In IN N
a DT N
competing-risks JJ N
analysis NN N
, , N
those DT N
factors NNS N
that WDT N
increased VBD N
the DT N
risk NN o
of IN o
arrhythmic JJ o
death NN o
also RB N
increased VBD N
the DT N
risk NN o
of IN o
nonarrhythmic JJ o
deaths NNS o
. . o

After IN N
adjustment NN N
for IN N
these DT N
factors NNS N
, , N
receiving VBG N
an DT N
ICD NNP N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN o
of IN o
arrhythmic JJ o
death NN o
( ( N
hazard JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.15 CD N
to TO N
0.71 CD N
) ) N
but CC N
an DT N
increase NN N
in IN N
nonarrhythmic JJ o
death NN o
( ( N
hazard JJ N
ratio NN N
, , N
1.70 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.00 CD N
to TO N
2.80 CD N
) ) N
. . N

In IN N
an DT N
adjusted JJ N
time-dependent JJ N
analysis NN N
, , N
patients NNS N
receiving VBG N
an DT N
ICD NNP N
and CC N
having VBG N
appropriate JJ N
ICD NNP N
therapy NN N
had VBD N
a DT N
15.1 CD N
% NN N
yearly RB o
hazard NN o
of IN o
mortality NN o
compared VBN N
with IN N
5.2 CD N
% NN N
in IN N
ICD NNP p
patients NNS p
with IN N
no DT N
appropriate JJ N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
sudden JJ o
death NN o
in IN N
ICD NNP p
patients NNS p
was VBD N
completely RB N
offset VBN N
by IN N
increased JJ N
nonarrhythmic JJ o
deaths NNS o
, , N
which WDT N
were VBD N
greatest JJS N
in IN N
patients NNS p
receiving VBG N
ICD NNP N
shock NN N
therapy NN N
( ( N
hazard JJ N
ratio NN N
, , N
6.0 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.8 CD N
to TO N
12.7 CD N
) ) N
. . N

CONCLUSIONS NNP N
in IN N
patients NNS p
receiving VBG p
ICDs NNP p
early RB p
after IN p
myocardial JJ p
infarction NN p
, , N
those DT N
factors NNS N
that WDT N
are VBP N
associated VBN N
with IN N
arrhythmia NN N
requiring VBG N
ICD NNP N
therapy NN N
are VBP N
also RB N
associated VBN N
with IN N
a DT N
high JJ N
risk NN N
of IN N
nonsudden JJ o
death NN o
, , N
negating VBG N
the DT N
benefit NN N
of IN N
ICDs NNP N
in IN N
this DT N
setting NN N
. . N

-DOCSTART- -12456431- O O

Gastroesophageal NNP N
reflux NN N
and CC N
tracheal JJ N
aspiration NN N
in IN N
the DT N
thoracotomy JJ N
position NN N
: : N
should MD N
ranitidine VB i
premedication NN N
be VB N
routine JJ N
? . N
UNLABELLED JJ N
Aspiration NN N
of IN N
gastric JJ N
contents NNS N
may MD N
contribute VB N
to TO N
pulmonary JJ N
complications NNS N
after IN N
thoracotomy NN N
. . N

The DT N
incidence NN o
of IN N
gastroesophageal NN o
reflux NN o
( ( o
GER NNP o
) ) o
and CC o
tracheal JJ o
acid JJ o
aspiration NN o
in IN N
patients NNS p
undergoing VBG p
thoracotomy NN p
in IN p
the DT p
lateral JJ p
position NN p
is VBZ N
unknown JJ N
. . N

Ranitidine NNP i
premedication NN N
reduces NNS N
gastric JJ N
volume NN N
, , N
increases VBZ N
gastric JJ N
pH NN N
, , N
and CC N
may MD N
reduce VB N
GER NNP o
. . o

We PRP N
used VBD N
continuous JJ N
intraluminal JJ N
esophageal NN N
and CC N
tracheal JJ N
pH NN N
monitoring NN N
probes NNS N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
ranitidine NN i
on IN N
the DT N
incidence NN N
of IN N
GER NNP o
and CC o
tracheal JJ o
aspiration NN o
in IN N
80 CD p
adult NN p
patients NNS p
undergoing VBG p
thoracotomy NN p
. . p

The DT N
study NN N
was VBD N
placebo-controlled JJ i
, , N
randomized VBN N
, , N
and CC N
double-blinded JJ N
. . N

Patients NNS p
at IN p
high JJ p
risk NN p
of IN p
GER NNP p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
. . p

The DT N
incidence NN o
of IN o
acid JJ o
GER NNP o
in IN N
the DT N
placebo NN i
and CC N
ranitidine NN i
groups NNS N
was VBD N
28.2 CD N
% NN N
and CC N
2.5 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
. . N

Multiple NNP N
episodes NNS o
of IN o
GER NNP o
occurred VBD N
in IN N
some DT N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
only RB N
. . N

The DT N
total JJ o
number NN o
of IN o
episodes NNS o
of IN o
GER NNP o
in IN N
the DT N
placebo NN i
and CC N
ranitidine NN i
groups NNS N
was VBD N
16 CD N
and CC N
1 CD N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
tracheal JJ o
acid JJ o
aspiration NN o
in IN N
the DT N
placebo NN i
and CC N
ranitidine NN i
groups NNS N
was VBD N
7.7 CD N
% NN N
and CC N
2.5 CD N
% NN N
, , N
respectively RB N
( ( N
not RB N
significant JJ N
) ) N
. . N

Patients NNS p
undergoing JJ p
thoracotomy NNS i
are VBP N
therefore RB N
at IN N
high JJ N
risk NN o
of IN o
acid JJ o
GER NNP o
, , N
which WDT N
may MD N
lead VB N
to TO N
tracheal VB o
acid JJ o
aspiration NN o
in IN N
an DT N
appreciable JJ N
proportion NN N
. . N

Premedication NN N
with IN N
ranitidine NN i
significantly RB N
reduces VBZ N
, , N
but CC N
does VBZ N
not RB N
eliminate VB N
, , N
the DT N
incidence NN N
of IN N
this DT N
potentially RB N
life-threatening JJ N
complication NN N
. . N

IMPLICATIONS NNP N
Gastroesophageal NNP o
reflux NN o
( ( o
GER NNP o
) ) o
and CC o
tracheal JJ o
aspiration NN o
of IN o
acid NN o
may MD N
increase VB N
morbidity NN N
and CC N
mortality NN N
in IN N
patients NNS N
undergoing VBG N
thoracotomy NN i
. . i

This DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
demonstrates VBZ N
frequent JJ N
incidences NNS N
of IN N
both DT N
acid JJ o
GER NNP o
and CC o
tracheal JJ o
acid JJ o
aspiration NN o
during IN N
surgery NN N
that WDT N
are VBP N
significantly RB N
reduced VBN N
by IN N
premedication NN N
with IN N
ranitidine NN i
. . i

-DOCSTART- -12970516- O O

Efficacy NN o
and CC o
tolerability NN o
of IN N
donepezil NN i
in IN N
vascular JJ p
dementia NN p
: : p
positive JJ N
results NNS N
of IN N
a DT N
24-week JJ N
, , N
multicenter NN N
, , N
international JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Clinical NNP N
observations NNS N
suggest VBP N
that IN N
patients NNS p
with IN p
vascular JJ p
dementia NN p
( ( p
VaD NNP p
) ) p
may MD N
benefit VB N
from IN N
treatment NN N
with IN N
cholinesterase NN i
inhibitors NNS i
. . i

This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
donepezil NN i
for IN N
relieving VBG N
symptoms NNS N
of IN N
dementia NN N
in IN N
VaD NNP N
. . N

METHODS NNP N
Patients NNPS p
( ( p
n=603 JJ p
; : p
mean JJ p
age NN p
, , p
73.9 CD p
years NNS p
; : p
55.2 CD p
% NN p
men NNS p
) ) p
with IN p
probable JJ p
( ( p
70.5 CD p
% NN p
) ) p
or CC p
possible JJ p
( ( p
29.5 CD p
% NN p
) ) p
VaD NNP p
, , p
according VBG p
to TO p
criteria NNS p
of IN p
the DT p
National NNP p
Institute NNP p
of IN p
Neurological NNP p
Disorders NNP p
and CC p
Stroke NNP p
( ( p
NINDS NNP p
) ) p
and CC p
the DT p
Association NNP p
Internationale NNP p
pour VBP p
la NN p
Recherche NNP p
et CC p
l'Enseignement JJ p
en NN p
Neurosciences NNP p
( ( p
AIREN NNP p
) ) p
, , N
were VBD N
randomized VBN N
to TO N
24 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
donepezil JJ i
5 CD N
mg/d NN N
( ( N
n=198 JJ N
) ) N
, , N
donepezil $ i
10 CD N
mg/d NN N
( ( N
5 CD N
mg/d NN N
for IN N
first JJ N
28 CD N
days NNS N
; : N
n=206 CC N
) ) N
, , N
or CC N
placebo NN i
( ( N
n=199 JJ N
) ) N
. . N

Analyses NNS N
were VBD N
based VBN N
on IN N
the DT N
intent-to-treat JJ N
population NN N
. . N

RESULTS NNP N
At IN N
week NN N
24 CD N
, , N
both DT N
donepezil NN i
groups NNS N
showed VBD N
significant JJ N
improvement NN o
in IN o
cognition NN o
versus NN N
placebo NN i
on IN N
the DT N
Alzheimer NNP o
's POS o
Disease NNP o
Assessment NNP o
Scale-cognitive JJ o
subscale NN o
( ( N
mean JJ N
change NN N
from IN N
baseline NN N
score NN N
effect NN N
size NN N
: : N
donepezil NN i
5 CD N
mg/d NN N
, , N
-1.90 NNP N
; : N
P=0.001 NNP N
; : N
donepezil VBZ i
10 CD N
mg/d NN N
, , N
-2.33 NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
improvements NNS N
in IN N
patients NNS o
' POS o
global JJ o
function NN o
were VBD N
seen VBN N
versus NN N
placebo NN i
at IN N
week NN N
24 CD N
( ( N
observed JJ N
cases NNS N
) ) N
, , N
on IN N
the DT N
Clinician NNP o
's POS o
Interview-Based JJ o
Impression NN o
of IN o
Change-Plus NNP o
version NN o
only RB N
for IN N
patients NNS N
on IN N
donepezil JJ i
5 CD N
mg/d NN N
( ( N
P=0.014 NNP N
) ) N
, , N
and CC N
on IN N
the DT N
Sum NNP o
of IN o
the DT o
Boxes NNP o
of IN o
the DT o
Clinical NNP o
Dementia NNP o
Rating NNP o
only RB N
for IN N
patients NNS N
on IN N
10 CD N
mg/d NN N
( ( N
P=0.007 NNP N
) ) N
. . N

Donepezil-treated JJ i
patients NNS N
showed VBD N
significant JJ N
benefits NNS N
in IN N
activities NNS o
of IN o
daily JJ o
living NN o
over IN N
placebo NN i
on IN N
the DT N
Alzheimer NNP o
's POS o
Disease NNP o
Functional NNP o
Assessment NNP o
and CC o
Change NNP o
Scale NNP o
( ( N
mean JJ N
change NN N
from IN N
baseline NN N
score NN N
effect NN N
size NN N
at IN N
week NN N
24 CD N
: : N
donepezil NN i
5 CD N
mg/d NN N
, , N
-1.31 NNP N
, , N
P=0.02 NNP N
; : N
donepezil VBZ i
10 CD N
mg/d NN N
, , N
-1.31 NNP N
, , N
P=0.02 NNP N
) ) N
. . N

Donepezil NNP i
was VBD N
well RB o
tolerated VBN o
. . o

Withdrawal NNP o
rates NNS o
due JJ o
to TO o
adverse JJ o
events NNS o
were VBD N
relatively RB N
low JJ N
( ( i
placebo NN i
, , N
11.1 CD N
% NN N
; : N
donepezil CC i
5 CD N
mg/d NN N
, , N
11.1 CD N
% NN N
; : N
donepezil CC i
10 CD N
mg/d NN N
, , N
21.8 CD N
% NN N
; : N
P=0.005 NNP N
versus IN N
placebo NN i
) ) i
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
demonstrate NN N
that IN N
donepezil NN o
is VBZ o
an DT o
effective JJ o
and CC o
well-tolerated JJ o
treatment NN o
for IN o
VaD NNP o
and CC N
show VB N
it PRP N
may MD N
have VB N
an DT N
important JJ N
place NN N
in IN N
the DT N
management NN N
of IN N
this DT N
condition NN N
. . N

-DOCSTART- -1331023- O O

The DT N
adrenocorticotrophic JJ i
hormone NN i
( ( i
4-9 JJ i
) ) i
analog NN i
ORG IN i
2766 CD i
benefits NNS N
autistic JJ p
children NNS p
: : p
report NN N
on IN N
a DT N
second JJ N
controlled JJ N
clinical JJ N
trial NN N
. . N

In IN N
a DT N
second JJ N
controlled VBN N
crossover NN N
trial NN N
, , N
20 CD p
autistic JJ p
children NNS p
received VBD p
40 CD i
mg/day NN i
of IN i
the DT i
neuropeptide NN i
ORG NNP i
2766 CD i
, , i
a DT i
synthetic JJ i
analog NN i
of IN i
ACTH NNP i
( ( i
4-9 JJ i
) ) i
, , p
for IN p
8 CD p
weeks NNS p
. . p

Parents NNS o
' POS o
checklist NN o
ratings NNS o
( ( o
ABC NNP o
) ) o
as RB N
well RB N
as IN N
clinicians NNS o
' POS o
ratings NNS o
( ( o
CGI NNP o
) ) o
pointed VBD N
to TO N
significant JJ N
improvements NNS N
after IN N
the DT N
course NN N
of IN N
treatment NN N
; : N
improvements NNS N
were VBD N
clearest VBN N
on IN N
the DT N
ABC NNP o
social JJ o
withdrawal NN o
subscale NN o
. . o

The DT N
analysis NN N
of IN N
individual JJ N
target NN N
symptoms NNS N
and CC N
the DT N
parents NNS N
' POS N
treatment NN N
preferences NNS N
substantiated VBD N
the DT N
beneficial JJ N
effects NNS N
of IN N
ORG NNP i
2766 CD i
. . i

In IN N
an DT N
ethologically RB N
analyzed JJ N
playroom NN N
session NN N
, , N
ORG NNP N
2766 CD N
treatment NN N
was VBD N
associated VBN N
with IN N
an DT N
improvement NN N
in IN N
the DT N
children NNS o
's POS o
play NN o
behavior NN o
and CC N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
social JJ o
interaction NN o
between IN o
child NN o
and CC o
experimenter NN o
. . o

Gaze NNP o
coordination NN o
between IN N
child NN N
and CC N
experimenter NN N
also RB N
was VBD N
improved VBN N
. . N

-DOCSTART- -1497864- O O

Clinical JJ N
effects NNS N
of IN N
naltrexone NN i
on IN N
autistic JJ p
behavior NN p
. . p

Eight NNP p
young JJ p
adults NNS p
who WP p
were VBD p
diagnosed VBN p
with IN p
autism NN p
were VBD N
given VBN N
the DT N
opiate JJ i
antagonist NN i
naltrexone NN i
to TO N
control VB N
self-injurious JJ N
behavior NN N
and CC N
maladaptive JJ N
idiosyncratic JJ N
mannerisms NNS N
. . N

The DT N
drug NN N
and CC N
placebo NN i
were VBD N
administered VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
design NN N
over IN N
17 CD N
weeks NNS N
. . N

Although IN N
one CD N
subject NN N
appeared VBD N
to TO N
have VB N
partial JJ o
decreases NNS o
in IN o
maladaptive JJ o
behaviors NNS o
associated VBN N
with IN N
naltrexone NN i
use NN N
, , N
the DT N
drugs NNS N
, , N
as IN N
administered VBN N
in IN N
this DT N
study NN N
, , N
did VBD N
not RB N
reduce VB o
the DT o
self-injurious JJ o
and CC o
other JJ o
maladaptive JJ o
behaviors NNS o
of IN N
the DT N
subjects NNS N
. . N

-DOCSTART- -7888291- O O

A DT N
comparison NN N
of IN N
the DT N
systemic JJ N
bioactivity NN N
of IN N
inhaled JJ N
budesonide NN i
and CC N
fluticasone NN i
propionate NN i
in IN N
normal JJ p
subjects NNS p
. . p

1 CD N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
systemic JJ N
bioactivity NN N
of IN N
low JJ N
and CC N
high JJ N
doses NNS N
of IN N
inhaled JJ i
budesonide NN i
and CC N
fluticasone NN i
propionate NN i
given VBN N
by IN N
respective JJ N
dry JJ N
powder NN N
inhaler NN N
devices NNS N
. . N

2 CD N
. . N

A DT N
randomised JJ N
, , N
single JJ N
blind IN N
cross-over JJ N
design NN N
was VBD N
used VBN N
in IN N
nine CD p
healthy JJ p
subjects NNS p
who WP N
were VBD N
given VBN N
800 CD i
micrograms JJ i
day-1 NN i
of IN i
budesonide NN i
Turbohaler NNP i
( ( i
B800 NNP i
) ) i
for IN N
1 CD N
week NN N
, , N
followed VBN N
by IN N
1 CD N
week NN N
of IN N
1600 CD N
micrograms NNS N
day-1 JJ N
( ( N
B1600 NNP N
) ) N
, , N
or CC N
fluticasone RB i
Diskhaler NNP i
750 CD i
micrograms NNS i
day-1 JJ i
( ( N
F750 NNP N
) ) N
for IN N
1 CD N
week NN N
followed VBN N
by IN N
1 CD N
week NN N
of IN N
1500 CD N
micrograms NNS N
day-1 JJ N
( ( N
F1500 NNP N
) ) N
. . N

There EX N
was VBD N
a DT N
1 CD N
week NN N
washout NN N
between IN N
treatments NNS N
with IN N
fluticasone NN N
or CC N
budesonide NN N
. . N

A DT N
twice JJ N
daily JJ N
dosing VBG N
regime NN N
was VBD N
used VBN N
and CC N
mouth-rinsing NN N
was VBD N
employed VBN N
to TO N
reduce VB N
gut JJ N
bioavailability NN N
as RB N
well RB N
as IN N
to TO N
obviate VB N
local JJ N
adverse JJ N
effects NNS N
. . N

3 CD N
. . N

Parameters NNS N
of IN N
hypothalmic-pituitary JJ o
adrenal JJ o
( ( o
HPA NNP o
) ) o
axis NN o
activity NN o
and CC N
bone NN o
metabolism NN o
were VBD N
measured VBN N
at IN N
baseline NN N
( ( N
B0/F0 NNP N
) ) N
, , N
at IN N
the DT N
end NN N
of IN N
each DT N
week NN N
of IN N
treatment NN N
and CC N
after IN N
the DT N
1 CD N
week NN N
washout NN N
( ( N
F0 NNP N
or CC N
B0 NNP N
) ) N
. . N

4 CD N
. . N

Both DT N
fluticasone NN i
and CC N
budesonide NN i
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
attenuated VBD N
the DT N
post NN o
tetracosactrin NN o
serum NN o
cortisol NN o
at IN N
low JJ N
and CC N
high JJ N
doses NNS N
whilst VBP N
early JJ N
morning NN N
cortisol NN N
was VBD N
unchanged JJ N
. . N

No DT N
dose-response JJ o
effect NN o
was VBD N
observed VBN N
with IN N
either DT N
drug NN N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN o
between IN N
treatment NN N
with IN N
fluticasone NN i
or CC N
budesonide NN i
. . i

5 CD N
. . N

Neither CC N
budesonide JJ N
nor CC N
fluticasone NN N
produced VBD N
significant JJ N
suppression NN N
of IN N
plasma NN N
osteocalcin NN N
, , N
although IN N
the DT N
higher JJR N
doses NNS N
of IN N
both DT N
drugs NNS N
significantly RB N
reduced VBD N
fasting JJ N
urinary JJ N
calcium NN N
levels NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -18588611- O O

A DT N
comparison NN N
between IN N
the DT N
effect NN N
of IN N
oxytocin NN i
only RB i
and CC N
oxytocin JJ i
plus CC i
propranolol NN i
on IN N
the DT N
labor NN o
( ( N
a DT N
double NN N
blind NN N
randomized VBN N
trial NN N
) ) N
. . N

OBJECTIVE CC N
The DT N
comparison NN N
between IN N
the DT N
effect NN N
of IN N
oxytocin NN i
alone RB i
or CC N
in IN i
combination NN i
with IN i
propranolol NN i
on IN N
labor NN o
. . o

METHODS NNP N
A NNP N
double JJ N
blind NN N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
performed VBN N
on IN N
150 CD p
nulliparas NNS p
with IN p
a DT p
gestational JJ p
age NN p
of IN p
39-41 JJ p
weeks NNS p
of IN p
pregnancy NN p
and CC p
a DT p
Bishop NNP p
score NN p
of IN p
< NN p
or CC p
=5 NN p
. . p

In IN N
the DT N
first JJ N
group NN N
( ( i
oxytocin JJ i
group NN N
= NNP N
75 CD N
) ) N
, , N
oxytocin FW i
alone RB i
was VBD N
used VBN N
for IN N
induction NN o
of IN o
labor NN o
. . o

In IN N
the DT N
second JJ N
group NN N
( ( i
propranolol JJ i
group NN N
= VBD N
75 CD N
cases NNS N
) ) N
, , N
before IN N
the DT N
beginning NN N
of IN N
oxytocin NN i
, , N
2 CD N
mg NN N
propranolol NN i
was VBD N
slowly RB N
injected VBN N
intravenously RB N
then RB N
the DT N
oxytocin NN i
was VBD N
initiated VBN N
. . N

RESULTS VB N
The DT N
number NN o
of IN o
patients NNS o
who WP o
delivered VBD o
in IN o
the DT o
first JJ o
day NN o
showed VBD N
no DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
mean JJ N
duration NN o
for IN o
obtaining VBG o
good JJ o
contractions NNS o
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN i
group NN N
in IN N
both CC N
the DT N
first JJ N
and CC N
second JJ N
day NN N
of IN N
induction NN N
The DT N
mean JJ N
interval NN N
between IN N
the DT N
beginning NN N
of IN N
induction NN N
until IN N
the DT N
beginning NN N
of IN N
active JJ N
phase NN N
at IN N
the DT N
first JJ N
day NN N
of IN N
induction NN N
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN i
group NN N
. . N

The DT N
mean JJ o
interval NN o
between IN o
the DT o
beginning NN o
of IN o
induction NN o
until IN o
delivery NN o
at IN o
the DT o
first JJ o
day NN o
of IN o
induction NN o
was VBD N
shorter RBR N
in IN N
the DT N
propranolol NN i
group NN N
. . N

The DT N
amount NN o
of IN o
necessary JJ o
oxytocin NN o
for IN N
the DT N
first JJ N
day NN N
of IN N
induction NN N
was VBD N
less RBR N
in IN N
the DT N
propranolol NN i
group NN N
. . N

CONCLUSION NNP N
Propranolol NNP i
may MD N
shorten VB N
the DT N
induction NN o
duration NN o
and CC o
labor NN o
and CC N
reduce VB N
the DT N
amount NN N
of IN N
necessary JJ N
oxytocin NN i
. . i

-DOCSTART- -19138400- O O

Recommendations NNS N
for IN N
implementing VBG N
stereotactic JJ i
radiotherapy NN i
in IN N
peripheral JJ p
stage NN p
IA NNP p
non-small NN p
cell NN p
lung NN p
cancer NN p
: : p
report NN N
from IN N
the DT N
Quality NNP N
Assurance NNP N
Working NNP N
Party NNP N
of IN N
the DT N
randomised JJ N
phase NN N
III NNP N
ROSEL NNP N
study NN N
. . N

BACKGROUND NNP N
A NNP N
phase NN N
III NNP N
multi-centre NN N
randomised VBD N
trial NN N
( ( N
ROSEL NNP N
) ) N
has VBZ N
been VBN N
initiated VBN N
to TO N
establish VB N
the DT N
role NN N
of IN N
stereotactic JJ i
radiotherapy NN i
in IN N
patients NNS p
with IN p
operable JJ p
stage NN p
IA NNP p
lung NN p
cancer NN p
. . p

Due NNP N
to TO N
rapid VB N
changes NNS N
in IN N
radiotherapy NN N
technology NN N
and CC N
evolving VBG N
techniques NNS N
for IN N
image-guided JJ N
delivery NN N
, , N
guidelines NNS N
had VBD N
to TO N
be VB N
developed VBN N
in IN N
order NN N
to TO N
ensure VB N
uniformity NN N
in IN N
implementation NN N
of IN N
stereotactic JJ i
radiotherapy NN i
in IN N
this DT N
multi-centre JJ N
study NN N
. . N

METHODS/DESIGN NNP N
A NNP N
Quality NNP N
Assurance NNP N
Working NNP N
Party NNP N
was VBD N
formed VBN N
by IN N
radiation NN N
oncologists NNS N
and CC N
clinical JJ N
physicists NNS N
from IN N
both DT N
academic JJ N
as RB N
well RB N
as IN N
non-academic JJ N
hospitals NNS N
that WDT N
had VBD N
already RB N
implemented VBN N
stereotactic JJ i
radiotherapy NN i
for IN N
lung NN N
cancer NN N
. . N

A DT N
literature NN i
survey NN i
was VBD N
conducted VBN N
and CC N
consensus JJ N
meetings NNS N
were VBD N
held VBN N
in IN N
which WDT N
both CC N
the DT N
knowledge NN N
from IN N
the DT N
literature NN N
and CC N
clinical JJ N
experience NN N
were VBD N
pooled VBN N
. . N

In IN N
addition NN N
, , N
a DT p
planning NN p
study NN p
was VBD p
performed VBN p
in IN p
26 CD p
stage NN p
I PRP p
patients NNS p
, , p
of IN p
which WDT p
22 CD p
were VBD p
stage NN p
1A CD p
, , N
in IN N
order NN N
to TO N
develop VB N
and CC N
evaluate VB N
the DT N
planning NN N
guidelines NNS N
. . N

Plans NNS N
were VBD N
optimised VBN N
according VBG N
to TO N
parameters NNS N
adopted VBN N
from IN N
RTOG NNP N
trials NNS N
using VBG N
both DT N
an DT N
algorithm NN N
with IN N
a DT N
simple JJ N
homogeneity NN N
correction NN N
( ( N
Type NNP N
A NNP N
) ) N
and CC N
a DT N
more RBR N
advanced JJ i
algorithm NN i
( ( N
Type NNP N
B NNP N
) ) N
. . N

Dose NNP N
conformity NN N
requirements NNS N
were VBD N
then RB N
formulated VBN N
based VBN N
on IN N
these DT N
results NNS N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
current JJ N
literature NN N
and CC N
expert JJ N
experience NN N
, , N
guidelines NNS o
were VBD o
formulated VBN o
for IN o
this DT o
phase NN o
III NNP o
study NN o
of IN o
stereotactic JJ o
radiotherapy NN o
versus NN o
surgery NN o
. . o

These DT N
guidelines NNS N
can MD N
serve VB N
to TO N
facilitate VB N
the DT N
design NN N
of IN N
future JJ N
multi-centre JJ N
clinical JJ N
trials NNS N
of IN N
stereotactic JJ i
radiotherapy NN i
in IN N
other JJ N
patient NN N
groups NNS N
and CC N
aid VB N
a DT N
more RBR N
uniform JJ N
implementation NN N
of IN N
this DT N
technique NN N
outside JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -20934759- O O

The DT N
maximal JJ i
double JJ i
step NN i
length RB i
test NN i
can MD N
evaluate VB N
more RBR N
adequately RB N
the DT N
decrease NN N
of IN N
physical JJ N
function NN N
with IN N
age NN N
, , N
than IN N
the DT N
maximal JJ N
single JJ N
step NN N
length JJ N
test NN N
. . N

The DT N
maximal JJ i
double JJ i
step NN i
length NN i
( ( N
MDSL NNP N
) ) N
test NN N
is VBZ N
a DT N
modified JJ N
version NN N
of IN N
the DT N
maximal JJ i
step NN i
length NN i
( ( i
MSL NNP i
) ) i
test NN i
used VBN N
to TO N
evaluate VB N
the DT N
dynamic JJ N
balance NN N
related VBN N
to TO N
falls NNS N
in IN N
the DT N
elderly JJ N
. . N

Although IN N
this DT N
test NN N
can MD N
evaluate VB N
their PRP$ N
physical JJ N
function NN N
using VBG N
movements NNS N
similar JJ N
to TO N
daily JJ N
activities NNS N
as IN N
compared VBN N
to TO N
MSL NNP i
, , N
it PRP N
has VBZ N
not RB N
been VBN N
clarified VBN N
whether IN N
it PRP N
can MD N
adequately RB N
evaluate VB N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
( ( N
ADL NNP N
) ) N
abilities NNS N
of IN N
the DT N
elderly JJ N
, , N
as IN N
they PRP N
decrease VBP N
with IN N
age NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
both DT N
MSL NNP i
and CC N
MDSL NNP i
on IN N
age NN N
and CC N
ADL NNP N
in IN p
elderly JJ p
subjects NNS p
. . p

Fifty-seven CD p
elderly JJ p
females NNS p
who WP p
live VBP p
independently RB p
( ( p
age NN p
74.8?5.6 CD p
years NNS p
) ) p
were VBD p
recruited VBN p
. . p

MSL NNP i
and CC i
MDSL NNP i
were VBD N
conducted VBN N
twice RB N
after IN N
completing VBG N
an DT N
ADL NNP N
questionnaire NN N
. . N

Intra-class JJ o
correlation NN o
coefficients NNS o
( ( o
ICCs NNP o
) ) o
of IN N
both DT N
tests NNS N
were VBD N
high JJ N
( ( N
for IN i
MSL NNP i
: : i
ICC=0.95 NNP N
, , N
for IN i
MDSL NNP i
: : i
ICC=0.81-0.82 NN N
) ) N
. . N

Age NNP N
and CC N
ADL NNP N
significantly RB N
correlated VBD N
to TO o
MDSL NNP o
( ( N
age NN N
: : N
r=-0.32-0.41 NN N
, , N
ADL NNP N
: : N
r=0.28-0.48 NN N
) ) N
, , N
but CC N
not RB N
to TO N
MSL NNP N
( ( N
age NN N
: : N
r=-0.19 NN N
, , N
ADL NNP N
: : N
r=0.15 NN N
) ) N
. . N

MDSL NNP i
has VBZ N
high JJ N
reliability NN N
as IN N
it PRP N
relates VBZ N
to TO N
age NN N
and CC N
ADL NNP N
. . N

It PRP N
may MD N
be VB N
more JJR N
useful JJ N
to TO N
evaluate VB N
ADL NNP N
required VBN N
for IN N
independent JJ N
living NN N
and CC N
prevent NN N
falls NNS N
in IN N
the DT N
elderly JJ N
better JJR N
than IN i
MSL NNP i
. . i

-DOCSTART- -25488965- O O

Institutional JJ N
clinical JJ N
trial NN N
accrual JJ N
volume NN N
and CC N
survival NN N
of IN N
patients NNS p
with IN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

PURPOSE NNP N
National NNP N
Comprehensive NNP N
Cancer NNP N
Network NNP N
guidelines NNS N
recommend VBP N
patients NNS p
with IN p
head NN p
and CC p
neck NN p
cancer NN p
( ( p
HNC NNP p
) ) p
receive VBP N
treatment NN N
at IN N
centers NNS N
with IN N
expertise NN N
, , N
but CC N
whether IN N
provider NN N
experience NN N
affects NNS N
survival NN N
is VBZ N
unknown JJ N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT N
effect NN N
of IN N
institutional JJ N
experience NN N
on IN N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
or CC p
IV NNP p
HNC NNP p
was VBD N
investigated VBN N
within IN N
a DT N
randomized JJ N
trial NN N
of IN N
the DT N
Radiation NNP N
Therapy NNP N
Oncology NNP N
Group NNP N
( ( N
RTOG NNP N
0129 CD N
) ) N
, , N
which WDT N
compared VBN N
cisplatin NN i
concurrent NN i
with IN i
standard JJ i
versus NN i
accelerated VBN i
fractionation NN i
radiotherapy NN i
. . i

As IN N
a DT N
surrogate NN N
for IN N
experience NN N
, , N
institutions NNS N
were VBD N
classified VBN N
as IN N
historically RB N
low- JJ N
( ( N
HLACs NNP N
) ) N
or CC N
high-accruing JJ N
centers NNS N
( ( N
HHACs NNP N
) ) N
based VBN N
on IN N
accrual JJ N
to TO N
21 CD p
RTOG NNP p
HNC NNP p
trials NNS p
( ( p
1997 CD p
to TO p
2002 CD p
) ) p
. . p

The DT N
effect NN N
of IN N
accrual JJ N
volume NN N
on IN N
OS NNP N
was VBD N
estimated VBN N
by IN N
Cox NNP N
proportional JJ N
hazards NNS N
models NNS N
. . N

RESULTS NNP N
Median JJ o
RTOG NNP o
accrual NN o
( ( N
1997 CD N
to TO N
2002 CD N
) ) N
at IN N
HLACs NNP N
was VBD N
four CD N
versus NN N
65 CD N
patients NNS N
at IN N
HHACs NNP N
. . N

Analysis NNP N
included VBD N
471 CD p
patients NNS p
in IN p
RTOG NNP p
0129 CD p
( ( p
2002 CD p
to TO p
2005 CD p
) ) p
with IN p
known VBN p
human JJ p
papillomavirus NN p
and CC p
smoking NN p
status NN p
. . p

Patients NNS N
at IN N
HLACs NNP N
versus NN N
HHACs NNP N
had VBD N
better JJR N
performance NN N
status NN N
( ( N
0 CD N
: : N
62 CD N
% NN N
v JJ N
52 CD N
% NN N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
and CC N
lower JJR N
T NNP N
stage NN N
( ( N
T4 NNP N
: : N
26.5 CD N
% NN N
v JJ N
35.3 CD N
% NN N
; : N
P NNP N
= NNP N
.002 NNP N
) ) N
but CC N
were VBD N
otherwise RB N
similar JJ N
. . N

Radiotherapy NNP o
protocol NN o
deviations NNS o
were VBD N
higher JJR N
at IN N
HLACs NNP N
versus NN N
HHACs NNP N
( ( N
18 CD N
% NN N
v JJ N
6 CD N
% NN N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

When WRB N
compared VBN N
with IN N
HHACs NNP N
, , N
patients NNS N
at IN N
HLACs NNP N
had VBD N
worse JJR N
OS NNP o
( ( N
5 CD N
years NNS N
: : N
51.0 CD N
% NN N
v JJ N
69.1 CD N
% NN N
; : N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

Treatment NN N
at IN N
HLACs NNP N
was VBD N
associated VBN N
with IN N
increased VBN N
death NN o
risk NN o
of IN N
91 CD N
% NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
1.91 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.37 CD N
to TO N
2.65 CD N
) ) N
after IN N
adjustment NN N
for IN N
prognostic JJ N
factors NNS N
and CC N
72 CD N
% NN N
( ( N
HR NNP N
, , N
1.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.23 CD N
to TO N
2.40 CD N
) ) N
after IN N
radiotherapy NN N
compliance NN N
adjustment NN N
. . N

CONCLUSION NNP N
OS NNP N
is VBZ N
worse JJR N
for IN N
patients NNS N
with IN N
HNC NNP N
treated VBD N
at IN N
HLACs NNP N
versus NN N
HHACs NNP N
to TO N
cooperative VB N
group NN N
trials NNS N
after IN N
accounting VBG N
for IN N
radiotherapy NN N
protocol NN N
deviations NNS N
. . N

Institutional JJ N
experience NN N
substantially RB N
influences VBZ N
survival NN N
in IN N
locally RB N
advanced JJ N
HNC NNP N
. . N

-DOCSTART- -14576501- O O

Prophylaxis NN N
with IN N
meropenem NN i
of IN N
septic JJ o
complications NNS o
in IN N
acute JJ N
pancreatitis NN N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
versus NN N
imipenem NN i
. . i

OBJECTIVES NNP N
Prophylactic JJ N
antibiotics NNS N
are VBP N
helpful JJ N
in IN N
decreasing VBG N
the DT N
incidence NN N
of IN N
septic JJ o
complications NNS o
in IN N
acute JJ N
pancreatitis NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
meropenem NN i
, , N
a DT N
new JJ i
carbapenem NN i
antibiotic JJ i
, , N
with IN N
that DT N
of IN N
imipenem NN i
, , N
which WDT N
is VBZ N
the DT N
standard JJ N
prophylactic JJ i
treatment NN i
in IN N
patients NNS p
with IN p
severe JJ p
acute NN p
pancreatitis NN p
. . p

METHODS NNP N
One CD p
hundred VBD p
seventy-six JJ p
patients NNS p
with IN p
necrotizing JJ p
pancreatitis NN p
were VBD N
prospectively RB N
randomized VBN N
to TO N
prophylactic JJ i
treatment NN i
with IN N
0.5 CD i
g NNS i
meropenem JJ i
t.i.d NN i
. . i

intravenously RB i
or CC i
0.5 CD i
g NNS i
imipenem JJ i
q.i.d NN i
. . i

intravenously RB i
. . i

The DT N
occurrence NN o
of IN o
infection NN o
of IN o
pancreatic JJ o
necrosis NN o
, , o
rate NN o
of IN o
extrapancreatic JJ o
infections NNS o
, , o
systemic JJ o
and CC o
local JJ o
complications NNS o
, , o
need VBP o
for IN o
surgery NN o
, , o
mortality NN o
rate NN o
, , o
and CC o
length NN o
of IN o
hospitalization NN o
were VBD N
recorded VBN N
for IN N
each DT N
group NN N
. . N

When WRB N
a DT N
septic JJ o
complication NN o
of IN N
pancreatic JJ N
necrosis NN N
was VBD N
suspected VBN N
, , N
fine JJ N
needle JJ N
aspiration NN N
with IN N
cultures NNS N
of IN N
the DT N
sample NN N
was VBD N
performed VBN N
. . N

Surgery NN N
was VBD N
performed VBN N
in IN N
cases NNS N
of IN N
verified JJ N
infected JJ N
necrosis NN N
. . N

CONCLUSION NNP N
No NNP N
difference NN N
was VBD N
observed VBN N
between IN N
patients NNS p
treated VBN p
with IN p
meropenem NN i
and CC p
those DT p
treated VBN p
with IN p
imipenem NN i
in IN p
terms NNS p
of IN p
incidence NN o
of IN o
pancreatic JJ o
infection NN o
( ( p
11.4 CD p
% NN p
versus IN p
13.6 CD p
% NN p
) ) p
and CC p
extrapancreatic JJ o
infections NNS o
( ( p
21.6 CD p
% NN p
versus IN p
23.9 CD p
% NN p
) ) p
and CC p
clinical JJ o
outcome NN o
. . o

Meropenem NNP i
is VBZ N
as RB N
effective JJ N
as IN N
imipenem NN i
in IN N
preventing VBG N
septic JJ o
complications NNS o
of IN N
patients NNS N
with IN N
severe JJ N
acute NN N
pancreatitis NN N
. . N

-DOCSTART- -8169405- O O

Multidose NNP N
, , N
live VBP N
attenuated VBN N
, , N
cold-recombinant JJ N
, , N
trivalent JJ N
influenza NN i
vaccine NN i
in IN N
infants NNS p
and CC p
young JJ p
children NNS p
. . p

Twenty-two NNP p
healthy JJ p
infants NNS p
and CC p
children NNS p
received VBD N
either DT N
cold-recombinant JJ i
, , i
trivalent JJ i
influenza NN i
vaccine NN i
or CC N
placebo NN i
in IN N
a DT N
three-dose JJ N
vaccine NN N
trial NN N
. . N

Most JJS N
( ( N
82 CD N
% NN N
) ) N
who WP N
received VBD N
vaccine NN N
were VBD N
seronegative JJ N
to TO N
all DT N
three CD i
vaccine NN i
strains NNS i
( ( i
10 CD i
( ( i
6 CD i
) ) i
TCID50/dose NNP i
each DT i
) ) i
: : i
A/Kawasaki/9/86 NNP i
( ( i
H1N1 NNP i
) ) i
, , i
A/Los NNP i
Angeles/2/87 NNP i
( ( i
H3N2 NNP i
) ) i
, , i
and CC i
B/Yamagata/16/88 NNP i
. . i

Vaccine NNP N
was VBD N
administered VBN N
intranasally RB N
at IN N
time NN N
0 CD N
and CC N
2 CD N
and CC N
4 CD N
months NNS N
later RB N
. . N

The DT N
vaccine NN N
was VBD N
well RB o
tolerated VBN o
and CC o
immunogenic JJ o
when WRB N
administered VBN N
in IN N
a DT N
multidose JJ N
regimen NNS N
. . N

The DT N
first JJ N
dose NN N
stimulated VBN N
antibody NN N
to TO N
H1 NNP N
, , N
H3 NNP N
, , N
and CC N
B NNP N
in IN N
59 CD N
% NN N
, , N
94 CD N
% NN N
, , N
and CC N
35 CD N
% NN N
of IN N
vaccinees NNS N
, , N
respectively RB N
, , N
by IN N
hemagglutination NN N
inhibition NN N
( ( N
HAI NNP N
) ) N
or CC N
ELISA NNP N
. . N

After IN N
two CD N
doses NNS N
of IN N
vaccine NN N
, , N
93 CD N
% NN N
, , N
93 CD N
% NN N
, , N
and CC N
80 CD N
% NN N
had VBD N
antibody VBN N
by IN N
HAI NNP N
or CC N
ELISA NNP N
to TO N
H1 NNP o
, , o
H3 NNP o
, , o
and CC o
B NNP o
, , N
respectively RB N
. . N

Most JJS N
vaccinees NNS N
( ( N
67 CD N
% NN N
) ) N
responded VBD N
to TO N
all DT N
three CD N
viruses NNS N
after IN N
two CD N
doses NNS N
of IN N
vaccine NN N
. . N

The DT N
third JJ N
dose NN N
contributed VBD N
little JJ N
to TO N
the DT N
vaccine NN o
's POS o
immunogenicity NN o
. . o

Multidose NNP N
trivalent JJ N
influenza NN N
vaccine NN N
is VBZ N
safe JJ N
and CC N
induces VBZ N
an DT N
immune JJ o
response NN o
in IN N
most JJS N
vaccinees NNS N
after IN N
two CD N
doses NNS N
. . N

-DOCSTART- -11956614- O O

Endometrial JJ p
cytodiagnosis NN p
using VBG N
a DT N
new JJ i
softcyte NN i
versus NN N
a DT i
conventional JJ i
endocyte NN i
. . i

A DT N
new JJ N
endometrial JJ N
cytologic NN N
sampling VBG N
device NN N
, , N
softcyte NN N
, , N
was VBD N
used VBN N
in IN N
cytological JJ p
screening NN p
for IN p
endometrial JJ p
cancer NN p
, , N
and CC N
was VBD N
compared VBN N
with IN N
the DT N
endocyte NN i
with IN N
regard NN N
to TO N
manipulability NN N
, , N
adverse JJ N
effects NNS N
( ( N
including VBG N
pain NN N
and CC N
hemorrhage NN N
) ) N
, , N
and CC N
cellular JJ N
findings NNS N
( ( N
including VBG N
the DT N
quantity NN N
of IN N
cells NNS N
collected VBN N
, , N
the DT N
success NN N
rate NN N
, , N
cell NN N
freshness NN N
, , N
and CC N
cellular JJ N
clumping NN N
) ) N
. . N

A DT N
total NN N
of IN N
315 CD p
women NNS p
( ( p
premenopause IN p
251 CD p
, , p
postmenopause RB p
64 CD p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO p
two CD p
groups NNS p
who WP p
underwent VBP p
the DT p
endometrial JJ i
cytological JJ i
screening NN i
with IN i
either CC i
the DT i
softcyte NN i
or CC i
the DT i
endocyte NN i
. . i

To TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
softcyte NN i
we PRP N
compared VBN N
it PRP N
with IN N
the DT N
endocyte NN i
. . i

Endometrial NNP N
cytology NN N
using VBG N
a DT N
softcyte NN i
or CC N
an DT N
endocyte NN i
achieved VBN N
high JJ N
correct JJ o
diagnosis NN o
rate NN o
for IN o
cancer NN o
, , N
and CC N
both DT N
instruments NNS N
are VBP N
valuable JJ N
as IN N
endometrial JJ N
cytologic NN N
sample NN N
devices NNS N
. . N

The DT N
softcyte NN N
causes VBZ N
only RB N
mild JJ o
pain NN o
on IN o
introduction NN o
and CC o
during IN o
collection NN o
, , N
and CC N
a DT N
large JJ N
quantity NN o
of IN o
cells NNS o
could MD N
be VB N
harvested VBN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
softcyte NN N
is VBZ N
a DT N
useful JJ N
cytologic NN N
sampling VBG N
device NN N
in IN N
screening VBG p
for IN p
endometrial JJ p
cancer NN p
. . p

-DOCSTART- -1479049- O O

Clonidine NNP i
treatment NN N
of IN N
hyperactive JJ p
and CC p
impulsive JJ p
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Many JJ N
autistic JJ p
children NNS p
have VBP N
associated VBN N
problems NNS N
of IN N
inattention NN o
, , o
impulsivity NN o
, , o
and CC o
hyperactivity NN o
that WDT N
limit VBZ N
the DT N
effectiveness NN N
of IN N
educational JJ N
and CC N
behavioral JJ N
interventions NNS N
. . N

Few NNP N
controlled VBD N
psychopharmacologic JJ N
trials NNS N
have VBP N
been VBN N
conducted VBN N
in IN N
autistic JJ p
children NNS p
to TO N
determine VB N
which WDT N
agents NNS N
may MD N
be VB N
effective JJ o
for IN N
these DT N
associated VBN N
features NNS N
. . N

Eight NNP p
male NN p
children NNS p
( ( p
8.1 CD p
+/- JJ p
2.8 CD p
years NNS p
) ) p
with IN p
autistic JJ p
disorder NN p
, , p
diagnosed VBN p
by IN p
DSM-III-R NNP p
criteria NNS p
, , N
completed VBD N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
crossover NN N
trial NN N
of IN N
clonidine NN i
. . i

Subjects NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
if IN p
they PRP p
had VBD p
inattention NN p
, , p
impulsivity NN p
, , p
and CC p
hyperactivity NN p
that WDT p
was VBD p
excessive JJ p
for IN p
their PRP$ p
developmental JJ p
level NN p
. . p

Subjects NNS p
had VBD p
not RB p
tolerated VBN p
or CC p
responded VBN p
to TO p
other JJ p
psychopharmacologic JJ p
treatments NNS p
( ( i
neuroleptics NNS i
, , i
methylphenidate NN i
, , i
or CC i
desipramine NN i
) ) i
. . p

Teacher PRP$ o
ratings NNS o
on IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
irritability NN o
, , o
stereotypy NN o
, , o
hyperactivity NN o
, , o
and CC o
inappropriate JJ o
speech NN o
factors NNS o
were VBD N
lower JJR N
during IN N
treatment NN N
with IN N
clonidine NN i
than IN N
during IN N
treatment NN N
with IN N
placebo NN i
. . i

Attention NNP N
deficit NN N
disorder NN N
with IN N
hyperactivity NN N
: : N
Comprehensive NNP o
Teacher NNP o
's POS o
Rating NNP o
Scale NNP o
ratings NNS o
were VBD N
not RB N
significantly RB N
improved VBN N
during IN N
the DT N
study NN N
, , N
except IN N
for IN N
oppositional JJ N
behavior NN N
. . N

Parent NN o
Conners NNPS o
Abbreviated NNP o
Parent-Teacher NNP o
Questionnaire NNP o
ratings NNS o
significantly RB N
improved VBN N
during IN N
clonidine JJ i
treatment NN N
. . N

Clonidine NNP N
led VBD N
to TO N
increased VBN N
ratings NNS N
of IN N
the DT N
side NN o
effects NNS o
of IN o
drowsiness NN o
and CC o
decreased JJ o
activity NN o
. . o

Clinician JJ N
ratings NNS N
( ( o
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
Autism NNP o
, , o
Hyperactivity NNP o
, , o
Anger NNP o
and CC o
Speech NNP o
Deviance NNP o
factors NNS o
; : o
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
; : o
Clinical NNP o
Global NNP o
Impressions NNP o
efficacy NN o
) ) o
of IN N
videotaped JJ N
sessions NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
clonidine NN i
and CC N
placebo NN i
. . i

Clonidine NNP i
was VBD N
modestly RB N
effective JJ N
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
irritability NN o
and CC o
hyperactivity NN o
in IN N
some DT N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

-DOCSTART- -22531825- O O

Breaking VBG N
it PRP N
down RP N
is VBZ N
better RBR N
: : N
haptic JJ i
decomposition NN i
of IN i
complex JJ i
movements NNS i
aids NNS N
in IN N
robot-assisted JJ i
motor NN o
learning NN o
. . o

Training VBG i
with IN i
haptic JJ i
guidance NN i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
technique NN N
for IN N
learning VBG N
complex JJ N
movements NNS N
in IN N
rehabilitation NN N
and CC N
sports NNS N
, , N
but CC N
it PRP N
is VBZ N
unclear JJ N
how WRB N
to TO N
best VB N
deliver RB N
guidance-based JJ N
training NN N
. . N

Here RB N
, , N
we PRP N
hypothesized VBD N
that IN N
breaking VBG N
down RP N
a DT N
complex JJ N
movement NN N
, , N
similar JJ N
to TO N
a DT N
tennis NN N
backhand NN N
, , N
into IN N
simpler NN N
parts NNS N
and CC N
then RB N
using VBG N
haptic JJ i
feedback NN i
from IN i
a DT i
robotic JJ i
exoskeleton NN i
would MD N
help VB N
the DT N
motor NN N
system NN N
learn VBP N
the DT N
movement NN N
. . N

We PRP N
also RB N
examined VBD N
how WRB N
the DT N
particular JJ N
form NN N
of IN N
the DT N
decomposition NN N
affected VBD N
learning NN o
. . o

Three CD p
groups NNS p
of IN p
unimpaired JJ p
participants NNS p
trained VBN p
with IN p
the DT p
target NN p
arm JJ p
movement NN p
broken VBD p
down RB p
in IN p
three CD p
ways NNS p
: : p
1 CD p
) ) p
elbow NN i
flexion/extension NN i
and CC i
the DT i
unified JJ i
shoulder NN i
motion NN i
independently RB i
( ( i
anatomical JJ i
decomposition NN i
) ) i
, , i
2 CD i
) ) i
three CD i
component JJ i
shoulder NN i
motions NNS i
in IN i
Euler NNP i
coordinates NNS i
and CC i
elbow JJ i
flexion/extension NN i
( ( i
Euler NNP i
decomposition NN i
) ) i
, , i
or CC i
3 CD i
) ) i
the DT i
motion NN i
of IN i
the DT i
tip NN i
of IN i
the DT i
elbow NN i
and CC i
motion NN i
of IN i
the DT i
hand NN i
with IN i
respect NN i
to TO i
the DT i
elbow NN i
, , i
independently RB i
( ( i
visual JJ i
decomposition NN i
) ) i
. . i

A DT N
control NN N
group NN N
practiced VBD N
the DT N
same JJ N
number NN o
of IN o
movements NNS o
, , i
but CC i
experienced VBD i
the DT i
target NN o
motion NN o
only RB o
, , N
achieving VBG N
eight CD N
times NNS N
more RBR N
direct JJ o
practice NN o
with IN N
this DT N
motion NN N
. . N

Despite IN N
less JJR p
experience NN p
with IN p
the DT p
target NN p
motion NN p
, , N
part NN o
training NN o
was VBD N
better RBR N
, , N
but CC N
only RB N
when WRB N
the DT N
arm NN N
trajectory NN N
was VBD N
decomposed VBN N
into IN N
anatomical JJ N
components NNS N
. . N

Varying VBG N
robotic JJ N
movement NN N
training NN N
to TO N
include VB N
practice NN N
of IN N
simpler NN i
, , i
anatomically-isolated JJ i
motions NNS i
may MD N
enhance VB N
its PRP$ N
efficacy NN o
. . o

-DOCSTART- -26279073- O O

Chromium NNP i
Supplementation NNP i
and CC N
the DT N
Effects NNS N
on IN N
Metabolic NNP o
Status NNP o
in IN N
Women NNP p
with IN p
Polycystic NNP p
Ovary NNP p
Syndrome NNP p
: : p
A DT N
Randomized NNP N
, , N
Double-Blind NNP N
, , N
Placebo-Controlled JJ N
Trial NNP N
. . N

BACKGROUND NNP N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
beneficial JJ N
effects NNS N
of IN N
chromium NN i
intake NN N
on IN N
markers NNS N
of IN N
insulin NN o
metabolism NN o
and CC N
lipid JJ o
profiles NNS o
in IN N
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
, , N
64 CD p
women NNS p
with IN p
PCOS NNP p
were VBD p
randomized VBN p
to TO N
receive VB N
200 CD i
?g NNP i
chromium NN i
picolinate NN i
supplements NNS i
( ( i
n JJ i
= NNP i
32 CD i
) ) i
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
32 CD N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

Fasting VBG o
blood NN o
samples NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
8 CD N
weeks NNS N
after IN N
the DT N
intervention NN N
to TO N
quantify VB N
markers NNS N
of IN N
insulin NN N
metabolism NN N
and CC N
lipid JJ N
concentrations NNS N
. . N

RESULTS NNP i
Chromium NNP i
supplementation NN N
in IN N
women NNS N
with IN N
PCOS NNP N
resulted VBD N
in IN N
significant JJ N
decreases NNS N
in IN o
serum JJ o
insulin NN o
levels NNS o
( ( N
-3.6 VB N
? . N
7.4 CD N
vs. IN N
+3.6 NN N
? . N
6.2 CD N
?IU/ml NN N
, , N
p NN N
< NNP N
0.001 CD o
) ) o
, , o
homeostasis JJ o
model NN o
of IN o
assessment-insulin JJ o
resistance NN o
( ( o
HOMA-IR NNP o
; : N
-0.8 NNP N
? . N
1.6 CD N
vs. IN N
+0.9 NN N
? . N
1.5 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , o
homeostatic JJ o
model NN o
assessment-beta NN o
cell NN o
function NN o
( ( o
HOMA-B NNP o
; : N
-15.5 NNP N
? . N
32.3 CD N
vs. IN N
+13.6 NN N
? . N
23.1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
a DT N
significant JJ N
increase NN N
in IN o
quantitative JJ o
insulin NN o
sensitivity NN o
check NN o
index NN o
( ( o
QUICKI NNP o
) ) o
score NN o
( ( o
+0.02 VB N
? . N
0.03 CD N
vs. IN N
-0.008 NN N
? . N
0.02 CD N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
compared VBN N
with IN i
the DT i
placebo NN i
. . i

In IN N
addition NN N
, , N
a DT N
trend NN N
toward IN N
a DT N
significant JJ N
effect NN N
of IN N
chromium NN i
supplementation NN N
on IN N
decreasing VBG N
serum NN o
triglycerides NNS o
( ( o
-12.4 VB o
? . o
74.4 CD N
vs. IN N
+15.2 NN N
? . N
32.4 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
very RB N
low-density JJ o
lipoprotein-cholesterol NN o
( ( o
-2.5 VB o
? . o
14.9 CD o
vs. IN N
+3.0 NN N
? . N
6.5 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
and CC N
cholesterol NN o
concentrations NNS o
( ( o
-8.6 VB o
? . o
21.9 CD o
vs. IN N
+0.7 NN N
? . N
22.4 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.09 CD N
) ) N
was VBD N
seen VBN N
. . N

CONCLUSIONS NNP N
Eight NNP i
weeks NNS i
of IN i
chromium JJ i
supplementation NN i
among IN p
PCOS NNP p
women NNS p
had VBD p
favorable JJ N
effects NNS o
on IN o
markers NNS o
of IN o
insulin NN o
metabolism NN o
. . o

-DOCSTART- -17516971- O O

Comparison NNP N
of IN N
self-administered JJ i
vaginal JJ i
misoprostol NN i
versus NN N
placebo NN i
for IN N
cervical JJ N
ripening VBG N
prior JJ N
to TO N
operative JJ N
hysteroscopy NN N
using VBG N
a DT N
sequential JJ N
trial NN N
design NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
impact NN N
of IN N
1000-microgram JJ N
self-administered JJ i
vaginal JJ i
misoprostol NN i
versus IN N
self-administered JJ i
vaginal JJ i
placebo NN i
at IN N
home NN N
on IN N
preoperative JJ N
cervical JJ N
ripening NN N
in IN N
both DT N
premenopausal NN p
and CC p
postmenopausal JJ p
women NNS p
prior RB p
to TO p
outpatient VB p
resectoscopy NN p
. . p

DESIGN NNP N
Randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
sequential JJ N
trial NN N
. . N

SETTING NN N
Norwegian JJ p
university NN p
teaching VBG p
hospital NN p
. . p

SAMPLE NNP N
Premenopausal NNP p
and CC p
postmenopausal JJ p
women NNS p
referred VBD p
to TO p
outpatient VB p
resectoscopy NN p
. . p

METHODS NNP N
The DT N
women NNS N
were VBD N
randomised VBN N
to TO N
either DT N
1000 CD N
micrograms NNS N
of IN N
self-administered JJ i
vaginal JJ i
misoprostol NN i
or CC N
self-administered JJ i
vaginal JJ i
placebo NN i
the DT N
evening NN N
before IN N
outpatient JJ N
resectoscopy NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Preoperative NNP o
cervical JJ o
dilatation NN o
, , o
acceptability NN o
and CC o
complications NNS o
. . o

RESULTS NNP N
( ( N
a DT N
) ) N
Intraoperative JJ N
findings NNS N
and CC N
distribution NN N
of IN o
cervical JJ o
dilatation NN o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Values NNS N
are VBP N
given VBN N
as IN N
median JJ o
( ( o
range NN o
) ) o
or CC o
n JJ o
( ( o
% NN o
) ) o
. . o

( ( N
b NN N
) ) N
Acceptability NN o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Values NNS N
are VBP N
given VBN N
as IN N
completely RB N
acceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
; : N
fairly RB N
acceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
; : N
fairly RB N
unacceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
and CC N
completely RB N
unacceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
. . N

( ( N
c NN N
) ) N
Pain NN o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Pain NNP o
was VBD N
measured VBN N
with IN N
a DT N
visual JJ N
analogue NN N
scale NN N
score NN N
, , N
scale JJ N
ranges NNS N
from IN N
0 CD N
( ( N
no DT N
pain NN N
) ) N
to TO N
10 CD N
( ( N
unbearable JJ N
pain NN N
) ) N
. . N

Values NNS N
are VBP N
given VBN N
as IN N
median JJ N
( ( N
range NN N
) ) N
. . N

( ( N
d NN N
) ) N
Occurrence NN o
of IN o
adverse JJ o
effects NNS o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Values NNS N
are VBP N
given VBN N
as IN N
n JJ N
( ( N
% NN N
) ) N
. . N

( ( N
e NN N
) ) N
Complications NNPS o
, , N
given VBN N
as IN N
n JJ N
( ( N
% NN N
) ) N
. . N

-DOCSTART- -22082673- O O

Atrial JJ i
fibrillation NN i
catheter NN i
ablation NN i
versus NN i
surgical JJ i
ablation NN i
treatment NN i
( ( i
FAST NNP i
) ) i
: : i
a DT N
2-center JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Catheter NNP i
ablation NN i
( ( i
CA NNP i
) ) i
and CC N
minimally RB i
invasive JJ i
surgical JJ i
ablation NN i
( ( i
SA NNP i
) ) i
have VBP N
become VBN N
accepted JJ N
therapy NN N
for IN N
antiarrhythmic JJ N
drug-refractory JJ N
atrial JJ N
fibrillation NN N
. . N

This DT N
study NN N
describes VBZ N
the DT N
first JJ N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
their PRP$ N
efficacy NN N
and CC N
safety NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
One CD p
hundred VBD p
twenty-four JJ p
patients NNS p
with IN p
antiarrhythmic JJ p
drug-refractory JJ p
atrial JJ p
fibrillation NN p
with IN p
left JJ p
atrial JJ p
dilatation NN p
and CC p
hypertension NN p
( ( p
42 CD p
patients NNS p
, , p
33 CD p
% NN p
) ) p
or CC p
failed VBN p
prior JJ p
CA NNP i
( ( p
82 CD p
patients NNS p
, , p
67 CD p
% NN p
) ) p
were VBD N
randomized VBN N
to TO N
CA NNP i
( ( N
63 CD N
patients NNS N
) ) N
or CC N
SA NNP i
( ( N
61 CD N
patients NNS N
) ) N
. . N

CA NNP i
consisted VBD N
of IN N
linear JJ N
antral JJ N
pulmonary JJ N
vein NN N
isolation NN N
and CC N
optional JJ N
additional JJ N
lines NNS N
. . N

SA NNP i
consisted VBD N
of IN N
bipolar JJ N
radiofrequency NN N
isolation NN N
of IN N
the DT N
bilateral JJ N
pulmonary JJ N
vein NN N
, , N
ganglionated VBD N
plexi JJ N
ablation NN N
, , N
and CC N
left VBD N
atrial JJ N
appendage NN N
excision NN N
with IN N
optional JJ N
additional JJ N
lines NNS N
. . N

Follow-up NN N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
was VBD N
performed VBN N
by IN N
ECG NNP N
and CC N
7-day JJ N
Holter NNP N
recording NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
, , N
freedom NN N
from IN N
left VBN N
atrial JJ N
arrhythmia NN N
> VBD N
30 CD N
seconds NNS N
without IN N
antiarrhythmic JJ i
drugs NNS i
after IN N
12 CD N
months NNS N
, , N
was VBD N
36.5 CD N
% NN N
for IN N
CA NNP i
and CC N
65.6 CD N
% NN N
for IN N
SA NNP i
( ( N
P=0.0022 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
effect NN N
for IN N
subgroups NNS N
, , N
which WDT N
was VBD N
consistent NN N
at IN N
both DT N
sites NNS N
. . N

The DT N
primary JJ N
safety NN N
end NN N
point NN N
of IN N
significant JJ N
adverse JJ N
events NNS N
during IN N
the DT N
12-month JJ N
follow-up NN N
was VBD N
significantly RB N
higher JJR N
for IN N
SA NNP i
than IN N
for IN N
CA NNP i
( ( N
n=21 JJ N
[ RB N
34.4 CD N
% NN N
] JJ N
versus NN N
n=10 NN N
[ VBD N
15.9 CD N
% NN N
] NN N
; : N
P=0.027 NNP N
) ) N
, , N
driven VBN N
mainly RB N
by IN N
procedural JJ N
complications NNS N
such JJ N
as IN N
pneumothorax NN N
, , N
major JJ N
bleeding NN N
, , N
and CC N
the DT N
need NN N
for IN N
pacemaker NN N
. . N

In IN N
the DT N
CA NNP i
group NN N
, , N
1 CD N
patient NN N
died VBD N
at IN N
1 CD N
month NN N
of IN N
subarachnoid JJ N
hemorrhage NN N
. . N

CONCLUSION NNP N
In IN N
atrial JJ p
fibrillation NN p
patients NNS p
with IN p
dilated JJ p
left JJ p
atrium NN p
and CC p
hypertension NN p
or CC p
failed VBD p
prior RB p
atrial JJ p
fibrillation NN p
CA NNP i
, , i
SA NNP i
is VBZ N
superior JJ N
to TO N
CA NNP i
in IN N
achieving VBG N
freedom NN N
from IN N
left VBN N
atrial JJ N
arrhythmias NNS N
after IN N
12 CD N
months NNS N
of IN N
follow-up NN N
, , N
although IN N
the DT N
procedural JJ N
adverse JJ N
event NN N
rate NN N
is VBZ N
significantly RB N
higher JJR N
for IN N
SA NNP i
than IN N
for IN N
CA NNP i
. . i

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00662701 NNP N
. . N

-DOCSTART- -12407485- O O

Lamivudine NNP i
300 CD N
mg NN N
QD NNP N
versus NN N
continued VBD N
lamivudine JJ i
150 CD N
mg NNS N
BID NNP N
with IN N
stavudine NN i
and CC N
a DT N
protease NN i
inhibitor NN i
in IN N
suppressed JJ p
patients NNS p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
sustained VBN N
virologic IN N
suppression NN N
) ) N
and CC N
safety/tolerability NN N
of IN N
a DT N
switch NN N
to TO N
lamivudine VB i
300 CD N
mg NNS N
once RB N
daily JJ N
( ( N
QD NNP N
) ) N
versus NN N
continued VBD N
lamivudine JJ i
150 CD N
mg JJ N
twice RB N
daily RB N
( ( N
BID NNP N
) ) N
in IN N
virologically RB p
suppressed VBN p
patients NNS p
( ( p
HIV-1 NNP p
RNA NNP p
< NNP p
400 CD p
copies/mL NN p
for IN p
> NN p
or CC p
=3 JJ p
months NNS p
) ) p
on IN p
stable JJ p
( ( p
> JJ p
or CC p
=6 JJ p
months NNS p
) ) p
therapy NN p
with IN p
lamivudine JJ i
150 CD i
mg NN i
BID NNP i
plus CC i
stavudine NN i
and CC i
either DT i
indinavir NN i
or CC i
nelfinavir NN i
. . i

METHOD NNP N
Eighty-nine NNP p
suppressed VBD p
patients NNS p
> CD p
or CC p
=18 CD p
years NNS p
old JJ p
with IN p
CD4 NNP p
counts VBZ p
> JJ p
50 CD p
cells/mm NN p
( ( p
3 CD p
) ) p
were VBD N
enrolled VBN N
in IN N
this DT N
phase NN N
II NNP N
, , N
open-label NN N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
stratified VBN N
( ( N
by IN N
pretrial JJ i
protease NN i
inhibitor NN i
[ NNP N
PI NNP N
] NNP N
) ) N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
. . N

Eighty-one JJ p
patients NNS p
received VBD N
either RB N
lamivudine JJ i
300 CD N
mg NN N
QD NNP N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
or CC N
150 CD N
mg NNS N
BID NNP N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
with IN N
their PRP$ N
pretrial JJ i
stavudine/PI NN i
regimens NNS i
for IN N
24 CD N
weeks NNS N
. . N

RESULTS VB N
A DT N
high JJ N
rate NN o
of IN o
virologic JJ o
suppression NN o
was VBD N
sustained VBN N
with IN N
both DT N
regimens NNS N
throughout IN N
the DT N
trial NN N
. . N

At IN N
week NN N
24 CD N
, , N
intent-to-treat NN N
: : N
exposed VBN N
( ( N
missing VBG N
= NNP N
failure NN N
) ) N
analyses VBZ N
showed VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
percentage NN o
of IN o
patients NNS o
with IN o
HIV-1 NNP o
RNA NNP o
< NNP N
400 CD N
copies/mL NN N
( ( N
95 CD N
% NN N
[ JJ N
QD NNP N
] NNP N
vs. IN N
90 CD N
% NN N
[ JJ N
BID NNP N
] NNP N
) ) N
or CC N
< $ N
50 CD N
copies/mL NN N
( ( N
82 CD N
% NN N
[ JJ N
QD NNP N
] NNP N
vs. IN N
81 CD N
% NN N
[ JJ N
BID NNP N
] NNP N
) ) N
or CC N
in IN N
the DT N
median JJ o
change NN o
from IN o
baseline NN o
in IN N
CD4 NNP o
counts NNS o
( ( N
+42 JJ N
cells/mm NN N
( ( N
3 CD N
) ) N
[ NN N
QD NNP N
] NNP N
vs. FW N
+22 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
[ FW N
BID NNP N
] NNP N
) ) N
. . N

Both DT N
regimens NNS N
were VBD N
well RB N
tolerated VBN N
. . N

No DT N
patient NN N
experienced VBD N
virologic JJ o
failure NN o
, , o
clinical JJ o
disease NN o
progression NN o
, , o
or CC o
a DT o
drug-related JJ o
serious JJ o
adverse JJ o
event NN o
during IN N
the DT N
trial NN N
. . N

Self-reported JJ o
medication NN o
adherence NN o
was VBD N
high JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Patients NNPS p
who WP p
experience VBP p
virologic JJ o
suppression NN o
with IN p
a DT p
regimen NNS p
of IN p
lamivudine JJ i
150 CD p
mg NN p
BID NNP p
in IN p
combination NN i
with IN i
stavudine/PI NN i
can MD N
maintain VB N
that DT N
suppression NN o
by IN N
continuing VBG N
their PRP$ N
regimen NNS N
or CC N
switching VBG N
to TO N
lamivudine VB i
300 CD N
mg NN N
QD NNP N
and CC N
continuing VBG N
the DT N
other JJ N
components NNS N
. . N

Adverse JJ N
event NN N
profiles NNS N
were VBD N
comparable JJ N
among IN N
treatment NN N
regimens NNS N
, , N
and CC N
no DT N
new JJ N
safety NN N
concerns NNS N
were VBD N
raised VBN N
. . N

-DOCSTART- -23821414- O O

Riluzole NNP i
as IN N
an DT N
adjunctive JJ N
therapy NN N
to TO N
risperidone VB i
for IN N
the DT N
treatment NN N
of IN N
irritability NN o
in IN p
children NNS p
with IN p
autistic JJ p
disorder NN p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
A DT N
hyperglutamatergic NN N
state NN N
has VBZ N
been VBN N
shown VBN N
to TO N
play VB N
a DT N
possible JJ N
role NN N
in IN N
the DT N
pathophysiology NN N
of IN N
autistic JJ p
disorders NNS p
. . p

Riluzole NNP i
is VBZ N
a DT N
glutamate-modulating JJ N
agent NN N
with IN N
neuroprotective JJ N
properties NNS N
, , N
which WDT N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
positive JJ N
effects NNS N
in IN N
many JJ N
neuropsychiatric JJ o
disorders NNS o
. . o

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
riluzole NN i
as IN N
an DT N
adjunctive JJ N
to TO N
risperidone VB N
in IN N
the DT N
treatment NN N
of IN N
irritability NN p
in IN p
autistic JJ p
children NNS p
who WP p
were VBD p
not RB p
optimally RB p
responding VBG p
to TO N
previous JJ N
medications NNS N
. . N

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
10-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

PARTICIPANTS VB N
The DT N
study NN N
enrolled VBD N
male NN p
and CC p
female JJ p
outpatients NNS p
aged VBN p
5-12 CD p
years NNS p
with IN p
a DT p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
based VBN p
on IN p
the DT p
DSM-IV-TR NNP p
criteria NNS p
and CC p
a DT p
score NN p
of IN p
?12 NN p
on IN p
the DT p
Aberrant NNP p
Behavior NNP p
Checklist-Community NNP p
( ( p
ABC-C NNP p
) ) p
irritability NN p
subscale NN p
who WP p
had VBD p
discontinued VBN p
other JJ p
medications NNS p
because IN p
of IN p
a DT p
lack NN p
of IN p
efficacy NN p
. . p

INTERVENTIONS NNP p
Subjects NNPS N
received VBD i
riluzole JJ i
( ( i
titrated VBN i
to TO N
50 CD N
or CC N
100 CD N
mg/day NNS N
based VBN N
on IN N
bodyweight NN i
) ) i
or CC i
placebo NN i
in IN i
addition NN i
to TO i
risperidone VB i
( ( i
titrated VBN i
up RB N
to TO N
2 CD N
or CC N
3 CD N
mg/day NNS N
based VBN N
on IN N
bodyweight NN N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

OUTCOME NN N
Patients NNPS N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
week NN N
5 CD N
, , N
and CC N
week NN N
10 CD N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
difference NN N
in IN N
the DT N
change NN N
in IN N
the DT N
ABC-C NNP o
irritability NN o
subscale NN o
score NN o
from IN N
baseline NN N
to TO N
week NN N
10 CD N
between IN N
the DT N
two CD N
groups NNS N
. . N

We PRP N
also RB N
compared VBN N
changes NNS o
in IN o
other JJ o
ABC-C JJ o
subscale NN o
scores NNS o
and CC o
Clinical NNP o
Global NNP o
Impressions-Improvement NNP o
( ( o
CGI-I NNP o
) ) o
scale NN o
scores NNS o
between IN o
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP p
Forty-nine JJ p
patients NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
, , p
and CC p
forty JJ p
children NNS p
completed VBD p
the DT p
trial NN p
( ( N
dropouts NNS N
: : N
placebo NN N
= VBZ N
4 CD N
, , N
riluzole JJ N
= FW N
5 CD N
) ) N
. . N

A DT N
significantly RB N
greater JJR N
improvement NN N
in IN N
the DT N
study NN N
primary JJ N
outcome NN N
( ( N
the DT o
ABC-C NNP o
irritability NN o
subscale NN o
score NN o
) ) o
was VBD o
achieved VBN N
by IN i
the DT i
riluzole-treated JJ i
children NNS N
compared VBN N
with IN i
the DT i
placebo NN i
group NN i
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT i
riluzole NN i
group NN i
also RB N
showed VBD N
significantly RB N
greater JJR N
improvement NN N
on IN o
the DT o
lethargy/social JJ o
withdrawal NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
stereotypic JJ o
behavior NN o
( ( o
P NNP o
= NNP o
0.03 CD N
) ) N
, , N
and CC o
hyperactivity/non-compliance NN o
subscales NNS o
( ( o
P NNP o
= NNP o
0.005 CD N
) ) N
, , N
but CC N
not RB o
on IN o
the DT o
inappropriate JJ o
speech NN o
subscale NN o
( ( o
P NNP N
= NNP N
0.20 CD N
) ) N
than IN N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

Eleven CD N
patients NNS N
in IN N
the DT i
riluzole NN i
group NN i
and CC N
five CD N
patients NNS N
in IN N
the DT N
placebo NN i
group NN i
were VBD N
classified VBN N
as IN N
responders NNS N
based VBN N
on IN N
their PRP$ o
CGI-I JJ o
scores NNS o
[ VBN N
? . N
( ( N
2 CD N
) ) N
( ( N
1 CD N
) ) N
= NN N
3.750 CD N
, , N
P NNP N
= VBZ N
0.05 CD N
] NN N
. . N

Children NNP N
in IN N
the DT i
riluzole NN i
group NN N
experienced VBD N
significantly RB N
more RBR N
increases NNS o
in IN o
their PRP$ o
appetite NN o
and CC o
bodyweight NN o
than IN N
children NNS N
in IN i
the DT i
placebo NN i
group NN N
by IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

CONCLUSION NNP N
Riluzole NNP i
add-on JJ i
therapy NN N
shows VBZ N
several JJ o
therapeutic JJ o
outcomes NNS o
, , o
particularly RB o
for IN N
improving VBG o
irritability NN o
, , o
in IN N
children NNS N
with IN N
autism NN N
. . N

However RB N
, , N
its PRP$ N
add-on JJ i
to TO i
risperidone VB i
also RB i
results NNS N
in IN N
significantly RB N
increased VBN o
appetite NN o
and CC o
weight JJ o
gain NN o
. . N

-DOCSTART- -17618948- O O

Parenteral JJ N
nutrition NN N
and CC N
protein NN N
sparing NN N
after IN N
surgery NN i
: : i
do VBP N
we PRP N
need VB N
glucose RB i
? . N
Although IN N
capable JJ N
of IN N
inducing VBG N
an DT N
anabolic JJ N
state NN N
after IN N
surgery NN N
, , N
parenteral JJ i
nutrition NN i
, , N
including VBG N
glucose NN i
, , N
leads VBZ N
to TO N
hyperglycemia VB N
. . N

Even RB N
moderate JJ N
increases NNS N
in IN N
blood NN N
glucose NN N
are VBP N
associated VBN N
with IN N
poor JJ N
surgical JJ N
outcome NN N
. . N

We PRP N
examined VBD N
the DT N
hypothesis NN N
that WDT N
amino NN i
acids NNS i
, , N
in IN N
the DT N
absence NN N
of IN N
glucose JJ i
supply NN N
, , N
spare JJ N
protein NN N
while IN N
preventing VBG N
hyperglycemia NN N
. . N

In IN N
this DT N
prospective JJ N
study NN N
, , N
14 CD p
patients NNS p
with IN p
colonic JJ p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
a DT N
6-hour JJ N
stable JJ N
isotope NN i
infusion NN i
study NN N
( ( N
3 CD N
hours NNS N
of IN N
fasting VBG i
followed VBN N
by IN N
3-hour JJ N
infusions NNS N
of IN N
amino NN i
acids NNS i
, , i
Travasol NNP i
[ NNP N
Baxter NNP N
, , N
Montreal NNP N
, , N
Canada NNP N
] VBD N
10 CD N
% NN N
at IN N
0.02 CD N
mL.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
, , N
with IN i
or CC i
without IN i
glucose JJ i
at IN N
4 CD N
mg.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
) ) N
on IN N
the DT N
second JJ N
day NN N
after IN N
colorectal JJ N
surgery NN N
. . N

Protein NNP o
breakdown NN o
, , o
protein JJ o
oxidation NN o
, , o
protein JJ o
balance NN o
, , o
and CC o
glucose JJ o
production NN o
were VBD N
assessed VBN N
by IN N
stable JJ N
isotope NN N
tracer NN N
kinetics NNS N
using VBG N
l- JJ N
[ JJ N
1- JJ N
( ( N
13 CD N
) ) N
C NNP N
] NNP N
leucine NN N
and CC N
[ JJ N
6,6- JJ N
( ( N
2 CD N
) ) N
H2 NNP N
] NNP N
glucose NN N
. . N

Circulating VBG o
concentrations NNS o
of IN o
glucose NN o
, , o
cortisol NN o
, , o
insulin NN o
, , o
and CC o
glucagon NN o
were VBD N
determined VBN N
. . N

The DT N
administration NN N
of IN N
amino JJ i
acids NNS i
increased VBD N
protein JJ o
balance NN o
from IN N
-16+/-4 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
in IN N
the DT N
fasted JJ N
state NN N
to TO N
16+/-3 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
. . N

Combined VBN N
infusion NN N
of IN N
amino JJ i
acids NNS i
and CC i
glucose VB i
increased JJ N
protein NN o
balance NN o
from IN N
-17+/-7 JJ N
to TO N
7+/-5 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
. . N

The DT N
increase NN N
in IN N
protein JJ o
balance NN o
during IN N
nutrition NN N
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
P=.07 NNP N
) ) N
. . N

Combined VBN N
administration NN N
of IN N
amino JJ i
acids NNS i
and CC i
glucose VB i
decreased VBN N
endogenous JJ o
glucose JJ o
production NN o
( ( N
P=.001 NNP N
) ) N
and CC N
stimulated VBN N
insulin NN o
secretion NN o
( ( N
P=.001 NNP N
) ) N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
the DT N
administration NN N
of IN N
amino JJ i
acids NNS i
alone RB N
. . N

Hyperglycemia NNP o
( ( N
blood NN N
glucose NN N
, , N
10.1+/-1.9 JJ N
micromol/L NN N
) ) N
occurred VBD N
only RB N
in IN N
the DT N
presence NN N
of IN N
glucose JJ i
infusion NN N
. . N

In IN N
summary JJ N
, , N
excluding VBG N
glucose NN i
from IN N
a DT N
short-term JJ N
feeding NN N
protocol NN N
does VBZ N
not RB N
diminish VB N
the DT N
protein-sparing JJ o
effect NN o
of IN N
amino NN i
acids NNS i
and CC N
avoids NNS N
hyperglycemia NN o
. . o

-DOCSTART- -2698934- O O

Chlorthalidone NN i
does VBZ N
not RB N
increase VB N
the DT N
hypotensive JJ o
effect NN o
of IN N
nifedipine NN i
in IN N
essential JJ N
hypertensives NNS N
: : N
a DT N
crossover NN p
multicentre NN p
study NN p
. . p

To TO N
determine VB N
whether IN N
the DT N
combination NN N
of IN N
nifedipine JJ i
+ NNP i
chlorthalidone NN i
exerts VBZ N
an DT N
additive JJ o
antihypertensive JJ o
effect NN o
when WRB N
compared VBN N
with IN N
single-drug JJ N
treatment NN N
, , N
we PRP N
studied VBD N
66 CD p
uncomplicated JJ p
essential JJ p
hypertensives NNS p
, , p
with IN p
diastolic JJ p
blood NN p
pressure NN p
of IN p
greater JJR p
than IN p
100 CD p
and CC p
less JJR p
than IN p
115 CD p
mmHg NN p
. . p

At IN N
the DT N
end NN N
of IN N
a DT N
1-month JJ N
washout NN N
placebo NN i
period NN N
, , N
using VBG N
a DT N
double-blind JJ N
crossover NN N
design NN N
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
nifedipine VB i
( ( N
20 CD N
mg NN N
twice RB N
a DT N
day NN N
) ) N
, , N
chlorthalidone NN i
( ( N
25 CD N
mg NN N
once RB N
a DT N
day NN N
) ) N
, , N
the DT N
two CD N
drugs NNS N
combined VBN N
at IN N
the DT N
same JJ N
doses NNS N
and CC N
the DT N
corresponding JJ N
placebo NN i
. . i

Compared VBN N
with IN N
the DT N
randomly NN N
allocated VBD N
placebo NN N
, , N
the DT N
three CD N
active JJ N
treatments NNS N
significantly RB N
reduced VBD N
blood NN o
pressure NN o
without IN N
changing VBG N
the DT N
heart NN o
rate NN o
or CC o
body NN o
weight NN o
. . o

Both CC N
the DT N
absolute NN o
and CC N
percentage NN o
decreases NNS o
in IN N
mean JJ o
blood NN o
pressure NN o
induced VBN N
by IN N
nifedipine NN i
and CC N
the DT N
combination NN N
compared VBN N
with IN N
placebo NN i
were VBD N
similar JJ N
and CC N
significantly RB N
greater JJR N
than IN N
those DT N
induced VBN N
by IN N
chlorthalidone NN i
. . i

Taken VB N
together RB N
, , N
these DT N
data NNS N
show VBP N
that IN N
the DT N
combination NN N
of IN N
nifedipine JJ i
+ FW i
chlorthalidone NN i
does VBZ N
not RB N
exert VB N
any DT N
additive JJ o
antihypertensive JJ o
effect NN o
compared VBN N
with IN N
nifedipine JJ i
alone RB N
. . N

This DT N
finding NN N
indicates VBZ N
that IN N
the DT N
combination NN N
of IN N
a DT N
dihydropyridine JJ i
calcium NN i
antagonist NN i
+ VBD i
a DT i
thiazide JJ i
diuretic NN i
is VBZ N
probably RB N
devoid JJ N
of IN N
any DT N
particular JJ N
clinical JJ o
significance NN o
in IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ p
essential JJ p
hypertensives NNS p
. . p

-DOCSTART- -11411192- O O

Treating VBG N
the DT N
substance-abusing JJ p
suicidal JJ p
patient NN p
. . p

Studies NNPS N
concerning VBG N
the DT N
treatment NN N
of IN N
substance-abusing JJ p
suicidal NN p
patients NNS p
are VBP N
scarce JJ N
despite IN N
the DT N
frequent JJ N
presence NN N
of IN N
suicidal JJ N
behavior NN N
among IN N
this DT N
population NN N
. . N

Indeed RB N
, , N
suicidality NN N
( ( N
ideation NN N
or CC N
behavior NN N
) ) N
is VBZ N
generally RB N
an DT N
exclusion NN N
criterion NN N
for IN N
participation NN N
in IN N
treatment NN N
studies NNS N
of IN N
subjects NNS p
with IN p
alcohol NN p
or CC p
drug NN p
abuse NN p
. . p

Consequently RB N
, , N
to TO N
date NN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
optimal JJ N
treatment NN N
of IN N
this DT N
population NN N
. . N

The DT N
first JJ N
study NN N
involving VBG N
substance-abusing JJ p
suicidal JJ p
patients NNS p
was VBD N
an DT N
open-label JJ N
trial NN N
conducted VBN N
in IN N
the DT N
early JJ N
1990s CD N
. . N

This DT N
study NN N
involved VBD N
12 CD p
patients NNS p
, , p
all DT p
of IN p
whom WP p
demonstrated VBD p
recent JJ p
suicidal JJ o
ideations NNS o
and CC p
had VBD p
made VBN p
a DT p
lifetime NN p
suicide NN p
attempt NN p
. . p

The DT N
results NNS N
of IN N
that DT N
open-label JJ i
study NN i
demonstrated VBD N
significant JJ N
within-group JJ N
improvement NN N
in IN N
both DT N
depressive JJ o
symptoms NNS o
( ( o
including VBG o
suicidal JJ o
ideations NNS o
) ) o
and CC o
level NN o
of IN o
drinking NN o
. . o

However RB N
, , N
substantial JJ N
residual JJ N
depressive NN o
symptoms NNS o
and CC o
drinking NN o
persisted VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
. . N

Also RB N
, , N
because IN N
no DT N
placebo NN i
control NN N
group NN N
was VBD N
utilized VBN N
, , N
the DT N
authors NNS N
of IN N
that DT N
study NN N
could MD N
not RB N
rule VB N
out IN N
the DT N
possibility NN N
that IN N
the DT N
apparent JJ N
therapeutic JJ N
effect NN N
from IN N
fluoxetine NN i
was VBD N
the DT N
result NN N
of IN N
the DT N
placebo NN i
effect NN N
. . N

To TO N
date NN N
, , N
only RB N
one CD N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
of IN N
subjects NNS p
with IN p
alcohol NN p
or CC p
substance NN p
abuse NN p
has VBZ N
included VBN N
substantial JJ N
numbers NNS N
of IN N
suicidal JJ N
patients NNS N
. . N

The DT N
study NN N
involved VBD N
51 CD p
subjects NNS p
, , p
of IN p
whom WP p
20 CD p
( ( p
39 CD p
% NN p
) ) p
had VBD p
made VBN p
a DT p
suicide JJ p
attempt NN p
in IN p
the DT p
current JJ p
depressive JJ p
episode NN p
, , p
31 CD p
( ( p
61 CD p
% NN p
) ) p
had VBD p
made VBN p
a DT p
suicide JJ p
attempt NN p
in IN p
their PRP$ p
lifetime NN p
, , p
and CC p
46 CD p
( ( p
90 CD p
% NN p
) ) p
had VBD p
reported VBN p
suicidal JJ p
ideations NNS p
in IN p
the DT p
week NN p
before IN p
hospitalization NN p
. . p

The DT N
results NNS N
of IN N
that DT N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
suggest VBP N
that IN N
fluoxetine NN i
was VBD N
effective JJ N
in IN N
decreasing VBG N
but CC N
not RB N
eliminating VBG N
both CC N
the DT N
depressive NN o
symptoms NNS o
( ( o
including VBG o
suicidal JJ o
ideations NNS o
) ) o
and CC o
the DT o
level NN o
of IN o
alcohol JJ o
consumption NN o
among IN N
a DT N
study NN N
group NN N
of IN N
subjects NNS N
with IN N
comorbid NN N
major JJ N
depressive JJ N
disorder NN N
and CC N
alcohol NN N
dependence NN N
, , N
many JJ N
of IN N
whom WP N
displayed VBD N
suicidal JJ N
ideations NNS N
. . N

A DT N
secondary JJ N
data NN N
analysis NN N
from IN N
that DT N
study NN N
suggested VBD N
that IN N
cigarette NN o
smoking NN o
is VBZ N
also RB N
significantly RB N
decreased VBN N
by IN N
fluoxetine NN i
, , N
but CC N
the DT N
magnitude NN N
of IN N
the DT N
decrease NN N
is VBZ N
limited JJ N
and CC N
few JJ N
of IN N
these DT N
patients NNS N
totally RB N
quit VBP N
smoking VBG N
with IN N
fluoxetine JJ N
treatment NN N
alone RB N
. . N

Another DT N
secondary JJ N
data NN N
analysis NN N
from IN N
that DT N
study NN N
suggested VBD N
that IN N
marijuana NN o
smoking NN o
was VBD N
also RB N
significantly RB N
decreased VBN N
in IN N
a DT N
subgroup NN N
of IN N
subjects NNS N
who WP N
demonstrated VBD N
cannabis NN N
abuse NN N
and CC N
that IN N
the DT N
magnitude NN N
of IN N
this DT N
improvement NN N
was VBD N
robust JJ N
. . N

A DT N
third JJ N
secondary JJ N
data NNS N
analysis NN N
from IN N
that DT N
study NN N
suggested VBD N
that IN N
cocaine NN o
abuse NN o
acts VBZ N
as IN N
a DT N
predictor NN N
of IN N
poor JJ N
outcome NN N
for IN N
both DT N
depressive JJ o
symptoms NNS o
( ( o
including VBG o
suicidality NN o
) ) o
and CC o
level NN o
of IN o
alcohol NN o
use NN o
in IN N
this DT N
population NN N
. . N

The DT N
results NNS N
of IN N
a DT N
1-year JJ N
naturalistic JJ N
follow-up NN N
study NN N
involving VBG N
the DT N
patients NNS N
from IN N
that DT N
study NN N
suggest VBP N
that IN N
the DT N
benefits NNS N
of IN N
fluoxetine NN i
in IN N
decreasing VBG N
depressive JJ o
symptoms NNS o
and CC o
level NN o
of IN o
drinking VBG o
persist NN N
1 CD N
year NN N
after IN N
entering VBG N
the DT N
treatment NN N
program NN N
. . N

To TO N
date NN N
, , N
no DT N
other JJ N
double-blind NN N
, , N
placebo-controlled JJ i
studies NNS N
involving VBG N
substantial JJ N
numbers NNS N
of IN N
substance-abusing JJ p
suicidal NN p
patients NNS p
have VBP N
been VBN N
reported VBN N
to TO N
either DT N
confirm NN N
or CC N
refute VB N
these DT N
findings NNS N
. . N

Further JJ N
studies NNS N
are VBP N
clearly RB N
warranted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
various JJ N
pharmacotherapeutic JJ N
agents NNS N
and CC N
various JJ N
psychotherapies NNS i
in IN N
the DT N
treatment NN N
of IN N
substance-abusing JJ p
suicidal JJ p
patients NNS p
. . p

-DOCSTART- -18556619- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
for IN N
reducing VBG N
risks NNS o
for IN o
sexually RB o
transmitted VBN o
infections NNS o
through IN N
enhanced JJ i
patient-based JJ i
partner NN i
notification NN i
. . i

OBJECTIVES IN N
We PRP N
sought VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
approaches NNS N
targeting VBG N
improved VBN N
sexually RB N
transmitted VBN N
infection NN N
( ( N
STI NNP N
) ) N
sexual JJ N
partner NN N
notification NN N
through IN N
patient JJ N
referral JJ N
. . N

METHODS NN N
From IN p
January NNP p
2002 CD p
through IN p
December NNP p
2004 CD p
, , p
600 CD p
patients NNS p
with IN p
Neisseria NNP p
gonorrhoeae NN p
or CC p
Chlamydia NNP p
trachomatis NN p
were VBD p
recruited VBN p
from IN p
STI NNP p
clinics NNS p
and CC N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
standard-of-care JJ i
group NN i
or CC N
a DT i
group NN i
that WDT i
was VBD i
counseled VBN i
at IN i
the DT i
time NN i
of IN i
diagnosis NN i
and CC i
given VBN i
additional JJ i
follow-up JJ i
contact NN i
. . i

Participants NNS N
completed VBD N
an DT N
interview NN N
at IN N
baseline NN N
, , N
1 CD N
month NN N
, , N
and CC N
6 CD N
months NNS N
and CC N
were VBD N
checked VBN N
at IN N
6 CD N
months NNS N
for IN N
gonorrhea NN N
or CC N
chlamydial JJ N
infection NN N
via IN N
nucleic JJ N
acid JJ N
amplification NN N
testing NN N
of IN N
urine NN N
. . N

RESULTS NNP N
Program NNP N
participants NNS N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
sexual JJ N
partner NN N
notification NN N
at IN N
1 CD N
month NN N
( ( N
86 CD N
% NN N
control NN N
, , N
92 CD N
% NN N
intervention NN N
; : N
adjusted VBN N
odds NNS N
ratio VBP N
[ JJ N
AOR NNP N
] NNP N
= NNP N
1.8 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
1.02 CD N
, , N
3.0 CD N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
no DT N
unprotected JJ o
sexual JJ o
intercourse NN o
at IN N
6 CD N
months NNS N
( ( N
38 CD N
% NN N
control NN N
, , N
48 CD N
% NN N
intervention NN N
; : N
AOR NNP N
= VBZ N
1.5 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.1 CD N
, , N
2.1 CD N
) ) N
. . N

Gonorrhea NNP o
or CC o
chlamydial JJ o
infection NN o
was VBD N
detected VBN N
in IN N
6 CD N
% NN N
of IN N
intervention NN N
and CC N
11 CD N
% NN N
of IN N
control NN N
participants NNS N
at IN N
follow-up NN N
( ( N
AOR NNP N
= NNP N
2.2 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.1 CD N
, , N
4.1 CD N
) ) N
, , N
with IN N
greatest JJS N
benefits NNS N
seen VBN N
among IN N
men NNS N
( ( N
for IN N
gender NN N
interaction NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

CONCLUSIONS VB N
This DT N
patient-based JJ N
sexual JJ N
partner NN N
notification NN N
program NN N
can MD N
help VB N
reduce VB N
risks NNS N
for IN N
subsequent JJ N
STIs NNP N
among IN N
urban JJ p
, , p
minority NN p
patients NNS p
presenting VBG N
for IN N
care NN N
at IN N
STI NNP N
clinics NNS N
. . N

-DOCSTART- -22040533- O O

Benefits NNS N
of IN N
adding VBG N
fluticasone NN i
propionate/salmeterol NN i
to TO N
tiotropium VB i
in IN N
moderate JJ p
to TO p
severe VB p
COPD NNP p
. . p

BACKGROUND NNP N
Combining NNP N
maintenance NN N
medications NNS N
with IN N
different JJ N
mechanisms NNS N
of IN N
action NN N
may MD N
improve VB N
outcomes NNS N
in IN N
COPD NNP N
. . N

In IN N
this DT N
study NN N
we PRP N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
fluticasone/salmeterol NN i
( ( i
FSC NNP i
) ) i
( ( N
250/50 CD N
mcg NN N
twice RB N
daily RB N
) ) N
when WRB N
added VBN N
to TO i
tiotropium VB i
( ( N
18 CD N
mcg NN N
once RB N
daily RB i
) ) i
( ( i
TIO NNP N
) ) N
in IN N
subjects NNS p
with IN p
symptomatic JJ p
moderate NN p
to TO p
severe VB p
COPD NNP p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
24-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel JJ N
group NN N
, , N
multi-center NN N
study NN p
. . p

Subjects VBZ p
40 CD p
years NNS p
or CC p
older JJR p
with IN p
cigarette NN p
smoking VBG p
history NN p
?10 JJ p
pack-years NNS p
and CC p
with IN p
the DT p
diagnosis NN p
of IN p
COPD NNP p
and CC p
post-bronchodilator NN p
FEV NNP p
( ( p
1 CD p
) ) p
?40 NN p
to TO p
? . p
80 CD p
% NN p
of IN p
predicted VBN p
normal JJ p
and CC p
FEV NNP p
( ( p
1 CD p
) ) p
/FVC NN p
of IN p
?0.70 NN p
were VBD p
enrolled VBN p
. . p

Following VBG N
a DT N
4-week JJ N
treatment NN N
with IN N
open-label JJ N
TIO NNP i
18 CD i
mcg NN i
once RB N
daily JJ N
, , N
subjects NNS N
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
either VB N
the DT N
addition NN N
of IN N
FSC NNP N
250/50 CD N
DISKUS NNP N
twice RB N
daily RB N
or CC N
matching VBG N
placebo NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD o
AM NNP o
pre-dose JJ o
FEV NNP o
( ( o
1 CD o
) ) o
and CC o
secondary JJ N
endpoints NNS N
included VBD N
other JJ o
measures NNS o
of IN o
lung NN o
function NN o
, , o
rescue NN o
albuterol NN o
use NN o
, , o
health NN o
status NN o
and CC o
exacerbations NNS o
. . o

RESULTS VB o
The DT o
addition NN N
of IN N
FSC NNP i
to TO i
TIO NNP N
significantly RB o
improved VBD o
lung JJ o
function NN o
indices NNS o
including VBG o
AM NNP o
pre-dose JJ o
FEV NNP o
( ( o
1 CD o
) ) o
, , o
2 CD o
h NN o
post-dose JJ o
FEV NNP o
( ( o
1 CD o
) ) o
, , o
AM NNP o
pre-dose JJ o
FVC NNP o
, , o
2 CD o
h NN o
post-dose JJ o
FVC NNP o
and CC o
AM NNP o
pre-dose JJ o
IC NNP o
compared VBN N
with IN N
TIO NNP N
alone RB N
. . N

Furthermore RB N
, , N
this DT N
combination NN N
was VBD N
superior JJ N
to TO N
TIO VB N
alone RB N
in IN N
reducing VBG o
rescue NN o
albuterol NN o
use NN o
. . o

However RB o
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS o
in IN o
health NN o
status NN o
or CC o
COPD NNP o
exacerbations NNS o
. . o

The DT o
incidence NN o
of IN N
adverse JJ o
events NNS o
was VBD o
similar JJ o
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
FSC NNP p
to TO p
subjects NNS p
with IN p
COPD NNP p
treated VBD p
with IN N
TIO NNP N
significantly RB N
improves VBZ o
lung JJ o
function NN o
without IN o
increasing VBG N
the DT o
risk NN o
of IN o
adverse JJ o
events NNS o
. . N

NCT00784550 NNP N
. . N

-DOCSTART- -7699494- O O

A DT N
comparison NN N
of IN N
1- JJ N
and CC N
3-minute JJ N
lockout NN N
periods NNS N
during IN N
patient-controlled JJ p
sedation NN p
with IN p
midazolam NN i
. . i

PURPOSE VB N
The DT N
maximum JJ N
effect NN N
of IN N
midazolam NN i
injected VBN N
intravenously RB N
occurs VBZ N
in IN N
about IN N
3 CD N
minutes NNS N
. . N

Patient-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
of IN N
midazolam NN i
at IN N
3-minute JJ N
intervals NNS N
provides VBZ N
comparable JJ N
conditions NNS N
to TO N
that DT N
of IN N
doctor-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
at IN N
1-minute JJ N
intervals NNS N
, , N
except IN N
for IN N
the DT N
longer JJR N
duration NN N
taken VBN N
for IN N
the DT N
patients NNS N
to TO N
achieve VB N
satisfactory JJ N
sedation NN N
prior RB N
to TO N
surgery NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
find VB N
out RP N
how WRB N
safe JJ N
it PRP N
would MD N
be VB N
to TO N
shorten VB N
the DT N
interval NN N
of IN N
increments NNS N
of IN N
midazolam NN i
to TO N
1 CD N
minute NN N
in IN N
patient-controlled JJ i
sedation NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
randomized VBN N
crossover NN N
study NN N
, , N
26 CD p
patients NNS p
undergoing JJ p
bilateral JJ p
lower JJR p
third JJ p
molar JJ p
surgery NN p
at IN p
two CD p
visits NNS p
had VBD N
patient-controlled JJ N
sedation NN N
with IN N
1 CD N
mg NNS N
midazolam JJ i
increments NNS N
at IN N
1-minute JJ i
or CC N
3-minute JJ i
intervals NNS i
at IN N
one CD N
visit NN N
and CC N
the DT N
alternative NN N
at IN N
the DT N
other JJ N
visit NN N
. . N

RESULTS VB N
The DT N
time NN N
taken VBN N
for IN N
patients NNS N
to TO N
achieve VB N
a DT N
degree NN o
of IN o
sedation NN o
that IN N
they PRP N
thought VBD N
was VBD N
sufficient JJ N
to TO N
tolerate VB N
the DT N
surgery NN N
was VBD N
significantly RB N
longer RBR N
when WRB N
the DT N
increment NN N
interval NN N
was VBD N
3 CD N
minutes NNS N
( ( N
t JJ N
= NNP N
-4.8 NNP N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Both DT N
techniques NNS N
provided VBD N
good JJ N
operating NN o
conditions NNS o
, , N
stable JJ N
vital JJ o
signs NNS o
, , N
mild NN N
to TO N
moderate VB N
sedation NN N
, , N
without IN N
loss NN o
of IN o
verbal JJ o
contact NN o
. . o

CONCLUSION VB N
A DT N
significant JJ N
majority NN N
preferred VBD N
the DT N
sedation NN N
technique NN N
with IN N
1-minute JJ N
increment NN N
intervals NNS N
( ( N
chi VB N
2 CD N
= JJ N
4.6 CD N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

-DOCSTART- -15002089- O O

Retrograde NNP N
tracing NN N
and CC N
electrophysiological JJ N
findings NNS N
of IN N
collateral NN N
sprouting NN N
after IN p
end-to-side JJ p
neurorrhaphy NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
seek VB N
more RBR N
potent JJ N
evidences NNS N
of IN N
collateral NN N
sprouting NN N
for IN N
both DT N
motor NN N
and CC N
sensory JJ N
nerve NN N
fibres NNS N
after IN p
end-to-side JJ p
neurorrhaphy NN p
using VBG N
a DT N
modified VBN N
double-labelling NN N
retrograde NN N
tracing VBG N
method NN N
and CC N
to TO N
investigate VB N
the DT N
function NN N
of IN N
regenerated JJ N
motor NN N
axons NNS N
with IN N
electrophysiological JJ N
evaluation NN N
. . N

Four CD p
groups NNS p
( ( p
n=4 JJ p
for IN p
each DT p
group NN p
) ) p
were VBD p
used VBN p
: : p
end-to-end JJ i
coaptation NN i
( ( p
six CD p
months NNS p
postoperatively RB p
) ) p
, , p
end-to-side JJ i
coaptation NN i
( ( p
four CD p
months NNS p
and CC p
six CD p
months NNS p
postoperatively RB p
) ) p
and CC p
normal JJ i
control NN i
. . i

Two CD N
fluorescent JJ i
tracers NNS i
( ( N
true JJ N
blue NN N
and CC N
diamidino NN N
yellow NN N
) ) N
were VBD N
applied VBN N
to TO N
the DT N
proximal JJ N
ends NNS N
of IN N
tibial JJ N
and CC N
common JJ N
peroneal NN N
nerves NNS N
, , N
respectively RB N
after IN N
four CD N
or CC N
six CD N
months NNS N
of IN N
nerve DT N
coaptation NN N
. . N

Five CD N
days NNS N
later RB N
, , N
we PRP N
only RB N
found VBD N
single-labelled JJ o
motor NN o
and CC o
sensory JJ o
neurons NNS o
in IN N
the DT N
normal JJ N
and CC N
end-to-end JJ N
coaptation NN N
groups NNS N
, , N
while IN N
some DT N
dual-labelled JJ N
neurons NNS N
can MD N
be VB N
identified VBN N
in IN N
end-to-side JJ N
coaptation NN N
groups NNS N
. . N

Four CD N
months NNS N
after IN N
surgery NN N
, , N
the DT N
motor NN o
nerve NN o
conduction NN o
velocity NN o
in IN o
end-to-side JJ o
coaptation NN N
was VBD N
significantly RB N
slower JJR N
than IN N
in IN N
the DT N
normal JJ N
control NN N
. . N

But CC N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
sixth JJ N
month NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
end-to-side JJ i
neurorrhaphy NN i
can MD N
induce VB N
the DT N
functional JJ N
collateral NN N
sprouting NN N
of IN N
both DT N
motor NN N
and CC N
sensory JJ N
axons NNS N
in IN N
the DT N
peripheral JJ N
nerve NN N
. . N

-DOCSTART- -6324934- O O

[ JJ o
Metastatic NNP o
breast NN o
cancer NN o
: : o
a DT N
comparative JJ N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
tamoxifen NN i
and CC N
the DT N
sequential JJ N
administration NN N
of IN N
tamoxifen NN i
and CC i
medroxyprogesterone NN i
acetate NN i
] NNP i
. . i

Seventy-nine JJ p
patients NNS p
with IN p
an DT p
histologically RB p
proven RB p
disseminated VBN p
breast NN p
cancer NN p
, , p
never RB p
treated VBN p
before IN p
with IN p
additive JJ p
hormonal JJ p
therapy NN p
, , p
entered VBD p
into IN p
a DT p
randomized JJ p
trial NN p
between IN p
june NN p
1981 CD p
and CC p
december VB p
1982 CD p
. . p

In IN N
the DT N
first JJ N
group NN N
44 CD N
patients NNS N
were VBD N
given VBN N
continually RB N
a DT N
daily JJ N
dose NN N
of IN N
tamoxifen NN i
( ( i
TAM NNP i
) ) i
of IN N
20 CD N
mg/m2 NN N
. . N

In IN N
the DT N
2nd CD N
group NN N
35 CD N
patients NNS N
were VBD N
given VBN N
a DT N
daily JJ N
dose NN N
of IN N
TAM NNP i
of IN N
20 CD N
mg/m2 NN N
for IN N
15 CD N
days NNS N
and CC N
then RB N
an DT N
oral JJ N
daily JJ N
dose NN N
of IN N
medroxyprogesterone NN i
acetate NN i
of IN N
350 CD N
mg/m2 NN N
for IN N
the DT N
next JJ N
15 CD N
days NNS N
. . N

In IN N
both DT N
groups NNS N
I PRP N
and CC N
II NNP N
, , N
the DT N
treatment NN N
was VBD N
stopped VBN N
at IN N
the DT N
first JJ N
manifestation NN N
of IN N
progression NN N
of IN N
the DT N
disease NN N
. . N

The DT N
hormonal JJ N
receptor NN N
status NN N
was VBD N
determined VBN N
in IN N
30 CD N
patients NNS N
of IN N
the DT N
group NN N
I PRP N
and CC N
23 CD N
patients NNS N
of IN N
the DT N
group NN N
II NNP N
. . N

An DT N
objective JJ N
response NN N
to TO N
treatment NN N
was VBD N
observed VBN N
in IN N
48 CD N
per IN N
cent NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
group NN N
I PRP N
and CC N
60 CD N
per IN N
cent NN N
of IN N
the DT N
group NN N
II NNP N
. . N

This DT N
difference NN N
is VBZ N
not RB N
significant JJ N
( ( N
X2 NNP N
= NNP N
1,05 CD N
) ) N
. . N

However RB N
, , N
the DT N
mean JJ o
duration NN o
of IN o
therapeutic JJ o
response NN o
is VBZ N
significantly RB N
higher RBR N
in IN N
the DT N
group NN N
II NNP N
( ( N
p JJ N
= NNP N
0,01 CD N
) ) N
. . N

-DOCSTART- -24637998- O O

Omitting VBG N
radiotherapy NN N
in IN N
early JJ N
positron NN p
emission NN p
tomography-negative JJ p
stage NN p
I/II NNP p
Hodgkin NNP p
lymphoma NN p
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
early JJ N
relapse NN N
: : N
Clinical JJ N
results NNS N
of IN N
the DT N
preplanned JJ N
interim JJ N
analysis NN N
of IN N
the DT N
randomized JJ N
EORTC/LYSA/FIL NNP N
H10 NNP N
trial NN N
. . N

PURPOSE NNP N
Combined-modality NNP i
treatment NN i
is VBZ N
standard JJ N
treatment NN N
for IN N
patients NNS p
with IN p
clinical JJ p
stage NN p
I/II NNP p
Hodgkin NNP p
lymphoma NN p
( ( p
HL NNP p
) ) p
. . p

We PRP N
hypothesized VBD N
that IN N
an DT N
early JJ N
positron NN i
emission NN i
tomography NN i
( ( i
PET NNP i
) ) i
scan NN N
could MD N
be VB N
used VBN N
to TO N
adapt VB N
treatment NN N
. . N

Therefore RB N
, , N
we PRP N
started VBD N
the DT N
randomized VBN N
EORTC/LYSA/FIL NNP N
Intergroup NNP N
H10 NNP N
trial NN N
evaluating VBG N
whether IN N
involved-node JJ i
radiotherapy NN i
( ( i
IN-RT NNP i
) ) i
could MD N
be VB N
omitted VBN N
without IN N
compromising VBG N
progression-free JJ N
survival NN N
in IN N
patients NNS p
attaining VBG p
a DT p
negative JJ p
early JJ p
PET NNP p
scan NN p
after IN p
two CD p
cycles NNS p
of IN p
ABVD NNP i
( ( i
doxorubicin NN i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine NN i
) ) i
as IN N
compared VBN N
with IN N
standard JJ N
combined-modality NN i
treatment NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP p
age NN p
15 CD p
to TO p
70 CD p
years NNS p
with IN p
untreated JJ p
clinical JJ p
stage NN p
I/II NNP p
HL NNP p
were VBD p
eligible JJ p
. . p

Here RB N
we PRP N
report VBP N
the DT N
clinical JJ N
outcome NN N
of IN N
the DT N
preplanned JJ N
interim JJ N
futility NN N
analysis NN N
scheduled VBN N
to TO N
occur VB N
after IN N
documentation NN N
of IN N
34 CD N
events NNS N
in IN N
the DT N
early JJ N
PET-negative JJ N
group NN N
. . N

Because IN N
testing VBG N
for IN N
futility NN N
in IN N
this DT N
noninferiority NN N
trial NN N
corresponds NNS N
to TO N
testing VBG N
the DT N
hypothesis NN N
of IN N
no DT N
difference NN N
, , N
a DT N
one-sided JJ N
superiority NN N
test NN N
was VBD N
conducted VBN N
. . N

RESULTS VB N
The DT p
analysis NN p
included VBD p
1,137 CD p
patients NNS p
. . p

In IN N
the DT N
favorable JJ p
subgroup NN p
, , N
85.8 CD N
% NN N
had VBD N
a DT N
negative JJ N
early JJ N
PET JJ i
scan JJ i
( ( N
standard JJ N
arm NN N
, , N
one CD N
event NN N
v NN N
experimental JJ N
arm NN N
, , N
nine CD N
events NNS N
) ) N
. . N

In IN N
the DT N
unfavorable JJ p
subgroup NN p
, , N
74.8 CD N
% NN N
had VBD N
a DT N
negative JJ N
early JJ N
PET JJ i
scan JJ i
( ( N
standard JJ N
arm NN N
, , N
seven CD N
events NNS N
v JJ N
experimental JJ N
arm NN N
, , N
16 CD N
events NNS N
) ) N
. . N

The DT N
independent JJ N
data NNS N
monitoring NN N
committee NN N
concluded VBD N
it PRP N
was VBD N
unlikely JJ N
that IN N
we PRP N
would MD N
show VB N
noninferiority NN N
in IN N
the DT N
final JJ N
results NNS N
for IN N
the DT N
experimental JJ N
arm NN N
and CC N
advised VBD N
stopping VBG N
random JJ N
assignment NN N
for IN N
early JJ N
PET-negative JJ i
patients NNS N
. . N

CONCLUSION NNP N
On IN N
the DT N
basis NN N
of IN N
this DT N
analysis NN N
, , N
combined-modality NN N
treatment NN N
resulted VBD N
in IN N
fewer JJR N
early JJ N
progressions NNS N
in IN N
clinical JJ o
stage NN o
I/II NNP o
HL NNP o
, , N
although IN N
early JJ N
outcome NN N
was VBD N
excellent JJ N
in IN N
both DT N
arms NNS N
. . N

The DT N
final JJ N
analysis NN N
will MD N
reveal VB N
whether IN N
this DT N
finding NN N
is VBZ N
maintained VBN N
over IN N
time NN N
. . N

-DOCSTART- -8831332- O O

Clonidine NN i
increases VBZ N
the DT N
sweating NN o
threshold NN o
, , N
but CC N
does VBZ N
not RB N
reduce VB N
the DT N
gain NN o
of IN o
sweating VBG o
. . o

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
clonidine NN i
produces VBZ N
a DT N
dose-dependent JJ N
increase NN o
in IN o
the DT o
sweating NN o
threshold NN o
but CC N
does VBZ N
not RB N
reduce VB o
the DT o
gain NN o
of IN o
sweating VBG o
. . o

Six NNP p
healthy JJ p
male NN p
volunteers NNS p
were VBD p
evaluated VBN p
, , N
each DT N
on IN N
three CD N
separate JJ N
days NNS N
in IN N
random JJ N
order NN N
. . N

In IN N
one CD N
, , N
saline NN i
was VBD N
administered VBN N
; : N
in IN N
another DT N
, , N
a DT N
2-micrograms/kg JJ i
bolus NN i
of IN i
clonidine NN i
was VBD N
followed VBN N
by IN N
an DT N
infusion NN N
at IN N
2 CD N
micrograms.kg-1.h-1 NN N
, , N
and CC N
on IN N
a DT N
third JJ N
day NN N
, , N
a DT N
4-micrograms/kg JJ N
bolus NN N
was VBD N
followed VBN N
by IN N
an DT N
infusion NN N
at IN N
4 CD N
micrograms.kg-1.h-1 JJ N
. . N

Core NN o
temperature NN o
was VBD N
measured VBN N
at IN N
the DT N
tympanic JJ N
membrane NN N
and CC N
mean JJ o
skin NN o
temperature NN o
was VBD N
determined VBN N
from IN N
four CD N
sites NNS N
. . N

A DT N
chest JJ o
sweating NN o
rate NN o
of IN N
40 CD N
g.m-2.h-1 NN N
was VBD N
considered VBN N
significant JJ N
. . N

The DT N
core NN N
temperature NN N
triggering VBG N
sweating NN o
, , N
adjusted VBN N
to TO N
a DT N
designated VBN N
mean NN N
skin JJ N
temperature NN N
of IN N
34 CD N
degrees NNS N
C NNP N
, , N
identified VBD N
the DT N
threshold NN N
for IN N
this DT N
response NN N
. . N

Gain NNP N
was VBD N
defined VBN N
by IN N
the DT N
adjusted VBN N
core NN o
temperature NN o
increase NN N
required VBN N
to TO N
augment VB N
sweating VBG N
from IN N
100 CD N
to TO N
300 CD N
g.m-2.h-1 NN N
. . N

degree JJ N
C-1 NNP N
. . N

Plasma NNP o
clonidine JJ o
concentrations NNS o
were VBD N
0.8 CD N
+/- JJ N
0.1 CD N
and CC N
1.6 CD N
+/- JJ N
0.2 CD N
ng/mL NN N
on IN N
the DT N
small- JJ N
and CC N
large-dose JJ N
days NNS N
, , N
respectively RB N
. . N

Clonidine NNP N
administration NN N
increased VBD N
the DT N
sweating NN N
threshold VBD N
approximately RB N
0.4 CD N
degree JJ N
C NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
the DT N
increase NN N
was VBD N
comparable JJ N
at IN N
each DT N
dose NN N
. . N

The DT N
gain NN o
of IN o
sweating NN o
was VBD N
approximately RB N
0.2 CD N
degree JJ N
C NNP N
and CC N
was VBD N
not RB N
influenced VBN N
by IN N
clonidine JJ N
administration NN N
. . N

The DT N
thermoregulatory JJ o
effects NNS o
of IN N
clonidine NN N
thus RB N
resemble JJ N
those DT N
of IN N
volatile JJ N
anesthetics NNS N
, , N
opioids NNS N
, , N
and CC N
propofol NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
antishivering VBG N
effect NN N
of IN N
clonidine NN N
results NNS N
from IN N
central JJ N
thermoregulatory JJ N
inhibition NN N
rather RB N
than IN N
a DT N
specific JJ N
peripheral JJ N
action NN N
on IN N
thermogenic JJ N
muscular JJ N
activity NN N
. . N

Unlike IN N
other JJ N
sedatives NNS N
and CC N
anesthetics NNS N
, , N
the DT N
concentration-dependence NN N
of IN N
clonidine NN N
demonstrates VBZ N
a DT N
ceiling NN N
beyond IN N
which WDT N
the DT N
administration NN N
of IN N
an DT N
additional JJ N
drug NN N
fails NNS N
to TO N
enhance VB N
the DT N
effect NN N
, , N
suggesting VBG N
that IN N
the DT N
thermoregulatory JJ N
effect NN N
of IN N
clonidine NN N
may MD N
be VB N
limited VBN N
, , N
even RB N
at IN N
high JJ N
plasma NN N
concentrations NNS N
. . N

The DT N
gain NN N
of IN N
sweating NN N
was VBD N
well RB N
preserved JJ N
indicating VBG N
that IN N
this DT N
response NN N
remains VBZ N
effective JJ N
in IN N
the DT N
presence NN N
of IN N
sedatives NNS N
and CC N
anesthetics NNS N
. . N

-DOCSTART- -20624257- O O

Effects NNS o
of IN N
intravenous JJ i
iron NN i
combined VBN i
with IN i
low-dose JJ i
recombinant JJ i
human JJ i
erythropoietin NN i
on IN N
transfusion NN o
requirements NNS o
in IN N
iron-deficient JJ p
patients NNS p
undergoing VBG p
bilateral JJ p
total JJ p
knee NN p
replacement NN p
arthroplasty NN p
. . p

BACKGROUND IN N
The DT N
authors NNS N
examined VBD N
the DT N
impact NN N
of IN N
parenteral JJ i
iron NN i
and CC i
recombinant JJ i
human JJ i
erythropoietin-? NN i
( ( i
rHuEPO-? JJ i
) ) i
administered VBN i
in IN N
the DT N
bilateral JJ N
total JJ N
knee NN N
replacement NN N
arthroplasty NN N
( ( N
TKRA NNP N
) ) N
, , N
on IN N
postoperative JJ o
anemia NN o
and CC o
transfusion NN o
requirements NNS o
in IN o
iron-deficient JJ p
patients NNS p
. . p

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP p
A NNP p
total NN p
of IN p
108 CD p
iron-deficient JJ p
patients NNS p
were VBD p
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
: : N
Group NNP N
C NNP N
( ( i
control NN i
) ) i
or CC i
Group NNP N
IE NNP N
( ( i
200 CD i
mg NN i
of IN i
iron NN i
sucrose NN i
intravenously RB i
over IN i
1 CD i
hr NNS i
and CC i
3000 CD i
IU NNP i
of IN i
rHuEPO-? JJ i
subcutaneously NN i
during IN N
the DT N
operation NN N
and CC N
during IN N
the DT N
postoperative JJ N
period NN N
if IN N
the DT N
hemoglobin NN N
[ NNP N
Hb NNP N
] NNP N
level NN N
was VBD N
70-80 JJ N
g/L NN N
) ) N
. . N

One CD N
or CC N
2 CD N
units NNS N
of IN N
blood NN N
were VBD N
transfused VBN N
to TO N
patients NNS N
in IN N
both DT N
groups NNS N
according VBG N
to TO N
postoperative JJ N
Hb NNP N
level NN N
( ( N
between IN N
60 CD N
and CC N
70 CD N
g/L NN N
or CC N
betweeen JJ N
50 CD N
and CC N
60 CD N
g/L NN N
, , N
respectively RB o
) ) o
. . o

Perioperative JJ o
laboratory NN o
and CC o
clinical JJ o
outcomes NNS o
( ( o
Hb NNP o
, , o
iron NN o
variables NNS o
, , o
postoperative JJ o
bleeding NN o
amount NN o
, , o
and CC o
number NN o
of IN o
units NNS o
of IN o
RBCs NNP o
transfused VBD o
and CC o
incidences NNS o
) ) o
were VBD o
documented VBN N
. . N

RESULTS NNP N
Although IN o
preoperative JJ o
Hb NNP o
and CC N
the DT N
amount NN o
of IN o
postoperative JJ o
bleeding NN o
were VBD o
comparable JJ N
in IN N
the DT N
two CD N
groups NNS o
, , o
Hb NNP o
levels NNS o
at IN o
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
days NNS N
and CC N
at IN N
2 CD N
and CC N
6 CD N
weeks NNS N
postoperation NN N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
IE NNP N
. . N

Furthermore NNP N
, , N
the DT N
transfusion NN o
rate NN o
was VBD o
significantly RB N
lower JJR N
in IN N
Group NNP N
IE NNP N
( ( N
20.4 CD N
% NN N
vs. FW N
53.7 CD N
% NN N
, , N
p=0.011 NN N
) ) N
and CC N
the DT N
mean JJ o
number NN o
of IN o
red JJ o
blood NN o
cell NN o
units NNS o
transfused VBD o
was VBD o
markedly RB N
lower JJR N
in IN N
Group NNP N
IE NNP N
( ( N
0.2?0.5 CD N
vs. FW N
0.8?0.8 CD N
, , N
p=0.005 NN o
) ) o
. . o

Postoperative NNP o
iron NN o
, , o
ferritin NN o
, , o
and CC o
transferrin JJ o
saturation NN o
levels NNS o
were VBD o
significantly RB N
higher JJR N
in IN N
Group NNP N
IE NNP N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
parenteral JJ i
iron NN i
and CC i
low-dose JJ i
rHuEPO-? NN i
in IN i
bilateral JJ i
TKRA NNP N
effectively RB o
attenuated VBD o
anemia NN o
and CC o
decreased VBN o
transfusion NN o
requirements NNS o
in IN o
iron-deficient JJ o
patients NNS p
. . p

-DOCSTART- -15383046- O O

Atrial NNP o
remodeling NN o
after IN N
mitral JJ i
valve NN i
surgery NN i
in IN N
patients NNS p
with IN p
permanent JJ p
atrial JJ p
fibrillation NN p
. . p

BACKGROUND NNP N
Mitral NNP N
valve NNP N
pathology NN N
is VBZ N
frequently RB N
associated VBN N
with IN N
auricular JJ N
dilatation NN N
and CC N
atrial JJ N
fibrillation NN N
. . N

Mitral JJ i
surgery NN i
allows VBZ N
an DT N
immediate JJ N
surgical JJ N
auricular NN N
remodeling NN N
and CC N
besides NNS N
in IN N
those DT N
cases NNS N
in IN N
which WDT N
sinus NN N
rhythm NN N
is VBZ N
reached VBN N
, , N
it PRP N
is VBZ N
followed VBN N
by IN N
a DT N
late JJ N
remodeling NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
process NN N
of IN N
postoperative JJ N
auricular JJ N
remodeling VBG N
in IN N
patients NNS p
with IN p
permanent JJ p
atrial JJ p
fibrillation NN p
undergoing VBG p
mitral JJ i
surgery NN i
. . i

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
, , N
50 CD p
patients NNS p
with IN p
permanent JJ p
atrial JJ p
fibrillation NN p
and CC p
dilated VBD p
left JJ p
atrium NN p
, , p
submitted VBN p
to TO p
surgical JJ p
mitral JJ p
repair NN p
, , N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Group NNP i
I PRP i
contained VBD i
25 CD i
patients NNS i
with IN i
left JJ i
auricular JJ i
reduction NN i
and CC i
mitral JJ i
surgery NN i
, , i
and CC i
Group NNP i
II NNP i
contained VBD i
25 CD i
patients NNS i
with IN i
isolated JJ i
valve NN i
surgery NN i
. . i

Both DT N
groups NNS N
were VBD N
considered VBN N
homogeneous JJ N
in IN N
the DT N
preoperative JJ N
assessment NN N
. . N

RESULTS NNP N
After IN N
a DT N
mean JJ N
follow-up NN N
of IN N
31 CD N
months NNS N
, , N
46 CD N
% NN N
of IN N
patients NNS N
included VBN N
in IN N
Group NNP N
I PRP N
versus VBP N
18 CD N
% NN N
of IN N
patients NNS N
included VBN N
in IN N
Group NNP N
II NNP N
restarted VBD N
sinus JJ o
rhythm NN o
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

An DT N
auricular JJ o
remodeling NN o
with IN o
size NN o
regression NN o
occurred VBD N
in IN N
those DT N
patients NNS N
who WP N
recovered VBD N
from IN N
sinus NN N
rhythm NN N
, , N
worthy NN N
of IN N
remark NN N
in IN N
Group NNP N
II NNP N
( ( N
-10.8 CD N
% NN N
of IN N
left JJ N
auricular JJ N
volume NN N
reduction NN N
in IN N
Group NNP N
I PRP N
compared VBN N
to TO N
-21.5 VB N
% NN N
in IN N
Group NNP N
II NNP N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

A DT N
new JJ o
atrial JJ o
enlargement NN o
took VBD N
place NN N
in IN N
those DT N
patients NNS N
who WP N
remained VBD N
with IN N
atrial JJ N
fibrillation NN N
( ( N
+16.8 CD N
% NN N
left VBD N
auricular JJ N
volume NN N
in IN N
Group NNP N
I PRP N
vs. VBP N
+8.4 CD N
% NN N
in IN N
Group NNP N
II NNP N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mitral NNP N
surgery NN N
produces VBZ N
an DT N
atrial JJ N
postoperative NN N
volume NN N
that IN N
decrease NN N
especially RB N
when WRB N
reduction NN N
techniques NNS N
are VBP N
employed VBN N
. . N

Late JJ N
left VBD N
atrial JJ N
remodeling VBG N
depended VBN N
on IN N
the DT N
type NN N
of IN N
atrial JJ o
rhythm NN o
and CC N
postoperative JJ o
surgical JJ o
volume NN o
. . o

-DOCSTART- -371644- O O

Management NN N
of IN N
unstable JJ p
angina NN p
at IN p
rest NN p
by IN N
verapamil NN i
. . i

A DT N
double-blind JJ N
cross-over NN N
study NN N
in IN N
coronary JJ N
care NN N
unit NN N
. . N

A NNP N
therapeutic JJ N
trial NN N
with IN N
verapamil NN i
, , N
a DT N
calcium-antagonist JJ i
drug NN i
, , N
was VBD N
performed VBN N
in IN N
12 CD p
patients NNS p
admitted VBN p
to TO p
our PRP$ p
coronary JJ p
care NN p
unit NN p
because IN p
of IN p
frequent JJ p
daily JJ p
attacks NNS p
of IN p
angina NN p
at IN p
rest NN p
attributed VBN p
to TO p
coronary JJ p
vasospasm NN p
. . p

After IN N
a DT N
48-hour JJ N
run-in JJ N
period NN N
, , N
oral JJ i
verapamil NN i
480 CD i
mg/day NN i
and CC i
placebo NN i
were VBD N
administered VBN N
alternately RB N
during IN N
4 CD N
randomised VBD N
48-hour CD N
periods NNS N
. . N

Transient NNP o
ischaemic JJ o
attacks NNS o
with IN o
ST NNP o
segment NN o
elevation NN o
or CC o
depression NN o
, , o
with IN o
or CC o
without IN o
pain NN o
, , N
were VBD N
documented VBN N
by IN N
continuous JJ o
electrocardiographic JJ o
monitoring NN o
. . o

The DT N
number NN o
of IN o
attacks NNS o
during IN N
the DT N
run-in JJ N
and CC N
2 CD N
placebo NN i
periods NNS N
were VBD N
128 CD N
, , N
123 CD N
, , N
and CC N
130 CD N
, , N
respectively RB N
, , N
and CC N
31 CD N
and CC N
23 CD N
during IN N
the DT N
2 CD N
treatment NN N
periods NNS N
( ( N
P NNP N
less JJR N
than IN N
0.006 CD N
and CC N
P NNP N
less JJR N
than IN N
0.003 CD N
) ) N
. . N

This DT N
drug NN N
therefore RB N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
frequent JJ p
attacks NNS o
of IN o
angina NN o
at IN o
rest NN o
. . o

-DOCSTART- -17395055- O O

Enhanced NNP N
inotropic NN N
state NN N
of IN N
the DT N
failing NN N
left VBD N
ventricle NN N
by IN N
cardiac JJ i
contractility NN i
modulation NN i
electrical JJ i
signals NNS i
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ N
myocardial JJ o
oxygen NN o
consumption NN o
. . o

BACKGROUND NNP N
Previous NNP N
studies NNS N
in IN N
patients NNS p
and CC p
in IN p
dogs NNS p
with IN p
experimentally RB p
induced JJ p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
showed VBD N
that IN N
electrical JJ i
signals NNS i
applied VBN N
to TO N
the DT N
failing VBG N
myocardium NN N
during IN N
the DT N
absolute JJ N
refractory NN N
period NN N
improved VBD N
left JJ o
ventricular NN o
( ( o
LV NNP o
) ) o
function NN o
. . o

We PRP N
examined VBD N
the DT N
effects NNS N
these DT N
same JJ N
cardiac NN i
contractility NN i
modulating NN i
( ( i
CCM NNP i
) ) i
electrical JJ i
signals NNS i
on IN N
myocardial JJ o
oxygen NN o
consumption NN o
( ( o
MVO NNP o
( ( o
2 CD o
) ) o
) ) o
in IN N
both DT p
patients NNS p
and CC p
dogs NNS p
with IN p
chronic JJ p
HF NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Six NNP p
dogs NNS p
with IN p
microembolizations-induced JJ i
HF NNP i
and CC p
9 CD p
HF NNP p
patients NNS p
underwent JJ p
CCM NNP i
leads NNS i
and CC i
generator NN i
( ( i
OPTIMIZER NNP i
II NNP i
) ) i
implantation NN i
. . i

After IN N
baseline NN N
measurements NNS N
, , N
CCM NNP i
signals NNS i
were VBD N
delivered VBN N
continuously RB N
for IN N
2 CD N
hours NNS N
in IN N
dogs NNS N
and CC N
for IN N
30 CD N
minutes NNS N
in IN N
patients NNS N
. . N

MVO NNP o
( ( o
2 CD o
) ) o
was VBD N
measured VBN N
before IN N
and CC N
after IN N
CCM NNP i
therapy NN i
. . i

In IN N
dogs NNS N
, , N
CCM NNP i
therapy NN i
increased VBD N
LV NNP o
ejection NN o
fraction NN o
at IN N
2 CD N
hours NNS N
( ( N
26 CD N
+/- JJ N
1 CD N
versus NN N
31 CD N
+/- JJ N
2 CD N
% NN N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
without IN N
increasing VBG N
MVO NNP o
( ( o
2 CD o
) ) o
( ( N
257 CD N
+/- JJ N
41 CD N
versus NN N
180 CD N
+/- JJ N
34 CD N
micromol/min NN N
) ) N
. . N

In IN N
patients NNS N
, , N
CCM NNP i
therapy NN i
increased VBD N
LV NNP o
peak NN o
+dP/dt NN o
by IN N
10.1 CD N
+/- JJ N
1.5 CD N
% NN N
. . N

As IN N
with IN N
dogs NNS N
, , N
the DT N
increase NN N
in IN N
LV NNP o
function NN o
after IN N
30 CD N
minutes NNS N
of IN N
CCM NNP i
therapy NN i
was VBD N
not RB N
associated VBN N
with IN N
increased VBN N
MVO NNP o
( ( o
2 CD o
) ) o
( ( N
13.6 CD N
+/- JJ N
9.7 CD N
versus NN N
12.5 CD N
+/- JJ N
7.2 CD N
mL NN N
O NNP N
( ( N
2 CD N
) ) N
/min NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
study NN N
results NNS N
suggest VBP N
that IN N
unlike IN N
cAMP-dependent JJ N
positive JJ N
inotropic NN N
drugs NNS N
, , N
the DT N
increase NN N
in IN N
LV NNP o
function NN o
during IN N
CCM NNP i
therapy NN i
is VBZ N
elicited VBN N
without IN N
increasing VBG N
MVO NNP o
( ( o
2 CD o
) ) o
. . o

-DOCSTART- -1911013- O O

Effects NNS N
of IN N
flumazenil NN i
on IN N
cerebral JJ o
blood NN o
flow NN o
and CC N
oxygen NN o
consumption NN o
after IN N
midazolam NN i
anaesthesia NN N
for IN N
craniotomy NN i
. . i

Cerebral JJ o
blood NN o
flow NN o
( ( o
CBF NNP o
) ) o
and CC N
cerebral JJ o
metabolic NN o
rate NN o
for IN o
oxygen NN o
( ( o
CMRO2 NNP o
) ) o
were VBD N
measured VBN N
by IN N
a DT N
modification NN N
of IN N
the DT N
Kety-Schmidt NNP N
technique NN N
using VBG N
i.v JJ N
. . N

xenon-133 NN N
in IN N
20 CD p
patients NNS p
undergoing JJ p
craniotomy NN p
for IN p
supratentorial JJ p
cerebral JJ p
tumours NNS p
. . p

Anaesthesia NNP N
was VBD N
induced VBN N
and CC N
maintained VBN N
with IN N
midazolam NN i
, , i
fentanyl NN i
and CC i
nitrous JJ i
oxide NN i
. . i

Pancuronium NN i
was VBD N
given VBN N
for IN N
neuromuscular JJ N
block NN N
. . N

The DT N
lungs NNS N
were VBD N
ventilated VBN N
to TO N
normocapnia VB N
. . N

The DT N
first JJ N
flow NN N
measurements NNS N
were VBD N
performed VBN N
approximately RB N
1 CD N
h NNS N
after IN N
induction NN N
of IN N
anaesthesia NN N
. . N

At IN N
the DT N
end NN N
of IN N
operation NN N
the DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
. . N

Ten CD N
patients NNS N
were VBD N
given VBN N
flumazenil JJ i
0.01 CD N
mg JJ N
kg-1 NN N
and CC N
5 CD N
min NN N
later RB N
the DT N
second JJ N
flow NN N
measurement NN N
was VBD N
performed VBN N
. . N

In IN N
the DT N
other JJ N
10 CD N
patients NNS N
the DT N
second JJ N
flow NN N
measurement NN N
was VBD N
performed VBN N
before IN N
the DT N
administration NN N
of IN N
flumazenil NN i
. . i

Plasma NNP o
concentrations NNS o
of IN o
midazolam NN o
were VBD N
measured VBN N
at IN N
the DT N
time NN N
of IN N
each DT N
measurement NN N
of IN N
CBF NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
plasma JJ o
concentration NN o
of IN o
midazolam NN o
, , o
CBF NNP o
or CC o
CMRO2 NNP o
. . o

Flumazenil NNP i
had VBD N
no DT o
effect NN o
on IN o
CBF NNP o
and CC N
CMRO2 NNP o
. . o

-DOCSTART- -11781402- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
MRI NNP N
study NN N
of IN N
anti-herpes NNS i
virus JJ i
therapy NN i
in IN p
MS NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
the DT N
antiherpes NNS i
drug NN i
valacyclovir NN i
on IN N
MRI-evident JJ o
lesions NNS o
in IN N
patients NNS p
with IN p
relapsing-remitting JJ p
MS NNP p
in IN p
a DT p
phase NN p
2 CD p
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
postulated VBN N
from IN N
virologic JJ N
studies NNS N
that WDT N
herpesvirus VBP N
infection NN N
could MD N
play VB N
a DT N
role NN N
in IN N
the DT N
progression NN N
of IN N
MS. NNP N
METHODS NNP N
Patients NNPS p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
if IN p
they PRP p
had VBD p
had VBN p
two CD p
or CC p
more JJR p
MS JJ p
relapses NNS p
in IN p
the DT p
2-year JJ p
period NN p
before IN p
enrollment NN p
. . p

Seventy JJ p
patients NNS p
with IN p
Expanded NNP p
Disability NNP p
Status NNP p
Scale NNP p
scores NNS p
of IN p
0 CD p
to TO p
5.5 CD p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
gram NN N
of IN N
valacyclovir NN i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
34 CD N
) ) N
three CD N
times NNS N
daily RB N
for IN N
24 CD N
weeks NNS N
. . N

Patients NNS N
underwent JJ N
MRI NNP N
every DT N
fourth JJ N
week NN N
for IN N
32 CD N
weeks NNS N
: : N
twice RB N
during IN N
pretreatment NN N
, , N
six CD N
times NNS N
during IN N
treatment NN N
, , N
and CC N
once RB N
after IN N
treatment NN N
. . N

Scoring VBG o
of IN o
neurologic JJ o
disability NN o
was VBD N
performed VBN N
at IN N
the DT N
start NN N
and CC N
end NN N
of IN N
the DT N
treatment NN N
period NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
number NN o
of IN o
new JJ o
active JJ o
MRI-evident JJ o
lesions NNS o
over IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
other JJ o
MRI NNP o
measures NNS o
and CC o
clinical JJ o
endpoints NNS o
. . o

RESULTS VB N
The DT N
mean JJ N
number NN N
of IN N
new JJ o
active JJ o
lesions NNS o
+/- JJ N
SD NNP N
per IN N
patient NN N
during IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
valacyclovir NN i
was VBD N
11.9 CD N
+/- JJ N
17.6 CD N
and CC N
that IN N
during IN N
placebo NN i
treatment NN N
was VBD N
14.5 CD N
+/- JJ N
21.4 CD N
. . N

A DT N
protocol-planned JJ N
exploratory NN N
analysis NN N
stratified VBD N
patients NNS N
according VBG N
to TO N
baseline NN N
activity NN N
; : N
this DT N
analysis NN N
showed VBD N
that IN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
disease NN N
activity NN N
in IN N
the DT N
valacyclovir NN i
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
developed VBD N
fewer JJR N
new JJ o
active JJ o
lesions NNS o
per IN N
scan JJ N
than IN N
did VBD N
those DT N
in IN N
the DT N
placebo NN N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
. . N

The DT N
median JJ N
number NN N
( ( N
Q NNP N
( ( N
1 CD N
) ) N
, , N
Q NNP N
( ( N
3 CD N
) ) N
range NN N
) ) N
of IN N
active JJ o
lesions NNS o
was VBD N
2.0 CD N
( ( N
1.38 CD N
, , N
3.96 CD N
) ) N
in IN N
the DT N
valacyclovir NN N
treatment NN N
group NN N
and CC N
6.5 CD N
( ( N
2.63 CD N
, , N
9.0 CD N
) ) N
in IN N
the DT N
placebo NN N
treatment NN N
group NN N
. . N

CONCLUSIONS NNP N
Valacyclovir NNP i
treatment NN N
did VBD N
not RB N
reduce VB N
the DT N
formation NN N
of IN N
active JJ o
lesions NNS o
in IN N
patients NNS p
with IN p
relapsing-remitting JJ p
MS NNP p
who WP p
had VBD p
two CD p
or CC p
more JJR p
relapses NNS p
during IN p
the DT p
previous JJ p
2-year JJ p
period NN p
. . p

In IN N
a DT N
subgroup NN N
of IN N
patients NNS N
with IN N
high JJ N
levels NNS N
of IN N
disease NN N
activity NN N
who WP N
had VBD N
more JJR N
than IN N
one CD N
active JJ N
MRI-evident JJ N
lesion NN N
during IN N
4 CD N
weeks NNS N
, , N
valacyclovir FW i
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
reduced JJ N
number NN N
of IN N
new JJ o
active JJ o
MRI-evident JJ o
lesions NNS o
and CC N
with IN N
an DT N
increase NN N
in IN N
the DT N
number NN N
of IN N
scans NNS N
free JJ N
of IN N
new JJ o
active JJ o
lesions NNS o
. . o

The DT N
results NNS N
of IN N
the DT N
exploratory NN N
subgroup NN N
analysis NN N
provide VBP N
support NN N
for IN N
further JJ N
studies NNS N
of IN N
antiherpes NNS i
therapy NN i
for IN N
patients NNS p
with IN p
MS NNP p
and CC p
high JJ p
levels NNS p
of IN p
MRI-evident JJ p
disease NN p
activity NN p
. . p

-DOCSTART- -24103072- O O

Long-term JJ N
exposure NN N
to TO N
belatacept VB N
in IN N
recipients NNS p
of IN p
extended JJ p
criteria NNS p
donor JJ p
kidneys NNS p
. . p

Patients NNS p
in IN p
the DT p
BENEFIT-EXT NNP p
study NN p
received VBD p
extended JJ p
criteria NNS p
donor JJ p
kidneys NNS p
and CC N
a DT N
more RBR i
intensive JJ i
( ( i
MI NNP i
) ) i
or CC i
less RBR i
intensive JJ i
( ( i
LI NNP i
) ) i
belatacept IN i
immunosuppression NN i
regimen NNS i
, , i
or CC i
cyclosporine VB i
A NNP i
( ( i
CsA NNP i
) ) i
. . i

Patients NNS p
who WP p
remained VBD p
on IN p
assigned JJ p
therapy NN p
through IN p
year NN p
3 CD p
were VBD p
eligible JJ p
to TO p
enter VB p
a DT p
long-term JJ p
extension NN p
( ( p
LTE NNP p
) ) p
study NN p
. . p

Three CD p
hundred VBD p
four CD p
patients NNS p
entered VBD p
the DT p
LTE NNP p
( ( p
n JJ p
= $ p
104 CD p
MI NNP p
; : p
n CC p
= $ p
113 CD p
LI NNP p
; : p
n CC p
= $ p
87 CD p
CsA NNP p
) ) p
, , p
and CC p
260 CD p
continued VBD p
treatment NN p
through IN p
year NN p
5 CD p
( ( p
n JJ p
= $ p
91 CD N
MI NNP N
; : N
n CC N
= $ N
100 CD N
LI NNP N
; : N
n CC N
= $ N
69 CD p
CsA NNP p
) ) p
. . p

Twenty CD p
patients NNS o
died VBD o
during IN o
the DT N
LTE NNP N
( ( N
n JJ N
= $ N
5 CD N
MI NNP N
; : N
n CC N
= $ N
9 CD N
LI NNP N
; : N
n CC N
= $ N
6 CD N
CsA NNP N
) ) N
, , N
and CC N
eight CD N
experienced VBD o
graft NN o
loss NN o
( ( o
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
; : N
n CC N
= $ N
5 CD N
CsA NNP N
) ) N
. . N

Three CD N
patients NNS N
experienced VBD N
an DT o
acute JJ o
rejection NN o
episode NN o
( ( N
n JJ N
= $ N
2 CD N
MI NNP N
; : N
n CC N
= $ N
1 CD N
LI NNP N
) ) N
. . N

The DT N
incidence NN N
rate NN N
of IN o
serious JJ o
adverse JJ o
events NNS o
, , o
viral JJ o
infections NNS o
and CC o
fungal JJ o
infections NNS o
was VBD N
similar JJ N
across IN N
groups NNS N
during IN N
the DT N
LTE NNP N
. . N

There EX N
were VBD N
four CD N
cases NNS o
of IN o
posttransplant JJ o
lymphoproliferative JJ o
disorder NN o
( ( o
PTLD NNP o
) ) N
from IN N
the DT N
beginning NN N
of IN N
the DT N
LTE NNP N
to TO N
year NN N
5 CD N
( ( N
n JJ N
= $ N
3 CD N
LI NNP N
; : N
n CC N
= $ N
1 CD N
CsA NNP N
) ) N
; : N
two CD N
of IN N
three CD N
PTLD NNP N
cases NNS N
in IN N
the DT N
LI NNP N
group NN N
were VBD N
in IN N
patients NNS p
who WP p
were VBD p
seronegative JJ p
for IN p
Epstein-Barr NNP p
virus NN p
( ( p
EBV NNP p
( ( p
- : p
) ) p
) ) p
at IN p
transplantation NN p
. . N

Mean NNP N
? . N
SD NNP N
calculated VBD o
GFR NNP o
at IN o
year NN N
5 CD N
was VBD N
55.9 CD N
? . N
17.5 CD N
( ( N
MI NNP N
) ) N
, , N
59.0 CD N
? . N
29.1 CD N
( ( N
LI NNP N
) ) N
and CC N
44.6 CD N
? . N
16.4 CD N
( ( N
CsA NNP N
) ) N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
. . N

Continued VBN N
treatment NN N
with IN N
belatacept NN N
was VBD N
associated VBN N
with IN N
a DT N
consistent JJ N
safety NN N
profile NN N
and CC N
sustained VBD N
improvement NN N
in IN N
renal JJ N
function NN N
versus NN N
CsA NNP N
over IN N
time NN N
. . N

-DOCSTART- -25149412- O O

Oxytocin NNP i
improves VBZ N
behavioural JJ o
and CC o
neural JJ o
deficits NNS o
in IN N
inferring VBG N
others NNS N
' POS N
social JJ N
emotions NNS N
in IN N
autism NN p
. . p

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
oxytocin NN i
's POS i
therapeutic JJ N
effects NNS N
on IN N
deficits NNS N
in IN N
social JJ N
communication NN N
and CC N
interaction NN N
in IN N
autism NN p
spectrum NN p
disorder NN p
through IN N
improvement NN N
of IN N
emotion NN o
recognition NN o
with IN N
direct JJ N
emotional JJ N
cues NNS N
, , N
such JJ N
as IN N
facial JJ N
expression NN N
and CC N
voice NN N
prosody NN N
. . N

Although IN N
difficulty NN N
in IN N
understanding VBG N
of IN N
others NNS N
' POS N
social JJ N
emotions NNS N
and CC N
beliefs NNS N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
also RB N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
autism NN p
spectrum NN p
disorder NN p
, , N
no DT N
study NN N
has VBZ N
examined VBN N
the DT N
potential JJ N
effect NN N
of IN N
oxytocin NN i
on IN N
this DT N
difficulty NN N
. . N

Here RB N
, , N
we PRP N
sequentially RB N
conducted VBD N
both DT N
a DT N
case-control NN N
study NN N
and CC N
a DT N
clinical JJ N
trial NN N
to TO N
investigate VB N
the DT N
potential JJ N
effects NNS N
of IN N
oxytocin NN i
on IN N
this DT N
difficulty NN N
at IN N
behavioural JJ N
and CC N
neural JJ N
levels NNS N
measured VBN N
using VBG N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
during IN N
a DT N
psychological JJ N
task NN N
. . N

This DT N
task NN N
was VBD N
modified VBN N
from IN N
the DT N
Sally-Anne NNP N
Task NNP N
, , N
a DT N
well-known JJ N
first-order NN N
false JJ N
belief NN N
task NN N
. . N

The DT N
task NN N
was VBD N
optimized VBN N
for IN N
investigation NN N
of IN N
the DT N
abilities NNS N
to TO N
infer VB N
another DT N
person NN N
's POS N
social JJ N
emotions NNS N
and CC N
beliefs NNS N
distinctively RB N
so RB N
as IN N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
oxytocin VBZ i
improves VBZ N
deficit NN N
in IN N
inferring VBG N
others NNS N
' POS N
social JJ N
emotions NNS N
rather RB N
than IN N
beliefs NNS N
, , N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
. . N

In IN N
the DT N
case-control NN N
study NN N
, , N
17 CD p
males NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
showed VBD N
significant JJ N
behavioural JJ o
deficits NNS o
in IN o
inferring VBG o
others NNS o
' POS o
social JJ o
emotions NNS o
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
but CC N
not RB N
in IN N
inferring VBG o
others NNS o
' POS o
beliefs NNS o
( ( N
P NNP N
= NNP N
0.064 CD N
) ) N
compared VBN N
with IN N
17 CD p
typically RB p
developing VBG p
demographically-matched JJ p
male NN p
participants NNS p
. . p

They PRP N
also RB N
showed VBD N
significantly RB N
less JJR N
activity NN N
in IN N
the DT N
right JJ o
anterior NN o
insula NN o
and CC N
posterior JJ o
superior JJ o
temporal JJ o
sulcus NN o
during IN N
inferring VBG N
others NNS N
' POS N
social JJ N
emotions NNS N
, , N
and CC N
in IN N
the DT N
dorsomedial JJ N
prefrontal JJ N
cortex NN N
during IN N
inferring VBG N
others NNS N
' POS N
beliefs NNS N
compared VBN N
with IN N
the DT N
typically RB N
developing VBG N
participants NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
and CC N
cluster JJR N
size NN N
> $ N
10 CD N
voxels NNS N
) ) N
. . N

Then RB N
, , N
to TO N
investigate VB N
potential JJ N
effects NNS N
of IN N
oxytocin NN i
on IN N
these DT N
behavioural JJ N
and CC N
neural JJ N
deficits NNS N
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
placebo-controlled JJ i
crossover NN N
within-subject JJ N
trial NN N
for IN N
single-dose JJ N
intranasal JJ N
administration NN N
of IN N
24 CD N
IU NNP N
oxytocin NN i
in IN N
an DT N
independent JJ N
group NN N
of IN N
20 CD p
males NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Behaviourally NNP o
, , o
oxytocin VBZ o
significantly RB N
increased VBN N
the DT N
correct JJ o
rate NN o
in IN o
inferring VBG o
others NNS o
' POS o
social JJ o
emotions NNS o
( ( N
P NNP N
= NNP N
0.043 CD N
, , N
one-tail NN N
) ) N
. . N

At IN N
the DT N
neural JJ N
level NN N
, , N
the DT N
peptide NN N
significantly RB N
enhanced VBD N
the DT N
originally-diminished JJ o
brain NN o
activity NN o
in IN o
the DT o
right JJ o
anterior JJ o
insula NN o
during IN N
inferring VBG N
others NNS N
' POS N
social JJ N
emotions NNS N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
but CC N
not RB N
in IN N
the DT N
dorsomedial JJ N
prefrontal JJ N
cortex NN N
during IN N
inferring VBG N
others NNS N
' POS N
beliefs NNS N
( ( N
P NNP N
= NNP N
0.858 CD N
) ) N
. . N

The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
oxytocin NN i
enhances VBZ N
the DT N
ability NN o
to TO o
understand VB o
others NNS o
' POS o
social JJ o
emotions NNS o
that WDT N
have VBP N
also RB N
required VBN N
second-order NN N
false JJ N
belief NN N
rather RB N
than IN N
first-order JJ N
false JJ N
beliefs NNS N
under IN N
conditions NNS N
without IN N
direct JJ N
emotional JJ N
cues NNS N
in IN N
autism NN p
spectrum NN p
disorder NN p
at IN N
both DT N
the DT N
behaviour NN N
and CC N
neural JJ N
levels NNS N
. . N

-DOCSTART- -21635675- O O

Short-term JJ N
metabolic JJ N
effects NNS o
of IN N
prednisone NN i
administration NN N
in IN N
healthy JJ p
subjects NNS p
. . p

AIMS NNP N
Supraphysiologic NNP N
glucocorticoid NN N
activity NN N
is VBZ N
well RB N
established VBN N
to TO N
cause VB N
impaired JJ N
glucose JJ o
tolerance NN o
and CC o
insulin NN o
resistance NN o
, , N
yet RB N
no DT N
study NN N
has VBZ N
evaluated VBN N
dose-dependent JJ N
effects NNS N
of IN N
low-dose JJ N
prednisone NN i
during IN N
short-term JJ N
oral JJ N
administration NN N
. . N

METHODS NNP N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
quantify VB N
the DT N
effects NNS N
of IN N
daily JJ N
10 CD i
or CC i
25 CD i
mg NNS i
prednisone JJ i
administration NN N
for IN N
one CD N
week NN N
on IN N
insulin NN N
sensitivity NN N
by IN N
employing VBG N
a DT N
two-step JJ i
hyperinsulinemic JJ i
euglycemic JJ i
glucose NN i
clamp NN i
( ( N
Step JJ N
1 CD N
: : N
insulin NN N
infusion NN N
= VBD N
20 CD N
mU/m?/min NN N
; : N
Step CC N
2 CD N
: : i
insulin NN i
infusion NN i
= VBD i
80 CD i
mU/m?/min NN i
) ) i
in IN i
healthy JJ p
, , p
lean JJ p
males NNS p
. . p

The DT o
amount NN o
of IN o
glucose NN o
infused VBN o
at IN o
steady-state JJ o
to TO o
maintain VB o
stable JJ o
blood NN o
glucose JJ o
[ $ o
90 CD N
mg/dl NN N
( ( N
4.95 CD N
mmol/l NN N
) ) N
] NN N
was VBD N
used VBN N
to TO N
calculate VB N
several JJ N
indices NNS N
of IN N
insulin NN N
sensitivity NN N
. . N

RESULTS NNP N
During IN N
Step NNP N
1 CD N
of IN N
the DT N
clamp NN o
, , o
whole JJ o
body NN o
glucose JJ o
disposal NN o
( ( o
M NNP o
) ) o
was VBD o
reduced VBN N
by IN N
35 CD N
% NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
M/I NNP N
was VBD N
reduced VBN N
by IN N
29 CD N
% NN N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
for IN N
25 CD N
mg NN N
prednisone NN i
compared VBN i
to TO N
placebo VB i
. . i

No DT N
appreciable JJ N
effect NN N
of IN N
10 CD N
mg NN N
prednisone NN N
was VBD N
observed VBN N
. . N

During IN N
Step NNP N
2 CD N
, , N
M NNP N
was VBD N
reduced VBN N
by IN N
33 CD N
% NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
and CC N
15 CD N
% NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
for IN N
25 CD N
and CC N
10 CD N
mg NN N
prednisone NN i
compared VBN i
to TO N
placebo VB i
; : i
and CC o
M/I NNP o
ratio NN o
was VBD o
reduced VBN N
by IN N
31 CD N
% NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
13 CD N
% NN N
( ( N
p JJ N
= NNP N
0.026 CD N
) ) N
, , N
respectively RB N
. . N

The DT o
insulin NN o
sensitivity NN o
index NN o
, , o
Si NNP o
, , o
calculated VBD N
as IN N
the DT N
quotient NN N
of IN N
augmentation NN N
of IN N
M/I NNP N
between IN N
Step NNP N
1 CD N
and CC N
2 CD N
, , N
was VBD N
reduced VBN N
by IN N
35.3 CD N
% NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
23.5 CD N
% NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
25 CD N
and CC N
10 CD N
mg NN N
prednisone NN i
, , i
respectively RB N
. . N

CONCLUSION NNP N
Administration NNP N
of IN N
relatively RB N
low JJ N
pharmacological JJ N
doses NNS N
of IN N
prednisone NN N
for IN N
one CD N
week NN N
impaired JJ o
insulin NN o
sensitivity NN o
in IN o
a DT N
dose-dependent JJ N
manner NN N
in IN N
healthy JJ p
males NNS p
. . p

These DT N
observed JJ N
changes NNS N
in IN N
insulin NN N
sensitivity NN N
are VBP N
likely JJ N
to TO N
be VB N
clinically RB N
relevant JJ N
, , N
especially RB N
in IN N
individuals NNS N
predisposed VBN N
to TO N
develop VB N
glucose JJ N
intolerance NN N
. . N

-DOCSTART- -12239448- O O

Stepwise NNP i
hook NN i
extension NN i
technique NN i
for IN N
radiofrequency NN N
ablation NN N
therapy NN N
of IN N
hepatocellular JJ p
carcinoma NN p
. . p

OBJECTIVE CC N
Our PRP$ N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
stepwise NN i
hook NN i
extension NN i
technique NN i
for IN i
radiofrequency NN i
ablation NN i
( ( i
RFA NNP i
) ) i
therapy NN i
of IN N
hepatocellular JJ p
carcinoma NN p
in IN N
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

METHOD NNP N
Twenty NNP p
patients NNS p
with IN p
hepatocellular JJ p
carcinoma NN p
measuring VBG p
< $ p
25 CD p
mm NN p
were VBD N
divided VBN N
randomly RB N
into IN N
two CD N
equal JJ N
groups NNS N
. . N

RFA NNP i
was VBD N
applied VBN N
using VBG N
our PRP$ N
new JJ N
stepwise NN i
hook NN i
extension NN i
technique NN i
in IN N
patients NNS N
of IN N
group NN N
1 CD N
, , N
and CC N
the DT N
full JJ i
extension NN i
method NN i
in IN N
group NN N
2 CD N
. . N

The DT N
10-hook JJ i
electrode NN i
of IN i
LeVeen NNP i
needle NN i
was VBD N
deployed VBN N
in IN N
four CD N
steps NNS N
to TO N
full JJ N
extension NN N
during IN N
ablation NN N
in IN N
group NN N
1 CD N
, , N
and CC N
full JJ N
extension NN N
at IN N
start NN N
of IN N
treatment NN N
in IN N
group NN N
2 CD N
. . N

RESULTS VB N
Roll-off NNP o
was VBD N
achieved VBN N
in IN N
all DT N
10 CD N
patients NNS N
of IN N
group NN N
1 CD N
, , N
indicative NN N
of IN N
sufficient JJ N
tumor NN N
coagulation NN N
, , N
but CC N
only RB N
in IN N
3 CD N
of IN N
10 CD N
patients NNS N
of IN N
group NN N
2 CD N
. . N

The DT N
median JJ o
time NN o
to TO o
completion NN o
of IN o
treatment NN o
was VBD N
6 CD N
min NN N
and CC N
55 CD N
s NN N
( ( N
range VB N
3 CD N
min NN N
to TO N
14 CD N
min NNS N
and CC N
3 CD N
s NN N
) ) N
and CC N
15 CD N
min NN N
( ( N
6-15 JJ N
min NN N
) ) N
, , N
respectively RB N
. . N

The DT N
total JJ o
power NN o
output NN o
used VBN N
for IN N
RF NNP N
was VBD N
lower JJR N
in IN N
group NN N
1 CD N
than IN N
in IN N
group NN N
2 CD N
( ( N
median JJ N
271 CD N
vs. FW N
1,045 CD N
W.m NNP N
) ) N
. . N

The DT N
diameters NNS o
of IN o
RFA-induced JJ o
lesions NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
( ( N
group NN N
1 CD N
: : N
27 CD N
, , N
range NN N
23-37 JJ N
mm NN N
; : N
group NN N
2 CD N
: : N
23 CD N
, , N
0-42 JJ N
mm NN N
) ) N
. . N

CONCLUSIONS NNP N
Application NNP N
of IN N
RFA NNP N
using VBG N
stepwise NN N
hook NN N
extension NN N
technique NN N
is VBZ N
superior JJ N
to TO N
the DT N
full JJ N
extension NN N
method NN N
since IN N
it PRP N
produces VBZ N
the DT N
same JJ o
therapeutic JJ o
effects NNS o
within IN N
a DT N
short JJ N
period NN N
using VBG N
a DT N
lower JJR N
energy NN N
. . N

-DOCSTART- -15562654- O O

[ JJ N
Comparison NNP N
of IN N
fracture NN o
resistance NN o
of IN N
pulpless NN i
teeth NNS i
restored VBD i
with IN i
fiber NN i
reinforced VBN i
composite JJ i
posts NNS i
and CC N
three CD i
kinds NNS i
of IN i
resin NN i
core NN i
material NN i
] NNP i
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
fracture NN o
resistances NNS o
of IN N
pulpless NN N
teeth NNS N
restored VBD N
with IN N
FRC NNP i
( ( i
Fiber NNP i
Reinforced NNP i
Composite NNP i
) ) i
posts NNS i
and CC N
three CD i
kinds NNS i
of IN i
resin NN i
core NN i
material NN i
. . i

METHODS NNP N
A NNP p
total NN p
of IN p
42 CD p
recently RB p
extracted VBN p
upper JJ p
incisors NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
3 CD p
groups NNS p
. . p

Group NNP N
A NNP N
was VBD N
restored VBN N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
Artglass NNP i
polymer NN i
core NN i
; : i
group NN N
B NNP N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
Charisma NNP i
composite JJ i
resin NN i
core NN i
; : i
and CC N
group NN N
C NNP N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
AB NNP i
composite JJ i
resin NN i
core NN i
. . i

In IN N
every DT N
group NN N
, , N
the DT N
core NN N
material NN N
was VBD N
processed VBN N
by IN N
hot-press NN N
and CC N
non JJ N
hot-press NN N
respectively RB N
. . N

The DT N
posts NNS N
size NN N
and CC N
shape NN N
were VBD N
identical JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

All DT p
teeth NNS p
were VBD p
fully RB p
covered VBN p
with IN p
polycarbonate JJ p
resin NN p
crowns NNS p
. . p

Fracture NN o
resistance NN o
was VBD N
measured VBN N
by IN N
applying VBG N
point NN N
force NN N
at IN N
130 CD N
degrees NNS N
to TO N
the DT N
long JJ N
axis NN N
of IN N
the DT N
teeth NN N
on IN N
an DT N
universal JJ N
testing NN N
machine NN N
. . N

RESULTS JJ N
Mean JJ o
fracture NN o
threshold NN o
was VBD N
505.4 CD N
N NNP N
+/- JJ N
42.0 CD N
N NNP N
and CC N
564.1 CD N
N NNP N
+/- JJ N
41.7 CD N
N NNP N
in IN N
group NN N
A NNP N
, , N
411.3 CD N
N NNP N
+/- JJ N
23.3 CD N
N NNP N
and CC N
315.3 CD N
N NNP N
+/- JJ N
19.1 CD N
N NNP N
in IN N
group NN N
B NNP N
and CC N
358.4 CD N
N NNP N
+/- JJ N
36.1 CD N
N NNP N
and CC N
423.4 CD N
N NNP N
+/- JJ N
47.5 CD N
N NNP N
in IN N
group NN N
C. NNP N
In IN N
all DT N
groups NNS N
, , N
there EX N
was VBD N
no DT o
posts NNS o
fracture NN o
and CC o
polycarbonate NN o
resin NN o
crowns NNS o
fragmentation NN o
. . o

CONCLUSION VB N
The DT N
composite JJ N
restoration NN N
of IN N
FRC NNP i
posts NNS i
combined VBD i
with IN i
resin NN i
core NN i
and CC i
resin VB i
crown NN i
can MD N
improve VB N
the DT N
fracture NN o
resistance NN o
of IN N
the DT N
pulpless JJ N
roots NNS N
. . N

The DT N
strength NN N
of IN N
resin NN N
core NN N
material NN N
can MD N
be VB N
increased VBN N
by IN N
hot-press JJ i
methods NNS i
. . i

-DOCSTART- -24077211- O O

Intrathecal JJ N
lentivirus-mediated JJ N
transfer NN N
of IN N
interleukin-10 JJ i
attenuates NNS N
chronic JJ o
constriction NN o
injury-induced JJ o
neuropathic JJ o
pain NN o
through IN N
modulation NN N
of IN N
spinal JJ N
high-mobility NN N
group NN N
box VBZ N
1 CD N
in IN N
rats NNS p
. . p

BACKGROUND NNP N
Neuropathic NNP N
pain NN N
is VBZ N
a DT N
complex JJ N
state NN N
of IN N
chronic JJ N
pain NN N
that WDT N
is VBZ N
usually RB N
accompanied VBN N
by IN N
peripheral JJ N
and CC N
central JJ N
nervous JJ N
system NN N
damage NN N
or CC N
dysfunction NN N
. . N

Previous JJ N
studies NNS N
have VBP N
indicated VBN N
that DT N
neuroinflammation NN N
in IN N
the DT N
spinal JJ N
cord NN N
is VBZ N
an DT N
important JJ N
contributor NN N
to TO N
neuropathological JJ N
and CC N
behavioral JJ N
abnormalities NNS N
. . N

A DT N
series NN N
of IN N
early JJ N
inflammatory NN N
markers NNS N
, , N
such JJ N
as IN N
IL-1 NNP N
, , N
TNF-? NNP N
, , N
and CC N
IFN-? NNP N
, , N
and CC N
advanced VBD N
inflammatory JJ N
markers NNS N
, , N
such JJ N
as IN N
high-mobility NN N
group NN N
box VBZ N
1 CD N
( ( N
HMGB1 NNP N
) ) N
, , N
are VBP N
involved VBN N
in IN N
neuroinflammation NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized NN N
, , N
double JJ N
blind NN N
, , N
controlled VBD p
animal JJ p
trial NN p
. . N

OBJECTIVE NN N
In IN N
this DT N
study NN N
, , N
a DT N
lentivirus NN i
delivering VBG i
human JJ i
IL-10 NNP i
( ( i
LV/hIL-10 NNP i
) ) i
was VBD i
administered VBN N
intrathecally RB N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
IL-10 NNP N
on IN N
allodynia NN o
and CC o
hyperalgesia NN o
in IN o
a DT N
chronic JJ N
constriction NN N
injury-induced JJ N
( ( N
CCI NNP p
) ) p
rat VBP p
model NN p
of IN p
neuropathic JJ N
pain NN N
. . N

METHODS NNP p
Sprague-Dawley NNP p
rats NNS p
weighting VBG p
260 CD p
- : p
320 CD p
g NN p
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
. . N

Group NNP N
Sham NNP N
( ( N
Sham NNP N
) ) N
, , N
Group NNP i
CCI?Normal NNP i
Saline NNP i
( ( i
NS NNP i
) ) i
, , i
Group NNP i
CCI?LV/hIL-10 NNP i
( ( i
LV/hIL-10 NNP i
) ) i
, , i
and CC i
Group NNP i
CCI?LV/control NNP i
( ( i
vector NN i
) ) i
. . i

Rats NNPS i
in IN N
each DT N
group NN N
were VBD N
intrathecally RB N
delivered VBN N
with IN N
NS NNP i
, , i
LV/control NNP i
, , i
or CC i
recombinant JJ i
vector NN i
LV/hIL-10 NNP i
in IN i
a DT i
total JJ N
volume NN N
of IN N
10 CD N
?l NN N
. . o

Paw NNP o
withdrawal VBD o
mechanical JJ o
thresholds NNS o
( ( o
PWMT NNP o
) ) o
and CC o
paw $ o
withdrawal NN o
thermal JJ o
latency NN o
PWTL NNP o
were VBD N
measured VBN N
one CD N
day NN N
before IN N
CCI NNP N
( ( N
baseline NN N
) ) N
and CC N
0 CD N
, , N
3 CD N
, , N
7 CD N
, , N
14 CD N
, , N
and CC N
28 CD N
days NNS N
after IN N
intrathecal JJ N
administration NN N
. . N

Cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
samples NNS N
were VBD N
collected VBN N
during IN N
surgical JJ N
plane NN N
anesthesia NN N
and CC N
the DT N
collected JJ N
CSF NNP N
samples NNS N
were VBD N
used VBN N
to TO N
assay VB N
for IN N
human JJ N
IL-10 NNP N
, , N
rat VBZ N
IL-1? NNP N
, , N
rat VBZ N
IL-6 NNP N
, , N
and CC N
rat VB N
TNF-? JJ N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

Animals NNS p
were VBD p
sacrificed VBN p
and CC p
the DT p
L4-5 NNP p
lumbar NN p
segment NN p
of IN p
the DT p
spinal JJ p
cord NN p
was VBD p
removed VBN p
for IN p
determination NN p
of IN p
green JJ p
fluorescent NN p
protein NN p
( ( p
GFP NNP p
) ) p
expression NN p
. . p

Immunohistochemical JJ p
analysis NN N
was VBD N
performed VBN N
using VBG N
anti JJ N
HMGB1 NNP N
antibodies NNS N
and CC N
the DT N
expression NN N
of IN N
HMGB1 NNP N
protein NN N
in IN N
the DT N
spinal JJ N
cord NN N
was VBD N
determined VBN N
by IN N
western JJ N
blot NN N
analysis NN N
after IN N
intrathecal JJ N
delivery NN N
( ( N
n JJ N
= RB N
8 CD N
each DT N
) ) N
. . N

RESULTS VB N
The DT N
results NNS N
show VBP N
that DT i
intrathecal JJ i
LV/hIL-10 NNP i
reverses NNS i
enhanced VBD o
pain NN o
states NNS o
. . o

Moreover RB N
, , N
the DT N
increased VBN o
level NN o
of IN o
HMGB1 NNP o
exhibited VBD o
in IN o
a DT o
late JJ o
stage NN o
of IN o
CCI NNP o
was VBD N
inhibited VBN N
by IN N
exogenous JJ N
overexpression NN N
of IN N
hIL-10 NN N
in IN N
the DT N
CCI NNP N
model NN o
. . o

Expression NN o
of IN o
HMGB1 NNP o
, , o
RAGE NNP o
, , o
and CC o
pAkt NNS o
were VBD o
lower JJR N
in IN N
CCI-induced NNP N
rats NNS N
treated VBD N
with IN N
LV/hIL-10 NNP N
than IN N
in IN N
those DT N
treated VBN N
with IN N
LV/control NNP N
( ( N
vector NN N
) ) N
or CC N
saline NN N
( ( N
NS NNP N
) ) N
. . N

Our PRP$ N
results NNS N
showed VBD N
that IN o
IL-10 NNP o
inhibits VBZ o
activation NN o
of IN o
the DT o
inflammatory JJ o
HMGB1-RAGE NNP o
pathway NN o
in IN N
the DT N
CCI NNP N
rat NN N
model NN N
. . N

LIMITATIONS NNP N
Further NNP N
experimental JJ N
investigations NNS N
are VBP N
needed VBN N
to TO N
clarify VB N
the DT N
specific JJ N
biological JJ N
roles NNS N
played VBN N
by IN N
HMGB1 NNP N
in IN N
IL-10-mediated NNP N
regulation NN o
of IN o
neuropathic JJ o
pain NN o
. . o

CONCLUSION NNP o
Our PRP$ N
results NNS N
indicate VBP N
that DT N
intrathecal JJ N
lentiviral-mediated JJ N
transfer NN N
of IN i
IL-10 NNP i
attenuates VBZ o
CCI-induced NNP o
neuropathic JJ o
pain NN o
in IN o
rats NNS p
. . N

The DT N
anti-thermal JJ N
hyperalgesia NN N
and CC N
anti-mechanical JJ N
allodynia NN N
may MD N
be VB N
partly RB N
attributable JJ N
to TO N
the DT N
decreased JJ N
expression NN N
of IN N
HMGB1 NNP N
and CC N
inhibition NN N
of IN N
HMGB1-RAGE NNP N
pathway NN N
. . N

-DOCSTART- -12168688- O O

A DT N
randomised VBN N
, , N
controlled VBD N
study NN N
of IN N
dietary JJ i
intervention NN i
in IN N
autistic JJ p
syndromes NNS p
. . p

Impaired NNP N
social JJ N
interaction NN N
, , N
communication NN N
and CC N
imaginative JJ N
skills NNS N
characterize VBP N
autistic JJ N
syndromes NNS N
. . N

In IN N
these DT N
syndromes NNS N
urinary JJ N
peptide NN N
abnormalities NNS N
, , N
derived VBN N
from IN N
gluten NN N
, , N
gliadin NN N
, , N
and CC N
casein NN N
, , N
are VBP N
reported VBN N
. . N

They PRP N
reflect VBP N
processes NNS N
with IN N
opioid JJ N
effect NN N
. . N

The DT N
aim NN N
of IN N
this DT N
single JJ N
blind NN N
study NN N
was VBD N
to TO N
evaluate VB N
effect NN N
of IN N
gluten NN i
and CC i
casein-free JJ i
diet NN i
for IN N
children NNS p
with IN p
autistic JJ p
syndromes NNS p
and CC p
urinary JJ p
peptide NN p
abnormalities NNS p
. . p

A DT N
randomly RB N
selected VBN N
diet JJ p
and CC p
control NN p
group NN p
with IN p
10 CD p
children NNS p
in IN p
each DT p
group NN p
participated VBD p
. . p

Observations NNS o
and CC o
tests NNS o
were VBD N
done VBN N
before RB N
and CC N
after IN N
a DT N
period NN N
of IN N
1 CD N
year NN N
. . N

The DT N
development NN o
for IN N
the DT N
group NN N
of IN N
children NNS N
on IN N
diet NN N
was VBD N
significantly RB N
better JJR N
than IN N
for IN N
the DT N
controls NNS i
. . i

-DOCSTART- -17935144- O O

Supportive-expressive JJ i
group NN i
therapy NN i
for IN N
primary JJ p
breast NN o
cancer NN o
patients NNS p
: : p
a DT N
randomized JJ N
prospective JJ N
multicenter NN N
trial NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
manualized JJ i
12-week JJ i
supportive-expressive JJ i
group NN i
therapy NN i
program NN i
among IN N
primary JJ p
breast NN o
cancer NN o
patients NNS p
treated VBN p
in IN p
community NN p
settings NNS p
, , N
to TO N
determine VB N
whether IN N
highly RB p
distressed JJ p
patients NNS p
were VBD N
most RBS N
likely JJ N
to TO N
benefit VB N
and CC N
whether IN N
therapist NN N
's POS N
training NN N
or CC N
experience NN N
was VBD N
related VBN N
to TO N
outcome VB N
. . N

METHOD NNP N
Three CD p
hundred VBD p
and CC p
fifty-three JJ p
women NNS p
within IN p
one CD p
year NN p
of IN p
diagnosis NN p
with IN p
primary JJ p
breast NN p
cancer NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
supportive-expressive JJ i
group NN i
therapy NN i
or CC i
to TO i
an DT i
education NN i
control NN i
condition NN i
. . i

Participants NNS p
were VBD p
recruited VBN p
from IN p
two CD p
academic JJ p
centers NNS p
and CC p
nine CD p
oncology NN p
practices NNS p
, , p
which WDT p
were VBD p
members NNS p
of IN p
NCI NNP p
's POS p
Community NNP p
Clinical NNP p
Oncology NNP p
Program NNP p
( ( p
CCOP NNP p
) ) p
and CC p
were VBD p
followed VBN p
over IN p
2 CD p
years NNS p
. . p

RESULTS VB N
A DT N
2x2x19 CD N
analysis NN N
of IN N
variance NN N
was VBD N
conducted VBN N
with IN N
main JJ N
effects NNS o
of IN o
treatment NN o
condition NN o
, , o
cohort NN o
, , o
and CC o
baseline NN o
distress NN o
and CC o
their PRP$ o
interactions NNS o
. . o

There EX N
was VBD N
no DT N
main JJ N
effect NN N
for IN N
treatment NN o
condition NN o
after IN N
removing VBG N
one CD N
subject NN N
with IN N
an DT N
extreme JJ N
score NN N
. . N

Highly NNP p
distressed JJ o
women NNS p
did VBD N
not RB N
derive VB N
a DT N
greater JJR o
benefit NN o
from IN N
treatment NN N
. . N

Therapist VB N
training NN N
and CC N
psychotherapy NN N
experience NN N
were VBD N
not RB N
associated VBN N
with IN N
a DT N
treatment NN N
effect NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
no DT N
evidence NN N
of IN N
reduction NN N
in IN N
distress NN o
as IN N
the DT N
result NN N
of IN N
a DT N
brief JJ i
supportive-expressive JJ i
intervention NN i
for IN N
women NNS p
with IN p
primary JJ p
breast NN o
cancer NN o
. . o

Future NNP N
studies NNS N
might MD N
productively RB N
focus VB N
on IN N
women NNS p
with IN p
higher JJR p
initial JJ p
levels NNS p
of IN p
distress NN o
. . o

-DOCSTART- -15353873- O O

A DT N
double JJ N
blind NN N
randomized VBD N
trial NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
eprosartan NN i
and CC i
enalapril NN i
on IN N
blood NN o
pressure NN o
, , o
platelets NNS o
, , o
and CC o
endothelium NN o
function NN o
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

The DT N
renin-angiotensin JJ N
system NN N
is VBZ N
the DT N
major JJ N
contributor NN N
to TO N
development NN N
of IN N
hypertension NN N
, , N
atherosclerosis NN N
, , N
and CC N
many JJ N
other JJ N
cardiovascular JJ N
diseases NNS N
. . N

Angiotensin NNP N
II NNP N
, , N
one CD N
of IN N
the DT N
main JJ N
effectors NNS N
of IN N
this DT N
system NN N
, , N
contributes VBZ N
to TO N
the DT N
pathogenesis NN N
of IN N
hypertension NN N
and CC N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
monocyte NN N
, , N
platelet NN N
, , N
and CC N
endothelium NN N
interactions NNS N
. . N

The DT N
effects NNS N
on IN N
platelet NN o
and CC o
endothelial JJ o
function NN o
, , N
either RB N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibitors NNS N
or CC N
angiotensin NN N
receptor NN N
antagonists NNS N
, , N
are VBP N
still RB N
not RB N
well RB N
understood RB N
. . N

A DT N
double-blind NN N
, , N
randomized VBN N
, , N
prospective JJ N
trial NN N
of IN N
either DT N
enalapril NN i
( ( N
10-20 JJ N
mg NNS N
daily RB N
) ) N
or CC N
eprosartan JJ i
( ( N
400-800 JJ N
mg NNS N
daily RB N
) ) N
over IN N
a DT N
10-week JJ N
period NN N
was VBD N
conducted VBN N
in IN N
42 CD p
patients NNS p
( ( p
27 CD p
males NNS p
, , p
15 CD p
females NNS p
) ) p
. . p

Platelet NNP N
activation NN N
was VBD N
evaluated VBN N
by IN N
measuring VBG N
platelet NN o
factor NN o
4 CD o
( ( o
PF-4 NNP o
) ) o
, , o
beta-thromboglobulin JJ o
( ( o
beta-TG JJ o
) ) o
, , o
the DT o
ratio NN o
of IN o
platelet NN o
factor NN o
4 CD o
to TO o
beta-thromboglobulin NN o
, , o
and CC o
endothelial JJ o
function NN o
by IN o
measuring VBG o
total JJ o
plasma JJ o
nitrate NN o
levels NNS o
, , o
von FW o
Willebrand NNP o
factor NN o
( ( o
vWF NN o
) ) o
levels NNS o
, , o
and CC o
blood NN o
flow NN o
using VBG o
venous JJ o
occlusive JJ o
plethysmography NN o
. . o

After IN N
a DT N
10-week JJ N
treatment NN N
with IN N
enalapril NN i
or CC i
eprosartan NN i
, , N
the DT N
sitting VBG o
blood NN o
pressure NN o
in IN N
both DT N
the DT N
enalapril NN i
group NN N
( ( N
from IN N
152.2 CD N
+/- JJ N
18.7 CD N
mmHg NN N
to TO N
141.9 CD N
+/- JJ N
23.5 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
eprosartan JJ i
group NN N
( ( N
from IN N
151 CD N
+/- JJ N
10.0 CD N
mmHg NN N
to TO N
142.3 CD N
+/- JJ N
12.9 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
was VBD N
significantly RB N
reduced VBN N
. . N

Significant NNP N
diastolic JJ o
blood NN o
pressure NN o
( ( o
DPB NNP o
) ) o
reduction NN N
( ( N
from IN N
94 CD N
+/- JJ N
8.7 CD N
to TO N
84.5 CD N
+/- JJ N
9.6 CD N
mmHg NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
a DT N
greater JJR N
DBP NNP o
reduction NN N
response NN N
were VBD N
found VBN N
in IN N
the DT N
eprosartan NN i
group NN N
( ( N
63 CD N
% NN N
in IN N
eprosartan JJ i
versus NN N
25 CD N
% NN N
in IN N
enalapril NN i
) ) i
. . N

Additionally RB N
, , N
dose-dependent JJ N
reductions NNS N
in IN N
the DT N
indices NNS N
of IN N
platelet NN o
activation NN o
and CC o
endothelial JJ o
dysfunction NN o
were VBD N
observed VBN N
in IN N
patients NNS N
administered VBN N
high JJ N
dose JJ N
treatments NNS N
of IN N
eprosartan NN i
and CC i
enalapril NN i
, , N
and CC N
the DT N
beneficial JJ N
effects NNS N
of IN N
these DT N
agents NNS N
were VBD N
not RB N
correlated VBN N
with IN N
the DT N
reduction NN N
of IN N
blood NN o
pressure NN o
using VBG N
both DT N
agents NNS N
. . N

Eprosartan NNP i
is VBZ N
effective JJ o
and CC N
well-tolerated JJ o
in IN N
the DT N
treatment NN N
of IN N
mid-to-moderate JJ N
hypertension NN N
, , N
and CC N
the DT N
DBP NNP o
response NN N
reduction NN N
to TO N
eprosartin VB i
was VBD N
better JJR N
than IN N
that DT N
to TO N
enalapril VB i
. . i

A DT N
high JJ N
dose NN N
of IN N
either DT N
eprosartan NN i
or CC i
enalapril VB i
significantly RB N
decreased VBN N
the DT N
indices NNS N
of IN N
platelet NN o
activation NN o
and CC N
endothelial JJ N
dysfunction NN N
in IN N
hypertensive JJ p
patients NNS p
. . p

The DT N
benefits NNS N
of IN N
both DT N
agents NNS N
can MD N
not RB N
be VB N
explained VBN N
solely RB N
by IN N
their PRP$ N
antihypertensive JJ N
effects NNS N
and CC N
possibly RB N
may MD N
be VB N
mediated VBN N
through IN N
their PRP$ N
unique JJ N
effect NN N
on IN N
angiotensin NN N
blockade NN N
. . N

-DOCSTART- -7944932- O O

Effect NN N
of IN N
interferon NN N
gamma NN N
on IN N
infection-related JJ N
death NN N
in IN N
patients NNS p
with IN p
severe JJ p
injuries NNS p
. . p

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
interferon NN i
gamma NN i
in IN N
reducing VBG N
infection NN o
and CC N
death NN N
in IN N
patients NNS p
sustaining VBG p
severe JJ p
injury NN p
. . p

DESIGN NNP N
Multicenter NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
with IN N
observation NN N
for IN N
60 CD N
days NNS N
and CC N
until IN N
discharge NN N
for IN N
patients NNS p
with IN p
major JJ p
infection NN p
on IN p
day NN p
60 CD p
. . p

SETTING CD N
Nine JJ p
university-affiliated JJ p
level NN p
1 CD p
trauma NN p
centers NNS p
. . p

PATIENTS VB N
Four CD p
hundred JJ p
sixteen JJ p
patients NNS p
with IN p
severe JJ p
injuries NNS p
, , p
assessed VBN p
by IN p
Injury NNP o
Severity NNP o
Score NNP o
and CC o
degree NN o
of IN o
contamination NN o
. . o

INTERVENTION NNP N
Recombinant NNP i
human JJ i
interferon NN i
gamma NN i
, , i
100 CD i
micrograms NNS i
, , i
was VBD i
administered VBN i
subcutaneously RB i
once RB i
daily JJ i
for IN i
21 CD i
days NNS i
( ( i
or CC i
until IN i
patient JJ i
discharge NN i
if IN i
prior JJ i
to TO i
21 CD i
days NNS i
) ) i
as IN i
an DT i
adjunct NN i
to TO i
standard VB i
antibiotic JJ i
and CC i
supportive JJ i
therapy NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Incidence NNP o
of IN o
major JJ o
infection NN o
, , o
death NN o
related VBN o
to TO o
infection NN o
, , o
and CC o
death NN o
. . o

RESULTS JJ N
Infection NN o
rates NNS o
were VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
; : N
however RB N
, , N
patients NNS N
treated VBD N
with IN N
interferon NN N
gamma NN N
experienced VBD N
fewer JJR N
deaths NNS o
related VBN N
to TO N
infection NN o
( ( N
seven CD N
[ RB N
3 CD N
% NN N
] NNP N
vs NN N
18 CD N
[ JJ N
9 CD N
% NN N
] NN N
; : N
P NNP N
= NNP N
.008 NNP N
) ) N
and CC N
fewer JJR N
overall JJ N
deaths NNS o
( ( N
21 CD N
[ RB N
10 CD N
% NN N
] NNP N
vs NN N
30 CD N
[ JJ N
14 CD N
% NN N
] NN N
; : N
P NNP N
= NNP N
.17 NNP N
) ) N
. . N

While IN N
12 CD N
early JJ o
deaths NNS o
( ( N
days NNS N
1 CD N
through IN N
7 CD N
) ) N
occurred VBD N
in IN N
each DT N
treatment NN N
group NN N
, , N
late RB N
death NN o
occurred VBD N
in IN N
18 CD N
placebo-treated JJ N
patients NNS N
and CC N
nine CD N
in IN N
interferon JJ i
gamma-treated JJ i
patients NNS N
. . N

The DT N
results NNS N
were VBD N
dominated VBN N
by IN N
findings NNS N
at IN N
one CD N
center NN N
, , N
which WDT N
had VBD N
the DT N
highest JJS N
enrollment NN N
and CC N
higher JJR N
infection NN N
and CC N
death NN N
rates NNS N
. . N

Statistical JJ N
analysis NN N
did VBD N
not RB N
eliminate VB N
the DT N
possibility NN N
of IN N
an DT N
unidentified JJ N
imbalance NN N
between IN N
arms NNS N
as IN N
an DT N
explanation NN N
for IN N
the DT N
results NNS N
. . N

CONCLUSION NNP N
Further NNP N
evaluation NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
validity NN N
of IN N
the DT N
observed JJ N
reduction NN N
in IN N
infection-related JJ o
deaths NNS N
in IN N
patients NNS p
treated VBN p
with IN p
interferon NN i
gamma NN i
. . i

-DOCSTART- -17179873- O O

Depression NNP o
and CC o
anxiety NN o
in IN N
women NNS p
with IN p
breast NN p
cancer NN p
and CC p
their PRP$ p
partners NNS p
. . p

BACKGROUND NNP N
Psychosocial NNP i
interventions NNS i
can MD N
improve VB N
psychological JJ o
quality NN o
of IN o
life NN o
( ( o
symptoms NNS o
of IN o
depression NN o
and CC o
anxiety NN o
) ) o
of IN N
both DT p
women NNS p
with IN p
breast NN p
cancer NN p
and CC p
their PRP$ p
partners NNS p
, , N
but CC N
are VBP N
not RB N
offered VBN N
routinely RB N
to TO N
women NNS p
and CC p
their PRP$ p
partners NNS p
. . p

OBJECTIVE NNP N
To TO N
test VB N
the DT N
hypotheses NNS N
that IN N
telephone-delivered JJ i
psychosocial JJ i
interventions NNS i
decrease NN N
depression NN o
and CC o
anxiety NN o
in IN N
women NNS p
with IN p
breast NN p
cancer NN p
and CC p
their PRP$ p
partners NNS p
. . p

METHODS NNP N
The DT N
design NN N
of IN N
the DT N
study NN N
was VBD N
a DT N
three-wave JJ N
repeated JJ N
measures NNS N
with IN N
a DT N
between-subjects NNS N
factor NN N
( ( N
treatment NN N
group NN N
) ) N
. . N

Ninety-six JJ p
women NNS p
and CC p
their PRP$ p
96 CD p
partners NNS p
were VBD N
assigned VBN N
randomly RB N
to TO N
participate VB N
in IN N
one CD N
of IN N
three CD i
different JJ i
6-week JJ i
programs NNS i
: : i
( ( i
a DT i
) ) i
telephone NN i
interpersonal JJ i
counseling NN i
( ( i
TIP-C NNP i
) ) i
; : i
( ( i
b NN i
) ) i
self-managed JJ i
exercise NN i
; : i
or CC i
( ( i
c NN i
) ) i
attention NN i
control NN i
( ( i
AC NNP i
) ) i
. . i

RESULTS VB N
The DT N
mixed-model JJ N
analysis NN N
of IN N
variance NN N
for IN N
symptoms NNS o
of IN o
depression NN o
among IN N
women NNS p
with IN p
breast NN p
cancer NN p
revealed VBD N
women NNS o
's POS o
depressive JJ o
symptom NN o
scores NNS o
decreased VBN N
over IN N
time NN N
in IN N
all DT N
groups NNS N
. . N

For IN N
anxiety NN N
, , N
women NNS p
's POS p
symptoms NNS o
of IN o
anxiety NN o
decreased VBN N
in IN N
the DT N
TIP-C NNP i
and CC N
exercise NN N
groups NNS N
over IN N
time NN N
, , N
but CC N
not RB N
in IN N
the DT N
AC NNP N
group NN N
. . N

A DT N
parallel JJ N
set NN N
of IN N
analyses NNS N
was VBD N
conducted VBN N
on IN N
partners NNS o
' POS o
depression NN o
and CC o
anxiety NN o
data NNS o
. . o

Symptoms NNS N
of IN N
depression NN o
and CC o
anxiety NN o
among IN N
the DT N
partners NNS p
decreased VBD N
substantially RB N
over IN N
the DT N
course NN N
of IN N
the DT N
investigation NN N
. . N

Similar JJ N
to TO N
the DT N
women NNS p
, , p
partners NNS p
' POS p
symptoms NNS o
of IN o
anxiety NN o
decreased VBN N
significantly RB N
in IN N
the DT N
TIP-C NNP i
and CC N
exercise NN N
groups NNS N
, , N
but CC N
not RB N
in IN N
the DT N
AC NNP N
group NN N
. . N

DISCUSSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
support NN N
that IN N
these DT N
telephone-delivered JJ N
psychosocial NN N
interventions NNS N
were VBD N
effective JJ o
for IN N
decreasing VBG N
symptoms NNS o
of IN o
depression NN o
and CC o
anxiety NN o
to TO N
improve VB N
psychological JJ o
quality NN o
of IN o
life NN o
when WRB N
compared VBN N
to TO N
an DT N
AC NNP N
group NN N
. . N

-DOCSTART- -24637941- O O

Sorafenib NNP i
dose JJ N
escalation NN N
is VBZ N
not RB N
uniformly RB N
associated VBN N
with IN N
blood NN N
pressure NN N
elevations NNS N
in IN N
normotensive JJ p
patients NNS p
with IN p
advanced JJ p
malignancies NNS p
. . p

Hypertension NN N
after IN N
treatment NN N
with IN N
vascular JJ i
endothelial JJ i
growth NN i
factor NN i
( ( i
VEGF NNP i
) ) i
receptor NN N
inhibitors NNS N
is VBZ N
associated VBN N
with IN N
superior JJ N
treatment NN N
outcomes NNS N
for IN N
advanced JJ p
cancer NN p
patients NNS p
. . p

To TO N
determine VB N
whether IN N
increased JJ N
sorafenib NN i
doses NNS N
cause VBP N
incremental JJ N
increases NNS N
in IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , N
we PRP N
measured VBD N
12-h JJ N
ambulatory NN N
BP NNP N
in IN N
41 CD p
normotensive JJ p
advanced VBD p
solid JJ p
tumor NN p
patients NNS p
in IN N
a DT N
randomized JJ N
dose-escalation NN N
study NN N
. . N

After IN N
7 CD N
days NNS N
' POS N
treatment NN N
( ( N
400 CD N
mg NN N
b.i.d NN o
. . o

) ) o
, , o
mean JJ o
diastolic JJ o
BP NNP o
( ( o
DBP NNP o
) ) o
increased VBD o
in IN N
both DT N
study NN N
groups NNS N
. . N

After IN N
dose JJ N
escalation NN N
, , N
group NN N
A NNP N
( ( N
400 CD N
mg NN N
t.i.d NN N
. . N

) ) N
had VBD N
marginally RB N
significant JJ N
further JJ N
increase NN o
in IN o
12-h JJ o
mean NN o
DBP NNP o
( ( N
P NNP N
= NNP N
0.053 CD N
) ) N
, , N
but CC N
group NN N
B NNP N
( ( N
600 CD N
mg NN N
b.i.d NN N
. . N

) ) N
did VBD N
not RB N
achieve VB N
statistically RB N
significant JJ N
increases NNS N
( ( N
P NNP N
= NNP N
0.25 CD N
) ) N
. . N

Within IN N
groups NNS N
, , N
individuals NNS N
varied VBD N
in IN o
BP NNP o
response NN o
to TO o
sorafenib VB o
dose JJ N
escalation NN N
, , N
but CC N
these DT N
differences NNS N
did VBD N
not RB N
correlate VB N
with IN N
changes NNS N
in IN N
steady-state JJ N
plasma NN N
sorafenib NN i
concentrations NNS i
. . N

These DT N
findings NNS p
in IN p
normotensive JJ p
patients NNS p
suggest VBP o
BP NNP o
is VBZ o
a DT N
complex JJ N
pharmacodynamic JJ N
biomarker NN N
of IN N
VEGF NNP N
inhibition NN N
. . N

Patients NNS N
have VBP N
intrinsic JJ N
differences NNS N
in IN N
sensitivity NN N
to TO N
sorafenib VB N
's POS N
BP-elevating JJ N
effects NNS N
. . N

-DOCSTART- -15307010- O O

Once-daily JJ N
versus NN N
twice-daily RB N
lamivudine NN i
, , i
in IN i
combination NN i
with IN i
zidovudine NN i
and CC i
efavirenz NN i
, , N
for IN N
the DT N
treatment NN N
of IN N
antiretroviral-naive JJ p
adults NNS p
with IN p
HIV NNP p
infection NN p
: : p
a DT N
randomized JJ N
equivalence NN o
trial NN N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
controlled VBN N
, , N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
that IN N
involved VBD N
554 CD p
antiretroviral-naive JJ p
human JJ p
immunodeficiency NN p
virus-infected JJ p
adults NNS p
( ( p
plasma JJ p
HIV NNP p
type NN p
1 CD p
[ JJ p
HIV-1 NNP p
] NNP p
RNA NNP p
level NN p
, , p
> NNP p
or=400 VBZ p
copies/mL NN p
; : p
CD4 NNP p
( ( p
+ NNP p
) ) p
cell NN p
count NN p
, , p
> VBZ p
100 CD p
cells/mm NN p
( ( p
3 CD p
) ) p
) ) p
and CC p
compared VBN p
a DT p
300-mg JJ p
once-daily JJ p
( ( p
q.d JJ p
. . p

) ) p
regimen NNS p
of IN p
lamivudine NN i
( ( i
3TC CD i
) ) i
versus NN p
a DT p
150-mg JJ p
twice-daily JJ p
( ( p
b.i.d NN p
. . p

) ) p
regimen NNS p
of IN p
3TC CD i
, , i
combined VBN i
with IN i
zidovudine NN i
( ( i
300 CD i
mg NN i
b.i.d NN i
. . i

) ) i
and CC i
efavirenz $ i
( ( p
600 CD p
mg NN p
q.d NN p
. . p

) ) p
, , p
during IN p
a DT p
48-week JJ p
period NN p
. . p

Treatments NNS N
were VBD N
considered VBN N
equivalent JJ o
if IN N
the DT N
95 CD o
% NN o
confidence NN o
interval NN o
( ( o
CI NNP o
) ) o
for IN N
the DT N
difference NN N
in IN N
proportions NNS o
of IN o
patients NNS o
achieving VBG o
an DT o
HIV-1 JJ o
RNA NNP o
level NN o
of IN o
< $ o
400 CD o
copies/mL NN o
was VBD N
within IN N
the DT N
bound NN N
of IN N
-12 NN N
% NN N
to TO N
12 CD N
% NN N
. . N

At IN N
week NN N
48 CD N
of IN N
the DT N
study NN N
, , N
an DT N
intent-to-treat JJ N
analysis NN N
in IN N
which WDT N
patients NNS N
with IN N
missing VBG N
data NNS N
were VBD N
considered VBN N
to TO N
have VB N
experienced VBN N
treatment NN N
failure NN o
showed VBD N
that IN N
the DT N
3TC CD i
q.d NN N
. . N

and CC N
3TC CD i
b.i.d NN N
. . N

regimens NNS N
were VBD N
equivalent JJ N
( ( N
HIV-1 NNP N
RNA NNP N
level NN N
< VBD N
400 CD N
copies/mL NN N
, , N
178 CD N
[ JJ N
64 CD N
% NN N
] NN N
of IN N
278 CD N
vs. FW N
174 CD N
[ $ N
63 CD N
% NN N
] NN N
of IN N
276 CD N
; : N
treatment NN N
difference NN N
, , N
1 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
-7.1 NNP N
% NN N
to TO N
8.9 CD N
% NN N
] NN N
; : N
HIV-1 NNP N
RNA NNP N
level NN N
< VBD N
50 CD N
copies/mL NN N
, , N
165 CD N
[ JJ N
59 CD N
% NN N
] NN N
of IN N
278 CD N
vs. FW N
168 CD N
[ $ N
61 CD N
% NN N
] NN N
of IN N
276 CD N
; : N
treatment NN N
difference NN N
, , N
1.7 CD N
% NN N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
-9.7 NNP N
% NN N
to TO N
6.6 CD N
% NN N
] NN N
) ) N
. . N

Median JJ o
increase NN o
above IN o
baseline NN o
in IN o
CD4 NNP o
( ( o
+ NNP o
) ) o
cell NN o
count NN o
was VBD N
similar JJ N
( ( N
q.d JJ N
. . N

group NN N
, , N
+144 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
; : N
b.i.d NN N
. . N

group NN N
, , N
+146 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
) ) N
, , N
and CC N
the DT N
incidences NNS o
of IN o
adverse JJ o
events NNS o
, , o
disease NN o
progression NN o
, , o
and CC o
HIV-associated JJ o
conditions NNS o
were VBD N
comparable JJ N
. . N

-DOCSTART- -19368912- O O

What WP N
is VBZ N
the DT N
optimum JJ N
maximal JJ N
gonadotropin NN i
dosage NN N
used VBN N
in IN N
microdose JJ p
flare-up JJ p
cycles NNS p
in IN p
poor JJ p
responders NNS p
? . N
OBJECTIVE NNP N
To TO N
find VB N
out RP N
the DT N
optimum JJ N
maximal JJ N
dosage NN N
of IN N
recombinant JJ i
follicle NN i
stimulating VBG i
hormone NN i
( ( i
rFSH NN i
) ) i
in IN N
microdose JJ p
gonadotropin-releasing JJ i
hormone NN i
analog NN i
( ( i
GnRH-a NNP i
) ) i
flare NN p
cycles NNS p
in IN p
poor JJ p
responders NNS p
. . p

DESIGN NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Private NNP N
infertility NN N
clinic NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
A NNP N
total NN p
of IN p
119 CD p
women NNS p
were VBD N
taken VBN N
into IN N
the DT N
study NN N
. . N

INTERVENTION NNP N
( ( N
S NNP N
) ) N
The DT N
study NN N
group NN N
underwent VBD N
a DT N
microdose JJ N
protocol NN N
with IN N
a DT N
GnRH-agonist JJ i
followed VBN i
by IN i
rFSH JJ i
administration NN i
. . i

On IN N
the DT N
third JJ N
day NN N
of IN N
GnRH-a NNP i
administration NN N
, , N
119 CD p
patients NNS p
were VBD N
randomized VBN N
in IN N
three CD N
groups NNS N
to TO N
receive VB N
daily JJ N
fixed VBN N
doses NNS N
of IN N
300 CD N
IU NNP N
of IN N
rFSH NN i
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
38 CD N
) ) N
, , N
or CC N
450 CD N
IU NNP N
of IN N
rFSH NN i
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
39 CD N
) ) N
, , N
or CC N
600 CD N
IU NNP N
of IN N
rFSH NN i
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
42 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Peak NNP o
E NNP o
( ( o
2 CD o
) ) o
levels NNS o
, , o
days NNS o
of IN o
stimulation NN o
with IN o
rFSH NN o
, , o
total JJ o
rFSH NN o
dosage NN o
, , o
total JJ o
number NN o
of IN o
oocytes NNS o
retrieved VBN o
, , o
M2 NNP o
oocytes VBZ o
retrieved VBN o
, , o
total JJ o
number NN o
of IN o
embryos NN o
, , o
number NN o
of IN o
embryos NN o
transferred VBN o
, , o
number NN o
of IN o
Grade-1 NNP o
embryos NN o
transferred VBD o
, , o
clinical JJ o
pregnancy NN o
rate NN o
( ( o
positive JJ o
fetal JJ o
cardiac JJ o
activity NN o
) ) o
, , o
and CC o
cancellation NN o
rates NNS o
of IN o
stimulation NN o
and CC o
embryo NN o
transfer NN o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
Clinical NNP o
pregnancy NN o
rates NNS o
were VBD N
13.1 CD N
% NN N
, , N
15.3 CD N
% NN N
, , N
and CC N
16.1 CD N
% NN N
for IN N
group NN N
A NNP N
, , N
group NN N
B NNP N
, , N
and CC N
group NN N
C NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
age NN N
, , N
peak JJ o
serum NN o
E NNP o
( ( o
2 CD o
) ) o
concentration NN o
, , o
days NNS o
of IN o
stimulation NN o
with IN o
rFSH NN o
, , o
total JJ o
number NN o
of IN o
M2 NNP o
oocytes VBZ o
retrieved VBN o
, , o
number NN o
of IN o
embryos NN o
transferred VBN o
, , o
clinical JJ o
pregnancy NN o
rates NNS o
, , o
and CC o
cancellation NN o
rates NNS o
of IN N
stimulation NN N
and CC N
embryo NN N
transfer NN N
between IN N
the DT N
three CD N
groups NNS N
except IN N
for IN N
total JJ N
rFSH JJ i
dosage NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
There EX N
is VBZ N
no DT N
need NN N
to TO N
use VB N
doses NNS N
above IN N
300 CD N
IU NNP N
of IN N
rFSH NN i
to TO N
increase VB N
the DT N
pregnancy NN N
rate NN N
in IN N
microdose JJ N
cycles NNS N
. . N

In IN N
addition NN N
, , N
because IN N
the DT N
duration NN N
of IN N
stimulation NN N
does VBZ N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
the DT N
usage NN N
of IN N
300 CD N
IU NNP N
rFSH NN i
in IN N
microdose JJ N
cycles NNS N
results NNS N
in IN N
less JJR N
total JJ N
amount NN N
of IN N
rFSH NN i
consumed VBN N
in IN N
a DT N
cycle NN N
compared VBN N
with IN N
higher JJR N
dosages NNS N
, , N
and CC N
this DT N
would MD N
obviously RB N
cost VB N
less JJR N
money NN N
to TO N
the DT N
patients NNS N
. . N

-DOCSTART- -21418212- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
Hanen NNP i
's POS i
'More JJR i
Than NNP i
Words NNP i
' POS i
in IN N
toddlers NNS p
with IN p
early JJ p
autism NN p
symptoms NNS p
. . p

BACKGROUND NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
compared VBN N
Hanen NNP i
's POS i
'More JJR i
than IN i
Words NNS i
' POS i
( ( i
HMTW NNP i
) ) i
, , i
a DT i
parent-implemented JJ i
intervention NN i
, , N
to TO N
a DT N
'business NN i
as IN i
usual JJ i
' POS i
control NN i
group NN N
. . N

METHODS NNP N
Sixty-two JJ p
children NNS p
( ( p
51 CD p
boys NNS p
and CC p
11 CD p
girls NNS p
; : p
M NNP p
age NN p
= VBD p
20 CD p
months NNS p
; : p
SD NNP p
= NNP p
2.6 CD p
) ) p
who WP p
met VBD p
criteria NNS p
for IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC p
their PRP$ p
parents NNS p
participated VBN p
in IN p
the DT p
study NN p
. . p

The DT N
HMTW NNP i
intervention NN i
was VBD N
provided VBN N
over IN N
3.5 CD N
months NNS N
. . N

There EX N
were VBD N
three CD N
measurement NN N
periods NNS N
: : N
prior RB i
to TO i
randomization NN i
( ( i
Time NNP i
1 CD i
) ) i
and CC i
at IN i
5 CD i
and CC i
9 CD i
months NNS i
post VBN i
enrollment NN i
( ( i
Times NNP i
2 CD i
and CC i
3 CD i
) ) i
. . i

Children NNP o
's POS o
communication NN o
and CC o
parental JJ o
responsivity NN o
were VBD i
measured VBN i
at IN i
each DT i
time NN i
point NN i
. . i

Children NNP o
's POS o
object JJ o
interest NN o
, , o
a DT o
putative JJ o
moderator NN o
, , i
was VBD i
measured VBN i
at IN i
Time NNP i
1 CD i
. . i

RESULTS VB N
There EX N
were VBD N
no DT N
main JJ N
effects NNS N
of IN N
the DT N
HMTW NNP i
intervention NN N
on IN N
either DT N
parental JJ o
responsivity NN o
or CC N
children NNS o
's POS o
communication NN o
. . o

However RB N
, , N
the DT N
effects NNS N
on IN N
residualized JJ N
gains NNS N
in IN N
parental JJ o
responsivity NN o
from IN N
Time NNP N
1 CD N
to TO N
both DT N
Times NNP N
2 CD N
and CC N
3 CD N
yielded VBN N
noteworthy JJ N
effect NN N
sizes NNS N
( ( N
Glass NNP N
's POS N
? . N
= JJ N
.71 NN N
, , N
.50 NNP N
respectively RB N
) ) N
. . N

In IN N
contrast NN N
, , N
there EX N
were VBD N
treatment NN N
effects NNS N
on IN o
child JJ o
communication NN o
gains NNS N
to TO N
Time VB N
3 CD N
that WDT N
were VBD N
moderated VBN N
by IN N
children NNS N
's POS N
Time NNP N
1 CD N
object JJ N
interest NN N
. . N

Children NNP N
with IN N
lower JJR N
levels NNS N
of IN N
Time NNP N
1 CD N
object JJ o
interest NN o
exhibited VBN N
facilitated JJ N
growth NN N
in IN o
communication NN o
; : o
children NNS N
with IN N
higher JJR N
levels NNS N
of IN o
object JJ o
interest NN o
exhibited VBD o
growth NN o
attenuation NN o
. . o

CONCLUSIONS VB N
The DT i
HMTW NNP i
intervention NN N
showed VBD N
differential JJ N
effects NNS N
on IN o
child NN o
communication NN o
depending VBG N
on IN N
a DT N
baseline NN N
child NN N
factor NN N
. . N

HMTW NNP i
facilitated VBD o
communication NN o
in IN N
children NNS N
with IN N
lower JJR N
levels NNS N
of IN N
Time NNP N
1 CD N
object JJ N
interest NN N
. . N

Parents NNS p
of IN p
children NNS p
who WP p
evidence NN p
higher JJR o
object JJ o
interest NN o
may MD N
require VB N
greater JJR N
support NN N
to TO N
implement VB N
the DT i
HMTW NNP i
strategies NNS N
, , N
or CC N
may MD N
require VB N
different JJ N
strategies NNS N
than IN N
those DT N
provided VBN N
by IN N
the DT i
HMTW NNP i
curriculum NN N
. . N

-DOCSTART- -26510263- O O

Effects NNS N
of IN N
propofol NN N
and CC N
isoflurane NN N
on IN N
haemodynamics NNS o
and CC o
the DT o
inflammatory JJ o
response NN o
in IN N
cardiopulmonary JJ N
bypass NN N
surgery NN N
. . N

Cardiopulmonary JJ p
bypass NN p
( ( p
CPB NNP p
) ) p
causes VBZ N
reperfusion JJ N
injury NN N
that IN N
when WRB N
most JJS N
severe JJ N
is VBZ N
clinically RB N
manifested VBN N
as IN N
a DT N
systemic JJ N
inflammatory NN N
response NN N
syndrome NN N
. . N

The DT N
anaesthetic JJ N
propofol NN N
may MD N
have VB N
anti-inflammatory JJ N
properties NNS N
that WDT N
may MD N
reduce VB N
such PDT N
a DT N
response NN N
. . N

We PRP N
hypothesised VBD N
differing VBG N
effects NNS N
of IN N
propofol NN N
and CC N
isoflurane NN N
on IN N
inflammatory JJ o
markers NNS o
in IN N
patients NNS p
having VBG p
CBR NNP p
Forty NNP p
patients NNS p
undergoing VBG p
elective JJ p
CPB NNP p
were VBD p
randomised VBN i
to TO i
receive VB i
either DT i
propofol NN i
or CC i
isoflurane NN i
for IN i
maintenance NN i
of IN i
anaesthesia NN i
. . i

CRP NNP o
, , o
IL-6 NNP o
, , o
IL-8 NNP o
, , o
HIF-1? NNP o
( ( o
ELISA NNP o
) ) o
, , o
CD11 NNP o
and CC o
CD18 NNP o
expression NN o
( ( o
flow JJ o
cytometry NN o
) ) o
, , o
and CC o
haemoxygenase NN o
( ( o
HO-1 NNP o
) ) o
promoter NN o
polymorphisms NN o
( ( o
PCR/electrophoresis NNP o
) ) o
were VBD N
measured VBN N
before IN N
anaesthetic JJ N
induction NN N
, , N
4 CD N
hours NNS N
post-CPB JJ N
, , N
and CC N
24 CD N
hours NNS N
later RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
4 CD N
hours NNS N
changes NNS N
in IN o
CRP NNP o
, , o
IL-6 NNP o
, , o
IL-8 NNP o
or CC o
CD18 NNP o
between IN N
the DT N
two CD N
groups NNS N
, , N
but CC N
those DT N
in IN N
the DT p
propofol NN p
group NN p
had VBD N
higher JJR o
HIF-1? NNP o
( ( o
P NNP N
= NNP N
0.016 CD N
) ) N
and CC N
lower JJR o
CD11 NNP o
expression NN o
( ( o
P NNP N
= NNP N
0.026 CD N
) ) N
. . N

After IN N
24 CD N
hours NNS N
, , N
compared VBN N
to TO N
the DT p
isoflurane NN p
group NN p
, , p
the DT p
propofol NN p
group NN p
had VBD p
significantly RB N
lower JJR N
levels NNS N
of IN N
CRP NNP o
( ( o
P NNP N
< NNP N
0.001 CD o
) ) o
, , o
IL-6 NNP o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
and CC o
IL-8 NNP o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
with IN N
higher JJR N
levels NNS o
CD11 NNP o
( ( o
P NNP N
= NNP N
0.009 CD N
) ) N
and CC o
CD18 NNP o
( ( o
P NNP N
= NNP N
0.002 CD N
) ) N
expression NN N
. . N

After IN N
24 CD N
hours NNS p
, , p
patients NNS p
on IN p
propofol NN p
had VBD p
increased VBN o
expression NN o
of IN o
shorter JJR o
HO-1 NNP o
GT NNP o
( ( o
n NN o
) ) o
repeats NNS o
than IN o
patients NNS p
on IN p
isoflurane NN p
( ( p
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Use NN N
of IN N
propofol NN N
in IN N
CPB NNP N
is VBZ N
associated VBN N
with IN N
a DT N
less JJR N
adverse JJ N
inflammatory NN N
profile NN N
than IN N
is VBZ N
isofluorane JJ N
, , N
and CC N
an DT N
increased VBN N
up-regulation NN N
of IN N
HO-1 NNP o
. . o

This DT N
supports VBZ N
the DT N
hypothesis NN N
that WDT N
propofol NN N
has VBZ N
anti-inflammatory JJ N
activity NN N
. . N

-DOCSTART- -15364709- O O

Further JJ N
evaluation NN N
of IN N
docosahexaenoic JJ i
acid NN i
in IN N
patients NNS p
with IN p
retinitis NN p
pigmentosa NN p
receiving VBG p
vitamin IN i
A NNP i
treatment NN p
: : p
subgroup NN N
analyses NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
docosahexaenoic JJ i
acid NNS i
will MD N
slow VB N
the DT N
course NN N
of IN N
retinal JJ N
degeneration NN N
in IN N
subgroups NNS N
of IN N
patients NNS p
with IN p
retinitis NN p
pigmentosa NN p
who WP p
are VBP p
receiving VBG p
vitamin IN i
A NNP i
. . i

DESIGN NNP N
A NNP N
cohort NN N
of IN N
208 CD p
patients NNS p
with IN p
retinitis NN p
pigmentosa NN p
, , p
aged VBD p
18 CD p
to TO p
55 CD p
years NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
1200 CD N
mg NN N
of IN N
docosahexaenoic NN i
acid NN i
plus CC i
15 CD i
000 CD i
IU/d NNP i
of IN i
vitamin NN i
A NNP i
given VBN i
as IN i
retinyl NN i
palmitate NN i
( ( i
DHA NNP i
+ VBZ i
A NNP i
group NN i
) ) i
or CC i
control VB i
fatty JJ i
acid JJ i
plus CC i
15 CD i
000 CD i
IU/d NNP i
of IN i
vitamin NN i
A NNP i
( ( i
control NN i
+ VBZ i
A NNP i
group NN i
) ) i
and CC N
followed VBD N
up RB N
over IN N
4 CD N
years NNS N
. . N

Seventy NNP p
percent NN p
of IN p
the DT p
patients NNS p
in IN p
each DT p
group NN p
were VBD p
taking VBG p
vitamin NN i
A NNP i
, , p
15 CD p
000 CD p
IU/d NNP p
, , p
prior RB p
to TO p
entry NN p
. . p

We PRP N
compared VBN N
rates NNS N
of IN N
decline NN N
in IN N
ocular JJ N
function NN N
in IN N
the DT N
DHA NNP i
+ VBZ i
A NNP i
vs NN N
control NN i
+ VBZ i
A DT i
groups NNS N
among IN N
the DT N
subgroups NNS N
defined VBN N
by IN N
use NN N
or CC N
nonuse NN N
of IN N
vitamin NN i
A NNP i
prior RB N
to TO N
entry NN N
. . N

We PRP N
also RB N
determined VBD N
whether IN N
decline NN N
in IN N
ocular JJ N
function NN N
was VBD N
related VBN N
to TO N
red JJ N
blood NN N
cell NN N
phosphatidylethanolamine NN N
docosahexaenoic NN N
acid JJ N
level NN N
, , N
dietary JJ N
omega-3 JJ N
fatty JJ N
acid NNS N
intake VBP N
, , N
or CC N
duration NN N
of IN N
vitamin NN N
A NNP N
use NN N
. . N

Main NNP N
outcome JJ N
measures NNS N
were VBD N
Humphrey NNP o
Field NNP o
Analyzer NNP o
visual JJ o
field NN o
sensitivity NN o
, , o
30-Hz JJ o
electroretinogram NN o
amplitude NN o
, , o
and CC o
visual JJ o
acuity NN o
. . o

RESULTS NNP N
Among IN N
patients NNS N
not RB i
taking VBG i
vitamin RP i
A DT i
prior JJ N
to TO N
entry NN N
, , N
those DT N
in IN N
the DT N
DHA NNP i
+ NNP i
A NNP i
group NN N
had VBD N
a DT N
slower JJR N
decline NN N
in IN N
field NN o
sensitivity NN o
and CC o
electroretinogram NN o
amplitude NN o
than IN N
those DT N
in IN N
the DT N
control NN i
+ VBZ i
A NNP i
group NN N
over IN N
the DT N
first JJ N
2 CD N
years NNS N
( ( N
P NNP N
=.01 NNP N
and CC N
P NNP N
=.03 NNP N
, , N
respectively RB N
) ) N
; : N
these DT N
differences NNS N
were VBD N
not RB N
observed VBN N
in IN N
years NNS N
3 CD N
and CC N
4 CD N
of IN N
follow-up JJ N
or CC N
among IN N
patients NNS N
taking VBG N
vitamin NN i
A NNP i
prior RB N
to TO N
entry NN N
. . N

In IN N
the DT N
entire JJ N
cohort NN N
, , N
red JJ N
blood NN N
cell NN N
phosphatidylethanolamine NN N
docosahexaenoic NN i
acid IN i
level NN N
was VBD N
inversely RB N
related VBN N
to TO N
rate NN N
of IN N
decline NN N
in IN N
total JJ o
field NN o
sensitivity NN o
over IN N
4 CD N
years NNS N
( ( N
test NN N
for IN N
trend NN N
, , N
P NNP N
=.05 NNP N
) ) N
. . N

This DT N
was VBD N
particularly RB N
evident JJ N
over IN N
the DT N
first JJ N
2 CD N
years NNS N
among IN N
those DT N
not RB i
on IN i
vitamin NN i
A NNP i
prior RB N
to TO N
entry NN N
( ( N
test NN N
for IN N
trend NN N
, , N
P NNP N
=.003 NNP N
) ) N
. . N

In IN N
the DT N
entire JJ N
control NN i
+ VBZ i
A NNP i
group NN N
, , N
dietary JJ i
omega-3 JJ i
fatty JJ i
acid NNS i
intake NN N
was VBD N
inversely RB N
related VBN N
to TO N
loss NN N
of IN N
total JJ o
field NN o
sensitivity NN o
over IN N
4 CD N
years NNS N
( ( N
intake VB N
, , N
< VB N
0.20 CD N
vs JJ N
> NN N
or CC N
=0.20 JJ N
g/d NN N
; : N
P NNP N
=.02 NNP N
) ) N
. . N

The DT N
duration NN o
of IN o
vitamin NN o
A DT o
supplementation NN o
prior RB N
to TO N
entry NN N
was VBD N
inversely RB N
related VBN N
to TO N
rate NN N
of IN N
decline NN N
in IN N
electroretinogram JJ N
amplitude NN N
( ( N
P NNP N
=.008 NNP N
) ) N
. . N

CONCLUSIONS NNP N
For IN N
patients NNS p
with IN p
retinitis NN p
pigmentosa NN p
beginning VBG N
vitamin IN i
A NNP i
therapy NN i
, , N
addition NN N
of IN N
docosahexaenoic NN i
acid NN i
, , N
1200 CD N
mg/d NN N
, , N
slowed VBD N
the DT N
course NN N
of IN N
disease NN N
for IN N
2 CD N
years NNS N
. . N

Among IN N
patients NNS p
on IN p
vitamin NN i
A NN i
for IN p
at IN p
least JJS p
2 CD p
years NNS p
, , N
a DT N
diet JJ N
rich JJ N
in IN N
omega-3 JJ i
fatty JJ i
acids NNS i
( ( N
> CD N
or CC N
=0.20 VB N
g/d NN N
) ) N
slowed VBD N
the DT N
decline NN N
in IN N
visual JJ N
field NN N
sensitivity NN N
. . N

-DOCSTART- -22727707- O O

Rosiglitazone NN i
and CC N
cognitive JJ N
function NN N
in IN N
clozapine-treated JJ i
patients NNS p
with IN p
schizophrenia NN p
: : p
a DT N
pilot NN N
study NN N
. . N

Studies NNS N
have VBP N
shown VBN N
that IN N
insulin NN N
resistance NN N
is VBZ N
associated VBN N
with IN N
cognitive JJ N
impairment NN N
. . N

Peroxisome VB i
proliferator-activated JJ i
receptor-? NN i
( ( i
PPAR-? NNP i
) ) i
agonists VBZ i
improve JJ N
insulin NN N
sensitivity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT o
effect NN o
of IN o
rosiglitazone NN o
, , o
a DT N
PPAR-? JJ N
agonist NN N
, , N
on IN N
cognition NN N
in IN N
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
. . p

In IN p
an DT N
eight-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
pilot NN N
trial NN p
, , p
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
were VBD p
randomized VBN N
to TO N
receive VB i
rosiglitazone NN i
( ( i
4mg/day CD i
) ) i
or CC i
placebo NN i
. . i

A DT i
neuropsychological JJ N
battery NN N
including VBG o
the DT o
Digit NNP o
Span NNP o
subtest JJS o
from IN o
the DT o
Wechsler NNP o
Adult NNP o
Intelligence NNP o
Scale-III NNP o
( ( o
WAIS-III NNP o
) ) o
, , o
the DT o
verbal JJ o
fluency NN o
test NN o
, , o
the DT o
Hopkins NNP o
Verbal NNP o
Learning NNP o
Test NNP o
( ( o
HVLT NNP o
) ) o
, , o
the DT o
Trail-Making JJ o
Test NNP o
( ( o
TMT NNP o
) ) o
and CC o
the DT o
Wisconsin NNP o
Card NNP o
Sorting NNP o
Test NNP o
( ( o
WCST NNP o
) ) o
was VBD o
administered VBN N
at IN N
baseline NN N
and CC N
week NN N
eight CD p
. . p

Nineteen JJ p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

There EX p
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
any DT N
demographic JJ o
or CC o
general JJ o
clinical JJ o
variables NNS o
between IN o
the DT N
rosiglitazone NN i
group NN i
( ( p
n=9 CC p
) ) p
and CC p
the DT p
placebo NN i
group NN i
( ( p
n=10 RB p
) ) p
. . p

When WRB p
baseline NN N
scores NNS N
were VBD N
controlled VBN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
change NN N
scores NNS N
of IN N
cognitive JJ o
performance NN o
over IN o
eight CD N
weeks NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
this DT N
pilot NN N
study NN i
, , i
rosiglitazone NN i
had VBD i
no DT N
cognitive JJ o
benefit NN o
in IN o
clozapine-treated JJ p
patients NNS p
with IN p
schizophrenia NN p
. . p

Future JJ p
studies NNS N
with IN N
longer JJR N
treatment NN N
duration NN N
and CC N
larger JJR N
sample NN N
size NN N
are VBP N
needed VBN N
to TO N
further RBR N
explore VB N
the DT N
potential JJ N
role NN N
of IN N
rosiglitazone NN i
in IN i
improving VBG N
cognitive JJ N
function NN N
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

-DOCSTART- -14514742- O O

Improved VBN N
acidosis NN N
correction NN N
and CC N
recovery NN N
of IN N
mesothelial JJ N
cell NN N
mass NN N
with IN N
neutral-pH JJ i
bicarbonate JJ i
dialysis NN i
solution NN i
among IN N
children NNS p
undergoing VBG p
automated VBN i
peritoneal JJ i
dialysis NN i
. . i

Acid-base JJ N
balance NN N
and CC N
peritoneal JJ N
membrane NN N
longevity NN N
are VBP N
of IN N
utmost JJ N
relevance NN N
for IN N
pediatric JJ p
patients NNS p
undergoing VBG p
peritoneal JJ i
dialysis NN i
( ( i
PD NNP i
) ) i
. . i

PD NNP N
fluids NNS N
with IN N
neutral JJ N
pH NN N
and CC N
reduced VBD N
glucose JJ N
degradation NN N
product NN N
contents NNS N
are VBP N
considered VBN N
more RBR N
biocompatible JJ N
, , N
because IN N
they PRP N
preserve VBP N
peritoneal JJ N
cell NN N
functions NNS N
in IN N
vitro NN N
. . N

To TO N
investigate VB N
the DT N
clinical JJ N
effects NNS o
of IN N
a DT N
novel JJ i
PD NNP i
fluid NN i
buffered VBD i
with IN i
34 CD i
mM NNS i
pure JJ i
bicarbonate NN i
at IN i
neutral JJ i
pH NN i
, , N
a DT N
randomized VBN N
, , N
prospective JJ N
, , N
crossover JJ N
comparison NN N
with IN N
conventional JJ i
, , i
acidic JJ i
, , i
35 CD i
mM NN i
lactate NN i
PD NNP i
fluid NN i
was VBD N
performed VBN N
for IN N
two CD N
consecutive JJ N
12-wk JJ N
periods NNS N
with IN N
28 CD p
children NNS p
( ( p
age NN p
, , p
6 CD p
mo NN p
to TO p
15 CD p
yr NN p
) ) p
undergoing NN p
automated VBN i
PD NNP i
( ( i
APD NNP i
) ) i
. . i

Blood NNP o
bicarbonate NN o
levels NNS o
and CC o
arterial JJ o
pH NN o
were VBD N
significantly RB N
higher JJR o
after IN N
3 CD N
mo NN N
of IN N
bicarbonate NN o
PD NNP o
( ( N
24.6 CD N
+/- JJ N
2.3 CD N
mM NN N
and CC N
7.43 CD N
+/- JJ N
0.06 CD N
, , N
respectively RB N
) ) N
, , N
compared VBN N
with IN N
lactate JJ o
PD NNP o
( ( N
22.8 CD N
+/- JJ N
3.9 CD N
mM NN N
and CC N
7.38 CD N
+/- JJ N
0.05 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
effect NN N
was VBD N
reversible JJ N
among IN N
patients NNS N
who WP N
returned VBD N
from IN N
bicarbonate NN N
to TO N
lactate VB N
fluid NN N
. . N

Low JJ N
initial JJ o
pH NN o
and CC N
young JJ N
patient NN N
age NN N
independently RB N
predicted VBD N
increased VBN N
blood NN o
pH NN o
during IN N
bicarbonate NN o
APD NNP o
. . o

Peritoneal NNP N
equilibration NN N
tests NNS N
revealed VBD N
subtle JJ o
changes NNS o
in IN o
solute NN o
transport NN o
, , N
with IN N
a DT N
less RBR o
steep JJ o
creatinine NN o
equilibration NN o
curve NN o
during IN N
bicarbonate JJ N
dialysis NN N
, , N
suggesting VBG N
reduced VBN N
peritoneal JJ N
vasodilation NN N
. . N

The DT N
peritoneal JJ o
release NN o
of IN o
carcinogen JJ o
antigen-125 NNS o
increased VBD o
twofold NN N
during IN N
bicarbonate NN N
APD NNP N
( ( N
29 CD N
+/- JJ N
15 CD N
versus NN N
15 CD N
+/- JJ N
8 CD N
U/ml NNP N
per IN N
4 CD N
h NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
recovery NN N
of IN N
the DT N
mesothelial JJ N
cell NN N
layer NN N
. . N

This DT N
effect NN N
was VBD N
fully RB N
reversed VBN N
when WRB N
the DT N
patients NNS N
returned VBD N
to TO N
lactate VB N
fluid NN N
. . N

Effluent JJ o
carcinogen NN o
antigen-125 JJ o
levels NNS o
were VBD N
inversely RB N
correlated VBN N
with IN N
peritoneal JJ N
glucose JJ N
exposure NN N
during IN N
lactate NN N
but CC N
not RB N
bicarbonate VB N
APD NNP N
, , N
indicating VBG N
improved VBN N
in IN N
vivo JJ N
mesothelial NN N
cell NN N
tolerance NN N
of IN N
high-dose JJ N
glucose NN N
with IN N
the DT N
neutral-pH JJ i
PD NNP i
fluid NN i
with IN i
reduced VBN i
glucose JJ i
degradation NN i
product NN i
content NN i
. . i

Among IN N
children NNS p
undergoing VBG p
APD NNP i
, , i
neutral-pH JJ i
, , i
bicarbonate-buffered JJ i
PD NNP i
fluid NN i
provides VBZ N
more RBR N
effective JJ N
correction NN N
of IN N
metabolic JJ N
acidosis NN N
and CC N
better JJR N
preservation NN N
of IN N
peritoneal NN N
cell NN N
mass NN N
than IN N
do VBP N
conventional JJ i
, , i
acidic JJ i
, , i
lactate-based JJ i
fluids NNS i
. . i

-DOCSTART- -21596605- O O

Poor NNP N
self-rated JJ N
health NN N
is VBZ N
not RB N
associated VBN N
with IN N
a DT N
high JJ N
total JJ N
allostatic JJ N
load NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
-- : p
but CC p
high JJ N
blood NN N
pressure NN N
is VBZ N
. . N

OBJECTIVE NNP N
Allostatic NNP N
load NN N
has VBZ N
been VBN N
linked VBN N
to TO N
self-rated JJ N
health NN N
( ( N
SRH NNP N
) ) N
, , N
cardiovascular JJ N
disease NN N
and CC N
mortality NN N
in IN N
non-diabetic JJ p
individuals NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
construct VB N
an DT N
allostatic JJ N
load NN N
score NN N
and CC N
to TO N
find VB N
any DT N
correlations NNS N
with IN N
SRH NNP N
. . N

METHODS NNP N
The DT N
subjects NNS p
included VBN p
in IN p
the DT p
study NN p
came VBD p
from IN p
a DT p
randomized VBN p
, , p
controlled VBD p
trial NN p
of IN p
type NN p
2 CD p
diabetes NNS p
. . p

Blood NN N
samples NNS N
were VBD N
drawn VBN N
, , N
urine NN N
was VBD N
collected VBN N
for IN N
24h CD N
, , N
and CC N
questionnaires NNS N
, , N
including VBG N
SRH NNP N
, , N
were VBD N
filled VBN N
out RP N
on IN N
three CD N
occasions NNS N
: : N
at IN N
baseline NN N
; : N
after IN N
the DT N
10-week JJ N
intervention NN N
; : N
and CC N
at IN N
a DT N
follow-up JJ N
3 CD N
months NNS N
after IN N
the DT N
intervention NN N
. . N

Allostatic JJ N
load NN N
was VBD N
estimated VBN N
using VBG N
a DT N
wide JJ N
range NN N
of IN N
variables NNS N
, , N
including VBG N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
pulse JJ o
pressure NN o
, , o
cortisol NN o
, , o
catecholamines NNS o
, , o
HbA NNP o
( ( o
1c CD o
) ) o
, , o
insulin NN o
, , o
plasma VBP o
glucose JJ o
and CC o
waist JJ o
circumference NN o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
association NN N
between IN N
SRH NNP N
and CC N
allostatic JJ N
load NN N
. . N

However RB N
, , N
three CD N
other JJ N
components NNS N
were VBD N
significantly RB N
correlated VBN N
with IN N
allostatic JJ N
load NN N
at IN N
the DT N
baseline NN N
investigation NN N
and CC N
the DT N
two CD N
follow-up JJ N
investigations NNS N
- : N
namely RB N
, , N
systolic JJ o
blood NN o
pressure NN o
, , o
diastolic JJ o
blood NN o
pressure NN o
and CC o
HbA NNP o
( ( o
1c CD o
) ) o
. . o

CONCLUSION VB N
The DT N
absence NN N
of IN N
an DT N
association NN N
between IN N
allostatic JJ N
load NN N
and CC N
SRH NNP o
in IN N
diabetic JJ p
individuals NNS p
contrasts NNS N
with IN N
previous JJ N
findings NNS N
in IN N
non-diabetic JJ p
women NNS p
, , N
and CC N
shows VBZ N
that IN N
it PRP N
is VBZ N
hazardous JJ N
to TO N
apply VB N
findings NNS N
in IN N
one CD N
population NN N
to TO N
another DT N
, , N
especially RB N
diabetic JJ p
and CC p
non-diabetic JJ p
populations NNS p
. . p

-DOCSTART- -24916506- O O

PTK2 NNP N
expression NN N
and CC N
immunochemotherapy JJ N
outcome NN N
in IN N
chronic JJ p
lymphocytic JJ p
leukemia NN p
. . p

Addition NN N
of IN N
rituximab NN i
( ( i
R NNP i
) ) i
to TO i
fludarabine VB i
and CC i
cyclophosphamide VB i
( ( N
FC NNP N
) ) N
has VBZ N
significantly RB N
improved VBN N
patient JJ o
outcomes NNS o
in IN p
chronic JJ p
lymphocytic JJ p
leukemia NN p
( ( p
CLL NNP p
) ) p
. . p

Whether NNP N
baseline NN N
gene NN N
expression NN N
can MD N
identify VB N
patients NNS p
who WP p
will MD p
benefit VB p
from IN p
immunochemotherapy NN p
over IN p
chemotherapy NN p
alone RB p
has VBZ p
not RB p
been VBN p
determined VBN p
. . p

We PRP p
assessed VBD p
genome-wide JJ o
expression NN o
of IN p
300 CD p
pretreatment NN p
specimens NNS p
from IN p
a DT p
subset NN p
of IN p
552 CD p
patients NNS p
in IN p
REACH NNP p
, , p
a DT p
study NN p
of IN p
FC NNP i
or CC p
R-FC NNP i
in IN p
relapsed JJ p
CLL NNP p
. . p

An DT p
independent JJ p
test NN p
set NN p
was VBD p
derived VBN p
from IN p
282 CD p
pretreatment NN p
specimens NNS p
from IN p
CLL8 NNP p
, , p
a DT p
study NN p
of IN p
FC NNP p
or CC p
R-FC NNP p
in IN p
treatment-na?ve JJ p
patients NNS p
. . p

Genes NNP N
specific JJ N
for IN N
benefit NN N
from IN i
R-FC NNP i
were VBD N
determined VBN N
by IN N
assessing VBG N
treatment-gene JJ N
interactions NNS N
in IN N
Cox NNP N
proportional JJ N
hazards NNS N
models NNS N
. . N

REACH JJ N
patients NNS N
with IN N
higher JJR N
pretreatment NN N
protein NN N
tyrosine JJ N
kinase NN N
2 CD N
( ( N
PTK2 NNP N
) ) N
messenger NN N
RNA NNP N
levels NNS N
derived VBN N
greater JJR N
benefit NN N
from IN i
R-FC NNP i
, , i
with IN N
significant JJ N
improvements NNS N
in IN o
progression-free JJ o
survival NN o
, , o
independent JJ N
of IN N
known JJ N
prognostic JJ N
factors NNS N
in IN N
a DT N
multivariate NN N
model NN N
. . N

Examination NN N
of IN o
PTK2 NNP o
gene NN o
expression NN o
in IN N
CLL8 NNP N
patients NNS N
yielded VBD N
similar JJ N
results NNS N
. . N

Furthermore NNP N
, , N
PTK2 NNP o
inhibition NN o
blunted VBD o
R-dependent NNP o
cell NN o
death NN o
in IN o
vitro NN o
. . o

This DT N
retrospective JJ N
analysis NN N
from IN N
2 CD N
independent JJ N
trials NNS N
revealed VBD N
that IN N
increased VBD o
PTK2 NNP o
expression NN o
is VBZ N
associated VBN N
with IN N
improved JJ N
outcomes NNS N
for IN p
CLL NNP p
patients NNS p
treated VBD N
with IN i
R-FC NNP i
vs NN i
FC NNP i
. . i

PTK2 NNP N
expression NN N
may MD N
be VB N
a DT N
useful JJ N
biomarker NN N
for IN N
patient JJ N
selection NN N
in IN N
future JJ N
trials NNS N
. . N

These DT N
trials NNS N
were VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00090051 NNP N
( ( N
REACH NNP N
) ) N
and CC N
# # N
NCT00281918 NNP N
( ( N
CLL8 NNP N
) ) N
. . N

-DOCSTART- -2371368- O O

Haloperidol NNP i
blood NN N
levels NNS N
and CC N
effects NNS N
in IN N
schizophrenia NN o
and CC p
schizoaffective JJ o
disorder NN p
: : p
a DT N
progress NN N
report NN N
. . N

To TO N
test VB N
the DT N
hypothesis NN N
of IN N
a DT N
therapeutic JJ N
window NN N
, , N
we PRP N
have VBP N
randomly RB N
assigned VBN N
acutely RB p
exacerbating VBG p
schizophrenic JJ o
or CC o
schizoaffective JJ o
patients NNS p
to TO N
one CD N
of IN N
three CD N
plasma NN N
levels NNS N
of IN N
haloperidol NN i
( ( i
HAL NNP i
) ) i
: : i
2-13 JJ N
, , N
13.1-24 JJ N
, , N
or CC N
24.1-35 JJ N
ng/ml NN N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
improve VB N
after IN N
6 CD N
weeks NNS N
of IN N
this DT N
treatment NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
three CD N
haloperidol NN i
levels NNS N
for IN N
another DT N
6 CD N
weeks NNS N
. . N

The DT N
improvement NN N
was VBD N
defined VBN N
as IN N
at IN N
least JJS N
50 CD N
percent JJ N
reduction NN N
of IN N
the DT N
Brief NNP o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
BPRS NNP o
) ) o
total NN o
score NN o
. . o

The DT N
results NNS N
obtained VBD N
in IN N
111 CD p
patients NNS p
do VBP N
not RB N
support VB N
any DT N
consistent JJ N
relationship NN N
between IN N
plasma JJ o
level NN o
of IN o
haloperidol NN o
and CC o
clinical JJ o
improvement NN o
. . o

Patients NNS N
in IN N
the DT N
high JJ N
haloperidol NN i
plasma NN N
range NN N
tended VBD N
to TO N
have VB N
more JJR N
side JJ o
effects NNS o
. . o

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
haloperidol NN i
doses NNS N
used VBN N
in IN N
clinical JJ N
practice NN N
may MD N
be VB N
higher JJR N
than IN N
necessary JJ N
. . N

-DOCSTART- -26448791- O O

Computer NNP i
Decision NNP i
Support NNP i
Changes NNP N
Physician NNP p
Practice NNP o
But CC N
Not RB N
Knowledge NNP o
Regarding VBG N
Autism NNP p
Spectrum NNP p
Disorders NNP p
. . p

OBJECTIVE NNP N
To TO N
examine VB N
whether IN N
adding VBG N
an DT N
autism NN N
module NN N
promoting VBG N
adherence NN N
to TO N
clinical JJ N
guidelines NNS N
to TO N
an DT N
existing VBG N
computer NN i
decision NN i
support NN i
system NN i
( ( N
CDSS NNP N
) ) N
changed VBD N
physician JJ N
knowledge NN N
and CC N
self-reported JJ N
clinical JJ N
practice NN N
. . N

METHODS NNP N
The DT p
CHICA NNP i
( ( i
Child NNP i
Health NNP i
Improvement NNP i
through IN i
Computer NNP i
Automation NNP i
) ) i
system NN i
, , p
a DT p
CDSS NNP i
, , p
was VBD p
enhanced VBN p
with IN p
a DT p
module NN p
to TO p
improve VB p
management NN o
of IN o
autism NN o
in IN p
2 CD p
of IN p
the DT p
4 CD p
community NN p
pediatric JJ p
clinics NNS p
using VBG p
the DT p
system NN p
. . p

We PRP N
examined VBD N
the DT N
knowledge NN N
and CC N
beliefs NN N
of IN N
pediatric JJ p
users NNS p
using VBG N
cross-sectional JJ p
surveys NNS p
administered VBN N
at IN N
3 CD N
time NN N
points NNS N
( ( N
baseline NN N
, , N
12 CD N
months NNS N
and CC N
24 CD N
months NNS N
post-implementation NN N
) ) N
between IN p
November NNP p
2010 CD p
and CC p
January NNP p
2013 CD p
. . p

Surveys NNS o
measured VBD N
knowledge NN o
, , o
beliefs NNS o
and CC o
self-reported JJ o
practice NN o
patterns NNS o
related VBN o
to TO o
autism NN o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
45 CD p
, , p
39 CD p
, , p
and CC p
42 CD p
pediatricians NNS p
responded VBD p
at IN p
each DT p
time NN p
point NN p
, , p
respectively RB p
, , p
a DT p
95-100 CD p
% NN p
response NN p
rate NN p
. . p

Respondents NNS N
' POS N
knowledge NN o
of IN o
autism NN o
and CC o
perception NN o
of IN o
role NN o
for IN o
diagnosis NN o
did VBD N
not RB N
vary JJ N
between IN N
control NN N
and CC N
intervention NN N
groups NNS N
either CC N
at IN N
baseline NN N
or CC N
any DT N
of IN N
the DT N
two CD N
post-intervention NN N
time NN N
points NNS N
. . N

At IN N
baseline NN N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
these DT N
groups NNS N
in IN N
rates NNS o
in IN o
the DT o
routine JJ o
use NN o
of IN o
parent-rated JJ o
screening NN o
instruments NNS o
for IN N
autism NN N
. . N

However RB N
, , N
by IN N
12 CD N
and CC N
24 CD N
months NNS N
post-implementation NN N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
intervention NN N
and CC N
control NN N
clinics NNS N
in IN N
terms NNS N
of IN N
the DT N
intervention NN N
clinics NNS N
consistently RB N
screening VBG N
eligible JJ N
patients NNS N
with IN N
a DT N
validated JJ N
autism NN N
tool NN N
. . N

Physicians NNS N
at IN N
all DT N
clinics NNS N
reported VBD N
ongoing JJ N
challenges NNS N
to TO N
community NN N
resources NNS N
for IN N
further JJ N
work-up NN N
and CC N
treatment NN N
related VBN N
to TO N
autism NN N
. . N

CONCLUSIONS VB N
A DT N
CDSS NNP i
module NN N
to TO N
improve VB N
primary JJ N
care NN N
management NN N
of IN N
ASD NNP N
in IN N
pediatric JJ N
practice NN N
led VBD N
to TO N
significant JJ N
improvements NNS N
in IN N
physician-reported JJ o
use NN o
of IN o
validated JJ o
screening NN o
tools NNS o
to TO N
screen VB N
for IN N
ASDs NNP N
. . N

However RB N
it PRP N
did VBD N
not RB N
lead VB N
to TO N
corresponding VBG N
changes NNS N
in IN N
physician JJ o
knowledge NN o
or CC o
attitudes NNS o
. . o

-DOCSTART- -22696626- O O

Effect NN N
of IN N
whole JJ i
body NN i
vibration NN i
on IN N
stereotypy NN o
of IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

The DT N
objective NN N
of IN N
this DT N
case NN N
was VBD N
report NN N
on IN N
the DT N
effects NNS o
of IN N
acute JJ N
whole JJ N
body NN N
vibration NN N
exposure NN N
on IN N
stereotyped JJ o
behaviour NN o
of IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

Four CD p
young JJ p
boys NNS p
( ( p
ages IN p
4-5 CD p
years NNS p
) ) p
diagnosed VBD p
with IN p
autism NN p
participated VBN p
. . p

The DT p
children NNS p
were VBD p
participants NNS p
in IN p
an DT p
early JJ i
intensive JJ i
behavioural JJ i
intervention NN i
clinic NN i
and CC N
during IN N
downtimes NNS N
stood VBD N
on IN N
a DT N
whole JJ i
body NN i
vibration NN i
platform NN N
with IN N
the DT N
machine NN N
turned VBD N
off RP N
( ( i
control VB i
condition NN i
) ) i
and CC N
on IN N
( ( i
treatment NN i
condition NN i
) ) i
for IN N
three CD N
to TO N
four CD N
, , N
30 CD N
s NN N
periods NNS N
( ( N
frequency=28 JJ N
Hz NNP N
; : N
amplitude VBZ N
0.97 CD N
mm NN N
) ) N
. . N

The DT N
outcome NN N
measure NN N
was VBD N
frequency NN o
of IN o
stereotypic NN o
behaviour NN o
, , N
which WDT N
was VBD N
evaluated VBN N
for IN N
5 CD N
min NN N
before IN N
and CC N
after IN N
standing VBG N
on IN N
the DT N
vibration NN N
platform NN N
. . N

The DT N
results NNS N
revealed VBD N
that IN N
whole JJ N
body NN N
vibration NN N
was VBD N
not RB N
able JJ N
to TO N
uniformly VB N
decrease VB N
the DT N
rates NNS o
of IN o
all DT o
types NNS o
of IN o
stereotypy NN o
; : o
that WDT N
is VBZ N
, , N
some DT N
stereotypy NNS o
decreased VBN N
while IN N
others NNS N
were VBD N
unchanged JJ N
. . N

Subjectively RB N
, , N
the DT N
children NNS p
enjoyed VBD N
whole JJ N
body NN N
vibration NN N
which WDT N
was VBD N
easy JJ o
to TO N
integrate VB N
into IN N
the DT N
behavioural JJ N
programme NN N
. . N

-DOCSTART- -23482575- O O

Effects NNS N
of IN N
low JJ N
and CC N
high JJ N
protein NN o
: : o
carbohydrate JJ o
ratios NNS o
in IN N
the DT N
diet NN N
of IN N
pregnant JJ p
gilts NNS p
on IN N
maternal JJ o
cortisol NN o
concentrations NNS o
and CC N
the DT N
adrenocortical JJ o
and CC o
sympathoadrenal JJ o
reactivity NN o
in IN p
their PRP$ p
offspring NN p
. . p

Inadequate NNP N
maternal JJ N
nutrition NN N
during IN N
gestation NN N
may MD N
cause VB N
an DT N
adverse JJ N
environment NN N
for IN N
the DT N
fetus NN N
leading VBG N
to TO N
alterations NNS N
of IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
and CC N
sympatho-adrenomedullary JJ N
( ( N
SAM NNP N
) ) N
systems NNS N
later RBR N
in IN N
life NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
diets NNS i
with IN i
low JJ i
and CC i
high JJ i
protein NN i
: : i
carbohydrate JJ i
ratios NNS N
on IN N
cortisol JJ o
concentrations NNS o
of IN N
pregnant JJ p
gilts NNS p
as RB N
well RB N
as IN N
the DT N
long-term JJ N
effects NNS N
on IN N
the DT N
function NN N
of IN N
the DT N
HPA NNP o
and CC o
SAM NNP o
axes NNS o
in IN p
their PRP$ p
offspring NN p
. . p

Throughout IN N
gestation NN N
, , N
33 CD p
German JJ p
Landrace NNP p
gilts NNS p
were VBD N
fed VBN N
high JJ i
( ( i
HP NNP i
, , i
30 CD i
% NN i
) ) i
, , i
low JJ i
( ( i
LP NNP i
, , i
6.5 CD i
% NN i
) ) i
, , i
or CC i
adequate NN i
( ( i
AP NNP i
, , i
12.1 CD i
% NN i
) ) i
protein NN i
diets NNS i
, , N
which WDT N
were VBD N
made VBN N
isocaloric JJ N
by IN N
adjusting VBG N
the DT N
carbohydrate NN N
content NN N
. . N

The DT N
salivary JJ N
cortisol NN N
concentrations NNS N
of IN p
the DT p
sows NNS p
were VBD N
measured VBN N
in IN N
the DT N
course NN N
of IN N
the DT N
gestation NN N
period NN N
. . N

The DT p
offspring VBG p
were VBD p
cross-fostered JJ p
, , N
and CC N
the DT N
plasma NN o
cortisol NN o
and CC o
catecholamine JJ o
concentrations NNS o
of IN N
the DT N
offspring NN p
were VBD N
determined VBN N
on IN N
postnatal JJ N
d NN N
( ( N
PND NNP N
) ) N
1 CD N
and CC N
27 CD N
and CC N
under IN N
specific JJ N
challenging JJ N
conditions NNS N
: : N
after IN N
weaning VBG N
( ( N
PND NNP N
29 CD N
) ) N
and CC N
after IN N
ACTH NNP N
and CC N
insulin NN N
challenges NNS N
( ( N
PND NNP N
68 CD N
and CC N
70 CD N
, , N
respectively RB N
) ) N
. . N

Glucocorticoid NNP o
receptor NN o
( ( o
GR NNP o
) ) o
binding NN o
and CC o
neurotransmitter JJ o
concentrations NNS o
were VBD N
measured VBN N
in IN N
stress-related JJ N
brain NN N
regions NNS N
, , N
and CC N
histological JJ N
analyses NNS N
of IN N
the DT N
adrenal JJ N
were VBD N
performed VBN N
. . N

Maternal NNP o
salivary JJ o
cortisol NN o
concentrations NNS o
increased VBD N
throughout IN N
gestation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
LP NNP N
gilts NNS N
had VBD N
greater JJR N
salivary JJ o
cortisol NNS o
compared VBN N
with IN N
the DT N
AP NNP N
and CC N
HP NNP N
gilts NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No UH N
differences NNS N
between IN N
diets NNS N
were VBD N
found VBN N
for IN N
cortisol NN N
, , N
corticosteroid-binding JJ N
globulin NN N
, , N
and CC N
catecholamine JJ N
concentrations NNS N
in IN N
plasma NN N
and CC N
for IN N
GR NNP N
binding NN N
in IN N
hippocampus NN N
and CC N
hypothalamus NN N
in IN N
piglets NNS p
at IN N
PND NNP N
1 CD N
and CC N
27 CD N
. . N

However RB N
, , N
the DT N
cortisol NN o
response NN o
to TO o
weaning NN o
was VBD N
increased VBN N
in IN N
LP NNP N
piglets NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
in IN N
HP NNP N
offspring VBG N
the DT N
basal NN o
plasma VBZ o
noradrenaline JJ o
concentrations NNS o
were VBD N
increased VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
cortisol NN o
response NN o
to TO o
the DT o
ACTH NNP o
and CC o
the DT o
insulin NN o
challenge NN o
did VBD N
not RB N
differ VB N
between IN N
diets NNS N
. . N

On IN N
PND NNP N
81 CD N
, , N
an DT N
increased VBN N
adrenal JJ o
medulla NN o
area NN o
was VBD N
observed VBN N
in IN N
LP NNP N
offspring VBG N
compared VBN N
with IN N
the DT N
AP NNP N
offspring NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Our PRP$ N
results NNS N
show VBP N
that IN N
maternal JJ i
diets NNS i
with IN i
aberrant JJ o
protein NN o
: : o
carbohydrate JJ o
ratios NNS o
during IN i
gestation NN i
have VBP N
moderate VBN N
long-term JJ N
effects NNS N
on IN N
the DT N
function NN o
of IN o
the DT o
HPA NNP o
and CC o
SAM NNP o
system NN o
in IN N
the DT N
offspring NN N
, , N
which WDT N
indicates VBZ N
that IN N
pigs NNS p
show VBP N
a DT N
considerable JJ N
plasticity NN N
to TO N
cope VB N
with IN N
maternal JJ N
malnutrition NN N
. . N

-DOCSTART- -22035883- O O

Comparison NNP N
of IN N
double- JJ N
and CC N
single-dose JJ N
methotrexate NN i
protocols NNS N
for IN N
treatment NN N
of IN N
ectopic JJ N
pregnancy NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
efficacy NN N
between IN N
double-dose JJ N
methotrexate NN i
and CC N
single-dose JJ N
methotrexate NN i
for IN N
treatment NN N
of IN N
tubal JJ N
ectopic NN N
pregnancy NN N
( ( N
EP NNP N
) ) N
. . N

METHODS NNP N
Between NNP p
March NNP p
2008 CD p
and CC p
February NNP p
2011,157 CD p
patients NNS p
who WP p
had VBD p
tubal JJ p
EP NNP p
diagnosed VBN p
by IN p
a DT p
non-laparoscopic JJ p
approach NN p
and CC p
were VBD p
hemodynamically RB p
stable JJ p
were VBD p
enrolled VBN p
in IN p
a DT p
prospective JJ p
study NN p
in IN p
Qassim NNP p
, , p
Saudi NNP p
Arabia NNP p
. . p

The DT N
participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
double-dose JJ i
( ( i
50mg/m CD i
( ( i
2 CD i
) ) i
intramuscularly RB i
on IN i
days NNS i
0 CD i
and CC i
4 CD i
; : i
group NN i
1 CD i
) ) i
or CC i
single-dose JJ i
( ( i
50mg/m CD i
( ( i
2 CD i
) ) i
intramuscularly RB i
on IN i
day NN i
0 CD i
; : i
group NN i
2 CD i
) ) i
methotrexate NN i
. . i

Serum NNP N
human JJ N
chorionic NN N
gonadotropin NN N
( ( N
?-hCG JJ N
) ) N
levels NNS N
were VBD N
followed VBN N
until IN N
negative JJ N
. . N

RESULTS VB N
The DT o
overall JJ o
success NN o
rate NN o
was VBD N
comparable JJ N
between IN N
groups NNS N
1 CD N
and CC N
2 CD N
( ( N
88.6 CD N
% NN N
versus IN N
82.0 CD N
% NN N
, , N
P=0.1 NNP N
) ) N
. . N

The DT o
duration NN o
of IN o
follow JJ o
up IN o
until IN o
negative JJ o
?-hCG NN o
was VBD o
shorter JJR N
in IN N
group NN N
1 CD N
( ( N
P=0.001 NNP N
) ) N
. . N

Receiver NNP N
operative JJ N
characteristics NNS N
showed VBD N
that IN N
higher JJR N
cut-off NN N
levels NNS N
of IN N
?-hCG NN o
and CC o
gestational JJ o
mass NN o
diameter NN o
were VBD o
associated VBN N
with IN o
successful JJ o
outcome NN o
in IN o
group NN N
1 CD N
. . N

Among IN N
participants NNS N
with IN N
initial JJ N
?-hCG NNS N
of IN N
3600-5500 JJ N
mIU/mL NN N
, , N
the DT N
success NN o
rate NN o
was VBD o
higher RBR N
in IN N
group NN N
1 CD N
( ( N
P=0.03 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS o
in IN o
adverse JJ o
effects NNS o
. . o

CONCLUSION NNP o
For IN N
treatment NN N
of IN N
EP NNP N
, , N
double-dose JJ i
methotrexate NN i
had VBD i
efficacy NN N
and CC N
safety NN N
comparable JJ N
to TO N
that DT N
of IN N
single-dose JJ N
methotrexate NN N
; : N
it PRP N
had VBD N
better JJR N
success NN N
among IN N
patients NNS N
with IN N
moderately RB N
high JJ N
?-hCG NN N
and CC N
led VBD N
to TO N
a DT N
shorter NN N
follow VB N
up RP N
. . N

-DOCSTART- -15891326- O O

Use NNP N
of IN N
an DT N
inspiratory JJ i
impedance NN i
threshold JJ i
device NN i
on IN i
a DT i
facemask NN i
and CC i
endotracheal VB i
tube NN i
to TO N
reduce VB N
intrathoracic JJ o
pressures NNS o
during IN N
the DT N
decompression NN N
phase NN N
of IN N
active JJ p
compression-decompression NN o
cardiopulmonary JJ o
resuscitation NN o
. . o

INTRODUCTION NNP N
Use NNP N
of IN N
an DT N
inspiratory JJ i
impedance NN i
threshold NN i
device NN i
( ( i
ITD NNP i
) ) i
significantly RB N
increases VBZ N
coronary JJ N
perfusion NN N
pressures NNS N
and CC N
survival NN N
in IN N
patients NNS p
ventilated VBN p
with IN p
an DT p
endotracheal JJ i
tube NN i
( ( i
ETT NNP i
) ) i
during IN p
active JJ i
compression-decompression NN i
cardiopulmonary JJ i
resuscitation NN i
. . i

We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
the DT N
ITD NNP i
could MD N
lower VB N
intratracheal NN N
pressures NNS N
when WRB N
attached VBN N
to TO N
either VB N
a DT N
facemask NN i
or CC i
ETT NNP i
. . i

METHODS NNP N
An DT i
active JJ i
and CC i
sham JJ i
ITD NNP i
were VBD N
randomly RB N
applied VBN N
first RB N
to TO N
a DT N
facemask NN i
and CC N
then RB N
to TO N
an DT N
ETT NNP i
during IN N
active JJ i
compression-decompression NN i
cardiopulmonary JJ i
resuscitation NN i
in IN p
13 CD p
out-of-hospital JJ p
cardiac JJ p
arrest NN p
patients NNS p
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
prospective JJ N
clinical JJ N
trial NN N
. . N

The DT N
compression-to-bag-valve JJ N
ventilation NN N
ratio NN N
was VBD N
15:2 CD N
. . N

Airway NN N
pressures NNS N
( ( N
surrogate NN N
for IN N
intrathoracic JJ N
pressure NN N
) ) N
were VBD N
measured VBN N
with IN N
a DT N
pressure NN N
transducer NN N
. . N

A DT i
sham NN i
and CC i
an DT i
active JJ i
ITD NNP i
were VBD N
used VBN N
for IN N
1 CD N
min NNS N
each DT N
in IN N
a DT N
randomized JJ N
order NN N
, , N
first RB N
on IN N
a DT N
facemask NN i
and CC N
then RB N
on IN N
an DT N
ETT NNP i
. . i

Statistical JJ N
analyses NNS N
were VBD N
made VBN N
using VBG N
Friedman NNP N
's POS N
and CC N
Wilcoxon NNP N
's POS N
rank-sum JJ N
tests NNS N
. . N

RESULTS NNP N
For IN N
the DT N
primary JJ N
end NN N
point NN N
, , N
mean JJ o
+/- JJ o
sd NN o
maximum JJ o
negative JJ o
intrathoracic NN o
pressures NNS o
( ( N
mm VB N
Hg NNP N
) ) N
during IN N
the DT N
decompression NN o
phase NN o
of IN o
cardiopulmonary JJ o
resuscitation NN o
were VBD N
-1.0 JJ N
+/- JJ N
0.73 CD N
mm NN N
Hg NNP N
with IN N
a DT N
sham NN i
vs. FW N
-4.6 NNP N
+/- JJ N
3.7 CD N
mm NN N
Hg NNP N
with IN N
an DT N
active JJ i
ITD NN i
on IN N
the DT N
facemask NN N
( ( N
p JJ N
= NNP N
.003 NNP N
) ) N
and CC N
-1.3 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
with IN N
a DT N
sham NN N
ITD NNP N
vs. IN N
-7.3 NNP N
+/- JJ N
4.5 CD N
mm NN N
Hg NNP N
with IN N
an DT N
active JJ N
ITD NNP N
on IN N
an DT N
ETT NNP N
( ( N
p JJ N
= NNP N
.0009 NNP N
) ) N
. . N

Decompression NNP o
phase NN o
airway NN o
pressures NNS o
with IN N
the DT N
facemask NN i
and CC i
ETT NNP i
were VBD N
not RB N
statistically RB N
different JJ N
. . N

CONCLUSIONS NNP N
Use NNP N
of IN N
an DT N
active JJ i
ITD NNP i
attached VBD i
to TO i
a DT i
facemask NN i
or CC i
an DT i
ETT NNP i
resulted VBD N
in IN N
a DT N
significantly RB N
lower JJR N
negative JJ o
intratracheal JJ o
pressure NN o
during IN N
the DT N
decompression NN N
phase NN N
of IN N
active JJ N
compression-decompression NN N
cardiopulmonary JJ N
resuscitation NN N
when WRB N
compared VBN N
with IN N
controls NNS N
. . N

Airway NNP N
pressures VBZ N
with IN N
an DT N
ITD NNP i
on IN N
either CC N
a DT i
facemask NN i
or CC N
ETT NNP i
were VBD N
similar JJ N
. . N

The DT N
ITD-facemask JJ i
combination NN i
was VBD N
practical JJ N
and CC N
enables VBZ N
rapid JJ N
deployment NN N
of IN N
this DT N
life-saving JJ N
technology NN N
. . N

-DOCSTART- -15247730- O O

Comparison NNP N
of IN N
nitinol JJ i
tipless NN i
stone NN i
baskets NNS i
in IN N
an DT N
in IN N
vitro JJ o
caliceal NN N
model NN N
. . N

PURPOSE NNP N
Tipless NNP i
stone NN i
baskets NNS i
facilitate VBP N
caliceal JJ p
calculi JJ p
extraction NN p
during IN p
flexible JJ p
ureteroscopy NN p
. . p

We PRP N
evaluated VBD N
the DT N
stone NN p
capture NN p
rate NN p
of IN p
9 CD p
commercially RB p
available JJ p
tipless NN i
stone NN i
baskets NNS i
in IN p
an DT p
in IN p
vitro NN p
model NN p
using VBG N
novice NN N
and CC N
expert NN N
operators NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
Microvasive NNP i
Zerotip NNP i
( ( i
2.4Fr CD i
, , i
3.0Fr CD i
) ) i
, , i
Cook NNP i
N-Circle NNP i
( ( i
2.2Fr CD i
, , i
3.0Fr CD i
, , i
3.2Fr CD i
) ) i
, , i
Bard NNP i
Dimension NNP i
( ( i
3.0Fr CD i
, , i
Sacred NNP i
Heart NNP i
Medical NNP i
Halo NNP i
( ( i
1.9Fr CD i
) ) i
, , i
Vantage NNP i
( ( i
1.9Fr CD i
) ) i
and CC i
Circon-ACMI JJ i
Sur-Catch-NT NNP i
( ( i
3.0Fr CD i
) ) i
were VBD N
tested VBN N
by IN N
3 CD p
novice NNS p
and CC p
3 CD p
experienced VBD p
basket NN p
operators NNS p
. . p

Each DT p
operator NN p
performed VBD p
stone JJ i
extraction NN i
of IN p
2 CD p
, , p
5 CD p
and CC p
8 CD p
mm NN p
calculi NN p
( ( N
size NN N
determined VBN N
by IN N
digital JJ N
caliper NN N
with IN N
3 CD N
repetitions NNS N
of IN N
each DT N
basket NN N
. . N

The DT N
time NN N
to TO N
extraction NN N
of IN N
the DT N
calculus NN N
from IN N
a DT N
convex NN N
based VBN N
test NN N
tube NN N
caliceal NN N
model NN N
was VBD N
recorded VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
repeated JJ N
measures NNS N
ANOVA NNP N
and CC N
Fisher NNP N
's POS N
pairwise NN N
comparisons NNS N
. . N

RESULTS NNP N
After IN N
a DT N
learning JJ N
curve NN N
of IN N
27 CD N
basket NN N
retrievals NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
stone NN o
capture NN o
times NNS o
between IN N
novice NN p
( ( N
38 CD N
+/- JJ N
54 CD N
seconds NNS N
) ) N
and CC N
expert JJ p
operators NNS p
( ( N
32 CD N
+/- JJ N
49 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.174 CD N
) ) N
. . N

For IN N
total JJ N
stone NN N
capture NN N
( ( N
all DT N
sizes NNS N
) ) N
the DT N
Sacred NNP N
Heart NNP N
Halo NNP N
resulted VBD N
in IN N
the DT N
most RBS N
rapid JJ o
stone NN o
extraction NN o
( ( N
17 CD N
+/- JJ N
14 CD N
seconds NNS N
) ) N
by IN N
novices NNS N
and CC N
experts NNS N
, , N
while IN N
the DT N
Sur-Catch NNP N
NT NNP N
resulted VBD N
in IN N
the DT N
slowest JJS N
stone NN N
extraction NN N
( ( N
78 CD N
+/- JJ N
90 CD N
, , N
seconds NNS N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
Halo NNP N
( ( N
14 CD N
+/- JJ N
9 CD N
seconds NNS N
) ) N
and CC N
Vantage NNP N
( ( N
19 CD N
+/- JJ N
12 CD N
seconds NNS N
) ) N
baskets NNS N
were VBD N
significantly RB N
faster JJR N
for IN N
2 CD N
mm NNS N
calculi NN N
than IN N
the DT N
N-Circle NNP N
( ( N
73 CD N
+/- JJ N
60 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.006 CD N
) ) N
, , N
Sur-Catch NNP N
( ( N
169 CD N
+/- JJ N
85 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.0005 CD N
) ) N
and CC N
Dimension NNP N
( ( N
73 CD N
+/- JJ N
70 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.017 CD N
) ) N
. . N

The DT N
Zerotip NNP N
functioned VBD N
well RB N
for IN N
2 CD N
mm NNS N
calculi NN N
in IN N
the DT N
hands NNS N
of IN N
expert NN N
operators NNS N
( ( N
15 CD N
+/- JJ N
9 CD N
seconds NNS N
) ) N
but CC N
not RB N
novice JJ N
operators NNS N
( ( N
94 CD N
+/- JJ N
95 CD N
seconds NNS N
) ) N
. . N

The DT N
Sur-Catch JJ N
NT NNP N
was VBD N
significantly RB N
slower JJR N
for IN N
2 CD N
mm NNS N
calculi NN N
than IN N
the DT N
N-Circle NNP N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
Dimension NNP N
( ( N
p JJ N
=.03 NN N
) ) N
, , N
Halo NNP N
( ( N
p JJ N
=.0005 NN N
) ) N
, , N
Vantage NNP N
( ( N
p JJ N
=.001 NN N
) ) N
and CC N
Zerotip NNP N
( ( N
p JJ N
=.002 NN N
) ) N
. . N

For IN N
5 CD N
mm NNS N
calculi VBP N
the DT N
Halo NNP N
was VBD N
superior JJ N
( ( N
12 CD N
+/- JJ N
8 CD N
seconds NNS N
) ) N
, , N
while IN N
the DT N
Zerotip NNP N
were VBD N
superior JJ N
for IN N
8 CD N
mm NNS N
calculi NN N
( ( N
8 CD N
+/- JJ N
3 CD N
seconds NNS N
) ) N
compared VBN N
to TO N
the DT N
N-Circle NNP N
( ( N
23 CD N
+/- JJ N
28 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.026 CD N
) ) N
, , N
Halo NNP N
( ( N
26 CD N
+/- JJ N
18 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.021 CD N
) ) N
and CC N
Vantage NNP N
( ( N
23 CD N
+/- JJ N
15 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.006 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
Sacred NNP N
Heart NNP N
Halo NNP N
and CC N
Vantage NNP N
baskets NNS N
resulted VBD N
in IN N
the DT N
most RBS o
expeditious JJ o
stone NN o
extraction NN o
, , N
especially RB N
for IN N
2 CD N
to TO N
5 CD N
mm NNS N
calculi VBP N
while IN N
the DT N
Microvasive NNP N
Zerotip NNP N
was VBD N
optimal JJ N
for IN N
8 CD N
mm NN N
calculi NN N
. . N

The DT N
Sur-Catch JJ N
NT NNP N
had VBD N
the DT N
slowest JJS o
stone JJ o
capture NN o
rate NN o
for IN N
all DT N
stone NN N
sizes VBZ N
. . N

Caliceal NNP N
models NNS N
of IN N
stone NN i
basketing NN i
may MD N
be VB N
useful JJ N
to TO N
train VB N
novice JJ N
urology NN p
residents NNS p
and CC p
nursing NN p
assistants NNS p
. . p

-DOCSTART- -21690083- O O

A DT N
pilot NN N
randomized VBN N
controlled JJ N
trial NN N
of IN N
DIR/Floortime? NNP i
parent NN i
training NN i
intervention NN i
for IN i
pre-school JJ p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

This DT N
pilot NN N
study NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
adding VBG i
home-based JJ i
Developmental NNP i
, , i
Individual-Difference NNP i
, , i
Relationship-Based JJ i
( ( i
DIR NNP i
) ) i
/Floortime? VBZ i
intervention NN i
to TO i
the DT N
routine JJ N
care NN N
of IN p
preschool NN p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
. . p

Measures NNS p
of IN N
functional JJ N
emotional JJ N
development NN N
and CC N
symptom JJ N
severity NN N
were VBD N
taken VBN N
. . N

It PRP N
was VBD N
found VBN N
that IN N
after IN N
the DT N
parents NNS N
added VBD i
home-based JJ i
DIR/Floortime? NNP i
intervention NN i
at IN i
an DT i
average NN N
of IN N
15.2 CD N
hours/week NN N
for IN N
three CD N
months NNS N
, , N
the DT N
intervention NN N
group NN N
made VBD N
significantly RB N
greater JJR N
gains NNS N
in IN N
all DT N
three CD N
measures NNS N
employed VBN N
in IN N
the DT N
study NN N
: : N
Functional NNP o
Emotional NNP o
Assessment NNP o
Scale NNP o
( ( o
FEAS NNP o
) ) o
( ( o
F NNP o
= NNP o
5.1 CD N
, , N
p NN N
= NNP N
.031 NNP N
) ) N
, , N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( N
F NNP N
= NNP N
2.1 CD N
, , N
p NN N
= NNP N
.002 NNP N
) ) N
, , N
and CC N
the DT o
Functional NNP o
Emotional NNP o
Questionnaires NNP o
( ( o
F NNP o
= NNP o
6.8 CD N
, , N
p NN N
= NNP N
.006 NNP N
) ) N
. . N

This DT N
study NN N
confirms VBZ N
the DT N
positive JJ N
results NNS N
obtained VBN N
by IN N
a DT N
previous JJ N
DIR NNP N
pilot NN N
study NN N
( ( N
Solomon NNP N
et RB N
al. RB N
, , N
2007 CD N
) ) N
. . N

-DOCSTART- -24214165- O O

An DT N
intervention NN N
for IN N
sensory JJ N
difficulties NNS N
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized JJ N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
a DT N
manualized VBN i
intervention NN i
for IN i
sensory JJ i
difficulties NNS i
for IN N
children NNS p
with IN p
autism NN p
, , p
ages VBZ p
4-8 CD p
years NNS p
, , N
using VBG N
a DT N
randomized JJ N
trial NN N
design NN N
. . N

Diagnosis NN N
of IN N
autism NN N
was VBD N
confirmed VBN N
using VBG N
gold JJ N
standard NN N
measures NNS N
. . N

Results NNP N
show VBP N
that IN N
the DT N
children NNS p
in IN p
the DT p
treatment NN p
group NN p
( ( p
n JJ p
= NNP p
17 CD p
) ) p
who WP N
received VBD N
30 CD i
sessions NNS i
of IN i
the DT i
occupational JJ i
therapy NN i
intervention NN i
scored VBD N
significantly RB N
higher JJR N
( ( N
p JJ N
= NN N
0.003 CD N
, , N
d NN N
= NNP N
1.2 CD N
) ) N
on IN N
Goal NNP o
Attainment NNP o
Scales NNP o
( ( o
primary JJ o
outcome NN o
) ) o
, , N
and CC N
also RB N
scored VBD N
significantly RB N
better RBR N
on IN N
measures NNS N
of IN N
caregiver NN o
assistance NN o
in IN o
self-care NN o
( ( N
p JJ N
= $ N
0.008 CD N
d NN N
= NNP N
0.9 CD N
) ) N
and CC N
socialization NN o
( ( N
p JJ N
= NN N
0.04 CD N
, , N
d NN N
= NNP N
0.7 CD N
) ) N
than IN N
the DT N
Usual NNP i
Care NNP i
control NN i
group NN p
( ( p
n JJ p
= NNP p
15 CD p
) ) p
. . p

The DT N
study NN N
shows VBZ N
high JJ N
rigor NN N
in IN N
its PRP$ N
measurement NN N
of IN N
treatment NN N
fidelity NN N
and CC N
use NN N
of IN N
a DT N
manualized VBN N
protocol NN N
, , N
and CC N
provides VBZ N
support NN N
for IN N
the DT N
use NN N
of IN N
this DT N
intervention NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

Findings NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
their PRP$ N
implications NNS N
for IN N
practice NN N
and CC N
future JJ N
research NN N
. . N

-DOCSTART- -18501909- O O

Penetration NN o
and CC o
accumulation NN o
of IN N
moxifloxacin NN i
in IN N
uterine JJ N
tissue NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
moxifloxacin NN i
penetrates VBZ N
the DT N
uterine JJ N
tissue NN N
and CC N
accumulates NNS N
at IN N
levels NNS N
sufficient JJ N
to TO N
eradicate VB o
the DT o
major JJ o
pathogens NNS o
causing VBG N
pelvic JJ p
inflammatory JJ p
disease NN p
( ( p
PID NNP p
) ) p
. . p

METHOD NNP N
In IN N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
open-label JJ N
, , N
parallel-group JJ N
study NN N
we PRP N
determined VBD N
the DT N
concentration NN N
of IN N
moxifloxacin NN N
in IN N
plasma NN N
and CC N
uterine JJ N
tissue NN N
after IN N
a DT N
single JJ N
, , N
400-mg JJ i
intravenous JJ i
dose NN i
of IN i
moxifloxacin NN i
. . i

Study NN N
participants NNS N
were VBD N
randomized VBN N
for IN N
time NN N
of IN N
tissue NN N
sampling NN N
, , N
which WDT N
was VBD N
performed VBN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
7 CD N
, , N
or CC N
24 CD N
hours NNS N
following VBG N
the DT N
moxifloxacin JJ i
infusion NN N
. . N

RESULTS NNP N
Of IN N
43 CD p
participants NNS p
, , p
40 CD p
were VBD p
randomized VBN p
to TO p
tissue VB p
sampling VBG p
. . p

Moxifloxacin NNP o
accumulated VBD o
in IN o
uterine JJ o
tissue NN o
and CC o
concentrations NNS o
were VBD N
highest JJS N
1 CD N
hour NN N
after IN N
infusion NN N
in IN N
both DT N
plasma NN N
and CC N
tissue NN N
. . N

Tissue NN o
to TO o
plasma VB o
ratios NNS o
remained VBD N
between IN N
1.7 CD N
and CC N
2.1 CD N
for IN N
24 CD N
hours NNS N
. . N

Moxifloxacin NNP N
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC o
well RB o
tolerated VBN o
. . o

CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ o
tissue NN o
concentrations NNS o
of IN N
moxifloxacin NN N
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP p
. . p

-DOCSTART- -17961229- O O

How WRB N
well RB N
do VB N
blood NN o
folate VB o
concentrations NNS o
predict VBP N
dietary JJ i
folate NN i
intakes NNS i
in IN N
a DT N
sample NN N
of IN N
Canadian JJ p
lactating VBG p
women NNS p
exposed VBN p
to TO p
high JJ p
levels NNS p
of IN p
folate NN p
? . N
An DT N
observational JJ N
study NN N
. . N

BACKGROUND NNP N
In IN N
1998 CD N
, , N
mandatory JJ N
folic JJ N
acid JJ N
fortification NN N
of IN N
white JJ i
flour NN i
and CC i
select JJ i
cereal NN i
grain NN i
products NNS i
was VBD N
implemented VBN N
in IN N
Canada NNP p
with IN N
the DT N
intention NN N
to TO N
increase VB N
dietary JJ i
folate JJ i
intakes NNS i
of IN N
reproducing VBG p
women NNS p
. . p

Folic NNP N
acid JJ N
fortification NN N
has VBZ N
produced VBN N
a DT N
dramatic JJ N
increase NN N
in IN N
blood NN N
folate JJ N
concentrations NNS N
among IN N
reproductive JJ N
age NN N
women NNS N
, , N
and CC N
a DT N
reduction NN N
in IN N
neural JJ N
tube NN N
defect NN N
( ( N
NTD NNP N
) ) N
-affected VBD N
pregnancies NNS N
. . N

In IN N
response NN N
to TO N
improved VBN N
blood NN N
folate NN N
concentrations NNS N
, , N
many JJ N
health NN N
care NN N
professionals NNS N
are VBP N
asking VBG N
whether IN N
a DT N
folic JJ i
acid NN i
supplement NN i
is VBZ N
necessary JJ N
for IN N
NTD NNP N
prevention NN N
among IN N
women NNS p
with IN p
high JJ p
blood NN p
folate NN p
values NNS p
, , N
and CC N
how WRB N
reliably RB N
high JJ N
RBC NNP N
folate NN N
concentrations NNS N
predict VBP N
folate JJ N
intakes NNS N
shown VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
to TO N
be VB N
protective JJ N
against IN N
NTDs NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
how WRB N
predictive JJ N
blood NN o
folate NN o
concentrations NNS o
and CC o
folate NN o
intakes NNS o
are VBP N
of IN N
each DT N
other JJ N
in IN N
a DT N
sample NN N
of IN N
well-educated JJ p
lactating VBG p
Canadian JJ p
women NNS p
exposed VBN p
to TO p
high JJ p
levels NNS p
of IN p
synthetic JJ p
folate NN p
. . p

METHODS NNP N
The DT N
relationship NN N
between IN N
blood NN o
folate NN o
concentrations NNS o
and CC N
dietary JJ o
folate NN o
intakes NNS o
, , N
determined VBN N
by IN N
weighed VBN i
food NN i
records NNS i
, , N
were VBD N
assessed VBN N
in IN N
a DT N
sample NN p
of IN p
predominantly RB p
university-educated JJ p
lactating VBG p
women NNS p
( ( p
32 CD p
+/- JJ p
4 CD p
yr NN p
) ) p
at IN p
4- JJ p
( ( p
n JJ p
= NNP p
53 CD p
) ) p
and CC p
16-wk JJ p
postpartum NN p
( ( p
n JJ p
= NNP p
55 CD p
) ) p
. . p

RESULTS NNP N
Median JJ N
blood NN o
folate NN o
concentrations NNS o
of IN N
all DT N
participants NNS N
were VBD N
well RB N
above IN N
plasma NN N
and CC N
RBC NNP N
folate VBP N
cut-off NN N
levels NNS N
indicative CD N
of IN N
deficiency NN N
( ( N
6.7 CD N
and CC N
317 CD N
nmol/L NN N
, , N
respectively RB N
) ) N
and CC N
all DT N
, , N
except IN N
for IN N
2 CD N
subjects NNS N
, , N
were VBD N
above IN N
the DT N
cut-off NN N
for IN N
NTD-risk NNP N
reduction NN N
( ( N
> $ N
906 CD N
nmol/L NN N
) ) N
. . N

Only RB N
modest JJ N
associations NNS N
existed VBD N
between IN N
total JJ o
folate NN o
intakes NNS o
and CC N
plasma NN o
( ( N
r JJ N
= NN N
0.46 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
RBC NNP N
( ( N
r VB N
= RB N
0.36 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
folate NN o
concentrations NNS o
at IN N
16-wk JJ N
postpartum NN N
. . N

Plasma NNP o
and CC o
RBC NNP o
folate VBP o
values NNS o
at IN N
16-wk JJ N
postpartum NN N
correctly RB N
identified VBD N
the DT N
quartile NN N
of IN N
folate JJ N
intake NN N
of IN N
only RB N
26 CD N
of IN N
55 CD N
( ( N
47 CD N
% NN N
) ) N
and CC N
18 CD N
of IN N
55 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
subjects NNS N
, , N
respectively RB N
. . N

The DT N
mean JJ N
RBC NNP o
folate NN o
concentration NN o
of IN N
women NNS N
consuming VBG N
151-410 JJ N
microg/d NN N
of IN N
synthetic JJ N
folate NN N
( ( N
2nd CD N
quartile NN N
of IN N
intake NN N
) ) N
did VBD N
not RB N
differ VB N
from IN N
that DT N
of IN N
women NNS N
consuming VBG N
> JJ N
410 CD N
microg/d NN N
( ( N
3rd CD N
and CC N
4th CD N
quartile NN N
) ) N
. . N

CONCLUSION NNP N
Folate NNP o
intakes NNS o
, , N
estimated VBN N
by IN N
food NN N
composition NN N
tables NNS N
, , N
and CC N
blood NN o
folate NN o
concentrations NNS o
are VBP N
not RB N
predictive JJ N
of IN N
each DT N
other JJ N
in IN N
Canadian JJ N
lactating VBG N
women NNS N
exposed VBN N
to TO N
high JJ N
levels NNS N
of IN N
folate NN o
. . o

Synthetic JJ N
intakes NNS N
> VBP N
151-410 JJ N
microg/d NN N
in IN N
these DT N
women NNS N
produced VBD N
little JJ N
additional JJ N
benefit NN N
in IN N
terms NNS N
of IN N
maximizing VBG N
RBC NNP N
content NN N
. . N

More JJR N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
blood NN o
folate NN o
concentration NN o
and CC N
NTD NNP N
risk NN N
. . N

Until IN N
data NNS N
from IN N
such JJ N
studies NNS N
are VBP N
available JJ N
, , N
women NNS N
planning VBG N
a DT N
pregnancy NN N
should MD N
continue VB N
to TO N
consume VB N
a DT N
daily JJ N
folic JJ i
acid JJ i
supplement NN i
of IN N
400 CD N
microg NN N
. . N

-DOCSTART- -16981667- O O

Long-term JJ o
results NNS o
of IN N
the DT N
MRC NNP i
AML10 NNP i
trial NN p
. . p

-DOCSTART- -15622265- O O

A DT N
randomized JJ N
, , N
evaluator-blind JJ N
, , N
multicenter JJ N
comparison NN N
of IN N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
Perlane NNP i
versus NN i
Zyplast NNP i
in IN N
the DT N
correction NN N
of IN N
nasolabial JJ p
folds NNS p
. . p

Bovine NNP i
collagen NN i
is VBZ N
widely RB N
used VBN N
as IN N
a DT N
dermal JJ N
filler NN N
for IN N
facial JJ N
soft-tissue JJ N
augmentation NN N
, , N
but CC N
it PRP N
provides VBZ N
only RB N
temporary JJ N
cosmetic JJ N
improvement NN N
. . N

Nonanimal NNP i
stabilized VBD i
hyaluronic JJ i
acid NN i
has VBZ N
reduced VBN N
potential JJ N
for IN N
immunogenicity NN N
and CC N
hypersensitivity NN N
and CC N
may MD N
provide VB N
a DT N
more RBR N
durable JJ N
aesthetic JJ N
result NN N
. . N

Sixty-eight JJ p
patients NNS p
with IN p
prominent JJ p
nasolabial JJ p
folds NNS p
were VBD p
randomized VBN p
to TO p
intradermal VB i
treatment NN i
with IN i
nonanimal JJ i
stabilized VBN i
hyaluronic JJ i
acid NN i
gel NN i
( ( i
Perlane NNP i
) ) i
and CC i
bovine JJ i
collagen NN i
( ( i
Zyplast NNP i
) ) i
on IN N
contralateral JJ N
sides NNS N
of IN N
the DT N
face NN N
. . N

On IN N
achievement NN N
of IN N
optimal JJ o
cosmetic JJ o
result NN o
( ( N
baseline NN N
) ) N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
; : N
bilateral JJ N
retreatment NN N
with IN N
Perlane NNP i
was VBD N
offered VBN N
at IN N
6 CD N
or CC N
9 CD N
months NNS N
after IN N
baseline NN N
. . N

Responses NNS N
were VBD N
evaluated VBN N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
baseline NN N
. . N

Investigator-based JJ o
and CC o
patient-based JJ o
ratings NNS o
indicated VBD N
that IN N
Perlane NNP i
was VBD N
more RBR N
effective JJ N
than IN N
Zyplast NNP i
in IN N
maintaining VBG N
cosmetic JJ o
correction NN N
. . N

According VBG N
to TO N
investigator-based JJ o
Wrinkle NNP o
Severity NNP o
Rating NNP o
Scale NNP o
assessments NNS o
at IN N
6 CD N
and CC N
9 CD N
months NNS N
after IN N
baseline NN N
, , N
Perlane NNP i
was VBD N
superior JJ o
in IN N
50.0 CD N
percent NN N
and CC N
48.8 CD N
percent NN N
of IN N
patients NNS N
, , N
respectively RB N
, , N
whereas IN N
Zyplast NNP i
was VBD N
superior JJ o
in IN N
10.3 CD N
percent NN N
and CC N
14.0 CD N
percent NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
< NNP N
0.0004 CD N
) ) N
. . N

Investigator-based JJ N
Global NNP o
Aesthetic NNP o
Improvement NNP o
Scale NNP o
assessment NN o
at IN N
9 CD N
months NNS N
after IN N
baseline NN N
indicated VBD N
that IN N
Perlane NNP i
was VBD N
superior JJ o
in IN N
48.8 CD N
percent NN N
of IN N
patients NNS N
, , N
whereas IN N
Zyplast NNP i
was VBD N
superior JJ o
in IN N
14.0 CD N
percent NN N
of IN N
patients NNS N
( ( N
p JJ N
= NNP N
0.0025 CD N
) ) N
. . N

Optimal NNP o
cosmetic JJ o
result NN o
was VBD N
achieved VBN N
with IN N
a DT N
smaller JJR o
volume NN o
of IN N
Perlane NNP i
than IN N
Zyplast NNP i
( ( N
mean NN N
, , N
1.2 CD N
ml NN N
versus NN N
2.1 CD N
ml NN N
) ) N
. . N

Local JJ N
injection-site JJ N
reactions NNS o
( ( o
redness NN o
, , o
swelling VBG o
, , o
pruritus NN o
, , o
and CC o
induration NN o
) ) o
were VBD N
less RBR N
frequent JJ N
with IN N
Perlane NNP i
than IN N
with IN N
Zyplast NNP i
. . i

Delayed-onset JJ N
reactions NNS N
were VBD N
rare JJ N
and CC N
did VBD N
not RB N
reoccur VB N
after IN N
Perlane NNP i
retreatment NN N
. . N

Perlane NNP i
has VBZ N
acceptable JJ N
long-term JJ o
safety NN o
and CC N
offers VBZ N
a DT N
longer-lasting JJ N
aesthetic JJ o
improvement NN o
than IN N
Zyplast NNP i
. . i

-DOCSTART- -1376306- O O

Induction NNP i
chemotherapy NN i
in IN N
head NN p
and CC p
neck NN p
cancer NN p
: : p
results NNS N
of IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

Between IN p
December NNP p
1982 CD p
and CC p
October NNP p
1986 CD p
, , p
131 CD p
patients NNS p
with IN p
stage JJ p
II-III-IV NNP p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
oropharynx NN p
or CC p
oral JJ p
cavity NN p
were VBD N
randomized VBN N
to TO N
induction VB i
chemotherapy NN i
, , i
consisting VBG i
of IN i
bleomycin NN i
( ( i
10 CD i
mg/m2/day NN i
in IN i
continuous JJ i
infusion NN i
from IN i
day NN i
1 CD i
to TO i
day NN i
5 CD i
) ) i
, , i
methotrexate NN i
( ( i
120 CD i
mg/m2 NN i
on IN i
day NN i
2 CD i
) ) i
followed VBN i
by IN i
folinic JJ i
acid NN i
, , i
5-fluorouracil JJ i
( ( i
5 CD i
FU NNP i
) ) i
( ( i
600 CD i
mg/m2 NN i
on IN i
day NN i
2 CD i
) ) i
, , i
and CC i
cisplatin NN i
( ( i
120 CD i
mg/m2 NN i
on IN i
day NN i
4 CD i
) ) i
every DT i
4 CD i
weeks NNS i
for IN i
a DT i
total NN i
of IN i
three CD i
cycles NNS i
followed VBN i
by IN i
definitive JJ i
locoregional JJ i
treatment NN i
versus IN i
locoregional JJ i
treatment NN i
alone RB i
. . i

The DT N
modalities NNS N
of IN N
definitive JJ N
treatment NN N
( ( i
radiotherapy JJ i
+/- JJ i
surgery NN i
) ) i
were VBD N
chosen VBN N
prior RB N
to TO N
randomization NN N
. . N

A DT p
total NN p
of IN p
116 CD p
patients NNS p
were VBD p
evaluable JJ p
. . p

Of IN N
55 CD N
patients NNS N
in IN N
the DT N
chemotherapy NN i
arm NN N
, , N
four CD N
( ( N
7 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
23 CD N
( ( N
42 CD N
% NN N
) ) N
a DT N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
following VBG N
the DT N
induction NN N
regimen NNS N
. . N

At IN N
the DT N
completion NN N
of IN N
locoregional JJ N
treatment NN N
, , N
76 CD N
% NN N
( ( N
42 CD N
of IN N
55 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
CR NNP N
compared VBN N
to TO N
89 CD N
% NN N
( ( N
54 CD N
of IN N
61 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN o
, , o
cause-specific JJ o
survival NN o
, , o
and CC o
pattern NN o
of IN o
relapse NN o
between IN N
both DT N
groups NNS N
. . N

The DT N
median JJ o
survival NN o
was VBD N
22 CD N
months NNS N
in IN N
the DT N
chemotherapy NN N
group NN N
and CC N
29 CD N
months NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Responders NNS N
to TO N
chemotherapy VB N
did VBD N
not RB N
fare VB N
better JJR N
than IN N
nonresponders NNS N
. . N

Chemotherapy-related JJ o
toxicities NNS o
were VBD N
few JJ N
and CC N
most JJS N
of IN N
them PRP N
related VBN N
to TO N
cisplatin VB N
which WDT N
was VBD N
reduced VBN N
to TO N
100 CD N
mg/m2 NN N
for IN N
35 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
deaths NNS o
and CC N
, , N
in IN N
the DT N
experimental JJ N
arm NN N
of IN N
the DT N
trial NN N
, , N
no DT N
increased VBN N
morbidity NN o
from IN N
locoregional JJ N
treatment NN N
. . N

This DT N
induction NN N
regimen NN N
does VBZ N
not RB N
offer VB N
any DT N
advantages NNS N
over IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -1467386- O O

Effect NN N
of IN N
m-chlorophenylpiperazine NN i
on IN N
plasma NN o
homovanillic JJ o
acid NN o
concentrations NNS o
in IN N
healthy JJ p
subjects NNS p
. . p

In IN N
view NN N
of IN N
the DT N
abundant JJ N
anatomical JJ N
and CC N
functional JJ N
interactions NNS N
between IN N
serotonin NN N
and CC N
dopamine NN N
systems NNS N
, , N
this DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
the DT N
serotonin JJ N
agonist NN N
, , N
m-chlorophenylpiperazine NN i
( ( i
mCPP NN i
) ) i
on IN N
plasma NN o
concentrations NNS o
of IN o
the DT o
dopamine NN o
metabolite NN o
, , o
homovanillic JJ o
acid NN o
. . o

Plasma NNP N
prolactin NN N
levels NNS N
, , N
body NN N
temperature NN N
, , N
and CC N
mCPP RB o
blood NN N
level NN N
were VBD N
also RB N
measured VBN N
. . N

mCPP NN i
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
placebo $ i
were VBD N
administered VBN N
orally RB N
to TO N
10 CD p
healthy JJ p
men NNS p
in IN N
a DT N
randomized JJ N
double-blind NN N
design NN N
. . N

Variables NNS N
were VBD N
measured VBN N
for IN N
210 CD N
min NNS N
after IN N
administration NN N
of IN N
capsules NNS N
. . N

mCPP NNS o
raised VBD o
prolactin NN o
and CC o
temperature NN o
as IN o
compared VBN o
to TO o
placebo VB o
, , N
but CC N
did VBD N
not RB N
affect VB N
plasma NN o
homovanillic JJ o
acid JJ o
concentrations NNS o
. . o

Results VB N
suggest JJS N
that IN N
mCPP NN o
does VBZ o
not RB o
alter VB o
dopamine NN o
function NN o
. . o

-DOCSTART- -1977089- O O

Nizatidine NNP i
versus NN N
ranitidine NN i
in IN N
the DT N
treatment NN N
of IN N
peptic JJ N
ulcer JJ N
disease NN N
: : N
report NN N
on IN N
the DT N
Dutch JJ N
investigation NN N
as IN N
part NN N
of IN N
a DT N
European NNP p
multicentre NN p
trial NN p
. . p

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
nizatidine NN i
was VBD N
evaluated VBN N
in IN N
comparison NN N
with IN N
ranitidine NN i
in IN N
230 CD p
patients NNS p
with IN p
endoscopically RB p
documented VBN p
gastric NN p
( ( p
71 CD p
) ) p
or CC p
duodenal JJ p
( ( p
159 CD p
) ) p
ulcers NNS p
. . p

Gastric NNP p
ulcer JJ p
patients NNS p
who WP p
satisfied VBD p
all DT p
criteria NNS p
for IN p
inclusion NN p
and CC p
exclusion NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
nizatidine VB i
300 CD i
mg NN i
nocte NN i
, , i
150 CD i
mg NN i
b.d NN i
. . i

or CC i
ranitidine VB i
150 CD i
mg NN i
b.d. NN N
, , N
duodenal JJ N
ulcer NN N
patients NNS N
to TO N
nizatidine VB i
300 CD i
mg JJ i
nocte NN i
or CC i
ranitidine VB i
300 CD i
mg NN i
nocte NN i
. . i

Endoscopic NNP o
healing NN o
was VBD N
defined VBN N
as IN N
complete JJ o
epithelialisation NN o
of IN o
all DT o
mucosal JJ o
lesions NNS o
. . o

Endoscopy NNP N
was VBD N
performed VBN N
at IN N
4 CD N
and CC N
, , N
if IN N
not RB N
healed VBN N
, , N
at IN N
8 CD N
weeks NNS N
. . N

Healing VBG o
rates NNS o
were VBD N
shown VBN N
to TO N
be VB N
comparable JJ N
for IN N
all DT N
treatment NN N
regimens NNS N
. . N

In IN N
both DT N
duodenal JJ N
ulcer NN N
treatment NN N
groups NNS N
, , N
and CC N
with IN N
both DT N
drugs NNS N
, , N
healing NN o
was VBD N
negatively RB N
influenced VBN N
by IN N
ulcer JJ o
size NN o
, , o
ulcer JJ o
number NN o
, , o
smoking VBG o
habits NNS o
and CC o
a DT o
disease NN o
duration NN o
of IN N
5 CD N
years NNS N
or CC N
more JJR N
. . N

Few JJ o
side NN o
effects NNS o
were VBD N
noted VBN N
. . N

Nizatidine NNP i
, , N
administered VBD N
as IN N
a DT N
300 CD N
mg NN N
nocte NN N
and CC N
as IN N
a DT N
150 CD N
mg NN N
b.d NN N
. . N

dose VB N
appeared VBD N
to TO N
be VB N
a DT N
safe JJ N
H2 NNP N
antagonist NN N
and CC N
was VBD N
as RB N
effective JJ o
as IN N
ranitidine NN i
in IN N
the DT N
treatment NN p
of IN p
duodenal JJ p
and CC p
gastric JJ p
ulceration NN p
. . p

-DOCSTART- -20973459- O O

High-calcium JJ i
milk NN i
prevents NNS N
overweight JJ N
and CC N
obesity NN N
among IN N
postmenopausal JJ p
women NNS p
. . p

BACKGROUND IN N
The DT N
Sixth NNP N
National NNP N
Nutrition NNP N
Survey NNP N
2003 CD N
revealed VBD N
that IN N
the DT N
highest JJS N
prevalence NN N
of IN N
overweight NN N
and CC N
obesity NN N
among IN N
Filipino NNP p
female JJ p
adults NNS p
( ( p
30.8 CD p
% NN p
) ) p
was VBD p
found VBN p
in IN p
the DT p
age NN p
group NN p
from IN p
40 CD p
to TO p
59 CD p
years NNS p
. . p

Obesity NN N
is VBZ N
associated VBN N
with IN N
a DT N
number NN N
of IN N
chronic JJ N
diseases NNS N
, , N
including VBG N
cardiovascular JJ N
disease NN N
, , N
hypertension NN N
, , N
and CC N
diabetes NNS N
. . N

Low JJ N
calcium NN N
intake NN N
has VBZ N
been VBN N
identified VBN N
as IN N
a DT N
potential JJ N
contributing NN N
factor NN N
to TO N
overweight NN N
and CC N
obesity NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effect NN N
of IN N
a DT N
high-calcium NN i
, , i
fortified VBN i
, , i
low-fat JJ i
milk NN i
drink NN i
with IN N
added JJ i
vitamin NN i
D NNP i
versus VBZ N
a DT N
low-calcium JJ i
placebo NN i
drink NN i
on IN N
anthropometric JJ N
measurements NNS N
of IN N
postmenopausal JJ p
women NNS p
. . p

METHODS NNP N
Women NNP p
who WP p
were VBD p
at IN p
least JJS p
5 CD p
years NNS p
postmenopausal NN p
were VBD p
invited VBN p
to TO p
participate VB p
in IN N
the DT N
study NN N
. . N

Potential JJ N
participants NNS N
underwent JJ N
three CD N
stages NNS N
of IN N
screening NN N
: : N
initial JJ N
interview NN N
, , N
dual-energy JJ N
x-ray JJ N
absorptiometry NN N
, , N
and CC N
blood NN N
testing NN N
for IN N
biochemical JJ N
screening NN N
. . N

Anthropometric JJ o
indices NNS o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Sixty NNP p
women NNS p
were VBD p
qualified VBN p
to TO p
participate VB p
in IN N
the DT N
study NN N
. . N

The DT N
women NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
, , N
one CD N
of IN N
which WDT N
received VBD N
400 CD N
ml NN N
of IN N
the DT N
high-calcium JJ i
milk NN i
daily RB N
for IN N
16 CD N
weeks NNS N
while IN N
the DT N
other JJ N
received VBD N
the DT N
placebo NN i
drink NN i
. . i

RESULTS NNP N
No NNP N
significant JJ N
increases NNS N
were VBD N
observed VBN N
in IN N
the DT N
anthropometric JJ o
indices NNS o
of IN N
the DT N
subjects NNS N
receiving VBG N
the DT N
high-calcium NN i
fortified VBD i
milk NN i
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

However RB N
, , N
there EX N
were VBD N
significant JJ N
increases NNS N
in IN N
the DT N
weight NN o
( ( N
p JJ N
= NNP N
.008 NNP N
) ) N
, , N
body JJ o
mass NN o
index NN o
( ( N
p JJ N
= NNP N
.007 NNP N
) ) N
, , N
and CC N
waist NN o
( ( N
p JJ N
= NNP N
.018 NNP N
) ) N
and CC N
hip NN o
( ( N
p JJ N
= NNP N
.003 NNP N
) ) N
circumferences NNS o
of IN N
the DT N
subjects NNS N
receiving VBG N
the DT N
placebo NN N
drink NN N
. . N

CONCLUSIONS VB N
A DT N
change NN N
in IN N
dietary JJ o
calcium NN o
intake NN o
may MD N
be VB N
a DT N
useful JJ N
measure NN N
as IN N
part NN N
of IN N
an DT N
overall JJ N
approach NN N
to TO N
prevent VB N
the DT N
occurrence NN N
of IN N
overweight NN N
and CC N
obesity NN N
among IN N
postmenopausal JJ p
women NNS p
. . p

-DOCSTART- -20822543- O O

A DT N
cluster NN N
randomised VBN N
trial NN N
to TO N
evaluate VB N
a DT N
physical JJ i
activity NN i
intervention NN i
among IN N
3-5 JJ p
year NN p
old JJ p
children NNS p
attending VBG p
long RB p
day NN p
care NN p
services NNS p
: : p
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Young NNP p
children NNS p
are VBP N
not RB N
participating VBG N
in IN N
recommended JJ N
levels NNS N
of IN N
physical JJ N
activity NN N
and CC N
exhibit NN N
high JJ N
levels NNS N
of IN N
sedentary JJ N
behaviour NN N
. . N

Childcare NNP N
services NNS N
provide RB N
access NN N
to TO N
large JJ N
numbers NNS N
of IN N
young JJ p
children NNS p
for IN N
prolonged JJ N
periods NNS N
, , N
yet RB N
there EX N
is VBZ N
limited JJ N
experimental JJ N
evidence NN N
regarding VBG N
the DT N
effectiveness NN N
of IN N
physical JJ N
activity NN N
interventions NNS N
implemented VBN N
in IN N
this DT N
setting NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
effectiveness NN N
and CC N
acceptability NN N
of IN N
a DT N
multi-component JJ N
physical JJ i
activity NN i
intervention NN i
, , N
delivered VBN N
by IN N
childcare NN N
service NN N
staff NN N
, , N
in IN N
increasing VBG N
the DT N
physical JJ N
activity NN N
levels NNS N
of IN N
children NNS p
attending VBG p
long RB p
day NN p
care NN p
services NNS p
. . p

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
employ VB N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
design NN N
. . N

Three CD p
hundred VBD p
children NNS p
aged VBN p
between IN p
3-5 CD p
years NNS p
from IN p
twenty NN p
randomly RB p
selected VBN p
long RB p
day NN p
care NN p
services NNS p
in IN p
the DT p
Hunter NNP p
Region NNP p
of IN p
New NNP p
South NNP p
Wales NNP p
, , p
Australia NNP p
will MD N
be VB N
invited VBN N
to TO N
participate VB N
in IN N
the DT N
trial NN N
. . N

Ten CD N
of IN N
the DT N
20 CD N
long JJ N
day NN N
care NN N
services NNS N
will MD N
be VB N
randomly RB N
allocated VBN N
to TO N
deliver VB N
the DT N
intervention NN N
with IN N
the DT N
remaining VBG N
ten NN N
services NNS N
allocated VBN N
to TO N
a DT N
wait JJ i
list NN i
control NN i
group NN N
. . N

The DT N
physical JJ i
activity NN i
intervention NN i
will MD i
consist VB i
of IN i
a DT i
number NN i
of IN i
strategies NNS i
including VBG i
: : i
delivering NN i
structured VBD i
fundamental JJ i
movement NN i
skill NN i
activities NNS i
, , i
increasing VBG i
physical JJ i
activity NN i
opportunities NNS i
, , i
increasing VBG i
staff NN i
role NN i
modelling NN i
, , i
providing VBG i
children NNS i
with IN i
a DT i
physical JJ i
activity NN i
promoting VBG i
indoor NN i
and CC i
outdoor JJ i
environment NN i
and CC i
limiting VBG i
children NNS i
's POS i
small JJ i
screen JJ i
recreation NN i
and CC i
sedentary JJ i
behaviours NNS i
. . i

Intervention NNP N
effectiveness NN N
will MD N
be VB N
measured VBN N
via IN N
child JJ o
physical JJ o
activity NN o
levels NNS o
during IN o
attendance NN o
at IN o
long RB o
day NN o
care NN o
. . o

The DT N
study NN N
also RB N
seeks VBZ N
to TO N
determine VB N
the DT N
acceptability NN o
and CC o
extent NN o
of IN o
implementation NN o
of IN o
the DT o
intervention NN o
by IN o
services NNS o
and CC N
their PRP$ N
staff NN N
participating VBG N
in IN N
the DT N
study NN N
. . N

DISCUSSION NNP N
The DT N
trial NN N
will MD N
address VB N
current JJ N
gaps NNS N
in IN N
the DT N
research NN N
evidence NN N
base NN N
and CC N
contribute NN N
to TO N
the DT N
design NN N
and CC N
delivery NN N
of IN N
future JJ N
interventions NNS N
promoting VBG N
physical JJ N
activity NN N
for IN N
young JJ p
children NNS p
in IN p
long JJ p
day NN p
care NN p
settings NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
Australian NNP p
New NNP p
Zealand NNP p
Clinical NNP p
Trials NNP p
Registry NNP p
ACTRN12610000087055 NNP N
. . N

-DOCSTART- -6850464- O O

Nonspecific NNP N
and CC N
selective JJ N
stimulation NN N
of IN N
the DT N
immune NN N
system NN N
in IN N
the DT N
treatment NN N
of IN N
carcinoma NN N
in IN N
humans NNS p
. . p

The DT N
experience NN N
of IN N
the DT N
Toronto NNP N
General NNP N
Hospital NNP N
in IN N
the DT N
use NN N
of IN N
nonspecific JJ N
stimulation NN N
of IN N
the DT N
immune NN N
system NN N
with IN N
bacille JJ i
Calmette-Gu?rin NNP i
( ( i
BCG NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
cancer NN N
of IN N
the DT N
gastrointestinal JJ N
tract NN N
, , N
malignant JJ N
melanoma NN N
and CC N
breast NN N
cancer NN N
is VBZ N
described VBN N
. . N

The DT N
results NNS N
are VBP N
presented VBN N
in IN N
terms NNS N
of IN o
survival NN o
curves NNS o
. . o

The DT N
use NN N
of IN i
BCG NNP i
administered VBD N
intraperitoneally RB N
in IN N
a DT N
randomized JJ p
study NN p
of IN p
patients NNS p
with IN p
gastric JJ p
, , p
pancreatic JJ p
and CC p
colorectal JJ p
cancer NN p
proved VBD N
of IN N
no DT o
benefit NN o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
when WRB i
BCG NNP i
was VBD N
given VBN N
orally RB N
in IN N
a DT N
randomized JJ p
study NN p
of IN p
patients NNS p
with IN p
resectable JJ p
cancer NN p
of IN p
the DT p
colon NN p
and CC N
in IN N
nonrandomized JJ N
consecutive JJ N
studies NNS N
of IN p
patients NNS p
with IN p
malignant JJ p
melanoma NN p
and CC p
stage NN p
IV NNP p
carcinoma NN p
of IN p
the DT p
breast NN o
survival NN o
was VBD N
increased VBN N
. . N

In IN N
a DT N
group NN N
of IN p
patients NNS p
with IN p
advanced JJ p
gastrointestinal JJ p
cancer NN p
selective JJ p
stimulation NN p
of IN p
the DT p
immune NN p
system NN p
with IN p
NED NNP p
137 CD p
produced VBD N
a DT N
significant JJ N
increase NN N
in IN o
survival NN o
when WRB N
compared VBN N
with IN N
the DT N
survival NN N
of IN N
historical JJ N
controls NNS N
( ( N
the DT N
patients NNS N
given VBN i
BCG NNP i
intraperitoneally RB N
along RB N
with IN N
5-fluorouracil JJ N
for IN N
gastrointestinal JJ N
cancer NN N
) ) N
. . N

The DT N
results NNS N
of IN N
these DT N
studies NNS N
suggest VBP N
the DT N
need NN N
for IN N
a DT N
more RBR N
rational JJ N
approach NN N
in IN N
manipulating VBG N
the DT N
immune JJ N
response NN N
that WDT N
would MD N
combine VB N
chemotherapy NN N
with IN N
selective JJ N
stimulation NN N
of IN N
the DT N
immune NN N
system NN N
. . N

-DOCSTART- -22240882- O O

Efficacy NN N
of IN N
a DT N
total JJ i
occlusive JJ i
ionic JJ i
silver-containing NN i
dressing VBG i
combination NN i
in IN N
decreasing VBG N
risk NN o
of IN o
surgical JJ o
site NN o
infection NN o
: : o
an DT N
RCT NNP N
. . N

OBJECTIVE NNP N
To TO N
perform VB N
a DT N
comparative JJ N
assessment NN N
of IN N
the DT N
efficacy NN N
of IN N
total JJ i
occlusive JJ i
ionic JJ i
silver-containing NN i
dressing NN i
( ( i
TOISD NNP i
) ) i
combination NN i
vs IN i
no DT i
dressing NN i
after IN N
colorectal JJ p
surgery NN p
. . p

METHOD NNP N
The DT N
surgical JJ N
sites NNS N
from IN N
both DT N
groups NNS N
were VBD N
swabbed VBN N
and CC N
sent VBN N
for IN N
culture NN N
and CC N
sensitivity NN N
upon IN N
wound JJ N
closure NN N
( ( N
superficial JJ N
incisional JJ N
skin NN N
surface NN N
) ) N
in IN N
the DT N
operating NN N
theatre NN N
, , N
as IN N
a DT N
baseline NN N
for IN N
bacterial JJ N
colonisation NN N
. . N

The DT p
patients NNS p
' POS p
surgical JJ p
wounds NNS p
in IN N
the DT N
study NN N
group NN N
were VBD N
dressed VBN N
with IN N
TOISD NNP i
combination NN N
and CC N
the DT N
patient NN N
's POS N
surgical JJ N
wounds NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
the DT N
conventional JJ N
method NN N
of IN N
no DT N
dressing NN N
. . N

A DT N
second JJ N
swab NN N
was VBD N
taken VBN N
from IN N
the DT N
superficial JJ N
incisional JJ N
skin NN N
surface NN N
for IN N
culture NN N
and CC N
sensitivity NN N
investigation NN N
between IN N
the DT N
fifth NN N
to TO N
seventh VB N
postoperative JJ N
day NN N
for IN N
comparison NN N
of IN N
the DT N
bacterial JJ N
colonisation NN N
in IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
One-hundred JJ p
and CC p
sixty-six JJ p
patients NNS p
were VBD p
recruited VBN p
. . p

Six CD p
patients NNS p
dropped VBD p
out RP p
before IN N
the DT N
fifth JJ N
postoperative JJ N
day NN N
, , N
leaving VBG N
79 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
and CC N
81 CD p
patients NNS p
in IN p
the DT p
study NN p
group NN p
. . p

Microbial NNP N
swab NN N
cultures NNS N
revealed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
mean=1.43?0.63 NN N
) ) N
in IN o
bacterial JJ o
colonisation NN o
. . o

The DT o
odds NNS o
ratio NN o
( ( o
OR NNP o
) ) o
of IN N
patients NNS N
with IN N
wounds NNS N
in IN N
the DT N
control NN N
group NN N
was VBD N
4.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
is VBZ N
1.884 CD N
, , N
8.964 CD N
) ) N
more RBR N
likely JJ N
to TO N
be VB N
contaminated VBN N
with IN N
bacteria NNS N
compared VBN N
with IN N
wounds NNS N
covered VBN N
with IN N
occlusive JJ N
ionic JJ N
silver-containing NN N
dressing NN N
. . N

CONCLUSION NNP N
TOISD NNP N
was VBD N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG o
bacterial JJ o
colonisation NN o
on IN N
the DT N
surgical JJ N
site NN N
compared VBN N
with IN N
no DT N
dressing NN N
. . N

However RB N
, , N
it PRP N
properties NNS N
were VBD N
unable JJ N
to TO N
be VB N
put VBN N
into IN N
use NN N
if IN N
there EX N
were VBD N
the DT N
surgical JJ N
sites NNS N
were VBD N
not RB N
infested VBN N
with IN N
bacterial JJ N
. . N

Although IN N
TOISD NNP N
might MD N
not RB N
be VB N
necessarily RB N
on IN N
surgical JJ N
incisional JJ N
site NN N
not RB N
infested VBN N
with IN N
bacteria NNS N
for IN N
the DT N
initial JJ N
post-operation NN N
days NNS N
, , N
it PRP N
is VBZ N
helpful JJ N
in IN N
preventing VBG N
further JJ N
transcription NN N
and CC N
division NN N
for IN N
opportunistic JJ N
bacteria NNS N
, , N
thus RB N
might MD N
reduce VB N
the DT o
risk NN o
of IN o
superficial JJ o
incisional JJ o
SSI NNP o
. . o

The DT N
use NN N
of IN N
TOSID NNP N
though IN N
statistically RB N
insignificant JJ N
compared VBN N
to TO N
no DT N
dressing NN N
, , N
could MD N
also RB N
be VB N
possible JJ N
in IN N
reducing VBG N
the DT o
risk NN o
and CC o
exaceration NN o
of IN o
deep JJ o
incisional JJ o
SSI NNP o
. . o

-DOCSTART- -8792266- O O

The DT N
long-term JJ N
effects NNS N
of IN N
auditory JJ i
training NN i
on IN N
children NNS p
with IN p
autism NN p
. . p

Eighty NNP p
children NNS p
, , p
3-17 JJ p
years NNS p
of IN p
age NN p
, , p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome NN p
and CC p
mild NN p
to TO p
severe VB p
distress NN p
in IN p
the DT p
presence NN p
of IN p
some DT p
sounds NNS p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
. . N

The DT N
experimental JJ N
group NN N
received VBD N
auditory JJ i
training NN i
and CC i
the DT i
control NN i
group NN i
listened VBD i
to TO i
the DT i
same JJ i
unmodified JJ i
music NN i
under IN i
the DT i
same JJ i
conditions NNS i
. . i

Significant JJ N
improvements NNS N
in IN N
behavior NN o
and CC o
severity NN o
of IN o
autism NN o
were VBD N
maintained VBN N
for IN N
12 CD N
months NNS N
by IN N
both DT N
groups NNS N
. . N

Informal NNP N
data NN N
suggested VBD N
that IN N
a DT N
range NN o
of IN o
abnormal JJ o
responses NNS o
to TO N
sound VB o
and CC o
other JJ o
sensory JJ o
abnormalities NNS o
may MD N
also RB N
have VB N
improved VBN N
. . N

Verbal NNP o
and CC o
performance NN o
IQ NNP o
increased VBD N
significantly RB N
3 CD N
to TO N
12 CD N
months NNS N
after IN N
interventions NNS N
. . N

Findings NNS N
suggest VBP N
that IN N
some DT N
aspect NN N
of IN N
both DT N
auditory JJ i
training NN i
and CC i
listening VBG i
to TO N
selected VBN N
unmodified JJ N
music NN N
may MD N
have VB N
a DT N
beneficial JJ o
effect NN o
on IN N
children NNS p
with IN p
autism NN p
and CC p
sound JJ p
sensitivity NN p
, , N
and CC N
indicate VBP N
a DT N
need NN N
for IN N
further JJ N
research NN N
into IN N
the DT N
effects NNS N
that WDT N
led VBD N
to TO N
these DT N
changes NNS N
and CC N
the DT N
mechanisms NNS N
involved VBN N
in IN N
the DT N
sensory JJ N
abnormalities NNS N
commonly RB N
associated VBN N
with IN N
autism NN N
. . N

-DOCSTART- -10188144- O O

Efficacy NN o
and CC o
safety NN o
of IN N
mizolastine JJ i
10 CD N
mg NN N
in IN N
a DT N
placebo-controlled JJ i
comparison NN N
with IN N
loratadine NN i
in IN N
chronic JJ p
idiopathic JJ p
urticaria NNS p
: : p
results NNS N
of IN N
the DT N
MILOR NNP N
Study NNP N
. . N

BACKGROUND NNP N
Mizolastine NNP i
is VBZ N
a DT N
novel JJ N
histamine NN N
H1-antagonist NN N
registered VBD N
in IN N
Europe NNP N
for IN N
the DT N
management NN N
of IN N
allergic JJ N
rhinitis NN N
and CC N
urticaria NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
clinical JJ N
efficacy NN o
and CC o
safety NN o
of IN N
mizolastine NN i
with IN i
loratadine NN i
and CC i
placebo NN i
in IN N
patients NNS p
with IN p
chronic JJ p
idiopathic JJ p
urticaria NN p
( ( p
CIU NNP p
) ) p
. . p

METHODS CC N
A DT N
multicentre NN N
, , N
double-blind NN N
, , N
parallel JJ N
group NN N
study NN N
was VBD N
designed VBN N
in IN N
which WDT N
247 CD p
patients NNS p
with IN p
CIU NNP p
were VBD N
randomised VBN N
after IN N
a DT N
1-week JJ N
placebo NN i
run-in JJ N
period NN N
to TO N
10 CD N
mg NNS N
daily JJ N
mizolastine NN i
( ( N
n JJ N
= NNP N
88 CD N
) ) N
, , N
10 CD N
mg JJ N
daily JJ N
loratadine NN i
( ( N
n JJ N
= NNP N
79 CD N
) ) N
, , N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
80 CD N
) ) N
for IN N
a DT N
4-week JJ N
treatment NN N
period NN N
. . N

RESULTS NNP N
Mizolastine NNP i
and CC N
loratadine VB i
both DT N
relieved JJ o
symptoms NNS o
of IN o
CIU NNP o
. . o

After IN N
2 CD N
weeks NNS N
' POS N
treatment NN N
, , N
the DT N
severity NN o
of IN o
pruritus NN o
( ( o
visual JJ o
analogue NN o
score NN o
( ( o
VAS NNP o
) ) o
assessed VBN o
by IN o
patients NNS o
) ) o
decreased VBD N
significantly RB N
in IN N
both CC N
the DT N
mizolastine NN i
and CC i
loratadine NN i
groups NNS N
compared VBN N
with IN N
placebo NN i
( ( i
mizolastine NN i
: : i
-36.7 NN N
mm NN N
, , N
P NNP N
= NNP N
0.0001 CD N
; : N
loratadine NN i
: : i
-29.8 NN N
, , N
P NNP N
= NNP N
0.0071 CD N
; : N
placebo NN i
: : i
-16.3 NN N
) ) N
; : N
this DT N
improvement NN N
with IN N
both DT N
active JJ N
treatments NNS N
was VBD N
maintained VBN N
throughout IN N
the DT N
treatment NN N
period NN N
, , N
the DT N
difference NN N
being VBG N
significant JJ N
only RB N
for IN N
the DT N
mizolastine NN N
group NN N
( ( N
P NNP N
= NNP N
0.0090 CD N
) ) N
. . N

Both DT N
active JJ N
treatments NNS N
were VBD N
also RB N
associated VBN N
with IN N
reduced JJ N
weekly JJ N
episodes NNS o
of IN o
urticaria NNS o
compared VBN N
with IN N
placebo NN i
, , N
which WDT N
was VBD N
significant JJ N
after IN N
2 CD N
weeks NNS N
' POS N
treatment NN N
( ( i
mizolastine NN i
: : i
7.9 CD N
episodes NNS N
, , N
P NNP N
= NNP N
0.0061 CD N
; : N
loratadine NN i
: : i
8.3 CD N
, , N
P NNP N
= NNP N
0.0221 CD N
; : N
placebo NN i
: : i
13.3 CD N
) ) N
. . N

Angioedema NNP o
was VBD N
improved VBN N
to TO N
a DT N
clinically RB N
significant JJ N
extent NN N
with IN N
mizolastine NN i
, , N
and CC N
loratadine NN i
compared VBN N
with IN N
placebo NN i
in IN N
those DT N
patients NNS p
who WP p
had VBD p
this DT p
symptom NN p
before IN p
treatment NN p
. . p

Overall JJ o
tolerability NN o
of IN N
both DT N
treatments NNS N
was VBD N
similar JJ N
to TO N
placebo VB i
, , N
and CC N
there EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
effects NNS o
on IN o
cardiac JJ o
repolarisation NN o
with IN N
either DT N
mizolastine NN i
or CC i
loratadine NN i
. . i

CONCLUSION NNP N
Mizolastine NNP i
( ( N
10 CD N
mg NNS N
daily RB N
) ) N
is VBZ N
confirmed VBN N
as IN N
an DT N
effective JJ o
and CC o
well RB o
tolerated JJ o
agent NN N
, , N
comparable JJ N
to TO N
loratadine VB N
and CC N
superior VB N
to TO N
placebo VB i
, , N
for IN N
the DT N
management NN N
of IN N
CIU NNP N
. . N

Mizolastine NNP i
acted VBD N
as RB N
rapidly RB N
as IN N
loratadine NN i
in IN N
improving VBG N
urticarial JJ o
symptoms NNS o
from IN N
the DT N
first JJ N
day NN N
of IN N
treatment NN N
. . N

-DOCSTART- -3318754- O O

An DT N
evaluation NN N
of IN N
family NN i
therapy NN i
in IN N
anorexia JJ p
nervosa NN p
and CC p
bulimia NN p
nervosa NN p
. . p

A DT N
controlled JJ N
trial NN N
comparing VBG N
family NN i
therapy NN i
with IN N
individual JJ N
supportive JJ N
therapy NN N
in IN N
anorexia JJ N
nervosa NN N
and CC N
bulimia NN N
nervosa NN N
was VBD N
undertaken VBN N
. . N

Eighty JJ p
patients NNS p
( ( p
57 CD p
with IN p
anorexia JJ p
nervosa NN p
; : p
23 CD p
with IN p
bulimia NN p
nervosa NN p
) ) p
were VBD p
first RB p
admitted VBN p
to TO p
a DT p
specialized JJ p
unit NN p
to TO p
restore VB p
their PRP$ p
weight NN p
to TO p
normal JJ p
. . p

Before IN N
discharge NN N
, , N
they PRP N
were VBD N
randomly RB N
allocated VBN N
to TO N
family NN i
therapy NN i
or CC i
the DT i
control NN i
treatment NN i
( ( i
individual JJ i
supportive JJ i
therapy NN i
) ) i
. . N

After IN N
one CD N
year NN N
of IN N
psychological JJ N
treatment NN N
, , N
they PRP N
were VBD N
reassessed VBN N
, , N
using VBG N
body NN o
weight NN o
, , o
menstrual JJ o
function NN o
, , o
and CC o
ratings NNS o
on IN o
the DT o
Morgan NNP o
and CC o
Russell NNP o
scales NNS o
. . o

Family NNP o
therapy NN o
was VBD o
found VBN o
to TO o
be VB o
more RBR o
effective JJ o
than IN o
individual JJ o
therapy NN o
in IN N
patients NNS p
whose WP$ p
illness NN p
was VBD p
not RB p
chronic JJ p
and CC p
had VBD p
begun VBN p
before IN p
the DT p
age NN p
of IN p
19 CD p
years NNS p
. . p

A DT N
more RBR N
tentative JJ N
finding NN N
was VBD N
the DT N
greater JJR N
value NN N
of IN N
individual JJ N
supportive JJ N
therapy NN N
in IN N
older JJR p
patients NNS p
. . p

To TO N
our PRP$ N
knowledge NN N
, , N
this DT N
is VBZ N
the DT N
first JJ N
controlled JJ N
trial NN N
of IN N
family NN N
therapy NN N
in IN N
anorexia JJ N
nervosa NN N
and CC N
clarifies VBZ N
the DT N
specific JJ N
indications NNS N
for IN N
this DT N
treatment NN N
. . N

-DOCSTART- -2271374- O O

Investigations NNS N
into IN N
the DT N
potential JJ N
effects NNS N
of IN N
multiple JJ N
dose JJ N
ketorolac NN N
on IN N
the DT N
pharmacokinetics NNS o
and CC o
pharmacodynamics NNS o
of IN o
racemic JJ o
warfarin NN o
. . o

1 CD N
. . N

The DT N
potential JJ N
interaction NN N
between IN N
racemic JJ i
warfarin NN i
given VBN N
as IN N
a DT N
25 CD i
mg NN i
single JJ i
oral JJ i
dose NN i
and CC i
chronically RB i
administered VBD i
ketorolac NN i
was VBD N
studied VBN N
in IN N
12 CD p
young JJ p
healthy JJ p
male NN p
volunteers NNS p
. . p

2 CD N
. . N

Ketorolac NNP i
produced VBD N
no DT o
major JJ o
change NN o
in IN o
the DT o
pharmacokinetics NNS o
of IN o
( ( o
R NNP o
) ) o
- : o
or CC o
( ( o
S NNP o
) ) o
-warfarin NN o
. . o

3 CD N
. . N

Ketorolac NNP i
did VBD o
not RB o
alter VB o
the DT o
pharmacodynamic JJ o
profile NN o
of IN o
racemic JJ o
warfarin NN o
. . o

4 CD N
. . N

Ketorolac NNP i
increased VBD o
template VB o
bleeding NN o
time NN o
by IN N
a DT N
factor NN N
of IN N
1.35 CD N
as IN N
compared VBN N
with IN N
placebo NN N
. . N

5 CD N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
the DT N
ketorolac-warfarin JJ N
interaction NN N
is VBZ N
unlikely JJ N
to TO N
be VB N
of IN N
major JJ N
clinical JJ N
significance NN N
; : N
however RB N
, , N
combined VBN N
use NN N
of IN N
ketorolac NN i
and CC N
warfarin NN i
in IN N
patients NNS N
should MD N
be VB N
undertaken VBN N
with IN N
due JJ N
caution NN N
and CC N
appropriate JJ N
monitoring NN N
. . N

-DOCSTART- -17443855- O O

Long-term JJ N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
Shouldice NNP i
, , i
Lichtenstein NNP i
and CC i
transabdominal JJ i
preperitoneal NN i
hernia NN i
repairs NNS i
. . i

INTRODUCTION NNP N
There EX N
is VBZ N
an DT N
ongoing JJ N
debate NN N
about IN N
the DT N
preferred JJ N
technique NN N
for IN N
inguinal JJ N
hernia NN N
repair NN N
. . N

In IN N
this DT N
randomized VBN N
study NN N
the DT N
long-term JJ N
results NNS N
of IN N
Shouldice NNP i
, , i
Lichtenstein NNP i
and CC N
transabdominal JJ i
preperitoneal NN i
( ( i
TAPP NNP i
) ) i
hernia NN i
repair NN i
were VBD N
compared VBN N
. . N

METHODS NNP N
Some DT p
280 CD p
men NNS p
with IN p
a DT p
primary JJ p
hernia NN p
were VBD p
randomized VBN p
prospectively RB N
to TO N
undergo VB N
Shouldice NNP i
, , i
tension-free JJ i
Lichtenstein NNP i
or CC i
laparoscopic JJ i
TAPP NNP i
repair NN i
. . i

Patients NNS N
were VBD N
examined VBN N
after IN N
52 CD N
months NNS N
to TO N
assess VB N
hernia NN o
recurrence NN o
, , o
nerve NN o
damage NN o
, , o
testicular JJ o
atrophy NN o
and CC o
patient JJ o
satisfaction NN o
. . o

RESULTS NNP N
Hernia NNP o
recurrence NN o
occurred VBD N
in IN N
six CD N
patients NNS N
after IN N
Shouldice NNP N
repair NN N
, , N
and CC N
in IN N
one CD N
patient NN N
each DT N
after IN N
Lichtenstein NNP N
and CC N
TAPP NNP N
repairs NNS N
. . N

All DT N
recurrences NNS o
after IN o
tension-free JJ o
repairs NNS o
were VBD N
diagnosed VBN N
within IN N
the DT N
first JJ N
year NN N
after IN N
surgery NN N
. . N

Nerve CC o
injuries NNS o
were VBD N
significantly RB N
more RBR N
frequent JJ N
after IN N
open JJ N
Shouldice NNP N
and CC N
Lichtenstein NNP N
repairs NNS N
. . N

Patient JJ o
satisfaction NN o
was VBD N
greatest JJS N
after IN N
laparoscopic JJ N
TAPP NNP N
repair NN N
. . N

CONCLUSION NNP N
Tension-free NNP N
repair NN N
was VBD N
superior JJ N
to TO N
the DT N
non-mesh JJ N
Shouldice NNP N
technique NN N
. . N

The DT N
open JJ N
anterior JJ N
approach NN N
to TO N
the DT N
groin NN N
was VBD N
associated VBN N
with IN N
demonstrable JJ N
nerve NN o
injury NN o
, , N
and CC N
laparoscopic JJ N
TAPP NNP N
repair NN N
was VBD N
the DT N
most RBS N
effective JJ N
approach NN N
in IN N
the DT N
hands NNS N
of IN N
an DT N
experienced JJ N
surgeon NN N
. . N

-DOCSTART- -8628584- O O

Relaxation NN i
and CC i
imagery NN i
and CC i
cognitive-behavioral JJ i
training NN i
reduce VB N
pain NN o
during IN N
cancer NN N
treatment NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
. . N

Few NNP N
controlled VBD N
clinical JJ N
trials NNS N
of IN N
psychological JJ N
interventions NNS N
for IN N
cancer NN o
pain NN o
relief NN o
exist NN N
in IN N
spite NN N
of IN N
frequent JJ N
support NN N
for IN N
their PRP$ N
importance NN N
as IN N
adjuncts NNS N
to TO N
medical JJ N
treatment NN N
. . N

This DT N
study NN N
compared VBN N
oral JJ N
mucositis NN N
pain NN N
levels NNS N
in IN N
4 CD p
groups NNS p
of IN p
cancer NN p
patients NNS p
receiving VBG p
bone NN p
marrow NN p
transplants NNS p
( ( p
BMT NNP p
) ) p
: : p
( ( p
1 CD p
) ) p
treatment NN i
as IN i
usual JJ i
control NN i
, , i
( ( i
2 CD i
) ) i
therapist NN i
support NN i
, , i
( ( i
3 CD i
) ) i
relaxation NN i
and CC i
imagery NN i
training NN i
, , i
and CC i
( ( i
4 CD i
) ) i
training NN i
in IN i
a DT i
package NN i
of IN i
cognitive-behavioral JJ i
coping NN i
skills NNS i
which WDT i
included VBD i
relaxation NN i
and CC i
imagery NN i
. . i

A DT N
total NN N
of IN N
94 CD p
patients NNS p
completed VBD p
the DT p
study NN p
which WDT p
involved VBD p
two CD p
training NN p
sessions NNS p
prior RB p
to TO p
treatment NN p
and CC p
twice RB p
a DT p
week NN p
'booster POS p
' POS p
sessions NNS p
during IN p
the DT p
first JJ p
5 CD p
weeks NNS p
of IN p
treatment NN p
. . p

Results NNS N
confirmed VBD N
our PRP$ N
hypothesis NN N
that IN N
patients NNS N
who WP N
received VBD N
either DT N
relaxation NN N
and CC N
imagery VB N
alone RB N
or CC N
patients NNS N
who WP N
received VBD N
the DT N
package NN N
of IN N
cognitive-behavioral JJ N
coping NN N
skills NNS N
would MD N
report VB N
less JJR N
pain NN o
than IN N
patients NNS N
in IN N
the DT N
other JJ N
2 CD N
groups NNS N
. . N

The DT N
hypothesis NN N
that IN N
the DT N
cognitive-behavioral JJ N
skills NNS N
package NN N
would MD N
have VB N
an DT N
additive JJ N
effect NN N
beyond IN N
relaxation NN N
and CC N
imagery NN N
alone RB N
was VBD N
not RB N
confirmed VBN N
. . N

Average JJ o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
report NN o
of IN o
pain NN o
within IN N
the DT N
therapist JJ N
support NN N
group NN N
was VBD N
not RB N
significantly RB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.103 CD N
) ) N
nor CC N
significantly RB N
higher JJR N
than IN N
the DT N
training NN N
groups NNS N
. . N

Patient JJ N
reports NNS N
of IN N
relative JJ N
helpfulness NN N
of IN N
the DT N
interventions NNS N
for IN N
managing VBG N
pain NN o
and CC o
nausea NN o
matched VBD N
the DT N
results NNS N
of IN N
VAS NNP N
reports NNS N
. . N

From IN N
these DT N
results NNS N
, , N
we PRP N
conclude VBP N
that DT N
relaxation NN N
and CC N
imagery NN N
training NN N
reduces NNS N
cancer NN o
treatment-related JJ o
pain NN o
; : o
adding VBG N
cognitive-behavioral JJ N
skills NNS N
to TO N
the DT N
relaxation NN N
with IN N
imagery NN N
does VBZ N
not RB N
, , N
on IN N
average NN N
, , N
further JJ N
improve VB N
pain NN o
relief NN o
. . o

-DOCSTART- -25912520- O O

Effects NNS N
of IN N
the DT N
Quest NNP i
to TO i
Lava NNP i
Mountain NNP i
Computer NNP i
Game NNP i
on IN N
Dietary NNP o
and CC o
Physical NNP o
Activity NNP o
Behaviors NNP o
of IN N
Elementary NNP p
School NNP p
Children NNP p
: : p
A DT N
Pilot NNP N
Group-Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Computer-based JJ i
educational JJ i
games NNS i
present VBP N
an DT N
opportunity NN N
for IN N
health NN N
education NN N
in IN N
school NN N
; : N
however RB N
, , N
their PRP$ N
feasibility NN N
in IN N
school NN N
settings NNS N
and CC N
effectiveness NN N
in IN N
changing VBG N
behavior NN N
are VBP N
poorly RB N
understood JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
, , N
acceptability NN N
, , N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP i
to TO i
Lava NNP i
Mountain NNP i
( ( i
QTLM NNP i
) ) i
computer NN i
game NN i
on IN N
dietary JJ o
behaviors NNS o
, , o
physical JJ o
activity NN o
behaviors NNS o
, , o
and CC o
psychosocial JJ o
factors NNS o
among IN N
ethnically RB p
diverse JJ p
children NNS p
in IN p
Texas NNP p
. . p

DESIGN NNP N
Quasi-experimental JJ N
group-randomized JJ N
controlled VBN N
trial NN N
conducted VBN N
during IN N
the DT N
2012-2013 JJ p
school NN p
year NN p
. . p

PARTICIPANTS/SETTING CC N
A DT p
total NN p
of IN p
107 CD p
children NNS p
in IN p
fourth JJ p
and CC p
fifth JJ p
grade NN p
consented VBN p
. . p

There EX p
was VBD p
an DT p
attrition NN p
rate NN p
of IN p
8.8 CD p
% NN p
with IN p
a DT p
final JJ p
sample NN p
size NN p
of IN p
44 CD p
children NNS p
in IN p
three CD p
intervention NN p
schools NNS p
, , p
and CC p
a DT p
sample NN p
of IN p
50 CD p
children NNS p
in IN p
three CD p
comparison NN p
schools NNS p
. . p

Dietary NNP N
intake NN N
was VBD N
measured VBN N
using VBG N
two CD N
random JJ N
24-hour JJ N
recalls NNS N
, , N
whereas JJ N
child NN N
self-report JJ N
surveys NNS N
measured VBN N
diet JJ o
, , o
physical JJ o
activity NN o
, , o
and CC o
psychosocial JJ o
factors NNS o
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

Process NNP N
data NN N
on IN N
QTLM NNP i
usability NN N
and CC N
back-end JJ N
server NN N
data NNS N
on IN N
QTLM NNP N
exposure NN N
and CC N
progress NN N
achieved VBN N
were VBD N
collected VBN N
. . N

INTERVENTION NNP N
QTLM NNP i
was VBD N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
in-school NN p
or CC p
afterschool JJ p
program NN p
. . p

Recommended JJ N
game NN N
exposure NN N
duration NN N
was VBD N
90 CD N
min/wk NN N
for IN N
6 CD N
weeks NNS N
. . N

STATISTICAL JJ N
ANALYSIS NNP N
Analysis NNP N
of IN N
covariance NN N
or CC N
logistic JJ N
regression NN N
models NNS N
evaluated VBN N
effects NNS N
of IN N
QTLM NNP i
on IN N
diet JJ o
, , o
physical JJ o
activity NN o
, , o
and CC o
psychosocial JJ o
factors NNS o
. . o

Post NNP N
hoc JJ N
exploratory NN N
analysis NN N
examined VBD N
the DT N
changes NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
outcome JJ N
variables NNS N
among IN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

Significance NN N
was VBD N
set VBN N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

RESULTS NNP N
Children NNP N
played VBD N
an DT N
average NN N
of IN N
274?110 CD N
minutes NNS N
( ( N
approximately RB N
4.6 CD N
hours NNS N
) ) N
of IN i
QTLM NNP i
during IN N
the DT N
6 CD N
weeks NNS N
( ( N
51 CD N
% NN N
of IN N
recommended JJ N
dosage NN N
) ) N
. . N

Compared VBN N
with IN N
the DT N
comparison NN N
group NN N
, , N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD o
decreased JJ o
sugar NN o
consumption NN o
( ( N
P=0.021 NNP N
) ) N
and CC o
higher JJR o
nutrition/physical JJ o
activity NN o
attitudes NNS o
( ( N
P=0.041 NNP N
) ) N
pre- NN N
to TO N
postintervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
QTLM NNP N
on IN o
physical JJ o
activity NN o
. . o

However RB N
, , N
post NN N
hoc NN N
analysis NN N
showed VBD N
that IN N
higher JJR i
QTLM NNP i
exposure NN N
and CC N
gaming VBG N
progress NN N
was VBD N
associated VBN N
with IN N
increased JJ o
frequency NN o
of IN o
physical JJ o
activity NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP i
QTLM NNP i
has VBZ N
some DT N
promising JJ N
acceptability NN N
and CC N
initial JJ N
effects NNS N
on IN o
diet JJ o
and CC o
physical JJ o
activity NN o
behaviors NNS o
among IN p
children NNS p
in IN p
elementary JJ p
school NN p
. . p

-DOCSTART- -11420161- O O

Effect NN N
of IN N
ischaemic JJ i
preconditioning NN i
, , i
cardiopulmonary JJ i
bypass NN i
and CC i
myocardial JJ i
ischaemic/reperfusion NN i
on IN N
free JJ o
radical JJ o
generation NN o
in IN N
CABG NNP p
patients NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
free JJ N
radicals NNS N
( ( N
FR NNP N
) ) N
generation NN N
after IN N
ischaemic JJ i
preconditioning NN i
and CC N
cardiopulmonary JJ i
bypass NN i
and CC N
during IN N
reperfusion NN N
in IN N
CABG NNP p
patients NNS p
, , N
and CC N
the DT N
role NN N
of IN N
ischaemic JJ i
preconditioning NN i
. . i

METHODS NNP N
Forty-three JJ p
CABG NNP p
patients NNS p
were VBD N
randomised VBN N
into IN N
an DT N
ischaemic JJ i
preconditioning NN i
and CC N
a DT N
control NN i
group NN i
. . i

The DT N
protocol NN N
for IN N
ischaemic JJ i
preconditioning NN i
was VBD N
two CD i
cycles NNS i
of IN i
2-min JJ i
ischaemia NN i
followed VBN i
by IN i
3-min JJ i
reperfusion NN i
. . i

Free JJ o
radicals NNS o
were VBD N
measured VBN N
using VBG N
electron NN N
spin NN N
resonance NN N
spectroscopy NN N
. . N

Global NNP o
and CC o
right JJ o
heart NN o
functions NNS o
were VBD N
collected VBN N
. . N

RESULTS VB N
The DT N
free JJ o
radicals NNS o
generation NN o
in IN o
coronary JJ o
sinus NN o
blood NN o
in IN N
the DT N
ischaemic JJ i
preconditioning NN i
group NN N
was VBD N
9.7 CD N
and CC N
16.6 CD N
% NN N
after IN N
the DT N
ischaemic JJ i
preconditioning NN i
protocol NN N
and CC N
10 CD N
min NN N
after IN N
declamping VBG N
, , N
6.8 CD N
and CC N
13.3 CD N
% NN N
in IN N
the DT N
controls NNS N
. . N

The DT N
free JJ o
radicals NNS o
in IN o
arterial JJ o
samples NNS o
were VBD N
, , N
respectively RB N
, , N
21 CD N
, , N
14 CD N
, , N
10 CD N
and CC N
9 CD N
% NN N
at IN N
10 CD N
min NN N
, , N
1 CD N
, , N
2 CD N
and CC N
24 CD N
h NN N
after IN N
reperfusion NN N
. . N

Cardiac NNP o
index NN o
( ( o
CI NNP o
) ) o
and CC o
right JJ o
ventricular NN o
ejection NN o
fraction NN o
( ( o
RVEF NNP o
) ) o
were VBD N
improved VBN N
by IN N
ischaemic JJ i
preconditioning NN i
. . i

CONCLUSION NNP N
Both NNP N
ischaemic JJ i
preconditioning NN i
and CC N
cardiopulmonary JJ i
bypass NN i
induced VBD N
free JJ o
radicals NNS o
generation NN o
. . o

Although IN N
ischaemic JJ i
preconditioning NN i
had VBD N
no DT N
effect NN N
on IN N
free JJ o
radicals NNS o
generation NN o
after IN N
the DT N
operation NN N
, , N
it PRP N
protected VBD N
against IN N
postoperative JJ N
stunning NN N
. . N

-DOCSTART- -21439528- O O

Efficacy NN N
and CC N
safety NN N
of IN N
transient JJ i
ulnar JJ i
artery NN i
compression NN i
to TO N
recanalize VB N
acute JJ N
radial JJ N
artery NN N
occlusion NN N
after IN N
transradial JJ N
catheterization NN N
. . N

Radial JJ N
artery NN N
occlusion NN N
( ( N
RAO NNP N
) ) N
can MD N
result VB N
from IN N
transradial JJ N
catheterization NN N
. . N

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
RAO NNP N
with IN N
2 CD N
heparin JJ N
dosage NN N
regimens NNS N
after IN N
transradial JJ N
coronary JJ N
angiography NN N
, , N
and CC N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
achieve VB N
acute JJ N
radial JJ N
artery NN N
recanalization NN N
. . N

Patients NNS p
referred VBD p
for IN p
coronary JJ p
angiography NN p
were VBD N
randomized VBN N
to TO N
very-low-dose JJ i
heparin NN i
( ( N
2,000 CD N
IU NNP N
) ) N
or CC N
low-dose JJ i
heparin NN i
( ( N
5,000 CD N
IU NNP N
) ) N
. . N

On IN N
sheath NN N
removal NN N
, , N
hemostasis NN N
was VBD N
obtained VBN N
using VBG N
the DT N
TR NNP N
band NN N
with IN N
a DT N
plethysmography-guided JJ N
patent NN N
hemostasis NN N
technique NN N
. . N

In IN N
the DT N
case NN N
of IN N
RAO NNP N
as IN N
assessed VBN N
by IN N
duplex JJ N
ultrasonography NN N
3 CD N
to TO N
4 CD N
hours NNS N
after IN N
hemostasis NN N
, , N
immediate JJ N
1-hour JJ N
ulnar JJ N
artery NN N
compression NN N
was VBD N
applied VBN N
. . N

Hematomas NNP N
> VBD N
15 CD N
cm NN N
( ( N
2 CD N
) ) N
were VBD N
also RB N
assessed VBN N
. . N

We PRP N
randomized VBD N
465 CD p
patients NNS p
, , N
222 CD N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
243 CD N
in IN N
the DT N
5,000-IU JJ N
group NN N
. . N

The DT N
baseline NN N
and CC N
procedural JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
incidence NN o
of IN o
initial JJ o
RAO NNP o
was VBD N
5.9 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
with IN N
a DT N
compression NN N
time NN N
of IN N
2.10 CD N
? . N
0.78 CD N
hours NNS N
and CC N
2.25 CD N
? . N
0.82 CD N
hours NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

After IN i
ulnar JJ i
artery NN i
compression NN i
, , i
the DT o
final JJ o
incidence NN o
of IN o
RAO NNP o
was VBD o
4.1 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
0.8 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

The DT o
incidence NN o
of IN o
local JJ o
hematoma NN o
was VBD o
2.3 CD N
% NN N
and CC N
3.7 CD N
% NN N
in IN N
the DT N
2,000- JJ N
and CC N
5,000-IU JJ N
groups NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.42 CD N
) ) N
. . N

In IN N
conclusion NN o
, , o
acute JJ o
RAO NNP o
after IN o
transradial JJ o
catheterization NN o
can MD o
be VB N
recanalized VBN N
by IN N
early JJ N
1-hour JJ i
homolateral JJ i
ulnar JJ i
artery NN i
compression NN i
. . i

This DT N
simple JJ N
nonpharmacologic JJ N
method NN N
was VBD o
effective JJ o
and CC o
safe JJ o
in IN o
patients NNS p
with IN p
very-low- JJ p
and CC p
low-dose JJ p
heparin NN p
. . p

Nevertheless NNP N
, , N
the DT N
incidence NN N
of IN N
final JJ N
RAO NNP N
remained VBD o
significantly RB o
lower JJR o
after IN o
a DT N
higher JJR N
anticoagulation NN N
level NN N
. . N

-DOCSTART- -25795561- O O

Offering VBG N
personalized VBN i
health NN i
behavior NN i
feedback NN i
did VBD N
not RB N
increase VB N
response NN o
rate NN o
: : o
a DT N
randomized NN p
controlled VBN N
trial NN N
. . N

-DOCSTART- -16772718- O O

Intermittent NNP i
recombinant JJ i
growth NN i
hormone NN i
treatment NN i
in IN N
short JJ p
children NNS p
born VBP p
small JJ p
for IN p
gestational JJ p
age NN p
: : p
four-year JJ N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
different JJ N
treatment NN N
regimens NNS N
. . N

BACKGROUND NNP N
Treatment NNP N
of IN N
short JJ p
children NNS p
born VBP p
small JJ p
for IN p
gestational JJ p
age NN p
SGA NNP p
with IN N
recombinant JJ i
human JJ i
growth NN i
hormone VBD i
r-hGH JJ i
increases NNS N
growth NN o
velocity NN o
during IN N
childhood NN N
. . N

As IN N
in IN N
other JJ N
indications NNS N
, , N
the DT N
growth NN o
velocity NN o
in IN N
these DT N
patients NNS N
is VBZ N
more JJR N
marked JJ N
during IN N
the DT N
first JJ N
year NN N
of IN N
treatment NN N
and CC N
then RB N
decreases VBZ N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
different JJ N
r-hGH JJ i
treatment NN i
schedules NNS N
( ( N
67 CD N
microg/kg/day NN N
in IN N
a DT N
discontinuous JJ N
or CC N
continuous JJ N
regimen NNS N
) ) N
during IN N
the DT N
second JJ N
year NN N
of IN N
r-hGH JJ N
treatment NN N
by IN N
comparing VBG N
height JJ o
velocity NN o
changes NNS N
and CC N
total JJ o
gain NN o
of IN o
height NN o
over IN N
a DT N
4-year JJ N
period NN N
. . N

METHODS $ N
58 CD p
growth-retarded JJ p
SGA NNP p
children NNS p
aged VBN p
2-5 CD p
years NNS p
were VBD p
randomized VBN p
to TO N
a DT N
TOTO NNP i
regimen NN i
( ( N
4 CD N
years NNS N
alternating VBG N
treatment NN N
( ( N
T NNP N
) ) N
and CC N
observation NN N
( ( N
O NNP N
) ) N
, , N
n JJ N
= NNP N
30 CD N
) ) N
or CC N
a DT N
TTOO JJ N
regimen NN N
( ( N
2 CD N
years NNS N
' POS N
treatment NN N
, , N
followed VBN N
by IN N
2 CD N
years NNS N
' POS N
observation NN N
, , N
n JJ N
= NNP N
28 CD N
) ) N
. . N

Height NNP o
velocity NN o
HV NNP o
and CC o
total JJ o
height NN o
gain NN o
were VBD N
assessed VBN N
during IN N
the DT N
4-year JJ N
study NN N
. . N

RESULTS NNP N
In IN N
both DT N
groups NNS N
, , N
HV NNP o
and CC o
HV NNP o
standard JJ o
deviation NN o
score VBD o
HV-SDSCA NNP o
increased VBD N
during IN N
treatment NN N
and CC N
decreased VBD N
during IN N
observation NN N
periods NNS N
. . N

Interruption NN N
of IN N
treatment NN N
in IN N
the DT N
TOTO NNP N
group NN N
did VBD N
not RB N
result VB N
in IN N
a DT N
better JJR N
gain NN o
in IN o
height JJ o
standard NN o
deviation NN o
score VBD o
H-SDSCA NNP o
when WRB N
compared VBN N
with IN N
the DT N
TTOO NNP N
group NN N
. . N

After IN N
4 CD N
years NNS N
of IN N
study NN N
, , N
the DT N
gain NN o
in IN o
H-SDSCA NNP o
was VBD N
1.4 CD N
+ NN N
or CC N
- : N
01 CD N
in IN N
the DT N
TOTO NNP N
group NN N
and CC N
1.6 CD N
+ NN N
or CC N
- : N
0.2 CD N
in IN N
the DT N
TTOO NNP N
group NN N
leading VBG N
to TO N
a DT N
mean JJ N
height NN o
of IN N
-2.0 NNP N
+ NNP N
or CC N
- : N
1.0 CD N
SDS NNP N
and CC N
-2.0 NNP N
+ NNP N
or CC N
- : N
0.8 CD N
SDS NNP N
, , N
respectively RB N
. . N

The DT N
rate NN o
of IN o
bone NN o
maturation NN o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
short JJ N
SGA NNP N
children NNS N
, , N
TOTO NNP i
and CC N
TTOO NNP i
regimens NNS N
produced VBD N
significant JJ N
improvements NNS N
in IN N
growth NN o
during IN N
r-hGH JJ i
treatment NN i
. . N

However RB N
, , N
treatment NN N
interruption NN N
after IN N
1 CD N
year NN N
did VBD N
not RB N
influence VB N
the DT N
overall JJ o
gain NN o
in IN o
height NN o
SDS NNP o
when WRB N
compared VBN N
with IN N
2 CD N
years NNS N
' POS N
continuous JJ N
treatment NN N
. . N

-DOCSTART- -15994014- O O

The DT N
assessment NN N
of IN N
erythema NN o
and CC o
thickness NN o
on IN o
burn NN o
related JJ o
scars NNS o
during IN N
pressure NN i
garment NN i
therapy NN i
as IN N
a DT N
preventive JJ N
measure NN N
for IN N
hypertrophic JJ N
scarring NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
threefold VBN N
: : N
( ( N
1 CD N
) ) N
Assess IN N
the DT N
pressure NN N
loss NN N
of IN N
two CD i
types NNS i
of IN i
pressure NN i
garments NNS i
that WDT N
are VBP N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
hypertrophic JJ p
scars NNS p
after IN p
burn JJ p
injury NN p
, , N
( ( N
2 CD N
) ) N
investigate VB N
the DT N
influence NN N
of IN N
two CD i
different JJ i
levels NNS i
of IN i
compression NN i
on IN N
erythema NN o
and CC o
thickness NN o
of IN o
burn NN o
scars NNS o
and CC N
( ( N
3 CD N
) ) N
examine VBP N
the DT N
association NN N
between IN N
erythema NN o
and CC o
thickness NN o
. . o

The DT N
study NN N
was VBD N
a DT N
prospective JJ N
trial NN N
in IN N
which WDT N
76 CD p
burn NN p
scars NNS p
in IN p
60 CD p
patients NNS p
were VBD p
objectively RB N
assessed VBN i
with IN i
the DT i
Minolta NNP o
Chromameter NNP o
CR-300 NNP o
for IN i
erythema NN i
and CC i
with IN i
the DT i
Dermascan NNP o
C NNP o
for IN o
thickness NN o
of IN o
the DT o
scar NN o
over IN i
a DT i
period NN i
of IN i
3 CD i
months NNS i
. . i

Each DT N
patient NN N
was VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
normal JJ i
or CC i
lower JJR i
compression NN i
class NN i
treatment NN i
, , i
with IN i
respectively JJ i
mean JJ i
values NNS i
of IN i
15 CD i
and CC i
10 CD i
mmHg NN i
pressure NN i
after IN i
wearing VBG i
the DT i
garment NN i
for IN i
1 CD i
month NN i
. . i

Measurements NNS i
for IN i
both DT i
parameters NNS i
were VBD i
taken VBN i
at IN i
0 CD i
, , i
1 CD i
, , i
2 CD i
and CC i
3 CD i
months NNS i
of IN i
treatment NN i
. . i

Pressure NN N
garments NNS N
with IN N
normal JJ N
compression NN N
did VBD N
lose VB N
significantly RB N
more JJR N
compression NN o
over IN N
1 CD N
month NN N
( ( N
4.82 CD N
mmHg NN N
) ) N
than IN N
did VBD N
the DT N
garments NNS N
from IN N
the DT N
low JJ N
compression NN N
class NN N
( ( N
2.57 CD N
mmHg NN N
) ) N
. . N

Scars NNS o
that WDT N
were VBD N
treated VBN N
with IN N
garments NNS N
from IN N
a DT N
normal JJ N
compression NN N
class NN N
did VBD N
score RB N
significantly RB N
better RBR N
for IN N
thickness NN o
compared VBN N
to TO N
the DT N
low JJ N
compression NN N
class NN N
. . N

The DT N
difference NN N
in IN N
thickness NN o
was VBD N
most RBS N
evident JJ N
at IN N
1 CD N
month NN N
. . N

Thereafter NNP N
no DT N
further JJ N
significant JJ N
improvement NN N
between IN N
the DT N
two CD N
different JJ N
treatments NNS N
over IN N
time NN N
could MD N
be VB N
obtained VBN N
. . N

This DT N
difference NN N
was VBD N
not RB N
found VBN N
for IN N
erythema NN o
. . o

Positive JJ N
correlations NNS N
could MD N
be VB N
found VBN N
between IN N
erythema NN o
and CC o
thickness NN o
values NNS o
at IN N
all DT N
of IN N
the DT N
three CD N
test NN N
points NNS N
while IN N
changes NNS N
in IN N
erythema NN o
and CC o
thickness NN o
only RB N
correlated VBD N
significantly RB N
after IN N
the DT N
first JJ N
month NN N
. . N

The DT N
pattern NN N
of IN N
change NN N
of IN N
both DT N
parameters NNS N
correlated VBN N
at IN N
a DT N
high JJ N
level NN N
of IN N
significance NN N
after IN N
3 CD N
months NNS N
of IN N
treatment NN N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
pressure NN N
garments NNS N
that WDT N
deliver VBP N
a DT N
pressure NN N
of IN N
at IN N
least JJS N
15 CD N
mmHg JJ N
pressure NN N
tend VBP N
to TO N
accelerate VB N
scar NN o
maturation NN o
and CC N
that IN N
measurements NNS N
of IN N
the DT N
pattern NN N
of IN N
change NN N
of IN N
the DT N
erythema NN N
can MD N
be VB N
used VBN N
to TO N
predict VB N
changes NNS N
in IN N
scar NN N
thickness NN N
and CC N
vice NN N
versa NN N
. . N

-DOCSTART- -23624061- O O

Are NNP N
postural JJ o
responses NNS o
to TO N
backward VB N
and CC N
forward VB N
perturbations NNS N
processed VBN N
by IN N
different JJ N
neural JJ N
circuits NNS N
? . N
Startle NNP N
pathways VBZ N
may MD N
contribute VB N
to TO N
rapid JJ N
accomplishment NN N
of IN N
postural JJ N
stability NN N
. . N

Here RB N
we PRP N
investigate VBP N
the DT N
possible JJ N
influence NN N
of IN N
a DT N
startling JJ i
auditory NN i
stimulus NN i
( ( i
SAS NNP i
) ) i
on IN N
postural JJ o
responses NNS o
. . o

We PRP N
formulated VBD N
four CD N
specific JJ N
questions NNS N
: : N
( ( N
1 CD N
) ) N
can MD N
a DT N
concurrent JJ N
SAS NNP N
shorten VBD N
the DT N
onset NN N
of IN N
automatic JJ N
postural JJ N
responses NNS N
? . N
; : N
and CC N
if IN N
so RB N
( ( N
2 CD N
) ) N
is VBZ N
this DT N
effect NN N
different JJ N
for IN N
forward RB N
versus FW N
backward NN N
perturbations NNS N
? . N
; : N
( ( N
3 CD N
) ) N
does VBZ N
this DT N
effect NN N
depend NN N
on IN N
prior JJ N
knowledge NN N
of IN N
the DT N
perturbation NN N
direction NN N
? . N
; : N
and CC N
( ( N
4 CD N
) ) N
is VBZ N
this DT N
effect NN N
different JJ N
for IN N
low- JJ N
and CC N
high-magnitude JJ N
perturbations NNS N
? . N
Balance NNP N
was VBD N
perturbed VBN N
in IN N
11 CD p
healthy JJ p
participants NNS p
by IN p
a DT p
movable JJ p
platform NN p
that IN p
suddenly RB p
translated VBN p
forward RB p
or CC p
backward RB p
. . p

Each DT N
participant NN N
received VBD N
160 CD N
perturbations NNS i
, , N
25 CD N
% NN N
of IN N
which WDT N
were VBD N
combined VBN N
with IN N
a DT N
SAS NNP i
. . i

We PRP N
varied VBD N
the DT N
direction NN N
and CC N
magnitude NN N
of IN N
the DT N
perturbations NNS N
, , N
as RB N
well RB N
as IN N
the DT N
prior JJ N
knowledge NN N
of IN N
perturbation NN N
direction NN N
. . N

Perturbation NN N
trials NNS N
were VBD N
interspersed VBN N
with IN N
SAS-only JJ i
trials NNS N
. . N

The DT N
SAS NNP i
accelerated VBD N
and CC N
strengthened VBD N
postural JJ o
responses NNS o
with IN N
clear JJ N
functional JJ N
benefits NNS N
( ( N
better JJR N
balance NN N
control NN N
) ) N
, , N
but CC N
this DT N
was VBD N
only RB N
true JJ N
for IN N
responses NNS N
that WDT N
protected VBD N
against IN N
falling VBG N
backwards NNS N
( ( N
i.e NN N
. . N

in IN N
tibialis JJ N
anterior JJ N
and CC N
rectus JJ N
femoris NN N
) ) N
. . N

These DT N
muscles NNS N
also RB N
demonstrated VBD N
the DT N
most RBS N
common JJ N
SAS-triggered JJ o
responses NNS o
without IN N
perturbation NN N
. . N

Increasing VBG N
the DT N
perturbation NN N
magnitude NN N
accelerated VBD N
postural JJ o
responses NNS o
, , N
but CC N
again RB N
with IN N
a DT N
larger JJR N
acceleration NN N
for IN N
backward JJ N
perturbations NNS N
. . N

We PRP N
conclude VBP N
that IN N
postural JJ N
responses NNS N
to TO N
backward VB N
and CC N
forward VB N
perturbations NNS N
may MD N
be VB N
processed VBN N
by IN N
different JJ N
neural JJ N
circuits NNS N
, , N
with IN N
influence NN N
of IN N
startle NN N
pathways NNS N
on IN N
postural JJ N
responses NNS N
to TO N
backward VB N
perturbations NNS N
. . N

These DT N
findings NNS N
give VBP N
directions NNS N
for IN N
future JJ N
studies NNS N
investigating VBG N
whether IN N
deficits NNS N
in IN N
startle JJ N
pathways NNS N
may MD N
explain VB N
the DT N
prominent JJ N
backward NN N
instability NN N
seen VBN N
in IN N
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
and CC p
progressive JJ p
supranuclear NN p
palsy NN p
. . p

-DOCSTART- -9720660- O O

The DT N
influence NN N
of IN N
sequential JJ N
annual JJ N
vaccination NN i
and CC i
of IN i
DHEA NNP i
administration NN i
on IN N
the DT N
efficacy NN N
of IN N
the DT N
immune JJ N
response NN N
to TO N
influenza VB p
vaccine NN p
in IN p
the DT p
elderly JJ p
. . p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
repeated VBN N
vaccination NN i
and CC N
of IN N
dehydroepiandrosterone NN i
( ( i
DHEA NNP i
) ) i
treatment NN N
on IN N
the DT N
immune JJ N
response NN N
to TO N
influenza VB i
vaccine NN i
in IN p
elderly JJ p
subjects NNS p
. . p

Seventy-one CD p
elderly JJ p
volunteers NNS p
, , p
aged VBN p
61-89 CD p
years NNS p
, , N
enrolled VBD N
in IN N
a DT N
prospective JJ N
randomized VBN N
, , N
double-blind JJ N
study NN N
to TO N
receive VB N
either DT N
DHEA NNP i
( ( N
50 CD N
mg NN N
qd NN N
p.o NN N
. . N

for IN N
4 CD N
consecutive JJ N
days NNS N
starting VBG N
2 CD N
days NNS N
before IN N
immunization NN N
) ) N
or CC N
placebo NN i
. . i

Antibody NNP N
response NN N
against IN N
the DT N
three CD N
strains NNS N
of IN N
vaccine NN N
was VBD N
measured VBN N
before IN N
and CC N
28 CD N
days NNS N
after IN N
vaccination NN N
, , N
and CC N
compared VBN N
between IN N
previously RB N
vaccinated VBN N
and CC N
non-vaccinated JJ N
subjects NNS N
. . N

DHEA NNP i
treatment NN i
did VBD N
not RB N
enhance VB N
established VBN o
immunity NN o
. . o

A DT N
significant JJ N
decrease NN N
in IN N
attainment NN N
of IN N
protective JJ o
antibody NN o
titer NN o
( ( N
titer NN N
of IN N
1:40 CD N
or CC N
greater JJR N
) ) N
against IN N
A/Texas NNP N
in IN N
subjects NNS N
with IN N
non-protective JJ N
baseline NN N
antibody NN N
titer NN N
was VBD N
recorded VBN N
following VBG N
DHEA NNP i
treatment NN i
compared VBN N
to TO N
placebo VB N
( ( N
52 CD N
vs. FW N
84 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Post-immunization NN o
titers NNS o
against IN N
influenza VBP N
A DT N
strains NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
those DT N
subjects NNS N
who WP N
were VBD N
never RB N
immunized VBN N
before RB N
. . N

Additionally RB N
, , N
post-vaccination JJ o
protective JJ o
titers NNS o
against IN N
the DT N
A/Johannesburg NNP N
strain NN N
were VBD N
more RBR N
prevalent JJ N
in IN N
those DT N
subjects NNS N
who WP N
were VBD N
never RB N
vaccinated VBN N
before RB N
. . N

The DT N
results NNS N
were VBD N
not RB N
the DT N
same JJ N
for IN N
anti-B/Harbin JJ N
antibodies-repeated JJ N
vaccination NN N
caused VBD N
a DT N
non-significant JJ N
increase NN N
in IN N
HI NNP N
titer NN N
in IN N
previously RB N
vaccinated VBN N
subjects NNS N
. . N

-DOCSTART- -18843564- O O

Physical JJ N
health NN N
-- : N
a DT N
cluster NN i
randomized VBN i
controlled VBN i
lifestyle JJ i
intervention NN i
among IN N
persons NNS p
with IN p
a DT p
psychiatric JJ p
disability NN p
and CC p
their PRP$ p
staff NN p
. . p

The DT N
objective NN N
was VBD N
to TO N
explore VB N
the DT N
impact NN N
on IN N
physical JJ N
health NN N
of IN N
a DT N
lifestyle JJ i
programme NN i
among IN N
persons NNS p
with IN p
psychiatric JJ p
disabilities NNS p
, , p
and CC p
their PRP$ p
caregivers NNS p
. . p

Their PRP$ N
satisfaction NN N
with IN N
the DT N
intervention NN N
was VBD N
also RB N
assessed VBN N
. . N

Somatic JJ N
comorbidity NN N
and CC N
an DT N
increased VBN N
mortality NN N
related VBN N
to TO N
the DT N
lifestyle NN N
among IN N
persons NNS p
with IN p
psychiatric JJ p
disabilities NNS p
are VBP N
well RB N
known VBN N
. . N

Few JJ N
randomized VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
aimed VBN N
specifically RB N
at IN N
lifestyle JJ N
issues NNS N
among IN N
persons NNS p
with IN p
a DT p
psychiatric JJ p
disability NN p
. . p

This DT N
trial NN N
includes VBZ N
clients NNS p
with IN p
psychiatric JJ p
disabilities NNS p
living VBG p
in IN p
supported JJ p
housing NN p
and CC p
their PRP$ p
staff NN p
. . p

Forty-one CD p
persons NNS p
with IN p
a DT p
DSM- NNP p
? . p
V NNP p
diagnosis NN p
of IN p
severe JJ p
mental JJ p
illness NN p
from IN p
psychiatric JJ p
disability NN p
from IN p
10 CD p
supported VBD p
housing NN p
facilities NNS p
and CC p
41 CD p
of IN p
their PRP$ p
caregivers NNS p
participated VBN p
in IN p
this DT p
12-month JJ p
study NN p
during IN p
2005-2006 JJ p
in IN p
Sweden NNP p
. . p

The DT N
supported JJ N
housing NN N
facilities NNS N
with IN N
residents NNS N
and CC N
staff NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
a DT N
health NN i
intervention NN i
programme NN i
or CC N
a DT N
control NN N
programme NN N
with IN N
an DT N
aesthetic JJ N
content NN N
. . N

The DT N
presence NN o
of IN o
metabolic JJ o
syndrome NN o
and CC o
changes NNS o
in IN o
the DT o
mean NN o
of IN o
physiological JJ o
parameters NNS o
such JJ o
as IN o
Hba1c NNP o
, , o
P-glucose NNP o
, , o
P-insulin NNP o
, , o
lipids NNS o
, , o
blood NN o
pressure NN o
, , o
physical JJ o
working NN o
capacity NN o
, , o
body NN o
mass NN o
index NN o
, , o
Heart NNP o
Score NNP o
were VBD o
investigated VBN o
and CC o
participants NNS o
' POS o
satisfaction NN o
assessed VBD N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
mean NN o
of IN o
metabolic JJ o
syndrome JJ o
criteria NNS o
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
at IN N
the DT N
follow-up NN N
. . N

The DT N
participants NNS N
expressed VBD N
satisfaction NN N
with IN N
the DT N
programme NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
health NN i
interventions NNS i
on IN N
lifestyle JJ N
issues NNS N
when WRB N
involving VBG N
carers NNS p
are VBP N
appreciated VBN N
, , N
feasible JJ N
and CC N
could MD N
be VB N
successful JJ N
in IN N
reducing VBG N
some DT N
health-related JJ o
risk NN o
factors NNS o
among IN N
persons NNS p
with IN p
psychiatric JJ p
disabilities NNS p
. . p

-DOCSTART- -16119805- O O

[ VB N
A NNP N
randomized JJ N
study NN N
of IN N
prophylactic JJ N
intravesical JJ N
instillation NN N
of IN N
pirarubicin NN i
( ( i
THP NNP i
) ) i
prior RB N
to TO N
transurethral JJ p
resection NN p
of IN p
superficial JJ o
bladder NN o
cancer NN o
] NNP o
. . N

A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
prophylactic JJ p
intravesical JJ i
instillation NN i
of IN i
pirarubicin NN i
( ( i
THP NNP i
) ) i
prior RB p
to TO p
transurethral JJ o
resection NN o
( ( o
TUR NNP o
) ) o
of IN o
superficial JJ o
bladder NN o
cancer NN o
. . o

A DT N
total NN N
of IN N
63 CD p
patients NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
the DT N
THP NNP i
group NN N
and CC N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
THP NNP N
group NN N
, , N
30 CD N
mg NN N
of IN N
THP NNP N
dissolved VBD N
in IN N
50 CD i
ml NNS i
saline NN i
was VBD N
administered VBN N
4 CD N
times NNS N
intravesically RB N
for IN N
4 CD N
consecutive JJ N
days NNS N
before IN N
TUR NNP N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
no DT i
instillation NN i
was VBD i
performed VBN i
before IN i
TUR NNP i
. . i

The DT N
patients NNS N
were VBD N
followed VBN N
by IN N
cystoscopy NN N
and CC N
urinary JJ N
cytology NN N
every DT N
3 CD N
months NNS N
. . N

The DT N
non-recurrence JJ o
rates NNS o
in IN N
the DT N
THP NNP N
group NN N
and CC N
control NN N
group NN N
were VBD N
54.1 CD N
% NN N
versus IN N
37.6 CD N
% NN N
at IN N
1 CD N
year NN N
and CC N
40.4 CD N
% NN N
versus IN N
26.8 CD N
% NN N
at IN N
2 CD N
years NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.086 CD N
) ) N
. . N

Time NN o
to TO o
recurrence VB o
for IN o
tumors NNS o
larger JJR o
than IN o
1 CD o
cm NN o
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
THP NNP N
group NN N
( ( N
P NNP N
= NNP N
0.0137 CD N
) ) N
. . N

Time NN o
to TO o
recurrence VB o
for IN o
single JJ o
and CC o
grade VBD o
1+2 CD o
tumors NNS o
tended VBD N
to TO N
be VB N
longer RBR N
in IN N
the DT N
THP NNP N
group NN N
( ( N
P NNP N
= NNP N
0.09 CD N
, , N
P NNP N
= NNP N
0.079 CD N
) ) N
. . N

No DT N
significant JJ N
adverse JJ o
effects NNS o
were VBD N
observed VBN N
in IN N
any DT N
patient NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
intravesical JJ N
THP NNP N
instillation NN N
prior RB N
to TO N
TUR NNP N
would MD N
be VB N
effective JJ o
for IN N
patients NNS N
with IN N
single JJ o
, , o
low JJ o
grade NN o
lesions NNS o
larger JJR o
than IN o
1 CD o
cm NN o
of IN N
superficial JJ o
bladder NN o
cancer NN o
. . o

-DOCSTART- -23984944- O O

Negative JJ N
emotional JJ N
experiences NNS N
during IN N
navigation NN N
enhance NN N
parahippocampal JJ N
activity NN N
during IN N
recall NN N
of IN N
place NN N
information NN N
. . N

It PRP N
is VBZ N
known VBN N
that IN N
the DT N
parahippocampal JJ N
cortex NN N
is VBZ N
involved VBN N
in IN N
object-place JJ N
associations NNS N
in IN N
spatial JJ N
learning NN N
, , N
but CC N
it PRP N
remains VBZ N
unknown JJ N
whether IN N
activity NN N
within IN N
this DT N
region NN N
is VBZ N
modulated VBN N
by IN N
affective JJ N
signals NNS N
during IN N
navigation NN N
. . N

Here RB N
we PRP N
used VBD N
fMRI NN i
to TO N
measure VB N
the DT N
neural JJ o
consequences NNS o
of IN o
emotional JJ o
experiences NNS o
on IN o
place NN o
memory NN o
during IN N
navigation NN N
. . N

A DT N
day NN N
before IN N
scanning VBG N
, , N
participants NNS p
undertook VBP p
an DT p
active JJ p
object NN p
location NN p
memory NN p
task NN p
within IN p
a DT p
virtual JJ p
house NN p
in IN p
which WDT p
each DT p
room NN p
was VBD p
associated VBN p
with IN p
a DT p
different JJ p
schedule NN p
of IN p
task-irrelevant JJ p
emotional JJ p
events NNS p
. . p

The DT N
events NNS N
varied VBN N
in IN N
valence NN N
( ( N
positive JJ N
, , N
negative JJ N
, , N
or CC N
neutral JJ N
) ) N
and CC N
in IN N
their PRP$ N
rate NN N
of IN N
occurrence NN N
( ( N
intermittent JJ N
vs. FW N
constant NN N
) ) N
. . N

On IN N
a DT N
subsequent JJ N
day NN N
, , N
we PRP N
measured VBD N
neural JJ o
activity NN o
while IN N
participants NNS p
were VBD N
shown VBN N
static JJ N
images NNS N
of IN N
the DT N
previously RB N
learned VBN N
virtual JJ N
environment NN N
, , N
now RB N
in IN N
the DT N
absence NN N
of IN N
any DT N
affective JJ N
stimuli NN N
. . N

Our PRP$ N
results NNS N
showed VBD N
that IN N
parahippocampal JJ o
activity NN o
was VBD N
significantly RB N
enhanced VBN N
bilaterally RB N
when WRB N
participants NNS p
viewed VBD N
images NNS N
of IN N
a DT N
room NN N
in IN N
which WDT N
they PRP N
had VBD N
previously RB N
encountered VBN N
negatively RB N
arousing VBG N
events NNS N
. . N

We PRP N
conclude VBP N
that IN N
such JJ N
automatic JJ o
enhancement NN o
of IN o
place NN o
representations NNS o
by IN N
aversive JJ N
emotional JJ N
events NNS N
serves VBZ N
as IN N
an DT N
important JJ N
adaptive NN N
mechanism NN N
for IN N
avoiding VBG N
future JJ N
threats NNS N
. . N

-DOCSTART- -2035777- O O

The DT N
effect NN N
of IN N
prophylactic JJ i
fentanyl NN i
on IN N
shivering VBG o
in IN o
elective JJ o
caesarean JJ o
section NN o
under IN p
epidural JJ p
analgesia NN p
. . p

The DT N
aims NNS N
of IN N
this DT N
randomised VBN N
double-blind NN N
study NN N
were VBD N
to TO N
investigate VB N
whether IN N
25 CD N
micrograms NNS N
of IN N
fentanyl NN i
administered VBN N
prophylactically RB N
by IN N
the DT N
epidural JJ N
route NN N
would MD N
influence VB N
the DT N
incidence NN o
of IN o
shivering VBG o
in IN N
parturients NNS p
who WP p
underwent VBP p
elective JJ p
Caesarean JJ p
section NN p
under IN p
epidural JJ p
analgesia NN p
and CC N
whether IN N
it PRP N
would MD N
affect VB N
the DT N
axillary JJ o
and CC o
calf JJ o
temperatures NNS o
. . o

There EX N
was VBD N
a DT N
50 CD N
% NN N
reduction NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
in IN N
the DT N
overall JJ N
incidence NN o
of IN o
shivering VBG o
in IN N
patients NNS p
who WP N
received VBD N
fentanyl NN i
and CC N
there EX N
was VBD N
some DT N
evidence NN N
to TO N
suggest VB N
that IN N
low-dose JJ N
epidural JJ N
fentanyl NN N
might MD N
reduce VB N
shivering VBG o
by IN N
an DT N
influence NN N
on IN N
thermoregulation NN o
. . o

-DOCSTART- -21586215- O O

Effect NN o
of IN N
a DT N
multi-faceted JJ i
intervention NN i
on IN N
gingival JJ o
health NN o
among IN p
adults NNS p
with IN p
systemic JJ p
sclerosis NN p
. . p

OBJECTIVES NNP N
To TO N
evaluate VB o
the DT o
effect NN o
of IN N
adaptive JJ i
oral JJ i
hygiene NN i
devices NNS i
and CC N
orofacial JJ i
exercise NN i
to TO N
improve VB N
gingival JJ o
health NN o
among IN p
adults NNS p
with IN p
systemic JJ p
sclerosis NN p
( ( p
SSc NNP p
) ) p
. . p

METHODS NNP N
Forty-eight JJ p
patients NNS p
with IN p
SSc NNP p
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
multifaceted VBN i
oral JJ i
health NN i
intervention NN i
or CC N
usual JJ i
dental JJ i
care NN i
control NN N
group NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD N
a DT N
rechargeable JJ N
, , N
powered JJ N
Oral-B? NNP i
oscillating-rotating-pulsating NN i
toothbrush NN i
and CC i
a DT i
Reach? NNP i
Access? NNP i
Flosser NNP i
that WDT i
has VBZ N
a DT N
toothbrush-like JJ N
handle NN N
. . N

For IN N
those DT N
with IN N
an DT N
oral JJ N
aperture NN N
of IN N
less JJR N
than IN N
40 CD N
mm NN N
, , N
orofacial JJ i
exercises NNS i
were VBD i
taught VBN N
. . N

Participants NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
each DT N
given VBN N
a DT N
manual JJ N
toothbrush NN N
and CC N
dental JJ N
floss NN N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
received VBD N
instructions NNS N
and CC N
demonstration NN N
on IN N
the DT N
use NN N
of IN N
the DT N
devices NNS N
, , N
and CC N
were VBD N
requested VBN N
to TO N
perform VB N
the DT N
respective JJ N
intervention NN N
twice RB N
a DT N
day NN N
for IN N
6 CD N
months NNS N
. . N

Evaluations NNS N
were VBD N
at IN N
baseline NN N
, , N
3- JJ N
, , N
and CC N
6-months NNS N
. . N

The DT N
main JJ o
outcome NN o
was VBD o
gingival JJ o
index NN o
( ( o
GI NNP o
) ) o
, , o
an DT o
indicator NN o
of IN o
gingival JJ o
inflammation NN o
. . o

RESULTS NNP o
Both NNP N
groups NNS N
showed VBD N
significant JJ N
reduction NN o
in IN o
GI NNP o
scores NNS o
at IN o
6 CD N
months NNS N
( ( N
ps JJ N
< NNP N
0.005 CD o
) ) o
. . o

Reduction NN o
in IN o
GI NNP o
scores NNS o
of IN o
the DT N
intervention NN N
group NN N
at IN N
6 CD N
months NNS N
was VBD N
20.8 CD N
% NN N
which WDT N
is VBZ N
considered VBN N
to TO N
be VB N
clinically RB N
significant JJ N
. . N

Compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
the DT N
intervention NN N
group NN N
showed VBD N
a DT N
significant JJ N
and CC N
larger JJR N
reduction NN o
in IN o
GI NNP o
score NN o
by IN o
8 CD N
% NN N
at IN N
6 CD N
months NNS N
( ( N
p=0.0007 NN N
) ) N
. . N

CONCLUSIONS JJ N
Results NNP N
support NN N
the DT N
use NN N
of IN i
adaptive JJ i
devices NNS i
and CC i
orofacial JJ i
exercise NN i
to TO i
improve VB o
gingival NN o
health NN o
in IN o
adults NNS p
with IN p
SSc NNP p
when WRB N
compared VBN N
to TO N
use VB N
of IN i
manual JJ i
toothbrushing NN i
and CC i
finger-held JJ i
flossing NN i
. . i

Recommending VBG i
and CC N
educating VBG p
patients NNS p
with IN p
SSc NNP p
to TO N
use VB N
adaptive JJ N
devices NNS N
to TO N
clean VB N
the DT N
tooth NN N
surfaces NNS N
looks VBZ N
promising VBG N
for IN N
long-term JJ o
oral JJ o
health NN o
improvement NN o
. . o

-DOCSTART- -17662102- O O

A DT N
pilot NN N
study NN N
of IN N
extended JJ N
duration NN N
peginterferon NN i
alfa-2a NN i
for IN N
patients NNS p
with IN p
hepatitis NN p
B NNP p
e VBZ p
antigen-negative JJ p
chronic JJ p
hepatitis NN p
B NNP p
. . p

OBJECTIVES NNP N
Forty-eight JJ N
weeks NNS N
of IN N
peginterferon NN i
alfa-2a NN i
is VBZ N
the DT N
approved JJ N
regimen NNS N
for IN N
chronic JJ p
hepatitis NN p
B NNP p
( ( p
CHB NNP p
) ) p
. . p

Standard NNP N
interferon NN N
is VBZ N
more RBR N
effective JJ N
for IN N
hepatitis NN N
B NNP N
e NN N
antigen NN N
( ( N
HBeAg NNP N
) ) N
-negative VBP N
CHB NNP N
when WRB N
given VBN N
for IN N
longer JJR N
than IN N
1 CD N
yr NN N
. . N

This DT N
study NN N
evaluated VBD N
peginterferon JJ i
alfa-2a NN i
for IN N
60 CD N
wk NN N
, , N
alone RB N
or CC N
in IN N
combination NN N
with IN N
lamivudine NN N
. . N

METHODS NNP N
Thirteen NNP p
patients NNS p
with IN p
HBeAg-negative JJ p
CHB NNP p
received VBD N
peginterferon JJ i
alfa-2a JJ i
( ( N
180 CD N
microg/week NN N
) ) N
for IN N
60 CD N
wk NN N
or CC N
peginterferon VB i
alfa-2a JJ i
( ( N
180 CD N
microg/week NN N
) ) N
for IN N
12 CD N
wk NN N
followed VBN N
by IN N
48 CD N
wk NN N
of IN N
peginterferon NN i
alfa-2a JJ i
plus CC i
lamivudine JJ i
. . i

The DT N
primary JJ N
end NN N
point NN N
, , N
sustained VBD o
virologic JJ o
response NN o
( ( o
SVR NNP o
) ) o
, , N
was VBD N
defined VBN N
as IN N
a DT N
reduction NN N
in IN N
hepatitis NN o
B NNP o
virus NN o
deoxyribonucleic NN o
acid NN o
( ( o
HBV NNP o
DNA NNP o
) ) o
of IN N
> NNP N
or=2 FW N
log10 NN N
copies/mL NN N
and CC N
HBV NNP o
DNA NNP o
< VBD o
20,000 CD o
copies/mL NN N
at IN N
24 CD N
wk NN N
of IN N
follow-up NN N
( ( N
week NN N
84 CD N
) ) N
. . N

Hepatitis $ o
B NNP o
surface NN o
antigen NN o
( ( o
HBsAg NNP o
) ) o
concentrations NNS o
were VBD N
analyzed VBN N
and CC N
compared VBN N
to TO N
changes NNS N
in IN N
HBV NNP o
DNA NNP o
. . o

RESULTS NNP N
SVR NNP o
was VBD N
achieved VBN N
by IN N
9/13 CD N
patients NNS N
( ( N
69 CD N
% NN N
) ) N
. . N

At IN N
week NN N
84 CD N
, , N
HBV NNP o
DNA NNP o
was VBD N
undetectable JJ N
by IN N
polymerase NN N
chain NN N
reaction NN N
in IN N
5/13 CD N
( ( N
38 CD N
% NN N
) ) N
patients NNS N
, , N
and CC N
3 CD N
additional JJ N
patients NNS N
had VBD N
a DT N
sustained VBN N
2-3 CD N
log NN o
reduction NN o
in IN o
HBV NNP o
DNA NNP o
. . o

Five CD N
patients NNS N
demonstrated VBD N
a DT N
> JJ N
90 CD N
% NN N
decrease NN N
in IN N
HBsAg NNP o
concentration NN o
at IN N
week NN N
60 CD N
, , N
including VBG N
3 CD N
with IN N
undetectable JJ N
HBV NNP o
DNA NNP o
at IN N
week NN N
84 CD N
and CC N
a DT N
fourth JJ N
who WP N
met VBD N
criteria NNS N
for IN N
SVR NNP o
. . o

CONCLUSIONS NNP N
Sixty NNP N
weeks NNS N
of IN N
peginterferon NN i
alfa-2a NN i
with IN N
or CC N
without IN N
lamivudine JJ N
resulted VBN N
in IN N
a DT N
higher JJR N
rate NN N
of IN N
SVR NNP o
compared VBN N
to TO N
historical JJ N
controls NNS N
with IN N
HBeAg-negative JJ p
CHB NNP p
treated VBD N
with IN N
48 CD N
wk NN N
of IN N
pegylated JJ i
interferon NN i
. . i

Larger JJR N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
if IN N
longer JJR N
duration NN N
therapy NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
standard JJ N
regimen NNS N
and CC N
results NNS N
in IN N
a DT N
greater JJR N
decline NN N
in IN N
HBsAg NNP o
concentration NN o
. . N

-DOCSTART- -16234574- O O

Ultrasound NNP i
therapy NN i
for IN N
recalcitrant JJ o
diabetic JJ o
foot NN o
ulcers NNS o
: : o
results NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
controlled VBN N
, , N
multicenter NN p
study NN N
. . N

An DT N
estimated JJ N
15 CD N
% NN N
of IN N
patients NNS N
with IN N
diabetes NNS N
will MD N
develop VB N
a DT N
foot NN o
ulcer NN o
sometime RB N
in IN N
their PRP$ N
life NN N
, , N
making VBG N
them PRP N
30 CD N
to TO N
40 CD N
times NNS N
more RBR N
likely JJ N
to TO N
undergo VB N
amputation NN N
due JJ N
to TO N
a DT N
non-healing JJ N
foot NN N
ulcer NN N
than IN N
the DT N
non-diabetic JJ N
population NN N
. . N

To TO N
determine VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
new JJ N
, , N
non-contact JJ i
, , i
kilohertz VB i
ultrasound JJ i
therapy NN i
for IN N
the DT N
healing NN N
of IN N
recalcitrant JJ o
diabetic JJ o
foot NN o
ulcers NNS o
- : N
as RB N
well RB N
as IN N
to TO N
evaluate VB N
the DT N
impact NN N
on IN N
total JJ N
closure NN N
and CC N
quantitative JJ N
bacterial JJ N
cultures NNS N
and CC N
the DT N
effect NN N
on IN N
healing NN N
of IN N
various JJ N
levels NNS N
of IN N
sharp/surgical JJ N
debridement NN N
- : N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
sham-controlled JJ N
, , N
multicenter NN p
study NN p
was VBD p
conducted VBN p
in IN p
hospital-based JJ p
and CC p
private JJ p
wound NN p
care NN p
clinics NNS p
. . p

Patients NNS p
( ( p
55 CD p
met VBD p
criteria NNS p
for IN p
efficacy NN p
analysis NN p
) ) p
received VBD p
standard NN p
of IN p
care NN p
, , p
which WDT p
included VBD p
products NNS p
that WDT p
provide VBP p
a DT p
moist NN p
environment NN p
, , p
offloading VBG p
diabetic JJ p
shoes NNS p
and CC p
socks NNS p
, , p
debridement NN p
, , p
wound JJ p
evaluation NN p
, , p
and CC p
measurement NN p
. . p

The DT N
therapy NN N
was VBD N
either RB N
active JJ i
40 CD i
KHz NNP i
ultrasound NN i
delivered VBN i
by IN i
a DT i
saline JJ i
mist NN i
or CC i
a DT i
sham NN i
device NN i
which WDT i
delivered VBD i
a DT i
saline JJ i
mist NN i
without IN i
the DT i
use NN i
of IN i
ultrasound NN i
. . i

After IN N
12 CD N
weeks NNS N
of IN N
care NN N
, , N
the DT N
proportion NN o
of IN o
wounds NNS o
healed VBN o
( ( N
defined VBN N
as IN N
complete JJ N
epithelialization NN N
without IN N
drainage NN N
) ) N
in IN N
the DT N
active JJ N
ultrasound NN N
therapy NN N
device NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
the DT N
sham NN N
control NN N
group NN N
( ( N
40.7 CD N
% NN N
versus IN N
14.3 CD N
% NN N
, , N
P NNP N
= NNP N
0.0366 CD N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
. . N

The DT N
ultrasound JJ i
treatment NN i
was VBD N
easy JJ N
to TO N
use VB N
and CC N
no DT N
difference NN N
in IN N
the DT N
number NN N
and CC N
type NN N
of IN N
adverse JJ o
events NNS o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
was VBD N
noted VBN N
. . N

Of IN N
interest NN N
, , N
wounds NNS N
were VBD N
debrided VBN N
at IN N
baseline NN N
followed VBN N
by IN N
a DT N
quantitative JJ N
culture NN N
biopsy NN N
. . N

The DT N
results NNS N
of IN N
these DT N
cultures NNS N
demonstrated VBD N
a DT N
significant JJ N
bioburden NN o
( ( N
greater JJR N
than IN N
10 CD N
( ( N
5 CD N
) ) N
) ) N
in IN N
the DT N
majority NN N
of IN N
cases NNS N
, , N
despite IN N
a DT N
lack NN N
of IN N
clinical JJ N
signs NNS N
of IN N
infection NN N
. . N

Compared VBN N
to TO N
control VB N
, , N
this DT N
therapeutic JJ N
modality NN N
was VBD N
found VBN N
to TO N
increase VB N
the DT N
healing VBG o
rate NN o
of IN N
recalcitrant NN N
, , N
diabetic JJ N
foot NN N
ulcers NNS N
. . N

-DOCSTART- -24517028- O O

Effects NNS N
of IN N
iron NN i
on IN N
the DT N
pharmacokinetics NNS o
of IN o
paracetamol NN o
in IN o
saliva NN o
. . o

Paracetamol NNP i
has VBZ N
been VBN N
reported VBN N
to TO N
chelate VB N
with IN N
iron NN i
. . i

It PRP N
was VBD N
found VBN N
that IN N
no DT N
in IN o
vitro JJ o
reaction NN o
between IN N
ferrous JJ N
ion NN N
and CC N
paracetamol NN N
. . N

Other JJ N
studies NNS N
found VBD N
that IN N
there EX N
is VBZ N
an DT N
aerobic JJ N
( ( N
in IN N
the DT N
gastrointestinal JJ N
tract NN N
) ) N
oxidation NN N
of IN N
ferrous JJ N
ion NN N
to TO N
ferric VB N
ion NN N
caused VBN N
in IN N
iron-paracetamol NN N
in IN N
vivo JJ N
reactions NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
iron NN N
interacts NNS N
with IN N
paracetamol NN N
and CC N
reduces NNS N
paracetamol JJ o
absorption NN o
. . o

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
study NN N
design NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
in IN o
vivo JJ o
interaction NN o
of IN o
paracetamol NN o
and CC o
ferrous JJ o
ion NN o
. . o

Paracetamol NNP i
( ( N
1.0 CD N
g NN N
) ) N
was VBD N
co-ignested JJ N
alone RB i
or CC i
with IN N
( ( i
300 CD i
mg NN i
) ) i
ferrous JJ i
sulphate NN i
by IN N
ten JJ p
healthy JJ p
male NN p
volunteers NNS p
, , N
using VBG N
saliva JJ N
drug NN N
levels NNS N
as IN N
a DT N
parameter NN N
. . N

Concomitant NNP N
administration NN N
of IN N
ferrous JJ i
sulphate NN i
and CC i
paracetamol NN i
, , N
decreased VBN N
AUC8 NNP o
from IN N
42.88 CD N
+/- JJ N
3.8-34.25 JJ N
+/- JJ N
2.8 CD N
microg NN N
h NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
and CC N
Cmax NNP o
from IN N
18.75 CD N
+/- JJ N
1.9 CD N
to TO N
15.9 CD N
+/- JJ N
1.7 CD N
microg NN N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
p JJ N
= NNP N
0.11 CD N
) ) N
, , N
while IN N
no DT N
change NN N
in IN N
tmax NN N
( ( N
p JJ N
= NNP N
0.5 CD N
) ) N
was VBD N
originated VBN N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
paracetamol NN o
pharmacokinetic JJ o
parameter NN o
oral JJ o
clearance NN o
( ( o
C1/F NNP o
) ) o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
and CC N
slightly RB N
increased VBN N
in IN N
volume NN o
of IN o
distribution NN o
( ( N
V NNP N
( ( N
d NN N
) ) N
/F NN N
) ) N
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Co-administration NN N
of IN N
iron NN i
and CC i
paracetamol JJ i
results NNS N
in IN N
decreased JJ o
paracetamol NN o
absorption NN o
due JJ N
to TO N
an DT N
interaction NN N
between IN N
iron NN N
and CC N
paracetamol NN N
. . N

-DOCSTART- -22480794- O O

Tinzaparin NNP i
versus NN i
dalteparin NN i
for IN N
periprocedure NN N
prophylaxis NN N
of IN N
thromboembolic JJ N
events NNS N
in IN N
hemodialysis NN p
patients NNS p
: : p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Low-molecular-weight JJ i
heparin NN i
( ( i
LMWH NNP i
) ) i
is VBZ N
cleared VBN N
predominantly RB N
by IN N
the DT N
kidneys NNS N
and CC N
hence NN N
there EX N
is VBZ N
uncertainty NN N
about IN N
the DT N
safety NN N
of IN N
its PRP$ N
use NN N
in IN N
hemodialysis NN p
( ( p
HD NNP p
) ) p
patients NNS p
. . p

Our PRP$ N
primary JJ N
objective NN N
was VBD N
to TO N
compare VB N
whether IN N
tinzaparin NN i
and CC N
dalteparin VB i
differentially RB N
accumulate JJ N
in IN N
HD NNP p
patients NNS p
. . p

STUDY NNP N
DESIGN NNP N
Open-label NNP N
randomized VBD N
controlled VBN N
trial NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
HD NNP p
patients NNS p
undergoing JJ p
periprocedure NN p
bridging VBG p
anticoagulation NN p
. . p

INTERVENTION NN N
After IN N
warfarin JJ i
therapy NN i
was VBD N
discontinued VBN N
, , N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
3 CD i
daily JJ i
doses NNS i
of IN i
tinzaparin NN i
( ( i
175 CD i
IU/kg NNP i
) ) i
or CC i
dalteparin NN i
( ( N
200 CD N
IU/kg NNP N
) ) N
, , N
with IN N
2 CD N
intervening VBG N
HD NNP N
treatments NNS N
between IN N
the DT N
first JJ N
dose NN N
of IN N
study JJ N
drug NN N
and CC N
their PRP$ N
procedure NN N
. . N

OUTCOMES CC N
The DT N
primary JJ N
outcome NN N
was VBD N
predialysis JJ o
anti-Xa JJ o
levels NNS o
20 CD o
to TO o
24 CD o
hours NNS o
after IN o
the DT o
third JJ o
LMWH NNP o
dose NN o
( ( N
therapeutic JJ N
target NN N
, , N
< JJ N
0.2 CD N
IU/mL NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
thromboembolic JJ o
events NNS o
and CC o
major JJ o
bleeding NN o
. . o

RESULTS NNP N
Of IN N
29 CD p
eligible JJ p
and CC p
consenting VBG p
patients NNS p
, , N
17 CD N
patients NNS N
received VBN N
tinzaparin JJ i
and CC N
12 CD N
patients NNS N
received VBD N
dalteparin JJ i
. . i

Mean JJ o
predialysis NN o
anti-Xa JJ o
level NN o
20-24 JJ o
hours NNS o
after IN N
the DT N
third JJ N
LMWH NNP N
dose NN N
was VBD N
0.37 CD N
? . N
0.23 CD N
( ( N
SD NNP N
) ) N
IU/mL NNP N
for IN i
tinzaparin NN i
and CC N
0.62 CD N
? . N
0.41 CD N
IU/mL NNP N
for IN i
dalteparin NN i
( ( i
P NNP N
= NNP N
0.1 CD N
) ) N
, , N
indicating VBG N
clinically RB N
important JJ N
accumulation NN N
for IN N
both DT N
drugs NNS N
. . N

No DT N
invasive JJ o
procedures NNS o
were VBD o
canceled VBN N
due JJ N
to TO N
study VB N
drug NN N
accumulation NN N
. . N

4 CD N
patients NNS N
experienced VBD o
serious JJ o
adverse JJ o
events NNS o
( ( o
1 CD N
major JJ N
bleed NN N
after IN N
traumatic JJ N
arteriovenous JJ N
fistula NN N
puncture NN N
in IN N
the DT i
tinzaparin NN i
arm NN i
, , N
2 CD N
non-ST-elevation JJ N
myocardial JJ N
infarctions NNS N
[ VBP N
1 CD N
in IN N
each DT N
group NN N
] NNP N
, , N
and CC N
1 CD N
upper-extremity JJ N
deep RB N
venous JJ N
thrombosis NN i
[ NNP i
dalteparin NN i
group NN i
] NNP N
) ) N
. . N

LIMITATIONS NNP N
Small NNP N
sample NN N
size NN N
. . N

CONCLUSIONS NNP i
Dalteparin NNP i
and CC i
tinzaparin VB i
significantly RB i
accumulate VB N
in IN N
HD NNP p
patients NNS p
at IN p
therapeutic JJ N
doses NNS N
. . N

Bridging VBG N
therapy NN N
with IN N
LMWHs NNP N
at IN N
therapeutic JJ N
doses NNS N
in IN N
HD NNP N
patients NNS N
who WP N
require VBP N
temporary JJ N
interruption NN N
of IN N
warfarin NN i
therapy NN i
has VBZ i
the DT N
potential NN N
for IN N
complications NNS N
and CC N
is VBZ N
of IN N
uncertain JJ N
benefit NN N
. . N

Other JJ N
anticoagulation NN N
strategies NNS N
, , N
including VBG N
no DT N
bridging NN N
therapy NN N
or CC N
intravenous JJ i
heparin NN i
, , i
need VBP N
comparative JJ N
evaluation NN N
in IN N
this DT N
unique JJ N
patient JJ N
population NN N
. . N

-DOCSTART- -25810108- O O

A DT N
randomised JJ N
controlled VBN N
comparison NN N
between IN N
stimulating VBG i
and CC i
standard JJ i
catheters NNS i
for IN N
lumbar NN o
plexus NN o
block NN o
. . o

The DT N
aim NN N
of IN N
this DT N
randomised VBN N
, , N
prospective JJ N
, , N
blinded VBD N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
stimulating JJ i
catheters NNS i
can MD N
decrease VB N
the DT N
minimum JJ o
effective JJ o
anaesthetic JJ o
volume NN o
in IN N
50 CD N
% NN N
of IN N
patients NNS p
during IN p
lumbar JJ p
plexus NN p
block NN p
using VBG N
mepivacaine JJ i
1.5 CD N
% NN N
compared VBN N
with IN N
standard JJ i
catheters NNS i
. . i

Fifty-eight JJ p
patients NNS p
of IN p
ASA NNP p
physical JJ p
status NN p
1-3 CD p
were VBD p
randomly RB p
allocated VBN p
to TO p
receive VB p
a DT p
lumbar NN i
plexus NN i
block NN i
via IN i
a DT i
stimulating NN i
or CC i
standard JJ i
catheter NN i
, , p
with IN p
29 CD p
in IN p
each DT p
group NN p
. . p

The DT N
first JJ N
dose NN N
was VBD N
30 CD N
ml NN N
and CC N
subsequent JJ N
doses NNS N
were VBD N
determined VBN N
using VBG N
the DT N
up-and-down JJ N
staircase NN N
method NN N
. . N

The DT N
minimum JJ N
effective JJ o
anaesthetic JJ o
volume50 NN o
was VBD N
12.2 CD N
ml NN N
( ( N
95 CD N
% NN N
CI NNP N
7.3-17.1 NNP N
ml NN N
) ) N
using VBG N
the DT N
stimulating NN N
catheter NN N
and CC N
24.8 CD N
ml NN N
( ( N
95 CD N
% NN N
CI NNP N
23.2-27.5 CD N
ml NN N
) ) N
with IN N
the DT N
standard JJ N
catheter NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Complete JJ o
lumbar NN o
plexus NN o
block NN o
was VBD N
achieved VBN N
with IN N
the DT N
initial JJ N
dose NN N
of IN N
mepivacaine NN N
in IN N
29 CD N
( ( N
100 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
stimulating JJ N
catheter NN N
group NN N
and CC N
20 CD N
( ( N
69 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
standard JJ N
catheter NN N
group NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
use NN N
of IN N
a DT N
stimulating JJ N
catheter NN N
halves VBZ N
the DT N
minimum JJ N
effective JJ N
anaesthetic JJ N
volume50 NN N
of IN N
mepivacaine JJ N
1.5 CD N
% NN N
while IN N
increasing VBG N
the DT N
success NN o
rate NN o
in IN N
patients NNS N
receiving VBG N
continuous JJ N
lumbar NN N
plexus NN N
block NN N
. . N

-DOCSTART- -24266855- O O

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
cyclosporine JJ i
reduction NN i
in IN N
de FW N
novo FW N
renal JJ N
allograft NN N
patients NNS p
receiving VBG p
sirolimus NN p
and CC p
corticosteroids NNS p
: : p
results NNS N
from IN N
an DT N
open-label JJ N
comparative NN N
study NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
a DT N
sirolimus NN i
, , i
corticosteroid NN i
, , i
and CC i
cyclosporine VB i
reduction NN i
regimen NNS N
in IN N
an DT N
open-label JJ N
, , N
12-month JJ N
trial NN N
of IN N
420 CD p
de FW p
novo FW p
renal JJ p
allograft NN p
recipients NNS p
at IN p
49 CD p
European JJ p
transplant NN p
centers NNS p
. . p

One CD N
month NN N
post-transplantation NN N
, , N
357 CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
standard-dose JJ i
cyclosporine NN i
( ( i
sCsA NN i
, , N
n JJ N
= NNP N
179 CD N
) ) N
or CC N
reduced-dose JJ i
cyclosporine NN i
( ( i
rCsA NN i
, , N
n JJ N
= NNP N
178 CD N
) ) N
. . N

All DT N
patients NNS N
also RB N
received VBD N
sirolimus JJ i
and CC i
corticosteroids NNS i
. . i

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
the DT N
rate NN o
of IN o
biopsy-confirmed JJ o
acute JJ o
rejection NN o
( ( o
BCAR NNP o
) ) o
and CC o
renal JJ o
function NN o
, , o
as IN o
measured VBN o
by IN o
serum JJ o
creatinine NN o
. . o

Baseline NNP N
demographic JJ N
and CC N
donor JJ N
characteristics NNS N
were VBD N
similar JJ N
between IN N
groups NNS N
. . N

BCAR NNP o
rates NNS N
at IN N
12 CD N
months NNS N
were VBD N
not RB N
significantly RB N
different JJ N
: : N
11.2 CD N
% NN N
for IN N
rCsA NN N
patients NNS N
and CC N
16.2 CD N
% NN N
for IN N
sCsA JJ N
patients NNS N
. . N

Mean NNP o
serum JJ o
creatinine NN o
( ( N
?SEM NNP N
) ) N
was VBD N
significantly RB N
lower JJR N
( ( N
1.75 CD N
? . N
0.10 CD N
vs. IN N
1.97 CD N
? . N
0.07 CD N
mg/dl NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
creatinine JJ o
clearance NN o
( ( o
?SEM NNP o
; : N
Nankivell NNP N
method NN N
) ) N
was VBD N
significantly RB N
higher JJR N
( ( N
57.8 CD N
? . N
1.78 CD N
vs. IN N
49.5 CD N
? . N
2.46 CD N
ml/min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
patients NNS N
receiving VBG N
rCsA JJ N
versus NN N
sCsA NN N
at IN N
1 CD N
year NN N
, , N
respectively RB o
. . o

Patient NNP o
and CC o
graft NN o
survival NN o
exceeded VBD o
98 CD N
% NN N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
differences NNS o
in IN o
infection NN o
or CC o
malignancy NN o
were VBD o
noted VBN N
between IN N
groups NNS N
. . N

The DT N
rCsA NN N
with IN N
sirolimus NN N
and CC N
corticosteroid JJ N
regimen NNS N
resulted VBD N
in IN N
excellent JJ o
12-month JJ o
patient NN o
and CC o
graft NN o
survival NN o
, , o
a DT o
low JJ o
incidence NN o
of IN o
BCAR NNP o
, , o
and CC o
improved VBD o
renal JJ o
function NN o
in IN o
renal JJ o
allograft NN N
recipients NNS N
. . N

Sirolimus NNP N
administered VBD N
with IN N
rCsA NN N
and CC N
corticosteroids NNS N
provided VBD N
adequate JJ o
immunosuppression NN o
while IN o
reducing VBG N
the DT N
potential NN N
for IN N
the DT o
nephrotoxic JJ o
effects NNS o
of IN o
cyclosporine NN o
. . o

These DT o
findings NNS N
may MD N
help VB N
to TO N
improve VB N
long-term JJ N
renal JJ N
allograft NN N
outcomes NNS N
. . N

-DOCSTART- -7809641- O O

[ VB N
A DT N
comparison NN N
of IN N
2 CD N
methods NNS N
of IN N
plastic NN i
cast NN i
fixation NN i
in IN N
treatment NN N
of IN N
loco NN p
classico NN p
radius NN p
fracture NN p
. . p

A DT N
prospective JJ N
, , N
randomized VBN N
study NN N
] NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
functional JJ N
and CC N
radiological JJ N
result NN N
of IN N
two CD N
different JJ N
positions NNS N
of IN N
the DT N
wrist NN N
in IN N
a DT N
plaster NN i
cast NN i
following VBG N
Colles NNP N
' POS N
fracture NN N
. . N

For IN N
this DT N
prospective JJ N
study NN N
, , N
each DT N
of IN N
50 CD p
patients NNS p
with IN p
type NN p
A DT p
2.2 CD p
, , p
A DT p
3.3 CD p
, , p
C NNP p
1.2 CD p
or CC p
C $ p
2.2 CD p
( ( p
AO NNP p
classification NN p
) ) p
fractures NNS p
of IN p
the DT p
radius NN p
was VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
in IN N
the DT N
same JJ N
way NN N
as IN N
far RB N
as IN N
anaesthesia NN N
and CC N
reduction NN N
were VBD N
concerned VBN N
. . N

The DT N
only JJ N
difference NN N
in IN N
treatment NN N
lay NN N
in IN N
the DT N
position NN N
of IN N
fixation NN N
in IN N
plaster NN N
. . N

In IN N
group NN N
1 CD N
the DT N
wrist NN i
was VBD i
immobilized VBN i
in IN i
neutral JJ i
flexion-extension NN i
. . i

In IN N
group NN N
2 CD N
the DT N
wrist NN N
was VBD N
dorsiflexed JJ i
20 CD i
degrees NNS i
, , i
while IN i
the DT i
carpus NN i
was VBD i
pushed VBN i
in IN i
a DT i
volar JJ i
direction NN i
by IN i
an DT i
impression NN i
in IN i
the DT i
plaster NN i
cast NN i
. . i

At IN N
review JJ N
2-7 CD N
years NNS N
after IN N
the DT N
accidents NNS N
, , N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
with IN N
reference NN N
to TO N
symptoms NNS o
, , o
range NN o
of IN o
motion NN o
at IN o
the DT o
wrist NN o
, , o
power NN o
of IN o
first JJ o
closure NN o
and CC o
radiographic JJ o
appearance NN o
. . o

In IN N
group NN N
1 CD N
there EX N
were VBD N
5 CD p
patients NNS p
with IN p
significant JJ p
disability NN p
, , N
compared VBN N
with IN N
only RB N
1 CD N
in IN N
group NN N
2 CD N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
range NN o
of IN o
movement NN o
between IN N
the DT N
two CD N
groups NNS N
for IN N
flexion NN N
and CC N
ulnar JJ N
abduction NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
loss NN o
of IN o
power NN o
of IN o
first JJ o
clenching NN o
( ( N
difference NN N
between IN N
injured VBN N
and CC N
healthy JJ N
hand NN N
) ) N
was VBD N
6.2 CD N
mmHg NN N
for IN N
group NN N
1 CD N
and CC N
3.8 CD N
mmHg NN N
for IN N
group NN N
2 CD N
( ( N
not RB N
significant JJ N
) ) N
. . N

The DT N
radiographic JJ N
examination NN N
showed VBD N
significant JJ N
differences NNS N
both DT N
in IN N
sagittal JJ N
inclination NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
in IN N
radial JJ N
shortening NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -21546263- O O

Immediate JJ N
effects NNS N
of IN N
a DT N
tibiofibular JJ i
joint NN i
manipulation NN i
on IN N
lower JJR N
extremity NN N
H-reflex JJ o
measurements NNS o
in IN N
individuals NNS p
with IN p
chronic JJ p
ankle NN p
instability NN p
. . p

Persistent JJ N
muscle NN N
inhibition NN N
of IN N
the DT N
fibularis NN N
longus NN N
and CC N
soleus NN N
muscles NNS N
and CC N
altered VBD N
joint JJ N
arthrokinematics NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
chronic JJ p
ankle NN p
instability NN p
( ( p
CAI NNP p
) ) p
. . p

Joint JJ N
mobilization NN N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
ankle NN N
joint JJ N
motion NN N
, , N
but CC N
effects NNS N
on IN N
surrounding VBG N
musculature NN N
is VBZ N
unknown JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
change NN N
in IN N
fibularis JJ N
longus NN N
and CC N
soleus JJ N
activation NN N
following VBG N
tibiofibular JJ i
joint JJ i
manipulation NN i
in IN N
individuals NNS p
with IN p
CAI NNP p
. . p

Forty-three JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
( ( i
proximal JJ i
tibiofibular NN i
manipulation NN i
, , i
distal JJ i
tibiofibular JJ i
manipulation NN i
, , i
or CC i
control NN i
) ) i
. . N

A DT N
two-way JJ N
mixed JJ N
model NN N
ANOVA NNP N
was VBD N
used VBN N
to TO N
compare VB N
changes NNS N
in IN N
the DT N
ratio NN N
of IN N
the DT N
maximum JJ o
H-reflex NNP o
and CC N
maximum JJ o
M-wave JJ o
measurements NNS o
( ( N
H/M NNP N
ratio NN N
) ) N
of IN N
the DT N
fibularis NN N
longus NN N
and CC N
soleus NN N
between IN N
groups NNS N
over IN N
time NN N
( ( N
pre NN N
, , N
post NN N
0 CD N
, , N
10 CD N
, , N
20 CD N
, , N
30 CD N
min NN N
) ) N
. . N

The DT N
distal JJ N
tibiofibular JJ i
joint NN i
manipulation NN i
group NN N
demonstrated VBD N
a DT N
significant JJ N
increase NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
in IN N
soleus NN o
H/M NNP o
ratio NN o
at IN N
all DT N
post-intervention JJ N
time NN N
periods NNS N
except IN N
20 CD N
min JJ N
post-intervention NN N
( ( N
P=.48 NNP N
) ) N
. . N

The DT N
proximal JJ N
tibiofibular JJ i
joint NN i
manipulation NN i
and CC N
control NN i
groups NNS N
did VBD N
not RB N
demonstrate VB N
a DT N
change NN N
in IN N
soleus NN o
H/M NNP o
ratios NNS o
. . o

All DT N
groups NNS N
demonstrated VBD N
a DT N
decrease NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
from IN N
baseline NN N
values NNS N
in IN N
fibularis JJ o
longus NN o
( ( N
10-30 JJ N
min NN N
post-intervention NN N
) ) N
and CC N
soleus NN o
( ( N
30 CD N
min RB N
post-intervention NN N
) ) N
H/M NNP o
ratios NNS o
. . o

Interventions NNS N
directed VBD N
at IN N
the DT N
distal JJ N
tibiofibular JJ N
joint NN N
acutely RB N
increase VB N
soleus JJ o
muscle NN o
activation NN o
. . o

-DOCSTART- -24965333- O O

Vitamin NNP i
D NNP i
supplementation NN i
ameliorates VBZ N
hypoinsulinemia NN o
and CC o
hyperglycemia NN o
in IN N
static JJ p
magnetic JJ p
field-exposed JJ p
rat NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
vitamin NN i
D NNP i
supplementation NN i
on IN N
glucose NN o
and CC o
lipid JJ o
metabolism NN o
in IN N
static JJ p
magnetic JJ p
field NN p
( ( p
SMF NNP p
) ) p
-exposed VBD p
rats NNS p
. . p

Rats NNS p
exposed VBD N
to TO N
SMF NNP N
( ( N
128 CD N
mT NN N
; : N
1 CD N
h/day NN N
) ) N
during IN N
5 CD N
consecutive JJ N
days NNS N
showed VBD N
an DT N
increase NN N
in IN N
plasma JJ o
glucose JJ o
level NN o
and CC o
a DT o
decrease NN o
in IN o
plasma JJ o
insulin NN o
concentration NN o
. . o

By IN N
contrast NN N
, , N
the DT N
same JJ N
treatment NN N
failed VBD N
to TO N
alter VB N
body NN o
weight NN o
and CC o
plasmatic JJ o
total NN o
cholesterol NN o
, , o
high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
-cholesterol NN o
, , o
low-density NN o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
-cholesterol NN o
, , o
and CC o
triglyceride NN o
levels NNS o
. . o

Interestingly RB N
, , N
supplementation NN N
with IN N
vitamin NN i
D NNP i
( ( N
1,600 CD N
IU/100 NNP N
g NN N
, , N
per IN N
os NN N
) ) N
corrected VBD N
and CC N
restored VBD N
glycemia NN o
and CC o
insulinemia NN o
in IN N
SMF-exposed JJ p
rats NNS p
. . p

The DT N
same JJ N
treatment NN N
had VBD N
no DT N
effects NNS N
on IN N
lipid JJ o
metabolism NN o
. . o

-DOCSTART- -20957980- O O

Ipilimumab NNP i
efficacy NN N
and CC N
safety NN N
in IN N
patients NNS p
with IN p
advanced JJ p
melanoma NN p
: : p
a DT N
retrospective JJ N
analysis NN N
of IN N
HLA NNP N
subtype NN N
from IN N
four CD N
trials NNS N
. . N

Ipilimumab NNP i
is VBZ N
a DT N
fully RB N
human JJ N
, , N
monoclonal JJ N
antibody NN N
that WDT N
blocks VBZ N
cytotoxic JJ N
T-lymphocyte JJ N
antigen-4 NN N
to TO N
potentiate VB N
an DT N
antitumor JJ N
T-cell NNP N
response NN N
. . N

This DT N
agent NN N
improved VBD N
overall JJ N
survival NN N
in IN N
a DT N
phase NN N
III NNP N
trial NN N
in IN N
previously RB p
treated VBN p
patients NNS p
with IN p
advanced JJ p
melanoma NN p
. . p

Because IN N
the DT N
mechanism NN N
of IN N
action NN N
for IN N
ipilimumab NN i
is VBZ N
thought VBN N
to TO N
be VB N
HLA NNP N
independent JJ N
, , N
most JJS N
trials NNS N
enrolled VBD p
patients NNS p
without IN p
regard NN p
to TO p
HLA NNP p
subtype NN p
. . p

However RB N
, , N
enrollment NN N
in IN N
the DT N
phase NN N
III NNP N
trial NN N
was VBD N
restricted VBN N
to TO N
class-I JJ p
HLA-A*0201-positive JJ p
patients NNS p
because IN N
two CD N
of IN N
the DT N
three CD N
arms NNS N
contained VBD N
an DT N
HLA-A*0201-restricted JJ i
gp100 NN i
vaccine NN i
. . i

HLA NNP N
typing NN N
was VBD N
also RB N
performed VBN N
prospectively RB N
in IN N
several JJ N
phase NN N
II NNP N
trials NNS N
and CC N
was VBD N
available JJ N
for IN N
93.5 CD p
% NN p
of IN p
patients NNS p
. . p

In IN N
this DT N
retrospective JJ N
analysis NN N
, , N
pooled VBD o
efficacy NN o
and CC o
safety NN o
data NNS o
are VBP N
presented VBN N
according VBG N
to TO N
HLA-A*0201 NNP N
status NN N
and CC N
dose NN N
from IN N
pretreated JJ p
patients NNS p
randomized VBN N
to TO N
0.3 CD N
, , N
3 CD N
, , N
or CC N
10 CD N
mg/kg NNS N
ipilimumab VBP N
in IN N
four CD N
phase NN N
II NNP N
trials NNS N
. . N

Median JJ o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
was VBD N
similar JJ N
for IN N
the DT N
187 CD N
HLA-A*0201-positive JJ N
[ JJ N
9.3 CD N
months NNS N
, , N
95 CD N
% NN N
CI NNP N
( ( N
confidence NN N
interval NN N
) ) N
7.4-11.5 CD N
] NN N
and CC N
266 CD N
HLA-A*0201-negative JJ p
patients NNS p
[ VBP N
11.4 CD N
months NNS N
, , N
95 CD N
% NN N
CI NNP N
9.3-15.1 CD N
] NNP N
randomized VBD N
to TO N
ipilimumab VB N
at IN N
all DT N
doses NNS N
across IN N
the DT N
four CD N
phase NN N
II NNP N
trials NNS N
. . N

These DT N
data NNS N
are VBP N
comparable JJ N
to TO N
the DT N
OS NNP o
for IN N
the DT N
137 CD p
HLA-A*0201-positive JJ p
patients NNS p
randomized VBN N
to TO N
ipilimumab VB N
in IN N
the DT N
phase NN N
III NNP N
study NN N
[ VBD N
10.1 CD N
months NNS N
, , N
95 CD N
% NN N
CI NNP N
8.0-13.8 CD N
] NNP N
. . N

Ipilimumab-induced JJ o
adverse JJ o
events NNS o
and CC o
immune-related JJ o
adverse JJ o
events NNS o
( ( o
skin NN o
, , o
gastrointestinal JJ o
, , o
hepatic JJ o
, , o
other JJ o
) ) o
also RB N
occurred VBD N
at IN N
similar JJ N
frequencies NNS N
among IN N
patients NNS N
in IN N
the DT N
phase NN N
II NNP N
and CC N
III NNP N
trials NNS N
, , N
regardless RB N
of IN N
HLA-A*0201 NNP N
status NN N
. . N

These DT N
findings NNS N
support VBP N
the DT N
hypothesis NN N
that IN N
ipilimumab-treated JJ i
patients NNS p
with IN N
advanced JJ N
melanoma NNS N
have VBP N
similar JJ N
outcomes NNS N
regardless RB N
of IN N
their PRP$ N
HLA-A*0201 JJ N
status NN N
. . N

-DOCSTART- -24231646- O O

Humoral NNP p
immunity NN p
after IN p
kidney NN p
transplantation NN p
: : p
impact NN N
of IN N
two CD N
randomized JJ N
immunosuppressive JJ N
protocols NNS N
. . N

BACKGROUND NNP N
Controlling NNP N
alloimmune JJ N
humoral JJ N
response NN N
is VBZ N
a DT N
challenge NN N
in IN N
transplantation NN N
. . N

Few JJ N
studies NNS N
have VBP N
evaluated VBN N
the DT N
impact NN N
of IN N
maintenance NN N
immunosuppression NN N
on IN N
blood NN N
humoral JJ N
parameters NNS N
. . N

MATERIAL/METHODS NNP N
We PRP N
performed VBD N
a DT N
post-hoc JJ N
analysis NN N
on IN N
307 CD p
kidney NN p
transplant NN p
recipients NNS p
included VBD p
in IN p
a DT p
prospective JJ p
randomized VBN p
trial NN p
comparing VBG p
tacrolimus/mycophenolate NN i
mofetil NN i
( ( i
Tac/MMF NNP i
) ) i
vs. FW i
cyclosporine/azathioprine NN i
( ( i
CsA/AZA NNP i
) ) i
, , N
both DT N
used VBN N
with IN N
antithymocyte JJ i
globulin NN i
induction NN i
and CC N
steroids NNS i
. . i

Humoral JJ N
parameters NNS N
were VBD N
analyzed VBN N
at IN N
D0 NNP N
, , N
D15 NNP N
, , N
and CC N
M12 NNP N
. . N

RESULTS NNP N
IgG NNP o
, , o
IgA NNP o
, , o
and CC o
IgM NNP o
levels NNS o
decreased VBN N
significantly RB N
as RB N
soon RB N
as IN N
D15 NNP N
in IN N
both DT N
groups NNS N
( ( N
?35 CD N
% NN N
, , N
?26 CD N
% NN N
, , N
and CC N
?35 CD N
% NN N
respectively RB N
, , N
vs. FW N
D0 NNP N
) ) N
. . N

At IN N
M12 NNP N
, , N
although IN o
peripheral JJ o
B-cell NNP o
counts NNS o
did VBD o
not RB o
differ VB N
between IN N
the DT N
groups NNS N
, , N
Tac/MMF NNP N
regimen NN N
was VBD N
associated VBN N
with IN N
lower JJR N
IgG NNP N
, , N
IgA NNP N
, , N
and CC N
IgM NNP N
levels NNS N
than IN N
CsA/AZA NNP N
( ( N
?5.9 CD N
% NN N
, , N
?14.6 CD N
% NN N
, , N
and CC N
?34 NNP N
% NN N
, , N
respectively RB N
) ) o
. . o

Hypogammaglobulinemia NNP o
at IN o
D15 NNP o
was VBD o
not RB N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN o
of IN o
infections NNS o
during IN N
the DT N
first JJ N
year NN N
. . N

The DT o
proportion NN o
of IN o
HLA-sensitized JJ o
patients NNS o
decreased VBN o
in IN N
the DT N
Tac/MMF NNP N
group NN N
( ( N
15.9 CD N
% NN N
at IN N
D0 NNP N
and CC N
6.7 CD N
% NN N
at IN N
M12 NNP N
, , N
p=0.02 NN N
) ) N
and CC N
remained VBD N
stable JJ N
in IN N
the DT N
CsA/AZA NNP N
group NN N
( ( N
10.3 CD N
% NN N
at IN N
D0 NNP N
and CC N
8.9 CD N
% NN N
at IN N
M12 NNP N
, , N
p=0.5 NN N
) ) N
. . N

More JJR N
patients NNS N
sensitized VBN N
at IN N
baseline NN N
became VBD N
non-sensitized JJ N
at IN N
M12 NNP N
with IN N
Tac/MMF NNP N
than IN N
with IN N
CsA/AZA NNP N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
humoral JJ N
immunosuppression NN N
is VBZ N
better RBR N
with IN N
Tac/MMF NNP N
than IN N
with IN N
CsA/AZA NNP N
during IN N
the DT N
first JJ N
year NN N
of IN N
kidney NN N
transplantation NN N
. . N

-DOCSTART- -17097398- O O

Topical NNP i
retapamulin NN i
ointment NN i
( ( N
1 CD N
% NN N
, , N
wt/wt NN N
) ) N
twice RB N
daily RB N
for IN N
5 CD N
days NNS N
versus IN N
oral JJ N
cephalexin NN i
twice RB N
daily RB N
for IN N
10 CD N
days NNS N
in IN N
the DT N
treatment NN N
of IN N
secondarily RB p
infected VBN p
dermatitis NN p
: : p
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
New NNP N
antibacterial JJ N
agents NNS N
with IN N
activity NN N
against IN N
pathogenic JJ N
strains NNS N
resistant VBP N
to TO N
established VBN N
antibiotics NNS N
are VBP N
needed VBN N
to TO N
treat VB N
patients NNS p
with IN p
secondarily RB p
infected VBN p
dermatitis NN p
( ( p
SID NNP p
) ) p
. . p

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
clinical JJ N
safety NN N
and CC N
efficacy NN N
of IN N
topical JJ i
retapamulin NN i
ointment VBD i
1 CD N
% NN N
versus JJ N
oral JJ N
cephalexin NN i
for IN N
the DT N
treatment NN N
of IN N
SID NNP N
. . N

METHODS NNP N
Patients NNPS p
with IN p
SID NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
retapamulin VB i
ointment JJ i
1 CD N
% NN N
( ( N
twice JJ N
daily RB N
[ NNP N
bid NN N
] NN N
) ) N
for IN N
5 CD N
days NNS N
, , N
or CC N
oral JJ i
cephalexin NN i
( ( N
500 CD N
mg RB N
bid NN N
) ) N
for IN N
10 CD N
days NNS N
. . N

The DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
was VBD N
clinical JJ o
response NN o
at IN N
follow-up NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
microbiologic JJ o
response NN o
at IN N
follow-up NN N
, , N
safety NN o
, , N
and CC N
compliance NN o
. . o

RESULTS NNP N
Retapamulin NNP i
was VBD N
as RB N
effective JJ N
as IN N
cephalexin NN i
( ( N
clinical JJ N
success NN N
rates NNS N
at IN N
follow-up NN N
: : N
85.9 CD N
% NN N
and CC N
89.7 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Microbiologic NNP o
success NN o
rates NNS o
at IN N
follow-up JJ N
were VBD N
87.2 CD N
% NN N
for IN N
retapamulin NN i
and CC N
91.8 CD N
% NN N
for IN N
cephalexin NN i
. . i

Retapamulin NNP i
was VBD N
well RB N
tolerated VBN o
and CC N
the DT N
topical JJ N
formulation NN N
was VBD N
preferred VBN N
over IN N
the DT N
oral JJ i
drug NN i
. . i

LIMITATIONS NNP N
An DT N
imbalance NN N
existed VBN N
in IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
the DT N
clinical JJ N
outcome NN N
unable JJ N
to TO N
determine VB N
( ( N
15 CD N
retapamulin NN i
, , N
2 CD N
cephalexin NN i
) ) i
, , N
mainly RB N
because IN N
of IN N
their PRP$ N
failure NN N
to TO N
attend VB N
the DT N
study NN N
visit NN N
. . N

If IN N
those DT N
who WP N
failed VBD N
to TO N
attend VB N
visits NNS N
( ( N
who WP N
did VBD N
not RB N
withdraw VB N
as IN N
a DT N
result NN N
of IN N
drug-related JJ N
events NNS N
) ) N
are VBP N
removed VBN N
from IN N
the DT N
analysis NN N
, , N
the DT N
clinical JJ N
success NN N
rates NNS N
are VBP N
89.9 CD N
% NN N
for IN N
retapamulin NN i
and CC N
89.7 CD N
% NN N
for IN N
cephalexin NN i
. . i

CONCLUSIONS NNP N
Retapamulin NNP i
ointment VBD i
1 CD N
% NN N
( ( N
bid NN N
) ) N
for IN N
5 CD N
days NNS N
was VBD N
as RB N
effective JJ N
as IN N
oral JJ N
cephalexin NN i
( ( N
bid NN N
) ) N
for IN N
10 CD N
days NNS N
in IN N
treatment NN N
of IN N
patients NNS p
with IN p
SID NNP p
, , N
and CC N
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -12452403- O O

Hypnosis NNP i
treatment NN i
for IN N
severe JJ o
irritable JJ o
bowel NN o
syndrome NN o
: : o
investigation NN N
of IN N
mechanism NN N
and CC N
effects NNS N
on IN N
symptoms NNS N
. . N

Hypnosis NNP i
improves VBZ N
irritable JJ o
bowel NN o
syndrome NN o
( ( N
IBS NNP N
) ) N
, , N
but CC N
the DT N
mechanism NN N
is VBZ N
unknown JJ N
. . N

Possible JJ N
physiological JJ N
and CC N
psychological JJ N
mechanisms NNS N
were VBD N
investigated VBN N
in IN N
two CD N
studies NNS N
. . N

Patients NNS p
with IN p
severe JJ p
irritable JJ p
bowel NN p
syndrome NN p
received VBD N
seven CD N
biweekly JJ i
hypnosis NN i
sessions NNS i
and CC i
used VBD i
hypnosis NN i
audiotapes NNS i
at IN N
home NN N
. . N

Rectal JJ N
pain NN N
thresholds NNS N
and CC N
smooth JJ N
muscle NN N
tone NN N
were VBD N
measured VBN N
with IN N
a DT N
barostat NN N
before IN N
and CC N
after IN N
treatment NN N
in IN N
18 CD p
patients NNS p
( ( p
study VB p
I PRP p
) ) p
, , N
and CC N
treatment NN N
changes NNS N
in IN N
heart NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
skin JJ N
conductance NN N
, , N
finger NN N
temperature NN N
, , N
and CC N
forehead JJ N
electromyographic JJ N
activity NN N
were VBD N
assessed VBN N
in IN N
24 CD p
patients NNS p
( ( p
study VB p
II NNP p
) ) p
. . p

Somatization NN N
, , N
anxiety NN N
, , N
and CC N
depression NN N
were VBD N
also RB N
measured VBN N
. . N

All DT o
central JJ o
IBS NNP o
symptoms NNS o
improved VBN N
substantially RB N
from IN N
treatment NN N
in IN N
both DT N
studies NNS N
. . N

Rectal JJ o
pain NN o
thresholds NNS o
, , o
rectal JJ o
smooth JJ o
muscle NN o
tone NN o
, , o
and CC o
autonomic JJ o
functioning NN o
( ( o
except IN o
sweat NN o
gland VBP o
reactivity NN o
) ) o
were VBD N
unaffected VBN N
by IN N
hypnosis NN N
treatment NN N
. . N

However RB N
, , N
somatization NN o
and CC o
psychological JJ o
distress NN o
showed VBD N
large JJ N
decreases NNS N
. . N

In IN N
conclusion NN N
, , N
hypnosis NN i
improves NNS N
IBS NNP o
symptoms NNS o
through IN N
reductions NNS N
in IN N
psychological JJ o
distress NN o
and CC o
somatization NN o
. . o

Improvements NNS N
were VBD N
unrelated JJ N
to TO N
changes NNS N
in IN N
the DT N
physiological JJ N
parameters NNS N
measured VBD N
. . N

-DOCSTART- -17971587- O O

Assessment NN N
of IN N
response NN N
to TO N
induction NN N
therapy NN N
and CC N
its PRP$ N
influence NN N
on IN N
5-year JJ o
failure-free JJ o
survival NN o
in IN p
group NN p
III NNP p
rhabdomyosarcoma NN p
: : p
the DT N
Intergroup NNP N
Rhabdomyosarcoma NNP N
Study-IV NNP N
experience NN N
-- : N
a DT N
report NN N
from IN N
the DT N
Soft NNP N
Tissue NNP N
Sarcoma NNP N
Committee NNP N
of IN N
the DT N
Children NNP N
's POS N
Oncology NNP N
Group NNP N
. . N

PURPOSE NNP N
Initial NNP N
response NN N
to TO N
induction NN i
chemotherapy NN i
predicts VBZ N
failure-free JJ o
survival NN o
( ( o
FFS NNP o
) ) o
in IN N
osteosarcoma NN p
and CC p
Ewing NNP p
's POS p
sarcoma NN p
. . p

For IN N
Intergroup NNP N
Rhabdomyosarcoma NNP N
Study NNP N
( ( N
IRS NNP N
) ) N
IV VBZ N
patients NNS p
with IN p
group NN p
III NNP p
rhabdomyosarcoma NN p
, , N
we PRP N
assessed VBD N
whether IN N
reported VBN N
response NN N
assessed VBN N
by IN N
anatomic JJ N
imaging NN N
at IN N
week NN N
8 CD N
predicted VBD N
FFS NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
We PRP N
studied VBD N
444 CD p
group NN p
III NNP p
patients NNS p
who WP p
received VBD p
induction NN i
therapy NN i
, , p
had VBD p
response NN p
assessed VBN p
at IN p
week NN p
8 CD p
by IN p
anatomic JJ i
imaging NN i
, , i
and CC i
continued VBD i
with IN i
protocol NN i
therapy NN i
. . i

Induction NNP i
chemotherapy NN i
was VBD N
generally RB N
followed VBN N
by IN N
radiation NN i
therapy NN i
( ( i
RT NNP i
) ) i
starting VBG N
after IN N
week NN N
9 CD N
. . N

Response NN o
to TO N
induction NN N
therapy NN N
was VBD N
determined VBN N
at IN N
weeks NNS N
0 CD N
and CC N
8 CD N
. . N

Local JJ N
institutions NNS N
coded VBD N
response NN N
. . N

RESULTS JJ N
Response JJ o
rate NN o
for IN N
the DT N
entire JJ N
cohort NN N
at IN N
week NN N
8 CD N
was VBD N
77 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
73 CD N
% NN N
to TO N
81 CD N
% NN N
; : N
complete JJ o
response NN o
[ NNP o
CR NNP o
] NNP o
, , N
21 CD N
% NN N
; : N
partial JJ o
response NN o
[ NNP o
PR NNP o
] NNP o
, , N
56 CD N
% NN N
) ) N
but CC N
response NN N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP o
( ( N
P NNP N
= NNP N
.57 NNP N
) ) N
. . N

Two CD N
hundred VBD N
seventy-two JJ N
patients NNS N
received VBD N
standard-timing JJ N
RT NNP N
at IN N
week NN N
9 CD N
and CC N
thus RB N
only RB N
chemotherapy NN N
during IN N
induction NN N
. . N

Response NNP o
rate NN o
was VBD N
81 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP o
, , N
76 CD N
% NN N
to TO N
86 CD N
% NN N
; : N
CR NNP o
, , N
22 CD N
% NN N
; : N
PR NNP o
, , N
59 CD N
% NN N
) ) N
. . N

In IN N
these DT N
patients NNS N
, , N
response NN N
did VBD o
not RB o
influence VB o
FFS NNP o
except IN N
for IN N
those DT N
with IN N
alveolar JJ N
histology NN N
. . N

One CD N
hundred VBD N
thirty-two NN N
other JJ N
patients NNS N
received VBN N
chemotherapy NN N
and CC N
RT NNP N
during IN N
induction NN N
( ( N
up-front JJ N
RT NNP N
) ) N
. . N

Response JJ o
rate NN o
was VBD N
65 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP o
, , N
57 CD N
% NN N
to TO N
73 CD N
% NN N
; : N
CR NNP o
, , N
12 CD N
% NN N
; : N
PR NNP o
, , N
53 CD N
% NN N
) ) N
, , N
but CC N
response NN N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP o
( ( N
P NNP N
= NNP N
.69 NNP N
) ) N
. . N

Forty JJ N
patients NNS N
received VBD N
no DT N
RT NNP N
at IN N
all DT N
( ( N
protocol JJ N
violation NN N
) ) N
and CC N
response NN N
to TO N
induction NN N
therapy NN N
had VBD N
no DT o
effect NN o
on IN N
FFS NNP o
. . o

CONCLUSION NNP N
In IN N
IRS-IV NNP N
, , N
response NN o
rate NN o
to TO N
induction NN N
therapy NN N
was VBD N
77 CD N
% NN N
in IN N
group NN p
III NNP p
patients NNS p
, , N
was VBD N
independent JJ N
of IN N
histology NN N
, , N
and CC N
had VBD N
no DT N
influence NN N
on IN N
FFS NNP o
overall JJ N
. . N

-DOCSTART- -9303285- O O

Dose-response JJ o
and CC o
concentration-response JJ o
relation NN N
of IN N
rocuronium NN i
infusion NN i
during IN N
propofol-nitrous JJ i
oxide NN i
and CC N
isoflurane-nitrous JJ i
oxide NN i
anaesthesia NN i
. . i

The DT o
dose-response JJ o
and CC o
concentration-response JJ o
relation NN o
of IN N
rocuronium NN i
infusion NN i
was VBD N
studied VBN N
in IN N
20 CD p
adult NN p
surgical JJ p
patients NNS p
during IN p
propofol-nitrous JJ i
oxide NN i
and CC i
isoflurane NN i
( ( i
1 CD i
MAC NNP i
) ) i
-nitrous JJ i
oxide JJ i
anaesthesia NN i
. . i

Neuromuscular JJ N
block NN N
was VBD N
kept VBN N
constant JJ N
, , N
initially RB N
at IN N
90 CD N
% NN N
and CC N
then RB N
at IN N
50 CD N
% NN N
with IN N
a DT N
closed-loop JJ i
feedback NN i
controller NN i
. . i

At IN N
90 CD N
% NN N
block NN N
the DT N
steady-state JJ o
infusion NN o
of IN i
rocuronium NN i
was VBD N
0.55 CD N
+/- JJ N
0.16 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
corresponding JJ i
concentration NN o
1714 CD N
+/- JJ N
281 CD N
ng JJ N
mL-1 NN N
in IN N
patients NNS N
receiving VBG N
propofol NN i
. . i

At IN N
50 CD N
% NN N
block NN N
the DT N
corresponding JJ o
infusion NN o
rate NN o
was VBD N
0.27 CD N
+/- JJ N
0.11 CD N
mg JJ N
kg-1 JJ N
h-1 NN N
and CC N
the DT N
concentration NN o
1077 CD N
+/- JJ N
244 CD N
ng JJ N
mL-1 NN N
, , N
respectively RB N
. . N

At IN N
50 CD N
% NN N
block NN N
isoflurane NN i
reduced VBD N
the DT N
rate NN o
of IN o
infusion NN o
by IN N
52 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
and CC N
the DT N
concentration NN o
by IN N
59 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
at IN N
90 CD N
% NN N
block NN N
both CC N
the DT N
mean JJ o
infusion NN o
rate NN o
and CC N
the DT N
concentration NN o
of IN o
rocuronium NN o
were VBD N
reduced VBN N
by IN N
35 CD N
% NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

The DT N
mean JJ o
rocuronium NN o
clearance NN o
at IN N
50 CD N
% NN N
block NN N
was VBD N
unaffected VBN N
by IN N
the DT N
type NN N
of IN N
anaesthesia NN i
; : i
it PRP N
was VBD N
4.1 CD N
+/- JJ N
1.6 CD N
and CC N
4.9 CD N
+/- JJ N
2.7 CD N
mL JJ N
kg-1 JJ N
min-1 NN N
in IN N
the DT N
groups NNS N
receiving VBG N
propofol NN i
and CC N
isoflurane NN i
anaesthesia NN i
, , N
respectively RB N
. . N

We PRP N
conclude VBP N
that IN N
isoflurane NN N
reduces VBZ N
the DT N
infusion NN o
requirements NNS o
of IN o
rocuronium NN o
by IN N
changing VBG N
the DT N
pharmacodynamic JJ N
behaviour NN N
. . N

-DOCSTART- -15198767- O O

Needle NNP i
versus NN i
loop NN i
diathermy NN i
excision NN i
of IN N
the DT N
transformation NN N
zone NN N
for IN N
the DT N
treatment NN N
of IN N
cervical JJ p
intraepithelial JJ p
neoplasia NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
lower JJR N
rates NNS N
or CC N
incomplete JJ N
resection NN N
of IN N
cervical JJ p
intraepithelial JJ p
neoplasia NN p
( ( p
CIN NNP p
) ) p
may MD N
be VB N
achieved VBN N
by IN N
needle JJ i
excision NN i
of IN i
the DT i
transformation NN i
zone NN i
( ( i
NETZ NNP i
) ) i
than IN i
with IN i
loop JJ i
excision NN i
( ( i
LLETZ NNP i
) ) i
. . i

DESIGN VB N
A DT N
prospective JJ N
randomised VBN N
controlled VBN N
trial NN N
. . N

SETTING VB N
A DT N
gynaecological JJ p
oncology NN p
centre NN p
and CC p
a DT p
teaching JJ p
hospital NN p
in IN p
West NNP p
London NNP p
. . p

POPULATION NNP N
Four CD p
hundred VBD p
and CC p
four CD p
women NNS p
due JJ p
to TO p
receive VB p
treatment NN p
for IN p
suspected JJ p
CIN NNP p
. . p

METHODS NNP N
Women NNP N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
LLETZ NNP i
or CC i
NETZ NNP i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
study NN N
was VBD N
designed VBN N
to TO N
demostrate VB N
a DT N
difference NN N
in IN N
the DT N
proportion NN o
of IN o
women NNS o
with IN o
clear JJ o
histological JJ o
margins NNS o
of IN N
82 CD N
% NN N
for IN N
LLETZ NNP i
compared VBN N
to TO N
94 CD N
% NN N
for IN N
NETZ NNP N
with IN N
90 CD N
% NN N
power NN N
at IN N
a DT N
5 CD N
% NN N
significance NN N
level NN N
, , N
allowing VBG N
for IN N
absence NN N
of IN N
CIN NNP N
in IN N
the DT N
treatment NN o
specimen NNS o
in IN N
15 CD N
% NN N
. . N

RESULTS NNP N
Four NNP p
randomised VBD p
women NNS p
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
, , N
as IN N
they PRP N
were VBD N
ineligible JJ N
for IN N
the DT N
study NN N
. . N

Three CD N
hundred VBD N
and CC N
forty-seven JJ N
( ( N
87 CD N
% NN N
) ) N
had VBD N
CIN NNP N
in IN N
the DT N
treatment NN N
specimen NNS N
and CC N
could MD N
be VB N
included VBN N
in IN N
the DT N
analysis NN N
of IN N
excision NN N
margins NNS N
. . N

More JJR N
women NNS N
in IN N
the DT N
NETZ NNP i
arm NN N
had VBD N
clear JJ o
histological JJ o
margins NNS o
( ( N
84.8 CD N
% NN N
vs JJ N
75 CD N
% NN N
, , N
( ( N
P= NNP N
0.03 CD N
) ) N
. . N

The DT N
median JJ o
volume NN o
of IN o
specimens NNS o
in IN N
the DT N
NETZ NNP N
arm NN N
was VBD N
739 CD N
mm NN N
( ( N
3 CD N
) ) N
larger JJR N
( ( N
P= NNP N
0.33 CD N
) ) N
and CC N
they PRP N
were VBD N
less RBR o
likely JJ o
to TO o
be VB o
removed VBN o
in IN N
multiple JJ N
pieces NNS N
( ( N
2.5 CD N
% NN N
vs JJ N
29.5 CD N
% NN N
, , N
RR NNP N
0.09 CD N
, , N
95 CD N
% NN N
CI NNP N
0.04 CD N
to TO N
0.20 CD N
) ) N
. . N

Needle NNP N
excision NN N
took VBD N
longer JJR o
to TO o
perform VB o
( ( o
median JJ o
treatment NN o
time NN o
210 CD N
vs NN N
90 CD N
seconds NNS N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
surgeons NNS N
more RBR N
often RB N
reported VBD o
the DT o
procedure NN o
as IN o
'difficult NN o
' '' o
( ( N
9.5 CD N
% NN N
vs JJ N
3.0 CD N
% NN N
, , N
RR NNP N
= VBD N
3.17 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
1.33 CD N
to TO N
7.58 CD N
) ) N
. . N

No DT N
difference NN N
in IN N
peri-operative JJ o
or CC o
post-operative JJ o
complication NN o
rates NNS o
could MD N
be VB N
demonstrated VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
NETZ NNP i
is VBZ N
more RBR N
likely JJ N
to TO N
produce VB N
a DT N
specimen NNS N
in IN N
one CD N
piece NN N
and CC N
with IN N
clear JJ N
margins NNS N
compared VBN N
to TO N
LLETZ NNP i
. . i

-DOCSTART- -3010510- O O

Intravenous JJ i
hyperimmune NN i
globulin NN i
prophylaxis NN i
against IN N
cytomegalovirus JJ N
interstitial JJ N
pneumonitis NN N
after IN N
allogenic JJ i
bone NN i
marrow NN i
transplantation NN i
. . i

In IN N
an DT N
attempt NN N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
lethal JJ N
cytomegalovirus NN o
( ( o
CMV NNP o
) ) o
interstitial NN o
pneumonitis NN o
after IN p
allogenic JJ i
bone NN i
marrow NN i
transplantation NN i
49 CD p
patients NNS p
were VBD p
randomized VBN p
in IN p
a DT p
multicenter NN p
controlled VBN p
study NN p
to TO N
receive VB N
either DT N
CMV-hyperimmune NNP i
globulin NN i
or CC N
a DT N
control NN i
immune JJ i
globulin NN i
with IN i
low JJ i
anticytomegalovirus NN i
titer NN i
. . i

Immune NNP i
globulin NN i
was VBD N
administered VBN N
intravenously RB N
6 CD N
times NNS N
with IN N
20 CD N
days NNS N
interval NN N
, , N
starting VBG N
on IN N
day NN N
7 CD N
before IN N
transplantation NN N
. . N

Patients NNS N
receiving VBG N
CMV NNP i
hyperimmune NN i
globulin NN i
or CC N
control NN i
immune JJ i
globulin NNS i
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
age NN N
, , N
diagnosis NN N
, , N
pretransplant JJ N
anti-CMV JJ N
titer NN N
, , N
incidence NN N
of IN N
graft-versus-host JJ N
disease NN N
and CC N
transfusions NNS N
. . N

In IN N
each DT N
group NN N
, , N
the DT N
incidence NN o
of IN o
histologically RB o
proven VBN o
CMV NNP o
interstitial JJ o
pneumonitis NN o
during IN N
the DT N
first JJ N
110 CD N
days NNS N
post RB N
BMT NNP N
was VBD N
recorded VBN N
. . N

Six NNP p
of IN p
23 CD p
patients NNS p
in IN N
the DT N
control NN i
group NN N
versus VBD N
1 CD N
of IN N
26 CD N
in IN N
the DT N
CMV NNP i
hyperimmune NNP i
globulin NN i
group NN N
died VBD o
of IN o
CMV NNP o
interstitial JJ o
pneumonitis NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
effect NN o
on IN o
idiopathic JJ o
pneumonitis NN o
or CC o
survival NN o
was VBD N
observed VBN N
. . N

-DOCSTART- -8499152- O O

Prognostic JJ N
value NN N
of IN N
clinical JJ N
, , N
laboratory NN N
, , N
and CC N
histological JJ N
characteristics NNS N
in IN N
multiple JJ N
myeloma NN N
: : N
improved JJ N
definition NN N
of IN N
risk NN N
groups NNS N
. . N

Follow-up NNP N
data NN N
of IN N
320 CD p
multiple JJ p
myeloma NN p
( ( p
MM NNP p
) ) p
patients NNS p
entering VBG p
the DT i
German JJ i
Myeloma NNP i
Treatment NNP i
Group NNP i
( ( i
GMTG NNP i
) ) i
trial NN p
MM01 NNP p
were VBD N
analysed VBN N
for IN N
factors NNS N
predicting VBG N
overall JJ o
( ( o
OAS NNP o
) ) o
and CC o
tumour $ o
related VBN o
survival NN o
( ( o
TRS NNP o
) ) o
. . N

Response NN N
to TO N
primary JJ i
induction NN i
chemotherapy NN i
was VBD N
relevant JJ N
for IN N
prognosis NN N
if IN N
a DT N
limit NN N
of IN N
25 CD N
% NN N
tumour NN N
cell NN N
mass NN N
( ( N
TCM NNP N
) ) N
reduction NN N
was VBD N
used VBN N
to TO N
separate JJ N
responders NNS N
from IN N
non-responders NNS N
. . N

Furthermore NNP N
, , N
TCM NNP o
, , o
histological JJ o
grading NN o
of IN o
myeloma NN o
cells NNS o
, , o
degree NN o
of IN o
bone NN o
marrow NN o
infiltration NN o
, , o
haemoglobin NN o
, , o
platelet NN o
counts NNS o
, , o
calcium NN o
, , o
creatinine NN o
, , o
albumin NN o
, , o
beta NN o
2M CD o
, , o
and CC o
Bence NNP o
Jones NNP o
proteinuria NNS o
correlated VBD N
to TO N
both DT N
OAS NNP N
and CC N
TRS NNP N
. . N

Age NNP N
was VBD N
relevant JJ N
for IN N
OAS NNP N
only RB N
. . N

The DT N
multivariate NN N
analysis NN N
revealed VBD N
histological JJ o
grading NN o
, , o
TCM NNP o
and CC o
platelets NNS o
as IN N
the DT N
most RBS N
reliable JJ N
prognostic JJ N
factors NNS N
. . N

Based VBN N
on IN N
these DT N
data NNS N
the DT N
Durie/Salmon NNP N
classification NN N
could MD N
be VB N
improved VBN N
by IN N
defining VBG N
poor JJ i
prognosis NN i
patients NNS p
( ( p
50 CD p
% NN p
TRS NNP p
: : p
16 CD p
months NNS p
) ) p
characterised VBN p
by IN p
pretreatment JJ p
platelets NNS p
of IN p
< NN p
or CC p
= $ p
150,000 CD p
and/or JJ N
poorly RB N
differentiated VBN N
myeloma NN N
cell NN N
morphology NN N
. . N

Patients NNS p
lacking VBG p
both DT p
risk NN p
factors NNS p
displayed VBD N
50 CD N
% NN N
survival JJ o
times NNS o
of IN N
46 CD N
months NNS N
in IN N
stage NN N
III NNP N
and CC N
88 CD N
months NNS N
in IN N
stage NN N
II NNP N
. . N

-DOCSTART- -18717189- O O

Efficacy NN o
of IN N
latanoprost NN i
when WRB N
stored VBN N
at IN N
room NN N
temperature NN N
. . N

We PRP N
compared VBN N
the DT N
ocular JJ N
hypotensive JJ N
effect NN o
for IN N
24 CD N
hours NNS N
and CC N
the DT N
tolerability NN N
of IN N
latanoprost NN i
stored VBN N
at IN N
4 CD N
degrees NNS N
C NNP N
and CC N
30 CD N
degrees NNS N
C. NNP N
Seventeen NNP p
healthy JJ p
volunteers NNS p
were VBD p
included VBN p
in IN p
this DT p
crossover NN p
trial NN p
. . p

Latanoprost VB i
0.005 CD N
% NN N
( ( i
Xalatan NNP i
) ) i
was VBD N
stored VBN N
at IN N
4 CD N
degrees NNS N
C NNP N
or CC N
30 CD N
degrees NNS N
C NNP N
for IN N
4 CD N
weeks NNS N
in IN N
the DT N
dark NN N
. . N

The DT N
subjects NNS N
enrolled VBD N
to TO N
the DT N
study NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
latanoprost NN i
stored VBD N
at IN N
4 CD N
degrees NNS N
C NNP N
or CC N
that IN N
stored VBN N
at IN N
30 CD N
degrees NNS N
C. NNP N
The DT N
eye NN N
drop NN N
was VBD N
applied VBN N
to TO N
the DT N
right JJ N
eye NN N
of IN N
each DT N
subject NN N
for IN N
3 CD N
days NNS N
. . N

The DT N
left NN N
eye NN N
served VBD N
as IN N
a DT N
control NN N
without IN N
administration NN N
. . N

Slit-lamp JJ i
biomicroscopy NN i
and CC N
circadian JJ i
intra NN i
ocular JJ i
pressure NN i
( ( i
IOP NNP i
) ) i
curve NN i
was VBD N
performed VBN N
at IN N
Day NNP N
3 CD N
, , N
every DT N
3 CD N
hours NNS N
from IN N
6 CD N
pm NN N
. . N

This DT N
procedure NN N
was VBD N
repeated VBN N
7 CD N
days NNS N
after IN N
changing VBG N
the DT N
drug NN N
from IN N
4 CD N
degrees NNS N
C NNP N
to TO N
30 CD N
degrees NNS N
C NNP N
or CC N
vice NN N
versa NN N
, , N
and CC N
application NN N
to TO N
the DT N
left NN N
eye NN N
for IN N
3 CD N
days NNS N
. . N

Eyes NNS N
treated VBD N
with IN N
latanoprost NN N
, , N
stored VBD N
both DT N
at IN N
4 CD N
degrees NNS N
C NNP N
and CC N
30 CD N
degrees NNS N
C NNP N
, , N
achieved VBD N
statistically RB o
significantly RB o
lower JJR o
mean NN o
IOPs NNP o
than IN N
untreated JJ N
eyes NNS N
at IN N
all DT N
time NN N
points NNS N
, , N
except IN N
at IN N
21 CD N
hours NNS N
treated VBN N
by IN N
the DT N
drug NN N
stored VBD N
at IN N
30 CD N
degrees NNS N
C. NNP N
We PRP N
subtracted VBD N
the DT N
IOP NNP N
of IN N
eyes NNS N
receiving VBG N
latanoprost NN N
from IN N
the DT N
IOP NNP N
of IN N
untreated JJ N
eyes NNS N
for IN N
each DT N
time NN N
point NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
the DT N
eye NN N
drops NNS N
( ( N
delta JJ N
IOP NNP N
) ) N
. . N

There EX N
were VBD N
no DT o
statistically RB o
significant JJ o
differences NNS o
between IN o
the DT o
delta NN o
IOPs NNP o
with IN o
the DT o
drug NN o
stored VBD o
at IN N
4 CD N
degrees NNS N
C NNP N
and CC N
30 CD N
degrees NNS N
C. NNP N
During IN N
the DT N
study NN N
, , N
no DT o
subject NN o
developed VBD o
a DT o
serious JJ o
adverse JJ o
event NN o
. . o

These DT N
results NNS N
suggest VBP N
that IN N
latanoprost NN N
stored VBN N
at IN N
30 CD N
degrees NNS N
C NNP N
for IN N
4 CD o
weeks NNS o
after IN o
opening VBG o
the DT o
bottle NN o
remains VBZ o
as IN o
effective JJ o
and CC o
safe JJ o
as IN N
latanoprost NN N
stored VBN N
under IN N
cold JJ N
conditions NNS N
. . N

-DOCSTART- -12709801- O O

Comparison NNP N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
faropenem JJ i
daloxate NN i
and CC i
cefuroxime NN i
axetil NN i
for IN N
the DT N
treatment NN N
of IN N
acute JJ o
bacterial JJ o
maxillary JJ o
sinusitis NN o
in IN p
adults NNS p
. . p

In IN N
this DT N
multicentre NN N
, , N
multinational JJ N
, , N
comparative JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
outpatients NNS p
with IN p
both DT p
clinical JJ p
signs NNS p
and CC p
symptoms NNS p
and CC p
radiographic JJ p
evidence NN p
of IN p
acute JJ p
sinusitis NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
for IN N
7 CD N
days NNS N
either CC N
a DT N
twice-daily JJ N
oral JJ N
regimen NNS N
of IN N
faropenem JJ i
daloxate NN i
( ( i
300 CD i
mg NN i
) ) i
or CC i
a DT i
twice JJ i
daily JJ i
oral JJ i
regimen NNS i
of IN i
cefuroxime NN i
axetil NN i
( ( N
250 CD N
mg NN N
) ) N
. . N

Among IN N
452 CD p
patients NNS p
considered VBN p
valid JJ p
for IN p
clinical JJ p
efficacy NN p
, , N
faropenem JJ i
daloxate NN i
treatment NN i
was VBD N
found VBN N
to TO N
be VB N
statistically RB N
equivalent JJ N
to TO N
cefuroxime VB i
axetil NN i
( ( N
89.0 CD N
% NN N
vs. FW N
88.4 CD N
% NN N
-95 CD N
% NN N
CI=-5.2 NNP N
% NN N
; : N
+6.4 CD N
% NN N
) ) N
at IN N
the DT N
7-16 JJ N
days NNS N
post-therapy JJ N
assessment NN N
. . N

At IN N
28-35 JJ N
days NNS N
post-therapy NN N
, , N
the DT N
continued JJ N
clinical JJ o
cure NN o
rate NN o
in IN N
the DT N
faropenem JJ i
daloxate NN i
group NN i
was VBD N
92.6 CD N
% NN N
and CC N
that IN N
for IN N
the DT N
cefuroxime NN i
axetil NN i
group NN N
was VBD N
94.9 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
-6.8 CD N
% NN N
; : N
+1.2 CD N
% NN N
) ) N
. . N

A DT N
total NN N
of IN N
148 CD N
organisms NNS N
was VBD N
obtained VBN N
in IN N
136 CD N
microbiologically RB N
valid JJ N
patients NNS N
( ( N
30.1 CD N
% NN N
) ) N
. . N

The DT N
predominant JJ N
causative JJ N
organisms NNS N
were VBD N
Streptococcus NNP N
pneumoniae NN N
( ( N
47.1 CD N
% NN N
) ) N
, , N
Haemophilus NNP N
influenzae NN N
( ( N
30.1 CD N
% NN N
) ) N
, , N
Staphylococcus NNP N
aureus NN N
( ( N
14.7 CD N
% NN N
) ) N
and CC N
Moraxella NNP N
catarrhalis NN N
( ( N
8.8 CD N
% NN N
) ) N
. . N

The DT N
bacteriological JJ o
success NN o
rate NN o
at IN N
the DT N
7-16 JJ N
days NNS N
post-therapy JJ N
evaluation NN N
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
: : N
91.5 CD N
% NN N
and CC N
90.8 CD N
% NN N
in IN N
the DT N
faropenem NN i
daloxate NN i
and CC i
cefuroxime NN i
axetil NN i
groups NNS i
, , N
respectively RB N
( ( N
95 CD N
% NN N
CI=-9.2 NNP N
% NN N
; : N
+9.5 CD N
% NN N
) ) N
. . N

Eradication NN o
or CC o
presumed VBN o
eradication NN o
was VBD N
detected VBN N
for IN N
97.3 CD N
% NN N
and CC N
96.3 CD N
% NN N
of IN N
S. NNP N
pneumoniae NN N
, , N
85.0 CD N
% NN N
and CC N
90.5 CD N
% NN N
of IN N
H. NNP N
influenzae NN N
, , N
88.9 CD N
% NN N
and CC N
90.9 CD N
% NN N
of IN N
S. NNP N
aureus NN N
and CC N
100.0 CD N
% NN N
and CC N
83.3 CD N
% NN N
of IN N
M. NNP N
catarrhalis NN N
in IN N
faropenem JJ i
daloxate NN i
and CC i
cefuroxime NN i
axetil NN i
recipients NNS N
, , N
respectively RB N
. . N

At IN N
least JJS N
one CD N
drug-related JJ o
event NN o
was VBD N
reported VBN N
by IN N
9.5 CD N
% NN N
of IN N
the DT N
faropenem JJ i
daloxate-treated JJ i
patients NNS N
and CC N
by IN N
10.3 CD N
% NN N
of IN N
those DT N
who WP N
received VBD N
cefuroxime RB i
axetil JJ i
. . i

The DT N
most RBS N
frequently RB N
reported VBD N
drug-related JJ N
events NNS N
were VBD N
diarrhoea NNS o
( ( N
2.2 CD N
% NN N
versus IN N
2.9 CD N
% NN N
) ) N
, , N
nausea/vomiting VBG o
( ( N
1.5 CD N
% NN N
vs. FW N
0.7 CD N
% NN N
) ) N
, , N
abdominal JJ o
pain NN o
( ( N
0.7 CD N
% NN N
vs JJ N
1.5 CD N
% NN N
) ) N
and CC N
skin JJ o
reactions NNS o
( ( N
1.5 CD N
% NN N
vs. FW N
1.1 CD N
% NN N
) ) N
. . N

Overall JJ N
, , N
faropenem JJ i
daloxate NN i
was VBD N
at IN N
least JJS N
as IN N
effective JJ N
clinically NN o
and CC o
bacteriologically RB o
as IN N
cefuroxime NN i
axetil NN i
and CC N
was VBD N
well RB N
tolerated VBN o
. . o

-DOCSTART- -12117831- O O

Relation NN N
between IN N
early JJ N
mitral JJ N
regurgitation NN N
and CC N
left VBD N
ventricular JJ N
thrombus NN N
formation NN N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
: : N
results NNS N
of IN N
the DT N
GISSI-3 NNP N
echo NN N
substudy NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
prevalence NN N
and CC N
correlates NNS N
of IN N
left JJ N
ventricular JJ N
thrombosis NN N
in IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
, , N
and CC N
whether IN N
the DT N
occurrence NN N
of IN N
early JJ N
mitral JJ N
regurgitation NN N
has VBZ N
a DT N
protective JJ N
effect NN N
against IN N
the DT N
formation NN N
of IN N
left JJ N
ventricular JJ N
thrombus NN N
. . N

DESIGN NNP N
AND CC N
SETTING NNP N
Multicentre NNP N
clinical JJ N
trial NN N
carried VBD N
out IN N
in IN N
47 CD p
Italian JJ p
coronary JJ p
care NN p
units NNS p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
757 CD p
patients NNS p
from IN p
the DT p
GISSI-3 NNP p
echo NN p
substudy NN p
population NN p
with IN p
their PRP$ p
first JJ p
acute JJ p
myocardial JJ p
infarct NN p
were VBD p
studied VBN p
by IN N
echocardiography NN i
at IN i
24-48 JJ i
hours NNS i
from IN i
symptom JJ i
onset NN i
( ( N
S1 NNP N
) ) N
, , N
at IN N
discharge NN N
( ( N
S2 NNP N
) ) N
, , N
at IN N
six CD N
weeks NNS N
( ( N
S3 NNP N
) ) N
, , N
and CC N
at IN N
six CD N
months NNS N
( ( N
S4 NNP N
) ) N
. . N

The DT N
diagnosis NN N
of IN N
left JJ N
ventricular JJ N
thrombosis NN N
was VBD N
based VBN N
on IN N
the DT N
detection NN N
of IN N
an DT N
echo JJ N
dense NN N
mass NN N
with IN N
defined JJ N
margins NNS N
visible JJ N
throughout IN N
the DT N
cardiac JJ N
cycle NN N
in IN N
at IN N
least JJS N
two CD N
orthogonal JJ N
views NNS N
. . N

RESULTS NNP N
In IN N
64 CD N
patients NNS N
( ( N
8 CD N
% NN N
) ) N
, , N
left VBD o
ventricular JJ o
thrombosis NN o
was VBD N
detected VBN N
in IN N
one CD N
or CC N
more JJR N
examinations NNS N
. . N

Compared VBN N
with IN N
the DT N
remaining VBG N
693 CD N
patients NNS N
, , N
subjects NNS N
with IN N
left JJ o
ventricular JJ o
thrombosis NN o
were VBD N
older JJR N
( ( N
mean NN N
( ( N
SD NNP N
) ) N
age NN N
: : N
64.6 CD N
( ( N
13.0 CD N
) ) N
v NN N
59.8 CD N
( ( N
11.7 CD N
) ) N
years NNS N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
, , N
and CC N
had VBD N
larger JJR o
infarcts NNS o
( ( N
extent NN N
of IN N
wall NN N
motion NN N
asynergy NN N
: : N
40.9 CD N
( ( N
11.5 CD N
) ) N
% NN N
v JJ N
24.9 CD N
( ( N
14 CD N
) ) N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
greater JJR N
depression NN o
of IN o
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
at IN o
S1 NNP o
( ( N
43.3 CD N
( ( N
6.9 CD N
) ) N
% NN N
v JJ N
48.1 CD N
( ( N
6.8 CD N
) ) N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
greater JJR N
left VBD o
ventricular JJ o
volumes NNS o
at IN o
S1 NNP o
( ( N
end VB N
diastolic NN N
volume NN N
: : N
87 CD N
( ( N
22 CD N
) ) N
v NN N
78 CD N
( ( N
18 CD N
) ) N
ml/m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
< VBP N
0.001 CD N
; : N
end VB N
systolic JJ N
volume NN N
: : N
50 CD N
( ( N
17 CD N
) ) N
v NN N
41 CD N
( ( N
14 CD N
) ) N
ml/m NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
prevalence NN o
of IN o
moderate JJ o
to TO o
severe VB o
mitral JJ o
regurgitation NN o
on IN o
colour NN o
Doppler NNP o
at IN o
S1 NNP o
was VBD N
greater JJR N
in IN N
patients NNS N
who WP N
had VBD N
left VBN o
ventricular JJ o
thrombosis NN o
at IN N
any DT N
time NN N
( ( N
10.2 CD N
% NN N
v JJ N
4.2 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

On IN N
stepwise NN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
the DT N
only JJ N
independent JJ N
variables NNS N
related VBN N
to TO N
the DT N
presence NN N
of IN N
left JJ o
ventricular JJ o
thrombosis NN o
were VBD N
the DT N
extent NN N
of IN N
wall NN N
motion NN N
asynergy NN N
and CC N
anterior JJ N
site NN N
of IN N
infarction NN N
. . N

CONCLUSIONS NNP N
Left NNP o
ventricular JJ o
thrombosis NN o
is VBZ N
not RB N
reduced VBN N
, , N
and CC N
may MD N
even RB N
be VB N
increased VBN N
, , N
by IN N
early JJ N
moderate NN N
to TO N
severe VB N
mitral JJ N
regurgitation NN N
after IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

The DT N
only JJ N
independent JJ N
determinant NN N
of IN N
left JJ N
ventricular JJ N
thrombosis NN N
is VBZ N
the DT N
extent NN N
of IN N
the DT N
akinetic-dyskinetic JJ N
area NN N
detected VBN N
on IN N
echocardiography NN N
between IN N
24-48 JJ N
hours NNS N
from IN N
symptom JJ N
onset NN N
. . N

-DOCSTART- -6416184- O O

[ NNS N
Randomized NNP N
study NN N
on IN N
the DT N
long-term JJ i
adjuvant JJ i
chemotherapy NN i
with IN N
ftorafur NN i
and CC N
mitomycin NN i
C NNP i
for IN N
stomach NN N
cancer NN N
: : N
second JJ N
report NN N
] NN N
. . N

In IN N
view NN N
of IN N
the DT N
usefulness NN N
of IN N
long-term JJ i
adjuvant JJ i
chemotherapy NN i
, , p
the DT p
Cooperative NNP p
Study NNP p
Group NNP p
of IN p
Surgical NNP p
Adjuvant NNP p
Chemotherapy NNP p
for IN p
Gastric NNP p
Cancer NNP p
adopted VBD p
as IN p
the DT p
second JJ p
cooperative NN p
study NN p
a DT p
prospective JJ p
randomized VBN p
trial NN p
on IN p
three CD p
groups NNS p
; : p
MMC NNP i
alone RB i
, , i
Futraful NNP i
alone RB i
and CC i
a DT i
combination NN i
of IN i
MMC NNP i
and CC i
Futraful NNP i
. . i

In IN N
the DT N
group NN N
of IN N
Futraful NNP i
alone RB N
the DT N
survival NN o
and CC o
disease-free JJ o
rate NN o
were VBD N
improved VBN N
in IN N
three CD N
years NNS N
after IN N
operation NN N
, , N
especially RB N
marked VBN N
in IN N
patients NNS p
with IN p
the DT p
advanced JJ p
stage NN p
. . p

Moreover RB N
, , N
the DT N
survival NN o
and CC o
disease-free JJ o
rate NN o
in IN N
the DT N
group NN N
of IN N
the DT N
combination NN i
therapy NN i
were VBD N
higher JJR N
than IN N
those DT N
in IN N
the DT N
group NN N
of IN N
Futraful NNP i
alone RB N
, , N
and CC N
the DT N
relapse NN o
rate NN o
was VBD N
lower JJR N
in IN N
the DT N
former JJ N
. . N

Therefore RB N
, , N
a DT N
long-term JJ i
combined JJ i
adjuvant JJ i
chemotherapy NN i
with IN i
MMC NNP i
and CC i
Futraful NNP i
seems VBZ N
to TO N
be VB N
one CD N
of IN N
the DT N
most RBS N
effective JJ N
chemotherapy NN i
regimens NNS N
for IN N
resectable JJ N
advanced JJ N
gastric JJ N
cancer NN N
. . N

-DOCSTART- -10934908- O O

On IN N
the DT N
search NN N
for IN N
the DT N
neurophysiological JJ p
manifestation NN p
of IN p
recollective JJ p
experience NN p
. . p

M.E NNP p
. . p

Smith NNP p
( ( p
1993 CD p
) ) p
obtained VBD p
event-related JJ p
brain NN p
potentials NNS p
( ( p
ERPs NNP p
) ) p
from IN N
subjects NNS p
performing VBG p
a DT p
recognition NN i
memory NN i
task NN i
using VBG p
remember NN p
( ( p
R NNP p
) ) p
and CC p
know $ p
( ( p
K NNP p
) ) p
judgments NNS p
, , N
and CC N
reported VBD N
observing VBG N
in IN N
the DT N
ERP NNP N
a DT N
neurophysiological JJ N
manifestation NN N
of IN N
recollective JJ N
experience NN N
as IN N
a DT N
difference NN N
between IN N
the DT N
positive JJ N
waveforms NNS N
elicited VBN N
by IN N
stimuli NNS N
that WDT N
yielded VBD N
R NNP N
and CC N
K NNP N
judgments NNS N
. . N

We PRP N
replicated VBD N
his PRP$ N
experiment NN N
and CC N
examined VBD N
the DT N
componential JJ N
structure NN N
of IN N
the DT N
R NNP N
> NNP N
K NNP N
effect NN N
in IN N
two CD N
ways NNS N
. . N

First NNP N
, , N
we PRP N
found VBD N
that IN N
correction NN N
for IN N
P300 NNP o
latency NN o
jitter NN o
eliminated VBD N
the DT N
effect NN N
reported VBN N
by IN N
Smith NNP N
. . N

Second NNP N
, , N
the DT N
application NN N
of IN N
principal JJ N
component JJ N
analysis NN N
indicated VBD N
that IN N
the DT N
positive JJ o
waveform NN o
elicited VBN N
by IN N
the DT N
words NNS N
in IN N
the DT N
test NN N
list NN N
was VBD N
a DT N
P300 NNP N
. . N

These DT N
analyses NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that IN N
there EX N
is VBZ N
a DT N
new JJ N
component NN N
( ( N
the DT N
memory-evoked JJ o
shift NN o
) ) o
that WDT N
is VBZ N
a DT N
specific JJ N
manifestation NN N
of IN N
recollection NN N
. . N

-DOCSTART- -15573541- O O

Not RB N
Now RB N
! . N
Supporting VBG N
interruption NN N
management NN N
by IN N
indicating VBG N
the DT N
modality NN N
and CC N
urgency NN N
of IN N
pending VBG N
tasks NNS N
. . N

Operators NNS p
in IN p
complex JJ p
event-driven JJ p
domains NNS p
must MD N
coordinate VB N
competing VBG N
attentional JJ N
demands NNS N
in IN N
the DT N
form NN N
of IN N
multiple JJ N
tasks NNS N
and CC N
interactions NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
this DT N
requirement NN N
can MD N
be VB N
supported VBN N
more RBR N
effectively RB N
through IN N
informative JJ N
interruption NN N
cueing NN N
( ( N
in IN N
this DT N
case NN N
, , N
partial JJ N
information NN N
about IN N
the DT N
nature NN N
of IN N
pending VBG N
tasks NNS N
) ) N
. . N

The DT N
48 CD p
participants NNS p
performed VBD p
a DT p
visually RB i
demanding VBG i
air NN i
traffic NN i
control NN i
( ( i
ATC NNP i
) ) i
task NN i
. . i

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
experimental JJ N
groups NNS N
that WDT N
differed VBD N
in IN N
the DT N
availability NN i
of IN i
information NN i
( ( i
not RB i
available JJ i
, , i
available JJ i
upon IN i
request NN i
, , i
available JJ i
automatically RB i
) ) i
about IN N
the DT N
urgency NN N
and CC N
modality NN N
of IN N
pending VBG N
interruption NN N
tasks NNS N
. . N

Within-subject JJ N
variables NNS N
included VBD N
ATC-related JJ o
workload NN o
and CC o
the DT o
modality NN o
, , o
frequency NN o
, , o
and CC o
priority NN o
of IN o
interruption NN o
tasks NNS o
. . o

The DT N
results NNS N
show VBP N
that IN N
advance NN N
knowledge NN N
about IN N
the DT N
nature NN N
of IN N
pending VBG N
tasks NNS N
led VBD N
participants NNS N
to TO N
delay VB N
visual JJ N
interruption NN N
tasks VBZ N
the DT N
longest JJS N
, , N
which WDT N
allowed VBD N
them PRP N
to TO N
avoid VB N
intramodal JJ N
interference NN N
and CC N
scanning NN N
costs NNS N
associated VBN N
with IN N
performing VBG N
these DT N
tasks NNS N
concurrently RB N
with IN N
ATC NNP N
tasks NNS N
. . N

The DT N
3 CD N
experimental JJ N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
their PRP$ N
interruption NN o
task NN o
performance NN o
; : o
however RB N
, , N
the DT N
group NN N
that WDT N
automatically RB N
received VBD N
task-related JJ N
information NN N
showed VBD N
better JJR N
ATC NNP N
performance NN N
, , N
thus RB N
experiencing VBG N
a DT N
net JJ N
performance NN N
gain NN N
. . N

Actual NNP N
or CC N
potential JJ N
applications NNS N
of IN N
this DT N
research NN N
include VBP N
the DT N
design NN N
of IN N
interfaces NNS N
in IN N
support NN N
of IN N
attention NN N
and CC N
interruption NN N
management NN N
in IN N
a DT N
wide JJ N
range NN N
of IN N
event-driven JJ N
environments NNS N
. . N

-DOCSTART- -2426069- O O

[ RB N
Preoperative NNP N
chemotherapy NN i
of IN N
esophageal JJ N
cancer NN N
] NNP N
. . N

A NNP p
series NN p
of IN p
25 CD p
patients NNS p
with IN p
advanced JJ p
esophageal NN p
cancer NN p
treated VBN p
from IN p
Mar NNP p
. . p

1981 CD p
to TO p
Sep. VB p
1982 CD p
by IN p
preoperative JJ i
chemotherapy NN i
plus CC i
surgery NN i
is VBZ N
reported VBN N
. . N

All PDT N
the DT N
patients NNS p
came VBD p
from IN p
the DT p
hospitals NNS p
of IN p
the DT p
cooperative JJ p
research NN p
group NN p
and CC N
were VBD N
randomized VBN N
into IN N
chemotherapy NN i
and CC N
control NN i
groups NNS N
. . N

They PRP N
were VBD N
proved VBN N
by IN N
X-ray NNP N
, , N
cytology NN N
and CC N
histopathology NN N
prior RB N
to TO N
treatment NN N
. . N

By IN p
histology NN p
, , p
22 CD p
cases NNS p
were VBD p
squamous JJ p
cell NN p
carcinoma NN p
, , p
1 CD p
adenocarcinoma NN p
and CC p
2 CD p
squamous JJ p
adenocarcinoma NN p
. . p

The DT N
COF NNP N
chemotherapy NN i
consisted VBD N
of IN N
Vincristine NNP i
1 CD i
mg NN i
, , i
cyclophosphamide RB i
600 CD i
mg NNS i
and CC i
5-fluorouracil JJ i
500 CD i
mg NN i
IV NNP i
on IN N
days NNS N
1 CD N
and CC N
8 CD N
with IN N
or CC N
without IN N
the DT N
addition NN N
of IN N
Pingyangmycin NNP i
, , N
a DT N
drug NN N
equivalent NN N
to TO N
Bleomycin NNP i
A5 NNP i
, , N
at IN N
the DT N
dose NN N
of IN N
10 CD N
mg NNS N
IM NNP N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
6 CD N
and CC N
8 CD N
. . N

The DT N
interval NN N
between IN N
the DT N
ending VBG N
of IN N
chemotherapy NN i
and CC N
the DT N
surgical JJ i
resection NN i
was VBD N
5-6 JJ N
days NNS N
. . N

The DT N
results NNS N
showed VBD N
that IN N
preoperative JJ N
chemotherapy NN N
caused VBD N
no DT o
myelosuppression NN o
, , N
but CC N
merely RB N
mild JJ o
gastrointestinal JJ o
symptoms NNS o
. . o

All DT N
patients NNS N
were VBD N
operated VBN N
and CC N
resected VBN N
without IN N
difficulty NN N
. . N

The DT N
subjective JJ N
improvement NN N
in IN N
various JJ N
degrees NNS N
and CC N
the DT N
shrinkage NN o
of IN o
tumor NN o
in IN o
the DT o
X-ray JJ o
films NNS o
were VBD N
present JJ N
in IN N
5/25 CD N
cases NNS N
who WP N
received VBD N
preoperative JJ N
chemotherapy NN i
. . i

The DT N
histopathological JJ o
changes NNS o
in IN N
the DT N
chemotherapy NN N
and CC N
control NN N
groups NNS N
( ( N
16 CD N
specimens NNS N
) ) N
were VBD N
different JJ N
. . N

In IN N
the DT N
chemotherapy NN i
group NN N
, , N
excessive JJ o
keratinization NN o
in IN o
the DT o
squamous JJ o
component NN o
of IN o
the DT o
esophageal NN o
cancerous JJ o
tissue NN o
appeared VBD N
in IN N
the DT N
resected JJ N
specimens NNS N
. . N

The DT N
incidence NN o
of IN o
degeneration NN o
and CC o
necrosis NN o
in IN o
the DT o
squamous JJ o
epithelium NN o
adjacent NN o
to TO o
carcinoma VB o
was VBD N
higher RBR N
in IN N
the DT N
chemotherapy NN i
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
results NNS N
suggested VBD N
that IN N
such JJ N
combined JJ N
modality NN N
is VBZ N
worth IN N
further JJ N
study NN N
. . N

-DOCSTART- -18390022- O O

Enrollment NN N
of IN N
racial JJ p
and CC p
ethnic JJ p
minorities NNS p
in IN p
the DT p
Prostate NNP p
, , p
Lung NNP p
, , p
Colorectal NNP p
and CC p
Ovarian JJ p
Cancer NNP p
Screening NNP p
Trial NNP p
. . p

BACKGROUND NNP N
Minority NNP p
populations NNS p
in IN p
the DT p
United NNP p
States NNPS p
, , p
especially RB p
blacks NNS p
and CC p
Hispanics NNPS p
, , N
are VBP N
generally RB N
underrepresented VBN N
among IN N
participants NNS N
in IN N
clinical JJ N
trials NNS N
. . N

Here RB N
, , N
we PRP N
report VBP N
the DT N
experience NN N
of IN N
enrolling VBG N
ethnic JJ p
minorities NNS p
in IN N
a DT N
large JJ N
cancer NN N
screening VBG N
trial NN N
. . N

METHODS NNP N
The DT N
Prostate NNP i
, , i
Colorectal NNP i
, , i
Lung NNP i
and CC i
Ovarian NNP i
( ( i
PLCO NNP i
) ) i
Cancer NNP i
Screening NNP i
Trial NNP N
is VBZ N
a DT N
multicenter NN N
randomized VBN N
trial NN N
designed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN p
of IN p
screening VBG i
for IN i
the DT i
PLCO NNP i
cancers NNS i
. . i

Subjects NNS p
were VBD p
recruited VBN p
at IN p
10 CD p
U.S. NNP p
centers NNS p
between IN p
1993 CD p
and CC p
2001 CD p
. . p

One CD N
screening NN N
center NN N
had VBD N
a DT N
major JJ N
special JJ i
recruitment NN i
effort NN i
for IN i
blacks NNS i
and CC N
another DT N
center NN N
had VBD N
a DT N
major JJ N
special JJ i
recruitment NN i
effort NN i
for IN i
Hispanics NNPS i
. . i

RESULTS NNP N
Among IN N
almost RB N
155,000 CD p
subjects NNS p
enrolled VBN p
in IN p
PLCO NNP p
, , p
minority NN p
enrollment NN p
was VBD p
as IN p
follows VBZ p
: : p
black JJ p
( ( p
5.0 CD p
% NN p
) ) p
, , p
Hispanic NNP p
( ( p
1.8 CD p
% NN p
) ) p
and CC p
Asian NNP p
( ( p
3.6 CD p
% NN p
) ) p
. . p

This DT N
compares VBZ N
to TO N
an DT N
age-eligible JJ N
population NN N
in IN N
the DT N
combined JJ N
catchment JJ N
areas NNS N
of IN N
the DT N
PLCO NNP p
centers NNS p
that WDT p
was VBD p
14.0 CD p
% NN p
black JJ p
, , p
2.9 CD p
% NN p
Hispanic NNP p
and CC p
5.4 CD p
% NN p
Asian JJ p
, , p
and CC p
an DT p
age-eligible JJ p
population NN p
across IN p
the DT p
U.S. NNP p
that WDT p
was VBD p
9.5 CD p
% NN p
black JJ p
, , p
6.5 CD p
% NN p
Hispanic NNP p
and CC p
3.0 CD p
% NN p
Asian JJ p
. . p

About IN N
half NN N
( ( p
45 CD p
% NN p
) ) p
of IN p
Hispanics NNPS p
were VBD p
recruited VBN o
at IN p
the DT p
center NN p
with IN p
the DT p
special JJ p
Hispanic JJ p
recruitment NN p
effort NN p
. . p

Seventy NNP p
percent NN p
of IN p
blacks NNS p
were VBD p
recruited VBN o
at IN p
two CD p
centers NNS p
; : p
the DT p
one NN p
with IN p
the DT p
major JJ p
special JJ p
recruitment NN p
effort NN N
and CC N
a DT N
center NN N
in IN N
Detroit NNP N
whose WP$ N
catchment JJ N
area NN N
was VBD N
20 CD N
% NN N
black JJ N
among IN N
age-eligibles NNS N
. . N

Blacks NNS N
, , N
Hispanics NNPS N
and CC N
( ( N
non-Hispanic JJ N
) ) N
whites NNS N
were VBD N
all DT N
more RBR N
highly RB N
educated VBN N
, , N
less RBR N
likely JJ N
to TO N
currently RB o
smoke VB o
and CC N
more RBR N
likely JJ N
to TO N
get VB N
regular JJ o
exercise NN o
than IN N
their PRP$ N
counterparts NNS N
in IN N
the DT N
general JJ N
population NN N
. . N

CONCLUSION NNP N
Significant NNP N
efforts NNS N
were VBD N
made VBN N
to TO N
recruit VB N
racial/ NN N
ethnic JJ N
minorities NNS N
into IN N
PLCO NNP N
, , N
and CC N
these DT N
efforts NNS N
resulted VBD N
in IN N
enrollment NN N
levels NNS N
that WDT N
were VBD N
comparable JJ N
to TO N
those DT N
seen VBN N
in IN N
many JJ N
recent JJ N
cancer NN N
screening NN N
or CC N
prevention NN N
trials NNS N
. . N

Blacks NNS N
and CC N
Hispanics NNPS N
were VBD N
nonetheless RB N
underrepresented VBN N
in IN N
PLCO NNP N
compared VBN N
to TO N
their PRP$ N
levels NNS N
among IN N
age-eligibles NNS N
in IN N
the DT N
overall JJ N
U.S. NNP N
population NN N
or CC N
in IN N
the DT N
aggregate JJ N
PLCO NNP N
catchment NN N
areas NNS N
. . N

-DOCSTART- -16508555- O O

Minimal NNP i
clinically RB i
important JJ i
change NN i
for IN N
pain NN o
intensity NN o
, , o
functional JJ o
status NN o
, , N
and CC N
general JJ N
health NN o
status NN o
in IN N
patients NNS p
with IN p
nonspecific JJ p
low JJ p
back RB p
pain NN p
. . p

STUDY NNP N
DESIGN NNP N
Cohort NNP N
study NN N
. . N

OBJECTIVES NNP N
To TO N
estimate VB N
the DT N
Minimal NNP o
Clinically NNP o
Important NNP o
Change NNP o
( ( o
MCIC NNP o
) ) o
of IN N
the DT N
pain NN o
intensity NN o
numerical JJ o
rating NN o
scale NN o
( ( o
PI-NRS NNP o
) ) o
, , N
the DT N
Quebec NNP o
Back NNP o
Pain NNP o
Disability NNP o
Scale NNP o
( ( o
QBPDS NNP o
) ) o
, , N
and CC N
the DT N
Euroqol NNP o
( ( o
EQ NNP o
) ) o
in IN N
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
. . p

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
MCIC NNP N
can MD N
provide VB N
valuable JJ N
information NN N
for IN N
researchers NNS N
, , N
healthcare NN N
providers NNS N
, , N
and CC N
policymakers NNS N
. . N

METHODS NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
with IN N
442 CD p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
were VBD p
used VBN p
. . p

The DT N
MCIC NNP i
was VBD N
estimated VBN N
over IN N
a DT N
12-week JJ N
period NN N
, , N
and CC N
three CD N
different JJ N
methods NNS N
were VBD N
used VBN N
: : N
1 CD N
) ) N
mean NN N
change NN N
scores NNS N
, , N
2 CD N
) ) N
minimal NN N
detectable JJ N
change NN N
, , N
and CC N
3 CD N
) ) N
optimal VBD N
cutoff NN N
point NN N
in IN N
receiver NN N
operant JJ N
curves NNS N
. . N

The DT N
global JJ N
perceived JJ N
effect NN N
scale NN N
( ( N
GPE NNP N
) ) N
was VBD N
used VBN N
as IN N
an DT N
external JJ N
criterion NN N
. . N

The DT N
effect NN N
of IN N
initial JJ N
scores NNS N
on IN N
the DT N
MCIC NNP i
was VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
The DT N
MCIC NNP o
of IN N
the DT N
PI-NRS NNP N
ranged VBD N
from IN N
3.5 CD N
to TO N
4.7 CD N
points NNS N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
2.5 CD N
to TO N
4.5 CD N
points NNS N
in IN N
chronic JJ N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
. . N

The DT N
MCIC NNP o
of IN o
the DT o
QBPDS NNP o
was VBD N
estimated VBN N
between IN N
17.5 CD N
to TO N
32.9 CD N
points NNS N
and CC N
8.5 CD N
to TO N
24.6 CD N
points NNS N
for IN N
( ( p
sub NN p
) ) p
acute NN p
and CC p
chronic JJ p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
. . p

The DT N
MCIC NNP o
for IN o
the DT o
EQ NNP o
ranged VBD N
from IN N
0.07 CD N
to TO N
0.58 CD N
in IN N
( ( N
sub NN N
) ) N
acute NN N
patients NNS N
and CC N
0.09 CD N
to TO N
0.28 CD N
in IN N
patients NNS N
with IN N
chronic JJ N
low JJ N
back RB N
pain NN N
. . N

CONCLUSION NNP N
Reporting VBG N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
have VBP N
made VBN N
a DT N
MCIC NNP i
adds VBZ N
to TO N
the DT N
interpretability NN N
of IN N
study NN N
results NNS N
. . N

We PRP N
present VBD N
a DT N
range NN N
of IN N
MCIC NNP i
values NNS N
and CC N
advocate VB N
the DT N
choice NN N
of IN N
a DT N
single JJ N
MCIC NNP i
value NN N
according VBG N
to TO N
the DT N
specific JJ N
context NN N
. . N

-DOCSTART- -23727103- O O

Anxiolytics NNS i
in IN N
patients NNS p
suffering VBG p
a DT p
suspected JJ p
acute JJ p
coronary JJ p
syndrome NN p
: : p
multi-centre NN p
randomised VBD N
controlled VBN N
trial NN N
in IN N
Emergency NNP N
Medical NNP N
Service NNP N
. . N

BACKGROUND NNP N
The DT N
prehospital JJ N
treatment NN N
of IN N
pain NN p
and CC p
discomfort NN p
among IN p
patients NNS p
who WP p
suffer VBP p
from IN p
acute JJ p
coronary JJ p
syndrome NN p
( ( p
ACS NNP p
) ) p
needs VBZ N
a DT N
treatment NN N
strategy NN N
which WDT N
combines VBZ N
relief NN N
of IN N
pain NN N
with IN N
relief NN N
of IN N
anxiety NN N
. . N

AIM IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
on IN N
pain NN N
and CC N
anxiety NN N
of IN N
the DT N
combination NN N
of IN N
an DT N
anxiolytic JJ i
and CC N
an DT N
analgesic JJ N
as IN N
compared VBN N
with IN N
an DT N
analgesic JJ i
alone NN N
in IN N
the DT N
prehospital JJ N
setting NN N
of IN N
suspected JJ N
ACS NNP N
. . N

METHODS NNP N
A DT N
multi-centre NN p
randomised VBN N
controlled VBN N
trial NN N
compared VBN N
the DT N
combination NN N
of IN N
Midazolam NNP i
( ( i
Mi NNP i
) ) i
+Morphine NN i
( ( i
Mo NNP i
) ) i
and CC i
Mo NNP i
alone RB i
. . i

All DT N
measures NNS N
took VBD N
part NN N
: : N
Prior NNP N
to TO N
randomisation NN N
, , N
15 CD N
min NN N
thereafter RB N
and CC N
on IN N
admission NN N
to TO N
a DT N
hospital NN N
. . N

Inclusion NN N
criteria NNS N
were VBD N
: : N
1 CD N
) ) N
pain NN N
raising VBG N
suspicion NN N
of IN N
ACS NNP N
and CC N
2 CD N
) ) N
pain NN N
score NN N
?4 NN N
. . N

PRIMARY NNP N
ENDPOINT NNP N
Pain NNP N
score NN N
after IN N
15 CD N
min NN N
. . N

RESULTS NNP N
In IN N
all DT p
, , p
890 CD p
patients NNS p
were VBD p
randomised VBN p
to TO p
Mi+Mo NNP N
and CC N
873 CD N
to TO N
Mo NNP N
alone RB o
. . o

Pain NN o
was VBD o
reduced VBN N
from IN N
a DT N
median NN N
of IN N
6 CD N
to TO N
4 CD N
and CC N
finally RB N
to TO N
3 CD N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean JJ N
dose NN N
of IN N
Mo NNP N
was VBD N
5.3 CD N
mg NN N
in IN N
Mi+Mo NNP i
and CC i
6.0 CD N
mg NN N
in IN N
Mo NNP i
alone RB i
( ( N
p JJ N
< NNP o
0.0001 CD o
) ) o
. . o

Anxiety NN o
was VBD o
reported VBN N
in IN N
66 CD N
% NN N
in IN N
Mi+Mo NNP N
and CC N
in IN N
64 CD N
% NN N
in IN N
Mo NNP N
alone RB N
at IN N
randomisation NN N
( ( N
NS NNP N
) ) N
; : N
15 CD N
min NN N
thereafter RB N
in IN N
31 CD N
% NN N
and CC N
39 CD N
% NN N
( ( N
p=0.002 NN N
) ) N
and CC N
finally RB N
in IN N
12 CD N
% NN N
and CC N
26 CD N
% NN N
respectively RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

On IN N
admission NN N
to TO N
a DT N
hospital NN o
nausea NN o
or CC o
vomiting NN o
was VBD o
reported VBN N
in IN N
9 CD N
% NN N
in IN N
Mi+Mo NNP i
and CC i
in IN N
13 CD N
% NN N
in IN N
Mo NNP N
alone RB N
( ( N
p=0.003 NN o
) ) o
. . o

Drowsiness NNP o
differed VBD o
; : N
15 CD N
% NN N
and CC N
14 CD N
% NN N
were VBD N
drowsy VBN N
in IN N
Mi+Mo NNP N
versus VBP N
2 CD N
% NN N
and CC N
3 CD N
% NN N
in IN N
Mo NNP N
alone RB N
respectively RB N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Despite IN N
the DT N
fact NN N
that IN N
the DT N
combination NN N
of IN N
anxiolytics NNS i
and CC i
analgesics NNS i
as IN i
compared VBN N
with IN N
analgesics NNS N
alone RB N
reduced VBN N
anxiety NN N
and CC N
the DT N
requirement NN N
of IN N
Morphine NNP N
in IN N
the DT N
prehospital JJ N
setting NN N
of IN N
acute JJ N
coronary JJ N
syndrome NN N
, , N
this DT N
strategy NN N
did VBD N
not RB N
reduce VB N
patients NNS N
' POS N
estimation NN N
of IN N
pain NN N
( ( N
primary JJ N
endpoint NN N
) ) N
. . N

More RBR N
effective JJ N
pain NN N
relief NN N
among IN N
these DT N
patients NNS N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -2521868- O O

Cimetidine NNP i
as IN N
an DT N
immunomodulator NN N
in IN N
the DT N
treatment NN N
of IN N
herpes NNS p
zoster NN p
. . p

As IN N
there EX N
is VBZ N
evidence NN N
of IN N
a DT N
possible JJ N
immunoregulatory JJ N
role NN N
for IN N
H2-histamine NNP i
receptor NN i
antagonists NNS i
, , N
we PRP N
carried VBD N
out RP N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
in IN N
vivo NN N
and CC N
in IN N
vitro JJ N
effect NN N
of IN N
cimetidine NN i
, , N
an DT N
H2-blocker NNP N
, , N
in IN N
the DT N
treatment NN N
of IN N
herpes NNS p
zoster JJ p
infection NN p
. . p

Cimetidine NNP i
treatment NN N
shortened VBD N
the DT N
median JJ o
interval NN o
until IN o
the DT o
first JJ o
decrease NN o
in IN o
pain NN o
, , N
the DT N
median JJ o
interval NN o
until IN o
the DT o
complete JJ o
resolution NN o
of IN o
pain NN o
and CC o
promoted VBN o
faster RBR o
complete JJ o
healing NN o
of IN o
skin NN o
lesions NNS o
than IN N
symptomatic JJ N
treatment NN N
. . N

The DT N
immunological JJ N
trends NNS N
observed VBN N
in IN N
vitro JJ N
support NN N
an DT N
important JJ N
role NN N
for IN N
histamine NN N
in IN N
the DT N
induction NN N
of IN N
immunosuppression NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
response NN N
to TO N
the DT N
mitogen NN N
phytohemagglutinin NN N
. . N

This DT N
effect NN N
of IN N
histamine NN N
was VBD N
antagonized VBN N
by IN N
cimetidine NN i
. . i

-DOCSTART- -24101016- O O

Immunological JJ o
changes NNS o
after IN N
minimally RB i
invasive JJ i
or CC i
conventional JJ i
esophageal JJ i
resection NN i
for IN N
cancer NN p
: : p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
This DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
substudy NN N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
conventional JJ i
open JJ i
esophagectomy NN i
[ NNP N
open JJ N
surgical JJ N
technique NN N
( ( N
OE NNP N
) ) N
] NN N
by IN N
thoracotomy NN i
and CC i
laparotomy NN i
with IN N
minimally RB i
invasive JJ i
esophagectomy NN i
[ NNP i
minimally RB i
invasive JJ i
procedure NN i
( ( i
MIE NNP i
) ) i
] NN i
by IN i
thoracoscopy NN i
and CC i
laparoscopy NN i
. . i

This DT N
additional JJ N
analysis NN N
focuses VBZ N
on IN N
the DT N
immunological JJ o
changes NNS o
and CC N
surgical JJ o
stress NN o
response NN o
in IN N
these DT N
two CD N
randomized VBD N
groups NNS N
of IN N
a DT N
single JJ N
center NN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
a DT p
resectable JJ p
esophageal NN p
cancer NN p
were VBD p
randomized VBN p
to TO p
OE NNP p
( ( p
n JJ p
= NNP p
13 CD p
) ) p
or CC p
MIE NNP p
( ( p
n JJ p
= NNP p
14 CD p
) ) p
. . p

All DT p
patients NNS p
received VBD p
neoadjuvant JJ i
chemoradiotherapy NN i
. . i

The DT N
immunological JJ o
response NN o
was VBD N
measured VBN N
by IN N
means NNS N
of IN N
leukocyte NN o
counts NNS o
, , o
HLA-DR NNP o
expression NN o
on IN o
monocytes NNS o
, , o
the DT o
acute-phase JJ o
response NN o
by IN o
means NNS o
of IN o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
interleukin-6 JJ o
( ( o
IL-6 NNP o
) ) o
, , o
and CC o
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
, , o
and CC o
the DT o
stress NN o
response NN o
was VBD o
measured VBN o
by IN o
cortisol NN o
, , o
growth NN o
hormone NN o
, , o
and CC o
prolactin NN o
. . o

All DT N
parameters NNS N
were VBD N
determined VBN N
at IN N
baseline NN N
( ( N
preoperatively RB N
) ) N
and CC N
24 CD N
, , N
72 CD N
, , N
96 CD N
, , N
and CC N
168 CD N
h NN N
postoperatively RB N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
MIE NNP N
group NN N
with IN N
regard NN N
to TO N
leukocyte VB o
counts NNS o
, , o
IL-8 NNP o
, , o
and CC o
prolactin NN o
at IN N
168 CD N
h NN N
( ( N
1 CD N
week NN N
) ) N
postoperatively RB N
. . N

For IN N
HLA-DR NNP o
expression NN o
, , o
IL-6 NNP o
, , o
and CC o
CRP NNP o
levels NNS o
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
, , N
although IN N
there EX N
was VBD N
a DT N
clear JJ N
rise NN N
in IN N
levels NNS N
upon IN N
operation NN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
substudy NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
minimally RB N
invasive JJ N
and CC N
conventional JJ N
open JJ N
esophagectomies NNS N
for IN N
cancer NN N
, , N
significantly RB N
better RBR N
preserved VBN N
leukocyte JJ o
counts NNS o
and CC o
IL-8 JJ o
levels NNS o
were VBD N
observed VBN N
in IN N
the DT N
MIE NNP N
group NN N
compared VBN N
to TO N
the DT N
open JJ N
group NN N
. . N

Both DT N
findings NNS N
can MD N
be VB N
related VBN N
to TO N
fewer JJR o
respiratory NN o
infections NNS o
found VBD N
postoperatively RB N
in IN N
the DT N
MIE NNP N
group NN N
. . N

Moreover RB N
, , N
significant JJ N
differences NNS N
in IN N
the DT N
prolactin NN o
levels NNS o
at IN N
168 CD N
h NN N
after IN N
surgery NN N
imply NN N
that IN N
the DT N
stress NN o
response NN o
is VBZ N
better RBR N
preserved VBN N
in IN N
the DT N
MIE NNP i
group NN N
. . N

These DT N
findings NNS N
indicate VBP N
that IN N
less JJR N
surgical JJ N
trauma NN N
could MD N
lead VB N
to TO N
better JJR N
preserved VBN N
acute-phase NN N
and CC N
stress NN N
responses NNS N
and CC N
fewer JJR N
clinical JJ N
manifestations NNS N
of IN N
respiratory JJ N
infections NNS N
. . N

-DOCSTART- -22026323- O O

Early JJ N
intervention NN N
for IN N
autism NN N
with IN N
a DT N
parent-delivered JJ i
Qigong JJ i
massage NN i
program NN i
: : i
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

A DT N
recent JJ N
randomized NN N
controlled VBD N
trial NN N
( ( N
RCT NNP N
) ) N
of IN N
a DT N
dual JJ i
parent NN i
and CC i
trainer-delivered JJ i
qigong JJ i
massage NN i
intervention NN N
for IN N
young JJ p
children NNS p
with IN p
autism NN p
resulted VBN N
in IN N
improvement NN N
of IN N
measures NNS N
of IN N
autism NN o
as RB N
well RB N
as IN N
improvement NN N
of IN N
abnormal JJ o
sensory JJ o
responses NNS o
and CC N
self-regulation NN o
. . o

The DT N
RCT NNP N
evaluated VBD N
the DT N
effects NNS N
of IN N
the DT N
parent-delivered JJ N
component NN N
of IN N
the DT N
intervention NN N
. . N

Forty-seven JJ p
children NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
treatment NN p
and CC p
wait-list JJ p
control NN p
groups NNS p
. . p

Treatment NNP N
group NN N
children NNS N
received VBD N
the DT N
parent-delivered JJ i
program NN i
for IN i
4 CD i
mo NN i
. . i

Trained JJ N
therapists NNS N
provided VBD N
parent NN i
training NN i
and CC i
support NN i
. . i

Improvement NN N
was VBD N
evaluated VBN N
in IN N
two CD N
settings NNS N
-- : N
preschool NN N
and CC N
home NN N
-- : N
by IN N
teachers NNS N
( ( N
blind IN N
to TO N
group NN N
) ) N
and CC N
parents NNS N
. . N

Results NNS N
showed VBD N
that IN N
the DT N
parent-delivered JJ N
program NN N
was VBD N
effective JJ N
in IN N
improving VBG N
measures NNS N
of IN N
autism NN N
( ( N
medium JJ N
effect NN N
size NN N
) ) N
and CC N
sensory JJ o
and CC o
self-regulatory JJ o
responses NNS o
( ( N
large JJ N
effect NN N
size NN N
) ) N
. . N

Teacher NNP N
data NN N
on IN N
measures NNS N
of IN N
autism NN N
were VBD N
confirmed VBN N
by IN N
parent NN N
data NNS N
. . N

Results NNS N
indicate VBP N
that IN N
the DT N
parent-delivered JJ i
component NN i
of IN N
the DT N
program NN N
provided VBD N
effective JJ N
early JJ N
intervention NN N
for IN N
autism NN N
that WDT N
was VBD N
suitable JJ N
for IN N
delivery NN N
at IN N
home NN N
. . N

-DOCSTART- -23173253- O O

[ RB N
Clinical NNP N
study NN N
of IN N
treating VBG N
knee NN o
osteoarthritis NN o
( ( N
Bi NNP N
syndrome NN N
of IN N
knee NN N
) ) N
by IN N
massage NN i
combined VBN i
Chinese JJ i
materia NNS i
medica VBP i
footbath JJ i
fumigation NN i
and CC i
washing VBG i
] NNP i
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
treating VBG N
knee NN p
osteoarthritis NN p
( ( p
KOA NNP p
, , p
Bi NNP p
syndrome NN p
of IN p
knee NN p
) ) p
by IN N
massage NN i
combined VBN i
Chinese JJ i
materia NNS i
medica NN i
( ( i
CMM NNP i
) ) i
footbath NN i
fumigation NN i
and CC i
washing NN i
, , N
and CC N
to TO N
observe VB N
the DT N
changes NNS N
of IN N
the DT N
Lysholm NNP o
knee NN o
score NN o
( ( o
LKSS NNP o
) ) o
. . o

METHODS NNP N
Totally RB p
61 CD p
patients NNS p
with IN p
grade NN p
I PRP p
to TO p
III NNP p
KOA NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
, , N
the DT N
treatment NN N
group NN N
and CC N
the DT N
control NN N
group NN N
. . N

Patients NNS N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
treated VBN N
with IN N
massage NN i
combined VBN i
CMM NNP i
footbath JJ i
fumigation NN i
and CC i
washing NN i
, , N
while IN N
those DT N
in IN N
the DT N
control NN N
group NN N
were VBD N
treated VBN N
with IN N
oral JJ i
administration NN i
of IN i
meloxicam NNS i
. . i

They PRP N
were VBD N
treated VBN N
for IN N
20 CD N
days NNS N
( ( N
times NNS N
) ) N
. . N

The DT N
LKSS NNP o
was VBD N
assessed VBN N
before IN N
treatment NN N
, , N
10 CD N
days NNS N
of IN N
treatment NN N
, , N
by IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
, , N
and CC N
1 CD N
month NN N
after IN N
treatment NN N
. . N

RESULTS NNP N
( ( N
1 CD N
) ) N
The DT N
therapeutic JJ o
efficacy NN o
in IN N
the DT N
treatment NN N
group NN N
was VBD N
superior JJ N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Thirteen JJ N
cases NNS N
were VBD N
clinically RB N
controlled VBN N
, , N
with IN N
11 CD N
markedly RB N
effective JJ N
, , N
6 CD N
effective JJ N
, , N
and CC N
1 CD N
ineffective NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
while IN N
5 CD N
cases NNS N
were VBD N
clinically RB N
controlled VBN N
, , N
with IN N
11 CD N
markedly RB N
effective JJ N
, , N
10 CD N
effective JJ N
, , N
and CC N
4 CD N
ineffective NN N
in IN N
the DT N
control NN N
group NN N
. . N

( ( N
2 CD N
) ) N
The DT N
LKSS NNP o
: : o
The DT N
post-treatment JJ N
LKSS NNP o
was VBD N
higher JJR N
than IN N
that DT N
before IN N
treatment NN N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
LKSS NNP o
at IN N
10 CD N
days NNS N
( ( N
times NNS N
) ) N
of IN N
treatment NN N
was VBD N
lower JJR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
, , N
but CC N
with IN N
no DT N
statistical JJ N
difference NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
LKSS NNP o
by IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
was VBD N
higher RBR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
3 CD N
) ) N
The DT N
case NN N
number NN N
of IN N
patients NNS N
in IN N
need NN N
of IN N
receiving VBG N
the DT N
treatment NN N
again RB N
within IN N
1-month JJ N
follow-up JJ N
and CC N
the DT N
difference NN N
between IN N
the DT N
LKSS NNP o
at IN N
follow-ups NNS N
and CC N
that IN N
by IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
were VBD N
lower JJR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Massage NNP i
combined VBD i
CMM NNP i
footbath NN i
fumigation NN i
and CC i
washing NN i
had VBD N
better RBR N
clinical JJ o
efficacy NN o
on IN N
patients NNS N
suffering VBG N
from IN N
KOA NNP N
. . N

-DOCSTART- -24105031- O O

Supplementation NN i
effect NN o
with IN i
slow-release JJ i
urea NN i
in IN N
feed NN N
blocks NNS N
for IN N
Thai NNP p
beef NN p
cattle NNS p
-- : p
nitrogen DT p
utilization NN p
, , p
blood NN p
biochemistry NN p
, , p
and CC p
hematology NN p
. . p

Four CD p
Thai NNP p
male NN p
native JJ p
beef NN p
cattle NNS p
, , p
initial JJ p
body NN p
weight NN p
( ( p
BW NNP p
) ) p
of IN p
100 CD p
? . p
3.0 CD p
kg NN p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
4 CD N
? . N
4 CD N
Latin NNP N
square JJ N
design NN N
to TO N
receive VB N
four CD i
dietary JJ i
treatments NNS i
with IN i
inclusion NN i
of IN i
urea JJ i
calcium NN i
sulphate NN i
mixture NN i
( ( i
U-cas NNP i
) ) i
in IN i
feed NN i
block NN i
( ( i
FB NNP N
) ) N
at IN N
0 CD N
, , N
120 CD N
, , N
150 CD N
, , N
and CC N
180 CD N
g/kg NN N
dry JJ N
matter NN N
( ( N
DM NNP N
) ) N
. . N

Total JJ N
intakes NNS N
were VBD N
increased VBN N
with IN N
the DT N
increasing VBG N
level NN N
of IN N
U-cas JJ i
supplementation NN i
in IN i
FB NNP N
and CC N
the DT N
result NN N
obtained VBD N
the DT N
highest JJS N
when WRB N
supplementation NN N
of IN N
U-cas NNP i
in IN i
FB NNP N
at IN N
180 CD N
, , N
followed VBN N
by IN N
150 CD N
, , N
120 CD N
, , N
and CC N
0 CD N
g/kg NN N
DM NNP N
, , N
respectively RB N
. . N

Moreover RB i
, , i
supplementation NN i
of IN i
U-cas NNP i
in IN i
FB NNP N
at IN N
180 CD N
g/kg NNS N
DM NNP N
could MD N
reduce VB o
total JJ o
N NNP o
excretion NN o
( ( o
4.1 CD N
g/day NN N
) ) N
, , N
as IN N
compared VBN N
to TO N
others NNS N
treatments NNS N
, , N
while IN N
N NNP N
retention NN N
and CC N
proportion NN N
of IN N
N NNP N
retention NN N
to TO N
N NNP o
intake VB o
were VBD o
increased VBN N
up RB N
to TO N
6.9 CD N
g/day NN N
and CC N
14.9 CD N
% NN N
, , N
respectively RB N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT o
blood NN o
biochemistry NN o
and CC o
hematological JJ o
parameters NNS o
were VBD o
not RB N
different JJ N
among IN N
treatments NNS N
except IN o
concentration NN o
of IN o
plasma JJ o
urea JJ o
N NNP o
, , o
plasma NN o
glucose NN o
, , o
and CC o
total JJ o
blood NN o
protein NN o
were VBD o
improved VBN N
especially RB N
with IN i
U-cas JJ i
supplementation NN i
at IN i
180 CD N
g/kg NN N
DM NNP N
in IN N
FB NNP N
. . N

In IN N
conclusion NN i
, , i
supplementation NN i
of IN i
U-cas NNP i
at IN i
180 CD N
g/kg NN N
in IN N
FB NNP N
improved VBD o
feed JJ o
intake NN o
, , o
N NNP o
utilization NN o
, , o
and CC o
blood NN o
biochemistry NN o
in IN o
Thai NNP p
native JJ p
beef NN p
cattle NNS p
fed VBP p
on IN p
rice NN p
straw NN p
. . p

-DOCSTART- -17174705- O O

Continuous JJ N
pralidoxime NN i
infusion NN N
versus NN N
repeated VBD N
bolus JJ N
injection NN N
to TO N
treat VB N
organophosphorus JJ p
pesticide NN p
poisoning NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
The DT N
role NN N
of IN N
oximes NNS N
for IN N
the DT N
treatment NN N
of IN N
organophosphorus JJ p
pesticide NN p
poisoning NN p
has VBZ N
not RB N
been VBN N
conclusively RB N
established VBN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
constant JJ N
pralidoxime NN i
infusion NN N
compared VBN N
with IN N
repeated JJ N
bolus NN N
doses NNS N
to TO N
treat VB N
patients NNS p
with IN p
moderately RB p
severe JJ p
poisoning VBG p
from IN p
organophosphorus JJ p
pesticides NNS p
. . p

METHODS NNP N
200 CD p
patients NNS p
were VBD p
recruited VBN p
to TO p
our PRP$ p
single-centre JJ p
, , p
open JJ p
randomised VBD p
controlled VBN p
trial NN p
after IN p
moderately RB p
severe JJ p
poisoning NN p
by IN p
anticholinesterase NN p
pesticide NN p
. . p

All DT N
were VBD N
given VBN N
a DT N
2 CD N
g NN N
loading VBG N
dose NN N
of IN N
pralidoxime NN i
over IN N
30 CD N
min NNS N
. . N

Patients NNS N
were VBD N
then RB N
randomly RB N
assigned VBN N
to TO N
control VB N
and CC N
study VB N
groups NNS N
. . N

Controls NNS N
were VBD N
given VBN N
a DT N
bolus NN i
dose NN i
of IN i
1 CD i
g NN i
pralidoxime NN i
over IN i
1 CD i
h NNS i
every DT i
4 CD i
h NN i
for IN i
48 CD i
h. PDT i
The DT N
study NN N
group NN N
had VBD N
a DT N
constant JJ i
infusion NN i
of IN i
1 CD i
g NN i
over IN i
an DT i
hour NN i
every DT i
hour NN i
for IN i
48 CD i
h. NN i
Thereafter NNP N
, , N
all DT N
patients NNS N
were VBD N
given VBN i
1 CD i
g JJ i
every DT i
4 CD i
h NN i
until IN i
they PRP i
could MD i
be VB i
weaned VBN i
from IN i
ventilators NNS i
. . i

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

Primary NNP N
outcome JJ N
measures NNS N
were VBD N
median JJ o
atropine NN o
dose NN o
needed VBD o
within IN o
24 CD o
h NN o
, , o
proportion NN o
of IN o
patients NNS o
who WP o
needed VBD o
intubation NN o
, , N
and CC N
number NN o
of IN o
days NNS o
on IN o
ventilation NN o
. . o

The DT N
study NN N
is VBZ N
registered VBN N
at IN N
http NN N
: : N
//www.clinicaltrials.gov NN N
with IN N
the DT N
identifier NN N
NCT00333944 NNP N
. . N

FINDINGS NNP N
100 CD p
patients NNS p
were VBD p
assigned VBN p
the DT p
high-dose JJ p
regimen NNS p
, , N
and CC N
100 CD p
the DT p
control NN p
regimen NN p
. . p

There EX N
were VBD N
no DT N
drop-outs JJ N
. . N

Patients NNS p
receiving VBG p
the DT p
high-dose JJ p
pralidoxime JJ p
regimen NNS p
required VBD N
less JJR N
atropine JJ o
during IN N
the DT N
first JJ N
24 CD N
h NN N
than IN N
controls NNS N
( ( N
median JJ N
6 CD N
mg NN N
vs NN N
30 CD N
mg NN N
; : N
difference NN N
24 CD N
mg NN N
[ VBD N
95 CD N
% NN N
CI NNP N
24-26 CD N
, , N
p VBZ N
< JJ N
0.0001 CD N
] NN N
) ) N
. . N

88 CD N
( ( N
88 CD N
% NN N
) ) N
and CC N
64 CD N
( ( N
64 CD N
% NN N
) ) N
of IN N
controls NNS N
and CC N
high-dose JJ N
patients NNS N
, , N
respectively RB N
, , N
needed VBD N
intubation NN o
during IN o
admission NN o
to TO o
hospital NN o
( ( N
relative JJ N
risk=0.72 NN N
, , N
0.62-0.86 JJ N
, , N
p=0.0001 NN N
) ) N
. . N

Control NNP N
patients NNS N
required VBD N
ventilatory JJ o
support NN o
for IN N
longer JJR N
( ( N
median JJ N
10 CD N
days NNS N
vs RB N
5 CD N
days NNS N
; : N
difference NN N
5 CD N
days NNS N
[ RB N
5-6 JJ N
, , N
p JJ N
< FW N
0.0001 CD N
] NN N
) ) N
. . N

INTERPRETATION VB N
A DT N
high-dose JJ N
regimen NN N
of IN N
pralidoxime NN N
, , N
consisting VBG N
of IN N
a DT N
constant JJ N
infusion NN N
of IN N
1 CD N
g/h NN N
for IN N
48 CD N
h NN N
after IN N
a DT N
2 CD N
g NN N
loading VBG N
dose NN N
, , N
reduces VBZ N
morbidity NN o
and CC o
mortality NN o
in IN N
moderately RB p
severe JJ p
cases NNS p
of IN p
acute JJ p
organophosphorus-pesticide JJ p
poisoning NN p
. . p

-DOCSTART- -10463377- O O

Double-blind NNP N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
on IN N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN o
a DT o
physostigmine JJ o
patch NN o
in IN N
patients NNS p
with IN p
senile JJ p
dementia NN p
of IN p
the DT p
Alzheimer NNP p
type NN p
. . p

Owing VBG N
to TO N
the DT N
pharmacokinetic JJ N
properties NNS N
of IN N
physostigmine NN N
when WRB N
administered VBN N
by IN N
conventional JJ N
routes NNS N
, , N
long-term JJ N
cholinergic JJ N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
is VBZ N
difficult JJ N
to TO N
manage VB N
. . N

In IN N
order NN N
to TO N
overcome VB N
the DT N
problems NNS N
associated VBN N
with IN N
the DT N
oral JJ N
and CC N
intravenous JJ N
application NN N
of IN N
physostigmine NN N
, , N
and CC N
to TO N
improve VB N
patients NNS o
' POS o
compliance NN o
, , N
a DT N
transdermal JJ N
therapeutic JJ N
system NN N
was VBD N
developed VBN N
. . N

The DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
this DT N
system NN N
were VBD N
evaluated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
multicenter RBR N
study NN N
comparing VBG N
patches NNS N
containing VBG N
30 CD i
mg NN i
and CC i
60 CD i
mg NNS i
physostigmine NN i
with IN i
a DT i
placebo NN i
patch NN i
. . i

The DT N
clinical JJ N
trial NN N
followed VBD N
the DT N
basic JJ N
principles NNS N
of IN N
the DT N
various JJ N
guidelines NNS N
on IN N
the DT N
evaluation NN N
of IN N
anti-dementia JJ N
drugs NNS N
, , N
and CC N
included VBD N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
probable JJ p
Alzheimer NNP p
's POS p
disease NN p
. . p

A DT p
total NN p
of IN p
204 CD p
patients NNS p
with IN p
probable JJ p
Alzheimer NNP p
's POS p
disease NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Of IN p
these DT p
, , p
136 CD p
patients NNS p
were VBD p
eligible JJ p
for IN p
the DT p
according-to-protocol JJ p
analysis NN p
of IN p
efficacy NN p
, , p
167 CD p
subjects NNS p
for IN p
the DT p
intention-to-treat JJ p
analysis NN p
of IN p
efficacy NN p
, , p
and CC p
181 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
safety NN p
analysis NN p
. . p

In IN N
contrast NN N
to TO N
the DT N
hypothesis NN N
to TO N
be VB N
tested VBN N
, , N
the DT N
efficacy NN o
of IN N
physostigmine NN N
was VBD N
not RB N
superior JJ N
to TO N
that DT N
of IN N
placebo NN N
after IN N
a DT N
treatment NN N
period NN N
of IN N
24 CD N
weeks NNS N
. . N

On IN N
the DT N
contrary JJ N
, , N
there EX N
was VBD N
even RB N
a DT N
slight NN N
, , N
but CC N
not RB N
statistically RB N
significant JJ N
, , N
trend NN N
toward IN N
a DT N
better JJR N
outcome NN N
in IN N
the DT N
placebo NN p
group NN p
. . p

Median JJ o
physostigmine NN o
plasma NN o
concentrations NNS o
of IN N
approximately RB N
100 CD N
pg/ml NNS N
were VBD N
measured VBN N
, , N
showing VBG N
a DT N
high JJ N
degree NN N
of IN N
interindividual JJ N
variability NN N
and CC N
no DT N
linear JJ N
dose NN N
relationship NN N
between IN N
the DT N
30 CD N
mg NN N
and CC N
60 CD N
mg NN N
dosages NNS N
. . N

Plasma NNP o
cholinesterase NN o
activity NN o
was VBD N
not RB N
significantly RB N
affected VBN N
by IN N
physostigmine NN N
. . N

The DT N
physostigmine JJ N
patch NN N
application NN N
in IN N
doses NNS N
of IN N
30 CD N
mg NNS N
and CC N
60 CD N
mg NNS N
apparently RB N
did VBD N
not RB N
lead VB N
to TO N
physostigmine VB o
plasma JJ o
concentrations NNS o
that WDT N
were VBD N
sufficient JJ N
to TO N
compensate VB N
for IN N
cholinergic JJ N
deficiencies NNS N
in IN N
affected JJ N
brain NN N
areas NNS N
and CC N
produce VB N
clinical JJ N
benefits NNS N
. . N

Both CC N
the DT N
drug NN N
and CC N
the DT N
transdermal JJ N
system NN N
were VBD N
generally RB N
well RB o
tolerated VBN o
under IN N
the DT N
study NN N
conditions NNS N
. . N

Modifications NNS N
of IN N
the DT N
patch NN N
system NN N
may MD N
perhaps RB N
make VB N
it PRP N
possible JJ N
to TO N
achieve VB N
higher JJR N
physostigmine NN o
plasma NN o
concentrations NNS o
, , N
which WDT N
seem VBP N
to TO N
be VB N
required VBN N
to TO N
induce VB N
the DT N
expected JJ N
beneficial JJ o
effects NNS o
during IN N
long-term JJ N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
. . N

-DOCSTART- -23076431- O O

Effects NNS N
of IN N
nitric JJ i
oxide JJ i
synthase NN i
inhibition NN i
on IN N
cutaneous JJ o
vasodilation NN o
in IN N
response NN N
to TO N
acupuncture VB i
stimulation NN N
in IN N
humans NNS p
. . p

OBJECTIVES IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
elucidate VB N
the DT N
mechanism NN N
of IN N
cutaneous JJ N
vasodilation NN N
following VBG N
acupuncture NN N
stimulation NN N
by IN N
investigating VBG N
the DT N
roles NNS N
of IN N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
and CC N
axon $ N
reflex JJ N
vasodilation NN N
. . N

METHODS NNP N
The DT N
subjects NNS N
were VBD N
17 CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

The DT N
role NN N
of IN N
NO NNP N
was VBD N
investigated VBN N
by IN N
administering VBG N
N NNP i
( ( i
G NNP i
) ) i
-nitro-l-arginine VBP i
methyl JJ i
ester NN i
hydrochloride NN i
( ( i
L-NAME NNP i
, , N
20 CD N
mM NN N
) ) N
, , N
an DT N
NO NNP i
synthase NN i
inhibitor NN i
or CC N
Ringer NNP i
's POS i
solution NN i
( ( N
control VB N
site NN N
) ) N
, , N
via IN N
intradermal JJ N
microdialysis NN N
( ( N
protocol JJ N
1 CD N
; : N
n=7 NN N
) ) N
. . N

The DT N
role NN N
of IN N
axon JJ N
reflex JJ N
vasodilation NN N
by IN N
local JJ N
sensory NN N
neurones NNS N
was VBD N
investigated VBN N
by IN N
comparing VBG N
vasodilation NN N
at IN N
sites NNS N
treated VBN N
with IN N
'eutectic JJ i
mixture NN i
of IN i
local JJ i
anaesthetics NNS i
' POS i
( ( i
EMLA NNP i
) ) i
cream NN N
( ( N
2.5 CD N
% NN N
lidocaine NN i
and CC N
2.5 CD N
% NN N
prilocaine NN i
) ) i
with IN N
untreated JJ N
sites NNS N
( ( N
control VB N
site NN N
) ) N
( ( N
protocol JJ N
2 CD N
; : N
n=10 NN N
) ) N
. . N

After IN N
5 CD N
min NN N
of IN N
baseline NN N
recording NN N
, , N
acupuncture NN i
was VBD N
applied VBN N
to TO N
PC4 NNP N
and CC N
a DT N
control NN N
site NN N
in IN N
proximity NN N
to TO N
PC4 NNP N
for IN N
10 CD N
min NNS N
and CC N
scanning NN N
was VBD N
performed VBN N
for IN N
60 CD N
min NN N
after IN N
acupuncture JJ N
stimulation NN N
. . N

Skin NNP o
blood NN o
flow NN o
( ( o
SkBF NNP o
) ) o
was VBD N
evaluated VBN N
by IN N
laser NN N
Doppler NNP o
perfusion NN o
imaging VBG o
. . o

Cutaneous JJ o
vascular JJ o
conductance NN o
( ( o
CVC NNP o
) ) o
was VBD N
calculated VBN N
from IN N
the DT N
ratio NN N
of IN N
SkBF NNP N
to TO N
mean VB N
arterial JJ N
blood NN N
pressure NN N
. . N

RESULTS NNP N
In IN N
the DT N
first JJ N
protocol NN N
, , N
sites NNS N
administered VBD N
L-NAME NNP N
showed VBD N
significant JJ N
reductions NNS N
in IN N
CVC NNP o
responses NNS o
following VBG N
acupuncture NN N
stimulation NN N
compared VBN N
to TO N
control VB N
sites NNS N
( ( N
administered VBN N
Ringer NNP i
's POS i
solution NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
second JJ N
protocol NN N
, , N
changes NNS o
in IN o
CVC NNP o
responses NNS o
after IN N
acupuncture JJ N
stimulation NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
treated VBN N
sites NNS N
with IN N
EMLA NNP i
cream NN N
and CC N
untreated JJ N
sites NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
cutaneous JJ N
vasodilation NN N
in IN N
response NN N
to TO N
acupuncture VB N
stimulation NN N
may MD N
not RB N
occur VB N
through IN N
an DT N
axon JJ N
reflex NN N
as IN N
previously RB N
reported VBN N
. . N

Rather NNP N
, , N
NO NNP N
mechanisms NN N
appear VBP N
to TO N
contribute VB N
to TO N
the DT N
vasodilator NN N
response NN N
. . N

-DOCSTART- -26551748- O O

Effects NNS N
of IN N
therapeutic JJ i
horse NN i
riding VBG i
on IN N
gait NN o
cycle NN o
parameters NNS o
and CC N
some DT N
aspects NNS o
of IN o
behavior NN o
of IN N
children NNS p
with IN p
autism NN p
. . p

We PRP N
studied VBD N
effects NNS N
of IN N
therapeutic JJ i
riding VBG i
on IN N
the DT N
development NN N
of IN N
children NNS p
with IN p
autism NN p
. . p

Experiments NNS N
in IN N
walking NN N
is VBZ N
appropriate JJ N
for IN N
assessing VBG N
the DT N
coordination NN N
of IN N
movement NN N
and CC N
for IN N
following VBG N
the DT N
changes NNS N
. . N

We PRP N
found VBD N
that IN N
therapeutic JJ i
riding NN i
should MD N
be VB N
considered VBN N
as IN N
a DT N
new JJ N
form NN N
of IN N
rehabilitation NN N
. . N

Twenty-six JJ p
pupils NNS p
( ( p
12 CD p
boys NNS p
and CC p
14 CD p
girls NNS p
) ) p
of IN p
a DT p
special JJ p
needs JJ p
school NN p
participated VBD p
in IN N
therapeutic JJ i
riding NN i
. . i

We PRP N
analyzed VBD N
walking VBG N
twice RB N
during IN N
a DT N
school-term JJ N
: : N
full JJ i
body NN i
analyses VBZ i
each DT N
time NN N
before IN N
and CC N
after IN N
one-month JJ i
therapy NN i
. . i

The DT N
research NN N
included VBD N
a DT N
non-riding JJ i
control NN i
group NN i
. . i

All DT N
together RB N
104 CD p
analyses NNS p
were VBD N
performed VBN N
. . N

We PRP N
measured VBD N
mental JJ N
skills NNS N
using VBG N
Pedagogical JJ o
Analysis NN o
and CC o
Curriculum NNP o
( ( o
PAC NNP o
) ) o
test NN o
consisting VBG N
of IN N
four CD N
parts NNS N
being VBG N
communication NN o
, , o
self PRP o
care NN o
, , o
motor NN o
skills NNS o
and CC N
socialization NN o
. . o

The DT N
Gait NNP N
Cycle NNP N
Analysis NNP N
consists VBZ N
of IN N
the DT N
time-series NNS N
analysis NN N
, , N
the DT N
analysis NN N
of IN N
part NN N
of IN N
the DT N
gait NN N
cycle NN N
and CC N
the DT N
measurement NN N
of IN N
joint JJ N
angles NNS N
in IN N
each DT N
plane NN N
. . N

We PRP N
found VBD N
significant JJ N
differences NNS N
between IN N
before IN N
and CC N
after IN N
the DT N
therapy NN N
in IN N
the DT N
length NN o
of IN o
the DT o
gait NN o
cycle NN o
that WDT N
became VBD N
more RBR N
stable JJ N
in IN N
the DT N
sagital JJ N
plane NN N
and CC N
concluded VBD N
that IN N
our PRP$ N
results NNS N
proved VBD N
that IN N
horse NN N
therapy NN N
may MD N
be VB N
successfully RB N
used VBN N
as IN N
an DT N
additional JJ N
therapy NN N
for IN N
children NNS p
with IN p
autism NN p
, , N
and CC N
it PRP N
may MD N
be VB N
a DT N
form NN N
of IN N
rehabilitation NN N
in IN N
cases NNS N
when WRB N
other JJ N
therapies NNS N
are VBP N
not RB N
successful JJ N
. . N

-DOCSTART- -12576246- O O

Low-dose JJ N
mifepristone NN i
for IN N
uterine JJ N
leiomyomata NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
5 CD N
and CC N
10 CD N
mg NN N
of IN N
mifepristone NN i
on IN N
uterine JJ o
leiomyoma NN o
size NN o
and CC o
symptoms NNS o
, , N
and CC N
to TO N
measure VB N
side JJ N
effects NNS N
. . N

METHODS NNP N
Forty NNP p
premenopausal JJ p
women NNS p
with IN p
large JJ p
, , p
symptomatic JJ p
leiomyomata NNS p
were VBD N
randomized VBN N
to TO N
receive VB i
either RB i
5 CD i
or CC i
10 CD i
mg NN i
of IN i
mifepristone JJ i
daily JJ i
for IN i
6 CD i
months NNS i
in IN i
an DT i
open-label JJ i
study NN i
. . i

Uterine NNP N
volume NN N
was VBD N
measured VBN N
at IN N
bimonthly JJ N
intervals NNS N
by IN N
sonography NN N
. . N

Serum NNP N
concentrations NNS N
of IN N
hemoglobin NN N
levels NNS N
, , N
follicle-stimulating JJ N
hormone NN N
, , N
and CC N
liver RB N
enzymes NNS N
were VBD N
obtained VBN N
, , N
and CC N
endometrial JJ N
samples NNS N
, , N
symptoms NNS N
, , N
and CC N
menstrual JJ N
bleeding NN N
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
Nineteen NNP p
of IN p
20 CD p
subjects NNS p
taking VBG N
5 CD N
mg NN N
and CC N
all DT N
20 CD N
subjects NNS N
taking VBG N
10 CD N
mg NN N
completed VBD N
all DT N
6 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

Mean NNP o
uterine JJ o
volume NN o
shrank NN o
by IN N
48 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
5-mg JJ N
group NN N
and CC N
49 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
10-mg JJ N
group NN N
, , N
a DT N
nonsignificant JJ N
difference NN N
. . N

Leiomyoma-related JJ o
symptoms NNS o
were VBD N
comparably RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

Amenorrhea NNP o
occurred VBD N
in IN N
60-65 CD N
% NN N
of IN N
both DT N
groups NNS N
. . N

Hemoglobin NNP o
levels NNS o
increased VBN N
by IN N
2.5 CD N
g/dL NNS N
in IN N
anemic JJ N
subjects NNS N
. . N

The DT N
incidence NN N
of IN N
hot JJ o
flashes NNS o
increased VBD N
significantly RB N
over IN N
baseline NN N
in IN N
the DT N
10-mg JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
5-mg JJ N
group NN N
. . N

Simple NNP o
endometrial JJ o
hyperplasia NN o
occurred VBD N
in IN N
28 CD N
% NN N
of IN N
all DT N
subjects NNS N
, , N
with IN N
no DT N
difference NN N
between IN N
groups NNS N
. . N

No DT N
atypical JJ o
hyperplasia NN o
was VBD N
noted VBN N
. . N

CONCLUSION NNP N
Mifepristone NNP i
in IN N
doses NNS N
of IN N
5 CD N
mg NNS N
or CC N
10 CD N
mg JJ N
results NNS N
in IN N
comparable JJ N
leiomyoma NN o
regression NN o
, , o
improvement NN o
in IN o
symptoms NNS o
, , o
and CC o
few JJ o
side NN o
effects NNS o
. . o

Further NNP N
study NN N
is VBZ N
needed VBN N
to TO N
assess VB N
the DT N
long-term JJ N
safety NN N
and CC N
efficacy NN N
of IN N
low-dose JJ N
mifepristone NN i
. . i

-DOCSTART- -25643864- O O

Randomized VBN N
Controlled JJ N
Trial NNP N
of IN N
Mind NNP i
Reading NNP i
and CC N
In IN i
Vivo NNP i
Rehearsal NNP i
for IN N
High-Functioning NNP p
Children NNP p
with IN p
ASD NNP p
. . p

This DT N
randomized VBD N
controlled JJ N
trial NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
a DT N
computer NN i
software NN i
( ( i
i.e. FW i
, , N
Mind NNP i
Reading NNP i
) ) i
and CC i
in IN i
vivo JJ i
rehearsal NN i
treatment NN i
on IN N
the DT N
emotion NN o
decoding NN o
and CC o
encoding VBG o
skills NNS o
, , o
autism NN o
symptoms NNS o
, , o
and CC o
social JJ o
skills NNS o
of IN N
43 CD p
children NNS p
, , p
ages VBZ p
7-12 CD p
years NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorder NN p
( ( p
HFASD NNP p
) ) p
. . p

Children NNP N
in IN N
treatment NN N
( ( N
n JJ N
= NNP N
22 CD N
) ) N
received VBD N
the DT N
manualized VBN i
protocol NN i
over IN i
12 CD N
weeks NNS N
. . N

Primary JJ N
analyses NNS N
indicated VBD o
significantly RB o
better JJR o
posttest JJS o
performance NN o
for IN o
the DT N
treatment NN i
group NN i
( ( i
compared VBN i
to TO i
controls NNS o
) ) o
on IN o
3 CD o
of IN o
the DT o
4 CD o
measures NNS o
of IN o
emotion NN o
decoding NN o
and CC o
encoding NN o
and CC o
these DT N
were VBD N
maintained VBN N
at IN N
5-week JJ N
follow-up NN N
. . N

Analyses NNS N
of IN N
secondary JJ N
measures NNS N
favored VBD N
the DT N
treatment NN i
group NN i
for IN i
1 CD N
of IN N
the DT N
2 CD N
measures NNS N
; : N
specifically RB o
, , o
ASD NNP o
symptoms NNS o
were VBD o
significantly RB o
lower JJR o
at IN o
posttest NN N
and CC N
follow-up NN N
. . N

-DOCSTART- -21654265- O O

An DT N
allopurinol-controlled JJ i
, , N
randomized VBN N
, , N
double-dummy JJ N
, , N
double-blind JJ N
, , N
parallel JJ N
between-group NN N
, , N
comparative JJ o
study NN o
of IN N
febuxostat NN i
( ( i
TMX-67 NNP i
) ) i
, , i
a DT i
non-purine-selective JJ i
inhibitor NN i
of IN i
xanthine JJ i
oxidase NN i
, , N
in IN N
patients NNS p
with IN p
hyperuricemia JJ p
including VBG p
those DT p
with IN p
gout NN p
in IN p
Japan NNP p
: : p
phase NN N
3 CD N
clinical JJ N
study NN N
. . N

BACKGROUND NNP N
Allopurinol NNP i
has VBZ N
been VBN N
widely RB N
used VBN N
for IN N
treatment NN N
of IN N
hyperuricemia NN N
, , N
however RB N
, , N
it PRP N
may MD N
be VB N
associated VBN N
with IN N
various JJ N
adverse JJ N
effects NNS N
. . N

Febuxostat NNP N
is VBZ N
potentially RB N
a DT N
safe JJ N
and CC N
efficacious JJ N
alternative NN N
. . N

OBJECTIVES NNP N
Febuxostat NNP i
or CC i
allopurinol NN i
was VBD N
administered VBN N
to TO N
patients NNS p
with IN p
hyperuricemia JJ p
including VBG p
gout NN p
for IN N
8 CD N
weeks NNS N
to TO N
compare VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
these DT N
drugs NNS N
. . N

METHODS NNP N
Doses NNP N
of IN N
febuxostat NN i
and CC i
allopurinol NN i
were VBD N
10 CD N
and CC N
100 CD N
mg/d NN N
, , N
respectively RB N
, , N
during IN N
a DT N
12-day JJ N
introduction NN N
period NN N
and CC N
were VBD N
increased VBN N
to TO N
40 CD N
and CC N
200 CD N
mg/d NN N
for IN N
the DT N
subsequent JJ N
treatment NN N
period NN N
of IN N
44 CD N
days NNS N
. . N

RESULTS NN N
: : N
The DT N
percent NN N
changes NNS o
in IN o
serum NN o
uric JJ o
acid NN o
levels NNS o
after IN N
8 CD N
weeks NNS N
were VBD N
-40.75 CD N
% NN N
for IN N
the DT N
febuxostat NN i
group NN N
and CC N
-34.41 CD N
% NN N
for IN N
the DT N
allopurinol NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
analysis NN N
of IN N
variance NN N
, , N
closing VBG N
testing VBG N
procedure NN N
) ) N
. . N

The DT N
percentage NN N
of IN N
patients NNS N
achieving VBG N
serum JJ o
uric JJ o
acid NN o
levels NNS o
6.0 CD N
mg/dL NN N
or CC N
less JJR N
after IN N
8 CD N
weeks NNS N
was VBD N
82.0 CD N
% NN N
for IN N
the DT N
febuxostat NN N
group NN N
and CC N
70.0 CD N
% NN N
for IN N
the DT N
allopurinol NN i
group NN N
( ( N
P NNP N
= NNP N
0.019 CD N
, , N
logistic JJ N
regression NN N
analysis NN N
) ) N
. . N

Regarding VBG N
safety NN o
, , N
213 CD N
adverse JJ o
events NNS o
were VBD N
observed VBN N
in IN N
the DT N
febuxostat NN i
group NN N
and CC N
220 CD N
events NNS N
in IN N
the DT N
allopurinol NN N
group NN N
. . N

For IN N
10 CD N
patients NNS N
( ( N
8.2 CD N
% NN N
) ) N
in IN N
the DT N
febuxostat NN i
group NN N
and CC N
14 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
allopurinol NN i
group NN N
, , N
association NN N
with IN N
the DT N
study NN N
drugs NNS N
could MD N
not RB N
be VB N
ruled VBN N
out RP N
. . N

There EX N
were VBD N
no DT N
severe JJ o
adverse JJ o
drug NN o
reactions NNS o
in IN N
the DT N
febuxostat NN i
group NN N
other JJ N
than IN N
a DT N
high JJ N
frequency NN N
of IN N
gout NN o
attacks NNS o
induced VBN N
by IN N
the DT N
sudden JJ o
reduction NN o
in IN o
blood NN o
uric JJ o
acid NN o
levels NNS o
during IN N
the DT N
early JJ N
treatment NN N
period NN N
. . N

CONCLUSIONS NNP N
Febuxostat NNP i
at IN N
40 CD N
mg/d NN N
demonstrated VBD N
more RBR N
potent JJ o
hypouricemic JJ o
effects NNS o
than IN N
allopurinol NN i
at IN N
200 CD N
mg/d NN N
, , N
was VBD N
efficacious JJ N
regardless NN N
of IN N
medical JJ N
history NN N
of IN N
gout NN N
, , N
and CC N
is VBZ N
considered VBN N
safe JJ N
for IN N
treatment NN N
of IN N
hyperuricemia NN o
. . o

-DOCSTART- -1457622- O O

EEG NNP N
mapping NN N
and CC N
psychopharmacological JJ N
studies NNS N
with IN N
denbufylline NN i
in IN N
SDAT NNP p
and CC p
MID NNP p
. . p

Computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
, , N
electroencephalograms FW N
( ( N
EEG NNP N
) ) N
, , N
clinical JJ N
and CC N
psychometric JJ N
data NNS N
were VBD N
obtained VBN N
in IN N
96 CD p
mildly RB p
to TO p
moderately RB p
demented JJ p
patients NNS p
( ( p
72 CD p
women NNS p
, , p
24 CD p
men NNS p
) ) p
, , p
aged VBN p
61-96 CD p
years NNS p
( ( p
mean VB p
82 CD p
) ) p
, , p
diagnosed VBD p
according VBG p
to TO p
DSM-III NNP p
criteria NNS p
. . p

Patients NNS p
were VBD p
off RP p
drugs NNS p
for IN p
at IN p
least JJS p
2 CD p
weeks NNS p
and CC p
subdiagnosed VBD p
according VBG p
to TO p
the DT p
modified VBN p
Marshall-Hachinski NNP p
ischemic JJ p
score NN p
and CC p
CT NNP p
in IN p
45 CD p
senile JJ p
dementia NN p
of IN p
the DT p
Alzheimer NNP p
type NN p
( ( p
SDAT NNP p
) ) p
and CC p
51 CD p
multiinfarct NN p
dementia NN p
( ( p
MID NNP p
) ) p
patients NNS p
. . p

Evaluations NNS N
were VBD N
carried VBN N
out RP N
before IN N
and CC N
12 CD N
weeks NNS N
after IN N
treatment NN N
with IN N
either DT N
100 CD N
mg NNS N
denbufylline JJ i
BID NNP N
or CC N
placebo NN i
and CC N
included VBD N
EEG NNP N
mapping NN N
, , N
the DT N
Sandoz NNP N
Clinical NNP N
Assessment NNP N
Geriatric NNP N
( ( N
SCAG NNP N
) ) N
score/factors NNS N
, , N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
, , N
the DT N
Digit NNP N
Symbol NNP N
Substitution NNP N
Test NNP N
( ( N
DSST NNP N
) ) N
, , N
the DT N
Trail-Making JJ N
Test NNP N
( ( N
TMT NNP N
) ) N
and CC N
the DT N
Digit NNP N
Span NNP N
Test NNP N
( ( N
DS NNP N
) ) N
. . N

Descriptive NNP N
data NNS N
analysis NN N
including VBG N
confirmatory JJ N
statements NNS N
found VBN N
delta/theta JJ o
activity NN o
enhanced VBD N
, , N
alpha NN o
and CC o
beta NN o
activity NN o
reduced VBN N
, , N
total JJ o
power NN o
augmented VBN N
, , N
and CC N
the DT N
centroid NN o
slowed VBD N
down RB N
over RB N
various JJ N
brain NN N
regions NNS N
in IN N
patients NNS N
as IN N
compared VBN N
with IN N
controls NNS N
. . N

The DT N
two CD N
subtypes NNS N
of IN N
dementia NN N
could MD N
be VB N
differentiated VBN N
in IN N
some DT N
conventional JJ N
EEG NNP N
variables NNS N
but CC N
mostly RB N
by IN N
means NNS N
of IN N
power NN N
asymmetry NN N
indices NNS N
. . N

Denbufylline NNP i
induced VBD N
a DT N
statistically RB N
significant JJ N
and CC N
clinically RB N
relevant JJ N
improvement NN o
in IN o
both DT o
SDAT NNP o
and CC o
MID NNP o
patients NNS N
, , N
whereas NNS N
after IN N
placebo NN i
this DT N
was VBD N
not RB N
the DT N
case NN N
in IN N
CGI NNP N
, , N
the DT N
TMT NNP N
, , N
and CC N
the DT N
DS NNP N
, , N
with IN N
interdrug JJ N
differences NNS N
being VBG N
significant JJ N
in IN N
all DT N
primary JJ N
target NN N
variables NNS N
such JJ N
as IN N
the DT N
CGI NNP o
, , o
MMS NNP o
, , o
SCAG NNP o
, , o
and CC o
DSST NNP o
. . o

Thus RB N
, , N
both DT N
the DT N
degenerative NN N
and CC N
vascular JJ N
type NN N
of IN N
dementia NN N
exhibited VBD N
a DT N
therapeutic JJ N
benefit NN N
that WDT N
could MD N
be VB N
objectified VBN N
at IN N
the DT N
neurophysiological JJ N
level NN N
by IN N
EEG NNP N
mapping NN N
in IN N
an DT N
improvement NN N
of IN N
vigilance NN N
. . N

-DOCSTART- -19371887- O O

Rapid JJ N
efficacy NN N
of IN N
the DT N
highly RB N
selective JJ N
alpha1A-adrenoceptor NN N
antagonist NN N
silodosin NN i
in IN N
men NNS p
with IN p
signs NNS p
and CC p
symptoms NNS p
of IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
: : p
pooled JJ N
results NNS N
of IN N
2 CD N
phase NN N
3 CD N
studies NNS N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
silodosin NN i
for IN N
treatment NN N
of IN N
benign JJ N
prostatic JJ N
hyperplasia NN N
symptoms NNS N
in IN N
2 CD N
randomized NNS N
, , N
placebo NN i
controlled VBD i
, , N
phase NN N
3 CD N
studies NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Men NNP p
50 CD p
years NNS p
or CC p
older JJR p
with IN p
an DT p
International NNP p
Prostate NNP p
Symptom NNP p
Score NNP p
of IN p
13 CD p
or CC p
greater JJR p
and CC p
peak JJ p
urinary JJ p
flow NN p
rate NN p
of IN p
4 CD p
to TO p
15 CD p
ml NNS p
per IN p
second JJ p
received VBN p
placebo NN i
or CC i
8 CD p
mg NNS p
silodosin JJ i
daily JJ p
with IN p
breakfast NN p
for IN p
12 CD p
weeks NNS p
. . p

The DT N
primary JJ N
end NN N
point NN N
was VBD N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
change NN N
from IN N
baseline NN N
to TO N
last JJ N
observation NN N
. . N

Change NN N
in IN N
peak NN o
urinary JJ o
flow NN o
rate NN o
was VBD N
a DT N
secondary JJ N
end NN N
point NN N
. . N

Differences NNS o
in IN o
treatment NN o
efficacy NN o
were VBD N
assessed VBN N
by IN N
ANCOVA NNP N
. . N

RESULTS NNP N
Of IN N
923 CD p
patients NNS p
( ( p
mean JJ p
age NN p
65 CD p
years NNS p
) ) p
466 CD p
received VBN p
silodosin NN p
and CC p
457 CD p
placebo NN p
. . p

After IN N
0.5 CD N
week NN N
( ( N
range VBP N
3 CD N
to TO N
4 CD N
days NNS N
) ) N
of IN N
treatment NN N
patients NNS N
receiving VBG N
silodosin NN i
vs NN N
placebo NN N
achieved VBD N
significant JJ N
improvement NN N
in IN N
total JJ o
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
( ( N
difference NN N
-1.9 NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
and CC N
irritative JJ o
( ( N
-0.5 JJ N
, , N
p JJ N
= NNP N
0.0002 CD N
) ) N
and CC N
obstructive JJ o
( ( N
-1.4 JJ N
, , N
p JJ N
< NNP N
0.0001 CD N
) ) N
subscores NNS N
. . N

The DT N
mean JJ N
+/- JJ N
SD NNP N
change NN N
from IN N
baseline NN N
in IN N
total JJ N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
was VBD N
-4.2 JJ N
+/- JJ N
5.3 CD N
for IN N
silodosin NN N
vs NN N
-2.3 VBD N
+/- JJ N
4.4 CD N
for IN N
placebo NN N
. . N

Differences NNS N
( ( N
silodosin JJ N
vs NN N
placebo NN N
) ) N
in IN N
International NNP o
Prostate NNP o
Symptom NNP o
Score NNP o
and CC N
subscores NNS N
increased VBN N
by IN N
week NN N
12 CD N
( ( N
p NN N
< RB N
0.0001 CD N
) ) N
. . N

Mean JJ N
change NN N
from IN N
baseline NN N
in IN N
peak JJ o
urinary JJ o
flow NN o
rate NN o
( ( N
ml FW N
per IN N
second NN N
) ) N
2 CD N
to TO N
6 CD N
hours NNS N
after IN N
initial JJ N
dose NN N
was VBD N
greater JJR N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
with IN N
silodosin NN N
( ( N
2.8 CD N
+/- JJ N
3.4 CD N
) ) N
than IN N
placebo NN N
( ( N
1.5 CD N
+/- JJ N
3.8 CD N
) ) N
. . N

Differences NNS N
remained VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
through IN N
week NN N
12 CD N
. . N

The DT N
most RBS N
common JJ N
treatment NN N
emergent JJ N
adverse JJ o
event NN o
was VBD N
( ( N
mostly RB N
mild VBN N
) ) N
retrograde NN o
ejaculation NN o
( ( N
silodosin JJ N
28.1 CD N
% NN N
of IN N
patients NNS N
, , N
placebo RB N
0.9 CD N
% NN N
) ) N
. . N

Few JJ N
patients NNS N
receiving VBG N
silodosin NN i
( ( N
2.8 CD N
% NN N
) ) N
discontinued VBN N
because IN N
of IN N
retrograde JJ o
ejaculation NN o
. . o

Proportions NNS N
of IN N
patients NNS N
with IN N
treatment NN N
emergent JJ N
orthostatic JJ o
hypotension NN o
were VBD N
similar JJ N
for IN N
silodosin NN N
( ( N
2.6 CD N
% NN N
) ) N
and CC N
placebo NN N
( ( N
1.5 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
silodosin NN N
produced VBN N
rapid JJ N
improvement NN N
in IN N
urinary JJ o
symptoms NNS o
that WDT N
was VBD N
sustained VBN N
for IN N
12 CD N
weeks NNS N
. . N

Silodosin NNP N
was VBD N
well RB N
tolerated VBN N
with IN N
a DT N
low JJ N
incidence NN N
of IN N
orthostatic JJ o
hypotension NN o
. . o

-DOCSTART- -21930490- O O

Side NNP N
branch NN N
occlusion NN N
with IN N
everolimus-eluting JJ i
and CC i
paclitaxel-eluting JJ i
stents NNS i
: : i
three-year JJ N
results NNS N
from IN N
the DT N
SPIRIT NNP N
III NNP N
randomised VBD N
trial NN N
. . N

AIMS NNP N
AND CC N
METHODS NNP N
The DT N
rates NNS N
of IN N
side NN N
branch NN N
occlusion NN N
and CC N
subsequent JJ N
periprocedural JJ N
MI NNP N
during IN N
everolimus-eluting JJ i
stent NN i
( ( i
EES NNP i
) ) i
and CC N
paclitaxel-eluting JJ i
stent NN i
( ( i
PES NNP i
) ) i
placement NN N
were VBD N
examined VBN N
in IN N
the DT N
randomised JJ N
SPIRIT NNP N
III NNP N
trial NN N
. . N

Periprocedural JJ N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
following VBG N
drug-eluting JJ N
stent JJ N
placement NN N
is VBZ N
associated VBN N
with IN N
long-term JJ N
adverse JJ N
outcomes NNS N
. . N

Occlusion NN N
of IN N
side NN N
branches NNS N
may MD N
be VB N
an DT N
important JJ N
factor NN N
contributing VBG N
to TO N
periprocedural JJ N
MIs NNP N
. . N

Consecutive JJ i
procedural JJ i
angiograms NNS i
of IN p
patients NNS p
randomly RB p
assigned VBN p
to TO p
EES NNP i
( ( p
n=669 NN p
) ) p
or CC i
PES NNP i
( ( p
n=333 RB p
) ) p
were VBD p
analysed VBN p
by IN p
an DT p
independent JJ p
angiographic JJ p
core NN p
laboratory NN p
. . p

Side NNP N
branch NN N
occlusion NN N
was VBD N
defined VBN N
as IN N
Thrombolysis NN N
In IN N
Myocardial NNP N
Infarction NNP N
( ( N
TIMI NNP N
) ) N
flow NN N
grade VBD N
0 CD N
or CC N
1 CD N
. . N

Clinical JJ N
outcomes NNS N
through IN N
three CD N
years NNS N
were VBD N
compared VBN N
by IN N
stent NN N
type NN N
and CC N
presence NN N
of IN N
side NN N
branch NN N
occlusion NN N
. . N

CONCLUSIONS VB N
A DT N
total NN N
of IN N
2,048 CD N
side NN N
branches NNS N
were VBD N
evaluated VBN N
( ( N
EES NNP N
N=1,345 NNP N
side NN N
branches NNS N
in IN N
688 CD N
stented JJ N
lesions NNS N
, , N
PES NNP N
N=703 NNP N
side NN N
branches NNS N
in IN N
346 CD N
stented JJ N
lesions NNS N
) ) N
. . N

Patients NNS N
with IN N
compared VBN N
to TO N
those DT N
without IN N
transient NN N
or CC N
final JJ N
side NN N
branch NN N
occlusion NN N
had VBD N
significantly RB N
higher JJR N
non-Q-wave JJ o
MI NNP o
( ( o
NQMI NNP o
) ) o
rates NNS o
in-hospital JJ N
( ( N
9.0 CD N
% NN N
vs. FW N
0.5 CD N
% NN N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

By IN N
multivariable JJ N
analysis NN N
side NN N
branch NN N
occlusion NN N
was VBD N
an DT N
independent JJ N
predictor NN N
of IN N
NQMI NNP o
( ( N
OR NNP N
4.45 CD N
; : N
95 CD N
% NN N
CI NNP N
[ NNP N
1.82 CD N
, , N
10.85 CD N
] NN N
) ) N
. . N

Transient NN N
or CC N
final JJ N
side NN N
branch NN N
occlusion NN N
occurred VBD N
less RBR N
frequently RB N
in IN N
patients NNS p
receiving VBG p
EES NNP p
compared VBN p
to TO p
PES NNP p
( ( N
2.8 CD N
% NN N
vs. FW N
5.2 CD N
% NN N
, , N
p=0.009 NN N
) ) N
, , N
contributing VBG N
to TO N
the DT N
numerically RB N
lower JJR N
rates NNS o
of IN o
in-hospital JJ o
NQMI NNP o
with IN N
EES NNP N
arm NN N
compared VBN N
to TO N
PES NNP N
( ( N
0.7 CD N
% NN N
vs. FW N
2.3 CD N
% NN N
, , N
p=0.05 NN N
) ) N
. . N

Patients NNS p
treated VBD p
with IN p
EES NNP i
rather RB p
than IN p
PES NNP i
were VBD N
less RBR N
likely JJ N
to TO N
develop VB N
side JJ o
branch NN o
occlusion NN o
during IN N
stent JJ N
placement NN N
, , N
contributing VBG N
to TO N
lower VB N
rates NNS N
of IN N
periprocedural JJ N
MI NNP N
with IN N
EES NNP i
compared VBN N
to TO N
PES NNP i
. . i

-DOCSTART- -20345030- O O

[ JJ N
Observation NNP N
of IN N
curative JJ N
effect NN N
on IN N
fixed-point NN N
spin NN N
reduction NN N
of IN N
spinal JJ i
manipulation NN i
therapy NN i
for IN N
cervical JJ p
vertigo NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
role NN N
of IN N
fixed-point JJ N
spin JJ N
reduction NN N
of IN N
spinal JJ i
manipulation NN i
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
cervical JJ p
vertigo NN p
and CC N
its PRP$ N
effect NN N
on IN N
cervical JJ N
artery NN N
spasm NN N
index NN N
( ( N
RI NNP N
) ) N
and CC N
atlantoaxial JJ N
displacement NN N
index NN N
( ( N
ADI NNP N
) ) N
. . N

METHODS NN N
From IN N
January NNP p
2002 CD p
to TO p
May NNP p
2008 CD p
, , p
168 CD p
patients NNS p
with IN p
cervical JJ p
vertigo NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
treatment NN p
group NN p
( ( p
84 CD p
cases NNS p
) ) p
and CC p
the DT p
control NN p
group NN p
( ( p
84 CD p
cases NNS p
) ) p
, , p
22 CD p
males NNS p
and CC p
62 CD p
females NNS p
in IN p
treatment NN p
group NN p
; : p
24 CD p
males NNS p
and CC p
60 CD p
females NNS p
in IN p
control NN p
group NN p
. . p

The DT N
patients NNS N
of IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
were VBD N
respectively RB N
treated VBN N
with IN N
fixed-point JJ i
spin NN i
reduction NN i
of IN i
spinal JJ i
manipulation NN i
therapy NN i
and CC i
dialectical JJ i
prescription NN i
. . i

The DT N
score NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
, , N
RI NNP N
, , N
ADI NNP N
were VBD N
observed VBN N
and CC N
compared VBN N
between IN N
two CD N
groups NNS N
. . N

RESULTS VB N
The DT N
score NN o
of IN o
symptoms NNS o
and CC o
signs NNS o
markedly RB N
decreased VBD N
after IN N
treatment NN N
, , N
in IN N
treatment NN N
group NN N
: : N
vertigo NN o
had VBD N
( ( N
2.75 CD N
+/- JJ N
1.01 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ o
pain NN o
( ( N
1.58 CD N
+/- JJ N
0.36 CD N
) ) N
, , N
headache NN o
( ( N
0.39 CD N
+/- JJ N
0.09 CD N
) ) N
, , N
nausea-vomiting JJ o
( ( N
1.58 CD N
+/- JJ N
1.30 CD N
) ) N
, , N
ear JJ o
noises NNS o
( ( N
0.48 CD N
+/- JJ N
0.32 CD N
) ) N
, , N
positive JJ o
neck NN o
rotation NN o
test NN o
( ( N
0.59 CD N
+/- JJ N
0.21 CD N
) ) N
; : N
and CC N
in IN N
control NN N
group NN N
: : N
vertigo NN o
had VBD N
( ( N
5.68 CD N
+/- JJ N
2.02 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ o
pain NN o
( ( N
3.12 CD N
+/- JJ N
1.82 CD N
) ) N
, , N
headache NN o
( ( N
1.86 CD N
+/- JJ N
0.65 CD N
) ) N
, , N
nausea-vomiting JJ o
( ( N
3.25 CD N
+/- JJ N
0.69 CD N
) ) N
, , N
ear JJ o
noises NNS o
( ( N
1.64 CD N
+/- JJ N
0.61 CD N
) ) N
, , N
positive JJ o
neck NN o
rotation NN o
test NN o
( ( N
1.79 CD N
+/- JJ N
0.67 CD N
) ) N
. . N

Cervical JJ o
artery NN o
spasm NN o
index NN o
and CC o
atlantoaxial JJ o
displacement NN o
index NN o
had VBD N
been VBN N
significantly RB N
improved VBN N
, , N
cervical JJ o
artery NN o
spasm NN o
index NN o
was VBD N
respectively RB N
0.54 CD N
+/- JJ N
0.07 CD N
and CC N
0.52 CD N
+/- JJ N
0.13 CD N
, , N
atlantoaxial JJ o
displacement NN o
index NN o
was VBD N
respectively RB N
2.92 CD N
+/- JJ N
0.82 CD N
and CC N
4.50 CD N
+/- JJ N
1.32 CD N
between IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
. . N

CONCLUSION NNP N
Fixed-point NNP N
spin NN N
reduction NN N
of IN N
spinal JJ i
manipulation NN i
therapy NN i
for IN N
cervical JJ p
vertigo NN p
can MD N
accurately RB N
correct VB N
single JJ N
or CC N
multiple JJ N
vertebral JJ p
body NN p
displacement NN p
, , N
restore VB N
normal JJ N
spinal JJ N
position NN N
, , N
reduce VB N
the DT N
oppression NN N
and CC N
stimulus NN N
of IN N
the DT N
vertebral JJ N
artery NN N
, , N
release NN N
ischemia NN N
of IN N
vestibular JJ N
labyrinth NN N
, , N
eliminate VB N
symptoms NNS N
of IN N
vertigo NN N
. . N

-DOCSTART- -7010854- O O

Clinical JJ N
evaluation NN N
of IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
metoprolol NN i
in IN N
combination NN N
with IN N
hydrochlorothiazide NN i
and CC N
hydralazine NN i
in IN N
an DT N
unselected JJ p
hypertensive JJ p
population NN p
. . p

One CD p
hundred VBD p
nineteen JJ p
patients NNS p
with IN p
essential JJ p
hypertension NN p
( ( p
96 CD p
completing VBG p
six CD p
months NNS p
and CC p
92 CD p
a DT p
one CD p
year NN p
study NN p
period NN p
) ) p
were VBD N
randomized VBN N
into IN N
four CD N
parallel NN N
groups NNS N
and CC N
treated VBN N
with IN N
one CD N
of IN N
four CD N
programs NNS N
: : N
200 CD i
mg NN i
of IN i
metoprolol JJ i
plus CC i
placebo NN i
; : i
200 CD i
mg NN i
of IN i
metoprolol NN i
plus CC i
25 CD i
mg NN i
of IN i
hydrochlorothiazide NN i
; : i
200 CD i
mg NN i
of IN i
metoprolol NN i
plus CC i
50 CD i
mg NN i
hydrochlorothiazide NN i
, , i
or CC i
; : i
200 CD i
mg NN i
metoprolol NN i
plus CC i
50 CD i
mg NN i
of IN i
hydralazine NN i
. . i

Blood NNP o
pressure NN o
reduction NN o
was VBD N
significant JJ N
in IN N
these DT N
all DT p
groups NNS p
and CC N
no DT N
differences NNS N
were VBD N
observed VBN N
in IN N
blood NN N
pressure NN N
reduction NN N
among IN N
the DT N
groups NNS N
. . N

During IN N
the DT N
one CD N
year NN N
therapy IN N
the DT N
levels NNS o
of IN o
serum NN o
bilirubin NN o
, , o
uric JJ o
acid NN o
and CC o
triglycerides NNS o
were VBD N
significantly RB N
increased VBN N
in IN N
all DT N
groups NNS N
but CC N
the DT N
group NN N
treated VBD N
with IN N
metoprolol NN i
and CC N
hydralazine NN i
. . i

Serum NNP o
cholesterol NN o
level NN o
did VBD N
not RB N
increase VB N
in IN N
any DT N
group NN N
during IN N
the DT N
one CD N
year NN N
therapy NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
combination NN N
therapy NN N
in IN N
mild NN o
to TO o
moderate VB o
hypertension NN o
should MD N
not RB N
be VB N
initiated VBN N
before IN N
individual JJ N
response NN N
to TO N
single JJ N
drug NN N
therapy NN N
is VBZ N
evaluated VBN N
. . N

Antihypertensive JJ N
drug NN N
treatment NN N
may MD N
cause VB N
some DT N
biochemical JJ N
changes NNS N
and CC N
those DT N
changes NNS N
seem VBP N
to TO N
be VB N
smallest JJS p
patients NNS p
treated VBN N
with IN N
combination NN N
of IN N
beta-blocker NN i
and CC N
hydralazine NN i
. . i

-DOCSTART- -22838229- O O

In IN N
vitro JJ N
biocompatibility NN N
tests NNS N
of IN N
glass NN N
ionomer NN N
cements NNS N
impregnated VBN N
with IN N
collagen NN N
or CC N
bioactive JJ N
glass NN N
to TO N
fibroblasts NNS N
. . N

AIM NNP N
AND CC N
DESIGN NNP N
To TO N
evaluate VB N
the DT N
biocompatibility NN N
of IN N
glass NN p
ionomer NN p
cement NN p
( ( N
GIC NNP N
) ) N
impregnated VBD N
with IN N
collagen NN N
or CC N
bioactive JJ N
glass NN N
to TO N
BHK-21 NNP N
fibroblasts NNS N
in IN N
vitro NN N
. . N

Mineral NNP N
Trioxide NNP N
Aggregate NNP N
was VBD N
used VBN N
as IN N
the DT N
standard NN N
for IN N
comparison NN N
. . N

Human NNP p
maxillary JJ p
central JJ p
incisors NNS p
( ( p
n JJ p
= NNP p
70 CD p
) ) p
were VBD N
instrumented VBN N
with IN N
a DT N
rotary JJ N
NiTi NNP N
system NN N
and CC N
filled VBN N
. . N

Following VBG N
resection NN N
of IN N
the DT N
apical JJ N
3mm CD N
, , N
root JJ p
end NN p
cavities NNS p
were VBD N
prepared JJ N
and CC N
restored VBN N
with IN N
conventional JJ i
GIC NNP i
( ( i
group NN i
1 CD i
) ) i
or CC i
GIC NNP i
with IN i
0.01 CD i
% NN i
, , i
0.1 CD i
% NN i
or CC i
1 CD i
% NN i
collagen NN i
( ( i
groups NNS i
2 CD i
, , i
3 CD i
, , i
4 CD i
respectively RB i
) ) i
or CC i
, , i
10 CD i
% NN i
, , i
30 CD i
% NN i
or CC i
50 CD i
% NN i
bioactive JJ i
glass NN i
( ( i
groups NNS i
5 CD i
, , i
6 CD i
, , i
7 CD i
respectively RB i
) ) i
, , i
or CC i
Mineral NNP i
Trioxide NNP i
Aggregate NNP i
( ( i
group NN i
8 CD i
) ) i
. . i

The DT N
root NN p
slices NNS p
were VBD N
incubated VBN N
in IN N
tissue NN N
culture NN N
plates VBZ N
with IN N
BHK-21 NNP N
fibroblast NN N
cell NN N
line NN N
. . N

Phase NNP N
contrast NN N
and CC N
scanning VBG N
electron NN N
microscopes NNS N
were VBD N
used VBN N
to TO N
score VB o
cell NN o
quantity NN o
, , o
morphology NN o
and CC o
cell NN o
attachment NN o
. . o

The DT N
data NNS N
were VBD N
statistically RB o
analyzed VBN o
by IN N
one CD N
way NN N
ANOVA NNP o
with IN o
Post NNP o
Hoc NNP o
Tukey NNP o
HSD NNP o
test NN o
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
AND NNP N
CONCLUSIONS NNP N
Group NNP N
5 CD N
showed VBD N
the DT N
highest JJS N
scores NNS N
which WDT N
was VBD N
significantly RB N
higher JJR N
than IN N
all DT N
other JJ N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
except IN N
group NN N
8 CD N
, , N
with IN N
which WDT N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Glass NNP N
ionomer JJ N
cement NN N
with IN N
10 CD N
% NN N
bioactive JJ N
glass NN N
showed VBD N
better JJR o
adhesion NN o
and CC o
spreading NN o
of IN o
cells NNS o
than IN N
glass NN N
ionomer NN N
cement NN N
with IN N
0.01 CD N
% NN N
collagen NN N
. . N

The DT N
biocompatibility NN o
of IN o
collagen NN o
and CC o
bioactive JJ o
glass NN o
was VBD N
concentration NN N
dependent NN N
. . N

The DT N
addition NN N
of IN N
bioactive JJ N
glass NN N
improved VBD o
the DT o
biocompatibility NN o
of IN o
glass NN o
ionomer NN o
cement NN o
to TO N
fibroblasts NNS N
better JJR N
than IN N
addition NN N
of IN N
collagen NN N
. . N

-DOCSTART- -21316048- O O

Anastrozole NNP i
single-dose JJ N
protocol NN N
in IN N
women NNS p
with IN p
oligo- JJ p
or CC p
anovulatory JJ p
infertility NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
phase NN N
II NNP N
dose-response NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
anastrozole NN i
and CC N
clomiphene NN i
citrate NN i
( ( i
CC NNP i
) ) i
on IN N
follicular NN o
development NN o
and CC o
ovulation NN o
in IN p
infertile JJ p
women NNS p
with IN p
ovulatory JJ p
dysfunction NN p
. . p

DESIGN NNP N
Phase NNP N
II NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
assessor-blind JJ N
, , N
multicenter NN N
, , N
dose-finding NN N
, , N
noninferiority NN N
study NN N
. . N

SETTING NNP N
Outpatient NNP N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Infertile NNP p
women NNS p
with IN p
ovulatory JJ p
dysfunction NN p
, , p
aged VBN p
18-35 CD p
years NNS p
, , p
and CC p
body NN p
mass NN p
index NN p
< VBD p
35 CD p
kg/m NN p
( ( p
2 CD p
) ) p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Single-dose JJ i
anastrozole NN i
at IN N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
20 CD N
mg NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
, , N
or CC N
30 CD N
mg NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
or CC N
a DT N
5-day JJ i
course NN i
of IN i
CC NNP i
at IN N
50 CD N
mg/d NN N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
as IN N
starting VBG N
doses NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
ovulation NN o
rate NN o
in IN N
the DT N
first JJ N
treatment NN N
cycle NN N
( ( N
cycle NN N
1 CD N
) ) N
. . N

Ovulation NN N
was VBD N
defined VBN N
as IN N
a DT N
midluteal JJ N
phase NN N
serum NN N
P NNP N
level NN N
? . N
10 CD N
ng/mL NN N
or CC N
clinical JJ N
pregnancy NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
In IN N
cycle NN N
1 CD N
the DT o
ovulation NN o
rates NNS o
for IN o
a DT N
single JJ N
dose NN N
of IN N
anastrozole NN i
at IN i
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
mg NNS N
were VBD N
46.2 CD N
% NN N
, , N
41.0 CD N
% NN N
, , N
23.1 CD N
% NN N
, , N
and CC N
28.9 CD N
% NN N
, , N
respectively RB N
, , N
whereas NNS N
that IN N
for IN N
CC NNP N
at IN N
50 CD N
mg/d NN N
was VBD N
61.5 CD N
% NN N
. . N

Among IN N
women NNS N
with IN N
fewer JJR N
than IN N
six CD N
menses NNS N
per IN N
year NN N
, , N
the DT o
cumulative JJ o
ovulation NN o
rates NNS o
over IN o
three CD N
cycles NNS N
were VBD N
comparable JJ N
in IN N
the DT i
anastrozole JJ i
5 CD i
mg NN N
( ( N
52.4 CD N
% NN N
) ) N
and CC N
CC $ N
50 CD N
mg/d NN N
( ( N
42.3 CD N
% NN N
) ) N
groups NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
In IN N
terms NNS N
of IN N
ovulation NN o
rates NNS o
in IN o
cycle NN N
1 CD N
, , N
single-dose JJ i
anastrozole NN i
at IN i
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
mg NN N
was VBD N
not RB N
as RB N
effective JJ N
as IN N
CC NNP N
at IN N
50 CD N
mg/d NN N
for IN N
5 CD N
days NNS N
( ( N
noninferiority NN N
was VBD N
not RB N
shown VBN N
) ) N
. . N

-DOCSTART- -21761341- O O

Increased VBN N
5?-reductase JJ o
type NN o
2 CD o
expression NN o
in IN p
human JJ p
breast NN p
carcinoma NN p
following VBG i
aromatase NN i
inhibitor NN i
therapy NN i
: : i
the DT N
correlation NN N
with IN o
decreased JJ o
tumor NN o
cell NN o
proliferation NN o
. . o

Tumor NNP o
cell NN o
proliferation NN o
and CC o
progression NN o
of IN o
breast NN o
cancer NN o
are VBP N
influenced VBN N
by IN N
female JJ N
sex NN N
steroids NNS N
. . N

However RB N
, , N
not RB N
all DT N
breast NN N
cancer NN N
patients NNS N
respond VBP N
to TO i
aromatase VB i
inhibitors NNS i
( ( i
AI NNP i
) ) i
, , i
and CC N
many JJ N
patients NNS N
become VBP N
unresponsive JJ N
or CC N
relapse NN N
. . N

Recent JJ N
studies NNS N
demonstrate VBP N
that IN N
not RB N
only RB N
estrogens VBZ N
but CC N
also RB N
androgens VBZ N
may MD N
serve VB N
as IN N
regulators NNS N
of IN N
estrogen-responsive JJ N
as RB N
well RB N
as IN N
estrogen-unresponsive JJ N
human JJ N
breast NN N
cancers NNS N
. . N

However RB N
, , N
the DT N
mechanism NN N
underlying VBG N
these DT N
androgenic JJ N
actions NNS N
has VBZ N
remained VBN N
relatively RB N
unknown JJ N
. . N

Therefore RB N
, , N
in IN N
this DT N
study NN N
, , N
we PRP N
evaluated VBD N
the DT o
effects NNS o
of IN N
AI NNP N
upon IN N
the DT o
expression NN o
of IN o
enzymes NNS o
involved VBN o
in IN o
intratumoral JJ o
androgen NN o
production NN o
including VBG o
17?-hydroxysteroid JJ o
dehydrogenase NN o
type NN o
5 CD o
( ( o
17?HSD5 CD o
) ) o
, , o
5?-reductase JJ o
types NNS o
1 CD o
and CC o
2 CD o
( ( o
5?Red1 CD o
and CC o
5?Red2 CD o
) ) o
as RB o
well RB o
as IN o
androgen NN o
receptor NN o
( ( o
AR NNP o
) ) o
levels NNS o
and CC o
correlated VBD o
the DT N
findings NNS o
with IN o
therapeutic JJ o
responses NNS o
including VBG o
Ki67 NNP o
labeling VBG o
index NN o
( ( o
Ki67 NNP o
) ) o
. . o

Eighty-two JJ o
postmenopausal NN p
invasive JJ p
ductal JJ p
carcinoma NN p
patients NNS p
were VBD p
enrolled VBN p
in IN p
CAAN NNP p
study NN p
from IN p
November NNP p
2001 CD p
to TO p
April NNP p
2004 CD p
. . p

Pre- JJ N
and CC N
post-treatment JJ N
specimens NNS N
of IN N
29 CD N
cases NNS N
were VBD N
available JJ N
for IN N
this DT N
study NN N
. . N

The DT N
status NN N
of IN o
17?HSD5 CD o
, , o
5?Red1 CD o
, , o
5?Red2 CD o
, , o
and CC o
Ki67 NNP o
in IN N
pre- JJ N
and CC N
post-treatment JJ N
specimens NNS N
were VBD N
evaluated VBN N
. . N

The DT N
significant JJ N
increments NNS o
of IN o
5?Red2 CD o
as RB o
well RB o
as IN o
AR NNP o
were VBD o
detected VBN N
in IN N
biological JJ N
response NN N
group NN N
whose WP$ o
Ki67 NNP o
LI NNP o
decreased VBN o
by IN N
more JJR N
than IN N
40 CD N
% NN N
of IN N
the DT N
pre-treatment JJ N
level NN N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
demonstrating VBG N
an DT N
increment NN N
of IN o
5?Red2 CD o
and CC o
AR NNP o
in IN o
the DT N
group NN N
of IN N
the DT N
patients NNS N
associated VBN N
with IN o
Ki67 NNP o
decrement NN N
following VBG N
AI NNP N
treatment NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
increased VBD o
5?Red2 CD o
and CC o
AR NNP o
following VBG o
AI NNP N
treatment NN N
may MD N
partly RB N
contribute VB N
to TO N
reduce VB N
the DT N
tumor NN N
cell NN N
proliferation NN N
through IN N
increasing VBG N
intratumoral JJ N
androgen NN N
concentrations NNS N
and CC N
its PRP$ N
receptor NN N
. . N

-DOCSTART- -23482762- O O

Satisfactory JJ N
sampling NN N
in IN N
cytological JJ p
cervical JJ p
diagnosis NN p
: : p
comparison NN N
between IN N
a DT N
conventional JJ i
and CC i
a DT i
new JJ i
sampling NN i
device NN i
. . i

AIM NNP N
Inadequate NNP N
cervical JJ N
sampling NN N
is VBZ N
the DT N
most RBS N
frequent JJ N
cause NN N
of IN N
misdiagnosis NN N
in IN N
cervical JJ p
cancer NN p
screening NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
ability NN N
of IN N
PapCone? NNP i
versus IN i
the DT i
conventional JJ i
sampling NN i
method NN i
( ( i
Ayre NNP i
's POS i
spatula NN i
plus CC i
cytobrush NN i
) ) i
to TO N
collect VB N
ectocervical JJ N
and CC N
glandular JJ N
cells NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN p
18 CD p
healthy JJ p
women NNS p
, , p
two CD p
ecto-endocervical JJ p
samples NNS p
, , p
obtained VBN p
by IN p
two CD p
different JJ p
methods NNS p
, , p
were VBD p
obtained VBN p
at IN p
a DT p
three-month JJ p
interval NN p
. . p

Qualitative JJ N
and CC N
quantitative JJ N
parameters NNS N
were VBD N
evaluated VBN N
. . N

Ultrastructure NN o
features NNS o
of IN o
sampling VBG o
devices NNS o
were VBD N
analyzed VBN N
by IN N
scanning VBG N
electron NN N
microscopy NN N
( ( N
SEM NNP N
) ) N
before IN N
and CC N
after IN N
sampling VBG N
. . N

RESULTS VB N
The DT N
? . N
( ( N
2 CD N
) ) N
test NN N
revealed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
: : N
PapCone? NNP N
caused VBD N
less JJR o
cell NN o
overlap NN o
and CC o
sampled VBD N
less JJR o
white JJ o
blood NN o
cells NNS o
( ( o
p JJ o
< NNP N
0.05 CD N
) ) N
and CC N
more RBR o
metaplastic JJ o
cells NNS o
( ( o
p JJ o
< NNP N
0.01 CD N
) ) N
. . N

SEM NNP N
evaluation NN o
highlighted VBD o
the DT N
porous JJ N
and CC N
spongy JJ N
structure NN N
of IN N
PapCone? NNP N
that WDT N
was VBD N
responsible JJ N
for IN N
the DT N
large JJ N
number NN N
of IN N
glandular JJ N
cells NNS N
on IN N
its PRP$ N
surface NN N
. . N

CONCLUSION NNP N
Cervical NNP N
smears NNS N
performed VBN N
by IN N
PapCone? NNP N
were VBD N
adequate JJ N
and CC N
generally RB N
easier JJR N
to TO N
screen VB N
than IN N
conventionally RB N
performed VBN N
ones NNS N
. . N

-DOCSTART- -25580916- O O

N-acetylcysteine NNP i
as IN N
an DT N
adjunctive JJ i
therapy NN i
to TO N
risperidone VB i
for IN N
treatment NN N
of IN N
irritability NN N
in IN p
autism NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
efficacy NN N
and CC N
safety NN N
. . N

OBJECTIVES NNP N
According VBG N
to TO N
the DT N
proposed VBN N
interference NN N
of IN N
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
with IN N
pathophysiologic JJ N
processes NNS N
of IN N
autistic JJ N
disorders NNS N
( ( N
ADs NNP N
) ) N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT o
effectiveness NN o
and CC o
safety NN o
of IN N
NAC NNP i
as IN N
an DT N
adjunct NN N
to TO N
risperidone VB i
in IN N
the DT N
treatment NN N
of IN N
ADs NNP N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
. . N

METHODS NNP N
The DT N
participants NNS p
were VBD p
referred VBN p
outpatients NNS p
between IN p
4 CD p
and CC p
12 CD p
years NNS p
of IN p
age NN p
with IN p
the DT p
diagnosis NN p
of IN p
ADs NNP p
and CC p
a DT p
score NN p
of IN p
more JJR p
than IN p
12 CD p
on IN p
Aberrant JJ o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Irritability NNP o
subscale NN o
score NN o
. . o

The DT N
participants NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ i
plus CC i
NAC NNP i
, , N
and CC N
the DT N
other JJ N
group NN N
received VBD N
risperidone JJ i
plus CC i
placebo NN i
. . i

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
NAC NNP i
was VBD N
600 CD N
to TO N
900 CD N
mg/d NN N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
mean JJ o
decrease NN o
in IN o
the DT o
ABC-C NNP o
irritability NN o
subscale NN o
score NN o
from IN N
baseline NN N
at IN N
5 CD N
and CC N
10 CD N
weeks NNS N
. . N

Changes NNS o
in IN o
other JJ o
subscales NNS o
were VBD N
considered VBN N
as IN N
secondary JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
Forty NNP p
patients NNS p
completed VBD p
the DT p
10-week JJ p
trial NN p
. . p

Baseline NNP N
characteristics NNS N
including VBG N
age NN o
, , o
sex NN o
and CC o
body NN o
weight NN o
, , N
as RB N
well RB N
as IN N
baseline NN o
scores NNS o
in IN N
5 CD N
subscales NNS o
did VBD N
not RB N
demonstrate VB N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Repeated-measures NNS N
analysis NN N
showed VBD N
significant JJ N
effect NN o
for IN N
time NN N
? . N
treatment NN N
interaction NN N
in IN o
irritability NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
and CC o
hyperactivity/noncompliance NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
subscales NNS N
. . N

By IN N
week NN N
10 CD N
, , N
the DT i
NAC NNP i
group NN N
showed VBD N
significantly RB N
more JJR o
reduction NN o
in IN o
irritability NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC o
hyperactivity/noncompliance NN o
( ( N
P NNP N
= NNP N
0.01 CD o
) ) o
subscales NNS o
scores NNS o
. . o

CONCLUSIONS NNP i
N-acetylcysteine JJ i
can MD N
be VB N
considered VBN N
as IN N
an DT N
adjuvant JJ N
therapy NN N
for IN N
ADs NNP N
with IN N
beneficial JJ o
therapeutic JJ o
outcomes NNS o
. . o

-DOCSTART- -12541005- O O

A DT N
pilot NN N
randomised VBN N
control NN N
trial NN N
of IN N
a DT N
parent NN i
training NN i
intervention NN i
for IN N
pre-school JJ p
children NNS p
with IN p
autism NN p
. . p

Preliminary JJ N
findings NNS N
and CC N
methodological JJ N
challenges NNS N
. . N

Few JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
conduct VB N
randomised VBN N
control NN N
trials NNS N
( ( N
RCTs NNP N
) ) N
of IN N
interventions NNS N
for IN N
pre-school JJ p
children NNS p
with IN p
autism NN p
. . p

We PRP N
report VBP N
findings NNS N
of IN N
a DT N
pilot NN N
RCT NNP N
for IN N
a DT N
parent NN i
training NN i
intervention NN i
with IN N
a DT N
focus NN N
on IN N
the DT N
development NN N
of IN N
joint JJ N
attention NN N
skills NNS N
and CC N
joint JJ N
action NN N
routines NNS N
. . N

Twenty-four CD p
children NNS p
meeting VBG p
ICD-10 NNP p
criteria NNS p
for IN p
childhood NN p
autism NN p
( ( p
mean JJ p
age NN p
= VBD p
23 CD p
months NNS p
) ) p
were VBD N
identified VBN N
using VBG N
the DT N
CHAT NNP i
screen NN i
and CC i
randomised VBD i
to TO i
the DT i
parent NN i
training VBG i
group NN i
or CC i
to TO i
local JJ i
services NNS i
only RB i
. . i

A DT N
follow-up NN N
was VBD N
conducted VBN N
12 CD N
months NNS N
later RB N
( ( N
mean JJ N
age NN N
= VBD N
35 CD N
months NNS N
) ) N
. . N

There EX N
was VBD N
some DT N
evidence NN N
that IN N
the DT N
parent NN p
training NN p
group NN p
made VBD N
more JJR N
progress NN N
in IN N
language NN o
development NN o
than IN N
the DT N
local JJ N
services NNS N
group NN N
. . N

However RB N
, , N
the DT N
present JJ N
pilot NN N
study NN N
was VBD N
compromised VBN N
by IN N
several JJ N
factors NNS N
: : N
a DT N
reliance NN N
on IN N
parental JJ N
report NN N
to TO N
measure VB N
language NN N
, , N
non-matching NN N
of IN N
the DT N
groups NNS N
on IN N
initial JJ N
IQ NNP N
, , N
and CC N
a DT N
lack NN N
of IN N
systematic JJ N
checking NN N
regarding VBG N
the DT N
implementation NN N
of IN N
the DT N
parent NN N
training NN N
intervention NN N
. . N

Furthermore RB N
, , N
three CD p
parents NNS p
in IN p
the DT p
local JJ p
services NNS p
group NN p
commenced VBD N
intensive JJ N
, , N
home-based JJ i
behavioural JJ i
intervention NN i
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

The DT N
difficulties NNS N
encountered VBN N
in IN N
the DT N
conduct NN N
of IN N
RCTs NNP N
for IN N
pre-school JJ p
children NNS p
with IN p
autism NN p
are VBP N
discussed VBN N
. . N

Methodological JJ N
challenges NNS N
and CC N
strategies NNS N
for IN N
future JJ N
well-designed JJ N
RCTs NNP N
for IN N
autism NN N
interventions NNS N
are VBP N
highlighted VBN N
. . N

-DOCSTART- -2644391- O O

The DT N
effectiveness NN N
of IN N
single-dose JJ N
metronidazole JJ i
therapy NN N
for IN N
patients NNS p
and CC p
their PRP$ p
partners NNS p
with IN p
bacterial JJ p
vaginosis NN p
. . p

A DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
clinical JJ N
trial NN N
was VBD N
performed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
2-g JJ N
single JJ N
dose NN N
of IN N
metronidazole NN i
for IN N
male JJ p
partners NNS p
of IN p
women NNS p
with IN p
bacterial JJ p
vaginosis NN p
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
improving VBG N
cure NN N
rate NN N
and CC N
decreasing VBG N
recurrence NN N
rate NN N
. . N

In IN N
addition NN N
, , N
the DT N
effectiveness NN N
of IN N
a DT N
2-g JJ N
single JJ i
dose NN i
of IN i
metronidazole NN i
was VBD N
compared VBN N
with IN N
a DT N
seven-day JJ i
course NN i
of IN i
500 CD i
mg NN i
of IN i
metronidazole JJ i
twice NN N
a DT N
day NN N
in IN N
patients NNS p
with IN p
bacterial JJ p
vaginosis NN p
. . p

Statistically NNP N
significant JJ N
benefits NNS N
of IN N
partner NN N
treatment NN N
were VBD N
noted VBN N
in IN N
the DT N
initial JJ N
cure NN N
rate NN N
by IN N
Gram-stained JJ N
smear JJ N
criteria NNS N
( ( N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
and CC N
in IN N
percentage NN N
of IN N
women NNS N
with IN N
symptoms NNS N
eight CD N
weeks NNS N
after IN N
initiating VBG N
therapy NN N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
) ) N
. . N

The DT N
seven-day JJ N
course NN N
of IN N
metronidazole NN N
was VBD N
superior JJ N
to TO N
the DT N
single-dose JJ N
regimen NNS N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
clue JJ N
cells NNS N
and CC N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
a DT N
positive JJ N
sniff NN N
test NN N
at IN N
the DT N
first JJ N
follow-up JJ N
visit NN N
; : N
however RB N
, , N
differences NNS N
in IN N
the DT N
initial JJ o
cure NN o
rate NN o
assessed VBN o
by IN o
clinical JJ o
criteria NNS o
and CC o
Gram-stained JJ o
smear JJ o
criteria NNS o
were VBD N
not RB N
statistically RB N
significant JJ N
between IN N
the DT N
two CD N
patient NN N
treatment NN N
regimens NNS N
. . N

Recurrence NN o
rates NNS o
by IN o
Gram-stained JJ o
smear JJ o
criteria NNS o
between IN N
patient NN N
and CC N
partner NN N
treatment NN N
groups NNS N
at IN N
five CD N
and CC N
eight CD N
weeks NNS N
after IN N
initiation NN N
of IN N
treatment NN N
were VBD N
also RB N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
patient NN N
regimens NNS N
. . N

Single-dose JJ N
metronidazole JJ i
treatment NN N
of IN N
the DT N
sexual JJ p
partner NN p
of IN p
women NNS p
with IN p
bacterial JJ p
vaginosis NN p
improves VBZ N
initial JJ N
bacterial JJ o
vaginosis NN o
cure NN o
rates NNS o
. . o

The DT N
seven-day JJ N
course NN N
of IN N
metronidazole NN N
was VBD N
not RB N
found VBN N
by IN N
statistical JJ N
analysis NN N
to TO N
be VB N
significantly RB N
superior JJ N
to TO N
single-dose JJ N
therapy NN N
when WRB N
considering VBG N
initial JJ N
cure NN N
rates NNS N
by IN N
clinical JJ N
or CC N
Gram-stained JJ N
smear JJ N
criteria NNS N
or CC N
recurrence NN N
rates NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -24263699- O O

Differences NNS N
in IN N
vision NN N
between IN N
clinic JJ N
and CC N
home NN N
and CC N
the DT N
effect NN N
of IN N
lighting VBG N
in IN N
older JJR p
adults NNS p
with IN p
and CC p
without IN p
glaucoma NN p
. . p

IMPORTANCE JJ N
Patients NNS N
often RB N
report VBP N
greater JJR N
visual JJ N
difficulties NNS N
at IN N
home NN N
than IN N
expected VBN N
from IN N
vision NN N
testing VBG N
in IN N
the DT N
clinic NN N
. . N

Such JJ N
discordance NN N
may MD N
be VB N
owing VBG N
to TO N
worse VB N
vision NN N
in IN N
the DT N
home NN N
than IN N
measured VBN N
in IN N
clinic NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
vision NN o
measured VBN N
between IN N
the DT N
clinic NN N
and CC N
home NN N
and CC N
evaluate JJ N
factors NNS N
, , N
including VBG N
lighting NN N
, , N
associated VBN N
with IN N
these DT N
differences NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
cross-sectional JJ N
study NN N
conducted VBN p
from IN p
2005-2009 CD p
involved JJ p
126 CD p
patients NNS p
with IN p
glaucoma NN p
and CC p
49 CD p
without IN p
glaucoma NN p
recruited VBN p
from IN p
the DT p
Glaucoma NNP p
and CC p
Comprehensive NNP p
Eye NNP p
Clinics NNP p
at IN p
Washington NNP p
University NNP p
, , p
St NNP p
Louis NNP p
, , p
Missouri NNP p
. . p

Patients NNPS N
underwent JJ N
clinic JJ N
and CC N
home NN N
visits NNS N
, , N
were VBD N
aged VBN p
55 CD p
to TO p
90 CD p
years NNS p
, , N
were VBD N
consecutively RB N
recruited VBN N
, , N
and CC N
met VBD N
inclusion NN N
criteria NNS N
for IN N
this DT N
study NN N
. . N

A DT p
total NN p
of IN p
166 CD p
eligible JJ p
patients NNS p
refused VBD p
participation NN p
. . p

EXPOSURE NNP N
Participants NNPS i
underwent JJ i
clinic NN i
and CC i
home NN i
visits NNS i
randomized VBN N
to TO N
order NN N
of IN N
completion NN N
. . N

At IN i
each DT i
visit NN i
, , i
masked VBN i
and CC i
certified VBN i
examiners NNS i
measured VBD i
binocular JJ o
distance NN o
visual JJ o
acuity NN o
( ( o
DVA NNP o
) ) o
with IN o
a DT o
nonbacklit JJ o
chart NN o
, , o
near IN o
visual JJ o
acuity NN o
( ( o
NVA NNP o
) ) o
, , o
contrast JJ o
sensitivity NN o
( ( o
CS NNP o
) ) o
, , o
CS NNP o
with IN o
glare NN o
, , o
and CC o
lighting VBG o
. . o

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Differences NNP o
in IN o
vision NN o
between IN o
the DT o
clinic NN o
and CC o
home NN o
. . o

RESULTS VB N
The DT N
mean JJ N
scores NNS N
for IN N
all DT o
vision NN o
tests NNS o
were VBD o
significantly RB o
better RBR o
in IN N
the DT N
clinic NN N
than IN N
home NN N
for IN N
participants NNS N
with IN N
and CC N
without IN N
glaucoma NN N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
matched-pair JJ N
t NN N
tests NNS N
) ) N
. . N

For IN N
DVA NNP N
, , N
29 CD N
% NN N
of IN N
participants NNS N
with IN N
glaucoma NN N
read VBP o
2 CD o
or CC o
more JJR o
lines NNS o
better RBR o
in IN N
the DT N
clinic NN N
than IN N
home NN N
and CC N
39 CD N
% NN N
with IN N
advanced JJ N
glaucoma NN N
read VBD N
3 CD N
or CC N
more JJR N
lines NNS N
better RBR N
. . N

For IN N
the DT N
entire JJ N
sample NN N
, , N
21 CD N
% NN N
of IN N
participants NNS N
read VBP o
2 CD o
or CC o
more JJR o
lines NNS o
better RBR N
in IN N
the DT N
clinic NN N
than IN N
home NN N
for IN N
NVA NNP N
and CC N
49 CD N
% NN N
read JJ N
2 CD N
or CC N
more JJR N
triplets NNS N
better RBR N
in IN N
the DT N
clinic NN N
for IN N
CS NNP N
with IN N
glare NN N
. . N

Lighting NNP N
was VBD N
the DT N
most RBS N
significant JJ N
factor NN N
associated VBN N
with IN N
differences NNS N
in IN N
vision NN N
between IN N
the DT N
clinic NN N
and CC N
home NN N
for IN N
DVA NNP o
, , o
NVA NNP o
, , o
and CC o
CS NNP o
with IN N
glare NN N
testing VBG N
( ( N
P NNP N
< NNP N
.05 NNP N
, , N
multiple JJ N
regression NN N
model NN N
) ) N
. . N

Median JJ o
home NN o
lighting NN o
was VBD N
4.3 CD N
times NNS N
and CC N
2.8 CD N
times NNS N
lower JJR N
than IN N
clinic JJ N
lighting NN N
in IN N
areas NNS N
tested VBN N
for IN N
DVA NNP N
and CC N
NVA NNP N
, , N
respectively RB N
. . N

Home NNP o
lighting NN o
was VBD N
below IN N
that DT N
recommended VBD N
in IN N
85 CD N
% NN N
or CC N
greater JJR N
of IN N
participants NNS N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
Vision NNP o
measured VBD N
in IN N
the DT N
clinic NN N
is VBZ N
generally RB N
better JJR N
than IN N
vision NN N
measured VBN N
at IN N
home NN N
, , N
with IN N
differences NNS N
mainly RB N
owing VBG N
to TO N
poor JJ N
home NN N
lighting NN N
. . N

Knowledge NNP N
that IN N
vision NN N
discrepancies NNS N
between IN N
patient JJ N
report NN N
and CC N
clinical JJ N
testing NN N
may MD N
be VB N
owing VBG N
to TO N
home NN N
lighting NN N
may MD N
initiate VB N
clinician-patient JJ N
discussions NNS N
to TO N
optimize VB N
home NN N
lighting NN N
and CC N
improve VB N
the DT N
vision NN N
of IN N
older JJR p
adults NNS p
in IN N
their PRP$ N
homes NNS N
. . N

-DOCSTART- -19590075- O O

Preparation NN N
and CC N
immune JJ N
activity NN N
analysis NN N
of IN N
H5N1 NNP p
subtype NN p
avian JJ p
influenza NN p
virus NN p
recombinant JJ p
protein-based JJ p
vaccine NN p
. . p

Avian JJ N
influenza NN N
is VBZ N
a DT N
severe JJ N
disease NN N
among IN N
farmed JJ p
poultry NN p
and CC p
free-living JJ p
birds NNS p
and CC N
a DT N
constant JJ N
threat NN N
to TO N
the DT N
commercial JJ p
chicken NN p
industry NN p
around IN N
the DT N
world NN N
. . N

Hemagglutinin NNP N
( ( N
HA NNP N
) ) N
is VBZ N
the DT N
major JJ N
immunogen NN N
on IN N
the DT N
envelope NN N
of IN N
influenza NN N
A NNP N
virus NN N
and CC N
is VBZ N
the DT N
predominant JJ N
inducer NN N
of IN N
neutralizing VBG N
antibody NN N
. . N

To TO N
obtain VB N
the DT N
bioactive JJ N
antigen NN N
proteins NNS N
in IN N
large JJ N
quantities NNS N
, , N
a DT N
new JJ N
protein NN N
expression NN N
vector NN N
pBCX NN N
was VBD N
constructed VBN N
, , N
which WDT N
is VBZ N
based VBN N
on IN N
the DT N
pET32a NN N
vector NN N
. . N

The DT N
HA NNP N
gene NN N
of IN N
the DT N
H5N1 NNP N
subtype NN N
of IN N
avian JJ N
influenza NN N
virus NN N
( ( N
AIV NNP N
) ) N
was VBD N
inserted VBN N
into IN N
the DT N
pBCX NN p
vector NN p
and CC N
expressed VBD N
efficiently RB N
in IN N
Escherichia NNP N
coli NN N
BL21 NNP N
( ( N
DE3 NNP N
) ) N
. . N

Fused VBN N
expression NN N
of IN N
the DT N
exogenous JJ N
gene NN N
and CC N
msyB NN N
produced VBD N
a DT N
97-kDa JJ N
msyB-HA JJ N
fusion NN N
protein NN N
. . N

Sodium NNP i
dodecyl VBZ i
sulfate-PAGE NN i
combined VBN i
with IN i
scanning VBG i
analysis NN i
demonstrated VBD N
that IN N
the DT N
msyB-HA JJ N
fusion NN N
protein NN N
accounted VBD N
for IN N
29.5 CD N
% NN N
of IN N
the DT N
total JJ N
bacterial JJ N
protein NN N
, , N
90.5 CD N
% NN N
being VBG N
soluble JJ N
. . N

The DT N
msyB-HA JJ N
fusion NN N
protein NN N
was VBD N
purified VBN N
with IN N
nondenaturing VBG N
50 CD N
% NN N
Ni-NTA JJ N
column NN N
chromatography NN N
, , N
and CC N
the DT N
result NN N
showed VBD N
that IN N
24 CD N
mg NN N
of IN N
purified JJ N
msyB-HA JJ N
fusion NN N
protein NN N
could MD N
be VB N
obtained VBN N
from IN N
1 CD N
L NNP N
of IN N
induced JJ N
expression NN N
bacterial JJ N
culture NN N
medium NN N
. . N

The DT N
comparative JJ N
results NNS N
in IN N
the DT N
present JJ N
study NN N
showed VBD N
that IN N
pBCX NN N
was VBD N
superior JJ N
to TO N
pET32a VB N
as IN N
a DT N
protein NN N
expression NN N
vector NN N
. . N

Western JJ N
blotting NN N
showed VBD N
the DT N
recombinant JJ N
msyB-HA NN N
( ( N
rHA NN N
) ) N
to TO N
have VB N
better JJR N
antigenic JJ o
activity NN o
, , N
which WDT N
may MD N
be VB N
the DT N
result NN N
from IN N
the DT N
better JJR N
posttranslation NN N
protein NN N
modification NN N
and CC N
folding NN N
in IN N
the DT N
pBCX NN N
expression NN N
system NN N
. . N

With IN N
the DT N
rHA NN N
fusion NN N
protein NN N
as IN N
antigen NN N
, , N
we PRP N
successfully RB N
prepared VBD N
and CC N
screened VBD N
specific JJ N
monoclonal JJ N
antibodys NN N
against IN N
the DT N
H5N1 NNP N
subtype NN N
AIV NNP N
, , N
which WDT N
indicated VBD N
that IN N
the DT N
rHA NN N
had VBD N
antigen VBN N
epitopes NNS N
and CC N
biofunctions NNS N
. . N

The DT N
immune JJ N
test NN N
confirmed VBD N
that IN N
the DT N
rHA NN N
protein NN N
vaccine NN N
could MD N
also RB N
induce VB N
high JJ N
neutralizing NN N
antibodies NNS N
, , N
and CC N
the DT N
AIV NNP N
challenge NN N
test NN N
proved VBD N
that IN N
the DT N
rHA JJ N
protein-based JJ N
vaccine NN N
could MD N
prevent VB N
the DT N
corresponding JJ N
infection NN N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
the DT N
recombinant JJ N
HA NNP N
protein NN N
produced VBN N
by IN N
the DT N
pBCX NN N
expression NN N
system NN N
could MD N
be VB N
used VBN N
as IN N
a DT N
recombinant JJ N
protein-based JJ N
vaccine NN N
and CC N
has VBZ N
potential NN N
for IN N
further JJ N
development NN N
for IN N
diagnosis NN N
. . N

-DOCSTART- -8104273- O O

Citalopram NNP i
for IN N
post-stroke JJ N
pathological JJ N
crying NN N
. . N

Post-stroke NNP N
pathological JJ N
crying NN N
is VBZ N
a DT N
distressing VBG N
condition NN N
in IN N
which WDT N
episodes VBZ N
occur VBP N
in IN N
response NN N
to TO N
minor VB N
stimuli NNS N
without IN N
associated VBN N
mood NN N
changes NNS N
. . N

There EX N
is VBZ N
preliminary JJ N
evidence NN N
of IN N
disturbed JJ N
serotoninergic JJ N
neurotransmission NN N
in IN N
such JJ N
cases NNS N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
the DT N
selective JJ o
serotonin NN o
reuptake NN o
inhibitor NN o
citalopram NN o
on IN N
uncontrolled JJ o
crying NN o
in IN N
stroke NN p
patients NNS p
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

16 CD p
consecutive JJ p
patients NNS p
( ( p
median JJ p
age NN p
58.5 CD p
years NNS p
, , p
range VB p
40-83 JJ p
) ) p
entered VBD N
the DT N
9-week JJ i
study NN i
a DT i
median NN i
of IN i
168 CD i
days NNS i
( ( i
range VB i
6-913 NNP i
) ) i
post NN i
stroke NN i
and CC i
were VBD i
treated VBN i
with IN i
citalopram JJ i
10-20 JJ i
mg NNS i
daily RB i
for IN i
3 CD i
weeks NNS i
. . i

Crying VBG o
history NN o
was VBD i
determined VBN i
from IN i
semistructured VBN i
interviews NNS i
and CC i
from IN i
diaries NNS i
kept VBN i
by IN i
the DT i
patients NNS i
. . i

Psychiatric NNP o
assessment NN o
was VBD N
made VBN N
with IN N
the DT N
Hamilton NNP o
depression NN o
scale NN o
( ( N
HDS NNP N
) ) N
, , N
and CC N
unwanted JJ o
effects NNS o
were VBD N
measured VBN N
with IN N
the DT N
UKU NNP o
side-effect JJ o
scale NN o
. . o

In IN N
13 CD p
patients NNS p
in IN p
whom WP p
frequency NN o
of IN o
crying NN o
could MD N
be VB N
assessed VBN N
, , N
the DT N
number NN o
of IN o
daily JJ o
crying VBG o
episodes NNS o
decreased VBN N
by IN N
at IN N
least JJS N
50 CD N
% NN N
in IN N
all DT N
cases NNS N
during IN N
citalopram JJ N
treatment NN N
vs NN N
2 CD N
patients NNS N
during IN N
placebo JJ N
treatment NN N
( ( N
p JJ N
< NN N
0.005 CD N
, , N
McNemar NNP N
's POS N
test NN N
) ) N
, , N
the DT N
effect NN N
being VBG N
rapid JJ N
( ( N
1-3 JJ N
days NNS N
) ) N
and CC N
pronounced VBN N
in IN N
11 CD N
( ( N
73 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
a DT N
concomitant JJ N
significant JJ N
decrease NN o
in IN o
depression NN o
rating NN o
from IN N
HDS NNP N
8.9 CD N
to TO N
5.3 CD N
( ( N
p NN N
< VBZ N
0.005 CD N
, , N
Wilcoxon NNP N
's POS N
test NN N
) ) N
. . N

Citalopram NNP N
was VBD N
well RB N
tolerated VBN N
, , N
the DT N
few JJ N
side-effects NNS N
being VBG N
mild JJ N
and CC N
transient JJ N
. . N

We PRP N
conclude VBP N
that IN N
serotoninergic JJ N
neurotransmission NN N
plays VBZ N
an DT N
important JJ N
part NN N
in IN N
post-stroke JJ N
pathological JJ N
crying NN N
and CC N
that DT N
citalopram NN i
is VBZ N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
. . N

-DOCSTART- -21512834- O O

Brief JJ N
report NN N
: : N
mediation NN N
of IN N
treatment NN N
effect NN N
in IN N
a DT N
communication NN N
intervention NN N
for IN N
pre-school JJ p
children NNS p
with IN p
autism NN p
. . p

Tests NNS N
of IN N
mediation NN N
in IN N
treatment NN N
trials NNS N
can MD N
illuminate VB N
processes NNS N
of IN N
change NN N
and CC N
suggest NN N
causal NN N
influences NNS N
in IN N
development NN N
. . N

We PRP N
conducted VBD N
a DT N
mediation NN N
analysis NN N
of IN N
a DT N
previously RB N
published VBN N
randomised VBN N
controlled JJ N
trial NN N
of IN N
parent-mediated JJ i
communication-focused JJ i
treatment NN i
for IN N
autism NN p
against IN p
ordinary JJ p
care NN p
, , p
with IN p
28 CD p
children NNS p
aged VBN p
2-5 CD p
years NNS p
( ( N
Aldred NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Child NNP N
Psychol NNP N
Psychiatr NNP N
45:1-11 CD N
, , N
2004 CD N
) ) N
. . N

The DT N
hypothesised JJ N
mediating NN N
process NN N
, , N
targeted VBN N
by IN N
the DT N
intervention NN N
, , N
was VBD N
an DT N
increase NN N
in IN o
parental JJ o
synchronous JJ o
response NN o
within IN o
parent-child JJ o
interaction NN o
. . o

The DT N
results NNS N
showed VBD o
partial JJ o
mediation NN o
, , o
with IN N
change NN N
in IN o
synchrony NN o
accounting NN o
for IN N
34 CD N
% NN N
of IN N
the DT N
positive JJ N
intervention NN N
effect NN N
on IN N
autism NN N
symptomatology NN N
( ( N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
communication NN N
and CC N
social JJ N
domain NN N
algorithm NN N
) ) N
; : N
the DT N
result NN N
was VBD N
confirmed VBN N
by IN N
bootstrap NN N
estimation NN N
. . N

Improved VBN o
parental JJ o
synchronous JJ o
response NN o
to TO N
child VB N
communication NN N
can MD N
alter VB N
short-term JJ N
autism NN N
symptom VBZ N
outcome RP N
with IN N
targeted JJ N
therapy NN N
. . N

-DOCSTART- -8787364- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
acellular JJ i
diphtheria NN i
, , i
pertussis NN i
and CC i
tetanus NN i
vaccines NNS o
in IN N
southern JJ p
Ghana NNP p
. . p

A NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
acellular JJ i
diphtheria/pertussis/tetanus NN i
( ( i
ADPT NNP i
) ) i
freeze-dried JJ i
and CC i
liquid JJ i
vaccines NNS i
in IN p
infants NNS p
was VBD p
conducted VBN p
in IN p
a DT p
peri-urban JJ p
community NN p
( ( p
Ashaiman NNP p
) ) p
in IN p
southern JJ p
Ghana NNP p
. . p

Immunogenicity NNP o
of IN N
the DT N
acellular JJ N
vaccines NNS N
, , N
persistence NN N
of IN N
antibodies NNS N
and CC N
adverse JJ N
reactions NNS N
were VBD N
compared VBN N
with IN N
those DT N
achieved VBN N
with IN N
a DT N
whole-cell JJ i
diphtheria-pertussis-tetanus NN i
( ( i
DPT NNP i
) ) i
vaccine NN i
. . i

The DT N
incidence NN N
of IN N
pertussis NN N
in IN N
the DT N
vaccine NN N
groups NNS N
and CC N
prevalence NN N
of IN N
pertussis NN p
in IN p
children NNS p
under IN p
5 CD p
years NNS p
of IN p
age NN p
in IN p
the DT p
study NN p
area NN p
were VBD p
also RB p
determined VBN p
. . p

The DT N
acellular JJ N
vaccines NNS N
produced VBN N
significantly RB N
fewer JJR N
local JJ o
and CC o
systemic JJ o
reactions NNS o
. . o

Local JJ o
reactions NNS o
such JJ N
as IN N
swelling VBG o
and CC o
redness NN o
were VBD N
observed VBN N
in IN N
2 CD p
% NN p
( ( p
8/399 CD p
) ) p
to TO p
2.3 CD p
% NN p
( ( p
9/385 CD p
) ) p
of IN p
the DT p
acellular JJ i
vaccine NN i
recipients NNS p
as IN p
against IN p
31 CD p
% NN p
( ( p
122/394 CD p
) ) p
in IN p
the DT p
whole-cell JJ p
vaccine NN p
group NN p
. . p

Fever NNP o
( ( N
> CD N
or CC N
= VB N
37.5 CD N
degrees NNS N
C NNP N
) ) N
occurred VBD N
in IN N
7.27 CD N
% NN N
( ( N
29/399 CD N
) ) N
to TO N
9.8 CD N
% NN N
( ( N
38/385 CD N
) ) N
in IN N
the DT N
acellular JJ i
vaccine NN i
groups NNS N
compared VBN N
with IN N
36.6 CD N
% NN N
( ( N
145/394 CD N
) ) N
in IN N
the DT N
whole-cell JJ N
vaccine NN N
group NN N
. . N

Geometric NNP o
mean JJ o
titres NNS o
( ( o
GMTs NNP o
) ) o
, , N
measured VBN N
by IN N
ELISA NNP o
, , N
to TO N
pertussis VB o
toxin NN o
( ( o
PT NNP o
) ) o
and CC o
filamentous JJ o
haemagglutinin NN o
( ( o
FHA NNP o
) ) o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
acellular JJ i
vaccine NN i
groups NNS N
than IN N
in IN N
the DT N
whole-cell JJ i
DPT NNP i
( ( i
WCDPT NNP i
) ) i
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
GMTs NNP o
of IN o
tetanus NN o
and CC o
diphtheria NN o
antitoxins NNS o
between IN N
the DT N
two CD N
groups NNS N
after IN N
each DT N
vaccination NN N
. . N

Twelve NNP N
months NNS N
after IN N
primary JJ N
vaccination NN N
, , N
GMTs NNP o
to TO o
PT NNP o
in IN N
the DT N
freeze-dried JJ N
, , N
liquid JJ N
ADPT NNP N
groups NNS N
and CC N
the DT N
WCDPT NNP N
group NN N
have VBP N
fallen VBN N
from IN N
56.23 CD N
, , N
62.63 CD N
and CC N
44.97 CD N
ELISA NNP N
U/ml NNP N
to TO N
6.08 CD N
, , N
6.18 CD N
and CC N
11.30 CD N
ELISA NNP N
U/ml NNP N
, , N
respectively RB N
. . N

GMTs NNP o
to TO o
FHA NNP o
in IN N
all PDT N
the DT N
vaccine NN N
groups NNS N
also RB N
dropped VBD N
during IN N
the DT N
same JJ N
period NN N
from IN N
49.94 CD N
, , N
41.73 CD N
and CC N
20.74 CD N
ELISA NNP N
U/ml NNP N
to TO N
7.26 CD N
, , N
7.72 CD N
and CC N
5.91 CD N
ELISA NNP N
U/ml NNP N
, , N
respectively RB N
. . N

In IN N
this DT N
comparative NN N
controlled VBD N
trial NN N
, , N
the DT N
ADPT NNP i
vaccines NNS i
were VBD N
more JJR N
immunogenic JJ o
, , N
with IN N
less JJR o
local JJ o
and CC o
systemic JJ o
reactions NNS o
, , N
than IN N
the DT N
WCDPT NNP i
vaccine NN i
but CC N
there EX N
was VBD N
a DT N
considerable JJ N
drop NN N
in IN N
antibody NN o
titres NNS o
in IN N
all PDT N
the DT N
vaccine NN N
groups NNS N
12 CD N
months NNS N
after IN N
primary JJ N
vaccination NN N
. . N

However RB N
, , N
the DT N
levels NNS N
of IN N
titres NNS N
of IN N
anti-PT JJ o
and CC o
anti-FHA JJ o
antibodies NNS o
in IN N
all PDT N
the DT N
three CD N
vaccines NNS N
that WDT N
confer VBP N
protection NN N
are VBP N
not RB N
known VBN N
. . N

Further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
provide VB N
this DT N
information NN N
in IN N
order NN N
to TO N
assess VB N
the DT N
need NN N
for IN N
subsequent JJ N
booster NN N
doses NNS N
after IN N
primary JJ N
immunization NN N
with IN N
both DT N
ADPT NNP i
and CC N
WCDPT NNP i
vaccines NNS N
. . N

-DOCSTART- -9786491- O O

Pharmacokinetics NNS N
of IN N
cefuroxime NN i
in IN N
healthy JJ o
volunteers NNS o
: : o
an DT N
update NN N
. . N

-DOCSTART- -23623047- O O

Impact NN N
of IN N
angiotensin NN i
II NNP i
receptor NN i
blocker NN i
therapy NN i
( ( i
olmesartan JJ i
or CC i
valsartan NN i
) ) i
on IN N
coronary JJ N
atherosclerotic JJ N
plaque NN N
volume NN N
measured VBN N
by IN N
intravascular JJ N
ultrasound NN N
in IN N
patients NNS p
with IN p
stable JJ p
angina JJ p
pectoris NN p
. . p

Coronary JJ N
plaques NNS N
can MD N
be VB N
reduced VBN N
by IN N
some DT N
medications NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
2 CD N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
( ( i
olmesartan NN i
at IN N
20 CD N
mg/day NN N
or CC i
valsartan NN i
at IN N
80 CD N
mg/day NN N
) ) N
on IN N
coronary JJ N
plaque NN N
by IN N
coronary JJ N
intravascular JJ N
ultrasound NN N
. . N

One CD p
hundred VBD p
hypertensive JJ p
patients NNS p
with IN p
stable JJ p
angina NNS p
pectoris NNS p
who WP p
underwent VBP p
elective JJ p
percutaneous JJ p
coronary JJ p
intervention NN p
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
1 CD N
of IN N
the DT N
2 CD N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
after IN N
coronary JJ N
intervention NN N
. . N

Nontarget NNP o
coronary JJ o
lesions NNS o
with IN o
mild NN o
to TO o
moderate VB o
stenosis NN o
were VBD N
measured VBN N
by IN N
volumetric JJ N
intravascular JJ N
ultrasound NN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

After IN N
6 CD N
months NNS N
, , N
both CC N
the DT N
olmesartan NN i
and CC N
the DT N
valsartan NN i
groups NNS N
showed VBD N
significant JJ N
reduction NN N
of IN N
the DT N
examined JJ o
coronary JJ o
plaque NN o
volume NN o
( ( N
46.2 CD N
? . N
24.1 CD N
mm? NN N
at IN N
baseline NN N
vs NN N
41.6 CD N
? . N
21.1 CD N
mm? NN N
at IN N
6 CD N
months NNS N
: : N
4.7 CD N
% NN N
decrease NN N
, , N
p VBP N
= JJ N
0.0002 CD N
; : N
and CC N
47.2 CD N
? . N
32.7 CD N
mm? NN N
at IN N
baseline NN N
vs NN N
42.5 CD N
? . N
30.2 CD N
mm? NN N
at IN N
6 CD N
months NNS N
: : N
4.8 CD N
% NN N
decrease NN N
, , N
p VBP N
= JJ N
0.002 CD N
, , N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN o
of IN o
plaque JJ o
regression NN o
between IN o
the DT N
2 CD N
groups NNS N
( ( N
p JJ N
= NNP N
0.96 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
from IN N
baseline NN N
in IN o
the DT o
coronary JJ o
plaque NN o
volume NN o
in IN p
patients NNS p
with IN p
stable JJ p
angina NNS p
pectoris NN p
who WP p
received VBD p
olmesartan PRP i
or CC i
valsartan VB i
for IN i
6 CD i
months NNS i
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
reduction NN o
of IN o
plaque NN o
volume NN o
achieved VBN N
by IN N
these DT N
2 CD N
medications NNS N
. . N

-DOCSTART- -3307623- O O

Oral JJ i
ribavirin NN i
treatment NN i
of IN N
influenza NN N
A NNP N
and CC N
B NNP N
. . N

A NNP N
loading VBG N
dose JJ N
and CC N
short-term JJ N
administration NN i
of IN i
oral JJ i
ribavirin NN i
significantly RB N
improved VBN N
symptoms NNS o
and CC o
signs NNS o
of IN o
influenza NN o
type NN o
A DT o
or CC o
B NNP o
infection NN o
in IN p
25 CD p
patients NNS p
. . p

The DT N
antiviral JJ N
effect NN N
was VBD N
not RB N
significant JJ N
. . N

No DT N
adverse JJ o
clinical JJ o
effects NNS o
or CC N
significant JJ N
laboratory NN N
values NNS N
were VBD N
observed VBN N
. . N

Oral JJ N
treatment NN N
of IN N
patients NNS p
with IN p
influenza NN p
A NNP p
or CC p
B NNP p
infection NN p
might MD N
be VB N
possible JJ N
with IN N
ribavirin NN i
. . i

-DOCSTART- -24781441- O O

Comparison NNP N
of IN N
olanzapine JJ i
long-acting JJ i
injection NN i
and CC i
oral JJ i
olanzapine NN i
: : i
a DT N
2-year JJ N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
in IN N
outpatients NNS p
with IN p
schizophrenia NN o
. . o

We PRP N
compared VBN N
long-term JJ N
treatment NN N
effectiveness NN N
of IN N
monthly JJ N
olanzapine JJ i
long-acting JJ i
injection NN i
( ( i
LAI NNP i
) ) i
with IN N
that DT N
of IN N
oral JJ i
olanzapine NN i
. . i

Outpatients NNS p
with IN p
2 CD p
or CC p
more JJR p
episodes NNS p
of IN p
psychotic JJ p
worsening NN p
in IN p
the DT p
past JJ p
24 CD p
months NNS p
with IN p
Positive NNP p
and CC p
Negative NNP p
Syndrome NNP p
Scale NNP p
total JJ p
score NN p
of IN p
lower JJR p
than IN p
70 CD p
were VBD p
randomized VBN p
to TO N
405 CD N
mg/4 JJ N
weeks NNS N
of IN N
olanzapine JJ i
LAI NNP i
( ( N
n JJ N
= NNP N
264 CD N
) ) N
or CC N
10 CD N
mg/d NN N
of IN N
oral JJ i
olanzapine NN i
( ( N
n JJ N
= NNP N
260 CD N
) ) N
for IN N
2 CD N
years NNS N
of IN N
open-label JJ N
treatment NN N
. . N

Dosing VBG N
thereafter RB N
was VBD N
flexible JJ N
( ( N
150-405 JJ N
mg/4 NN N
weeks NNS N
of IN N
LAI NNP i
vs FW N
5-20 JJ N
mg/d NN N
of IN N
oral JJ N
) ) N
. . N

Primary JJ N
outcome NN N
was VBD N
time NN o
to TO o
all-cause JJ o
discontinuation NN o
. . o

At IN N
baseline NN N
, , N
patients NNS N
were VBD N
clinically RB N
stable JJ N
( ( N
mean JJ N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
total JJ N
score NN N
of IN N
57 CD N
) ) N
. . N

Seventeen JJ N
percent NN N
of IN N
patients NNS N
had VBD N
been VBN N
psychiatrically RB N
hospitalized VBN N
in IN N
the DT N
previous JJ N
6 CD N
months NNS N
, , N
and CC N
4.6 CD N
% NN N
were VBD N
rated VBN N
nonadherent JJ N
in IN N
the DT N
month NN N
before IN N
study NN N
entry NN N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
median JJ N
time NN N
to TO N
all-cause JJ N
discontinuation NN N
( ( N
645 CD N
days NNS N
for IN N
LAI NNP N
, , N
678 CD N
days NNS N
for IN N
oral JJ N
; : N
P NNP N
= NNP N
0.61 CD N
) ) N
, , N
discontinuation NN N
rate NN N
( ( N
53.8 CD N
% NN N
for IN N
LAI NNP N
, , N
51.2 CD N
% NN N
for IN N
oral JJ N
; : N
P NNP N
= NNP N
0.60 CD N
) ) N
, , N
or CC N
relapse NN N
rate NN N
( ( N
20.1 CD N
% NN N
for IN N
LAI NNP i
, , N
18.5 CD N
% NN N
for IN N
oral JJ N
; : N
P NNP N
= NNP N
0.66 CD N
) ) N
. . N

Postbaseline NNP N
psychiatric JJ o
hospitalization NN N
rate NN N
was VBD N
low JJ N
for IN N
both DT N
groups NNS N
( ( N
7.6 CD N
% NN N
for IN N
LAI NNP i
, , N
9.2 CD N
% NN N
for IN N
oral JJ N
) ) N
, , N
but CC N
mean JJ N
hospitalization NN N
duration NN N
was VBD N
significantly RB N
longer JJR N
for IN N
oral JJ N
patients NNS N
( ( N
1.80 CD N
days NNS N
[ VBP N
20 CD N
for IN N
those DT N
hospitalized VBN N
] VBP N
vs JJ N
0.43 CD N
days NNS N
[ VBP N
6 CD N
for IN N
those DT N
hospitalized JJ N
] NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
clinically RB N
significant JJ N
group NN N
differences NNS N
in IN N
adverse JJ N
events NNS N
or CC N
safety NN N
measures NNS N
. . N

No DT N
post-injection JJ N
delirium/sedation NN o
syndrome NN o
events NNS N
occurred VBD N
. . N

In IN N
conclusion NN N
, , N
olanzapine JJ o
LAI NNP o
and CC N
oral JJ N
olanzapine NN o
were VBD N
similarly RB N
effective JJ o
and CC N
well RB N
tolerated VBN o
for IN N
up RB N
to TO N
2 CD N
years NNS N
of IN N
treatment NN N
in IN N
patients NNS p
with IN p
schizophrenia NN o
. . o

Treatment NNP o
discontinuation NN o
for IN N
olanzapine JJ i
LAI NNP i
was VBD N
similar JJ N
to TO N
that DT N
of IN N
oral JJ N
olanzapine NN i
, , N
despite IN N
the DT N
3-hour JJ N
post-injection NN N
observation NN N
period NN N
and CC N
other JJ N
precautionary JJ N
procedures NNS N
related VBN N
to TO N
risk NN N
of IN N
post-injection JJ N
delirium/sedation NN N
syndrome NN N
. . N

-DOCSTART- -11056317- O O

Update NN N
on IN N
tamoxifen NN i
to TO p
prevent VB p
breast NN p
cancer NN p
. . p

The DT N
Italian JJ p
Tamoxifen NNP i
Prevention NNP p
Study NNP p
. . p

-DOCSTART- -18556898- O O

A DT N
sensory JJ i
integration NN i
therapy NN i
program NN i
on IN N
sensory JJ p
problems NNS p
for IN p
children NNS p
with IN p
autism NN p
. . p

The DT N
study NN N
was VBD N
planned VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
sensory JJ i
integration NN i
therapy NN i
program NN i
on IN N
sensory JJ o
problems NNS o
of IN N
children NNS p
with IN p
autism NN p
. . p

This DT N
study NN N
was VBD N
conducted VBN N
at IN N
the DT N
Trakya NNP p
University NNP p
Training NNP p
and CC p
Research NNP p
Center NNP p
for IN p
Mentally NNP p
and CC p
Physically NNP p
Handicapped NNP p
Children NNP p
in IN p
Turkey NNP p
. . p

The DT N
children NNS N
were VBD N
separated VBN N
into IN N
two CD N
groups NNS N
, , N
each DT N
comprising VBG p
15 CD p
children NNS p
between IN p
7 CD p
and CC p
11 CD p
years NNS p
of IN p
age NN p
with IN p
autism NN p
, , p
according VBG p
to TO p
DSM-IV NNP p
criteria NNS p
. . p

The DT N
children NNS N
in IN N
each DT N
group NN N
were VBD N
assessed VBN N
initially RB N
on IN N
a DT N
checklist NN N
, , N
Sensory NNP N
Evaluation NNP N
Form NNP N
for IN N
Children NNP N
with IN N
Autism NNP N
, , N
developed VBD N
to TO N
evaluate VB N
sensory JJ o
characteristics NNS o
of IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
participants NNS N
were VBD N
assessed VBN N
again RB N
on IN N
the DT N
checklist NN N
. . N

Statistically NNP N
significant JJ N
differences NNS N
between IN N
groups NNS N
indicated VBD N
that IN N
the DT N
sensory JJ i
integration NN i
therapy NN i
program NN i
positively RB N
affected VBD N
treated JJ N
children NNS N
. . N

-DOCSTART- -26902035- O O

Oxidized VBN i
Regenerated VBD i
Cellulose NNP i
Reduces NNPS N
the DT N
Amount NNP N
of IN N
Fluid NNP N
Drainage NNP N
after IN N
Liver NNP N
Resection NNP N
: : N
A DT N
Randomized NNP N
Prospective NNP N
Clinical NNP N
Trial NNP N
. . N

BACKGROUND/AIMS NNP N
Oxidized NNP i
regenerated VBD i
cellulose NN i
( ( i
ORC NNP i
) ) i
has VBZ N
been VBN N
registered VBN N
as IN N
adjuncts NNS N
to TO N
stimulate VB N
hemostasis NN N
in IN N
liver NN N
surgery NN N
. . N

However RB N
, , N
most JJS N
previous JJ N
studies NNS N
were VBD N
primarily RB N
designed VBN N
to TO N
study VB N
the DT N
intra-operative JJ N
hemostatic JJ N
efficacy NN N
, , N
and CC N
the DT N
effect NN N
on IN N
prophylactic JJ N
application NN N
was VBD N
never RB N
studied VBN N
as IN N
a DT N
primary JJ N
endpoint NN N
. . N

This DT N
randomized JJ N
prospective JJ N
clinical JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
whether IN N
ORC NNP i
is VBZ N
safe JJ N
and CC N
effective JJ N
when WRB N
used VBN N
as IN N
a DT N
prophylactic JJ N
agent NN N
covering VBG N
the DT N
raw JJ N
cut NN N
surface NN N
during IN p
the DT p
hepatectomy NN p
to TO N
reduce VB N
the DT N
volume NN N
and CC N
duration NN N
of IN N
drainage NN N
. . N

METHODOLOGY NNP N
Between NNP p
June NNP p
2011 CD p
and CC p
August NNP p
2012 CD p
, , p
a DT p
total NN p
of IN p
40 CD p
patients NNS p
undergoing JJ p
major JJ p
hepatectomy NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
ORC NNP i
or CC i
control NN i
groups NNS i
( ( N
20 CD N
in IN N
each DT N
group NN N
) ) N
. . N

Patient JJ o
characteristics NNS o
, , o
resection-related JJ o
factors NNS o
, , o
debit NN o
of IN o
drainage NN o
and CC o
postoperative JJ o
complications NNS o
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS VB N
The DT p
two CD p
groups NNS p
were VBD p
comparable JJ p
in IN p
terms NNS p
of IN p
demographics NNS o
, , o
indications NNS o
for IN o
surgery NN o
, , o
extent NN o
of IN o
hepatectomy NN o
, , o
and CC o
intraoperative JJ o
blood NN o
loss NN o
. . o

The DT N
amount NN o
of IN o
drainage NN o
after IN o
operation NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
ORC NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
406.9 CD N
? . N
308.1 CD N
vs. IN N
627.0 CD N
? . N
301.6 CD N
ml NN N
, , N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

CONCLUSIONS NNP N
Application NNP N
of IN N
ORC NNP i
covering VBG i
the DT N
raw JJ N
cut NN N
surface NN N
during IN N
the DT N
hepatectomy NN N
can MD N
significantly RB N
decrease VB N
the DT N
amount NN N
of IN N
drainage NN N
. . N

-DOCSTART- -22050040- O O

Once-daily RB N
topical JJ i
brimonidine NN i
tartrate NN i
gel VBD i
0?5 CD N
% NN N
is VBZ N
a DT N
novel JJ N
treatment NN N
for IN p
moderate JJ p
to TO p
severe VB o
facial JJ o
erythema NN o
of IN o
rosacea NN o
: : o
results NNS N
of IN N
two CD N
multicentre NNS N
, , N
randomized VBN N
and CC N
vehicle-controlled JJ N
studies NNS N
. . N

BACKGROUND NNP p
Erythema NNP p
of IN p
rosacea NN p
is VBZ N
thought VBN N
to TO N
result VB N
from IN N
abnormal JJ N
cutaneous JJ N
vasomotor NN N
activity NN N
. . N

Brimonidine NNP i
tartrate NN i
( ( i
BT NNP i
) ) i
is VBZ N
a DT N
highly RB N
selective JJ N
? . N
( ( N
2 CD N
) ) N
-adrenergic NN N
receptor NN N
agonist NN N
with IN N
vasoconstrictive JJ N
activity NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
optimal JJ N
concentration NN N
and CC N
dose JJ N
regimen NNS N
of IN N
topical JJ i
BT NNP i
gel NN i
for IN i
the DT N
treatment NN N
of IN N
erythema NN o
of IN o
rosacea NN o
and CC o
to TO N
evaluate VB N
its PRP$ o
efficacy NN o
and CC o
safety NN o
. . o

METHODS NNP N
In IN N
study NN p
A NNP p
, , p
122 CD p
subjects NNS p
were VBD p
randomized VBN p
to TO p
receive VB p
a DT p
single JJ p
application NN p
of IN p
BT NNP i
0?07 CD i
% NN p
, , p
0?18 CD p
% NN p
, , p
0?5 CD p
% NN p
or CC i
vehicle NN i
. . i

In IN i
study NN p
B NNP p
( ( p
4-week JJ p
treatment NN p
and CC p
4-week JJ p
follow-up NN p
) ) p
, , p
269 CD p
subjects NNS p
were VBD p
randomized VBN N
to TO N
receive VB i
BT NNP i
0?5 CD i
% NN N
once RB N
daily JJ N
, , N
BT NNP i
0?18 CD i
% NN N
once RB N
daily JJ N
, , N
vehicle NN i
once RB i
daily RB i
, , N
BT NNP i
0?18 CD i
% NN N
twice JJ N
daily RB N
or CC N
vehicle NN i
twice RB N
daily RB N
. . N

Evaluations NNS N
included VBD N
Clinician NNP o
's POS o
Erythema NNP o
Assessment NNP o
( ( o
CEA NNP o
) ) o
, , o
Patient NNP o
's POS o
Self-Assessment JJ o
( ( o
PSA NNP o
) ) o
, , o
Chroma NNP o
Meter NNP o
measurements NNS o
and CC o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
In IN N
study NN N
A NNP N
, , N
a DT N
single JJ N
application NN N
of IN N
topical JJ N
BT NNP o
gel NN o
reduced VBD o
facial JJ o
erythema NN o
in IN o
a DT o
dose-dependent JJ o
fashion NN N
. . N

A DT N
significant JJ N
difference NN N
between IN N
BT NNP N
0?5 CD N
% NN N
and CC N
vehicle NN N
in IN o
Chroma NNP o
Meter NNP o
redness NN o
value NN o
was VBD o
observed VBN N
from IN N
30min CD N
to TO N
12h CD N
after IN N
application NN N
. . N

In IN N
study NN N
B NNP N
, , N
BT NNP N
0?5 CD N
% NN N
once RB N
daily JJ N
had VBD N
a DT N
statistically RB o
superior JJ o
success NN o
profile NN o
( ( o
defined VBN N
as IN N
a DT N
two-grade JJ N
improvement NN o
on IN o
both DT o
CEA NNP o
and CC o
PSA NNP o
over IN o
12h CD N
) ) N
compared VBN N
with IN N
vehicle NN N
once RB N
daily RB N
on IN N
days NNS N
1 CD N
, , N
15 CD N
and CC N
29 CD N
( ( N
all DT N
P NNP N
< NNP N
0?001 CD N
) ) N
. . N

No DT o
tachyphylaxis NN o
, , o
rebound NN o
of IN o
erythema NN o
or CC o
aggravation NN o
of IN o
other JJ o
disease NN o
signs NNS o
( ( o
telangiectasia NN o
, , o
inflammatory JJ o
lesions NNS o
) ) o
was VBD o
observed VBN N
. . N

All DT N
regimens NNS N
were VBD o
safe JJ o
and CC o
well RB o
tolerated VBN o
with IN N
similarly RB N
low JJ N
incidence NN N
of IN o
adverse JJ o
events NNS o
. . o

CONCLUSIONS NNP o
Once-daily JJ N
BT NNP N
gel VBD N
0?5 CD N
% NN N
is VBZ N
well RB N
tolerated JJ N
and CC N
provides VBZ N
significantly RB o
greater JJR o
efficacy NN o
than IN o
vehicle NN N
gel NN N
for IN N
the DT N
treatment NN N
of IN N
moderate JJ p
to TO p
severe VB p
erythema NN p
of IN p
rosacea NN p
. . p

-DOCSTART- -18626761- O O

Engagement NN i
with IN i
electronic JJ i
screen JJ i
media NNS i
among IN N
students NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
four CD N
types NNS N
of IN N
electronic JJ i
screen JJ i
media NNS i
( ( i
ESM NNP i
) ) i
: : i
animated VBN i
video NN i
, , i
video NN i
of IN i
self NN i
, , i
video NN i
of IN i
a DT i
familiar JJ i
person NN i
engaged VBD i
with IN i
an DT i
immersive JJ i
virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
game NN i
, , i
and CC i
immersion NN i
of IN i
self NN i
in IN i
the DT i
VR NNP i
game NN i
. . i

Forty-two JJ p
students NNS p
with IN p
autism NN p
, , p
varying VBG p
in IN p
age NN p
and CC p
expressive JJ p
communication NN p
ability NN p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
experimental JJ p
conditions NNS p
. . p

Gaze NNP o
duration NN o
and CC o
vocalization NN o
served VBD N
as IN N
dependent JJ N
measures NNS N
of IN N
engagement NN N
. . N

The DT N
results NNS N
reveal VBP N
differential JJ N
responding NN N
across IN N
ESM NNP o
, , N
with IN N
some DT N
variation NN N
related VBN N
to TO N
the DT N
engagement NN N
metric JJ N
employed VBN N
. . N

Preferences NNS N
for IN N
seeing VBG o
themselves PRP o
on IN o
the DT o
screen NN o
, , o
as RB o
well RB o
as IN o
for IN o
viewing VBG o
the DT o
VR NNP o
scenarios NNS o
, , N
emerged VBD N
from IN N
the DT N
data NNS N
. . N

While IN N
the DT N
study NN N
did VBD N
not RB N
yield VB N
definitive JJ N
data NNS N
about IN N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
ESM NNP i
alternatives NNS N
, , N
it PRP N
does VBZ N
provide VB N
a DT N
foundation NN N
for IN N
future JJ N
research NN N
, , N
including VBG N
guidance NN N
related VBN N
to TO N
participant JJ N
profiles NNS N
, , N
stimulus NN N
characteristics NNS N
, , N
and CC N
data NNS N
coding NN N
challenges NNS N
. . N

-DOCSTART- -17156651- O O

[ JJ o
Efficacy NNP o
and CC o
safety NN o
of IN N
extended-release JJ N
niacin JJ i
alone NN i
or CC i
with IN i
atorvastatin NN i
for IN N
lipid JJ N
profile JJ N
modification NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
extended-release JJ i
niacin NN i
( ( i
niacin JJ i
ER NNP i
) ) i
either CC i
alone RB i
or CC i
in IN i
combination NN i
with IN i
atorvastatin NN i
for IN N
the DT N
lipid JJ N
profile NN N
modification NN N
in IN N
the DT N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
and CC p
its PRP$ p
equivalents NNS p
. . p

METHODS NNP N
One CD p
hundred CD p
and CC p
ten JJ p
patients NNS p
with IN p
CHD NNP p
and CC p
its PRP$ p
equivalents NNS p
with IN p
serum JJ p
total JJ p
cholesterol NN p
( ( p
TC NNP p
) ) p
> VBD p
or CC p
= $ p
3.5 CD p
mmol/L NN p
were VBD N
randomly RB N
assigned VBN N
into IN N
three CD N
treatment NN N
groups NNS N
: : N
( ( N
1 CD N
) ) N
atorvastatin NN i
group NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
, , N
receiving VBG N
atorvastatin NN i
10 CD N
mg/d NN N
for IN N
8 CD N
weeks NNS N
; : N
( ( N
2 CD N
) ) N
niacin NN i
ER NNP i
group NN N
( ( N
n JJ N
= NNP N
38 CD N
) ) N
, , N
given VBN N
niacin NNS i
ER NNP i
500 CD N
mg/d NN N
for IN N
4 CD N
weeks NNS N
and CC N
then RB N
1000 CD N
mg/d NN N
for IN N
4 CD N
weeks NNS N
; : N
( ( N
3 CD N
) ) N
combination NN i
treatment NN i
group NN N
( ( N
n JJ N
= NNP N
34 CD N
) ) N
, , N
treated VBN i
with IN i
atorvastatin NN i
( ( i
10 CD i
mg/d NN i
) ) i
plus CC i
niacin JJ i
ER NNP i
, , N
with IN N
the DT N
dose JJ N
initiating NN N
from IN N
500 CD N
mg/d NN N
, , N
and CC N
increasing VBG N
to TO N
1000 CD N
mg/d NN N
after IN N
4 CD N
weeks NNS N
, , N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
serums NNS o
lipid JJ o
profiles NNS o
and CC o
adverse JJ o
effects NNS o
were VBD N
assessed VBN N
in IN N
all PDT N
the DT N
patients NNS N
before IN N
treatment NN N
, , N
and CC N
4 CD N
and CC N
8 CD N
weeks NNS N
after IN N
treatment NN N
. . N

RESULTS NNP N
( ( N
1 CD N
) ) N
After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
serum JJ o
level NN o
of IN o
triglyceride NN o
( ( o
TG NNP o
) ) o
and CC o
high-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
HDL-C NNP o
) ) o
were VBD N
reduced VBN N
by IN N
30 CD N
% NN N
and CC N
16 CD N
% NN N
respectively RB N
in IN N
the DT N
niacin JJ N
ER NNP N
group NN N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
8 CD N
weeks NNS N
, , N
the DT N
TC NNP o
, , o
low-density NN o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
, , o
and CC o
TG NNP o
in IN o
the DT o
atorvastatin NN o
group NN o
decreased VBN N
by IN N
19 CD N
% NN N
, , N
26 CD N
% NN N
, , N
and CC N
17 CD N
% NN N
respectively RB N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Combination NNP N
treatment NN N
decreased VBD N
the DT N
TC NNP o
, , o
LDL-C NNP o
, , o
and CC o
TG NNP o
levels NNS o
by IN N
28 CD N
% NN N
, , N
38 CD N
% NN N
, , N
and CC N
39 CD N
% NN N
respectively RB N
, , N
and CC N
increased VBD N
the DT N
HDL-C NNP o
level NN o
by IN N
23 CD N
% NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
improvement NN N
in IN N
TC NNP o
and CC o
LDL-C NNP o
achieved VBN N
by IN N
combination NN N
treatment NN N
was VBD N
superior JJ N
to TO N
treatment NN N
of IN N
atorvastatin NN N
alone RB N
and CC N
treatment NN N
of IN N
niacin JJ N
ER NNP N
alone RB N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
2 CD N
) ) N
The DT N
rate NN N
of IN N
achieving VBG N
the DT N
LDL-C JJ o
goal NN N
of IN N
The DT N
National NNP N
Cholesterol NNP N
Education NNP N
Program NNP N
( ( N
NCEP NNP N
) ) N
in IN N
Adult NNP N
Treatment NNP N
Panel NNP N
III NNP N
( ( N
ATP NNP N
III NNP N
) ) N
in IN N
the DT N
combination NN N
therapy NN N
group NN N
was VBD N
73.5 CD N
% NN N
, , N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
atorvastatin NN N
and CC N
niacin JJ N
groups NNS N
( ( N
47.7 CD N
% NN N
and CC N
42.1 CD N
% NN N
respectively RB N
, , N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
3 CD N
) ) N
Adverse NNP N
effect NN N
, , N
such JJ N
as IN N
flushing NN o
( ( N
15.8 CD N
% NN N
) ) N
and CC N
gastrointestinal JJ o
symptoms NNS o
( ( N
23.7 CD N
% NN N
) ) N
were VBD N
found VBN N
in IN N
the DT N
niacin JJ N
ER NNP N
group NN N
, , N
however RB N
, , N
no DT N
more JJR N
adverse JJ N
effects NNS N
were VBD N
found VBN N
in IN N
the DT N
combination NN N
therapy NN N
group NN N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
events NNS N
in IN N
all DT N
groups NNS N
. . N

CONCLUSION NNP N
Niacin NNP N
ER NNP N
has VBZ N
a DT N
favorable JJ N
effect NN o
in IN o
modulating VBG o
the DT o
blood NN o
lipid JJ o
profile NN o
, , N
especially RB N
in IN N
reducing VBG o
TG NNP o
and CC o
elevating VBG o
HDL-C NNP o
. . o

Combined VBN N
statin NN N
with IN N
niacin NN N
may MD N
produce VB N
a DT N
more JJR N
global JJ o
and CC o
effective JJ o
improvement NN o
in IN o
lipid JJ o
blood NN o
levels NNS o
than IN N
monotherapy NN N
and CC N
is VBZ N
generally RB N
safe JJ o
and CC o
well RB o
tolerable JJ o
. . o

-DOCSTART- -8435382- O O

Torasemide NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
cirrhosis NN p
and CC p
ascites NNS p
. . p

The DT N
effects NNS N
of IN N
torasemide NN i
( ( i
20 CD i
mg/day NN i
) ) i
and CC N
furosemide JJ i
( ( i
50 CD i
mg/day NN i
) ) i
, , N
each DT N
given VBN N
over IN N
4 CD N
days NNS N
, , N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
and CC N
crossover NN N
study NN N
carried VBD N
out RP N
in IN N
seven CD p
patients NNS p
with IN p
cirrhosis NN p
and CC p
tense NN p
ascites NNS p
. . p

Patients NNS p
also RB N
received VBD N
a DT N
low-sodium NN i
( ( i
40 CD i
mmol/day NN i
) ) i
diet NN i
and CC i
the DT i
aldosterone NN i
antagonist NN i
, , i
potassium NN i
canrenoate NN i
( ( N
100 CD N
mg RB N
b.i.d. NN N
) ) N
. . N

Torasemide NNP i
induced VBD N
a DT N
remarkably RB N
higher RBR N
natriuretic JJ o
( ( N
120 CD N
+/- JJ N
15 CD N
vs. FW N
33 CD N
+/- JJ N
6 CD N
mmol/day NN N
, , N
p NN N
< NNP N
0.02 CD N
) ) N
and CC N
diuretic JJ o
( ( N
1450 CD N
+/- NN N
63 CD N
vs. IN N
900 CD N
+/- JJ N
58 CD N
ml NN N
, , N
p NN N
< NNP N
0.005 CD N
) ) N
effect NN N
than IN N
furosemide NN i
. . i

Body NNP o
weight JJ o
loss NN o
was VBD N
also RB N
significantly RB N
higher JJR N
( ( N
2.5 CD N
+/- JJ N
1.6 CD N
vs. FW N
0.2 CD N
+/- JJ N
1.3 CD N
kg NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
during IN N
the DT N
torasemide JJ i
period NN N
. . N

Kaliuresis NNP o
was VBD N
similar JJ N
during IN N
the DT N
two CD N
treatment NN N
periods NNS N
, , N
despite IN N
the DT N
striking JJ N
differences NNS N
observed VBN N
in IN N
natriuresis NN N
. . N

Neither CC N
torasemide JJ i
nor CC N
furosemide JJ i
induced VBD N
any DT N
significant JJ N
change NN N
in IN N
serum NN o
electrolyte NN o
or CC o
creatinine NN o
concentrations NNS o
, , o
or CC o
in IN o
ammonia JJ o
levels NNS o
. . o

The DT N
results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
torasemide NN i
is VBZ N
suitable JJ N
for IN N
the DT N
treatment NN N
of IN N
sodium NN N
retention NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
and CC p
ascites NNS p
. . p

-DOCSTART- -25719544- O O

Mask NNP i
ventilation NN i
with IN N
two CD N
different JJ N
face NN N
masks NNS N
in IN N
the DT N
delivery NN N
room NN N
for IN N
preterm JJ p
infants NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
If IN N
an DT N
infant NN p
fails VBZ p
to TO p
initiate VB p
spontaneous JJ p
breathing NN p
after IN p
birth NN p
, , N
international JJ N
guidelines NNS N
recommend VBP N
a DT N
positive JJ N
pressure NN N
ventilation NN N
( ( N
PPV NNP N
) ) N
. . N

However RB N
, , N
PPV NNP N
by IN N
face NN i
mask NN i
is VBZ N
frequently RB N
inadequate JJ N
because IN N
of IN N
leak NN N
between IN N
the DT N
face NN N
and CC N
mask NN N
. . N

Despite IN N
a DT N
variety NN N
of IN N
available JJ N
face NN N
masks NNS N
, , N
none NN N
have VBP N
been VBN N
prospectively RB N
compared VBN N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
and CC N
compare VB N
leak NN o
between IN o
two CD o
commercially RB o
available JJ o
round NN o
face NN o
masks NNS o
( ( i
Fisher NNP i
& CC i
Paykel NNP i
( ( i
F NNP i
& CC i
P NNP i
) ) i
and CC i
Laerdal NNP i
) ) i
in IN N
preterm NN p
infants NNS p
< VBP p
33 CD p
weeks NNS p
gestational JJ p
age NN p
in IN p
the DT p
delivery NN p
room NN p
. . p

METHODS NNP N
Infants NNPS p
born VBN p
at IN p
the DT p
Royal NNP p
Alexandra NNP p
Hospital NNP p
from IN p
April NNP p
to TO p
September NNP p
2013 CD p
at IN p
< $ p
33 CD p
weeks NNS p
gestational JJ p
age NN p
who WP p
received VBD p
mask NN i
PPV NNP i
in IN p
the DT p
delivery NN p
room NN p
routinely RB N
had VBD N
a DT N
flow NN N
sensor NN N
placed VBD N
between IN N
the DT N
mask NN N
and CC N
T-piece NNP N
resuscitator NN N
. . N

Infants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
PPV NNP i
with IN i
either CC i
a DT i
F NNP i
& CC i
P NNP i
or CC i
Laerdal NNP i
face NN i
mask NN i
. . i

All DT N
resuscitators NNS N
were VBD N
trained VBN N
in IN N
the DT N
use NN N
of IN N
both DT N
face NN N
masks NNS N
. . N

We PRP N
compared VBN N
mask NN o
leak NN o
, , o
airway NN o
pressures NNS o
, , o
tidal JJ o
volume NN o
and CC o
ventilation NN o
rate NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Fifty-six JJ p
preterm JJ p
infants NNS p
( ( p
n=28 NN p
in IN p
each DT p
group NN p
) ) p
were VBD p
enrolled VBN p
; : p
mean?s.d NN p
. . p

gestational JJ p
age NN p
28?3 CD p
weeks NNS p
; : p
birth NN p
weight VBD p
1210?448 CD p
g NN p
; : p
and CC p
30 CD p
( ( p
52 CD p
% NN p
) ) p
were VBD p
male JJ p
. . p

Apgar JJ p
scores NNS N
at IN N
1 CD N
and CC N
5 CD N
min NNS N
were VBD N
5?3 CD N
and CC N
7?2 CD N
, , N
respectively RB N
. . N

Infants NNS N
randomized VBD i
to TO i
the DT i
F NNP i
& CC i
P NNP i
face NN i
mask NN i
and CC i
Laerdal NNP i
face NN i
mask NN i
had VBD i
similar JJ o
mask NN o
leak NN o
( ( o
30 CD o
( ( N
25-38 JJ N
) ) N
versus NN N
35 CD N
( ( N
24-46 JJ N
) ) N
% NN N
, , N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
, , N
respectively RB N
, , N
P=0.40 NNP N
) ) N
and CC o
tidal JJ o
volume NN o
( ( o
7.1 CD N
( ( N
4.9-8.9 JJ N
) ) N
versus NN N
6.6 CD N
( ( N
5.2-8.9 JJ N
) ) N
ml NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
P=0.69 NNP N
) ) N
during IN N
PPV NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN o
ventilation NN o
rate NN o
, , o
inflation NN o
time NN o
or CC o
airway NN o
pressures NNS o
between IN o
groups NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
either DT N
face NN N
mask NN N
during IN N
PPV NNP N
in IN N
the DT N
delivery NN N
room NN N
yields NNS N
similar JJ o
mask NN o
leak NN o
in IN o
preterm JJ p
infants NNS p
< VBP p
33 CD p
weeks NNS p
gestational JJ p
age NN p
. . p

-DOCSTART- -22456820- O O

Are NNP N
prenatal JJ i
ultrasound JJ i
scans NNS i
associated VBN N
with IN N
the DT N
autism NN o
phenotype NN o
? . N
Follow-up NNP N
of IN N
a DT N
randomised VBN N
controlled VBN i
trial NN N
. . N

An DT N
existing VBG N
randomised VBD N
controlled VBN i
trial NN N
was VBD N
used VBN N
to TO N
investigate VB N
whether IN N
multiple JJ i
ultrasound JJ i
scans NNS i
may MD N
be VB N
associated VBN N
with IN N
the DT N
autism NN o
phenotype NN o
. . o

From IN p
2,834 CD p
single JJ p
pregnancies NNS p
, , p
1,415 CD p
were VBD p
selected VBN p
at IN p
random NN p
to TO N
receive VB N
ultrasound JJ i
imaging NN i
and CC i
continuous JJ i
wave NN i
Doppler NNP i
flow NN i
studies NNS i
at IN N
five CD N
points NNS N
throughout IN N
pregnancy NN N
( ( N
Intensive NNP N
) ) N
and CC N
1,419 CD N
to TO N
receive VB N
a DT N
single JJ i
imaging NN i
scan NN i
at IN N
18 CD N
weeks NNS N
( ( N
Regular NNP N
) ) N
, , N
with IN N
further JJ N
scans NNS N
only RB N
as RB N
indicated VBN N
on IN N
clinical JJ N
grounds NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
Autism NNP o
Spectrum NNP o
Disorder NNP o
between IN N
the DT N
Regular NNP N
( ( N
9/1,125 CD N
, , N
0.8 CD N
% NN N
) ) N
and CC N
Intensive NNP N
( ( N
7/1,167 CD N
, , N
0.6 CD N
% NN N
) ) N
groups NNS N
, , N
nor CC N
a DT N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
level NN o
of IN o
autistic-like JJ o
traits NNS o
in IN N
early JJ N
adulthood NN N
. . N

There EX N
is VBZ N
no DT N
clear JJ N
link NN N
between IN N
the DT N
frequency NN o
and CC N
timing NN o
of IN N
prenatal JJ i
ultrasound JJ i
scans NNS i
and CC N
the DT N
autism NN o
phenotype NN o
. . o

-DOCSTART- -18273636- O O

Prospective JJ N
randomized VBN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
fast-track JJ i
elective JJ i
open JJ i
infrarenal JJ i
aneurysm NN i
repair NN i
. . i

BACKGROUND NNP N
AND CC N
AIMS NNP N
Fast-track NNP N
programs NNS N
have VBP N
been VBN N
introduced VBN N
in IN N
many JJ N
surgical JJ N
fields NNS N
to TO N
minimize VB N
postoperative JJ o
morbidity NN o
and CC o
mortality NN o
. . o

Morbidity NN o
after IN N
elective JJ p
open JJ p
infrarenal JJ p
aneurysm NN p
repair NN p
is VBZ N
as RB N
high JJ N
as IN N
30 CD N
% NN N
; : N
mortality NN o
ranges VBZ N
up IN N
to TO N
10 CD N
% NN N
. . N

In IN N
terms NNS N
of IN N
open JJ p
infrarenal JJ p
aneurysm NN p
repair NN p
, , N
no DT N
randomized VBN N
controlled VBN N
trials NNS N
exist VBP N
to TO N
introduce VB N
and CC N
evaluate VB N
such JJ N
patient JJ N
care NN N
programs NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
study NN N
involved VBD N
prospective JJ N
randomization NN N
of IN N
82 CD p
patients NNS p
in IN p
a DT p
traditional JJ p
and CC p
a DT p
fast-track JJ i
treatment NN p
arm NN p
. . p

Main NNP N
differences NNS N
consisted VBD N
in IN N
preoperative JJ i
bowel NN i
washout NN i
( ( N
none NN N
vs. FW N
3 CD N
l NN N
cleaning VBG N
solution NN N
) ) N
and CC N
analgesia $ N
( ( N
patient NN N
controlled VBN N
analgesia JJ N
vs. FW N
patient NN N
controlled VBD N
epidural JJ N
analgesia NN N
) ) N
. . N

Study NN N
endpoints NNS N
were VBD N
morbidity NN o
and CC o
mortality NN o
, , o
need VBP o
for IN o
postoperative JJ o
mechanical JJ o
ventilation NN o
, , o
and CC o
length NN o
of IN o
stay NN o
( ( o
LOS NNP o
) ) o
on IN o
intensive JJ o
care NN o
unit NN o
( ( o
ICU NNP o
) ) o
. . o

RESULTS VB N
The DT N
need NN N
for IN N
assisted JJ o
postoperative JJ o
ventilation NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
traditional JJ N
group NN N
( ( N
33.3 CD N
% NN N
vs. FW N
5.4 CD N
% NN N
; : N
p CC N
= VB N
0.011 CD N
) ) N
. . N

Median JJ o
LOS NNP o
on IN o
ICU NNP o
was VBD N
shorter RBR N
in IN N
the DT N
fast-track JJ N
group NN N
, , N
41 CD N
vs. FW N
20 CD N
h. PDT N
The DT N
rate NN o
of IN o
postoperative JJ o
medical JJ o
complications NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
fast-track JJ N
group NN N
, , N
16.2 CD N
% NN N
vs. FW N
35.7 CD N
% NN N
( ( N
p JJ N
= NNP N
0.045 CD N
) ) N
. . N

CONCLUSION NN N
We PRP N
introduced VBD N
and CC N
evaluated VBD N
an DT N
optimized JJ N
patient NN i
care NN i
program NN i
for IN N
patients NNS p
undergoing VBG p
open JJ p
infrarenal JJ p
aortic JJ p
aneurysm NN p
repair NN p
which WDT N
showed VBD N
a DT N
significant JJ N
advantage NN N
for IN N
fast-track JJ N
patients NNS N
in IN N
terms NNS N
of IN N
postoperative JJ o
morbidity NN o
. . o

-DOCSTART- -14713377- O O

Intervention NN N
in IN N
children NNS p
with IN p
Developmental NNP p
Coordination NNP p
Disorder NNP p
: : p
the DT N
role NN N
of IN N
parents NNS i
and CC i
teachers NNS i
. . i

BACKGROUND NNP N
Children NNP p
with IN p
Developmental NNP p
Coordination NNP p
Disorder NNP p
( ( p
DCD NNP p
) ) p
are VBP N
a DT N
heterogeneous JJ N
group NN N
who WP N
have VBP N
a DT N
marked JJ N
impairment NN N
in IN N
the DT N
performance NN N
of IN N
functional JJ N
skills NNS N
. . N

Provision NN N
for IN N
these DT N
children NNS N
is VBZ N
usually RB N
made VBN N
via IN N
a DT N
paediatrician JJ N
through IN N
occupational JJ i
or CC N
physiotherapy JJ i
though IN N
, , N
with IN N
a DT N
prevalence NN N
rate NN N
of IN N
5 CD N
% NN N
, , N
regular JJ N
provision NN N
is VBZ N
not RB N
possible JJ N
due JJ N
to TO N
limited JJ N
professional JJ N
resources NNS N
. . N

AIMS VB N
The DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS i
and CC i
teachers NNS i
, , N
with IN N
guidance NN N
, , N
can MD N
assist VB N
in IN N
the DT N
management NN N
of IN N
children NNS p
with IN p
DCD NNP p
; : p
whether IN N
children NNS p
with IN p
DCD NNP p
are VBP N
helped VBN N
in IN N
this DT N
way NN N
and CC N
how WRB N
this DT N
may MD N
contribute VB N
to TO N
our PRP$ N
understanding NN N
of IN N
the DT N
condition NN N
. . N

SAMPLE NNP N
Thirty-one CD p
children NNS p
with IN p
DCD NNP p
aged VBD p
7 CD p
to TO p
9 CD p
years NNS p
participated VBN p
in IN p
the DT p
study NN p
. . p

METHODS NNP N
Following VBG N
assessment NN N
, , N
individual JJ N
profiles NNS N
were VBD N
developed VBN N
and CC N
each DT N
week NN N
teachers NNS i
and CC i
parents NNS i
were VBD N
given VBN N
guidelines NNS N
for IN N
working VBG N
with IN N
the DT N
children NNS N
and CC N
each DT N
child NN N
had VBD N
three CD N
to TO N
four CD N
sessions NNS N
a DT N
week NN N
lasting VBG N
approximately RB N
for IN N
20 CD N
minutes NNS N
. . N

In IN N
Phase NNP N
1 CD N
, , N
one CD N
group NN N
of IN N
children NNS N
worked VBN N
with IN N
teachers NNS N
and CC N
the DT N
other JJ N
group NN N
worked VBD N
with IN N
parents NNS N
. . N

In IN N
Phase NNP N
2 CD N
, , N
the DT N
two CD N
groups NNS N
of IN N
children NNS N
swapped VBN N
over IN N
. . N

The DT N
children NNS N
were VBD N
assessed VBN N
regularly RB N
throughout IN N
the DT N
project NN N
using VBG N
the DT N
Movement NNP N
ABC NNP N
, , N
together RB N
with IN N
diaries NNS N
and CC N
comments NNS N
from IN N
teachers NNS N
and CC N
parents NNS N
. . N

RESULTS NN N
At IN N
the DT N
end NN N
of IN N
the DT N
40-week JJ N
study NN N
, , N
27 CD p
children NNS p
showed VBD N
significant JJ N
improvement NN N
in IN N
their PRP$ N
motor NN o
skills NNS o
. . o

CONCLUSIONS NNP N
Both NNP N
teachers NNS i
and CC i
parents NNS i
were VBD N
able JJ N
to TO N
provide VB N
effective JJ o
intervention NN o
for IN N
the DT N
majority NN N
of IN N
the DT N
children NNS N
. . N

It PRP N
is VBZ N
possible JJ N
that IN N
the DT N
children NNS N
who WP N
did VBD N
not RB N
improve VB N
have VB N
difficulties NNS N
that WDT N
are VBP N
of IN N
a DT N
more RBR N
complex JJ N
type NN N
which WDT N
require VBP N
more JJR N
specialist JJ i
therapy NN i
to TO N
meet VB N
their PRP$ N
need NN N
. . N

-DOCSTART- -9587285- O O

Evaluation NN N
of IN N
lidocaine NN i
in IN N
human JJ p
inferior JJ p
alveolar JJ p
nerve NN p
block NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
measure VB N
the DT N
degree NN o
of IN o
anesthesia NN o
following VBG N
the DT N
administration NN N
of IN N
3.6 CD N
ml NN N
of IN N
2 CD N
% NN N
lidocaine JJ i
solutions NNS i
with IN N
either DT N
1:50,000 CD N
, , N
1:80,000 CD N
, , N
or CC N
1:100,000 CD N
for IN N
inferior JJ N
alveolar JJ N
nerve NN N
block NN N
and CC N
to TO N
compare VB N
the DT N
results NNS N
with IN N
those DT N
obtained VBN N
following VBG N
the DT N
administration NN N
of IN N
1.8 CD N
ml NN N
of IN N
the DT N
same JJ N
solutions NNS N
( ( N
1 CD N
) ) N
. . N

With IN N
the DT N
use NN N
of IN N
a DT N
repeated JJ N
measures NNS N
design NN N
, , N
30 CD p
subjects NNS p
randomly RB p
received VBD p
an DT p
inferior JJ i
alveolar JJ i
injection NN i
at IN p
three CD p
successive JJ p
appointments NNS p
. . p

The DT N
first JJ N
molar NN N
, , N
first RB N
premolar JJ N
, , N
lateral JJ N
incisor NN N
, , N
and CC N
contralateral JJ N
canine NN N
( ( N
control NN N
) ) N
were VBD N
blindly RB N
tested VBN N
with IN N
an DT N
Analytic NNP N
Technology NNP N
pulp NN N
tester NN N
at IN N
3-min JJ N
cycles NNS N
for IN N
50 CD N
min NN N
. . N

The DT N
degree NN o
of IN o
anesthesia NN o
was VBD N
comparable JJ N
for IN N
the DT N
three CD N
solutions NNS N
following VBG N
the DT N
administration NN N
of IN N
3.6 CD N
ml NNS N
of IN N
each DT N
solution NN N
. . N

Retrospective JJ N
evaluation NN N
showed VBD N
that IN N
the DT N
volume NN N
of IN N
the DT N
solution NN N
influenced VBD N
the DT N
degree NN N
of IN N
anesthesia NN N
. . N

-DOCSTART- -17519148- O O

Comparison NNP N
of IN N
the DT N
impact NN N
of IN N
vaginal JJ N
and CC N
oral JJ N
administration NN N
of IN N
combined JJ N
hormonal JJ i
contraceptives NNS i
on IN N
hepatic JJ N
proteins NNS N
sensitive JJ N
to TO N
estrogen VB N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
a DT N
new JJ N
combined VBN N
hormonal JJ i
contraceptive JJ i
vaginal JJ i
ring NN i
( ( i
CVR NNP i
) ) i
delivering VBG N
the DT N
nonandrogenic JJ i
progestin NN i
Nestorone NNP i
( ( i
NES NNP i
) ) i
and CC N
ethinyl JJ i
estradiol NN i
( ( N
EE NNP N
) ) N
on IN N
several JJ N
key JJ N
estrogen-sensitive JJ N
hepatic JJ N
proteins NNS N
that WDT N
may MD N
be VB N
markers NNS N
for IN N
the DT N
risk NN N
of IN N
arterial JJ N
or CC N
venous JJ N
disease NN N
events NNS N
and CC N
on IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
. . N

Because IN N
the DT N
pharmacologic JJ N
androgenicity NN N
of IN N
the DT N
progestin NN N
in IN N
these DT N
formulations NNS N
influences VBZ N
the DT N
hepatic JJ N
impact NN N
of IN N
EE NNP N
, , N
we PRP N
selected VBD N
an DT N
oral JJ p
contraceptive NN p
( ( p
OC NNP p
) ) p
delivering VBG N
the DT N
androgenic JJ N
progestin NN N
levonorgestrel NN N
( ( N
LNG NNP N
) ) N
and CC N
EE NNP N
as IN N
the DT N
comparator NN N
. . N

We PRP N
also RB N
investigated VBD N
the DT N
effect NN N
of IN N
delivery NN N
route NN N
, , N
which WDT N
is VBZ N
known VBN N
to TO N
modify VB N
the DT N
hepatic JJ N
effects NNS N
of IN N
estradiol NN N
, , N
but CC N
has VBZ N
not RB N
been VBN N
widely RB N
studied VBN N
with IN N
EE NNP N
. . N

STUDY NNP N
METHODS NNP N
Women NNP p
, , p
aged VBD p
18-34 CD p
years NNS p
, , p
with IN p
no DT p
contraindications NNS p
to TO p
the DT p
use NN p
of IN p
combined JJ p
OCs NNP p
, , p
were VBD p
randomized VBN i
to TO i
three CD i
cycles NNS i
of IN i
treatment NN i
with IN i
a DT i
CVR NNP i
delivering NN i
NES/EE NNP i
( ( i
150/15 CD i
microg/day NN i
) ) i
or CC i
a DT i
combined JJ i
OC NNP i
providing VBG i
LNG NNP i
and CC i
EE NNP i
( ( i
150/30 CD i
microg NN i
per IN i
tablet NN i
) ) i
. . N

Each DT i
cycle NN i
consisted VBD i
of IN i
21 CD i
days NNS i
of IN i
active JJ i
treatment NN i
, , i
followed VBN i
by IN i
7 CD i
days NNS i
without IN i
treatment NN i
. . i

During IN N
the DT N
last JJ N
weeks NNS N
of IN N
the DT N
pretreatment NN N
and CC N
third JJ N
treatment NN N
cycles NNS N
, , N
blood NN o
samples NNS o
were VBD i
obtained VBN i
for IN i
determinations NNS i
of IN i
plasma JJ o
concentrations NNS o
of IN o
angiotensinogen NN o
, , o
an DT o
estrogen-sensitive JJ o
hepatic JJ o
protein NN o
, , o
and CC o
serum JJ o
concentrations NNS o
of IN o
sex NN o
hormone-binding JJ o
globulin NN o
( ( o
SHBG NNP o
) ) o
, , o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
high-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
HDL-C NNP o
) ) o
, , o
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
, , o
triglycerides NNS o
( ( o
TG NNP o
) ) o
and CC o
estrogen- JJ o
and CC o
androgen-sensitive JJ o
proteins NNS o
. . o

BP NNP o
was VBD N
also RB N
measured VBN N
. . N

RESULTS NNP N
Of IN p
47 CD p
women NNS p
randomized VBN p
, , p
45 CD p
completed VBD p
the DT p
study NN p
( ( p
CVR NNP p
: : p
23 CD p
; : p
OC NNP p
: : p
22 CD p
) ) p
. . p

Within-group JJ N
comparisons NNS N
over IN N
time NN N
by IN N
repeated-measure JJ N
analysis NN N
of IN N
variance NN N
demonstrated VBN N
statistically RB N
significant JJ N
changes NNS N
over IN N
time NN N
with IN N
both DT N
treatments NNS N
for IN N
all DT N
hepatic JJ N
proteins NNS N
( ( N
p JJ N
< NNP N
.02 NNP N
) ) N
but CC N
not RB N
for IN N
TC NNP N
. . N

The DT N
within-group JJ N
effects NNS N
, , N
presented VBN N
as IN N
relative JJ N
percent NN N
difference NN N
[ VBD N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
] NN N
, , N
were VBD N
greatest JJS N
for IN N
angiotensinogen NN o
[ JJ N
CVR NNP N
: : N
227 CD N
% NN N
( ( N
195-262 CD N
% NN N
) ) N
; : N
OC NNP N
: : N
251.3 CD N
% NN N
( ( N
218-288 CD N
% NN N
) ) N
] NN N
and CC N
SHBG NNP N
[ NNP N
CVR NNP N
: : N
306 CD N
% NN N
( ( N
237-389 CD N
% NN N
) ) N
; : N
OC NNP N
: : N
55 CD N
% NN N
( ( N
30-86 JJ N
) ) N
] NN N
. . N

Both DT N
treatments NNS N
were VBD N
associated VBN N
with IN N
small JJ N
changes NNS N
in IN N
systolic JJ o
BP NNP o
and CC o
diastolic JJ o
BP NNP o
( ( N
DBP NNP N
) ) N
, , N
but CC N
only RB N
the DT N
within-group JJ N
change NN N
in IN N
DBP NNP o
for IN N
the DT N
OC NNP N
group NN N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
.04 NNP N
) ) N
. . N

Between-treatment JJ N
comparisons NNS N
of IN N
third JJ N
treatment NN N
cycle NN N
mean NN N
values NNS N
were VBD N
performed VBN N
by IN N
analysis NN N
of IN N
covariance NN N
( ( N
baseline JJ N
values NNS N
as IN N
covariate NN N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
between-treatment JJ N
differences NNS N
were VBD N
found VBN N
for IN N
angiotensinogen NN o
, , o
sensitive JJ o
only RB o
to TO o
estrogen VB o
, , o
or CC o
BP NNP o
. . o

Statistically NNP N
significant JJ N
treatment NN N
differences NNS N
were VBD N
found VBN N
for IN N
all DT N
estrogen- JJ o
and CC o
androgen-sensitive JJ o
proteins NNS o
( ( N
p JJ N
< NN N
or CC N
= VB N
.002 NN N
) ) N
but CC N
not RB N
for IN N
TC NNP o
. . o

When WRB N
presented VBN N
as IN N
relative JJ N
percent NN N
difference NN N
between IN N
the DT N
effects NNS N
of IN N
treatment NN N
( ( N
CVR-OC/OC NNP N
; : N
95 CD N
% NN N
CI NNP N
of IN N
percent NN N
difference NN N
) ) N
, , N
the DT N
difference NN N
was VBD N
largest JJS N
for IN N
SHBG NNP o
( ( N
159 CD N
% NN N
[ JJ N
117-210 CD N
% NN N
] NN N
) ) N
; : N
smaller JJR N
relative JJ N
percent NN N
differences NNS N
were VBD N
found VBN N
for IN N
HDL-C NNP o
[ NNP N
31.9 CD N
% NN N
( ( N
18.5-46.8 CD N
% NN N
) ) N
] NN N
, , N
LDL-C NNP o
[ NNP N
23.6 CD N
% NN N
( ( N
33.4 CD N
% NN N
to TO N
-2.4 VB N
% NN N
) ) N
] NN N
and CC N
TG NNP o
[ VBP N
39.0 CD N
% NN N
( ( N
14.0-69.4 CD N
% NN N
) ) N
] NN N
, , N
but CC N
not RB N
TC NNP N
. . N

CONCLUSION NNP N
Vaginal NNP N
delivery NN N
of IN N
a DT N
combined JJ N
hormonal JJ N
contraceptive NN N
did VBD N
not RB N
reduce VB N
the DT N
EE-associated JJ o
changes NNS o
in IN o
estrogen-sensitive JJ o
hepatic JJ o
proteins NNS o
observed VBN N
after IN N
use NN N
of IN N
a DT N
combined JJ N
OC NNP N
. . N

Significant NNP N
treatment NN N
differences NNS N
between IN N
the DT N
NES/EE NNP i
CVR NNP i
and CC N
the DT N
LNG/EE NNP i
OC NNP i
were VBD N
found VBN N
for IN N
SHBG NNP N
, , N
HDL-C NNP N
, , N
LDL-C NNP N
, , N
and CC N
TG NNP N
, , N
proteins VBZ N
sensitive JJ N
to TO N
androgen VB N
as RB N
well RB N
as IN N
estrogen NN N
. . N

No DT N
treatment NN N
difference NN N
was VBD N
observed VBN N
for IN N
angiotensinogen NN N
, , N
which WDT N
is VBZ N
sensitive JJ N
only RB N
to TO N
estrogen VB N
. . N

The DT N
observed JJ N
treatment NN N
differences NNS N
were VBD N
therefore RB N
most RBS N
likely JJ N
due JJ N
to TO N
the DT N
difference NN N
in IN N
androgenicity NN N
between IN N
NES NNP N
and CC N
LNG NNP N
. . N

-DOCSTART- -18166533- O O

Impact NN N
of IN N
a DT N
16-community JJ p
trial NN p
to TO p
promote VB p
judicious JJ p
antibiotic JJ p
use NN p
in IN p
Massachusetts NNP p
. . p

OBJECTIVES NNP N
Reducing VBG N
unnecessary JJ N
antibiotic JJ N
use NN N
, , N
particularly RB N
among IN N
children NNS N
, , N
continues VBZ N
to TO N
be VB N
a DT N
public JJ N
health NN N
priority NN N
. . N

Previous JJ N
intervention NN N
studies NNS N
have VBP N
been VBN N
limited VBN N
by IN N
size NN N
or CC N
design NN N
and CC N
have VBP N
shown VBN N
mixed JJ N
results NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
a DT N
multifaceted VBN i
, , i
community-wide JJ i
intervention NN i
on IN i
overall JJ i
antibiotic JJ i
use NN i
for IN N
young JJ p
children NNS p
and CC N
on IN N
use NN N
of IN N
broad-spectrum JJ N
agents NNS N
. . N

In IN N
addition NN N
, , N
we PRP N
sought VBD N
to TO N
compare VB N
the DT N
intervention NN N
's POS N
impact NN N
on IN N
commercially RB p
and CC p
Medicaid-insured JJ p
children NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
community-level JJ p
, , p
cluster-randomized JJ p
trial NN p
in IN p
16 CD p
nonoverlapping VBG p
Massachusetts NNP p
communities NNS p
, , p
studied VBN p
from IN p
1998 CD p
to TO p
2003 CD p
. . p

During IN N
3 CD N
years NNS N
, , N
we PRP N
implemented VBD N
a DT N
physician JJ i
behavior-change NN i
strategy NN i
that WDT i
included VBD i
guideline JJ i
dissemination NN i
, , i
small-group JJ i
education NN i
, , i
frequent JJ i
updates NNS i
and CC i
educational JJ i
materials NNS i
, , i
and CC i
prescribing VBG i
feedback NN i
. . i

Parents NNS i
received VBD i
educational JJ i
materials NNS i
by IN i
mail NN i
and CC i
in IN i
primary JJ i
care NN i
practices NNS i
, , i
pharmacies NNS i
, , i
and CC i
child NN i
care NN i
settings NNS i
. . i

Using VBG N
health-plan JJ i
data NNS i
, , N
we PRP N
measured VBD N
changes NNS N
in IN N
antibiotics NNS N
dispensed VBN N
per IN N
person-year NN N
of IN N
observation NN N
among IN N
children NNS p
who WP p
were VBD p
aged VBN p
3 CD p
to TO p
< VB p
72 CD p
months NNS p
, , p
resided VBN p
in IN p
study NN p
communities NNS p
, , p
and CC p
were VBD p
insured VBN p
by IN p
a DT p
participating VBG p
commercial JJ p
health NN p
plan NN p
or CC p
Medicaid NNP p
. . p

RESULTS VB N
The DT N
data NNS N
include VBP N
223,135 CD p
person-years NNS p
of IN p
observation NN p
. . p

Antibiotic-use JJ o
rates NNS o
at IN N
baseline NN N
were VBD N
2.8 CD N
, , N
1.7 CD N
, , N
and CC N
1.4 CD N
antibiotics NNS N
per IN N
person-year NN N
among IN N
those DT N
aged VBN N
3 CD N
to TO N
< VB N
24 CD N
, , N
24 CD N
to TO N
< VB N
48 CD N
, , N
and CC N
48 CD N
to TO N
< VB N
72 CD N
months NNS N
, , N
respectively RB N
. . N

We PRP N
observed VBD N
a DT N
substantial JJ N
downward JJ N
trend NN N
in IN N
antibiotic JJ o
prescribing NN o
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
intervention NN N
. . N

The DT N
intervention NN N
had VBD N
no DT N
additional JJ N
effect NN N
among IN N
children NNS N
aged VBD N
3 CD N
to TO N
< VB N
24 CD N
months NNS N
but CC N
was VBD N
responsible JJ N
for IN N
a DT N
4.2 CD N
% NN N
decrease NN N
among IN N
those DT N
aged VBN N
24 CD N
to TO N
< VB N
48 CD N
months NNS N
and CC N
a DT N
6.7 CD N
% NN N
decrease NN N
among IN N
those DT N
aged VBN N
48 CD N
to TO N
< VB N
72 CD N
months NNS N
. . N

The DT N
intervention NN N
effect NN N
was VBD N
greater JJR N
among IN N
Medicaid-insured JJ N
children NNS N
and CC N
for IN N
broad-spectrum JJ N
agents NNS N
. . N

CONCLUSIONS VB N
A DT N
sustained JJ N
, , N
multifaceted VBN N
, , N
community-level JJ N
intervention NN N
was VBD N
only RB N
modestly RB N
successful JJ N
at IN N
decreasing VBG N
overall JJ o
antibiotic JJ o
use NN o
beyond IN N
substantial JJ N
secular JJ N
trends NNS N
. . N

The DT N
more RBR N
robust JJ N
impact NN N
among IN N
Medicaid-insured JJ p
children NNS p
and CC N
for IN N
specific JJ N
medication NN N
classes NNS N
provides VBZ N
an DT N
argument NN N
for IN N
specific JJ N
targeting NN N
of IN N
resources NNS N
for IN N
patient NN N
and CC N
physician JJ N
behavior NN N
change NN N
. . N

-DOCSTART- -3533340- O O

NSAID NNP N
ionisation NN N
in IN N
the DT N
management NN N
of IN N
soft-tissue JJ o
rheumatism NN o
: : o
role NN N
played VBN N
by IN N
the DT N
drug NN N
, , N
electrical JJ o
stimulation NN o
and CC o
suggestion NN o
. . o

Four CD N
treatments NNS N
for IN i
soft-tissue JJ i
rheumatism NN i
-- : i
sham JJ i
ionisation NN i
, , i
placebo NN i
ionisation NN i
, , i
and CC i
pharmacological JJ i
ionisation NN i
with IN i
pirprofen NN i
( ( N
two-dose JJ N
levels NNS N
) ) N
-- : N
were VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
double-blind NN N
, , N
between-patient NN p
controlled VBD p
trial NN p
in IN p
73 CD p
outpatients NNS p
affected VBN p
by IN p
scapulo-humeral JJ p
periarthritis NN p
or CC p
elbow NN p
epicondylitis NN p
. . p

Treatment NNP N
lasted VBD N
two CD N
weeks NNS N
( ( N
5 CD N
sessions NNS N
a DT N
week NN N
) ) N
. . N

Progress NN N
was VBD N
measured VBN N
by IN N
patient NN N
's POS N
assessment NN N
on IN N
pain NN o
at IN o
rest NN o
and CC o
on IN o
movement NN o
and CC N
by IN N
physician NN N
's POS N
assessment NN N
on IN N
functional JJ N
impairment NN N
. . N

At IN N
two CD N
weeks NNS N
each DT o
treatment NN o
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
degree NN N
of IN N
improvement NN o
; : o
however RB N
, , N
pharmacological JJ N
ionisation NN N
produced VBD N
a DT N
significantly RB N
higher JJR N
improvement NN N
in IN N
symptoms NNS o
. . o

No DT N
differences NNS N
were VBD N
detected VBN N
between IN N
sham JJ N
ionisation NN N
and CC N
placebo NN N
ionisation NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
ionisation NN N
procedure NN N
displays NNS N
per IN N
se FW N
a DT N
moderate JJ N
therapeutic JJ o
effect NN o
which WDT N
seems VBZ N
to TO N
be VB N
due RB N
more JJR N
to TO N
a DT N
simple JJ N
placebo NN N
effect NN N
than IN N
to TO N
the DT N
biological JJ N
effect NN N
of IN N
electricity NN N
. . N

-DOCSTART- -10557909- O O

Effect NN N
of IN N
guided JJ i
imagery NN i
on IN N
length NN o
of IN o
stay NN o
, , o
pain NN o
and CC o
anxiety NN o
in IN N
cardiac JJ p
surgery NN p
patients NNS p
. . p

-DOCSTART- -16266472- O O

[ IN N
The DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
enalapril NN i
and CC i
indapamide NN i
on IN N
the DT N
peripheral JJ o
blood NN o
pressure NN o
and CC o
central JJ o
blood NN o
pressure NN o
through IN N
pulse JJ N
wave NN N
analysis NN N
] NNP N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS o
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitor NN i
enalapril NN i
and CC i
diuretic JJ i
indapamide NN i
on IN N
the DT N
peripheral JJ o
blood NN o
pressure NN o
and CC o
the DT o
central JJ o
blood NN o
pressure NN o
in IN N
Chinese JJ p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
, , N
randomized VBN N
study NN N
. . N

Informed VBN N
consent NN N
were VBD N
given VBN N
by IN N
all DT N
patients NNS N
. . N

After IN N
2 CD N
weeks NNS N
of IN N
placebo JJ i
run-in JJ N
period NN N
, , N
105 CD p
patients NNS p
with IN p
mild JJ p
or CC p
moderate JJ p
essential JJ p
hypertension NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
enalapril NN i
( ( N
10 CD N
mg NNS N
per IN N
day NN N
) ) N
or CC i
indapamide NN i
( ( N
2.5 CD N
mg NNS N
per IN N
day NN N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

Radial JJ N
pulse JJ N
wave NN N
recordings NNS N
were VBD N
performed VBN N
in IN N
all PDT N
the DT N
patients NNS N
before IN N
the DT N
active JJ N
treatments NNS N
were VBD N
given VBN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Only RB p
those DT p
patients NNS p
who WP p
have VBP p
finished VBN p
8 CD p
weeks NNS p
of IN p
active JJ p
treatment NN p
in IN p
both DT p
groups NNS p
were VBD p
included VBN p
into IN p
the DT p
final JJ p
analysis NN p
. . p

RESULTS NNP N
One CD p
hundred VBD p
one CD p
patients NNS p
( ( p
51 CD p
in IN p
enalapril NN i
group NN p
and CC p
50 CD p
in IN p
indapamide JJ i
group NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

No DT N
significant JJ N
difference NN N
( ( N
all DT N
P NNP N
values NNS N
> VBP N
0.05 CD N
) ) N
was VBD N
found VBN N
in IN N
baseline NN N
data NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
all PDT N
the DT N
parameters NNS o
of IN o
pulse JJ o
wave NN o
( ( N
except IN N
heart NN N
rates NNS N
in IN N
both DT N
groups NNS N
and CC N
augmentation NN N
index NN N
in IN N
indapamide JJ i
group NN N
) ) N
decreased VBD N
significantly RB N
. . N

Comparison NNP N
of IN N
the DT N
2 CD N
groups NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
all DT N
P NNP N
values NNS N
> VBP N
0.05 CD N
) ) N
in IN N
all PDT N
the DT N
parameters NNS N
of IN N
pulse JJ N
wave NN N
except IN N
that IN N
the DT N
central JJ o
systolic JJ o
blood NN o
pressure NN o
, , o
augmentation NN o
and CC o
augmentation NN o
index NN o
were VBD N
significantly RB N
lower JJR N
in IN N
enalapril NN i
group NN N
than IN N
in IN N
indapamide JJ i
group NN N
. . N

In IN N
enalapril JJ i
group NN N
, , N
the DT N
reduced JJ N
values NNS N
of IN N
systolic JJ o
blood NN o
pressure NN o
and CC o
pulse JJ o
pressure NN o
in IN o
central JJ o
aorta NNS o
were VBD N
significantly RB N
larger JJR N
than IN N
those DT N
in IN N
brachial JJ N
artery NN N
. . N

However RB N
, , N
the DT N
difference NN o
was VBD N
not RB N
observed VBN N
in IN N
indapamide JJ i
group NN N
. . N

CONCLUSIONS NNP N
Enalapril NNP i
and CC i
indapamide NN i
are VBP N
both DT N
similarly RB N
effective JJ N
in IN N
reducing VBG N
peripheral JJ o
arterial JJ o
blood NN o
pressure NN o
. . o

Moreover RB N
, , N
enalapril NN i
is VBZ N
more RBR N
effective JJ N
in IN N
reducing VBG N
central JJ o
systolic JJ o
pressure NN o
and CC o
augmentation NN o
index NN o
than IN N
indapamide NN i
. . i

The DT N
difference NN N
is VBZ N
probably RB N
due JJ N
to TO N
the DT N
reduction NN N
of IN N
wave NN o
reflection NN o
caused VBN N
by IN N
enalapril NN i
. . i

-DOCSTART- -25452054- O O

Randomized VBN N
trial NN N
of IN N
a DT N
secondhand NN i
smoke NN i
exposure NN i
reduction NN i
intervention NN i
among IN N
hospital-based JJ p
pregnant JJ p
women NNS p
. . p

OBJECTIVE VB N
This DT N
study NN N
sought VBD N
to TO N
assess VB N
the DT N
effectiveness NN o
of IN N
a DT N
secondhand NN i
tobacco NN i
smoke NN i
( ( i
SHS NNP i
) ) i
prevention NN i
program NN i
based VBN N
on IN N
an DT N
expanded VBN N
Health NNP o
Belief NNP o
Model NNP o
( ( N
HBM NNP N
) ) N
incorporating VBG N
self-efficacy NN N
among IN N
pregnant JJ p
women NNS p
in IN p
a DT p
hospital NN p
setting NN p
in IN p
Taiwan NNP p
. . p

METHODOLOGY NNP N
This DT N
study NN N
utilized VBD N
a DT N
two-group JJ p
longitudinal JJ p
randomized VBN p
controlled JJ N
trial NN N
design NN N
. . N

Participants NNS i
in IN i
the DT i
intervention NN i
group NN i
( ( i
n=50 RB i
) ) i
enrolled VBD i
in IN i
a DT i
SHS NNP i
prevention NN i
program NN i
based VBN i
on IN i
the DT i
HBM NNP i
, , i
while IN i
participants NNS i
in IN i
the DT i
comparison NN i
group NN i
( ( i
n=50 NN i
) ) i
received VBD i
standard JJ i
government-mandated JJ i
counseling NN i
care NN i
. . i

Both DT i
groups NNS i
were VBD i
given VBN i
questionnaires NNS o
as IN i
a DT i
pre-test JJ i
, , i
two CD i
weeks NNS i
into IN i
the DT i
intervention NN i
, , i
and CC i
one CD i
month NN i
following VBG i
the DT i
conclusion NN i
of IN i
the DT i
intervention NN i
. . i

The DT N
questionnaire NN N
and CC N
intervention NN N
were VBD N
developed VBN N
based VBN N
on IN N
the DT N
understanding NN N
gained VBN N
through IN N
a DT N
series NN N
of IN N
in-depth JJ N
interviews NNS N
and CC N
a DT N
focus-group JJ N
conducted VBN N
among IN N
pregnant JJ N
women NNS N
. . N

Exhaled JJ o
carbon NN o
monoxide NN o
was VBD N
also RB N
measured VBN N
and CC N
used VBN N
as IN N
a DT N
proxy NN N
for IN N
SHS NNP o
exposure NN o
. . o

RESULTS NNP N
Intervention NNP N
group NN N
scores NNS N
were VBD N
all DT N
significantly RB N
higher JJR N
than IN N
comparison NN N
group NN N
scores VBZ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
indicating VBG N
a DT N
significant JJ N
increase NN N
in IN N
knowledge NN o
, , o
HBM NNP o
scores VBZ o
, , o
cues NNS o
to TO o
action NN o
, , o
self-efficacy NN o
, , o
preventative JJ o
behaviors NNS o
, , o
and CC o
a DT o
significant JJ o
decrease NN o
in IN o
smoking NN o
exposure NN o
. . o

These DT N
differences NNS N
remained VBD N
significant JJ N
at IN N
the DT N
one-month JJ N
follow-up JJ N
assessment NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
should MD N
encourage VB N
health NN N
professionals NNS N
to TO N
educate VB N
pregnant JJ p
women NNS p
regarding VBG N
the DT N
harms NNS N
of IN N
SHS NNP N
while IN N
both DT N
empowering VBG N
and CC N
equipping VBG N
them PRP N
with IN N
the DT N
tools NNS N
to TO N
confront VB N
their PRP$ N
family NN N
members NNS N
and CC N
effectively RB N
reduce VB N
their PRP$ N
SHS NNP o
exposure NN o
while IN N
promoting VBG N
smoke-free JJ N
social JJ N
norms NNS N
. . N

-DOCSTART- -15979021- O O

The DT N
effect NN N
of IN N
venlafaxine NN i
on IN N
ongoing VBG N
and CC N
experimentally RB N
induced JJ N
pain NN N
in IN N
neuropathic JJ p
pain NN p
patients NNS p
: : p
a DT N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIM NNP N
The DT N
aim NN N
of IN N
this DT N
randomized VBN N
double JJ N
blind NN N
placebo NN i
controlled VBD N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effectiveness NN N
and CC N
the DT N
safety NN N
of IN N
venlafaxine JJ i
XR NNP i
75 CD i
and CC i
150 CD i
mg NN i
on IN N
ongoing VBG N
pain NN N
and CC N
on IN N
quantitative JJ N
sensory NN N
tests NNS N
in IN N
60 CD p
patients NNS p
with IN p
neuropathic JJ p
pain NN p
for IN p
8 CD p
weeks NNS p
. . p

METHODS NNP N
Evaluation NNP N
parameters NNS N
consisted VBD N
of IN N
ongoing VBG N
pain NN N
intensity NN N
( ( N
VAS NNP N
) ) N
, , N
patient JJ N
satisfaction NN N
, , N
side NN N
effects NNS N
, , N
global JJ N
efficacy NN N
and CC N
tolerance NN N
. . N

Quantitative JJ N
sensory NN N
measurements NNS N
taken VBN N
from IN N
the DT N
affected JJ N
area NN N
before IN N
and CC N
after IN N
the DT N
drug NN N
treatment NN N
included VBD N
pin-prick JJ N
hyperalgesia NN N
, , N
allodynia NN N
, , N
detection NN N
and CC N
pain NN N
thresholds NNS N
to TO N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
, , N
temporal JJ N
summation NN N
of IN N
repetitive JJ N
electrical JJ N
and CC N
heat NN N
stimuli NNS N
. . N

RESULTS VB p
A DT p
total NN p
of IN p
55 CD p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

VAS NNP o
scores NNS o
decreased VBD N
significantly RB N
compared VBN N
to TO N
the DT N
baseline NN N
measurements NNS N
in IN N
all DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS p
regarding VBG p
pain NN o
intensity NN o
and CC o
escape NN o
medication NN o
. . o

The DT N
areas NNS o
of IN o
allodynia NN o
and CC o
pin-prick JJ o
hyperalgesia NN o
decreased VBN N
significantly RB N
in IN N
venlafaxine NN N
groups NNS N
compared VBN N
to TO N
the DT N
placebo NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
regarding VBG N
the DT N
detection NN N
thresholds NNS N
( ( N
electrical JJ N
and CC N
heat NN N
) ) N
. . N

The DT N
pain NN o
threshold NN o
and CC o
the DT o
summation NN o
threshold NN o
to TO o
electrical JJ o
stimuli NNS o
and CC o
the DT o
summation NN o
threshold NN o
to TO o
heat VB o
stimuli NNS o
increased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine JJ i
groups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
degree NN o
of IN o
the DT o
temporal JJ o
summation NN o
to TO o
electrical JJ o
and CC o
heat NN o
stimuli NNS o
decreased VBN N
significantly RB N
following VBG N
treatment NN N
in IN N
both DT N
venlafaxine NN i
groups NNS N
compared VBN N
to TO N
the DT N
placebo NN N
. . N

CONCLUSION VB N
The DT N
study NN N
showed VBD N
significant JJ N
effect NN N
of IN N
venlafaxine NN i
in IN N
the DT N
manifestations NNS N
of IN N
hyperalgesia NN N
and CC N
temporal JJ N
summation NN N
, , N
but CC N
not RB N
on IN N
the DT N
ongoing JJ N
pain NN N
intensity NN N
. . N

Furthermore RB N
, , N
the DT N
quantitative JJ N
sensory NN N
tests NNS N
provided VBD N
complementing VBG N
information NN N
to TO N
the DT N
clinical JJ N
measures NNS N
. . N

-DOCSTART- -18288059- O O

[ VB N
How WRB N
to TO N
treat VB N
the DT N
relapse NN o
of IN o
NSCLC NNP o
after IN N
surgery NN N
and CC N
chemotherapy NN N
? . N
IFTC NNP N
0702 CD N
randomized VBD N
phase NN N
III NNP N
study NN N
] NNP N
. . N

BACKGROUND NNP N
As IN N
chemotherapy NN N
gains NNS N
wider VBP N
acceptance NN N
for IN N
the DT N
treatment NN N
of IN N
earlier JJR N
stages NNS N
of IN N
NSCLC NNP N
, , N
particularly RB N
in IN N
the DT N
adjuvant NN N
and CC N
neoadjuvant JJ N
setting NN N
, , N
physicians NNS N
face VBP N
a DT N
growing VBG N
population NN N
of IN N
high JJ p
performance NN p
status NN p
patients NNS p
who WP p
have VBP p
relapsed VBN p
after IN p
their PRP$ p
first-line JJ p
chemotherapy NN p
. . p

The DT N
type NN N
of IN N
second-line JJ i
chemotherapy NN i
after IN N
initial JJ N
adjuvant NN N
or CC N
neoadjuvant JJ N
treatment NN N
with IN N
a DT N
platinum-based JJ i
regimen NN i
remains VBZ N
largely RB N
undefined JJ N
. . N

The DT N
current JJ N
study NN N
has VBZ N
been VBN N
designed VBN N
to TO N
compare VB N
the DT N
classical JJ N
mono NN i
chemotherapy NN i
docetaxel NN i
with IN N
a DT N
docetaxel NN i
cisplatin NN i
doublet NN i
. . i

METHODS NNP N
Patients NNPS N
will MD N
be VB N
randomized VBN N
in IN N
2 CD N
arms NNS N
. . N

Arm NN N
: : N
docetaxel NN i
cisplatin NN i
( ( N
cycles NNS N
repeated VBN N
every DT N
21 CD N
days NNS N
) ) N
, , N
4 CD N
cycles NNS N
followed VBN N
by IN N
2 CD N
cycles NNS N
of IN N
docetaxel NN N
alone RB N
in IN N
case NN N
of IN N
objective JJ o
response NN o
or CC N
stabilisation NN o
. . o

Arm NN N
B NN N
: : N
docetaxel NN i
alone RB i
( ( N
cycles NNS N
repeated VBN N
every DT N
21 CD N
days NNS N
) ) N
, , N
4 CD N
cycles NNS N
followed VBN N
by IN N
2 CD N
cycles NNS N
of IN N
docetaxel NN N
alone RB N
in IN N
case NN N
of IN N
objective JJ o
response NN o
or CC N
stabilisation NN o
. . o

EXPECTED NNP N
RESULTS NNP N
300 CD p
patients NNS p
will MD p
be VB p
randomized VBN p
with IN N
a DT N
statistical JJ N
hypothesis NN N
of IN N
a DT N
progression NN o
free JJ o
survival NN o
of IN N
3 CD N
months NNS N
in IN N
the DT N
control NN N
arm NN N
and CC N
of IN N
4.5 CD N
months NNS N
in IN N
the DT N
experimental JJ N
arm NN N
. . N

-DOCSTART- -20056901- O O

Modafinil NNP i
effects NNS N
during IN N
acute JJ p
continuous JJ p
positive JJ p
airway NN p
pressure NN p
withdrawal NN p
: : p
a DT N
randomized JJ N
crossover NN N
double-blind JJ N
placebo-controlled JJ N
trial NN N
. . N

RATIONALE NNP N
Continuous NNP i
positive JJ i
airway NN i
pressure NN i
( ( i
CPAP NNP i
) ) i
use NN N
is VBZ N
associated VBN N
with IN N
reduced JJ N
motor NN N
vehicle NN N
accidents NNS N
in IN N
patients NNS p
with IN p
obstructive JJ p
sleep NN p
apnea NN p
( ( p
OSA NNP p
) ) p
. . p

However RB N
, , N
interruption NN N
of IN N
CPAP NNP N
therapy NN N
is VBZ N
common JJ N
and CC N
is VBZ N
associated VBN N
with IN N
a DT N
decline NN N
in IN N
daytime JJ N
function NN N
. . N

OBJECTIVES IN N
We PRP N
hypothesized VBD N
that IN N
the DT N
wakefulness NN N
promoter NN N
, , N
modafinil NN N
, , N
would MD N
ameliorate VB N
this DT N
decline NN N
. . N

METHODS JJ N
Patients NNPS p
were VBD p
admitted VBN p
to TO p
the DT p
laboratory NN p
for IN p
three CD p
consecutive JJ p
nights NNS p
. . p

CPAP NNP i
was VBD N
used VBN N
for IN N
the DT N
first JJ N
night NN N
, , N
followed VBN N
by IN N
a DT N
baseline NN N
day NN N
, , N
and CC N
was VBD N
then RB N
withdrawn NN N
for IN N
the DT N
two CD N
subsequent JJ N
nights NNS N
( ( N
nasal JJ N
airflow RB N
monitored VBD N
) ) N
. . N

On IN N
each DT N
of IN N
the DT N
mornings NNS N
after IN N
the DT N
two CD N
CPAP NNP N
withdrawal NN N
nights NNS N
, , N
patients NNS N
received VBD N
200 CD i
mg NNS i
modafinil NN i
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
21 CD N
) ) N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
design NN N
. . N

Treatment NN N
periods NNS N
were VBD N
separated VBN N
by IN N
a DT N
5-week JJ N
washout NN N
. . N

Driving NNP o
simulator NN o
performance NN o
, , o
neurocognitive JJ o
performance NN o
, , o
and CC o
subjective JJ o
alertness NN o
were VBD N
measured VBN N
by IN N
the DT N
AusEd NNP N
driving NN N
simulator NN N
, , N
psychomotor NN N
vigilance NN N
task NN N
, , N
and CC N
Karolinska NNP N
Sleepiness NNP N
Scale NNP N
, , N
respectively RB N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
During IN N
CPAP NNP N
withdrawal NN N
, , N
severe JJ o
sleep-disordered JJ o
breathing NN o
was VBD N
evident JJ N
and CC N
administration NN N
of IN N
modafinil NNS N
improved VBN N
simulated JJ o
driving NN o
performance NN o
( ( o
steering VBG o
variability NN o
, , N
P NNP N
< NNP N
0.0001 CD N
; : N
mean JJ o
reaction NN o
time NN o
, , N
P NNP N
< NNP N
or= VBZ N
0.0002 CD N
; : N
lapses NNS o
, , N
P NNP N
< NNP N
or= VBZ N
0.01 CD N
on IN N
a DT N
concurrent JJ N
task NN N
) ) N
, , N
psychomotor JJ o
vigilance NN o
task NN o
( ( N
mean JJ N
1/reaction CD N
time NN N
and CC N
lapses NNS N
, , N
both DT N
P NNP N
< NNP N
or= IN N
0.0002 CD N
) ) N
, , N
and CC N
subjective JJ o
sleepiness NN o
( ( N
P NNP N
< NNP N
or= IN N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Modafinil NNP N
prevented VBD N
the DT N
decline NN N
in IN N
simulated JJ N
driving NN o
performance NN o
, , o
neurocognitive JJ o
performance NN o
, , N
and CC N
subjective JJ o
sleepiness NN o
in IN N
patients NNS p
with IN p
OSA NNP p
with IN N
acutely RB N
interrupted VBN N
CPAP NNP N
therapy NN N
. . N

Clinical JJ N
trial NN N
registered VBD N
with IN N
the DT N
Australian JJ N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
at IN N
www.anzctr.org.au NN N
( ( N
ACTRN12606000027516 NNP N
) ) N
. . N

-DOCSTART- -16337719- O O

Safety NN o
and CC o
immunogenicity NN o
of IN N
IMVAMUNE NNP i
, , N
a DT N
promising JJ N
candidate NN N
as IN N
a DT N
third JJ N
generation NN N
smallpox NN N
vaccine NN N
. . N

A DT N
Phase NN N
I PRP N
trial NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
safety NN o
and CC o
immunogenicity NN o
of IN N
the DT N
third JJ i
generation NN i
smallpox VBD i
vaccine JJ i
MVA-BN NNP i
( ( i
IMVAMUNE NNP i
) ) i
, , N
a DT N
highly RB N
attenuated VBN N
clone NN N
derived VBN N
from IN N
the DT N
Modified NNP N
Vaccinia NNP N
Virus NNP N
Ankara NNP N
strain NN N
571 CD N
, , N
in IN p
naive JJ p
and CC p
pre-immunized JJ p
subjects NNS p
. . p

A DT p
total NN p
of IN p
86 CD p
healthy JJ p
subjects NNS p
received VBD N
the DT N
vaccine NN i
in IN N
five CD N
groups NNS N
using VBG N
different JJ N
doses NNS N
and CC N
routes NNS N
of IN N
administration NN N
. . N

All DT N
38 CD N
subjects NNS N
seroconverted VBN N
in IN N
the DT N
groups NNS N
receiving VBG N
the DT N
highest JJS N
dose NN N
( ( N
10 CD N
( ( N
8 CD N
) ) N
TCID50 NN N
) ) N
. . N

All DT N
vaccinations NNS N
were VBD N
well RB o
tolerated VBN o
with IN N
mainly RB N
mild NN o
or CC o
moderate JJ o
pain NN o
at IN o
the DT o
injection NN o
site NN o
being VBG N
the DT N
most RBS N
frequent JJ N
symptom NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
MVA-BN NNP N
has VBZ N
the DT N
potential JJ N
to TO N
be VB N
developed VBN N
as IN N
an DT N
efficient NN o
and CC o
safe JJ o
alternative NN N
to TO N
the DT N
conventional JJ N
smallpox JJ N
vaccines NNS N
such JJ N
as IN N
Lister-Elstree NNP i
or CC i
Dryvax NNP i
. . i

Unique NNP N
attributes VBZ N
render VBP N
it PRP N
a DT N
promising JJ N
candidate NN N
for IN N
prophylactic JJ N
mass NN N
immunization NN N
, , N
even RB N
in IN N
subjects NNS N
for IN N
whom WP N
conventional JJ N
smallpox NN N
vaccines NNS N
are VBP N
contraindicated VBN N
. . N

-DOCSTART- -24315475- O O

Radiation NN N
and CC N
contrast NN N
agent NN N
doses NNS N
reductions NNS N
by IN N
using VBG N
80-kV JJ N
tube NN N
voltage NN N
in IN N
coronary JJ N
computed VBD N
tomographic JJ N
angiography NN N
: : N
a DT N
comparative JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
80-kilovoltage NN i
( ( i
kV NN i
) ) i
tube NN i
voltage NN i
coronary JJ i
computed VBD i
tomographic JJ i
angiography NN i
( ( i
CCTA NNP i
) ) i
with IN N
a DT N
reduced JJ N
amount NN N
of IN N
contrast NN N
agent NN N
on IN N
qualitative JJ N
and CC N
quantitative JJ N
image NN N
quality NN N
parameters NNS N
and CC N
on IN N
radiation NN N
dose NN N
in IN p
patients NNS p
with IN p
a DT p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
) ) p
< VBD p
23.0 CD p
kg/m NN p
( ( p
2 CD p
) ) p
. . p

METHODS NNP N
One CD p
hundred CD p
and CC p
twenty JJ p
consecutive JJ p
patients NNS p
with IN p
a DT p
BMI NNP p
< NNP p
23.0 CD p
kg/m NN p
( ( p
2 CD p
) ) p
and CC p
a DT p
low JJ p
calcium NN p
load NN p
undergoing VBG p
retrospective JJ i
electrocardiogram NN i
( ( i
ECG NNP i
) ) i
-gated VBD i
dual-source JJ i
CCTA NNP i
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
[ VBD i
standard-tube JJ i
voltage NN i
( ( i
120-kV JJ i
) ) i
vs. FW i
low-tube JJ i
voltage NN i
( ( i
80-kV JJ i
) ) i
] NN i
. . N

The DT N
injection NN N
flow NN N
rate NN N
of IN N
contrast NN N
agent NN N
( ( N
350 CD N
mg RB N
I/mL NNP N
) ) N
was VBD N
adjusted VBN N
to TO N
body VB N
weight NN N
of IN N
each DT N
patient NN N
( ( N
4.5-5.5 JJ N
mL/s NN N
in IN N
the DT N
120-kV JJ N
group NN N
and CC N
2.8-3.8 JJ N
mL/s NN N
in IN N
the DT N
80-kV JJ N
group NN N
) ) N
. . N

Radiation NN o
and CC o
contrast NN o
agent NN o
doses NNS o
were VBD N
evaluated VBN N
. . N

Quantitative JJ o
image NN o
quality NN o
parameters NNS o
and CC o
figure NN o
of IN o
merit NN o
( ( o
FOM NNP o
) ) o
of IN N
coronary JJ N
artery NN N
were VBD N
evaluated VBN N
. . N

Each DT N
coronary JJ N
segment NN N
was VBD N
evaluated VBN N
for IN N
image NN o
quality NN o
on IN N
a DT N
4-point JJ N
scale NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
the DT N
120-kV JJ N
group NN N
, , N
effective JJ o
dose NN o
and CC o
amount NN o
of IN o
contrast NN o
agent NN o
in IN N
the DT N
80-kV JJ i
group NN N
were VBD N
decreased VBN N
by IN N
57.8 CD N
% NN N
and CC N
30.5 CD N
% NN N
( ( N
effective JJ N
dose:2.7 NN N
? . N
0.5 CD N
vs. IN N
6.4 CD N
? . N
1.3 CD N
mSv NN N
; : N
amount NN N
of IN N
contrast NN N
agent:57.1 NN N
? . N
3.2 CD N
vs. IN N
82.1 CD N
? . N
6.1 CD N
mL NN N
; : N
both DT N
p VBP N
< $ N
0.0001 CD N
) ) N
, , N
respectively RB o
. . o

Image NNP o
noise NN o
was VBD o
22.7 CD N
? . N
2.1HU CD N
for IN N
120-kV JJ N
images NNS N
and CC N
33.2 CD N
? . N
5.2 CD N
HU NNP N
for IN N
80-kV JJ N
images NNS N
( ( N
p JJ N
< NNP N
0.0001 CD o
) ) o
. . o

Signal-to-noise JJ o
ratio NN o
( ( o
SNR NNP o
) ) o
and CC o
contrast-to-noise JJ o
ratio NN o
( ( o
CNR NNP o
) ) o
in IN o
the DT o
proximal JJ o
right JJ o
coronary NN o
artery NN o
( ( o
RCA NNP o
) ) o
and CC o
left VBD o
main JJ o
coronary JJ o
artery NN o
( ( o
LMA NNP o
) ) o
were VBD N
all DT N
lower JJR N
in IN N
80-kV CD N
than IN N
120-kV JJ N
images NNS N
( ( N
SNR NNP N
in IN N
the DT N
proximal JJ N
RCA NNP N
: : N
16.5 CD N
? . N
1.8 CD N
vs. IN N
19.4 CD N
? . N
2.8 CD N
; : N
SNR NNP N
in IN N
the DT N
LMA NNP N
: : N
16.3 CD N
? . N
2.0 CD N
vs.19.6 NN N
? . N
2.7 CD N
; : N
CNR NNP N
in IN N
the DT N
proximal JJ N
RCA NNP N
: : N
19.4 CD N
? . N
2.3 CD N
vs.22.9 NN N
? . N
3.0 CD N
; : N
CNR NNP N
in IN N
the DT N
LMA NNP N
: : N
18.8 CD N
? . N
2.4 CD N
vs. IN N
22.7 CD N
? . N
2.9 CD N
; : N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
. . N

FOM NNP o
were VBD o
all DT o
significantly RB N
higher JJR N
in IN N
80-kV CD N
than IN N
120-kV JJ N
images NNS N
( ( N
proximal JJ N
RCA NNP N
: : N
146.7 CD N
? . N
45.1 CD N
vs. IN N
93.4 CD N
? . N
32.0 CD N
; : N
LMA NNP N
: : N
139.1 CD N
? . N
47.2 CD N
vs. IN N
91.6 CD N
? . N
31.1 CD N
; : N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
image NN o
quality NN o
score NN o
between IN o
the DT N
two CD N
groups NNS N
( ( N
3.3 CD N
? . N
0.8 CD N
vs. IN N
3.3 CD N
? . N
0.8 CD N
, , N
p=0.068 NN N
) ) N
despite IN N
decreased VBN o
SNR NNP o
and CC o
CNR NNP o
of IN o
coronary JJ o
artery NN o
in IN N
the DT N
80-kV JJ N
group NN N
. . N

CONCLUSION VB N
The DT i
80-kV JJ i
protocol NN i
significantly RB N
reduces VBZ o
radiation NN o
and CC o
contrast NN o
agent NN o
doses NNS o
in IN o
CCTA NNP o
in IN p
patients NNS p
with IN p
a DT p
low JJ p
BMI NNP p
< NN p
23.0 CD p
kg/m NN p
( ( p
2 CD p
) ) p
and CC p
a DT p
low JJ p
calcium NN p
load NN p
while IN N
maintaining VBG N
image NN N
quality NN N
. . N

-DOCSTART- -688257- O O

Adriamycin NNP i
and CC i
chlorambucil VB i
versus NN i
adriamycin NN i
and CC i
thiabendazole NN i
in IN N
the DT N
treatment NN N
of IN N
extensive JJ o
, , o
non-small JJ o
cell NN o
carcinoma NN o
of IN o
the DT o
lung NN o
: : o
a DT p
Southwest NNP p
Oncology NNP p
Group NNP p
pilot NN N
study NN N
. . N

-DOCSTART- -21800222- O O

Nasal NNP i
versus NN i
oronasal RB i
continuous JJ i
positive JJ i
airway NN i
pressure NN i
masks NNS i
for IN N
obstructive JJ p
sleep JJ p
apnea NN p
: : p
a DT N
pilot NN N
investigation NN N
of IN N
pressure NN N
requirement NN N
, , N
residual JJ N
disease NN N
, , N
and CC N
leak NN N
. . N

PURPOSE VB N
This DT N
single-blinded JJ N
, , N
randomized VBN N
, , N
controlled VBN N
pilot NN N
study NN N
aimed VBN N
to TO N
investigate VB N
whether IN N
there EX N
is VBZ N
a DT N
difference NN N
between IN N
nasal NN i
and CC i
oronasal NN i
masks NNS i
in IN N
therapeutic JJ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
( ( N
CPAP NNP N
) ) N
requirement NN N
, , N
residual JJ N
disease NN N
, , N
or CC N
leak VB N
when WRB N
treating VBG N
obstructive JJ p
sleep NN p
apnea NN p
( ( p
OSA NNP p
) ) p
and CC N
if IN N
differences NNS N
were VBD N
related VBN N
to TO N
measures NNS N
of IN N
upper JJ N
airway NN N
size NN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
severe JJ p
OSA NNP p
currently RB p
using VBG p
CPAP NNP p
at IN p
?4 NNP p
h/night NN p
with IN p
a DT p
nasal JJ i
mask NN i
were VBD i
examined VBN p
( ( p
including VBG p
Mallampati NNP p
scale NN p
, , p
incisal NN p
relationship NN p
, , p
and CC p
mandibular JJ p
protrusion NN p
) ) p
and CC p
then RB N
randomized VBN N
to TO N
receive VB i
auto-positive JJ i
airway NN i
pressure NN i
( ( i
PAP NNP i
) ) i
or CC i
fixed VBN i
CPAP NNP i
at IN i
a DT i
manually RB i
titrated JJ i
pressure NN i
for IN i
1 CD N
week NN N
each DT N
at IN N
home NN N
, , N
with IN N
immediate JJ N
crossover NN N
. . N

Within IN N
each DT N
week NN N
, , N
a DT N
nasal JJ i
mask NN i
and CC i
two CD i
oronasal NN i
masks NNS i
were VBD i
to TO N
be VB N
used VBN N
for IN N
two CD N
or CC N
three CD N
nights NNS N
each DT N
in IN N
random JJ N
order NN N
. . N

Data NNS N
were VBD N
downloaded VBN N
from IN N
the DT N
device NN N
. . N

RESULTS NNP p
Twelve NNP p
patients NNS p
completed VBD p
the DT p
trial NN p
( ( p
mean VB p
? . p
SD NNP p
AHI NNP p
59.8 CD p
? . p
28.6 CD p
events/h NN p
; : p
CPAP NNP p
11.1 CD p
? . p
3.2 CD p
cmH NN p
( ( p
2 CD p
) ) p
O NNP p
; : p
BMI NNP p
37.7 CD p
? . p
5.0 CD p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
. . p

During IN p
auto-PAP JJ o
, , o
the DT o
median JJ o
95th CD o
percentile JJ o
pressure NN o
delivered VBN o
with IN N
all DT N
masks NNS N
was VBD N
within IN N
0.5 CD N
cmH NN N
( ( N
2 CD N
) ) N
O NNP N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

During IN N
CPAP NNP N
, , N
median JJ o
residual JJ o
AHI NNP o
was VBD o
0.61 CD N
( ( N
IQR NNP N
= NNP N
1.18 CD N
) ) N
for IN N
the DT i
nasal NN i
mask NN i
, , i
1.70 CD N
( ( N
IQR NNP N
= NNP N
4.04 CD N
) ) N
for IN i
oronasal NN i
mask NN i
1 CD N
, , N
and CC N
2.48 CD N
( ( N
IQR NNP N
= NNP N
3.74 CD N
) ) N
for IN i
oronasal NN i
mask NN i
2 CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
. . N

The DT o
95th CD o
percentile NN o
leak NN o
was VBD N
lowest JJS N
with IN N
the DT N
nasal JJ N
mask NN N
during IN N
both DT N
CPAP NNP N
and CC N
auto-PAP NN N
( ( N
both DT N
p VBP N
< $ N
0.01 CD N
) ) N
. . N

Differences NNS N
in IN N
pressure NN N
or CC N
residual JJ N
disease NN N
were VBD N
not RB N
related VBN N
to TO N
measures NNS N
of IN N
upper JJ N
airway NN N
shape NN N
or CC N
body NN N
habitus NN N
. . N

CONCLUSIONS NNP N
In IN N
obese JJ N
OSA NNP N
patients NNS N
changing VBG N
from IN N
a DT N
nasal NN N
to TO i
oronasal VB i
mask NN i
increased VBN o
leak NN o
and CC o
residual JJ o
AHI NNP o
but CC o
did VBD N
not RB N
affect VB N
the DT N
therapeutic JJ N
pressure NN N
requirement NN N
. . N

The DT N
findings NNS N
of IN N
the DT N
current JJ N
study NN N
highlight VBD N
mask RB N
leak JJ N
as IN N
the DT N
major JJ N
difficulty NN N
in IN N
the DT N
use NN N
of IN N
oronasal NN i
masks NNS i
. . N

-DOCSTART- -15914517- O O

Are NNP N
brand-name JJ N
and CC N
generic JJ i
warfarin NN i
interchangeable JJ N
? . N
Multiple JJ N
n-of-1 JJ N
randomized NN N
, , N
crossover NN N
trials NNS N
. . N

BACKGROUND NNP N
Warfarin NNP i
is VBZ N
a DT N
commonly RB N
used VBN N
anticoagulant NN N
in IN N
North NNP N
America NNP N
. . N

Several JJ N
generic JJ N
formulations NNS N
have VBP N
been VBN N
approved VBN N
, , N
raising VBG N
concern NN N
over IN N
the DT N
safety NN o
and CC N
efficacy NN o
of IN N
these DT N
products NNS N
compared VBN N
with IN N
brand-name JJ N
Coumadin NNP i
. . i

OBJECTIVE NNP N
To TO N
ensure VB N
that IN N
generic JJ N
warfarin NN N
products NNS N
can MD N
be VB N
safely RB N
interchanged VBN N
with IN N
Coumadin NNP N
. . N

METHODS NNP N
Multiple NNP N
n-of-1 JJ N
randomized NN N
, , N
double-blind NN N
, , N
crossover NN N
trials NNS N
switched VBD N
outpatients NNS p
( ( p
N NNP p
= NNP p
7 CD p
) ) p
between IN N
a DT N
generic JJ i
warfarin NN i
formulation NN i
( ( i
Apo-warfarin NNP i
) ) i
and CC i
Coumadin NNP i
over IN i
30 CD i
weeks NNS i
. . i

Study NNP p
patients NNS p
took VBD p
each DT p
drug NN p
for IN p
five CD p
3-week JJ p
periods NNS p
, , p
with IN p
international JJ o
normalized VBN o
ratio NN o
( ( o
INR NNP o
) ) o
measurements VBZ p
taken VBN p
twice RB p
per IN p
period NN p
. . p

Inter- JJ N
and CC N
intrapatient JJ N
differences NNS N
between IN N
generic JJ N
warfarin NN i
and CC N
Coumadin NNP i
were VBD N
compared VBN N
, , N
and CC N
overall JJ N
study NN N
patient NN N
results NNS N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
a DT N
Coumadin NNP N
control NN N
group NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
warfarin NN N
products NNS N
in IN N
terms NNS N
of IN N
mean JJ o
INR NNP o
results NNS o
or CC N
number NN o
of IN o
dosage JJ o
adjustments NNS o
required VBN o
. . o

There EX N
also RB N
was VBD N
no DT N
difference NN N
in IN N
INR NNP o
variation NN o
based VBN N
on IN N
warfarin JJ N
formulation NN N
( ( N
p JJ N
> NNP N
0.69 CD N
) ) N
, , N
nor CC N
was VBD N
a DT N
patient NN N
and CC N
warfarin JJ N
interaction NN N
found VBD N
( ( N
p JJ N
> NNP N
0.81 CD N
) ) N
. . N

The DT N
INR NNP o
results NNS o
were VBD N
not RB N
influenced VBN N
by IN N
whether IN N
patients NNS N
were VBD N
maintained VBN N
on IN N
Coumadin NNP N
only RB N
( ( N
control VB N
group NN N
) ) N
or CC N
interchanged VBN N
between IN N
Coumadin NNP i
and CC N
generic JJ i
warfarin NN i
( ( N
p JJ N
= NNP N
0.98 CD N
) ) N
. . N

CONCLUSIONS VB N
It PRP N
appears VBZ N
that IN N
patients NNS N
can MD N
safely RB o
and CC o
effectively RB o
switch VB o
between IN N
generic JJ N
warfarin NN i
and CC N
Coumadin NNP i
. . i

-DOCSTART- -26082615- O O

Efficacy NN o
of IN N
fimasartan/hydrochlorothiazide JJ i
combination NN i
in IN N
hypertensive JJ p
patients NNS p
inadequately RB p
controlled VBN p
by IN p
fimasartan JJ i
monotherapy NN i
. . i

BACKGROUND IN N
The DT N
study NN N
reported VBD N
here RB N
compared VBN N
the DT N
blood NN o
pressure NN o
( ( N
BP NNP N
) ) N
-lowering VBG N
efficacy NN N
of IN N
fimasartan JJ i
alone NN i
with IN N
that DT N
of IN N
fimasartan/hydrochlorothiazide NN i
( ( i
HCTZ NNP i
) ) i
combination NN i
in IN N
patients NNS p
whose WP$ p
BP NNP p
goal NN p
was VBD p
not RB p
achieved VBN p
after IN p
4 CD p
weeks NNS p
of IN p
treatment NN p
with IN p
once-daily JJ p
fimasartan JJ i
60 CD p
mg. JJ p
METHODS NNP N
Patients NNPS p
with IN p
sitting VBG o
diastolic JJ o
blood NN o
pressure NN o
( ( o
siDBP NN o
) ) o
?90 VBZ p
mmHg NN p
with IN p
4 CD p
weeks NNS p
of IN p
once-daily JJ i
fimasartan JJ i
60 CD i
mg NNS p
were VBD p
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
once-daily JJ i
fimasartan NN i
60 CD i
mg/HCTZ NN i
12.5 CD i
mg NN i
or CC i
fimasartan JJ i
60 CD i
mg NN N
for IN N
4 CD N
weeks NNS N
. . N

After IN N
4 CD N
weeks NNS N
, , N
the DT N
dose NN N
was VBD N
increased VBN N
from IN i
fimasartan JJ i
60 CD i
mg/HCTZ NN i
12.5 CD i
mg NN N
to TO N
fimasartan VB i
120 CD i
mg/HCTZ NN i
12.5 CD i
mg NN N
or CC N
from IN i
fimasartan JJ i
60 CD i
mg NN N
to TO N
fimasartan VB i
120 CD i
mg NN N
if IN N
siDBP NN N
was VBD N
?90 JJ N
mmHg NN N
. . N

RESULTS NNP N
Of IN N
the DT N
263 CD p
randomized JJ p
patients NNS p
, , p
256 CD p
patients NNS p
who WP p
had VBD p
available JJ o
efficacy NN o
data NNS o
were VBD o
analyzed VBN p
. . p

The DT p
fimasartan/HCTZ JJ i
treatment NN i
group NN N
showed VBD N
a DT N
greater JJR N
reduction NN o
of IN o
siDBP NN o
compared VBN o
to TO N
the DT N
fimasartan JJ i
treatment NN i
group NN N
at IN N
Week NNP N
4 CD N
( ( N
6.88?8.10 CD N
mmHg NN N
vs NN N
3.38?7.33 CD N
, , N
P=0.0008 NNP N
) ) N
, , N
and CC N
the DT N
effect NN N
persisted VBN N
at IN N
Week NNP N
8 CD N
( ( N
8.67?9.39 CD N
mmHg NN N
vs NN N
5.02?8.27 CD N
mmHg NN N
, , N
P=0.0023 NNP N
) ) o
. . o

Reduction NN o
of IN o
sitting VBG o
systolic JJ o
BP NNP o
in IN o
the DT o
fimasartan/HCTZ JJ i
treatment NN i
group NN N
was VBD N
also RB N
greater JJR N
than IN N
that DT N
in IN N
the DT i
fimasartan JJ i
treatment NN i
group NN N
( ( N
at IN N
Week NNP N
4 CD N
, , N
10.50?13.76 CD N
mmHg NN N
vs NN N
5.75?12.18 CD N
mmHg NN N
, , N
P=0.0069 NNP N
and CC N
, , N
at IN N
Week NNP N
8 CD N
, , N
13.45?15.15 CD N
mmHg NN N
vs NN N
6.84?13.57 CD N
mmHg NN N
, , N
P=0.0007 NNP N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
a DT o
reduction NN o
of IN o
siDBP NN o
?10 NNP o
mmHg NN o
from IN o
baseline NN N
and/or NN o
a DT o
mean JJ o
siDBP NN o
< VBD N
90 CD N
mmHg NN N
after IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
was VBD N
higher RBR N
in IN N
the DT N
fimasartan/HCTZ JJ i
treatment NN i
group NN i
than IN N
in IN N
the DT i
fimasartan JJ i
treatment NN i
group NN N
( ( N
53.6 CD N
% NN N
vs JJ N
39.8 CD N
% NN N
, , N
P=0.0359 NNP N
) ) N
. . N

The DT N
overall JJ o
incidence NN o
of IN o
adverse JJ o
drug NN o
reaction NN o
was VBD N
11.79 CD N
% NN N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
combination NN N
treatment NN i
of IN i
fimasartan NN i
and CC i
HCTZ NNP i
achieved VBD i
better RBR N
BP NNP N
control NN N
than IN i
fimasartan JJ i
monotherapy NN i
, , i
and CC N
had VBD N
comparable JJ N
safety NN N
and CC N
tolerance NN N
to TO i
fimasartan VB i
monotherapy NN i
. . i

-DOCSTART- -21636141- O O

Short-term JJ N
effect NN N
of IN N
pitavastatin NN i
on IN N
the DT N
reactive JJ o
hyperemic JJ o
index NN o
in IN N
post-menopausal JJ p
women NNS p
with IN p
high JJ p
levels NNS p
in IN p
serum JJ p
LDL-cholesterol NNP p
. . p

-DOCSTART- -9028057- O O

Opioid-immune JJ N
interactions NNS N
in IN N
autism NN p
: : p
behavioural JJ N
and CC N
immunological JJ N
assessment NN N
during IN N
a DT N
double-blind JJ N
treatment NN N
with IN N
naltrexone NN i
. . i

The DT N
emerging VBG N
concept NN N
of IN N
opioid JJ N
peptides NNS N
as IN N
a DT N
new JJ N
class NN N
of IN N
chemical JJ N
messengers NNS N
of IN N
the DT N
neuroimmune JJ N
axis NN N
and CC N
the DT N
presence NN N
of IN N
a DT N
number NN N
of IN N
immunological JJ N
abnormalities NNS N
in IN N
infantile JJ N
autism NN N
prompted VBD N
us PRP N
to TO N
correlate VB N
biological JJ N
( ( N
hormonal JJ N
and CC N
immunological JJ N
) ) N
determinations NNS N
and CC N
behavioural JJ N
performances NNS N
during IN N
treatment NN N
with IN N
the DT N
potent NN N
opiate JJ N
antagonist NN N
, , N
naltrexone NN i
( ( i
NAL NNP i
) ) i
. . i

Twelve NNP p
autistic JJ p
patients NNS p
ranging VBG p
from IN p
7 CD p
to TO p
15 CD p
years NNS p
, , p
diagnosed VBD p
according VBG p
to TO p
DSM-III-R NNP p
, , N
entered VBD N
a DT N
double-blind JJ i
crossover NN i
study NN i
with IN i
NAL NNP i
at IN i
the DT i
doses NNS i
of IN i
0.5 CD i
, , i
1.0 CD i
and CC i
1.5 CD i
mg/kg NN i
every DT i
48 CD i
hours NNS i
. . i

The DT i
behavioural JJ i
evaluation NN i
was VBD i
conducted VBN i
using VBG i
the DT i
specific JJ i
BSE NNP o
and CC o
CARS NNP o
rating NN o
scales NNS o
NAL NNP i
treatment NN i
produced VBD i
a DT i
significant JJ i
reduction NN i
of IN i
the DT i
autistic JJ o
symptomatology NN o
in IN i
seven CD i
( ( i
responders NNS i
) ) i
out IN i
of IN i
12 CD i
children NNS i
. . i

The DT N
behavioural JJ N
improvement NN N
was VBD N
accompanied VBN N
by IN N
alterations NNS N
in IN N
the DT N
distribution NN N
of IN N
the DT N
major JJ N
lymphocyte NN N
subsets NNS N
, , N
with IN N
a DT N
significant JJ N
increase NN N
of IN N
the DT N
T-helper-inducers NNP o
( ( o
CD4+CD8- NNP o
) ) o
and CC N
a DT N
significant JJ N
reduction NN N
of IN N
the DT N
T-cytotoxic-suppressor NNP o
( ( o
CD4-CD8+ NNP o
) ) o
resulting VBG N
in IN N
a DT N
normalization NN N
of IN N
the DT N
CD4/CD8 NNP o
ratio NN o
. . o

Changes NNS N
in IN N
natural JJ o
killer NN o
cells NNS o
and CC o
activity NN o
were VBD N
inversely RB N
related VBN N
to TO N
plasma VB N
beta-endorphin JJ N
levels NNS N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
the DT N
mechanisms NNS N
underlying VBG N
opioid-immune JJ N
interactions NNS N
are VBP N
altered VBN N
in IN N
this DT N
population NN p
of IN p
autistic JJ p
children NNS p
and CC N
that DT N
an DT N
immunological JJ N
screening NN N
may MD N
have VB N
prognostic JJ N
value NN N
for IN N
the DT N
pharmacological JJ i
therapy NN i
with IN i
opiate JJ i
antagonists NNS i
. . i

-DOCSTART- -25283504- O O

Pharmacodynamic JJ N
analysis NN N
of IN N
intravenous JJ i
recombinant JJ i
urate JJ i
oxidase NN i
using VBG N
an DT N
indirect JJ p
pharmacological JJ p
response NN p
model NN p
in IN p
healthy JJ p
subjects NNS p
. . p

AIM NNP N
Pharmacodynamic NNP N
analysis NN N
of IN N
intravenous JJ i
recombinant JJ i
urate JJ i
oxidase NN i
produced VBN N
by IN N
Escherichia NNP N
coli NN N
was VBD N
performed VBN N
in IN p
healthy JJ p
subjects NNS p
using VBG p
a DT p
pharmacokinetic/pharmacodynamic JJ p
( ( p
PK/PD NNP p
) ) p
model NN p
. . p

METHODS CC N
A DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ i
study NN N
was VBD N
performed VBN N
in IN p
40 CD p
healthy JJ p
Chinese JJ p
subjects NNS p
( ( p
4 CD p
groups NNS p
of IN p
10 CD p
subjects NNS p
each DT p
, , p
placebo VBZ p
4:1 CD p
ratio NN p
) ) p
who WP p
received VBD p
infusions NNS p
of IN p
uricase NN i
( ( p
single JJ p
doses NNS p
of IN p
0.1 CD p
, , p
0.2 CD p
, , p
and CC p
0.3 CD p
mg/kg NN p
; : p
multiple JJ p
doses NNS p
of IN p
0.2 CD p
mg?kg NN p
( ( p
-1 NNP p
) ) p
?d NN p
( ( p
-1 NNP p
) ) p
for IN p
7 CD p
d NN p
) ) p
. . p

PK JJ N
profiles NNS N
were VBD N
determined VBN N
through IN o
plasma JJ o
uricase JJ o
activity NN o
, , o
and CC N
PD NNP N
profiles NNS N
were VBD N
established VBN N
using VBG o
uric JJ o
acid NN o
levels NNS o
in IN o
plasma NN o
and CC o
urine NN o
. . o

The DT N
plasma NN N
PD NNP N
parameter NN N
was VBD N
estimated VBN N
as IN N
changes NNS N
in IN N
plasma NN o
uric JJ o
acid NN o
levels NNS o
as IN o
the DT N
effect NN N
in IN N
the DT N
indirect JJ N
response NN N
model NN o
. . o

Adverse JJ o
events NNS o
were VBD o
also RB N
monitored VBN N
. . N

RESULTS VB N
A DT N
two-compartment JJ N
PK NNP N
model NN N
with IN N
constant JJ N
iv NN N
input NN N
and CC N
first-order NN N
output NN N
was VBD N
used VBN N
to TO N
describe VB N
the DT N
kinetic JJ N
process NN N
of IN N
plasma JJ N
uricase NN N
. . N

The DT N
low JJ N
value NN N
( ( N
2.8 CD N
U/L NNP N
) ) N
of IN N
drug NN N
concentration NN N
that WDT N
achieved VBD N
50 CD N
% NN N
of IN N
maximum JJ N
effect NN N
( ( N
EC50 NNP N
) ) N
indicated VBD N
that IN N
low JJ N
plasma NN N
uricase NN N
concentrations NNS N
were VBD N
sufficient JJ N
to TO N
produce VB o
pharmacological JJ o
effects NNS o
. . o

A DT N
strong JJ N
relationship NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
=0.9991 NN N
) ) N
between IN N
the DT o
mean JJ o
uric JJ o
acid NN o
concentration NN o
in IN o
blood NN o
and CC o
the DT o
mean JJ o
uric JJ o
acid JJ o
excretion NN o
rate NN o
in IN o
urine NN o
in IN o
the DT N
range NN N
of IN N
11 CD N
to TO N
30 CD N
h NN N
after IN N
single JJ N
dosing NN N
was VBD N
found VBN N
. . N

Infusions NNS p
of IN p
uricase NN i
were VBD i
well RB p
tolerated VBN p
in IN p
all DT p
subjects NNS p
. . p

CONCLUSION VB N
The DT N
PK/PD NNP N
model NN N
predicted VBD N
the DT p
effective JJ p
dose NN p
to TO p
be VB p
0.1 CD p
mg/kg NN p
in IN p
healthy JJ p
subjects NNS p
. . p

The DT N
excretion NN N
rate NN N
of IN N
uric JJ N
acid NN N
in IN N
urine NN N
may MD N
be VB N
used VBN N
as IN N
a DT N
new JJ N
index NN N
for IN N
pharmacological JJ N
effects NNS N
in IN N
further JJ N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -20122038- O O

Enhancing VBG N
caregiver NN N
health NN N
: : N
findings NNS N
from IN N
the DT N
resources NNS N
for IN N
enhancing VBG N
Alzheimer NNP p
's POS p
caregiver NN p
health NN p
II NNP p
intervention NN p
. . p

OBJECTIVES NNP N
To TO N
examine VB N
the DT N
relationships NNS N
between IN N
changes NNS N
from IN N
baseline NN N
to TO N
post-Resources NNS i
for IN i
Enhancing VBG i
Alzheimer NNP i
's POS i
Caregiver NNP i
Health NNP i
( ( i
REACH NNP i
) ) i
intervention NN i
in IN N
caregiver NN N
( ( N
CG NNP N
) ) N
self-reported JJ N
health NN N
, , N
burden NN N
, , N
and CC N
bother RB N
. . N

DESIGN NNP N
Randomized NNP N
, , N
multisite RB N
clinical JJ N
trial NN N
. . N

SETTING NN N
CG NNP p
and CC p
care VB p
recipient NN p
( ( p
CR NNP p
) ) p
homes NNS p
in IN p
five CD p
U.S. NNP p
cities NNS p
. . p

PARTICIPANTS VB N
Four CD p
hundred CD p
ninety-five JJ p
dementia NN p
CG NNP p
and CC p
CR NNP p
dyads NNS p
( ( p
169 CD p
Hispanic NNP p
, , p
160 CD p
white JJ p
, , p
and CC p
166 CD p
African JJ p
American NNP p
) ) p
receiving VBG p
intervention NN p
and CC p
their PRP$ p
controls NNS p
. . p

INTERVENTION NNP N
CGs NNP N
were VBD N
assigned VBN N
to TO N
the DT N
REACH NNP i
intervention NN i
or CC i
a DT i
no-treatment JJ i
control NN i
group NN i
. . i

Intervention NNP N
subjects VBZ N
received VBN N
individual JJ N
risk NN N
profiles NNS N
and CC N
the DT N
REACH NNP i
intervention NN i
through IN i
nine CD N
in-home JJ i
and CC N
three CD N
telephone NN i
sessions NNS i
over IN N
6 CD N
months NNS N
. . N

Control NNP N
subjects VBZ N
received VBN N
two CD N
brief JJ N
check-in JJ i
telephone NN i
calls VBZ i
during IN N
this DT N
6-month JJ N
period NN N
. . N

MEASUREMENTS PDT N
The DT N
primary JJ N
outcome NN N
was VBD N
change NN o
in IN o
CG NNP o
health NN o
status NN o
from IN N
baseline NN N
to TO N
after IN N
the DT N
intervention NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
CG NNP o
burden NN o
and CC o
bother NN o
after IN o
the DT o
intervention NN o
. . o

RESULTS NNP N
After IN N
the DT N
intervention NN N
, , N
CGs NNP N
reported VBD N
better RBR N
self-rated JJ o
health NN o
, , o
sleep VBP o
quality NN o
, , o
physical JJ o
health NN o
, , o
and CC o
emotional JJ o
health NN o
, , N
which WDT N
was VBD N
related VBN N
to TO N
less JJR N
burden JJ N
and CC N
bother NN N
with IN N
their PRP$ N
caregiving NN N
role NN N
than IN N
for IN N
CGs NNP N
not RB N
receiving VBG N
the DT N
intervention NN N
. . N

Changes NNS N
in IN N
depression NN o
appeared VBD N
to TO N
mediate VB N
these DT N
relationships NNS N
. . N

Several JJ N
racial JJ N
and CC N
ethnic JJ N
group NN N
differences NNS N
existed VBD N
in IN N
physical JJ o
and CC o
emotional JJ o
health NN o
, , N
as RB N
well RB N
as IN N
in IN N
total JJ o
frustration NN o
with IN o
caregiving NN o
, , o
emotional JJ o
burden NN o
, , o
and CC o
CG-rated JJ o
bother NN o
with IN N
CR NNP N
's POS N
activities NNS N
of IN N
daily JJ N
living NN N
and CC N
instrumental JJ N
activities NNS N
of IN N
daily JJ N
living NN N
at IN N
baseline NN N
and CC N
at IN N
follow-up JJ N
, , N
although IN N
differences NNS N
between IN N
baseline NN N
and CC N
posttest NN N
did VBD N
not RB N
vary JJ N
according VBG N
to TO N
race NN N
. . N

CONCLUSION VB N
A DT N
structured JJ N
, , N
multicomponent JJ N
skills NNS N
training VBG N
intervention NN N
that WDT N
targeted VBD N
CG NNP N
self-care JJ N
behaviors NNS N
as IN N
one CD N
of IN N
five CD N
target NN N
areas NNS N
, , N
improved VBN N
self-reported JJ o
health NN o
status NN o
, , N
and CC N
decreased VBD N
burden NN o
and CC N
bother NN N
in IN N
racially RB p
and CC p
ethnically RB p
diverse JJ p
CGs NNP p
of IN p
people NNS p
with IN p
dementia NN p
. . p

-DOCSTART- -23630033- O O

Study NNP N
design NN N
and CC N
rationale NN N
of IN N
a DT N
dose-ranging JJ N
trial NN N
of IN N
LX4211 NNP i
, , N
a DT N
dual JJ N
inhibitor NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
, , N
in IN N
type JJ p
2 CD p
diabetes NNS p
inadequately RB p
controlled VBN p
on IN p
metformin NN p
monotherapy NN p
. . p

Sodium-glucose JJ N
cotransporters NNS N
1 CD N
( ( N
SGLT1 NNP N
) ) N
and CC N
2 CD N
( ( N
SGLT2 NNP N
) ) N
are VBP N
the DT N
major JJ N
cellular JJ N
transporters NNS N
responsible JJ N
for IN N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
glucose VBP N
absorption NN N
and CC N
renal JJ N
glucose NN N
reabsorption NN N
, , N
respectively RB N
. . N

LX4211 NNP i
, , N
a DT N
dual JJ N
inhibitor NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
, , N
reduces VBZ N
glucose JJ N
absorption NN N
from IN N
the DT N
GI NNP N
tract NN N
and CC N
enhances NNS N
urinary JJ N
glucose JJ N
excretion NN N
. . N

Although IN N
several JJ N
SGLT2-selective JJ N
inhibitors NNS N
have VBP N
been VBN N
tested VBN N
in IN N
large JJ N
phase NN N
2 CD N
studies NNS N
, , N
dual JJ N
inhibition NN N
of IN N
SGLT1 NNP N
and CC N
SGLT2 NNP N
is VBZ N
novel JJ N
at IN N
this DT N
stage NN N
of IN N
drug NN N
development NN N
, , N
and CC N
it PRP N
has VBZ N
implications NNS N
for IN N
clinical-trial JJ N
design NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
design NN N
and CC N
rationale NN N
of IN N
a DT N
phase NN N
2 CD N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
group NN N
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN o
LX4211 NNP o
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus NN p
who WP p
have VBP p
inadequate JJ p
glycemic NNS o
control NN o
on IN p
metformin NN p
monotherapy NN p
. . p

The DT N
primary JJ N
endpoint NN N
is VBZ N
the DT N
change NN N
in IN N
glycated JJ o
hemoglobin NN o
A1c NNP o
from IN N
baseline NN N
to TO N
week NN N
12 CD N
. . N

Secondary JJ N
endpoints NNS N
include VBP N
the DT N
proportion NN o
of IN o
subjects NNS o
achieving VBG o
a DT o
glycated JJ o
hemoglobin NN o
A1c NNP o
value NN o
of IN o
< $ o
7 CD o
% NN o
, , o
change NN o
from IN o
baseline NN o
in IN o
fasting VBG o
plasma NN o
glucose NN o
and CC o
postprandial JJ o
glucose NN o
( ( o
as IN o
part NN o
of IN o
an DT o
oral JJ o
glucose NN o
tolerance NN o
test NN o
) ) o
, , o
body NN o
weight NN o
, , o
and CC o
blood NN o
pressure NN o
. . o

Safety NN o
is VBZ N
evaluated VBN N
with IN N
particular JJ N
focus NN N
on IN N
hypoglycemia NN o
, , o
GI NNP o
symptoms NNS o
, , o
and CC o
incidence NN o
of IN o
genitourinary JJ o
tract NN o
infections NNS o
. . o

-DOCSTART- -9989713- O O

Effectiveness NN N
of IN N
active JJ i
physical JJ i
training NN i
as IN N
treatment NN N
for IN N
long-standing JJ p
adductor-related JJ p
groin NN p
pain NN p
in IN p
athletes NNS p
: : p
randomised VBN N
trial NN N
. . N

BACKGROUND NNP N
Groin NNP N
pain NN N
is VBZ N
common JJ N
among IN N
athletes NNS N
. . N

A DT N
major JJ N
cause NN N
of IN N
long-standing JJ N
problems NNS N
is VBZ N
adductor-related JJ p
groin NN p
pain NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
randomised JJ N
clinical JJ N
trial NN N
was VBD N
to TO N
compare VB N
an DT N
active JJ i
training NN i
programme NN i
( ( i
AT NNP i
) ) i
with IN i
a DT i
physiotherapy NN i
treatment NN i
without IN i
active JJ i
training NN i
( ( i
PT NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
adductor-related JJ p
groin NN p
pain NN p
in IN p
athletes NNS p
. . p

METHODS NNP N
68 CD p
athletes NNS p
with IN p
long-standing JJ p
( ( p
median JJ p
40 CD p
weeks NNS p
) ) p
adductor-related JJ p
groin NN p
pain NN p
-- : p
after IN p
examination NN p
according VBG p
to TO p
a DT p
standardised VBN p
protocol NN p
-- : p
were VBD p
randomly RB p
assigned VBN p
to TO p
AT NNP i
or CC p
PT NNP i
. . i

The DT N
treatment NN N
period NN N
was VBD N
8-12 JJ N
weeks NNS N
. . N

4 CD N
months NNS N
after IN N
the DT N
end NN N
of IN N
treatment NN N
a DT N
standardised JJ N
examination NN N
was VBD N
done VBN N
. . N

The DT N
examining VBG N
physician NN N
was VBD N
unaware JJ N
of IN N
the DT N
treatment NN N
allocation NN N
. . N

The DT N
ultimate JJ N
outcome NN N
measure NN N
was VBD N
full JJ o
return NN o
to TO o
sports NNS o
at IN o
the DT o
same JJ o
level NN o
without IN o
groin NN o
pain NN o
. . o

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
23 CD p
patients NNS p
in IN p
the DT p
AT NNP p
group NN p
and CC p
four CD p
in IN p
the DT p
PT NNP p
group NN p
returned VBD p
to TO p
sports NNS p
without IN p
groin NN o
pain NN o
( ( p
odds NNS p
ratio NN N
, , N
multiple-logistic-regression NN N
analysis NN N
, , N
12.7 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
3.4-47.2 CD N
] NNP N
) ) N
. . N

The DT N
subjective JJ N
global JJ N
assessments NNS N
of IN N
the DT N
effect NN N
of IN N
the DT N
treatments NNS N
showed VBD N
a DT N
significant JJ N
( ( N
p=0.006 NN N
) ) N
linear VBP N
trend NN N
towards NNS N
a DT N
better JJR N
effect NN N
in IN N
the DT N
AT NNP N
group NN N
. . N

A DT N
per-protocol JJ N
analysis NN N
did VBD N
not RB N
show VB N
appreciably RB N
different JJ N
results NNS N
. . N

INTERPRETATION NNP N
AT NNP N
with IN N
a DT N
programme NN N
aimed VBN N
at IN N
improving VBG N
strength NN N
and CC N
coordination NN N
of IN N
the DT N
muscles NNS N
acting VBG N
on IN N
the DT N
pelvis NN N
, , N
in IN N
particular JJ N
the DT N
adductor NN N
muscles NNS N
, , N
is VBZ N
very RB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
athletes NNS N
with IN N
long-standing JJ N
adductor-related JJ N
groin NN N
pain NN N
. . N

The DT N
potential JJ N
preventive JJ N
value NN N
of IN N
a DT N
short JJ N
programme NN N
based VBN N
upon IN N
the DT N
principles NNS N
of IN N
AT NNP N
should MD N
be VB N
assessed VBN N
in IN N
future JJ N
, , N
randomised VBN N
, , N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -10071998- O O

Anesthesia NNP N
for IN N
in IN p
vitro JJ p
fertilization NN p
: : p
the DT N
addition NN N
of IN N
fentanyl NN i
to TO N
1.5 CD N
% NN N
lidocaine NN i
. . i

UNLABELLED NNP N
Ultrasonically RB N
guided VBD N
transvaginal JJ N
oocyte NN N
retrieval NN N
is VBZ N
relatively RB N
short JJ N
procedure NN N
that WDT N
is VBZ N
performed VBN N
on IN N
an DT N
out-patient JJ N
basis NN N
. . N

The DT N
optimal JJ N
anesthetic JJ N
technique NN N
should MD N
allow VB N
good JJ N
surgical JJ N
anesthesia NN N
with IN N
minimal JJ N
side NN N
effects NNS N
, , N
a DT N
short JJ N
recovery NN N
time NN N
, , N
and CC N
, , N
if IN N
possible JJ N
, , N
a DT N
high JJ N
rate NN N
of IN N
successful JJ N
pregnancy NN N
. . N

Spinal JJ i
anesthesia NN i
is VBZ N
often RB N
used VBN N
in IN N
this DT N
institution NN N
, , N
as RB N
well RB N
as IN N
many JJ N
others NNS N
, , N
for IN N
this DT N
procedure NN N
. . N

The DT N
addition NN N
of IN N
fentanyl NN N
may MD N
be VB N
effective JJ N
for IN N
both DT N
intraoperative JJ N
and CC N
postoperative JJ N
pain NN N
relief NN N
. . N

We PRP N
assessed VBD N
the DT N
effect NN N
of IN N
adding VBG N
fentanyl NN N
to TO N
1.5 CD N
% NN N
lidocaine NN N
in IN N
women NNS p
undergoing VBG p
ultrasonically RB p
guided VBN p
oocyte NN p
retrieval NN p
. . p

Seventy-eight JJ p
women NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
45 CD i
mg NN i
of IN i
hyperbaric JJ i
1.5 CD i
% NN i
lidocaine NN i
with IN i
or CC i
without IN i
10 CD i
microg NN i
of IN i
fentanyl NN i
. . i

Visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
pain NN o
scores NNS o
were VBD N
lower JJR N
in IN N
the DT N
operating NN N
room NN N
( ( N
OR NNP N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
postanesthesia $ N
care NN N
unit NN N
( ( N
PACU NNP N
) ) N
( ( N
P NNP N
< NNP N
0.0005 CD N
) ) N
for IN N
the DT N
group NN N
that WDT N
received VBD N
fentanyl RB N
. . N

In IN N
addition NN N
, , N
the DT N
amount NN o
of IN o
narcotic JJ o
required VBN o
in IN N
the DT N
PACU NNP N
was VBD N
less RBR N
in IN N
the DT N
fentanyl NN N
group NN N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
VAS NNP o
scores VBZ o
the DT N
evening NN N
of IN N
or CC N
24 CD N
h NN N
after IN N
the DT N
procedure NN N
. . N

The DT N
amount NN o
of IN o
analgesics NNS o
and CC o
narcotics NNS o
required VBN o
after IN o
discharge NN o
was VBD N
the DT N
same JJ N
for IN N
both DT N
groups NNS N
. . N

Timed NNP o
variables NNS o
, , o
such JJ o
as IN o
time NN o
to TO o
urination NN o
, , o
ambulation NN o
, , o
and CC o
discharge NN o
, , N
were VBD N
the DT N
same JJ N
for IN N
both DT N
groups NNS N
of IN N
women NNS N
. . N

The DT N
addition NN N
of IN N
fentanyl NN N
to TO N
lidocaine VB N
for IN N
transvaginal JJ N
oocyte NN N
retrieval NN N
results NNS N
in IN N
a DT N
more RBR N
comfortable JJ N
patient NN N
in IN N
the DT N
OR NNP N
and CC N
PACU NNP N
. . N

IMPLICATIONS NNP N
This DT N
study NN N
demonstrates VBZ N
that IN N
when WRB N
fentanyl NN N
is VBZ N
added VBN N
to TO N
a DT N
local JJ N
anesthetic NN N
, , N
lidocaine NN N
, , N
with IN N
spinal JJ N
anesthesia NN N
for IN N
egg NN N
retrieval NN N
procedures NNS N
, , N
patients NNS N
are VBP N
more RBR N
comfortable JJ N
during IN N
the DT N
procedure NN N
compared VBN N
with IN N
those DT N
who WP N
receive VBP N
lidocaine NN N
alone RB N
. . N

In IN N
addition NN N
, , N
the DT N
narcotic JJ N
requirements NNS N
of IN N
patients NNS N
are VBP N
less RBR N
in IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
. . N

-DOCSTART- -7516831- O O

Optimized VBN N
strategy NN N
for IN N
detection NN N
of IN N
early JJ p
stage NN p
, , p
curable JJ p
prostate NN p
cancer NN p
: : p
role NN N
of IN N
prescreening VBG N
with IN N
prostate-specific JJ N
antigen NN N
. . N

In IN p
1,002 CD p
men NNS p
aged VBN p
45-80 JJ p
y NN p
, , N
81 CD N
% NN N
of IN N
the DT N
cancers NNS N
detectable JJ N
by IN N
serum JJ o
prostate-specific JJ o
antigen NN o
( ( o
PSA NNP o
) ) o
, , o
digital JJ o
rectal JJ o
examination NN o
( ( o
DRE NNP o
) ) o
, , o
and CC o
transrectal JJ o
ultrasonography NN o
( ( o
TRUS NNP o
) ) o
were VBD N
present JJ N
in IN N
a DT N
subpopulation NN N
( ( N
19 CD N
% NN N
of IN N
total JJ N
) ) N
identified VBN N
by IN N
serum NN N
PSA NNP N
above IN N
the DT N
threshold JJ N
value NN N
of IN N
3.0 CD N
micrograms/L NN N
. . N

This DT N
study NN N
was VBD N
extended VBN N
to TO N
7,350 CD p
men NNS p
using VBG p
serum NN p
PSA NNP i
and CC p
DRE NNP i
as IN p
first JJ p
approach NN p
, , p
followed VBN p
by IN p
TRUS NNP i
only RB p
when WRB p
1 CD p
of IN p
these DT p
2 CD p
tests NNS p
was VBD p
abnormal JJ p
. . p

Because IN N
the DT N
aim NN N
of IN N
prostate NN N
cancer NN N
detection NN N
is VBZ N
to TO N
find VB N
cancers NNS N
at IN N
an DT N
early JJ N
, , N
potentially RB N
curable JJ N
stage NN N
, , N
it PRP N
is VBZ N
of IN N
major JJ N
interest NN N
that IN N
71.8 CD N
% NN N
of IN N
evaluable JJ N
cancers NNS N
were VBD N
clinical JJ N
stage NN N
B NNP N
; : N
8.4 CD N
% NN N
and CC N
10.7 CD N
% NN N
were VBD N
stages NNS N
C1 NNP N
and CC N
C2 NNP N
, , N
respectively RB N
; : N
only RB N
9.2 CD N
% NN N
were VBD N
stage JJ N
D NNP N
( ( N
metastatic JJ N
) ) N
at IN N
first JJ N
visit NN N
while IN N
none NN N
was VBD N
at IN N
stage NN N
D NNP N
at IN N
follow-up JJ N
visits NNS N
. . N

This DT N
study NN N
, , N
the DT N
first JJ N
performed VBN N
in IN N
an DT N
unselected JJ p
, , p
unscreened JJ p
population NN p
, , N
shows VBZ N
that IN N
serum NN o
PSA NNP o
is VBZ N
the DT N
most RBS N
sensitive JJ o
technique NN o
to TO N
identify VB N
men NNS N
at IN N
high JJ N
risk NN o
of IN o
having VBG o
prostate NN o
cancer NN o
and CC N
that IN N
12 CD N
% NN N
more JJR N
cancers NNS N
can MD N
be VB N
found VBN N
at IN N
first JJ N
visit NN N
by IN N
doing VBG N
DRE NNP i
in IN N
addition NN N
to TO N
PSA NNP i
. . i

Follow-ups NNS N
can MD N
be VB N
done VBN N
every DT N
second JJ N
year NN N
using VBG N
serum JJ o
PSA NNP o
alone RB o
, , N
as IN N
97 CD N
% NN N
of IN N
the DT N
cancers NNS N
detected VBD N
at IN N
annual JJ N
follow-up NN N
by IN N
DRE NNP i
+ NNP N
PSA NNP i
were VBD N
PSA+ NNP i
. . N

Cancers NNS N
are VBP N
discovered VBN N
by IN N
the DT N
present JJ N
approach NN N
at IN N
an DT N
estimated JJ o
cost NN o
of IN N
$ $ N
2,665 CD N
per IN N
cancer NN N
. . N

Such JJ N
cancers NNS N
are VBP N
potentially RB N
curable JJ o
in IN N
at IN N
least JJS N
80 CD N
% NN N
of IN N
cases NNS N
detected VBN N
at IN N
first JJ N
visit NN N
and CC N
in IN N
97 CD N
% NN N
of IN N
cases NNS N
at IN N
follow-up NN N
. . N

This DT N
strategy NN N
offers VBZ N
the DT N
possibility NN N
to TO N
improve VB N
markedly RB N
morbidity NN o
and CC o
mortality NN o
from IN o
prostate NN o
cancer NN o
, , N
presently RB N
the DT N
second JJ N
leading JJ N
cause NN N
of IN N
cancer NN N
death NN N
in IN N
North JJ N
American JJ N
men NNS N
. . N

-DOCSTART- -16729400- O O

Nitroglycerin NNP i
, , i
nitroprusside RB i
, , N
or CC N
both DT N
, , N
in IN N
preventing VBG N
radial JJ o
artery NN o
spasm NN o
during IN N
transradial JJ p
artery NN p
catheterization NN p
. . p

OBJECTIVE NNP N
Radial JJ N
artery NN N
spasm NN N
remains VBZ N
a DT N
major JJ N
complication NN N
of IN N
transradial JJ N
coronary JJ N
interventions NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
three CD N
different JJ N
intra-arterial JJ N
vasodilating NN i
cocktails NNS i
in IN N
reducing VBG N
the DT N
incidence NN N
of IN N
radial JJ o
artery NN o
spasm NN o
in IN N
patients NNS p
undergoing VBG p
transradial JJ p
coronary JJ p
angiography NN p
. . p

The DT N
secondary JJ N
goal NN N
was VBD N
to TO N
assess VB N
the DT N
predictors NNS o
of IN o
arterial JJ o
spasm NN o
in IN N
this DT N
large JJ N
group NN N
of IN N
patients NNS N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
379 CD p
patients NNS p
undergoing VBG p
the DT p
procedure NN p
were VBD p
randomly RB p
enrolled VBN p
in IN N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

Every DT N
patient NN N
in IN N
each DT N
of IN N
the DT N
3 CD N
groups NNS N
received VBD N
intra-arterial JJ N
heparin NN i
, , i
lidocaine NN i
and CC N
diltiazem NN i
. . i

Along IN N
with IN N
that DT N
, , N
patients NNS N
in IN N
Group NNP N
A NNP N
received VBD N
nitroglycerin JJ i
; : i
patients NNS N
in IN N
Group NNP N
B NNP N
received VBD N
nitroprusside JJ i
instead RB N
of IN N
nitroglycerin NN i
; : i
and CC N
patients NNS N
in IN N
Group NNP N
C NNP N
received VBD N
both DT N
nitroglycerin NNS i
and CC i
nitroprusside RB i
. . i

A DT N
single JJ N
experienced NN N
operator NN N
, , N
blinded VBD N
to TO N
the DT N
study NN N
drug NN N
, , N
subjectively RB N
determined VBD N
the DT N
presence NN N
of IN N
spasm NN o
. . o

RESULTS NNP N
Of IN N
379 CD N
patients NNS N
, , N
a DT N
total NN N
of IN N
44 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
experienced VBD N
spasm NN N
. . N

The DT N
occurrence NN N
of IN N
spasm NN o
was VBD N
similar JJ N
, , N
independent JJ N
of IN N
the DT N
vasodilator NN N
cocktail NN N
used VBN N
( ( N
Group NNP N
A NNP N
: : N
12.2 CD N
% NN N
, , N
Group NNP N
B NNP N
: : N
13.4 CD N
% NN N
, , N
Group NNP N
C NNP N
: : N
9.5 CD N
% NN N
; : N
p CC N
= VB N
0.597 CD N
) ) N
. . N

After IN N
multivariate JJ N
analysis NN N
, , N
the DT N
following JJ N
variables NNS N
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
predictors NNS N
of IN N
spasm NN N
: : N
radial JJ N
artery NN N
diameter NN N
( ( N
RD NNP N
) ) N
/height VBD N
index NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
RD/BSA NNP N
index NN N
( ( N
p JJ N
= NNP N
0.012 CD N
) ) N
, , N
and CC N
sheath NN N
outer NN N
diameter NN N
( ( N
OD NNP N
) ) N
/RD NNP N
index NN N
( ( N
p JJ N
= NNP N
0.024 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
the DT N
addition NN N
of IN N
a DT N
direct JJ i
nitric JJ i
oxide NN i
donor NN i
to TO N
nitroglycerin VB i
in IN N
an DT N
antispastic JJ N
cocktail NN N
did VBD N
not RB N
reduce VB o
the DT o
risk NN o
of IN o
spasm NN o
, , N
and CC N
the DT N
use NN N
of IN N
nitroglycerin NN i
was VBD N
found VBN N
to TO N
be VB N
as RB o
effective JJ o
as IN o
nitroprusside NN i
. . i

Also RB N
, , N
morphometric JJ N
and CC N
mechanical JJ N
factors NNS N
play VBP N
a DT N
significant JJ N
role NN N
in IN N
predicting VBG o
the DT o
occurrence NN o
of IN o
radial JJ o
spasm NN o
. . o

The DT N
sex NN N
of IN N
the DT N
patient NN N
, , N
presence NN N
of IN N
diabetes NNS N
, , N
body NN N
surface JJ N
area NN N
and CC N
smoking VBG N
history NN N
appeared VBD N
to TO N
play VB N
no DT N
role NN N
in IN N
predicting VBG o
the DT o
occurrence NN o
of IN o
radial JJ o
spasm NN o
. . o

-DOCSTART- -25088089- O O

Modelling VBG p
broilers NNS p
' POS p
abdominal JJ p
fat NN p
in IN N
response NN N
to TO N
dietary JJ N
treatments NNS N
. . N

Neural JJ N
networks NNS N
are VBP N
capable JJ N
of IN N
modelling VBG N
any DT N
complex JJ N
function NN N
and CC N
can MD N
be VB N
used VBN N
in IN N
poultry NN p
production NN p
. . p

Dietary JJ i
crude NN i
fibre NN i
( ( i
CF NNP i
) ) i
and CC N
exogenous JJ i
enzymes NNS i
( ( i
exEn NN i
) ) i
extensively RB N
affected VBD N
abdominal JJ N
fat NN N
( ( N
AF NNP N
) ) N
of IN N
broilers NNS N
. . N

Current JJ N
methods NNS N
to TO N
study VB N
AF NNP N
and CC N
its PRP$ N
correlation NN N
with IN N
dietary JJ N
CF NNP N
levels NNS N
and CC N
exEn NN N
supplements NNS N
are VBP N
costly JJ N
, , N
laborious JJ N
and CC N
time-consuming JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
an DT N
artificial JJ N
neural JJ N
network-genetic JJ N
algorithm NN N
( ( N
ANN-GA NNP N
) ) N
to TO N
model VB N
data NNS N
on IN N
the DT N
response NN o
of IN o
broiler NN o
chickens NNS o
( ( o
AF NNP o
) ) o
to TO p
CF NNP i
and CC p
exEn NN i
from IN p
0 CD p
to TO p
42 CD p
days NNS p
of IN p
age NN p
. . p

A DT N
data NN N
set NN N
containing VBG N
eight CD N
treatments NNS N
was VBD N
divided VBN N
to TO N
the DT N
train NN N
, , N
validation NN N
, , N
and CC N
test NN N
data NNS N
set NN N
of IN N
the DT N
ANN NNP N
models NNS N
. . N

The DT N
information NN N
about IN N
feeding VBG N
eight CD N
diets NNS N
at IN N
two CD N
periods NNS N
[ VBP N
starter NN N
( ( N
0-21 JJ N
days NNS N
of IN N
age NN N
) ) N
and CC N
grower NN N
( ( N
22-42 JJ N
days NNS N
of IN N
age NN N
) ) N
] WDT N
were VBD N
used VBN N
to TO N
estimate VB N
AF NNP N
of IN N
broilers NNS p
by IN p
ANN-GA. NNP N
A NNP N
multilayer NN N
feed-forward JJ N
neural JJ N
network NN N
with IN N
different JJ N
structures NNS N
was VBD N
developed VBN N
using VBG N
matlab NN N
software NN N
, , N
and CC N
optimal JJ N
values NNS N
for IN N
the DT N
ANN NNP N
weights NNS N
were VBD N
obtained VBN N
using VBG N
the DT N
genetic JJ N
algorithm NN N
( ( N
GA NNP N
) ) o
. . o

Crude NNP o
fibre NN o
, , o
and CC o
exEn NN o
were VBD o
used VBN N
as IN N
input NN N
variables NNS N
and CC N
AF NNP N
of IN N
broilers NNS N
was VBD N
output NN N
variable JJ N
. . N

The DT N
best JJS N
model NN N
of IN N
ANN-GA NNP N
was VBD N
determined VBN N
based VBN N
on IN N
the DT N
train NN o
root NN o
mean NN o
square NN o
error NN o
( ( o
RMSE NNP o
) ) o
. . o

The DT o
best JJS N
selected VBN N
ANN-GA NNP N
showed VBD N
desirable JJ N
results NNS N
, , N
RMSE NNP N
, , N
0.1286 CD N
% NN N
and CC N
R NNP N
( ( N
2 CD N
) ) N
coefficient NN N
, , N
0.876 CD N
for IN N
test NN N
data NNS N
. . N

-DOCSTART- -18215978- O O

Association NNP N
of IN N
efavirenz JJ i
hypersusceptibility NN N
with IN N
virologic JJ N
response NN N
in IN N
ACTG NNP i
368 CD i
, , N
a DT N
randomized JJ N
trial NN N
of IN N
abacavir NN i
( ( i
ABC NNP i
) ) i
in IN N
combination NN N
with IN N
efavirenz NN i
( ( i
EFV NNP i
) ) i
and CC N
indinavir NN i
( ( i
IDV NNP i
) ) i
in IN N
HIV-infected JJ p
subjects NNS p
with IN p
prior JJ p
nucleoside JJ p
analog NN p
experience NN p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
association NN N
of IN N
efavirenz JJ N
hypersusceptibility NN N
( ( N
EFV-HS NNP N
) ) N
with IN N
clinical JJ N
outcome NN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
trial NN N
of IN N
EFV NNP i
plus CC i
indinavir NN i
( ( i
EFV+IDV NNP i
) ) i
vs. FW i
EFV+IDV NNP i
plus CC i
abacavir NN i
( ( i
ABC NNP i
) ) i
in IN N
283 CD p
nucleoside-experienced JJ p
HIV-infected JJ p
patients NNS p
. . p

METHOD NNP N
AND CC N
RESULTS NNP N
Rates NNS o
of IN o
virologic JJ o
failure NN o
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
arms NNS N
at IN N
week NN N
16 CD N
( ( N
p JJ N
= NNP N
.509 NNP N
) ) N
. . N

Treatment JJ o
discontinuations NNS o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
ABC NNP N
arm NN N
( ( N
p JJ N
= NNP N
.001 NNP N
) ) N
. . N

Using VBG N
logistic JJ N
regression NN N
, , N
there EX N
was VBD N
no DT N
association NN N
between IN N
virologic JJ o
failure NN o
and CC o
either DT o
baseline NN o
ABC NNP o
resistance NN o
or CC o
regimen NNS o
sensitivity NN o
score NN o
. . o

Using VBG N
3 CD N
different JJ N
genotypic NN N
scoring VBG N
systems NNS N
, , N
EFV-HS NNP i
was VBD N
significantly RB N
associated VBN N
with IN N
reduced JJ o
virologic JJ o
failure NN o
at IN N
week NN N
16 CD N
, , N
independent JJ N
of IN N
treatment NN N
assignment NN N
. . N

In IN N
some DT N
patients NNS N
on IN N
the DT N
nucleoside-sparing JJ N
arm NN N
, , N
the DT N
nucleoside-resistance JJ N
mutation NN N
L74V NNP N
was VBD N
selected VBN N
for IN N
in IN N
combination NN N
with IN N
the DT N
uncommonly JJ N
occurring VBG N
EFV-resistance JJ N
mutations NNS N
K103N+L100I NNP N
; : N
L74V NNP N
was VBD N
not RB N
detected VBN N
as IN N
a DT N
minority NN N
variant NN N
, , N
using VBG N
clonal JJ N
sequence NN N
analysis NN N
, , N
when WRB N
the DT N
nucleoside-sparing JJ N
regimen NN N
was VBD N
initiated VBN N
. . N

CONCLUSION NNP N
Premature NNP N
treatment NN o
discontinuations NNS o
in IN N
the DT N
ABC NNP N
arm NN N
and CC N
the DT N
presence NN N
of IN N
EFV-HS NNP i
HIV NNP i
variants NNS N
in IN N
this DT N
patient NN N
population NN N
likely RB N
made VBD N
it PRP N
difficult JJ N
to TO N
detect VB N
a DT N
benefit NN N
of IN N
adding VBG o
ABC NNP o
to TO o
EFV+IDV NNP o
. . o

In IN N
addition NN N
, , N
L74V NNP N
, , N
when WRB N
combined VBN N
with IN N
K103N+L100I NNP N
, , N
may MD N
confer VB N
a DT N
selective JJ N
advantage NN N
to TO N
the DT N
virus NN N
that WDT N
is VBZ N
independent JJ N
of IN N
its PRP$ N
effects NNS o
on IN o
nucleoside JJ o
resistance NN o
. . o

-DOCSTART- -8106772- O O

Primary JJ N
prophylaxis NN N
with IN N
pyrimethamine NN i
for IN N
toxoplasmic JJ N
encephalitis NN N
in IN N
patients NNS p
with IN p
advanced JJ p
human JJ p
immunodeficiency NN p
virus NN p
disease NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

Terry NNP N
Beirn NNP N
Community NNP N
Programs NNP N
for IN N
Clinical NNP N
Research NNP N
on IN N
AIDS NNP N
. . N

Pyrimethamine NNP i
, , N
25 CD N
mg NN N
thrice NN N
weekly RB N
, , N
was VBD N
evaluated VBN N
as IN N
primary JJ N
prophylaxis NN N
for IN N
toxoplasmic JJ N
encephalitis NN N
( ( N
TE NNP N
) ) N
in IN N
a DT N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
in IN N
patients NNS p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
disease NN p
, , p
absolute JJ p
CD4 NNP p
lymphocyte NN p
count NN p
of IN p
< $ p
200/microL CD p
( ( p
or CC p
prior RB p
AIDS-defining NNP p
opportunistic JJ p
infection NN p
) ) p
, , p
and CC p
the DT p
presence NN p
of IN p
serum NN p
IgG NNP p
to TO p
Toxoplasma NNP p
gondii NN p
. . p

Leucovorin NNP i
was VBD N
coadministered VBN N
only RB N
for IN N
hematologic JJ N
toxicity NN N
. . N

There EX N
was VBD N
a DT N
significantly RB N
higher JJR N
death NN o
rate NN o
among IN N
patients NNS N
receiving VBG N
pyrimethamine NN i
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
2.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.3-4.8 JJ N
; : N
P NNP N
= NNP N
.006 NNP N
) ) N
, , N
even RB N
after IN N
adjusting VBG N
for IN N
factors NNS N
predictive CD N
of IN N
survival NN N
. . N

The DT N
TE NNP o
event NN o
rate NN o
was VBD N
low JJ N
in IN N
both DT N
treatment NN N
groups NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

Only RB N
1 CD N
of IN N
218 CD p
patients NNS p
taking VBG p
trimethoprim-sulfamethoxazole JJ i
but CC N
7 CD N
of IN N
117 CD p
taking VBG p
aerosolized JJ i
pentamidine NN i
for IN N
prophylaxis NN N
against IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
developed VBD N
TE NNP N
( ( N
adjusted VBN N
RR NNP N
for IN N
the DT N
trimethoprim-sulfamethoxazole JJ i
group NN N
, , N
0.16 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.01-1.79 NNP N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
. . N

Thus RB N
, , N
for IN N
HIV-infected JJ p
patients NNS p
receiving VBG N
trimethoprim-sulfamethoxazole JJ i
, , N
additional JJ N
prophylaxis NN N
for IN N
TE NNP N
appears VBZ N
unnecessary JJ N
. . N

-DOCSTART- -17625432- O O

Efficacy NN o
of IN N
amantadine NN i
on IN N
quality NN o
of IN o
life NN o
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
treated VBD p
with IN p
interferon-alpha JJ i
and CC i
ribavirin NN i
: : i
results NNS N
from IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
trial NN N
. . N

AIM VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
amantadine JJ N
reduces NNS N
deterioration NN o
of IN o
quality NN o
of IN o
life NN o
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
during IN p
and CC p
after IN p
treatment NN p
with IN p
interferon-alpha JJ p
( ( p
IFN-alpha NNP p
) ) p
and CC p
ribavirin NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
, , N
placebo-controlled JJ i
, , N
multicenter JJ N
trial NN N
, , N
previously RB p
untreated JJ p
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
were VBD N
treated VBN N
with IN N
IFN-alpha NNP i
plus CC i
ribavirin JJ i
[ NN i
17 CD i
] NN i
and CC N
randomized VBN N
for IN N
treatment NN N
with IN N
amantadine NN i
( ( N
200 CD N
mg/day NN N
, , N
orally RB N
, , N
n=136 NN N
) ) N
or CC i
placebo NN i
( ( N
n=131 JJ N
) ) N
. . N

Quality NN o
of IN o
life NN o
was VBD N
assessed VBN N
with IN N
the DT N
'Profile NN o
of IN o
Mood NNP o
States NNPS o
' POS o
scale NN o
and CC o
the DT o
'Everyday JJ o
Life NNP o
' POS o
questionnaire NN o
at IN N
baseline NN N
, , N
treatment NN N
week NN N
( ( N
TW NNP N
) ) N
8 CD N
, , N
TW24 NNP N
, , N
TW48 NNP N
, , N
and CC N
at IN N
follow-up JJ N
. . N

RESULTS VB N
Early JJ N
during IN N
treatment NN N
at IN N
TW8 NNP N
, , N
quality NN o
of IN o
life NN o
was VBD N
not RB N
different JJ N
between IN N
patients NNS p
in IN p
the DT p
control NN p
and CC p
the DT p
amantadine NN p
group NN p
. . p

At IN N
TW24 NNP N
, , N
the DT N
control NN N
group NN N
but CC N
not RB N
the DT N
amantadine NN i
group NN N
, , N
however RB N
, , N
showed VBD N
significant JJ N
deterioration NN N
of IN N
the DT N
modalities NNS o
depression NN o
, , o
fatigue NN o
, , o
and CC o
vigor NN o
compared VBN N
with IN N
baseline NN N
. . N

Especially RB N
, , N
nonresponders NNS N
in IN N
the DT N
amantadine NN N
group NN N
showed VBD N
significantly RB N
lower JJR o
deterioration NN o
of IN o
depression NN o
, , o
anger NN o
, , o
mind NN o
function NN o
, , o
everyday JJ o
life NN o
, , o
and CC o
zest JJS o
for IN o
life NN o
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
. . N

After IN N
treatment NN N
, , N
the DT N
beneficial JJ o
effects NNS o
of IN N
amantadine NN N
disappeared VBN N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
amantadine NN i
to TO N
IFN-alpha NNP i
plus CC i
ribavirin JJ i
combination NN N
therapy NN N
may MD N
reduce VB N
deterioration NN o
of IN o
depression NN o
, , o
fatigue NN o
, , o
and CC o
vigor NN o
during IN N
treatment NN N
but CC N
does VBZ N
not RB N
affect JJ N
quality NN o
of IN o
life NN o
after IN N
treatment NN N
. . N

-DOCSTART- -24384588- O O

Weight NNP N
and CC N
lean JJ N
body NN N
mass NN N
change NN N
with IN N
antiretroviral JJ i
initiation NN i
and CC N
impact NN N
on IN N
bone NN N
mineral JJ N
density NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
that IN N
initiating VBG N
different JJ N
antiretroviral JJ i
therapy NN i
( ( i
ART NNP i
) ) i
regimens VBZ N
has VBZ N
on IN N
weight NN N
, , N
BMI NNP N
, , N
and CC N
lean JJ N
body NN N
mass NN N
( ( N
LBM NNP N
) ) N
and CC N
explore VB N
how WRB N
changes NNS N
in IN N
body NN N
composition NN N
are VBP N
associated VBN N
with IN N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
. . N

METHODS NNP N
A5224s NNP p
was VBD p
a DT p
sub-study NN p
of IN p
A5202 NNP p
, , p
a DT p
prospective JJ p
trial NN p
of IN p
1857 CD p
ART-naive JJ p
participants NNS p
randomized VBN p
to TO p
blinded VBN i
abacavir-lamivudine NN i
( ( i
ABC/3TC NNP i
) ) i
or CC i
tenofovir JJ i
DF-emtricitabine NNP i
( ( i
TDF/FTC NNP i
) ) i
with IN i
open-label JJ i
efavirenz NN i
( ( i
EFV NNP i
) ) i
or CC i
atazanavir-ritonavir JJ i
( ( i
ATV/r NNP i
) ) i
. . i

All DT N
participants NNS N
underwent JJ N
dual-energy JJ i
absorptiometry NN i
( ( i
DXA NNP i
) ) i
and CC i
abdominal JJ i
computed VBN i
tomography NN i
for IN i
body NN i
composition NN i
. . i

Analyses NNS N
used VBD N
two-sample JJ N
t-tests NNS N
and CC N
linear JJ N
regression NN N
. . N

RESULTS NNP N
A5224s NNP N
included VBD N
269 CD p
participants NNS p
: : p
85 CD p
% NN p
men NNS p
, , p
47 CD p
% NN p
white JJ p
non-Hispanic JJ p
, , p
median JJ p
age NN p
38 CD p
years NNS p
, , p
HIV-1 NNP p
RNA NNP p
4.6 CD p
log10 NN p
copies/ml NN p
, , p
and CC p
CD4 NNP p
cell VBP p
count NN p
233 CD p
cells/?l NN p
. . p

Overall JJ N
, , N
significant JJ N
gains NNS N
occurred VBD N
in IN o
weight NN o
, , o
BMI NNP o
, , o
and CC o
LBM NNP o
at IN N
96 CD N
weeks NNS N
post-randomization NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Assignment NN N
to TO i
ATV/r NNP i
( ( i
vs. FW i
EFV NNP i
) ) i
resulted VBD N
in IN N
significantly RB N
greater JJR o
weight NN o
( ( N
mean JJ N
difference NN N
3.35 CD N
kg NN N
) ) N
and CC o
BMI NNP o
gain NN o
( ( N
0.88 CD N
kg/m NN N
; : N
both DT N
P=0.02 NNP N
) ) N
, , N
but CC N
not RB o
LBM NNP o
( ( N
0.67 CD N
kg NN N
; : N
P=0.15 NNP N
) ) N
, , N
whereas JJ N
ABC/3TC NNP N
and CC N
TDF/FTC NNP N
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
P?0.10 NNP N
) ) N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
only RB N
lower JJR N
baseline NN o
CD4 NNP o
cell NN o
count NN o
and CC o
higher JJR o
HIV-1 NNP o
RNA NNP o
were VBD o
associated VBN N
with IN N
greater JJR N
increase NN N
in IN N
weight NN o
, , o
BMI NNP o
, , o
or CC o
LBM NNP o
. . o

In IN o
multivariable JJ N
analyses NNS N
, , N
increased VBD o
LBM NNP o
was VBD o
associated VBN N
with IN N
an DT N
increased VBN o
hip NN o
BMD NNP o
. . o

CONCLUSION NNP o
ABC/3TC NNP N
vs. IN N
TDF/FTC NNP i
did VBD i
not RB N
differ VB N
in IN N
change NN N
in IN N
weight NN o
, , o
BMI NNP o
, , o
or CC o
LBM NNP o
; : o
ATV/r NNP o
vs. FW N
EFV NNP N
resulted VBD N
in IN N
greater JJR o
weight NN o
and CC o
BMI NNP o
gain NN o
but CC N
not RB N
LBM NNP o
. . o

A NNP o
positive JJ N
association NN N
between IN N
increased VBN N
LBM NNP N
and CC N
increased VBD N
hip NN N
BMD NNP N
should MD N
be VB N
further RB N
investigated VBN N
through IN N
prospective JJ N
interventional JJ N
studies NNS N
to TO N
verify VB N
the DT N
impact NN N
of IN N
increased JJ N
LBM NNP N
on IN N
hip NN N
BMD NNP N
. . N

-DOCSTART- -19242343- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
six CD N
epoetin JJ i
alfa NN i
dosing VBG N
regimens NNS N
in IN N
anemic JJ p
critically RB p
ill JJ p
patients NNS p
without IN p
acute JJ p
blood NN p
loss NN p
. . p

OBJECTIVE UH N
To TO N
describe VB N
the DT N
pharmacokinetic JJ N
profiles NNS N
of IN N
six CD N
different JJ N
dosing VBG N
regimens NNS N
for IN N
epoetin NN i
alfa NN i
, , N
and CC N
whether IN N
more JJR N
rapid JJ N
and CC N
robust JJ N
reticulocytosis NN N
can MD N
be VB N
elicited VBN N
with IN N
more RBR N
frequent JJ N
administration NN N
of IN N
epoetin JJ i
alfa NN i
in IN N
anemic JJ p
critically RB p
ill JJ p
patients NNS p
. . p

DESIGN NNP N
Randomized NNP N
, , N
open-label NN N
, , N
multicenter NN N
, , N
28-day JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Ten CD p
centers NNS p
in IN p
the DT p
United NNP p
States NNPS p
. . p

PATIENTS VB N
Adult NNP p
( ( p
age NN p
> VBN p
or=18 CD p
years NNS p
) ) p
critically RB p
ill JJ p
patients NNS p
with IN p
hemoglobin JJ p
< NNP p
or=12 NN p
g/dL NN p
, , p
expected VBN p
hospitalization NN p
of IN p
> NNP p
or=7 NNP p
days NNS p
, , p
with IN p
no DT p
ongoing VBG p
acute RB p
blood NN p
loss NN p
. . p

INTERVENTIONS NNP N
One CD N
of IN N
six CD i
dosing VBG i
epoetin NN i
alfa NN i
regimens VBZ i
for IN N
15 CD N
days NNS N
, , N
as IN N
follows VBZ N
: : N
40,000 CD i
IU NNP i
once RB i
weekly RB i
, , N
subcutaneously RB N
( ( N
group NN N
A NNP N
) ) N
or CC N
intravenously RB N
( ( N
IV NNP N
) ) N
( ( N
group NN N
B NNP N
) ) N
; : N
15,000 CD i
IU NNP i
every DT i
other JJ i
day NN i
, , i
subcutaneously RB i
( ( N
group NN N
C NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
D NNP N
) ) N
; : N
or CC N
40,000 CD i
IU NNP i
day NN i
1 CD N
and CC N
3 CD N
, , N
subcutaneously RB i
( ( N
group NN N
E NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
F NNP N
) ) N
, , N
followed VBN N
by IN N
15,000 CD N
IU NNP N
once RB N
every DT N
other JJ N
day NN N
on IN N
[ NN N
corrected VBN N
] JJ N
days NNS N
5-15 JJ N
[ NNP N
corrected VBD N
] NN N
MEASUREMENTS NNP N
Serum NNP o
erythropoietin NN o
concentration NN o
, , o
absolute JJ o
reticulocyte NN o
count NN o
, , o
and CC o
adverse JJ o
events NNS o
. . o

MAIN NNP N
RESULTS NNP N
Of IN N
the DT N
60 CD N
patients NNS N
who WP N
were VBD N
enrolled VBN N
( ( N
60 CD N
% NN N
men NNS N
, , N
mean JJ N
age NN N
53 CD N
years NNS N
, , N
mean VBP N
Acute NNP N
Physiology NNP N
and CC N
Chronic NNP N
Health NNP N
Evaluation NNP N
II NNP N
score NN N
, , N
19.5 CD N
) ) N
, , N
30 CD N
were VBD N
evaluable JJ N
for IN N
both DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
( ( N
50 CD N
% NN N
) ) N
. . N

Erythropoietin NNP o
exposure NN o
was VBD N
approximately RB N
ten JJ N
times NNS N
greater JJR N
for IN N
IV NNP N
dosing VBG N
than IN N
for IN N
subcutaneous JJ i
dosing NN i
. . i

Mean NNP o
absolute JJ o
reticulocyte NN o
count NN o
peaked VBD N
at IN N
day NN N
11 CD N
or CC N
15 CD N
in IN N
each DT N
group NN N
and CC N
appeared VBD N
to TO N
be VB N
greater JJR N
for IN N
subcutaneous JJ N
dosing NN i
( ( N
mean JJ N
peak NN N
response NN N
149-169 JJ N
x NN N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
compared VBN N
with IN N
IV NNP N
dosing VBG i
( ( N
mean JJ N
peak NN N
response NN N
138-147 JJ N
x NN N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
at IN N
most JJS N
visits NNS N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ o
events NNS o
were VBD N
pyrexia NNS o
( ( N
18 CD N
% NN N
) ) N
, , N
hypokalemia NN o
( ( N
15 CD N
% NN N
) ) N
, , N
and CC N
hypophosphatemia NN o
( ( N
15 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
of IN N
anemic JJ N
critically NN N
ill JJ N
patients NNS N
treated VBN N
with IN N
epoetin JJ i
alfa NN i
, , N
all DT N
dosing VBG N
regimens NNS N
were VBD N
well RB N
tolerated VBN o
and CC N
appeared VBN N
to TO N
effect NN N
reticulocytosis NN o
, , N
with IN N
a DT N
peak NN N
at IN N
day NN N
11 CD N
or CC N
15 CD N
in IN N
most JJS N
patients NNS N
. . N

The DT N
pharmacokinetics NNS N
of IN N
epoetin JJ i
alfa NN i
did VBD N
not RB N
predict VB N
pharmacodynamic JJ o
response NN o
in IN N
anemic JJ N
critically RB N
ill JJ N
patients NNS N
. . N

-DOCSTART- -18067498- O O

Enhancing VBG N
attitudes NNS o
and CC N
intentions NNS o
in IN N
prospective JJ p
blood NN p
donors NNS p
: : p
evaluation NN N
of IN N
a DT N
new JJ N
donor NN i
recruitment NN i
brochure NN i
. . i

BACKGROUND NNP N
Although IN N
little JJ N
empiric JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
concerning VBG N
the DT N
efficacy NN N
of IN N
blood NN i
donor NN i
recruitment NN i
materials NNS i
, , N
research NN N
suggests VBZ N
that IN N
simple JJ N
attempts NNS N
to TO N
enhance VB N
knowledge NN N
may MD N
not RB N
be VB N
sufficient JJ N
to TO N
motivate VB o
donation NN o
. . o

In IN N
contrast NN N
, , N
recent JJ N
donor NN N
motivation NN N
studies NNS N
highlight VBD N
the DT N
importance NN N
of IN N
anxiety NN o
, , o
attitudes NNS o
, , N
and CC N
perceived VBD o
ability NN o
to TO o
cope VB o
with IN o
donation NN o
( ( N
i.e. JJ N
, , N
self-efficacy NN N
) ) N
as IN N
crucial JJ N
determinants NNS N
of IN N
donation NN N
intention NN N
. . N

Therefore RB N
, , N
recruitment JJ N
materials NNS N
that WDT N
specifically RB N
address VBP N
these DT N
constructs NNS N
have VBP N
the DT N
potential JJ N
to TO N
outperform VB N
traditional JJ N
educational JJ N
brochures NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Participants NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
read VB N
one CD N
of IN N
three CD N
brochures NNS i
: : i
1 CD N
) ) N
a DT i
new JJ i
brochure NN i
addressing VBG i
common JJ i
donor NN i
concerns NNS i
and CC i
suggesting VBG i
specific JJ i
coping VBG i
strategies NNS i
, , i
2 CD i
) ) i
a DT i
standard JJ i
blood NN i
center NN i
brochure NN i
, , N
or CC N
3 CD N
) ) N
a DT i
control JJ i
brochure NN i
on IN i
healthy JJ i
eating NN i
and CC i
exercise NN i
. . i

Standardized JJ N
questionnaires NNS N
were VBD N
completed VBN N
before IN N
and CC N
after IN N
the DT N
brochures NNS N
to TO N
assess VB N
change NN N
in IN N
blood NN o
donation NN o
anxiety NN o
, , o
attitude NN o
, , o
self-efficacy NN o
, , o
and CC o
intention NN o
. . o

RESULTS NNP N
Although IN N
no DT N
significant JJ N
changes NNS N
were VBD N
noted VBN N
for IN N
the DT N
control NN N
brochure NN N
, , N
after IN N
reading VBG N
the DT N
new JJ N
brochure NN N
participants NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
attitude NN o
, , o
anxiety NN o
, , o
self-efficacy NN o
, , o
and CC o
donation NN o
intention NN o
. . o

The DT N
standard JJ N
donation NN N
brochure NN N
had VBD N
an DT N
intermediate JJ N
effect NN N
. . N

CONCLUSION NNP N
Efforts NNPS N
to TO N
address VB N
common JJ N
donor NN N
fears NNS N
and CC N
to TO N
provide VB N
useful JJ N
coping VBG N
suggestions NNS N
may MD N
improve VB N
the DT N
effectiveness NN N
of IN N
blood NN o
donation NN o
recruitment NN o
materials NNS o
. . o

-DOCSTART- -18982929- O O

Can MD N
HMG NNP i
Co-A NNP i
reductase NN i
inhibitors NNS i
( ( i
statins NNS i
) ) i
slow VBP N
the DT N
progression NN N
of IN N
age-related JJ p
macular JJ p
degeneration NN p
? . N
The DT N
age-related JJ N
maculopathy NN N
statin NN N
study NN N
( ( N
ARMSS NNP N
) ) N
. . N

Age-related JJ p
macular JJ p
degeneration NN p
( ( p
AMD NNP p
) ) p
is VBZ N
responsible JJ N
for IN N
the DT N
majority NN N
of IN N
visual JJ N
impairment NN N
in IN N
the DT N
Western JJ N
world NN N
. . N

The DT N
role NN N
of IN N
cholesterol-lowering JJ N
medications NNS N
, , N
HMG NNP i
Co-A NNP i
reductase NN i
inhibitors NNS i
or CC i
statins NNS i
, , N
in IN N
reducing VBG N
the DT N
risk NN N
of IN N
AMD NNP N
or CC N
of IN N
delaying VBG N
its PRP$ N
progression NN N
has VBZ N
not RB N
been VBN N
fully RB N
investigated VBN N
. . N

A DT N
3-year JJ N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
of IN N
40 CD i
mg NN i
simvastatin NN i
per IN i
day NN i
compared VBN i
to TO i
placebo VB i
in IN N
subjects NNS p
at IN p
high JJ p
risk NN p
of IN p
AMD NNP p
progression NN p
is VBZ N
described VBN N
. . N

This DT N
paper NN N
outlines VBZ N
the DT N
primary JJ N
aims NNS N
of IN N
the DT N
Age-Related NNP N
Maculopathy NNP N
Statin NNP N
Study NNP N
( ( N
ARMSS NNP N
) ) N
, , N
and CC N
the DT N
methodology NN N
involved VBN N
. . N

Standardized NNP N
clinical JJ N
grading NN N
of IN N
macular JJ N
photographs NN N
and CC N
comparison NN N
of IN N
serial JJ N
macular JJ N
digital NN N
photographs NN N
, , N
using VBG N
the DT N
International NNP N
grading NN N
scheme NN N
, , N
form VB N
the DT N
basis NN N
for IN N
assessment NN N
of IN N
primary JJ N
study NN N
outcomes NNS N
. . N

In IN N
addition NN N
, , N
macular JJ N
function NN N
is VBZ N
assessed VBN N
at IN N
each DT N
visit NN N
with IN N
detailed JJ N
psychophysical JJ N
measurements NNS N
of IN N
rod NN N
and CC N
cone NN N
function NN N
. . N

Information NN N
collected VBN N
in IN N
this DT N
study NN N
will MD N
assist VB N
in IN N
the DT N
assessment NN N
of IN N
the DT N
potential JJ N
value NN N
of IN N
HMG NNP i
Co-A NNP i
reductase NN i
inhibitors NNS i
( ( i
statins NNS i
) ) i
in IN N
reducing VBG N
the DT N
risk NN N
of IN N
AMD NNP N
progression NN N
. . N

-DOCSTART- -23902627- O O

Determinants NNS N
of IN N
exclusive JJ i
breastfeeding NN i
in IN N
an DT N
urban JJ p
population NN p
of IN p
primiparas NNS p
in IN p
Lebanon NNP p
: : p
a DT N
cross-sectional JJ N
study NN N
. . N

BACKGROUND NNP N
The DT N
proportion NN N
of IN N
mothers NNS p
who WP p
exclusively RB i
breastfeed VBP i
their PRP$ p
babies NNS p
up IN N
to TO N
6 CD N
months NNS N
remains VBZ N
low JJ N
. . N

Determinants NNS N
of IN N
breastfeeding VBG N
practices NNS N
have VBP N
been VBN N
largely RB N
documented VBN N
in IN N
high-income JJ N
countries NNS N
. . N

Little JJ N
evidence NN N
exists NNS N
on IN N
possible JJ N
predictors NNS N
of IN N
breastfeeding VBG N
behaviors NNS N
in IN N
the DT N
Middle NNP N
East NNP N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
assess VB N
the DT N
prevalence NN N
of IN N
breastfeeding VBG i
in IN N
Beirut NNP p
and CC N
determine VB N
the DT N
factors NNS N
that WDT N
impact VBP N
breastfeeding VBG p
behavior NN p
in IN p
this DT p
population NN p
. . p

METHODS NNP N
Data NNP N
for IN N
this DT N
longitudinal JJ N
study NN N
is VBZ N
nested VBN N
within IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
assessing VBG N
the DT N
impact NN N
of IN N
a DT N
24-hour JJ i
hotline NN i
and CC i
postpartum NN i
support NN i
film NN i
on IN N
postpartum NN N
stress NN N
. . N

Healthy JJ p
first-time JJ p
mothers NNS p
delivering VBG p
in IN p
the DT p
capital NN p
Beirut NNP p
between IN p
March NNP p
and CC p
July NNP p
2009 CD p
, , N
were VBD N
interviewed VBN N
at IN N
1-3 JJ N
days NNS N
and CC N
8-12 JJ N
weeks NNS N
post NN N
delivery NN N
. . N

A DT N
multiple JJ i
logistic JJ i
regression NN i
analysis NN i
was VBD N
used VBN N
to TO N
determine VB N
the DT N
factors NNS N
associated VBN N
with IN N
exclusive JJ N
breastfeeding NN i
at IN N
8-12 JJ N
weeks NNS N
postpartum NN N
. . N

RESULTS VB N
The DT N
overall JJ o
breastfeeding NN o
rate NN o
at IN N
8-12 JJ N
weeks NNS N
postpartum NN N
was VBD N
67 CD N
% NN N
. . N

The DT N
exclusive JJ o
breastfeeding NN o
rate NN o
was VBD N
27.4 CD N
% NN N
. . N

Factors NNS N
associated VBD N
with IN N
exclusive JJ N
breastfeeding NN N
included VBD N
maternal JJ o
work NN o
( ( N
OR=3.92 NNP N
; : N
p-value JJ N
< NNP N
0.001 CD N
) ) N
, , N
planned VBN o
pregnancy NN o
( ( N
OR=2.42 NNP N
, , N
p-value=0.010 NN N
) ) N
, , N
intention NN o
to TO o
breastfeed VB o
( ( N
OR=3.28 NNP N
; : N
p-value=0.043 NN N
) ) N
, , N
source NN o
of IN o
maternal JJ o
emotional JJ o
support NN o
( ( N
OR=1.87 NNP N
, , N
p-value=0.039 NN N
) ) N
and CC N
the DT N
use NN o
the DT o
postpartum NN o
support NN o
video NN o
, , o
the DT o
hotline NN o
service NN o
or CC o
both DT o
( ( N
OR=2.55 NNP N
, , N
p-value=0.044 NN N
; : N
OR=3.87 NNP N
, , N
p-value=0.004 NN N
and CC N
OR=4.13 NNP N
, , N
p-value=0.003 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
proportion NN N
of IN N
healthy JJ p
first-time JJ p
mothers NNS p
who WP p
exclusively RB p
breastfeed VBP p
in IN p
Beirut NNP p
is VBZ N
extremely RB N
low JJ N
. . N

Factors NNS N
associated VBD N
with IN N
breastfeeding NN N
behavior NN N
are VBP N
diverse JJ N
. . N

Future JJ N
research NN N
and CC N
interventions NNS N
should MD N
target VB N
different JJ N
levels NNS N
of IN N
the DT N
maternal-child JJ N
pair NN N
's POS N
ecosystem NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
, , N
NCT00857051 NNP N
. . N

-DOCSTART- -25840597- O O

Subcutaneous JJ o
versus NN o
intravenous JJ o
bortezomib NN o
in IN N
two CD N
different JJ N
induction NN N
therapies NNS N
for IN N
newly RB N
diagnosed VBN N
multiple JJ N
myeloma NN N
: : N
an DT N
interim JJ N
analysis NN N
from IN N
the DT N
prospective JJ N
GMMG-MM5 NNP N
trial NN N
. . N

We PRP N
investigated VBD N
the DT N
impact NN N
of IN N
subcutaneous JJ o
versus NN i
intravenous JJ o
bortezomib NN o
in IN N
the DT N
MM5 NNP N
trial NN N
of IN N
the DT N
German-Speaking NNP N
Myeloma NNP N
Multicenter NNP N
Group NNP N
which WDT N
compared VBN N
bortezomib NN i
, , i
doxorubicin NN i
, , i
and CC i
dexamethasone NN i
with IN i
bortezomib NN i
, , i
cyclophosphamide NN i
, , i
and CC i
dexamethasone NN i
induction NN N
therapy NN N
in IN N
newly RB p
diagnosed VBN p
multiple JJ p
myeloma NN p
. . p

Based VBN N
on IN N
data NNS N
from IN N
relapsed VBN N
myeloma NN N
, , N
the DT N
route NN N
of IN N
administration NN N
for IN N
bortezomib NN N
was VBD N
changed VBN N
from IN N
intravenous JJ N
to TO N
subcutaneous JJ N
after IN N
314 CD p
of IN p
604 CD p
patients NNS p
had VBD p
been VBN p
enrolled VBN p
. . p

We PRP N
analyzed VBD N
598 CD p
patients NNS p
who WP p
received VBD p
at IN p
least JJS p
one CD p
dose NN p
of IN p
trial NN p
medication NN p
. . p

Adverse JJ o
events NNS o
were VBD N
reported VBN N
more RBR N
frequently RB N
in IN N
patients NNS p
treated VBN p
with IN p
intravenous JJ p
bortezomib NNS p
( ( N
intravenous=65 JJ N
% NN N
; : N
subcutaneous=56 CC N
% NN N
, , N
P=0.02 NNP N
) ) N
. . N

Rates NNS o
of IN o
grade JJ o
2 CD o
or CC o
more JJR o
peripheral JJ o
neuropathy NNS o
were VBD N
higher JJR N
in IN N
patients NNS p
treated VBN p
with IN p
intravenous JJ p
bortezomib NN p
during IN N
the DT N
third JJ N
cycle NN N
( ( N
intravenous=8 JJ N
% NN N
; : N
subcutaneous=2 CC N
% NN N
, , N
P=0.001 NNP N
) ) N
. . N

Overall JJ o
response NN o
rates NNS o
were VBD N
similar JJ N
in IN N
patients NNS N
treated VBN N
intravenously RB N
or CC N
subcutaneously RB N
. . N

The DT N
presence NN N
of IN N
International NNP o
Staging NNP o
System NNP o
stage NN o
III NNP o
disease NN o
, , o
renal JJ o
impairment NN o
or CC o
adverse JJ o
cytogenetic JJ o
abnormalities NNS o
did VBD N
not RB N
have VB N
a DT N
negative JJ N
impact NN N
on IN N
overall JJ N
response NN N
rates NNS N
in IN N
either DT N
group NN N
. . N

To TO N
our PRP$ N
knowledge NN N
this DT N
is VBZ N
the DT N
largest JJS N
study NN N
to TO N
present VB N
data NNS N
comparing VBG N
subcutaneous JJ N
with IN N
intravenous JJ N
bortezomib NNS N
in IN N
newly RB N
diagnosed VBN N
myeloma NN o
. . o

We PRP N
show VBP N
better JJR N
tolerance NN o
and CC N
similar JJ N
overall JJ N
response NN o
rates NNS N
for IN N
subcutaneous JJ N
compared VBN N
to TO N
intravenous JJ N
bortezomib NN N
. . N

The DT N
clinical JJ N
trial NN N
is VBZ N
registered VBN N
at IN N
eudract.ema.europa.eu NN N
as IN N
n. JJ N
2010-019173-16 JJ N
. . N

-DOCSTART- -18339046- O O

Effect NN N
of IN N
sport-tinted JJ i
contact NN i
lenses NNS i
for IN N
contrast NN N
enhancement NN N
on IN N
retinal JJ N
straylight NN N
measurements NNS N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
tinted JJ i
contact NN i
lenses NNS i
( ( i
CL NNP i
) ) i
designed VBN N
for IN N
outdoor JJ N
sports NNS N
activity NN N
on IN N
the DT N
psychometric JJ N
determination NN N
of IN N
retinal JJ N
straylight NN N
using VBG N
the DT N
compensation NN N
comparison NN N
method NN N
. . N

METHODS NNP N
Thirteen NNP p
emmetropic JJ p
subjects NNS p
were VBD N
randomly RB N
fitted VBN N
with IN N
two CD i
different JJ i
tinted VBN i
Nike NNP i
Maxsight NNP i
( ( i
Bausch NNP i
& CC i
Lomb NNP i
, , i
Rochester NNP i
, , i
NY NNP i
, , i
USA NNP i
) ) i
CL NNP i
in IN i
one CD i
eye NN i
, , i
while IN i
the DT i
contralateral JJ i
eye NN i
was VBD i
fitted VBN i
with IN i
a DT i
clear JJ i
lens NNS i
made VBN i
of IN i
the DT i
same JJ i
material NN i
( ( i
Optima NNP i
38 CD i
, , i
Bausch NNP i
& CC i
Lomb NNP i
) ) i
. . i

Three CD N
valid JJ N
straylight NN o
measurements NNS o
were VBD N
taken VBN N
on IN N
each DT N
eye NN N
before IN N
and CC N
a DT N
few JJ N
minutes NNS N
after IN N
lens JJ N
insertion NN N
, , N
when WRB N
lens VBZ N
stabilization NN N
had VBD N
occurred VBN N
. . N

RESULTS VB N
The DT N
subjects NNS N
' POS N
mean NN o
straylight NN o
values NNS o
were VBD N
0.90 CD N
+/- JJ N
0.09 CD N
at IN N
baseline NN N
and CC N
0.95 CD N
+/- JJ N
0.10 CD N
with IN N
the DT N
clear JJ N
Optima NNP N
38 CD N
CL NNP N
. . N

Straylight NNP o
values NNS o
were VBD N
0.97 CD N
+/- JJ N
0.10 CD N
and CC N
1.0 CD N
+/- JJ N
0.10 CD N
log JJ N
units NNS N
with IN N
the DT N
amber NN N
and CC N
grey-green JJ N
tinted JJ N
CL NNP N
, , N
respectively RB N
. . N

Differences NNS N
in IN N
straylight NN o
between IN N
baseline NN N
( ( N
without IN N
CL NNP N
) ) N
and CC N
with IN N
the DT N
clear JJ N
CL NNP N
in IN N
place NN N
were VBD N
neither RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.066 CD N
) ) N
nor CC N
was VBD N
there EX N
a DT N
significant JJ N
difference NN N
between IN N
baseline NN N
and CC N
the DT N
amber NN N
CL NNP N
( ( N
p JJ N
= NNP N
0.052 CD N
) ) N
. . N

However RB N
, , N
the DT N
grey-green JJ N
CL NNP N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
from IN N
baseline NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
. . N

Differences NNS N
in IN N
straylight NN N
with IN N
the DT N
clear JJ N
CL NNP N
compared VBN N
with IN N
the DT N
grey-green JJ N
CL NNP N
were VBD N
also RB N
statistically RB N
different JJ N
from IN N
zero NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
showing VBG N
an DT N
increased VBN N
straylight NN o
value NN o
for IN N
the DT N
tinted JJ N
CL NNP N
. . N

These DT N
differences NNS N
were VBD N
variable JJ N
, , N
but CC N
consistent JJ N
for IN N
each DT N
subject NN N
, , N
thus RB N
those DT N
showing VBG N
higher JJR N
or CC N
lower JJR N
changes NNS N
with IN N
one CD N
tinted JJ N
lens VBZ N
tended VBN N
to TO N
show VB N
the DT N
same JJ N
trend NN N
with IN N
the DT N
second JJ N
lens NNS N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.736 CD N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
increases NNS N
having VBG N
been VBN N
found VBN N
in IN N
straylight JJ N
values NNS N
with IN N
tinted VBN N
contact NN N
lenses NNS N
, , N
those DT N
changes NNS N
are VBP N
not RB N
likely JJ N
to TO N
induce VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
visual JJ N
function NN N
under IN N
photopic NN N
conditions NNS N
, , N
even RB N
for IN N
the DT N
grey-green JJ N
CL NNP N
, , N
which WDT N
seems VBZ N
to TO N
increase VB N
straylight JJ N
values NNS N
more RBR N
significantly RB N
than IN N
the DT N
amber JJ N
CL NNP N
. . N

This DT N
difference NN N
between IN N
the DT N
tinted JJ N
CL NNP N
could MD N
suggest VB N
a DT N
wavelength JJ N
dependence NN N
of IN N
straylight NN N
values NNS N
, , N
although IN N
this DT N
should MD N
be VB N
investigated VBN N
further JJ N
by IN N
controlling VBG N
for IN N
pupil NN N
size NN N
and CC N
subjects NNS N
' POS N
pigmentation NN N
, , N
as RB N
well RB N
as IN N
by IN N
using VBG N
neutral JJ N
density NN N
filters NNS N
. . N

-DOCSTART- -25892145- O O

Afatinib NNP i
versus NN N
methotrexate NN i
as IN N
second-line JJ N
treatment NN N
in IN N
patients NNS p
with IN p
recurrent NN p
or CC p
metastatic JJ p
squamous-cell JJ p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
progressing VBG p
on IN p
or CC p
after IN p
platinum-based JJ p
therapy NN p
( ( p
LUX-Head NNP p
& CC p
Neck NNP p
1 CD p
) ) p
: : p
an DT N
open-label JJ N
, , N
randomised JJ N
phase NN N
3 CD N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
recurrent NN p
or CC p
metastatic JJ p
squamous-cell JJ p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
( ( p
HNSCC NNP p
) ) p
progressing NN p
after IN p
first-line JJ p
platinum NN p
regimens NNS p
have VBP N
a DT N
poor JJ N
prognosis NN N
and CC N
few JJ N
treatment NN N
options NNS N
. . N

Afatinib NNP i
, , N
an DT N
irreversible JJ N
ERBB NNP N
family NN N
blocker NN N
, , N
has VBZ N
shown VBN N
efficacy NN N
in IN N
a DT N
phase NN N
2 CD N
study NN N
in IN N
this DT N
setting NN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
afatinib NNS i
compared VBN N
with IN N
methotrexate NN i
as IN N
second-line JJ N
treatment NN N
in IN N
patients NNS p
with IN p
recurrent NN p
or CC p
metastatic JJ p
HNSCC NNP p
progressing NN p
on IN p
or CC p
after IN p
platinum-based JJ p
therapy NN p
. . p

METHODS NNP N
In IN p
this DT p
open-label JJ p
, , p
phase JJ p
3 CD p
, , p
randomised VBD p
controlled VBN p
trial NN p
conducted VBN p
in IN p
101 CD p
centres NNS p
in IN p
19 CD p
countries NNS p
, , p
we PRP p
enrolled VBD p
patients NNS p
aged VBN p
18 CD p
years NNS p
or CC p
older JJR p
with IN p
histologically RB p
or CC p
cytologically RB p
confirmed VBN p
HNSCC NNP p
that WDT p
was VBD p
recurrent NN p
, , p
metastatic JJ p
, , p
or CC p
both DT p
who WP p
had VBD p
progressed VBN p
on IN p
or CC p
after IN p
first-line JJ p
platinum-based JJ p
therapy NN p
, , p
were VBD p
not RB p
amenable JJ p
for IN p
salvage NN p
surgery NN p
or CC p
radiotherapy NN p
, , p
and CC p
who WP p
had VBD p
an DT p
Eastern JJ p
Cooperative NNP p
Oncology NNP p
Group NNP p
( ( p
ECOG NNP p
) ) p
performance NN p
status NN p
of IN p
0 CD p
or CC p
1 CD p
. . p

Previous JJ p
treatment NN p
with IN p
more JJR p
than IN p
one CD p
systemic JJ p
regimen NN p
in IN p
this DT p
setting NN p
was VBD p
not RB p
allowed VBN p
; : p
previous JJ p
treatment NN p
with IN p
EGFR-targeted JJ i
antibody NN i
therapy NN i
( ( i
but CC i
not RB i
EGFR-targeted JJ i
tyrosine-kinase JJ i
inhibitors NNS i
) ) i
was VBD p
allowed VBN p
. . p

We PRP N
randomly VBP N
assigned VBN N
eligible JJ N
patients NNS N
in IN N
a DT N
2:1 CD N
ratio NN N
to TO N
receive VB N
oral JJ i
afatinib NN i
( ( i
40 CD i
mg/day NN i
) ) i
or CC i
intravenous JJ i
methotrexate NN i
( ( i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
per IN i
week NN i
) ) i
, , N
stratified VBN N
by IN N
ECOG NNP N
performance NN N
status NN N
and CC N
previous JJ N
EGFR-targeted JJ N
antibody NN N
therapy NN N
for IN N
recurrent NN N
or CC N
metastatic JJ N
disease NN N
. . N

Randomisation NN N
was VBD N
done VBN N
centrally RB N
with IN N
an DT N
interactive JJ N
voice NN N
or CC N
web-based JJ N
response NN N
system NN N
. . N

Clinicians NNPS N
and CC N
patients NNS N
were VBD N
not RB N
masked VBN N
to TO N
treatment NN N
allocation NN N
; : N
independent JJ N
review NN N
of IN N
tumour JJ N
response NN N
was VBD N
done VBN N
in IN N
a DT N
blinded JJ N
manner NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
progression-free JJ o
survival NN o
as IN N
assessed VBN N
by IN N
an DT N
independent JJ N
, , N
central JJ N
imaging VBG N
review NN N
committee NN N
. . N

Efficacy NN o
analyses NNS o
were VBD N
done VBN N
in IN N
the DT N
intention-to-treat JJ N
population NN N
and CC N
safety NN o
analyses NNS o
were VBD N
done VBN N
in IN N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
study JJ N
drug NN N
. . N

This DT N
ongoing JJ N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01345682 NNP N
. . N

FINDINGS NNP N
Between NNP N
Jan NNP p
10 CD p
, , p
2012 CD p
, , p
and CC p
Dec NNP p
12 CD p
, , p
2013 CD p
, , p
we PRP p
enrolled VBD p
483 CD p
patients NNS p
and CC N
randomly RB N
assigned VBD N
322 CD N
to TO N
afatinib VB i
and CC N
161 CD N
to TO N
methotrexate VB i
. . i

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
6?7 CD N
months NNS N
( ( N
IQR NNP N
3?1-9?0 NNP o
) ) o
, , o
progression-free JJ o
survival NN o
was VBD o
longer RBR N
in IN N
the DT N
afatinib NN i
group NN i
than IN N
in IN N
the DT N
methotrexate NN i
group NN i
( ( N
median JJ N
2?6 CD N
months NNS N
[ RB N
95 CD N
% NN N
CI NNP N
2?0-2?7 CD N
] NN N
for IN N
the DT N
afatinib NN N
group NN N
vs VBD N
1?7 CD N
months NNS N
[ JJ N
1?5-2?4 JJ N
] NN N
for IN N
the DT N
methotrexate NN N
group NN N
; : N
hazard CC N
ratio VB N
[ JJ N
HR NNP N
] NNP N
0?80 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0?65-0?98 CD N
] NNP N
, , N
p=0?030 NN N
) ) N
. . N

The DT N
most RBS N
frequent JJ N
grade NN N
3 CD N
or CC N
4 CD N
drug-related JJ o
adverse JJ o
events NNS o
were VBD o
rash JJ o
or CC o
acne NN o
( ( N
31 CD N
[ RB N
10 CD N
% NN N
] NN N
of IN N
320 CD N
patients NNS N
in IN N
the DT N
afatinib NN N
group NN N
vs VBD N
none NN N
of IN N
160 CD N
patients NNS N
in IN N
the DT N
methotrexate NN N
group NN o
) ) o
, , o
diarrhoea NN o
( ( o
30 CD N
[ RB N
9 CD N
% NN N
] NN N
vs NN N
three CD N
[ $ N
2 CD N
% NN N
] NN N
) ) N
, , N
stomatitis NN o
( ( N
20 CD N
[ RB N
6 CD N
% NN N
] NNP N
vs NN N
13 CD N
[ JJ N
8 CD N
% NN N
] NN N
) ) N
, , N
fatigue NN o
( ( o
18 CD o
[ RB N
6 CD N
% NN N
] JJ N
vs NN N
five CD N
[ JJ N
3 CD N
% NN N
] NN N
) ) N
, , N
and CC o
neutropenia NN o
( ( N
1 CD N
[ NNP N
< VBD N
1 CD N
% NN N
] NNP N
vs NN N
11 CD N
[ JJ N
7 CD N
% NN N
] NN N
) ) N
; : N
serious JJ o
adverse JJ o
events NNS o
occurred VBD o
in IN N
44 CD N
( ( N
14 CD N
% NN N
) ) N
of IN i
afatinib-treated JJ i
patients NNS N
and CC N
18 CD N
( ( N
11 CD N
% NN N
) ) N
of IN i
methotrexate-treated JJ i
patients NNS N
. . N

INTERPRETATION NNP i
Afatinib NNP i
was VBD i
associated VBN N
with IN N
significant JJ N
improvements NNS N
in IN o
progression-free JJ o
survival NN o
and CC o
had VBD N
a DT N
manageable JJ N
safety NN N
profile NN N
. . N

These DT N
findings NNS N
provide VBP N
important JJ N
new JJ N
insights NNS N
into IN N
the DT N
treatment NN N
of IN N
this DT N
patient JJ N
population NN N
and CC N
support NN N
further JJ N
investigations NNS N
with IN N
irreversible JJ N
ERBB NNP N
family NN N
blockers NNS N
in IN N
HNSCC NNP N
. . N

FUNDING NN N
Boehringer NNP N
Ingelheim NNP N
. . N

-DOCSTART- -8779018- O O

Deep JJ o
vein NN o
thrombosis NN o
after IN p
major JJ p
reconstructive JJ p
spinal NN p
surgery NN p
. . p

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
study NN N
was VBD N
performed VBN N
. . N

OBJECTIVES IN N
The DT N
goals NNS N
of IN N
the DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
incidence NN N
of IN N
deep JJ o
vein NN o
thrombosis NN o
after IN p
major JJ p
adult NN p
spinal JJ p
surgery NN p
and CC N
the DT N
optimal JJ N
mode NN N
of IN N
prophylaxis NN N
in IN N
this DT N
surgical JJ N
population NN N
. . N

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Few NNP N
studies NNS N
have VBP N
evaluated VBN N
deep JJ o
vein NN o
thrombosis NN o
incidence NN N
and CC N
prophylaxis NN o
after IN N
major JJ p
adult NN p
spinal JJ p
surgery NN p
. . p

Incidence NN N
rates NNS N
have VBP N
ranged VBN N
from IN N
0.9-14 CD N
% NN N
. . N

METHODS NNP N
Three CD p
hundred VBD p
twenty-nine JJ p
patients NNS p
were VBD N
evaluated VBN N
. . N

One CD p
hundred VBD p
ten JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
3 CD N
different JJ N
deep JJ o
vein NN o
thrombosis NN o
prophylaxis NN o
groups NNS N
. . N

These DT N
patients NNS N
had VBD N
duplex JJ o
doppler NN o
scans NNS o
between IN N
the DT N
fifth NN N
and CC N
seventh JJ N
postoperative JJ N
days NNS N
. . N

The DT N
remaining VBG N
219 CD N
patients NNS N
formed VBD N
a DT N
nonrandomized JJ N
group NN N
and CC N
received VBD N
either CC N
thrombosis JJ i
embolic JJ i
deterrent NN i
stockings NNS i
alone RB i
or CC i
thrombosis VB i
embolic JJ i
deterrent NN i
stockings NNS i
and CC i
pneumatic JJ i
compression NN i
boots NNS i
for IN N
deep JJ N
vein NN N
thrombosis NN N
prophylaxis NN N
. . N

The DT N
type NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
prophylaxis NN N
in IN N
this DT N
group NN N
was VBD N
based VBN N
on IN N
surgeon NN N
preference NN N
. . N

All DT N
329 CD N
patients NNS N
were VBD N
followed VBN N
for IN N
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
of IN o
thromboembolic JJ o
disease NN o
. . o

Patients NNS N
were VBD N
followed VBN N
clinically RB N
for IN N
a DT N
minimum NN N
of IN N
1 CD N
year NN N
. . N

RESULTS NNP N
All DT N
110 CD N
prophylaxis NNS N
study NN N
group NN N
patients NNS N
were VBD N
clinically RB N
asymptomatic JJ o
and CC N
109 CD N
duplex JJ o
scans NNS o
were VBD N
normal JJ N
. . N

One CD N
scan NN N
was VBD N
indeterminate JJ N
and CC N
a DT N
follow-up JJ N
venogram NN o
was VBD N
negative JJ N
. . N

Two CD N
patients NNS N
in IN N
the DT N
coumadin NN N
group NN N
( ( N
5.7 CD N
% NN N
) ) N
experienced VBD N
excessive JJ o
blood NN o
loss NN o
. . o

One CD N
of IN N
the DT N
219 CD N
patients NNS N
from IN N
the DT N
nonrandomized VBN N
group NN N
developed VBD N
a DT N
clinically RB o
detectable JJ o
proximal JJ o
deep JJ o
vein NN o
thrombosis NN o
which WDT N
was VBD N
confirmed VBN N
by IN N
duplex JJ o
ultra-sonography NN o
. . o

The DT N
overall JJ N
clinical JJ o
incidence NN o
of IN N
deep JJ o
vein NN o
thrombosis NN o
was VBD N
0.3 CD N
% NN N
( ( N
1 CD N
in IN N
329 CD N
patients NNS N
) ) N
. . N

CONCLUSIONS VB N
This DT N
low JJ N
0.3 CD N
% NN N
rate NN N
is VBZ N
in IN N
agreement NN N
with IN N
recent JJ N
studies NNS N
that WDT N
focus VBP N
on IN N
thromboembolic JJ o
disease NN o
. . o

Given VBN N
the DT N
low JJ N
incidence NN N
, , N
routine JJ N
screening NN N
for IN N
asymptomatic JJ N
thrombi NN N
appears VBZ N
unwarranted JJ N
. . N

In IN N
addition NN N
, , N
mechanical JJ N
prophylaxis NN N
with IN N
graduated JJ N
compression NN N
stockings NNS N
and CC N
pneumatic JJ N
compression NN N
boots NNS N
is VBZ N
preferable JJ N
to TO N
anticoagulation VB N
therapy NN N
. . N

-DOCSTART- -3370523- O O

Moisture-vapour-permeable JJ i
film NN i
as IN N
an DT N
outpatient JJ p
burn NN p
dressing VBG p
. . p

This DT N
study NN N
compares VBZ N
a DT N
moisture-vapour-permeable JJ i
film NN i
( ( i
MVPF NNP i
) ) i
with IN N
silver NN i
sulphadiazine NN i
in IN N
a DT N
randomized JJ N
prospective JJ N
manner NN N
for IN N
the DT N
treatment NN N
of IN N
outpatient NN p
burns NNS p
. . p

The DT N
two CD p
treatment NN p
groups NNS p
were VBD p
closely RB p
matched VBN p
in IN p
age NN p
, , p
sex NN p
, , p
per IN p
cent NN p
of IN p
BSA NNP p
burned VBD p
, , p
and CC p
in IN p
burn JJ p
severity NN p
and CC p
locations NNS p
. . p

The DT N
MVPF NNP i
group NN N
demonstrated VBD N
a DT N
39.0 CD N
per IN N
cent NN N
greater JJR N
reduction NN N
in IN N
pain NN o
after IN N
application NN N
of IN N
the DT N
dressing NN N
over IN N
the DT N
silver JJ i
sulphadiazine NN i
group NN N
. . N

Patients NNS N
in IN N
the DT N
MVPF NNP i
film NN N
group NN N
also RB N
reported VBD N
significantly RB N
less JJR N
difficulty NN o
in IN o
wound NN o
care NN o
and CC N
in IN N
dressing VBG o
interference NN o
with IN o
their PRP$ o
daily JJ o
functions NNS o
. . o

The DT N
clinical JJ o
infection NN o
rate NN o
and CC o
time NN o
to TO o
healing VBG o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
management NN o
of IN N
outpatient NN p
burns NNS p
, , N
MVPF NNP i
was VBD N
found VBN N
to TO N
be VB N
superior JJ N
to TO N
silver VB i
sulphadiazine NN i
. . i

-DOCSTART- -17490965- O O

Trace NNP i
element NN i
supplementation NN i
after IN N
major JJ p
burns NNS p
modulates VBZ N
antioxidant JJ N
status NN N
and CC N
clinical JJ N
course NN N
by IN N
way NN N
of IN N
increased JJ N
tissue NN o
trace NN o
element NN o
concentrations NNS o
. . o

BACKGROUND NNP N
After IN N
major JJ p
burns NNS p
, , p
patients NNS p
can MD N
develop VB N
nutritional JJ p
deficiencies NNS p
including VBG p
trace NN o
element NN o
( ( o
TE NNP o
) ) o
deficiencies NNS p
. . p

Various JJ N
complications NNS N
, , N
such JJ N
as IN N
infections NNS N
and CC N
delayed VBN N
wound NN N
healing NN N
, , N
influence VB N
the DT N
clinical JJ N
course NN N
of IN N
such JJ N
patients NNS N
. . N

OBJECTIVES IN N
We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
large JJ N
, , N
intravenous JJ N
doses NNS N
of IN N
TE NNP i
supplements NNS i
on IN N
circulating NN N
and CC N
cutaneous JJ N
TE NNP N
tissue NN N
concentrations NNS N
, , N
on IN N
antioxidant JJ o
status NN o
, , N
and CC N
on IN N
clinical JJ o
outcome NN o
after IN N
major JJ p
burns NNS p
. . p

DESIGN NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
in IN N
21 CD p
patients NNS p
aged VBD p
35 CD p
+/- JJ p
11 CD p
y NN p
( ( p
x JJ p
+/- NNP p
SD NNP p
) ) p
with IN p
burns NNS p
on IN p
45 CD p
+/- JJ p
21 CD p
% NN p
of IN p
their PRP$ p
body NN p
surface NN p
area NN p
. . p

Intravenous JJ i
copper NN i
, , i
selenium NN i
, , i
and CC i
zinc NN i
( ( i
TE NNP i
group NN i
) ) i
or CC i
vehicle NN i
( ( N
V NNP N
group NN N
) ) N
was VBD N
given VBN N
with IN N
a DT N
saline JJ N
solution NN N
for IN N
14-21 JJ N
d. NN N
Blood NNP N
and CC N
urine JJ N
samples NNS N
were VBD N
collected VBN N
until IN N
day NN N
20 CD N
, , N
and CC N
skin FW N
biopsy NN N
specimens NNS N
were VBD N
collected VBN N
on IN N
days NNS N
3 CD N
, , N
10 CD N
, , N
and CC N
20 CD N
. . N

RESULTS VB N
The DT N
age NN N
of IN N
the DT N
patients NNS N
and CC N
the DT N
severity NN N
of IN N
their PRP$ N
burns NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
. . N

Plasma NNP o
TE NNP o
concentrations NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
TE NNP N
group NN N
. . N

In IN N
burned JJ N
areas NNS N
, , N
skin JJ o
contents NNS o
of IN o
both DT o
selenium NN o
( ( N
P=0.05 NNP N
) ) N
and CC N
zinc NN o
( ( N
P=0.04 NNP N
) ) N
increased VBD N
significantly RB N
by IN N
day NN N
20 CD N
. . N

Plasma NNP o
and CC o
tissue NN o
antioxidant NN o
status NN o
was VBD N
improved VBN N
by IN N
supplementation NN N
. . N

The DT N
number NN o
of IN o
infections NNS o
in IN N
the DT N
first JJ N
30 CD N
d NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TE NNP N
group NN N
( ( N
P=0.015 NNP N
) ) N
, , N
with IN N
a DT N
median JJ N
number NN N
of IN N
2 CD N
versus NN N
4 CD N
infections NNS N
per IN N
patient NN N
in IN N
the DT N
TE NNP N
and CC N
V NNP N
groups NNS N
, , N
respectively RB N
, , N
as IN N
a DT N
result NN N
of IN N
a DT N
reduction NN N
in IN N
pulmonary JJ o
infections NNS N
( ( N
P=0.03 NNP N
) ) N
. . N

Wound IN o
healing NN o
was VBD N
improved VBN N
in IN N
the DT N
TE NNP N
group NN N
, , N
with IN N
lower JJR N
requirements NNS o
for IN o
regrafting VBG o
( ( N
P=0.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
TE NNP i
supplementation NN N
was VBD N
associated VBN N
with IN N
higher JJR N
circulating NN o
plasma NN o
and CC o
skin JJ o
tissue NN o
contents NNS o
of IN o
selenium NN o
and CC o
zinc NN o
and CC N
improved VBN N
antioxidant JJ o
status NN o
. . o

These DT N
changes NNS N
were VBD N
associated VBN N
with IN N
improved JJ N
clinical JJ o
outcome NN o
, , o
including VBG o
fewer JJR o
pulmonary JJ o
infections NNS o
and CC o
better JJR o
wound NN o
healing NN o
. . o

-DOCSTART- -23749007- O O

Ultracision NNP i
versus NN i
electrocautery NN i
in IN N
performing VBG N
modified JJ N
radical JJ N
mastectomy NN N
and CC N
axillary JJ N
lymph NN N
node NN N
dissection NN N
for IN N
breast NN p
cancer NN p
: : p
a DT N
prospective JJ N
randomized VBN N
control NN N
trial NN N
. . N

BACKGROUND NNP N
Treatment NNP N
for IN N
breast NN N
cancer NN N
has VBZ N
improved VBN N
dramatically RB N
over IN N
the DT N
decades NNS N
. . N

Nevertheless RB N
, , N
modified VBD N
radical JJ N
mastectomy NN N
with IN N
axillary JJ N
dissection NN N
remains VBZ N
the DT N
standard JJ N
treatment NN N
for IN N
most JJS N
patients NNS p
, , p
especially RB p
those DT p
with IN p
big JJ p
tumours NNS p
. . p

The DT N
conventional JJ N
technology NN N
is VBZ N
to TO N
use VB N
diathermy NN N
to TO N
cut VB N
and CC N
coagulate VB N
blood NN N
vessels NNS N
. . N

The DT N
Ultracision NNP N
dissector NN N
has VBZ N
been VBN N
widely RB N
used VBN N
in IN N
laparoscopic NN N
surgery NN N
and CC N
is VBZ N
documented VBN N
to TO N
be VB N
safe JJ N
and CC N
fast JJ N
for IN N
cutting VBG N
and CC N
coagulating VBG N
tissue NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
ultracision NN i
to TO i
electrocautery VB i
, , N
looking VBG N
in IN N
terms NNS N
of IN N
amount NN N
of IN N
post NN N
operative JJ N
drainage NN N
, , N
duration NN N
of IN N
drain NN N
days NNS N
, , N
seroma JJ N
formation NN N
and CC N
other JJ N
complications NNS N
. . N

METHODOLOGY NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ p
randomized VBN p
control NN p
trial NN p
of IN p
modified JJ i
radical JJ i
mastectomy NN i
performed VBD p
for IN p
breast NN p
cancer NN p
in IN p
Pusat NNP p
Perubatan NNP p
Universiti NNP p
Kebangsaan NNP p
Malaysia NNP p
( ( p
PPUKM NNP p
) ) p
between IN p
1st CD p
June NNP p
2007 CD p
to TO p
31st CD p
December NNP p
2008 CD p
. . p

Patients NNS p
were VBD p
randomized VBN p
in IN p
two CD p
groups NNS p
: : p
group NN p
A NNP p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
underwent NN p
modified VBD i
radical JJ i
mastectomy NN i
using VBG i
ultracision NN i
( ( i
UC NNP i
) ) i
and CC p
group NN p
B NNP p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
with IN p
the DT p
conventional JJ i
electrocautery NN i
( ( i
EC NNP i
) ) i
method NN i
. . i

Main NNP N
outcome JJ N
measures NNS N
were VBD N
amount NN o
of IN o
drainage NN o
and CC o
duration NN o
of IN o
drain NN o
days NNS o
. . o

An DT N
unpaired JJ N
2-tailed JJ N
Student NN N
's POS N
t JJ N
test NN N
and CC N
the DT N
?2 JJ N
test NN N
to TO N
compare VB N
the DT N
groups NNS N
. . N

RESULTS VB p
A DT p
total NN p
of IN p
40 CD p
patients NNS p
were VBD p
involved VBN p
in IN p
this DT p
study NN p
. . p

The DT p
majority NN p
of IN p
patients NNS p
were VBD p
Malay NNP p
( ( p
55 CD p
% NN p
) ) p
followed VBN p
by IN p
Chinese NNP p
( ( p
35 CD p
% NN p
) ) p
, , p
Indian JJ p
( ( p
5 CD p
% NN p
) ) p
and CC p
others NNS p
( ( p
5 CD p
% NN p
) ) p
. . p

The DT o
mean JJ o
volume NN o
of IN o
drainage NN o
from IN o
the DT o
axilla NN o
in IN N
the DT N
EC NNP N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
UC NNP N
group NN N
[ VBD N
489.5 CD N
versus NN N
188.1 CD N
mls NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
] NN N
. . N

The DT o
mean JJ o
volume NN o
of IN o
drainage NN o
from IN o
the DT o
breast NN o
and CC o
the DT o
total JJ o
drainage NN o
from IN o
both CC o
the DT o
breast NN o
and CC o
axilla NN o
was VBD N
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
EC NNP N
group NN N
compared VBN N
to TO N
UC NNP N
[ NNP N
169.3 CD N
versus NN N
58.8 CD N
mls NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
663.7 CD N
versus NN N
247.0 CD N
mls NN N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
respectively RB N
] JJ N
. . N

The DT N
drainage NN N
consequently RB N
showed VBD N
significant JJ o
reduction NN o
in IN o
terms NNS o
of IN o
drain NN o
days NNS o
in IN N
the DT N
axilla NN N
[ VBZ N
6 CD N
days NNS N
versus RB N
3 CD N
days NNS N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
] NN N
and CC N
the DT N
breast NN N
[ JJ N
3 CD N
days NNS N
versus RB N
2 CD N
days NNS N
( ( N
p JJ N
< NNP N
0.002 CD N
) ) N
] NN N
in IN N
the DT N
UC NNP N
compared VBN N
to TO N
the DT N
EC NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ o
complication NN o
in IN N
both DT N
arms NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
use NN N
of IN N
ultracision NN N
able JJ N
to TO N
reduce VB N
the DT o
amount NN o
of IN o
drainage NN o
and CC o
the DT o
number NN o
of IN o
drain NN o
days NNS o
after IN N
performing VBG N
modified VBD N
radical JJ N
mastectomy NN N
. . N

In IN N
doing VBG N
so RB N
, , N
the DT N
use NN N
of IN N
this DT N
technology NN N
enable JJ N
us PRP N
to TO N
discharge VB N
patients NNS N
earlier RBR N
without IN N
significant JJ N
morbidities NNS N
. . N

-DOCSTART- -605912- O O

Effect NN N
of IN N
carbon NN i
monoxide NN i
on IN N
exercise NN o
performance NN o
in IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

We PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
breathing VBG i
100 CD i
ppm NN i
of IN i
carbon NN i
monoxide NN i
versus NN i
compressed VBD i
, , i
purified VBD i
air NN i
for IN N
1 CD N
hour NN N
on IN N
exercise NN o
performance NN o
in IN N
10 CD p
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

The DT N
mean JJ o
arterial JJ o
carboxyhemoglobin NN o
was VBD N
1.48 CD N
per IN N
cent NN N
in IN N
the DT N
carbon NN N
monoxide NN N
control NN N
period NN N
and CC N
increased VBD N
from IN N
1.43 CD N
to TO N
4.08 CD N
per IN N
cent NN N
after IN N
breathing VBG N
carbon NN N
monoxide NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
mean JJ o
arterial JJ o
carboxyhemoglobin NN o
level NN o
was VBD N
1.52 CD N
percent NN N
in IN N
the DT N
air NN N
control NN N
period NN N
and CC N
decreased VBN N
from IN N
1.47 CD N
to TO N
1.34 CD N
per IN N
cent NN N
after IN N
purified VBN N
air NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
mean JJ o
exercise NN o
time NN o
until IN o
marked JJ o
dyspnea NNS o
decreased VBN N
from IN N
218.5 CD N
seconds NNS N
in IN N
the DT N
carbon NN N
monoxide NN N
control NN N
period NN N
to TO N
146.6 CD N
seconds NNS N
after IN N
breathing VBG N
carbon NN N
monoxide NN N
( ( N
P NNP N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
mean JJ o
exercise NN o
time NN o
was VBD N
219.9 CD N
seconds NNS N
in IN N
the DT N
air NN N
control NN N
period NN N
and CC N
221.3 CD N
seconds NNS N
after IN N
purified VBN N
air NN N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

Breathing VBG N
100 CD N
ppm NN N
of IN N
carbon NN i
monoxide NN i
for IN N
1 CD N
hour NN N
caused VBD N
a DT N
significant JJ N
reduction NN N
in IN N
exercise NN o
performance NN o
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

-DOCSTART- -3911965- O O

Double-blind NNP N
trial NN N
comparing VBG N
the DT N
effectiveness NN N
of IN N
the DT N
homeopathic JJ i
preparation NN i
Galphimia NNP i
potentiation NN i
D6 NNP i
, , i
Galphimia NNP i
dilution NN i
10 CD i
( ( i
-6 NN i
) ) i
and CC i
placebo NN i
on IN N
pollinosis NN o
. . o

The DT N
preparation NN N
of IN N
homeopathic JJ i
drugs NNS i
is VBZ N
based VBN N
on IN N
potentiation NN N
. . N

In IN N
this DT N
potentiation NN N
the DT N
primary JJ N
substance NN N
is VBZ N
specially RB N
mixed JJ N
with IN N
a DT N
carrier NN N
( ( N
typically RB N
90 CD N
% NN N
ethanol NN i
) ) i
in IN N
the DT N
ratio NN N
1:10 CD N
. . N

Usually RB N
this DT N
potentiation NN N
is VBZ N
done VBN N
repeatedly RB N
and CC N
the DT N
final JJ N
drug NN N
is VBZ N
labeled VBN N
, , N
e.g. NN N
, , N
D6 NNP i
which WDT N
means VBZ N
a DT N
6 CD N
times NNS N
decimal JJ N
potentiation NN N
. . N

In IN N
a DT N
controlled JJ N
randomized VBN N
strictly RB N
double-blind JJ N
trial NN N
with IN N
164 CD p
patients NNS p
the DT N
effectiveness NN N
of IN N
homeopathically RB N
prepared JJ N
Galphimia NNP i
D6 NNP i
, , i
a DT i
conventional JJ i
Galphimia NNP i
dilution NN i
10 CD N
( ( N
-6 NN N
) ) N
and CC N
a DT N
placebo NN i
was VBD N
investigated VBN N
for IN N
the DT N
therapy NN N
of IN N
pollinosis NN o
. . o

The DT N
average JJ o
duration NN o
of IN o
treatment NN o
was VBD N
about RB N
5 CD N
weeks NNS N
. . N

Although IN N
no DT N
statistical JJ N
significance NN N
was VBD N
achieved VBN N
, , N
it PRP N
is VBZ N
remarkable JJ N
that IN N
there EX N
was VBD N
a DT N
clear JJ N
trend NN N
for IN N
the DT N
superiority NN o
of IN N
Galphimia NNP o
D6 NNP o
while IN N
the DT N
Galphimia NNP o
dilution NN o
10 CD o
( ( o
-6 NN o
) ) o
was VBD N
about IN N
equally RB N
effective JJ N
compared VBN N
with IN N
placebo NN i
. . i

The DT N
study NN N
itself PRP N
demonstrates VBZ N
that IN N
it PRP N
is VBZ N
possible JJ N
to TO N
do VB N
strictly RB N
controlled VBN N
trials NNS N
for IN N
homeopathic JJ i
drugs NNS i
and CC N
with IN N
medical JJ N
practitioners NNS N
. . N

-DOCSTART- -8866262- O O

Secondary JJ N
caries NNS N
formation NN N
in IN N
vitro NN N
around IN N
glass NN p
ionomer-lined JJ p
amalgam NN p
and CC p
composite JJ p
restorations NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
in IN N
vitro JJ N
secondary JJ N
caries NNS N
study NN N
was VBD N
to TO N
examine VB N
the DT N
glass-ionomer JJ i
liner NN i
's POS i
effect NN N
on IN N
wall-lesion NN N
inhibition NN N
when WRB N
a DT N
conventional JJ N
and CC N
a DT N
light-cured JJ N
glass NN i
ionomer NN i
liner NN i
was VBD N
placed VBN N
under IN N
amalgam NN i
and CC N
composite JJ i
resin NN i
restorations NNS N
. . N

Class NNP N
V NNP N
preparations NNS N
in IN N
extracted JJ p
upper JJ p
premolars NNS p
were VBD p
used VBN p
and CC p
ten JJ p
restorations NNS p
were VBD p
used VBN p
for IN p
each DT p
of IN p
the DT p
following JJ p
groups NNS p
: : p
( ( i
i NN i
) ) i
two CD i
layers NNS i
of IN i
copal JJ i
varnish JJ i
and CC i
amalgam NN i
; : i
( ( i
ii NN i
) ) i
conventional JJ i
glass-ionomer JJ i
and CC i
amalgam NN i
; : i
( ( i
iii NN i
) ) i
light-cured JJ i
glass-ionomer NN i
and CC i
amalgam NN i
; : i
( ( i
iv NN i
) ) i
bonding NN i
agent NN i
and CC i
light-cured JJ i
composite JJ i
resin NN i
; : i
( ( i
v NN i
) ) i
conventional JJ i
glass-ionomer JJ i
, , i
bonding JJ i
agent NN i
and CC i
light-cured JJ i
composite JJ i
resin NN i
; : i
( ( i
vi NN i
) ) i
light-cured JJ i
glass-ionomer NN i
, , i
extended VBD i
0.3 CD i
mm NN i
short NN i
of IN i
the DT i
enamel JJ i
margin NN i
bonding VBG i
agent NN i
and CC i
light-cured JJ i
composite JJ i
resin NN i
; : i
and CC i
( ( i
vii NN i
) ) i
light-cured JJ i
glass-ionomer NN i
, , i
extended VBD i
1 CD i
mm NN i
short NN i
of IN i
the DT i
enamel NN i
margin NN i
, , i
bonding VBG i
agent NN i
and CC i
light-cured JJ i
composite JJ i
resin NN i
. . i

The DT N
teeth NNS p
were VBD N
thermocycled VBN N
and CC N
artificial JJ i
caries NNS i
were VBD N
created VBN N
using VBG N
an DT N
acid-gel NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
showed VBD N
that IN N
artificial JJ o
recurrent NN o
caries NNS o
can MD N
be VB N
reduced VBN o
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
a DT N
glass-ionomer JJ i
liner NN i
under IN i
amalgam JJ i
restorations NNS i
. . i

The DT N
results NNS N
also RB N
showed VBD N
that IN N
when WRB N
the DT N
light-cured JJ N
glass-ionomer JJ i
liner NN N
was VBD N
placed VBN N
0.3 CD N
mm NN N
from IN N
the DT N
cavosurface NN N
margin NN N
under IN N
composite JJ N
resin NN N
restoration NN N
, , N
the DT N
artificial JJ o
recurrent NN o
caries NNS o
reduced VBN o
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

-DOCSTART- -18837418- O O

The DT N
value NN o
of IN o
transbronchial JJ o
lung NN o
biopsy NN o
using VBG N
jumbo JJ N
forceps NNS N
via IN N
rigid JJ N
bronchoscope NN N
in IN N
diffuse NN p
lung NN p
disease NN p
. . p

BACKGROUND NNP N
Transbronchial NNP N
lung NN N
biopsy NN N
( ( N
TBLB NNP N
) ) N
is VBZ N
a DT N
valuable JJ N
procedure NN N
used VBN N
to TO N
obtain VB N
a DT N
parenchymal JJ o
specimen NNS o
in IN N
the DT N
evaluation NN N
of IN N
diffuse NN N
lung NN N
infiltrates NNS N
. . N

Large JJ N
forceps NNS N
are VBP N
expected VBN N
to TO N
result VB N
in IN N
larger JJR N
specimens NNS N
and CC N
improve VB N
diagnostic JJ N
yield NN N
. . N

AIM CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
diagnostic JJ N
yield NN N
of IN N
TBLB NNP N
using VBG N
large JJ N
modified VBN N
flexible JJ N
gastroenterological JJ N
forceps NNS N
( ( N
Jumbo NNP N
forceps NNS N
) ) N
compared VBN N
with IN N
'normal NNP N
' POS N
flexible JJ N
forceps NNS N
via IN N
rigid JJ N
bronchoscopy NN N
in IN N
patients NNS N
with IN N
diffuse NN p
parenchymal JJ p
lung NN p
disease NN p
( ( p
DPLD NNP p
) ) p
. . p

METHODS PDT N
The DT N
study NN N
was VBD N
a DT N
prospective JJ N
analysis NN N
of IN N
95 CD p
patients NNS p
who WP p
underwent VBP i
fluoroscopy NN i
guided VBD i
TBLB NNP i
over IN i
a DT i
two CD i
year NN i
period NN i
. . i

Patients NNS p
with IN p
a DT p
lung NN p
mass NN p
or CC p
solitary JJ p
lung NN p
nodule NN p
undergoing VBG p
TBLB NNP p
were VBD p
excluded VBN p
. . p

The DT N
larger JJR i
and CC i
small JJ i
forceps NNS i
were VBD N
used VBN N
in IN N
a DT N
random JJ N
sequence NN N
to TO N
avoid VB N
a DT N
reduction NN N
in IN N
diagnostic JJ N
yield NN N
of IN N
the DT N
second JJ N
series NN N
of IN N
biopsies NNS N
related VBN N
to TO N
possible JJ N
bleeding NN N
by IN N
first JJ N
series NN N
of IN N
biopsies NNS N
. . N

To TO N
minimize VB N
the DT N
consequence NN N
of IN N
haemorrhage NN N
, , N
we PRP N
performed VBD N
every DT N
rigid JJ N
bronchoscopy NN i
, , i
placing VBG i
a DT i
non NN i
inflated VBN i
Fogarty NNP i
balloon NN i
and CC i
a DT i
rigid JJ i
aspirator NN i
( ( i
diameter JJ i
4 CD i
mm NN i
) ) i
in IN i
lobar NN i
bronchus NN i
near IN i
the DT i
biopsy NN i
segment NN i
. . i

The DT i
Fogarty NNP i
balloon NN i
has VBZ i
been VBN i
inflated VBN i
in IN i
case NN i
of IN i
bleeding NN i
. . i

After IN N
the DT N
bleeding NN N
was VBD N
controlled VBN N
we PRP N
continued VBD N
to TO N
operate VB N
up RP N
to TO N
the DT N
biopsy NN N
segment NN N
. . N

RESULTS NNP N
Diagnostic JJ o
yield NN o
of IN N
TBLB NNP N
using VBG N
Jumbo NNP N
forceps NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
using VBG N
normal JJ N
flexible JJ N
forceps NNS N
via IN N
rigid JJ N
bronchoscopy NN N
in IN N
patients NNS p
with IN p
DPLD NNP p
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
74 CD p
out IN p
of IN p
95 CD p
patients NNS p
( ( p
78 CD p
% NN p
) ) p
the DT N
diagnosis NN N
was VBD N
placed VBN N
with IN N
Jumbo NNP p
forcep NN p
while IN p
the DT p
smaller JJR p
forcep NN p
was VBD p
diagnostic JJ p
in IN p
62 CD p
out IN p
of IN p
95 CD p
patients NNS p
( ( p
65 CD p
% NN p
) ) p
. . p

Large JJ N
forceps NNS N
obtained VBD N
significantly RB N
more RBR N
tissue NN o
than IN N
the DT N
small JJ N
forceps NNS N
; : N
the DT N
biopsy NN N
specimen NNS N
taken VBN N
with IN N
normal JJ N
forcep NNS N
measured VBN N
in IN N
average JJ N
1.4 CD N
x JJ N
1.0 CD N
mm NN N
and CC N
the DT N
larger JJR N
biopsy NN N
taken VBN N
with IN N
jumbo JJ N
forcep NNS N
measured VBN N
in IN N
average JJ N
2.5 CD N
x JJ N
1.9 CD N
mm NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
large JJ N
biopsy NN N
forceps NNS N
to TO N
perform VB N
TBLB NNP N
via IN N
rigid JJ N
bronchoscope NN N
can MD N
significantly RB N
increase VB N
diagnostic JJ N
yield NN N
in IN N
the DT N
pathological JJ N
diagnosis NN N
of IN N
diffuse NN p
infiltrative JJ p
lung NN p
disease NN p
. . p

-DOCSTART- -25314063- O O

?-Smooth JJ o
muscle NN o
actin NN o
expression NN o
and CC o
desmoplastic JJ o
stromal JJ o
reaction NN o
in IN p
pancreatic JJ p
cancer NN p
: : p
results NNS N
from IN N
the DT N
CONKO-001 NNP N
study NN N
. . N

BACKGROUND NNP N
Previous JJ N
investigations NNS N
in IN N
pancreatic JJ N
cancer NN N
suggest VBP N
a DT N
prognostic JJ N
role NN N
for IN N
?-smooth JJ N
muscle NN N
actin NN N
( ( N
?-SMA JJ N
) ) N
expression NN N
and CC N
stromal JJ N
density NN N
in IN N
the DT N
peritumoural JJ N
stroma NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
further JJ N
validate VB N
the DT N
impact NN N
of IN N
?-SMA JJ N
expression NN N
and CC N
stromal JJ N
density NN N
in IN N
resectable JJ p
pancreatic JJ p
cancer NN p
patients NNS p
treated VBN p
with IN p
adjuvant JJ i
gemcitabine NN i
compared VBN i
with IN p
untreated JJ p
patients NNS p
. . p

METHODS NNP p
CONKO-001 NNP N
was VBD N
a DT N
prospective JJ N
randomised JJ N
phase NN N
III NNP N
study NN N
investigating VBG N
the DT N
role NN N
of IN i
adjuvant JJ i
gemcitabine NN i
as IN i
compared VBN N
with IN N
observation NN p
. . p

Tissue NNP p
samples NNS p
of IN p
162 CD p
patients NNS p
were VBD p
available JJ p
for IN p
immunohistochemistry NN N
on IN N
tissue NN N
microarrays NNS N
to TO N
evaluate VB N
the DT N
impact NN o
of IN o
?-SMA JJ o
expression NN o
and CC o
stromal JJ o
density NN o
impact NN o
on IN o
patient JJ o
outcome NN o
. . o

RESULTS NNP o
High NNP o
?-SMA JJ o
expression NN o
in IN o
tumour JJ o
stroma NN o
was VBD o
associated VBN o
with IN o
worse JJ o
patient NN o
outcome NN o
( ( o
DFS NNP o
: : o
P=0.05 NNP N
, , N
OS NNP N
: : N
P=0.047 NN o
) ) o
. . o

A DT o
dense JJ o
stroma NN o
reaction NN o
was VBD o
associated VBN o
with IN N
improved JJ o
disease-free JJ o
survival NN o
( ( o
DFS NNP o
) ) o
and CC o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
in IN N
the DT N
overall JJ N
study NN N
population NN N
( ( N
DFS NNP N
: : N
P=0.001 NNP N
, , N
OS NNP N
: : N
P=0.001 NN N
) ) N
. . N

This DT N
positive JJ o
prognostic JJ o
impact NN o
was VBD o
restricted VBN o
to TO N
patients NNS N
with IN N
no DT N
adjuvant JJ N
treatment NN N
( ( N
DFS NNP N
: : N
P NNP N
< VBZ N
0.001 CD N
, , N
OS NNP N
: : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
multivariable JJ N
analysis NN o
, , o
?-SMA JJ o
and CC o
stromal JJ o
density NN o
expression NN o
were VBD o
independently RB o
predictive JJ N
factors NNS N
for IN o
survival NN o
. . o

CONCLUSIONS VB o
Our PRP$ N
data NNS N
confirm VBP N
the DT N
negative JJ o
prognostic JJ o
impact NN o
of IN N
high JJ N
?-SMA JJ N
expression NN p
in IN p
pancreatic JJ p
cancer NN p
patients NNS p
after IN p
curatively RB p
intended VBN N
resection NN N
. . N

In IN N
contrast NN N
to TO N
former JJ N
investigations NNS N
, , N
we PRP N
found VBD N
a DT N
positive JJ N
prognostic JJ o
impact NN o
for IN N
a DT N
dense NN N
stroma NN N
. . N

This DT N
significant JJ N
influence NN N
was VBD N
restricted VBN N
to TO N
patients NNS N
who WP N
received VBD N
no DT N
adjuvant JJ N
therapy NN N
. . N

-DOCSTART- -12616671- O O

Pharmacokinetic JJ o
and CC o
safety NN o
assessments NNS o
of IN N
concurrent JJ p
administration NN p
of IN p
risperidone NN i
and CC p
donepezil NN i
. . i

Treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
sometimes RB N
uses VBZ N
combinations NNS N
of IN N
drugs NNS N
because IN N
dementia NN N
is VBZ N
frequently RB N
associated VBN N
with IN N
behavioral JJ N
symptoms NNS N
. . N

Risperidone NN i
and CC N
donepezil NN i
are VBP N
both DT N
metabolized VBN N
through IN N
cytochrome NN N
P450 NNP N
2D6 CD N
and CC N
3A4 CD N
, , N
raising VBG N
the DT N
possibility NN N
of IN N
drug NN N
interactions NNS N
with IN N
combination NN N
therapy NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
significant JJ N
drug NN o
interactions NNS o
occur VBP N
with IN N
concomitant JJ N
administration NN N
of IN N
donepezil NN i
and CC N
risperidone NN i
. . i

In IN N
an DT N
open-label JJ N
, , N
three-way JJ N
crossover NN N
study NN N
, , N
24 CD p
healthy JJ p
men NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
0.5 CD N
mg NN N
of IN N
risperidone NN i
twice JJ N
daily RB N
, , N
5 CD N
mg NN N
of IN N
donepezil NN i
once RB N
daily JJ N
, , N
or CC N
both DT i
drugs NNS i
for IN N
14 CD N
consecutive JJ N
days NNS N
, , N
followed VBN N
by IN N
a DT N
21-day JJ N
washout NN N
period NN N
. . N

The DT N
treatment NN N
ratios NNS o
of IN o
AUC NNP o
and CC N
associated VBD N
90 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
for IN N
risperidone NN N
active JJ N
moiety NN N
, , N
defined VBD N
as IN N
risperidone NN N
plus CC N
9-hydroxyrisperidone CD N
( ( N
ratio VB N
= RB N
110.2 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
= NNP N
103.7-117.2 JJ N
) ) N
, , N
and CC N
for IN N
donepezil NN N
( ( N
ratio JJ N
= RB N
97.1 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
= NNP N
90.0-103.6 CD N
) ) N
were VBD N
within IN N
the DT N
80 CD N
% NN N
to TO N
125 CD N
% NN N
of IN N
bioequivalence NN N
range NN N
. . N

The DT N
treatment NN o
ratios NNS o
of IN o
Cmax NNP o
and CC o
associated VBD o
90 CD o
% NN o
CIs NNP o
for IN N
risperidone NN N
active JJ N
moiety NN N
( ( N
ratio JJ N
= RB N
114.6 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
= NNP N
107.0-122.8 JJ N
) ) N
and CC N
for IN N
donepezil NN N
( ( N
ratio JJ N
= RB N
96.1 CD N
% NN N
; : N
90 CD N
% NN N
CI NNP N
= NNP N
90.0-102.6 CD N
) ) N
were VBD N
also RB N
within IN N
the DT N
bioequivalence NN N
range NN N
. . N

Therefore NNP N
, , N
no DT N
significant JJ N
pharmacokinetic JJ o
differences NNS N
occurred VBD N
in IN N
either CC N
risperidone VB N
active JJ N
moiety NN N
or CC N
donepezil NN N
when WRB N
given VBN N
alone RB N
or CC N
in IN N
combination NN N
. . N

Adverse JJ o
events NNS o
( ( o
predominantly RB o
headache NN o
, , o
nervousness NN o
, , o
and CC o
somnolence NN o
) ) o
were VBD N
minor JJ N
and CC N
comparable JJ N
for IN N
all DT N
treatment NN N
groups NNS N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
no DT N
clinically RB o
meaningful JJ o
drug NN o
interactions NNS o
occurred VBD N
between IN N
risperidone NN N
1 CD N
mg JJ N
daily JJ N
and CC N
donepezil JJ N
5 CD N
mg JJ N
daily RB N
at IN N
steady JJ N
state NN N
, , N
and CC N
therefore RB N
no DT N
dosage NN N
adjustment NN N
is VBZ N
required VBN N
when WRB N
both DT N
drugs NNS N
are VBP N
combined VBN N
with IN N
the DT N
dosage NN N
regimen NNS N
studied VBN N
. . N

Additional JJ N
investigations NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
potential NN N
for IN N
interactions NNS N
in IN N
elderly JJ N
patients NNS N
with IN N
dementia NNS N
who WP N
may MD N
eliminate VB N
risperidone NN N
and CC N
donepezil VB N
more JJR N
slowly RB N
and CC N
thus RB N
be VB N
more RBR N
vulnerable JJ N
to TO N
clinical JJ N
drug NN N
interactions NNS N
than IN N
the DT N
young JJ p
healthy JJ p
subjects NNS p
examined VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -16204903- O O

Treatment NN N
of IN N
anal JJ p
fissures NNS p
using VBG N
a DT N
combination NN N
of IN N
minoxidil NN i
and CC N
lignocaine NN i
: : i
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
. . N

AIM NNP N
Anal NNP N
fissures NNS N
are VBP N
associated VBN N
with IN N
hypertonia NN N
of IN N
the DT N
internal JJ N
anal JJ N
sphincter NN N
and CC N
pain NN N
. . N

We PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
local JJ N
application NN N
of IN N
a DT N
combination NN N
of IN N
minoxidil NN i
and CC N
lignocaine NN i
in IN N
healing VBG N
anal JJ N
fissures NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
, , N
90 CD p
patients NNS p
with IN p
anal JJ p
fissure NN p
were VBD p
recruited VBN p
. . p

Patients NNS N
received VBD N
local JJ i
applications NNS i
of IN i
ointments NNS i
containing VBG i
5 CD i
% NN i
lignocaine NN i
( ( i
n=28 JJ i
) ) i
, , i
0.5 CD i
% NN i
minoxidil NN i
( ( N
n=36 JJ N
) ) N
, , N
or CC i
both DT i
( ( N
n=26 NN N
) ) N
. . N

Healing VBG o
of IN o
anal JJ o
fissure NN o
at IN N
6 CD N
weeks NNS N
was VBD N
used VBN N
as IN N
the DT N
primary JJ N
end-point NN N
. . N

RESULTS NNP N
Rates NNPS o
of IN o
complete JJ o
healing NN o
of IN o
fissure NN o
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
( ( i
lignocaine VB i
alone RB N
8/27 CD N
, , N
minoxidil VBD i
alone RB N
10/34 CD N
, , N
combination NN N
7/22 CD N
; : N
p=ns NN N
) ) N
. . N

Mean NNP o
( ( o
SD NNP o
) ) o
time NN o
taken VBN o
for IN o
complete JJ o
healing VBG o
with IN o
combination NN o
treatment NN o
[ VBZ N
1.9 CD N
( ( N
0.6 CD N
) ) N
weeks NNS N
] NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
with IN N
minoxidil NN i
alone RB N
( ( N
3.1 CD N
[ RB N
1.7 CD N
] JJ N
weeks NNS N
; : N
p=0.001 NN N
) ) N
or CC N
with IN N
lignocaine JJ i
alone NN N
( ( N
3.3 CD N
[ RB N
0.8 CD N
] JJ N
weeks NNS N
; : N
p=0.002 NN N
) ) N
. . N

Rates NNS o
of IN o
pain NN o
relief NN o
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Stoppage NN o
of IN o
bleeding VBG o
occurred VBD N
more RBR N
often RB N
with IN N
combination NN N
treatment NN N
than IN N
with IN N
lignocaine JJ i
alone RB N
. . N

No DT N
patient NN N
had VBD N
systemic JJ o
or CC o
local JJ o
side NN o
effects NNS o
. . o

CONCLUSION NNP N
Combination NNP N
treatment NN N
with IN N
minoxidil NN i
and CC N
lignocaine NN i
helps VBZ N
in IN N
faster RBR N
healing NN N
of IN N
anal JJ N
fissures NNS N
and CC N
provides VBZ N
better RBR N
symptomatic JJ N
relief NN N
than IN N
either DT N
drug NN N
alone RB N
. . N

-DOCSTART- -16784930- O O

Effects NNS N
of IN N
levosimendan JJ i
versus FW N
dobutamine NN i
on IN N
inflammatory NN N
and CC N
apoptotic JJ N
pathways NNS N
in IN N
acutely RB p
decompensated VBN p
chronic JJ p
heart NN p
failure NN p
. . p

A DT N
single JJ N
levosimendan NN i
administration NN N
has VBZ N
recently RB N
been VBN N
shown VBN N
to TO N
result VB N
in IN N
clinical JJ N
and CC N
hemodynamic JJ N
improvement NN N
in IN N
patients NNS p
with IN p
decompensated JJ p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
, , p
but CC p
without IN p
survival JJ p
benefits NNS p
. . p

In IN N
this DT N
study NN N
, , N
the DT N
effects NNS N
of IN N
levosimendan NN i
and CC N
dobutamine NN i
on IN N
plasma NN N
levels NNS N
of IN N
proinflammatory NN N
and CC N
proapoptotic JJ N
mediators NNS N
in IN N
decompensated JJ N
HF NNP N
were VBD N
compared VBN N
and CC N
correlated VBN N
with IN N
the DT N
concomitant JJ N
effects NNS N
on IN N
cardiac JJ N
function NN N
and CC N
prognosis NN N
. . N

Sixty-nine JJ p
patients NNS p
were VBD p
randomized VBN p
to TO N
received VB N
24-hour JJ N
intravenous JJ N
infusions NNS N
of IN N
levosimendan NN i
( ( N
n JJ N
= NNP N
23 CD N
) ) N
, , N
dobutamine NN i
( ( N
n JJ N
= NNP N
23 CD N
) ) N
, , N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
23 CD N
) ) N
. . N

Echocardiographic NNP o
, , o
hemodynamic JJ o
, , o
and CC o
biochemical JJ o
assessments NNS o
were VBD N
performed VBN N
at IN N
baseline NN N
, , N
immediately RB N
after IN N
treatment NN N
, , N
and CC N
48 CD N
hours NNS N
later RB N
. . N

Patients NNS N
were VBD N
subsequently RB N
followed VBN N
for IN N
4 CD N
months NNS N
for IN N
disease NN N
progression NN N
. . N

End-systolic JJ o
wall NN o
stress NN o
, , o
the DT o
left NN o
ventricular JJ o
ejection NN o
fraction NN o
, , o
pulmonary JJ o
capillary JJ o
wedge NN o
pressure NN o
, , o
and CC o
cardiac JJ o
index NN o
were VBD N
significantly RB N
improved VBN N
in IN N
the DT N
levosimendan NN N
group NN N
but CC N
remained VBD N
practically RB N
unaffected VBN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Plasma NNP o
N-terminal-pro-B-type JJ o
natriuretic JJ o
peptide NN o
, , o
tumor NN o
necrosis NN o
factor-alpha NN o
, , o
and CC o
soluble JJ o
Fas NNP o
ligand NN o
levels NNS o
were VBD N
significantly RB N
decreased VBN N
only RB N
in IN N
the DT N
levosimendan NN i
group NN N
( ( N
from IN N
1,900 CD N
+/- JJ N
223 CD N
to TO N
1,378 CD N
+/- JJ N
170 CD N
pg/ml NN N
, , N
13.4 CD N
+/- JJ N
1.0 CD N
to TO N
12.3 CD N
+/- JJ N
1.2 CD N
pg/ml NN N
, , N
and CC N
68.2 CD N
+/- JJ N
3.7 CD N
to TO N
59.8 CD N
+/- JJ N
3.6 CD N
pg/ml NN N
, , N
respectively RB N
; : N
p VB N
< $ N
0.05 CD N
for IN N
all DT N
) ) N
; : N
interleukin-6 NN o
was VBD N
also RB N
borderline JJ N
reduced VBN N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

Levosimendan-induced JJ o
reduction NN o
in IN o
end-systolic JJ o
wall NN o
stress NN o
was VBD N
significantly RB N
correlated VBN N
with IN N
respective JJ N
decreases NNS N
in IN N
N-terminal-pro-B-type NNP o
natriuretic JJ o
peptide NN o
( ( N
r JJ N
= NN N
0.671 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
, , N
tumor JJ o
necrosis NN o
factor-alpha NN o
( ( N
r JJ N
= NN N
0.586 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
, , N
soluble JJ o
Fas NNP o
( ( N
r VB N
= RB N
0.441 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
soluble JJ o
Fas NNP o
ligand NN o
( ( N
r JJ N
= NN N
0.614 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

Event-free JJ o
survival NN o
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
levosimendan NN i
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
superiority NN N
of IN N
levosimendan NN i
over IN N
dobutamine NN i
in IN N
improving VBG N
central JJ o
hemodynamics NNS o
and CC N
left VBD o
ventricular JJ o
performance NN o
in IN N
decompensated JJ p
HF NNP p
seems VBZ N
to TO N
be VB N
related VBN N
to TO N
its PRP$ N
anti-inflammatory JJ N
and CC N
antiapoptotic JJ N
effects NNS N
. . N

-DOCSTART- -21324150- O O

Efficacy NN N
of IN N
a DT N
family NN i
practice-based JJ i
lifestyle JJ i
intervention NN i
program NN i
to TO N
increase VB N
physical JJ o
activity NN o
and CC N
reduce VB N
clinical JJ N
and CC N
physiological JJ N
markers NNS N
of IN N
vascular JJ N
health NN N
in IN N
patients NNS p
with IN p
high JJ p
normal JJ p
blood NN p
pressure NN p
and/or RB p
high JJ p
normal JJ p
blood NN p
glucose NN p
( ( p
SNAC NNP p
) ) p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous JJ N
interventions NNS N
to TO N
increase VB N
physical JJ o
activity NN o
and CC N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
have VBP N
been VBN N
targeted VBN N
at IN N
individuals NNS N
with IN N
established VBN N
disease NN N
; : N
less CC N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
intervention VB N
among IN N
individuals NNS p
with IN p
high JJ p
risk NN p
for IN p
disease NN p
nor CC N
has VBZ N
there RB N
been VBN N
determination NN N
of IN N
the DT N
influence NN N
of IN N
setting VBG N
in IN N
which WDT N
the DT N
intervention NN N
is VBZ N
provided VBN N
. . N

In IN N
particular JJ N
, , N
family NN N
practice NN N
represents VBZ N
an DT N
ideal JJ N
setting NN N
for IN N
the DT N
provision NN N
and CC N
long-term JJ N
maintenance NN N
of IN N
lifestyle JJ N
interventions NNS N
for IN N
patients NNS p
at IN p
risk NN p
( ( p
ie JJ p
high-normal JJ p
blood NN p
pressure NN p
or CC p
impaired JJ p
glucose JJ p
tolerance NN p
) ) p
. . p

METHODS/DESIGN PDT N
The DT N
Staged NNP p
Nutrition NNP p
and CC p
Activity NNP p
Counseling NNP p
( ( p
SNAC NNP p
) ) p
study NN p
is VBZ N
a DT N
randomized JJ N
clustered JJ N
design NN N
clinical JJ N
trial NN N
that WDT N
will MD N
investigate VB N
the DT N
effectiveness NN N
and CC N
efficacy NN N
of IN N
a DT N
multi-component JJ i
lifestyle JJ i
intervention NN i
on IN N
cardiovascular JJ p
disease NN p
risk NN p
factors NNS p
and CC p
vascular JJ p
function NN p
in IN p
patients NNS p
at IN p
risk NN p
in IN p
primary JJ p
care NN p
. . p

Patients NNS N
will MD N
be VB N
randomized VBN N
by IN N
practice NN N
to TO N
either VB N
a DT N
standard NN i
of IN i
care NN i
lifestyle JJ i
intervention NN i
or CC N
a DT N
behaviourally-based JJ i
, , i
matched VBD i
prescriptive JJ i
physical JJ i
activity NN i
and CC i
diet JJ i
change NN i
program NN i
. . i

The DT N
primary JJ N
goal NN N
is VBZ N
to TO N
increase VB N
physical JJ o
activity NN o
and CC N
improve VB N
dietary JJ o
intake NN o
according VBG N
to TO N
Canada NNP o
's POS o
Guides NNP o
to TO o
Physical NNP o
Activity NNP o
Healthy NNP o
Eating NNP o
over IN N
24 CD N
months NNS N
. . N

The DT N
primary JJ N
intention NN N
to TO N
treat VB N
analysis NN N
will MD N
compare VB N
behavioral JJ N
, , N
physiological JJ N
and CC N
metabolic JJ N
outcomes NNS N
at IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
post-randomization JJ N
including VBG N
estimation NN N
of IN N
incident JJ N
hypertension NN o
and/or NN N
diabetes VBZ o
. . o

DISCUSSION VB N
The DT N
design NN N
features NNS N
of IN N
our PRP$ N
trial NN N
, , N
and CC N
the DT N
practical JJ N
problems NNS N
( ( N
and CC N
solutions NNS N
) ) N
associated VBN N
with IN N
implementing VBG N
these DT N
design NN N
features NNS N
, , N
particularly RB N
those DT N
that IN N
result NN N
in IN N
potential JJ N
delay NN N
between IN N
recruitment NN N
, , N
baseline NN N
data NNS N
collection NN N
, , N
randomization NN N
, , N
intervention NN N
, , N
and CC N
assessment NN N
will MD N
be VB N
discussed VBN N
. . N

Results NNS N
of IN N
the DT N
SNAC NNP N
trial NN N
will MD N
provide VB N
scientific JJ N
rationale NN N
for IN N
the DT N
implementation NN N
of IN N
this DT N
lifestyle JJ N
intervention NN N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
: : N
ISRCTN:42921300 NNP N
. . N

-DOCSTART- -2185565- O O

[ IN N
The DT N
Antonio NNP i
Raichs NNP i
memorial JJ i
lecture NN i
. . i

Future JJ o
trends NNS o
in IN o
marrow JJ o
transplantation NN o
] NN o
. . o

-DOCSTART- -8964276- O O

A DT N
randomised JJ N
open JJ N
multicentre NN N
comparative JJ N
trial NN N
of IN N
lamotrigine NN i
and CC i
carbamazepine NN i
as IN N
monotherapy NN N
in IN N
patients NNS p
with IN p
newly RB p
diagnosed VBN p
or CC p
recurrent JJ p
epilepsy NN p
. . p

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
lamotrigine NN i
and CC i
carbamazepine NN i
as IN N
monotherapy NN N
in IN N
patients NNS p
with IN p
untreated JJ p
, , p
newly RB p
diagnosed VBN p
or CC p
recurrent JJ p
partial JJ p
and/or NN p
generalised VBD p
tonic-clonic JJ p
seizures NNS p
, , N
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
, , N
open JJ N
, , N
multicentre JJ N
study NN N
. . N

Patients NNS N
received VBD N
24 CD N
weeks NNS N
' POS N
treatment NN N
with IN N
oral JJ i
lamotrigine NN i
100 CD i
mg NN i
( ( i
LTG NNP i
100 CD i
, , i
n RB i
= VBZ i
115 CD i
) ) i
or CC i
200 CD i
mg NN i
( ( i
LTG NNP i
200 CD i
, , i
n RB i
= VBZ i
111 CD i
) ) i
or CC i
carbamazepine $ i
600 CD i
mg NN i
( ( i
CBZ NNP i
600 CD N
, , N
n RB N
= VBZ N
117 CD N
) ) N
. . N

Efficacy NN o
measurements NNS o
were VBD N
comparable JJ N
between IN N
the DT N
three CD N
treatment NN N
groups NNS N
, , N
although IN N
the DT N
higher JJR N
lamotrigine NN i
dose NN N
was VBD N
possibly RB N
most RBS N
effective JJ N
, , N
with IN N
60.4 CD N
% NN N
completing VBG N
seizure NN N
free JJ N
compared VBN N
with IN N
51.3 CD N
% NN N
( ( N
LTG NNP N
100 CD N
) ) N
and CC N
54.7 CD N
% NN N
( ( N
CBZ NNP N
600 CD N
) ) N
. . N

Both DT N
dosage NN N
regimens NNS N
of IN N
lamotrigine NN i
were VBD N
well RB N
tolerated VBN o
. . o

More JJR N
patients NNS p
on IN p
CBZ NNP i
600 CD p
reported VBD N
adverse JJ o
experiences NNS o
, , N
66 CD N
% NN N
versus IN N
53 CD N
% NN N
( ( i
LTG NNP i
100 CD N
) ) N
and CC N
58 CD N
% NN N
( ( i
LTG NNP i
200 CD N
) ) N
, , N
and CC N
of IN N
these DT N
a DT N
greater JJR N
proportion NN N
were VBD N
attributed VBN N
to TO N
CBZ NNP i
600 CD N
treatment NN N
, , N
53 CD N
% NN N
versus IN N
23 CD N
% NN N
( ( N
LTG NNP N
100 CD N
) ) N
and CC N
28 CD N
% NN N
( ( N
LTG NNP N
200 CD N
) ) N
. . N

Similarly RB N
, , N
a DT N
greater JJR N
proportion NN N
of IN N
the DT N
CBZ NNP i
600 CD N
group NN N
required VBD N
a DT N
change NN N
in IN N
dose NN N
, , N
47 CD N
% NN N
versus IN N
20 CD N
% NN N
( ( i
LTG NNP i
100 CD N
) ) N
and CC N
17 CD N
% NN N
( ( i
LTG NNP i
200 CD N
) ) N
or CC N
withdrew $ N
completely RB N
due JJ N
to TO N
adverse JJ o
experiences NNS o
, , N
10.3 CD N
% NN N
versus IN N
4.3 CD N
% NN N
( ( i
LTG NNP i
100 CD N
) ) N
and CC N
4.5 CD N
% NN N
( ( i
LTG NNP i
200 CD N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
experience NN o
leading VBG N
to TO N
withdrawal VB N
was VBD N
rash NN o
, , N
with IN N
approximately RB N
double JJ N
the DT N
proportion NN N
of IN N
reports NNS N
occurring VBG N
in IN N
patients NNS N
on IN N
CBZ NNP i
600 CD N
( ( N
5.1 CD N
% NN N
) ) N
compared VBN N
with IN N
lamotrigine NN i
( ( N
1.7 CD N
% NN N
on IN N
LTG NNP i
100 CD N
and CC N
2.7 CD N
% NN N
on IN N
LTG NNP i
200 CD N
) ) N
. . N

Overall JJ N
lamotrigine NN i
appeared VBD N
equally RB N
effective JJ N
but CC N
better RB N
tolerated VBD N
compared VBN N
with IN N
carbamazepine NN i
. . i

-DOCSTART- -25178668- O O

Angiographic NNP o
and CC o
electrocardiographic JJ o
parameters NNS o
of IN N
myocardial JJ N
reperfusion NN N
in IN N
angioplasty NN N
of IN N
patients NNS p
with IN p
ST NNP p
elevation NN p
acute NN p
myocardial JJ p
infarction NN p
loaded VBN N
with IN N
ticagrelor NN i
or CC i
clopidogrel NN i
( ( p
MICAMI-TICLO NNP p
trial NN p
) ) p
. . N

INTRODUCTION NNP N
Ticagrelor NNP N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
outcomes NNS N
in IN N
patients NNS p
with IN p
ACS NNP p
. . p

However RB N
, , N
the DT N
effects NNS N
of IN N
this DT N
drug NN N
on IN N
parameters NNS N
of IN N
microvascular JJ o
flow NN o
in IN N
patients NNS p
presenting VBG p
with IN p
ST-segment JJ p
elevation NN p
myocardial JJ p
infarction NN p
( ( p
STEMI NNP p
) ) p
have VBP N
not RB N
been VBN N
completely RB N
evaluated VBN N
. . N

METHODS NNP N
Ninety-two JJ p
patients NNS p
presenting VBG p
with IN p
STEMI NNP p
where WRB N
randomized VBN N
to TO N
a DT N
loading VBG N
dose NN N
of IN N
clopidogrel NN i
( ( N
600 CD N
mg NN N
) ) N
or CC N
ticagrelor NN i
( ( N
180 CD N
mg NN N
) ) N
before IN N
undergoing VBG N
primary JJ N
angioplasty NN i
. . i

We PRP N
assessed VBD N
angiographic JJ o
and CC o
electrocardiographic JJ o
parameters NNS o
of IN o
myocardial JJ o
reperfusion NN o
. . o

Blinded VBN N
operators NNS N
calculated VBD N
angiographic JJ o
corrected VBN o
TIMI NNP o
Frame NNP o
count NN o
( ( o
cTFC NN o
) ) o
and CC o
myocardial JJ o
blush NN o
grade NN o
( ( o
MBG NNP o
) ) o
before IN N
and CC N
after IN N
stent JJ N
implantation NN N
. . N

ST NNP o
segment NN o
resolution NN o
was VBD N
also RB N
measured VBN N
in IN N
all DT N
patients NNS N
. . N

Primary JJ N
endpoint NN N
was VBD N
cTFC VBN o
after IN o
PCI NNP o
. . o

Secondary JJ N
endpoints NNS N
were VBD N
cTFC JJ o
prior RB o
to TO o
PCI NNP o
, , o
TIMI NNP o
flow NN o
grade NN o
, , o
MBG NNP o
and CC o
the DT o
percentage NN o
of IN o
ST NNP o
resolution NN o
. . o

RESULTS NNP N
Of IN p
the DT p
92 CD p
randomized JJ p
patients NNS p
, , p
70 CD p
patients NNS p
were VBD p
analyzed VBN p
. . p

Mean JJ p
age NN p
of IN p
patients NNS p
was VBD p
58.8?10 CD p
years NNS p
. . p

Patients NNS p
presented VBN p
with IN p
a DT p
mean JJ o
ischemic JJ o
time NN o
of IN p
4.4?2.6 CD p
hours NNS p
. . p

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT o
time NN o
between IN o
loading VBG o
dose NN o
and CC o
stent JJ o
deployment NN o
( ( o
35.2?36.4 CD N
in IN N
ticagrelor NN N
and CC N
42.7?29.5 CD N
min NN N
in IN N
clopidogrel NN N
, , N
p=0.36 NN o
) ) o
. . o

cTFC NN o
before IN o
angioplasty NN N
was VBD N
significantly RB N
lower JJR N
in IN N
ticagrelor NN N
than IN N
in IN N
clopidogrel NN N
( ( N
81.1?29.4 CD N
vs. FW N
95.1?17.5 CD N
frames NNS N
respectively RB N
, , N
p=0.01 NN N
) ) N
. . N

After IN N
angioplasty IN N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
ticagrelor NN N
and CC N
clopidogrel NN o
in IN o
cTFC NN o
( ( N
24.6?9.3 CD N
vs. FW N
27.0?13.4 CD N
frames NNS N
respectively RB N
, , N
p=0.62 NN N
) ) N
; : N
MBG NNP o
grade VBD o
3 CD N
was VBD N
present JJ N
in IN N
76.4 CD N
vs. FW N
69.4 CD N
% NN N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
p=0.41 NN N
) ) N
. . o

The DT o
percentage NN o
of IN o
ST NNP o
resolution NN o
did VBD o
not RB o
show VB N
any DT N
differences NNS N
between IN N
groups NNS N
( ( N
84.8?23.4 CD N
in IN N
ticagrelor NN N
vs. FW N
70.8?33.7 CD N
in IN N
clopidogrel NN N
, , N
p=0.36 NN N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
clopidogrel NN N
, , N
ticagrelor NN N
loading NN N
in IN N
patients NNS p
presenting VBG p
with IN p
STEMI NNP p
is VBZ p
not RB N
associated VBN N
with IN N
an DT N
improvement NN o
of IN o
angiographic JJ o
and CC o
electrocardiographic JJ o
parameters NNS o
of IN o
myocardial JJ o
reperfusion NN N
after IN N
angioplasty NN N
. . N

-DOCSTART- -11334068- O O

Comments NNS N
on IN N
Comparison NNP N
of IN N
gastrointestinal JJ o
tolerance NN o
feeding NN i
proctocols NNS i
in IN N
critically RB p
ill JJ p
patients NNS p
: : p
a DT N
prospective JJ N
, , N
randomized VBN p
controlled VBD p
clinical JJ p
trial NN p
. . N

-DOCSTART- -23274597- O O

Pseudoephedrine NNP i
and CC N
preexercise NN i
feeding NN i
: : i
influence NN N
on IN N
performance NN o
. . o

PURPOSE VB N
This DT N
study NN N
examined VBD N
the DT N
influence NN N
of IN N
preexercise NN N
food NN N
intake NN N
on IN N
plasma NN o
pseudoephedrine NN o
( ( o
PSE NNP o
) ) o
concentrations NNS o
and CC o
subsequent JJ o
high-intensity NN o
exercise NN o
. . o

In IN N
addition NN N
, , N
urinary JJ N
PSE NNP N
concentrations NNS N
were VBD N
measured VBN N
under IN N
the DT N
same JJ N
conditions NNS N
and CC N
compared VBN N
with IN N
the DT N
present JJ N
threshold NN N
of IN N
the DT N
World NNP N
Anti-Doping NNP N
Agency NNP N
( ( N
WADA NNP N
) ) N
. . N

METHODS NNP N
Ten NNP p
highly RB p
trained VBD p
male JJ p
cyclists NNS p
and CC p
triathletes NNS p
( ( p
age NN p
= VBZ p
30.6 CD p
? . p
6.6 CD p
yr NN p
, , p
body NN p
mass NN p
[ NNP p
BM NNP p
] NNP p
= VBD p
72.9 CD p
? . p
5.1 CD p
kg NN p
, , p
and CC p
V?O2max NNP p
= VBD p
64.8 CD p
? . p
4.5 CD p
mL?kg?min NN p
; : p
mean VB p
? . p
SD NNP p
) ) p
undertook VBD N
four CD N
cycling NN N
time NN N
trials NNS N
( ( N
TT NNP N
) ) N
, , N
each DT N
requiring VBG N
the DT N
completion NN N
of IN N
a DT N
set NN N
amount NN N
of IN N
work NN N
( ( N
7 CD N
kJ?kg NNS N
BM NNP N
) ) N
in IN N
the DT N
shortest JJS N
possible JJ N
time NN N
. . N

Participants NNS N
were VBD N
randomized VBN i
into IN i
a DT i
fed NN i
or CC i
nonfed JJ i
condition NN i
and CC i
orally RB i
ingested VBD i
2.8 CD i
mg?kg NN i
BM NNP i
of IN i
PSE NNP i
or CC i
a DT i
placebo NN i
( ( i
PLA NNP i
) ) i
90 CD i
min NN i
before IN i
exercise NN i
; : i
in IN i
the DT i
fed NN i
trials NNS i
, , i
they PRP i
consumed VBD i
a DT i
meal NN i
providing VBG i
1.5 CD i
g?kg JJ i
BM NNP i
of IN i
CHO NNP i
. . N

Venous NNP N
blood NN N
was VBD N
sampled VBN N
at IN N
30 CD N
, , N
50 CD N
, , N
and CC N
70 CD N
min NN N
and CC N
pre-warm-up NN N
and CC N
postexercise NN N
for IN N
the DT N
analysis NN N
of IN N
plasma NN N
PSE NNP N
and CC N
catecholamine JJ N
concentrations NNS N
, , N
and CC N
urine NN N
was VBD N
also RB N
collected VBN N
for IN N
the DT N
analysis NN N
of IN N
PSE NNP N
concentration NN N
. . N

RESULTS NNP N
Independent NNP N
of IN N
the DT N
preexercise NN N
meal NN N
, , N
2.8 CD N
mg?kg NN N
BM NNP N
of IN N
PSE NNP N
did VBD N
not RB N
significantly RB o
improve VB o
cycling VBG o
TT NNP o
performance NN o
. . o

The DT o
fed JJ o
trials NNS o
resulted VBD N
in IN N
lower JJR o
plasma NN o
PSE NNP o
concentrations NNS o
at IN o
all DT o
time NN o
points NNS N
compared VBN N
with IN N
the DT N
nonfed JJ N
trials NNS N
. . N

Both DT o
plasma JJ o
epinephrine NN o
and CC o
blood NN o
lactate NN o
concentrations NNS o
were VBD o
higher JJR o
in IN N
the DT N
PSE NNP N
compared VBN N
with IN N
the DT N
PLA NNP N
trials NNS N
, , N
and CC N
preexercise NN o
and CC o
postexercise NN o
urinary JJ o
PSE NNP o
concentrations NNS o
were VBD o
significantly RB o
higher JJR N
than IN N
the DT N
threshold NN N
( ( N
150 CD N
?g?mL NN N
) ) N
used VBN N
by IN N
WADA NNP N
to TO N
determine VB N
illicit NN N
PSE NNP N
use NN N
. . N

CONCLUSION NNP N
Irrespective NNP N
of IN N
the DT N
preexercise NN N
meal NN o
, , o
cycling VBG o
TT NNP o
performance NN o
of IN N
approximately RB N
30 CD N
min NN N
was VBD N
not RB N
improved VBN N
after IN N
PSE NNP N
supplementation NN N
. . N

Furthermore NNP N
, , N
2.8 CD N
mg?kg NN N
BM NNP N
of IN N
PSE NNP N
taken VBN N
90 CD N
min NN N
before IN N
exercise NN N
, , N
with IN N
or CC N
without IN N
food NN N
, , N
resulted VBD N
in IN N
urinary JJ N
PSE NNP N
concentrations NNS N
exceeding VBG N
the DT N
present JJ N
WADA NNP N
threshold NN N
. . N

-DOCSTART- -17082978- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
cognitive JJ i
behavioural JJ i
intervention NN i
for IN N
anger JJ N
management NN N
in IN N
children NNS p
diagnosed VBN p
with IN p
Asperger NNP p
syndrome NN p
. . p

The DT N
purpose NN N
of IN N
the DT N
study NN N
described VBD N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive JJ N
behavioural JJ N
intervention NN N
for IN N
anger JJ N
management NN N
with IN N
children NNS p
diagnosed VBN p
with IN p
Asperger NNP p
syndrome NN p
. . p

Forty-five JJ p
children NNS p
and CC p
their PRP$ p
parents NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
intervention NN i
or CC N
wait-list JJ i
control NN i
conditions NNS i
. . i

Children NNP N
in IN N
the DT N
intervention NN N
participated VBD N
in IN N
six CD i
2-h JJ i
weekly JJ i
sessions NNS i
while IN N
parents NNS N
participated VBN N
in IN N
a DT N
larger JJR N
parent NN N
group NN N
. . N

Parent NN N
reports NNS N
indicated VBD N
a DT N
significant JJ N
decrease NN N
in IN N
episodes NNS o
of IN o
anger NN o
following VBG N
intervention NN N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
their PRP$ N
own JJ N
confidence NN o
in IN N
managing VBG o
anger NN o
in IN o
their PRP$ o
child NN o
. . o

Qualitative JJ N
information NN N
gathered VBN N
from IN N
parents NNS N
and CC N
teachers NNS N
indicated VBD N
some DT N
generalization NN N
of IN N
strategies NNS N
learned VBN N
in IN N
the DT N
clinic JJ N
setting NN N
to TO N
both DT N
home NN N
and CC N
school NN N
settings NNS N
. . N

Limitations NNS N
of IN N
the DT N
study NN N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
also RB N
discussed VBN N
. . N

-DOCSTART- -26153884- O O

Replacing VBG i
Non-Active JJ i
Video NNP i
Gaming NNP i
by IN i
Active NNP i
Video NNP i
Gaming NNP i
to TO N
Prevent NNP N
Excessive NNP p
Weight NNP p
Gain NNP p
in IN p
Adolescents NNP p
. . p

OBJECTIVE CC N
The DT N
aim NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
and CC N
adherence NN N
to TO N
an DT N
active JJ i
video NN i
game NN i
promotion NN i
intervention NN i
on IN N
anthropometrics NNS N
, , N
sedentary JJ N
screen NN N
time NN N
and CC N
consumption NN N
of IN N
sugar-sweetened JJ N
beverages NNS N
and CC N
snacks NNS N
among IN N
non-active JJ i
video NN i
gaming VBG i
adolescents NNS p
who WP p
primarily RB p
were VBD p
of IN p
healthy JJ p
weight NN p
. . p

METHODS NNP N
We PRP N
assigned VBD N
270 CD p
gaming NN p
( ( p
i.e NN p
. . p

? . p
2 CD p
hours/week JJ p
non-active JJ p
video NN p
game NN p
time NN p
) ) p
adolescents NNS p
randomly RB p
to TO p
an DT p
intervention NN i
group NN i
( ( i
n JJ p
= NNP p
140 CD i
) ) i
( ( i
receiving VBG i
active JJ i
video NN i
games NNS i
and CC i
encouragement NN i
to TO i
play VB i
) ) i
or CC i
a DT p
waiting-list JJ i
control NN i
group NN i
( ( i
n JJ p
= NNP p
130 CD o
) ) o
. . o

BMI-SDS NNP o
( ( o
SDS NNP N
= NNP N
adjusted VBD N
for IN N
mean JJ N
standard JJ N
deviation NN N
score NN N
) ) N
, , N
waist JJ N
circumference-SDS NN N
, , N
hip NN N
circumference NN N
and CC N
sum NN N
of IN N
skinfolds NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
at IN N
four CD N
and CC N
ten JJ N
months NNS N
follow-up RB N
( ( N
primary JJ N
outcomes NNS N
) ) N
. . N

Sedentary JJ N
screen NN N
time NN N
, , N
physical JJ N
activity NN N
, , N
consumption NN N
of IN N
sugar-sweetened JJ N
beverages NNS N
and CC N
snacks NNS N
, , N
and CC N
process NN N
measures NNS N
( ( N
not RB N
at IN N
baseline NN N
) ) N
were VBD N
assessed VBN N
with IN N
self-reports NNS N
at IN N
baseline NN N
, , N
one CD N
, , N
four CD N
and CC N
ten JJ N
months NNS N
follow-up RB N
. . N

Multi-level-intention NN N
to TO N
treat-regression NN N
analyses NNS N
were VBD N
conducted VBN N
. . N

RESULTS VB N
The DT i
control NN i
group NN i
decreased VBD i
significantly RB N
more JJR N
than IN N
the DT i
intervention NN i
group NN i
on IN i
BMI-SDS NNP o
( ( o
? . N
= RB N
0.074 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.008 CD N
; : N
0.14 CD N
) ) N
, , N
and CC N
sum NN o
of IN o
skinfolds NNS o
( ( o
? . o
= RB N
3.22 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.27 CD N
; : N
6.17 CD N
) ) N
( ( N
overall JJ N
effects NNS N
) ) N
. . N

The DT N
intervention NN i
group NN i
had VBD i
a DT N
significantly RB N
higher JJR N
decrease NN o
in IN o
self-reported JJ o
non-active JJ o
video NN o
game NN o
time NN o
( ( o
? . o
= NN N
-1.76 NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-3.20 NN N
; : o
-0.32 CC o
) ) o
and CC o
total JJ o
sedentary JJ o
screen NN o
time NN o
( ( N
Exp NNP N
( ( N
? . N
= RB N
0.81 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.74 CD N
; : N
0.88 CD N
) ) N
than IN N
the DT i
control NN i
group NN i
( ( N
overall JJ N
effects NNS N
) ) N
. . N

The DT N
process NN N
evaluation NN N
showed VBD N
that IN p
14 CD p
% NN p
of IN p
the DT p
adolescents NNS p
played VBD p
the DT N
Move NNP N
video NN N
games NNS N
every DT N
week NN N
? . N
1 CD N
hour/week NN N
during IN N
the DT N
whole JJ N
intervention NN N
period NN N
. . N

CONCLUSIONS VB i
The DT i
active JJ i
video NN i
game NN i
intervention NN i
did VBD i
not RB i
result VB N
in IN N
lower JJR N
values NNS N
on IN N
anthropometrics NNS p
in IN p
a DT p
group NN p
of IN p
'excessive JJ p
' POS p
non-active JJ p
video NN p
gamers NNS p
( ( p
mean JJ p
~ VBP p
14 CD p
hours/week NN p
) ) p
who WP p
primarily RB p
were VBD p
of IN p
healthy JJ p
weight NN p
compared VBN N
to TO N
a DT N
control NN N
group NN N
throughout IN N
a DT N
ten-month-period NN N
. . N

Even RB N
some DT N
effects NNS N
in IN N
the DT N
unexpected JJ N
direction NN N
were VBD N
found VBN N
, , N
with IN N
the DT N
control NN i
group NN i
showing VBG i
lower JJR N
BMI-SDS NNP N
and CC N
skin NN N
folds NNS N
than IN N
the DT N
intervention NN i
group NN i
. . i

The DT N
intervention NN N
did VBD N
result VB N
in IN N
less JJR N
self-reported JJ N
sedentary JJ N
screen NN N
time NN N
, , N
although IN N
these DT N
results NNS N
are VBP N
likely JJ N
biased VBN N
by IN N
social JJ N
desirability NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
NTR3228 NNP N
. . N

-DOCSTART- -9676351- O O

[ JJ N
Pharmacokinetics NNS N
of IN N
theophylline NN N
in IN N
sustained-release JJ N
formulation NN N
in IN N
young JJ p
asthmatics NNS p
] VBP p
. . N

Pharmacokinetics NNS N
of IN N
two CD i
theophylline NN i
( ( i
CAS NNP i
58-55-9 NNP i
) ) i
sustained VBD i
release NN i
preparations NNS i
( ( i
T NNP i
: : i
Bronchoretard NNP i
Capsules/R NNP i
: : i
Capsule JJ i
formulation NN i
from IN i
the DT i
US NNP i
market NN i
) ) i
were VBD N
investigated VBN N
in IN N
an DT N
open JJ N
randomised VBD N
two-way RB N
crossover JJ N
design NN N
. . N

The DT N
capsules NNS N
of IN N
the DT N
test NN N
formulation NN N
were VBD N
opened VBN N
and CC N
administered VBN N
on IN N
a DT N
tablespoonful NN N
of IN N
apple NN N
sauce NN N
. . N

Nineteen JJ p
asthmatics NNS p
aged VBD p
6 CD p
to TO p
12 CD p
years NNS p
participated VBN N
in IN N
this DT N
study NN N
. . N

Following VBG i
individual JJ i
dosing NN i
of IN i
100-300 JJ i
mg NNS i
theophylline VB i
twice RB i
a DT i
day NN i
, , i
a DT i
pharmacokinetic JJ i
profile NN i
for IN i
24 CD i
h NN i
was VBD i
derived VBN i
after IN i
seven CD i
days NNS i
of IN i
multiple JJ i
dosing NN i
. . i

All DT i
relevant JJ o
parameters NNS o
for IN o
rate NN o
( ( o
Cmax NNP o
ss NN o
, , o
Cmin NNP o
ss NN o
, , o
Cav NNP o
ss NN o
, , o
plateau NN o
time NN o
, , o
peak-trough JJ o
fluctuation NN o
, , o
nocturnal JJ o
excess NN o
, , o
tmax VB o
ss NN o
) ) o
and CC i
extent NN o
of IN o
absorption NN o
( ( o
AUCss NNP o
) ) o
were VBD i
calculated VBN i
for IN i
both DT i
formulations NNS i
. . i

With IN N
long JJ N
plateau NN o
times NNS o
( ( N
T NNP N
: : N
17.3 CD N
h NN N
) ) N
and CC N
small JJ o
peak-trough JJ o
fluctuations NNS o
( ( N
T NNP N
: : N
49.0 CD N
% NN N
) ) N
, , N
established VBN N
quality NN N
criteria NNS N
for IN N
high JJ N
quality NN N
theophylline NN N
preparations NNS N
were VBD N
fulfilled VBN N
by IN N
the DT N
test NN N
formulation NN N
. . N

Furthermore NNP N
, , N
symmetrical JJ o
peaks NNS o
resulted VBD N
after IN N
morning NN N
and CC N
evening VBG N
administration NN N
of IN N
the DT N
test NN N
formulation NN N
. . N

In IN N
conclusion NN N
, , N
smooth JJ N
and CC N
predictable JJ N
concentration/time NN o
profiles NNS o
were VBD N
achieved VBN N
, , N
enabling VBG N
an DT N
efficacious JJ N
and CC N
safe JJ N
therapy NN N
of IN N
asthma NN N
. . N

This DT N
individual JJ N
mode NN N
of IN N
administration NN N
allows VBZ N
not RB N
only RB N
a DT N
perfect JJ N
dose JJ N
titration NN N
in IN N
young JJ p
asthmatics NNS p
, , N
but CC N
is VBZ N
also RB N
helpful JJ N
to TO N
patients NNS p
who WP p
have VBP p
difficulty NN p
in IN p
swallowing VBG p
large JJ p
dosage NN p
forms NNS p
. . p

-DOCSTART- -23893098- O O

Competitive JJ N
employment NN N
for IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
early JJ N
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

For IN N
most JJS N
youth NN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
, , N
employment NN N
upon IN N
graduation NN N
from IN N
high JJ N
school NN N
or CC N
college NN N
is VBZ N
elusive JJ N
. . N

Employment JJ N
rates NNS N
are VBP N
reported VBN N
in IN N
many JJ N
studies NNS N
to TO N
be VB N
very RB N
low JJ N
despite IN N
many JJ N
years NNS N
of IN N
intensive JJ N
special JJ N
education NN N
services NNS N
. . N

This DT N
paper NN N
presented VBD N
the DT N
preliminary JJ N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
Project NNP i
SEARCH NNP i
plus CC i
ASD NNP i
Supports NNP i
on IN N
the DT N
employment NN N
outcomes NNS N
for IN N
youth NN p
with IN p
ASD NNP p
between IN p
the DT p
ages NNS p
of IN p
18-21 JJ p
years NNS p
of IN p
age NN p
. . p

This DT o
model NN o
provides VBZ o
very RB o
promising JJ o
results NNS o
in IN o
that DT o
the DT o
employment NN o
outcomes NNS o
for IN o
youth NN o
in IN o
the DT o
treatment NN o
group NN o
were VBD o
much RB o
higher JJR o
in IN o
non-traditional JJ o
jobs NNS o
with IN o
higher JJR o
than IN o
minimum JJ o
wage NN o
incomes NNS o
than IN o
for IN o
youth NN o
in IN o
the DT o
control NN o
condition NN o
. . o

Specifically RB o
, , o
21 CD o
out IN o
of IN o
24 CD o
( ( o
87.5 CD o
% NN o
) ) o
treatment NN o
group NN o
participants NNS o
acquired VBD o
employment NN o
while IN o
1 CD o
of IN o
16 CD o
( ( o
6.25 CD o
% NN o
) ) o
of IN o
control NN o
group NN o
participants NNS o
acquired VBD o
employment NN o
. . o

-DOCSTART- -24323035- O O

Randomized VBN N
, , N
placebo-controlled JJ N
, , N
phase JJ N
III NNP N
trial NN N
of IN N
sunitinib JJ N
plus CC N
prednisone JJ N
versus NN N
prednisone NN N
alone RB N
in IN N
progressive JJ p
, , p
metastatic JJ p
, , p
castration-resistant JJ p
prostate NN p
cancer NN p
. . p

PURPOSE NNP N
We PRP N
evaluated VBD N
angiogenesis-targeted JJ o
sunitinib NN o
therapy NN o
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
of IN N
metastatic JJ p
castration-resistant JJ p
prostate NN p
cancer NN p
( ( p
mCRPC NN p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Men NNP p
with IN p
progressive JJ p
mCRPC NN p
after IN p
docetaxel-based JJ p
chemotherapy NN p
were VBD N
randomly RB N
assigned VBN N
2:1 CD N
to TO N
receive VB N
sunitinib NN i
37.5 CD i
mg/d NN i
continuously RB i
or CC i
placebo VB i
. . i

Patients NNS N
also RB N
received VBD N
oral JJ i
prednisone NN i
5 CD i
mg NN i
twice RB i
daily RB i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
survival NN o
( ( N
OS NNP N
) ) N
; : N
secondary JJ N
end NN N
points NNS N
included VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . N

Two CD N
interim JJ N
analyses NNS N
were VBD N
planned VBN N
. . N

RESULTS NNP N
Overall NNP N
, , N
873 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
receive VB N
sunitinib NN N
( ( N
n JJ N
= NNP N
584 CD N
) ) N
or CC N
placebo NN N
( ( N
n JJ N
= NNP N
289 CD N
) ) N
. . N

The DT N
independent JJ N
data NNS N
monitoring VBG N
committee NN N
stopped VBD N
the DT N
study NN N
for IN N
futility NN N
after IN N
the DT N
second JJ N
interim JJ N
analysis NN N
. . N

After IN N
a DT N
median JJ N
overall JJ N
follow-up NN N
of IN N
8.7 CD N
months NNS N
, , N
median JJ o
OS NNP o
was VBD N
13.1 CD N
months NNS N
and CC N
11.8 CD N
months NNS N
for IN N
sunitinib NN N
and CC N
placebo NN N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.914 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.762 CD N
to TO N
1.097 CD N
; : N
stratified VBN N
log-rank JJ N
test NN N
, , N
P NNP N
= NNP N
.168 NNP N
) ) N
. . N

PFS NNP o
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
sunitinib NN N
arm NN N
( ( N
median JJ N
5.6 CD N
v JJ N
4.1 CD N
months NNS N
; : N
HR NNP N
, , N
0.725 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.591 CD N
to TO N
0.890 CD N
; : N
stratified VBN N
log-rank JJ N
test NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Toxicity NN o
and CC o
rates NNS o
of IN o
discontinuations NNS o
because IN o
of IN o
adverse JJ o
events NNS o
( ( N
AEs NNP N
; : N
27 CD N
% NN N
v JJ N
7 CD N
% NN N
) ) N
were VBD N
greater JJR N
with IN N
sunitinib JJR N
than IN N
placebo NN N
. . N

The DT N
most RBS N
common JJ N
treatment-related JJ N
grade NN N
3/4 CD N
AEs NNP N
were VBD N
fatigue JJ o
( ( N
9 CD N
% NN N
v JJ N
1 CD N
% NN N
) ) N
, , N
asthenia RB o
( ( N
8 CD N
% NN N
v JJ N
2 CD N
% NN N
) ) N
, , N
and CC N
hand-foot JJ o
syndrome NN o
( ( N
7 CD N
% NN N
v JJ N
0 CD N
% NN N
) ) N
. . N

Frequent JJ N
treatment-emergent JJ N
grade NN N
3/4 CD N
hematologic JJ o
abnormalities NNS o
were VBD N
lymphopenia JJ o
( ( N
20 CD N
% NN N
v JJ N
11 CD N
% NN N
) ) N
, , N
anemia NN o
( ( N
9 CD N
% NN N
v JJ N
8 CD N
% NN N
) ) N
, , N
and CC N
neutropenia NN o
( ( N
6 CD N
% NN N
v NN N
< CD N
1 CD N
% NN N
) ) N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
sunitinib NN N
to TO N
prednisone VB N
did VBD N
not RB N
improve VB N
OS NNP o
compared VBN N
with IN N
placebo NN N
in IN N
docetaxel-refractory JJ N
mCRPC NN N
. . N

The DT N
role NN N
of IN N
antiangiogenic JJ N
therapy NN N
in IN N
mCRPC NN N
remains VBZ N
investigational JJ N
. . N

-DOCSTART- -22537359- O O

Placebo-controlled JJ N
pilot NN N
trial NN N
of IN N
mecamylamine NN i
for IN N
treatment NN N
of IN N
autism NN o
spectrum NN o
disorders NNS o
. . o

OBJECTIVE NNP N
To TO N
explore VB N
possible JJ N
benefits NNS N
of IN N
a DT N
nicotinic JJ i
acetylcholine NN i
receptor NN i
( ( i
nAChR JJ i
) ) i
agent NN i
for IN N
autistic JJ o
symptoms NNS o
based VBN N
on IN N
postmortem NN N
observation NN N
of IN N
nAChR JJ N
abnormalities NNS N
( ( N
deficient JJ N
?4?2 NN N
nAChRs NN N
, , N
excess JJ N
?7 NNP N
nAChRs NN N
) ) N
in IN N
brains NNS p
of IN p
patients NNS p
with IN p
autism NN p
. . p

METHOD NNP i
Mecamylamine NNP i
, , i
because IN i
of IN N
its PRP$ N
safety NN N
record NN N
in IN N
children NNS N
with IN N
other JJ N
disorders NNS N
, , N
was VBD N
chosen VBN N
for IN N
this DT N
first JJ N
exploration NN p
. . p

Twenty NNP p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
age NN p
4-12 CD p
years NNS p
were VBD p
randomly RB N
assigned VBN N
for IN N
14 CD N
weeks NNS N
to TO N
placebo VB i
( ( i
n=8 NN i
) ) N
or CC N
mecamylamine NN i
( ( i
n=12 JJ i
) ) N
in IN N
ascending VBG N
fixed JJ N
doses NNS N
: : N
0.5 CD N
mg/day NN N
for IN N
6 CD N
weeks NNS N
, , N
2.5 CD N
mg NN N
for IN N
2 CD N
weeks NNS N
, , N
then RB N
5 CD N
mg/day NN N
for IN N
6 CD N
weeks NNS N
. . N

Improvement NNP N
was VBD N
rated VBN N
by IN N
a DT N
blinded JJ N
independent JJ N
evaluator NN N
. . N

Because IN N
of IN N
small JJ N
sample NN N
, , N
data NNS N
analysis NN N
was VBD N
descriptive JJ N
. . N

RESULTS NNP p
Eighteen JJ p
participants NNS p
( ( p
10 CD p
mecamylamine NN i
, , i
8 CD i
placebo NN i
) ) i
completed VBD i
the DT p
study NN p
. . p

All DT p
doses NNS N
were VBD N
well RB o
tolerated VBN o
; : o
the DT o
only JJ N
side NN N
effect NN N
of IN N
note NN N
was VBD N
constipation NN o
( ( o
50 CD o
% NN N
compared VBN N
with IN N
25 CD N
% NN N
of IN N
placebo NN i
group NN i
) ) N
. . N

Three CD N
children NNS N
had VBD N
clinically RB o
nonsignificant JJ o
electrocardiographic JJ o
QT NNP o
prolongation NN o
. . o

Both DT o
groups NNS N
showed VBD N
modest JJ N
to TO N
moderate VB N
improvement NN N
, , N
but CC N
differences NNS N
between IN N
groups NNS N
were VBD N
negligible JJ N
. . N

On IN N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
the DT N
Ohio NNP o
Autism NNP o
Clinical NNP o
Impressions NNP o
Scale NNP o
, , o
90 CD o
% NN N
of IN N
the DT N
active JJ N
treatment NN N
group NN N
showed VBD N
improvement NN N
at IN N
some DT N
point NN N
( ( N
but CC N
only RB N
40 CD N
% NN N
sustained VBD N
it PRP N
) ) N
, , N
compared VBN N
with IN N
62 CD N
% NN N
on IN N
placebo NN i
. . i

Of IN i
the DT N
four CD N
in IN N
active JJ N
treatment NN N
that WDT N
sustained VBD N
improvement NN N
, , N
three CD N
had VBD N
a DT N
maximum JJ N
dose NN N
of IN N
0.13-0.15 JJ N
mg/kg/day NN N
, , N
while IN N
those DT N
who WP N
regressed VBD N
had VBD N
doses NNS N
?0.18 JJ N
mg/kg/day NN N
. . N

Graphed VBN N
means NNS N
suggested VBD N
better RBR N
outcome NN N
with IN N
lower JJR N
mg/kg NN N
and CC N
longer JJR N
medication NN N
duration NN N
. . N

Four CD N
parents NNS N
spontaneously RB N
reported VBD N
reduced JJ o
hyperactivity NN o
and CC o
irritability NN o
and CC o
better JJR o
verbalization NN o
and CC o
continued JJ i
mecamylamine NN i
at IN i
their PRP$ i
own JJ N
expense NN N
. . N

CONCLUSION NNP i
Mecamylamine NNP i
appeared VBD i
to TO N
be VB N
safe JJ N
, , N
but CC N
not RB N
very RB N
effective JJ o
in IN o
autism NN o
. . o

The DT o
suggestion NN N
of IN N
better JJR N
results NNS N
at IN N
lower JJR N
doses NNS N
and CC N
longer JJR N
exposure NN N
warrants NNS N
consideration NN N
for IN N
future JJ N
trials NNS N
. . N

The DT N
next JJ N
step NN N
would MD N
be VB N
exploration NN N
of IN N
a DT N
more RBR N
specific JJ i
?4?2 NNP i
nAChR JJ i
agonist NN i
, , i
such JJ i
as IN i
varenicline NN i
. . i

-DOCSTART- -2339965- O O

Heat-exercise JJ p
performance NN p
of IN p
pyridostigmine-treated JJ i
subjects NNS p
wearing VBG p
chemical NN p
protective JJ p
clothing NN p
. . p

Pyridostigmine NNP i
bromide NN i
is VBZ N
currently RB N
the DT N
pretreatment NN N
of IN N
choice NN N
for IN N
operation NN N
in IN N
a DT N
chemical NN N
warfare NN N
( ( N
CW NNP N
) ) N
environment NN N
. . N

Under IN N
CW NNP N
conditions NNS N
, , N
subjects NNS N
are VBP N
exposed VBN N
to TO N
thermal VB p
stress NN p
caused VBN p
by IN p
CW NNP p
protective JJ p
clothing NN p
. . p

This DT N
investigation NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
pyridostigmine JJ i
affects VBZ N
various JJ N
physiological JJ N
and CC N
biophysical JJ N
parameters NNS N
of IN N
human JJ N
temperature NN N
regulation NN N
in IN N
subjects NNS N
wearing VBG N
CW NNP N
protective JJ N
clothing NN N
. . N

Pyridostigmine NNP i
was VBD i
administered VBN i
orally RB i
in IN N
a DT N
randomized JJ N
double-blind JJ N
cross-over NN N
study NN N
in IN N
four CD N
doses NNS N
of IN N
30 CD N
mg NN N
every DT N
8 CD N
h. NN N
An DT N
average NN N
of IN N
33 CD N
% NN N
whole JJ N
blood NN N
cholinesterase NN N
inhibition NN N
was VBD N
induced VBN N
in IN N
the DT N
pyridostigmine NN i
treated VBD N
group NN N
4 CD N
h NN N
after IN N
ingestion NN N
of IN N
last JJ N
tablet NN N
. . N

The DT N
subjects NNS N
were VBD N
exposed VBN N
to TO N
170 CD N
min NNS N
exercise-heat JJ N
stress NN N
( ( N
Tdb NNP N
= VBZ N
33 CD N
degrees NNS N
C NNP N
; : N
rh VBZ N
= $ N
60 CD N
% NN N
) ) N
consisting NN N
of IN N
60 CD N
min NNS N
in IN N
a DT N
sitting JJ N
position NN N
and CC N
two CD N
50-min JJ N
walks NNS N
( ( N
1.39 CD N
m.s-1 NN N
, , N
5 CD N
% NN N
grade NN N
) ) N
separated VBN N
by IN N
10 CD N
min NN N
of IN N
rest NN N
. . N

Non-evaporative NNP o
heat NN o
exchange NN o
was VBD N
significantly RB N
higher JJR N
, , N
-14.0 JJ N
and CC N
-10.6 JJ N
W.m-2 NNP N
( ( N
p NN N
less JJR N
than IN N
0.03 CD N
) ) N
, , N
for IN N
the DT N
pyridostigmine-treated JJ i
subjects NNS N
. . N

No DT N
additional JJ N
differences NNS N
were VBD N
found VBN N
between IN N
treatments NNS N
in IN N
the DT N
physiological JJ N
responses NNS N
and CC N
heat NN N
balance NN N
parameters NNS N
at IN N
the DT N
end NN N
of IN N
exposure NN N
: : N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
was VBD N
( ( N
mean JJ N
+/- JJ N
S.D NNP N
. . N

) ) N
154 CD N
+/- JJ N
16 CD N
and CC N
151 CD N
+/- JJ N
24 CD N
bpm NN N
, , N
rectal JJ N
temperature NN N
( ( N
Tre NNP N
) ) N
was VBD N
39.0 CD N
+/- JJ N
0.4 CD N
and CC N
38.9 CD N
+/- JJ N
0.2 CD N
degrees NNS N
C NNP N
, , N
heat NN N
storage NN N
over IN N
the DT N
2 CD N
h NN N
of IN N
exercise NN N
was VBD N
62 CD N
+/- JJ N
15 CD N
and CC N
70 CD N
+/- JJ N
15 CD N
W.m-2 JJ N
, , N
and CC N
sweat NN N
rate NN N
was VBD N
832 CD N
+/- JJ N
185 CD N
and CC N
748 CD N
+/- JJ N
52 CD N
g.h-1 NN N
, , N
in IN N
the DT N
pyridostigmine NN N
and CC N
placebo NN N
treatments NNS N
, , N
respectively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -9366821- O O

Effectiveness NN o
of IN N
norgestimate NN i
and CC N
ethinyl NN i
estradiol NN i
in IN N
treating VBG N
moderate JJ p
acne NN p
vulgaris NN p
. . p

BACKGROUND NNP N
An DT N
excess NN N
of IN N
androgen NN N
is VBZ N
believed VBN N
to TO N
contribute VB N
to TO N
development NN N
of IN N
acne NN N
in IN N
some DT N
patients NNS N
. . N

Because IN N
oral JJ i
contraceptives NNS i
( ( N
OCs NNP N
) ) N
may MD N
reduce VB N
the DT N
active JJ o
androgen NN o
level NN o
, , N
hormonal JJ N
therapy NN N
with IN N
OCs NNP N
has VBZ N
been VBN N
used VBN N
successfully RB N
to TO N
treat VB N
patients NNS p
with IN p
acne NN p
, , N
although IN N
this DT N
treatment NN N
has VBZ N
previously RB N
not RB N
been VBN N
studied VBN N
in IN N
placebo-controlled JJ N
trials NNS N
. . N

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
a DT N
triphasic JJ i
, , i
combination NN i
OC NNP i
( ( i
ORTHO NNP i
TRI-CYCLEN NNP i
[ NNP i
Ortho-McNeil NNP i
Pharmaceutical NNP i
, , i
Raritan NNP i
, , i
N.J. NNP i
] NNP i
, , i
norgestimate/ethinyl RB i
estradiol NN i
) ) i
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
moderate JJ N
acne NN N
vulgaris NN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
fifty-seven RB p
healthy JJ p
female NN p
subjects NNS p
, , p
15 CD p
to TO p
49 CD p
years NNS p
of IN p
age NN p
with IN p
moderate JJ p
acne NNS p
vulgaris NN p
, , N
were VBD N
enrolled VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

Each DT N
month NN N
for IN N
6 CD N
months NNS N
, , N
subjects VBZ N
received VBN N
either RB N
3 CD N
consecutive JJ N
weeks NNS N
of IN N
the DT N
OC NNP i
( ( N
i.e. FW N
, , N
tablets NNS N
containing VBG N
a DT N
fixed VBN N
dose NN N
of IN N
ethinyl JJ i
estradiol NN i
[ VBD i
0.035 CD i
mg NN i
] NN i
and CC i
increasing VBG i
doses NNS i
of IN i
norgestimate JJ i
[ NNS N
0.180 CD N
mg NNS N
, , N
0.215 CD N
mg NN N
, , N
0.250 CD N
mg NN N
] NN N
) ) N
followed VBN N
by IN N
7 CD N
days NNS N
of IN N
inactive JJ i
drug NN i
or CC i
placebo NN i
( ( N
color-matched JJ N
tablets NNS N
) ) N
. . N

Efficacy NN o
was VBD N
assessed VBN N
by IN N
facial JJ o
acne JJ o
lesion NN o
counts NNS o
, , N
an DT N
investigator NN N
's POS N
global JJ o
assessment NN o
, , N
a DT N
subject NN o
's POS o
self-assessment NN o
, , N
and CC N
an DT N
analysis NN N
of IN N
within-cycle JJ o
variation NN o
( ( o
cycle NN o
6 CD o
) ) o
in IN o
lesion NN o
counts NNS o
. . o

RESULTS NNP N
Of IN N
the DT N
160 CD p
subjects NNS p
in IN N
whom WP N
efficacy NN N
could MD N
be VB N
evaluated VBN N
, , N
the DT N
OC NNP N
group NN N
showed VBD N
a DT N
statistically RB N
significantly RB N
greater JJR N
improvement NN o
than IN N
the DT N
placebo NN p
group NN p
for IN N
all DT N
primary JJ N
efficacy NN N
measures NNS N
. . N

The DT N
mean JJ o
decrease NN o
in IN o
inflammatory JJ o
lesion NN o
count NN o
from IN N
baseline NN N
to TO N
cycle NN N
6 CD N
was VBD N
11.8 CD N
( ( N
62.0 CD N
% NN N
) ) N
versus NN N
7.6 CD N
( ( N
38.6 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
, , N
and CC N
the DT N
mean JJ o
decrease NN o
in IN o
total JJ o
lesion NN o
count NN o
was VBD N
29.1 CD N
( ( N
53.1 CD N
% NN N
) ) N
versus NN N
14.1 CD N
( ( N
26.8 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
in IN N
the DT N
OC NNP N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
investigator NN o
's POS o
global JJ o
assessment NN o
, , N
93.7 CD N
% NN N
of IN N
the DT N
active JJ N
treatment NN N
group NN N
versus VBD N
65.4 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
were VBD N
rated VBN N
as IN N
improved VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Six CD N
of IN N
the DT N
seven CD N
secondary JJ o
efficacy NN o
measures NNS o
( ( o
total JJ o
comedones NNS o
, , o
open JJ o
comedones NNS o
, , o
closed VBD o
comedones NNS o
, , o
papules NNS o
, , o
pustules NNS o
, , o
and CC o
the DT o
subject NN o
's POS o
self-assessment NN o
of IN o
study NN o
treatment NN o
) ) o
were VBD N
also RB N
significantly RB N
more RBR N
favorable JJ N
in IN N
the DT N
OC NNP N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSION NNP N
An DT N
OC NNP N
containing VBG N
0.035 CD N
mg NN N
of IN N
ethinyl JJ i
estradiol NN i
combined VBN N
with IN N
the DT N
triphasic JJ N
regimen NNS N
of IN N
norgestimate NN N
is VBZ N
a DT N
safe JJ o
and CC o
effective JJ o
treatment NN o
of IN o
moderate JJ o
acne NNS o
vulgaris VBP o
in IN p
women NNS p
with IN p
no DT p
known VBN p
contraindication NN p
to TO p
OC NNP p
therapy NN p
. . p

-DOCSTART- -12042231- O O

Effectiveness NN N
of IN N
a DT N
brief JJ N
cognitive-behavioural JJ i
therapy NN i
intervention NN i
in IN N
the DT N
treatment NN N
of IN N
schizophrenia NN o
. . o

BACKGROUND NNP N
Little NNP N
evidence NN N
exists VBZ N
to TO N
indicate VB N
whether IN N
community NN N
psychiatric JJ N
nurses NNS N
can MD N
achieve VB N
the DT N
results NNS N
reported VBN N
by IN N
expert JJ N
cognitive-behavioural JJ i
therapists NNS i
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

AIMS NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
a DT N
brief JJ N
cognitive-behavioural JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
intervention NN i
in IN N
a DT N
representative JJ p
community NN p
sample NN p
of IN p
patients NNS p
with IN p
schizophrenia NN p
in IN p
secondary JJ p
care NN p
settings NNS p
. . p

METHOD NNP N
A NNP N
pragmatic JJ N
randomised VBD N
trial NN N
was VBD N
performed VBN N
involving VBG N
422 CD p
patients NNS p
and CC p
carers NNS p
to TO p
compare VB p
a DT p
brief JJ p
CBT NNP i
intervention NN i
against IN p
treatment NN p
as IN p
usual JJ p
. . p

RESULTS JJ N
Patients NNPS N
who WP N
received VBD N
CBT NNP i
( ( i
n=257 NN i
) ) i
improved VBN N
in IN N
overall JJ o
symptomatology NN o
( ( N
P=0.015 NNP N
; : N
number NN o
needed VBN o
to TO o
treat VB o
[ JJ N
NNT NNP N
] NNP N
=13 NNP N
) ) N
, , N
insight JJ o
( ( N
P NNP N
< NNP N
0.001 CD N
; : N
NNT=10 NNP N
) ) N
and CC N
depression NN o
( ( N
P=0.003 NNP N
; : N
NNT=9 NNP N
) ) N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
n=165 RB N
) ) N
. . N

Insight NNP o
was VBD N
clinically RB N
significantly RB N
improved VBN N
( ( N
risk NN N
ratio=1.15 NN N
, , N
95 CD N
% NN N
CI NNP N
1.01-1.31 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
increase NN N
in IN N
suicidal JJ o
ideation NN o
. . o

CONCLUSIONS NNP N
Community NNP N
psychiatric JJ N
nurses NNS N
can MD N
safely RB o
and CC o
effectively RB o
deliver VB N
a DT N
brief JJ N
CBT NNP i
intervention NN i
to TO N
patients NNS N
with IN N
schizophrenia NN N
and CC N
their PRP$ N
carers NNS N
. . N

-DOCSTART- -8437833- O O

Diode NNP i
laser NN i
photocoagulation NN i
for IN N
threshold JJ p
retinopathy NN p
of IN p
prematurity NN p
. . p

A DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Although IN N
peripheral JJ i
cryotherapy NN i
decreases VBZ N
the DT N
incidence NN N
of IN N
unfavorable JJ N
anatomic JJ N
outcomes NNS N
in IN N
threshold JJ N
retinopathy NN p
of IN p
prematurity NN p
( ( p
ROP NNP p
) ) p
, , N
apnea RB N
, , N
bradycardia NN N
, , N
and CC N
lid JJ N
edema NN N
can MD N
occur VB N
. . N

Argon NNP i
laser NN i
indirect JJ i
ophthalmoscope NN i
photocoagulation NN i
has VBZ N
been VBN N
used VBN N
as IN N
an DT N
alternative NN N
to TO N
cryotherapy VB i
, , N
with IN N
fewer JJR N
adverse JJ o
effects NNS o
. . o

Retinal JJ N
lesions NNS N
placed VBN N
with IN N
diode NN i
lasers NNS i
are VBP N
deeper JJR N
than IN N
similar JJ N
argon NN i
laser NN i
lesions NNS N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
difference NN N
could MD N
influence VB N
the DT N
response NN o
to TO N
ablative JJ i
therapy NN i
. . i

METHODS JJ N
Patients NNPS p
were VBD N
enrolled VBN N
under IN N
a DT N
prospective JJ N
, , N
randomized VBN N
protocol NN N
. . N

One CD N
eye NN N
of IN N
each DT N
patient NN N
with IN N
symmetric JJ N
, , N
threshold JJ N
ROP NNP N
was VBD N
treated VBN N
with IN N
an DT N
814/815 CD N
nm JJ N
diode NN i
laser NN i
, , N
while IN N
the DT N
other JJ N
eye NN N
was VBD N
treated VBN N
with IN N
cryotherapy NN i
. . i

Patients NNS N
with IN N
asymmetric JJ N
diseases NNS N
also RB N
were VBD N
randomized VBN N
for IN N
treatment NN N
in IN N
the DT N
threshold NN N
eye NN N
. . N

RESULTS NNP N
Nineteen JJ p
infants NNS p
( ( p
33 CD p
eyes NNS p
) ) p
were VBD p
treated VBN p
, , p
ranging VBG p
from IN p
485 CD p
to TO p
863 CD p
g NNS p
birth JJ p
weight NN p
( ( p
23 CD p
to TO p
27 CD p
weeks NNS p
gestational JJ p
age NN p
) ) p
; : p
18 CD p
patients NNS p
( ( p
32 CD p
eyes NNS p
) ) p
were VBD N
followed VBN N
for IN N
3 CD N
months NNS N
or CC N
longer JJR N
. . N

Four CD p
patients NNS p
( ( p
8 CD p
eyes NNS p
) ) p
had VBD p
bilateral JJ p
zone CD p
1 CD p
disease NN p
. . p

Postconceptional JJ p
age NN p
was VBD p
36 CD p
to TO p
45 CD p
weeks NNS p
at IN p
the DT p
time NN p
of IN p
treatment NN p
. . p

The DT N
diode NN i
laser NN i
treatment NN N
was VBD N
better RBR N
tolerated VBN o
than IN N
cryotherapy NN i
, , N
and CC N
the DT N
treatment NN N
apparatus NN N
was VBD N
more RBR N
easily RB N
transported VBN N
. . N

Apneic NNP o
episodes VBZ o
requiring VBG o
intubation NN o
resulted VBD N
from IN N
two CD N
cryotherapy NN i
sessions NNS N
but CC N
no DT N
diode NN i
laser NN i
sessions NNS N
. . N

Five CD N
cryotherapy-treated JJ i
eyes NNS N
required VBN N
retreatment NN o
because IN N
of IN N
persistent JJ N
disease NN N
with IN N
adjacent JJ N
skip NN N
areas NNS N
. . N

In IN N
the DT N
group NN N
followed VBD N
for IN N
3 CD N
to TO N
15 CD N
months NNS N
, , N
1 CD N
cryotherapy-treated JJ i
eye NN N
and CC N
1 CD N
diode NN N
laser-treated JJ i
eye NN N
progressed VBD o
to TO o
stage VB o
5 CD o
retinal JJ o
detachment NN o
. . o

CONCLUSION NNP N
Compared NNP N
with IN N
cryotherapy NN i
, , N
the DT N
diode NN i
laser NN i
was VBD N
more RBR N
convenient JJ N
, , N
technically RB N
easier JJR N
to TO N
administer VB N
, , N
and CC N
better RB N
tolerated VBN N
by IN N
the DT N
patient NN N
. . N

Although IN N
the DT N
number NN N
of IN N
patients NNS N
was VBD N
too RB N
small JJ N
for IN N
meaningful JJ N
statistical JJ N
analysis NN N
of IN N
outcome NN N
, , N
diode VB i
laser RBR i
peripheral JJ i
retinal JJ i
ablation NN i
appeared VBD N
to TO N
be VB N
as RB N
effective JJ N
as IN N
cryotherapy NN i
for IN N
the DT N
treatment NN N
of IN N
threshold JJ N
ROP NNP N
. . N

-DOCSTART- -3156347- O O

[ JJ N
Trial NNP N
of IN N
a DT N
calcium NN i
antagonist NN i
in IN N
dysmenorrhea NN o
] NN o
. . N

-DOCSTART- -11343038- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
single-dose JJ N
intravenous JJ N
secretin NN i
as IN N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
a DT N
single JJ N
injection NN N
of IN N
intravenous JJ N
secretin NN i
results NNS N
in IN N
measurable JJ N
improvements NNS N
in IN N
socialization NN N
and/or NN N
communication NN N
skills NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

STUDY NNP N
DESIGN NNP N
Sixty NNP p
subjects VBZ p
with IN p
autism NN p
were VBD N
randomly RB N
selected VBN N
and CC N
assigned VBN N
to TO N
either DT N
treatment NN N
or CC N
placebo NN i
group NN N
. . N

Subjects VBZ N
in IN N
the DT N
treatment NN N
group NN N
received VBD N
2.0 CD i
clinical JJ i
units NNS i
of IN i
secretin NN i
per IN i
kilogram NN i
of IN i
body NN i
weight NN i
as IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
. . N

Subjects NNS N
in IN N
the DT N
placebo NN i
group NN N
received VBD N
normal JJ i
saline JJ i
solution NN i
. . i

Neurodevelopmental NNP N
and CC N
behavioral JJ N
assessments NNS N
were VBD N
performed VBN N
for IN N
all DT N
subjects NNS N
before IN N
injection NN N
and CC N
at IN N
3 CD N
and CC N
6 CD N
weeks NNS N
after IN N
injection NN N
. . N

RESULTS NNP N
Assessment NNP o
of IN o
language NN o
skills NNS o
and CC o
parents NNS o
' POS o
behavioral JJ o
assessments NNS o
revealed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
and CC N
placebo NN N
groups NNS N
. . N

Raters NNS o
' POS o
assessments NNS o
of IN o
severity NN o
of IN o
autistic JJ o
symptoms NNS o
did VBD N
not RB N
differ VB N
for IN N
the DT N
2 CD N
groups NNS N
at IN N
6 CD N
weeks NNS N
after IN N
injection NN N
. . N

A DT N
marginally RB N
statistically RB N
significant JJ N
improvement NN N
in IN N
autistic JJ N
behaviors NNS N
was VBD N
seen VBN N
in IN N
the DT N
treatment NN N
group NN N
at IN N
3 CD N
weeks NNS N
after IN N
injection NN N
( ( N
P NNP N
=.051 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
single JJ N
dose NN N
of IN N
intravenous JJ N
secretin NN i
does VBZ N
not RB N
appear VB N
to TO N
have VB N
significant JJ N
effects NNS N
on IN N
either DT N
parents NNS N
' POS N
perception NN N
of IN N
autistic JJ N
behaviors NNS N
or CC N
language NN N
skills NNS N
at IN N
6 CD N
weeks NNS N
after IN N
injection NN N
. . N

Transient NNP N
, , N
marginally RB N
significant JJ N
improvements NNS N
in IN N
autistic JJ N
behaviors NNS N
may MD N
occur VB N
in IN N
some DT N
children NNS N
. . N

-DOCSTART- -15477567- O O

Effects NNS p
of IN p
brain-penetrating JJ i
ACE NNP i
inhibitors NNS i
on IN p
Alzheimer NNP o
disease NN o
progression NN o
. . o

-DOCSTART- -12021946- O O

Treatment NN N
of IN N
acute JJ N
ischaemic JJ N
stroke NN N
with IN N
the DT N
low-affinity NN N
, , N
use-dependent JJ N
NMDA NNP i
antagonist NN i
AR-R15896AR NNP i
. . i

A NNP N
safety NN o
and CC o
tolerability NN o
study NN N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
A NNP N
low-affinity NN N
, , N
use-dependent JJ N
N-Methyl-D-Aspartate NNP i
( ( i
NMDA NNP i
) ) i
antagonist NN i
AR-R15896AR NNP i
has VBZ N
neuroprotective JJ N
properties NNS N
in IN N
animal JJ p
models NNS p
of IN p
ischaemic JJ p
stroke NN p
. . p

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
a DT N
new JJ N
and CC N
higher JJR N
dosage NN N
regimen NNS N
that WDT N
would MD N
enable VB N
acute JJ p
stroke NN p
patients NNS p
to TO N
achieve VB N
and CC N
maintain VB N
neuroprotective JJ N
plasma NN N
concentrations NNS N
. . N

METHODS NNP N
A DT N
randomised JJ N
, , N
multi-centre JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
group NN N
study NN N
was VBD N
carried VBN N
out RP N
at IN N
19 CD p
centres NNS p
in IN p
France NNP p
, , p
Germany NNP p
and CC p
the DT p
Netherlands NNP p
in IN p
patients NNS p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
acute JJ p
ischaemic JJ p
stroke NN p
, , p
and CC p
onset NN p
of IN p
symptoms NNS p
within IN p
12 CD p
hours NNS p
before IN p
start NN p
of IN p
study JJ p
drug NN p
administration NN p
. . p

Two CD i
loading VBG i
doses NNS i
of IN i
3.5 CD i
mg/kg NNS i
of IN i
AR-R15896AR NNP i
over IN N
60 CD N
minutes NNS N
, , N
followed VBN N
by IN N
a DT N
2.5 CD N
mg/kg NN N
infusion NN N
over IN N
the DT N
next JJ N
120 CD N
minutes NNS N
were VBD N
given VBN N
. . N

Eight NNP N
hours NNS N
after IN N
the DT N
start NN N
of IN N
the DT N
loading VBG N
dose JJ N
infusion NN N
, , N
the DT N
first JJ N
maintenance NN N
dose NN N
( ( N
120 CD N
mg NN N
) ) N
was VBD N
administered VBN N
over IN N
60 CD N
minutes NNS N
. . N

Eight NNP N
further JJ N
maintenance NN N
infusions NNS N
were VBD N
administered VBN N
at IN N
intervals NNS N
of IN N
8 CD N
hours NNS N
over IN N
a DT N
total JJ N
treatment NN N
period NN N
of IN N
3 CD N
days NNS N
. . N

Main JJ N
variables NNS N
were VBD N
safety NN o
, , o
tolerability NN o
and CC o
pharmacokinetics NNS o
. . o

Follow-up JJ N
assessments NNS N
also RB N
included VBD N
the DT N
Barthel NNP o
Index NNP o
( ( o
BI NNP o
) ) o
and CC N
the DT N
NIH NNP o
Stroke NNP o
Scale NNP o
( ( o
NIHSS NNP o
) ) o
at IN N
4-7 JJ N
days NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
last JJ N
infusion NN N
and CC N
at IN N
30 CD N
days NNS N
after IN N
the DT N
onset NN N
of IN N
stroke NN N
. . N

RESULTS CC N
103 CD p
patients NNS p
with IN p
acute JJ p
ischaemic JJ p
stroke NN p
were VBD p
randomised VBN p
to TO N
either DT N
treatment NN N
with IN N
AR-R15896AR NNP i
( ( N
70 CD N
patients NNS N
) ) N
or CC N
placebo NN i
( ( N
33 CD N
patients NNS N
) ) N
. . N

Mortality NNP o
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
the DT N
AR-R15896AR NNP i
group NN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
10 CD N
% NN N
vs. FW N
6 CD N
% NN N
) ) N
. . N

Serious JJ o
adverse JJ o
events NNS o
during IN N
treatment NN N
due JJ N
to TO N
psychiatric JJ N
conditions NNS N
were VBD N
associated VBN N
with IN N
AR-R15896AR NNP i
( ( N
3 CD N
vs. FW N
0 CD N
) ) N
. . N

Other JJ N
side NN N
effects NNS N
were VBD N
more JJR N
common JJ N
in IN N
the DT N
group NN N
treated VBD N
with IN N
AR-R15896AR NNP i
: : i
vomiting NN o
( ( N
29 CD N
% NN N
vs. FW N
9 CD N
% NN N
) ) N
, , N
nausea NN o
( ( N
23 CD N
% NN N
vs. FW N
12 CD N
% NN N
) ) N
, , N
fever RB o
( ( N
17 CD N
% NN N
vs. FW N
12 CD N
% NN N
) ) N
, , N
agitation NN o
( ( N
7 CD N
% NN N
vs. FW N
3 CD N
% NN N
) ) N
, , N
dizziness NN o
( ( N
7 CD N
% NN N
vs. FW N
0 CD N
% NN N
) ) N
, , N
and CC N
hallucinations NNS o
( ( N
6 CD N
% NN N
vs. FW N
0 CD N
% NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
with IN N
respect NN N
to TO N
the DT N
proportions NNS N
of IN N
patients NNS N
with IN N
favourable JJ N
outcome NN N
) ) N
was VBD N
detected VBN N
in IN N
either CC N
the DT N
analysis NN N
of IN N
the DT N
BI NNP N
or CC N
the DT N
NIHSS NNP N
. . N

Pharmacokinetic NNP N
data NN N
showed VBD N
that IN N
plasma JJ o
concentrations NNS o
of IN o
AR-R15896AR NNP o
were VBD N
in IN N
the DT N
expected JJ N
neuroprotective JJ N
range NN N
. . N

CONCLUSION NNP N
In IN N
most JJS N
of IN N
the DT N
patients NNS N
with IN N
acute JJ N
stroke NN N
receiving VBG N
AR-R15896AR NNP i
the DT N
intended JJ N
high JJ o
plasma NN o
levels NNS o
were VBD N
reached VBN N
within IN N
a DT N
short JJ N
time NN N
period NN N
. . N

However RB N
, , N
active JJ N
treatment NN N
produced VBD N
more JJR N
side NN o
effects NNS o
than IN N
placebo NN i
, , N
thus RB N
indicating VBG N
safety NN N
concerns NNS N
and CC N
tolerability NN N
issues NNS N
for IN N
use NN N
in IN N
high JJ N
doses NNS N
in IN N
an DT N
acute JJ N
stroke NN N
population NN N
. . N

-DOCSTART- -15673894- O O

Spinal JJ N
2-chloroprocaine JJ i
: : i
the DT N
effect NN N
of IN N
added JJ N
clonidine NN i
. . i

Preservative-free JJ N
2-chloroprocaine JJ i
( ( i
2-CP JJ i
) ) i
is VBZ N
being VBG N
investigated VBN N
for IN N
short-acting JJ N
spinal JJ N
anesthesia NN N
. . N

Clonidine NNP i
improves VBZ N
the DT N
quality NN N
of IN N
spinal JJ o
bupivacaine NN o
and CC N
ropivacaine NN o
, , N
but CC N
in IN N
traditional JJ N
doses NNS N
( ( N
1-2 JJ N
microg/kg NN N
) ) N
it PRP N
produces VBZ N
systemic JJ N
side NN N
effects NNS N
. . N

It PRP N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
combination NN N
with IN N
2-CP JJ i
. . i

In IN N
this DT N
double-blind NN N
, , N
randomized VBN p
crossover NN p
study NN p
, , N
we PRP N
compared VBN N
spinal JJ i
2-CP JJ i
( ( p
30 CD p
mg NN p
) ) p
with IN i
and CC i
without IN i
clonidine NN i
( ( p
15 CD p
microg NN p
) ) p
in IN p
eight CD p
volunteers NNS p
. . p

Pinprick NNP o
anesthesia NN o
, , o
motor NN o
strength NN o
, , o
tolerance NN o
to TO o
electrical JJ o
stimulation NN o
and CC o
thigh JJ o
tourniquet NN o
, , o
and CC o
time NN o
to TO o
ambulation NN o
were VBD N
assessed VBN N
. . N

Peak NNP o
block NN o
height NN o
was VBD N
similar JJ N
between IN N
2-CP JJ N
( ( N
T8 NNP N
[ NNP N
range NN N
, , N
T6 NNP N
to TO N
L2 NNP N
] NNP N
) ) N
and CC N
2-CP JJ N
with IN N
clonidine NN i
( ( N
T8 NNP N
[ NNP N
range NN N
, , N
T4 NNP N
to TO N
T11 NNP N
] NNP N
) ) N
( ( N
P NNP N
= NNP N
0.57 CD N
) ) N
. . N

Sensory JJ o
anesthesia NN o
was VBD N
prolonged VBN N
with IN N
clonidine NN i
at IN N
L1 NNP N
( ( N
51 CD N
+/- JJ N
23 CD N
min NN N
versus NN N
76 CD N
+/- JJ N
11 CD N
min NN N
; : N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
as IN N
was VBD N
complete JJ o
block NN o
regression NN o
( ( N
99 CD N
+/- JJ N
18 CD N
min NN N
versus NN N
131 CD N
+/- JJ N
15 CD N
min NN N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Lower JJR o
extremity NN o
motor NN o
blockade NN o
was VBD N
increased VBN N
with IN N
clonidine NN N
( ( N
return NN N
to TO N
baseline VB N
Bromage NNP N
score NN N
: : N
65 CD N
+/- JJ N
13 CD N
min NN N
versus NN N
79 CD N
+/- JJ N
19 CD N
min NN N
, , N
P NNP N
= NNP N
0.004 CD N
; : N
return NN N
to TO N
90 CD N
% NN N
gastrocnemius JJ o
strength NN o
: : o
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

Clonidine NNP i
increased VBD N
tourniquet JJ o
tolerance NN o
from IN N
33 CD N
to TO N
45 CD N
min NN N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
and CC N
increased JJ N
time NN o
to TO o
ambulation NN o
, , o
spontaneous JJ o
voiding NN o
, , o
and CC o
discharge NN o
( ( N
99 CD N
+/- JJ N
18 CD N
min NN N
versus NN N
131 CD N
+/- JJ N
15 CD N
min NN N
for IN N
all DT N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
hemodynamic JJ o
measurements NNS o
, , N
and CC N
no DT N
subject NN N
reported VBD N
transient JJ o
neurologic NN o
symptoms NNS o
. . o

We PRP N
conclude VBP N
that IN N
small-dose JJ N
clonidine NN i
increases VBZ N
the DT N
duration NN N
and CC N
improves VBZ N
the DT N
quality NN o
of IN o
2-CP JJ o
spinal JJ o
anesthesia NN o
without IN N
systemic JJ o
side NN o
effects NNS o
. . o

-DOCSTART- -19397502- O O

Pulse NNP N
oximeter NN N
perfusion NN N
index NN N
as IN N
an DT N
early JJ N
indicator NN N
of IN N
sympathectomy NN N
after IN N
epidural JJ N
anesthesia NN N
. . N

BACKGROUND IN N
The DT N
pulse JJ N
oximeter NN N
perfusion NN N
index NN N
( ( N
PI NNP N
) ) N
has VBZ N
been VBN N
used VBN N
to TO N
indicate VB N
sympathectomy-induced JJ N
vasodilatation NN N
. . N

We PRP N
hypothesized VBD N
that IN N
pulse JJ N
oximeter NN N
PI NNP N
provides VBZ N
an DT N
earlier JJR N
and CC N
clearer JJR N
indication NN N
of IN N
sympathectomy NN N
following VBG N
epidural JJ N
anesthesia NNS N
than IN N
skin JJ N
temperature NN N
and CC N
arterial JJ N
pressure NN N
. . N

METHODS NNP N
Forty NNP p
patients NNS p
received VBD i
lumbar JJ i
epidural JJ i
catheters NNS i
. . i

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB i
either RB i
10 CD i
ml VBD i
0.5 CD i
% NN i
bupivacaine NN i
or CC i
10 CD i
ml JJ i
0.25 CD i
% NN i
bupivacaine NN i
. . i

PI NNP o
in IN o
the DT o
toe NN o
, , o
mean JJ o
arterial JJ o
pressure NN o
( ( o
MAP NNP o
) ) o
and CC o
toe JJ o
temperature NN o
were VBD i
all DT i
assessed VBN i
at IN i
baseline NN i
and CC i
at IN i
5 CD i
, , i
10 CD i
and CC i
20 CD i
min NN i
following VBG i
epidural JJ i
anesthesia NN i
. . i

The DT N
effect NN o
of IN N
epidural JJ i
anesthesia NN i
over IN N
time NN N
was VBD N
assessed VBN N
by IN N
repeated JJ N
measures NNS o
analysis NN o
of IN o
variance NN o
. . o

Additionally RB N
, , N
we PRP N
defined VBD N
clinically RB o
evident JJ o
sympathectomy NN o
criteria NNS o
( ( o
a DT o
100 CD o
% NN o
increase NN o
in IN o
the DT o
PI NNP o
, , o
a DT o
15 CD o
% NN o
decrease NN o
in IN o
MAP NNP o
and CC o
a DT o
1 CD o
degrees NNS o
C NNP o
increase NN o
in IN o
toe JJ o
temperature NN o
) ) o
. . o

The DT N
numbers NNS N
of IN N
patients NNS N
demonstrating VBG N
these DT N
changes NNS o
for IN N
each DT N
test NN N
were VBD N
compared VBN N
using VBG N
the DT N
McNemar NNP o
test NN o
for IN N
each DT N
time NN N
point NN N
. . N

RESULTS NNP N
Twenty-nine JJ p
subjects NNS p
had VBD N
photoplethysmography NN o
signals NNS o
that WDT N
met VBD N
a DT N
priori JJ N
signal NN N
quality NN N
criteria NNS N
for IN N
analysis NN N
. . N

By IN N
20 CD N
min NNS N
, , N
PI NNP o
increased VBN N
by IN N
326 CD N
% NN N
, , N
compared VBN N
with IN N
a DT N
10 CD N
% NN N
decrease NN N
and CC N
a DT N
3 CD N
% NN N
increase NN N
in IN N
MAP NNP o
and CC o
toe JJ o
temperature NN o
, , N
respectively RB N
. . N

For IN N
PI NNP N
15/29 CD N
, , N
26/29 CD N
and CC N
29/29 CD N
of IN N
the DT N
subjects NNS N
met VBD N
the DT N
sympathectomy NN o
criteria NNS o
at IN N
5 CD N
, , N
10 CD N
and CC N
20 CD N
min NN N
, , N
respectively RB N
, , N
compared VBN N
with IN N
4/29 CD N
, , N
6/29 CD N
and CC N
18/29 CD N
for IN N
MAP NNP o
changes NNS N
and CC N
3/29 CD N
, , N
8/29 CD N
and CC N
14/29 CD N
for IN N
toe NN N
temperature NN o
changes NNS o
. . o

CONCLUSIONS NNP N
PI NNP N
was VBD N
an DT N
earlier JJR N
, , N
clearer JJR N
and CC N
more RBR N
sensitive JJ N
indicator NN N
of IN N
the DT N
development NN N
of IN N
epidural-induced JJ N
sympathectomy NN N
than IN N
either DT N
skin JJ o
temperature NN o
or CC N
MAP NNP o
. . o

-DOCSTART- -18752063- O O

Positive JJ N
effects NNS N
of IN N
methylphenidate NN i
on IN N
social JJ o
communication NN o
and CC o
self-regulation NN o
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
and CC p
hyperactivity NN p
. . p

This DT N
report NN N
examined VBD N
the DT N
effect NN N
of IN N
methylphenidate NN i
on IN N
social JJ o
communication NN o
and CC o
self-regulation NN o
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
and CC p
hyperactivity NN p
in IN N
a DT N
secondary JJ N
analysis NN N
of IN N
RUPP NNP p
Autism NNP p
Network NNP p
data NNS p
. . p

Participants NNS p
were VBD p
33 CD p
children NNS p
( ( p
29 CD p
boys NNS p
) ) p
between IN p
the DT p
ages NNS p
of IN p
5 CD p
and CC p
13 CD p
years NNS p
who WP N
participated VBD N
in IN N
a DT N
four-week JJ N
crossover NN N
trial NN N
of IN N
placebo NN i
and CC N
increasing VBG i
doses NNS i
of IN i
methylphenidate NN i
given VBN N
in IN N
random JJ N
order NN N
each DT N
for IN N
one CD N
week NN N
. . N

Observational JJ N
measures NNS N
of IN N
certain JJ N
aspects NNS N
of IN N
children NNS N
's POS N
social JJ o
communication NN o
, , o
self-regulation NN o
, , o
and CC o
affective JJ o
behavior NN o
were VBD N
obtained VBN N
each DT N
week NN N
. . N

A DT N
significant JJ N
positive JJ N
effect NN N
of IN N
methylphenidate NN N
was VBD N
seen VBN N
on IN N
children NNS N
's POS N
use NN N
of IN N
joint JJ o
attention NN o
initiations NNS o
, , o
response NN o
to TO o
bids NNS o
for IN o
joint JJ o
attention NN o
, , o
self-regulation NN o
, , o
and CC o
regulated VBD o
affective JJ o
state NN o
. . o

The DT N
results NNS N
go VBP N
beyond IN N
the DT N
recent JJ N
literature NN N
and CC N
suggest VBP N
that IN N
methylphenidate NN i
may MD N
have VB N
positive JJ N
effects NNS N
on IN N
social JJ o
behaviors NNS o
in IN N
children NNS p
with IN p
PDD NNP p
and CC p
hyperactivity NN p
. . p

-DOCSTART- -10685817- O O

Treatment NN N
of IN N
whiplash NN N
associated VBN N
neck RB N
pain VBP N
[ RB N
corrected VBN N
] NN N
with IN N
botulinum JJ i
toxin-A NN i
: : i
a DT N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
Up NNP N
to TO N
87 CD N
% NN N
of IN N
patients NNS N
with IN N
whiplash NN N
associated VBN N
disorder NN N
( ( N
WAD NNP N
) ) N
have VBP N
some DT N
degree NN N
of IN N
muscle NN N
spasm NN N
that WDT N
is VBZ N
contributory JJ N
to TO N
both DT N
pain NN N
and CC N
dysfunction NN N
. . N

Botulinum NNP i
toxin NN i
A NNP i
( ( i
BTX-A NNP i
) ) i
produces VBZ N
prolonged JJ N
muscle NN N
relaxation NN N
that WDT N
is VBZ N
dose-dependent JJ N
and CC N
can MD N
be VB N
easily RB N
targeted VBN N
to TO N
affected JJ N
muscles NNS N
. . N

BTX-A NNP N
therapy NN N
may MD N
be VB N
an DT N
effective JJ N
form NN N
of IN N
therapy NN N
offering VBG N
an DT N
alternative NN N
or CC N
adjunct NN N
to TO N
conventional JJ N
modalities NNS N
. . N

We PRP N
investigated VBD N
BTX-A NNP i
as IN N
therapy NN N
in IN N
patients NNS p
with IN p
WAD NNP p
. . p

METHODS NNP N
This DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
study NN N
compares VBZ N
outcome JJ N
measures NNS N
in IN N
26 CD p
patients NNS p
with IN p
chronic JJ p
neck NN p
pain NN p
( ( p
WAD-II NNP p
chronic NN p
) ) p
subsequent NN p
to TO p
a DT p
motor NN p
vehicle NN p
accident NN p
. . p

One-half NN N
of IN N
the DT N
patients NNS N
received VBD N
100 CD i
units NNS i
BTX-A NNP i
, , i
diluted VBD i
in IN i
1 CD i
ml NNS i
saline NN i
, , i
while IN i
the DT i
other JJ i
half NN i
received VBD i
just RB i
saline NN i
( ( N
1 CD N
ml NN N
) ) N
. . N

Five CD N
trigger NN N
points NNS N
received VBD N
0.2 CD N
ml NNS N
each DT N
of IN N
injectant JJ N
via IN N
a DT N
30 CD N
gauge NN N
needle NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
total JJ o
subjective JJ o
neck NN o
, , o
shoulder NN o
, , o
and CC o
head NN o
pain NN o
based VBN o
on IN o
visual JJ o
analog NN o
scales NNS o
; : o
objective JJ o
total JJ o
range NN o
of IN o
neck NN o
motion NN o
( ( o
ROM NNP o
) ) o
, , o
and CC o
the DT o
Vernon-Mior NNP o
subjective JJ o
function NN o
index NN o
. . o

Followup CD N
assessments NNS N
were VBD N
carried VBN N
out RP N
at IN N
2 CD N
and CC N
4 CD N
weeks NNS N
post-treatment JJ N
. . N

RESULTS NNP N
Fourteen NNP p
subjects VBZ p
receiving VBG p
BTX-A NNP i
and CC p
12 CD p
receiving NN p
saline NN p
completed VBD p
the DT p
study NN p
. . p

The DT N
treatment NN N
group NN N
showed VBD N
a DT N
trend NN o
toward IN o
improvement NN o
in IN o
ROM NNP o
and CC o
reduction NN o
in IN o
pain NN o
at IN N
2 CD N
weeks NNS N
post-injection NN N
. . N

At IN N
4 CD N
weeks NNS N
post-injection NN N
the DT N
treatment NN N
group NN N
was VBD N
significantly RB N
improved VBN N
from IN N
preinjection NN N
levels NNS N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

The DT N
placebo NN N
group NN N
showed VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
at IN N
any DT N
post-treatment JJ N
time NN N
. . N

The DT N
Vernon-Mior JJ o
scale NN o
revealed VBD N
a DT N
trend NN N
to TO N
improvement NN o
for IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
BTX-A NNP i
treatment NN N
of IN N
subjects NNS N
with IN N
chronic JJ N
WAD NNP N
II NNP N
neck NN N
pain NN N
resulted VBD N
in IN N
a DT N
significant JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
improvement NN N
in IN N
ROM NNP o
and CC N
subjective JJ o
pain NN o
compared VBN N
to TO N
a DT N
placebo NN N
group NN N
, , N
but CC N
only RB N
a DT N
trend NN N
to TO N
improvement NN N
in IN N
subjective JJ o
functioning NN o
. . o

-DOCSTART- -16870004- O O

Enhanced NNP o
bioavailability NN o
of IN o
zeaxanthin NN o
in IN N
a DT N
milk-based JJ N
formulation NN N
of IN N
wolfberry NN N
( ( N
Gou NNP N
Qi NNP N
Zi NNP N
; : N
Fructus NNP N
barbarum IN N
L. NNP N
) ) N
. . N

The DT N
carotenoid NN N
zeaxanthin NN i
is VBZ N
concentrated VBN N
within IN N
the DT N
macula NN N
. . N

Increased VBD N
macular JJ N
zeaxanthin NN i
is VBZ N
suggested VBN N
to TO N
lower VB N
the DT N
risk NN o
of IN o
age-related JJ o
macular JJ o
degeneration NN o
. . o

The DT N
small JJ N
red JJ N
berry NN N
, , N
wolfberry NN N
( ( N
Fructus NNP N
barbarum VBZ N
L. NNP N
; : N
Gou NNP N
Qi NNP N
Zi NNP N
and CC N
Kei NNP N
Tze NNP N
) ) N
, , N
is VBZ N
one CD N
of IN N
the DT N
richest JJS N
natural JJ N
sources NNS N
of IN N
zeaxanthin NN i
. . i

However RB N
, , N
carotenoid JJ o
bioavailability NN o
is VBZ N
low JJ N
, , N
and CC N
food-based JJ N
products NNS N
with IN N
enhanced JJ N
bioavailability NN o
are VBP N
of IN N
interest NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
zeaxanthin JJ o
bioavailability NN o
from IN N
three CD N
wolfberry NN N
formulations NNS N
. . N

Berries NNS N
were VBD N
homogenised VBN N
in IN N
hot JJ N
( ( N
80 CD N
degrees NNS N
C NNP N
) ) N
water NN N
, , N
warm NN N
( ( N
40 CD N
degrees NNS N
C NNP N
) ) N
skimmed VBD N
milk NN N
and CC N
hot JJ N
( ( N
80 CD N
degrees NNS N
C NNP N
) ) N
skimmed VBD N
milk NN N
, , N
with IN N
freeze JJ N
drying NN N
of IN N
each DT N
preparation NN N
into IN N
a DT N
powdered JJ N
form NN N
. . N

A DT N
zeaxanthin-standardised JJ i
dose NN i
( ( N
15 CD N
mg NN N
) ) N
of IN N
each DT N
was VBD N
consumed VBN N
, , N
in IN N
randomised JJ N
order NN N
, , N
together RB N
with IN N
a DT N
standardised VBN N
breakfast NN N
by IN N
twelve NN p
healthy JJ p
, , p
consenting VBG p
subjects NNS p
in IN N
a DT N
cross-over JJ N
trial NN N
, , N
with IN N
a DT N
3-5-week JJ N
washout NN N
period NN N
between IN N
treatments NNS N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
via IN N
a DT N
venous JJ N
cannula NN N
immediately RB N
before IN N
( ( N
fasting VBG N
) ) N
and CC N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
and CC N
10 CD N
h JJ N
post-ingestion NN N
. . N

Zeaxanthin NNP o
concentration NN o
in IN N
the DT N
triacylglycerol-rich JJ N
lipoprotein JJ N
fraction NN N
of IN N
plasma NN N
was VBD N
measured VBN N
by IN N
HPLC NNP o
. . o

Results NNP N
showed VBD N
that IN N
triacylglycerol-rich JJ o
lipoprotein NN o
zeaxanthin NN o
peaked VBD o
at IN N
6 CD N
h JJ N
post-ingestion NN N
for IN N
all DT N
formulations NNS N
. . N

Zeaxanthin NNP o
bioavailability NN o
from IN N
the DT N
hot JJ N
milk NN N
formulation NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
than IN N
from IN N
the DT N
others NNS N
. . N

Mean JJ o
area NN o
under IN o
the DT o
curve NN o
( ( N
n JJ N
12 CD N
) ) N
results NNS N
were VBD N
9.73 CD N
( ( N
sem VB N
2.45 CD N
) ) N
, , N
3.24 CD N
( ( N
sem VB N
0.72 CD N
) ) N
and CC N
3.14 CD N
( ( N
sem VB N
1.09 CD N
) ) N
nmol NN N
x NNP N
h/l NN N
for IN N
the DT N
hot JJ N
milk NN N
, , N
warm JJ N
milk NN N
and CC N
hot JJ N
water NN N
formulations NNS N
, , N
respectively RB N
. . N

Results NNS N
showed VBD N
clearly RB N
that DT N
homogenisation NN N
of IN N
wolfberry NN N
in IN N
hot JJ N
skimmed VBN N
milk NN N
results NNS N
in IN N
a DT N
formulation NN N
that WDT N
has VBZ N
a DT N
3-fold JJ o
enhanced JJ o
bioavailability NN o
of IN o
zeaxanthin NN o
compared VBN N
with IN N
both DT N
the DT N
'classical JJ N
' POS N
hot JJ N
water NN N
and CC N
warm NN N
skimmed VBD N
milk JJ N
treatment NN N
of IN N
the DT N
berries NNS N
. . N

-DOCSTART- -23870503- O O

Can MD N
a DT N
questionnaire NN i
predict NN N
vitamin NN N
D NNP o
status NN o
in IN N
postmenopausal NN p
women NNS p
? . N
OBJECTIVE NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
questionnaire NN i
can MD N
identify VB N
individuals NNS N
with IN N
vitamin NN o
D NNP o
insufficiency NN o
( ( p
VDI NNP p
) ) p
. . p

DESIGN NNP N
Women NNP N
completed VBD N
the DT N
Vitamin NNP i
D NNP i
& CC i
Sun NNP i
( ( i
VIDSUN NNP i
) ) i
questionnaire NN i
and CC N
we PRP N
measured VBD i
their PRP$ i
serum JJ o
25-hydrocyvitamin JJ o
D NNP o
( ( o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
) ) o
levels NNS o
. . o

We PRP N
assessed VBD N
the DT N
sensitivity NN o
and CC o
specificity NN o
of IN N
the DT N
questionnaire NN N
to TO N
identify VB o
VDI NNP o
( ( o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
level NN o
< VBD N
50 CD N
nmol/l NN N
) ) N
. . N

SETTING NNP N
Clinical JJ N
Research NNP N
Unit NNP N
, , N
University NNP N
of IN N
Wisconsin-Madison NNP N
. . N

SUBJECTS NNP N
Postmenopausal NNP p
women NNS p
. . p

RESULTS NNP N
We PRP N
recruited VBD N
609 CD p
postmenopausal JJ p
women NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
61 CD p
( ( p
sd JJ p
6 CD p
years NNS p
) ) p
, , p
of IN p
whom WP p
113 CD p
( ( p
19 CD p
% NN p
) ) p
had VBD p
VDI NNP p
. . p

Women NNP N
with IN N
VDI NNP o
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
black JJ o
( ( N
17 CD N
% NN N
v. JJ N
2 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
heavier JJR N
( ( o
BMI NNP o
33.0 CD N
( ( N
sd VB N
7 CD N
) ) N
kg/m2 NN N
v. $ N
29.0 CD N
( ( N
sd VB N
7 CD N
) ) N
kg/m2 NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
less RBR N
likely JJ o
to TO o
tan VB o
in IN o
the DT o
past JJ o
year NN o
( ( N
49 CD N
% NN N
v. JJ N
72 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
use VBP N
sunscreen JJ o
( ( N
57 CD N
% NN N
v. JJ N
72 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
or CC N
report VB o
sun NN o
exposure NN o
in IN o
the DT o
last JJ o
3 CD o
months NNS o
. . o

They PRP N
consumed VBD N
less JJR N
vitamin JJ o
D NNP o
from IN o
supplements NNS o
( ( N
2.15 CD N
( ( N
sd VB N
5.24 CD N
) ) N
?g/d NN N
( ( N
86 CD N
( ( N
sd VB N
210 CD N
) ) N
IU/d NNP N
) ) N
v. VBZ N
4.55 CD N
( ( N
sd VB N
8.48 CD N
) ) N
?g/d NN N
( ( N
188 CD N
( ( N
sd VB N
344 CD N
) ) N
IU/d NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

In IN N
logistic JJ N
regression NN N
models NNS o
, , o
black JJ o
race NN o
, , o
BMI NNP o
, , o
suntan NN o
within IN o
the DT o
past JJ o
year NN o
, , o
sun NN o
exposure NN o
in IN o
the DT o
past JJ o
3 CD o
months NNS o
, , o
sunscreen JJ o
use NN o
and CC o
supplemental JJ o
vitamin NN o
D NNP o
intake NN o
were VBD o
the DT N
most RBS N
useful JJ N
questions NNS N
to TO N
identify VB N
VDI NNP N
. . N

From IN N
these DT N
six CD N
items NNS N
, , N
a DT N
composite JJ N
score NN N
of IN N
? . N
2.25 CD N
demonstrated VBD N
?89 CD N
% NN N
sensitivity NN o
but CC o
?35 CD o
% NN o
specificity NN o
for IN o
VDI NNP o
. . N

CONCLUSIONS NNP N
The DT N
VIDSUN NNP N
questionnaire NN N
provides VBZ N
an DT N
initial JJ N
tool NN N
to TO N
identify VB N
postmenopausal JJ N
women NNS N
at IN N
high JJ N
or CC N
low JJ N
risk NN N
of IN N
VDI NNP o
. . o

Existing VBG N
studies NNS N
suggest VBP N
that IN N
inclusion NN N
of IN N
physical JJ N
activity NN N
and CC N
TAG NNP N
levels NNS N
might MD N
improve VB N
the DT N
performance NN N
of IN N
the DT N
VIDSUN NNP N
questionnaire NN N
. . N

-DOCSTART- -14628158- O O

Removal NN i
of IN i
hypertrophied JJ i
anal JJ i
papillae NN i
and CC i
fibrous JJ i
anal JJ i
polyps NN i
increases NNS N
patient JJ o
satisfaction NN o
after IN p
anal JJ p
fissure NN p
surgery NN p
. . p

BACKGROUND NNP N
Hypertrophied NNP N
anal JJ N
papillae NN N
and CC N
fibrous JJ N
anal JJ N
polyps NNS N
are VBP N
frequently RB N
found VBN N
in IN N
association NN N
with IN N
chronic JJ N
fissure NN N
in IN N
ano NN N
. . N

Usually RB N
, , N
no DT N
specific JJ N
attention NN N
is VBZ N
given VBN N
to TO N
them PRP N
and CC N
they PRP N
are VBP N
considered VBN N
normal JJ N
findings NNS N
. . N

The DT N
present JJ N
prospective JJ N
study NN N
was VBD N
aimed VBN N
at IN N
determining VBG N
whether IN N
removal NN i
of IN i
hypertrophied JJ i
anal JJ i
papillae NN i
and CC i
fibrous JJ i
anal JJ i
polyps NNS i
while IN N
dealing VBG N
with IN N
chronic JJ N
fissure NN N
in IN N
ano JJ N
confers NNS N
long-term JJ o
benefit NN o
to TO N
patients NNS p
. . p

METHODS NNP N
Between NNP p
July NNP p
1999 CD p
and CC p
December NNP p
2000 CD p
, , p
140 CD p
patients NNS p
undergoing JJ p
anal JJ p
sphincterotomy NN p
were VBD N
randomized VBN i
into IN i
two CD i
groups NNS i
to TO i
have VB i
their PRP$ i
fibrous JJ i
polyps NNS i
and CC i
hypertrophied VBD i
anal JJ i
papillae NN i
either DT i
removed VBN i
by IN i
radiofrequency NN i
surgery NN i
or CC i
left VBN i
intact JJ i
. . i

After IN N
two CD N
years NNS N
, , N
they PRP N
underwent VBP N
a DT N
detailed JJ N
interview NN o
by IN o
an DT o
independent JJ o
, , o
masked JJ o
investigator NN o
. . o

RESULTS NNP N
Overall JJ N
84 CD N
% NN N
of IN N
patients NNS p
who WP p
had VBD p
polyp NN p
and CC p
papilla NN p
removal NN p
rated VBD N
the DT N
outcome NN o
of IN o
their PRP$ o
surgery NN o
as IN N
excellent NN N
or CC N
good JJ N
in IN N
comparison NN N
to TO N
58 CD N
% NN N
of IN N
controls NNS N
. . N

The DT N
mean JJ N
satisfaction NN N
grading NN N
was VBD N
9.2 CD N
on IN N
a DT N
visual JJ o
analogue NN o
scale NN o
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
8.1 CD N
in IN N
controls NNS N
( ( N
p=0.004 NN N
) ) N
. . N

CONCLUSION NNP N
Removal NNP i
of IN i
hypertrophied JJ i
anal JJ i
papillae NN i
and CC i
fibrous JJ i
anal JJ i
polyps NNS i
should MD N
be VB N
an DT N
essential JJ N
part NN N
of IN N
treatment NN N
of IN N
chronic JJ N
fissure NN N
in IN N
ano NN N
. . N

Persistence NN N
of IN N
these DT N
structures NNS N
leaves VBZ N
behind IN N
a DT N
sense NN N
of IN N
incomplete JJ N
treatment NN N
, , N
reducing VBG N
the DT N
overall JJ o
satisfaction NN o
on IN N
the DT N
part NN N
of IN N
the DT N
patient NN N
. . N

Radiofrequency NNP i
procedure NN i
is VBZ N
useful JJ N
in IN N
eradication NN N
of IN N
these DT N
concomitant JJ N
pathologies NNS N
. . N

-DOCSTART- -17947289- O O

Children NNP p
with IN p
autism NN p
's POS p
response NN o
to TO o
novel VB o
stimuli NNS o
while IN N
participating VBG N
in IN N
interventions NNS N
targeting VBG N
joint JJ i
attention NN i
or CC N
symbolic JJ i
play NN i
skills NNS N
. . N

Thirty-five JJ p
children NNS p
diagnosed VBN p
with IN p
autism NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
joint JJ i
attention NN i
or CC i
a DT i
symbolic JJ i
play NN i
intervention NN i
. . i

During IN N
the DT N
5-8 JJ N
week NN N
treatment NN N
, , N
three CD N
novel NN N
probes NNS N
were VBD N
administered VBN N
to TO N
determine VB N
mastery NN o
of IN o
joint JJ o
attention NN o
skills NNS o
. . o

The DT N
probes NNS N
consisted VBD N
of IN N
auditory NN N
and CC N
visual JJ N
stimuli NN N
, , N
such JJ N
as IN N
a DT N
loud JJ N
spider NN N
crawling NN N
or CC N
a DT N
musical JJ N
ball NN N
bouncing NN N
. . N

The DT N
current JJ N
study NN N
examined VBD N
affect JJ o
, , o
gaze JJ o
, , o
joint JJ o
attention NN o
behaviors NNS o
, , N
and CC N
verbalizations NNS o
at IN N
three CD N
different JJ N
time NN N
points NNS N
of IN N
intervention NN N
. . N

Results NNS N
revealed VBD N
that IN N
children NNS N
randomized VBN N
to TO N
the DT N
joint JJ i
attention NN i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
acknowledge VB o
the DT o
probe NN o
and CC o
engage NN o
in IN o
shared VBN o
interactions NNS o
between IN N
intervener NN N
and CC N
probe NN N
upon IN N
termination NN N
of IN N
intervention NN N
. . N

Additionally RB N
, , N
the DT N
joint JJ N
attention NN N
group NN N
improved VBD N
in IN N
the DT N
proportion NN o
of IN o
time NN o
spent VBN o
sharing VBG o
coordinated VBN o
joint JJ o
looks NNS o
between IN N
intervener NN N
and CC N
probe NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
generalization NN N
of IN N
joint JJ N
attention NN N
skills NNS N
to TO N
a DT N
novel JJ N
probe NN N
did VBD N
occur VB N
for IN N
the DT N
group NN N
targeting VBG N
joint JJ N
attention NN N
and CC N
provides VBZ N
further JJ N
evidence NN N
of IN N
the DT N
effectiveness NN N
of IN N
the DT N
joint JJ N
attention NN N
intervention NN N
. . N

-DOCSTART- -16757200- O O

Clinical JJ N
evaluation NN N
of IN N
the DT N
intraoral JJ i
fluoride NN i
releasing VBG i
system NN i
in IN N
radiation-induced JJ p
xerostomic JJ p
subjects NNS p
. . p

Part CC N
2 CD N
: : N
Phase NN N
I PRP N
study VBP N
. . N

Radiation-induced JJ N
xerostomia NN N
can MD N
result VB N
in IN N
the DT N
rapid JJ N
onset NN N
and CC N
progression NN N
of IN N
dental JJ N
caries NNS N
in IN N
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

Topically RB N
applied VBN N
fluorides NNS N
have VBP N
been VBN N
successfully RB N
used VBN N
to TO N
inhibit VB N
the DT N
formation NN N
of IN N
dental JJ N
caries NNS N
in IN N
this DT N
population NN N
. . N

However RB N
, , N
because IN N
intensive JJ N
daily JJ N
self-application NN N
is VBZ N
required VBN N
, , N
compliance NN N
is VBZ N
an DT N
issue NN N
. . N

The DT N
intraoral JJ i
fluoride-releasing NN i
system NN i
( ( i
IFRS NNP i
) ) i
containing VBG i
a DT i
sodium NN i
fluoride NN i
core NN i
is VBZ N
a DT N
newly RB N
developed VBN N
, , N
sustained-release JJ N
, , N
passive JJ N
drug NN N
delivery NN N
system NN N
that WDT N
does VBZ N
not RB N
require VB N
patient JJ N
involvement NN N
except IN N
for IN N
periodic JJ N
replacement NN N
, , N
thus RB N
reducing VBG N
the DT N
effect NN N
of IN N
patient NN N
compliance NN N
on IN N
its PRP$ N
effectiveness NN N
in IN N
dental JJ N
caries NNS N
prevention NN N
. . N

Twenty-two JJ p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
from IN p
U. NNP p
T. NNP p
M. NNP p
D. NNP p
Anderson NNP p
Cancer NNP p
Center NNP p
, , p
with IN p
radiation-induced JJ p
xerostomia NN p
, , N
were VBD N
entered VBN N
into IN N
a DT N
pilot NN N
study NN N
to TO N
contrast VB N
the DT N
daily JJ N
home NN N
use NN N
of IN N
a DT N
0.4 CD N
% NN N
stannous JJ N
fluoride-gel-containing JJ i
tray NN i
( ( N
control VB N
group NN N
) ) N
to TO N
IFRS NNP i
( ( N
study VB N
group NN N
) ) N
with IN N
respect NN N
to TO N
tolerability NN N
and CC N
adherence NN N
, , N
and CC N
to TO N
obtain VB N
information NN N
on IN N
relative JJ N
caries NNS N
preventive VBP N
efficacy NN N
. . N

Participants NNS N
were VBD N
stratified VBN N
on IN N
the DT N
basis NN N
of IN N
radiation NN N
exposure NN N
and CC N
randomly RB N
assigned VBN N
to TO N
treatment NN N
with IN N
either DT N
IFRS NNP N
or CC N
stannous JJ N
fluoride JJ N
gel NN N
. . N

Patients NNS p
in IN p
both DT p
groups NNS p
were VBD N
fitted VBN N
with IN N
two CD N
IFRS NNP i
retainers NNS i
and CC N
also RB N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
1100-ppm JJ i
fluoride JJ i
conventional JJ i
sodium NN i
fluoride NN i
dentifrice NN i
twice RB i
daily RB i
. . i

The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
single-blinded JJ N
, , N
parallel-cell JJ N
trial NN N
. . N

Pre-existing NNP N
carious JJ N
lesions NNS N
were VBD N
restored VBN N
prior RB N
to TO N
the DT N
beginning NN N
of IN N
the DT N
study NN N
. . N

The DT N
efficacy NN N
variable NN N
was VBD N
determined VBN N
by IN N
the DT N
mean JJ N
number NN N
of IN N
new JJ N
or CC N
recurrent JJ N
decayed JJ N
surfaces NNS N
. . N

Patients NNS N
were VBD N
examined VBN N
for IN N
caries NNS N
4 CD N
, , N
8 CD N
, , N
12 CD N
, , N
24 CD N
, , N
36 CD N
, , N
and CC N
48 CD N
weeks NNS N
after IN N
initiation NN N
of IN N
treatment NN N
. . N

Reports NNS N
of IN N
adverse JJ N
reactions NNS N
were VBD N
based VBN N
on IN N
information NN N
volunteered VBN N
by IN N
patients NNS N
and CC N
that WDT N
were VBD N
elicited VBN N
during IN N
interviews NNS N
. . N

At IN N
baseline NN N
, , N
the DT N
resting NN N
and CC N
stimulated VBD N
salivary JJ N
flow NN N
rates NNS N
( ( N
g/5min NN N
) ) N
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
study NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNS p
in IN p
the DT p
control NN p
group NN p
had VBD N
received VBN N
significantly RB N
more JJR N
radiation NN N
than IN N
those DT N
in IN N
the DT N
test NN N
group NN N
( ( N
68Gy CD N
vs. IN N
60Gy CD N
; : N
p=0.047 NN N
) ) N
. . N

No DT N
marked JJ N
differences NNS N
in IN N
follow-up JJ N
new JJ N
and CC N
recurrent JJ o
caries NNS o
were VBD N
found VBN N
between IN N
the DT N
stannous JJ N
fluoride JJ N
gel NN N
control NN N
and CC N
IFRS NNP N
groups NNS N
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
rate NN o
of IN o
new JJ o
or CC o
recurrent JJ o
carious JJ o
lesions NNS o
in IN o
the DT o
group NN o
treated VBD N
with IN N
the DT N
fluoride NN N
gel NN N
was VBD N
slightly RB N
lower JJR N
than IN N
in IN N
the DT N
IFRS NNP N
group NN N
, , N
based VBN N
on IN N
carious JJ N
lesions NNS N
at IN N
the DT N
baseline NN N
examination NN N
( ( N
Poisson NNP N
mean VBP N
number NN N
of IN N
new JJ N
or CC N
recurrent JJ N
carious JJ N
lesions NNS N
for IN N
the DT N
control NN N
group=0.55 NN N
per IN N
year NN N
vs. FW N
0.83 CD N
per IN N
year NN N
for IN N
the DT N
study NN N
group NN N
, , N
p=0.705 NN N
; : N
odds NNS o
ratio NN o
of IN o
the DT o
occurrence NN o
of IN o
any DT o
new JJ o
or CC o
recurrent JJ o
caries NNS o
during IN N
follow-up JJ N
for IN N
control NN N
group NN N
vs. FW N
the DT N
study NN N
group=0.80 NN N
; : N
p=0.781 NN N
) ) N
. . N

This DT N
pilot NN N
study NN N
revealed VBD N
that IN N
the DT N
IFRS NNP N
was VBD N
well-tolerated JJ o
and CC o
safe JJ o
in IN N
this DT N
study NN N
population NN N
associated VBN N
with IN N
minimal JJ N
complications NNS o
during IN N
the DT N
duration NN N
of IN N
this DT N
study NN N
and CC N
was VBD N
comparable JJ N
in IN N
efficacy NN o
to TO o
a DT o
SnF NNP o
( ( o
2 CD o
) ) o
gel NN o
in IN N
preventing VBG N
caries NNS N
development NN N
. . N

The DT N
IFRS NNP N
provided VBD N
similar JJ N
rates NNS o
of IN o
control NN o
for IN N
caries NNS N
formation NN N
to TO N
a DT N
fluoride-gel-containing JJ N
tray NN N
. . N

The DT N
IFRS NNP N
is VBZ N
designed VBN N
to TO N
release VB N
a DT N
daily JJ N
dose NN N
of IN N
0.12mg CD N
of IN N
sodium NN i
fluoride NN i
, , N
which WDT N
can MD N
be VB N
evenly RB N
distributed VBN N
throughout IN N
the DT N
oral JJ N
cavity NN N
for IN N
a DT N
single JJ N
application NN N
of IN N
4 CD N
months NNS N
. . N

It PRP N
would MD N
be VB N
more RBR N
convenient JJ N
than IN N
the DT N
daily JJ N
home NN N
application NN N
of IN N
a DT N
tray NN N
of IN N
0.4 CD N
% NN N
stannous JJ N
fluoride NN N
or CC N
1.1 CD N
% NN N
sodium NN N
fluoride NN N
gel NN N
, , N
and CC N
avoids VBZ N
the DT N
problem NN N
of IN N
variable JJ N
patient NN N
compliance NN N
. . N

-DOCSTART- -14749563- O O

The DT N
long-term JJ N
effect NN N
of IN N
oxandrolone NN i
on IN N
hepatic JJ N
acute NN N
phase NN N
proteins VBZ N
in IN N
severely RB p
burned JJ p
children NNS p
. . p

BACKGROUND NNP N
Acute NNP N
phase NN N
protein NN N
production NN N
is VBZ N
a DT N
hallmark NN N
of IN N
severe JJ N
burns NNS N
. . N

We PRP N
wondered VBD N
whether IN N
anabolic JJ i
treatment NN i
with IN N
oxandrolone NN N
would MD N
affect VB N
these DT N
proteins NNS N
. . N

METHODS NNP N
Thirty-five JJ p
children NNS p
with IN p
> NN p
or CC p
=40 CD p
% NN p
total JJ p
body NN p
surface NN p
area NN p
burns NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
placebo NN i
or CC i
oxandrolone NN i
( ( N
0.1 CD N
mg/kg NN N
by IN N
mouth JJ N
twice JJ N
daily RB N
) ) N
from IN N
postoperative JJ N
day NN N
5 CD N
to TO N
1 CD N
year NN N
postburn NN N
. . N

Levels NNP N
of IN N
constitutive JJ N
proteins NNS N
and CC N
acute JJ N
phase NN N
proteins NNS N
were VBD N
measured VBN N
at IN N
admission NN N
; : N
at IN N
discharge NN N
; : N
and CC N
at IN N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
burn NN N
. . N

Total JJ o
albumin JJ o
supplementation NN o
and CC o
hepatic JJ o
transaminases NNS o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
Constitutive JJ o
proteins NNS o
such JJ o
as IN o
albumin NN o
, , o
prealbumin NN o
, , o
and CC o
retinol-binding JJ o
protein NN o
levels NNS o
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
acute JJ o
phase NN o
proteins NNS o
such JJ o
as IN o
alpha JJ o
1-acid JJ o
glycoprotein NN o
, , o
C3 NNP o
complement NN o
, , o
alpha JJ o
2-macroglobulin JJ o
, , o
and CC o
fibrinogen NN o
levels NNS o
significantly RB N
decreased VBN N
in IN N
the DT N
oxandrolone NN N
group NN N
compared VBN N
with IN N
placebo NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Albumin NNP o
supplementation NN o
during IN o
the DT o
acute JJ o
hospitalization NN o
was VBD N
reduced VBN N
in IN N
the DT N
oxandrolone NN N
group NN N
. . N

Hepatic JJ o
transaminases NNS o
remained VBD N
within IN N
normal JJ o
levels NNS o
. . o

CONCLUSION NNP N
Treatment NNP N
with IN N
oxandrolone NN N
in IN N
severe JJ N
burns NNS N
significantly RB N
increases VBZ N
constitutive JJ o
protein NN o
and CC N
reduces NNS N
acute JJ o
phase NN o
protein NN o
levels NNS o
. . o

-DOCSTART- -16230666- O O

Effects NNS N
of IN N
supplementation NN N
of IN N
whole JJ N
corn NN N
germ NN N
on IN N
reproductive JJ o
performance NN o
, , o
calf JJ o
performance NN o
, , o
and CC o
leptin JJS o
concentration NN o
in IN N
primiparous JJ p
and CC p
mature JJ p
beef NN p
cows NNS p
. . p

A DT N
2-yr JJ N
study NN N
using VBG N
primiparous JJ p
and CC p
multiparous JJ p
, , p
spring-calving JJ p
, , p
crossbred JJ p
beef NN p
cows NNS p
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
supplemental JJ i
whole JJ i
corn NN i
germ NN i
on IN N
reproductive JJ o
performance NN o
, , o
calf JJ o
performance NN o
, , o
and CC o
serum NN o
leptin NN o
concentrations NNS o
. . o

Each DT N
year NN N
, , N
cows NNS p
were VBD N
blocked VBN i
by IN i
age NN i
and CC i
BCS NNP i
and CC i
assigned VBD i
randomly RB i
to TO i
one CD i
of IN i
three CD i
treatments NNS i
: : i
PRE NNP i
( ( i
n JJ i
= NNP i
115 CD i
) ) i
cows NNS i
received VBD i
1.14 CD i
kg/d NNS i
( ( i
DM NNP i
basis NN i
) ) i
of IN i
whole JJ i
corn NN i
germ NN i
for IN i
approximately RB i
45 CD i
d NN i
before IN i
calving VBG i
; : i
POST NNP i
( ( i
n JJ i
= NNP i
109 CD i
) ) i
cows NNS i
were VBD i
fed VBN i
1.14 CD i
kg/d NNS i
of IN i
whole JJ i
corn NN i
germ NN i
for IN i
approximately RB i
45 CD i
d NN i
after IN i
calving VBG i
; : i
and CC i
control VB i
cows NNS i
( ( i
n JJ i
= NNP i
118 CD i
) ) i
were VBD i
fed VBN i
similar JJ i
energy NN i
and CC i
protein NN i
from IN i
dry-rolled JJ i
corn NN i
( ( i
1.82 CD i
kg NN i
of IN i
DM/d NNP i
) ) i
for IN i
45 CD i
d NN i
before IN i
and CC i
after IN i
calving VBG i
. . i

Additionally RB N
, , N
PRE NNP N
cows NNS N
were VBD N
grouped VBN i
with IN i
controls NNS i
after IN i
calving VBG i
, , i
and CC i
POST NNP i
cows NNS i
were VBD i
grouped VBN i
with IN i
control NN i
cows NNS i
before IN i
calving NN i
, , i
so IN i
that DT i
corn NN i
germ-supplemented JJ i
cows NNS i
received VBD i
the DT i
control NN i
supplement NN i
in IN i
the DT i
alternate NN i
feeding NN i
period NN i
. . i

Cow NNP o
BW NNP o
( ( N
538 CD N
+/- JJ N
13 CD N
kg NN N
) ) N
and CC N
BCS NNP N
( ( N
5.4 CD N
+/- JJ N
0.13 CD N
) ) N
did VBD N
not RB N
differ VB N
among IN N
treatments NNS N
at IN N
any DT N
time NN N
during IN N
the DT N
experiment NN N
. . N

Calf NNP o
birth NN o
weight NN o
( ( N
39 CD N
+/- JJ N
2 CD N
kg NN N
) ) N
, , N
weaning VBG o
weight NN o
( ( N
225 CD N
+/- JJ N
7 CD N
kg NN N
) ) N
, , N
and CC N
age-adjusted JJ o
weaning NN o
weight NN o
( ( N
234 CD N
+/- JJ N
8 CD N
kg NN N
) ) N
did VBD N
not RB N
differ VB N
because IN N
of IN N
dam JJ N
supplementation NN N
regimen NNS N
. . N

Treatment NN N
did VBD N
not RB N
affect VB N
the DT N
proportion NN N
of IN N
cows NNS N
exhibiting VBG N
ovarian JJ o
luteal NN o
activity NN o
before IN N
the DT N
start NN N
of IN N
the DT N
breeding NN N
season NN N
( ( N
67 CD N
% NN N
) ) N
or CC N
pregnancy NN N
rate NN N
( ( N
91 CD N
% NN N
) ) N
. . N

The DT N
interval NN N
from IN N
exposure NN o
to TO N
bulls NNS N
until IN N
subsequent JJ N
calving VBG N
did VBD N
not RB N
differ VB N
( ( N
P NNP N
= NNP N
0.16 CD N
) ) N
among IN N
PRE NNP N
( ( N
298 CD N
+/- JJ N
2.3 CD N
d NN N
) ) N
, , N
POST NNP N
( ( N
303 CD N
+/- JJ N
2.6 CD N
d NN N
) ) N
, , N
and CC N
control NN N
( ( N
304 CD N
+/- JJ N
2.3 CD N
d NN N
) ) N
cows VBZ N
. . N

Leptin NNP o
concentrations NNS o
did VBD N
not RB N
differ VB N
among IN N
treatments NNS N
and CC N
were VBD N
2.15 CD N
+/- JJ N
0.75 CD N
, , N
1.88 CD N
+/- JJ N
0.76 CD N
, , N
and CC N
1.91 CD N
+/- JJ N
0.75 CD N
ng/mL NN N
for IN N
control NN N
, , N
POST NNP N
, , N
and CC N
PRE NNP N
cows NNS N
, , N
respectively RB N
. . N

Age NNP N
and CC N
week NN N
relative VBP N
to TO N
calving VBG N
influenced JJ N
leptin JJ N
concentration NN N
. . N

Primiparous JJ p
cows NNS p
had VBD N
similar JJ N
leptin NN o
concentrations NNS o
to TO N
3-yr-old JJ N
and CC N
mature JJ N
cows NNS p
for IN N
wk NN N
-7 NN N
and CC N
-6 JJ N
relative NN N
to TO N
calving NN N
, , N
but CC N
lower JJR N
( ( N
P NNP N
< NNP N
0.10 CD N
) ) N
concentrations NNS N
than IN N
mature NN N
cows NNS N
for IN N
wk NN N
-5 NN N
, , N
and CC N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
concentrations NNS N
than IN N
either DT N
3-yr-old JJ N
or CC N
mature JJ N
cows NNS N
for IN N
wk NN N
-4 NN N
to TO N
+7 VB N
relative JJ N
to TO N
calving VBG N
. . N

Serum NNP N
leptin NN N
was VBD N
correlated VBN N
with IN N
BCS NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
; : N
r NN N
= VBZ N
0.35 CD N
) ) N
at IN N
initiation NN N
of IN N
the DT N
feeding JJ N
period NN N
and CC N
was VBD N
correlated VBN N
with IN N
BCS NNP N
( ( N
P NNP N
= NNP N
0.02 CD N
; : N
r NN N
= VBZ N
0.12 CD N
) ) N
and CC N
weight NN N
( ( N
P NNP N
< NNP N
0.01 CD N
; : N
r NN N
= VBZ N
0.14 CD N
) ) N
at IN N
the DT N
completion NN N
of IN N
the DT N
supplement JJ N
period NN N
, , N
but CC N
it PRP N
was VBD N
not RB N
correlated VBN N
with IN N
initial JJ N
BW NNP N
or CC N
interim JJ N
BCS NNP N
. . N

Calving VBG N
interval NN N
was VBD N
not RB N
correlated VBN N
( ( N
P NNP N
> NNP N
0.12 CD N
) ) N
with IN N
weekly JJ N
measures NNS N
of IN N
serum NN o
leptin NN o
concentration NN o
. . o

Supplementing VBG N
beef NN p
cows NNS p
with IN N
whole JJ N
corn NN N
germ NN N
had VBD N
no DT N
effect NN N
on IN N
cow NN N
performance NN N
, , N
calf JJ N
performance NN N
, , N
or CC N
serum NN N
leptin JJ N
concentrations NNS N
of IN N
cows NNS N
. . N

-DOCSTART- -14616151- O O

Esomeprazole NNP i
resolves VBZ N
chronic JJ o
heartburn NN o
in IN N
patients NNS p
without IN p
erosive JJ p
oesophagitis NN p
. . p

BACKGROUND NNP N
Patients NNPS p
with IN p
chronic JJ o
heartburn NN o
but CC p
with IN p
no DT p
endoscopic JJ p
evidence NN p
of IN p
erosive JJ p
oesophagitis NN p
require NN p
gastric JJ p
acid JJ p
suppression NN p
to TO p
relieve VB o
symptoms NNS o
. . o

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
esomeprazole NN i
in IN N
patients NNS p
with IN p
frequent JJ o
heartburn NN o
for IN p
> NN p
or CC p
= $ p
6 CD p
months NNS p
and CC p
no DT p
evidence NN p
of IN p
erosive JJ p
oesophagitis NN p
on IN p
endoscopy NN p
. . p

METHODS NNP N
Two CD N
randomized VBD N
, , N
double-blind JJ N
, , N
4-week JJ N
, , N
multi-centre JJ N
trials NNS N
with IN N
identical JJ N
methodology NN N
compared VBN N
once-daily RB N
esomeprazole JJ i
, , N
40 CD p
mg NN p
( ( p
n JJ p
= NNP p
241 CD p
) ) p
or CC p
20 CD p
mg NN p
( ( p
n JJ p
= NNP p
234 CD p
) ) p
, , p
with IN p
placebo NN i
( ( p
n JJ p
= NNP p
242 CD p
) ) p
for IN N
the DT N
rigorous JJ N
end-point NN N
of IN N
complete JJ o
resolution NN o
of IN o
heartburn NN o
. . o

Secondary JJ N
end-points NNS N
included VBD N
the DT N
percentage NN o
of IN o
heartburn-free JJ o
days NNS o
and CC o
the DT o
time NN o
to TO o
first RB o
and CC o
sustained JJ o
resolution NN o
of IN o
heartburn NN o
. . o

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
either DT N
dose NN N
of IN N
esomeprazole JJ i
were VBD N
two CD N
to TO N
three CD N
times NNS N
more RBR N
likely JJ N
to TO N
achieve VB N
complete JJ o
resolution NN o
of IN o
heartburn NN o
than IN N
patients NNS N
treated VBN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
percentage NN o
of IN o
heartburn-free JJ o
days NNS o
was VBD N
significantly RB N
higher JJR N
with IN N
esomeprazole JJ i
40 CD N
mg NN N
( ( N
63 CD N
% NN N
, , N
66 CD N
% NN N
) ) N
or CC N
20 CD N
mg NN N
( ( N
63 CD N
% NN N
, , N
68 CD N
% NN N
) ) N
than IN N
with IN N
placebo NN i
( ( N
46 CD N
% NN N
, , N
36 CD N
% NN N
; : N
P NNP N
< NNP N
or CC N
= VB N
0.001 CD N
) ) N
in IN N
each DT N
of IN N
the DT N
two CD N
studies NNS N
. . N

Esomeprazole NNP i
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
shorter JJR N
mean JJ N
time NN N
to TO N
first VB N
( ( N
6-7 JJ N
days NNS N
) ) N
and CC N
sustained VBN N
( ( N
12-17 JJ N
days NNS N
) ) N
resolution NN o
of IN o
heartburn NN o
compared VBN N
with IN N
placebo NN i
( ( N
first JJ N
, , N
10-12 JJ N
days NNS N
; : N
sustained VBN N
, , N
21-22 JJ N
days NNS N
; : N
P NNP N
< NNP N
or CC N
= VB N
0.008 CD N
) ) N
. . N

The DT N
spectrum NN o
and CC o
frequency NN o
of IN o
adverse JJ o
events NNS o
with IN N
esomeprazole NN i
were VBD N
similar JJ N
to TO N
those DT N
with IN N
placebo NN i
. . i

CONCLUSIONS NNP N
Esomeprazole NNP i
, , N
at IN N
daily JJ N
doses NNS N
of IN N
40 CD N
mg NNS N
or CC N
20 CD N
mg NN N
, , N
is VBZ N
effective JJ o
and CC o
safe JJ o
for IN N
the DT N
treatment NN N
of IN N
chronic JJ o
heartburn NN o
in IN N
patients NNS p
without IN p
erosive JJ p
oesophagitis NN p
. . p

-DOCSTART- -8456467- O O

Long-term JJ o
consequences NNS o
of IN N
different JJ N
immunosuppressive JJ i
regimens NNS i
for IN N
renal JJ p
allografts NNS p
. . p

The DT N
long-term JJ o
effects NNS o
of IN N
four CD N
different JJ i
immunosuppressive JJ i
regimens NNS i
on IN N
renal JJ N
allografts NNS N
have VBP N
been VBN N
investigated VBN N
up RP N
to TO N
four CD N
years NNS N
. . N

A DT N
total NN N
of IN N
128 CD p
recipients NNS p
of IN p
first JJ p
cadaveric JJ p
renal NN p
allograft NN p
were VBD N
randomized VBN N
, , N
after IN N
an DT N
initial JJ N
induction NN N
period NN N
, , N
to TO N
receive VB N
either RB N
triple JJ N
drug NN N
therapy NN N
-- : N
i.e. NN N
, , N
( ( N
low-dose JJ N
) ) N
cyclosporine NN i
, , i
azathioprine NN i
, , i
and CC i
methylprednisolone NN i
, , i
or CC i
any DT i
possible JJ i
combination NN i
of IN i
two CD i
drugs NNS i
-- : i
i.e. NN i
, , N
Aza NNP i
plus CC i
CsA NNP i
, , i
Aza NNP i
plus CC i
MP NNP i
, , i
and CC i
CsA NNP i
plus CC i
MP NNP i
. . i

The DT N
actual JJ N
four-year JJ N
graft NN o
survival NN o
rates NNS o
for IN N
the DT N
triple JJ N
therapy NN N
, , N
Aza NNP i
plus CC i
CsA NNP i
, , i
Aza NNP i
plus CC i
MP NNP i
, , i
and CC i
CsA NNP i
plus CC i
MP NNP i
groups NNS N
were VBD N
72 CD N
% NN N
, , N
69 CD N
% NN N
, , N
75 CD N
% NN N
, , N
and CC N
59 CD N
% NN N
, , N
and CC N
patient JJ N
survival NN N
rates NNS N
were VBD N
78 CD N
% NN N
, , N
81 CD N
% NN N
, , N
81 CD N
% NN N
, , N
and CC N
84 CD N
% NN N
, , N
respectively RB N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
. . N

The DT N
cumulative JJ N
number NN N
of IN N
chronic JJ o
rejections NNS o
up IN N
to TO N
4 CD N
years NNS N
was VBD N
0.09 CD N
, , N
0.29 CD N
, , N
0.25 CD N
, , N
and CC N
0.34 CD N
per IN N
patient NN N
per IN N
group NN N
( ( N
P NNP N
= NNP N
ns NN N
) ) N
, , N
respectively RB N
. . N

At IN N
2 CD N
, , N
3 CD N
, , N
and CC N
4 CD N
years NNS N
posttransplantation NN N
, , N
the DT N
graft NN o
function NN o
was VBD N
significantly RB N
worse JJR N
in IN N
the DT N
Aza NNP i
plus CC i
MP NNP i
group NN N
compared VBN N
with IN N
the DT N
triple JJ N
therapy NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Of IN N
the DT N
98 CD p
patients NNS p
who WP p
did VBD p
not RB p
have VB p
type NN p
I PRP p
or CC p
II NNP p
diabetes VBZ p
at IN p
the DT p
time NN p
of IN p
transplantation NN p
, , N
17 CD N
developed VBD N
posttransplantation NN o
diabetes NNS o
mellitus VBP o
or CC N
an DT N
abnormal JJ o
glucose NN o
tolerance NN o
test NN o
within IN N
2 CD N
years NNS N
posttransplantation NN N
. . N

All PDT N
these DT N
patients NNS N
had VBD N
received VBN N
steroids NNS i
and CC N
none NN N
of IN N
the DT N
patients NNS N
without IN N
steroids NNS N
had VBD N
these DT N
abnormalities NNS N
. . N

At IN N
two CD N
years NNS N
the DT N
mean NN N
cholesterol NN o
level NN o
was VBD N
highest JJS N
in IN N
the DT N
Aza NNP i
plus CC i
MP NNP i
group NN N
, , N
6.8 CD N
mmol/L NN N
and CC N
lowest JJS N
in IN N
the DT N
group NN N
receiving VBG N
triple JJ i
therapy NN i
, , N
5.8 CD N
mmol/L NN N
( ( N
P NNP N
= NNP N
ns NN N
) ) N
. . N

The DT N
use NN N
of IN N
( ( N
low-dose JJ N
) ) N
CsA NNP N
was VBD N
not RB N
associated VBN N
with IN N
lipid JJ o
abnormalities NNS o
or CC N
with IN N
disturbances NNS o
in IN o
glucose JJ o
metabolism NN o
. . o

A DT N
protocol NN N
graft NN N
biopsy NN N
was VBD N
performed VBN N
at IN N
two CD N
years NNS N
on IN N
all DT N
functioning VBG N
kidneys NNS N
, , N
and CC N
the DT N
histological JJ o
changes NNS o
were VBD N
scored VBN N
blindly RB N
. . N

No DT N
CsA-specific JJ o
changes NNS o
, , N
except IN N
isometric JJ o
vacuolation NN o
in IN o
tubuli NN o
, , N
were VBD N
found VBN N
. . N

Histological JJ o
alterations NNS o
characteristic NN o
of IN o
chronic JJ o
rejection NN o
were VBD N
expressed VBN N
as IN N
chronic NN o
allograft NN o
damage NN o
index NN o
. . o

Chronic NNP o
allograft NN o
damage NN o
index NN o
was VBD N
lowest JJS N
in IN N
the DT N
triple JJ N
therapy NN N
group NN N
, , N
1.5 CD N
, , N
compared VBN N
with IN N
the DT N
other JJ N
groups NNS N
, , N
3.2-4.3 JJ N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
indicating VBG N
the DT N
least JJS N
histopathological JJ o
change NN o
in IN N
the DT N
triple JJ N
therapy NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
this DT N
long-term JJ N
study NN N
did VBD N
not RB N
show VB N
any DT N
serious JJ N
cyclosporine-related JJ o
side-effects NNS o
when WRB N
used VBN N
in IN N
low JJ N
dose NN N
in IN N
combination NN N
with IN N
two CD N
other JJ N
drugs NNS N
. . N

Some DT N
side-effects NNS N
, , N
such JJ N
as IN N
posttransplant JJ o
diabetes NNS o
mellitus NNS o
and CC N
probably RB N
some DT o
lipid JJ o
abnormalities NNS o
, , N
could MD N
rather RB N
be VB N
traced VBN N
to TO N
a DT N
higher JJR N
dose NN N
of IN N
steroids NNS i
. . i

Moreover RB N
, , N
the DT N
triple JJ i
drug NN i
therapy NN i
was VBD N
more RBR N
efficacious JJ N
than IN N
any DT N
double JJ N
drug NN N
regimen NNS N
in IN N
the DT N
prevention NN N
of IN N
chronic JJ o
histological JJ o
changes NNS o
in IN o
renal JJ o
allografts NNS o
. . o

-DOCSTART- -9395031- O O

Long-term JJ N
follow-up NN N
of IN N
three CD N
randomized JJ N
trials NNS N
comparing VBG N
idarubicin NN i
and CC i
daunorubicin NN i
as IN N
induction NN N
therapies NNS N
for IN N
patients NNS p
with IN p
untreated JJ p
acute NN p
myeloid NN p
leukemia NN p
. . p

BACKGROUND NNP N
Most NNP N
clinical JJ N
trials NNS N
for IN N
acute NN N
leukemia NN N
have VBP N
reported VBN N
results NNS N
after IN N
2-3 JJ N
years NNS N
of IN N
follow-up NN N
. . N

Comparisons NNS N
between IN N
the DT N
original JJ N
data NNS N
and CC N
longer-term JJ N
follow-up JJ N
data NNS N
may MD N
be VB N
of IN N
interest NN N
, , N
particularly RB N
with IN N
regard NN N
to TO N
promising VBG N
new JJ N
therapies NNS N
. . N

METHODS NNP N
In IN p
1996 CD p
, , p
survival NN p
data NNS p
were VBD p
updated VBN p
from IN p
three CD p
prospective JJ p
, , p
randomized JJ p
comparisons NNS p
of IN p
idarubicin NN i
and CC i
daunorubicin NN i
that WDT p
began VBD p
in IN p
1984 CD p
and CC p
1985 CD p
. . p

These DT p
were VBD p
trials NNS p
of IN p
the DT p
Memorial NNP p
Sloan-Kettering NNP p
Cancer NNP p
Center NNP p
( ( p
MSKCC NNP p
) ) p
, , p
the DT p
U.S. NNP p
Multicenter NNP p
Study NNP p
Group NNP p
, , p
and CC p
the DT p
Southeastern NNP p
Cancer NNP p
Study NNP p
Group NNP p
( ( p
SEG NNP p
) ) p
. . p

The DT N
original JJ N
results NNS N
of IN N
these DT N
trials NNS N
were VBD N
reported VBN N
in IN N
1991 CD N
and CC N
1992 CD N
. . N

RESULTS VB N
The DT N
original JJ N
results NNS N
of IN N
the DT N
SEG NNP N
trial NN N
demonstrated VBD N
no DT N
significant JJ o
difference NN o
between IN o
idarubicin NN o
and CC o
daunorubicin NN o
. . o

The DT N
updated JJ N
survival NN o
analysis NN o
showed VBD N
similar JJ N
results NNS N
. . N

The DT N
MSKCC NNP N
trial NN N
revealed VBD N
a DT N
significant JJ N
advantage NN o
of IN o
idarubicin NNS o
compared VBN N
with IN N
daunorubicin NN N
in IN N
both CC N
the DT N
original JJ N
and CC N
the DT N
updated JJ N
analyses NNS N
. . N

The DT N
U.S. NNP N
Multicenter NNP N
trial NN N
found VBD N
a DT N
significant JJ N
difference NN N
favoring VBG N
idarubicin NN N
in IN N
the DT N
original JJ N
analysis NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
in IN N
the DT N
updated JJ N
analysis NN N
. . N

CONCLUSIONS VB N
It PRP N
is VBZ N
essential JJ N
that IN N
the DT N
median JJ N
length NN N
of IN N
follow-up JJ N
be VB N
clearly RB N
stated VBN N
in IN N
any DT N
clinical JJ N
trial NN N
. . N

When WRB N
the DT N
results NNS N
obtained VBD N
with IN N
a DT N
particularly RB N
promising JJ N
new JJ N
drug NN N
or CC N
procedure NN N
are VBP N
presented VBN N
early RB N
in IN N
the DT N
course NN N
of IN N
study NN N
( ( N
within IN N
1-2 CD N
years NNS N
) ) N
, , N
the DT N
investigators NNS N
should MD N
strongly RB N
consider VB N
a DT N
repeat NN N
evaluation NN N
after IN N
an DT N
additional JJ N
3-5 CD N
years NNS N
of IN N
follow-up NN N
. . N

-DOCSTART- -1659236- O O

A DT N
randomized JJ N
trial NN N
of IN N
an DT N
interim JJ N
methadone NN i
maintenance NN p
clinic NN N
. . N

BACKGROUND NNP N
Interim NNP N
methadone NN i
maintenance NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
method NN N
of IN N
providing VBG N
clinically RB o
effective JJ o
services NNS N
to TO N
heroin VB p
addicts NNS p
waiting VBG p
for IN p
treatment NN p
in IN p
standard JJ p
comprehensive JJ p
methadone NN p
maintenance NN p
programs NNS p
. . p

METHODS NNP N
A NNP N
clinic NN N
that WDT N
provided VBD N
initial JJ N
medical JJ N
evaluation NN N
, , N
methadone NN N
medication NN N
, , N
and CC N
AIDS NNP N
education NN N
, , N
but CC N
did VBD N
not RB N
include VB N
formal JJ N
drug NN N
abuse NN N
counseling NN N
or CC N
other JJ N
social JJ N
support NN N
services NNS N
was VBD N
established VBN N
in IN N
New NNP p
York NNP p
City NNP p
. . p

A NNP p
sample NN p
of IN p
301 CD p
volunteer NN p
subjects NNS p
recruited VBN p
from IN p
the DT p
waiting VBG p
list NN p
for IN p
treatment NN p
in IN p
the DT p
Beth NNP p
Israel NNP p
methadone NN i
program NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
immediate VB N
entry NN N
into IN N
the DT N
interim JJ i
clinic NN i
or CC i
a DT i
control NN i
group NN i
. . i

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
initial JJ N
levels NNS o
of IN o
illicit JJ o
drug NN o
use NN o
across IN N
the DT N
experimental JJ N
and CC N
control NN N
groups NNS N
. . N

One-month JJ N
urinalysis JJ N
follow-up NN N
data NNS N
showed VBD N
a DT N
significant JJ N
reduction NN o
in IN o
heroin NN o
use NN o
in IN N
the DT N
experimental JJ N
group NN N
( ( N
from IN N
63 CD N
% NN N
positive JJ N
at IN N
intake NN N
to TO N
29 CD N
% NN N
positive JJ N
) ) N
with IN N
no DT N
change NN N
in IN N
the DT N
control NN N
group NN N
( ( N
62 CD N
% NN N
to TO N
60 CD N
% NN N
positive JJ N
) ) N
. . N

No DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
cocaine NN o
urinalyses NNS o
( ( N
approximately RB N
70 CD N
% NN N
positive JJ N
for IN N
both DT N
groups NNS N
at IN N
intake NN N
and CC N
follow-up NN N
) ) N
. . N

A DT N
higher JJR N
percentage NN N
of IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
treatment NN N
at IN N
16-month JJ N
follow-up NN N
( ( N
72 CD N
% NN N
vs JJ N
56 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Limited NNP N
services NNS N
interim VBP N
methadone JJ N
maintenance NN N
can MD N
reduce VB N
heroin NNS o
use VBP o
among IN N
persons NNS p
awaiting VBG p
entry NN p
into IN p
comprehensive JJ p
treatment NN p
and CC N
increase VB N
the DT N
percentage NN N
entering VBG N
treatment NN N
. . N

-DOCSTART- -9919095- O O

The DT p
preparation NN p
of IN p
patients NNS p
for IN p
cardiac JJ p
surgery NN p
. . p

This DT N
study NN N
examines VBZ N
the DT N
impact NN N
of IN N
a DT N
preadmission NN i
telephone NN i
intervention NN i
on IN N
anxiety NN o
, , o
knowledge NN o
, , o
and CC o
readiness NN o
for IN o
discharge NN o
for IN N
patients NNS p
attending VBG p
a DT p
preadmission NN p
teaching VBG p
program NN p
prior RB p
to TO p
cardiac VB p
surgery NN p
. . p

The DT N
primary JJ N
goal NN N
of IN N
the DT N
telephone NN i
intervention NN i
was VBD N
to TO N
provide VB N
support NN N
by IN N
giving VBG N
additional JJ N
information NN N
about IN N
individual JJ N
concerns NNS N
. . N

The DT N
telephone NN N
intervention NN N
did VBD N
not RB N
have VB N
an DT N
effect NN N
on IN N
anxiety NN o
and CC o
knowledge NN o
. . o

A DT N
significantly RB N
higher JJR N
level NN o
of IN o
anxiety NN o
was VBD N
found VBN N
in IN N
the DT N
experimental JJ N
group NN N
on IN N
admission NN N
, , N
but CC N
this DT N
difference NN N
became VBD N
nonsignificant JJ N
when WRB N
baseline NN N
level NN N
and CC N
length NN N
of IN N
waiting VBG N
time NN N
were VBD N
entered VBN N
as IN N
covariates NNS N
. . N

The DT N
more RBR N
anxious JJ N
group NN N
rated VBD N
their PRP$ N
perceived JJ o
knowledge NN o
level NN N
lower RBR N
, , N
despite IN N
the DT N
fact NN N
that IN N
both DT N
groups NNS N
had VBD N
similar JJ N
scores NNS o
in IN o
actual JJ o
knowledge NN o
. . o

Given VBN N
the DT N
potential JJ N
barrier NN N
that IN N
anxiety NN N
can MD N
pose VB N
for IN N
patient NN N
learning NN N
, , N
nurses NNS N
need VBP N
to TO N
adapt VB N
their PRP$ N
interventions NNS N
to TO N
deal VB N
with IN N
the DT N
patients NNS N
' POS N
feelings NNS N
of IN N
anxiety NN o
that IN N
accompany JJ N
cardiac JJ N
surgery NN N
to TO N
make VB N
the DT N
learning NN N
process NN N
effective JJ N
. . N

-DOCSTART- -23874533- O O

A DT N
chinese JJ N
mind-body NN N
exercise NN N
improves VBZ N
self-control NN o
of IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Self-control JJ o
problems NNS N
commonly RB N
manifest VBP N
as IN N
temper NN N
outbursts NNS N
and CC N
repetitive/rigid/impulsive JJ N
behaviors NNS N
, , N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
, , N
which WDT N
often RB N
contributes VBZ N
to TO N
learning VBG N
difficulties NNS N
and CC N
caregiver NN N
burden NN N
. . N

The DT N
present JJ N
study NN N
aims NNS N
to TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
traditional JJ i
Chinese JJ i
Chan-based JJ i
mind-body NN i
exercise NN i
, , i
Nei NNP i
Yang NNP i
Gong NNP i
, , N
with IN N
that DT N
of IN N
the DT N
conventional JJ i
Progressive NNP i
Muscle NNP i
Relaxation NNP i
( ( i
PMR NNP i
) ) i
technique NN i
in IN N
enhancing VBG N
the DT N
self-control NN o
of IN N
children NNS p
with IN p
ASD NNP p
. . p

Forty-six NNP p
age- JJ p
and CC p
IQ-matched JJ p
ASD NNP p
children NNS p
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
group NN i
training NN i
in IN i
Nei NNP i
Yang NNP i
Gong NNP i
( ( i
experimental JJ i
group NN i
) ) i
or CC i
PMR NNP i
( ( i
control VB i
group NN i
) ) i
twice RB i
per IN i
week NN i
for IN i
four CD i
weeks NNS i
. . i

The DT N
participants NNS N
' POS N
self-control NN N
was VBD N
measured VBN i
by IN i
three CD i
neuropsychological JJ o
tests NNS o
and CC i
parental JJ o
rating NN o
on IN o
standardized JJ o
questionnaires NNS o
, , i
and CC i
the DT i
underlying JJ i
neural JJ i
mechanism NN i
was VBD i
assessed VBN i
by IN i
the DT i
participants NNS i
' POS i
brain NN i
EEG NNP i
activity NN i
during IN i
an DT i
inhibitory-control JJ i
task NN i
before IN i
and CC i
after IN i
intervention NN i
. . i

The DT N
results NNS N
show VBP N
that IN N
the DT N
experimental JJ N
group NN N
demonstrated VBD N
significantly RB N
greater JJR N
improvement NN o
in IN o
self-control NN o
than IN N
the DT N
control NN N
group NN N
, , N
which WDT N
concurs VBZ N
with IN N
the DT N
parental JJ N
reports NNS N
of IN N
reduced VBN N
autistic JJ o
symptoms NNS o
and CC N
increased VBD N
control NN o
of IN o
temper NN o
and CC o
behaviors NNS o
. . o

In IN N
addition NN N
, , N
the DT N
experimental JJ N
group NN N
showed VBD N
enhanced JJ o
EEG NNP o
activity NN o
in IN N
the DT N
anterior JJ N
cingulate NN N
cortex NN N
, , N
a DT N
region NN N
that WDT N
mediates VBZ N
self-control NN N
, , N
whereas IN N
the DT N
PMR NNP N
group NN N
did VBD N
not RB N
. . N

The DT N
present JJ N
findings NNS N
support VBP N
the DT N
potential JJ N
application NN N
of IN N
Chinese JJ N
Chan-based JJ i
mind-body NN i
exercises NNS i
as IN N
a DT N
form NN N
of IN N
neuropsychological JJ N
rehabilitation NN N
for IN N
patients NNS p
with IN p
self-control JJ o
problems NNS p
. . p

Chinese JJ N
Clinical JJ N
Trial NNP N
Registry NNP N
; : N
Registration NNP N
No NNP N
. . N

: : N
ChiCTR-TRC-12002561 JJ N
; : N
URL NNP N
: : N
www.chictr.org NN N
. . N

-DOCSTART- -19371522- O O

Randomized VBN N
evaluation NN N
of IN N
octreotide JJ i
vs FW N
prochlorperazine NN i
for IN N
ED NNP N
treatment NN N
of IN N
migraine NN o
headache NN o
. . o

UNLABELLED JJ N
Patients NNS p
with IN p
headaches NNS p
account VBP N
for IN N
approximately RB N
2 CD N
% NN N
of IN N
all DT N
ED NNP N
visits NNS N
, , N
with IN N
migraines NNS N
being VBG N
the DT N
most RBS N
common JJ N
defined VBD N
primary JJ N
headache NN N
syndrome NN N
. . N

Our PRP$ N
goals NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
intravenous JJ N
octreotide NN i
( ( i
OC NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
migraines NNS N
, , N
when WRB N
compared VBN N
to TO N
standard VB N
therapy NN N
with IN N
prochlorperazine NN i
. . i

METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
double-blinded JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

Each DT N
subject NN N
received VBD N
either CC N
100 CD i
microg NN i
of IN i
octreotide NN i
or CC i
10 CD i
mg NN i
of IN i
prochlorperazine NN i
intravenously RB i
for IN N
a DT N
2-minute JJ N
period NN N
. . N

RESULTS NNP N
Comparison NNP N
of IN N
the DT N
change NN N
in IN N
median JJ o
visual JJ o
analog NN o
scale NN o
scores NNS o
for IN N
60 CD N
minutes NNS N
demonstrated VBD N
that IN N
octreotide NN i
was VBD N
less RBR N
effective JJ N
at IN N
reducing VBG N
pain NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
producing VBG N
clinical JJ N
success NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Restlessness JJ o
consistent JJ o
with IN o
akathisia NN o
was VBD N
noted VBN N
by IN N
35 CD N
% NN N
of IN N
the DT N
PC NN N
group NN N
and CC N
8 CD N
% NN N
of IN N
the DT N
OC NNP N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

At IN N
60 CD N
minutes NNS N
, , N
rescue NN o
medication NN o
was VBD N
required VBN N
by IN N
48 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
OC NNP N
group NN N
, , N
whereas RB N
10 CD N
% NN N
of IN N
the DT N
PC NNP N
group NN N
required VBD N
such JJ N
therapy NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

All DT p
44 CD p
patients NNS p
were VBD N
contacted VBN N
for IN N
follow-up NN N
at IN N
48 CD N
to TO N
72 CD N
hours NNS N
after IN N
enrollment NN N
. . N

At IN N
that DT N
time NN N
, , N
10 CD N
% NN N
of IN N
the DT N
prochlorperazine NN i
and CC N
25 CD N
% NN N
of IN N
the DT N
octreotide JJ i
patients NNS N
had VBD N
experienced VBN N
some DT N
headache NN o
recurrence NN o
( ( N
P NNP N
= NNP N
.1 NNP N
) ) N
. . N

CONCLUSION NNP N
Prochlorperazine NNP N
was VBD N
statistically RB N
superior JJ N
to TO N
octreotide VB N
in IN N
clinical JJ o
success NN o
rate NN o
and CC N
decrease NN N
in IN N
pain NN o
in IN N
migraine NN p
patients NNS p
but CC N
caused VBD N
more JJR N
restlessness NN o
and CC N
sedation NN o
. . o

-DOCSTART- -18485420- O O

Atypical JJ N
recruitment NN N
of IN N
medial JJ N
prefrontal JJ N
cortex NN N
in IN N
autism NN p
spectrum NN p
disorders NNS p
: : p
an DT N
fMRI NN i
study NN N
of IN N
two CD N
executive NN i
function NN i
tasks NNS i
. . i

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
an DT N
uneven JJ N
profile NN N
of IN N
executive JJ N
dysfunction NN N
in IN N
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

For IN N
example NN N
, , N
some DT N
authors NNS N
have VBP N
reported VBN N
deficits NNS N
on IN N
newly RB N
developed VBN N
tests NNS N
of IN N
executive NN N
function NN N
sensitive JJ N
to TO N
rostral JJ N
prefrontal JJ N
function NN N
, , N
despite IN N
spared VBN N
, , N
or CC N
even RB N
superior JJ N
, , N
performance NN N
on IN N
other JJ N
tests NNS N
. . N

We PRP N
investigated VBD N
the DT N
performance NN N
of IN N
a DT N
group NN N
of IN N
high-functioning JJ p
participants NNS p
with IN p
ASD NNP p
( ( p
N=15 NNP p
) ) p
and CC p
an DT p
age- JJ p
and CC p
IQ-matched JJ p
control NN p
group NN p
( ( p
N=18 NNP p
) ) p
on IN N
two CD i
executive NN i
function NN i
tests NNS i
, , N
whilst VBP N
undergoing JJ i
functional JJ i
magnetic JJ i
resonance NN i
imaging NN i
( ( i
fMRI NN i
) ) i
. . i

Behaviourally NNP N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
a DT N
classical JJ i
test NN i
of IN i
executive NN i
function NN i
( ( N
random JJ N
response NN N
generation NN N
) ) N
, , N
BOLD NNP o
signal NN o
differed VBD N
between IN N
the DT N
groups NNS N
in IN N
the DT N
cerebellum NN N
but CC N
not RB N
in IN N
the DT N
frontal JJ N
lobes NN N
. . N

However RB N
, , N
on IN N
a DT N
new JJ i
test NN i
of IN i
executive NN i
function NN i
( ( N
selection NN N
between IN N
stimulus-oriented JJ N
and CC N
stimulus-independent JJ N
thought NN N
) ) N
, , N
the DT N
ASD NNP N
group NN N
exhibited VBD N
significantly RB N
greater JJR N
signal-change NN o
in IN o
medial JJ o
rostral JJ o
prefrontal NN o
cortex NN o
( ( o
especially RB o
Brodmann NNP o
Area NNP o
10 CD o
) ) o
in IN N
the DT N
comparison NN N
of IN N
stimulus-oriented JJ N
versus NN N
stimulus-independent JJ N
attention NN N
. . N

In IN N
addition NN N
, , N
the DT N
new JJ N
test NN N
( ( N
but CC N
not RB N
the DT N
classical JJ N
test NN N
) ) N
provided VBD N
evidence NN N
for IN N
abnormal JJ o
functional JJ o
organisation NN o
of IN o
medial JJ o
prefrontal JJ o
cortex NN o
in IN o
ASD NNP o
. . o

These DT N
results NNS N
underline VBP N
the DT N
heterogeneity NN N
of IN N
different JJ N
tests NNS N
of IN N
executive NN N
function NN N
, , N
and CC N
suggest VBP N
that IN N
executive NN N
functioning NN N
in IN N
ASD NNP p
is VBZ N
associated VBN N
with IN N
task-specific JJ N
functional JJ N
change NN N
. . N

-DOCSTART- -6345111- O O

Double-blind NNP N
comparison NN N
of IN N
liquid NN i
antacid NN i
and CC i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
symptomatic JJ p
reflux NN p
esophagitis NN p
. . p

Although IN N
antacids NNS i
have VBP N
been VBN N
the DT N
mainstay NN N
of IN N
pharmacologic JJ N
therapy NN N
for IN N
reflux NN N
esophagitis NN N
, , N
their PRP$ N
effectiveness NN N
has VBZ N
not RB N
been VBN N
tested VBN N
in IN N
a DT N
placebo-controlled JJ i
double-blind JJ N
trial NN N
. . N

We PRP N
report VBP N
a DT N
double-blind JJ N
comparison NN N
of IN N
liquid JJ i
antacid NN i
vs NN i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
reflux NN N
esophagitis NN N
in IN N
32 CD p
patients NNS p
with IN p
chronic JJ p
heartburn NN p
. . p

Entry NN p
criteria NNS p
included VBD p
the DT p
presence NN p
of IN p
symptomatic JJ p
gastroesophageal NN p
reflux NN p
confirmed VBN p
by IN p
both DT p
an DT p
acid JJ p
perfusion NN p
( ( p
Bernstein NNP p
) ) p
test NN p
and CC p
by IN p
intraesophageal JJ p
pH NN p
probe NN p
. . p

Drug NNP N
treatment NN N
consisted VBD N
of IN N
15 CD N
ml NN N
( ( N
80 CD N
mEq NN N
) ) N
doses VBZ N
of IN N
antacid NN i
( ( i
Maalox NNP i
Therapeutic NNP i
Concentration NNP i
, , N
William NNP N
H. NNP N
Rorer NNP N
) ) N
or CC N
placebo VB i
taken VBN N
7 CD N
times NNS N
daily RB N
, , N
ie NN N
, , N
1 CD N
and CC N
3 CD N
hr NN N
after IN N
meals NNS N
and CC N
at IN N
bedtime NN N
. . N

Both DT N
groups NNS N
showed VBD N
significant JJ N
improvement NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
in IN N
both DT N
frequency NN o
and CC o
severity NN o
of IN o
heartburn NN o
. . o

The DT N
time NN o
to TO o
reproduce VB o
heartburn NN o
with IN N
the DT N
timed JJ N
Bernstein NNP N
test NN N
was VBD N
increased VBN N
with IN N
both DT N
active JJ i
drug NN i
and CC N
placebo NN i
therapy NN i
. . i

The DT N
mean JJ N
increase NN N
was VBD N
402 CD N
% NN N
( ( N
41 CD N
+/- JJ N
20 CD N
sec NN N
to TO N
169 CD N
+/- JJ N
66 CD N
sec NN N
) ) N
for IN N
the DT N
placebo NN N
group NN N
and CC N
286 CD N
% NN N
( ( N
42 CD N
+/- JJ N
16 CD N
to TO N
120 CD N
+/- JJ N
57 CD N
sec NN N
) ) N
in IN N
the DT N
antacid NN N
group NN N
. . N

Both CC N
the DT N
antacid NN i
and CC N
placebo NN i
groups NNS N
showed VBD N
improvement NN N
in IN N
the DT N
degree NN o
of IN o
esophagitis NN o
as IN N
assessed VBN N
endoscopically RB N
. . N

The DT N
current JJ N
study NN N
asked VBD N
: : N
does VBZ N
regular JJ N
antacid NN N
therapy NN N
have VBP N
a DT N
favorable JJ N
influence NN N
on IN N
the DT N
natural JJ N
history NN N
of IN N
symptomatic JJ o
reflux NN o
esophagitis NN o
, , N
ie NN N
, , N
does VBZ N
therapy VB N
heal NN N
or CC N
otherwise RB N
change NN N
esophagitis NN N
so IN N
that DT N
painful JJ N
episodes NNS N
are VBP N
either RB N
less RBR N
frequent JJ N
, , N
less RBR N
severe JJ N
, , N
or CC N
both DT N
? . N
We PRP N
found VBD N
that IN N
the DT N
natural JJ o
history NN o
of IN o
symptomatic JJ o
reflux NN o
esophagitis NN o
was VBD N
to TO N
improve VB N
with IN N
either DT N
antacid NN i
or CC N
placebo NN i
. . i

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
antacid NN i
or CC N
placebo NN i
on IN N
the DT N
( ( N
short-term JJ N
) ) N
natural JJ o
history NN o
of IN o
the DT o
disease NN o
. . o

-DOCSTART- -22124576- O O

Growth NNP N
hormone NN N
effects NNS N
on IN N
cortical JJ o
bone NN o
dimensions NNS o
in IN N
young JJ p
adults NNS p
with IN p
childhood-onset JJ p
growth NN p
hormone NN p
deficiency NN p
. . p

UNLABELLED JJ N
Growth NNP i
hormone NN i
( ( i
GH NNP i
) ) i
treatment NN i
in IN N
young JJ p
adults NNS p
with IN p
childhood-onset JJ p
GH NNP p
deficiency NN p
has VBZ N
beneficial JJ N
effects NNS N
on IN N
bone NN o
mass NN o
. . o

The DT N
present JJ N
study NN N
shows VBZ N
that IN N
cortical JJ N
bone NN N
dimensions NNS N
also RB N
benefit VBP N
from IN N
GH NNP N
treatment NN N
, , N
with IN N
endosteal JJ N
expansion NN N
and CC N
increased VBD N
cortical JJ N
thickness NN N
leading VBG N
to TO N
improved VBN o
bone NN o
strength NN o
. . o

INTRODUCTION NNP N
In IN p
young JJ p
adults NNS p
with IN p
childhood-onset JJ p
growth NN p
hormone NN p
deficiency NN p
( ( p
CO NNP p
GHD NNP p
) ) p
, , N
GH NNP N
treatment NN N
after IN N
final JJ N
height NN N
is VBZ N
reached VBN N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
beneficial JJ N
effects NNS N
on IN N
spine NN N
and CC N
hip NN N
bone NN N
mineral JJ N
density NN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
influence NN N
of IN N
GH NNP o
on IN o
cortical JJ o
bone NN o
dimensions NNS o
. . o

METHODS NNP N
Patients NNPS p
( ( p
n JJ p
= VBZ p
160 CD p
; : p
mean JJ p
age NN p
, , p
21.2 CD p
years NNS p
; : p
63 CD p
% NN p
males NNS p
) ) p
with IN p
CO NNP p
GHD NNP p
were VBD N
randomised VBN N
2:1 CD N
to TO i
GH NNP i
or CC i
no DT i
treatment NN i
for IN i
24 CD N
months NNS o
. . o

Cortical NNP o
bone NN o
dimensions NNS o
were VBD o
evaluated VBN o
by IN o
digital JJ o
x-ray JJ o
radiogrammetry NN o
of IN o
the DT o
metacarpal JJ N
bones NNS N
every DT N
6 CD N
months NNS N
. . N

RESULTS NNP N
After IN N
24 CD N
months NNS o
, , o
cortical JJ o
thickness NN o
was VBD o
increased VBN o
compared VBN N
with IN N
the DT N
controls NNS N
( ( N
6.43 CD N
% NN N
, , N
CI NNP N
3.34 CD N
to TO N
9.61 CD N
% NN N
; : N
p CC N
= VB N
0.0001 CD o
) ) o
and CC o
metacarpal JJ o
index NN o
( ( o
MCI NNP o
) ) o
( ( N
6.14 CD N
% NN N
, , N
CI NNP N
3.95 CD N
to TO N
8.38 CD N
% NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
, , N
while IN o
the DT o
endosteal JJ o
diameter NN o
decreased VBN o
( ( o
-4.64 CD o
% NN N
, , N
CI NNP N
-7.15 NNP N
to TO N
-2.05 VB N
; : N
p VB N
< $ N
0.001 CD N
) ) o
. . o

Total JJ o
bone NN o
width NN o
did VBD o
not RB N
change VB N
significantly RB N
( ( N
0.68 CD N
% NN N
, , N
CI NNP N
-1.17 NNP N
to TO N
2.57 CD N
% NN N
; : N
not RB N
significant JJ N
( ( N
NS NNP N
) ) N
) ) N
. . N

A DT N
gender NN N
effect NN N
was VBD N
seen VBN o
on IN o
bone NN o
width NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
endosteal JJ o
diameter NN o
( ( o
p JJ o
< NNP N
0.01 CD N
) ) N
and CC N
cortical JJ o
thickness NN o
( ( o
p JJ o
< NNP o
0.01 CD N
) ) N
, , N
but CC N
not RB N
with IN N
MCI NNP N
( ( N
NS NNP N
) ) N
. . N

CONCLUSIONS NNP N
Cortical NNP N
bone NN N
reacts VBZ N
promptly RB N
to TO N
reinstitution NN N
of IN N
GH NNP N
beyond IN N
the DT N
attainment NN N
of IN N
final JJ N
height NN N
by IN N
increasing VBG N
the DT o
cortical JJ o
thickness NN o
through IN o
endosteal JJ N
bone NN N
growth NN N
. . N

This DT N
leads VBZ o
to TO o
a DT o
higher JJR o
peak NN o
bone NN o
mass NN o
and CC o
may MD N
reduce VB o
the DT o
risk NN o
of IN o
cortical JJ o
bone NN o
fragility NN o
later RB N
in IN N
life NN N
. . N

-DOCSTART- -12553591- O O

Lack NN N
of IN N
benefit NN N
of IN N
intravenous JJ i
synthetic JJ i
human NN i
secretin NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
. . p

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
an DT N
intravenous JJ i
infusion NN i
of IN i
synthetic JJ i
human JJ i
secretin NN i
improves VBZ N
language NN o
and CC N
behavioral JJ o
symptoms NNS o
in IN N
children NNS p
with IN p
autism NN p
. . p

Forty-two JJ p
children NNS p
with IN p
the DT p
diagnosis NN p
of IN p
autism NN p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
in IN N
this DT N
double-blind JJ N
cross-over JJ N
trial NN N
. . N

One CD N
group NN N
received VBD N
2 CD i
IU/kg NNP i
of IN i
intravenous JJ i
synthetic JJ i
human NN i
secretin NN i
at IN N
the DT N
first JJ N
visit NN N
, , N
followed VBN N
by IN N
an DT N
equal JJ N
volume NN N
of IN N
intravenous JJ i
saline NN i
placebo NN i
at IN N
week NN N
6 CD N
. . N

The DT N
other JJ N
group NN N
received VBD N
treatments NNS N
in IN N
the DT N
reverse NN N
order NN N
. . N

All DT N
children NNS N
were VBD N
evaluated VBN N
at IN N
weeks NNS N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
with IN N
standardized JJ N
assessments NNS o
of IN o
language NN o
, , o
behavior NN o
, , o
and CC o
autism NN o
symptomatology NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
mean JJ o
scores NNS o
on IN o
any DT o
measure NN o
of IN o
language NN o
, , o
behavior NN o
, , o
or CC o
autism NN o
symptom JJ o
severity NN o
after IN N
treatment NN N
with IN N
secretin NN N
compared VBN N
to TO N
treatment NN N
with IN N
placebo NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
do VBP N
not RB N
support VB N
secretin NN N
as IN N
a DT N
treatment NN N
for IN N
autism NN N
. . N

-DOCSTART- -11205419- O O

Cognitive JJ o
performance NN o
and CC N
serotonergic JJ o
function NN o
in IN N
users NNS p
of IN p
ecstasy NN p
. . p

RATIONALE NNP N
( ( N
+/- JJ N
) ) N
3,4-Methylenedioxymethamphetamine CD i
( ( i
MDMA NNP i
or CC i
ecstasy NN i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
cause VB N
long JJ N
term NN N
damage NN N
to TO N
serotonergic VB N
cerebral JJ N
neurons NNS N
in IN N
animals NNS N
. . N

The DT N
neurotoxic JJ o
effects NNS o
in IN N
humans NNS p
are VBP N
less JJR N
clear JJ N
and CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
functional JJ N
consequences NNS N
, , N
although IN N
some DT N
studies NNS N
suggest VBP N
memory NN N
impairment NN N
. . N

Given VBN N
the DT N
widespread JJ N
use NN N
of IN N
MDMA NNP i
, , N
our PRP$ N
lack NN N
of IN N
knowledge NN N
raises NNS N
concerns NNS N
. . N

OBJECTIVE IN N
We PRP N
investigated VBD N
, , N
in IN N
humans NNS N
, , N
the DT N
relation NN N
between IN N
past JJ N
use NN N
of IN N
ecstasy NN N
and CC N
cognitive JJ N
performance NN N
as RB N
well RB N
as IN N
serotonergic JJ N
function NN N
. . N

METHODS NNP N
Two CD p
groups NNS p
of IN p
21 CD p
males NNS p
with IN p
moderate JJ p
and CC p
heavy JJ p
recreational JJ p
use NN p
of IN p
MDMA NNP i
, , p
respectively RB p
, , p
and CC p
a DT p
control NN p
group NN p
of IN p
20 CD p
males NNS p
without IN p
use NN p
of IN p
MDMA NNP i
were VBD p
compared VBN p
. . p

All DT N
were VBD N
from IN N
the DT N
same JJ p
subculture NN p
. . p

Reaction NN o
time NN o
, , o
direct JJ o
recall NN o
, , N
and CC N
recognition NN o
were VBD N
assessed VBN N
. . N

Serotonergic NNP o
function NN o
was VBD N
measured VBN N
by IN N
the DT N
neuro-endocrine JJ N
response NN N
to TO N
a DT N
placebo-controlled JJ i
, , N
crossover JJ N
challenge NN N
with IN N
dexfenfluramine NN i
. . i

RESULTS NNP N
Ecstasy NNP N
users NNS N
showed VBD N
a DT N
broad JJ N
pattern NN N
of IN N
statistically RB N
significant JJ N
, , N
but CC N
clinically RB N
small JJ o
, , o
impairment NN o
of IN o
memory NN o
and CC o
prolonged JJ o
reaction NN o
times NNS o
. . o

Heavy JJ N
users NNS N
were VBD N
affected JJ N
stronger JJR N
than IN N
moderate JJ N
users NNS N
. . N

Release NNP o
of IN o
cortisol NN o
but CC N
not RB N
of IN N
prolactin NN o
after IN N
dexfenfluramine JJ i
administration NN N
was VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
of IN N
ecstasy JJ N
users NNS N
compared VBN N
with IN N
the DT N
controls NNS N
. . N

Analyses NNS N
of IN N
covariance NN N
showed VBD N
that IN N
likely JJ N
confounding VBG N
variables NNS N
including VBG N
recent JJ N
exposure NN N
to TO N
ecstasy VB N
, , N
psychosocial JJ N
profiles NNS N
and CC N
use NN N
of IN N
other JJ N
drugs NNS N
did VBD N
not RB N
explain VB N
the DT N
differences NNS N
found VBD N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
provide VBP N
further JJ N
evidence NN N
that IN N
use NN N
of IN N
ecstasy NN N
may MD N
be VB N
associated VBN N
with IN N
impairment NN o
of IN o
memory NN o
and CC o
of IN o
serotonergic JJ o
function NN o
. . o

These DT N
findings NNS N
are VBP N
compatible JJ N
with IN N
neurotoxicity NN o
of IN N
ecstasy NN N
as IN N
shown VBN N
in IN N
animals NNS N
. . N

-DOCSTART- -11579299- O O

Induction NNP i
versus NN N
noninduction NN i
in IN N
renal JJ p
transplant NN p
recipients NNS p
with IN p
tacrolimus-based JJ p
immunosuppression NN p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
induction NN N
treatment NN N
with IN N
antithymocyte NN i
globulins NNS i
( ( i
ATG NNP i
) ) i
followed VBN N
by IN N
tacrolimus JJ i
therapy NN N
with IN N
immediate JJ N
tacrolimus NNS N
therapy NN N
in IN N
renal JJ p
transplant NN p
recipients NNS p
. . p

METHODS NNP N
This DT N
12-month JJ N
, , N
open JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
in IN N
15 CD p
centers NNS p
in IN p
France NNP p
and CC p
1 CD p
center NN p
in IN p
Belgium NNP p
; : p
309 CD p
patients NNS p
were VBD p
randomized VBN p
to TO p
receive VB p
either DT p
induction NN i
therapy NN i
with IN i
ATG NNP i
( ( p
n=151 NN p
) ) p
followed VBN p
by IN p
initiation NN p
of IN p
tacrolimus NN i
on IN p
day NN p
9 CD p
or CC p
immediate JJ p
tacrolimus-based JJ i
triple NN i
therapy NN i
( ( p
n=158 JJ p
) ) p
. . p

In IN N
both DT N
study NN N
arms NNS N
, , N
the DT N
initial JJ N
daily JJ N
tacrolimus NN i
dose NN N
was VBD N
0.2 CD N
mg/kg NN N
. . N

Steroid JJ i
boluses NNS i
were VBD N
given VBN N
in IN N
the DT N
first JJ N
2 CD N
days NNS N
and CC N
tapered JJ N
thereafter NN N
from IN N
20 CD N
mg/day NN N
to TO N
5 CD N
mg/day NN N
. . N

Azathioprine NNP i
was VBD N
administered VBN N
at IN N
1-2 JJ N
mg/kg NNS N
per IN N
day NN N
. . N

RESULTS NNP N
At IN N
month NN N
12 CD N
, , N
biopsy-confirmed JJ o
acute NN o
rejections NNS o
were VBD N
reported VBN N
for IN N
15.2 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
30.4 CD N
% NN N
( ( N
noninduction NN N
) ) N
of IN N
patients NNS N
( ( N
P=0.001 NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
steroid-sensitive JJ o
acute JJ o
rejections NNS o
was VBD N
7.9 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
22.2 CD N
% NN N
( ( N
noninduction NN N
) ) N
( ( N
P=0.001 NNP N
) ) N
. . N

Steroid-resistant JJ o
acute JJ o
rejections NNS o
were VBD N
reported VBN N
for IN N
8.6 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
8.9 CD N
% NN N
( ( N
noninduction NN N
) ) N
of IN N
patients NNS N
. . N

A DT N
total NN N
of IN N
nine CD N
patients NNS N
died VBD o
. . o

Patient NNP o
survival NN o
and CC o
graft NN o
survival NN o
at IN N
month NN N
12 CD N
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
( ( N
97.4 CD N
% NN N
vs. FW N
96.8 CD N
% NN N
and CC N
92.1 CD N
% NN N
vs. FW N
91.1 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Statistically NNP N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN o
of IN o
adverse JJ o
events NNS o
were VBD N
found VBN N
for IN N
cytomegalovirus NN o
( ( o
CMV NNP o
) ) o
infection NN o
( ( N
induction NN N
, , N
32.5 CD N
% NN N
vs. FW N
noninduction NN N
, , N
19.0 CD N
% NN N
, , N
P=0.009 NNP N
) ) N
, , N
leukopenia NN o
( ( N
37.3 CD N
% NN N
vs. FW N
9.5 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
fever RB o
( ( N
25.2 CD N
% NN N
vs. FW N
10.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
herpes VBZ o
simplex JJ o
( ( N
17.9 CD N
% NN N
vs. FW N
5.7 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
thrombocytopenia NN o
( ( N
11.3 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
, , N
P=0.007 NNP N
) ) N
. . N

In IN N
the DT N
induction NN N
group NN N
, , N
serum NN o
sickness NN o
was VBD N
observed VBN N
in IN N
10.6 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
incidence NN N
of IN N
new JJ o
onset NN o
diabetes NNS o
mellitus NN o
was VBD N
3.4 CD N
% NN N
( ( N
induction NN N
) ) N
and CC N
4.5 CD N
% NN N
( ( N
noninduction NN N
) ) N
. . N

CONCLUSION NNP N
Low NNP N
incidences NNS N
of IN N
acute JJ o
rejection NN o
were VBD N
found VBN N
in IN N
both DT N
treatment NN N
arms NNS N
. . N

Induction NNP N
treatment NN N
with IN N
ATG NNP i
has VBZ N
the DT N
advantage NN N
of IN N
a DT N
lower JJR N
incidence NN N
of IN N
acute JJ N
rejection NN N
, , N
but CC N
it PRP N
significantly RB N
increases VBZ N
adverse JJ o
events NNS o
, , N
particularly RB N
CMV NNP o
infection NN o
. . o

-DOCSTART- -9180065- O O

Randomised VBN N
controlled JJ N
trial NN N
of IN N
graded JJ i
exercise NN i
in IN N
patients NNS p
with IN p
the DT p
chronic JJ o
fatigue NN o
syndrome NN o
. . o

OBJECTIVE UH N
To TO N
test VB N
the DT N
efficacy NN N
of IN N
a DT N
graded JJ i
aerobic JJ i
exercise NN i
programme NN i
in IN N
the DT N
chronic JJ o
fatigue NN o
syndrome NN o
. . o

DESIGN NNP N
Randomised VBD N
controlled VBN N
trial NN N
with IN N
control NN N
treatment NN N
crossover NN N
after IN N
the DT N
first JJ N
follow VB N
up RP N
examination NN N
. . N

SETTING NN N
Chronic NNP N
fatigue NN N
clinic NN N
in IN N
a DT N
general JJ N
hospital NN N
department NN N
of IN N
psychiatry NN N
. . N

SUBJECTS NNP N
66 CD p
patients NNS p
with IN p
the DT p
chronic JJ p
fatigue NN p
syndrome NN p
who WP p
had VBD p
neither CC p
a DT p
psychiatric JJ p
disorder NN p
nor CC p
appreciable JJ p
sleep JJ p
disturbance NN p
. . p

INTERVENTIONS NNP N
Random NNP N
allocation NN N
to TO N
12 CD N
weeks NNS N
of IN N
either DT N
graded VBN i
aerobic NN i
exercise NN i
or CC N
flexibility NN i
exercises NNS i
and CC i
relaxation NN i
therapy NN i
. . i

Patients NNS N
who WP N
completed VBD N
the DT N
flexibility NN i
programme NN i
were VBD N
invited VBN N
to TO N
cross VB N
over IN N
to TO N
the DT N
exercise NN i
programme NN i
afterwards NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT o
self NN o
rated VBN o
clinical JJ o
global JJ o
impression NN o
change NN o
score NN o
, , o
very RB o
much JJ o
better RBR o
or CC o
much RB o
better JJR o
being VBG o
considered VBN o
as IN o
clinically RB o
important JJ o
. . o

RESULTS VB N
Four CD N
patients NNS N
receiving VBG N
exercise NN i
and CC N
three CD N
receiving VBG N
flexibility NN i
treatment NN i
dropped VBD N
out RP N
before IN N
completion NN N
. . N

15 CD N
of IN N
29 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR N
after IN N
completing VBG N
exercise NN i
treatment NN i
compared VBN N
with IN N
eight CD N
of IN N
30 CD N
patients NNS N
who WP N
completed VBD N
flexibility NN i
treatment NN i
. . i

Analysis NN N
by IN N
intention NN N
to TO N
treat VB N
gave VBD N
similar JJ N
results NNS N
( ( N
17/33 CD N
v RB N
9/33 CD N
patients NNS N
better RBR N
) ) N
. . N

Fatigue NNP o
, , o
functional JJ o
capacity NN o
, , o
and CC o
fitness NN o
were VBD N
significantly RB N
better RBR N
after IN N
exercise NN i
than IN N
after IN N
flexibility NN i
treatment NN i
. . i

12 CD N
of IN N
22 CD N
patients NNS N
who WP N
crossed VBD N
over IN N
to TO N
exercise VB i
after IN N
flexibility NN N
treatment NN N
rated VBN N
themselves PRP N
as IN N
better JJR N
after IN N
completing VBG N
exercise NN N
treatment NN N
32 CD N
of IN N
47 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR N
three CD N
months NNS N
after IN N
completing VBG N
supervised JJ N
exercise NN i
treatment NN i
35 CD N
of IN N
47 CD N
patients NNS N
rated VBN N
themselves PRP N
as IN N
better JJR o
one CD N
year NN N
after IN N
completing VBG N
supervised JJ i
exercise NN i
treatment NN i
. . i

CONCLUSION NNP N
These DT N
findings NNS N
support VBP N
the DT N
use NN N
of IN N
appropriately RB N
prescribed VBN N
graded VBN i
aerobic JJ i
exercise NN i
in IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
the DT p
chronic JJ p
fatigue NN p
syndrome NN p
. . p

-DOCSTART- -19143691- O O

Ondansetron NNP i
has VBZ N
similar JJ N
clinical JJ o
efficacy NN o
against IN N
both DT N
nausea NN o
and CC N
vomiting NN o
. . o

Ondansetron NNP i
is VBZ N
widely RB N
believed VBN N
to TO N
prevent VB N
postoperative JJ N
vomiting VBG o
more RBR N
effectively RB N
than IN N
nausea NN o
. . o

We PRP p
analysed VBD p
data NNS p
from IN p
5161 CD p
patients NNS p
undergoing VBG p
general JJ p
anaesthesia NN i
who WP N
were VBD N
randomly RB N
stratified VBN N
to TO N
receive VB N
a DT N
combination NN N
of IN N
six CD N
interventions NNS N
, , N
one CD N
of IN N
which WDT N
was VBD N
4 CD N
mg NN N
ondansetron NN i
vs NN i
placebo NN i
. . i

For IN N
the DT N
purpose NN N
of IN N
this DT N
study NN N
a DT N
20 CD N
% NN N
difference NN N
in IN N
the DT N
relative JJ N
risks NNS N
for IN N
the DT N
two CD N
outcomes NNS N
was VBD N
considered VBN N
clinically RB N
relevant JJ N
. . N

Nausea NN o
was VBD N
reduced VBN N
from IN N
38 CD N
% NN N
( ( N
969/2585 CD N
) ) N
in IN N
the DT N
control NN N
to TO N
28 CD N
% NN N
( ( N
715/2576 CD N
) ) N
in IN N
the DT N
ondansetron NN i
group NN N
, , N
corresponding VBG N
to TO N
a DT N
relative JJ N
risk NN N
of IN N
0.74 CD N
, , N
or CC N
a DT N
relative JJ N
risk NN N
reduction NN N
of IN N
26 CD N
% NN N
. . N

Vomiting NNP o
was VBD N
reduced VBN N
from IN N
17 CD N
% NN N
( ( N
441/2585 CD N
) ) N
to TO N
11 CD N
% NN N
( ( N
293/2576 CD N
) ) N
, , N
corresponding VBG N
to TO N
a DT N
relative JJ N
risk NN N
of IN N
0.67 CD N
, , N
or CC N
a DT N
relative JJ N
risk NN N
reduction NN N
of IN N
33 CD N
% NN N
. . N

The DT N
relative JJ N
risks NNS N
of IN N
0.67 CD N
and CC N
0.74 CD N
were VBD N
clinically RB N
similar JJ N
and CC N
the DT N
difference NN N
between IN N
them PRP N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

We PRP N
thus RB N
conclude VBP N
that IN N
ondansetron NN i
prevents NNS N
postoperative JJ o
nausea NN o
and CC o
postoperative JJ o
vomiting NN o
equally RB N
well RB N
. . N

-DOCSTART- -11395821- O O

Laparoscopic NNP i
vs NN N
open JJ i
appendectomy NN i
in IN N
overweight JJ p
patients NNS p
. . p

BACKGROUND NNP N
Laparoscopic NNP i
appendectomy NN i
( ( i
LA NNP i
) ) i
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
faster JJ N
recovery NN N
and CC N
less RBR N
postoperative JJ N
pain NN N
than IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
few JJ N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
clinical JJ N
outcome NN N
of IN N
LA NNP i
in IN N
overweight JJ p
patients NNS p
. . p

METHODS NNP N
A NNP p
group NN p
of IN p
106 CD p
patients NNS p
with IN p
a DT p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
) ) p
> VBD p
26.4 CD p
, , p
representing VBG p
the DT p
upper JJ p
quintile NN p
of IN p
500 CD p
prospectively RB p
randomized JJ p
patients NNS p
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

They PRP N
were VBD N
randomized VBN N
to TO N
undergo VB N
either DT N
laparoscopic NN i
or CC i
open JJ i
appendectomy NN i
( ( i
OA NNP i
) ) i
. . i

Operating NN o
and CC o
anesthesia NN o
times NNS o
, , o
postoperative JJ o
pain NN o
, , o
complications NNS o
, , o
hospital NN o
stay NN o
, , o
functional JJ o
index NN o
( ( N
1 CD N
week NN N
postoperatively RB N
) ) N
, , N
sick JJ o
leave VBP o
, , o
and CC o
time NN o
to TO o
full JJ o
recovery NN o
were VBD N
documented VBN N
. . N

RESULTS NNP N
In IN N
OA NNP i
, , N
the DT N
operating NN o
time NN o
for IN N
overweight JJ o
patients NNS p
was VBD N
significantly RB N
longer JJR N
than IN N
that DT N
for IN N
patients NNS N
in IN N
the DT N
normal JJ N
weight NN N
range NN N
( ( N
40 CD N
vs RB N
35 CD N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
LA NNP i
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
operating NN o
time NN o
between IN N
the DT N
normal JJ N
and CC N
overweight JJ N
patients NNS N
. . N

Overweight JJ N
patients NNS N
who WP N
underwent JJ N
LA NNP i
had VBD N
longer RBR N
operating NN o
and CC o
anesthesia NN o
times NNS o
than IN N
their PRP$ N
OA NNP i
counterparts NNS N
( ( N
55 CD N
vs RB N
40 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
; : N
and CC N
125 CD N
vs NN N
100 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

Postoperative JJ o
pain NN o
was VBD N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP i
than IN N
in IN N
those DT N
treated VBN N
with IN N
the DT N
laparoscopic NN i
technique NN i
. . i

Postoperative JJ o
pain NN o
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP i
than IN N
in IN N
patients NNS N
of IN N
normal JJ N
weight NN N
after IN N
4 CD N
weeks NNS N
; : N
the DT N
clinical JJ N
significance NN N
may MD N
, , N
however RB N
, , N
be VB N
of IN N
less JJR N
importance NN N
since IN N
the DT N
values NNS N
are VBP N
low JJ N
( ( N
0.26 CD N
vs NN N
0.09 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
operating VBG N
techniques NNS N
in IN N
terms NNS N
of IN N
complications NNS N
. . N

Hospital NNP o
stay NN o
was VBD N
longer JJR N
for IN N
overweight NN N
patients NNS N
than IN N
for IN N
normal-weight JJ N
patients NNS N
undergoing VBG N
OA NNP i
( ( N
3.0 CD N
vs NN N
2.0 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
functional JJ N
index NN N
did VBD N
not RB N
differ VB N
between IN N
any DT N
group NN N
of IN N
patients NNS N
. . N

Sick NNP o
leave NN o
was VBD N
longer JJR N
for IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP i
than IN N
for IN N
normal-weight JJ N
patients NNS N
treated VBN N
with IN N
the DT N
same JJ N
technique NN N
( ( N
17 CD N
vs RB N
13 CD N
days NNS N
, , N
p VBP N
< RB N
0.01 CD N
) ) N
. . N

In IN N
the DT N
laparoscopic NN i
group NN N
, , N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
overweight NN p
and CC p
normal-weight JJ p
patients NNS p
. . p

Time NN o
to TO o
full JJ o
recovery NN o
was VBD N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP i
than IN N
in IN N
the DT N
overweight JJ N
patients NNS N
in IN N
the DT N
LA NNP i
group NN N
( ( N
22 CD N
vs RB N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
, , N
overweight JJ N
patients NNS N
who WP N
were VBD N
submitted VBN N
to TO N
LA NNP i
had VBD N
less RBR N
postoperative JJ o
pain NN o
and CC N
a DT N
faster RBR N
postoperative JJ o
recovery NN o
than IN N
overweight JJ N
patients NNS N
who WP N
had VBD N
OA NNP i
. . i

LA NNP i
also RB N
abolished VBD N
some DT N
of IN N
the DT N
negative JJ N
effects NNS N
that WDT N
overweight VBD N
had VBD N
on IN N
operating NN o
time NN o
, , o
hospital NN o
stay NN o
, , o
and CC o
sick JJ o
leave NN o
with IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
anesthesia NN N
and CC N
operating NN N
times NNS N
were VBD N
significantly RB N
longer RBR N
in IN N
LA NNP i
for IN N
both DT N
overweight JJ N
patients NNS N
and CC N
those DT N
with IN N
a DT N
normal JJ N
BMI NNP N
. . N

-DOCSTART- -19641009- O O

Design NNP N
, , N
implementation NN N
and CC N
results NNS N
of IN N
the DT N
quality NN N
control NN N
program NN N
for IN N
the DT N
Australian JJ N
government NN N
's POS N
point NN N
of IN N
care NN N
testing VBG N
in IN N
general JJ N
practice NN N
trial NN N
. . N

BACKGROUND NN N
From IN N
2005 CD N
to TO N
2007 CD N
the DT N
Australian JJ N
Government NNP N
funded VBD N
a DT N
multicentre NN N
, , N
clustered VBD N
randomized VBN N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
clinical JJ N
effectiveness NN N
, , N
cost-effectiveness NN N
, , N
satisfaction NN N
and CC N
safety NN N
of IN N
point NN N
of IN N
care NN N
testing VBG N
( ( N
PoCT NNP N
) ) N
in IN N
general JJ N
practice NN N
( ( N
GP NNP N
) ) N
. . N

PoC NNP N
tests NNS N
measured VBD N
( ( N
and CC N
devices NNS N
used VBN N
) ) N
in IN N
the DT N
trial NN N
were VBD N
haemoglobin JJ o
A1c NNP o
and CC o
urine JJ o
albumin NN o
: : o
creatinine NN o
ratio NN o
( ( o
DCA NNP o
2000 CD o
) ) o
, , o
lipids NNS o
( ( o
Cholestech NNP o
LDX NNP o
) ) o
and CC o
international JJ o
normalized VBN o
ratio NN o
( ( o
CoaguChek NNP o
S NNP o
) ) o
. . o

METHODS NNP N
An DT N
internal JJ N
quality NN N
control NN N
( ( N
QC NNP N
) ) N
program NN N
was VBD N
developed VBN N
as IN N
part NN N
of IN N
a DT N
quality NN N
management NN N
framework NN N
for IN N
the DT N
trial NN N
. . N

PoCT NNP p
device NN p
operators NNS p
were VBD N
provided VBN N
with IN N
a DT N
colour-coded JJ i
QC NNP i
Result NNP i
Sheet NNP i
and CC i
QC NNP i
Action NNP i
Sheet NNP i
for IN i
on-site JJ i
recording NN i
and CC i
interpreting NN i
of IN i
their PRP$ i
results NNS i
. . i

Within-practice JJ N
imprecision NN N
for IN N
QC NNP N
testing NN N
was VBD N
calculated VBN N
and CC N
compared VBN N
with IN N
the DT N
analytical JJ N
goals NNS N
for IN N
imprecision NN N
set VBN N
prior RB N
to TO N
the DT N
trial NN N
. . N

RESULTS VB N
The DT N
average JJ N
participation NN N
rate NN N
for IN N
QC NNP N
testing NN N
was VBD N
91 CD N
% NN N
or CC N
greater JJR N
. . N

Median JJ o
within-practice JJ o
imprecision NN o
met VBD N
the DT N
analytical JJ N
goals NNS N
for IN N
all DT N
PoC NNP N
tests NNS N
, , N
except IN N
for IN N
high-density NN o
lipoprotein-cholesterol NN o
( ( o
HDL-C NNP o
) ) o
where WRB N
observed JJ N
performance NN N
was VBD N
outside IN N
the DT N
minimum JJ N
goal NN N
for IN N
one CD N
level NN N
and CC N
one CD N
lot NN N
number NN N
of IN N
QC NNP N
. . N

Most JJS N
practices NNS N
achieved VBD N
the DT N
imprecision NN o
goals NNS N
for IN N
all DT N
analytes NNS N
, , N
with IN N
the DT N
principal JJ N
exception NN N
of IN N
HDL-C NNP o
. . o

CONCLUSIONS NNP N
Results NNP N
from IN N
QC NNP N
testing VBG N
indicate NN N
that WDT N
PoCT NNP N
in IN N
the DT N
GP NNP N
trial NN N
met VBD N
the DT N
analytical JJ N
goals NNS N
set VBN N
for IN N
the DT N
trial NN N
, , N
with IN N
the DT N
exception NN N
of IN N
HDL-C NNP N
. . N

-DOCSTART- -998549- O O

Adequacy NN N
of IN N
vitamin NN i
B6 NNP i
supplementation NN i
during IN N
pregnancy NN p
: : p
a DT N
prospective JJ N
study NN N
. . N

This DT N
prospective JJ N
study NN N
assesses VBZ N
the DT N
effect NN N
of IN N
2.5 CD i
, , i
4 CD i
, , i
and CC i
10 CD i
mg NN i
of IN i
pyridoxine JJ i
supplementation NN i
during IN i
pregnancy NN i
on IN i
maternal JJ o
and CC o
fetal JJ o
plasma NN o
levels NNS o
of IN o
pyridoxal NN o
5'-phosphate JJ o
( ( o
PLP NNP o
) ) o
and CC N
on IN N
the DT N
degree NN o
of IN o
coenzyme NN o
saturation NN o
( ( o
activation JJ o
factor NN o
) ) o
of IN o
aspartate NN o
aminotransferase NN o
and CC o
alanine JJ o
aminotransferase NN o
( ( o
alphaEGOT JJ o
and CC o
alphaEGPT NN o
) ) o
in IN o
maternal JJ o
erythrocytes NNS o
. . o

More JJR N
than IN N
4 CD i
mg NN i
of IN i
pyridoxine JJ i
supplementation NN i
daily RB i
was VBD N
required VBN N
for IN N
most JJS N
pregnancies NNS N
to TO N
maintain VB N
maternal JJ o
plasma NN o
PLP NNP o
levels NNS o
within IN N
the DT N
range NN N
observed VBD N
during IN N
the DT N
first JJ N
trimester NN N
and CC N
in IN N
the DT N
nonpregnant JJ N
state NN N
. . N

The DT N
plasma NN o
PLP NNP o
concentrations NNS o
in IN o
maternal JJ o
and CC o
cord JJ o
blood NN o
were VBD N
highly RB N
correlated VBN N
and CC N
indicated VBD N
a DT N
dependence NN N
of IN N
fetal JJ N
vitamin NN N
B6 NNP N
nutrition NN N
on IN N
maternal JJ N
circulating NN N
PLP NNP N
. . N

Measurements NNS o
of IN o
alphaEGOT NN o
and CC o
alphaEGPT NN o
were VBD N
not RB N
as RB N
reproducible JJ N
as IN N
plasma JJ o
PLP NNP o
assays NNS o
and CC N
were VBD N
less RBR N
sensitive JJ N
and CC N
quantitative JJ N
indicators NNS N
. . N

In IN N
the DT N
majority NN N
of IN N
subjects NNS N
, , N
the DT N
changes NNS o
in IN o
alphaEGOT NN o
and CC o
alphaEGPT NN o
with IN N
time NN N
correlated VBN N
poorly RB N
with IN N
the DT N
changes NNS N
in IN N
plasma NN o
PLP NNP o
. . o

However RB N
, , N
when WRB N
the DT N
data NNS N
were VBD N
analyzed VBN N
without IN N
regard NN N
for IN N
their PRP$ N
dependence NN N
on IN N
time NN N
, , N
they PRP N
demonstrated VBD N
a DT N
negative JJ N
, , N
linear JJ N
correlation NN N
between IN N
alphaEGOT NN o
and CC N
log NN N
plasma NN o
PLP NNP o
and CC N
between IN N
alphaEGPT NN o
and CC o
log NN o
plasma NN o
PLP NNP o
for IN N
the DT N
group NN N
on IN N
2.5 CD N
mg NN N
of IN N
pyridoxine NN i
and CC N
for IN N
all PDT N
the DT N
subjects NNS N
combined VBN N
. . N

Finally RB N
, , N
the DT N
dietary NN N
records NNS N
showed VBD N
that IN N
most JJS N
of IN N
the DT N
subjects NNS N
consumed VBD N
less JJR N
than IN N
2 CD N
mg NN N
of IN N
vitamin JJ i
B6 NNP i
daily RB N
from IN N
their PRP$ N
food NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
current JJ N
Recommended NNP N
Dietary NNP N
Allowance NNP N
for IN N
vitamin NN i
B6 NNP i
during IN N
pregnancy NN N
( ( N
2.5 CD N
mg NN N
) ) N
is VBZ N
too RB N
low JJ N
and CC N
that DT N
supplementation NN N
of IN N
this DT N
vitamin NN N
in IN N
an DT N
amount NN N
more JJR N
than IN N
4 CD N
mg JJ N
daily JJ N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -23394513- O O

Antihistamines NNS i
do VBP N
not RB N
inhibit VB N
the DT N
wheal NN N
induced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
autologous JJ N
serum NN N
in IN N
resistant JJ N
chronic JJ N
idiopathic JJ N
urticaria NN N
. . N

Some DT N
patients NNS p
with IN p
chronic JJ p
idiopathic JJ p
urticaria NN p
( ( p
CIU NNP p
) ) p
are VBP N
resistant JJ N
to TO N
conventional JJ N
doses NNS N
of IN N
antihistamines NNS i
( ( i
AHs NNP i
) ) i
. . i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
check VB N
whether IN N
the DT N
skin JJ o
wheal NN o
and CC o
flare JJ o
reaction NN o
produced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
autologous JJ i
serum NN i
( ( i
AS IN i
) ) i
and CC N
by IN N
histamine NN i
differs NNS N
in IN N
AH-resistant NNP p
and CC p
AH NNP p
responder VBP p
CIU NNP p
patients NNS p
. . p

CIU NNP p
patients NNS p
with IN p
treatment NN p
failure NN p
under IN p
fexofenadine NN i
at IN p
180 CD p
mg NN p
q.d NN p
. . p

increased VBD i
their PRP$ i
daily JJ i
dose NN i
of IN N
AH NNP N
to TO N
4 CD N
tablets NNS N
daily RB N
. . N

Those DT p
with IN p
significant JJ p
improvement NN p
of IN p
urticaria JJ p
activity NN p
score NN p
under IN p
fexofenadine NN i
at IN p
180 CD p
mg NNS p
were VBD N
included VBN N
in IN N
the DT N
CIU NNP N
group NN N
. . N

Subjects VBZ N
with IN N
treatment NN N
failure NN N
despite IN N
a DT N
full JJ N
8-week JJ N
fourfold JJ N
fexofenadine NN i
treatment NN N
were VBD N
included VBN N
in IN N
the DT N
resistant JJ N
CIU NNP N
( ( N
R-CIU NNP N
group NN N
) ) N
. . N

The DT p
control NN p
group NN p
consisted VBD p
of IN p
sex- JJ p
and CC p
age-matched JJ p
patents NNS p
with IN p
allergic JJ p
rhinitis NN p
. . p

The DT N
AS NNP N
skin JJ N
test NN N
and CC N
intradermal JJ N
histamine-induced JJ i
wheal NN N
and CC N
flare JJ N
reaction NN N
were VBD N
performed VBN N
at IN N
baseline NN N
( ( N
without IN N
AH NNP N
) ) N
, , N
after IN N
8 CD N
and CC N
16 CD N
weeks NNS N
( ( N
under IN N
AH NNP N
treatment NN N
) ) N
. . N

Forty-six JJ p
subjects NNS p
were VBD p
included VBN p
in IN p
the DT p
CIU NNP p
group NN p
, , p
21 CD p
were VBD p
in IN p
the DT p
R-CIU NNP p
group NN p
, , p
and CC p
44 CD p
were VBD p
in IN p
the DT p
control NN p
group NN p
. . p

Under IN N
AH NNP N
therapy NN N
, , N
the DT N
skin JJ o
reaction NN o
to TO o
intradermal VB o
histamine JJ o
injection NN o
was VBD N
significantly RB N
diminished VBN N
in IN N
all DT N
study NN N
groups NNS N
. . N

In IN N
the DT N
R-CIU NNP N
group NN N
, , N
fexofenadine NN i
at IN N
180 CD N
mg NNS N
did VBD N
not RB N
suppress VB N
AS-induced NNP o
wheal JJ o
reaction NN o
( ( N
5.96 CD N
? . N
2.25 CD N
mm NN N
; : N
p CC N
= VB N
0.85 CD N
) ) N
, , N
and CC N
with IN N
a DT N
fourfold JJ i
AH NNP i
dose VB N
some DT o
reduction NN o
of IN o
AS-induced NNP o
wheal NN o
( ( N
3.79 CD N
? . N
1.74 CD N
mm NN N
; : N
p CC N
= VB N
0.008 CD N
) ) N
was VBD N
observed VBN N
but CC N
remained VBD N
larger JJR N
than IN N
in IN N
the DT N
CIU NNP N
( ( N
2.31 CD N
? . N
1.12 CD N
; : N
p NN N
= VBZ N
0.006 CD N
) ) N
and CC N
control NN N
groups NNS N
( ( N
2.52 CD N
? . N
1.36 CD N
; : N
p NN N
= VBZ N
0.037 CD i
) ) i
. . i

AHs NNP i
do VBP N
not RB N
inhibit VB N
the DT N
wheal NN N
induced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
AS NNP N
in IN N
R-CIU NNP N
. . N

-DOCSTART- -10706930- O O

The DT N
effects NNS N
of IN N
hormone NN i
replacement NN i
therapy NN i
on IN N
hemostatic JJ N
variables NNS N
in IN N
women NNS p
with IN p
angiographically RB p
verified VBN p
coronary JJ p
artery NN p
disease NN p
: : p
results NNS N
from IN N
the DT N
estrogen NN N
in IN N
women NNS p
with IN p
atherosclerosis NN p
study NN p
. . p

Data NNP N
on IN N
the DT N
effect NN N
of IN N
hormone NN i
replacement NN i
therapy NN i
on IN N
hemostasis NN N
are VBP N
inconsistent JJ N
, , N
and CC N
there EX N
are VBP N
few JJ N
data NNS N
in IN N
women NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

In IN N
a DT N
single-center NN N
, , N
open JJ N
, , N
randomized VBN N
study NN N
, , N
118 CD p
postmenopausal JJ p
women NNS p
with IN p
angiographically RB p
verified VBN p
coronary JJ p
artery NN p
disease NN p
were VBD N
randomized VBN N
to TO N
hormone VB N
replacement NN N
therapy NN N
, , N
given VBN N
as IN N
long-cycle JJ i
transdermal JJ i
17-beta-estradiol JJ i
( ( N
50 CD N
microg/24 RB N
hour NN N
) ) N
for IN N
3 CD N
months NNS N
with IN N
sequential JJ i
medroxy-progesterone NN i
acetate NN i
for IN N
14 CD N
days NNS N
, , N
or CC N
to TO N
a DT N
control NN i
group NN N
receiving VBG i
no DT i
therapy NN i
. . i

Hemostatic JJ N
parameters NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
3 CD N
and CC N
12 CD N
months NNS N
of IN N
therapy NN N
. . N

The DT N
coagulation NN o
inhibitors NNS o
antithrombin VBP o
, , o
protein JJ o
C NNP o
, , o
and CC o
protein NN o
S NNP o
, , N
but CC N
not RB N
tissue VB o
factor NN o
pathway NN o
inhibitor NN o
, , N
decreased VBN N
significantly RB N
from IN N
baseline NN N
in IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
at IN N
both DT N
3 CD N
and CC N
12 CD N
months NNS N
as IN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

The DT N
absolute NN N
decreases VBZ N
within IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
were VBD N
3 CD N
to TO N
10 CD N
% NN N
. . N

No DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
were VBD N
observed VBN N
for IN N
the DT N
coagulation NN o
products NNS o
prothrombin VBP o
fragment JJ o
1+2 CD o
or CC o
thrombin-antithrombin JJ o
complex NN o
or CC o
for IN o
D-dimer NNP o
, , N
although IN N
there EX N
were VBD N
significant JJ N
decreases NNS N
in IN N
the DT N
levels NNS N
within IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
. . N

Levels NNP o
of IN o
fibrinogen NN o
, , o
activated VBD o
factor NN o
VII NNP o
, , o
and CC o
factor NN o
VII NNP o
antigen NN o
were VBD N
not RB N
significantly RB N
influenced VBN N
by IN N
hormone NN N
replacement NN N
therapy NN N
treatment NN N
. . N

Similarly RB N
, , N
nonsignificant JJ N
changes NNS N
were VBD N
detected VBN N
for IN N
the DT N
fibrinolytic JJ o
parameters NNS o
tissue VBP o
plasminogen JJ o
activator NN o
activity NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
antigen NN o
, , o
and CC o
global JJ o
fibrinolytic JJ o
activity NN o
, , o
but CC o
plasminogen NN o
activator NN o
inhibitor NN o
type VBD o
1 CD o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
hormone NN N
replacement NN N
therapy NN N
group NN N
due JJ N
to TO N
a DT N
questionable JJ N
increase NN N
in IN N
the DT N
levels NNS N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
treatment NN N
with IN N
transdermal JJ i
estradiol NNS i
combined VBN i
with IN i
long-cycle NN i
progestins NNS i
was VBD N
associated VBN N
with IN N
no DT N
net JJ N
activation NN o
of IN o
coagulation NN o
despite IN N
reduced JJ N
levels NNS N
of IN N
coagulation NN o
inhibitors NNS o
. . o

-DOCSTART- -16670650- O O

Effects NNS N
on IN N
parental JJ o
mental JJ o
health NN o
of IN N
an DT N
education NN i
and CC i
skills NNS i
training VBG i
program NN i
for IN N
parents NNS p
of IN p
young JJ p
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
impact NN N
of IN N
a DT N
parent NN i
education NN i
and CC i
behavior JJ i
management NN i
intervention NN i
( ( i
PEBM NNP i
) ) i
on IN N
the DT N
mental JJ N
health NN N
and CC N
adjustment NN N
of IN N
parents NNS p
with IN p
preschool JJ p
children NNS p
with IN p
autism NN p
. . p

METHOD NNP N
A NNP N
randomized JJ N
, , N
group-comparison JJ N
design NN N
involving VBG N
a DT N
parent NN i
education NN i
and CC i
counseling VBG i
intervention NN i
to TO N
control VB N
for IN N
nonspecific JJ N
therapist NN N
effects NNS N
and CC N
a DT N
control NN N
sample NN N
was VBD N
used VBN N
. . N

Two CD p
metropolitan JJ p
and CC p
two CD p
rural JJ p
regions NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
intervention NN N
groups NNS N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
or CC N
control NN N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

The DT p
parents NNS p
of IN p
consecutive JJ p
children NNS p
with IN p
autism NN p
( ( p
2 CD p
( ( p
1/2 CD p
) ) p
-5 CD p
years NNS p
old JJ p
) ) p
from IN p
the DT p
autism NN p
assessment NN p
services NNS p
for IN p
the DT p
intervention NN p
regions NNS p
were VBD N
then RB N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
20-week JJ i
manual-based JJ i
parent NN i
education NN i
and CC i
behavior JJ i
management NN i
intervention NN i
( ( i
n JJ i
= NNP i
35 CD i
) ) i
or CC i
a DT i
manual-based JJ i
parent NN i
education NN i
and CC i
counseling VBG i
intervention NN i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

The DT N
main JJ N
outcome JJ N
measure NN N
of IN N
parental JJ o
mental JJ o
health NN o
was VBD N
the DT N
General NNP o
Health NNP o
Questionnaire NNP o
used VBD N
pre- NN N
and CC N
postintervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Both NNP N
treatments NNS N
resulted VBD N
in IN N
significant JJ o
and CC o
progressive JJ o
improvement NN o
in IN o
overall JJ o
mental JJ o
health NN o
at IN N
follow-up NN N
( ( N
F NNP N
= NNP N
2 CD N
, , N
97 CD N
, , N
p FW N
=.007 NN N
) ) N
and CC N
mental JJ o
health NN o
significantly RB o
improved VBN o
over RP o
time NN o
in IN N
the DT N
54 CD N
% NN N
of IN N
principal JJ N
caregivers NNS N
who WP N
had VBD N
the DT N
highest JJS N
levels NNS N
of IN N
mental JJ N
health NN N
problems NNS N
. . N

The DT N
parent NN o
education NN o
and CC o
behavior JJ o
management NN o
intervention NN N
was VBD N
effective JJ N
in IN N
alleviating VBG o
a DT o
greater JJR o
percentage NN o
of IN o
anxiety NN o
, , o
insomnia NN o
, , o
and CC o
somatic JJ o
symptoms NNS o
and CC o
family NN o
dysfunction NN o
than IN N
parent NN N
education NN N
and CC N
counseling VBG N
at IN N
6-month JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
A DT N
20-week JJ N
parent NN i
education NN i
and CC i
skills NNS i
training VBG i
program NN i
for IN N
parents NNS p
of IN p
young JJ p
children NNS p
newly RB p
diagnosed VBN p
with IN p
autism NN p
provides VBZ N
significant JJ N
improvements NNS N
in IN N
parental JJ o
mental JJ o
health NN o
and CC o
adjustment NN o
, , N
justifying VBG N
its PRP$ N
addition NN N
to TO N
early JJ N
intervention NN N
programs NNS N
at IN N
least JJS N
for IN N
parents NNS p
with IN p
mental JJ p
health NN p
problems NNS p
. . p

-DOCSTART- -24113340- O O

Effects NNS N
of IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
performing VBG N
eye-hand JJ N
integration NN N
tasks NNS N
: : N
four CD N
preliminary JJ N
studies NNS N
with IN N
children NNS p
showing VBG p
low-functioning JJ p
autism NN p
. . p

This DT N
report NN N
, , N
based VBN N
on IN N
four CD N
studies NNS N
with IN N
children NNS p
with IN p
low-functioning JJ p
autism NN p
, , N
aimed VBN N
at IN N
evaluating VBG N
the DT N
effects NNS N
of IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
delivered VBN N
on IN N
the DT N
left NN N
and CC N
right JJ N
premotor NN N
cortices NNS N
on IN N
eye-hand JJ N
integration NN N
tasks NNS N
; : N
defining VBG N
the DT N
long-lasting JJ N
effects NNS N
of IN N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
; : i
and CC N
investigating VBG N
the DT N
real JJ N
efficacy NN N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
by IN N
comparing VBG N
three CD N
kinds NNS N
of IN N
treatments NNS N
( ( N
high-frequency JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
, , N
a DT N
traditional JJ N
eye-hand JJ N
integration NN N
training NN N
, , N
and CC N
both DT N
treatments NNS N
combined VBN N
) ) N
. . N

Results $ N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
eye-hand JJ o
performances NNS o
only RB N
when WRB N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
was VBD N
delivered VBN N
on IN N
the DT N
left JJ N
premotor NN N
cortex NN N
; : N
a DT N
persistent NN N
improvement NN N
up IN N
to TO N
1 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
the DT N
stimulation NN N
; : N
better JJR N
outcomes NNS N
in IN N
the DT N
treatment NN N
combining VBG N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
and CC N
eye-hand JJ N
integration NN N
training NN N
. . N

Based VBN N
on IN N
these DT N
preliminary JJ N
findings NNS N
, , N
further JJ N
evaluations NNS N
on IN N
the DT N
usefulness NN N
of IN N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
rehabilitation NN N
of IN N
children NNS o
with IN o
autism NN o
are VBP N
strongly RB N
recommended VBN N
. . N

-DOCSTART- -22131601- O O

MSLT NNP i
in IN N
primary JJ N
insomnia NN o
: : o
stability NN N
and CC N
relation NN N
to TO N
nocturnal JJ o
sleep NN o
. . o

STUDY NNP N
OBJECTIVES NNP N
To TO N
assess VB N
the DT N
stability NN N
of IN N
the DT N
multiple JJ i
sleep JJ i
latency NN i
test NN i
( ( i
MSLT NNP i
) ) i
in IN N
primary JJ o
insomnia NN o
and CC N
its PRP$ N
relation NN N
to TO N
total JJ o
sleep JJ o
time NN o
. . o

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo NN N
controlled VBD N
, , N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient NN N
with IN N
sleep JJ N
laboratory NN N
assessments NNS N
in IN N
months NNS N
1 CD N
and CC N
8 CD N
of IN N
treatment NN N
. . N

PARTICIPANTS VB N
Ninety-five JJ p
primary JJ p
insomniacs NN p
, , p
32-64 CD p
years NNS p
old JJ p
and CC p
55 CD p
age- JJ p
and CC p
sex-matched JJ p
general JJ p
population-based JJ p
, , p
representative JJ p
controls NNS p
. . p

INTERVENTIONS NNP N
After IN N
a DT N
screening JJ N
nocturnal JJ i
polysomnograms NNS i
( ( i
NPSG NNP i
) ) i
and CC N
MSLT NNP i
the DT N
following JJ N
day NN N
, , N
participants NNS p
with IN p
primary JJ p
insomnia NNS p
were VBD N
randomized VBN N
to TO N
take VB N
zolpidem NN i
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
45 CD N
) ) N
nightly RB N
for IN N
12 CD N
months NNS N
. . N

During IN N
months NNS N
1 CD N
and CC N
8 CD N
, , N
while IN N
taking VBG N
their PRP$ N
prescribed JJ N
treatments NNS N
, , N
NPSGs NNP N
and CC N
MSLTs NNP i
the DT N
following JJ N
day NN N
were VBD N
conducted VBN N
. . N

A DT N
population-based JJ N
sample NN N
served VBD N
as IN N
controls NNS N
and CC N
received VBD N
a DT N
single JJ N
NPSG NNP N
followed VBN N
by IN N
MSLT NNP i
. . i

RESULTS NNP N
Mean NNP o
daily JJ o
sleep NN o
latency NN o
on IN o
the DT o
screening VBG o
MSLT NNP o
of IN o
insomniacs NN o
was VBD N
normally RB N
distributed VBN N
across IN N
the DT N
full JJ N
range NN N
of IN N
MSLT NNP i
scores NNS N
and CC N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
a DT N
population-based JJ N
representative NN N
control NN N
sample NN N
( ( N
P NNP N
< NNP N
0.006 CD N
) ) N
. . N

The DT N
insomniacs NN N
with IN N
the DT N
highest JJS N
screening NN o
MSLTs NNP o
had VBD N
the DT N
shortest JJS N
screening NN o
total JJ o
sleep JJ o
times NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
MSLTs NNP i
of IN N
insomniacs NN N
during IN N
treatment NN N
in IN N
study JJ N
month NN N
1 CD N
were VBD N
correlated VBN N
( ( N
r VB N
= RB N
0.44 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
their PRP$ N
month NN N
8 CD N
MSLT NNP N
. . N

The DT N
mean JJ o
MSLT NNP o
score NN o
of IN N
the DT N
zolpidem NNP N
group NN N
did VBD N
not RB N
differ VB N
from IN N
that DT N
of IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
the DT N
stability NN N
within IN N
treatment NN N
groups NNS N
also RB N
did VBD N
not RB N
differ VB N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
support NN N
the DT N
hypothesis NN N
that IN N
some DT N
insomniacs NN p
show VBP N
a DT N
reliable JJ N
disorder NN N
of IN N
hyperarousal NN o
with IN N
increased JJ N
wake NN o
drive NN o
both DT N
at IN N
night NN N
and CC N
during IN N
the DT N
day NN N
. . N

-DOCSTART- -17694216- O O

Effect NN N
of IN N
liquid-polish JJ i
coating NN i
on IN N
in IN o
vivo NN o
biofilm NN o
accumulation NN o
on IN N
provisional JJ p
restorations NNS p
: : p
part NN N
1 CD N
. . N

OBJECTIVE NNP N
Biofilm NNP o
accumulation NN o
on IN o
provisional JJ o
restorations NNS o
may MD N
affect VB N
the DT N
surrounding VBG N
tissues NNS N
' POS N
integrity NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
in IN N
vivo NN N
biofilm NN N
formation NN N
on IN N
polymethyl NN i
methacrylate NN i
( ( i
PMMA NNP i
) ) i
self-cured VBD i
acrylic JJ i
resin NN i
provisional JJ i
crowns NNS i
. . i

METHOD NNP N
AND CC N
MATERIALS NNP N
Three NNP p
types NNS p
of IN p
PMMA NNP p
surfaces NNS p
were VBD p
tested VBN p
: : p
( ( p
1 CD p
) ) p
polished VBN p
, , p
( ( p
2 CD p
) ) p
polished VBN p
and CC p
coated VBN p
with IN p
bonding NN p
agent NN p
, , p
and CC p
( ( p
3 CD p
) ) p
polished VBN p
and CC p
coated VBN p
with IN p
light-cured JJ p
liquid JJ p
polish NN p
. . p

After IN N
12 CD N
hours NNS N
in IN N
the DT N
oral JJ N
cavity NN N
, , N
the DT N
crown NN i
was VBD N
removed VBN N
and CC N
examined VBN N
by IN N
confocal JJ i
laser NN i
scanning VBG i
microscope NN i
( ( N
CLSM NNP N
) ) N
and CC N
scanning VBG i
electron NN i
microscope NN i
( ( N
SEM NNP N
) ) N
. . N

RESULTS NNP N
Biofilm NNP o
, , o
250 CD o
Mum NNP o
thick NN o
, , N
was VBD N
observed VBN N
with IN N
CLSM NNP N
on IN N
the DT N
polished VBN N
acrylic JJ N
surface NN N
. . N

Significantly RB N
less RBR N
bacterial JJ o
accumulation NN o
was VBD N
observed VBN N
on IN N
the DT N
crowns NNS N
coated VBN N
with IN N
bonding NN N
agent NN N
, , N
whereas IN N
no DT N
biofilm NN o
was VBD N
observed VBN N
on IN N
the DT N
crowns NNS N
coated VBN N
with IN N
liquid JJ N
polish JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

SEM NNP N
examination NN N
confirmed VBD N
these DT N
findings NNS N
. . N

CONCLUSIONS NNP N
Bonding NNP N
resin NN N
or CC N
liquid JJ N
polish JJ N
coatings NNS N
significantly RB N
reduce VB N
early JJ N
biofilm NN o
formation NN o
, , N
which WDT N
in IN N
turn NN N
might MD N
affect VB N
the DT N
overall JJ N
plaque NN N
accumulation NN N
on IN N
provisional JJ N
restorations NNS N
. . N

-DOCSTART- -16119478- O O

Clinical JJ N
efficacy NN N
of IN N
fluvoxamine NN i
and CC N
functional JJ N
polymorphism NN N
in IN N
a DT N
serotonin NN N
transporter NN N
gene NN N
on IN N
childhood NN p
autism NN p
. . p

We PRP N
studied VBD N
the DT N
correlation NN N
between IN N
response NN N
to TO N
fluvoxamine VB i
and CC N
serotonin VB N
transporter NN N
gene NN N
promoter NN N
region NN N
polymorphism NN N
( ( N
5-HTTLPR JJ N
) ) N
. . N

Eighteen JJ p
children NNS p
with IN p
autistic JJ p
disorder NN p
completed VBD N
a DT N
12-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
randomized VBN N
crossover NN N
study NN N
of IN N
fluvoxamine NN i
. . i

Behavioral JJ o
assessments NNS o
were VBD N
obtained VBN N
before IN N
and CC N
at IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

5-HTTLPR JJ N
( ( N
long JJ N
( ( N
l NN N
) ) N
or CC N
short JJ N
( ( N
s PRP N
) ) N
) ) N
, , N
was VBD N
analyzed VBN N
by IN N
the DT N
PCR NNP i
method NN i
. . i

Ten CD N
out IN N
of IN N
18 CD N
patients NNS N
responded VBD N
to TO N
fluvoxamine VB i
treatment NN N
; : N
allele CC o
type JJ o
analysis NN o
revealed VBD N
that IN N
clinical JJ N
global JJ N
effectiveness NN N
was VBD N
noted VBN N
significantly RB N
more RBR N
in IN N
the DT N
l NN N
allele NN N
than IN N
in IN N
the DT N
s NN N
allele NN N
. . N

However RB N
, , N
with IN N
respect NN N
to TO N
language NN o
use NN o
, , N
a DT N
significant JJ N
effectiveness NN N
was VBD N
noted VBN N
in IN N
the DT N
s NN N
allele NN N
. . N

5-HTTLPR JJ N
may MD N
influence VB N
the DT N
individual NN N
responses VBZ N
to TO N
fluvoxamine VB i
administration NN N
. . N

-DOCSTART- -9225710- O O

Treatment NN N
with IN N
buspirone NN i
in IN N
a DT N
patient NN p
with IN p
autism NN p
. . p

This DT N
study NN N
evaluates VBZ N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
buspirone NN i
hydrochloride NN i
for IN N
the DT N
treatment NN N
of IN N
a DT N
patient NN p
with IN p
autism NN p
and CC p
hyperactivity NN p
disorder NN p
and CC N
determines VBZ N
the DT N
effect NN N
of IN N
buspirone NN i
on IN N
the DT N
number NN N
of IN N
performance NN N
tasks NNS N
completed VBN N
by IN N
the DT N
patient NN N
at IN N
school NN N
. . N

A DT N
3-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
was VBD N
performed VBN N
in IN p
a DT p
private JJ p
physician NN p
, , p
office-based JJ p
practice NN p
. . p

A DT p
child NN p
with IN p
autism NN p
, , p
which WDT p
was VBD p
diagnosed VBN p
by IN p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Third NNP p
Edition NNP p
, , p
Revised VBN p
, , p
criteria NNS p
, , p
was VBD p
studied VBN p
. . p

The DT N
child NN N
received VBD N
placebo NN i
for IN i
3 CD i
weeks NNS i
and CC i
buspirone NN i
for IN N
3 CD N
weeks NNS N
; : N
there EX N
was VBD N
a DT N
1-week JJ N
interval NN N
between IN N
the DT N
2 CD N
treatments NNS N
. . N

The DT N
outcome NN N
was VBD N
measured VBN N
by IN N
using VBG N
Conners NNS o
abbreviated VBD o
parent NN o
and CC o
teacher NN o
questionnaires NNS o
and CC N
by IN N
determining VBG N
the DT N
number NN N
of IN N
daily JJ N
performance NN N
tasks NNS N
completed VBN N
by IN N
the DT N
child NN N
at IN N
school NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
by IN N
linear JJ N
models NNS N
and CC N
standard JJ N
F NNP N
tests NNS N
. . N

Buspirone NNP i
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC o
efficacious JJ o
, , o
without IN o
side JJ o
effects NNS o
, , N
for IN N
decreasing VBG N
hyperactivity NN o
and CC N
increasing VBG N
completed VBN o
performance NN o
tasks NNS o
. . o

The DT N
beneficial JJ N
effects NNS N
of IN N
buspirone NN i
in IN N
helping VBG N
this DT N
patient NN N
with IN N
autism NN p
in IN N
his PRP$ N
natural JJ N
daily JJ N
settings NNS N
suggest VBP N
that IN N
buspirone NN N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
neuroleptic JJ N
agents NNS N
in IN N
the DT N
medical JJ N
therapy NN N
of IN N
autism NN N
; : N
further JJ N
study NN N
in IN N
other JJ N
patients NNS N
is VBZ N
needed VBN N
. . N

-DOCSTART- -20356587- O O

Metformin NNP i
, , i
naltrexone NN i
, , i
or CC i
the DT i
combination NN i
of IN i
prednisolone NN i
and CC i
antiandrogenic JJ i
oral JJ i
contraceptives NNS i
as IN N
first-line JJ N
therapy NN N
in IN N
hyperinsulinemic JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

To TO N
compare VB N
the DT N
short-term JJ N
effects NNS N
of IN N
metformin NN i
( ( i
M NNP i
) ) i
, , i
naltrexone RB i
( ( i
N NNP i
) ) i
, , i
and CC i
a DT i
combination NN i
of IN i
OC NNP i
and CC i
prednisolone NN i
( ( i
OC/Pr NNP i
) ) i
on IN N
the DT N
metabolic JJ o
state NN o
and CC N
the DT N
ovarian JJ o
function NN o
of IN N
PCOS NNP p
women NNS p
, , N
we PRP N
randomized VBD N
29 CD p
women NNS p
to TO N
a DT N
3-month JJ N
course NN N
of IN N
therapy NN N
. . N

We PRP N
observed VBD N
significant JJ N
improvements NNS N
in IN N
hyperandrogenemia NN o
and CC o
ovulation NN o
rates NNS o
in IN N
PCOS NNP p
women NNS p
of IN N
all DT N
three CD N
groups NNS N
, , N
in IN N
the DT N
absence NN N
of IN N
changes NNS N
in IN N
the DT N
metabolic JJ o
state NN o
, , N
suggesting VBG N
that IN N
insulin NN N
resistance NN N
in IN N
PCOS NNP p
patients NNS p
is VBZ N
only RB N
one CD N
of IN N
several JJ N
factors NNS N
leading VBG N
to TO N
hyperandrogenemic VB N
ovarian JJ N
failure NN N
. . N

-DOCSTART- -2761917- O O

Randomized NNP N
clinical JJ N
trial NN N
comparing VBG N
systemic JJ N
interferon NN i
with IN N
diathermocoagulation NN i
in IN N
primary JJ p
multiple NNS p
and CC p
widespread JJ p
anogenital JJ p
condyloma NN p
. . p

Two CD p
hundred VBD p
three CD p
patients NNS p
( ( p
median JJ p
age NN p
26 CD p
years NNS p
; : p
range VB p
18-45 JJ p
) ) p
with IN p
untreated JJ p
multiple NNS p
and CC p
widespread JJ p
anogenital JJ p
condyloma NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
study NN N
arms NNS N
in IN N
order NN N
to TO N
compare VB N
the DT N
efficacy NN o
, , o
toxicity NN o
, , o
and CC o
tolerability NN o
of IN N
recombinant JJ i
interferon NN i
alpha-2b NN i
with IN i
those DT i
of IN i
diathermocoagulation NN i
. . i

Of IN N
200 CD p
evaluable JJ p
patients NNS p
, , N
51 CD N
were VBD N
treated VBN N
intramuscularly RB i
( ( N
IM NNP N
) ) N
with IN N
3 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
U NNP N
( ( N
3 CD N
MU NNP N
) ) N
/m2 VBP N
daily JJ N
for IN N
3 CD N
weeks NNS N
( ( N
total JJ N
dose RB N
63 CD N
MU/m2 NNP N
) ) N
, , N
50 CD N
received VBD N
subcutaneous JJ i
thrice-weekly JJ i
injections NNS i
of IN i
3 CD i
MU/m2 NNP i
for IN i
4 CD i
weeks NNS i
( ( N
total JJ N
dose RB N
36 CD N
MU/m2 NNP N
) ) N
, , N
51 CD N
underwent JJ N
diathermocoagulation NN i
, , N
and CC N
48 CD N
were VBD N
not RB N
treated VBN N
and CC N
were VBD N
used VBN N
as IN N
a DT N
control NN N
group NN N
. . N

Six NNP N
months NNS N
after IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
the DT N
overall JJ o
response NN o
rate NN o
( ( o
complete JJ o
and CC o
partial JJ o
responses NNS o
) ) o
was VBD N
70 CD N
% NN N
: : N
57 CD N
and CC N
82 CD N
% NN N
for IN N
patients NNS N
receiving VBG N
interferon JJ i
alpha-2b NN i
( ( N
IM NNP N
and CC N
subcutaneously RB N
) ) N
and CC N
diathermocoagulation NN i
, , N
respectively RB N
, , N
and CC N
8 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
. . N

After IN N
6 CD N
months NNS N
from IN N
therapy NN N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
complete JJ o
response NN o
were VBD N
found VBN N
among IN N
the DT N
different JJ N
types NNS N
of IN N
treatment NN N
: : N
20 CD N
, , N
20 CD N
, , N
and CC N
35 CD N
% NN N
for IN N
the DT N
two CD N
interferon NN N
groups NNS N
and CC N
the DT N
diathermocoagulation NN i
group NN N
, , N
respectively RB N
. . N

Fifteen NNP N
and CC N
two CD N
complete JJ N
responders NNS N
in IN N
the DT N
cauterization NN N
and CC N
interferon NN N
groups NNS N
, , N
respectively RB N
, , N
experienced VBD N
disease NN o
recurrence NN o
( ( N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
. . N

All DT N
patients NNS N
given VBN N
interferon JJ i
therapy NN i
complained VBD N
of IN N
flu-like NN o
symptoms NNS o
, , N
which WDT N
declined VBD N
progressively RB N
after IN N
the DT N
first JJ N
week NN N
of IN N
treatment NN N
. . N

Fatigue NNP o
, , N
lasting VBG N
as RB N
long RB N
as IN N
patients NNS N
received VBD N
interferon NN i
, , N
was VBD N
the DT N
most RBS N
prevalent JJ N
chronic JJ N
side NN o
effect NN o
. . o

We PRP N
conclude VBP N
that IN N
systemic JJ N
recombinant JJ N
interferon NN N
alpha-2b NN N
is VBZ N
active JJ N
in IN N
treating VBG N
patients NNS N
with IN N
primary JJ N
condyloma NN N
lesions NNS N
and CC N
does VBZ N
so RB N
as RB N
well RB N
as IN N
cauterization NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -21434379- O O

[ NN N
Using VBG N
gaviscon JJ i
preparation NN i
for IN N
relief NN N
of IN N
esophageal NN N
, , N
extraesophageal JJ N
syndromes NNS N
and CC N
functional JJ N
dyspepsia NN N
in IN N
elderly JJ p
patients NNS p
with IN p
GERD NNP p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
alginate JJ N
drug NN N
Geviskon NNP i
and CC N
aluminum-magnesium JJ i
antacids NNS i
to TO N
relieve VB N
symptoms NNS N
of IN N
esophageal NN N
, , N
extraesophageal JJ N
syndrome NN N
and CC N
functional JJ N
dyspepsia NN N
at IN N
3 CD N
and CC N
7 CD N
days NNS N
of IN N
study NN N
in IN N
patients NNS p
with IN p
GERD NNP p
elderly RB p
. . p

MATERIALS NNP N
AND NNP N
METHODS NNP N
An DT N
open JJ N
, , N
longitudinal JJ N
, , N
randomized VBN N
, , N
parallel-group NN N
. . N

The DT N
study NN N
included VBD N
60 CD p
patients NNS p
with IN p
A NNP p
degree NN p
of IN p
ERD NNP p
, , p
consistently RB p
received VBN p
in-patient JJ p
treatment NN p
in IN p
the DT p
Municipal NNP p
KGVV NNP p
, , p
mean JJ p
age NN p
79.0 CD p
+/- JJ p
6.8 CD p
years NNS p
. . p

During IN N
the DT N
first JJ N
12 CD N
hours NNS N
of IN N
hospital NN N
stay NN N
by IN N
sealed JJ N
envelopes NNS N
them PRP N
randomly RB N
divided VBD N
into IN N
equal JJ N
groups NNS N
of IN N
comparison NN N
, , N
given VBN N
3 CD N
times NNS N
a DT N
day NN N
: : N
alginate JJ i
product NN i
-- : i
Geviskon NNP i
forte VBP i
dose NN i
of IN i
10 CD i
ml NNS i
and CC i
aluminum-magnesium JJ i
antacid JJ i
drug NN i
at IN i
a DT i
dose NN i
of IN i
1 CD i
sachet NN i
. . i

Assess IN N
the DT N
frequency NN o
and CC N
severity NN o
of IN o
esophageal NN o
symptoms NNS o
, , o
extraesophageal JJ o
syndrome NN o
, , o
functional JJ o
dyspepsia NN o
at IN N
3 CD N
and CC N
7 CD N
days NNS N
of IN N
study NN N
on IN N
5-point JJ N
scale NN N
Likert NNP N
. . N

The DT N
degree NN o
of IN o
esophageal NN o
mucosal JJ o
injury NN o
was VBD N
determined VBN N
during IN N
endoscopy NN N
before IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
technique NN N
of IN N
alginate NN N
compared VBN N
with IN N
antacids NNS i
provided VBN N
significantly RB N
more RBR N
complete JJ N
and CC N
earlier RBR N
effect NN N
on IN N
the DT N
relief NN o
of IN o
heartburn NN o
, , o
regurgitation NN o
, , o
chronic JJ o
cough NN o
, , o
sore RB o
throat NN o
, , o
and CC o
EBS NNP o
. . o

Only RB N
Geviskon NNP i
influenced VBD N
the DT N
symptoms NNS N
of IN N
PPD NNP N
in IN N
patients NNS p
with IN p
GERD NNP p
. . p

CONCLUSION NNP N
The DT N
clinical JJ N
features NNS N
Geviskon VBP N
the DT N
frequency NN N
and CC N
timing NN N
of IN N
relief NN N
of IN N
symptoms NNS N
of IN N
esophageal NN o
, , o
extraesophageal JJ o
syndrome NN o
, , o
functional JJ o
dyspepsia NN o
with IN p
GERD NNP p
in IN p
the DT p
older JJR p
age NN p
groups NNS p
is VBZ N
higher JJR N
than IN N
that DT N
of IN N
antacids NNS N
. . N

Suspension NNP N
Geviskon NNP N
may MD N
be VB N
recommended VBN N
in IN N
patients NNS p
with IN p
middle JJ p
and CC p
old JJ p
age NN p
as IN N
an DT N
effective JJ N
and CC N
safe JJ N
symptomatic JJ N
funds NNS N
in IN N
the DT N
first JJ N
days NNS N
of IN N
exchange NN N
rate NN N
earlier RBR N
generations NNS N
of IN N
PPI NNP N
therapy NN N
, , N
as RB N
well RB N
as IN N
monotherapy NN N
-- : N
to TO N
maintain VB N
remission NN N
. . N

-DOCSTART- -23965288- O O

Assessment NN N
of IN N
global JJ o
functioning NN o
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
utility NN N
of IN N
the DT N
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
. . o

Assessment NN N
of IN N
global JJ o
functioning NN o
is VBZ N
an DT N
important JJ N
consideration NN N
in IN N
treatment NN N
outcome NN N
research NN N
; : N
yet RB N
, , N
there EX N
is VBZ N
little JJ N
guidance NN N
on IN N
its PRP$ N
evidence-based JJ N
assessment NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
utility NN N
and CC N
validity NN N
of IN N
clinician-rated JJ N
global JJ o
functioning NN o
using VBG N
the DT N
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
in IN N
a DT N
sample NN p
of IN p
higher JJR p
functioning NN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
comorbid NN p
anxiety NN p
disorders NNS p
enrolled VBD p
in IN p
a DT p
randomized NN p
controlled VBN i
trial NN p
( ( p
n JJ p
= NNP p
30 CD p
) ) p
. . p

Pretreatment JJ N
Developmental JJ o
Disability-Child JJ o
Global NNP o
Assessment NNP o
Scale NNP o
scores NNS N
correlated VBD N
with IN N
severity NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
core VBP N
symptoms NNS N
( ( N
r VB N
= NNP N
-.388 NNP N
, , N
p NN N
= NNP N
.034 NNP N
) ) N
, , N
pragmatic JJ N
communication NN N
( ( N
r JJ N
= NNP N
.407 NNP N
, , N
p NN N
= NNP N
.032 NNP N
) ) N
, , N
and CC N
verbal JJ N
ability NN N
( ( N
r JJ N
= NNP N
.449 NNP N
, , N
p NN N
= NNP N
.013 NNP N
) ) N
and CC N
did VBD N
not RB N
correlate VB N
with IN N
severity NN N
of IN N
anxiety NN o
symptoms NNS o
or CC N
with IN N
parent-reported JJ N
adaptive JJ N
behavior NN N
. . N

Change NN o
in IN o
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
scores VBZ o
during IN N
treatment NN N
was VBD N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
symptomatic JJ o
improvement NN o
( ( N
r JJ N
= NNP N
.414 NNP N
, , N
p NN N
= NNP N
.040 NNP N
) ) N
and CC N
with IN N
improved JJ N
general JJ o
communication NN o
( ( N
r JJ N
= NNP N
.499 NNP N
, , N
p NN N
= NNP N
.013 NNP N
) ) N
. . N

Results JJ N
support NN N
the DT N
importance NN N
of IN N
assessing VBG N
global JJ o
functioning NN o
in IN N
addition NN N
to TO N
symptom VB o
change NN o
and CC N
treatment NN o
response NN o
in IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -2647294- O O

Randomized VBN N
trial NN N
of IN N
recombinant JJ i
alpha JJ i
2b-interferon JJ i
with IN i
or CC i
without IN i
indomethacin NNS i
in IN N
patients NNS p
with IN p
metastatic JJ p
malignant JJ p
melanoma NN p
. . p

alpha-Interferon NN i
has VBZ N
antitumor VBN N
activity NN N
in IN N
a DT N
variety NN N
of IN N
malignancies NNS N
but CC N
is VBZ N
frequently RB N
associated VBN N
with IN N
unacceptable JJ N
toxic JJ o
side-effects NNS o
. . o

The DT N
routine JJ N
use NN N
of IN N
agents NNS N
potentially RB N
capable JJ N
of IN N
reducing VBG N
these DT N
side-effects NNS N
has VBZ N
not RB N
been VBN N
recommended VBN N
out IN N
of IN N
concern NN N
for IN N
possible JJ N
reductions NNS N
in IN N
the DT N
therapeutic JJ N
activity NN N
of IN N
interferon NN N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
alpha-interferon JJ N
given VBN N
with IN N
or CC N
without IN N
indomethacin JJ i
to TO N
patients NNS p
with IN p
malignant JJ p
melanoma NN p
to TO N
determine VB N
what WP N
effect NN N
, , N
if IN N
any DT N
, , N
indomethacin NN i
might MD N
have VB N
on IN N
the DT N
toxic NN o
, , o
immunomodulatory NN o
, , o
and CC o
therapeutic JJ o
properties NNS o
of IN N
interferon NN N
in IN N
this DT N
disease NN N
. . N

53 CD p
patients NNS p
were VBD p
stratified VBN p
according VBG p
to TO p
performance NN p
status NN p
and CC N
randomized VBN N
to TO N
receive VB N
alpha JJ i
2b-interferon CD i
, , N
20 CD N
million CD N
units NNS N
per IN N
m2 NN N
i.v. NN N
, , N
5 CD N
days NNS N
per IN N
week NN N
for IN N
4 CD N
weeks NNS N
followed VBN N
by IN N
10 CD N
million CD N
units NNS N
per IN N
m2 NN N
s.c. NN N
three CD N
times NNS N
per IN N
week NN N
, , N
either RB N
with IN N
or CC N
without IN N
indomethacin NN i
, , N
25 CD N
mg NN N
orally RB N
three CD N
times NNS N
a DT N
day NN N
. . N

The DT N
overall JJ o
major JJ o
response NN o
rate NN o
was VBD N
13 CD N
% NN N
( ( N
three CD N
complete JJ N
responders NNS N
and CC N
three CD N
partial JJ N
responders NNS N
among IN N
47 CD N
evaluable JJ N
patients NNS N
) ) N
and CC N
was VBD N
the DT N
same JJ N
on IN N
both DT N
arms NNS N
. . N

The DT N
mean JJ o
maximal JJ o
temperature NN o
elevation NN o
induced VBN N
by IN N
interferon NN N
was VBD N
significantly RB N
reduced VBN N
( ( N
from IN N
102.1 CD N
to TO N
100.7 CD N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
by IN N
indomethacin NN i
, , N
but CC N
the DT N
incidence NN o
and CC o
severity NN o
of IN o
interferon-related JJ o
fatigue NN o
, , o
reduction NN o
in IN o
performance NN o
status NN o
, , o
headache NN o
, , o
depression NN o
, , o
confusion NN o
, , o
elevations NNS o
in IN o
liver JJ o
function NN o
tests NNS o
, , o
and CC o
myelosuppression NN o
were VBD N
no DT N
different JJ N
in IN N
either DT N
arm NN N
of IN N
the DT N
study NN N
. . N

Indomethacin NNP i
did VBD N
not RB N
reduce VB N
the DT N
frequency NN o
of IN o
dose JJ o
reductions NNS o
for IN o
toxic JJ o
side-effects NNS o
and CC N
did VBD N
not RB N
permit VB N
the DT N
administration NN o
of IN o
higher JJR o
interferon NN o
doses NNS o
. . o

Peripheral NNP o
blood VBD o
natural JJ o
killer NN o
activity NN o
was VBD N
significantly RB N
enhanced VBN N
in IN N
patients NNS N
during IN N
maintenance NN N
therapy NN N
whether IN N
or CC N
not RB N
they PRP N
received VBD N
indomethacin NN N
. . N

Indomethacin NNP i
appeared VBD N
to TO N
inhibit VB N
augmentation NN o
of IN o
natural JJ o
killer NN o
activity NN o
during IN N
high JJ N
dose JJ N
induction NN N
therapy NN N
. . N

Immunological JJ o
changes NNS o
did VBD N
not RB N
correlate VB N
with IN N
response NN N
status NN N
. . N

We PRP N
conclude VBP N
that IN N
indomethacin NN N
can MD N
reduce VB N
the DT N
fever NN o
associated VBN N
with IN N
interferon NN N
therapy NN N
in IN N
patients NNS p
with IN p
malignant JJ p
melanoma NN p
without IN N
interfering VBG N
with IN N
its PRP$ N
therapeutic JJ o
or CC o
chronic JJ o
immunomodulatory NN o
activities NNS o
. . o

Since IN N
fever NN o
is VBZ N
rarely RB N
the DT N
dose-limiting JJ N
toxicity NN N
of IN N
interferon NN N
, , N
indomethacin NN i
is VBZ N
of IN N
marginal JJ N
benefit NN N
to TO N
patients NNS p
with IN p
malignant JJ p
melanoma NN p
receiving VBG N
interferon NN N
at IN N
the DT N
doses NNS N
outlined VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -16919138- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
melatonin NN i
for IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
and CC p
sleep JJ p
problems NNS p
. . p

BACKGROUND NNP N
Melatonin NNP N
is VBZ N
often RB N
used VBN N
for IN N
autistic JJ p
children NNS p
with IN p
sleep NN p
disorders NNS p
, , N
despite IN N
a DT N
lack NN N
of IN N
published VBN N
evidence NN N
in IN N
this DT N
population NN N
. . N

METHODS NNP N
A NNP N
randomized JJ N
, , N
placebo-controlled JJ i
double-blind NN N
crossover NN N
trial NN N
of IN N
melatonin NN i
was VBD N
undertaken VBN N
in IN N
11 CD p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

RESULTS NNP N
Seven NNP p
children NNS p
completed VBD p
the DT p
trial NN p
. . p

Sleep JJ o
latency NN o
was VBD N
2.6 CD N
h NN N
[ JJ N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
2.28-2.93 CD N
] JJ N
baseline NN N
, , N
1.91 CD N
h NN N
( ( N
95 CD N
% NN N
CI NNP N
1.78-2.03 CD N
) ) N
with IN N
placebo NN N
and CC N
1.06 CD N
h NN N
( ( N
95 CD N
% NN N
CI NNP N
0.98-1.13 NN N
) ) N
with IN N
melatonin NN N
. . N

Wakings NNS o
per IN o
night NN o
were VBD N
0.35 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.18-0.53 NN N
) ) N
baseline NN N
, , N
0.26 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.20-0.34 NN N
) ) N
with IN N
placebo NN i
and CC N
0.08 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.04-0.12 NN N
) ) N
with IN N
melatonin NN N
. . N

Total JJ o
sleep JJ o
duration NN o
was VBD N
8.05 CD N
h NN N
( ( N
95 CD N
% NN N
CI NNP N
7.65-8.44 CD N
) ) N
baseline NN N
, , N
8.75 CD N
h NN N
( ( N
95 CD N
% NN N
CI NNP N
8.56-8.98 CD N
) ) N
with IN N
placebo NN N
and CC N
9.84 CD N
h NN N
( ( N
95 CD N
% NN N
CI NNP N
9.68-9.99 CD N
) ) N
with IN N
melatonin NN N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
study NN N
was VBD N
small JJ N
owing NN N
to TO N
recruitment VB N
difficulties NNS N
, , N
it PRP N
still RB N
provides VBZ N
evidence NN N
of IN N
effectiveness NN o
of IN N
melatonin NN N
in IN N
children NNS p
with IN p
sleep JJ p
difficulties NNS p
and CC p
ASD NNP p
, , N
which WDT N
we PRP N
predict VBP N
a DT N
larger JJR N
study NN N
would MD N
confirm VB N
. . N

-DOCSTART- -24902456- O O

Evaluation NN N
of IN N
postprocedure NN N
cognitive JJ o
function NN o
using VBG N
3 CD N
distinct JJ N
standard JJ N
sedation NN i
regimens NNS i
for IN N
endoscopic NN N
procedures NNS N
. . N

The DT N
primary JJ N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
postprocedure NN o
cognitive JJ o
function NN o
associated VBN N
with IN N
3 CD N
distinct JJ N
standard JJ i
sedation NN i
regimens NNS i
used VBN N
for IN N
endoscopic NN p
procedures NNS p
. . p

A DT N
secondary JJ N
aim NN N
was VBD N
to TO N
identify VB N
complications NNS N
requiring VBG N
provider NN N
interventions NNS N
. . N

Subjects NNS p
scheduled VBN p
for IN p
colonoscopies NNS p
were VBD N
approached VBN N
for IN N
enrollment NN N
the DT N
day NN N
of IN N
their PRP$ N
procedure NN N
. . N

A DT N
convenience NN p
sample NN p
of IN p
96 CD p
subjects NNS p
was VBD N
randomly RB N
assigned VBN N
. . N

Cognitive JJ N
function NN N
was VBD N
recorded VBN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
using VBG N
the DT N
Mini-Mental JJ i
State NNP i
Examination NNP i
( ( N
MMSE NNP N
) ) N
and CC N
24 CD N
and CC N
48 CD N
hours NNS N
postoperatively RB N
using VBG N
the DT N
Telephone NNP o
Interview NNP o
of IN o
Cognitive NNP o
Status NNP o
( ( o
TICS NNP o
) ) o
. . o

The DT N
propofol JJ i
plus CC i
fentanyl JJ i
group NN N
had VBD N
a DT N
mean JJ o
TICS NNP o
score NN o
of IN N
34.53 CD N
at IN N
24 CD N
hours NNS N
compared VBN N
with IN N
34.96 CD N
at IN N
48 CD N
hours NNS N
( ( N
P NNP N
= NNP N
.017 NNP N
) ) N
. . N

The DT N
midazolam NN i
plus CC i
fentanyl JJ i
group NN N
had VBD N
a DT N
mean JJ o
TICS NNP o
score NN o
of IN N
34.76 CD N
at IN N
24 CD N
hours NNS N
compared VBN N
with IN N
36.26 CD N
at IN N
48 CD N
hours NNS N
( ( N
P NNP N
= NNP N
.004 NNP N
) ) N
. . N

The DT N
propofol-alone JJ i
group NN N
had VBD N
a DT N
mean JJ o
TICS NNP o
score NN o
of IN N
35.09 CD N
at IN N
24 CD N
hours NNS N
compared VBN N
with IN N
35.98 CD N
at IN N
48 CD N
hours NNS N
( ( N
P NNP N
= NNP N
.924 NNP N
) ) N
. . N

The DT N
results NNS N
of IN N
this DT N
investigation NN N
indicate VBP N
that IN N
the DT N
sedation NN N
regimen NNS N
of IN N
propofol NN i
alone RB N
has VBZ N
the DT N
least JJS N
impact NN N
on IN N
postprocedure NN o
cognitive JJ o
function NN o
. . o

Additionally RB N
, , N
the DT N
number NN o
of IN o
jaw JJ o
lift NN o
interventions NNS o
was VBD N
significantly RB N
higher JJR N
in IN N
both DT N
groups NNS N
who WP N
received VBD N
fentanyl NN i
. . i

-DOCSTART- -2064495- O O

Niacin NNP i
revisited VBD N
. . N

A DT N
randomized JJ N
, , N
controlled JJ N
trial NN N
of IN N
wax-matrix JJ i
sustained-release JJ i
niacin NN i
in IN N
hypercholesterolemia NN o
. . o

Two CD p
hundred VBD p
one CD p
male NN p
and CC p
female JJ p
subjects NNS p
, , p
aged VBD p
20 CD p
to TO p
70 CD p
years NNS p
, , p
with IN p
elevated VBN p
low-density NN p
lipoprotein NN p
cholesterol NN p
values NNS p
( ( p
in IN p
the DT p
75th CD p
to TO p
95th CD p
percentiles NNS p
) ) p
, , p
participated VBN p
in IN N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind NN N
study NN N
using VBG N
a DT N
new JJ N
form NN N
of IN N
niacin NN i
( ( i
Enduracin NNP i
) ) i
, , N
which WDT N
employs VBZ N
a DT N
wax-matrix JJ N
vehicle NN N
for IN N
sustained JJ N
release NN N
. . N

Four CD N
niacin JJ i
treatment NN N
groups NNS N
( ( N
daily JJ N
doses NNS N
of IN N
2000 CD N
, , N
1500 CD N
, , N
1250 CD N
, , N
and CC N
1000 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
placebo- JJ i
and CC i
diet-treated JJ i
controls NNS i
to TO N
determine VB N
side-effect JJ N
profile NN N
and CC N
optimal JJ N
range NN N
of IN N
efficacy NN N
. . N

The DT N
groups NNS N
given VBN N
2000 CD N
and CC N
1500 CD N
mg NN N
demonstrated VBD N
significant JJ N
reductions NNS N
in IN N
values NNS N
of IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
( ( N
-26 CD N
% NN N
and CC N
-19.3 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
total JJ o
cholesterol NN o
( ( N
-18.4 CD N
% NN N
and CC N
-13.3 NNP N
% NN N
) ) N
, , N
and CC N
total JJ o
cholesterol-high-density NN o
lipoprotein NN o
cholesterol NN o
ratio NN o
( ( N
-20.4 CD N
% NN N
and CC N
-19.4 CD N
% NN N
) ) N
when WRB N
compared VBN N
with IN N
diet- JJ N
and CC N
placebo-treated JJ N
controls NNS N
. . N

Smaller NN N
improvements NNS N
were VBD N
seen VBN N
in IN N
high-density NN o
lipoprotein NN o
cholesterol NN o
and CC o
triglyceride NN o
levels NNS o
. . o

Blood NNP N
chemistry NN N
monitoring NN N
indicated VBD N
that DT N
reduction NN N
in IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
strongly RB N
correlated VBN N
with IN N
an DT N
increase NN N
in IN N
baseline JJ N
levels NNS N
of IN N
some DT N
enzymes NNS N
for IN N
niacin-treated JJ N
subjects NNS N
. . N

The DT N
improved JJ N
side-effect JJ N
profile NN N
of IN N
the DT N
wax-matrix JJ N
form NN N
of IN N
niacin NN i
was VBD N
particularly RB N
notable JJ N
. . N

The DT N
dropout NN o
rate NN o
due JJ N
to TO N
side VB o
effects NNS o
was VBD N
only RB N
3.4 CD N
% NN N
and CC N
was VBD N
coupled VBN N
with IN N
good JJ N
medication NN N
compliance NN N
. . N

-DOCSTART- -24919102- O O

Balance NNP N
training NN N
in IN N
elderly JJ p
women NNS p
using VBG p
public JJ p
parks NNS p
. . p

This DT N
study NN N
evaluates VBZ N
the DT N
effects NNS N
of IN N
a DT N
balance NN i
training NN i
program NN i
developed VBN p
in IN p
public JJ p
parks NNS p
on IN N
functionality NN N
and CC N
general JJ N
state NN N
of IN N
health NN N
in IN N
elderly JJ p
women NNS p
. . p

It PRP N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

Women NNP p
older JJR p
than IN p
65 CD p
years NNS p
( ( p
n JJ p
= VBZ p
28 CD p
; : p
68.5 CD p
? . p
2.9 CD p
) ) p
participated VBN N
in IN N
a DT N
balance NN i
training NN i
program NN i
that WDT N
lasted VBD N
6 CD N
weeks NNS N
, , N
with IN N
sessions NNS N
taking VBG N
place NN N
twice RB N
a DT N
week NN N
( ( N
12 CD N
exercises/session NN N
, , N
50 CD N
min NN N
) ) N
. . N

Balance NNP o
was VBD N
analyzed VBN N
by IN N
the DT N
Berg NNP o
Balance NNP o
Scale NNP o
and CC o
Timed NNP o
Up NNP o
& CC o
Go NNP o
Test NNP o
. . o

The DT o
generic JJ o
health NN o
status NN o
was VBD N
measured VBN N
by IN N
the DT N
SF-12 NNP N
Health NNP N
Survey NNP N
. . N

These DT N
tests NNS N
showed VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

Public JJ p
parks NNS p
are VBP N
adequate JJ N
installations NNS N
for IN N
developing VBG N
balance NN N
. . N

-DOCSTART- -22008443- O O

Effect NN N
of IN N
ischemic JJ o
postconditioning NN o
in IN N
correction NN N
of IN N
tetralogy NN N
of IN N
Fallot NNP N
. . N

Inappropriate NNP N
myocardial JJ N
protection NN N
is VBZ N
considered VBN N
one CD N
of IN N
the DT N
main JJ N
causes NNS N
of IN N
mortality NN N
and CC N
morbidity NN N
in IN N
the DT N
correction NN N
of IN N
tetralogy NN p
of IN p
Fallot NNP p
( ( p
TOF NNP p
) ) p
. . p

Results NNS N
of IN N
previous JJ N
reports NNS N
about IN N
the DT N
effects NNS N
of IN N
ischemic JJ N
postconditioning NN N
on IN N
myocardial JJ o
protection NN o
in IN N
animals NNS N
and CC N
humans NNS N
are VBP N
very RB N
encouraging JJ N
. . N

This DT N
randomized JJ N
and CC N
controlled JJ N
trial NN N
aimed VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
ischemic JJ o
postconditioning VBG o
on IN N
protection NN o
against IN o
myocardial JJ o
ischemia NN o
reperfusion NN N
injury NN N
in IN N
TOF NNP p
patients NNS p
receiving VBG p
cardioplegia NN p
. . p

From IN p
January NNP p
2008 CD p
to TO p
June NNP p
2010 CD p
, , p
80 CD p
consecutive JJ p
children NNS p
undergoing VBG p
correction NN p
of IN p
TOF NNP p
were VBD N
enrolled VBN i
and CC i
randomly RB i
assigned VBN i
to TO i
either VB i
a DT i
postconditioning NN i
group NN i
( ( i
three CD i
cycles NNS i
of IN i
30 CD i
seconds NNS i
of IN i
ischemia NN i
and CC i
30 CD i
seconds NNS i
of IN i
reperfusion NN i
using VBG i
re-clamping JJ i
and CC i
de-clamping JJ i
starting VBG i
30 CD i
seconds NNS i
after IN i
the DT i
initial JJ i
de-clamping NN i
of IN i
the DT i
aorta NN i
, , i
n JJ i
= NNP i
41 CD i
) ) i
or CC i
a DT i
control NN i
group NN i
( ( i
n JJ i
= NNP i
39 CD i
) ) i
. . i

Cardiac NNP o
troponin NN o
I PRP o
( ( i
cTnI NN i
) ) i
was VBD i
assayed VBN i
preoperatively RB i
, , i
and CC i
then RB i
4 CD i
hours NNS i
, , i
8 CD i
hours NNS i
, , i
12 CD i
hours NNS i
, , i
20 CD i
hours NNS i
, , i
and CC i
48 CD i
hours NNS i
after IN i
persistent JJ i
reperfusion NN i
. . i

The DT N
pre- JJ N
, , N
intra- JJ N
and CC N
postoperative JJ N
relevant JJ N
data NNS N
of IN N
all DT N
selected VBN N
patients NNS N
were VBD N
analyzed VBN N
. . N

As IN N
a DT N
result NN N
, , N
ischemic JJ N
postconditioning NN N
reduced VBD N
postoperative JJ o
peak NN o
release NN o
by IN N
45 CD N
% NN N
for IN N
cTnI NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
0.43 CD N
? . N
0.18 CD N
ng/mL JJ N
versus NN N
0.78 CD N
? . N
0.15 CD N
ng/mL NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Ischemic NNP N
postconditioned VBD N
patients NNS N
had VBD N
a DT N
lower JJR o
peak NN o
inotropic NN o
score NN o
during IN o
the DT N
first JJ N
postoperative JJ N
24 CD N
hours NNS N
( ( N
5.6 CD N
? . N
2.2 CD N
?g/kg/minute JJ N
versus NN N
8.6 CD N
? . N
3.6 CD N
?g/kg/minute NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) o
, , o
extubation JJ o
time NN o
( ( N
21.5 CD N
? . N
7.3 CD N
hours NNS N
versus IN N
30.2 CD N
? . N
12.4 CD N
hours NNS N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
and CC o
length NN o
of IN o
ICU NNP o
stay NN o
( ( o
43.4 CD o
? . N
12.6 CD N
hours NNS N
versus IN N
56.3 CD N
? . N
17.8 CD N
hours NNS N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
, , N
while IN N
they PRP N
had VBD N
a DT N
higher JJR o
cardiac JJ o
output NN o
on IN o
the DT N
first JJ N
postoperative JJ N
day NN N
( ( N
1.41 CD N
? . N
0.26 CD N
L/minute NNP N
versus NN N
1.28 CD N
? . N
0.25 CD N
L/minute NNP N
, , N
P NNP N
= NNP N
0.0255 CD N
) ) N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
ischemic JJ N
postconditioning NN N
may MD N
to TO N
some DT N
extent NN N
provide VBP N
myocardial JJ N
protection NN N
in IN p
children NNS p
undergoing VBG p
correction NN p
of IN p
tetralogy NN p
of IN p
Fallot NNP p
. . p

-DOCSTART- -21385351- O O

Vascular JJ N
pedicle NN N
width NN N
in IN N
acute JJ p
lung JJ p
injury NN p
: : p
correlation NN N
with IN N
intravascular JJ N
pressures NNS N
and CC N
ability NN N
to TO N
discriminate VB N
fluid NN N
status NN N
. . N

INTRODUCTION NNP N
Conservative NNP i
fluid NN i
management NN i
in IN N
patients NNS p
with IN p
acute JJ p
lung NN p
injury NN p
( ( p
ALI NNP p
) ) p
increases VBZ N
time NN N
alive JJ N
and CC N
free JJ N
from IN N
mechanical JJ i
ventilation NN i
. . i

Vascular JJ o
pedicle NN o
width NN o
( ( o
VPW NNP o
) ) o
is VBZ N
a DT N
non-invasive JJ N
measurement NN N
of IN N
intravascular JJ N
volume NN N
status NN N
. . N

The DT N
VPW NNP N
was VBD N
studied VBN N
in IN N
ALI NNP p
patients NNS p
to TO N
determine VB N
the DT N
correlation NN N
between IN N
VPW NNP N
and CC N
intravascular JJ N
pressure NN N
measurements NNS N
and CC N
whether IN N
VPW NNP N
could MD N
predict VB N
fluid JJ N
status NN N
. . N

METHODS NNP N
This DT N
retrospective JJ N
cohort NN N
study NN N
involved VBD N
152 CD p
patients NNS p
with IN p
ALI NNP p
enrolled VBD p
in IN p
the DT p
Fluid NNP p
and CC p
Catheter NNP p
Treatment NNP p
Trial NNP p
( ( p
FACTT NNP p
) ) p
from IN p
five CD p
NHLBI NNP p
ARDS NNP p
( ( p
Acute NNP p
Respiratory NNP p
Distress NNP p
Syndrome NNP p
) ) p
Network NNP p
sites NNS p
. . p

VPW NNP o
and CC o
central JJ o
venous JJ o
pressure NN o
( ( o
CVP NNP o
) ) o
or CC o
pulmonary JJ o
artery NN o
occlusion NN o
pressure NN o
( ( o
PAOP NNP o
) ) o
from IN N
the DT N
first JJ N
four CD N
study NN N
days NNS N
were VBD N
correlated VBN N
. . N

The DT N
relationships NNS o
between IN o
VPW NNP o
, , o
positive JJ o
end-expiratory JJ o
pressure NN o
( ( o
PEEP NNP o
) ) o
, , o
cumulative JJ o
fluid NN o
balance NN o
, , o
and CC o
PAOP NNP o
were VBD N
also RB N
evaluated VBN N
. . N

Receiver NNP N
operator NN N
characteristic NN N
( ( N
ROC NNP N
) ) N
curves NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
ability NN N
of IN N
VPW NNP o
to TO N
detect VB N
PAOP NNP N
< NNP N
8 CD N
mmHg NN N
and CC N
PAOP NNP N
? . N
18 CD N
mm NN N
Hg NNP N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
71 CD p
and CC p
152 CD p
patients NNS p
provided VBD p
118 CD N
and CC N
276 CD N
paired VBN N
VPW/PAOP NNP N
and CC N
VPW/CVP NNP N
measurements NNS N
, , N
respectively RB N
. . N

VPW NNP N
correlated VBD N
with IN N
PAOP NNP N
( ( N
r VB N
= RB N
0.41 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
less RBR N
well RB N
with IN N
CVP NNP N
( ( N
r VB N
= RB N
0.21 CD N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

In IN N
linear JJ N
regression NN N
, , N
VPW NNP N
correlated VBD N
with IN o
PAOP NNP o
1.5-fold JJ o
better JJR N
than IN N
cumulative JJ N
fluid NN N
balance NN N
and CC N
2.5-fold JJ N
better JJR N
than IN N
PEEP NNP N
. . N

VPW NNP N
discriminated VBD N
achievement NN N
of IN N
PAOP NNP o
< NNP o
8 CD N
mm NN N
Hg NNP N
( ( N
AUC NNP N
= NNP N
0.73 CD N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
with IN o
VPW NNP o
?67 NNP o
mm VBD N
demonstrating VBG N
71 CD N
% NN N
sensitivity NN N
( ( N
95 CD N
% NN N
CI NNP N
30 CD N
to TO N
95 CD N
% NN N
) ) N
and CC N
68 CD N
% NN N
specificity NN N
( ( N
95 CD N
% NN N
CI NNP N
59 CD N
to TO N
75 CD N
% NN N
) ) N
. . N

For IN N
discriminating VBG N
a DT N
hydrostatic JJ N
component NN N
of IN N
the DT N
edema NN N
( ( N
that WDT N
is VBZ N
, , N
PAOP NNP N
? . N
18 CD N
mm NN N
Hg NNP N
) ) N
, , o
VPW NNP o
? . N
72 CD N
mm NN N
demonstrated VBD N
61.4 CD N
% NN N
sensitivity NN N
( ( N
95 CD N
% NN N
CI NNP N
47 CD N
to TO N
74 CD N
% NN N
) ) N
and CC N
61 CD N
% NN N
specificity NN N
( ( N
49 CD N
to TO N
71 CD N
% NN N
) ) N
( ( N
area NN N
under IN N
the DT N
curve NN N
( ( N
AUC NNP N
) ) N
0.69 CD N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
VPW NNP N
correlates VBZ N
with IN N
PAOP NNP N
better JJR N
than IN N
CVP NNP N
in IN p
patients NNS p
with IN p
ALI NNP p
. . p

Due NNP p
to TO N
its PRP$ N
only JJ N
moderate JJ N
sensitivity NN N
and CC N
specificity NN N
, , N
the DT N
ability NN N
of IN N
VPW NNP N
to TO N
discriminate VB N
fluid NN N
status NN N
in IN p
patients NNS p
with IN p
acute JJ p
lung NN p
injury NN p
is VBZ N
limited JJ N
and CC N
should MD N
only RB N
be VB N
considered VBN N
when WRB N
intravascular JJ N
pressures NNS N
are VBP N
unavailable JJ N
. . N

-DOCSTART- -20966820- O O

Five-year JJ N
outcome NN N
of IN N
surgical JJ N
treatment NN N
of IN N
migraine NN o
headaches NNS o
. . o

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
surgical JJ N
deactivation NN N
of IN N
migraine NN o
headache NN o
trigger NN N
sites NNS N
. . N

METHODS NNP N
One CD p
hundred VBD p
twenty-five JJ p
volunteers NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
treatment NN p
( ( p
n JJ p
= NNP p
100 CD p
) ) p
or CC p
control VB p
group NN p
( ( p
n JJ p
= NNP p
25 CD p
) ) p
after IN p
examination NN p
by IN p
the DT p
team NN p
neurologist NN p
to TO p
ensure VB p
a DT p
diagnosis NN p
of IN p
migraine NN o
headache NN o
. . o

Patients NNS N
were VBD N
asked VBN N
to TO N
complete VB N
the DT N
Medical NNP o
Outcomes NNP o
Study NNP o
36-Item JJ o
Short NNP o
Form NNP o
Health NNP o
Survey NNP o
, , o
Migraine-Specific NNP o
Quality NNP o
of IN o
Life NNP o
, , o
and CC o
Migraine NNP o
Disability NNP o
Assessment NNP o
questionnaires VBZ o
before IN N
treatment NN N
and CC N
at IN N
12- JJ N
and CC N
60-month JJ N
postoperative JJ N
follow-up NN N
. . N

The DT N
treatment NN N
group NN N
received VBD N
botulinum RB i
toxin NN i
to TO N
confirm VB N
the DT N
trigger NN N
sites VBZ N
; : N
controls NNS N
received VBD N
saline JJ i
injections NNS i
. . i

Treated VBN N
patients NNS N
underwent JJ N
surgical JJ i
deactivation NN i
of IN N
trigger NN N
site NN N
( ( N
s JJ N
) ) N
. . N

Results NNS N
were VBD N
analyzed VBN N
at IN N
1 CD N
year NN N
( ( N
previously RB N
published VBN N
) ) N
and CC N
5 CD N
years NNS N
postoperatively RB N
( ( N
the DT N
subject NN N
of IN N
this DT N
report NN N
) ) N
. . N

RESULTS JJ N
Eighty-nine NNP N
of IN N
100 CD p
patients NNS p
in IN p
the DT p
treatment NN p
group NN p
underwent JJ N
surgery NN N
, , N
and CC N
79 CD N
were VBD N
followed VBN N
for IN N
5 CD N
years NNS N
. . N

Ten CD N
patients NNS N
underwent JJ N
deactivation NN i
of IN N
additional JJ N
( ( N
different JJ N
) ) N
trigger NN N
sites NNS N
during IN N
the DT N
follow-up JJ N
period NN N
and CC N
were VBD N
not RB N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
. . N

The DT N
final JJ N
outcome NN N
with IN N
or CC N
without IN N
inclusion NN N
of IN N
these DT N
10 CD N
patients NNS N
was VBD N
not RB N
statistically RB N
different JJ N
. . N

Sixty-one NN N
( ( N
88 CD N
percent NN N
) ) N
of IN N
69 CD N
patients NNS N
have VBP N
experienced VBN N
a DT N
positive JJ o
response NN o
to TO N
the DT N
surgery NN N
after IN N
5 CD N
years NNS N
. . N

Twenty NNP N
( ( N
29 CD N
percent NN N
) ) N
reported VBD N
complete JJ o
elimination NN o
of IN o
migraine NN o
headache NN o
, , N
41 CD N
( ( N
59 CD N
percent NN N
) ) N
noticed VBD N
a DT N
significant JJ N
decrease NN N
, , N
and CC N
eight CD N
( ( N
12 CD N
percent NN N
) ) N
experienced VBD N
no DT N
significant JJ N
change NN N
. . N

When WRB N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
, , N
all DT N
measured VBD N
variables NNS N
at IN N
60 CD N
months NNS N
improved VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
the DT N
5-year JJ N
follow-up JJ N
data NNS N
, , N
there EX N
is VBZ N
strong JJ N
evidence NN N
that IN N
surgical JJ N
manipulation NN N
of IN N
one CD N
or CC N
more JJR N
migraine JJ N
trigger NN N
sites NNS N
can MD N
successfully RB N
eliminate VB o
or CC o
reduce VB o
the DT o
frequency NN o
, , o
duration NN o
, , o
and CC o
intensity NN o
of IN o
migraine NN o
headache NN o
in IN N
a DT N
lasting JJ N
manner NN N
. . N

-DOCSTART- -20884344- O O

Hypoxic NNP i
exercise NN i
training NN i
reduces NNS N
senescent JJ o
T-lymphocyte JJ o
subsets NNS o
in IN o
blood NN o
. . o

The DT N
integration NN N
and CC N
control NN N
of IN N
systemic JJ N
immune JJ N
responses NNS N
depends VBZ N
on IN N
the DT N
regulated JJ N
trafficking NN N
of IN N
T-lymphocytes NNP N
. . N

This DT N
study NN N
elucidates VBZ N
how WRB N
various JJ N
exercises NNS N
regimens VBZ N
with/without IN N
hypoxia NN N
affect VBP N
phenotypic NN o
characteristics NNS o
of IN o
T-lymphocyte NNP o
subsets NNS o
in IN o
blood NN o
. . o

Fifty NNP p
sedentary JJ p
males NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
five CD N
groups NNS N
. . N

Each DT N
group NN N
( ( N
n=10 NN N
) ) N
received VBD N
one CD N
of IN N
five CD N
interventions NNS N
: : N
normoxic NN i
( ( i
21 CD i
% NN i
O? NNP i
) ) i
resting NN i
( ( i
N-C NNP i
) ) i
, , i
hypoxic NN i
( ( i
15 CD i
% NN i
O? NNP i
) ) i
resting NN i
( ( i
H-C NNP i
) ) i
, , i
normoxic JJ i
exercise NN i
( ( i
50 CD i
% NN i
W NNP i
( ( i
max NN i
) ) i
under IN i
21 CD i
% NN i
O? NNP i
, , i
N-T NNP i
) ) i
, , i
hypoxic-relative JJ i
exercise NN i
( ( i
50 CD i
% NN i
maximal JJ i
heart NN i
rate NN i
reserve NN i
under IN i
15 CD i
% NN i
O? NNP i
, , i
H-RT NNP i
) ) i
, , i
or CC i
hypoxic-absolute JJ i
exercise NN i
( ( i
50 CD i
% NN i
W NNP i
( ( i
max NN i
) ) i
under IN i
15 CD i
% NN i
O? NNP i
, , i
H-AT NNP i
) ) i
for IN i
30 CD N
min/day NN N
, , N
5 CD N
days/week NN N
for IN N
4 CD N
weeks NNS N
. . N

Before IN N
the DT N
intervention NN N
, , N
strenuous JJ N
exercise NN N
up RB N
to TO N
exhaustion NN N
increased VBD N
the DT o
mobilization NN o
of IN o
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
, , o
or CC o
CD8 NNP o
( ( o
bright VBN o
) ) o
lymphocytes VBZ o
expressing VBG o
activated VBN o
( ( o
CD11a NNP o
) ) o
or CC o
senescent NN o
( ( o
KLRG1 NNP o
) ) o
molecules VBZ o
into IN o
the DT o
peripheral JJ o
blood NN o
compartment NN o
. . o

The DT o
H-AT NNP o
for IN N
4 CD N
weeks NNS N
up-regulated JJ o
co-stimulatory JJ o
molecule NN o
CD28 NNP o
expression NN o
and CC o
was VBD o
accompanied VBN o
by IN N
depressed JJ N
KLRG1 NNP o
level NN o
on IN o
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
, , o
or CC o
CD8 NNP o
( ( o
bright VBN o
) ) o
lymphocytes VBZ o
at IN o
rest NN o
or CC o
following VBG N
exercise NN N
. . N

Simultaneously RB i
, , i
this DT i
intervention NN i
increased VBD i
interferon-? JJ o
( ( o
IFN-? NNP o
) ) o
level NN o
and CC o
unchanged JJ o
interleukin-4 JJ o
level NN o
, , o
as RB o
well RB o
as IN N
, , N
decreased VBD o
myeloperoxidase NN o
( ( o
MPO NNP o
) ) o
and CC o
interleukin-6 JJ o
levels NNS o
in IN o
plasma NN o
. . o

However RB N
, , N
no DT N
significant JJ N
changes NNS N
in IN N
resting VBG N
and CC N
exercise-induced JJ o
mobilizations NNS o
of IN o
various JJ o
T-lymphocyte JJ o
subsets NNS o
and CC o
productions NNS o
of IN o
cytokines NNS o
and CC o
MPO NNP o
occurred VBD o
following VBG N
the DT i
N-C NNP i
, , i
H-C NNP i
, , i
N-T NNP i
, , i
and CC i
H-RT NNP i
interventions NNS i
. . i

Therefore RB i
, , i
we PRP N
conclude VBP N
that IN N
4-week JJ N
H-AT NNP i
intervention NN i
reduced VBD o
senescent JJ o
T-lymphocyte JJ o
subsets NNS o
with IN o
increasing VBG o
IFN-? NNP o
level NN o
in IN o
blood NN o
, , o
which WDT o
responses NNS N
are VBP N
accompanied VBN N
by IN o
depressed JJ o
oxidative JJ o
stress NN o
and CC o
pro-inflammatory JJ o
cytokine NN o
production NN o
. . o

These DT N
findings NNS N
can MD N
help VB N
to TO N
determine VB N
an DT N
effective JJ N
hypoxic NN i
exercise NN i
regimen NNS i
to TO N
minimize VB o
immune JJ o
dysfunction NN o
by IN N
retarding VBG N
T-lymphocyte JJ o
senescence NN o
. . o

-DOCSTART- -9761783- O O

Oxidative JJ N
DNA NNP N
damage NN N
measured VBD N
in IN N
human JJ N
lymphocytes NNS N
: : N
large JJ N
differences NNS N
between IN N
sexes NNS N
and CC N
between IN N
countries NNS N
, , N
and CC N
correlations NNS N
with IN N
heart NN N
disease NN N
mortality NN N
rates NNS N
. . N

The DT N
'antioxidant JJ N
hypothesis NN N
' POS N
proposes NNS N
that IN N
vitamin NN i
C NNP i
, , i
vitamin NN i
E NNP i
, , i
carotenoids NNS i
, , N
and CC N
other JJ N
antioxidants NNS i
occurring VBG N
in IN N
fruit NN N
and CC N
vegetables NNS N
afford VBP N
protection NN N
against IN N
heart NN N
disease NN N
and CC N
cancer NN N
by IN N
preventing VBG N
oxidative JJ N
damage NN N
to TO N
lipids NNS N
and CC N
to TO N
DNA NNP N
, , N
respectively RB N
. . N

To TO N
test VB N
elements NNS N
of IN N
this DT N
hypothesis NN N
, , N
we PRP N
have VBP N
measured VBN i
blood NN i
levels NNS i
of IN N
dietary JJ N
antioxidants NNS N
, , N
and CC N
8-oxodeoxyguanosine JJ i
( ( N
8-oxo-dG JJ N
) ) N
concentrations NNS N
in IN N
lymphocyte NN i
DNA NN i
, , N
in IN N
healthy JJ p
men NNS p
and CC p
women NNS p
from IN p
five CD p
European JJ p
countries NNS p
: : p
France NNP p
, , p
Ireland NNP p
, , p
The DT p
Netherlands NNP p
, , p
Spain NNP p
, , p
and CC p
the DT p
U.K NNP p
. . p

Volunteers NNS p
, , p
aged VBD p
25 CD p
45 CD p
, , p
all DT p
nonsmokers NNS p
, , N
gave VBD N
blood NN N
samples NNS N
before IN N
and CC N
after IN N
a DT N
12-wk JJ i
carotenoid NN i
supplementation NN i
regime NN i
. . i

Vitamin NNP N
C NNP N
was VBD N
measured VBN N
in IN N
plasma NN N
and CC N
vitamin NN N
E NNP N
and CC N
carotenoids NNS N
were VBD N
measured VBN N
in IN N
serum NN N
by IN N
high-performance NN N
liquid NN i
chromatography NN i
( ( N
HPLC NNP N
) ) N
. . N

8-oxo-dG CD N
was VBD N
assayed VBN N
by IN N
HPLC NNP N
( ( N
with IN N
coulometric JJ N
detection NN N
) ) N
in IN N
DNA NNP N
isolated VBD N
from IN N
lymphocytes NNS N
from IN N
the DT N
same JJ N
blood NN N
samples NNS N
. . N

Mean JJ N
values NNS N
were VBD N
calculated VBN N
for IN N
groups NNS N
of IN N
volunteers NNS N
at IN N
each DT N
sampling NN N
time NN N
according VBG N
to TO N
country NN N
, , N
sex NN N
, , N
and CC N
supplementation NN N
( ( N
between IN N
9 CD N
and CC N
24 CD N
individual JJ N
samples NNS N
contributing VBG N
to TO N
each DT N
mean NN N
) ) N
. . N

We PRP N
found VBD N
that IN N
8-oxo-dG JJ o
levels NNS o
in IN o
lymphocyte NN o
DNA NNP o
vary NN N
significantly RB N
according VBG N
to TO N
sex NN N
and CC N
country NN N
. . N

A DT N
low JJ N
mean JJ o
8-oxo-dG JJ o
concentration NN o
is VBZ N
seen VBN N
in IN N
DNA NNP N
of IN N
women NNS N
from IN N
all DT N
five CD N
countries NNS N
, , N
and CC N
of IN N
men NNS N
from IN N
France NNP N
and CC N
Spain NNP N
. . N

8-oxo-dG NN o
is VBZ N
significantly RB N
higher JJR N
( ( N
up IN N
to TO N
about IN N
threefold NN N
) ) N
in IN N
lymphocyte NN N
DNA NN N
from IN N
men NNS N
in IN N
Ireland NNP N
and CC N
the DT N
U.K. NNP N
Oxidative NNP o
DNA NNP o
damage NN o
is VBZ N
not RB N
significantly RB N
affected VBN N
by IN N
carotenoid JJ N
supplementation NN N
; : N
nor CC N
is VBZ N
there EX N
any DT N
association NN N
with IN N
mean JJ o
baseline NN o
levels NNS o
of IN o
antioxidants NNS o
, , N
which WDT N
are VBP N
generally RB N
similar JJ N
in IN N
the DT N
five CD N
countries NNS N
. . N

The DT N
five CD N
countries NNS N
sampled VBN N
lie NN N
on IN N
an DT N
axis NN N
from IN N
northern JJ N
to TO N
southern JJ N
Europe NNP N
with IN N
a DT N
steep JJ N
gradient NN N
in IN N
terms NNS N
of IN N
premature JJ N
heart NN N
disease NN N
. . N

There EX N
is VBZ N
a DT N
strong JJ N
association NN N
between IN N
premature NN o
coronary JJ o
heart NN o
disease NN o
mortality NN o
in IN N
men NNS N
and CC N
the DT N
mean JJ N
levels NNS N
of IN N
8-oxo-dG NN N
for IN N
the DT N
five CD N
countries NNS N
( ( N
r NN N
= VBZ N
0.95 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Women NNS N
have VBP N
low JJ N
coronary JJ o
heart NN o
disease NN o
mortality NN o
rates NNS o
, , N
which WDT N
do VBP N
not RB N
correlate VB N
with IN N
8-oxo-dG JJ N
. . N

In IN N
terms NNS N
of IN N
cancer NN N
deaths NNS N
, , N
only RB N
colorectal JJ N
cancer NN N
in IN N
men NNS N
shows VBZ N
a DT N
significant JJ o
positive JJ o
correlation NN o
( ( N
r JJ N
= NN N
0.91 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
stomach NN o
cancer NN o
in IN N
women NNS N
is VBZ N
negatively RB N
correlated VBN N
with IN N
DNA NNP N
oxidation NN N
( ( N
r JJ N
= NNP N
-0.92 NNP N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

-DOCSTART- -7584286- O O

Why WRB N
are VBP N
there RB N
sometimes RB N
concreteness JJ o
effects NNS o
in IN o
memory NN o
for IN N
prose NN N
? . N
Four CD p
experiments NNS p
explored VBD N
on-line JJ N
encoding NN N
strategies NNS N
and CC N
memory NN p
for IN p
high JJ p
imagery NN p
and CC p
low JJ p
imagery NN p
texts NN p
. . p

Results NNP N
consistently RB N
indicated VBD N
that IN N
concreteness NN o
effects NNS o
in IN o
memory NN o
for IN o
text JJ o
depend NN N
on IN N
how WRB N
materials NNS N
are VBP N
presented VBN N
in IN N
several JJ N
different JJ N
respects NNS N
. . N

Most JJS N
importantly RB N
, , N
the DT N
experiments NNS N
clarified VBD N
apparently RB N
contradictory JJ N
results NNS N
of IN N
previous JJ N
studies NNS N
by IN N
indicating VBG N
that IN N
concreteness NN o
effects NNS o
generally RB N
do VBP N
not RB N
occur VB N
in IN N
memory NN N
for IN N
prose NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
between-subjects NNS p
, , N
and CC N
that IN N
their PRP$ N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
of IN N
presentation NN N
. . N

In IN N
addition NN N
, , N
moving VBG N
window JJ N
analyses NNS N
of IN N
text JJ i
processing NN i
strategies NNS i
indicated VBD N
that IN N
differential JJ N
strategies NNS N
observed VBN N
in IN N
previous JJ N
studies NNS N
when WRB N
subjects NNS p
listened VBD N
to TO N
high JJ N
vs NN N
low JJ N
imagery NN N
text NN N
do VBP N
not RB N
generalize VB N
to TO N
reading NN N
of IN N
the DT N
same JJ N
materials NNS N
. . N

Potential JJ N
explanations NNS N
for IN N
the DT N
pattern NN N
of IN N
results NNS N
are VBP N
evaluated VBN N
, , N
and CC N
implications NNS N
for IN N
theories NNS N
of IN N
mental JJ N
imagery NN N
and CC N
memory NN N
are VBP N
considered VBN N
. . N

-DOCSTART- -380614- O O

Clofibrate NNP o
and CC o
diabetes VBZ o
control NN o
in IN N
patients NNS p
treated VBN p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
. . i

1 CD N
. . N

Twenty-two JJ p
maturity-onset JJ p
type NN p
diabetics NNS p
treated VBD p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
entered VBD N
a DT N
single-blind JJ N
crossover NN N
study NN N
using VBG N
placebo NN i
( ( N
periods VB N
A DT N
and CC N
C NNP N
, , N
2 CD N
months NNS N
each DT N
) ) N
and CC N
clofibrate NN i
( ( N
2 CD N
g/day NN N
; : N
period NN N
B NNP N
; : N
2 CD N
months NNS N
) ) N
. . N

2 CD N
. . N

In IN N
thirteen JJ p
patients NNS p
, , p
under IN p
reasonably RB p
good JJ p
control NN p
, , N
clofibrate NN i
did VBD N
not RB N
reduce VB o
fasting VBG o
or CC o
post-prandial JJ o
blood NN o
glucose NN o
, , N
nor CC N
24 CD o
h NN o
glycosuria NN o
; : o
no DT N
improvement NN N
was VBD N
noted VBN N
in IN N
the DT N
M-value NNP o
, , o
an DT o
index NN o
of IN o
diabetes NNS o
control NN o
. . o

3 CD N
. . N

In IN N
contrast NN N
, , N
in IN N
nine CD N
patients NNS N
, , N
with IN N
poor JJ N
diabetes NNS o
control NN o
, , N
clofibrate NN i
reduced VBD N
24 CD o
h NN o
glycosuria NN o
and CC N
significantly RB N
improved VBD N
the DT N
M-value NNP o
. . o

4 CD N
. . N

In IN N
all DT N
patients NNS N
, , N
clofibrate JJ i
therapy NN i
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
19-23 JJ N
% NN N
reduction NN N
in IN N
plasma NN o
fibrinogen NN o
. . o

5 CD N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
addition NN N
of IN N
clofibrate NN i
may MD N
be VB N
useful JJ N
in IN N
maturity-onset JJ p
diabetics NNS p
not RB p
adequately RB p
controlled VBN p
by IN p
diet NN p
combined VBN p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
. . i

-DOCSTART- -3324498- O O

Pouch JJ i
versus NN i
esophagojejunostomy NN o
after IN N
total JJ p
gastrectomy NN o
: : o
a DT p
randomized JJ p
clinical JJ p
trial NN p
. . p

-DOCSTART- -24214840- O O

Promoting VBG N
gynecologic JJ N
cancer NN N
awareness NN i
at IN N
a DT N
critical JJ N
juncture NN N
-- : N
where WRB N
women NNS N
and CC N
providers NNS N
meet VBP N
. . N

Given VBN N
the DT N
absence NN N
of IN N
effective JJ N
population-based JJ N
screening NN N
tests NNS N
for IN N
ovarian JJ N
, , N
uterine JJ N
, , N
vaginal JJ N
, , N
and CC N
vulvar NN N
cancers NNS N
, , N
early JJ N
detection NN N
can MD N
depend VB N
on IN N
women NNS N
and CC N
health NN N
care NN N
providers NNS N
recognizing VBG N
the DT N
potential JJ N
significance NN N
of IN N
symptoms NNS N
. . N

In IN N
2008 CD N
, , N
the DT N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
and CC N
Prevention NNP N
's POS N
( ( N
CDC NNP N
) ) N
Inside NNP N
Knowledge NNP N
campaign NN N
began VBD N
distributing VBG N
consumer NN i
education NN i
materials NNS i
promoting VBG i
awareness NN i
of IN i
gynecologic JJ i
cancer NN i
symptoms NNS i
. . i

We PRP N
investigated VBD N
providers NNS p
' POS p
in-office NN p
use NN p
of IN p
CDC NNP p
gynecologic JJ p
cancer NN p
materials NNS p
and CC p
their PRP$ p
recognition NN p
of IN p
the DT p
symptoms NNS p
highlighted VBN p
in IN p
the DT p
materials NNS p
. . p

We PRP N
analyzed VBD N
data NNS p
from IN p
a DT p
national JJ p
2012 CD p
survey NN p
of IN p
US NNP p
primary JJ p
care NN p
physicians NNS p
, , p
nurse JJ p
practitioners NNS p
, , p
and CC p
gynecologists NNS p
( ( p
N NNP p
= NNP p
1,380 CD p
) ) p
. . p

Less JJR p
than IN N
a DT N
quarter NN N
of IN N
providers NNS N
( ( N
19.4 CD N
% NN N
) ) N
reported VBD N
using VBG N
CDC NNP N
gynecologic NN N
cancer NN N
education NN N
materials NNS N
in IN N
their PRP$ N
offices NNS N
. . N

The DT N
provider NN N
characteristics NNS N
associated VBN N
with IN N
the DT N
use NN N
of IN N
CDC NNP N
materials NNS N
were VBD N
not RB N
consistent JJ N
across IN N
specialties NNS N
. . N

However RB o
, , o
recognition NN o
of IN o
symptoms NNS o
associated VBN o
with IN N
gynecologic JJ N
cancers NNS N
was VBD N
consistently RB N
higher JJR N
among IN N
providers NNS N
who WP N
reported VBD N
using VBG N
CDC NNP N
materials NNS N
. . N

The DT N
possibility NN N
that IN N
providers NNS N
were VBD N
educated VBN N
about IN N
gynecologic JJ N
cancer NN N
symptoms NNS N
through IN N
the DT N
dissemination NN N
of IN N
materials NNS N
intended VBN N
for IN N
their PRP$ N
patients NNS N
is VBZ N
intriguing JJ N
and CC N
warrants NNS N
further JJ N
investigation NN N
. . N

Distributing VBG N
consumer NN N
education NN N
materials NNS N
in IN N
health NN N
care NN N
provider NN N
offices NNS N
remains VBZ N
a DT N
priority NN N
for IN N
the DT N
Inside NNP N
Knowledge NNP N
campaign NN N
, , N
as IN N
the DT N
setting NN N
where WRB N
women NNS N
and CC N
health NN p
care NN p
providers NNS p
interact VBP p
is VBZ N
one CD N
of IN N
the DT N
most RBS N
crucial JJ N
venues NNS N
to TO N
promote VB N
awareness NN N
of IN N
gynecologic JJ N
cancer NN N
symptoms NNS N
. . N

-DOCSTART- -8208469- O O

[ RB N
Perioperative NNP N
teicoplanin NN i
prophylaxis NN i
in IN N
patients NNS p
undergoing VBG p
breast JJ p
reconstruction NN p
with IN p
the DT p
abdominal JJ p
wall NN p
. . p

A DT N
case-control NN N
study NN N
] NNP N
. . N

The DT N
authors NNS N
report VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
antibiotic JJ N
prophylaxis NN N
of IN N
postoperative JJ N
infection NN N
following VBG N
breast NN p
reconstruction NN p
by IN p
transposition NN p
of IN p
rectus NN p
abdominis NN p
myocutaneous JJ p
flap NN p
( ( N
TRAMF NNP N
) ) N
. . N

The DT N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
a DT N
short-term JJ N
parenteral JJ i
prophylaxis NN i
with IN i
Teicoplanin NNP i
and CC N
the DT N
end-point NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
evaluation NN N
of IN N
wound NN N
contamination NN N
assessed VBN N
by IN N
means NNS N
of IN N
microbiologic JJ N
culture NN N
of IN N
drainage NN N
fluid NN N
. . N

From IN p
October NNP p
1990 CD p
to TO p
March NNP p
1992 CD p
38 CD p
patients NNS p
were VBD p
recruited VBN p
: : p
20 CD p
patients NNS p
in IN p
the DT p
antibiotic JJ p
prophylaxis NN p
arm NN p
and CC p
18 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
. . p

Analysis NN N
of IN N
drainage NN N
fluids NNS N
showed VBD N
a DT N
higher JJR o
contamination NN o
rate NN o
( ( N
15/18 CD N
= RB N
83 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
as IN N
compared VBN N
to TO N
the DT N
prophylaxis NN N
arm NN N
( ( N
2/20 CD N
= RB N
10 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Moreover RB N
, , N
11 CD N
patients NNS N
in IN N
the DT N
control NN N
arm NN N
suffered VBD N
from IN N
fever NN o
> $ o
37.5 CD o
degrees NNS o
C NNP o
for IN N
at IN N
least JJS N
3 CD N
days NNS N
as RB N
compared VBN N
to TO N
1 CD N
patient NN N
in IN N
the DT N
antibiotic JJ N
prophylaxis NN N
group NN N
; : N
the DT N
postoperative JJ o
stay NN o
was VBD N
13.3 CD N
+/- JJ N
4.3 CD N
and CC N
9.0 CD N
+/- JJ N
1.6 CD N
in IN N
the DT N
control NN N
and CC N
antibiotic JJ N
arm NN N
respectively RB N
. . N

No NNP N
antibiotic JJ o
related JJ o
side NN o
effects NNS o
were VBD N
evidenced VBN N
through IN N
the DT N
study NN N
. . N

These DT N
results NNS N
seem VBP N
to TO N
confirm VB N
the DT N
value NN N
of IN N
parenteral JJ N
short-term JJ N
antibiotic JJ N
prophylaxis NN N
of IN N
postoperative JJ N
infection NN N
in IN N
such JJ N
kind NN N
of IN N
clean JJ N
operative JJ N
procedure NN N
. . N

-DOCSTART- -8520804- O O

Lack NN N
of IN N
interaction NN N
between IN N
pantoprazole NN i
and CC i
digoxin NN i
at IN N
therapeutic JJ N
doses NNS N
in IN p
man NN p
. . p

Substituted JJ i
benzimidazole JJ i
inhibitors NNS i
of IN N
the DT N
gastric JJ N
H+/K+ATPase NNP N
may MD N
interact VB N
with IN N
the DT N
cytochrome NN N
P450 NNP N
enzyme NN N
system NN N
and CC N
alter VB N
the DT N
pharmacokinetics NNS N
of IN N
coadministered JJ N
drugs NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
changes NNS N
in IN N
intragastric JJ N
pH NN N
might MD N
alter VB N
the DT N
absorption NN N
of IN N
other JJ N
drugs NNS N
. . N

The DT N
primary JJ N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
pantoprazole JJ i
modifies NNS N
the DT N
steady-state JJ N
serum NN N
concentrations NNS N
of IN N
orally RB N
administered VBN N
digoxin NN i
. . i

Secondary JJ N
aims NNS N
were VBD N
the DT N
influence NN N
of IN N
digoxin NN i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
pantoprazole NN i
as RB N
well RB N
as IN N
safety NN N
and CC N
tolerability NN N
. . N

Eighteen NNP p
healthy JJ p
volunteers NNS p
received VBD N
a DT N
single JJ N
oral JJ i
dose NN i
of IN i
pantoprazole NN i
( ( i
40 CD i
mg NN i
) ) i
and CC i
serum JJ i
concentrations NNS i
were VBD N
determined VBN N
. . N

Three CD N
to TO N
10 CD N
days NNS N
later RB N
, , N
subjects NNS N
received VBD N
in IN N
a DT N
single-blind NN N
, , N
randomized VBN N
, , N
crossover JJ N
fashion NN N
oral JJ N
beta-acetyldigoxin NN i
( ( N
0.2 CD N
mg NN N
) ) N
twice RB N
daily RB N
and CC N
concomitant JJ i
oral JJ i
pantoprazole NN i
( ( N
40 CD N
mg NN N
) ) N
or CC N
placebo JJ i
once RB N
daily JJ N
for IN N
5 CD N
days NNS N
. . N

Serum NNP N
concentrations NNS N
of IN N
pantoprazole NN i
and CC i
digoxin NN i
were VBD N
determined VBN N
on IN N
day NN N
5 CD N
. . N

Primary JJ N
characteristics NNS N
for IN N
confirmative JJ N
assessment NN N
of IN N
no DT N
interaction NN N
were VBD N
AUC NNP o
and CC o
Cmax NNP o
of IN o
digoxin NN o
. . o

Lack NNP N
of IN N
interaction NN N
in IN N
the DT N
sense NN N
of IN N
equivalence NN N
was VBD N
concluded VBN N
for IN N
both DT N
digoxin NN N
( ( N
with IN N
and CC N
without IN N
pantoprazole NN i
) ) i
and CC N
pantoprazole JJ i
( ( i
with IN i
and CC i
without IN i
digoxin NN i
) ) i
as IN N
the DT N
90 CD N
% NN N
-confidence NN N
intervals NNS N
of IN N
the DT N
respective JJ N
AUC- NNP o
and CC o
Cmax-ratios NNP o
were VBD N
within IN N
the DT N
equivalence NN N
range NN N
of IN N
0.8-1.25 NNP N
. . N

Pantoprazole NNP i
did VBD N
not RB N
influence VB N
the DT N
characteristic JJ N
ECG NNP N
modifications NNS N
( ( N
T-wave NNP N
) ) N
caused VBN N
by IN N
digoxin NN N
. . N

Both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN o
and CC N
no DT N
adverse JJ o
events NNS o
or CC N
clinically RB N
relevant JJ N
alterations NNS N
in IN N
vital JJ N
signs NNS N
or CC N
clinical JJ N
laboratory NN N
parameters NNS N
were VBD N
observed VBN N
during IN N
treatment NN N
. . N

In IN N
conclusion NN N
, , N
pantoprazole NN i
and CC i
digoxin NN i
may MD N
be VB N
administered VBN N
concomitantly RB N
without IN N
the DT N
need NN N
for IN N
dose JJ N
adjustment NN N
. . N

-DOCSTART- -4605864- O O

[ JJ i
Pivampicillin NNP i
treatment NN N
of IN N
uro-genital JJ o
infections NNS o
in IN p
gynaecological JJ p
patients NNS p
. . p

A DT N
clinical JJ N
evaluation NN N
] NN N
. . N

-DOCSTART- -22146934- O O

Brief JJ N
report NN N
: : N
effect NN N
of IN N
a DT N
focused JJ i
imitation NN i
intervention NN i
on IN N
social JJ o
functioning NN o
in IN N
children NNS p
with IN p
autism NN p
. . p

Imitation NNP N
is VBZ N
an DT N
early JJ N
skill NN N
thought VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
social JJ N
development NN N
, , N
leading VBG N
some DT N
to TO N
suggest VB N
that IN N
teaching VBG N
imitation NN N
to TO N
children NNS p
with IN p
autism NN p
should MD N
lead VB N
to TO N
improvements NNS N
in IN N
social JJ o
functioning NN o
. . o

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
focused JJ i
imitation NN i
intervention NN i
on IN N
initiation NN N
of IN N
joint JJ o
attention NN o
and CC o
social-emotional JJ o
functioning NN o
in IN N
27 CD p
young JJ p
children NNS p
with IN p
autism NN p
. . p

Results NNS N
indicated VBD N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB N
more RBR N
gains NNS N
in IN N
joint JJ o
attention NN o
initiations NNS o
at IN N
post-treatment JJ N
and CC N
follow-up JJ N
and CC N
social-emotional JJ o
functioning NN o
at IN N
follow-up NN N
than IN N
the DT N
control NN N
group NN N
. . N

Although IN N
gains NNS o
in IN o
social JJ o
functioning NN o
were VBD N
associated VBN N
with IN N
treatment NN N
, , N
a DT N
mediation NN N
analysis NN N
did VBD N
not RB N
support VB N
imitation NN i
as IN N
the DT N
mechanism NN N
of IN N
action NN N
. . N

These DT N
findings NNS N
suggest VBP N
the DT N
intervention NN N
improves VBZ N
social JJ o
functioning NN o
in IN o
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -7410734- O O

Scaling VBG N
clinical JJ N
judgments NNS N
of IN N
symptom JJ N
pathology NN N
by IN N
means NNS N
of IN N
the DT N
psychophysiological JJ N
method NN N
of IN N
magnitude NN N
estimation NN N
. . N

Summing VBG N
scores NNS N
across IN N
heterogeneous JJ N
symptom NN N
items NNS N
without IN N
consideration NN N
of IN N
their PRP$ N
differing JJ N
psychopathological JJ N
significance NN N
has VBZ N
been VBN N
criticized VBN N
as IN N
producing VBG N
an DT N
inadequate JJ N
picture NN N
of IN N
an DT N
individual NN N
's POS N
clinical JJ N
status NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
derive JJ N
symptom JJ N
item NN N
weights NNS N
representing VBG N
clinically RB N
judged VBN N
seriousness NN N
of IN N
each DT N
symptom NN N
through IN N
the DT N
application NN N
of IN N
Steven NNP i
's POS i
psychophysical JJ i
method NN i
of IN i
magnitude NN i
estimation NN i
. . i

A DT N
nationwide JJ N
sample NN N
of IN N
129 CD p
clinicians NNS p
rated VBD N
the DT N
pathological JJ N
significance NN N
of IN N
221 CD N
symptom JJ N
items NNS N
in IN N
a DT N
design NN N
such JJ N
that IN N
every DT N
rater NN N
rated VBD N
121 CD N
items NNS N
, , N
21 CD N
of IN N
which WDT N
were VBD N
rated VBN N
by IN N
all DT N
raters NNS N
and CC N
100 CD N
of IN N
which WDT N
were VBD N
rated VBN N
only RB N
by IN N
the DT N
A NNP N
or CC N
B NNP N
subgroup NN N
to TO N
which WDT N
each DT N
rater NN N
was VBD N
randomly RB N
assigned VBN N
. . N

Each DT N
item NN N
was VBD N
rated VBN N
as IN N
to TO N
the DT N
seriousness NN N
of IN N
the DT N
pathology NN N
it PRP N
would MD N
represent VB N
if IN N
manifested VBN N
by IN N
either CC N
a DT N
boy NN N
child NN N
, , N
girl JJ N
child NN N
, , N
boy JJ N
adolescent NN N
, , N
or CC N
girl JJ N
adolescent NN N
, , N
with IN N
one-fourth NN N
of IN N
the DT N
raters NNS N
assigned VBD N
to TO N
each DT N
condition NN N
. . N

The DT N
results NNS N
of IN N
211 CD N
two-way JJ i
analyses NNS i
of IN i
variance NN i
revealed VBD N
that IN N
age NN N
and CC N
age NN o
and CC o
sex NN o
in IN N
interaction NN N
, , N
but CC N
not RB N
sex VB N
alone RB N
, , N
significantly RB N
influenced VBD N
the DT N
clinical JJ N
ratings NNS N
. . N

The DT N
resulting VBG N
magnitude JJ o
estimation NN o
ratings NNS o
of IN o
symptom JJ o
pathology NN o
ranged VBD N
from IN N
1.0 CD N
to TO N
9.9 CD N
. . N

They PRP N
were VBD N
demonstrated VBN N
to TO N
have VB N
satisfactoy VBN N
reliability NN N
and CC N
convergent NN N
validity NN N
and CC N
to TO N
have VB N
the DT N
psychophysical JJ N
characteristics NNS N
of IN N
a DT N
prothetic JJ N
continuum NN N
. . N

-DOCSTART- -10594393- O O

Ursodeoxycholic JJ i
acid NN i
has VBZ N
no DT N
influence NN N
on IN N
function NN N
after IN N
restorative JJ N
proctocolectomy NN o
in IN N
ulcerative JJ p
colitis NN p
. . p

BACKGROUND NNP N
Poor NNP N
pouch JJ N
function NN N
is VBZ N
associated VBN N
with IN N
impaired JJ N
bile NN N
acid NN N
absorption NN N
and CC N
increased VBD N
faecal JJ N
loss NN N
of IN N
bile JJ N
acids NNS N
. . N

Bile NNP i
acid JJ i
replacement NN i
therapy NN i
might MD N
therefore RB N
be VB N
of IN N
clinical JJ N
benefit NN N
, , N
provided VBD N
that IN N
diarrhoea NN N
is VBZ N
not RB N
aggravated VBN N
by IN N
therapy NN N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
role NN N
of IN N
exogenous JJ i
bile NN i
acid NN i
therapy NN i
in IN N
patients NNS p
with IN p
poor JJ p
pouch JJ p
function NN p
after IN N
restorative JJ N
proctocolectomy NN N
for IN N
ulcerative JJ N
colitis NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Twenty NNP p
ulcerative JJ p
colitis NN p
patients NNS p
with IN p
poor JJ p
pouch JJ p
function NN p
( ( p
score NN p
> VBZ p
4 CD p
on IN p
a DT p
12-point JJ p
score NN p
) ) p
were VBD N
recruited VBN N
for IN N
inclusion NN N
to TO N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
crossover NN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
ursodeoxycholic JJ i
acid NN i
( ( N
10 CD N
mg/kg NNS N
per IN N
day NN N
in IN N
two CD N
divided JJ N
doses NNS N
for IN N
1 CD N
month NN N
) ) N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
16 CD p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
functional JJ o
score NN o
or CC o
bowel NN o
frequency NN o
following VBG N
treatment NN N
irrespective NN N
of IN N
whether IN N
the DT N
active JJ N
treatment NN N
was VBD N
given VBN N
before IN N
or CC N
after IN N
placebo NN N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
ursodeoxycholic JJ i
acid NN i
given VBN N
over IN N
4 CD N
weeks NNS N
had VBD N
no DT N
influence NN N
on IN N
functional JJ o
score NN o
or CC o
bowel NN o
frequency NN o
after IN N
restorative JJ N
proctocolectomy NN N
for IN N
U.C NNP o
. . o

-DOCSTART- -16648775- O O

The DT N
double-blind JJ N
sham-controlled JJ N
study NN N
of IN N
high-frequency NN i
rTMS NN i
( ( N
20 CD N
Hz NNP N
) ) N
for IN N
negative JJ N
symptoms NNS N
in IN N
schizophrenia NN p
: : p
negative JJ N
results NNS N
. . N

The DT N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
HF-rTMS NNP i
) ) i
over IN N
the DT N
prefrontal JJ N
cortex NN N
is VBZ N
a DT N
promising JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN p
. . p

Using VBG N
double-blind JJ N
sham-controlled JJ N
parallel NN N
design NN N
, , N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
HF-rTMS NNP i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
on IN N
negative JJ N
symptoms NNS N
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

Sixteen NNP p
schizophrenia NN p
patients NNS p
with IN p
predominantly RB p
negative JJ p
symptoms NNS p
on IN p
stable JJ p
antipsychotic JJ p
medication NN p
were VBD N
treated VBN N
with IN N
20 CD i
Hz NNP i
rTMS NN i
( ( N
90 CD N
% NN N
of IN N
motor NN N
threshold NN N
, , N
2000 CD N
stimuli NN N
per IN N
session NN N
) ) N
over IN N
ten JJ N
days NNS N
within IN N
2 CD N
weeks NNS N
with IN N
six CD N
weeks NNS N
follow-up RB N
. . N

The DT N
effect NN N
was VBD N
assessed VBN N
using VBG N
PANSS NNP o
, , o
CGI NNP o
, , o
MADRS NNP o
and CC o
neuropsychological JJ o
tests NNS o
. . o

We PRP N
failed VBD N
to TO N
find VB N
any DT N
significant JJ N
effect NN N
of IN N
active JJ o
rTMS NN o
. . o

Sham NNP o
rTMS NN o
showed VBD N
a DT N
trend NN N
for IN N
improvement NN o
over IN o
time NN o
on IN N
positive JJ o
and CC o
negative JJ o
subscales NNS o
of IN o
PANSS NNP o
and CC o
MADRS NNP o
. . o

Between-group NNP N
comparisons NNS N
failed VBD N
to TO N
reveal VB N
any DT N
significant JJ N
differences NNS N
on IN N
any DT N
rating NN o
scales NNS o
except IN N
a DT N
positive JJ o
subscale NN o
of IN o
PANSS NNP o
after IN N
8 CD N
weeks NNS N
. . N

Results NNS N
from IN N
our PRP$ N
study NN N
did VBD N
not RB N
confirm VB N
that IN N
HF-rTMS NNP o
over IN N
the DT N
left JJ N
DLPCF NNP o
affects VBZ o
the DT o
negative JJ o
symptoms NNS o
of IN o
schizophrenia NN o
and CC N
alternative JJ N
rTMS NN N
approaches NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -18208642- O O

Comparison NNP N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
epoetin NN i
zeta NN i
to TO i
epoetin VB i
alfa NN i
in IN N
the DT N
maintenance NN p
phase NN p
of IN p
renal JJ p
anaemia NN p
treatment NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
therapeutic JJ N
efficacy NN N
and CC N
safety NN N
of IN N
epoetin JJ i
zeta NN i
, , N
compared VBN N
with IN N
epoetin NN i
alfa NN i
, , N
in IN N
maintaining VBG N
target NN N
haemoglobin NN N
( ( N
Hb NNP N
) ) N
concentrations NNS N
in IN N
patients NNS p
with IN p
anaemia NN p
and CC p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
maintained VBD p
on IN p
haemodialysis NN p
. . p

METHODS NNP N
Patients NNPS N
received VBD N
epoetin JJ i
zeta NN i
or CC i
epoetin NN i
alfa NN i
intravenously RB N
, , N
1-3 JJ N
times/week NN N
for IN N
12 CD N
weeks NNS N
, , N
then RB N
the DT N
alternative JJ N
treatment NN N
for IN N
12 CD N
weeks NNS N
, , N
in IN N
this DT N
double-blind NN N
, , N
crossover NN N
, , N
phase NN N
III NNP N
trial NN N
. . N

Eligible JJ p
patients NNS p
were VBD p
18-75 CD p
years NNS p
old JJ p
with IN p
CKD NNP p
stage NN p
5 CD p
maintained VBN p
on IN p
haemodialysis NN p
. . p

Patients NNS N
had VBD N
received VBN N
epoetin NN i
for IN N
> NN N
or CC N
= $ N
3 CD N
months NNS N
upon IN N
study NN N
entry NN N
and CC N
had VBD N
achieved VBN N
a DT N
target NN N
Hb NNP N
level NN N
of IN N
10.5-12.5 JJ N
g/dL NN N
with IN N
a DT N
stable JJ N
epoetin NN i
dose NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
efficacy NN N
endpoints NNS N
were VBD N
intra-individual JJ N
differences NNS N
( ( N
test-reference NN N
) ) N
in IN N
mean JJ N
Hb NNP N
levels NNS N
and CC N
mean JJ N
weekly JJ N
dose/kg NN N
of IN N
body NN N
weight NN N
. . N

Safety NN N
endpoints NNS N
included VBD N
occurrence NN o
of IN o
neutralizing VBG o
anti-erythro JJ o
poietin NN o
antibodies NNS o
, , o
tolerability NN o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . N

RESULTS NNP N
In IN p
total JJ p
, , p
313 CD p
patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
epoetin NN i
zeta NN i
( ( N
n JJ N
= NNP N
155 CD N
) ) N
or CC N
epoetin JJ i
alfa NN i
( ( N
n JJ N
= NNP N
158 CD N
) ) N
; : N
146 CD N
and CC N
145 CD N
patients NNS N
( ( N
respectively RB N
) ) N
switched VBD N
treatment NN N
after IN N
12 CD N
weeks NNS N
. . N

Mean NNP o
( ( o
range NN o
) ) o
Hb NNP o
levels NNS o
were VBD N
11.35 CD N
( ( N
8.96-14.22 CD N
) ) N
g/dL NN N
and CC N
11.54 CD N
( ( N
8.74-13.84 CD N
) ) N
g/dL NN N
for IN N
patients NNS N
receiving VBG N
epoetin JJ N
zeta NN N
and CC N
epoetin NN N
alfa NN N
, , N
respectively RB N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
[ NNP N
test-reference NN N
] NN N
: : N
0.09-0.28 JJ N
g/dL NN N
, , N
within IN N
the DT N
predefined JJ N
equivalence NN N
range NN N
of IN N
+/-0.6 NNP N
g/dL NN N
) ) N
. . N

Mean NNP o
( ( o
range NN o
) ) o
weekly JJ o
doses NNS o
were VBD N
92.68 CD N
( ( N
12.74-398.41 JJ N
) ) N
IU/kg/wk NNP N
and CC N
92.58 CD N
( ( N
10.53-393.07 JJ N
) ) N
IU/kg/wk NNP N
for IN N
patients NNS N
receiving VBG N
epoetin JJ i
zeta NN i
and CC N
epoetin NN i
alfa NN i
, , N
respectively RB N
( ( N
95 CD N
% NN N
CI NNP N
[ NNP N
test-reference NN N
] NN N
: : N
-4.67 NN N
and CC N
4.29 CD N
IU/kg/wk NNP N
, , N
within IN N
the DT N
equivalence NN N
range NN N
of IN N
+/-45.00 NNP N
IU/kg/wk NNP N
) ) N
. . N

Patients NNPS N
underwent JJ N
minor JJ N
nominal JJ N
dose NN N
adjustments NNS N
during IN N
treatment NN N
crossover NN N
. . N

AE NNP N
profile NN N
was VBD N
similar JJ N
for IN N
both DT N
products NNS N
; : N
the DT N
most RBS N
commonly RB N
reported VBD N
AEs NNP N
were VBD N
infections NNS o
and CC o
infestations NNS o
( ( N
in IN N
26.5 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
epoetin JJ N
zeta NN N
and CC N
23.6 CD N
% NN N
receiving VBG N
epoetin JJ N
alfa NN N
) ) N
. . N

No UH N
patients NNS N
developed VBD N
neutralizing VBG o
anti-erythropoietin JJ o
antibodies NNS o
. . o

CONCLUSIONS NNP N
Epoetin NNP i
zeta NN i
is VBZ N
therapeutically RB N
equivalent JJ N
to TO N
epoetin VB N
alfa NN N
in IN N
the DT N
maintenance NN N
of IN N
target NN N
Hb NNP N
levels NNS N
in IN N
patients NNS p
with IN p
renal JJ p
anaemia NN p
. . p

No DT N
unexpected JJ N
AEs NNP N
were VBD N
seen VBN N
. . N

-DOCSTART- -19301089- O O

The DT N
effect NN N
of IN N
risedronate NN i
treatment NN N
on IN N
serum NN N
cytokines NNS N
in IN N
postmenopausal JJ p
osteoporosis NN p
: : p
a DT N
6-month JJ N
randomized NN N
and CC N
controlled VBD N
study NN N
. . N

There EX N
is VBZ N
much JJ N
evidence NN N
suggesting VBG N
that IN N
the DT N
decline NN N
in IN N
ovarian JJ N
function NN N
after IN N
menopause NN N
is VBZ N
associated VBN N
with IN N
spontaneous JJ N
increases NNS N
in IN N
proinflammatory JJ N
cytokines NNS N
. . N

Treatment NN N
with IN N
risedronate NN i
is VBZ N
accompanied VBN N
by IN N
significant JJ N
changes NNS N
in IN N
bone NN N
turnover NN N
and CC N
bone JJ N
mineral JJ N
density NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
risedronate NN i
treatment NN N
on IN N
the DT N
level NN N
of IN N
serum JJ N
cytokines NNS N
including VBG N
receptor NN N
activator NN N
of IN N
nuclear JJ N
factor-kappaB JJ N
ligand NN N
( ( N
RANKL NNP N
) ) N
and CC N
osteoprotegerin $ N
among IN N
postmenopausal JJ p
women NNS p
with IN p
osteoporosis NN p
. . p

The DT N
study NN N
group NN N
consisted VBD N
of IN N
61 CD p
postmenopausal JJ p
women NNS p
with IN p
osteoporosis NN p
. . p

Patients NNS N
were VBD N
randomly RB N
divided VBN N
in IN N
two CD N
groups NNS N
: : N
In IN N
group NN N
1 CD N
( ( N
n JJ N
= NNP N
41 CD N
) ) N
postmenopausal NN N
women NNS N
received VBD N
oral JJ i
risedronate NN i
( ( N
35 CD N
mg/week NN N
) ) N
, , N
calcium NN i
( ( N
1,000 CD N
mg/day NN N
) ) N
, , N
and CC N
vitamin NN i
D NNP i
( ( N
400 CD N
IU/day NNP N
) ) N
for IN N
12 CD N
months NNS N
. . N

In IN N
group NN N
2 CD N
( ( N
control NN N
group NN N
; : N
n CC N
= VB N
20 CD N
) ) N
patients NNS N
received VBD N
only RB N
oral JJ i
calcium NN i
( ( N
1,000 CD N
mg/day NN N
) ) N
and CC N
vitamin $ i
D NNP i
( ( N
400 CD N
IU/day NNP N
) ) N
. . N

Bone NNP o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
of IN o
lumbar NN o
spine NN o
( ( o
L1-L4 NNP o
) ) o
and CC o
proximal JJ o
femur NN o
were VBD N
determined VBN N
using VBG N
dual JJ N
X-ray JJ N
absorptiometry NN N
at IN N
baseline NN N
and CC N
after IN N
one CD N
year NN N
. . N

Venous NNP o
blood NN o
samples NNS o
were VBD N
obtained VBN N
for IN N
determination NN N
of IN N
serum JJ o
cytokines NNS o
including VBG o
interleukin-1beta JJ o
( ( o
IL-1beta NNP o
) ) o
, , o
tumor JJ o
necrosis NN o
factor-alpha NN o
( ( o
TNF-alpha NNP o
) ) o
, , o
RANKL NNP o
, , o
osteoprotegerin NN o
, , o
and CC o
markers NNS o
of IN o
bone NN o
formation NN o
and CC o
resorption NN o
. . o

Levels NNP o
of IN o
serum NN o
cytokines NNS o
were VBD N
measured VBN N
before IN N
therapy NN N
and CC N
after IN N
three CD N
and CC N
6 CD N
months NNS N
. . N

Markers NNS o
of IN o
bone NN o
metabolism NN o
were VBD N
studied VBN N
before IN N
therapy NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

In IN N
group NN N
1 CD N
( ( N
risedronate VB N
plus CC N
calcium/vitamin VB N
D-treated JJ N
patients NNS N
) ) N
, , N
serum JJ o
levels NNS o
of IN o
RANKL NNP o
and CC o
IL-1beta NNP o
significantly RB o
decreased VBD o
and CC N
the DT N
level NN o
of IN o
osteoprotegerin JJ o
significantly RB o
increased VBN o
after IN N
three CD N
and CC N
6 CD N
months NNS N
, , N
but CC N
no DT N
significant JJ o
difference NN o
was VBD o
found VBN o
in IN o
TNF-alpha NNP o
level NN o
. . o

In IN N
group NN N
2 CD N
, , N
however RB N
, , N
the DT N
level NN o
of IN o
serum JJ o
cytokines NNS o
did VBD N
not RB N
change NN N
after IN N
three CD N
and CC N
6 CD N
months NNS N
. . N

In IN N
cases NNS N
of IN N
bone NN o
turnover NN o
, , o
both DT o
markers NNS o
of IN o
bone NN o
resorption NN o
and CC o
formation NN o
significantly RB o
decreased VBN o
after IN N
6 CD N
months NNS N
in IN N
group NN N
1 CD N
. . N

In IN N
conclusion NN N
risedronate NN N
could MD N
improve VB N
osteoporosis NN N
by IN N
increasing VBG N
osteoprotegerin NN N
and CC N
reducing VBG N
RANKL NNP N
and CC N
IL-1beta NNP N
. . N

-DOCSTART- -8403942- O O

[ VB N
The DT N
effect NN N
of IN N
indobufen NN i
on IN N
aortocoronary JJ p
bypass NN p
patency NN p
after IN N
1 CD N
week NN N
and CC N
after IN N
1 CD N
year NN N
] NN N
. . N

A DT N
randomized JJ N
clinical JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
effect NN N
of IN N
conventional JJ i
antiaggregation NN i
therapy NN i
( ( i
ASA NNP i
plus CC i
dipyridamole NN i
) ) i
versus NN N
indobufen NN i
in IN N
patients NNS p
after IN p
aortocoronary JJ p
bypass NN p
( ( p
ACB NNP p
) ) p
surgery NN p
. . p

The DT N
patency NN N
of IN N
venous JJ N
ACB NNP N
using VBG N
coronary JJ N
DSA NNP N
one CD N
week NN N
and CC N
one CD N
year NN N
after IN N
surgery NN N
was VBD N
evaluated VBN N
in IN N
52 CD p
patients NNS p
divided VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
study NN N
included VBD N
only RB N
ACB NNP p
's POS p
with IN p
intraoperative JJ p
blood NN p
flow NN p
rates NNS p
< VBP N
or CC N
= VBP N
40 CD N
ml/min NN N
as IN N
it PRP N
is VBZ N
just RB N
these DT N
ACB NNP N
's POS N
which WDT N
are VBP N
at IN N
the DT N
highest JJS N
risk NN N
of IN N
early JJ N
and CC N
late JJ N
occlusions NNS N
. . N

While IN N
, , N
in IN N
the DT N
ASA NNP i
plus CC i
dipyridamole-treated JJ i
group NN N
, , N
occlusions NNS o
were VBD N
found VBN N
in IN N
11 CD N
of IN N
the DT N
39 CD N
reconstructions NNS N
( ( N
28.2 CD N
% NN N
) ) N
, , N
the DT N
proportion NN N
was VBD N
nine CD N
out IN N
of IN N
37 CD N
procedures NNS N
( ( N
24.3 CD N
% NN N
) ) N
in IN N
the DT N
indobufen NN i
group NN N
. . N

One CD N
year NN N
after IN N
surgery NN N
, , N
occlusion NN o
was VBD N
found VBN N
in IN N
14 CD N
out IN N
of IN N
32 CD N
ACB NNP N
's POS N
( ( N
43.7 CD N
% NN N
) ) N
in IN N
the DT N
ASA NNP N
plus CC N
dipyridamole JJ i
group NN N
compared VBN N
to TO N
14 CD N
occlusions NNS N
in IN N
31 CD N
ACB NNP N
's POS N
( ( N
45.2 CD N
% NN N
) ) N
in IN N
the DT N
indobufen NN i
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
number NN o
of IN o
occlusions NNS o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Because IN N
of IN N
some DT N
benefits NNS N
of IN N
indobufen NN N
compared VBN N
to TO N
ASA NNP N
( ( o
shorter JJR o
time NN o
of IN o
effect NN o
, , o
superior JJ o
tolerance NN o
in IN o
patients NNS o
with IN o
ulceration NN o
) ) o
, , N
the DT N
former JJ N
drug NN N
can MD N
be VB N
recommended VBN N
for IN N
use NN N
in IN N
some DT N
indicated JJ N
cases NNS N
. . N

-DOCSTART- -24821891- O O

Sociopsychological JJ N
tailoring VBG N
to TO N
address VB N
colorectal JJ N
cancer NN N
screening VBG N
disparities NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Interventions NNP i
tailored VBD i
to TO i
sociopsychological JJ i
factors NNS i
associated VBN i
with IN i
health NN i
behaviors NNS i
have VBP N
promise NN N
for IN N
reducing VBG N
colorectal JJ N
cancer NN N
screening VBG N
disparities NNS N
, , N
but CC N
limited VBD N
research NN N
has VBZ N
assessed VBN N
their PRP$ N
impact NN N
in IN N
multiethnic JJ N
populations NNS N
. . N

We PRP N
examined VBD N
whether IN N
an DT N
interactive JJ i
multimedia NN i
computer NN i
program NN i
( ( i
IMCP NNP i
) ) i
tailored VBD N
to TO N
expanded VB N
health NN N
belief NN N
model NN N
sociopsychological JJ N
factors NNS N
could MD N
promote VB N
colorectal JJ N
cancer NN N
screening NN N
in IN N
a DT N
multiethnic JJ p
sample NN p
. . p

METHODS NNP N
We PRP N
undertook VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
, , N
comparing VBG N
an DT N
IMCP NNP i
tailored VBD i
to TO i
colorectal JJ i
cancer NN i
screening VBG i
self-efficacy NN i
, , i
knowledge NN i
, , i
barriers NNS i
, , i
readiness NN i
, , i
test NN i
preference NN i
, , i
and CC i
experiences NNS i
with IN i
a DT i
nontailored JJ i
informational JJ i
program NN i
, , N
both DT N
delivered VBN N
before IN N
office NN N
visits NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
record-documented JJ o
colorectal JJ o
cancer NN o
screening VBG o
during IN o
a DT o
12-month JJ o
follow-up JJ o
period NN o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
postvisit JJ o
sociopsychological JJ o
factor NN o
status NN o
and CC o
discussion NN o
, , o
as RB o
well RB o
as IN o
clinician JJ o
recommendation NN o
of IN o
screening VBG o
during IN o
office NN o
visits NNS o
. . o

We PRP N
enrolled VBD p
1,164 CD p
patients NNS p
stratified VBN p
by IN p
ethnicity NN p
and CC p
language NN p
( ( p
49.3 CD p
% NN p
non-Hispanic JJ p
, , p
27.2 CD p
% NN p
Hispanic/English NNP p
, , p
23.4 CD p
% NN p
Hispanic/Spanish NNP p
) ) p
from IN p
26 CD p
offices NNS p
around IN p
5 CD p
centers NNS p
( ( p
Sacramento NNP p
, , p
California NNP p
; : p
Rochester NNP p
and CC p
the DT p
Bronx NNP p
, , p
New NNP p
York NNP p
; : p
Denver NNP p
, , p
Colorado NNP p
; : p
and CC p
San NNP p
Antonio NNP p
, , p
Texas NNP p
) ) p
. . p

RESULTS NNP N
Adjusting NNP N
for IN N
ethnicity/language NN N
, , N
study NN N
center NN N
, , N
and CC N
the DT N
previsit NN N
value NN N
of IN N
the DT N
dependent NN N
variable NN N
, , N
compared VBN N
with IN N
control NN N
patients NNS N
, , N
the DT N
IMCP NNP N
led VBD N
to TO N
significantly RB N
greater JJR N
colorectal JJ o
cancer NN o
screening VBG o
knowledge NN o
, , o
self-efficacy NN o
, , o
readiness NN o
, , o
test NN o
preference NN o
specificity NN o
, , o
discussion NN o
, , o
and CC o
recommendation NN o
. . o

During IN N
the DT N
followup JJ N
period NN N
, , N
132 CD N
( ( N
23 CD N
% NN N
) ) N
IMCP NNP N
and CC N
123 CD N
( ( N
22 CD N
% NN N
) ) N
control NN N
patients NNS N
received VBD N
screening VBG o
( ( N
adjusted VBN N
difference NN N
= $ N
0.5 CD N
percentage NN N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
-4.3 NNP N
to TO N
5.3 CD N
) ) N
. . N

IMCP NNP o
effects NNS N
did VBD N
not RB N
differ VB N
significantly RB N
by IN N
ethnicity/language NN N
. . N

CONCLUSIONS NNP N
Sociopsychological NNP N
factor NN N
tailoring NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
nontailored JJ N
information NN N
in IN N
encouraging VBG N
colorectal JJ N
cancer NN N
screening NN N
in IN N
a DT N
multiethnic JJ p
sample NN p
, , N
despite IN N
enhancing VBG N
sociopsychological JJ N
factors NNS N
and CC N
visit NN N
behaviors NNS N
associated VBN N
with IN N
screening NN N
. . N

The DT N
utility NN N
of IN N
sociopsychological JJ N
tailoring NN N
in IN N
addressing VBG N
screening VBG N
disparities NNS N
remains VBZ N
uncertain JJ N
. . N

-DOCSTART- -15914128- O O

Effects NNS N
of IN N
two CD N
combined JJ N
oral JJ i
contraceptives NNS i
containing VBG N
ethinyl NN i
estradiol $ i
20 CD N
microg NN N
combined VBN N
with IN N
either DT N
drospirenone NN i
or CC i
desogestrel NN i
on IN N
lipids NNS N
, , N
hemostatic JJ N
parameters NNS N
and CC N
carbohydrate JJ N
metabolism NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
ethinyl NN i
estradiol NN i
20 CD i
microg/drospirenone NN i
3 CD i
mg NN i
( ( N
EE NNP N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
) ) N
administered VBD N
according VBG N
to TO N
a DT N
24/4 JJ N
regimen NN N
with IN N
ethinyl JJ i
estradiol NN i
20 CD i
microg/desogestrel NN i
150 CD N
microg NN N
( ( N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
) ) N
administered VBD N
according VBG N
to TO N
the DT N
conventional JJ N
21/7 CD N
regimen NNS N
on IN N
lipid JJ N
, , N
carbohydrate NN N
and CC N
hemostatic JJ N
parameters NNS N
. . N

STUDY NNP N
DESIGN NNP N
In IN N
this DT N
open-label JJ N
study NN N
, , N
healthy JJ p
women NNS p
were VBD p
randomized VBN p
to TO p
EE VB p
20 CD p
microg/DRSP NN p
3 CD p
mg NN p
or CC p
EE NNP p
20 CD p
microg/DSG NN p
150 CD p
microg NN p
for IN p
seven CD p
cycles NNS p
. . p

Mean JJ N
differences NNS N
in IN N
high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
- : o
and CC o
low-density JJ o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
-cholesterol NN o
levels NNS o
at IN N
cycle NN N
7 CD N
compared VBN N
to TO N
baseline VB N
were VBD N
assessed VBN N
. . N

Secondary JJ N
variables NNS N
included VBD N
changes NNS N
in IN N
other JJ o
lipid JJ o
, , o
hemostatic JJ o
and CC o
carbohydrate JJ o
parameters NNS o
. . o

RESULTS NNP N
Both NNP N
treatments NNS N
increased VBD N
HDL-cholesterol NNP o
, , N
but CC N
decreased VBD N
LDL-cholesterol NNP o
by IN N
a DT N
comparable JJ N
extent NN N
. . N

Although IN N
slightly RB N
elevated VBN N
in IN N
both DT N
groups NNS N
, , N
blood NN o
glucose NN o
and CC o
C-peptide JJ o
levels NNS o
measured VBN N
during IN N
oral JJ N
glucose JJ N
tolerance NN N
tests NNS N
were VBD N
within IN N
normal JJ N
reference NN N
ranges VBZ N
at IN N
cycle NN N
7 CD N
. . N

Overall JJ N
, , N
the DT N
differences NNS N
in IN N
lipid JJ o
, , o
hemostatic JJ o
or CC o
carbohydrate JJ o
parameters NNS o
were VBD N
not RB N
significant JJ N
between IN N
the DT N
two CD N
treatments NNS N
. . N

CONCLUSION NNP N
EE NNP N
20 CD N
microg/DRSP NN N
3 CD N
mg NN N
has VBZ N
a DT N
good JJ N
safety NN N
profile NN N
comparable JJ N
with IN N
EE NNP N
20 CD N
microg/DSG NN N
150 CD N
microg NN N
. . N

-DOCSTART- -19563641- O O

A DT N
phase NN N
III NNP N
clinical JJ N
trial NN N
of IN N
exercise NN i
modalities NNS N
on IN N
treatment NN N
side-effects NNS N
in IN N
men NNS p
receiving VBG p
therapy NN p
for IN p
prostate NN p
cancer NN p
. . p

BACKGROUND NNP N
Androgen NNP i
deprivation NN i
therapy NN i
( ( i
ADT NNP i
) ) i
is VBZ N
accompanied VBN N
by IN N
a DT N
number NN N
of IN N
adverse JJ N
side NN N
effects NNS N
including VBG N
reduced VBD N
bone JJ N
mass NN N
and CC N
increased VBD N
risk NN N
for IN N
fracture NN N
, , N
reduced VBN N
lean JJ N
mass NN N
and CC N
muscle NN N
strength NN N
, , N
mood NN N
disturbance NN N
and CC N
increased VBD N
fat JJ N
mass NN N
compromising VBG N
physical JJ N
functioning NN N
, , N
independence NN N
, , N
and CC N
quality NN N
of IN N
life NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
is VBZ N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
long JJ N
term NN N
exercise NN i
on IN N
reversing VBG N
musculoskeletal-related JJ o
side NN o
effects NNS o
, , N
and CC N
cardiovascular JJ o
and CC o
diabetes VBZ o
risk NN o
factors NNS o
in IN N
men NNS p
receiving VBG p
androgen NN i
deprivation NN i
for IN p
their PRP$ p
prostate NN p
cancer NN p
. . p

Specifically RB N
, , N
we PRP N
aim VBP N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
12-month JJ N
exercise NN i
program NN i
designed VBN N
to TO N
load VB N
the DT N
musculoskeletal NN N
system NN N
and CC N
reduce VB N
cardiovascular NN N
and CC N
diabetes VBZ N
disease JJ N
progression NN N
on IN N
the DT N
following JJ N
primary JJ N
endpoints NNS N
: : N
1 CD N
) ) N
bone NN o
mineral JJ o
density NN o
; : o
2 CD o
) ) o
cardiorespiratory NN o
function NN o
and CC o
maximal JJ o
oxygen NN o
capacity NN o
; : o
3 CD o
) ) o
body NN o
composition NN o
( ( o
lean JJ o
mass NN o
and CC o
fat JJ o
mass NN o
) ) o
; : o
4 CD o
) ) o
blood NN o
pressure NN o
and CC o
cardiovascular JJ o
function NN o
; : o
5 CD o
) ) o
lipids NNS o
and CC o
glycemic JJ o
control NN o
; : o
and CC o
6 CD o
) ) o
quality NN o
of IN o
life NN o
and CC o
psychological JJ o
distress NN o
. . o

METHODS/DESIGN NNP N
Multi-site NNP N
randomized VBD N
controlled JJ N
trial NN N
of IN N
195 CD p
men NNS p
( ( p
65 CD p
subjects NNS p
per IN p
arm NN p
) ) p
undergoing NN p
treatment NN p
for IN p
prostate NN p
cancer NN p
involving VBG p
ADT NNP i
in IN p
the DT p
cities NNS p
of IN p
Perth NNP p
and CC p
Brisbane NNP p
in IN p
Australia NNP p
. . p

Participants NNS N
will MD N
be VB N
randomized VBN N
to TO N
( ( N
1 CD N
) ) N
resistance/impact NN i
loading VBG i
exercise NN i
, , i
( ( i
2 CD i
) ) i
resistance/cardiovascular NN i
exercise NN i
groups NNS i
and CC i
( ( i
3 CD i
) ) i
usual JJ i
care/delayed VBN i
exercise NN i
. . i

Participants NNS N
will MD N
then RB N
undergo VB N
progressive JJ i
training NN i
for IN N
12 CD N
months NNS N
. . N

Measurements NNS N
for IN N
primary JJ N
and CC N
secondary JJ N
endpoints NNS N
will MD N
take VB N
place NN N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
end NN N
of IN N
the DT N
intervention NN N
) ) N
. . N

DISCUSSION VB N
The DT N
principal JJ N
outcome NN N
of IN N
this DT N
project NN N
will MD N
be VB N
the DT N
determination NN o
of IN o
the DT o
strength NN o
of IN o
effect NN o
of IN o
exercise NN o
on IN o
the DT o
well NN o
established VBN o
musculoskeletal NN o
, , o
cardiovascular JJ o
and CC o
insulin JJ o
metabolism NN o
side NN o
effects NNS o
of IN o
androgen NN o
deprivation NN o
in IN o
prostate JJ o
cancer NN o
patients NNS o
. . o

As IN N
this DT N
project NN N
is VBZ N
much RB N
longer JJR N
term NN N
than IN N
previous JJ N
investigations NNS N
in IN N
the DT N
area NN N
of IN N
exercise NN i
and CC N
cancer NN N
, , N
we PRP N
will MD N
gain VB N
knowledge NN N
as IN N
to TO N
the DT N
continuing VBG N
effects NNS N
of IN N
exercise NN N
in IN N
this DT N
patient JJ N
population NN N
specifically RB N
targeting VBG N
bone NN o
density NN o
, , o
cardiovascular JJ o
function NN o
, , o
lean JJ o
and CC o
fat JJ o
mass NN o
, , o
physical JJ o
function NN o
and CC o
falls VBZ o
risk NN o
as IN N
primary JJ N
study NN N
endpoints NNS N
. . N

In IN N
terms NNS N
of IN N
advancement NN N
of IN N
prostate NN N
cancer NN N
care NN N
, , N
we PRP N
expect VBP N
dissemination NN N
of IN N
the DT N
knowledge NN N
gained VBN N
from IN N
this DT N
project NN N
to TO N
reduce VB N
fracture NN o
risk NN o
, , o
improve VB o
physical JJ o
and CC o
functional JJ o
ability NN o
, , o
quality NN o
of IN o
life NN o
and CC o
ultimately RB o
survival JJ o
rate NN o
in IN N
this DT N
population NN N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRY NNP N
A NNP N
Phase NNP N
III NNP N
clinical JJ N
trial NN N
of IN N
exercise NN N
modalities NNS N
on IN N
treatment NN N
side-effects NNS N
in IN N
men NNS N
receiving VBG N
therapy NN N
for IN N
prostate NN N
cancer NN N
; : N
ACTRN12609000200280 NNP N
. . N

-DOCSTART- -3123115- O O

Serum NNP o
C-peptide NNP o
after IN N
6 CD N
months NNS N
on IN N
glibenclamide NN i
remains VBZ N
higher JJR N
than IN N
during IN N
insulin JJ N
treatment NN N
. . N

Serum NNP o
C-peptide NNP o
was VBD N
measured VBN N
fasting NN N
and CC N
6 CD i
minutes NNS i
after IN i
glucagon NN i
( ( i
1 CD i
mg NN i
given VBN i
intravenously RB i
) ) i
in IN N
49 CD p
patients NNS p
with IN p
non-insulin-dependent JJ p
diabetes NNS p
mellitus NNS p
, , N
after IN i
4 CD i
and CC i
6 CD i
months NNS i
of IN i
successive JJ i
periods NNS i
of IN i
treatment NN i
with IN i
insulin NN i
and CC i
oral JJ i
hypoglycaemics NNS i
( ( i
glibenclamide NN i
and CC i
metformin NN i
) ) i
, , N
given VBN N
in IN N
random JJ N
order NN N
. . N

Glycaemic NNP o
control NN o
was VBD N
not RB N
significantly RB N
different JJ N
on IN N
the DT N
two CD N
treatments NNS N
, , N
but CC N
C-peptide NNP o
was VBD N
much RB N
higher JJR N
while IN N
the DT N
patients NNS N
were VBD N
on IN N
glibenclamide NN N
. . N

We PRP N
conclude VBP N
that IN N
glibenclamide NN i
stimulates VBZ N
pancreatic JJ N
insulin NN N
production NN N
even RB N
after IN N
6 CD N
months NNS N
treatment NN N
. . N

-DOCSTART- -24418366- O O

The DT N
effect NN N
of IN N
recent JJ p
bereavement NN p
on IN N
outcomes NNS N
in IN N
a DT N
primary JJ o
care NN o
depression NN o
intervention NN N
study NN N
. . N

OBJECTIVES NNP N
Although IN N
bereavement NN N
and CC N
depression NN N
are VBP N
both DT N
common JJ N
in IN N
older JJR N
primary JJ N
care NN N
patients NNS N
, , N
the DT N
effect NN N
of IN N
bereavement NN N
on IN N
depression NN o
intervention NN N
outcomes NNS N
is VBZ N
unknown JJ N
. . N

We PRP N
examined VBD N
whether IN N
standard JJ i
interventions NNS i
for IN N
depression NN N
in IN N
primary JJ N
care NN N
were VBD N
as IN N
effective JJ N
for IN N
bereaved VBN p
as IN p
for IN p
non-bereaved JJ p
depressed JJ p
patients NNS p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Twenty CD p
community-based JJ p
primary JJ p
care NN p
practices NNS p
in IN p
New NNP p
York NNP p
City NNP p
, , p
greater JJR p
Philadelphia NNP p
, , p
and CC p
Pittsburgh NNP p
. . p

Randomization NNP N
to TO N
either DT N
intervention NN i
or CC N
usual JJ i
care NN i
occurred VBN i
by IN i
practice NN i
. . i

PARTICIPANTS CC p
Patients NNPS p
aged VBD p
60 CD p
years NNS p
or CC p
older JJR p
who WP p
met VBD p
criteria NNS p
for IN p
major JJ p
depression NN p
or CC p
clinically RB p
significant JJ p
minor JJ p
depression NN p
( ( p
N NNP p
= NNP p
599 CD p
) ) p
. . p

Patients NNS p
who WP p
did VBD p
not RB p
complete VB p
the DT p
bereavement JJ p
measure NN p
or CC p
who WP p
were VBD p
missing VBG p
4-month JJ p
data NNS p
were VBD p
excluded VBN p
( ( p
final JJ p
N NNP p
= NNP p
417 CD p
) ) p
. . p

INTERVENTION NNP i
Study-trained JJ i
depression NN i
care NN i
managers NNS i
offered VBD i
guideline-concordant JJ i
recommendations NNS i
to TO i
primary VB i
care NN i
physicians NNS i
at IN i
intervention NN i
sites NNS i
and CC i
assisted VBD i
patients NNS i
with IN i
treatment NN i
adherence NN i
. . i

Patients NNS i
who WP i
did VBD i
not RB i
wish VB i
to TO i
take VB i
antidepressants NNS i
could MD i
receive VB i
interpersonal JJ i
psychotherapy NN i
. . i

MEASUREMENTS NNP o
Bereavement NNP o
was VBD o
captured VBN N
using VBG N
the DT o
Louisville NNP o
Older NNP o
Persons NNP o
Events NNP o
Schedule NNP o
. . o

Depression NNP o
severity NN o
was VBD o
assessed VBN N
using VBG N
the DT o
24-item JJ o
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
( ( o
HDRS NNP o
) ) o
. . o

Outcomes CC N
at IN N
4 CD N
months NNS N
were VBD o
remission NN o
( ( o
HDRS NNP o
?7 NNP o
) ) o
and CC o
response NN o
( ( o
HDRS NNP o
reduction NN N
?50 CD N
% NN N
from IN N
baseline NN N
) ) N
. . N

RESULTS NNP N
Logistic JJ N
regressions NNS N
indicated VBD N
that IN N
, , N
for IN N
non-bereaved JJ N
participants NNS o
, , o
response NN o
and CC o
remission NN o
were VBD o
higher JJR o
in IN N
intervention NN N
than IN N
usual JJ N
care NN N
. . N

However RB N
, , N
recently RB N
bereaved VBD N
older JJR N
adults NNS N
were VBD N
less RBR N
likely JJ N
to TO N
achieve VB N
response NN o
or CC o
remission NN o
at IN o
4 CD o
months NNS o
if IN N
treated VBN N
in IN N
the DT N
intervention NN N
condition NN N
. . N

CONCLUSIONS NNP N
Standard NNP N
depression NN N
care NN N
management NN N
appears VBZ N
to TO N
be VB N
ineffective JJ N
among IN N
recently RB N
bereaved VBN N
older JJR N
primary JJ N
care NN N
patients NNS N
. . N

Greater NNP N
attention NN N
should MD N
be VB N
paid VBN N
in IN N
primary JJ N
care NN N
to TO N
emotional JJ p
distress NN p
in IN p
the DT p
context NN p
of IN p
bereavement NN p
. . p

-DOCSTART- -23323659- O O

Divergence NN o
in IN N
student NN p
and CC p
educator NN p
conceptual JJ p
structures NNS p
during IN N
auscultation NN p
training NN p
. . p

CONTEXT NNP N
Simulation-based JJ N
medical JJ N
education NN N
allows VBZ N
trainees NNS N
to TO N
engage VB N
in IN N
self-regulated JJ N
learning NN N
( ( N
SRL NNP N
) ) N
, , N
yet RB N
research NN N
aimed VBN N
at IN N
elucidating VBG N
the DT N
mechanisms NN N
of IN N
SRL NNP N
in IN N
this DT N
context NN N
is VBZ N
relatively RB N
absent JJ N
. . N

We PRP N
compared VBN N
'unguided VBD i
' POS i
SRL NNP i
with IN N
'directed NNP i
' POS i
SRL NNP i
( ( N
DSRL NNP N
) ) N
, , N
wherein JJ N
learners NNS N
followed VBD N
an DT N
expert-designed JJ N
booklet NN N
. . N

METHODS NNP N
Year $ p
1 CD p
medical JJ p
students NNS p
( ( p
n JJ p
= NNP p
37 CD p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO p
practise VB p
identifying VBG p
seven CD p
cardiac JJ p
murmurs NNS p
using VBG p
a DT p
simulator NN i
and CC i
video NN i
only RB i
( ( i
SRL NNP i
group NN i
) ) i
or CC i
a DT i
simulator NN i
and CC i
video NN i
plus CC i
the DT i
booklet NN i
( ( p
DSRL NNP p
group NN p
) ) p
. . N

All DT N
participants NNS N
completed VBD N
a DT N
22-item JJ N
test NN N
3 CD N
weeks NNS N
later RB N
. . N

To TO N
compare VB N
interventions NNS N
, , N
we PRP N
analysed VBD N
students NNS N
' POS N
diagnostic JJ N
accuracy NN N
. . N

As IN N
a DT N
novel JJ N
source NN N
of IN N
evidence NN N
, , N
we PRP N
documented VBD N
how WRB N
participants NNS N
autonomously RB N
sequenced VBD N
the DT N
seven CD N
murmurs NNS N
during IN N
initial JJ N
and CC N
delayed JJ N
practice NN N
sessions NNS N
. . N

In IN N
addition NN N
, , N
we PRP p
surveyed VBD p
clinical JJ p
educators NNS p
( ( p
n JJ p
= NNP p
17 CD p
) ) p
to TO N
find VB N
out RP N
how WRB N
they PRP N
would MD N
sequence VB N
their PRP$ N
teaching NN N
of IN N
these DT N
murmurs NNS N
. . N

RESULTS VB N
The DT N
DSRL NNP N
group NN N
used VBD N
50 CD N
% NN N
more JJR N
training NN N
time NN N
than IN N
the DT N
SRL NNP N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
groups NNS N
' POS N
diagnostic JJ N
accuracy NN N
, , N
however RB N
, , N
did VBD N
not RB N
differ VB N
significantly RB N
on IN N
the DT N
post-test NN N
, , N
retention NN N
test NN N
or CC N
transfer VB N
test NN N
items NNS N
( ( N
p VB N
> RB N
0.12 CD N
) ) N
. . N

Despite IN N
practising VBG N
with IN N
the DT N
expert-defined JJ N
'timing-based JJ N
' POS N
approach NN N
to TO N
murmur VB N
diagnosis NN N
( ( N
i.e JJ N
. . N

systolic JJ N
versus IN N
diastolic NN N
) ) N
, , N
84 CD N
% NN N
of IN N
DSRL NNP N
participants NNS N
implemented VBD N
a DT N
location-based JJ N
approach NN N
( ( N
i.e JJ N
. . N

practising VBG N
aortic JJ N
murmurs NNS N
separately RB N
from IN N
mitral JJ N
murmurs NNS N
) ) N
during IN N
a DT N
second JJ N
, , N
unguided JJ N
practice NN N
session NN N
. . N

Notably RB N
, , N
most JJS N
SRL JJ N
participants NNS N
used VBD N
that IN N
same JJ N
approach NN N
spontaneously RB N
. . N

By IN N
contrast NN N
, , N
clinical JJ N
educators NNS N
were VBD N
split VBN N
in IN N
their PRP$ N
use NN N
of IN N
the DT N
timing-based JJ N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
and CC N
the DT N
location-based JJ N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
approaches NNS N
. . N

Chi-squared JJ N
analyses NNS N
suggested VBD N
educators NNS N
' POS N
conceptions NNS N
for IN N
organising VBG N
murmurs NNS N
differed VBN N
significantly RB N
from IN N
students NNS N
' POS N
conceptions NNS N
. . N

CONCLUSIONS NNP N
Contrary NNP N
to TO N
our PRP$ N
predictions NNS N
, , N
directing VBG N
students NNS N
' POS N
SRL NNP N
produced VBD N
no DT N
additional JJ o
benefit NN o
and CC N
increased VBD N
their PRP$ N
practice NN o
time NN o
. . o

Our PRP$ N
findings NNS N
suggest VBP N
one CD N
potential JJ N
source NN N
of IN N
these DT N
results NNS N
was VBD N
a DT N
divergence NN N
between IN N
student NN N
and CC N
educator NN N
conceptions NNS N
for IN N
structuring VBG N
the DT N
practice NN N
of IN N
cardiac JJ N
auscultation NN N
skills NNS N
. . N

This DT N
phenomenon NN N
has VBZ N
not RB N
been VBN N
well RB N
articulated VBN N
in IN N
the DT N
medical JJ N
education NN N
literature NN N
, , N
and CC N
may MD N
have VB N
important JJ N
implications NNS N
in IN N
many JJ N
( ( N
especially RB N
technology-mediated VBN N
) ) N
educational JJ N
contexts NN N
. . N

-DOCSTART- -8733449- O O

A DT N
double-blind JJ N
comparative NN N
study NN N
of IN N
ofloxacin JJ i
otic JJ i
drops NNS i
versus IN N
neomycin-polymyxin JJ i
B-hydrocortisone NNP i
otic JJ i
drops NNS i
in IN N
the DT N
medical JJ N
treatment NN N
of IN N
chronic JJ p
suppurative JJ p
otitis NN p
media NNS p
. . p

Active NNP p
chronic JJ p
suppurative NN p
otitis NN p
media NNS p
poses VBZ N
a DT N
management NN N
problem NN N
when WRB N
patients NNS p
are VBP p
being VBG p
considered VBN p
for IN p
surgical JJ p
treatment NN p
. . p

Topical JJ N
antibiotics NNS N
have VBP N
demonstrated VBN N
varying VBG N
degrees NNS N
of IN N
success NN N
in IN N
the DT N
management NN N
of IN N
discharging VBG p
ears NNS p
. . p

The DT N
introduction NN N
of IN N
quinolones NNS N
has VBZ N
revived VBN N
interest NN N
in IN N
these DT N
topical JJ N
agents NNS N
. . N

This DT N
double-blind NN N
study NN N
compares VBZ N
two CD N
antibiotics NNS i
, , N
namely RB N
ofloxacin JJ i
and CC i
neomycin-polymyxin JJ i
B NNP i
, , N
with IN N
similar JJ N
in IN N
vitro JJ N
sensitivities NNS N
to TO N
Gram NNP N
positive JJ N
and CC N
Gram NNP N
negative JJ N
organisms NNS N
. . N

Fifty-two JJ p
patients NNS p
were VBD p
selected VBN p
randomly RB N
and CC N
the DT N
results NNS N
show VBP N
that IN N
ofloxacin NN i
eardrops NNS i
have VBP N
marginal JJ N
benefits NNS N
in IN N
symptomatic JJ o
improvement NN o
( ( N
89 CD N
per IN N
cent NN N
versus NN N
79 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.27 CD N
) ) N
and CC N
bacterial JJ o
eradication NN o
( ( N
81 CD N
per IN N
cent NN N
versus NN N
75 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.81 CD N
) ) N
in IN N
active JJ o
chronic JJ o
suppurative NN o
otitis NN o
media NNS o
. . o

Significantly RB N
fewer JJR N
patients NNS N
( ( N
seven CD N
per IN N
cent NN N
versus NN N
29 CD N
per IN N
cent NN N
, , N
p VBP N
= RB N
0.04 CD N
) ) N
in IN N
the DT N
ofloxacin NN N
group NN N
had VBD o
active JJ o
disease NN o
at IN N
the DT N
end NN N
of IN N
the DT N
two-week JJ N
treatment NN N
. . N

We PRP N
recommend VBP N
the DT N
use NN N
of IN N
ofloxacin JJ i
eardrops NNS i
in IN N
managing VBG N
active JJ p
chronic JJ p
suppurative NN p
otitis NN p
media NNS p
since IN N
it PRP N
has VBZ N
high JJ N
clinical JJ o
efficacy NN o
, , N
contains VBZ N
no DT N
steroid JJ N
component NN N
and CC N
has VBZ N
no DT N
demonstrated VBN N
risk NN o
of IN o
ototoxicity NN o
. . o

-DOCSTART- -8282676- O O

Naltrexone NN i
in IN p
autistic JJ p
children NNS p
: : p
behavioral NN N
symptoms NNS N
and CC N
attentional JJ N
learning NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
critically RB N
the DT N
short-term JJ N
efficacy NN o
and CC o
safety NN o
of IN N
naltrexone NN i
in IN p
autistic JJ p
children NNS p
and CC N
its PRP$ N
effects NNS N
on IN N
discrimination NN N
learning NN N
in IN N
the DT N
laboratory NN N
. . N

METHOD NNP N
A NNP N
parallel JJ N
group NN N
design NN N
was VBD N
employed VBN N
. . N

After IN N
a DT N
2-week JJ N
placebo NN N
baseline NN N
period NN N
, , N
children NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
naltrexone CD i
or CC i
to TO i
placebo VB i
for IN N
a DT N
period NN N
of IN N
3 CD N
weeks NNS N
followed VBN N
by IN N
a DT N
one-week JJ N
posttreatment NN N
placebo NN N
period NN N
. . N

Multiple JJ N
raters NNS N
and CC N
rating NN N
scales NNS N
were VBD N
employed VBN N
in IN N
a DT N
variety NN N
of IN N
conditions NNS N
. . N

Forty-one CD p
children NNS p
, , p
all DT p
inpatients NNS p
, , p
ages VBZ p
2.9 CD p
to TO p
7.8 CD p
years NNS p
, , p
completed VBD p
the DT p
study NN p
. . p

Naltrexone NNP i
reduced VBD N
hyperactivity NN o
and CC N
had VBD N
no DT N
effect NN N
on IN N
discrimination NN o
learning NN o
in IN N
the DT N
laboratory NN N
. . N

There EX N
was VBD N
a DT N
suggestion NN N
that IN N
it PRP N
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
decreasing VBG N
self-injurious JJ o
behavior NN o
. . o

Untoward JJ o
effects NNS o
were VBD N
mild JJ N
and CC N
transient NN N
. . N

CONCLUSION NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
naltrexone RB N
significantly RB N
reduced VBN N
only RB N
hyperactivity NN o
, , N
and CC N
no DT N
serious JJ o
untoward JJ o
effects NNS o
were VBD N
observed VBN N
. . N

The DT N
effectiveness NN N
of IN N
naltrexone NN i
in IN N
the DT N
treatment NN N
of IN N
autism NN N
and CC N
self-injurious JJ N
behavior NN N
requires VBZ N
additional JJ N
assessment NN N
in IN N
a DT N
sample NN N
of IN N
children NNS p
with IN p
moderate JJ p
to TO p
severe VB p
self-injurious JJ p
behavior NN p
. . p

-DOCSTART- -21909698- O O

Randomised VBN N
multicentre JJ N
trial NN N
of IN N
circular JJ i
stapling NN i
devices NNS i
. . i

PURPOSE NNP N
In IN N
a DT N
register NN N
study NN N
, , N
the DT N
risk NN N
of IN N
anastomotic JJ o
leakage NN o
correlated VBD N
to TO N
the DT N
choice NN N
of IN N
circular JJ i
stapling VBG i
device NN i
with IN N
a DT N
4 CD N
% NN N
difference NN N
between IN N
the DT N
two CD N
brands NNS N
used VBN N
. . N

Based VBN N
on IN N
those DT N
data NNS N
, , N
a DT N
randomised JJ N
multicentre NN N
study NN N
was VBD N
started VBN N
to TO N
explore VB N
the DT N
risk NN N
of IN N
an DT N
anastomotic JJ o
leakage NN o
based VBN N
upon IN N
the DT N
surgical JJ i
device NN i
. . i

METHODS NNP N
Patients NNPS p
above IN p
18 CD p
years NNS p
with IN p
a DT p
rectal JJ p
cancer NN p
, , p
able JJ p
to TO p
give VB p
informed JJ p
consent NN p
, , p
and CC p
scheduled VBD p
for IN p
an DT p
anterior JJ p
resection NN p
were VBD p
eligible JJ p
for IN p
the DT p
study NN p
. . p

Perioperative JJ N
randomisation NN N
was VBD N
to TO N
Ethicon? NNP i
PROXIMATE? NNP i
ILS? NNP i
or CC i
Autosuture? NNP i
Premium NNP i
Plus NNP i
CEEA? NNP o
. . o

Anastomotic JJ o
leakage NN o
was VBD o
defined VBN N
as IN N
a DT o
clinically RB o
manifest JJS o
leak NN o
. . o

RESULTS NNP o
Five CD p
hundred VBD p
twenty-nine NN p
patients NNS p
were VBD p
randomised VBN p
( ( p
58 CD p
% NN p
male NN p
) ) p
. . o

A DT o
leak NN o
occurred VBD o
in IN N
8.3 CD N
% NN N
. . N

The DT N
anastomoses NNS N
created VBN N
by IN N
PROXIMATE? NNP i
ILS? NNP o
leaked VBD o
in IN N
25/265 CD N
( ( N
9.4 CD N
% NN N
) ) N
anastomoses VBZ N
, , N
and CC i
the DT i
Premium NNP i
Plus NNP i
CEEA? NNP i
leaked VBD i
in IN N
19/260 CD N
( ( N
7.3 CD N
% NN N
) ) N
, , N
p JJ N
= NNP N
.419 NNP N
. . N

CONCLUSION NNP N
No DT N
difference NN N
in IN N
the DT N
leak NN o
rate NN o
could MD o
be VB N
revealed VBN N
. . N

Several JJ N
centres NNS N
replaced VBD N
one CD N
of IN N
the DT N
staplers NNS N
by IN N
a DT N
new JJ N
product NN N
, , N
and CC N
the DT N
study NN N
was VBD N
ended VBN N
before IN N
the DT N
stipulated JJ N
number NN N
of IN N
patients NNS N
was VBD N
reached VBN N
. . N

In IN N
the DT N
future NN N
, , N
surgical JJ N
devices NNS N
may MD N
have VB N
to TO N
prove VB o
superiority NN o
in IN o
randomised JJ N
trials NNS N
or CC N
be VB N
monitored VBN N
in IN N
quality NN N
registers NNS N
before IN N
they PRP N
can MD N
be VB N
introduced VBN N
into IN N
day NN N
to TO N
day NN N
surgical JJ N
practice NN N
. . N

The DT N
study NN N
was VBD N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
: : N
NCT00399009 NN N
. . N

-DOCSTART- -20106358- O O

Comparable JJ N
patencies NNS N
of IN N
the DT N
radial JJ i
artery NN i
and CC N
right JJ N
internal JJ i
thoracic NN i
artery NN i
or CC N
saphenous JJ i
vein NNS i
beyond IN N
5 CD N
years NNS N
: : N
results NNS N
from IN N
the DT N
Radial NNP N
Artery NNP N
Patency NNP N
and CC N
Clinical NNP N
Outcomes NNP N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
optimum JJ N
conduit NN N
for IN N
coronary JJ N
targets NNS N
other JJ N
than IN N
the DT N
left JJ N
anterior JJ N
descending VBG N
artery NN N
, , N
we PRP N
evaluated VBD N
long-term JJ N
patencies NNS N
and CC N
clinical JJ N
outcomes NNS N
of IN N
the DT N
radial JJ N
artery NN N
, , N
right JJ N
internal JJ N
thoracic NN N
artery NN N
, , N
and CC N
saphenous JJ N
vein NN N
through IN N
the DT N
Radial NNP N
Artery NNP N
Patency NNP N
and CC N
Clinical NNP N
Outcomes NNP N
trial NN N
. . N

METHODS NNP N
As IN N
part NN N
of IN N
a DT N
10-year JJ N
prospective JJ N
, , N
randomized VBN N
, , N
single-center JJ N
trial NN N
, , N
patients NNS p
undergoing VBG p
primary JJ p
coronary JJ p
surgery NN p
were VBD p
allocated VBN p
to TO p
the DT p
radial JJ p
artery NN p
( ( p
n JJ p
= NNP p
198 CD p
) ) p
or CC p
free JJ p
right JJ p
internal JJ p
thoracic NN p
artery NN p
( ( p
n JJ p
= NNP p
196 CD p
) ) p
if IN p
aged VBN p
less JJR p
than IN p
70 CD p
years NNS p
( ( p
group NN p
1 CD p
) ) p
, , p
or CC p
radial JJ p
artery NN p
( ( p
n JJ p
= NNP p
113 CD p
) ) p
or CC p
saphenous JJ p
vein NN p
( ( p
n JJ p
= NNP p
112 CD p
) ) p
if IN p
aged VBN p
at IN p
least JJS p
70 CD p
years NNS p
( ( p
group NN p
2 CD p
) ) p
. . p

All DT p
patients NNS p
received VBD p
a DT p
left JJ i
internal JJ i
thoracic NN i
artery NN i
to TO i
the DT i
left VBN i
anterior JJ i
descending NN i
, , N
and CC N
the DT N
randomized JJ N
conduit NN N
was VBD N
used VBN N
to TO N
graft VB N
the DT N
second JJ N
largest JJS N
target NN N
. . N

Protocol-directed JJ i
angiography NN i
has VBZ N
been VBN N
performed VBN N
at IN N
randomly RB N
assigned VBN N
intervals NNS N
, , N
weighted VBD N
toward IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
. . N

Grafts NNS N
are VBP N
defined VBN N
as IN N
failed JJ N
if IN N
there EX N
was VBD N
occlusion NN N
, , N
string VBG N
sign NN N
, , N
or CC N
greater JJR N
than IN N
80 CD N
% NN N
stenosis NN N
, , N
independently RB N
reported VBN N
by IN N
3 CD N
assessors NNS N
. . N

Analysis NN N
is VBZ N
by IN N
intention NN N
to TO N
treat VB N
. . N

RESULTS NNP N
At IN N
mean NN N
follow VBP N
up RB N
of IN N
5.5 CD N
years NNS N
, , N
protocol NN N
angiography NN N
has VBZ N
been VBN N
performed VBN N
in IN p
groups NNS p
1 CD p
and CC p
2 CD p
in IN p
237 CD p
and CC p
113 CD p
patients NNS p
, , p
respectively RB p
. . p

There EX N
are VBP N
no DT N
significant JJ N
differences NNS N
within IN N
each DT N
group NN N
in IN N
preoperative JJ N
comorbidity NN N
, , N
age NN N
, , N
or CC N
urgency NN N
. . N

Patencies NNS o
were VBD N
similar JJ N
for IN N
either DT N
of IN N
the DT N
2 CD N
conduits NNS N
in IN N
each DT N
group NN N
( ( N
log JJ N
rank NN N
analysis NN N
, , N
P NNP N
= NNP N
.06 NNP N
and CC N
P NNP N
= NNP N
.54 NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
differences NNS N
in IN N
estimated VBN N
5-year JJ o
patencies NNS o
were VBD N
6.6 CD N
% NN N
( ( N
radial JJ N
minus NN N
right JJ N
internal JJ N
thoracic NN N
artery NN N
) ) N
in IN N
group NN N
1 CD N
and CC N
2.9 CD N
% NN N
( ( N
radial JJ N
minus NN N
saphenous JJ N
vein NN N
graft NN N
) ) N
in IN N
group NN N
2 CD N
. . N

CONCLUSION NN N
At IN N
mean JJ N
5-year JJ N
angiography NN N
in IN N
largely RB N
asymptomatic JJ N
patients NNS N
, , N
the DT N
selection NN N
of IN N
arterial JJ N
or CC N
venous JJ N
conduit NN N
for IN N
the DT N
second JJ N
graft NN N
has VBZ N
not RB N
significantly RB N
affected JJ N
patency NN N
. . N

This DT N
finding NN N
offers VBZ N
surgeons NNS N
, , N
for IN N
now RB N
, , N
enhanced VBD N
flexibility NN N
in IN N
planning VBG N
revascularization NN N
. . N

-DOCSTART- -15506067- O O

[ JJ i
Rilmenidine NNP i
sympatholytic JJ N
activity NN N
preserves NNS N
mental JJ o
and CC o
orthostatic JJ o
sympathetic JJ o
response NN o
and CC N
epinephrine JJ o
secretion NN o
] NNP o
. . N

BACKGROUND NNP N
Heightened VBD N
central JJ N
sympathetic JJ N
nervous JJ N
outflow NN N
is VBZ N
common JJ N
in IN N
essential JJ N
hypertension NN N
, , N
contributing VBG N
to TO N
hypertension NN o
development NN N
and CC N
perhaps RB N
also RB N
to TO N
complications NNS N
. . N

Acute NNP N
sympathetic JJ N
nervous JJ N
activation NN N
is VBZ N
a DT N
proven JJ N
trigger NN N
for IN N
adverse JJ o
cardiovascular JJ o
events NNS o
. . o

Accordingly RB N
, , N
antihypertensive JJ N
drugs NNS N
inhibiting VBG N
sympathetic JJ N
outflow JJ N
represent NN N
a DT N
theoretically RB N
attractive JJ N
therapeutic JJ N
option NN N
. . N

OBJECTIVES NNP N
To TO N
study VB N
the DT N
sympatholytic JJ o
and CC o
blood NN o
pressure NN o
lowering VBG o
activity NN o
of IN N
the DT N
imidazoline NN N
binding NN N
agent NN N
rilmenidine NN i
at IN N
rest NN N
and CC N
during IN N
reflex JJ N
sympathetic JJ N
activation NN N
. . N

DESIGN NNP N
AND CC N
METHODS NNP N
The DT N
HERA NNP N
study NN N
( ( N
Hyperium NNP N
Effect NNP N
on IN N
the DT N
sympathetic JJ N
Reflex NNP N
activation NN N
and CC N
Adrenaline NNP N
) ) N
is VBZ N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
6-week JJ N
cross-over JJ N
trial NN N
, , N
with IN N
a DT N
1-week JJ N
placebo NN i
run-in JJ N
period NN N
, , N
two CD N
2-week JJ N
active JJ N
treatment NN N
intervals NNS N
( ( i
rilmenidine VB i
1 CD i
mg JJ i
bid NN i
, , i
placebo NN i
) ) i
and CC N
intervening VBG N
one CD N
week NN N
placebo NN i
wash-out NN N
. . N

In IN N
15 CD p
hypertensive JJ p
patients NNS p
, , N
noradrenaline JJ o
and CC o
adrenaline JJ o
plasma NN o
kinetics NNS o
and CC o
intra-arterial JJ o
blood NN o
pressure NN o
measurements NNS o
were VBD N
performed VBN N
at IN N
rest NN N
, , N
after IN N
mental JJ N
stress NN N
( ( N
difficult JJ N
mental JJ N
arithmetic NN N
) ) N
and CC N
during IN N
head-up JJ N
tilting NN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
2-week JJ N
dosing NN N
periods NNS N
. . N

RESULTS VB N
The DT N
noradrenaline JJ N
spillover NN N
rate NN N
, , N
indicative NN N
of IN N
whole JJ N
body NN N
sympathetic JJ N
activity NN N
, , N
was VBD N
reduced VBN N
35 CD N
% NN N
by IN N
rilmenidine NN N
at IN N
rest NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
remained VBD N
significantly RB N
lower JJR N
during IN N
mental JJ N
stress NN N
and CC N
tilting NN N
, , N
although IN N
the DT N
increases NNS N
in IN N
noradrenaline JJ o
spillover NN o
with IN N
both DT N
stimuli NNS N
were VBD N
preserved VBN N
. . N

The DT N
effects NNS N
on IN N
intraarterial JJ o
blood NN o
pressure NN o
ran VBD N
in IN N
parallel NN N
, , N
a DT N
fall NN N
in IN N
supine JJ N
resting NN N
pressure NN N
, , N
but CC N
no DT N
reduction NN N
in IN N
BP NNP o
rise NN o
during IN N
mental JJ N
stress NN N
and CC N
a DT N
lack NN N
of IN N
fall NN N
in IN N
BP NNP o
with IN N
tilting VBG N
. . N

On IN N
placebo NN N
, , N
adrenaline JJ o
secretion NN o
was VBD N
162 CD N
+/- JJ N
27 CD N
ng/min NN N
( ( N
mean JJ N
, , N
SE NNP N
) ) N
at IN N
rest NN N
, , N
increased VBN N
by IN N
77 CD N
+/- JJ N
42 CD N
ng/min NN N
with IN N
mental JJ N
stress NN N
( ( N
p=0.019 NN N
) ) N
and CC N
was VBD N
unchanged JJ N
with IN N
tilting VBG N
. . N

Rilmenidine NNP N
left VBD N
adrenaline JJ o
secretion NN o
untouched VBN N
under IN N
all DT N
conditions NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
confirms VBZ N
a DT N
sympatholytic JJ N
effect NN N
of IN N
rilmenidine NN N
during IN N
supine JJ N
rest NN N
but CC N
demonstrates VBZ N
that IN N
sympathetic JJ o
responses NNS o
during IN N
mental JJ N
stress NN N
and CC N
tilting NN N
are VBP N
preserved VBN N
, , N
the DT N
latter JJ N
underlying VBG N
a DT N
perhaps RB N
surprising JJ N
absence NN N
of IN N
postural JJ N
hypotension NN N
on IN N
the DT N
drug NN N
. . N

The DT N
absence NN N
of IN N
suppression NN N
of IN N
reflexive JJ N
sympathetic JJ N
responses NNS N
contrasts NNS N
with IN N
the DT N
effects NNS N
of IN N
rilmenidine NN N
in IN N
experimental JJ N
animals NNS N
, , N
and CC N
emphasises VBZ N
the DT N
previously RB N
demonstrated VBN N
unique JJ N
importance NN N
in IN N
humans NNS N
of IN N
suprabulbar NN N
noradrenergic JJ N
neuronal JJ N
projections NNS N
from IN N
the DT N
brainstem NN N
, , N
which WDT N
are VBP N
inhibited VBN N
by IN N
imidazoline JJ N
binding NN N
agents NNS N
, , N
in IN N
regulating VBG N
tonic JJ o
sympathetic JJ o
activity NN o
in IN N
essential JJ N
hypertension NN N
. . N

Sympathetic JJ N
nervous JJ N
inhibition NN N
with IN N
rilmenidine NN N
contrasted VBN N
with IN N
an DT N
absence NN N
of IN N
suppression NN N
of IN N
the DT N
secretion NN N
of IN N
adrenaline NN N
affirming NN N
that WDT N
here RB N
, , N
as IN N
elsewhere RB N
, , N
sympathetic JJ o
nervous JJ o
and CC o
adrenal JJ o
medullary JJ o
function NN o
can MD N
be VB N
disconnected VBN N
. . N

-DOCSTART- -25893544- O O

Icosapent NNP i
Ethyl NNP i
( ( i
Eicosapentaenoic NNP i
Acid NNP i
Ethyl NNP i
Ester NNP i
) ) i
: : i
Effects NNS N
Upon IN N
High-Sensitivity NNP N
C-Reactive JJ N
Protein NNP N
and CC N
Lipid NNP N
Parameters NNP N
in IN N
Patients NNP p
With IN p
Metabolic NNP p
Syndrome NNP p
. . p

BACKGROUND NNP N
The DT N
aim NN N
of IN N
this DT N
analysis NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
icosapent JJ i
ethyl NN i
( ( i
eicosapentaenoic JJ i
acid NN i
ethyl NN i
ester NN i
, , i
IPE NNP i
) ) i
on IN N
high-sensitivity NN N
C-reactive JJ N
protein NN N
( ( N
hsCRP NN N
) ) N
and CC N
lipid JJ N
parameters NNS N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
, , p
with IN p
and CC p
without IN p
stable JJ p
statin NN p
therapy NN p
. . p

METHODS NNP N
This DT N
post NN N
hoc NN N
exploratory NN N
analysis NN N
evaluated VBD N
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
treated VBN p
with IN p
IPE NNP i
4 CD p
grams/day NN p
, , p
IPE NNP p
2 CD p
grams/day NN p
, , p
or CC p
placebo NN i
in IN p
phase NN p
3 CD p
, , p
randomized VBN p
, , p
placebo-controlled JJ p
studies NNS p
entitled VBN p
: : p
MARINE NNP p
[ NNP p
triglyceride NN p
( ( p
TG NNP p
) ) p
levels NNS p
?500 CD p
and CC p
?2000 CD p
mg/dL NN p
] NN p
and CC p
ANCHOR NNP p
[ NNP p
TG NNP p
levels NNS p
?200 NNP p
and CC p
< $ p
500 CD p
mg/dL NN p
, , p
despite IN p
low-density JJ p
lipoprotein NN p
cholesterol NN p
( ( p
LDL-C NNP p
) ) p
control NN p
with IN p
stable JJ p
statin NN p
therapy NN p
] NNP p
. . p

RESULTS NNP N
Compared VBD N
with IN i
placebo NN i
in IN i
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
in IN p
MARINE NNP p
( ( p
n=204 NN p
) ) p
and CC p
ANCHOR NNP p
( ( p
n=645 NN p
) ) p
, , p
at IN N
the DT N
approved JJ N
dose NN N
of IN N
4 CD N
grams/day NN N
, , N
IPE NNP N
significantly RB o
lowered VBD o
hsCRP NN o
levels NNS o
40.0 CD o
% NN N
( ( N
P=0.0007 NNP N
) ) N
in IN N
MARINE NNP N
and CC N
23.0 CD N
% NN N
( ( N
P=0.0003 NNP N
) ) N
in IN N
ANCHOR NNP N
. . N

Compared VBN N
with IN i
placebo NN i
in IN i
MARINE NNP N
, , N
which WDT N
included VBD N
patients NNS N
with IN N
and CC N
without IN N
statin JJ N
therapy NN i
, , i
IPE NNP i
4 CD i
grams/day NN i
significantly RB o
reduced VBN o
hsCRP NN o
levels NNS o
78.0 CD o
% NN N
in IN N
statin-treated JJ N
patients NNS N
( ( N
P=0.0035 NNP N
, , N
n=16 NN N
) ) N
. . N

Compared VBN N
with IN i
placebo NN i
in IN i
MARINE NNP N
, , N
IPE NNP N
4 CD N
grams/day NN N
significantly RB o
reduced VBN o
TG NNP o
levels NNS o
( ( N
35.0 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
non-high-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
non-HDL-C JJ o
; : o
19.9 CD o
% NN o
; : o
P NNP o
< NNP o
0.0001 CD N
) ) N
, , N
and CC o
apolipoprotein RB o
B NNP o
levels NNS o
( ( N
ApoB NNP N
) ) N
( ( N
9.1 CD N
% NN N
; : N
P=0.0015 NNP N
) ) N
without IN N
raising VBG o
LDL-C JJ o
levels NNS o
. . o

Compared VBN o
with IN N
placebo NN N
in IN N
ANCHOR NNP N
, , N
IPE NNP i
4 CD i
grams/day NN i
significantly RB o
reduced VBN o
TG NNP o
( ( o
21.7 CD o
% NN o
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
non-HDL-C JJ o
( ( N
13.5 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
ApoB NNP o
( ( o
8.8 CD o
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
LDL-C NNP o
( ( o
5.2 CD o
% NN N
; : N
P=0.0236 NNP N
) ) N
, , N
and CC o
HDL-C NNP o
levels NNS o
( ( o
4.0 CD o
% NN N
; : N
P=0.0053 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
placebo NN N
, , N
IPE NNP N
4 CD N
grams/day NN N
significantly RB N
lowered VBD N
hsCRP NN N
levels NNS N
and CC N
improved VBN N
lipids NNS N
without IN N
raising VBG N
LDL-C JJ N
levels NNS N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
and CC p
high JJ p
( ( p
?200 JJ p
and CC p
< JJ p
500 CD p
mg/dL NN p
) ) p
or CC p
very RB p
high JJ p
( ( p
?500 CD p
and CC p
?2000 NNP p
mg/dL NN p
) ) p
TG NNP p
levels NNS p
, , p
with IN p
or CC p
without IN p
stable JJ p
statin NN p
therapy NN p
. . p

-DOCSTART- -19661796- O O

Preliminary JJ N
evaluation NN N
of IN N
psychoeducational JJ i
support NN i
interventions NNS i
on IN N
quality NN o
of IN o
life NN o
in IN N
rural JJ p
breast NN p
cancer NN p
survivors NNS p
after IN p
primary JJ p
treatment NN p
. . p

Although IN N
most JJS N
cancer NN p
survivors NNS p
are VBP N
at IN N
risk NN N
for IN N
being VBG N
lost VBN N
in IN N
the DT N
transition NN N
from IN N
treatment NN N
to TO N
survivorship VB N
, , N
rural JJ p
breast NN p
cancer NN p
survivors NNS p
face VBP N
special JJ N
challenges NNS N
that WDT N
might MD N
place VB N
them PRP N
at IN N
particular JJ N
risk NN N
. . N

This DT N
small-scale JJ N
preliminary JJ N
study NN N
had VBD N
2 CD N
specific JJ N
aims NNS N
: : N
( ( N
aim IN N
1 CD N
) ) N
establish VB N
the DT N
feasibility NN N
of IN N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
participation VBP N
in IN N
a DT N
longitudinal JJ i
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
intervention NN i
trial NN N
and CC N
( ( N
aim VB N
2 CD N
) ) N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
Breast NNP i
Cancer NNP i
Education NNP i
Intervention NNP i
( ( i
BCEI NNP i
) ) i
on IN N
overall JJ o
QOL NNP o
. . o

Fifty-three JJ p
rural JJ p
breast NN p
cancer NN p
survivors NNS p
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
experimental JJ N
( ( N
n JJ N
= NNP N
27 CD N
) ) N
or CC N
a DT N
wait-control JJ N
arm NN N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
. . N

Participants NNS N
in IN N
the DT N
experimental JJ N
arm NN N
received VBD N
the DT N
BCEI NNP N
consisting NN N
of IN N
3 CD i
face-to-face JJ i
education NN i
and CC i
support NN i
sessions NNS i
and CC N
2 CD N
face-to-face NN N
and CC N
3 CD N
telephone NN i
follow-up JJ i
sessions NNS i
, , N
along IN N
with IN N
supplemental JJ N
written VBN N
and CC N
audiotape JJ N
materials NNS N
over IN N
a DT N
6-month JJ N
period NN N
. . N

Breast NNP i
Cancer NNP i
Education NNP i
Intervention NNP i
modules NNS i
and CC i
interventions NNS i
are VBP N
organized VBN N
within IN N
a DT N
QOL NNP N
framework NN N
. . N

To TO N
address VB N
the DT N
possible JJ N
effects NNS N
of IN N
attention NN N
, , N
wait-control JJ N
participants NNS N
received VBD N
3 CD N
face-to-face JJ N
sessions NNS N
and CC N
3 CD N
telephone NN N
sessions NNS N
during IN N
the DT N
first JJ N
6 CD N
months NNS N
of IN N
participation NN N
in IN N
the DT N
study NN N
, , N
but CC N
not RB N
the DT N
BCEI NNP i
intervention NN i
. . i

Research NNP N
questions NNS N
addressing VBG N
aim NN N
1 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
can MD N
rural VB N
breast NN N
cancer NN N
survivors NNS N
be VB N
recruited VBN N
into IN N
a DT N
longitudinal JJ N
intervention NN N
trial NN N
, , N
and CC N
( ( N
b NN N
) ) N
can MD N
their PRP$ N
participation NN N
be VB N
retained VBN N
. . N

Research NNP N
questions NNS N
for IN N
aim NN N
2 CD N
were VBD N
as IN N
follows VBZ N
: : N
( ( N
a DT N
) ) N
do VBP N
participants NNS N
who WP N
received VBD N
the DT N
BCEI NNP N
show NN N
improvement NN N
in IN N
overall JJ o
QOL NNP o
, , N
and CC N
( ( N
b NN N
) ) N
is VBZ N
the DT N
QOL NNP o
improvement NN o
sustained VBD N
over IN N
time NN N
. . N

Data NNS N
were VBD N
analyzed VBN N
using VBG N
repeated-measures JJ N
general JJ N
linear NN N
mixed JJ N
models NNS N
. . N

Results NNS N
demonstrated VBD N
the DT N
ability NN N
to TO N
recruit VB N
and CC N
retain VB N
53 CD N
rural JJ N
breast NN N
cancer NN N
survivors NNS N
, , N
that IN N
the DT N
experimental JJ N
arm NN N
showed VBD N
improvement NN N
in IN N
overall JJ o
QOL NNP o
( ( N
P NNP N
= NNP N
.013 NNP N
) ) N
, , N
and CC N
that IN N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
overall JJ o
QOL NNP o
between IN N
the DT N
experimental JJ N
and CC N
wait-control JJ N
groups NNS N
at IN N
both DT N
months NNS N
3 CD N
and CC N
6 CD N
. . N

Thus RB N
, , N
it PRP N
appears VBZ N
that IN N
at IN N
least JJS N
some DT N
rural JJ p
breast NN p
cancer NN p
survivors NNS p
can MD N
and CC N
will MD N
participate VB N
in IN N
a DT N
larger JJR N
trial NN N
and CC N
will MD N
maintain VB N
their PRP$ N
participation NN N
and CC N
that IN N
those DT N
that WDT N
do VBP N
participate VB N
experience NN N
significant JJ N
QOL NNP o
benefit NN N
. . N

-DOCSTART- -21595978- O O

Tailored NNP i
, , i
iterative JJ i
, , i
printed JJ i
dietary JJ i
feedback NN i
is VBZ N
as RB N
effective JJ N
as IN N
group NN N
education NN N
in IN N
improving VBG N
dietary JJ N
behaviours NNS N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
control NN N
trial NN N
in IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
. . p

BACKGROUND NNP N
Tailored NNP N
nutrition NN N
interventions NNS N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
non-tailored JJ N
materials NNS N
in IN N
changing VBG N
dietary JJ N
behaviours NNS N
, , N
particularly RB N
fat JJ N
intake NN N
and CC N
fruit NN N
and CC N
vegetable JJ N
intake NN N
. . N

But CC N
further JJ N
research NN N
examining VBG N
efficacy NN N
of IN N
tailored JJ N
nutrition NN N
education NN N
in IN N
comparison NN N
to TO N
other JJ N
nutrition JJ N
education NN N
methods NNS N
and CC N
across IN N
a DT N
wider NN N
range NN N
of IN N
dietary JJ N
behaviours NNS N
is VBZ N
needed VBN N
. . N

The DT p
Stages NNPS p
to TO p
Healthy NNP p
Eating NNP p
Patterns NNP p
Study NNP p
( ( p
STEPs NNP p
) ) p
was VBD N
an DT N
intervention NN N
study NN N
, , N
in IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
, , N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
delivered VBN N
by IN N
mail NN N
in IN N
improving VBG N
short-term JJ N
dietary JJ N
behaviour NN N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat NN N
, , N
fruit NN N
, , N
vegetable JJ N
and CC N
grain NN N
and CC N
cereal NN N
intake NN N
. . N

METHODS NNP N
STEPs NNP N
was VBD N
a DT N
3-month JJ N
randomised VBN N
controlled VBN N
trial NN N
with IN N
a DT N
pre NN N
and CC N
post-test JJ N
design NN N
. . N

There EX N
were VBD N
three CD N
experimental JJ N
conditions NNS N
: : N
1 CD N
) ) N
tailored VBN i
, , i
iterative JJ i
, , i
printed JJ i
dietary JJ i
feedback NN i
( ( i
TF NNP i
) ) i
with IN N
three CD N
instalments NNS N
mail-delivered JJ N
over IN N
a DT N
3-month JJ N
period NN N
that WDT N
were VBD N
re-tailored VBN N
to TO N
most RBS N
recent JJ N
assessment NN N
of IN N
dietary JJ N
intake NN N
, , N
intention NN N
to TO N
change VB N
and CC N
assessment NN N
of IN N
self-adequacy NN N
of IN N
dietary JJ N
intake NN N
. . N

Tailoring VBG N
for IN N
dietary JJ N
intake NN N
was VBD N
performed VBN N
on IN N
data NNS N
from IN N
a DT N
validated JJ N
63-item JJ N
combination NN N
FFQ NNP N
designed VBN N
for IN N
the DT N
purpose JJ N
2 CD N
) ) N
small JJ N
group NN N
nutrition NN i
education NN i
sessions NNS i
( ( N
GE NNP N
) ) N
: : N
consisting NN N
of IN N
two CD N
90-minute JJ N
dietitian-led JJ N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
and CC N
3 CD N
) ) N
and CC N
a DT N
wait-listed JJ N
control NN N
( ( N
C NNP N
) ) N
group NN N
who WP N
completed VBD N
the DT N
dietary JJ i
measures NNS i
and CC i
socio-demographic JJ i
questionnaires NNS i
at IN N
baseline NN N
and CC N
3-months JJ N
later NN N
. . N

Dietary NNP N
outcome NN N
measures NNS N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ o
fat JJ o
intake NN o
( ( o
g NN o
) ) o
, , N
and CC N
the DT N
intake NN o
of IN o
fruit NN o
( ( o
serves NNS o
) ) o
, , o
vegetables NNS o
( ( o
serves NNS o
) ) o
, , o
grain NN o
and CC o
cereals NNS o
as IN N
total JJ o
and CC o
wholegrain NN o
( ( o
serves NNS o
) ) o
were VBD N
collected VBN N
using VBG N
7-day JJ N
estimated VBN N
dietary JJ N
records NNS N
. . N

Descriptive JJ N
statistics NNS N
, , N
paired VBD N
t-tests NNS N
and CC N
general JJ N
linear JJ N
models NNS N
adjusted VBN N
for IN N
baseline NN N
dietary JJ N
intake NN N
, , N
age NN N
and CC N
gender NN N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
different JJ N
nutrition NN N
interventions NNS N
. . N

RESULTS VB N
The DT N
TF NNP i
group NN N
reported VBD N
a DT N
significantly RB N
greater JJR N
increase NN N
in IN N
fruit JJ o
intake NN o
( ( N
0.3 CD N
serves/d NN N
P NNP N
= NNP N
0.031 CD N
) ) N
in IN N
comparison NN N
to TO N
GE NNP N
and CC N
the DT N
C NNP N
group NN N
. . N

All DT N
three CD N
intervention NN N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
total JJ o
saturated JJ o
fat JJ o
intake NN o
. . o

GE NNP N
also RB N
had VBD N
a DT N
within-group JJ N
increase NN N
in IN N
mean JJ o
vegetable JJ o
intake NN o
after IN N
3 CD N
months NNS N
, , N
but CC N
this DT N
increase NN N
was VBD N
not RB N
different JJ N
from IN N
changes NNS N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
was VBD N
more RBR N
effective JJ N
than IN N
small JJ N
group NN N
nutrition NN N
education NN N
in IN N
improving VBG N
the DT N
short-term JJ N
fruit NN N
intake VB N
behaviour NN N
, , N
and CC N
as IN N
effective JJ N
in IN N
improving VBG N
saturated VBN N
fat JJ N
intake NN N
of IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
. . p

This DT N
showed VBD N
that IN N
a DT N
low-level JJ N
dietary JJ N
intervention NN N
could MD N
achieve VB N
modest JJ N
dietary JJ N
behaviour NN N
changes NNS N
that WDT N
are VBP N
of IN N
public JJ N
health NN N
significance NN N
. . N

-DOCSTART- -1827322- O O

Controversies NNS N
in IN N
the DT N
management NN i
of IN N
Hodgkin NNP p
's POS p
disease NN p
. . p

-DOCSTART- -10352397- O O

Low-dose JJ i
growth NN i
hormone NN i
treatment NN i
with IN i
diet JJ i
restriction NN i
accelerates VBZ o
body JJ o
fat JJ o
loss NN o
, , o
exerts VBZ o
anabolic JJ o
effect NN o
and CC o
improves VBZ o
growth NN o
hormone NN o
secretory NN o
dysfunction NN o
in IN N
obese JJ p
adults NNS p
. . p

Growth NNP i
hormone NN i
( ( N
GH NNP N
) ) N
can MD N
induce VB N
an DT N
accelerated JJ o
lipolysis NN o
. . o

Impaired NNP N
secretion NN N
of IN N
GH NNP N
in IN N
obesity NN N
results NNS N
in IN N
the DT N
consequent JJ N
loss NN N
of IN N
the DT N
lipolytic JJ o
effect NN o
of IN o
GH NNP o
. . o

Dietary NNP N
restriction NN N
as IN N
a DT N
basic JJ N
treatment NN N
for IN N
obesity NN N
is VBZ N
complicated VBN N
by IN N
poor JJ N
compliance NN N
, , N
protein NN N
catabolism NN N
, , N
and CC N
slow VB N
rates NNS N
or CC N
weight JJ N
loss NN N
. . N

GH NNP N
has VBZ N
an DT N
anabolic JJ N
effect NN N
by IN N
increasing VBG o
insulin-like JJ o
growth NN o
factor NN o
( ( o
IGF NNP o
) ) o
-I NN o
. . o

We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
GH NNP N
treatment NN N
and CC N
dietary JJ N
restriction NN N
on IN N
lipolytic JJ o
and CC o
anabolic JJ o
actions NNS o
, , o
as RB o
well RB o
as IN o
the DT o
consequent NN o
changes NNS o
in IN o
insulin NN o
and CC o
GH NNP o
secretion NN o
in IN o
obesity NN o
. . o

24 CD p
obese JJ p
subjects NNS p
( ( p
22 CD p
women NNS p
and CC p
2 CD p
men NNS p
; : p
22-46 CD p
years NNS p
old JJ p
) ) p
were VBD N
fed VBN N
a DT N
diet NN i
of IN N
25 CD N
kcal/kg NNS N
ideal JJ N
body NN N
weight NN N
( ( N
IBW NNP N
) ) N
with IN N
1.2 CD N
g NNS N
protein/kg JJ N
IBW NNP N
daily RB N
and CC N
were VBD N
treated VBN N
with IN N
recombinant JJ i
human JJ i
GH NNP i
( ( N
n JJ N
= NN N
12 CD N
, , N
0.18 CD N
U/kg NNP N
IBW/week NNP N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NN N
12 CD N
, , N
vehicle NN N
injection NN N
) ) N
in IN N
a DT N
12-week JJ N
randomized NN N
, , N
double-blind JJ N
and CC N
placebo-controlled JJ N
trial NN N
. . N

GH NNP i
treatment NN N
caused VBD N
a DT N
1.6-fold JJ N
increase NN N
in IN N
the DT N
fraction NN o
of IN o
body NN o
weight NN o
lost VBD o
as IN o
fat NN o
and CC o
a DT o
greater JJR o
loss NN o
of IN o
visceral JJ o
fat JJ o
area NN o
than IN N
placebo NN N
treatment NN N
( ( N
35.3 CD N
vs. FW N
28.5 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
there EX N
was VBD N
a DT N
loss NN N
in IN N
lean JJ o
body NN o
mass NN o
( ( N
-2.62 JJ N
+/- JJ N
1.51 CD N
kg NN N
) ) N
and CC N
a DT N
negative JJ o
nitrogen NN o
balance NN o
( ( N
-4.52 JJ N
+/- JJ N
3.51 CD N
g/day NN N
) ) N
. . N

By IN N
contrast NN N
, , N
the DT N
GH NNP i
group NN N
increased VBD N
in IN N
lean JJ o
body NN o
mass NN o
( ( N
1.13 CD N
+/- JJ N
1.04 CD N
kg NN N
) ) N
and CC N
had VBD N
a DT N
positive JJ o
nitrogen NN o
balance NN o
( ( N
1.81 CD N
+/- JJ N
2.06 CD N
g/day NN N
) ) N
. . N

GH NNP i
injections NNS i
caused VBD N
a DT N
1.6-fold JJ N
increase NN o
in IN o
IGF-I NNP o
, , N
despite IN N
caloric JJ N
restriction NN N
. . N

GH NNP o
response NN o
to TO o
L-dopa NNP o
stimulation NN o
was VBD N
blunted VBN o
in IN N
all DT N
subjects NNS N
and CC N
it PRP N
was VBD N
increased VBN N
after IN N
treatment NN N
in IN N
both DT N
groups NNS N
. . N

GH NNP i
treatment NN N
did VBD N
not RB N
induce VB N
a DT N
further JJ N
increase NN N
in IN N
insulin JJ o
levels NNS o
during IN N
an DT N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
but CC N
significantly RB N
decreased VBD N
free JJ o
fatty JJ o
acid NN o
( ( o
FFA NNP o
) ) o
levels NNS o
during IN N
OGTT NNP N
. . N

The DT N
decrease NN N
in IN N
FFA NNP o
area NN o
under IN N
the DT N
curve NN N
during IN N
OGTT NNP N
was VBD N
positively RB N
correlated VBN N
with IN N
visceral JJ o
fat JJ o
loss NN o
. . o

This DT N
study NN N
demonstrates VBZ N
that IN N
in IN N
obese JJ p
subjects NNS p
given VBN N
a DT N
hypocaloric JJ N
diet NN N
, , N
GH NNP N
accelerates VBZ N
body NN o
fat JJ o
loss NN o
, , o
exerts VBZ o
anabolic JJ o
effects NNS o
and CC o
improves NNS o
GH NNP o
secretion NN o
. . o

These DT N
findings NNS N
suggest VBP N
a DT N
possible JJ N
therapeutic JJ N
role NN N
of IN N
low-dose JJ N
GH NNP i
with IN N
caloric JJ N
restriction NN N
for IN N
obesity NN N
. . N

-DOCSTART- -26151440- O O

A DT N
controlled JJ N
trial NN N
of IN N
the DT N
SibworkS NNP i
group NN i
program NN i
for IN N
siblings NNS p
of IN p
children NNS p
with IN p
special JJ p
needs NNS p
. . p

Siblings NNS p
of IN p
children NNS p
with IN p
a DT p
disability NN p
are VBP N
an DT N
at IN N
risk NN N
group NN N
for IN N
emotional JJ N
and CC N
behavioral JJ N
problems NNS N
. . N

This DT N
study NN N
evaluated VBD N
an DT N
intervention NN N
to TO N
promote VB N
the DT N
emotional JJ N
and CC N
behavioral JJ N
functioning NN N
of IN N
siblings NNS p
of IN p
children NNS p
with IN p
disabilities NNS p
and CC p
chronic JJ p
health NN p
conditions NNS p
. . p

SibworkS NNP i
is VBZ N
a DT N
six-week JJ N
manual-based JJ N
, , N
cognitive-behavioral JJ N
group NN N
support NN N
program NN N
focussed VBN N
on IN N
strengthening VBG N
siblings NNS N
' POS N
perceived VBN N
social JJ N
support NN N
, , N
self-esteem JJ N
, , N
problem-solving JJ N
skills NNS N
, , N
adaptive JJ N
coping NN N
behaviors NNS N
and CC N
positive JJ N
sibling NN N
relationships NNS N
. . N

Fifty-six JJ p
children NNS p
aged VBN p
7-12 CD p
were VBD N
allocated VBN N
to TO N
either CC N
the DT N
SibworkS NNP i
program NN i
( ( N
n=30 JJ N
) ) N
or CC N
waitlist JJ i
control NN i
( ( N
n=26 JJ N
) ) N
in IN N
alternating VBG N
sequence NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
siblings NNS N
' POS N
emotional JJ o
and CC o
behavioral JJ o
functioning NN o
. . o

Additional JJ N
outcomes NNS N
were VBD N
self-esteem JJ o
, , o
perceived VBD o
social JJ o
support NN o
, , o
the DT o
sibling NN o
relationship NN o
and CC o
coping NN o
behaviors NNS o
. . o

Siblings NNS N
were VBD N
followed-up JJ N
immediately RB N
after IN N
the DT N
intervention NN N
and CC N
at IN N
3-months JJ N
. . N

Siblings NNS N
participating VBG N
in IN N
the DT N
SibworkS NNP i
intervention NN N
were VBD N
reported VBN N
to TO N
have VB N
fewer JJR N
emotional JJ N
and CC N
behavioral JJ N
difficulties NNS N
than IN N
siblings NNS N
in IN N
the DT N
control NN N
group NN N
immediately RB N
following VBG N
the DT N
intervention NN N
and CC N
at IN N
the DT N
3-month JJ N
follow-up NN N
. . N

Participation NN N
in IN N
SibworkS NNP i
was VBD N
associated VBN N
with IN N
fewer JJR N
emotional JJ o
and CC o
behavioral JJ o
difficulties NNS o
for IN N
siblings NNS N
. . N

Implications NNS N
for IN N
practice NN N
and CC N
future JJ N
research NN N
include VBP N
recommendations NNS N
for IN N
improving VBG N
program NN N
participation NN N
. . N

-DOCSTART- -1710660- O O

New NNP N
hope NN N
for IN N
children NNS p
with IN p
Kawasaki NNP p
disease NN p
. . p

Kawasaki NNP N
disease NN N
is VBZ N
now RB N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
acquired VBN p
heart NN p
disease NN p
in IN p
America NNP p
's POS p
children NNS p
. . p

It PRP N
is VBZ N
an DT N
acute JJ N
febrile NN N
illness NN N
that WDT N
may MD N
cause VB N
coronary JJ N
artery NN N
aneurysm NN N
formation NN N
in IN N
infected JJ p
children NNS p
. . p

The DT N
results NNS N
of IN N
a DT N
multicenter NN N
, , N
randomized VBN N
trial NN N
on IN N
the DT N
effect NN N
of IN N
intravenous JJ i
administration NN i
of IN i
gamma JJ i
globulin NN i
( ( i
IVGG NNP i
) ) i
plus CC i
aspirin JJ i
versus NN i
aspirin NN i
alone RB i
upon IN N
coronary JJ N
aneurysm NN N
formation NN N
show VBP N
a DT N
decrease NN N
in IN N
coronary JJ o
aneurysm NN o
formation NN o
from IN N
the DT N
usual JJ N
20 CD N
% NN N
-30 NN N
% NN N
to TO N
3 CD N
% NN N
. . N

Administration NNP N
of IN N
IVGG NNP i
presents VBZ N
some DT N
unique JJ N
challenges NNS N
for IN N
nurses NNS N
. . N

Also RB N
, , N
the DT N
pediatric JJ N
nurse NN N
must MD N
educate VB N
parents NNS N
and CC N
children NNS p
about IN N
this DT N
disease NN N
to TO N
prepare VB N
them PRP N
for IN N
discharge NN N
and CC N
long-term JJ N
follow-up JJ N
care NN N
. . N

-DOCSTART- -23073171- O O

Effects NNS N
of IN N
conjugated JJ i
linoleic JJ i
acid NN i
supplementation NN i
and CC N
exercise NN i
on IN N
post-heparin JJ o
lipoprotein NN o
lipase NN o
, , o
butyrylcholinesterase NN o
, , o
blood NN o
lipid JJ o
profile NN o
and CC o
glucose JJ o
metabolism NN o
in IN N
young JJ p
men NNS p
. . p

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
conjugated JJ i
linoleic JJ i
acid NN i
( ( i
CLA NNP i
) ) i
supplementation NN i
and CC N
endurance NN i
exercise NN i
training-induced JJ N
changes NNS N
on IN N
post-heparin JJ o
lipoprotein NN o
lipase NN o
( ( o
PH-LPL NNP o
) ) o
and CC N
butyrylcholinesterase NN o
( ( o
BChE NNP o
) ) o
activities NNS o
along IN N
with IN N
leptin NN N
, , N
insulin NN N
and CC N
lipid JJ N
levels NNS N
in IN N
plasma NN N
by IN N
a DT N
randomized JJ N
double JJ N
blind NN N
experiment NN N
. . N

Eighteen NNP p
sedentary JJ p
male NN p
volunteers NNS p
were VBD N
randomly RB i
divided VBN N
into IN N
CLA NNP i
and CC N
Placebo NNP i
( ( i
PLC NNP i
) ) i
supplementation NN N
groups NNS N
. . N

Both DT N
groups NNS N
underwent JJ N
daily JJ i
supplementation NN i
of IN i
either CC i
3g CD i
CLA NNP i
or CC i
3g CD i
placebo NN i
for IN i
30 CD i
days NNS i
, , i
respectively RB i
, , i
and CC i
performed VBD i
exercise NN i
on IN i
a DT i
bicycle NN i
ergometer NN i
3 CD i
times NNS i
per IN i
week NN i
for IN i
30-40 JJ i
min NN i
at IN i
50 CD i
% NN i
VO2 NNP i
peak NN i
workload NN i
. . i

For IN N
plasma NN o
glucose NN o
, , o
insulin NN o
and CC o
leptin NN o
levels NNS o
and CC o
BChE NNP o
activity NN o
fasting VBG o
blood NN o
was VBD N
used VBN N
. . N

For IN N
PH-LPL JJ o
measurements NNS o
, , N
blood NN N
was VBD N
collected VBN N
15 CD N
min NNS N
after IN N
50 CD N
IU/kg NNP N
iv NN N
heparin NN N
injection NN N
. . N

In IN N
all DT N
groups NNS N
, , N
there EX N
is VBZ N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
BChE NNP o
( ( N
p JJ N
= NN N
0.03 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
and CC N
leptin $ o
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
, , N
insulin JJ o
and CC o
HOMA-IR JJ o
levels NNS o
( ( N
p VB N
= RB N
0.02 CD N
) ) N
. . N

Exercise NN o
with IN o
or CC o
without IN o
CLA NNP o
supplementation NN o
decreased VBD N
insulin NN o
levels NNS o
and CC N
increased VBD N
insulin NN o
sensitivity NN o
. . o

PH-LPL JJ o
activity NN o
was VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
displaying VBG N
increased VBN N
fatty JJ N
acid JJ N
mobilization NN N
. . N

We PRP N
conclude VBP N
that IN N
though IN N
CLA NNP i
supplementation NN N
and CC N
exercise NN N
can MD N
affect VB N
these DT N
parameters NNS N
, , N
CLA NNP i
is VBZ N
not RB N
more RBR N
effective JJ N
than IN N
exercise NN N
alone RB N
. . N

Hence NNP N
, , N
a DT N
prolonged JJ N
supplementation NN N
regime NN N
may MD N
be VB N
more RBR N
effective JJ N
. . N

Taken VB N
together RB N
in IN N
our PRP$ N
small JJ N
study NN N
group NN N
, , N
our PRP$ N
findings NNS N
display VBP N
that IN N
BChE NNP o
is VBZ N
a DT N
potential JJ N
marker NN N
for IN N
synthetic JJ N
function NN N
of IN N
liver NN N
, , N
fat JJ N
metabolism NN N
, , N
an DT N
obesity NN N
marker NN N
, , N
a DT N
function NN N
long RB N
overlooked VBD N
. . N

-DOCSTART- -23510984- O O

A DT N
randomized JJ N
, , N
placebo-controlled JJ i
phase NN N
2 CD N
study NN N
of IN N
ganitumab NN i
or CC i
conatumumab NN i
in IN N
combination NN N
with IN N
FOLFIRI NNP N
for IN N
second-line JJ N
treatment NN N
of IN N
mutant JJ N
KRAS NNP N
metastatic JJ N
colorectal NN N
cancer NN N
. . N

BACKGROUND NNP N
Targeted VBD N
agents NNS N
presently RB N
available JJ N
for IN N
mutant JJ N
KRAS NNP N
metastatic JJ N
colorectal NN N
cancer NN N
( ( N
mCRC NN N
) ) N
are VBP N
bevacizumab JJ i
and CC N
aflibercept JJ i
. . i

We PRP N
evaluated VBD N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
conatumumab NN i
( ( N
an DT N
agonistic JJ N
monoclonal NN N
antibody NN N
against IN N
human JJ N
death NN N
receptor NN N
5 CD N
) ) N
and CC N
ganitumab NN i
( ( N
a DT N
monoclonal NN N
antibody NN N
against IN N
the DT N
type NN N
1 CD N
insulin-like JJ N
growth NN N
factor NN N
receptor NN N
) ) N
combined VBN N
with IN N
standard JJ N
FOLFIRI NNP N
chemotherapy NN N
as IN N
a DT N
second-line JJ N
treatment NN N
in IN N
patients NNS N
with IN N
mutant JJ N
KRAS NNP N
mCRC NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
mutant JJ p
KRAS NNP p
metastatic JJ p
adenocarcinoma NN p
of IN p
the DT p
colon NN p
or CC p
rectum VB p
refractory NN p
to TO p
fluoropyrimidine- JJ i
and CC i
oxaliplatin-based JJ i
chemotherapy NN i
were VBD N
randomized VBN N
1 CD N
: : N
1 CD N
: : N
1 CD N
to TO N
receive VB N
intravenous JJ i
FOLFIRI NNP i
plus CC i
conatumumab JJ i
10 CD i
mg/kg NN i
( ( i
Arm NNP i
A NNP i
) ) i
, , i
ganitumab $ i
12 CD i
mg/kg NN i
( ( i
Arm NNP i
B NNP i
) ) i
, , i
or CC i
placebo NN i
( ( N
Arm NNP N
C NNP N
) ) N
Q2W NNP N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

RESULTS NNP N
In IN N
total JJ N
, , N
155 CD p
patients NNS p
were VBD p
randomized VBN p
. . p

Median JJ o
PFS NNP o
in IN N
Arms NNP N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
was VBD N
6.5 CD N
months NNS N
( ( N
HR NNP N
, , N
0.69 CD N
; : N
P NNP N
= NNP N
0.147 CD N
) ) N
, , N
4.5 CD N
months NNS N
( ( N
HR NNP N
, , N
1.01 CD N
; : N
P NNP N
= NNP N
0.998 CD N
) ) N
, , N
and CC N
4.6 CD N
months NNS N
, , N
respectively RB N
; : N
median JJ o
overall JJ o
survival NN o
was VBD N
12.3 CD N
months NNS N
( ( N
HR NNP N
, , N
0.89 CD N
; : N
P NNP N
= NNP N
0.650 CD N
) ) N
, , N
12.4 CD N
months NNS N
( ( N
HR NNP N
, , N
1.27 CD N
; : N
P NNP N
= NNP N
0.357 CD N
) ) N
, , N
and CC N
12.0 CD N
months NNS N
; : N
and CC N
objective JJ o
response NN o
rate NN o
was VBD N
14 CD N
% NN N
, , N
8 CD N
% NN N
, , N
and CC N
2 CD N
% NN N
. . N

The DT N
most RBS N
common JJ N
grade NN N
?3 JJ o
adverse JJ o
events NNS o
in IN o
Arms NNP N
A/B/C NNP N
included VBD o
neutropenia NN o
( ( o
30 CD N
% NN N
/25 CD N
% NN N
/18 NNP N
% NN N
) ) N
and CC o
diarrhea NN o
( ( o
18 CD N
% NN N
/2 CD N
% NN N
/10 NNP N
% NN N
) ) N
. . N

CONCLUSIONS NNP i
Conatumumab NNP i
, , i
but CC N
not RB i
ganitumab VB i
, , i
plus CC i
FOLFIRI NNP i
was VBD i
associated VBN N
with IN N
a DT N
trend NN N
toward IN o
improved JJ o
PFS NNP o
. . o

Both NNP N
combinations NNS N
had VBD o
acceptable JJ o
toxicity NN o
. . o

-DOCSTART- -11315533- O O

Children NNP p
with IN p
persistent JJ p
conduct NN p
problems NNS p
who WP p
dropout VBP p
of IN p
treatment NN p
. . p

Dropout NNP o
of IN N
treatment NN N
is VBZ N
one CD N
of IN N
the DT N
key JJ N
issues NNS N
in IN N
outcome NN N
in IN N
a DT N
child NN p
and CC p
adolescent JJ p
mental JJ p
health NN p
service NN p
. . p

We PRP N
report VBP N
two CD N
studies NNS N
focusing VBG N
on IN N
the DT N
treatment NN N
process NN N
and CC N
the DT N
dropout NN o
rate NN o
of IN o
children NNS o
with IN p
persistent JJ p
conduct NN p
problems NNS p
presenting VBG p
to TO p
a DT p
community NN p
mental JJ p
health NN p
service NN p
, , N
using VBG N
a DT N
prospective JJ N
design NN N
. . N

The DT N
first JJ p
study NN p
included VBD p
32 CD p
children NNS p
and CC N
used VBD N
a DT N
randomised JJ N
controlled JJ N
treatment NN N
design NN N
comparing VBG N
a DT N
CBT NNP i
approach NN i
with IN i
conjoint JJ i
family NN i
therapy NN i
and CC i
an DT i
eclectic JJ i
approach NN i
. . i

The DT N
overall JJ o
dropout NN o
rate NN o
was VBD N
36 CD N
% NN N
. . N

Dropout NN o
occurred VBD N
significantly RB N
less RBR N
frequently RB N
in IN N
the DT N
CBT NNP i
group NN N
. . N

The DT N
dropout NN N
group NN N
was VBD N
associated VBN N
with IN N
mothers NNS p
who WP p
were VBD p
younger JJR o
and CC o
less RBR o
educated VBN o
, , N
a DT N
poorer NN o
rating NN o
by IN o
the DT o
clinicians NNS o
at IN N
the DT N
last JJ N
meeting NN N
, , N
parental JJ o
dissatisfaction NN o
with IN o
the DT o
treatment NN o
service NN o
and CC N
perception NN o
that IN o
the DT o
treatment NN o
was VBD N
less JJR N
organised JJ N
and CC N
having VBG N
less JJR N
behavioural JJ N
tasks NNS N
. . N

In IN N
the DT N
second JJ N
study NN N
we PRP N
used VBD N
a DT N
naturalistic JJ i
follow-up JJ i
design NN i
. . i

Forty-six JJ p
children NNS p
were VBD p
included VBN p
. . p

The DT N
overall JJ o
dropout NN o
rate NN o
was VBD N
48 CD N
% NN N
. . N

Again NNP N
, , N
the DT N
children NNS p
who WP p
defaulted VBD p
were VBD N
rated VBN N
by IN N
clinicians NNS N
as IN N
less RBR N
likely JJ N
to TO N
have VB N
improved VBN N
and CC N
dropout NN N
was VBD N
also RB N
significantly RB N
associated VBN N
with IN N
parental JJ o
perception NN o
of IN o
a DT o
less RBR o
organised JJ o
treatment NN o
. . o

In IN N
both DT N
studies NNS N
dropout VBP o
usually RB N
occurred VBN N
after IN N
assessment NN N
and CC N
at IN N
the DT N
early JJ N
phase NN N
of IN N
treatment NN N
. . N

-DOCSTART- -9230648- O O

Gonadotropin-releasing VBG i
hormone NN i
agonist NN N
in IN N
the DT N
treatment NN N
of IN N
premenstrual JJ N
symptoms NNS N
with IN N
and CC N
without IN N
ongoing VBG N
dysphoria NN N
: : N
a DT N
controlled VBN N
study NN N
. . N

Gonadotropin-releasing VBG i
hormone NN i
( ( i
GnRH NNP i
) ) i
agonists NNS i
have VBP N
been VBN N
shown VBN N
to TO N
reduce VB N
symptoms NNS o
of IN o
premenstrual JJ o
syndrome NN o
( ( o
PMS NNP o
) ) o
. . o

This DT N
randomized JJ N
, , N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
the DT N
GnRH NNP i
agonist NN i
, , N
leuprolide JJ N
acetate NN N
depot NN N
, , N
in IN N
a DT N
clearly RB p
defined VBN p
PMS NNP p
sample JJ p
versus NNS p
women NNS p
with IN p
premenstrual JJ p
symptoms NNS p
in IN p
combination NN p
with IN p
dysphoric NN p
symptoms NNS p
throughout IN p
the DT p
cycle NN p
, , p
termed VBD p
the DT p
premenstrual JJ p
exacerbation NN p
( ( p
PME NNP p
) ) p
group NN p
. . p

Evaluation NN N
included VBD N
the DT N
Structured NNP o
Clinical NNP o
Interview NNP o
for IN o
DSM-III-R NNP o
, , N
administered VBN N
in IN N
the DT N
follicular JJ N
phase NN N
, , N
and CC N
the DT N
subject NN o
Penn NNP o
Dally NNP o
Symptoms NNP o
Report NNP o
( ( o
DSR NNP o
) ) o
maintained VBD N
throughout IN N
the DT N
study NN N
. . N

Thirty-three NNP p
eligible JJ p
women NNS p
were VBD N
randomized VBN N
to TO N
double-blind VB N
treatment NN N
and CC N
administered VBD N
3.75 CD i
mg NN i
of IN i
depot NN i
leuprolide NN i
or CC i
a DT i
placebo NN i
once RB N
a DT N
month NN N
for IN N
3 CD N
months NNS N
. . N

The DT N
subjects NNS N
were VBD N
seen VBN N
for IN N
efficacy NN o
evaluations NNS N
at IN N
the DT N
end NN N
of IN N
each DT N
cycle NN N
. . N

Outcome CC N
measures NNS N
were VBD N
the DT N
DSRs NNP o
and CC o
the DT o
17-item JJ o
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
( ( o
HAM-D17 NNP o
) ) o
. . o

The DT N
PMS NNP N
leuprolide JJ i
subjects NNS N
improved VBN N
significantly RB N
compared VBN N
with IN N
the DT N
PMS NNP N
placebo NN N
and CC N
PME NNP N
leuprolide RB N
groups NNS N
. . N

The DT N
PME NNP N
leuprolide NN i
group NN N
, , N
who WP N
had VBD N
dysphoric NN o
symptoms NNS o
throughout IN N
the DT N
cycle NN N
, , N
did VBD N
not RB N
improve VB N
. . N

Depression NNP o
symptoms NNS o
were VBD N
at IN N
clinical JJ N
levels NNS N
premenstrually RB N
in IN N
the DT N
PMS NNP N
and CC N
PME NNP N
groups NNS N
; : N
following VBG N
treatment NN N
they PRP N
remitted VBD N
in IN N
the DT N
PMS NNP N
group NN N
but CC N
not RB N
in IN N
the DT N
PME NNP N
leuprolide JJ i
subjects NNS N
. . N

Efficacy NN N
did VBD N
not RB N
occur VB N
until IN N
after IN N
several JJ N
months NNS N
of IN N
leuprolide JJ i
treatment NN N
, , N
but CC N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
PMS NNP o
symptoms NNS o
worsened VBD N
with IN N
the DT N
onset NN N
of IN N
treatment NN N
. . N

These DT N
results NNS N
replicate VBP N
the DT N
findings NNS N
in IN N
our PRP$ N
preliminary JJ N
open-label NN N
study NN N
. . N

Leuprolide NNP i
reduced VBD N
PMS NNP o
symptoms NNS o
to TO N
minimal JJ N
levels NNS N
where WRB N
symptoms NNS N
were VBD N
limited VBN N
to TO N
the DT N
luteal JJ N
phase NN N
. . N

Leuprolide NNP i
was VBD N
not RB N
effective JJ N
for IN N
women NNS N
with IN N
ongoing VBG N
dysphoric NN N
symptoms NNS N
, , N
suggesting VBG N
that IN N
premenstrual JJ N
depression NN N
may MD N
have VB N
mechanisms NNS N
different JJ N
from IN N
those DT N
of IN N
other JJ N
dysphoric JJ N
mood NN N
disorders NNS N
. . N

-DOCSTART- -6729651- O O

High-dose JJ i
weekly JJ i
fractionation NN i
radiotherapy NN i
in IN N
advanced JJ p
cancer NN p
of IN p
the DT p
uterine JJ p
cervix NN p
. . p

A DT N
trial NN N
comparing VBG N
two CD p
different JJ p
radiotherapy NN i
techniques NNS p
and CC N
schedules NNS N
in IN N
the DT N
treatment NN N
of IN N
83 CD p
patients NNS p
with IN p
advanced JJ p
cancer NN p
of IN p
the DT p
uterine JJ p
cervix NN p
( ( p
stage JJ p
IIIB NNP p
) ) p
employing VBG p
external JJ i
irradiation NN i
alone RB p
is VBZ N
described VBN N
. . N

The DT N
one CD N
technique NN N
, , N
used VBD N
routinely RB N
in IN N
this DT N
department NN N
, , N
employed VBD N
a DT N
conventional JJ N
daily JJ N
fractionation NN N
schedule NN N
while IN N
the DT N
other JJ N
used VBD N
a DT N
high-dose JJ N
weekly JJ N
fractionation NN N
regimen NNS N
. . N

The DT N
techniques NNS N
are VBP N
described VBN N
. . N

The DT N
aim NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
morbidity NN o
of IN N
these DT N
two CD N
methods NNS N
of IN N
treatment NN N
. . N

Dose NNP N
distribution NN N
curves NNS N
in IN N
cross-section NN N
and CC N
midsagittal JJ N
planes NNS N
are VBP N
shown VBN N
and CC N
calculations NNS N
or CC N
equivalent JJ N
doses NNS N
at IN N
various JJ N
selected VBN N
points NNS N
using VBG N
Ellis NNP N
's POS N
nominal JJ N
single-dose JJ N
formula NN N
are VBP N
tabulated VBN N
. . N

The DT N
2-year JJ N
survival NN o
figures NNS N
were VBD N
33 CD N
% NN N
for IN N
the DT N
daily JJ N
fractionation NN N
technique NN N
and CC N
22 CD N
% NN N
for IN N
the DT N
weekly JJ N
regimen NN N
. . N

Serious JJ o
late JJ o
complication NN o
rates NNS o
were VBD N
6 CD N
% NN N
for IN N
the DT N
daily JJ N
regimen NNS N
and CC N
22 CD N
% NN N
for IN N
the DT N
weekly JJ N
schedule NN N
. . N

These DT N
differences NNS N
are VBP N
not RB N
statistically RB N
significant JJ N
. . N

Late JJ o
complication NN o
rates NNS o
in IN N
the DT N
weekly JJ N
fractionation NN N
regimen NNS N
appeared VBD N
to TO N
be VB N
lower JJR N
than IN N
figures NNS N
quoted VBN N
by IN N
other JJ N
authors NNS N
. . N

Local JJ N
control NN N
within IN N
the DT N
irradiated JJ N
volume NN N
was VBD N
better RBR N
in IN N
the DT N
group NN N
treated VBN N
by IN N
the DT N
daily JJ N
fractionation NN N
method NN N
. . N

-DOCSTART- -8561526- O O

A DT N
community-based JJ p
randomized JJ N
trial NN N
of IN N
praziquantel NN i
to TO N
control VB N
schistosomiasis NN N
morbidity NN N
in IN N
schoolchildren NN p
in IN p
Zambia NNP p
. . p

A DT N
community-based JJ p
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
of IN N
praziquantel NN i
was VBD N
carried VBN N
out RP N
in IN N
an DT p
area NN p
of IN p
Zambia NNP p
endemic FW p
for IN p
schistosomiasis NN p
. . p

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
treatment NN N
on IN N
Schistosoma NNP p
mansoni NNP p
morbidity NN N
. . N

A DT N
total NN N
of IN N
377 CD p
infected JJ p
children NNS p
, , p
aged VBD p
seven CD p
to TO p
19 CD p
years NNS p
, , N
was VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
: : N
one CD N
of IN N
190 CD N
( ( N
group NN N
A NNP N
) ) N
and CC N
one CD N
of IN N
187 CD N
( ( N
group NN N
B NNP N
) ) N
. . N

All DT p
children NNS p
were VBD p
treated VBN p
with IN p
40 CD p
mg NNS p
praziquantel/kg NN i
at IN p
the DT p
start NN p
of IN p
the DT p
study NN p
. . p

Six CD N
months NNS N
later RB N
, , N
the DT N
children NNS p
in IN N
group NN N
A NNP N
were VBD N
re-treated JJ N
with IN N
the DT N
same JJ N
dose NN N
of IN N
praziquantel NN i
, , N
while IN N
the DT N
children NNS p
in IN N
group NN N
B NNP N
were VBD N
given VBN N
placebos NNS i
. . i

All DT N
children NNS p
were VBD N
followed VBN N
up RP N
three CD N
, , N
six CD N
and CC N
12 CD N
months NNS N
after IN N
the DT N
initial JJ N
treatment NN N
, , N
morbidity NN o
being VBG N
clinically RB N
evaluated VBN N
at IN N
the DT N
six- JJ N
and CC N
12-month JJ N
follow-ups NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
, , N
in IN N
both DT N
groups NNS N
of IN N
children NNS p
, , N
there EX N
were VBD N
significant JJ N
reductions NNS N
in IN N
splenomegaly NN o
, , o
hepatomegaly NN o
, , o
and CC o
subjective JJ o
symptoms NNS o
of IN o
morbidity NN o
six CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
treatment NN N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
, , N
between IN N
the DT N
two CD N
groups NNS N
, , N
in IN N
the DT N
prevalences NNS N
of IN N
these DT N
symptoms NNS N
of IN N
morbidity NN o
. . o

It PRP N
therefore RB N
appears VBZ N
that IN N
once-yearly JJ N
treatment NN N
of IN N
children NNS p
, , p
in IN p
this DT p
and CC p
similar JJ p
endemic JJ p
areas NNS p
, , N
is VBZ N
sufficient JJ N
to TO N
reduce VB N
schistosomiasis NN N
morbidity NN N
to TO N
, , N
and CC N
maintain VB N
it PRP N
at IN N
, , N
a DT N
tolerable JJ N
level NN N
. . N

-DOCSTART- -17961835- O O

Effects NNS N
of IN N
gabapentin NN i
on IN N
experimental JJ N
somatic JJ o
pain NN o
and CC o
temporal JJ o
summation NN o
. . o

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Gabapentin NNP i
is VBZ N
used VBN N
for IN N
treatment NN N
of IN N
neuropathic JJ N
pain NN N
, , N
but CC N
its PRP$ N
effect NN N
on IN N
different JJ N
somatic JJ N
pain NN N
modalities NNS N
and CC N
integrative JJ N
mechanisms NNS N
are VBP N
not RB N
completely RB N
understood JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
double-blind JJ N
, , N
placebo-controlled JJ i
experimental NN N
pain NN N
study NN N
, , N
conducted VBN N
on IN N
20 CD p
healthy JJ p
volunteers NNS p
, , N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
1200 CD N
mg NN N
gabapentin NN N
on IN N
multi-modal JJ N
experimental JJ N
cutaneous JJ N
and CC N
muscle NN N
pain NN N
models NNS N
. . N

METHODS NNP N
The DT N
following VBG N
pain NN N
models NNS N
were VBD N
applied VBN N
: : N
( ( N
1 CD N
) ) N
pain NN N
thresholds NNS N
to TO N
single JJ i
and CC i
repeated VBD i
cutaneous JJ i
and CC i
intramuscular JJ i
electrical JJ i
stimulation NN i
( ( i
temporal JJ i
summation NN i
to TO i
5 CD i
stimuli NNS i
delivered VBN i
at IN i
2 CD i
Hz NNP i
) ) i
; : i
( ( N
2 CD N
) ) N
stimulus-response NN i
function NN i
relating VBG i
pain NN o
intensity NN o
scores NNS o
( ( o
visual JJ o
analog NN o
scale NN o
, , o
VAS NNP o
) ) o
to TO i
increasing VBG i
current JJ i
intensities NNS i
for IN i
electrical JJ i
skin NN i
and CC i
muscle NN i
stimuli NNS i
( ( i
single JJ i
and CC i
repeated VBD i
, , i
determined VBD i
at IN i
baseline NN i
) ) i
; : i
and CC N
( ( N
3 CD N
) ) N
the DT N
pain NN o
intensity NN o
( ( o
VAS NNP o
) ) o
and CC o
pain $ o
areas NNS o
after IN o
intramuscular JJ o
injection NN o
of IN i
hypertonic JJ i
saline NN i
. . i

Pain NN o
assessments NNS N
were VBD N
performed VBN N
prior RB N
to TO N
, , N
and CC N
at IN N
4 CD N
, , N
6 CD N
, , N
and CC N
8 CD N
hours NNS N
after IN N
medication NN N
. . N

RESULTS VB N
When WRB N
responses NNS N
were VBD N
averaged VBN N
across IN N
the DT N
post-dose JJ N
times NNS N
, , N
gabapentin NN i
: : i
( ( N
1 CD N
) ) N
significantly RB N
increased VBD N
the DT N
temporal JJ o
summation NN o
pain NN o
threshold NN o
in IN N
skin NN N
compared VBN N
with IN N
placebo NN i
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
; : N
( ( N
2 CD N
) ) N
significantly RB N
reduced VBD N
the DT N
area NN o
under IN o
the DT o
pain NN o
intensity NN o
curve NN o
to TO o
hypertonic VB o
saline JJ o
injections NNS o
in IN N
the DT N
muscle NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
significantly RB N
reduced VBD N
the DT N
area NN o
of IN o
pain NN o
evoked VBN o
by IN o
hypertonic JJ o
saline NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Gabapentin NNP i
reduces VBZ N
temporal JJ o
summation NN o
of IN o
skin JJ o
stimuli NNS o
at IN o
pain NN o
threshold JJ o
intensities NNS o
; : o
this DT N
may MD N
have VB N
potential JJ N
as IN N
a DT N
biomarker NN N
for IN N
drugs NNS N
with IN N
efficacy NN N
on IN N
neurogenic JJ N
pain NN N
. . N

The DT N
data NN N
also RB N
suggest VBP N
that IN N
tonic JJ o
muscle NN o
pain NN o
is VBZ N
responsive JJ N
to TO N
gabapentin VB N
treatment NN N
and CC N
suggest VB N
further RB N
clinical JJ N
studies NNS N
. . N

-DOCSTART- -15476575- O O

Neridronate NNP i
prevents NNS N
bone NN o
loss NN o
in IN N
patients NNS p
receiving VBG p
androgen JJ i
deprivation NN i
therapy NN i
for IN p
prostate NN p
cancer NN p
. . p

UNLABELLED VBN N
Today NN N
, , N
androgen NN i
deprivation NN i
therapy NN i
is VBZ N
a DT N
cornerstone NN N
of IN N
treatment NN N
for IN N
advanced JJ p
prostate NN p
cancer NN p
, , N
although IN N
it PRP N
presents VBZ N
important JJ N
complications NNS N
such JJ N
as IN N
osteoporosis NN o
. . o

Neridronate NNP i
, , i
a DT i
relatively RB i
new JJ i
bisphosphonate NN i
, , N
is VBZ N
able JJ N
to TO N
prevent VB N
bone NN o
loss NN o
in IN N
patients NNS p
with IN p
prostate JJ p
cancer NN p
during IN p
androgen JJ p
ablation NN p
. . p

INTRODUCTION NNP N
Androgen-deprivation NNP N
therapy NN N
( ( N
ADT NNP N
) ) N
is VBZ N
a DT N
cornerstone NN N
of IN N
treatment NN N
for IN N
advanced JJ p
prostate NN p
cancer NN p
. . p

This DT N
therapy NN N
has VBZ N
iatrogenic JJ N
complications NNS N
, , N
such JJ N
as IN N
osteoporosis NN N
. . N

The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
neridronate NN N
, , N
a DT N
relatively RB N
new JJ N
bisphosphonate NN N
, , N
to TO N
prevent VB N
bone JJ N
loss NN N
during IN N
androgen JJ N
ablation NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Forty-eight NNP p
osteoporotic JJ p
patients NNS p
with IN p
prostate JJ p
cancer NN p
, , p
treated VBN p
with IN p
3-month JJ p
depot NN p
triptorelina NN i
, , N
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
two CD N
different JJ N
treatment NN N
groups NNS N
: : N
group NN N
A NNP N
( ( p
n JJ p
= NNP p
24 CD p
) ) p
was VBD N
treated VBN N
with IN N
a DT N
daily JJ i
calcium NN i
and CC i
cholecalciferol NN i
supplement NN i
( ( N
500 CD N
mg NN N
of IN N
elemental JJ N
calcium NN N
and CC N
400 CD N
IU NNP N
cholecalciferol NN N
) ) N
, , N
and CC N
group NN N
B NNP N
( ( p
n JJ p
= NNP p
24 CD p
) ) p
received VBN N
in IN N
addition NN N
to TO N
the DT N
same JJ N
daily JJ i
calcium NN i
and CC i
cholecalciferol NN i
supplement NN i
, , N
25 CD N
mg NN N
of IN N
neridronate JJ i
given VBN N
intramuscularly RB N
every DT N
month NN N
. . N

All DT N
patients NNS N
also RB N
received VBD N
bicalutamide RB i
for IN N
4 CD N
weeks NNS N
. . N

Lumbar NNP o
and CC o
femoral JJ o
BMD NNP o
was VBD N
evaluated VBN N
by IN N
DXA NNP N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
year NN N
of IN N
therapy NN N
; : N
moreover CC N
, , N
deoxypyridinoline NN o
( ( o
DPD NNP o
) ) o
and CC o
bone $ o
alkaline JJ o
phosphatase NN o
( ( o
BALP NNP o
) ) o
were VBD N
determined VBN N
at IN N
the DT N
beginning NN N
, , N
midway RB N
through IN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS NNP N
After IN N
6 CD N
and CC N
12 CD N
months NNS N
, , N
whereas JJ N
patients NNS N
treated VBD N
only RB N
with IN N
calcium NN N
and CC N
cholecalciferol NN N
( ( N
group NN N
A NNP N
) ) N
showed VBD N
a DT N
marked JJ o
bone NN o
loss NN o
, , N
with IN N
increased JJ o
levels NNS o
of IN o
DPD NNP o
and CC o
BALP NNP o
compared VBN N
with IN N
baseline NN N
values NNS N
, , N
patients NNS N
treated VBD N
also RB N
with IN N
neridronate NN N
( ( N
group NN N
B NNP N
) ) N
had VBD N
substantially RB N
unchanged JJ N
levels NNS N
of IN N
these DT N
markers NNS N
. . N

After IN N
1 CD N
year NN N
of IN N
treatment NN N
, , N
lumbar NN o
and CC o
total JJ o
hip NN o
BMD NNP o
decreased VBD o
significantly RB o
in IN N
patients NNS N
treated VBN N
only RB N
with IN N
calcium NN N
and CC N
cholecalciferol NN N
( ( N
group NN N
A NNP N
) ) N
, , N
whereas IN N
it PRP N
did VBD N
not RB N
change VB o
significantly RB o
at IN N
any DT N
skeletal JJ N
site NN N
in IN N
patients NNS N
treated VBN N
also RB N
with IN N
neridronate NN N
( ( N
group NN N
B NNP N
) ) N
. . N

No DT N
relevant JJ o
side NN o
effects NNS o
were VBD N
recorded VBN N
during IN N
our PRP$ N
study NN N
. . N

CONCLUSIONS NNP N
Neridronate NNP i
is VBZ N
an DT N
effective JJ N
treatment NN N
in IN N
preventing VBG N
bone NN o
loss NN o
in IN N
the DT N
hip NN N
and CC N
lumbar NN N
spine NN N
in IN N
men NNS p
receiving VBG p
ADT NNP p
for IN p
prostate NN p
cancer NN p
. . p

-DOCSTART- -6436868- O O

Ascorbic NNP i
acid NN i
and CC N
performance NN o
in IN N
man NN N
. . N

Effects NNS N
on IN N
performance NN o
of IN N
1 CD N
, , N
2 CD N
and CC N
4 CD N
g NN N
ascorbic JJ i
acid NN i
were VBD N
studied VBN N
from IN N
0.5-5.5 JJ N
h NN N
after IN N
ingestion NN N
in IN N
six CD p
healthy JJ p
females NNS p
. . p

Diazepam NNP i
( ( i
5 CD i
mg NN i
) ) i
was VBD i
included VBN i
as IN i
an DT i
active JJ i
control NN i
, , N
and CC N
it PRP N
impaired VBD N
digit JJ o
symbol NN o
substitution NN o
, , o
visuomotor NN o
coordination NN o
and CC o
complex JJ o
reaction NN o
time NN o
. . o

There EX N
were VBD N
no DT N
effects NNS N
of IN N
any DT N
dose NN N
of IN N
ascorbic JJ i
acid NN i
on IN N
performance NN o
. . o

-DOCSTART- -16596861- O O

Nurse-led JJ N
cardiac NN N
clinics NNS N
for IN N
adults NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
. . p

This DT N
information NN N
on IN N
best NN N
practice NN N
is VBZ N
based VBN N
on IN N
a DT N
systematic JJ i
review NN i
of IN i
research NN i
, , N
published VBN N
by IN N
Blackwell NNP N
Publishing NNP N
Asia NNP N
and CC N
conducted VBN N
by IN N
the DT N
Centre NNP N
for IN N
Evidence-based JJ N
Nursing NNP N
South NNP N
Australia NNP N
, , N
a DT N
collaborating VBG N
centre NN N
of IN N
the DT N
Joanna NNP N
Briggs NNP N
Institute NNP N
( ( N
JBI NNP N
) ) N
. . N

The DT N
primary JJ N
references NNS N
on IN N
which WDT N
this DT N
information NN N
is VBZ N
based VBN N
are VBP N
provided VBN N
in IN N
the DT N
systematic JJ N
review NN N
report NN N
available JJ N
online JJ N
via IN N
Blackwell NNP N
Synergy NNP N
www.blackwell-synergy.com NN N
and CC N
to TO N
members NNS N
of IN N
the DT N
institute NN N
via IN N
the DT N
web JJ N
site NN N
: : N
www.joannabriggs.edu.au NN N
. . N

This DT N
information NN N
sheet NN N
covers VBZ N
the DT N
following JJ N
: : N
Nurse-led JJ N
education NN N
and CC N
self-help NN N
. . N

Education NN N
and CC N
motivational JJ N
interview NN N
. . N

Audit NNP N
and CC N
recall NN N
. . N

Secondary JJ N
prevention NN N
. . N

-DOCSTART- -11100343- O O

Somatostatin NNP i
and CC i
ranitidine NN i
in IN N
the DT N
treatment NN N
of IN N
non-variceal JJ p
upper JJ p
gastrointestinal JJ p
bleeding NN p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
study NN N
. . N

BACKGROUND/AIMS IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
of IN N
somatostatin NN i
vs. FW i
ranitidine NN i
in IN N
controlling VBG N
acute JJ o
non-variceal JJ o
gastrointestinal JJ o
bleeding NN o
. . o

METHODOLOGY NNP N
A NNP p
total NN p
of IN p
48 CD p
patients NNS p
with IN p
acute JJ p
upper JJ p
gastrointestinal NN p
bleeding NN p
due JJ p
to TO p
duodenal JJ p
or CC p
gastric JJ p
ulcer NN p
were VBD N
divided VBN N
into IN N
2 CD N
groups NNS N
. . N

Group NNP N
I PRP N
consisted VBD N
of IN N
15 CD p
patients NNS p
with IN p
Forrest NNP p
IB NNP p
and CC N
Group NNP N
II NNP N
consisted VBD N
of IN N
30 CD p
patients NNS p
with IN p
Forrest NNP p
II NNP p
. . p

Two CD N
regimens NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
all DT N
patients NNS N
within IN N
half PDT N
an DT N
hour NN N
after IN N
the DT N
endoscopic JJ N
procedure NN N
: : N
1 CD N
) ) N
somatostatin-UCB NN i
250 CD N
mcg NN N
i.v NN N
. . N

bolus CC N
followed VBN N
by IN N
continuous JJ N
i.v NN N
. . N

infusion NN N
at IN N
a DT N
rate NN N
of IN N
6 CD N
mg/d NN N
for IN N
72 CD N
h NN N
, , N
or CC N
2 CD N
) ) N
ranitidine NN i
300 CD N
mg/d NN N
by IN N
continuous JJ N
i.v NN N
. . N

infusion NN N
for IN N
72 CD N
h. JJ N
RESULTS NNP N
In IN N
Group NNP N
I PRP N
, , N
although IN N
mean JJ o
blood NN o
transfusion NN o
requirements NNS o
( ( N
no DT N
. . N

of IN N
units NNS N
) ) N
were VBD N
lower JJR N
in IN N
patients NNS N
treated VBN N
with IN N
somatostatin NN i
than IN N
in IN N
those DT N
treated VBN N
with IN N
ranitidine NN i
, , N
this DT N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
2.56 CD N
+/- JJ N
3.05 CD N
vs. FW N
5.17 CD N
+/- JJ N
4.96 CD N
, , N
respectively RB N
; : N
P NNP N
> NNP N
0.05 CD N
) ) N
; : N
the DT N
time NN o
of IN o
bleeding VBG o
stop NN o
was VBD N
shorter RBR N
in IN N
the DT N
somatostatin NN i
group NN N
than IN N
in IN N
the DT N
ranitidine NN N
group NN N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
3.24 CD N
+/- JJ N
2.45 CD N
vs. FW N
11.25 CD N
+/- JJ N
11.63 CD N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.0383 CD N
) ) N
. . N

The DT N
rebleeding NN o
and CC o
the DT o
mortality NN o
rates NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
both DT N
Group NNP N
I PRP N
and CC N
Group NNP N
II NNP N
. . N

CONCLUSIONS NNP N
Somatostatin NNP i
is VBZ N
more RBR N
effective JJ o
than IN N
ranitidine NN N
in IN N
controlling VBG N
acute JJ o
non-variceal JJ o
gastrointestinal JJ o
bleeding NN o
in IN N
patients NNS N
with IN N
Forrest NNP N
IB NNP N
bleeding NN N
activity NN N
. . N

Somatostatin NNP i
has VBZ N
no DT N
additional JJ o
benefit NN o
in IN N
those DT N
with IN N
Forrest NNP N
II NNP N
bleeding NN N
activity NN N
. . N

-DOCSTART- -24325899- O O

Randomized VBN N
study NN N
comparing VBG N
use NN N
of IN N
THUNDERBEAT NNP N
technology NN N
vs FW N
standard JJ N
electrosurgery NN N
during IN N
laparoscopic JJ p
radical JJ p
hysterectomy NN p
and CC p
pelvic JJ p
lymphadenectomy NN p
for IN p
gynecologic JJ p
cancer NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
operative JJ N
time NN N
with IN N
use NN N
of IN N
THUNDERBEAT NNP i
( ( N
TB NNP N
) ) N
vs FW N
standard JJ i
electrosurgery NN i
( ( N
SES NNP N
) ) N
during IN N
laparoscopic JJ N
radical JJ N
hysterectomy NN N
and CC N
pelvic JJ N
lymphadenectomy NN N
to TO N
treat VB N
gynecologic JJ p
tumors NNS p
. . p

DESIGN NNP N
Evidence NNP N
obtained VBD N
from IN N
a DT N
properly RB N
designed VBN N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING NN N
Gynecologic NNP p
Oncology NNP p
Unit NNP p
of IN p
the DT p
Catholic NNP p
University NNP p
of IN p
the DT p
Sacred NNP p
Heart NNP p
in IN p
Rome NNP p
, , p
Italy NNP p
. . p

PATIENTS NNP N
Fifty JJ p
patients NNS p
with IN p
early JJ p
cervical JJ p
cancer NN p
( ( p
FIGO NNP p
stages VBZ p
IA2 NNP p
, , p
IB1 NNP p
, , p
IIA NNP p
< VBZ p
2 CD p
cm NN p
) ) p
or CC p
locally RB p
advanced JJ p
cervical JJ p
cancer NN p
( ( p
FIGO NNP p
stages VBZ p
IB2 NNP p
, , p
IIA NNP p
> NNP p
2cm CD p
, , p
IIB NNP p
) ) p
who WP p
received VBD p
neoadjuvant JJ i
treatment NN i
( ( i
chemotherapy NN i
or CC i
radiochemotherapy NN i
) ) i
and CC p
demonstrated VBD p
a DT p
complete JJ p
or CC p
partial JJ p
clinical JJ p
response NN p
and CC p
early JJ p
stage NN p
endometrioid JJ p
endometrial JJ p
cancer NN p
( ( p
FIGO NNP p
stages VBZ p
IB NNP p
, , p
II NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
TB NNP N
( ( N
arm IN N
A NNP N
) ) N
or CC N
SES NNP N
( ( N
arm NN N
B NNP N
) ) N
. . N

INTERVENTION NNP N
Laparoscopic NNP i
radical JJ i
hysterectomy NN i
with IN i
bilateral JJ i
pelvic JJ i
lymphadenectomy NN i
, , N
using VBG N
an DT N
easily RB N
reproducible JJ N
technique NN N
was VBD N
performed VBN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Fifty NNP p
patients NNS p
were VBD p
available JJ p
for IN p
analysis NN p
, , p
with IN p
25 CD p
women NNS p
randomly RB p
assigned VBD p
to TO p
TB NNP p
( ( p
arm IN p
A NNP p
) ) p
and CC p
25 CD p
to TO p
SES NNP p
( ( p
arm NN p
B NNP p
) ) p
. . p

The DT N
median JJ o
operative JJ o
time NN o
was VBD N
85 CD N
minutes NNS N
for IN N
TB NNP N
vs NN N
115 CD N
minutes NNS N
for IN N
SES NNP N
( ( N
p JJ N
= NNP N
.001 NNP N
) ) N
. . N

At IN N
multivariate JJ N
analysis NN N
, , N
endometrial JJ N
cancer NN N
( ( N
p JJ N
= NNP N
.001 NNP N
) ) N
and CC N
TB NNP N
( ( N
p JJ N
= NNP N
.001 NN N
) ) N
were VBD N
independently RB N
associated VBN N
with IN N
shorter JJR o
operating NN o
time NN o
. . o

No DT N
differences NNS o
in IN N
perioperative JJ o
outcomes NNS o
and CC o
postoperative JJ o
complications NNS o
were VBD N
observed VBN N
between IN N
the DT N
2 CD N
arms NNS N
. . N

Patients NNS N
who WP N
underwent VBP N
TB NNP N
reported VBD N
less RBR N
postoperative JJ o
pain NN o
, , N
both DT N
at IN N
rest NN N
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
and CC N
after IN N
the DT N
Valsalva NNP N
maneuver NN N
( ( N
p JJ N
= NNP N
.008 NNP N
) ) N
, , N
with IN N
less JJR N
additional JJ N
analgesic NN N
therapy NN N
other JJ N
than IN N
standard JJ N
therapy NN N
required VBN N
in IN N
patients NNS N
who WP N
underwent VBP N
SES NNP N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION NNP N
TB NNP N
is VBZ N
associated VBN N
with IN N
shorter RBR o
operative JJ o
time NN o
and CC o
less RBR o
postoperative JJ o
pain NN o
than IN N
is VBZ N
the DT N
standard NN N
technique NN N
( ( N
SES NNP N
) ) N
in IN N
patients NNS p
with IN p
uterine JJ p
cancer NN p
. . p

-DOCSTART- -7977921- O O

Preventing VBG N
disability NN o
and CC o
falls VBZ o
in IN o
older JJR o
adults NNS o
: : o
a DT N
population-based JJ N
randomized JJ N
trial NN N
. . N

OBJECTIVES NNP N
Because IN N
preventing VBG N
disability NN o
and CC o
falls VBZ o
in IN o
older JJR o
adults NNS o
is VBZ N
a DT N
national JJ N
priority NN N
, , N
a DT N
randomized VBN N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
test VB N
a DT N
multicomponent JJ N
intervention NN N
program NN N
. . N

METHODS NNP N
From IN p
a DT p
random JJ p
sample NN p
of IN p
health NN p
maintenance NN p
organization NN p
( ( p
HMO NNP p
) ) p
enrollees VBZ p
65 CD p
years NNS p
and CC p
older JJR p
, , p
1559 CD p
ambulatory NN p
seniors NNS p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
a DT i
nurse JJ i
assessment NN i
visit NN i
and CC i
follow-up JJ i
interventions NNS i
targeting VBG i
risk NN i
factors NNS i
for IN i
disability NN i
and CC i
falls NNS i
( ( N
group NN N
1 CD N
, , N
n RB N
= VBZ N
635 CD N
) ) N
; : N
a DT i
general JJ i
health NN i
promotion NN i
nurse JJ i
visit NN i
( ( N
group NN N
2 CD N
, , N
n RB N
= VBZ N
317 CD N
) ) N
; : N
and CC N
usual JJ i
care NN i
( ( N
group NN N
3 CD N
, , N
n RB N
= VBZ N
607 CD N
) ) N
. . N

Data NNP N
collection NN N
consisted VBD N
of IN N
a DT N
baseline NN N
and CC N
two CD N
annual JJ N
follow-up JJ N
surveys NNS N
. . N

RESULTS NNP N
After IN N
1 CD N
year NN N
, , N
group NN N
1 CD N
subjects NNS N
reported VBD N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
declining VBG o
functional JJ o
status NN o
and CC N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
falls NNS o
than IN N
group NN N
3 CD N
subjects NNS N
. . N

Group NNP N
2 CD N
subjects NNS N
had VBD N
intermediate JJ N
levels NNS N
of IN N
most JJS N
outcomes NNS N
. . N

After IN N
2 CD N
years NNS N
of IN N
follow-up NN N
, , N
the DT N
differences NNS N
narrowed VBD N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
a DT N
modest JJ N
, , N
one-time JJ N
prevention NN N
program NN N
appeared VBD N
to TO N
confer VB N
short-term JJ o
health NN o
benefits NNS o
on IN N
ambulatory NN p
HMO NNP p
enrollees NNS p
, , N
although IN N
benefits NNS o
diminished VBN o
by IN N
the DT N
second JJ N
year NN N
of IN N
follow-up NN N
. . N

The DT N
mechanisms NN N
by IN N
which WDT N
the DT N
intervention NN N
may MD N
have VB N
improved VBN N
outcomes NNS N
require VBP N
further JJ N
investigation NN N
. . N

-DOCSTART- -15774238- O O

Effect NN N
of IN N
a DT N
nutritional JJ i
supplement NN i
containing VBG i
vitamin NN i
E NNP i
, , i
selenium NN i
, , i
vitamin FW i
c NNS i
and CC i
coenzyme JJ i
Q10 NNP i
on IN N
serum NN o
PSA NNP o
in IN N
patients NNS p
with IN p
hormonally RB p
untreated JJ p
carcinoma NN p
of IN p
the DT p
prostate NN p
: : p
a DT N
randomised JJ N
placebo-controlled JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effect NN N
of IN N
a DT N
nutritional JJ N
supplement NN N
containing VBG N
vitamin NN i
E NNP i
, , i
selenium NN i
, , i
vitamin FW i
C NNP i
and CC N
coenzyme JJ i
Q10 NNP i
on IN N
changes NNS N
in IN N
serum NN o
levels NNS o
of IN o
PSA NNP o
in IN N
patients NNS p
with IN p
hormonally RB p
untreated JJ p
carcinoma NN p
of IN p
the DT p
prostate NN p
and CC p
rising VBG p
serum NN o
PSA NNP o
levels NNS o
. . o

METHODS NNP N
Eighty NNP p
patients NNS p
were VBD p
randomised VBN p
to TO N
receive VB N
a DT N
daily JJ N
supplement NN N
with IN N
either DT N
vitamin NN i
E NNP i
, , i
selenium NN i
, , i
vitamin FW i
C NNP i
, , i
coenzyme NN i
Q10 NNP i
( ( N
intervention NN N
group NN N
) ) N
or CC N
placebo NN i
over IN N
21 CD N
weeks NNS N
. . N

Serum NNP o
levels NNS o
of IN o
PSA NNP o
were VBD N
assessed VBN N
at IN N
baseline NN N
( ( N
-2 UH N
, , N
-1 NNP N
, , N
0 CD N
weeks NNS N
) ) N
and CC N
after IN N
6 CD N
, , N
13 CD N
, , N
19 CD N
, , N
20 CD N
and CC N
21 CD N
weeks NNS N
. . N

Mean JJ N
changes NNS N
in IN N
log NN N
serum JJ o
level NN o
of IN o
PSA NNP o
, , o
testosterone NN o
, , o
dihydrotestosterone NN o
, , o
luteinizing VBG o
hormone NN o
and CC o
sex NN o
hormone NN o
binding VBG o
globulin NN o
over IN N
21 CD N
weeks NNS N
between IN N
the DT N
verum NN N
and CC N
the DT N
placebo NN N
group NN N
were VBD N
compared VBN N
by IN N
analysis NN N
of IN N
covariance NN N
. . N

RESULTS NNP N
Seventy NNP p
patients NNS p
completed VBD p
the DT p
study NN p
( ( p
36 CD p
verum NN p
; : p
34 CD p
placebo NN p
) ) p
. . p

Compliance NN N
was VBD N
> JJ N
90 CD N
% NN N
in IN N
all DT N
patients NNS N
. . N

In IN N
the DT N
intervention NN N
group NN N
, , N
plasma NN o
levels NNS o
of IN o
vitamin NN o
E NNP o
, , o
selenium NN o
and CC o
coenzyme JJ o
Q10 NNP o
increased VBD N
significantly RB N
over IN N
the DT N
21 CD N
weeks NNS N
study JJ N
period NN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
serum NN o
levels NNS o
of IN o
PSA NNP o
, , o
testosterone NN o
, , o
dihydrotestosterone NN o
, , o
luteinizing VBG o
hormone NN o
or CC o
sex NN o
hormone NN o
binding VBG o
globulin NN o
( ( N
p JJ N
> NNP N
0.2 CD N
) ) N
were VBD N
observed VBN N
between IN N
the DT N
intervention NN N
and CC N
control NN N
group NN N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
indicate VBP N
that DT N
supplementation NN N
of IN N
a DT N
combination NN N
of IN N
vitamin NN i
E NNP i
, , i
selenium NN i
, , i
vitamin FW i
C NNP i
and CC N
coenzyme-Q10 NN i
does VBZ N
not RB N
affect VB N
serum JJ o
level NN o
of IN o
PSA NNP o
or CC o
hormone NN o
levels NNS o
in IN N
patients NNS p
with IN p
hormonally RB p
untreated JJ p
carcinoma NN p
of IN p
the DT p
prostate NN p
. . p

-DOCSTART- -12410073- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
porcine NN i
versus NN N
synthetic JJ i
secretin NN i
for IN N
reducing VBG N
symptoms NNS o
of IN o
autism NN o
. . o

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
biologic NN i
and CC N
synthetic JJ i
porcine NN i
secretin NN i
to TO N
placebo VB i
on IN N
a DT N
variety NN N
of IN N
autism NN p
symptoms NNS N
. . N

METHOD NNP N
Eighty-five JJ p
children NNS p
with IN p
autism NN p
without IN p
other JJ p
medical JJ p
conditions NNS p
and CC p
not RB p
taking VBG p
other JJ p
psychotropic NN i
medications NNS i
participated VBD p
( ( p
ages NNS p
between IN p
3 CD p
and CC p
12 CD p
years NNS p
, , p
mean JJ p
IQ NNP p
= NNP p
55 CD p
) ) p
. . p

Children NNP N
were VBD N
grouped VBN N
into IN N
trios NNS N
matched VBN N
by IN N
age NN N
and CC N
communication NN N
level NN N
and CC N
then RB N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
groups NNS N
: : N
biologic NN i
secretin NN i
( ( N
2 CD N
CU/kg NNP N
) ) N
, , N
synthetic JJ i
secretin NN i
( ( N
0.4 CD N
microg/kg NN N
) ) N
, , N
and CC N
placebo NN i
. . i

Measures NNS N
collected VBD N
1 CD N
week NN N
before RB N
and CC N
4 CD N
weeks NNS N
after IN N
infusion NN N
included VBD N
autism NN o
symptoms NNS o
, , o
language NN o
skills NNS o
, , o
and CC o
problem NN o
behaviors NNS o
, , o
gathered VBN o
from IN o
parents NNS o
, , o
teachers NNS o
, , o
and CC o
investigators NNS o
, , N
who WP N
were VBD N
all DT N
blind NNS N
to TO N
treatment NN N
. . N

Two-factor NN N
, , N
repeated-measures JJ N
analyses NNS N
of IN N
variance NN N
( ( N
3 CD N
treatment NN N
levels NNS N
by IN N
2 CD N
repeated JJ N
measures NNS N
, , N
pre- NN N
and CC N
postinfusion NN N
) ) N
were VBD N
used VBN N
to TO N
examine VB N
efficacy NN N
. . N

RESULTS NNP N
Direct JJ N
observation NN N
measures NNS N
did VBD N
not RB N
show VB N
change NN N
over IN N
time NN N
related VBN N
to TO N
secretin VB i
. . i

Parent NN N
reports NNS N
showed VBD N
an DT N
overall JJ N
reduction NN N
of IN N
symptom JJ o
severity NN o
for IN N
all DT N
treatment NN N
groups NNS N
, , N
including VBG N
the DT N
placebo NN i
group NN N
. . N

One CD N
teacher-report NN N
measure NN N
showed VBD N
decreases NNS N
in IN N
autism NN N
symptoms NNS N
in IN N
the DT N
placebo NN i
and CC N
synthetic JJ i
secretin NN i
groups NNS N
. . N

CONCLUSIONS NNP N
No NNP N
evidence NN N
that IN N
either DT N
biologic NN i
or CC N
synthetic JJ i
secretin NN i
provided VBD N
amelioration NN N
of IN N
symptoms NNS N
beyond IN N
placebo NN i
was VBD N
observed VBN N
. . N

This DT N
held VBD N
true JJ N
when WRB N
children NNS p
with IN p
and CC p
without IN p
gastrointestinal JJ p
problems NNS p
were VBD N
examined VBN N
separately RB N
. . N

-DOCSTART- -26224825- O O

Cost NNP o
effectiveness NN o
of IN o
treatment NN o
with IN o
percutaneous JJ o
Kirschner NNP o
wires VBZ o
versus IN i
volar JJ i
locking VBG i
plate NN i
for IN N
adult NN p
patients NNS p
with IN p
a DT p
dorsally RB p
displaced JJ p
fracture NN p
of IN p
the DT p
distal JJ p
radius NN p
: : p
analysis NN N
from IN N
the DT N
DRAFFT NNP N
trial NN N
. . N

We PRP N
present VBD N
an DT N
economic JJ N
evaluation NN N
using VBG N
data NNS N
from IN N
the DT N
Distal NNP N
Radius NNP N
Acute NNP N
Fracture NNP N
Fixation NNP N
Trial NNP N
( ( N
DRAFFT NNP N
) ) N
to TO N
compare VB N
the DT N
relative JJ N
cost NN N
effectiveness NN N
of IN N
percutaneous JJ i
Kirschner NNP i
wire NN i
( ( i
K-wire NNP i
) ) i
fixation NN i
and CC i
volar JJ i
locking-plate JJ i
fixation NN i
for IN N
patients NNS p
with IN p
dorsally-displaced JJ p
fractures NNS p
of IN p
the DT p
distal JJ p
radius NN p
. . p

The DT N
cost NN N
effectiveness NN N
analysis NN N
( ( o
cost NN o
per IN o
quality-adjusted JJ o
life NN o
year NN o
; : o
QALY NNP o
) ) o
was VBD N
derived VBN N
from IN N
a DT N
multi-centre JJ N
, , N
two-arm JJ N
, , N
parallel JJ N
group NN N
, , N
assessor-blind NN N
, , N
randomised VBD N
controlled VBN N
trial NN N
which WDT N
took VBD N
place NN N
in IN N
18 CD p
trauma NN p
centres NNS p
in IN p
the DT p
United NNP p
Kingdom NNP p
. . p

Data NNP p
from IN p
460 CD p
patients NNS p
were VBD p
available JJ p
for IN p
analysis NN p
, , N
which WDT N
includes VBZ N
both CC N
a DT N
National NNP N
Health NNP N
Service NNP N
cost NN N
perspective NN N
including VBG N
costs NNS o
of IN o
surgery NN o
, , o
implants NNS o
and CC N
healthcare NN o
resource NN o
use NN o
over IN N
a DT N
12-month JJ N
period NN N
after IN N
surgery NN N
, , N
and CC N
a DT N
societal JJ N
perspective NN N
, , N
which WDT N
includes VBZ N
the DT N
cost NN o
of IN o
time NN o
off IN o
work NN o
and CC N
the DT N
need NN N
for IN N
additional JJ o
private JJ o
care NN o
. . o

There EX N
was VBD N
only RB N
a DT N
small JJ N
difference NN N
in IN N
QALYs NNP o
gained VBD N
for IN N
patients NNS p
treated VBN p
with IN p
locking-plate JJ i
fixation NN i
over IN p
those DT p
treated VBN p
with IN p
K-wires NNP i
. . i

At IN N
a DT N
mean JJ N
additional JJ N
cost NN N
of IN N
?714 NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
588 CD N
to TO N
865 CD N
) ) N
per IN N
patient NN N
, , N
locking-plate JJ N
fixation NN N
presented VBD N
an DT o
incremental JJ o
cost NN o
effectiveness NN o
ratio NN o
( ( o
ICER NNP o
) ) o
of IN N
?89,322 NN N
per IN N
QALY NNP N
within IN N
the DT N
first JJ N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

Sensitivity NN N
analyses NNS N
were VBD N
undertaken VBN N
to TO N
assess VB N
the DT o
ICER NNP o
of IN o
locking-plate JJ i
fixation NN i
compared VBN i
with IN i
K-wires NNP i
. . i

These DT N
were VBD N
greater JJR N
than IN N
?30,000 NN N
. . N

Compared VBN N
with IN i
locking-plate JJ i
fixation NN i
, , i
K-wire NNP i
fixation NN i
is VBZ N
a DT N
'cost JJ N
saving NN N
' '' N
intervention NN N
, , N
with IN N
similar JJ N
health NN N
benefits NNS N
. . N

-DOCSTART- -10201101- O O

Reduction NN i
of IN i
stimulus JJ o
overselectivity NN o
with IN i
nonverbal JJ i
differential JJ i
observing NN i
responses NNS i
. . i

Three CD p
individuals NNS p
with IN p
mental JJ p
retardation NN p
exhibited VBD p
stimulus JJ o
overselectivity NN o
in IN p
a DT p
delayed JJ p
matching-to-sample NN p
task NN p
in IN N
which WDT N
two CD i
sample NN i
stimuli NNS i
were VBD N
displayed VBN N
on IN N
each DT N
trial NN N
. . N

Intermediate NNP N
accuracy NN o
scores NNS o
indicated VBD N
that IN N
participants NNS N
could MD N
match VB N
one CD N
of IN N
the DT N
samples NNS N
but CC N
not RB N
both DT N
of IN N
them PRP N
. . N

Accuracy NN o
in IN N
a DT N
baseline NN N
condition NN N
was VBD N
compared VBN N
to TO N
accuracy VB o
with IN N
a DT N
differential JJ N
observing NN N
response NN N
procedure NN N
. . N

This DT N
procedure NN N
prompted VBD N
participants NNS N
to TO N
make VB N
simultaneous JJ N
identity-matching JJ N
responses NNS N
that WDT N
required VBD N
observation NN N
and CC N
discrimination NN N
of IN N
both DT N
sample JJ N
stimuli NN N
. . N

These DT N
observing VBG N
responses NNS N
were VBD N
never RB N
followed VBN N
by IN N
differential JJ N
consequences NNS N
. . N

When WRB N
observing VBG N
responses NNS N
were VBD N
prompted VBN N
, , N
participants NNS N
' POS N
accuracy NN o
scores NNS o
improved VBN N
. . N

In IN N
a DT N
return NN N
to TO N
the DT N
baseline NN N
condition NN N
, , N
when WRB N
differential JJ i
observing NN i
responses NNS i
were VBD N
no RB N
longer RB N
prompted VBN N
, , N
accuracy NN o
returned VBD N
to TO N
intermediate JJ N
levels NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
stimulus JJ o
overselectivity NN o
can MD N
be VB N
greatly RB N
reduced VBN N
by IN N
a DT N
behavioral JJ N
intervention NN N
that IN N
controls VBZ N
observing VBG N
behavior NN N
and CC N
verifies NNS N
discrimination NN N
, , N
but CC N
that IN N
exposure NN N
to TO N
such JJ N
procedures NNS N
alone VBP N
may MD N
be VB N
insufficient JJ N
for IN N
lasting VBG o
benefits NNS o
. . o

-DOCSTART- -24564308- O O

Comparison NNP N
of IN N
the DT N
cardiorespiratory JJ N
effects NNS N
of IN N
a DT N
combination NN i
of IN i
ketamine NN i
and CC i
propofol NN i
, , i
propofol VB i
alone RB i
, , i
or CC i
a DT i
combination NN i
of IN i
ketamine NN i
and CC i
diazepam NN i
before IN i
and CC i
after IN i
induction NN i
of IN i
anesthesia NN i
in IN i
dogs NNS i
sedated VBN i
with IN i
acepromazine NN i
and CC i
oxymorphone NN i
. . i

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
cardiorespiratory JJ o
effects NNS o
of IN N
IV NNP N
administration NN N
of IN N
propofol NN i
( ( N
4 CD N
mg/kg NN N
) ) N
, , N
ketamine JJ i
hydrochloride NN i
and CC i
propofol NN i
( ( N
2 CD N
mg/kg RB N
each DT N
; : N
K-P NNP N
) ) N
, , N
or CC N
ketamine VB i
hydrochloride NN i
( ( N
5 CD N
mg/kg NN N
) ) N
and CC N
diazepam NN i
( ( N
0.2 CD N
mg/kg NN N
; : N
K-D NNP N
) ) N
before IN N
and CC N
after IN N
induction NN N
of IN N
anesthesia NN i
( ( N
IoA NNP N
) ) N
in IN N
dogs NNS p
sedated VBN p
with IN p
acepromazine JJ i
maleate NN i
and CC p
oxymorphone NN i
hydrochloride NN i
. . i

ANIMALS $ p
10 CD p
healthy JJ p
adult NN p
Beagles NNP p
. . p

PROCEDURES NNP N
Each DT N
dog NN N
was VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
2 CD N
of IN N
3 CD N
treatments NNS N
( ( N
1-week JJ N
interval NN N
) ) N
. . N

For IN N
instrumentation NN N
prior RB N
to TO N
each DT N
treatment NN N
, , N
each DT N
dog NN N
was VBD N
anesthetized VBN i
with IN i
isoflurane NN i
. . i

After IN N
full JJ N
recovery NN N
, , N
acepromazine NN i
( ( N
0.02 CD N
mg/kg NN N
) ) N
and CC N
oxymorphone NN i
( ( N
0.05 CD N
mg/kg NN N
) ) N
were VBD N
administered VBN N
IV NNP N
. . N

Fifteen NNP N
minutes NNS N
later RB N
( ( N
before IN N
IoA NNP N
) ) N
, , N
each DT N
dog NN N
received VBD N
treatment NN N
IV NNP N
with IN N
propofol NN i
, , i
K-P NNP i
, , i
or CC i
K-D. NNP i
Cardiorespiratory NNP o
and CC o
arterial JJ o
blood NN o
gas NN o
variables NNS o
were VBD N
assessed VBN N
before RB N
, , N
immediately RB N
after IN N
, , N
and CC N
5 CD N
minutes NNS N
after IN N
IoA NNP N
. . N

RESULTS NNP N
Compared VBD N
with IN N
findings NNS N
before IN N
IoA NNP N
, , N
dogs NNS N
receiving VBG N
the DT N
K-P NNP i
or CC N
K-D NNP i
treatment NN N
had VBD N
increased VBN N
cardiac JJ o
output NN o
, , o
oxygen NN o
delivery NN o
, , o
and CC o
heart NN o
rate NN o
5 CD N
minutes NNS N
after IN N
IoA NNP N
; : N
K-P NNP i
administration NN N
did VBD N
not RB N
change VB N
mean JJ o
arterial JJ o
blood NN o
pressure NN o
or CC o
stroke NN o
volume NN o
and CC o
decreased JJ o
systemic JJ o
vascular JJ o
resistance NN o
. . o

Propofol NNP N
decreased VBD N
mean JJ o
arterial JJ o
blood NN o
pressure NN o
and CC o
systemic JJ o
vascular JJ o
resistance NN o
immediately RB N
after IN N
IoA NNP N
but CC N
did VBD N
not RB N
change VB N
heart NN o
rate NN o
, , o
cardiac JJ o
output NN o
, , o
or CC o
oxygen NN o
delivery NN o
. . o

All DT N
treatments NNS N
caused VBD N
some DT N
degree NN o
of IN o
apnea NN o
, , o
hypoventilation NN o
, , o
and CC o
hypoxemia NN o
( ( N
Pao2 NNP N
< VBZ N
80 CD N
mm NN N
Hg NNP N
) ) N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
In IN N
dogs NNS N
, , N
K-P NNP i
treatment NN N
maintained VBD N
mean JJ o
arterial JJ o
blood NN o
pressure NN o
better RBR N
than IN N
propofol VB N
alone JJ N
and CC N
increased JJ N
heart NN o
rate NN o
, , o
cardiac JJ o
output NN o
, , o
or CC o
oxygen NN o
delivery NN o
, , N
as IN N
did VBD N
the DT N
K-D NNP i
treatment NN N
. . N

Supplemental JJ N
100 CD N
% NN N
oxygen NN N
should MD N
be VB N
provided VBN N
during IN N
IoA NNP N
with IN N
all DT N
3 CD N
treatments NNS N
. . N

-DOCSTART- -25532076- O O

Cariprazine NN i
in IN N
the DT N
treatment NN N
of IN N
acute NN N
mania NN N
in IN N
bipolar JJ N
I PRP N
disorder VBP N
: : N
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
phase JJ N
III NNP N
trial NN N
. . N

BACKGROUND VB N
This DT N
Phase NNP N
III NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
investigated VBD N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
flexibly-dosed JJ N
cariprazine NN i
in IN N
patients NNS p
with IN p
acute JJ p
manic NN p
or CC p
mixed JJ p
episodes NNS p
associated VBN p
with IN p
bipolar JJ p
I PRP p
disorder VBP p
. . p

METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
3 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN p
with IN p
cariprazine JJ i
3-12mg/day JJ p
( ( p
n=158 JJ p
) ) p
or CC i
placebo NN i
( ( p
n=154 JJ p
) ) p
. . p

The DT N
primary JJ N
efficacy NN N
parameter NN N
was VBD N
change NN N
from IN N
baseline NN N
to TO N
Week VB N
3 CD N
in IN N
Young NNP o
Mania NNP o
Rating NNP o
Scale NNP o
( ( o
YMRS NNP o
) ) o
total NN o
score NN o
. . o

The DT N
secondary JJ N
efficacy NN N
parameter NN N
was VBD N
change NN N
from IN N
baseline NN N
to TO N
Week VB N
3 CD N
in IN N
Clinical JJ o
Global NNP o
Impressions-Severity NNP o
( ( o
CGI-S NNP o
) ) o
score NN o
. . o

RESULTS JJ N
Mean JJ N
change NN N
from IN N
baseline NN N
to TO N
Week VB N
3 CD N
in IN N
YMRS NNP N
total JJ N
score NN N
was VBD N
significantly RB N
greater JJR N
for IN N
patients NNS N
receiving VBG N
cariprazine JJ i
3-12mg/day JJ N
versus NN N
placebo NN N
( ( N
P=0.0004 NNP N
) ) N
. . N

Significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
YMRS NNP o
total JJ o
score NN o
mean JJ N
change NN N
were VBD N
observed VBN N
by IN N
Day NNP N
4 CD N
( ( N
first JJ N
postbaseline NN N
assessment NN N
) ) N
and CC N
maintained VBN N
throughout IN N
double-blind JJ N
treatment NN N
( ( N
all DT N
assessments NNS N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Cariprazine NNP i
also RB N
demonstrated VBD N
statistically RB N
significant JJ N
superiority NN N
over IN N
placebo NN N
on IN N
YMRS NNP o
response NN o
( ( N
?50 CD N
% NN N
improvement NN i
: : i
cariprazine NN i
, , i
58.9 CD i
% NN i
; : i
placebo NN i
, , i
44.1 CD N
% NN N
; : N
P=0.0097 NNP N
) ) N
and CC o
remission NN o
( ( o
YMRS NNP N
total JJ N
score?12 NN N
: : N
cariprazine NN N
, , N
51.9 CD N
% NN N
; : N
placebo NN N
, , N
34.9 CD N
% NN N
; : N
P=0.0025 NNP N
) ) N
and CC N
mean JJ N
change NN N
in IN N
CGI-S NNP N
( ( N
P=0.0027 NNP N
) ) N
score NN N
and CC N
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
( ( o
PANSS NNP o
) ) o
( ( o
P=0.0035 NNP o
) ) N
total NN N
score NN N
. . N

The DT N
most RBS N
common JJ i
cariprazine-related JJ i
( ( i
?10 CD i
% NN i
and CC i
twice RB i
placebo NN i
) ) i
treatment NN i
emergent JJ N
adverse JJ N
events NNS N
( ( N
TEAEs NNP N
) ) o
were VBD o
akathisia JJ o
, , o
extrapyramidal JJ o
disorder NN o
, , o
tremor NN o
, , o
dyspepsia NN o
, , o
and CC o
vomiting VBG o
. . o

Mean JJ o
change NN N
from IN N
baseline NN o
in IN o
metabolic JJ o
parameters NNS o
were VBD o
generally RB N
small JJ N
and CC N
similar JJ N
between IN N
groups NNS N
. . N

LIMITATIONS NNP N
Lack NNP N
of IN N
active JJ N
comparator NN N
arm NN N
; : N
short JJ N
duration NN N
of IN N
study NN N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
cariprazine VB i
3-12mg/day JJ i
was VBD N
effective JJ N
and CC N
generally RB N
well RB N
tolerated VBN N
in IN N
the DT N
treatment NN N
of IN N
manic NN N
and CC N
mixed JJ N
episodes NNS N
associated VBN N
with IN N
bipolar JJ N
I PRP N
disorder VBP N
. . N

-DOCSTART- -7826791- O O

Co-administration NN i
of IN i
pethidine NN i
and CC i
clonidine NN i
: : i
a DT N
spinal JJ N
anaesthetic JJ N
technique NN N
for IN N
total JJ i
hip NN i
replacement NN i
. . i

Co-administration NN N
of IN N
pethidine NN i
0.75 CD i
mg NN i
kg-1 NN i
and CC i
clonidine NN i
75 CD i
micrograms NNS i
intrathecally RB N
provided VBD N
good JJ N
intraoperative JJ N
anaesthesia NN N
for IN N
total JJ i
hip NN i
replacement NN i
, , N
similar JJ N
to TO N
that DT N
obtained VBN N
using VBG N
0.5 CD i
% NN i
isobaric JJ i
bupivacaine NN i
. . i

Sensory NNP N
and CC N
motor NN N
block NN N
were VBD N
of IN N
shorter JJR N
duration NN N
than IN N
that DT N
after IN N
0.5 CD N
% NN N
isobaric JJ i
bupivacaine NN i
and CC N
0.5 CD N
% NN N
isobaric JJ i
bupivacaine NN i
with IN i
morphine JJ i
0.5 CD N
mg NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
sensory JJ N
block NN N
, , N
P NNP N
< VBZ N
0.001 CD N
motor NN N
block NN N
) ) N
. . N

Postoperative JJ o
morphine NN o
consumption NN o
, , N
measured VBN N
using VBG N
a DT N
patient-controlled JJ N
system NN N
, , N
was VBD N
similar JJ N
to TO N
that DT N
in IN N
patients NNS p
in IN p
the DT p
bupivacaine NN i
only RB p
group NN p
( ( i
pethidine-clonidine JJ i
: : i
median JJ N
39 CD N
mg/24 NN N
h NN N
; : N
bupivacaine NN i
: : i
median JJ N
34 CD N
mg/24 NN N
h NN N
) ) N
but CC N
greater JJR N
than IN N
that DT N
in IN N
the DT N
bupivacaine-morphine JJ i
group NN p
( ( N
median JJ N
8 CD N
mg/24 NN N
h NN N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Visual JJ o
analogue NN o
pain NN o
scores NNS o
after IN N
operation NN N
were VBD N
similar JJ N
to TO N
those DT N
with IN N
bupivacaine JJ i
alone NN i
at IN N
all DT N
but CC N
one CD N
of IN N
the DT N
recording NN N
times NNS N
but CC N
were VBD N
greater JJR N
than IN N
those DT N
in IN N
patients NNS N
who WP N
received VBD N
bupivacaine NN i
and CC i
morphine NN i
at IN N
4 CD N
, , N
6 CD N
and CC N
10 CD N
h NN N
after IN N
operation NN N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
P NNP N
< NNP N
0.04 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
combination NN N
did VBD N
not RB N
offer VB N
any DT N
major JJ N
advantage NN N
over IN N
conventional JJ N
agents NNS N
. . N

-DOCSTART- -25012645- O O

The DT N
effect NN N
of IN N
resistance NN i
training NN i
during IN i
radiotherapy NN i
on IN N
spinal JJ o
bone NN o
metastases NNS o
in IN p
cancer NN p
patients NNS p
- : N
a DT N
randomized JJ N
trial NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
resistance NN i
training NN i
versus IN N
passive JJ i
physical JJ i
therapy NN i
on IN N
bone NN o
density NN o
in IN o
the DT o
metastatic JJ o
bone NN o
during IN N
radiation NN i
therapy NN i
( ( i
RT NNP i
) ) i
as IN N
combined VBN N
treatment NN N
in IN N
patients NNS p
with IN p
spinal JJ p
bone NN p
metastases NNS p
. . p

Secondly RB N
, , N
to TO N
quantify VB N
pathological JJ N
fractures NNS N
after IN N
combined VBN N
treatment NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
60 CD p
patients NNS p
were VBD p
allocated VBN p
from IN p
September NNP p
2011 CD p
until IN p
March NNP p
2013 CD p
into IN p
one CD p
of IN p
the DT p
two CD p
groups NNS p
: : p
resistance NN i
training NN i
( ( N
group NN N
A NNP N
) ) N
or CC N
passive JJ i
physical JJ i
therapy NN i
( ( N
group NN N
B NNP N
) ) N
with IN N
thirty NN N
patients NNS N
in IN N
each DT N
group NN N
during IN N
RT NNP N
. . N

Bone NNP o
density NN o
in IN o
metastatic JJ o
and CC o
non-metastatic JJ o
vertebral JJ o
bone NN o
was VBD N
assessed VBN N
at IN N
baseline NN N
, , N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
RT NNP N
. . N

RESULTS NNP N
Bone NNP o
density NN o
in IN o
all DT o
metastases NNS o
increased VBN N
significantly RB N
by IN N
28.3 CD N
% NN N
( ( N
IQR NNP N
11.4-139.0 CD N
) ) N
and CC N
80.3 CD N
% NN N
( ( N
IQR NNP N
32.6-250.6 CD N
) ) N
after IN N
3 CD N
and CC N
6 CD N
months NNS N
in IN N
group NN N
A NNP N
( ( N
both DT N
p VBP N
< $ N
0.01 CD N
) ) N
. . N

The DT N
bone NN o
density NN o
in IN N
group NN N
A NNP N
was VBD N
significantly RB N
increased VBN N
compared VBN N
to TO N
control VB i
group NN N
after IN N
3 CD N
and CC N
6months CD N
( ( N
both DT N
p VBP N
< NN N
0.01 CD N
, , N
median JJ N
59.7 CD N
; : N
IQR NNP N
21.1-98.3 CD N
and CC N
median JJ N
62.9 CD N
; : N
IQR NNP N
-9.7 NNP N
to TO N
161.7 CD N
) ) N
. . N

The DT N
bone NN o
density NN o
data NNS o
in IN N
group NN N
B NNP N
showed VBD N
no DT N
significant JJ N
increase NN N
over IN N
the DT N
course NN N
of IN N
time NN N
( ( N
p JJ N
= NN N
0.289 CD N
, , N
median JJ N
5.5 CD N
, , N
IQR NNP N
0.0-62.2 CD N
and CC N
p VB N
= JJ N
0.057 CD N
, , N
median JJ N
52.1 CD N
, , N
IQR NNP N
0.0-162.7 NN N
) ) N
. . N

23.3 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
30.0 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
group NN N
B NNP N
had VBD N
pathological JJ o
fractures NNS o
, , N
no DT N
fracture NN N
was VBD N
assigned VBN N
to TO N
intervention NN N
, , N
and CC N
no DT N
difference NN N
between IN N
groups NNS N
after IN N
3 CD N
and CC N
6 CD N
months NNS N
was VBD N
observed VBN N
( ( N
p JJ N
= NN N
0.592 CD N
and CC N
p VB N
= NNP N
0.604 CD N
) ) N
. . N

CONCLUSIONS VB N
Our PRP$ N
trial NN N
demonstrated VBD N
that IN N
resistance NN i
training NN i
concomitant NN i
to TO i
RT NNP i
can MD N
improve VB N
bone NN o
density NN o
in IN N
spinal JJ N
bone NN N
metastases NNS N
. . N

This DT N
combined JJ N
treatment NN N
is VBZ N
effective JJ N
, , N
practicable JJ N
, , N
and CC N
without IN N
side JJ o
effects NNS o
for IN N
patients NNS N
. . N

Importantly RB N
, , N
the DT N
pathological JJ o
fracture NN o
rate NN o
in IN N
the DT N
intervention NN N
group NN N
was VBD N
not RB N
increased VBN N
. . N

The DT N
results NNS N
offer VBP N
a DT N
rationale NN N
for IN N
future JJ N
large JJ N
controlled VBN N
investigations NNS N
to TO N
confirm VB N
these DT N
findings NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
trial NN N
identifier NN N
NCT01409720 NNP N
. . N

-DOCSTART- -21416590- O O

An DT N
interactive JJ i
computer NN i
program NN i
can MD N
effectively RB N
educate VB N
potential JJ p
users NNS p
of IN p
cystic JJ p
fibrosis NN p
carrier NN p
tests NNS p
. . p

The DT N
demand NN N
for IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
carrier NN N
testing VBG N
is VBZ N
steadily RB N
growing VBG N
, , N
not RB N
only RB N
from IN N
individuals NNS p
with IN p
raised VBN p
a DT p
priori FW p
carrier NN p
risk NN p
, , N
but CC N
also RB N
from IN N
the DT N
general JJ N
population NN N
. . N

This DT N
trend NN N
will MD N
likely RB N
exceed VB N
the DT N
availability NN N
of IN N
genetic JJ N
counselors NNS N
, , N
making VBG N
it PRP N
impossible JJ N
to TO N
provide VB N
standard JJ N
face-to-face JJ N
genetic JJ N
counseling NN N
to TO N
all PDT N
those DT N
asking VBG N
for IN N
the DT N
test NN N
. . N

In IN N
order NN N
to TO N
reduce VB N
the DT N
time NN N
needed VBN N
to TO N
educate VB N
individuals NNS N
on IN N
the DT N
basics NNS N
of IN N
the DT N
disease NN N
, , N
its PRP$ N
genetic JJ N
transmission NN N
, , N
and CC N
carrier NN N
testing VBG N
peculiarities NNS N
, , N
we PRP N
developed VBD N
an DT N
educational JJ i
method NN i
based VBN i
on IN i
an DT i
interactive JJ i
computer NN i
program NN i
( ( i
IC NNP i
) ) i
. . i

To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
this DT N
program NN N
and CC N
to TO N
compare VB N
it PRP N
to TO N
a DT N
classical JJ N
genetic JJ N
counseling NN N
session NN N
, , N
we PRP N
conducted VBD N
a DT N
comparative JJ N
trial NN N
. . N

In IN N
a DT N
population NN N
setting NN N
of IN N
people NNS N
undergoing VBG N
assisted JJ N
reproduction NN N
, , N
44 CD p
individuals NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
receiving VBG N
standard JJ i
one-on-one JJ i
genetic JJ i
counseling NN i
or CC i
education NN i
by IN i
the DT i
IC NNP i
program NN i
. . i

We PRP N
measured VBD N
pre- JJ N
and CC N
post-intervention NN N
knowledge NN N
about IN N
CF NNP N
genetic JJ N
transmission NN N
and CC N
carrier NN N
testing NN N
. . N

Starting VBG o
from IN o
an DT o
equivalent JJ o
baseline NN o
of IN o
correct JJ o
answers NNS o
to TO o
a DT o
specially RB o
designed VBN o
multiple-choice NN o
questionnaire NN o
( ( o
47 CD o
% NN o
in IN o
the DT o
counselor NN o
group NN o
and CC o
45 CD o
% NN o
in IN o
the DT o
computer NN o
group NN o
) ) o
both DT o
groups NNS o
showed VBD o
a DT o
highly RB o
significant JJ o
and CC o
similar JJ o
increase NN o
( ( o
reaching VBG o
84 CD o
% NN o
in IN o
the DT o
counselor NN o
group NN o
and CC o
85 CD o
% NN o
in IN o
the DT o
computer NN o
group NN o
) ) o
. . o

The DT N
computer NN N
program NN N
under IN N
evaluation NN N
can MD N
successfully RB N
educate VB N
individuals NNS N
considering VBG N
genetic JJ N
testing NN N
for IN N
CF NNP N
. . N

-DOCSTART- -6849726- O O

Interactions NNS N
of IN N
morphine NN i
and CC N
methotrimeprazine NN i
in IN N
mouse NN p
and CC p
man NN p
with IN N
respect NN N
to TO N
analgesia VB o
, , o
respiration NN o
and CC o
sedation NN o
. . o

Interactions NNS N
between IN N
morphine NN i
and CC i
methotrimeprazine NN i
have VBP N
been VBN N
studied VBN N
in IN N
mice NN p
and CC p
man NN p
with IN N
respect NN N
to TO N
analgesia VB o
or CC o
antinociceptive JJ o
activity NN o
, , o
respiratory NN o
effects NNS o
and CC o
sedation NN o
. . o

The DT N
volunteer NN N
study NN N
was VBD N
a DT N
double-blind JJ N
cross-over JJ N
trial NN N
with IN N
10 CD p
volunteers NNS p
. . p

In IN N
mice NN p
, , N
methotrimeprazine VBZ i
only RB N
possessed JJ N
antinociceptive JJ o
activity NN o
in IN N
doses NNS N
which WDT N
caused VBD N
marked JJ o
sedation NN o
. . o

However RB N
, , N
small JJ N
non-sedative JJ N
doses NNS N
of IN N
methotrimeprazine NN N
potentiated VBN N
the DT N
analgesic JJ o
action NN o
of IN o
morphine NN o
. . o

The DT N
volunteer NN N
study NN N
did VBD N
not RB N
confirm VB N
this DT N
finding NN N
in IN N
man NN p
. . p

Methotrimeprazine NNP i
7.5 CD N
mg NN N
i.m NN N
. . N

caused VBN N
significant JJ o
sedation NN o
, , N
but CC N
did VBD N
not RB N
alter VB N
the DT N
effects NNS N
of IN N
morphine NN i
5 CD N
mg NN N
on IN N
pain NN o
threshold NN o
or CC o
ventilatory NN o
response NN o
to TO N
carbon VB N
dioxide NN N
. . N

-DOCSTART- -11085402- O O

Use NNP N
of IN N
World NNP i
Wide NNP i
Web-based JJ i
directories NNS i
for IN N
tracing VBG p
subjects NNS p
in IN p
epidemiologic JJ p
studies NNS p
. . p

The DT N
recent JJ N
availability NN N
of IN N
World NNP N
Wide NNP N
Web-based JJ N
directories NNS N
has VBZ N
opened VBN N
up RP N
a DT N
new JJ N
approach NN N
for IN N
tracing VBG p
subjects NNS p
in IN p
epidemiologic JJ p
studies NNS p
. . p

The DT N
completeness NN N
of IN N
two CD p
World NNP i
Wide NNP i
Web-based JJ i
directories NNS i
( ( i
Canada411 NNP i
and CC i
InfoSpace NNP i
Canada NNP i
) ) i
for IN N
subject JJ N
tracing NN N
was VBD N
evaluated VBN N
by IN N
using VBG N
a DT N
randomized VBN N
crossover NN N
design NN N
for IN N
346 CD p
adults NNS p
randomly RB p
selected VBN p
from IN p
respondents NNS p
in IN p
an DT p
ongoing JJ p
cohort NN p
study NN p
. . p

About IN N
half NN N
( ( N
56.4 CD N
% NN N
) ) N
of IN N
the DT N
subjects NNS N
were VBD N
successfully RB N
located VBN N
by IN N
using VBG N
either CC N
Canada411 NNP i
or CC i
InfoSpace NNP i
. . i

Of IN N
the DT N
43.6 CD N
% NN N
of IN N
the DT N
subjects NNS N
who WP N
could MD N
not RB N
be VB N
located VBN N
using VBG N
either CC N
directory NN N
, , N
the DT N
majority NN N
( ( N
73.5 CD N
% NN N
) ) N
were VBD N
female JJ N
. . N

Overall JJ N
, , N
there EX N
was VBD N
no DT N
clear JJ N
advantage NN o
of IN N
one CD N
directory NN N
over IN N
the DT N
other JJ N
. . N

Although IN N
Canada411 NNP N
could MD N
find VB o
significantly RB o
more RBR o
subjects NNS o
than IN N
InfoSpace NNP N
, , N
the DT N
number NN o
of IN o
potential JJ o
matches NNS o
returned VBN N
by IN N
Canada411 NNP N
was VBD N
also RB N
higher JJR N
, , N
which WDT N
meant VBD N
that IN N
a DT N
longer RBR N
list NN N
of IN N
potential JJ N
matches NNS N
had VBD N
to TO N
be VB N
examined VBN N
before IN N
a DT N
true JJ N
match NN N
could MD N
be VB N
found VBN N
. . N

One CD N
strategy NN N
to TO N
minimize VB N
the DT N
number NN N
of IN N
potential JJ N
matches NNS N
per IN N
true JJ N
match NN N
is VBZ N
to TO N
first JJ N
search NN N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
then RB N
by IN N
Canada411 NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
name NN N
, , N
and CC N
finally RB N
by IN N
InfoSpace NNP N
with IN N
the DT N
last JJ N
name NN N
and CC N
first JJ N
initial JJ N
. . N

Internet-based JJ N
searches NNS N
represent VBP N
a DT N
potentially RB N
useful JJ N
approach NN N
to TO N
tracing VBG N
subjects NNS p
in IN p
epidemiologic JJ p
studies NNS p
. . p

-DOCSTART- -3812946- O O

Intravenous JJ i
regional JJ i
anaesthesia NN i
below IN N
the DT N
knee NN N
. . N

A DT N
cross-over JJ N
study NN N
with IN N
prilocaine NN i
in IN p
volunteers NNS p
. . p

The DT N
quality NN N
of IN N
anaesthesia NN N
provided VBN N
by IN N
three CD N
dosages NNS N
of IN N
prilocaine NN i
, , N
40 CD N
ml VBD N
0.5 CD N
% NN N
, , N
20 CD N
ml VBD N
1 CD N
% NN N
, , N
or CC N
40 CD N
ml JJ N
1 CD N
% NN N
, , N
administered VBN N
in IN N
random NN N
order NN N
, , N
for IN N
intravenous JJ N
regional JJ N
anaesthesia NN N
of IN N
the DT N
lower JJR N
extremity NN N
below IN N
the DT N
knee NN N
was VBD N
compared VBN N
in IN N
six CD p
volunteers NNS p
. . p

Limited JJ N
sensory NN N
blockade NN N
was VBD N
achieved VBN N
in IN N
the DT N
groups NNS N
with IN N
40 CD N
ml NNS N
0.5 CD N
% NN N
and CC N
20 CD N
ml NNS N
1 CD N
% NN N
during IN N
the DT N
30-minute JJ N
test NN N
period NN N
. . N

One CD N
subject NN N
was VBD N
not RB N
fully RB N
anaesthetised VBN N
with IN N
any DT N
of IN N
the DT N
dosages NNS N
used VBN N
. . N

Recovery NNP o
was VBD o
rapid JJ o
( ( N
mean JJ N
12-13 CD N
minutes NNS N
) ) N
in IN N
these DT N
two CD N
groups NNS N
. . N

In IN N
two CD N
subjects NNS N
given VBN N
40 CD N
ml NN N
of IN N
1 CD N
% NN N
, , N
complete JJ o
recovery NN o
took VBD N
90 CD N
minutes NNS N
. . N

At IN N
30 CD N
minutes NNS N
, , N
the DT N
degree NN o
of IN o
flexion NN o
remaining VBG o
in IN o
the DT o
great JJ o
toe NN o
( ( N
control VB N
100 CD N
% NN N
) ) N
was VBD N
4 CD N
% NN N
in IN N
the DT N
groups NNS N
who WP N
received VBD N
40 CD N
ml NN N
of IN N
0.5 CD N
% NN N
and CC N
1 CD N
% NN N
, , N
but CC N
34 CD N
% NN N
in IN N
those DT N
who WP N
received VBD N
20 CD N
ml NN N
of IN N
1 CD N
% NN N
respectively RB N
. . N

Full NNP o
motor NN o
recovery NN o
was VBD N
achieved VBN N
in IN N
8-9 JJ N
minutes NNS N
. . N

Five CD N
of IN N
six CD N
volunteers NNS N
who WP N
received VBD N
the DT N
400-mg JJ N
dose NN N
experienced VBD N
subjective JJ o
signs NNS o
of IN o
central JJ o
nervous JJ o
system NN o
side NN o
effects NNS o
when WRB N
the DT N
cuff NN N
was VBD N
released VBN N
. . N

In IN N
this DT N
group NN N
, , N
the DT N
mean JJ o
plasma JJ o
level NN o
of IN N
prilocaine NN i
at IN N
2 CD N
minutes NNS N
was VBD N
1.22 CD N
micrograms/ml NN N
, , N
maximum JJ N
2.12 CD N
micrograms/ml NN N
. . N

In IN N
a DT N
radiological JJ N
examination NN N
, , N
no DT o
leak NN o
of IN o
contrast NN o
medium NN o
under IN o
the DT o
tourniquet NN o
cuff NN o
( ( o
300 CD o
mmHg NN o
) ) o
was VBD N
detected VBN N
. . N

The DT N
development NN N
of IN N
anaesthesia NN N
was VBD N
fastest JJS o
following VBG N
the DT N
largest JJS N
dose NN N
, , N
but CC N
the DT N
large JJ o
number NN o
of IN o
central JJ o
side NN o
effects NNS o
makes VBZ N
that IN N
dosage NN N
less RBR o
suitable JJ o
for IN o
clinical JJ o
work NN o
. . o

-DOCSTART- -19304046- O O

Mastication NN o
and CC o
late JJ o
mandibular NN o
fracture NN o
after IN N
surgery NN i
of IN N
impacted JJ p
third JJ p
molars NNS p
associated VBN p
with IN p
no DT p
gross JJ p
pathology NN p
. . p

PURPOSE VB N
This DT N
study NN N
was VBD N
undertaken VBN N
with IN N
the DT N
null JJ N
hypothesis NN N
that IN N
in IN N
patients NNS p
, , p
fully RB p
denate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
, , N
mastication NN N
does VBZ N
not RB N
affect VB N
late JJ N
mandibular JJ o
fracture NN o
after IN p
surgical JJ i
removal NN i
of IN p
impacted JJ p
third JJ p
molars NNS p
( ( p
M3s NNP p
) ) p
associated VBN p
with IN p
no DT p
gross JJ p
pathology NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Five NNP p
hundred VBD p
sixty NN p
patients NNS p
, , p
fully RB p
dentate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
who WP p
had VBD p
no DT p
gross JJ p
pathology NN p
associated VBN p
with IN p
their PRP$ p
impacted VBN p
lower JJR p
M3s NNP p
, , N
were VBD N
recruited VBN N
in IN N
this DT N
study NN N
. . N

They PRP N
were VBD N
operated VBN i
on IN i
under IN N
local JJ i
anesthesia NN i
using VBG N
a DT N
standard NN N
technique NN N
and CC N
randomly RB N
assigned VBN N
into IN N
2 CD N
groups NNS N
for IN N
nonroutine NN N
( ( N
NR NNP N
group NN N
) ) N
and CC N
routine JJ N
( ( N
R NNP N
group NN N
) ) N
postoperative NN N
instructions NNS N
. . N

In IN N
the DT N
NR NNP N
group NN N
, , N
patients NNS N
were VBD N
postoperatively RB N
educated VBN N
in IN N
the DT N
possibility NN N
of IN N
mandibular JJ o
fracture NN o
and CC N
were VBD N
given VBN N
an DT N
emphasis NN N
on IN N
the DT N
necessity NN N
of IN N
limiting VBG o
mastication NN o
to TO N
a DT N
soft JJ N
diet NN N
for IN N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
R NNP N
group NN N
, , N
patients NNS N
were VBD N
given VBN N
no DT N
such JJ N
education NN N
or CC N
emphasis NN N
. . N

Patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
2 CD N
months NNS N
, , N
and CC N
data NNS o
concerning VBG o
patients NNS o
' POS o
age NN o
and CC o
gender NN o
; : o
tooth CC o
position NN o
, , o
angulation NN o
, , o
and CC o
depth NN o
; : o
date NN o
and CC o
site NN o
of IN o
surgery NN o
; : o
and CC o
occurrence NN o
of IN o
late JJ o
mandibular JJ o
fracture NN o
were VBD o
recorded VBN o
and CC N
statistically RB N
analyzed VBN N
. . N

A DT N
value NN N
of IN N
P NNP N
less JJR N
than IN N
.05 NN N
was VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS NNP N
In IN N
no DT N
patient NN N
group NN N
was VBD N
there RB N
a DT N
late JJ o
mandibular JJ o
fracture NN o
recorded VBN N
. . N

All DT N
patients NNS N
completed VBD N
the DT N
follow-up JJ N
period NN N
, , N
and CC N
most JJS N
of IN N
the DT N
R NNP N
group NN N
patients NNS N
had VBD N
normal JJ N
eating JJ N
habits NNS N
10 CD N
to TO N
14 CD N
days NNS N
after IN N
surgery NN N
. . N

In IN N
no DT N
patient NN N
group NN N
was VBD N
there RB N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
relation NN N
to TO N
gender VB N
( ( N
P NNP N
= NNP N
.735 NNP N
) ) N
, , N
site NN N
of IN N
surgery NN N
( ( N
P NNP N
= NNP N
.552 NNP N
) ) N
, , N
class NN N
horizontal JJ N
space NN N
available JJ N
( ( N
P NNP N
= NNP N
.427 NNP N
) ) N
, , N
class NN N
highest JJS N
portion NN N
of IN N
the DT N
M3 NNP N
crown NN N
( ( N
P NNP N
= NNP N
.424 NNP N
) ) N
, , N
angulations NNS N
of IN N
the DT N
teeth NN N
( ( N
P NNP N
= NNP N
.925 NNP N
) ) N
, , N
and CC N
severity NN o
of IN o
impaction NN o
( ( N
P NNP N
= NNP N
.445 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
, , p
fully RB p
dentate VB p
or CC p
with IN p
1 CD p
or CC p
2 CD p
teeth NNS p
missing VBG p
and CC p
older JJR p
than IN p
25 CD p
years NNS p
who WP p
have VBP p
no DT p
jawbone NN p
atrophy NN p
and CC p
no DT p
systemic JJ p
problems NNS p
that WDT p
may MD p
impair VB o
bone NN o
strength NN o
, , N
mastication NN N
seems VBZ N
not RB N
to TO N
affect VB N
late JJ o
mandibular JJ o
fracture NN o
after IN N
surgical JJ N
removal NN N
of IN N
impacted JJ N
M3s NNP N
associated VBN N
with IN N
no DT N
gross JJ N
pathology NN N
. . N

The DT N
remote JJ N
possible JJ N
risk NN N
of IN N
the DT N
late JJ o
fracture NN o
shown VBN N
in IN N
our PRP$ N
patients NNS N
indicates VBZ N
the DT N
need NN N
for IN N
no DT N
special JJ N
precautions NNS N
. . N

-DOCSTART- -16304214- O O

Comparison NNP N
of IN N
antihypertensives NNS o
after IN N
coronary JJ p
artery NN p
surgery NN p
. . p

Hypertension NN o
following VBG N
coronary JJ p
artery JJ p
bypass NN p
grafting NN p
is VBZ N
a DT N
common JJ N
problem NN N
that WDT N
may MD N
result VB N
in IN N
postoperative JJ o
myocardial JJ o
infraction NN o
or CC N
bleeding NN o
, , o
Hemodynamic NNP o
effects NNS o
were VBD N
compared VBN N
in IN N
45 CD p
hypertensive JJ p
coronary JJ p
bypass NN p
patients NNS p
randomized VBN N
to TO N
receive VB N
either DT N
diltiazem NN i
, , i
nitroglycerin NN i
, , i
or CC i
sodium NN i
nitroprusside RB i
. . i

Diltiazem NNP i
was VBD N
administered VBN N
as IN N
an DT N
intravenous JJ N
bolus NN N
of IN N
0.3 CD N
mg.kg-1 NN N
within IN N
5 CD N
min NN N
, , N
followed VBN N
by IN N
infusion NN N
of IN N
0.1-0.8 JJ N
mg.kg-1.h-1 NN N
in IN N
group NN N
1 CD N
. . N

Nitroglycerin NNP i
was VBD N
infused VBN N
at IN N
a DT N
rate NN N
of IN N
1-3 JJ N
microg.kg.h-1 NN N
in IN N
group NN N
2 CD N
, , N
and CC N
sodium NN i
nitroprusside NN i
was VBD N
given VBN N
at IN N
a DT N
rate NN N
of IN N
1-3 JJ N
microg.kg-1.min-1 NN N
in IN N
group NN N
3 CD N
. . N

Hemodynamic JJ o
measurements NNS o
were VBD N
carried VBN N
out RP N
before IN N
infusion NN N
( ( N
T1 NNP N
) ) N
and CC N
at IN N
30 CD N
min NN N
( ( N
T2 NNP N
) ) N
, , N
2 CD N
h NN N
( ( N
T3 NNP N
) ) N
, , N
and CC N
12 CD N
h NN N
( ( N
T4 NNP N
) ) N
after IN N
initiation NN N
of IN N
treatment NN N
in IN N
the DT N
intensive JJ N
care NN N
unit NN N
. . N

Mean NNP o
arterial JJ o
pressure NN o
decreased VBN N
significantly RB N
in IN N
all DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
among IN N
groups NNS N
at IN N
T1 NNP N
and CC N
T2 NNP N
. . N

At IN N
T3 NNP N
, , N
heart NN o
rate NN o
in IN N
group NN N
2 CD N
was VBD N
significantly RB N
higher JJR N
than IN N
group NN N
1 CD N
. . N

At IN N
T3 NNP N
and CC N
T4 NNP N
, , N
the DT N
double JJ N
product NN N
was VBD N
highest JJS N
in IN N
group NN N
3 CD N
( ( N
group NN N
1 CD N
vs. NN N
3 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
hemodynamic JJ o
effects NNS o
of IN N
the DT N
3 CD N
drugs NNS N
are VBP N
similar JJ N
within IN N
the DT N
first JJ N
30 CD N
min NN N
. . N

However RB N
, , N
after IN N
30 CD N
min NN N
, , N
diltiazem NN i
affords NNS N
better RBR N
myocardial JJ o
performance NN o
and CC o
more RBR o
effective JJ o
control NN o
of IN o
hypertension NN o
. . o

-DOCSTART- -23613224- O O

Home-based JJ i
versus NN i
hospital-based JJ i
high-intensity NN i
interval NN i
training NN i
in IN N
cardiac JJ i
rehabilitation NN i
: : i
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
High-intensity NNP i
interval NN i
training NN i
( ( i
HIT NNP i
) ) i
as IN N
exercise NN N
therapy NN N
is VBZ N
gradually RB N
implemented VBN N
in IN N
cardiac JJ N
rehabilitation NN N
as IN N
the DT N
cardiovascular JJ N
benefits NNS N
from IN N
exercise NN N
is VBZ N
intensity JJ N
dependent NN N
. . N

However RB N
, , N
in IN N
previous JJ N
studies NNS N
, , N
HIT NNP N
has VBZ N
been VBN N
performed VBN N
with IN N
strict JJ N
supervision NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
feasibility NN o
and CC o
effectiveness NN o
of IN N
different JJ N
modes NNS N
of IN N
HIT NNP N
in IN N
cardiac JJ N
rehabilitation NN N
. . N

DESIGN VB N
a DT N
randomized JJ N
clinical JJ N
study NN N
. . N

METHODS NNP N
Ninety NNP p
participants NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
( ( p
80 CD p
men/10 NN p
women NNS p
, , p
mean JJ p
age NN p
57 CD p
? . p
8 CD p
years NNS p
) ) p
were VBD p
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
exercise NN N
modes NNS N
: : i
group NN i
exercise NN i
( ( i
GE NNP i
) ) i
, , i
treadmill JJ i
exercise NN i
( ( i
TE NNP i
) ) i
, , i
or CC i
home-based JJ i
exercise NN i
( ( i
HE NNP i
) ) i
. . i

HIT NNP i
was VBD N
performed VBN N
twice RB N
a DT N
week NN N
for IN N
12 CD N
weeks NNS N
with IN N
an DT N
exercise NN N
intensity NN N
of IN N
85-95 CD N
% NN N
of IN N
peak JJ N
heart NN N
rate NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN o
was VBD o
change NN o
in IN o
peak NN o
oxygen NN o
uptake NN o
( ( o
peak JJ o
VO2 NNP o
) ) o
. . N

RESULTS NNP p
Eighty-three JJ p
participants NNS p
( ( p
92 CD p
% NN p
) ) p
completed VBD p
the DT p
intervention NN p
without IN p
any DT p
severe JJ o
adverse JJ o
events NNS o
. . o

Peak NNP o
VO2 NNP o
increased VBD N
from IN N
34.7 CD N
? . N
7.3 CD N
to TO N
39.0 CD N
? . N
8.0 CD N
ml/kg/min NN N
, , N
32.7 CD N
? . N
6.5 CD N
to TO N
36.0 CD N
? . N
6.2 CD N
ml/kg/min NN N
, , N
and CC N
34.4 CD N
? . N
4.8 CD N
to TO N
37.2 CD N
? . N
5.2 CD N
ml/kg/min NN N
in IN N
TE NNP N
, , N
GE NNP N
, , N
and CC N
HE NNP N
, , N
respectively RB N
. . N

Mean NNP N
group NN N
difference NN N
for IN N
TE NNP N
vs NN N
. . N

HE NNP N
was VBD N
1.6 CD N
ml/kg/min NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
CI NNP N
, , N
0.7 CD N
to TO N
3.1 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
, , N
TE NNP N
vs. FW N
GE NNP N
1.1 CD N
ml/kg/min NN N
( ( N
95 CD N
% NN N
CI-0.5 NNP N
to TO N
2.5 CD N
, , N
p NN N
= NNP N
0.27 CD N
) ) N
, , N
and CC N
GE NNP N
vs NN N
. . N

HE $ N
0.6 CD N
ml/kg/min NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.0 NNP N
to TO N
2.1 CD N
, , N
p NN N
= NNP N
1 CD N
) ) N
. . N

However RB N
, , N
on-treatment JJ N
analysis NN N
showed VBD o
no DT o
significant JJ o
difference NN o
between IN o
groups NNS N
. . N

CONCLUSION NNP N
HIT NNP N
was VBD N
efficiently RB N
performed VBN N
in IN N
three CD N
settings NNS N
of IN N
cardiac JJ N
rehabilitation NN N
, , N
with IN N
respect NN N
to TO o
target VB o
exercise NN o
intensity NN o
, , o
exercise NN o
attendance NN o
, , o
and CC o
increase VB o
in IN o
peak JJ o
VO2 NNP o
. . o

Exercise NNP N
mode NN N
was VBD N
not RB N
essential JJ N
for IN o
exercise NN o
capacity NN o
. . N

-DOCSTART- -6113821- O O

Schizophrenia NNP N
. . N

A DT N
follow-up JJ N
study NN N
of IN N
the DT N
results NNS N
of IN N
five CD N
forms NNS N
of IN N
treatment NN N
. . N

Two CD p
hundred VBD p
twenty-eight JJ p
first-admission NN p
schizophrenic JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
following VBG N
five CD N
treatments NNS N
: : N
psychotherapy NN i
alone RB i
, , i
drug NN i
alone RB i
, , i
psychotherapy JJ i
plus CC i
drug NN i
, , i
electroconvulsive JJ i
therapy NN i
( ( i
ECT NNP i
, , i
and CC i
milieu NN i
. . i

A DT N
there- JJ N
to TO N
five-year JJ N
follow-up NN N
examined VBD N
their PRP$ N
course NN N
after IN N
release NN N
from IN N
the DT N
hospital NN N
. . N

The DT N
drug NN N
alone RB N
and CC N
ECT NNP N
groups NNS N
tended VBD N
to TO N
have VB N
the DT N
best JJS N
outcome NN o
and CC N
the DT N
psychotherapy NN N
alone RB N
group NN N
the DT N
worst JJS N
. . N

The DT N
positive JJ o
effect NN o
from IN N
prior JJ N
drug NN N
treatment NN N
began VBD N
to TO N
dissipate VB N
after IN N
three CD N
years NNS N
postadmission NN N
. . N

For IN N
the DT N
in-hospital JJ N
treatment NN N
successes NNS N
, , N
the DT N
advantage NN o
from IN N
drug NN N
treatment NN N
and CC N
the DT N
disadvantage NN o
from IN N
psychotherapy NN N
were VBD N
less JJR N
apparent JJ N
. . N

Overall JJ N
, , N
the DT N
follow-up JJ N
outcome NN N
is VBZ N
far RB N
from IN N
reassuring VBG N
, , N
whatever WP N
the DT N
type NN N
of IN N
treatment NN N
. . N

Even RB N
though IN N
a DT N
few JJ N
patients NNS N
may MD N
do VB N
well RB N
, , N
much JJ N
remains VBZ N
to TO N
be VB N
done VBN N
in IN N
and CC N
out IN N
of IN N
the DT N
hospital NN N
. . N

-DOCSTART- -15472185- O O

The DT N
effect NN N
of IN N
calcium NN i
supplementation NN i
on IN N
bone NN N
density NN N
in IN N
premenarcheal JJ p
females NNS p
: : p
a DT N
co-twin JJ p
approach NN N
. . N

The DT N
age NN N
and CC N
developmental JJ N
stage NN N
at IN N
which WDT N
calcium NN i
supplementation NN i
produces VBZ N
the DT N
greatest JJS N
bone NN N
effects NNS N
remain VBP N
controversial JJ N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
calcium NN i
supplementation NN i
may MD N
improve VB N
bone NN o
accrual JJ o
in IN N
premenarcheal JJ p
females NNS p
. . p

Fifty-one CD p
pairs NNS p
of IN p
premenarcheal JJ p
female NN p
twins NNS p
( ( p
27 CD p
monozygotic NN p
and CC p
24 CD p
dizygotic JJ p
; : p
mean JJ p
+/- JJ p
sd NN p
age NN p
, , p
10.3 CD p
+/- JJ p
1.5 CD p
yr NN p
) ) p
participated VBD N
in IN N
a DT N
randomized JJ N
, , N
single-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
one CD N
twin NN N
of IN N
each DT N
pair NN N
receiving VBG i
a DT i
1200-mg JJ i
calcium NN i
carbonate NN i
( ( i
Caltrate NNP i
) ) i
supplement NN i
. . i

Areal NNP o
bone JJ o
mineral NN o
density NN o
( ( o
aBMD NN o
) ) o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
6 CD N
, , N
12 CD N
, , N
18 CD N
and CC N
24 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
within-pair JJ p
differences NNS p
in IN p
height NN p
, , p
weight NN p
, , p
or CC p
calcium NN p
intake NN p
at IN p
baseline NN p
. . p

Calcium NNP N
supplementation NN N
was VBD N
associated VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
increased VBN N
aBMD NNS o
compared VBN N
with IN N
placebo NN N
, , N
adjusted VBN N
for IN N
age NN N
, , N
height NN N
, , N
and CC N
weight NN N
at IN N
the DT N
following JJ N
time NN N
points NNS N
from IN N
baseline NN N
: : N
total JJ N
hip NN N
, , N
6 CD N
months NNS N
( ( N
1.9 CD N
% NN N
) ) N
, , N
12 CD N
months NNS N
( ( N
1.6 CD N
% NN N
) ) N
, , N
and CC N
18 CD N
months NNS N
( ( N
2.4 CD N
% NN N
) ) N
; : N
lumbar CC N
spine NN N
, , N
12 CD N
months NNS N
( ( N
1.0 CD N
% NN N
) ) N
; : N
femoral JJ N
neck NN N
, , N
6 CD N
months NNS N
( ( N
1.9 CD N
% NN N
) ) N
. . N

Adjusted VBN o
total JJ o
body NN o
bone JJ o
mineral JJ o
content NN o
was VBD N
higher RBR N
in IN N
the DT N
calcium NN N
group NN N
at IN N
6 CD N
months NNS N
( ( N
2.0 CD N
% NN N
) ) N
, , N
12 CD N
months NNS N
( ( N
2.5 CD N
% NN N
) ) N
, , N
18 CD N
months NNS N
( ( N
4.6 CD N
% NN N
) ) N
, , N
and CC N
24 CD N
months NNS N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Calcium NNP i
supplementation NN i
was VBD N
effective JJ N
in IN N
increasing VBG N
aBMD NN o
at IN N
regional JJ N
sites NNS N
over IN N
the DT N
first JJ N
12-18 JJ N
months NNS N
, , N
but CC N
these DT N
gains NNS N
were VBD N
not RB N
maintained VBN N
to TO N
24 CD N
months NNS N
. . N

-DOCSTART- -20001837- O O

Effects NNS N
of IN N
Thai NNP N
traditional JJ N
massage NN N
on IN N
autistic JJ p
children NNS p
's POS p
behavior NN p
. . p

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
access NN N
whether IN N
there EX N
were VBD N
any DT N
therapeutic JJ N
effects NNS N
of IN N
Thai NNP i
Traditional NNP i
Massage NNP i
( ( i
TTM NNP i
) ) i
on IN N
major JJ N
behavioral JJ p
and CC p
emotional JJ p
disturbances NNS p
in IN p
Thai NNP p
autistic JJ p
children NNS p
. . p

DESIGN NN N
This DT N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
study NN N
. . N

SETTINGS/LOCATION NNP N
The DT p
study NN p
was VBD p
conducted VBN p
at IN p
the DT p
Rehabilitation NNP p
Centre NNP p
of IN p
the DT p
Thai NNP p
Red NNP p
Cross NNP p
Society NNP p
. . p

SUBJECTS NNP N
A NNP p
total NN p
of IN p
60 CD p
autistic JJ p
children NNS p
between IN p
the DT p
ages NNS p
of IN p
3 CD p
and CC p
10 CD p
completed VBD p
this DT p
study NN p
. . p

INTERVENTIONS NNP N
Standard NNP i
sensory JJ i
integration NN i
therapy NN i
( ( i
SI NNP i
) ) i
was VBD N
compared VBN N
to TO N
the DT N
SI NNP N
with IN N
TTM NNP i
treatments NNS N
. . N

OUTCOME NNP N
MEASURES NNP N
Parents NNP N
and CC N
teachers NNS N
assessed VBD N
major JJ o
behavior NN o
disturbances NNS o
using VBG N
the DT N
Conners NNPS o
' POS o
Rating VBG o
Scales NNS o
at IN N
0 CD N
and CC N
8 CD N
weeks NNS N
. . N

Sleep JJ o
Diary NNP o
( ( o
SD NNP o
) ) o
, , N
recorded VBN N
by IN N
the DT N
parents NNS N
, , N
assessed VBD N
the DT N
patient NN N
's POS N
sleeping NN N
patterns NNS N
every DT N
week NN N
. . N

RESULTS NNP N
Sixty NNP p
( ( p
60 CD p
) ) p
autistic JJ p
children NNS p
, , p
mean JJ p
age NN p
4.67 CD p
+/- JJ p
1.82 CD p
, , p
were VBD p
recruited VBN p
. . p

No DT N
statistical JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
demographic JJ N
and CC N
baseline JJ N
data NN N
among IN N
both DT N
groups NNS N
. . N

From IN N
both CC N
the DT N
Conners NNPS o
' POS o
Teacher NNP o
Questionnaire NNP o
and CC o
SD NNP o
, , N
statistical JJ N
improvement NN N
was VBD N
detected VBN N
for IN N
conduct NN o
problem NN o
, , o
hyperactivity NN o
, , o
inattention-passivity NN o
, , o
hyperactivity NN o
index NN o
, , o
and CC o
sleeping VBG o
behavior NN o
. . o

However RB N
, , N
results NNS N
from IN N
the DT N
Conners NNP o
' POS o
Parent NNP o
Questionnaire NNP o
revealed VBD N
an DT N
improvement NN N
only RB N
for IN N
anxiety NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
massage NN N
group NN N
, , N
whereas IN N
when WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
conduct NN o
problem NN o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
anxiety NN o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
was VBD N
found VBN N
. . N

Results NNS N
indicated VBD N
that IN N
TTM NNP N
may MD N
have VB N
a DT N
positive JJ N
effect NN N
in IN N
improving VBG N
stereotypical JJ o
behaviors NNS o
in IN N
autistic JJ N
children NNS N
. . N

CONCLUSIONS NNP N
Over IN N
a DT N
period NN N
of IN N
8 CD N
weeks NNS N
, , N
our PRP$ N
findings NNS N
suggested VBD N
that IN N
TTM NNP N
could MD N
be VB N
used VBN N
as IN N
a DT N
complementary JJ N
therapy NN N
for IN N
autistic JJ N
children NNS N
in IN N
Thailand NNP p
. . p

-DOCSTART- -2286596- O O

A DT N
comparative JJ N
study NN N
of IN N
ofloxacin NN i
and CC N
amoxycillin/clavulanate NN i
in IN N
hospitalized JJ p
patients NNS p
with IN p
lower JJR o
respiratory NN o
tract JJ o
infections NNS o
. . o

We PRP N
conducted VBD N
an DT N
open JJ N
randomized VBN N
trial NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
parenteral JJ N
and CC N
oral JJ N
ofloxacin NN i
with IN N
that DT N
of IN N
amoxycillin/clavulanate NN i
. . i

A DT N
total NN N
of IN N
121 CD p
patients NNS p
was VBD p
studied VBN p
; : p
92 CD p
were VBD p
clinically RB p
evaluable JJ p
. . p

Of IN N
these DT N
, , N
59 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
ofloxacin NN i
and CC p
33 CD p
with IN p
the DT p
comparator NN p
drug NN p
. . p

Patients NNS N
were VBD N
given VBN N
the DT N
drugs NNS N
intravenously RB N
for IN N
a DT N
minimum NN N
of IN N
three CD N
days NNS N
followed VBN N
by IN N
oral JJ N
preparations NNS N
for IN N
the DT N
next JJ N
seven CD N
to TO N
ten VB N
days NNS N
. . N

Ofloxacin NNP i
was VBD N
usually RB N
administered VBN N
as IN N
a DT N
200 CD N
mg NN N
dose NN N
bd NN N
. . N

In IN N
the DT N
ofloxacin NN i
treated VBN N
group NN N
all DT N
patients NNS N
showed VBD N
clinical JJ o
improvement NN o
. . o

In IN N
the DT N
comparator NN N
group NN N
94 CD N
% NN N
improved VBN N
clinically RB N
( ( N
either CC N
a DT N
complete JJ N
or CC N
partial JJ N
response NN N
) ) N
, , N
while IN N
6 CD N
% NN N
were VBD N
clinical JJ N
failures NNS N
. . N

Of IN N
the DT N
bacteriologically RB N
evaluable JJ N
patients NNS N
19 CD N
of IN N
20 CD N
showed VBD N
a DT N
satisfactory JJ o
bacteriological JJ o
response NN o
in IN N
the DT N
ofloxacin NN N
treated VBD N
group NN N
, , N
while IN N
in IN N
the DT N
comparator NN N
group NN N
the DT N
bacteriological JJ N
response NN N
was VBD N
judged VBN N
satisfactory NN N
in IN N
14 CD N
of IN N
17 CD N
patients NNS N
. . N

A DT N
small JJ N
proportion NN N
of IN N
patients NNS N
( ( N
7 CD N
% NN N
) ) N
treated VBD N
with IN N
ofloxacin NN i
suffered VBD N
mild JJ o
adverse JJ o
effects NNS o
( ( o
nausea NN o
, , o
vomiting VBG o
, , o
headache NN o
, , o
hypotension NN o
and CC o
rash NN o
) ) o
. . o

On IN N
the DT N
whole NN N
, , N
ofloxacin NN N
was VBD N
well RB N
tolerated VBN o
by IN N
our PRP$ N
patients NNS N
. . N

The DT N
two CD N
deaths NNS o
that IN N
occurred VBD N
were VBD N
in IN N
the DT N
comparator NN N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
ofloxacin NN i
in IN N
both DT N
oral JJ N
and CC N
parenteral JJ N
forms NNS N
is VBZ N
an DT N
effective JJ o
and CC o
safe JJ o
drug NN N
in IN N
the DT N
treatment NN N
of IN N
lower JJR N
respiratory NN N
tract JJ N
infections NNS N
. . N

-DOCSTART- -17093162- O O

Folate NNP N
and CC N
arsenic JJ N
metabolism NN N
: : N
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
folic JJ i
acid-supplementation NN i
trial NN p
in IN p
Bangladesh NNP p
. . p

BACKGROUND NNP N
Populations NNPS p
in IN p
South NNP p
and CC p
East NNP p
Asia NNP p
and CC p
many JJ p
other JJ p
regions NNS p
of IN p
the DT p
world NN p
are VBP p
chronically RB p
exposed VBN p
to TO p
arsenic-contaminated JJ p
drinking NN p
water NN p
. . p

To TO N
various JJ N
degrees NNS N
, , N
ingested VBN N
inorganic JJ N
arsenic NN N
( ( N
InAs NNP N
) ) N
is VBZ N
methylated VBN N
to TO N
monomethylarsonic JJ N
acid NN N
( ( N
MMA NNP N
) ) N
and CC N
dimethylarsinic JJ N
acid NN N
( ( N
DMA NNP N
) ) N
via IN N
folate-dependent JJ N
one-carbon JJ N
metabolism NN N
; : N
impaired JJ N
methylation NN N
is VBZ N
associated VBN N
with IN N
adverse JJ N
health NN N
outcomes NNS N
. . N

Consequently RB N
, , N
folate JJ N
nutritional JJ N
status NN N
may MD N
influence VB N
arsenic JJ o
methylation NN o
and CC N
toxicity NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
folic JJ i
acid DT i
supplementation NN i
of IN N
arsenic-exposed JJ p
adults NNS p
would MD N
increase VB N
arsenic JJ N
methylation NN N
. . N

DESIGN NNP N
Two CD p
hundred VBD p
adults NNS p
in IN p
a DT p
rural JJ p
region NN p
of IN p
Bangladesh NNP p
, , p
previously RB p
found VBN p
to TO p
have VB p
low JJ p
plasma JJ p
concentrations NNS p
of IN p
folate NN p
( ( p
< JJ p
/=9 NNP p
nmol/L NN p
) ) p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
folic JJ i
acid-supplementation NN i
trial NN N
. . N

Plasma NNP o
concentrations NNS o
of IN o
folate NN o
and CC o
homocysteine NN o
and CC o
urinary JJ o
concentrations NNS o
of IN o
arsenic JJ o
metabolites NNS o
were VBD N
analyzed VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
wk NN N
of IN N
supplementation NN i
with IN i
folic JJ i
acid NN i
at IN N
a DT N
dose NN N
of IN N
400 CD N
microg/d NN N
or CC i
placebo NN i
. . i

RESULTS VB N
The DT N
increase NN N
in IN N
the DT N
proportion NN o
of IN o
total JJ o
urinary JJ o
arsenic NN o
excreted VBD N
as IN N
DMA NNP N
in IN N
the DT N
folic JJ N
acid NN N
group NN N
( ( N
72 CD N
% NN N
before IN N
and CC N
79 CD N
% NN N
after IN N
supplementation NN N
) ) N
was VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN i
group NN N
, , N
as IN N
was VBD N
the DT N
reduction NN N
in IN N
the DT N
proportions NNS N
of IN N
total JJ o
urinary JJ o
arsenic NN o
excreted VBD o
as IN N
MMA NNP N
( ( N
13 CD N
% NN N
and CC N
10 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
as IN N
InAs NNP N
( ( N
15 CD N
% NN N
and CC N
11 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
folic JJ i
acid JJ i
supplementation NN N
to TO N
participants NNS p
with IN p
low JJ p
plasma NN p
folate NN p
enhances NNS N
arsenic JJ N
methylation NN N
. . N

Because IN N
persons NNS N
whose WP$ N
urine JJ N
contains NNS N
low JJ N
proportions NNS N
of IN N
DMA NNP N
and CC N
high JJ N
proportions NNS N
of IN N
MMA NNP N
and CC N
InAs NNP N
have VBP N
been VBN N
reported VBN N
to TO N
be VB N
at IN N
greater JJR N
risk NN N
of IN N
skin NN N
and CC N
bladder NN N
cancers NNS N
and CC N
peripheral JJ N
vascular JJ N
disease NN N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
folic JJ i
acid DT i
supplementation NN N
may MD N
reduce VB N
the DT N
risk NN N
of IN N
arsenic-related JJ N
health NN N
outcomes NNS N
. . N

-DOCSTART- -10606880- O O

Partial JJ N
depletion NN o
of IN o
tissue NN o
factor NN o
pathway NN o
inhibitor NN o
during IN N
subcutaneous JJ N
administration NN N
of IN N
unfractionated JJ N
heparin NN i
, , N
but CC N
not RB N
with IN N
two CD N
low JJ N
molecular JJ N
weight NN N
heparins NNS N
. . N

Tissue NNP N
factor NN N
pathway NN N
inhibitor NN N
( ( N
TFPI NNP N
) ) N
is VBZ N
released VBN N
to TO N
circulating VBG N
blood NN N
after IN N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
and CC N
subcutaneous JJ N
( ( N
s.c. NN N
) ) N
injections NNS N
of IN N
heparins NNS N
, , N
and CC N
may MD N
thus RB N
contribute VB N
to TO N
the DT N
antithrombotic JJ N
effect NN N
of IN N
heparins NNS N
. . N

We PRP N
have VBP N
recently RB N
shown VBN N
that IN N
total JJ N
TFPI NNP o
activity NN o
, , o
plasma VBP o
free JJ o
TFPI NNP o
antigen NN o
, , N
and CC N
heparin NN o
releasable JJ o
TFPI NNP o
were VBD N
partially RB N
depleted VBN N
during IN N
repeated VBN N
and CC N
continuous JJ N
i.v NN N
. . N

infusion NN N
of IN N
unfractionated JJ i
heparin NN i
( ( N
UFH NNP N
) ) N
, , N
but CC N
not RB N
during IN N
s.c. JJ N
treatment NN N
with IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
LMWH NNP N
) ) N
. . N

The DT N
difference NN N
may MD N
be VB N
attributed VBN N
to TO N
a DT N
different JJ N
mode NN N
of IN N
action NN N
or CC N
the DT N
different JJ N
mode NN N
of IN N
administration NN N
. . N

In IN N
the DT N
present JJ N
randomized VBN N
cross-over NN N
study NN N
, , N
s.c. JJ N
administration NN N
of IN N
therapeutic JJ N
doses NNS N
of IN N
UFH NNP i
was VBD N
compared VBN N
with IN N
s.c. JJ N
administration NN i
of IN i
two CD i
LMWHs NNP i
. . i

12 CD p
healthy JJ p
male NN p
volunteers NNS p
were VBD N
treated VBN N
for IN N
3 CD N
d NN N
with IN N
UFH NNP i
, , N
250 CD N
U/kg NNP N
twice RB N
daily RB N
, , N
dalteparin NN i
, , i
200 CD i
U/kg NNP i
once RB i
daily RB i
, , i
and CC i
enoxaparin RB i
, , N
1.5 CD N
mg/kg NN N
once RB N
daily JJ N
. . N

Six CD p
participants NNS p
were VBD N
also RB N
treated VBN N
with IN N
UFH NNP i
, , N
300 CD N
U/kg NNP N
once RB N
daily RB N
. . N

On IN N
day NN N
5 CD N
a DT N
single JJ N
dose NN N
of IN N
either DT N
drug NN N
was VBD N
given VBN N
. . N

Peak NNP o
levels NNS o
of IN o
total JJ o
TFPI NNP o
activity NN o
and CC o
free JJ o
TFPI NNP o
antigen NN o
were VBD N
detected VBN N
1 CD N
h NN N
after IN N
injection NN N
, , N
whereas IN N
maximal JJ o
prolongation NN o
of IN o
activated VBN o
partial JJ o
thromboplastin NN o
time NN o
( ( o
APTT NNP o
) ) o
and CC o
peak JJ o
levels NNS o
of IN o
anti-factor JJ o
Xa NNP o
activity NN o
and CC o
anti-factor NN o
IIa NNP o
activity NN o
were VBD N
detected VBN N
after IN N
4 CD N
h. NN N
On IN N
UFH NNP i
administered VBD N
twice RB N
daily RB N
, , N
free JJ o
TFPI NNP o
antigen NN o
decreased VBN N
by IN N
44 CD N
% NN N
from IN N
baseline JJ N
level NN N
before IN N
the DT N
first JJ N
injection NN N
on IN N
day NN N
1 CD N
to TO N
pre-injection NN N
level NN N
on IN N
day NN N
5 CD N
. . N

On IN N
UFH NNP i
administered VBD N
once RB N
daily JJ N
, , N
basal JJ o
free JJ o
TFPI NNP o
antigen NN o
decreased VBN N
by IN N
50 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
27 CD N
% NN N
on IN N
day NN N
2 CD N
, , N
3 CD N
and CC N
5 CD N
respectively RB N
, , N
compared VBN N
with IN N
day NN N
1 CD N
. . N

Minimal JJ o
depletion NN o
of IN o
TFPI NNP o
was VBD N
detected VBN N
during IN N
treatment NN N
with IN N
LMWHs NNP N
. . N

The DT N
study NN N
demonstrates VBZ N
the DT N
different JJ N
modes NNS N
of IN N
action NN N
of IN N
LMWHs NNP i
and CC N
UFH NNP i
and CC N
may MD N
help VB N
to TO N
explain VB N
the DT N
superior JJ N
antithrombotic JJ N
efficacy NN N
of IN N
LMWHs NNP N
. . N

-DOCSTART- -20937044- O O

Clinical JJ N
trial NN N
: : N
once-daily JJ N
mesalamine NN i
granules NNS N
for IN N
maintenance NN N
of IN N
remission NN N
of IN N
ulcerative JJ N
colitis NN N
- : N
a DT N
6-month JJ N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Ulcerative NNP N
colitis NN N
( ( N
UC NNP N
) ) N
is VBZ N
a DT N
chronic JJ N
relapsing NN N
and CC N
remitting VBG N
idiopathic JJ N
inflammatory JJ N
bowel NN N
disorder NN N
. . N

AIM NNP N
To TO N
evaluate VB N
once-daily JJ N
mesalamine NN i
( ( i
mesalazine NN i
) ) i
granules NNS i
( ( i
MG NNP i
) ) i
for IN N
maintenance NN N
of IN N
remission NN N
of IN N
UC NNP N
. . N

METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS p
( ( p
n=209 JJ p
MG NNP p
, , p
n=96 RB p
placebo NN p
) ) p
with IN p
UC NNP p
in IN p
remission NN p
[ NNS o
revised VBN o
Sutherland NNP o
Disease NNP o
Activity NNP o
Index NNP o
( ( o
SDAI NNP o
) ) o
rectal NN p
bleeding=0 NN p
, , p
mucosal JJ p
appearance NN p
< VBD p
2 CD p
] NN p
who WP p
took VBD p
MG NNP i
1.5 CD i
g NN i
or CC i
placebo VB i
once-daily RB i
for IN i
up IN i
to TO i
6 CD i
months NNS i
. . i

Primary NNP N
efficacy NN N
endpoint NN N
: : N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
remained VBD N
relapse-free JJ N
at IN N
month NN N
6/end CD N
of IN N
treatment NN N
. . N

Relapse NNP N
was VBD N
defined VBN N
as IN N
SDAI NNP N
rectal NN N
bleeding VBG N
score NN N
?1 NN N
and CC N
a DT N
mucosal JJ N
appearance NN N
score NN N
?2 NN N
, , N
a DT N
UC NNP N
flare NN N
, , N
or CC N
initiation NN N
of IN N
medication NN N
to TO N
treat VB N
a DT N
UC NNP N
flare NN N
. . N

RESULTS VB N
The DT N
percentage NN o
of IN o
relapse-free JJ o
patients NNS o
at IN p
month NN p
6/end CD p
of IN p
treatment NN p
was VBD p
higher JJR N
with IN N
MG NNP i
than IN N
placebo NN i
( ( i
78.9 CD i
% NN N
vs. FW N
58.3 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
the DT N
intent-to-treat JJ N
analysis NN N
. . N

Significant JJ N
differences NNS N
( ( N
P NNP N
? . N
0.025 CD N
) ) N
favouring VBG i
MG NNP i
were VBD i
observed VBN N
for IN N
most JJS N
secondary JJ N
endpoints NNS N
including VBG N
improvement NN o
in IN o
rectal JJ o
bleeding NN o
, , o
physician NN o
's POS o
disease NN o
activity NN o
rating NN o
, , o
stool JJ o
frequency NN o
, , o
the DT o
SDAI NNP o
at IN o
month NN o
6/end CD o
of IN o
treatment NN o
, , o
patients NNS o
classified VBD N
as IN N
a DT N
treatment NN N
success NN N
and CC N
relapse-free JJ N
duration NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ N
events NNS N
was VBD N
similar JJ N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Once-daily JJ i
mesalamine NN i
( ( i
mesalazine NN i
) ) i
was VBD i
effective JJ i
in IN N
maintaining VBG N
remission NN N
of IN N
UC NNP N
for IN N
6 CD N
months NNS N
. . N

-DOCSTART- -1908729- O O

Recombinant JJ i
human JJ i
granulocyte-macrophage NN i
colony NN i
stimulating VBG i
factor NN i
( ( i
rhGM-CSF NN i
) ) i
reduces VBZ N
infection-related JJ o
mortality NN o
after IN p
allogeneic JJ p
T-cell NNP p
depleted VBD p
BMT NNP p
. . p

-DOCSTART- -17054808- O O

Endocrine NNP o
response NN o
to TO N
cataract VB i
surgery NN i
under IN i
total JJ i
intravenous JJ i
anaesthesia NN i
, , i
local JJ i
anaesthesia NN i
under IN i
sedation NN i
or CC i
local JJ i
anaesthesia NN i
alone RB i
: : i
a DT N
comparative JJ N
study NN N
. . N

-DOCSTART- -16733916- O O

[ JJ N
Profiles NNP N
of IN N
irregular JJ o
bleeding NN o
induced VBN N
by IN N
low-dose JJ i
hormone NN i
therapy NN i
and CC N
Chinese JJ i
formulated VBN i
herbs NN i
products NNS i
] NNP i
. . N

OBJECTIVE NNP N
To TO N
compare VB N
profiles NNS N
and CC N
related JJ N
factors NNS N
of IN N
irregular JJ o
bleeding NN o
induced VBN N
by IN N
different JJ N
types NNS N
of IN N
low-dose JJ i
hormone NN i
therapy NN i
( ( i
HT NNP i
) ) i
and CC N
a DT N
Chinese JJ i
formulated VBN i
herbs NN i
products NNS i
. . i

METHODS NNP N
Applied NNP N
with IN N
open-labeled JJ N
, , N
randomized VBN N
, , N
and CC N
clinical JJ N
trial NN N
design NN N
, , N
136 CD p
postmenopausal JJ p
women NNS p
were VBD N
assigned VBN N
into IN N
four CD N
groups NNS N
: : N
group NN N
A DT N
: : N
estradiol NN i
valerate NN i
( ( i
E2 NNP i
V NNP i
) ) i
1 CD i
mg/d NN i
+ NNP i
medroxyprogesterone NN i
acetate NN i
( ( i
MPA NNP i
) ) i
2 CD i
mg/d NN i
; : i
group NN i
B NNP i
: : i
conjugated JJ i
equine NN i
estrogen NN i
0.45 CD i
mg/d NN i
+ NNP i
MPA NNP i
2 CD i
mg/d NN N
; : N
group NN i
C NNP i
: : i
tibolone NN i
1.25 CD N
mg/d NN N
; : N
group NN i
D NNP i
: : i
a DT i
Chinese JJ i
formulated VBN i
herbs JJ i
product NN i
( ( i
Kuntai NNP i
) ) i
4 CD N
# # N
tid NN N
. . N

Each DT N
subject NN N
took VBD N
element NN N
calcium NN i
400 CD N
mg/d NN N
and CC N
vitamin NN i
D NNP i
200 CD N
IU/d NNP N
concomitantly RB N
. . N

Modified NNP N
Kupperman NNP o
scores NNS o
were VBD N
assessed VBN N
on IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
thereafter RB N
and CC N
irregular JJ o
bleeding NN o
was VBD N
recorded VBN N
on IN N
menopausal NN N
diary JJ N
every DT N
day NN N
. . N

The DT N
duration NN N
of IN N
this DT N
study NN N
was VBD N
1 CD N
year NN N
. . N

Results VB N
The DT N
efficacies NNS o
were VBD N
similar JJ N
in IN N
three CD N
HT-managed JJ N
groups NNS N
, , N
but CC N
was VBD N
better JJR N
than IN N
in IN N
group NN N
D NNP N
, , N
although IN N
the DT N
latter NN N
was VBD N
also RB N
effective JJ o
in IN N
alleviating VBG N
menopausal NN N
symptoms NNS N
. . N

Hazard NNP o
ratio NN o
( ( o
HR NNP o
) ) o
of IN o
irregular JJ o
bleeding NN o
was VBD N
1.00 CD N
in IN N
group NN N
C NNP N
, , N
2.43 CD N
in IN N
group NN N
A NNP N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.08-5.46 JJ N
) ) N
, , N
3.12 CD N
in IN N
group NN N
B NNP N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.42-6.88 JJ N
) ) N
, , N
and CC N
0.73 CD N
in IN N
group NN N
D NNP N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.26-2.04 NN N
) ) N
. . N

Most JJS N
cases NNS N
initially RB N
experienced VBD N
bleeding NN o
in IN N
the DT N
first JJ N
3 CD N
months NNS N
but CC N
such JJ N
initiation NN o
was VBD N
a DT N
bit NN N
later RB N
in IN N
group NN N
C. NNP N
Endometrium NNP o
, , N
as IN N
detected VBN N
by IN N
B-mode NNP N
ultrasound NN N
, , N
increased VBD N
approximately RB N
1 CD N
mm NNS N
in IN N
HT NNP N
groups NNS N
, , N
while IN N
it PRP N
was VBD N
a DT N
bit NN N
thicker NN N
in IN N
group NN N
C. NNP N
Long NNP N
periods NNS N
in IN N
reproductive JJ N
age NN N
and CC N
short JJ N
time NN N
since IN N
menopause NN N
were VBD N
high JJ N
risk NN N
factors NNS N
for IN N
irregular JJ o
bleeding NN o
. . o

CONCLUSION NNP N
Profiles NNP N
of IN N
irregular JJ o
bleeding NN o
in IN N
3 CD N
commonly RB N
used JJ N
types NNS N
of IN N
low-dose JJ i
HT NNP i
are VBP N
different JJ N
and CC N
some DT N
factors NNS N
such JJ N
as IN N
long JJ N
period NN N
in IN N
reproductive JJ N
age NN N
and CC N
short JJ N
time NN N
since IN N
menopause NN N
may MD N
contribute VB N
to TO N
bleeding VBG N
initiation NN N
. . N

-DOCSTART- -25441055- O O

Does NNP N
cognition NN N
predict VB N
treatment NN N
response NN N
and CC N
remission NN N
in IN N
psychotherapy NN i
for IN N
late-life JJ p
depression NN p
? . N
OBJECTIVES UH N
To TO N
identify VB N
cognitive JJ N
predictors NNS N
of IN N
geriatric JJ p
depression NN p
treatment NN N
outcome NN N
. . N

METHOD NNP N
Older JJR p
participants NNS p
completed VBD p
baseline JJ p
measures NNS p
of IN p
memory NN p
and CC p
executive NN p
function NN p
, , p
health NN p
, , p
and CC p
baseline NN p
and CC p
post-treatment JJ p
Hamilton NNP p
Depression NNP p
Scales NNP p
( ( p
HAM-D NNP p
) ) p
in IN p
a DT p
12-week JJ p
trial NN p
comparing VBG p
psychotherapies NNS i
( ( i
problem-solving JJ i
vs. FW i
supportive NN i
; : i
N NNP p
= NNP p
46 CD p
) ) p
. . p

We PRP N
examined VBD N
cognitive JJ N
predictors NNS N
to TO N
identify VB N
treatment NN N
responders NNS N
( ( N
i.e. JJ N
, , N
HAM-D JJ o
scores NNS o
reduced VBN N
by IN N
?50 NNP N
% NN N
) ) N
and CC N
remitters NNS N
( ( N
i.e. JJ N
, , N
post-treatment JJ N
HAM-D NNP N
score NN N
?10 NN N
) ) N
. . N

RESULTS NNP N
Empirically NNP N
derived VBD N
decision NN N
trees NNS N
identified VBN N
poorer JJR N
performance NN o
on IN o
switching VBG o
( ( N
i.e. FW N
, , N
Trails NNP N
B NNP N
) ) N
, , N
with IN N
a DT N
cut-score NN N
of IN N
?82 NNP N
predicting VBG N
psychotherapy NN i
responders NNS i
. . N

No DT N
other JJ N
cognitive NN N
or CC N
health NN N
variables NNS N
predicted VBD N
psychotherapy NN o
outcomes NNS o
in IN N
the DT N
decision NN N
trees NNS N
. . N

CONCLUSIONS NNP i
Psychotherapies NNPS i
that WDT i
support NN i
or CC N
improve VB o
the DT o
executive NN o
skill NN o
of IN o
switching VBG N
may MD N
augment VB N
treatment NN N
response NN N
for IN p
older JJR p
patients NNS p
exhibiting VBG p
executive JJ o
dysfunction NN o
in IN o
depression NN o
. . o

If IN o
replicated VBN o
, , N
Trails NNP N
B NNP N
has VBZ N
potential JJ N
as IN N
a DT N
brief JJ N
cognitive JJ N
tool NN N
for IN N
clinical JJ N
decision-making NN p
in IN p
geriatric JJ p
depression NN p
. . p

-DOCSTART- -11691528- O O

Carotid NNP N
sinus CC N
syndrome NN N
: : N
a DT N
modifiable JJ N
risk NN N
factor NN N
for IN N
nonaccidental JJ o
falls NNS o
in IN p
older JJR p
adults NNS p
( ( N
SAFE NNP N
PACE NNP N
) ) N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
cardiac JJ i
pacing NN i
reduces NNS N
falls VBZ o
in IN N
older JJR p
adults NNS p
with IN p
cardioinhibitory JJ p
carotid NNS p
sinus VBP p
hypersensitivity NN p
( ( p
CSH NNP p
) ) p
. . p

BACKGROUND NNP N
Cardioinhibitory NNP N
carotid NN N
sinus NN N
syndrome JJ N
causes NNS N
syncope NN p
, , N
and CC N
symptoms NNS N
respond NN N
to TO N
cardiac VB i
pacing NN i
. . i

There EX N
is VBZ N
circumstantial JJ N
evidence NN N
for IN N
an DT N
association NN N
between IN N
falls NNS o
and CC N
the DT N
syndrome NN N
. . N

METHODS NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
done VBN N
of IN N
consecutive JJ p
older JJR p
patients NNS p
( ( p
> JJ p
50 CD p
years NNS p
) ) p
attending VBG p
an DT p
accident NN p
and CC p
emergency NN p
facility NN p
because IN p
of IN p
a DT p
non-accidental JJ o
fall NN o
. . o

Patients NNS N
were VBD N
randomized VBN N
to TO N
dual-chamber VB i
pacemaker NN i
implant NN i
( ( i
paced JJ i
patients NNS i
) ) i
or CC N
standard JJ i
treatment NN i
( ( i
controls NNS i
) ) i
. . i

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
number NN o
of IN o
falls NNS o
during IN o
one CD o
year NN o
of IN o
follow-up NN o
. . o

RESULTS NNP N
One CD p
hundred VBD p
seventy-five JJ p
eligible JJ p
patients NNS p
( ( p
mean JJ p
age NN p
73 CD p
+/- JJ p
10 CD p
years NNS p
; : p
60 CD p
% NN p
women NNS p
) ) p
were VBD p
randomized VBN p
to TO p
the DT p
trial NN p
: : p
pacemaker NN i
87 CD p
; : p
controls NNS i
88 CD p
. . p

Falls NNP o
( ( o
without IN o
loss NN o
of IN o
consciousness NN o
) ) o
were VBD N
reduced VBN N
by IN N
two-thirds NNS N
: : N
controls NNS N
reported VBD N
669 CD N
falls NNS N
( ( N
mean JJ N
9.3 CD N
; : N
range NN N
0 CD N
to TO N
89 CD N
) ) N
, , N
and CC N
paced VBD N
patients NNS N
216 CD N
falls NNS N
( ( N
mean JJ N
4.1 CD N
; : N
range NN N
0 CD N
to TO N
29 CD N
) ) N
. . N

Thus RB N
, , N
paced VBD N
patients NNS N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
fall VB o
( ( N
odds NNS N
ratio VBP N
0.42 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
0.23 CD N
, , N
0.75 CD N
) ) N
than IN N
were VBD N
controls NNS N
. . N

Syncopal JJ o
events NNS o
were VBD N
also RB N
reduced VBN N
during IN N
the DT N
follow-up JJ N
period NN N
, , N
but CC N
there EX N
were VBD N
much RB N
fewer JJR N
syncopal JJ o
events NNS o
than IN N
falls-28 JJ o
episodes NNS N
in IN N
paced JJ N
patients NNS N
and CC N
47 CD N
in IN N
controls NNS N
. . N

Injurious JJ o
events NNS o
were VBD N
reduced VBN N
by IN N
70 CD N
% NN N
( ( N
202 CD N
in IN N
controls NNS N
compared VBN N
to TO N
61 CD N
in IN N
paced JJ N
patients NNS N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
a DT N
strong JJ N
association NN N
between IN N
non-accidental JJ o
falls NNS N
and CC N
cardioinhibitory NN N
CSH NNP N
. . N

These DT N
patients NNS N
would MD N
not RB N
usually RB N
be VB N
referred VBN N
for IN N
cardiovascular JJ N
assessment NN N
. . N

Carotid NNP N
sinus JJ N
hypersensitivity NN N
should MD N
be VB N
considered VBN N
in IN N
all DT N
older JJR p
adults NNS p
who WP p
have VBP p
non-accidental JJ p
falls NNS p
. . p

-DOCSTART- -22735897- O O

Randomized VBN N
controlled JJ N
trial NN N
: : N
Multimodal NNP i
Anxiety NNP i
and CC i
Social NNP i
Skill NNP i
Intervention NNP i
for IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Anxiety NN p
is VBZ p
common JJ p
among IN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC N
may MD N
amplify VB N
the DT N
core NN N
social JJ N
disability NN N
, , N
thus RB N
necessitating VBG N
combined VBN N
treatment NN N
approaches NNS N
. . N

This DT N
pilot NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
evaluated VBD N
the DT N
feasibility NN o
and CC N
preliminary JJ o
outcomes NNS o
of IN N
the DT N
Multimodal NNP i
Anxiety NNP i
and CC i
Social NNP i
Skills NNP i
Intervention NNP i
( ( i
MASSI NNP i
) ) i
program NN i
in IN p
a DT p
sample NN p
of IN p
30 CD p
adolescents NNS p
with IN p
ASD NNP p
and CC p
anxiety NN p
symptoms NNS p
of IN p
moderate JJ p
or CC p
greater JJR p
severity NN p
. . p

The DT N
treatment NN N
was VBD N
acceptable JJ N
to TO N
families NNS N
, , N
subject JJ o
adherence NN o
was VBD N
high JJ N
, , N
and CC N
therapist JJ o
fidelity NN o
was VBD N
high JJ N
. . N

A DT N
16 CD N
% NN N
improvement NN N
in IN N
ASD NNP o
social JJ o
impairment NN o
( ( N
within-group JJ N
effect NN N
size NN N
= NNP N
1.18 CD N
) ) N
was VBD N
observed VBN N
on IN N
a DT N
parent-reported JJ N
scale NN N
. . N

Although IN N
anxiety NN o
symptoms NNS o
declined VBD N
by IN N
26 CD N
% NN N
, , N
the DT N
change NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

These DT N
findings NNS N
suggest VBP N
MASSI NNP i
is VBZ N
a DT N
feasible JJ o
treatment NN N
program NN N
and CC N
further JJ N
evaluation NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -22818151- O O

[ NNS p
Localised VBN p
prostate JJ p
cancer NN p
: : p
the DT N
PREFERE NNP N
trial NN N
] NNP N
. . N

Prostate NNP N
cancer NN N
is VBZ N
the DT N
most RBS N
common JJ N
carcinoma NN p
of IN p
the DT p
elderly JJ p
man NN p
and CC N
holds VBZ N
the DT N
third JJ N
place NN N
in IN N
the DT N
ranking NN N
of IN N
cancer-specific JJ o
mortality NN o
. . o

However RB N
, , N
mortality NN o
rates NNS o
of IN N
3 CD N
% NN N
are VBP N
low JJ N
, , N
and CC N
half NN N
of IN N
the DT N
patients NNS N
will MD N
die VB N
from IN N
intercurrent JJ N
disease NN N
. . N

Due NNP N
to TO N
the DT N
significantly RB N
improved VBN N
diagnostic JJ N
methods NNS N
and CC N
the DT N
increasing VBG N
use NN N
of IN N
PSA NNP N
screening NN N
, , N
there EX N
has VBZ N
been VBN N
a DT N
stage NN N
migration NN N
towards NNS N
early RB N
tumour VBP N
stages NNS N
that WDT N
are VBP N
prognostically RB N
heterogeneous JJ N
and CC N
require NN N
differentiated VBN N
treatment NN N
. . N

Based VBN N
on IN N
the DT N
discussions NNS N
of IN N
the DT N
Joint NNP N
Federal NNP N
Committee NNP N
( ( N
G-BA NNP N
) ) N
and CC N
the DT N
conceptual JJ N
work NN N
of IN N
the DT N
MDS NNP N
, , N
the DT N
Competence NNP N
Centre NNP N
Oncology NNP N
of IN N
the DT N
MDK NNP N
, , N
the DT N
IQWIG NNP N
and CC N
the DT N
National NNP N
Association NNP N
of IN N
Statutory NNP N
Health NNP N
Insurance NNP N
Funds NNP N
( ( N
GKV-Spitzenverband NNP N
) ) N
, , N
a DT N
prospective JJ N
randomised VBN N
multicentre JJ N
trial NN N
was VBD N
developed VBN N
comparing VBG N
the DT N
four CD N
treatments NNS N
actually RB N
recommended VBN N
by IN N
the DT N
German JJ N
and CC N
European JJ N
guidelines NNS N
for IN N
localised JJ N
prostate NN N
cancer NN N
( ( o
radical JJ o
prostatectomy NN o
, , o
percutaneous JJ o
radiotherapy NN o
and CC o
permanent JJ o
seed NN o
implantation NN o
and CC o
active JJ o
surveillance NN o
) ) o
allowing VBG N
a DT N
rejection NN N
of IN N
one CD N
or CC N
two CD N
treatment NN N
options NNS N
. . N

The DT N
trial NN N
is VBZ N
expected VBN N
to TO N
start VB N
at IN N
the DT N
beginning NN N
of IN N
next JJ N
year NN N
. . N

-DOCSTART- -18618513- O O

Randomized VBN N
trial NN N
of IN N
a DT N
decision NN N
aid NN N
for IN N
individuals NNS p
considering VBG p
genetic JJ p
testing NN p
for IN p
hereditary JJ p
nonpolyposis NN p
colorectal NN p
cancer NN p
risk NN p
. . p

BACKGROUND NNP N
Despite IN N
the DT N
potential JJ N
benefits NNS N
of IN N
genetic JJ N
testing VBG N
for IN N
hereditary JJ N
nonpolyposis NN N
colorectal NN N
cancer NN N
( ( N
HNPCC NNP N
) ) N
risk NN N
, , N
individuals NNS N
can MD N
find VB N
the DT N
genetic JJ N
testing VBG N
decision-making JJ N
process NN N
complicated VBN N
and CC N
challenging VBG N
. . N

The DT N
goal NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
measure VB N
the DT N
effectiveness NN o
of IN o
a DT o
tailored JJ o
decision NN o
aid NN o
designed VBN N
specifically RB N
to TO N
assist VB N
individuals NNS N
to TO N
make VB N
informed JJ N
decisions NNS N
regarding VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
risk NN N
. . N

METHODS NNP N
In IN N
all DT N
, , N
153 CD p
individuals NNS p
were VBD N
randomized VBN N
to TO N
receive VB i
the DT i
decision NN i
aid NN i
or CC i
a DT i
control JJ i
pamphlet NN i
at IN i
the DT i
end NN i
of IN i
their PRP$ i
first JJ i
genetic JJ i
counseling NN i
consultation NN i
. . i

Of IN N
these DT N
, , N
109 CD N
( ( N
71.2 CD N
% NN N
) ) N
completed VBD N
the DT N
first JJ N
questionnaire NN o
1 CD N
week NN N
after IN N
consultation NN N
, , N
whereas IN N
95 CD N
( ( N
62.1 CD N
% NN N
) ) N
completed VBD N
the DT N
6-month JJ N
follow-up JJ o
questionnaire NN o
. . o

RESULTS CC N
Although IN N
the DT N
decision NN N
aid NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
postdecisional JJ N
regret NN N
or CC N
actual JJ N
genetic JJ N
testing VBG N
decision NN N
, , N
the DT N
trial NN N
results NNS N
demonstrated VBD N
that IN N
participants NNS N
who WP N
received VBD N
the DT N
decision NN i
aid NN i
had VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
decisional JJ o
conflict NN o
( ( o
ie JJ o
, , o
uncertainty NN o
) ) o
regarding VBG N
genetic JJ o
testing NN o
( ( N
chi-square JJ N
( ( N
1 CD N
) ) N
= NN N
8.97 CD N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
classified VBN N
as IN N
having VBG N
made VBN N
an DT N
informed JJ o
choice NN o
concerning VBG N
genetic JJ N
testing NN N
( ( N
chi-square JJ N
( ( N
1 CD N
) ) N
= NN N
4.37 CD N
; : N
P NNP N
= NNP N
.037 NNP N
) ) N
than IN N
participants NNS N
who WP N
received VBD N
a DT N
control NN i
pamphlet NN i
. . i

Also RB N
, , N
men NNS N
who WP N
received VBD N
the DT N
decision NN i
aid NN i
had VBD N
significantly RB N
higher JJR o
knowledge NN o
levels NNS o
regarding VBG N
genetic JJ N
testing NN N
compared VBN N
with IN N
men NNS p
who WP N
received VBD N
the DT N
control NN i
pamphlet NN i
, , N
whereas JJ N
no DT N
such JJ N
differences NNS N
were VBD N
found VBN N
for IN N
women NNS p
( ( N
chi-square NN N
( ( N
2 CD N
) ) N
= NN N
6.76 CD N
; : N
P NNP N
= NNP N
.034 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
decision NN i
aid NN i
for IN N
individuals NNS N
considering VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
is VBZ N
an DT N
effective JJ N
intervention NN N
to TO N
reduce VB N
uncertainty NN N
and CC N
assist JJ N
individuals NNS N
to TO N
make VB N
an DT N
informed JJ N
choice NN N
regarding VBG N
genetic JJ N
testing NN N
for IN N
HNPCC NNP N
after IN N
genetic JJ N
counseling NN N
. . N

-DOCSTART- -15189781- O O

Effect NN N
of IN N
simvastatin NN i
and CC i
fenofibrate NN i
on IN N
endothelium NN N
in IN N
Type NNP p
2 CD p
diabetes NNS p
. . p

Statins NNS N
and CC N
fibrates NNS N
influence VBP N
endothelial JJ N
activity NN N
and CC N
consequently RB N
atherogenesis NN N
but CC N
the DT N
mechanisms NNS N
are VBP N
not RB N
well RB N
understood RB N
. . N

Twenty NNP p
Type NNP p
2 CD p
diabetic JJ p
patients NNS p
with IN p
dyslipidemia NN p
were VBD p
treated VBN p
3 CD N
months NNS N
with IN N
simvastatin NN i
( ( N
20 CD N
mg NNS N
daily RB N
) ) N
and CC N
then RB N
3 CD N
months NNS N
with IN N
fenofibrate NN i
( ( N
200 CD N
mg NNS N
daily RB N
) ) N
with IN N
2 CD N
months NNS N
of IN N
wash-out NN N
between IN N
the DT N
two CD N
treatments NNS N
. . N

Laboratory JJ N
parameters NNS N
of IN N
oxidative JJ N
stress NN N
, , N
fibrinolysis NN N
and CC N
endothelial JJ N
function NN N
were VBD N
evaluated VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
each DT N
treatment NN N
period NN N
. . N

The DT N
significant JJ N
decrease NN N
in IN N
serum JJ o
total JJ o
and CC o
LDL-cholesterol JJ o
concentrations NNS o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
caused VBN N
by IN N
simvastatin NN N
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
serum JJ o
N-acetyl-beta-glucosaminidase JJ o
activity NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
ascorbic JJ o
acid NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
plasminogen JJ o
activator NN o
inhibitor NN o
( ( N
PAI-1 NNP N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
vonWillebrand FW o
factor NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
E-selectin NNP o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
vascular JJ o
endothelial JJ o
growth NN o
factor NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
concentrations NNS N
and CC N
with IN N
a DT N
decrease NN o
in IN o
plasma NN o
glutathione NN o
( ( o
P NNP o
< NNP o
0.01 CD o
) ) o
levels NNS o
. . o

Fenofibrate NNP N
caused VBD N
a DT N
significant JJ N
decrease NN N
in IN N
serum JJ o
triglyceride JJ o
concentration NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
plasma NN o
malondialdehyde NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
an DT N
increase NN o
in IN o
plasma JJ o
PAI-1 NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
P-selectin NNP o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
concentrations NNS N
. . N

We PRP N
conclude VBP N
that IN N
simvastatin NN N
and CC N
fenofibrate NN N
interact NN N
, , N
by IN N
different JJ N
mechanisms NNS N
, , N
with IN N
oxidative JJ N
stress NN N
, , N
a DT N
key JJ N
factor NN N
in IN N
the DT N
modification NN N
of IN N
fibrinolysis NN N
and CC N
endothelial JJ N
function NN N
in IN N
Type NNP N
2 CD N
diabetes NNS N
. . N

-DOCSTART- -2180462- O O

Comparative JJ N
evaluation NN N
of IN N
cefotaxime NN i
and CC i
cephamandole NN i
in IN N
the DT N
prevention NN N
of IN N
post-operative JJ o
infective JJ o
complications NNS o
following VBG p
emergency NN p
abdominal JJ i
surgery NN i
. . i

In IN N
previous JJ N
published VBN N
work NN N
we PRP N
described VBD N
57 CD p
patients NNS p
undergoing JJ p
emergency NN i
abdominal JJ i
surgery NN i
, , p
prospectively RB p
randomised VBN N
to TO N
receive VB N
either DT N
cefotaxime NN i
or CC i
cephamandole NN i
as IN N
a DT N
single-antibiotic JJ N
, , N
three-dose JJ N
, , N
peri-operative JJ N
prophylaxis NN N
against IN N
post-operative JJ N
infective JJ N
complications NNS N
. . N

This DT N
earlier JJR N
work NN N
suggested VBD N
that IN N
cefotaxime NN i
might MD N
be VB N
more RBR N
effective JJ N
than IN N
cephamandole NN i
in IN N
preventing VBG N
wound JJ N
sepsis NN N
in IN N
emergency NN N
abdominal JJ N
surgery NN N
. . N

We PRP N
describe VBP N
here RB N
our PRP$ N
findings NNS N
in IN N
a DT p
further JJ p
63 CD p
patients NNS p
undergoing JJ p
emergency NN i
abdominal JJ i
surgery NN i
who WP N
were VBD N
similarly RB N
allocated VBN N
into IN N
either CC N
a DT N
cefotaxime NN i
or CC N
cephamandole JJ i
antibiotic JJ N
group NN N
. . N

Infective JJ o
complications NNS o
occurred VBD N
in IN N
12/32 CD N
( ( N
37 CD N
per IN N
cent NN N
) ) N
of IN N
the DT N
cefotaxime NN i
group NN N
and CC N
15/31 CD N
( ( N
48 CD N
per IN N
cent NN N
) ) N
of IN N
the DT N
cephamandole NN i
group NN N
. . N

Wound IN o
infections NNS o
occurred VBD N
in IN N
5/32 CD N
( ( N
16 CD N
per IN N
cent NN N
) ) N
of IN N
the DT N
cefotaxime NN i
group NN N
and CC N
9/31 CD N
( ( N
29 CD N
per IN N
cent NN N
) ) N
of IN N
the DT N
cephamandole NN i
group NN N
. . N

The DT N
organisms NNS N
cultured VBD N
and CC N
their PRP$ N
sensitivities NNS N
are VBP N
discussed VBN N
in IN N
detail NN N
. . N

The DT p
total NN p
of IN p
120 CD p
patients NNS p
studied VBN p
in IN N
the DT N
two CD N
series NN N
showed VBD N
wound JJ o
infection NN o
to TO N
occur VB N
in IN N
13 CD N
per IN N
cent NN N
of IN N
the DT N
62 CD N
patients NNS N
receiving VBG N
cefotaxime NN i
and CC N
30 CD N
per IN N
cent NN N
of IN N
the DT N
58 CD N
patients NNS N
receiving VBG N
cephamandole NN i
. . i

This DT N
difference NN N
reaches VBZ N
statistical JJ N
significance NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Possible JJ N
mechanisms NN N
to TO N
explain VB N
this DT N
finding NN N
are VBP N
discussed VBN N
. . N

Again NNP N
we PRP N
found VBD N
the DT N
regime NN N
of IN N
4 CD N
g NN N
of IN N
cefotaxime JJ i
given VBN N
peri-operatively RB N
to TO N
be VB N
a DT N
simple JJ o
, , o
safe JJ o
and CC o
effective JJ o
single JJ o
agent NN o
as IN o
prophylaxis NN o
for IN o
emergency NN o
abdominal JJ o
surgery NN o
. . o

-DOCSTART- -25193142- O O

Parent NN p
and CC p
family NN p
outcomes NNS p
of IN p
PEERS NNS i
: : i
a DT p
social JJ i
skills NNS i
intervention NN i
for IN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Raising VBG N
a DT N
child NN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
is VBZ N
associated VBN N
with IN N
increased VBN N
family NN p
chaos NN N
and CC N
parent NN p
distress NN N
. . N

Successful JJ N
long-term JJ N
treatment NN N
outcomes NNS N
are VBP N
dependent JJ N
on IN N
healthy JJ N
systemic JJ N
functioning NN N
, , N
but CC N
the DT N
family NN o
impact NN o
of IN o
treatment NN o
is VBZ N
rarely RB N
evaluated VBN N
. . N

The DT i
Program NNP i
for IN i
the DT i
Education NNP i
and CC i
Enrichment NNP i
of IN i
Relational NNP i
Skills NNP i
( ( i
PEERS NNP i
) ) i
is VBZ N
a DT N
social JJ N
skills NNS N
intervention NN N
designed VBN N
for IN N
adolescents NNS p
with IN p
high-functioning JJ p
ASD NNP p
. . p

This DT N
study NN N
assessed VBD N
the DT N
impact NN N
of IN N
PEERS NNS o
on IN N
family NN o
chaos NN o
, , o
parenting VBG o
stress NN o
, , o
and CC o
parenting VBG o
self-efficacy NN o
via IN N
a DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Results NNP N
suggested VBD N
beneficial JJ N
effects NNS N
for IN N
the DT N
experimental JJ N
group NN N
in IN N
the DT N
domain NN N
of IN N
family NN o
chaos NN o
compared VBN N
to TO N
the DT N
waitlist NN N
control NN N
, , N
while IN N
parents NNS p
in IN p
the DT p
PEERS NNP i
experimental JJ p
group NN p
also RB N
demonstrated VBD N
increased JJ N
parenting VBG o
self-efficacy NN o
. . o

These DT N
findings NNS N
highlight VBD N
adjunctive JJ N
family NN N
system NN N
benefits NNS N
of IN N
PEERS NNP i
intervention NN i
and CC N
suggest VBP N
the DT N
need NN N
for IN N
overall JJ N
better JJR N
understanding NN N
of IN N
parent NN N
and CC N
family NN N
outcomes NNS N
of IN N
ASD NNP N
interventions NNS N
. . N

-DOCSTART- -9833745- O O

Mexiletine NN i
for IN N
HIV-infected JJ p
patients NNS p
with IN p
painful JJ p
peripheral JJ p
neuropathy NN p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
treatment NN N
trial NN N
. . N

Although IN N
mexiletine NN i
, , N
an DT N
antiarrhythmic JJ N
with IN N
local JJ N
anesthetic JJ N
properties NNS N
, , N
has VBZ N
been VBN N
reported VBN N
to TO N
relieve VB N
discomfort NN N
in IN N
diabetic JJ N
neuropathy NN N
, , N
its PRP$ N
usefulness NN N
in IN N
the DT N
treatment NN N
of IN N
HIV-related NNP p
painful JJ p
peripheral JJ p
neuropathy NN p
( ( p
PPN NNP p
) ) p
has VBZ N
not RB N
been VBN N
determined VBN N
. . N

The DT N
tolerance NN o
and CC o
effectiveness NN o
of IN N
mexiletine NN i
in IN N
HIV-related JJ N
PPN NNP N
were VBD N
assessed VBN N
in IN N
22 CD p
patients NNS p
who WP N
were VBD N
randomized VBN N
to TO N
receive VB i
mexiletine NN i
( ( i
maximum JJ i
dose NN i
, , i
600 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
for IN i
6 CD i
weeks NNS i
, , i
followed VBN i
by IN i
the DT i
alternative JJ i
intervention NN i
for IN i
6 CD i
weeks NNS i
after IN i
a DT i
1-week JJ i
washout NN i
period NN i
. . i

The DT N
daily JJ o
pain NN o
response NN o
was VBD o
assessed VBN o
using VBG o
a DT o
visual JJ o
analogue NN o
scale NN o
card NN o
in IN i
19 CD i
patients NNS i
who WP i
received VBD i
at IN i
least JJS i
2 CD i
weeks NNS i
of IN i
the DT i
drug NN i
, , i
16 CD i
of IN i
whom WP i
were VBD i
crossed-over RB i
to TO i
receive VB i
the DT i
alternate NN i
agent NN i
. . i

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
mean JJ o
daily JJ o
pain NN o
scores NNS o
for IN N
patients NNS N
receiving VBG N
mexiletine JJ i
versus NN N
placebo NN N
, , N
irrespective NN N
of IN N
the DT N
order NN N
in IN N
which WDT N
the DT N
agents NNS N
were VBD N
received VBN N
. . N

Comparing VBG N
the DT N
mean JJ o
individual JJ o
daily RB o
pain NN o
scores NNS o
for IN N
each DT N
phase NN N
of IN N
study NN N
, , N
5 CD N
patients NNS N
( ( N
31 CD N
% NN N
) ) N
had VBD N
significantly RB N
less RBR N
pain RB o
while IN N
receiving VBG N
mexiletine NN i
compared VBN N
with IN N
their PRP$ N
response NN N
to TO N
placebo VB i
, , N
5 CD N
patients NNS N
( ( N
31 CD N
% NN N
) ) N
had VBD N
significantly RB N
less RBR N
pain RB o
while IN N
receiving VBG N
placebo NN i
, , N
and CC N
no DT N
difference NN N
was VBD N
noted VBN N
in IN N
6 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
. . N

Crossover NNP o
and CC o
multivariate NN o
analyses NNS o
for IN N
repeated VBN N
measures NNS N
showed VBD N
no DT N
apparent JJ N
difference NN N
in IN N
the DT N
response NN N
to TO N
mexiletine VB i
versus NN N
placebo NN i
. . i

Dose-limiting JJ o
adverse JJ o
events NNS o
occurred VBD N
in IN N
39 CD N
% NN N
of IN N
those DT N
receiving VBG N
mexiletine NN i
, , N
but CC N
only RB N
1 CD N
patient NN N
( ( N
5 CD N
% NN N
) ) N
discontinued VBN N
placebo NN i
. . i

Mexiletine NNP i
was VBD N
only RB N
modestly RB N
well RB N
tolerated VBN N
despite IN N
its PRP$ N
relatively RB N
brief JJ N
period NN N
of IN N
administration NN N
, , N
and CC N
no DT N
evidence NN N
was VBD N
found VBN N
to TO N
support VB N
its PRP$ N
benefit NN N
in IN N
HIV-related NNP N
PPN NNP N
. . N

Although IN N
a DT N
first-drug JJ N
effect NN N
was VBD N
not RB N
demonstrated VBN N
, , N
a DT N
powerful JJ N
placebo NN N
effect NN N
was VBD N
seen VBN N
in IN N
some DT N
patients NNS N
. . N

-DOCSTART- -9261669- O O

High-dose JJ i
pyridoxine NN i
and CC i
magnesium NN i
administration NN i
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
: : p
an DT N
absence NN N
of IN N
salutary JJ N
effects NNS N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Several JJ N
reports NNS N
have VBP N
described VBN N
salutary JJ N
effects NNS N
such JJ N
as IN N
decreased JJ N
physical JJ N
aggression NN N
and CC N
improved VBN N
social JJ N
responsiveness NN N
being VBG N
associated VBN N
with IN N
the DT N
administration NN N
of IN N
high JJ N
doses NNS N
of IN N
pyridoxine NN i
and CC i
magnesium NN i
( ( i
HDPM NNP i
) ) i
in IN N
open-labeled JJ N
and CC N
controlled JJ N
studies NNS N
of IN N
patients NNS p
with IN p
autism NN p
. . p

Despite IN N
this DT N
fact NN N
, , N
this DT N
intervention NN N
remains VBZ N
controversial JJ N
. . N

A DT N
10-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
examine VB N
both DT N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
HDPM NNP i
in IN N
autism NN N
. . N

Twelve CD p
patients NNS p
were VBD p
enrolled VBN p
, , p
and CC p
10 CD p
patients NNS p
( ( p
mean JJ p
age NN p
6 CD p
years NNS p
3 CD p
months NNS p
) ) p
were VBD p
able JJ p
to TO p
complete VB p
the DT p
study NN p
. . p

HDPM NNP i
at IN N
an DT N
average JJ N
dose NN N
of IN N
638.9 CD N
mg NN N
of IN N
pyridoxine NN i
and CC N
216.3 CD N
mg NN N
of IN N
magnesium NN i
oxide NN i
was VBD N
ineffective JJ N
in IN N
ameliorating VBG o
autistic JJ o
behaviors NNS o
as IN N
assessed VBN N
by IN N
the DT N
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
CPRS NNP o
) ) o
, , o
the DT o
Clinical NNP o
Global NNP o
Impression NNP o
Scale NNP o
, , o
and CC o
the DT o
NIMH NNP o
Global NNP o
Obsessive NNP o
Compulsive NNP o
Scale NNP o
. . o

Furthermore NNP N
, , N
no DT N
clinically RB N
significant JJ N
side NN N
effects NNS N
were VBD N
noted VBN N
during IN N
HDPM NNP i
administration NN N
. . N

A DT N
trend NN N
for IN N
a DT N
transient JJ N
change NN N
on IN N
the DT N
CPRS NNP N
was VBD N
found VBN N
that IN N
was VBD N
possibly RB N
due JJ N
to TO N
a DT N
placebo NN N
response NN N
. . N

This DT N
study NN N
raises VBZ N
doubts NNS N
about IN N
the DT N
clinical JJ N
effectiveness NN N
of IN N
HDPM NNP i
in IN N
autistic JJ N
disorder NN N
. . N

-DOCSTART- -12614412- O O

Ambulatory NNP i
phlebectomy NN i
versus NN N
compression NN i
sclerotherapy NN i
: : i
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
no DT N
randomized VBN N
controlled VBN N
trial NN N
has VBZ N
assessed VBN N
the DT N
effects NNS N
of IN N
either DT N
compression NN i
sclerotherapy NN i
or CC N
ambulatory JJ i
phlebectomy NN i
, , N
both DT N
techniques NNS N
are VBP N
used VBN N
to TO N
treat VB N
varicose JJ N
veins NNS N
worldwide RB N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
compare VB N
recurrence NN N
rates NNS N
of IN N
varicose JJ N
veins NNS N
and CC N
complications NNS N
after IN N
compression NN i
sclerotherapy NN i
and CC N
ambulatory JJ i
phlebectomy NN i
. . i

METHODS NNP N
From IN N
September NNP p
1996 CD p
to TO p
October NNP p
1998 CD p
, , p
we PRP p
randomly RB p
allocated VBD p
49 CD p
legs NNS p
to TO p
compression VB i
sclerotherapy NN i
and CC p
49 CD p
legs NNS p
to TO p
ambulatory JJ i
phlebectomy NN i
. . i

Our PRP$ N
primary JJ N
outcome NN N
parameters NNS N
were VBD N
as IN N
follows VBZ N
: : N
recurrence NN N
rates NNS N
at IN N
1 CD N
and CC N
2 CD N
years NNS N
and CC N
complications NNS N
related VBN N
to TO N
therapy VB N
. . N

Eighty-two JJ p
patients NNS p
were VBD p
included VBN p
, , p
of IN p
whom WP p
16 CD p
were VBD p
included VBN p
with IN p
both DT p
of IN p
their PRP$ p
legs NNS p
. . p

The DT p
number NN p
of IN p
treated JJ p
legs NN p
was VBD p
therefore RB p
98 CD p
, , N
but CC N
two CD p
patients NNS p
were VBD N
lost VBN N
to TO N
follow-up JJ N
. . N

RESULTS VB N
One CD o
year NN o
recurrence NN o
amounted VBD N
to TO N
1 CD N
out IN N
of IN N
48 CD N
for IN N
phlebectomy NN i
and CC N
12 CD N
out IN N
of IN N
48 CD N
for IN N
compression NN i
sclerotherapy NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
at IN N
2 CD N
years NNS N
, , N
six CD N
additional JJ N
recurrences NNS o
were VBD N
found VBN N
, , N
but CC N
then RB N
solely RB N
for IN N
compression NN i
sclerotherapy NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
differences NNS N
in IN N
complications NNS N
occurring VBG N
more RBR N
in IN N
phlebectomy NN N
than IN N
in IN N
compression NN i
sclerotherapy NN i
therapy NN N
were VBD N
blisters NNS o
, , o
teleangiectatic JJ o
matting NN o
, , o
scar NN o
formation NN o
, , o
and CC o
bruising VBG o
from IN o
bandaging VBG o
. . o

CONCLUSION NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
ambulatory JJ i
phlebectomy NN i
is VBZ N
an DT N
effective JJ N
therapy NN N
for IN N
varicose JJ N
veins NNS N
of IN N
the DT N
leg NN N
. . N

Recurrence NN N
rates NNS N
are VBP N
significantly RB N
lower JJR N
than IN N
for IN N
compression NN i
sclerotherapy NN i
therapy NN i
. . i

If IN N
varicose JJ N
veins NNS N
persist VBP N
4 CD N
weeks NNS N
after IN N
compression NN i
sclerotherapy NN i
, , N
it PRP N
can MD N
be VB N
argued VBN N
that IN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
future JJ N
recurrence NN N
ambulatory JJ i
phlebectomy NN i
should MD N
be VB N
considered VBN N
as IN N
the DT N
better JJR N
treatment NN N
option NN N
. . N

-DOCSTART- -16752282- O O

Different JJ o
loss NN o
of IN o
BMD NNP o
using VBG N
uncemented JJ i
press-fit NN i
and CC i
whole JJ i
polyethylene NN i
cups NNS i
fixed VBN i
with IN i
cement NN i
: : i
repeated VBN N
DXA NNP N
studies NNS N
in IN N
96 CD p
hips NNS p
randomized VBN p
to TO p
3 CD p
types NNS p
of IN p
fixation NN p
. . p

BACKGROUND NNP N
In IN N
cemented JJ N
THA NNP N
, , N
aseptic JJ N
loosening NN N
of IN N
the DT N
cup NN N
is VBZ N
more RBR N
common JJ N
than IN N
loosening NN N
of IN N
the DT N
stem NN N
, , N
while IN N
periprosthetic JJ N
osteolysis NN N
of IN N
the DT N
socket NN N
resulting VBG N
in IN N
difficult JJ N
reconstruction NN N
problems NNS N
has VBZ N
emerged VBN N
as IN N
the DT N
most RBS N
significant JJ N
problem NN N
with IN N
cementless JJ N
cup NN N
fixation NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
90 CD p
patients NNS p
( ( p
96 CD p
hips NNS p
) ) p
scheduled VBN p
for IN p
THA NNP p
were VBD N
stratified VBN N
in IN N
three CD N
groups NNS N
according VBG N
to TO N
the DT N
method NN N
of IN N
fixation NN N
of IN N
the DT N
acetabular JJ N
component NN N
: : N
acrylic JJ i
bone NN i
cement NN i
with IN i
fluoride NN i
( ( i
Cemex-F NNP i
) ) i
, , i
porous-coated JJ i
press-fit JJ i
cup NN i
with IN i
ceramic JJ i
coating NN i
( ( i
Trilogy NNP i
, , i
uncemented VBD i
) ) i
and CC i
acrylic JJ i
cement NN i
with IN i
gentamicin NN i
( ( i
Palacos NNP i
) ) i
. . i

All DT p
patients NNS p
received VBD p
the DT p
Spectron NNP i
EF NNP i
stem NN i
. . i

Acetabular NNP o
bone VBD o
mineral JJ o
density NN o
was VBD N
measured VBN N
with IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
( ( N
DXA NNP N
) ) N
1 CD N
week NN N
postoperatively RB N
, , N
and CC N
after IN N
12 CD N
and CC N
24 CD N
months NNS N
. . N

The DT N
periprosthetic JJ o
BMD NNP o
was VBD N
evaluated VBN N
in IN N
5 CD N
ROIs NNP N
positioned VBD N
around IN N
the DT N
acetabular JJ N
component NN N
. . N

RESULTS NNP N
In IN N
the DT N
uncemented JJ N
sockets NNS N
, , N
the DT N
BMD NNP o
had VBD N
decreased VBN N
proximally RB N
and CC N
medially RB N
to TO N
the DT N
cup NN N
after IN N
2 CD N
years NNS N
. . N

The DT N
difference NN o
was VBD N
significant JJ N
in IN N
the DT N
proximal JJ N
region NN N
as IN N
compared VBN N
to TO N
the DT N
control NN i
group NN i
( ( i
Palacos NNP i
) ) i
. . i

No DT N
difference NN o
was VBD N
noted VBN N
between IN N
the DT N
2 CD N
groups NNS N
with IN N
cemented JJ N
components NNS N
after IN N
2 CD N
years NNS N
. . N

Stepwise NN N
linear JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
loss NN N
of IN N
periprosthetic JJ N
BMD NNP o
in IN N
the DT N
proximal JJ N
high-pressure NN N
region NN N
after IN N
2 CD N
years NNS N
increased VBD N
with IN N
higher RBR N
postoperative JJ o
BMD NNP o
and CC N
when WRB N
the DT N
uncemented JJ N
design NN N
had VBD N
been VBN N
used VBN N
. . N

INTERPRETATION NNP N
Contrary NNP N
to TO N
previous JJ N
studies NNS N
of IN N
cemented JJ N
stems NNS N
, , N
the DT N
use NN N
of IN N
fluoride JJ i
cement NN i
did VBD N
not RB N
influence VB N
the DT N
periprosthetic JJ o
BMD NNP o
2 CD N
years NNS N
after IN N
the DT N
examination NN N
. . N

Increased VBN N
loss NN N
of IN N
BMD NNP o
with IN N
use NN N
of IN N
uncemented JJ N
press-fit JJ N
cups NNS N
in IN N
the DT N
region NN N
in IN N
which WDT N
osteolytic JJ N
lesions NNS N
are VBP N
commonly RB N
found VBN N
suggests VBZ N
that IN N
stress NN N
shielding NN N
may MD N
initiate VB N
the DT N
development NN N
of IN N
this DT N
complication NN N
. . N

Longer JJR N
follow-up NN N
will MD N
, , N
however RB N
, , N
be VB N
necessary JJ N
to TO N
substantiate VB N
this DT N
hypothesis NN N
. . N

-DOCSTART- -11918753- O O

Effects NNS N
of IN N
enalapril NN i
and CC i
eprosartan NN i
on IN N
the DT N
renal JJ N
vascular NN N
nitric JJ N
oxide NN N
system NN N
in IN N
human JJ p
essential JJ p
hypertension NN p
. . p

BACKGROUND NNP N
Experimental NNP N
data NNS N
in IN N
humans NNS N
on IN N
the DT N
contribution NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
and CC N
angiotensin NN N
II NNP N
type NN N
1 CD N
receptor NN N
blockers NNS N
to TO N
the DT N
nitric JJ N
oxide NN N
system NN N
of IN N
the DT N
renal JJ N
vasculature NN N
are VBP N
inconsistent JJ N
. . N

Enalapril NNP i
and CC i
eprosartan RB i
, , N
alone RB N
and CC N
in IN N
combination NN N
, , N
were VBD N
used VBN N
to TO N
determine VB N
their PRP$ N
short-term JJ N
effects NNS o
on IN N
the DT N
renal JJ N
nitric JJ N
oxide NN N
system NN N
and CC N
renal JJ N
hemodynamics NNS N
of IN N
human JJ p
subjects NNS p
with IN p
essential JJ p
hypertension NN p
. . p

METHODS NNP N
Twenty NNP p
male NN p
, , p
white JJ p
patients NNS p
( ( p
27 CD p
+/- JJ p
1 CD p
years NNS p
) ) p
with IN p
mild JJ p
essential JJ p
hypertension NN p
( ( p
143 CD p
+/- JJ p
11/95 CD p
+/- JJ p
6 CD p
mm NN p
Hg NNP p
) ) p
were VBD N
included VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
fourfold JJ N
cross-over NN N
study NN N
with IN N
placebo NN i
, , i
enalapril NN i
( ( i
20 CD i
mg/day NN i
) ) i
, , i
eprosartan FW i
( ( i
600 CD i
mg/day NN i
) ) i
, , i
or CC i
combination NN i
of IN i
both DT i
drugs NNS i
( ( N
10 CD N
and CC N
300 CD N
mg/day NN N
, , N
respectively RB N
) ) N
each DT N
over IN N
a DT N
one CD N
week NN N
period NN N
followed VBN N
by IN N
a DT N
two-week JJ N
washout NN N
phase NN N
. . N

After IN N
each DT N
study NN N
phase VBD N
the DT N
glomerular JJ o
filtration NN o
rate NN o
( ( o
GFR NNP o
) ) o
and CC o
renal JJ o
plasma NN o
flow NN o
( ( o
RPF NNP o
) ) o
were VBD N
determined VBN N
. . N

Basal NNP N
nitric JJ N
oxide JJ N
synthesis NN N
of IN N
the DT N
renal JJ o
vasculature NN o
was VBD N
assessed VBN N
by IN N
the DT N
decrease NN N
in IN N
RPF NNP o
after IN N
inhibition NN N
of IN N
nitric JJ N
oxide JJ N
synthase NN N
with IN N
NG-monomethyl-L-arginine NNP N
( ( N
L-NMMA NNP N
; : N
4.25 CD N
mg/kg NN N
) ) N
. . N

RESULTS CC N
After IN N
one CD N
week NN N
of IN N
therapy NN N
, , N
the DT N
combination NN i
therapy NN i
decreased VBD N
casual JJ o
blood NN o
pressure NN o
by IN N
5 CD N
+/- JJ N
2/3 CD N
+/- JJ N
1 CD N
mm NN N
Hg NNP N
versus NN N
placebo NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Neither CC N
enalapril JJ N
alone RB N
( ( N
-2 JJ N
+/- JJ N
2/1 CD N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
, , N
NS NNP N
vs. FW N
placebo NN N
) ) N
nor CC N
eprosartan JJ N
alone NN N
( ( N
-1 JJ N
+/- JJ N
1/0 CD N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
, , N
NS NNP N
vs. FW N
placebo NN N
) ) N
had VBD N
a DT N
clear-cut JJ N
significant JJ N
effect NN N
on IN N
casual JJ o
blood NN o
pressure NN o
. . o

In IN N
the DT N
combination NN N
phase NN N
, , N
RPF NNP o
increased VBN N
by IN N
123 CD N
+/- JJ N
36 CD N
mL/min NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Neither CC N
enalapril JJ i
alone RB N
( ( N
+59 JJ N
+/- JJ N
46 CD N
mL/min NN N
, , N
P NNP N
= NNP N
0.21 CD N
) ) N
nor CC N
eprosartan JJ i
alone NN N
( ( N
+113 JJ N
+/- JJ N
51 CD N
mL/min NN N
, , N
P NNP N
= NNP N
0.06 CD N
) ) N
had VBD N
a DT N
clear-cut JJ N
significant JJ N
effect NN N
on IN N
RPF NNP o
. . o

Changes NNS N
of IN N
RPF NNP N
induced VBN N
by IN N
treatment NN N
correlated VBN N
with IN N
the DT N
L-NMMA NNP N
induced JJ N
decrease NN N
in IN N
RPF NNP o
in IN N
the DT N
combination NN N
( ( N
r JJ N
= NN N
0.70 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
eprosartan JJ N
phase NN N
( ( N
r JJ N
= NN N
0.86 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
in IN N
the DT N
enalapril JJ N
phase NN N
( ( N
r JJ N
= NNP N
-0.44 NNP N
, , N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

Renal JJ o
vascular JJ o
resistance NN o
was VBD N
reduced VBN N
by IN N
each DT N
active JJ N
treatment NN N
with IN N
the DT N
most RBS N
prominent JJ N
reduction NN N
in IN N
the DT N
combination NN N
phase NN N
. . N

GFR NNP o
was VBD N
unaffected VBN N
by IN N
any DT N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
contrast NN N
to TO N
the DT N
effects NNS N
of IN N
either DT N
substance NN N
alone RB N
, , N
a DT N
combination NN N
of IN N
half PDT N
the DT N
dose NN N
of IN N
eprosartan NN i
with IN N
half PDT N
the DT N
dose NN N
of IN N
enalapril NN i
had VBD N
a DT N
prominent JJ N
effect NN o
on IN o
renal JJ o
perfusion NN o
. . o

The DT N
effects NNS N
of IN N
eprosartan NN i
on IN N
RPF NNP N
are VBP N
mediated VBN N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
by IN N
an DT N
increased JJ N
bioavailability NN o
of IN o
nitric JJ o
oxide NN o
in IN N
the DT N
renal JJ N
vasculature NN N
. . N

-DOCSTART- -19705924- O O

Pharmacokinetic-pharmacodynamic JJ o
modelling NN o
of IN N
the DT N
antihistaminic NN p
( ( p
H1 NNP p
) ) p
effect NN p
of IN p
bilastine NN i
. . i

OBJECTIVE UH N
To TO N
model VB N
the DT N
pharmacokinetic JJ o
and CC o
pharmacodynamic JJ o
relationship NN N
of IN N
bilastine NN i
, , N
a DT N
new JJ N
histamine NN N
H NNP N
( ( N
1 CD N
) ) N
receptor NN N
antagonist NN N
, , N
from IN N
single- JJ N
and CC N
multiple-dose JJ N
studies NNS p
in IN p
healthy JJ p
adult NN p
subjects NNS p
. . p

METHODS NNP N
The DT N
pharmacokinetic JJ N
model NN N
was VBD N
developed VBN N
from IN N
different JJ N
single-dose JJ N
and CC N
multiple-dose JJ N
studies NNS N
. . N

In IN p
the DT p
single-dose JJ p
studies NNS p
, , p
a DT p
total NN p
of IN p
183 CD p
subjects NNS p
received VBD p
oral JJ p
doses NNS p
of IN p
bilastine NN i
2.5 CD N
, , N
5 CD N
, , N
10 CD N
, , N
20 CD N
, , N
50 CD N
, , N
100 CD N
, , N
120 CD N
, , N
160 CD N
, , N
200 CD N
and CC N
220 CD N
mg NN N
. . N

In IN p
the DT p
multiple-dose JJ p
studies NNS p
, , p
127 CD p
healthy JJ p
subjects NNS p
received VBD p
bilastine JJ i
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
50 CD N
, , N
80 CD N
, , N
100 CD N
, , N
140 CD N
or CC N
200 CD N
mg/day NN N
as IN N
multiple JJ N
doses NNS N
during IN N
a DT N
4- JJ N
, , N
7- JJ N
or CC N
14-day JJ N
period NN N
. . N

The DT N
pharmacokinetic JJ o
profile NN o
of IN N
bilastine NN N
was VBD N
investigated VBN N
using VBG N
a DT N
simultaneous JJ N
analysis NN N
of IN N
all DT N
concentration-time JJ o
data NNS o
by IN N
means NNS N
of IN N
nonlinear JJ N
mixed-effects NNS N
modelling VBG N
population NN N
pharmacokinetic JJ N
software NN N
NONMEM NNP N
version NN N
6.1 CD N
. . N

Plasma JJ o
concentrations NNS o
were VBD N
modelled VBN N
according VBG N
to TO N
a DT N
two-compartment JJ N
open JJ N
model NN N
with IN N
first-order JJ N
absorption NN N
and CC N
elimination NN N
. . N

For IN N
the DT N
pharmacodynamic JJ N
analysis NN N
, , N
the DT N
inhibitory JJ N
effect NN N
of IN N
bilastine NN i
( ( N
inhibition NN N
of IN N
histamine-induced JJ N
wheal NN N
and CC N
flare NN N
) ) N
was VBD N
assessed VBN N
on IN N
a DT N
preselected JJ N
time NN N
schedule NN N
, , N
and CC N
the DT N
predicted JJ N
typical JJ o
pharmacokinetic JJ o
profile NN o
( ( N
based VBN N
on IN N
the DT N
pharmacokinetic JJ N
model NN N
previously RB N
developed VBN N
) ) N
was VBD N
used VBN N
. . N

An DT N
indirect JJ N
response NN N
model NN N
was VBD N
developed VBN N
to TO N
describe VB N
the DT N
pharmacodynamic JJ o
relationships NNS o
between IN N
flare NN N
or CC N
wheal JJ N
areas NNS N
and CC N
bilastine NN o
plasma NN o
concentrations NNS o
. . o

Finally RB N
, , N
once RB N
values NNS N
of IN N
the DT N
concentration NN o
that WDT o
produced VBD o
50 CD o
% NN o
inhibition NN o
( ( o
IC NNP o
( ( o
50 CD o
) ) o
) ) o
had VBD N
been VBN N
estimated VBN N
for IN N
wheal NN N
and CC N
flare NN N
effects NNS N
, , N
simulations NNS N
were VBD N
carried VBN N
out IN N
to TO N
predict VB N
plasma JJ o
concentrations NNS o
for IN N
the DT N
doses NNS N
of IN N
bilastine NN i
5 CD N
, , N
10 CD N
and CC N
20 CD N
mg NN N
at IN N
steady JJ N
state NN N
( ( N
72-96 JJ N
hours NNS N
) ) N
. . N

RESULTS VB N
A DT N
non-compartmental JJ N
analysis NN N
resulted VBD N
in IN N
linear JJ N
kinetics NNS N
of IN N
bilastine NN i
in IN N
the DT N
dose JJ N
range NN N
studied VBN N
. . N

Bilastine NNP N
was VBD N
characterized VBN N
by IN N
two-compartmental JJ N
kinetics NNS N
with IN N
a DT N
rapid-absorption NN N
phase NN N
( ( N
first-order JJ N
absorption NN N
rate NN N
constant JJ N
= NN N
1.50 CD N
h NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
plasma JJ o
peak NN o
concentrations NNS o
were VBD N
observed VBN N
at IN N
1 CD N
hour NN N
following VBG N
administration NN N
and CC N
the DT N
maximal JJ o
response NN o
was VBD N
observed VBN N
at IN N
approximately RB N
4 CD N
hours NNS N
or CC N
later RB N
. . N

Concerning VBG N
the DT N
selected VBN N
pharmacodynamic JJ N
model NN N
to TO N
fit VB N
the DT N
data NN N
( ( N
type NN N
I PRP N
indirect VBP N
response NN N
model NN N
) ) N
, , N
this DT N
selection NN N
is VBZ N
attributable JJ N
to TO N
the DT N
presence NN N
of IN N
inhibitory JJ o
bilastine NN o
plasma NN o
concentrations NNS o
that WDT N
decrease VBP N
the DT N
input NN o
response NN o
function NN o
, , N
i.e NN N
. . N

the DT N
production NN N
of IN N
the DT N
skin JJ N
reaction NN N
. . N

This DT N
model NN N
resulted VBD N
in IN N
the DT N
best JJS N
fit NN N
of IN N
wheal NN N
and CC N
flare NN N
data NNS N
. . N

The DT N
estimates NNS N
( ( N
with IN N
relative JJ N
standard JJ N
errors NNS N
expressed VBD N
in IN N
percentages NNS N
in IN N
parentheses NNS N
) ) N
of IN N
the DT N
apparent JJ o
zero-order NN o
rate NN o
constant NN o
for IN o
flare NN o
or CC o
wheal NN o
spontaneous JJ o
appearance NN o
( ( N
k NN N
( ( N
in IN N
) ) N
) ) N
, , N
the DT N
first-order JJ o
rate NN o
constant NN o
for IN o
flare NN o
or CC o
wheal JJ o
disappearance NN o
( ( N
k NN N
( ( N
out IN N
) ) N
) ) N
and CC N
bilastine JJ o
IC NNP o
( ( o
50 CD o
) ) o
values NNS o
were VBD N
0.44 CD N
ng/mL/h NNS N
( ( N
14.60 CD N
% NN N
) ) N
, , N
1.09 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
15.14 CD N
% NN N
) ) N
and CC N
5.15 CD N
ng/mL NN N
( ( N
16.16 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
wheal JJ N
inhibition NN N
, , N
and CC N
11.10 CD N
ng/mL/h NN N
( ( N
8.48 CD N
% NN N
) ) N
, , N
1.03 CD N
h NN N
( ( N
-1 NN N
) ) N
( ( N
8.35 CD N
% NN N
) ) N
and CC N
1.25 CD N
ng/mL NN N
( ( N
14.56 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
for IN N
flare JJ N
inhibition NN N
. . N

The DT N
simulation NN N
results NNS N
revealed VBD N
that IN N
bilastine NN o
plasma NN o
concentrations NNS o
do VBP N
not RB N
remain VB N
over IN N
the DT N
IC NNP N
( ( N
50 CD N
) ) N
value NN N
throughout IN N
the DT N
inter-dose JJ N
period NN N
for IN N
doses NNS N
of IN N
5 CD N
and CC N
10 CD N
mg NN N
. . N

However RB N
, , N
with IN N
a DT N
dose NN N
of IN N
20 CD N
mg NN N
of IN N
bilastine NN i
administered VBN N
every DT N
24 CD N
hours NNS N
, , N
plasma JJ o
concentrations NNS o
remained VBD N
over IN N
the DT N
IC NNP N
( ( N
50 CD N
) ) N
value NN N
during IN N
the DT N
considered JJ N
period NN N
for IN N
the DT N
flare NN N
effect NN N
, , N
and CC N
up RB N
to TO N
20 CD N
hours NNS N
for IN N
the DT N
wheal JJ N
effect NN N
. . N

CONCLUSION NNP N
Pharmacokinetic NNP N
and CC N
pharmacodynamic JJ N
relationships NNS N
of IN N
bilastine NN N
were VBD N
reliably RB N
described VBN N
with IN N
the DT N
use NN N
of IN N
an DT N
indirect JJ N
response NN N
pharmacodynamic JJ N
model NN N
; : N
this DT N
led VBD N
to TO N
an DT N
accurate JJ N
prediction NN N
of IN N
the DT N
pharmacodynamic JJ N
activity NN N
of IN N
bilastine NN N
. . N

-DOCSTART- -11961446- O O

Short-term NNP i
intravenous JJ i
antibiotic JJ i
treatment NN i
of IN N
acute JJ p
hematogenous JJ p
bone NN p
and CC p
joint JJ p
infection NN p
in IN p
children NNS p
: : p
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

Thirty-three JJ p
cases NNS p
of IN p
acute JJ p
hematogenous JJ p
bone NN p
or CC p
joint JJ p
infection NN p
in IN p
children NNS p
were VBD N
randomly RB N
treated VBN N
with IN N
short-term JJ i
( ( N
7 CD N
days NNS N
for IN N
joint JJ N
infection NN N
, , N
10 CD N
days NNS N
for IN N
bone JJ N
infection NN N
) ) N
or CC N
long-term JJ i
( ( N
14 CD N
days NNS N
and CC N
21 CD N
days NNS N
, , N
respectively RB N
) ) N
intravenous JJ i
antibiotics NNS i
after IN N
surgical JJ i
drainage NN i
. . i

The DT N
treatment NN N
outcome NN N
was VBD N
measured VBN N
through IN N
a DT N
detailed JJ o
scoring NN o
system NN o
that WDT o
included VBD o
the DT o
ability NN o
to TO o
eradicate VB o
infection NN o
, , o
the DT o
functional JJ o
status NN o
of IN o
the DT o
limb NN o
, , o
and CC o
the DT o
radiographic JJ o
appearance NN o
of IN o
the DT o
bone NN o
and CC o
joint NN o
. . o

The DT N
results NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
showing VBG N
the DT N
added JJ N
benefit NN N
of IN N
a DT N
shorter JJR N
hospital NN N
stay NN N
for IN N
children NNS p
with IN p
blood-borne JJ p
musculoskeletal JJ p
infection NN p
. . p

The DT N
use NN N
of IN N
this DT N
scoring VBG N
system NN N
in IN N
choosing VBG N
the DT N
route NN N
of IN N
antibiotic JJ i
administration NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -20657150- O O

Tensile IN o
bond NN o
strength NN o
of IN p
a DT p
lithium-disilicate JJ i
pressed JJ i
glass NN i
ceramic NN i
to TO p
dentin VB p
of IN N
different JJ N
surface NN N
treatments NNS N
. . N

The DT N
effects NNS N
of IN N
desensitizer NN N
, , N
disinfectant NN N
, , N
saliva NN N
, , N
blood NN N
, , N
and CC N
hydrogen NN N
peroxide NN N
on IN N
the DT N
tensile JJ o
bond NN o
strength NN o
between IN N
adhesive JJ p
and CC p
ceramic JJ p
as RB N
well RB N
as IN N
between IN N
adhesive JJ N
and CC N
dentin NN N
were VBD N
examined VBN N
. . N

Sixty NNP p
7x3 CD p
mm NN p
pressed VBN p
ceramic JJ p
discs NN p
of IN p
IPS NNP p
e.max NN p
were VBD N
fabricated VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
six CD N
groups NNS N
of IN N
different JJ N
dentin NN i
surface NN i
treatments NNS i
( ( i
control NN i
, , i
desensitizer NN i
, , i
disinfectant NN i
, , i
saliva NN i
, , i
blood NN i
, , i
and CC i
hydrogen VB i
peroxide NN i
) ) i
. . N

Representative JJ N
samples NNS N
of IN N
fractured JJ N
specimens NNS N
were VBD N
observed VBN N
by IN N
SEM NNP N
( ( i
scanning VBG i
electron RB i
microscopy NN i
) ) i
. . N

There EX N
were VBD N
significant JJ N
differences NNS N
between IN N
the DT N
control NN N
group NN N
and CC N
saliva NN N
, , N
blood NN N
, , N
and CC N
hydrogen NN N
peroxide NN N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
any DT N
other JJ N
dentin JJ N
surface NN N
treatment NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Results NNS N
of IN N
this DT N
study NN N
suggested VBD N
that IN N
only RB N
saliva NN N
, , N
blood NN N
, , N
and CC N
hydrogen NN N
peroxide NN N
influenced VBD N
the DT N
tensile NN o
bond NN o
strength NN o
between IN N
dentin NN N
and CC N
ceramic NN N
. . N

-DOCSTART- -23648162- O O

[ NN N
Study NNP N
of IN N
setting VBG i
of IN i
ventilator NN o
volume NN i
tidal NN i
and CC i
airway JJ i
pressure NN i
alarm NN i
threshold NN i
with IN N
continuous JJ i
extra-sternum JJ i
heart NN i
compression NN i
in IN N
cardiopulmonary JJ p
resuscitation NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
setting NN N
of IN N
ventilator NN i
volume NN i
tidal NN i
( ( i
VT NNP i
) ) i
and CC i
airway JJ i
pressure NN i
alarm NN i
threshold NN i
during IN N
cardiopulmonary JJ i
resuscitation NN i
( ( i
CPR NNP i
) ) i
by IN N
continuous JJ i
extra-sternum JJ i
heart NN i
compression NN i
. . i

METHODS NNP N
Forty NNP p
cases NNS p
with IN p
respiration NN p
and CC p
cardiac JJ p
arrest NN p
in IN p
the DT p
department NN p
of IN p
critical JJ p
care NN p
medicine NN p
were VBD p
randomly RB p
divided VBN p
into IN N
low JJ i
VT NNP i
ventilation NN i
group NN i
and CC i
conventional JJ i
VT NNP i
group NN i
. . i

Both DT N
groups NNS N
were VBD N
given VBN N
the DT N
volume NN N
control NN N
mode NN N
. . N

In IN N
the DT N
low JJ i
VT NNP i
ventilation NN i
group NN N
, , N
VT NNP N
was VBD N
set VBN N
on IN N
6 CD N
- : N
7 CD N
ml/kg NN N
, , N
and CC N
high JJ N
pressure NN N
alarm NN N
threshold NN N
was VBD N
adjusted VBN N
to TO N
60 CD N
cm NNS N
H2O NNP N
by IN N
the DT N
conventional JJ i
40 CD N
cm NN N
H2O NNP N
during IN N
CPR NNP N
. . N

In IN N
the DT N
conventional JJ i
VT NNP i
group NN i
, , N
VT NNP N
and CC N
high JJ N
pressure NN N
alarm NN N
threshold NN N
were VBD N
set VBN N
at IN N
8 CD N
- : N
12 CD N
ml/kg NN N
and CC N
40 CD N
cm NN N
H2O NNP N
, , N
respectively RB N
. . N

Real-time JJ o
actual JJ o
VT NNP o
, , o
peak JJ o
inspiratory JJ o
pressure NN o
( ( o
PIP NNP o
) ) o
, , o
and CC o
arterial JJ o
blood NN o
gas NN o
test NN o
, , o
blood NN o
lactic JJ o
acid NN o
at IN o
10 CD o
minutes NNS o
and CC o
30 CD o
minutes NNS o
after IN o
CPR NNP o
were VBD N
observed VBN N
. . N

RESULTS NNP N
At IN N
10 CD N
minutes NNS N
after IN N
CPR NNP N
, , N
in IN N
the DT N
low JJ i
VT NNP i
ventilation NN i
group NN N
, , N
arterial JJ o
blood NN o
pH NN o
, , o
arterial JJ o
partial JJ o
pressure NN o
of IN o
oxygen NN o
( ( o
PaO2 NNP o
) ) o
, , o
arterial JJ o
partial JJ o
pressure NN o
of IN o
carbon NN o
dioxide NN o
( ( o
PaCO2 NNP o
) ) o
, , o
HCO3 NNP o
( ( o
- : o
) ) o
, , o
arterial JJ o
oxygen NN o
saturation NN o
( ( o
SaO2 NNP o
) ) o
and CC o
blood NN o
lactic JJ o
acid NN o
were VBD N
better RB N
as IN N
compared VBN N
with IN N
those DT N
in IN N
the DT N
conventional JJ i
VT NNP i
ventilation NN i
group NN N
( ( N
pH NN N
: : N
7.21?0.09 CD N
vs. IN N
7.13?0.07 CD N
, , N
PaO2 NNP N
: : N
45.35?5.92 CD N
mm NN N
Hg NNP N
vs. IN N
40.70?4.70 CD N
mm NN N
Hg NNP N
, , N
PaCO2 NNP N
: : N
57.10?7.59 CD N
mm NN N
Hg NNP N
vs. IN N
61.60?5.47 CD N
mm NN N
Hg NNP N
, , N
HCO3 NNP N
( ( N
- : N
) ) N
: : N
18.50?3.50 CD N
mmol/L NN N
vs. FW N
14.75?2.65 CD N
mmol/L NN N
, , N
SaO2 NNP N
: : N
0.796?0.069 CD N
vs. IN N
0.699?0.066 CD N
, , N
blood NN N
lactic JJ N
acid NN N
: : N
7.07?1.60 CD N
mmol/L NN N
vs. FW N
8.13?1.56 CD N
mmol/L NN N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
success NN o
rate NN o
of IN o
resuscitation NN o
in IN o
the DT o
low JJ o
VT NNP i
ventilation NN i
group NN N
was VBD N
higher JJR N
than IN N
that DT N
of IN N
the DT N
conventional JJ i
VT NNP i
ventilation NN i
group NN N
( ( N
45 CD N
% NN N
vs. FW N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
PIP NNP N
( ( N
cm JJ N
H2O NNP N
) ) N
of IN N
low JJ i
VT NNP i
ventilation NN i
group NN N
was VBD N
lower JJR N
than IN N
that DT N
of IN N
the DT N
conventional JJ i
VT NNP i
group NN i
( ( i
37.25?7.99 CD i
cm NN N
H2O NNP N
vs. IN N
42.70?7.40 CD N
cm NN N
H2O NNP N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
all PDT N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
barotrauma VBP o
did VBD o
not RB N
occur VB N
. . N

CONCLUSION VB N
The DT N
strategy NN N
of IN i
low JJ i
ventilator NN i
VT NNP o
( ( N
6 CD N
- : N
7 CD N
ml/kg NN N
) ) N
with IN N
appropriate JJ o
elevation NN o
of IN o
airway JJ o
pressure NN o
alarm NN o
threshold NN o
was VBD o
better JJR N
than IN N
that DT i
of IN i
conventional JJ i
ventilation NN i
setting NN i
, , N
with IN N
no DT N
increase NN N
in IN N
incidence NN o
of IN o
barotraumas NN o
during IN o
CPR NNP N
. . N

-DOCSTART- -7552649- O O

Active JJ i
treatment NN i
programs NNS i
for IN N
patients NNS p
with IN p
chronic JJ p
low JJ p
back RB p
pain NN p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
observer-blinded JJ N
study NN N
. . N

Several JJ N
new JJ N
studies NNS N
have VBP N
indicated VBN N
that IN N
an DT N
active JJ N
approach NN N
to TO N
patients NNS p
with IN p
chronic JJ p
disabling VBG p
low JJ p
back RB p
pain NN p
( ( p
LBP NNP p
) ) p
seems VBZ N
effective JJ N
. . N

Some DT N
of IN N
these DT N
studies NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
dealing VBG N
with IN N
the DT N
patient NN N
's POS N
total JJ N
situation NN N
in IN N
comprehensive JJ N
multidisciplinary JJ N
programs NNS N
-- : N
the DT N
bio-psycho-social JJ N
model NN N
. . N

However RB N
, , N
these DT N
programs NNS N
are VBP N
expensive JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
rehabilitation NN N
outcome NN N
from IN N
three CD N
different JJ N
active JJ N
programs NNS N
in IN N
terms NNS N
of IN N
: : N
( ( o
1 CD o
) ) o
return-to-work NN o
rate NN o
, , o
( ( o
2 CD o
) ) o
days NNS o
of IN o
sick JJ o
leave NN o
, , o
( ( o
3 CD o
) ) o
health-care NN o
contacts NNS o
, , o
( ( o
4 CD o
) ) o
pain NN o
and CC o
disability NN o
scores NNS o
, , o
and CC o
( ( o
5 CD o
) ) o
staying VBG o
physically RB o
active JJ o
. . o

The DT p
subjects NNS p
included VBD p
132 CD p
patients NNS p
randomized VBN p
to TO p
the DT p
study NN p
, , p
of IN p
whom WP p
123 CD p
started VBD p
one CD p
of IN p
the DT p
treatment NN p
programs NNS p
. . p

They PRP p
had VBD p
all DT p
had VBN p
at IN p
least JJS p
6 CD p
months NNS p
of IN p
chronic JJ p
LBP NNP p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
three CD N
programs NNS N
: : N
group NN N
1 CD N
-- : N
a DT N
full-time JJ i
, , i
intensive JJ i
3-week JJ i
multidisciplinary JJ i
program NN i
, , i
including VBG i
active JJ i
physical JJ i
and CC i
ergonomic JJ i
training NN i
and CC i
psychological JJ i
pain NN i
management NN i
, , N
followed VBN N
by IN N
1 CD N
day NN N
weekly VB N
for IN N
the DT N
subsequent JJ N
3 CD N
weeks NNS N
; : N
group NN N
2 CD i
-- : i
active JJ i
physical JJ i
training NN i
, , i
twice RB i
a DT i
week NN i
for IN i
6 CD i
weeks NNS i
, , i
for IN i
a DT i
total NN i
of IN i
24h CD i
; : i
group NN N
3 CD i
-- : i
psychological JJ i
pain NN i
management NN i
combined VBN i
with IN i
active JJ i
physical JJ i
training NN i
, , N
twice RB N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
also RB N
for IN N
a DT N
total NN N
of IN N
24h CD N
. . N

The DT N
results NNS N
presented VBN N
here RB N
are VBP N
based VBN N
on IN N
data NNS N
collected VBN N
4 CD N
months NNS N
following VBG N
treatment NN N
, , N
which WDT N
shows VBZ N
an DT N
86 CD N
% NN N
response NN N
rate NN N
. . N

The DT N
initial JJ N
examination NN N
and CC N
the DT N
follow-up JJ N
evaluation NN N
were VBD N
performed VBN N
by IN N
a DT N
blinded VBN N
observer NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
4 CD N
months NNS N
after IN N
treatment NN N
, , N
the DT N
intensive JJ N
multidisciplinary JJ N
program NN N
is VBZ N
superior JJ N
to TO N
the DT N
less RBR N
intensive JJ N
programs NNS N
in IN N
terms NNS N
of IN N
return-to-work NN N
rate NN N
, , N
health-care JJ N
contacts NNS N
, , N
pain NN N
and CC N
disability NN N
scores NNS N
, , N
and CC N
staying VBG N
physically RB N
active JJ N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -21892106- O O

A DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
of IN N
two CD N
regimens NNS N
of IN N
moderate JJ N
dose JJ N
chemoradiation NN i
therapy NN i
for IN N
patients NNS p
with IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
not RB p
suitable JJ p
for IN p
curative JJ p
therapy NN p
: : p
Trans NNPS N
Tasman NNP N
Radiation NNP N
Oncology NNP N
Study NNP N
TROG NNP N
03.07 CD N
. . N

BACKGROUND VB N
There EX N
are VBP N
patients NNS N
with IN N
stage JJ N
I-III JJ N
non-small JJ N
cell NN N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
who WP N
are VBP N
not RB N
suitable JJ N
for IN N
curative JJ i
radical JJ i
chemoradiation NN i
therapy NN i
. . i

There EX N
are VBP N
patients NNS N
with IN N
an DT N
isolated JJ N
solitary JJ N
extracranial JJ N
metastasis NN N
who WP N
have VBP N
improved VBN N
outcomes NNS N
compared VBN N
with IN N
those DT N
with IN N
cranial JJ N
or CC N
multiple JJ N
metastases NNS N
. . N

Patients NNS N
of IN N
good JJ N
performance NN N
status NN N
receiving VBG N
moderate JJ N
dose NN N
radiation NN i
therapy NN i
have VBP N
improved VBN N
survival JJ N
. . N

Two CD N
regimens NNS N
of IN N
moderate JJ i
dose JJ i
chemoradiation NN i
therapy NN i
for IN N
such JJ N
patients NNS N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
. . N

METHODS JJ N
Patients NNPS p
were VBD p
eligible JJ p
if IN p
they PRP p
had VBD p
stage VBN p
I-IIIB NNP p
NSCLC NNP p
, , p
unsuitable JJ p
for IN p
curative JJ p
therapy NN p
, , p
or CC p
stage NN p
IV NNP p
with IN p
a DT p
PET-detected JJ p
extracranial JJ p
solitary JJ p
metastasis NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
following JJ N
groups-arm NN N
A DT N
: : N
40 CD N
Gy/20 NNP i
fractions/4 JJ N
weeks NNS N
with IN N
concurrent JJ N
weekly JJ i
vinorelbine NN i
25 CD i
mg/m NN i
+ NNP i
cisplatin VBZ i
20 CD N
mg/m NN N
or CC N
arm NN N
B NN N
: : N
30 CD N
Gy/15 NNP i
fractions/3 JJ N
weeks NNS N
with IN N
concurrent JJ N
weekly JJ i
gemcitabine NN i
200 CD i
mg. NN i
Primary NNP N
end NN N
points NNS N
were VBD N
feasibility NN o
, , o
response NN o
rates NNS o
, , o
and CC o
toxicity NN o
. . o

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ o
survival NN o
, , o
overall JJ o
survival NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

RESULTS NNP N
Eighty-four JJ p
patients NNS p
were VBD p
randomized VBN p
. . p

Compliance NN o
was VBD N
above IN N
90 CD N
% NN N
for IN N
both DT N
arms NNS N
. . N

The DT N
overall JJ o
response NN o
rate NN o
was VBD N
51 CD N
% NN N
in IN N
arm NN N
A NN N
and CC N
38 CD N
% NN N
in IN N
arm NN N
B NNP N
( ( N
p JJ N
= NNP N
0.147 CD N
) ) N
. . N

Grade $ o
3/4 CD o
toxicity NN o
in IN N
both DT N
arms NNS N
was VBD N
acceptable JJ N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
median JJ o
progression-free JJ o
survival NN o
between IN N
the DT N
two CD N
arms NNS N
( ( N
5.5 CD N
versus NN N
5.0 CD N
months NNS N
, , N
p VBP N
= RB N
0.19 CD N
) ) N
. . N

Patients NNS N
in IN N
arm NN N
A NN N
had VBD N
longer RBR N
median JJ o
survival NN o
but CC N
this DT N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
( ( N
13.1 CD N
versus NN N
8.3 CD N
months NNS N
, , N
p VBP N
= RB N
0.25 CD N
) ) N
. . N

No DT N
difference NN N
in IN N
quality NN o
of IN o
life NN o
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Arm NNP N
A NNP N
was VBD N
chosen VBN N
for IN N
a DT N
future JJ N
phase NN N
II NNP N
comparison NN N
with IN N
radiation NN i
therapy NN i
alone RB N
as IN N
it PRP N
demonstrated VBD N
a DT N
response NN o
rate NN N
greater JJR N
than IN N
50 CD N
% NN N
, , N
and CC N
data NNS N
suggested VBD N
that IN N
arm NN N
A NNP N
had VBD N
superior JJ N
survival NN N
to TO N
arm NN N
B NNP N
. . N

-DOCSTART- -25644279- O O

Randomized VBN N
trial NN N
of IN N
interferon- JJ i
and CC N
ribavirin-free JJ i
ombitasvir/paritaprevir/ritonavir NN i
in IN N
treatment-experienced JJ p
hepatitis NN p
C NNP p
virus-infected JJ p
patients NNS p
. . p

UNLABELLED NNP N
Approximately RB N
2 CD N
million CD N
Japanese JJ p
individuals NNS p
are VBP N
infected VBN N
with IN N
hepatitis NN N
C NNP N
virus NN N
and CC N
are VBP N
at IN N
risk NN N
for IN N
cirrhosis NN N
, , N
end-stage JJ N
liver NN N
disease NN N
, , N
and CC N
hepatocellular JJ N
carcinoma NN N
. . N

Patients NNS N
in IN N
whom WP N
interferon NN i
( ( i
IFN NNP i
) ) i
/ribavirin NN i
( ( i
RBV NNP i
) ) i
therapy NN i
has VBZ N
failed VBN N
remain NN N
at IN N
risk NN N
as IN N
effective JJ N
therapeutic JJ N
options NNS N
are VBP N
limited VBN N
. . N

This DT N
phase NN N
2 CD N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
evaluated VBD N
an DT N
IFN- JJ i
and CC i
RBV-free JJ i
regimen NNS N
of IN N
once-daily JJ N
ombitasvir NN i
( ( i
ABT-267 NNP i
) ) i
, , N
an DT N
NS5A NNP i
inhibitor NN i
, , i
plus CC i
paritaprevir NN i
( ( i
ABT-450 NNP i
) ) i
, , N
an DT N
NS3/4A NNP i
protease NN i
inhibitor NN i
dosed VBD i
with IN i
ritonavir NN i
( ( i
paritaprevir/ritonavir NN i
) ) i
, , N
in IN N
pegylated JJ p
IFN/RBV NNP i
treatment-experienced JJ p
Japanese JJ p
patients NNS p
with IN p
hepatitis NN p
C NNP p
virus NN p
subtype NN p
1b CD p
or CC p
genotype VB p
2 CD p
infection NN p
. . p

Patients NNS p
without IN p
cirrhosis NN p
( ( p
aged VBN p
18-75 CD p
years NNS p
) ) p
with IN p
subtype NN p
1b CD p
infection NN p
received VBD N
ombitasvir JJ i
25 CD i
mg NN i
plus CC i
paritaprevir/ritonavir JJ i
100/100 CD N
mg NN N
or CC N
150/100 CD N
mg NN N
for IN N
12 CD N
or CC N
24 CD N
weeks NNS N
; : N
patients NNS p
with IN p
genotype JJ p
2 CD p
infection NN p
received VBD N
ombitasvir JJ i
25 CD i
mg NN i
plus CC i
paritaprevir/ritonavir JJ i
100/100 CD i
mg NN i
or CC i
150/100 CD i
mg NN i
for IN i
12 CD i
weeks NNS i
. . i

Sustained VBN o
virologic JJ o
response NN o
( ( o
SVR NNP o
) ) o
at IN N
posttreatment NN N
week NN N
24 CD N
( ( N
SVR24 NNP N
) ) N
was VBD N
the DT N
primary JJ N
endpoint NN N
. . N

Adverse JJ N
events NNS N
were VBD N
collected VBN N
throughout IN N
the DT N
study NN N
. . N

One CD p
hundred VBD p
ten JJ p
patients NNS p
received VBD N
?1 JJ N
dose NN N
of IN N
study NN N
medication NN N
. . N

In IN N
the DT N
subtype NN N
1b CD N
cohort NN o
, , o
SVR24 NNP o
rates NNS o
were VBD o
high JJ N
( ( N
88.9 CD N
% NN N
-100 NNP N
% NN N
) ) N
regardless NN N
of IN N
paritaprevir NN N
dose NN N
or CC N
treatment NN N
duration NN N
. . N

In IN N
the DT N
genotype NN N
2 CD N
cohort NN o
, , o
SVR24 NNP o
rates NNS o
were VBD o
57.9 CD N
% NN N
and CC N
72.2 CD N
% NN N
with IN N
100 CD N
mg NNS N
and CC N
150 CD N
mg NN N
of IN N
paritaprevir NN N
, , N
respectively RB N
. . N

The DT o
SVR24 NNP o
rate NN o
was VBD o
higher RBR N
in IN N
patients NNS N
with IN N
subtype JJ N
2a CD N
( ( N
90 CD N
% NN N
) ) N
than IN N
2b CD N
( ( N
27 CD N
% NN N
) ) N
. . N

Concordance NN N
between IN o
SVR12 NNP o
and CC o
SVR24 NNP o
was VBD o
100 CD N
% NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
overall JJ N
were VBD o
nasopharyngitis NN o
( ( o
29 CD N
% NN N
) ) N
and CC o
headache NN o
( ( o
14 CD N
% NN N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT p
difficult-to-treat JJ p
population NN p
of IN p
patients NNS p
in IN p
whom WP p
prior RB p
pegylated VBN p
IFN/RBV NNP p
had VBD p
failed VBN i
, , i
ombitasvir/paritaprevir/ritonavir RB i
demonstrated VBD i
potent JJ N
antiviral JJ N
activity NN N
with IN N
a DT N
favorable JJ N
safety NN N
profile NN N
among IN p
Japanese JJ p
patients NNS p
with IN p
hepatitis NN p
C NNP p
virus NN p
genotype NN p
1b CD p
or CC p
2a CD p
infection NN p
. . p

-DOCSTART- -15223903- O O

Predicting VBG N
the DT N
costs NNS o
of IN N
allogeneic JJ i
sibling VBG i
stem-cell JJ i
transplantation NN i
: : i
results NNS N
from IN N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
French JJ p
study NN p
. . p

BACKGROUND NNP N
Allogeneic NNP i
hematopoietic JJ i
stem-cell NN i
transplantation NN i
is VBZ N
a DT N
widely RB N
used VBN N
, , N
cost-intensive JJ N
procedure NN N
. . N

Our PRP$ N
purpose NN N
was VBD N
to TO N
estimate VB N
costs NNS o
and CC N
determine VB N
cost NN o
predictors NNS o
. . o

METHODS NNP N
We PRP N
used VBD N
data NNS i
from IN i
a DT i
prospective JJ i
French JJ i
study NN i
comparing VBG p
four CD p
doses NNS p
of IN p
immunoglobulins NNS i
. . i

Resource NNP N
use NN N
of IN N
hematopoietic JJ p
stem-cell NN p
transplant NN p
recipients NNS p
during IN N
the DT N
first JJ N
6 CD N
months NNS N
posttransplant JJ N
, , N
both DT N
inpatient NN N
and CC N
ambulatory NN N
costs NNS N
, , N
in IN N
85 CD p
patients NNS p
from IN p
five CD p
centers NNS p
were VBD p
collected VBN p
prospectively RB p
and CC p
costed VBN p
. . N

Baseline NNP N
data NN N
and CC N
clinical JJ N
events NNS N
were VBD N
retrieved VBN N
. . N

Protocol-driven JJ N
costs NNS N
were VBD N
excluded VBN N
. . N

Multivariable JJ o
analysis NN o
evaluated VBD N
the DT N
association NN N
between IN N
costs NNS o
and CC o
patient NN o
's POS o
pretransplant JJ o
status NN o
and CC o
transplant-related JJ o
complications NNS o
. . o

Because IN N
of IN N
the DT N
absence NN N
of IN N
differences NNS N
in IN N
outcome NN N
among IN N
the DT N
four CD N
randomization NN N
groups NNS N
, , N
cost NN o
data NNS o
for IN N
all DT N
patients NNS N
were VBD N
pooled VBN N
. . N

RESULTS NNP N
Total JJ o
costs NNS o
per IN N
patient NN N
were VBD N
the DT N
following JJ N
: : N
mean JJ N
76,237 CD N
Euros NNP N
; : N
standard JJ N
deviation NN N
32,565 CD N
Euros NNP N
; : N
median JJ N
69,516 CD N
Euros NNPS N
; : N
range VB N
183,758 CD N
to TO N
14,761Euros CD N
. . N

The DT N
major JJ N
cost NN N
driver NN N
was VBD N
hospital JJ N
days NNS N
. . N

No DT N
association NN N
was VBD N
found VBN N
between IN N
costs NNS o
and CC o
baseline NN o
status NN o
. . o

The DT N
predictors NNS N
of IN N
higher JJR N
costs NNS N
( ( N
adding VBG N
an DT N
average JJ N
20,000 CD N
Euros/patient NN N
) ) N
were VBD N
the DT N
occurrence NN N
of IN N
transplant-related JJ o
complications NNS o
: : o
graft-versus-host JJ N
disease NN N
and CC N
repeated VBD o
infections NNS o
that WDT N
were VBD N
unpredictable JJ N
before RB N
transplant NN N
in IN N
this DT N
homogeneous JJ p
group NN p
of IN p
patients NNS p
. . p

CONCLUSION NNP N
Our PRP$ N
data NNS N
highlight VBD N
the DT N
discrepancy NN N
between IN N
the DT N
Diagnosis NNP N
Related NNP N
Group NNP N
prospective JJ N
payment NN N
system NN N
and CC N
actual JJ o
costs NNS o
. . o

The DT N
actual JJ o
cost NN o
of IN N
geno-identical JJ N
stem-cell JJ N
transplantation NN N
results NNS N
from IN N
posttransplant JJ N
complications NNS N
that WDT N
can MD N
not RB N
be VB N
predicted VBN N
prospectively RB N
and CC N
require VB N
ex NN N
post NN N
cost NN N
adjustment NN N
. . N

-DOCSTART- -20357382- O O

Effect NN N
of IN N
ranolazine NN i
on IN N
A1C NNP N
and CC N
glucose JJ N
levels NNS N
in IN N
hyperglycemic JJ p
patients NNS p
with IN p
non-ST JJ p
elevation NN p
acute NN p
coronary JJ p
syndrome NN p
. . p

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
relationships NNS N
between IN N
glycemia NN N
at IN N
randomization NN N
, , N
concurrent JJ i
antidiabetic JJ i
therapy NN i
, , N
and CC N
change NN N
in IN N
A1C NNP N
and CC N
fasting VBG N
plasma NN N
glucose NN N
( ( N
FPG NNP N
) ) N
in IN N
patients NNS p
with IN p
diabetes NNS p
receiving VBG p
standard JJ p
treatment NN p
for IN p
diabetes NNS p
and CC p
randomized VBN p
to TO p
ranolazine VB i
or CC i
placebo VB i
within IN p
the DT p
MERLIN-TIMI-36 NNP p
( ( p
MERLIN NNP p
) ) p
study NN p
. . p

Ranolazine NNP i
is VBZ N
a DT N
novel JJ N
first-in-class JJ N
drug NN N
approved VBD N
for IN N
treating VBG N
angina JJ N
pectoris NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Randomization NNP N
and CC N
4-month JJ N
glycemic NN i
and CC i
antidiabetes VBZ i
drug NN i
usage NN i
data NNS i
from IN N
MERLIN NNP N
were VBD N
analyzed VBN N
using VBG N
Spotfire NNP N
and CC N
SAS NNP N
version NN N
9.1 CD N
software NN N
. . N

RESULTS NNP N
In IN N
patients NNS p
with IN p
diabetes NNS p
and CC p
A1C NNP p
of IN p
> NNP p
or=8-10 JJ p
% NN p
at IN p
randomization NN p
( ( p
n JJ p
= NNP p
171 CD p
) ) p
, , N
there EX N
was VBD N
an DT N
absolute JJ N
A1C NNP o
reduction NN o
in IN N
the DT N
ranolazine NN i
group NN N
of IN N
1.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.4 NNP N
to TO N
-1.0 VB N
) ) N
, , N
and CC N
the DT N
placebo-adjusted JJ i
( ( p
n JJ p
= NNP p
182 CD p
) ) p
decrease NN N
in IN N
A1C NNP o
by IN N
ranolazine NN N
was VBD N
0.59 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-0.99 NNP N
to TO N
-0.20 VB N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS p
with IN p
FPG NNP p
of IN p
150-400 JJ p
mg/dl NN p
at IN p
randomization NN p
, , p
ranolazine NN i
( ( p
n JJ p
= NNP p
131 CD p
) ) p
compared VBN N
with IN N
placebo NN i
( ( p
n JJ p
= NNP p
147 CD p
) ) p
reduced VBN N
FPG NNP N
by IN N
25.7 CD N
mg/dl NNS N
( ( N
95 CD N
% NN N
CI NNP N
-43.3 NNP N
to TO N
-8.1 VB N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

When WRB N
changes NNS N
in IN N
either DT N
A1C NNP o
or CC o
FPG NNP o
were VBD N
correlated VBN N
to TO N
A1C NNP o
or CC o
FPG NNP o
at IN N
randomization NN N
, , N
the DT N
slopes NNS N
were VBD N
significantly RB N
steeper JJR N
for IN N
ranolazine NN i
than IN N
placebo NN i
( ( N
A1C NNP N
, , N
P NNP N
= NNP N
0.046 CD N
; : N
FPG NNP N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
indicating VBG N
that IN N
lowering VBG N
of IN N
A1C NNP o
and CC o
FPG NNP o
by IN N
ranolazine NN i
is VBZ N
related VBN N
to TO N
hyperglycemia VB N
at IN N
randomization NN N
. . N

Ranolazine NNP N
, , N
compared VBN N
with IN N
placebo NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
serious JJ o
hypoglycemic JJ o
events NNS o
, , N
associated VBN N
with IN N
significant JJ N
changes NNS N
in IN N
concurrent JJ o
antidiabetic JJ o
therapy NN o
, , N
or CC N
dependent NN N
on IN N
a DT N
history NN o
of IN o
angina NN o
. . o

CONCLUSIONS NNP N
Ranolazine NNP i
, , N
when WRB N
added VBN N
to TO N
concurrent VB N
antidiabetes NNS N
treatment NN N
, , N
lowers NNS N
FPG NNP o
and CC o
A1C NNP o
in IN N
patients NNS p
with IN p
cardiovascular JJ p
disease NN p
and CC p
poorly RB p
controlled VBN p
diabetes NNS p
. . p

-DOCSTART- -1835619- O O

Clinical JJ N
outcome NN N
of IN N
postoperative JJ N
adjuvant JJ N
immunochemotherapy NN N
with IN N
sizofiran NN i
for IN N
patients NNS p
with IN p
resectable JJ p
gastric JJ p
cancer NN p
: : p
a DT N
randomised VBN N
controlled VBN N
study NN N
. . N

Adjuvant NNP i
immunochemotherapy NN i
using VBG i
the DT i
antitumour JJ i
polysaccharide NN i
sizofiran NN i
( ( i
SPG NNP i
) ) i
, , N
an DT N
extract NN N
from IN N
the DT N
culture NN N
broth NN N
of IN N
Schizophyllum NNP N
commune NN N
Fries NNS N
, , N
was VBD N
prescribed VBN N
randomly RB N
for IN N
386 CD p
Japanese JJ p
patients NNS p
with IN p
resectable JJ p
gastric JJ p
cancer NN p
. . p

Although IN N
the DT N
overall JJ o
survival NN o
probability NN o
for IN N
5 CD N
years NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
SPG NNP N
and CC N
control NN N
groups NNS N
, , N
in IN N
264 CD p
patients NNS p
with IN p
curatively RB p
resected VBN p
cancer NN p
, , N
the DT N
probability NN N
to TO N
5 CD N
year NN N
survival NN N
and CC N
to TO N
recurrence VB o
in IN N
the DT N
sizofiran-administered JJ N
patients NNS N
was VBD N
better JJR N
than IN N
in IN N
the DT N
controls NNS N
. . N

In IN N
the DT N
multivariate NN o
analysis NN o
, , N
four CD N
of IN N
six CD N
prognostic JJ N
factors NNS N
correlated VBD N
with IN N
the DT N
prognosis NN N
of IN N
the DT N
264 CD p
patients NNS p
who WP N
underwent VBP N
curative JJ N
surgery NN N
, , N
that WDT N
is VBZ N
, , N
nodal JJ o
involvement NN o
( ( N
chi JJ N
2 CD N
= JJ N
21.426 CD N
, , N
P NNP N
= NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
, , N
age NN o
distribution NN o
( ( N
chi JJ N
2 CD N
= JJ N
9.262 CD N
, , N
P NNP N
= NNP N
0.010 CD N
) ) N
, , N
sizofiran JJ o
administration NN o
( ( N
chi JJ N
2 CD N
= JJ N
6.507 CD N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
, , N
and CC N
primary JJ o
tumour NN o
size NN o
( ( N
chi JJ N
2 CD N
= JJ N
9.345 CD N
, , N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

Thus RB N
, , N
patients NNS p
with IN p
a DT p
curatively RB p
resected VBN p
gastric JJ p
cancer NN p
had VBD N
a DT N
better JJR N
prognosis NN N
when WRB N
sizofiran NN i
was VBD N
prescribed VBN N
in IN N
combination NN N
with IN N
antitumour JJ N
drugs NNS N
. . N

-DOCSTART- -2780120- O O

Milk NN o
intolerance NN o
in IN N
children NNS p
with IN p
persistent JJ p
sleeplessness NN p
: : p
a DT N
prospective JJ N
double-blind NN N
crossover NN N
evaluation NN N
. . N

From IN N
July NNP N
1986 CD N
to TO N
July NNP N
1988 CD N
, , N
146 CD p
children NNS p
less JJR p
than IN p
5 CD p
years NNS p
of IN p
age NN p
were VBD p
referred VBN p
by IN p
their PRP$ p
physicians NNS p
to TO p
our PRP$ p
university NN p
sleep NN p
clinic NN p
for IN p
continual JJ p
waking NN p
and CC p
crying VBG p
during IN p
sleep JJ p
hours NNS p
. . p

For IN N
85 CD p
children NNS p
( ( N
58.2 CD N
% NN N
) ) N
, , N
the DT N
sleeplessness NN N
was VBD N
attributed VBN N
to TO N
inappropriate VB N
sleep JJ N
habits NNS N
. . N

For IN N
17 CD p
children NNS p
( ( N
11.6 CD N
% NN N
) ) N
, , N
no DT N
explanation NN N
was VBD N
found VBN N
for IN N
the DT N
sleep JJ N
difficulties NNS N
in IN N
spite NN N
of IN N
an DT N
extensive JJ N
workup NN N
. . N

Their PRP$ N
median JJ p
age NN p
at IN p
referral NN p
was VBD p
13.5 CD p
months NNS p
( ( p
range VB p
2.5 CD p
to TO p
29 CD p
months NNS p
) ) p
. . N

Their PRP$ N
persistent JJ N
sleeplessness NN N
was VBD N
tentatively RB N
attributed VBN N
to TO N
an DT N
undiagnosed JJ N
intolerance NN N
to TO N
cow VB N
's POS N
milk NN N
. . N

Cow NNP i
's POS i
milk NN i
was VBD i
excluded VBN i
from IN i
their PRP$ i
diet NN i
. . i

In IN N
15 CD N
children NNS N
sleep JJ N
normalized VBN N
after IN N
5 CD N
weeks NNS N
( ( N
range VB N
4 CD N
to TO N
6 CD N
weeks NNS N
) ) N
. . N

As IN N
seen VBN N
from IN N
the DT N
parents NNS N
' POS N
logs NNS N
, , N
the DT N
median JJ o
time NN o
needed VBN o
by IN o
the DT o
children NNS o
to TO o
fall VB o
asleep RB o
decreased VBN N
from IN N
15 CD N
minutes NNS N
( ( N
range VB N
15 CD N
to TO N
60 CD N
minutes NNS N
) ) N
to TO N
10 CD N
minutes NNS N
( ( N
range VB N
10 CD N
to TO N
15 CD N
minutes NNS N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

The DT N
number NN o
of IN o
complete JJ o
arousals NNS o
decreased VBD N
from IN N
5 CD N
( ( N
range NN N
1 CD N
to TO N
12 CD N
) ) N
to TO N
less JJR N
than IN N
1 CD N
per IN N
night NN N
( ( N
range VB N
0 CD N
to TO N
2 CD N
) ) N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Total JJ o
sleep JJ o
time NN o
per IN o
24 CD o
hours NNS o
increased VBD N
from IN N
5.5 CD N
hours NNS N
( ( N
range VB N
3 CD N
to TO N
8.5 CD N
hours NNS N
) ) N
to TO N
13.0 CD N
hours NNS N
( ( N
range VB N
10 CD N
to TO N
14.5 CD N
hours NNS N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Sleep JJ o
normalized VBN N
in IN N
one CD N
child NN N
who WP N
continued VBD N
to TO N
receive VB N
no DT N
cow NN N
's POS N
milk NN N
only RB N
after IN N
the DT N
hydrolyzed JJ N
hypoallergenic JJ N
diet NN N
was VBD N
discontinued VBN N
. . N

In IN N
every DT N
child NN N
, , N
a DT N
double-blind JJ N
crossover NN N
challenge NN N
was VBD N
conducted VBN N
involving VBG N
a DT N
control NN i
diet JJ i
containing VBG i
no DT i
cow NN i
's POS i
milk NN i
and CC i
a DT i
diet JJ i
containing VBG i
cow NN i
's POS i
milk NN i
. . i

The DT N
challenge NN N
induced VBD N
the DT N
reappearance NN o
of IN o
insomnia NN o
and CC o
agitated VBD o
behavior NN o
in IN N
all DT N
except IN N
one CD N
child NN N
. . N

The DT N
child NN N
's POS N
initial JJ N
sleep JJ N
difficulties NNS N
were VBD N
retrospectively RB N
attributed VBN N
to TO N
inappropriate VB N
sleep JJ N
habits NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -20683712- O O

Sunlight JJ i
exposure NN i
or CC i
vitamin NN i
D NNP i
supplementation NN i
for IN N
vitamin JJ p
D-deficient JJ p
non-western JJ p
immigrants NNS p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

UNLABELLED NNP N
Vitamin NNP i
D NNP i
deficiency NN N
is VBZ N
very RB N
common JJ N
in IN N
non-western JJ p
immigrants NNS p
. . p

In IN N
this DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
vitamin NN i
D NNP i
800 CD N
IU/day NNP N
or CC N
100,000 CD N
IU/3 JJ N
months NNS N
were VBD N
compared VBN N
with IN N
advised JJ i
sunlight NN i
exposure NN i
. . i

Vitamin NNP i
D NNP i
supplementation NN i
was VBD N
more RBR N
effective JJ N
than IN N
advised JJ i
sunlight JJ i
exposure NN i
in IN N
improving VBG N
vitamin NN N
D NNP N
status NN N
and CC N
lowering VBG N
parathyroid JJ N
hormone NN N
levels NNS N
. . N

INTRODUCTION NNP N
Vitamin NNP N
D NNP N
deficiency NN N
( ( N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
< VBD N
25 CD N
nmol/l NN N
) ) N
is VBZ N
common JJ N
among IN N
non-western JJ N
immigrants NNS N
. . N

It PRP N
can MD N
be VB N
treated VBN N
with IN N
vitamin NN i
D NNP i
supplementation NN i
or CC i
sunlight JJ i
exposure NN i
. . i

METHODS NNP i
To TO N
determine VB N
whether IN N
the DT N
effect NN i
of IN i
vitamin NN i
D NNP i
( ( i
3 CD i
) ) i
supplementation NN i
( ( i
daily JJ i
800 CD i
IU NNP i
or CC i
100,000 CD i
IU/3 NNP i
months NNS i
) ) i
or CC i
sunlight JJ i
exposure NN i
advice NN i
is VBZ i
similar JJ N
with IN N
regard NN N
to TO N
serum VB N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
and CC N
parathyroid VB N
hormone NN N
( ( N
PTH NNP N
) ) N
concentrations NNS N
. . N

Randomized NNP N
clinical JJ N
trial NN p
in IN p
11 CD p
general JJ p
practices NNS p
in IN p
The DT p
Netherlands NNP p
. . p

Non-western JJ p
immigrants NNS p
, , p
aged VBN p
18-65 CD p
years NNS p
( ( p
n JJ p
= NNP p
232 CD p
) ) p
and CC p
serum $ p
25 CD p
( ( p
OH NNP p
) ) p
D NNP p
< $ p
25 CD p
nmol/l NN p
were VBD p
randomly RB N
assigned VBN N
to TO N
supplementation NN i
( ( i
daily JJ i
800 CD i
IU NNP N
or CC N
100,000 CD N
IU/3 NNP N
months NNS N
) ) N
or CC i
advice NN i
for IN i
sunlight JJ i
exposure NN i
for IN i
6 CD N
months NNS N
( ( N
March-September NNP o
) ) o
. . o

Blood NN o
samples NNS o
were VBD o
collected VBN N
at IN N
baseline NN N
, , N
during IN N
treatment NN N
( ( N
3 CD N
months NNS N
, , N
6 CD N
months NNS N
) ) N
, , N
and CC N
at IN N
follow-up JJ N
( ( N
12 CD N
months NNS N
) ) N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
multilevel JJ N
regression NN N
modelling NN N
. . N

RESULTS VB N
The DT N
intention-to-treat JJ N
analysis NN N
included VBD p
211 CD p
persons NNS p
. . N

Baseline NNP o
serum NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
was VBD o
22.5 CD N
? . N
11.1 CD N
nmol/l NN N
. . N

After IN N
6 CD N
months NNS N
, , N
mean VBP o
serum JJ o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
increased VBD o
to TO N
53 CD N
nmol/l NNS N
with IN N
800 CD N
IU/day NNP N
, , N
to TO N
50.5 CD N
nmol/l NNS N
with IN N
100,000 CD N
IU/3 NNP N
months NNS N
, , N
and CC N
to TO N
29.1 CD N
nmol/l NNS N
with IN N
advised JJ i
sunlight NN i
exposure NN i
( ( i
supplementation NN i
vs FW i
sunshine NN i
p NN i
< NNP i
0.001 CD o
) ) o
. . o

Serum NNP o
PTH NNP o
decreased VBD o
significantly RB N
in IN N
all DT N
groups NNS N
after IN N
3 CD N
months NNS N
, , N
more RBR N
in IN N
the DT N
supplementation NN i
groups NNS i
than IN i
in IN i
the DT i
advised JJ i
sunlight NN i
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
effect NN N
on IN N
physical JJ N
performance NN N
and CC N
functional JJ N
limitations NNS N
. . N

CONCLUSION NNP i
Vitamin NNP i
D NNP i
supplementation NN i
is VBZ i
more RBR i
effective JJ i
than IN i
advised JJ i
sunlight JJ i
exposure NN i
for IN i
treating VBG i
vitamin NN N
D NNP N
deficiency NN p
in IN p
non-western JJ p
immigrants NNS p
. . p

-DOCSTART- -11554438- O O

Dose NNP N
dependent JJ N
pharmacokinetics NNS N
of IN N
theophylline NN i
: : i
Michaelis-Menten JJ N
parameters NNS N
for IN N
its PRP$ N
major JJ N
metabolic JJ N
pathways NNS N
. . N

Dose NNP N
Dependency NNP N
for IN N
pharmacokinetics NNS N
of IN N
theophylline NN i
and CC N
the DT N
formation NN N
of IN N
its PRP$ N
major JJ N
metabolites NNS N
, , N
3-methylxanthine JJ N
( ( N
3-MX JJ N
) ) N
; : N
1-methyluric JJ N
acid NN N
( ( N
1-MU JJ N
) ) N
; : N
1,3-dimethyluric JJ N
acid NN N
( ( N
DMU NNP N
) ) N
, , N
were VBD N
examined VBN N
by IN N
administering VBG N
three CD N
single JJ N
oral JJ N
doses NNS N
( ( N
250 CD N
, , N
375 CD N
, , N
500 CD N
mg NN N
) ) N
of IN N
theophylline NN i
to TO N
six CD p
healthy JJ p
adult NN p
volunteers NNS p
. . p

The DT N
serum NN N
and CC N
urine JJ N
concentrations NNS N
of IN N
theophylline NN i
and CC N
the DT N
metabolites NNS N
in IN N
serum NN N
and CC N
urine NN N
were VBD N
determined VBN N
by IN N
high-performance NN N
liquid NN N
chromatography NN N
. . N

Total JJ o
clearance NN o
of IN N
theophylline NN i
decreased VBN N
and CC N
its PRP$ N
half JJ N
life NN N
increased VBD N
over IN N
the DT N
range NN N
of IN N
doses NNS N
administered VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
dose NN N
related JJ N
decrease NN N
in IN N
the DT N
fractional JJ N
recovery NN N
of IN N
3-MX JJ N
and CC N
1-MU JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
dose NN N
related JJ N
increase NN N
in IN N
fractional JJ o
excretion NN o
of IN o
DMU NNP o
and CC N
unchanged JJ N
theophylline NN N
( ( N
p JJ N
< NN N
0.01 CD N
and CC N
p VB N
< JJ N
0.001 CD N
respectively RB N
) ) N
. . N

No DT N
significant JJ N
dose NN N
related VBN N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
renal JJ o
clearance NN o
of IN o
3-MX JJ o
, , o
1-MU JJ o
and CC o
DMU NNP o
, , N
indicating VBG N
linear JJ N
urinary JJ N
excretion NN N
kinetics NNS N
of IN N
the DT N
metabolites NNS N
. . N

Theophylline NNP o
metabolic JJ o
clearance NN o
to TO o
3-MX JJ o
as RB N
well RB N
as IN N
to TO N
1-MU CD N
decreased VBN N
with IN N
increasing VBG N
dose NN N
but CC N
clearance NN N
to TO N
DMU NNP N
remained VBD N
unnaffected JJ N
by IN N
the DT N
size NN N
of IN N
dose NN N
. . N

The DT N
individual JJ N
Michaelis-Menten NNP o
parameters NNS o
Km NNP o
and CC o
Vmax NNP o
were VBD N
estimated VBN N
for IN N
six CD p
subjects NNS p
receiving VBG N
three CD N
different JJ N
single JJ N
doses NNS N
. . N

The DT N
Km NNP o
values NNS o
for IN o
theophylline JJ o
metabolism NN o
to TO o
3-MX JJ o
, , o
1-MU JJ o
and CC o
DMU NNP o
were VBD N
2.4+/-0.6 JJ N
, , N
5.1+/-1.8+/- JJ N
and CC N
112.3+/-36.8 JJ N
mg/L NN N
respectively RB N
and CC N
the DT N
Vmax NNP o
values NNS o
were VBD N
3.5+/-0.7 JJ N
, , N
7.5+/-2.6 JJ N
and CC N
112.3+/-36.8 JJ N
mg/hr NN N
respectively RB N
. . N

The DT N
Km NNP o
values NNS o
for IN o
the DT o
N-demethylation NNP o
pathways NNS o
( ( o
3MX CD o
and CC o
1-MU JJ o
) ) o
were VBD N
lower JJR N
corresponding VBG N
to TO N
therapeutic JJ N
serum NN N
concentrations NNS N
of IN N
drug NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
elimination NN N
kinetics NNS N
of IN N
theophylline NN i
is VBZ N
nonlinear JJ N
in IN N
the DT N
human NN N
in IN N
the DT N
therapeutic JJ N
range NN N
of IN N
serum JJ o
concenntrations NNS o
and CC N
can MD N
be VB N
explained VBN N
by IN N
saturable JJ N
formation NN N
kinetics NNS N
of IN N
3-MX JJ N
and CC N
1-MU JJ N
. . N

In IN N
contrast NN N
to TO N
previous JJ N
studies NNS N
we PRP N
did VBD N
n't RB N
find VB N
obvious JJ N
indication NN N
for IN N
nonlinear JJ N
formation NN N
of IN N
DMU NNP N
at IN N
therapeutic JJ N
concentration NN N
range NN N
. . N

-DOCSTART- -11549539- O O

Effect NN N
of IN N
antioxidant JJ i
supplementation NN i
on IN N
ozone-induced JJ p
lung NN p
injury NN p
in IN p
human JJ p
subjects NNS p
. . p

To TO N
determine VB N
whether IN N
antioxidants NNS i
can MD N
influence VB N
human JJ N
susceptibility NN N
to TO N
ozone NN N
( ( N
O NNP N
( ( N
3 CD N
) ) N
) ) N
-induced VBD N
changes NNS N
in IN N
lung NN o
function NN o
and CC o
airway JJ o
inflammation NN o
, , N
we PRP N
placed VBD N
31 CD p
healthy JJ p
nonsmoking VBG p
adults NNS p
( ( p
18 CD p
to TO p
35 CD p
yr NNS p
old JJ p
) ) p
on IN N
a DT N
diet JJ i
low JJ i
in IN i
ascorbate NN i
for IN N
3 CD N
wk NN N
. . N

At IN N
1 CD N
wk NN N
, , N
subjects NNS N
were VBD N
exposed VBN N
to TO N
filtered VB i
air NN i
for IN i
2 CD i
h NNS i
while IN i
exercising VBG i
( ( i
20 CD i
L/min/m NNP i
( ( i
2 CD i
) ) i
) ) i
, , i
and CC i
then RB i
underwent JJ i
bronchoalveolar JJ i
lavage NN i
( ( i
BAL NNP i
) ) i
and CC i
were VBD i
randomly RB i
assigned VBN i
to TO i
receive VB i
either CC i
a DT i
placebo NN i
or CC i
250 CD i
mg NN i
of IN i
vitamin NN i
C NNP i
, , i
50 CD i
IU NNP i
of IN i
alpha-tocopherol NN i
, , i
and CC i
12 CD i
oz NN i
of IN i
vegetable JJ i
cocktail JJ i
daily NN i
for IN i
2 CD i
wk NN i
. . i

Subjects NNS N
were VBD N
then RB N
exposed VBN i
to TO i
0.4 CD i
ppm NNS i
O NNP i
( ( i
3 CD i
) ) i
for IN i
2 CD i
h NN i
and CC i
underwent NN i
a DT i
second JJ i
BAL NNP i
. . i

On IN N
the DT N
day NN N
of IN N
the DT N
O NNP N
( ( N
3 CD N
) ) N
exposure NN N
, , N
supplemented VBN N
subjects NNS N
were VBD N
found VBN N
to TO N
have VB N
significantly RB N
increased VBN N
levels NNS o
of IN o
plasma NN o
ascorbate NN o
, , o
tocopherols NNS o
, , o
and CC o
carotenoids NNS o
as IN N
compared VBN N
with IN N
those DT N
of IN N
the DT N
placebo NN i
group NN N
. . N

Pulmonary NNP N
function NN N
testing VBG N
showed VBD N
that IN N
O NNP o
( ( o
3 CD o
) ) o
-induced VBD o
reductions NNS o
in IN o
FEV NNP o
( ( o
1 CD o
) ) o
and CC o
FVC NNP o
were VBD N
30 CD N
% NN N
and CC N
24 CD N
% NN N
smaller JJR N
, , N
respectively RB N
, , N
in IN N
the DT N
supplemented JJ N
cohort NN N
. . N

In IN N
contrast NN N
, , N
the DT N
inflammatory JJ o
response NN o
to TO o
O NNP o
( ( o
3 CD o
) ) o
inhalation NN N
, , N
as IN N
represented VBN N
by IN N
the DT N
percent NN o
neutrophils NNS o
and CC o
the DT o
concentration NN o
of IN o
interleukin-6 JJ o
recovered VBN N
in IN N
the DT N
BAL NNP N
fluid NN N
at IN N
1 CD N
h NN N
after IN N
O NNP N
( ( N
3 CD N
) ) N
exposure NN N
was VBD N
not RB N
different JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
dietary JJ i
antioxidants NNS i
protect VBP N
against IN N
O NNP o
( ( o
3 CD o
) ) o
-induced VBD o
pulmonary JJ o
function NN o
decrements NNS N
in IN N
humans NNS N
. . N

-DOCSTART- -11208371- O O

Effect NN N
of IN N
surgical JJ i
technique NN i
in IN N
subtotal JJ i
and CC i
bilateral JJ i
thyroidectomy NN i
on IN N
risk NN N
of IN N
postoperative JJ N
parathyroid NN N
insufficiency NN N
development NN N
-- : N
our PRP$ N
experience NN N
. . N

One CD N
of IN N
the DT N
postoperative JJ N
complications NNS N
after IN N
strumectomy NN N
is VBZ N
hypoparathyroidism NN N
. . N

Therefore RB N
, , N
the DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
surgical JJ i
technique NN i
on IN N
the DT N
development NN o
of IN o
parathyroid JJ o
gland NN o
insufficiency NN o
in IN p
our PRP$ p
group NN p
of IN p
patients NNS p
. . p

Subtotal NNP N
, , N
bilateral JJ i
strumectomies NNS i
were VBD N
performed VBN N
according VBG N
to TO N
Rothmund NNP N
's POS N
suggestions NNS N
. . N

Randomized NNP N
controlled VBD N
trial NN N
was VBD N
performed VBN N
in IN N
two CD p
groups NNS p
. . p

In IN N
the DT N
first JJ p
group NN p
of IN p
19 CD p
patients NNS p
, , p
main JJ i
trunk NN i
of IN i
the DT i
inferior JJ i
thyroid JJ i
artery NN i
was VBD i
ligated VBN i
and CC p
in IN p
the DT p
second JJ p
one CD p
consisting NN p
of IN p
18 CD p
patients NNS p
, , p
only RB i
the DT i
branches NNS i
of IN i
this DT i
artery NN i
were VBD i
ligated VBN i
. . i

Total JJ o
calcium NN o
and CC o
PTH NNP o
levels NNS o
were VBD N
evaluated VBN N
pre- JJ N
and CC N
postoperatively RB N
. . N

Based VBN N
on IN N
the DT N
biochemical JJ N
and CC N
clinical JJ N
data NNS N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
development NN o
of IN o
postoperative JJ o
hypoparathyroidism NN o
in IN N
relation NN N
to TO N
performed VB N
surgical JJ i
techniques NNS i
were VBD N
observed VBN N
. . N

-DOCSTART- -8015504- O O

Early JJ N
effects NNS N
of IN N
continuous JJ N
low-dosage JJ N
all-norgestrel NN i
administered VBD N
alone RB N
or CC N
with IN N
estrogen NN N
. . N

Twenty-six JJ p
postmenopausal JJ p
women NNS p
participated VBD N
in IN N
a DT N
double-blind JJ N
trial NN N
involving VBG N
treatment NN N
according VBG N
to TO N
a DT N
Latin NNP N
square JJ N
design NN N
with IN N
either DT N
( ( N
i NN N
) ) N
dl-norgestrel NN i
alone RB i
( ( N
0.075 CD N
mg/day NN N
) ) N
continuously RB N
for IN N
two CD N
cycles NNS N
, , N
( ( N
ii NN N
) ) N
estradiol-17 JJ i
beta NN i
alone RB i
( ( N
1 CD N
mg NN N
on IN N
25 CD N
of IN N
28 CD N
days NNS N
) ) N
for IN N
two CD N
cycles NNS N
, , N
or CC N
( ( N
iii NN N
) ) N
the DT N
combined JJ i
hormones NNS i
for IN N
six CD N
cycles NNS N
. . N

A DT N
placebo NN i
control NN i
cycle NN N
followed VBD N
each DT N
hormonal JJ N
treatment NN N
. . N

Plasma NNP o
triglycerides NNS o
decreased VBN o
by IN N
an DT N
average JJ N
22 CD N
% NN N
during IN N
treatment NN N
with IN N
either DT N
dl-norgestrel JJ i
alone NN N
( ( N
123 CD N
+/- JJ N
11 CD N
vs. FW N
160 CD N
+/- JJ N
10 CD N
mg/dl NN N
, , N
n JJ N
= NN N
25 CD N
, , N
P NNP N
< NNP N
0.005 CD N
) ) N
or CC N
combination NN N
therapy NN N
( ( N
126 CD N
+/- JJ N
11 CD N
vs. FW N
162 CD N
+/- JJ N
11 CD N
, , N
n RB N
= JJ N
25 CD N
, , N
P NNP N
< NNP N
0.005 CD N
) ) N
as IN N
compared VBN N
with IN N
control NN N
. . N

Plasma NNP o
total JJ o
cholesterol NN o
fell VBD N
by IN N
5 CD N
% NN N
during IN N
two CD N
cycles NNS N
of IN N
treatment NN N
with IN N
either DT N
dl-norgestrel JJ i
alone NN N
( ( N
229 CD N
+/- JJ N
11 CD N
vs. FW N
242 CD N
+/- JJ N
10 CD N
mg/dl NN N
, , N
n JJ N
= NN N
25 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
or CC N
combination NN N
therapy NN N
( ( N
233 CD N
+/- JJ N
11 CD N
vs. FW N
246 CD N
+/- JJ N
10 CD N
, , N
n RB N
= JJ N
25 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
versus NN N
placebo NN N
. . N

During IN N
the DT N
fifth NN N
and CC N
sixth JJ N
cycles NNS N
of IN N
combination NN N
therapy NN N
94 CD N
% NN N
of IN N
cycles NNS N
were VBD N
free JJ o
of IN o
flushing VBG o
( ( N
vs. FW N
31 CD N
% NN N
for IN N
control NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
64 CD N
% NN N
of IN N
cycles NNS N
were VBD N
free JJ o
of IN o
spotting VBG o
not RB o
requiring VBG o
protection NN o
( ( N
control VB N
75 CD N
% NN N
) ) N
, , N
96 CD N
% NN N
of IN N
cycles NNS N
were VBD N
free JJ o
of IN o
vaginal JJ o
bleeding NN o
( ( N
control VB N
100 CD N
% NN N
) ) N
, , N
endometrial JJ N
biopsy NN N
showed VBD N
inactive JJ o
endometrium NN o
in IN N
nine CD N
of IN N
the DT N
10 CD N
subjects NNS N
re-biopsied JJ N
, , N
fasting VBG o
blood NN o
pyruvate NN o
decreased VBN o
by IN N
20 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
diastolic JJ o
blood NN o
pressure NN o
fell VBD o
by IN N
4 CD N
% NN N
compared VBN N
with IN N
control NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
whereas VBP N
glucose JJ o
tolerance NN o
was VBD o
unchanged JJ o
. . o

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
vasomotor NN o
flushing VBG o
beginning VBG N
with IN N
the DT N
third JJ N
to TO N
fourth JJ N
cycles NNS N
of IN N
combination NN N
therapy NN N
. . N

-DOCSTART- -23285026- O O

No DT N
pain NN o
relief NN o
with IN N
the DT N
rubber NN i
hand NN i
illusion NN i
. . i

The DT N
sense NN N
of IN N
body NN N
ownership NN N
can MD N
be VB N
easily RB N
disrupted VBN N
during IN N
illusions NNS N
and CC N
the DT N
most RBS N
common JJ N
illusion NN N
is VBZ N
the DT N
rubber JJ i
hand NN i
illusion NN i
. . i

An DT N
idea NN N
that WDT N
is VBZ N
rapidly RB N
gaining VBG N
popularity NN N
in IN N
clinical JJ N
pain NN N
medicine NN N
is VBZ N
that IN N
body NN i
ownership NN i
illusions NNS i
can MD N
be VB N
used VBN N
to TO N
modify VB N
pathological JJ N
pain NN N
sensations NNS N
and CC N
induce VB N
analgesia NN N
. . N

However RB N
, , N
this DT N
idea NN N
has VBZ N
not RB N
been VBN N
empirically RB N
evaluated VBN N
. . N

Two CD N
separate JJ N
research NN N
laboratories NNS N
undertook VBP N
independent JJ N
randomized VBN N
repeated JJ N
measures NNS N
experiments NNS N
, , N
both DT N
designed VBN N
to TO N
detect VB N
an DT N
effect NN N
of IN N
the DT N
rubber NN i
hand NN i
illusion NN i
on IN N
experimentally RB N
induced JJ N
hand NN o
pain NN o
. . o

In IN N
Experiment JJ N
1 CD N
, , N
16 CD p
healthy JJ p
volunteers NNS p
rated VBD N
the DT N
pain NN o
evoked VBN N
by IN N
noxious JJ i
heat NN i
stimuli NNS i
( ( N
5 CD N
s NN N
duration NN N
; : N
interstimulus CC N
interval JJ N
25 CD N
s NN N
) ) N
of IN N
set NN N
temperatures NNS N
( ( N
47? CD N
, , N
48? CD N
and CC N
49?C CD N
) ) N
during IN N
the DT N
rubber NN i
hand NN i
illusion NN i
or CC i
during IN i
a DT i
control JJ i
condition NN i
. . i

There EX i
was VBD N
a DT N
main JJ N
effect NN N
of IN N
stimulus JJ o
temperature NN o
on IN o
pain NN o
ratings NNS o
, , o
but CC o
no DT N
main JJ o
effect NN o
of IN o
condition NN o
( ( o
p JJ o
= NNP N
0.32 CD N
) ) N
, , N
nor CC N
a DT o
condition NN o
x JJ o
temperature NN o
interaction NN o
( ( o
p JJ o
= NNP N
0.31 CD p
) ) p
. . p

In IN p
Experiment JJ p
2 CD p
, , p
20 CD p
healthy JJ p
volunteers NNS p
underwent JJ p
quantitative JJ N
sensory NN N
testing VBG N
to TO N
determine VB o
heat NN o
and CC o
cold JJ o
pain NN o
thresholds NNS o
during IN o
the DT N
rubber NN i
hand NN i
illusion NN i
or CC i
during IN N
a DT N
control JJ N
condition NN N
. . N

Secondary JJ N
analyses NNS N
involved VBN o
heat NN o
and CC o
cold JJ o
detection NN o
thresholds NNS o
and CC o
paradoxical JJ o
heat NN o
sensations NNS o
. . o

Again NNP o
, , N
there EX N
was VBD N
no DT N
main JJ o
effect NN o
of IN o
condition NN o
on IN o
heat NN o
pain NN o
threshold NN o
( ( o
p JJ o
= NNP N
0.17 CD N
) ) N
, , N
nor CC N
on IN N
cold JJ o
pain NN o
threshold NN o
( ( o
p JJ o
= NNP N
0.65 CD N
) ) N
, , N
nor CC N
on IN N
any DT N
of IN N
the DT N
secondary JJ o
measures NNS o
( ( o
p VB o
< $ N
0.56 CD N
for IN N
all DT N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
rubber NN i
hand NN i
illusion NN i
does VBZ i
not RB N
induce VB o
analgesia NN o
. . o

-DOCSTART- -21949005- O O

Learning VBG N
through IN N
interaction NN N
in IN N
children NNS p
with IN p
autism NN p
: : p
preliminary JJ N
data NNS N
from IN N
asocial-communication-based JJ N
intervention NN N
. . N

The DT N
study NN N
evaluates VBZ N
a DT N
social-communication-based JJ i
approach NN i
to TO N
autism VB N
intervention NN N
aimed VBN N
at IN N
improving VBG N
the DT N
social JJ o
interaction NN o
skills NNS o
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

We PRP N
report VBP N
preliminary JJ N
results NNS N
from IN N
an DT N
ongoing JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
51 CD p
children NNS p
aged VBN p
2 CD p
years NNS p
0 CD p
months NNS p
to TO p
4 CD p
years NNS p
11 CD p
months NNS p
. . p

Participants NNS N
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
target NN N
treatment NN N
or CC N
community NN N
treatment NN N
group NN N
. . N

Families NNS N
in IN N
the DT N
target NN N
treatment NN N
group NN N
were VBD N
given VBN N
2 CD N
hours NNS N
of IN N
therapy NN i
and CC i
coaching VBG i
each DT N
week NN N
in IN N
an DT N
intervention NN N
emphasizing VBG N
social-interaction NN i
and CC i
the DT i
parent-child JJ i
relationship NN i
. . i

Children NNP N
in IN N
the DT N
community NN i
treatment NN i
group NN N
received VBD N
a DT N
variety NN i
of IN i
services NNS i
averaging VBG i
3.9 CD i
hours NNS i
per IN i
week NN i
. . i

After IN N
12 CD N
months NNS N
, , N
outcomes NNS N
were VBD N
measured VBN N
to TO N
determine VB N
changes NNS N
in IN N
the DT N
groups NNS N
in IN N
social JJ N
interaction NN N
and CC N
communication NN N
. . N

In IN N
addition NN N
, , N
a DT N
regression NN N
analysis NN N
was VBD N
conducted VBN N
to TO N
determine VB N
whether IN N
changes NNS N
in IN N
social JJ N
interaction NN N
skills NNS N
were VBD N
associated VBN N
with IN N
language NN N
development NN N
. . N

Results NNS N
suggest VBP N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB N
greater JJR N
gains NNS o
in IN o
social JJ o
interaction NN o
skills NNS o
in IN N
comparison NN N
to TO N
the DT N
community NN N
treatment NN N
group NN N
, , N
but CC N
no DT N
between-group JJ N
differences NNS N
were VBD N
found VBN N
for IN N
standard JJ o
language NN o
assessments NNS o
. . o

Initiation NN o
of IN o
joint JJ o
attention NN o
, , o
involvement NN o
, , o
and CC o
severity NN o
of IN o
language NN o
delay NN o
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
improvement NN N
of IN N
language NN o
skills NNS o
in IN N
children NNS p
with IN p
autism NN p
. . p

Finally RB N
caregiver JJ N
skills NNS N
targeted VBN N
by IN N
the DT N
intervention NN N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
associated VBN N
with IN N
changes NNS N
in IN N
children NNS o
's POS o
interaction NN o
skills NNS o
. . o

-DOCSTART- -9174876- O O

Effect NN N
of IN N
inhaled JJ N
heparin NN i
on IN N
adenosine-induced JJ p
bronchial JJ p
hyperreactivity NN p
. . p

Glycosaminoglycan JJ i
heparin NN i
possesses VBZ N
multiple JJ N
noncoagulant JJ N
properties NNS N
including VBG N
antiinflammatory JJ N
actions NNS N
. . N

We PRP N
have VBP N
previously RB N
shown VBN N
that IN N
heparin NN i
attenuates VBZ N
the DT N
methacholine-induced JJ N
bronchoconstriction NN N
in IN N
humans NNS p
. . p

In IN N
contrast NN N
to TO N
methacholine VB N
, , N
a DT N
stimulus NN N
that WDT N
induces VBZ N
airway RP N
constriction NN N
mainly RB N
by IN N
direct JJ N
stimulation NN N
of IN N
airway JJ N
smooth JJ N
muscle NN N
cells NNS N
, , N
adenosine JJ N
airway RB N
responsiveness JJ N
reflects VBZ N
indirectly RB N
induced VBN N
airway RP N
narrowing VBG N
via IN N
inflammatory JJ N
mediators NNS N
or CC N
neural JJ N
reflex JJ N
mechanisms NNS N
. . N

Whether NNP N
heparin NN i
modulates VBZ N
bronchial JJ N
hyperreactivity NN N
induced VBN N
by IN N
adenosine NN N
, , N
is VBZ N
not RB N
well RB N
known VBN N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
inhaled JJ i
heparin NN i
on IN N
adenosine-induced JJ N
bronchoconstriction NN N
and CC N
compared VBN N
the DT N
inhibitory JJ N
role NN N
of IN N
heparin NN i
on IN N
the DT N
adenosine NN N
challenge NN N
test NN N
with IN N
that DT N
on IN N
the DT N
methacholine NN N
challenge NN N
test NN N
. . N

Fifteen JJ p
subjects NNS p
( ( p
7 CD p
males NNS p
, , p
8 CD p
females NNS p
) ) p
with IN p
mild JJ p
asthma NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Bronchial JJ N
provocation NN N
tests NNS N
were VBD N
performed VBN N
in IN N
a DT N
single-blind NN N
, , N
crossover NN N
, , N
randomized VBN N
order NN N
, , N
and CC N
repeated VBD N
45 CD N
minutes NNS N
after IN N
placebo NN i
or CC N
aerosolized VBN i
heparin JJ i
inhalation NN i
( ( N
1,000 CD N
U/kg NNP N
) ) N
. . N

The DT N
heparin NN i
increased VBD N
the DT N
geometric JJ o
mean NN o
log NN o
methacholine NN o
PD20 NNP o
value NN o
from IN N
0.47 CD N
+/- JJ N
0.16 CD N
( ( N
2.95 CD N
mg/ml NN N
) ) N
to TO N
0.96 CD N
+/- JJ N
0.10 CD N
( ( N
8.91 CD N
mg/ml NN N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.0009 CD N
) ) N
in IN N
15 CD N
patients NNS N
and CC N
the DT N
geometric JJ o
mean NN o
log NN o
adenosine NN o
PD20 NNP o
values VBZ o
from IN N
1.59 CD N
+/- JJ N
0.23 CD N
( ( N
38.9 CD N
mg/ml NN N
) ) N
to TO N
1.98 CD N
+/- JJ N
0.14 CD N
( ( N
97.7 CD N
mg/ml NN N
) ) N
( ( N
NS NNP N
) ) N
in IN N
7 CD N
patients NNS N
whose WP$ N
baseline JJ N
adenosine NN N
PD20 NNP N
levels NNS N
were VBD N
less JJR N
than IN N
200 CD N
mg/ml NN N
. . N

The DT N
degree NN o
of IN o
protection NN o
by IN N
heparin NN i
against IN N
adenosine-induced JJ N
bronchoconstriction NN N
was VBD N
not RB N
correlated VBN N
with IN N
that DT N
against IN N
methacholine-induced JJ N
bronchoconstriction NN N
( ( N
r JJ N
= NN N
0.60 CD N
, , N
NS NNP N
) ) N
. . N

The DT N
data NN N
suggest NN N
that WDT N
inhaled VBD N
heparin NN i
may MD N
have VB N
an DT N
inhibitory JJ N
effect NN N
on IN N
the DT N
methacholine NN N
bronchial JJ N
challenge NN N
, , N
and CC N
thus RB N
, , N
most JJS N
likely JJ N
directs VBZ N
its PRP$ N
effect NN N
against IN N
smooth JJ N
muscle NN N
. . N

Heparin NNP i
caused VBD N
less JJR N
attenuation NN N
of IN N
a DT N
challenge NN N
with IN N
adenosine NN N
and CC N
probably RB N
does VBZ N
not RB N
affect VB N
mast NN N
cell NN N
degranulation NN N
. . N

-DOCSTART- -12017793- O O

Effect NNP N
of IN N
four CD i
intermediate JJ i
layer NN i
treatments NNS i
on IN N
microleakage NN p
of IN p
Class NNP p
II NNP p
composite JJ p
restorations NNS p
. . p

This DT N
in IN N
vitro NN N
study NN N
examines VBZ N
the DT N
marginal JJ N
sealing NN N
ability NN N
of IN N
four CD i
different JJ i
intermediate JJ i
materials NNS i
applied VBN N
before IN N
placement NN N
of IN N
a DT N
condensable JJ i
composite NN i
. . i

Class NNP p
II NNP p
preparations NNS p
were VBD N
made VBN N
with IN N
gingival JJ N
margins NNS N
placed VBD N
1.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
cementoenamel JJ N
junction NN N
of IN N
60 CD p
extracted JJ p
teeth NNS p
, , N
randomly RB N
assigned VBN N
to TO N
five CD p
groups NNS p
of IN p
12 CD p
. . p

Following VBG N
restoration NN N
, , N
teeth EX N
were VBD N
thermocycled VBN N
, , N
soaked VBN N
in IN N
0.5 CD N
% NN N
basic JJ N
fuchsin NN i
, , N
and CC N
sectioned VBD N
longitudinally RB N
. . N

The DT N
resin-modified JJ i
glass NN i
ionomer NN i
cement NN i
demonstrated VBD N
significantly RB N
less JJR o
microleakage NN o
than IN N
the DT N
use NN N
of IN N
a DT N
dentin NN i
bonding NN i
agent NN i
alone RB i
or CC N
in IN N
combination NN i
with IN i
flowable JJ i
composite JJ i
, , N
flowable JJ N
compomer NN N
, , N
or CC N
autoploymerizing VBG N
composite JJ N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
Dunn NNP N
's POS N
test NN N
) ) N
. . N

This DT N
study NN N
supports VBZ N
the DT N
use NN N
of IN N
the DT N
glass NN i
ionomer NN i
open JJ i
sandwich NN i
technique NN i
in IN N
deep JJ p
Class NNP p
II NNP p
direct JJ p
composite JJ p
restorations NNS p
. . p

-DOCSTART- -24335055- O O

Vitamin NNP i
D NNP i
supplementation NN i
increases NNS N
calcium VBP o
absorption NN o
without IN N
a DT N
threshold JJ N
effect NN N
. . N

BACKGROUND IN N
The DT N
maximal JJ N
calcium NN N
absorption NN N
in IN N
response NN N
to TO N
vitamin VB i
D NNP i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
biomarker NN N
for IN N
vitamin NN i
D NNP i
sufficiency NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
there EX N
is VBZ N
a DT N
threshold JJ N
beyond IN N
which WDT N
increasing VBG N
doses NNS N
of IN N
vitamin NN i
D NNP i
, , N
or CC N
concentrations NNS N
of IN N
serum JJ i
25-hydroxyvitamin JJ i
D NNP i
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
, , N
no RB N
longer RBR N
increase VB N
calcium NN o
absorption NN o
. . o

DESIGN NNP N
This DT N
was VBD N
a DT N
placebo-controlled JJ i
, , N
dose-response JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
of IN N
the DT N
effect NN N
of IN N
vitamin NN i
D NNP i
on IN N
calcium NN N
absorption NN N
in IN N
healthy JJ p
postmenopausal NN p
women NNS p
. . p

Seventy-six NNP p
healthy JJ p
postmenopausal NN p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB i
or CC N
800 CD N
IU NNP N
( ( N
20 CD N
?g NN N
) ) N
, , N
2000 CD N
IU NNP N
( ( N
50 CD N
?g NN N
) ) N
, , N
or CC N
4000 CD N
IU NNP N
( ( N
100 CD N
?g NN N
) ) i
vitamin NN i
D? NNP i
for IN N
8 CD N
wk NN N
. . N

The DT N
technique NN N
of IN N
dual JJ N
isotopes NNS N
of IN N
stable JJ N
calcium NN N
was VBD N
used VBN N
with IN N
a DT N
calcium NN N
carrier NN N
to TO N
measure VB N
calcium JJ N
absorption NN N
at IN N
baseline NN N
and CC N
after IN N
8 CD N
wk NN N
. . N

RESULTS NNP p
Seventy-one JJ p
women NNS p
with IN p
a DT p
mean NN p
? . p
SD NNP p
age NN p
of IN p
58.8 CD p
? . p
4.9 CD p
y NN p
completed VBD N
the DT N
study NN N
. . N

The DT o
mean JJ o
calcium NN o
intake NN o
was VBD N
1142 CD N
? . N
509 CD N
mg/d NN N
and CC N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
was VBD N
63 CD N
? . N
14 CD N
nmol/L NN N
at IN N
baseline NN N
. . N

A DT N
statistically RB N
significant JJ N
linear JJ N
trend NN N
of IN N
an DT N
increase NN N
in IN o
calcium JJ o
absorption NN o
adjusted VBN o
for IN N
age NN N
and CC N
body NN N
mass NN N
index NN N
with IN N
increasing VBG i
vitamin NN i
D? NNP i
dose NN i
or CC N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
concentration NN N
was VBD N
observed VBN N
. . N

A DT N
6.7 CD N
% NN N
absolute JJ N
increase NN N
in IN N
calcium JJ o
absorption NN o
was VBD N
found VBN N
in IN N
the DT N
highest JJS N
vitamin NN i
D? NNP i
group NN N
( ( N
100 CD N
?g NN N
) ) N
. . N

No DT N
evidence NN N
of IN N
nonlinearity NN N
was VBD N
observed VBN N
in IN N
the DT N
dose-response JJ N
curve NN N
. . N

CONCLUSIONS NNP N
No NNP N
evidence NN N
of IN N
a DT N
threshold NN N
of IN N
calcium NN N
absorption NN N
was VBD N
found VBN N
with IN N
a DT N
serum NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
range NN N
from IN N
40 CD N
to TO N
130 CD N
nmol/L NNS N
. . N

Calcium NNP o
absorption NN o
in IN o
this DT N
range NN N
is VBZ N
not RB N
a DT N
useful JJ N
biomarker NN N
to TO N
determine VB N
nutritional JJ N
recommendations NNS i
for IN i
vitamin NN i
D NNP i
. . N

-DOCSTART- -15191260- O O

Is VBZ N
individual JJ i
peer NN i
support NN i
a DT N
promising NN N
intervention NN N
for IN N
persons NNS p
with IN p
heart NN p
failure NN p
? . N
Peer NNP i
support NN i
has VBZ N
been VBN N
used VBN N
effectively RB N
in IN N
a DT N
variety NN N
of IN N
patient JJ N
populations NNS N
, , N
but CC N
its PRP$ N
effectiveness NN N
in IN N
improving VBG N
outcomes NNS N
in IN N
persons NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
has VBZ N
not RB N
been VBN N
explored VBN N
. . N

We PRP N
trained VBD N
9 CD p
persons NNS p
with IN p
heart NN p
failure NN p
to TO p
mentor VB i
other JJ i
heart NN i
failure NN i
patients NNS i
and CC N
tested VBD N
the DT N
effectiveness NN N
of IN N
this DT N
approach NN N
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

A DT N
low JJ N
proportion NN N
( ( p
37 CD p
% NN p
) ) p
of IN p
the DT p
eligible JJ p
population NN p
of IN p
hospitalized JJ p
patients NNS p
agreed VBD p
to TO p
participate VB p
. . p

At IN N
the DT N
end NN N
of IN N
the DT N
3-month JJ N
trial NN N
, , N
there EX N
was VBD N
significantly RB N
higher JJR N
heart NN o
failure NN o
self-care NN o
in IN N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
only JJ N
difference NN N
in IN N
social JJ N
support NN N
was VBD N
a DT N
significant JJ N
decline NN N
in IN N
perceived JJ N
support NN o
reciprocity NN o
in IN N
the DT N
intervention NN N
group NN N
( ( N
F NNP N
= NNP N
5.94 CD N
, , N
P NNP N
= NNP N
.004 NNP N
) ) N
. . N

No DT N
significant JJ N
group NN N
differences NNS N
in IN N
heart NN o
failure NN o
readmissions NNS o
, , o
length NN o
of IN o
stay NN o
, , o
or CC o
cost NN o
were VBD N
evident JJ N
at IN N
90-days CD N
, , N
although IN N
the DT N
heart NN o
failure NN o
readmission NN o
rate NN o
was VBD N
96 CD N
% NN N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
when WRB N
compared VBN N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
reasons NNS N
for IN N
low JJ o
overall JJ o
enrollment NN o
and CC o
high JJ o
readmission NN o
rates NNS o
in IN N
the DT N
intervention NN N
group NN N
require VBP N
further JJ N
study NN N
. . N

Including VBG N
additional JJ N
self-care JJ N
education NN N
by IN N
a DT N
professional JJ N
, , N
rather RB N
than IN N
leaving VBG N
all PDT N
the DT N
education NN N
to TO N
the DT N
mentor NN N
, , N
could MD N
strengthen VB N
the DT N
peer NN N
support NN N
intervention NN N
trialed VBN N
in IN N
this DT N
study NN N
. . N

Small NNP N
group NN N
meetings NNS N
may MD N
be VB N
less JJR N
intrusive JJ N
and CC N
more RBR N
desirable JJ N
for IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -16208798- O O

Single-use NNP N
plaque NN N
removal NN N
efficacy NN o
of IN N
three CD p
power NN i
toothbrushes NNS i
. . i

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
safety NN o
and CC o
plaque NN o
removal NN o
efficacy NN o
of IN N
two CD i
oscillating/rotating/pulsating VBG i
toothbrushes NNS i
( ( i
Oral-B NNP i
ProfessionalCare NNP i
7000 CD i
[ NNP i
PC NN i
7000 CD i
] NN i
and CC i
Oral-B JJ i
3D CD i
Excel NNP i
[ VBD i
3DE CD i
] NN i
) ) i
and CC i
a DT i
high-frequency NN i
toothbrush NN i
( ( i
Sonicare NNP i
Advance NNP i
, , i
Philips NNP i
Oral NNP i
Healthcare NNP i
; : i
SA NNP i
) ) i
in IN N
a DT N
single-use NN N
, , N
examiner-blind NN N
, , N
three CD N
period NN N
crossover NN N
study NN N
. . N

METHODS NNP N
After IN p
refraining VBG p
from IN p
all DT p
oral JJ p
hygiene NN p
procedures NNS p
for IN p
23-25 JJ p
hours NNS p
, , p
subjects NNS p
received VBD p
an DT p
oral JJ p
tissue NN p
examination NN p
and CC N
those DT N
with IN N
pre-brushing JJ N
whole JJ N
mouth NN N
mean JJ N
plaque NN N
scores NNS N
> VBP N
or CC N
= VBP N
0.6 CD N
based VBN N
on IN N
the DT N
Rustogi NNP N
et CC N
al NN N
. . N

Modified NNP N
Navy NNP N
Plaque NNP N
Index NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
sequence NN N
. . N

After IN N
brushing VBG N
with IN N
the DT N
assigned JJ N
toothbrush NN N
and CC N
a DT N
commercially RB N
available JJ N
dentifrice NN N
for IN N
2 CD N
minutes NNS N
, , N
oral JJ o
tissues NNS o
were VBD o
then RB o
re-examined JJ o
and CC o
post-brushing JJ o
plaque NN o
scores NNS o
recorded VBN o
. . o

Following VBG N
a DT N
brief JJ N
washout JJ N
period NN N
between IN N
two CD N
additional JJ N
visits NNS N
, , N
the DT N
above NN N
procedures NNS N
were VBD N
repeated VBN N
with IN N
the DT N
two CD N
alternate NN N
toothbrushes NNS N
. . N

One CD N
examiner NN N
, , N
blinded VBD N
to TO N
the DT N
treatment NN N
sequence NN N
, , N
performed VBD N
all DT N
clinical JJ N
measurements NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
79 CD p
subjects NNS p
( ( p
28 CD p
males NNS p
and CC p
51 CD p
females NNS p
) ) p
were VBD p
enrolled VBN p
and CC p
completed VBN p
the DT p
study NN p
. . p

Each DT N
toothbrush NN N
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC N
significantly RB N
reduced VBN N
plaque NN o
levels NNS o
after IN N
a DT N
single JJ N
brushing NN N
. . N

The DT N
PC NN N
7000 CD N
and CC N
3DE CD N
were VBD N
equally RB N
more RBR N
effective JJ N
in IN N
plaque NN o
removal NN o
than IN N
the DT N
SA NNP N
, , N
at IN N
all DT N
tooth DT N
areas NNS N
, , N
reducing VBG N
plaque NN o
by IN N
59.0 CD N
% NN N
, , N
59.7 CD N
% NN N
and CC N
51.8 CD N
% NN N
, , N
respectively RB N
on IN N
whole JJ N
mouth NN N
surfaces NNS N
, , N
and CC N
by IN N
67.5 CD N
% NN N
, , N
67.8 CD N
% NN N
and CC N
59.4 CD N
% NN N
, , N
respectively RB N
on IN N
approximal JJ N
surfaces NNS N
. . N

CONCLUSIONS VB N
The DT N
action NN N
of IN N
the DT N
oscillating/rotating/pulsating NN N
toothbrushes NNS N
( ( N
Oral-B NNP N
ProfessionalCare NNP N
7000 CD N
and CC N
Oral-B NNP N
3D CD N
Excel NNP N
) ) N
was VBD N
more RBR N
effective JJ N
in IN N
plaque NN N
removal NN N
than IN N
the DT N
high-frequency NN N
toothbrush NN N
( ( N
Sonicare NNP N
Advance NNP N
) ) N
. . N

-DOCSTART- -1254157- O O

[ IN N
The DT N
problems NNS N
of IN N
prophylactic JJ i
chemotherapy NN i
, , N
the DT N
second-look JJ N
operation NN N
and CC N
the DT N
maintenance NN N
of IN N
the DT N
remission NN N
in IN N
the DT N
treatment NN N
of IN N
ovarian JJ N
cancer NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

The DT N
results NNS N
of IN N
the DT N
treatment NN N
of IN N
1022 CD p
ovarian JJ p
cancers NNS p
were VBD N
reviewed VBN N
and CC N
the DT N
problems NNS N
of IN N
prophylactic JJ i
chemotherapy NN i
, , N
a DT N
second JJ N
look NN N
operation NN N
and CC N
the DT N
maintenance NN N
of IN N
the DT N
remission NN N
were VBD N
studied VBN N
. . N

In IN N
ovarian JJ p
cancers NNS p
of IN p
stage NN p
1 CD p
and CC p
stage NN p
2 CD p
, , N
a DT N
post-operative JJ i
prophylactic JJ i
chemotherapy NN i
is VBZ N
useful JJ N
only RB N
in IN N
cases NNS N
with IN N
tumor NN N
cells NNS N
in IN N
the DT N
secretions NNS N
of IN N
the DT N
pouch NN N
of IN N
Douglas NNP N
or CC N
in IN N
the DT N
ascites NNS N
and CC N
in IN N
cases NNS N
where WRB N
a DT N
sensitivity NN N
to TO N
the DT N
chemotherapy NN N
can MD N
be VB N
assumed VBN N
. . N

In IN N
about RB N
50 CD N
% NN N
of IN N
primarily RB p
inoperable JJ p
stage NN p
3 CD p
ovarian JJ p
cancers NNS p
, , N
the DT N
random NN N
treatment NN N
with IN N
cyclophosphamide NN i
( ( i
Endoxan NNP i
) ) i
results NNS N
in IN N
a DT N
clinical JJ o
remission NN o
. . o

A DT N
significant JJ N
five CD o
year NN o
cure NN o
rate NN o
can MD N
only RB N
be VB N
obtained VBN N
if IN N
the DT N
uterus NN N
and CC N
the DT N
adnexa NN N
are VBP N
removed VBN N
. . N

Radical JJ N
operation NN N
during IN N
the DT N
remission NN N
appears VBZ N
to TO N
be VB N
very RB N
important JJ N
for IN N
survival NN o
of IN N
the DT N
patient NN N
. . N

For IN N
the DT N
maintenance NN N
of IN N
the DT N
remission NN N
continuous JJ N
chemotherapy NN i
for IN N
at IN N
least JJS N
2 CD N
years NNS N
following VBG N
treatment NN N
by IN N
operation NN N
and CC N
radiotherapy NN i
is VBZ N
necessary JJ N
. . N

-DOCSTART- -7692109- O O

Randomized VBN N
controlled VBD N
study NN N
of IN N
chemoprophylaxis NN N
in IN N
transurethral JJ p
prostatectomy NN p
. . p

We PRP N
studied VBD N
599 CD p
evaluable JJ p
patients NNS p
with IN p
benign JJ p
prostatic JJ p
hypertrophy NN p
at IN p
7 CD p
urological JJ p
units NNS p
. . p

Before IN N
transurethral JJ p
prostatectomy NN p
the DT N
patients NNS N
were VBD N
randomized VBN N
into IN N
3 CD N
groups NNS N
: : N
group NN i
1 CD i
-- : i
197 CD i
patients NNS i
given VBN i
single-dose JJ i
ceftriaxone NN i
( ( i
2 CD i
gm NN i
. . i

) ) i
, , i
group NN i
2 CD i
-- : i
203 CD i
patients NNS i
given VBN i
160/800 CD i
mg. JJ i
trimethoprimsulfamethoxazole NN i
and CC i
group NN i
3 CD i
-- : i
199 CD i
controls NNS i
given VBN i
no DT i
antimicrobial JJ i
prophylaxis NN i
. . i

Patients NNS p
with IN p
a DT p
preoperative JJ p
indwelling NN o
catheter NN o
, , o
positive JJ o
urine JJ o
culture NN o
, , o
signs NNS o
of IN o
active JJ o
infection NN o
or CC o
preoperative JJ o
antibiotic JJ o
treatment NN o
were VBD p
excluded VBN p
. . p

Postoperative NNP o
infectious JJ o
complications NNS o
were VBD N
demonstrated VBN N
in IN N
15 CD N
of IN N
197 CD N
( ( N
7.6 CD N
% NN N
) ) N
, , N
25 CD N
of IN N
203 CD N
( ( N
12.3 CD N
% NN N
) ) N
and CC N
43 CD N
of IN N
199 CD N
( ( N
21.6 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
study NN N
groups NNS N
, , N
respectively RB N
. . N

The DT N
difference NN N
in IN N
infectious JJ o
complications NNS o
between IN N
groups NNS N
1 CD N
and CC N
3 CD N
was VBD N
statistically RB N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
between IN N
groups NNS N
2 CD N
and CC N
3 CD N
it PRP N
was VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Single-dose JJ N
antibiotic JJ N
prophylaxis NN N
proved VBD N
to TO N
be VB N
useful JJ N
in IN N
the DT N
prevention NN N
of IN N
serious JJ o
infectious JJ o
complications NNS o
after IN N
transurethral JJ p
prostatectomy NN p
. . p

-DOCSTART- -8676619- O O

Fludarabine NN i
in IN N
chronic JJ p
leukaemia NN p
. . p

-DOCSTART- -11746070- O O

Evaluating VBG N
the DT N
impact NN N
of IN N
peer NN i
, , i
nurse JJ i
case-managed JJ i
, , i
and CC i
standard JJ i
HIV NNP i
risk-reduction NN i
programs NNS i
on IN N
psychosocial JJ o
and CC o
health-promoting JJ o
behavioral JJ o
outcomes NNS o
among IN N
homeless JJ p
women NNS p
. . p

Investigators NNS N
examined VBD N
the DT N
6-month JJ N
impact NN N
of IN N
three CD N
cognitive-behavioral JJ i
HIV NNP i
risk-reduction NN i
programs NNS i
on IN N
behavioral JJ o
factors NNS o
( ( N
substance NN N
use NN N
and CC N
sexual JJ N
risk NN N
behaviors NNS N
) ) N
and CC N
cognitive JJ o
and CC o
psychological JJ o
resources NNS o
of IN N
325 CD p
women NNS p
who WP p
resided VBD p
in IN p
emergency NN p
or CC p
sober-living NN p
shelters NNS p
and CC p
their PRP$ p
308 CD p
intimate JJ p
sexual JJ p
partners NNS p
. . p

Participants NNS N
were VBD N
randomized VBN N
by IN N
shelter NN N
to TO N
a DT N
peer-mentored JJ o
, , o
a DT o
nurse JJ o
case-managed JJ o
, , o
or CC o
a DT o
standard JJ o
care NN o
HIV NNP o
risk-reduction NN o
program NN i
. . i

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
all DT N
groups NNS N
in IN N
all DT N
behavioral JJ o
factors NNS o
and CC o
cognitive JJ o
and CC o
psychological JJ o
resources NNS o
except IN N
for IN N
self-esteem NN o
. . o

Participants NNS N
in IN N
the DT N
peer-mentored JJ i
and CC i
nurse JJ i
case-managed JJ i
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
from IN N
the DT N
standard JJ i
group NN i
in IN N
self-esteem NN o
, , o
life NN o
satisfaction NN o
, , o
psychological JJ o
well-being NN o
, , o
use NN o
of IN o
noninjection NN o
drugs NNS o
, , o
sex NN o
with IN o
multiple JJ o
partners NNS o
, , o
and CC o
unprotected JJ o
sex NN o
at IN N
6 CD N
months NNS N
( ( N
n JJ N
= NNP N
633 CD N
) ) N
. . N

It PRP N
was VBD N
concluded VBN N
that IN N
a DT N
standard JJ N
approach NN N
by IN N
health NN N
care NN N
professionals NNS N
appears VBZ N
to TO N
effectively RB N
modify VB o
HIV NNP o
risk NN o
behaviors NNS o
for IN N
a DT N
majority NN N
of IN N
homeless JJ p
participants NNS p
and CC N
may MD N
have VB N
important JJ N
economic JJ N
and CC N
policy NN N
implications NNS N
. . N

Further NNP N
, , N
the DT N
impact NN N
of IN N
short-term JJ N
programs NNS N
that WDT N
address VBP N
psychological JJ N
vulnerabilities NNS N
of IN N
impoverished JJ p
populations NNS p
needs NNS N
to TO N
be VB N
studied VBN N
further JJ N
. . N

-DOCSTART- -12492271- O O

Ankle NNP i
cryotherapy NN i
facilitates VBZ N
soleus JJ o
function NN o
. . o

STUDY NNP N
DESIGN NNP N
A NNP N
2-factor JJ N
( ( N
group NN N
and CC N
time NN N
) ) N
experimental JJ N
design NN N
with IN N
repeated JJ N
measures NNS N
on IN N
time NN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
ankle JJ i
cryotherapy NN i
on IN N
voluntary JJ o
and CC o
resting VBG o
motor NN o
function NN o
of IN o
the DT o
soleus NN o
over IN N
a DT N
60-minute JJ N
period NN N
. . N

To TO N
determine VB N
if IN N
a DT N
relationship NN N
exists VBZ N
between IN N
changes NNS N
in IN N
torque NN o
production NN o
and CC N
Hoffmann NNP o
reflex NN o
( ( o
H-reflex NNP o
) ) o
following VBG N
ankle JJ i
joint JJ i
cryotherapy NN i
treatment NN N
. . N

BACKGROUND NNP N
Controversy NNP N
surrounds VBZ N
the DT N
use NN N
of IN N
cryotherapy NN N
prior JJ N
to TO N
activity NN N
and CC N
rehabilitation NN N
. . N

While IN N
cooling VBG N
muscle NN N
may MD N
have VB N
a DT N
deleterious JJ N
effect NN N
on IN N
motor NN o
function NN o
, , N
cooling VBG N
the DT N
joint JJ N
may MD N
enhance VB N
motor NN o
function NN o
around IN N
the DT N
joint JJ N
. . N

The DT N
H-reflex NNP o
is VBZ N
a DT N
good JJ N
resting NN N
measure NN N
of IN N
motoneuronal JJ N
activity NN N
. . N

However RB N
, , N
its PRP$ N
relationship NN N
to TO N
voluntary JJ N
activity NN N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
AND CC N
MEASURES NNP N
Thirty NNP p
subjects NNS p
were VBD N
pretested VBN N
( ( N
baseline NN N
) ) N
for IN N
normalized VBN N
H-reflex NNP o
( ( N
defined VBN N
as IN N
the DT N
ratio NN N
of IN N
maximum JJ N
H-reflex NNP N
[ NNP N
Hmax NNP N
] NNP N
to TO N
maximum VB N
direct JJ N
motor NN N
response NN N
[ NNP N
Mmax NNP N
] NNP N
) ) N
and CC N
peak JJ o
plantar NN o
flexion NN o
torque NN o
. . o

A DT i
crushed JJ i
ice NN i
bag NN i
was VBD i
placed VBN i
over IN i
the DT i
ankle NN i
of IN N
15 CD N
subjects NNS N
for IN N
30 CD N
minutes NNS N
. . N

H-reflex NNP o
and CC o
torque NN o
measurements NNS o
were VBD N
collected VBN N
immediately RB N
following VBG N
the DT N
cryotherapy NN N
treatment NN N
at IN N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
minutes NNS N
. . N

Surface NN o
temperatures NNS o
were VBD N
recorded VBN N
from IN N
the DT N
ankle NN N
and CC N
electrode VB N
site NN N
with IN N
each DT N
measurement NN N
interval NN N
. . N

RESULTS NNP N
Both DT N
peak JJ o
H-reflex NNP o
and CC o
plantar VB o
flexion NN o
torque NN o
at IN N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
minutes NNS N
increased VBD N
relative JJ N
to TO N
baseline VB N
measurements NNS N
. . N

Each DT N
measurement NN N
was VBD N
also RB N
greater JJR N
than IN N
the DT N
corresponding JJ N
control NN N
at IN N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
minutes NNS N
. . N

A DT N
weak JJ N
correlation NN N
( ( N
r JJ N
= VBZ N
0.38 CD N
; : N
P NNP N
= NNP N
0.036 CD N
) ) N
existed VBD N
between IN N
changes NNS N
in IN N
H-reflex NNP o
and CC o
plantar VB o
flexion NN o
torque NN o
at IN N
30 CD N
minutes NNS N
. . N

CONCLUSIONS VB N
The DT N
soleus NN N
motoneuron NN N
pool NN N
is VBZ N
facilitated VBN N
following VBG N
a DT N
30-minute JJ N
crushed JJ i
ice NN i
application NN i
to TO N
the DT N
ankle NN N
and CC N
over IN N
a DT N
60-minute JJ N
postcooling NN N
period NN N
. . N

These DT N
data NNS N
support NN N
the DT N
use NN N
of IN N
joint JJ N
cooling VBG N
prior JJ N
to TO N
activity NN p
and CC p
rehabilitation NN p
. . p

-DOCSTART- -24417452- O O

Evaluating VBG N
intervention NN i
using VBG N
time NN i
aids NNS i
in IN N
children NNS p
with IN p
disabilities NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
complex JJ i
intervention NN i
using VBG i
time NN i
aids NNS i
for IN N
children NNS p
with IN p
intellectual JJ p
and CC p
developmental JJ p
disabilities NNS p
who WP p
exhibit VBP p
limitations NNS p
in IN p
daily JJ p
time NN p
management NN p
. . p

METHODS NNP N
Participating VBG p
children NNS p
( ( p
n JJ p
= NNP p
47 CD p
) ) p
( ( p
F17/M30 NNP p
) ) p
were VBD p
aged VBN p
6-11 JJ p
with IN p
ADHD NNP p
, , p
autism NN p
spectrum NN p
disorders NNS p
, , p
mild NN p
or CC p
moderate JJ p
intellectual JJ p
disability NN p
, , p
spina NN p
bifida NN p
, , p
and CC p
cerebral JJ p
palsy NN p
. . p

This DT N
study NN N
used VBD N
a DT N
Randomized NNP N
Block NNP N
and CC N
Waiting NNP N
List NNP N
control NN N
group NN N
design NN N
, , N
with IN N
25 CD N
children NNS N
allocated VBN N
to TO N
control VB i
and CC N
22 CD N
to TO N
intervention NN i
group NN N
. . N

In IN p
total JJ p
10 CD p
children NNS p
( ( p
21.3 CD p
% NN p
) ) p
, , p
five CD p
from IN p
each DT p
group NN p
, , p
dropped VBD p
out RP p
, , p
leaving VBG p
37 CD p
children NNS p
in IN p
the DT p
data NN p
analysis NN p
. . p

RESULTS NNP N
Children NNP N
in IN N
both DT N
groups NNS N
gained VBD N
significantly RB N
in IN N
time-processing JJ o
ability NN o
between IN N
the DT N
first JJ N
and CC N
second JJ N
data NNS N
collection NN N
, , N
but CC N
the DT N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
improved VBD N
time-processing JJ o
ability NN o
significantly RB N
more RBR N
than IN N
controls NNS N
. . N

The DT N
control NN N
group NN N
also RB N
displayed VBD N
significant JJ N
changes NNS N
after IN N
receiving VBG N
intervention NN N
between IN N
the DT N
second JJ N
and CC N
third JJ N
data NNS N
collection NN N
. . N

The DT N
intervention NN N
had VBD N
a DT N
large JJ N
effect NN N
( ( N
ES NNP N
Cohen NNP N
's POS N
d NN N
= VBZ N
0.81 CD N
) ) N
on IN N
time-processing JJ o
ability NN o
and CC N
a DT N
medium NN N
effect NN N
( ( N
ES NNP N
Cohen NNP N
's POS N
d NN N
= VBZ N
0.68 CD N
) ) N
on IN N
managing VBG o
one CD o
's POS o
time NN o
. . o

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
preliminary JJ N
evidence NN N
that IN N
time-processing JJ o
ability NN o
and CC N
managing VBG o
one CD o
's POS o
time NN o
can MD N
be VB N
improved VBN N
by IN N
intervention NN N
using VBG N
time NN N
aids NNS N
in IN N
children NNS p
with IN p
intellectual JJ p
and CC p
developmental JJ p
disabilities NNS p
, , N
supporting VBG N
the DT N
need NN N
to TO N
consider VB N
time NN N
aids NNS N
in IN N
intervention NN N
in IN N
these DT N
children NNS N
. . N

-DOCSTART- -9769784- O O

Efficacy NN o
of IN N
dose-intensified JJ N
MEC NNP i
( ( i
methotrexate NN i
, , i
epirubicin NN i
and CC i
cisplatin NN i
) ) i
chemotherapy NN N
for IN N
advanced JJ p
urothelial JJ p
carcinoma NN p
: : p
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
MEC NNP i
and CC N
M-VAC NNP i
( ( i
methotrexate NN i
, , i
vinblastine NN i
, , i
doxorubicin NN i
and CC i
cisplatin NN i
) ) i
. . N

Japanese JJ p
Urothelial JJ p
Cancer NNP p
Research NNP p
Group NNP p
. . p

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
antitumor NN o
activity NN o
in IN N
patients NNS p
with IN p
T3b NNP p
, , p
T4 NNP p
or CC p
metastatic JJ p
urothelial JJ p
carcinoma NN p
treated VBN p
with IN p
MEC NNP i
or CC p
M-VAC NNP i
chemotherapy NN p
, , N
by IN N
performing VBG N
a DT N
multi-center JJ N
randomized JJ N
prospective JJ N
study NN N
. . N

METHODS NNP N
From IN p
1991 CD p
to TO p
1995 CD p
, , p
89 CD p
patients NNS p
with IN p
T3b NNP p
, , p
T4 NNP p
or CC p
metastatic JJ p
urothelial JJ p
carcinoma NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
methotrexate NN i
, , i
epirubicin NN i
and CC i
cisplatin NN i
chemotherapy NN i
group NN i
( ( i
arm JJ i
1 CD i
: : i
S-MEC JJ i
therapy NN i
; : i
n CC i
= VB i
29 CD i
) ) i
, , i
a DT i
dose-intensified JJ i
MEC NNP i
therapy NN i
combined VBN i
with IN i
G-CSF NNP i
group NN i
( ( i
arm JJ i
2 CD i
: : i
I-MEC JJ i
therapy NN i
; : i
n CC i
= VB i
30 CD i
) ) i
or CC i
a DT i
methotrexate NN i
, , i
vinblastine NN i
, , i
doxorubicin NN i
and CC i
cisplatin NN i
chemotherapy NN i
( ( i
arm JJ i
3 CD i
: : i
M-VAC JJ i
therapy NN i
; : i
n CC i
= VB i
30 CD i
) ) i
. . i

At IN N
the DT N
registration NN N
center NN N
, , N
the DT N
patients NNS N
were VBD N
stratified VBN N
into IN N
previously RB N
untreated JJ N
patients NNS N
and CC N
patients NNS N
with IN N
recurrence NN N
after IN N
radical JJ N
operation NN N
and CC N
then RB N
randomly RB N
allocated VBN N
to TO N
the DT N
treatment NN N
groups NNS N
. . N

In IN N
each DT N
arm NN N
, , N
two CD N
or CC N
more JJR N
courses NNS N
of IN N
chemotherapy NN N
( ( N
4-week JJ N
cycles NNS N
) ) N
were VBD N
performed VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
88 CD N
eligible JJ N
patients NNS N
, , N
four CD N
treated VBN N
with IN N
S-MEC NNP i
therapy NN i
and CC N
two CD N
treated VBN N
with IN N
I-MEC NNP i
therapy NN N
showed VBD N
CR NNP N
. . N

The DT N
response NN o
rates NNS o
( ( o
CR NNP o
+ NNP o
PR NNP o
) ) o
were VBD N
52 CD N
% NN N
( ( N
15/29 CD N
) ) N
with IN N
S-MEC NNP i
therapy NN i
, , N
76 CD N
% NN N
( ( N
22/29 CD N
) ) N
with IN N
I-MEC NNP i
therapy NN N
and CC N
47 CD N
% NN N
( ( N
14/30 CD N
) ) N
with IN N
M-VAC NNP i
therapy NN N
. . N

The DT N
response NN o
rate NN o
with IN o
I-MEC NNP o
therapy NN o
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
with IN N
M-VAC NNP i
therapy NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Although IN N
the DT N
incidence NN N
of IN N
leukopenia NN N
was VBD N
low JJ N
with IN N
I-MEC NNP o
therapy NN o
, , N
the DT N
incidence NN N
of IN N
thrombocytopenia NN o
was VBD N
high JJ N
with IN N
this DT N
therapy NN N
. . N

CONCLUSION NNP N
MEC NNP i
therapy NN i
used VBN N
in IN N
this DT N
study NN N
is VBZ N
promising VBG N
in IN N
terms NNS N
of IN N
the DT N
antitumor NN o
effects NNS o
. . o

-DOCSTART- -18522171- O O

[ JJ i
Radiotherapy NNP i
of IN N
malignant JJ p
brain NN p
gliomas NN p
using VBG N
teniposide JJ i
] NNP i
. . N

Efficacy NN o
of IN N
radiochemotherapy NN i
of IN N
malignantly-converted JJ p
brain NN p
gliomas NN p
using VBG N
teniposide NN i
was VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

Combined VBN N
use NN N
of IN N
cytostatics NNS i
and CC i
irradiation NN i
appeared VBD N
safe JJ N
, , N
tolerable JJ N
and CC N
significantly RB N
more RBR N
effective JJ N
than IN N
radiotherapy RB i
alone RB i
as IN N
assessed VBN N
by IN N
local JJ o
control NN o
of IN o
tumor NN o
and CC o
survival NN o
. . o

-DOCSTART- -11013281- O O

Treatment NN N
of IN N
brain NN N
metastases NNS N
of IN N
small-cell JJ N
lung NN N
cancer NN N
: : N
comparing NN N
teniposide NN i
and CC N
teniposide NN i
with IN i
whole-brain JJ i
radiotherapy NN i
-- : i
a DT i
phase NN N
III NNP N
study NN N
of IN N
the DT N
European JJ N
Organization NNP N
for IN N
the DT N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
Lung NNP N
Cancer NNP N
Cooperative NNP N
Group NNP N
. . N

PURPOSE NNP N
Approximately RB N
60 CD N
% NN N
of IN N
patients NNS p
with IN p
small-cell JJ p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
develop VB N
brain NN N
metastases NNS N
. . N

Whole-brain JJ i
radiotherapy NN i
( ( i
WBRT NNP i
) ) i
gives VBZ N
symptomatic JJ N
improvement NN N
in IN N
more JJR N
than IN N
50 CD N
% NN N
of IN N
these DT N
patients NNS N
. . N

Because IN N
brain NN N
metastases NNS N
are VBP N
a DT N
sign NN N
of IN N
systemic JJ N
progression NN N
, , N
and CC N
chemotherapy NN N
was VBD N
found VBN N
to TO N
be VB N
effective JJ N
as IN N
well RB N
, , N
it PRP N
becomes VBZ N
questionable JJ N
whether IN N
WBRT NNP i
is VBZ N
the DT N
only JJ N
appropriate JJ N
therapy NN N
in IN N
this DT N
situation NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
phase NN N
III NNP N
study NN N
, , N
SCLC NNP p
patients NNS p
with IN p
brain NN p
metastases NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
teniposide NN i
with IN N
or CC N
without IN N
WBRT NNP i
. . i

Teniposide NNP i
120 CD N
mg/m NN N
( ( N
2 CD N
) ) N
was VBD N
given VBN N
intravenously RB N
three CD N
times NNS N
a DT N
week NN N
, , N
every DT N
3 CD N
weeks NNS N
. . N

WBRT NNP i
( ( N
10 CD N
fractions NNS N
of IN N
3 CD N
Gy NNP N
) ) N
had VBD N
to TO N
start VB N
within IN N
3 CD N
weeks NNS N
from IN N
the DT N
start NN N
of IN N
chemotherapy NN i
. . i

Response NNP N
was VBD N
measured VBN N
clinically RB o
and CC N
by IN N
computed JJ o
tomography NN o
of IN o
the DT o
brain NN o
. . o

RESULTS NNP N
One CD p
hundred VBD p
twenty NN p
eligible JJ p
patients NNS p
were VBD N
randomized VBN N
. . N

A DT N
57 CD N
% NN N
response NN o
rate NN o
was VBD N
seen VBN N
in IN N
the DT N
combined-modality NN N
arm NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
43 CD N
% NN N
to TO N
69 CD N
% NN N
) ) N
, , N
and CC N
a DT N
22 CD N
% NN N
response NN o
rate NN o
was VBD N
seen VBN N
in IN N
the DT N
teniposide-alone JJ i
arm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
12 CD N
% NN N
to TO N
34 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Time NN o
to TO o
progression NN o
in IN o
the DT o
brain NN o
was VBD N
longer RBR o
in IN N
the DT N
combined-modality NN N
group NN N
( ( N
P=.005 NNP N
) ) N
. . N

Clinical JJ o
response NN o
and CC N
response NN o
outside IN N
the DT N
brain NN N
were VBD N
not RB N
different JJ N
. . N

The DT N
median JJ o
survival NN o
time NN o
was VBD N
3.5 CD N
months NNS N
in IN N
the DT N
combined-modality NN N
arm NN N
and CC N
3.2 CD N
months NNS N
in IN N
the DT N
teniposide-alone JJ i
arm NN N
. . N

Overall JJ o
survival NN o
in IN N
both DT N
groups NNS N
was VBD N
not RB N
different JJ N
( ( N
P=.087 NNP N
) ) N
. . N

CONCLUSION NNP N
Adding NNP N
WBRT NNP i
to TO N
teniposide VB N
results NNS N
in IN N
a DT N
much RB N
higher JJR N
response NN o
rate NN o
of IN N
brain NN N
metastases NNS N
and CC N
in IN N
a DT N
longer JJR N
time NN N
to TO N
progression NN N
of IN N
brain NN N
metastases NNS N
than IN N
teniposide RB i
alone JJ N
. . N

Survival NNP o
was VBD N
poor JJ N
in IN N
both DT N
groups NNS N
and CC N
not RB N
significantly RB N
different JJ N
. . N

-DOCSTART- -21704300- O O

Preoperative JJ N
beta-blocker NN i
usage NN i
: : i
is VBZ N
it PRP N
really RB N
worthy JJ N
of IN N
being VBG N
a DT N
quality NN N
indicator NN N
? . N
BACKGROUND NNP N
Since IN N
2007 CD N
, , N
the DT N
use NN N
of IN N
preoperative JJ i
?-blockers NNS i
has VBZ N
been VBN N
used VBN N
as IN N
a DT N
quality NN N
standard NN N
for IN p
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
. . p

Recent JJ N
studies NNS N
have VBP N
called VBN N
into IN N
question NN N
of IN N
the DT N
benefit NN N
of IN N
empiric JJ N
preoperative JJ N
?-blocker NN N
use NN N
. . N

METHODS NNP N
Data NNP N
were VBD N
extracted VBN N
from IN N
our PRP$ N
Society NN N
of IN N
Thoracic NNP N
Surgeons NNP N
certified VBD N
database NN N
for IN p
patients NNS p
undergoing VBG p
isolated JJ p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
from IN p
2000 CD p
to TO p
2008 CD p
. . p

We PRP N
compared VBN N
the DT N
outcomes NNS N
for IN p
patients NNS p
who WP p
received VBD i
preoperative JJ i
?-blockers NNS i
with IN i
those DT p
of IN p
patients NNS p
who WP p
did VBD p
not RB p
. . p

RESULTS VB p
The DT N
study NN N
group NN N
had VBD N
12,855 CD p
patients NNS p
, , p
of IN p
whom WP p
7,967 CD p
( ( p
62.0 CD p
% NN p
) ) p
were VBD p
treated VBN p
preoperatively RB p
with IN p
?-blockers NNS p
. . p

Using VBG p
propensity NN N
matching NN N
, , N
we PRP N
selected VBD N
two CD N
matched JJ N
groups NNS N
of IN N
4,474 CD N
patients NNS N
with IN N
preoperative JJ i
?-blocker NN i
use NN i
and CC N
4,474 CD N
not RB N
using VBG N
preoperative JJ N
?-blockers NNS N
. . N

In IN N
the DT N
unmatched JJ N
cohort NN N
, , N
only RB N
deep JJ o
sternal JJ o
infection NN o
( ( o
0.3 CD o
% NN o
versus IN N
0.5 CD N
% NN N
without IN N
?-blockers NNS N
; : N
p=0.032 NN N
) ) o
, , o
pneumonia NN o
( ( o
1.9 CD o
% NN o
versus IN N
2.4 CD N
% NN N
without IN N
?-blockers NNS N
; : N
p=0.039 NN N
) ) N
, , o
and CC o
intraoperative JJ o
blood NN o
usage NN o
( ( o
37.2 CD N
% NN N
versus IN N
34.1 CD N
% NN N
without IN N
?-blockers NNS N
; : N
p VB N
< $ N
0.001 CD N
) ) N
reached VBD N
statistically RB N
significant JJ N
difference NN N
. . N

In IN N
the DT N
matched JJ N
groups NNS N
, , N
there EX N
was VBD N
no DT N
difference NN o
between IN o
adverse JJ o
event NN o
rates NNS o
in IN o
patients NNS N
treated VBN N
with IN N
?-blockers NNS N
and CC N
those DT N
who WP N
were VBD N
not RB N
. . N

The DT N
number NN N
of IN N
patients NNS N
requiring VBG N
intraoperative JJ o
blood NN o
product NN o
use NN o
was VBD o
significantly RB o
higher JJR N
among IN N
?-blocker-treated JJ N
patients NNS N
( ( N
p=0.004 NN N
) ) N
. . N

Calculating VBG N
the DT N
adjusted VBN N
odds NNS N
ratios NNS N
showed VBD N
that IN N
in IN N
the DT N
matched JJ N
groups NNS N
, , N
the DT N
preoperative JJ N
use NN N
of IN N
?-blockers NNS N
was VBD N
not RB N
an DT N
independent JJ N
predictor NN N
of IN N
mortality NN N
. . N

CONCLUSIONS VB N
A DT N
rational NN N
for IN N
preoperative JJ N
?-blockade JJ N
exists NNS N
. . N

However RB N
, , N
as IN N
with IN N
any DT N
medical JJ N
intervention NN N
, , N
its PRP$ N
application NN N
should MD N
be VB N
tailored VBN N
to TO N
specific JJ N
clinical JJ N
scenarios NNS N
. . N

With IN N
no DT N
differences NNS N
in IN o
mortality NN o
or CC o
morbidity NN o
, , N
our PRP$ N
findings NNS N
do VBP N
not RB N
support VB N
preoperative JJ N
?-blockade NN N
as IN N
a DT N
useful JJ N
quality NN N
indicator NN o
for IN o
coronary JJ N
artery NN N
bypass NN N
graft NN N
surgery NN N
. . N

-DOCSTART- -11004058- O O

The DT N
effect NN N
of IN N
systemic JJ N
lidocaine NN i
on IN N
pain NN o
and CC o
secondary JJ o
hyperalgesia NN o
associated VBN N
with IN N
the DT N
heat/capsaicin NN N
sensitization NN N
model NN N
in IN p
healthy JJ p
volunteers NNS p
. . p

UNLABELLED CC N
Although IN N
effective JJ N
in IN N
neuropathic JJ N
pain NN N
, , N
the DT N
efficacy NN N
of IN N
systemic JJ N
lidocaine NN i
in IN N
non-neuropathic JJ p
pain NN p
remains VBZ N
uncertain JJ N
. . N

We PRP N
investigated VBD N
the DT N
analgesic JJ N
effect NN N
of IN N
systemic JJ i
lidocaine NN i
on IN N
the DT N
heat/capsaicin NN N
sensitization NN N
model NN N
of IN N
experimental JJ p
pain NN p
in IN p
24 CD p
volunteers NNS p
. . p

Sensitization NN N
was VBD N
produced VBN N
by IN N
heating VBG i
the DT i
skin NN i
to TO N
45 CD N
degrees NNS N
C NNP N
for IN N
5 CD N
min NN N
, , N
followed VBN N
by IN N
a DT N
30-min JJ N
application NN N
of IN N
0.075 CD i
% NN i
capsaicin NN i
cream NN i
, , N
and CC N
maintained VBN N
by IN N
periodically RB N
reheating VBG N
the DT N
sensitized JJ N
skin NN N
. . N

Subjects VBZ N
received VBN N
IV NNP N
lidocaine NN i
( ( N
bolus JJ N
2 CD N
mg/kg NN N
, , N
then RB N
infusion NN N
3 CD N
mg. NN N
kg NN N
. . N

h NN N
) ) N
, , N
or CC N
saline NN i
for IN N
85 CD N
min NN N
. . N

Areas NNP N
of IN N
secondary JJ N
hyperalgesia NN N
, , N
heat NN N
pain NN N
detection NN N
thresholds NNS N
, , N
and CC N
painfulness NN N
of IN N
stimulation NN N
with IN N
45 CD N
degrees NNS N
C NNP N
for IN N
1 CD N
min NNS N
( ( N
long JJ N
thermal JJ N
stimulation NN N
) ) N
were VBD N
quantified VBN N
. . N

Systemic NNP N
lidocaine NN i
reduced VBD N
the DT N
area NN o
of IN o
secondary JJ o
hyperalgesia NN o
to TO N
brush VB N
, , N
but CC N
not RB N
to TO N
von VB N
Frey NNP N
hair JJ N
stimulation NN N
. . N

Lidocaine NNP i
did VBD N
not RB N
alter VB N
heat NN o
pain NN o
detection NN o
thresholds NNS o
or CC o
painfulness NN o
of IN o
long JJ o
thermal JJ o
stimulation NN o
in IN N
normal JJ N
skin NN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
at IN N
infusion NN N
rates NNS N
in IN N
the DT N
low- JJ p
to TO p
mid-antiarrhythmic JJ p
range NN p
, , N
lidocaine NN N
has VBZ N
no DT N
effect NN N
on IN N
acute NN o
nociceptive JJ o
pain NN o
but CC N
does VBZ N
have VB N
a DT N
limited JJ N
and CC N
selective JJ N
effect NN N
on IN N
secondary JJ o
hyperalgesia NN o
. . o

IMPLICATIONS VBZ N
The DT N
efficacy NN o
of IN N
systemic JJ N
lidocaine NN i
in IN N
nonneuropathic JJ o
pain NN o
remains VBZ N
uncertain JJ N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
effect NN N
of IN N
systemic JJ N
lidocaine NN i
on IN N
experimental-induced JJ o
hyperalgesia NN o
in IN p
25 CD p
volunteers NNS p
. . p

Hyperalgesia NNP o
was VBD N
induced VBN N
by IN N
using VBG N
an DT N
experimental JJ N
pain NN N
model NN N
that WDT N
uses VBZ N
heat NN N
and CC N
capsaicin NN N
in IN N
combination NN N
. . N

Systemic NNP N
lidocaine NN i
showed VBD N
a DT N
selective JJ N
effect NN o
on IN N
secondary JJ N
hyperalgesia NN N
. . N

-DOCSTART- -24256459- O O

Randomized VBN N
controlled VBD N
effectiveness JJ N
trial NN N
of IN N
executive NN i
function NN i
intervention NN i
for IN N
children NNS p
on IN p
the DT p
autism NN p
spectrum NN p
. . p

BACKGROUND NNP N
Unstuck NNP i
and CC i
On IN i
Target NNP i
( ( i
UOT NNP i
) ) i
is VBZ N
an DT N
executive JJ i
function NN i
( ( i
EF NNP i
) ) i
intervention NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
targeting VBG N
insistence NN N
on IN N
sameness NN N
, , N
flexibility NN N
, , N
goal-setting NN N
, , N
and CC N
planning VBG N
through IN N
a DT N
cognitive-behavioral JJ N
program NN N
of IN N
self-regulatory JJ N
scripts NNS N
, , N
guided/faded VBD N
practice NN N
, , N
and CC N
visual/verbal JJ N
cueing NN N
. . N

UOT NNP i
is VBZ N
contextually-based JJ N
because IN N
it PRP N
is VBZ N
implemented VBN N
in IN N
school NN N
and CC N
at IN N
home NN N
, , N
the DT N
contexts NN N
in IN N
which WDT N
a DT N
child NN N
uses VBZ N
EF NNP N
skills NNS N
. . N

METHODS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
UOT NNP i
compared VBN N
with IN N
a DT N
social JJ i
skills NNS i
intervention NN i
( ( i
SS NNP i
) ) i
, , N
3rd-5th JJ p
graders NNS p
with IN p
ASD NNP p
( ( p
mean JJ p
IQ NNP p
= NNP p
108 CD p
; : p
UOT NNP p
n VBD p
= JJ p
47 CD p
; : p
SS NNP p
n VBD p
= NNP p
20 CD p
) ) p
received VBD p
interventions NNS p
delivered VBN p
by IN p
school NN p
staff NN p
in IN p
small JJ p
group NN p
sessions NNS p
. . p

Students NNS p
were VBD p
matched VBN p
for IN p
gender NN p
, , p
age NN p
, , p
race NN p
, , p
IQ NNP p
, , p
ASD NNP p
symptomotolgy NN p
, , p
medication NN p
status NN p
, , p
and CC p
parents NNS p
' POS p
education NN p
. . p

Interventions NNS p
were VBD N
matched VBN N
for IN N
'dose NNP N
' POS N
of IN N
intervention NN N
and CC N
training NN N
. . N

Measures NNS N
of IN N
pre-post NN N
change NN N
included VBD o
classroom NN o
observations NNS o
, , o
parent/teacher CC o
report NN o
, , o
and CC o
direct JJ o
child NN o
measures NNS o
of IN o
problem-solving NN o
, , o
EF NNP o
, , o
and CC o
social JJ o
skills NNS o
. . o

Schools NNS o
were VBD N
randomized VBN N
and CC N
evaluators NNS N
, , N
but CC N
not RB N
parents NNS N
or CC N
teachers NNS N
, , N
were VBD N
blinded VBN N
to TO N
intervention VB N
type NN N
. . N

RESULTS JJ N
Interventions NNPS N
were VBD N
administered VBN N
with IN N
high JJ N
fidelity NN N
. . N

Children NNP N
in IN N
both DT N
groups NNS N
improved VBN N
with IN N
intervention NN N
, , N
but CC N
mean JJ N
change NN N
scores NNS N
from IN N
pre- NN N
to TO N
postintervention NN N
indicated VBN N
significantly RB N
greater JJR N
improvements NNS i
for IN i
UOT NNP i
than IN i
SS NNP i
groups NNS i
in IN o
: : o
problem-solving NN o
, , o
flexibility NN o
, , o
and CC o
planning/organizing VBG o
. . o

Also RB o
, , N
classroom NN N
observations NNS N
revealed VBD N
that IN N
participants NNS i
in IN i
UOT NNP i
made VBD i
greater JJR N
improvements NNS i
than IN i
SS NNP i
participants NNS i
in IN N
their PRP$ N
ability NN N
to TO N
follow VB N
rules NNS N
, , N
make VBP N
transitions NNS N
, , N
and CC N
be VB N
flexible JJ N
. . N

Children NNP N
in IN N
both DT N
groups NNS N
made VBD N
equivalent JJ N
improvements NNS o
in IN o
social JJ o
skills NNS o
. . o

CONCLUSIONS NNP o
These DT N
data NNS N
support NN N
the DT N
effectiveness NN N
of IN N
the DT N
first JJ N
contextually-based JJ N
EF NNP N
intervention NN p
for IN p
children NNS p
with IN p
ASD NNP i
. . i

UOT NNP i
improved VBD N
classroom NN N
behavior NN N
, , N
flexibility NN N
, , N
and CC N
problem-solving NN p
in IN p
children NNS p
with IN p
ASD NNP p
. . p

Individuals NNS N
with IN N
variable JJ N
background/training NN N
in IN N
ASD NNP N
successfully RB N
implemented VBD i
UOT NNP i
in IN i
mainstream JJ N
educational JJ N
settings NNS N
. . N

-DOCSTART- -25380801- O O

Effect NN N
of IN N
fermented VBN i
milk NN i
containing VBG i
Lactobacillus NNP i
casei NN i
strain NN i
Shirota NNP i
on IN N
constipation-related JJ o
symptoms NNS o
and CC o
haemorrhoids NNS o
in IN N
women NNS p
during IN p
puerperium NN p
. . p

Constipation NN o
and CC o
haemorrhoids NNS o
are VBP N
common JJ N
complaints NNS N
after IN N
childbirth NN N
. . N

The DT N
objective NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
impact NN N
of IN N
fermented JJ i
milk NN i
containing VBG i
Lactobacillus NNP i
casei NN i
strain NN i
Shirota NNP i
( ( i
LcS NNP i
) ) i
on IN p
stool NN o
consistency NN o
and CC o
frequency NN o
, , o
constipation-related JJ o
symptoms NNS o
and CC o
quality NN o
of IN o
life NN o
, , p
and CC p
incidence NN o
of IN o
haemorrhoids NNS o
in IN p
women NNS p
during IN p
puerperium NN p
. . p

Forty NNP p
women NNS p
who WP p
had VBD p
natural JJ p
childbirth NN p
were VBD p
randomised VBN p
to TO p
group NN p
consuming VBG p
either CC p
one CD p
bottle/day NN p
of IN p
fermented JJ i
milk NN i
containing VBG i
at IN i
least JJS i
6.5?109 CD i
cfu NN i
of IN i
LcS NNP i
, , i
or CC i
placebo NN i
, , i
for IN p
6 CD p
weeks NNS p
after IN p
childbirth NN p
. . p

Subjects NNS N
filled VBN N
in IN N
a DT N
diary NN N
on IN N
their PRP$ N
bowel NN N
habits NNS N
including VBG o
number NN o
of IN o
bowel JJ o
movement NN o
, , o
stool NN o
consistency NN o
and CC o
incidence NN o
of IN o
haemorrhoids NNS o
, , o
and CC o
answered VBD o
questionnaires NNS o
on IN o
constipation-related JJ o
symptoms NNS o
( ( o
PAC-SYM NNP o
) ) o
and CC o
quality NN o
of IN o
life NN o
( ( o
PAC-QOL NNP o
) ) o
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
probiotic JJ N
group NN N
showed VBD N
the DT N
better JJR N
scores NNS N
on IN o
overall JJ o
PAC-SYM NNP o
( ( N
P=0.013 NNP N
) ) N
, , N
PAC-SYM JJ o
subscales NNS o
of IN o
abdominal JJ o
symptoms NNS o
( ( N
P=0.043 NNP N
) ) N
and CC N
rectal JJ N
symptoms NNS N
( ( N
P=0.031 NNP N
) ) N
, , N
and CC N
PAC-QOL NNP N
satisfaction NN N
subscale NN N
( ( N
P=0.037 NNP N
) ) N
in IN N
comparison NN N
with IN N
the DT N
placebo NN N
group NN N
. . N

In IN N
the DT N
probiotic JJ N
group NN N
, , N
two CD N
to TO N
four CD N
subjects NNS N
experienced JJ o
haemorrhoids NNS o
during IN N
the DT N
first JJ N
3 CD N
weeks NNS N
of IN N
treatment NN N
. . N

The DT N
number NN N
decreased VBN N
in IN N
week NN N
4 CD N
and CC N
no DT N
one NN N
had VBD o
haemorrhoids VBN o
on IN N
most JJS N
days NNS N
in IN N
week NN N
5-6 JJ N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
on IN N
average JJ N
four CD N
subjects NNS N
had VBD o
haemorrhoids NNS o
from IN N
the DT N
beginning NN N
, , N
and CC N
no DT N
obvious JJ N
change NN N
was VBD N
observed VBN N
until IN N
week NN N
6 CD N
. . N

No DT N
statistically RB N
significant JJ N
effect NN N
was VBD N
observed VBN N
on IN o
stool NN o
consistency NN o
and CC o
frequency NN o
. . o

The DT N
study NN N
products NNS N
did VBD N
not RB N
cause VB N
any DT N
adverse JJ N
event NN N
in IN N
the DT N
subjects NNS N
. . N

Results NNS N
of IN N
this DT N
study NN N
indicate VBP N
that IN N
continuous JJ N
consumption NN N
of IN N
fermented VBN N
milk NN N
containing VBG i
LcS NNP i
might MD N
alleviate VB o
constipation-related JJ o
symptoms NNS o
, , o
provide VBP N
satisfactory JJ o
bowel NN o
habit NN o
and CC N
result NN N
in IN N
earlier JJR o
recovery NN o
from IN o
haemorrhoids NNS o
in IN p
women NNS p
during IN p
puerperium NN p
. . p

Nonetheless RB N
, , N
there EX N
are VBP N
several JJ N
limitations NNS N
in IN N
interpretation NN N
of IN N
the DT N
results NNS N
attributed VBD N
to TO N
the DT N
study NN N
design NN N
, , N
including VBG N
lack NN N
of IN N
baseline NN N
data NNS N
. . N

Further NNP N
study NN N
is VBZ N
required VBN N
in IN N
order NN N
to TO N
confirm VB N
the DT N
efficacy NN N
. . N

-DOCSTART- -22342106- O O

A DT N
randomized VBN N
controlled VBN N
pilot JJ N
trial NN N
of IN N
oral JJ N
N-acetylcysteine NNP i
in IN N
children NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
An DT N
imbalance NN N
in IN N
the DT N
excitatory/inhibitory JJ N
systems NNS N
with IN N
abnormalities NNS N
in IN N
the DT N
glutamatergic NN N
pathways VBZ N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
autism NN N
. . N

Furthermore NNP N
, , N
chronic JJ N
redox NN N
imbalance NN N
was VBD N
also RB N
recently RB N
linked VBN N
to TO N
this DT N
disorder NN N
. . N

The DT N
goal NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
assess VB N
the DT N
feasibility NN N
of IN N
using VBG N
oral JJ i
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
, , N
a DT N
glutamatergic JJ N
modulator NN N
and CC N
an DT N
antioxidant NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
behavioral JJ N
disturbance NN N
in IN N
children NNS p
with IN p
autism NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
12-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
of IN N
NAC NNP i
in IN p
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Subjects VBZ N
randomized VBN N
to TO N
NAC NNP i
were VBD N
initiated VBN N
at IN N
900 CD N
mg NNS N
daily RB N
for IN N
4 CD N
weeks NNS N
, , N
then RB N
900 CD N
mg NNS N
twice RB N
daily RB N
for IN N
4 CD N
weeks NNS N
and CC N
900 CD N
mg NN N
three CD N
times NNS N
daily RB N
for IN N
4 CD N
weeks NNS N
. . N

The DT N
primary JJ N
behavioral JJ N
measure NN N
( ( o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
[ NNP o
ABC NNP o
] NNP o
irritability NN o
subscale NN o
) ) o
and CC N
safety NN N
measures NNS N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
weeks NNS N
. . N

Secondary JJ N
measures NNS N
included VBD N
the DT N
ABC NNP o
stereotypy NN o
subscale NN o
, , o
Repetitive JJ o
Behavior NNP o
Scale-Revised JJ o
, , o
and CC o
Social NNP o
Responsiveness NNP o
Scale NNP o
. . o

RESULTS NNP N
Thirty-three JJ p
subjects NNS p
( ( p
31 CD p
male NN p
subjects NNS p
, , p
2 CD p
female JJ p
subjects NNS p
; : p
aged VBN p
3.2-10.7 CD p
years NNS p
) ) p
were VBD p
randomized VBN p
in IN p
the DT p
study NN p
. . p

Follow-up NNP N
data NN N
was VBD N
available JJ N
on IN N
14 CD p
subjects NNS p
in IN p
the DT p
NAC NNP p
group NN p
and CC p
15 CD p
in IN p
the DT p
placebo NN i
group NN p
. . p

Oral NNP N
NAC NNP i
was VBD N
well RB N
tolerated VBN o
with IN N
limited JJ N
side NN N
effects NNS N
. . N

Compared VBN N
with IN N
placebo NN i
, , i
NAC NNP i
resulted VBD N
in IN N
significant JJ N
improvements NNS N
on IN N
ABC NNP o
irritability NN o
subscale NN o
( ( N
F NNP N
= NNP N
6.80 CD N
; : N
p NN N
< NNP N
.001 NNP N
; : N
d VBZ N
= NNP N
.96 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Data NNP N
from IN N
this DT N
pilot NN N
investigation NN N
support NN N
the DT N
potential JJ N
usefulness NN N
of IN N
NAC NNP i
for IN N
treating VBG N
irritability NN N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Large NNP N
randomized VBD N
controlled VBN N
investigations NNS N
are VBP N
warranted VBN N
. . N

-DOCSTART- -3960619- O O

Zinc NNP o
and CC o
copper NN o
balances NNS o
in IN N
preterm JJ p
infants NNS p
. . p

Preterm NNP p
infants NNS p
are VBP N
at IN N
risk NN N
for IN N
copper NN N
and CC N
zinc NN N
depletion NN N
if IN N
sufficient JJ N
quantities NNS N
of IN N
these DT N
nutrients NNS N
are VBP N
not RB N
provided VBN N
in IN N
a DT N
bioavailable JJ N
form NN N
in IN N
postnatal JJ N
life NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
whey-predominant JJ i
, , i
50 CD i
% NN i
medium NN i
chain NN i
triglyceride IN i
formula NN i
with IN i
relatively RB i
high JJ i
concentrations NNS i
of IN i
zinc NN i
and CC i
copper NN i
would MD N
promote VB N
the DT N
achievement NN N
of IN N
the DT N
in IN o
utero JJ o
accretion NN o
rate NN o
for IN o
zinc NN o
and CC o
copper NN o
in IN N
the DT N
preterm NN p
infant NN p
. . p

Two CD p
groups NNS p
of IN p
five CD p
preterm JJ p
infants NNS p
were VBD N
fed VBN N
a DT N
diet JJ N
containing VBG N
12.5 CD i
mg/L NN i
of IN i
zinc NN i
and CC N
either DT N
0.9 CD i
mg/L NN i
or CC i
2.1 CD i
mg/L NN i
of IN i
copper NN i
. . i

Seventy-two-hour JJ N
metabolic JJ N
balance NN N
studies NNS N
were VBD N
performed VBN N
at IN N
an DT N
average JJ N
postconceptual JJ N
age NN N
of IN N
34 CD N
weeks NNS N
and CC N
an DT N
average JJ N
weight NN N
of IN N
1,549 CD N
g. NN N
All DT N
infants NNS N
were VBD N
in IN N
positive JJ o
zinc NN o
balance NN o
and CC N
nine CD N
of IN N
ten NNS N
achieved VBN N
the DT N
in IN o
utero JJ o
accretion NN o
rate NN o
for IN o
zinc NN o
for IN N
a DT N
34-week JJ N
gestation NN N
fetus NN N
( ( N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
0.432 CD N
mg/d NN N
) ) N
. . N

Three CD N
infants NNS N
receiving VBG N
the DT N
high JJ N
copper NN N
formula NN N
and CC N
two CD N
receiving VBG N
the DT N
lower JJR N
copper NN N
formula NN N
were VBD N
in IN N
positive JJ o
copper NN o
balance NN o
. . o

Two CD N
infants NNS N
from IN N
each DT N
group NN N
achieved VBD N
the DT N
in IN o
utero JJ o
accretion NN o
rate NN o
for IN o
copper NN o
for IN N
a DT N
34-week JJ N
gestation NN N
fetus NN N
( ( N
0.088 CD N
mg/d NN N
) ) N
. . N

A DT N
formula NN N
that WDT N
provides VBZ N
12.5 CD N
mg/L NN N
of IN N
zinc NN N
permits NNS N
positive JJ o
zinc NN o
balance NN o
and CC o
zinc NN o
retention NN o
similar JJ N
to TO N
in IN N
utero JJ N
rates NNS N
. . N

A DT N
formula NN N
that WDT N
provides VBZ N
as RB N
much JJ N
as IN N
2.1 CD N
mg/L NN N
of IN N
copper NN N
, , N
however RB N
, , N
may MD N
not RB N
always RB N
permit VBP N
positive JJ N
copper NN o
balance NN o
. . o

-DOCSTART- -8396304- O O

Cimetidine NNP i
is VBZ N
not RB N
more RBR N
effective JJ o
than IN N
placebo NN i
in IN N
acute JJ p
infectious JJ p
mononucleosis NN p
. . p

-DOCSTART- -18716736- O O

Behavior NNP N
in IN N
children NNS p
with IN p
Down NNP p
syndrome NN p
. . p

OBJECTIVE UH N
To TO N
highlight VB N
the DT N
differences NNS N
in IN N
behaviors NNS N
in IN N
children NNS p
with IN p
diagnosis NN p
of IN p
Down NNP p
syndrome NN p
. . p

METHOD NNP N
Eight NNP p
children NNS p
with IN p
Down NNP p
syndrome NN p
who WP p
displayed VBD p
autistic JJ p
features NNS p
were VBD p
compared VBN p
with IN p
eight CD p
Down NNP p
syndrome NN p
children NNS p
without IN p
autistic JJ p
features NNS p
. . p

These DT N
children NNS N
were VBD N
randomly RB N
selected VBN N
and CC N
were VBD N
matched VBN N
for IN N
age NN N
and CC N
level NN N
of IN N
retardation NN N
. . N

Standardized JJ i
Psychological JJ i
tests NNS i
were VBD N
administered VBN N
to TO N
tap VB N
the DT N
behavioral JJ N
differences NNS N
. . N

Mann-Whitney NNP o
U NNP o
test NN o
was VBD N
used VBN N
for IN N
significance NN N
of IN N
difference NN N
between IN N
both CC N
the DT N
groups NNS N
. . N

RESULTS NNP N
Down NNP N
syndrome JJ N
children NNS N
without IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
had VBD N
better JJR N
communication NN o
and CC o
socialization NN o
skills NNS o
than IN N
children NNS N
with IN N
Down NNP N
syndrome NN N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
. . N

Down NNP N
syndrome JJ N
children NNS N
with IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
displayed VBD N
more RBR o
restricted JJ o
repetitive NN o
and CC o
stereotyped VBD o
patterns NNS o
of IN o
behaviors NNS o
, , o
interests NNS o
and CC o
activities NNS o
. . o

CONCLUSION NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
manifests VBZ N
as IN N
a DT N
distinct JJ N
behavioral JJ o
phenomenon NN o
in IN N
Down NNP N
syndrome NN N
. . N

Hence NN N
it PRP N
is VBZ N
important JJ N
for IN N
professionals NNS N
to TO N
consider VB N
the DT N
possibility NN N
of IN N
a DT N
dual JJ N
diagnosis NN N
which WDT N
will MD N
entitle VB N
the DT N
child NN N
to TO N
a DT N
more JJR N
specialized JJ N
and CC N
effective JJ N
educational JJ N
and CC N
intervention NN N
services NNS N
. . N

-DOCSTART- -24371832- O O

Effects NNS N
of IN N
water NN i
extracts NNS i
of IN i
Graptopetalum NNP i
paraguayense NN i
on IN N
blood NN o
pressure NN o
, , o
fasting VBG o
glucose NN o
, , o
and CC o
lipid JJ o
profiles NNS o
of IN N
subjects NNS p
with IN p
metabolic JJ p
syndrome NN p
. . p

This DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
water NN i
extracts NNS i
of IN i
Graptopetalum NNP i
paraguayense NN i
( ( i
WGP NNP i
, , i
4 CD i
g/d NN i
) ) i
on IN N
blood NN o
pressure NN o
, , o
blood NN o
glucose JJ o
level NN o
, , o
and CC o
lipid JJ o
profiles NNS o
in IN N
subjects NNS p
with IN p
metabolic JJ p
syndrome NN p
( ( p
MS NNP p
) ) p
. . p

Participants NNS p
with IN p
MS NNP p
( ( p
n JJ p
= NNP p
54 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
placebo NN i
( ( N
n JJ N
= NNP N
28 CD N
) ) N
and CC N
WGP NNP i
groups NNS N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
, , N
and CC N
the DT N
intervention NN N
was VBD N
administered VBN N
for IN N
12 CD N
weeks NNS N
. . N

Systolic NNP o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
, , o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
, , o
fasting VBG o
glucose NN o
( ( o
FG NNP o
) ) o
, , o
lipid JJ o
profiles NNS o
( ( o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
triglyceride RB o
( ( o
TG NNP o
) ) o
, , o
low JJ o
density NN o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
, , o
and CC o
high JJ o
density NN o
lipoprotein NN o
( ( o
HDL-C NNP o
) ) o
) ) o
, , o
and CC o
antioxidant JJ o
enzymes NNS o
activities NNS N
( ( N
catalase NN N
( ( N
CAT NNP N
) ) N
, , N
superoxide JJ N
dismutase NN N
( ( N
SOD NNP N
) ) N
, , N
and CC N
glutathione NN N
peroxidase NN N
( ( N
GPx NNP N
) ) N
) ) N
were VBD N
measured VBN N
. . N

Forty-two JJ p
subjects NNS p
completed VBD p
the DT p
study NN p
( ( i
placebo NN i
, , p
n JJ p
= VBP p
19 CD p
; : p
WGP NNP i
, , p
n JJ p
= NNP p
23 CD p
) ) p
. . N

FG NNP o
, , o
SBP NNP o
, , o
and CC o
LDL-C JJ o
levels NNS o
were VBD o
significantly RB o
lower JJR o
and CC N
HDL-C NNP o
level NN o
and CC o
antioxidant JJ o
enzymes NNS o
activities NNS o
( ( o
CAT NNP o
and CC o
SOD NNP o
) ) o
were VBD o
significantly RB o
higher JJR o
after IN N
WGP NNP N
supplementation NN N
. . N

Blood NNP o
pressure NN o
, , o
FG NNP o
, , o
and CC o
lipid JJ o
profiles NNS o
were VBD N
significantly RB N
correlated VBN N
with IN N
antioxidant JJ N
enzymes NNS N
activities NNS N
after IN N
supplementation NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
present JJ N
study NN N
demonstrated VBD N
a DT N
significant JJ N
reduction NN N
in IN N
blood NN o
pressure NN o
, , o
blood NN o
glucose NN o
, , o
and CC o
lipid JJ o
profiles NNS o
and CC N
an DT N
increase NN N
in IN N
antioxidant JJ o
enzymes NNS o
activities NNS o
in IN N
subjects NNS p
with IN p
MS NNP p
after IN N
WGP NNP i
supplementation NN N
. . N

Taken VB N
together RB N
, , N
the DT N
antioxidative JJ N
capacity NN N
of IN N
WGP NNP i
might MD N
exert VB N
a DT N
beneficial JJ N
effect NN N
on IN N
MS NNP N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
NCT01463748 NNP N
. . N

-DOCSTART- -10971307- O O

Influence NN N
of IN N
asimadoline NN i
, , N
a DT N
new JJ N
kappa-opioid JJ N
receptor NN N
agonist NN N
, , N
on IN N
tubular JJ N
water NN N
absorption NN N
and CC N
vasopressin NN p
secretion NN p
in IN p
man NN p
. . p

AIMS VBZ N
The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS o
of IN N
asimadoline NN i
, , N
a DT N
new JJ N
kappa-opioid JJ N
agonist NN N
, , N
on IN N
renal JJ N
function NN N
and CC N
on IN N
hormones NNS N
related VBN N
to TO N
body NN N
fluid JJ N
balance NN N
as RB N
well RB N
as IN N
its PRP$ N
tolerability NN N
in IN N
healthy JJ p
subjects NNS p
. . p

METHODS NNP N
In IN N
a DT N
placebo-controlled JJ i
, , N
randomised JJ N
, , N
double-blind JJ N
crossover NN N
design NN N
we PRP N
studied VBD N
the DT N
effects NNS N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
1 CD i
, , i
5 CD i
, , i
and CC i
10 CD i
mg NN i
of IN i
asimadoline NN i
, , N
in IN N
24 CD p
healthy JJ p
volunteers NNS p
. . p

Two CD N
hour NN N
control NN N
urine JJ N
collections NNS N
were VBD N
followed VBN N
by IN N
2 CD N
h NNS N
postdose JJ N
urine JJ N
collections NNS N
and CC N
subsequently RB N
2.5 CD i
% NN i
saline NN i
was VBD N
given VBN N
i.v NN N
. . N

at IN N
a DT N
rate NN N
of IN N
0.3 CD N
ml NNS N
min NN N
( ( N
-1 NNP N
) ) N
kg NN N
( ( N
-1 JJ N
) ) N
during IN N
another DT N
2 CD N
h NN N
urine JJ N
collection NN N
. . N

Blood NNP N
was VBD N
obtained VBN N
hourly RB N
. . N

Arginine-vasopressin NNP o
( ( o
AVP NNP o
) ) o
, , o
atrial JJ o
natriuretic JJ o
peptide NN o
( ( o
alpha-hANP JJ o
) ) o
, , o
endothelin FW o
( ( o
ET-1 NNP o
) ) o
and CC o
cAMP NN o
were VBD N
determined VBN N
by IN N
r.i.a NN N
. . N

or CC N
ELISA NNP N
. . N

RESULTS NNP N
GC-MS JJ N
measurements NNS N
revealed VBD N
Cmax NNP o
values NNS o
of IN o
asimadoline NN o
in IN o
plasma NN o
ranging VBG N
from IN N
18 CD N
ng JJ N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
1 CD N
mg NN N
dose NN N
, , N
91 CD N
ng NN N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
5 CD N
mg NN N
dose NN N
, , N
to TO N
214 CD N
ng NNS N
ml NN N
( ( N
-1 NN N
) ) N
at IN N
the DT N
10 CD N
mg NN N
dose NN N
after IN N
an DT N
average NN N
of IN N
1.1-1.4 JJ N
h. NN N
Without NNP N
effects NNS N
on IN N
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
GFR NNP o
or CC o
urine JJ o
electrolyte JJ o
excretion NN o
, , o
urine JJ o
volume NN o
increased VBD N
after IN N
1-2 JJ N
h NN N
after IN N
administration NN N
of IN N
5 CD N
and CC N
10 CD N
mg NNS N
asimadoline VBP N
from IN N
3.3+/-1.3 JJ N
to TO N
5.6+/-1.4 JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
from IN N
3.2 CD N
+/-1.6 JJ N
to TO N
5.5+/-2.2 JJ N
ml NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
respectively RB N
. . N

CH2O NNP o
rose VBD N
from IN N
0.2+/-1.5 JJ N
to TO N
2.0+/-1.6 JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
from IN N
0.6+/-1.6 JJ N
to TO N
3.0+/-1.6 JJ N
ml NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Urinary JJ o
excretion NN o
of IN N
AVP NNP N
was VBD N
suppressed VBN N
only RB N
with IN N
the DT N
10 CD N
mg NNS N
dose RB N
from IN N
46+/-23 JJ N
to TO N
25+/-15 JJ N
fmol NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
without IN N
and CC N
from IN N
410+/-206 JJ N
to TO N
181+/-125 JJ N
fmol NN N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
stimulation NN N
by IN N
2.5 CD N
% NN N
saline NN N
. . N

Plasma NNP o
AVP NNP o
was VBD N
suppressed VBN N
only RB N
by IN N
the DT N
10 CD N
mg NN N
dose NN N
of IN N
asimadoline NN N
in IN N
six CD N
of IN N
eight CD N
subjects NNS N
during IN N
the DT N
2.5 CD N
% NN N
saline JJ N
infusion NN N
. . N

Changes NNS N
in IN N
the DT N
alpha-hANP JJ N
or CC N
ET-1 JJ N
systems NNS N
were VBD N
not RB N
affected VBN N
by IN N
asimadoline NN N
. . N

CONCLUSIONS NNP N
Asimadoline NNP i
is VBZ N
diuretic JJ N
in IN N
man NN N
after IN N
single JJ N
doses NNS N
of IN N
5 CD N
or CC N
10 CD N
mg NN N
probably RB N
through IN N
a DT N
direct JJ N
effect NN N
at IN N
the DT N
renal JJ N
tubular JJ N
level NN N
. . N

Suppression NN N
of IN N
AVP NNP N
secretion NN N
was VBD N
observed VBN N
only RB N
at IN N
the DT N
highest JJS N
dose JJ N
level NN N
of IN N
10 CD N
mg NN N
of IN N
asimadoline NN N
. . N

-DOCSTART- -26573368- O O

A DT N
randomised JJ N
double-blind JJ N
placebo-controlled JJ i
trial NN N
investigating VBG N
the DT N
behavioural JJ N
effects NNS N
of IN N
vitamin NN i
, , i
mineral JJ i
and CC i
n-3 JJ i
fatty JJ i
acid JJ i
supplementation NN i
in IN N
typically RB p
developing VBG p
adolescent JJ p
schoolchildren NN p
. . p

Nutrient JJ N
deficiencies NNS N
have VBP N
been VBN N
implicated VBN N
in IN N
anti-social JJ N
behaviour NN N
in IN N
schoolchildren NN N
; : N
hence NN N
, , N
correcting VBG N
them PRP N
may MD N
improve VB N
sociability NN N
. . N

We PRP N
therefore RB N
tested VBD N
the DT N
effects NNS N
of IN N
vitamin NN i
, , i
mineral JJ i
and CC i
n-3 JJ i
supplementation NN i
on IN N
behaviour NN N
in IN N
a DT N
12-week JJ N
double-blind NN N
randomised VBD N
placebo-controlled JJ N
trial NN N
in IN N
typically RB p
developing VBG p
UK NNP p
adolescents NNS p
aged VBN p
13-16 CD p
years NNS p
( ( p
n RB p
196 CD p
) ) p
. . p

Changes NNS N
in IN N
erythrocyte JJ N
n-3 JJ N
and CC N
6 CD N
fatty JJ N
acids NNS N
and CC N
some DT N
mineral NN N
and CC N
vitamin NN N
levels NNS N
were VBD N
measured VBN N
and CC N
compared VBN N
with IN N
behavioural JJ N
changes NNS N
, , N
using VBG N
Conners NNP N
' POS N
teacher NN N
ratings NNS N
and CC N
school NN N
disciplinary JJ N
records NNS N
. . N

At IN N
baseline NN N
, , N
the DT N
children NNS N
's POS N
PUFA NNP N
( ( N
n-3 JJ N
and CC N
n-6 JJ N
) ) N
, , N
vitamin FW o
and CC o
mineral JJ o
levels NNS o
were VBD N
low JJ N
, , N
but CC N
they PRP N
improved VBD N
significantly RB N
in IN N
the DT N
group NN N
treated VBD N
with IN N
n-3 JJ N
, , N
vitamins NNS i
and CC i
minerals NNS i
( ( N
P=0?0005 NNP N
) ) N
. . N

On IN N
the DT o
Conners NNP o
disruptive JJ o
behaviour NN o
scale NN o
, , o
the DT N
group NN N
given VBN N
the DT i
active JJ i
supplements NNS i
improved VBN N
, , N
whereas IN N
the DT i
placebo NN i
group NN N
worsened VBD N
( ( N
F=5?555 NNP N
, , N
d=0?35 NN N
; : N
P=0?02 NNP N
) ) N
. . N

The DT N
general JJ o
level NN o
of IN o
disciplinary JJ o
infringements NNS o
was VBD o
low JJ N
, , N
thus RB N
making VBG N
it PRP N
difficult JJ N
to TO N
obtain VB N
improvements NNS N
. . N

However RB N
, , N
throughout IN N
the DT N
school NN N
term NN N
school NN o
disciplinary JJ o
infringements NNS o
increased VBN o
significantly RB N
( ( N
by IN N
25 CD N
% NN N
; : N
Bayes NNP N
factor=115 NN N
) ) N
in IN N
both CC N
the DT N
treated VBN N
and CC N
untreated JJ N
groups NNS N
. . N

However RB N
, , N
when WRB N
the DT N
subjects NNS N
were VBD N
split VBN N
into IN N
high JJ N
and CC N
low JJ N
baseline NN N
infringements NNS N
, , N
the DT N
low JJ N
subset NN N
increased VBD N
their PRP$ N
offences NNS N
, , N
whereas IN N
the DT N
high-misbehaviour JJ N
subset NN N
appeared VBD N
to TO N
improve VB N
after IN N
treatment NN N
. . N

But CC N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
determine VB N
whether IN N
this DT N
was VBD N
merely RB N
a DT N
statistical JJ N
artifact NN N
. . N

Thus RB N
, , N
when WRB N
assessed VBN N
using VBG N
the DT N
validated JJ N
and CC N
standardised JJ N
Conners NNP N
teacher NN N
tests NNS N
( ( N
but CC N
less JJR N
clearly RB N
when WRB N
using VBG N
school NN N
discipline NN N
records NNS N
in IN N
a DT N
school NN N
where WRB N
misbehaviour NN N
was VBD N
infrequent NN i
) ) i
, , i
supplementary JJ i
nutrition NN i
might MD i
have VB N
a DT N
protective JJ N
effect NN N
against IN N
worsening VBG N
behaviour NN N
. . N

-DOCSTART- -2672925- O O

Amiprilose NNP i
hydrochloride NN i
for IN N
rheumatoid JJ p
arthritis NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
assess VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
amiprilose JJ i
hydrochloride NN i
( ( i
HCl NNP i
) ) i
, , N
a DT N
novel JJ N
synthetic JJ N
carbohydrate NN N
with IN N
anti-inflammatory JJ N
and CC N
immunomodulatory JJ N
properties NNS N
, , N
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
. . p

DESIGN NNP N
Prospective NNP N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
, , N
double-blind JJ N
placebo-controlled JJ i
12-week JJ N
trial NN N
. . N

PATIENTS VB N
Two CD p
hundred CD p
and CC p
one CD p
functional JJ p
class NN p
I PRP p
and CC p
II NNP p
patients NNS p
with IN p
definite JJ p
or CC p
classic JJ p
rheumatoid NN p
arthritis NN p
, , p
previously RB p
untreated VBN p
with IN p
disease NN p
modifying VBG p
antirheumatic JJ p
drugs NNS p
. . p

INTERVENTIONS NN N
Patients NNPS N
were VBD N
withdrawn VBN N
from IN N
nonsteroidal JJ N
anti-inflammatory JJ N
drug NN N
therapy NN N
. . N

Those DT N
who WP N
flared VBD N
were VBD N
randomly RB N
assigned VBN N
to TO N
amiprilose VB i
HCl NNP i
, , i
6 CD i
g/d NN i
, , i
or CC i
placebo NN i
for IN N
12 CD N
weeks NNS N
. . N

No DT N
concomitant JJ N
anti-inflammatory NN N
or CC N
antirheumatic JJ N
drug NN N
therapy NN N
was VBD N
permitted VBN N
during IN N
the DT N
study NN N
. . N

Combination NNP N
acetaminophen NN N
and CC N
propoxyphene NN N
napsylate NN N
was VBD N
the DT N
only JJ N
supplemental JJ N
analgesic JJ N
medication NN N
allowed VBN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
number NN o
of IN o
painful JJ o
joints NNS o
and CC o
swollen JJ o
joints NNS o
, , o
joint JJ o
pain NN o
and CC o
joint JJ o
swelling NN o
indices NNS o
, , o
left VBD o
and CC o
right JJ o
grip NN o
strength NN o
, , o
investigator NN o
global JJ o
assessment NN o
, , o
and CC o
patient JJ o
global JJ o
assessment NN o
returned VBD N
to TO N
baseline VB N
for IN N
the DT N
amiprilose JJ i
group NN N
and CC N
showed VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
differences NNS N
from IN N
the DT N
placebo NN i
group NN N
within IN N
4 CD N
to TO N
6 CD N
weeks NNS N
. . N

The DT N
protocol NN N
criteria NNS N
for IN N
overall JJ o
therapeutic JJ o
response NN o
were VBD N
satisfied VBN N
by IN N
41 CD N
% NN N
of IN N
the DT N
amiprilose JJ i
patients NNS N
, , N
compared VBN N
with IN N
21 CD N
% NN N
of IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

Approximately RB N
0.5 CD N
tablet NNS N
per IN N
day NN N
less CC N
analgesic JJ o
medication NN o
was VBD N
taken VBN N
by IN N
the DT N
amiprilose JJ N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
at IN N
weeks NNS N
6 CD N
and CC N
12 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
morning NN o
stiffness NN o
, , o
walking VBG o
time NN o
, , o
erythrocyte JJ o
sedimentation NN o
rate NN o
, , o
C-reactive JJ o
protein NN o
, , o
or CC o
rheumatoid VB o
factor NN o
between IN N
the DT N
groups NNS N
. . N

A DT N
similar JJ N
number NN N
of IN N
adverse JJ o
experiences NNS o
were VBD N
reported VBN N
by IN N
the DT N
patients NNS N
on IN N
amiprilose JJ i
( ( N
67 CD N
% NN N
) ) N
and CC N
on IN N
placebo NN i
( ( N
63 CD N
% NN N
) ) N
. . N

One CD N
patient NN N
on IN N
amiprilose NN i
developed VBN N
thrombocytopenia NN o
of IN N
unknown JJ N
cause NN N
; : N
no DT N
other JJ N
reported VBD N
adverse JJ o
effects NNS o
were VBD N
serious JJ N
. . N

CONCLUSIONS NNP N
Amiprilose NNP i
HCl NNP i
has VBZ N
significant JJ N
anti-inflammatory JJ o
activity NN o
and CC N
a DT N
favorable JJ o
safety NN o
profile NN o
when WRB N
used VBN N
as IN N
the DT N
sole JJ N
antirheumatic JJ N
therapy NN N
in IN N
patients NNS p
with IN p
active JJ p
rheumatoid NN p
arthritis NN p
. . p

Synthetic JJ N
carbohydrates NNS N
may MD N
represent VB N
an DT N
important JJ N
new JJ N
class NN N
of IN N
drugs NNS N
for IN N
the DT N
treatment NN N
of IN N
inflammatory NN N
, , N
autoimmune JJ N
diseases NNS N
. . N

-DOCSTART- -26109247- O O

A DT N
Randomized NNP N
Controlled NNP N
Trial NNP N
to TO N
Improve VB N
Social NNP N
Skills NNP N
in IN N
Young NNP p
Adults NNP p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
: : p
The DT N
UCLA NNP i
PEERS NNP i
( ( i
? . i
) ) i
Program NNP i
. . i

Research NNP N
suggests VBZ N
that IN N
impaired JJ N
social JJ N
skills NNS N
are VBP N
often RB N
the DT N
most RBS N
significant JJ N
challenge NN N
for IN N
those DT N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
yet RB N
few JJ N
evidence-based JJ o
social JJ o
skills NNS o
interventions NNS N
exist VBP N
for IN p
adults NNS p
on IN p
the DT p
spectrum NN p
. . p

This DT N
replication NN N
trial NN N
tested VBD N
the DT o
effectiveness NN o
of IN i
PEERS NNP i
, , i
a DT i
caregiver-assisted JJ i
social JJ i
skills NNS i
program NN i
for IN p
high-functioning JJ p
young JJ p
adults NNS p
with IN p
ASD NNP p
. . p

Using VBG N
a DT N
randomized VBN p
controlled JJ p
design NN p
, , p
22 CD p
young JJ p
adults NNS p
18-24 JJ p
years NNS p
of IN p
age NN p
were VBD p
randomly RB p
assigned VBN p
to TO N
a DT N
treatment NN i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
or CC i
delayed VBN i
treatment NN i
control NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
group NN N
. . N

Results NNP N
revealed VBD N
that IN N
the DT N
treatment NN N
group NN N
improved VBD N
significantly RB N
in IN o
overall JJ o
social JJ o
skills NNS o
, , o
frequency NN o
of IN o
social JJ o
engagement NN o
, , o
and CC o
social JJ o
skills NNS o
knowledge NN o
, , o
and CC N
significantly RB N
reduced VBN o
ASD NNP o
symptoms NNS o
related VBN o
to TO o
social JJ o
responsiveness NN o
following VBG o
PEERS NNP o
. . o

Most JJS N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
a DT N
16-week JJ N
follow-up JJ N
assessment NN N
with IN N
new JJ N
improvements NNS N
observed VBN N
. . N

-DOCSTART- -19365397- O O

Deep JJ o
vein NN o
thrombosis NN o
in IN N
acute JJ p
spinal JJ p
cord NN p
injury NN p
. . p

STUDY NNP N
DESIGN NNP N
Randomized NNP N
study NN N
. . N

OBJECTIVES NNP N
To TO N
find VB N
out RP N
the DT N
incidence NN N
of IN N
deep JJ N
vein NN N
thrombosis NN N
( ( N
DVT NNP N
) ) N
in IN N
acute JJ p
spinal JJ p
cord NN p
injury NN p
( ( p
SCI NNP p
) ) p
patients NNS p
with IN p
and CC p
without IN p
therapeutic JJ i
prophylaxis NN i
. . i

SETTING NN N
Patients NNPS p
admitted VBN p
in IN p
the DT p
department NN p
of IN p
Physical NNP p
Medicine NNP p
& CC p
Rehabilitation NNP p
, , p
SMS NNP p
Medical NNP p
College NNP p
, , p
Jaipur NNP p
, , p
India NNP p
. . p

METHODS NNP N
All DT p
297 CD p
patients NNS p
received VBD p
physical JJ i
therapy NN i
measures NNS i
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

166 CD N
patients NNS N
received VBD N
prophylactic JJ i
heparin NN i
, , N
whereas JJ N
131 CD N
patients NNS N
did VBD N
not RB N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
three CD N
cases NNS N
( ( N
1.8 CD N
% NN N
) ) N
in IN N
study NN N
group NN N
and CC N
four CD N
cases NNS N
( ( N
3 CD N
% NN N
) ) N
in IN N
control NN N
group NN N
developed VBD N
DVT NNP N
. . N

This DT N
difference NN o
was VBD o
statistically RB o
insignificant JJ o
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Incidence NNP o
of IN o
DVT NNP o
in IN N
SCI NNP N
is VBZ N
low JJ o
in IN N
our PRP$ N
study NN N
. . N

-DOCSTART- -25526832- O O

Improving VBG N
peer NN o
engagement NN o
of IN N
children NNS p
with IN p
autism NN p
on IN p
the DT p
school NN p
playground NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
test VB N
the DT N
effects NNS N
of IN N
a DT N
psychosocial JJ i
intervention NN i
, , i
Remaking VBG i
Recess NNP i
, , N
on IN N
peer NN N
engagement NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Using VBG N
a DT N
randomized VBN N
, , N
wait-list-controlled JJ N
design NN N
, , N
the DT N
intervention NN N
was VBD N
implemented VBN N
during IN N
recess NN N
at IN N
four CD p
elementary JJ p
schools NNS p
. . p

The DT N
immediate JJ i
treatment NN i
( ( i
IT NNP i
) ) i
group NN p
consisted VBD p
of IN p
13 CD p
( ( p
2 CD p
female NN p
) ) p
elementary JJ p
school NN p
students NNS p
with IN p
ASD NNP p
and CC p
the DT p
wait-list NN i
( ( i
WL NNP i
) ) i
group NN i
contained VBD p
11 CD p
( ( p
4 CD p
female NN p
) ) p
students NNS p
with IN p
ASD NNP p
. . p

All DT p
of IN p
the DT p
children NNS p
with IN p
ASD NNP p
were VBD N
fully RB N
included VBN N
in IN N
the DT N
general JJ N
education NN N
program NN N
. . N

Analyses VBZ N
revealed VBD N
that IN N
time NN o
spent VBN o
engaged VBN o
with IN o
peers NNS o
was VBD o
significantly RB o
increased VBN o
for IN N
the DT N
IT NNP N
group NN N
and CC N
maintained VBD N
over IN N
the DT N
follow-up JJ N
. . N

School NNP N
playground JJ N
staff NN N
in IN N
the DT N
IT NNP N
group NN N
showed VBD o
increased JJ o
behaviors NNS o
aimed VBN o
at IN o
improving VBG o
peer NN o
engagement NN o
for IN o
children NNS o
with IN p
ASD NNP p
compared VBN N
to TO N
playground VB N
staff NN N
at IN N
the DT N
WL NNP N
sites NNS N
. . N

These DT N
improvements NNS o
did VBD o
not RB o
maintain VB o
to TO N
follow-up JJ N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
a DT N
low JJ N
dose NN N
, , N
brief JJ N
intervention NN N
can MD N
be VB N
beneficial JJ N
in IN N
increasing VBG N
peer NN o
engagement NN o
for IN o
children NNS o
with IN o
autism NN o
in IN N
inclusive JJ N
settings NNS N
, , N
but CC N
continued VBD N
support NN N
of IN N
playground JJ N
staff NN N
is VBZ N
likely JJ N
needed VBN N
. . N

-DOCSTART- -23862237- O O

[ JJ N
Therapeutic NNP N
efficacy NN N
of IN N
compound NN i
Xuanju NNP i
capsule NN N
on IN N
type NN p
III NNP p
prostatitis NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
Compound NNP i
Xuanju NNP i
Capsule NNP N
on IN N
type NN N
III NNP N
prostatitis NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
242 CD p
patients NNS p
with IN p
type JJ p
III NNP p
prostatitis NN p
diagnosed VBN p
by IN p
the DT p
NIH NNP p
criteria NNS p
were VBD N
randomly RB i
divided VBN i
into IN i
an DT i
experimental JJ i
and CC i
a DT i
control NN i
group NN i
of IN i
equal JJ i
number NN i
, , i
the DT i
former JJ i
treated VBN i
with IN i
Compound NNP i
Xuanju NNP i
Capsule NNP i
+ NNP i
Tamsulosin NNP i
Hydrochloride NNP i
, , i
and CC i
the DT i
latter NN i
with IN i
Quinolinone NNP i
antibiotics NNS i
+ VBP i
Tamsulosin NNP i
and CC i
Hydrochloride NNP i
, , i
both DT i
for IN i
6 CD i
months NNS i
. . i

After IN N
treatment NN N
, , N
we PRP N
assessed VBD N
the DT N
therapeutic JJ o
effects NNS o
based VBN o
on IN o
the DT o
NIH-CPSI JJ o
scores NNS o
and CC o
the DT o
improvement NN o
of IN o
relevant JJ o
complications NNS o
. . o

RESULTS NNP N
All PDT p
the DT p
242 CD p
patients NNS p
completed VBD p
the DT p
treatment NN p
. . p

The DT N
total JJ o
effectiveness NN o
rate NN o
was VBD N
77.69 CD N
% NN N
( ( N
94/121 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
, , N
71.56 CD N
% NN N
( ( N
78/109 CD N
) ) N
in IN N
those DT N
with IN N
complications NNS N
. . N

In IN N
comparison NN N
, , N
it PRP N
was VBD N
only RB N
47.10 CD N
% NN N
( ( N
57/121 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
31.78 CD N
% NN N
( ( N
34/107 CD N
) ) N
in IN N
those DT N
with IN N
complications NNS N
. . N

Both DT N
the DT N
NIH-CPSI NNP o
scores NNS o
and CC o
the DT o
improvement NN o
of IN o
complications NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
experimental JJ N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Compound NNP i
Xuanju NNP i
Capsule NNP N
has VBZ N
a DT N
good JJ N
therapeutic JJ N
effect NN N
on IN N
type NN N
III NNP N
prostatitis NN N
. . N

-DOCSTART- -21935685- O O

Effect NN N
of IN N
intravenous JJ N
dezocine NN i
on IN N
fentanyl-induced JJ p
cough NN o
during IN p
general JJ p
anesthesia JJ p
induction NN p
: : p
a DT N
double-blinded JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
suppressive JJ N
effect NN N
of IN N
intravenous JJ N
dezocine NN i
on IN N
fentanyl-induced JJ N
cough NN o
during IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

METHODS NNP N
A NNP N
total NN p
of IN p
120 CD p
patients NNS p
, , p
American NNP p
Society NNP p
of IN p
Anesthesiologists NNP p
( ( p
ASA NNP p
) ) p
physical JJ p
status NN p
I-II NNP p
, , p
were VBD p
randomized VBN p
into IN p
two CD p
equally RB p
sized JJ p
groups NNS p
( ( p
n JJ p
= NNP p
60 CD p
) ) p
. . p

These DT N
two CD N
groups NNS N
were VBD N
given VBN N
either RB N
intravenous JJ i
dezocine NN i
0.1 CD N
mg/kg NN N
or CC i
a DT i
matching JJ i
placebo NN i
( ( N
equal JJ N
volume NN N
of IN N
0.9 CD N
% NN N
saline NN N
) ) N
10 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

Patients NNS N
were VBD N
induced VBN N
with IN N
midazolam JJ i
0.1 CD i
mg/kg NN i
, , i
fentanyl VBP i
5 CD i
?g/kg NN i
, , i
propofol JJ i
1-1.5 JJ i
mg/kg NN i
, , i
and CC i
suxamethonium NN i
1.5 CD N
mg/kg NN N
. . N

The DT N
injection NN N
time NN N
of IN N
fentanyl NN N
was VBD N
less JJR N
than IN N
2 CD N
s NNS N
in IN N
all DT N
patients NNS N
. . N

The DT N
occurrence NN N
of IN o
cough NN o
was VBD N
recorded VBN N
2 CD N
min NN N
after IN N
fentanyl JJ N
bolus NN N
. . N

RESULTS NNP p
No NNP p
patient NN p
in IN p
the DT p
dezocine NN p
group NN p
had VBD o
cough VBN o
, , o
and CC p
42 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
had VBD o
cough NN o
. . o

This DT N
difference NN N
was VBD N
statistically RB N
different JJ N
between IN N
these DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

CONCLUSION NNP N
These DT N
results NNS N
demonstrate VBP N
that IN N
intravenous JJ i
dezocine NN i
0.1 CD N
mg/kg NN N
10 CD N
min NN N
prior RB N
to TO N
induction NN N
was VBD N
effective JJ N
in IN N
suppressing VBG p
fentanyl-induced JJ o
cough NN o
in IN p
our PRP$ p
patients NNS p
. . p

-DOCSTART- -24027014- O O

Effectiveness NN N
of IN N
a DT N
theory-based JJ i
intervention NN i
to TO N
increase VB N
colorectal JJ o
cancer NN o
screening VBG o
among IN p
Iranian JJ p
health NN p
club NN p
members NNS p
: : p
a DT N
randomized JJ N
trial NN N
. . N

Colorectal JJ N
cancer NN N
is VBZ N
the DT N
third JJ N
most RBS N
commonly RB N
diagnosed JJ N
cancer NN N
and CC N
the DT N
fourth JJ N
leading VBG N
cause NN N
of IN N
death NN N
in IN N
the DT N
world NN N
. . N

There EX N
are VBP N
few JJ N
published VBN N
studies NNS N
that WDT N
have VBP N
used VBN N
theory-based JJ i
interventions NNS i
designed VBN N
to TO N
increase VB N
colorectal JJ N
cancer NN N
screening VBG N
in IN N
community NN N
lay VBP N
health NN N
organizations NNS N
. . N

The DT N
present JJ N
study NN N
was VBD N
guided VBN N
by IN N
the DT N
theoretical JJ N
concepts NNS N
of IN N
the DT N
preventive JJ N
health NN N
model NN N
. . N

Twelve NNP p
health NN p
clubs NNS p
of IN p
a DT p
municipal JJ p
district NN p
in IN p
Tehran NNP p
were VBD p
randomized VBN p
to TO N
two CD N
study NN N
groups NNS N
with IN N
equal JJ N
ratio NN N
. . N

The DT N
control NN N
group NN N
received VBD i
usual JJ i
services NNS i
throughout IN i
the DT i
study NN i
while IN N
the DT N
intervention NN N
group NN N
also RB N
received VBD i
a DT i
theory-based JJ i
educational JJ i
program NN i
on IN i
colorectal JJ i
cancer NN i
screening VBG i
plus CC i
a DT i
reminder NN i
call NN i
. . i

Screening VBG o
behavior NN o
, , N
the DT N
main JJ N
outcome NN N
, , N
was VBD N
assessed VBN N
4 CD N
months NNS N
after IN N
randomization NN N
. . N

A DT p
total NN p
of IN p
360 CD p
members NNS p
aged VBN p
50 CD p
and CC p
older JJR p
from IN p
12 CD p
health NN p
clubs NNS p
completed VBD p
a DT p
baseline NN p
survey NN p
. . p

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD N
increased JJ o
knowledge NN o
of IN o
colorectal JJ o
cancer NN o
and CC o
screening NN o
tests NNS o
at IN N
4 CD N
months NNS N
follow-up JJ N
( ( N
p NN N
's POS N
< NNP N
.001 NNP N
) ) N
. . N

Moreover RB N
, , N
exposure NN N
to TO N
the DT N
theory-based JJ i
intervention NN i
significantly RB N
improved VBN o
self-efficacy NN o
, , o
perceived VBN o
susceptibility NN o
, , o
efficacy NN o
of IN o
screening NN o
, , o
social JJ o
support NN o
, , o
and CC o
intention NN o
to TO o
be VB o
screened VBN o
for IN o
colorectal JJ o
cancer NN o
, , N
from IN N
baseline NN N
to TO N
4 CD N
months NNS N
follow-up JJ N
( ( N
p NN N
's POS N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
screening NN o
rate NN o
for IN o
colorectal JJ o
cancer NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
= JJ N
15.93 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
5.57 CD N
, , N
45.53 CD N
) ) N
. . N

Our PRP$ N
theory-based JJ N
intervention NN N
was VBD N
found VBN N
to TO N
have VB N
a DT N
significant JJ N
effect NN N
on IN N
colorectal JJ o
cancer NN o
screening VBG o
use NN N
as IN N
measured VBN N
by IN N
self-report NN N
. . N

The DT N
findings NNS N
could MD N
have VB N
implications NNS N
for IN N
colorectal JJ N
cancer NN N
screening VBG N
program NN N
development NN N
and CC N
implementation NN N
in IN N
primary JJ N
health NN N
care NN N
settings NNS N
and CC N
through IN N
other JJ N
community NN N
organizations NNS N
. . N

-DOCSTART- -16128933- O O

Effect NN N
of IN N
esomeprazole NN i
on IN N
nighttime JJ N
heartburn NN N
and CC N
sleep JJ N
quality NN N
in IN N
patients NNS p
with IN p
GERD NNP p
: : p
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

OBJECTIVES NNP N
Sleep NNP N
disturbances NNS N
are VBP N
common JJ N
in IN N
patients NNS p
with IN p
gastroesophageal JJ p
reflux NN p
disease NN p
( ( p
GERD NNP p
) ) p
. . p

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
esomeprazole NN N
on IN N
nighttime JJ o
heartburn NN o
, , o
GERD-related JJ o
sleep NN o
disturbances NNS o
, , o
sleep JJ o
quality NN o
, , o
work NN o
productivity NN o
, , o
and CC o
regular JJ o
activities NNS o
. . o

METHODS NNP N
This DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
included VBD N
adults NNS p
with IN p
GERD-associated JJ o
sleep JJ o
disturbances NNS o
and CC o
moderate-to-severe JJ o
nighttime JJ o
heartburn NN o
( ( p
recorded VBN p
by IN p
patient JJ p
diary JJ p
during IN p
screening VBG p
) ) p
. . p

Patients NNS p
received VBD p
oral JJ i
esomeprazole JJ i
40 CD i
mg NN i
( ( i
n JJ i
= NNP i
220 CD i
) ) i
or CC i
20 CD i
mg NN i
( ( i
n JJ i
= NNP i
226 CD i
) ) i
or CC i
placebo NN i
( ( i
n JJ i
= NNP i
229 CD i
) ) i
once RB i
daily JJ i
for IN i
4 CD i
wk NN i
. . i

The DT N
primary JJ N
outcome NN N
was VBD N
relief NN N
of IN N
nighttime JJ o
heartburn NN o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
resolution NN o
of IN o
sleep JJ o
disturbances NNS o
, , o
sleep VBP o
quality NN o
measured VBN o
by IN o
the DT o
Pittsburgh NNP o
Sleep NNP o
Quality NNP o
Index NNP o
( ( o
PSQI NNP o
) ) o
questionnaire NN o
, , o
and CC o
work NN o
productivity NN o
measured VBN o
by IN o
the DT o
Work NNP o
Productivity NNP o
and CC o
Activity NNP o
Impairment NNP o
Questionnaire NNP o
. . o

RESULTS NNP N
Nighttime NNP o
heartburn NN o
was VBD N
relieved VBN N
in IN N
53.1 CD N
% NN N
( ( N
111/209 CD N
) ) N
, , N
50.5 CD N
% NN N
( ( N
111/220 CD N
) ) N
, , N
and CC N
12.7 CD N
% NN N
( ( N
28/221 CD N
) ) N
of IN N
patients NNS N
who WP N
received VBD N
esomeprazole JJ N
40 CD N
mg NN N
, , N
esomeprazole JJ N
20 CD N
mg NN N
, , N
and CC N
placebo NN N
, , N
respectively RB N
. . N

Differences NNS N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
versus NN N
placebo NN N
were VBD N
40.5 CD N
% NN N
( ( N
32.4 CD N
% NN N
, , N
48.5 CD N
% NN N
) ) N
and CC N
37.8 CD N
% NN N
( ( N
29.9 CD N
% NN N
, , N
45.7 CD N
% NN N
) ) N
and CC N
were VBD N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

GERD-related JJ o
sleep JJ o
disturbances NNS o
resolved VBN N
in IN N
significantly RB N
more JJR N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
patients NNS N
who WP N
received VBD N
esomeprazole JJ N
40 CD N
( ( N
73.7 CD N
% NN N
) ) N
or CC N
20 CD N
mg NN N
( ( N
73.2 CD N
% NN N
) ) N
than IN N
in IN N
those DT N
who WP N
received VBD N
placebo NN N
( ( N
41.2 CD N
% NN N
) ) N
. . N

Both DT N
esomeprazole JJ N
groups NNS N
had VBD N
greater JJR N
PSQI NNP o
global JJ o
score NN o
changes NNS N
from IN N
baseline NN N
( ( N
p JJ N
< $ N
0.0001 CD N
vs NN N
placebo NN N
) ) N
and CC N
more JJR N
( ( N
p JJ N
< $ N
0.0001 CD N
vs NN N
placebo NN N
) ) N
work NN N
hours NNS N
saved VBD N
per IN N
week NN N
per IN N
patient NN N
compared VBN N
with IN N
baseline NN N
( ( N
esomeprazole JJ N
40 CD N
mg NN N
, , N
11.6 CD N
h NN N
; : N
esomeprazole CC N
20 CD N
mg NN N
, , N
12.3 CD N
h NN N
; : N
placebo NN N
, , N
6.2 CD N
h NN N
) ) N
. . N

CONCLUSIONS NNP N
Esomeprazole NNP N
reduced VBD N
nighttime JJ N
heartburn NN N
and CC N
GERD-related JJ N
sleep NN N
disturbances NNS N
and CC N
improved JJ N
sleep JJ N
quality NN N
and CC N
work NN N
productivity NN N
. . N

-DOCSTART- -16596465- O O

A DT N
crossover NN N
study NN N
of IN N
risperidone NN i
in IN N
children NNS p
, , p
adolescents NNS p
and CC p
adults NNS p
with IN p
mental JJ p
retardation NN p
. . p

Risperidone NN i
has VBZ N
shown VBN N
safety NN o
and CC o
efficacy NN o
for IN N
aggressive JJ N
and CC N
destructive JJ p
behaviors NNS N
in IN N
short-term JJ N
studies NNS N
. . N

This DT N
longer-duration NN N
study NN N
includes VBZ N
a DT N
broad JJ N
sample NN N
. . N

Forty NNP p
subjects NNS p
, , p
aged VBN p
8-56 CD p
years NNS p
( ( p
mean=22 NN p
) ) p
, , p
all DT p
with IN p
mental JJ p
retardation NN p
and CC p
36 CD p
with IN p
autism NN p
spectrum NN p
disorders NNS p
participated VBD p
in IN N
this DT N
22-week JJ N
crossover NN N
study NN N
, , N
with IN N
24 CD N
weeks NNS N
of IN N
open JJ N
maintenance NN N
thereafter RB N
. . N

Of IN N
40 CD N
subjects NNS N
, , N
23 CD N
( ( N
57.5 CD N
% NN N
) ) N
responded VBD N
fully RB N
( ( N
50 CD N
% NN N
decrease NN o
in IN o
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
Irritability NNP o
subscale NNP o
score NN o
) ) o
, , N
while IN N
35 CD N
subjects NNS N
( ( N
87.5 CD N
% NN N
) ) N
showed VBD N
a DT N
25 CD N
% NN N
decrease NN o
. . o

Gender NNP N
, , N
mood NN N
disorder NN N
, , N
and CC N
antiseizure NN N
medications NNS N
did VBD N
not RB N
alter VB N
response NN N
. . N

Increased VBN o
appetite NN o
and CC o
weight JJ o
gain NN o
were VBD N
common JJ N
. . N

Low JJ N
dose JJ N
risperidone NN N
was VBD N
effective JJ o
for IN o
aggressive JJ o
behavior NN o
in IN N
persons NNS N
with IN N
MR. NNP N
More NNP N
long-term JJ N
studies NNS N
are VBP N
needed VBN N
, , N
incorporating VBG N
weight NN N
control NN N
interventions NNS N
. . N

-DOCSTART- -22465608- O O

Comparison NNP N
of IN N
dual-axis JJ i
rotational JJ i
coronary NN i
angiography NN i
( ( i
XPERSWING NN i
) ) i
versus IN N
conventional JJ i
technique NN N
in IN N
routine JJ N
practice NN N
. . N

INTRODUCTION NNP N
AND NNP N
OBJECTIVES NNP N
Coronary NNP N
angiography NN i
is VBZ N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
study NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

This DT N
technique NN N
requires VBZ N
several JJ N
orthogonal JJ N
projections NNS N
. . N

Rotational JJ i
angiography NN i
is VBZ N
a DT N
new JJ N
technique NN N
which WDT N
involves VBZ N
pre-set JJ N
rotation NN N
of IN N
the DT N
X-ray JJ N
tube NN N
around IN N
the DT N
patient NN N
and CC N
allows VBZ N
visualization NN N
of IN N
each DT N
coronary JJ N
artery NN N
in IN N
different JJ N
views NNS N
, , N
using VBG N
a DT N
single JJ N
contrast NN N
injection NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
conventional JJ i
coronary JJ i
angiography NN i
( ( i
A DT i
) ) i
vs FW i
rotational JJ i
angiography NN i
( ( N
B NNP N
) ) N
, , N
focusing VBG N
on IN N
radiation NN N
dose NN N
, , N
amount NN N
of IN N
contrast NN N
administered VBN N
, , N
and CC N
total JJ N
procedure NN N
time NN N
for IN N
both DT N
diagnostic JJ N
and CC N
therapeutic JJ N
percutaneous JJ N
coronary JJ N
interventions NNS N
. . N

METHODS NNP N
Prospective NNP p
study NN p
of IN p
104 CD p
consecutive JJ p
patients NNS p
undergoing VBG p
coronary JJ i
angiography NN i
who WP p
were VBD p
randomized VBN p
to TO N
one CD N
of IN N
these DT N
techniques NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
amount NN o
of IN o
contrast NN o
administered VBN o
( ( N
A DT N
vs NN N
B NNP N
, , N
93.1 CD N
[ NN N
41.7 CD N
] NNP N
vs NN N
50.9 CD N
[ NN N
14.7 CD N
] NNP N
mL NN N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
and CC N
radiation NN o
exposure NN o
( ( N
27.6 CD N
[ RB N
11.5 CD N
] JJ N
vs NN N
18 CD N
[ NN N
6.4 CD N
] NN N
mGycm NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

A DT N
significant JJ N
increase NN N
in IN N
total JJ o
procedure NN o
time NN o
was VBD N
noted VBN N
in IN N
the DT N
rotational JJ N
angiography NN N
arm NN N
. . N

However RB N
, , N
when WRB N
only RB N
the DT N
last JJ N
50 CD N
patients NNS N
were VBD N
analyzed VBN N
, , N
we PRP N
found VBD N
no DT N
difference NN N
in IN N
procedure NN o
time NN o
between IN N
the DT N
groups NNS N
, , N
probably RB N
related VBN N
to TO N
the DT N
learning VBG N
curve NN N
of IN N
the DT N
operators NNS N
. . N

Angioplasty NNP o
was VBD N
performed VBN N
in IN N
29 CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
28 CD N
patients NNS N
in IN N
group NN N
B NNP N
. . N

Contrast NNP o
reduction NN o
was VBD N
maintained VBN N
in IN N
the DT N
rotational JJ N
angiography NN N
group NN N
compared VBN N
to TO N
the DT N
conventional JJ N
technique NN N
( ( N
A NNP N
vs NN N
B NNP N
, , N
335.1 CD N
[ NN N
192.1 CD N
] NNP N
vs NN N
238.5 CD N
[ NN N
114.4 CD N
] NNP N
mL NN N
; : N
P=.02 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
rotational JJ i
angiography NN i
technique NN N
leads VBZ N
to TO N
a DT N
significant JJ N
decrease NN N
in IN N
radiation NN o
exposure NN o
and CC N
contrast NN o
dose NN o
administered VBN N
for IN N
diagnostic JJ N
procedures NNS N
when WRB N
compared VBN N
to TO N
conventional JJ i
coronary JJ i
angiography NN i
. . i

In IN N
patients NNS N
who WP N
undergo VBP N
percutaneous JJ N
coronary JJ N
intervention NN N
, , N
contrast NN N
reduction NN N
remains VBZ N
significant JJ N
. . N

-DOCSTART- -7955250- O O

Late JJ N
hemodynamic JJ N
effects NNS N
of IN N
the DT N
preserved JJ N
papillary JJ N
muscles NNS N
during IN N
mitral JJ p
valve FW p
replacement NN p
. . p

BACKGROUND VB N
The DT N
late JJ N
hemodynamic JJ N
effects NNS N
of IN N
preserving VBG N
the DT N
papillary JJ N
muscles NNS N
during IN N
mitral JJ i
valve FW i
replacement NN i
have VBP N
not RB N
been VBN N
evaluated VBN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Sixteen NNP p
patients NNS p
who WP p
had VBD p
chronic JJ p
mitral JJ p
regurgitation NN p
due JJ p
to TO p
myxomatous JJ p
degeneration NN p
were VBD p
randomized VBN p
to TO p
preservation NN i
( ( i
Pres NNP i
group NN p
, , p
n RB p
= VBZ p
8 CD p
) ) p
or CC i
no DT i
preservation NN i
( ( i
No NNP i
Pres NNP i
group NN p
, , p
n RB p
= VBZ p
8 CD p
) ) p
of IN i
the DT i
chordae NN i
tendineae NN i
and CC i
papillary JJ i
muscles NNS i
during IN i
mitral JJ i
valve FW i
replacement NN i
. . i

Rest NNP i
and CC i
exercise NN i
nuclear JJ i
ventriculograms NNS i
were VBD N
performed VBN N
early RB N
( ( N
3 CD N
months NNS N
) ) N
and CC N
late JJ N
( ( N
5 CD N
years NNS N
) ) N
after IN N
surgery NN N
. . N

Early RB N
after IN N
surgery NN N
, , N
the DT N
No NNP N
Pres NNP N
group NN N
had VBD N
lower JJR o
ejection NN o
fractions NNS o
and CC o
stroke VBD o
work NN o
indexes NNS o
( ( N
P NNP N
< NNP N
.05 NNP N
by IN N
repeated-measures NNS N
[ NNP N
rm NN N
] NNP N
ANOVA NNP N
) ) N
than IN N
the DT N
Pres NNP N
group NN N
did VBD N
at IN N
similar JJ N
end-diastolic JJ N
volume NN N
indexes NNS N
. . N

The DT N
No NNP N
Pres NNP N
group NN N
had VBD N
similar JJ N
cardiac NN o
indexes NNS o
after IN N
exercise NN N
because IN N
heart NN o
rate NN o
increased VBD o
( ( N
P NNP N
< NNP N
.005 NNP N
by IN N
rm NN N
ANOVA NNP N
) ) N
. . N

Late JJ N
after IN N
surgery NN N
, , N
ejection NN o
fraction NN o
was VBD N
greater JJR N
at IN N
similar JJ N
end-diastolic JJ o
volume NN o
indexes NNS o
( ( N
P NNP N
< NNP N
.005 NNP N
by IN N
rm NN N
ANCOVA NNP N
) ) N
, , N
and CC N
preload NN o
recruitable JJ o
stroke NN o
work NN o
indexes NNS o
( ( N
P NNP N
< NNP N
.001 NNP N
by IN N
rm NN N
ANCOVA NNP N
) ) N
were VBD N
better RBR N
in IN N
the DT N
Pres NNP N
group NN N
. . N

CONCLUSIONS NNP N
Preserving VBG N
chordal JJ N
attachments NNS N
enhanced VBD N
the DT N
late JJ N
hemodynamic JJ N
recovery NN N
after IN N
mitral JJ N
valve FW N
replacement NN N
for IN N
mitral JJ N
regurgitation NN N
. . N

-DOCSTART- -288173- O O

Bronchial JJ p
carcinoma NN p
. . p

II NNP N
. . N

Quantitative JJ N
measurements NNS N
of IN N
the DT N
quality NN o
of IN o
survival NN o
. . o

A DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
the DT N
result NN N
of IN N
therapy NN N
in IN N
inoperable JJ p
patients NNS p
with IN p
advanced JJ p
disease NN p
. . p

Forty-eight JJ p
bronchial JJ p
carcinoma NN p
patients NNS p
in IN p
clinicoanatomical JJ p
stage NN p
4 CD p
of IN p
the DT p
disease NN p
( ( p
advanced JJ p
disease NN p
) ) p
were VBD N
randomly RB p
assigned VBN p
to TO N
groups NNS p
for IN N
radiotherapy NN i
, , i
chemotherapy NN i
( ( i
cyclophosphamide NN i
) ) i
and CC i
placebo JJ i
treatment NN i
, , N
respectively RB N
. . N

The DT N
results NNS N
were VBD N
assessed VBN N
by IN N
the DT N
survival JJ o
time NN o
and CC o
quality NN o
of IN o
survival NN o
. . o

The DT N
median JJ o
survival NN o
time NN o
was VBD N
4.7 CD N
months NNS N
for IN N
radiotherapy NN i
, , N
4.7 CD N
months NNS N
for IN N
cyclophosphamide NN i
and CC N
1.7 CD N
months NNS N
for IN N
placebo NN i
. . i

The DT N
median JJ o
total JJ o
sum NN o
of IN o
vitagram NN o
points NNS o
was VBD N
28.1 CD N
for IN N
radiotherapy NN i
, , N
20.7 CD N
for IN N
cyclophosphamide NN i
and CC N
6.8 CD N
for IN N
placebo NN i
. . i

When WRB N
calculated JJ N
per IN N
month NN N
, , N
the DT N
median JJ o
sum NN o
of IN o
vitagram NN o
points NNS o
was VBD N
5.9 CD N
for IN N
radiotherapy NN i
, , N
5.7 CD N
for IN N
cyclophosphamide NN i
and CC N
4.8 CD N
for IN N
placebo NN i
. . i

Statistically RB N
the DT N
results NNS N
give VBP N
no DT N
reason NN N
to TO N
believe VB N
that IN N
placebo NN i
is VBZ N
better JJR N
than IN N
radiotherapy NN i
, , N
but CC N
it PRP N
can MD N
not RB N
be VB N
excluded VBN N
that IN N
radiotherapy NN i
patients NNS N
could MD N
have VB N
a DT N
much RB N
longer JJR N
survival NN o
. . o

As IN N
for IN N
cyclophosphamide NN i
versus NN N
radiotherapy NN i
, , N
the DT N
differences NNS N
are VBP N
to TO N
uncertain VB N
for IN N
any DT N
conclusion NN N
to TO N
be VB N
drawn VBN N
. . N

-DOCSTART- -1853794- O O

A DT N
comparison NN N
of IN N
single-dose JJ i
versus NN N
conventional-dose JJ i
antibiotic JJ i
treatment NN i
of IN N
bacteriuria NN p
in IN p
elderly JJ p
women NNS p
. . p

The DT N
efficacy NN N
of IN N
single-dose JJ i
antibiotic JJ i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
bacteriuria NN p
in IN p
a DT p
group NN p
of IN p
non-catheterized JJ p
elderly JJ p
women NNS p
was VBD N
compared VBN N
with IN N
that DT N
of IN N
conventional JJ i
7-10 JJ i
day NN i
courses NNS i
of IN i
antibiotic JJ i
therapy NN i
. . i

Thirty-one JJ p
women NNS p
received VBD p
single-dose JJ i
treatment NN i
and CC p
22 CD p
conventional-dose JJ i
treatment NN i
. . i

The DT N
cure NN o
rates NNS o
at IN N
1 CD N
and CC N
6 CD N
weeks NNS N
for IN N
the DT N
single-dose JJ N
treatments NNS N
were VBD N
52 CD N
% NN N
and CC N
38 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
cure NN o
rates NNS o
for IN N
the DT N
conventional-dose JJ N
treatments NNS N
at IN N
1 CD N
and CC N
6 CD N
weeks NNS N
were VBD N
59 CD N
% NN N
and CC N
52 CD N
% NN N
, , N
respectively RB N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
there EX N
may MD N
be VB N
a DT N
place NN N
for IN N
the DT N
use NN N
of IN N
single-dose JJ i
antibiotic JJ i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
selected VBN p
elderly JJ p
women NNS p
with IN p
bacteriuria NN p
, , N
but CC N
larger JJR N
studies NNS N
are VBP N
needed VBN N
. . N

-DOCSTART- -1759534- O O

Long-term JJ N
growth NN N
hormone NN N
treatment NN N
in IN N
growth NN p
hormone NN p
deficient NN p
adults NNS p
. . p

Growth NNP i
hormone NN i
treatment NN i
in IN N
GH-deficient NNP p
adults NNS p
has VBZ N
proved VBN N
beneficial JJ N
in IN N
recent JJ N
short-term JJ N
trials NNS N
, , N
but CC N
long-term JJ N
results NNS N
have VBP N
not RB N
yet RB N
been VBN N
reported VBN N
. . N

Thirteen JJ p
GH-deficient JJ p
adults NNS p
( ( p
4 CD p
females NNS p
, , p
9 CD p
males NNS p
; : p
mean FW p
( ( p
SEM NNP p
) ) p
age NN p
26.4 CD p
( ( p
1.7 CD p
) ) p
years NNS p
) ) p
, , N
who WP N
had VBD N
completed VBN N
4 CD N
months NNS N
of IN N
GH NNP i
therapy NN i
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ i
cross-over NN N
study NN N
were VBD N
followed VBN N
, , N
for IN N
further JJ N
16.1 CD N
( ( N
0.8 CD N
) ) N
months NNS N
of IN N
uninterrupted JJ N
GH NNP i
therapy NN i
in IN N
an DT N
open JJ N
design NN N
. . N

A DT N
significant JJ N
mean JJ N
increase NN N
of IN N
1.3 CD N
cm NN N
in IN N
linear JJ o
height NN o
was VBD N
recorded VBN N
, , N
whereas IN N
body NN o
mass NN o
index NN o
remained VBD N
unchanged JJ N
. . N

Mean JJ o
muscle NN o
volume NN o
of IN o
the DT o
thigh NN o
, , o
estimated VBN o
by IN o
computerised JJ o
tomography NN o
, , N
increased VBD N
significantly RB N
compared VBN N
with IN N
that DT N
of IN N
the DT N
initial JJ N
placebo NN i
period NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
a DT N
slight JJ N
decrease NN N
was VBD N
recorded VBN N
in IN N
adipose JJ o
tissue NN o
volume NN o
of IN o
the DT o
thigh NN o
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
and CC N
subscapular JJ o
skinfold NN o
thickness NN o
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Still RB N
, , N
the DT N
muscle NN o
to TO o
fat VB o
ratio NN o
of IN o
the DT o
thigh NN o
was VBD N
significantly RB N
lower JJR N
compared VBN N
with IN N
that DT N
of IN N
normal JJ p
subjects NNS p
( ( N
72.6/27.4 CD N
vs RB N
77.9/22.1 CD N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
mean JJ o
isometric JJ o
strength NN o
of IN o
the DT o
quadriceps JJ o
muscles NNS o
increased VBD o
significantly RB N
during IN N
long-term JJ N
GH NNP N
therapy NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
but CC N
remained VBD N
lower JJR N
compared VBN N
with IN N
that DT N
of IN N
normal JJ N
subjects NNS N
( ( N
1.66 CD N
( ( N
0.10 CD N
) ) N
vs NN N
2.13 CD N
( ( N
0.11 CD N
) ) N
Nm/kg NNP N
body NN N
weight NN N
) ) N
. . N

Exercise NN o
capacity NN o
performed VBN o
on IN o
a DT o
bicycle NN o
ergometer NN o
increased VBD N
significantly RB N
after IN N
long-term JJ N
therapy NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
but CC N
still RB N
did VBD N
not RB N
reach VB N
the DT N
values NNS N
seen VBN N
in IN N
normal JJ N
subjects NNS N
( ( N
22.5 CD N
( ( N
3.4 CD N
) ) N
vs NN N
37.4 CD N
( ( N
4.2 CD N
) ) N
watt.min.kg-1 NN N
. . N

No DT N
adverse JJ o
reactions NNS o
were VBD N
recorded VBN N
during IN N
long-term JJ N
therapy NN N
and CC N
hemoglobin NN o
A1c NNP o
remained VBD N
unchanged JJ N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
long-term JJ N
GH NNP N
replacement NN N
therapy NN N
in IN N
GH-deficient NNP N
adults NNS N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
several JJ N
physiological JJ N
features NNS N
which WDT N
are VBP N
subnormal JJ N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -17391914- O O

Information NNP i
source NN i
affects VBZ N
peers NNS N
' POS N
initial JJ N
attitudes NNS N
toward IN N
autism NN o
. . o

Authors NNS N
examined VBD N
the DT N
effects NNS N
of IN N
information NN N
source NN N
on IN N
peers NNS N
' POS N
cognitive NN o
and CC o
behavioral JJ o
attitudes NNS o
toward IN N
an DT N
unfamiliar JJ p
child NN p
with IN p
autism NN p
. . p

Children NNP p
( ( p
N=296 NNP p
; : p
M NNP p
age=10.21 IN p
years NNS p
) ) p
received VBD N
information NN N
about IN N
an DT N
unfamiliar JJ p
child NN p
with IN p
autism NN p
from IN N
one CD N
of IN N
the DT N
following JJ N
sources NNS N
: : N
( ( N
a DT N
) ) N
videotape NN i
, , N
( ( N
b NN N
) ) N
teacher NN i
, , N
( ( N
c NN N
) ) N
hypothetical JJ i
mother NN i
, , N
( ( N
d NN N
) ) N
hypothetical JJ i
father NN i
, , N
or CC N
( ( N
e NN N
) ) N
hypothetical JJ i
doctor NN i
. . i

Interactive JJ N
effects NNS N
between IN N
source NN N
, , N
and CC N
sex NN N
and CC N
grade NN N
were VBD N
found VBN N
for IN N
cognitive JJ N
and CC N
behavioral JJ N
attitudes NNS N
. . N

Fifth-graders NNS p
reported VBD N
more RBR N
favorable JJ N
cognitive JJ o
and CC o
behavioral JJ o
attitudes NNS o
when WRB N
information NN N
was VBD N
provided VBN N
by IN N
extra-familial JJ N
sources NNS N
( ( N
i.e. NN N
, , N
doctor NN N
) ) N
versus NN N
parent NN N
sources NNS N
. . N

Mother NNP N
yielded VBD N
more RBR o
persuasive JJ o
effects NNS o
on IN o
behavioral JJ o
attitudes NNS o
for IN N
third-graders NNS N
versus JJ N
fifth-graders NNS N
. . N

Attitudes NNS N
toward IN N
autism NN N
differ VBP N
depending VBG N
on IN N
who WP N
provides VBZ N
information NN N
about IN N
the DT N
disability NN N
. . N

Persuasion NNP N
theory NN N
appears VBZ N
useful JJ N
to TO N
guide VB N
evaluation NN N
of IN N
educational JJ N
interventions NNS N
to TO N
improve VB N
attitudes NNS o
towards IN o
autism NN o
. . o

Implications NNS N
of IN N
the DT N
findings NNS N
, , N
study NN N
limitations NNS N
, , N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -663366- O O

[ NN N
Maintaining VBG N
sinus NNS N
rhythm NN N
with IN N
quinidine NN i
and CC i
amiodarone NN i
after IN p
electric JJ p
cardioversion NN p
] NN p
. . N

-DOCSTART- -1723467- O O

Effects NNS N
of IN N
nifedipine NN i
and CC N
nitrendipine NN i
on IN N
insulin NN o
secretion NN o
in IN N
obese JJ p
patients NNS p
. . p

Data NNS N
on IN N
the DT N
influence NN N
of IN N
calcium NN N
antagonists NNS N
on IN N
glucose JJ o
tolerance NN o
and CC o
insulin NN o
release NN o
in IN N
humans NNS N
are VBP N
conflicting VBG N
. . N

The DT N
present JJ N
double-blind NN N
, , N
double-dummy JJ N
, , N
controlled VBD N
trial NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
short-term JJ N
( ( N
7 CD N
days NNS N
) ) N
treatment NN N
with IN N
nitrendipine NN i
, , i
20 CD i
mg NN i
b.i.d NN i
. . i

; : i
nitrendipine NN i
, , i
20 CD i
mg NN i
once RB i
daily JJ i
; : i
or CC i
placebo VB i
on IN N
blood NN o
glucose NN o
and CC o
plasma JJ o
insulin NN o
and CC o
C-peptide JJ o
response NN o
to TO N
an DT N
intravenous JJ N
glucose NN N
load NN N
in IN N
mildly RB p
or CC p
transiently RB p
hypertensive JJ p
nondiabetic JJ p
obese JJ p
patients NNS p
. . p

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
fasting VBG o
glucose NN o
, , o
insulin NN o
, , o
and CC o
C-peptide NNP o
, , o
or CC o
in IN o
the DT o
glucose JJ o
disappearance NN o
rate NN o
and CC o
in IN o
any DT o
of IN o
the DT o
parameters NNS o
for IN o
insulin NN o
and CC o
C-peptide NNP o
response NN o
after IN N
i.v NN N
. . N

glucose VB N
, , N
between IN N
the DT N
three CD N
groups NNS N
of IN N
patients NNS N
. . N

However RB N
, , N
a DT N
slight JJ N
decrease NN N
in IN N
early JJ o
insulin NN o
response NN o
to TO o
glucose VB o
was VBD N
observed VBN N
in IN N
the DT N
nifedipine NN N
and CC N
the DT N
nitrendipine JJ N
groups NNS N
. . N

This DT N
study NN N
confirms VBZ N
that IN N
calcium NN N
antagonists NNS N
have VBP N
no DT N
clinically RB o
relevant JJ o
effect NN o
on IN N
glucose JJ N
homeostasis NN N
even RB N
if IN N
a DT N
slight JJ N
alteration NN N
of IN N
insulin NN o
release NN o
after IN N
glucose JJ N
load NN N
can MD N
not RB N
be VB N
ruled VBN N
out RP N
. . N

-DOCSTART- -12088604- O O

Improving VBG N
patient JJ i
involvement NN i
in IN N
chronic JJ N
disease NN N
management NN N
: : N
the DT N
views NNS N
of IN N
patients NNS N
, , N
GPs NNP N
and CC N
specialists NNS N
on IN N
a DT N
guidebook NN N
for IN N
ulcerative JJ N
colitis NN N
. . N

Patient JJ N
information NN N
, , N
shared VBN N
care NN N
and CC N
decision-making NN N
are VBP N
recognised VBN N
as IN N
beneficial JJ N
to TO N
chronic VB N
disease NN N
management NN N
. . N

As IN N
part NN N
of IN N
an DT N
RCT NNP N
, , N
opinions NNS N
of IN N
ulcerative JJ p
colitis NN p
patients NNS p
and CC p
their PRP$ p
doctors NNS p
were VBD N
sought VBN N
on IN N
a DT N
guidebook NN N
designed VBN N
to TO N
support VB i
self-care NN i
and CC N
mediate VB i
doctor/patient JJ i
interaction NN i
during IN N
consultations NNS N
. . N

Semi-structured JJ i
interviews NNS i
were VBD N
conducted VBN N
with IN N
6 CD p
specialists NNS p
and CC p
16 CD p
GPs NNP p
. . p

Patients NNS p
' POS p
views NNS p
were VBD p
obtained VBN p
from IN p
written VBN p
responses NNS p
to TO p
a DT p
postal JJ i
questionnaire NN i
( ( p
136 CD p
replies NNS p
) ) p
. . p

Inclusion NN N
of IN N
lay NN N
knowledge NN N
and CC N
clarification NN N
of IN N
treatment NN N
decision NN N
processes NNS N
increased VBD N
patients NNS N
' POS N
perception NN N
of IN N
involvement NN N
in IN N
disease NN N
management NN N
through IN N
increased VBN N
identification NN N
and CC N
awareness NN N
of IN N
others NNS N
' POS N
self-management JJ N
experiences NNS N
. . N

Doctors NNS N
focused VBD N
on IN N
the DT N
importance NN N
of IN N
improving VBG N
patients NNS N
' POS N
compliance NN N
and CC N
use NN N
of IN N
services NNS N
. . N

However RB N
, , N
the DT N
guidebook NN N
was VBD N
seldom RB N
used VBN N
as IN N
it PRP N
had VBD N
been VBN N
intended VBN N
during IN N
consultations NNS N
. . N

Patients NNS N
felt VBD N
constrained VBN N
by IN N
time NN N
limits NNS N
and CC N
consultants NNS N
did VBD N
not RB N
actively RB N
encourage VB N
guidebook NN N
use NN N
. . N

Based VBN N
on IN N
the DT N
findings NNS N
, , N
we PRP N
suggest VBP N
an DT N
approach NN N
utilising VBG o
the DT o
guidebook NN o
to TO N
improve VB N
patient JJ o
participation NN o
in IN N
disease NN N
management NN N
. . N

-DOCSTART- -11517983- O O

Comparison NNP N
of IN N
thiopentone/guaifenesin NN i
, , i
ketamine/guaifenesin NN i
and CC i
ketamine/midazolam NN i
for IN N
the DT N
induction NN N
of IN N
horses NNS p
to TO p
be VB p
anaesthetised VBN p
with IN p
isoflurane NN p
. . p

Forty-eight JJ p
horses NNS p
subjected VBN p
to TO p
elective VB p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD p
groups NNS p
of IN p
16 CD p
horses NNS p
. . p

After IN N
premedication NN N
with IN N
0.1 CD N
mg/kg NNS N
acepromazine VBP i
intramuscularly RB N
and CC N
0.6 CD N
mg/kg NNS N
xylazine JJ i
intravenously RB N
, , N
anaesthesia NN N
was VBD N
induced VBN N
either RB N
with IN N
2 CD N
g NNS N
thiopentone NN i
in IN N
500 CD N
ml NN N
of IN N
a DT N
10 CD N
per IN N
cent NN N
guaifenesin NN i
solution NN N
, , N
given VBN N
intravenously RB N
at IN N
a DT N
dose NN N
of IN N
1 CD N
ml/kg NNS N
( ( N
group NN N
TG NNP N
) ) N
, , N
or CC N
with IN N
100 CD N
mg/kg NNS N
guaifenesin NN i
and CC i
2.2 CD i
mg/kg NN i
ketamine NN i
given VBN N
intravenously RB N
( ( N
group NN N
KG NNP N
) ) N
, , N
or CC N
with IN N
0.06 CD N
mg/kg NNS N
midazolam NN i
, , N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN i
given VBN N
intravenously RB N
( ( N
group NN N
KM NNP N
) ) N
. . N

Anaesthesia NNP o
was VBD N
maintained VBN N
with IN N
isoflurane NN i
. . i

The DT N
mean NN o
( ( o
sd NN o
) ) o
end NN o
tidal JJ o
isoflurane NN o
concentration NN o
( ( o
per IN o
cent NN o
) ) o
needed VBD N
to TO N
maintain VB N
a DT N
light JJ o
surgical JJ o
anaesthesia NN o
( ( N
stage NN N
III NNP N
, , N
plane NN N
2 CD N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
KM NNP N
( ( N
0.91 CD N
[ RB N
0.03 CD N
] NN N
) ) N
than IN N
in IN N
groups NNS N
TG NNP N
( ( N
1.11 CD N
[ RB N
0.03 CD N
] NN N
) ) N
and CC N
KG NNP N
( ( N
1.14 CD N
[ RB N
0.03 CD N
] NN N
) ) N
. . N

The DT N
mean NN o
( ( o
sd NN o
) ) o
arterial JJ o
pressure NN o
( ( o
mmHg NN o
) ) o
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
KG NNP N
( ( N
67.4 CD N
[ RB N
2.07 CD N
] NN N
) ) N
than IN N
in IN N
groups NNS N
TC NNP N
( ( N
75.6 CD N
[ RB N
2.23 CD N
] NN N
) ) N
and CC N
KM NNP N
( ( N
81.0 CD N
[ RB N
2.16 CD N
] NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
logarithm NN N
of IN N
the DT N
heart NN o
rate NN o
, , o
recovery NN o
time NN o
or CC o
quality NN o
of IN o
recovery NN o
between IN N
the DT N
three CD N
induction NN N
groups NNS N
. . N

However RB N
, , N
pronounced VBD N
ataxia NN N
was VBD N
observed VBN N
in IN N
the DT N
horses NNS N
of IN N
group NN N
KM NNP N
, , N
especially RB N
after IN N
periods NNS N
of IN N
anaesthesia NN o
lasting VBG N
less JJR N
than IN N
75 CD N
minutes NNS N
. . N

-DOCSTART- -8227803- O O

Increased VBN N
blood NN o
pressure NN o
and CC o
neural JJ o
tone NN o
in IN N
the DT N
silent JJ N
ischemia NN N
of IN N
hypertension NN N
: : N
disparate JJ N
effects NNS N
of IN N
immediate JJ N
release NN N
nifedipine NN i
. . i

OBJECTIVES CC N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
1 CD N
) ) N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
blood NN o
pressure NN o
and CC N
associated JJ N
neural JJ o
tonicity NN o
in IN N
ambient JJ N
ischemia NN N
of IN N
a DT N
group NN N
of IN N
hypertensive JJ p
patients NNS p
with IN p
stable JJ p
angina NN p
, , N
and CC N
2 CD N
) ) N
to TO N
determine VB N
the DT N
efficacy NN o
of IN N
immediate JJ N
release NN N
nifedipine JJ i
therapy NN N
in IN N
controlling VBG N
the DT N
total JJ N
ischemic JJ N
burden NN N
in IN N
both DT N
office-measured JJ N
and CC N
ambulatory JJ N
blood NN N
pressure NN N
. . N

BACKGROUND NNP N
Low NNP N
heart NN N
rate NN N
ischemia NN N
, , N
as IN N
detected VBN N
by IN N
Holter NNP N
ambulatory JJ N
electrocardiographic JJ N
monitoring NN N
, , N
suggests VBZ N
that IN N
reduced VBD N
coronary JJ N
flow NN N
is VBZ N
the DT N
major JJ N
factor NN N
leading VBG N
to TO N
ischemia VB N
. . N

We PRP N
previously RB N
found VBD N
that IN N
91 CD N
% NN N
of IN N
the DT N
ischemic JJ N
episodes NNS N
in IN N
our PRP$ N
hypertensive JJ p
patients NNS p
with IN p
stable JJ p
angina NNS p
were VBD N
silent JJ N
. . N

METHODS NNP N
We PRP N
measured VBD N
plasma JJ N
norepinephrine JJ N
content NN N
during IN N
ischemic JJ N
events NNS N
from IN N
blood NN N
obtained VBN N
from IN N
automatic JJ N
pump NN N
withdrawal NN N
with IN N
the DT N
assistance NN N
of IN N
a DT N
real-time JJ i
ST NNP i
segment NN i
depression NN i
monitor NN i
. . i

We PRP N
then RB N
related VBD N
the DT N
norepinephrine JJ N
content NN N
to TO N
ischemic VB N
episodes NNS N
assessed VBN N
by IN N
48-h JJ N
Holter NNP N
recording NN N
, , N
blood NN N
pressure NN N
reading NN N
by IN N
ambulatory JJ N
blood NN N
pressure NN N
monitoring NN N
and CC N
patients NNS N
' POS N
diaries NNS N
. . N

Measurements NNS N
were VBD N
taken VBN N
during IN N
the DT N
placebo NN i
period NN N
and CC N
immediate-release JJ N
nifedipine NN i
therapy NN i
in IN N
30 CD p
hypertensive JJ p
patients NNS p
( ( p
20 CD p
with IN p
and CC p
10 CD p
without IN p
stable JJ p
angina NN p
) ) p
. . p

RESULTS NNP N
More JJR N
than IN N
half NN N
of IN N
the DT N
patients NNS N
had VBD N
ischemic JJ o
episodes NNS o
; : o
95 CD N
% NN N
of IN N
these DT N
were VBD N
silent JJ N
. . N

Ischemic NNP o
episodes VBZ o
peaked VBN N
in IN N
the DT N
early JJ N
morning NN N
, , N
and CC N
55 CD N
% NN N
occurred VBD N
during IN N
routine JJ N
sedentary JJ N
activities NNS N
. . N

There EX N
was VBD N
a DT N
10 CD N
% NN N
to TO N
15 CD N
% NN N
increase NN N
in IN N
heart NN o
rate NN o
at IN N
the DT N
onset NN N
of IN N
ischemia NN N
associated VBN N
with IN N
a DT N
30 CD N
% NN N
higher JJR N
plasma JJ o
norepinephrine JJ o
level NN o
. . o

Seventy-five JJ N
percent NN N
of IN N
patients NNS N
had VBD N
increased VBN N
norepinephrine NN o
after IN N
nifedipine JJ i
therapy NN N
. . N

Nifedipine NNP N
therapy NN N
controlled VBD N
measured VBN N
blood NN o
pressure NN o
but CC N
not RB N
24-h JJ o
ambulatory NN o
blood NN o
pressure NN o
. . o

Ischemic NNP o
episodes NNS o
were VBD N
reduced VBN N
only RB N
in IN N
patients NNS N
whose WP$ N
ambulatory JJ N
blood NN N
pressure NN N
was VBD N
controlled VBN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
increased VBD N
neural JJ o
tone NN o
at IN N
the DT N
time NN N
of IN N
the DT N
ischemic JJ N
event NN N
may MD N
play VB N
a DT N
role NN N
in IN N
reducing VBG N
coronary JJ N
perfusion NN N
leading VBG N
to TO N
silent JJ N
ischemia NN N
. . N

Nifedipine NNP i
therapy NN i
( ( i
immediate JJ i
release NN i
) ) i
was VBD N
effective JJ N
in IN N
control NN o
of IN o
ischemia NN o
only RB N
when WRB N
both DT N
ambulatory NN N
and CC N
office-measured JJ N
blood NN o
pressure NN o
were VBD N
controlled VBN N
. . N

-DOCSTART- -18670875- O O

Venlafaxine NNP i
versus NN N
clonidine NN i
for IN N
the DT N
treatment NN p
of IN p
hot JJ o
flashes NNS o
in IN p
breast NN p
cancer NN p
patients NNS p
: : p
a DT N
double-blind NN N
, , N
randomized VBN N
cross-over NN N
study NN N
. . N

PURPOSE NNP N
Breast NNP p
cancer NN p
patients NNS p
with IN p
treatment-induced JJ p
menopause NN p
experience NN p
frequent NN p
and CC p
severe JJ o
hot JJ o
flashes NNS o
( ( o
HF NNP o
) ) o
. . o

We PRP N
compared VBN N
venlafaxine NN i
and CC N
clonidine NN i
for IN N
the DT N
treatment NN N
of IN N
HF NNP N
with IN N
regard NN N
to TO N
side VB o
effects NNS o
, , o
efficacy NN o
, , o
quality NN o
of IN o
life NN o
and CC o
sexual JJ o
functioning NN o
. . o

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
cross-over JJ N
study NN N
, , N
60 CD p
breast NN p
cancer NN p
patients NNS p
experiencing VBG p
HF NNP p
were VBD p
randomized VBN p
to TO N
8 CD N
weeks NNS N
venlafaxine NN i
followed VBN N
by IN N
2 CD N
weeks NNS N
wash-out RB N
, , N
and CC N
8 CD N
weeks NNS N
clonidine NN i
or CC N
vice NN N
versa NN N
. . N

HF NNP o
frequency NN o
and CC o
severity NN o
, , o
side NN o
effects NNS o
, , o
quality NN o
of IN o
life NN o
and CC o
sexuality NN o
were VBD N
assessed VBN N
. . N

RESULTS NNP N
Thirty NNP p
patients NNS p
started VBD N
with IN N
venlafaxine NN i
and CC N
30 CD N
with IN N
clonidine NN i
. . i

Premature JJ N
discontinuation NN N
for IN N
toxicity NN o
occurred VBD N
in IN N
14/59 CD N
during IN N
venlafaxine NN i
and CC N
5/53 CD N
during IN N
clonidine NN i
( ( N
P NNP N
= NNP N
.038 NNP N
) ) N
. . N

Venlafaxine NNP i
induced VBD N
more JJR N
side JJ o
effects NNS o
. . o

Median JJ o
reduction NN o
in IN o
HF NNP o
score NN o
was VBD N
49 CD N
% NN N
for IN N
venlafaxine NN i
and CC N
55 CD N
% NN N
for IN N
clonidine NN i
( ( N
ns JJ N
) ) N
. . N

CONCLUSION NNP N
Venlafaxine NNP i
and CC N
clonidine NN i
are VBP N
equally RB N
, , N
but CC N
moderately RB N
effective JJ N
in IN N
HF NNP o
reduction NN o
. . o

Side NN o
effects NNS o
are VBP N
the DT N
main JJ N
reason NN N
for IN N
drug NN N
discontinuation NN N
, , N
occurring VBG N
more RBR N
often RB N
with IN N
venlafaxine NN i
. . i

-DOCSTART- -9670112- O O

Glucosamine NNP o
in IN o
serum NN o
of IN N
patients NNS p
after IN p
myocardial JJ p
infarction NN p
subjected VBN N
to TO N
rehabilitation VB i
training NN i
. . i

This DT N
paper NN N
presents VBZ N
results NNS N
of IN N
3 CD N
weeks NNS N
physical JJ i
training NN i
on IN N
glucosamine JJ o
level NN o
in IN o
serum NN o
of IN N
male NN p
patients NNS p
after IN p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
aged VBD p
between IN p
38 CD p
and CC p
61 CD p
. . p

Patients NNS N
were VBD N
randomised VBN N
in IN N
two CD N
groups NNS N
: : N
the DT p
training NN i
group NN i
( ( p
n JJ p
= NNP p
21 CD p
) ) p
, , p
staying VBG p
in IN p
Cardiac NNP p
Rehabilitation NNP p
Department NNP p
and CC p
the DT p
control NN i
group NN i
( ( i
n JJ i
= NNP i
11 CD i
) ) i
, , i
discharged VBD i
home NN i
for IN N
3 CD N
weeks NNS N
. . N

Each DT N
group NN N
received VBD N
identical JJ N
dietary JJ N
instructions NNS N
. . N

The DT p
training NN p
group NN p
performed VBD N
exercises NNS i
every DT i
day NN i
: : i
on IN i
bicycle NN i
ergometer NN i
during IN i
30 CD i
minutes NNS i
( ( i
5 CD i
times NNS i
a DT i
week NN i
) ) i
, , i
overall-conditioning JJ i
exercises NNS i
for IN i
30 CD i
minutes NNS i
daily RB i
and CC i
30 CD i
to TO i
60 CD i
minutes NNS i
of IN i
walking VBG i
each DT i
day NN i
. . i

Before IN i
administering VBG i
of IN i
the DT i
therapy NN i
and CC i
3 CD i
weeks NNS i
later RB i
all DT i
MI NNP i
patients NNS i
performed VBD i
the DT i
bicycle NN i
ergometer NN i
exercise NN i
test NN i
until IN i
the DT i
ventilatory NN o
threshold NN o
was VBD i
reached VBN i
. . i

Before IN i
that DT i
test NN i
and CC i
3 CD i
minutes NNS i
after IN i
its PRP$ i
termination NN i
capillary NN i
and CC i
venous JJ i
blood NN i
samples NNS i
were VBD i
drawn VBN i
. . i

In IN i
the DT i
capillary JJ i
blood NN i
samples NNS i
indices NNS o
of IN o
acid-base JJ o
balance NN o
, , o
lactate JJ o
level NN o
, , o
and CC o
glucose JJ o
level NN o
were VBD i
determined VBN i
. . i

In IN N
venous JJ N
blood NN N
samples NNS N
the DT N
serum NN o
levels NNS o
of IN o
immunoreactive JJ o
insulin NN o
, , o
C-peptide NNP o
and CC o
glucosamine NN o
were VBD N
determined VBN N
as RB N
well RB N
as IN N
binding NN o
of IN o
125I-insulin JJ o
to TO o
erythrocyte VB o
receptors NNS o
. . o

Obtained VBN N
results NNS N
show VBP N
that IN N
administered JJ N
therapy NN N
increased VBD N
physical JJ o
fitness NN o
and CC N
decreased VBN N
of IN N
glucosamine NN o
concentration NN o
, , o
insulinaemia NN o
and CC o
insulin NN o
resistance NN o
. . o

-DOCSTART- -11741555- O O

Prognostic JJ N
significance NN N
of IN N
the DT N
dobutamine NN N
echocardiography NN N
test NN N
in IN N
idiopathic JJ o
dilated VBN o
cardiomyopathy NN o
. . o

Dobutamine NNP i
stress NN i
echo NN i
provides VBZ N
potentially RB N
useful JJ o
information NN o
on IN N
idiopathic JJ i
dilated VBN i
cardiomyopathy NN i
( ( p
IDC NNP p
) ) p
. . p

From IN p
February NNP p
1 CD p
, , p
1997 CD p
, , p
to TO p
October NNP p
1 CD p
, , p
1999 CD p
, , p
186 CD p
patients NNS p
( ( p
131 CD p
men NNS p
and CC p
55 CD p
women NNS p
, , p
mean JJ p
age NN p
56 CD p
+/- JJ p
12 CD p
years NNS p
) ) p
with IN p
IDC NNP p
, , p
ejection NN p
fraction NN p
< VBD p
35 CD p
% NN p
, , p
and CC p
angiographically RB p
normal JJ p
coronary JJ p
arteries NNS p
were VBD p
studied VBN p
by IN p
high-dose NN i
( ( p
up IN p
to TO p
40 CD p
micro/kg/min NN p
) ) p
dobutamine NN i
echo NN i
in IN p
6 CD p
centers NNS p
, , p
all DT p
quality NN p
controlled VBN p
for IN p
stress NN p
echo NN p
reading NN p
. . p

In IN N
all DT N
patients NNS N
, , N
wall JJ N
motion NN N
score NN N
index NN N
( ( N
WMSI NNP N
) ) N
( ( N
from IN N
1 CD N
= NNS N
normal JJ N
to TO N
4 CD N
= NNP N
dyskinetic NN N
in IN N
a DT N
16- JJ N
segment NN N
model NN N
of IN N
the DT N
left JJ N
ventricle NN N
) ) N
was VBD N
evaluated VBN N
by IN N
echo NN N
at IN N
baseline NN N
and CC N
peak JJ N
dobutamine NN N
. . N

One CD N
hundred VBD N
eighty-four JJ N
patients NNS N
were VBD N
followed VBN N
up RP N
( ( N
mean JJ N
15 CD N
+/- JJ N
13 CD N
months NNS N
) ) N
and CC N
only RB N
cardiac JJ o
death NN o
was VBD N
considered VBN N
as IN N
an DT N
end NN N
point NN N
. . N

There EX N
were VBD N
29 CD N
cardiac JJ N
deaths NNS N
. . N

Significant JJ N
parameters NNS N
for IN N
survival JJ N
prediction NN N
at IN N
univariate JJ N
analysis NN N
are VBP N
: : N
DeltaWMSI NNP N
( ( N
chi-square JJ N
20.1 CD N
; : N
p NN N
< VBZ N
0.0000 CD N
) ) N
, , N
New NNP N
York NNP N
Heart NNP N
Association NNP N
( ( N
NYHA NNP N
) ) N
class NN N
( ( N
chi-square JJ N
17.57 CD N
; : N
p NN N
< VBZ N
0.0000 CD N
) ) N
, , N
rest JJS N
ejection NN N
fraction NN N
( ( N
chi-square JJ N
10.41 CD N
; : N
p NN N
= VBZ N
0.0013 CD N
) ) N
, , N
angiotensin-converting JJ N
enzyme NN N
inhibitors NNS N
( ( N
chi-square JJ N
8.23 CD N
; : N
p NN N
= VBZ N
0.0041 CD N
) ) N
, , N
and CC N
hypertension NN N
( ( N
chi-square JJ N
8.08 CD N
, , N
p NN N
= NNP N
0.0045 CD N
) ) N
. . N

In IN N
the DT N
multivariate NN N
stepwise NN N
analysis NN N
only RB N
DeltaWMSI NNP N
and CC N
NYHA NNP N
were VBD N
independent JJ N
predictors NNS N
of IN N
outcome NN N
( ( N
DeltaWMSI NNP N
= NNP N
hazard VBD N
ratio NN N
0.02 CD N
, , N
p NN N
< VBD N
0.0000 CD N
; : N
NYHA NNP N
class NN N
= NNP N
hazard NN N
ratio NN N
3.83 CD N
, , N
p NN N
< NNP N
0.0000 CD N
) ) N
. . N

Kaplan-Meier NNP N
survival NN N
estimates NNS N
showed VBD N
a DT N
better JJR o
outcome NN o
for IN N
patients NNS N
with IN N
a DT N
large JJ o
inotropic NN o
response NN o
( ( N
DeltaWMSI NNP N
> NNP N
or CC N
=0.44 NNP N
, , N
a DT N
cutoff NN N
identified VBN N
by IN N
receiver-operating JJ N
characteristic JJ N
curves NNS N
analysis NN N
) ) N
than IN N
for IN N
those DT N
with IN N
a DT N
small JJ N
or CC N
no DT N
myocardial JJ N
inotropic NN N
response NN N
to TO N
dobutamine VB N
( ( N
93.6 CD N
% NN N
vs JJ N
69.4 CD N
% NN N
, , N
p NN N
= NNP N
0.00033 CD N
) ) N
. . N

Thus RB N
, , N
in IN N
patients NNS p
with IN p
IDC NNP p
, , N
an DT N
extensive JJ N
contractile NN N
reserve NN N
identified VBN N
by IN N
high-dose JJ N
dobutamine NN N
stress NN N
echocardiography NN N
is VBZ N
associated VBN N
with IN N
a DT N
better JJR o
survival NN o
. . o

-DOCSTART- -24599830- O O

Effects NNS N
of IN N
phosphorus-restricted JJ i
diet JJ i
and CC i
phosphate-binding JJ i
therapy NN i
on IN N
outcomes NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
. . p

BACKGROUND NNP N
Phosphorus NNP N
is VBZ N
associated VBN N
with IN N
mortality NN N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
not RB p
on IN p
dialysis NN p
, , N
possibly RB N
through IN N
phosphorus-dependent JJ N
vascular JJ N
calcification NN N
. . N

Although IN N
a DT N
phosphorus-restricted JJ i
diet JJ i
reduces NNS N
serum VBP N
phosphorus NN N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
it PRP N
reduces VBZ N
vascular JJ N
calcification NN N
progression NN N
in IN N
CKD NNP N
. . N

This DT N
study NN N
evaluated VBD N
whether IN N
a DT N
combined JJ i
strategy NN i
of IN i
phosphorus-restricted JJ i
diet JJ i
and CC i
phosphate-binding JJ i
therapy NN i
can MD N
reduce VB N
the DT N
risk NN o
of IN o
all-cause JJ o
mortality NN o
and/or JJ o
dialysis NN o
initiation NN o
by IN N
attenuating VBG N
coronary JJ o
artery NN o
calcification NN o
( ( o
CAC NNP o
) ) o
progression NN o
in IN N
non-dialysis JJ p
CKD NNP p
patients NNS p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
analysis NN N
of IN N
a DT N
subgroup NN p
of IN p
patients NNS p
from IN p
a DT p
study NN p
that WDT p
evaluated VBD p
the DT p
impact NN p
of IN p
two CD p
phosphorus NN p
binder NN p
regimens NNS p
on IN p
hard JJ p
outcomes NNS p
in IN p
CKD NNP p
. . p

Patients NNS p
( ( p
n JJ p
= NNP p
113 CD p
) ) p
with IN p
stage NN p
3-4 JJ p
CKD NNP p
and CC p
evidence NN p
of IN p
CAC NNP p
on IN p
a DT p
phosphorus-restricted JJ i
diet NN i
were VBD i
randomized VBN N
to TO N
receive VB N
either DT i
calcium NN i
carbonate NN i
or CC i
sevelamer NN i
added VBN i
to TO N
their PRP$ i
phosphorus-restricted JJ i
diet NN i
. . i

End-points NNS N
were VBD o
death NN o
for IN o
any DT o
cause NN o
and CC o
initiation NN o
of IN o
dialysis NN o
. . o

Patients NNS N
were VBD N
monitored VBN N
to TO N
the DT N
first JJ N
event NN N
or CC N
to TO N
conclusion NN N
of IN N
the DT N
36-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
treatment NN N
with IN i
calcium NN i
carbonate NN i
was VBD i
associated VBN N
with IN o
increased JJ o
CAC NNP o
progression NN o
and CC o
occurrence NN o
of IN o
all-cause JJ o
mortality NN o
, , o
dialysis NN o
initiation NN o
, , o
and CC o
the DT o
composite JJ o
end-point NN o
. . o

After IN N
adjustment NN N
for IN N
confounders NNS i
, , i
sevelamer NN i
use NN i
was VBD N
the DT N
only JJ N
independent JJ N
predictive JJ N
factor NN N
of IN N
reduced JJ o
risk NN o
of IN o
each DT o
endpoint NN o
but CC o
only RB N
if IN N
CAC NNP o
progression NN o
was VBD o
either CC N
absent JJ N
or CC N
moderate JJ o
. . o

Accelerated VBN o
progression NN o
( ( o
annual JJ N
CAC NNP N
increase NN N
> VBD N
75th CD N
percentile NN N
of IN N
the DT N
study NN N
cohort NN N
) ) N
increased VBD N
the DT o
risk NN o
of IN o
all-cause JJ o
mortality NN o
and CC o
composite JJ o
end-point NN o
( ( o
p JJ N
= NNP N
0.01 CD N
) ) N
independently RB N
of IN N
the DT N
use NN N
of IN N
sevelamer NN N
. . N

CONCLUSIONS VB N
A DT N
significant JJ N
reduction NN o
in IN o
all-cause JJ o
mortality NN o
, , o
dialysis NN o
initiation NN o
, , o
and CC o
composite JJ o
end-point NN o
risk NN o
was VBD o
achieved VBN N
by IN N
combining VBG i
phosphorus-restricted JJ i
diet JJ i
and CC i
sevelamer JJ i
in IN i
non-dialysis JJ N
CKD NNP N
patients NNS p
with IN p
absent NN N
or CC N
moderate VB N
but CC N
not RB N
accelerated JJ o
CAC NNP o
progression NN o
. . o

Future JJ o
studies NNS N
should MD N
investigate VB N
the DT N
role NN N
of IN N
serum NN N
phosphorus NN N
, , N
the DT N
usefulness NN N
of IN N
a DT N
phosphorus-restricted JJ N
diet NN N
, , N
and CC N
the DT N
appropriateness NN N
of IN N
current JJ N
normal JJ N
ranges NNS N
of IN N
serum NN N
phosphorus NN N
concentration NN N
in IN N
relation NN N
to TO N
events NNS N
in IN N
non-dialyzed JJ N
CKD NNP N
patients NNS N
. . N

-DOCSTART- -1119679- O O

The DT N
injured JJ p
colon NN p
: : p
therapeutic JJ N
considerations NNS N
. . N

A DT N
prospective JJ N
randomized NN N
study NN p
was VBD p
carried VBN p
out RP p
at IN p
the DT p
Detroit NNP p
General NNP p
Hospital NNP p
over IN p
a DT p
two CD p
year NN p
period NN p
to TO p
evaluate VB p
methods NNS p
of IN p
management NN p
in IN p
165 CD p
patients NNS p
with IN p
colonic JJ i
injuries NNS i
. . i

Results NNS N
of IN N
the DT N
study NN N
show NN N
that IN N
primary JJ i
closure NN i
is VBZ N
a DT N
safe JJ o
and CC N
reiable JJ o
method NN N
of IN N
management NN N
when WRB N
rigid JJ N
criteria NNS N
are VBP N
incorporated VBN N
in IN N
an DT N
ongoing JJ N
protocol NN N
. . N

Moreover RB N
, , N
the DT N
technic NN N
of IN N
exteriorization NN i
is VBZ N
a DT N
safe JJ o
adjunct NN N
to TO N
management NN N
and CC N
is VBZ N
recommended VBN N
in IN N
any DT p
patient NN p
with IN p
a DT p
colonic JJ p
injury NN p
above IN p
18 CD p
cm NN p
in IN N
which WDT N
one CD N
suture NN N
line NN N
is VBZ N
required VBN N
and CC N
in IN N
which WDT N
the DT N
additional JJ N
operating NN N
time NN N
of IN N
twenty NN N
minutes NNS N
will MD N
not RB N
compromise VB N
the DT N
management NN N
of IN N
secondary JJ N
injuries NNS N
. . N

Patients NNS N
not RB N
fulfilling VBG N
these DT N
criteria NNS N
should MD N
have VB N
primary JJ o
colostomy NN o
. . o

These DT N
principles NNS N
make VBP N
it PRP N
possible JJ N
to TO N
reduce VB N
the DT N
need NN N
for IN N
primary JJ o
colostomy NN o
to TO N
approximately RB N
50 CD N
per IN N
cent NN N
in IN N
a DT N
large JJ N
ongoing VBG N
group NN N
of IN N
patients NNS p
with IN p
colonic JJ p
injury NN p
. . p

-DOCSTART- -2182235- O O

Variability NN N
of IN N
thrombolytic JJ i
coronary JJ i
reperfusion NN i
: : i
an DT N
angiographic JJ N
study NN N
of IN N
streptokinase NN i
and CC N
anistreplase NN i
. . i

A DT N
total NN N
of IN N
1,615 CD p
angiographic JJ p
readings NNS p
in IN p
240 CD p
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
were VBD N
analyzed VBN N
from IN N
a DT N
randomized JJ N
trial NN N
of IN N
intravenous JJ i
anistreplase NN i
( ( i
Eminase NNP i
) ) i
, , i
also RB i
known VBN i
as IN i
anisoylated JJ i
plasminogen NN i
streptokinase JJ i
activator NN i
complex NN i
( ( i
APSAC NNP i
) ) i
, , N
versus FW N
intracoronary JJ N
streptokinase NN i
. . i

Coronary JJ N
arteriography NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
15 CD N
, , N
30 CD N
, , N
45 CD N
, , N
60 CD N
, , N
75 CD N
, , N
and CC N
90 CD N
minutes NNS N
after IN N
drug NN N
infusion NN N
. . N

Coronary NNP N
flow NN N
in IN N
the DT N
infarct-related JJ N
artery NN N
was VBD N
defined VBN N
using VBG N
the DT N
TIMI NNP N
criteria NNS N
. . N

Some DT N
serial JJ o
change NN o
in IN o
perfusion NN o
was VBD N
noted VBN N
in IN N
25 CD N
% NN N
of IN N
the DT N
total JJ N
patient JJ N
population NN N
and CC N
in IN N
49 CD N
% NN N
of IN N
all DT N
reperfusion NN N
patients NNS N
. . N

Complete JJ o
loss NN o
of IN o
perfusion NN o
( ( N
grade JJ N
2 CD N
or CC N
3 CD N
to TO N
grade VB N
0 CD N
or CC N
1 CD N
) ) N
occurred VBD N
in IN N
35 CD N
% NN N
of IN N
all DT N
reperfused JJ N
patients NNS N
. . N

Half NNP p
of IN p
these DT p
patients NNS p
ultimately RB N
developed VBD N
complete JJ N
loss NN o
of IN o
perfusion NN o
at IN N
the DT N
study NN N
endpoint NN N
. . N

All DT N
of IN N
these DT N
changes NNS N
in IN N
flow NN N
were VBD N
statistically RB N
more JJR N
common JJ N
for IN N
the DT N
circumflex JJ N
coronary JJ N
artery NN N
and CC N
early JJ N
treatment NN N
( ( N
less JJR N
than IN N
4 CD N
h NN N
) ) N
, , N
but CC N
did VBD N
not RB N
differ VB N
for IN N
anistreplase NN i
or CC N
streptokinase NN i
. . i

We PRP N
conclude VBP N
that DT N
frequent JJ N
alterations NNS o
in IN o
coronary JJ o
blood NN o
flow NN o
occur VBD N
early JJ N
during IN N
reperfusion NN i
therapy NN i
and CC N
that IN N
these DT N
findings NNS N
may MD N
explain VB N
reports NNS N
with IN N
varying VBG N
results NNS N
of IN N
thrombolytic JJ i
therapy NN i
. . i

Any DT N
angiographic JJ N
assessment NN N
of IN N
thrombolytic JJ i
drug NN i
efficacy NN N
should MD N
take VB N
these DT N
variations NNS N
as RB N
well RB N
as IN N
interobserver NN N
variability NN N
into IN N
account NN N
. . N

-DOCSTART- -3923528- O O

New NNP i
drug NN i
trials NNS i
in IN N
attention NN p
deficit NN p
disorder NN p
. . p

-DOCSTART- -4908199- O O

A DT p
randomized VBN p
controlled JJ p
trial NN p
of IN p
ergotamine JJ i
tartrate NN i
. . i

-DOCSTART- -20199680- O O

The DT N
development NN N
of IN N
a DT N
web- JJ i
and CC i
a DT i
print-based JJ i
decision NN i
aid NN i
for IN N
prostate NN o
cancer NN o
screening VBG o
. . o

BACKGROUND NNP N
Whether NNP N
early JJ N
detection NN N
and CC N
treatment NN N
of IN N
prostate NN N
cancer NN N
( ( N
PCa NNP N
) ) N
will MD N
reduce VB N
disease-related JJ o
mortality NN o
remains VBZ N
uncertain JJ N
. . N

As IN N
a DT N
result NN N
, , N
tools NNS N
are VBP N
needed VBN N
to TO N
facilitate VB N
informed JJ N
decision NN o
making NN o
. . o

While IN N
there EX N
have VBP N
been VBN N
several JJ N
decision NN N
aids NNS N
( ( N
DAs NNP N
) ) N
developed VBD N
and CC N
tested VBD N
, , N
very RB N
few JJ N
have VBP N
included VBN N
an DT N
exercise NN N
to TO N
help VB N
men NNS N
clarify VB N
their PRP$ N
values NNS o
and CC o
preferences NNS o
about IN N
PCa NNP N
screening NN N
. . N

Further NNP N
, , N
only RB N
one CD N
DA NNP N
has VBZ N
utilized VBN N
an DT N
interactive JJ N
web-based JJ N
format NN N
, , N
which WDT N
allows VBZ N
for IN N
an DT N
expansion NN N
and CC N
customization NN N
of IN N
the DT N
material NN N
. . N

We PRP N
describe VBP N
the DT N
development NN N
of IN N
two CD N
DAs NNP N
, , N
a DT N
booklet NN i
and CC N
an DT N
interactive JJ i
website NN i
, , N
each DT N
with IN N
a DT N
values NNS N
clarification NN N
component NN N
and CC N
designed VBN N
for IN N
use NN N
in IN N
diverse JJ N
settings NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
two CD N
feasibility NN N
studies NNS N
to TO N
assess VB N
men NNS p
's POS p
( ( p
45-70 CD p
years NNS p
) ) p
Internet NNP p
access NN p
and CC p
their PRP$ p
willingness NN p
to TO p
use VB p
a DT p
web- JJ i
vs. FW i
a DT i
print-based JJ i
tool NN i
. . i

The DT N
booklet NN N
was VBD N
adapted VBN N
from IN N
two CD N
previous JJ N
versions NNS N
evaluated VBN N
in IN N
randomized VBN i
controlled JJ i
trials NNS i
( ( i
RCTs NNP i
) ) i
and CC N
the DT N
website NN i
was VBD N
created VBN N
to TO N
closely RB N
match VB N
the DT N
content NN N
of IN N
the DT N
revised JJ N
booklet NN N
. . N

Usability NNP o
testing NN o
was VBD N
conducted VBN N
to TO N
obtain VB N
feedback NN N
regarding VBG N
draft JJ N
versions NNS N
of IN N
the DT N
materials NNS N
. . N

The DT N
tools NNS N
were VBD N
also RB N
reviewed VBN N
by IN N
a DT N
plain NN N
language NN N
expert NN N
and CC N
the DT N
interdisciplinary JJ N
research NN N
team NN N
. . N

Feedback NN N
on IN N
the DT N
content NN N
and CC N
presentation NN N
led VBD N
to TO N
iterative JJ N
modifications NNS N
of IN N
the DT N
tools NNS N
. . N

RESULTS VB N
The DT N
feasibility NN N
studies NNS N
confirmed VBD N
that IN N
the DT N
Internet NNP o
was VBD N
a DT N
viable JJ N
medium NN N
, , N
as IN N
the DT N
majority NN N
of IN N
men NNS N
used VBN o
a DT o
computer NN o
, , N
had VBD N
access NN o
to TO o
the DT o
Internet NNP o
, , N
and CC N
Internet NNP o
use NN o
increased VBD N
over IN N
time NN N
. . N

Feedback NN N
from IN N
the DT N
usability NN N
testing VBG N
on IN N
the DT N
length NN o
, , o
presentation NN o
, , o
and CC o
content NN o
of IN o
the DT o
materials NNS o
was VBD N
incorporated VBN N
into IN N
the DT N
final JJ N
versions NNS N
of IN N
the DT N
booklet NN N
and CC N
website NN N
. . N

Both CC N
the DT N
feasibility NN o
studies NNS o
and CC o
the DT o
usability NN o
testing VBG o
highlighted VBD N
the DT N
need NN N
to TO N
address VB N
men NNS p
's POS p
informed VBN p
decision NN p
making VBG p
regarding VBG N
screening NN N
. . N

CONCLUSIONS NNP N
Informed NNP N
decision NN N
making VBG N
for IN N
PCa NNP N
screening NN N
is VBZ N
crucial JJ N
at IN N
present JJ N
and CC N
may MD N
be VB N
important JJ N
for IN N
some DT N
time NN N
, , N
particularly RB N
if IN N
a DT N
definitive JJ N
recommendation NN N
either DT N
for IN N
or CC N
against IN N
screening VBG N
does VBZ N
not RB N
emerge VB N
from IN N
ongoing VBG N
prostate NN N
cancer NN N
screening VBG N
trials NNS N
. . N

We PRP N
have VBP N
detailed VBN N
our PRP$ N
efforts NNS N
at IN N
developing VBG N
print- JJ N
and CC N
web-based JJ N
DAs NNP N
to TO N
assist VB N
men NNS N
in IN N
determining VBG N
how WRB N
to TO N
best VB N
meet VB N
their PRP$ N
PCa NNP N
screening NN N
preferences NNS N
. . N

Following VBG N
completion NN N
of IN N
our PRP$ N
ongoing JJ N
RCT NNP N
designed VBN N
to TO N
test VB N
these DT N
materials NNS N
, , N
our PRP$ N
goal NN N
will MD N
be VB N
to TO N
develop VB N
a DT N
dissemination NN o
project NN o
for IN N
the DT N
more RBR N
effective JJ N
tool NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00623090 NNP N
. . N

-DOCSTART- -23942708- O O

Impact NN N
of IN N
a DT N
leptin JJ N
single JJ N
nucleotide NN N
polymorphism NN N
and CC N
zilpaterol NN i
hydrochloride NN i
on IN N
growth NN N
and CC N
carcass NN N
characteristics NNS N
in IN N
finishing VBG p
steers NNS p
. . p

A DT p
total NN p
of IN p
4,178 CD p
steers NNS p
( ( p
mean JJ p
initial JJ p
BW NNP p
= NN p
403.9 CD p
? . p
16.04 CD p
kg NN p
) ) p
were VBD p
used VBN p
to TO p
test VB p
the DT N
interactive JJ N
effects NNS N
, , N
if IN N
any DT N
, , N
of IN i
leptin JJ i
R25C NNP i
genotypes NNS i
( ( N
CC NNP N
, , N
CT NNP N
, , N
or CC N
TT NNP N
) ) N
and CC i
zilpaterol $ i
hydrochloride NN i
( ( i
ZH NNP i
) ) i
feeding VBG N
duration NN N
on IN N
growth NN N
performance NN N
and CC N
carcass NN N
traits NNS N
. . N

Steers NNS N
were VBD N
blocked VBN N
by IN N
arrival NN N
at IN N
the DT N
feed NN N
yard NN N
, , N
genotyped VBD N
for IN N
the DT N
leptin NN N
SNP NNP N
, , N
allotted VBD N
to TO N
genotype-specific JJ N
pens NNS N
( ( N
90 CD N
steers/pen NN N
) ) N
, , N
and CC N
assigned VBD N
randomly RB N
within IN N
genotype NN N
and CC N
block NN N
to TO N
0 CD N
or CC N
21 CD N
d NN N
of IN N
dietary JJ N
ZH NNP N
. . N

All DT N
pens NNS N
within IN N
a DT N
block NN N
were VBD N
slaughtered VBN N
on IN N
the DT N
same JJ N
day NN N
( ( N
132.1 CD N
? . N
10.9 CD N
d NN N
on IN N
feed NN N
) ) N
. . N

Final NNP N
BW NNP N
of IN N
steers NNS N
fed VBP N
ZH NNP N
was VBD N
6.0 CD N
kg NN N
heavier NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
, , N
and CC N
ZH-fed NNP N
steers NNS N
had VBD N
greater JJR N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
ADG NNP N
than IN N
steers NNS N
not RB N
fed VBN N
ZH NNP N
. . N

Feeding VBG N
ZH NNP N
decreased VBD o
DMI NNP o
in IN o
steers NNS N
with IN N
increased JJ N
frequency NN N
of IN N
the DT N
T NNP N
allele NN N
( ( N
9.67 CD N
, , N
9.53 CD N
, , N
and CC N
9.28 CD N
kg/d NN N
for IN N
CC NNP N
, , N
CT NNP N
, , N
and CC N
TT NNP N
, , N
respectively RB N
) ) N
, , N
but CC o
DMI NNP o
increased VBD o
with IN N
the DT N
frequency NN N
of IN N
the DT N
T NNP N
allele NN N
( ( N
9.68 CD N
, , N
9.90 CD N
, , N
and CC N
10.1 CD N
kg NN N
for IN N
CC NNP N
, , N
CT NNP N
, , N
and CC N
TT NNP N
, , N
respectively RB N
) ) N
when WRB N
ZH NNP N
was VBD N
not RB N
fed VBN N
( ( N
leptin JJ N
genotype NN N
? . N
ZH NNP N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

At IN N
the DT N
conclusion NN N
of IN N
the DT N
study NN o
, , o
ultrasonic JJ o
fat NN o
was VBD o
greatest JJS N
for IN N
TT NNP N
steers NNS N
( ( N
11.4 CD N
? . N
0.28 CD N
mm NN N
) ) N
and CC N
least JJS N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
for IN N
CC NNP N
steers NNS N
( ( N
11.0 CD N
? . N
0.25 CD N
mm NN N
) ) N
. . N

Regardless NNP N
of IN N
ZH-feeding NNP N
duration NN N
, , N
TT NNP N
steers NNS N
produced VBD N
a DT N
greater JJR N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
percentage NN o
of IN o
USDA NNP o
yield NN o
grade NN o
( ( o
YG NNP o
) ) o
4 CD N
or CC N
higher JJR N
carcasses NNS N
( ( N
5.4 CD N
vs. FW N
2.7 CD N
% NN N
) ) N
and CC N
a DT N
lesser JJR N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
percentage NN N
of IN N
YG NNP N
1 CD N
carcasses NNS N
( ( N
17.7 CD N
vs. FW N
26.8 CD N
% NN N
) ) N
than IN N
CC NNP N
steers NNS N
. . N

In IN N
addition NN N
, , N
ZH-fed NNP N
steers NNS N
produced VBD N
a DT N
greater JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
percentage NN o
of IN o
USDA NNP o
YG NNP o
1 CD o
carcasses NNS o
( ( o
25.9 CD o
vs. FW N
16.2 CD N
% NN N
) ) N
and CC N
a DT N
lesser JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
percentage NN N
of IN N
YG NNP N
4 CD N
or CC N
higher JJR N
carcasses NNS N
( ( N
1.6 CD N
vs. FW N
6.0 CD N
% NN N
) ) N
than IN N
steers NNS N
fed VBP N
the DT N
control NN N
diet NN N
. . N

Marbling VBG o
scores NNS o
and CC o
the DT o
percentage NN o
of IN o
carcasses NNS o
grading VBG o
USDA NNP o
Choice NNP o
and CC o
Prime NNP o
were VBD o
greater JJR N
in IN N
TT NNP N
than IN N
CC NNP N
steers NNS N
when WRB N
fed VBN N
diets NNS N
devoid VBP N
of IN N
ZH NNP N
, , N
but CC N
both DT N
marbling NN o
and CC o
quality NN o
grades NNS o
did VBD o
not RB N
differ VB N
among IN N
leptin JJ N
genotypes NNS N
when WRB N
fed VBN N
ZH NNP N
for IN N
21 CD N
d NN N
( ( N
leptin JJ N
genotype NN N
? . N
ZH NNP N
, , N
P NNP N
? . N
0.03 CD N
) ) N
. . N

The DT o
amount NN o
of IN o
HCW NNP o
gain NN o
tended VBD o
to TO N
be VB N
less JJR N
( ( N
P NNP N
= NNP N
0.095 CD N
) ) N
for IN N
steers NNS N
of IN N
the DT N
TT NNP N
genotype NN N
( ( N
12.7 CD N
kg NN N
) ) N
than IN N
either DT N
CC NNP N
( ( N
16.3 CD N
kg NN N
) ) N
or CC N
CT NNP N
( ( N
17.0 CD N
kg NN N
) ) N
genotypes NNS N
. . N

Results NNS N
indicated VBD N
that IN N
leptin NN N
R25C NNP N
genotype NN N
impacted VBD N
most RBS N
traits NNS N
associated VBN N
with IN N
fatness JJ N
whereas NNS N
feeding VBG N
ZH NNP N
for IN N
21 CD N
d NN N
affected VBD N
HCW NNP N
and CC N
ADG NNP N
positively RB N
but CC N
impacted VBD N
feed NN N
intake NN N
, , N
marbling NN N
, , N
and CC N
USDA NNP N
quality NN N
grades NNS N
negatively RB N
. . N

-DOCSTART- -15837967- O O

Phase NNP N
III NNP N
study NN N
of IN N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
( ( N
ECOG NNP N
2597 CD N
) ) N
: : N
induction NN i
chemotherapy NN i
followed VBN i
by IN i
either DT i
standard JJ i
thoracic NN i
radiotherapy NN i
or CC i
hyperfractionated VBN i
accelerated JJ i
radiotherapy NN i
for IN N
patients NNS p
with IN p
unresectable JJ p
stage NN p
IIIA NNP p
and CC p
B NNP p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
compare VB N
once-daily JJ i
radiation NN i
therapy NN i
( ( i
qdRT NN i
) ) i
with IN N
hyperfractionated VBN i
accelerated JJ i
radiation NN i
therapy NN i
( ( i
HART NNP i
) ) i
after IN N
two CD N
cycles NNS N
of IN N
induction NN i
chemotherapy NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Eligible JJ p
patients NNS p
were VBD p
treatment NN p
naive JJ p
, , p
and CC p
had VBD p
stage NN p
IIIA NNP p
and CC p
B NNP p
unresectable JJ p
non-small-cell JJ p
lung NN p
cancer NN p
, , p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
performance NN p
status NN p
0/1 CD p
, , p
and CC p
normal JJ p
organ JJ p
function NN p
. . p

Induction NNP i
chemotherapy NN i
consisted VBD N
of IN N
two CD N
cycles NNS N
of IN N
carboplatin JJ i
area NN N
under IN N
time-concentration NN N
curve NN N
6 CD N
mg/mL NN N
. . N

min NN N
plus CC N
paclitaxel JJ i
225 CD N
mg/m2 NN N
on IN N
day NN N
1 CD N
. . N

RT NNP N
consisted VBD N
of IN N
arm NN N
1 CD N
( ( N
qdRT NN N
) ) N
, , N
64 CD N
Gy NNP N
( ( N
2 CD N
Gy/d NNP N
) ) N
, , N
versus JJ N
arm NN N
2 CD N
( ( N
HART NNP N
) ) N
, , N
57.6 CD N
Gy NNP N
( ( N
1.5 CD N
Gy NNP N
tid NN N
for IN N
2.5 CD N
weeks NNS N
) ) N
. . N

A DT N
total NN p
of IN p
388 CD p
patients NNS p
were VBD N
needed VBN N
to TO N
detect VB N
a DT N
50 CD N
% NN N
increase NN N
in IN N
median JJ N
survival NN N
from IN N
14 CD N
months NNS N
of IN N
qdRT NN i
to TO N
21 CD N
months NNS N
of IN N
HART NNP i
; : i
accrual NN N
was VBD N
not RB N
achieved VBN N
and CC N
the DT N
study NN N
closed VBD N
prematurely RB N
. . N

RESULTS NNP N
Of IN N
141 CD p
patients NNS p
enrolled VBD p
, , N
83 CD N
% NN N
were VBD N
randomly RB N
assigned VBN N
after IN N
chemotherapy NN N
to TO N
qdRT VB i
( ( N
n JJ N
= NNP N
59 CD N
) ) N
or CC N
HART NNP i
( ( N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Median JJ o
survival NN o
was VBD N
20.3 CD N
and CC N
14.9 CD N
months NNS N
for IN N
HART NNP i
and CC N
qdRT NN i
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.28 NNP N
) ) N
. . N

Overall JJ o
response NN o
was VBD N
25 CD N
% NN N
and CC N
22 CD N
% NN N
for IN N
HART NNP i
and CC N
qdRT NN i
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.69 NNP N
) ) N
. . N

Two- JJ o
and CC o
3-year JJ o
survival NN o
was VBD N
44 CD N
% NN N
and CC N
34 CD N
% NN N
for IN N
HART NNP i
, , N
and CC N
24 CD N
% NN N
and CC N
14 CD N
% NN N
for IN N
qdRT NN i
, , N
respectively RB N
. . N

Grade VB o
> NN o
or CC o
= $ o
3 CD o
toxicities NNS o
included VBD N
esophagitis NN N
in IN N
14 CD N
v JJ N
nine CD p
patients NNS p
, , N
and CC N
pneumonitis NN N
in IN N
0 CD N
v NNS N
6 CD N
patients NNS N
for IN N
HART NNP i
and CC N
qdRT NN i
, , N
respectively RB N
. . N

Any DT N
subsequent JJ N
trials NNS N
of IN N
the DT N
HART NNP i
regimen NNS N
must MD N
address VB N
the DT N
issues NNS N
that WDT N
led VBD N
to TO N
early JJ N
closure NN N
, , N
including VBG N
slow JJ o
accrual NN o
, , o
logistics NNS o
of IN o
HART NNP o
, , o
mucosal NN o
toxicity NN o
, , N
and CC N
the DT N
fact NN N
that IN N
concurrent JJ N
chemoradiotherapy NN N
now RB N
seems VBZ N
more RBR N
effective JJ N
than IN N
sequential JJ N
treatment NN N
. . N

CONCLUSION NNP N
After IN N
two CD N
cycles NNS N
of IN N
induction NN i
chemotherapy NN i
with IN N
carboplatin-paclitaxel NN i
, , i
HART NNP i
is VBZ N
feasible JJ N
with IN N
an DT N
acceptable JJ N
toxicity NN N
profile NN N
. . N

Although IN N
statistical JJ N
significance NN N
was VBD N
not RB N
achieved VBN N
and CC N
the DT N
study NN N
closed VBD N
early RB N
, , N
there EX N
was VBD N
a DT N
positive JJ N
statistical JJ N
trend NN N
suggesting VBG N
a DT N
survival JJ N
advantage NN N
with IN N
the DT N
HART NNP i
regimen NNS N
. . N

-DOCSTART- -18679829- O O

Genetic JJ i
testing VBG i
for IN i
BRCA1 NNP N
: : N
effects NNS N
of IN N
a DT N
randomised JJ N
study NN N
of IN N
knowledge NN N
provision NN N
on IN N
interest NN N
in IN N
testing VBG N
and CC N
long JJ N
term NN N
test NN N
uptake NN N
; : N
implications NNS N
for IN N
the DT N
NICE NNP N
guidelines NNS N
. . N

INTRODUCTION JJ N
Interest NNP N
in IN N
searching VBG N
for IN N
mutations NNS N
in IN N
BRCA1 NNP N
and CC N
BRCA2 NNP N
is VBZ N
high JJ N
. . N

Knowledge NNP N
regarding VBG N
these DT N
genes NNS N
and CC N
the DT N
advantages NNS N
and CC N
limitations NNS N
of IN N
genetic JJ N
testing NN N
is VBZ N
limited VBN N
. . N

It PRP N
is VBZ N
unknown JJ N
whether IN N
increasing VBG N
knowledge NN N
about IN N
breast NN N
cancer NN N
genetic JJ N
testing VBG N
alters NNS N
interest NN N
in IN N
testing VBG N
. . N

METHODS NNP N
Three CD p
hundred VBD p
and CC p
seventy JJ p
nine CD p
women NNS p
( ( p
260 CD p
with IN p
a DT p
family NN p
history NN p
of IN p
breast NN p
cancer NN p
; : p
119 CD p
with IN p
breast NN p
cancer NN p
) ) p
from IN p
The DT p
Royal NNP p
Marsden NNP p
NHS NNP p
Foundation NNP p
Trust NNP p
were VBD N
randomised VBN N
to TO N
receive VB i
or CC i
not RB i
receive JJ i
written VBN i
educational JJ i
information NN i
on IN N
cancer NN N
genetics NNS N
. . N

A DT N
questionnaire NN i
was VBD N
completed VBN N
assessing VBG N
interest NN o
in IN o
BRCA1 NNP o
testing VBG o
and CC N
knowledge NN N
on IN N
breast NN N
cancer NN N
genetics NNS N
and CC N
screening VBG N
. . N

Actual JJ N
uptake NN N
of IN N
BRCA1 NNP o
testing NN o
is VBZ N
reported VBN N
with IN N
a DT N
six CD N
year NN N
follow-up RB N
. . N

RESULTS NNP N
Eighty NNP N
nine CD N
percent NN N
of IN N
women NNS N
at IN N
risk NN N
of IN N
breast NN N
cancer NN N
and CC N
76 CD N
% NN N
of IN N
women NNS N
with IN N
breast NN N
cancer NN N
were VBD N
interested JJ N
in IN N
BRCA1 NNP o
testing NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Provision NN N
of IN N
educational JJ N
information NN N
did VBD N
not RB N
affect VB N
level NN o
of IN o
interest NN o
. . o

Knowledge NNP o
about IN o
breast NN o
cancer NN o
susceptibility NN o
genes NNS o
was VBD N
poor JJ N
. . N

According VBG N
to TO N
the DT N
NICE NNP N
guidelines NNS N
regarding VBG N
eligibility NN N
for IN N
BRCA1 NNP N
and CC N
BRCA2 NNP N
testing NN N
, , N
the DT N
families NNS N
of IN N
66 CD N
% NN N
of IN N
the DT N
at IN N
risk NN N
group NN N
and CC N
13 CD N
% NN N
of IN N
the DT N
women NNS N
with IN N
breast NN N
cancer NN N
would MD N
be VB N
eligible JJ N
for IN N
testing VBG N
( ( N
probability NN N
of IN N
BRCA1 NNP N
mutation NN N
> NNP N
or=20 CD N
% NN N
) ) N
. . N

Within IN N
six CD N
years NNS N
of IN N
randomisation NN N
, , N
genetic JJ o
testing NN o
was VBD N
actually RB N
undertaken VBN N
on IN N
12 CD N
women NNS N
, , N
only RB N
10 CD N
of IN N
whom WP N
would MD N
now RB N
be VB N
eligible JJ N
, , N
on IN N
the DT N
NICE NNP N
guidelines NNS N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
strong JJ N
interest NN N
in IN N
BRCA1 NNP N
testing VBG N
. . N

Despite IN N
considerable JJ N
ignorance NN N
of IN N
factors NNS N
affecting VBG N
the DT N
inheritance NN N
of IN N
breast NN N
cancer NN N
, , N
education NN N
neither RB N
reduced VBN N
nor CC N
increased JJ N
interest NN o
to TO o
undergo VB o
testing VBG o
. . o

The DT N
NICE NNP N
guidelines NNS N
successfully RB N
triage VBP N
those DT N
with IN N
a DT N
high JJ N
breast NN N
cancer NN N
risk NN N
to TO N
be VB N
managed VBN N
in IN N
cancer NN N
genetics NNS N
clinics NNS N
. . N

-DOCSTART- -24216497- O O

The DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN i
and CC i
isoflurane NN i
after IN N
premedication NN N
of IN N
healthy JJ p
dogs NNS p
undergoing VBG p
elective JJ p
surgery NN p
. . p

Sevoflurane NNP i
and CC i
isoflurane NN i
are VBP N
commonly RB N
used VBN N
in IN N
veterinary JJ N
anesthesia NN N
. . N

The DT N
objective NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
sevoflurane NN i
and CC i
isoflurane NN i
via IN N
direct JJ N
arterial JJ N
blood NN N
pressure NN N
measurements NNS N
and CC N
the DT N
lithium NN N
dilution NN N
cardiac NN N
output NN N
( ( N
LDCO NNP N
) ) N
on IN N
premedicated VBN p
healthy JJ p
dogs NNS p
undergoing VBG p
elective JJ p
tibial JJ p
plateau NN p
leveling VBG p
osteotomy NN p
( ( p
TPLO NNP p
) ) p
. . p

Nineteen JJ p
client-owned JJ p
dogs NNS p
were VBD N
included VBN N
. . N

All DT N
dogs NNS N
were VBD N
premedicated VBN N
with IN N
hydromorphone NN i
( ( N
0.05 CD N
mg/kg NN N
IV NNP N
and CC N
glycopyrrolate VB i
0.01 CD N
mg/kg NNS N
subcutaneously RB N
) ) N
. . N

Ten CD p
dogs NNS p
were VBD p
anesthetized VBN p
with IN p
sevoflurane NN i
and CC p
nine CD p
dogs NNS p
were VBD p
anesthetized VBN p
with IN p
isoflurane NN i
. . i

Eighteen JJ N
dogs NNS N
were VBD N
instrumented VBN N
with IN N
a DT N
dorsal NN N
pedal JJ N
arterial JJ N
catheter NN N
, , N
and CC N
one CD N
dog NN N
had VBD N
a DT N
femoral JJ N
arterial JJ N
catheter NN N
. . N

All DT N
dogs NNS N
had VBD N
continuous JJ N
, , N
direct JJ o
systolic NN o
( ( o
SAP NNP o
) ) o
, , o
diastolic JJ o
( ( o
DAP NNP o
) ) o
, , o
and CC o
mean JJ o
arterial NN o
( ( o
MAP NNP o
) ) o
blood NN o
pressure NN o
readings NNS o
as RB N
well RB N
as IN N
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
, , o
cardiac JJ o
output NN o
( ( o
CO NNP o
) ) o
, , o
cardiac JJ o
index NN o
( ( o
CI NNP o
) ) o
, , o
systemic JJ o
vascular NN o
resistance NN o
( ( o
SVR NNP o
) ) o
, , o
systemic JJ o
vascular NN o
resistance NN o
index NN o
( ( o
SVRI NNP o
) ) o
, , o
stroke VBD o
volume NN o
variation NN o
( ( o
SVV NNP o
) ) o
, , o
and CC o
pulse JJ o
pressure NN o
variation NN o
( ( o
PPV NNP o
) ) o
recorded VBD N
q $ N
5 CD N
min NN N
during IN N
the DT N
surgical JJ N
procedure NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
statistical JJ N
difference NN N
in IN N
all DT N
parameters NNS N
between IN N
the DT N
sevoflurane NN i
and CC N
isoflurane NN i
treatment NN N
groups NNS N
. . N

Both DT N
sevoflurane NN i
and CC N
isoflurane NN i
inhalant JJ N
anesthetics NNS N
appear VBP N
to TO N
have VB N
similar JJ N
hemodynamic JJ N
effects NNS N
when WRB N
used VBN N
as IN N
part NN N
of IN N
a DT N
multimodal JJ N
anesthetic JJ N
protocol NN N
in IN N
premedicated VBN p
healthy JJ p
dogs NNS p
undergoing VBG p
an DT p
elective JJ p
surgical JJ p
procedure NN p
. . p

-DOCSTART- -20647058- O O

Rationale NNP N
and CC N
design NN N
of IN N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
an DT N
evidence-based JJ i
prescription NN i
drug NN i
label NN i
on IN p
actual JJ p
medication NN p
use NN p
. . p

BACKGROUND NNP N
Medication NNP N
errors NNS N
are VBP N
an DT N
important JJ N
public JJ N
health NN N
concern NN N
, , N
and CC N
poor JJ N
understanding NN N
of IN N
medication NN N
labels NNS N
are VBP N
a DT N
root NN N
cause NN N
. . N

Research NN N
shows VBZ N
that IN N
labels NNS N
are VBP N
variable JJ N
, , N
of IN N
poor JJ N
quality NN N
, , N
and CC N
not RB N
patient-centered JJ N
. . N

No DT N
real-world JJ N
trials NNS N
have VBP N
evaluated VBN N
whether IN N
improved JJ N
medication NN N
labels NNS N
can MD N
affect VB N
appropriate JJ N
medication NN N
use NN N
, , N
adherence NN N
or CC N
health NN N
outcomes NNS N
. . N

TRIAL NNP N
DESIGN NNP N
We PRP N
developed VBD N
an DT N
evidence-based JJ i
prescription NN i
label NN i
that WDT N
addresses VBZ N
both DT N
content NN N
and CC N
format NN N
. . N

The DT N
enhanced JJ i
label NN i
includes VBZ N
a DT N
universal JJ N
medication NN N
schedule NN N
( ( N
UMS NNP N
) ) N
that WDT N
standardizes VBZ N
the DT N
directions NNS N
for IN N
use NN N
incorporating VBG N
1 CD N
) ) N
standard NN N
time NN N
periods NNS N
for IN N
administration NN N
( ( N
morning NN N
, , N
noon NN N
, , N
evening NN N
, , N
and CC N
bedtime NN N
) ) N
, , N
2 CD N
) ) N
numeric JJ N
vs. FW N
alpha NN N
characters NNS N
, , N
3 CD N
) ) N
'carriage NN N
returns NNS N
' POS N
to TO N
separate VB N
daily JJ N
dose NN N
and CC N
4 CD N
) ) N
a DT N
graphic JJ N
aid NN N
to TO N
visually RB N
depict VB N
dose NN N
and CC N
frequency NN N
. . N

We PRP N
will MD N
evaluate VB N
the DT N
effect NN N
of IN N
providing VBG N
this DT N
label NN i
to TO N
randomly VB p
sampled VBN p
patients NNS p
who WP p
receive VBP p
their PRP$ p
care NN p
from IN p
free JJ p
clinics NNS p
, , p
mobile JJ p
vans NNS p
and CC p
federally RB p
qualified JJ p
health NN p
centers NNS p
( ( p
FQHCs NNP p
) ) p
in IN p
Northern NNP p
Virginia NNP p
. . p

We PRP N
will MD N
recruit VB N
patients NNS p
with IN p
diabetes NNS p
or CC p
hypertension NN p
; : p
these DT N
patients NNS N
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
receive VB N
all DT N
of IN N
their PRP$ N
medications NNS N
with IN N
improved JJ N
labels NNS N
or CC N
to TO N
receive VB N
prescriptions NNS N
with IN N
standard JJ N
labels NNS N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
the DT N
patient NN o
's POS o
ability NN o
to TO o
correctly RB o
demonstrate VB o
dosing VBG o
instructions NNS o
. . o

Other JJ N
outcomes NNS N
include VBP N
adherence NN o
, , o
error NN o
rates NNS o
and CC o
health NN o
outcomes NNS o
. . o

CONCLUSION NN N
To TO N
our PRP$ N
knowledge NN N
, , N
this DT N
trial NN N
is VBZ N
the DT N
first JJ N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prescription NN N
label NN N
improvement NN N
on IN N
understanding NN o
, , o
medication NN o
use NN o
and CC N
outcomes NNS N
in IN N
a DT N
clinical JJ N
setting NN N
. . N

If IN N
successful JJ N
, , N
these DT N
findings NNS N
could MD N
be VB N
implemented VBN N
broadly RB N
to TO N
promote VB N
safe JJ N
and CC N
appropriate JJ N
medication NN N
use NN N
and CC N
to TO N
support VB N
evidence-based JJ N
standards NNS N
in IN N
the DT N
development NN N
of IN N
labels NNS N
. . N

-DOCSTART- -16232016- O O

Comparison NNP N
of IN N
methods NNS N
for IN N
intravenous JJ N
infusion NN i
of IN i
fat JJ i
emulsion NN i
during IN N
extracorporeal JJ N
membrane JJ N
oxygenation NN N
. . N

STUDY NNP N
OBJECTIVES NNP N
To TO N
characterize VB N
the DT N
effects NNS N
of IN N
infusing VBG N
fat JJ i
emulsion NN i
during IN N
neonatal JJ N
extracorporeal JJ N
membrane NN N
oxygenation NN N
( ( N
ECMO NNP N
) ) N
by IN N
comparing VBG N
results NNS N
from IN N
patients NNS N
receiving VBG N
fat JJ i
emulsion NN i
through IN N
the DT N
ECMO NNP N
circuit NN N
with IN N
those DT N
receiving VBG N
fat JJ N
emulsion NN N
through IN N
separate JJ N
intravenous JJ N
access NN N
. . N

A DT N
second JJ N
goal NN N
was VBD N
to TO N
identify VB N
the DT N
optimal JJ N
route NN N
for IN N
administration NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
open-label JJ N
trial NN N
. . N

SETTING NN N
Neonatal NNP p
intensive JJ p
care NN p
unit NN p
in IN p
a DT p
106-bed JJ p
quaternary JJ p
care NN p
pediatric JJ p
hospital NN p
. . p

SUBJECTS NNP N
Nine NNP p
neonates VBZ p
receiving VBG p
ECMO NNP p
who WP p
required VBD p
intravenous JJ p
nutrition NN i
. . i

Intervention NNP N
. . N

Patients NNS N
received VBD N
1-3 JJ i
g/kg/day NN i
of IN i
fat JJ i
emulsion NN i
into IN i
either CC i
the DT i
ecmo NN i
circuit NN i
or CC i
separate JJ i
intravenous JJ i
access NN i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
ECMO NNP N
circuit NN N
and CC N
samples NNS N
of IN N
blood NN N
were VBD N
evaluated VBN N
hourly RB N
for IN N
phase NN N
separation NN N
, , N
layering VBG N
out IN N
of IN N
the DT N
emulsion NN N
from IN N
blood NN N
, , N
agglutination NN N
, , N
and CC N
blood NN N
clots NNS N
. . N

After IN N
completion NN N
, , N
the DT N
oxygenators NNS N
were VBD N
dissected VBN N
and CC N
examined VBN N
. . N

Data NNS N
were VBD N
compared VBN N
with IN N
an DT N
unpaired JJ N
t NN N
test NN N
. . N

The DT N
characteristics NNS N
of IN N
the DT N
groups NNS N
were VBD N
similar JJ N
, , N
except IN N
for IN N
a DT N
higher JJR N
mean JJ N
weight NN o
in IN N
the DT N
ECMO NNP N
circuit NN N
group NN N
( ( N
3.6 CD N
+/- JJ N
0.3 CD N
kg NN N
vs NN N
2.8 CD N
+/- JJ N
0.4 CD N
kg NN N
, , N
p=0.03 NN N
) ) N
. . N

The DT N
mean JJ o
+/- JJ o
SD NNP o
triglyceride NN o
level NN o
during IN N
the DT N
study NN N
was VBD N
87 CD N
+/- JJ N
79 CD N
mg/dl NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

Two CD N
patients NNS N
in IN N
each DT N
group NN N
had VBD N
elevated VBN N
triglyceride NN o
levels NNS o
. . o

No DT N
cases NNS N
of IN N
phase NN o
separation NN o
occurred VBD N
. . N

In IN N
the DT N
five CD N
patients NNS N
who WP N
received VBD N
fat JJ i
emulsion NN i
into IN N
the DT N
ECMO NNP N
circuit NN N
, , N
three CD N
had VBD N
layering VBG o
out IN o
of IN o
the DT o
emulsion NN o
and CC N
agglutination NN o
, , N
and CC N
all DT N
developed JJ N
clots NNS o
in IN N
the DT N
circuit NN N
despite IN N
adequate JJ N
anticoagulation NN N
. . N

Of IN N
the DT N
four CD N
patients NNS N
in IN N
the DT N
intravenous-access JJ N
group NN N
, , N
one CD N
had VBD N
layering NN N
and CC N
agglutination NN N
, , N
and CC N
two CD N
had VBD N
blood NN N
clots NNS N
. . N

CONCLUSIONS NNP N
Although IN N
both DT N
methods NNS N
were VBD N
associated VBN N
with IN N
layering VBG o
out RP o
, , o
agglutination NN o
, , o
and CC o
clot NN o
formation NN o
, , N
these DT N
effects NNS N
occurred VBD N
more RBR N
frequently RB N
with IN N
administration NN N
into IN N
the DT N
ECMO NNP N
circuit NN N
, , N
particularly RB N
in IN N
areas NNS N
of IN N
stasis NN N
. . N

This DT N
may MD N
result VB N
in IN N
disruption NN N
of IN N
normal JJ N
ECMO NNP N
blood NN N
flow NN N
and CC N
impaired JJ N
delivery NN N
of IN N
calories NNS N
. . N

Fat NNP i
emulsion NN i
should MD N
therefore RB N
be VB N
administered VBN N
through IN N
separate JJ N
intravenous JJ N
access NN N
during IN N
ECMO NNP N
whenever WRB N
possible JJ N
. . N

-DOCSTART- -18298579- O O

Effect NN N
of IN N
food NN i
on IN N
the DT N
antiviral JJ o
activity NN o
of IN N
didanosine JJ i
enteric-coated JJ i
capsules NNS i
: : i
a DT N
pilot NN N
comparative NN N
study NN N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
food NN i
on IN N
the DT N
antiviral JJ N
activity NN N
of IN N
enteric-coated JJ i
( ( i
EC NNP i
) ) i
capsules NNS i
of IN i
didanosine NN i
( ( i
ddI NN i
) ) i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
pilot NN N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
of IN N
28-day JJ N
ddI-EC JJ i
capsules NNS i
monotherapy-administered VBN i
in IN N
a DT N
fasted JJ i
state NN i
( ( p
group NN p
1 CD p
, , p
n=11 NN p
) ) p
or CC p
with IN i
food NN i
( ( p
group NN p
2 CD p
, , p
n=10 RB p
) ) p
to TO p
treatment-na?ve JJ p
chronically RB p
HIV-1-infected JJ p
individuals NNS p
. . p

To TO N
assess VB N
the DT o
antiviral JJ o
efficacy NN o
, , o
HIV-1 NNP o
RNA NNP o
was VBD N
determined VBN N
at IN N
baseline NN N
, , N
day NN N
3 CD N
, , N
day NN N
7 CD N
and CC N
weekly JJ N
thereafter NN N
. . N

The DT N
area NN N
under IN N
the DT N
HIV-1 NNP N
RNA NNP N
curve NN N
minus NN N
baseline NN N
weighted VBN N
by IN N
time NN o
( ( o
AUCMB/day NNP o
) ) o
was VBD N
calculated VBN N
. . N

RESULTS JJ o
Mean JJ o
baseline JJ o
HIV-1 NNP o
RNA NNP o
was VBD N
4.2 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
in IN N
group NN N
1 CD N
and CC N
3.8 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
in IN N
group NN N
2 CD N
. . N

After IN N
28 CD N
days NNS N
, , N
the DT o
mean JJ o
HIV-1 NNP o
RNA NNP o
reduction NN o
was VBD N
0.99 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
[ $ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.45-1.53 CD N
] NN N
for IN N
group NN N
1 CD N
and CC N
0.89 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.38-1.40 NN N
) ) N
for IN N
group NN N
2 CD N
. . N

AUCMB/day JJ o
values NNS o
were VBD N
0.775 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.33-1.22 NN N
) ) N
and CC N
0.774 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.48-1.07 NN N
) ) N
, , N
respectively RB N
, , N
showing VBG N
no DT N
difference NN N
in IN N
the DT N
rate NN N
of IN N
decrease NN N
of IN o
HIV-1 NNP o
RNA NNP o
( ( N
P=0.995 NNP N
) ) N
. . N

Mean NNP o
ddI JJ o
plasma NN o
levels NNS o
at IN N
day NN N
28 CD N
were VBD N
0.0234 CD N
mg/L NN N
for IN N
group NN N
1 CD N
and CC N
0.0227 CD N
mg/L NN N
for IN N
group NN N
2 CD N
( ( N
P=0.96 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
pilot NN N
study NN N
, , N
the DT N
administration NN N
of IN i
food NN i
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
the DT o
antiviral JJ o
activity NN o
of IN o
ddI-EC JJ o
capsules NNS o
. . o

-DOCSTART- -18082528- O O

Comparison NNP N
with IN N
computed JJ i
tomography NN i
of IN N
two CD N
ultrasound JJ N
devices NNS N
for IN N
diagnosis NN N
of IN N
abdominal JJ p
aortic JJ p
aneurysm NN p
. . p

Screening VBG N
for IN N
abdominal JJ p
aortic JJ p
aneurysms NNS p
( ( p
AAAs NNP p
) ) p
in IN p
patients NNS p
at IN p
risk NN p
will MD N
become VB N
more RBR N
cost JJ N
effective JJ N
if IN N
a DT N
simple NN N
, , N
inexpensive JJ N
, , N
and CC N
reliable JJ N
ultrasound JJ N
device NN N
is VBZ N
available JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
2-dimensional JJ N
, , N
handheld JJ i
ultrasound JJ i
device NN i
and CC N
a DT N
newly RB N
developed VBN N
ultrasound JJ i
volume NN i
scanner NN i
( ( N
based VBN N
on IN N
bladder NN N
scan JJ N
technology NN N
) ) N
with IN N
computed VBN i
tomography NN i
( ( i
CT NNP i
) ) i
for IN N
diagnosing VBG N
AAA NNP N
. . N

A NNP N
total NN N
of IN N
146 CD p
patients NNS p
( ( p
mean JJ p
age NN p
69 CD p
+/- JJ p
10 CD p
years NNS p
; : p
127 CD p
men NNS p
) ) p
were VBD N
screened VBN N
for IN N
the DT N
presence NN N
of IN N
AAAs NNP N
( ( N
diameter NN N
> VBZ N
3 CD N
cm NN N
) ) N
using VBG N
CT. NNP N
All NNP N
patients NNS N
were VBD N
examined VBN N
with IN N
the DT N
handheld NN N
ultrasound JJ N
device NN N
and CC N
the DT N
volume NN N
scanner NN N
. . N

Maximal JJ o
diameters NNS o
and CC o
volumes NNS o
were VBD N
used VBN N
for IN N
the DT N
analyses NNS N
. . N

AAAs NNP N
were VBD N
diagnosed VBN N
by IN N
CT NNP i
in IN N
116 CD N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
. . N

The DT N
absolute JJ o
difference NN o
of IN o
aortic JJ o
diameter NN o
between IN N
ultrasound NN i
and CC N
CT NNP i
was VBD N
< JJ N
5 CD N
mm NN N
in IN N
88 CD N
% NN N
of IN N
patients NNS N
. . N

Limits NNS N
of IN N
agreement NN N
between IN N
ultrasound NN N
and CC N
CT NNP i
( ( N
-6.6 NNP N
to TO N
9.4 CD N
mm NN N
) ) N
exceeded VBD N
the DT N
limits NNS N
of IN N
clinical JJ N
acceptability NN N
( ( N
+/-5 JJ N
mm NN N
) ) N
. . N

An DT N
excellent JJ N
correlation NN o
between IN N
ultrasound NN i
and CC N
CT NNP i
was VBD N
observed VBN N
( ( N
r JJ N
= NNP N
0.98 CD N
) ) N
. . N

The DT N
correlation NN o
coefficient NN o
between IN N
the DT N
volume NN N
scanner NN N
and CC N
CT NNP i
was VBD N
0.86 CD N
, , N
with IN N
agreement NN N
of IN N
90 CD N
% NN N
and CC N
kappa JJ N
value NN N
of IN N
0.73 CD N
. . N

Using VBG N
an DT N
optimal JJ o
cut-off NN o
value NN o
of IN N
> $ N
56 CD N
ml NN N
, , N
defined VBN N
by IN N
receiver-operating JJ o
characteristic JJ o
curve NN o
analysis NN o
, , o
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
the DT o
positive JJ o
and CC o
negative JJ o
predictive JJ o
values NNS o
of IN N
the DT N
volume NN N
scanner NN N
for IN N
detecting VBG N
AAA NNP N
were VBD N
90 CD N
% NN N
, , N
90 CD N
% NN N
, , N
97 CD N
% NN N
, , N
and CC N
71 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
conclusion NN N
, , N
this DT N
study NN N
shows VBZ N
that IN N
a DT N
2-dimensional JJ N
, , N
handheld JJ N
ultrasound JJ N
device NN N
and CC N
a DT N
newly RB N
developed VBN N
ultrasound JJ N
volume NN N
scanner NN N
can MD N
effectively RB N
identify VB N
patients NNS p
with IN p
AAAs NNP p
confirmed VBN p
by IN p
CT NNP p
. . p

-DOCSTART- -2468745- O O

Randomized NNP N
clinical JJ N
trial NN N
comparing VBG N
mitoxantrone NN i
with IN N
doxorubicin NN i
in IN N
previously RB p
treated VBN p
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
. . p

Three CD p
hundred VBD p
twenty-five JJ p
women NNS p
with IN p
metastatic JJ p
adenocarcinoma NN p
of IN p
the DT p
breast NN p
who WP p
had VBD p
failed VBN p
one CD p
prior JJ p
chemotherapeutic JJ p
regimen NNS p
for IN p
advanced JJ p
disease NN p
were VBD N
randomized VBN N
to TO N
receive VB N
14 CD N
mg/m2 NN N
of IN N
mitoxantrone NN i
or CC N
75 CD N
mg/m2 NN N
of IN N
doxorubicin NN i
intravenously RB N
( ( N
IV NNP N
) ) N
every DT N
3 CD N
weeks NNS N
. . N

Enrollment NN N
was VBD N
closed VBN N
on IN N
October NNP N
31 CD N
, , N
1984 CD N
, , N
after IN N
165 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
mitoxantrone VB i
and CC N
160 CD N
patients NNS N
to TO N
doxorubicin VB i
. . i

Patients NNS N
randomized VBD N
to TO N
the DT N
two CD N
treatment NN N
groups NNS N
were VBD N
compared VBN N
for IN N
response NN o
rate NN o
, , o
duration NN o
of IN o
response NN o
, , o
time NN o
to TO o
progression NN o
or CC o
death NN o
, , o
time NN o
to TO o
treatment NN o
failure NN o
( ( o
TTF NNP o
) ) o
, , o
and CC o
survival NN o
. . o

The DT N
response NN o
rate NN o
to TO N
mitoxantrone NN i
was VBD N
20.6 CD N
% NN N
, , N
to TO N
doxorubicin VB i
29.3 CD N
% NN N
( ( N
P NNP N
= NNP N
.07 NNP N
) ) N
. . N

The DT N
median JJ o
response NN o
duration NN o
was VBD N
151 CD N
days NNS N
for IN N
the DT N
mitoxantrone NN i
group NN N
and CC N
126 CD N
days NNS N
for IN N
the DT N
doxorubicin NN i
group NN N
( ( N
P NNP N
= NNP N
.16 NNP N
) ) N
. . N

The DT N
median JJ o
TTF NNP o
was VBD N
70 CD N
days NNS N
in IN N
the DT N
mitoxantrone NN i
group NN N
and CC N
104 CD N
days NNS N
in IN N
the DT N
doxorubicin NN i
group NN N
( ( N
P NNP N
= NNP N
.36 NNP N
) ) N
. . N

The DT N
median JJ o
survival NN o
of IN N
patients NNS N
initially RB N
randomized VBN N
to TO N
receive VB N
mitoxantrone NN i
was VBD N
273 CD N
days NNS N
; : N
for IN N
doxorubicin NN i
268 CD N
days NNS N
( ( N
P NNP N
= NNP N
.40 NNP N
) ) N
. . N

There EX N
were VBD N
three CD N
responses NNS N
among IN N
77 CD N
patients NNS N
crossed VBN N
over IN N
to TO N
mitoxantrone VB i
after IN N
initial JJ N
treatment NN N
with IN N
doxorubicin NN i
. . i

The DT o
major JJ o
dose-limiting JJ o
toxicity NN o
for IN N
both DT N
drugs NNS N
was VBD N
leukopenia RB o
. . o

There EX N
was VBD N
significantly RB N
less JJR o
severe JJ o
and CC o
less RBR o
frequent JJ o
toxicity NN o
with IN N
mitoxantrone JJ i
administration NN N
. . N

Severe NNP o
nausea NN o
and CC o
vomiting NN o
occurred VBD N
in IN N
9.5 CD N
% NN N
of IN N
mitoxantrone NN i
patients NNS N
and CC N
25.3 CD N
% NN N
of IN N
doxorubicin NN i
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
.001 NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
severe JJ o
stomatitis NN o
and CC o
mucositis NN o
was VBD N
0.6 CD N
% NN N
in IN N
the DT N
mitoxantrone NN i
group NN N
and CC N
8.4 CD N
% NN N
in IN N
the DT N
doxorubicin NN i
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Severe JJ N
alopecia NN o
occurred VBD N
in IN N
5.1 CD N
% NN N
of IN N
mitoxantrone NN i
patients NNS N
and CC N
61.0 CD N
% NN N
of IN N
doxorubicin NN i
patients NNS N
( ( N
P NNP N
less JJR N
than IN N
.001 NN N
) ) N
. . N

A DT N
life-table JJ N
comparison NN N
of IN N
the DT N
cumulative JJ N
dose NN N
to TO N
the DT N
development NN N
of IN N
a DT N
cardiac JJ N
event NN N
showed VBD N
that IN N
mitoxantrone NN i
had VBD N
significantly RB N
less JJR N
cardiotoxicity NN o
than IN N
doxorubicin NN i
( ( N
P NNP N
= NNP N
.0005 NNP N
) ) N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
mitoxantrone NN i
is VBZ N
active JJ N
as IN N
a DT N
single JJ N
agent NN N
in IN N
the DT N
treatment NN N
of IN N
metastatic JJ o
breast NN o
cancer NN o
. . o

Compared VBN N
with IN N
doxorubicin NN i
it PRP N
appears VBZ N
to TO N
be VB N
marginally RB o
less RBR o
active JJ o
and CC o
significantly RB o
less JJR o
toxic JJ o
. . o

We PRP N
conclude VBP N
that IN N
mitoxantrone NN i
can MD N
be VB N
used VBN N
alone RB N
or CC N
with IN N
other JJ N
standard NN N
drugs NNS N
to TO N
palliate VB N
the DT N
symptoms NNS N
of IN N
metastatic JJ N
breast NN N
cancer NN N
, , N
especially RB N
in IN N
settings NNS N
where WRB N
drug NN o
toxicity NN o
is VBZ N
an DT N
important JJ N
consideration NN N
. . N

-DOCSTART- -15886667- O O

Racial JJ i
differences NNS i
in IN i
primary JJ i
and CC i
repeat VB i
lower JJR i
extremity NN i
amputation NN i
: : i
results NNS N
from IN N
a DT N
multihospital NN i
study NN i
. . i

OBJECTIVE CC N
African JJ p
Americans NNPS p
have VBP N
a DT N
much RB N
higher JJR N
risk NN o
of IN o
major JJ o
( ( o
above- JJ o
or CC o
below-knee NN o
) ) o
lower JJR o
extremity NN o
amputation NN o
and CC N
a DT N
lower JJR i
rate NN o
of IN o
limb-preserving JJ o
vascular JJ o
surgery NN o
or CC i
angioplasty NN i
than IN N
white JJ N
patients NNS N
. . N

This DT N
article NN N
analyzes VBZ N
two CD N
potential JJ N
pathways NNS N
for IN N
racial JJ N
disparities NNS N
: : N
primary JJ N
amputation NN N
, , N
defined VBD N
as IN N
a DT N
major JJ N
amputation NN i
performed VBN N
without IN N
any DT N
prior JJ N
attempt NN N
at IN N
revascularization NN i
, , N
and CC N
repeat NN N
amputation NN i
, , N
defined VBD N
as IN N
a DT N
major JJ N
amputation NN i
subsequent NN N
to TO N
a DT N
previous JJ N
through-foot NN N
or CC N
major JJ N
amputation NN N
. . N

METHODS NNP N
Randomly NNP p
selected VBD p
medical JJ i
records NNS i
were VBD i
reviewed VBN i
for IN i
248 CD i
African JJ i
American NNP i
, , i
30 CD i
Hispanic NNP i
, , i
and CC i
235 CD i
white JJ i
or CC i
other-race JJ i
patients NNS i
undergoing VBG i
above- JJ i
or CC i
below-knee JJ i
amputation NN i
between IN i
1995 CD i
and CC i
2003 CD i
at IN i
three CD i
Chicago NNP i
teaching VBG i
hospitals NNS i
. . i

Chronic NNP i
disease NN i
prevalence NN i
and CC i
severity NN i
, , i
preadmission NN i
functional JJ i
status NN i
, , i
clinical JJ i
presentation NN i
, , i
and CC i
vascular JJ i
history NN i
were VBD N
used VBN N
to TO N
test VB N
the DT N
risk-adjusted JJ N
effect NN N
of IN N
race NN N
and CC N
ethnicity NN N
on IN N
rates NNS o
of IN o
primary JJ o
and CC o
repeat JJ o
amputation NN o
. . o

RESULTS NNP N
Controlling VBG N
for IN N
demographic JJ N
, , N
functional JJ N
, , N
chronic JJ N
disease NN N
, , N
and CC N
clinical JJ N
characteristics NNS N
, , N
African JJ N
American JJ N
patients NNS N
were VBD N
1.7 CD N
times NNS N
more RBR N
likely JJ N
to TO N
have VB N
undergone JJ N
both DT N
primary JJ N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
and CC N
repeat NN N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
amputation NN i
than IN N
white JJ N
or CC N
other-race JJ N
amputees NNS N
. . N

Race NNP N
remained VBD N
a DT N
significant JJ N
independent JJ N
risk NN N
factor NN N
even RB N
after IN N
controlling VBG N
for IN N
the DT N
higher JJR N
severity NN N
of IN N
illness NN N
, , N
greater JJR N
disability NN N
, , N
and CC N
more RBR N
complex JJ N
presentation NN N
of IN N
African JJ p
American JJ p
amputees NNS p
. . p

CONCLUSIONS NNP N
Higher JJR N
rates NNS N
of IN N
primary JJ o
and CC o
repeat JJ o
amputation NN o
for IN N
African JJ N
American JJ N
patients NNS N
at IN N
study NN N
hospitals NNS N
, , N
which WDT N
all DT N
have VBP N
significant JJ N
vascular JJ N
surgery NN N
capacity NN N
and CC N
an DT N
aggressive JJ N
policy NN N
of IN N
limb NN N
salvage NN N
, , N
suggest VBP N
that IN N
these DT N
rates NNS N
may MD N
be VB N
even RB N
higher JJR N
at IN N
less JJR N
well RB N
equipped JJ N
institutions NNS N
. . N

Improving VBG N
access NN N
to TO N
primary JJ N
and CC N
preventive JJ N
care NN N
for IN N
lower-income JJ N
patients NNS N
could MD N
reduce VB N
amputation NN o
rates NNS o
among IN N
African JJ N
Americans NNPS N
. . N

-DOCSTART- -2089829- O O

Tetracaine/adrenaline/cocaine NNP i
for IN N
local JJ p
anesthesia NN p
. . p

-DOCSTART- -12424317- O O

Global JJ p
contour NN p
saliency NN p
and CC N
local JJ N
colinear NN N
interactions NNS N
. . N

Our PRP$ p
visual JJ p
system NN p
can MD p
link VB p
components NNS p
of IN p
contours NNS p
and CC p
segregate JJ p
contours NNS p
from IN p
complex JJ p
backgrounds NNS p
based VBN p
on IN p
geometric JJ p
grouping NN p
rules NNS p
. . p

This DT p
is VBZ p
an DT p
important JJ p
intermediate JJ p
step NN p
in IN p
object JJ o
recognition NN o
. . o

The DT p
substrate NN p
for IN p
contour JJ p
integration NN p
may MD p
be VB p
based VBN p
on IN p
contextual JJ p
interactions NNS p
and CC p
intrinsic JJ p
horizontal NN p
connections NNS p
seen VBN p
in IN p
primary JJ p
visual JJ p
cortex NN p
( ( p
V1 NNP p
) ) p
. . p

We PRP p
examined VBD p
the DT p
perceptual JJ p
rules NNS p
governing VBG p
contour NN p
saliency NN p
to TO p
determine VB p
whether IN p
the DT p
spatial JJ p
extents NNS p
of IN p
contextual JJ p
interactions NNS p
and CC p
horizontal JJ p
connections NNS p
match VBP p
those DT p
mediating JJ p
saliency NN p
. . p

To TO p
quantify VB p
these DT p
rules NNS p
, , p
we PRP p
used VBD p
stimuli NNS i
composed VBN i
of IN i
randomly RB i
oriented VBN i
nonoverlapping JJ i
line NN i
segments NNS i
. . i

Salient NN p
contours NN p
within IN p
this DT p
complex JJ p
background NN p
were VBD p
formed VBN p
by IN p
colinear JJ p
alignment NN p
of IN p
nearby JJ p
segments NNS p
. . p

Contour NNP o
detectability NN o
was VBD p
measured VBN p
using VBG p
a DT p
2-interval-forced-choice JJ i
design NN i
. . i

Contour NNP o
detectability NN o
deteriorated VBN N
with IN N
increasing VBG N
spacing VBG o
between IN N
contour JJ N
elements NNS N
and CC N
improved VBN N
as IN N
the DT N
number NN N
of IN N
colinear JJ N
line NN N
elements NNS N
was VBD N
increased VBN N
. . N

At IN N
short JJ N
contour NN N
spacing NN N
, , N
the DT N
detectability NN N
reached VBD N
a DT N
plateau NN N
with IN N
alignment NN N
of IN N
a DT N
few JJ N
line NN N
segments NNS N
that IN N
together RB N
formed VBD N
a DT N
contour NN N
subtending VBG N
several JJ N
visual JJ N
degrees NNS N
. . N

At IN N
intermediate JJ N
spacing NN N
, , N
saliency NN o
built VBD N
up RP N
progressively RB N
with IN N
a DT N
greater JJR N
number NN N
of IN N
colinear JJ N
lines NNS N
, , N
extending VBG N
up RP N
to TO N
30 CD N
degrees NNS N
. . N

When WRB N
contour NN N
spacing NN N
was VBD N
beyond IN N
a DT N
critical JJ N
range NN N
( ( N
about IN N
2 CD N
degrees NNS N
) ) N
, , N
however RB N
, , N
the DT N
detectability NN o
dropped VBD N
to TO N
chance NN N
levels NNS N
, , N
regardless RB N
of IN N
the DT N
number NN N
of IN N
colinear JJ N
lines NNS N
. . N

Contour NNP o
detectability NN o
was VBD N
found VBN N
to TO N
be VB N
a DT N
function NN N
not RB N
only RB N
of IN N
the DT N
relative JJ N
spacing NN N
of IN N
contour JJ N
elements NNS N
with IN N
respect NN N
to TO N
the DT N
noise NN N
elements NNS N
but CC N
also RB N
of IN N
the DT N
average JJ o
density NN o
of IN N
the DT N
overall JJ N
pattern NN N
. . N

Furthermore NNP N
, , N
training VBG N
significantly RB N
improved VBN N
contour JJ o
detection NN o
, , N
increasing VBG N
the DT N
critical JJ o
spacing NN o
of IN N
line NN N
elements NNS N
beyond IN N
which WDT N
contours NNS N
were VBD N
no RB N
longer RBR N
detectable JJ N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
global JJ o
contour NN o
integration NN o
is VBZ N
based VBN N
on IN N
mechanisms NNS N
of IN N
limited JJ N
spatial JJ N
extent NN N
, , N
comparable JJ N
to TO N
the DT N
interactions NNS N
observed VBD N
in IN N
V1 NNP N
. . N

These DT N
interactions NNS N
can MD N
cascade VB N
over IN N
larger JJR N
distances NNS N
provided VBD N
the DT N
spacing NN N
of IN N
stimulus JJ N
elements NNS N
is VBZ N
kept VBN N
within IN N
a DT N
limited JJ N
range NN N
. . N

-DOCSTART- -17471343- O O

Preliminary JJ N
analysis NN N
of IN N
the DT N
final JJ N
multicenter NN N
investigation NN N
of IN N
rheopheresis NN i
for IN N
age NN p
related VBN p
macular JJ p
degeneration NN p
( ( p
AMD NNP p
) ) p
trial NN N
( ( N
MIRA-1 NNP N
) ) N
results NNS N
. . N

PURPOSE NNP N
To TO N
present VB N
an DT N
initial JJ N
evaluation NN N
of IN N
the DT N
final JJ N
data NN N
from IN N
the DT N
Multicenter NNP N
Investigation NNP N
of IN N
Rheopheresis NNP i
for IN N
age-related JJ N
macular JJ N
degeneration NN N
( ( N
AMD NNP N
) ) N
( ( N
MIRA-1 NNP N
) ) N
trial NN N
. . N

This DT N
was VBD N
a DT N
12-month JJ N
randomized NN N
, , N
prospective JJ N
, , N
multicenter NN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ i
, , N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
approved VBD N
clinical JJ N
trial NN N
designed VBN N
to TO N
compare VB N
rheopheresis NN i
treatment NN i
with IN N
placebo-control JJ i
treatment NN i
. . i

METHODS NNP N
Patients NNPS p
that WDT p
had VBD p
nonexudative JJ p
age-related JJ p
macular JJ p
degeneration NN p
( ( p
AMD NNP p
) ) p
and CC p
certain JJ p
hemorheologic JJ p
abnormalities NNS p
were VBD N
randomized VBN N
to TO N
either DT N
rheopheresis NN i
or CC i
sham NN i
treatment NN i
in IN N
a DT N
2:1 CD N
fashion NN N
. . N

Best-corrected JJ N
visual JJ N
acuity NN N
was VBD N
determined VBN N
before RB N
and CC N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
following VBG N
treatment NN N
. . N

Adverse JJ N
events NNS N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
216 CD p
patients NNS p
were VBD N
randomized VBN N
. . N

Of IN N
these DT N
, , N
18 CD N
were VBD N
not RB N
included VBN N
in IN N
the DT N
vision NN o
or CC o
adverse JJ o
events NNS o
evaluation NN N
because IN N
they PRP N
did VBD N
not RB N
complete VB N
one CD N
treatment NN N
. . N

This DT N
decreased VBD N
the DT N
number NN N
of IN N
patients NNS N
that WDT N
were VBD N
evaluated VBN N
for IN N
adverse JJ N
events NNS N
to TO N
198 CD p
patients NNS p
. . p

In IN N
this DT N
group NN N
, , N
there EX N
were VBD N
27 CD N
serious JJ N
adverse JJ N
events NNS N
, , N
but CC N
only RB N
1.8 CD N
% NN N
of IN N
treatments NNS N
were VBD N
suspended VBN N
because IN N
of IN N
adverse JJ N
events NNS N
. . N

At IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
104 CD N
treated JJ N
patients NNS N
and CC N
63 CD N
placebo NN i
patients NNS N
that WDT N
had VBD N
follow-up NN N
. . N

The DT N
treated JJ N
patients NNS N
had VBD N
a DT N
logMAR JJ o
vision NN o
improvement NN o
of IN N
0.02 CD N
+/- JJ N
0.213 CD N
, , N
and CC N
the DT N
placebo NN i
patients NNS N
had VBD N
a DT N
vision NN o
improvement NN o
of IN N
0.02 CD N
+/- JJ N
0.20 CD N
. . N

This DT N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.977 NNP N
) ) N
. . N

The DT N
repeated JJ N
measure NN N
P NNP N
value NN N
for IN N
the DT N
entire JJ N
time NN N
interval NN N
was VBD N
not RB N
significant JJ N
( ( N
P NNP N
= NNP N
.69 NNP N
) ) N
. . N

There EX N
appeared VBD N
to TO N
be VB N
patients NNS N
entered VBN N
into IN N
the DT N
study NN N
that WDT N
did VBD N
not RB N
meet VB N
inclusion NN N
criteria NNS N
. . N

Excluding VBG N
37 CD N
% NN N
of IN N
the DT N
treated JJ N
patients NNS N
and CC N
29 CD N
% NN N
of IN N
the DT N
placebo NN N
data NNS N
from IN N
the DT N
analysis NN N
, , N
there EX N
appeared VBD N
to TO N
be VB N
statistically RB N
significant JJ N
improvement NN N
in IN N
the DT N
treated JJ N
patients NNS N
compared VBN N
to TO N
the DT N
control NN N
patients NNS N
at IN N
1 CD N
year NN N
with IN N
a DT N
P NNP N
value NN N
of IN N
.001 NNP N
( ( N
repeated VBN N
measures NNS N
P NNP N
value NN N
= NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
At IN N
best JJS N
this DT N
was VBD N
a DT N
flawed VBN N
study NN N
in IN N
that DT N
37 CD N
% NN N
of IN N
the DT N
treated JJ N
cases NNS N
did VBD N
not RB N
meet VB N
inclusion NN N
criteria NNS N
, , N
and CC N
at IN N
worst JJS N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
effect NN N
. . N

Even RB N
though IN N
the DT N
number NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
is VBZ N
small JJ N
, , N
because IN N
this DT N
study NN N
did VBD N
not RB N
show VB N
an DT N
effect NN N
in IN N
the DT N
intent-to-treat JJ N
group NN N
, , N
rheopheresis NN i
should MD N
not RB N
be VB N
performed VBN N
for IN N
AMD NNP N
outside NN N
of IN N
an DT N
approved JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

-DOCSTART- -3075724- O O

Plasma NNP N
3,4-dihydroxyphenylethyleneglycol CD N
and CC N
3-methoxy-4-hydroxyphenylethyleneglycol JJ N
as IN N
indicators NNS N
of IN N
central JJ N
noradrenergic JJ N
activity NN N
. . N

A DT N
comparative JJ N
study NN N
on IN N
control NN p
subjects NNS p
and CC p
depressed JJ p
patients NNS p
. . p

Animal NNP N
studies NNS N
have VBP N
suggested VBN N
interspecies NNS N
differences NNS N
in IN N
brain NN N
norepinephrine NN N
( ( N
NE NNP N
) ) N
metabolism NN N
, , N
especially RB N
with IN N
regard NN N
to TO N
the DT N
relative JJ N
proportions NNS N
of IN N
3,4-dihydroxyphenylethyleneglycol JJ N
( ( N
DOPEG NNP N
) ) N
compared VBN N
to TO N
3-methoxy-4-hydroxyphenylethyleneglycol CD N
( ( N
MOPEG NNP N
) ) N
. . N

In IN N
order NN N
to TO N
question VB N
the DT N
value NN N
of IN N
both DT N
glycol JJ N
metabolites NNS N
as IN N
peripheral JJ N
indices NNS N
of IN N
central JJ o
noradrenergic JJ o
activity NN o
, , N
a DT N
comparative JJ N
study NN N
of IN N
plasma NN N
DOPEG NNP N
and CC N
MOPEG NNP N
( ( N
measured VBN N
by IN N
HPLC NNP N
) ) N
related VBD N
to TO N
depression NN N
, , N
sex NN N
, , N
age NN N
and CC N
diagnostic JJ N
categories NNS N
( ( N
DSM-III NNP N
) ) N
was VBD N
carried VBN N
out RP N
on IN N
depressed JJ p
and CC p
control JJ p
subjects NNS p
. . p

In IN N
addition NN N
, , N
two CD p
groups NNS p
of IN p
8 CD p
patients NNS p
were VBD N
randomly RB N
submitted VBN N
to TO N
a DT N
desipramine NN i
150 CD i
mg/day NN i
, , i
or CC i
a DT i
metapramine JJ i
450 CD i
mg/day JJ i
antidepressant JJ i
treatment NN i
influencing VBG N
the DT N
formation NN N
of IN N
DOPEG NNP N
and CC N
MOPEG NNP N
in IN N
a DT N
different JJ N
way NN N
. . N

The DT N
study NN N
did VBD N
not RB N
demonstrate VB N
any DT N
difference NN N
between IN N
DOPEG NNP N
and CC N
MOPEG NNP N
for IN N
most JJS N
of IN N
the DT N
experimental JJ N
factors NNS N
. . N

We PRP N
found VBD N
also RB N
a DT N
significant JJ N
positive JJ o
correlation NN o
between IN o
plasma NN o
levels NNS o
of IN o
DOPEG NNP o
and CC o
MOPEG NNP o
. . o

Our PRP$ N
results NNS N
support VB N
the DT N
idea NN N
that IN N
each DT N
of IN N
these DT N
two CD N
biological JJ N
indices NNS N
can MD N
be VB N
used VBN N
in IN N
the DT N
assessment NN N
of IN N
central JJ o
noradrenergic JJ o
activity NN o
. . o

-DOCSTART- -19895777- O O

Screening VBG i
, , i
brief JJ i
intervention NN i
, , i
and CC i
referral JJ i
to TO i
treatment NN i
( ( i
SBIRT NNP i
) ) i
in IN N
a DT N
Polish JJ p
emergency NN p
department NN p
: : p
three-month JJ N
outcomes NNS N
of IN N
a DT N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
A DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
screening NN i
, , i
brief JJ i
intervention NN i
, , i
and CC i
referral JJ i
to TO i
treatment NN i
( ( i
SBIRT NNP i
) ) i
for IN N
drinking NN p
and CC p
related JJ p
problems NNS p
among IN p
at-risk JJ p
and CC p
dependent JJ p
drinkers NNS p
was VBD N
conducted VBN N
in IN N
an DT N
emergency NN p
department NN p
( ( p
ED NNP p
) ) p
in IN p
Sosnowiec NNP p
, , p
Poland NNP p
, , p
among IN p
patients NNS p
ages VBZ p
18 CD p
years NNS p
and CC p
older JJR p
. . p

METHOD NNP N
Data NNP p
were VBD p
collected VBN p
over IN p
a DT p
23-week JJ p
period NN p
, , p
from IN p
4:00 CD p
PM NNP p
to TO p
midnight VB p
, , N
and CC N
resulted VBD N
in IN N
446 CD p
patients NNS p
being VBG p
recruited VBN p
into IN p
the DT p
study NN p
( ( p
90 CD p
% NN p
of IN p
those DT p
who WP p
screened VBD p
positive JJ p
) ) p
and CC N
randomized VBN N
to TO N
three CD N
conditions NNS N
following VBG N
a DT N
two-stage JJ N
process NN N
: : N
screened VBN i
only RB i
( ( N
n JJ N
= NNP N
147 CD N
) ) N
, , N
assessed VBN i
( ( N
n JJ N
= NNP N
152 CD N
) ) N
, , N
and CC N
received VBN i
intervention NN i
( ( N
n JJ N
= NNP N
147 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
assessment NN i
( ( N
85 CD N
% NN N
) ) N
and CC N
intervention NN i
( ( N
83 CD N
% NN N
) ) N
conditions NNS N
were VBD N
blindly RB N
reassessed VBN N
at IN N
3 CD N
months NNS N
via IN N
a DT N
telephone NN N
interview NN N
. . N

RESULTS NNP N
At IN N
3-month JJ N
follow-up NN N
, , N
both DT N
groups NNS N
showed VBD N
significant JJ N
decreases NNS N
in IN N
the DT N
proportion NN N
who WP N
were VBD N
positive JJ N
for IN N
at-risk JJ N
drinking NN N
, , N
the DT N
primary JJ N
outcome NN N
variable NN N
. . N

Both DT N
groups NNS N
also RB N
showed VBD N
significant JJ N
decreases NNS N
in IN N
drinking NN o
days NNS o
per IN o
week NN o
, , o
drinks NNS o
per IN o
drinking NN o
day NN o
, , o
maximum JJ o
drinks NNS o
per IN o
occasion NN o
, , o
and CC o
negative JJ o
consequences NNS o
of IN o
drinking NN o
. . o

Using VBG N
analysis NN N
of IN N
covariance NN N
to TO N
control VB N
for IN N
baseline NN N
measures NNS N
and CC N
demographic JJ N
characteristics NNS N
, , N
no DT N
difference NN N
in IN N
outcome JJ N
measures NNS N
was VBD N
found VBN N
between IN N
intervention NN i
and CC N
assessment JJ i
conditions NNS N
. . N

Subgroup NNP N
analysis NN N
found VBD N
some DT N
significant JJ N
interactions NNS N
between IN N
intervention NN i
and CC N
secondary JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
main JJ N
findings NNS N
were VBD N
similar JJ N
to TO N
those DT N
from IN N
other JJ N
brief-intervention NN N
studies NNS N
in IN N
Western JJ N
cultures NNS N
, , N
findings NNS N
here RB N
also RB N
suggest VBP N
that IN N
intervention NN N
may MD N
have VB N
differential JJ N
benefits NNS N
for IN N
specific JJ N
subgroups NNS N
of IN N
patients NNS N
in IN N
the DT N
ED NNP N
, , N
an DT N
area NN N
of IN N
research NN N
that WDT N
may MD N
warrant VB N
additional JJ N
study NN N
of IN N
brief JJ N
intervention NN N
in IN N
the DT N
ED NNP N
setting NN N
. . N

-DOCSTART- -16939848- O O

Preventing VBG N
paclitaxel-induced JJ o
peripheral JJ o
neuropathy NN o
: : o
a DT N
phase NN N
II NNP N
trial NN N
of IN N
vitamin NN i
E NNP i
supplementation NN i
. . i

A DT N
randomized JJ N
, , N
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
vitamin NN i
E NNP i
supplementation NN i
for IN N
prophylaxis NN N
against IN N
paclitaxel-induced JJ o
peripheral JJ o
neuropathy NN o
( ( o
PIPN NNP o
) ) o
. . o

Thirty-two JJ p
patients NNS p
undergoing VBG p
six CD p
courses NNS p
of IN p
paclitaxel-based JJ i
chemotherapy NN i
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
chemotherapy NN i
with IN i
vitamin NN i
E NNP i
( ( N
300 CD N
mg NN N
twice RB N
a DT N
day NN N
, , N
Group NNP N
I PRP N
) ) N
or CC N
chemotherapy NN i
without IN i
vitamin NN i
E NNP i
supplementation NN i
( ( N
Group NNP N
II NNP N
) ) N
. . N

A DT N
detailed JJ o
neurological JJ o
examination NN o
and CC o
electrophysiological JJ o
study NN o
was VBD N
performed VBN N
during IN N
and CC N
3 CD N
months NNS N
after IN N
chemotherapy NN i
. . i

The DT N
severity NN o
of IN o
PIPN NNP o
was VBD o
summarized VBN o
by IN o
means NNS o
of IN o
a DT o
modified JJ o
Peripheral NNP o
Neuropathy NNP o
( ( o
PNP NNP o
) ) o
score NN o
. . o

The DT N
incidence NN o
of IN o
neurotoxicity NN o
differed VBN N
significantly RB N
between IN N
groups NNS N
, , N
occurring VBG N
in IN N
3/16 CD N
( ( N
18.7 CD N
% NN N
) ) N
patients NNS N
assigned VBN N
to TO N
the DT N
vitamin NN i
E NNP i
supplementation NN i
group NN N
and CC N
in IN N
10/16 CD N
( ( N
62.5 CD N
% NN N
) ) N
controls VBZ N
( ( N
P=0.03 NNP N
) ) N
. . N

The DT N
relative JJ o
risk NN o
( ( o
RR NNP o
) ) o
of IN o
developing VBG o
PIPN NNP o
was VBD N
significantly RB N
higher JJR N
in IN N
controls NNS N
than IN N
in IN N
vitamin JJ i
E NNP i
group NN N
patients NNS N
( ( N
RR=0.3 NNP N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
=0.1-0.9 NN N
) ) N
. . N

Mean JJ o
PNP NNP o
scores NNS o
were VBD N
2.25+/-5.1 CD N
( ( N
range VB N
0-15 NNP N
) ) N
for IN N
patients NNS N
in IN N
Group NNP N
I PRP N
and CC N
11+/-11.63 JJ N
( ( N
range VB N
0-32 NN N
) ) N
for IN N
those DT N
in IN N
Group NNP N
II NNP N
( ( N
P=0.01 NNP N
) ) N
. . N

Vitamin NNP i
E NNP i
supplementation NN i
was VBD N
well RB N
tolerated VBN o
and CC N
showed VBD N
an DT N
excellent JJ N
safety NN o
profile NN o
. . o

This DT N
study NN N
shows VBZ N
that IN N
vitamin NN i
E NNP i
effectively RB N
and CC N
safely RB N
protects VBZ N
patients NNS p
with IN p
cancer NN p
from IN N
the DT N
occurrence NN o
of IN o
paclitaxel-induced JJ o
peripheral JJ o
nerve NN o
damage NN o
. . o

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
is VBZ N
needed VBN N
to TO N
confirm VB N
these DT N
results NNS N
. . N

-DOCSTART- -3056498- O O

Comparison NNP N
of IN N
four CD N
continuously RB N
administered VBN N
progestogen NN i
plus CC i
oestradiol JJ i
combinations NNS N
for IN N
climacteric JJ o
complaints NNS o
. . o

Sixty NNP p
women NNS p
with IN p
climacteric JJ p
complaints NNS p
who WP p
had VBD p
not RB p
menstruated VBN p
for IN p
at IN p
least JJS p
1 CD p
year NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
one CD N
of IN N
four CD N
hormonal JJ N
replacement NN N
regimens NNS N
. . N

All DT N
four CD N
formulations NNS N
were VBD N
administered VBN N
daily RB N
and CC N
continuously RB N
and CC N
each DT N
contained VBD N
2 CD N
mg NN N
of IN N
micronized JJ i
oestradiol-17 JJ i
beta NN i
in IN i
combination NN i
with IN i
either DT i
norethisterone NN i
acetate NN i
1 CD i
mg NN i
( ( N
group NN N
A NNP N
) ) N
or CC N
0.5 CD N
mg NN N
( ( N
group NN N
B NNP N
) ) N
or CC i
megestrol VB i
acetate JJ i
5 CD i
mg NN i
( ( N
group NN N
C NNP N
) ) N
or CC N
2.5 CD N
mg NN N
( ( N
group NN N
D NNP N
) ) N
. . N

The DT N
clinical JJ o
efficacy NN o
was VBD N
the DT N
same JJ N
although IN N
the DT N
alleviation NN N
of IN N
vasomotor NN o
symptoms NNS o
was VBD N
somewhat RB N
slower JJR N
in IN N
those DT N
women NNS N
receiving VBG N
preparation NN N
A NNP N
. . N

The DT N
endometrium NN o
was VBD N
atrophied VBN N
in IN N
nearly RB N
all DT N
biopsies NNS o
. . o

Irregular JJ o
uterine JJ o
bleeding NN o
was VBD N
almost RB N
entirely RB N
confined VBN N
to TO N
the DT N
earlier JJR N
phase NN N
of IN N
the DT N
study NN N
and CC N
was VBD N
substantially RB N
less JJR N
with IN N
the DT N
formulation NN N
containing VBG N
1 CD N
mg JJ N
norethisterone NN i
acetate NN i
. . i

It PRP N
is VBZ N
concluded VBN N
that IN N
a DT N
continuous JJ N
oestradiol-progestogen JJ i
combination NN i
can MD N
be VB N
used VBN N
for IN N
long-term JJ N
treatment NN N
of IN N
climacteric JJ o
complaints NNS o
in IN p
postmenopausal JJ p
women NNS p
and CC N
that IN N
after IN N
4 CD N
months NNS N
the DT N
clinical JJ o
efficacy NN o
is VBZ N
the DT N
same JJ N
irrespective NN N
of IN N
the DT N
type NN N
and CC N
dose NN N
of IN N
progestogen NN i
administered VBN N
. . N

-DOCSTART- -9413463- O O

Randomised VBN N
trial NN N
of IN N
efficacy NN o
and CC o
safety NN o
of IN N
oral JJ i
ganciclovir NN i
in IN N
the DT N
prevention NN N
of IN N
cytomegalovirus NN N
disease NN N
in IN N
liver-transplant JJ p
recipients NNS p
. . p

The DT N
Oral NNP N
Ganciclovir NNP i
International NNP N
Transplantation NNP N
Study NNP N
Group NNP N
[ NNP N
corrected VBD N
] NNP N
. . N

BACKGROUND NNP N
Cytomegalovirus NNP N
( ( N
CMV NNP N
) ) N
disease NN N
is VBZ N
a DT N
frequent JJ N
cause NN N
of IN N
serious JJ N
morbidity NN N
after IN N
solid-organ JJ N
transplantation NN N
. . N

The DT N
prophylactic JJ N
regimens NNS N
used VBN N
to TO N
prevent VB N
CMV NNP N
infection NN N
and CC N
disease NN N
have VBP N
shown VBN N
limited JJ N
benefit NN N
in IN N
seronegative JJ N
recipients NNS N
. . N

We PRP N
studied VBD N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
oral JJ i
ganciclovir NN i
in IN N
the DT N
prevention NN N
of IN N
CMV NNP N
disease NN N
following VBG N
orthotopic NN p
liver JJ p
transplantation NN p
. . p

METHODS NNP N
Between NNP p
December NNP p
, , p
1993 CD p
, , p
and CC p
April NNP p
, , p
1995 CD p
, , p
304 CD p
liver-transplant JJ p
recipients NNS p
were VBD N
randomised VBN N
to TO N
receive VB N
oral JJ i
ganciclovir NN i
1000 CD i
mg NN N
or CC N
matching VBG N
placebo NN i
three CD N
times NNS N
a DT N
day NN N
. . N

Seronegative JJ p
recipients NNS p
of IN p
seronegative JJ p
livers NNS p
were VBD N
excluded VBN N
. . N

Study NNP N
drug NN N
was VBD N
administered VBN N
as RB N
soon RB N
as IN N
the DT N
patient NN N
was VBD N
able JJ N
to TO N
take VB N
medication NN N
by IN N
mouth NN N
( ( N
no DT N
later RB N
than IN N
day NN N
10 CD N
) ) N
until IN N
the DT N
98th CD N
day NN N
after IN N
transplantation NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
specified VBN N
times NNS N
throughout IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
surgery NN N
for IN N
evidence NN N
of IN N
CMV NNP o
infection NN o
, , o
CMV NNP o
disease NN o
, , o
rejection NN o
, , o
opportunistic JJ o
infections NNS o
, , o
and CC o
possible JJ o
drug NN o
toxicity NN o
. . o

FINDINGS IN N
The DT N
Kaplan-Meier NNP N
estimate NN N
of IN N
the DT N
6-month JJ o
incidence NN o
of IN o
CMV NNP o
disease NN o
was VBD N
29 CD N
( ( N
18.9 CD N
% NN N
) ) N
of IN N
154 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
compared VBN N
with IN N
seven CD N
( ( N
4.8 CD N
% NN N
) ) N
of IN N
150 CD N
in IN N
the DT N
ganciclovir NN i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
the DT N
high-risk JJ N
group NN N
of IN N
seronegative JJ N
recipients NNS N
( ( N
R- NNP N
) ) N
of IN N
seropositive JJ N
livers NNS N
( ( N
D+ NNP N
) ) N
, , N
incidence NN o
of IN o
CMV NNP o
disease NN o
was VBD N
11 CD N
( ( N
44.0 CD N
% NN N
) ) N
of IN N
25 CD N
in IN N
the DT N
placebo NN i
group NN N
, , N
three CD N
( ( N
14.8 CD N
% NN N
) ) N
of IN N
21 CD N
in IN N
the DT N
ganciclovir NN i
group NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

Significant JJ N
benefit NN N
was VBD N
also RB N
observed VBN N
in IN N
those DT N
receiving VBG N
antibodies NNS N
to TO N
lymphocytes NNS N
, , N
where WRB N
the DT N
incidence NN N
of IN N
CMV NNP o
disease NN o
was VBD N
12 CD N
( ( N
32.9 CD N
% NN N
) ) N
of IN N
37 CD N
in IN N
the DT N
placebo NN i
group NN N
and CC N
two CD N
( ( N
4.6 CD N
% NN N
) ) N
of IN N
44 CD N
in IN N
the DT N
ganciclovir NN i
group NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

Oral JJ N
ganciclovir NN N
reduced VBD N
the DT N
incidence NN o
of IN o
CMV NNP o
infection NN o
( ( i
placebo JJ i
79 CD N
[ JJ N
51.5 CD N
% NN N
] NN N
of IN N
154 CD N
; : N
ganciclovir CC i
37 CD N
[ JJ N
24.5 CD N
% NN N
] NN N
of IN N
150 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
and CC N
also RB N
reduced VBN N
symptomatic JJ o
herpes-simplex JJ o
infections NNS o
( ( N
Kaplan-Meier NNP N
estimates NNS N
: : N
placebo NN i
36 CD N
[ JJ N
23.5 CD N
% NN N
] NN N
of IN N
154 CD N
; : N
ganciclovir JJ N
five CD N
[ JJ N
3.5 CD N
% NN N
] NN N
of IN N
150 CD N
; : N
p NN N
< VBZ N
0.001 CD N
) ) N
. . N

INTERPRETATION NNP N
Oral NNP N
ganciclovir NN i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
method NN N
for IN N
the DT N
prevention NN N
of IN N
CMV NNP N
disease NN N
after IN N
orthotopic NN p
liver NN p
transplantation NN p
. . p

-DOCSTART- -20865678- O O

Influence NN N
of IN N
exercise NN i
training NN i
on IN N
leptin NN o
levels NNS o
in IN N
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
: : p
A DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
influence NN N
of IN N
exercise NN i
training NN i
on IN N
leptin NN N
levels NNS N
in IN N
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
. . p

METHODS NNP N
Sixty-four JJ p
male NN p
patients NNS p
, , p
mean JJ p
age NN p
55.6 CD p
? . p
6.0 CD p
years NNS p
, , p
were VBD N
randomized VBN N
either RB N
to TO N
six CD N
weeks NNS N
of IN i
aerobic JJ i
training NN i
, , i
three CD N
times NNS N
a DT N
week NN N
, , N
at IN N
60-80 CD N
% NN N
of IN N
maximal JJ N
heart NN N
rate NN N
( ( N
training VBG N
group NN N
, , N
Ex NNP N
, , N
n JJ N
= NNP N
32 CD N
) ) N
or CC N
to TO N
a DT N
control NN i
group NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
. . N

Exercise NNP N
stress JJ N
test NN N
was VBD N
performed VBN N
and CC N
body JJ N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
waist-to-hip JJ N
ratio NN N
( ( N
WHR NNP N
) ) N
, , N
waist JJ N
circumference NN N
and CC N
plasma NN N
leptin NN N
levels NNS N
were VBD N
measured VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS NNP o
Physical JJ o
capacity NN o
increased VBD N
significantly RB N
only RB N
in IN N
Ex NNP N
patients NNS N
( ( N
max JJ N
workload NN N
in IN N
METs NNP N
from IN N
7.7 CD N
? . N
1.4 CD N
to TO N
8.2 CD N
? . N
1.4 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
initial JJ N
and CC N
final JJ N
results NNS N
in IN N
either DT N
group NN N
in IN N
terms NNS N
of IN N
BMI NNP N
, , N
WHR NNP N
or CC N
waist JJ N
circumference NN N
. . N

Although IN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN o
, , o
leptin NN o
levels NNS o
did VBD o
not RB N
change VB N
in IN N
Ex NNP N
patients NNS N
( ( N
6.7 CD N
? . N
3.2 CD N
vs NN N
6.9 CD N
? . N
3.6 CD N
ng/mL NN N
, , N
NS NNP N
) ) N
, , N
they PRP N
did VBD N
increase VB N
significantly RB N
in IN N
the DT N
control NN N
group NN N
( ( N
8.0 CD N
? . N
4.0 CD N
vs NN N
9.3 CD N
? . N
5.2 CD N
ng/mL NN N
, , N
p NN N
< NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
short JJ N
period NN N
of IN i
exercise NN i
training NN i
in IN i
CAD NNP i
patients NNS p
improved VBD o
their PRP$ o
physical JJ o
capacity NN o
, , o
but CC o
did VBD o
not RB N
influence VB o
BMI NNP o
, , o
WHR NNP o
and CC o
waist JJ o
circumference NN o
. . o

Exercise NN o
training NN i
prevented VBD i
an DT N
increase NN N
in IN N
leptin JJ N
levels NNS N
during IN N
the DT N
study NN N
period NN N
. . N

-DOCSTART- -8770304- O O

Comparison NNP N
of IN N
analgesic JJ N
effect NN N
of IN N
locally RB N
and CC N
systemically RB N
administered VBN N
ketorolac NN i
in IN N
mastectomy JJ p
patients NNS p
. . p

BACKGROUND NNP N
Ketorolac NNP i
is VBZ N
a DT N
parenteral JJ N
nonsteroidal JJ N
antiinflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
. . N

Two CD N
features NNS N
have VBP N
limited VBN N
its PRP$ N
clinical JJ N
utility NN N
: : N
tendency NN N
to TO N
elicit VB N
kidney NN N
failure NN N
and CC N
inability NN N
to TO N
produce VB N
complete JJ N
analgesia NN N
. . N

Because IN N
most JJS N
NSAIDs NNP i
are VBP N
weak JJ N
acids NNS N
( ( N
pKa IN N
3-5 NNP N
) ) N
and CC N
become VBN N
concentrated JJ N
in IN N
acidic JJ N
tissues NNS N
, , N
such JJ N
as IN N
injured JJ N
and CC N
inflamed JJ N
tissues NNS N
, , N
we PRP N
hypothesized VBD N
that IN N
local JJ N
administration NN N
may MD N
enhance VB N
its PRP$ N
analgesic JJ N
efficacy NN N
while IN N
lowering VBG N
the DT N
potential NN N
for IN N
systemic JJ N
complications NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
of IN N
60 CD p
group NN p
I-II NNP p
( ( p
American JJ p
Society NNP p
of IN p
Anesthesiology NNP p
criteria NNS p
) ) p
mastectomy NN p
patients NNS p
, , p
20 CD p
in IN p
each DT p
group NN p
. . p

Near IN N
the DT N
end NN N
of IN N
surgery NN N
and CC N
every DT N
6 CD N
h NN N
postoperatively RB N
, , N
20 CD N
ml NN N
of IN N
the DT N
study NN N
solution NN N
containing VBG N
normal JJ i
saline NN i
with IN i
or CC i
without IN i
30 CD i
mg NN i
of IN i
ketorolac NN i
were VBD N
administered VBN N
simultaneously RB N
either CC N
via IN N
a DT N
Jackson-Pratt JJ N
drain NN N
or CC N
intravenously RB N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

The DT N
quality NN o
of IN o
pain NN o
control NN o
, , o
the DT o
amount NN o
and CC o
character NN o
of IN o
the DT o
drain NN o
fluid NN o
, , o
incidence NN o
of IN o
nausea NN o
and CC o
vomiting NN o
, , o
length NN o
of IN o
stay NN o
in IN o
the DT o
postoperative JJ o
care NN o
unit NN o
, , o
and CC o
amount NN o
of IN o
morphine NN o
used VBN N
for IN N
treatment NN N
of IN N
break-through JJ N
pain NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Intraoperative NNP N
administration NN N
of IN N
ketorolac NN i
resulted VBD N
in IN N
better JJR N
quality NN o
of IN o
pain NN o
control NN o
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
regardless NN N
of IN N
route NN N
of IN N
administration NN N
. . N

The DT N
incidence NN o
of IN o
nausea NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
drain NN o
output NN o
in IN N
the DT N
ketorolac NN i
groups NNS N
did VBD N
not RB N
exceed VB N
the DT N
output NN N
in IN N
the DT N
placebo NN i
group NN N
. . N

CONCLUSION NNP N
Analgesic NNP N
of IN N
the DT N
locally RB N
administered VBN N
ketorolac NN i
is VBZ N
equally RB N
effective JJ o
to TO N
the DT N
efficacy NN o
of IN N
ketorolac NN i
administered VBN N
intravenously RB N
. . N

-DOCSTART- -24839884- O O

Internet-based JJ N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
for IN N
hyperactivity NN o
in IN p
autism NN p
. . p

OBJECTIVE NNP N
Preliminary NNP N
evidence NN N
suggests VBZ N
that IN N
omega-3 JJ i
fatty JJ i
acids NNS i
may MD N
reduce VB N
hyperactivity NN o
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

We PRP N
sought VBD N
to TO N
examine VB N
the DT N
feasibility NN N
of IN N
a DT N
novel NN N
, , N
Internet-based JJ N
clinical JJ N
trial NN N
design NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
this DT N
supplement NN N
. . N

METHOD NNP N
E-mail JJ i
invitations NNS i
were VBD N
sent VBN N
to TO N
parents NNS p
of IN p
children NNS p
aged VBN p
5 CD p
to TO p
8 CD p
years NNS p
enrolled VBN p
in IN p
the DT p
Interactive NNP p
Autism NNP p
Network NNP p
. . p

All DT N
study NN i
procedures NNS i
, , i
including VBG i
screening NN i
, , i
informed JJ i
consent NN i
, , i
and CC i
collection NN i
of IN i
outcome NN i
measures NNS i
took VBD i
place NN i
over IN i
the DT i
Internet NNP i
. . i

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
parent- JJ o
and CC o
teacher-rated JJ o
changes NNS o
in IN o
hyperactivity NN o
on IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC-H NNP o
) ) o
. . o

RESULTS NNP N
During IN N
the DT N
6-week JJ N
recruitment NN N
period NN N
, , N
57 CD p
children NNS p
from IN p
28 CD p
states NNS p
satisfied VBD p
all DT p
eligibility NN p
criteria NNS p
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
1.3 CD N
grams NNS N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
or CC i
an DT i
identical JJ i
placebo NN i
daily RB N
for IN N
6 CD N
weeks NNS N
. . N

Outcome JJ N
assessments NNS N
were VBD N
obtained VBN N
from IN N
all DT N
57 CD N
participants NNS N
and CC N
57 CD N
teachers NNS N
, , N
and CC N
the DT N
study NN N
was VBD N
completed VBN N
in IN N
3 CD N
months NNS N
. . N

Children NNP N
in IN N
the DT N
omega-3 JJ i
fatty JJ i
acid NN i
group NN N
had VBD N
a DT N
greater JJR N
reduction NN N
in IN N
hyperactivity NN o
( ( N
-5.3 JJ N
points NNS N
) ) N
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
( ( N
-2.6 CD N
points NNS N
) ) N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
1.9-point JJ N
greater JJR N
improvement NN N
in IN N
the DT N
omega-3 JJ i
group NN i
, , N
95 CD N
% NN N
CI NNP N
= NNP N
-2.2 NNP N
to TO N
5.2 CD N
) ) N
. . N

Adverse JJ o
events NNS o
were VBD N
rare JJ N
and CC N
not RB N
associated VBN N
with IN N
omega-3 JJ i
fatty JJ i
acids NNS i
. . i

Participant NNP N
feedback NN o
was VBD N
positive JJ N
. . N

CONCLUSION NNP N
Internet-based JJ N
, , N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
therapies NNS N
in IN N
children NNS p
with IN p
ASD NNP p
are VBP N
feasible JJ N
and CC N
may MD N
lead VB N
to TO N
marked JJ N
reductions NNS N
in IN N
the DT N
time NN N
and CC N
cost NN N
of IN N
completing VBG N
trials NNS N
. . N

A NNP N
larger JJR N
sample NN N
size NN N
is VBZ N
required VBN N
to TO N
definitively RB N
determine VB N
the DT N
efficacy NN o
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
. . i

Clinical JJ N
trial NN N
registration NN N
information-Omega-3 JJ i
Fatty NNP i
Acids NNP i
for IN N
Hyperactivity NNP N
Treatment NNP N
in IN N
Autism NNP N
Spectrum NNP N
Disorder NNP N
; : N
http NN N
: : N
//clinicaltrials.gov NN N
; : N
NCT01694667 NNP N
. . N

-DOCSTART- -9706929- O O

Incidence NN N
and CC N
time NN N
course NN N
of IN N
cardiovascular JJ o
side NN o
effects NNS o
during IN N
spinal JJ i
anesthesia NN i
after IN p
prophylactic JJ p
administration NN p
of IN p
intravenous JJ i
fluids NNS i
or CC i
vasoconstrictors NNS i
. . i

UNLABELLED IN N
We PRP N
studied VBD N
the DT N
time NN N
course NN N
of IN N
arterial JJ N
hypotension NN N
and/or IN N
bradycardia NN N
requiring VBG N
treatment NN N
during IN N
spinal JJ p
anesthesia NN p
and CC N
compared VBN N
the DT N
efficacy NN N
of IN N
i.v NN i
. . i

fluid NN i
or CC i
vasoconstrictor NN i
administration NN i
for IN N
the DT N
prevention NN N
of IN N
these DT N
side NN N
effects NNS N
. . N

Patients NNS p
( ( p
n JJ p
= NN p
1066 CD p
) ) p
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
volume NN i
group NN i
( ( i
lactated VBN i
Ringer NNP i
's POS i
solution NN i
15 CD N
mL/kg NN N
within IN N
15 CD N
min NN N
before IN N
spinal JJ N
anesthesia NN N
) ) N
, , N
a DT N
dihydroergotamine NN i
group NN N
( ( N
10 CD N
microg/kg NN N
i.m NN N
. . N

15 CD N
min NN N
before IN N
anesthesia NN i
) ) i
, , i
or CC i
a DT i
placebo NN i
group NN i
. . i

All DT p
patients NNS p
breathed VBD p
O2-enriched NNP p
air NN p
during IN p
spinal JJ i
anesthesia NN i
( ( p
4 CD p
mL NN p
of IN p
plain JJ p
0.5 CD p
% NN p
bupivacaine NN i
) ) i
. . p

With IN N
the DT N
placebo NN i
, , N
there EX N
were VBD N
side JJ o
effects NNS o
( ( N
mean JJ N
incidence NN N
22.9 CD N
% NN N
) ) N
for IN N
up IN N
to TO N
45 CD N
min NN N
after IN N
the DT N
start NN N
of IN N
anesthesia NN N
. . N

Dihydroergotamine NNP i
reduced VBD N
the DT N
incidence NN o
of IN o
side NN o
effects NNS o
, , N
preferentially RB N
the DT N
late JJ N
ones NNS N
, , N
more JJR N
( ( N
mean JJ N
incidence NN N
11.8 CD N
% NN N
) ) N
than IN N
fluid JJ N
administration NN N
( ( N
mean JJ N
incidence NN N
16.9 CD N
% NN N
) ) N
, , N
which WDT N
was VBD N
effective JJ N
only RB N
during IN N
the DT N
first JJ N
15 CD N
min NN N
of IN N
anesthesia NN N
. . N

Both DT N
heart NN o
rate NN o
and CC o
arterial JJ o
pressure NN o
decreased VBD o
within IN N
15 CD N
min NN N
before IN N
the DT N
manifestation NN N
of IN N
symptoms NNS N
. . N

In IN N
a DT N
subgroup NN N
of IN N
patients NNS N
, , N
the DT N
incidence NN o
of IN o
side NN o
effects NNS o
( ( N
8 CD N
% NN N
) ) N
was VBD N
greatly RB N
reduced VBN N
by IN N
the DT N
intraoperative JJ N
application NN N
of IN N
both DT N
sedatives NNS N
and CC N
opioids NNS N
. . N

We PRP N
conclude VBP N
that IN N
cardiovascular JJ o
side NN o
effects NNS o
may MD N
occur VB N
at IN N
any DT N
time NN N
during IN N
spinal JJ N
anesthesia NN N
. . N

Fluid NNP N
administration NN N
reduced VBD N
the DT N
incidence NN o
of IN o
early JJ o
events NNS o
, , N
but CC N
dihydroergotamine VBZ N
the DT N
late JJ o
events NNS o
. . o

IMPLICATIONS NNP N
Cardiovascular NNP o
side NN o
effects NNS o
requiring VBG N
treatment NN N
occurred VBD N
at IN N
any DT N
time NN N
during IN N
spinal JJ N
anesthesia NN N
in IN N
our PRP$ N
placebo-controlled JJ i
study NN N
, , N
regardless RB N
of IN N
the DT N
prophylactic JJ N
regimen NNS N
( ( i
fluid JJ i
infusions NNS i
versus VBP N
dihydroergotamine NN i
) ) i
. . N

-DOCSTART- -8450514- O O

Antinuclear JJ o
antibodies NNS o
with IN N
enalapril NN i
. . i

-DOCSTART- -9669262- O O

Effect NN N
of IN N
pravastatin NN i
on IN N
cardiovascular JJ o
events NNS o
in IN N
women NNS p
after IN p
myocardial JJ p
infarction NN p
: : p
the DT N
cholesterol NN N
and CC N
recurrent JJ N
events NNS N
( ( N
CARE NNP N
) ) N
trial NN N
. . N

OBJECTIVES IN N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
pravastatin NN i
on IN N
recurrent NN o
cardiovascular JJ o
events NNS o
in IN N
women NNS p
with IN p
average JJ p
cholesterol NN p
levels NNS p
after IN p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
. . p

BACKGROUND NNP N
Little JJ N
information NN N
is VBZ N
available JJ N
on IN N
the DT N
effectiveness NN N
of IN N
lipid JJ N
lowering VBG N
in IN N
secondary JJ N
prevention NN N
of IN N
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
in IN p
women NNS p
; : p
in IN p
particular JJ p
, , p
those DT p
with IN p
CHD NNP p
and CC p
average JJ p
cholesterol NN p
levels NNS p
. . p

METHODS NNP N
In IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
, , N
576 CD p
postmenopausal NN p
women NNS p
, , p
between IN p
3 CD p
and CC p
20 CD p
months NNS p
after IN p
MI NNP p
, , p
with IN p
a DT p
total JJ p
cholesterol NN p
level NN p
< VBD p
240 CD p
mg/dl NN p
and CC p
a DT p
low JJ p
density NN p
lipoprotein NN p
cholesterol NN p
level NN p
115 CD p
to TO p
174 CD p
mg/dl NNS p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
pravastatin NN i
40 CD i
mg/day NN i
or CC N
matching VBG N
placebo NN i
for IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
5 CD N
years NNS N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
combined VBN o
coronary JJ o
events NNS o
( ( o
coronary JJ o
death NN o
, , o
nonfatal JJ o
MI NNP o
, , o
percutaneous JJ o
transluminal JJ o
coronary NN o
angioplasty NN o
[ NNP o
PTCA NNP o
] NNP o
or CC o
coronary JJ o
artery NN o
bypass NN o
graft NN o
surgery NN o
[ NNP o
CABG NNP o
] NNP o
) ) o
, , o
the DT o
primary JJ o
trial NN o
end NN o
point NN o
( ( o
coronary JJ o
death NN o
or CC o
nonfatal JJ o
MI NNP o
) ) o
and CC o
stroke NN o
. . o

RESULTS NNP N
Women NNP N
treated VBD N
with IN N
pravastatin NN N
had VBD N
a DT N
risk NN o
reduction NN o
of IN N
43 CD N
% NN N
for IN N
the DT N
primary JJ N
end NN N
point NN N
( ( N
p JJ N
= NNP N
0.035 CD N
) ) N
, , N
46 CD N
% NN N
for IN N
combined JJ N
coronary JJ N
events NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
, , N
48 CD N
% NN N
for IN N
PTCA NNP N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
, , N
40 CD N
% NN N
for IN N
CABG NNP N
( ( N
p JJ N
= NNP N
0.14 CD N
) ) N
and CC N
56 CD N
% NN N
for IN N
stroke NN N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
. . N

The DT p
3,583 CD p
men NNS p
in IN p
the DT p
CARE NNP p
trial NN p
also RB N
showed VBD N
a DT N
reduction NN N
in IN N
risk NN o
, , N
but CC N
the DT N
magnitude NN N
tended VBD N
to TO N
be VB N
less JJR N
. . N

Pravastatin NNP i
improved VBD N
plasma JJ o
lipids NNS o
similarly RB N
in IN N
men NNS p
and CC p
women NNS p
. . p

There EX N
were VBD N
no DT N
differences NNS N
in IN N
risk NN o
of IN o
coronary JJ o
events NNS o
in IN N
the DT N
placebo NN N
group NN N
between IN N
men NNS N
and CC N
women NNS N
. . N

Minor JJ N
differences NNS N
between IN N
men NNS N
and CC N
women NNS N
were VBD N
present JJ N
in IN N
baseline NN N
characteristics NNS N
and CC N
treatment NN N
for IN N
MI NNP N
, , N
in IN N
general JJ N
, , N
conferring VBG N
a DT N
higher JJR N
risk NN N
status NN N
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
CABG NNP o
in IN N
the DT N
women NNS N
. . N

CONCLUSIONS NNP N
Pravastatin NNP i
led VBD N
to TO N
significant JJ N
early JJ N
reduction NN N
of IN N
a DT N
wide JJ N
range NN N
of IN N
cardiovascular JJ o
events NNS o
in IN N
post-MI JJ p
women NNS p
with IN p
average JJ p
cholesterol NN p
levels NNS p
. . p

-DOCSTART- -11710599- O O

Absence NN o
of IN o
cervical JJ o
radiation NN o
myelitis NN o
after IN N
hyperfractionated VBN i
radiation NN i
therapy NN i
with IN N
and CC N
without IN N
concurrent JJ i
chemotherapy NN i
for IN N
locally RB p
advanced JJ p
, , p
unresectable JJ p
, , p
nonmetastatic JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
risk NN o
of IN o
developing VBG o
radiation NN o
myelitis NN o
after IN N
a DT N
cervical JJ N
spinal NN N
cord NN N
dose NN N
of IN N
50.6 CD N
Gy NNP i
given VBN N
via IN N
1.1 CD N
Gy NNP N
b.i.d NN N
. . N

fractionation NN N
during IN N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
of IN N
hyperfractionated JJ i
radiation NN i
therapy NN i
( ( i
HFX NNP i
RT NNP i
) ) i
to TO N
a DT N
total JJ N
dose NN N
of IN N
77 CD N
Gy NNP i
given VBN N
in IN N
70 CD N
fractions NNS N
of IN N
1.1 CD N
Gy NNP N
b.i.d. NN N
, , N
with IN N
and CC N
without IN N
concurrent JJ N
low-dose JJ N
, , N
daily JJ N
cisplatin NN i
( ( i
CDDP NNP i
) ) i
for IN N
head NN p
and CC p
neck NN p
cancer NN p
. . p

METHODS NNP N
Of IN N
130 CD p
patients NNS p
with IN p
locally RB p
advanced VBN p
, , p
unresectable JJ p
, , p
nonmetastatic JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
( ( p
SCC NNP p
H NNP p
& CC p
N NNP p
) ) p
who WP N
entered VBD N
a DT N
prospective JJ N
, , N
randomised JJ N
trial NN N
, , N
101 CD N
patients NNS N
received VBD N
50.6 CD i
Gy NNP i
to TO i
a DT N
portion NN N
of IN N
their PRP$ N
spinal JJ N
cord NN N
and CC N
survived VBD N
> NNS N
1 CD N
year NN N
following VBG N
the DT N
beginning NN N
of IN N
therapy NN N
. . N

Forty-five JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
HFX NNP i
RT NNP i
alone RB N
and CC N
fifty-six JJ N
patients NNS N
also RB N
received VBD N
CDDP NNP i
. . i

RESULTS NNP N
None NN N
of IN N
these DT N
101 CD N
patients NNS N
developed VBD N
cervical JJ o
radiation NN o
myelitis NN o
. . o

Therefore RB N
, , N
it PRP N
was VBD N
not RB N
possible JJ N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
potentially RB o
contributing VBG o
factors NNS o
on IN N
the DT N
occurrence NN o
of IN o
radiation NN o
myelitis NN o
, , N
such JJ N
as IN N
interfraction NN o
interval NN o
, , o
cord NN o
length NN o
, , o
and CC o
administration NN o
of IN o
concurrent JJ o
CDDP NNP o
. . o

CONCLUSIONS NNP N
Given NNP N
the DT N
increasing VBG N
number NN N
of IN N
studies NNS N
with IN N
both DT N
altered VBN N
fractionated VBN N
regimens NNS N
and CC N
concurrent JJ N
radio-chemotherapy NN i
in IN N
SCC NNP N
H NNP N
& CC N
N NNP N
, , N
new JJ N
studies NNS N
with IN N
more JJR N
patients NNS N
are VBP N
needed VBN N
to TO N
gain VB N
better JJR N
insight NN N
into IN N
the DT N
risks NNS o
of IN o
developing VBG o
cervical JJ o
radiation NN o
myelitis NN o
. . o

-DOCSTART- -22236501- O O

Impact NN N
of IN N
antisecretory JJ i
treatment NN i
on IN N
respiratory NN o
symptoms NNS o
of IN o
gastroesophageal JJ o
reflux JJ o
disease NN o
in IN p
children NNS p
. . p

The DT N
effect NN o
of IN N
antisecretory NN i
treatment NN i
on IN N
extraesophageal NN o
symptoms NNS o
of IN o
gastroesophageal JJ o
reflux JJ o
disease NN o
was VBD N
evaluated VBN N
. . N

Seventy-eight JJ p
children NNS p
presenting VBG p
with IN p
typical JJ p
and CC p
extraesophageal JJ p
symptoms NNS p
of IN p
gastroesophageal JJ p
reflux JJ p
disease NN p
underwent VBD p
a DT p
multichannel JJ p
intraluminal JJ p
impedance NN p
and CC p
pH NN p
monitoring NN p
( ( p
MII/pH NNP p
) ) p
. . p

Children NNP N
with IN N
a DT N
positive JJ N
MII/pH NNP N
were VBD N
randomly RB N
treated VBN N
with IN N
proton NN i
pump NN i
inhibitors NNS i
( ( i
PPIs NNP i
) ) i
or CC i
histamine JJ i
H NNP i
( ( i
2 CD i
) ) i
-receptor NN i
antagonists NNS i
( ( i
H NNP i
( ( i
2 CD i
) ) i
RAs NNPS i
) ) i
during IN N
3 CD N
months NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
, , N
all DT N
patients NNS N
were VBD N
recalled VBN N
. . N

A DT N
second JJ N
treatment NN N
period NN N
of IN N
3 CD N
months NNS N
was VBD N
given VBN N
to TO N
those DT N
patients NNS N
who WP N
were VBD N
not RB N
symptom-free JJ N
after IN N
3 CD N
months NNS N
. . N

Thirty-five CD N
of IN N
the DT N
forty-one NN N
( ( N
85.4 CD N
% NN N
) ) N
children NNS N
with IN N
a DT N
pathologic JJ N
MII/pH NNP N
presented VBD N
with IN N
extraesophageal NN o
symptoms NNS o
and CC N
were VBD N
treated VBN N
with IN N
PPIs NNP i
( ( i
omeprazole JJ i
; : i
n:19 CC N
) ) N
or CC N
H NNP i
( ( i
2 CD i
) ) i
RAs NNP i
( ( i
ranitidine NN i
; : i
n:16 CC N
) ) N
for IN N
12 CD N
weeks NNS N
. . N

After IN N
3 CD N
months NNS N
, , N
11/19 CD N
( ( N
57.9 CD N
% NN N
) ) N
PPI-treated JJ i
patients NNS N
had VBD N
a DT N
complete JJ N
resolution NN o
of IN o
symptoms NNS o
; : o
6/8 CD N
nonresponders NNS N
were VBD N
treated VBN N
with IN N
PPI NNP i
for IN N
another DT N
3 CD N
months NNS N
and CC N
became VBD N
all DT N
symptom-free JJ o
. . o

The DT N
other JJ N
two CD N
underwent JJ N
a DT N
Nissen NNP N
fundoplication NN N
. . N

Only RB N
5/16 CD N
( ( N
31.2 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
H NNP i
( ( i
2 CD i
) ) i
RAs NNPS i
had VBD N
a DT N
complete JJ o
resolution NN o
of IN o
symptoms NNS o
after IN N
3 CD N
months NNS N
; : N
1/11 CD N
was VBD N
treated VBN N
again RB N
with IN N
H NNP i
( ( i
2 CD i
) ) i
RAs NNP i
during IN N
3 CD N
months NNS N
, , N
and CC N
10/11 CD N
were VBD N
changed VBN N
to TO N
PPIs NNP i
. . i

In IN N
3/10 CD N
, , N
a DT N
partial JJ o
resolution NN o
of IN o
symptoms NNS o
was VBD N
achieved VBN N
, , N
while IN N
in IN N
7/10 CD N
, , N
a DT N
complete JJ o
remission NN o
was VBD N
obtained VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Antisecretory NNP i
reflux JJ i
treatment NN i
improves VBZ N
extraesophageal JJ o
reflux NN o
symptoms NNS o
. . o

The DT N
efficacy NN o
of IN N
PPIs NNP i
is VBZ N
superior JJ N
to TO N
that DT N
of IN N
H NNP i
( ( i
2 CD i
) ) i
RAs NNPS i
in IN N
these DT N
children NNS N
. . N

-DOCSTART- -1412152- O O

Desmopressin NNP i
has VBZ N
no DT N
beneficial JJ N
effect NN N
on IN N
excessive JJ N
postoperative JJ o
bleeding NN o
or CC p
blood NN p
product NN p
requirements NNS p
associated VBN p
with IN p
cardiopulmonary JJ p
bypass NN p
. . p

Cardiopulmonary JJ N
bypass NN N
during IN N
open-heart JJ N
surgery NN N
is VBZ N
sometimes RB N
associated VBN N
with IN N
excessive JJ N
perioperative JJ o
bleeding NN o
. . o

Following VBG N
a DT N
non-randomized JJ N
study NN N
suggesting VBG N
that IN N
desmopressin NN i
acetate NN i
( ( i
desmopressin NN i
) ) i
reduced VBD N
blood NN N
product NN N
requirements NNS N
in IN N
these DT N
patients NNS N
, , N
we PRP N
conducted VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
randomized JJ N
trial NN N
of IN N
desmopressin NN i
( ( N
0.3 CD N
micrograms/kg NN N
, , N
i. JJ N
v. NN N
) ) N
in IN N
92 CD p
patients NNS p
with IN p
overt JJ p
bleeding NN p
and CC p
a DT p
prolonged JJ p
bleeding NN p
time NN p
. . p

Mean JJ N
blood NN o
loss NN o
during IN N
the DT N
first JJ N
24 CD N
h JJ N
post-treatment NN N
was VBD N
similar JJ N
in IN N
the DT N
desmopressin NN i
and CC i
placebo NN i
groups NNS i
( ( N
582 CD N
vs RB N
465 CD N
ml NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.15 CD N
) ) N
. . N

Red-cell NNP N
( ( N
p JJ N
= NNP N
0.76 CD N
) ) N
, , N
fresh JJ N
frozen JJ N
plasma NN N
( ( N
r JJ N
= NNP N
0.66 CD N
) ) N
and CC N
platelet JJ N
unit NN N
( ( N
p JJ N
= NNP N
0.74 CD N
) ) N
requirements NNS N
were VBD N
also RB N
similar JJ N
. . N

The DT N
haemostatic JJ N
effect NN N
of IN N
desmopressin NN N
has VBZ N
been VBN N
attributed VBN N
to TO N
the DT N
release NN N
of IN N
von JJ N
Willebrand NNP N
factor NN N
( ( N
vWF NN N
) ) N
and CC N
a DT N
reduced JJ N
bleeding NN o
time NN o
. . o

In IN N
our PRP$ N
study NN N
, , N
vWF NN o
and CC o
factor NN o
VIII NNP o
: : o
C NNP o
levels NNS o
increased VBN N
while IN N
the DT N
bleeding NN o
time NN o
decreased VBN N
significantly RB N
at IN N
90 CD N
min NN N
and CC N
24 CD N
h NN N
in IN N
both DT N
groups NNS N
and CC N
, , N
although IN N
vWF NN o
and CC o
factor NN o
VIII NNP o
: : o
C NN o
levels NNS o
were VBD N
slightly RB N
higher JJR N
in IN N
desmopressin-treated JJ N
patients NNS N
at IN N
90 CD N
min NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Thrombin-antithrombin JJ o
III NNP o
complex NN o
, , o
fibrinogen NN o
degradation NN o
product NN o
and CC o
tissue NN o
plasminogen NN o
activator NN o
levels NNS o
, , N
reflecting VBG N
activation NN o
of IN o
the DT o
coagulation NN o
and CC o
fibrinolytic JJ o
systems NNS o
, , N
respectively RB N
, , N
decreased VBD N
uniformly RB N
in IN N
both DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
desmopressin NN N
is VBZ N
not RB N
useful JJ N
in IN N
reducing VBG N
blood NN o
loss NN o
or CC o
blood NN o
product NN o
requirements NNS o
in IN N
patients NNS p
with IN p
excessive JJ p
immediate JJ p
postoperative JJ p
bleeding NN p
. . p

-DOCSTART- -8213019- O O

Evaluation NN N
of IN N
postural JJ o
stability NN o
by IN N
computerised JJ i
posturography NN i
following VBG N
outpatient JJ p
paediatric JJ i
anaesthesia NN i
. . i

Comparison NNP N
of IN N
propofol/alfentanil/N2O NN i
anaesthesia NN i
with IN i
thiopentone/halothane/N2O JJ i
anaesthesia NN i
. . i

Simple JJ N
clinical JJ N
tests NNS N
, , N
like IN N
Romberg NNP N
's POS N
test NN N
or CC N
a DT N
walking JJ N
test NN N
, , N
have VBP N
proved VBN N
to TO N
be VB N
inadequate JJ N
guidelines NNS N
for IN N
safe JJ o
discharge NN o
after IN N
outpatient JJ N
anaesthesia NN N
. . N

A DT N
randomised JJ N
study NN N
was VBD N
therefore RB N
planned VBN N
to TO N
compare VB N
postural JJ N
stability NN N
measured VBN N
by IN N
computerised JJ N
posturography NN N
in IN N
31 CD p
oral JJ i
midazolam-atropine NN i
premedicated VBD p
children NNS p
aged VBN p
6.9 CD p
( ( p
s.e NN p
. . p

0.4 CD p
) ) p
years NNS p
who WP p
had VBD p
been VBN p
anaesthetised VBN i
with IN p
either DT p
propofol/alfentanil/N2O NN i
or CC i
thiopentone/halothane/N2O NN i
. . i

The DT N
sway JJ o
velocity NN o
of IN N
the DT N
children NNS N
was VBD N
measured VBN N
before IN N
premedication NN N
and CC N
1 CD N
, , N
2 CD N
and CC N
3 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
anaesthesia NN N
. . N

Results NNP N
show VBP N
that IN N
sway JJ o
velocity NN o
had VBD N
returned VBN N
to TO N
baseline VB N
values NNS N
3 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
anaesthesia NN N
in IN N
all DT N
children NNS N
who WP N
had VBD N
received VBN N
propofol/alfentanil/N2O NNS i
and CC N
in IN N
12 CD N
of IN N
the DT N
15 CD N
children NNS N
who WP N
had VBD N
received VBN N
thiopentone/halothane/N2O RB i
. . i

The DT N
quantified JJ N
version NN N
of IN N
the DT N
Romberg NNP o
test NN o
performed VBD N
with IN N
eyes NNS N
open VBP N
or CC N
closed VBD N
was VBD N
not RB N
impaired VBN N
after IN N
anaesthesia NN N
, , N
compared VBN N
with IN N
the DT N
control NN N
values VBZ N
, , N
indicating VBG N
that IN N
in IN N
children NNS N
poor JJ N
equilibrium NN N
is VBZ N
not RB N
compensated VBN N
by IN N
vision NN N
. . N

The DT N
clinical JJ N
recovery NN N
with IN N
respect NN N
to TO N
the DT N
times NNS N
to TO N
eye NN o
opening NN o
, , N
to TO N
responding VBG N
to TO N
command VB N
or CC N
to TO N
being VBG N
fully RB N
awake VB N
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
anaesthesia NN N
methods NNS N
. . N

On IN N
the DT N
basis NN N
of IN N
recovery NN N
assessed VBN N
by IN N
postural JJ N
stability NN N
, , N
propofol/alfentanil/N2O NN i
anaesthesia NN i
was VBD N
not RB N
preferable JJ N
to TO N
thiopentone/halothane/N2O VB i
anaesthesia NN i
after IN N
minor JJ N
paediatric JJ N
otolaryngological JJ i
surgery NN i
. . i

-DOCSTART- -16909273- O O

A DT N
comparative JJ o
study NN o
of IN o
the DT o
pharmacokinetics NNS o
of IN N
ibuprofen JJ i
arginate NN i
versus NN i
dexibuprofen NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

OBJECTIVE NNP N
Ibuprofen NNP i
arginate NN i
is VBZ N
a DT N
salt JJ N
formulation NN N
of IN N
ibuprofen NN i
designed VBN N
to TO N
reach VB N
target NN N
concentrations NNS N
rapidly RB N
. . N

The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
12-h JJ N
pharmacokinetic JJ o
profile NN o
of IN N
S NNP i
( ( i
+ NNP i
) ) i
-ibuprofen VBD i
following VBG N
administration NN N
of IN N
single JJ N
doses NNS N
of IN N
ibuprofen JJ i
arginate NN i
( ( N
600 CD N
mg NN N
) ) N
and CC N
dexibuprofen NN i
( ( N
400 CD N
mg NN N
) ) N
in IN N
healthy JJ p
volunteers NNS p
. . p

METHODS NNP N
Twenty-four JJ p
volunteers NNS p
were VBD p
recruited VBN p
into IN p
an DT p
open-label JJ p
, , p
randomised JJ p
, , p
two-period JJ p
, , p
single-centre JJ p
study NN p
with IN N
crossover NN N
design NN N
. . N

RESULTS NNP N
Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
. . N

Ibuprofen NNP i
arginate NN i
and CC N
dexibuprofen NN i
showed VBD N
similar JJ N
bioavailability NN o
for IN o
S NNP o
( ( o
+ NNP o
) ) o
-ibuprofen NN o
. . o

Compared VBN N
with IN N
dexibuprofen NN i
, , i
ibuprofen JJ i
arginate NN i
demonstrated VBD N
a DT N
45 CD N
% NN N
higher JJR N
maximum JJ o
concentration NN o
( ( o
C NNP o
( ( o
max NN o
) ) o
) ) o
, , N
and CC N
a DT N
time NN o
to TO o
peak VB o
concentration NN o
( ( o
T NNP o
( ( o
max NN o
) ) o
) ) o
2 CD N
h NN N
sooner NN N
. . N

CONCLUSION NNP N
Ibuprofen NNP i
arginate NN i
approaches NNS N
maximum JJ N
concentrations NNS N
of IN N
S NNP N
( ( N
+ NNP N
) ) N
-ibuprofen VBP N
faster RBR N
and CC N
higher JJR N
than IN N
dexibuprofen NN i
. . i

-DOCSTART- -6119875- O O

Acute NNP N
intervention NN N
studies NNS N
in IN N
patients NNS p
with IN p
myocardial JJ p
infarction NN p
using VBG N
atenolol NN i
, , i
propranolol NN i
, , i
oxprenolol NN i
and CC N
disopyramide JJ i
phosphate NN i
. . i

The DT N
value NN N
of IN N
beta-blockade JJ i
and CC N
of IN N
disopyramide JJ i
phosphate NN i
in IN N
the DT N
immediate JJ N
treatment NN N
of IN N
patients NNS p
with IN p
suspected JJ p
acute JJ p
myocardial JJ p
infarction NN p
was VBD N
assessed VBN N
in IN N
two CD N
placebo NN N
controlled VBD N
trials NNS N
. . N

In IN p
the DT p
first JJ p
study NN p
388 CD p
patients NNS p
with IN p
suspected JJ p
acute JJ p
myocardial JJ p
infarction NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
propranolol NN i
, , i
atenolol NN i
, , i
or CC i
placebo NN i
, , N
and CC N
when WRB N
analysed VBN N
on IN N
an DT N
initial JJ N
intention NN N
to TO N
treat VB N
basis NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
three CD N
groups NNS N
in IN N
respect NN N
of IN N
the DT N
mortality NN o
at IN N
one CD N
year NN N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
no DT N
evidence NN N
to TO N
suggest VB N
that IN N
either DT N
atenolol NN i
, , N
or CC N
propranolol NN i
reduced VBD N
the DT N
incidence NN N
of IN o
'serious JJ o
' POS o
ventricular JJ o
arrhythmias NNS o
in IN N
the DT N
coronary JJ N
care NN N
unit NN N
. . N

In IN N
the DT N
second JJ N
study NN N
473 CD p
patients NNS p
with IN p
suspected JJ p
acute JJ p
myocardial JJ p
infarction NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
oxprenolol NN i
, , i
disopyramide JJ i
phosphate NN i
, , i
or CC i
placebo NN i
. . i

Again NNP N
no DT o
significant JJ o
differences NNS o
were VBD N
seen VBN N
with IN N
respect NN N
to TO N
the DT N
mortality NN o
at IN N
six CD N
weeks NNS N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
a DT N
significantly RB N
increased VBN N
incidence NN o
of IN o
heart NN o
failure NN o
in IN N
the DT N
group NN N
which WDT N
received VBD N
disopyramide JJ i
phosphate NN i
. . i

Patients NNS p
who WP N
received VBD N
this DT N
drug NN N
also RB N
showed VBD N
a DT N
reduced JJ N
number NN o
of IN o
dysrhythmic JJ o
episodes NNS o
on IN o
24-hour JJ o
ECG NNP o
recordings NNS o
, , N
but CC N
this DT N
trend NN N
did VBD N
not RB N
achieve VB N
statistical JJ N
significance NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
none NN N
of IN N
the DT N
three CD i
beta-blockers NNS i
tested VBN N
nor CC N
disopyramide JJ i
phosphate NN i
is VBZ N
likely JJ N
to TO N
reduce VB o
the DT o
mortality NN o
from IN o
acute JJ o
myocardial JJ o
infarction NN o
when WRB N
given VBN N
prophylactically RB N
, , N
although IN N
disopyramide JJ i
phosphate NN i
does VBZ N
reduce VB o
the DT o
incidence NN o
of IN o
'serious JJ o
' POS o
ventriicular JJ o
arrhythmias NNS o
. . o

-DOCSTART- -15778725- O O

Prospective JJ N
randomised VBD N
trial NN N
of IN N
amifostine JJ i
cytoprotection NN i
in IN N
myeloma NN p
patients NNS p
undergoing VBG p
high-dose JJ i
melphalan NN i
conditioned VBN p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
. . p

In IN N
this DT N
prospective JJ N
multicentre NN N
trial NN N
, , N
90 CD p
patients NNS p
undergoing VBG p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
ASCT NNP p
) ) p
were VBD p
randomised VBN p
to TO N
receive VB N
( ( N
n=43 NN N
) ) N
or CC N
not RB N
receive JJ N
( ( N
n=47 JJ N
) ) N
amifostine VBP i
910 CD i
mg/m NN i
( ( i
2 CD i
) ) i
prior RB i
to TO i
melphalan VB i
200 CD i
mg/m NN i
( ( i
2 CD i
) ) i
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
regimen-related JJ o
toxicity NN o
, , o
engraftment NN o
, , o
supportive JJ o
care NN o
, , o
response NN o
and CC o
survival NN o
. . o

Both DT p
groups NNS p
underwent VBD N
ASCT NNP i
at IN N
a DT N
median NN N
of IN N
8 CD N
months NNS N
from IN N
diagnosis NN N
and CC N
were VBD N
matched VBN N
for IN N
disease NN N
characteristics NNS N
, , N
prior JJ N
therapy NN N
and CC N
pre-ASCT JJ N
disease NN N
responsiveness NN N
. . N

Amifostine NNP i
infusional JJ N
side-effects NNS N
were VBD N
frequent JJ N
, , N
occurring VBG N
in IN N
65 CD N
% NN N
of IN N
patients NNS N
, , N
but CC N
of IN N
mild JJ N
severity NN N
. . N

Amifostine NNP i
use NN N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN o
in IN N
the DT N
median JJ o
grade NN o
of IN o
oral JJ o
mucositis NN o
( ( N
1 CD N
vs NN N
2 CD N
, , N
P=0.01 NNP N
) ) N
and CC N
the DT N
frequency NN o
of IN o
severe JJ o
( ( o
WHO NNP o
grades VBZ o
3 CD o
or CC o
4 CD o
) ) o
mucositis NN o
( ( N
12 CD N
vs RB N
33 CD N
% NN N
, , N
P=0.02 NNP N
) ) N
, , N
but CC N
no DT N
reduction NN N
in IN N
the DT N
requirement NN N
for IN N
parenteral JJ N
nutrition NN N
or CC N
analgesic JJ N
use NN N
. . N

Conversion NN N
to TO N
complete VB N
remission NN N
post-ASCT NN o
occurred VBD N
in IN N
30 CD N
and CC N
14 CD N
% NN N
of IN N
the DT N
amifostine NN i
and CC N
control NN N
groups NNS N
, , N
respectively RB N
( ( N
P=0.09 NNP N
) ) N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
median JJ o
progression-free NN o
or CC o
overall JJ o
survival NN o
times NNS o
for IN N
the DT N
two CD N
groups NNS N
. . N

We PRP N
conclude VBP N
that IN N
amifostine NN i
can MD N
be VB N
safely RB N
administered VBN N
prior RB N
to TO N
high-dose JJ N
melphalan NN N
and CC N
significantly RB N
reduces VBZ N
the DT N
frequency NN o
and CC o
severity NN o
of IN o
therapy-induced JJ o
oral JJ o
mucositis NN o
. . o

-DOCSTART- -12485538- O O

Risperidone NNP i
improves VBZ N
behavior RB o
in IN N
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -10499652- O O

Gabexate NNP i
mesilate NN i
and CC N
antithrombin NN i
III NNP i
for IN N
intraoperative JJ N
anticoagulation NN N
in IN N
heparin NN p
pretreated VBN p
patients NNS p
. . p

Thirty NNP p
patients NNS p
scheduled VBN p
for IN p
elective JJ p
myocardial JJ p
revascularization NN p
and CC p
having VBG p
undergone JJ p
preoperative JJ p
heparin NN p
treatment NN p
have VBP N
been VBN N
admitted VBN N
to TO N
this DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
test VB N
two CD N
different JJ N
strategies NNS N
for IN N
preserving VBG N
circulating VBG o
antithrombin JJ o
III NNP o
( ( o
AT-III NNP o
) ) o
during IN N
cardiopulmonary JJ N
bypass NN N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
10 CD N
) ) N
were VBD N
treated VBN N
with IN N
a DT N
standard JJ i
heparinization NN i
( ( N
300 CD N
IU/kg NNP N
) ) N
. . N

Patients NNS N
in IN N
group NN N
A NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
received VBD N
the DT N
same JJ N
management NN N
plus CC N
two CD i
doses NNS i
of IN i
purified JJ i
antithrombin NN i
III NNP i
( ( N
1000 CD N
IU NNP N
each DT N
) ) N
. . N

Patients NNS N
in IN N
group NN N
GA NNP N
received VBD N
200 CD i
IU/kg NNP i
heparin NN i
and CC i
a DT i
continuous JJ i
infusion NN i
of IN i
heparin NN i
( ( i
100 CD i
IU/kg/h NNP i
) ) i
and CC i
gabexate JJ i
mesilate NN i
( ( N
2 CD N
mg/kg/h NN N
) ) N
plus CC N
the DT N
same JJ N
dose NN N
of IN N
antithrombin JJ i
III NNP i
as IN N
group NN N
A NNP N
. . N

Both NNP N
group NN N
A NNP N
and CC N
group NN N
GA NNP N
demonstrated VBD N
a DT N
preservation NN o
of IN o
circulating VBG o
AT-III NNP o
when WRB N
compared VBN N
to TO N
group NN N
C NNP N
; : N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
group NN N
GA NNP N
. . N

The DT N
total JJ o
heparin NN o
dosage NN o
was VBD N
less RBR N
in IN N
group NN N
GA NNP N
than IN N
in IN N
groups NNS N
A NNP N
and CC N
C. NNP N
Purified NNP N
AT-III NNP N
administration NN N
is VBZ N
recommended VBN N
in IN N
heparin NN p
pretreated JJ p
patients NNS p
; : p
the DT N
addition NN N
of IN N
gabexate NN N
mesilate NN N
to TO N
this DT N
protocol NN N
decreases VBZ N
the DT N
heparin NN o
requirement NN o
and CC N
increases VBZ N
the DT N
AT-III JJ o
preservation NN o
. . o

-DOCSTART- -21946197- O O

[ JJ N
Impact NNP N
of IN N
heparin NN i
on IN N
coagulation NN o
index NN o
during IN N
the DT N
therapy NN N
of IN N
molecular JJ N
adsorbent NN N
recirculating VBG N
system NN N
in IN N
patients NNS p
with IN p
liver JJ p
failure NN p
] NNP p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
impact NN N
of IN N
coagulative JJ N
parameters NNS N
on IN N
different JJ o
anticoagulation NN o
systems NNS o
in IN N
molecular JJ N
adsorbent NN N
recirculating VBG N
system NN N
( ( N
MARS NNP N
) ) N
in IN N
subjects NNS p
with IN p
liver JJ p
failure NN p
, , N
and CC N
to TO N
evaluate VB N
the DT N
safety NN N
of IN N
different JJ N
anticoagulation NN o
methods NNS N
. . N

METHODS NNP N
A NNP N
prospective JJ N
experimental JJ N
observation NN N
was VBD N
designed VBN N
. . N

According VBG N
to TO N
anticoagulation NN N
Methods NNP N
, , N
174 CD p
MARS NNP i
treatment NN p
sessions NNS p
for IN p
146 CD p
patients NNS p
with IN p
liver JJ p
failure NN p
and CC p
prothrombin JJ p
time NN p
activity NN p
percentage NN p
( ( p
PTA NNP p
) ) p
? . p
40 CD p
% NN p
were VBD p
randomly RB p
divided VBN p
into IN p
2 CD p
groups NNS p
: : p
92 CD p
MARS NNP i
treatment NN i
sessions NNS i
in IN i
the DT i
heparin-free JJ i
group NN i
and CC i
82 CD p
in IN p
the DT i
low-dose JJ i
heparin NN i
group NN i
. . p

Time NNP N
points NNS N
of IN N
0 CD N
, , N
0.5 CD N
, , N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
and CC N
6 CD N
h NNS N
were VBD N
selected VBN N
to TO N
observe VB N
the DT N
coagulation NN o
changes NNS o
of IN o
prothrombin NN o
time NN o
( ( o
PT NNP o
) ) o
, , o
PTA NNP o
, , o
thrombin JJ o
time NN o
( ( o
TT NNP o
) ) o
, , o
activated VBN o
partial JJ o
thromboplastin NN o
time NN o
( ( o
APTT NNP o
) ) o
and CC o
international JJ o
normalized VBN o
ratio NN o
( ( o
INR NNP o
) ) o
dynamically RB o
. . o

Adverse JJ N
events NNS N
such JJ N
as IN N
line NN o
/ VBP o
filter NN o
coagulation NN o
, , o
rupture NN o
and CC o
bleeding NN o
were VBD o
also RB N
investigated VBN N
and CC N
compared VBN N
due JJ N
to TO N
frequency NN N
and CC N
severity NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
PT NNP o
, , o
PTA NNP o
, , o
INR NNP o
between IN o
the DT N
2 CD N
groups NNS N
, , N
but CC N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
APTT NNP o
and CC o
TT NNP o
and CC o
fibrinogen NN o
( ( o
Fbg NNP o
) ) o
. . o

APTT NNP o
and CC o
TT NNP o
levels NNS o
in IN o
the DT i
low-dose JJ i
heparin NN i
group NN i
was VBD N
increased VBN N
rapidly RB N
after IN N
the DT N
first JJ N
given VBN N
dose NN N
of IN N
anticoagulant JJ i
heparin NN i
and CC i
reached VBD N
the DT N
peak NN N
within IN N
30 CD N
min.The NN N
levels NNS N
at IN N
each DT N
time NN N
point NN N
was VBD N
statistically RB N
different JJ N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
significant JJ N
difference NN N
in IN N
the DT o
Fbg NNP o
level NN o
was VBD o
obtained VBN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
the DT i
low-dose JJ i
heparin NN i
group NN i
it PRP N
was VBD N
stabilized VBN N
and CC N
increased VBN N
slightly RB N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
. . N

While IN N
in IN N
the DT i
heparin-free JJ i
group NN i
it PRP N
was VBD N
decreased VBN N
gradually RB N
and CC N
reached VBD N
a DT N
ravine NN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
. . N

A DT N
curve NN o
was VBD o
observed VBN o
after IN o
2.5 CD N
h NN N
treatment NN N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P=0.001 NNP N
) ) N
. . N

There EX N
were VBD N
2 CD N
cases NNS N
of IN N
severe JJ o
bleeding NN o
after IN o
MARS NNP i
was VBD i
finished VBN N
in IN N
the DT N
heparin NN N
group NN N
, , N
and CC N
1 CD N
was VBD o
terminated VBN o
because IN o
of IN N
degree JJ o
III NNP o
clotting NN o
in IN o
the DT i
heparin-free JJ i
group NN i
. . N

CONCLUSION NNP N
Fibrinogen NNP N
should MD N
be VB N
adsorbed VBN N
while IN N
the DT N
blood NN N
touches VBZ N
the DT i
MARS NNP i
circuit NN i
path NN N
and CC N
anticoagulants NNS N
can MD N
prevent VB N
it PRP N
. . N

Comprehensive JJ N
analysis NN N
of IN N
blood NN o
platelet NN o
count NN o
( ( o
BPC NNP o
) ) o
, , o
fibrin JJ o
degradation NN o
products NNS o
( ( o
FDP NNP o
) ) o
, , o
D-dimer NNP o
and CC o
clinical JJ o
symptoms NNS o
is VBZ o
critical JJ N
and CC N
required VBN N
to TO N
determine VB N
the DT N
coagulation NN N
status NN N
to TO N
select VB N
an DT N
anticoagulation NN N
system NN N
before IN i
MARS NNP i
. . i

The DT N
use NN N
of IN N
low JJ i
dose JJ i
heparin NN i
in IN i
MARS NNP i
improves VBZ i
the DT o
disorder NN o
of IN o
hypercoagulable JJ o
state NN o
during IN o
the DT N
high JJ N
coaguation NN N
period NN N
, , N
while IN i
heparin-free JJ i
during IN i
low JJ N
coagulation NN N
period NN N
can MD N
effectively RB N
prevent VB N
the DT N
occurrence NN N
of IN N
bleeding NN N
and CC N
improve VB N
the DT N
mechanism NN N
of IN N
blood NN o
coagulation NN o
by IN o
reducing VBG N
heparin-like JJ N
substance NN N
in IN N
the DT N
blood NN N
. . N

-DOCSTART- -9196141- O O

Dose-response JJ N
relationship NN N
of IN N
complementary JJ i
radiotherapy NN i
following VBG N
four CD N
cycles NNS N
of IN N
combination NN i
chemotherapy NN i
in IN N
intermediate-stage JJ N
Hodgkin NNP p
's POS p
disease NN p
. . p

PURPOSE NNP N
To TO N
determine VB N
the DT N
appropriate JJ N
irradiation NN N
dose NN N
after IN N
four CD N
cycles NNS N
of IN N
modern JJ i
combination NN i
chemotherapy NN i
in IN p
nonbulky JJ p
involved JJ p
field NN p
( ( p
IF/BF NNP p
) ) p
and CC p
noninvolved VBN p
extended-field NN p
( ( p
EF/IF NNP p
) ) p
sites VBZ p
in IN p
patients NNS p
with IN p
intermediate-stage JJ p
Hodgkin NNP p
's POS p
disease NN p
( ( p
HD NNP p
) ) p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
HD NNP p
patients NNS p
in IN p
stage NN p
I PRP p
to TO p
IIIA NNP p
with IN p
a DT p
large JJ p
mediastinal JJ p
mass NN p
, , p
E NNP p
stage NN p
, , p
or CC p
massive JJ p
spleen JJ p
involvement NN p
were VBD N
treated VBN N
with IN N
two CD N
double JJ N
cycles NNS i
of IN i
alternating VBG i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
COPP NNP i
) ) i
plus CC i
doxorubicin JJ i
, , i
bleomycin NN i
, , i
vinblastine NN i
, , i
and CC i
dacarbazine NN i
( ( i
ABVD NNP i
) ) i
followed VBN i
by IN i
EF NNP i
irradiation NN i
in IN N
two CD N
successive JJ N
trials NNS N
( ( N
HD1 NNP N
and CC N
HD5 NNP N
) ) N
. . N

In IN N
the DT N
HD1 NNP N
trial NN N
( ( N
1983 CD N
to TO N
1988 CD N
) ) N
, , N
146 CD p
patients NNS p
who WP p
responded VBD p
to TO p
chemotherapy VB p
were VBD p
randomized VBN p
to TO p
receive VB p
20 CD p
Gy NNP p
( ( p
70 CD p
patients NNS p
) ) p
or CC p
40 CD p
Gy NNP p
( ( p
76 CD p
patients NNS p
) ) p
of IN p
EF NNP p
irradiation NN p
in IN p
all DT p
fields NNS p
outside IN p
bulky JJ p
disease NN p
sites NNS p
. . p

A DT p
cohort NN p
of IN p
111 CD p
patients NNS p
who WP p
fulfilled VBD p
the DT p
same JJ p
inclusion NN p
criteria NNS p
in IN p
the DT p
subsequent JJ p
trial NN p
HD5 NNP p
( ( p
1988 CD p
to TO p
1993 CD p
) ) p
were VBD p
treated VBN p
with IN p
30 CD p
Gy NNP p
. . p

Bulky NNP N
disease NN N
always RB N
received VBD N
40 CD N
Gy NNP N
. . N

RESULTS NNP N
Freedom-from-treatment-failure NNP o
( ( o
FFTF NNP o
) ) o
and CC o
survival NN o
( ( o
SV NNP o
) ) o
curves VBZ o
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
20- JJ N
, , N
30- JJ N
, , N
and CC N
40-Gy JJ N
groups NNS N
. . N

However RB N
, , N
acute JJ o
toxicities NNS o
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
40-Gy JJ N
arm NN N
. . N

Analysis NN o
of IN o
relapse NN o
patterns NNS o
showed VBD N
that IN N
18 CD N
of IN N
26 CD N
relapsing VBG N
patients NNS N
either CC N
failed VBD N
to TO N
respond VB N
in IN N
initial JJ N
bulky NN N
sites NNS N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
had VBD N
an DT N
extranodal JJ N
relapse NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
both DT N
( ( N
n JJ N
= NNP N
4 CD N
) ) N
. . N

After IN N
5 CD N
years NNS N
, , N
the DT N
cumulative JJ N
risk NN o
for IN o
relapse NN o
in IN N
bulky NN N
sites NNS N
is VBZ N
10 CD N
% NN N
, , N
despite IN N
40 CD N
Gy NNP N
of IN N
radiation NN i
. . i

CONCLUSION NNP N
Our PRP$ N
results NNS N
strongly RB N
suggest VBP N
that IN N
there EX N
is VBZ N
no DT N
relevant JJ N
radiotherapy NN o
dose JJ o
effect NN o
in IN N
the DT N
range NN N
between IN N
20 CD N
Gy NNP N
and CC N
40 CD N
Gy NNP N
in IN N
IF/BF NNP N
and CC N
EF/IF NNP N
after IN N
4 CD N
months NNS N
of IN N
modern JJ p
polychemotherapy NN i
in IN p
patients NNS p
with IN p
intermediate-stage JJ p
HD NNP p
. . p

Relapse NNP N
patterns VBZ N
indicate VB N
that IN N
patients NNS N
destined VBD N
to TO N
relapse VB N
need VB N
more JJR N
systemic JJ N
, , N
rather RB N
than IN N
local JJ N
, , N
treatment NN N
. . N

Based VBN N
on IN N
our PRP$ N
data NNS N
, , N
we PRP N
conclude VBP N
that IN N
20 CD N
Gy NNP N
is VBZ N
sufficient JJ N
in IN N
EF/IF NNP N
of IN N
intermediate-stage JJ N
HD NNP N
following VBG N
four CD N
cycles NNS N
of IN N
modern JJ N
polychemotherapy NN i
. . i

-DOCSTART- -21171314- O O

[ RB i
Accelerated NNP i
postoperative JJ i
radiotherapy NN i
in IN N
patients NNS p
with IN p
advanced JJ p
larynx NN p
cancer NN p
] NNP p
. . N

AIM NNP N
The DT N
aim NN N
of IN N
study NN N
was VBD N
test JJ N
efficacy NN o
of IN N
accelerated JJ i
postoperative JJ i
radiotherapy NN i
-- : i
concomitant JJ i
boost NN i
in IN N
patients NNS p
with IN p
advanced JJ p
larynx NN p
cancer NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
The DT N
prospective JJ N
study NN N
included VBD N
112 CD p
patients NNS p
with IN p
advanced JJ p
larynx NN p
cancer NN p
after IN p
radical JJ i
surgical JJ i
treatment NN i
. . i

Patients NNS N
had VBD N
postoperative JJ i
radiation NN i
therapy NN i
, , i
conventional JJ i
( ( i
C NNP i
) ) i
or CC i
accelerated VBN i
( ( i
CB NNP i
) ) i
. . i

RESULTS VB N
The DT N
3-year JJ o
overall JJ o
survival NN o
in IN N
CB NNP i
was VBD N
59 CD N
% NN N
, , N
in IN N
C NNP N
-- : N
58 CD N
% NN N
( ( N
p JJ N
= NNP N
0.2 CD N
) ) N
, , N
3-year JJ o
locoregional JJ o
control NN o
in IN N
CB NNP i
-- : i
83 CD i
% NN i
, , N
in IN N
C NNP N
-- : N
75 CD N
% NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
the DT N
3-year JJ o
disease NN o
free JJ o
survival NN o
was VBD N
in IN N
CB NNP i
-- : i
72 CD i
% NN i
, , N
C NNP N
-- : N
66 CD N
% NN N
( ( N
p JJ N
= NNP N
0.1 CD N
) ) N
. . N

CONCLUSION NNP N
Concomitant NNP i
boost VBD i
postoperative JJ i
radiation NN i
therapy NN i
did VBD N
not RB N
improve VB N
overall JJ o
survival NN o
, , o
loco-regional JJ o
control NN o
, , o
disease NN o
free JJ o
survival NN o
. . o

Patients NNS p
with IN p
close JJ p
surgical JJ p
margins NNS p
, , N
longer JJR N
interval NN N
between IN N
surgery NN N
and CC N
radiation NN N
, , N
high JJ N
level NN N
of IN N
hemoglobin NN N
, , N
T4 NNP N
had VBD N
benefit VBN N
from IN N
accelerated VBN i
radiotherapy NN i
. . i

-DOCSTART- -7995325- O O

The DT N
effects NNS N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
17 CD i
beta-oestradiol JJ i
and CC N
progesterone NN i
on IN N
finger NN o
skin JJ o
circulation NN o
in IN N
healthy JJ p
women NNS p
and CC p
in IN p
women NNS p
with IN p
primary JJ p
Raynaud NNP p
's POS p
phenomenon NN p
. . p

The DT N
effects NNS N
of IN N
sex NN N
, , N
the DT N
menstrual JJ N
cycle NN N
, , N
oral JJ N
contraceptives NNS N
, , N
pregnancy NN N
, , N
and CC N
the DT N
menopause NN N
on IN N
skin JJ N
perfusion NN N
in IN N
healthy JJ p
women NNS p
and CC N
in IN N
patients NNS p
with IN p
Raynaud NNP p
's POS p
phenomenon NN p
suggest VBP N
a DT N
role NN N
of IN N
female JJ N
sex NN N
hormones NNS N
. . N

However RB N
, , N
no DT N
clear JJ N
relation NN N
between IN N
skin JJ o
blood NN o
flow NN o
and CC N
circulating VBG N
concentrations NNS N
of IN N
oestrogens NNS N
or CC N
progestogens NNS N
has VBZ N
yet RB N
been VBN N
found VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
orally RB N
administered VBN N
17 CD i
beta-oestradiol JJ i
and CC i
progesterone NN i
on IN N
finger NN o
skin NN o
blood NN o
flow NN o
before IN N
and CC N
during IN N
heat NN N
and CC N
cold JJ N
challenge NN N
in IN N
17 CD p
healthy JJ p
normotensive JJ p
women NNS p
and CC p
in IN p
12 CD p
women NNS p
with IN p
Raynaud NNP p
's POS p
phenomenon NN p
. . p

In IN N
each DT N
subject NN N
standardized VBN N
finger NN N
heating NN N
( ( N
45 CD N
degrees NNS N
C NNP N
water NN N
bath NN N
, , N
10 CD N
min NN N
) ) N
and CC N
cooling VBG N
tests NNS N
( ( N
15 CD N
degrees NNS N
C NNP N
water NN N
bath NN N
, , N
5 CD N
min NN N
and CC N
20 CD N
min JJ N
recovery NN N
) ) N
were VBD N
performed VBN N
twice RB N
on IN N
the DT N
second JJ N
( ( N
or CC N
third JJ N
) ) N
day NN N
of IN N
two CD N
consecutive JJ N
menstrual JJ N
cycles NNS N
. . N

17 CD i
beta-Oestradiol JJ i
( ( N
9 CD N
mg NN N
) ) N
or CC N
progesterone NN i
( ( N
300 CD N
mg NN N
) ) N
were VBD N
given VBN N
before IN N
the DT N
second JJ N
test NN N
, , N
after IN N
a DT N
first JJ N
test NN N
with IN N
placebo NN i
. . i

Both DT N
hormonal JJ N
doses NNS N
resulted VBN N
in IN N
( ( N
high JJ N
) ) N
physiological JJ o
concentrations NNS o
. . o

Fingertip NNP o
skin JJ o
temperature NN o
and CC o
laser NN o
Doppler NNP o
flux NN o
were VBD N
measured VBN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
test NN o
results NNS o
after IN N
placebo NN N
and CC N
after IN N
progesterone NN N
. . N

Although IN N
values NNS N
of IN N
fingertip NN N
skin NN N
temperature NN N
and CC N
laser NN N
Doppler NNP N
flux NN N
after IN N
17 CD N
beta-oestradiol NN N
tended VBD N
to TO N
be VB N
higher JJR N
only RB N
the DT N
precooling NN N
values NNS N
in IN N
the DT N
healthy JJ N
subjects NNS N
reached VBD N
significance NN N
: : N
fingertip NN N
skin NN N
temperature NN N
respectively RB N
with IN N
placebo NN N
and CC N
with IN N
oestradiol NN N
( ( N
mean JJ N
( ( N
SD NNP N
) ) N
) ) N
: : N
32.7 CD N
( ( N
1.0 CD N
) ) N
and CC N
33.1 CD N
( ( N
0.8 CD N
) ) N
degrees NNS N
C NNP N
; : N
laser JJR N
Doppler NNP N
flux NN N
with IN N
placebo NN N
and CC N
with IN N
oestradiol NN N
: : N
33.6 CD N
( ( N
11.7 CD N
) ) N
and CC N
42.2 CD N
( ( N
9.5 CD N
) ) N
perfusion NN N
units NNS N
; : N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -1878735- O O

Human NNP i
recombinant JJ i
GM-CSF NNP i
in IN N
allogeneic JJ N
bone NN N
marrow NN N
transplantation NN N
for IN N
leukaemia NN N
: : N
double-blind JJ N
placebo NN N
controlled VBN N
trial NN N
. . N

A DT N
double-blind NN N
randomised VBN N
trial NN N
compared VBN N
20 CD p
patients NNS p
with IN p
leukaemia JJ p
receiving VBG p
human JJ i
recombinant JJ i
granulocyte NN i
macrophage NN i
colony NN i
stimulating VBG i
factor NN i
( ( i
GM NNP i
CSF NNP i
) ) i
, , p
with IN p
20 CD p
patients NNS p
receiving VBG p
placebo NN i
for IN i
14 CD i
days NNS i
after IN i
allogeneic JJ i
matched VBD i
sibling VBG i
bone NN i
marrow NN i
transplantation NN i
. . i

The DT N
median JJ o
neutrophil NN o
count NN o
at IN N
14 CD N
days NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM NNP i
CSF NNP i
group NN N
( ( N
1.90 CD N
vs. FW N
0.46 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
. . N

The DT N
duration NN o
of IN o
hospital NN o
stay NN o
, , o
the DT o
number NN o
of IN o
antibiotic JJ o
days NNS o
, , o
and CC o
the DT o
number NN o
of IN o
fever JJ o
days NNS o
was VBD N
the DT N
same JJ N
for IN N
both DT p
patient JJ p
groups NNS p
. . p

The DT N
lymphocyte NN o
count NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM-CSF NNP i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
between IN N
days NNS N
10 CD N
and CC N
15 CD N
after IN N
transplantation NN N
. . N

The DT N
GM-CSF NNP i
group NN N
had VBD N
lower JJR N
haemoglobin NN o
concentrations NNS o
and CC o
platelets NNS o
counts NNS o
, , o
and CC o
higher JJR o
plasma NN o
urea JJ o
creatinine NN o
and CC o
bilirubin NN o
, , N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
GM NNP i
CSF NNP i
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
leukaemic JJ o
relapse NN o
. . o

-DOCSTART- -12006271- O O

N-butyl JJ N
cyanoacrylate NN N
embolization NN N
of IN N
cerebral JJ N
arteriovenous JJ N
malformations NNS N
: : N
results NNS N
of IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
multi-center JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Liquid NNP N
N-butyl NNP N
cyanoacrylate NN N
( ( N
n-BCA JJ N
) ) N
use NN N
for IN N
the DT N
treatment NN N
of IN N
arteriovenous JJ N
malformations NNS N
( ( N
AVM NNP N
) ) N
in IN N
the DT N
brain NN N
has VBZ N
become VBN N
part NN N
of IN N
medical JJ N
practice NN N
. . N

However RB N
, , N
no DT N
study NN N
has VBZ N
led VBN N
to TO N
the DT N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
's POS N
approval NN N
of IN N
n-BCA JJ N
for IN N
intravascular JJ N
use NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
verify VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
an DT N
n-BCA/Tantalum JJ N
Powder/Ethiodized NNP N
Oil NNP N
mixture NN N
, , N
compared VBN N
with IN N
conventional JJ N
treatment NN N
( ( N
Trufill NNP N
polyvinyl VBZ N
alcohol NN N
[ NNP N
PVA NNP N
] NNP N
) ) N
for IN N
preoperative JJ N
embolization NN N
of IN N
cerebral JJ N
AVM NNP N
. . N

METHODS NNP N
Between NNP p
October NNP p
15 CD p
, , p
1996 CD p
, , p
and CC p
March NNP p
24 CD p
, , p
1999 CD p
, , p
104 CD p
patients NNS p
at IN p
13 CD p
centers NNS p
were VBD p
prospectively RB p
randomized VBN p
to TO N
undergo VB N
embolization NN i
using VBG i
an DT i
n-BCA/Tantalum JJ i
Powder/Ethiodol NNP i
mixture NN i
or CC i
Trufill NNP i
PVA NNP i
. . i

The DT N
pre-embolization NN N
therapy NN N
goals NNS N
were VBD N
determined VBN N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
pedicles NNS N
to TO N
be VB N
embolized VBN N
and CC N
the DT N
percent NN N
of IN N
nidus JJ N
reduction NN N
expected VBN N
. . N

Embolization NN N
results NNS N
were VBD N
evaluated VBN N
by IN N
a DT N
central JJ N
laboratory NN N
. . N

Subsequent JJ N
surgical JJ N
resection NN N
data NNS N
were VBD N
recorded VBN N
. . N

Safety NNP N
evaluation NN N
data NNS N
included VBD N
recording VBG N
device NN o
complications NNS o
, , o
procedure NN o
complications NNS o
, , o
and CC o
intracranial JJ o
events/overall NN o
neurologic JJ o
outcomes NNS o
, , N
which WDT N
could MD N
be VB N
either CC N
device-related JJ N
, , N
procedure-related JJ N
, , N
or CC N
both DT N
. . N

RESULTS VB N
The DT N
reduction NN N
of IN N
AVM NNP o
dimensions NNS o
( ( N
79.4 CD N
% NN N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
86.9 CD N
% NN N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
and CC N
the DT N
mean JJ o
number NN o
of IN o
vessels NNS o
embolized VBN o
( ( N
2.2 CD N
in IN N
the DT N
n-BCA JJ N
group NN N
and CC N
2.1 CD N
in IN N
the DT N
PVA NNP N
group NN N
) ) N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Coils NNS N
were VBD N
used VBN N
more RBR N
commonly RB N
with IN N
PVA NNP N
embolization NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

No UH N
differences NNS N
were VBD N
detected VBN N
in IN N
surgical JJ o
resection NN o
time NN o
, , o
number NN o
of IN o
patients NNS o
who WP o
required VBD o
transfusion NN o
, , o
volume NN o
and CC o
number NN o
of IN o
transfusion NN o
units NNS o
, , o
or CC o
type NN o
and CC o
volume NN o
of IN o
fluid JJ o
replacement NN o
. . o

Glasgow NNP o
Outcome NNP o
Scale NNP o
scores NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
before IN N
treatment NN N
, , N
after IN N
embolization NN N
, , N
or CC N
after IN N
resection NN N
. . N

Two CD N
of IN N
42 CD N
patients NNS N
who WP N
underwent JJ N
resection NN N
and CC N
had VBD N
been VBN N
treated VBN N
with IN N
n-BCA JJ N
experienced JJ N
post-resection NN o
hematoma NN o
, , N
compared VBN N
with IN N
eight CD N
of IN N
45 CD N
patients NNS N
who WP N
underwent JJ N
resection NN N
and CC N
had VBD N
been VBN N
treated VBN N
with IN N
PVA NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION VB N
This DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
showed VBD N
that IN N
n-BCA JJ N
is VBZ N
equivalent JJ N
to TO N
PVA NNP N
as IN N
a DT N
preoperative JJ N
embolic JJ N
agent NN N
for IN N
treatment NN N
of IN N
cerebral JJ p
AVM NNP p
as IN N
determined VBN N
by IN N
percent NN N
of IN N
nidus JJ N
reduction NN N
and CC N
number NN N
of IN N
feeding VBG N
pedicles NNS N
embolized VBN N
. . N

-DOCSTART- -8571077- O O

No DT N
effect NN N
of IN N
beta-carotene JJ i
supplementation NN i
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
to TO N
in IN o
vitro JJ o
oxidation NN o
among IN p
hypercholesterolaemic JJ p
, , p
postmenopausal JJ p
women NNS p
. . p

The DT N
effect NN N
of IN N
beta-carotene NN i
on IN N
the DT N
susceptibility NN N
of IN N
low JJ N
density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
to TO N
oxidative JJ N
modification NN N
was VBD N
investigated VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
placebo-controlled JJ N
study NN N
. . N

Hypercholesterolaemic NNP p
, , p
postmenopausal JJ p
women NNS p
were VBD N
given VBN N
30 CD i
mg JJ i
beta-carotene JJ i
per IN i
day NN i
( ( N
n JJ N
= $ N
15 CD N
subjects NNS N
) ) N
or CC N
placebo JJ i
capsules NNS i
( ( N
n JJ N
= $ N
15 CD N
subjects NNS N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

They PRP N
were VBD N
instructed VBN N
to TO N
follow VB N
the DT N
American NNP N
Heart NNP N
Association NNP N
Step NNP N
One NNP N
diet NN N
. . N

LDL NNP N
, , N
isolated VBD N
before IN N
and CC N
after IN N
treatment NN N
was VBD N
subjected VBN N
to TO N
copper-catalysed JJ N
lipid JJ N
peroxidation NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
LDL NNP o
from IN o
the DT o
beta-carotene NN o
and CC N
placebo NN i
groups NNS N
, , N
as IN N
assessed VBN N
by IN N
measuring VBG N
the DT N
lag NN o
time NN o
for IN o
formation NN o
of IN o
conjugated JJ o
dienes NNS o
; : o
the DT N
rate NN o
of IN o
formation NN o
and CC o
the DT o
amount NN o
of IN o
conjugated VBN o
dienes NNS o
formed VBN o
; : o
the DT N
amount NN o
of IN o
lipid JJ o
peroxides NNS o
generated VBD o
; : o
and CC N
the DT N
relative JJ N
electrophoretic JJ o
mobility NN o
, , N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
. . N

Dietary JJ N
records NNS N
showed VBD N
that IN N
the DT N
subjects NNS N
were VBD N
consuming VBG N
similar JJ N
amounts NNS N
and CC N
types NNS N
of IN N
fat NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
lipid JJ o
composition NN o
and CC o
fatty JJ o
acid JJ o
pattern NN o
of IN o
LDL NNP o
from IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
results NNS N
indicated VBD N
that IN N
supplementation NN N
with IN N
beta-carotene JJ i
in IN N
non-smoking JJ p
, , p
hypercholesterolaemic JJ p
, , p
postmenopausal JJ p
women NNS p
had VBD N
no DT N
protective JJ o
effect NN o
on IN N
the DT N
susceptibility NN N
of IN N
LDL NNP N
to TO N
copper-catalysed JJ N
modification NN N
in IN N
vitro NN N
. . N

-DOCSTART- -8498878- O O

A DT N
double-blind JJ N
comparison NN N
of IN N
clomipramine NN i
, , i
desipramine NN i
, , i
and CC i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
clomipramine NN i
hydrochloride NN i
, , N
a DT N
serotonin JJ N
reuptake NN N
blocker NN N
with IN N
unique JJ N
anti-obsessional JJ N
properties NNS N
, , N
is VBZ N
differentially RB N
effective JJ N
for IN N
obsessive-compulsive JJ N
and CC N
stereotyped VBD N
motor NN N
behaviors NNS N
in IN N
autistic JJ N
disorder NN N
compared VBN N
with IN N
placebo NN i
and CC N
with IN N
the DT N
noradrenergic JJ i
tricyclic JJ i
antidepressant NN i
agent NN i
, , i
desipramine JJ i
hydrochloride NN i
. . i

DESIGN NNP N
Following VBG N
a DT N
2-week JJ N
, , N
single-blind JJ N
placebo NN i
washout IN N
phase NN N
, , N
12 CD p
autistic JJ p
subjects NNS p
completed VBD N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
comparison NN N
of IN N
clomipramine NN i
and CC i
placebo NN i
, , N
and CC N
12 CD p
different JJ p
subjects NNS p
completed VBD N
a DT N
similar JJ N
comparison NN N
of IN N
clomipramine NN i
and CC N
desipramine NN i
. . i

SETTING CC N
Outpatient JJ N
clinic NN N
. . N

PATIENTS VB N
A DT p
referral JJ p
sample NN p
of IN p
30 CD p
male NN p
and CC p
female JJ p
autistic JJ p
patients NNS p
were VBD p
enrolled VBN p
, , p
and CC p
24 CD p
completed VBD p
the DT p
study NN p
. . p

MEASURES NNP N
Key NNP N
outcome NN N
measures NNS N
were VBD N
the DT N
Autism NNP o
Relevant NNP o
Subscale NNP o
of IN o
the DT o
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
, , o
the DT o
Modified NNP o
Comprehensive NNP o
Psychopathological NNP o
Rating NNP o
Scale-Obsessive-Compulsive JJ o
Disorder NNP o
Subscale NNP o
, , o
and CC o
the DT o
Clinical NNP o
Global NNP o
Impressions NNP o
Scale NNP o
. . o

RESULTS NNP N
Clomipramine NNP i
was VBD N
superior JJ N
to TO N
both DT N
placebo NN N
and CC N
desipramine NN N
on IN N
ratings NNS N
of IN N
autistic JJ o
symptoms NNS o
( ( o
including VBG o
stereotypies NNS o
) ) o
, , o
anger NN o
, , o
and CC o
compulsive JJ o
, , o
ritualized JJ o
behaviors NNS o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
with IN N
no DT N
differences NNS N
between IN N
desipramine NN i
and CC N
placebo NN i
. . i

Clomipramine NNP i
was VBD N
equal JJ N
to TO N
desipramine VB i
and CC N
both DT N
tricyclic JJ N
agents NNS N
were VBD N
superior JJ N
to TO N
placebo VB N
for IN N
amelioration NN N
of IN N
hyperactivity NN o
. . o

CONCLUSION NNP N
Biological NNP N
links NNS N
between IN N
compulsions NNS N
and CC N
stereotyped VBD N
, , N
repetitive JJ N
behaviors NNS N
in IN N
autistic JJ p
disorder NN p
should MD N
be VB N
explored VBN N
. . N

-DOCSTART- -2491829- O O

Failure NN N
of IN N
lithium NN i
to TO N
reduce VB N
period NN N
of IN N
neutropenia NN N
during IN N
induction NN i
therapy NN i
of IN N
acute JJ p
myeloid NN p
leukemia NN p
. . p

Fifty-four CD p
patients NNS p
treated VBN p
with IN p
daunorubicin NN i
, , i
cytosine JJ i
arabinoside NN i
and CC i
thioquanine NN i
for IN p
acute JJ p
myeloid NN p
leukemia NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ i
lithium NN i
carbonate NN i
1200 CD i
mg JJ i
daily JJ i
or CC i
no DT i
lithium NN i
. . i

The DT N
duration NN o
of IN o
neutropenia NN o
( ( N
less JJR N
than IN N
0.5 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
was VBD N
similar JJ N
between IN N
controls NNS N
( ( N
median JJ N
22.5 CD N
days NNS N
) ) N
and CC N
patients NNS N
treated VBN N
with IN N
lithium NN i
( ( N
median JJ N
24 CD N
days NNS N
) ) N
. . N

The DT N
number NN o
of IN o
remissions NNS o
, , o
relapse-free JJ o
survival NN o
and CC o
survival NN o
were VBD N
similar JJ o
for IN N
the DT N
lithium NN i
treated VBD N
and CC N
control VB N
groups NNS N
of IN N
patients NNS N
. . N

There EX N
was VBD N
no DT N
apparent JJ N
clinical JJ o
efficacy NN o
in IN N
the DT N
use NN N
of IN N
lithium NN i
to TO N
reduce VB N
the DT N
period NN N
of IN N
neutropenia NN N
in IN N
patients NNS p
undergoing JJ p
remission NN p
induction NN i
therapy NN i
for IN p
acute JJ p
myeloid NN p
leukemia NN p
. . p

-DOCSTART- -12105288- O O

Combining VBG N
weight-loss JJ N
counseling NN N
with IN N
the DT N
weight NN N
watchers NNS N
plan VBP N
for IN N
obese JJ p
breast NN p
cancer NN p
survivors NNS p
. . p

OBJECTIVE IN N
The DT N
objective NN N
was VBD N
to TO N
develop VB N
effective JJ N
weight-loss JJ N
methods NNS N
for IN N
women NNS p
who WP p
have VBP p
had VBN p
breast VBN p
cancer NN p
, , N
because IN N
obesity NN N
may MD N
result VB N
in IN N
an DT N
adverse JJ N
prognosis NN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
This DT N
randomized VBN N
pilot NN N
study NN N
tested VBD N
an DT N
individualized JJ N
approach NN N
toward IN N
weight JJ o
loss NN o
in IN N
obese JJ p
women NNS p
who WP p
have VBP p
had VBD p
a DT p
diagnosis NN p
of IN p
breast NN p
cancer NN p
. . p

An DT N
individualized JJ N
approach NN N
was VBD N
applied VBN N
either CC N
alone RB i
or CC i
combined VBN i
with IN i
the DT i
commercial JJ i
Weight NNP i
Watchers NNP i
program NN i
. . i

Forty-eight JJ p
women NNS p
( ( p
body NN p
mass NN p
index NN p
of IN p
30 CD p
to TO p
44 CD p
kg/m NNS p
( ( p
2 CD p
) ) p
) ) p
were VBD p
enrolled VBN p
. . p

RESULTS NNP N
Weight NNP o
change NN o
after IN N
12 CD N
months NNS N
of IN N
intervention NN N
was VBD N
as IN N
follows VBZ N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
: : N
0.85 CD N
+/- JJ N
6.0 CD N
kg NN N
in IN N
the DT N
control NN i
group NN i
, , N
-2.6 VBZ N
+/- JJ N
5.9 CD N
kg NN N
in IN N
the DT N
Weight NNP i
Watchers NNP i
group NN i
, , N
-8.0 VBZ N
+/- JJ N
5.5 CD N
kg NN N
in IN N
the DT N
individualized JJ N
group NN N
, , N
and CC N
-9.4 VBD N
+/- JJ N
8.6 CD N
kg NN N
in IN N
the DT N
comprehensive JJ i
group NN i
that WDT i
used VBD i
both DT i
individualized JJ i
counseling NN i
and CC i
Weight NNP i
Watchers NNP i
. . i

Weight NNP o
loss NN o
relative NN N
to TO N
control VB N
was VBD N
statistically RB N
significant JJ N
in IN N
the DT N
comprehensive JJ N
group NN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
randomization NN N
, , N
whereas JJ N
weight NN o
loss NN o
in IN N
the DT N
individualized JJ N
group NN N
was VBD N
significant JJ N
only RB N
at IN N
12 CD N
months NNS N
. . N

Weight NNP o
loss NN o
of IN N
10 CD N
% NN N
or CC N
more JJR N
of IN N
initial JJ N
body NN N
weight NN N
was VBD N
observed VBN N
in IN N
6 CD N
of IN N
10 CD N
women NNS N
in IN N
the DT N
comprehensive JJ N
group NN N
at IN N
12 CD N
months NNS N
. . N

In IN N
the DT N
comprehensive JJ N
and CC N
Weight NNP N
Watchers-only NNP N
groups NNS N
, , N
weight JJ o
loss NN o
was VBD N
significantly RB N
related VBN N
to TO N
frequency NN N
of IN N
attendance NN N
at IN N
Weight NNP N
Watchers NNP N
meetings NNS N
, , N
and CC N
attendance NN N
was VBD N
more RBR N
frequent JJ N
in IN N
the DT N
comprehensive JJ N
group NN N
. . N

DISCUSSION NNP N
These DT N
data NNS N
indicate VBP N
that IN N
the DT N
most RBS N
weight JJ o
loss NN o
was VBD N
achieved VBN N
when WRB N
the DT N
counseling NN N
approach NN N
combined VBD N
both DT N
Weight NNP N
Watchers NNPS N
and CC N
individualized JJ N
contacts NNS N
. . N

This DT N
was VBD N
effective JJ N
even RB N
though IN N
most JJS N
of IN N
the DT N
individualized JJ N
contacts NNS N
were VBD N
by IN N
telephone NN N
. . N

-DOCSTART- -14989068- O O

[ RB N
Clinical NNP N
study NN N
on IN N
dan NN i
shao NN i
tang NN i
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
of IN N
deficiency NN N
of IN N
yin NN N
with IN N
damp-heat JJ N
symptom NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Dan NNP i
Shao NNP i
Tang NNP i
( ( i
DST NNP i
) ) i
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
( ( N
IgAN NNP N
) ) N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

METHODS NNP N
90 CD p
patients NNS p
with IN p
IgAN NNP p
of IN p
deficiency NN p
of IN p
Yin NNP p
with IN p
damp-heat JJ p
symptom NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

50 CD N
patients NNS N
in IN N
treatment NN N
group NN N
were VBD N
treated VBN N
with IN N
DST NNP i
and CC i
western JJ i
medicine NN i
and CC N
40 CD N
patients NNS N
in IN N
control NN N
group NN N
were VBD N
treated VBN N
only RB i
with IN i
western JJ i
medicine NN i
. . i

The DT N
effects NNS N
and CC N
changes NNS N
of IN N
the DT N
indexes NNS N
including VBG N
renal JJ o
function NN o
, , o
hematuria NN o
, , o
proteinuria NN o
, , o
blood NN o
IgA NNP o
before IN N
and CC N
after IN N
treatment NN N
were VBD N
observed VBN N
. . N

RESULTS NNP N
After IN N
six CD N
months NNS N
treatment NN N
, , N
the DT N
general JJ o
effective JJ o
rate NN o
in IN N
treatment NN N
group NN N
was VBD N
70.00 CD N
% NN N
, , N
which WDT N
was VBD N
markedly RB N
higher JJR N
than IN N
that DT N
in IN N
control NN N
group NN N
( ( N
37.50 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Treatment NNP N
group NN N
is VBZ N
obviously RB N
better JJR N
than IN N
control NN N
group NN N
on IN N
decreasing VBG o
hematuria NN o
, , o
proteinuria NN o
, , o
blood NN o
IgA NNP o
and CC o
improving VBG o
renal JJ o
function NN o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
DST NNP i
is VBZ N
effective JJ N
on IN N
IgAN NNP N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

-DOCSTART- -17472664- O O

Clinical JJ N
evaluation NN N
of IN N
imidapril NN i
in IN N
congestive JJ p
heart NN p
failure NN p
in IN p
dogs NNS p
: : p
results NNS N
of IN N
the DT N
EFFIC NNP N
study NN N
. . N

OBJECTIVES CC N
The DT N
clinical JJ N
efficacy NN o
and CC o
safety NN o
of IN N
imidapril NN i
were VBD N
evaluated VBN N
in IN N
dogs NNS p
that WDT p
presented VBD p
with IN p
mild NN p
to TO p
severe VB p
congestive JJ p
heart NN p
failure NN p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
stage NN p
II NNP p
to TO p
IV NNP p
) ) p
by IN N
comparing VBG N
the DT N
success NN N
rate NN N
of IN N
imidapril NN i
with IN N
a DT N
positive JJ N
control NN N
by IN N
a DT N
non-inferiority JJ N
approach NN N
. . N

METHODS NNP N
This DT N
good JJ N
, , N
clinical JJ N
practice NN N
compliant NN N
, , N
multicentre NN N
study NN N
( ( N
EFFIC NNP N
study NN N
) ) N
enrolled VBD p
142 CD p
client-owned JJ p
dogs NNS p
and CC p
was VBD p
conducted VBN p
in IN p
20 CD p
locations NNS p
in IN p
France NNP p
, , p
Belgium NNP p
and CC p
Germany NNP p
. . p

Dogs NNP p
of IN p
various JJ p
breed NN p
, , p
age NN p
and CC p
weight NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

These DT N
dogs NNS N
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
that WDT N
were VBD N
treated VBN N
for IN N
84 CD N
days NNS N
with IN N
either DT N
the DT N
test NN N
product NN N
, , N
imidapril NN i
, , N
or CC N
the DT N
positive JJ N
control NN N
, , N
benazepril NN i
, , N
and CC N
followed VBD N
up RP N
in IN N
parallel NN N
over IN N
this DT N
period NN N
. . N

Both DT N
treatments NNS N
were VBD N
administered VBN N
at IN N
a DT N
dose NN N
of IN N
0.25 CD N
mg/kg NN N
once RB N
a DT N
day NN N
with IN N
the DT N
possibility NN N
of IN N
doubling VBG N
this DT N
dose NN N
to TO N
0.5 CD N
mg/kg NN N
if IN N
considered VBN N
necessary JJ N
from IN N
a DT N
clinical JJ N
point NN N
of IN N
view NN N
. . N

In IN N
addition NN N
, , N
concomitant JJ N
treatment NN N
was VBD N
given VBN N
to TO N
dogs NNS p
presenting VBG N
with IN N
pulmonary JJ N
oedema NN N
and/or NN N
ascites NNS N
, , N
supraventricular JJ N
tachyarrhythmia NN N
and/or NN N
dilated VBD N
cardiomyopathy NN N
. . N

The DT N
evolution NN o
of IN o
the DT o
New NNP o
York NNP o
Heart NNP o
Association NNP o
stage NN o
and CC N
the DT N
functional JJ o
signs NNS o
score NN o
were VBD N
evaluated VBN N
as IN N
primary JJ N
efficacy NN N
criteria NNS N
. . N

RESULTS VB N
The DT N
success NN o
rate NN o
in IN N
the DT N
imidapril NN i
group NN N
was VBD N
66 CD N
compared VBN N
with IN N
68 CD N
per IN N
cent NN N
in IN N
the DT N
benazepril NN i
group NN N
. . N

Regarding VBG N
safety NN N
, , N
35 CD N
dogs NNS N
in IN N
each DT N
group NN N
experienced VBD N
at IN N
least JJS N
one CD N
adverse JJ o
event NN o
. . o

Nine NNP N
dogs NNS N
in IN N
each DT N
group NN N
experienced VBD N
at IN N
least JJS N
one CD N
serious JJ o
adverse JJ o
event NN N
. . N

The DT N
difference NN N
between IN N
these DT N
results NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

CLINICAL JJ N
SIGNIFICANCE NNP N
Imidapril NNP i
is VBZ N
as RB N
efficacious JJ o
and CC o
safe JJ o
as IN N
the DT N
reference NN N
product NN N
, , N
benazepril NN i
. . i

-DOCSTART- -10602739- O O

Ciprofloxacin NNP i
, , i
lomefloxacin NN i
, , i
or CC i
levofloxacin CC i
as IN N
treatment NN N
for IN N
chronic JJ o
osteomyelitis NN o
. . o

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
three CD N
oral JJ i
fluoroquinolones NNS i
( ( i
lomefloxacin NN i
, , i
levofloxacin NN i
, , i
and CC i
ciprofloxacin NN i
) ) i
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
osteomyelitis NN N
were VBD N
analyzed VBN N
. . N

Twenty-seven JJ p
patients NNS p
had VBD p
documented VBN p
infections NNS p
with IN p
quinolone-sensitive JJ p
organisms NNS p
and CC N
received VBD N
either DT i
lomefloxacin NN i
, , i
levofloxacin NN i
, , i
or CC i
ciprofloxacin NN i
. . i

Levofloxacin NNP N
was VBD N
effective JJ N
therapy NN N
for IN N
9 CD N
of IN N
15 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
. . N

Lomefloxacin NNP N
was VBD N
effective JJ N
therapy NN N
for IN N
five CD N
of IN N
seven CD N
( ( N
71 CD N
% NN N
) ) N
patients NNS N
, , N
and CC N
ciprofloxacin NN N
was VBD N
effective JJ N
therapy NN N
for IN N
two CD N
of IN N
five CD N
patients NNS N
( ( N
40 CD N
% NN N
) ) N
. . N

Average JJ N
follow-up NN N
was VBD N
11.8 CD N
months NNS N
for IN N
patients NNS N
who WP N
completed VBD N
the DT N
course NN N
of IN N
therapy NN N
, , N
and CC N
the DT N
average JJ N
duration NN o
of IN o
therapy NN o
was VBD N
60.6 CD N
days NNS N
. . N

Gram-positive JJ o
bacteria NNS o
were VBD N
isolated VBN N
from IN N
18 CD N
patients NNS N
, , N
and CC N
11 CD N
patients NNS N
were VBD N
cured VBN o
. . o

Oral JJ N
fluoroquinolones NNS N
can MD N
be VB N
safe JJ o
, , o
effective JJ o
therapy NN N
if IN N
they PRP N
are VBP N
given VBN N
for IN N
a DT N
prolonged JJ N
course NN N
as IN N
treatment NN N
for IN N
infections NNS N
caused VBN N
by IN N
susceptible JJ N
gram-positive JJ N
as RB N
well RB N
as IN N
gram-negative JJ N
organisms NNS N
and CC N
in IN N
combination NN N
with IN N
adequate JJ N
surgical JJ N
debridement NN N
. . N

-DOCSTART- -2755692- O O

An DT N
evaluation NN N
of IN N
sealing VBG o
ability NN o
of IN N
calcium NN i
hydroxide NN i
sealers NNS i
. . i

Solid NNP N
core NN N
filling VBG N
material NN N
such JJ N
as IN N
gutta-percha NN N
has VBZ N
been VBN N
used VBN N
to TO N
fill VB N
the DT N
root NN N
canal NN N
in IN N
conjunction NN N
with IN N
a DT N
sealer NN N
to TO N
prevent VB N
apical JJ N
leakage NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
apical JJ i
seal NN i
of IN N
five CD N
different JJ N
root NN i
canal JJ i
sealers NNS i
. . i

Sixty NNP p
roots NNS p
of IN p
maxillary JJ p
central JJ p
incisors NNS p
were VBD N
cleansed VBN N
and CC N
shaped VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
six CD N
groups NNS N
of IN N
ten JJ N
roots NNS N
each DT N
. . N

The DT N
root NN N
canals NNS N
were VBD N
obturated VBN N
with IN N
gutta-percha JJ i
and CC N
one CD N
of IN N
the DT N
sealers NNS i
by IN N
the DT N
lateral-vertical JJ N
condensation NN N
technique NN N
. . N

Groups NNP N
I PRP N
, , N
II NNP N
, , N
III NNP N
, , N
IV NNP N
, , N
and CC N
V NNP N
consisted VBD N
of IN N
roots NNS N
in IN N
which WDT N
the DT N
canal NN i
was VBD i
filled VBN i
with IN i
gutta-percha JJ i
along IN i
with IN i
either DT i
Roth NNP i
's POS i
sealer NN i
, , i
AH26 NNP i
, , i
Sealapex NNP i
, , i
CRCS NNP i
, , i
or CC i
Nogenol NNP i
sealer NN i
, , i
respectively RB i
. . i

Group NNP N
VI NNP N
was VBD N
filled VBN i
with IN i
gutta-percha JJ i
and CC i
without IN i
sealer NN i
to TO i
serve VB i
as IN i
a DT i
control NN i
. . i

The DT N
access NN N
opening NN N
was VBD N
filled VBN N
with IN N
amalgam NN i
. . i

Each DT p
tooth NN p
was VBD N
then RB N
placed VBN N
in IN N
a DT N
capped JJ N
vial NN N
containing VBG N
2 CD N
X JJ N
2 CD N
inch JJ N
gauze NN N
pads NNS N
saturated VBD N
with IN N
distilled JJ N
water NN N
, , N
and CC N
the DT N
sealer NN N
was VBD N
allowed VBN N
to TO N
set VB N
at IN N
37 CD N
degrees NNS N
C NNP N
in IN N
the DT N
humidor NN N
for IN N
48 CD N
hours NNS N
. . N

The DT N
roots NNS N
, , N
except IN N
for IN N
the DT N
apical JJ N
2 CD N
mm NN N
, , N
were VBD N
coated VBN N
with IN N
two CD N
layers NNS N
of IN N
nail JJ N
polish NN N
. . N

The DT N
roots NNS N
were VBD N
stained VBN N
with IN N
india JJ N
ink NN N
, , N
decalcified VBN N
, , N
dehydrated VBN N
, , N
and CC N
then RB N
placed VBN N
in IN N
methylsalicylate NN N
to TO N
make VB N
them PRP N
transparent NN N
. . N

The DT N
leakage NN N
was VBD N
measured VBN N
with IN N
a DT N
filar JJ N
micrometer NN N
eyepiece NN N
under IN N
a DT N
dissecting NN N
microscope NN N
. . N

The DT N
mean JJ o
apical JJ o
leakage NN o
of IN N
six CD N
groups NNS N
was VBD N
as IN N
follows VBZ N
: : N
I PRP N
= VBP N
0.45 CD N
mm NN N
, , N
II NNP N
= VBZ N
0.277 CD N
mm NN N
, , N
III NNP N
= VBZ N
0.343 CD N
mm NN N
, , N
IV NNP N
= VBZ N
0.263 CD N
mm NN N
, , N
V NNP N
= VBZ N
0.336 CD N
mm NN N
, , N
and CC N
VI NNP N
= NNP N
2.310 CD N
mm NN N
. . N

Results NNP N
showed VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
apical JJ N
seal NN N
produced VBN N
by IN N
gutta-percha NN N
and CC N
the DT N
tested JJ N
root NN N
canal JJ N
sealers NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -21844080- O O

Comparative JJ o
effectiveness NN o
of IN N
exercise NN N
electrocardiography NN N
with IN N
or CC N
without IN N
myocardial JJ N
perfusion NN N
single JJ N
photon NN N
emission NN N
computed VBD N
tomography NN N
in IN N
women NNS p
with IN p
suspected JJ p
coronary JJ p
artery NN p
disease NN p
: : p
results NNS N
from IN N
the DT N
What WP N
Is VBZ N
the DT N
Optimal NNP N
Method NNP N
for IN N
Ischemia NNP N
Evaluation NNP N
in IN N
Women NNP N
( ( N
WOMEN NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
paucity NN N
of IN N
randomized JJ N
trials NNS N
regarding VBG N
diagnostic JJ N
testing NN N
in IN N
women NNS p
with IN p
suspected JJ p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
. . p

It PRP N
remains VBZ N
unclear JJ N
whether IN N
the DT N
addition NN N
of IN N
myocardial JJ N
perfusion NN N
imaging NN N
( ( N
MPI NNP N
) ) N
to TO N
the DT N
standard JJ N
ECG NNP N
exercise NN N
treadmill NN N
test NN N
( ( N
ETT NNP N
) ) N
provides VBZ N
incremental JJ N
information NN N
to TO N
improve VB N
clinical JJ N
decision NN N
making NN N
in IN N
women NNS p
with IN p
suspected JJ p
CAD NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
randomized VBD N
symptomatic JJ p
women NNS p
with IN p
suspected JJ p
CAD NNP p
, , p
an DT i
interpretable JJ i
ECG NNP i
, , i
and CC i
?5 NNP i
metabolic JJ i
equivalents NNS i
on IN i
the DT p
Duke NNP p
Activity NNP p
Status NNP p
Index NNP p
to TO p
1 CD N
of IN N
2 CD N
diagnostic JJ N
strategies NNS i
: : i
ETT NNP i
or CC i
exercise NN i
MPI NNP i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD o
2-year JJ o
incidence NN o
of IN o
major JJ o
adverse JJ o
cardiac NN o
events NNS o
, , o
defined VBN o
as IN o
CAD NNP o
death NN o
or CC o
hospitalization NN o
for IN o
an DT o
acute JJ o
coronary JJ o
syndrome NN o
or CC o
heart NN o
failure NN o
. . o

A DT N
total NN p
of IN p
824 CD p
women NNS p
were VBD p
randomized VBN N
to TO N
ETT NNP i
or CC i
exercise NN i
MPI NNP i
. . i

For IN N
women NNS N
randomized VBN N
to TO N
ETT NNP o
, , o
ECG NNP o
results NNS o
were VBD N
normal JJ N
in IN N
64 CD N
% NN N
, , N
indeterminate NN N
in IN N
16 CD N
% NN N
, , N
and CC N
abnormal JJ N
in IN N
20 CD N
% NN N
. . N

By IN N
comparison NN N
, , N
the DT o
exercise NN o
MPI NNP o
results NNS o
were VBD o
normal JJ N
in IN N
91 CD N
% NN N
, , N
mildly RB N
abnormal JJ N
in IN N
3 CD N
% NN N
, , N
and CC N
moderate VB N
to TO N
severely RB N
abnormal JJ N
in IN N
6 CD N
% NN N
. . N

At IN N
2 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
major JJ o
adverse JJ o
cardiac NN o
events NNS o
( ( o
98.0 CD N
% NN N
for IN N
ETT NNP N
and CC N
97.7 CD N
% NN N
for IN N
MPI NNP N
; : N
P=0.59 NNP N
) ) N
. . N

Compared VBN N
with IN N
ETT NNP o
, , o
index NN o
testing VBG o
costs NNS o
were VBD o
higher JJR N
for IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
whereas JJ N
downstream NN N
procedural NN N
costs NNS N
were VBD N
slightly RB N
lower JJR N
( ( N
P=0.0008 NNP N
) ) N
. . N

Overall UH N
, , N
the DT o
cumulative JJ o
diagnostic JJ o
cost NN o
savings NNS o
was VBD o
48 CD N
% NN N
for IN N
ETT NNP N
compared VBN N
with IN N
exercise NN N
MPI NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
low-risk JJ N
, , N
exercising VBG N
women NNS N
, , N
a DT N
diagnostic JJ N
strategy NN N
that WDT N
uses VBZ N
ETT NNP N
versus NN N
exercise NN N
MPI NNP N
yields NNS N
similar JJ N
2-year JJ N
posttest NN N
outcomes NNS N
while IN N
providing VBG N
significant JJ N
diagnostic JJ N
cost NN N
savings NNS N
. . N

The DT N
ETT NNP N
with IN N
selective JJ N
follow-up JJ N
testing NN N
should MD N
be VB N
considered VBN N
as IN N
the DT N
initial JJ N
diagnostic JJ N
strategy NN N
in IN N
symptomatic JJ p
women NNS p
with IN p
suspected JJ p
CAD NNP p
. . p

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00282711 NNP N
. . N

-DOCSTART- -24158898- O O

Sequential JJ i
therapy NN i
versus IN i
standard JJ i
triple-drug JJ i
therapy NN i
for IN N
Helicobacter NNP N
pylori JJ N
eradication NN N
: : N
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Antimicrobial NNP N
resistance NN N
has VBZ N
decreased VBN N
eradication NN N
rates NNS N
for IN N
Helicobacter NNP p
pylori JJ p
infection NN p
worldwide NN N
. . N

A DT N
sequential JJ N
treatment NN N
schedule NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
, , N
but CC N
studies NNS N
published VBN N
to TO N
date NN N
were VBD N
performed VBN N
in IN N
Italy NNP N
. . N

We PRP N
undertook VBD N
this DT N
study NN N
to TO N
determine VB N
whether IN N
these DT N
results NNS N
could MD N
be VB N
replicated VBN N
in IN p
India NNP p
. . p

METHODS NNP N
A NNP N
randomized JJ N
, , N
open-labeled JJ N
, , N
prospective JJ N
controlled VBN N
trial NN N
comparing VBG N
sequential JJ i
vs. FW i
standard JJ i
triple-drug JJ i
therapy NN i
was VBD N
carried VBN N
out RP N
at IN p
Lokmanya NNP p
Tilak NNP p
Municipal NNP p
General NNP p
Hospital NNP p
, , p
Mumbai NNP p
. . p

Two CD p
hundred CD p
and CC p
thirty-one JJ p
patients NNS p
with IN p
dyspepsia NNS p
were VBD N
randomized VBN N
to TO N
a DT N
10-day JJ i
sequential JJ i
regimen NNS i
( ( i
40 CD i
mg NN i
of IN i
pantoprazole NN i
, , i
1 CD i
g NN i
of IN i
amoxicillin NN i
, , i
each DT i
administered VBN i
twice RB i
daily RB i
for IN i
the DT i
first JJ i
5 CD i
days NNS i
, , i
followed VBN i
by IN i
40 CD i
mg NNS i
of IN i
pantoprazole NN i
, , i
500 CD i
mg NN i
of IN i
clarithromycin NN i
, , i
and CC i
500 CD i
mg NN i
of IN i
tinidazole NN i
, , i
each DT i
administered VBN i
twice RB i
daily RB i
for IN i
the DT i
remaining VBG i
5 CD i
days NNS i
) ) i
or CC i
to TO i
standard VB i
14-day JJ i
therapy NN i
( ( i
40 CD i
mg NN i
of IN i
pantoprazole NN i
, , i
500 CD i
mg NN i
of IN i
clarithromycin NN i
, , i
and CC i
1 CD i
g NN i
of IN i
amoxicillin NN i
, , i
each DT i
administered VBN i
twice RB i
daily RB i
) ) i
. . i

RESULTS VB N
The DT N
eradication NN o
rate NN o
achieved VBN N
with IN N
the DT N
sequential JJ i
regimen NN i
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
obtained VBN N
with IN N
the DT N
triple JJ i
therapy NN i
. . i

Per-protocol JJ o
eradication NN o
rate NN o
of IN N
sequential JJ i
therapy NN i
was VBD N
92.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
85.8-96.1 CD N
% NN N
) ) N
vs. FW N
81.8 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
73.9-87.8 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.027 CD N
) ) N
for IN N
standard JJ i
drug NN i
therapy NN o
. . o

Intention-to-treat JJ o
eradication NN o
rates NNS o
were VBD o
88.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
80.9-93.0 CD N
% NN N
) ) N
vs. FW N
79.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
71.1-85.4 CD N
% NN N
) ) N
, , N
p JJ N
= NN N
0.029 CD N
, , N
respectively RB o
. . o

The DT o
incidence NN o
of IN o
major JJ o
and CC o
minor JJ o
side NN o
effects NNS o
between IN N
therapy NN N
groups NNS N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
14.6 CD N
% NN N
in IN N
the DT N
triple JJ N
therapy NN N
group NN N
vs. FW N
23.5 CD N
% NN N
in IN N
sequential JJ N
group NN N
, , N
p VBP N
= RB N
0.12 CD N
) ) N
. . N

Follow NNP N
up RP N
was VBD N
incomplete JJ N
in IN N
3.3 CD N
% NN N
and CC N
4.7 CD N
% NN N
patients NNS N
in IN N
standard JJ i
and CC i
sequential JJ i
therapy NN i
groups NNS i
, , N
respectively RB N
. . i

Sequential JJ i
therapy NN i
includes VBZ i
one CD N
additional JJ N
antibiotic NN N
( ( N
tinidazole NN i
) ) N
that WDT N
is VBZ N
not RB N
contained VBN N
in IN N
standard JJ i
therapy NN i
. . i

CONCLUSIONS NNP i
Sequential NNP i
therapy NN i
was VBD i
significantly RB N
better JJR N
than IN N
standard JJ i
therapy NN i
for IN i
eradicating VBG o
H. NNP o
pylori JJ o
infection NN o
. . o

-DOCSTART- -15960694- O O

Just-in-time JJ N
evidence-based JJ N
e-mail JJ N
reminders NNS N
in IN N
home NN N
health NN N
care NN N
: : N
impact NN p
on IN p
nurse JJ p
practices NNS p
. . p

OBJECTIVE NNP N
To TO N
test VB N
the DT N
effectiveness NN N
of IN N
two CD N
interventions NNS N
designed VBN N
to TO N
improve VB N
the DT N
adoption NN N
of IN N
evidence-based JJ N
practices NNS N
by IN N
home NN p
health NN p
nurses NNS p
caring VBG p
for IN p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
patients NNS p
. . p

DATA NNP N
SOURCES/STUDY NNP N
SETTING NNP N
Information NNP p
on IN p
nurse NN p
practices NNS p
was VBD p
abstracted VBN p
from IN p
the DT p
clinical JJ p
records NNS p
of IN p
patients NNS p
admitted VBN p
between IN p
June NNP p
2000 CD p
and CC p
November NNP p
2001 CD p
to TO p
the DT p
care NN p
of IN p
354 CD p
study NN p
nurses NNS p
at IN p
a DT p
large JJ p
, , p
urban JJ p
, , p
nonprofit JJ p
home NN p
care NN p
agency NN p
. . p

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
employed VBD N
a DT N
randomized JJ N
design NN N
with IN N
nurses NNS N
assigned VBN N
to TO N
usual JJ N
care NN N
or CC N
one CD N
of IN N
two CD N
intervention NN N
groups NNS N
upon IN N
identification NN N
of IN N
an DT N
eligible JJ N
patient NN N
. . N

The DT N
basic JJ N
intervention NN N
was VBD N
a DT N
one-time JJ i
e-mail JJ i
reminder NN i
highlighting VBG i
six CD i
HF-specific JJ i
clinical JJ i
recommendations NNS i
. . i

The DT N
augmented JJ N
intervention NN N
consisted VBN N
of IN N
the DT N
initial JJ i
e-mail JJ i
reminder NN i
supplemented VBN i
by IN i
provider NN i
prompts NNS i
, , i
patient JJ i
education NN i
material NN i
, , i
and CC i
clinical JJ i
nurse NN i
specialist NN i
outreach NN i
. . i

DATA NNP N
COLLECTION NNP N
At IN N
each DT N
home NN N
health NN N
visit NN N
provided VBN N
by IN N
a DT N
study NN N
nurse NN N
to TO N
an DT N
eligible JJ N
HF NNP N
patient NN N
during IN N
the DT N
45-day JJ N
follow-up JJ N
period NN N
, , N
a DT N
structured JJ N
chart NN N
abstraction NN N
tool NN N
was VBD N
used VBN N
to TO N
collect VB N
information NN N
on IN N
whether IN N
the DT N
nurse NN N
provided VBD N
the DT N
care NN N
practices NNS N
highlighted VBN N
in IN N
the DT N
e-mail JJ N
reminder NN N
. . N

PRINCIPAL NNP N
FINDINGS NNP N
Both NNP N
the DT N
basic JJ N
and CC N
the DT N
augmented JJ N
interventions NNS N
greatly RB N
increased VBD N
the DT N
practice NN o
of IN o
evidence-based JJ o
care NN o
, , N
according VBG N
to TO N
patient NN N
records NNS N
, , N
in IN N
the DT N
areas NNS N
of IN N
patient JJ N
assessment NN N
and CC N
instructions NNS N
about IN N
HF NNP N
disease NN N
management NN N
. . N

While IN N
not RB N
all DT N
results NNS N
were VBD N
statistically RB N
significant JJ N
at IN N
conventional JJ N
levels NNS N
, , N
intervention NN o
effects NNS o
were VBD N
positive JJ N
in IN N
virtually RB N
all DT N
cases NNS N
and CC N
effect NN o
magnitudes NNS o
frequently RB o
were VBD N
large JJ N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
randomized JJ N
trial NN N
strongly RB N
support VB N
the DT N
efficacy NN o
of IN N
just-in-time JJ o
evidence-based JJ o
reminders NNS o
as IN N
a DT N
means NN N
of IN N
changing VBG N
clinical JJ N
practice NN N
among IN N
home NN p
health NN p
nurses NNS p
who WP N
are VBP N
geographically RB N
dispersed VBN N
and CC N
spend VBP N
much RB N
of IN N
their PRP$ N
time NN N
in IN N
the DT N
field NN N
. . N

-DOCSTART- -8960488- O O

Dental JJ N
bacteremia NN N
in IN p
children NNS p
. . p

Bacteremia NNP N
resulting VBG N
from IN N
dental JJ i
extraction NN i
is VBZ i
regarded VBN N
as IN N
an DT N
important JJ N
cause NN N
of IN N
bacterial JJ N
endocarditis NN N
, , N
and CC N
it PRP N
is VBZ N
therefore RB N
recommended JJ N
that IN N
patients NNS p
undergoing VBG p
tooth DT p
extraction NN p
be VB N
given VBN N
prophylactic JJ i
antibiotics NNS i
. . i

As IN N
dental JJ N
procedures NNS N
other JJ N
than IN N
extractions NNS N
may MD N
also RB N
cause VB N
bacteremias NN N
, , N
we PRP N
studied VBD N
a DT N
variety NN N
of IN N
dental JJ N
procedures NNS N
routinely RB N
used VBN N
in IN N
pediatric JJ N
dentistry NN N
. . N

Blood NNP o
samples NNS o
for IN N
cultures NNS N
were VBD N
obtained VBN N
30 CD N
s NNS N
after IN N
each DT N
of IN N
13 CD N
dental JJ N
operative JJ N
procedures NNS N
in IN N
735 CD p
anesthetized JJ p
children NNS p
aged VBN p
2-16 CD p
years NNS p
. . p

Four CD N
procedures NNS N
used VBN N
for IN N
conservative JJ N
dentistry NN N
caused VBD N
bacteremias NNS o
significantly RB N
more RBR N
often RB N
than IN N
the DT N
baseline JJ N
value NN N
of IN N
9.4 CD N
% NN N
: : N
polishing NN i
teeth VBZ i
24.5 CD N
% NN N
, , N
intraligamental JJ i
injection NN i
96.6 CD N
% NN N
, , N
rubber VB i
dam JJ i
placement NN i
29.4 CD N
% NN N
, , N
and CC N
matrix NNS i
band VBP i
with IN i
wedge NN i
placement NN i
32.1 CD N
% NN N
. . N

In IN N
comparison NN N
, , N
toothbrushing VBG N
alone RB N
caused VBD N
a DT N
bacteremia NN o
on IN N
38.5 CD N
% NN N
of IN N
occasions NNS N
. . N

The DT N
organisms NNS N
isolated VBN N
were VBD N
typical JJ N
of IN N
odontogenic JJ o
bacteremias NN o
in IN N
that DT N
50 CD N
% NN N
of IN N
the DT N
isolates NNS N
were VBD N
identified VBN N
as IN N
varieties NNS N
of IN N
viridans NNS N
streptococci VBP N
. . N

These DT N
data NNS N
show VBP N
that IN N
a DT N
wider JJR N
variety NN N
of IN N
dental NN N
procedures NNS N
than IN N
was VBD N
previously RB N
documented VBN N
cause NN N
bacteremia NN o
. . o

-DOCSTART- -12093460- O O

A DT N
pilot NN N
study NN N
of IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
supplemental JJ N
arginine NN i
to TO N
enhance VB N
immune JJ N
function NN N
in IN N
persons NNS p
with IN p
HIV/AIDS NNP p
. . p

OBJECTIVE NNP N
We PRP N
collected VBD N
preliminary JJ N
data NNS N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
supplemental JJ N
arginine NN i
to TO N
improve VB N
natural JJ N
killer NN N
cell NN N
cytotoxicity NN N
in IN N
a DT N
sample NN N
of IN N
persons NNS p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
and CC p
acquired VBD p
immunodeficiency NN p
syndrome NN p
( ( p
AIDS NNP p
) ) p
. . p

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
pilot NN N
study NN N
in IN N
an DT N
academic JJ N
medical JJ N
center-based JJ N
infectious JJ N
disease NN N
clinic NN N
, , N
11 CD p
clinically RB p
stable JJ p
, , p
HIV-infected JJ p
adults NNS p
had VBD p
been VBN p
treated VBN p
with IN p
highly RB p
active JJ p
, , p
antiretroviral JJ i
therapy NN i
and CC p
had VBD p
HIV NNP p
plasma NN p
RNA NNP p
levels NNS p
of IN p
less JJR p
than IN p
10 CD p
000 CD p
copies/mL NN p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
19.6 CD i
g NN i
of IN i
arginine/d NN i
( ( N
n JJ N
= NNP N
6 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
5 CD N
) ) N
for IN N
14 CD N
d. NN N
Plasma NNP o
HIV NNP o
RNA NNP o
levels NNS o
, , o
neuropsychologic RB o
functioning NN o
, , o
and CC o
self-reported JJ o
adverse JJ o
events NNS o
were VBD N
analyzed VBN N
for IN N
safety NN N
of IN N
treatment NN N
. . N

Efficacy NN o
was VBD N
measured VBN N
by IN N
natural JJ N
killer NN N
cell NN N
cytotoxicity NN N
. . N

RESULTS NNP N
None NN N
of IN N
the DT N
participants NNS N
experienced VBD N
any DT N
adverse JJ o
clinical NN o
, , o
virologic NN o
, , o
or CC o
neuropsychologic JJ o
events NNS o
that WDT N
necessitated VBD N
withdrawal NN N
from IN N
the DT N
study NN N
. . N

The DT N
arginine-supplemented JJ i
group NN N
showed VBD N
a DT N
mean JJ o
natural JJ o
killer NN o
cell NN o
cytotoxicity NN o
increase NN N
of IN N
18.9 CD N
lytic JJ N
units NNS N
, , N
whereas IN N
the DT N
placebo NN N
group NN N
showed VBD N
an DT N
increase NN N
of IN N
0.3 CD N
lytic JJ N
units NNS N
. . N

This DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.79 CD N
) ) N
. . N

CONCLUSIONS NNP N
Short-term JJ N
arginine NN i
supplementation NN N
is VBZ N
safe JJ N
for IN N
persons NNS p
with IN p
HIV/AIDS NNP p
. . p

Additional NNP N
studies NNS N
with IN N
larger JJR N
samples NNS N
and CC N
longer JJR N
periods NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
arginine JJ N
supplementation NN N
on IN N
other JJ N
indices NNS N
of IN N
immune JJ N
function NN N
and CC N
on IN N
clinical JJ N
outcomes NNS N
such JJ N
as IN N
intercurrent JJ N
illnesses NNS N
. . N

